drug,adverse_event,comp_term,is_overlapping,similarity
XEOMIN,Hypersensitivity,Precautions Dysphagia and,0,0.5257009267807007
XEOMIN,Hypersensitivity,reactions to XEOMIN are discussed in greater detail in other sections of,0,0.6445651650428772
XEOMIN,Dysphagia,Dysphagia and Breathing Difficulties in Treatment,1,0.8230819702148438
XEOMIN,Dysphagia,Dysphagia and,1,0.9282095432281494
XEOMIN,Dysphagia,Dysphagia and Breathing,1,0.8738216161727905
XEOMIN,Dysphagia,cervical dystonia,0,0.5939018130302429
XEOMIN,Dysphagia,and Dysphagia,1,0.9268420934677124
XEOMIN,Breathing Difficulties,and Warnings,0,0.5421971678733826
XEOMIN,Breathing Difficulties,Dysphagia Breathing Difficulties in Treatment of,1,0.8246653079986572
XEOMIN,Breathing Difficulties,and Warnings and Precautions Dysphagia and,0,0.6262839436531067
XEOMIN,Breathing Difficulties,Spread of,0,0.500250518321991
XEOMIN,Breathing Difficulties,and Precautions Spread of,0,0.5196155309677124
XEOMIN,Breathing Difficulties,Breathing Difficulties in Treatment,1,0.912757396697998
XEOMIN,Breathing Difficulties,Precautions Spread of Effects,0,0.5556197166442871
XEOMIN,Breathing Difficulties,and Precautions,0,0.5501430034637451
XEOMIN,Breathing Difficulties,Precautions Dysphagia Breathing Difficulties in Treatment of cervical dystonia,1,0.7401078343391418
XEOMIN,Spread of Effects from Toxin,dystonia see Warnings and Spread of Effects from Toxin see,1,0.7964558601379395
XEOMIN,Spread of Effects from Toxin,and Precautions,0,0.5696677565574646
XEOMIN,dysphagia,site pain and musculoskeletal,0,0.5223532915115356
XEOMIN,dysphagia,dysphagia neck pain muscle,1,0.7829279899597168
XEOMIN,dysphagia,dysphagia,1,1.0
XEOMIN,dysphagia,pain muscle weakness injection site pain and,0,0.5388007164001465
XEOMIN,neck pain,neck pain muscle weakness injection site pain,1,0.7965306043624878
XEOMIN,neck pain,injection,0,0.5006465911865234
XEOMIN,neck pain,most commonly,0,0.4687093496322632
XEOMIN,neck pain,are neck pain muscle,1,0.87636399269104
XEOMIN,neck pain,neck pain muscle weakness,1,0.8497850298881531
XEOMIN,neck pain,and placebo are neck pain,1,0.8160827159881592
XEOMIN,neck pain,and musculoskeletal pain Blepharospasm,0,0.6534010171890259
XEOMIN,neck pain,musculoskeletal pain,0,0.7486284971237183
XEOMIN,neck pain,neck pain,1,0.9999998807907104
XEOMIN,neck pain,commonly observed adverse reactions,0,0.5204709768295288
XEOMIN,injection site pain,injection site,1,0.8863976001739502
XEOMIN,injection site pain,injection site pain and musculoskeletal pain Blepharospasm,1,0.8234094977378845
XEOMIN,injection site pain,muscle injection,1,0.7159873247146606
XEOMIN,injection site pain,muscle injection site pain and musculoskeletal,1,0.8716647028923035
XEOMIN,injection site pain,pain muscle injection site,1,0.8781063556671143
XEOMIN,eyelid ptosis,eyelid ptosis dry eye dry mouth diarrhea,1,0.8246747255325317
XEOMIN,eyelid ptosis,pain muscle injection site,1,0.48556986451148987
XEOMIN,eyelid ptosis,most,0,0.48525410890579224
XEOMIN,dry eye,are eyelid dry eye dry mouth diarrhea headache,1,0.7876243591308594
XEOMIN,dry eye,most,0,0.484833687543869
XEOMIN,dry eye,nasopharyngitis and,0,0.5644375681877136
XEOMIN,dry eye,dry eye dry mouth diarrhea headache,1,0.7822693586349487
XEOMIN,dry eye,placebo are eyelid dry eye dry mouth diarrhea headache visual,1,0.7456997632980347
XEOMIN,dry eye,eyelid dry,1,0.904924213886261
XEOMIN,dry eye,placebo are eyelid dry eye dry mouth diarrhea,1,0.7886158227920532
XEOMIN,dry eye,The most commonly observed adverse reactions of patients,0,0.5148249268531799
XEOMIN,dry eye,patients,0,0.5436002016067505
XEOMIN,dry eye,are eyelid dry eye dry mouth diarrhea headache visual,1,0.7755800485610962
XEOMIN,dry mouth,are eyelid ptosis dry dry mouth diarrhea headache visual impairment,1,0.6847014427185059
XEOMIN,dry mouth,patients,0,0.5740906000137329
XEOMIN,dry mouth,dry mouth diarrhea headache visual impairment,1,0.7594640254974365
XEOMIN,dry mouth,dry mouth diarrhea headache visual impairment dyspnea,1,0.7569136619567871
XEOMIN,dry mouth,eyelid ptosis dry dry mouth diarrhea headache,1,0.7151895761489868
XEOMIN,dry mouth,dry mouth diarrhea,1,0.8809130191802979
XEOMIN,dry mouth,dry dry mouth diarrhea headache visual impairment,1,0.7811182141304016
XEOMIN,dry mouth,are eyelid ptosis dry dry mouth,1,0.8110228776931763
XEOMIN,dry mouth,impairment dyspnea nasopharyngitis and,0,0.602612316608429
XEOMIN,headache,dry eye dry mouth diarrhea,0,0.5205615758895874
XEOMIN,headache,adverse reactions of patients and placebo are eyelid ptosis dry,0,0.5304813385009766
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis and,1,0.7197442054748535
XEOMIN,headache,headache visual,1,0.862754225730896
XEOMIN,headache,headache,1,1.0
XEOMIN,headache,headache visual impairment,1,0.7846415042877197
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis,1,0.7272346019744873
XEOMIN,headache,visual impairment,0,0.5156145691871643
XEOMIN,visual impairment,and respiratory,0,0.5447319149971008
XEOMIN,visual impairment,ptosis dry eye dry mouth diarrhea,0,0.6365522146224976
XEOMIN,visual impairment,infection,0,0.5417380332946777
XEOMIN,visual impairment,dry mouth diarrhea visual impairment,1,0.8260206580162048
XEOMIN,visual impairment,eyelid ptosis dry,0,0.6051415205001831
XEOMIN,dyspnea,dyspnea nasopharyngitis,1,0.8048471212387085
XEOMIN,dyspnea,dyspnea nasopharyngitis and respiratory,1,0.7751730680465698
XEOMIN,dyspnea,dyspnea,1,1.0
XEOMIN,nasopharyngitis,nasopharyngitis and,1,0.9384024143218994
XEOMIN,nasopharyngitis,headache visual impairment nasopharyngitis,1,0.8135786056518555
XEOMIN,nasopharyngitis,impairment,0,0.5236275792121887
XEOMIN,respiratory tract infection,impairment dyspnea nasopharyngitis respiratory tract infection Glabellar Lines,1,0.7240241765975952
XEOMIN,respiratory tract infection,impairment,0,0.5619474649429321
XEOMIN,respiratory tract infection,dyspnea nasopharyngitis respiratory tract infection Glabellar Lines The,1,0.7330482602119446
XEOMIN,respiratory tract infection,Glabellar Lines The most commonly observed adverse reaction of patients and,0,0.5061720013618469
XEOMIN,respiratory tract infection,visual impairment dyspnea nasopharyngitis respiratory tract infection,1,0.7461865544319153
XEOMIN,respiratory tract infection,observed adverse reaction,0,0.5653063654899597
XEOMIN,respiratory tract infection,respiratory tract infection Glabellar Lines The most commonly,1,0.7694091796875
XEOMIN,headache,ADVERSE REACTIONS contact Merz Pharmaceuticals LLC at,0,0.5199236273765564
XEOMIN,headache,The most,0,0.5171458721160889
XEOMIN,headache,observed adverse reaction of patients and placebo,0,0.5426073670387268
XEOMIN,headache,of patients and placebo headache To report,1,0.7555232048034668
XEOMIN,dysphagia,dysphagia neck pain muscle weakness injection,1,0.7649931907653809
XEOMIN,dysphagia,XEOMIN Units or Units dysphagia neck pain,1,0.7341548204421997
XEOMIN,dysphagia,weakness injection site pain and musculoskeletal pain,0,0.5304831266403198
XEOMIN,dysphagia,pain muscle weakness injection site pain and musculoskeletal pain,0,0.5191310048103333
XEOMIN,dysphagia,or Units dysphagia neck pain muscle weakness injection,1,0.7718345522880554
XEOMIN,dysphagia,Table Most Commo,0,0.5944693088531494
XEOMIN,dysphagia,Units or Units dysphagia neck pain muscle weakness injection,1,0.7504512071609497
XEOMIN,neck pain,included neck,1,0.7260710597038269
XEOMIN,neck pain,Units,0,0.4478202164173126
XEOMIN,neck pain,Units or Units included neck,1,0.6625073552131653
XEOMIN,neck pain,and musculoskeletal pain Table,0,0.659690260887146
XEOMIN,neck pain,neck pain muscle weakness injection,1,0.8001041412353516
XEOMIN,neck pain,muscle weakness injection site pain,0,0.627036452293396
XEOMIN,neck pain,site pain and musculoskeletal pain Table Most Common,0,0.6428536772727966
XEOMIN,neck pain,injection site pain and,0,0.6150804758071899
XEOMIN,neck pain,or Units included neck,1,0.6812398433685303
XEOMIN,neck pain,observed in patients who,0,0.5301934480667114
XEOMIN,muscle weakness,muscle weakness injection site,1,0.80857253074646
XEOMIN,muscle weakness,TEAEs and Greater t,0,0.48625442385673523
XEOMIN,muscle weakness,Units included dysphagia neck muscle weakness injection site pain and,1,0.6976941823959351
XEOMIN,muscle weakness,muscle weakness injection site pain and,1,0.7920666933059692
XEOMIN,muscle weakness,Units included dysphagia neck muscle weakness injection site pain,1,0.6856025457382202
XEOMIN,muscle weakness,observed in,0,0.47762492299079895
XEOMIN,injection site pain,site pain and musculoskeletal pain,1,0.7621763348579407
XEOMIN,injection site pain,neck pain muscle injection site pain and,1,0.8455088138580322
XEOMIN,injection site pain,pain muscle,0,0.6602263450622559
XEOMIN,injection site pain,pain Table Most Common TEAEs and Greater than,0,0.6338320970535278
XEOMIN,injection site pain,and musculoskeletal,0,0.549697756767273
XEOMIN,injection site pain,Table Most Common,0,0.44910600781440735
XEOMIN,injection site pain,injection site pain,1,0.9999999403953552
XEOMIN,musculoskeletal pain,and,0,0.504734992980957
XEOMIN,blepharospasm,blepharospasm previously treated,1,0.9146708250045776
XEOMIN,blepharospasm,the placebocontrolled Phase trial in patients,0,0.5568585991859436
XEOMIN,blepharospasm,blepharospasm previously treated with,1,0.9063478112220764
XEOMIN,blepharospasm,blepharospasm previously,1,0.9593496322631836
XEOMIN,blepharospasm,Phase trial in patients blepharospasm previously treated with onabotulinumtoxinA Botox,1,0.8508079648017883
XEOMIN,blepharospasm,previously treated with onabotulinumtoxinA Botox see Clinical,0,0.6480641961097717
XEOMIN,blepharospasm,in patients blepharospasm previously treated with,1,0.8909974098205566
XEOMIN,blepharospasm,Botox see Clinical Studies patients,0,0.5844635963439941
XEOMIN,eyelid ptosis,Botox see Clinical Studies patients,0,0.566932201385498
XEOMIN,eyelid ptosis,dry eye dry mouth diarrhea headache visual impairment dyspnea nasopharyngitis,0,0.599300742149353
XEOMIN,dry mouth,Phase study were eyelid ptosis dry eye,0,0.6102182865142822
XEOMIN,dry mouth,dry mouth diarrhea headache,1,0.800921618938446
XEOMIN,dry mouth,diarrhea headache visual impairment dyspnea nasopharyngitis and respiratory tract infection,0,0.5951672792434692
XEOMIN,dry mouth,dry,1,0.7593777179718018
XEOMIN,dry mouth,eyelid ptosis dry dry mouth,1,0.8265263438224792
XEOMIN,dry mouth,respiratory,0,0.5479685664176941
XEOMIN,dry mouth,eyelid ptosis dry dry mouth diarrhea headache visual,1,0.70680171251297
XEOMIN,dry mouth,in,0,0.529272198677063
XEOMIN,dry mouth,patients and greater than placebo,0,0.5562849640846252
XEOMIN,dry mouth,dry mouth,1,0.9999998807907104
XEOMIN,diarrhea,diarrhea headache,1,0.8032464981079102
XEOMIN,diarrhea,diarrhea,1,0.9999999403953552
XEOMIN,diarrhea,dyspnea nasopharyngitis,0,0.5930317640304565
XEOMIN,diarrhea,eyelid ptosis dry eye,0,0.5114153623580933
XEOMIN,diarrhea,ptosis dry eye dry diarrhea headache visual impairment dyspnea,1,0.6829899549484253
XEOMIN,headache,and greater than placebo in the Phase study were eyelid ptosis,0,0.5459058880805969
XEOMIN,headache,dry,0,0.550058901309967
XEOMIN,headache,dry mouth headache visual impairment dyspnea nasopharyngitis,1,0.6710072755813599
XEOMIN,headache,ptosis dry,0,0.553773820400238
XEOMIN,visual impairment,mouth diarrhea,0,0.5341179370880127
XEOMIN,dyspnea,in patients,0,0.5757851600646973
XEOMIN,dyspnea,headache visual dyspnea nasopharyngitis and,1,0.6732450723648071
XEOMIN,dyspnea,the Phase study were eyelid ptosis dry eye dry mouth diarrhea,0,0.5378374457359314
XEOMIN,dyspnea,in the Phase study were eyelid ptosis dry eye dry,0,0.5237504243850708
XEOMIN,dyspnea,were eyelid ptosis dry eye dry,0,0.5020806789398193
XEOMIN,dyspnea,in the Phase study were eyelid,0,0.5041434168815613
XEOMIN,nasopharyngitis,and respiratory tract infection No serious adverse events occurred in patients,0,0.6146636009216309
XEOMIN,nasopharyngitis,headache visual impairment,0,0.5535837411880493
XEOMIN,nasopharyngitis,nasopharyngitis,1,1.0000001192092896
XEOMIN,nasopharyngitis,ase study were eyelid ptosis dry eye dry mouth,0,0.5495232343673706
XEOMIN,nasopharyngitis,diarrhea headache visual impairment nasopharyngitis and respiratory,1,0.7408900260925293
XEOMIN,nasopharyngitis,nasopharyngitis and respiratory,1,0.873315691947937
XEOMIN,nasopharyngitis,impairment nasopharyngitis and respiratory,1,0.8097611665725708
XEOMIN,respiratory tract infection,visual impairment dyspnea nasopharyngitis respiratory tract,1,0.7062650918960571
XEOMIN,respiratory tract infection,eye dry mouth diarrhea headache visual,0,0.5612982511520386
XEOMIN,respiratory tract infection,id ptosis dry,0,0.5116626024246216
XEOMIN,respiratory tract infection,respiratory tract infection No,1,0.8895004391670227
XEOMIN,respiratory tract infection,nasopharyngitis respiratory tract infection,1,0.8633017539978027
XEOMIN,dyspnea,of Clinical Tr,0,0.5696752667427063
XEOMIN,dyspnea,than Placebo DoubleBlind Phase of,0,0.5092242956161499
XEOMIN,dyspnea,dyspnea Table,1,0.8767045736312866
XEOMIN,dyspnea,serious adverse dyspnea Table Most Common,1,0.8119546175003052
XEOMIN,dyspnea,dyspnea Table Most Common TEAEs and,1,0.8181484937667847
XEOMIN,dyspnea,dyspnea Table Most Common TEAEs,1,0.8258645534515381
XEOMIN,dyspnea,dyspnea Table Most,1,0.867662787437439
XEOMIN,facial paresis,subjects were headache,0,0.5874431729316711
XEOMIN,facial paresis,adverse events,0,0.510018527507782
XEOMIN,injection site hematoma,occurred in two placebotreated sub,0,0.520690381526947
XEOMIN,eyelid edema,were,0,0.4560202360153198
XEOMIN,eyelid edema,hematoma eyelid,1,0.7545427083969116
XEOMIN,eyelid edema,site hematoma eyelid edema Four,1,0.8515276908874512
XEOMIN,eyelid edema,eyelid edema,1,1.0000001192092896
XEOMIN,eyelid edema,eyelid edema Four serious adverse,1,0.8896790742874146
XEOMIN,eyelid edema,hematoma eyelid edema Four serious adverse events occurred,1,0.8024120926856995
XEOMIN,eyelid edema,eyelid edema Four,1,0.9385027885437012
XEOMIN,eyelid edema,subjects were headache facial,0,0.5855011940002441
XEOMIN,eyelid edema,subjects Six,0,0.46008574962615967
XEOMIN,brow ptosis,brow ptosis General disorders,1,0.8954448103904724
XEOMIN,brow ptosis,subjects Six,0,0.46361204981803894
XEOMIN,brow ptosis,Facial paresis,0,0.674572229385376
XEOMIN,Injection site hematoma,Injection site,1,0.8221349120140076
XEOMIN,Injection site hematoma,conditions,0,0.5151150226593018
XEOMIN,Injection site hematoma,Injection site hematoma,1,0.9999999403953552
XEOMIN,Injection site hematoma,tion,0,0.512897789478302
XEOMIN,Injection site hematoma,tion site,0,0.5988460779190063
XEOMIN,Injection site hematoma,site hematoma Injection si,1,0.9224587082862854
XEOMIN,Injection site hematoma,tion site Injection site hematoma Injection si,1,0.9620344638824463
XEOMIN,Injection site hematoma,site Injection,1,0.7837860584259033
XEOMIN,Injection site swelling,pain,0,0.6234201192855835
XEOMIN,Sensation of pressure,Sensation of pressure Eye,1,0.8636179566383362
XEOMIN,Sensation of pressure,pain,0,0.6190113425254822
XEOMIN,injection site hematoma,followed injection site,1,0.7933487892150879
XEOMIN,injection site hematoma,injection site hematoma in subjects Adverse reactions,1,0.9188913106918335
XEOMIN,injection site hematoma,reported for subjects followed injection site hematoma in,1,0.9367265105247498
XEOMIN,injection site hematoma,reported for subjects followed injection site,1,0.7673219442367554
XEOMIN,injection site hematoma,than of subjects were facial paresis,0,0.49233680963516235
XEOMIN,injection site hematoma,subjects followed injection,1,0.7084007263183594
XEOMIN,injection site hematoma,injection site hematoma in subjects Adverse,1,0.9486076831817627
XEOMIN,injection site hematoma,followed injection site hematoma,1,0.9768633842468262
XEOMIN,injection site hematoma,site hematoma in,1,0.8847140073776245
XEOMIN,facial paresis,subjects Adverse reactions reported in less than,0,0.5419566035270691
XEOMIN,facial paresis,subjects were,0,0.49204906821250916
XEOMIN,facial paresis,subjects facial,1,0.721531331539154
XEOMIN,facial paresis,facial paresis brow ptosis muscle disorder elevation,1,0.8263832330703735
XEOMIN,brow ptosis,facial,0,0.6130610704421997
XEOMIN,brow ptosis,brow ptosis muscle disorder,1,0.9011834859848022
XEOMIN,brow ptosis,of eyebrow injection site pain,0,0.6823416948318481
XEOMIN,brow ptosis,facial brow ptosis,1,0.9714391827583313
XEOMIN,brow ptosis,subjects were facial brow ptosis muscle disorder elevation of eyebrow,1,0.8803187608718872
XEOMIN,brow ptosis,injection site pain and eyelid edema,0,0.585721492767334
XEOMIN,brow ptosis,eyelid edema Immunoge,0,0.6013104915618896
XEOMIN,brow ptosis,brow ptosis muscle disorder elevation,1,0.8800138235092163
XEOMIN,brow ptosis,brow,1,0.8329496383666992
XEOMIN,muscle disorder,muscle disorder elevation of eyebrow injection site,1,0.7097207307815552
XEOMIN,muscle disorder,were,0,0.4696659445762634
XEOMIN,elevation of eyebrow,pain and eyelid edema Immunogenicity As with all,0,0.5261557102203369
XEOMIN,elevation of eyebrow,of eyebrow injection site pain and eyelid,1,0.7228006720542908
XEOMIN,injection site pain,elevation of injection site,1,0.843847930431366
XEOMIN,injection site pain,site pain and eyelid edema Immunogenicity,1,0.7209547758102417
XEOMIN,injection site pain,muscle disorder elevation of injection site pain and,1,0.8478015661239624
XEOMIN,injection site pain,disorder elevation of injection,1,0.7320274114608765
XEOMIN,eyelid edema,eyelid edema Immunogenicity As with,1,0.8477833271026611
XEOMIN,eyelid edema,site pain eyelid edema,1,0.9132876396179199
XEOMIN,eyelid edema,eyelid edema Immunogenicity As with all,1,0.8262523412704468
XEOMIN,eyelid edema,site pain eyelid edema Immunogenicity As with,1,0.8282151222229004
XEOMIN,eye swelling,drug eye,1,0.6747324466705322
XEOMIN,eye swelling,eye swelling eyelid,1,0.9313449859619141
XEOMIN,eyelid edema,eyelid edema dysphagia,1,0.8654940128326416
XEOMIN,eyelid edema,drug eye,1,0.6542109251022339
XEOMIN,eyelid edema,drug exposure,0,0.5362746119499207
XEOMIN,dysphagia,dysphagia nausea flulike symptoms injection site,1,0.766553521156311
XEOMIN,dysphagia,dysphagia nausea flulike symptoms,1,0.8078827261924744
XEOMIN,dysphagia,dysphagia nausea flulike,1,0.8120760917663574
XEOMIN,dysphagia,causal relationship to drug exposure eye swelling,0,0.48725682497024536
XEOMIN,nausea,nausea flulike symptoms,1,0.8170050382614136
XEOMIN,nausea,causal relationship to drug exposure eye swelling,0,0.5778987407684326
XEOMIN,nausea,edema nausea flulike symptoms injection site,1,0.7236950397491455
XEOMIN,nausea,eye swelling eyelid edema nausea flulike,1,0.7367890477180481
XEOMIN,nausea,nausea flulike symptoms injection,1,0.7813944816589355
XEOMIN,flu-like symptoms,eyelid edema dysphagia flu-like,1,0.7367002964019775
XEOMIN,flu-like symptoms,swelling eyelid edema dysphagia flu-like symptoms injection site,1,0.7570264935493469
XEOMIN,flu-like symptoms,allergic,0,0.5943447947502136
XEOMIN,injection site pain,injection site pain injection site,1,0.9649953842163086
XEOMIN,injection site pain,eye swelling eyelid edema dysphagia nausea,0,0.5280874967575073
XEOMIN,injection site pain,dysphagia nausea flulike injection site pain injection site reaction,1,0.8204574584960938
XEOMIN,injection site pain,dysphagia,0,0.48977699875831604
XEOMIN,injection site pain,site pain injection site,1,0.9486261606216431
XEOMIN,injection site pain,injection,1,0.788942813873291
XEOMIN,injection site pain,exposure eye swelling eyelid,0,0.5107994079589844
XEOMIN,injection site pain,nausea flulike injection site pain injection site reaction allergic,1,0.8479715585708618
XEOMIN,injection site pain,drug exposure eye swelling eyelid edema dysphagia nausea flulike,0,0.5767518877983093
XEOMIN,injection site pain,edema dysphagia nausea flulike injection site,1,0.7459361553192139
XEOMIN,injection site reaction,injection,1,0.7873796820640564
XEOMIN,injection site reaction,symptoms,0,0.5481665134429932
XEOMIN,injection site reaction,site injection site reaction,1,0.9607086181640625
XEOMIN,injection site reaction,site injection site reaction allergic dermatitis localized allergic reactions,1,0.8964806795120239
XEOMIN,injection site reaction,site reaction allergic dermatitis localized allergic,1,0.7864887714385986
XEOMIN,injection site reaction,swelling,0,0.5692324638366699
XEOMIN,injection site reaction,like swelling edema,0,0.5600273013114929
XEOMIN,injection site reaction,eyelid edema dysphagia nausea flulike,0,0.5258523225784302
XEOMIN,allergic dermatitis,pain injection,0,0.5108067989349365
XEOMIN,allergic dermatitis,reaction,0,0.5924883484840393
XEOMIN,allergic dermatitis,dysphagia nausea flulike symptoms injection site pain injection site,0,0.5314011573791504
XEOMIN,localized allergic reactions,reaction allergic localized,1,0.9478264451026917
XEOMIN,herpes zoster,dermatitis,0,0.6408579349517822
XEOMIN,muscular weakness,edema erythema pruritus or rash,0,0.5329826474189758
XEOMIN,muscular weakness,muscular,1,0.7599583864212036
XEOMIN,muscular weakness,muscular weakness muscle spasm dysarthria myalgia and,1,0.8517988920211792
XEOMIN,muscular weakness,localized allergic reactions like swelling edema erythema,0,0.5284024477005005
XEOMIN,muscular weakness,muscle spasm dysarthria myalgia and,0,0.7037076950073242
XEOMIN,muscular weakness,spasm dysarthria myalgia and hypersensitivity,0,0.6418232917785645
XEOMIN,muscular weakness,pruritus or rash herpes muscular weakness,1,0.7648553848266602
XEOMIN,muscular weakness,muscle spasm dysarthria,0,0.699699878692627
XEOMIN,muscular weakness,rash herpes muscular weakness muscle,1,0.7951898574829102
XEOMIN,muscle spasm,pruritus or rash herpes zoster muscular weakness,0,0.6440232396125793
XEOMIN,muscle spasm,muscular weakness,0,0.72471684217453
XEOMIN,muscle spasm,herpes zoster muscular muscle,1,0.6615778207778931
XEOMIN,muscle spasm,muscle,1,0.7549057006835938
XEOMIN,muscle spasm,zoster muscular muscle spasm dysarthria myalgia and hypersensitivity,1,0.7403281927108765
XEOMIN,muscle spasm,muscle spasm dysarthria myalgia and hypersensitivity,1,0.8089745044708252
XEOMIN,muscle spasm,muscle spasm dysarthria,1,0.8337834477424622
XEOMIN,muscle spasm,ergic reactions like swelling edema erythema,0,0.6323332190513611
XEOMIN,muscle spasm,muscle spasm,1,1.0
XEOMIN,muscle spasm,herpes,0,0.5215997695922852
XEOMIN,dysarthria,muscle dysarthria myalgia,1,0.8031126856803894
XEOMIN,dysarthria,herpes,0,0.50005042552948
XEOMIN,myalgia,myalgia,1,0.9999996423721313
XEOMIN,myalgia,spasm myalgia and,1,0.8087482452392578
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,REACTIONS following adverse reactions,1,0.6583431959152222
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,scussed in greater detail in o,1,0.6024234294891357
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,to XEOMIN are di,0,0.591062605381012
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,the labeling Hypersensitivity see Contraindications,0,0.5635554194450378
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,scussed in greater detail in o ther sections,1,0.5936727523803711
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,detail in o ther sections,1,0.5438408851623535
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,XEOMIN are scussed in greater detail in o ther sections,1,0.6136822700500488
XEOMIN,spread from the area of injection,"Precautions (5.3)  ]  
 *  Dyspha gia",1,0.6063715219497681
XEOMIN,spread from the area of injection,detail in o ther sections,1,0.5526896715164185
XEOMIN,spread from the area of injection,and Warnings Precautions (5.3) ] *,1,0.5813453197479248
XEOMIN,spread from the area of injection,and,0,0.49610400199890137
XEOMIN,spread from the area of injection,Precautions (5.3) ] * Dyspha gia,1,0.6063715219497681
XEOMIN,spread from the area of injection,gia and Breathing,0,0.5199434757232666
XEOMIN,spread from the area of injection,* Dyspha gia and Breathing Difficulties,1,0.51361483335495
XEOMIN,spread from the area of injection,"Contraindications and Warnings Precautions (5.3)  ]  
 *  Dyspha gia and Breathing Difficulties in",1,0.5394772291183472
XEOMIN,toxin effects,cervical dyst,1,0.5572000741958618
XEOMIN,toxin effects,of,0,0.5009933114051819
XEOMIN,toxin effects,cervical dyst onia see,1,0.546694278717041
XEOMIN,toxin effects,Difficulties in Treatment cervical,1,0.5208069086074829
XEOMIN,toxin effects,Breathing Difficulties in Treatment cervical dyst onia see Warnings and,1,0.5646874904632568
XEOMIN,toxin effects,cervical dyst onia see Warnings and,1,0.6026023626327515
XEOMIN,toxin effects,of Effects from Toxin see Warnings,0,0.8943759202957153
XEOMIN,toxin effects,and,0,0.5122621655464172
XEOMIN,asthenia,Difficulties in,0,0.5516207218170166
XEOMIN,asthenia,and Pre cautions Spread of Effects from,1,0.5612763166427612
XEOMIN,asthenia,Difficulties in Treatment,0,0.5811006426811218
XEOMIN,asthenia, and Pre cautions Spread of Effects,1,0.5515408515930176
XEOMIN,asthenia,cervical dystonia see  and Pre cautions Spread of Effects,1,0.5918530821800232
XEOMIN,asthenia,see and Pre,1,0.5370208024978638
XEOMIN,asthenia,Toxin see Warnings and Precautions,0,0.5263956785202026
XEOMIN,generalized muscle weakness,(5.4) ] * Sprea,1,0.47421956062316895
XEOMIN,generalized muscle weakness,d of Effects from Toxin see Warnings and Precautions EXCERPT Cervical,0,0.5333930253982544
XEOMIN,generalized muscle weakness,dystonia see Warnings and utions (5.4) ] *,1,0.6131258010864258
XEOMIN,generalized muscle weakness,Warnings and utions (5.4) ] *,1,0.4998817443847656
XEOMIN,generalized muscle weakness,Preca,0,0.5087147951126099
XEOMIN,generalized muscle weakness,utions (5.4) ] *,1,0.47868937253952026
XEOMIN,generalized muscle weakness,and utions (5.4) ] *,1,0.46444618701934814
XEOMIN,generalized muscle weakness,"utions (5.4)   ] 
 *  Sprea d of",1,0.49529826641082764
XEOMIN,generalized muscle weakness,"Warnings and utions (5.4)   ] 
 *  Sprea d of Effects from Toxin",1,0.5372616052627563
XEOMIN,diplopia,see Warnings and Precautions Spread,0,0.49072301387786865
XEOMIN,blurred vision,Toxin [s ee Warnings and,1,0.5317764282226562
XEOMIN,blurred vision,Effects,0,0.5723796486854553
XEOMIN,blurred vision,Precautions Spread of from Toxin [s,1,0.5314750671386719
XEOMIN,ptosis,Effects from Toxin   Warn,1,0.507501482963562
XEOMIN,ptosis,Precautions Spread of from Toxin [s,1,0.5009085536003113
XEOMIN,ptosis,  Warn ings and Precautions EXCERPT,1,0.4921838641166687
XEOMIN,dysphagia,from Toxin see gs and Pr,1,0.556978702545166
XEOMIN,dysphagia,  Warn ings and Precautions EXCERPT,1,0.5254542231559753
XEOMIN,dysphagia,The most commonly observed,0,0.5338462591171265
XEOMIN,dysphagia,gs and Pr ecautions EXCERPT Cervical Dystonia,1,0.5849597454071045
XEOMIN,dysphagia,gs and Pr ecautions EXCERPT Cervical Dystonia The,1,0.5836806297302246
XEOMIN,dysphagia,ecautions EXCERPT Cervical,0,0.5903075337409973
XEOMIN,dysphagia,Warnings and Precautions Spread,0,0.5062857270240784
XEOMIN,dysphagia,Effects from Toxin see gs and Pr ecautions EXCERPT Cervical Dystonia The,1,0.5902768969535828
XEOMIN,dysphagia,Toxin see,0,0.5398060083389282
XEOMIN,dysphagia,Effects from Toxin see gs and Pr ecautions EXCERPT Cervical,1,0.5645040273666382
XEOMIN,dysphonia,autions ( EXCERPT Cervical,1,0.560948371887207
XEOMIN,dysphonia,Warnings and Precautions Spread of Effects from Toxin see Warnings and Prec,0,0.49598681926727295
XEOMIN,dysphonia,Dystonia The,0,0.6377704739570618
XEOMIN,dysphonia,autions ( EXCERPT Cervical Dystonia The most,1,0.610777735710144
XEOMIN,dysphonia,autions ( EXCERPT Cervical Dystonia,1,0.6199581027030945
XEOMIN,dysphonia,and autions ( EXCERPT Cervical Dystonia The,1,0.6104243993759155
XEOMIN,dysphonia,and autions ( EXCERPT Cervical,1,0.5526328086853027
XEOMIN,dysphonia,see Warnings and autions,1,0.5029146075248718
XEOMIN,dysphonia,most commonly observed,0,0.4999513626098633
XEOMIN,dysphonia,Warnings and autions (,1,0.5397533178329468
XEOMIN,dysarthria,"Warnings and 1)  ]  
   EXCERPT Cervical",1,0.5548763871192932
XEOMIN,dysarthria,Warnings and autions (,1,0.5547075271606445
XEOMIN,dysarthria,1) ] EXCERPT,1,0.47349971532821655
XEOMIN,urinary incontinence,EXCERPT:,1,0.4894495904445648
XEOMIN,urinary incontinence,ecautions Spread of,0,0.502727746963501
XEOMIN,urinary incontinence,EXCERPT: Cervi cal,1,0.6021798849105835
XEOMIN,urinary incontinence,commonly observed adverse reactions of patients and,0,0.5236908197402954
XEOMIN,urinary incontinence,EXCERPT: Cervi cal Dystonia The most,1,0.572162389755249
XEOMIN,urinary incontinence,commonly observed adverse reactions of patients and placebo are dys,0,0.521438717842102
XEOMIN,urinary incontinence,see Warnings and   EXCERPT:     Cervi cal Dystonia,1,0.5749152898788452
XEOMIN,urinary incontinence,patients,0,0.5733685493469238
XEOMIN,breathing difficulties,Toxin see Warnings and Precautions,0,0.510836124420166
XEOMIN,breathing difficulties,Precautions EXCERPT Cervical ystonia:  The most com monly,1,0.5742394924163818
XEOMIN,breathing difficulties,EXCERPT Cervical ystonia: The most,1,0.5595256090164185
XEOMIN,breathing difficulties,injection site pain and musculoskeletal pain Blepharospasm The most,0,0.531930148601532
XEOMIN,breathing difficulties,"ck pain, muscle weakne ss injection site pain and",1,0.5490890741348267
XEOMIN,breathing difficulties,"dysphagia ck pain,",1,0.5936458110809326
XEOMIN,breathing difficulties,muscle weakne ss,1,0.5540506839752197
XEOMIN,breathing difficulties,"placebo are dysphagia ck pain, muscle weakne ss",1,0.5634401440620422
XEOMIN,breathing difficulties,"ck pain, muscle weakne ss",1,0.5812561511993408
XEOMIN,breathing difficulties,pain,0,0.5260907411575317
XEOMIN,breathing difficulties,"pain, muscle weakne ss injection site",1,0.5345380902290344
XEOMIN,breathing difficulties,dysphagia ne,0,0.6241716742515564
XEOMIN,breathing difficulties,"are dysphagia ck pain, muscle weakne",1,0.58982914686203
XEOMIN,breathing difficulties,muscle weakne ss injection site pain and,1,0.5348988175392151
XEOMIN,breathing difficulties,musculoskeletal pain,0,0.5037391185760498
XEOMIN,breathing difficulties,"pain, muscle weakne ss injection site pain",1,0.5223923921585083
XEOMIN,death,"  ).
",1,0.6060086488723755
XEOMIN,death,"  ).
 Blepharospasm The",1,0.4827721118927002
XEOMIN,death,ebo are dysphagia neck pain muscle,0,0.4907258152961731
XEOMIN,death,are dysphagia neck pain muscle weakness injection site pain,0,0.505754828453064
XEOMIN,death,"  ).
 Blepharospasm The most commonly",1,0.47690534591674805
XEOMIN,death,"musculoskeletal   ).
 Blepharospasm The most commonly",1,0.49781715869903564
XEOMIN,spread of effect,report SUS PECTED ADVERSE REACTIONS contact Merz,1,0.593366265296936
XEOMIN,spread of effect,PECTED ADVERSE REACTIONS contact Merz Pharmaceuticals LLC at or FDA,0,0.5674024224281311
XEOMIN,spread of effect,PECTED ADVERSE REACTIONS contact Merz Pharmaceuticals LLC at,0,0.5592758655548096
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,wwwfdagovmedwatch Clinical,0,0.5187588930130005
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,trials are conducted under,1,0.5298953056335449
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,are conducted,1,0.5322949290275574
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,wwwfdagovmedwatch Clinical Trials Experience clinical trials are conducted,1,0.5249632596969604
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,Clinical Trials Experience,0,0.5283603668212891
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,are conducted under widely,1,0.5986960530281067
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,Trials Experience  clinical trials are conducted under widely varying conditions adverse,1,0.6024235486984253
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,Experience  clinical trials are conducted under,1,0.5317639112472534
XEOMIN,spread from the area of injection,directly compared to  in the clinical trials of anothe r drug and,1,0.5784817337989807
XEOMIN,spread from the area of injection,are conducted under widely,1,0.5787261724472046
XEOMIN,spread from the area of injection,trials of anothe r drug,1,0.5983856916427612
XEOMIN,spread from the area of injection,directly compared to in the clinical trials,1,0.591550350189209
XEOMIN,toxin effects,in,1,0.5242084860801697
XEOMIN,toxin effects,"rates in practice.
 Cervical Dystonia",1,0.5183887481689453
XEOMIN,toxin effects,not reflect the rates in,1,0.4672171175479889
XEOMIN,toxin effects,"in practice.
 Cervical",1,0.5114426016807556
XEOMIN,toxin effects,"not reflect the rates in practice.
 Cervical Dystonia The data",1,0.5274097919464111
XEOMIN,toxin effects,rates in the,0,0.46920904517173767
XEOMIN,toxin effects,rates in practice.,1,0.4666129946708679
XEOMIN,toxin effects,"reflect the rates in practice.
 Cervical Dystonia",1,0.5312585830688477
XEOMIN,death,ents  with cervical dystonia see,1,0.4813392460346222
XEOMIN,death,trial in ents  with cervical,1,0.47068172693252563
XEOMIN,death,ents  with cervical dystonia see Clinical,1,0.47029244899749756
XEOMIN,death,cervical dystonia see Clinical Studies In this study patients received XE,0,0.5054007172584534
XEOMIN,dysphagia,"visual impairment dyspnea ngitis,",1,0.6418020725250244
XEOMIN,dysphagia,commonly observed adverse,0,0.5521720051765442
XEOMIN,dysphagia,diarrhea headache visual impairment dyspnea,0,0.6499855518341064
XEOMIN,dysphagia,ptosis dry eye dry,0,0.5257883071899414
XEOMIN,dysphagia,"visual impairment dyspnea ngitis, a nd respiratory tract",1,0.6311044692993164
XEOMIN,dysphagia,"headache visual impairment dyspnea ngitis, a nd respiratory tract",1,0.6318913102149963
XEOMIN,dysphagia,"ngitis, a",1,0.5399044752120972
XEOMIN,dysphagia,"ngitis, a nd respiratory",1,0.5636078715324402
XEOMIN,dysphagia,"impairment dyspnea ngitis, a nd respiratory tract",1,0.649933934211731
XEOMIN,Corneal exposure,( 6.1 ).,1,0.4955509901046753
XEOMIN,Corneal exposure,"is e (  6.1  ).



",1,0.49577954411506653
XEOMIN,Corneal exposure,ellar Lines The most commonly observed adverse,0,0.5733529925346375
XEOMIN,Corneal exposure,6.1 ). To report SUSPECTED ADVERSE REACTIONS,1,0.5814115405082703
XEOMIN,Corneal exposure,report,0,0.5421254634857178
XEOMIN,Corneal exposure,6.1 ). To report SUSPECTED,1,0.49719077348709106
XEOMIN,Corneal exposure,most commonly observed adverse reaction of patients and placebo,0,0.543127179145813
XEOMIN,reduced blinking,report SUSPECTED,0,0.4727528691291809
XEOMIN,reduced blinking,contact Merz Pharmaceuticals LLC 6646 or FDA at 1 FDA or wwwfdagovmedwatch Clinical,1,0.5025856494903564
XEOMIN,reduced blinking,wwwfdagovmedwatch Clinical,0,0.5231671333312988
XEOMIN,reduced blinking,at,0,0.5306379795074463
XEOMIN,reduced blinking,at 1 FDA or,1,0.5298871397972107
XEOMIN,reduced blinking,Merz Pharmaceuticals LLC,0,0.496486097574234
XEOMIN,reduced blinking,Experience Because clinic,0,0.5125226974487305
XEOMIN,corneal exposure,clinical trials,0,0.5396996736526489
XEOMIN,asthenia,cervical dystonia see Clinical tudies ( In this,1,0.5755081176757812
XEOMIN,asthenia,clinical trials,0,0.5343873500823975
XEOMIN,asthenia,tudies,1,0.5763665437698364
XEOMIN,generalized muscle weakness,"In this study, 15 patients received XEOMIN were randomized",1,0.5253200531005859
XEOMIN,generalized muscle weakness,Clinical .1) ]. In,1,0.5137031674385071
XEOMIN,diplopia,patients received XEOMIN were randomized to,1,0.4407769441604614
XEOMIN,blurred vision,study patients eceived,1,0.5437821745872498
XEOMIN,blurred vision,Clinical Studies In this,0,0.5377533435821533
XEOMIN,blurred vision,randomized to receive a total dose of Units and were randomized to,0,0.5246313810348511
XEOMIN,blurred vision,total dose of Units and were randomized,0,0.5147638320922852
XEOMIN,blurred vision,eceived XEOMIN were,1,0.5154504776000977
XEOMIN,blurred vision,Clinical Studies In this study patients r,0,0.5433968305587769
XEOMIN,ptosis,this study patients received 78 wer,1,0.5053700804710388
XEOMIN,dysphagia,receive a total dose,0,0.5532329678535461
XEOMIN,dysphagia,Units and were randomized to receive a total dose of,0,0.5073078870773315
XEOMIN,dysphagia,study patients,0,0.5256924033164978
XEOMIN,dysphagia,randomize d to,1,0.5213069915771484
XEOMIN,dysphagia,randomize d to receive a,1,0.5168686509132385
XEOMIN,dysphagia,Studies In this,0,0.5253486633300781
XEOMIN,dysphagia,patients received XEOMIN randomize d to receive,1,0.527060866355896
XEOMIN,dysphagia,total dose of,0,0.5455417633056641
XEOMIN,dysphagia,randomize,1,0.46217137575149536
XEOMIN,dysphonia,patients received XEOMIN were,0,0.47412148118019104
XEOMIN,dysphonia,to,1,0.5150046944618225
XEOMIN,dysphonia,this study patients received XEOMIN,0,0.47476866841316223
XEOMIN,dysphonia,patients received XEOMIN were to receiv e a total dose,1,0.4711337685585022
XEOMIN,dysphonia,Studies In this,0,0.49043548107147217
XEOMIN,dysarthria,total do se of,1,0.5406126976013184
XEOMIN,dysarthria,were randomized to a total do se of,1,0.4708346426486969
XEOMIN,dysarthria,were randomized to a,1,0.46865329146385193
XEOMIN,dysarthria,a total do se of,1,0.5573165416717529
XEOMIN,dysarthria,a total do se of Units and were,1,0.5376832485198975
XEOMIN,dysarthria,total do se of Units and were,1,0.524139940738678
XEOMIN,dysarthria,receive a total dose of Units,0,0.5079784393310547
XEOMIN,dysarthria,XEOMIN were randomized to a total do se of Units and,1,0.48318925499916077
XEOMIN,dysarthria,XEOMIN were randomized to a total,1,0.4758588671684265
XEOMIN,urinary incontinence,were,0,0.5028992891311646
XEOMIN,breathing difficulties,and randomized,1,0.39764273166656494
XEOMIN,breathing difficulties,patients were to years,0,0.5503659248352051
XEOMIN,breathing difficulties,"years old 53 years), and",1,0.4883439242839813
XEOMIN,breathing difficulties,years old 53,1,0.4926546812057495
XEOMIN,breathing difficulties,"53 years), and",1,0.4454096555709839
XEOMIN,breathing difficulties,were pr,1,0.4983885884284973
XEOMIN,breathing difficulties,and were pr edominantly female,1,0.4741431474685669
XEOMIN,breathing difficulties,At study baseline approximately had,0,0.492829829454422
XEOMIN,breathing difficulties,of Units XEOMINtreated patients were to,0,0.5422408580780029
XEOMIN,breathing difficulties,female and Caucasian At,0,0.49736449122428894
XEOMIN,breathing difficulties,to years old 53,1,0.4957486391067505
XEOMIN,breathing difficulties,"to years old 53 years), and were pr edominantly female",1,0.4892723560333252
XEOMIN,death,female and Caucasian At study,0,0.45046544075012207
XEOMIN,death,had severe cervical dystonia Approximatel,0,0.5313897132873535
XEOMIN,death,aseli ne approximately,1,0.4929165840148926
XEOMIN,death,had moderate and,0,0.5295973420143127
XEOMIN,death,aseli,1,0.500035285949707
XEOMIN,spread of toxin effects,Approximately of XEOMINtreated patients,0,0.5546200275421143
XEOMIN,spread of toxin effects,"study baseline y 25% had mild, 50% had",1,0.541440486907959
XEOMIN,spread of toxin effects,At study baseline y 25%,1,0.5168657302856445
XEOMIN,spread of toxin effects,"baseline y 25% had mild, 50% had moderate and had",1,0.540780782699585
XEOMIN,spread of toxin effects,"study baseline y 25% had mild, 50% had moderate",1,0.5444089770317078
XEOMIN,spread of toxin effect,musculoskeletal pain 2: Most Common TEAEs ( and Greater than,1,0.483287513256073
XEOMIN,spread of toxin effect,At study baseline y 25%,1,0.5208972692489624
XEOMIN,spread of toxin effect,pain 2: Most Common TEAEs,1,0.4962528347969055
XEOMIN,spread of toxin effect,and musculoskeletal pain 2: Most Common TEAEs ( and Greater than Placebo DoubleBlind,1,0.5181010961532593
XEOMIN,spread of toxin effect,muscle weakness injection site pain,0,0.5453945994377136
XEOMIN,spread of toxin effect,ded dysphagia neck pain muscle weakness injection site,0,0.5695317983627319
XEOMIN,spread of toxin effect,2: Most Common TEAEs ( and Greater than,1,0.5080239176750183
XEOMIN,spread of toxin effect,musculoskeletal pain 2: Most Common TEAEs ( and,1,0.47947120666503906
XEOMIN,spread of toxin effect,2: Most,1,0.4856348931789398
XEOMIN,spread of toxin effect,2: Most Common TEAEs ( and,1,0.49280768632888794
XEOMIN,Hypersensitivity reactions,         7%                Gastrointestinal,1,0.5163668394088745
XEOMIN,Hypersensitivity reactions,Musculoskeletal          7%                Gastrointestinal disorders,1,0.527076780796051
XEOMIN,Hypersensitivity reactions,pain,0,0.5572292804718018
XEOMIN,anaphylaxis,"     
 Gast rointestinal disorders",1,0.5185889005661011
XEOMIN,anaphylaxis,"     
 Gast",1,0.493188738822937
XEOMIN,anaphylaxis,"     
 Gast rointestinal",1,0.5748153924942017
XEOMIN,anaphylaxis,pain,0,0.5758615732192993
XEOMIN,anaphylaxis,"sculoskeletal      
 Gast rointestinal",1,0.5778992176055908
XEOMIN,serum sickness,pain intestinal dis,1,0.5102715492248535
XEOMIN,serum sickness,"     
 Gast rointestinal",1,0.5546908974647522
XEOMIN,serum sickness,intestinal dis,1,0.536357045173645
XEOMIN,serum sickness,pain intestinal,1,0.4958871603012085
XEOMIN,Dysphagia,blepharos pasm previously treated with onabotulinumtoxinA,1,0.5327566862106323
XEOMIN,Dysphagia,blepharos pasm previously treated with,1,0.5497443675994873
XEOMIN,Dysphagia,blepharos pasm previously treated,1,0.5586522221565247
XEOMIN,Dysphagia,Phase trial in patients blepharos pasm previously treated,1,0.5226567983627319
XEOMIN,Dysphagia,patients blepharos,1,0.5340819954872131
XEOMIN,Aspiration,XEOMIN at,1,0.5505565404891968
XEOMIN,Aspiration,Studies patients  XEOMIN at a mean dose,1,0.512209415435791
XEOMIN,Aspiration,minimum Units maximum,0,0.5118141174316406
XEOMIN,Aspiration,patients  XEOMIN at,1,0.5392035245895386
XEOMIN,dysphagia,ately 33 Units per eye minimum Units,1,0.45992201566696167
XEOMIN,dysphagia,ately 33 Units,1,0.5057910680770874
XEOMIN,dysphagia,Clinical Studies patients received XEOMIN at a mean dose of approxim,0,0.5154682993888855
XEOMIN,dysphagia,XEOMINtreated patients were to,0,0.5474245548248291
XEOMIN,dysphagia,of ately 33  Units per eye minimum,1,0.45815521478652954
XEOMIN,weaken neck muscles,age mean years predominantly,0,0.4309166967868805
XEOMIN,weaken neck muscles,mean years predominantly,0,0.41748446226119995
XEOMIN,weaken neck muscles,since diagn osis of,1,0.5613545179367065
XEOMIN,weaken neck muscles,an time since diagn osis of,1,0.5170875787734985
XEOMIN,weaken neck muscles,age mean years predominantly female Caucasian and had,0,0.4659106135368347
XEOMIN,weaken neck muscles,an time,1,0.4510956108570099
XEOMIN,weaken neck muscles,and had a an time since diagn osis,1,0.5313383340835571
XEOMIN,weaken neck muscles,and had a an time since diagn,1,0.47530999779701233
XEOMIN,weaken neck muscles,an time since,1,0.4468730092048645
XEOMIN,loss of breathing capacity,occurring in of,0,0.5735262632369995
XEOMIN,loss of breathing capacity,diagnosis of approximately years The adverse events occurring,0,0.5930127501487732
XEOMIN,loss of breathing capacity,patients and greater,1,0.5047571659088135
XEOMIN,loss of breathing capacity,OMIN-treated patients,1,0.4860890507698059
XEOMIN,loss of breathing capacity,occurring in of OMIN-treated patients and,1,0.5262887477874756
XEOMIN,breathing difficulties,headache visual impairment dyspnea,0,0.7568027973175049
XEOMIN,breathing difficulties,dry eye dry mouth diarrhea headache visual,0,0.5614392757415771
XEOMIN,breathing difficulties,one placebotreated,0,0.4474450945854187
XEOMIN,breathing difficulties,impairment dyspnea nasopharyngitis  respiratory tract inf ection No,1,0.732816219329834
XEOMIN,breathing difficulties,visual impairment dyspnea nasopharyngitis  respiratory tract inf ection No serious adverse,1,0.7120862007141113
XEOMIN,breathing difficulties,nasopharyngitis,0,0.5338537096977234
XEOMIN,breathing difficulties,diarrhea headache,0,0.492997407913208
XEOMIN,breathing difficulties,respiratory tract inf ection No,1,0.6491197347640991
XEOMIN,respiratory failure,adverse even ts occurred in patients,1,0.5751385688781738
XEOMIN,respiratory failure,erious adverse even ts occurred,1,0.5936510562896729
XEOMIN,respiratory failure,in patients,0,0.5760097503662109
XEOMIN,respiratory failure,No erious adverse even,1,0.4745909571647644
XEOMIN,respiratory failure,infection No erious adverse,1,0.5336962938308716
XEOMIN,respiratory failure,infection No erious adverse even,1,0.5106089115142822
XEOMIN,respiratory failure,visual impairment dyspnea nasopharyngitis and,0,0.6669996380805969
XEOMIN,respiratory failure,received XEOMIN one placebotreated patient,0,0.5023295879364014
XEOMIN,respiratory failure,erious adverse even ts occurred in patients who,1,0.5776243805885315
XEOMIN,dysphagia,System Organ,0,0.5108646154403687
XEOMIN,dysphagia,          DoubleBlind Phase,1,0.4897305369377136
XEOMIN,dysphagia,Trial,0,0.5231741666793823
XEOMIN,transmission of viral diseases,N with glabellar lines,0,0.48736217617988586
XEOMIN,transmission of viral diseases,adverse events in there is some basis to,1,0.5804930925369263
XEOMIN,transmission of viral diseases,is some basis to believe,1,0.49082016944885254
XEOMIN,transmission of viral diseases,there is some basis to believe there is a causal,1,0.5277020335197449
XEOMIN,Creutzfeldt-Jakob disease,drug and the occurrenc e of the adverse,1,0.5132386088371277
XEOMIN,Creutzfeldt-Jakob disease,causal relationship between he drug and the occurrenc e of the adverse event,1,0.5010141134262085
XEOMIN,Creutzfeldt-Jakob disease,is a causal,0,0.5224736928939819
XEOMIN,Creutzfeldt-Jakob disease,a causal relationship between he drug and,1,0.5099605321884155
XEOMIN,Creutzfeldt-Jakob disease,between he drug and the occurrenc,1,0.5099924802780151
XEOMIN,Creutzfeldt-Jakob disease,between he drug and the occurrenc e,1,0.5148482918739319
XEOMIN,Creutzfeldt-Jakob disease,a causal relationship between he drug and the,1,0.5086022615432739
XEOMIN,Creutzfeldt-Jakob disease,there is some,0,0.5480682849884033
XEOMIN,Creutzfeldt-Jakob disease,there is,0,0.5534199476242065
XEOMIN,CJD,of  the adverse,1,0.5268509387969971
XEOMIN,CJD,of  the adverse event Because clinical,1,0.5076635479927063
XEOMIN,CJD,under widely varying,0,0.49943986535072327
XEOMIN,CJD,is a causal relationship between the drug,0,0.5417743921279907
XEOMIN,CJD,clinical trials are conducted under,0,0.5035009384155273
XEOMIN,CJD,basis to believe there is a causal relationship between the drug and the,0,0.5502892732620239
XEOMIN,CJD,of  the adverse event Because,1,0.5128663778305054
XEOMIN,CJD,of  the,1,0.5000750422477722
QUTENZA,Application-Associated Pain,in the Application-Associated Pain see Warnings and Precautions Increase,1,0.8780636787414551
QUTENZA,Application-Associated Pain,of  the,1,0.5156913995742798
QUTENZA,Application-Associated Pain,Application-Associated Pain see Warnings,1,0.9190683364868164
QUTENZA,Application-Associated Pain,Application-Associated Pain,1,1.0
QUTENZA,Application-Associated Pain,Application-Associated Pain see,1,0.9644237756729126
QUTENZA,Application-Associated Pain,in the Application-Associated,1,0.7561401724815369
QUTENZA,Application-Associated Pain,Warnings,0,0.5813415050506592
QUTENZA,Application-Associated Pain,Increase in Blood Pressure see Warnings and,0,0.540299654006958
QUTENZA,Increase in Blood Pressure,and Increase in,1,0.7262579202651978
QUTENZA,Increase in Blood Pressure,in Blood Pressure see Warnings and,1,0.7946020364761353
QUTENZA,Increase in Blood Pressure,Increase in,1,0.745843768119812
QUTENZA,Increase in Blood Pressure,Pain see Warnings and Increase in Blood Pressure,1,0.7923216819763184
QUTENZA,Increase in Blood Pressure,Warnings and Increase in Blood Pressure see Warnings and Precautions EXCERPT,1,0.8454903364181519
QUTENZA,Increase in Blood Pressure,Increase in Blood Pressure,1,1.0
QUTENZA,Increase in Blood Pressure,Increase in Blood Pressure see Warnings and Precautions,1,0.8964426517486572
QUTENZA,Increase in Blood Pressure,Pain see Warnings and Precautions,0,0.5379440784454346
QUTENZA,application site erythema,control application site erythema application,1,0.926649808883667
QUTENZA,application site erythema,Pain see Warnings and Precautions,0,0.5495662689208984
QUTENZA,application site erythema,are,0,0.5225416421890259
QUTENZA,application site erythema,control application site erythema,1,0.9233020544052124
QUTENZA,application site erythema,site papules,0,0.7441052198410034
QUTENZA,application site erythema,pruritus and application site,0,0.8240264654159546
QUTENZA,application site erythema,pain application site pruritus and application site papules To,0,0.7696035504341125
QUTENZA,application site pain,and application site papules To report SUSPECTED,0,0.6931324005126953
QUTENZA,application site pain,application site pain application site pruritus,1,0.8646105527877808
QUTENZA,application site pruritus,application site,1,0.766069769859314
QUTENZA,application site papules,site papules,1,0.9161388874053955
QUTENZA,application site papules,ADVERSE REACTIONS,0,0.5535683631896973
QUTENZA,application site papules,contact,0,0.5148938894271851
QUTENZA,application site papules,To report SUSPECTED ADVERSE REACTIONS contact,0,0.5490700602531433
QUTENZA,application site papules,site pruritus and,0,0.7254889011383057
QUTENZA,application site papules,pruritus application site papules,1,0.9139584302902222
QUTENZA,application site papules,application site papules To report SUSPECTED ADVERSE REACTIONS,1,0.8615586757659912
QUTENZA,application site erythema,pruritus and application site papules Table,0,0.7753691673278809
QUTENZA,application site erythema,site papules Table,0,0.6788039803504944
QUTENZA,application site erythema,group application site,1,0.6976890563964844
QUTENZA,application site erythema,application site,0,0.7776039838790894
QUTENZA,application site erythema,application site erythema,1,1.0000001192092896
QUTENZA,application site erythema,in the control,0,0.48583275079727173
QUTENZA,application site erythema,application,0,0.7184333205223083
QUTENZA,application site erythema,control group application site erythema application site pain application site,1,0.8627142906188965
QUTENZA,application site erythema,control group application site erythema application,1,0.8885285258293152
QUTENZA,application site pain,an incidence,0,0.5409001111984253
QUTENZA,application site pain,site pain application,1,0.892951488494873
QUTENZA,application site pain,application site pruritus and application site papules Table summarizes all adverse,0,0.7449386715888977
QUTENZA,application site pain,application site application site,1,0.852308452129364
QUTENZA,application site pain,application site pain,1,1.0
QUTENZA,application site pain,application site pruritus and application site papules Table,0,0.7776182889938354
QUTENZA,application site pain,application site application site pain,1,0.9872874617576599
QUTENZA,application site pain,Table summarizes all,0,0.4296204447746277
QUTENZA,application site pain,group were application site application,1,0.8191518783569336
QUTENZA,application site pain,site papules Table,0,0.5493830442428589
QUTENZA,application site pruritus,application site application site pruritus,1,0.9918707609176636
QUTENZA,application site pruritus,site erythema application site application site pruritus and,1,0.9251313209533691
QUTENZA,application site pruritus,application site pruritus and application site papules Table,1,0.9262040853500366
QUTENZA,application site pruritus,control group were application site erythema application site pain,0,0.7895653247833252
QUTENZA,application site pruritus,application site pruritus and,1,0.9917286038398743
QUTENZA,application site pruritus,site pruritus and application site papules,1,0.9197262525558472
QUTENZA,application site pruritus,application site pruritus,1,0.9999998211860657
QUTENZA,application site pruritus,site,0,0.6565320491790771
QUTENZA,application site pruritus,reactions,0,0.5381360650062561
QUTENZA,application site pruritus,application site pruritus and application site,1,0.9877607822418213
QUTENZA,application site papules,application site papules Table summarizes all,1,0.8751505017280579
QUTENZA,application site papules,application site pruritus and application site,1,0.8353294134140015
QUTENZA,application site papules,were application site erythema application site pain application site,0,0.7915416955947876
QUTENZA,application site papules,site,0,0.6914087533950806
QUTENZA,application site papules,pain application site pruritus application site papules Table summarizes,1,0.8566498756408691
QUTENZA,application site reactions,majority,0,0.49186015129089355
QUTENZA,application site reactions,observed on the day of,0,0.48338472843170166
QUTENZA,application site reactions,The,0,0.5291873812675476
QUTENZA,application site reactions,group for which the incidence was greater,0,0.510326623916626
QUTENZA,application site reactions,application site,1,0.8525087237358093
QUTENZA,application site reactions,site reactions were,1,0.8350276947021484
QUTENZA,application site reactions,application site reactions were transient and,1,0.8131859302520752
QUTENZA,application site reactions,transient and,0,0.5228685736656189
QUTENZA,application site reactions,in,0,0.5130836367607117
QUTENZA,application site reactions,group The majority application,1,0.553417980670929
QUTENZA,increases in pain,increases in pain were commonly observed on the,1,0.9273181557655334
QUTENZA,increases in pain,group The majority application,1,0.4309055209159851
QUTENZA,increases in pain,and selflimited increases in pain,1,0.8855474591255188
QUTENZA,increases in pain,increases,1,0.7275830507278442
QUTENZA,Pain increases,Pain increases occurring during patch application usually,1,0.8049069046974182
QUTENZA,Pain increases,patients treated with Pain increases,1,0.8985785245895386
QUTENZA,Pain increases,Qutenza,0,0.4610285758972168
QUTENZA,Pain increases,Pain,1,0.8433629274368286
QUTENZA,Pain increases,treated with Pain increases,1,0.9466453790664673
QUTENZA,Application Site Erythema,Site Conditions,0,0.6677226424217224
QUTENZA,Application Site Erythema,Administration Site Application Site Erythema Application,1,0.9477618932723999
QUTENZA,Application Site Erythema,Application Site Erythema Application Site,1,0.9840023517608643
QUTENZA,Application Site Erythema,ders and Administration Site Application Site,1,0.7452502250671387
QUTENZA,Application Site Erythema,Site Erythema Application,1,0.964945375919342
QUTENZA,Application Site Erythema,Application Site Erythema,1,1.0000001192092896
QUTENZA,Application Site Papules,Site,0,0.6914087533950806
QUTENZA,Application Site Papules,Application Site Papules,1,1.0
QUTENZA,Application Site Papules,on Site Pruritus,0,0.7002314329147339
QUTENZA,Application Site Papules,on Site Application Site Papules Application,1,0.9402500987052917
QUTENZA,Application Site Papules,Site Application Site Papules Application Sit,1,0.9532409906387329
QUTENZA,Application Site Edema,Application Site Edema Application S,1,0.9413114786148071
QUTENZA,Application Site Edema,on Site Application Site Edema,1,0.9532694816589355
QUTENZA,Application Site Edema,on Site Application Site Edema Application,1,0.9391553401947021
QUTENZA,Application Site Edema,Application Site Edema Application,1,0.9753732085227966
QUTENZA,Application Site Edema,Site Edema,1,0.8971108794212341
QUTENZA,Application Site Edema,Site Application Site,1,0.7795531749725342
QUTENZA,Application Site Swelling,Application Site,1,0.8017745018005371
QUTENZA,Application Site Dryness,Site Application Site Dryness Infections,1,0.8860881328582764
QUTENZA,Application Site Dryness,Application Site,1,0.8171898126602173
QUTENZA,Application site urticaria,Disorders and Administration Site Application site,1,0.724094033241272
QUTENZA,Application site urticaria,Application site urticaria,1,1.000000238418579
QUTENZA,Application site urticaria,and Administration Site Application site urticaria Application,1,0.9411016702651978
QUTENZA,Application site paresthesia,Conditions Application,0,0.6619367599487305
QUTENZA,Application site paresthesia,Site Conditions Application site Application site paresthesia Application site dermatitis,1,0.8589802384376526
QUTENZA,Application site paresthesia,site paresthesia,1,0.9114612340927124
QUTENZA,Application site paresthesia,site Application,1,0.7622268795967102
QUTENZA,Application site paresthesia,Application site dermatitis Application site hyperesthesia Application site excoriation Applica,0,0.8149070739746094
QUTENZA,Application site paresthesia,Conditions Application site Application site paresthesia Application site dermatitis Application,1,0.8638476133346558
QUTENZA,Application site paresthesia,Application site Application site paresthesia,1,0.9615637063980103
QUTENZA,Application site paresthesia,Application site paresthesia Application site dermatitis Application,1,0.9114651679992676
QUTENZA,Application site paresthesia,Site Conditions Application site Application,1,0.717863142490387
QUTENZA,Application site paresthesia,Application site paresthesia Application site dermatitis,1,0.8883880376815796
QUTENZA,Application site dermatitis,Administration Site Conditions Application site urticaria Application site paresthesia,0,0.8146090507507324
QUTENZA,Application site dermatitis,Application site hyperesthesia Application site excoriation Application,0,0.7190787196159363
QUTENZA,Application site dermatitis,site dermatitis Application site hyperesthesia Application,1,0.8281766176223755
QUTENZA,Application site dermatitis,site dermatitis,1,0.8794867992401123
QUTENZA,Application site dermatitis,Application site paresthesia,0,0.734765887260437
QUTENZA,Application site dermatitis,site dermatitis Application site hyperesthesia Application site,1,0.8596051931381226
QUTENZA,Application site dermatitis,site dermatitis Application site,1,0.9627120494842529
QUTENZA,Application site dermatitis,urticaria Application site Application site,1,0.8139030933380127
QUTENZA,Application site excoriation,Application site warmth Application site anesthesia Application site,0,0.7114985585212708
QUTENZA,Application site excoriation,bruising Application site,0,0.7987383604049683
QUTENZA,Application site warmth,hyperesthesia Application,0,0.5811229944229126
QUTENZA,Application site warmth,hyperesthesia Application site excoriation,0,0.6282827854156494
QUTENZA,Application site warmth,Application site warmth Application site anesthesia,1,0.8419524431228638
QUTENZA,Application site warmth,site hyperesthesia Application site Application site warmth Application,1,0.8734183311462402
QUTENZA,Application site warmth,site anesthesia Application site bruising,0,0.6277697086334229
QUTENZA,Application site warmth,site Application site warmth,1,0.9705275297164917
QUTENZA,Application site anesthesia,Application site anesthesia,1,1.0
QUTENZA,Application site anesthesia,Application site,0,0.7833560705184937
QUTENZA,Application site bruising,inflammation Application site exfoliation Peripheral edema,0,0.7409180998802185
QUTENZA,Application site bruising,Application site Application,1,0.7805389165878296
QUTENZA,Application site bruising,edema Nervous,0,0.6084498763084412
QUTENZA,Application site bruising,site inflammation Application site exfoliation,0,0.7427597045898438
QUTENZA,Application site inflammation,Application site inflammation Application,1,0.9644604921340942
QUTENZA,Application site inflammation,site inflammation Application site exfoliation,0,0.833831787109375
QUTENZA,Application site exfoliation,Application site exfoliation,1,1.0
QUTENZA,Application site exfoliation,site inflammation Application site exfoliation,0,0.914370596408844
QUTENZA,Application site exfoliation,site Application site exfoliation Peripheral edema Nervous System Disorders,1,0.8200211524963379
QUTENZA,Application site exfoliation,sensation Peripheral sensory neu,0,0.5395961403846741
QUTENZA,Application site exfoliation,site exfoliation Peripheral edema,1,0.8141782283782959
QUTENZA,Application site exfoliation,bruising Application site Application,1,0.7448986768722534
QUTENZA,Application site exfoliation,Application site,1,0.7373605966567993
QUTENZA,Application site exfoliation,Application site,0,0.7373605966567993
QUTENZA,Application site exfoliation,Application site bruising,0,0.7555790543556213
QUTENZA,Peripheral edema,Application site inflammation Application site exfoliation,0,0.6316261291503906
QUTENZA,Peripheral edema,Peripheral edema Nervous System,1,0.882315993309021
QUTENZA,Peripheral edema,Peripheral edema Nervous System Disorders,1,0.8698493242263794
QUTENZA,Peripheral edema,site inflammation Application site Peripheral edema,1,0.8674248456954956
QUTENZA,Peripheral edema,inflammation Application site exfoliation,0,0.6317424774169922
QUTENZA,Headache,exfoliation Peripheral edema Nervous System Disorders,0,0.5559573173522949
QUTENZA,Headache,Headache Burning,1,0.8637050986289978
QUTENZA,Headache,ion site inflammation Application site exfoliation Peripheral edema Nervous System,0,0.5781432390213013
QUTENZA,Headache,inflammation,0,0.5965821743011475
QUTENZA,Headache,Headache Burning sensation,1,0.7970198392868042
QUTENZA,Headache,sensory,0,0.5573318600654602
QUTENZA,Burning sensation,System Disorders,0,0.4991549551486969
QUTENZA,Burning sensation,edema Nervous System Disorders Burning sensation Peripheral sensory neuropathy,1,0.8281432390213013
QUTENZA,Burning sensation,nflammation Application site,0,0.5186688899993896
QUTENZA,Burning sensation,Dizziness Dysgeusia Hyperesthesia Hypoesthesia,0,0.5880012512207031
QUTENZA,Burning sensation,Nervous System Disorders Headache,0,0.5343484878540039
QUTENZA,Burning sensation,Disorders Burning sensation,1,0.9247801899909973
QUTENZA,Burning sensation,Nervous System,0,0.5681043863296509
QUTENZA,Burning sensation,Peripheral edema,0,0.6192066669464111
QUTENZA,Peripheral sensory neuropathy,sensory neuropathy Dizziness Dysgeusia Hyperesthesia Hypoesthesia,1,0.7907520532608032
QUTENZA,Peripheral sensory neuropathy,sensation,0,0.6487637758255005
QUTENZA,Peripheral sensory neuropathy,exfoliation Peripheral edema Nervous System Disorders Headache Burning sensation,0,0.6773868203163147
QUTENZA,Peripheral sensory neuropathy,Burning Peripheral,1,0.6098878979682922
QUTENZA,Dizziness,Dizziness Dysgeusia Hyperesthesia Hypoesthesia Respiratory Thoracic,1,0.7736002206802368
QUTENZA,Dizziness,Dizziness Dysgeusia Hyperesthesia Hypoesthesia Respiratory,1,0.7968827486038208
QUTENZA,Dizziness,System Disorders Headache,0,0.6030982732772827
QUTENZA,Dizziness,Hyperesthesia Hypoesthesia Respiratory,0,0.6201069355010986
QUTENZA,Dizziness,Dizziness Dysgeusia Hyperesthesia Hypoesthesia,1,0.808719277381897
QUTENZA,Dizziness,Dizziness Dysgeusia Hyperesthesia,1,0.8352411389350891
QUTENZA,Dizziness,Peripheral sensory Dizziness Dysgeusia Hyperesthesia Hypoesthesia Respiratory,1,0.7713502645492554
QUTENZA,Hypoesthesia,Hypoesthesia Respiratory Thoracic and Mediastinal,1,0.8348541259765625
QUTENZA,Hypoesthesia,Peripheral,0,0.5155887603759766
QUTENZA,Hypoesthesia,Hypoesthesia Respiratory Thoracic and Mediastinal Disorders,1,0.820407509803772
QUTENZA,Hypoesthesia,Peripheral sensory neuropathy Dizziness Dysgeusia,0,0.6424340009689331
QUTENZA,Hypoesthesia,Headache Burning sensation Peripheral sensory neuropathy Dizziness Dysgeusia,0,0.6217927932739258
QUTENZA,Hypoesthesia,Dizziness,0,0.5970367193222046
QUTENZA,Hypoesthesia,neuropathy Dizziness Dysgeusia,0,0.635026216506958
QUTENZA,Hypoesthesia,Dysgeusia Hyperesthesia,0,0.6982738971710205
QUTENZA,Cough,Cough Throat,1,0.8854749798774719
QUTENZA,Cough,Cough Throat irritation Skin and Subcutaneous,1,0.7575159072875977
QUTENZA,Cough,Mediastinal Cough Throat irritation,1,0.7699124813079834
QUTENZA,Throat irritation,Hypoesthesia Respiratory Thoracic,0,0.5989103317260742
QUTENZA,Throat irritation,Hyperesthesia Hypoesthesia Respiratory Thoracic and Mediastinal,0,0.620021641254425
QUTENZA,Throat irritation,Cough,0,0.660223126411438
QUTENZA,Throat irritation,Tissue Disorders,0,0.5047013759613037
QUTENZA,Throat irritation,Throat irritation,1,1.0000001192092896
QUTENZA,sneezing,and ions (5. Increase in Blood Pressure see,1,0.5577242374420166
QUTENZA,sneezing,Throat irritation,1,0.5968732833862305
QUTENZA,sneezing,and ions (5. Increase in Blood,1,0.5403268337249756
QUTENZA,sneezing,in Blood Pressure see Warnings,0,0.5479564666748047
QUTENZA,sneezing,ions (5. Increase in,1,0.5314122438430786
QUTENZA,increases in blood pressure,"ACTIONS, contact Acorda The rapeutics at",1,0.4859826862812042
QUTENZA,increases in blood pressure,ions (5. Increase in,1,0.6959797739982605
QUTENZA,increases in blood pressure,or,0,0.490090548992157
QUTENZA,increases in blood pressure,"ACTIONS,",1,0.5011898279190063
QUTENZA,increases in blood pressure,To report SUSPECTED ADVERSE,0,0.5431854724884033
QUTENZA,coughing,in the Qutenza,0,0.4658348560333252
QUTENZA,coughing,in,0,0.5063506364822388
QUTENZA,coughing,an e greate r than in,1,0.5091184377670288
QUTENZA,coughing,e greate r than in,1,0.500671923160553
QUTENZA,coughing,at an e,1,0.5327925682067871
QUTENZA,coughing,and at an e greate,1,0.5114061832427979
QUTENZA,coughing,application site erythema application site pain application,0,0.5257390737533569
QUTENZA,coughing,than in the control,0,0.4617336392402649
QUTENZA,coughing,at an e greate r,1,0.5289815068244934
QUTENZA,sneezing,incidence greater an in th,1,0.6005303859710693
QUTENZA,sneezing,in th e,1,0.5533391237258911
QUTENZA,sneezing,and at an,0,0.5287541151046753
QUTENZA,procedural pain,day of treatme nt in patients treated,1,0.5406523942947388
QUTENZA,procedural pain,day,1,0.49004992842674255
QUTENZA,procedural pain,of treatme nt,1,0.5914673209190369
QUTENZA,procedural pain,observed on day of treatme,1,0.5517063140869141
QUTENZA,procedural pain,day of,1,0.43573522567749023
QUTENZA,procedural pain,observed on  day of treatme nt in,1,0.5459545254707336
QUTENZA,increases in blood pressure,"reactions with a maximum ntensity of ""mild"" or ""mode rate",1,0.5556598901748657
QUTENZA,increases in blood pressure,day of,1,0.42484211921691895
QUTENZA,Increases in blood pressure,in,0,0.5081762671470642
QUTENZA,Increases in blood pressure,"Qutenza group than the Control group) 
 Body S ystemPreferred Term",1,0.5148797035217285
QUTENZA,increases in pain,Disorders and Administration Site Conditions,0,0.5812897682189941
QUTENZA,increases in pain,"Control tes(N = 495)%   
 General Disorders and",1,0.559457540512085
QUTENZA,increases in pain,Body,0,0.544708251953125
QUTENZA,increases in pain,tes(N = 495)% General Disorders and Administration,1,0.5668827295303345
QUTENZA,increases in pain,"minutesN Control tes(N = 495)%   
 General Disorders",1,0.5496838092803955
QUTENZA,increases in pain,Qutenza minutesN,0,0.4647037982940674
QUTENZA,increases in pain,General Disorders and Administration,0,0.5793454647064209
QUTENZA,increases in pain,tes(N = 495)% General Disorders and,1,0.5695913434028625
QUTENZA,increases in pain,"Term Qutenza minutesN Control tes(N = 495)%   
",1,0.4655991792678833
QUTENZA,adverse cardiovascular effects,                     42        Application,1,0.46220678091049194
ZYTIGA,Hypertension,of the Hypertension Hypokalemia and Fluid Retention,1,0.7458072900772095
ZYTIGA,Hypertension,                     42        Application,1,0.4969874918460846
ZYTIGA,Hypertension,Hypertension Hypokalemia and Fluid Retention due,1,0.7514136433601379
ZYTIGA,Hypertension,sections of the Hypertension Hypokalemia and Fluid,1,0.7435660362243652
ZYTIGA,Hypertension,Hypertension Hypokalemia,1,0.8087964653968811
ZYTIGA,Hypertension,more detail in other sections of,0,0.5136115550994873
ZYTIGA,Hypertension,Mineralocorticoid Excess seeWarnings,0,0.648299515247345
ZYTIGA,Hypertension,Hypertension Hypokalemia and Fluid,1,0.7742840051651001
ZYTIGA,Hypertension,Hypertension Hypokalemia and Fluid Retention,1,0.7566090822219849
ZYTIGA,Hypertension,more detail in other sections of the,0,0.5064883828163147
ZYTIGA,Hypertension,of the Hypertension Hypokalemia and,1,0.7836465835571289
ZYTIGA,Hypokalemia,Fluid Retention due to Mineralocorticoid Excess seeWarnings and Precautions Adr,0,0.6102025508880615
ZYTIGA,Hypokalemia,Hypokalemia and Fluid Retention due to,1,0.8553208112716675
ZYTIGA,Hypokalemia,Hypokalemia and Fluid Retention,1,0.8714654445648193
ZYTIGA,Hypokalemia,following are discussed in,0,0.4978240132331848
ZYTIGA,Hypokalemia,due to Mineralocorticoid,0,0.646910548210144
ZYTIGA,Hypokalemia,labeling,0,0.4707198739051819
ZYTIGA,Hypokalemia,Hypokalemia and,1,0.952055037021637
ZYTIGA,Fluid Retention,due to Mineralocorticoid Excess seeWarnings and Precautions,0,0.6004692316055298
ZYTIGA,Adrenocortical Insufficiency,seeWarnings,0,0.48945701122283936
ZYTIGA,Adrenocortical Insufficiency,Precautions Hepatotoxicity seeWarnings and,0,0.5097393989562988
ZYTIGA,Adrenocortical Insufficiency,Precautions Hepatotoxicity seeWarnings,0,0.5127670168876648
ZYTIGA,Hepatotoxicity,Hepatotoxicity,1,1.0
ZYTIGA,Hepatotoxicity,Hepatotoxicity seeWarnings,1,0.900870144367218
ZYTIGA,Hepatotoxicity,seeWarnings and Hepatotoxicity seeWarnings and Precautions,1,0.8079724311828613
ZYTIGA,Hepatotoxicity,d Precautions Adrenocortical Insufficiency seeWarnings,0,0.5627624988555908
ZYTIGA,Hepatotoxicity,Precautions Adrenocortical Insufficiency seeWarnings and,0,0.5586696863174438
ZYTIGA,Hepatotoxicity,Insufficiency seeWarnings and Hepatotoxicity,1,0.8088628053665161
ZYTIGA,Hepatotoxicity,Hepatotoxicity seeWarnings and,1,0.9024435877799988
ZYTIGA,Hepatotoxicity,most common adverse reactions,0,0.6129553318023682
ZYTIGA,fatigue,fatigue joint swelling or,1,0.7964791059494019
ZYTIGA,fatigue,fatigue joint swelling or discomfort edema,1,0.7777146100997925
ZYTIGA,fatigue,joint swelling or discomfort,0,0.6104898452758789
ZYTIGA,joint swelling,hypertension dyspnea,0,0.5107597708702087
ZYTIGA,joint swelling,urinary,0,0.5347222089767456
ZYTIGA,joint swelling,joint swelling,1,0.9999998211860657
ZYTIGA,joint swelling,joint swelling or discomfort,1,0.947035014629364
ZYTIGA,joint swelling,Precautions,0,0.5719364285469055
ZYTIGA,edema,edema hot flush diarrhea vomiting cough,1,0.7762387990951538
ZYTIGA,edema,flush diarrhea vomiting cough hypertension dyspnea,0,0.6107335090637207
ZYTIGA,edema,joint swelling or edema hot flush,1,0.7936067581176758
ZYTIGA,edema,edema hot flush diarrhea vomiting,1,0.7665978670120239
ZYTIGA,edema,or edema hot flush diarrhea vomiting cough,1,0.7657490968704224
ZYTIGA,hot flush,or discomfort hot flush,1,0.8926018476486206
ZYTIGA,hot flush,edema hot flush diarrhea vomiting,1,0.7949696779251099
ZYTIGA,diarrhea,diarrhea vomiting cough hypertension dyspnea urinary,1,0.796384334564209
ZYTIGA,diarrhea,edema hot flush diarrhea vomiting,1,0.7402688264846802
ZYTIGA,diarrhea,reactions are fatigue joint swelling or discomfort,0,0.5370209217071533
ZYTIGA,diarrhea,urinary tract infection and contusion The,0,0.5799405574798584
ZYTIGA,cough,reactions are fatigue joint,0,0.5596132278442383
ZYTIGA,hypertension,diarrhea vomiting hypertension dyspnea urinary tract infection,1,0.6928665637969971
ZYTIGA,hypertension,reactions are fatigue joint,0,0.5152814984321594
ZYTIGA,hypertension,vomiting hypertension dyspnea,1,0.7112700939178467
ZYTIGA,dyspnea,vomiting cough dyspnea urinary tract infection and contusion,1,0.6657669544219971
ZYTIGA,dyspnea,reactions are fatigue joint,0,0.5533830523490906
ZYTIGA,dyspnea,dyspnea urinary,1,0.879477858543396
ZYTIGA,urinary tract infection,hypertension urinary tract infection,1,0.841107189655304
ZYTIGA,urinary tract infection,vomiting cough hypertension urinary tract infection,1,0.7807039022445679
ZYTIGA,contusion,flush diarrhea vomiting cough hypertension dyspnea urinary tract infection,0,0.490043044090271
ZYTIGA,contusion,contusion The,1,0.976855993270874
ZYTIGA,contusion,The most common laboratory abnormalities are,0,0.46168768405914307
ZYTIGA,contusion,contusion The most common,1,0.8578456044197083
ZYTIGA,anemia,common laboratory abnormalities anemia elevated alkaline,1,0.7462897896766663
ZYTIGA,anemia,contusion The most common,1,0.4921429455280304
ZYTIGA,anemia,and contusion The most,0,0.501365065574646
ZYTIGA,anemia,anemia elevated alkaline phosphatase hypertriglyceridemia,1,0.723438560962677
ZYTIGA,anemia,alkaline phosphatase,0,0.5876822471618652
ZYTIGA,elevated alkaline phosphatase,hypercholesterolemia hyperglycemia elevated AST,0,0.6656023263931274
ZYTIGA,elevated alkaline phosphatase,elevated alkaline phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia,1,0.8501396179199219
ZYTIGA,elevated alkaline phosphatase,hypertriglyceridemia lymphopenia hypercholesterolemia hyperglycemia elevated,0,0.6254748106002808
ZYTIGA,elevated alkaline phosphatase,laboratory,0,0.5196064710617065
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia lymphopenia hypercholesterolemia hyperglycemia elevated AST,1,0.8181837797164917
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia lymphopenia hypercholesterolemia,1,0.836529016494751
ZYTIGA,hypertriglyceridemia,lymphopenia hypercholesterolemia hyperglycemia elevated AST,0,0.7435706853866577
ZYTIGA,hypertriglyceridemia,hypercholesterolemia hyperglycemia elevated AST hypophosphatemia elevated,0,0.7403085231781006
ZYTIGA,lymphopenia,elevated ALT,0,0.5310474634170532
ZYTIGA,lymphopenia,abnormalities are anemia elevated alkaline phosphatase hypertriglyceridemia,0,0.5984102487564087
ZYTIGA,lymphopenia,lymphopenia hypercholesterolemia,1,0.844807505607605
ZYTIGA,lymphopenia,lymphopenia hypercholesterolemia hyperglycemia elevated AST,1,0.7619579434394836
ZYTIGA,hyperglycemia,anemia elevated,0,0.6410377025604248
ZYTIGA,hypophosphatemia,hypophosphatemia,1,1.0000001192092896
ZYTIGA,hypophosphatemia,hypophosphatemia elevated ALT,1,0.8336353898048401
ZYTIGA,elevated ALT,elevated ALT and,1,0.9747697114944458
ZYTIGA,elevated ALT,elevated AST elevated ALT and hypokalemia To report SUSPECTED,1,0.7490689754486084
ZYTIGA,elevated ALT,elevated ALT and hypokalemia To report,1,0.7855024337768555
ZYTIGA,elevated ALT,report,0,0.5292840600013733
ZYTIGA,elevated ALT,AST elevated,1,0.7853437662124634
ZYTIGA,elevated ALT,ADVERSE REACTIONS contact Janssen Biotech Inc at,0,0.5207185745239258
ZYTIGA,elevated ALT,To report SUSPECTED ADVERSE REACTIONS contact Janssen Biotech,0,0.5239121317863464
ZYTIGA,elevated ALT,elevated ALT,1,0.9999998807907104
ZYTIGA,elevated ALT,elevated ALT and hypokalemia To report SUSPECTED,1,0.7736238241195679
ZYTIGA,elevated ALT,elevated AST elevated ALT,1,0.8784654140472412
ZYTIGA,hypokalemia,hypokalemia To,1,0.9379230737686157
ZYTIGA,joint swelling,acetate arm were joint,1,0.7086827754974365
ZYTIGA,joint swelling,joint swelling or,1,0.9737367033958435
ZYTIGA,joint swelling,flush diarrhea vomiting cough hypertension dyspnea urinary,0,0.5197367072105408
ZYTIGA,joint swelling,were,0,0.4680904746055603
ZYTIGA,joint swelling,clinical trials that occurred more commonly in the abiraterone acetate arm,0,0.5280649662017822
ZYTIGA,joint swelling,edema hot flush diarrhea vomiting cough hypertension dyspnea urinary tract in,0,0.6082408428192139
ZYTIGA,joint swelling,abiraterone acetate arm were,0,0.567076563835144
ZYTIGA,joint swelling,were joint swelling or,1,0.9476568102836609
ZYTIGA,edema,vomiting,0,0.5595202445983887
ZYTIGA,edema,edema hot flush,1,0.8311785459518433
ZYTIGA,hot flush,infection,0,0.5244804620742798
ZYTIGA,hot flush,cough,0,0.5121049880981445
ZYTIGA,hot flush,vomiting cough hypertension dyspnea urinary tract infection,0,0.6245918273925781
ZYTIGA,diarrhea,hot diarrhea vomiting cough hypertension dyspnea,1,0.7843031883239746
ZYTIGA,diarrhea,vomiting cough hypertension dyspnea urinary tract infection,0,0.6536754965782166
ZYTIGA,diarrhea,abiraterone acetate,0,0.4932340383529663
ZYTIGA,diarrhea,or discomfort edema,0,0.5856654644012451
ZYTIGA,diarrhea,or discomfort edema hot diarrhea vomiting cough hypertension,1,0.7525779008865356
ZYTIGA,diarrhea,or discomfort,0,0.5818447470664978
ZYTIGA,vomiting,vomiting cough hypertension dyspnea,1,0.794523298740387
ZYTIGA,vomiting,vomiting cough hypertension dyspnea urinary,1,0.7774802446365356
ZYTIGA,vomiting,most common,0,0.5076273679733276
ZYTIGA,vomiting,dyspnea urinary tract infection and contusion The most common laborator,0,0.5673487186431885
ZYTIGA,vomiting,discomfort edema,0,0.5617491006851196
ZYTIGA,cough,and contusion The,0,0.5134639739990234
ZYTIGA,cough,most common,0,0.521499752998352
ZYTIGA,cough,cough hypertension dyspnea,1,0.8026391267776489
ZYTIGA,cough,and contusion The most common,0,0.5002955198287964
ZYTIGA,cough,dyspnea,0,0.6503340005874634
ZYTIGA,cough,cough hypertension dyspnea urinary tract,1,0.7565127611160278
ZYTIGA,cough,cough hypertension,1,0.8215840458869934
ZYTIGA,cough,vomiting,0,0.6370449066162109
ZYTIGA,hypertension,vomiting,0,0.5085110664367676
ZYTIGA,hypertension,hypertension dyspnea urinary,1,0.7801080346107483
ZYTIGA,hypertension,hypertension dyspnea urinary tract infection,1,0.7488709688186646
ZYTIGA,hypertension,hypertension dyspnea,1,0.7981570959091187
ZYTIGA,dyspnea,dyspnea urinary tract,1,0.8462398648262024
ZYTIGA,dyspnea,dyspnea urinary tract infection and contusion,1,0.7468822002410889
ZYTIGA,dyspnea,fatigue joint swelling or discomfort edema,0,0.5678765773773193
ZYTIGA,dyspnea,diarrhea vomiting cough dyspnea,1,0.736700177192688
ZYTIGA,dyspnea,common laboratory abnormalities,0,0.5383021831512451
ZYTIGA,urinary tract infection,tract infection and contusion,1,0.703900158405304
ZYTIGA,urinary tract infection,urinary tract infection,1,1.000000238418579
ZYTIGA,urinary tract infection,urinary tract infection and,1,0.9348657727241516
ZYTIGA,urinary tract infection,most common laboratory abnormalities reported in the two randomized,0,0.5344811677932739
ZYTIGA,contusion,dyspnea urinary tract infection contusion The most common laboratory,1,0.6966457962989807
ZYTIGA,contusion,most common laboratory abnormalities reported in the two randomized,0,0.45907533168792725
ZYTIGA,contusion,rt edema hot flush diarrhea,0,0.48427024483680725
ZYTIGA,contusion,randomized,0,0.5012089014053345
ZYTIGA,contusion,contusion The most,1,0.9071968793869019
ZYTIGA,contusion,urinary tract infection contusion The,1,0.7940020561218262
ZYTIGA,contusion,infection and,0,0.5809546709060669
ZYTIGA,contusion,contusion The most common laboratory,1,0.8190841674804688
ZYTIGA,anemia,elevated,0,0.5247365236282349
ZYTIGA,anemia,elevated alkaline phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia,0,0.5766583681106567
ZYTIGA,anemia,acetate arm,0,0.5267397165298462
ZYTIGA,anemia,anemia,1,1.0
ZYTIGA,anemia,the abiraterone acetate arm anemia elevated alkaline,1,0.7020039558410645
ZYTIGA,anemia,commonly,0,0.5206304788589478
ZYTIGA,anemia,anemia elevated,1,0.8546483516693115
ZYTIGA,elevated alkaline phosphatase,hypercholesterolemia hyperglycemia elevated,0,0.6500347256660461
ZYTIGA,elevated alkaline phosphatase,abiraterone acetate arm were elevated alkaline phosphatase hypertriglyceridemia lymphopenia,1,0.7431367635726929
ZYTIGA,elevated alkaline phosphatase,more,0,0.5184345245361328
ZYTIGA,elevated alkaline phosphatase,trials that occurred more commonly in the,0,0.49858739972114563
ZYTIGA,elevated alkaline phosphatase,that occurred more commonly in the abiraterone acetate arm,0,0.5446991920471191
ZYTIGA,elevated alkaline phosphatase,were elevated alkaline phosphatase hypertriglyceridemia lymphopenia,1,0.8098892569541931
ZYTIGA,elevated alkaline phosphatase,alkaline phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia,1,0.81043541431427
ZYTIGA,elevated alkaline phosphatase,occurred more commonly in the abiraterone,0,0.5504550933837891
ZYTIGA,elevated alkaline phosphatase,alkaline phosphatase hypertriglyceridemia lymphopenia,1,0.7885375022888184
ZYTIGA,elevated alkaline phosphatase,arm were elevated alkaline phosphatase hypertriglyceridemia,1,0.8602476119995117
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia,1,1.0
ZYTIGA,hypertriglyceridemia,phosphatase,0,0.49921104311943054
ZYTIGA,hypertriglyceridemia,AST hypophosphatemia,0,0.5381368398666382
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia lymphopenia hypercholesterolemia hyperglycemia,1,0.8325043320655823
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia lymphopenia hypercholesterolemia hyperglycemia elevated,1,0.8432122468948364
ZYTIGA,hypertriglyceridemia,elevated AST hypophosphatemia elevated ALT,0,0.5970422029495239
ZYTIGA,lymphopenia,lymphopenia hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1,0.7661398649215698
ZYTIGA,lymphopenia,alkaline phosphatase lymphopenia hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1,0.7151579856872559
ZYTIGA,hypercholesterolemia,hypercholesterolemia hyperglycemia,1,0.8872829675674438
ZYTIGA,hypercholesterolemia,hypercholesterolemia hyperglycemia elevated AST hypophosphatemia elevated,1,0.7896319031715393
ZYTIGA,hypercholesterolemia,hypercholesterolemia hyperglycemia elevated AST,1,0.7836296558380127
ZYTIGA,hypercholesterolemia,alkaline phosphatase hypertriglyceridemia,0,0.7014949321746826
ZYTIGA,hypercholesterolemia,alkaline phosphatase hypertriglyceridemia hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1,0.7265385985374451
ZYTIGA,hypercholesterolemia,hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1,0.7806227207183838
ZYTIGA,hyperglycemia,hyperglycemia,1,1.0000001192092896
ZYTIGA,hyperglycemia,hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1,0.758903980255127
ZYTIGA,hyperglycemia,lymphopenia hypercholesterolemia,0,0.6326426267623901
ZYTIGA,hyperglycemia,hyperglycemia elevated AST hypophosphatemia elevated ALT,1,0.7765777111053467
ZYTIGA,hyperglycemia,elevated,0,0.6195037364959717
ZYTIGA,hyperglycemia,hyperglycemia elevated AST,1,0.8256328105926514
ZYTIGA,elevated AST,elevated AST,1,1.0
ZYTIGA,elevated AST,Study Metastatic,0,0.5673839449882507
ZYTIGA,elevated AST,elevated AST hypophosphatemia elevated ALT and hypokalemia,1,0.7929448485374451
ZYTIGA,elevated AST,lymphopenia,0,0.5485919713973999
ZYTIGA,elevated AST,phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia elevated,1,0.6666251420974731
ZYTIGA,elevated AST,lymphopenia hypercholesterolemia elevated AST hypophosphatemia,1,0.7280770540237427
ZYTIGA,elevated AST,lymphopenia hypercholesterolemia elevated AST,1,0.8267771601676941
ZYTIGA,hypophosphatemia,hypercholesterolemia hyperglycemia elevated hypophosphatemia elevated ALT and hypokalemia,1,0.7396345138549805
ZYTIGA,hypophosphatemia,phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia elevated,1,0.6323696374893188
ZYTIGA,hypophosphatemia,AST,0,0.43924468755722046
ZYTIGA,hypophosphatemia,hypophosphatemia elevated ALT and,1,0.8439196348190308
ZYTIGA,hypophosphatemia,ALT and hypokalemia Study Metastatic CRPC Following Chemotherapy,0,0.6017417907714844
ZYTIGA,hypophosphatemia,hypophosphatemia elevated,1,0.9029968976974487
ZYTIGA,elevated ALT,hypercholesterolemia hyperglycemia elevated AST elevated ALT,1,0.7588475346565247
ZYTIGA,elevated ALT,elevated ALT and hypokalemia Study Metastatic CRPC,1,0.6732890605926514
ZYTIGA,elevated ALT,Study Metastatic,0,0.5441219210624695
ZYTIGA,Joint swelling,tissue disorders,0,0.6237209439277649
ZYTIGA,Joint swelling,Joint swelling discomfort M,1,0.9210324287414551
ZYTIGA,Joint swelling,ective tissue disorders,0,0.627878725528717
ZYTIGA,Urinary tract infection,d Urinary tract infection Upper resp,1,0.8404186964035034
ZYTIGA,Urinary tract infection,ective tissue disorders,0,0.5405268669128418
ZYTIGA,Urinary tract infection,d,0,0.5340964198112488
ZYTIGA,chest discomfort,pain,0,0.690449595451355
ZYTIGA,chest discomfort,chest discomfort,1,0.9999999403953552
ZYTIGA,chest discomfort,or,0,0.4829446077346802
ZYTIGA,low serum phosphorus,serum phosphorus and,1,0.8913575410842896
ZYTIGA,low serum phosphorus,Study low serum phosphorus,1,0.9376496076583862
ZYTIGA,low serum phosphorus,equal to rate in the ZYTIGA arm,0,0.4914189279079437
ZYTIGA,low serum phosphorus,serum phosphorus and low potassium occurred at,1,0.8855429887771606
ZYTIGA,low potassium,occurred at a greater than or equal to rate,0,0.47272568941116333
ZYTIGA,low potassium,interest,0,0.48294597864151
ZYTIGA,low potassium,low serum phosphorus low,1,0.6868916749954224
ZYTIGA,low potassium,of interest,0,0.4621243476867676
ZYTIGA,low potassium,ZYTIGA,0,0.4378398656845093
ZYTIGA,low potassium,shows laboratory abnormalities of interest from Study Grade low serum,0,0.6176073551177979
ZYTIGA,low potassium,low potassium occurred at a greater,1,0.8954810500144958
ZYTIGA,low potassium,at a greater than or equal to rate in the ZYTIGA arm,0,0.4918522238731384
ZYTIGA,low potassium,low potassium occurred at a greater than,1,0.8782066702842712
ZYTIGA,Hypertriglyceridemia,Hypertriglyceridemia High,1,0.9426175951957703
ZYTIGA,Hypertriglyceridemia,All Grades Grade,0,0.44449010491371155
ZYTIGA,lymphopenia,placebo in Study lymphopenia hyperglycemia and high alanine aminotransferase,1,0.7379766702651978
ZYTIGA,lymphopenia,All Grades Grade,0,0.4988473653793335
ZYTIGA,lymphopenia,lymphopenia hyperglycemia and high,1,0.840770959854126
ZYTIGA,lymphopenia,lymphopenia hyperglycemia and high alanine,1,0.8097370862960815
ZYTIGA,hyperglycemia,hyperglycemia and high alanine,1,0.8348784446716309
ZYTIGA,hyperglycemia,Study Grade hyperglycemia and high alanine,1,0.8018534183502197
ZYTIGA,hyperglycemia,placebo in Study Grade hyperglycemia and high,1,0.8027492761611938
ZYTIGA,hyperglycemia,hyperglycemia and high alanine aminotransferase occurred,1,0.8006844520568848
ZYTIGA,hyperglycemia,hyperglycemia and high,1,0.9084573984146118
ZYTIGA,hyperglycemia,and high alanine aminotransferase occurred at a greater than rate in the,0,0.6505876779556274
ZYTIGA,hyperglycemia,aminotransferase occurred at a greater than,0,0.6135645508766174
ZYTIGA,high alanine aminotransferase,ZYTIGA arm compared,0,0.5141087174415588
ZYTIGA,high alanine aminotransferase,greater than rate in the ZYTIGA arm,0,0.6076300144195557
ZYTIGA,high alanine aminotransferase,arm,0,0.516731858253479
ZYTIGA,high alanine aminotransferase,to placebo in Study Grade,0,0.5220140814781189
ZYTIGA,high alanine aminotransferase,high alanine aminotransferase occurred at a greater than,1,0.951930046081543
ZYTIGA,high alanine aminotransferase,lymphopenia hyperglycemia high,1,0.6594470143318176
ZYTIGA,high alanine aminotransferase,at,0,0.6066396236419678
ZYTIGA,cardiac failure,data for studies cardiac failure occurred more commonly in patients,1,0.7892481088638306
ZYTIGA,cardiac failure,at,0,0.5113077163696289
ZYTIGA,cardiac failure,data for studies and,0,0.5360325574874878
ZYTIGA,cardiac failure,cardiac failure occurred more,1,0.880038857460022
ZYTIGA,cardiac failure,cardiac failure occurred more commonly in,1,0.8144856095314026
ZYTIGA,cardiac failure,combined data for studies cardiac,1,0.6922365427017212
ZYTIGA,cardiac failure,cardiac failure occurred more commonly,1,0.8343597650527954
ZYTIGA,cardiac failure,cardiac,1,0.7925599813461304
ZYTIGA,cardiac failure,versus cardiac failure occurred,1,0.8846657276153564
ZYTIGA,cardiac failure,placebo,0,0.5415149927139282
ZYTIGA,cardiac failure,cardiac failure occurred,1,0.9148013591766357
ZYTIGA,cardiac failure,patients taking ZYTIGA and led to treatment discontinuations and,0,0.5408167839050293
ZYTIGA,deaths,deaths,1,0.9999999403953552
ZYTIGA,deaths,to treatment discontinuations deaths Grade cardiac failure occurred in,1,0.6516801714897156
ZYTIGA,deaths,led to treatment discontinuations deaths Grade cardiac failure occurred,1,0.6574894785881042
ZYTIGA,deaths,patients,0,0.5095301270484924
ZYTIGA,deaths,deaths Grade cardiac,1,0.7486095428466797
ZYTIGA,deaths,taking placebo There were no treatment dis,0,0.48546215891838074
ZYTIGA,cardiac failure,occurred in of patients taking placebo There were no treatment discontinuations and one death,0,0.4935535788536072
ZYTIGA,cardiac failure,and deaths cardiac failure occurred in of patients taking,1,0.8106076717376709
ZYTIGA,cardiac failure,and deaths cardiac,1,0.7415264844894409
ZYTIGA,cardiac failure,treatment discontinuations and deaths cardiac failure occurred in of,1,0.7541511058807373
ZYTIGA,cardiac failure,cardiac failure occurred in of patients taking,1,0.8258633017539978
ZYTIGA,cardiac failure,and,0,0.5432097911834717
ZYTIGA,cardiac failure,cardiac failure,1,0.9999998211860657
ZYTIGA,cardiac failure,cardiac failure occurred in of patients,1,0.8596728444099426
ZYTIGA,death,death due to cardiac,1,0.7329674363136292
ZYTIGA,death,treatment discontinuations and death due to cardiac failure in,1,0.6316285729408264
ZYTIGA,death,discontinuations and death due to cardiac failure in,1,0.6662690043449402
ZYTIGA,death,majority,0,0.5077160596847534
ZYTIGA,death,and death due,1,0.8230299353599548
ZYTIGA,death,discontinuations and death due to cardiac failure,1,0.6739931702613831
ZYTIGA,cardiac failure,of patients taking placebo There were no treatment discontinuations,0,0.4582371115684509
ZYTIGA,cardiac failure,in the placebo group In Study and the majority of arrhythmias were grade or,0,0.5806660056114197
ZYTIGA,cardiac failure,and one death due cardiac,1,0.7060303092002869
ZYTIGA,cardiac failure,to,0,0.5444164276123047
ZYTIGA,cardiac failure,There were no treatment discontinuations and one death due to,0,0.5261889696121216
ZYTIGA,cardiac failure,due cardiac failure in the placebo group In,1,0.7695096135139465
ZYTIGA,cardiac failure,cardiac failure in the placebo group,1,0.772668182849884
ZYTIGA,cardiac failure,group In Study and the majority of,0,0.47421860694885254
ZYTIGA,arrhythmias,arrhythmias were grade,1,0.8696927428245544
ZYTIGA,arrhythmias,Study and the majority arrhythmias were grade or There was,1,0.8071855902671814
ZYTIGA,arrhythmias,Study and the majority arrhythmias,1,0.8294539451599121
ZYTIGA,arrhythmias,arrhythmias were,1,0.9376112222671509
ZYTIGA,arrhythmias,patient with sudden,0,0.6338818073272705
ZYTIGA,arrhythmias,the placebo group In Study,0,0.5110112428665161
ZYTIGA,death,in the ZYTIGA arms and no deaths in,0,0.5630323886871338
ZYTIGA,death,no,0,0.5774315595626831
ZYTIGA,death,death,1,0.9999998807907104
ZYTIGA,death,death associated with arrhythmia and one,1,0.7081955671310425
ZYTIGA,death,In Study and,0,0.5148959159851074
ZYTIGA,death,e placebo group In Study and the majority,0,0.4663085341453552
ZYTIGA,death,death associated with arrhythmia and,1,0.7139641046524048
ZYTIGA,death,death associated with,1,0.8348889946937561
ZYTIGA,death,in the ZYTIGA arms and,0,0.4965577721595764
ZYTIGA,arrhythmia,and no deaths in the placebo arms,0,0.537075400352478
ZYTIGA,arrhythmia,arrhythmia and one,1,0.8952042460441589
ZYTIGA,arrhythmia,was one death associated,0,0.5550121665000916
ZYTIGA,arrhythmia,arrhythmia and one patient with sudden,1,0.8525120615959167
ZYTIGA,arrhythmia,arrhythmia,1,0.9999998211860657
ZYTIGA,arrhythmia,arrhythmia and,1,0.9363540410995483
ZYTIGA,sudden death,patient sudden,1,0.7399468421936035
ZYTIGA,sudden death,arrhythmias were grade or There was one death associated with arrhythmia and one patient,0,0.7461262345314026
ZYTIGA,sudden death,sudden,1,0.7507690191268921
ZYTIGA,sudden death,with arrhythmia and,0,0.7042931318283081
ZYTIGA,sudden death,patient sudden death,1,0.8828504085540771
ZYTIGA,sudden death,and one patient sudden death,1,0.8247847557067871
ZYTIGA,sudden death,and one patient sudden,1,0.6660997271537781
ZYTIGA,sudden death,one patient sudden,1,0.6770443916320801
ZYTIGA,sudden death,patient sudden death in the ZYTIGA arms,1,0.7602159380912781
ZYTIGA,deaths,deaths in the placebo arms,1,0.6908823847770691
ZYTIGA,deaths,due to cardiorespiratory arrest in,0,0.5554836988449097
ZYTIGA,deaths,arms and deaths in the placebo arms There,1,0.6309243440628052
ZYTIGA,deaths,deaths in the,1,0.9474965333938599
ZYTIGA,deaths,arrest,0,0.4569488763809204
ZYTIGA,deaths,and deaths in the,0,0.8985113501548767
ZYTIGA,deaths,and deaths in the placebo arms,0,0.6798673868179321
ZYTIGA,deaths,in the ZYTIGA arms and no deaths in the,0,0.5721120834350586
ZYTIGA,deaths,deaths due to,1,0.8684725761413574
ZYTIGA,deaths,placebo arms There deaths due,1,0.6712511777877808
ZYTIGA,deaths,There deaths due to cardiorespiratory arrest in,1,0.7256331443786621
ZYTIGA,deaths,the placebo arms There deaths due,1,0.6591153144836426
ZYTIGA,deaths,deaths due to cardiorespiratory arrest in,1,0.7255078554153442
ZYTIGA,deaths,There deaths due to,1,0.8664491176605225
ZYTIGA,cardiorespiratory arrest,arms and no,0,0.5436981916427612
ZYTIGA,cardiorespiratory arrest,arms and,0,0.5552955865859985
ZYTIGA,cardiorespiratory arrest,due cardiorespiratory arrest in the ZYTIGA arms and,1,0.8512778282165527
ZYTIGA,deaths,deaths in,1,0.9592404365539551
ZYTIGA,deaths,bo arms There were deaths,0,0.7364249229431152
ZYTIGA,deaths,bo arms There were deaths due to cardiorespiratory arrest in,0,0.7195050120353699
ZYTIGA,Myocardial ischemia,arms,0,0.5135642886161804
ZYTIGA,Myocardial ischemia,deaths in,0,0.48777511715888977
ZYTIGA,Myocardial ischemia,in the placebo Myocardial,1,0.734534740447998
ZYTIGA,Myocardial ischemia,Myocardial,1,0.8381391763687134
ZYTIGA,Myocardial ischemia,Myocardial ischemia or,1,0.9374614357948303
ZYTIGA,Myocardial ischemia,Myocardial ischemia or myocardial infarction,1,0.8908873796463013
ZYTIGA,Myocardial ischemia,the placebo Myocardial ischemia or myocardial,1,0.825016975402832
ZYTIGA,Myocardial ischemia,infarction led to death in,0,0.6404141187667847
ZYTIGA,Myocardial ischemia,in the placebo Myocardial ischemia or myocardial infarction,1,0.8071640729904175
ZYTIGA,myocardial infarction,placebo arms Myocardial ischemia myocardial infarction led to,1,0.7680801153182983
ZYTIGA,myocardial infarction,Myocardial ischemia or,1,0.8110307455062866
ZYTIGA,myocardial infarction,deaths in the ZYTIGA arms,0,0.5021818280220032
ZYTIGA,death,Myocardial ischemia,0,0.5823484659194946
ZYTIGA,death,death in,1,0.8954504132270813
ZYTIGA,death,myocardial infarction led death in patients,1,0.6653950214385986
ZYTIGA,death,Post Marketing,0,0.4866921007633209
ZYTIGA,deaths,Experience The following additional adverse,0,0.5744725465774536
ZYTIGA,deaths,the placebo arms deaths in the ZYTIGA,1,0.6294703483581543
ZYTIGA,non-infectious pneumonitis,Disorders,0,0.5454138517379761
ZYTIGA,myopathy,myopathy,1,1.0000001192092896
ZYTIGA,myopathy,myopathy including rhabdomyolysis,1,0.8780083060264587
ZYTIGA,Mineralocorticoid excess,discu,0,0.5034833550453186
ZYTIGA,Mineralocorticoid excess,are ssed in more detail in o ther sections of,1,0.47475314140319824
ZYTIGA,Mineralocorticoid excess,REACTIONS The following are discu,0,0.5228477120399475
ZYTIGA,Hepatotoxicity,cholesterolemi a hyperglycemia,1,0.5401071310043335
ZYTIGA,Hepatotoxicity,cholesterolemi a hyperglycemia elevated,1,0.5426734685897827
ZYTIGA,Hepatotoxicity,hypertriglyceridemia lymphopenia cholesterolemi a hyperglycemia,1,0.5671142339706421
ZYTIGA,Hepatotoxicity,phosphatase hypertriglyceridemia lymphopenia cholesterolemi a hyperglycemia,1,0.5767242908477783
ZYTIGA,Increases in liver enzymes,hypophosphatemia elevated ALT and,0,0.6189521551132202
ZYTIGA,hypertension,Experience Because clinical trials e conducted,1,0.541761040687561
ZYTIGA,hypertension,e conducted under widely,1,0.5066491961479187
ZYTIGA,hypertension,rates observed in the,0,0.5493052005767822
ZYTIGA,hypertension,e conducted,1,0.5289674997329712
ZYTIGA,hypertension,a drug ca,0,0.5844870209693909
ZYTIGA,hypertension,ar,0,0.5609455108642578
ZYTIGA,hypokalemia,der widely,1,0.4539530873298645
ZYTIGA,hypokalemia,der widely varying conditions adverse reaction,1,0.5154473781585693
ZYTIGA,hypokalemia,the clinical trials,0,0.5219712257385254
ZYTIGA,hypokalemia,Experience Because clinical trials are,0,0.48805561661720276
ZYTIGA,hypokalemia,varying conditions adverse reaction rates,0,0.5250681042671204
ZYTIGA,hypokalemia,the clinical,0,0.537642776966095
ZYTIGA,fluid retention,directly compared to rates,0,0.4729609191417694
ZYTIGA,fluid retention,"g conditions, a dverse",1,0.5321336388587952
ZYTIGA,fluid retention,"widely g conditions, a dverse reaction rates",1,0.51750648021698
ZYTIGA,fluid retention,compared to,0,0.5152786374092102
ZYTIGA,fluid retention,"conditions, a dverse",1,0.5226137042045593
ZYTIGA,increased mineralocorticoid levels,reaction rates,0,0.5479736328125
ZYTIGA,increased mineralocorticoid levels,adverse reaction  observed in the clinical trials o f a drug,1,0.5660442113876343
ZYTIGA,hypertension,randomized placebocontrolled multicenter clinical trials enrolled patients,0,0.5487414598464966
ZYTIGA,hypertension,placebocontrolled multicenter clinical trials enrolled patients who,0,0.538404107093811
ZYTIGA,hypertension,in clinical practice Two,1,0.5615085363388062
ZYTIGA,hypertension,in the clinical trials of another drug,0,0.5608336925506592
ZYTIGA,hypertension,reflect the rates  in clinical practice Two randomized placebocontrolled multicenter,1,0.5578733682632446
ZYTIGA,hypertension,reflect,0,0.5730059146881104
ZYTIGA,hypertension,reflect the rates in,1,0.5331699848175049
ZYTIGA,hypokalemia,drug,0,0.5597527027130127
ZYTIGA,hypokalemia,not reflect the rates observed in,0,0.46985459327697754
ZYTIGA,hypokalemia,metastatic,0,0.5277788639068604
ZYTIGA,hypokalemia,"rolled, mul ticenter clinical trials",1,0.501262366771698
ZYTIGA,hypokalemia,placebocont,0,0.553519606590271
ZYTIGA,hypokalemia,"randomized rolled, mul",1,0.477480411529541
ZYTIGA,hypokalemia,clinical trials enrolled patients who had,0,0.5247746706008911
ZYTIGA,hypokalemia,patients who had metastatic castrationresistant prostate,0,0.49180105328559875
ZYTIGA,Adrenal insufficiency,Following Chemotherapy Study nrolled 1195 patients,1,0.4851621389389038
ZYTIGA,Adrenal insufficiency,who had received prior docetaxel chemotherapy Patients were not,0,0.4747041165828705
ZYTIGA,Adrenal insufficiency,Metastatic CRPC,0,0.5321459770202637
ZYTIGA,Adrenal insufficiency,eligible,0,0.5200872421264648
ZYTIGA,Adrenal insufficiency,nrolled 1195 patients,1,0.49364280700683594
ZYTIGA,Adrenal insufficiency,with metastatic CRPC who had received prior docetaxel chemotherapy Patients were not eligible if A,0,0.514432430267334
ZYTIGA,Adrenal insufficiency,Study Metastatic CRPC Following Chemotherapy Study e,0,0.5198079347610474
ZYTIGA,Adrenal insufficiency,docetaxel chemotherapy Patients,0,0.5074067115783691
ZYTIGA,Adrenocortical insufficiency,were,0,0.4936678111553192
ZYTIGA,Adrenocortical insufficiency,ho had received prior docetaxel chemotherapy Patients were,0,0.5221208930015564
ZYTIGA,Adrenocortical insufficiency,ULN Table,0,0.4727426767349243
ZYTIGA,Adrenocortical insufficiency,prior docetaxel chemotherapy Patients were not,0,0.5214348435401917
ZYTIGA,Adrenocortical insufficiency,ALT N,1,0.4827117323875427
ZYTIGA,Adrenocortical insufficiency,N in the absence of liver me tastases Patients with,1,0.6175163388252258
ZYTIGA,Adrenocortical insufficiency,andor ALT N,1,0.5019596219062805
ZYTIGA,Adrenocortical insufficiency,received prior docetaxel chemotherapy Patients were not eligible if,0,0.5135325193405151
ZYTIGA,Adrenocortical insufficiency,ALT N in,1,0.537463903427124
ZYTIGA,Adrenocortical insufficiency,Patients were not eligible if AST,0,0.5437628626823425
ZYTIGA,adrenocortical insufficiency,to ZYTIGA in Study,0,0.48770058155059814
ZYTIGA,adrenocortical insufficiency,PrednisoneN SystemOrgan Class Adve,0,0.6427500247955322
ZYTIGA,deaths,Vascular       ,1,0.5104371309280396
ZYTIGA,deaths,PrednisoneN SystemOrgan Class Adve,0,0.48571664094924927
TOVIAZ,dry mouth,dry mouth placebo Toviaz,1,0.83323734998703
TOVIAZ,dry mouth,Toviaz dry,1,0.6941130757331848
TOVIAZ,dry mouth,Toviaz dry mouth,1,0.8544194102287292
TOVIAZ,constipation,constipation placebo Toviaz mg Toviaz mg,1,0.7680104970932007
TOVIAZ,constipation,constipation,1,1.0
TOVIAZ,constipation,constipation placebo Toviaz mg,1,0.7705544233322144
TOVIAZ,angina,angina chest pain gastroenteritis and,1,0.7778115272521973
TOVIAZ,angina,except for four patients receiving Toviaz who reported,0,0.5078580379486084
TOVIAZ,angina,gastroenteritis and QT prolongation on ECG The most commonly reported,0,0.5739400386810303
TOVIAZ,angina,angina chest pain,1,0.8994224071502686
TOVIAZ,angina,gastroenteritis and QT prolongation on ECG,0,0.5746594667434692
TOVIAZ,angina,Toviaz who,0,0.4689595699310303
TOVIAZ,chest pain,each chest pain gastroenteritis and QT prolongation,1,0.7352277636528015
TOVIAZ,chest pain,Toviaz who,0,0.4212794303894043
TOVIAZ,chest pain,chest pain gastroenteritis and QT,1,0.7350172996520996
TOVIAZ,chest pain,chest pain gastroenteritis and,1,0.7984670996665955
TOVIAZ,chest pain,adverse event each chest pain gastroenteritis and QT,1,0.7155142426490784
TOVIAZ,chest pain,chest pain,1,0.9999999403953552
TOVIAZ,gastroenteritis,chest gastroenteritis and QT,1,0.7552304863929749
TOVIAZ,gastroenteritis,chest pain,1,0.5271377563476562
TOVIAZ,gastroenteritis,gastroenteritis and QT prolongation on ECG,1,0.7594475746154785
TOVIAZ,gastroenteritis,gastroenteritis and QT prolongation,1,0.769993782043457
TOVIAZ,gastroenteritis,adverse event in patients treated,0,0.49556541442871094
TOVIAZ,gastroenteritis,in patients,0,0.4943152070045471
TOVIAZ,gastroenteritis,chest gastroenteritis and QT prolongation on,1,0.7451753616333008
TOVIAZ,gastroenteritis,four patients receiving Toviaz who reported one serious adverse,0,0.49857521057128906
TOVIAZ,gastroenteritis,gastroenteritis and QT prolongation on,1,0.7755506038665771
TOVIAZ,QT prolongation,angina chest pain gastroenteritis QT prolongation,1,0.7387272119522095
TOVIAZ,QT prolongation,serious adverse event,0,0.5497841238975525
TOVIAZ,QT prolongation,serious adverse,0,0.5148807168006897
TOVIAZ,QT prolongation,adverse event in patients treated with,0,0.5191737413406372
TOVIAZ,QT prolongation,chest pain gastroenteritis QT prolongation on ECG The most,1,0.7163445353507996
TOVIAZ,dry mouth,olongation on ECG The most commonly reported adverse event in patients treated with,0,0.4902345836162567
TOVIAZ,dry mouth,adverse event in patients,0,0.5125767588615417
TOVIAZ,dry mouth,treated with Toviaz dry mouth The incidence of dry,1,0.8391824960708618
TOVIAZ,dry mouth,dry mouth The,1,0.9648938179016113
TOVIAZ,dry mouth,Toviaz was,0,0.5054364204406738
TOVIAZ,dry mouth,dry mouth,1,1.0
TOVIAZ,Dry mouth,compared to placebo,0,0.5856350064277649
TOVIAZ,Dry mouth,as compared,0,0.5031532049179077
TOVIAZ,Dry mouth,Dry mouth led to discontinuation,1,0.8627520203590393
TOVIAZ,Dry mouth,receiving,0,0.5039269328117371
TOVIAZ,Dry mouth,led to discontinuation in and of patients receiving placebo Toviaz mg and,0,0.5827053189277649
TOVIAZ,dry mouth,receiving placebo Toviaz mg and Toviaz mg respectively For those,0,0.573786735534668
TOVIAZ,dry mouth,those patients who dry,1,0.7502620816230774
TOVIAZ,dry mouth,dry mouth most had,1,0.9079738259315491
TOVIAZ,constipation,was in those taking placebo in those taking,0,0.6380712389945984
TOVIAZ,constipation,in those taking,0,0.5959880948066711
TOVIAZ,constipation,reported adverse event constipation The incidence of constipation,1,0.8108579516410828
TOVIAZ,constipation,constipation The incidence of,1,0.8402080535888672
TOVIAZ,constipation,constipation The incidence of constipation,1,0.8451253771781921
TOVIAZ,constipation,placebo,0,0.619885265827179
TOVIAZ,constipation,constipation was in those taking placebo,1,0.7936357259750366
TOVIAZ,constipation,those taking mgday and in those taking,0,0.584151566028595
TOVIAZ,Upper respiratory tract infection,ract Upper respiratory tract infection Eye,1,0.7857296466827393
TOVIAZ,Upper respiratory tract infection,those taking mgday and in those taking,0,0.48625391721725464
TOVIAZ,Upper respiratory tract infection,tract infection Eye disorders,1,0.638562023639679
TOVIAZ,Upper respiratory tract infection,ract Upper respiratory tract,1,0.8163477182388306
TOVIAZ,Upper respiratory tract infection,respiratory tract infection,1,0.9014788866043091
TOVIAZ,Upper respiratory tract infection,ract Upper respiratory tract infection,1,0.8373393416404724
TOVIAZ,dry mouth,were similar to those observed in the week placebocontrolled,0,0.573418915271759
TOVIAZ,dry mouth,week placebocontrolled studies and dry,1,0.6586984395980835
TOVIAZ,constipation,dry constipation dry,1,0.8363453149795532
TOVIAZ,constipation,week placebocontrolled studies and dry,1,0.6066240072250366
TOVIAZ,constipation,constipation dry,1,0.8619378209114075
TOVIAZ,constipation,to those observed in the week placebocontrolled studies and included dry mouth,0,0.6177524328231812
TOVIAZ,constipation,most adverse events of,0,0.5513830184936523
TOVIAZ,constipation,constipation dry eyes dyspepsia and abdominal,1,0.7920259237289429
TOVIAZ,constipation,and,0,0.5457766056060791
TOVIAZ,constipation,week placebocontrolled studies and included dry,0,0.6164953112602234
TOVIAZ,constipation,constipation dry eyes dyspepsia and,1,0.8074691295623779
TOVIAZ,constipation,the,0,0.5920759439468384
TOVIAZ,dry eyes,dry eyes dyspepsia and abdominal pain Similar,1,0.7587927579879761
TOVIAZ,dry eyes,dry mouth dry eyes dyspepsia and,1,0.8014615774154663
TOVIAZ,dry eyes,and included dry mouth dry eyes,1,0.8541966676712036
TOVIAZ,dry eyes,to the controlled studies most,0,0.5107486248016357
TOVIAZ,dry eyes,dry eyes,1,1.0
TOVIAZ,dry eyes,dry eyes dyspepsia and abdominal,1,0.7950435280799866
TOVIAZ,dry eyes,Similar to the controlled studies most adverse events,0,0.5122300386428833
TOVIAZ,dry eyes,dry eyes dyspepsia and,1,0.8411020040512085
TOVIAZ,dyspepsia,mouth constipation dry dyspepsia and abdominal,1,0.775587797164917
TOVIAZ,dyspepsia,dry eyes dyspepsia and,1,0.8294469118118286
TOVIAZ,dyspepsia,dyspepsia and abdominal,1,0.8827191591262817
TOVIAZ,dyspepsia,mouth constipation dry dyspepsia,1,0.8027493357658386
TOVIAZ,dyspepsia,included dry mouth,0,0.6009308099746704
TOVIAZ,dyspepsia,dyspepsia and abdominal pain Similar to,1,0.8503516912460327
TOVIAZ,abdominal pain,abdominal pain Similar to,1,0.9046461582183838
TOVIAZ,abdominal pain,abdominal pain Similar to the controlled studies,1,0.7956239581108093
TOVIAZ,abdominal pain,included dry mouth constipation dry,0,0.5310052633285522
TOVIAZ,abdominal pain,constipation dry eyes dyspepsia abdominal pain,1,0.773269534111023
TOVIAZ,abdominal pain,abdominal,1,0.787818968296051
TOVIAZ,abdominal pain,and included,0,0.4360106587409973
TOVIAZ,constipation,mild to,0,0.5578810572624207
TOVIAZ,constipation,Similar to the controlled studies most,0,0.5368388891220093
TOVIAZ,urinary retention,of up to years urinary,1,0.7981934547424316
TOVIAZ,urinary retention,years,0,0.5024152994155884
TOVIAZ,urinary retention,cases constipation cases irritable bowel,0,0.6030192375183105
TOVIAZ,urinary retention,constipation cases,0,0.6421443223953247
TOVIAZ,urinary retention,the openlabel treatment period of up to,0,0.5607346296310425
TOVIAZ,urinary retention,to years urinary retention cases,1,0.9013100862503052
TOVIAZ,diverticulitis,retention,0,0.4863947629928589
TOVIAZ,diverticulitis,diverticulitis,1,1.0
TOVIAZ,diverticulitis,cases constipation cases irritable bowel syndrome cases and electrocardiogram QT,0,0.5743875503540039
TOVIAZ,diverticulitis,diverticulitis cases,1,0.8817066550254822
TOVIAZ,diverticulitis,urinary retention diverticulitis cases constipation,1,0.7748010158538818
TOVIAZ,diverticulitis,cases,0,0.5355205535888672
TOVIAZ,diverticulitis,the openlabel treatment period of,0,0.48360297083854675
TOVIAZ,diverticulitis,diverticulitis cases constipation cases irritable bowel,1,0.7917693853378296
TOVIAZ,constipation,up to years included,0,0.504260241985321
TOVIAZ,constipation,cases,0,0.5309268236160278
TOVIAZ,constipation,urinary retention cases diverticulitis constipation cases irritable,1,0.7430779933929443
TOVIAZ,constipation,cases diverticulitis cases,0,0.5956005454063416
TOVIAZ,constipation,diverticulitis constipation cases,1,0.7836087942123413
TOVIAZ,constipation,constipation cases irritable,1,0.8083045482635498
TOVIAZ,constipation,constipation cases,1,0.859752357006073
TOVIAZ,constipation,constipation cases irritable bowel syndrome,1,0.7901246547698975
TOVIAZ,constipation,irritable bowel syndrome cases,0,0.6725208759307861
TOVIAZ,QT corrected interval prolongation,QT corrected interval prolongation cases Postmarketing Experience The,1,0.9053137302398682
TOVIAZ,QT corrected interval prolongation,following events have been reported in associ,0,0.4838889539241791
TOVIAZ,QT corrected interval prolongation,bowel syndrome cases and QT corrected interval,1,0.8270307779312134
TOVIAZ,QT corrected interval prolongation,interval prolongation cases Postmarketing Experience,1,0.8079178333282471
TOVIAZ,QT corrected interval prolongation,bowel syndrome cases and QT corrected interval prolongation,1,0.8544319868087769
TOVIAZ,QT corrected interval prolongation,cases,0,0.45936986804008484
TOVIAZ,Blurred vision,use in worldwide postmarketing,0,0.49911683797836304
TOVIAZ,Blurred vision,Blurred vision Cardiac,1,0.8866118788719177
TOVIAZ,Blurred vision,postmarketing,0,0.5044237971305847
TOVIAZ,Blurred vision,association,0,0.47031840682029724
TOVIAZ,Blurred vision,Cardiac disorders Palpitations General disorders,0,0.47559040784835815
TOVIAZ,Blurred vision,Blurred,1,0.8454650640487671
TOVIAZ,Palpitations,Palpitations,1,0.9999999403953552
TOVIAZ,Palpitations,Blurred vision Cardiac Palpitations General disorders and,1,0.769538402557373
TOVIAZ,Palpitations,disorders and administrative,0,0.5223054885864258
TOVIAZ,Hypersensitivity reactions,disorders and administrative site Hypersensitivity reactions including,1,0.8286160230636597
TOVIAZ,Hypersensitivity reactions,disorders and administrative,0,0.5100419521331787
TOVIAZ,angioedema,angioedema with airway obstruction face edema,1,0.8638862371444702
TOVIAZ,angioedema,Dizziness headache s,0,0.5831727981567383
TOVIAZ,angioedema,reactions angioedema with airway obstruction,1,0.8680329918861389
TOVIAZ,angioedema,administrative site conditions Hypersensitivity reactions,0,0.6358693838119507
TOVIAZ,angioedema,angioedema with airway,1,0.8872776627540588
TOVIAZ,angioedema,site conditions,0,0.49276700615882874
TOVIAZ,angioedema,Dizziness headache,0,0.5823985934257507
TOVIAZ,angioedema,face edema,0,0.7221431732177734
TOVIAZ,face edema,reactions including angioedema with,0,0.6923755407333374
TOVIAZ,Dizziness,subcutaneous tissue,0,0.43756988644599915
TOVIAZ,Dizziness,Skin,0,0.491688072681427
TOVIAZ,Dizziness,Dizziness headache,1,0.9148300886154175
TOVIAZ,Dizziness,Dizziness headache somnolence Skin,1,0.797004759311676
TOVIAZ,Dizziness,Dizziness headache somnolence Skin and,1,0.7960566878318787
TOVIAZ,Dizziness,with airway obstruction face edema Central nervous system,0,0.6386929750442505
TOVIAZ,headache,headache somnolence,1,0.8482702374458313
TOVIAZ,headache,headache,1,0.9999998807907104
TOVIAZ,headache,system disorders,0,0.5078222751617432
TOVIAZ,headache,headache somnolence Skin and,1,0.7947061061859131
TOVIAZ,headache,somnolence Skin and subcutaneous tissue disorders Urticaria pruritus Because these sp,0,0.5533889532089233
TOVIAZ,headache,headache somnolence Skin and subcutaneous,1,0.7864087820053101
TOVIAZ,headache,nervous system disorders headache somnolence Skin and subcutaneous tissue,1,0.7301805019378662
TOVIAZ,headache,headache somnolence Skin and subcutaneous tissue,1,0.7758383750915527
TOVIAZ,somnolence,Dizziness somnolence Skin and subcutaneous tissue,1,0.7641395330429077
TOVIAZ,somnolence,headache somnolence Skin and subcutaneous tissue,1,0.7512490153312683
TOVIAZ,somnolence,somnolence Skin and subcutaneous,1,0.8362530469894409
TOVIAZ,somnolence,nervous system disorders,0,0.570435643196106
TOVIAZ,somnolence,somnolence Skin and,1,0.8731153607368469
TOVIAZ,somnolence,disorders Dizziness,0,0.5742265582084656
TOVIAZ,somnolence,disorders Dizziness somnolence,1,0.8265892267227173
TOVIAZ,pruritus,pruritus Because these spontaneously reported,1,0.8488311767578125
TOVIAZ,pruritus,these spontaneously reported events are from the worldwide postmarketing experience t,0,0.5355358123779297
TOVIAZ,pruritus,rders Dizziness headache somnolence Skin and subcutaneous tissue disorders Urticaria,0,0.6858468055725098
TOVIAZ,pruritus,postmarketing experience t,0,0.5516250133514404
TOVIAZ,Angioedema of the face,EXCERPT The most,0,0.4502488374710083
TOVIAZ,Angioedema of the face,most tly reported adverse e vents for,1,0.5903440117835999
TOVIAZ,Central Nervous System Effects,Toviaz mgday in 2 or 3 studies with treatment  periods,1,0.5423195362091064
TOVIAZ,Central Nervous System Effects,EXCERPT The most,0,0.4826415777206421
TOVIAZ,Central Nervous System Effects,mgday in Phase,0,0.5064613819122314
TOVIAZ,Central Nervous System Effects,2 or,1,0.4930794835090637
TOVIAZ,Central Nervous System Effects,of or weeks Approximately,0,0.4697313606739044
TOVIAZ,Central Nervous System Effects,mgday in 2 or 3 studies,1,0.5471585988998413
TOVIAZ,Central Nervous System Effects,studies with treatment periods of or weeks Approximately,1,0.5866143703460693
TOVIAZ,Central Nervous System Effects,received Toviaz mgday in 2 or 3 studies,1,0.5330544710159302
TOVIAZ,Central Nervous System Effects,3 studies with treatment periods of or weeks Approximately,1,0.5750216245651245
TOVIAZ,Somnolence,or studies with treatment riods of 8,1,0.4955016076564789
TOVIAZ,Somnolence,3 studies with treatment periods of or weeks Approximately,1,0.49924612045288086
TOVIAZ,Somnolence,exposure to Toviaz in,0,0.5593688488006592
TOVIAZ,Somnolence,and received Toviaz mgday in Phase or studies,0,0.544695258140564
TOVIAZ,Somnolence,riods of 8 or weeks Approximately of,1,0.4973594844341278
TOVIAZ,Somnolence,or,0,0.48896336555480957
TOVIAZ,Somnolence,to Toviaz,0,0.4958083927631378
TOVIAZ,Angioedema of the face,received Toviaz ay.,1,0.5278896689414978
TOVIAZ,Angioedema of the face,ay. In Phase 2 and placebocontrolled trials combined the,1,0.5292432308197021
TOVIAZ,Angioedema,and respectively All serious adverse events were judged,0,0.5501549243927002
TOVIAZ,Angioedema,Toviaz and,1,0.4921271800994873
TOVIAZ,Angioedema,receiving,0,0.4877484440803528
TOVIAZ,Angioedema,Toviaz and Tovia,1,0.4897962212562561
TOVIAZ,Angioedema,adverse events,0,0.6068222522735596
TOVIAZ,Angioedema,and Tovia,1,0.49463510513305664
TOVIAZ,Angioedema,Toviaz  and Tovia z mg were and,1,0.4727112054824829
TOVIAZ,Angioedema,patients receiving placebo Toviaz  and Tovia,1,0.5511273741722107
TOVIAZ,upper airway swelling,in patients,0,0.548286497592926
TOVIAZ,upper airway swelling,placebo Toviaz mg and Toviaz mg were,0,0.5013682842254639
TOVIAZ,CNS anticholinergic effects,that were reported in the combined,0,0.4923548102378845
TOVIAZ,headache,an place bo and,1,0.49720901250839233
TOVIAZ,headache,greater an place bo,1,0.48447734117507935
TOVIAZ,headache,an place bo and in,1,0.49177151918411255
TOVIAZ,headache,of patients treated with Toviaz or mg once daily for up to weeks,0,0.5460553169250488
TOVIAZ,headache,combined,0,0.5253323912620544
TOVIAZ,headache,incidence greater an place bo,1,0.5533486604690552
TOVIAZ,headache,an incidence greater an place bo and,1,0.5681822299957275
TOVIAZ,headache,for up,0,0.5183771848678589
TOVIAZ,somnolence,ore of,1,0.48711201548576355
TOVIAZ,somnolence,or ore,1,0.4716307818889618
TOVIAZ,somnolence,in or ore of pat ients treated with Toviaz or,1,0.5367595553398132
TOVIAZ,somnolence,of pat ients,1,0.49964284896850586
STRIBILD,Lactic Acidosis,the Lactic Acidosis Severe Hepatomegaly with Steatosis see,1,0.7918289303779602
STRIBILD,Lactic Acidosis,of pat ients,1,0.5094183087348938
STRIBILD,Lactic Acidosis,ONS The following adverse,0,0.592145562171936
STRIBILD,Lactic Acidosis,Steatosis see Boxed,0,0.5521777868270874
STRIBILD,Lactic Acidosis,Hepatomegaly with Steatosis see,0,0.5607180595397949
STRIBILD,Lactic Acidosis,of the Lactic Acidosis,1,0.9638523459434509
STRIBILD,Lactic Acidosis,reactions are discussed in other sections of the labeling,0,0.576514720916748
STRIBILD,Lactic Acidosis,other sections of the Lactic,1,0.6954684853553772
STRIBILD,Lactic Acidosis,other sections of the Lactic Acidosis,1,0.8872621059417725
STRIBILD,Hepatomegaly,Hepatomegaly with Steatosis,1,0.8745129108428955
STRIBILD,Hepatomegaly,Warnings,0,0.5319738388061523
STRIBILD,Hepatomegaly,Lactic Hepatomegaly,1,0.9049286842346191
STRIBILD,Hepatomegaly,are discussed in,0,0.487981379032135
STRIBILD,Hepatomegaly,Hepatomegaly with Steatosis see,1,0.8649498224258423
STRIBILD,Hepatomegaly,Lactic Hepatomegaly with Steatosis see Boxed,1,0.8193050026893616
STRIBILD,Hepatomegaly,in other sections of the labeling Lactic AcidosisSevere,0,0.555217444896698
STRIBILD,Steatosis,Steatosis see Boxed Warning Warnings and,1,0.8112128973007202
STRIBILD,Steatosis,Hepatomegaly Steatosis see Boxed,1,0.8102540969848633
STRIBILD,Steatosis,Steatosis see,1,0.9425815343856812
STRIBILD,Steatosis,Steatosis,1,1.0000001192092896
STRIBILD,Steatosis,labeling Lactic AcidosisSevere Hepatomegaly Steatosis see Boxed,1,0.7360588908195496
STRIBILD,Steatosis,are discussed in other sections of the labeling Lactic AcidosisSevere Hepatomegaly with,0,0.592081606388092
STRIBILD,Acute Exacerbations of Hepatitis B,and Precautions Severe,0,0.5512855052947998
STRIBILD,Acute Exacerbations of Hepatitis B,Hepatomegaly with Steatosis see Boxed Warning Warnings and Precautions,0,0.6145485639572144
STRIBILD,Acute Exacerbations of Hepatitis B,Precautions Acute Exacerbations of Hepatitis B,1,0.9332535266876221
STRIBILD,Acute Exacerbations of Hepatitis B,Precautions,0,0.5493873357772827
STRIBILD,Acute Exacerbations of Hepatitis B,and Precautions Acute Exacerbations of Hepatitis B,1,0.941001832485199
STRIBILD,Acute Exacerbations of Hepatitis B,Precautions Acute Exacerbations of Hepatitis B see Boxed,1,0.9177678823471069
STRIBILD,Acute Exacerbations of Hepatitis B,Boxed Warning Warnings and Precautions New Onset or Worsening Renal,0,0.5976163148880005
STRIBILD,Worsening Renal Impairment,Renal Impairment see Warnings and,1,0.8492809534072876
STRIBILD,Worsening Renal Impairment,and Precautions New Onset Worsening,1,0.6660242080688477
STRIBILD,Worsening Renal Impairment,Precautions New Onset Worsening Renal,1,0.8363189697265625
STRIBILD,Bone Effects,Warnings and Precautions Immune Reconstitution Syndrome see,0,0.5570677518844604
STRIBILD,Immune Reconstitution Syndrome,and Precautions,0,0.48165464401245117
STRIBILD,nausea,diarrhea To report,0,0.5997385382652283
STRIBILD,nausea,nausea and diarrhea,1,0.8321149945259094
STRIBILD,nausea,nausea and,1,0.9323806166648865
STRIBILD,nausea,nausea,1,1.0
STRIBILD,nausea,nausea and diarrhea To,1,0.8195135593414307
STRIBILD,nausea,equal to all grades nausea and diarrhea,1,0.7807009220123291
STRIBILD,nausea,STRIBILD incidence greater than or equal to all,0,0.5332514047622681
STRIBILD,diarrhea,drug reactions to STRIBILD incidence,0,0.5726487636566162
STRIBILD,diarrhea,grades are nausea diarrhea To,1,0.76524817943573
STRIBILD,diarrhea,ADVERSE,0,0.5763810873031616
STRIBILD,diarrhea,are nausea diarrhea,1,0.765141487121582
STRIBILD,diarrhea,and,0,0.5738846063613892
STRIBILD,diarrhea,diarrhea To report SUSPECTED ADVERSE,1,0.8081265091896057
STRIBILD,diarrhea,STRIBILD incidence greater than or equal to all grades are nausea,0,0.6007866263389587
STRIBILD,diarrhea,Inc,0,0.5422906279563904
STRIBILD,diarrhea,incidence greater than or equal,0,0.5424835681915283
STRIBILD,renal adverse reactions,renal adverse,1,0.9033263325691223
STRIBILD,suicidal ideation,preexisting history,0,0.41694924235343933
STRIBILD,suicidal ideation,observed with STRIBILD suicidal ideation and,1,0.9039511680603027
STRIBILD,suicidal ideation,reactions observed with STRIBILD suicidal,1,0.7695423364639282
STRIBILD,suicidal ideation,suicide attempt all in subjects with,0,0.7628500461578369
STRIBILD,suicidal ideation,STRIBILD suicidal ideation and suicide attempt,1,0.8899141550064087
STRIBILD,suicidal ideation,suicide attempt all,0,0.7772777080535889
STRIBILD,suicidal ideation,with STRIBILD suicidal ideation and suicide,1,0.9020463228225708
STRIBILD,suicidal ideation,with STRIBILD Additional,0,0.4953695833683014
STRIBILD,suicidal ideation,suicidal ideation and suicide,1,0.928973913192749
STRIBILD,suicidal ideation,suicidal ideation and,1,0.9575129747390747
STRIBILD,suicide attempt,suicide attempt,1,0.9999998807907104
STRIBILD,suicide attempt,included suicidal ideation suicide attempt all in,1,0.8867357969284058
STRIBILD,suicide attempt,ideation,0,0.562533438205719
STRIBILD,suicide attempt,and,0,0.47143733501434326
STRIBILD,suicide attempt,adverse drug reactions observed with STRIBILD included suicidal ideation and,0,0.6759735345840454
STRIBILD,suicide attempt,ideation suicide attempt all in subjects,1,0.854476809501648
STRIBILD,suicide attempt,included suicidal ideation suicide attempt,1,0.915054202079773
STRIBILD,suicide attempt,included suicidal ideation,0,0.81602543592453
STRIBILD,nausea,nausea flatulence and headache,1,0.7722600698471069
STRIBILD,nausea,nausea flatulence and headache The,1,0.7722381949424744
STRIBILD,nausea,headache The proportion of subjects who discontinued treatment wit,0,0.5556871294975281
STRIBILD,nausea,nausea flatulence,1,0.8438194394111633
STRIBILD,flatulence,flatulence and headache The proportion of,1,0.8033319115638733
STRIBILD,flatulence,flatulence and headache The,1,0.8375935554504395
STRIBILD,flatulence,subjects switching,0,0.48458051681518555
STRIBILD,flatulence,equal to of subjects switching to STRIBILD were,0,0.555353045463562
STRIBILD,flatulence,flatulence and,1,0.9155404567718506
STRIBILD,headache,headache The,1,0.9590147733688354
STRIBILD,headache,headache The proportion of subjects who,1,0.7815940380096436
STRIBILD,headache,headache The proportion,1,0.8601984977722168
STRIBILD,headache,headache The proportion of,1,0.8426023721694946
STRIBILD,headache,to STRIBILD were nausea flatulence,0,0.6100655794143677
STRIBILD,headache,of subjects who discontinued treatment with STRIBILD the RTVboosted,0,0.48025771975517273
STRIBILD,depression,depression abdominal pain,1,0.773921012878418
STRIBILD,depression,clinical,0,0.5523715615272522
STRIBILD,depression,abdominal,0,0.5181883573532104
STRIBILD,depression,other clinical depression abdominal pain,1,0.735041618347168
STRIBILD,abdominal pain,other clinical trials abdominal pain,1,0.8075941205024719
STRIBILD,abdominal pain,abdominal,0,0.7878189086914062
STRIBILD,dyspepsia,fever pain nasopharyngitis pneumonia sinusitis upper respiratory tract infection a,0,0.5089781284332275
STRIBILD,dyspepsia,dyspepsia,1,1.0000001192092896
STRIBILD,dyspepsia,dyspepsia vomiting fever,1,0.8419675827026367
STRIBILD,dyspepsia,other,0,0.5068238973617554
STRIBILD,dyspepsia,other antiretroviral agents in,0,0.4481815695762634
STRIBILD,vomiting,trials depression abdominal pain vomiting fever pain nasopharyngitis,1,0.714551568031311
STRIBILD,vomiting,other antiretroviral agents in,0,0.45820319652557373
STRIBILD,vomiting,vomiting fever pain nasopharyngitis,1,0.7828185558319092
STRIBILD,vomiting,pneumonia sinusitis upper respiratory tract infection arthralgia,0,0.558611273765564
STRIBILD,vomiting,vomiting fever pain nasopharyngitis pneumonia sinusitis,1,0.7509350776672363
STRIBILD,vomiting,trials depression abdominal pain dyspepsia,0,0.6401757001876831
STRIBILD,fever,nasopharyngitis,0,0.6111522912979126
STRIBILD,fever,fever pain nasopharyngitis pneumonia,1,0.7572380304336548
STRIBILD,fever,fever pain,1,0.8658289909362793
STRIBILD,fever,upper respiratory tract infection arthralgia back,0,0.6014789938926697
STRIBILD,fever,fever pain nasopharyngitis pneumonia sinusitis upper,1,0.7448391914367676
STRIBILD,fever,abdominal pain dyspepsia fever pain nasopharyngitis pneumonia,1,0.6769948601722717
STRIBILD,pain,pain,1,0.9999999403953552
STRIBILD,pain,respiratory tract infection arthralgia back pain m,0,0.6588155031204224
STRIBILD,pneumonia,pneumonia sinusitis upper respiratory tract,1,0.7367337942123413
STRIBILD,pneumonia,dyspepsia vomiting fever pain pneumonia sinusitis upper respiratory tract,1,0.6669019460678101
STRIBILD,pneumonia,vomiting fever pain pneumonia sinusitis,1,0.7311477661132812
STRIBILD,pneumonia,fever pain pneumonia,1,0.8085646629333496
STRIBILD,pneumonia,back pain myalgia paresthesia,0,0.4849637448787689
STRIBILD,pneumonia,pneumonia sinusitis upper respiratory,1,0.7286351919174194
STRIBILD,pneumonia,trials,0,0.5363502502441406
STRIBILD,sinusitis,sinusitis upper respiratory tract infection arthralgia,1,0.8209644556045532
STRIBILD,sinusitis,arthralgia back pain myalgia paresthesia,0,0.5081847906112671
STRIBILD,sinusitis,paresthesia,0,0.5278629064559937
STRIBILD,sinusitis,pain nasopharyngitis sinusitis upper,1,0.7957066893577576
STRIBILD,sinusitis,pneumonia,0,0.6165457963943481
STRIBILD,sinusitis,depression abdominal pain dyspepsia,0,0.5083141326904297
STRIBILD,sinusitis,fever pain nasopharyngitis sinusitis upper respiratory tract infection arthralgia,1,0.7349333763122559
STRIBILD,sinusitis,sinusitis upper respiratory tract,1,0.8403936624526978
STRIBILD,upper respiratory tract infection,nasopharyngitis,0,0.7350237369537354
STRIBILD,upper respiratory tract infection,upper respiratory tract infection arthralgia back pain,1,0.7797063589096069
STRIBILD,arthralgia,neuropathy,0,0.5781493186950684
STRIBILD,arthralgia,including peripheral,0,0.5009986162185669
STRIBILD,arthralgia,arthralgia,1,1.0
STRIBILD,arthralgia,arthralgia back,1,0.8999618291854858
STRIBILD,arthralgia,arthralgia back pain myalgia paresthesia peripheral,1,0.8401256799697876
STRIBILD,back pain,back pain myalgia paresthesia,1,0.834726095199585
STRIBILD,back pain,pain nasopharyngitis pneumonia sinusitis upper respiratory tract,0,0.6212136149406433
STRIBILD,back pain,back pain myalgia paresthesia peripheral neuropathy including,1,0.7950600981712341
STRIBILD,back pain,infection arthralgia,0,0.6170127391815186
STRIBILD,myalgia,myalgia paresthesia peripheral neuropathy,1,0.7988375425338745
STRIBILD,myalgia,myalgia,1,0.9999996423721313
STRIBILD,myalgia,myalgia paresthesia,1,0.8609486818313599
STRIBILD,paresthesia,pain paresthesia peripheral,1,0.8251315355300903
STRIBILD,paresthesia,myalgia paresthesia peripheral neuropathy,1,0.7384586334228516
STRIBILD,paresthesia,peripheral neuropathy including peripheral,0,0.6553279757499695
STRIBILD,peripheral neuropathy,neuropathy anxiety,0,0.789525032043457
STRIBILD,peripheral neuropathy,anxiety increased cough and rhinitis Skin,0,0.5131049156188965
STRIBILD,peripheral neuropathy,pain myalgia peripheral neuropathy,1,0.8664077520370483
STRIBILD,peripheral neuropathy,myalgia peripheral neuropathy including peripheral neuritis and,1,0.8447866439819336
STRIBILD,peripheral neuritis,paresthesia peripheral neuropathy peripheral neuritis,1,0.8856332302093506
STRIBILD,peripheral neuritis,peripheral,0,0.7223132848739624
STRIBILD,peripheral neuritis,neuropathy peripheral,1,0.8686543703079224
STRIBILD,peripheral neuritis,discoloration has,0,0.47812628746032715
STRIBILD,peripheral neuritis,myalgia paresthesia peripheral neuropathy peripheral neuritis,1,0.8389862775802612
STRIBILD,anxiety,neuropathy including peripheral neuritis,0,0.5264014005661011
STRIBILD,anxiety,higher frequency amon,0,0.5040730834007263
STRIBILD,anxiety,anxiety increased cough and rhinitis Skin,1,0.7247045636177063
STRIBILD,increased cough,increased cough,1,0.9999999403953552
STRIBILD,increased cough,with,0,0.521680474281311
STRIBILD,increased cough,and,0,0.4849338233470917
STRIBILD,increased cough,increased cough and rhinitis,1,0.9030437469482422
STRIBILD,increased cough,neuropathy including peripheral,0,0.5051965117454529
STRIBILD,rhinitis,Skin discoloration has been reported with higher,0,0.5217632055282593
STRIBILD,rhinitis,has been reported with,0,0.5153692960739136
STRIBILD,rhinitis,increased cough rhinitis Skin discoloration,1,0.7368060946464539
STRIBILD,rhinitis,rhinitis,1,1.0
STRIBILD,rhinitis,rhinitis Skin,1,0.8714437484741211
STRIBILD,Skin discoloration,including peripheral neuritis and neuropathy anxiety increased cough,0,0.568527340888977
STRIBILD,Skin discoloration,cough and Skin discoloration has been,1,0.8348899483680725
STRIBILD,Skin discoloration,among emtricitabinetreated subjects it,0,0.5383957624435425
STRIBILD,hyperpigmentation on the palms,was manifested hyperpigmentation on the palms andor,1,0.9692806005477905
STRIBILD,hyperpigmentation on the palms,among emtricitabinetreated subjects it,0,0.5329577922821045
STRIBILD,hyperpigmentation on the palms,hyperpigmentation on the palms andor,1,0.996715784072876
STRIBILD,hyperpigmentation on the palms,manifested hyperpigmentation on the palms andor soles,1,0.9572417736053467
STRIBILD,hyperpigmentation on the palms,it was manifested by,0,0.5136713981628418
STRIBILD,hyperpigmentation on the palms,hyperpigmentation on the palms andor soles and was,1,0.9694509506225586
STRIBILD,hyperpigmentation on the palms,higher frequency among,0,0.5755337476730347
STRIBILD,hyperpigmentation on the palms,subjects it was manifested hyperpigmentation on the palms andor,1,0.9655309915542603
STRIBILD,hyperpigmentation on the palms,it was manifested hyperpigmentation on the palms andor,1,0.9670838117599487
STRIBILD,hyperpigmentation on the palms,subjects it was manifested hyperpigmentation on the palms andor soles and,1,0.9551302194595337
STRIBILD,Urine RBC,Urine,1,0.8119107484817505
STRIBILD,Urine RBC,Urine RBC Hematuria RBCHPF,1,0.9305786490440369
STRIBILD,Urine RBC,nase,0,0.4859307110309601
STRIBILD,Urine RBC,nase Urine RBC,1,0.9152158498764038
STRIBILD,Urine RBC,ULN,0,0.5209378004074097
STRIBILD,decreases in BMD,TRUVADA group N Mean,0,0.4870731830596924
STRIBILD,decreases in BMD,STRIBILD group were comparable to the ATV RTV TRUVADA,0,0.4661151170730591
STRIBILD,decreases in BMD,Mean decreases,1,0.7240391969680786
STRIBILD,decreases in BMD,decreases in BMD from,1,0.9805453419685364
STRIBILD,decreases in BMD,in BMD,1,0.8054603338241577
STRIBILD,decreases in BMD,Mean decreases in BMD from baseline to Week in,1,0.8986715078353882
STRIBILD,decreases in BMD,Mean decreases in BMD,1,0.9683558940887451
STRIBILD,decreases in BMD,subset of subjects STRIBILD group N ATV RTV TRUVADA group N Mean,0,0.5176392793655396
STRIBILD,decreases in BMD,RTV TRUVADA group N Mean,0,0.46477311849594116
STRIBILD,bone fractures,respectively In Studies bone fractures occurred,1,0.8417245149612427
STRIBILD,bone fractures,RTV TRUVADA group N Mean,0,0.4262358844280243
STRIBILD,bone fractures,in the,0,0.5373106002807617
STRIBILD,bone fractures,STRIBILD group subjects,0,0.4878644049167633
STRIBILD,Proteinuria,treatmentnaive subjects receiving tenofovir,0,0.48521411418914795
STRIBILD,Proteinuria,Proteinuria all,1,0.9376955628395081
STRIBILD,Proteinuria,week trial of treatmentnaive subjects receiving tenofovir DF lamivudine,0,0.5440168380737305
STRIBILD,Proteinuria,Proteinuria all grades occurred in,1,0.8536472320556641
STRIBILD,Proteinuria,receiving,0,0.47019362449645996
STRIBILD,Proteinuria,Proteinuria all grades occurred,1,0.8515162467956543
STRIBILD,Proteinuria,Proteinuria all grades,1,0.8946406245231628
STRIBILD,Proteinuria,Proteinuria all grades occurred in of,1,0.8534143567085266
STRIBILD,increase serum creatinine,has been shown increase serum,1,0.7935941815376282
STRIBILD,increase serum creatinine,decrease estimated creatinine clearance due to inhibition of tubular secretion of,0,0.7115316390991211
STRIBILD,increase serum creatinine,cobicistat component of STRIBILD has,0,0.5462719202041626
STRIBILD,increase serum creatinine,has been shown increase serum creatinine,1,0.9472072124481201
STRIBILD,increase serum creatinine,increase serum creatinine and decrease estimated,1,0.9145901203155518
STRIBILD,increase serum creatinine,to,0,0.49822187423706055
STRIBILD,increase serum creatinine,shown,0,0.5035257935523987
STRIBILD,increase serum creatinine,component of STRIBILD has been,0,0.5092147588729858
STRIBILD,increase serum creatinine,serum creatinine and decrease estimated creatinine clearance,1,0.8144760727882385
STRIBILD,increase serum creatinine,been shown,0,0.4906207323074341
STRIBILD,decrease estimated creatinine clearance,tubular,0,0.5326171517372131
STRIBILD,decrease estimated creatinine clearance,to increase serum creatinine and,0,0.7371918559074402
STRIBILD,decrease estimated creatinine clearance,creatinine clearance due to inhibition,1,0.8831506967544556
STRIBILD,decrease estimated creatinine clearance,inhibition of,0,0.6183959245681763
STRIBILD,decrease estimated creatinine clearance,serum creatinine decrease estimated creatinine clearance due to inhibition of,1,0.9080228805541992
STRIBILD,decrease estimated creatinine clearance,of tubular secretion of creatinine without affecting renal glomerular function I,0,0.7387123107910156
STRIBILD,decrease estimated creatinine clearance,increase serum creatinine decrease estimated creatinine,1,0.8689748048782349
STRIBILD,affecting renal glomerular function,affecting renal glomerular,1,0.9555579423904419
STRIBILD,affecting renal glomerular function,In Studies and increases in serum creatinine and,0,0.6921406984329224
STRIBILD,affecting renal glomerular function,in serum,0,0.556248664855957
STRIBILD,affecting renal glomerular function,affecting,1,0.6092954874038696
STRIBILD,affecting renal glomerular function,affecting renal,1,0.8755667209625244
STRIBILD,affecting renal glomerular function,creatinine affecting renal glomerular function In Studies and,1,0.8523030281066895
STRIBILD,affecting renal glomerular function,tubular secretion of creatinine affecting,1,0.75217205286026
STRIBILD,affecting renal glomerular function,clearance due to,0,0.4960249662399292
STRIBILD,increases in serum creatinine,increases in serum creatinine and decreases,1,0.9548342823982239
STRIBILD,increases in serum creatinine,function In Studies increases in,1,0.6701254844665527
STRIBILD,increases in serum creatinine,serum creatinine and,1,0.9072962403297424
STRIBILD,increases in serum creatinine,STRIBILD,0,0.49593234062194824
STRIBILD,increases in serum creatinine,without,0,0.4738718867301941
STRIBILD,decreases in estimated creatinine clearance,in serum creatinine decreases in estimated creatinine,1,0.8987723588943481
STRIBILD,decreases in estimated creatinine clearance,creatinine and,0,0.7856081128120422
STRIBILD,decreases in estimated creatinine clearance,in estimated creatinine clearance occurred early,1,0.9037604928016663
STRIBILD,elevations in serum creatinine,Table Change from,0,0.49175193905830383
STRIBILD,elevations in serum creatinine,changes in serum creatinine and eGFR levels at Week,0,0.8358342051506042
STRIBILD,Elevated Serum Creatinine,Studies and at Week,0,0.5017780065536499
STRIBILD,Elevated Serum Creatinine,Serum Creatinine and,0,0.9049309492111206
STRIBILD,Elevated Serum Creatinine,and at Week STR,0,0.5435710549354553
STRIBILD,Elevated Serum Creatinine,Serum Creatinine All Grades in,1,0.8418728113174438
STRIBILD,Elevated Serum Creatinine,Elevated Serum Creatinine,1,1.000000238418579
STRIBILD,Elevated Serum Creatinine,Serum Creatinine All Grades,1,0.8405510783195496
STRIBILD,Elevations in Serum Creatinine,All Grades,0,0.4742010831832886
STRIBILD,Elevations in Serum Creatinine,Subjects Elevations in Serum Creatinine All Grades Emt,1,0.866264820098877
STRIBILD,Elevations in Serum Creatinine,in Serum Creatinine All Grades Emt,1,0.7993662357330322
STRIBILD,Elevations in Serum Creatinine,Subjects with,0,0.5201987624168396
STRIBILD,Elevations in Serum Creatinine,mLminute Subjects Elevations in,1,0.7106653451919556
STRIBILD,Elevations in Serum Creatinine,All Grades Emt,0,0.5002090334892273
STRIBILD,Elevations in Serum Creatinine,Subjects,0,0.5079123973846436
STRIBILD,abnormalities of ALT,abnormalities of ALT M,1,0.8991614580154419
STRIBILD,abnormalities of ALT,Subjects,0,0.5552701950073242
STRIBILD,abnormalities of ALT,of ALT M,1,0.7117796540260315
STRIBILD,abnormalities of ALT,with other antiretroviral agents in other,0,0.5137896537780762
STRIBILD,abnormalities of ALT,abnormalities of ALT M greater than U per,1,0.8774932622909546
STRIBILD,abnormalities of ALT,or abnormalities of ALT M greater than U per,1,0.8699326515197754
STRIBILD,abnormalities of ALT,trials Grade or abnormalities of ALT M greater than U,1,0.7961364388465881
STRIBILD,abnormalities of ALT,or abnormalities of,1,0.7959467172622681
STRIBILD,abnormalities of ALT,abnormalities of ALT,1,0.9999999403953552
STRIBILD,abnormalities of ALT,clinical trials Grade or abnormalities of ALT,1,0.8384755253791809
STRIBILD,allergic reaction,Immune System Disorders,0,0.6019251942634583
STRIBILD,allergic reaction,Immune System allergic reaction,1,0.8913076519966125
STRIBILD,allergic reaction,and,0,0.49174970388412476
STRIBILD,allergic reaction,allergic reaction including angioedema Metabolism and,1,0.8392085433006287
STRIBILD,allergic reaction,Immune System allergic reaction including,1,0.8758928775787354
STRIBILD,allergic reaction,specific for emtricitabine,0,0.5720074772834778
STRIBILD,allergic reaction,been identified Immune System allergic reaction including angioedema Metabolism and Nutrition,1,0.798736572265625
STRIBILD,allergic reaction,emtricitabine have been,0,0.548043429851532
STRIBILD,angioedema,angioedema Metabolism,1,0.859013557434082
STRIBILD,angioedema,emtricitabine have been,0,0.5645276308059692
STRIBILD,angioedema,Disorders,0,0.6099629402160645
STRIBILD,angioedema,Nutrition Disorders,0,0.547492504119873
STRIBILD,angioedema,lactic acidosis hypokalemia,0,0.5224937200546265
STRIBILD,angioedema,identified,0,0.5209757089614868
STRIBILD,angioedema,angioedema Metabolism and Nutrition Disorders lactic,1,0.8122849464416504
STRIBILD,angioedema,and Nutrition Disorders lactic,0,0.5664587020874023
STRIBILD,lactic acidosis,Nutrition lactic acidosis hypokalemia,1,0.8400973081588745
STRIBILD,lactic acidosis,angioedema Metabolism,1,0.6134278774261475
STRIBILD,lactic acidosis,Thoracic,0,0.49294182658195496
STRIBILD,lactic acidosis,angioedema Metabolism and Nutrition lactic acidosis hypokalemia hypophosphatemia,1,0.7416921854019165
STRIBILD,lactic acidosis,lactic acidosis hypokalemia hypophosphatemia Respiratory,1,0.8273273706436157
STRIBILD,lactic acidosis,Thoracic and Mediastinal Disorders dyspnea,0,0.508588433265686
STRIBILD,lactic acidosis,angioedema Metabolism and Nutrition lactic acidosis hypokalemia hypophosphatemia Respiratory Thoracic and,1,0.7447011470794678
STRIBILD,hypokalemia,hypokalemia hypophosphatemia Respiratory Thoracic,1,0.7784699201583862
STRIBILD,hypokalemia,hypokalemia,1,1.0000001192092896
STRIBILD,hypokalemia,and Mediastinal,0,0.44973886013031006
STRIBILD,hypokalemia,hypokalemia hypophosphatemia Respiratory Thoracic and,1,0.7787774801254272
STRIBILD,hypokalemia,hypokalemia hypophosphatemia Respiratory Thoracic and Mediastinal,1,0.7719748020172119
STRIBILD,hypokalemia,Disorders lactic hypokalemia hypophosphatemia Respiratory Thoracic and Mediastinal,1,0.7578138113021851
STRIBILD,hypophosphatemia,lactic acidosis hypophosphatemia Respiratory,1,0.8208609819412231
STRIBILD,hypophosphatemia,hypokalemia,1,0.6917717456817627
STRIBILD,hypophosphatemia,hypophosphatemia Respiratory Thoracic and Mediastinal Disorders,1,0.8287951946258545
STRIBILD,hypophosphatemia,hypophosphatemia Respiratory Thoracic,1,0.8528327941894531
STRIBILD,dyspnea,hypophosphatemia Respiratory Thoracic and Mediastinal Disorders,0,0.6596542596817017
STRIBILD,dyspnea,dyspnea Gastrointestinal Disorders pancreatitis,1,0.7804077863693237
STRIBILD,dyspnea,dyspnea Gastrointestinal Disorders pancreatitis increased amylase,1,0.7459412813186646
STRIBILD,dyspnea,dyspnea,1,1.0
STRIBILD,dyspnea,Gastrointestinal Disorders pancreatitis,0,0.5217652320861816
STRIBILD,dyspnea,dyspnea Gastrointestinal Disorders,1,0.8253926634788513
STRIBILD,dyspnea,Mediastinal Disorders,0,0.6414200067520142
STRIBILD,dyspnea,cidosis hypokalemia,0,0.5238227248191833
STRIBILD,pancreatitis,pancreatitis increased amylase abdominal pain Hepatobiliary,1,0.804684042930603
STRIBILD,increased amylase,hepatitis increased liver e,0,0.6317572593688965
STRIBILD,abdominal pain,increased abdominal pain Hepatobiliary Disorders hepatic,1,0.7835192680358887
STRIBILD,abdominal pain,hepatitis increased liver e,0,0.4941072463989258
STRIBILD,abdominal pain,Hepatobiliary Disorders hepatic steatosis hepatitis increased liver enzymes most com,0,0.5526648759841919
STRIBILD,abdominal pain,Disorders pancreatitis increased abdominal pain,1,0.8072137832641602
STRIBILD,abdominal pain,abdominal pain Hepatobiliary Disorders hepatic,1,0.7926585674285889
STRIBILD,abdominal pain,hepatitis increased liver enzymes most com,0,0.5229758024215698
STRIBILD,abdominal pain,abdominal pain Hepatobiliary Disorders hepatic steatosis hepatitis,1,0.7703655958175659
STRIBILD,abdominal pain,Disorders pancreatitis increased abdominal pain Hepatobiliary Disorders,1,0.7673348784446716
STRIBILD,abdominal pain,dyspnea Gastrointestinal Disorders pancreatitis,0,0.6727596521377563
STRIBILD,abdominal pain,abdominal pain,1,0.9999998807907104
STRIBILD,hepatic steatosis,hepatic steatosis hepatitis,1,0.9170871376991272
STRIBILD,hepatic steatosis,pain Hepatobiliary hepatic steatosis hepatitis increased liver enzymes,1,0.8136675953865051
STRIBILD,hepatic steatosis,Hepatobiliary hepatic steatosis,1,0.9046999216079712
STRIBILD,hepatic steatosis,increased liver enzymes,0,0.7364879846572876
STRIBILD,hepatic steatosis,pain Hepatobiliary hepatic steatosis hepatitis,1,0.8312137126922607
STRIBILD,hepatic steatosis,Hepatobiliary,0,0.6970117092132568
STRIBILD,hepatitis,commonly AST ALT gamma GT Skin,0,0.5174258351325989
STRIBILD,hepatitis,hepatic steatosis,0,0.717839241027832
STRIBILD,rash,rash Musculoskeletal and Connective Tissue,1,0.7961054444313049
STRIBILD,rash,Skin and Subcutaneous Tissue rash Musculoskeletal,1,0.787258505821228
STRIBILD,rash,rash Musculoskeletal and,1,0.8439619541168213
STRIBILD,rhabdomyolysis,rhabdomyolysis,1,0.9999999403953552
STRIBILD,rhabdomyolysis,Disorders rash Musculoskeletal and Connective,0,0.5755608677864075
STRIBILD,rhabdomyolysis,muscular,0,0.6450914740562439
STRIBILD,rhabdomyolysis,as bone pain and which may contribute to,0,0.5197714567184448
STRIBILD,rhabdomyolysis,rhabdomyolysis osteomalacia manifested as bone pain,1,0.7764973640441895
STRIBILD,rhabdomyolysis,Tissue rhabdomyolysis,1,0.9019212126731873
STRIBILD,rhabdomyolysis,bone pain and,0,0.5196481943130493
STRIBILD,rhabdomyolysis,Musculoskeletal and Connective Tissue Disorders,0,0.5982316136360168
STRIBILD,rhabdomyolysis,rhabdomyolysis osteomalacia manifested as,1,0.8036066293716431
STRIBILD,bone pain,osteomalacia manifested bone pain and which,1,0.805834174156189
STRIBILD,bone pain,rhabdomyolysis osteomalacia manifested as,1,0.5771803259849548
STRIBILD,bone pain,manifested bone pain,1,0.8935390710830688
STRIBILD,bone pain,myopathy Renal and Urinary,0,0.49620842933654785
STRIBILD,bone pain,bone pain and which may contribute,1,0.9062656164169312
STRIBILD,bone pain,osteomalacia manifested bone pain and which may contribute,1,0.805780291557312
STRIBILD,bone pain,manifested bone pain and,1,0.8823543787002563
STRIBILD,bone pain,bone pain and,1,0.9562143683433533
STRIBILD,fractures,Renal and Urinary,0,0.5325919389724731
STRIBILD,fractures,fractures muscular weakness,1,0.7655837535858154
STRIBILD,fractures,osteomalacia manifested as bone pain and which,0,0.6435127854347229
STRIBILD,fractures,which may contribute fractures muscular weakness myopathy Renal,1,0.7461447715759277
STRIBILD,fractures,e Disorders rhabdomyolysis,0,0.5604429841041565
STRIBILD,acute renal failure,renal failure renal failure acute,1,0.9643396139144897
STRIBILD,acute renal failure,and Urinary acute renal failure renal failure acute tubular necrosis,1,0.8589129447937012
STRIBILD,acute renal failure,proximal renal tubulopathy interstitial,0,0.6428825259208679
STRIBILD,acute renal failure,renal failure acute,0,0.9763739705085754
STRIBILD,acute renal failure,and Urinary acute renal failure renal,1,0.9310861825942993
STRIBILD,acute renal failure,Fanconi syndrome proximal renal tubulopathy,0,0.6325215101242065
STRIBILD,acute renal failure,syndrome proximal renal,0,0.6870453357696533
STRIBILD,acute renal failure,and Urinary acute renal failure,1,0.9410034418106079
STRIBILD,acute renal failure,Urinary acute renal failure renal failure acute tubular necrosis,1,0.8477650284767151
STRIBILD,renal failure,renal failure acute tubular necrosis Fanconi syndrome,1,0.7283469438552856
STRIBILD,renal failure,myopathy Renal and Urinary Disorders,0,0.74565589427948
STRIBILD,renal failure,myopathy,0,0.6030786037445068
STRIBILD,renal failure,Urinary Disorders acute renal renal failure acute tubular necrosis,1,0.7643336057662964
STRIBILD,acute tubular necrosis,acute tubular necrosis,1,1.0
STRIBILD,acute tubular necrosis,renal failure renal acute tubular necrosis,1,0.9432063698768616
STRIBILD,acute tubular necrosis,renal acute tubular necrosis,1,0.9800923466682434
STRIBILD,Fanconi syndrome,renal tubulopathy,0,0.5397286415100098
STRIBILD,Fanconi syndrome,acute tubular,0,0.5103150606155396
STRIBILD,Fanconi syndrome,Urinary Disorders acute renal failure renal failure,0,0.5314942002296448
STRIBILD,proximal renal tubulopathy,diabetes,0,0.5364819765090942
STRIBILD,proximal renal tubulopathy,tubular necrosis Fanconi proximal renal tubulopathy interstitial nephritis including acute cases,1,0.8200535178184509
STRIBILD,proximal renal tubulopathy,Fanconi proximal renal,1,0.7587507367134094
STRIBILD,proximal renal tubulopathy,renal,0,0.7287794351577759
STRIBILD,proximal renal tubulopathy,proximal renal tubulopathy interstitial nephritis including acute cases,1,0.8992971181869507
STRIBILD,proximal renal tubulopathy,proximal renal tubulopathy,1,1.0
STRIBILD,proximal renal tubulopathy,renal tubulopathy interstitial nephritis including,1,0.8223003149032593
STRIBILD,proximal renal tubulopathy,insipidus,0,0.5405054688453674
STRIBILD,proximal renal tubulopathy,nephritis including acute cases nephrogenic,0,0.6629751920700073
STRIBILD,proximal renal tubulopathy,proximal renal tubulopathy interstitial nephritis including,1,0.9175772666931152
STRIBILD,interstitial nephritis,insufficiency increased creatinine,0,0.6040940284729004
STRIBILD,interstitial nephritis,interstitial nephritis including,1,0.9737817645072937
STRIBILD,interstitial nephritis,renal interstitial nephritis including acute cases nephrogenic diabetes,1,0.87697434425354
STRIBILD,interstitial nephritis,renal interstitial nephritis,1,0.9786872267723083
STRIBILD,renal insufficiency,General Disorders,0,0.5612410306930542
STRIBILD,renal insufficiency,renal insufficiency increased creatinine proteinuria,1,0.8291569948196411
STRIBILD,renal insufficiency,acute cases nephrogenic diabetes renal insufficiency increased,1,0.7967252731323242
STRIBILD,renal insufficiency,renal insufficiency increased creatinine proteinuria polyuria General,1,0.8077261447906494
STRIBILD,renal insufficiency,polyuria General Disorders and,0,0.6401822566986084
STRIBILD,renal insufficiency,acute cases nephrogenic diabetes renal insufficiency,1,0.801040530204773
STRIBILD,renal insufficiency,cases nephrogenic diabetes renal insufficiency,1,0.8184728622436523
STRIBILD,proteinuria,Disorders and Administration Site,0,0.5448317527770996
STRIBILD,proteinuria,proteinuria polyuria General Disorders and,1,0.8618245124816895
STRIBILD,asthenia,Disorders and Administration Site asthenia The following adverse reactions listed,1,0.7512837648391724
STRIBILD,asthenia,proteinuria polyuria General Disorders and,1,0.4996075928211212
STRIBILD,asthenia,Administration Site asthenia The following,1,0.8020303249359131
STRIBILD,asthenia,asthenia The following adverse,1,0.8376036882400513
STRIBILD,proximal renal tubulopathy,occur,0,0.44471049308776855
STRIBILD,proximal renal tubulopathy,renal tubulopathy rhabdomyolysis osteomalacia hypokalemia muscular weakness,1,0.7593100666999817
STRIBILD,proximal renal tubulopathy,rhabdomyolysis osteomalacia hypokalemia muscular weakness myopathy hypophosphatemia,0,0.5864847898483276
STRIBILD,proximal renal tubulopathy,reactions listed under the,0,0.5170048475265503
STRIBILD,osteomalacia,osteomalacia hypokalemia muscular,1,0.8360495567321777
STRIBILD,osteomalacia,reactions listed under the,0,0.49714311957359314
STRIBILD,osteomalacia,system headings,0,0.44722527265548706
STRIBILD,osteomalacia,muscular weakness myopathy,0,0.6311544179916382
STRIBILD,osteomalacia,hypokalemia,0,0.645020604133606
STRIBILD,osteomalacia,hypokalemia muscular,0,0.6092128753662109
STRIBILD,osteomalacia,osteomalacia hypokalemia,1,0.862699031829834
STRIBILD,osteomalacia,osteomalacia hypokalemia muscular weakness myopathy,1,0.8426550626754761
STRIBILD,osteomalacia,osteomalacia,1,1.0
STRIBILD,osteomalacia,proximal renal tubulopathy osteomalacia hypokalemia muscular weakness myopathy hypophosphatemia,1,0.6868563890457153
STRIBILD,osteomalacia,osteomalacia hypokalemia muscular weakness myopathy hypophosphatemia,1,0.8273607492446899
STRIBILD,hypokalemia,hypokalemia muscular,1,0.9052834510803223
STRIBILD,hypokalemia,hypokalemia muscular weakness myopathy hypophosphatemia,1,0.8327113389968872
STRIBILD,hypokalemia,consequence of,0,0.5158682465553284
STRIBILD,hypokalemia,osteomalacia,0,0.645020604133606
STRIBILD,hypokalemia,hypokalemia muscular weakness,1,0.884667158126831
STRIBILD,hypokalemia,proximal renal tubulopathy rhabdomyolysis hypokalemia muscular weakness myopathy hypophosphatemia,1,0.7321207523345947
STRIBILD,hypokalemia,renal tubulopathy rhabdomyolysis hypokalemia muscular,1,0.7593333721160889
STRIBILD,hypokalemia,a consequence of proximal,0,0.5181326866149902
STRIBILD,muscular weakness,a consequence,0,0.49288317561149597
STRIBILD,muscular weakness,a consequence of proximal,0,0.5256338119506836
STRIBILD,muscular weakness,tubulopathy rhabdomyolysis osteomalacia muscular,1,0.7481898069381714
STRIBILD,muscular weakness,rhabdomyolysis osteomalacia muscular weakness myopathy,1,0.7912337779998779
STRIBILD,HEPATOMEGALY,labeling Lactic AcidosisSevere Hepatomegaly with Stea,0,0.763664960861206
STRIBILD,STEATOSIS,drug reactions are cussed,1,0.4701128602027893
STRIBILD,STEATOSIS,REACTIONS,0,0.4852551817893982
STRIBILD,STEATOSIS,The following,0,0.4758149981498718
STRIBILD,STEATOSIS,are cussed,1,0.48342660069465637
STRIBILD,STEATOSIS,cussed in other sections of the,1,0.4942656457424164
STRIBILD,STEATOSIS,adverse drug reactions are cussed in other,1,0.4859916567802429
STRIBILD,STEATOSIS,Steatosis,0,1.0000001192092896
STRIBILD,LACTIC ACIDOSIS,AcidosisSevere omegaly with St,1,0.7207191586494446
STRIBILD,HEPATOMEGALY,[see  Boxed  Warning Warnings,1,0.5094732046127319
STRIBILD,HEPATOMEGALY,AcidosisSevere omegaly with St,1,0.522950291633606
STRIBILD,STEATOSIS,"Steatosis see Boxed g ,",1,0.8418182134628296
STRIBILD,STEATOSIS,see Boxed Warnin,0,0.47817087173461914
STRIBILD,STEATOSIS,"g , War nings",1,0.48949337005615234
STRIBILD,STEATOSIS,see,0,0.491096168756485
STRIBILD,STEATOSIS,Severe Acute Exacerbations,0,0.5198203325271606
STRIBILD,STEATOSIS,"Boxed g , War",1,0.4402865171432495
STRIBILD,STEATOSIS,"see Boxed g  ,  War nings",1,0.4687919616699219
STRIBILD,STEATOSIS,Warnin,0,0.4875917434692383
STRIBILD,STEATOSIS,"Steatosis see Boxed g  ,  War nings and Precautions Severe Acute",1,0.7948688864707947
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"s (5.1)  ] . 
 *  Severe Acute Ex acerbations of",1,0.755027174949646
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,Warnin,0,0.4853355884552002
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,Acute Ex acerbations of Hepatitis,1,0.903468132019043
STRIBILD,Lactic acidosis,Precautions Severe Acute ons,1,0.60146164894104
STRIBILD,Lactic acidosis,Precautions,0,0.5459334850311279
STRIBILD,Lactic acidosis,Acute ons of Hepatiti s,1,0.5845034718513489
STRIBILD,Lactic acidosis,and,0,0.4959595799446106
STRIBILD,Lactic acidosis,of Hepatiti,1,0.5029893517494202
STRIBILD,Lactic acidosis,Exacerbati,0,0.5672472715377808
STRIBILD,Lactic acidosis,ons of Hepatiti,1,0.5252129435539246
STRIBILD,hepatomegaly,of Hepatitis B see xed Warning ,1,0.6268763542175293
STRIBILD,hepatomegaly,ons of Hepatiti,1,0.692612886428833
STRIBILD,hepatomegaly,B see xed,1,0.478732168674469
STRIBILD,hepatomegaly,of Hepatitis B see xed Warning  Warnings,1,0.6145389080047607
STRIBILD,hepatomegaly,Onset or Worsening Renal,0,0.5109408497810364
STRIBILD,steatosis,rnings an d Precautions New Onset,1,0.5441105365753174
STRIBILD,steatosis,Onset or Worsening Renal,0,0.5471788644790649
STRIBILD,steatosis,see,0,0.491096168756485
STRIBILD,steatosis,rnings an d Precautions,1,0.48358094692230225
STRIBILD,steatosis,rnings an d Precautions New Onset or,1,0.5408108234405518
STRIBILD,steatosis,B see Boxed Warning rnings an d,1,0.4851258397102356
STRIBILD,steatosis,Precautions Severe,0,0.4911515712738037
STRIBILD,acute exacerbations of hepatitis B,SUSPECTED A,0,0.5031479597091675
STRIBILD,acute exacerbations of hepatitis B,Gilead S ciences Inc at GILEAD or,1,0.457455575466156
STRIBILD,acute exacerbations of hepatitis B,"report SUSPECTED DVERSE REACTIONS, contact Gilead S",1,0.5157413482666016
STRIBILD,acute exacerbations of hepatitis B,"DVERSE REACTIONS, contact Gilead S ciences",1,0.5103633403778076
STRIBILD,LACTIC ACIDOSIS,of STRIBILD is based,1,0.4334181249141693
STRIBILD,LACTIC ACIDOSIS,History The safety of STRIBILD,1,0.510161280632019
STRIBILD,LACTIC ACIDOSIS,History The safety of STRIBILD is  based on,1,0.5082998275756836
STRIBILD,LACTIC ACIDOSIS,The safety assessment,0,0.5517429113388062
STRIBILD,HEPATOMEGALY,based  the Week 14 pooled data from,1,0.46239882707595825
STRIBILD,HEPATOMEGALY,The safety assessment,0,0.4859955906867981
STRIBILD,HEPATOMEGALY,the Week,1,0.4695115387439728
STRIBILD,HEPATOMEGALY,of STRIBILD is based the,1,0.4403603672981262
STRIBILD,HEPATOMEGALY,Antiretroviral Treatment History The safety assessment of STRIBILD is,0,0.4918256103992462
STRIBILD,HEPATOMEGALY,STRIBILD is based the,1,0.4570215940475464
STRIBILD,HEPATOMEGALY,is based  the Week 14 pooled data from,1,0.45508337020874023
STRIBILD,HEPATOMEGALY,subjects in two randomized,0,0.460929811000824
STRIBILD,HEPATOMEGALY,is based the Week 14,1,0.44609513878822327
STRIBILD,STEATOSIS,the Week ed data f rom subjects in two randomized,1,0.5008635520935059
STRIBILD,STEATOSIS,STRIBILD is based the,1,0.5337975025177002
STRIBILD,STEATOSIS,the Week ed,1,0.5124566555023193
STRIBILD,STEATOSIS,the Week ed data,1,0.48585665225982666
STRIBILD,STEATOSIS,doubleblind activecontrolled clinical trials,0,0.5171191096305847
STRIBILD,STEATOSIS,on the Week ed data f,1,0.5025247931480408
STRIBILD,STEATOSIS,based on the Week ed data f,1,0.5007743239402771
STRIBILD,STEATOSIS,on the,0,0.5120353102684021
STRIBILD,STEATOSIS,based on the Week ed,1,0.5177871584892273
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,is based on the Week pooled data from subjects in,0,0.4583491086959839
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"randomized, double-blind, ac tivecontrolled clinical trials Study and",1,0.5093408823013306
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,safety assessment of STRIBILD is,0,0.529560923576355
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,The,0,0.49421989917755127
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,clinical trials Study and Study in antiretroviral treatmentnaive,0,0.5273276567459106
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"from subjects two randomized,",1,0.4249182939529419
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"two randomized, double-blind, ac tivecontrolled",1,0.44868969917297363
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"from subjects two randomized, double-blind, ac",1,0.44067108631134033
STRIBILD,Lactic acidosis,HIV infected adult subjects see Clinical Studies A total of subjects received STR,0,0.4679487347602844
STRIBILD,Lactic acidosis,Study in antiretroviral reatment-naive  HIV infected adult,1,0.4888884127140045
STRIBILD,Lactic acidosis,reatment-naive  HIV infected,1,0.4749099910259247
STRIBILD,Lactic acidosis,A total of subjects received,0,0.4995700418949127
STRIBILD,Lactic acidosis,in antiretroviral reatment-naive  HIV infected adult,1,0.48661622405052185
STRIBILD,Lactic acidosis,in antiretroviral reatment-naive  HIV infected adult subjects,1,0.48902416229248047
STRIBILD,Lactic acidosis,Clinical Studies A total of subjects,0,0.5113397240638733
STRIBILD,Lactic acidosis,Clinical Studies A total,0,0.5181170701980591
STRIBILD,Lactic acidosis,Study in antiretroviral reatment-naive  HIV infected adult subjects see,1,0.4871331453323364
STRIBILD,Lactic acidosis,antiretroviral reatment-naive  HIV infected adult subjects,1,0.4784339964389801
STRIBILD,hepatomegaly,and Study in,0,0.46972909569740295
STRIBILD,hepatomegaly,in antiretroviral treatmentnaive HIV ed adult sub jects see Clinical,1,0.44927978515625
STRIBILD,steatosis,daily in,0,0.4970249533653259
STRIBILD,steatosis,treatmentnaive HIV infected adult subjects,0,0.5055116415023804
STRIBILD,steatosis,HIV infected adult [see,1,0.4910147488117218
STRIBILD,steatosis,Study,0,0.5476764440536499
STRIBILD,fatal,subjects see,0,0.4879864454269409
STRIBILD,fatal,es (1,1,0.4904571771621704
STRIBILD,fatal,antiretroviral treatmentnaive HIV infected adult subjects,0,0.45742636919021606
STRIBILD,fatal,treatmentnaive HIV,0,0.456600546836853
STRIBILD,acute exacerbations of hepatitis B,mg PLA (efavirenz 600 mg/emtricitabin,1,0.5132268667221069
STRIBILD,acute exacerbations of hepatitis B,treatmentnaive HIV,0,0.5225629210472107
STRIBILD,acute exacerbations of hepatitis B,RTV TRUVADA,0,0.5047597289085388
STRIBILD,acute exacerbations of hepatitis B,mgtenofovir DF mg PLA (efavirenz 600 mg/emtricitabin,1,0.5353439450263977
STRIBILD,acute exacerbations of hepatitis B,mgcobicistat mgemtricitabine mgtenofovir DF,0,0.5362561941146851
STRIBILD,acute exacerbations of hepatitis B,ATV ritonavir RTV TRUVADA emtricitabine mg,0,0.5579140186309814
STRIBILD,acute exacerbations of hepatitis B,(efavirenz 600 mg/emtricitabin e mgtenofovir,1,0.5526474714279175
STRIBILD,acute exacerbations of hepatitis B,(efavirenz 600 mg/emtricitabin e mgtenofovir DF mg or,1,0.5447306632995605
STRIBILD,acute exacerbations of hepatitis B,RTV TRUVADA emtricitabine mg,0,0.5254974365234375
STRIBILD,worsening renal impairment,see Boxed,0,0.45445114374160767
STRIBILD,worsening renal impairment,adverse drug reactions re,1,0.5979681015014648
STRIBILD,Fanconi syndrome,idosis/Severe He,1,0.5468271374702454
STRIBILD,Fanconi syndrome,discussed in other,0,0.4960305690765381
STRIBILD,Fanconi syndrome,Lactic idosis/Severe He patomegaly with Steatosis see,1,0.5600782632827759
STRIBILD,Fanconi syndrome,Precautions Severe,0,0.5181451439857483
STRIBILD,Fanconi syndrome,labeling Lactic idosis/Severe He,1,0.5636281967163086
STRIBILD,Fanconi syndrome,the,0,0.49473893642425537
STRIBILD,Fanconi syndrome,patomegaly with Steatosis,0,0.5608709454536438
STRIBILD,Decreases in bone mineral density,is,0,0.4640505015850067
STRIBILD,Decreases in bone mineral density,sed on the Week 144 pooled data f rom subjects in,1,0.5386713743209839
STRIBILD,Decreases in bone mineral density,The,0,0.5018057823181152
STRIBILD,Decreases in bone mineral density,rom subjects in two randomized doubleblind activecontrolled clinical trials Study and,0,0.5377039313316345
STRIBILD,Decreases in bone mineral density,Week 144 pooled data f rom subjects in two,1,0.5495608448982239
STRIBILD,Decreases in bone mineral density,of STRIBILD is,0,0.47385647892951965
STRIBILD,Decreases in bone mineral density,the Week 144 pooled data f rom subjects in two,1,0.5596591234207153
STRIBILD,Decreases in bone mineral density,History,0,0.44333702325820923
STRIBILD,Immune reconstitution syndrome,adult subjects see Clinical Studies A total of subjects received,0,0.5244655609130859
STRIBILD,Immune reconstitution syndrome,total of subjects received STRIBILD once dail,0,0.5337222814559937
STRIBILD,Immune reconstitution syndrome,"subjects received STRIBILD once y in these two studies.



 Th e proportion of",1,0.5570564866065979
STRIBILD,Lactic acidosis,mgemtricitabine r DF 300 mg); A TRIPLA efavirenz mgemtricitabine,1,0.50161212682724
STRIBILD,Lactic acidosis,total of subjects received STRIBILD once dail,0,0.49670130014419556
STRIBILD,Lactic acidosis,with STRIBILD elvitegravir mgcobicistat mgemtricitabine,0,0.5392290353775024
STRIBILD,Lactic acidosis,ntinued treatment with STRIBILD elvitegravir,0,0.5220606923103333
STRIBILD,Lactic acidosis,efavirenz mgemtricitabine mgtenofovir DF mg or atazanavir ATV ritonavir,0,0.46775826811790466
STRIBILD,Lactic acidosis,r DF 300 mg); A TRIPLA efavirenz mgemtricitabine mgtenofovir,1,0.5084395408630371
STRIBILD,Lactic acidosis,mgemtricitabine r DF,1,0.5215120911598206
STRIBILD,Lactic acidosis,r DF 300 mg); A TRIPLA,1,0.5629425048828125
STRIBILD,hepatomegaly,ATRIPLA efav,0,0.49463531374931335
STRIBILD,hepatomegaly,mg ATRIPLA irenz 600 mg,1,0.5211731195449829
STRIBILD,hepatomegaly,mgcobicistat mgemtricitabine mgtenofovir,0,0.5971787571907043
STRIBILD,hepatomegaly,mgtenofovir DF mg ATRIPLA irenz,1,0.5490725040435791
STRIBILD,hepatomegaly,mgtenofovir DF mg ATRIPLA irenz 600 mg emtricitabine mgtenofovir DF,1,0.5465884208679199
STRIBILD,hepatomegaly,ATRIPLA irenz,1,0.4694822430610657
STRIBILD,fatal,ovir  DF mg or atazanavir ATV,1,0.47636282444000244
STRIBILD,fatal,ovir  DF mg or,1,0.5202606320381165
STRIBILD,fatal,mgtenof,0,0.5347504019737244
STRIBILD,fatal,mgtenofovir DF mg ATRIPLA,0,0.49331632256507874
STRIBILD,fatal,ovir  DF,1,0.49753934144973755
STRIBILD,proximal renal tubular dysfunction,dreams,0,0.40461769700050354
STRIBILD,proximal renal tubular dysfunction,SUBCUTANEOUS TISSUE DISORDERS,0,0.5532921552658081
STRIBILD,proximal renal tubular dysfunction,4% SKIN AND,1,0.47508907318115234
STRIBILD,proximal renal tubular dysfunction,SUBCUTANEOUS,0,0.5177088379859924
STRIBILD,proximal renal tubular dysfunction,Abnormal dreams,0,0.4569275379180908
STRIBILD,proximal renal tubular dysfunction,with a -existing history of depression or psychiatric illness,1,0.46490705013275146
STRIBILD,proximal renal tubular dysfunction,VirologicallySuppressed HIVInfected Subjects,0,0.4552724361419678
STRIBILD,proximal renal tubular dysfunction,depression or psychiatric illness In,1,0.47306227684020996
STRIBILD,proximal renal tubular dysfunction,in subjects with a -existing history of depression or,1,0.4759378731250763
STRIBILD,increases in serum creatinine,agents in other clinical trials depression abdominal,0,0.5320121049880981
STRIBILD,increases in serum creatinine,"pneumonia, si",1,0.48747557401657104
STRIBILD,increases in serum creatinine,"fever pain asopharyngitis, pneumonia, si",1,0.5042204856872559
STRIBILD,increases in serum creatinine,"asopharyngitis, pneumonia, si nusitis",1,0.5094190835952759
STRIBILD,declines in estimated creatinine clearance,"tract infection, arthralgia back pain myalgia paresthesia",1,0.4974023103713989
STRIBILD,declines in estimated creatinine clearance,myalgia,0,0.49159353971481323
STRIBILD,decreases in bone mineral density,"occurred in subjects receiving STRIBILD, 41%",1,0.5831536054611206
STRIBILD,decreases in bone mineral density,occurred in subjects receiving,1,0.5319176912307739
STRIBILD,decreases in bone mineral density,of subjects receiving ATRIPLA,0,0.5390695333480835
STRIBILD,decreases in bone mineral density,"all grades occurred in subjects receiving STRIBILD,",1,0.5021341443061829
STRIBILD,increases in biochemical markers of bone metabolism,receiving,0,0.48170626163482666
STRIBILD,increases in biochemical markers of bone metabolism,TRUVADA The cobicistat component of STRIBILD has been shown,0,0.5035715103149414
STRIBILD,increases in biochemical markers of bone metabolism,"receiving STRIBILD of  receiving ATRIPLA, and 42% of subjects receiving A",1,0.5454657077789307
STRIBILD,increases in biochemical markers of bone metabolism,"STRIBILD of  receiving ATRIPLA, and 42% of subjects receiving A TV RTV",1,0.497254341840744
STRIBILD,increases in biochemical markers of bone metabolism,"of  receiving ATRIPLA, and 42% of subjects receiving A TV RTV TRUVADA The cobicistat",1,0.49229127168655396
STRIBILD,increases in biochemical markers of bone metabolism,42% of subjects receiving A TV RTV TRUVADA The,1,0.4563860595226288
STRIBILD,increases in biochemical markers of bone metabolism,"receiving STRIBILD of receiving ATRIPLA, and 42% of subjects receiving",1,0.5437225103378296
STRIBILD,increased bone turnover,serum creatinine and,0,0.609502911567688
STRIBILD,increased bone turnover,subjects receiving ATV RTV UVADA. The cobicist,1,0.45142531394958496
STRIBILD,increased bone turnover,"UVADA.



 The cobicist at component",1,0.5095009803771973
STRIBILD,increased bone turnover,The cobicist at component,1,0.5027307271957397
STRIBILD,increased bone turnover,ATV RTV UVADA. The cobicist,1,0.4445350170135498
STRIBILD,increased bone turnover,RTV TR,0,0.46701595187187195
STRIBILD,increased bone turnover,receiving ATRIPLA and of subjects receiving,0,0.5012816190719604
STRIBILD,osteomalacia,ATRIPLAN ATV RTV TRUVADAN Seru,0,0.5048270225524902
STRIBILD,osteomalacia,RTV TRUVADAN m Creatinine,1,0.5279443860054016
STRIBILD,osteomalacia,Seru,0,0.48655736446380615
STRIBILD,osteomalacia,ATV RTV TRUVADAN m Creatinine,1,0.5275093913078308
STRIBILD,osteomalacia,m Creatinine mgdL,1,0.5704576373100281
STRIBILD,osteomalacia,STRIBILDN ATRIPLAN ATV RTV,0,0.40463972091674805
STRIBILD,proximal renal tubulopathy,LDN ATRIPLAN ATV RTV TRUVADAN Serum Creatinine,0,0.5826292634010315
STRIBILD,proximal renal tubulopathy,Serum Creatinine 0.14,1,0.6017276048660278
STRIBILD,proximal renal tubulopathy,RTV TRUVADAN Serum Creatinine               0.14 (+/-0.1,1,0.5771346092224121
STRIBILD,proximal renal tubulopathy,eGFR by CockcroftGault,0,0.5487648248672485
STRIBILD,proximal renal tubulopathy,eGFR by CockcroftGault mLminute,0,0.5503807067871094
STRIBILD,proximal renal tubulopathy,Creatinine mgdL,0,0.6437985897064209
STRIBILD,proximal renal tubulopathy,Serum Creatinine               0.14 (+/-0.1 eGFR by CockcroftGault,1,0.6106581687927246
STRIBILD,proximal renal tubulopathy,TRUVADAN,0,0.49576282501220703
STRIBILD,proximal renal tubulopathy,Serum Creatinine               0.14 (+/-0.1 eGFR by CockcroftGault mLminute,1,0.6084821224212646
STRIBILD,bone pain,-0.12)   ,1,0.44931310415267944
STRIBILD,bone pain,Creatinine -0.12)    eGFR,1,0.5024653673171997
STRIBILD,bone pain,-0.12)    eGFR,1,0.5071496367454529
STRIBILD,bone pain,Serum,0,0.4976053237915039
STRIBILD,bone pain,-0.12)    eGFR by CockcroftGault,1,0.483988881111145
STRIBILD,pain in extremities,mgdL,0,0.44829535484313965
STRIBILD,pain in extremities,Creatinine 0.09 (+/-0.15)      eGFR by CockcroftGault mLminute,1,0.5128566026687622
STRIBILD,fractures,CockcroftGault,0,0.44632524251937866
STRIBILD,fractures,mL/minute Subjects with,1,0.5040504932403564
STRIBILD,fractures,eGFR by mL/minute Subjects with Elevation,1,0.4869111478328705
STRIBILD,fractures,mL/minute,1,0.47391772270202637
STRIBILD,fractures,mL/minute Subjects,1,0.49368375539779663
STRIBILD,fractures,Subjects with Elevation,0,0.5621925592422485
STRIBILD,Arthralgias,with  in Serum C reatinine All,1,0.5684071183204651
STRIBILD,Arthralgias,Subjects with Elevation,0,0.5482255220413208
STRIBILD,Arthralgias,reatinine,0,0.5338107943534851
STRIBILD,Arthralgias,Serum C,1,0.5009053349494934
STRIBILD,Arthralgias,Subjects,0,0.5374791622161865
STRIBILD,Arthralgias,with in,1,0.5079838037490845
STRIBILD,Arthralgias,in Serum C reatinine All,1,0.5686180591583252
STRIBILD,Arthralgias,Subjects with,0,0.5467205047607422
STRIBILD,Arthralgias,reatinine All Grades,0,0.5406102538108826
STRIBILD,muscle pain,(All G rades,1,0.45613914728164673
STRIBILD,muscle pain,nine (All G,1,0.4199472665786743
STRIBILD,muscle pain,with Elevations,0,0.46813851594924927
STRIBILD,muscle pain,Elevations in,0,0.47323447465896606
STRIBILD,muscle pain,in Serum nine (All G rades,1,0.4799128472805023
STRIBILD,proximal renal tubulopathy,in Serum Creatinine All             6              Emtricitabine or Tenofovir DF,1,0.5585529804229736
STRIBILD,proximal renal tubulopathy,Elevations in,0,0.4448690414428711
STRIBILD,proximal renal tubulopathy,Elevations in Serum,0,0.5579128265380859
STRIBILD,proximal renal tubulopathy,Emtricitabine or Tenofovir DF In addition to the laboratory,0,0.49989256262779236
STRIBILD,proximal renal tubulopathy,in Serum,0,0.5335416793823242
STRIBILD,proximal renal tubulopathy,            6              Emtricitabine or Tenofovir DF,1,0.47554811835289
STRIBILD,proximal renal tubulopathy,Creatinine,0,0.613745391368866
STRIBILD,proximal renal tubulopathy,            6              Emtricitabine or,1,0.49763697385787964
STRIBILD,proximal renal tubulopathy,or Tenofovir DF In addition to the laboratory,0,0.4895683526992798
STRIBILD,proximal renal tubulopathy,Tenofovir DF In addition to the laboratory abnormalities,0,0.5147369503974915
STRIBILD,proximal renal tubulopathy,Elevations in Serum Creatinine All Grades,0,0.6171087622642517
STRIBILD,central obesity,than U,0,0.46688640117645264
STRIBILD,central obesity,F ter than 170 U  per,1,0.5410729646682739
STRIBILD,central obesity,than 170 U per,1,0.5263960361480713
STRIBILD,central obesity,alkaline phosphatase,0,0.4642191231250763
STRIBILD,central obesity,170 U per,1,0.5356937646865845
STRIBILD,central obesity,U per L F ter than,1,0.5002174377441406
STRIBILD,dorsocervical fat enlargement,"r L), alkaline phosphatase (g reater than U per L",1,0.5498526096343994
STRIBILD,dorsocervical fat enlargement,U per L F ter than,1,0.5157411098480225
STRIBILD,dorsocervical fat enlargement,Grade or laboratory abnormalities of ALT M greater than U per L F greater than U pe,0,0.5774813890457153
STRIBILD,dorsocervical fat enlargement,ULN serum glucose less than,0,0.5582290291786194
STRIBILD,buffalo hump,per L alkaline phosphatase ater than 55 U per L bilirubin greater,1,0.4835304617881775
STRIBILD,buffalo hump,ULN serum glucose less than,0,0.4733811020851135
STRIBILD,buffalo hump,alkaline phosphatase ater than 55 U per L bilirubin greater,1,0.47840267419815063
STRIBILD,buffalo hump,U,0,0.4872669577598572
STRIBILD,buffalo hump,U per L bilirubin greater than ULN serum glucose less than or greater than mg p,0,0.47784844040870667
STRIBILD,buffalo hump,phosphatase ater,1,0.49673497676849365
STRIBILD,facial wasting,or greater than mg,0,0.5049574375152588
STRIBILD,facial wasting,than U per L alkaline phosphatase greater than U per L,0,0.49844789505004883
STRIBILD,facial wasting,per L greater than 2 ULN serum glucose,1,0.5239670276641846
STRIBILD,facial wasting,phosphatase greater than U per L bilirubin,0,0.5023159384727478
STRIBILD,facial wasting,per L greater than 2 ULN serum glucose less than,1,0.5330361127853394
STRIBILD,facial wasting,than,0,0.5212757587432861
STRIBILD,facial wasting,greater,1,0.49101781845092773
STRIBILD,breast enlargement,"per L bilirubin greater * ULN),",1,0.5626015663146973
STRIBILD,breast enlargement,L bilirubin,0,0.5074950456619263
STRIBILD,breast enlargement,U per,0,0.5210038423538208
STRIBILD,breast enlargement,"greater * ULN), serum glu",1,0.5871596336364746
STRIBILD,breast enlargement," * ULN), serum glu cose less",1,0.5354539155960083
STRIBILD,cushingoid appearance,ess than 40 or greate r than mg,1,0.5423308610916138
STRIBILD,cushingoid appearance,"per L bilirubin greater * ULN),",1,0.5160219669342041
STRIBILD,cushingoid appearance,or greate r than mg per dL,1,0.49958905577659607
STRIBILD,cushingoid appearance,ess than 40 or greate,1,0.5125296115875244
STRIBILD,cushingoid appearance,glycosuria greater than or equal to neutrophils,0,0.49767476320266724
STRIBILD,cushingoid appearance,than ULN serum glucose ess than 40 or greate r than mg per dL,1,0.5576784610748291
STRIBILD,cushingoid appearance,40 or greate r than mg per,1,0.5284811854362488
STRIBILD,cushingoid appearance,40 or greate r than,1,0.4951724410057068
STRIBILD,cushingoid appearance,greater than or equal to neutrophils less than per,0,0.5029631853103638
STRIBILD,Immune reconstitution syndrome,similar percentage of subjects receiving STRIBILD ATRIPLA and,0,0.5393028259277344
STRIBILD,Immune reconstitution syndrome,greater than mg per dL,0,0.5131920576095581
STRIBILD,Immune reconstitution syndrome,triglycerides,0,0.48161429166793823
STRIBILD,Immune reconstitution syndrome,percentage of subjects receiving STRIBILD ATRIPLA and,0,0.5265997648239136
STRIBILD,Immune reconstitution syndrome,TRUVADA were,0,0.5104928016662598
STRIBILD,Immune reconstitution syndrome,"clinical trials of STRIBILD, a similar",1,0.5157554745674133
STRIBILD,Immune reconstitution syndrome,"STRIBILD, a similar",1,0.47691142559051514
STRIBILD,Immune reconstitution syndrome,Lipids In clinical,1,0.5136152505874634
STRIBILD,Mycobacterium avium infection,Changes from baseline in total cholesterol HDLcholesterol,0,0.5292262434959412
STRIBILD,Mycobacterium avium infection,and 12% of ATV + RTV TRUVADA subjects,1,0.48028451204299927
STRIBILD,Mycobacterium avium infection,additional of STRIBILD subjects were,0,0.47713831067085266
STRIBILD,Mycobacterium avium infection,% of,1,0.4619474709033966
STRIBILD,Mycobacterium avium infection,RTV TRUVADA subjects Changes from baseline in total,0,0.4943181872367859
STRIBILD,Mycobacterium avium infection,agents compared % of ATRIPLA and 12% of ATV +  RTV,1,0.48388636112213135
STRIBILD,Mycobacterium avium infection,% of ATRIPLA and 12% of ATV +  RTV TRUVADA subjects Changes from,1,0.5105533003807068
STRIBILD,cytomegalovirus,ATV V,1,0.5127384662628174
STRIBILD,cytomegalovirus,ATRIPLA and of ATV V + TRUVADA,1,0.5632659792900085
STRIBILD,cytomegalovirus,and of ATV V + TRUVADA sub jects Changes from baseline in,1,0.5396556854248047
STRIBILD,PCP,triglycerides,0,0.5213441252708435
STRIBILD,PCP,subjects Changes from baseline in,0,0.5300989151000977
STRIBILD,PCP,ota,1,0.4697285294532776
STRIBILD,Autoimmune disorders,5. Tabl e Lipid Values Mean Change,1,0.5102074146270752
STRIBILD,Autoimmune disorders,are in Table,1,0.5270724296569824
STRIBILD,Graves' disease,Mean Ch ange from Baseline at Week,1,0.47078871726989746
STRIBILD,Graves' disease,STRIBILD or Comparator in Studies and,0,0.47577524185180664
STRIBILD,Graves' disease,"presented in Table Table Values, Mean Ch ange from Baseline at Week",1,0.4692167043685913
STRIBILD,Graves' disease,Table,0,0.5115064382553101
STRIBILD,Graves' disease,Mean Ch,1,0.47200101613998413
STRIBILD,Graves' disease,"Table Values, Mean",1,0.4678003191947937
STRIBILD,Graves' disease,and triglycerides,0,0.5578042268753052
STRIBILD,Guillain-Barre syndrome,Change from Baseline t Week 144 in Subjects  Receiving,1,0.5101589560508728
STRIBILD,Guillain-Barre syndrome,and triglycerides,0,0.4937024712562561
STRIBILD,Guillain-Barre syndrome,t Week 144 in Subjects Receiving,1,0.5322487354278564
STRIBILD,Guillain-Barre syndrome,t Week 144 in Subjects  Receiving STRIBILD,1,0.5155194401741028
STRIBILD,Guillain-Barre syndrome,from Baseline t Week 144 in,1,0.4949830174446106
STRIBILD,Guillain-Barre syndrome,STRIBILD or Comparator in,0,0.42553094029426575
STRIBILD,Guillain-Barre syndrome,Mean Change from Baseline t Week 144 in Subjects,1,0.4759575128555298
STRIBILD,Guillain-Barre syndrome,Change from Baseline t Week 144,1,0.49559906125068665
STRIBILD,Guillain-Barre syndrome,t Week 144 in Subjects,1,0.500307023525238
STRIBILD,Guillain-Barre syndrome,Table Lipid Values Mean Change,0,0.46793049573898315
STRIBILD,Guillain-Barre syndrome,in Subjects Receiving STRIBILD or Comparator in,1,0.4787144660949707
FARXIGA,Hypotension,Hypotension see Warnings,1,0.8688455820083618
FARXIGA,Hypotension,Hypotension see Warnings and Precautions Impairment,1,0.8233239650726318
FARXIGA,Impairment in Renal Function,and Precautions Hypoglycemia with Concomitant Use with Insulin and,0,0.5083829760551453
FARXIGA,Impairment in Renal Function,see Warnings and Impairment in Renal Function,1,0.8690593242645264
FARXIGA,Hypoglycemia,Insulin Secretagogues see Warnings and Precautions,0,0.6802602410316467
FARXIGA,Hypoglycemia,Hypoglycemia,1,1.0
FARXIGA,Hypoglycemia,Insulin Secretagogues see,0,0.6958556175231934
FARXIGA,Hypoglycemia,Hypoglycemia with Concomitant Use,1,0.8263707160949707
FARXIGA,Hypoglycemia,Hypoglycemia with,1,0.939792811870575
FARXIGA,Genital Mycotic Infections,Mycotic Infections see Warnings and Precautions,1,0.764262855052948
FARXIGA,Genital Mycotic Infections,Secretagogues see Warnings and Genital Mycotic Infections,1,0.8191131353378296
FARXIGA,Genital Mycotic Infections,Warnings and Genital,1,0.6783738136291504
FARXIGA,Genital Mycotic Infections,and,0,0.489551842212677
FARXIGA,Genital Mycotic Infections,Genital Mycotic,1,0.9515314102172852
FARXIGA,Genital Mycotic Infections,in LowDensity Lipoprotein Cholesterol,0,0.45189324021339417
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,Precautions Bladder Cancer see Warnings and Precautio,0,0.5190584659576416
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,and Increases in Low-Density Lipoprotein Cholesterol,1,0.9879308938980103
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,in Low-Density Lipoprotein Cholesterol LDLC see Warnings,1,0.8097738027572632
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,Genital Mycotic Infections see,0,0.4695771336555481
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,Infections see Warnings and Increases in Low-Density Lipoprotein,1,0.8458684682846069
FARXIGA,Bladder Cancer,Bladder,1,0.8055363893508911
FARXIGA,Bladder Cancer,in LowDensity Lipoprotein,0,0.4613667130470276
FARXIGA,Bladder Cancer,Warnings and Bladder Cancer,1,0.824222207069397
FARXIGA,Bladder Cancer,see Warnings and Bladder,1,0.6994155645370483
FARXIGA,Bladder Cancer,Bladder Cancer see Warnings and Precautions The,1,0.8318790197372437
FARXIGA,Bladder Cancer,common adverse reactions associated with,0,0.4842502772808075
FARXIGA,Bladder Cancer,Warnings and Precautions The most common,0,0.47729432582855225
FARXIGA,Bladder Cancer,LowDensity Lipoprotein,0,0.4702575206756592
FARXIGA,female genital mycotic infections,greater incidence female genital mycotic infections nasopharyngitis and,1,0.9039676189422607
FARXIGA,female genital mycotic infections,LowDensity Lipoprotein,0,0.4164438247680664
FARXIGA,female genital mycotic infections,FARXIGA or greater incidence female genital,1,0.7149056196212769
FARXIGA,female genital mycotic infections,or greater incidence female,1,0.6400194764137268
FARXIGA,female genital mycotic infections,female genital mycotic infections nasopharyngitis and urinary tract,1,0.8836933374404907
FARXIGA,female genital mycotic infections,mycotic infections nasopharyngitis,1,0.7534248232841492
FARXIGA,female genital mycotic infections,mycotic infections nasopharyngitis and,1,0.751132607460022
FARXIGA,female genital mycotic infections,female genital mycotic infections,1,1.0
FARXIGA,female genital mycotic infections,mycotic infections nasopharyngitis and urinary tract infections,1,0.7219438552856445
FARXIGA,female genital mycotic infections,incidence female,1,0.6452863812446594
FARXIGA,female genital mycotic infections,genital mycotic infections nasopharyngitis and urinary tract infections,1,0.8342511057853699
FARXIGA,nasopharyngitis,nasopharyngitis and urinary tract,1,0.8475939035415649
FARXIGA,nasopharyngitis,nasopharyngitis and urinary tract infections EXCERPT,1,0.8336448073387146
FARXIGA,nasopharyngitis,nasopharyngitis,1,1.0000001192092896
FARXIGA,nasopharyngitis,incidence were female genital,0,0.5370614528656006
FARXIGA,nasopharyngitis,nasopharyngitis and,1,0.9384024143218994
FARXIGA,urinary tract infections,FARXIGA or greater incidence,0,0.5482159852981567
FARXIGA,urinary tract infections,urinary tract,1,0.8227918148040771
FARXIGA,urinary tract infections,tract infections EXCERPT,1,0.7509381771087646
FARXIGA,urinary tract infections,urinary tract infections EXCERPT To report SUSPECTED,1,0.8375468254089355
FARXIGA,vulvovaginal mycotic infection,reactions listed in order of,0,0.46768346428871155
FARXIGA,vulvovaginal mycotic infection,following adverse reactions,0,0.5156041383743286
FARXIGA,vulvovaginal mycotic infection,ections include the following adverse reactions listed,0,0.5512109994888306
FARXIGA,vulvovaginal mycotic infection,vaginal infection vulvovaginal candidiasis,0,0.904577374458313
FARXIGA,vulvovaginal mycotic infection,frequency reported for vulvovaginal mycotic infection vaginal infection,1,0.9110168218612671
FARXIGA,vulvovaginal mycotic infection,of frequency reported for vulvovaginal mycotic infection vaginal infection vulvovaginal candidiasis vulvovaginitis,1,0.9071429967880249
FARXIGA,vulvovaginal mycotic infection,reported for vulvovaginal mycotic infection,1,0.9454869627952576
FARXIGA,vulvovaginal mycotic infection,vulvovaginal mycotic infection vaginal,1,0.9769022464752197
FARXIGA,vaginal infection,order of,0,0.45931029319763184
FARXIGA,vaginal infection,in order of,0,0.49145013093948364
FARXIGA,vaginal infection,vaginal infection vulvovaginal,1,0.8750318884849548
FARXIGA,vaginal infection,for females vulvovaginal mycotic vaginal infection,1,0.8189551830291748
FARXIGA,vaginal infection,for females vulvovaginal mycotic vaginal,1,0.8054715394973755
FARXIGA,vaginal infection,for females vulvovaginal mycotic,0,0.7826708555221558
FARXIGA,vaginal infection,females vulvovaginal mycotic vaginal,1,0.8142307996749878
FARXIGA,vulvovaginal candidiasis,genital candidiasis,0,0.8558120727539062
FARXIGA,vulvovaginal candidiasis,vulvovaginal candidiasis vulvovaginitis genital infection genital,1,0.9163082838058472
FARXIGA,vulvovaginal candidiasis,vaginal vulvovaginal candidiasis vulvovaginitis genital infection,1,0.9308990240097046
FARXIGA,vulvovaginal candidiasis,vulvovaginal candidiasis vulvovaginitis genital,1,0.931309700012207
FARXIGA,vulvovaginal candidiasis,reported for females vulvovaginal mycotic infection,0,0.8541384935379028
FARXIGA,vulvovaginal candidiasis,vulvovaginal candidiasis vulvovaginitis genital infection,1,0.9312098622322083
FARXIGA,vulvovaginal candidiasis,vulvovaginal candidiasis,1,1.0
FARXIGA,vulvovaginitis,vaginal,0,0.7085480690002441
FARXIGA,vulvovaginitis,vulvovaginitis genital,1,0.8612841367721558
FARXIGA,vulvovaginitis,vulvovaginitis genital infection,1,0.89085853099823
FARXIGA,vulvovaginitis,vulvovaginitis,1,1.0
FARXIGA,vulvovaginitis,females,0,0.5903046131134033
FARXIGA,vulvovaginitis,mycotic infection vaginal infection vulvovaginal candidiasis,0,0.788818359375
FARXIGA,genital infection,genital infection genital candidiasis,1,0.8799382448196411
FARXIGA,genital infection,mycotic infection vaginal infection vulvovaginal candidiasis,0,0.753065824508667
FARXIGA,genital infection,genital infection genital,1,0.91893070936203
FARXIGA,genital infection,vulvovaginal candidiasis,0,0.7048554420471191
FARXIGA,genital candidiasis,candidiasis vulvovaginitis genital genital candidiasis,1,0.937788724899292
FARXIGA,genital candidiasis,vulvovaginal candidiasis,0,0.8558120727539062
FARXIGA,genital candidiasis,genital,1,0.8089237809181213
FARXIGA,genital candidiasis,genital candidiasis,1,0.9999998807907104
FARXIGA,genital candidiasis,vulvovaginitis,0,0.7212105989456177
FARXIGA,genital candidiasis,genital candidiasis fungal genital,1,0.9263173341751099
FARXIGA,genital candidiasis,vulvovaginal candidiasis vulvovaginitis genital genital candidiasis,1,0.914863646030426
FARXIGA,genital candidiasis,genital candidiasis fungal genital infection,1,0.9517291784286499
FARXIGA,fungal genital infection,candidiasis,0,0.7574511766433716
FARXIGA,fungal genital infection,candidiasis vulvovaginitis genital,0,0.8697558641433716
FARXIGA,fungal genital infection,genital,0,0.7746154069900513
FARXIGA,fungal genital infection,aginal infection vulvovaginal candidiasis vulvovaginitis genital infection genital candidiasis,0,0.8426505923271179
FARXIGA,fungal genital infection,genital infection,0,0.8742716312408447
FARXIGA,fungal genital infection,genital fungal genital,1,0.9304115772247314
FARXIGA,fungal genital infection,vulvovaginitis genital infection genital fungal genital,1,0.9199126958847046
FARXIGA,fungal genital infection,infection genital,0,0.8570265769958496
FARXIGA,fungal genital infection,infection genital fungal genital,1,0.9706945419311523
FARXIGA,vulvitis,infection genital candidiasis fungal genital infection,0,0.6439610719680786
FARXIGA,vulvitis,vulvitis genitourinary tract infection vulval,1,0.8225935697555542
FARXIGA,vulvitis,vulvitis genitourinary,1,0.8348230719566345
FARXIGA,vulvitis,vulvovaginitis genital infection genital candidiasis,0,0.753425121307373
FARXIGA,vulvitis,vulvitis genitourinary tract infection vulval abscess,1,0.8173704147338867
FARXIGA,genitourinary tract infection,genitourinary tract infection vulval abscess and,1,0.8361980319023132
FARXIGA,genitourinary tract infection,vulvitis genitourinary tract infection vulval abscess,1,0.7987653017044067
FARXIGA,genitourinary tract infection,fungal,0,0.5957801342010498
FARXIGA,genitourinary tract infection,females Placebo,0,0.48968708515167236
FARXIGA,vulval abscess,vulval abscess,1,0.9999998807907104
FARXIGA,vulval abscess,females Placebo,0,0.4986022710800171
FARXIGA,vulval abscess,females,0,0.5245786905288696
FARXIGA,vulval abscess,vulval abscess and vaginitis,1,0.943414568901062
FARXIGA,vulval abscess,vulval abscess and vaginitis bacterial,1,0.9192171692848206
FARXIGA,vulval abscess,tract infection,0,0.6078276634216309
FARXIGA,vulval abscess,genital,0,0.6641117930412292
FARXIGA,vulval abscess,genital infection vulvitis genitourinary tract,0,0.743742823600769
FARXIGA,vulval abscess,tract vulval abscess,1,0.929240882396698
FARXIGA,vulval abscess,bacterial N for females,0,0.6052163243293762
FARXIGA,vaginitis bacterial,abscess vaginitis bacterial,1,0.9133238792419434
FARXIGA,vaginitis bacterial,for females Placebo,0,0.5102343559265137
FARXIGA,vaginitis bacterial,infection vulvitis genitourinary tract infection vulval abscess,0,0.7350792288780212
FARXIGA,vaginitis bacterial,N for females Placebo FARXIGA,0,0.5064759850502014
FARXIGA,vaginitis bacterial,vaginitis bacterial,1,1.0000001192092896
FARXIGA,urinary tract infection,urinary tract infection cystitis Escherichia urinary,1,0.8362041711807251
FARXIGA,urinary tract infection,tract infection cystitis Escherichia urinary tract,1,0.8334294557571411
FARXIGA,urinary tract infection,infection,0,0.736952543258667
FARXIGA,urinary tract infection,tract infection genitourinary,0,0.810410737991333
FARXIGA,urinary tract infection,order of frequency urinary tract,1,0.7195344567298889
FARXIGA,urinary tract infection,order of frequency urinary tract infection,1,0.8120367527008057
FARXIGA,urinary tract infection,urinary tract infection cystitis Escherichia,1,0.8385187387466431
FARXIGA,urinary tract infection,tract infection genitourinary tract infection pyelonephritis trig,0,0.8193949460983276
FARXIGA,cystitis,tract infection,0,0.6783909201622009
FARXIGA,cystitis,cystitis,1,1.0000001192092896
FARXIGA,cystitis,cystitis Escherichia urinary tract infection,1,0.8271104693412781
FARXIGA,cystitis,cystitis Escherichia,1,0.8268179893493652
FARXIGA,cystitis,cystitis Escherichia urinary tract infection genitourinary,1,0.8115233778953552
FARXIGA,cystitis,the following adverse reactions,0,0.5830594301223755
FARXIGA,cystitis,cystitis Escherichia urinary,1,0.8152843713760376
FARXIGA,cystitis,cystitis Escherichia urinary tract,1,0.8119115233421326
FARXIGA,Escherichia urinary tract infection,reported urinary tract infection Escherichia,1,0.9372757077217102
FARXIGA,Escherichia urinary tract infection,tract infection Escherichia urinary tract infection,1,0.9491767287254333
FARXIGA,Escherichia urinary tract infection,urinary tract infection genitourinary tract infection,1,0.8480535745620728
FARXIGA,Escherichia urinary tract infection,Escherichia urinary tract infection genitourinary tract,1,0.909915030002594
FARXIGA,Escherichia urinary tract infection,Escherichia urinary tract infection genitourinary tract infection pyelonephritis trigonitis,1,0.8707227110862732
FARXIGA,Escherichia urinary tract infection,tract infection genitourinary tract,1,0.761823296546936
FARXIGA,Escherichia urinary tract infection,kidney,0,0.6396797299385071
FARXIGA,Escherichia urinary tract infection,Escherichia urinary tract infection,1,1.0
FARXIGA,Escherichia urinary tract infection,tract infection genitourinary tract infection,1,0.7796112298965454
FARXIGA,Escherichia urinary tract infection,infection Escherichia urinary,1,0.9492630362510681
FARXIGA,genitourinary tract infection,infection and prostatitis,0,0.7412159442901611
FARXIGA,pyelonephritis,trigonitis urethritis kidney infection and,0,0.7340990304946899
FARXIGA,pyelonephritis,infection,0,0.6553933024406433
FARXIGA,pyelonephritis,infection and prostatitis,0,0.6643598079681396
FARXIGA,pyelonephritis,pyelonephritis trigonitis urethritis kidney,1,0.850764274597168
FARXIGA,trigonitis,trigonitis urethritis kidney infection,1,0.7670260667800903
FARXIGA,trigonitis,infection genitourinary tract infection trigonitis urethritis kidney infection,1,0.6851170659065247
FARXIGA,trigonitis,kidney infection and,0,0.5034652948379517
FARXIGA,trigonitis,trigonitis urethritis kidney infection and prostatitis,1,0.7350021600723267
FARXIGA,kidney infection,kidney infection,1,0.9999998211860657
FARXIGA,kidney infection,pyelonephritis trigonitis kidney infection and prostatitis Back,1,0.7611292004585266
FARXIGA,kidney infection,tract infection pyelonephritis trigonitis urethritis,0,0.7154138088226318
FARXIGA,kidney infection,and prostatitis,0,0.6095757484436035
FARXIGA,kidney infection,trigonitis kidney,1,0.6933963298797607
FARXIGA,kidney infection,infection pyelonephritis trigonitis kidney infection,1,0.8208056688308716
FARXIGA,kidney infection,trigonitis kidney infection and prostatitis,1,0.7592170834541321
FARXIGA,kidney infection,infection genitourinary tract infection pyelonephritis,0,0.801662266254425
FARXIGA,kidney infection,urethritis,0,0.680483341217041
FARXIGA,kidney infection,prostatitis,0,0.6366996169090271
FARXIGA,prostatitis,infection prostatitis,1,0.9270029067993164
FARXIGA,prostatitis,prostatitis,0,1.0
FARXIGA,prostatitis,prostatitis Back,1,0.8900868892669678
FARXIGA,prostatitis,kidney,0,0.6148045063018799
FARXIGA,prostatitis,ction genitourinary tract infection pyelonephritis trigonitis,0,0.6646304130554199
FARXIGA,prostatitis,urethritis kidney infection prostatitis Back,1,0.8028910756111145
FARXIGA,Increased urination,Increased Increased urination includes the following,1,0.9723519086837769
FARXIGA,Increased urination,ction genitourinary tract infection pyelonephritis trigonitis,0,0.6526871919631958
FARXIGA,Increased urination,Increased,0,0.7301944494247437
FARXIGA,Increased urination,Increased Increased urination,1,0.9930107593536377
FARXIGA,pollakiuria,reported,0,0.50483238697052
FARXIGA,pollakiuria,polyuria and,0,0.6135674715042114
FARXIGA,pollakiuria,the,0,0.4586166739463806
FARXIGA,polyuria,urine,0,0.7216074466705322
FARXIGA,polyuria,frequency reported,0,0.49080750346183777
FARXIGA,polyuria,ation,0,0.5203893184661865
FARXIGA,balanitis,infection male penile i,0,0.6444723606109619
FARXIGA,balanitis,balanitis fungal genital infection balanitis,1,0.8501834869384766
FARXIGA,balanitis,of frequency reported for balanitis fungal genital infection,1,0.8099107146263123
FARXIGA,balanitis,balanitis,1,0.9999999403953552
FARXIGA,balanitis,genital infection,0,0.6402209997177124
FARXIGA,balanitis,frequency reported for balanitis fungal genital,1,0.8085519075393677
FARXIGA,balanitis,of frequency reported for balanitis fungal genital infection balanitis,1,0.8160947561264038
FARXIGA,balanitis,balanitis fungal genital infection balanitis candida,1,0.839808464050293
FARXIGA,balanitis,males,0,0.5276550650596619
FARXIGA,fungal genital infection,fungal genital infection,1,0.9999998807907104
FARXIGA,fungal genital infection,balanitis,1,0.6204725503921509
FARXIGA,fungal genital infection,reported for males fungal,1,0.7604144811630249
FARXIGA,fungal genital infection,balanitis,0,0.6204725503921509
FARXIGA,fungal genital infection,adverse reactions listed in order of frequency reported,0,0.5244355201721191
FARXIGA,fungal genital infection,penile,0,0.6825211644172668
FARXIGA,fungal genital infection,for males fungal,1,0.7569091320037842
FARXIGA,fungal genital infection,frequency reported for males,0,0.5064417123794556
FARXIGA,fungal genital infection,genital infection balanitis candida genital candidiasis,1,0.8700218200683594
FARXIGA,fungal genital infection,the following adverse reactions listed in order of frequency reported for,0,0.5298810005187988
FARXIGA,fungal genital infection,frequency reported for males balanitis,0,0.6162158250808716
FARXIGA,balanitis candida,balanitis candida genital,1,0.9179515242576599
FARXIGA,balanitis candida,balanitis fungal genital balanitis candida genital candidiasis,1,0.9155596494674683
FARXIGA,balanitis candida,balanitis candida,1,1.0
FARXIGA,balanitis candida,balanitis candida genital candidiasis genital,1,0.912077009677887
FARXIGA,balanitis candida,candidiasis genital infection male penile,0,0.7407370805740356
FARXIGA,balanitis candida,balanitis,1,0.8835455775260925
FARXIGA,balanitis candida,reactions listed in order of frequency reported for males balanitis fungal,0,0.7898029088973999
FARXIGA,balanitis candida,balanitis fungal genital,0,0.8687509298324585
FARXIGA,genital candidiasis,genital infection male penile infection balanoposthitis balanoposthitis,0,0.7147859930992126
FARXIGA,genital infection male,balanitis candida genital genital infection male,1,0.875920832157135
FARXIGA,genital infection male,genital infection male penile infection balanoposthitis balanoposthitis,0,0.8666293621063232
FARXIGA,penile infection,penile infection balanoposthitis balanoposthitis,1,0.8580081462860107
FARXIGA,penile infection,genital infection male penile infection balanoposthitis balanoposthitis,0,0.8586048483848572
FARXIGA,penile infection,genital infection,0,0.8503224849700928
FARXIGA,penile infection,penile infection balanoposthitis,1,0.8633249402046204
FARXIGA,penile infection,genital candidiasis genital infection penile,1,0.8761192560195923
FARXIGA,penile infection,genital candidiasis genital infection penile infection,1,0.882652759552002
FARXIGA,penile infection,infection,0,0.7605979442596436
FARXIGA,penile infection,infection posthitis N for males,0,0.7559304237365723
FARXIGA,penile infection,genital infection balanitis candida genital,0,0.7719638347625732
FARXIGA,penile infection,candidiasis genital infection penile,1,0.8775554895401001
FARXIGA,penile infection,infection penile infection balanoposthitis balanoposthitis infective genital,1,0.8697628378868103
FARXIGA,balanoposthitis,genital candidiasis genital infection male penile,0,0.5132463574409485
FARXIGA,balanoposthitis,balanoposthitis balanoposthitis infective genital infection posthitis,1,0.8629831075668335
FARXIGA,balanoposthitis,male penile balanoposthitis balanoposthitis infective genital infection,1,0.7943822145462036
FARXIGA,balanoposthitis,genital candidiasis genital infection male penile infection,0,0.5063468217849731
FARXIGA,balanoposthitis,infection male penile balanoposthitis balanoposthitis infective genital infection,1,0.7654634714126587
FARXIGA,balanoposthitis infective,FARXIGA mg FARXIGA mg,0,0.4830933213233948
FARXIGA,balanoposthitis infective,balanoposthitis,0,0.864212155342102
FARXIGA,balanoposthitis infective,infection male penile infection balanoposthitis infective,1,0.8971501588821411
FARXIGA,balanoposthitis infective,male penile infection balanoposthitis infective genital infection,1,0.8867781162261963
FARXIGA,balanoposthitis infective,balanoposthitis infective genital infection posthitis,1,0.9169257283210754
FARXIGA,genital infection,penile infection balanoposthitis balanoposthitis genital infection posthitis N for males,1,0.7593963146209717
FARXIGA,genital infection,balanoposthitis infective genital infection posthitis,1,0.7604613304138184
FARXIGA,genital infection,balanoposthitis balanoposthitis genital infection posthitis N for males,1,0.7286981344223022
FARXIGA,genital infection,males Placebo FARXIGA,0,0.5315045714378357
FARXIGA,genital infection,infection balanoposthitis balanoposthitis genital infection posthitis N for,1,0.798230767250061
FARXIGA,genital infection,genital infection,1,1.0
FARXIGA,genital infection,penile infection balanoposthitis balanoposthitis genital,1,0.793602705001831
FARXIGA,genital infection,balanoposthitis genital infection posthitis N for males,1,0.7351055145263672
FARXIGA,genital infection,infection,0,0.8034336566925049
FARXIGA,genital infection,FARXIGA mg FARXIGA,0,0.501659095287323
FARXIGA,genital infection,balanoposthitis balanoposthitis genital infection,1,0.8035830855369568
FARXIGA,posthitis,male penile infection balanoposthitis balanoposthitis infective,0,0.6588224768638611
FARXIGA,posthitis,posthitis N for males Placebo,1,0.7545431852340698
FARXIGA,osmotic diuresis,patients mean eGFR mLmin m Volume Depletion FARXIGA causes an,0,0.5192155838012695
FARXIGA,osmotic diuresis,osmotic diuresis,1,0.9999999403953552
FARXIGA,osmotic diuresis,Volume Depletion FARXIGA causes osmotic,1,0.7413452863693237
FARXIGA,osmotic diuresis,mLmin m Volume Depletion,0,0.5824737548828125
FARXIGA,osmotic diuresis,volume,0,0.5300730466842651
FARXIGA,osmotic diuresis,Volume Depletion FARXIGA causes osmotic diuresis,1,0.7727322578430176
FARXIGA,osmotic diuresis,an,0,0.507617712020874
FARXIGA,osmotic diuresis,in intravascular volume Adverse reactions related,0,0.5517237186431885
FARXIGA,volume depletion,volume depletion including reports of dehydration hypovolemia,1,0.8227041959762573
FARXIGA,dehydration,related to,0,0.5365936160087585
FARXIGA,dehydration,reports dehydration hypovolemia orthostatic hypotension or,1,0.7710967659950256
FARXIGA,dehydration,reports dehydration hypovolemia,1,0.8096672296524048
FARXIGA,dehydration,reports of,0,0.5279295444488525
FARXIGA,dehydration,hypotension or hypotension are shown in Table for the,0,0.6209546327590942
FARXIGA,hypovolemia,hypovolemia orthostatic,1,0.8322108387947083
FARXIGA,hypovolemia,hypotension or hypotension are shown in Table for the,0,0.743842601776123
FARXIGA,hypovolemia,to,0,0.4998873174190521
FARXIGA,hypovolemia,reactions related,0,0.5300245881080627
FARXIGA,hypovolemia,the study and,0,0.4943368434906006
FARXIGA,hypovolemia,ravascular volume Adverse reactions related to volume depletion,0,0.6883984804153442
FARXIGA,hypovolemia,in Table for the study and study,0,0.4740404188632965
FARXIGA,hypovolemia,hypovolemia orthostatic hypotension or hypotension,1,0.8444692492485046
FARXIGA,hypovolemia,ravascular,0,0.6115199327468872
FARXIGA,orthostatic hypotension,orthostatic,1,0.8745036721229553
FARXIGA,orthostatic hypotension,for,0,0.5116969347000122
FARXIGA,orthostatic hypotension,reports of dehydration orthostatic hypotension or hypotension are shown,1,0.855522096157074
FARXIGA,orthostatic hypotension,orthostatic hypotension or hypotension,1,0.9514042139053345
FARXIGA,orthostatic hypotension,and,0,0.46735048294067383
FARXIGA,orthostatic hypotension,Table for the study,0,0.5050698518753052
FARXIGA,orthostatic hypotension,in Table for the,0,0.4845182001590729
FARXIGA,orthostatic hypotension,dehydration orthostatic hypotension or hypotension are shown,1,0.8631868362426758
FARXIGA,orthostatic hypotension,of dehydration orthostatic hypotension or hypotension are shown in,1,0.8569449186325073
FARXIGA,orthostatic hypotension,reports of dehydration hypovolemia,0,0.6373928785324097
FARXIGA,Volume Depletion,Volume Depletion,1,1.0000001192092896
FARXIGA,Volume Depletion,Precautions,0,0.499392569065094
FARXIGA,Volume depletion,Volume depletion includes reports of dehydration,1,0.8432047367095947
FARXIGA,Volume depletion,Precautions,0,0.499392569065094
FARXIGA,dehydration,DepletionVolume depletion includes reports dehydration hypovolemia orthostatic hypotension or hypotension,1,0.7696613073348999
FARXIGA,dehydration,Precautions,0,0.5305547714233398
FARXIGA,dehydration,dehydration hypovolemia orthostatic hypotension or,1,0.7839853763580322
FARXIGA,dehydration,or hypotension in Clinical Studies with,0,0.5863145589828491
FARXIGA,dehydration,of,0,0.5759959816932678
FARXIGA,dehydration,dehydration hypovolemia,1,0.8346420526504517
FARXIGA,dehydration,dehydration hypovolemia orthostatic,1,0.7909348011016846
FARXIGA,dehydration,dehydration,1,1.0
FARXIGA,hypovolemia,hypovolemia orthostatic hypotension,1,0.8516474962234497
FARXIGA,hypovolemia,dehydration,1,0.6917111873626709
FARXIGA,hypovolemia,hypovolemia orthostatic hypotension or hypotension in,1,0.855362057685852
FARXIGA,orthostatic hypotension,DepletionVolume depletion,0,0.5383272767066956
FARXIGA,orthostatic hypotension,dehydration orthostatic,1,0.8375071287155151
FARXIGA,orthostatic hypotension,or hypotension in Clinical Studies with FARXIGA,0,0.7297182679176331
FARXIGA,orthostatic hypotension,includes reports of dehydration orthostatic hypotension or hypotension,1,0.8471722602844238
FARXIGA,hypotension,Studies,0,0.5089513659477234
FARXIGA,increases in serum creatinine,Renal Function,0,0.69112229347229
FARXIGA,increases in serum creatinine,increases,1,0.6883146166801453
FARXIGA,increases in serum creatinine,serum creatinine and decreases in eGFR,1,0.8349553346633911
FARXIGA,increases in serum creatinine,with,0,0.5033762454986572
FARXIGA,increases in serum creatinine,in serum creatinine,1,0.9192668199539185
FARXIGA,increases in serum creatinine,serum creatinine and,1,0.9072962403297424
FARXIGA,increases in serum creatinine,of,0,0.4573213756084442
FARXIGA,increases in serum creatinine,In patients with normal,0,0.5814641714096069
FARXIGA,decreases in eGFR,in serum,0,0.5554977655410767
FARXIGA,decreases in eGFR,increases in serum creatinine decreases,1,0.6881040334701538
FARXIGA,decreases in eGFR,Table In,0,0.46193379163742065
FARXIGA,Renal-related adverse reactions,Renal-related adverse reactions including renal failure and,1,0.9615344405174255
FARXIGA,Renal-related adverse reactions,Week,0,0.46183228492736816
FARXIGA,Renal-related adverse reactions,baseline values at Renal-related adverse reactions including renal failure and blood,1,0.8762348890304565
FARXIGA,Renal-related adverse reactions,values at Renal-related adverse reactions,1,0.934788167476654
FARXIGA,renal failure,adverse reactions renal,1,0.7793207168579102
FARXIGA,renal failure,renal failure and blood,1,0.8556581139564514
FARXIGA,renal failure,reactions renal failure,1,0.8608297109603882
FARXIGA,renal failure,baseline values at Week,0,0.49128472805023193
FARXIGA,renal failure,and eGFR returned to baseline values at,0,0.5877827405929565
FARXIGA,blood creatinine increase,including renal failure,0,0.6395084857940674
FARXIGA,blood creatinine increase,Elderly patients and,0,0.49745842814445496
FARXIGA,blood creatinine increase,values at Week Renalrelated adverse reactions including renal failure and,0,0.6843676567077637
FARXIGA,blood creatinine increase,failure blood creatinine increase,1,0.9321609735488892
FARXIGA,blood creatinine increase,baseline values at Week Renalrelated adverse reactions including,0,0.6801919341087341
FARXIGA,blood creatinine increase,including renal failure blood creatinine,1,0.8435468077659607
FARXIGA,blood creatinine increase,including renal failure blood creatinine increase were more frequent in,1,0.8930094838142395
FARXIGA,blood creatinine increase,failure blood creatinine increase were more,1,0.9191067218780518
FARXIGA,Renal Impairment-Related Adverse Reaction,Least,0,0.430661678314209
FARXIGA,Renal Impairment-Related Adverse Reaction,with at Least Renal Impairment-Related Adverse Reaction,1,0.9586687088012695
FARXIGA,Renal Impairment-Related Adverse Reaction,Pool of PlaceboControlled,0,0.5483692288398743
FARXIGA,Renal Impairment-Related Adverse Reaction,Table Proportion of Patients with at Least One,0,0.5273892879486084
FARXIGA,Renal Impairment-Related Adverse Reaction,with at Least Renal Impairment-Related,1,0.803276538848877
FARXIGA,bone fractures,Studies In this study patients experienced,0,0.5058262348175049
FARXIGA,bone fractures,this study patients,0,0.5083666443824768
FARXIGA,bone fractures,No fractures occurred in the placebo group,0,0.6236294507980347
FARXIGA,bone fractures,bone fractures for treatment durations up to,1,0.8449251651763916
FARXIGA,bone fractures,In this study patients bone fractures for,1,0.8608205318450928
FARXIGA,bone fractures,this study patients bone fractures,1,0.860431969165802
FARXIGA,bone fractures,Studies In,0,0.4890950918197632
FARXIGA,bone fractures,In this study patients,0,0.5128717422485352
FARXIGA,fractures,fractures occurred in the,1,0.9079790115356445
FARXIGA,fractures,fractures occurred in the placebo,1,0.7605143785476685
FARXIGA,fractures,up to,0,0.5132753849029541
FARXIGA,fractures,to weeks No,0,0.5008070468902588
FARXIGA,fractures,fractures occurred in,1,0.9109109044075012
FARXIGA,fractures,bone fractures,0,0.9157623052597046
FARXIGA,fractures,in the FARXIGA mg group,0,0.48163771629333496
FARXIGA,fractures,fractures were in patients who,1,0.8673586249351501
FARXIGA,fractures,was no apparent pattern,0,0.48420485854148865
FARXIGA,fractures,in patients who had a,0,0.5762746334075928
FARXIGA,fractures,weeks There was no apparent pattern with,0,0.5135852098464966
FARXIGA,fractures,fractures were in patients who had a,0,0.862419605255127
FARXIGA,fractures,in patients who had a baseline eGFR of,0,0.47174686193466187
FARXIGA,fractures,first weeks,0,0.530211329460144
FARXIGA,fracture,fracture Hypoglycemia,1,0.7126160860061646
FARXIGA,fracture,first weeks,0,0.4916224479675293
FARXIGA,fracture,site of,0,0.48141005635261536
FARXIGA,fracture,There was no apparent pattern with respect,0,0.457915723323822
FARXIGA,fracture,hypoglycemia by study see Clinical Studies,0,0.49494045972824097
FARXIGA,fracture,fracture,1,1.0
FARXIGA,hypoglycemia,to the,0,0.5068550109863281
FARXIGA,hypoglycemia,The frequency hypoglycemia by study,1,0.8425823450088501
FARXIGA,hypoglycemia,The frequency hypoglycemia by study see Clinical,1,0.8288851976394653
FARXIGA,hypoglycemia,hypoglycemia by,1,0.9330409169197083
FARXIGA,hypoglycemia,study see Clinical Studies is shown in Table,0,0.5001973509788513
FARXIGA,hypoglycemia,Table Hypoglycemia,0,0.8738279342651367
FARXIGA,hypoglycemia,hypoglycemia by study see Clinical,1,0.8492270708084106
FARXIGA,Hypoglycemia,of hypoglycemia by study see Clinical Studies is shown in,0,0.8094048500061035
FARXIGA,Hypoglycemia,Hypoglycemia was more frequent when FARXIGA,1,0.8010756969451904
FARXIGA,hypoglycemia,requiring,0,0.49150413274765015
FARXIGA,hypoglycemia,hypoglycemia were defined as symptomatic,1,0.8618557453155518
FARXIGA,hypoglycemia,assistance due to severe,0,0.5538507699966431
FARXIGA,hypoglycemia,hypoglycemia,1,1.0
FARXIGA,hypoglycemia,nsulin see Warnings and Precautions Table Incidence,0,0.5412265062332153
FARXIGA,hypoglycemia,defined as symptomatic episodes requiring external third party assistance,0,0.529518723487854
FARXIGA,impairment in consciousness,severe,0,0.5679002404212952
FARXIGA,impairment in consciousness,in consciousness or behavior with a capillary,1,0.6689431667327881
FARXIGA,impairment in consciousness,assistance due to impairment in consciousness or behavior with a capillary,1,0.7884707450866699
FARXIGA,impairment in consciousness,impairment in consciousness,1,1.0
FARXIGA,impairment in consciousness,impairment in consciousness or behavior,1,0.9305282831192017
FARXIGA,impairment in consciousness,requiring external third party,0,0.45929813385009766
FARXIGA,impairment in consciousness,requiring external third party assistance due to severe,0,0.572593092918396
FARXIGA,impairment in consciousness,assistance due to impairment in consciousness,1,0.909390389919281
FARXIGA,impairment in consciousness,capillary or plasma glucose value mgdL and prompt,0,0.5002660751342773
FARXIGA,plasma glucose value <54 mg/dL,a,0,0.47598081827163696
FARXIGA,plasma glucose value <54 mg/dL,capillary plasma glucose value <54 mg/dL and prompt,1,0.9161328077316284
FARXIGA,plasma glucose value <54 mg/dL,with a capillary plasma,1,0.5077323317527771
FARXIGA,plasma glucose value <54 mg/dL,and MinorMinor,0,0.4656739830970764
FARXIGA,plasma glucose value <54 mg/dL,with a capillary plasma glucose value <54,1,0.9127422571182251
FARXIGA,hypoglycemia,were defined as either a symptomatic,0,0.5272347927093506
FARXIGA,hypoglycemia,hypoglycemia were defined as either,1,0.8869163393974304
FARXIGA,plasma glucose measurement <63 mg/dL,with a capillary plasma glucose measurement,1,0.8397086262702942
FARXIGA,plasma glucose measurement <63 mg/dL,measurement <63 mg/dL,1,0.8351410627365112
FARXIGA,plasma glucose measurement <63 mg/dL,episode with a capillary plasma glucose measurement <63 mg/dL,1,0.9095697402954102
FARXIGA,plasma glucose measurement <63 mg/dL,<63 mg/dL regardless of,1,0.747366189956665
FARXIGA,plasma glucose measurement <63 mg/dL,plasma glucose measurement <63 mg/dL regardless of need,1,0.9509983062744141
FARXIGA,plasma glucose measurement <63 mg/dL,a capillary plasma glucose measurement <63 mg/dL,1,0.923495888710022
FARXIGA,plasma glucose measurement <63 mg/dL,of need for external,0,0.4871106743812561
FARXIGA,plasma glucose measurement <63 mg/dL,with a capillary or,0,0.541767954826355
FARXIGA,plasma glucose measurement <63 mg/dL,capillary plasma,1,0.5860417485237122
FARXIGA,plasma glucose measurement <63 mg/dL,an asymptomatic capillary plasma glucose measurement <63 mg/dL that does not qualify,1,0.8819873332977295
FARXIGA,plasma glucose measurement <63 mg/dL,external assistance,0,0.4857984781265259
FARXIGA,plasma glucose measurement <63 mg/dL,an asymptomatic capillary plasma glucose measurement <63,1,0.8814619779586792
FARXIGA,plasma glucose measurement <63 mg/dL,<63 mg/dL that does not qualify,1,0.7355269193649292
FARXIGA,plasma glucose measurement <63 mg/dL,mgdL regardless of,0,0.5186641216278076
FARXIGA,plasma glucose measurement <63 mg/dL,Hypoglycemia in Controlled Clinical,0,0.726690411567688
FARXIGA,plasma glucose measurement <63 mg/dL,asymptomatic capillary plasma glucose measurement <63 mg/dL,1,0.9053725004196167
FARXIGA,Hypoglycemia,Controlled Clinical,0,0.5240064859390259
FARXIGA,Hypoglycemia,mgdL that does not,0,0.48980551958084106
FARXIGA,Hypoglycemia,qualify as a major Hypoglycemia in Controlled Clinical,1,0.8169745206832886
FARXIGA,Hypoglycemia,qualify as a major Hypoglycemia in Controlled Clinical Studies,1,0.8101271390914917
FARXIGA,Hypoglycemia,as a major Hypoglycemia in Controlled,1,0.8553892374038696
FARXIGA,Hypoglycemia,Controlled,0,0.4927072525024414
FARXIGA,Genital mycotic infections,mycotic infections were more frequent,1,0.7656834125518799
FARXIGA,Genital mycotic infections,Genital mycotic infections were more frequent with FARXIGA,1,0.8379988670349121
FARXIGA,Genital mycotic infections,Genital Mycotic,0,0.9515314102172852
FARXIGA,Genital mycotic infections,frequent with FARXIGA Genital,1,0.6880403757095337
FARXIGA,Genital mycotic infections,more frequent with FARXIGA Genital mycotic infections were reported in of,1,0.8420683145523071
FARXIGA,Genital mycotic infections,were more frequent with FARXIGA treatment,0,0.5122908353805542
FARXIGA,Genital mycotic infections,of patients on placebo,0,0.4391096532344818
FARXIGA,Genital mycotic infections,mycotic infections were reported,1,0.804302453994751
FARXIGA,Genital mycotic infections,of,0,0.48464953899383545
FARXIGA,Genital mycotic infections,more frequent with FARXIGA Genital,1,0.684589147567749
FARXIGA,Genital mycotic infections,on FARXIGA,0,0.488324910402298
FARXIGA,Genital mycotic infections,with FARXIGA Genital mycotic infections,1,0.8685097098350525
FARXIGA,genital infection,study due genital infection,1,0.8583550453186035
FARXIGA,genital infection,on FARXIGA,0,0.5031225681304932
FARXIGA,genital infection,study due genital,1,0.7542948722839355
FARXIGA,genital infection,due to,0,0.5407780408859253
FARXIGA,genital infection,d on,0,0.5349628925323486
FARXIGA,genital infection,patients and of patients,0,0.5016555786132812
FARXIGA,Infections,Infections were more frequently reported in,1,0.7485843300819397
FARXIGA,Infections,patients and of patients,0,0.5641552209854126
FARXIGA,Infections,Infections,1,0.9999999403953552
FARXIGA,Infections,patients,0,0.5940079689025879
FARXIGA,Infections,patients and of patients treated with,0,0.589928388595581
FARXIGA,Infections,Infections were more,1,0.8423154950141907
FARXIGA,Infections,Infections were more frequently reported,1,0.7407823801040649
FARXIGA,genital mycotic infections,reported,0,0.5050978660583496
FARXIGA,genital mycotic infections,mycotic infections were vulvovaginal mycotic infections in,1,0.8662369251251221
FARXIGA,genital mycotic infections,with,0,0.5301762819290161
FARXIGA,genital mycotic infections,frequently reported,0,0.519135594367981
FARXIGA,genital mycotic infections,vulvovaginal mycotic infections in females and balanitis in males,0,0.8413667678833008
FARXIGA,genital mycotic infections,genital mycotic infections were,1,0.9704849123954773
FARXIGA,genital mycotic infections,mycotic infections were,1,0.8359996676445007
FARXIGA,genital mycotic infections,infections,0,0.7496838569641113
FARXIGA,vulvovaginal mycotic infections,infections vulvovaginal,1,0.9152418375015259
FARXIGA,vulvovaginal mycotic infections,mycotic infections,1,0.8001575469970703
FARXIGA,genital mycotic infection,than those with,0,0.4744272828102112
FARXIGA,genital mycotic infection,to have genital mycotic infection,1,0.9492859244346619
FARXIGA,Hypersensitivity reactions,respectively Hypersensitivity Hypersensitivity reactions,1,0.9103472232818604
FARXIGA,Hypersensitivity reactions,respectively Hypersensitivity Hypersensitivity,1,0.8645616769790649
FARXIGA,Hypersensitivity reactions,were reported,0,0.5120830535888672
FARXIGA,angioedema,angioedema urticaria,1,0.9100886583328247
FARXIGA,angioedema,the clinical,0,0.5373086333274841
FARXIGA,angioedema,angioedema urticaria hypersensitivity were,1,0.8707382678985596
FARXIGA,angioedema,urticaria hypersensitivity were reported with FARXIGA,0,0.6548194885253906
FARXIGA,angioedema,the clinical program se,0,0.5032950043678284
FARXIGA,angioedema,angioedema urticaria hypersensitivity were reported,1,0.8598940968513489
FARXIGA,angioedema,angioedema urticaria hypersensitivity were reported with,1,0.8524916768074036
FARXIGA,angioedema,angioedema urticaria hypersensitivity,1,0.8900028467178345
FARXIGA,urticaria,urticaria hypersensitivity were reported,1,0.8400095701217651
FARXIGA,urticaria,Across the clinical program serious anaph,0,0.49892887473106384
FARXIGA,urticaria,urticaria hypersensitivity were reported with FARXIGA,1,0.7719132900238037
FARXIGA,urticaria,clinical program serious,0,0.459314227104187
FARXIGA,urticaria,urticaria hypersensitivity were,1,0.8622860908508301
FARXIGA,hypersensitivity,reactions eg angioedema hypersensitivity were reported with FARXIGA,1,0.7540950775146484
FARXIGA,hypersensitivity,urticaria hypersensitivity were,1,0.8532482385635376
FARXIGA,hypersensitivity,were,0,0.4843417704105377
FARXIGA,hypersensitivity,eg angioedema urticaria,0,0.7251749038696289
FARXIGA,anaphylactic reactions,cutaneous adverse reactions and angioedema were reported in of,0,0.7486035823822021
FARXIGA,anaphylactic reactions,Across the clinical program anaphylactic reactions and severe cutaneous adverse reactions,1,0.8230106830596924
FARXIGA,anaphylactic reactions,anaphylactic reactions and severe cutaneous adverse reactions,1,0.8613840341567993
FARXIGA,anaphylactic reactions,treatment Across the clinical program,0,0.4847128689289093
FARXIGA,anaphylactic reactions,anaphylactic reactions and severe cutaneous,1,0.8746176362037659
FARXIGA,anaphylactic reactions,clinical program anaphylactic,1,0.8195545673370361
FARXIGA,anaphylactic reactions,and angioedema were reported in,0,0.7170475721359253
FARXIGA,anaphylactic reactions,anaphylactic reactions and,1,0.9680274724960327
FARXIGA,cutaneous adverse reactions,serious anaphylactic reactions and,0,0.7103431224822998
FARXIGA,cutaneous adverse reactions,reactions and,0,0.6228978633880615
FARXIGA,cutaneous adverse reactions,anaphylactic reactions and cutaneous adverse reactions and angioedema were,1,0.8440550565719604
FARXIGA,angioedema,comparatortreated patients and of FARXIGAtreated,0,0.5469760894775391
FARXIGA,angioedema,the clinical program serious anaphylactic reactions and severe,0,0.6574327945709229
FARXIGA,angioedema,severe cutaneous adverse reactions angioedema were reported,1,0.8388442993164062
FARXIGA,angioedema,the clinical program serious anaphylactic,0,0.6649488806724548
FARXIGA,hematocrit values >55%,By hematocrit values >55% were reported in of,1,0.9370841979980469
FARXIGA,hematocrit values >55%,the clinical program serious anaphylactic,0,0.5273928642272949
FARXIGA,hematocrit values >55%,hematocrit values >55% were reported in,1,0.9695000648498535
FARXIGA,hyperphosphatemia,hyperphosphatemia mgdL for,1,0.8952134251594543
FARXIGA,hyperphosphatemia,hematocrit values >55% were reported in,1,0.5447153449058533
FARXIGA,hyperphosphatemia,laboratory abnormalities of,0,0.5929825305938721
FARXIGA,hyperphosphatemia,marked,0,0.4635341763496399
FARXIGA,hyperphosphatemia,hyperphosphatemia,1,1.0
FARXIGA,hyperphosphatemia,of,0,0.507131814956665
FARXIGA,hyperphosphatemia,with marked,0,0.4740597903728485
FARXIGA,hyperphosphatemia,hyperphosphatemia mgdL for age years,1,0.8702517747879028
FARXIGA,hyperphosphatemia,proportions of,0,0.525968074798584
FARXIGA,Hypotension,are described below and elsewhere in the labeling Hypotension see Warnings and,0,0.7989023327827454
FARXIGA,Impairment in renal function,[see Warning s and Precautions Genital Mycotic,1,0.49801450967788696
FARXIGA,Impairment in renal function,Insulin and Secretagogues,1,0.5083736181259155
FARXIGA,Impairment in renal function,Concomitant,0,0.5233266353607178
FARXIGA,Hypoglycemia,and Precautions Genital Mycotic ons,1,0.4715242385864258
FARXIGA,Hypoglycemia,Mycotic ons [see Wa,1,0.47963470220565796
FARXIGA,Increased LDL-C,(5% or g reater incidence were,1,0.5533319115638733
FARXIGA,Increased LDL-C,ARXIGA (5% or g reater,1,0.5145095586776733
FARXIGA,Increased LDL-C,see Warnings and Precautions The most common adverse,0,0.5610591769218445
FARXIGA,Increased LDL-C,nasopharyngitis and urinary tract,0,0.49360546469688416
FARXIGA,Increased LDL-C,adverse reactions associated with ARXIGA (5% or g reater incidence were female genital,1,0.5237042903900146
FARXIGA,Increased LDL-C,urinary,0,0.5408687591552734
FARXIGA,Increased LDL-C,ARXIGA,1,0.4598742127418518
FARXIGA,Increased LDL-C,incidence were female genital mycotic infections nasopharyngitis,0,0.4747266173362732
FARXIGA,Bladder Cancer,asopharyngitis,1,0.46889737248420715
FARXIGA,bladder cancers,infections nasopharyngitis and urinary t infections.   EXCERPT,1,0.5963451862335205
FARXIGA,bladder cancers,asopharyngitis,1,0.47021251916885376
FARXIGA,intravascular volume contraction,and may not eflect the rates observed in cli,1,0.579692006111145
FARXIGA,intravascular volume contraction,eflect the rates observed in cli nical practice Pool,1,0.5860354900360107
FARXIGA,intravascular volume contraction,directly compared to rates in the clinical trials of another drug and may not r,0,0.5410068035125732
FARXIGA,intravascular volume contraction,may not eflect the rates observed,1,0.58641117811203
FARXIGA,intravascular volume contraction,rates in the clinical trials of another drug and,0,0.5518043637275696
FARXIGA,intravascular volume contraction,drug and may not eflect the rates observed in cli,1,0.6000370383262634
FARXIGA,intravascular volume contraction,drug and may not eflect the rates observed in,1,0.595144510269165
FARXIGA,Symptomatic hypotension,in the clinical trials of another drug and,0,0.5206195116043091
FARXIGA,Symptomatic hypotension,"cal practice.



     P ool of PlaceboControlled Studies",1,0.5307220816612244
FARXIGA,Symptomatic hypotension,observed in cal,1,0.4654955267906189
FARXIGA,Symptomatic hypotension,cal practice. P ool,1,0.48368316888809204
FARXIGA,Symptomatic hypotension,reflect the rates observed in clini,0,0.5479263067245483
FARXIGA,Symptomatic hypotension,cal practice. P ool of PlaceboControlled Studies for,1,0.5299665927886963
FARXIGA,Symptomatic hypotension,practice. P ool of PlaceboControlled Studies,1,0.5298820734024048
FARXIGA,Symptomatic hypotension,the rates observed in cal,1,0.45970618724823
FARXIGA,increases serum creatinine,placebo (N FARXIGA,1,0.5135767459869385
FARXIGA,increases serum creatinine,Pa,0,0.43957099318504333
FARXIGA,increases serum creatinine,duration of weeks tients received,1,0.5092185735702515
FARXIGA,increases serum creatinine,mg,0,0.5733392238616943
FARXIGA,increases serum creatinine,FARXIGA mg,0,0.5249658226966858
FARXIGA,increases serum creatinine,placebo (N FARXIGA mg N or,1,0.537482738494873
FARXIGA,increases serum creatinine,of the population,0,0.44571781158447266
FARXIGA,decreases eGFR,5 m g N or FARXIGA,1,0.551109790802002
FARXIGA,decreases eGFR,Patients,0,0.5714542865753174
FARXIGA,decreases eGFR,N once daily The mean age of the population was years and,0,0.467898964881897
FARXIGA,decreases eGFR,to,0,0.5030860900878906
FARXIGA,decreases eGFR,the,0,0.4976503551006317
FARXIGA,decreases eGFR,FARXIGA 5 m g N or FARXIGA,1,0.5487270355224609
FARXIGA,decreases eGFR,patients to FARXIGA with a,0,0.5601438283920288
FARXIGA,decreases eGFR,FARXIGA 5 m g,1,0.5585318803787231
FARXIGA,decreases eGFR,N or FARXIGA mg N once daily The mean,0,0.5686043500900269
FARXIGA,decreases eGFR,FARXIGA 5 m g N or,1,0.5583689212799072
FARXIGA,hypoglycemia,and ately,1,0.49607178568840027
FARXIGA,hypoglycemia,ed in,0,0.5104209184646606
FARXIGA,hypoglycemia,ately impair ed in of,1,0.5425795316696167
FARXIGA,hypoglycemia,ately impair,1,0.5300998687744141
FARXIGA,genital mycotic infections,FARXIGA Adverse Reac,0,0.5135858058929443
FARXIGA,genital mycotic infections,in PlaceboControlled Studies Reported in of Patients Treated with FARXIGA Adverse Reac,0,0.48519572615623474
FARXIGA,genital mycotic infections,"FARXIGA 

 Table 1: Adverse Reacti ons in PlaceboControlled",1,0.5154145956039429
FARXIGA,genital mycotic infections,"FARXIGA 

 Table 1: Adverse Reacti ons in PlaceboControlled Studies",1,0.5137068629264832
FARXIGA,genital mycotic infections,Studies Reported,0,0.5210431814193726
FARXIGA,genital mycotic infections,PlaceboControlled Studies Reported in of Patients Treated with FARXIGA Adverse,0,0.4916568398475647
FARXIGA,genital mycotic infections,Studies Reported in of Patients Treated with FARXIGA,0,0.5140461921691895
FARXIGA,genital mycotic infections,of patients,0,0.48672980070114136
FARXIGA,genital mycotic infections,"mg or FARXIGA 

 Table 1: Adverse Reacti ons in PlaceboControlled Studies",1,0.5128976106643677
FARXIGA,genital mycotic infections,mg or FARXIGA,0,0.49672096967697144
FARXIGA,Increases in LDL-C,                   Placebo N FARXIGA,1,0.5197016596794128
FARXIGA,Increases in LDL-C,                   Placebo N,1,0.5199007987976074
FARXIGA,Increases in LDL-C,                   Placebo N FARXIGA mg,1,0.5036931037902832
FARXIGA,Increases in LDL-C,Studies,0,0.5858867168426514
FARXIGA,Increases in LDL-C,FARXIGA,0,0.46549251675605774
FARXIGA,Increases in LDL-C,                   Placebo,1,0.5375933647155762
FARXIGA,bladder cancer,for females vulvovaginal,0,0.471805214881897
FARXIGA,bladder cancer,n order of fre quency reported for females vulvovaginal,1,0.4872085452079773
FARXIGA,bladder cancer,reactions,0,0.4894264340400696
FARXIGA,bladder cancer,infection vulvovaginal candidi,0,0.517829179763794
FARXIGA,bladder cancer,order of fre quency,1,0.4879123270511627
FARXIGA,bladder cancer,adverse reactions listed n,1,0.5013790726661682
FARXIGA,bladder cancer,"genitourinary tract infection lval abscess,  and vaginitis",1,0.5634555816650391
FARXIGA,bladder cancer,infection,0,0.5440798997879028
FARXIGA,bladder cancer,fungal genital,0,0.5159743428230286
FARXIGA,bladder cancer,and vaginitis,0,0.5295349955558777
FARXIGA,bladder cancer,"infection lval abscess,  and vaginitis bacterial N for",1,0.5547153949737549
FARXIGA,bladder cancer,N for,0,0.47954365611076355
VICTRELIS,fatigue,nausea headache and dysgeusia To report SUSPECTED ADVERSE,0,0.6086611151695251
VICTRELIS,fatigue,with PegIntron and REBETOL fatigue anemia nausea headache and dysgeusia,1,0.6655294299125671
VICTRELIS,fatigue,nausea headache and dysgeusia,0,0.6113068461418152
VICTRELIS,fatigue,fatigue anemia nausea headache,1,0.8108400106430054
VICTRELIS,fatigue,fatigue anemia nausea,1,0.8229102492332458
VICTRELIS,anemia,anemia nausea headache and dysgeusia,1,0.8074355721473694
VICTRELIS,anemia,anemia,1,1.0
VICTRELIS,nausea,nausea headache and,1,0.8757563829421997
VICTRELIS,nausea,were fatigue nausea headache,1,0.8002122640609741
VICTRELIS,headache,report SUSPECTED ADVERSE REACTIONS contact Merck Sharp Dohme,0,0.549602746963501
VICTRELIS,headache,headache and,1,0.9235891103744507
VICTRELIS,dysgeusia,headache dysgeusia To report SUSPECTED,1,0.8351197242736816
VICTRELIS,dysgeusia,headache and,1,0.5758670568466187
VICTRELIS,dysgeusia,SUSPECTED ADVERSE REACTIONS contact Merck Sharp Dohme Corp a,0,0.5489190220832825
VICTRELIS,dysgeusia,fatigue anemia nausea headache dysgeusia To report SUSPECTED,1,0.7345216870307922
VICTRELIS,dysgeusia,dysgeusia To report,1,0.9115936756134033
VICTRELIS,dysgeusia,Dohme Corp a,0,0.5134509801864624
VICTRELIS,dysgeusia,To report SUSPECTED ADVERSE REACTIONS contact Merck Sharp,0,0.533389687538147
VICTRELIS,dysgeusia,dysgeusia To,1,0.9564273357391357
VICTRELIS,Anemia,Anemia see Warnings and Precautions Neutropenia,1,0.7927038073539734
VICTRELIS,Anemia,section of the Anemia see Warnings and Precautions Neutropenia,1,0.7838668823242188
VICTRELIS,Anemia,section of the Anemia,1,0.8519848585128784
VICTRELIS,Anemia,are discussed in detail,0,0.5054616928100586
VICTRELIS,Anemia,Anemia see,1,0.8968639373779297
VICTRELIS,Anemia,Anemia see Warnings,1,0.8328568339347839
VICTRELIS,Anemia,Anemia,1,1.0
VICTRELIS,Anemia,discussed,0,0.5223901271820068
VICTRELIS,Anemia,adverse drug reactions ADRs are discussed in detail in another section of,0,0.5073556900024414
VICTRELIS,Anemia,another section of the Anemia see,1,0.8608607649803162
VICTRELIS,Neutropenia,of the labeling,0,0.48606958985328674
VICTRELIS,Pancytopenia,see Warnings and Precautions,0,0.5120078325271606
VICTRELIS,Pancytopenia,see Contraindications and,0,0.5107254981994629
VICTRELIS,Pancytopenia,Pancytopenia see Warnings and,1,0.893780529499054
VICTRELIS,Hypersensitivity,see Warnings and Hypersensitivity,1,0.8033761382102966
VICTRELIS,Hypersensitivity,Pancytopenia see Warnings and,1,0.5650990009307861
VICTRELIS,Hypersensitivity,Hypersensitivity,1,1.0
VICTRELIS,Hypersensitivity,Pancytopenia see Warnings and Hypersensitivity see,1,0.7524977922439575
VICTRELIS,Hypersensitivity,Hypersensitivity see Contraindications,1,0.8155152797698975
VICTRELIS,Hypersensitivity,Hypersensitivity see Contraindications and Warnings,1,0.8145236372947693
VICTRELIS,Hypersensitivity,and Warnings and,0,0.5324444770812988
VICTRELIS,Hypersensitivity,Warnings and Precautions Pancytopenia,0,0.5605349540710449
VICTRELIS,Hypersensitivity,see Warnings and Hypersensitivity see,1,0.8140698075294495
VICTRELIS,fatigue,fatigue anemia,1,0.835168182849884
VICTRELIS,fatigue,fatigue,1,1.0
VICTRELIS,fatigue,was used in combination with,0,0.5344207286834717
VICTRELIS,fatigue,dysgeusia when VICTRELIS,0,0.5392336249351501
VICTRELIS,fatigue,fatigue anemia nausea headache and,1,0.792381763458252
VICTRELIS,anemia,in,0,0.564868688583374
VICTRELIS,anemia,in combination,0,0.5490519404411316
VICTRELIS,anemia,assessment in adult,0,0.5313540697097778
VICTRELIS,anemia,headache and dysgeusia when VICTRELIS,0,0.5669523477554321
VICTRELIS,anemia,were anemia nausea headache and,1,0.8155865669250488
VICTRELIS,anemia,in combination with PegIntron and,0,0.5564620494842529
VICTRELIS,anemia,of investigators causality assessment in adult subjects were fatigue,0,0.5551121234893799
VICTRELIS,nausea,fatigue nausea headache and dysgeusia,1,0.7574027180671692
VICTRELIS,nausea,used in combination with PegIntron and REBETOL,0,0.587246298789978
VICTRELIS,nausea,subjects regardless,0,0.5108088254928589
VICTRELIS,nausea,was used in combination with PegIntron and,0,0.5812386870384216
VICTRELIS,headache,were fatigue anemia,0,0.5312497019767761
VICTRELIS,headache,regardless of investigators causality assessment in adult subjects were,0,0.4789915084838867
VICTRELIS,headache,subjects were fatigue anemia nausea,0,0.580901563167572
VICTRELIS,headache,headache and dysgeusia when VICTRELIS,1,0.7287898063659668
VICTRELIS,dysgeusia,fatigue anemia nausea headache dysgeusia when VICTRELIS was used in,1,0.667831540107727
VICTRELIS,dysgeusia,headache and dysgeusia when VICTRELIS,1,0.8058739900588989
VICTRELIS,dysgeusia,were fatigue anemia,0,0.5313435792922974
VICTRELIS,dysgeusia,dysgeusia when VICTRELIS was,1,0.8466688990592957
VICTRELIS,dysgeusia,investigators causality assessment in adult,0,0.5262086987495422
VICTRELIS,dysgeusia,combination,0,0.5296840667724609
VICTRELIS,anemia,anemia and,1,0.9244570732116699
VICTRELIS,anemia,anemia and fatigue were reported as,1,0.8306673765182495
VICTRELIS,anemia,anemia and fatigue,1,0.8676987290382385
VICTRELIS,anemia,with PegIntronREBETOL anemia and fatigue were reported,1,0.7271499633789062
VICTRELIS,fatigue,PegIntronREBETOL Only anemia fatigue were,1,0.7139413952827454
VICTRELIS,fatigue,anemia and fatigue,1,0.814905047416687
VICTRELIS,fatigue,fatigue were reported as events,1,0.8415685296058655
VICTRELIS,fatigue,fatigue were reported as events that,1,0.8411847352981567
VICTRELIS,fatigue,similar to those seen in,0,0.5078948736190796
VICTRELIS,fatigue,fatigue were reported as,1,0.8844581246376038
VICTRELIS,fatigue,to discontinuation in more than,0,0.5907642841339111
VICTRELIS,anemia,anemia which,1,0.9385321140289307
VICTRELIS,anemia,frequently in subjects receiving the,0,0.5151348114013672
VICTRELIS,anemia,anemia which occurred more,1,0.8378523588180542
VICTRELIS,anemia,VICTRELIS with PegIntronR,0,0.5499593019485474
VICTRELIS,anemia,anemia which occurred more frequently,1,0.8063558340072632
VICTRELIS,anemia,anemia which occurred more frequently in,1,0.8111109733581543
VICTRELIS,anemia,occurred more frequently in subjects,0,0.5063508749008179
VICTRELIS,alteration of taste,of taste was,1,0.8127556443214417
VICTRELIS,alteration of taste,and ribavirin Gastrointestinal Disorders alteration of taste was an adverse,1,0.8208633661270142
VICTRELIS,alteration of taste,and ribavirin Gastrointestinal Disorders alteration of taste was an,1,0.8249906301498413
VICTRELIS,alteration of taste,Gastrointestinal Disorders alteration of taste was an adverse event,1,0.8538727760314941
VICTRELIS,alteration of taste,of taste was an,1,0.8143467307090759
VICTRELIS,alteration of taste,and ribavirin Gastrointestinal Disorders Dysgeusia,0,0.6997328996658325
VICTRELIS,alteration of taste,alteration of taste was an adverse,1,0.9520060420036316
VICTRELIS,dry mouth,dry mouth nausea vomiting and diarrhea,1,0.8204294443130493
VICTRELIS,vomiting,increased frequency in subjects receiving VICTRELIS in,0,0.573287844657898
VICTRELIS,vomiting,were also reported at an increased frequency,0,0.5267162322998047
VICTRELIS,vomiting,vomiting and diarrhea were also reported,1,0.8093291521072388
VICTRELIS,vomiting,and diarrhea were also reported at an increased frequency in subjects receiving VICTRELIS in,0,0.6313042640686035
VICTRELIS,vomiting,vomiting and diarrhea,1,0.8437063097953796
VICTRELIS,vomiting,such as dry mouth vomiting and diarrhea,1,0.7777247428894043
VICTRELIS,vomiting,subjects receiving VICTRELIS,0,0.5694064497947693
VICTRELIS,vomiting,vomiting and,1,0.9646890163421631
VICTRELIS,vomiting,dry mouth vomiting and diarrhea,1,0.7753528356552124
VICTRELIS,vomiting,VICTRELIS in,0,0.47046512365341187
VICTRELIS,platelet counts of less than 50 * 10 9 per L,with PegIntronREBETOL had,0,0.5374844074249268
VICTRELIS,platelet counts of less than 50 * 10 9 per L,9 per L compared to of,1,0.7018157839775085
VICTRELIS,platelet counts of less than 50 * 10 9 per L,counts of less than 50 * 10 9 per L compared to of subjects,1,0.8272338509559631
VICTRELIS,platelet counts of less than 50 * 10 9 per L,to,0,0.5046745538711548
VICTRELIS,platelet counts of less than 50 * 10 9 per L,platelet counts of less than 50 * 10  9  per L compared,1,0.9803066253662109
VICTRELIS,platelet counts of less than 50 * 10 9 per L,PegIntronREBETOL platelet counts of less than 50 * 10  9  per L compared to of subjects receiving,1,0.8235747814178467
VICTRELIS,agranulocytosis,pancytopenia thrombocytopenia see,0,0.6447147130966187
VICTRELIS,pancytopenia,Blood and Lymphatic System,0,0.5934878587722778
VICTRELIS,pancytopenia,and Precautions Gastrointestinal,0,0.5414931774139404
VICTRELIS,pancytopenia,pancytopenia thrombocytopenia see Warnings and Precautions,1,0.8563567996025085
VICTRELIS,pancytopenia,Lymphatic System Disorders pancytopenia,1,0.8372859954833984
VICTRELIS,pancytopenia,Warnings and Precautions,0,0.518828809261322
VICTRELIS,pancytopenia,Disorders pancytopenia,1,0.9217482209205627
VICTRELIS,thrombocytopenia,Blood and Lymphatic System,0,0.5757757425308228
VICTRELIS,thrombocytopenia,thrombocytopenia see Warnings and,1,0.878383994102478
VICTRELIS,thrombocytopenia,System Disorders agranulocytosis thrombocytopenia see Warnings and Precautions,1,0.7553575038909912
VICTRELIS,thrombocytopenia,and Precautions Gastrointestinal Disorders mouth ulceration,0,0.5087229609489441
VICTRELIS,thrombocytopenia,thrombocytopenia see Warnings and Precautions Gastrointestinal,1,0.8256173133850098
VICTRELIS,thrombocytopenia,agranulocytosis thrombocytopenia see Warnings,1,0.8013461828231812
VICTRELIS,mouth ulceration,Skin and,0,0.6023136377334595
VICTRELIS,mouth ulceration,mouth ulceration stomatitis Infections and,1,0.8984532356262207
VICTRELIS,mouth ulceration,mouth ulceration stomatitis Infections and Infestations pneumonia,1,0.8224887847900391
VICTRELIS,mouth ulceration,Disorders,0,0.5660207271575928
VICTRELIS,mouth ulceration,mouth ulceration stomatitis Infections and Infestations,1,0.8646158576011658
VICTRELIS,mouth ulceration,Infestations pneumonia sepsis Skin,0,0.5537909269332886
VICTRELIS,mouth ulceration,Warnings and Precautions Gastrointestinal mouth ulceration stomatitis Infections and,1,0.8000644445419312
VICTRELIS,mouth ulceration,Precautions Gastrointestinal mouth ulceration stomatitis Infections and,1,0.8159834146499634
VICTRELIS,mouth ulceration,Gastrointestinal,0,0.5935550928115845
VICTRELIS,stomatitis,stomatitis,1,1.0
VICTRELIS,stomatitis,stomatitis Infections and Infestations pneumonia,1,0.7773232460021973
VICTRELIS,stomatitis,and Subcutaneous,0,0.5537266135215759
VICTRELIS,pneumonia,pneumonia sepsis Skin and Subcutaneous Tissue,1,0.7520678639411926
VICTRELIS,pneumonia,pneumonia sepsis Skin and,1,0.7778822183609009
VICTRELIS,pneumonia,pneumonia,1,0.9999997615814209
VICTRELIS,pneumonia,pneumonia sepsis Skin and Subcutaneous,1,0.7595658302307129
VICTRELIS,pneumonia,see Warnings and,0,0.5557147264480591
VICTRELIS,pneumonia,Infections and pneumonia sepsis Skin and Subcutaneous,1,0.7425230741500854
VICTRELIS,pneumonia,ulceration stomatitis Infections,0,0.5255029201507568
VICTRELIS,pneumonia,Infections and,0,0.6817795038223267
VICTRELIS,sepsis,sepsis Skin and Subcutaneous,1,0.8258665204048157
VICTRELIS,sepsis,Infections and,0,0.7093727588653564
VICTRELIS,sepsis,sepsis Skin and,1,0.8457983136177063
VICTRELIS,sepsis,Infestations sepsis Skin and Subcutaneous Tissue,1,0.7613332271575928
VICTRELIS,sepsis,stomatitis Infections and Infestations sepsis Skin,1,0.7546725273132324
VICTRELIS,sepsis,stomatitis,0,0.610670804977417
VICTRELIS,sepsis,mouth ulceration,0,0.550472617149353
VICTRELIS,angioedema,pneumonia sepsis Skin and Subcutaneous Tissue,0,0.5665782690048218
VICTRELIS,urticaria,urticaria see Warnings and Precautions drug,1,0.8079378604888916
VICTRELIS,urticaria,ons and,0,0.5184249877929688
VICTRELIS,urticaria,Infestations pneumonia,0,0.5047456622123718
VICTRELIS,urticaria,urticaria see,1,0.9012218713760376
VICTRELIS,exfoliative rash,symptoms DRESS exfoliative rash,1,0.9031608700752258
VICTRELIS,exfoliative rash,systemic symptoms DRESS syndrome,0,0.5848522782325745
VICTRELIS,exfoliative rash,symptoms DRESS exfoliative rash exfoliative dermatitis StevensJohnson syndrome,1,0.8242183327674866
VICTRELIS,exfoliative rash,exfoliative rash exfoliative dermatitis,1,0.9611850380897522
VICTRELIS,exfoliative rash,syndrome,0,0.5538885593414307
VICTRELIS,exfoliative rash,DRESS,0,0.4879915118217468
VICTRELIS,exfoliative rash,dermatitis StevensJohnson syndrome toxic skin eruption,0,0.6915880441665649
VICTRELIS,exfoliative rash,eosinophilia,0,0.5895201563835144
VICTRELIS,exfoliative rash,exfoliative rash exfoliative dermatitis StevensJohnson syndrome,1,0.8575048446655273
VICTRELIS,exfoliative dermatitis,syndrome exfoliative exfoliative dermatitis StevensJohnson syndrome toxic skin eruption,1,0.7967041730880737
VICTRELIS,exfoliative dermatitis,exfoliative rash exfoliative dermatitis StevensJohnson syndrome,1,0.8417589664459229
VICTRELIS,exfoliative dermatitis,drug rash with eosinophilia and,0,0.6418619155883789
VICTRELIS,exfoliative dermatitis,syndrome exfoliative exfoliative dermatitis StevensJohnson syndrome toxic,1,0.8084810972213745
VICTRELIS,exfoliative dermatitis,StevensJohnson,0,0.4560650587081909
VICTRELIS,exfoliative dermatitis,syndrome exfoliative exfoliative,1,0.8467251062393188
VICTRELIS,exfoliative dermatitis,exfoliative exfoliative dermatitis,1,0.9921703338623047
VICTRELIS,exfoliative dermatitis,exfoliative dermatitis StevensJohnson,1,0.9256811738014221
VICTRELIS,exfoliative dermatitis,and systemic,0,0.5351047515869141
VICTRELIS,Stevens-Johnson syndrome,Stevens-Johnson syndrome toxic skin eruption,1,0.8691396713256836
VICTRELIS,Stevens-Johnson syndrome,exfoliative Stevens-Johnson syndrome toxic skin eruption,1,0.8356017470359802
VICTRELIS,Stevens-Johnson syndrome,toxic skin eruption toxicoderma,0,0.6442614197731018
VICTRELIS,Stevens-Johnson syndrome,Stevens-Johnson syndrome toxic skin,1,0.8705959320068359
VICTRELIS,Stevens-Johnson syndrome,rash exfoliative Stevens-Johnson syndrome,1,0.8581489324569702
VICTRELIS,Embryofetal Toxicity,peginterferon alfa and ribavirin prescribing information for,0,0.511100172996521
VICTRELIS,fetal death,(greater th an of subjects in,1,0.4961826801300049
VICTRELIS,fetal death,peginterferon alfa and ribavirin prescribing information for,0,0.4900380074977875
VICTRELIS,fetal death,reactions,0,0.5211551189422607
VICTRELIS,fetal death,adverse (greater th,1,0.5109172463417053
VICTRELIS,fetal death,(greater th an of,1,0.5040100812911987
VICTRELIS,Anemia,"ONS, c ontact Merck",1,0.5833330154418945
VICTRELIS,decrease in hemoglobin concentrations,or www.fda.gov/med watch Clinical Trials Experience,1,0.4980003833770752
VICTRELIS,decrease in hemoglobin concentrations,Sharp Dohme Corp a subsidiary of Merck Co Inc at,0,0.5005953311920166
VICTRELIS,decrease in hemoglobin concentrations,Inc at or FDA -800-FDA-1088 or      www.fda.gov/med watch Clinical Trials Experience,1,0.485448956489563
VICTRELIS,decrease in hemoglobin concentrations,FDA -800-FDA-1088,1,0.5083033442497253
VICTRELIS,decrease in hemoglobin concentrations,-800-FDA-1088 or www.fda.gov/med,1,0.49634313583374023
VICTRELIS,decrease in hemoglobin concentrations,at or FDA -800-FDA-1088 or      www.fda.gov/med watch Clinical,1,0.4951592683792114
VICTRELIS,decrease in hemoglobin concentrations,Merck Sharp Dohme Corp a subsidiary of Merck,0,0.5063544511795044
VICTRELIS,decrease in hemoglobin concentrations,at or FDA -800-FDA-1088 or      www.fda.gov/med watch,1,0.5027376413345337
VICTRELIS,decrease in hemoglobin concentrations,Because clinical trials are,0,0.4969053268432617
VICTRELIS,Neutropenia,Because trials are,1,0.47654658555984497
VICTRELIS,worsening of neutropenia,in c,0,0.42502129077911377
VICTRELIS,worsening of neutropenia,rates in the clinical trials of another drug and,0,0.5652438402175903
VICTRELIS,worsening of neutropenia,observed,0,0.4858727753162384
VICTRELIS,worsening of neutropenia,are conducted under widely varying,0,0.49925631284713745
VICTRELIS,worsening of neutropenia,are conducted under widely,0,0.49165964126586914
VICTRELIS,acute hypersensitivity reactions,to rates in the clinical trials of another drug and may not,0,0.47093889117240906
VICTRELIS,acute hypersensitivity reactions,of another drug and may not reflect the rat,0,0.4857678711414337
VICTRELIS,urticaria,practice The ng seriou,1,0.48657187819480896
VICTRELIS,urticaria,of another drug and may not reflect the rat,0,0.489689439535141
VICTRELIS,urticaria,practice The ng seriou s and otherwise important adverse,1,0.5277644991874695
VICTRELIS,urticaria,ng seriou s,1,0.4997054934501648
VICTRELIS,urticaria,in practice The ng seriou,1,0.4575713872909546
VICTRELIS,urticaria,The followi,0,0.4711100459098816
VICTRELIS,urticaria,trials of another drug and may,0,0.510073721408844
VICTRELIS,urticaria,observed in practice The ng seriou,1,0.47571203112602234
VICTRELIS,urticaria,in another section,0,0.5049105882644653
VICTRELIS,urticaria,drug and may not reflect the rates observed in practice The,0,0.46586620807647705
VICTRELIS,angioedema,in practice The following and otherw ise important,1,0.4547332525253296
VICTRELIS,angioedema,drug and may not reflect the rates observed in practice The,0,0.48412513732910156
VICTRELIS,angioedema,reactions ADRs are,0,0.5856980681419373
VICTRELIS,angioedema,not reflect the rates observed in practice The following serious,0,0.4811721742153168
VICTRELIS,birth defects,"Warnings and ]  
 *  Pancy",1,0.5181475877761841
VICTRELIS,birth defects,not reflect the rates observed in practice The following serious,0,0.47290217876434326
VICTRELIS,birth defects,"and ]  
 *  Pancy topenia",1,0.46436700224876404
VICTRELIS,birth defects,Precautions Hypersensitivity see Contraindications,0,0.5331236124038696
VICTRELIS,birth defects,* Pancy topenia see,1,0.48962685465812683
VICTRELIS,birth defects,Neutropenia see Warnings and,0,0.5263947248458862
VICTRELIS,birth defects,see Warnings and ] *,1,0.539362907409668
VICTRELIS,birth defects,Precautions Hypersensitivity,0,0.513391375541687
VICTRELIS,birth defects,see Warnings and,0,0.5332001447677612
VICTRELIS,birth defects,and ] * Pancy,1,0.4831260144710541
VICTRELIS,death of the exposed fetus,[see Warnings and,1,0.5260319709777832
VICTRELIS,death of the exposed fetus,and Precautions [see Warnings and,1,0.5444390773773193
VICTRELIS,death of the exposed fetus,Precautions [see,1,0.5605949759483337
VICTRELIS,death of the exposed fetus,see Warnings and Precautions [see Warnings and Precaut,1,0.5348784923553467
VICTRELIS,death of the exposed fetus,Hypersensitivity see Contraindications,0,0.5073143243789673
VICTRELIS,death of the exposed fetus,see,0,0.4952264428138733
VICTRELIS,Anemia,combination with PegIntronREBETOL with a fourweek leadi,0,0.5653797388076782
VICTRELIS,Anemia,mg three times daily in combination with PegIntronREBETOL with a,0,0.5563343167304993
VICTRELIS,Anemia,he,1,0.5561442375183105
VICTRELIS,additional decrease in hemoglobin concentrations,PegIntronREBETOL compared to PegInt,0,0.5744473934173584
VICTRELIS,hemoglobin values less than 10 g per dL,"more than of jects in any arm.



 Adverse reactions that led",1,0.4985494315624237
VICTRELIS,hemoglobin values less than 10 g per dL,PegIntronREBETOL compared to PegInt,0,0.5636633038520813
VICTRELIS,hemoglobin values less than 10 g per dL,of jects in,1,0.5022896528244019
VICTRELIS,hemoglobin less than 10 g per dL,than in bjects receiving PegIntron/REBET OL,1,0.5941574573516846
VICTRELIS,hemoglobin less than 10 g per dL,of jects in,1,0.4992336332798004
VICTRELIS,hemoglobin less than 10 g per dL,bjects receiving PegIntron/REBET OL alone,1,0.5926675796508789
VICTRELIS,hemoglobin less than 10 g per dL,receiving the combination of,0,0.5137335062026978
VICTRELIS,hemoglobin less than 10 g per dL,bjects receiving PegIntron/REBET,1,0.5821834802627563
VICTRELIS,hemoglobin less than 10 g per dL,bjects receiving PegIntron/REBET OL alone Serious adverse events,1,0.5627517700195312
VICTRELIS,hemoglobin less than 10 g per dL,reported in of,0,0.4920603334903717
VICTRELIS,hemoglobin less than 10 g per dL,were,0,0.512501060962677
VICTRELIS,hemoglobin less than 10 g per dL,in bjects receiving,1,0.522225558757782
VICTRELIS,hemoglobin less than 10 g per dL,receiving the combination of VICTRELIS with PegIntronREBETOL than in su,0,0.5571471452713013
VICTRELIS,hemoglobin less than 10 g per dL,than in bjects receiving PegIntron/REBET OL alone Serious,1,0.5950236320495605
VICTRELIS,anemia,of cts re,1,0.4847587049007416
VICTRELIS,anemia,of investigators causality assessment reported in greater than,0,0.5079004764556885
VICTRELIS,anemia,assessment reported in greater than or equal,0,0.4761251211166382
VICTRELIS,anemia,assessment reported in greater than or equal to,0,0.4805397391319275
VICTRELIS,dyspnea,to of subjects receiving e,1,0.5354617834091187
VICTRELIS,dyspnea,e combi nation of VICTRELIS with PegIntronREBETOL,1,0.5269609689712524
VICTRELIS,dyspnea,e,1,0.536642849445343
VICTRELIS,dyspnea,receiving e combi nation of,1,0.5299162864685059
VICTRELIS,dyspnea,with PegIntronREBETOL and reported at a rate of greater than or,0,0.5227300524711609
VICTRELIS,dyspnea,and reported at a rate of greater than or,0,0.5416662693023682
VICTRELIS,exertional dyspnea,tion,1,0.5488440990447998
VICTRELIS,exertional dyspnea,rate of greater than or equal to than PegIntronREBETOL,0,0.5576463341712952
VICTRELIS,exertional dyspnea,of VICTRELIS with,1,0.48215168714523315
VICTRELIS,dizziness,of VICTRELIS th,1,0.4915619492530823
VICTRELIS,dizziness,th PegInt ronREBETOL,1,0.5835819840431213
VICTRELIS,dizziness,of VICTRELIS th PegInt,1,0.5297077894210815
VICTRELIS,dizziness,of VICTRELIS th PegInt ronREBETOL,1,0.5696254968643188
VICTRELIS,dizziness,th PegInt ronREBETOL and,1,0.5792220830917358
VICTRELIS,syncope,EBETOL ,1,0.5429176092147827
VICTRELIS,syncope,combination of VICTRELIS with EBETOL  and reported,1,0.5608657598495483
VICTRELIS,syncope,than or equal to of subjects receiving the combination of VICTRELIS,0,0.5447450876235962
VICTRELIS,syncope,EBETOL  and reported at,1,0.5540227890014648
VICTRELIS,syncope,EBETOL  and reported at a,1,0.5567760467529297
VICTRELIS,anemia, >=5%  than,1,0.48334115743637085
VICTRELIS,anemia,Combination of,0,0.5674468278884888
VICTRELIS,anemia,UntreatedSPRINT and SPRINT,0,0.5291192531585693
VICTRELIS,anemia,Events Previously,0,0.5013220310211182
VICTRELIS,anemia,PegIntronREBETOL alone Adverse Events Previously UntreatedSPRINT,0,0.5355381965637207
VICTRELIS,anemia,with PegIntronREBETOL,0,0.5496653318405151
VICTRELIS,anemia, >=5%  than PegIntronREBETOL,1,0.5309123992919922
VICTRELIS,anemia,Rate  >=5%  than PegIntronREBETOL,1,0.5196853876113892
VICTRELIS,anemia,Subjects Reporting Adv,0,0.5307732820510864
VICTRELIS,anemia,of Subjects Reporting erse E vents Percentage,1,0.513584554195404
VICTRELIS,anemia,of Subjects Reporting erse E vents Percentage of,1,0.5106613636016846
VICTRELIS,anemia,erse,1,0.5161022543907166
VICTRELIS,anemia,Adv,0,0.5409919619560242
VICTRELIS,anemia,Reporting erse E,1,0.5457944869995117
VICTRELIS,anemia,erse E vents Percentage of Subjects,1,0.511987566947937
VICTRELIS,pancytopenia,3 ). Adverse,1,0.478248655796051
VICTRELIS,pancytopenia,and ribavirin,0,0.5845781564712524
VICTRELIS,pancytopenia,Table 3 ). Adverse events such as,1,0.511677086353302
VICTRELIS,acute hypersensitivity reactions,and Clinical Studies (14),1,0.5200331211090088
VICTRELIS,urticaria, prescrib ing information,1,0.5002603530883789
VICTRELIS,urticaria,for ribavirin If,0,0.5003094673156738
VICTRELIS,urticaria,Precautions and Clinical Studies  prescrib ing information,1,0.5230324268341064
VICTRELIS,urticaria,ribavirin is permanently,0,0.48509103059768677
VICTRELIS,urticaria,and Clinical Studies  prescrib ing information for,1,0.4907546043395996
VICTRELIS,urticaria,permanently discontinued then peginterferon,0,0.5020542740821838
VICTRELIS,urticaria,and Precautions and Clinical,0,0.5231857299804688
VICTRELIS,urticaria,and Clinical Studies  prescrib ing information for ribavirin,1,0.4846055805683136
VICTRELIS,urticaria,Clinical Studies  prescrib ing,1,0.5020096302032471
VICTRELIS,angioedema,alfa,0,0.544911801815033
VICTRELIS,angioedema,and Clinical Studies see g informat ion for,1,0.5478180646896362
VICTRELIS,angioedema,g informat ion for ribavirin If ribavirin,1,0.5070613622665405
VICTRELIS,angioedema,see g informat ion for ribavirin If,1,0.5106960535049438
VICTRELIS,angioedema,and Clinical Studies see g,1,0.5547870397567749
VICTRELIS,angioedema,see prescribin,0,0.5715938806533813
VIMIZIM,Anaphylaxis,Anaphylaxis and hypersensitivity,1,0.8847521543502808
VIMIZIM,Anaphylaxis,see prescribin,0,0.5624130368232727
VIMIZIM,Anaphylaxis,the Anaphylaxis and hypersensitivity,1,0.8891461491584778
VIMIZIM,hypersensitivity reactions,common adverse,0,0.5642164945602417
VIMIZIM,pyrexia,a higher incidence than placebotreated patients,0,0.519415020942688
VIMIZIM,pyrexia,incidence than placebotreated patients pyrexia vomiting headache nausea,1,0.8095194101333618
VIMIZIM,pyrexia,pyrexia vomiting headache nausea abdominal,1,0.879558801651001
VIMIZIM,pyrexia,pyrexia,1,1.0000001192092896
VIMIZIM,vomiting,nausea abdominal pain chills and fatigue To report,0,0.7021360993385315
VIMIZIM,vomiting,occurring at a higher incidence than placebotreated,0,0.5682780146598816
VIMIZIM,headache,placebotreated patients were,0,0.5060896873474121
VIMIZIM,headache,and fatigue To report SUSPECTED,0,0.5796384811401367
VIMIZIM,headache,patients were pyrexia headache nausea abdominal pain chills and,1,0.6800848245620728
VIMIZIM,headache,abdominal pain chills and fatigue,0,0.613710880279541
VIMIZIM,headache,incidence than placebotreated,0,0.5199825167655945
VIMIZIM,headache,were pyrexia headache nausea,1,0.7245738506317139
VIMIZIM,headache,headache nausea abdominal pain chills,1,0.7749998569488525
VIMIZIM,nausea,a higher incidence than placebotreated patients were pyrexia,0,0.6490908861160278
VIMIZIM,nausea,nausea,1,1.0
VIMIZIM,chills,vomiting headache nausea abdominal pain,0,0.555880069732666
VIMIZIM,chills,chills and,1,0.9623491764068604
VIMIZIM,chills,headache nausea abdominal chills and fatigue To report,1,0.6953310966491699
VIMIZIM,chills,chills,1,0.9999998807907104
VIMIZIM,chills,chills and fatigue,1,0.8379969000816345
VIMIZIM,fatigue,han,0,0.4909265339374542
VIMIZIM,Fatigue,pain,0,0.672707736492157
VIMIZIM,Fatigue,Fatigue,1,1.0
VIMIZIM,Fatigue,Fatigue Extension Trial An,1,0.8034936189651489
VIMIZIM,Fatigue,An,0,0.5596491694450378
VIMIZIM,Fatigue,Fatigue Extension Trial An openlabel,1,0.7759903073310852
VIMIZIM,Fatigue,Extension,0,0.5211449861526489
VIMIZIM,Fatigue,An openlabel,0,0.46845555305480957
VIMIZIM,Fatigue,Trial An openlabel extensio,0,0.47168105840682983
VIMIZIM,ANAPHYLAXIS,are conducted under widely varying conditions adverse reaction rates,0,0.6490468382835388
VIMIZIM,ANAPHYLAXIS,ADVERSE REACTIONS Because nical trial,1,0.6660975217819214
VIMIZIM,ANAPHYLAXIS,nical trial s are conducted under widely,1,0.520302951335907
VIMIZIM,ANAPHYLAXIS,trials are conducted under idely varyi,1,0.5014103651046753
VIMIZIM,ANAPHYLAXIS,under idely varyi ng conditions adverse,1,0.5686298608779907
VIMIZIM,ANAPHYLAXIS,trials are conducted under,0,0.4733259081840515
VIMIZIM,ANAPHYLAXIS,conducted under idely varyi ng conditions adverse reaction rates,1,0.6930022239685059
VIMIZIM,anaphylactic reactions,varying conditions adverse action rates observed ,1,0.5268495082855225
VIMIZIM,anaphylactic reactions,trials are conducted under,0,0.4988492429256439
VIMIZIM,anaphylactic reactions,conditions adverse action rates,1,0.5299268960952759
VIMIZIM,anaphylactic reactions,conditions adverse action rates observed  in the clinical,1,0.5468735694885254
VIMIZIM,anaphylactic reactions,of a drug cannot be directly compared,0,0.49470996856689453
VIMIZIM,anaphylactic reactions,in the,0,0.4920470416545868
VIMIZIM,anaphylactic reactions,clinical trials,0,0.546962559223175
VIMIZIM,anaphylactic reactions,varying conditions adverse action rates observed  in the,1,0.5284855365753174
VIMIZIM,anaphylactic reactions,adverse action,1,0.5342806577682495
VIMIZIM,anaphylactic reactions,a drug cannot be directly compared to rates in the clinical trials,0,0.47321146726608276
VIMIZIM,anaphylactic reactions,adverse action rates observed  in the,1,0.5108201503753662
VIMIZIM,Anaphylaxis,a drug cannot,0,0.5001935362815857
VIMIZIM,Anaphylaxis,cannot be directly ed to rates,1,0.4582180380821228
VIMIZIM,Anaphylaxis,cannot be directly ed,1,0.5234107375144958
VIMIZIM,Anaphylaxis,drug cannot be directly ed to rates,1,0.4846581220626831
VIMIZIM,Anaphylaxis,to rates,1,0.5214191675186157
VIMIZIM,Anaphylaxis,drug cannot be directly ed to rates in,1,0.5098263025283813
VIMIZIM,Anaphylaxis,another drug and may not reflect the rates observed in practice The,0,0.4794481694698334
VIMIZIM,Anaphylaxis,the rates observed in,0,0.46855980157852173
VIMIZIM,cough,cannot,0,0.5658426284790039
VIMIZIM,erythema,observed in practice The following serious adverse,0,0.564001202583313
VIMIZIM,erythema,be,0,0.5499938130378723
VIMIZIM,erythema,of,1,0.513292670249939
VIMIZIM,erythema,compared to rates,0,0.47548800706863403
VIMIZIM,erythema,of anot her drug and may,1,0.5059055685997009
VIMIZIM,erythema,clinical  of anot her,1,0.5620740056037903
VIMIZIM,erythema,in the clinical  of anot her drug and may,1,0.560684323310852
VIMIZIM,erythema,in the clinical  of anot her drug and may not,1,0.5001651048660278
VIMIZIM,erythema,of anot,1,0.5012654662132263
VIMIZIM,erythema,cannot be directly compared to,0,0.4721062183380127
VIMIZIM,throat tightness,clinical trials of r drug and may,1,0.5135915875434875
VIMIZIM,throat tightness,r,1,0.5110238790512085
VIMIZIM,urticaria,a drug cannot be directly compared to rates in,0,0.5056635141372681
VIMIZIM,urticaria, reflect  the rates observed,1,0.4789138436317444
VIMIZIM,urticaria, reflect  the,1,0.493598997592926
VIMIZIM,urticaria,drug and may  reflect  the,1,0.47689077258110046
VIMIZIM,urticaria,to rates,0,0.5090755224227905
VIMIZIM,urticaria,following serious adverse reactions are described below,0,0.6050878167152405
VIMIZIM,flushing,reflect e,1,0.6073768138885498
VIMIZIM,flushing,and may not reflect e rates  observed,1,0.4885953664779663
VIMIZIM,flushing,observed in practice The following serious adverse reactions are described below and,0,0.5410670042037964
VIMIZIM,flushing,serious adverse,0,0.539818286895752
VIMIZIM,flushing,e rates,1,0.49811458587646484
VIMIZIM,flushing,The following serious adverse reactions,0,0.5448449850082397
VIMIZIM,flushing,rates in the clinical trials of another drug and,0,0.5134515762329102
VIMIZIM,cyanosis,in the lab,0,0.5077897906303406
VIMIZIM,hypotension,following serious adverse reactions,0,0.562558650970459
VIMIZIM,rash,and elsewhere in the labeling,0,0.5116257071495056
VIMIZIM,rash,the rates observed in  The following serious adverse,1,0.5474668145179749
VIMIZIM,rash,adverse reactions are described below,0,0.6321265697479248
VIMIZIM,rash,elsewhere in,0,0.5053973197937012
VIMIZIM,rash, The following serious adverse,1,0.5909333825111389
VIMIZIM,rash,clinical trials of another drug and may not reflect,0,0.5121484994888306
VIMIZIM,rash,clinical trials of another drug,0,0.5348993539810181
VIMIZIM,rash, The following serious adverse reactions are,1,0.5996134281158447
VIMIZIM,rash,serious adverse reactions are described,0,0.6303238868713379
VIMIZIM,dyspnea,observed in practice The ollowin g serious adverse reactions are,1,0.5633867979049683
VIMIZIM,dyspnea,serious adverse reactions are described,0,0.5612770318984985
VIMIZIM,dyspnea,observed in practice,0,0.5142743587493896
VIMIZIM,dyspnea,the labeling,0,0.5070472359657288
VIMIZIM,dyspnea,another drug and may not reflect the rates observed in practice,0,0.517656683921814
VIMIZIM,dyspnea,elsewhere,0,0.529119610786438
VIMIZIM,dyspnea,ollowin g serious adverse reactions,1,0.5885192155838013
VIMIZIM,dyspnea,ollowin,1,0.5369412302970886
VIMIZIM,chest discomfort,following,0,0.4544455409049988
VIMIZIM,chest discomfort,and may not reflect the rates,0,0.429851233959198
VIMIZIM,gastrointestinal symptoms,are described below a nd elsewhere in the,1,0.5241883397102356
VIMIZIM,gastrointestinal symptoms,following serious adverse ons are,1,0.5781060457229614
VIMIZIM,gastrointestinal symptoms,adverse ons are,1,0.5864689350128174
VIMIZIM,gastrointestinal symptoms,ons are,1,0.5246668457984924
VIMIZIM,gastrointestinal symptoms,below a nd,1,0.4776853919029236
VIMIZIM,gastrointestinal symptoms,described below a nd,1,0.5202991366386414
VIMIZIM,gastrointestinal symptoms,the rates observed in practice The following serious,0,0.5395725965499878
VIMIZIM,gastrointestinal symptoms,adverse ons are described below a nd elsewhere,1,0.6067999005317688
VIMIZIM,gastrointestinal symptoms,observed in practice The following,0,0.5116134285926819
VIMIZIM,nausea,below and here,1,0.49155738949775696
VIMIZIM,nausea,Anaphylaxis and hypersensitivity reactions,0,0.5543407201766968
VIMIZIM,nausea,described,0,0.5242804288864136
VIMIZIM,nausea,Anaphylaxis and hypersensitivity reactions see Warnings,0,0.5756937265396118
VIMIZIM,nausea,here i,1,0.5316873788833618
VIMIZIM,nausea,here i n,1,0.5373085737228394
VIMIZIM,abdominal pain,"elsewhere the labeling:
 Anaphylaxis and hypersensitivity",1,0.5040122270584106
VIMIZIM,abdominal pain,here i,1,0.4846472144126892
VIMIZIM,abdominal pain,below and elsewhere the labeling:,1,0.4678509831428528
VIMIZIM,abdominal pain,erved in practice The following serious adverse reactions are described,0,0.5223835706710815
VIMIZIM,abdominal pain,the labeling: Anaphylaxis and hypersensitivity,1,0.5004727244377136
VIMIZIM,abdominal pain,"below and elsewhere the labeling:
 Anaphylaxis and hypersensitivity reactions see",1,0.5021464824676514
VIMIZIM,abdominal pain,the labeling:,1,0.4672567844390869
VIMIZIM,abdominal pain,below,0,0.5023555159568787
VIMIZIM,retching,. Anap hylaxis and hypersensitivity reactions,1,0.5443649291992188
VIMIZIM,retching,"elsewhere in the 
 . Anap hylaxis and hypersensitivity",1,0.5713232755661011
VIMIZIM,retching,. Anap hylaxis and,1,0.509132981300354
VIMIZIM,retching,and Precautions The most,0,0.49872592091560364
VIMIZIM,retching,elsewhere in the .,1,0.46579885482788086
VIMIZIM,retching,and hypersensitivity reactions see,0,0.5282702445983887
VIMIZIM,vomiting,labeling s and hy,1,0.5013329982757568
VIMIZIM,vomiting,and hypersensitivity reactions see,0,0.5583151578903198
VIMIZIM,vomiting,s and hy persensitivity reactions see,1,0.5294404029846191
VIMIZIM,vomiting,persensitivity reactions see Warnings and Precautions The most,0,0.552847683429718
VIMIZIM,urticaria,ns [ see Warnings and,1,0.5140469074249268
VIMIZIM,urticaria,ns are described below and elsewhere in the,0,0.49184727668762207
VIMIZIM,urticaria,and Precautions The most common adverse reactions observed ac,0,0.5782660245895386
VIMIZIM,urticaria,and,0,0.4860531687736511
VIMIZIM,urticaria,ns [ see Warnings and Precautions The,1,0.51869136095047
VIMIZIM,urticaria,described below and elsewhere in the labeling,0,0.48663944005966187
VIMIZIM,ANAPHYLAXIS,d fatigue ( To report SUSPECTED ADVERSE,1,0.5271043181419373
VIMIZIM,ANAPHYLAXIS,described below and elsewhere in the labeling,0,0.4853711724281311
VIMIZIM,ANAPHYLAXIS,pain chills d fatigue ( To,1,0.546305775642395
VIMIZIM,ANAPHYLAXIS,contact BioMarin at or FDA at,0,0.5287325382232666
VIMIZIM,ANAPHYLAXIS,ADVERSE,0,0.5765934586524963
VIMIZIM,ANAPHYLAXIS,vomiting headache,0,0.6014935970306396
VIMIZIM,ANAPHYLAXIS,nausea abdominal pain chills d fatigue ( To report,1,0.5560217499732971
VIMIZIM,anaphylactic reactions,or www fdagovmedwatch,1,0.4800514578819275
VIMIZIM,anaphylactic reactions,BioMarin at or FDA  1-800-FDA-1088 or www fdagovmedwatch,1,0.5125731229782104
VIMIZIM,Anaphylaxis,trial of Vimizim was,0,0.4941323399543762
VIMIZIM,Anaphylaxis,"Clinical Trials e

  A 24-w eek randomized doubleblind placebocontrolled",1,0.5404154062271118
VIMIZIM,Anaphylaxis,"wwwfdagovmedwatch Clinical Trials e

  A 24-w eek randomized",1,0.506461501121521
VIMIZIM,Anaphylaxis,"Clinical Trials e

  A 24-w eek randomized doubleblind placebocontrolled clinical",1,0.5381038188934326
VIMIZIM,Anaphylaxis,e,1,0.5451995134353638
VIMIZIM,Anaphylaxis,"wwwfdagovmedwatch Clinical Trials e

  A 24-w eek randomized doubleblind placebocontrolled",1,0.544603168964386
VIMIZIM,Anaphylaxis,wwwfdagovmedwatch Clinical,0,0.4991444945335388
VIMIZIM,Anaphylaxis,A 24-w eek randomized,1,0.5209328532218933
VIMIZIM,Anaphylaxis,e A 24-w eek,1,0.5252543687820435
VIMIZIM,cough,MPS IVA,0,0.5158791542053223
VIMIZIM,cough, doub leblind placebocontrolled clinical,1,0.5336393713951111
VIMIZIM,cough,with MPS IVA,0,0.5417053699493408
VIMIZIM,cough, doub,1,0.5042056441307068
VIMIZIM,cough,Vimizim was,0,0.512678861618042
VIMIZIM,cough, doub leblind placebocontrolled,1,0.5370018482208252
VIMIZIM,cough,Trials Experience A week  doub leblind placebocontrolled clinical trial of,1,0.5373245477676392
VIMIZIM,cough,MPS IVA a,0,0.5052032470703125
VIMIZIM,erythema,"-blind, ",1,0.49867311120033264
VIMIZIM,erythema,of Vimizim was conducted in patients with MPS IVA ages,0,0.49459022283554077
VIMIZIM,erythema,"-blind,  placebocontrolled clinical trial of Vimizim",1,0.5033034086227417
VIMIZIM,erythema,randomized,0,0.5001010298728943
VIMIZIM,erythema,"-blind,  placebocontrolled",1,0.5341205596923828
VIMIZIM,erythema,"A week randomized -blind,  placebocontrolled clinical trial of",1,0.5277291536331177
VIMIZIM,erythema,Trials Experience A week,0,0.5177558660507202
VIMIZIM,throat tightness,A week randomized doubleblind acebo-controlled clinical trial of,1,0.5048109889030457
VIMIZIM,throat tightness,Trials Experience A week,0,0.4865323305130005
VIMIZIM,throat tightness,A week randomized doubleblind,0,0.4352686405181885
VIMIZIM,throat tightness,A week randomized doubleblind pl,0,0.41807302832603455
VIMIZIM,throat tightness,week randomized doubleblind acebo-controlled clinical trial of Vimizim,1,0.49585944414138794
VIMIZIM,throat tightness,acebo-controlled,1,0.49086230993270874
VIMIZIM,throat tightness,Experience A,0,0.5290278196334839
VIMIZIM,throat tightness,Experience A week randomized doubleblind pl,0,0.4373898506164551
VIMIZIM,urticaria,years old Approximately h,0,0.5249227285385132
VIMIZIM,urticaria,c,0,0.534778356552124
VIMIZIM,urticaria,randomized doubleblind placebocontrolled linical t rial of Vimizim was,1,0.5299256443977356
VIMIZIM,flushing,al of Vi mizim was conducted in patients,1,0.5443025231361389
VIMIZIM,flushing,c,0,0.5488337278366089
VIMIZIM,flushing,MPS,0,0.5199463367462158
VIMIZIM,flushing,randomized doubleblind placebocontrolled clinical al,1,0.540603518486023
VIMIZIM,flushing,doubleblind,0,0.5152508616447449
VIMIZIM,flushing,tri,0,0.524383544921875
VIMIZIM,flushing,randomized doubleblind placebocontrolled clinical al of Vi mizim,1,0.5390546917915344
VIMIZIM,hypotension,nducted in  patients with MPS IVA,1,0.556209146976471
VIMIZIM,hypotension,tri,0,0.4961792826652527
VIMIZIM,hypotension,half of the patients,0,0.5075199604034424
VIMIZIM,hypotension,of Vimizim,0,0.46916675567626953
VIMIZIM,hypotension,trial of Vimizim was nducted in  patients with MPS,1,0.5602633953094482
VIMIZIM,hypotension,nducted in,1,0.5254567861557007
VIMIZIM,rash,Vimizim was conducted 6 pa tients with MPS IVA,1,0.5328668355941772
VIMIZIM,rash,nducted in,1,0.48414260149002075
VIMIZIM,dyspnea,was conducted in ents,1,0.569352388381958
VIMIZIM,dyspnea,ents wi th MPS IVA ages,1,0.5388234853744507
VIMIZIM,dyspnea,Vimizim was conducted in ents wi th MPS IVA,1,0.5407781004905701
VIMIZIM,dyspnea,ents wi th MPS,1,0.531997561454773
VIMIZIM,chest discomfort,"IVA, ages 5 to years old",1,0.4324929118156433
VIMIZIM,chest discomfort,male Of the patients wer,0,0.5572559833526611
VIMIZIM,chest discomfort,doubleblind,0,0.44215598702430725
VIMIZIM,chest discomfort,"in patients MPS IVA, ages",1,0.5017563104629517
VIMIZIM,gastrointestinal symptoms,MPS IVA ages years,1,0.4659603238105774
VIMIZIM,gastrointestinal symptoms,ages to,0,0.47628605365753174
VIMIZIM,gastrointestinal symptoms,years old. Approximatel y half of,1,0.47952595353126526
VIMIZIM,gastrointestinal symptoms,Asian,0,0.5022363662719727
VIMIZIM,gastrointestinal symptoms,patients were White Asian Black,0,0.508940577507019
VIMIZIM,gastrointestinal symptoms,years old. Approximatel,1,0.4845954179763794
VIMIZIM,gastrointestinal symptoms,of the patients were,0,0.5273918509483337
VIMIZIM,urticaria,of the s (49%) w,1,0.48048704862594604
VIMIZIM,urticaria,male Of the patients were White Asian Black and Other,0,0.46977171301841736
VIMIZIM,urticaria,were White Asian Black and,0,0.4570302963256836
VIMIZIM,urticaria,Black and Other race The majori,0,0.48065370321273804
VIMIZIM,urticaria,the s (49%) w ere male Of the,1,0.46668288111686707
VIMIZIM,urticaria,of the s,1,0.5030872821807861
VIMIZIM,urticaria,half of the s (49%) w ere male,1,0.440064400434494
VIMIZIM,urticaria,with MPS IVA ages to years old Approximately,0,0.5069000124931335
VIMIZIM,urticaria,(49%) w ere,1,0.4685627222061157
VIMIZIM,urticaria,(49%) w ere male,1,0.4626311659812927
VIMIZIM,Hypersensitivity Reactions,the clinical trials,0,0.5403373837471008
VIMIZIM,Hypersensitivity Reactions,clinical trials are under widely varying,1,0.4749045670032501
VIMIZIM,Hypersensitivity Reactions,observed in the clinical trials of a drug cannot be directly compared,0,0.5156352519989014
VIMIZIM,Hypersensitivity Reactions,clinical trials are conducted,0,0.5230253338813782
VIMIZIM,Hypersensitivity Reactions,under widely varying condi tions,1,0.4819658398628235
VIMIZIM,anaphylaxis,the,0,0.5629771947860718
VIMIZIM,anaphylaxis,conditions adverse tion rates  observed in the,1,0.5171647071838379
VIMIZIM,anaphylaxis,tion rates observed in the clinical trials,1,0.4912358224391937
VIMIZIM,anaphylaxis,tion rates observed,1,0.46842116117477417
VIMIZIM,anaphylaxis,compared to rates in the,0,0.4730494022369385
VIMIZIM,anaphylaxis,are,0,0.4791463017463684
VIMIZIM,anaphylaxis,a,0,0.5750720500946045
VIMIZIM,anaphylaxis,widely varying conditions adverse tion rates,1,0.5099772214889526
VIMIZIM,anaphylaxis,conditions adverse tion,1,0.5551373958587646
VIMIZIM,Acute Respiratory Complications,observed across premarketing clinical trials were,0,0.5125533938407898
VIMIZIM,Acute Respiratory Complications,common adverse reactio ns,1,0.6261609792709351
VIMIZIM,Acute Respiratory Complications,clinical trials were similar in type and frequency as,0,0.46550989151000977
VIMIZIM,Acute Respiratory Complications,and Precautions,0,0.556627631187439
VIMIZIM,Acute Respiratory Complications,and The most common adverse reactio ns observed across premarketing clinical,1,0.5976324677467346
VIMIZIM,Acute Respiratory Complications,see Warnings and The most common adverse reactio ns observed across,1,0.5821353197097778
VIMIZIM,Acute Respiratory Complications,reactions see Warnings and The most,1,0.5329879522323608
VIMIZIM,Acute Respiratory Complications,reactions see Warnings and The,1,0.5402577519416809
VIMIZIM,hypersensitivity reactions,he placebo-controlled tria l,1,0.49529072642326355
VIMIZIM,hypersensitivity reactions,t,0,0.505772054195404
VIMIZIM,hypersensitivity reactions,he placebo-controlled,1,0.49269044399261475
VIMIZIM,hypersensitivity reactions,he,1,0.4911104142665863
VIMIZIM,hypersensitivity reactions,as those observed in he placebo-controlled tria l see Table The,1,0.5320258140563965
VIMIZIM,Anaphylaxis,corticosteroids :   The mos t common adverse,1,0.5397934317588806
VIMIZIM,Anaphylaxis,he,1,0.5180472135543823
VIMIZIM,Anaphylaxis,antipyretics or corticosteroids :   The mos t,1,0.5531830787658691
VIMIZIM,Anaphylaxis,The mos t,1,0.4061841368675232
VIMIZIM,Anaphylaxis,additional antihistamine antipyretics or,0,0.6722069382667542
VIMIZIM,Anaphylaxis,: The mos t common adverse,1,0.5077177882194519
VIMIZIM,Anaphylaxis,reactions in Vimizim patients and occurring at,0,0.6502330899238586
VIMIZIM,hypersensitivity,occurring at a higher incidence than,0,0.6378023624420166
VIMIZIM,hypersensitivity,corticosteroids,0,0.6107702255249023
VIMIZIM,hypersensitivity,The most mon adverse reac,1,0.5815500020980835
VIMIZIM,hypersensitivity,in Vimizim patients and occurring at a higher incidence than placebotreated patients,0,0.5734249353408813
VIMIZIM,hypersensitivity,mon adverse reac,1,0.6162068843841553
VIMIZIM,hypersensitivity,occurring at,0,0.589421272277832
VIMIZIM,hypersensitivity,com,0,0.5361325740814209
VIMIZIM,anaphylaxis,chills and To repo,1,0.5453609228134155
VIMIZIM,anaphylaxis,To repo,1,0.4628901481628418
VIMIZIM,anaphylaxis,"abdominal pain chills and 
   To repo rt",1,0.5686257481575012
VIMIZIM,anaphylactic reactions,REACTIONS tact BioMarin at 1-866,1,0.6363790035247803
VIMIZIM,anaphylactic reactions,To repo,1,0.4182690382003784
VIMIZIM,anaphylactic reactions,REACTIONS tact BioMarin at,1,0.6904075145721436
VIMIZIM,anaphylactic reactions,tact BioMarin at 1-866 or FDA at,1,0.5445026755332947
VIMIZIM,anaphylactic reactions,FDA or wwwfdagovmedwatch Clinical,0,0.47062984108924866
VIMIZIM,anaphylactic reactions,SUSPECTED ADVERSE REACTIONS tact BioMarin at 1-866 or FDA at FDA or,1,0.6298567056655884
VIMIZIM,anaphylactic reactions,SUSPECTED ADVERSE REACTIONS tact BioMarin at 1-866,1,0.668197751045227
VIMIZIM,anaphylactic reactions,tact BioMarin at 1-866,1,0.5596835613250732
VIMIZIM,erythema,VERSE REACTIONS contact BioMarin at or,0,0.5651944279670715
VIMIZIM,erythema,"or .  



  Clinical Trials Experience",1,0.5290167331695557
VIMIZIM,erythema,".  



  Clinical",1,0.5339599847793579
VIMIZIM,erythema,randomized doubleblind placebocontrolled,0,0.5359029769897461
VIMIZIM,erythema,"FDA or .  



  Clinical",1,0.5034325122833252
VIMIZIM,throat tightness,or wwwfdagovmedwatch,0,0.4951639175415039
VIMIZIM,throat tightness,Clinical T rials Experience A,1,0.5547581911087036
VIMIZIM,throat tightness,or   6.1 Clinical T rials Experience A week randomized,1,0.5160548090934753
VIMIZIM,urticaria,Vimizim was,0,0.47860270738601685
VIMIZIM,urticaria,FDA at FDA or wwwfdagovmedwatch Clinical Tri,0,0.47784358263015747
VIMIZIM,urticaria,als,1,0.5291042923927307
VIMIZIM,urticaria,week randomized doubleblind placebocontrolled clinical trial of,0,0.5257593989372253
VIMIZIM,urticaria,wwwfdagovmedwatch Clinical als Exper ience,1,0.4771217703819275
VIMIZIM,urticaria,or FDA at FDA or,0,0.46873539686203003
VIMIZIM,flushing,"or wwwfdagovmedwatch Clinical Trials nce

  A week randomized",1,0.5041040182113647
VIMIZIM,flushing,or FDA at FDA or,0,0.5223081111907959
VIMIZIM,flushing,Experie,0,0.5362156629562378
VIMIZIM,flushing,nce A week,1,0.5003303289413452
VIMIZIM,flushing,was conducted,0,0.5909397602081299
VIMIZIM,hypotension,week ra,0,0.4860832691192627
VIMIZIM,hypotension,FDA or wwwfdagovmedwatch Clinical Trials Experience A week,0,0.5099233984947205
VIMIZIM,hypotension,"A week ndomized, d oubleblind placebocontrolled clinical trial",1,0.5540201663970947
VIMIZIM,hypotension,"ndomized, d",1,0.5038105249404907
VIMIZIM,hypotension,conducted,0,0.534555196762085
VIMIZIM,hypotension,"Experience A week ndomized, d oubleblind placebocontrolled clinical trial of",1,0.551891565322876
VIMIZIM,hypotension,"A week ndomized, d",1,0.5112330913543701
VIMIZIM,hypotension,"ndomized, d oubleblind placebocontrolled clinical trial of",1,0.5423139333724976
VIMIZIM,hypotension,"ndomized, d oubleblind placebocontrolled",1,0.5560011863708496
VIMIZIM,rash,ble- blind placebocontrolled clinical trial,1,0.5298393964767456
VIMIZIM,dyspnea,was conducted in patients with MPS IVA,0,0.5520069003105164
VIMIZIM,chest discomfort,A week randomized,0,0.4350975453853607
VIMIZIM,gastrointestinal symptoms,of Vimizim was co nducted,1,0.4853803813457489
VIMIZIM,gastrointestinal symptoms,Approximately half of the patients,0,0.49505364894866943
VIMIZIM,gastrointestinal symptoms,l trial of Vimizim was co nducted in patients with MPS,1,0.47658464312553406
VIMIZIM,abdominal pain,conducted in atients with M PS,1,0.44836172461509705
VIMIZIM,abdominal pain,l trial of Vimizim was co nducted in patients with MPS,1,0.46856701374053955
VIMIZIM,retching,"conducted in patients with  IVA, ag es to years",1,0.4939241111278534
VIMIZIM,retching,l trial of Vimizim was co nducted in patients with MPS,1,0.4705640375614166
VIMIZIM,retching,"IVA, ag es to",1,0.513267993927002
VIMIZIM,retching,years old Approximately half of the,0,0.48797836899757385
VIMIZIM,retching,conducted,0,0.5019687414169312
VIMIZIM,retching,"with IVA,",1,0.48626184463500977
VIMIZIM,retching,of Vimizim was conducted in patients with MPS,0,0.4802924692630768
VIMIZIM,retching,Approximately half of the patients were male Of the patients,0,0.49549227952957153
VIMIZIM,retching,"conducted in patients with IVA, ag",1,0.49519577622413635
VIMIZIM,vomiting,was conducted in,0,0.4982401728630066
VIMIZIM,urticaria,ages to years old half,1,0.4662508964538574
VIMIZIM,urticaria,conducted,0,0.484690397977829
VIMIZIM,urticaria,ages to years old half of,1,0.47019049525260925
VIMIZIM,urticaria,patients were male Of the,0,0.46022507548332214
VIMIZIM,urticaria,MPS,0,0.4769382178783417
VIMIZIM,urticaria,years old half,1,0.4989423155784607
VIMIZIM,anaphylaxis,majority,0,0.48911958932876587
VIMIZIM,anaphylaxis,to years old Approximately,0,0.47846412658691406
VIMIZIM,anaphylaxis,Black,0,0.5173310041427612
VIMIZIM,anaphylaxis,with MPS IVA ages,0,0.505312442779541
VIMIZIM,anaphylaxis,Black and Other race The majority of pa,0,0.4658864140510559
VIMIZIM,anaphylaxis,),1,0.49823760986328125
VIMIZIM,hypersensitivity,n All patients were treated with antihistamines prior,0,0.6710604429244995
VIMIZIM,hypersensitivity,groups,0,0.5103983879089355
VIMIZIM,hypersensitivity,Vimizim mgkg every other week,1,0.5450375080108643
VIMIZIM,hypersensitivity,n Vimizim mgkg every other week n or placebo n,1,0.5378133654594421
VIMIZIM,hypersensitivity,n Vimizim mgkg every other week n,1,0.536436140537262
VIMIZIM,anaphylaxis,=59). All patients were treated with antihistamines,1,0.6416087746620178
VIMIZIM,anaphylaxis,or,0,0.5218456983566284
VIMIZIM,anaphylaxis,placebo,0,0.611868143081665
VIMIZIM,anaphylaxis,placebo =59).  All  patients were,1,0.5130041837692261
VIMIZIM,anaphylaxis,=59). All patients were,1,0.47186341881752014
VIMIZIM,anaphylaxis,week n or placebo =59).,1,0.5087404251098633
VIMIZIM,anaphylaxis,placebo =59).,1,0.5477323532104492
VIMIZIM,anaphylaxis,=59). All,1,0.5021775960922241
VIMIZIM,anaphylaxis,Table,0,0.5167748928070068
VIMIZIM,Hypersensitivity,or placebo n All tients were trea ted with antihistamines prior to,1,0.6515645384788513
VIMIZIM,Hypersensitivity,Table,0,0.5423492789268494
VIMIZIM,Hypersensitivity,tients were trea ted,1,0.532905101776123
VIMIZIM,Hypersensitivity,were trea ted with antihistamines prior,1,0.6842697262763977
VIMIZIM,Hypersensitivity,week n or placebo,0,0.5143928527832031
VIMIZIM,Hypersensitivity,antihistamines prior to each infusion Table summarizes,0,0.6342452764511108
VIMIZIM,Hypersensitivity,week n Vimizim mgkg once every other week n or placebo n,0,0.5344640612602234
VIMIZIM,Hypersensitivity,once,0,0.5314786434173584
VIMIZIM,hypersensitivity,the ntrolled trial,1,0.5150339603424072
VIMIZIM,hypersensitivity,that occurred in,0,0.5465988516807556
VIMIZIM,anaphylactic reactions,2 mg/kg once per w,1,0.4965011477470398
VIMIZIM,anaphylactic reactions,with an incidence of in,0,0.5657791495323181
VIMIZIM,anaphylactic reactions,a higher,0,0.4716358184814453
VIMIZIM,anaphylactic reactions,treated with zim 2 mg/kg once per w,1,0.5100865364074707
VIMIZIM,anaphylactic reactions,once per w eek and with a,1,0.46335089206695557
VIMIZIM,anaphylactic reactions,zim 2 mg/kg once per w,1,0.4802181124687195
VIMIZIM,anaphylactic reactions,in patients treated with,0,0.5799014568328857
VIMIZIM,anaphylactic reactions,in patients treated with zim,1,0.551101565361023
VIMIZIM,urticaria,and wit h a higher incidence,1,0.5588104128837585
VIMIZIM,peripheral edema,a higher inciden ce than in the placebotreated,1,0.52916020154953
VIMIZIM,peripheral edema,a higher,1,0.4872526526451111
VIMIZIM,peripheral edema,Table Adverse Reactions That Occurred,0,0.5791901350021362
VIMIZIM,peripheral edema,incidence of in patients treated with Vimizim mgkg once per week and with,0,0.517520546913147
VIMIZIM,peripheral edema,once per week and a higher,1,0.5205645561218262
VIMIZIM,peripheral edema,in the Plac,0,0.5672897100448608
VIMIZIM,cough, than in,1,0.5348759889602661
VIMIZIM,cough, than,1,0.5854002237319946
VIMIZIM,cough, than in the,1,0.5464513897895813
VIMIZIM,cough,placebotreated patients Table Adverse Reactions That Occurred in the PlaceboCon,0,0.5495831370353699
VIMIZIM,dyspnea,Occurred,0,0.5660114288330078
VIMIZIM,dyspnea,a higher incidence than n,1,0.5740427374839783
VIMIZIM,dyspnea,incidence than n,1,0.5567684173583984
VIMIZIM,dyspnea,Occurred in the,0,0.566533625125885
VIMIZIM,dyspnea,the p lacebotreated patients Table Adverse,1,0.5853468775749207
VIMIZIM,dyspnea,Table Adverse Reactions That Occurred in the PlaceboControlled T,0,0.49671345949172974
VIMIZIM,dyspnea,Adverse,0,0.5797537565231323
VIMIZIM,dyspnea,patients,0,0.5550453662872314
VIMIZIM,dyspnea,higher incidence than n the,1,0.5593961477279663
VIMIZIM,dyspnea,patients Table Adverse Reactions That Occurred in,0,0.5277737379074097
VIMIZIM,hypersensitivity reactions,antibody titers were sustained or,0,0.6269433498382568
VIMIZIM,hypersensitivity reactions,or,0,0.48290157318115234
VIMIZIM,hypersensitivity reactions,developed ant idrug antibodies associations between,1,0.6025500893592834
VIMIZIM,hypersensitivity reactions,antibodies associations between antibody titers and reductions in treatment effect,0,0.604759693145752
VIMIZIM,hypersensitivity reactions,reductions in treatment effect or the oc,0,0.5106467008590698
BEPREVE,taste following instillation,irritation headache,0,0.5738613605499268
BEPREVE,taste following instillation,taste following instillation Other,1,0.9835399389266968
BEPREVE,taste following instillation,of patients was a taste following instillation Other adverse reactions which,1,0.8606767058372498
BEPREVE,taste following instillation,taste following instillation Other adverse reactions,1,0.8994219899177551
BEPREVE,taste following instillation,a taste following instillation,1,0.9847338199615479
BEPREVE,eye irritation,SUSPECTED ADVERSE REACTIONS contact,0,0.6660212278366089
BEPREVE,eye irritation,eye irritation headache and nasopharyngitis To report,1,0.8008708357810974
BEPREVE,eye irritation,eye irritation,1,1.0
BEPREVE,eye irritation,eye irritation headache and,1,0.9085956811904907
BEPREVE,eye irritation,in of subjects eye irritation,1,0.9465445280075073
BEPREVE,eye irritation,reactions which occurred in of subjects,0,0.5693788528442383
BEPREVE,eye irritation,REACTIONS contact,0,0.5990898609161377
BEPREVE,headache,headache and nasopharyngitis To,1,0.8010303378105164
BEPREVE,headache,REACTIONS contact,0,0.4985228180885315
BEPREVE,headache,headache and nasopharyngitis,1,0.7891227006912231
BEPREVE,headache,headache and nasopharyngitis To report,1,0.7755486965179443
BEPREVE,headache,and nasopharyngitis To report,0,0.5705560445785522
BEPREVE,headache,of subjects were eye headache and nasopharyngitis To report,1,0.7523288130760193
BEPREVE,headache,nasopharyngitis To report SUSPECTED ADVERSE REACTIONS contact Bausch Lomb In,0,0.5500353574752808
BEPREVE,headache,adverse reactions which occurred,0,0.5653785467147827
BEPREVE,nasopharyngitis,which occurred in of subjects were eye irritation,0,0.5466827750205994
BEPREVE,nasopharyngitis,irritation headache,0,0.5717568397521973
BEPREVE,nasopharyngitis,Bausch Lomb,0,0.42685994505882263
BEPREVE,nasopharyngitis,contact Bausch Lomb Incorporated,0,0.4336106777191162
BEPREVE,taste following instillation,taste,1,0.8014873266220093
BEPREVE,taste following instillation,following instillation Other adverse,1,0.7971993684768677
BEPREVE,taste following instillation,was a mild,0,0.5705865621566772
BEPREVE,eye irritation,occurring in of subjects,0,0.528641402721405
BEPREVE,headache,Hypersensitivity reactions,0,0.5215178728103638
BEPREVE,headache,and nasopharyngitis Post,0,0.5973979830741882
BEPREVE,headache,subjects were eye headache and nasopharyngitis,1,0.7591097354888916
BEPREVE,nasopharyngitis,reported rarely during,0,0.494615763425827
BEPREVE,nasopharyngitis,in of subjects were,0,0.5059815049171448
BEPREVE,nasopharyngitis,adverse,0,0.5424414277076721
BEPREVE,Hypersensitivity reactions,Because these,0,0.5334497690200806
BEPREVE,Hypersensitivity reactions,Post Marketing Hypersensitivity reactions have been,1,0.8151854872703552
BEPREVE,Hypersensitivity reactions,Marketing Hypersensitivity reactions,1,0.8526485562324524
BEPREVE,Hypersensitivity reactions,and nasopharyngitis Post Marketing Hypersensitivity reactions,1,0.7829844355583191
BEPREVE,hypersensitivity reactions,body rash and swelling of,0,0.6534085869789124
BEPREVE,hypersensitivity reactions,hypersensitivity reactions include itching body,1,0.8531875014305115
BEPREVE,hypersensitivity reactions,estimate their frequency or establish a casual relationship to drug,0,0.5032039284706116
BEPREVE,hypersensitivity reactions,hypersensitivity reactions,1,1.0
BEPREVE,hypersensitivity reactions,drug exposure hypersensitivity,1,0.8102323412895203
BEPREVE,hypersensitivity reactions,hypersensitivity reactions include itching body rash,1,0.8477986454963684
BEPREVE,itching,reactions itching body rash,1,0.8197382688522339
BEPREVE,itching,hypersensitivity reactions include itching body rash,1,0.7932195663452148
BEPREVE,itching,drug exposure The hypersensitivity reactions,0,0.6350605487823486
BEPREVE,itching,lips tongue,0,0.5540128350257874
BEPREVE,itching,itching body rash and swelling of,1,0.8400981426239014
BEPREVE,itching,itching body rash and swelling,1,0.830258846282959
BEPREVE,itching,itching body rash and,1,0.8447253704071045
BEPREVE,body rash,body rash and swelling of lips tongue,1,0.8212178349494934
BEPREVE,body rash,The hypersensitivity reactions include body rash and swelling,1,0.8143940567970276
BEPREVE,body rash,The hypersensitivity reactions include body rash,1,0.8807891011238098
BEPREVE,swelling of lips,itching body rash swelling of lips,1,0.8345422744750977
BEPREVE,swelling of lips,itching body rash swelling of lips tongue andor throat,1,0.7822249531745911
BEPREVE,swelling of lips,rash swelling of,1,0.7550922632217407
BEPREVE,swelling of lips,itching body rash swelling of,1,0.6735901832580566
BEPREVE,swelling of lips,exposure,0,0.56131911277771
PRISTIQ,Hypersensitivity,in Adolescents and Young,0,0.5568428039550781
PRISTIQ,Hypersensitivity,other sections of the Hypersensitivity see Contraindications,1,0.7879232168197632
PRISTIQ,Hypersensitivity,Hypersensitivity,1,1.0
PRISTIQ,Hypersensitivity,in other sections of the label,0,0.5365169644355774
PRISTIQ,Hypersensitivity,sections,0,0.5373249053955078
PRISTIQ,Hypersensitivity,and Behaviors in,0,0.5387970209121704
PRISTIQ,Hypersensitivity,of the Hypersensitivity see Contraindications Suicidal Thoughts,1,0.7477102279663086
PRISTIQ,Hypersensitivity,Suicidal Thoughts and Behaviors in Adolescents and,0,0.44110721349716187
PRISTIQ,Suicidal Thoughts,Hypersensitivity,0,0.4356451630592346
PRISTIQ,Suicidal Thoughts,Suicidal Thoughts and Behaviors,1,0.8886561393737793
PRISTIQ,Suicidal Thoughts,Suicidal Thoughts,1,0.9999998807907104
PRISTIQ,Serotonin Syndrome,ughts and Behaviors in Adolescents and Young Adults see,0,0.53477543592453
PRISTIQ,Serotonin Syndrome,Adolescents and Young Adults,0,0.5038036704063416
PRISTIQ,Serotonin Syndrome,and Serotonin Syndrome,1,0.9606994390487671
PRISTIQ,Serotonin Syndrome,ughts and Behaviors in Adolescents and Young Adults see Warnings,0,0.5518293380737305
PRISTIQ,Serotonin Syndrome,Adults see Warnings and Serotonin Syndrome see,1,0.8272651433944702
PRISTIQ,Elevated Blood Pressure,Blood Pressure see Warnings and,1,0.7903575897216797
PRISTIQ,Elevated Blood Pressure,Syndrome see,0,0.4982558786869049
PRISTIQ,Elevated Blood Pressure,Elevated Blood Pressure see Warnings and Precautions,1,0.8854156732559204
PRISTIQ,Elevated Blood Pressure,Serotonin Syndrome see Warnings,0,0.5542958974838257
PRISTIQ,Abnormal Bleeding,Closure Glaucoma see Warnings and Precauti,0,0.5088552236557007
PRISTIQ,Abnormal Bleeding,Abnormal Bleeding see Warnings,1,0.8884531259536743
PRISTIQ,Abnormal Bleeding,Pressure see Warnings,0,0.48831069469451904
PRISTIQ,Abnormal Bleeding,Elevated Blood Pressure see Warnings and Precautions,0,0.5957286357879639
PRISTIQ,Abnormal Bleeding,and Precautions Angle Closure Glaucoma see Warnings,0,0.5095059275627136
PRISTIQ,Angle Closure Glaucoma,Warnings and Angle,1,0.6310313940048218
PRISTIQ,Angle Closure Glaucoma,Angle Closure Glaucoma see Warnings and Precautions Activation,1,0.8677638173103333
PRISTIQ,Angle Closure Glaucoma,Precautions,0,0.5054117441177368
PRISTIQ,Mania,Precautions Discontinuation Syndrome,0,0.4831535816192627
PRISTIQ,Mania,Precautions Activation Mania,1,0.6549714803695679
PRISTIQ,Mania,Mania Hypomania see Warnings and,1,0.7840877771377563
PRISTIQ,Mania,Mania Hypomania see Warnings,1,0.7797879576683044
PRISTIQ,Mania,and Precautions Activation Mania Hypomania,1,0.8028309345245361
PRISTIQ,Discontinuation Syndrome,Precautions,0,0.4933788776397705
PRISTIQ,Discontinuation Syndrome,Discontinuation Syndrome see Warnings and Precautions Seizure,1,0.852001428604126
PRISTIQ,Discontinuation Syndrome,and Discontinuation Syndrome see Warnings and Precautions Seizure,1,0.837459921836853
PRISTIQ,Seizure,and Seizure see Warnings and,1,0.8162415027618408
PRISTIQ,Seizure,Discontinuation Syndrome see Warnings and Precautions Seizure,1,0.7264087200164795
PRISTIQ,Seizure,Seizure see,1,0.9302836656570435
PRISTIQ,Seizure,Warnings and Precautions Hyponatremia see Warnings,0,0.588595986366272
PRISTIQ,Seizure,Warnings and Seizure see Warnings and Precautions,1,0.7542945146560669
PRISTIQ,Interstitial Lung Disease,and Precautions,0,0.48996487259864807
PRISTIQ,Interstitial Lung Disease,nings,0,0.5190531015396118
PRISTIQ,Interstitial Lung Disease,see Warnings and Interstitial Lung,1,0.7995234727859497
PRISTIQ,Interstitial Lung Disease,Hyponatremia see Warnings and Interstitial,1,0.629700779914856
PRISTIQ,Interstitial Lung Disease,Hyponatremia see Warnings and Interstitial Lung Disease and Eosinophilic Pneumonia see Warnings,1,0.7618533372879028
PRISTIQ,Interstitial Lung Disease,Hyponatremia see Warnings and Interstitial Lung Disease and,1,0.7899346351623535
PRISTIQ,Interstitial Lung Disease,Warnings and Precautions,0,0.5073807239532471
PRISTIQ,Eosinophilic Pneumonia,Disease Eosinophilic,1,0.8095086812973022
PRISTIQ,Eosinophilic Pneumonia,Lung Disease,0,0.6519569158554077
PRISTIQ,Eosinophilic Pneumonia,and,0,0.45571351051330566
PRISTIQ,Eosinophilic Pneumonia,Interstitial Lung Disease and,0,0.6445621252059937
PRISTIQ,Eosinophilic Pneumonia,Lung Disease Eosinophilic,1,0.8530140519142151
PRISTIQ,Eosinophilic Pneumonia,common adverse,0,0.5191122889518738
PRISTIQ,nausea,nausea dizziness insomnia hyperhidrosis constipation somnolence,1,0.7441952228546143
PRISTIQ,nausea,mg dose groups,0,0.5550904273986816
PRISTIQ,nausea,reactions incidence and twice,0,0.584649920463562
PRISTIQ,dizziness,were dizziness insomnia hyperhidrosis constipation,1,0.734605073928833
PRISTIQ,dizziness,reactions incidence and twice,0,0.5297639966011047
PRISTIQ,dizziness,groups were dizziness insomnia hyperhidrosis constipation somnolence,1,0.7300904989242554
PRISTIQ,dizziness,dizziness insomnia hyperhidrosis,1,0.7786527872085571
PRISTIQ,dizziness,dizziness,1,1.0
PRISTIQ,dizziness,decreased appetite anxiety and specific male,0,0.5468016862869263
PRISTIQ,dizziness,dizziness insomnia hyperhidrosis constipation,1,0.7589978575706482
PRISTIQ,dizziness,dizziness insomnia,1,0.8460532426834106
PRISTIQ,insomnia,were nausea insomnia hyperhidrosis,1,0.7044754028320312
PRISTIQ,insomnia,dizziness insomnia,1,0.8437963724136353
PRISTIQ,insomnia,and twice the rate of placebo in the or mg dose groups,0,0.495871901512146
PRISTIQ,insomnia,insomnia,1,1.0000001192092896
PRISTIQ,hyperhidrosis,hyperhidrosis constipation somnolence decreased,1,0.7859843373298645
PRISTIQ,hyperhidrosis,dizziness hyperhidrosis constipation somnolence,1,0.7710314989089966
PRISTIQ,hyperhidrosis,hyperhidrosis constipation somnolence decreased appetite,1,0.7771393060684204
PRISTIQ,hyperhidrosis,hyperhidrosis,1,0.9999998807907104
PRISTIQ,hyperhidrosis,were nausea dizziness hyperhidrosis,1,0.8216450214385986
PRISTIQ,hyperhidrosis,hyperhidrosis constipation somnolence decreased appetite anxiety,1,0.7912458181381226
PRISTIQ,somnolence,nausea dizziness insomnia hyperhidrosis somnolence decreased appetite anxiety and specific,1,0.7353892922401428
PRISTIQ,somnolence,hyperhidrosis constipation somnolence decreased appetite anxiety,1,0.6996263265609741
PRISTIQ,decreased appetite,insomnia hyperhidrosis constipation decreased,1,0.638788104057312
PRISTIQ,decreased appetite,mg dose groups were nausea dizziness insomnia hyperhidrosis constipation somnolence,0,0.5890425443649292
PRISTIQ,decreased appetite,constipation decreased appetite anxiety,1,0.7888385057449341
PRISTIQ,decreased appetite,disorders,0,0.5750875473022461
PRISTIQ,decreased appetite,dose groups were nausea dizziness insomnia hyperhidrosis constipation,0,0.6022257804870605
PRISTIQ,decreased appetite,male sexual function disorders To,0,0.5392292141914368
PRISTIQ,decreased appetite,decreased appetite anxiety and specific male,1,0.835515022277832
PRISTIQ,anxiety,somnolence,0,0.6334123015403748
PRISTIQ,anxiety,anxiety and specific male,1,0.8030704855918884
PRISTIQ,anxiety,anxiety,1,1.0
PRISTIQ,nausea,In a,0,0.5343363285064697
PRISTIQ,nausea,headache and vomiting each In a longerterm,0,0.7649809122085571
PRISTIQ,nausea,longerterm,0,0.5012291073799133
PRISTIQ,nausea,nausea dizziness headache and vomiting each,1,0.8344671726226807
PRISTIQ,nausea,than placebo of the PRISTIQ treated patients in the shortterm studies up to weeks were,0,0.5587427020072937
PRISTIQ,nausea,in the,0,0.5482624173164368
PRISTIQ,dizziness,months the most common was,0,0.48594945669174194
PRISTIQ,dizziness,to months,0,0.48622235655784607
PRISTIQ,dizziness,PRISTIQ treated patients in the,0,0.5189659595489502
PRISTIQ,dizziness,were nausea,0,0.6912974119186401
PRISTIQ,headache,headache and vomiting each,1,0.7831721305847168
PRISTIQ,headache,headache and,1,0.9235892295837402
PRISTIQ,headache,in,0,0.5469977855682373
PRISTIQ,headache,weeks were nausea,0,0.5784193277359009
PRISTIQ,vomiting,to weeks were nausea,0,0.7384318113327026
PRISTIQ,vomiting,months the most,0,0.4669244587421417
PRISTIQ,vomiting,vomiting each In,1,0.9047321081161499
PRISTIQ,vomiting,headache vomiting,1,0.8770869970321655
PRISTIQ,vomiting,vomiting each In a longerterm,1,0.8779706954956055
PRISTIQ,vomiting,eated patients in the shortterm studies up to weeks were nausea dizziness,0,0.6644627451896667
PRISTIQ,vomiting,vomiting,1,0.9999999403953552
PRISTIQ,vomiting,vomiting Common adverse reactions in placebocontrolled,1,0.776592493057251
PRISTIQ,vomiting,MDD studies The most commonly ob,0,0.4933677911758423
PRISTIQ,vomiting,common vomiting Common adverse reactions in,1,0.8292292952537537
PRISTIQ,vomiting,the most common vomiting,1,0.873988151550293
PRISTIQ,vomiting,vomiting Common adverse reactions,1,0.8523938655853271
PRISTIQ,vomiting,vomiting Common adverse,1,0.8744794130325317
PRISTIQ,vomiting,common was,0,0.49118733406066895
PRISTIQ,nausea,mg dose groups nausea dizziness insomnia hyperhidrosis,1,0.6961904168128967
PRISTIQ,nausea,common was,0,0.47856956720352173
PRISTIQ,nausea,mg dose,0,0.5711305141448975
PRISTIQ,nausea,nausea dizziness,1,0.9056505560874939
PRISTIQ,dizziness,mg dose groups were dizziness insomnia hyperhidrosis constipation,1,0.6937438249588013
PRISTIQ,dizziness,nausea dizziness insomnia hyperhidrosis constipation somnolence,1,0.7249585390090942
PRISTIQ,dizziness,decreased appetite anxiety and,0,0.5572715997695923
PRISTIQ,hyperhidrosis,hyperhidrosis constipation,1,0.8359665870666504
PRISTIQ,hyperhidrosis,groups were nausea dizziness hyperhidrosis,1,0.7706704139709473
PRISTIQ,hyperhidrosis,dizziness hyperhidrosis,1,0.866637110710144
PRISTIQ,constipation,constipation somnolence,1,0.7988170385360718
PRISTIQ,constipation,in the or mg dose groups were nausea dizziness insomnia hyperhidrosis,0,0.5975066423416138
PRISTIQ,constipation,nausea dizziness insomnia constipation somnolence decreased,1,0.6908998489379883
PRISTIQ,constipation,constipation somnolence decreased,1,0.7674756050109863
PRISTIQ,constipation,constipation somnolence decreased appetite anxiety and,1,0.7623811364173889
PRISTIQ,constipation,dizziness insomnia constipation somnolence decreased appetite,1,0.7260356545448303
PRISTIQ,decreased appetite,the incidence of common ad,0,0.5342763662338257
PRISTIQ,decreased appetite,constipation decreased appetite anxiety and specific male,1,0.7710749506950378
PRISTIQ,decreased appetite,decreased,1,0.7124268412590027
PRISTIQ,decreased appetite,and,0,0.46837252378463745
PRISTIQ,decreased appetite,nausea dizziness insomnia hyperhidrosis,0,0.6095930337905884
PRISTIQ,anxiety,sexual function disorders Table shows the incidence of common adverse,0,0.566239595413208
PRISTIQ,anxiety,of common adverse rea,0,0.536838710308075
PRISTIQ,male sexual function disorders,reactions that occurred in of PRISTIQ,0,0.5143712162971497
PRISTIQ,male sexual function disorders,sexual function disorders Table,1,0.8552234172821045
PRISTIQ,male sexual function disorders,decreased appetite anxiety and male sexual function disorders Table shows the incidence,1,0.8302546739578247
PRISTIQ,male sexual function disorders,sexual function disorders Table shows,1,0.8571993112564087
PRISTIQ,male sexual function disorders,function disorders Table shows the,1,0.6957619190216064
PRISTIQ,male sexual function disorders,that,0,0.4758026599884033
PRISTIQ,sexual function adverse reactions,the incidence sexual function adverse reactions,1,0.9739982485771179
PRISTIQ,sexual function adverse reactions,occurred in of PRISTIQ treated MDD patients in any fixeddose,0,0.5775129795074463
PRISTIQ,sexual function adverse reactions,MDD,0,0.5067235231399536
PRISTIQ,sexual function adverse reactions,adverse reactions,1,0.8049978017807007
PRISTIQ,sexual function adverse reactions,sexual function adverse reactions that occurred in of PRISTIQ,1,0.8770656585693359
PRISTIQ,Sexual Function Adverse Reactions,Sexual Function Adverse Reactions,1,1.0
PRISTIQ,Sexual Function Adverse Reactions,pooled week,0,0.4790184497833252
PRISTIQ,Sexual Function Adverse Reactions,clinical studies Sexual Function Adverse Reactions,1,0.9337314367294312
PRISTIQ,Sexual Function Adverse Reactions,Function Adverse Reactions in,1,0.8409351110458374
PRISTIQ,Tachycardia,were,0,0.5056999325752258
PRISTIQ,Tachycardia,at an,0,0.5399824380874634
PRISTIQ,Tachycardia,were Cardiac Tachycardia General disorders and administration site,1,0.8202265501022339
PRISTIQ,Tachycardia,Tachycardia General,1,0.907665491104126
PRISTIQ,Tachycardia,with PRISTIQ were Cardiac Tachycardia General disorders,1,0.7846670150756836
PRISTIQ,Asthenia,Asthenia Investigations Weight,1,0.7918586134910583
PRISTIQ,Asthenia,Weight increased liver function test abnormal blood prolactin,0,0.5038584470748901
PRISTIQ,Asthenia,administration site Asthenia Investigations,1,0.7786148190498352
PRISTIQ,Weight increased,Weight increased liver,1,0.7820945978164673
PRISTIQ,Weight increased,abnormal blood,0,0.5599581003189087
PRISTIQ,Weight increased,Weight,1,0.8204559087753296
PRISTIQ,liver function test abnormal,ers and administration site,0,0.4591693580150604
PRISTIQ,blood prolactin increased,nditions Asthenia Investigations Weight increased liver function,0,0.6261091828346252
PRISTIQ,blood prolactin increased,blood prolactin increased Musculoskeletal,1,0.8683856129646301
PRISTIQ,blood prolactin increased,function,0,0.5149080753326416
PRISTIQ,blood prolactin increased,test blood prolactin increased,1,0.9585469961166382
PRISTIQ,blood prolactin increased,Investigations Weight increased,0,0.6115658283233643
PRISTIQ,blood prolactin increased,test blood prolactin increased Musculoskeletal and connective tissue disorders,1,0.8065892457962036
PRISTIQ,blood prolactin increased,function test blood prolactin,1,0.8282456398010254
PRISTIQ,blood prolactin increased,prolactin increased Musculoskeletal and connective tissue,1,0.8055530190467834
PRISTIQ,blood prolactin increased,liver function test blood prolactin,1,0.8103578090667725
PRISTIQ,Musculoskeletal stiffness,Musculoskeletal,1,0.8681606650352478
PRISTIQ,Syncope,Psychiatric disorders,0,0.5618408918380737
PRISTIQ,Syncope,Syncope convulsion dystonia Psychiatric disorders Depersonalization,1,0.7562006711959839
PRISTIQ,Syncope,Syncope,1,0.9999998807907104
PRISTIQ,Syncope,Musculoskeletal stiffness Nervous system Syncope convulsion dystonia Psychiatric disorders Depersonalization,1,0.6617743372917175
PRISTIQ,Syncope,dystonia,0,0.6364766359329224
PRISTIQ,convulsion,convulsion,1,1.0000001192092896
PRISTIQ,dystonia,disorders Syncope dystonia Psychiatric disorders Depersonalization bruxism,1,0.7793988585472107
PRISTIQ,dystonia,convulsion,1,0.5695306658744812
PRISTIQ,dystonia,disorders Depersonalization bruxism Renal and urinary,0,0.6061403155326843
PRISTIQ,Depersonalization,Depersonalization bruxism Renal,1,0.7941969633102417
PRISTIQ,Depersonalization,Syncope convulsion,0,0.5395264625549316
PRISTIQ,Depersonalization,Depersonalization,1,0.9999998807907104
PRISTIQ,Depersonalization,Nervous system disorders Syncope convulsion dystonia Psychiatric disorders,0,0.5923235416412354
PRISTIQ,Depersonalization,Depersonalization bruxism,1,0.832295298576355
PRISTIQ,bruxism,bruxism Renal,1,0.8221681118011475
PRISTIQ,bruxism,bruxism Renal and urinary,1,0.8486372232437134
PRISTIQ,Urinary retention,and subcutaneous tissue disorders Rash alopecia photosensitivity reaction angi,0,0.4750399589538574
PRISTIQ,Urinary retention,Renal and urinary Urinary retention Skin,1,0.8085224628448486
PRISTIQ,Urinary retention,Urinary retention,1,0.9999999403953552
PRISTIQ,Urinary retention,and urinary Urinary retention Skin,1,0.8628624677658081
PRISTIQ,Urinary retention,alopecia photosensitivity,0,0.4616076946258545
PRISTIQ,Urinary retention,urinary Urinary,1,0.7778246402740479
PRISTIQ,Urinary retention,Urinary retention Skin and subcutaneous tissue,1,0.8347716331481934
PRISTIQ,Urinary retention,bruxism Renal and urinary Urinary retention,1,0.8104803562164307
PRISTIQ,Urinary retention,tissue disorders Rash alopecia,0,0.47492843866348267
PRISTIQ,Rash,clinical studies there,0,0.4977007508277893
PRISTIQ,Rash,and urinary disorders Urinary retention Skin and,0,0.5847663283348083
PRISTIQ,alopecia,alopecia,1,1.0
PRISTIQ,alopecia,subcutaneous tissue disorders alopecia,1,0.8263418674468994
PRISTIQ,alopecia,alopecia photosensitivity,1,0.7776137590408325
PRISTIQ,alopecia,alopecia photosensitivity reaction angioedema In clinical,1,0.7463077306747437
PRISTIQ,photosensitivity,photosensitivity reaction angioedema In,1,0.8474435806274414
PRISTIQ,photosensitivity,alopecia photosensitivity reaction angioedema In clinical,1,0.7900128960609436
PRISTIQ,photosensitivity,studies there were uncommon reports of ischemic cardiac adve,0,0.47466519474983215
PRISTIQ,photosensitivity,photosensitivity,1,0.9999998807907104
PRISTIQ,angioedema,In clinical studies there were uncommon reports of ischemic cardiac adverse,0,0.5529495477676392
PRISTIQ,angioedema,Rash alopecia photosensitivity angioedema In,1,0.7905213832855225
PRISTIQ,angioedema,tissue disorders,0,0.6037100553512573
PRISTIQ,angioedema,of ischemic,0,0.5347280502319336
PRISTIQ,angioedema,angioedema In clinical,1,0.9148639440536499
PRISTIQ,angioedema,angioedema In clinical studies there were,1,0.8621945381164551
PRISTIQ,angioedema,studies there were uncommon,0,0.5238530039787292
PRISTIQ,ischemic cardiac adverse reactions,there were uncommon reports ischemic cardiac adverse reactions,1,0.9322044849395752
PRISTIQ,ischemic cardiac adverse reactions,studies there were uncommon,0,0.5109903216362
PRISTIQ,ischemic cardiac adverse reactions,studies there,0,0.445472776889801
PRISTIQ,ischemic cardiac adverse reactions,cardiac adverse reactions including myocardial ischemia,1,0.9442669153213501
PRISTIQ,ischemic cardiac adverse reactions,coronary,0,0.664206862449646
PRISTIQ,ischemic cardiac adverse reactions,were uncommon reports ischemic cardiac adverse,1,0.8704577088356018
PRISTIQ,ischemic cardiac adverse reactions,ischemic cardiac adverse reactions including myocardial ischemia,1,0.9548147916793823
PRISTIQ,ischemic cardiac adverse reactions,myocardial ischemia myocardial infarction and coronary occlusion requiring revasculari,0,0.7394482493400574
PRISTIQ,myocardial ischemia,myocardial ischemia myocardial infarction and coronary,1,0.8998933434486389
PRISTIQ,myocardial ischemia,myocardial ischemia myocardial infarction and,1,0.9090914726257324
PRISTIQ,myocardial infarction,adverse reactions including myocardial myocardial,1,0.7397161722183228
PRISTIQ,myocardial infarction,including myocardial myocardial infarction,1,0.8934683799743652
PRISTIQ,myocardial infarction,myocardial myocardial infarction,1,0.9878934025764465
PRISTIQ,myocardial infarction,and coronary occlusion,0,0.7351486086845398
PRISTIQ,myocardial infarction,revascularization these,0,0.6541593670845032
PRISTIQ,myocardial infarction,including myocardial myocardial,1,0.7594796419143677
PRISTIQ,myocardial infarction,occlusion requiring revascularization these patients had multiple underlying cardiac,0,0.6888116598129272
PRISTIQ,myocardial infarction,requiring revascularization these,0,0.6556651592254639
PRISTIQ,myocardial infarction,myocardial infarction and coronary occlusion requiring,1,0.8569722175598145
PRISTIQ,myocardial infarction,of ischemic cardiac adverse reactions,0,0.7094632387161255
PRISTIQ,coronary occlusion,including,0,0.5055273771286011
PRISTIQ,coronary occlusion,myocardial infarction and,0,0.715065062046051
PRISTIQ,coronary occlusion,factors,0,0.4892348647117615
PRISTIQ,coronary occlusion,infarction coronary occlusion,1,0.9398203492164612
PRISTIQ,coronary occlusion,of ischemic cardiac adverse reactions including myocardial ischemia myocardial infarction,0,0.6863248348236084
PRISTIQ,Elevations in fasting serum total cholesterol,with PRISTIQ,0,0.5240895748138428
PRISTIQ,Lipid Abnormalities,of Patients Lipid Abnormalities,1,0.9491162300109863
PRISTIQ,Lipid Abnormalities,Incidence of Patients Lipid Abnormalities,1,0.9068078994750977
PRISTIQ,Lipid Abnormalities,Incidence of Patients Lipid Abnormalities of Potential Clinical Significance PRISTIQ,1,0.8180865049362183
PRISTIQ,Lipid Abnormalities,Lipid,1,0.7845122814178467
PRISTIQ,Lipid Abnormalities,Lipid Abnormalities of Potential Clinical,1,0.9250975847244263
PRISTIQ,Lipid Abnormalities,Clinical,0,0.5547807216644287
PRISTIQ,Lipid Abnormalities,Lipid Abnormalities of Potential Clinical Significance PRISTIQ,1,0.838660478591919
PRISTIQ,proteinuria,proteinuria was not associated with,1,0.8449229001998901
PRISTIQ,increases in BUN,creatinine and was generally transient Table Incidence,0,0.6045826077461243
PRISTIQ,increases in BUN,in BUN or,1,0.7574024200439453
PRISTIQ,increases in BUN,Table Incidence of Patients with Proteinuria,0,0.5695061683654785
PRISTIQ,increases in BUN,and was generally transient Table Incidence of,0,0.6171802878379822
PRISTIQ,increases in BUN,and was generally,0,0.5014297366142273
PRISTIQ,increases in BUN,proteinuria was not associated increases in BUN or creatinine,1,0.6953614950180054
PRISTIQ,Proteinuria,Proteinuria in the Fixeddose Clinical Studies,1,0.8534715175628662
PRISTIQ,Proteinuria,Incidence of Patients Proteinuria in the Fixeddose Clinical Studies,1,0.8203072547912598
PRISTIQ,Proteinuria,of Patients Proteinuria,1,0.9193509817123413
PRISTIQ,Proteinuria,Fixeddose Clinical,0,0.4863821268081665
PRISTIQ,Proteinuria,Clinical Studies PRISTIQ,0,0.5424680709838867
PRISTIQ,Proteinuria,in the Fixeddose Clinical Studies PRISTIQ,0,0.545890212059021
PRISTIQ,hypertension,studies was associated with hypertension defined as,1,0.7514828443527222
PRISTIQ,hypertension,in the Fixeddose Clinical Studies PRISTIQ,0,0.5744038820266724
PRISTIQ,hypertension,SDBP,0,0.495309978723526
PRISTIQ,hypertension,hypertension defined as treatmentemergent supine diastolic,1,0.8016249537467957
PRISTIQ,hypertension,hypertension defined as,1,0.8617459535598755
PRISTIQ,hypertension,studies was associated with hypertension,1,0.7754954695701599
PRISTIQ,hypertension,hypertension revealed a,1,0.8613811731338501
PRISTIQ,hypertension,hypertension revealed a consistent increase in,1,0.8124517798423767
PRISTIQ,hypertension,hypertension,1,0.9999999403953552
PRISTIQ,hypertension,hypertension revealed a consistent increase,1,0.8199529647827148
PRISTIQ,hypertension,for sustained,0,0.5734808444976807
PRISTIQ,hypertension,who developed sustained,0,0.5140649080276489
PRISTIQ,hypertension,hypertension This was,1,0.9034038782119751
PRISTIQ,hypertension,a higher rate at,0,0.5636053085327148
PRISTIQ,Elevation of Supine Diastolic Blood Pressure,Patients with Sustained,0,0.573922872543335
PRISTIQ,Elevation of Supine Diastolic Blood Pressure,Group Proportion,0,0.49743199348449707
PRISTIQ,Elevation of Supine Diastolic Blood Pressure,Elevation of Supine,1,0.7913528084754944
PRISTIQ,Elevation of Supine Diastolic Blood Pressure,of Patients with Elevation of Supine Diastolic Blood Pressure,1,0.9611772894859314
PRISTIQ,systolic orthostatic hypotension,with doses of to systolic orthostatic,1,0.8767869472503662
PRISTIQ,systolic orthostatic hypotension,orthostatic hypotension decrease mm Hg,1,0.8597947359085083
PRISTIQ,systolic orthostatic hypotension,standing position occurred,0,0.554879903793335
PRISTIQ,systolic orthostatic hypotension,to systolic orthostatic hypotension decrease mm Hg from supine,1,0.913641095161438
PRISTIQ,SUICIDAL THOUGHTS,following advers,1,0.4793562591075897
PRISTIQ,SUICIDAL THOUGHTS,following advers e reactions are,1,0.4941321015357971
PRISTIQ,SUICIDAL THOUGHTS,sections of the label,0,0.45072925090789795
PRISTIQ,SUICIDAL THOUGHTS,of the,0,0.46202218532562256
PRISTIQ,SUICIDAL THOUGHTS,discussed in,0,0.5257771611213684
PRISTIQ,SUICIDAL THOUGHTS,greater detail in,1,0.41439664363861084
PRISTIQ,SUICIDAL THOUGHTS,discussed greater detail in other sections of the,1,0.4568951427936554
PRISTIQ,SUICIDAL THOUGHTS,detail in,1,0.45621782541275024
PRISTIQ,SUICIDAL THOUGHTS,REACTIONS The following adverse,0,0.5120035409927368
PRISTIQ,suicidal thoughts,  Contraindicatio ns,1,0.435880184173584
PRISTIQ,suicidal thoughts,  Contraindicatio ns Suicidal Thoughts and Behaviors,1,0.7631791830062866
PRISTIQ,suicidal thoughts,Precautions tonin Syndrome [s,1,0.5214405059814453
PRISTIQ,suicidal thoughts,and Young Adults see Warnings and Precautions,0,0.52935791015625
PRISTIQ,suicidal thoughts,tonin,1,0.47493380308151245
PRISTIQ,suicidal thoughts,tonin Syndrome [s ee Warnings and Precautions,1,0.5213425159454346
PRISTIQ,suicidal thoughts,Behaviors in Adolescents and Young Adults see Warnings,0,0.5723572969436646
PRISTIQ,suicidal thoughts,see Warnings and Precautions tonin Syndrome [s,1,0.5257482528686523
PRISTIQ,suicidal thoughts,Warnings and Precautions tonin Syndrome [s ee,1,0.5276973247528076
PRISTIQ,suicidal thoughts,Young Adults see,0,0.4799554944038391
PRISTIQ,suicidal thoughts,Sero,0,0.5064927339553833
PRISTIQ,SUICIDAL THOUGHTS,incidence and twice the rate of,0,0.4855734705924988
PRISTIQ,SUICIDAL THOUGHTS,Most ommon adverse rea ctions incidence and,1,0.49432095885276794
PRISTIQ,SUICIDAL THOUGHTS,see Warnings and Precautions EXCERPT,0,0.5382766127586365
PRISTIQ,SUICIDAL THOUGHTS,ommon,1,0.4328409433364868
PRISTIQ,SUICIDAL THOUGHTS,mg,0,0.4724932312965393
PRISTIQ,SUICIDAL THOUGHTS,and Precautions EXCERPT Most ommon adverse rea ctions incidence and twice,1,0.5044732689857483
PRISTIQ,SUICIDAL THOUGHTS,Precautions EXCERPT Most ommon,1,0.5297495126724243
PRISTIQ,suicidal thinking,"dizziness somnia, hyperhidr",1,0.4790474772453308
PRISTIQ,suicidal thinking,male,0,0.48979896306991577
PRISTIQ,suicidal thinking,ence,0,0.44107943773269653
PRISTIQ,suicidal thinking,or mg dose groups were nausea dizziness,0,0.4784162640571594
PRISTIQ,Clinical Worsening,following adverse ons are discussed  in greater detail in,1,0.6837171912193298
PRISTIQ,Clinical Worsening,or mg dose groups were nausea dizziness,0,0.560048520565033
PRISTIQ,Clinical Worsening,of the label Hypersensitivity see,0,0.49658718705177307
PRISTIQ,Suicide Risk,sections of the,0,0.450766921043396
PRISTIQ,Suicide Risk,n greater de tail in,1,0.5097872614860535
PRISTIQ,Suicide Risk,adverse reactions are discussed n greater de,1,0.5936727523803711
PRISTIQ,Serotonin Syndrome,Contraindications  Suicidal,1,0.5569138526916504
PRISTIQ,Serotonin Syndrome,ons are discussed in,0,0.5942007303237915
PRISTIQ,Serotonin Syndrome,Hypersensitivity Contraindications  Suicidal Thoughts and Behaviors,1,0.6167440414428711
PRISTIQ,Serotonin syndrome,and Behaviors in,0,0.5581339597702026
PRISTIQ,Serotonin syndrome,"Hypersensitivity see )  ]  
 *    Suici dal Thoughts and Behaviors",1,0.5953408479690552
PRISTIQ,Serotonin syndrome,"see )  ]  
 *    Suici",1,0.5007246136665344
PRISTIQ,Elevated Blood Pressure,Warnings and Precautions [see Warnings,1,0.5615878105163574
PRISTIQ,Abnormal Bleeding,Disease and Eosinophilic Pneumonia see Warnings and,0,0.5500380992889404
PRISTIQ,Abnormal Bleeding,the rate of placebo in the or,0,0.5032238960266113
PRISTIQ,Abnormal Bleeding,and       EXCERPT:    Most,1,0.4518071413040161
PRISTIQ,Abnormal Bleeding,Pneumonia see Warnings and       EXCERPT:    Most common adverse,1,0.531627357006073
PRISTIQ,Abnormal Bleeding,      EXCERPT:   ,1,0.4860996603965759
PRISTIQ,Abnormal Bleeding,and Precautions,0,0.5352029800415039
PRISTIQ,Abnormal Bleeding,placebo in the,0,0.5040684342384338
PRISTIQ,Abnormal Bleeding,      EXCERPT:    Most common,1,0.49865126609802246
PRISTIQ,Abnormal Bleeding,      EXCERPT:    Most common adverse reactions,1,0.5424887537956238
PRISTIQ,bleeding,placebo in the or mg dose groups were nausea,0,0.5073758363723755
PRISTIQ,bleeding,incidenc e and twice the,1,0.5590587854385376
PRISTIQ,bleeding,adverse,0,0.5555754899978638
PRISTIQ,Angle Closure Glaucoma,ADVERSE REACTIONS contact Wyeth,0,0.48332586884498596
PRISTIQ,Angle Closure Glaucoma,appetite anxie,0,0.4731464385986328
PRISTIQ,Angle Closure Glaucoma,SUSPECTED ADVERSE,0,0.5242564678192139
PRISTIQ,Angle Closure Glaucoma,anxie,0,0.46688395738601685
PRISTIQ,Angle Closure Glaucoma,"somnolence decreased appetite ty, and",1,0.47515037655830383
PRISTIQ,Angle closure glaucoma,ADVERSE REACTIONS contact Wyeth,0,0.48332586884498596
PRISTIQ,Angle closure glaucoma,male xual function disorder,1,0.48044225573539734
PRISTIQ,Activation of Mania,wwwfdagovmedwatch Clinical Studies Experience,0,0.5144394636154175
PRISTIQ,Discontinuation Syndrome,r widely varying conditi,1,0.4994560778141022
PRISTIQ,Discontinuation Syndrome,varying conditi ons,1,0.5867747068405151
PRISTIQ,Discontinuation Syndrome,drug cannot,0,0.5329689383506775
PRISTIQ,Discontinuation Syndrome,widely varying conditi ons adverse reaction rates,1,0.5719074010848999
PRISTIQ,Hyponatremia,reflect the s observed i,1,0.47094956040382385
PRISTIQ,Hyponatremia,widely varying conditi ons adverse reaction rates,1,0.5126434564590454
PRISTIQ,Interstitial Lung Disease,exposure PRIST,0,0.5340465903282166
PRISTIQ,Interstitial Lung Disease,patients,0,0.5657748579978943
PRISTIQ,Interstitial Lung Disease,in patients diagnosed with major depressive disorder who participated in multipledose pre,0,0.5204351544380188
PRISTIQ,Interstitial Lung Disease,practice Patient exposure IQ was evaluated for safe ty in,1,0.5295028686523438
PRISTIQ,Interstitial Lung Disease,practice,0,0.5482320785522461
PRISTIQ,Interstitial Lung Disease,the rates observed in clinical practice Patient exposure PRIST,0,0.5530946254730225
PRISTIQ,Interstitial Lung Disease,evaluated for safe ty in,1,0.5220389366149902
PRISTIQ,Interstitial Lung Disease,exposure IQ was,1,0.4624210000038147
PRISTIQ,Interstitial Lung Disease,clinical practice Patient exposure IQ was evaluated for safe,1,0.5247406363487244
PRISTIQ,Interstitial Lung Disease,practice Patient exposure IQ was,1,0.5110359191894531
PRISTIQ,Eosinophilic Pneumonia,disorder who,0,0.5047184228897095
PRISTIQ,Eosinophilic Pneumonia,"was evaluated for safety 8,394",1,0.4928382635116577
PRISTIQ,Eosinophilic Pneumonia,for safety in,0,0.4800899028778076
PRISTIQ,Eosinophilic Pneumonia,"8,394 patients diagno sed with major",1,0.5355596542358398
PRISTIQ,Eosinophilic Pneumonia,"8,394 patients diagno sed with major depressive disorder",1,0.5123953223228455
PRISTIQ,worsening of depression,with of,0,0.5150357484817505
PRISTIQ,suicidality,At the dose of 50,1,0.5277912616729736
PRISTIQ,suicidality,discontinuation rate due to an adverse reaction for PRISTIQ was similar to the rate f,0,0.5040610432624817
PRISTIQ,suicidality,the rate,0,0.49390143156051636
PRISTIQ,suicidality,mg the discontinuation rate due to an adverse reaction for PRISTIQ,0,0.4936448335647583
PRISTIQ,suicidality,placebotreated patients At the dose of 50  mg the discontinuation,1,0.5288316011428833
PRISTIQ,suicidality,the dose of 50  mg the discontinuation,1,0.5165682435035706
PRISTIQ,suicidality,of 50 mg the discontinuation rate due,1,0.5300189256668091
PRISTIQ,suicidal thinking,adverse reaction s 8.7%. The m,1,0.46592503786087036
PRISTIQ,suicidal thinking,to an adverse reaction s,1,0.48511096835136414
PRISTIQ,suicidal thinking,adverse reaction s 8.7%.,1,0.4597936272621155
PRISTIQ,suicidal thinking,common adverse reactions leading to discontinuation in at least and at a,0,0.47452929615974426
PRISTIQ,suicidal thinking,to,0,0.4733899235725403
PRISTIQ,suicidal thinking,mg dose of PRISTIQ the discontinuation rate due to an,0,0.4751012623310089
PRISTIQ,suicidal thinking,an adverse reaction s 8.7%.,1,0.4639924168586731
PRISTIQ,suicidal thinking,at a,0,0.48057863116264343
PRISTIQ,suicidal thinking,8.7%. The m ost,1,0.43618935346603394
PRISTIQ,suicidal thinking,reaction s 8.7%. The,1,0.45446085929870605
PRISTIQ,suicidality,least and at a rate greater,0,0.48798057436943054
PRISTIQ,suicidality,was The most common rse reactio ns leading to,1,0.47040680050849915
PRISTIQ,suicidality,ns leading to discontinuation in at,0,0.49366092681884766
PRISTIQ,suicidality,rse reactio,1,0.45067673921585083
PRISTIQ,suicidality,studies up,0,0.4740557074546814
PRISTIQ,suicidality,weeks were nausea dizziness he and,1,0.5214145183563232
PRISTIQ,suicidality,he and vomi ting each In,1,0.44759097695350647
PRISTIQ,suicidality,he and vomi,1,0.43524885177612305
PRISTIQ,suicidality,he and vomi ting each In a longerterm,1,0.4699666500091553
PRISTIQ,suicidality,and vomi ting each In a,1,0.4700666666030884
PRISTIQ,suicidality,and twice rate of pla cebo at any,1,0.4919552803039551
PRISTIQ,suicidality,Adverse,0,0.5526836514472961
PRISTIQ,suicidality,Adverse  in any Fix edDose Group,1,0.4993421733379364
PRISTIQ,suicidality,Adverse in,1,0.5218544006347656
PRISTIQ,suicidality,Common Adverse in any Fix,1,0.52278733253479
PRISTIQ,suicidality,Reporting Reaction PRISTIQ Organ Class Preferred Term Placebo n mg,1,0.4886067807674408
PRISTIQ,suicidality,PRISTIQ Organ Class Preferred Term,1,0.4719082713127136
PRISTIQ,suicidality,Reporting Reaction PRISTIQ Organ Class,1,0.5055574178695679
PRISTIQ,suicidality,Organ Class Preferred Term Placebo n mg,1,0.4710600972175598
PRISTIQ,Suicidality,"   
  
  Ca",1,0.5084913372993469
PRISTIQ,suicides,disorders and on site  conditions,1,0.5073089599609375
PRISTIQ,suicides,"   
  
  Ca",1,0.48870474100112915
PRISTIQ,suicides,and on,1,0.49938297271728516
PRISTIQ,suicides,on site conditions,1,0.4203161597251892
PRISTIQ,suicides,on site conditions Fatigue,1,0.49545952677726746
PRISTIQ,serotonin syndrome,delayed,0,0.5036506056785583
PRISTIQ,serotonin syndrome,                7  Erectile dysfunction,1,0.5445073246955872
PRISTIQ,tachycardia,ebo(n=397)  mgn,1,0.5206599235534668
PRISTIQ,tachycardia,PRISTIQ ebo(n=397)  mgn mgn mgn,1,0.5545135140419006
PRISTIQ,tachycardia,ebo(n=397)  mgn mgn,1,0.5239413976669312
PRISTIQ,tachycardia,PRISTIQ,0,0.5255647897720337
PRISTIQ,tachycardia,Plac,0,0.5182628035545349
PRISTIQ,tachycardia,mgn mgn mgn mgn Women,0,0.47049278020858765
PRISTIQ,tachycardia,ebo(n=397)  mgn mgn mgn mgn,1,0.5223901867866516
PRISTIQ,tachycardia,ebo(n=397)  mgn mgn mgn mgn Women,1,0.5160491466522217
PRISTIQ,labile blood pressure,Placebon,0,0.516272783279419
PRISTIQ,labile blood pressure,PRISTIQ 50 mg(n=209) 10,1,0.5540809631347656
PRISTIQ,labile blood pressure, 50 mg(n=209)      10,1,0.5541906356811523
PRISTIQ,labile blood pressure,PRISTIQ  50 mg(n=209)      10 mgn mgn,1,0.546602725982666
PRISTIQ,labile blood pressure,mgn Women,0,0.4731292128562927
PRISTIQ,labile blood pressure,PRISTIQ  50 mg(n=209)      10 mgn mgn mgn Women only,1,0.5648781657218933
PRISTIQ,labile blood pressure,PRISTIQ  50 mg(n=209)      10 mgn mgn mgn,1,0.5421878099441528
PRISTIQ,labile blood pressure,50 mg(n=209) 10 mgn mgn mgn Women only,1,0.5623797178268433
PRISTIQ,dizziness,mg(n=267) mgn,1,0.49687790870666504
PRISTIQ,dizziness,mgn,0,0.47678348422050476
PRISTIQ,dizziness,mg(n=267),1,0.5217753648757935
PRISTIQ,dizziness,mgn Women only Anorgasmia,0,0.4499305486679077
PRISTIQ,dizziness,mgn mgn Women only Anorgasmia,0,0.4515153467655182
PRISTIQ,diaphoresis,Placebon mgn,0,0.5216727256774902
PRISTIQ,diaphoresis,PRISTIQ Placebon mgn    200 mg(n mgn Women only,1,0.5415711402893066
PRISTIQ,diaphoresis,200 mg(n mgn Women only,1,0.5459282994270325
PRISTIQ,diaphoresis,200 mg(n mgn Women only Anorgasmia,1,0.5631316900253296
PRISTIQ,diaphoresis,mgn 200 mg(n,1,0.5605897903442383
PRISTIQ,diaphoresis,Placebon mgn    200 mg(n mgn,1,0.5523151159286499
PRISTIQ,diaphoresis,Placebon mgn    200 mg(n mgn Women only Anorgasmia,1,0.5569640398025513
PRISTIQ,diaphoresis,Placebon,0,0.49686354398727417
PRISTIQ,diaphoresis,200,1,0.5366544127464294
PRISTIQ,diaphoresis,mgn    200 mg(n mgn Women only,1,0.5474563837051392
PRISTIQ,flushing,mgn,0,0.534400463104248
PRISTIQ,flushing,76)      mgn Women only Anorgasmia,1,0.5110330581665039
PRISTIQ,hyperthermia,mgn mgn,0,0.5398381948471069
PRISTIQ,hyperthermia,0 mg(n=163),1,0.5516061782836914
PRISTIQ,hyperthermia,mgn mgn 0,1,0.5113298892974854
PRISTIQ,hyperthermia,0,1,0.5956583619117737
PRISTIQ,hyperreflexia,Women only           1  ,1,0.4461553990840912
PRISTIQ,hyperreflexia,0,1,0.5473664402961731
PRISTIQ,hyperreflexia,          1  ,1,0.5134106874465942
PRISTIQ,hyperreflexia,          1   Other,1,0.4914361536502838
PRISTIQ,hyperreflexia,Women only           1   Other,1,0.4361940622329712
PRISTIQ,hyperreflexia,Anorgasmia,0,0.5445882678031921
PRISTIQ,incoordination,Women only              1 Other adverse reactions observ,1,0.5196669101715088
PRISTIQ,incoordination,Anorgasmia,0,0.5801100730895996
PRISTIQ,incoordination,             1 Other adverse reactions observ,1,0.5250778198242188
PRISTIQ,incoordination,Other adverse reactions observ,0,0.5295683145523071
PRISTIQ,incoordination,Women only,0,0.5300108790397644
PRISTIQ,seizures,         Other adverse reactions observed in,1,0.5928161144256592
PRISTIQ,gastrointestinal symptoms,               3         ,1,0.46038195490837097
PRISTIQ,gastrointestinal symptoms,         Other adverse reactions observed in,1,0.6078879833221436
PRISTIQ,gastrointestinal symptoms,reactions observed,0,0.5395572781562805
PRISTIQ,gastrointestinal symptoms,only,0,0.4651292562484741
PRISTIQ,gastrointestinal symptoms,premarketing and postmarketing clinical,0,0.5006778240203857
PRISTIQ,gastrointestinal symptoms,men only,0,0.4327455759048462
PRISTIQ,gastrointestinal symptoms,only                3         ,1,0.4091314375400543
PRISTIQ,gastrointestinal symptoms,               3          Other adverse,1,0.5692890882492065
PRISTIQ,increases in blood pressure,of,0,0.4564134478569031
PRISTIQ,increases in blood pressure,es were considered potentia lly clinically significant,1,0.612233579158783
PRISTIQ,increases in blood pressure,clinically significant The,0,0.5399191379547119
PRISTIQ,increases in blood pressure,es were,1,0.5075394511222839
PRISTIQ,increases in blood pressure,were considered potentia,1,0.5372214913368225
PRISTIQ,increases in blood pressure,studies Some of these es were considered potentia,1,0.5975674390792847
PRISTIQ,increases in blood pressure,considered potentia lly clinically,1,0.5877098441123962
PRISTIQ,increases in blood pressure,controlled studies Some of these abnormaliti,0,0.6091451048851013
PRISTIQ,increases in blood pressure,the controlled studies Some of,0,0.5777927041053772
PRISTIQ,elevated blood pressure,100 mg 200 m,1,0.5522741079330444
PRISTIQ,elevated blood pressure,Placebo     100 mg        200 m,1,0.5334362983703613
PRISTIQ,elevated blood pressure,Placebo     100 mg        200 m g,1,0.546401858329773
PRISTIQ,elevated blood pressure,mg 200 m g mg,1,0.5378822088241577
PRISTIQ,elevated blood pressure,CholesterolIncrease of mgdl and an absolute value,0,0.5279415845870972
PRISTIQ,elevated blood pressure,PRISTIQ Placebo     100 mg        200 m g mg Total,1,0.5347112417221069
PRISTIQ,elevated blood pressure,Placebo 100 mg 200 m,1,0.5334362983703613
PRISTIQ,elevated blood pressure,an,0,0.5441344380378723
PRISTIQ,blood pressure increases,>= 261 mgdl LDL,1,0.5162297487258911
PRISTIQ,blood pressure increases,CholesterolIncrease of mgdl and absolute value of >= 261 mgdl LDL Cholesterol,1,0.5295770168304443
PRISTIQ,blood pressure increases,mgdl LDL Cholesterol,0,0.5080775022506714
PRISTIQ,blood pressure increases,mgdl,0,0.389751136302948
PRISTIQ,blood pressure increases,mg Total CholesterolIncrease of mgdl and,0,0.5328220129013062
PRISTIQ,bleeding,Proteinuria,0,0.5155832767486572
PRISTIQ,bleeding,greater than,0,0.5200636386871338
PRISTIQ,bleeding,         Proteinuria Proteinuria greater,1,0.5212621688842773
PRISTIQ,bleeding,         Proteinuria Proteinuria,1,0.516930103302002
PRISTIQ,bleeding,        ,1,0.6097152829170227
PRISTIQ,bleeding,         Proteinuria,1,0.5155832767486572
PRISTIQ,gastrointestinal bleeding,ot associated with increases in BUN or creatinine and was generally transient,0,0.5560654997825623
PRISTIQ,gastrointestinal bleeding,e (%) of Patients with Pr oteinuria in the,1,0.5258495211601257
PRISTIQ,gastrointestinal bleeding,in BUN or creatinine and was,0,0.5644237399101257
PRISTIQ,gastrointestinal bleeding,Table e (%) of Patients with Pr oteinuria in the,1,0.5324028730392456
PRISTIQ,gastrointestinal bleeding,in the Fixeddose Clinical,0,0.5809513926506042
PRISTIQ,gastrointestinal bleeding,creatinine and was generally,0,0.5113914012908936
PRISTIQ,gastrointestinal bleeding,generally transient Table e (%) of Patients with Pr oteinuria in,1,0.5347112417221069
PRISTIQ,gastrointestinal bleeding,(%) of Patients with Pr oteinuria in,1,0.5130767822265625
PRISTIQ,gastrointestinal bleeding,of Patients with Pr oteinuria,1,0.5231765508651733
PRISTIQ,gastrointestinal bleeding,e (%) of Patients with Pr oteinuria in the Fixeddose,1,0.5450344085693359
PRISTIQ,Bleeding,einuria  in the,1,0.523517906665802
PRISTIQ,Bleeding,of Patients with Pr oteinuria,1,0.5457217693328857
PRISTIQ,Bleeding,with einuria  in the,1,0.5512532591819763
PRISTIQ,ecchymosis,          ,1,0.5825116634368896
PRISTIQ,hematoma,Proteinuria in the Fixeddose,0,0.4916270673274994
PRISTIQ,hematoma,        ,1,0.608422040939331
PRISTIQ,hematoma,         PRISTIQ Placebo mg mg,1,0.4609605073928833
PRISTIQ,epistaxis,Clinical Studies,0,0.5402831435203552
PRISTIQ,epistaxis,mg mg mg,0,0.4880468249320984
PRISTIQ,epistaxis,Proteinuria in the Fixeddose Clinical,0,0.4988362491130829
PRISTIQ,epistaxis,Placebo,0,0.5493744611740112
PRISTIQ,epistaxis,in the Fixeddose,0,0.5680571794509888
PRISTIQ,epistaxis,with Proteinuria in the Fixeddose Clinical Studies,0,0.5047246217727661
PRISTIQ,epistaxis,   PRISTI Q Placebo,1,0.5287227630615234
PRISTIQ,epistaxis,Fixeddose Clinical    PRISTI Q Placebo mg mg mg,1,0.5638436079025269
PRISTIQ,petechiae,"    
     Placebo mg mg",1,0.5074920058250427
PRISTIQ,petechiae,   PRISTI Q Placebo,1,0.5055440664291382
PRISTIQ,petechiae,mg,0,0.5032660961151123
PRISTIQ,petechiae,"    
     Placebo mg mg mg",1,0.4995405375957489
PRISTIQ,petechiae,Placebo mg mg,0,0.5074920058250427
PRISTIQ,petechiae,"    
     Placebo",1,0.5445584654808044
PRISTIQ,petechiae,the Fixeddose Clinical Studies PRISTIQ,0,0.5444207787513733
PRISTIQ,hemorrhages,Studies PRISTIQ lacebo      mg mg,1,0.5500103235244751
PRISTIQ,hemorrhages,the Fixeddose Clinical Studies PRISTIQ,0,0.5416465997695923
PRISTIQ,hemorrhages,lacebo      mg mg,1,0.508348822593689
PRISTIQ,hemorrhages,lacebo     ,1,0.5045741200447083
PRISTIQ,hemorrhages,linical Studies,0,0.5340120792388916
PRISTIQ,hemorrhages,linical Studies PRISTIQ lacebo      mg mg mg,1,0.5440694093704224
PRISTIQ,hemorrhages,lacebo      mg,1,0.4963819086551666
PRISTIQ,hemorrhages,lacebo      mg mg mg,1,0.5207371711730957
PRISTIQ,Angle-Closure Glaucoma,Vital sign chan,0,0.49402451515197754
PRISTIQ,angle closure attack,PRISTIQ patients,1,0.48463380336761475
PRISTIQ,angle closure attack,in,0,0.5357283353805542
PRISTIQ,angle closure attack,observed in placebocontrolled shortterm premarketing studies with,0,0.5494642853736877
PRISTIQ,angle closure attack,shortterm premarketing studies with PRISTIQ in,0,0.5291292667388916
PRISTIQ,angle closure attack,Signs,0,0.49911394715309143
PRISTIQ,angle closure attack,patients with MDD (d oses to mg,1,0.4838036894798279
PRISTIQ,angle closure attack,patients with MDD (d,1,0.4576522707939148
PRISTIQ,mania,for,0,0.5610526204109192
PRISTIQ,Activation of mania,PRISTIQ Placebo mg            200 mg   mg,1,0.5546720027923584
PRISTIQ,Activation of mania,for,0,0.5391657948493958
PRISTIQ,Activation of mania,PRISTIQ Placebo mg            200 mg   mg Blood pressure,1,0.5286327600479126
PRISTIQ,Activation of mania,bp,0,0.5152571201324463
PRISTIQ,Activation of mania,200 mg mg Blood pressure Supine,1,0.5277727246284485
PRISTIQ,Activation of mania,200 mg mg Blood pressure,1,0.5313743948936462
PRISTIQ,Activation of mania,200 mg mg Blood pressure Supine systolic,1,0.5204744338989258
PRISTIQ,Activation of mania,Blood pressure Supine systolic bp mm Hg,0,0.4786173701286316
PRISTIQ,Activation of mania,PRISTIQ Placebo mg 200 mg,1,0.5586248636245728
PRISTIQ,dizziness,to 400,1,0.5080043077468872
PRISTIQ,dizziness,to 400 m g,1,0.5218582153320312
PRISTIQ,dizziness,defined as,0,0.4663187265396118
PRISTIQ,dizziness,PRISTIQ at all,0,0.5340781211853027
PRISTIQ,dizziness, to 400 m g per day in controlled,1,0.5316728353500366
PRISTIQ,dizziness,per  to 400 m g per day,1,0.5311106443405151
PRISTIQ,dizziness,controlled studies was associated with sustained hypertension defined as treatmenteme,0,0.5055539608001709
PRISTIQ,nausea,per da y in controlled,1,0.4970707297325134
PRISTIQ,nausea,controlled studies was associated with sustained hypertension defined as treatmenteme,0,0.48145240545272827
PRISTIQ,nausea,mg,0,0.5488860607147217
PRISTIQ,nausea,mg per day to per,1,0.5469657182693481
PRISTIQ,headache,in,1,0.5469977855682373
PRISTIQ,headache,doses from mg,0,0.5470033884048462
PRISTIQ,headache,treatmentemergent supine diast,0,0.5562800168991089
PRISTIQ,headache,as,0,0.564278781414032
PRISTIQ,headache,treatmentemergent supine,0,0.5649896860122681
PRISTIQ,irritability,day in led studies  was associated with,1,0.524499773979187
PRISTIQ,irritability,treatmentemergent supine,0,0.5468604564666748
PRISTIQ,insomnia,to mg per day in controlled studies,0,0.48870033025741577
PRISTIQ,insomnia,s associ ated with sustained hypertension defined,1,0.4744735360145569
PRISTIQ,insomnia,s associ ated with,1,0.5139824748039246
PRISTIQ,insomnia,in controlled studies s associ ated with sustained hypertension,1,0.4727899432182312
PRISTIQ,insomnia,blood,0,0.5143740177154541
PRISTIQ,insomnia,day in controlled studies s,1,0.5137307047843933
PRISTIQ,insomnia,studies s associ ated with sustained hypertension defined,1,0.45110374689102173
PRISTIQ,insomnia,supine diastolic blood pressure,0,0.49372005462646484
PRISTIQ,insomnia,from mg per day to mg per day in controlled studies wa,0,0.49877843260765076
PRISTIQ,insomnia,s associ ated with sustained hypertension,1,0.48348522186279297
PRISTIQ,diarrhea,pressure,0,0.5505751967430115
PRISTIQ,diarrhea,supine diastolic blood pressure SDBP,0,0.5535299777984619
PRISTIQ,diarrhea,sustained hypertension defined as treatmentemergent supine,0,0.5045448541641235
PRISTIQ,diarrhea,studies was ed with  sustained hypertension,1,0.5103549957275391
PRISTIQ,anxiety,studies was associated with stained hypertension,1,0.5327993631362915
PRISTIQ,anxiety,sustained hypertension defined as treatmentemergent supine,0,0.5193478465080261
PRISTIQ,anxiety,studies was associated with stained,1,0.5063402652740479
PRISTIQ,anxiety,with stained hypertension defined as treatmentemergent,1,0.5288428068161011
PRISTIQ,anxiety,from mg per day to mg per,0,0.5225152373313904
PRISTIQ,anxiety,as treatmentemergent supine diastolic blood pressure SDBP mm Hg,0,0.5750418901443481
PRISTIQ,anxiety,stained hypertension defined as,1,0.5076863765716553
PRISTIQ,hyperhidrosis,mm Hg and mm Hg above baseline,0,0.57792067527771
PRISTIQ,hyperhidrosis,ent-emergent  supine diastolic blood,1,0.5327304601669312
PRISTIQ,hyperhidrosis,with sustained hypertension defined as treatm,0,0.6035561561584473
PRISTIQ,hyperhidrosis,treatm,0,0.5624173283576965
PRISTIQ,hyperhidrosis,SDBP mm Hg and mm Hg above baseline for consecutive on,0,0.5739474892616272
PRISTIQ,hyperhidrosis,ent-emergent ,1,0.5344417095184326
PRISTIQ,hyperhidrosis,defined as ent-emergent  supine diastolic blood pressure SDBP,1,0.5618652105331421
PRISTIQ,hyperhidrosis,ent-emergent  supine,1,0.5745622515678406
PRISTIQ,seizure,doses of to mg lic ort hostatic hypotension decrease mm,1,0.5134642124176025
PRISTIQ,seizure,ent-emergent  supine diastolic blood,1,0.5311617851257324
PRISTIQ,seizure,lic ort hostatic hypotension decrease mm Hg,1,0.5175723433494568
PRISTIQ,Hyponatremia,adverse reac,1,0.5171018838882446
PRISTIQ,Hyponatremia,adverse reac tion has been identified,1,0.5647129416465759
PRISTIQ,Hyponatremia,postapproval use of PRISTIQ Because these reactions are,0,0.5107793807983398
PRISTIQ,Hyponatremia,Postmarketing Experience The adverse reac,1,0.5143725275993347
PRISTIQ,hyponatremia,reactions are d voluntaril,1,0.47235774993896484
PRISTIQ,hyponatremia,d voluntaril y from a population of,1,0.44924598932266235
PRISTIQ,hyponatremia,are d,1,0.4835558533668518
PRISTIQ,hyponatremia,are d voluntaril,1,0.46372124552726746
PRISTIQ,hyponatremia,d voluntaril y,1,0.46135300397872925
PRISTIQ,hyponatremia,reactions are d,1,0.500384509563446
PRISTIQ,hyponatremia,these reactions are d,1,0.5121241807937622
PRISTIQ,SIADH,oluntarily from a,0,0.4719386696815491
PRISTIQ,SIADH, freq uency or establish,1,0.5150490999221802
PRISTIQ,SIADH, freq uency,1,0.5102444291114807
PRISTIQ,SIADH,to reliably estimate  freq uency or establish a causal,1,0.4821378290653229
PRISTIQ,SIADH,oluntarily from a population of uncertain size it is not always possible to reliably,0,0.4720735549926758
PRISTIQ,SIADH, freq uency or establish a,1,0.5069491863250732
PRISTIQ,SIADH,establish,0,0.510118842124939
PRISTIQ,SIADH, freq,1,0.512145459651947
PRISTIQ,SIADH,reliably estimate  freq uency or establish a causal,1,0.48432281613349915
PRISTIQ,serum sodium lower than 110 mmol/L,frequency or lish a causal relationship to drug exposure,1,0.5194476842880249
PRISTIQ,serum sodium lower than 110 mmol/L, freq,1,0.5248968601226807
PRISTIQ,serum sodium lower than 110 mmol/L,their frequency or lish a causal relationship to drug exposure Skin and subcutaneous,1,0.513397216796875
PRISTIQ,serum sodium lower than 110 mmol/L,lish a causal relationship,1,0.5107253193855286
PRISTIQ,serum sodium lower than 110 mmol/L,relationship to drug exposure Skin and subcutaneous,1,0.4872424900531769
PRISTIQ,serum sodium lower than 110 mmol/L,of uncertain size it is not,0,0.4773664176464081
PRISTIQ,serum sodium lower than 110 mmol/L,lish a causal,1,0.5193394422531128
PRISTIQ,serum sodium lower than 110 mmol/L,disorders StevensJohnson syndrome,0,0.49415016174316406
PRISTIQ,serum sodium lower than 110 mmol/L,subcutaneous tissue disorders StevensJohnson syndrome,0,0.5019263625144958
PRISTIQ,serum sodium lower than 110 mmol/L,lish a causal relationship to drug exposure Skin and subcutaneous,1,0.5207369327545166
TAFINLAR,Primary Malignancies,in another section of the label,0,0.4965701699256897
TAFINLAR,Primary Malignancies,Primary Malignancies see Warnings and Precautions Tumor,1,0.8480732440948486
TAFINLAR,Primary Malignancies,WildType,0,0.43896979093551636
TAFINLAR,Primary Malignancies,in,0,0.5285663604736328
TAFINLAR,Primary Malignancies,Primary Malignancies,1,1.0
TAFINLAR,Primary Malignancies,Primary Malignancies see Warnings and Precautions,1,0.860970139503479
TAFINLAR,Primary Malignancies,Precautions Tumor Promotion in BRAF WildType,0,0.623701274394989
TAFINLAR,Primary Malignancies,label Primary Malignancies see Warnings and,1,0.840868353843689
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,and Tumor Promotion in BRAF Wild-Type Melanoma see Warnings and Precautions Hemorrhage,1,0.8923088908195496
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,Precautions Tumor Promotion in BRAF WildType,0,0.916068434715271
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,and Tumor,1,0.6526767015457153
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,New,0,0.5265712738037109
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,and Tumor Promotion,1,0.7764320373535156
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,of the label,0,0.4554060399532318
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,see Warnings and Precautions,0,0.4523976445198059
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,Primary Malignancies see Warnings,0,0.6050941944122314
TAFINLAR,Hemorrhage,and,0,0.5080123543739319
TAFINLAR,Hemorrhage,see Warnings and Precautions Venous Thromboembolism see Warnings and,0,0.586310625076294
TAFINLAR,Hemorrhage,Precautions Venous Thromboembolism see,0,0.5888469815254211
TAFINLAR,Venous Thromboembolism,see Warnings,0,0.5064588189125061
TAFINLAR,Venous Thromboembolism,and Precautions,0,0.5173854827880859
TAFINLAR,Venous Thromboembolism,Venous Thromboembolism,1,0.9999998807907104
TAFINLAR,Venous Thromboembolism,Hemorrhage see Warnings and Venous,1,0.6687880754470825
TAFINLAR,Venous Thromboembolism,see Warnings and Venous Thromboembolism see Warnings and,1,0.8407981395721436
TAFINLAR,Venous Thromboembolism,see Warnings and Precautions Cardiomyopathy see,0,0.5305754542350769
TAFINLAR,Cardiomyopathy,and Precautions,0,0.4637523889541626
TAFINLAR,Ocular Toxicities,Cardiomyopathy,0,0.5655567049980164
TAFINLAR,Ocular Toxicities,Warnings and Ocular Toxicities,1,0.9252605438232422
TAFINLAR,Febrile Reactions,see Warnings and Precautions Febrile Reactions,1,0.9014900922775269
TAFINLAR,Febrile Reactions,and Precautions Serious Skin Toxicity,0,0.6166975498199463
TAFINLAR,Febrile Reactions,Warnings and,0,0.5684912204742432
TAFINLAR,Febrile Reactions,and Precautions Serious,0,0.5812162160873413
TAFINLAR,Febrile Reactions,and Precautions Febrile Reactions see Warnings and,1,0.8696544170379639
TAFINLAR,Febrile Reactions,and Precautions Febrile Reactions,1,0.9071369171142578
TAFINLAR,Skin Toxicity,Precautions Skin Toxicity see Warnings and Precautions,1,0.8480029106140137
TAFINLAR,Skin Toxicity,and Precautions Febrile Reactions,1,0.5665969848632812
TAFINLAR,Skin Toxicity,Hyperglycemia,0,0.5177434682846069
TAFINLAR,Skin Toxicity,and Precautions,0,0.5232111215591431
TAFINLAR,Skin Toxicity,see Warnings and Precautions Hyperglycemia,0,0.5587829947471619
TAFINLAR,Skin Toxicity,Hyperglycemia see Warnings and Precautions,0,0.5546343326568604
TAFINLAR,Skin Toxicity,Precautions Skin Toxicity,1,0.9096419811248779
TAFINLAR,Skin Toxicity,Skin Toxicity see Warnings,1,0.9206185936927795
TAFINLAR,Hyperglycemia,Hyperglycemia see,1,0.9331082105636597
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,see Warnings and Glucose-6-Phosphate,1,0.7487337589263916
TAFINLAR,hyperkeratosis,as a single agent hyperkeratosis,1,0.8863185048103333
TAFINLAR,hyperkeratosis,see Warnings and Glucose-6-Phosphate,1,0.5345552563667297
TAFINLAR,hyperkeratosis,headache pyrexia arthralgia papilloma alopecia and,0,0.6111322641372681
TAFINLAR,hyperkeratosis,hyperkeratosis headache pyrexia,1,0.7628759741783142
TAFINLAR,hyperkeratosis,single agent hyperkeratosis headache pyrexia,1,0.7491514682769775
TAFINLAR,hyperkeratosis,common adverse reactions for TAFINLAR as a single agent,0,0.5018157958984375
TAFINLAR,hyperkeratosis,palmarplantar erythrodysesthesia,0,0.58028244972229
TAFINLAR,hyperkeratosis,arthralgia papilloma alopecia and,0,0.6521947383880615
TAFINLAR,hyperkeratosis,alopecia and palmarplantar,0,0.6371307373046875
TAFINLAR,headache,headache pyrexia arthralgia,1,0.7630218267440796
TAFINLAR,headache,arthralgia papilloma alopecia,0,0.567475438117981
TAFINLAR,headache,TAFINLAR as a single agent are,0,0.5235549807548523
TAFINLAR,headache,agent are headache pyrexia arthralgia papilloma alopecia and,1,0.7232053279876709
TAFINLAR,headache,are headache pyrexia arthralgia papilloma,1,0.7111339569091797
TAFINLAR,headache,pyrexia arthralgia papilloma,0,0.5292375683784485
TAFINLAR,headache,headache pyrexia arthralgia papilloma alopecia and,1,0.7189892530441284
TAFINLAR,headache,headache,1,0.9999998807907104
TAFINLAR,pyrexia,pyrexia arthralgia papilloma alopecia,1,0.7927473187446594
TAFINLAR,pyrexia,TAFINLAR as a single agent are hyperkeratosis headache,0,0.5604144334793091
TAFINLAR,pyrexia,pyrexia arthralgia papilloma alopecia and palmarplantar,1,0.7640485763549805
TAFINLAR,pyrexia,alopecia,0,0.5316762924194336
TAFINLAR,pyrexia,pyrexia arthralgia papilloma,1,0.7593901753425598
TAFINLAR,pyrexia,and palmarplantar,0,0.5223119854927063
TAFINLAR,alopecia,palmarplantar erythrodysesthesia syndrome Most,0,0.5397673845291138
TAFINLAR,alopecia,erythrodysesthesia syndrome Most common,0,0.5200098752975464
TAFINLAR,alopecia,hyperkeratosis headache pyrexia arthralgia alopecia and,1,0.7509671449661255
TAFINLAR,alopecia,arthralgia alopecia and palmarplantar erythrodysesthesia syndrome,1,0.7454278469085693
TAFINLAR,alopecia,headache,0,0.5982310771942139
TAFINLAR,alopecia,single agent are hyperkeratosis headache pyrexia arthralgia,0,0.6212763786315918
TAFINLAR,alopecia,palmarplantar erythrodysesthesia syndrome Most common,0,0.5262150764465332
TAFINLAR,alopecia,agent are hyperkeratosis headache pyrexia,0,0.6040732860565186
TAFINLAR,alopecia,alopecia and palmarplantar,1,0.7908678650856018
TAFINLAR,alopecia,alopecia and palmarplantar erythrodysesthesia syndrome Most,1,0.7531027793884277
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,common adverse reactions for TAFINLAR in combination with trametinib,0,0.5396441221237183
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome Most common,1,0.9598519802093506
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,TAFINLAR,0,0.4675282835960388
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,erythrodysesthesia syndrome Most common,1,0.8273149728775024
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia,1,0.9416069388389587
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,papilloma alopecia and,0,0.5417548418045044
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,alopecia palmar-plantar erythrodysesthesia syndrome,1,0.9203183054924011
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome Most common adverse,1,0.9425175189971924
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,papilloma alopecia palmar-plantar,1,0.6981254816055298
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,erythrodysesthesia syndrome,1,0.8774870038032532
TAFINLAR,pyrexia,pyrexia chills fatigue rash nausea,1,0.8682467937469482
TAFINLAR,pyrexia,in combination with trametinib pyrexia,1,0.7617607116699219
TAFINLAR,pyrexia,pyrexia chills fatigue,1,0.8745065927505493
TAFINLAR,pyrexia,Most common adverse reactions for TAFINLAR in,0,0.5098026990890503
TAFINLAR,pyrexia,diarrhea abdominal pain peripheral edema cough headac,0,0.585174560546875
TAFINLAR,chills,adverse,0,0.5076675415039062
TAFINLAR,chills,edema cough headache arth,0,0.5247220993041992
TAFINLAR,chills,cough,0,0.5872958302497864
TAFINLAR,chills,fatigue,0,0.5319256782531738
TAFINLAR,chills,chills fatigue rash nausea,1,0.8256543874740601
TAFINLAR,chills,fatigue rash nausea vomiting diarrhea abdominal pain,0,0.5716288685798645
TAFINLAR,chills,in combination,0,0.5356756448745728
TAFINLAR,chills,Most common adverse reactions for TAFINLAR in combination with,0,0.5094242095947266
TAFINLAR,chills,are chills fatigue rash,1,0.7776174545288086
TAFINLAR,chills,chills fatigue rash nausea vomiting diarrhea,1,0.7761427164077759
TAFINLAR,fatigue,fatigue rash nausea vomiting diarrhea,1,0.7496107816696167
TAFINLAR,fatigue,fatigue rash nausea,1,0.8207619190216064
TAFINLAR,rash,TAFINLAR in combination with trametinib are pyrexia chills fatigue,0,0.621067464351654
TAFINLAR,nausea,nausea vomiting diarrhea,1,0.8330716490745544
TAFINLAR,nausea,nausea vomiting diarrhea abdominal pain,1,0.8021020293235779
TAFINLAR,nausea,TAFINLAR,0,0.4975786805152893
TAFINLAR,nausea,nausea,1,1.0
TAFINLAR,nausea,pyrexia chills fatigue nausea vomiting,1,0.778568685054779
TAFINLAR,nausea,e,0,0.5176461935043335
TAFINLAR,nausea,pyrexia chills fatigue nausea vomiting diarrhea abdominal pain,1,0.7373784780502319
TAFINLAR,nausea,nausea vomiting diarrhea abdominal,1,0.8180133700370789
TAFINLAR,nausea,nausea vomiting diarrhea abdominal pain peripheral,1,0.7663103342056274
TAFINLAR,vomiting,fatigue rash vomiting,1,0.8161266446113586
TAFINLAR,vomiting,nausea vomiting diarrhea abdominal pain peripheral,1,0.7510340809822083
TAFINLAR,vomiting,vomiting diarrhea abdominal pain peripheral,1,0.7551321983337402
TAFINLAR,vomiting,vomiting diarrhea abdominal pain,1,0.7925929427146912
TAFINLAR,vomiting,combination with trametinib are pyrexia chills fatigue rash,0,0.5784385800361633
TAFINLAR,vomiting,vomiting,1,0.9999999403953552
TAFINLAR,vomiting,night,0,0.5020125508308411
TAFINLAR,vomiting,trametinib are pyrexia chills,0,0.5904914140701294
TAFINLAR,vomiting,rash,0,0.6140508651733398
TAFINLAR,vomiting,vomiting diarrhea abdominal pain peripheral edema,1,0.7655084729194641
TAFINLAR,diarrhea,rash nausea diarrhea abdominal pain peripheral,1,0.734944224357605
TAFINLAR,diarrhea,vomiting diarrhea abdominal pain peripheral edema,1,0.7640993595123291
TAFINLAR,diarrhea,fatigue rash nausea diarrhea abdominal,1,0.7334712743759155
TAFINLAR,diarrhea,diarrhea abdominal,1,0.8145192265510559
TAFINLAR,diarrhea,night,0,0.54402756690979
TAFINLAR,diarrhea,in combination with trametinib are pyrexia chills,0,0.5406994223594666
TAFINLAR,diarrhea,diarrhea abdominal pain,1,0.8202997446060181
TAFINLAR,diarrhea,diarrhea abdominal pain peripheral edema,1,0.7839174270629883
TAFINLAR,abdominal pain,are pyrexia chills fatigue rash nausea vomiting,0,0.553969144821167
TAFINLAR,abdominal pain,abdominal pain peripheral edema cough headache arthralgia,1,0.7982268333435059
TAFINLAR,abdominal pain,abdominal pain peripheral edema cough headache,1,0.7879610657691956
TAFINLAR,abdominal pain,abdominal pain peripheral,1,0.847931981086731
TAFINLAR,abdominal pain,vomiting abdominal pain,1,0.8816165924072266
TAFINLAR,abdominal pain,in combination with trametinib are,0,0.5186309814453125
TAFINLAR,abdominal pain,fatigue rash nausea vomiting abdominal pain peripheral edema cough headache arthralgia,1,0.6770047545433044
TAFINLAR,peripheral edema,nausea vomiting diarrhea abdominal peripheral,1,0.6714235544204712
TAFINLAR,peripheral edema,headache arthralgia,0,0.5898823738098145
TAFINLAR,cough,edema,0,0.5597254037857056
TAFINLAR,cough,peripheral,0,0.49138855934143066
TAFINLAR,arthralgia,sweats decreased appetite constipation and,0,0.5009799003601074
TAFINLAR,arthralgia,arthralgia night sweats decreased,1,0.7737847566604614
TAFINLAR,night sweats,arthralgia,0,0.5076186656951904
TAFINLAR,night sweats,headache night sweats decreased appetite constipation,1,0.7401143908500671
TAFINLAR,night sweats,diarrhea abdominal pain peripheral edema cough,0,0.5603576898574829
TAFINLAR,night sweats,To report,0,0.4951176941394806
TAFINLAR,night sweats,constipation and myalgia EXCERPT To report SUSPECTED A,0,0.5313369035720825
TAFINLAR,night sweats,headache night sweats decreased appetite,1,0.7614381909370422
TAFINLAR,night sweats,report SUSPECTED A,0,0.4945562481880188
TAFINLAR,decreased appetite,report SUSPECTED ADVERSE,0,0.5178104639053345
TAFINLAR,decreased appetite,night decreased appetite,1,0.8767974376678467
TAFINLAR,decreased appetite,decreased appetite constipation,1,0.8846323490142822
TAFINLAR,decreased appetite,peripheral,0,0.5125735402107239
TAFINLAR,decreased appetite,headache arthralgia,0,0.5225815773010254
TAFINLAR,decreased appetite,sweats,0,0.5417640209197998
TAFINLAR,decreased appetite,headache arthralgia night decreased appetite,1,0.8075923919677734
TAFINLAR,decreased appetite,decreased,1,0.7124267816543579
TAFINLAR,decreased appetite,vomiting diarrhea abdominal pain peripheral edema cough headache arthralgia night,0,0.6177173256874084
TAFINLAR,constipation,constipation and myalgia EXCERPT,1,0.7919500470161438
TAFINLAR,constipation,a abdominal,0,0.5975669622421265
TAFINLAR,constipation,REACTIONS contact,0,0.4788200259208679
TAFINLAR,constipation,sweats decreased constipation,1,0.7925904989242554
TAFINLAR,constipation,constipation and myalgia,1,0.8149057626724243
TAFINLAR,constipation,SUSPECTED ADVERSE,0,0.5786075592041016
TAFINLAR,constipation,constipation,1,1.0000001192092896
TAFINLAR,myalgia,myalgia EXCERPT To,1,0.901165783405304
TAFINLAR,myalgia,myalgia,1,0.9999996423721313
TAFINLAR,myalgia,myalgia EXCERPT,1,0.9142522215843201
TAFINLAR,myalgia,myalgia EXCERPT To report SUSPECTED,1,0.8237659931182861
TAFINLAR,myalgia,contact,0,0.511900782585144
TAFINLAR,hyperkeratosis,papilloma alopecia and palmarplantar erythrodysesthesia syndrome,0,0.6448774933815002
TAFINLAR,hyperkeratosis,in order of decreasing hyperkeratosis headache pyrexia arthralgia,1,0.7653783559799194
TAFINLAR,hyperkeratosis,adverse reactions in patients treated with TAFINLAR were in order of decreasing frequency,0,0.5008121132850647
TAFINLAR,hyperkeratosis,hyperkeratosis headache pyrexia arthralgia papilloma alopecia,1,0.7819704413414001
TAFINLAR,hyperkeratosis,hyperkeratosis,1,1.0000001192092896
TAFINLAR,hyperkeratosis,decreasing frequency,0,0.49603500962257385
TAFINLAR,headache,in,0,0.5469977855682373
TAFINLAR,headache,of decreasing,0,0.47090500593185425
TAFINLAR,headache,headache pyrexia arthralgia papilloma alopecia,1,0.727817177772522
TAFINLAR,pyrexia,with TAFINLAR were,0,0.5244342088699341
TAFINLAR,pyrexia,pyrexia arthralgia,1,0.877504825592041
TAFINLAR,pyrexia,PPES The in,0,0.570000410079956
TAFINLAR,alopecia,alopecia and palmarplantar erythrodysesthesia syndrome PPES,1,0.7277448177337646
TAFINLAR,alopecia,headache pyrexia arthralgia alopecia and,1,0.7711762189865112
TAFINLAR,alopecia,alopecia and,1,0.9345930814743042
TAFINLAR,alopecia,hyperkeratosis headache pyrexia arthralgia alopecia and palmarplantar,1,0.7143063545227051
TAFINLAR,alopecia,alopecia,1,1.0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,of decreasing frequency hyperkeratosis headache pyrexia arthralgia papilloma,0,0.638996422290802
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,The incidence of adverse events resulting in,0,0.5508669018745422
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,pyrexia arthralgia,0,0.6125776171684265
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,The incidence of adverse events resulting in permanent discontinuation of study,0,0.5519231557846069
TAFINLAR,PPES,PPES The incidence of adverse events,1,0.8049497008323669
TAFINLAR,PPES,PPES,1,1.0
TAFINLAR,PPES,PPES The incidence of adverse,1,0.8118963241577148
TAFINLAR,PPES,papilloma alopecia and,0,0.5608315467834473
TAFINLAR,PPES,and palmarplantar erythrodysesthesia,0,0.522486686706543
TAFINLAR,PPES,PPES The,1,0.9665642976760864
TAFINLAR,pyrexia,pyrexia PPES chills fatigue and,1,0.8414887189865112
TAFINLAR,pyrexia,PPES The incidence of adverse,1,0.5449923276901245
TAFINLAR,pyrexia,pyrexia PPES,1,0.8545370101928711
TAFINLAR,pyrexia,reduction of TAFINLAR pyrexia PPES chills fatigue and,1,0.7881288528442383
TAFINLAR,pyrexia,most frequent adverse reactions leading to dose reduction of TAFINLAR,0,0.5108001232147217
TAFINLAR,pyrexia,reduction of TAFINLAR pyrexia,1,0.8100066184997559
TAFINLAR,pyrexia,chills fatigue and headache Table,0,0.6517896056175232
TAFINLAR,PPES,leading to dose reduction,0,0.5611559748649597
TAFINLAR,chills,chills fatigue and headache Table,1,0.7239686250686646
TAFINLAR,chills,chills fatigue and,1,0.8506633043289185
TAFINLAR,fatigue,fatigue and headache Table Selected,1,0.7696679830551147
TAFINLAR,fatigue,fatigue and,1,0.9332206845283508
TAFINLAR,fatigue,Adverse Reactions Occurring,0,0.5333883166313171
TAFINLAR,fatigue,Occurring in All Gra,0,0.5328775644302368
TAFINLAR,fatigue,fatigue and headache,1,0.8380155563354492
TAFINLAR,fatigue,PPES fatigue and headache Table Selected Common,1,0.7135900259017944
TAFINLAR,fatigue,pyrexia PPES chills,0,0.5308617353439331
TAFINLAR,fatigue,chills,0,0.5319256782531738
TAFINLAR,headache,fatigue and,0,0.5872812271118164
TAFINLAR,headache,chills fatigue headache,1,0.7893843650817871
TAFINLAR,headache,Reactions Occurring in All Grades,0,0.5219595432281494
TAFINLAR,headache,to dose reduction of TAFINLAR were pyrexia PPES chills fatigue,0,0.5691853165626526
TAFINLAR,headache,headache Table Selected,1,0.7865661382675171
TAFINLAR,headache,dose reduction of TAFINLAR were pyrexia PPES,0,0.5252070426940918
TAFINLAR,hyperkeratosis,hyperkeratosis n and constipation n,1,0.8535147905349731
TAFINLAR,hyperkeratosis,skin papilloma and papilloma d,0,0.6611049175262451
TAFINLAR,hyperkeratosis,hyperkeratosis n and,1,0.9235882759094238
TAFINLAR,hyperkeratosis,constipation n c Includes skin papilloma and,0,0.6132923364639282
TAFINLAR,hyperkeratosis,n c,0,0.45613527297973633
TAFINLAR,constipation,n,0,0.5436203479766846
TAFINLAR,papilloma,papilloma d Includes,1,0.8302664160728455
TAFINLAR,papilloma,papilloma d Includes squamous cell carcinoma,1,0.7953616380691528
TAFINLAR,papilloma,skin papilloma papilloma d Includes squamous cell,1,0.7831549644470215
TAFINLAR,papilloma,papilloma,1,1.0000001192092896
TAFINLAR,papilloma,to hyperkeratosis n and constipation n c,0,0.5487797260284424
TAFINLAR,squamous cell carcinoma of the skin,Includes skin papilloma,0,0.7315601706504822
TAFINLAR,squamous cell carcinoma of the skin,cutaneous squamous cell carcinoma were required to,0,0.8788731098175049
TAFINLAR,squamous cell carcinoma of the skin,papilloma d squamous cell carcinoma of the skin and keratoacanthoma,1,0.8449544906616211
TAFINLAR,squamous cell carcinoma of the skin,skin papilloma and papilloma d,0,0.7292984127998352
TAFINLAR,squamous cell carcinoma of the skin,carcinoma were,0,0.7147013545036316
TAFINLAR,squamous cell carcinoma of the skin,papilloma d squamous cell carcinoma of the,1,0.7576022148132324
TAFINLAR,squamous cell carcinoma of the skin,the skin and,1,0.7418226003646851
TAFINLAR,squamous cell carcinoma of the skin,cutaneous squamous cell carcinoma were,0,0.9359367489814758
TAFINLAR,squamous cell carcinoma of the skin,d squamous cell,1,0.6909226179122925
TAFINLAR,keratoacanthoma,be reported as Grade per pr,0,0.4383732080459595
TAFINLAR,keratoacanthoma,skin keratoacanthoma e Cases of,1,0.9328653812408447
TAFINLAR,keratoacanthoma,keratoacanthoma e Cases,1,0.9295417666435242
TAFINLAR,keratoacanthoma,keratoacanthoma e Cases of cutaneous,1,0.9410536289215088
TAFINLAR,keratoacanthoma,skin papilloma and papilloma d Includes squamous cell carcinoma of the,0,0.6921835541725159
TAFINLAR,keratoacanthoma,keratoacanthoma e Cases of,1,0.9365981817245483
TAFINLAR,cutaneous squamous cell carcinoma,not applicable,0,0.44225233793258667
TAFINLAR,cutaneous squamous cell carcinoma,Includes squamous cell carcinoma of the,0,0.8455734252929688
TAFINLAR,hypophosphatemia,hypophosphatemia n Other clinically important adverse,1,0.8421096801757812
TAFINLAR,hypophosphatemia,laboratory abnormality limited hypophosphatemia n Other clinically,1,0.8730409145355225
TAFINLAR,hypophosphatemia,abnormality limited hypophosphatemia n Other clinically important adverse,1,0.8446742296218872
TAFINLAR,hypophosphatemia,Grade laboratory abnormality limited hypophosphatemia,1,0.8876161575317383
TAFINLAR,hypophosphatemia,hypophosphatemia n Other clinically,1,0.8994784355163574
TAFINLAR,hypophosphatemia,hypophosphatemia,1,1.0000001192092896
TAFINLAR,hypophosphatemia,limited to,0,0.4729519486427307
TAFINLAR,bullous rash,bullous rash Renal,1,0.8214609622955322
TAFINLAR,bullous rash,limited to,0,0.45009636878967285
TAFINLAR,bullous rash,Hypersensitivity manifesting bullous rash,1,0.8880940079689026
TAFINLAR,bullous rash,ntestinal Disorders Pancreatitis,0,0.45269840955734253
TAFINLAR,bullous rash,Disorders Hypersensitivity manifesting bullous rash Renal and Urinary Disorders Interstitial,1,0.7596240639686584
TAFINLAR,bullous rash,Disorders Hypersensitivity manifesting bullous rash Renal,1,0.785125732421875
TAFINLAR,bullous rash,System Disorders,0,0.501710057258606
TAFINLAR,bullous rash,Hypersensitivity manifesting bullous,1,0.8527668118476868
TAFINLAR,bullous rash,and,0,0.47971564531326294
TAFINLAR,bullous rash,Urinary Disorders Interstitial nephritis BRAF VE or,0,0.5624806880950928
TAFINLAR,bullous rash,manifesting bullous,1,0.753929615020752
TAFINLAR,Interstitial nephritis,Disorders Hypersensitivity manifesting as bullous rash,0,0.5739434957504272
TAFINLAR,Interstitial nephritis,Interstitial nephritis,1,1.0
TAFINLAR,Interstitial nephritis,Interstitial nephritis BRAF VE,1,0.9052818417549133
TAFINLAR,Interstitial nephritis,Interstitial nephritis BRAF VE or VK Unresectable,1,0.8350328207015991
TAFINLAR,Interstitial nephritis,Interstitial nephritis BRAF VE or,1,0.9282305240631104
TAFINLAR,Interstitial nephritis,bullous rash,0,0.558681309223175
TAFINLAR,Interstitial nephritis,Urinary Interstitial,1,0.830663800239563
TAFINLAR,Interstitial nephritis,Interstitial nephritis BRAF VE or VK,1,0.8687303066253662
TAFINLAR,Interstitial nephritis,VE or VK Unresectable or Metastatic Melanoma The,0,0.49216771125793457
TAFINLAR,Interstitial nephritis,Renal and Urinary Interstitial nephritis BRAF VE,1,0.913581371307373
TAFINLAR,pyrexia,led to dose reductions in and dose,0,0.5248860120773315
TAFINLAR,pyrexia,Adverse reactions led to,0,0.5465437769889832
TAFINLAR,pyrexia,discontinuation pyrexia Adverse,1,0.8032271265983582
TAFINLAR,pyrexia,interruptions,0,0.49885717034339905
TAFINLAR,Pyrexia,Pyrexia,1,1.0000001192092896
TAFINLAR,Pyrexia,in combination with Pyrexia chills,1,0.8641208410263062
TAFINLAR,chills,chills and decreas,0,0.9342026710510254
TAFINLAR,nausea,and pyrexia,0,0.6461712121963501
TAFINLAR,nausea,in combination,0,0.5352102518081665
TAFINLAR,nausea,nausea were the most,1,0.899040937423706
TAFINLAR,nausea,reductions,0,0.5136265158653259
TAFINLAR,pyrexia,dose reductions pyrexia chills and decreased ejection,1,0.7719111442565918
TAFINLAR,pyrexia,reductions,0,0.49801844358444214
TAFINLAR,pyrexia,pyrexia chills,1,0.9102816581726074
TAFINLAR,pyrexia,cited for,0,0.47661495208740234
TAFINLAR,pyrexia,dose reductions pyrexia,1,0.8541029095649719
TAFINLAR,pyrexia,for dose reductions pyrexia chills and decreased ejection fraction,1,0.7522996664047241
TAFINLAR,peripheral edema,the,0,0.5091594457626343
TAFINLAR,peripheral edema,terms rash rash generalized rash,0,0.5613158941268921
TAFINLAR,peripheral edema,the following peripheral edema edema and lymphedema,1,0.9041972160339355
TAFINLAR,peripheral edema,peripheral edema edema and,1,0.9644557237625122
TAFINLAR,peripheral edema,rash,0,0.568449854850769
TAFINLAR,peripheral edema,Events version,0,0.46064913272857666
TAFINLAR,lymphedema,lymphedema c Includes the following,1,0.8551725149154663
TAFINLAR,lymphedema,lymphedema c Includes,1,0.8561389446258545
TAFINLAR,lymphedema,lymphedema c Includes the following terms,1,0.8293291926383972
TAFINLAR,lymphedema,lymphedema,1,1.0
TAFINLAR,lymphedema,peripheral edema edema lymphedema,1,0.8796582221984863
TAFINLAR,rash,erythematous rash papular rash vesicular rash,0,0.7779062986373901
TAFINLAR,rash,rash rash generalized rash pruritic,1,0.8450002670288086
TAFINLAR,rash,rash rash generalized rash pruritic rash,1,0.844205915927887
TAFINLAR,rash,rash rash generalized rash,1,0.8608335256576538
TAFINLAR,rash,rash vesicular,0,0.8321149349212646
TAFINLAR,rash generalized,rash generalized,1,1.0
TAFINLAR,rash pruritic,rash pruritic,1,1.000000238418579
TAFINLAR,rash pruritic,rash papular rash vesicular rash macular,0,0.7591224312782288
TAFINLAR,rash pruritic,rash,0,0.8689223527908325
TAFINLAR,rash erythematous,dema and lymphedema c Includes the following,0,0.5651648044586182
TAFINLAR,rash erythematous,rash rash generalized rash rash erythematous rash papular rash,1,0.8563043475151062
TAFINLAR,rash erythematous,rash rash erythematous rash,1,0.9722155332565308
TAFINLAR,rash erythematous,papular rash,0,0.7709236741065979
TAFINLAR,rash erythematous,terms rash rash generalized rash pruritic,0,0.7701977491378784
TAFINLAR,rash erythematous,macular and rash maculopapular d Includes,0,0.6311098337173462
TAFINLAR,rash erythematous,papular rash vesicular,0,0.7085426449775696
TAFINLAR,rash papular,following terms rash rash,0,0.7824349403381348
TAFINLAR,rash papular,the following terms,0,0.48472535610198975
TAFINLAR,rash vesicular,pruritic rash erythematous rash rash vesicular rash macular and rash maculopapular,1,0.8213508129119873
TAFINLAR,rash vesicular,the following terms,0,0.4779198169708252
TAFINLAR,rash vesicular,rash erythematous rash rash vesicular,1,0.9470539093017578
TAFINLAR,rash vesicular,erythematous rash rash vesicular,1,0.9448031187057495
TAFINLAR,rash vesicular,rash vesicular,1,0.9999999403953552
TAFINLAR,rash vesicular,rash rash,0,0.809415876865387
TAFINLAR,rash vesicular,rash rash generalized rash pruritic rash erythematous rash papular,0,0.7536919116973877
TAFINLAR,rash vesicular,maculopapular d Includes the following terms abdominal pain,0,0.5412083864212036
TAFINLAR,rash vesicular,rash vesicular rash,1,0.9806627035140991
TAFINLAR,rash macular,pruritic rash erythematous rash papular rash vesicular,0,0.6744480133056641
TAFINLAR,rash macular,papular rash rash,1,0.7127484679222107
TAFINLAR,rash macular,abdominal pain,0,0.4695526659488678
TAFINLAR,rash macular,rash macular and rash,1,0.9707970023155212
TAFINLAR,rash macular,rash pruritic rash,0,0.6737441420555115
TAFINLAR,rash macular,rash macular and rash maculopapular,1,0.9326000213623047
TAFINLAR,rash macular,pain,0,0.49271243810653687
TAFINLAR,rash maculo-papular,Includes the following terms abdominal pain abdominal pain upper abdominal pain,0,0.49078568816185
TAFINLAR,rash maculo-papular,rash maculo-papular d,1,0.9301693439483643
TAFINLAR,rash maculo-papular,pain,0,0.4839564561843872
TAFINLAR,rash maculo-papular,rash vesicular rash,0,0.7019344568252563
TAFINLAR,rash maculo-papular,rash maculo-papular d Includes the following,1,0.9152571558952332
TAFINLAR,abdominal pain upper,pain,0,0.6561351418495178
TAFINLAR,abdominal pain upper,abdominal pain lower and abdominal discomfort e Includes the following terms brain,0,0.7576289176940918
TAFINLAR,abdominal pain upper,following terms brain stem,0,0.5021703243255615
TAFINLAR,abdominal pain lower,abdominal pain abdominal pain abdominal pain lower,1,0.9715902805328369
TAFINLAR,abdominal pain lower,pain abdominal pain lower,1,0.9907602071762085
TAFINLAR,abdominal pain lower,maculopapular d Includes the following terms abdominal pain,0,0.6969630718231201
TAFINLAR,abdominal pain lower,abdominal pain lower,1,0.9999998211860657
TAFINLAR,abdominal discomfort,terms brain,0,0.46523523330688477
TAFINLAR,abdominal discomfort,abdominal discomfort e,1,0.9264794588088989
TAFINLAR,abdominal discomfort,e Includes the following,0,0.4710399806499481
TAFINLAR,abdominal discomfort,pain lower abdominal discomfort,1,0.9127873778343201
TAFINLAR,abdominal discomfort,abdominal,0,0.8028988838195801
TAFINLAR,brain stem hemorrhage,brain stem hemorrhage cerebral hemorrhage gastric,1,0.9182923436164856
TAFINLAR,brain stem hemorrhage,brain,1,0.6938852071762085
TAFINLAR,brain stem hemorrhage,brain stem hemorrhage cerebral,1,0.957816481590271
TAFINLAR,brain stem hemorrhage,e Includes the following brain,1,0.6353352069854736
TAFINLAR,brain stem hemorrhage,hematuria,0,0.5861397385597229
TAFINLAR,brain stem hemorrhage,gingival hemorrhage hematuria vaginal hemorr,0,0.6493434906005859
TAFINLAR,cerebral hemorrhage,hemorrhage hematuria vaginal hemorrhage hemorrhage intr,0,0.6729044318199158
TAFINLAR,cerebral hemorrhage,gastric hemorrhage epistaxis,0,0.6543077826499939
TAFINLAR,cerebral hemorrhage,cerebral hemorrhage gastric hemorrhage epistaxis gingival hemorrhage,1,0.8079220056533813
TAFINLAR,cerebral hemorrhage,stem cerebral,1,0.6834924817085266
TAFINLAR,gastric hemorrhage,gastric hemorrhage epistaxis gingival,1,0.8188027143478394
TAFINLAR,gastric hemorrhage,hemorrhage cerebral gastric hemorrhage epistaxis gingival hemorrhage hematuria vaginal,1,0.7864551544189453
TAFINLAR,gastric hemorrhage,brain stem hemorrhage cerebral gastric hemorrhage epistaxis,1,0.784396231174469
TAFINLAR,gastric hemorrhage,brain stem hemorrhage cerebral gastric hemorrhage,1,0.8445972204208374
TAFINLAR,gastric hemorrhage,stem hemorrhage cerebral gastric hemorrhage epistaxis gingival,1,0.7930476665496826
TAFINLAR,gastric hemorrhage,cerebral,0,0.5026340484619141
TAFINLAR,gastric hemorrhage,hemorrhage cerebral hemorrhage,0,0.7085262537002563
TAFINLAR,gastric hemorrhage,brain stem hemorrhage cerebral gastric hemorrhage epistaxis gingival hemorrhage hematuria vaginal,1,0.7580567002296448
TAFINLAR,gastric hemorrhage,hemorrhage,0,0.8111099600791931
TAFINLAR,epistaxis,hemorrhage gastric epistaxis gingival hemorrhage hematuria,1,0.7479435205459595
TAFINLAR,epistaxis,hemorrhage,0,0.5992766618728638
TAFINLAR,epistaxis,epistaxis gingival hemorrhage hematuria vaginal hemorrhage,1,0.7620708346366882
TAFINLAR,epistaxis,epistaxis gingival hemorrhage,1,0.8546054363250732
TAFINLAR,epistaxis,epistaxis,1,1.000000238418579
TAFINLAR,gingival hemorrhage,hemorrhage gingival hemorrhage,1,0.9872164726257324
TAFINLAR,gingival hemorrhage,hemorrhage gingival hemorrhage hematuria vaginal hemorrhage hemorrhage,1,0.8557178974151611
TAFINLAR,gingival hemorrhage,eye hemorrhage and,0,0.6865091323852539
TAFINLAR,hematuria,hemorrhage epistaxis gingival hematuria vaginal hemorrhage hemorrhage intracranial,1,0.7338091135025024
TAFINLAR,hematuria,eye hemorrhage and,0,0.6294779777526855
TAFINLAR,hematuria,hematuria vaginal hemorrhage hemorrhage intracranial,1,0.7958328127861023
TAFINLAR,hematuria,hematuria vaginal hemorrhage hemorrhage intracranial eye,1,0.8028063178062439
TAFINLAR,hematuria,vaginal hemorrhage hemorrhage intracranial,0,0.6352977752685547
TAFINLAR,hematuria,cerebral hemorrhage,0,0.6322335004806519
TAFINLAR,hematuria,epistaxis gingival hematuria,1,0.740138053894043
TAFINLAR,hematuria,hematuria vaginal,1,0.8677421808242798
TAFINLAR,hematuria,intracranial eye hemorrhage and,0,0.5840238928794861
TAFINLAR,hematuria,eye,0,0.4941539764404297
TAFINLAR,vaginal hemorrhage,gastric hemorrhage epistaxis gingival,0,0.6497648358345032
TAFINLAR,hemorrhage intracranial,hemorrhage intracranial,1,0.9999997615814209
TAFINLAR,hemorrhage intracranial,vaginal hemorrhage intracranial,1,0.8619633913040161
TAFINLAR,hemorrhage intracranial,gingival hemorrhage hematuria vaginal hemorrhage intracranial,1,0.806443989276886
TAFINLAR,eye hemorrhage,hemorrhage hemorrhage eye hemorrhage,1,0.9741449356079102
TAFINLAR,eye hemorrhage,vaginal hemorrhage intracranial,1,0.6346840858459473
TAFINLAR,eye hemorrhage,hematuria vaginal hemorrhage hemorrhage eye hemorrhage and vitreous,1,0.8014868497848511
TAFINLAR,eye hemorrhage,hemorrhage hematuria vaginal hemorrhage,0,0.6857282519340515
TAFINLAR,eye hemorrhage,eye hemorrhage and vitreous hemorrhage,1,0.8903294801712036
TAFINLAR,eye hemorrhage,following terms renal failure and,0,0.534909725189209
TAFINLAR,eye hemorrhage,hematuria vaginal hemorrhage hemorrhage eye hemorrhage,1,0.8181432485580444
TAFINLAR,vitreous hemorrhage,hemorrhage vitreous hemorrhage,1,0.9859150648117065
TAFINLAR,vitreous hemorrhage,following terms renal failure and,0,0.5113751292228699
TAFINLAR,vitreous hemorrhage,vitreous hemorrhage f Includes,1,0.9324754476547241
TAFINLAR,vitreous hemorrhage,hemorrhage intracranial eye hemorrhage vitreous hemorrhage,1,0.9248224496841431
TAFINLAR,vitreous hemorrhage,intracranial eye hemorrhage vitreous hemorrhage f Includes,1,0.9061241745948792
TAFINLAR,vitreous hemorrhage,vaginal hemorrhage hemorrhage intracranial,0,0.6287145018577576
TAFINLAR,renal failure,renal failure and renal failure acute Other,1,0.8367122411727905
TAFINLAR,renal failure,vitreous hemorrhage f,0,0.5176639556884766
TAFINLAR,renal failure,eye hemorrhage and vitreous,0,0.5425373911857605
TAFINLAR,renal failure,hemorrhage and vitreous hemorrhage,0,0.5698745250701904
TAFINLAR,renal failure,the following renal failure,1,0.9142597317695618
TAFINLAR,renal failure,renal failure and,1,0.9442847371101379
TAFINLAR,renal failure,terms,0,0.4368124008178711
TAFINLAR,renal failure,Includes the following renal failure,1,0.9275705814361572
TAFINLAR,renal failure,following renal,1,0.7830478549003601
TAFINLAR,renal failure acute,renal failure acute Other clinically,1,0.9243716597557068
TAFINLAR,renal failure acute,renal failure acute Other clinically important adverse reactions,1,0.8425645232200623
TAFINLAR,renal failure acute,failure acute,1,0.7742786407470703
TAFINLAR,renal failure acute,following terms renal failure,0,0.8012816905975342
TAFINLAR,renal failure acute,failure acute Other,1,0.7266238927841187
TAFINLAR,renal failure acute,failure renal failure acute,1,0.9765065908432007
TAFINLAR,renal failure acute,and vitreous hemorrhage f Includes the,0,0.5310543775558472
TAFINLAR,renal failure acute,renal failure renal failure acute Other clinically important adverse reactions,1,0.8469994068145752
TAFINLAR,renal failure acute,renal failure renal,1,0.8415330052375793
TAFINLAR,Vision blurred,Gastrointestinal,0,0.4607502222061157
TAFINLAR,Vision blurred,blindness,0,0.7934509515762329
TAFINLAR,Vision blurred,were,0,0.5100084543228149
TAFINLAR,Vision blurred,trametinib were Eye Vision blurred,1,0.7822723984718323
TAFINLAR,Vision blurred,in combination,0,0.5157853364944458
TAFINLAR,Vision blurred,patients treated with TAFINLAR in combination with trametinib,0,0.48856112360954285
TAFINLAR,transient blindness,Gastrointestinal Disorders Stomatitis pancreatitis General Disorders and,0,0.4794745445251465
TAFINLAR,transient blindness,Eye Disorders Vision transient blindness,1,0.9328460097312927
TAFINLAR,transient blindness,Disorders and Administr,0,0.5229893326759338
TAFINLAR,transient blindness,Disorders,0,0.5663959383964539
TAFINLAR,transient blindness,were Eye Disorders Vision transient,1,0.8697744011878967
TAFINLAR,transient blindness,combination with trametinib were Eye Disorders,0,0.6616582870483398
TAFINLAR,transient blindness,Vision transient,1,0.9211958050727844
TAFINLAR,transient blindness,Vision transient blindness Gastrointestinal Disorders Stomatitis pancreatitis,1,0.7745062112808228
TAFINLAR,Stomatitis,transient blindness Gastrointestinal Stomatitis pancreatitis General Disorders and Administration,1,0.6098127365112305
TAFINLAR,Stomatitis,Vision transient,1,0.4620135724544525
TAFINLAR,Stomatitis,Vision blurred,0,0.45785558223724365
TAFINLAR,Stomatitis,Stomatitis pancreatitis,1,0.8083123564720154
TAFINLAR,Stomatitis,Stomatitis,1,1.0
TAFINLAR,Stomatitis,Stomatitis pancreatitis General Disorders and Administration,1,0.7518290281295776
TAFINLAR,Stomatitis,blurred transient blindness Gastrointestinal Stomatitis pancreatitis General,1,0.6368129253387451
TAFINLAR,Stomatitis,Stomatitis pancreatitis General Disorders and,1,0.7792749404907227
TAFINLAR,Stomatitis,Disorders Vision blurred,0,0.47823306918144226
TAFINLAR,pancreatitis,pancreatitis,1,0.9999998211860657
TAFINLAR,pancreatitis,Eye Disorders Vision,0,0.48573845624923706
TAFINLAR,pancreatitis,Stomatitis,0,0.6072069406509399
TAFINLAR,pancreatitis,pancreatitis General Disorders and Administration Site,1,0.7979387044906616
TAFINLAR,pancreatitis,pancreatitis General,1,0.9009006023406982
TAFINLAR,pancreatitis,Site Conditions,0,0.47784730792045593
TAFINLAR,pancreatitis,pancreatitis General Disorders and Administration,1,0.8116825819015503
TAFINLAR,pancreatitis,Eye Disorders Vision blurred,0,0.4730033576488495
TAFINLAR,Asthenia,Asthenia,1,1.0000001192092896
TAFINLAR,Asthenia,Administration Site Asthenia Infections and Infestations Cellulitis,1,0.716278612613678
TAFINLAR,Asthenia,and Administration Site Asthenia,1,0.8095965385437012
TAFINLAR,Asthenia,Asthenia Infections and Infestations Cellulitis folliculitis,1,0.7637031674385071
TAFINLAR,Asthenia,Infections and Infestations Cellulitis folliculitis paronychia rash,0,0.5707439184188843
TAFINLAR,Asthenia,Administration Site Asthenia Infections,1,0.7989063262939453
TAFINLAR,Asthenia,Asthenia Infections and,1,0.8892074227333069
TAFINLAR,Asthenia,and Administration Site Conditions,0,0.5418373346328735
TAFINLAR,Asthenia,Asthenia Infections and Infestations Cellulitis,1,0.7679584622383118
TAFINLAR,Asthenia,Disorders and Administration,0,0.5667911767959595
TAFINLAR,Cellulitis,and Cellulitis folliculitis paronychia rash,1,0.719161868095398
TAFINLAR,Cellulitis,Disorders and Administration,0,0.5105020999908447
TAFINLAR,Cellulitis,Conditions,0,0.6084230542182922
TAFINLAR,Cellulitis,Cellulitis folliculitis paronychia rash,1,0.7203090190887451
TAFINLAR,Cellulitis,and Cellulitis,1,0.9203998446464539
TAFINLAR,Cellulitis,paronychia rash pustular Neoplasms Benign Malignant and Unspecified,0,0.5402090549468994
TAFINLAR,Cellulitis,and,0,0.520575761795044
TAFINLAR,Cellulitis,Cellulitis folliculitis paronychia rash pustular,1,0.7008873224258423
TAFINLAR,Cellulitis,and Infestations,0,0.5373010039329529
TAFINLAR,folliculitis,Conditions Asthenia Infections and Infestations Cellulitis,0,0.658744215965271
TAFINLAR,folliculitis,folliculitis paronychia rash pustular Neoplasms,1,0.772232174873352
TAFINLAR,paronychia,Malignant and Unspecified including cysts and polyps S,0,0.5284950137138367
TAFINLAR,paronychia,Infections and Infestations Cellulitis folliculitis,0,0.5933235883712769
TAFINLAR,rash pustular,folliculitis rash pustular Neoplasms Benign Malignant and,1,0.8267598152160645
TAFINLAR,rash pustular,Infections and Infestations Cellulitis folliculitis,0,0.6264299154281616
TAFINLAR,rash pustular,rash pustular,1,0.9999999403953552
TAFINLAR,rash pustular,Malignant and Unspecified including cysts and polyps Skin,0,0.621706485748291
TAFINLAR,rash pustular,Cellulitis folliculitis rash pustular,1,0.8973596096038818
TAFINLAR,Skin papilloma,polyps,0,0.6126129627227783
TAFINLAR,Skin papilloma,Skin and Subcutaneous Tissue Disorders Palmarplantar erythrodysesthesia,0,0.6181138157844543
TAFINLAR,Skin papilloma,Tissue Disorders Palmarplantar erythrodysesthesia,0,0.5654693841934204
TAFINLAR,Skin papilloma,Unspecified including cysts and Skin papilloma,1,0.8274352550506592
TAFINLAR,Skin papilloma,including cysts and Skin papilloma Skin and Subcutaneous Tissue Disorders,1,0.8492769002914429
TAFINLAR,Skin papilloma,pustular Neoplasms Benign Malignant and,0,0.6445159912109375
TAFINLAR,Skin papilloma,Skin papilloma Skin and Subcutaneous Tissue Disorders,1,0.9039220809936523
TAFINLAR,Skin papilloma,erythrodysesthesia,0,0.44354042410850525
TAFINLAR,Skin papilloma,and Skin papilloma,1,0.9572457075119019
TAFINLAR,Skin papilloma,cysts and Skin papilloma Skin and Subcutaneous Tissue,1,0.8773735761642456
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome hyperkeratosis hyperhidrosis Vascular Disorders Hypertension,1,0.9086284637451172
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,and Skin papilloma,1,0.5523784160614014
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome hyperkeratosis hyperhidrosis Vascular,1,0.9214115142822266
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,Disorders Hypertension,0,0.5770547389984131
TAFINLAR,hyperkeratosis,Table,0,0.5142176151275635
TAFINLAR,hyperkeratosis,erythrodysesthesia hyperkeratosis hyperhidrosis Vascular Disorders,1,0.7202854156494141
TAFINLAR,hyperkeratosis,Table TreatmentEmergent,0,0.5619040727615356
TAFINLAR,hyperkeratosis,erythrodysesthesia syndrome,0,0.5553901195526123
TAFINLAR,hyperkeratosis,hyperkeratosis hyperhidrosis Vascular,1,0.7932476997375488
TAFINLAR,hyperhidrosis,Palmarplantar erythrodysesthesia syndrome hyperhidrosis Vascular Disorders Hypertension Table,1,0.7374897003173828
TAFINLAR,hyperhidrosis,hyperkeratosis hyperhidrosis Vascular,1,0.8536747694015503
TAFINLAR,hyperhidrosis,hyperhidrosis Vascular Disorders,1,0.8627098798751831
TAFINLAR,hyperhidrosis,Subcutaneous Tissue Disorders,0,0.6257942914962769
TAFINLAR,hyperhidrosis,Tissue Disorders Palmarplantar,0,0.5602477788925171
TAFINLAR,hyperhidrosis,syndrome hyperhidrosis,1,0.8990057706832886
TAFINLAR,hyperhidrosis,Tissue Disorders Palmarplantar erythrodysesthesia syndrome,0,0.5976003408432007
TAFINLAR,hyperhidrosis,hyperhidrosis Vascular Disorders Hypertension Table,1,0.80409175157547
TAFINLAR,Hypertension,hyperkeratosis hyperhidrosis Vascular Hypertension Table TreatmentEmergent Laboratory,1,0.7239258289337158
TAFINLAR,Hypertension,Tissue Disorders Palmarplantar erythrodysesthesia syndrome,0,0.5401972532272339
TAFINLAR,Hypertension,Abnormalities Occurring at All,0,0.5370964407920837
TAFINLAR,QTcF prolongation,QT Prolongation In QTcF prolongation to,1,0.9359290599822998
TAFINLAR,QTcF prolongation,Abnormalities Occurring at All,0,0.5362027883529663
TAFINLAR,QTcF prolongation,In QTcF prolongation,1,0.992158055305481
TAFINLAR,QTcF prolongation,in of patients treated with TAFINLAR,0,0.5865943431854248
TAFINLAR,QTcF prolongation,to msec occurred in of patients treated with TAFINLAR in combination,0,0.597632646560669
TAFINLAR,QTcF prolongation,TAFINLAR,0,0.5689030885696411
TAFINLAR,QTcF prolongation,Prolongation In,0,0.7585874795913696
TAFINLAR,QTcF prolongation,QTcF prolongation to msec,1,0.8914145231246948
TAFINLAR,QTcF was increased,in of,0,0.5053101778030396
TAFINLAR,QTcF was increased,and in,0,0.5294607877731323
TAFINLAR,QTcF was increased,TAFINLAR as a single agent,0,0.5482794046401978
TAFINLAR,QTcF was increased,agent QTcF was increased more than,1,0.8810151815414429
TAFINLAR,QTcF was increased,a single agent QTcF was increased more than msec from baseline,1,0.852759599685669
TAFINLAR,QTcF was increased,QTcF was,1,0.887703537940979
TAFINLAR,QTcF was increased,QTcF was increased more than msec,1,0.9098907709121704
TAFINLAR,QTcF was increased,The,0,0.5041719079017639
TAFINLAR,Retinal vein occlusion,and Precautions ( Cardiomyopathy see Warnings and Precautions,1,0.512412428855896
TAFINLAR,Retinal vein occlusion,Precautions,0,0.4776560664176941
TAFINLAR,Retinal vein occlusion,Precautions Venous Thromboembolism see ings,1,0.6077110171318054
TAFINLAR,Retinal vein occlusion,Precautions Venous Thromboembolism,0,0.589491069316864
TAFINLAR,Retinal vein occlusion,see ings and Precautions (,1,0.49772077798843384
TAFINLAR,Retinal vein occlusion,Ocular Toxicities see War,0,0.6150808334350586
TAFINLAR,Interstitial lung disease,[see W arnings and Precautions Ocular Toxicities,1,0.5145549178123474
TAFINLAR,Interstitial lung disease,Thromboembolism see Warnings and Cardiomyopathy,1,0.5344219207763672
TAFINLAR,Interstitial lung disease,Warnings and Cardiomyopathy [see W,1,0.539661705493927
TAFINLAR,Interstitial lung disease,Precautions Ocular Toxicities see,0,0.5237748622894287
TAFINLAR,Interstitial lung disease,ings and Precautions,0,0.5095030069351196
TAFINLAR,Interstitial lung disease,Warnings,0,0.5158098936080933
TAFINLAR,"primary malignancies, cutaneous",see Warnings and,0,0.49626821279525757
TAFINLAR,"primary malignancies, cutaneous",cautions (5.5)] * Ocular Toxicities see Warnings and,1,0.48404449224472046
TAFINLAR,"primary malignancies, cutaneous","Cardiomyopathy see Warnings and cautions (5.5)]  
 *    Ocular  Toxicities",1,0.45791977643966675
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,agent are hyperkeratosis hea,0,0.584176778793335
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,GlucosePhosphate,0,0.4669886827468872
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,common adverse reactions for TAFINLAR,0,0.5017414093017578
TAFINLAR,Increased cell proliferation,Warnings and * Most common,1,0.4910268783569336
TAFINLAR,Increased cell proliferation,Precautions,0,0.4949323534965515
TAFINLAR,Hemorrhage,agent,0,0.4917975664138794
TAFINLAR,Hemorrhage,as a single agent  hyperkera tosis headache pyrexia,1,0.5933339595794678
TAFINLAR,Hemorrhage, hyperkera tosis headache pyrexia,1,0.5999643802642822
TAFINLAR,Hemorrhage, hyperkera tosis headache pyrexia arthralgia,1,0.6095713376998901
TAFINLAR,hemorrhagic events,"eadache, pyrexia, arthralgia papilloma",1,0.5569497346878052
TAFINLAR,hemorrhagic events,"single agent are hyperkeratosis eadache, pyrexia,  arthralgia papilloma alopecia and palmarplantar",1,0.5629547834396362
TAFINLAR,hemorrhagic events,"are hyperkeratosis eadache, pyrexia,  arthralgia papilloma alopecia and",1,0.55092453956604
TAFINLAR,hemorrhagic events,palmarplantar,0,0.5076524019241333
TAFINLAR,Venous Thromboembolism,Most common adverse for TAFINLAR in,1,0.5268814563751221
TAFINLAR,Venous Thromboembolism,trametinib are pyrexia chills fatigue rash nausea vomiting diarrhea abdominal pai,0,0.5535001754760742
TAFINLAR,Venous Thromboembolism,vomiting diarrhea abdominal,0,0.4607563316822052
TAFINLAR,Venous Thromboembolism,palmarplantar erythrodysesthesia syndrome Most common adverse,0,0.5339050889015198
TAFINLAR,Venous Thromboembolism,are pyrexia chills fatigue rash nausea,0,0.5086215734481812
TAFINLAR,Venous Thromboembolism,in combi,1,0.49719762802124023
TAFINLAR,Venous Thromboembolism,fatigue rash nausea vomiting diarrhea abdominal pai,0,0.5458924770355225
TAFINLAR,Deep vein thrombosis,TAFINLAR in tion,1,0.4987911880016327
TAFINLAR,Deep vein thrombosis,nausea vomiting diarrhea abdominal pain peripheral,0,0.5020896196365356
TAFINLAR,Deep vein thrombosis,tion with trametinib are,1,0.5551145076751709
TAFINLAR,Deep vein thrombosis,peripheral edema,0,0.6161564588546753
TAFINLAR,pulmonary embolism,"trametinib pyrexia, chills,",1,0.5309852361679077
TAFINLAR,pulmonary embolism,nausea vomiting,0,0.49904143810272217
TAFINLAR,Cardiomyopathy,"lgia, night sw",1,0.4553981125354767
TAFINLAR,Cardiomyopathy,"edema cough headache lgia,",1,0.5310433506965637
TAFINLAR,Cardiomyopathy,"cough headache lgia, night sw eats decreased",1,0.49152788519859314
TAFINLAR,Cardiomyopathy,"lgia, night sw eats decreased appetite constipation",1,0.4941106140613556
TAFINLAR,Cardiomyopathy,"cough headache lgia, night sw eats decreased appetite constipation",1,0.49062380194664
TAFINLAR,Cardiomyopathy,"peripheral edema cough headache lgia, night sw",1,0.5072339773178101
TAFINLAR,Cardiomyopathy,headache arthra,0,0.46448493003845215
TAFINLAR,Ocular Toxicities,at 1-800-FDA-10,1,0.4495072364807129
TAFINLAR,Ocular Toxicities,at 1-800-FDA-10 or wwwfdagovmedwatch Clinical Trials Experience,1,0.4992581009864807
TAFINLAR,Ocular Toxicities,at or,0,0.4935781955718994
TAFINLAR,Ocular Toxicities,EXCERPT To report SUSPECTED,0,0.49171602725982666
TAFINLAR,Ocular Toxicities,A at 1-800-FDA-10 or,1,0.45099908113479614
TAFINLAR,Ocular Toxicities,or wwwfdagovmedwatch Clinical Trials Experience Because clinical trials a,0,0.5087683200836182
TAFINLAR,Ocular Toxicities,Trials Experience Because clinical trials,0,0.47312402725219727
TAFINLAR,Febrile Reactions,of a drug cann,0,0.47449991106987
TAFINLAR,pyrexia,"widely varying s, adve rse reaction",1,0.6056561470031738
TAFINLAR,pyrexia,of a drug cann,0,0.5430704355239868
TAFINLAR,pyrexia,"s, adve rse reaction rates",1,0.5844544768333435
TAFINLAR,pyrexia,"s, adve rse reaction rates observed",1,0.5775118470191956
TAFINLAR,Skin Toxicity,in the cl inical trials of another drug,1,0.567518949508667
TAFINLAR,Hyperglycemia,with trametinib BRAF,0,0.5291812419891357
TAFINLAR,Hyperglycemia,as a single agent in combinatio,1,0.5254427194595337
TAFINLAR,Hyperglycemia,agent and,0,0.48421597480773926
TAFINLAR,Hyperglycemia,Precautions section and,0,0.492830753326416
TAFINLAR,Hyperglycemia,BRAF VE Unresectable or Metastatic Melanoma The,0,0.5153993368148804
TAFINLAR,Hyperglycemia,or Metastatic,0,0.5504357814788818
TAFINLAR,Hyperglycemia,as a single,0,0.455652117729187
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,Unresectable or Metastatic Melanoma The,0,0.480677992105484
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,agent was evaluated in 586 patients with BRAF V mutationpositive unresectable,1,0.541608452796936
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,Unresectable or Metastatic Melanoma The safety,0,0.4671138823032379
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,The safety of TAFINLAR a single agent,1,0.472635954618454
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,treated or untreat,0,0.5530351400375366
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,Metastatic Melanoma The,0,0.45811009407043457
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,of TAFINLAR a,1,0.45915594696998596
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,melanoma,0,0.5055618286132812
TAFINLAR,Embryofetal Toxicity,"unresectable or ic melanoma, previou sly treated or untreated who",1,0.46676743030548096
TAFINLAR,Embryofetal Toxicity,melanoma,0,0.4845122992992401
TAFINLAR,Embryofetal Toxicity,single agent was evaluated in,0,0.4898748993873596
TAFINLAR,Embryofetal Toxicity,"ic melanoma, previou sly treated or",1,0.46493685245513916
TAFINLAR,Embryofetal Toxicity,"ic melanoma, previou",1,0.4884624779224396
TAFINLAR,Embryofetal Toxicity,evaluated in patients with BRAF,0,0.4953286051750183
TAFINLAR,fetal harm,metastatic melanoma previously or untreat ed who received TAFINLAR mg,1,0.48609673976898193
TAFINLAR,fetal harm,evaluated in patients with BRAF,0,0.4776480197906494
TAFINLAR,fetal harm,melanoma previously or untreat ed who received TAFINLAR,1,0.48954302072525024
TAFINLAR,fetal harm,or untreat ed who,1,0.49651023745536804
TAFINLAR,fetal harm,or untreat,1,0.544626772403717
TAFINLAR,fetal harm,metastatic melanoma previously,0,0.4656425714492798
TAFINLAR,fetal harm,until disease progression,0,0.4972057044506073
TAFINLAR,fetal harm,or untreat ed,1,0.5508130192756653
TAFINLAR,"primary malignancies, cutaneous",The median daily dose,0,0.48483434319496155
TAFINLAR,"primary malignancies, cutaneous",TAFINLAR was studied,0,0.5132604241371155
TAFINLAR,"primary malignancies, cutaneous","d in an open-label, randomized,",1,0.5386267900466919
TAFINLAR,"primary malignancies, cutaneous","in an open-label, randomized, activecontrolled",1,0.5252816677093506
TAFINLAR,"primary malignancies, cutaneous",patients treated,0,0.5571682453155518
TAFINLAR,"primary malignancies, cutaneous","singlearm trials d in an open-label,",1,0.5492607951164246
TAFINLAR,"primary malignancies, cutaneous",was mg range to mg,0,0.46477121114730835
TAFINLAR,"primary malignancies, cutaneous",openlabel singlearm trials d,1,0.5259492993354797
TAFINLAR,"primary malignancies, cutaneous",trial The median daily,0,0.48018622398376465
TAFINLAR,cutaneous squamous cell carcinoma,from of Trial,1,0.4447186589241028
TAFINLAR,cutaneous squamous cell carcinoma,and,0,0.4601627588272095
TAFINLAR,cutaneous squamous cell carcinoma,randomized controlled trial all,0,0.49393749237060547
TAFINLAR,cutaneous squamous cell carcinoma,abnormalities identified from of Trial 1 [see,1,0.5091288089752197
TAFINLAR,cutaneous squamous cell carcinoma,of Trial 1,1,0.4314749836921692
TAFINLAR,cutaneous squamous cell carcinoma,laboratory abnormalities identified from of Trial 1,1,0.49131259322166443
TAFINLAR,cutaneous squamous cell carcinoma,from of Trial 1  [see Clinical Studies Trial a multicenter international openlabel,1,0.5148482322692871
TAFINLAR,cutaneous squamous cell carcinoma,laboratory abnormalities identified from analyses,0,0.4728323817253113
TAFINLAR,keratoacanthoma,international openlabel randomized controlled trial,0,0.5000671148300171
TAFINLAR,keratoacanthoma,14.1)]. Trial a,1,0.4865996241569519
TAFINLAR,keratoacanthoma,14.1)]. Trial a multicenter,1,0.4834531843662262
TAFINLAR,keratoacanthoma,of Trial see Clinical 14.1)].  Trial  a multicenter,1,0.49639296531677246
TAFINLAR,keratoacanthoma,a multicenter international openlabel randomized controlled trial allocated,0,0.4968986213207245
TAFINLAR,keratoacanthoma,Clinical 14.1)]. Trial,1,0.5046209692955017
TAFINLAR,keratoacanthoma,international,0,0.47341465950012207
TAFINLAR,keratoacanthoma,Clinical Studies,0,0.4873369336128235
TAFINLAR,melanoma,ulticent er,1,0.5301910638809204
TAFINLAR,melanoma,Clinical Studies,0,0.5498465299606323
TAFINLAR,basal cell carcinoma,mg,0,0.49534738063812256
TAFINLAR,basal cell carcinoma,allocated with unresectable or metastatic BRAF VE,1,0.580337405204773
TAFINLAR,basal cell carcinoma,with unresectable or metastatic,1,0.5683133602142334
TAFINLAR,basal cell carcinoma,controlled trial allocated with unresectable,1,0.5067310333251953
TAFINLAR,basal cell carcinoma,with unresectable or,1,0.48203450441360474
TAFINLAR,basal cell carcinoma,with unresectable,1,0.4596533477306366
TAFINLAR,basal cell carcinoma,TAFINLAR mg,0,0.5707023739814758
TAFINLAR,basal cell carcinoma,with unresectable or metastatic BRAF VE mutationpositive,1,0.6103360652923584
TAFINLAR,basal cell carcinoma,randomized controlled trial allocated patients,0,0.48764222860336304
TAFINLAR,cutaneous squamous cell carcinomas,metastatic,0,0.5720598101615906
TAFINLAR,cutaneous squamous cell carcinomas,unresectable or metastatic BRAF 0E mutation-positive,1,0.5867120027542114
TAFINLAR,cutaneous squamous cell carcinomas,or dacarbazine mgm intravenously,0,0.49419069290161133
TAFINLAR,cutaneous squamous cell carcinomas,to r eceive,1,0.4847739338874817
TAFINLAR,keratoacanthomas,n or dacarbazine mgm intravenously every weeks,0,0.5083262920379639
TAFINLAR,keratoacanthomas,metastatic BRAF VE mutationpositive melanoma to,0,0.5542415380477905
TAFINLAR,keratoacanthomas,to e TAFINLAR 150,1,0.5238929986953735
TAFINLAR,keratoacanthomas,mutationpositive melanoma to e TAFINLAR 150,1,0.6032736897468567
TAFINLAR,keratoacanthomas,mutationpositive melanoma to e TAFINLAR 150 m g orally twice,1,0.5866396427154541
TAFINLAR,cuSCC,orall y twice daily n or,1,0.44992467761039734
TAFINLAR,cuSCC,orall y twice,1,0.4798900783061981
TAFINLAR,cuSCC,n or dacarbazine mgm intravenously,0,0.4984843134880066
TAFINLAR,cuSCC,orall,1,0.508519172668457
TAFINLAR,cuSCC,orall y twice daily,1,0.46684062480926514
TAFINLAR,cuSCC,orall y,1,0.5050373077392578
TAFINLAR,cuSCC,abnormal left ventricular ejection fraction or cardiac,0,0.49165093898773193
TAFINLAR,cuSCC,fraction or cardiac v,0,0.5102626085281372
TAFINLAR,cuSCC,alve  morphology Grade corrected,1,0.5374146699905396
TAFINLAR,cuSCC,cardiac v,0,0.5254471898078918
TAFINLAR,cuSCC,alve  morphology Grade corrected QT interval,1,0.515610933303833
TAFINLAR,cuSCC,corrected QT,0,0.5156520009040833
TAFINLAR,cuSCC,n The,0,0.5060312747955322
TAFINLAR,cuSCC,alve  morphology Grade corrected QT,1,0.5333739519119263
TAFINLAR,cuSCC,morphology Grade,0,0.5308330059051514
TAFINLAR,cuSCC,T int erval milliseconds on,1,0.46535348892211914
TAFINLAR,cuSCC,T int erval,1,0.448552668094635
TAFINLAR,cuSCC,corrected T int,1,0.4661627411842346
TAFINLAR,cuSCC,or,0,0.49679145216941833
TAFINLAR,cuSCC,history of ose-6 phosphate dehydrogenase,1,0.4433642029762268
TAFINLAR,cuSCC,known history of,0,0.480583518743515
TAFINLAR,cuSCC,ose-6 phosphate dehydrogenase deficiency The,1,0.44906455278396606
TAFINLAR,cuSCC,ose-6 phosphate dehydrogenase,1,0.4338719844818115
TAFINLAR,cuSCC,ose-6 phosphate dehydrogenase deficiency The median,1,0.4671362042427063
TAFINLAR,cuSCC,months for,0,0.4789944887161255
TAFINLAR,cuSCC,on treatment was,0,0.48999255895614624
TAFINLAR,cuSCC,edian duration on treatment was months,1,0.4464077353477478
TAFINLAR,cuSCC,edian,1,0.4322154223918915
TAFINLAR,cuSCC,dehydrogenase deficiency The edian duration,1,0.4421323239803314
TAFINLAR,cuSCC,months for patients treated with,0,0.5054490566253662
TAFINLAR,cuSCC,edian duration on treatment,1,0.4511653482913971
TAFINLAR,cuSCC,edian duration on,1,0.4193820357322693
TAFINLAR,cuSCC,edian duration,1,0.4197613298892975
TAFINLAR,cuSCC,on treatment was months for patients treated with TAFINLAR and months for dacarbaz,0,0.4678685963153839
TAFINLAR,cuSCC,months for patients treated with TAFINLAR and months for,0,0.4470197856426239
TAFINLAR,cuSCC,treatment was months for patients treated with TAFINLAR and months,0,0.4378066658973694
TAFINLAR,cuSCC,with TAFINLAR and,0,0.46457380056381226
TAFINLAR,cuSCC,with TAFINLAR and months  daca rbazinetreated,1,0.4359666109085083
TAFINLAR,cuSCC,male white and had a medi,0,0.4982849657535553
TAFINLAR,cuSCC,TAFINLAR and months  daca rbazinetreated patients The population,1,0.46912896633148193
TAFINLAR,cuSCC,had a medi,0,0.517496645450592
TAFINLAR,cuSCC,patie nts,1,0.4785330593585968
TAFINLAR,cuSCC,patie nts The population,1,0.4504270851612091
TAFINLAR,cuSCC,months for patients treated with TAFINLAR and,0,0.43923354148864746
TAFINLAR,cuSCC,exposed,0,0.48018619418144226
TAFINLAR,cuSCC,patie nts The population exposed to,1,0.4822792410850525
TAFINLAR,cuSCC,TAFINLAR and months for patie nts The population exposed,1,0.48595184087753296
TAFINLAR,primary malignant melanomas,"exposed to TAFINLAR was e, 99% white, and had a",1,0.5488935112953186
TAFINLAR,primary malignant melanomas,The most commonly occurring adverse,0,0.5431522727012634
TAFINLAR,primary malignant melanomas,a med ian,1,0.5678802728652954
TAFINLAR,primary malignant melanomas,reactions in patients treated,0,0.483187198638916
TAFINLAR,primary malignant melanomas,reactions in patients treated w,0,0.47173815965652466
TAFINLAR,primary malignant melanomas,population exposed to TAFINLAR was mal,0,0.507028341293335
TAFINLAR,primary malignant melanomas,and had a med ian age of years,1,0.5000708103179932
TAFINLAR,basal cell carcinoma,"pyrexia, ar",1,0.4325370192527771
TAFINLAR,basal cell carcinoma,"of decreasing frequency hyperkeratosis eadache, pyrexia, ar",1,0.6240144968032837
TAFINLAR,basal cell carcinoma,PPES The incide,0,0.45781129598617554
TAFINLAR,basal cell carcinoma,syndrome PPES,0,0.42977988719940186
TAFINLAR,basal cell carcinoma,palmarplantar erythrodysesthesia syndrome PPES The,0,0.49863773584365845
TAFINLAR,basal cell carcinoma,ted with dacarbazine,1,0.5531348586082458
TAFINLAR,basal cell carcinoma,ted,1,0.48375242948532104
TAFINLAR,basal cell carcinoma,was for patients treated with TAFINLAR and for patients trea,0,0.5313573479652405
TAFINLAR,basal cell carcinoma,TAFINLAR and for patients ted with,1,0.5882532596588135
TAFINLAR,basal cell carcinoma,for patients trea,0,0.4928836524486542
TAFINLAR,basal cell carcinoma,was for patients treated with TAFINLAR,0,0.5696991682052612
TAFINLAR,basal cell carcinoma,reduction of,0,0.47341692447662354
TAFINLAR,SCC,of Patients Treated,0,0.49515119194984436
TAFINLAR,SCC,Patients,0,0.5136155486106873
TAFINLAR,SCC,Selected Common Adverse,0,0.5014916658401489
TAFINLAR,SCC, Re actions Occurring,1,0.5192789435386658
TAFINLAR,SCC, Re actions,1,0.5116860866546631
TAFINLAR,SCC,Treated,0,0.5123164057731628
TAFINLAR,SCC,fatigue and headache Table Selected Common,0,0.47931715846061707
TAFINLAR,SCC, Re,1,0.5057352185249329
TAFINLAR,SCC,headache Table,0,0.4522227346897125
TAFINLAR,keratoacanthoma,>=10% ( All Grades,1,0.45594197511672974
TAFINLAR,keratoacanthoma,Table Selected Common Adverse,0,0.48844054341316223
TAFINLAR,keratoacanthoma,Treated With,0,0.5308665037155151
TAFINLAR,keratoacanthoma,Selected Common Adverse Reactions,0,0.49239879846572876
TAFINLAR,keratoacanthoma,Adverse Reactions ring in >=10% (,1,0.4775048792362213
TAFINLAR,primary melanoma,All Grades,1,0.46366074681282043
TAFINLAR,primary melanoma,d Skin and subcutaneous tissue disorders,0,0.5639657974243164
TAFINLAR,primary melanoma,All Grades 3 an,1,0.42937883734703064
TAFINLAR,primary melanoma,and b All Grades,1,0.4658876061439514
TAFINLAR,primary melanoma,b All     Grades  3 an d Skin and subcutaneous tissue,1,0.5629485845565796
TAFINLAR,deep venous thrombosis,                      ,1,0.5780510306358337
TAFINLAR,deep venous thrombosis,polyps,0,0.5679036378860474
TAFINLAR,DVT,polyps,0,0.5167014598846436
TAFINLAR,DVT,including,0,0.5234873294830322
TAFINLAR,pulmonary embolism,and                   ,1,0.5302199125289917
TAFINLAR,pulmonary embolism,including,0,0.557273268699646
TAFINLAR,pulmonary embolism,including cysts and                    Papilloma,1,0.5508948564529419
TAFINLAR,pulmonary embolism,                  ,1,0.5878928899765015
TAFINLAR,pulmonary embolism,                   Papilloma c,1,0.5542542338371277
TAFINLAR,PE,and    Papilloma,1,0.5473713874816895
TAFINLAR,PE,                  ,1,0.6041461229324341
TAFINLAR,PE,   Papilloma,1,0.5535622239112854
TAFINLAR,PE,   Papilloma c,1,0.5153675079345703
TAFINLAR,Retinal detachments,"           
  Incre ased alkaline",1,0.4678206741809845
TAFINLAR,Retinal detachments,   Papilloma c,1,0.4877743124961853
TAFINLAR,Retinal detachments,a,0,0.5017454624176025
TAFINLAR,Retinal detachments,"           
  Incre ased",1,0.49756908416748047
TAFINLAR,Retinal detachments,ased,0,0.45610302686691284
TAFINLAR,RPED,bnor mality limited,1,0.5349054336547852
TAFINLAR,RPED,a,0,0.5164869427680969
TAFINLAR,RPED,  Pa ncreatitis Immune System,1,0.5021573305130005
TAFINLAR,RPED,TAFINLAR were Gastrointestinal   Pa ncreatitis Immune,1,0.5210283994674683
TAFINLAR,RPED,Disorders Hypersensitivity,0,0.5111640691757202
TAFINLAR,RPED,  Pa,1,0.5591657161712646
TAFINLAR,RPED,manifesting as bullous rash,0,0.42404288053512573
TAFINLAR,Uveitis,toxicity Among these patients were,0,0.5106934309005737
TAFINLAR,Uveitis, or una cceptable toxicity Among these patients,1,0.5069106817245483
TAFINLAR,Uveitis,or una,1,0.46711426973342896
TAFINLAR,Uveitis,or una cceptable,1,0.4729319214820862
TAFINLAR,Uveitis,until disease,0,0.5498955845832825
TAFINLAR,Uveitis,to,0,0.542834460735321
TAFINLAR,Uveitis,daily until disease,0,0.545483410358429
TAFINLAR,Uveitis,orally once daily until disease progression,0,0.5425766706466675
TAFINLAR,iritis,able t oxicity Among these patients,1,0.5171071887016296
TAFINLAR,iritis,orally once daily until disease progression,0,0.5460163950920105
TAFINLAR,iritis,able t,1,0.4778006374835968
TAFINLAR,iritis,orally once daily,0,0.5454023480415344
TAFINLAR,iritis,were,0,0.47565215826034546
TAFINLAR,Uveitis,r great er than,1,0.45346754789352417
TAFINLAR,Uveitis,exposed to trametinib r great er than to months while,1,0.539397656917572
TAFINLAR,Uveitis,to trametinib r great,1,0.5474317073822021
TAFINLAR,Uveitis,trametinib fo,0,0.5348643064498901
TAFINLAR,Uveitis,fo,0,0.46057194471359253
TAFINLAR,Uveitis,trametinib r great er than to,1,0.5411597490310669
TAFINLAR,iritis,while were exposed to TAFINLAR and were exposed to trametinib for,0,0.5202158689498901
TAFINLAR,iritis,to TAFINLAR and,0,0.49237677454948425
TAFINLAR,iritis,greater than 12,1,0.5039938688278198
TAFINLAR,iritis,trametinib for greater than  12 mo nths while were exposed to,1,0.5246794819831848
TAFINLAR,iritis,to,0,0.5398239493370056
TAFINLAR,iritis,greater than  12 mo nths while were,1,0.47450578212738037
TAFINLAR,iritis,12 mo nths while,1,0.459509938955307
TAFINLAR,iritis,for greater,0,0.48444074392318726
TAFINLAR,iritis,12 mo nths while were exposed,1,0.5314345359802246
TAFINLAR,iritis,and were exposed to trametinib for,0,0.5074918270111084
TAFINLAR,uveitis,while were exposed,0,0.5006384253501892
TAFINLAR,uveitis,exposed to nib for greater than one year,1,0.5353765487670898
TAFINLAR,uveitis,greater than one year The median,0,0.4565405547618866
TAFINLAR,uveitis,male,0,0.48077690601348877
TAFINLAR,uveitis,nib,1,0.5183473229408264
TAFINLAR,uveitis,nib for greater than one year,1,0.48014283180236816
TAFINLAR,uveitis,and were exposed to nib for greater than one year,1,0.519275963306427
TAFINLAR,uveitis,and were exposed to nib for,1,0.5030691623687744
TAFINLAR,febrile reactions,coronary syndrome,0,0.5061735510826111
TAFINLAR,febrile reactions,(14.2)] . Pa tients with,1,0.5370059013366699
TAFINLAR,febrile reactions,of acute coronary syndrome within months current evidence of,0,0.5230280756950378
TAFINLAR,febrile reactions,evidence of,0,0.4932687282562256
TAFINLAR,febrile reactions,as a single agent mg orally,0,0.5065274238586426
TAFINLAR,febrile reactions,daily n see Clinical ies (14.2)] .,1,0.5306501984596252
TAFINLAR,febrile reactions,with abnormal LVEF history of acute coronary syndrome within months current evidence of C,0,0.47031521797180176
TAFINLAR,fever,see Clinical Studies s,1,0.526238739490509
TAFINLAR,fever,s wit h abnormal LVEF history of,1,0.5278077721595764
TAFINLAR,fever,s wit h abnormal LVEF history,1,0.5403763055801392
TAFINLAR,fever,Clinical Studies s,1,0.5215226411819458
TAFINLAR,fever,Studies s wit,1,0.5185877680778503
TAFINLAR,fever,Clinical Studies s wit h abnormal LVEF history of,1,0.4951988458633423
TAFINLAR,fever,see Clinical Studies s wit h abnormal LVEF history,1,0.4993304908275604
TAFINLAR,fever,Studies s wit h abnormal LVEF,1,0.5353533029556274
TAFINLAR,fever,s wit h abnormal,1,0.6223907470703125
TAFINLAR,hypotension,Studies Patients,0,0.5349817872047424
TAFINLAR,hypotension,abnormal LVEF history of e coronary  syndrome within months current,1,0.5476539134979248
TAFINLAR,hypotension,e coronary,1,0.5246307253837585
TAFINLAR,hypotension,Clinical Studies Patients,0,0.5335357785224915
TAFINLAR,hypotension,greater congestive heart,0,0.6104645729064941
TAFINLAR,rigors,Class II or greater congestive heart,0,0.5535069704055786
TAFINLAR,rigors,Studies Patients with abnormal,0,0.5317273736000061
TAFINLAR,rigors,n see Clinical Studies Patients with abnormal LVEF history of acute coronary,0,0.5098364353179932
TAFINLAR,chills,evidence of Class II,0,0.45756229758262634
TAFINLAR,chills,syndrome hin 6  months current,1,0.5245420932769775
TAFINLAR,chills,York,0,0.5119611620903015
TAFINLAR,chills,LVEF history of acute coronary,0,0.45685961842536926
TAFINLAR,chills,hin 6 months current,1,0.4728055000305176
TAFINLAR,chills,syndrome hin 6,1,0.5085848569869995
TAFINLAR,chills,hin 6 months current evidence of Class,1,0.4604231119155884
TAFINLAR,chills,of acute coronary syndrome hin,1,0.5117648839950562
TAFINLAR,dehydration,greater congestive heart failure New York Heart,0,0.5383334159851074
TAFINLAR,dehydration,"syndrome within nths,",1,0.5105948448181152
TAFINLAR,dehydration,LVEF history,0,0.49856263399124146
TAFINLAR,dehydration,"coronary syndrome within nths, curre",1,0.4644240736961365
TAFINLAR,dehydration,York Heart Association history RV,0,0.44090086221694946
TAFINLAR,renal failure,idence of Cla ss II or greater,1,0.4890739321708679
TAFINLAR,renal failure,months current idence of Cla ss II or,1,0.4677971601486206
TAFINLAR,renal failure,RVO or RPED QTc,0,0.5154740810394287
TAFINLAR,renal failure,ss II or greater congestive heart failure New,0,0.5802103281021118
TAFINLAR,renal failure,greater congestive heart,0,0.5292614102363586
TAFINLAR,pyrexia,treatment ory hyp ertension uncontrolled arrhythmias history,1,0.5126640796661377
TAFINLAR,pyrexia,greater congestive heart,0,0.5118752717971802
TAFINLAR,pyrexia,ory hyp ertension uncontrolled arrhythmias,1,0.5494133234024048
TAFINLAR,pyrexia,ory,1,0.5338011980056763
TAFINLAR,pyrexia,pneumonitis or interstitial lung disease or a,0,0.5370615124702454
TAFINLAR,pyrexia,ory hyp ertension uncontrolled arrhythmias history,1,0.5243074297904968
TAFINLAR,pyrexia,ory hyp ertension uncontrolled arrhythmias history of,1,0.5184097290039062
TAFINLAR,pyrexia,msec treatment refract,0,0.5571513175964355
TAFINLAR,pyrexia,QTc interval msec treatment ory hyp,1,0.510330080986023
TAFINLAR,pyrexia,pneumonitis or interstitial lung disease or,0,0.5290051698684692
TAFINLAR,pyrexia,msec,0,0.5005345344543457
TAFINLAR,fever,as 10 months for,1,0.4542171359062195
TAFINLAR,fever,as 10,1,0.5147258639335632
TAFINLAR,fever,nt gr oup when used,1,0.5439859628677368
TAFINLAR,fever,orally oncedaily nt gr,1,0.5556497573852539
TAFINLAR,fever,nt gr,1,0.5483625531196594
TAFINLAR,fever,for,0,0.5544297695159912
TAFINLAR,fever,of patients receiving,0,0.5154501795768738
TAFINLAR,fever,"


 I n Trial of patients receiving",1,0.5076225996017456
TAFINLAR,fever,"TAFINLAR as a single 


 I n Trial of patients",1,0.5215461254119873
TAFINLAR,fever,"


 I",1,0.5096811652183533
TAFINLAR,febrile reactions,R in combination with trametinib experienced adverse,1,0.5451439619064331
TAFINLAR,febrile reactions,receiving R in combination,1,0.5291895866394043
TAFINLAR,febrile reactions,resulting in permanent discontinuation,0,0.4589405655860901
TAFINLAR,febrile reactions,Trial of patients receiving R in combination  with trametinib experienced,1,0.513088583946228
TAFINLAR,fever,resulting in,0,0.5373647212982178
TAFINLAR,fever,Trial of patients receiving TAFINLAR,0,0.5024880170822144
TAFINLAR,fever,receiving TAFINLAR in combination trame tinib,1,0.537918210029602
TAFINLAR,fever,trame tinib,1,0.49858731031417847
TAFINLAR,fever,trame tinib experienced adverse reactions,1,0.5687423944473267
TAFINLAR,fever,resulting in permanent,0,0.5244501829147339
TAFINLAR,fever,trame,1,0.47604840993881226
TAFINLAR,fever,trame tinib experienced adverse,1,0.5637323260307312
TAFINLAR,chills,resulting,0,0.559465765953064
TAFINLAR,chills,TAFINLAR in combination with trametinib experienced adverse reactions resulting in,0,0.5075214505195618
TAFINLAR,chills,ent di scontinuation of trial medications,1,0.5128465890884399
TAFINLAR,fever,reactions led dose  reductions in,1,0.5046454071998596
TAFINLAR,fever,ent di scontinuation of trial medications,1,0.5530123710632324
TAFINLAR,fever,of patients treated with,0,0.5340168476104736
TAFINLAR,fever,reactions led dose ,1,0.5858251452445984
TAFINLAR,fever,led dose  reductions in and,1,0.47754278779029846
TAFINLAR,fever,dose  reductions in and dose,1,0.4926820397377014
TAFINLAR,fever,Adverse reactions led dose  reductions in and dose interruptions,1,0.5219772458076477
TAFINLAR,fever,dose ,1,0.5820996761322021
TAFINLAR,fever,dose  reductions in,1,0.48154783248901367
TAFINLAR,fever,reactions led to,0,0.5444352626800537
TAFINLAR,fever,decreased ejection fraction were the most common reasons cited for dose interruptions,0,0.45378339290618896
TAFINLAR,hypotension,ction were the,1,0.4925355315208435
TAFINLAR,hypotension,ction were,1,0.5067884922027588
TAFINLAR,rigors,TAFINLAR and trametinib when used,0,0.5232110023498535
TAFINLAR,chills,ejection fraction were the most,0,0.48510223627090454
TAFINLAR,chills,were the,0,0.5359392166137695
TAFINLAR,chills,most mon re asons cited for dose,1,0.48948296904563904
TAFINLAR,chills,mon re asons cited for dose,1,0.5014317631721497
TAFINLAR,chills,cited for dose interruptions of TAFINLAR and trametinib when used in combination,0,0.4614676237106323
TAFINLAR,chills,mon re,1,0.4941682815551758
TAFINLAR,chills,and pyrexia chills and decreased ejection,0,0.7430976629257202
TAFINLAR,Fever,r >=5 Grades or of,1,0.4970639646053314
TAFINLAR,Fever,With TAFINLAR in Combination With Trametinib in,0,0.4883197844028473
TAFINLAR,Fever,Grades or of,0,0.5147489309310913
TAFINLAR,Fever,at All Grades r >=5 Grades or of,1,0.4927077889442444
TAFINLAR,chills,atient s Treated With TAFINLAR,1,0.5272448658943176
TAFINLAR,chills,TAFINLAR in Combination With Trametinib in Trial Adverse Reactions,0,0.5059887170791626
TAFINLAR,chills,Grades or of atient s Treated With TAFINLAR,1,0.5135138034820557
TAFINLAR,chills,atient,1,0.5361990928649902
TAFINLAR,chills,of atient,1,0.5562338829040527
TAFINLAR,rigors,Grades or,0,0.5850491523742676
TAFINLAR,dehydration,in Combinat ion With Trametinib in,1,0.5094825029373169
TAFINLAR,dehydration,in Combinat ion,1,0.5383294820785522
TAFINLAR,dehydration,of Patients Treated With in Combinat,1,0.5411622524261475
TAFINLAR,syncope,ions    TAFINLAR plus Trametinib,1,0.5088486075401306
TAFINLAR,fever,TAFINLAR N All Gradesa 3 and,1,0.5171030163764954
TAFINLAR,fever,General disorders and ive s ite conditions Pyrexia,1,0.7055046558380127
TAFINLAR,fever,All,0,0.5447283983230591
TAFINLAR,fever,and ive,1,0.5061636567115784
TAFINLAR,fever,ive s ite conditions,1,0.5836502313613892
TAFINLAR,fever,disorders and ive s ite conditions,1,0.5346410870552063
TAFINLAR,fever,and General disorders and ive s,1,0.526708722114563
TAFINLAR,fever,ite conditions Pyrexia,0,0.7407348155975342
TAFINLAR,fever,ite,0,0.49360525608062744
TAFINLAR,fever,and ive s ite,1,0.5042762756347656
MULTAQ,worsening heart failure,worsening heart failure,1,1.0
MULTAQ,worsening heart failure,safety concerns are described elsewhere in the label,0,0.4864766001701355
MULTAQ,Liver Injury,Liver Injury,1,1.0
MULTAQ,Liver Injury,Warnings,0,0.5121397972106934
MULTAQ,Liver Injury,label New or worsening heart failure see,0,0.5238708257675171
MULTAQ,Pulmonary toxicity,Pulmonary toxicity,1,0.9999998211860657
MULTAQ,Pulmonary toxicity,hypomagnesemia,0,0.49363023042678833
MULTAQ,Pulmonary toxicity,Pulmonary toxicity see,1,0.9592143297195435
MULTAQ,Pulmonary toxicity,see Warnings and Precautions Hypokalemia and hypomagnesemia with potassiumdeple,0,0.5371993184089661
MULTAQ,Pulmonary toxicity,Injury see Warnings and Pulmonary toxicity,1,0.8495351672172546
MULTAQ,Pulmonary toxicity,Liver Injury see Warnings and,0,0.6072657108306885
MULTAQ,Hypokalemia,Hypokalemia and hypomagnesemia,1,0.8852561712265015
MULTAQ,Hypokalemia,toxicity see Warnings and Hypokalemia and hypomagnesemia with,1,0.8009954690933228
MULTAQ,Hypokalemia,toxicity see Warnings and Hypokalemia,1,0.8290143013000488
MULTAQ,Hypokalemia,Warnings and Hypokalemia and hypomagnesemia,1,0.8408556580543518
MULTAQ,Hypokalemia,toxicity see Warnings and Hypokalemia and hypomagnesemia with potassiumdepleting diuretics,1,0.7793713808059692
MULTAQ,Hypokalemia,and Hypokalemia and hypomagnesemia,1,0.879844069480896
MULTAQ,Hypokalemia,Precautions,0,0.48359861969947815
MULTAQ,hypomagnesemia,hypomagnesemia with potassiumdepleting diuretics,1,0.8483257293701172
MULTAQ,hypomagnesemia,Precautions,0,0.49942582845687866
MULTAQ,QT prolongation,QT prolongation see Warnings and,1,0.8617400527000427
MULTAQ,QT prolongation,Warnings and Precautions EXCERPT Most common,0,0.4900321960449219
MULTAQ,QT prolongation,and,0,0.4777429699897766
MULTAQ,QT prolongation,adverse reactions,0,0.5154265761375427
MULTAQ,QT prolongation,EXCERPT Most common adverse reactions,0,0.4942599833011627
MULTAQ,diarrhea,diarrhea,1,0.9999999403953552
MULTAQ,diarrhea,diarrhea nausea abdominal pain vomiting and,1,0.8074325323104858
MULTAQ,diarrhea,are,0,0.5518276691436768
MULTAQ,diarrhea,Most common adverse reactions diarrhea nausea abdominal,1,0.719363272190094
MULTAQ,diarrhea,adverse reactions diarrhea nausea abdominal,1,0.740702748298645
MULTAQ,diarrhea,pain vomiting and asthenia To report,0,0.6010606288909912
MULTAQ,diarrhea,diarrhea nausea abdominal,1,0.8262825012207031
MULTAQ,diarrhea,reactions,0,0.5872281789779663
MULTAQ,diarrhea,diarrhea nausea abdominal pain vomiting,1,0.8273833394050598
MULTAQ,nausea,Most common adverse reactions are,0,0.6053780317306519
MULTAQ,nausea,reactions are nausea abdominal pain vomiting and,1,0.7931763529777527
MULTAQ,nausea,report SUSPECTED ADVERSE REACTIONS,0,0.6271838545799255
MULTAQ,nausea,diarrhea,0,0.6490728855133057
MULTAQ,nausea,common,0,0.5215053558349609
MULTAQ,nausea,nausea abdominal pain,1,0.8380759954452515
MULTAQ,nausea,pain vomiting and asthenia To report,0,0.7569764852523804
MULTAQ,nausea,asthenia To report SUSPECTED,0,0.5900220274925232
MULTAQ,abdominal pain,Most common adverse reactions are,0,0.5320231318473816
MULTAQ,abdominal pain,abdominal pain vomiting,1,0.8824350833892822
MULTAQ,abdominal pain,vomiting and asthenia To report SUSPECTED ADVERSE,0,0.6285265684127808
MULTAQ,abdominal pain,abdominal pain vomiting and asthenia,1,0.8259251117706299
MULTAQ,abdominal pain,abdominal pain vomiting and asthenia To,1,0.8182920813560486
MULTAQ,abdominal pain,EXCERPT Most,0,0.4544866681098938
MULTAQ,vomiting,nausea abdominal pain,0,0.7287442684173584
MULTAQ,vomiting,vomiting and asthenia,1,0.8844265937805176
MULTAQ,vomiting,vomiting and asthenia To,1,0.8788343667984009
MULTAQ,vomiting,vomiting and,1,0.9646890163421631
MULTAQ,vomiting,and,0,0.5051023960113525
MULTAQ,vomiting,report,0,0.538638710975647
MULTAQ,vomiting,diarrhea nausea abdominal vomiting and,1,0.8044047355651855
MULTAQ,vomiting,asthenia To report,0,0.5460768938064575
MULTAQ,asthenia,and,0,0.5410805344581604
MULTAQ,asthenia,contact sanofiaventis US LLC,0,0.48436439037323
MULTAQ,gastrointestinal disorders,therapy with MULTAQ gastrointestinal disorders versus in the placebo,1,0.7536851167678833
MULTAQ,gastrointestinal disorders,contact sanofiaventis US LLC,0,0.5056207180023193
MULTAQ,gastrointestinal disorders,gastrointestinal disorders versus,1,0.9105902910232544
MULTAQ,gastrointestinal disorders,gastrointestinal disorders,1,1.0000001192092896
MULTAQ,gastrointestinal disorders,group and QT prolongation versus,0,0.5271050333976746
MULTAQ,gastrointestinal disorders,gastrointestinal disorders versus in,1,0.8832520246505737
MULTAQ,gastrointestinal disorders,gastrointestinal disorders versus in the,1,0.8932046890258789
MULTAQ,QT prolongation,QT prolongation,1,1.0
MULTAQ,QT prolongation,QT prolongation versus in the placebo group,1,0.7982525825500488
MULTAQ,QT prolongation,reactions,0,0.542993426322937
MULTAQ,QT prolongation,placebo group The most,0,0.49862802028656006
MULTAQ,QT prolongation,placebo group,0,0.5193799734115601
MULTAQ,QT prolongation,QT prolongation versus,1,0.9077107906341553
MULTAQ,QT prolongation,group QT prolongation versus in the placebo group,1,0.7971947193145752
MULTAQ,QT prolongation,QT,1,0.8148610591888428
MULTAQ,diarrhea,reactions more common,0,0.5639116764068604
MULTAQ,diarrhea,diarrhea nausea abdominal pain,1,0.8311716318130493
MULTAQ,diarrhea,daily in the studies diarrhea nausea abdominal,1,0.771790623664856
MULTAQ,diarrhea,diarrhea nausea,1,0.8461776971817017
MULTAQ,nausea,nausea,1,1.0
MULTAQ,abdominal pain,abdominal pain vomiting and asthenia Table,1,0.7948629856109619
MULTAQ,abdominal pain,abdominal pain vomiting and asthenia Table displays,1,0.7764315605163574
MULTAQ,abdominal pain,were diarrhea abdominal pain vomiting and asthenia,1,0.7573158144950867
MULTAQ,abdominal pain,studies were diarrhea abdominal,1,0.7006986737251282
MULTAQ,abdominal pain,abdominal pain,1,0.9999998807907104
MULTAQ,abdominal pain,the studies were diarrhea abdominal pain vomiting and,1,0.7234025001525879
MULTAQ,abdominal pain,diarrhea abdominal pain vomiting,1,0.8211984634399414
MULTAQ,vomiting,vomiting and asthenia Table,1,0.8295265436172485
MULTAQ,asthenia,were,0,0.534627377986908
MULTAQ,asthenia,asthenia Table displays adverse reactions,1,0.7337392568588257
MULTAQ,asthenia,daily in the studies were diarrhea nausea abdominal,0,0.5444265604019165
MULTAQ,asthenia,than with p,0,0.5315414667129517
MULTAQ,asthenia,asthenia,1,1.0000001192092896
MULTAQ,asthenia,vomiting asthenia,1,0.7582573294639587
MULTAQ,asthenia,pain vomiting asthenia Table displays adverse reactions,1,0.6959171295166016
MULTAQ,asthenia,asthenia Table displays adverse reactions more,1,0.734234631061554
MULTAQ,asthenia,daily than with p,0,0.5259438157081604
MULTAQ,rashes,rashes generalized,1,0.90589839220047
MULTAQ,rashes,daily than with p,0,0.495870977640152
MULTAQ,rashes,rashes generalized macular maculopapular erythematous pruritus,1,0.7679325938224792
MULTAQ,rashes,Including,0,0.5432747602462769
MULTAQ,rashes,tissue rashes,1,0.8511325120925903
MULTAQ,rashes,rashes generalized macular maculopapular erythematous,1,0.7830908298492432
MULTAQ,rashes,rashes generalized macular,1,0.7954210042953491
MULTAQ,rashes,tissue rashes generalized macular maculopapular,1,0.7536789178848267
MULTAQ,pruritus,pruritus eczema dermatitis dermatitis,1,0.86244136095047
MULTAQ,eczema,pruritus,0,0.7295900583267212
MULTAQ,eczema,dermatitis dermatitis allergic,0,0.7660856246948242
MULTAQ,eczema,macular maculopapular erythematous eczema dermatitis dermatitis allergic,1,0.7347380518913269
MULTAQ,dermatitis,erythematous pruritus,0,0.7573909163475037
MULTAQ,dermatitis,pruritus dermatitis,1,0.8633013963699341
MULTAQ,dermatitis,dermatitis,0,1.000000238418579
MULTAQ,dermatitis,pruritus,0,0.7849487066268921
MULTAQ,dermatitis,dermatitis dermatitis allergic P,1,0.8366114497184753
MULTAQ,dermatitis,maculopapular erythematous pruritus dermatitis dermatitis allergic,1,0.761249840259552
MULTAQ,dermatitis,erythematous,0,0.7261456251144409
MULTAQ,dermatitis allergic,dermatitis,1,0.8969511985778809
MULTAQ,dermatitis allergic,dermatitis allergic Photosensitivity react,1,0.8193120360374451
MULTAQ,dermatitis allergic,dermatitis,0,0.8969511985778809
MULTAQ,dermatitis allergic,rashes generalized macular maculopapular erythematous pruritus eczema,0,0.7382862567901611
MULTAQ,dermatitis allergic,pruritus eczema dermatitis allergic,1,0.8511587381362915
MULTAQ,Photosensitivity reaction,s dermatitis Photosensitivity reaction and dysgeusia have also been,1,0.810794472694397
MULTAQ,Photosensitivity reaction,rashes generalized macular maculopapular erythematous pruritus eczema,0,0.6313035488128662
MULTAQ,Photosensitivity reaction,dysgeusia have also been,0,0.49124348163604736
MULTAQ,Photosensitivity reaction,dermatitis,0,0.6145099997520447
MULTAQ,dysgeusia,reaction dysgeusia have also been reported,1,0.8712767958641052
MULTAQ,dysgeusia,dermatitis,0,0.5880855917930603
MULTAQ,heart failure,New,0,0.5413501858711243
MULTAQ,heart failure,or heart failure see Warnings and Precautions Atrial,1,0.7705268859863281
MULTAQ,Atrial flutter,failure see Warnings and Atrial flutter,1,0.8103055953979492
MULTAQ,Atrial flutter,Atrial flutter with atrioventricular conduction,1,0.9015083909034729
MULTAQ,Atrial flutter,see,0,0.5005031824111938
MULTAQ,Atrial flutter,Hepatic Liver,0,0.49194008111953735
MULTAQ,Atrial flutter,failure see Warnings and Atrial flutter with atrioventricular,1,0.8311344981193542
MULTAQ,Liver Injury,been reported very rarely Liver,1,0.733264684677124
MULTAQ,Liver Injury,very rarely Hepatic,0,0.6846010088920593
MULTAQ,Liver Injury,very rarely Liver Injury see Warnings and,1,0.7955911159515381
MULTAQ,Liver Injury,Liver Injury see Warnings,1,0.8656759262084961
MULTAQ,Liver Injury,very rarely Liver Injury see,1,0.8272769451141357
MULTAQ,Interstitial lung disease,Interstitial lung disease including pneumonitis,1,0.905634880065918
MULTAQ,Interstitial lung disease,lung disease,1,0.8567994832992554
MULTAQ,Interstitial lung disease,Precautions Interstitial,1,0.6812453866004944
MULTAQ,pneumonitis,see Warnings and Precautions Immune Anaphylactic,0,0.5374820828437805
MULTAQ,pulmonary fibrosis,pneumonitis pulmonary fibrosis see Warnings and,1,0.8226876258850098
MULTAQ,pulmonary fibrosis,see Warnings and Precautions Immune Anaphylactic,0,0.49298030138015747
MULTAQ,pulmonary fibrosis,including,0,0.5309814214706421
MULTAQ,pulmonary fibrosis,pulmonary fibrosis see Warnings and,1,0.8563315868377686
MULTAQ,pulmonary fibrosis,pneumonitis pulmonary,1,0.7733100652694702
MULTAQ,pulmonary fibrosis,Precautions Immune Anaphylactic reactions including,0,0.4643835425376892
MULTAQ,Anaphylactic reactions,including leukocytoclastic vasculitis,0,0.5701035261154175
MULTAQ,Anaphylactic reactions,ding pneumonitis and pulmonary fibrosis see Warnings,0,0.5260988473892212
MULTAQ,Anaphylactic reactions,including,0,0.537660539150238
MULTAQ,Anaphylactic reactions,and pulmonary fibrosis see Warnings and Precautions,0,0.5255441665649414
MULTAQ,Anaphylactic reactions,including angioedema Vascular Vasculitis,0,0.6681673526763916
MULTAQ,Anaphylactic reactions,Anaphylactic reactions,1,1.0000001192092896
MULTAQ,Anaphylactic reactions,Vasculitis,0,0.5834410190582275
MULTAQ,Anaphylactic reactions,see Warnings and Precautions Anaphylactic reactions including angioedema Vascular Vasculitis,1,0.8463457822799683
MULTAQ,angioedema,angioedema Vascular Vasculitis,1,0.8603359460830688
MULTAQ,angioedema,angioedema Vascular Vasculitis including leukocytoclastic,1,0.8111896514892578
MULTAQ,angioedema,Warnings and,0,0.5275458693504333
MULTAQ,angioedema,and,0,0.5059272646903992
MULTAQ,Vasculitis,Anaphylactic reactions including angioedema Vasculitis including leukocytoclastic vasculitis,1,0.7157607078552246
MULTAQ,Vasculitis,and,0,0.4881463050842285
MULTAQ,Vasculitis,including leukocytoclastic vasculitis,0,0.8145164251327515
MULTAQ,Vasculitis,Vasculitis including,1,0.906830906867981
MULTAQ,Vasculitis,Vasculitis,1,1.0
MULTAQ,Vasculitis,including angioedema Vasculitis including leukocytoclastic,1,0.7760215997695923
MULTAQ,Vasculitis,Vasculitis including leukocytoclastic,1,0.8382828831672668
MULTAQ,DEATH,REACTIONS The following,0,0.5665934085845947
MULTAQ,DEATH,elsewhere in the label New or worsening,0,0.5620312690734863
MULTAQ,DEATH,ADVERSE REACTIONS The following,0,0.5471159219741821
MULTAQ,DEATH,conce rns are,1,0.4635787606239319
MULTAQ,DEATH,REACTIONS The following conce rns are described elsewhere,1,0.5528727769851685
MULTAQ,DEATH,ADVERSE REACTIONS The following conce rns,1,0.523363471031189
MULTAQ,DEATH,following conce rns are described elsewhere in,1,0.47627606987953186
MULTAQ,DEATH,described elsewhere in the label New,0,0.4773027300834656
MULTAQ,STROKE,safety s are  described elsewhere in the,1,0.48211145401000977
MULTAQ,STROKE,described elsewhere in the label New,0,0.4813150465488434
MULTAQ,STROKE,failure see Warnings and Precaut,0,0.5274998545646667
MULTAQ,STROKE,s are described elsewhere in,1,0.5153396725654602
MULTAQ,DEATH,njury see Warnings,1,0.558315098285675
MULTAQ,DEATH,toxicity,0,0.6380199790000916
MULTAQ,DEATH,heart failure see Warnings,0,0.5681092739105225
MULTAQ,DEATH,see Warnings and Precautions Pulmonary toxicity see Warnings and Precautions,0,0.5651816129684448
MULTAQ,DEATH,and Precautions Liver njury see Warnings and Precautions,1,0.5411413908004761
MULTAQ,DEATH,njury see Warnings and Precautions Pulmonary,1,0.5548022985458374
MULTAQ,STROKE,see W arnings and Precautions Pulmonary,1,0.5255519151687622
MULTAQ,STROKE,New or worsening heart,0,0.6006967425346375
MULTAQ,HEART FAILURE,or worsening heart failure see Warnings and Precautions Liver Injury see,0,0.726553201675415
MULTAQ,HEART FAILURE,gs and Precau tions Pulmonary toxicity see Warnings,1,0.5390527248382568
MULTAQ,HEART FAILURE,gs and Precau tions,1,0.4895162880420685
MULTAQ,death,ADVERSE REACTIONS contact sanofiaventis US LLC at or FDA at FDA,0,0.476326584815979
MULTAQ,death,r www fdagovmedwatch Clinical Trials Experience,1,0.49091416597366333
MULTAQ,death,FDA r www,1,0.5351712107658386
MULTAQ,death,r www,1,0.556200385093689
MULTAQ,death,at or FDA at FDA,0,0.5247645974159241
MULTAQ,death,r www fdagovmedwatch Clinical Trials,1,0.4889349043369293
MULTAQ,death,safety,0,0.6184514760971069
MULTAQ,death,evaluation,0,0.5055985450744629
MULTAQ,stroke,da.gov medwatch Clinical Trials,1,0.5107138156890869
MULTAQ,stroke,evaluation of dronedarone mg tw,0,0.5652598142623901
MULTAQ,stroke,da.gov medwatch Clinical Trials Experience The,1,0.5172543525695801
MULTAQ,stroke,FDA or da.gov medwatch Clinical Trials Experience The,1,0.5096868276596069
MULTAQ,stroke,FDA or da.gov medwatch,1,0.4990183115005493
MULTAQ,stroke,evaluation of dronedarone,0,0.5655629634857178
MULTAQ,heart failure,in patients with AF or AFL,0,0.6275988817214966
MULTAQ,heart failure,linical Trial s Experience,1,0.5342251062393188
MULTAQ,heart failure,or wwwfdagovmedwatch linical Trial,1,0.560434877872467
MULTAQ,heart failure,The safety evaluation of dronedarone,0,0.5225054025650024
MULTAQ,heart failure,or wwwfdagovmedwatch linical Trial s,1,0.5561163425445557
MULTAQ,heart failure,The safety evaluation of dronedarone mg twice,0,0.5154743790626526
MULTAQ,DEATH,these studies a of 62,1,0.5151938199996948
MULTAQ,DEATH,studies a of 62,1,0.5123119354248047
MULTAQ,DEATH,daily,0,0.6019447445869446
MULTAQ,DEATH,In these studies a of 62,1,0.5029718279838562
MULTAQ,DEATH,of 62 patients were,1,0.4602317214012146
MULTAQ,DEATH,of 62 patients were randomized and treated,1,0.45616716146469116
MULTAQ,DEATH,of 62 patients were randomized,1,0.44625258445739746
MULTAQ,DEATH,patients with,0,0.49460989236831665
MULTAQ,DEATH,and treated patients with MULTAQ mg twice,0,0.4675009250640869
MULTAQ,STROKE, patie nts,1,0.5106552839279175
MULTAQ,HEART FAILURE,ADONIS ERATO and DAFNE In these studies a total of,0,0.5057249069213867
MULTAQ,HEART FAILURE,of patients ere randomize,1,0.5504218339920044
MULTAQ,death,occurred,0,0.6193585395812988
MULTAQ,death,versu s in the placebo group,1,0.4838621914386749
MULTAQ,death,versu s in the placebo,1,0.4973333775997162
MULTAQ,death,the placebo group The most frequent adverse,0,0.48174145817756653
MULTAQ,stroke,prolongation 0.5% i,1,0.5463147163391113
MULTAQ,heart failure,prolongation versus in,0,0.5454975366592407
MULTAQ,heart failure,studies,0,0.5228303074836731
MULTAQ,heart failure,The most freq uent adverse,1,0.5359549522399902
MULTAQ,heart failure,placebo The most freq,1,0.519000768661499
MULTAQ,heart failure,placebo The,1,0.5219677686691284
MULTAQ,heart failure,adverse reactions observed with MULTAQ mg twice daily in the studies were,0,0.5284802913665771
MULTAQ,Liver injury,rnings and P recautions,1,0.4448966979980469
MULTAQ,Liver injury,adverse reactions observed with MULTAQ mg twice daily in the studies were,0,0.5406029224395752
MULTAQ,Liver injury,rnings and P,1,0.46149393916130066
MULTAQ,Liver injury,Wa,0,0.4407283067703247
MULTAQ,Liver injury,Precautions Pulmonary toxicity see rnings,1,0.5761147737503052
MULTAQ,Liver injury,with potassiumdepleting diuretics see,0,0.45791831612586975
MULTAQ,Liver injury,hypomagnesemia with potassiumdepleting diuretics,0,0.4473510980606079
MULTAQ,Liver injury,and hypomagnesemia with potassiumdepleting diuretics see,0,0.45854413509368896
MULTAQ,Liver injury,and hypomagnesemia with,0,0.49623990058898926
MULTAQ,Hypokalemia,prolongatio,1,0.5201122760772705
MULTAQ,Hypokalemia,Warnings and,0,0.5057637691497803
MULTAQ,Hypokalemia,prolongatio n see Warnings and,1,0.5173232555389404
MULTAQ,Hypokalemia,QT,0,0.5257551074028015
MULTAQ,Hypokalemia,and Precautions prolongatio,1,0.5050183534622192
MULTAQ,Hypokalemia,prolongatio n see Warnings and Precautions,1,0.5119092464447021
MULTAQ,Hypokalemia,prolongatio n,1,0.5110571384429932
MULTAQ,Hypokalemia,common adverse reactions ar,0,0.5133005380630493
MULTAQ,Hypokalemia,and Precautions prolongatio n see Warnings and,1,0.49547824263572693
MULTAQ,Hypokalemia,Most,0,0.4681382477283478
MULTAQ,hypomagnesemia,prolongation e,1,0.5260999202728271
MULTAQ,hypomagnesemia,QT prolongation e,1,0.5410290360450745
MULTAQ,hypomagnesemia,Warnings an d,1,0.5354061722755432
MULTAQ,Teratogen,"


   To  report SUSPECTED ADVERSE REACTIONS contact",1,0.5377427935600281
MULTAQ,Teratogen,Warnings an d,1,0.5377788543701172
MULTAQ,Teratogen,diarrhea nausea abdominal pain,0,0.48635587096214294
MULTAQ,Teratogen,"


   To  report",1,0.5287593007087708
MULTAQ,Teratogen,"


   To  report SUSPECTED ADVERSE REACTIONS",1,0.531015157699585
MULTAQ,Teratogen,US LLC at or FDA,0,0.5557335019111633
MULTAQ,death,studies a total f 628 patients were randomized and treated,1,0.45769137144088745
MULTAQ,death,US LLC at or FDA,0,0.4913382828235626
MULTAQ,death,these studies a total f 628 patients,1,0.44561508297920227
MULTAQ,death,these studies a total f 628,1,0.4915943741798401
MULTAQ,death,patients were randomized,0,0.460940957069397
MULTAQ,death,total f 628,1,0.5069882869720459
MULTAQ,death,twice daily and with,0,0.5256466865539551
MULTAQ,death,these studies a total f,1,0.5230165719985962
MULTAQ,death,studies a total f 628 patients were randomized and,1,0.45389121770858765
MULTAQ,cardiovascular death,and placebo. The mean ex posure across studies,1,0.4995785355567932
MULTAQ,cardiovascular death,these studies a total f,1,0.5218379497528076
MULTAQ,cardiovascular death,twice daily and placebo. The mean ex posure across studies,1,0.5172778367996216
MULTAQ,cardiovascular death,twice daily and placebo. The mean ex,1,0.5002841949462891
MULTAQ,cardiovascular death,daily and placebo. The mean ex posure across,1,0.5129407048225403
MULTAQ,cardiovascular death,and with,0,0.49929285049438477
MULTAQ,cardiovascular death,and placebo. The mean ex,1,0.4916227161884308
MULTAQ,cardiovascular death,randomized and treated patients with,0,0.5250902771949768
MULTAQ,heart failure events,In clinical trials,0,0.5708863735198975
MULTAQ,heart failure events,mean exposure across studies 12,1,0.5297435522079468
MULTAQ,heart failure events,12 months. In ATHENA the maximum,1,0.47315043210983276
MULTAQ,heart failure events,months. In ATHENA,1,0.48446816205978394
MULTAQ,heart failure events,months. In ATHENA the,1,0.48207443952560425
MULTAQ,heart failure events,studies 12 months.,1,0.46479305624961853
MULTAQ,heart failure events,mean exposure across studies 12 months. In ATHENA,1,0.5331552028656006
MULTAQ,heart failure events,months. In ATHENA the maximum followup was,1,0.48817989230155945
MULTAQ,worsening of heart failure,laboratory ECG,1,0.5453286170959473
MULTAQ,heart failure,              Placebo Dronedarone mg twice,1,0.505599856376648
MULTAQ,heart failure,mg twice,0,0.5226655006408691
MULTAQ,heart failure,              Placebo Dronedarone mg twice daily,1,0.5007122755050659
MULTAQ,heart failure,             ,1,0.579070508480072
MULTAQ,heart failure,Frequent than               Placebo,1,0.5123418569564819
MULTAQ,heart failure,at Least of Patients,0,0.5654683113098145
MULTAQ,interstitial lung disease,allergic,0,0.5770285129547119
MULTAQ,interstitial lung disease,also been reported at an incidence less than in patients treated,0,0.5699916481971741
MULTAQ,interstitial lung disease,dermatitis,0,0.622087836265564
MULTAQ,interstitial lung disease,"
         Photosensitivit y reaction and dysgeusia have",1,0.5347939729690552
MULTAQ,interstitial lung disease,have also been reported,0,0.49186840653419495
MULTAQ,interstitial lung disease,"
         Photosensitivit y reaction and dysgeusia",1,0.5324172973632812
MULTAQ,pneumonitis,treated with MULTAQ,0,0.5001064538955688
MULTAQ,pulmonary fibrosis,been repor ted at an,1,0.5123172402381897
MULTAQ,Hypokalemia,Placebo MULTAQ,0,0.5351892709732056
MULTAQ,Hypokalemia,twice,0,0.5063743591308594
MULTAQ,Hypokalemia,            N N Early increases in,1,0.5240330100059509
MULTAQ,Hypokalemia,Placebo MULTAQ mg twice             N N Early increases in,1,0.5590801239013672
MULTAQ,Hypokalemia,            N N Early,1,0.5023982524871826
MULTAQ,Hypokalemia,N,0,0.5072420835494995
MULTAQ,Hypokalemia,MULTAQ mg twice             N N,1,0.5564013719558716
MULTAQ,hypomagnesemia,N Early increases in creatinine,0,0.5739948749542236
MULTAQ,hypomagnesemia,       (N=2875 N Early,1,0.47450143098831177
MULTAQ,hypomagnesemia,       (N=2875 N Early increases,1,0.5006805658340454
MULTAQ,hypomagnesemia,twice daily,0,0.502227783203125
MULTAQ,hypomagnesemia,       (N=2875 N Early increases in creatinine,1,0.5897494554519653
MULTAQ,increase in serum creatinine,Postmarketing Experience The wing adverse reactions have  been identified during,1,0.5120930671691895
MULTAQ,increase in serum creatinine,       (N=2875 N Early increases in creatinine,1,0.8761736154556274
MULTAQ,increase in serum creatinine,events in any particular,0,0.4754427969455719
MULTAQ,increase in serum creatinine,use of,0,0.49576687812805176
MULTAQ,increase in serum creatinine,subgroup Postmarketing Experience The wing adverse reactions have  been identified during postapproval use,1,0.5160039663314819
MULTAQ,increase in serum creatinine,The wing,1,0.4202858805656433
MULTAQ,increase in serum creatinine,subgroup Postmarketing Experience The wing adverse reactions have  been,1,0.5041748285293579
MULTAQ,increase in serum creatinine,of MULTAQ Because these reactions are reported voluntarily,0,0.478873610496521
MULTAQ,increase in serum creatinine,are reported,0,0.5182728171348572
MULTAQ,increase in serum creatinine,adverse reactions have been identified during postapproval use,1,0.5535259246826172
MULTAQ,pre-renal azotemia,particular subgroup Postmarketing Experience The following adverse,0,0.5857008695602417
MULTAQ,acute renal failure,The,0,0.4918312132358551
MULTAQ,heart failure,have been identified during postapproval use of MULTAQ,0,0.5183571577072144
MULTAQ,heart failure,of MULTAQ Because these tions,1,0.452248752117157
MULTAQ,heart failure,postapproval use of MULTAQ Because these reac,0,0.5169715881347656
MULTAQ,heart failure,is not always possible to,0,0.4740886986255646
MULTAQ,heart failure,MULTAQ Because these tions are rep orted voluntarily from,1,0.45742079615592957
MULTAQ,heart failure,tions are rep orted voluntarily from a,1,0.452303946018219
MULTAQ,hypovolemia,use of MULTAQ Because these reactions,0,0.5360263586044312
MULTAQ,hypovolemia,it is no t always possible to reliably,1,0.48446929454803467
MULTAQ,hypovolemia,"e, it is no t always possible to reliably",1,0.4780014455318451
MULTAQ,hypovolemia,is no t,1,0.5069704055786133
MULTAQ,hypovolemia,"population of an unknown e, it is no",1,0.4831162691116333
MULTAQ,hypovolemia,"e, it is no t always possible to",1,0.4456784129142761
MULTAQ,hypovolemia,is no,1,0.49751853942871094
MULTAQ,hypovolemia,frequency or establish a,0,0.5066488981246948
MULTAQ,increases in creatinine levels,with 1:1 atrioventricular c onduction has been reported very,1,0.5265881419181824
MULTAQ,increases in creatinine levels,1:1 atrioventricular c onduction has been,1,0.5140289068222046
MULTAQ,increases in creatinine levels,Warnings and Precautions Atrial er with 1:1 atrioventricular c onduction has been reported very,1,0.5445404052734375
MULTAQ,increases in creatinine levels,Atrial er with,1,0.5355650186538696
TANZEUM,Thyroid C-cell Tumors,the prescribing information Risk of,0,0.4686591327190399
TANZEUM,Thyroid C-cell Tumors,information Risk,0,0.4776308536529541
TANZEUM,Thyroid C-cell Tumors,Precautions Acute Pancreatitis,0,0.46253079175949097
TANZEUM,Thyroid C-cell Tumors,serious reactions are described below or elsewhere in the prescribing information Risk of,0,0.49507230520248413
TANZEUM,Thyroid C-cell Tumors,see Warnings and Precautions,0,0.4799591600894928
TANZEUM,Acute Pancreatitis,ng information Risk of Thyroid Ccell,0,0.497587651014328
TANZEUM,Acute Pancreatitis,Acute Pancreatitis see Warnings and Precautions Hypoglycemia,1,0.8206789493560791
TANZEUM,Acute Pancreatitis,Tumors see Warnings and Precautions,0,0.4756059944629669
TANZEUM,Acute Pancreatitis,Hypoglycemia with Concomitant Use,0,0.5482505559921265
TANZEUM,Acute Pancreatitis,Warnings and Acute Pancreatitis,1,0.8450307250022888
TANZEUM,Acute Pancreatitis,Tumors see Warnings and Acute Pancreatitis see Warnings and Precautions Hypoglycemia,1,0.736375093460083
TANZEUM,Hypoglycemia,Hypoglycemia with Concomitant Use of,1,0.8329154253005981
TANZEUM,Hypersensitivity Reactions,Hypersensitivity Reactions,1,1.0
TANZEUM,Hypersensitivity Reactions,Impairment see,0,0.5113434195518494
TANZEUM,Hypersensitivity Reactions,Hypersensitivity Reactions see Warnings and Precautions,1,0.8611944913864136
TANZEUM,Hypersensitivity Reactions,Hypersensitivity Reactions see,1,0.9621642827987671
TANZEUM,Hypersensitivity Reactions,th Concomitant Use of Insulin Secretagogues or Insulin see Warnings,0,0.5743224620819092
TANZEUM,Renal Impairment,Hypersensitivity Reactions see Warnings and,0,0.507102906703949
TANZEUM,Renal Impairment,Warnings and Renal Impairment,1,0.8447463512420654
TANZEUM,Renal Impairment,Warnings and Precautions EXCERPT,0,0.4952544569969177
TANZEUM,Renal Impairment,and Renal Impairment,1,0.964095950126648
TANZEUM,upper respiratory tract infection,placebo upper respiratory tract infection,1,0.8252722024917603
TANZEUM,upper respiratory tract infection,and Renal Impairment,1,0.5683310031890869
TANZEUM,upper respiratory tract infection,tract infection diarrhea,1,0.6821131706237793
TANZEUM,upper respiratory tract infection,placebo upper,1,0.6149227619171143
TANZEUM,upper respiratory tract infection,in patients on placebo upper respiratory tract infection diarrhea nausea injection site reaction,1,0.6864442825317383
TANZEUM,upper respiratory tract infection,in patients on placebo upper respiratory tract infection diarrhea nausea,1,0.7166884541511536
TANZEUM,upper respiratory tract infection,tract infection diarrhea nausea injection,1,0.6461194157600403
TANZEUM,upper respiratory tract infection,upper respiratory tract infection diarrhea nausea injection,1,0.8159866333007812
TANZEUM,upper respiratory tract infection,in patients on placebo upper respiratory tract infection,1,0.7920493483543396
TANZEUM,diarrhea,respiratory tract diarrhea nausea injection site reaction cough,1,0.6896090507507324
TANZEUM,diarrhea,upper respiratory tract infection diarrhea nausea injection,1,0.6868559718132019
TANZEUM,diarrhea,in,0,0.5786314606666565
TANZEUM,diarrhea,diarrhea nausea injection site reaction cough,1,0.732945442199707
TANZEUM,diarrhea,placebo were upper respiratory tract,0,0.5295016169548035
TANZEUM,diarrhea,upper respiratory tract infection,0,0.5937740206718445
TANZEUM,diarrhea,diarrhea,1,1.0
TANZEUM,nausea,more,0,0.5293051600456238
TANZEUM,nausea,nausea,1,0.9999999403953552
TANZEUM,nausea,tract infection nausea injection site,1,0.7657372951507568
TANZEUM,nausea,nausea injection site reaction cough,1,0.7643529772758484
TANZEUM,nausea,respiratory,0,0.5726417303085327
TANZEUM,nausea,site reaction cough back,0,0.6165603995323181
TANZEUM,nausea,reaction cough back pain arthralgia sinusitis and,0,0.6189477443695068
TANZEUM,nausea,tract infection nausea injection site reaction,1,0.7286475896835327
TANZEUM,nausea,patients on placebo,0,0.5789394378662109
TANZEUM,nausea,nausea injection site reaction,1,0.7763731479644775
TANZEUM,cough,site cough back pain arthralgia,1,0.7836384773254395
TANZEUM,cough,nausea injection site reaction,1,0.5911825299263
TANZEUM,cough,To report,0,0.526266872882843
TANZEUM,back pain,were upper respiratory,0,0.4286181926727295
TANZEUM,arthralgia,reaction cough back arthralgia sinusitis,1,0.7268157601356506
TANZEUM,arthralgia,were upper respiratory,0,0.4786396920681
TANZEUM,arthralgia,To report SUSPECTED ADVERSE REACTIONS contact,0,0.5182116031646729
TANZEUM,sinusitis,sinusitis and influenza To report,1,0.8082661032676697
TANZEUM,sinusitis,reaction cough back pain sinusitis and influenza,1,0.7730651497840881
TANZEUM,sinusitis,pain sinusitis and,1,0.8906534314155579
TANZEUM,sinusitis,cough back pain sinusitis and influenza To,1,0.7859246134757996
TANZEUM,influenza,influenza To report SUSPECTED ADVERSE REACTIONS,1,0.7492492198944092
TANZEUM,influenza,back,0,0.592722475528717
TANZEUM,influenza,injection site reaction cough back pain arthralgia,0,0.5912750959396362
TANZEUM,influenza,sinusitis influenza,1,0.7782996296882629
TANZEUM,influenza,SUSPECTED ADVERSE REACTIONS contact,0,0.5420271158218384
TANZEUM,influenza,influenza To,1,0.8651840686798096
TANZEUM,influenza,pain arthralgia sinusitis influenza To,1,0.744398295879364
TANZEUM,influenza,back pain arthralgia sinusitis influenza To report SUSPECTED ADVERSE REACTIONS,1,0.6877272129058838
TANZEUM,influenza,influenza,1,0.9999998211860657
TANZEUM,hypoglycemia,hypoglycemia associated,1,0.9016743898391724
TANZEUM,hypoglycemia,hypoglycemia associated with the,1,0.9097907543182373
TANZEUM,hypoglycemia,hypoglycemia associated with the use of,1,0.8566822409629822
TANZEUM,hypoglycemia,hypoglycemia associated with the use,1,0.856103777885437
TANZEUM,hypoglycemia,pool of placebocontrolled,0,0.5813583731651306
TANZEUM,injection site reactions,for other events injection site reactions,1,0.937435507774353
TANZEUM,injection site reactions,hypoglycemia associated,1,0.515141487121582
TANZEUM,injection site reactions,injection site reactions reported Gastrointestinal Adverse,1,0.8610546588897705
TANZEUM,injection site reactions,placebo and for TANZEUM b See below,0,0.6168167591094971
TANZEUM,gastrointestinal complaints,of placebocontrolled gastrointestinal complaints occurred more,1,0.8013235330581665
TANZEUM,gastrointestinal complaints,placebo and for TANZEUM b See below,0,0.5508740544319153
TANZEUM,gastrointestinal complaints,gastrointestinal complaints occurred,1,0.9509456157684326
TANZEUM,gastrointestinal complaints,occurred,0,0.4942376911640167
TANZEUM,diarrhea,diarrhea and nausea see,1,0.8272230625152588
TANZEUM,diarrhea,diarrhea and nausea see Table,1,0.7893307209014893
TANZEUM,diarrhea,receiving placebo In addition diarrhea and,1,0.7417500019073486
TANZEUM,diarrhea,diarrhea and nausea,1,0.8338502049446106
TANZEUM,diarrhea,Table the,0,0.5769242644309998
TANZEUM,nausea,nausea see,1,0.9198585748672485
TANZEUM,nausea,addition to diarrhea,0,0.6192173957824707
TANZEUM,nausea,nausea see Table the,1,0.8514230251312256
TANZEUM,nausea,to diarrhea and,0,0.6124089956283569
TANZEUM,nausea,gastrointestinal adverse reactions also,0,0.6682262420654297
TANZEUM,nausea,and,0,0.5219223499298096
TANZEUM,gastrointestinal adverse reactions,patients receiving,0,0.5790982842445374
TANZEUM,gastrointestinal adverse reactions,adverse reactions also occurred more frequently,1,0.7465993165969849
TANZEUM,gastrointestinal adverse reactions,receiving,0,0.4898418188095093
TANZEUM,gastrointestinal adverse reactions,adverse reactions,1,0.8465213775634766
TANZEUM,gastrointestinal adverse reactions,the gastrointestinal adverse,1,0.9158908128738403
TANZEUM,gastrointestinal adverse reactions,and nausea,0,0.6479909420013428
TANZEUM,gastrointestinal adverse reactions,gastrointestinal adverse reactions,1,0.9999999403953552
TANZEUM,gastrointestinal adverse reactions,TANZEUM vomiting versus for placebo,0,0.654752254486084
TANZEUM,vomiting,disease,0,0.5900768637657166
TANZEUM,vomiting,patients receiving,0,0.5660642385482788
TANZEUM,vomiting,reactions also occurred more,0,0.607205331325531
TANZEUM,vomiting,in patients receiving vomiting,1,0.901726484298706
TANZEUM,vomiting,vomiting versus for placebo versus TANZEUM,1,0.7905141115188599
TANZEUM,vomiting,patients receiving vomiting versus for placebo versus TANZEUM,1,0.7734959721565247
TANZEUM,vomiting,patients,0,0.5116122961044312
TANZEUM,vomiting,frequently in patients receiving vomiting versus for,1,0.8442022800445557
TANZEUM,gastroesophageal reflux disease,vomiting versus for placebo versus TANZEUM,0,0.6047244071960449
TANZEUM,gastroesophageal reflux disease,gastroesophageal reflux disease versus for placebo versus,1,0.8629419803619385
TANZEUM,gastroesophageal reflux disease,for placebo versus gastroesophageal reflux disease versus,1,0.8435266017913818
TANZEUM,dyspepsia,dyspepsia,1,1.0
TANZEUM,dyspepsia,dyspepsia versus for placebo versus,1,0.8373585939407349
TANZEUM,dyspepsia,for placebo versus TANZEUM dyspepsia versus,1,0.7983860969543457
TANZEUM,dyspepsia,TANZEUM dyspepsia versus for placebo versus,1,0.7897933721542358
TANZEUM,dyspepsia,placebo versus TANZEUM dyspepsia versus,1,0.8019436001777649
TANZEUM,Constipation,Constipation also contributed to,1,0.8690673112869263
TANZEUM,GI reactions,GI reactions as mild in of cases,1,0.8878620266914368
TANZEUM,GI reactions,and severe in,0,0.5463210344314575
TANZEUM,GI reactions,GI reactions,1,1.0
TANZEUM,GI reactions,severity GI,1,0.8028444647789001
TANZEUM,GI reactions,graded the severity of,0,0.5201477408409119
TANZEUM,GI reactions,GI reactions as mild in,1,0.9106441736221313
TANZEUM,GI reactions,In the group treated with,0,0.5550618171691895
TANZEUM,injection site reactions,Reactions In,0,0.7565255165100098
TANZEUM,injection site reactions,the pool of placebocontrolled injection,1,0.7303285002708435
TANZEUM,injection site reactions,addition to the term injection s,0,0.7263308763504028
TANZEUM,injection site reactions,occurred more frequently,0,0.5340267419815063
TANZEUM,injection site reactions,placebo Injection Site Reactions In,0,0.8915532231330872
TANZEUM,injection site reactions,pool of placebocontrolled injection site reactions,1,0.8781867027282715
TANZEUM,injection site reactions,pool of placebocontrolled injection site reactions occurred more,1,0.8636351823806763
TANZEUM,injection site reactions,term injection s,0,0.730077862739563
TANZEUM,injection site reactions,Site,0,0.6561587452888489
TANZEUM,injection site reactions,to the term,0,0.4904981851577759
TANZEUM,injection site reaction,injection site reaction see Table,1,0.9553054571151733
TANZEUM,injection site reaction,more frequently on TANZEUM than on placebo In addition to,0,0.5880555510520935
TANZEUM,injection site reaction,site reactions also,0,0.7826493978500366
TANZEUM,injection site reaction,site reaction,1,0.8388305902481079
TANZEUM,injection site reaction,types of injection site reactions also,0,0.9464921355247498
TANZEUM,injection site reaction,injection site reaction,1,0.9999999403953552
TANZEUM,injection site reaction,In addition to the injection,1,0.7590552568435669
TANZEUM,injection site reaction,occurred,0,0.5680716633796692
TANZEUM,injection site reaction,also occurred,0,0.545961320400238
TANZEUM,injection site reaction,addition,0,0.5251553058624268
TANZEUM,injection site reactions,types injection site reactions,1,0.9685300588607788
TANZEUM,injection site reactions,following other types injection site reactions also occurred,1,0.9431742429733276
TANZEUM,injection site reactions,occurred more frequently on TANZEUM injection site hematoma versus for placebo ver,0,0.7410374879837036
TANZEUM,injection site reactions,the following other types injection site reactions,1,0.9393916726112366
TANZEUM,injection site reactions,site reaction see Table the following,0,0.7875597476959229
TANZEUM,injection site reactions,versus for,0,0.5081324577331543
TANZEUM,injection site reactions,more frequently on TANZEUM injection site hematoma,0,0.744581937789917
TANZEUM,injection site hematoma,occurred more frequently on injection site hematoma versus for placebo versus TANZEUM,1,0.8556509613990784
TANZEUM,injection site hematoma,more frequently on TANZEUM injection site hematoma,0,0.886135458946228
TANZEUM,injection site hematoma,erythema versus for,0,0.5548971891403198
TANZEUM,injection site hematoma,occurred more frequently on injection site hematoma versus for placebo versus,1,0.8730506896972656
TANZEUM,injection site hematoma,the following other types of injection site reactions,0,0.7623699903488159
TANZEUM,injection site erythema,hematoma versus for placebo versus TANZEUM,0,0.6382954120635986
TANZEUM,injection site rash,site rash versus for placebo versus TANZEUM,1,0.7805780172348022
TANZEUM,injection site rash,injection site rash,1,0.9999998807907104
TANZEUM,injection site rash,TANZEUM injection site hypersensitivity versus,0,0.7839342355728149
TANZEUM,injection site rash,placebo versus injection,1,0.7077406644821167
TANZEUM,injection site rash,placebo versus TANZEUM,0,0.5703251361846924
TANZEUM,injection site rash,versus,0,0.48023685812950134
TANZEUM,injection site rash,for placebo versus injection site rash versus,1,0.8716593384742737
TANZEUM,injection site rash,versus TANZEUM injection site erythema,0,0.8164937496185303
TANZEUM,injection site rash,versus for placebo versus,0,0.580941915512085
TANZEUM,injection site hypersensitivity,versus injection site hypersensitivity versus,1,0.9538528323173523
TANZEUM,injection site hypersensitivity,versus,0,0.49829307198524475
TANZEUM,injection site hypersensitivity,versus TANZEUM and injection site hemorrhage versus for,0,0.7567695379257202
TANZEUM,injection site hypersensitivity,placebo versus TANZEUM injection site rash versus for,0,0.759425163269043
TANZEUM,injection site hypersensitivity,versus injection site hypersensitivity versus for,1,0.9178460836410522
TANZEUM,injection site hypersensitivity,versus for,0,0.49062320590019226
TANZEUM,injection site hemorrhage,placebo versus TANZEUM injection site hemorrhage,1,0.8162279725074768
TANZEUM,injection site hemorrhage,placebo versus TANZEUM and,0,0.5414890050888062
TANZEUM,injection site hemorrhage,versus TANZEUM injection site hemorrhage,1,0.8837887048721313
TANZEUM,injection site hemorrhage,placebo versus TANZEUM injection,1,0.6272721886634827
TANZEUM,injection site hemorrhage,versus TANZEUM and,0,0.4661329388618469
TANZEUM,injection site hemorrhage,TANZEUM injection site,1,0.7210867404937744
TANZEUM,Injection site pruritus,versus Injection,1,0.7051324248313904
TANZEUM,Injection site pruritus,injection site reactions wer,0,0.7866555452346802
TANZEUM,Injection site pruritus,site pruritus also contributed to,1,0.8172319531440735
TANZEUM,Injection site pruritus,Injection site pruritus also contributed to,1,0.9597680568695068
TANZEUM,Injection site pruritus,for placebo versus Injection site pruritus also contributed,1,0.9007784128189087
TANZEUM,Injection site pruritus,placebo versus Injection site pruritus also contributed to,1,0.9061751961708069
TANZEUM,Injection site pruritus,versus Injection site pruritus,1,0.9754717350006104
TANZEUM,injection site reactions,injection site reactions were judged as,1,0.9432885646820068
TANZEUM,injection site reactions,judged as mild by investigators in both groups for TANZEUM versus for placebo,0,0.602958083152771
TANZEUM,injection site reactions,were judged as mild by investigators in both groups for TANZEUM,0,0.5776472091674805
TANZEUM,injection site reactions,site reactions,1,0.8039926290512085
TANZEUM,injection site reactions,majority injection,1,0.704567551612854
TANZEUM,injection site reactions,The majority injection,1,0.7093956470489502
TANZEUM,injection site reactions,reported reactions The majority injection site,1,0.9188368916511536
TANZEUM,injection site reactions,site reactions were,1,0.7703661322593689
TANZEUM,injection site reactions,frequently reported reactions,0,0.742753267288208
TANZEUM,injection site reactions,reactions The majority of,0,0.6795387268066406
TANZEUM,injection site reactions,The,0,0.49629849195480347
TANZEUM,injection site reaction,injection site,1,0.9133154153823853
TANZEUM,injection site reaction,for placebo More patients on TANZEUM than on placebo,0,0.5813367366790771
TANZEUM,injection site reaction,than reactions versus had a reaction judged by inve,0,0.6440520286560059
TANZEUM,injection site reaction,injection site reaction versus experienced more than reactions,1,0.8942217826843262
TANZEUM,injection site reaction,versus for,0,0.4977627992630005
TANZEUM,injection site reaction,a reaction judged,0,0.7016633749008179
TANZEUM,injection site reaction,injection site reaction versus experienced,1,0.926139771938324
TANZEUM,hypoglycemia,hypoglycemia were similar to those listed,1,0.8694248795509338
TANZEUM,hypoglycemic episode,at least one documented hypoglycemic,1,0.8607284426689148
TANZEUM,hypoglycemic episode,hypoglycemic episode on,1,0.9817274808883667
TANZEUM,hypoglycemic episode,hypoglycemic episode on TANZEUM and the,1,0.8685885071754456
TANZEUM,hypoglycemic episode,one documented hypoglycemic episode,1,0.9203576445579529
TANZEUM,hypoglycemic episode,hypoglycemic episode on TANZEUM and,1,0.890940248966217
TANZEUM,hypoglycemic episode,one hypoglycemic episode,1,0.9419093728065491
TANZEUM,hypoglycemic episode,least one hypoglycemic episode,1,0.9515146017074585
TANZEUM,Hypoglycemia,TANZEUM was added,0,0.44554847478866577
TANZEUM,Hypoglycemia,Hypoglycemia was more,1,0.925687849521637
TANZEUM,hypoglycemia,no documented symptomatic or hypoglycemia,1,0.7710093855857849
TANZEUM,hypoglycemia,Hypoglycemia was more,1,0.925687849521637
TANZEUM,hypoglycemia,and these data are omitted from the table,0,0.45712441205978394
TANZEUM,hypoglycemia,from the table c Plasma gluc,0,0.6490501761436462
TANZEUM,hypoglycemia,hypoglycemia were,1,0.9714431762695312
TANZEUM,hypoglycemia,In this trial no documented symptomatic or,0,0.5343966484069824
TANZEUM,Plasma glucose concentration <=70 mg/dL,the table Plasma glucose concentration <=70 mg/dL and,1,0.9556025862693787
TANZEUM,Plasma glucose concentration <=70 mg/dL,In this trial no documented symptomatic or,0,0.5496508479118347
TANZEUM,Plasma glucose concentration <=70 mg/dL,the table Plasma glucose concentration,1,0.8608149290084839
TANZEUM,Plasma glucose concentration <=70 mg/dL,of hypoglycemic symptoms,0,0.7053215503692627
TANZEUM,Plasma glucose concentration <=70 mg/dL,table Plasma glucose concentration <=70 mg/dL,1,0.9680309295654297
TANZEUM,Plasma glucose concentration <=70 mg/dL,concentration <=70 mg/dL and presence of hypoglycemic,1,0.8919978141784668
TANZEUM,Plasma glucose concentration <=70 mg/dL,the table Plasma glucose concentration <=70 mg/dL,1,0.9605205655097961
TANZEUM,Plasma glucose concentration <=70 mg/dL,are omitted from the table,0,0.46849340200424194
TANZEUM,hypoglycemic symptoms,to administer a resuscitative action e,0,0.4412315785884857
TANZEUM,hypoglycemic symptoms,and presence hypoglycemic symptoms d,1,0.9130960702896118
TANZEUM,hypoglycemia,another person to administer a,0,0.5302735567092896
TANZEUM,pneumonia,adverse reaction pneumonia was reported more,1,0.7533414363861084
TANZEUM,pneumonia,another person to administer a,0,0.5235036611557007
TANZEUM,pneumonia,cases pneumonia in the group,1,0.8154219388961792
TANZEUM,pneumonia,pneumonia in the group receiving,1,0.8000062108039856
TANZEUM,pneumonia,TANZEUM versus,0,0.5384572744369507
TANZEUM,pneumonia,group More,0,0.5129067897796631
TANZEUM,pneumonia,cases pneumonia in the group receiving TANZEUM,1,0.7660486698150635
TANZEUM,pneumonia,group receiving TANZEUM were serious for,0,0.5348950624465942
TANZEUM,pneumonia,pneumonia in the group receiving TANZEUM,1,0.7754290699958801
TANZEUM,pneumonia,than in patients in the allcomparators group More cases,0,0.4906814396381378
TANZEUM,atrial fibrillation,atrial fibrillation,1,1.0
TANZEUM,atrial fibrillation,illationFlutte r In the pool of placebo and activecontrolled,0,0.5965656042098999
TANZEUM,atrial fibrillation,atrial fibrillation and atrial,1,0.932091236114502
TANZEUM,atrial flutter,fibrillation atrial flutter,1,0.9437622427940369
TANZEUM,atrial flutter,atrial fibrillation atrial flutter,1,0.9498789310455322
TANZEUM,atrial flutter,comparators and respectivel,0,0.45281070470809937
TANZEUM,atrial flutter,atrial flutter were reported,1,0.9428328275680542
TANZEUM,atrial flutter,fibrillation atrial flutter were reported more frequently,1,0.8672102689743042
TANZEUM,atrial flutter,atrial flutter were,1,0.9774034023284912
TANZEUM,atrial flutter,atrial flutter,1,1.0
TANZEUM,appendicitis,trials serious events appendicitis occurred,1,0.8285641670227051
TANZEUM,appendicitis,atrial flutter,1,0.532608151435852
TANZEUM,appendicitis,appendicitis occurred in of patients treated,1,0.8278077840805054
TANZEUM,appendicitis,TANZEUM compared with among all,0,0.4732080399990082
TANZEUM,appendicitis,serious events appendicitis occurred in,1,0.8317373394966125
TANZEUM,appendicitis,appendicitis,1,1.000000238418579
TANZEUM,appendicitis,events of,0,0.511622428894043
TANZEUM,appendicitis,In the pool of,0,0.44103455543518066
TANZEUM,ALT increase,least one event ALT increase of fold or greater above,1,0.7772024273872375
TANZEUM,ALT increase,In the pool of,0,0.4827994108200073
TANZEUM,ALT increase,ALT increase of fold or,1,0.8099355697631836
TANZEUM,ALT increase,greater above the upper limit of normal In one of the cases an,0,0.6416690349578857
TANZEUM,ALT increase,subject in the allcomparator group experienced at least one,0,0.5410481691360474
TANZEUM,ALT increase,fold or greater above the upper limit of normal,0,0.6353789567947388
TANZEUM,elevation in ALT,total bilirubin times the,0,0.4992074966430664
TANZEUM,elevation in ALT,third,0,0.49123114347457886
TANZEUM,elevation in ALT,the third case,0,0.4353436827659607
TANZEUM,elevation in ALT,refute,0,0.5049192905426025
TANZEUM,elevation in ALT,elevation in ALT times the,1,0.9192008972167969
TANZEUM,elevation in ALT,in ALT,1,0.8135520815849304
TANZEUM,elevation in ALT,elevation in ALT times,1,0.9076394438743591
TANZEUM,elevation in ALT,a drugrelated causality,0,0.4616907238960266
TANZEUM,increase in total bilirubin,by increase,1,0.6590157747268677
TANZEUM,increase in total bilirubin,total bilirubin,1,0.9021502733230591
TANZEUM,increase in total bilirubin,normal and,0,0.5014362335205078
TANZEUM,increase in total bilirubin,normal was accompanied by increase in total bilirubin,1,0.9327777624130249
TANZEUM,increase in total bilirubin,of TANZEUM The etiolo,0,0.5432897210121155
TANZEUM,increase in total bilirubin,normal and occurred days,0,0.5330709218978882
TANZEUM,increase in total bilirubin,in total bilirubin times the upper limit,1,0.8486420512199402
TANZEUM,increase in total bilirubin,case elevation in ALT times the upper limit of,0,0.5339095592498779
TANZEUM,increase in total bilirubin,total bilirubin times,1,0.8400907516479492
TANZEUM,hepatocellular injury,of TANZEUM The etiology of,0,0.51400226354599
TANZEUM,hepatocellular injury,etiology hepatocellular injury,1,0.8888516426086426
TANZEUM,hepatocellular injury,TANZEUM The etiology hepatocellular injury,1,0.8053693771362305
TANZEUM,increased GGT,more frequently in the group treated with TANZEUM and for placebo,0,0.6268882155418396
TANZEUM,increased GGT,event of,0,0.4666001796722412
TANZEUM,increased GGT,increased GGT occurred more frequently,1,0.9511821269989014
TANZEUM,increased GGT,trials the adverse event increased GGT,1,0.8928847908973694
TANZEUM,increased GGT,increased GGT occurred,1,0.980984091758728
TANZEUM,increased GGT,and,0,0.4757530093193054
TANZEUM,increase in heart rate,established,0,0.5035200715065002
TANZEUM,increase in heart rate,been established,0,0.5024420619010925
TANZEUM,THYROID C-CELL TUMORS,ng serious reactions,1,0.47972455620765686
TANZEUM,THYROID C-CELL TUMORS,ng serious reactions are described below or elsewhere,1,0.5112435817718506
TANZEUM,THYROID C-CELL TUMORS,ng serious,1,0.4938243627548218
TANZEUM,THYROID C-CELL TUMORS,ng serious reactions ,1,0.47972455620765686
TANZEUM,THYROID C-CELL TUMORS,The ng serious reactions  are described below or,1,0.5000492930412292
TANZEUM,THYROID C-CELL TUMORS,o,0,0.4924567937850952
TANZEUM,THYROID C-CELL TUMORS,described below r elsewhere in the pr,1,0.49955666065216064
TANZEUM,THYROID C-CELL TUMORS,below,0,0.47233256697654724
TANZEUM,THYROID C-CELL TUMORS,described,0,0.47635605931282043
TANZEUM,THYROID C-CELL TUMORS,elsewhere in the pr escribing information Risk of Thyroid,1,0.6784850358963013
TANZEUM,thyroid C-cell tumors,(5.2)] *,1,0.46545541286468506
TANZEUM,thyroid C-cell tumors,"see Warnings and ecautions (5.2)]  
 * Hypoglycemia with Concomitant Use of",1,0.5710573196411133
TANZEUM,thyroid C-cell tumors,Precautions,0,0.468729704618454
TANZEUM,thyroid C-cell tumors,ecautions (5.2)] *,1,0.48818373680114746
TANZEUM,C-cell tumors,Precautions Renal,0,0.5052989721298218
TANZEUM,C-cell tumors,Insulin Secretagogues or Insulin see Warnings and,0,0.5504506230354309
TANZEUM,C-cell tumors,autions (5.3) Hypersensitivity Reactions see Warnings,1,0.5391743183135986
TANZEUM,C-cell tumors,Insulin see Warnings and autions (5.3),1,0.5173641443252563
TANZEUM,C-cell tumors,Hypersensitivity Reactions see Warnings and Precautions Renal,0,0.5173018574714661
TANZEUM,C-cell tumors,and Precautions Renal Impairment,0,0.4632733464241028
TANZEUM,thyroid C-cell tumors,Renal Impairment see,1,0.45476946234703064
TANZEUM,thyroid C-cell tumors,and *    Renal Impairment see Warnings and Precautions EXCERPT,1,0.47480013966560364
TANZEUM,thyroid C-cell tumors,and *    Renal Impairment see Warnings,1,0.4754863679409027
TANZEUM,thyroid C-cell tumors,and *    Renal Impairment see Warnings and,1,0.4781103730201721
TANZEUM,thyroid C-cell tumors,Reactions see Warnings and * Renal Impairment,1,0.4812603294849396
TANZEUM,thyroid C-cell tumors,Reactions see Warnings and *    Renal Impairment see Warnings and Precautions EXCERPT,1,0.48792457580566406
TANZEUM,thyroid C-cell tumors,Warnings,0,0.5146732330322266
TANZEUM,thyroid C-cell tumors,Warnings and * Renal Impairment,1,0.49357011914253235
TANZEUM,thyroid C-cell tumors,reported in,0,0.4872879981994629
TANZEUM,medullary thyroid carcinoma,Renal,0,0.5154287815093994
TANZEUM,medullary thyroid carcinoma,and Precautions,0,0.4326207637786865
TANZEUM,medullary thyroid carcinoma,patients treated with,0,0.5272539854049683
TANZEUM,medullary thyroid carcinoma,see gs and Precautions (5.5)],1,0.41946911811828613
TANZEUM,medullary thyroid carcinoma,Renal Impairment see gs and Precautions,1,0.4550504684448242
TANZEUM,medullary thyroid carcinoma,Warnin,0,0.47981321811676025
TANZEUM,medullary thyroid carcinoma,Impairment see Warnin,0,0.47925591468811035
TANZEUM,medullary thyroid carcinoma,with TANZEUM and more freq,0,0.503800630569458
TANZEUM,MTC,and more,0,0.5267365574836731
TANZEUM,MTC,Impairment see Warnings and     EXCERPT,1,0.49469733238220215
TANZEUM,MTC,    EXCERPT Adverse,1,0.4862701892852783
TANZEUM,thyroid C-cell tumors,see Cli,0,0.496619313955307
TANZEUM,thyroid C-cell tumors,olled trials TANZEUM was used as monotherapy in trial and as addon therapy in trials see Cli,0,0.5270597338676453
TANZEUM,thyroid C-cell tumors,trials see nical Studies (14)]   These data reflect,1,0.5132253766059875
TANZEUM,thyroid C-cell tumors,therapy in trials see nical Studies (14)]   These data reflect exposure of,1,0.5245243906974792
TANZEUM,thyroid C-cell tumors,in trials see nical Studies (14)],1,0.5425286293029785
TANZEUM,thyroid C-cell tumors,mean duration of,0,0.4351344704627991
TANZEUM,thyroid C-cell tumors,nical Studies (14)]   These data reflect,1,0.4940256178379059
TANZEUM,thyroid C-cell tumors,nical Studies (14)] These data reflect,1,0.4940256178379059
TANZEUM,thyroid C-cell tumors,Studies (14)] These,1,0.4808374047279358
TANZEUM,C-cell tumors,TANZEUM and a mean,0,0.5037424564361572
TANZEUM,C-cell tumors,years or older and,0,0.4808811843395233
TANZEUM,C-cell tumors,of exposure to EUM of 93 wee,1,0.48808079957962036
TANZEUM,C-cell tumors,exposure to EUM of 93,1,0.49859490990638733
TANZEUM,C-cell tumors,reflect exposure of patients to TANZEUM and a,0,0.5304677486419678
TANZEUM,thyroid C-cell tumors,years or older and 53,1,0.4573392868041992
TANZEUM,thyroid C-cell tumors,years or older and 53 of participants were male,1,0.45543527603149414
TANZEUM,medullary thyroid carcinoma,or older and of pants were male. The popula tion in,1,0.4290279746055603
TANZEUM,medullary thyroid carcinoma,years or older and 53,1,0.42575550079345703
TANZEUM,medullary thyroid carcinoma,of,0,0.4277973175048828
TANZEUM,medullary thyroid carcinoma,of partici,0,0.42109423875808716
TANZEUM,medullary thyroid carcinoma,and of pants were male. The popula tion in,1,0.42269769310951233
TANZEUM,medullary thyroid carcinoma,were male. The popula tion,1,0.4219494163990021
TANZEUM,medullary thyroid carcinoma,were male. The popula tion in these studies was,1,0.440726101398468
TANZEUM,medullary thyroid carcinoma,The popula,1,0.4061245322227478
TANZEUM,medullary thyroid carcinoma,studies was white AfricanAfrican American Asian,0,0.38757407665252686
TANZEUM,MTC,white AfricanAfrican American Asian and HispanicLatino At,0,0.5021728277206421
TANZEUM,MTC,white AfricanAfrican American Asian,0,0.48881393671035767
TANZEUM,MTC,or older and of participants were,0,0.5379853248596191
TANZEUM,MTC,on  in,1,0.5530903339385986
TANZEUM,MTC,and HispanicLatino,0,0.5024420619010925
TANZEUM,MTC,The on  in these studies,1,0.5095958709716797
TANZEUM,MTC,American Asian and HispanicLatino,0,0.483944296836853
TANZEUM,Thyroid C-cell Tumors,described b elow,1,0.458465576171875
TANZEUM,Thyroid C-cell Tumors,elsewhere in the prescribing information Risk of Thyroid Ccell Tumors see Warnin,0,0.7874202132225037
TANZEUM,Thyroid C-cell Tumors,are described b elow or elsewhere in,1,0.46910035610198975
TANZEUM,Thyroid C-cell Tumors,Tumors see Warnin,0,0.6355257034301758
TANZEUM,Thyroid C-cell Tumors,tions are described b elow or elsewhere,1,0.4768998622894287
TANZEUM,Thyroid C-cell Tumors,The following serious,0,0.4948709011077881
TANZEUM,Thyroid C-cell Tumors,reac,0,0.45955073833465576
TANZEUM,Pancreatitis,prescribin,0,0.49864763021469116
TANZEUM,Pancreatitis,Ccell Tumors see,0,0.5188652276992798
TANZEUM,Hypoglycemia,Hypoglycemi,0,0.9025231599807739
TANZEUM,Hypoglycemia,and Precautions a with Conco mitant Use of Insulin,1,0.670028567314148
TANZEUM,Hypersensitivity Reactions,with,0,0.5276298522949219
TANZEUM,Hypersensitivity Reactions,treated,0,0.6035287976264954
TANZEUM,Hypersensitivity Reactions,treated with TANZEUM and,0,0.5947923064231873
TANZEUM,Renal Impairment,"placebo, wer e",1,0.4870041310787201
TANZEUM,Renal Impairment,"on placebo, wer e upper respiratory",1,0.502897322177887
TANZEUM,Renal Impairment,"on placebo, wer e upper respiratory tract infection",1,0.5193254947662354
TANZEUM,thyroid C-cell tumors,Controlled,1,0.4894488453865051
TANZEUM,thyroid C-cell tumors,Controlled Trials The,1,0.5218582153320312
TANZEUM,thyroid C-cell tumors,"in practice Pool of Controlled Trials  

 The",1,0.5117098093032837
TANZEUM,C-cell tumors, monotherapy  in,1,0.5363155007362366
TANZEUM,C-cell tumors, monotherapy  in trial,1,0.5250504016876221
TANZEUM,C-cell tumors,data reflect,0,0.4564625024795532
TANZEUM,C-cell tumors,are,0,0.47727930545806885
TANZEUM,C-cell tumors, monotherapy  in trial and,1,0.5296804904937744
TANZEUM,C-cell tumors,in Table are derived from placebocontrolled trials,0,0.5362510681152344
TANZEUM,thyroid C-cell tumors,and a,0,0.4690423309803009
TANZEUM,MTC,TANZEUM and a mean duration of exposure to TANZEUM of weeks The,0,0.5558363199234009
TANZEUM,MTC, 92 patients to TANZEUM,1,0.5752376317977905
TANZEUM,MTC,reflect exposure  92 patients to TANZEUM and,1,0.563477635383606
TANZEUM,MTC,in trials see,0,0.5144200325012207
TANZEUM,MTC,exposure,0,0.5174269080162048
TANZEUM,MTC,patients to,0,0.5505532026290894
TANZEUM,MTC,mean,0,0.5361987352371216
TANZEUM,MTC,nts were years or older,1,0.5748939514160156
TANZEUM,MTC,nts,1,0.5701398849487305
TANZEUM,MTC,in these studies was,0,0.5156702995300293
TANZEUM,MTC,was years of nts were years or,1,0.5454899072647095
TANZEUM,MTC,participants was years,0,0.5279186964035034
TANZEUM,MTC,of nts were years,1,0.5579826235771179
TANZEUM,MTC,diabetes for an average,0,0.43099504709243774
TANZEUM,MTC,pat hy Baseline estimated renal,1,0.5167302489280701
TANZEUM,hypoglycemia,Adverse Reactions In the pool of placebocontroll,0,0.5744748115539551
TANZEUM,hypoglycemia,pool of,0,0.45842382311820984
TANZEUM,hypoglycemia,"of ed trials, g astrointestinal complaints occurred more",1,0.5048190355300903
TANZEUM,hypoglycemia,of ed,1,0.5248567461967468
TANZEUM,hypoglycemia,"trials, g astrointestinal complaints occurred more frequently",1,0.51343834400177
TANZEUM,hypoglycemia,"ed trials, g astrointestinal",1,0.5241419076919556
TANZEUM,hypoglycemia,"ed trials,",1,0.5116757154464722
TANZEUM,hypoglycemia,the following tinal advers e,1,0.47996532917022705
TANZEUM,hypoglycemia,addition to diarrhea,0,0.5508610606193542
TANZEUM,hypersensitivity reaction,versus TANZEUM gastroesophageal reflux disease versus for placebo versus TAN,0,0.5212685465812683
TANZEUM,hypersensitivity reaction,"versus ZEUM), and",1,0.5257009863853455
TANZEUM,hypersensitivity reaction,and dyspepsia (2.8 versus for,1,0.5219324231147766
TANZEUM,hypersensitivity reaction,to the,0,0.531233549118042
TANZEUM,pruritus,reflux disease,0,0.5536677837371826
TANZEUM,pruritus,us 3.4% for,1,0.48719149827957153
TANZEUM,pruritus,contributed to the frequently,0,0.47592926025390625
TANZEUM,pruritus,versus TANZEUM and dyspepsia us 3.4%  for placebo,1,0.5933472514152527
TANZEUM,pruritus,us 3.4% for placebo versus TANZEUM,1,0.5669249296188354
TANZEUM,pruritus,dyspepsia us,1,0.5647530555725098
TANZEUM,pruritus,TANZEUM and dyspepsia us 3.4%  for placebo,1,0.5849565267562866
TANZEUM,pruritus,reported,0,0.5490114092826843
TANZEUM,pruritus,vers,0,0.522808313369751
TANZEUM,rash,r pl,1,0.5397531986236572
TANZEUM,rash,versus TANZEUM Constipation also contributed to the frequently,0,0.5311895608901978
TANZEUM,rash,r pl acebo,1,0.5294485092163086
TANZEUM,rash,r pl acebo versus TANZEUM,1,0.5340690612792969
TANZEUM,dyspnea,versus  TANZEUM Constipation also contributed to,1,0.5634291172027588
TANZEUM,dyspnea,dyspepsia versus for versus  TANZEUM Constipation,1,0.6014679074287415
TANZEUM,dyspnea,dyspepsia versus for versus ,1,0.6512395143508911
TANZEUM,dyspnea,the group treated w,0,0.5136420726776123
TANZEUM,dyspnea,versus  TANZEUM Constipation also contributed,1,0.5707100629806519
TANZEUM,dyspnea,versus  TANZEUM Constipation,1,0.5560498237609863
TANZEUM,dyspnea,versus ,1,0.5349725484848022
TANZEUM,dyspnea,disease versus for placebo,0,0.5176548957824707
TANZEUM,dyspnea,placebo,0,0.5143555402755737
TANZEUM,dyspnea,for versus  TANZEUM Constipation also,1,0.5751504898071289
TANZEUM,worsening of chronic renal failure,"Site ions  



 In the pool of placebo- controlled trials injection site",1,0.4821428656578064
TANZEUM,worsening of chronic renal failure,placebo,0,0.44168442487716675
TANZEUM,worsening of chronic renal failure,Injection Site ions In the,1,0.49624305963516235
TANZEUM,worsening of chronic renal failure,of placebo- controlled trials injection site reactions,1,0.4693863093852997
TANZEUM,worsening of chronic renal failure,adverse reactions occurred in of individuals on TANZEUM,0,0.5500704050064087
TANZEUM,worsening of chronic renal failure,Site,0,0.4758709669113159
TANZEUM,worsening of chronic renal failure,In the pool of placebo- controlled trials injection site,1,0.48590993881225586
TANZEUM,vomiting,types of site rea ctions,1,0.41705554723739624
TANZEUM,vomiting,In the pool of placebo- controlled trials injection site,1,0.5236545205116272
TANZEUM,vomiting,types of injection,0,0.5481293201446533
TANZEUM,vomiting,the following other types of injection,0,0.5430300831794739
TANZEUM,vomiting,types of,0,0.49422115087509155
TANZEUM,diarrhea,ions als o occurred,1,0.5809838175773621
TANZEUM,diarrhea,on TANZEUM injection site hematoma,0,0.4826277196407318
TANZEUM,diarrhea,injection site ions als o occurred more frequently on,1,0.5472202301025391
TANZEUM,diarrhea,to the term injection site reaction see Table the following other types,0,0.5241310000419617
TANZEUM,diarrhea,see Table the following other types of injection site react,0,0.5153590440750122
TANZEUM,diarrhea,types of injection site ions,1,0.5085170269012451
TANZEUM,diarrhea,frequently on TANZEUM injection site hematoma versus for placebo,0,0.4951266944408417
TANZEUM,dehydration,injection site reactions also urred,1,0.5430043935775757
TANZEUM,dehydration,injection site hematoma versus for placebo versus TANZEUM injec,0,0.5482951402664185
TANZEUM,dehydration,urred more frequently on TANZEUM injection site,1,0.5644140243530273
TANZEUM,dehydration,njection site reaction,0,0.5160459280014038
TANZEUM,dehydration,occ,0,0.46616071462631226
TANZEUM,dehydration,urred more,1,0.5237022638320923
TANZEUM,dehydration,reactions also occ,0,0.5179935097694397
TANZEUM,dehydration,versus for placebo versus TANZEUM,0,0.5642261505126953
TANZEUM,renal function declined,"for placebo s TANZEUM), injection",1,0.45673608779907227
TANZEUM,renal function declined,injection s ite rash,1,0.46645617485046387
TANZEUM,renal function declined,for,0,0.4736977815628052
TANZEUM,renal function declined,site,0,0.4587625563144684
TANZEUM,renal function declined,ersus for placebo versus TANZEUM injection site erythema,0,0.4613095819950104
TANZEUM,renal function declined,"for placebo s TANZEUM),",1,0.4362289309501648
TANZEUM,renal function declined,for placebo,0,0.4544350206851959
BELEODAQ,Infection,Infection see Warnings and Precautions Hepatotoxicity,1,0.7092516422271729
BELEODAQ,Infection,Infection see,1,0.8705997467041016
BELEODAQ,Infection,Infection see Warnings,1,0.8067978620529175
BELEODAQ,Hepatotoxicity,Infection see Warnings and Hepatotoxicity see Warnings,1,0.8169815540313721
BELEODAQ,Hepatotoxicity,Infection see Warnings,1,0.5729438066482544
BELEODAQ,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions,1,0.8759649395942688
BELEODAQ,Hepatotoxicity,Hepatotoxicity see Warnings,1,0.8999106287956238
BELEODAQ,Hepatotoxicity,see Warnings and,0,0.575476348400116
BELEODAQ,Hepatotoxicity,see Warnings and Precautions,0,0.5665377378463745
BELEODAQ,Gastrointestinal Toxicity,and Gastrointestinal Toxicity see,1,0.9649758338928223
BELEODAQ,Gastrointestinal Toxicity,see Warnings and Precautions,0,0.5885888338088989
BELEODAQ,Gastrointestinal Toxicity,see Warnings and Gastrointestinal Toxicity see,1,0.8980362415313721
BELEODAQ,Gastrointestinal Toxicity,Syndrome see Warnings and Gastrointestinal Toxicity see Warnings and Precautions,1,0.8232625722885132
BELEODAQ,Gastrointestinal Toxicity,adverse reactions observed in the tr,0,0.6702336072921753
BELEODAQ,Gastrointestinal Toxicity,see Warnings and Gastrointestinal Toxicity see Warnings and Precautions The,1,0.8479450941085815
BELEODAQ,Gastrointestinal Toxicity,and Precautions The most common adverse reactions observed,0,0.5993566513061523
BELEODAQ,nausea,refractory PTCL treated with Beleodaq,0,0.49025049805641174
BELEODAQ,nausea,tions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq,0,0.49875837564468384
BELEODAQ,nausea,with Beleodaq nausea fatigue pyrexia anemia and,1,0.7494668364524841
BELEODAQ,nausea,see,0,0.539847731590271
BELEODAQ,nausea,nausea,1,1.0
BELEODAQ,fatigue,with,0,0.5535378456115723
BELEODAQ,pyrexia,were nausea pyrexia anemia and vomiting see,1,0.7924370765686035
BELEODAQ,pyrexia,with,0,0.5324455499649048
BELEODAQ,anemia,Beleodaq were nausea fatigue anemia and,1,0.7710002660751343
BELEODAQ,anemia,with,0,0.5693405270576477
BELEODAQ,nausea,nausea fatigue pyrexia,1,0.8081904649734497
BELEODAQ,nausea,nausea fatigue pyrexia anemia,1,0.781575620174408
BELEODAQ,nausea,reactions nausea fatigue pyrexia anemia and vomiting,1,0.7965474128723145
BELEODAQ,nausea,nausea fatigue pyrexia anemia and vomiting,1,0.7976959943771362
BELEODAQ,nausea,report SUSPECTED ADVERSE,0,0.5773508548736572
BELEODAQ,fatigue,reactions are fatigue pyrexia anemia and vomiting,1,0.7115069627761841
BELEODAQ,fatigue,report SUSPECTED ADVERSE,0,0.5327715277671814
BELEODAQ,fatigue,pyrexia anemia and vomiting To report SUSPECTED,0,0.5912452936172485
BELEODAQ,fatigue,common adverse reactions are fatigue pyrexia anemia and vomiting To,1,0.6756129860877991
BELEODAQ,fatigue,fatigue pyrexia anemia and,1,0.7817109227180481
BELEODAQ,fatigue,fatigue pyrexia,1,0.8012109994888306
BELEODAQ,fatigue,fatigue pyrexia anemia and vomiting,1,0.7367894649505615
BELEODAQ,fatigue,are fatigue pyrexia anemia and,1,0.7616161704063416
BELEODAQ,fatigue,most common adverse reactions are nausea,0,0.5637637376785278
BELEODAQ,pyrexia,pyrexia anemia and vomiting To,1,0.7927047610282898
BELEODAQ,pyrexia,EXCERPT,0,0.5209224224090576
BELEODAQ,anemia,anemia and vomiting To report SUSPECTED,1,0.7703749537467957
BELEODAQ,anemia,EXCERPT The most common adverse reactions are nausea fatigue,0,0.5586519241333008
BELEODAQ,anemia,anemia,1,1.0
BELEODAQ,anemia,pyrexia,0,0.5942764282226562
BELEODAQ,vomiting,anemia vomiting,1,0.8423249125480652
BELEODAQ,vomiting,pyrexia,0,0.6160907745361328
BELEODAQ,vomiting,fatigue pyrexia anemia vomiting To report SUSPECTED,1,0.7478716373443604
BELEODAQ,vomiting,vomiting To,1,0.9564907550811768
BELEODAQ,vomiting,vomiting To report SUSPECTED ADVERSE REACTIONS,1,0.8437035083770752
BELEODAQ,vomiting,are nausea fatigue pyrexia anemia and,0,0.642311692237854
BELEODAQ,vomiting,ADVERSE REACTIONS contact Spectrum Pharmaceuticals Inc at,0,0.5537142753601074
BELEODAQ,pneumonia,pneumonia pyrexia infection,1,0.7772016525268555
BELEODAQ,pneumonia,and multiorgan,0,0.5485625863075256
BELEODAQ,pneumonia,after their last dose of Beleodaq,0,0.5385833978652954
BELEODAQ,pneumonia,pneumonia pyrexia infection anemia increased,1,0.7211034297943115
BELEODAQ,pneumonia,pneumonia pyrexia infection anemia,1,0.7460302114486694
BELEODAQ,pneumonia,multiorgan,0,0.5488318204879761
BELEODAQ,pneumonia,multiorgan failure One t,0,0.5523130893707275
BELEODAQ,pyrexia,their last dose of Beleodaq The most common,0,0.5320531725883484
BELEODAQ,pyrexia,creatinine thrombocytopenia and multiorgan failure,0,0.5219970941543579
BELEODAQ,pyrexia,pyrexia infection anemia,1,0.8419613242149353
BELEODAQ,infection,pneumonia infection anemia increased creatinine thrombocytopenia and,1,0.63666832447052
BELEODAQ,infection,pyrexia infection anemia,1,0.6504871845245361
BELEODAQ,infection,increased creatinine thrombocytopenia and,0,0.5582033395767212
BELEODAQ,infection,common serious,0,0.5383667349815369
BELEODAQ,infection,were pneumonia pyrexia,0,0.6075177788734436
BELEODAQ,infection,infection anemia increased creatinine thrombocytopenia and,1,0.6677911877632141
BELEODAQ,anemia,failure,0,0.5085068345069885
BELEODAQ,anemia,pneumonia pyrexia anemia,1,0.7693166136741638
BELEODAQ,anemia,anemia increased creatinine,1,0.788631021976471
BELEODAQ,anemia,were pneumonia pyrexia anemia increased,1,0.7205532789230347
BELEODAQ,increased creatinine,infection increased,1,0.6411039233207703
BELEODAQ,increased creatinine,increased creatinine,1,1.0000001192092896
BELEODAQ,increased creatinine,increased creatinine thrombocytopenia,1,0.8633071780204773
BELEODAQ,increased creatinine,death associated with hepatic,0,0.5176870226860046
BELEODAQ,increased creatinine,pneumonia pyrexia infection increased creatinine,1,0.8111912608146667
BELEODAQ,increased creatinine,increased creatinine thrombocytopenia and multiorgan failure One,1,0.7855981588363647
BELEODAQ,thrombocytopenia,infection anemia increased,0,0.5759830474853516
BELEODAQ,thrombocytopenia,serious adverse,0,0.4772059917449951
BELEODAQ,thrombocytopenia,associated with hepatic failure was reported,0,0.530109703540802
BELEODAQ,multi-organ failure,creatinine thrombocytopenia multi-organ failure One treatmentrelated,1,0.804526150226593
BELEODAQ,multi-organ failure,associated with hepatic failure was reported,0,0.7019033432006836
BELEODAQ,multi-organ failure,multi-organ failure One treatmentrelated,1,0.9221822619438171
BELEODAQ,hepatic failure,death associated hepatic,1,0.7406338453292847
BELEODAQ,hepatic failure,One treatmentrelated death associated hepatic,1,0.7216735482215881
BELEODAQ,hepatic failure,the trial One patient with baseline,0,0.5359740257263184
BELEODAQ,hepatic failure,hyperuricemia and bulky disease experience,0,0.5259630680084229
BELEODAQ,hepatic failure,One patient with,0,0.5567175149917603
BELEODAQ,hepatic failure,hepatic failure was reported,1,0.9389727115631104
BELEODAQ,tumor lysis syndrome,tumor lysis,1,0.8857731819152832
BELEODAQ,tumor lysis syndrome,experienced,0,0.43815791606903076
BELEODAQ,tumor lysis syndrome,Grade,0,0.4498928189277649
BELEODAQ,tumor lysis syndrome,the first cycle of treatment and died,0,0.5487788915634155
BELEODAQ,tumor lysis syndrome,lysis syndrome during the first,1,0.8055314421653748
BELEODAQ,died,ventricular fibrillation was reported in,0,0.5669508576393127
BELEODAQ,multi-organ failure,lysis syndrome,0,0.5887895822525024
BELEODAQ,multi-organ failure,multi-organ failure A treatmentrelated death,1,0.8976935148239136
BELEODAQ,multi-organ failure,treatment and died due multi-organ failure,1,0.8715623617172241
BELEODAQ,multi-organ failure,died due multi-organ failure,1,0.8923205137252808
BELEODAQ,multi-organ failure,multi-organ failure A treatmentrelated death from,1,0.8990336060523987
BELEODAQ,multi-organ failure,due multi-organ failure A treatmentrelated death from,1,0.8976602554321289
BELEODAQ,death,death from ventricular,1,0.7531131505966187
BELEODAQ,death,to multiorgan failure A death from ventricular fibrillation was reported,1,0.645200252532959
BELEODAQ,QTc prolongation,Twentyfive patients discontinued tr,0,0.5395187139511108
BELEODAQ,QTc prolongation,Adverse,0,0.49975472688674927
BELEODAQ,QTc prolongation,clinical trial with Beleodaq ECG analysis did,0,0.6976480484008789
BELEODAQ,QTc prolongation,QTc prolongation,1,0.9999997615814209
BELEODAQ,QTc prolongation,Twentyfive patients,0,0.5474480390548706
BELEODAQ,QTc prolongation,analysis did not QTc prolongation Discontinuations due to Adverse Reactions,1,0.8133281469345093
BELEODAQ,QTc prolongation,Discontinuations due to Adverse,0,0.5646212100982666
BELEODAQ,QTc prolongation,not QTc prolongation,1,0.8909488916397095
BELEODAQ,febrile neutropenia,treatment,0,0.5600511431694031
BELEODAQ,febrile neutropenia,discontinuation of treatment included febrile neutropenia,1,0.8103060722351074
BELEODAQ,febrile neutropenia,febrile neutropenia,1,1.0
BELEODAQ,febrile neutropenia,included febrile neutropenia,1,0.9549489617347717
BELEODAQ,febrile neutropenia,Modifications due to Adverse Reactions,0,0.541810154914856
BELEODAQ,febrile neutropenia,febrile neutropenia fatigue and,1,0.8712180852890015
BELEODAQ,febrile neutropenia,febrile neutropenia fatigue and multiorgan failure Dosage,1,0.8071845173835754
BELEODAQ,febrile neutropenia,treatment included febrile,1,0.7531976103782654
BELEODAQ,fatigue,fatigue and,1,0.9332207441329956
BELEODAQ,fatigue,fatigue and multiorgan failure Dosage,1,0.7974664568901062
BELEODAQ,leukopenia,are escribed i n more detail in other,1,0.5205628275871277
BELEODAQ,leukopenia,fatigue and multiorgan failure Dosage,1,0.5465571880340576
BELEODAQ,leukopenia,escribed i,1,0.503516674041748
BELEODAQ,leukopenia,adverse reactions are escribed i n more,1,0.5235412120819092
BELEODAQ,leukopenia,the prescribing information Hematologic Toxicity,0,0.602607250213623
BELEODAQ,leukopenia,escribed i n more,1,0.5336745381355286
BELEODAQ,leukopenia,are,0,0.484359472990036
BELEODAQ,leukopenia,prescribing information Hematologic,0,0.6073211431503296
BELEODAQ,leukopenia,escribed i n more detail in,1,0.5326781868934631
BELEODAQ,neutropenia,more detail in other sections,1,0.48670345544815063
BELEODAQ,neutropenia,escribed i n more detail in,1,0.5135700106620789
BELEODAQ,lymphopenia,in ther sectio,1,0.5115251541137695
BELEODAQ,lymphopenia,information Hematologic Toxicity see,0,0.632900059223175
BELEODAQ,lymphopenia,ther sectio ns of the prescribing information,1,0.48125723004341125
BELEODAQ,lymphopenia,in ther sectio ns of the prescribing information,1,0.48934638500213623
BELEODAQ,anemia,he pre,1,0.5547276735305786
BELEODAQ,Infection,Toxicity see Warnings and * In,1,0.5825705528259277
BELEODAQ,Infection,*,1,0.5794081091880798
BELEODAQ,Infection,"see Warnings and 
 *    In fection",1,0.5492814779281616
BELEODAQ,Infection,and Precautions Hepatotoxicity,0,0.5566254258155823
BELEODAQ,Infection,Warnings and *,1,0.568816065788269
BELEODAQ,fatal,arnin gs and Precautions,1,0.5248169898986816
BELEODAQ,fatal,arnin gs,1,0.5020948648452759
BELEODAQ,fatal,arnin gs and Precautions Hepatotoxicity,1,0.5567158460617065
BELEODAQ,fatal,see Warnings and Precautions Infection,0,0.47722336649894714
BELEODAQ,fatal,and,0,0.5288088321685791
BELEODAQ,fatal,Infection see,0,0.49946129322052
BELEODAQ,infections,Infection see s and Prec autions,1,0.8178519606590271
BELEODAQ,infections,Infection see,0,0.8162178993225098
BELEODAQ,infections,see Warnings and Precautions Tumor Lys,0,0.612747311592102
BELEODAQ,infections,s,1,0.5757824182510376
BELEODAQ,infections,autions Hepatotoxicity see Warnings and,0,0.5568662285804749
BELEODAQ,infections,Toxicity see Warnings and,0,0.5693378448486328
BELEODAQ,infections,Infection see s,1,0.7948189973831177
BELEODAQ,pneumonia,5.2 ) Hepatotoxicity see,1,0.5019152164459229
BELEODAQ,pneumonia,( 5.2 ) Hepatotoxicity see Warnings and Precautions,1,0.5284380912780762
BELEODAQ,pneumonia,Infection see,0,0.6451056003570557
BELEODAQ,pneumonia,Precautions Infection see Warnings and Precautions,0,0.5923004746437073
BELEODAQ,pneumonia,see Warnings and Precautions Tumor Lysis Syndrome see,0,0.5430494546890259
BELEODAQ,pneumonia,see Warnings and ( 5.2,1,0.5541327595710754
BELEODAQ,pneumonia,Toxicity see Warnings and Precautions Infection see Warnings,0,0.5797537565231323
BELEODAQ,pneumonia,Lysis,0,0.514666736125946
BELEODAQ,pneumonia,Hepatotoxicity see Warnings and,0,0.5142002105712891
BELEODAQ,sepsis,* H epatotoxicity see Warnings and Precautions,1,0.5723288059234619
BELEODAQ,sepsis,Warnings and *    H epatotoxicity see Warnings,1,0.5674937963485718
BELEODAQ,sepsis,see Warnings,0,0.5682778358459473
BELEODAQ,sepsis,and Precautions Infection see Warnings and,0,0.6285364627838135
BELEODAQ,sepsis,and *    H epatotoxicity see,1,0.572563886642456
BELEODAQ,sepsis,Precautions Infection,0,0.6615025997161865
BELEODAQ,Hepatotoxicity,and Prec autions Tumor Lysis Syndrome see,1,0.5569750070571899
BELEODAQ,Hepatotoxicity,Infection see,0,0.527174711227417
BELEODAQ,Hepatotoxicity,see nings and Prec autions Tumor Lysis Syndrome see,1,0.5564633011817932
BELEODAQ,Hepatotoxicity,and Prec,1,0.4871189594268799
BELEODAQ,Hepatotoxicity,see nings and Prec,1,0.4960842728614807
BELEODAQ,Hepatotoxicity,Hepatotoxicity see nings,1,0.8917074203491211
BELEODAQ,Tumor lysis syndrome,on adverse reactions observed in the trial of,1,0.5633994340896606
BELEODAQ,Tumor lysis syndrome,on,1,0.5048500299453735
BELEODAQ,Tumor lysis syndrome,refractory PTCL treated with Beleodaq were nause,0,0.5694422721862793
BELEODAQ,Tumor lysis syndrome,relapsed or refractory PTCL,0,0.577668309211731
BELEODAQ,Tumor lysis syndrome,on adverse reactions observed in the,1,0.5573102235794067
BELEODAQ,thrombocytopenia,d vomiting To report SUSPECTED ADVERSE REACTIONS contact Spectrum Pharmaceutical,0,0.5307799577713013
BELEODAQ,thrombocytopenia,"s, Inc. at 1-888 or FDA",1,0.4628017246723175
BELEODAQ,thrombocytopenia,"s, Inc. at 1-888 or FDA at FDA",1,0.44165730476379395
BELEODAQ,thrombocytopenia,"REACTIONS contact Spectrum s, Inc. at 1-888 or FDA at FDA",1,0.4803001880645752
BELEODAQ,thrombocytopenia,"REACTIONS contact Spectrum s, Inc. at",1,0.4712003469467163
BELEODAQ,thrombocytopenia,report SUSPECTED,0,0.48732662200927734
BELEODAQ,thrombocytopenia,at 1-888 or FDA,1,0.47753727436065674
BELEODAQ,leukopenia,92-9617 or FDA at,1,0.4442898631095886
BELEODAQ,leukopenia,92-9617 or,1,0.4189927577972412
BELEODAQ,leukopenia,Inc 92-9617 or,1,0.42211419343948364
BELEODAQ,leukopenia,wwwfdagovmedwatch Clinical,0,0.46481719613075256
BELEODAQ,leukopenia,contact Spectrum Pharmaceuticals,0,0.5002197027206421
BELEODAQ,leukopenia,REACTIONS,0,0.5170283317565918
BELEODAQ,leukopenia,FDA or wwwfdagovmedwatch,0,0.453163206577301
BELEODAQ,leukopenia,contact Spectrum Pharmaceuticals Inc 92-9617 or,1,0.4755493998527527
BELEODAQ,neutropenia,Pharmaceuticals Inc at or DA at 1-800,1,0.4666316509246826
BELEODAQ,neutropenia,Inc at or DA,1,0.4483604431152344
BELEODAQ,neutropenia,DA at 1-800,1,0.4085391163825989
BELEODAQ,neutropenia,at 1-800 FDA,1,0.45847225189208984
BELEODAQ,neutropenia,at or DA,1,0.44950756430625916
BELEODAQ,neutropenia,F,0,0.48564741015434265
BELEODAQ,neutropenia,at or DA at 1-800,1,0.42776069045066833
BELEODAQ,lymphopenia,clinical trials,0,0.5526587963104248
BELEODAQ,lymphopenia,clinical trials ar,0,0.5140823125839233
BELEODAQ,lymphopenia,FDA at 1088     or wwwfdagovmedwatch,1,0.4673415422439575
BELEODAQ,lymphopenia,at 1088     or,1,0.4385666847229004
BELEODAQ,lymphopenia,1088 or wwwfdagovmedwatch,1,0.4753454625606537
BELEODAQ,lymphopenia,Trials Experience,0,0.516355574131012
BELEODAQ,lymphopenia,1088 or wwwfdagovmedwatch Clinical,1,0.4828161597251892
BELEODAQ,lymphopenia,Clinical Trials Experience Because clinical trials ar,0,0.5203551054000854
BELEODAQ,lymphopenia,FDA,0,0.4928942918777466
BELEODAQ,anemia,.fda.g ovmedwatch,1,0.4975709319114685
BELEODAQ,fatal,in practice Adverse Reactions in Patients with Peripheral,0,0.504935622215271
BELEODAQ,fatal,t the rates,1,0.48037657141685486
BELEODAQ,fatal,t the rates observed in practice,1,0.45062708854675293
BELEODAQ,fatal,t the,1,0.5744321346282959
BELEODAQ,infections,rates obse rved in practice,1,0.4990510046482086
BELEODAQ,infections,reflect rates,1,0.46295273303985596
BELEODAQ,infections,not reflect rates obse,1,0.4574096202850342
BELEODAQ,infections,TCell Lymphoma The safe,0,0.5228605270385742
BELEODAQ,infections,may not reflect rates obse rved,1,0.4497109651565552
BELEODAQ,infections,rates obse,1,0.5106067061424255
BELEODAQ,infections,Reactions in Patients with Peripheral TCell Lymphoma The safe,0,0.5301967859268188
BELEODAQ,infections,reflect rates obse rved in practice Adverse Reactions,1,0.5813798308372498
BELEODAQ,infections,in Patients with Peripheral TCell Lymphoma The,0,0.5279959440231323
BELEODAQ,pneumonia,"tice.



 Adverse Reactions in",1,0.5236263275146484
BELEODAQ,pneumonia,"in tice.



 Adverse Reactions in Patients",1,0.5043796300888062
BELEODAQ,pneumonia,Adverse Reactions in Patients with Peripheral TCell Lymphoma The safety of,0,0.48174425959587097
BELEODAQ,pneumonia,"tice.



 Adverse Reactions",1,0.5162500143051147
BELEODAQ,pneumonia,"rates observed in tice.



 Adverse",1,0.5061106085777283
BELEODAQ,pneumonia,"tice.



 Adverse",1,0.5078769326210022
BELEODAQ,pneumonia,Lymphoma The safety of,0,0.5437770485877991
BELEODAQ,pneumonia,"observed in tice.



 Adverse Reactions in Patients",1,0.515913188457489
BELEODAQ,pneumonia,in,0,0.5434114933013916
BELEODAQ,sepsis,observed in,0,0.5645334720611572
BELEODAQ,sepsis,practice verse  Reactions in Patients with,1,0.5687024593353271
BELEODAQ,sepsis,observed in the clinical trials of Beleodaq,0,0.5879406929016113
BELEODAQ,fatal, dail y on Days of,1,0.5004968643188477
BELEODAQ,fatal,minutes by IV infusion  dail y on Days of,1,0.4857276678085327
BELEODAQ,fatal,IV infusion  dail,1,0.531064510345459
BELEODAQ,liver function test abnormalities,of 1-day cycle [see Clinical,1,0.5499633550643921
BELEODAQ,liver function test abnormalities,1-day cycle  [see Clinical Studie s The median,1,0.5503239631652832
BELEODAQ,liver function test abnormalities,daily on Days of 1-day cycle [see Clinical Studie,1,0.5631402134895325
BELEODAQ,liver function test abnormalities,Clinical Studie s The median duration,1,0.5404662489891052
BELEODAQ,liver function test abnormalities,on Days of 1-day cycle [see Clinical Studie,1,0.56661057472229
BELEODAQ,liver function test abnormalities,on Days of 1-day cycle  [see Clinical Studie,1,0.56661057472229
BELEODAQ,liver function test abnormalities,Clinical Studie s,1,0.5218846797943115
BELEODAQ,liver function test abnormalities,Days of 1-day cycle,1,0.48611173033714294
BELEODAQ,liver function test abnormalities,Days of 1-day cycle [see,1,0.48366057872772217
BELEODAQ,liver function test abnormalities,range cycles,0,0.4709366261959076
BELEODAQ,Tumor lysis syndrome,Preferred,0,0.4819486439228058
BELEODAQ,Tumor lysis syndrome,with psed or Refractory P TCL NCICTC,1,0.541029155254364
BELEODAQ,Tumor lysis syndrome,psed,1,0.5006872415542603
BELEODAQ,Tumor lysis syndrome,Preferred Term Percentage,0,0.4514884650707245
BELEODAQ,Tumor lysis syndrome,with psed or Refractory P TCL NCICTC Grade MedDRA Preferred,1,0.5641504526138306
BELEODAQ,Tumor lysis syndrome,of Patients by Preferred Term and Severity in,0,0.5034826993942261
BELEODAQ,Tumor lysis syndrome,MedDRA Preferred Term Percentage of Patie,0,0.4891582131385803
BELEODAQ,Tumor lysis syndrome,NCICTC Grade MedDRA,0,0.49266317486763
BELEODAQ,Tumor lysis syndrome,or Refractory P,1,0.5205042958259583
BELEODAQ,Tumor lysis syndrome,with psed or Refractory,1,0.5355486869812012
HALAVEN,neutropenia,reactions incidence neutropenia anemia astheniafatigue alopecia peripheral neuropathy,1,0.7744840383529663
HALAVEN,neutropenia,with psed or Refractory,1,0.5331666469573975
HALAVEN,neutropenia,common adverse reactions incidence neutropenia anemia astheniafatigue alopecia peripheral neuropathy,1,0.7163920402526855
HALAVEN,neutropenia,common adverse reactions incidence neutropenia,1,0.8087297081947327
HALAVEN,neutropenia,reactions incidence neutropenia anemia,1,0.8044127225875854
HALAVEN,neutropenia,reactions incidence neutropenia anemia astheniafatigue,1,0.7925535440444946
HALAVEN,neutropenia,adverse reactions incidence neutropenia anemia astheniafatigue alopecia,1,0.750971794128418
HALAVEN,neutropenia,neutropenia anemia astheniafatigue alopecia,1,0.7927311062812805
HALAVEN,neutropenia,alopecia,0,0.580955982208252
HALAVEN,neutropenia,neutropenia anemia astheniafatigue,1,0.8099592328071594
HALAVEN,anemia,anemia astheniafatigue,1,0.8321226835250854
HALAVEN,anemia,neutropenia anemia astheniafatigue,1,0.7540758848190308
HALAVEN,anemia,RSE REACTIONS EXCERPT The most common adverse reactions incidence were neutropenia,0,0.612598180770874
HALAVEN,anemia,anemia,1,1.0
HALAVEN,anemia,anemia astheniafatigue alopecia peripheral neuropathy,1,0.7857146263122559
HALAVEN,anemia,anemia astheniafatigue alopecia,1,0.7940425276756287
HALAVEN,anemia,anemia astheniafatigue alopecia peripheral,1,0.7824866771697998
HALAVEN,anemia,incidence were anemia astheniafatigue alopecia peripheral,1,0.7544316053390503
HALAVEN,anemia,constipation,0,0.5758628845214844
HALAVEN,asthenia,asthenia fatigue alopecia peripheral neuropathy,1,0.7434921264648438
HALAVEN,asthenia,asthenia fatigue alopecia peripheral neuropathy nausea,1,0.7669357061386108
HALAVEN,asthenia,asthenia,1,1.0000001192092896
HALAVEN,fatigue,were neutropenia anemia asthenia,0,0.6012778282165527
HALAVEN,fatigue,anemia fatigue,1,0.82509845495224
HALAVEN,alopecia,alopecia peripheral neuropathy nausea,1,0.7836217880249023
HALAVEN,alopecia,alopecia peripheral,1,0.8213419318199158
HALAVEN,alopecia,incidence were neutropenia anemia,0,0.5320603847503662
HALAVEN,alopecia,adverse reactions incidence were,0,0.5123099088668823
HALAVEN,peripheral neuropathy,peripheral neuropathy nausea and,1,0.880060076713562
HALAVEN,peripheral neuropathy,neutropenia anemia astheniafatigue peripheral,1,0.6816369295120239
HALAVEN,peripheral neuropathy,peripheral neuropathy nausea and constipation To report,1,0.8264885544776917
HALAVEN,peripheral neuropathy,astheniafatigue,0,0.46715211868286133
HALAVEN,peripheral neuropathy,REACTIONS contact Eisai Inc a,0,0.43872931599617004
HALAVEN,peripheral neuropathy,anemia astheniafatigue peripheral,1,0.7017062306404114
HALAVEN,nausea,were neutropenia anemia astheniafatigue alopecia peripheral neuropathy,0,0.5840741395950317
HALAVEN,nausea,nausea and,1,0.9323806762695312
HALAVEN,nausea,constipation To report SUSPECTED ADVERSE,0,0.601837158203125
HALAVEN,nausea,anemia astheniafatigue alopecia peripheral nausea and constipation To report SUSPECTED,1,0.704831600189209
HALAVEN,constipation,nausea constipation To,1,0.8444358706474304
HALAVEN,constipation,constipation To report SUSPECTED ADVERSE,0,0.8439298272132874
HALAVEN,constipation,constipation To report,1,0.8780911564826965
HALAVEN,constipation,alopecia peripheral neuropathy nausea and,0,0.5733612179756165
HALAVEN,constipation,constipation To,1,0.9169237613677979
HALAVEN,Neutropenia,other sections of the Neutropenia,1,0.8548427224159241
HALAVEN,Neutropenia,alopecia peripheral neuropathy nausea and,0,0.5922544002532959
HALAVEN,Neutropenia,Warnings,0,0.5334770679473877
HALAVEN,Neutropenia,sections of the Neutropenia see,1,0.8742636442184448
HALAVEN,Neutropenia,Warnings and Precautions Peripheral neuropathy see,0,0.5711207985877991
HALAVEN,Peripheral neuropathy,see Warnings and Peripheral neuropathy see Warnings and Precautions QT,1,0.7614085078239441
HALAVEN,Peripheral neuropathy,Warnings and Precautions Peripheral neuropathy see,0,0.8774169683456421
HALAVEN,Peripheral neuropathy,and Peripheral neuropathy see Warnings and,1,0.8805486559867859
HALAVEN,Peripheral neuropathy,Peripheral neuropathy see Warnings,1,0.8893578052520752
HALAVEN,Peripheral neuropathy,see Warnings and Pr,0,0.48283451795578003
HALAVEN,Peripheral neuropathy,and,0,0.4624190032482147
HALAVEN,QT interval prolongation,QT interval prolongation see,1,0.9773228168487549
HALAVEN,QT interval prolongation,Peripheral neuropathy see Warnings,1,0.5066149234771729
HALAVEN,QT interval prolongation,and QT interval prolongation see Warnings and Precautions,1,0.8942985534667969
HALAVEN,QT interval prolongation,ns Peripheral neuropathy see,0,0.5065265893936157
HALAVEN,QT interval prolongation,Warnings and QT interval prolongation see Warnings and Precautions The,1,0.8711432814598083
HALAVEN,QT interval prolongation,neuropathy see Warnings and QT interval prolongation,1,0.8009158372879028
HALAVEN,QT interval prolongation,Peripheral neuropathy see Warnings and Precautions,0,0.518794596195221
HALAVEN,neutropenia,in patients receiving HALAVEN were,0,0.5566239356994629
HALAVEN,neutropenia,nausea and constipation The,0,0.5334280133247375
HALAVEN,neutropenia,The most comm,0,0.45296189188957214
HALAVEN,anemia,HALAVEN were anemia astheniafatigue alopecia peripheral neuropathy,1,0.7496098875999451
HALAVEN,anemia,and constipation The most,0,0.5303241014480591
HALAVEN,anemia,The most,0,0.5145248174667358
HALAVEN,asthenia,were neutropenia asthenia,1,0.8146402835845947
HALAVEN,asthenia,The most,0,0.5106662511825562
HALAVEN,fatigue,HALAVEN were neutropenia anemia fatigue alopecia peripheral neuropathy nausea and,1,0.684067964553833
HALAVEN,fatigue,asthenia,1,0.6107425689697266
HALAVEN,fatigue,fatigue alopecia peripheral neuropathy nausea,1,0.7707791328430176
HALAVEN,fatigue,fatigue alopecia peripheral,1,0.7247433662414551
HALAVEN,alopecia,and constipation The most common serious adverse reactions,0,0.5210705399513245
HALAVEN,alopecia,alopecia peripheral neuropathy nausea and,1,0.7813180685043335
HALAVEN,alopecia,reported in patients,0,0.5285748243331909
HALAVEN,alopecia,astheniafatigue,0,0.570955753326416
HALAVEN,alopecia,alopecia peripheral neuropathy nausea and constipation,1,0.7541365623474121
HALAVEN,alopecia,most common,0,0.49945127964019775
HALAVEN,peripheral neuropathy,were,0,0.4590964913368225
HALAVEN,peripheral neuropathy,neutropenia anemia astheniafatigue peripheral neuropathy nausea and constipation,1,0.7039114236831665
HALAVEN,peripheral neuropathy,astheniafatigue alopecia,0,0.4885156750679016
HALAVEN,peripheral neuropathy,were neutropenia anemia astheniafatigue peripheral,1,0.6766452789306641
HALAVEN,nausea,peripheral,0,0.4734607934951782
HALAVEN,constipation,constipation The most,1,0.8839656114578247
HALAVEN,constipation,astheniafatigue alopecia,0,0.5162941813468933
HALAVEN,constipation,constipation The most common serious adverse,1,0.8282225131988525
HALAVEN,constipation,constipation,1,1.0
HALAVEN,constipation,constipation The most common serious,1,0.8371210098266602
HALAVEN,febrile neutropenia,patients receiving HALAVEN febrile neutropenia and neutropenia The most,1,0.7797753810882568
HALAVEN,febrile neutropenia,constipation The most common serious adverse,1,0.4541071355342865
HALAVEN,febrile neutropenia,in patients receiving HALAVEN febrile neutropenia and neutropenia,1,0.8005061149597168
HALAVEN,febrile neutropenia,febrile neutropenia and neutropenia The most,1,0.9054468870162964
HALAVEN,febrile neutropenia,most common,0,0.5043412446975708
HALAVEN,febrile neutropenia,receiving HALAVEN febrile neutropenia and,1,0.8126548528671265
HALAVEN,febrile neutropenia,adverse reaction resulting in discontinuation of,0,0.5407149791717529
HALAVEN,febrile neutropenia,The most common serious,0,0.5010184049606323
HALAVEN,neutropenia,HALAVEN were febrile neutropenia neutropenia The,1,0.8182934522628784
HALAVEN,neutropenia,The most common serious,0,0.5083692073822021
HALAVEN,neutropenia,was peripheral,0,0.5306172370910645
HALAVEN,neutropenia,discontinuation of HALAVEN was peripheral neuro,0,0.542790412902832
HALAVEN,neutropenia,neutropenia The most,1,0.9045102596282959
HALAVEN,neutropenia,neutropenia The most common adverse reaction,1,0.8212219476699829
HALAVEN,neutropenia,neutropenia The most common,1,0.8785052299499512
HALAVEN,neutropenia,were febrile neutropenia neutropenia The most common adverse reaction,1,0.7883192896842957
HALAVEN,neutropenia,neutropenia,1,1.0
HALAVEN,peripheral neuropathy,adverse,0,0.549394965171814
HALAVEN,peripheral neuropathy,administered to patients with multiple,0,0.55280601978302
HALAVEN,peripheral neuropathy,of HALAVEN peripheral,1,0.6447845101356506
HALAVEN,peripheral neuropathy,and neutropenia The most common adverse reaction,0,0.5463046431541443
HALAVEN,peripheral neuropathy,peripheral neuropathy In clinical trials HALAVEN has,1,0.822925865650177
HALAVEN,peripheral neuropathy,of HALAVEN peripheral neuropathy,1,0.8413808345794678
HALAVEN,peripheral neuropathy,in discontinuation of HALAVEN peripheral neuropathy In,1,0.7588208913803101
HALAVEN,Peripheral neuropathy,system Peripheral neuropathy,1,0.9181861877441406
HALAVEN,Peripheral neuropathy,disorders,0,0.5852333307266235
HALAVEN,Peripheral neuropathy,system disorders,0,0.5382242202758789
HALAVEN,Peripheral neuropathy,system,0,0.45744138956069946
HALAVEN,Peripheral neuropathy,Peripheral,1,0.7185572385787964
HALAVEN,Peripheral neuropathy,rvous system Peripheral neuropathy,1,0.8774796724319458
HALAVEN,Peripheral neuropathy,Peripheral neuropathy,1,1.0000001192092896
HALAVEN,Headache,General,0,0.5580604076385498
HALAVEN,Headache,ripheral neuropathy Headache,1,0.7686042785644531
HALAVEN,Headache,Headache General disorders,1,0.8275213241577148
HALAVEN,Headache,ripheral neuropathy b,0,0.5028800368309021
HALAVEN,Headache,Headache General,1,0.9000304341316223
HALAVEN,Headache,b,0,0.5286486148834229
HALAVEN,Headache,General disorders,0,0.5545405745506287
HALAVEN,Headache,Headache,1,0.9999998807907104
HALAVEN,Asthenia,Fatigue Mucosal inflamma,0,0.5663682818412781
HALAVEN,Asthenia,Fatigue,0,0.6107425689697266
HALAVEN,Asthenia,Asthenia Fatigue Mucosal inflamma,1,0.7328647375106812
HALAVEN,Arthralgia,Arthralgia Myalgia Back,1,0.8526193499565125
HALAVEN,Arthralgia,Arthralgia Myalgia,1,0.8964070677757263
HALAVEN,Arthralgia,Arthralgia,1,1.0
HALAVEN,Arthralgia,Myalgia,0,0.7334238290786743
HALAVEN,Arthralgia,Arthralgia Myalgia Back pain,1,0.8676302433013916
HALAVEN,Myalgia,Myalgia Back pain,1,0.8980801701545715
HALAVEN,Myalgia,disorders,0,0.6134374737739563
HALAVEN,Bone pain,Back Bone pain,1,0.891068696975708
HALAVEN,Bone pain,Bone pain Pain in,1,0.9521998167037964
HALAVEN,Bone pain,Bone pain Pain,1,0.9863152503967285
HALAVEN,Bone pain,Pain in,0,0.7574515342712402
HALAVEN,Bone pain,Pain,0,0.8075031638145447
HALAVEN,Bone pain,Back Bone pain Pain in extremity,1,0.8352175951004028
HALAVEN,Anorexia,Anorexia Respiratory,1,0.8018190264701843
HALAVEN,Anorexia,nutrition Anorexia Respiratory thoracic,1,0.7664508819580078
HALAVEN,Anorexia,Anorexia,1,1.0
HALAVEN,Urinary Tract Infection,a based upon,0,0.48097971081733704
HALAVEN,Urinary Tract Infection,and,0,0.5330232381820679
HALAVEN,Urinary Tract Infection,a based,0,0.506889283657074
HALAVEN,Urinary Tract Infection,and Urinary Tract Infection a,1,0.8949283361434937
HALAVEN,Urinary Tract Infection,a,0,0.5364865064620972
HALAVEN,neuropathy peripheral,neuropathy peripheral neuropathy peripheral,1,0.9808120131492615
HALAVEN,neuropathy peripheral,neuropathy polyneuropathy peripheral,0,0.961308479309082
HALAVEN,neuropathy peripheral,b neuropathy peripheral neuropathy,1,0.9219825863838196
HALAVEN,neuropathy peripheral,b neuropathy,1,0.8148688077926636
HALAVEN,neuropathy peripheral,neuropathy peripheral,1,0.9999997615814209
HALAVEN,neuropathy,neuropathy peripheral motor neuropathy,1,0.7877286672592163
HALAVEN,neuropathy,data b includes neuropathy,0,0.8062973022460938
HALAVEN,neuropathy,upon laboratory data b includes neuropathy peripheral,0,0.8145660161972046
HALAVEN,neuropathy,data b includes neuropathy neuropathy peripheral,1,0.7897319793701172
HALAVEN,neuropathy,neuropathy,1,1.0000001192092896
HALAVEN,neuropathy,neuropathy peripheral motor neuropathy polyneuropathy,1,0.8359177112579346
HALAVEN,neuropathy,neuropathy peripheral,1,0.8752395510673523
HALAVEN,peripheral motor neuropathy,peripheral motor neuropathy,1,1.000000238418579
HALAVEN,peripheral motor neuropathy,neuropathy peripheral,0,0.857935905456543
HALAVEN,peripheral motor neuropathy,b includes neuropathy peripheral peripheral motor neuropathy,1,0.9305381178855896
HALAVEN,peripheral motor neuropathy,motor neuropathy polyneuropathy peripheral sensoryneuropathy and paraesthesia,1,0.8753468990325928
HALAVEN,polyneuropathy,polyneuropathy peripheral sensoryneuropathy and paraesthesia,1,0.8514618873596191
HALAVEN,polyneuropathy,polyneuropathy peripheral sensoryneuropathy and paraesthesia c,1,0.828822672367096
HALAVEN,polyneuropathy,polyneuropathy peripheral sensoryneuropathy and,1,0.8792396783828735
HALAVEN,polyneuropathy,includes neuropathy peripheral,0,0.8287690281867981
HALAVEN,peripheral sensoryneuropathy,peripheral sensoryneuropathy and paraesthesia c not,1,0.9296820759773254
HALAVEN,peripheral sensoryneuropathy,peripheral sensoryneuropathy and paraesthesia c not applicable,1,0.8811506032943726
HALAVEN,peripheral sensoryneuropathy,includes neuropathy peripheral neuropathy peripheral motor,0,0.8052955269813538
HALAVEN,peripheral sensoryneuropathy,peripheral sensoryneuropathy and paraesthesia c,1,0.9285372495651245
HALAVEN,peripheral sensoryneuropathy,neuropathy peripheral motor neuropathy peripheral sensoryneuropathy and paraesthesia c not applicable,1,0.859707772731781
HALAVEN,paraesthesia,Grade,0,0.5528827905654907
HALAVEN,paraesthesia,specify Grade,0,0.5215392112731934
HALAVEN,paraesthesia,paraesthesia c not applicable grading,1,0.7718418836593628
HALAVEN,paraesthesia,paraesthesia c,1,0.8645795583724976
HALAVEN,paraesthesia,paraesthesia c not applicable,1,0.8042021989822388
HALAVEN,paraesthesia,sensoryneuropathy paraesthesia c not applicable grading,1,0.7292211651802063
HALAVEN,paraesthesia,paraesthesia,1,1.0
HALAVEN,paraesthesia,polyneuropathy,0,0.6155025362968445
HALAVEN,paraesthesia,and,0,0.5026886463165283
HALAVEN,paraesthesia,polyneuropathy peripheral sensoryneuropathy,0,0.6344517469406128
HALAVEN,alopecia,Cytopenias Grade neutropenia,0,0.5312820672988892
HALAVEN,alopecia,alopecia Cytopenias Grade neutropenia occurred,1,0.7651845216751099
HALAVEN,alopecia,specify Grade alopecia Cytopenias Grade neutropenia occurred,1,0.7394375205039978
HALAVEN,alopecia,neutropenia occurred,0,0.5558967590332031
HALAVEN,alopecia,does not specify Grade alopecia Cytopenias Grade neutropenia,1,0.6895380616188049
HALAVEN,alopecia,alopecia Cytopenias Grade,1,0.7609014511108398
HALAVEN,alopecia,alopecia Cytopenias,1,0.8109290599822998
HALAVEN,alopecia,alopecia Cytopenias Grade neutropenia occurred in,1,0.7656259536743164
HALAVEN,alopecia,alopecia,1,1.0
HALAVEN,alopecia,specify Grade alopecia Cytopenias Grade,1,0.7503623962402344
HALAVEN,neutropenia,two patients,0,0.47772184014320374
HALAVEN,neutropenia,of patients two,0,0.48567038774490356
HALAVEN,neutropenia,in of,0,0.495252788066864
HALAVEN,neutropenia,neutropenia Febrile,1,0.8528774976730347
HALAVEN,Febrile neutropenia,of patients two patients died from complications,0,0.49655961990356445
HALAVEN,Febrile neutropenia,patients experienced Grade neutropenia,0,0.7843608856201172
HALAVEN,Febrile neutropenia,experienced Grade Febrile neutropenia occurred in of,1,0.8763599395751953
HALAVEN,Febrile neutropenia,Febrile neutropenia occurred,1,0.9437251687049866
HALAVEN,Febrile neutropenia,Febrile neutropenia,1,1.0
HALAVEN,Febrile neutropenia,who received HALAVEN in Study,0,0.45624619722366333
HALAVEN,febrile neutropenia,febrile neutropenia Dose,1,0.9004199504852295
HALAVEN,febrile neutropenia,neutropenia occurred in of patients two patients died from complications of,0,0.7339910268783569
HALAVEN,febrile neutropenia,patients died from complications,0,0.5004310607910156
HALAVEN,febrile neutropenia,from complications febrile neutropenia,1,0.8956494331359863
HALAVEN,febrile neutropenia,died from complications febrile neutropenia Dose reduction,1,0.7933726906776428
HALAVEN,febrile neutropenia,in of patients,0,0.5045614242553711
HALAVEN,febrile neutropenia,febrile,1,0.8051060438156128
HALAVEN,febrile neutropenia,complications febrile neutropenia Dose,1,0.8670305609703064
HALAVEN,febrile neutropenia,complications febrile neutropenia,1,0.8944533467292786
HALAVEN,neutropenia,neutropenia was required in,1,0.8795367479324341
HALAVEN,neutropenia,complications febrile neutropenia,1,0.7947350144386292
HALAVEN,neutropenia,neutropenia mm was,1,0.8578209280967712
HALAVEN,neutropenia,to recovery from neutropenia mm was days,1,0.7993381023406982
HALAVEN,neutropenia,thrombocytopenia occurred in of patients,0,0.6469761729240417
HALAVEN,neutropenia,neutropenia mm was days Grade,1,0.8174842596054077
HALAVEN,neutropenia,neutropenia mm,1,0.8680272102355957
HALAVEN,neutropenia,to recovery from neutropenia mm was days Grade,1,0.7858330607414246
HALAVEN,neutropenia,or greater thrombocytopenia occurred in of patients,0,0.6303516626358032
HALAVEN,neutropenia,time to recovery from neutropenia mm was days Grade or,1,0.772695004940033
HALAVEN,thrombocytopenia,days Grade or thrombocytopenia occurred in,1,0.8411861658096313
HALAVEN,thrombocytopenia,neutropenia mm,1,0.6155422925949097
HALAVEN,thrombocytopenia,thrombocytopenia occurred,1,0.9365172386169434
HALAVEN,thrombocytopenia,mm was days Grade or greater,0,0.4895196557044983
HALAVEN,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
HALAVEN,thrombocytopenia,thrombocytopenia occurred in of patients,1,0.8972774147987366
HALAVEN,thrombocytopenia,Grade or thrombocytopenia occurred in,1,0.8434240818023682
HALAVEN,peripheral neuropathy,peripheral neuropathy and,1,0.967347264289856
HALAVEN,peripheral neuropathy,thrombocytopenia,1,0.5454070568084717
HALAVEN,peripheral neuropathy,peripheral neuropathy and of patients,1,0.9205807447433472
HALAVEN,peripheral neuropathy,enrolled patients had,0,0.4993281066417694
HALAVEN,peripheral neuropathy,Dose reduction due,0,0.5393635034561157
HALAVEN,peripheral neuropathy,patients had peripheral,1,0.7333696484565735
HALAVEN,peripheral neuropathy,of enrolled patients had peripheral neuropathy and of patients had,1,0.8584563136100769
HALAVEN,peripheral neuropathy,due to peripheral,0,0.7073605060577393
HALAVEN,peripheral neuropathy,peripheral neuropathy,1,1.0000001192092896
HALAVEN,peripheral neuropathy,Dose reduction due peripheral neuropathy was required by of,1,0.8306849002838135
HALAVEN,peripheral neuropathy,Dose reduction due peripheral neuropathy was required by of patients,1,0.8272042274475098
HALAVEN,peripheral neuropathy,peripheral neuropathy was,1,0.9593360424041748
HALAVEN,peripheral neuropathy,reduction due peripheral neuropathy,1,0.8974123001098633
HALAVEN,peripheral neuropathy,neuropathy at baseline Dose reduction due,0,0.796942949295044
HALAVEN,peripheral neuropathy,due to,0,0.48580509424209595
HALAVEN,peripheral neuropathy,who received HALAVEN Four,0,0.45948028564453125
HALAVEN,peripheral motor neuropathy,motor neuropathy of,1,0.9264002442359924
HALAVEN,peripheral motor neuropathy,of any grade and of patients developed Grade peripheral motor neuropathy Liver,0,0.794714093208313
HALAVEN,peripheral motor neuropathy,Grade peripheral motor,0,0.783069908618927
HALAVEN,peripheral motor neuropathy,peripheral motor,1,0.822951078414917
HALAVEN,peripheral motor neuropathy,patients with Grade or ALT levels at,0,0.48222529888153076
HALAVEN,peripheral motor neuropathy,Function Test Abnormalities Among patients with Grade or,0,0.5566171407699585
HALAVEN,peripheral motor neuropathy,of patients developed peripheral motor neuropathy Liver Function Test Abnormalities,1,0.8062466382980347
HALAVEN,peripheral motor neuropathy,peripheral motor neuropathy Liver,1,0.8540202379226685
HALAVEN,peripheral motor neuropathy,developed peripheral,1,0.6197108030319214
HALAVEN,peripheral motor neuropathy,of patients developed peripheral motor neuropathy,1,0.9382820725440979
HALAVEN,ALT elevation,or ALT elevation One HALAVENtreated,1,0.8446459770202637
HALAVEN,ALT elevation,developed peripheral,1,0.47948622703552246
HALAVEN,ALT elevation,ALT elevation,1,1.0
HALAVEN,ALT elevation,ALT elevation One HALAVENtreated,1,0.8325936794281006
HALAVEN,ALT elevation,ALT elevation One HALAVENtreated patient without,1,0.7586864829063416
HALAVEN,ALT elevation,Grade or ALT elevation,1,0.8806854486465454
HALAVEN,elevations in bilirubin,had concomitant elevations,1,0.7010620832443237
HALAVEN,elevations in bilirubin,elevations in bilirubin and ALT these abnormalities resolved,1,0.8915186524391174
HALAVEN,elevations in bilirubin,patient,0,0.5258752703666687
HALAVEN,elevations in bilirubin,and did not recur,0,0.45067399740219116
HALAVEN,elevations in bilirubin,had concomitant elevations in bilirubin,1,0.9365172386169434
HALAVEN,increased lacrimation,Eye increased lacrimation Gastrointestinal Disorders dyspepsia abdominal,1,0.8350054621696472
HALAVEN,increased lacrimation,had concomitant elevations in bilirubin,1,0.626412570476532
HALAVEN,increased lacrimation,increased lacrimation Gastrointestinal Disorders,1,0.8696392774581909
HALAVEN,abdominal pain,Disorders and Administration Site Conditions,0,0.5239627361297607
HALAVEN,stomatitis,stomatitis,1,1.0
HALAVEN,stomatitis,stomatitis dry mouth General Disorders and,1,0.8021585941314697
HALAVEN,stomatitis,abdominal stomatitis,1,0.8515692949295044
HALAVEN,stomatitis,Disorders and Administration Site Conditions,0,0.5504829287528992
HALAVEN,stomatitis,stomatitis dry,1,0.8604615330696106
HALAVEN,dry mouth,increased lacrimation Gastrointestinal Disorders dyspepsia abdominal pain,0,0.6070666313171387
HALAVEN,dry mouth,dry mouth General Disorders and Administration Site,1,0.8408359885215759
HALAVEN,dry mouth,dry,1,0.7593775987625122
HALAVEN,dry mouth,edema Infections,0,0.5381952524185181
HALAVEN,dry mouth,dry mouth General Disorders and Administration,1,0.853972315788269
HALAVEN,peripheral edema,Site Conditions,0,0.5177547931671143
HALAVEN,peripheral edema,peripheral edema Infections and Infestations upper,1,0.8438757658004761
HALAVEN,peripheral edema,upper respiratory tract,0,0.5161360502243042
HALAVEN,peripheral edema,and Administration,0,0.499210923910141
HALAVEN,peripheral edema,Disorders and Administration Site peripheral edema Infections and Infestations upper,1,0.8054373264312744
HALAVEN,upper respiratory tract infection,and upper respiratory tract infection Metabolism and Nutrition,1,0.7984803915023804
HALAVEN,upper respiratory tract infection,and Administration,0,0.4733589291572571
HALAVEN,upper respiratory tract infection,Infections and upper,1,0.7779678702354431
HALAVEN,hypokalemia,hypokalemia Musculoskeletal,1,0.8673940896987915
HALAVEN,hypokalemia,hypokalemia Musculoskeletal and Connective Tissue,1,0.8241639137268066
HALAVEN,hypokalemia,hypokalemia Musculoskeletal and,1,0.8753456473350525
HALAVEN,muscle spasms,Musculoskeletal and Connective,0,0.6529266834259033
HALAVEN,muscular weakness,Connective Tissue Disorders muscle muscular weakness,1,0.8352898359298706
HALAVEN,muscular weakness,muscular weakness Nervous System Disorders dysgeusia dizziness,1,0.8007936477661133
HALAVEN,muscular weakness,hypokalemia Musculoskeletal and Connective Tissue Disorders muscle,0,0.7198885679244995
HALAVEN,muscular weakness,dysgeusia,0,0.544282078742981
HALAVEN,muscular weakness,System Disorders dysgeusia,0,0.5243797302246094
HALAVEN,dysgeusia,insomnia depression Skin,0,0.545372724533081
HALAVEN,dysgeusia,dysgeusia dizziness,1,0.908621072769165
HALAVEN,dysgeusia,dysgeusia dizziness Psychiatric Disorders insomnia,1,0.8228051662445068
HALAVEN,dysgeusia,dysgeusia dizziness Psychiatric Disorders,1,0.8406055569648743
HALAVEN,dysgeusia,dysgeusia dizziness Psychiatric Disorders insomnia depression,1,0.8516653776168823
HALAVEN,dysgeusia,dysgeusia,1,1.0000001192092896
HALAVEN,dysgeusia,Psychiatric Disorders,0,0.5937008857727051
HALAVEN,dysgeusia,Disorders insomnia depression,0,0.5508043169975281
HALAVEN,dysgeusia,Nervous System dysgeusia dizziness Psychiatric Disorders insomnia depression,1,0.7998098134994507
HALAVEN,dizziness,muscle spasms muscular weakness Nervous System Disorders,0,0.5642685890197754
HALAVEN,dizziness,dizziness,1,0.9999998807907104
HALAVEN,dizziness,dizziness Psychiatric Disorders insomnia depression,1,0.8382303714752197
HALAVEN,dizziness,dizziness Psychiatric Disorders,1,0.8501567840576172
HALAVEN,dizziness,weakness Nervous System Disorders dizziness Psychiatric Disorders,1,0.7763636112213135
HALAVEN,dizziness,Nervous System Disorders dizziness Psychiatric Disorders insomnia,1,0.7398828268051147
HALAVEN,insomnia,Disorders,0,0.5353491306304932
HALAVEN,insomnia,insomnia depression Skin,1,0.7732172012329102
HALAVEN,insomnia,insomnia depression Skin and,1,0.7773157358169556
HALAVEN,insomnia,and Subcutaneous Tissue Disorders rash Postmarketing,0,0.4581427574157715
HALAVEN,depression,Disorders rash Postmarketing,0,0.5112097859382629
HALAVEN,depression,rash Postmarketing,0,0.49785614013671875
HALAVEN,depression,Tissue Disorders rash Postmarketing Experience,0,0.5109378099441528
HALAVEN,depression,depression Skin and Subcutaneous,1,0.8042587041854858
HALAVEN,depression,Disorders dysgeusia,0,0.5223486423492432
HALAVEN,rash,following adverse drug reactions,0,0.6131859421730042
HALAVEN,rash,rash Postmarketing,1,0.7967089414596558
HALAVEN,rash,The following adverse drug reactions have,0,0.6015170812606812
HALAVEN,lymphopenia,Hepatobiliary Disorders,0,0.5453828573226929
HALAVEN,lymphopenia,lymphopenia Gastrointestinal,1,0.8651584386825562
HALAVEN,lymphopenia,System lymphopenia Gastrointestinal Disorders pancreatitis Hepatobiliary,1,0.7693421840667725
HALAVEN,lymphopenia,Lymphatic System lymphopenia,1,0.9089277386665344
HALAVEN,lymphopenia,or establish a,0,0.45168638229370117
HALAVEN,lymphopenia,Blood and Lymphatic System lymphopenia Gastrointestinal Disorders,1,0.8161265850067139
HALAVEN,lymphopenia,lymphopenia Gastrointestinal Disorders pancreatitis,1,0.8035746812820435
HALAVEN,lymphopenia,or establish a causal relationship to drug exposure Blood and Lymphatic System Disorders,0,0.6821057200431824
HALAVEN,pancreatitis,Disorders hepatotoxicity Immune,0,0.5563305616378784
HALAVEN,pancreatitis,pancreatitis Hepatobiliary,1,0.8052257299423218
HALAVEN,pancreatitis,lymphopenia Gastrointestinal pancreatitis Hepatobiliary Disorders,1,0.6989942789077759
HALAVEN,pancreatitis,hepatotoxicity Immune System,0,0.5912303328514099
HALAVEN,hepatotoxicity,hepatotoxicity Immune System Disorders,1,0.8280747532844543
HALAVEN,hepatotoxicity,hepatotoxicity Immune System Disorders drug hypersensitivity,1,0.79087233543396
HALAVEN,hepatotoxicity,isorders lymphopenia Gastrointestinal Disorders pancreatitis,0,0.5831426382064819
HALAVEN,hepatotoxicity,Gastrointestinal Disorders pancreatitis Hepatobiliary hepatotoxicity Immune System Disorders,1,0.7174147367477417
HALAVEN,hepatotoxicity,pancreatitis Hepatobiliary,0,0.6978990435600281
HALAVEN,hepatotoxicity,hypersensitivity Infections and Infestations pneumonia,0,0.4805788993835449
HALAVEN,hypersensitivity,Immune System Disorders hypersensitivity Infections and Infestations,1,0.7847090363502502
HALAVEN,hypersensitivity,hypersensitivity Infections and Infestations pneumonia,0,0.7657870054244995
HALAVEN,pneumonia,Infections and Infestations,0,0.600534200668335
HALAVEN,pneumonia,hypersensitivity Infections and pneumonia sepsisneutropenic,1,0.7396357655525208
HALAVEN,pneumonia,pneumonia sepsisneutropenic,1,0.8104236125946045
HALAVEN,pneumonia,hypersensitivity Infections,0,0.5810123682022095
HALAVEN,pneumonia,drug hypersensitivity Infections and Infestations,0,0.5338727235794067
HALAVEN,sepsis,Infections and Infestations sepsis neutropenic sepsis Metabolism,1,0.7616688013076782
HALAVEN,sepsis,drug hypersensitivity Infections and Infestations,0,0.5605968236923218
HALAVEN,sepsis,hypersensitivity Infections and Infestations,0,0.5952651500701904
HALAVEN,sepsis,sepsis neutropenic,1,0.8237115144729614
HALAVEN,neutropenic sepsis,and Nutrition Disorders hypomagnesemia dehydration,0,0.510019838809967
HALAVEN,neutropenic sepsis,hypomagnesemia dehydration Respiratory thoracic,0,0.5093189477920532
HALAVEN,neutropenic sepsis,Infestations,0,0.5363079905509949
HALAVEN,neutropenic sepsis,sepsis,0,0.8224642872810364
HALAVEN,neutropenic sepsis,pneumonia neutropenic sepsis Metabolism and,1,0.8248860836029053
HALAVEN,neutropenic sepsis,and Infestations pneumonia neutropenic,1,0.7908070087432861
HALAVEN,neutropenic sepsis,pneumonia neutropenic sepsis,1,0.9037537574768066
HALAVEN,neutropenic sepsis,dehydration,0,0.5362505316734314
HALAVEN,neutropenic sepsis,Immune System Disorders drug hypersensitivity Infections and Infestations pneumonia sepsis,0,0.654829740524292
HALAVEN,neutropenic sepsis,neutropenic sepsis Metabolism and Nutrition Disorders hypomagnesemia,1,0.7667516469955444
HALAVEN,hypomagnesemia,hypomagnesemia dehydration,1,0.885560154914856
HALAVEN,hypomagnesemia,disorders,0,0.5547371506690979
HALAVEN,hypomagnesemia,sepsis Metabolism and Nutrition hypomagnesemia dehydration Respiratory,1,0.8142858743667603
HALAVEN,hypomagnesemia,and Infestations,0,0.4429165720939636
HALAVEN,hypomagnesemia,Respiratory,0,0.4660646915435791
HALAVEN,hypomagnesemia,hypomagnesemia dehydration Respiratory thoracic and mediastinal,1,0.8211266994476318
HALAVEN,hypomagnesemia,Nutrition Disorders,0,0.5960726737976074
HALAVEN,hypomagnesemia,dehydration Respiratory thoracic and mediastinal disorders interstitial lung,0,0.5676989555358887
HALAVEN,dehydration,Respiratory thoracic and mediastinal disorders interstitial,0,0.4772542119026184
HALAVEN,dehydration,dehydration Respiratory thoracic and,1,0.8098880052566528
HALAVEN,dehydration,Nutrition Disorders dehydration Respiratory thoracic and,1,0.7654480934143066
HALAVEN,dehydration,Disorders dehydration Respiratory thoracic and mediastinal disorders,1,0.7527298927307129
HALAVEN,dehydration,Nutrition Disorders dehydration Respiratory thoracic and mediastinal disorders,1,0.7305307388305664
HALAVEN,dehydration,and Nutrition Disorders dehydration Respiratory,1,0.7845289707183838
HALAVEN,interstitial lung disease,Skin and Subcutaneous Tissue Disorders,0,0.6425254344940186
HALAVEN,interstitial lung disease,thoracic and mediastinal interstitial lung disease Skin and Subcutaneous Tissue,1,0.7980085611343384
HALAVEN,interstitial lung disease,and Subcutaneous,0,0.5652783513069153
HALAVEN,interstitial lung disease,thoracic and mediastinal interstitial lung disease Skin and Subcutaneous Tissue Disorders,1,0.8061188459396362
HALAVEN,interstitial lung disease,lung disease Skin and Subcutaneous,1,0.7647996544837952
HALAVEN,interstitial lung disease,interstitial lung disease Skin and Subcutaneous Tissue,1,0.8421112298965454
HALAVEN,interstitial lung disease,lung disease Skin and,1,0.775554895401001
HALAVEN,interstitial lung disease,and mediastinal interstitial lung disease Skin and Subcutaneous,1,0.8084651231765747
HALAVEN,Neutropenia,were neutropenia anemia astheniafatigue alopecia peripheral,0,0.782424807548523
HALAVEN,Neutropenia,REACTIONS EXCERPT The most on adverse,1,0.5209136009216309
HALAVEN,Neutropenia,reactions incidence were neutropenia anemia,0,0.8053293228149414
HALAVEN,Neutropenia,most on adverse  reactions incidence,1,0.5227036476135254
HALAVEN,Neutropenia,ADVERSE REACTIONS EXCERPT The most comm,0,0.5254777669906616
HALAVEN,Neutropenia,on adverse reactions,1,0.531531810760498
HALAVEN,Peripheral Neuropathy,REACTIONS contact Eisai,0,0.4539620280265808
HALAVEN,Peripheral Neuropathy,"alopecia peripheral hy, nausea, and const ipation To report",1,0.6586516499519348
HALAVEN,Peripheral Neuropathy,neutropenia anemia astheniafatigue,0,0.5051206946372986
HALAVEN,Peripheral Neuropathy,astheniafatigue alopecia,0,0.4885156750679016
HALAVEN,Peripheral Neuropathy,"hy, nausea, and const ipation To report SUSPECTED",1,0.515630304813385
HALAVEN,Peripheral Neuropathy,"hy,",1,0.4476891756057739
HALAVEN,Peripheral Neuropathy,report,0,0.4884711503982544
HALAVEN,Peripheral Neuropathy,"hy, nausea, and const ipation To",1,0.5217737555503845
HALAVEN,Embryo-Fetal Toxicity,Inc at or ontact,1,0.5098116397857666
HALAVEN,Embryo-Fetal Toxicity,FDA at 1-800-F DA or wwwfdagovmedwatch Clinical Trials,1,0.5147491693496704
HALAVEN,Embryo-Fetal Toxicity,FDA at 1-800-F DA or wwwfdagovmedwatch Clinical,1,0.513484537601471
HALAVEN,Embryo-Fetal Toxicity,ontact FDA at 1-800-F DA or wwwfdagovmedwatch Clinical,1,0.5193321704864502
HALAVEN,Embryo-Fetal Toxicity,at or ontact FDA at 1-800-F,1,0.49807053804397583
HALAVEN,Embryo-Fetal Toxicity,Clinical Trials Experience Because,0,0.5202915668487549
HALAVEN,Embryo-Fetal Toxicity,FDA at 1-800-F DA,1,0.49637818336486816
HALAVEN,Embryo-Fetal Toxicity,ontact FDA at 1-800-F,1,0.5085517168045044
HALAVEN,Fetal harm,contact FDA,0,0.5088974237442017
HALAVEN,Fetal harm,ADVERSE REACTIONS contact Eisai Inc at or contact FDA at FDA,0,0.5176255702972412
HALAVEN,QT Prolongation,clinical tri als are conducted under,1,0.5304943919181824
HALAVEN,QT Prolongation,Clinical Trials Experience se clinical tri als,1,0.5368647575378418
HALAVEN,QT Prolongation,wwwfdagovmedwatch Clinical Trials Experience se clinical tri als,1,0.5210175514221191
HALAVEN,neutropenia,practice The following adverse ns are,1,0.5386255979537964
HALAVEN,neutropenia,reactions reported,0,0.507210373878479
HALAVEN,neutropenia,reported patients re,1,0.49965304136276245
HALAVEN,neutropenia,and Precautions The most common adverse,0,0.5258963704109192
HALAVEN,febrile neutropenia,patients ng HALAVEN,1,0.5174598693847656
HALAVEN,febrile neutropenia,HALAVEN were neu tropenia anemia astheniafatigue alopecia,1,0.5816344022750854
HALAVEN,febrile neutropenia,and constipation The m,0,0.4576038420200348
HALAVEN,febrile neutropenia,patients ng HALAVEN were neu tropenia anemia astheniafatigue alopecia peripheral,1,0.5747739672660828
HALAVEN,febrile neutropenia,patients ng HALAVEN were neu,1,0.5440025329589844
HALAVEN,neutropenia,reactions,1,0.5213229656219482
HALAVEN,neutropenia,common serious reactions,1,0.5263139009475708
HALAVEN,neutropenia,reactions r eported in patients receiving,1,0.5490713119506836
HALAVEN,neutropenia,The most common serious reactions r eported in patients,1,0.525728702545166
HALAVEN,neutropenia,serious,0,0.5266036987304688
HALAVEN,peripheral neuropathy,Caucasian,0,0.5014333724975586
HALAVEN,peripheral neuropathy,"), Asian (2%), and ot her The adverse reactions described",1,0.5212677717208862
HALAVEN,peripheral neuropathy,"was Caucasian ), Asian (2%), and ot her The adverse reactions described",1,0.5303241610527039
HALAVEN,peripheral neuropathy,"), Asian (2%), and ot",1,0.46677345037460327
HALAVEN,peripheral neuropathy,"), Asian (2%), and ot her The adverse reactions",1,0.5102666020393372
HALAVEN,peripheral neuropathy,"Caucasian ), Asian (2%), and ot",1,0.49965935945510864
HALAVEN,peripheral neuropathy,"(2%), and ot her The adverse reactions described",1,0.5461493134498596
HALAVEN,peripheral neuropathy,The adverse,0,0.5314178466796875
HALAVEN,peripheral neuropathy,in,0,0.5055330991744995
HALAVEN,peripheral neuropathy,racial and ethnic distribution,0,0.461593896150589
HALAVEN,peripheral neuropathy,"), Asian (2%), and ot her The",1,0.4196505844593048
HALAVEN,peripheral neuropathy,"Caucasian ),",1,0.47163015604019165
HALAVEN,Peripheral neuropathy,1 [,1,0.470150887966156
HALAVEN,Peripheral neuropathy,Study 1 [ see Clinical Studies,1,0.5081017017364502
HALAVEN,Peripheral neuropathy,Study 1 [ see Clinical Studies In Study,1,0.49722737073898315
HALAVEN,Peripheral neuropathy,patients reated in Study 1 [,1,0.5141226053237915
HALAVEN,Peripheral neuropathy,were identified in patients reated in Study 1,1,0.49695900082588196
HALAVEN,Peripheral neuropathy,patients,0,0.5399518609046936
HALAVEN,Peripheral neuropathy,were identified in patients reated in Study 1 [   see,1,0.49192744493484497
HALAVEN,Peripheral neuropathy,1 [ see Clinical,1,0.5138247013092041
HALAVEN,Peripheral neuropathy,patients reated in,1,0.5163864493370056
HALAVEN,Neuropathy,e either H ALAVEN,1,0.5289828777313232
HALAVEN,Neuropathy,either H ALAVEN mgm,1,0.48091959953308105
HALAVEN,Neuropathy,were randomized to e either H ALAVEN mgm on Days and,1,0.49383947253227234
HALAVEN,Neuropathy,e either H ALAVEN mgm on Days and,1,0.4834080934524536
HALAVEN,Neuropathy,receiv,0,0.5238882303237915
HALAVEN,neuropathy,A total 503,1,0.44780096411705017
HALAVEN,neuropathy,503 patie nts received,1,0.5081794261932373
HALAVEN,neuropathy,patients in the control group received therapy consisting,0,0.5214908123016357
HALAVEN,neuropathy,total 503 patie,1,0.4551801085472107
HALAVEN,fetal harm,with a atient,1,0.5102333426475525
HALAVEN,fetal harm,Reactions with a atient Inc idence of at Least in,1,0.520190954208374
HALAVEN,fetal harm,a atient Inc idence,1,0.4807027578353882
HALAVEN,fetal harm,Reactions with a atient Inc,1,0.4987928867340088
HALAVEN,fetal harm,in Study MedDRA ver HALAVEN,0,0.550918698310852
HALAVEN,fetal harm,atient Inc idence of at Least in,1,0.48893073201179504
HALAVEN,fetal harm,patients in either group Table Adverse Reactions with a PerP,0,0.5405067205429077
HALAVEN,Embryo-fetal toxicity,a PerPatient Incidence of at,0,0.5104392766952515
HALAVEN,Embryo-fetal toxicity,10.0 HA LAVEN n Control Group,1,0.47053101658821106
HALAVEN,Embryo-fetal toxicity,Table Adverse Reactions with a PerPatient Incidence of at Least in,0,0.5920337438583374
HALAVEN,Embryo-fetal toxicity,at,0,0.5144590139389038
HALAVEN,Embryo-fetal toxicity,in Study,0,0.4935944378376007
HALAVEN,Embryo-fetal toxicity,Least in Study dDRA,1,0.4975481629371643
HALAVEN,Embryo-fetal toxicity,dDRA ver 10.0      HA LAVEN,1,0.48878857493400574
HALAVEN,teratogenicity,Control Group n All Grades Grade All Grades,0,0.4821133017539978
HALAVEN,teratogenicity,    n=503      Control Group n All,1,0.4605303406715393
HALAVEN,teratogenicity,Control,0,0.49917060136795044
HALAVEN,teratogenicity,    n=503      Control,1,0.46158790588378906
HALAVEN,teratogenicity,    n=503      Control Group n All Grades,1,0.4854741394519806
HALAVEN,QT prolongation,orders          Peripheral neuropathy b,1,0.4881824254989624
HALAVEN,QT prolongation,Peripheral neuropathy,0,0.4861176013946533
HALAVEN,QT prolongation,disorders ripheral neurop athy b,1,0.5279027223587036
HALAVEN,QT prolongation,athy b Headache,0,0.47632160782814026
HALAVEN,QT prolongation,disorders ripheral neurop athy,1,0.5292772054672241
HALAVEN,QT prolongation,athy b,0,0.4798413813114166
HALAVEN,QT prolongation,disorders ripheral,1,0.4863598346710205
HALAVEN,QT prolongation,disorders,0,0.5451624393463135
HALAVEN,QT prolongation,ripheral,1,0.43816447257995605
HALAVEN,QT prolongation,ripheral neurop,1,0.5126520395278931
XIAFLEX,Tendon ruptures,the Tendon ruptures or other serious injury to,1,0.9265049695968628
XIAFLEX,Tendon ruptures,ripheral neurop,1,0.5660070180892944
XIAFLEX,Tendon ruptures,Tendon ruptures or other serious injury to,1,0.9273886680603027
XIAFLEX,Tendon ruptures,elsewhere in,0,0.49420812726020813
XIAFLEX,Tendon ruptures,see Warnings,0,0.4882505536079407
XIAFLEX,Tendon ruptures,detail elsewhere in,0,0.49277329444885254
XIAFLEX,Tendon ruptures,Tendon ruptures or other serious injury,1,0.9265094995498657
XIAFLEX,Tendon ruptures,or other serious injury to the injected extremity see Warnings and Precautions Th,0,0.6103807091712952
XIAFLEX,Tendon ruptures,Tendon ruptures or,1,0.9824159145355225
XIAFLEX,Tendon ruptures,Warnings and Precautions,0,0.48111021518707275
XIAFLEX,injury to the injected extremity,or other injury to the injected extremity see Warnings and Precautions,1,0.8974201679229736
XIAFLEX,injury to the injected extremity,Warnings and Precautions,0,0.5278652906417847
XIAFLEX,injury to the injected extremity,the injected extremity see,1,0.9412859678268433
XIAFLEX,injury to the injected extremity,other injury,1,0.7404134273529053
XIAFLEX,injury to the injected extremity,reactions in,0,0.5373077988624573
XIAFLEX,injury to the injected extremity,to the injected extremity see Warnings and Precautions The,1,0.8638128042221069
XIAFLEX,Corporal rupture,Corporal rupture,1,1.000000238418579
XIAFLEX,Corporal rupture,to the injected extremity see Warnings and Precautions The,1,0.5672714114189148
XIAFLEX,Corporal rupture,Corporal rupture penile fracture and severe penile,1,0.8353283405303955
XIAFLEX,Corporal rupture,Warnings and Precautions In,0,0.470668226480484
XIAFLEX,Corporal rupture,detail elsewhere in the Corporal,1,0.730212390422821
XIAFLEX,Corporal rupture,and Precautions In othe,0,0.4969860911369324
XIAFLEX,Corporal rupture,the Corporal rupture,1,0.9835267066955566
XIAFLEX,penile fracture,Precautions,0,0.5044069290161133
XIAFLEX,penile fracture,rupture,0,0.57895827293396
XIAFLEX,penile hematoma,rupture penile fracture and penile,1,0.7642320990562439
XIAFLEX,penile hematoma,and penile hematoma,1,0.971436619758606
XIAFLEX,penile hematoma,and Precautions In other XIAFLEXtreated patients a,0,0.49662280082702637
XIAFLEX,penile hematoma,rupture penile fracture and penile hematoma,1,0.8837682008743286
XIAFLEX,penile hematoma,penile hematoma see Warnings and,1,0.9079244136810303
XIAFLEX,penile ecchymoses,penile ecchymoses or hematoma sudden penile detumescence,1,0.871188759803772
XIAFLEX,penile ecchymoses,penile ecchymoses or hematoma,1,0.9094587564468384
XIAFLEX,penile ecchymoses,Warnings and Precautions,0,0.5323456525802612
XIAFLEX,penile ecchymoses,combination,0,0.4738231599330902
XIAFLEX,penile ecchymoses,penile ecchymoses or,1,0.9777013063430786
XIAFLEX,penile ecchymoses,see Warnings,0,0.49806374311447144
XIAFLEX,penile ecchymoses,penile ecchymoses,1,1.0
XIAFLEX,penile detumescence,combination of penile ecchymoses or hematoma,0,0.7367698550224304
XIAFLEX,penile detumescence,a penile popping sound or sensation was,0,0.7353811264038086
XIAFLEX,penile detumescence,or hematoma penile detumescence andor a,1,0.8773354291915894
XIAFLEX,penile detumescence,or hematoma penile,1,0.7628971934318542
XIAFLEX,penile detumescence,penile popping sound,0,0.7341030836105347
XIAFLEX,penile detumescence,penile detumescence andor a penile popping sound,1,0.8811582326889038
XIAFLEX,penile detumescence,penile detumescence andor a penile popping,1,0.9132154583930969
XIAFLEX,"penile ""popping"" sound","sudden penile detumescence andor penile ""popping""",1,0.8840896487236023
XIAFLEX,"penile ""popping"" sound",penile,0,0.7794668674468994
XIAFLEX,"penile ""popping"" sound",was reported,0,0.4997292160987854
XIAFLEX,"penile ""popping"" sound","detumescence andor penile ""popping"" sound or sensation",1,0.9479595422744751
XIAFLEX,corporal rupture,cannot be excluded see Warnings and Precautions EXCERPT,0,0.46990740299224854
XIAFLEX,edema peripheral,placebo,0,0.5492635369300842
XIAFLEX,edema peripheral,placebo edema,1,0.7688643336296082
XIAFLEX,edema peripheral,edema peripheral,1,1.0
XIAFLEX,edema peripheral,placebo edema peripheral,1,0.8927856087684631
XIAFLEX,edema peripheral,patients treated with XIAFLEX and at,0,0.5447944402694702
XIAFLEX,swelling of the injected hand,and at an incidence greater than placebo,0,0.5926176309585571
XIAFLEX,swelling of the injected hand,swelling of the injected hand contusion,1,0.9398418664932251
XIAFLEX,swelling of the injected hand,of the injected hand contusion injection,1,0.8493115901947021
XIAFLEX,contusion,contusion injection site hemorrhage injection site,1,0.7780516147613525
XIAFLEX,contusion,injection site hemorrhage injection site,0,0.5616223812103271
XIAFLEX,contusion,contusion,1,0.9999998211860657
XIAFLEX,contusion,contusion injection site hemorrhage injection,1,0.7945112586021423
XIAFLEX,contusion,of the injected contusion injection site hemorrhage injection,1,0.7888408899307251
XIAFLEX,contusion,placebo were edema peripheral eg,0,0.5140469074249268
XIAFLEX,contusion,injected contusion injection site hemorrhage injection,1,0.79657381772995
XIAFLEX,injection site reaction,injection site injection site reaction and pain in the,1,0.9228323698043823
XIAFLEX,injection site reaction,placebo were edema peripheral eg,0,0.5950043797492981
XIAFLEX,injection site reaction,site reaction and pain,1,0.8286881446838379
XIAFLEX,injection site reaction,extremity,0,0.4938817024230957
XIAFLEX,injection site reaction,edema peripheral eg swelling of the injected hand,0,0.7035259008407593
XIAFLEX,injection site reaction,site injection site reaction and pain in the injected,1,0.9224666357040405
XIAFLEX,injection site reaction,Peyronies Disease The,0,0.476643830537796
XIAFLEX,pain in the injected extremity,reaction pain in the injected extremity,1,0.9701094627380371
XIAFLEX,pain in the injected extremity,Peyronies Disease The,0,0.50245201587677
XIAFLEX,pain in the injected extremity,injection site reaction pain,1,0.8298999071121216
XIAFLEX,penile hematoma,incidence greater,0,0.5125287771224976
XIAFLEX,penile hematoma,greater than placebo penile hematoma penile swelling and,1,0.8688364624977112
XIAFLEX,penile swelling,penile swelling and penile pain,1,0.9489550590515137
XIAFLEX,penile swelling,treated with XIAFLEX and at an incidence greater than placebo were,0,0.5519859790802002
XIAFLEX,penile swelling,than placebo were penile penile swelling,1,0.8917217254638672
XIAFLEX,penile pain,and at,0,0.4754972755908966
XIAFLEX,penile pain,penile,1,0.8716261386871338
XIAFLEX,penile pain,penile swelling penile,1,0.882736086845398
XIAFLEX,penile pain,penile pain,1,1.0000001192092896
XIAFLEX,penile pain,swelling penile pain,1,0.9253275990486145
XIAFLEX,penile pain,penile pain To report SUSPECTED,1,0.9028434753417969
XIAFLEX,penile pain,report SUSPECTED ADVERSE REACTIONS contact,0,0.5203316807746887
XIAFLEX,penile pain,penile hematoma penile swelling and,0,0.793857216835022
XIAFLEX,adverse reaction of the injected extremity,XIAFLEXtreated patients had adverse reaction of the injected extremity,1,0.9284923076629639
XIAFLEX,adverse reaction of the injected extremity,of the injected extremity,1,0.9121138453483582
XIAFLEX,adverse reaction of the injected extremity,patients had adverse reaction of the injected extremity after,1,0.9747124314308167
XIAFLEX,adverse reaction of the injected extremity,these local reactions resolved without,0,0.5456682443618774
XIAFLEX,adverse reaction of the injected extremity,patients had,0,0.5554255247116089
XIAFLEX,adverse reaction of the injected extremity,injected extremity after up to,1,0.8888224363327026
XIAFLEX,edema peripheral,edema peripheral mostly swelling,1,0.9149179458618164
XIAFLEX,edema peripheral,clinical trials in patients with Dupuytrens contracture included,0,0.5681819915771484
XIAFLEX,edema peripheral,Dupuytrens contracture edema peripheral mostly swelling of the injected,1,0.7393293976783752
XIAFLEX,edema peripheral,reactions in the,0,0.5182726383209229
XIAFLEX,edema peripheral,patients with Dupuytrens contracture edema peripheral,1,0.7892149686813354
XIAFLEX,edema peripheral,Dupuytrens contracture edema peripheral mostly swelling of,1,0.7663791179656982
XIAFLEX,edema peripheral,edema,1,0.8613424301147461
XIAFLEX,edema peripheral,with Dupuytrens contracture edema peripheral mostly swelling,1,0.7696081399917603
XIAFLEX,swelling of the injected hand,edema peripheral mostly,0,0.6740726232528687
XIAFLEX,swelling of the injected hand,peripheral swelling of,1,0.736119270324707
XIAFLEX,contusion,reaction and pain in the,0,0.6441388726234436
XIAFLEX,contusion,contusion injection,1,0.8798757791519165
XIAFLEX,contusion,hand,0,0.5526405572891235
XIAFLEX,contusion,injected contusion injection,1,0.8668844699859619
XIAFLEX,contusion,contusion injection site hemorrhage,1,0.7930612564086914
XIAFLEX,contusion,contracture included edema peripheral mostly swelling of,0,0.5682156085968018
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection site reaction and,1,0.9465888738632202
XIAFLEX,injection site hemorrhage,injected hand injection site hemorrhage injection,1,0.8749887943267822
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection,1,0.9725891351699829
XIAFLEX,injection site hemorrhage,of the injected hand injection site hemorrhage injection site reaction,1,0.8837178945541382
XIAFLEX,injection site hemorrhage,injected hand injection,1,0.6992270946502686
XIAFLEX,injection site hemorrhage,the injected hand injection,1,0.7067944407463074
XIAFLEX,injection site reaction,injection site reaction,1,0.9999999403953552
XIAFLEX,injection site reaction,contusion injection site injection,1,0.8101992607116699
XIAFLEX,injection site reaction,adverse reactions that were repo,0,0.6971021890640259
XIAFLEX,injection site reaction,hand contusion injection site injection site reaction,1,0.8677703142166138
XIAFLEX,injection site reaction,injection site reaction and pain in the treated,1,0.9102608561515808
XIAFLEX,injection site reaction,contusion injection site injection site,1,0.8098770380020142
XIAFLEX,injection site reaction,shows the incidence,0,0.5561478137969971
XIAFLEX,pain in the treated extremity,greater than or equal to,0,0.4510975182056427
XIAFLEX,pain in the treated extremity,reaction pain in the treated extremity Table shows the incidence of,1,0.8497651815414429
XIAFLEX,swelling of the injected hand,of these events swelling of the injected hand b Includes the,1,0.9671977758407593
XIAFLEX,swelling of the injected hand,greater than or equal to,0,0.4315430521965027
XIAFLEX,swelling of the injected hand,body system and ecchymosis,0,0.59195876121521
XIAFLEX,swelling of the injected hand,of the injected hand b Includes the,1,0.894429087638855
XIAFLEX,swelling of the injected hand,injected hand b Includes the terms,1,0.8063873648643494
XIAFLEX,swelling of the injected hand,of the injected hand b Includes the terms,1,0.8515996336936951
XIAFLEX,swelling of the injected hand,swelling of the injected hand b Includes the terms contusion,1,0.9096004962921143
XIAFLEX,swelling of the injected hand,the injected hand b,1,0.8914405107498169
XIAFLEX,contusion,contusion any body,1,0.9111634492874146
XIAFLEX,contusion,terms injection site reaction,0,0.5609347820281982
XIAFLEX,contusion,contusion any body system and,1,0.8692328333854675
XIAFLEX,contusion,system and ecchymosis c Includes the terms injection site reaction injection,0,0.6106133460998535
XIAFLEX,contusion,the terms injection site reaction injection s,0,0.5710651874542236
XIAFLEX,contusion,any body system and ecchymosis c,0,0.609902024269104
XIAFLEX,contusion,contusion any body system and ecchymosis,1,0.8363661766052246
XIAFLEX,ecchymosis,body system and,0,0.5326841473579407
XIAFLEX,ecchymosis,contusion any body system ecchymosis c Includes the terms,1,0.7859233021736145
XIAFLEX,ecchymosis,of,0,0.5297476053237915
XIAFLEX,ecchymosis,ecchymosis c Includes,1,0.8576738238334656
XIAFLEX,ecchymosis,terms,0,0.5112113356590271
XIAFLEX,ecchymosis,site reaction injection,0,0.5436961054801941
XIAFLEX,ecchymosis,ecchymosis c Includes the terms,1,0.8307392597198486
XIAFLEX,ecchymosis,any body system ecchymosis c Includes,1,0.8274438381195068
XIAFLEX,injection site reaction,injection site reaction injection site,1,0.9628591537475586
XIAFLEX,injection site reaction,injection site reaction injection,1,0.9766649007797241
XIAFLEX,injection site reaction,injection,1,0.7873796224594116
XIAFLEX,injection site reaction,Includes the injection site reaction,1,0.9617234468460083
XIAFLEX,injection site reaction,the injection site,1,0.9058444499969482
XIAFLEX,injection site reaction,injection site inflammation injection site irritation injection,0,0.8713998794555664
XIAFLEX,injection site reaction,and ecchymosis c Includes the terms,0,0.5217600464820862
XIAFLEX,injection site reaction,the injection site reaction injection site,1,0.9618139266967773
XIAFLEX,injection site erythema,injection site injection site,1,0.8322829008102417
XIAFLEX,injection site irritation,site injection site irritation injection site pain and injection,1,0.9370294809341431
XIAFLEX,injection site irritation,injection site injection site,1,0.8577308654785156
XIAFLEX,injection site irritation,injection,1,0.7715621590614319
XIAFLEX,injection site irritation,injection site warmth d Includes the terms injection site,0,0.761671781539917
XIAFLEX,injection site irritation,injection site pain and injection site warmth,0,0.874582052230835
XIAFLEX,injection site irritation,site irritation injection site pain,1,0.9515745639801025
XIAFLEX,injection site irritation,injection site injection site irritation injection site pain and,1,0.9495749473571777
XIAFLEX,injection site irritation,site pain and injection site warmth d Includes the terms,0,0.8000538349151611
XIAFLEX,injection site irritation,injection site pain and injection site warmth d Includes the terms injection,0,0.8210130929946899
XIAFLEX,injection site pain,site injection site pain,1,0.9722466468811035
XIAFLEX,injection site pain,injection site pain and injection site warmth d Includes the terms injection,0,0.8704550266265869
XIAFLEX,injection site pain,inflammation injection site injection site pain and injection site warmth,1,0.905616819858551
XIAFLEX,injection site pain,site injection site pain and injection site,1,0.9590818881988525
XIAFLEX,injection site pain,reaction injection site erythema injection site inflammation injection,0,0.8270437121391296
XIAFLEX,injection site pain,inflammation injection site injection site pain,1,0.9529204368591309
XIAFLEX,injection site pain,Includes the terms injection site swelling and injection site,0,0.8282305002212524
XIAFLEX,injection site pain,injection site pain and injection site warmth,1,0.9243281483650208
XIAFLEX,injection site pain,site inflammation injection site injection site pain,1,0.9541318416595459
XIAFLEX,injection site warmth,pain injection site,1,0.8024584650993347
XIAFLEX,injection site warmth,site pain injection site warmth,1,0.9223612546920776
XIAFLEX,injection site warmth,injection site pain injection site warmth d Includes the terms,1,0.8648191690444946
XIAFLEX,injection site warmth,site,0,0.6174647212028503
XIAFLEX,injection site warmth,swelling,0,0.5766916275024414
XIAFLEX,injection site warmth,terms injection site swelling and injection site edema e Includes,0,0.7762038707733154
XIAFLEX,injection site warmth,injection site inflammation,0,0.8236725330352783
XIAFLEX,injection site warmth,injection site warmth d,1,0.9613910913467407
XIAFLEX,injection site swelling,d Includes the injection site swelling,1,0.959219217300415
XIAFLEX,injection site swelling,and injection site edema e Includes the terms pruritus and injection,0,0.8212568163871765
XIAFLEX,injection site swelling,site edema e,0,0.7342010140419006
XIAFLEX,injection site swelling,Includes the injection site swelling and injection site edema,1,0.9430351257324219
XIAFLEX,injection site swelling,injection,1,0.7757757902145386
XIAFLEX,injection site swelling,site swelling and,1,0.828933835029602
XIAFLEX,pruritus,pruritus and,1,0.9434140920639038
XIAFLEX,pruritus,site swelling and,1,0.5639885663986206
XIAFLEX,pruritus,and axillary mass,0,0.5563348531723022
XIAFLEX,pruritus,pruritus and injection site,1,0.8278529644012451
XIAFLEX,pruritus,Includes,0,0.5414654612541199
XIAFLEX,injection site pruritus,Adverse Reaction,0,0.6394822597503662
XIAFLEX,injection site pruritus,site pruritus,1,0.8693145513534546
XIAFLEX,injection site pruritus,injection site pruritus f Includes,1,0.9663536548614502
XIAFLEX,injection site pruritus,injection site pruritus f Includes the terms lymphadenopathy,1,0.8928185701370239
XIAFLEX,injection site pruritus,site pruritus f Includes the terms,1,0.7824017405509949
XIAFLEX,lymphadenopathy,mass Adverse Reaction,0,0.48666319251060486
XIAFLEX,lymphadenopathy,Adverse Reaction,0,0.5138155817985535
XIAFLEX,lymphadenopathy,and axillary mass Adverse Reaction XIAFLEXN PlaceboN,0,0.5733038187026978
XIAFLEX,lymphadenopathy,lymphadenopathy and axillary mass Adverse Reaction,1,0.7804064154624939
XIAFLEX,axillary mass,All,0,0.481526255607605
XIAFLEX,axillary mass,axillary mass Adverse Reaction XIAFLEXN PlaceboN All,1,0.798782467842102
XIAFLEX,axillary mass,PlaceboN All Adverse Reactions,0,0.49056124687194824
XIAFLEX,axillary mass,lymphadenopathy axillary mass,1,0.8976253867149353
XIAFLEX,axillary mass,terms lymphadenopathy axillary,1,0.7824492454528809
XIAFLEX,axillary mass,axillary mass Adverse Reaction,1,0.8683678507804871
XIAFLEX,axillary mass,XIAFLEXN,0,0.5355210304260254
XIAFLEX,axillary mass,lymphadenopathy axillary,1,0.8081141710281372
XIAFLEX,axillary mass,terms lymphadenopathy axillary mass Adverse Reaction XIAFLEXN PlaceboN,1,0.7839548587799072
XIAFLEX,axillary mass,the terms pruritus and,0,0.5110464096069336
XIAFLEX,Contusion,Contusion b Injection Site Hemorrhage Injection,1,0.7721047401428223
XIAFLEX,Contusion,Adverse Reactions Edema Peripheral Contusion b Injection Site,1,0.7328436970710754
XIAFLEX,Injection Site Hemorrhage,Peripheral a Contusion Injection,1,0.6941947937011719
XIAFLEX,Injection Site Reaction,Hemorrhage,0,0.5326687097549438
XIAFLEX,Pain in Extremity,c,0,0.5013211965560913
XIAFLEX,Pain in Extremity,Pain in Extremity Tenderness Injection Site Swelling d,1,0.8154061436653137
XIAFLEX,Tenderness,Tenderness Injection Site Swelling d,1,0.716239333152771
XIAFLEX,Tenderness,Pain in Extremity,0,0.5965726971626282
XIAFLEX,Tenderness,in Tenderness Injection Site Swelling d,1,0.7239565849304199
XIAFLEX,Tenderness,in Extremity,0,0.5871400833129883
XIAFLEX,Tenderness,Injection,0,0.5821726322174072
XIAFLEX,Tenderness,Injection Site Swelling d Pruritus e,0,0.5966512560844421
XIAFLEX,Tenderness,hage,0,0.5488477945327759
XIAFLEX,Tenderness,Tenderness Injection Site,1,0.7529771327972412
XIAFLEX,Injection Site Swelling,in Extremity Injection Site Swelling d Pruritus e Lymphadenopathy,1,0.8552637100219727
XIAFLEX,Injection Site Swelling,Tenderness Injection Site,1,0.8406568169593811
XIAFLEX,Injection Site Swelling,f Skin Lacera,0,0.49827462434768677
XIAFLEX,Injection Site Swelling,e Lymphadenopathy f,0,0.577133059501648
XIAFLEX,Injection Site Swelling,e Lymphadenopathy,0,0.5809577703475952
XIAFLEX,Injection Site Swelling,Injection Site Swelling d Pruritus e Lymphadenopathy,1,0.8724113702774048
XIAFLEX,Injection Site Swelling,Extremity Injection Site Swelling d,1,0.8932335376739502
XIAFLEX,Injection Site Swelling,Lymphadenopathy,0,0.583644688129425
XIAFLEX,Injection Site Swelling,Lymphadenopathy f Skin,0,0.5904109477996826
XIAFLEX,Injection Site Swelling,Pain in Extremity Injection Site Swelling,1,0.9036057591438293
XIAFLEX,Injection Site Swelling,Injection,1,0.7757757902145386
XIAFLEX,Pruritus,e Lymphadenopathy f Skin Laceration Lymph,0,0.5933632850646973
XIAFLEX,Pruritus,Pruritus,1,0.9999999403953552
XIAFLEX,Pruritus,Pruritus e,1,0.889051079750061
XIAFLEX,Pruritus,Extremity Tenderness Injection Site Swelling d,0,0.6025288105010986
XIAFLEX,Lymphadenopathy,Swelling d,0,0.6394617557525635
XIAFLEX,Lymphadenopathy,Lymph Node,0,0.7871414422988892
XIAFLEX,Lymphadenopathy,Lymphadenopathy,1,0.9999997615814209
XIAFLEX,Lymphadenopathy,Lymphadenopathy f,1,0.9278088212013245
XIAFLEX,Lymphadenopathy,Pruritus Lymphadenopathy f Skin Laceration Lymph,1,0.7897051572799683
XIAFLEX,Lymphadenopathy,nderness Injection Site Swelling d Pruritus,0,0.5819926857948303
XIAFLEX,Lymphadenopathy,Lymphadenopathy f Skin Laceration,1,0.8449764251708984
XIAFLEX,Skin Laceration,Pruritus e Lymphadenopathy Skin Laceration,1,0.79296875
XIAFLEX,Lymph Node Pain,Lymph Node,1,0.8841069936752319
XIAFLEX,Lymph Node Pain,f Skin Lymph Node Pain Erythema,1,0.8554670810699463
XIAFLEX,Lymph Node Pain,Lymphadenopathy f Skin,0,0.6749100685119629
XIAFLEX,Lymph Node Pain,e Lymphadenopathy f,0,0.7339392900466919
XIAFLEX,Lymph Node Pain,Skin,0,0.5282397270202637
XIAFLEX,Lymph Node Pain,Lymph Node Pain Erythema Axillary,1,0.8695124387741089
XIAFLEX,Lymph Node Pain,Lymph Node Pain Erythema Axillary Pain Some,1,0.8808108568191528
XIAFLEX,Erythema,Node Erythema Axillary Pain Some patients,1,0.7212913632392883
XIAFLEX,Erythema,Lymph Node Pain Erythema Axillary Pain Some,1,0.7053103446960449
XIAFLEX,Erythema,Erythema Axillary Pain Some,1,0.7927063703536987
XIAFLEX,Axillary Pain,Some patients developed vasovagal syncope after finger,0,0.46705567836761475
XIAFLEX,Axillary Pain,Skin,0,0.5576158165931702
XIAFLEX,vasovagal syncope,patients vasovagal syncope after,1,0.9301354885101318
XIAFLEX,vasovagal syncope,Skin,0,0.489960640668869
XIAFLEX,vasovagal syncope,Erythema Axillary Pain Some patients developed,0,0.4484657943248749
XIAFLEX,vasovagal syncope,vasovagal syncope,1,1.0
XIAFLEX,vasovagal syncope,Pain,0,0.4741201400756836
XIAFLEX,vasovagal syncope,vasovagal syncope after,1,0.9461174011230469
XIAFLEX,vasovagal syncope,Pain Some patients,0,0.4807792007923126
XIAFLEX,vasovagal syncope,extension procedures The safety of,0,0.5488513708114624
XIAFLEX,Lymphadenopathy,site,0,0.5483675003051758
XIAFLEX,Lymphadenopathy,Lymphadenopathy Blood,1,0.8709540367126465
XIAFLEX,Lymphadenopathy,Lymphadenopathy Blood bl,1,0.8620262145996094
XIAFLEX,Lymphadenopathy,pain,0,0.5247596502304077
XIAFLEX,Injection site hemorrhage,pain,0,0.5776587128639221
XIAFLEX,Injection site hemorrhage,y Injection site hemorrhage,1,0.9294862151145935
XIAFLEX,Injection site hemorrhage,site hemorrhage Injection site,1,0.9568955302238464
XIAFLEX,Injection site hemorrhage,Injection site,1,0.8568670749664307
XIAFLEX,Injection site hemorrhage,Injection site hemorrhage Injection,1,0.9725891351699829
XIAFLEX,Injection site hemorrhage,Injection site,0,0.8568670749664307
XIAFLEX,Injection site hemorrhage,y,0,0.46086180210113525
XIAFLEX,Corporal rupture,Corporal rupture was reported,1,0.9578810930252075
XIAFLEX,Corporal rupture,y,0,0.4667528569698334
XIAFLEX,Corporal rupture,Serious Penile Corporal rupture was reported as an adverse,1,0.8049066066741943
XIAFLEX,Corporal rupture,adverse reaction after XIAFLEX injections,0,0.5070654153823853
XIAFLEX,Corporal rupture,total of XIAFLEX,0,0.47156673669815063
XIAFLEX,Corporal rupture,XIAFLEX injections in of XIAFLEX treated,0,0.49655815958976746
XIAFLEX,Corporal rupture,Penile Corporal rupture,1,0.8583952784538269
XIAFLEX,Corporal rupture,was reported as an adverse reaction after XIAFLEX injections in of XIAFLEX,0,0.4930839538574219
XIAFLEX,Corporal rupture,Other Serious Penile Corporal,1,0.710120439529419
XIAFLEX,Corporal rupture,Corporal rupture was reported as an,1,0.95500648021698
XIAFLEX,penile ecchymoses,a combination penile ecchymoses or,1,0.9194837808609009
XIAFLEX,penile ecchymoses,Other Serious Penile Corporal,1,0.7713168859481812
XIAFLEX,penile ecchymoses,penile,1,0.8036227226257324
XIAFLEX,penile ecchymoses,of a combination penile ecchymoses,1,0.9219964742660522
XIAFLEX,penile detumescence,or hematoma penile detumescence,1,0.8955260515213013
XIAFLEX,penile detumescence,was reported and in these cases,0,0.5263150334358215
XIAFLEX,penile detumescence,patients,0,0.5163339376449585
XIAFLEX,penile detumescence,ecchymoses or hematoma penile detumescence,1,0.8879282474517822
XIAFLEX,penile detumescence,penile ecchymoses,0,0.8064039945602417
XIAFLEX,"penile ""popping"" sound",andor penile,1,0.71064692735672
XIAFLEX,"penile ""popping"" sound",or sensation was reported and in these cases a diagnosis of corporal rupture,0,0.6763492822647095
XIAFLEX,"penile ""popping"" sound","detumescence andor penile ""popping"" sound",1,0.9625377655029297
XIAFLEX,corporal rupture,managed without surgical intervention but,0,0.5715432167053223
XIAFLEX,corporal rupture,corporal rupture,1,1.000000238418579
XIAFLEX,corporal rupture,corporal rupture cannot,1,0.9059717655181885
XIAFLEX,corporal rupture,These patients were managed without surgical intervention but the longterm co,0,0.5255074501037598
XIAFLEX,corporal rupture,managed without surgical intervention but the longterm,0,0.5545927286148071
XIAFLEX,corporal rupture,cannot be excluded These patients were managed without,0,0.4908497631549835
XIAFLEX,corporal rupture,patients were managed without,0,0.4906737804412842
XIAFLEX,corporal rupture,diagnosis of,0,0.4991532862186432
XIAFLEX,corporal rupture,these cases a,0,0.5014863610267639
XIAFLEX,penile hematoma,unknown penile hematoma,1,0.9402601718902588
XIAFLEX,penile hematoma,these cases a,0,0.47295087575912476
XIAFLEX,penile hematoma,unknown penile hematoma was also reported,1,0.9073517322540283
XIAFLEX,penile hematoma,Severe,0,0.5248192548751831
XIAFLEX,penile hematoma,as an adverse reaction in of patients,0,0.49846476316452026
XIAFLEX,penile hematoma,longterm consequences are unknown penile hematoma,1,0.8762176036834717
XIAFLEX,penile hematoma,consequences are unknown penile,1,0.7410680055618286
XIAFLEX,penile hematoma,Peyronies disease penile hematoma penile swelling,1,0.8823059797286987
XIAFLEX,penile hematoma,of adverse reactions,0,0.5003066658973694
XIAFLEX,penile hematoma,Peyronies disease penile hematoma,1,0.9216695427894592
XIAFLEX,penile hematoma,penile hematoma penile swelling and penile,1,0.9221296906471252
XIAFLEX,penile swelling,penile penile swelling and,1,0.9728578329086304
XIAFLEX,penile swelling,Peyronies disease penile hematoma,1,0.7853889465332031
XIAFLEX,penile swelling,incidence of adverse reactions that were reported in,0,0.5269142389297485
XIAFLEX,penile swelling,penile penile swelling and penile pain Table,1,0.895182728767395
XIAFLEX,penile swelling,the incidence of adverse reactions that,0,0.5260672569274902
XIAFLEX,penile swelling,penile swelling and penile pain Table,1,0.8946105241775513
XIAFLEX,penile swelling,with,0,0.5382037162780762
XIAFLEX,penile swelling,penile swelling and penile,1,0.9690854549407959
XIAFLEX,penile swelling,of adverse reactions that were reported,0,0.5298175811767578
XIAFLEX,penile pain,penile pain Table shows,1,0.8957879543304443
XIAFLEX,penile pain,penile hematoma penile swelling penile,1,0.8031679391860962
XIAFLEX,penile pain,incidence of adverse reactions that were reported in greater than or equal,0,0.5006251931190491
XIAFLEX,penile pain,Peyronies disease were,0,0.73578941822052
XIAFLEX,penile pain,penile,0,0.8716261386871338
XIAFLEX,penile pain,penile pain Table,1,0.8882120847702026
XIAFLEX,penile pain,Peyronies disease were penile hematoma penile swelling,0,0.7761379480361938
XIAFLEX,penile pain,hematoma penile swelling penile pain,1,0.8628286123275757
XIAFLEX,injection site hematoma,Placebo After Up to Four Treatment Cycles in Studies and Combined a Includes,0,0.5142861604690552
XIAFLEX,injection site hematoma,Studies and,0,0.45793020725250244
XIAFLEX,injection site hematoma,and Combined a injection,1,0.6726127862930298
XIAFLEX,injection site hematoma,Studies and Combined a injection site hematoma and,1,0.9460160732269287
XIAFLEX,injection site hematoma,penile hematoma were reported with,0,0.7186568975448608
XIAFLEX,injection site hematoma,verbatim term of penile bruising,0,0.5998958945274353
XIAFLEX,injection site hematoma,Combined,0,0.4605931043624878
XIAFLEX,penile hematoma,Combined a Includes,0,0.46246346831321716
XIAFLEX,penile hematoma,site hematoma penile hematoma were reported with,1,0.9387218356132507
XIAFLEX,penile hematoma,penile hematoma,1,1.0000001192092896
XIAFLEX,penile hematoma,site hematoma penile hematoma,1,0.9587647318840027
XIAFLEX,penile hematoma,to Four Treatment Cycles in Studies and Combined a Includes injection,0,0.4571240544319153
XIAFLEX,penile bruising,penile bruising or injection site,1,0.9192355275154114
XIAFLEX,penile bruising,in of subjects b Includes injection site swelling,0,0.6293643712997437
XIAFLEX,injection site bruising,the,0,0.4871726632118225
XIAFLEX,injection site bruising,penile bruising injection site bruising in of subjects b,1,0.8521358966827393
XIAFLEX,injection site bruising,and penile hematoma,0,0.5803026556968689
XIAFLEX,injection site bruising,of penile bruising injection site,1,0.8497616648674011
XIAFLEX,injection site bruising,injection site bruising in of subjects,1,0.9704040288925171
XIAFLEX,injection site bruising,injection site bruising in,1,0.9960111379623413
XIAFLEX,injection site bruising,edema penile swelling,0,0.5549519062042236
XIAFLEX,injection site bruising,penile bruising injection,1,0.799557626247406
XIAFLEX,penile edema,penile edema penile,1,0.9502161145210266
XIAFLEX,penile edema,penile edema penile swelling local,1,0.9116244316101074
XIAFLEX,penile edema,b Includes injection site swelling,0,0.6279861330986023
XIAFLEX,penile edema,swelling scrotal swelling and,0,0.7602807283401489
XIAFLEX,penile edema,b Includes,0,0.5114768743515015
XIAFLEX,penile edema,site penile edema,1,0.9580238461494446
XIAFLEX,penile swelling,injection site edema c Includes,0,0.6178974509239197
XIAFLEX,penile swelling,penile swelling,1,0.9999999403953552
XIAFLEX,penile swelling,and injection site edema,0,0.6304267048835754
XIAFLEX,penile swelling,bruising in of subjects b Includes injection site,0,0.5619983673095703
XIAFLEX,penile swelling,injection site swelling penile penile swelling,1,0.9081807136535645
XIAFLEX,penile swelling,swelling scrotal,0,0.8406604528427124
XIAFLEX,penile swelling,swelling penile penile swelling,1,0.9889320135116577
XIAFLEX,penile swelling,swelling penile penile,1,0.9852879047393799
XIAFLEX,local swelling,swelling and injection site edema,0,0.7721011638641357
XIAFLEX,local swelling,local swelling scrotal,1,0.8187373876571655
XIAFLEX,local swelling,local swelling scrotal swelling and injection site,1,0.7825689315795898
XIAFLEX,local swelling,penile,0,0.5405459403991699
XIAFLEX,local swelling,Includes injection site pain,0,0.6144487857818604
XIAFLEX,local swelling,pain penile pain,0,0.5916777849197388
XIAFLEX,local swelling,penile edema penile local swelling,1,0.814979612827301
XIAFLEX,local swelling,b Includes injection site,0,0.5819510221481323
XIAFLEX,local swelling,local swelling scrotal swelling and injection,1,0.7828437685966492
XIAFLEX,scrotal swelling,swelling local scrotal,1,0.9504326581954956
XIAFLEX,scrotal swelling,scrotal swelling and injection site,1,0.8947221040725708
XIAFLEX,scrotal swelling,site edema c,0,0.6003521680831909
XIAFLEX,scrotal swelling,site swelling penile edema penile swelling,0,0.7641730308532715
XIAFLEX,scrotal swelling,injection site swelling,0,0.6577335596084595
XIAFLEX,injection site edema,local swelling scrotal swelling injection site edema c,1,0.8422778844833374
XIAFLEX,injection site edema,injection site swelling,0,0.9272210597991943
XIAFLEX,injection site edema,injection site pain penile pain and injection site,0,0.7541147470474243
XIAFLEX,injection site edema,injection site,0,0.8342510461807251
XIAFLEX,injection site edema,site edema c Includes injection,1,0.9098221659660339
XIAFLEX,injection site edema,scrotal swelling injection site edema,1,0.8761054277420044
XIAFLEX,injection site edema,swelling scrotal swelling injection site edema c Includes,1,0.8398613333702087
XIAFLEX,injection site edema,injection site,1,0.8342510461807251
XIAFLEX,injection site edema,Includes injection site pain,0,0.8157434463500977
XIAFLEX,injection site edema,scrotal swelling injection site edema c,1,0.8567599058151245
XIAFLEX,injection site pain,and injection site edema c Includes,0,0.7873367667198181
XIAFLEX,injection site pain,c injection site pain,1,0.9260449409484863
XIAFLEX,injection site pain,injection site pain penile pain,1,0.8567643761634827
XIAFLEX,injection site pain,c injection site pain penile pain,1,0.8419833183288574
XIAFLEX,injection site pain,site pain,1,0.7816486954689026
XIAFLEX,injection site pain,a penile swelling local swelling scrotal swelling,0,0.5322257280349731
XIAFLEX,injection site pain,site pain penile pain and injection site,1,0.8526710271835327
XIAFLEX,penile pain,Includes injection site penile pain,1,0.8782310485839844
XIAFLEX,penile pain,c,0,0.49807578325271606
XIAFLEX,penile pain,scrotal swelling and injection site edema c Includes injection site pain,0,0.7579102516174316
XIAFLEX,penile pain,c Includes injection site penile pain and injection,1,0.8522001504898071
XIAFLEX,contusion,injection site discomfort d contusion ecchymoses,1,0.7393591403961182
XIAFLEX,contusion,scrotal swelling and injection site edema c Includes injection site pain,0,0.5603565573692322
XIAFLEX,contusion,d Includes,0,0.5188910365104675
XIAFLEX,contusion,discomfort d contusion ecchymoses penile hemorrhage,1,0.7506604790687561
XIAFLEX,contusion,contusion ecchymoses,1,0.8630470633506775
XIAFLEX,contusion,and injection site hemorrhage Adverse,0,0.5495920181274414
XIAFLEX,ecchymoses,ecchymoses penile hemorrhage and,1,0.8202004432678223
XIAFLEX,ecchymoses,ecchymoses penile hemorrhage and injection,1,0.7644609212875366
XIAFLEX,ecchymoses,ecchymoses penile,1,0.840289294719696
XIAFLEX,ecchymoses,Includes ecchymoses penile hemorrhage and injection site,1,0.7464189529418945
XIAFLEX,ecchymoses,es injection,0,0.6328998804092407
XIAFLEX,ecchymoses,ecchymoses,1,0.9999999403953552
XIAFLEX,ecchymoses,injection site pain,0,0.560821533203125
XIAFLEX,penile hemorrhage,Includes contusion penile,1,0.793046772480011
XIAFLEX,penile hemorrhage,Includes contusion penile hemorrhage and injection site hemorrhage Adverse,1,0.844832181930542
XIAFLEX,penile hemorrhage,hemorrhage Adverse,0,0.6978251934051514
XIAFLEX,penile hemorrhage,penile hemorrhage and injection,1,0.9200978875160217
XIAFLEX,penile hemorrhage,Includes contusion penile hemorrhage and injection,1,0.8454277515411377
XIAFLEX,penile hemorrhage,ecchymoses,0,0.6188108921051025
XIAFLEX,injection site hemorrhage,hemorrhage and,0,0.7292686700820923
XIAFLEX,injection site hemorrhage,Reaction,0,0.5216471552848816
XIAFLEX,injection site hemorrhage,hemorrhage injection site hemorrhage Adverse Reaction,1,0.9130291938781738
XIAFLEX,injection site hemorrhage,injection,1,0.751477837562561
XIAFLEX,injection site hemorrhage,site hemorrhage Adverse Reaction,1,0.802669107913971
XIAFLEX,injection site hemorrhage,site hemorrhage Adverse Reaction XIAFLEXN PlaceboN,1,0.7683939337730408
XIAFLEX,injection site hemorrhage,Adverse,0,0.5170131921768188
XIAFLEX,injection site hemorrhage,discomfort,0,0.5423964858055115
XIAFLEX,Penile hematoma,se Penile hematoma a Penile,1,0.9582537412643433
XIAFLEX,Penile hematoma,discomfort,0,0.541279673576355
XIAFLEX,Penile hematoma,se Reactions,0,0.4898653030395508
XIAFLEX,Penile swelling,a,0,0.48107489943504333
XIAFLEX,Penile swelling,Penile swelling,1,0.9999999403953552
XIAFLEX,Penile swelling,Penile swelling b,1,0.9194973111152649
XIAFLEX,Penile pain,elling Penile pain c,1,0.872989296913147
XIAFLEX,Penile pain,Penile swelling b,1,0.8278475403785706
XIAFLEX,Penile pain,b,0,0.4865248203277588
XIAFLEX,Penile pain,Penile pain,1,1.0000001192092896
XIAFLEX,Penile pain,Penile,1,0.8716261386871338
XIAFLEX,Penile ecchymoses,d,0,0.5018525123596191
XIAFLEX,Penile ecchymoses,Penile ecchymoses d,1,0.9095382690429688
XIAFLEX,Penile ecchymoses,in Penile,1,0.8037796020507812
XIAFLEX,Penile ecchymoses,Penile ecchymoses d Blood bl,1,0.8856580257415771
XIAFLEX,Penile ecchymoses,Penile ecchymoses,1,1.0
XIAFLEX,Penile ecchymoses,d Blood bl,0,0.5151650905609131
XIAFLEX,Injection site vesicles,l Injection site vesicles Localized,1,0.9567473530769348
XIAFLEX,Injection site vesicles,d Blood bl,0,0.565814733505249
XIAFLEX,Injection site vesicles,Injection site vesicles Localized,1,0.9629307389259338
XIAFLEX,Injection site vesicles,l,0,0.5044165253639221
XIAFLEX,Injection site vesicles,site vesicles,1,0.9041640758514404
XIAFLEX,injection site hematoma,severe,0,0.5124794840812683
XIAFLEX,injection site hematoma,hematoma,0,0.8123620748519897
XIAFLEX,injection site hematoma,site hematoma were,1,0.8803504705429077
XIAFLEX,injection site hematoma,Severe penile hematoma or injection site,1,0.8418532609939575
XIAFLEX,injection site hematoma,of,0,0.4825701415538788
XIAFLEX,injection site hematoma,of XIAFLEXtreated patients and,0,0.5557836294174194
XIAFLEX,injection site hematoma,hematoma or injection site,1,0.9716027975082397
XIAFLEX,injection site hematoma,Severe,0,0.5124794840812683
XIAFLEX,popping sensation in the penis,penile popping,0,0.9094958305358887
XIAFLEX,popping sensation in the penis,sometimes accompanied,0,0.510229229927063
XIAFLEX,popping sensation in the penis,in the penis sometimes,1,0.7799738645553589
XIAFLEX,popping sensation in the penis,popping noise,0,0.8012803792953491
XIAFLEX,popping sensation in the penis,and sometimes accompanied,0,0.49803611636161804
XIAFLEX,popping sensation in the penis,sensations A popping noise popping sensation in the,1,0.8553849458694458
XIAFLEX,popping sensation in the penis,noise popping,1,0.7434506416320801
XIAFLEX,detumescence,accompanied detumescence hematoma andor pain were reported,1,0.6856096982955933
XIAFLEX,detumescence,noise popping,1,0.5565226078033447
XIAFLEX,detumescence,detumescence,1,0.9999999403953552
XIAFLEX,detumescence,detumescence hematoma andor pain were,1,0.7224642038345337
XIAFLEX,detumescence,as snapping or,0,0.6078078746795654
XIAFLEX,detumescence,detumescence hematoma andor pain,1,0.7290926575660706
XIAFLEX,detumescence,snapping or cracking and sometimes accompanied by,0,0.6387428045272827
XIAFLEX,detumescence,cracking and sometimes accompanied detumescence hematoma andor pain,1,0.6513811349868774
XIAFLEX,detumescence,the penis sometimes described as snapping or cracking and,0,0.5415797233581543
XIAFLEX,hematoma,andor pain were reported in XIAFLEXtreated patients and placebotrea,0,0.5542157888412476
XIAFLEX,hematoma,hematoma,1,1.0
XIAFLEX,pain,accompanied by detumescence hematoma pain were reported,1,0.7383753657341003
XIAFLEX,pain,hematoma,1,0.5659217238426208
XIAFLEX,pain,andor,0,0.5230066776275635
XIAFLEX,pain,described as snapping or cracking and,0,0.5609367489814758
XIAFLEX,pain,were reported,0,0.5097116827964783
XIAFLEX,pain,reported in XIAFLEXtreated patients and placebotreated patients,0,0.5854223966598511
XIAFLEX,CORPORAL RUPTURE,ADVERSE REACTIONS The lowing serious a dverse reactions,1,0.5108911991119385
XIAFLEX,CORPORAL RUPTURE,reported in XIAFLEXtreated patients and placebotreated patients,0,0.5263200998306274
XIAFLEX,CORPORAL RUPTURE,ADVERSE REACTIONS The,0,0.48485469818115234
XIAFLEX,CORPORAL RUPTURE,REACTIONS The lowing serious a,1,0.5534863471984863
XIAFLEX,CORPORAL RUPTURE,The lowing serious a dverse reactions in patients,1,0.5446603298187256
XIAFLEX,CORPORAL RUPTURE,Dupuytrens contracture are discussed in greater,0,0.5608764886856079
XIAFLEX,CORPORAL RUPTURE,The lowing serious a dverse reactions in,1,0.5490298271179199
XIAFLEX,CORPORAL RUPTURE,serious a,1,0.5498621463775635
XIAFLEX,CORPORAL RUPTURE,serious a dverse reactions,1,0.552046537399292
XIAFLEX,PENILE FRACTURE,following serious erse reactions ,1,0.5359554886817932
XIAFLEX,PENILE FRACTURE,serious a dverse reactions,1,0.523329496383667
XIAFLEX,PENILE FRACTURE,The following serious erse reactions,1,0.5345207452774048
XIAFLEX,PENILE FRACTURE,erse reactions in patients,1,0.5263594388961792
XIAFLEX,PENILE FRACTURE,erse reactions in patients with Dupuytrens,1,0.5203722715377808
XIAFLEX,PENILE FRACTURE,serious erse reactions  in patients with Dupuytrens,1,0.5181298851966858
XIAFLEX,PENILE FRACTURE,REACTIONS The following serious erse reactions,1,0.5250787734985352
XIAFLEX,PENILE INJURY,adverse reactions in patients with,0,0.504758358001709
XIAFLEX,PENILE INJURY,reactions in patients with,0,0.5148642063140869
XIAFLEX,CORPORAL RUPTURE,in,0,0.48487192392349243
XIAFLEX,PENILE FRACTURE,detail elsewhere in the Tendon ruptures,1,0.5785217881202698
XIAFLEX,PENILE FRACTURE,in,0,0.4990050792694092
XIAFLEX,PENILE FRACTURE,ents with Dupuytrens contracture are discussed in greater detail,0,0.5410038232803345
XIAFLEX,PENILE FRACTURE,Tendon ruptures or other serious,1,0.5740989446640015
XIAFLEX,PENILE FRACTURE,Tendon ruptures,1,0.5668970942497253
XIAFLEX,PENILE FRACTURE,elsewhere in the Tendon ruptures or other serious,1,0.5735194683074951
XIAFLEX,PENILE FRACTURE,in the Tendon ruptures or other serious injury,1,0.5934724807739258
XIAFLEX,PENILE FRACTURE,discussed in greater detail elsewhere in the labeling,0,0.4708697497844696
XIAFLEX,Corporal rupture,and utions,1,0.4969024956226349
XIAFLEX,Corporal rupture,extremity see Warnings and utions,1,0.5617190599441528
XIAFLEX,Corporal rupture,utions (5.1)] The following serious,1,0.5292394161224365
XIAFLEX,penile fracture,extremity see Warnings and     The followi ng,1,0.5254477262496948
XIAFLEX,penile fracture,utions (5.1)] The following serious,1,0.5073503851890564
XIAFLEX,penile fracture,see Warnings and     The followi ng serious,1,0.49095088243484497
XIAFLEX,penile ecchymoses,re penile hematom a,1,0.8016243577003479
XIAFLEX,penile ecchymoses,Corporal rupture,0,0.652712345123291
XIAFLEX,penile ecchymoses,labeling Corporal rupture penile fracture and seve,0,0.7742152214050293
XIAFLEX,penile ecchymoses,re,1,0.5078819990158081
XIAFLEX,penile ecchymoses,XIAFLEXtreated patients,0,0.5228332281112671
XIAFLEX,penile ecchymoses,penile hematom a see,1,0.8070050477981567
XIAFLEX,penile ecchymoses,re penile hematom a see Warnings and,1,0.7676493525505066
XIAFLEX,penile ecchymoses,ssed in greater detail elsewhere in the labeling Corporal rupture penile,0,0.7801132202148438
XIAFLEX,"penile ""popping"" sound",and Precautions other,1,0.46839725971221924
XIAFLEX,corporal rupture,patients a combination of,0,0.4923022985458374
XIAFLEX,corporal rupture,or hematoma en,1,0.6252743005752563
XIAFLEX,penile hematoma,penile detumescence andor a penile,0,0.7855428457260132
XIAFLEX,penile hematoma,of,0,0.4880974590778351
XIAFLEX,penile hematoma,"andor a penile ping"" sound or  sensation",1,0.6791784763336182
XIAFLEX,penile hematoma,"a penile ping"" sound or  sensation was reported and",1,0.6779353022575378
XIAFLEX,penile hematoma,a,0,0.4728362262248993
XIAFLEX,penile hematoma,combination of penile ecchymoses or hematoma sudden penile detumescence,0,0.8757439851760864
XIAFLEX,penile hematoma,sound or,1,0.4641379117965698
XIAFLEX,penile hematoma,"penile ping"" sound or  sensation was reported and",1,0.6768354773521423
XIAFLEX,penile hematoma,hematoma,0,0.8017942905426025
XIAFLEX,penile hematoma,"a penile ping"" sound",1,0.6683244705200195
XIAFLEX,penile injury,injection s ite reaction and pain,1,0.5580823421478271
XIAFLEX,penile injury,", injection s ite reaction and pain",1,0.5568976402282715
XIAFLEX,penile injury,", injection s ite",1,0.5593861937522888
XIAFLEX,penile injury,the injected,0,0.5529848337173462
XIAFLEX,penile injury,"site , injection s ite reaction and",1,0.5242722630500793
XIAFLEX,penile injury,"injection site , injection s ite",1,0.5208178758621216
XIAFLEX,penile injury,the injected extremity Peyronies,0,0.7201570272445679
XIAFLEX,penile injury,"hand contusion injection site , injection",1,0.6060622334480286
XIAFLEX,CORPORAL RUPTURE,penile s welling,1,0.5848842859268188
XIAFLEX,CORPORAL RUPTURE,"were penile matoma, penile",1,0.5753210783004761
XIAFLEX,CORPORAL RUPTURE,"were penile matoma, penile s welling and",1,0.5869108438491821
XIAFLEX,CORPORAL RUPTURE,"were penile matoma, penile s",1,0.5634067058563232
XIAFLEX,CORPORAL RUPTURE,To report SUSPECTED ADVERSE,0,0.4922698140144348
XIAFLEX,CORPORAL RUPTURE,ADVERSE REACTIONS contact,0,0.48116251826286316
XIAFLEX,CORPORAL RUPTURE,report SUSPECTED ADVERSE REACTIONS contact Auxilium Pharmaceutica,0,0.47199803590774536
XIAFLEX,CORPORAL RUPTURE,and at an incidence,0,0.5506284832954407
XIAFLEX,CORPORAL RUPTURE,"placebo were penile matoma, penile s",1,0.5318923592567444
XIAFLEX,CORPORAL RUPTURE,penile pain To report SUSPECTED ADVERSE REACTIONS contact Auxilium,0,0.562345027923584
XIAFLEX,PENILE FRACTURE,penile lling and penil e pain To report,1,0.7744747400283813
XIAFLEX,PENILE FRACTURE,penile pain To report SUSPECTED ADVERSE REACTIONS contact Auxilium,0,0.6930417418479919
XIAFLEX,PENILE INJURY,at or,0,0.5085529088973999
XIAFLEX,PENILE INJURY,penile pain To port,1,0.7947988510131836
XIAFLEX,PENILE INJURY,penile pain To port SUSPECTE,1,0.7988640069961548
XIAFLEX,PENILE INJURY,port SUSPECTE D ADVERSE REACTIONS contact Auxilium,1,0.5292985439300537
XIAFLEX,PENILE INJURY,or FDA at FDA,0,0.44147825241088867
XIAFLEX,PENILE INJURY,To,0,0.47206878662109375
XIAFLEX,PENILE INJURY,pain To port SUSPECTE,1,0.5705257058143616
XIAFLEX,Corporal rupture,"at FDA or medwatch.    


 Clinical",1,0.45575833320617676
XIAFLEX,Corporal rupture,pain To port SUSPECTE,1,0.5626406073570251
XIAFLEX,Corporal rupture,contact Auxilium Pharmaceuticals Inc,0,0.42243093252182007
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical Studies Experience",1,0.4805416166782379
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical",1,0.5029487609863281
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical Studies Experience in",1,0.4844994843006134
XIAFLEX,Corporal rupture,"at FDA or medwatch.    


 Clinical Studies",1,0.44933485984802246
XIAFLEX,Corporal rupture,"or medwatch.    


",1,0.5078788995742798
XIAFLEX,penile fracture,studies are conduc,0,0.46064889430999756
XIAFLEX,penile fracture,Patients with Dupuytrens Contracture Because clinical studies,0,0.5139433145523071
XIAFLEX,penile fracture,"FDA or 

  6.1 Clinica l Studies Experience in",1,0.44799327850341797
XIAFLEX,penile fracture,clinical,0,0.532328724861145
XIAFLEX,penile fracture,Patients with Dupuytrens,0,0.5046901702880859
XIAFLEX,penile fracture,FDA or 6.1 Clinica,1,0.4276624917984009
XIAFLEX,corporal rupture,reaction rates observed the clinical stu,1,0.5379816293716431
XIAFLEX,penile hematoma,and may,0,0.4298928678035736
XIAFLEX,penile hematoma,ectly compared,1,0.4592055082321167
XIAFLEX,penile hematoma,ectly compared  to,1,0.46077853441238403
XIAFLEX,penile hematoma,ectly compared to rates,1,0.4440900683403015
XIAFLEX,penile hematoma,observed,0,0.45843979716300964
XIAFLEX,penile hematoma,drug cannot be ectly compared  to rates,1,0.42194664478302
XIAFLEX,penile hematoma,ectly compared to rates in the clinical,1,0.4689818322658539
XIAFLEX,penile hematoma,cannot be ectly,1,0.44047874212265015
XIAFLEX,penile hematoma,rates observed in,0,0.4377448558807373
XIAFLEX,Tendon rupture,erse reactions in patients with,1,0.5088763236999512
XIAFLEX,Tendon rupture,with,0,0.4860074520111084
XIAFLEX,Tendon rupture,erse reactions in patients with Dupuytrens,1,0.5632529258728027
XIAFLEX,injury to the injected finger,serious adverse reactions in with Dupuytren's contracture,1,0.6117398142814636
XIAFLEX,injury to the injected finger,discussed in greater detail,0,0.4560011029243469
XIAFLEX,injury to the injected finger,in the,0,0.49895626306533813
XIAFLEX,injury to the injected finger,in with Dupuytren's contracture,1,0.5845171213150024
XIAFLEX,injury to the injected finger,patients,0,0.5323787927627563
XIAFLEX,injury to the injected finger,ADVERSE REACTIONS The following serious adverse reactions in,0,0.5647656917572021
XIAFLEX,Corporal rupture,i,0,0.4670613706111908
XIAFLEX,Corporal rupture,n greater detail elsewhere in the labeling Corporal,1,0.6720117926597595
XIAFLEX,Corporal rupture,Corporal rupture penile fracture and,0,0.8546493053436279
XIAFLEX,Corporal rupture,discussed i,0,0.47432392835617065
XIAFLEX,Corporal rupture,are discussed n,1,0.46741783618927
XIAFLEX,penile fracture,hematoma,0,0.505085289478302
XIAFLEX,penile fracture,adverse reactions in patients with Peyronies,0,0.672553539276123
XIAFLEX,penile fracture,lsewhere,1,0.4805870056152344
XIAFLEX,penile fracture,reactions in patients,0,0.4924266040325165
XIAFLEX,penile fracture,discussed in greater detail lsewhere in the labeling,1,0.4733520746231079
XIAFLEX,penile fracture,in greater detail lsewhere in,1,0.48314785957336426
XIAFLEX,injury to the penis,elsewhere in the labeling orporal rupture,1,0.5851622819900513
XIAFLEX,injury to the penis,the labeling orporal rupture (pe nile fracture and severe penile,1,0.7914466261863708
XIAFLEX,injury to the penis,orporal rupture (pe,1,0.6424729824066162
XIAFLEX,injury to the penis,orporal rupture (pe nile fracture and severe,1,0.6218618750572205
XIAFLEX,injury to the penis,greater detail elsewhere in the labeling C,0,0.4659081697463989
XIAFLEX,permanent injury,"ecchymoses or hematoma sudden detumescence,",1,0.6058128476142883
XIAFLEX,permanent injury,patients a combination of penile ecchymoses,0,0.582219123840332
XIAFLEX,permanent injury,"detumescence, an dor a penile popping",1,0.5787175893783569
XIAFLEX,corporal rupture,and in these cases a diagnosis of corporal,0,0.7661934494972229
XIAFLEX,penile fracture,andor a penile popping nd or sensation,1,0.7470821142196655
XIAFLEX,penile fracture,and in these cases a diagnosis of corporal,0,0.5818126797676086
XIAFLEX,penile fracture,andor,0,0.49634644389152527
XIAFLEX,penile fracture,a penile popping nd,1,0.7859426736831665
XIAFLEX,penile fracture,or sensation,1,0.5342186689376831
XIAFLEX,penile fracture,or sensation was reported and in,1,0.533686637878418
XIAFLEX,penile fracture,penile popping nd or sensation,1,0.7435007095336914
XIAFLEX,penile fracture,popping nd or sensation,1,0.5468286275863647
XIAFLEX,penile fracture,bination of penile ecchymoses or hematoma sudden penile detumescence,0,0.7481118440628052
XIAFLEX,penile fracture,or hematoma sudden penile detumescence andor a penile popping sou,0,0.7530622482299805
XIAFLEX,penile fracture,detumescence andor a penile popping,0,0.7656069993972778
XIAFLEX,anaphylaxis,EXCERPT,0,0.49662381410598755
XIAFLEX,anaphylaxis,and in these cases a,0,0.503398597240448
XIAFLEX,anaphylaxis,cases a diagnosis of al rupture  cannot,1,0.4942174553871155
XIAFLEX,anaphylaxis,EXCERPT Dupuytrens Contrac,0,0.48006224632263184
XIAFLEX,anaphylaxis,al rupture,1,0.5288563966751099
XIAFLEX,anaphylaxis,cases a diagnosis of al rupture  cannot be excluded see,1,0.5032602548599243
XIAFLEX,anaphylaxis,of al,1,0.48586738109588623
XIAFLEX,permanent injury,Patients with Dupuytrens Contracture Because clinical studies are,0,0.5534913539886475
XIAFLEX,permanent injury,Dupuytrens Contracture Because clinical,0,0.5746300220489502
XIAFLEX,permanent injury,Because clinical,0,0.5308138728141785
XIAFLEX,permanent injury,"FDA at FDA or 



 

  6.1 Cli",1,0.4515956938266754
XIAFLEX,permanent injury,FDA or 6.1 Cli,1,0.4443845748901367
XIAFLEX,permanent injury,6.1 Cli nical,1,0.4845961332321167
XIAFLEX,permanent injury,ilium Pharmaceuticals Inc at or FDA at FDA or,0,0.4844285547733307
XIAFLEX,tendon rupture,FDA or wwwfdagovmedwatch Clinical dies Experienc,1,0.4730144143104553
XIAFLEX,tendon rupture,or,0,0.48483505845069885
XIAFLEX,tendon rupture,dies Experienc e in Patients with Dupuytrens,1,0.566014289855957
XIAFLEX,tendon rupture,Clinical dies Experienc e in Patients with,1,0.5218217372894287
XIAFLEX,tendon rupture,dies,1,0.505567193031311
XIAFLEX,ligament damage,or FDA at FDA or wwwfdagovmedwatch Clinical,0,0.47220709919929504
XIAFLEX,ligament damage,wwwfdagovmedwatch Clinical Studies Experience Patients,1,0.5014423727989197
XIAFLEX,ligament damage,FDA at FDA,0,0.4321390986442566
XIAFLEX,ligament damage,Studies Experience  Patients with  Dupuytrens Contracture Because clinical,1,0.5952763557434082
XIAFLEX,ligament damage,Dupuytrens Contracture Because clinical studies are conducted under widely varying,0,0.5963818430900574
XIAFLEX,ligament damage,Patients with Dupuytrens Contracture,1,0.5984156131744385
XIAFLEX,ligament damage,or wwwfdagovmedwatch,0,0.46776145696640015
XIAFLEX,ligament damage,clinical studies are conducted under widely varying conditions a,0,0.5047467947006226
XIAFLEX,ligament damage,Patients with Dupuytrens Contracture Because clinical studies,1,0.5986112356185913
XIAFLEX,pulley rupture,ata described,1,0.5093168020248413
XIAFLEX,pulley rupture,ata described below are,1,0.5168787240982056
XIAFLEX,ligament injury,be,0,0.47095680236816406
XIAFLEX,ligament injury,through Day in patients with,0,0.5090637803077698
XIAFLEX,complex regional pain syndrome,"based two pooled randomized, double-",1,0.4853920042514801
XIAFLEX,complex regional pain syndrome,through Day in patients with,0,0.5806728601455688
XIAFLEX,complex regional pain syndrome,"are based two pooled randomized, double-",1,0.48897868394851685
XIAFLEX,complex regional pain syndrome,"based two pooled randomized, double- blind placebocontrolled",1,0.5560909509658813
XIAFLEX,complex regional pain syndrome,"pooled randomized, double- blind placebocontrolled trials through",1,0.5448718070983887
XIAFLEX,complex regional pain syndrome,"based two pooled randomized, double- blind placebocontrolled trials",1,0.549052357673645
XIAFLEX,complex regional pain syndrome,"pooled randomized, double- blind placebocontrolled trials through Day",1,0.5434042811393738
XIAFLEX,complex regional pain syndrome,"randomized, double- blind placebocontrolled trials through Day",1,0.5422255396842957
XIAFLEX,complex regional pain syndrome,in patients with Dupuytrens contracture,0,0.5599706172943115
XIAFLEX,complex regional pain syndrome,"below are based two pooled randomized, double- blind placebocontrolled trials",1,0.5350211262702942
XIAFLEX,complex regional pain syndrome,blind placebocontrolled trials through,0,0.5428374409675598
XIAFLEX,CRPS,"ind, placebocontrolled trials",1,0.5302441716194153
XIAFLEX,CRPS,"ind, placebocontrolled trials through",1,0.5333908796310425
XIAFLEX,CRPS,"two pooled randomized ind, placebocontrolled trials through",1,0.5144222974777222
XIAFLEX,CRPS,"ind, placebocontrolled",1,0.5462184548377991
XIAFLEX,sensory abnormality of the hand,and In these trials patients were,0,0.5046812295913696
XIAFLEX,sensory abnormality of the hand,trials through,1,0.48707303404808044
XIAFLEX,sensory abnormality of the hand,pooled randomized doubleblind acebo-controlled trials through Day in patients with Dupuytrens,1,0.5629420280456543
XIAFLEX,sensory abnormality of the hand,based on two,0,0.476552277803421
XIAFLEX,sensory abnormality of the hand,based,0,0.4674772620201111
XIAFLEX,sensory abnormality of the hand,in patients with Dupuytrens contracture Studies and In these trials patients were,0,0.5760635137557983
XIAFLEX,skin laceration,pooled randomized doubleblind,0,0.502021849155426
XIAFLEX,skin laceration,doubleblind placebocontrolled trials through 0 in patients,1,0.4994804859161377
XIAFLEX,skin laceration,doubleblind placebocontrolled trials through 0 in patients w ith Dupuytrens,1,0.5087153911590576
XIAFLEX,skin laceration,in patients w ith Dupuytrens contracture Studies and,1,0.5528392195701599
XIAFLEX,skin laceration,were treated with up to,0,0.5774988532066345
XIAFLEX,skin laceration,0,1,0.5535785555839539
XIAFLEX,skin laceration,treated with up to,0,0.5761127471923828
XIAFLEX,skin laceration,0 in patients w ith Dupuytrens,1,0.493854820728302
XIAFLEX,skin laceration,placebocontrolled trials through 0 in,1,0.49803170561790466
XIAFLEX,skin laceration,of,0,0.5110718607902527
XIAFLEX,skin laceration,with u p to injections,1,0.5337337255477905
XIAFLEX,skin laceration,see Clinical Studies,0,0.5196837186813354
XIAFLEX,skin laceration,Studies These trials,0,0.5041195750236511
XIAFLEX,skin laceration,to facilitate ruption of the  cord,1,0.5070840120315552
XIAFLEX,skin laceration,to facilitate ruption,1,0.49593469500541687
XIAFLEX,skin laceration,of patients,0,0.5231072902679443
XIAFLEX,skin laceration,ruption of the cord,1,0.5416861772537231
XIAFLEX,skin laceration,cord see Clinical Studies These trials were comprised of patients of,0,0.5110305547714233
XIAFLEX,Corporal rupture,XIAFLEXtreated and placebotreated ts had an advers,1,0.46800652146339417
XIAFLEX,penile ecchymoses,within weeks XIAFLEX injection s The adverse reaction,1,0.5435745120048523
XIAFLEX,penile ecchymoses,XIAFLEXtreated and placebotreated ts had an advers,1,0.44909024238586426
XIAFLEX,penile ecchymoses,injection,0,0.5465686321258545
XIAFLEX,penile detumescence,profile was simi lar,1,0.4761303663253784
XIAFLEX,penile detumescence,for each,0,0.5163755416870117
XIAFLEX,penile detumescence,on profile was simi lar,1,0.48793062567710876
XIAFLEX,penile detumescence,The adverse on profile,1,0.5869407653808594
XIAFLEX,"penile ""popping"" sound",of,0,0.4962542653083801
XIAFLEX,"penile ""popping"" sound","h injection, regardles s of the number",1,0.5236702561378479
XIAFLEX,"penile ""popping"" sound","injection, regardles",1,0.5408375263214111
XIAFLEX,corporal rupture,of pruritus increased with more,1,0.4543410539627075
XIAFLEX,corporal rupture,the nce,1,0.49877721071243286
XIAFLEX,corporal rupture,injection regardless of the,0,0.4881022274494171
XIAFLEX,corporal rupture,nce of pruritus  increased,1,0.46402597427368164
XIAFLEX,corporal rupture,administered However the nce of pruritus  increased with more injections see,1,0.473256915807724
XIAFLEX,corporal rupture,the nce of,1,0.5099692344665527
XIAFLEX,corporal rupture,nce of pruritus,1,0.47027552127838135
XIAFLEX,corporal rupture,Adverse Reactions Occurring  of XIAFLEX-Trea ted Patients with Dupuytrens,1,0.5057371854782104
XIAFLEX,corporal rupture,ted Patients with Dupuytrens Contracture and at a Greater,0,0.5880203247070312
XIAFLEX,corporal rupture,Reactions Occurring of XIAFLEX-Trea,1,0.5014773607254028
XIAFLEX,corporal rupture,in,0,0.48487192392349243
XIAFLEX,corporal rupture,and Table Adverse,0,0.5189346075057983
XIAFLEX,penile fracture,of d Patients with Dupuytrens Contracture and at,1,0.5286795496940613
XIAFLEX,penile fracture,and Table Adverse,0,0.4667014479637146
XIAFLEX,penile fracture,and at a Greater Incidence than Placebo in the PlaceboControlled,0,0.4678895175457001
XIAFLEX,penile fracture,Contracture and at a Greater Incidence than,0,0.5343676805496216
XIAFLEX,penile fracture,d Patients with Dupuytrens Contracture,1,0.5240914225578308
XIAFLEX,penile fracture,d Patients with Dupuytrens Contracture and at,1,0.521221399307251
XIAFLEX,penile fracture,d,1,0.5011197924613953
XIAFLEX,allergic reactions,"   
         Some  patients developed vasovagal",1,0.5603944063186646
XIAFLEX,allergic reactions,finger extension procedures The safety,0,0.5114907026290894
XIAFLEX,allergic reactions,procedures The safety,0,0.543563961982727
XIAFLEX,allergic reactions,"Pain Erythema Axillary    
         Some  patients developed",1,0.6157902479171753
XIAFLEX,allergic reactions,"   
         Some  patients developed vasovagal syncope",1,0.5501844882965088
XIAFLEX,pruritus,two concurrent,0,0.529495120048523
XIAFLEX,pruritus,after finger extension procedures The safety of two concurrent injec,0,0.5302578210830688
XIAFLEX,pruritus,tients d eveloped vasovagal syncope after,1,0.4695276618003845
XIAFLEX,pruritus,Erythema Axillary Pain Some tients d,1,0.6659932136535645
XIAFLEX,pruritus,vasovagal,0,0.5312038660049438
XIAFLEX,pruritus,pa,0,0.5316743850708008
XIAFLEX,pruritus,tients,1,0.5550169348716736
XIAFLEX,pruritus,The sa fety of,1,0.5152222514152527
XIAFLEX,pruritus,syncope after,0,0.4949595332145691
XIAFLEX,pruritus,The sa fety of two,1,0.4994979798793793
XIAFLEX,pruritus,"finger extension 
 The sa fety",1,0.5547947883605957
XIAFLEX,pruritus,hand was eva,0,0.5011159181594849
XIAFLEX,pruritus,finger extension The,1,0.5315109491348267
XIAFLEX,pruritus,"syncope after finger extension 
 The sa fety of",1,0.5084761381149292
XIAFLEX,pruritus,"finger extension 
 The sa",1,0.5361781120300293
XIAFLEX,pruritus,The sa,1,0.5152860879898071
XIAFLEX,localized pruritus,72 hours after injection,1,0.5337237119674683
XIAFLEX,localized pruritus,procedures were performed to 72,1,0.5283204317092896
XIAFLEX,localized pruritus,to 72 hours after injection The patient demographics were,1,0.5496110916137695
XIAFLEX,localized pruritus,were performed to 72 hours after ,1,0.5174587965011597
XIAFLEX,localized pruritus,Study In Study finger,0,0.5357139706611633
XIAFLEX,localized pruritus,to 72 hours after  injection The,1,0.537399172782898
XIAFLEX,localized pruritus,to Studies and Out of,0,0.4712721109390259
XIAFLEX,localized pruritus,hours after,1,0.48677611351013184
XIAFLEX,localized pruritus,were performed to 72,1,0.4888961613178253
XIAFLEX,pruritus,nt injec tions of,1,0.5368951559066772
XIAFLEX,pruritus,same hand XIAFLEX injections in Study one patient,0,0.5486888289451599
XIAFLEX,pruritus,patients who received two nt injec,1,0.5412182807922363
XIAFLEX,pruritus,received two nt,1,0.5111822485923767
XIAFLEX,pruritus,received two nt injec tions of XIAFLEX,1,0.5486470460891724
XIAFLEX,pruritus,of XIAFLEX mg in the same hand XIAFLEX injections in Study,0,0.5482674837112427
XIAFLEX,pruritus,who received two nt injec tions of XIAFLEX,1,0.5460846424102783
XIAFLEX,pruritus,nt injec tions of XIAFLEX mg in,1,0.5552563667297363
XIAFLEX,allergic reactions,tendon,0,0.4756145179271698
XIAFLEX,allergic reactions,within 3 day s of,1,0.4962705373764038
XIAFLEX,allergic reactions,of the treated inger within,1,0.584886372089386
XIAFLEX,allergic reactions,Table shows the incidence of adverse reactions that were,0,0.7247687578201294
XIAFLEX,allergic reactions,rupture of the treated inger within 3 day s of the injection Table,1,0.5396701097488403
XIAFLEX,allergic reactions,treated inger within 3 day s,1,0.5684027671813965
XIAFLEX,injection site hemorrhage,"Edema          
 Contusion      Pain",1,0.599959135055542
XIAFLEX,injection site hemorrhage,Table shows the incidence of adverse reactions that were,0,0.576787531375885
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain",1,0.5825052857398987
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain in",1,0.5808289051055908
CIMZIA,upper respiratory tract infection,respiratory tract infection,1,0.9014788866043091
CIMZIA,upper respiratory tract infection,common adverse reactions incidence and higher,0,0.5610542297363281
CIMZIA,upper respiratory tract infection,tract infection To report SUSPECTED ADVERSE REACTIONS,0,0.6905726194381714
CIMZIA,upper respiratory tract infection,upper respiratory tract infection rash and urinary,1,0.7996962070465088
CIMZIA,upper respiratory tract infection,and higher than upper respiratory tract infection rash,1,0.7921834588050842
CIMZIA,upper respiratory tract infection,urinary tract infection To report SUSPECTED ADVERSE REACTIONS,0,0.6527543663978577
CIMZIA,upper respiratory tract infection,respiratory tract infection rash and urinary,1,0.7430014610290527
CIMZIA,rash,rash and urinary,1,0.820946455001831
CIMZIA,urinary tract infection,contact UCB Inc at or FDA at,0,0.5313047170639038
CIMZIA,urinary tract infection,and,0,0.5330232381820679
CIMZIA,urinary tract infection,infection rash urinary,1,0.7598739862442017
CIMZIA,urinary tract infection,To report SUSPECTED ADVERSE,0,0.5600088238716125
CIMZIA,urinary tract infection,rash urinary,1,0.7122592926025391
CIMZIA,urinary tract infection,urinary tract infection To report,1,0.8673498630523682
CIMZIA,Infections,Experience The most serious,0,0.5678161382675171
CIMZIA,Infections,Malignancies see Warnings and,0,0.5770276784896851
CIMZIA,Infections,see Warnings and Precautions,0,0.6157455444335938
CIMZIA,Infections,Infections,1,1.000000238418579
CIMZIA,Malignancies,Malignancies see Warnings and,1,0.8141406774520874
CIMZIA,Malignancies,see Warnings and Precautions,0,0.5292477607727051
CIMZIA,Malignancies,Malignancies see Warnings,1,0.8174512982368469
CIMZIA,Malignancies,Malignancies see Warnings and Precautions Heart,1,0.7592407464981079
CIMZIA,Malignancies,Malignancies,1,1.0
CIMZIA,Malignancies,Malignancies see,1,0.9168466925621033
CIMZIA,Malignancies,Warnings and,0,0.5644186735153198
CIMZIA,Malignancies,Serious Infections,0,0.5939157009124756
CIMZIA,Heart Failure,see Warnings and Heart Failure,1,0.8109112977981567
CIMZIA,Heart Failure,and Precautions,0,0.47052475810050964
CIMZIA,Heart Failure,see Warnings and Heart,1,0.650793194770813
CIMZIA,Heart Failure,see Warnings and Heart Failure see Warnings,1,0.7995537519454956
CIMZIA,Heart Failure,Heart Failure see Warnings and Precautions,1,0.8239251375198364
CIMZIA,Heart Failure,Malignancies see Warnings and Heart Failure,1,0.7362993359565735
CIMZIA,Heart Failure,Malignancies see Warnings and Heart Failure see Warnings and,1,0.7499903440475464
CIMZIA,Heart Failure,Warnings,0,0.5409492254257202
CIMZIA,Heart Failure,Malignancies see Warnings and Heart,1,0.6340583562850952
CIMZIA,Heart Failure,and Heart Failure see Warnings and Precautions,1,0.8092237710952759
CIMZIA,upper respiratory infections,infections Adverse Reactions Most Commonly,0,0.631568968296051
CIMZIA,upper respiratory infections,respiratory infections rash and urinary tract,1,0.7404594421386719
CIMZIA,upper respiratory infections,ontrolled trials of all patient populations combined the most common adverse reactions were,0,0.5292957425117493
CIMZIA,upper respiratory infections,and urinary tract infections,0,0.6643369793891907
CIMZIA,upper respiratory infections,upper,1,0.6547590494155884
CIMZIA,upper respiratory infections,trials of all patient populations,0,0.5166356563568115
CIMZIA,upper respiratory infections,common adverse reactions upper respiratory infections,1,0.8092238903045654
CIMZIA,rash,Adverse Reactions Most,0,0.6150084733963013
CIMZIA,rash,respiratory rash and urinary tract,1,0.7310374975204468
CIMZIA,rash,infections Adverse,0,0.5935928821563721
CIMZIA,rash,infections Adverse Reactions Most Commonly Leading to,0,0.5917497873306274
CIMZIA,rash,rash and,1,0.9337756037712097
CIMZIA,rash,rash and urinary tract infections,1,0.7759832143783569
CIMZIA,rash,rash,1,1.0000001192092896
CIMZIA,urinary tract infections,reactions,0,0.5283640623092651
CIMZIA,urinary tract infections,rash and,0,0.531702995300293
CIMZIA,urinary tract infections,respiratory infections rash,0,0.5653665661811829
CIMZIA,urinary tract infections,most common adverse reactions were,0,0.5631876587867737
CIMZIA,abdominal pain,abdominal pain,1,0.9999998807907104
CIMZIA,abdominal pain,abdominal pain CIMZIA placebo diarrhea,1,0.729315996170044
CIMZIA,abdominal pain,higher incidence than placebo abdominal,1,0.7023028135299683
CIMZIA,abdominal pain,than placebo abdominal,1,0.7288955450057983
CIMZIA,abdominal pain,CIMZIA,0,0.434199720621109
CIMZIA,abdominal pain,than placebo abdominal pain,1,0.8283355236053467
CIMZIA,abdominal pain,abdominal pain CIMZIA placebo diarrhea CIMZIA,1,0.7196269035339355
CIMZIA,abdominal pain,and intestinal obstruction C,0,0.6779005527496338
CIMZIA,diarrhea,CIMZIA placebo,0,0.526347279548645
CIMZIA,diarrhea,diarrhea CIMZIA placebo and intestinal obstruction,1,0.7150770425796509
CIMZIA,diarrhea,diarrhea CIMZIA placebo and,1,0.7381528615951538
CIMZIA,diarrhea,abdominal pain CIMZIA diarrhea CIMZIA placebo and intestinal obstruction,1,0.6714290380477905
CIMZIA,diarrhea,were abdominal,0,0.6288600564002991
CIMZIA,diarrhea,diarrhea CIMZIA placebo and intestinal,1,0.7284820079803467
CIMZIA,diarrhea,placebo The proportion,0,0.5366390943527222
CIMZIA,intestinal obstruction,CIMZIA placebo intestinal obstruction,1,0.7644702792167664
CIMZIA,tuberculosis infections,and pyrexia urticaria pneumonia and,0,0.598724365234375
CIMZIA,tuberculosis infections,tuberculosis infections and pyrexia urticaria,1,0.7550275921821594
CIMZIA,tuberculosis infections,were,0,0.5092037916183472
CIMZIA,tuberculosis infections,to discontinuation of CIMZIA tuberculosis,1,0.6635470390319824
CIMZIA,tuberculosis infections,discontinuation of CIMZIA tuberculosis infections,1,0.7161593437194824
CIMZIA,tuberculosis infections,placebo The most common adverse reactions leading to discontinuation of CIMZIA,0,0.5047734975814819
CIMZIA,urticaria,urticaria pneumonia and rash Controlled Studies,1,0.7559432983398438
CIMZIA,urticaria,urticaria pneumonia and,1,0.7963697910308838
CIMZIA,urticaria,urticaria pneumonia,1,0.7955721616744995
CIMZIA,urticaria,Crohns,0,0.538520336151123
CIMZIA,urticaria,urticaria pneumonia and rash Controlled,1,0.7715731859207153
CIMZIA,urticaria,and urticaria,1,0.9043649435043335
CIMZIA,urticaria,se reactions leading to discontinuation of CIMZIA,0,0.5763763189315796
CIMZIA,pneumonia,pneumonia and rash,1,0.7944163084030151
CIMZIA,pneumonia,tuberculosis infections and pyrexia pneumonia,1,0.7045085430145264
CIMZIA,pneumonia,Controlled Studies with,0,0.540075421333313
CIMZIA,pneumonia,pneumonia and rash Controlled Studies with,1,0.7300958037376404
CIMZIA,rash,CIMZIA were tuberculosis infections and pyrexia urticaria,0,0.6240444183349609
CIMZIA,rash,scontinuation of CIMZIA were tuberculosis infections and,0,0.5443190932273865
CIMZIA,upper respiratory infections,upper respiratory infections eg,1,0.940254807472229
CIMZIA,upper respiratory infections,with CIMZIA upper respiratory infections eg nasopharyngitis,1,0.7779310941696167
CIMZIA,upper respiratory infections,to placebo in controlled clinical studies with,0,0.4859771430492401
CIMZIA,upper respiratory infections,upper respiratory infections,1,1.000000238418579
CIMZIA,upper respiratory infections,clinical studies,0,0.5456936359405518
CIMZIA,upper respiratory infections,studies with CIMZIA upper respiratory infections,1,0.771957516670227
CIMZIA,upper respiratory infections,upper respiratory,1,0.8601452708244324
CIMZIA,nasopharyngitis,nasopharyngitis laryngitis viral infection in of,1,0.8262815475463867
CIMZIA,nasopharyngitis,nasopharyngitis laryngitis viral infection in,1,0.8255094289779663
CIMZIA,nasopharyngitis,clinical,0,0.5915635824203491
CIMZIA,laryngitis,laryngitis viral,1,0.8729708194732666
CIMZIA,laryngitis,laryngitis viral infection in of CIMZIAtreated,1,0.7997910976409912
CIMZIA,viral infection,eg nasopharyngitis viral,1,0.7470753788948059
CIMZIA,urinary tract infections,patients and of placebotreated urinary tract,1,0.7355327606201172
CIMZIA,urinary tract infections,urinary tract infections eg bladder infection bacteriuria,1,0.8637949228286743
CIMZIA,bladder infection,urinary tract infections bladder infection,1,0.9223942160606384
CIMZIA,bladder infection,of CIMZIAtreated patients,0,0.5570803284645081
CIMZIA,bladder infection,of placebotreated patients,0,0.5153582692146301
CIMZIA,bladder infection,and in of placebotreated,0,0.48511838912963867
CIMZIA,bladder infection,patients urinary tract infections bladder infection bacteriuria cystitis in of,1,0.8311254978179932
CIMZIA,bacteriuria,bacteriuria cystitis in of CIMZIAtreated,1,0.8100018501281738
CIMZIA,bacteriuria,bacteriuria cystitis in,1,0.8801382780075073
CIMZIA,bacteriuria,infection,0,0.6830134987831116
CIMZIA,bacteriuria,infections eg bladder bacteriuria cystitis in of CIMZIAtreated patients,1,0.7563385963439941
CIMZIA,bacteriuria,eg bladder bacteriuria,1,0.8896023035049438
CIMZIA,bacteriuria,eg,0,0.49181270599365234
CIMZIA,bacteriuria,in of placebotreated patients,0,0.5104533433914185
CIMZIA,bacteriuria,patients and in of placebotreated patients and,0,0.5018941760063171
CIMZIA,cystitis,bladder infection cystitis in of CIMZIAtreated,1,0.8303524851799011
CIMZIA,cystitis,patients and in of placebotreated patients and,0,0.5308790802955627
CIMZIA,cystitis,bladder infection cystitis,1,0.9150534868240356
CIMZIA,cystitis,cystitis in of CIMZIAtreated patients and,1,0.8174231052398682
CIMZIA,cystitis,bladder infection cystitis in of,1,0.899295449256897
CIMZIA,cystitis,tract infections eg bladder infection,0,0.7475881576538086
CIMZIA,cystitis,placebotreated patients urinary tract infections eg bladder,0,0.734663188457489
CIMZIA,cystitis,placebotreated patients and,0,0.5420490503311157
CIMZIA,cystitis,cystitis in of CIMZIAtreated patients,1,0.8110294342041016
CIMZIA,cystitis,cystitis in of,1,0.9377924203872681
CIMZIA,arthralgia,patients arthralgia,1,0.9030498266220093
CIMZIA,arthralgia,cystitis in of,1,0.5542744398117065
CIMZIA,arthralgia,Reactions The most commonly occurring,0,0.5098310708999634
CIMZIA,arthralgia,patients and in of placebotreated patients,0,0.5141388177871704
CIMZIA,arthralgia,and in of placebotreated,0,0.4727046489715576
CIMZIA,arthralgia,placebotreated patients arthralgia CIMZIA placebo Other,1,0.7438085675239563
CIMZIA,arthralgia,arthralgia CIMZIA placebo Other,1,0.7707828879356384
CIMZIA,arthralgia,arthralgia,1,1.0
CIMZIA,Anemia,Anemia,1,1.0
CIMZIA,Anemia,or other doses include Blood and lymphatic system,0,0.6194887161254883
CIMZIA,Anemia,other doses include Blood and lymphatic system,0,0.6288244128227234
CIMZIA,leukopenia,Cardiac disorders,0,0.4519791305065155
CIMZIA,leukopenia,doses,0,0.5616355538368225
CIMZIA,leukopenia,leukopenia lymphadenopathy pancytopenia and thrombophilia,1,0.8106006979942322
CIMZIA,leukopenia,disorders Anemia,0,0.6245878338813782
CIMZIA,leukopenia,lymphatic system disorders leukopenia lymphadenopathy pancytopenia and thrombophilia,1,0.7146857976913452
CIMZIA,leukopenia,Angina pectoris,0,0.48239263892173767
CIMZIA,leukopenia,disorders Angina pectoris,0,0.4684017300605774
CIMZIA,leukopenia,system disorders leukopenia lymphadenopathy pancytopenia,1,0.7813321948051453
CIMZIA,lymphadenopathy,lymphadenopathy pancytopenia and thrombophilia Cardiac disorders,1,0.7916584014892578
CIMZIA,lymphadenopathy,disorders Anemia lymphadenopathy pancytopenia and,1,0.7786584496498108
CIMZIA,pancytopenia,pancytopenia and thrombophilia Cardiac disorders,1,0.8146981000900269
CIMZIA,pancytopenia,disorders Angina,0,0.4960513114929199
CIMZIA,pancytopenia,pancytopenia,1,1.0
CIMZIA,pancytopenia,er doses include Blood and lymphatic system disorders,0,0.5545036792755127
CIMZIA,pancytopenia,pectoris arrhythmias,0,0.5204176306724548
CIMZIA,pancytopenia,atrial fibrillation,0,0.5080620050430298
CIMZIA,pancytopenia,Blood and,0,0.6638709306716919
CIMZIA,pancytopenia,lymphatic system disorders Anemia leukopenia,0,0.6219250559806824
CIMZIA,pancytopenia,system disorders Anemia leukopenia pancytopenia and thrombophilia Cardiac disorders,1,0.7301286458969116
CIMZIA,thrombophilia,Angina pectoris arrhythmias atrial fibrillation,0,0.5547613501548767
CIMZIA,thrombophilia,pectoris arrhythmias atrial fibrillation cardiac failure,0,0.5602601170539856
CIMZIA,thrombophilia,thrombophilia Cardiac disorders Angina pectoris arrhythmias,1,0.8014537692070007
CIMZIA,Angina pectoris,atrial fibrillation cardiac failure hypertensive heart,0,0.6237754821777344
CIMZIA,Angina pectoris,lymphadenopathy pancytopenia,0,0.5107861757278442
CIMZIA,Angina pectoris,s Anemia,0,0.5463938117027283
CIMZIA,Angina pectoris,arrhythmias atrial fibrillation cardiac failure hypertensive heart disease,0,0.6472559571266174
CIMZIA,Angina pectoris,arrhythmias atrial,0,0.6110427379608154
CIMZIA,arrhythmias,myocardial,0,0.6551011204719543
CIMZIA,arrhythmias,hypertensive heart,0,0.6639527082443237
CIMZIA,arrhythmias,arrhythmias,1,0.9999998807907104
CIMZIA,arrhythmias,arrhythmias atrial fibrillation cardiac failure hypertensive,1,0.8244261145591736
CIMZIA,arrhythmias,lymphadenopathy,0,0.5244113802909851
CIMZIA,atrial fibrillation,atrial fibrillation cardiac failure hypertensive heart disease,1,0.7999171018600464
CIMZIA,atrial fibrillation,atrial fibrillation,1,1.0
CIMZIA,atrial fibrillation,arrhythmias,0,0.7667038440704346
CIMZIA,atrial fibrillation,disorders Angina pectoris atrial,1,0.722144365310669
CIMZIA,atrial fibrillation,atrial fibrillation cardiac failure hypertensive heart,1,0.8124088048934937
CIMZIA,atrial fibrillation,myocardial ischemia,0,0.6117470264434814
CIMZIA,cardiac failure,myocardial infarction myocardial ischemia pericardial,0,0.6295921802520752
CIMZIA,cardiac failure,pectoris arrhythmias atrial cardiac failure,1,0.7640633583068848
CIMZIA,cardiac failure,atrial fibrillation,0,0.6939050555229187
CIMZIA,cardiac failure,pectoris arrhythmias atrial cardiac,1,0.6427484154701233
CIMZIA,hypertensive heart disease,atrial fibrillation cardiac hypertensive,1,0.821348249912262
CIMZIA,hypertensive heart disease,pericarditis stroke and transie,0,0.592983603477478
CIMZIA,hypertensive heart disease,heart disease myocardial infarction,1,0.763923168182373
CIMZIA,hypertensive heart disease,pectoris arrhythmias atrial fibrillation cardiac failure,0,0.6306065917015076
CIMZIA,hypertensive heart disease,arrhythmias atrial fibrillation cardiac hypertensive heart disease myocardial infarction,1,0.7991353869438171
CIMZIA,hypertensive heart disease,hypertensive heart disease,1,1.0
CIMZIA,hypertensive heart disease,fibrillation cardiac hypertensive heart disease myocardial infarction myocardial ischemia,1,0.7904573082923889
CIMZIA,hypertensive heart disease,heart disease myocardial infarction myocardial ischemia pericardial,1,0.6917856335639954
CIMZIA,myocardial infarction,myocardial ischemia pericardial,0,0.7379801273345947
CIMZIA,myocardial ischemia,hypertensive heart disease myocardial myocardial,1,0.7341479063034058
CIMZIA,myocardial ischemia,myocardial myocardial ischemia pericardial effusion pericarditis stroke and,1,0.7838401794433594
CIMZIA,myocardial ischemia,pericarditis stroke and transient ischemic attack,0,0.6471817493438721
CIMZIA,myocardial ischemia,myocardial,1,0.8381392359733582
CIMZIA,myocardial ischemia,pericarditis stroke and,0,0.6015917062759399
CIMZIA,myocardial ischemia,heart disease myocardial myocardial ischemia,1,0.9204168319702148
CIMZIA,myocardial ischemia,myocardial ischemia pericardial effusion pericarditis stroke and,1,0.7758791446685791
CIMZIA,myocardial ischemia,myocardial myocardial ischemia,1,0.9899799227714539
CIMZIA,myocardial ischemia,disease myocardial myocardial ischemia,1,0.905863881111145
CIMZIA,myocardial ischemia,transient ischemic attack Eye disorders,0,0.635582447052002
CIMZIA,pericardial effusion,pericardial effusion pericarditis,1,0.9280577898025513
CIMZIA,pericardial effusion,transient ischemic attack Eye disorders,0,0.5168920755386353
CIMZIA,pericardial effusion,pericardial effusion pericarditis stroke,1,0.8561217784881592
CIMZIA,pericarditis,lure hypertensive heart disease myocardial infarction myocardial,0,0.5612020492553711
CIMZIA,pericarditis,pericarditis stroke,1,0.846516489982605
CIMZIA,pericarditis,attack,0,0.5357668399810791
CIMZIA,pericarditis,pericardial,0,0.8656249642372131
CIMZIA,pericarditis,transient ischemic attack Eye disorders,0,0.48798805475234985
CIMZIA,stroke,transient ischemic attack Eye disorders Optic neuritis retinal hemorrhage and,0,0.6656476855278015
CIMZIA,stroke,stroke and transient ischemic,1,0.8489143252372742
CIMZIA,transient ischemic attack,stroke transient ischemic attack Eye,1,0.8645205497741699
CIMZIA,transient ischemic attack,stroke and transient ischemic,1,0.8821244239807129
CIMZIA,transient ischemic attack,and,0,0.4944442808628082
CIMZIA,transient ischemic attack,effusion pericarditis stroke transient,1,0.7247455716133118
CIMZIA,transient ischemic attack,Optic neuritis retinal hemorrhage,0,0.49590861797332764
CIMZIA,transient ischemic attack,pericarditis stroke transient ischemic attack,1,0.8418009281158447
CIMZIA,transient ischemic attack,General disorders and,0,0.53849196434021
CIMZIA,transient ischemic attack,transient ischemic attack Eye disorders Optic neuritis retinal,1,0.7973908185958862
CIMZIA,transient ischemic attack,transient ischemic attack Eye disorders Optic neuritis,1,0.79316246509552
CIMZIA,Optic neuritis,ischemic attack Eye Optic neuritis retinal hemorrhage and uveitis,1,0.7745152711868286
CIMZIA,Optic neuritis,transient ischemic attack Eye disorders Optic neuritis retinal,1,0.7696722745895386
CIMZIA,Optic neuritis,transient ischemic attack Eye Optic neuritis,1,0.8244639039039612
CIMZIA,Optic neuritis,transient ischemic attack Eye Optic neuritis retinal hemorrhage and uveitis General,1,0.7582484483718872
CIMZIA,retinal hemorrhage,Bleeding and injection s,0,0.6321274042129517
CIMZIA,retinal hemorrhage,retinal hemorrhage,1,0.9999998807907104
CIMZIA,retinal hemorrhage,ischemic attack Eye disorders,0,0.681840181350708
CIMZIA,retinal hemorrhage,and uveitis General disorders and administration,0,0.6390900015830994
CIMZIA,retinal hemorrhage,retinal hemorrhage and uveitis General disorders and,1,0.8832013607025146
CIMZIA,retinal hemorrhage,retinal hemorrhage and,1,0.9784584045410156
CIMZIA,retinal hemorrhage,and,0,0.43977612257003784
CIMZIA,retinal hemorrhage,and transient ischemic,0,0.5148797035217285
CIMZIA,uveitis,uveitis General disorders,1,0.8734010457992554
CIMZIA,uveitis,uveitis General disorders and administration site,1,0.8442112803459167
CIMZIA,uveitis,uveitis General disorders and,1,0.8929774761199951
CIMZIA,uveitis,Bleeding and,0,0.4994162321090698
CIMZIA,uveitis,and,0,0.49059057235717773
CIMZIA,uveitis,and injection site reactions,0,0.5362012982368469
CIMZIA,uveitis,uveitis General disorders and administration,1,0.853600025177002
CIMZIA,Bleeding,Bleeding and injection site reactions,1,0.7655853629112244
CIMZIA,Bleeding,uveitis General disorders and administration,1,0.5248721837997437
CIMZIA,Bleeding,Bleeding and,1,0.9582266807556152
CIMZIA,Bleeding,Bleeding,1,1.0
CIMZIA,injection site reactions,hemorrhage and uveitis General,0,0.5626907348632812
CIMZIA,injection site reactions,liver enzymes and hepatitis Immune system,0,0.5595860481262207
CIMZIA,injection site reactions,uveitis General disorders and,0,0.530852198600769
CIMZIA,injection site reactions,Elevated liver enzymes and hepatitis Immune system,0,0.5757941007614136
CIMZIA,injection site reactions,conditions Bleeding injection site reactions,1,0.9026174545288086
CIMZIA,injection site reactions,Elevated liver enzymes,0,0.5569576025009155
CIMZIA,injection site reactions,enzymes and hepatitis Immune system disorde,0,0.5883879661560059
CIMZIA,injection site reactions,Hepatobiliary disorders Elevated liver,0,0.5117642283439636
CIMZIA,injection site reactions,Bleeding injection site reactions,1,0.9187355041503906
CIMZIA,injection site reactions,uveitis General disorders and administration site conditions,0,0.6522157192230225
CIMZIA,hepatitis,disorders Alopecia totalis Psychiatric disorders,0,0.4882819354534149
CIMZIA,hepatitis,hepatitis Immune,1,0.8462759256362915
CIMZIA,hepatitis,hepatitis Immune system disorders Alopecia totalis,1,0.73946213722229
CIMZIA,hepatitis,and,0,0.5565871000289917
CIMZIA,Alopecia totalis,and suicide attempt,0,0.48392659425735474
CIMZIA,Alopecia totalis,Alopecia totalis Psychiatric disorders Anxiety,1,0.8407005071640015
CIMZIA,Anxiety,disorders,0,0.6315838098526001
CIMZIA,Anxiety,and hepatitis Immune,0,0.5068564414978027
CIMZIA,Anxiety,Anxiety,1,1.0
CIMZIA,bipolar disorder,bipolar disorder,1,1.0
CIMZIA,bipolar disorder,totalis Psychiatric disorders bipolar,1,0.800247073173523
CIMZIA,bipolar disorder,Psychiatric disorders bipolar disorder and suicide attempt Renal,1,0.7326193451881409
CIMZIA,bipolar disorder,Immune system disorders Alopecia totalis Psychiatric disorders,0,0.6104562282562256
CIMZIA,bipolar disorder,Psychiatric disorders bipolar disorder and suicide,1,0.8100516200065613
CIMZIA,bipolar disorder,bipolar disorder and suicide,1,0.8177866339683533
CIMZIA,bipolar disorder,bipolar disorder and suicide attempt,1,0.7964919805526733
CIMZIA,bipolar disorder,Psychiatric,0,0.6824061870574951
CIMZIA,bipolar disorder,epatitis Immune system,0,0.5259989500045776
CIMZIA,bipolar disorder,Anxiety,0,0.6210278868675232
CIMZIA,suicide attempt,suicide attempt Renal,1,0.8328744173049927
CIMZIA,suicide attempt,and urinary disorders Nephrotic syndrome and renal,0,0.4322378635406494
CIMZIA,suicide attempt,disorder and,0,0.5086284875869751
CIMZIA,suicide attempt,disorders Alopecia totalis Psychiatric,0,0.5110750198364258
CIMZIA,suicide attempt,suicide attempt Renal and,1,0.8443067669868469
CIMZIA,suicide attempt,suicide attempt,1,0.9999998807907104
CIMZIA,suicide attempt,syndrome and renal failure Reproductive,0,0.5080594420433044
CIMZIA,suicide attempt,bipolar disorder and,0,0.5453228950500488
CIMZIA,suicide attempt,disorder suicide,1,0.7719234228134155
CIMZIA,Nephrotic syndrome,attempt Renal and urinary Nephrotic,1,0.8339303135871887
CIMZIA,Nephrotic syndrome,and breast disorders,0,0.5508804321289062
CIMZIA,Nephrotic syndrome,urinary Nephrotic syndrome,1,0.9436113238334656
CIMZIA,renal failure,Nephrotic syndrome renal,1,0.7654319405555725
CIMZIA,renal failure,urinary disorders Nephrotic syndrome renal failure Reproductive system and,1,0.7404883503913879
CIMZIA,renal failure,disorders Nephrotic syndrome,0,0.6584329009056091
CIMZIA,renal failure,urinary disorders Nephrotic syndrome renal failure Reproductive,1,0.7439372539520264
CIMZIA,Menstrual disorder,Menstrual,1,0.8967345952987671
CIMZIA,Menstrual disorder,Menstrual disorder Skin and subcutaneous tissue disorders,1,0.851320743560791
CIMZIA,Menstrual disorder,Skin and subcutaneous,0,0.5632466077804565
CIMZIA,Menstrual disorder,system and breast Menstrual disorder Skin and,1,0.8343099355697632
CIMZIA,Menstrual disorder,Reproductive system and breast Menstrual,1,0.7586543560028076
CIMZIA,erythema nodosum,tissue disorders erythema,1,0.7577574253082275
CIMZIA,erythema nodosum,Dermatitis,0,0.6591295003890991
CIMZIA,erythema nodosum,erythema nodosum and,1,0.9655863642692566
CIMZIA,urticaria,Controlled Studies with,0,0.5068444609642029
CIMZIA,urticaria,urticaria Vascular disorders Thrombophlebitis,1,0.7854108214378357
CIMZIA,urticaria,Thrombophlebitis vasculitis,0,0.5764508843421936
CIMZIA,vasculitis,with Rheumatoid Arthritis CIMZIA was studied primarily in placebo,0,0.5521369576454163
CIMZIA,vasculitis,urticaria Vascular disorders vasculitis Controlled Studies with Rheumatoid,1,0.7760640382766724
CIMZIA,vasculitis,vasculitis Controlled,1,0.8438911437988281
CIMZIA,infections,infections,1,0.9999999403953552
CIMZIA,infections,disease was,0,0.6529420614242554
CIMZIA,infections,infections in,1,0.9291234016418457
CIMZIA,infections,in Crohns disease was for CIMZIAtreated patients and,0,0.5918512344360352
CIMZIA,infections,Infections The incidence infections in controlled,1,0.7569500207901001
CIMZIA,infections,placebotreated patients infections consisted,1,0.773497462272644
CIMZIA,infections,and for placebotreated patients infections consisted,1,0.7858031988143921
CIMZIA,infections,infections for CIMZIA for,0,0.728002667427063
CIMZIA,infections,infections consisted primarily of upper,1,0.7940489649772644
CIMZIA,infections,placebo,0,0.5347623825073242
CIMZIA,infections,consisted primarily of upper respiratory,0,0.5826027393341064
CIMZIA,infections,infections consisted,1,0.9042253494262695
CIMZIA,infections,infections consisted primarily of,1,0.8462815284729004
CIMZIA,infections,infections consisted primarily,1,0.8577137589454651
CIMZIA,upper respiratory infections,during,0,0.5091053247451782
CIMZIA,upper respiratory infections,infections consisted primarily upper respiratory infections for,1,0.8811699151992798
CIMZIA,upper respiratory infections,serious infections during the controlled,0,0.6372032165527344
CIMZIA,upper respiratory infections,for placebotreated patients The,0,0.5050507187843323
CIMZIA,upper respiratory infections,infections consisted primarily upper respiratory infections for CIMZIA,1,0.7920214533805847
CIMZIA,upper respiratory infections,upper respiratory infections for,1,0.9502437710762024
CIMZIA,upper respiratory infections,infections consisted primarily upper respiratory infections for CIMZIA for placebo,1,0.7777623534202576
CIMZIA,infections,infections during the,1,0.8586493134498596
CIMZIA,infections,the controlled clinical studies was per patientyear for,0,0.545881986618042
CIMZIA,infections,controlled clinical studies was per,0,0.5390671491622925
CIMZIA,infections,upper respiratory infections for CIMZIA for placebo The incidence,0,0.6134535670280457
CIMZIA,infections,for CIMZIA for placebo The incidence,0,0.5565165281295776
CIMZIA,infections,infections for CIMZIA for placebo The incidence of,0,0.6552499532699585
CIMZIA,infections,patients infections,1,0.8308287262916565
CIMZIA,infections,infections observed,1,0.8681918382644653
CIMZIA,infections,pneumonia and pyelonephritis The incidence,0,0.6396127939224243
CIMZIA,infections,for placebotreated patients,0,0.5771968364715576
CIMZIA,infections,was,0,0.54056715965271
CIMZIA,viral infections,included,0,0.5482534766197205
CIMZIA,viral infections,viral infections pneumonia and pyelonephritis The incidence,1,0.7356936931610107
CIMZIA,viral infections,and pyelonephritis The incidence of new cases of infections in controlled,0,0.6340471506118774
CIMZIA,viral infections,viral,1,0.7639639973640442
CIMZIA,viral infections,included bacterial viral infections,1,0.8067238330841064
CIMZIA,viral infections,and for placebotreated patients Serious,0,0.5371713638305664
CIMZIA,viral infections,patients Serious infections observed included,0,0.6736055612564087
CIMZIA,viral infections,infections observed included bacterial and,0,0.7040696144104004
CIMZIA,pneumonia,in controlled clinical studies,0,0.5380315184593201
CIMZIA,pneumonia,bacterial and viral infections,0,0.669639527797699
CIMZIA,pneumonia,patients Serious infections observed included bacterial and viral,0,0.6315023303031921
CIMZIA,pneumonia,pneumonia and pyelonephritis,1,0.8206565976142883
CIMZIA,pneumonia,pneumonia and pyelonephritis The incidence of,1,0.7594839334487915
CIMZIA,pneumonia,pneumonia and,1,0.9008134603500366
CIMZIA,pyelonephritis,of new cases of,0,0.5731280446052551
CIMZIA,pyelonephritis,pyelonephritis The incidence,1,0.8627751469612122
CIMZIA,pyelonephritis,pneumonia pyelonephritis,1,0.8847551345825195
CIMZIA,pyelonephritis,and,0,0.48382842540740967
CIMZIA,pyelonephritis,pyelonephritis,1,0.9999999403953552
CIMZIA,infections,new cases infections in controlled clinical,1,0.7321915626525879
CIMZIA,infections,pyelonephritis The incidence,1,0.6027075052261353
CIMZIA,infections,clinical studies in rheumatoid arthritis,0,0.5253010988235474
CIMZIA,infections,bacterial and viral infections pneumonia and pyelonephritis The incidence of,0,0.729874849319458
CIMZIA,infections,and pyelonephritis The incidence of new cases of,0,0.6373245120048523
CIMZIA,infections,pneumonia and pyelonephritis The incidence of new,0,0.6521959900856018
CIMZIA,infections,studies in rheumatoid arthritis was per,0,0.5296415090560913
CIMZIA,infections,pyelonephritis The incidence of new cases of,0,0.6154484748840332
CIMZIA,infections,infections in controlled,1,0.7919450998306274
CIMZIA,infections,for,0,0.5639742016792297
CIMZIA,infections,infections consisted primarily of upper respiratory,1,0.7406262159347534
CIMZIA,infections,upper respiratory tract infections herpes infections urinary tract,0,0.6845332980155945
CIMZIA,infections,The,0,0.5522017478942871
CIMZIA,infections,ntyear for all,0,0.5426303148269653
CIMZIA,infections,patientyear for placebotreated patients infections consisted primarily of upper respiratory,1,0.7161548137664795
CIMZIA,infections,for placebotreated patients infections,1,0.7636892795562744
CIMZIA,upper respiratory tract infections,primarily upper respiratory tract infections herpes infections urinary tract,1,0.823166012763977
CIMZIA,upper respiratory tract infections,infections,1,0.7467784881591797
CIMZIA,herpes infections,tract infections,0,0.6939094066619873
CIMZIA,herpes infections,lower,0,0.4563727378845215
CIMZIA,urinary tract infections,respiratory tract infections herpes urinary tract,1,0.7888269424438477
CIMZIA,urinary tract infections,infections herpes urinary tract,1,0.8073718547821045
CIMZIA,lower respiratory tract infections,arthritis studies there,0,0.5451558828353882
CIMZIA,lower respiratory tract infections,infections urinary tract infections and,0,0.6963671445846558
CIMZIA,lower respiratory tract infections,tract infections lower respiratory,1,0.9430180788040161
CIMZIA,lower respiratory tract infections,infections lower respiratory tract infections,1,0.9658755660057068
CIMZIA,lower respiratory tract infections,tract infections lower,1,0.8086217641830444
CIMZIA,infection,groups per,0,0.5191011428833008
CIMZIA,infection,reactions in the CIMZIA treatment groups compared to,0,0.5668209791183472
CIMZIA,infection,infection adverse reactions,1,0.7800744771957397
CIMZIA,infection,controlled rheumatoid arthritis studies there,0,0.5278658866882324
CIMZIA,infection,to the placebo groups,0,0.505057692527771
CIMZIA,infection,treatment groups compared to,0,0.5062183141708374
CIMZIA,infection,the controlled rheumatoid arthritis studies there were more new cases of serious,0,0.5410601496696472
CIMZIA,infection,cases of infection adverse,1,0.7856057286262512
CIMZIA,infections,mg,0,0.5425026416778564
CIMZIA,infections,of infections in the mg,1,0.7829375863075256
CIMZIA,infections,patientyear for placebo,0,0.4869052767753601
CIMZIA,infections,per,0,0.5281754732131958
CIMZIA,infections,other week dose,0,0.5532492399215698
CIMZIA,infections,infections in the mg every other,1,0.8071717619895935
CIMZIA,infections,per patientyear for all CIMZIA doses vs per patientyear for placebo Rates of,0,0.5420984029769897
CIMZIA,infections,of,0,0.5444138050079346
CIMZIA,infections,infections included tuberculosis,1,0.7725037932395935
CIMZIA,infections,tuberculosis,0,0.6540960073471069
CIMZIA,infections,infections included,1,0.8911205530166626
CIMZIA,infections,patientyear,0,0.5563787817955017
CIMZIA,infections,infections included tuberculosis pneumonia cellulitis and,1,0.7485122084617615
CIMZIA,tuberculosis,per patientyear Serious infections tuberculosis pneumonia cellulitis and pyelonephritis In,1,0.6839392185211182
CIMZIA,tuberculosis,infections included tuberculosis pneumonia cellulitis and,1,0.7363107800483704
CIMZIA,tuberculosis,tuberculosis pneumonia cellulitis,1,0.7465401887893677
CIMZIA,pneumonia,pneumonia,1,0.9999997615814209
CIMZIA,pneumonia,occurred in more,0,0.5394684076309204
CIMZIA,pneumonia,weeks,0,0.5440908074378967
CIMZIA,pneumonia,included,0,0.5703050494194031
CIMZIA,pneumonia,In the placebo group no serious infection occurred,0,0.5476915836334229
CIMZIA,pneumonia,Serious infections included pneumonia cellulitis and pyelonephritis In the,1,0.7556966543197632
CIMZIA,pneumonia,patientyear Serious,0,0.5395591259002686
CIMZIA,cellulitis,cellulitis,1,1.0
CIMZIA,cellulitis,patientyear Serious infections included tuberculosis,0,0.5649283528327942
CIMZIA,pyelonephritis,pyelonephritis In the,1,0.9551308155059814
CIMZIA,pyelonephritis,were per patientyear Serious infections included tuberculosis pneumonia cellulitis and,0,0.5770429372787476
CIMZIA,pyelonephritis,pyelonephritis In,1,0.9638298749923706
CIMZIA,pyelonephritis,per patientyear Serious infections included tuberculosis pneumonia,0,0.5533269643783569
CIMZIA,pyelonephritis,infection occurred in more than one subject There,0,0.588259756565094
CIMZIA,infection,no infection occurred in,1,0.7276602387428284
CIMZIA,infection,infection occurred in more than one subject There,0,0.7903457880020142
CIMZIA,infection,the placebo group no infection occurred in more than one,1,0.6239689588546753
CIMZIA,infection,group no infection occurred in more than one,1,0.673098087310791
CIMZIA,infection,infection,1,0.9999999403953552
CIMZIA,infection,placebo group,0,0.518618106842041
CIMZIA,infection,infection occurred,1,0.9021573066711426
CIMZIA,infection,the placebo group no serious,0,0.4882124662399292
CIMZIA,infection,no infection,1,0.7552223205566406
CIMZIA,tuberculosis,tuberculosis is approximately per,1,0.8228909373283386
CIMZIA,tuberculosis,rate tuberculosis is,1,0.7948514223098755
CIMZIA,tuberculosis,tuberculosis is,1,0.8974146246910095
CIMZIA,tuberculosis,overall rate tuberculosis is,1,0.7873069643974304
CIMZIA,tuberculosis,all,0,0.567755937576294
CIMZIA,tuberculosis,tuberculosis is approximately per patientyears across,1,0.7655346989631653
CIMZIA,tuberculosis,patientyears across all indications The majority of cases,0,0.5046502947807312
CIMZIA,tuberculosis,all indications The,0,0.5142330527305603
CIMZIA,TB,rates TB Reports include cases,1,0.746070146560669
CIMZIA,TB,all indications The,0,0.5079196691513062
CIMZIA,TB,across all,0,0.5586788654327393
CIMZIA,TB,TB,1,1.0
CIMZIA,pulmonary TB,lymphatic peritoneal as well pulmonary TB The median time to onset,1,0.7305166721343994
CIMZIA,pulmonary TB,TB,1,0.8824950456619263
CIMZIA,pulmonary TB,pulmonary TB The median time to onset,1,0.778955340385437
CIMZIA,TB,all indications was days In the studies with CIMZIA,0,0.5435025691986084
CIMZIA,TB,TB among exposed,1,0.8079816102981567
CIMZIA,TB,there were,0,0.5407947301864624
CIMZIA,TB,cases Rare cases of opportunistic infections ha,0,0.5549036860466003
CIMZIA,fatal,fatal cases Rare cases,1,0.7266894578933716
CIMZIA,fatal,patients including fatal,1,0.7630352973937988
CIMZIA,fatal,fatal cases,1,0.8154102563858032
CIMZIA,fatal,studies with CIMZIA in RA there were cases of TB among exposed,0,0.4944344162940979
CIMZIA,opportunistic infections,cases Rare cases opportunistic infections,1,0.9231086373329163
CIMZIA,opportunistic infections,studies with CIMZIA in RA there were cases of TB among exposed,0,0.598270058631897
CIMZIA,malignancies,malignancies was,1,0.9185260534286499
CIMZIA,malignancies,studies with CIMZIA in RA there were cases of TB among exposed,0,0.5540676116943359
CIMZIA,malignancies,For some,0,0.5342512130737305
CIMZIA,malignancies,In clinical studies of,0,0.6142085194587708
CIMZIA,malignancies,malignancies was similar for CIMZIAtreated,1,0.7367333173751831
CIMZIA,malignancies,malignancies was similar for CIMZIAtreated and,1,0.7387595772743225
CIMZIA,malignancies,malignancies have been,1,0.9034545421600342
CIMZIA,malignancies,malignancies have been observed among patients,1,0.8484492301940918
CIMZIA,malignancies,ignancies,0,0.6027137041091919
CIMZIA,worsening heart failure,new worsening heart failure,1,0.9641324281692505
CIMZIA,worsening heart failure,were,0,0.4653487205505371
CIMZIA,worsening heart failure,majority of these cases were,0,0.4828832149505615
CIMZIA,worsening heart failure,worsening heart failure,1,1.0
CIMZIA,worsening heart failure,worsening,1,0.7822939157485962
CIMZIA,lupus-like syndrome,One of the Crohns disease patients treated with CIMZIA developed symptoms of,0,0.6030560731887817
CIMZIA,lupus-like syndrome,clinical,0,0.534610390663147
CIMZIA,lupus-like syndrome,In clinical trials of TNF blockers including CIMZIA,0,0.5500273704528809
CIMZIA,lupus-like syndrome,lupus-like syndrome In clinical,1,0.9546009302139282
CIMZIA,lupus-like syndrome,lupus-like syndrome In,1,0.9850324392318726
CIMZIA,lupus-like syndrome,of TNF blockers including,0,0.5555689930915833
CIMZIA,lupus-like syndrome,CIMZIA developed symptoms of lupus-like syndrome In,1,0.8291348814964294
CIMZIA,lupus-like syndrome,lupus-like syndrome,1,0.9999998807907104
CIMZIA,lupus-like syndrome,some patients,0,0.5522558689117432
CIMZIA,ANA,treated with CIMZIA in,0,0.546359658241272
CIMZIA,ANA,ANA,1,0.9999999403953552
CIMZIA,ANA,patients have ANA Four patients out of,1,0.7289721965789795
CIMZIA,ANA,patients have ANA Four patients out,1,0.6768254637718201
CIMZIA,ANA,RA some patients have ANA Four patients,1,0.6820771098136902
CIMZIA,ANA,ANA Four patients out of patients,1,0.7529246807098389
CIMZIA,ANA,in RA clinical studies,0,0.519564151763916
CIMZIA,lupus-like syndrome,with CIMZIA in RA clinical studies developed clinical signs suggestive of,0,0.6175535917282104
CIMZIA,lupus-like syndrome,the development of autoimmune diseases is unknown,0,0.6715165972709656
CIMZIA,lupus-like syndrome,treatment with CIMZIA on the development of autoimmune diseases is unknown,0,0.6403814554214478
CIMZIA,lupus-like syndrome,clinical signs suggestive of lupus-like,1,0.8622047901153564
CIMZIA,lupus-like syndrome,lupus-like syndrome The impact of,1,0.910869836807251
CIMZIA,lupus-like syndrome,CIMZIA in RA clinical,0,0.5990509986877441
CIMZIA,lupus-like syndrome,with CIMZIA on the development of autoimmune diseases is,0,0.6727895140647888
CIMZIA,lupus-like syndrome,suggestive of lupus-like syndrome The impact of,1,0.8918336629867554
CIMZIA,abdominal pain,arthralgia,0,0.5667781829833984
CIMZIA,abdominal pain,abdominal pain arthralgia,1,0.8634744882583618
CIMZIA,arthralgia,arthralgia edema peripheral erythema,1,0.8011574745178223
CIMZIA,arthralgia,to antibodynegative patients N,0,0.5101504921913147
CIMZIA,arthralgia,compared to antibodynegative patients N,0,0.4964960515499115
CIMZIA,arthralgia,injection site pain pain,0,0.5917727947235107
CIMZIA,arthralgia,pain in,0,0.6603759527206421
CIMZIA,arthralgia,compared to antibodynegative patients N abdominal,0,0.5007384419441223
CIMZIA,arthralgia,patients N abdominal arthralgia edema peripheral erythema,1,0.7425510883331299
CIMZIA,arthralgia,peripheral erythema nodosum injection site erythema injection site pain pain in extremit,0,0.6070367097854614
CIMZIA,arthralgia,pain,0,0.6960327625274658
CIMZIA,edema peripheral,N abdominal pain edema,1,0.7464061379432678
CIMZIA,edema peripheral,pain edema peripheral,1,0.9424971342086792
CIMZIA,injection site erythema,erythema,0,0.8195369839668274
CIMZIA,injection site erythema,erythema injection,1,0.9154949188232422
CIMZIA,injection site erythema,respiratory,0,0.466933935880661
CIMZIA,injection site erythema,injection site erythema injection site pain,1,0.9406224489212036
CIMZIA,injection site erythema,bodynegative patients N abdominal pain arthralgia,0,0.5592256188392639
CIMZIA,injection site erythema,pain,0,0.5570164918899536
CIMZIA,injection site erythema,injection site erythema injection site pain pain in,1,0.9240785837173462
CIMZIA,injection site erythema,arthralgia edema peripheral erythema injection site erythema injection site pain pain,1,0.8656132221221924
CIMZIA,injection site erythema,peripheral erythema injection site erythema injection,1,0.9154806137084961
CIMZIA,injection site pain,site injection site pain,1,0.9722466468811035
CIMZIA,pain in extremity,erythema injection site pain,0,0.6951407194137573
CIMZIA,pain in extremity,injection site pain in extremity,1,0.852972686290741
CIMZIA,pain in extremity,pain in extremity,1,1.000000238418579
CIMZIA,pain in extremity,pain in extremity and,1,0.97773277759552
CIMZIA,pain in extremity,erythema injection site pain in extremity and upper,1,0.7780179977416992
CIMZIA,pain in extremity,injection site pain,0,0.68547123670578
CIMZIA,pain in extremity,in extremity and upper respiratory tract infection,1,0.7525936961174011
CIMZIA,upper respiratory tract infection,in extremity upper respiratory tract infection The overall percentage,1,0.782252848148346
CIMZIA,upper respiratory tract infection,in extremity and upper respiratory tract infection,1,0.8012716770172119
CIMZIA,upper respiratory tract infection,tract infection The overall percentage,1,0.6751980185508728
CIMZIA,upper respiratory tract infection,extremity upper respiratory tract infection,1,0.8140131235122681
CIMZIA,upper respiratory tract infection,extremity upper respiratory tract infection The,1,0.8132587671279907
CIMZIA,upper respiratory tract infection,tract infection The,1,0.7392715811729431
CIMZIA,upper respiratory tract infection,pain in extremity upper respiratory tract,1,0.7449625730514526
CIMZIA,hypersensitivity reactions,hypersensitivity reactions,1,1.0
CIMZIA,hypersensitivity reactions,hypersensitivity reactions have,1,0.959457516670227
CIMZIA,hypersensitivity reactions,Hypersensitivity Reactions The,0,0.9648957848548889
CIMZIA,hypersensitivity reactions,hypersensitivity reactions have been reported rarely,1,0.85166335105896
CIMZIA,hypersensitivity reactions,that could be compatible hypersensitivity reactions have been reported rarely following,1,0.834836483001709
CIMZIA,angioedema,angioedema dermatitis allergic dizziness postural dyspnea,1,0.8304837942123413
CIMZIA,dermatitis allergic,to patients dermatitis allergic dizziness postural dyspnea,1,0.7620986700057983
CIMZIA,dermatitis allergic,angioedema dermatitis allergic dizziness postural dyspnea,1,0.7832667827606201
CIMZIA,dermatitis allergic,to patients dermatitis allergic,1,0.8915901184082031
CIMZIA,dermatitis allergic,reactions have been reported rarely following,0,0.5374736785888672
CIMZIA,dermatitis allergic,administration to,0,0.44726961851119995
CIMZIA,dermatitis allergic,dermatitis allergic,1,0.9999998807907104
CIMZIA,dyspnea,CIMZIA administration to patients angioedema dermatitis allergic,0,0.4989471435546875
CIMZIA,dyspnea,following CIMZIA,0,0.47003936767578125
CIMZIA,dyspnea,dyspnea hot,1,0.9183907508850098
CIMZIA,dyspnea,flush hypotension injection site reactions malaise pyrexia rash serum sickness and vas,0,0.5507065057754517
CIMZIA,dyspnea,to patients angioedema dermatitis allergic,0,0.5287305116653442
CIMZIA,dyspnea,dyspnea,1,1.0
CIMZIA,dyspnea,dyspnea hot flush hypotension injection,1,0.7673133611679077
CIMZIA,dyspnea,allergic dizziness dyspnea hot flush hypotension,1,0.7027915716171265
CIMZIA,hot flush,dermatitis,0,0.49865034222602844
CIMZIA,hot flush,allergic dizziness postural dyspnea,0,0.5739518404006958
CIMZIA,hot flush,dizziness postural hot flush hypotension,1,0.7636877298355103
CIMZIA,hot flush,postural hot flush hypotension injection,1,0.7456018924713135
CIMZIA,hot flush,CIMZIA administration to patients,0,0.5135825872421265
CIMZIA,hot flush,hot flush hypotension injection site,1,0.7761302590370178
CIMZIA,hot flush,CIMZIA administration to patients angioedema dermatitis allergic dizziness,0,0.5567710399627686
CIMZIA,hot flush,dizziness postural hot flush,1,0.8217563629150391
CIMZIA,hypotension,reactions malaise pyrexia,0,0.5690703392028809
CIMZIA,hypotension,hypotension injection site reactions malaise,1,0.7847684621810913
CIMZIA,hypotension,pyrexia rash,0,0.518848180770874
CIMZIA,hypotension,hypotension,1,1.0
CIMZIA,hypotension,hypotension injection site reactions malaise pyrexia,1,0.7533725500106812
CIMZIA,hypotension,injection site reactions malaise pyrexia rash serum sickness and vasovagal syncope,0,0.6099969148635864
CIMZIA,injection site reactions,injection site reactions malaise pyrexia rash serum,1,0.8146079182624817
CIMZIA,injection site reactions,injection site reactions malaise pyrexia rash serum sickness and vasovagal syncope,0,0.799635648727417
CIMZIA,injection site reactions,hot flush injection site reactions malaise pyrexia rash serum sickness,1,0.7754931449890137
CIMZIA,injection site reactions,sickness and vasovagal syncope see Warnings,0,0.5385897755622864
CIMZIA,injection site reactions,injection site reactions malaise pyrexia rash serum sickness,1,0.822906494140625
CIMZIA,injection site reactions,postural dyspnea hot flush injection site,1,0.6868555545806885
CIMZIA,malaise,malaise,1,0.9999999403953552
CIMZIA,malaise,site malaise pyrexia rash serum sickness and,1,0.7289677262306213
CIMZIA,malaise,flush hypotension injection site malaise pyrexia rash serum,1,0.643752932548523
CIMZIA,malaise,hypotension injection site malaise pyrexia rash serum sickness,1,0.6642473936080933
CIMZIA,malaise,malaise pyrexia rash serum,1,0.7331698536872864
CIMZIA,malaise,sickness and,0,0.6469433903694153
CIMZIA,malaise,syncope see Warnings,0,0.5668063759803772
CIMZIA,malaise,Warnings and,0,0.523356020450592
CIMZIA,malaise,site malaise pyrexia rash serum,1,0.7032909393310547
CIMZIA,malaise,injection,0,0.5215990543365479
CIMZIA,pyrexia,injection site reactions pyrexia rash serum sickness,1,0.7522337436676025
CIMZIA,pyrexia,injection,0,0.5745663642883301
CIMZIA,pyrexia,injection site reactions pyrexia rash serum sickness and,1,0.7518737316131592
CIMZIA,pyrexia,allergic dizziness postural dyspnea hot flush,0,0.5904903411865234
CIMZIA,pyrexia,pyrexia,1,1.0000001192092896
CIMZIA,rash,and Precautions Post,0,0.5632048845291138
CIMZIA,rash,hypotension injection site,0,0.4823610782623291
CIMZIA,rash,dyspnea hot flush hypotension injection site reactions malaise pyrexia,0,0.5862985253334045
CIMZIA,rash,rash serum,1,0.8480432033538818
CIMZIA,systemic vasculitis,systemic vasculitis has been identified,1,0.9160363078117371
CIMZIA,systemic vasculitis,been identified during postapproval use of TNF,0,0.593501091003418
CIMZIA,systemic vasculitis,systemic vasculitis has been,1,0.9570412635803223
CIMZIA,systemic vasculitis,Vascular systemic vasculitis,1,0.9378751516342163
CIMZIA,systemic vasculitis,to drug exposure Vascular systemic,1,0.6934999823570251
CIMZIA,systemic vasculitis,drug exposure Vascular disorder,0,0.6443725824356079
CIMZIA,systemic vasculitis,has been,0,0.4912909269332886
CIMZIA,skin reactions,skin reactions including StevensJohnson syndrome toxic epidermal,1,0.8122604489326477
CIMZIA,skin reactions,of TNF blockers,0,0.5213236212730408
CIMZIA,skin reactions,erythema multiforme,0,0.6912449598312378
CIMZIA,skin reactions,Skin case of skin reactions,1,0.9201681613922119
CIMZIA,skin reactions,erythema multiforme and,0,0.7029507160186768
CIMZIA,skin reactions,skin reactions including,1,0.9753355979919434
CIMZIA,skin reactions,Skin case of skin reactions including StevensJohnson,1,0.8471925854682922
CIMZIA,Stevens-Johnson syndrome,skin reactions Stevens-Johnson syndrome,1,0.9033139944076538
CIMZIA,Stevens-Johnson syndrome,use of TNF blockers Skin case of severe,0,0.6310297846794128
CIMZIA,Stevens-Johnson syndrome,severe skin reactions Stevens-Johnson syndrome,1,0.8891093730926514
CIMZIA,Stevens-Johnson syndrome,blockers Skin case of severe skin reactions,0,0.6787075400352478
CIMZIA,Stevens-Johnson syndrome,case,0,0.6029670238494873
CIMZIA,Stevens-Johnson syndrome,toxic epidermal necrolysis erythema multiforme and,0,0.6966880559921265
CIMZIA,Stevens-Johnson syndrome,Stevens-Johnson syndrome toxic epidermal necrolysis erythema,1,0.865953803062439
CIMZIA,Stevens-Johnson syndrome,severe skin reactions Stevens-Johnson,1,0.8484134674072266
CIMZIA,Stevens-Johnson syndrome,Skin case of severe,0,0.6540646553039551
CIMZIA,toxic epidermal necrolysis,all subtypes including pustular,0,0.5958999395370483
CIMZIA,toxic epidermal necrolysis,including StevensJohnson toxic epidermal necrolysis erythema multiforme,1,0.8675172328948975
CIMZIA,toxic epidermal necrolysis,worsening psoriasis all subtypes,0,0.6221403479576111
CIMZIA,toxic epidermal necrolysis,toxic epidermal necrolysis erythema multiforme and new,1,0.917203426361084
CIMZIA,toxic epidermal necrolysis,toxic epidermal necrolysis erythema multiforme and,1,0.9203586578369141
CIMZIA,toxic epidermal necrolysis,epidermal necrolysis erythema multiforme and new,1,0.8324782252311707
CIMZIA,erythema multiforme,erythema multiforme and new or worsening,1,0.9254277348518372
CIMZIA,erythema multiforme,including StevensJohnson syndrome toxic,0,0.5874672532081604
CIMZIA,erythema multiforme,severe skin,0,0.6795831322669983
CIMZIA,erythema multiforme,erythema multiforme and new or worsening psoriasis,1,0.8906022310256958
CIMZIA,erythema multiforme,toxic,0,0.48647356033325195
CIMZIA,erythema multiforme,and new or worsening psoriasis all subtypes including pustular and,0,0.6653856039047241
CIMZIA,erythema multiforme,toxic epidermal necrolysis,0,0.6714895963668823
CIMZIA,erythema multiforme,epidermal erythema multiforme and new or,1,0.8925060629844666
CIMZIA,erythema multiforme,erythema multiforme,1,1.0000001192092896
CIMZIA,psoriasis,psoriasis all subtypes including,1,0.8392683863639832
CIMZIA,psoriasis,erythema multiforme,1,0.6617262363433838
CIMZIA,psoriasis,been,0,0.5189284086227417
CIMZIA,INFECTIONS,ADVERSE REACTIONS The most,1,0.5855624675750732
CIMZIA,INFECTIONS,incidence and higher than placebo upper respiratory,0,0.539751410484314
CIMZIA,INFECTIONS,REACTIONS,0,0.5630027055740356
CIMZIA,INFECTIONS,EXCERPT,0,0.5357322692871094
CIMZIA,INFECTIONS,most c,1,0.510037899017334
CIMZIA,INFECTIONS,The most c ommon,1,0.5161067843437195
CIMZIA,INFECTIONS,The most c ommon adverse reactions,1,0.6089062094688416
CIMZIA,INFECTIONS,ADVERSE REACTIONS EXCERPT,0,0.5993524789810181
CIMZIA,INFECTIONS,The most c ommon adverse,1,0.5531555414199829
CIMZIA,MALIGNANCY,adverse r eactions incidence and higher,1,0.5732479691505432
CIMZIA,MALIGNANCY,adverse r,1,0.5568653345108032
CIMZIA,MALIGNANCY,EXCERPT The most adverse r,1,0.5323629379272461
CIMZIA,MALIGNANCY, adverse r eactions incidence,1,0.560681939125061
CIMZIA,MALIGNANCY,The most  adverse r eactions incidence,1,0.541556715965271
CIMZIA,MALIGNANCY,most  adverse r eactions incidence and higher than,1,0.5595482587814331
CIMZIA,MALIGNANCY,REACTIONS EXCERPT The most  adverse r eactions,1,0.5318815112113953
CIMZIA,INFECTIONS,common adverse reactions %,1,0.5781694054603577
CIMZIA,INFECTIONS,most common adverse,0,0.5636426210403442
CIMZIA,INFECTIONS,EXCERPT The most common adverse reactions,0,0.5960958003997803
CIMZIA,INFECTIONS,adverse reactions % and high er,1,0.5533192157745361
CIMZIA,INFECTIONS,and high er than,1,0.5274215936660767
CIMZIA,MALIGNANCY,reactions incidence and higher an placebo,1,0.5304194688796997
CIMZIA,MALIGNANCY,ADVERSE REACTIONS,0,0.5739119052886963
CIMZIA,MALIGNANCY,an,1,0.594395101070404
CIMZIA,MALIGNANCY,an placebo,1,0.5357731580734253
CIMZIA,MALIGNANCY,and higher an placebo,1,0.5366654992103577
CIMZIA,MALIGNANCY,incidence and higher an placebo,1,0.5490524172782898
CIMZIA,MALIGNANCY,an placebo upper respiratory tract infection rash,1,0.4915602207183838
CIMZIA,MALIGNANCY,and higher an placebo upper respiratory,1,0.5156538486480713
CIMZIA,Active tuberculosis,conducted un der widely,1,0.5011025071144104
CIMZIA,Active tuberculosis,der widely varying and controlled conditions adverse reaction rates observed in,0,0.5533425211906433
CIMZIA,Active tuberculosis,der widely varying and controlled conditions,0,0.5034281611442566
CIMZIA,reactivation of latent tuberculosis,"controlled conditions, a dverse",1,0.5206939578056335
CIMZIA,reactivation of latent tuberculosis,"widely arying and controlled conditions, a dverse reaction",1,0.5678383111953735
CIMZIA,reactivation of latent tuberculosis,"are conducted under widely arying and controlled conditions, a dverse",1,0.5020432472229004
CIMZIA,reactivation of latent tuberculosis,"controlled conditions, a",1,0.5149499177932739
CIMZIA,reactivation of latent tuberculosis,"and controlled conditions, a dverse reaction rates observed",1,0.5446668267250061
CIMZIA,reactivation of latent tuberculosis,"controlled conditions, a dverse reaction rates observed",1,0.5455384850502014
CIMZIA,reactivation of latent tuberculosis,"conducted under widely arying and controlled conditions, a",1,0.5220141410827637
CIMZIA,reactivation of latent tuberculosis,"under widely arying and controlled conditions, a",1,0.523622989654541
CIMZIA,reactivation of latent tuberculosis,Precautions Because clinical studies,0,0.5472962260246277
CIMZIA,histoplasmosis,mmon adverse reactions were upper respiratory infections rash and,0,0.56694096326828
CIMZIA,histoplasmosis,in clinical practice In premarketing controlled trials of,0,0.5054590106010437
CIMZIA,histoplasmosis,the most co mmon adverse reactions were upper,1,0.5114537477493286
CIMZIA,histoplasmosis,all patient populations ed the most co mmon adverse reactions were,1,0.4935312867164612
CIMZIA,coccidioidomycosis,adverse reactio ns,1,0.5006640553474426
CIMZIA,coccidioidomycosis,the most on adverse reactio ns,1,0.4877214729785919
CIMZIA,coccidioidomycosis,on adverse reactio ns were upper respiratory infections,1,0.5464987754821777
CIMZIA,coccidioidomycosis,combined the most on,1,0.46722355484962463
CIMZIA,coccidioidomycosis,on adverse reactio ns were upper respiratory,1,0.5142688751220703
CIMZIA,coccidioidomycosis,populations combined the most on adverse,1,0.4450451135635376
CIMZIA,coccidioidomycosis,urinary,0,0.5177280902862549
CIMZIA,coccidioidomycosis,controlled trials of all,0,0.5450871586799622
CIMZIA,coccidioidomycosis,combined the most on adverse,1,0.48379144072532654
CIMZIA,candidiasis,combined the most,0,0.47937533259391785
CIMZIA,candidiasis,(>= 8%) we re upper,1,0.4762759804725647
CIMZIA,candidiasis,premarketing controlled trials of all patient populations combined the most,0,0.5112783908843994
CIMZIA,candidiasis,8%) we re upper respiratory,1,0.4836920499801636
CIMZIA,candidiasis,most common adverse (>=,1,0.523452639579773
CIMZIA,candidiasis,adverse (>=,1,0.5471841096878052
CIMZIA,candidiasis,adverse  (>= 8%) we re,1,0.5330170392990112
CIMZIA,aspergillosis,upper respir atory infections,1,0.6065201759338379
CIMZIA,aspergillosis,reactions  upper respir atory,1,0.5189149975776672
CIMZIA,aspergillosis,Adverse Reactions Most,0,0.5718058347702026
CIMZIA,blastomycosis,patient populations combined,0,0.5117480754852295
CIMZIA,blastomycosis,upper ory,1,0.4498988687992096
CIMZIA,blastomycosis,and urinary,0,0.5475620031356812
CIMZIA,blastomycosis,ory infection s rash,1,0.5669289231300354
CIMZIA,pneumocystosis,"reactions were upper respiratory ),",1,0.4781668186187744
CIMZIA,histoplasmosis,infections (8 Adverse,1,0.5800851583480835
CIMZIA,histoplasmosis, infections (8 Adverse Reactions Most Commonly,1,0.5666680335998535
CIMZIA,histoplasmosis,urinary tract,0,0.5489605665206909
CIMZIA,histoplasmosis,infections (8 Adverse Reactions,1,0.573383092880249
CIMZIA,invasive fungal infections,and urinary tract   Adverse Reactions Most C ommonly Leading to Discontinuation of,1,0.5428750514984131
CIMZIA,invasive fungal infections,infections (8 Adverse Reactions,1,0.6558234691619873
CIMZIA,invasive fungal infections,tract   Adverse Reactions Most C ommonly Leading to,1,0.5626671314239502
CIMZIA,invasive fungal infections,Controlled Trials,0,0.5538580417633057
CIMZIA,invasive fungal infections,rash and urinary,0,0.5684964060783386
CIMZIA,invasive fungal infections,and urinary tract Adverse,1,0.5542548298835754
CIMZIA,invasive fungal infections,urinary tract Adverse Reactions Most C,1,0.5465325117111206
CIMZIA,invasive fungal infections,and urinary tract Adverse Reactions,1,0.5652062892913818
CIMZIA,Lymphoma,The data described,0,0.49993202090263367
CIMZIA,Lymphoma,lect exp osure to,1,0.5488061904907227
CIMZIA,Lymphoma,with Crohns Disease,0,0.605216920375824
CIMZIA,Lymphoma,below lect,1,0.5516000986099243
CIMZIA,malignancies,studies of patients with Crohns disease In the safety,0,0.5554648637771606
CIMZIA,malignancies,at 400 mg,1,0.5507853031158447
CIMZIA,malignancies,Studies with Crohns Disease The data described below reflect exposure to CI,0,0.5861276388168335
CIMZIA,malignancies,population,0,0.5541651248931885
CIMZIA,malignancies,reflect exposure to MZIA at 400,1,0.5317344665527344
CIMZIA,malignancies,reflect exposure to MZIA at 400  mg subcutaneous dosing in,1,0.5450552701950073
CIMZIA,malignancies,below reflect exposure to CI,0,0.549411416053772
CIMZIA,fatal,studies of patients with Crohns,0,0.45101121068000793
CIMZIA,fatal,utane ous,1,0.5068977475166321
CIMZIA,fatal,utane ous dosing in,1,0.5314997434616089
CIMZIA,fatal,reflect,0,0.5250794887542725
CIMZIA,fatal,utane ous dosing in studies,1,0.5254133939743042
CIMZIA,fatal,utane,1,0.5099982619285583
CIMZIA,INFECTIONS,to placebo,1,0.48583289980888367
CIMZIA,INFECTIONS,placebo including,0,0.5294345021247864
CIMZIA,INFECTIONS,mg and subjects received placebo including subjects randomized,0,0.49196282029151917
CIMZIA,INFECTIONS,to placebo in Study CD following open,1,0.5253266096115112
CIMZIA,MALIGNANCY,at Weeks In controlled and uncontrolled,0,0.5424334406852722
CIMZIA,infections,controlled and uncontrolled studies ients rece,1,0.5520446300506592
CIMZIA,infections,at some dose level of whom patients received mg CIMZIA,0,0.567349910736084
CIMZIA,infections,dose level of whom patients received mg CIMZIA Approximately,0,0.5491482019424438
CIMZIA,infections,and uncontrolled studies,0,0.5227072834968567
CIMZIA,infections,ients rece ived CIMZIA at,1,0.5857609510421753
CIMZIA,infections,open label dosing of CIMZIA,0,0.5621277093887329
CIMZIA,infections,CIMZIA at,0,0.5514179468154907
CIMZIA,infections,In controlled and uncontrolled studies,0,0.5354457497596741
CIMZIA,death,Approximately of,0,0.5135513544082642
CIMZIA,death,dose  of w hom,1,0.5677670836448669
CIMZIA,death,at some dose  of w,1,0.5629317760467529
CIMZIA,death,and uncontrolled studies patients received CIMZIA at some dose,0,0.47282615303993225
CIMZIA,tuberculosis,atients rece ived mg,1,0.5696346759796143
CIMZIA,TB,ed mg CIMZIA Approximately of subjects,1,0.5396891236305237
CIMZIA,TB,atients rece ived mg,1,0.5740698575973511
CIMZIA,TB,male,0,0.555991530418396
CIMZIA,TB,studies patients received CIMZIA at some dose level of whom,0,0.5194246768951416
CIMZIA,TB,ed mg CIMZIA Approximately of,1,0.5185590982437134
CIMZIA,TB,and,0,0.5556939840316772
CIMZIA,TB,male and were,0,0.5503181219100952
CIMZIA,TB,ed,1,0.5484064817428589
CIMZIA,TB,patients ed mg CIMZIA Approximately,1,0.5130395293235779
CIMZIA,TB,ed mg CIMZIA Approximately,1,0.5269140601158142
CIMZIA,bacterial sepsis,CIMZIA. App,1,0.47615891695022583
CIMZIA,invasive fungal infections,received mg CIMZIA ximately 55% of subjects,1,0.5658113360404968
CIMZIA,invasive fungal infections,of subjects w ere,1,0.4789949059486389
CIMZIA,invasive fungal infections,patients received mg CIMZIA ximately 55% of subjects w ere female,1,0.5588256120681763
CIMZIA,invasive fungal infections,of,0,0.480390727519989
CIMZIA,invasive fungal infections,patients received mg CIMZIA ximately 55% of subjects w ere female were,1,0.5603691339492798
CIMZIA,histoplasmosis,were between the,0,0.46823233366012573
CIMZIA,histoplasmosis,"Approximately of subjects were , 45% were",1,0.44805729389190674
CIMZIA,histoplasmosis,received mg CIMZIA Approximately of,0,0.5212183594703674
CIMZIA,histoplasmosis,"were , 45% were mal",1,0.4232385754585266
CIMZIA,histoplasmosis,mg CIMZIA Approximately of subjects,0,0.5091410279273987
CIMZIA,infections due to other opportunistic pathogens,female were male and,0,0.44745534658432007
CIMZIA,infections due to other opportunistic pathogens,were male 94% were Caucasian. The majority of patients in the,1,0.4951920509338379
CIMZIA,Lymphoma,acebo) i n controlled clinical,1,0.5264610648155212
CIMZIA,malignancies,in d clinical s,1,0.6183854341506958
CIMZIA,malignancies,acebo) i n controlled clinical,1,0.5707600116729736
CIMZIA,malignancies,placebo in d,1,0.5305677652359009
CIMZIA,malignancies,to placebo in d,1,0.5233895778656006
CIMZIA,malignancies,placebo in d clinical s,1,0.5564219355583191
CIMZIA,malignancies,a higher incidence,0,0.6002556085586548
CIMZIA,malignancies,clinical s tudies,1,0.658623456954956
CIMZIA,malignancies,in d clinical,1,0.5910769701004028
CIMZIA,malignancies,in,0,0.5390459299087524
CIMZIA,malignancies,placebo in d clinical,1,0.5447853803634644
CIMZIA,Invasive fungal infections,ADVERSE,0,0.5355530977249146
CIMZIA,Invasive fungal infections,"TIONS,",1,0.5006223917007446
CIMZIA,Invasive fungal infections,FDA at FDA,0,0.5035930275917053
CIMZIA,Invasive fungal infections,"TIONS, contact UCB, Inc. a",1,0.4516010284423828
CIMZIA,lymphoma,Infections see Wa,0,0.527290940284729
CIMZIA,lymphoma,rnings a nd Precautions Malignancies see Warnings,1,0.6428012251853943
CIMZIA,lymphoma,nd Precautions,0,0.4764630198478699
CIMZIA,lymphoma,were Serious Infections see rnings a,1,0.5286303758621216
CIMZIA,malignancies,Warnings and ons (5.1)  ] Malignancies see Warnings and,1,0.751806914806366
CIMZIA,malignancies,were Serious Infections see rnings a,1,0.6003513336181641
CIMZIA,malignancies,The,0,0.5621463060379028
CIMZIA,"Heart failure, worsening",varying and,0,0.5233312845230103
CIMZIA,"Heart failure, worsening",Precautions Heart ailure [see Warnings,1,0.6512812376022339
CIMZIA,"Heart failure, worsening",[see Warnings an,1,0.5308512449264526
CIMZIA,"Heart failure, worsening",and,0,0.47761672735214233
CIMZIA,"Heart failure, worsening",and Precautions Heart ailure [see  Warnings an,1,0.6424157619476318
CIMZIA,"Heart failure, worsening",Heart ailure [see,1,0.7011027336120605
CIMZIA,"Heart failure, worsening",clinical studies are conducted under widely varying,0,0.5494102239608765
CIMZIA,"Heart failure, worsening",Heart,0,0.6980829834938049
CIMZIA,"Heart failure, worsening",ailure [see  Warnings an d Precautions,1,0.5280303955078125
CIMZIA,Anaphylaxis,widely varying and controlled conditions adverse reaction rates observed in,0,0.6603919863700867
CIMZIA,Anaphylaxis,Failure see Warnings and,0,0.48780620098114014
CIMZIA,Anaphylaxis,Precautions Heart Failure see Warnings and Precautions,0,0.5527970194816589
CIMZIA,Anaphylaxis,conducted under widely varying and controlled,0,0.46807143092155457
CIMZIA,Anaphylaxis,reaction,0,0.6809225678443909
CIMZIA,Anaphylaxis,Precautions,0,0.5991294384002686
CIMZIA,Anaphylaxis,Because cl,0,0.5190180540084839
CIMZIA,Anaphylaxis,under widely varying and controlled conditions,0,0.4902037978172302
CIMZIA,allergic reactions,are ucted,1,0.544217586517334
CIMZIA,allergic reactions,in,0,0.5088167190551758
CIMZIA,allergic reactions,Because clinical studies are ucted under widely varying and,1,0.5114254355430603
CIMZIA,allergic reactions,Because clinical,0,0.5131521821022034
CIMZIA,allergic reactions,clinical studies are ucted under widely varying and,1,0.51804518699646
CIMZIA,allergic reactions,studies are ucted under widely varying and,1,0.5300289392471313
CIMZIA,Hepatitis B virus reactivation,rates in the clinical studi,0,0.4865376651287079
CIMZIA,Hepatitis B virus reactivation,Because clinical studies are conducted under widely varying and controlled,0,0.511769711971283
CIMZIA,Hepatitis B virus reactivation,"widely varying and controlled nditions,",1,0.47091683745384216
CIMZIA,Hepatitis B virus reactivation,"widely varying and controlled nditions, adverse reaction",1,0.5306062698364258
CIMZIA,Hepatitis B virus reactivation,"nditions, adverse reaction rat es observed in clinical",1,0.502309262752533
CIMZIA,Hepatitis B virus reactivation,to rates in,0,0.4489981532096863
CIMZIA,Hepatitis B virus reactivation,Because clinical studies,0,0.5126625299453735
CIMZIA,Hepatitis B virus reactivation,widely varying,0,0.47590458393096924
CIMZIA,Hepatitis B virus reactivation,to rates in the,0,0.44661933183670044
CIMZIA,Demyelinating disease,"a broader patient population n clinical practice.
 In premarketing controlled",1,0.5395203828811646
CIMZIA,Demyelinating disease,to rates in the,0,0.4717872142791748
CIMZIA,Cytopenias,clinical practice In premarketing,0,0.5527077913284302
CIMZIA,Cytopenias,opulations combined the,1,0.4977664351463318
CIMZIA,Cytopenias,patient opulations combined the most common,1,0.5069437026977539
CIMZIA,Cytopenias,In,0,0.500049352645874
CIMZIA,pancytopenia,adverse reactions were upper respiratory infections rash and,0,0.5088551044464111
CIMZIA,pancytopenia,ombined,1,0.486091673374176
CIMZIA,pancytopenia,all patient populations ombined,1,0.5221977233886719
CIMZIA,Lupus-like syndrome,rash and urinary tract %). Adverse,1,0.5773007869720459
CIMZIA,Lupus-like syndrome,"and urinary tract %).



     Adverse",1,0.5360962748527527
CIMZIA,Lupus-like syndrome,%). Adverse Reactions Most Commonly,1,0.5458221435546875
CIMZIA,Lupus-like syndrome,"tract %).



     Adverse Reactions",1,0.5642458200454712
CIMZIA,Lupus-like syndrome,%). Adverse Reactions,1,0.5687782168388367
CIMZIA,Lupus-like syndrome,"and urinary tract %).



     Adverse Reactions",1,0.5376556515693665
CIMZIA,infections,who,0,0.530794084072113
CIMZIA,infections,ons in the controlled clinical studies,1,0.5673217177391052
CIMZIA,infections,to,0,0.5410861968994141
CIMZIA,death,for CIMZIA and for,0,0.5104532837867737
CIMZIA,death,was for CIMZIA and for placebo The,0,0.4565226137638092
CIMZIA,death,for placebo The most mon,1,0.5152939558029175
CIMZIA,death,CIMZIA and,0,0.4638811945915222
CIMZIA,death,The most mon a,1,0.5536683201789856
CIMZIA,death,CIMZIA and for placebo The most com,0,0.4786908030509949
CIMZIA,death,mon a dverse reactions,1,0.5546239018440247
CIMZIA,Opportunistic infections,for,0,0.5228063464164734
CIMZIA,Opportunistic infections,a higher incidence than,0,0.5912351608276367
CIMZIA,Opportunistic infections,common  reactions leading to th e,1,0.49084728956222534
CIMZIA,Opportunistic infections,placebo The most common,0,0.49331995844841003
CIMZIA,Opportunistic infections,reactions leading to th e discontinuation of CIMZIA,1,0.5046923756599426
CIMZIA,Opportunistic infections,reactions leading to th,1,0.47378838062286377
CIMZIA,Opportunistic infections, reactions leading to th e,1,0.4768163561820984
CIMZIA,aspergillosis,in (0.4% CIMZ IA,1,0.49538159370422363
CIMZIA,aspergillosis,reactions leading to th,1,0.5294791460037231
CIMZIA,aspergillosis,patients and with a,0,0.5326224565505981
CIMZIA,aspergillosis,were abdominal in (0.4% CIMZ,1,0.5306850671768188
CIMZIA,aspergillosis,(0.4% CIMZ IA placebo,1,0.494600772857666
CIMZIA,aspergillosis,were abdominal in (0.4% CIMZ IA placebo diarrhea CIMZIA placebo,1,0.4978770613670349
CIMZIA,blastomycosis,", 0.2%",1,0.4476052522659302
CIMZIA,blastomycosis,"abdominal pain , 0.2% placeb o diarrhea CIMZIA placebo and",1,0.4939648509025574
CIMZIA,blastomycosis,placebo and intestinal,0,0.4513181149959564
CIMZIA,blastomycosis,", 0.2% placeb",1,0.4790034294128418
CIMZIA,blastomycosis,"placebo were abdominal pain , 0.2% placeb o diarrhea CIMZIA",1,0.48663926124572754
CIMZIA,blastomycosis,", 0.2% placeb o diarrhea CIMZIA",1,0.5134176015853882
CIMZIA,blastomycosis,obstruction,0,0.4635530114173889
CIMZIA,candidiasis,", diarrhea CIMZIA placebo",1,0.5863560438156128
CIMZIA,candidiasis,CIMZIA,0,0.557231068611145
CIMZIA,candidiasis,", diarrhea",1,0.6107172966003418
CIMZIA,candidiasis,"were abdominal pain CIMZIA ,",1,0.5911083817481995
CIMZIA,candidiasis,patients and with a higher incidence than placebo were abdominal,0,0.5268844366073608
CIMZIA,coccidioidomycosis,".4% CIMZIA, 0%",1,0.5409583449363708
CIMZIA,coccidioidomycosis,pain CIMZIA placebo .4%,1,0.5431373119354248
CIMZIA,coccidioidomycosis,0% pla cebo,1,0.49461841583251953
CIMZIA,coccidioidomycosis,and intestinal,0,0.529035747051239
CIMZIA,histoplasmosis,proportion,0,0.47302567958831787
CIMZIA,histoplasmosis,"placebo diarrhea CIMZIA bo), and intes",1,0.49250489473342896
CIMZIA,histoplasmosis,"CIMZIA bo), and",1,0.5045692920684814
CIMZIA,histoplasmosis,"diarrhea CIMZIA bo), and intes tinal obstruction CIMZIA",1,0.5627577304840088
CIMZIA,histoplasmosis,"diarrhea CIMZIA bo), and intes tinal obstruction",1,0.5635108947753906
CIMZIA,histoplasmosis,placebo The proportion of patients with,0,0.4554716944694519
CIMZIA,legionellosis,arthritis who,0,0.5139930248260498
CIMZIA,legionellosis,and nal obstructi,1,0.5588690042495728
CIMZIA,tuberculosis,on of patients with rheumatoid arthritis who discontinued treatment due,0,0.5225553512573242
CIMZIA,tuberculosis,The proporti on,1,0.5137341618537903
CIMZIA,tuberculosis,CIMZIA The,1,0.49860456585884094
CIMZIA,infection,CIMZIA at mg subcutaneous ing in,1,0.5936657190322876
CIMZIA,infection,ing in st udies of patients with,1,0.6319836378097534
CIMZIA,reactivation of tuberculosis,"emale, 45% were male, and 94 were Caucasian",1,0.46685799956321716
CIMZIA,reactivation of tuberculosis,CIMZIA at mg subcutaneous ing in,1,0.5211703181266785
CIMZIA,reactivation of tuberculosis,"of subjects were emale, 45% were male, and 94",1,0.48184680938720703
CIMZIA,reactivation of tuberculosis,whom patients received mg CIMZIA Approximately of subjects,0,0.5329239368438721
CIMZIA,tuberculosis infections,and were aucasian. The majority  of patients in the,1,0.5229499340057373
CIMZIA,tuberculosis infections,whom patients received mg CIMZIA Approximately of subjects,0,0.5154902935028076
CIMZIA,tuberculosis infections,subjects were female were male and,0,0.44839197397232056
CIMZIA,tuberculosis infections,aucasian. The majority  of patients in the active,1,0.5408700704574585
CIMZIA,malignancies,Period of Rheumatoid Arthritis Studies with Concomitant Methotrexate Adverse ReactionPre,0,0.5715468525886536
CIMZIA,malignancies,Dosed Every Other Week Placebo-Cont rolled,1,0.4955981969833374
CIMZIA,malignancies,Every Other,0,0.5507792830467224
CIMZIA,malignancies,Arthritis Studies,0,0.5756676197052002
CIMZIA,malignancies,during,0,0.5345190763473511
CIMZIA,malignancies,rolled Period,0,0.4884573221206665
CIMZIA,malignancies,Studies with Concomitant Methotrexate Adverse,0,0.6227993965148926
CIMZIA,malignancies,Week Placebo-Cont rolled Period,1,0.4731801748275757
CIMZIA,malignancies,piratory tract infection,0,0.5681278705596924
CIMZIA,malignancies,Upper res,1,0.4982373118400574
CIMZIA,malignancies,CIMZIA mg EOW,0,0.478707492351532
CIMZIA,malignancies,Upper res piratory,1,0.5444722175598145
CIMZIA,malignancies,MTXN CIMZIA mg EOW,0,0.5087088942527771
CIMZIA,malignancies,EOW Upper res,1,0.4604458212852478
CIMZIA,malignancies,CIMZIA mg EOW MTXN,0,0.5167850852012634
CIMZIA,malignancies,Upper res piratory tract infection,1,0.5335286259651184
CIMZIA,malignancies,"CIMZIA mg EOW  
 Upper res piratory tract",1,0.5256917476654053
CIMZIA,malignancies,"MTXN CIMZIA mg EOW  
 Upper res piratory tract",1,0.5390570163726807
CIMZIA,lymphoma,teroidal antiinflammatory,1,0.5487273931503296
CIMZIA,lymphoma,patients rec,0,0.5558436512947083
CIMZIA,lymphoma,controlled clinical trials had similar adverse reactions,0,0.513496994972229
CIMZIA,lymphoma,patients eiving C,1,0.5346781015396118
CIMZIA,lymphoma,those patients eiving C IMZIA,1,0.5384708642959595
CIMZIA,Hodgkin's lymphoma,e Reactions Other infrequent adverse,1,0.5110974907875061
CIMZIA,Hodgkin's lymphoma,every other week Other e Reactions,1,0.476540744304657
CIMZIA,Hodgkin's lymphoma,Other e Reactions,1,0.4964155852794647
CIMZIA,Hodgkin's lymphoma,Other,0,0.5153898000717163
CIMZIA,Hodgkin's lymphoma,those patients,0,0.5511059165000916
CIMZIA,Hodgkin's lymphoma,receiving CIMZIA mg every other,0,0.4590628743171692
CIMZIA,Hodgkin's lymphoma,Other Advers,0,0.49128782749176025
CIMZIA,Hodgkin's lymphoma,week Other e,1,0.4801422357559204
CIMZIA,lymphoma,"
     Ps oriatic Arthritis Clinical",1,0.4909089207649231
CIMZIA,lymphoma,CIMZIA has been studied in patients with psoriatic arthri,0,0.49369555711746216
CIMZIA,lymphoma,CIMZIA was,0,0.4247388541698456
CIMZIA,lymphoma,was similar to the ty profi le,1,0.5333871245384216
CIMZIA,lymphoma,similar to the ty,1,0.5465034246444702
CIMZIA,lymphoma,with RA Infections,0,0.5671623945236206
CIMZIA,lymphoma,AS The safety profile for patients in study AS treated with CIMZIA was similar to the safe,0,0.48774993419647217
CIMZIA,lymphoma,RA,0,0.5152214169502258
CIMZIA,lymphoma,safety profile for patients in study AS treated with CIMZIA was,0,0.4791135787963867
CIMZIA,lymphoma,to the ty,1,0.524709939956665
CIMZIA,lymphoma,to the ty profi,1,0.4911639392375946
CIMZIA,lymphoma,was similar to,0,0.5002330541610718
CIMZIA,hepatosplenic T-cell lymphoma,tions consisted primarily of upper respiratory infections for,1,0.4835761785507202
CIMZIA,hepatosplenic T-cell lymphoma,tions consisted primarily of upper respiratory infections for CIMZIA,1,0.44620293378829956
CIMZIA,hepatosplenic T-cell lymphoma,for placebotreated patients The tions consisted primarily of  upper respiratory infections,1,0.49181538820266724
CIMZIA,hepatosplenic T-cell lymphoma,patients The tions,1,0.4722181260585785
CIMZIA,hepatosplenic T-cell lymphoma,patients The tions consisted primarily of  upper,1,0.490273118019104
CIMZIA,hepatosplenic T-cell lymphoma,The tions consisted primarily of  upper respiratory infections for CIMZIA,1,0.4459712505340576
CIMZIA,hepatosplenic T-cell lymphoma,patients The tions consisted primarily of,1,0.4821544289588928
CIMZIA,hepatosplenic T-cell lymphoma,placebotreated patients The tions consisted primarily of,1,0.50132155418396
CIMZIA,hepatosplenic T-cell lymphoma,tions consisted primarily of,1,0.4697778820991516
CIMZIA,hepatosplenic T-cell lymphoma,The tions,1,0.5005884766578674
CIMZIA,HSTCL,of per r espiratory infections,1,0.42488718032836914
CIMZIA,HSTCL,The tions,1,0.5284518003463745
CIMZIA,HSTCL,of per,1,0.4841196537017822
CIMZIA,HSTCL,infections consisted primarily,0,0.4247910976409912
CIMZIA,HSTCL,of serious,0,0.4799033999443054
CIMZIA,HSTCL,infections consisted primarily of per r,1,0.44579315185546875
CIMZIA,fatal,incidence of serious s dur ing the controlled clinical,1,0.6287578344345093
CIMZIA,fatal,of serious,0,0.6479211449623108
CIMZIA,fatal,CIMZIA for placebo The incidence of serious,0,0.5179196000099182
CIMZIA,chronic leukemia,groups,0,0.50931316614151
CIMZIA,chronic leukemia,serious fection,1,0.5259923934936523
CIMZIA,chronic leukemia,fection adverse  reactions,1,0.5004820823669434
CIMZIA,chronic leukemia,fection adverse reactions,1,0.5004820823669434
CIMZIA,chronic leukemia,of serious fection,1,0.510635256767273
CIMZIA,chronic leukemia,fection adverse reactions in,1,0.4965778887271881
CIMZIA,chronic leukemia,serious fection adverse,1,0.5151289701461792
CIMZIA,chronic leukemia,fection adverse reactions in the CIMZIA treatment,1,0.48542389273643494
CIMZIA,chronic leukemia,CIMZIA treatment groups compared to the placebo groups per patientyear for,0,0.4833805561065674
CIMZIA,chronic leukemia,reactions in the CIMZIA treatment groups compared to the placebo groups per patientyear,0,0.48303842544555664
CIMZIA,worsening congestive heart failure,no serious infection occurred in more than one subject There,1,0.43277204036712646
CIMZIA,worsening congestive heart failure,placebo,0,0.5009251832962036
CIMZIA,worsening congestive heart failure,"placebo , no serious infection occurred in",1,0.433582603931427
CIMZIA,worsening congestive heart failure,pyelonephritis,0,0.5070695877075195
CIMZIA,new onset CHF,one subject.,1,0.4650919437408447
CIMZIA,new onset CHF,one subject.  There,1,0.4511120319366455
CIMZIA,worsening congestive heart failure,Infections I,0,0.4645460247993469
CIMZIA,worsening congestive heart failure,Opportunistic Infections n completed and,1,0.4787377119064331
CIMZIA,worsening congestive heart failure,the overall rate of tuberc,0,0.5383115410804749
CIMZIA,worsening congestive heart failure,completed and ongoing global cli nical studies in all,1,0.5164194107055664
CIMZIA,worsening congestive heart failure,all indications including CIMZIAtreated,0,0.5249192118644714
CIMZIA,worsening congestive heart failure,Opportunistic,0,0.4832901358604431
CIMZIA,worsening congestive heart failure,Tuberculosis and Opportunistic Infections,0,0.4828604459762573
CIMZIA,worsening congestive heart failure,n completed and ongoing global,1,0.5062976479530334
CIMZIA,CHF,din g CIMZIAtreated,1,0.564430832862854
CIMZIA,CHF,din g CIMZIAtreated patients,1,0.584812343120575
CIMZIA,CHF,all indications din g CIMZIAtreated patients,1,0.5671528577804565
CIMZIA,CHF,completed and ongoing global,0,0.5147116184234619
CIMZIA,CHF,g CIMZIAtreated patients the overall rate of tuberculosis is approximately,0,0.5312706232070923
CIMZIA,hypersensitivity reactions,ude,1,0.4757944643497467
CIMZIA,hypersensitivity reactions,"ude cases of miliary, lymp hatic peritoneal as well as",1,0.5738874077796936
CIMZIA,hypersensitivity reactions,median time to onset of TB for all patients exposed,0,0.5153461694717407
CIMZIA,angioedema,indications was days In the studies with CIMZIA,0,0.5674189329147339
CIMZIA,angioedema,for all patients,1,0.5412112474441528
CIMZIA,angioedema,to onset TB,1,0.48936736583709717
CIMZIA,angioedema,to onset TB for all patients exposed to CIMZIA,1,0.5171450972557068
CIMZIA,angioedema,pulmonary TB The,0,0.4444774389266968
CIMZIA,hypotension,as pulmonary TB The median time to onset of TB for all,0,0.46626368165016174
CIMZIA,hypotension,IMZIA across all indications was days In the studies,0,0.5016182065010071
CIMZIA,hypotension,days In the studies with CIMZIA in RA there were,0,0.4690014719963074
CIMZIA,hypotension,xposed to C IMZIA,1,0.4435965120792389
CIMZIA,hypotension,to C IMZIA across,1,0.47398388385772705
CIMZIA,hypotension,for all patients xposed to,1,0.5383691191673279
CIMZIA,hypotension,to C,1,0.5361801385879517
CIMZIA,rash,exposed to ZIA  across all indications was days,1,0.6146224737167358
CIMZIA,rash,to C,1,0.530746579170227
CIMZIA,rash,ZIA  across,1,0.48068737983703613
CIMZIA,serum sickness,all indic ations was days,1,0.5370945930480957
CIMZIA,serum sickness,CIMZIA ross all indic ations was days In the,1,0.4814571738243103
CIMZIA,serum sickness,RA,0,0.48256415128707886
CIMZIA,serum sickness,CIMZIA in,0,0.5053471326828003
CIMZIA,serum sickness,CIMZIA ross all,1,0.47263672947883606
CIMZIA,serum sickness,ross all indic ations was days,1,0.5100080966949463
CIMZIA,reactivation of hepatitis B virus,rol patients see Warnings and Precautions Heart,0,0.5318892002105713
CIMZIA,reactivation of hepatitis B virus,receiving,0,0.5144720077514648
CIMZIA,reactivation of hepatitis B virus,ose TNF blockers compared to cont rol patients see,1,0.5201125144958496
CIMZIA,reactivation of hepatitis B virus,For some TNF blockers more cases,0,0.5269370675086975
CIMZIA,reactivation of hepatitis B virus,malignancies have been,0,0.5192468166351318
CIMZIA,reactivation of hepatitis B virus,compared to cont rol,1,0.4706819951534271
CIMZIA,reactivation of hepatitis B virus,Failure,0,0.5056974291801453
CIMZIA,HBV reactivation,patients see Warnings and,0,0.4885629713535309
CIMZIA,HBV reactivation,of new or worsening,0,0.5229511260986328
CIMZIA,HBV reactivation,"and Precautions Heart ailure    



 I n placebocontrolled and",1,0.51627516746521
CIMZIA,HBV reactivation,ckers compared to control patients see Warnings,0,0.4947090148925781
CIMZIA,HBV reactivation,ailure I n placebocontrolled,1,0.5183800458908081
CIMZIA,HBV reactivation,ailure I n placebocontrolled and openlabel rheumatoid,1,0.5520536303520203
CIMZIA,HBV reactivation,ailure I,1,0.4315459728240967
CIMZIA,fatal,"dies, cases of new or",1,0.5925167798995972
CIMZIA,fatal,"dies, cases of new or worsening",1,0.662757396697998
CIMZIA,fatal,"openlabel rheumatoid arthritis dies, cases",1,0.5906438231468201
CIMZIA,fatal,placebocontrolled,0,0.5149608850479126
CIMZIA,fatal,arthritis stu,0,0.4676057696342468
CIMZIA,fatal,"dies, cases",1,0.6335253119468689
CIMZIA,HBV reactivation,moderate and occurred ng the,1,0.5541659593582153
CIMZIA,HBV reactivation,Autoantibodies In clini,0,0.5206390619277954
CIMZIA,HBV reactivation,to moderate and occurred ng the,1,0.5458801984786987
CIMZIA,HBV reactivation,see,0,0.4837266802787781
CIMZIA,HBV reactivation,occurred ng the,1,0.5290106534957886
CIMZIA,HBV reactivation,and Precautions,0,0.4990389347076416
CIMZIA,HBV reactivation,first yea r of exposure see,1,0.5272276401519775
CIMZIA,HBV reactivation,moderate and occurred ng the first yea,1,0.5585542917251587
CIMZIA,HBV reactivation,Precautions Autoantibodies,0,0.5512005686759949
CIMZIA,HBV reactivation,ng the first yea r,1,0.545602560043335
CIMZIA,central nervous system demyelinating disease,treated with t immunosuppressants had a lower rate of ant,1,0.563050389289856
CIMZIA,central nervous system demyelinating disease,with t immunosuppressants had a lower rate of ant,1,0.5599831938743591
CIMZIA,peripheral demyelinating disease,immunosuppressants had a lower rate,0,0.5535164475440979
CIMZIA,peripheral demyelinating disease,than patients not g immunosuppressants at baseline and respectively The following adverse,1,0.5704734325408936
CIMZIA,peripheral demyelinating disease,than,0,0.46963778138160706
CIMZIA,peripheral demyelinating disease,patients not g immunosuppressants at baseline,1,0.5838284492492676
CIMZIA,peripheral demyelinating disease,not g immunosuppressants at baseline and respectively The following,1,0.5607731342315674
CIMZIA,peripheral demyelinating disease,g,1,0.42616933584213257
CIMZIA,peripheral demyelinating disease,patients not g immunosuppressants at baseline and respectively,1,0.5761783719062805
CIMZIA,Guillain-Barre syndrome,patients who were antibodypositive N,0,0.5715606212615967
CIMZIA,Guillain-Barre syndrome,"immunosuppressants at baseline , respectively). The fo",1,0.5372880101203918
CIMZIA,Guillain-Barre syndrome,were antibodypositive,0,0.5238573551177979
CIMZIA,Guillain-Barre syndrome,at,0,0.4964601397514343
CIMZIA,Guillain-Barre syndrome,"taking immunosuppressants at baseline , respectively).",1,0.5429449081420898
CIMZIA,Guillain-Barre syndrome,than patients not taking immunosuppressants at baseline and,0,0.5389599800109863
CIMZIA,Guillain-Barre syndrome,"taking immunosuppressants at baseline , respectively). The fo llowing",1,0.5642019510269165
CIMZIA,Guillain-Barre syndrome,who were antibodypositive,0,0.5034987330436707
CIMZIA,Guillain-Barre syndrome,"baseline ,",1,0.45442941784858704
CIMZIA,neurological disorders,"(N = 1,242): abdomina l pain arthralgia edema peripheral",1,0.5390283465385437
CIMZIA,seizure disorder,"pain ralgia, edema pe ripheral erythema",1,0.5313220620155334
CIMZIA,seizure disorder,"(N = 1,242): abdomina l pain arthralgia edema peripheral",1,0.5133184194564819
CIMZIA,seizure disorder,abdominal,0,0.5016188621520996
CIMZIA,seizure disorder,"N abdominal pain ralgia, edema pe ripheral erythema nodosum injection",1,0.48957857489585876
CIMZIA,seizure disorder,"pain ralgia, edema",1,0.5554904937744141
CIMZIA,seizure disorder,"ralgia, edema pe ripheral erythema nodosum injection site",1,0.4610098600387573
CIMZIA,seizure disorder,edema pe ripheral,1,0.5459851622581482
CIMZIA,seizure disorder,"N abdominal pain ralgia, edema pe ripheral erythema nodosum injection site",1,0.4661591053009033
CIMZIA,seizure disorder,in,0,0.5091750025749207
CIMZIA,seizure disorder,N,0,0.49361452460289
CIMZIA,optic neuritis,injection,0,0.5180561542510986
CIMZIA,optic neuritis,"pheral, erythe ma nodosum",1,0.5594513416290283
CIMZIA,optic neuritis,"pheral, erythe ma nodosum injection",1,0.5384237766265869
CIMZIA,optic neuritis,upper,0,0.44863516092300415
CIMZIA,optic neuritis,peri,0,0.4689004123210907
CIMZIA,optic neuritis,"pheral, erythe ma",1,0.43122193217277527
CIMZIA,optic neuritis,arthralgia,0,0.5509368181228638
CIMZIA,peripheral neuropathy,edema peripheral erythema nod,0,0.6740612387657166
CIMZIA,peripheral neuropathy,pain pain in extremity and upper respiratory,0,0.5927523374557495
CIMZIA,peripheral neuropathy,"osum, injection site",1,0.5187067985534668
CIMZIA,peripheral neuropathy,pain in extremity and upper respiratory,0,0.6029672622680664
CIMZIA,peripheral neuropathy,infection The,0,0.4944852590560913
CIMZIA,peripheral neuropathy,"peripheral erythema osum, injection site  erythema injection site",1,0.6320222616195679
CIMZIA,peripheral neuropathy,site,0,0.4996761977672577
CIMZIA,peripheral neuropathy,pain pain in extremity,0,0.6341931819915771
CIMZIA,peripheral neuropathy,"osum, injection site  erythema injection site",1,0.5291392803192139
CIMZIA,peripheral neuropathy,"peripheral erythema osum, injection site  erythema injection site pain pain",1,0.6508708000183105
CIMZIA,pancytopenia,percentage of patients with to certolizu mab pegol detectable on at,1,0.5353158712387085
CIMZIA,pancytopenia,pain pain in extremity,0,0.4937095642089844
CIMZIA,pancytopenia,to certolizu mab pegol,1,0.5005062818527222
CIMZIA,pancytopenia,with to certolizu mab pegol detectable,1,0.5256402492523193
CIMZIA,pancytopenia,with to certolizu,1,0.471379816532135
CIMZIA,aplastic anemia,tectable on at least one occasion was,1,0.48150551319122314
CIMZIA,aplastic anemia,overall percentage of patients with,0,0.4996573030948639
CIMZIA,aplastic anemia,of patients with antibodies to,0,0.5258045196533203
CIMZIA,aplastic anemia,percentage of patients,0,0.44790637493133545
CIMZIA,aplastic anemia,certolizumab pegol tectable on at  least one,1,0.5186043381690979
CIMZIA,aplastic anemia,certolizumab pegol tectable on at  least one occasion,1,0.5135307312011719
CIMZIA,aplastic anemia,certolizumab pegol tectable,1,0.5038027167320251
CIMZIA,aplastic anemia,on at least one occasion,1,0.47493672370910645
CIMZIA,Adverse reactions of the hematologic system,antibodies with,0,0.5784438848495483
CIMZIA,Adverse reactions of the hematologic system,of,0,0.47799330949783325
CIMZIA,Adverse reactions of the hematologic system,was  in the rheumatoid arthritis placebo-contro lled trials Approximately one,1,0.5160240530967712
CIMZIA,Adverse reactions of the hematologic system,in the rheumatoid arthritis placebo-contro lled trials Approximately one,1,0.5144640207290649
CIMZIA,Adverse reactions of the hematologic system,in the rheumatoid arthritis placebo-contro,1,0.5252948999404907
CIMZIA,Adverse reactions of the hematologic system,occasion,0,0.4636346697807312
CIMZIA,Adverse reactions of the hematologic system,arthritis placebo-contro lled trials,1,0.5022271871566772
CIMZIA,Adverse reactions of the hematologic system,arthritis placebo-contro lled,1,0.5167166590690613
CIMZIA,Adverse reactions of the hematologic system,ents with antibodies to certolizumab pegol,0,0.5744310617446899
CIMZIA,Adverse reactions of the hematologic system,on at least one occasion was,0,0.49670863151550293
CIMZIA,cytopenia,of in the rheumatoid arthritis,0,0.5096348524093628
CIMZIA,cytopenia,arthritis placebocontrolled trials Approximately,0,0.5348248481750488
CIMZIA,cytopenia,"Approximately one rd (3%, 3 of",1,0.4822893738746643
CIMZIA,cytopenia,one,0,0.4904499053955078
CIMZIA,cytopenia,"rd (3%, 3 of of these",1,0.4821200668811798
CIMZIA,cytopenia,of in the rheumatoid,0,0.5069729685783386
CIMZIA,cytopenia,arthritis placebocontrolled trials Approximately one,0,0.5326263308525085
CIMZIA,cytopenia,rheumatoid arthritis placebocontrolled,0,0.5271447896957397
CIMZIA,cytopenia,"trials Approximately one rd (3%, 3 of of",1,0.5307320356369019
CIMZIA,cytopenia,"one rd (3%, 3 of of these patients had",1,0.5055390000343323
CIMZIA,leukopenia,09) of the se patients,1,0.5199045538902283
CIMZIA,leukopenia,patients had antibodies with neutralizing activity in vitro Patients,0,0.49600130319595337
CIMZIA,leukopenia,trials Approximately one third 09) of,1,0.5486306548118591
CIMZIA,leukopenia,antibodies with neutralizing activity in vitro,0,0.48815053701400757
CIMZIA,leukopenia,09) of,1,0.49230486154556274
CIMZIA,leukopenia,third of,0,0.5032315254211426
CIMZIA,leukopenia,trials Approximately one third,0,0.5422123670578003
CIMZIA,leukopenia,Approximately one third 09) of the,1,0.5262571573257446
CIMZIA,pancytopenia,placebocontrolled trials Approximately,0,0.5375840663909912
CIMZIA,pancytopenia,Approximately one,0,0.4669398069381714
CIMZIA,pancytopenia,patients ha d,1,0.5141165256500244
CIMZIA,pancytopenia,placebocontrolled trials,0,0.5425204038619995
CIMZIA,pancytopenia,trials Approximately one third of of,0,0.5201137065887451
CIMZIA,pancytopenia,of patients ha,1,0.5272965431213379
CIMZIA,thrombocytopenia,vitro Patients treated with,0,0.5580168962478638
CIMZIA,infections,"X, the ACR response was",1,0.4911441504955292
CIMZIA,infections,"with concomitant X, the",1,0.5328356623649597
CIMZIA,infections,the ACR response was lower among,1,0.4923551082611084
CIMZIA,infections,"X, the ACR response was lower",1,0.45706379413604736
CIMZIA,infections,recommended CIMZIA dosage of mg,0,0.538930356502533
CIMZIA,infections,"concomitant X, the ACR",1,0.5325746536254883
CIMZIA,infections,"X, the ACR response was lower among",1,0.47675055265426636
CIMZIA,infections,d antibodi es,1,0.577829897403717
CIMZIA,infections,patients d antibodi es to allow for meaningful,1,0.6035361289978027
CIMZIA,infections,RAIII too few patients d antibodi,1,0.5527626276016235
CIMZIA,infections,ACR,0,0.52034592628479
CIMZIA,infections,RAII versus respectively In Study RAIII too few patients,0,0.5343730449676514
CIMZIA,infections,d antibodi,1,0.5475410223007202
CIMZIA,infections,es to allow for meaningful analysis of ACR,0,0.5177407264709473
CIMZIA,lupus-like syndrome,including,0,0.5265846252441406
CIMZIA,lupus-like syndrome,ELISA and are highly ent on the,1,0.5815185904502869
CIMZIA,lupus-like syndrome,the sensitiv ity and,1,0.5288615226745605
GRANIX,Splenic Rupture,of the Splenic,1,0.8083176612854004
GRANIX,Splenic Rupture,other sections of the Splenic Rupture,1,0.9024479389190674
GRANIX,Splenic Rupture,the Splenic Rupture,1,0.9832443594932556
GRANIX,Splenic Rupture,Syndrome,0,0.5408424139022827
GRANIX,Splenic Rupture,other sections of the Splenic,1,0.7673234343528748
GRANIX,Splenic Rupture,sections of the Splenic Rupture see Warnings,1,0.8781110644340515
GRANIX,Splenic Rupture,serious adverse reactions are discussed in greater detail in,0,0.5554322004318237
GRANIX,Splenic Rupture,Splenic Rupture see Warnings and,1,0.898208737373352
GRANIX,Acute Respiratory Distress Syndrome,of the labeling Splenic Rupture see,0,0.5326367616653442
GRANIX,Allergic Reactions,see Warnings and Precautions Allergic,1,0.8163412809371948
GRANIX,Capillary Leak Syndrome,Cell Disease see Warnings and Precautions,0,0.5471155047416687
GRANIX,Capillary Leak Syndrome,Warnings and Capillary Leak Syndrome see Warnings and Precautions Potential,1,0.8630930781364441
GRANIX,Capillary Leak Syndrome,Warnings and Precautions Potential for Tumor Growth Stimulatory,0,0.549015462398529
GRANIX,Capillary Leak Syndrome,Precautions,0,0.5585256218910217
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,and,0,0.4651455879211426
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Warnings and,0,0.5540750026702881
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Potential Tumor Growth Stimulatory Effects,1,0.9322364926338196
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Potential Tumor Growth Stimulatory Effects on Malignant,1,0.97028648853302
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Precautions Potential Tumor Growth Stimulatory Effects on Malignant Cells see Warnings and Precautions The,1,0.8957774639129639
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Growth Stimulatory Effects on Malignant Cells see Warnings and Precautions,1,0.9225237369537354
GRANIX,bone pain,bone pain EXCERPT,1,0.9043858051300049
GRANIX,bone pain,placebo group bone pain EXCERPT,1,0.813808798789978
GRANIX,bone pain,bone pain EXCERPT Most,1,0.8944586515426636
GRANIX,bone pain,placebo group bone pain,1,0.8271675109863281
GRANIX,bone pain,at the recommended dose and was numerically two times more frequent than,0,0.5034443736076355
GRANIX,bone pain,the placebo group bone,1,0.7387629747390747
GRANIX,bone pain,the placebo group bone pain,1,0.8293262720108032
GRANIX,bone pain,EXCERPT Most,0,0.4657341241836548
GRANIX,bone pain,two times more,0,0.45151206851005554
GRANIX,bone pain,at or FDA,0,0.473807156085968
GRANIX,bone pain,placebo group was bone pain EXCERPT Most common adverse reaction,0,0.7448670864105225
GRANIX,bone pain,pain,0,0.8075032234191895
GRANIX,bone pain,reaction to GRANIX bone pain To report SUSPECTED ADVERSE,1,0.7708643674850464
GRANIX,bone pain,REACTIONS contact TEVA at or FDA,0,0.5070957541465759
GRANIX,bone pain,reaction to GRANIX bone pain To report SUSPECTED ADVERSE REACTIONS,1,0.752701997756958
GRANIX,bone pain,bone pain To report SUSPECTED,1,0.8725457191467285
GRANIX,bone pain,REACTIONS contact TEVA at or FDA at,0,0.5122771263122559
GRANIX,bone pain,bone pain To report SUSPECTED ADVERSE,1,0.8531376123428345
GRANIX,Bone pain,Bone pain was the most frequent,1,0.8801906108856201
GRANIX,Bone pain,reaction that occurred in,0,0.5090715885162354
GRANIX,Bone pain,L after nadir was Bone pain was the most frequent,1,0.8302366137504578
GRANIX,Bone pain,Bone pain,1,1.0000001192092896
GRANIX,Bone pain,Bone pain was,1,0.9594427347183228
GRANIX,Bone pain,Bone pain was the most,1,0.9081007838249207
GRANIX,Bone pain,tinued to a maximum of days or until an ANC of x L after nadir,0,0.4808861315250397
GRANIX,Bone pain,to a maximum of days or until an ANC of x L after nadir,0,0.47078728675842285
GRANIX,Bone pain,Bone pain was the most frequent treatmentemergent,1,0.8293794393539429
GRANIX,bone pain,placebo,0,0.5685698986053467
GRANIX,bone pain,overall incidence,0,0.5026327967643738
GRANIX,bone pain,incidence bone pain in Cycle of treatment was,1,0.7999882698059082
GRANIX,bone pain,bone pain in Cycle of treatment was,1,0.8402937650680542
GRANIX,bone pain,The overall incidence bone pain,1,0.8620142340660095
GRANIX,bone pain,numerically two times more frequent than in the placebo,0,0.5273891687393188
GRANIX,bone pain,of,0,0.48049741983413696
GRANIX,bone pain,bone pain,1,1.0000001192092896
GRANIX,bone pain,overall incidence of,0,0.5138037204742432
GRANIX,bone pain,incidence bone,1,0.7291027307510376
GRANIX,leukocytosis,Reactions Other adverse,0,0.5398892164230347
GRANIX,leukocytosis,leukocytosis were reported,1,0.920661449432373
GRANIX,leukocytosis,Other,0,0.4995567202568054
GRANIX,leukocytosis,complications attributable leukocytosis,1,0.8468927145004272
GRANIX,leukocytosis,leukocytosis,1,1.0000001192092896
GRANIX,leukocytosis,GRANIX No complications attributable leukocytosis were,1,0.7533527612686157
GRANIX,leukocytosis,were reported in clinical studies Additional Adverse Reactions Other adverse reactions kno,0,0.536665141582489
GRANIX,leukocytosis,No complications attributable leukocytosis were reported,1,0.8201865553855896
GRANIX,leukocytosis,s than,0,0.4921925663948059
GRANIX,myalgia,myalgia headache vomiting,1,0.7926223874092102
GRANIX,myalgia,factors myalgia,1,0.8717954158782959
GRANIX,myalgia,acute febrile neutrophilic dermatosis,0,0.4704969525337219
GRANIX,myalgia,colonystimulating factors myalgia,1,0.7974247932434082
GRANIX,myalgia,myalgia headache vomiting Sweets syndrome acute,1,0.7718905210494995
GRANIX,headache,headache vomiting Sweets,1,0.7728416323661804
GRANIX,headache,myalgia headache vomiting Sweets syndrome acute,1,0.6895432472229004
GRANIX,headache,include headache vomiting Sweets syndrome acute febrile,1,0.6925654411315918
GRANIX,vomiting,vomiting Sweets syndrome,1,0.7864394187927246
GRANIX,vomiting,myalgia,0,0.5050665140151978
GRANIX,Sweet's syndrome,include myalgia headache Sweet's syndrome acute febrile neutrophilic dermatosis,1,0.7861348390579224
GRANIX,Sweet's syndrome,myalgia,0,0.5368248820304871
GRANIX,Sweet's syndrome,acute,0,0.47869938611984253
GRANIX,acute febrile neutrophilic dermatosis,myalgia headache vomiting Sweets acute febrile neutrophilic dermatosis cutaneous vasculitis and thrombocytopenia,1,0.7633611559867859
GRANIX,acute febrile neutrophilic dermatosis,acute,0,0.6362512111663818
GRANIX,acute febrile neutrophilic dermatosis,with all therapeutic pr,0,0.4933716356754303
GRANIX,acute febrile neutrophilic dermatosis,include myalgia headache vomiting Sweets syndrome,0,0.4940764904022217
GRANIX,acute febrile neutrophilic dermatosis,febrile neutrophilic dermatosis cutaneous vasculitis and thrombocytopenia Immunogenicity,1,0.8317227363586426
GRANIX,acute febrile neutrophilic dermatosis,neutrophilic dermatosis cutaneous vasculitis and thrombocytopenia,1,0.798305869102478
GRANIX,acute febrile neutrophilic dermatosis,vomiting Sweets acute febrile,1,0.699962854385376
GRANIX,acute febrile neutrophilic dermatosis,vomiting Sweets,0,0.4796549081802368
GRANIX,acute febrile neutrophilic dermatosis,vasculitis and thrombocytopenia Immunogenicity As,0,0.5817142724990845
GRANIX,acute febrile neutrophilic dermatosis,Immunogenicity As with,0,0.5107859969139099
GRANIX,acute febrile neutrophilic dermatosis,vomiting Sweets acute febrile neutrophilic,1,0.7717638611793518
GRANIX,cutaneous vasculitis,neutrophilic cutaneous vasculitis and thrombocytopenia Immunogenicity As with,1,0.8052796125411987
GRANIX,cutaneous vasculitis,vomiting Sweets acute febrile neutrophilic,1,0.5431904792785645
GRANIX,cutaneous vasculitis,neutrophilic cutaneous vasculitis,1,0.9012846350669861
GRANIX,cutaneous vasculitis,neutrophilic cutaneous vasculitis and thrombocytopenia Immunogenicity,1,0.8118804693222046
GRANIX,cutaneous vasculitis,acute febrile neutrophilic cutaneous vasculitis and thrombocytopenia Immunogenicity,1,0.788192629814148
GRANIX,thrombocytopenia,vasculitis thrombocytopenia Immunogenicity As with all,1,0.7435705661773682
GRANIX,thrombocytopenia,neutrophilic cutaneous vasculitis,1,0.5778549313545227
GRANIX,Splenic Rupture,potential ser,0,0.5496192574501038
GRANIX,Splenic Rupture,ious adverse re actions,1,0.46541744470596313
GRANIX,Splenic Rupture,following potential ious adverse,1,0.5190026760101318
GRANIX,Splenic Rupture,The following potential ser,0,0.5424739122390747
GRANIX,Splenic Rupture,discussed in greater detail in other sections of the,0,0.46957892179489136
GRANIX,Splenic Rupture,following potential ious adverse re,1,0.5250676274299622
GRANIX,Splenic Rupture,actions are discussed in greater detail in other sections of the labeling Splenic,0,0.691200852394104
GRANIX,Acute Respiratory Distress Syndrome,Rupture see Warnings and Precautions Acute,0,0.5968308448791504
GRANIX,Acute Respiratory Distress Syndrome,Precautions Acute,0,0.5823783278465271
GRANIX,Acute Respiratory Distress Syndrome,potential serious adverse reactions are discussed in greater,0,0.5612133741378784
GRANIX,Acute Respiratory Distress Syndrome,in other se,0,0.4807163178920746
GRANIX,Acute Respiratory Distress Syndrome,labeling: Spleni c,1,0.48000216484069824
GRANIX,Acute Respiratory Distress Syndrome,ctions of the labeling: Spleni c Rupture see Warnings and,1,0.523637056350708
GRANIX,ARDS,reactions are discussed,0,0.5465035438537598
GRANIX,ARDS,Rupt,1,0.572808563709259
GRANIX,ARDS,the labeling Rupt ure see Warnings and Precautions,1,0.5178515911102295
GRANIX,ARDS,Rupt ure see Warnings,1,0.5696099400520325
GRANIX,ARDS,Rupt ure see Warnings and Precautions,1,0.5714994072914124
GRANIX,ARDS,labeling Rupt ure see Warnings and Precautions,1,0.5442532300949097
GRANIX,ARDS,Rupt ure see Warnings and,1,0.5627696514129639
GRANIX,Allergic reactions,Acute,0,0.5708471536636353
GRANIX,Allergic reactions,see Warnings and,0,0.5639482736587524
GRANIX,Allergic reactions,Precautions Acute Respiratory Distress [,1,0.5908478498458862
GRANIX,Allergic reactions,Precautions Acute Respiratory Distress [ see Warnings,1,0.6144078373908997
GRANIX,Allergic reactions,Warnings and Precautions Acute Respiratory Distress Syndrome,0,0.5946894884109497
GRANIX,Allergic reactions, [  see  Warnings  and Precautions Serious Allergic Reactions,1,0.8293511867523193
GRANIX,Allergic reactions,see Warnings,0,0.5780279636383057
GRANIX,angioneurotic edema,d Precautions (5.2),1,0.5122722387313843
GRANIX,dermatitis allergic,Serious Al lergic Reactions,1,0.5460434556007385
GRANIX,dermatitis allergic,Sickle Cell,0,0.48281386494636536
GRANIX,dermatitis allergic,Warnings and ] Serious Al,1,0.5279852151870728
GRANIX,dermatitis allergic,with Sickle Cell,0,0.45537376403808594
GRANIX,dermatitis allergic,"Warnings and   ]



  Serious Al lergic Reactions see",1,0.5864235758781433
GRANIX,dermatitis allergic,],1,0.5427864789962769
GRANIX,hypersensitivity,Cell Disease see Warnings,0,0.5543586015701294
GRANIX,hypersensitivity,stress Syndrome see Warnings and Precautions Serious Allergic Reactions,0,0.7135127782821655
GRANIX,hypersensitivity,stress Syndrome,0,0.5992937088012695
GRANIX,hypersensitivity,Allergic Reactions Warnings and Pre,1,0.7297267913818359
GRANIX,hypersensitivity,Syndrome,0,0.606599748134613
GRANIX,hypersensitivity,Allergic Reactions Warnings,1,0.7281715869903564
GRANIX,rash,Warnings and utio,1,0.5409299731254578
GRANIX,rash,Allergic Reactions Warnings,1,0.6621143817901611
GRANIX,rash,Disease see Warnings and Precautions,0,0.5944076776504517
GRANIX,rash,and Precautions Serious Allergic Reactions,0,0.6541402339935303
GRANIX,rash,utio ns,1,0.46106696128845215
GRANIX,rash,utio ns Use in,1,0.47188785672187805
GRANIX,rash,utio ns Use,1,0.46209716796875
GRANIX,rash,utio ns Use in Patients,1,0.481195330619812
GRANIX,rash,Reactions see Warnings and utio ns Use in Patients with,1,0.5806257724761963
GRANIX,pruritic rash,Warnings,0,0.5900185704231262
GRANIX,pruritic rash,Cell Disease see Warnings and,0,0.5359628200531006
GRANIX,pruritic rash,Precautions,0,0.594589352607727
GRANIX,pruritic rash,Warnings and,0,0.5662193298339844
GRANIX,pruritic rash,(5.3) ] Use in Patients,1,0.5129437446594238
GRANIX,pruritic rash,and Precautions,0,0.5595952868461609
GRANIX,urticaria,se in Pat,1,0.5414787530899048
GRANIX,urticaria,se in Pat ients with,1,0.5234993100166321
GRANIX,urticaria,utions Serious Allergic Reactions see Warnings and Precautions,0,0.6841744184494019
GRANIX,urticaria,Warnings and Precautions se,1,0.5218321084976196
GRANIX,urticaria,and Precautions se in Pat ients with Sickle Cell,1,0.48864632844924927
GRANIX,urticaria,Cell Disease see,0,0.5061143040657043
GRANIX,urticaria,Capillary Leak Syndr,0,0.5298022627830505
GRANIX,urticaria,Reactions see Warnings and Precautions,0,0.5603952407836914
GRANIX,urticaria,se in Pat ients with Sickle Cell,1,0.49073997139930725
GRANIX,Sickle cell crisis,Leak Syndrome see Warnings,0,0.553737998008728
GRANIX,Sickle cell crisis,Capillary Leak Syndrome see Warnings and,0,0.5810471773147583
GRANIX,Sickle cell crisis,Sickle ell Disease [,1,0.7959887981414795
GRANIX,Sickle cell crisis,Precautions Capillary Leak Syndrome see Warnings,0,0.5687955617904663
GRANIX,Sickle cell crisis,ell Disease [  see Warnings and Precautions,1,0.5953339338302612
GRANIX,fatal,ons ( Capillary Leak Syndrome,1,0.5163376927375793
GRANIX,fatal,Leak Syndrome see,0,0.5108762979507446
GRANIX,fatal,ons ( Capillary Leak Syndrome see Warnings,1,0.5337334871292114
GRANIX,fatal,and ons (,1,0.5162569880485535
GRANIX,Capillary Leak Syndrome,"autions (5.5)    ]



  Potential for Tumor",1,0.538698673248291
GRANIX,Capillary Leak Syndrome,and ons (,1,0.5414180755615234
GRANIX,Capillary Leak Syndrome,"see Warnings and autions (5.5)    ]



  Potential for Tumor Growth Stimulatory",1,0.5358808636665344
GRANIX,Capillary Leak Syndrome,Growth Stimulatory Effects on Malignant Cells see Warnings and,0,0.5350595712661743
GRANIX,Capillary Leak Syndrome,Cells see Warnings,0,0.5604604482650757
GRANIX,Splenic rupture,most common tre atmentemergent adverse,1,0.5262221097946167
GRANIX,Splenic rupture,common tre,1,0.4803149104118347
GRANIX,Splenic rupture,on Malignant Cells see Warnings,0,0.5504989624023438
GRANIX,Splenic rupture,and Precautions most common tre atmentemergent adverse reaction,1,0.5282703042030334
GRANIX,Splenic rupture,Cells see Warnings and Precautions The,0,0.5212593674659729
GRANIX,fatal,Precautions The most common ent a dverse reaction that,1,0.5490501523017883
GRANIX,fatal,Cells see Warnings and Precautions The,0,0.5085004568099976
GRANIX,fatal,in patients treated,0,0.525611400604248
GRANIX,fatal,Precautions,0,0.4998426139354706
GRANIX,fatal,ent a dverse reaction that occurred,1,0.6001594066619873
GRANIX,fatal,ent,1,0.5189303159713745
GRANIX,fatal,ent a dverse reaction,1,0.5879950523376465
GRANIX,fatal,common treatmentemerg,0,0.49122726917266846
GRANIX,Acute respiratory distress syndrome,TEVA at or FDA at FDA or wwwfdagovmedwatch Clin,0,0.5032907724380493
GRANIX,Acute respiratory distress syndrome,EXCERPT Most,0,0.4564349055290222
GRANIX,Acute respiratory distress syndrome,To eport,1,0.5121276378631592
GRANIX,Acute respiratory distress syndrome,GRANIX is bone,0,0.460440069437027
GRANIX,Acute respiratory distress syndrome,"ADVERSE REACTIONS,",1,0.5906864404678345
GRANIX,Acute respiratory distress syndrome,at or FDA at FDA or wwwfdagovmedwatch Clin,0,0.5104220509529114
GRANIX,Acute respiratory distress syndrome,"ADVERSE REACTIONS, contact",1,0.5497321486473083
GRANIX,Acute respiratory distress syndrome,eport SUSPECTED,1,0.5226196646690369
GRANIX,ARDS,ntac t TEVA at or FDA,1,0.48152095079421997
GRANIX,ARDS,ADVERSE REACTIONS ntac t TEVA at or FDA,1,0.4936679005622864
GRANIX,ARDS,at or FDA at FDA,0,0.5195765495300293
GRANIX,allergic reactions,red to rates in th e clinical trials of,1,0.5383783578872681
GRANIX,allergic reactions,drug cannot be,0,0.4694710075855255
GRANIX,allergic reactions,rates in th e clinical trials of,1,0.5229027271270752
GRANIX,anaphylaxis,trials of a nother drug and may not,1,0.5021592974662781
GRANIX,anaphylaxis,to rates in the trials of,1,0.515649139881134
GRANIX,fatal,age was years 95% o,1,0.4883781671524048
GRANIX,fatal,to rates in the trials of,1,0.492026686668396
GRANIX,fatal,95% o,1,0.502267599105835
GRANIX,fatal,95% o f patients were Caucasian,1,0.451948881149292
GRANIX,sickle cell crises,patients were Cau casian In the nonHodgkins lymphoma,1,0.5488032102584839
GRANIX,sickle cell crises,patients were Cau casian In,1,0.5677756071090698
GRANIX,sickle cell crises,patients were Cau casian,1,0.5561376214027405
GRANIX,Capillary leak syndrome,daily beg inning one,1,0.4308086633682251
GRANIX,Capillary leak syndrome,of days or,0,0.4735454320907593
GRANIX,Capillary leak syndrome,after chemotherapy for at least five days and continued to a maximum of days or,0,0.5280901193618774
GRANIX,Capillary leak syndrome,aneously once daily beg inning one day after chemotherapy,1,0.5273122191429138
GRANIX,CLS,nin g one,1,0.4472186267375946
GRANIX,CLS,subcutaneously once daily nin g one,1,0.45759743452072144
GRANIX,CLS,subcutaneously once daily nin,1,0.46243515610694885
GRANIX,CLS,one day after chemotherapy for at least five days and continued to,0,0.4889237880706787
GRANIX,hypotension,"or until an NC of >=10,",1,0.5217215418815613
GRANIX,hypotension,"NC of >=10, x L after nadir was",1,0.5580642223358154
GRANIX,hypotension,"NC of >=10, x L after",1,0.5393898487091064
GRANIX,hypotension,"of >=10, x",1,0.4692383408546448
GRANIX,hypotension,pain,0,0.6133730411529541
GRANIX,hypotension,days or,0,0.42225173115730286
GRANIX,hypoalbuminemia,to a maximum of days or until,0,0.45817166566848755
GRANIX,hypoalbuminemia,maximum of,0,0.4444948434829712
GRANIX,hypoalbuminemia,ANC 0 x 10  6  /L a fter,1,0.5430082678794861
GRANIX,hypoalbuminemia,0 x 10  6  /L a fter nadir was reached,1,0.5013427734375
GRANIX,hypoalbuminemia,frequent treatmentemergent adverse reaction,0,0.49962127208709717
GRANIX,hypoalbuminemia,ANC 0 x 10,1,0.5521489381790161
GRANIX,hypoalbuminemia,or until an ANC 0,1,0.5038674473762512
GRANIX,edema,of x L er na,1,0.5450005531311035
GRANIX,edema,and continued to a maximum of days or until an ANC of x L,0,0.5305584669113159
GRANIX,edema,er na dir was reached Bone pain,1,0.621832549571991
GRANIX,edema,er na dir was reached,1,0.5370903015136719
GRANIX,edema,adverse,0,0.5746562480926514
GRANIX,edema,Bone pain was the most frequent treatmentemergent adverse reaction that,0,0.5676158666610718
GRANIX,edema,was,0,0.5097800493240356
GRANIX,hemoconcentration,of days or until an ANC of x L after nadir,0,0.46162134408950806
GRANIX,hemoconcentration,reached. B one pain was the,1,0.5730180740356445
GRANIX,hemoconcentration,at,0,0.5576975345611572
GRANIX,hemoconcentration,of days or,0,0.4650549292564392
GRANIX,myeloid malignancies,less than patients with nonmyeloid malignancies,0,0.8041760921478271
GRANIX,myeloid malignancies,No complications attributable to leukocytosis were reported,1,0.6043735146522522
GRANIX,myeloid malignancies,less than patients with nonmyeloid,0,0.7493612766265869
GRANIX,myeloid malignancies,attributable to leukocytosis were reported in clinical,0,0.6626063585281372
GRANIX,myelodysplasia,less than patients with,0,0.4602687656879425
GRANIX,myelodysplasia,reported in clinical studies,0,0.49977943301200867
GRANIX,myelodysplasia,complications ibutable to le ukocytosis were reported in,1,0.600804328918457
GRANIX,myelodysplasia,receiving GRANIX No complications ibutable to le,1,0.48738062381744385
GRANIX,myelodysplasia,in clinical studies,0,0.49444031715393066
GRANIX,myelodysplasia,ibutable to le ukocytosis were reported,1,0.6031766533851624
GRANIX,myelodysplasia,less than,0,0.45094573497772217
GRANIX,myelodysplasia,erved in less than patients with nonmyeloid malignancies receiving GRANIX,0,0.5635367631912231
GRANIX,myelodysplasia,complications ibutable to le ukocytosis were,1,0.6018270254135132
TUDORZA,Paradoxical bronchospasm,see Warnings and Precautions,0,0.4816977083683014
TUDORZA,Paradoxical bronchospasm,glaucoma see Warnings,0,0.5162434577941895
TUDORZA,Paradoxical bronchospasm,Paradoxical bronchospasm see Warnings and Precautions Worsening,1,0.9197653532028198
TUDORZA,Paradoxical bronchospasm,in other Paradoxical bronchospasm,1,0.969680666923523
TUDORZA,Paradoxical bronchospasm,other Paradoxical bronchospasm see Warnings and Precautions,1,0.9133144617080688
TUDORZA,Paradoxical bronchospasm,Paradoxical bronchospasm,1,1.0
TUDORZA,Paradoxical bronchospasm,detail in other Paradoxical bronchospasm see Warnings and Precautions,1,0.9036823511123657
TUDORZA,Worsening of narrow-angle glaucoma,and Worsening of narrow-angle glaucoma see Warnings and Precautions,1,0.9174565076828003
TUDORZA,Worsening of narrow-angle glaucoma,Paradoxical bronchospasm see Warnings and Precautions Worsening,1,0.6221092939376831
TUDORZA,Worsening of narrow-angle glaucoma,other sections Paradoxical bronchospasm see Warnings and,0,0.5625616312026978
TUDORZA,Worsening of narrow-angle glaucoma,Worsening of narrow-angle glaucoma see Warnings and,1,0.9481006860733032
TUDORZA,Worsening of narrow-angle glaucoma,Warnings and Precautions Worsening of urinary retention see Warnings and,0,0.6194921731948853
TUDORZA,Worsening of narrow-angle glaucoma,Worsening of narrow-angle glaucoma see Warnings and Precautions Worsening,1,0.9415229558944702
TUDORZA,Worsening of narrow-angle glaucoma,and Worsening,1,0.7103160619735718
TUDORZA,Worsening of narrow-angle glaucoma,bronchospasm see Warnings and Worsening of narrow-angle glaucoma,1,0.8300795555114746
TUDORZA,Worsening of narrow-angle glaucoma,Precautions Worsening of urinary retention,0,0.598221480846405
TUDORZA,Worsening of narrow-angle glaucoma,narrow-angle glaucoma see Warnings,1,0.8678885698318481
TUDORZA,Worsening of narrow-angle glaucoma,of narrow-angle glaucoma see Warnings and Precautions Worsening,1,0.9237703084945679
TUDORZA,Worsening of urinary retention,Precautions,0,0.4902268648147583
TUDORZA,Worsening of urinary retention,Reactions see,0,0.48505645990371704
TUDORZA,Worsening of urinary retention,Warnings and Worsening of urinary retention,1,0.9415714740753174
TUDORZA,Worsening of urinary retention,narrowangle,0,0.4787901043891907
TUDORZA,Worsening of urinary retention,and Worsening of urinary retention,1,0.9935605525970459
TUDORZA,Worsening of urinary retention,urinary retention,1,0.9149725437164307
TUDORZA,Worsening of urinary retention,narrowangle glaucoma see Warnings,0,0.5326442718505859
TUDORZA,Worsening of urinary retention,urinary retention see Warnings and Precautions Immediate,1,0.8117766976356506
TUDORZA,Worsening of urinary retention,Warnings and,0,0.5403435230255127
TUDORZA,Worsening of urinary retention,and,0,0.47074639797210693
TUDORZA,Immediate Hypersensitivity Reactions,retention see Warnings,0,0.47703269124031067
TUDORZA,headache,REACTIONS Contact,0,0.4985228180885315
TUDORZA,headache,and greater than placebo headache,1,0.7873638272285461
TUDORZA,nasopharyngitis,greater,0,0.4992123246192932
TUDORZA,nasopharyngitis,nasopharyngitis and,1,0.9384024143218994
TUDORZA,nasopharyngitis,than placebo are nasopharyngitis and cough To,1,0.7899340391159058
TUDORZA,nasopharyngitis,reactions incidence and greater than placebo are,0,0.5139567852020264
TUDORZA,cough,are headache nasopharyngitis cough To report SUSPECTED,1,0.7327793836593628
TUDORZA,cough,reactions incidence and greater than placebo are,0,0.5651669502258301
TUDORZA,cough,placebo are headache nasopharyngitis,0,0.6281655430793762
TUDORZA,cough,reactions incidence and greater than placebo are headache,0,0.5684816837310791
TUDORZA,cough,ommon adverse reactions incidence and greater than placebo,0,0.5594460368156433
TUDORZA,cough,report SUSPECTED ADVERSE REACTIONS,0,0.5680658221244812
TUDORZA,cough,cough To report SUSPECTED,1,0.8173993825912476
TUDORZA,cough,To report SUSPECTED ADVERSE REACTIONS Contact AstraZeneca at,0,0.5387044548988342
TUDORZA,dry mouth,diabetes dry mouth st degree,1,0.7867106199264526
TUDORZA,dry mouth,To report SUSPECTED ADVERSE REACTIONS Contact AstraZeneca at,0,0.5199925303459167
TUDORZA,dry mouth,mellitus,0,0.579472541809082
TUDORZA,dry mouth,failure and cardiorespiratory,0,0.5712535381317139
TUDORZA,dry mouth,dry mouth st,1,0.9368312358856201
TUDORZA,dry mouth,degree AV block osteoarthritis cardiac,0,0.47332489490509033
TUDORZA,dry mouth,than were diabetes dry mouth,1,0.838445782661438
TUDORZA,dry mouth,dry mouth st degree,1,0.818374514579773
TUDORZA,AV block,Longterm,0,0.5034208297729492
TUDORZA,AV block,cardiorespiratory arrest,0,0.599276065826416
TUDORZA,AV block,mellitus dry mouth st AV block osteoarthritis cardiac failure and cardiorespiratory,1,0.6508145332336426
TUDORZA,AV block,Longterm Safety Trials,0,0.5267714262008667
TUDORZA,AV block,AV block,1,1.0
TUDORZA,AV block,mellitus dry,0,0.47895288467407227
TUDORZA,AV block,AV block osteoarthritis cardiac failure,1,0.7421854734420776
TUDORZA,AV block,mellitus,0,0.4813001751899719
TUDORZA,AV block,AV block osteoarthritis cardiac failure and,1,0.7481157779693604
TUDORZA,osteoarthritis,cardiorespiratory arrest Longterm Safety Trials TUDORZA,0,0.5171606540679932
TUDORZA,osteoarthritis,AV osteoarthritis cardiac,1,0.8081168532371521
TUDORZA,osteoarthritis,osteoarthritis cardiac failure and cardiorespiratory arrest,1,0.7896517515182495
TUDORZA,osteoarthritis,Longterm Safety,0,0.5154431462287903
TUDORZA,osteoarthritis,AV osteoarthritis cardiac failure and cardiorespiratory,1,0.813152015209198
TUDORZA,osteoarthritis,Safety Trials,0,0.5374281406402588
TUDORZA,osteoarthritis,mouth st degree AV osteoarthritis cardiac failure and,1,0.7966194152832031
TUDORZA,osteoarthritis,arrest Longterm Safety Trials,0,0.5270419120788574
TUDORZA,osteoarthritis,incidence of less than were diabetes mellitus dry mouth,0,0.5354018807411194
TUDORZA,cardiac failure,block,0,0.517792820930481
TUDORZA,cardiac failure,less than were diabetes mellitus dry mouth st degree,0,0.5416010618209839
TUDORZA,cardiac failure,arrest Longterm Safety Trials TUDORZA PRESSAIR was stud,0,0.5358672738075256
TUDORZA,cardiac failure,osteoarthritis,0,0.585914134979248
TUDORZA,cardio-respiratory arrest,st degree AV block osteoarthritis cardiac failure,0,0.6084321737289429
TUDORZA,cardio-respiratory arrest,cardiac failure cardio-respiratory arrest Longterm Safety Trials TUDORZA,1,0.7956791520118713
TUDORZA,cardio-respiratory arrest,cardio-respiratory arrest Longterm Safety,1,0.8761781454086304
TUDORZA,cardio-respiratory arrest,block osteoarthritis cardiac failure cardio-respiratory arrest Longterm Safety Trials TUDORZA PRESSAIR,1,0.7238353490829468
TUDORZA,cardio-respiratory arrest,mouth st degree AV block osteoarthritis,0,0.5300246477127075
TUDORZA,cardio-respiratory arrest,osteoarthritis cardiac failure,0,0.591503381729126
TUDORZA,cardio-respiratory arrest,mellitus,0,0.48977214097976685
TUDORZA,immediate hypersensitivity reactions,immediate hypersensitivity reactions including anaphylaxis angioedema including swelling,1,0.9055755138397217
TUDORZA,immediate hypersensitivity reactions,postmarketing experience with TUDORZA immediate hypersensitivity reactions including anaphylaxis,1,0.7973392009735107
TUDORZA,immediate hypersensitivity reactions,the,0,0.48659348487854004
TUDORZA,immediate hypersensitivity reactions,with TUDORZA immediate hypersensitivity reactions including anaphylaxis,1,0.8495214581489563
TUDORZA,anaphylaxis,lips tongue or throat,0,0.540534257888794
TUDORZA,anaphylaxis,reactions anaphylaxis angioedema including swelling of the,1,0.8401718139648438
TUDORZA,anaphylaxis,angioedema including swelling of the lips,0,0.660839319229126
TUDORZA,anaphylaxis,In postmarketing experience with TUDORZA,0,0.5211031436920166
TUDORZA,anaphylaxis,urticaria rash bronchospasm,0,0.7058534026145935
TUDORZA,angioedema,reactions including angioedema including swelling,1,0.8734804391860962
TUDORZA,angioedema,urticaria rash bronchospasm,0,0.6156385540962219
TUDORZA,angioedema,immediate hypersensitivity reactions including angioedema including swelling of,1,0.831912636756897
TUDORZA,angioedema,or itching have,0,0.6176987290382385
TUDORZA,angioedema,PRESSAIR,0,0.5810322165489197
TUDORZA,angioedema,including,0,0.5568766593933105
TUDORZA,angioedema,angioedema including swelling of,1,0.9204513430595398
TUDORZA,angioedema,immediate hypersensitivity reactions including angioedema including swelling of the,1,0.8347036838531494
TUDORZA,angioedema,experience,0,0.5180530548095703
TUDORZA,angioedema,angioedema including swelling of the lips,1,0.8730495572090149
TUDORZA,angioedema,including angioedema including swelling of,1,0.9070479869842529
TUDORZA,urticaria,or urticaria,1,0.8719205856323242
TUDORZA,urticaria,angioedema including swelling of the lips,1,0.6617178916931152
TUDORZA,urticaria,the lips tongue or urticaria rash bronchospasm or,1,0.7671934962272644
TUDORZA,urticaria,urticaria rash bronchospasm or,1,0.8165910243988037
TUDORZA,urticaria,including swelling of the lips tongue,0,0.5771097540855408
TUDORZA,urticaria,the lips tongue or urticaria rash bronchospasm or itching have,1,0.7631734609603882
TUDORZA,rash,tongue or throat rash bronchospasm,1,0.7057713866233826
TUDORZA,rash,including swelling of the lips tongue,0,0.6149346828460693
TUDORZA,rash,rash bronchospasm or itching have,1,0.7964746952056885
TUDORZA,rash,or throat rash bronchospasm or itching have,1,0.75965416431427
TUDORZA,rash,throat rash bronchospasm or itching have,1,0.7553286552429199
TUDORZA,rash,have been,0,0.5225191116333008
TUDORZA,bronchospasm,rash,0,0.5710412263870239
TUDORZA,bronchospasm,itching have been,0,0.49833858013153076
TUDORZA,bronchospasm,of,0,0.49989235401153564
TUDORZA,itching,have been reported,0,0.521025538444519
TUDORZA,itching,itching have been reported,1,0.9126831293106079
TUDORZA,itching,swelling of the lips tongue or,0,0.5899763703346252
TUDORZA,Paradoxical bronchospasm,other sections aradoxical bronchospasm,1,0.8171753883361816
TUDORZA,Paradoxical bronchospasm,aradoxical bronchospasm,1,0.8292542695999146
TUDORZA,Paradoxical bronchospasm,Worsening of narrowangle glaucoma see Warnings and Pr,0,0.5548672080039978
TUDORZA,Paradoxical bronchospasm,detail in other sections aradoxical bronchospasm  see Warnings and,1,0.7888860702514648
TUDORZA,Paradoxical bronchospasm,detail in other sections,0,0.47579529881477356
TUDORZA,Paradoxical bronchospasm,greater detail,0,0.46494370698928833
TUDORZA,Paradoxical bronchospasm,glaucoma see,0,0.48939430713653564
TUDORZA,Paradoxical bronchospasm,in other sections aradoxical bronchospasm ,1,0.8185266256332397
TUDORZA,Worsening of narrow-angle glaucoma,see Warnings and Precautions Immediate Hypersensitivity Reactions,0,0.517142653465271
TUDORZA,Worsening of narrow-angle glaucoma,Worsening of narrowangle,0,0.7922335863113403
TUDORZA,Worsening of narrow-angle glaucoma,Worsening of urinar y retention see Warnings and,1,0.6358479261398315
TUDORZA,Worsening of narrow-angle glaucoma,and Precautions Immediate Hypersensitivity,0,0.4896394908428192
TUDORZA,Worsening of urinary retention,Warnings and Precautions EXCERPT t common adverse reactions (>=,1,0.5182291269302368
TUDORZA,Worsening of urinary retention,and Precautions Immediate Hypersensitivity,0,0.4563438892364502
TUDORZA,Worsening of urinary retention,EXCERPT t,1,0.47639575600624084
TUDORZA,Worsening of urinary retention,t common adverse reactions (>= incidence and greater,1,0.5521962642669678
TUDORZA,Worsening of urinary retention,adverse reactions (>= incidence and greater than placebo,1,0.5638009905815125
TUDORZA,Worsening of urinary retention,Immediate Hypersensitivity Reactions,0,0.46431538462638855
TUDORZA,Worsening of urinary retention,and Precautions EXCERPT t common adverse reactions (>= incidence and greater than placebo,1,0.5349185466766357
TUDORZA,hypersensitivity reactions,8 or www.fda.gov/medwatch. Clinical Trials,1,0.4694514274597168
TUDORZA,paradoxical bronchospasm,PRESSAIR at recommended dose,1,0.6088557839393616
TUDORZA,paradoxical bronchospasm,of,0,0.48653608560562134
TUDORZA,paradoxical bronchospasm,the,0,0.4258645176887512
TUDORZA,Immediate hypersensitivity reactions,"N=640)             
                 n n",1,0.43968990445137024
TUDORZA,Immediate hypersensitivity reactions,the,0,0.48659348487854004
TUDORZA,Immediate hypersensitivity reactions,"Term N=640)             
                ",1,0.45314928889274597
TUDORZA,Immediate hypersensitivity reactions,"Term N=640)             
                 n",1,0.4619442820549011
TUDORZA,Immediate hypersensitivity reactions,"Term N=640)             
                 n n",1,0.45915108919143677
TUDORZA,Immediate hypersensitivity reactions,"N=640)             
                 n n Heada",1,0.452047199010849
TUDORZA,Immediate hypersensitivity reactions,"N=640)             
                 n",1,0.4412797689437866
TUDORZA,anaphylaxis,            n,1,0.5308606624603271
TUDORZA,anaphylaxis,N,0,0.5308606624603271
TUDORZA,swelling of the lips,                    ,1,0.5684724450111389
TUDORZA,swelling of the lips,N,0,0.4564788043498993
TUDORZA,swelling of the lips,n,0,0.4564788043498993
TUDORZA,swelling of the lips,                     n Headache,1,0.5025061964988708
JEVTANA,Bone Marrow Suppression,of the Bone,1,0.638108491897583
JEVTANA,Bone Marrow Suppression,Bone Marrow Suppression see,1,0.9862053394317627
JEVTANA,Bone Marrow Suppression,in,0,0.5055801868438721
JEVTANA,Bone Marrow Suppression,of the Bone Marrow Suppression see Warnings and Precautions Hypersensitivity,1,0.8779025077819824
JEVTANA,Bone Marrow Suppression,Warnings,0,0.5365753173828125
JEVTANA,Bone Marrow Suppression,Bone Marrow Suppression see Warnings and Precautions,1,0.9041202068328857
JEVTANA,Bone Marrow Suppression,are discussed in greater detail in another section of,0,0.47423887252807617
JEVTANA,Bone Marrow Suppression,Hypersensitivity Reactions see Warnings and,0,0.5626711845397949
JEVTANA,Bone Marrow Suppression,Reactions,0,0.5519360303878784
JEVTANA,Bone Marrow Suppression,adverse reactions are discussed in greater detail in another section,0,0.5321948528289795
JEVTANA,Hypersensitivity Reactions,Precautions Gastrointestinal,0,0.5643105506896973
JEVTANA,Hypersensitivity Reactions,see Warnings and Hypersensitivity Reactions,1,0.8284075856208801
JEVTANA,Hypersensitivity Reactions,Hypersensitivity Reactions,1,1.0
JEVTANA,Hypersensitivity Reactions,Warnings and Hypersensitivity Reactions,1,0.8339098691940308
JEVTANA,Hypersensitivity Reactions,see Warnings and Hypersensitivity,1,0.7859774231910706
JEVTANA,Hypersensitivity Reactions,Gastrointestinal Adverse Reactions see Warnings,0,0.6553065180778503
JEVTANA,Gastrointestinal Adverse Reactions,Gastrointestinal Adverse Reactions see,1,0.9822663068771362
JEVTANA,Gastrointestinal Adverse Reactions,see Warnings,0,0.6365659236907959
JEVTANA,Gastrointestinal Adverse Reactions,ecautions Hypersensitivity Reactions see Warnings and Precautions,0,0.7041012644767761
JEVTANA,Gastrointestinal Adverse Reactions,Precautions,0,0.5805532336235046
JEVTANA,Gastrointestinal Adverse Reactions,and,0,0.4665977954864502
JEVTANA,Embryo-Fetal Toxicity,in Patients,0,0.475271999835968
JEVTANA,Embryo-Fetal Toxicity,Impairment see Warnings and Embryo-Fetal,1,0.8151798248291016
JEVTANA,Embryo-Fetal Toxicity,Patients with Hepatic Impairment see Warnings and,0,0.5636023283004761
JEVTANA,Embryo-Fetal Toxicity,Most common all grades,0,0.46765804290771484
JEVTANA,Embryo-Fetal Toxicity,Impairment see Warnings and Embryo-Fetal Toxicity see Warnings,1,0.8778983950614929
JEVTANA,Embryo-Fetal Toxicity,Impairment see,0,0.5681415796279907
JEVTANA,Embryo-Fetal Toxicity,Precautions EXCERPT Most common,0,0.49988430738449097
JEVTANA,neutropenia,reactions are,0,0.5060797929763794
JEVTANA,anemia,grades adverse reactions are anemia leukopenia thrombocytopenia diarrhea,1,0.681663990020752
JEVTANA,anemia,reactions are,0,0.544013261795044
JEVTANA,anemia,adverse reactions are anemia leukopenia thrombocytopenia,1,0.7155128717422485
JEVTANA,anemia,anemia leukopenia,1,0.8123772144317627
JEVTANA,anemia,reactions are anemia leukopenia,1,0.7633882164955139
JEVTANA,anemia,reactions are anemia leukopenia thrombocytopenia diarrhea,1,0.6912004947662354
JEVTANA,anemia,reactions are anemia leukopenia thrombocytopenia diarrhea fatigue,1,0.7045079469680786
JEVTANA,anemia,anemia leukopenia thrombocytopenia diarrhea fatigue nausea,1,0.7613462209701538
JEVTANA,leukopenia,leukopenia thrombocytopenia,1,0.8635250329971313
JEVTANA,thrombocytopenia,neutropenia,0,0.699449896812439
JEVTANA,thrombocytopenia,vomiting constipation,0,0.4591051936149597
JEVTANA,thrombocytopenia,thrombocytopenia diarrhea fatigue nausea,1,0.8336455821990967
JEVTANA,thrombocytopenia,are neutropenia anemia thrombocytopenia,1,0.8449857234954834
JEVTANA,thrombocytopenia,neutropenia anemia thrombocytopenia diarrhea fatigue nausea,1,0.7434874773025513
JEVTANA,thrombocytopenia,grades adverse reactions are neutropenia,0,0.6048437356948853
JEVTANA,thrombocytopenia,are neutropenia,0,0.6586247682571411
JEVTANA,thrombocytopenia,fatigue nausea vomiting constipation asthenia abdominal pain,0,0.540486216545105
JEVTANA,thrombocytopenia,thrombocytopenia diarrhea fatigue nausea vomiting,1,0.8336665630340576
JEVTANA,thrombocytopenia,Most common all grades adverse reactions,0,0.5152490139007568
JEVTANA,fatigue,anemia leukopenia thrombocytopenia diarrhea,0,0.5722944736480713
JEVTANA,fatigue,fatigue nausea vomiting constipation,1,0.8055264949798584
JEVTANA,fatigue,leukopenia thrombocytopenia fatigue nausea vomiting constipation,1,0.6534682512283325
JEVTANA,fatigue,fatigue,1,1.0
JEVTANA,fatigue,fatigue nausea vomiting constipation asthenia abdominal,1,0.7775453329086304
JEVTANA,fatigue,neutropenia anemia leukopenia thrombocytopenia fatigue nausea vomiting constipation,1,0.6722686290740967
JEVTANA,fatigue,constipation asthenia,0,0.6254329681396484
JEVTANA,nausea,constipation asthenia abdominal pain hematuria back pain anorexia,0,0.619434118270874
JEVTANA,nausea,nausea vomiting constipation asthenia abdominal pain,1,0.7955789566040039
JEVTANA,nausea,anemia leukopenia thrombocytopenia diarrhea nausea vomiting,1,0.7266125679016113
JEVTANA,vomiting,vomiting constipation asthenia,1,0.835193932056427
JEVTANA,vomiting,vomiting constipation asthenia abdominal pain,1,0.8055009841918945
JEVTANA,vomiting,neutropenia anemia leukopenia thrombocytopenia diarrhea fatigue nausea,0,0.6147428154945374
JEVTANA,vomiting,anemia leukopenia thrombocytopenia,0,0.5202808976173401
JEVTANA,vomiting,vomiting constipation asthenia abdominal,1,0.8237531781196594
JEVTANA,vomiting,vomiting constipation,1,0.8638814687728882
JEVTANA,vomiting,vomiting constipation asthenia abdominal pain hematuria,1,0.767643392086029
JEVTANA,constipation,constipation asthenia abdominal,1,0.7940489649772644
JEVTANA,constipation,constipation asthenia,1,0.8350676894187927
JEVTANA,constipation,nausea constipation asthenia abdominal pain hematuria,1,0.7494409084320068
JEVTANA,constipation,constipation asthenia abdominal pain hematuria,1,0.7873910069465637
JEVTANA,constipation,nausea constipation,1,0.8485351800918579
JEVTANA,constipation,asthenia abdominal pain hematuria back pain anorexia peripheral,0,0.6572883129119873
JEVTANA,constipation,back pain anorexia peripheral neuropathy pyrexia,0,0.5931329727172852
JEVTANA,constipation,constipation,1,1.0
JEVTANA,constipation,constipation asthenia abdominal pain,1,0.8003224730491638
JEVTANA,asthenia,nausea vomiting asthenia abdominal pain hematuria back pain,1,0.6646624803543091
JEVTANA,asthenia,constipation asthenia abdominal pain,1,0.714921236038208
JEVTANA,asthenia,asthenia abdominal pain hematuria back,1,0.7577512860298157
JEVTANA,asthenia,vomiting,0,0.5399789214134216
JEVTANA,asthenia,asthenia abdominal pain,1,0.8269996047019958
JEVTANA,asthenia,asthenia abdominal,1,0.81001216173172
JEVTANA,asthenia,asthenia abdominal pain hematuria back pain,1,0.7633463144302368
JEVTANA,abdominal pain,thrombocytopenia diarrhea fatigue nausea vomiting constipation asthenia,0,0.6313887238502502
JEVTANA,hematuria,hematuria back pain anorexia peripheral,1,0.8060204982757568
JEVTANA,hematuria,diarrhea fatigue nausea vomiting constipation asthenia abdominal,0,0.5609476566314697
JEVTANA,hematuria,anorexia peripheral neuropathy pyrexia dyspnea dysgeusia cough arthralgia,0,0.5029242038726807
JEVTANA,back pain,asthenia abdominal pain back,1,0.7750403881072998
JEVTANA,back pain,constipation asthenia abdominal pain back pain anorexia peripheral neuropathy pyrexia dyspnea,1,0.6751747131347656
JEVTANA,back pain,pyrexia dyspnea dysgeusia cough arthralgia and,0,0.5557408332824707
JEVTANA,back pain,neuropathy pyrexia dyspnea dysgeusia,0,0.5077144503593445
JEVTANA,back pain,abdominal pain back pain anorexia peripheral,1,0.7512716054916382
JEVTANA,anorexia,anorexia,1,1.0
JEVTANA,anorexia,fatigue nausea,0,0.5794488787651062
JEVTANA,anorexia,fatigue nausea vomiting constipation asthenia,0,0.6741915941238403
JEVTANA,anorexia,anorexia peripheral,1,0.825499415397644
JEVTANA,anorexia,pyrexia,0,0.6030768156051636
JEVTANA,peripheral neuropathy,back pain anorexia,0,0.5169245004653931
JEVTANA,peripheral neuropathy,cough arthralgia and alopecia,0,0.5228748321533203
JEVTANA,peripheral neuropathy,hematuria back pain peripheral neuropathy,1,0.8050011396408081
JEVTANA,peripheral neuropathy,pain peripheral neuropathy pyrexia dyspnea,1,0.7919564247131348
JEVTANA,peripheral neuropathy,abdominal pain hematuria back pain,0,0.5398340821266174
JEVTANA,peripheral neuropathy,peripheral neuropathy pyrexia dyspnea dysgeusia cough arthralgia,1,0.8022576570510864
JEVTANA,peripheral neuropathy,back pain peripheral neuropathy pyrexia dyspnea,1,0.7601213455200195
JEVTANA,peripheral neuropathy,dysgeusia cough arthralgia and alopecia To report,0,0.5352741479873657
JEVTANA,pyrexia,and alopecia,0,0.5202113389968872
JEVTANA,pyrexia,pain hematuria,0,0.5369160771369934
JEVTANA,pyrexia,To report,0,0.5053576827049255
JEVTANA,pyrexia,peripheral,0,0.54638671875
JEVTANA,pyrexia,pyrexia dyspnea dysgeusia cough arthralgia and,1,0.8094671964645386
JEVTANA,pyrexia,peripheral pyrexia,1,0.8808008432388306
JEVTANA,pyrexia,arthralgia and alopecia To,0,0.5632849931716919
JEVTANA,pyrexia,pyrexia dyspnea,1,0.8428323864936829
JEVTANA,pyrexia,SUSPECTED,0,0.49647918343544006
JEVTANA,pyrexia,alopecia To,0,0.5059045553207397
JEVTANA,dyspnea,arthralgia and alopecia,0,0.5208770036697388
JEVTANA,dyspnea,pain,0,0.6137456297874451
JEVTANA,dyspnea,asthenia abdominal pain hematuria back pain anorexia,0,0.5341815948486328
JEVTANA,dyspnea,dyspnea dysgeusia cough arthralgia and,1,0.8238162994384766
JEVTANA,dyspnea,dyspnea dysgeusia cough arthralgia and alopecia,1,0.7916797399520874
JEVTANA,dyspnea,dyspnea dysgeusia,1,0.8186730146408081
JEVTANA,dysgeusia,pain hematuria back pain anorexia peripheral,0,0.5550332069396973
JEVTANA,dysgeusia,REACTIONS,0,0.5330706834793091
JEVTANA,dysgeusia,neuropathy pyrexia dyspnea,0,0.6284531354904175
JEVTANA,dysgeusia,dysgeusia cough arthralgia and,1,0.8280699253082275
JEVTANA,dysgeusia,dysgeusia,1,1.0000001192092896
JEVTANA,dysgeusia,pyrexia dyspnea,0,0.634215235710144
JEVTANA,dysgeusia,peripheral neuropathy pyrexia dyspnea,0,0.6057602167129517
JEVTANA,dysgeusia,report SUSPECTED ADVERSE,0,0.5515912771224976
JEVTANA,cough,REACTIONS contact,0,0.5254197716712952
JEVTANA,cough,cough arthralgia and,1,0.8297725915908813
JEVTANA,cough,pyrexia dyspnea cough arthralgia,1,0.7743254899978638
JEVTANA,cough,cough arthralgia and alopecia,1,0.7549124956130981
JEVTANA,cough,cough arthralgia and alopecia To report,1,0.7432529330253601
JEVTANA,cough,and alopecia To,0,0.5226176381111145
JEVTANA,cough,cough arthralgia and alopecia To,1,0.7727721929550171
JEVTANA,cough,pyrexia dyspnea,0,0.6507239937782288
JEVTANA,cough,peripheral neuropathy pyrexia dyspnea cough,1,0.7114647030830383
JEVTANA,arthralgia,arthralgia and alopecia To report SUSPECTED,1,0.7870439887046814
JEVTANA,alopecia,alopecia To report SUSPECTED ADVERSE,1,0.8291671276092529
JEVTANA,alopecia,arthralgia and alopecia To report SUSPECTED,1,0.7959877252578735
JEVTANA,alopecia,peripheral neuropathy pyrexia,0,0.5145527720451355
JEVTANA,alopecia,To report SUSPECTED ADVERSE REACTIONS contact sanofiaventis,0,0.5378952026367188
JEVTANA,alopecia,US,0,0.5052621364593506
JEVTANA,alopecia,alopecia To report SUSPECTED,1,0.8477494120597839
JEVTANA,Deaths,plus prednisone,0,0.5190374851226807
JEVTANA,Deaths,treated in a single randomized trial compared to,0,0.4755309820175171
JEVTANA,Deaths,disease progression within days of last study drug,0,0.5292232036590576
JEVTANA,Deaths,to mitoxantrone plus Deaths due to causes other,1,0.6869925856590271
JEVTANA,fatal,n,0,0.5532088279724121
JEVTANA,fatal,most fatal adverse reactions in JEVTANAtreated,1,0.6667729616165161
JEVTANA,fatal,fatal adverse reactions in,1,0.7593940496444702
JEVTANA,fatal,common,0,0.5453147888183594
JEVTANA,fatal,failure n The ma,0,0.5895376205444336
JEVTANA,fatal,fatal adverse reactions in JEVTANAtreated,1,0.6727104187011719
JEVTANA,infections,infections n and renal,1,0.7713443040847778
JEVTANA,renal failure,patients were infections n and,0,0.5436322689056396
JEVTANA,renal failure,n,0,0.538683295249939
JEVTANA,renal failure,JEVTANAtreated,0,0.5243923664093018
JEVTANA,renal failure,patients were infections n renal failure n The,1,0.8019826412200928
JEVTANA,fatal,infections n and renal failure n The majority,0,0.5320171117782593
JEVTANA,fatal,patients fatal infectionrelated adverse reactions occurred,1,0.6869915127754211
JEVTANA,fatal,fatal infectionrelated,1,0.7649058699607849
JEVTANA,fatal,renal failure n The majority of,0,0.5712865591049194
JEVTANA,fatal,fatal infectionrelated adverse,1,0.7530527114868164
JEVTANA,fatal,patients fatal infectionrelated,1,0.7199000120162964
JEVTANA,fatal,fatal infectionrelated adverse reactions,1,0.7153594493865967
JEVTANA,fatal,of patients fatal infectionrelated adverse,1,0.7027181386947632
JEVTANA,fatal,fatal,1,1.0000001192092896
JEVTANA,fatal,dose of JEVTANA Other fatal adverse re,0,0.6828190088272095
JEVTANA,fatal,fatal adverse,1,0.8618949055671692
JEVTANA,fatal,after a,0,0.5074662566184998
JEVTANA,fatal,included ventricular fibrillation cerebral hemorrhag,0,0.5884718894958496
JEVTANA,ventricular fibrillation,reactions in JEVTANAtreated patients ventricular fibrillation cerebral hemorrhage and dyspnea,1,0.7998096346855164
JEVTANA,ventricular fibrillation,fatal adverse,1,0.5548344254493713
JEVTANA,ventricular fibrillation,in JEVTANAtreated patients included,0,0.5421649217605591
JEVTANA,ventricular fibrillation,adverse reactions,0,0.529261589050293
JEVTANA,ventricular fibrillation,cerebral hemorrhage and dyspnea,0,0.6080900430679321
JEVTANA,ventricular fibrillation,dyspnea,0,0.583486795425415
JEVTANA,cerebral hemorrhage,cerebral hemorrhage,1,1.000000238418579
JEVTANA,cerebral hemorrhage,cerebral hemorrhage and dyspnea The,1,0.8388105630874634
JEVTANA,cerebral hemorrhage,included ventricular cerebral hemorrhage and,1,0.8568633794784546
JEVTANA,cerebral hemorrhage,cerebral,1,0.7491788864135742
JEVTANA,cerebral hemorrhage,cerebral hemorrhage and dyspnea The most common,1,0.8132800459861755
JEVTANA,dyspnea,e,0,0.5366429090499878
JEVTANA,dyspnea,cerebral hemorrhage and,0,0.5375409126281738
JEVTANA,dyspnea,ventricular fibrillation cerebral,0,0.527590811252594
JEVTANA,dyspnea,hemorrhage dyspnea The most common grade adverse,1,0.7912243604660034
JEVTANA,dyspnea,fibrillation cerebral hemorrhage dyspnea The,1,0.7729724645614624
JEVTANA,dyspnea,hemorrhage dyspnea The,1,0.8628638982772827
JEVTANA,dyspnea,dyspnea The most common grade,1,0.8315025568008423
JEVTANA,dyspnea,hemorrhage dyspnea,1,0.8727731108665466
JEVTANA,anemia,neutropenia thrombocytopenia diarrhea fatigue,0,0.650201678276062
JEVTANA,anemia,adverse,0,0.5440919399261475
JEVTANA,anemia,anemia leukopenia neutropenia thrombocytopenia diarrhea,1,0.7453793883323669
JEVTANA,anemia,anemia leukopenia neutropenia,1,0.8041319847106934
JEVTANA,leukopenia,grade adverse reactions were leukopenia neutropenia thrombocytopenia diarrhea fatigue,1,0.7247649431228638
JEVTANA,leukopenia,anemia leukopenia neutropenia,1,0.8468547463417053
JEVTANA,leukopenia,leukopenia neutropenia thrombocytopenia diarrhea,1,0.8300655484199524
JEVTANA,leukopenia,most common grade adverse reactions were anemia,0,0.5905861854553223
JEVTANA,leukopenia,leukopenia neutropenia thrombocytopenia diarrhea fatigue nausea,1,0.8309528827667236
JEVTANA,leukopenia,grade adverse reactions were anemia,0,0.5993540287017822
JEVTANA,leukopenia,leukopenia neutropenia thrombocytopenia diarrhea fatigue,1,0.8199089765548706
JEVTANA,leukopenia,leukopenia neutropenia,1,0.9149845838546753
JEVTANA,neutropenia,neutropenia thrombocytopenia,1,0.8478608131408691
JEVTANA,thrombocytopenia,leukopenia thrombocytopenia diarrhea fatigue,1,0.7308240532875061
JEVTANA,thrombocytopenia,neutropenia thrombocytopenia,1,0.9027583003044128
JEVTANA,thrombocytopenia,leukopenia neutropenia,0,0.6395708322525024
JEVTANA,thrombocytopenia,abdominal pain hematuria,0,0.5605058670043945
JEVTANA,diarrhea,diarrhea fatigue nausea vomiting constipation,1,0.804045557975769
JEVTANA,diarrhea,grade adverse reactions,0,0.5744153261184692
JEVTANA,diarrhea,reactions were,0,0.5469532012939453
JEVTANA,diarrhea,diarrhea,1,0.9999999403953552
JEVTANA,fatigue,anemia leukopenia,0,0.552216649055481
JEVTANA,fatigue,neutropenia thrombocytopenia diarrhea,0,0.5205497741699219
JEVTANA,nausea,nausea,1,1.0
JEVTANA,nausea,leukopenia neutropenia thrombocytopenia diarrhea nausea vomiting constipation,1,0.6954482793807983
JEVTANA,nausea,neutropenia thrombocytopenia diarrhea nausea vomiting,1,0.7381230592727661
JEVTANA,nausea,back pain anorexia peripheral,0,0.5377722382545471
JEVTANA,nausea,were anemia leukopenia neutropenia thrombocytopenia,0,0.5605551600456238
JEVTANA,nausea,nausea vomiting constipation,1,0.82795250415802
JEVTANA,nausea,nausea vomiting constipation asthenia abdominal,1,0.8003418445587158
JEVTANA,nausea,thrombocytopenia diarrhea fatigue,0,0.6362184286117554
JEVTANA,nausea,nausea vomiting,1,0.9235453605651855
JEVTANA,vomiting,diarrhea fatigue vomiting constipation asthenia abdominal pain,1,0.6894549131393433
JEVTANA,vomiting,neutropenia thrombocytopenia,0,0.511048436164856
JEVTANA,vomiting,diarrhea fatigue,0,0.5627238750457764
JEVTANA,vomiting,anorexia peripheral neuropathy pyr,0,0.574468731880188
JEVTANA,constipation,diarrhea fatigue nausea constipation asthenia abdominal pain,1,0.7383861541748047
JEVTANA,constipation,diarrhea fatigue nausea constipation asthenia abdominal pain hematuria back,1,0.7262735366821289
JEVTANA,constipation,back pain anorexia peripheral neuropathy,0,0.5965968370437622
JEVTANA,constipation,anemia leukopenia,0,0.44921183586120605
JEVTANA,constipation,were anemia leukopenia neutropenia thrombocytopenia,0,0.4800049960613251
JEVTANA,asthenia,asthenia,1,1.0000001192092896
JEVTANA,asthenia,pain anorexia peripheral neuropathy pyrexia dyspnea,0,0.6228262782096863
JEVTANA,asthenia,nausea vomiting asthenia abdominal pain hematuria back,1,0.6689368486404419
JEVTANA,asthenia,thrombocytopenia diarrhea fatigue nausea vomiting constipation,0,0.5935978889465332
JEVTANA,asthenia,peripheral neuropathy,0,0.528841495513916
JEVTANA,asthenia,diarrhea fatigue nausea vomiting asthenia abdominal pain hematuria,1,0.636858344078064
JEVTANA,asthenia,diarrhea fatigue nausea vomiting,0,0.5473313331604004
JEVTANA,hematuria,hematuria back pain,1,0.8608982563018799
JEVTANA,hematuria,hematuria back,1,0.8986773490905762
JEVTANA,hematuria,pain,0,0.5417877435684204
JEVTANA,hematuria,neuropathy pyrexia dyspnea dysguesia cough arthralgia,0,0.5320316553115845
JEVTANA,hematuria,hematuria,1,1.0
JEVTANA,hematuria,asthenia abdominal hematuria back pain anorexia,1,0.7582910060882568
JEVTANA,back pain,ocytopenia diarrhea fatigue nausea vomiting constipation,0,0.5195164680480957
JEVTANA,back pain,constipation asthenia abdominal pain back pain,1,0.7797502279281616
JEVTANA,back pain,ocytopenia diarrhea fatigue nausea,0,0.5154255032539368
JEVTANA,back pain,pain back pain,1,0.9696731567382812
JEVTANA,back pain,abdominal,0,0.5411316156387329
JEVTANA,back pain,back pain anorexia peripheral neuropathy pyrexia dyspnea,1,0.6864742040634155
JEVTANA,anorexia,pain,0,0.5658106207847595
JEVTANA,anorexia,back anorexia,1,0.8563717603683472
JEVTANA,anorexia,constipation asthenia abdominal pain,0,0.5945006012916565
JEVTANA,anorexia,neuropathy pyrexia dyspnea dysguesia cough arthralgia and,0,0.6071722507476807
JEVTANA,peripheral neuropathy,asthenia abdominal pain hematuria back pain,0,0.5694973468780518
JEVTANA,peripheral neuropathy,peripheral neuropathy pyrexia dyspnea,1,0.800818920135498
JEVTANA,peripheral neuropathy,peripheral neuropathy pyrexia dyspnea dysguesia cough,1,0.8142324686050415
JEVTANA,pyrexia,anorexia peripheral pyrexia dyspnea dysguesia cough,1,0.7419179677963257
JEVTANA,pyrexia,peripheral neuropathy pyrexia dyspnea dysguesia cough,1,0.6978746056556702
JEVTANA,pyrexia,pyrexia dyspnea dysguesia,1,0.822655975818634
JEVTANA,pyrexia,peripheral pyrexia dyspnea dysguesia cough,1,0.8029307126998901
JEVTANA,pyrexia,hematuria back pain anorexia peripheral,0,0.5837833285331726
JEVTANA,pyrexia,pyrexia dyspnea dysguesia cough,1,0.8263957500457764
JEVTANA,pyrexia,neuropathy,0,0.5295626521110535
JEVTANA,pyrexia,ing constipation asthenia abdominal pain,0,0.5490926504135132
JEVTANA,dyspnea,dyspnea dysguesia cough,1,0.85917067527771
JEVTANA,dyspnea,neuropathy dyspnea dysguesia cough arthralgia and alopecia,1,0.7155800461769104
JEVTANA,dyspnea,and alopecia The most common grade adverse,0,0.5307146906852722
JEVTANA,dyspnea,dyspnea dysguesia cough arthralgia,1,0.8548616170883179
JEVTANA,dyspnea,dyspnea dysguesia,1,0.8762943148612976
JEVTANA,dyspnea,grade adverse reaction,0,0.5492466688156128
JEVTANA,dyspnea,abdominal,0,0.5499125719070435
JEVTANA,dyspnea,asthenia abdominal,0,0.5208220481872559
JEVTANA,dyspnea,pain hematuria back,0,0.5114960670471191
JEVTANA,dysguesia,dysguesia cough arthralgia and alopecia The,1,0.758305013179779
JEVTANA,dysguesia,abdominal pain hematuria back pain anorexia peripheral neuropathy pyrexia dyspnea,0,0.5641601085662842
JEVTANA,dysguesia,grade adverse reactions in patien,0,0.5253703594207764
JEVTANA,dysguesia,back pain,0,0.45662721991539
JEVTANA,cough,hematuria back,0,0.5021536946296692
JEVTANA,cough,abdominal pain hematuria back pain anorexia peripheral,0,0.5227878093719482
JEVTANA,cough,pyrexia dyspnea cough arthralgia and,1,0.7676061391830444
JEVTANA,cough,pyrexia,0,0.6231146454811096
JEVTANA,cough,pain hematuria back pain anorexia peripheral neuropathy pyrexia dyspnea dysguesia,0,0.5607854723930359
JEVTANA,cough,cough arthralgia,1,0.8342176675796509
JEVTANA,cough,most common grade adverse reactions,0,0.541675329208374
JEVTANA,arthralgia,arthralgia,1,1.0
JEVTANA,arthralgia,most common,0,0.4867054522037506
JEVTANA,arthralgia,dysguesia arthralgia and alopecia The,1,0.7785379886627197
JEVTANA,arthralgia,peripheral neuropathy,0,0.539757251739502
JEVTANA,arthralgia,arthralgia and alopecia The most common,1,0.7924648523330688
JEVTANA,arthralgia,neuropathy pyrexia dyspnea dysguesia arthralgia and alopecia The most,1,0.6709488034248352
JEVTANA,arthralgia,arthralgia and alopecia The most,1,0.8083950877189636
JEVTANA,neutropenia,JEVTANA neutropenia leukopenia anemia febrile neutropenia diarrhea,1,0.7803716659545898
JEVTANA,neutropenia,arthralgia and alopecia The most common,1,0.5533976554870605
JEVTANA,neutropenia,asthenia,0,0.5753526091575623
JEVTANA,neutropenia,anemia febrile neutropenia,0,0.8299453258514404
JEVTANA,neutropenia,neutropenia leukopenia anemia febrile neutropenia,1,0.8347690105438232
JEVTANA,neutropenia,received JEVTANA neutropenia leukopenia anemia,1,0.8077961206436157
JEVTANA,neutropenia,anemia febrile neutropenia diarrhea fatigue and,0,0.7605994939804077
JEVTANA,neutropenia,ecia The most common grade,0,0.4782520830631256
JEVTANA,neutropenia,patients who received JEVTANA neutropenia leukopenia,1,0.762999951839447
JEVTANA,leukopenia,diarrhea fatigue and asthenia,0,0.5618228912353516
JEVTANA,leukopenia,leukopenia anemia febrile neutropenia diarrhea,1,0.8231950998306274
JEVTANA,leukopenia,leukopenia anemia,1,0.9205602407455444
JEVTANA,leukopenia,diarrhea fatigue and,0,0.5435459017753601
JEVTANA,leukopenia,leukopenia anemia febrile neutropenia,1,0.8277038931846619
JEVTANA,anemia,discontinuations due to,0,0.5374895930290222
JEVTANA,anemia,were neutropenia anemia febrile neutropenia,1,0.7153170108795166
JEVTANA,anemia,JEVTANA were neutropenia leukopenia,0,0.6301791667938232
JEVTANA,anemia,febrile neutropenia diarrhea fatigue and asthenia Treatment discontinuations,0,0.6224361658096313
JEVTANA,anemia,asthenia Treatment discontinuations due to,0,0.568352997303009
JEVTANA,febrile neutropenia,who received JEVTANA were neutropenia leukopenia anemia,0,0.7034575939178467
JEVTANA,febrile neutropenia,febrile neutropenia,1,1.0000001192092896
JEVTANA,febrile neutropenia,febrile neutropenia diarrhea fatigue and,1,0.8346314430236816
JEVTANA,diarrhea,due to adverse,0,0.5863628387451172
JEVTANA,diarrhea,discontinuations due,0,0.5160828828811646
JEVTANA,diarrhea,anemia,0,0.5841463804244995
JEVTANA,diarrhea,anemia febrile diarrhea fatigue and,1,0.7292922139167786
JEVTANA,diarrhea,diarrhea fatigue and asthenia Treatment,1,0.7286182641983032
JEVTANA,diarrhea,diarrhea fatigue,1,0.8042935729026794
JEVTANA,diarrhea,were neutropenia leukopenia anemia febrile,0,0.5544664859771729
JEVTANA,fatigue,JEVTANA were neutropenia leukopenia,0,0.5365515947341919
JEVTANA,fatigue,fatigue and asthenia,1,0.8662711381912231
JEVTANA,fatigue,JEVTANA were neutropenia leukopenia anemia febrile neutropenia diarrhea,0,0.5579675436019897
JEVTANA,fatigue,neutropenia fatigue and asthenia,1,0.7649485468864441
JEVTANA,fatigue,discontinuations due to adverse,0,0.5800893902778625
JEVTANA,fatigue,patients who,0,0.5412501096725464
JEVTANA,fatigue,fatigue and asthenia Treatment discontinuations due,1,0.7576888799667358
JEVTANA,fatigue,febrile neutropenia fatigue,1,0.787307858467102
JEVTANA,asthenia,asthenia Treatment discontinuations,1,0.7853472828865051
JEVTANA,asthenia,neutropenia diarrhea fatigue asthenia Treatment discontinuations due to adverse,1,0.711872398853302
JEVTANA,asthenia,and,0,0.5410805344581604
JEVTANA,asthenia,asthenia Treatment discontinuations due to adverse,1,0.7677262425422668
JEVTANA,asthenia,neutropenia,0,0.5753526091575623
JEVTANA,asthenia,asthenia Treatment discontinuations due to,1,0.7856957912445068
JEVTANA,renal failure,JEVTANAtreated patients,0,0.5610837936401367
JEVTANA,renal failure,JEVTANA group were neutropenia renal,1,0.669066846370697
JEVTANA,renal failure,were reported in of JEVTANAtreated patients and of mitoxantronetreated pa,0,0.5547298789024353
JEVTANA,renal failure,patients and,0,0.551500141620636
JEVTANA,Hematologic Abnormalities,Hematologic,1,0.8821858167648315
JEVTANA,Hematologic Abnormalities,or Mitoxantrone,0,0.5602588057518005
JEVTANA,Hematologic Abnormalities,Hematologic Abnormalities in of Patients Receiving,1,0.8953837156295776
JEVTANA,Hematologic Abnormalities,Combination with,0,0.5089277029037476
JEVTANA,Hematologic Abnormalities,patients,0,0.5333606004714966
JEVTANA,Hematologic Abnormalities,JEVTANA in Combination with Prednisone or Mitoxantrone in Combinatio,0,0.5982913970947266
JEVTANA,Hematologic Abnormalities,using NCI CTCAE version and,0,0.45729538798332214
JEVTANA,infectious adverse events,infectious adverse events,1,1.0
JEVTANA,infectious adverse events,using NCI CTCAE version and,0,0.5268263816833496
JEVTANA,infectious adverse events,or septic shock All had grade,0,0.5869943499565125
JEVTANA,infectious adverse events,Five patients experienced infectious,1,0.7311156988143921
JEVTANA,sepsis,One,0,0.5745940208435059
JEVTANA,sepsis,Associated Clinical Events Five patients experienced fatal infectious adverse events,0,0.622361421585083
JEVTANA,sepsis,sepsis or septic shock All had,1,0.8435615301132202
JEVTANA,neutropenia,neutropenia and,1,0.938434362411499
JEVTANA,neutropenia,death,0,0.5374757051467896
JEVTANA,neutropenia,adverse events sepsis or septic shock,0,0.5710166692733765
JEVTANA,febrile neutropenia,neutropenia and one febrile,1,0.915258526802063
JEVTANA,febrile neutropenia,One additional patients,0,0.5176599621772766
JEVTANA,death,neutropenia One additional death was attributed,1,0.6751339435577393
JEVTANA,death,One additional patients,0,0.48723891377449036
JEVTANA,death,infection Twentytwo,0,0.5262448787689209
JEVTANA,death,One additional,0,0.550091028213501
JEVTANA,death,neutropenia One additional,0,0.5394421815872192
JEVTANA,death,neutropenia,0,0.5374757051467896
JEVTANA,death,death was attributed,1,0.8010717630386353
JEVTANA,death,death was attributed to neutropenia without,1,0.6634545922279358
JEVTANA,death,death was,1,0.9069555401802063
JEVTANA,death,infection Twentytwo patients discontinued,0,0.4882243871688843
JEVTANA,death,death was attributed to,1,0.7714152932167053
JEVTANA,infection,infection Twentytwo patients,1,0.7603079080581665
JEVTANA,infection,neutropenia febrile neutropenia i,0,0.5998281836509705
JEVTANA,infection,neutropenia without a infection Twentytwo patients discontinued,1,0.5871759653091431
JEVTANA,infection,infection Twentytwo patients discontinued JEVTANA,1,0.6407308578491211
JEVTANA,infection,attributed to neutropenia without a documented,0,0.579175591468811
JEVTANA,infection,infection Twentytwo patients discontinued,1,0.6583411693572998
JEVTANA,infection,neutropenia One additional patients death was attributed to neutropenia without a documented,0,0.542725682258606
JEVTANA,infection,One additional patients death was attributed,0,0.5309455394744873
JEVTANA,neutropenia,neutropenia febrile neutropenia infection or,1,0.8303689956665039
JEVTANA,neutropenia,neutropenia febrile,1,0.8528774976730347
JEVTANA,neutropenia,neutropenia infection or sepsis The most common adverse reaction leading to treatment d,0,0.7492919564247131
JEVTANA,neutropenia,neutropenia,1,1.0
JEVTANA,neutropenia,reaction leading,0,0.4849368929862976
JEVTANA,neutropenia,neutropenia febrile neutropenia infection,1,0.833338737487793
JEVTANA,neutropenia,neutropenia infection or sepsis The most common adverse reaction leading to,0,0.7599368095397949
JEVTANA,neutropenia,patients discontinued,0,0.4712021052837372
JEVTANA,febrile neutropenia,febrile neutropenia infection or,1,0.937679648399353
JEVTANA,febrile neutropenia,treatment due to febrile neutropenia,1,0.9039871096611023
JEVTANA,febrile neutropenia,leading,0,0.4557519257068634
JEVTANA,febrile neutropenia,treatment due to febrile neutropenia infection,1,0.8940660953521729
JEVTANA,febrile neutropenia,JEVTANA,0,0.4797065854072571
JEVTANA,febrile neutropenia,to neutropenia,0,0.8361972570419312
JEVTANA,infection,infection or,1,0.9036926031112671
JEVTANA,infection,neutropenia febrile infection or,1,0.7176477909088135
JEVTANA,infection,febrile infection,1,0.7995361089706421
JEVTANA,infection,leading to treatment discontinuation in the,0,0.5130183696746826
JEVTANA,infection,febrile neutropenia,0,0.6385393142700195
JEVTANA,infection,The most common adverse reaction leading,0,0.5957083702087402
JEVTANA,sepsis,neutropenia febrile neutropenia infection sepsis,1,0.7904505729675293
JEVTANA,sepsis,The most common adverse reaction leading,0,0.5669097900390625
JEVTANA,sepsis,neutropenia infection sepsis The,1,0.8342133164405823
JEVTANA,hematuria,including those requiring medical intervention were more common,0,0.5282595753669739
JEVTANA,hematuria,hematuria including those requiring,1,0.9082335233688354
JEVTANA,hematuria,neutropenia Hematuria Adverse events hematuria,1,0.8214207291603088
JEVTANA,hematuria,neutropenia Hematuria Adverse events hematuria including,1,0.8168426752090454
JEVTANA,hematuria,hematuria including those requiring medical intervention,1,0.8889577388763428
JEVTANA,hematuria,the JEVTANA group was neutropenia Hematuria Adverse,0,0.7236867547035217
JEVTANA,hematuria,events hematuria including those,1,0.8652443885803223
JEVTANA,hematuria,Hematuria Adverse events hematuria including those requiring medical,1,0.8544514179229736
JEVTANA,hematuria,hematuria was in JEVTANAtreated patients and,1,0.876343846321106
JEVTANA,hematuria,medical intervention,0,0.5254324674606323
JEVTANA,hematuria,hematuria was in JEVTANAtreated patients,1,0.8767597675323486
JEVTANA,hematuria,hematuria were wellbalanced between arms and,1,0.8399693965911865
JEVTANA,hematuria,and do not account for the increased,0,0.4530494809150696
JEVTANA,hematuria,JEVTANAtreated patients and in mitoxantronetreated patients Other factors associated with,0,0.5276708006858826
JEVTANA,hematuria,hematuria were wellbalanced between,1,0.8936187028884888
JEVTANA,hematuria,hematuria on the,1,0.9611940383911133
JEVTANA,hematuria,Laboratory Abnormalities The incidences of grade,0,0.5616317987442017
JEVTANA,hematuria,rate,0,0.5324727296829224
JEVTANA,increased AST,increased AST increased ALT and increased,1,0.9373762607574463
JEVTANA,increased AST,rate,0,0.580690324306488
JEVTANA,increased ALT,AST,0,0.5727646350860596
JEVTANA,increased ALT,incidences of grade increased increased,1,0.6797423362731934
JEVTANA,increased ALT,increased ALT and increased bilirubin were,1,0.7834943532943726
JEVTANA,increased ALT,increased increased ALT,1,0.9900727868080139
JEVTANA,increased ALT,grade increased increased ALT,1,0.8448700308799744
JEVTANA,increased ALT,increased ALT,1,1.0
JEVTANA,increased ALT,incidences of,0,0.5390920639038086
JEVTANA,increased ALT,Elderly Population The following,0,0.5113485455513
JEVTANA,increased bilirubin,ALT,0,0.5410916805267334
JEVTANA,increased bilirubin,following grade adverse reactions were,0,0.581119954586029
JEVTANA,increased bilirubin,Hepatic Laboratory Abnormalities The incidences of,0,0.6733246445655823
JEVTANA,asthenia,asthenia vs pyrexia vs dizziness,1,0.7550826668739319
JEVTANA,pyrexia,tract infection vs,0,0.56483393907547
JEVTANA,pyrexia,neutropenia vs asthenia pyrexia vs dizziness vs,1,0.7510454654693604
JEVTANA,pyrexia,vs neutropenia vs asthenia pyrexia vs dizziness vs,1,0.7515727281570435
JEVTANA,dizziness,infection vs and dehydration,0,0.5751066207885742
JEVTANA,dizziness,urinary tract infection vs,0,0.506066083908081
JEVTANA,dizziness,dizziness vs urinary tract infection,1,0.8042563199996948
JEVTANA,urinary tract infection,urinary tract infection vs and dehydration,1,0.8174425363540649
JEVTANA,urinary tract infection,dizziness urinary,1,0.6911044120788574
JEVTANA,urinary tract infection,and,0,0.5330232381820679
JEVTANA,urinary tract infection,vs,0,0.49372315406799316
JEVTANA,urinary tract infection,and dehydration vs respectively The incidence of,0,0.5940512418746948
JEVTANA,urinary tract infection,vs pyrexia vs dizziness urinary,1,0.6960972547531128
JEVTANA,urinary tract infection,respectively The incidence of,0,0.5613582134246826
JEVTANA,urinary tract infection,tract infection vs and,1,0.7497074007987976
JEVTANA,urinary tract infection,urinary tract infection,1,1.000000238418579
JEVTANA,dehydration,dehydration vs respectively The incidence of,1,0.8413640260696411
JEVTANA,dehydration,dehydration vs respectively The,1,0.8933273553848267
JEVTANA,dehydration,adverse reactions were high,0,0.5592272281646729
JEVTANA,dehydration,the following grade adverse reactions,0,0.5662668943405151
JEVTANA,dehydration,dehydration vs respectively The incidence,1,0.8409230709075928
JEVTANA,dehydration,vs respectively The incidence,0,0.5358695983886719
JEVTANA,dehydration,following grade adverse,0,0.5197144150733948
JEVTANA,dehydration,tract infection vs,0,0.5251655578613281
JEVTANA,neutropenia,neutropenia vs,1,0.9198790788650513
JEVTANA,neutropenia,Use in,0,0.5149027109146118
JEVTANA,neutropenia,vs see,0,0.4871196150779724
JEVTANA,neutropenia,compared to younger neutropenia vs and febrile neutropenia,1,0.8249174952507019
JEVTANA,neutropenia,neutropenia vs and,1,0.8802570104598999
JEVTANA,neutropenia,higher in patients years of age compared,0,0.5178716778755188
JEVTANA,febrile neutropenia,patients neutropenia vs febrile,1,0.8973483443260193
JEVTANA,febrile neutropenia,Use,0,0.5130497217178345
JEVTANA,febrile neutropenia,neutropenia vs febrile,1,0.9184155464172363
JEVTANA,febrile neutropenia,febrile neutropenia vs see Use,1,0.8644629716873169
JEVTANA,febrile neutropenia,vs febrile neutropenia,1,0.9351258277893066
JEVTANA,febrile neutropenia,Postmarketing Experience Th,0,0.4863417446613312
JEVTANA,febrile neutropenia,Specific Populations,0,0.522862434387207
JEVTANA,febrile neutropenia,younger patients neutropenia vs febrile neutropenia,1,0.8698229789733887
JEVTANA,Gastritis,Gastritis,1,1.000000238418579
JEVTANA,NEUTROPENIA, following ,1,0.4862444996833801
JEVTANA,NEUTROPENIA, following  serious adverse reactions are,1,0.5184057950973511
JEVTANA,NEUTROPENIA,REACTIONS  following  serious adverse,1,0.5195297598838806
JEVTANA,NEUTROPENIA,in greater detail in another,0,0.4705258905887604
JEVTANA,NEUTROPENIA, following  serious,1,0.4951971769332886
JEVTANA,NEUTROPENIA,ADVERSE,0,0.49466508626937866
JEVTANA,HYPERSENSITIVITY,us adverse react,1,0.6677476763725281
JEVTANA,HYPERSENSITIVITY,REACTIONS The following us adverse react ions are discussed in,1,0.6368927955627441
JEVTANA,NEUTROPENIA,are,0,0.49599558115005493
JEVTANA,NEUTROPENIA,reactions,0,0.5213229656219482
JEVTANA,NEUTROPENIA,serious adverse reactions are sed in grea,1,0.5319802165031433
JEVTANA,NEUTROPENIA,discus,0,0.46424373984336853
JEVTANA,NEUTROPENIA,serious adverse reactions are sed,1,0.5332162380218506
JEVTANA,NEUTROPENIA,sed in,1,0.4652916193008423
JEVTANA,NEUTROPENIA,sed in grea ter,1,0.49542903900146484
JEVTANA,NEUTROPENIA,serious adverse reactions are sed in,1,0.5289815664291382
JEVTANA,NEUTROPENIA,adverse reactions are sed in grea,1,0.5337280035018921
JEVTANA,HYPERSENSITIVITY,etail in another,1,0.5142706036567688
JEVTANA,NEUTROPENIA,of the Bone Marr,1,0.471993625164032
JEVTANA,NEUTROPENIA,section of the Bone,1,0.5083527565002441
JEVTANA,NEUTROPENIA,Suppression see Warnings and Precautions Hypersensitivity Reactions,0,0.5258772373199463
JEVTANA,HYPERSENSITIVITY,see Warnings and,0,0.5318863391876221
JEVTANA,HYPERSENSITIVITY,Precautions Hypersensitivity Reactions see Warnings and,0,0.7981643676757812
JEVTANA,HYPERSENSITIVITY,Warnings and Precautions Hypersensitivity Reactions,0,0.8173304200172424
JEVTANA,HYPERSENSITIVITY,ppression [see Warnings and Precautions Hypersensitivity,1,0.8149038553237915
JEVTANA,HYPERSENSITIVITY,Bone Marrow ppression [see,1,0.5790921449661255
JEVTANA,HYPERSENSITIVITY,ppression [see Warnings and Precautions Hypersensitivity Reactions,1,0.8053985834121704
JEVTANA,HYPERSENSITIVITY,ppression [see Warnings,1,0.5968910455703735
JEVTANA,HYPERSENSITIVITY,label Bone Marrow ppression [see   Warnings and Precautions Hypersensitivity Reactions,1,0.7275246381759644
JEVTANA,HYPERSENSITIVITY,ppression [see Warnings and Precautions,1,0.5959323644638062
JEVTANA,HYPERSENSITIVITY,see,0,0.5282117128372192
JEVTANA,Neutropenic,Warnings,0,0.5175702571868896
JEVTANA,Neutropenic,Precautions Hypersensitivity Reactions see and Precaut ions,1,0.5379906892776489
JEVTANA,Neutropenic,and Precaut ions Gastrointestinal Adverse Reactions see,1,0.574988603591919
JEVTANA,Neutropenic,Reactions see and Precaut ions Gastrointestinal Adverse,1,0.5812644362449646
JEVTANA,Neutropenic,Reactions see and,1,0.5109425187110901
JEVTANA,Neutropenic,see and,1,0.48462727665901184
JEVTANA,Neutropenic,Precautions Hypersensitivity Reactions see and Precaut ions Gastrointestinal Adverse,1,0.5661615133285522
JEVTANA,deaths,Precautions Hypersensitivity Reactions see Warnings and Precauti,0,0.4776105284690857
JEVTANA,deaths,ons (5 Gastrointestinal Adverse Reactions see,1,0.5166223049163818
JEVTANA,deaths,Precauti,0,0.4815022945404053
JEVTANA,deaths,ons (5,1,0.5412001609802246
JEVTANA,deaths,Warnings,0,0.5453442931175232
JEVTANA,hypersensitivity, Elderly Patient s,1,0.5030282735824585
JEVTANA,hypersensitivity,Warnings,0,0.562137246131897
JEVTANA,hypersensitivity,Use Elderly,1,0.49109166860580444
JEVTANA,hypersensitivity,Use in Patients,0,0.5692740678787231
JEVTANA,hypersensitivity,Impairment see Warni,0,0.5410948991775513
JEVTANA,hypersensitivity,Elderly Patient s,1,0.5030282735824585
JEVTANA,hypersensitivity,see Warnings and Precautions Use,0,0.5479159951210022
JEVTANA,hypersensitivity,in,0,0.5626283884048462
JEVTANA,hypersensitivity,see Warnings,0,0.546981155872345
JEVTANA,hypersensitivity,Hepatic Impairment,0,0.5387149453163147
JEVTANA,generalized rash,Warnings and tions (5.5)  ] .,1,0.5336047410964966
JEVTANA,generalized rash,Hepatic Impairment,0,0.5071308016777039
JEVTANA,erythema,Patients see,0,0.5295078754425049
JEVTANA,erythema,Impairment see Warnings and Precautions EmbryoFetal,0,0.5232268571853638
JEVTANA,hypotension,n Patients with Hepatic Impairment,1,0.527293860912323
JEVTANA,hypotension,Impairment see Warnings and Precautions EmbryoFetal Toxicity,0,0.4986500144004822
JEVTANA,hypotension,n Patients with Hepatic Impairment see Warnings,1,0.5246809124946594
JEVTANA,hypotension,n Patients,1,0.5345277786254883
JEVTANA,hypotension,Precautions Use n Patients  with Hepatic Impairment,1,0.5468041896820068
JEVTANA,hypotension,n Patients with Hepatic,1,0.5122215747833252
JEVTANA,hypotension,Warnings and Precautions Use i,0,0.5348398685455322
JEVTANA,hypotension,n Patients with,1,0.5380264520645142
JEVTANA,hypotension,Warnings and Precautions Use n Patients,1,0.5364058017730713
JEVTANA,bronchospasm,Hepatic,1,0.47992923855781555
JEVTANA,bronchospasm,irment see,0,0.4649820327758789
JEVTANA,bronchospasm,Hepatic Impa,1,0.44980499148368835
JEVTANA,bronchospasm,Precautions EmbryoFetal Toxicity see Warnings and,0,0.5165457725524902
JEVTANA,Neutropenic,pain hematuria,0,0.5457528233528137
JEVTANA,deaths,consti pation asthenia abdominal pain hematuria,1,0.5010696649551392
JEVTANA,deaths,consti pation asthenia abdominal,1,0.48757320642471313
JEVTANA,deaths,consti pation asthenia abdominal pain,1,0.4795168340206146
JEVTANA,deaths,pain hematuria back pain anorexia peripheral,0,0.5158848762512207
JEVTANA,deaths,consti pation asthenia,1,0.5058085918426514
JEVTANA,deaths,anemia,0,0.5397846698760986
JEVTANA,deaths,thrombocytopenia diarrhea fatigue nausea consti pation asthenia,1,0.5385125279426575
JEVTANA,deaths,neuropathy pyrexia,0,0.4849172830581665
JEVTANA,hypersensitivity reactions,trials are conducted under widely varying,1,0.519601583480835
JEVTANA,hypersensitivity reactions,neuropathy pyrexia,0,0.5645445585250854
JEVTANA,hypersensitivity reactions,conditions,0,0.5968698263168335
JEVTANA,hypersensitivity reactions,trials are,1,0.5236164331436157
JEVTANA,hypersensitivity reactions,or wwwfdagovmedwatch Clinical,0,0.45232024788856506
JEVTANA,hypersensitivity reactions,trials are conducted under widely,1,0.5255578756332397
JEVTANA,hypersensitivity reactions,trials are conducted under widely varying conditions,1,0.534548282623291
JEVTANA,generalized rash,be directly compared to rates in other trials and may not,0,0.4998634159564972
JEVTANA,hypotension,reaction rates,0,0.538742184638977
JEVTANA,bronchospasm,be directly compared to rates in,1,0.4572870433330536
JEVTANA,bronchospasm,trials are conducted under widely varying conditions the adverse,0,0.517219603061676
JEVTANA,hypersensitivity reactions,rates in other trials and may not reflect the,1,0.5041419863700867
JEVTANA,hypersensitivity reactions,be directly to rates in other,1,0.488664448261261
JEVTANA,hypersensitivity reactions,be directly  to rates in other trials  and may not reflect the,1,0.502589225769043
JEVTANA,hypersensitivity reactions,directly to rates in other,1,0.4956344664096832
JEVTANA,hypersensitivity reactions,cannot be directly to rates in,1,0.4867810904979706
JEVTANA,hypersensitivity reactions,cannot be,0,0.4174017906188965
JEVTANA,hypersensitivity reactions,cannot be directly  to rates in other trials  and may not,1,0.4927932918071747
JEVTANA,hypersensitivity reactions,rates in other trials and may not,1,0.4872647523880005
JEVTANA,hypersensitivity reactions,directly  to rates in other trials  and,1,0.5168336629867554
JEVTANA,Bone marrow suppression,serious erse reactions are disc ussed in greater detail,1,0.5732408761978149
JEVTANA,Bone marrow suppression,rates in other trials and may not,1,0.5202186703681946
JEVTANA,Bone marrow suppression,erse reactions are disc,1,0.5769976377487183
JEVTANA,Bone marrow suppression,REACTIONS The,0,0.530767023563385
JEVTANA,Bone marrow suppression,are disc ussed in,1,0.5006058216094971
JEVTANA,Bone marrow suppression,The following serious erse reactions are disc ussed in greater detail in,1,0.5771334767341614
JEVTANA,Bone marrow suppression,serious erse reactions are disc ussed in greater,1,0.5768188238143921
JEVTANA,neutropenia,r detail in another section of the,1,0.489795446395874
JEVTANA,febrile neutropenia,serious adverse reactions are discussed,0,0.566726803779602
JEVTANA,febrile neutropenia,of the * Bone Marrow,1,0.6027811765670776
JEVTANA,febrile neutropenia,and,0,0.4605851471424103
JEVTANA,febrile neutropenia,"section of the 
 *  Bone Marrow Su ppression see Warnings and Precautions",1,0.647788941860199
JEVTANA,febrile neutropenia,Hypersensitivity,0,0.5377736687660217
JEVTANA,neutropenic infections,the label Bone Marrow ression [see  Warnings and Precautions Hypersensitivity Reactions see,1,0.6177449226379395
JEVTANA,neutropenic infections,Hypersensitivity,0,0.5620136260986328
JEVTANA,neutropenic infections,and Precautions Hypersensitivity,0,0.5555857419967651
JEVTANA,neutropenic infections,Marrow ression [see  Warnings,1,0.6609594225883484
JEVTANA,neutropenic infections,Bone Marrow ression [see,1,0.6428258419036865
JEVTANA,neutropenic infections,Precautions Hypersensitivity Reactions see,0,0.5618663430213928
JEVTANA,Hypersensitivity,ngs and Precauti ons Use in Patients,1,0.527686595916748
JEVTANA,Hypersensitivity,ngs,1,0.5432054400444031
JEVTANA,Hypersensitivity,ngs and Precauti ons Use,1,0.5188103318214417
JEVTANA,Hypersensitivity,in Elderly Patients see ngs and Precauti ons,1,0.504082441329956
JEVTANA,Gastrointestinal disorders,see Warnings and Precautions EXCERPT Most common all,0,0.5373390316963196
JEVTANA,Gastrointestinal disorders,adverse reactions (>=10%) are neutropenia anemia leukopenia,1,0.5567114949226379
JEVTANA,Gastrointestinal disorders,are neutropenia anemia leukopenia thrombocytopenia,0,0.5308159589767456
JEVTANA,Gastrointestinal disorders,diarrhea fatigue nausea vomiting constip,0,0.710862934589386
JEVTANA,Gastrointestinal disorders,see Warnings and Precautions EXCERPT Most,0,0.5323939919471741
JEVTANA,Gastrointestinal disorders,EXCERPT Most common all adverse,1,0.5622401237487793
JEVTANA,Gastrointestinal disorders,common all adverse reactions,1,0.5685654282569885
JEVTANA,Nausea,re neu tropenia anemia,1,0.5598746538162231
JEVTANA,Nausea,grades adverse reactions re neu tropenia anemia leukopenia thrombocytopenia diarrhea,1,0.6123208999633789
JEVTANA,Nausea,a,0,0.5310678482055664
JEVTANA,Nausea,vomiting constipation a,0,0.7268245816230774
JEVTANA,vomiting,vomiting constipation asthenia,0,0.835193932056427
JEVTANA,vomiting,"openia,  anemia",1,0.48650842905044556
JEVTANA,vomiting,common all grades adverse reactions are,0,0.606468677520752
JEVTANA,vomiting,"openia,  anemia leukopenia thrombocytopenia",1,0.507795512676239
JEVTANA,diarrhea,", leukop enia thrombocytopenia diarrhea fatigue",1,0.7238589525222778
JEVTANA,diarrhea,"openia,  anemia leukopenia thrombocytopenia",1,0.5354487895965576
JEVTANA,Mortality,diarrhea fatigue nausea vomiting constipation asthenia abdominal pain hematuria back pain,0,0.5858698487281799
JEVTANA,Mortality,ocytopeni,1,0.5000680685043335
JEVTANA,Mortality,pain hematuria,0,0.5238732695579529
JEVTANA,Mortality,ocytopeni a diarrhea fatigue,1,0.5510680675506592
JEVTANA,diarrhea,adverse reactions are,0,0.5793918371200562
JEVTANA,Deaths,and al opecia To report,1,0.49746352434158325
JEVTANA,Deaths,To,0,0.5320875644683838
JEVTANA,gastrointestinal hemorrhage,SUSPECTED ADVERSE REACTIONS,1,0.564751386642456
JEVTANA,gastrointestinal hemorrhage,arthralgia and To report SUSPECTED ADVERSE,1,0.5393471121788025
JEVTANA,gastrointestinal hemorrhage,cough arthralgia and To report SUSPECTED ADVERSE REACTIONS,1,0.5376540422439575
JEVTANA,gastrointestinal hemorrhage,dysgeusia cough arthralgia and To report,1,0.5953782796859741
JEVTANA,neutropenic enterocolitis,contac,0,0.5143769383430481
JEVTANA,neutropenic enterocolitis,sanofi-aventis U.S. LLC at or,1,0.47673723101615906
JEVTANA,neutropenic enterocolitis,SUSPECTED ADVERSE REACTIONS t sanofi-aventis,1,0.5448880195617676
JEVTANA,neutropenic enterocolitis,geusia cough arthralgia and alopecia To report SUSPECTED ADVERSE REACTIONS,0,0.5436482429504395
JEVTANA,Renal failure, www.fda.gov/ medwatch,1,0.5285083055496216
JEVTANA,Renal failure, www.fda.gov/ medwatch Clinical,1,0.5353503823280334
JEVTANA,Renal failure,at FDA  www.fda.gov/ medwatch Clinical Trial,1,0.5153958797454834
JEVTANA,Renal failure, www.fda.gov/ medwatch Clinical Trial,1,0.517166256904602
JEVTANA,Renal failure,Clinical Trial Experience Because clinical trials,0,0.505186915397644
JEVTANA,fatal,.1 Cl inical,1,0.5364792346954346
JEVTANA,fatal,Trial Experience Because clinical trials are conducted under,0,0.4544995427131653
JEVTANA,fatal,be directly to ra,1,0.513056218624115
JEVTANA,fatal,observed,0,0.5462473630905151
JEVTANA,fatal,to ra tes in,1,0.5350134968757629
JEVTANA,fatal,to ra tes in other trials,1,0.48284828662872314
JEVTANA,fatal,and may not reflect the rates observed in clinical,0,0.4773535132408142
JEVTANA,fatal,cannot be directly to ra tes in,1,0.49789464473724365
JEVTANA,neutropenia,rates observed in clinical practice T,0,0.5188086628913879
JEVTANA,neutropenia,clinical practice he,1,0.5201016664505005
JEVTANA,neutropenia,safety o f JEVTANA in,1,0.49027180671691895
JEVTANA,neutropenia,practice,0,0.5045949816703796
JEVTANA,neutropenia,in clinical practice he safety o f,1,0.5010645389556885
JEVTANA,febrile neutropenia,The safety of TANA,1,0.43826302886009216
JEVTANA,febrile neutropenia,may not reflect the rates observed in,0,0.4677698016166687
JEVTANA,febrile neutropenia,safety of TANA in combination with prednisone,1,0.5367088913917542
JEVTANA,febrile neutropenia,of JEV,0,0.48070237040519714
JEVTANA,febrile neutropenia,rates observed in clinical practice The safety of JEV,0,0.5631544589996338
JEVTANA,febrile neutropenia,practice The,0,0.43475568294525146
JEVTANA,febrile neutropenia,in combination,1,0.49889901280403137
JEVTANA,febrile neutropenia,rates,0,0.4779745042324066
JEVTANA,febrile neutropenia,evaluated in patients with hormonerefractory metastatic,0,0.5380353927612305
JEVTANA,Hepatic impairment,patients wit,0,0.47921475768089294
JEVTANA,Hepatic impairment,h hormone-refracto,1,0.5487263798713684
JEVTANA,fetal harm,progression within of,1,0.47819948196411133
JEVTANA,fetal harm,of last s tudy,1,0.5055716037750244
JEVTANA,fetal harm,progression within  of last s,1,0.48689305782318115
JEVTANA,fetal harm,Deaths due to causes other than disease progression within days,0,0.5424410104751587
JEVTANA,neutropenia,patients were infections n and,0,0.5713136196136475
JEVTANA,neutropenia,tions in JE VTANAtreated patients were,1,0.5663849711418152
JEVTANA,neutropenia,common fatal adverse tions in,1,0.5073505640029907
JEVTANA,neutropenia,patients and mitoxantronetreated patients The most common,0,0.57389235496521
JEVTANA,neutropenia,n The majority,0,0.484096884727478
JEVTANA,neutropenia,majority of,0,0.488342821598053
JEVTANA,neutropenia,common fatal adverse reac,0,0.4803464412689209
JEVTANA,neutropenia,fatal adverse tions in JE VTANAtreated patients were infections,1,0.575424313545227
JEVTANA,anemia,infections n and renal failure n The majority,0,0.5495285987854004
JEVTANA,anemia,of patients,0,0.5042108297348022
JEVTANA,anemia,patients,0,0.538127064704895
JEVTANA,anemia,ANA-tr,1,0.5406818985939026
JEVTANA,anemia,ANA-tr eated,1,0.5870130062103271
JEVTANA,anemia,in ANA-tr eated patients were infections n,1,0.5753340721130371
JEVTANA,anemia,ANA-tr eated patients were infections,1,0.5662200450897217
JEVTANA,anemia,ANA-tr eated patients were,1,0.5709149837493896
JEVTANA,anemia,fatal adverse,0,0.49900656938552856
JEVTANA,thrombocytopenia,most,0,0.4697872996330261
JEVTANA,pancytopenia,were ions (n=5) a nd,1,0.5223506689071655
JEVTANA,pancytopenia,most,0,0.4803018867969513
JEVTANA,pancytopenia,JEVTANAtreated patients were,0,0.5479023456573486
JEVTANA,pancytopenia,ions (n=5) a nd renal failure,1,0.5581226348876953
JEVTANA,pancytopenia,of,0,0.5207081437110901
JEVTANA,pancytopenia,were ions,1,0.5327906608581543
JEVTANA,pancytopenia,failure n The majority of patients of,0,0.4658031463623047
JEVTANA,Neutropenic,adverse reactions in JEVTANAtreated patients were,0,0.5922929048538208
JEVTANA,Neutropenic,JEVTANAtreated patients were infections n and renal fai,0,0.5831267833709717
JEVTANA,deaths,jority of patients of fatal,0,0.7351620197296143
JEVTANA,deaths,reactions in JEVTANAtreated patients were infections n,0,0.5122323036193848
JEVTANA,deaths,of fatal infectionrelated adverse reactions occurred after,0,0.6813490390777588
JEVTANA,deaths,n and renal failure The ma,1,0.5365229845046997
JEVTANA,deaths,The ma jority of,1,0.5118101835250854
JEVTANA,deaths,failure The ma jority of patients of fatal,1,0.6525871753692627
JEVTANA,deaths,The ma,1,0.4724305272102356
JEVTANA,deaths,The,1,0.5492459535598755
JEVTANA,deaths,failure The ma,1,0.48987504839897156
JEVTANA,fatal,of fatal infectionrelated adverse reactions,0,0.7008489966392517
JEVTANA,fatal,after,1,0.5450894832611084
JEVTANA,fatal,reactions after a single,1,0.5573203563690186
JEVTANA,fatal,infectionrelated adverse reactions after a single dose of JEVTANA,1,0.5156283378601074
JEVTANA,fatal,adverse reactions after a single dose,1,0.5477279424667358
JEVTANA,fatal,patients of,0,0.5112035274505615
JEVTANA,fatal,after a single dose,1,0.5086231231689453
JEVTANA,fatal,after a,1,0.5074662566184998
JEVTANA,fatal,fatal infectionrelated adverse reactions after,1,0.704120397567749
JEVTANA,infectious adverse events,e n The majority of patients,0,0.5097715258598328
JEVTANA,infectious adverse events,a,1,0.5209754705429077
JEVTANA,infectious adverse events,of JEVTANA. Other fatal adverse,1,0.6209863424301147
JEVTANA,infectious adverse events,ventricular fibrillation cerebr,0,0.5176764130592346
JEVTANA,sepsis,ther f,1,0.5070770978927612
JEVTANA,sepsis,in JEVTANAtreated,0,0.6031776070594788
JEVTANA,sepsis,adverse reactions occurred,0,0.5967880487442017
JEVTANA,sepsis,ventricular fibrillation,0,0.5335803031921387
JEVTANA,sepsis,ther f atal adverse reactions in,1,0.5824658870697021
JEVTANA,sepsis,JEVTANAtreated patients included ventricular,0,0.5907485485076904
JEVTANA,sepsis,ther f atal adverse,1,0.5764409303665161
JEVTANA,neutropenia,reated pati ents included ventricular fibrillation cerebral,1,0.48010390996932983
JEVTANA,neutropenia,ents,0,0.4808855652809143
JEVTANA,neutropenia,ventricular fibrillation cerebral,0,0.46991515159606934
JEVTANA,neutropenia,reated pati ents included ventricular,1,0.5134485960006714
JEVTANA,febrile neutropenia,reactions,0,0.5120879411697388
JEVTANA,febrile neutropenia, ventricular fibril,1,0.46382391452789307
JEVTANA,febrile neutropenia,The most common grade,0,0.5012770295143127
JEVTANA,febrile neutropenia,ventricular fibril lation cerebral hemorrhage and dyspnea,1,0.5052660703659058
JEVTANA,febrile neutropenia,dose of JEVTANA Other fatal adverse,0,0.5476201176643372
JEVTANA,febrile neutropenia,grade adverse,0,0.5110841393470764
JEVTANA,febrile neutropenia,most,0,0.46163511276245117
JEVTANA,febrile neutropenia,ventricular,1,0.4728659987449646
JEVTANA,febrile neutropenia,in,0,0.4780074954032898
JEVTANA,death,", and dyspnea The most common grade",1,0.5522476434707642
JEVTANA,death,", and",1,0.5977352857589722
JEVTANA,death,were anemia leukopenia neutrope,0,0.4814315140247345
JEVTANA,neutropenia,leukopenia neutropenia thrombocytopenia diarrhe,0,0.7635684609413147
JEVTANA,neutropenia,hemorrhage and dyspnea The ost common  grade adverse reactions were anemia,1,0.6063552498817444
JEVTANA,infection,common grade erse reac tions were,1,0.510986328125
JEVTANA,infection,leukopenia neutropenia thrombocytopenia diarrhe,0,0.6057919859886169
JEVTANA,infection,common grade erse,1,0.5112744569778442
JEVTANA,neutropenia,nausea,0,0.5792617797851562
JEVTANA,neutropenia,"nemia, leuk openia neutropenia thrombocytopenia diarrhea fatigue",1,0.7658020853996277
JEVTANA,neutropenia,vomiting constipation,0,0.4714916944503784
JEVTANA,neutropenia,"grade adverse reactions were nemia,",1,0.5710151791572571
JEVTANA,neutropenia,"nemia, leuk openia neutropenia thrombocytopenia diarrhea",1,0.7650998830795288
JEVTANA,Hypersensitivity reactions,mg dailyn,0,0.519044041633606
JEVTANA,Hypersensitivity reactions,"sone 
                     JEVTANA mgm every weeks",1,0.4696577787399292
JEVTANA,Hypersensitivity reactions,"with sone 
                    ",1,0.4862862825393677
JEVTANA,Hypersensitivity reactions,"sone 
                    ",1,0.48048171401023865
JEVTANA,Hypersensitivity reactions,"sone 
                     JEVTANA mgm",1,0.4713965952396393
JEVTANA,hypersensitivity reactions,n Any Adverse,0,0.5531917810440063
JEVTANA,generalized rash,Grade n Grade n de 1-4n (%)   Gr ade,1,0.5251678228378296
JEVTANA,generalized rash,n Any Adverse,0,0.5874193906784058
JEVTANA,generalized rash,Grade n Grade n de 1-4n (%) Gr,1,0.52484130859375
JEVTANA,generalized rash,Grade n de,1,0.49468564987182617
JEVTANA,generalized rash,Grade n Grade n de,1,0.49804556369781494
JEVTANA,generalized rash,ade n,0,0.4954300820827484
JEVTANA,erythema,Any Adverse,0,0.5896440744400024
JEVTANA,erythema,de 3-4n Any Adverse Reaction,1,0.5845720171928406
JEVTANA,erythema,n Gra,0,0.547948956489563
JEVTANA,erythema,n de,1,0.552854061126709
JEVTANA,erythema,Grade,0,0.4989776909351349
JEVTANA,erythema,Grade n de,1,0.5236250758171082
JEVTANA,erythema,de 3-4n Any Adverse,1,0.5651045441627502
JEVTANA,erythema,de,1,0.556380569934845
JEVTANA,hypotension,")    
  
   Any Adverse Reaction",1,0.5422539710998535
JEVTANA,hypotension,Grade n Grade n Grade,0,0.4858630895614624
JEVTANA,hypotension,")    
  
  ",1,0.4994714856147766
JEVTANA,hypotension,Grade n,0,0.4919544458389282
JEVTANA,hypotension,Any Adverse Reaction,0,0.5524107217788696
JEVTANA,bronchospasm,Grade n Adverse,1,0.484091192483902
JEVTANA,bronchospasm,Grade n,0,0.45619040727615356
JEVTANA,bronchospasm,Grade n Grade n Adverse,1,0.48208051919937134
JEVTANA,bronchospasm,Adverse Reac tion Blo,1,0.573028564453125
JEVTANA,neutropenia,ons and,0,0.5247950553894043
JEVTANA,neutropenia,ry Tract Infection,0,0.5288172364234924
JEVTANA,neutropenia,"and   
   Urina ry Tract",1,0.519388735294342
JEVTANA,fetal harm, (7%)      Nervous System,1,0.5110652446746826
JEVTANA,fetal harm,ry Tract Infection,0,0.5413068532943726
JEVTANA,fetal harm, (7%)      Nervous System Disorders,1,0.5286368131637573
JEVTANA,fetal harm,Nervous System Disorders,0,0.5447803139686584
JEVTANA,fetal harm,Muscle  (7%)     ,1,0.49678003787994385
JEVTANA,fetotoxic,         ,1,0.5911524891853333
JEVTANA,fetotoxic,Disorders,0,0.5387829542160034
JEVTANA,abortifacient,             ,1,0.6081676483154297
JEVTANA,abortifacient,Nervous,0,0.5391085743904114
JEVTANA,abortifacient,              Peripheral,1,0.5197876691818237
ILARIS,infections,infections,1,1.000000238418579
ILARIS,infections,were observed The type and frequency of adverse,0,0.5935204029083252
ILARIS,infections,to moderate although infections,1,0.7909154295921326
ILARIS,infections,infections were observed,1,0.8679201602935791
ILARIS,infections,infections were observed The type,1,0.8247627019882202
ILARIS,infections,infections were,1,0.9091304540634155
ILARIS,Opportunistic infections,patients treated with ILARIS,0,0.5427824854850769
ILARIS,nasopharyngitis,nasopharyngitis diarrhea influenza headache and,1,0.8291373252868652
ILARIS,nasopharyngitis,CAPS treated with ILARIS nasopharyngitis diarrhea influenza,1,0.7202609777450562
ILARIS,nasopharyngitis,nasopharyngitis,1,1.0000001192092896
ILARIS,nasopharyngitis,The most common adverse drug,0,0.5194483995437622
ILARIS,nasopharyngitis,CAPS treated with ILARIS nasopharyngitis diarrhea influenza headache,1,0.7214468717575073
ILARIS,nasopharyngitis,with ILARIS,0,0.47937989234924316
ILARIS,influenza,headache and,0,0.5362299084663391
ILARIS,influenza,influenza headache and nausea,1,0.7802876830101013
ILARIS,headache,headache and nausea SJIA The most,1,0.7900623083114624
ILARIS,headache,and nausea SJIA The most common adverse,0,0.6361477375030518
ILARIS,headache,headache and nausea,1,0.8234978318214417
ILARIS,headache,reported by patients with CAPS treated with ILARIS are nasopharyngitis,0,0.5543530583381653
ILARIS,infections,are,0,0.540595531463623
ILARIS,infections,infections nasopharyngitis and upper respiratory tract,1,0.7115540504455566
ILARIS,infections,infections nasopharyngitis and upper respiratory,1,0.7277255058288574
ILARIS,nasopharyngitis,infections nasopharyngitis and upper respiratory,1,0.8357238173484802
ILARIS,nasopharyngitis,are nasopharyngitis and upper respiratory,1,0.8442318439483643
ILARIS,nasopharyngitis,treated with ILARIS are nasopharyngitis,1,0.7983551621437073
ILARIS,nasopharyngitis,SJIA treated with,0,0.5866537094116211
ILARIS,nasopharyngitis,tract infections abdominal pain,0,0.5860898494720459
ILARIS,nasopharyngitis,pain and injection site reactions,0,0.5085611343383789
ILARIS,nasopharyngitis,drug reactions greater than reported by patients with SJIA treated with ILARIS,0,0.5518278479576111
ILARIS,nasopharyngitis,nasopharyngitis and,1,0.9384024143218994
ILARIS,upper respiratory tract infections,infections nasopharyngitis upper respiratory tract infections,1,0.8828964829444885
ILARIS,upper respiratory tract infections,nasopharyngitis and,1,0.7279658317565918
ILARIS,upper respiratory tract infections,site reactions To report SUSPECTED,0,0.4454438090324402
ILARIS,upper respiratory tract infections,upper respiratory tract infections abdominal pain and injection,1,0.7908323407173157
ILARIS,upper respiratory tract infections,SJIA treated with ILARIS are infections,0,0.6422232389450073
ILARIS,upper respiratory tract infections,SJIA treated with ILARIS are infections nasopharyngitis,0,0.6868070960044861
ILARIS,upper respiratory tract infections,by patients with SJIA treated with ILARIS are infections nasopharyngitis and,0,0.6858396530151367
ILARIS,abdominal pain,site reactions To,0,0.44560903310775757
ILARIS,abdominal pain,and upper respiratory tract abdominal pain and injection,1,0.7666768431663513
ILARIS,abdominal pain,To report SUSPECTED,0,0.5150184631347656
ILARIS,abdominal pain,with ILARIS are infections nasopharyngitis and upper respiratory tract,0,0.5166465640068054
ILARIS,abdominal pain,upper respiratory tract abdominal,1,0.6944127678871155
ILARIS,injection site reactions,Novartis,0,0.5938898921012878
ILARIS,vertigo,intraabdominal abscess following,0,0.4357627332210541
ILARIS,vertigo,CAPS patients Among these vertigo patients infections patients including intraabdominal,1,0.7508811354637146
ILARIS,infections,including,0,0.5713518857955933
ILARIS,infections,infections patients including intraabdominal,1,0.7545521259307861
ILARIS,infections,vertigo,0,0.5305938124656677
ILARIS,infections,Among these were vertigo infections,1,0.7061748504638672
ILARIS,infections,infections patients including intraabdominal abscess following,1,0.7373392581939697
ILARIS,infections,vertigo infections patients,1,0.6821942329406738
ILARIS,infections,infections patients including intraabdominal abscess,1,0.742124080657959
ILARIS,infections,infections patients,1,0.8473749160766602
ILARIS,infections,vertigo infections patients including,1,0.6900100708007812
ILARIS,intra-abdominal abscess,infections patients intra-abdominal abscess following appendectomy patient,1,0.8499146103858948
ILARIS,intra-abdominal abscess,infections patients,1,0.6054027080535889
ILARIS,nasopharyngitis,with ILARIS treatment in the,0,0.4984121322631836
ILARIS,nasopharyngitis,patients nasopharyngitis diarrhea influenza,1,0.8290616273880005
ILARIS,diarrhea,the CAPS patients were diarrhea,1,0.8075141310691833
ILARIS,diarrhea,with ILARIS treatment in the,0,0.5074045658111572
ILARIS,diarrhea,diarrhea influenza headache,1,0.7538550496101379
ILARIS,diarrhea,treatment,0,0.5861543416976929
ILARIS,diarrhea,were diarrhea influenza headache and nausea,1,0.7325598001480103
ILARIS,diarrhea,diarrhea influenza,1,0.8379879593849182
ILARIS,diarrhea,diarrhea influenza headache and nausea One,1,0.7472244501113892
ILARIS,influenza,headache and nausea One patient discontinued treatment,0,0.5438026189804077
ILARIS,influenza,due,0,0.5137470364570618
ILARIS,influenza,influenza headache and nausea One patient,1,0.7544090747833252
ILARIS,influenza,to potential,0,0.5074073076248169
ILARIS,headache,in the,0,0.5695481896400452
ILARIS,headache,with ILARIS treatment in,0,0.5007050037384033
ILARIS,headache,headache and nausea One,1,0.8076650500297546
ILARIS,headache,patients were nasopharyngitis diarrhea headache and nausea One patient,1,0.7029726505279541
ILARIS,nausea,investigated the,0,0.4825916290283203
ILARIS,nausea,due,0,0.5327111482620239
ILARIS,nausea,One patient discontinued treatment due to potential infection CAPS Study investigated the,0,0.5362618565559387
ILARIS,nausea,nasopharyngitis diarrhea influenza headache nausea,1,0.7182310223579407
ILARIS,nausea,CAPS patients were nasopharyngitis diarrhea influenza,0,0.6116083264350891
ILARIS,nausea,nausea One patient,1,0.8492496013641357
ILARIS,nausea,the CAPS patients,0,0.5704621076583862
ILARIS,nausea,headache nausea One patient discontinued treatment,1,0.6943449378013611
ILARIS,infection,in an week openlabel period Part follo,0,0.5543997287750244
ILARIS,infection,CAPS Study investigated the safety of ILARIS in an week openlabel period,0,0.5562138557434082
ILARIS,infection,openlabel period Part follo,0,0.5081719160079956
ILARIS,infection,infection CAPS Study investigated the safety,1,0.6890047788619995
ILARIS,infection,infection CAPS Study,1,0.7271009683609009
ILARIS,Nasopharyngitis,Adverse Nasopharyngitis,1,0.8990893363952637
ILARIS,Nasopharyngitis,infection CAPS Study investigated the safety,1,0.5534015893936157
ILARIS,Nasopharyngitis,Nasopharyngitis Diarrhea,1,0.8949661254882812
ILARIS,Nasopharyngitis,ferred Term ILARISNn n of Patients with Adverse,0,0.5539451837539673
ILARIS,Nasopharyngitis,with Adverse Nasopharyngitis Diarrhea,1,0.8455215096473694
ILARIS,Diarrhea,Events Diarrhea,1,0.8392971754074097
ILARIS,Diarrhea,Nasopharyngitis Diarrhea,1,0.7927175760269165
ILARIS,Diarrhea,Diarrhea Influenza,1,0.8379879593849182
ILARIS,Diarrhea,Diarrhea,1,0.9999999403953552
ILARIS,Diarrhea,Diarrhea Influenza Rhinitis,1,0.7544881105422974
ILARIS,Diarrhea,with Adverse,0,0.5997950434684753
ILARIS,Influenza,Nasopharyngitis Influenza,1,0.8217262029647827
ILARIS,Influenza,with Adverse,0,0.5370047688484192
ILARIS,Influenza,Influenza,1,0.9999999403953552
ILARIS,Influenza,Nasopharyngitis Influenza Rhinitis Nausea,1,0.7304386496543884
ILARIS,Influenza,Influenza Rhinitis,1,0.7882454991340637
ILARIS,Rhinitis,Rhinitis Nausea Headache,1,0.8530846834182739
ILARIS,Rhinitis,Diarrhea Rhinitis,1,0.8310922980308533
ILARIS,Rhinitis,Diarrhea Influenza,0,0.5906037092208862
ILARIS,Nausea,Nausea Headache Bronchitis,1,0.7363490462303162
ILARIS,Nausea,Nausea Headache,1,0.8831434845924377
ILARIS,Nausea,Influenza Rhinitis,0,0.5766304135322571
ILARIS,Nausea,Influenza Nausea Headache Bronchitis,1,0.7186173796653748
ILARIS,Headache,Headache,1,0.9999998807907104
ILARIS,Headache,Nausea,0,0.668434739112854
ILARIS,Headache,Rhinitis Nausea,0,0.6001165509223938
ILARIS,Headache,Headache Bronchitis,1,0.7471713423728943
ILARIS,Headache,Rhinitis Headache Bronchitis Gastroenteritis,1,0.689300537109375
ILARIS,Bronchitis,Bronchitis Gastroenteritis,1,0.8461439609527588
ILARIS,Bronchitis,Bronchitis Gastroenteritis Pharyngitis,1,0.8184436559677124
ILARIS,Gastroenteritis,Bronchitis,0,0.6490577459335327
ILARIS,Gastroenteritis,Headache Gastroenteritis Pharyngitis Weight increased,1,0.7173355221748352
ILARIS,Gastroenteritis,Headache,0,0.5231096744537354
ILARIS,Gastroenteritis,Gastroenteritis Pharyngitis Weight,1,0.7418332695960999
ILARIS,Pharyngitis,Bronchitis Gastroenteritis,0,0.6411900520324707
ILARIS,Pharyngitis,Bronchitis Pharyngitis Weight increased Musculoskeletal pain,1,0.7651790976524353
ILARIS,Pharyngitis,Pharyngitis Weight,1,0.8643528819084167
ILARIS,Pharyngitis,increased Musculoskeletal,0,0.49450868368148804
ILARIS,Pharyngitis,Gastroenteritis,0,0.6537085175514221
ILARIS,Weight increased,Weight increased Musculoskeletal pain,1,0.7859230041503906
ILARIS,Weight increased,Gastroenteritis Weight,1,0.6735354661941528
ILARIS,Weight increased,Gastroenteritis,0,0.4945547580718994
ILARIS,Musculoskeletal pain,Vertigo has been,0,0.47236886620521545
ILARIS,Musculoskeletal pain,Musculoskeletal pain Vertigo Vertigo Vertigo has,1,0.800001859664917
ILARIS,Vertigo,Vertigo Vertigo Vertigo has,1,0.9425681829452515
ILARIS,Vertigo,Vertigo Vertigo Vertigo has been reported,1,0.8947598934173584
ILARIS,Vertigo,Musculoskeletal Vertigo Vertigo Vertigo has been reported,1,0.8234363794326782
ILARIS,Vertigo,reported in to of patie,0,0.4553360044956207
ILARIS,Vertigo,CAPS studies exclusively in,0,0.46937036514282227
ILARIS,Vertigo,Vertigo,1,1.0
ILARIS,Vertigo,Vertigo has been reported in,1,0.9294644594192505
ILARIS,Vertigo,Vertigo Vertigo has,1,0.9548951387405396
ILARIS,Vertigo,sculoskeletal pain Vertigo Vertigo,0,0.8052229881286621
ILARIS,Vertigo,sculoskeletal pain,0,0.5462112426757812
ILARIS,Vertigo,Vertigo,0,1.0
ILARIS,Vertigo,sculoskeletal,0,0.5079535841941833
ILARIS,subcutaneous injection site reactions,reactions in Part one patient,0,0.6688838005065918
ILARIS,subcutaneous injection site reactions,were observed in of,0,0.5260983109474182
ILARIS,subcutaneous injection site reactions,In CAPS subcutaneous injection site reactions were observed in,1,0.9403148889541626
ILARIS,subcutaneous injection site reactions,Site Reactions In CAPS subcutaneous injection site reactions were,1,0.9367972612380981
ILARIS,local tolerability reaction,local tolerability reaction No severe injectionsite,1,0.8828381896018982
ILARIS,local tolerability reaction,Part one patient,0,0.5276073217391968
ILARIS,local tolerability reaction,a moderate tolerability reaction and in Part one patient had a mild,0,0.7833424806594849
ILARIS,local tolerability reaction,patient had a local,1,0.6479061841964722
ILARIS,local tolerability reaction,tolerability reaction No,1,0.8861295580863953
ILARIS,local tolerability reaction,a local tolerability reaction,1,0.9896420240402222
ILARIS,local tolerability reaction,reported and none led to discontinuation of,0,0.5408719778060913
ILARIS,injection-site reactions,injection-site reactions were reported and none,1,0.8742785453796387
ILARIS,injection-site reactions,mild local,0,0.5620152354240417
ILARIS,injection-site reactions,reported,0,0.5289402604103088
ILARIS,injection-site reactions,reaction No injection-site reactions,1,0.8820765018463135
ILARIS,injection-site reactions,reported and,0,0.5310940742492676
ILARIS,injection-site reactions,patient had a mild local,0,0.6290255784988403
ILARIS,infections,infections abdominal,1,0.7866441011428833
ILARIS,infections,patient had a mild local,0,0.6030129194259644
ILARIS,infections,treatment in SJIA patients infections abdominal,1,0.6855976581573486
ILARIS,infections,patients,0,0.5940079689025879
ILARIS,infections,site,0,0.5783182382583618
ILARIS,infections,infections abdominal pain and injection site,1,0.7179483771324158
ILARIS,infections,and injection site reactions Serious infections eg,0,0.6912619471549988
ILARIS,infections,injection site reactions Serious infections,0,0.6994099617004395
ILARIS,infections,both trials The adverse drug reactions associated with ILARIS treatment in SJIA,0,0.546502411365509
ILARIS,abdominal pain,were abdominal pain and injection site,1,0.8113692998886108
ILARIS,abdominal pain,both trials The adverse drug reactions associated with ILARIS treatment in SJIA,0,0.5093274712562561
ILARIS,abdominal pain,varicella gastroenteritis,0,0.5780787467956543
ILARIS,abdominal pain,were infections,0,0.5509181022644043
ILARIS,abdominal pain,in SJIA patients were abdominal pain and injection site,1,0.7061315178871155
ILARIS,abdominal pain,associated with ILARIS treatment in SJIA,0,0.473960816860199
ILARIS,abdominal pain,were abdominal pain,1,0.9727976322174072
ILARIS,abdominal pain,patients were abdominal,1,0.7643933296203613
ILARIS,abdominal pain,SJIA patients were infections,0,0.4781435430049896
ILARIS,abdominal pain,site reactions Serious infections eg pneumonia varicella gastroenteritis,0,0.5473123788833618
ILARIS,infections,sepsis otitis,0,0.6661816835403442
ILARIS,pneumonia,site reactions Serious infections pneumonia varicella gastroenteritis measles sepsis otitis,1,0.6803561449050903
ILARIS,pneumonia,sepsis otitis,0,0.620018482208252
ILARIS,pneumonia,infections pneumonia varicella,1,0.7669517397880554
ILARIS,pneumonia,pneumonia varicella gastroenteritis measles,1,0.7456543445587158
ILARIS,pneumonia,pneumonia,1,0.9999997615814209
ILARIS,pneumonia,pneumonia varicella,1,0.7580022811889648
ILARIS,pneumonia,infections pneumonia varicella gastroenteritis measles sepsis,1,0.7216094732284546
ILARIS,pneumonia,pneumonia varicella gastroenteritis measles sepsis,1,0.7497578859329224
ILARIS,pneumonia,site reactions Serious infections pneumonia varicella gastroenteritis,1,0.7113924622535706
ILARIS,pneumonia,sepsis otitis media sinusitis adenovirus lymph node absce,0,0.6280490159988403
ILARIS,varicella,varicella gastroenteritis measles sepsis,1,0.810691237449646
ILARIS,varicella,measles sepsis otitis,0,0.6191365122795105
ILARIS,varicella,infections eg varicella gastroenteritis,1,0.8099754452705383
ILARIS,varicella,reactions Serious infections eg varicella,1,0.8035567998886108
ILARIS,varicella,sepsis otitis media,0,0.5215098857879639
ILARIS,varicella,were infections abdominal pain and injection site reactions Serious,0,0.5579469203948975
ILARIS,varicella,gastroenteritis measles sepsis otitis media sinusitis adenovirus lymph node abscess,0,0.6458206176757812
ILARIS,varicella,varicella gastroenteritis,1,0.8733456134796143
ILARIS,measles,media sinusitis adenovirus lymph,0,0.5399942398071289
ILARIS,measles,eg pneumonia varicella measles sepsis otitis media,1,0.7093068361282349
ILARIS,measles,varicella measles sepsis otitis media sinusitis,1,0.7476656436920166
ILARIS,measles,measles sepsis otitis media,1,0.8032337427139282
ILARIS,measles,eg pneumonia varicella gastroenteritis,0,0.6267959475517273
ILARIS,measles,infections eg pneumonia varicella measles sepsis,1,0.6826763153076172
ILARIS,sepsis,node abscess,0,0.5913020372390747
ILARIS,sepsis,Serious infections eg pneumonia varicella,0,0.6103088855743408
ILARIS,sepsis,sepsis otitis,1,0.8232008218765259
ILARIS,sepsis,injection site,0,0.5437339544296265
ILARIS,sepsis,sepsis otitis media sinusitis,1,0.7783660888671875
ILARIS,sepsis,lymph node abscess pharyngitis were observed in,0,0.5893346071243286
ILARIS,otitis media,site reactions Serious infections eg pneumonia varicella gastroenteritis measles,0,0.6113641262054443
ILARIS,otitis media,measles otitis media sinusitis,1,0.7716183662414551
ILARIS,otitis media,lymph node abscess pharyngitis were observed in approximately to,0,0.5807985067367554
ILARIS,otitis media,gastroenteritis measles otitis media sinusitis,1,0.752042293548584
ILARIS,otitis media,measles otitis media sinusitis adenovirus lymph,1,0.7680121064186096
ILARIS,otitis media,were observed in approximately,0,0.5370990037918091
ILARIS,adenovirus,adenovirus lymph node abscess pharyngitis were,1,0.7278887033462524
ILARIS,adenovirus,were observed,0,0.48123133182525635
ILARIS,adenovirus,approximately to to per pat,0,0.504926323890686
ILARIS,adenovirus,gastroenteritis measles,0,0.6139143705368042
ILARIS,adenovirus,adenovirus lymph node abscess pharyngitis,1,0.7289949059486389
ILARIS,lymph node abscess,gastroenteritis measles,0,0.48444104194641113
ILARIS,lymph node abscess,media,0,0.48538368940353394
ILARIS,lymph node abscess,in approximately to to per,0,0.44998615980148315
ILARIS,lymph node abscess,pharyngitis were observed in,0,0.5782316327095032
ILARIS,lymph node abscess,sinusitis lymph node abscess pharyngitis,1,0.8112503886222839
ILARIS,lymph node abscess,media sinusitis lymph node abscess,1,0.8559097647666931
ILARIS,lymph node abscess,patientdays,0,0.47571220993995667
ILARIS,lymph node abscess,sepsis otitis media sinusitis lymph node abscess,1,0.7983962893486023
ILARIS,lymph node abscess,otitis media sinusitis lymph,1,0.7124863862991333
ILARIS,pharyngitis,lymph node pharyngitis were observed in approximately,1,0.8305802345275879
ILARIS,pharyngitis,otitis media sinusitis lymph,1,0.6393329501152039
ILARIS,Infections,Infections eg nasopharyngitis,1,0.8079581260681152
ILARIS,nasopharyngitis,and infestations All Infections nasopharyngitis viral upper respiratory tract,1,0.7715084552764893
ILARIS,nasopharyngitis,Infections eg nasopharyngitis,1,0.8598413467407227
ILARIS,nasopharyngitis,tract infection pneumonia,0,0.6070126295089722
ILARIS,nasopharyngitis,nasopharyngitis viral upper,1,0.8336904048919678
ILARIS,nasopharyngitis,pneumonia rhinitis pharyngitis tonsillitis sinusiti,0,0.6894858479499817
ILARIS,nasopharyngitis,ISNn IR PlaceboNn IR,0,0.5766756534576416
ILARIS,pneumonia,upper respiratory tract infection,0,0.7039812207221985
ILARIS,pneumonia,pneumonia rhinitis pharyngitis tonsillitis,1,0.744525671005249
ILARIS,pneumonia,pneumonia rhinitis,1,0.7779860496520996
ILARIS,pneumonia,pneumonia rhinitis pharyngitis tonsillitis sinusitis,1,0.7378305196762085
ILARIS,pneumonia,tract pneumonia rhinitis pharyngitis,1,0.7164158821105957
ILARIS,pneumonia,viral,0,0.5641254186630249
ILARIS,pneumonia,nasopharyngitis,0,0.6376098394393921
ILARIS,rhinitis,rhinitis pharyngitis tonsillitis sinusitis,1,0.8281123638153076
ILARIS,pharyngitis,eg nasopharyngitis viral,0,0.6635017395019531
ILARIS,pharyngitis,respiratory tract infection pneumonia pharyngitis tonsillitis sinusitis urinary tract,1,0.7543929815292358
ILARIS,pharyngitis,pharyngitis tonsillitis sinusitis urinary,1,0.8404214978218079
ILARIS,pharyngitis,pharyngitis tonsillitis,1,0.908743143081665
ILARIS,tonsillitis,tonsillitis,1,1.0
ILARIS,tonsillitis,viral upper respiratory tract,0,0.6283279657363892
ILARIS,tonsillitis,urinary,0,0.5187543630599976
ILARIS,tonsillitis,tonsillitis sinusitis urinary,1,0.8220808506011963
ILARIS,tonsillitis,infection gastroenteritis,0,0.6273761987686157
ILARIS,tonsillitis,tonsillitis sinusitis urinary tract infection gastroenteritis,1,0.7987068891525269
ILARIS,tonsillitis,tonsillitis sinusitis urinary tract infection,1,0.8135660290718079
ILARIS,sinusitis,sinusitis urinary tract infection gastroenteritis,1,0.7791434526443481
ILARIS,sinusitis,sinusitis,1,0.9999998807907104
ILARIS,sinusitis,urinary tract infection gastroenteritis,0,0.5482671856880188
ILARIS,sinusitis,tract infection pneumonia rhinitis,0,0.6566454768180847
ILARIS,sinusitis,sinusitis urinary tract,1,0.8002466559410095
ILARIS,sinusitis,sinusitis urinary tract infection,1,0.8304242491722107
ILARIS,sinusitis,tract infection,0,0.6652610301971436
ILARIS,urinary tract infection,tonsillitis urinary tract infection gastroenteritis viral,1,0.7540794610977173
ILARIS,urinary tract infection,tract infection,0,0.8207153677940369
ILARIS,gastroenteritis,urinary tract gastroenteritis viral,1,0.8112193942070007
ILARIS,gastroenteritis,tract infection,0,0.6791278719902039
ILARIS,gastroenteritis,sinusitis urinary tract gastroenteritis,1,0.7830749750137329
ILARIS,gastroenteritis,gastroenteritis viral,1,0.898992657661438
ILARIS,gastroenteritis,gastroenteritis,1,0.9999998211860657
ILARIS,anaphylactic reactions,Hypersensitivity During clinical trials anaphylactic reactions,1,0.8293977975845337
ILARIS,anaphylactic reactions,tract infection,0,0.5184305906295776
ILARIS,anaphylactic reactions,During clinical trials anaphylactic reactions have been reported In CAPS,1,0.8411945104598999
ILARIS,hypersensitivity reactions,discontinued due,0,0.4689459204673767
ILARIS,hypersensitivity reactions,hypersensitivity reactions,1,1.0
ILARIS,hypersensitivity reactions,no patients discontinued due hypersensitivity,1,0.7172608971595764
ILARIS,hypersensitivity reactions,due hypersensitivity,1,0.8530678749084473
ILARIS,hypersensitivity reactions,discontinued due hypersensitivity reactions ILARIS should,1,0.7271004915237427
ILARIS,hypersensitivity reactions,discontinued due hypersensitivity reactions,1,0.8112109899520874
ILARIS,hypersensitivity reactions,to any patients with known clinical hypersensitivity,0,0.7945404648780823
ILARIS,hypersensitivity reactions,hypersensitivity reactions ILARIS should not be administered,1,0.74024498462677
ILARIS,decreased white blood cell counts,portion of SJIA decreased white blood cell counts WBC less than,1,0.8340693712234497
ILARIS,decreased white blood cell counts,no patients discontinued due hypersensitivity,1,0.5120493173599243
ILARIS,decreased white blood cell counts,decreased white blood cell counts WBC less,1,0.9432227611541748
ILARIS,decreased white blood cell counts,randomized placebocontrolled portion of SJIA,0,0.5685825347900391
ILARIS,decreased white blood cell counts,decreased white blood cell counts WBC,1,0.9449412822723389
ILARIS,decreases in absolute neutrophil count,group,0,0.4801567792892456
ILARIS,ANC less than 0.5x10 9 /L,than 0.5x10 9 /L,1,0.8885416984558105
ILARIS,ANC less than 0.5x10 9 /L,placebo group One case ANC less than 0.5x10  9  /L,1,0.794827401638031
ILARIS,ANC less than 0.5x10 9 /L,One case ANC less than 0.5x10  9  /L was observed in the ILARIS,1,0.8116859793663025
ILARIS,ANC less than 0.5x10 9 /L,placebo group Mild less,0,0.5663538575172424
ILARIS,ANC less than 0.5x10 9 /L,in the,0,0.5296090245246887
ILARIS,ANC less than 0.5x10 9 /L,than 0.5x10 9 /L was,1,0.8742530345916748
ILARIS,ANC less than 0.5x10 9 /L,placebo group One case ANC less than 0.5x10  9  /L was observed in the ILARIS,1,0.7334027886390686
ILARIS,decreases in platelet counts,platelet counts were observed in,1,0.8558881282806396
ILARIS,Elevations of transaminases,placebotreated patient Hepatic Elevations of transaminases,1,0.8992576003074646
ILARIS,Elevations of transaminases,platelet counts were observed in,1,0.5923091173171997
ILARIS,Elevations of transaminases,patient Hepatic Elevations of transaminases have,1,0.9446303248405457
ILARIS,Elevations of transaminases,placebotreated patient Hepatic Elevations of transaminases have been observed,1,0.9163352847099304
ILARIS,high ALT,SJIA Study,0,0.537808895111084
ILARIS,high ALT,Study,0,0.5494033098220825
ILARIS,high ALT,high ALT andor,1,0.9065439701080322
ILARIS,high ALT,high ALT,1,0.9999998807907104
ILARIS,high ALT,andor AST greater than or equal to times upper limit of normal ULN were reported in,0,0.6843600273132324
ILARIS,high ALT,high ALT andor AST greater than or,1,0.8185943365097046
ILARIS,high ALT,high ALT andor AST,1,0.8644702434539795
ILARIS,high ALT,or,0,0.5418886542320251
ILARIS,elevations of serum bilirubin,elevations of serum bilirubin,1,1.0
ILARIS,elevations of serum bilirubin,or,0,0.4925583600997925
ILARIS,elevations of serum bilirubin,Asymptomatic and elevations of serum,1,0.7230901122093201
ILARIS,infections,upper respiratory tract The majority of the events,0,0.5916935205459595
ILARIS,infections,were in fections,1,0.57408607006073
ILARIS,infections,upper respiratory tract The of,1,0.5604061484336853
ILARIS,infections,respiratory tract The of the eve,1,0.5555022358894348
ILARIS,infections,infections nasopharyngitis and upper respiratory,0,0.7277255058288574
ILARIS,infections,tract inf ections abdominal pain,1,0.5724760890007019
ILARIS,infections,and upper  tract inf ections,1,0.5723361968994141
ILARIS,infections,ections abdominal pain and injection site,0,0.5882829427719116
ILARIS,infections,and upper  tract inf,1,0.5595118999481201
ILARIS,infections,tract inf ections abdominal pain and,1,0.5902475118637085
ILARIS,Infections,ls of a dr ug cannot be directly,1,0.5398586988449097
ILARIS,Infections,tract inf ections abdominal pain and,1,0.5902475118637085
ILARIS,Infections,observed in the clinical ls of a dr ug cannot,1,0.5532048940658569
ILARIS,Infections,ls of,1,0.5592529773712158
ILARIS,Infections,clinical ls,1,0.5713969469070435
ILARIS,Infections,reaction,0,0.4934256672859192
ILARIS,Infections,in the clinical ls of a dr,1,0.5630999803543091
ILARIS,Infections,observed in the clinical ls of a,1,0.5975019931793213
ILARIS,Infections,varying,0,0.5246672630310059
ILARIS,Infections,conditions adverse,0,0.5943299531936646
ILARIS,Infections,clinical trials of another,0,0.5526983141899109
ILARIS,Infections,clinical ls of a dr ug cannot be directly compared,1,0.5241266489028931
ILARIS,Infections,another drug and may not reflect,0,0.5215423107147217
ILARIS,Infections,widely varying conditions adverse reaction,0,0.577130913734436
ILARIS,infections,reflect,0,0.4814472496509552
ILARIS,infections,"


   Trea tment of CAPS The data",1,0.4956006705760956
ILARIS,infections,"


   Trea tment of CAPS The",1,0.5295122265815735
ILARIS,infections,"


   Trea tment",1,0.5192422866821289
ILARIS,infections,in,0,0.5424151420593262
ILARIS,opportunistic infections,104 adult and,1,0.5044031143188477
ILARIS,opportunistic infections,CAPS,0,0.5342646837234497
ILARIS,opportunistic infections,e,1,0.47995874285697937
ILARIS,opportunistic infections,to ILARIS in 104 adult and pediatric CAPS,1,0.5709758996963501
ILARIS,aspergillosis,in adult and iatric CAPS p atients,1,0.6026127338409424
ILARIS,aspergillosis,to ILARIS in 104 adult and pediatric CAPS,1,0.5700815916061401
ILARIS,aspergillosis,MWS,0,0.4612902104854584
ILARIS,aspergillosis,Onset Multisystem,0,0.48225462436676025
ILARIS,aspergillosis,ILARIS in adult and iatric CAPS,1,0.5547745227813721
ILARIS,aspergillosis,CAPS p,1,0.5410553216934204
ILARIS,atypical mycobacterial infections,"ients, including 20 FCAS, 72 MWS,",1,0.45642319321632385
ILARIS,atypical mycobacterial infections,CAPS p,1,0.5051828026771545
ILARIS,atypical mycobacterial infections,"ients, including 20",1,0.48366615176200867
ILARIS,atypical mycobacterial infections,"20 FCAS, 72 MWS, MWSNOMID Neonatal Onset Multisystem Inflammatory",1,0.5844540596008301
ILARIS,herpes zoster,Onset Mu ltisystem Inflammatory,1,0.5632703304290771
ILARIS,herpes zoster,atal Onset Mu ltisystem,1,0.49391210079193115
ILARIS,herpes zoster,including FCAS MWS MWSNOMID atal Onset Mu,1,0.5336595773696899
ILARIS,herpes zoster,atal Onset,1,0.5349864363670349
ILARIS,herpes zoster,and misdiagnosed in,0,0.5276781320571899
ILARIS,herpes zoster,Onset Mu ltisystem,1,0.4984881579875946
ILARIS,herpes zoster,atal Onset Mu ltisystem Inflammatory,1,0.5665775537490845
ILARIS,infections,least s. A total of serious adverse,1,0.5520685911178589
ILARIS,infections,atal Onset Mu ltisystem Inflammatory,1,0.6380372643470764
ILARIS,infections,least s. A total of serious adverse reactions,1,0.5881344676017761
ILARIS,infections,A total of serious adverse,1,0.5700271725654602
ILARIS,infections,year,0,0.5381292104721069
ILARIS,reactivation of tuberculosis,period Part followed,0,0.5128864049911499
ILARIS,reactivation of tuberculosis,"openlabel iod (Part 1), followed by a ",1,0.4812576174736023
ILARIS,reactivation of tuberculosis,period Part followed by,0,0.5109903812408447
ILARIS,reactivation of tuberculosis,an week,0,0.48685014247894287
ILARIS,reactivation of tuberculosis,CAPS Study investigated the safety of ILARIS in,0,0.4973166286945343
ILARIS,reactivation of tuberculosis,followed by a,0,0.516689658164978
ILARIS,reactivation of tuberculosis,in an week openlabel per,0,0.4847894310951233
ILARIS,reactivation of tuberculosis,ILARIS in an week,0,0.45405206084251404
ILARIS,opportunistic infections,"a , randomized withdrawal  period Part followed by",1,0.4759661853313446
ILARIS,opportunistic infections,ILARIS in an week,0,0.47853049635887146
ILARIS,opportunistic infections,"by a ,",1,0.48885881900787354
ILARIS,opportunistic infections,"followed by a , randomized",1,0.503188967704773
ILARIS,opportunistic infections,randomized withdrawal period Part followed by,1,0.4780294895172119
ILARIS,opportunistic infections,randomized withdrawal,1,0.5109577178955078
ILARIS,opportunistic infections,"a , randomized withdrawal  period Part followed by a",1,0.47652721405029297
ILARIS,opportunistic infections,period Part followed by a week,0,0.44348084926605225
ILARIS,malignancies,Weight increased M,0,0.5220832824707031
ILARIS,malignancies,Weight,0,0.5292277932167053
ILARIS,Hypersensitivity reactions,Weight increased Musculoskeletal pain 4,1,0.5136563777923584
ILARIS,Hypersensitivity reactions,4 (11) Vertigo Vertigo,1,0.48031142354011536
ILARIS,Hypersensitivity reactions,"Weight increased Musculoskeletal pain        4 (11)            
 Vertigo Vertigo has been reported",1,0.5231666564941406
ILARIS,Hypersensitivity reactions,pain Vertigo,0,0.4929196834564209
ILARIS,Hypersensitivity reactions,4 (11) Vertigo Vertigo has,1,0.47446465492248535
ILARIS,Hypersensitivity reactions,4 (11) Vertigo Vertigo has been,1,0.4791873097419739
ILARIS,Hypersensitivity reactions,4 (11) Vertigo Vertigo has been reported,1,0.49216631054878235
ILARIS,Hypersensitivity reactions,reported in to of patients in CAPS,0,0.5614047050476074
ILARIS,Hypersensitivity reactions,4 (11) Vertigo,1,0.4711320996284485
ILARIS,anaphylactic reactions,has been reported,0,0.507217526435852
ILARIS,anaphylactic reactions,to of tients in CAPS studies,1,0.5284245014190674
ILARIS,anaphylactic reactions,a serious adverse event in two cases All,0,0.5997526049613953
ILARIS,anaphylactic reactions,adverse event in two cases All events reso,0,0.58926922082901
ILARIS,anaphylactic reactions,CAPS studies exclusively in MWS patients and,1,0.4989358186721802
ILARIS,interfere with normal immune response,have received ILARIS in trials. The safety of,1,0.6016494035720825
ILARIS,interfere with normal immune response,received ILARIS in  trials. The safety of ILARIS compare,1,0.5546287298202515
ILARIS,MAS,"is, adenovirus",1,0.4569026231765747
ILARIS,MAS,dve rse,1,0.534939169883728
ILARIS,MAS,both studies dve,1,0.5020725727081299
ILARIS,MAS,dve rse reactions are listed,1,0.4986765384674072
ILARIS,MAS,ILARIS in both studies dve rse reactions are listed according,1,0.5312478542327881
AMPYRA,Seizures,Seizures Anaphylaxis and,1,0.7973853349685669
AMPYRA,Seizures,the Seizures Anaphylaxis and Urinary Tract Infections,1,0.7730593681335449
AMPYRA,Seizures,Seizures,1,0.9999998211860657
AMPYRA,Seizures,Seizures Anaphylaxis and Urinary,1,0.7710513472557068
AMPYRA,Seizures,common adverse,0,0.5459936857223511
AMPYRA,Seizures,the Seizures Anaphylaxis,1,0.7913047075271606
AMPYRA,Seizures,and Urinary Tract,0,0.5727686882019043
AMPYRA,Anaphylaxis,the label Anaphylaxis and Urinary Tract Infections EXCERPT,1,0.7859776616096497
AMPYRA,Anaphylaxis,and Urinary Tract,0,0.5311442017555237
AMPYRA,Anaphylaxis,Anaphylaxis,1,0.9999999403953552
AMPYRA,Urinary Tract Infections,Seizures Anaphylaxis Urinary,1,0.6325652599334717
AMPYRA,Urinary Tract Infections,Anaphylaxis,0,0.5303464531898499
AMPYRA,Urinary Tract Infections,the label Seizures Anaphylaxis Urinary Tract Infections,1,0.7090097069740295
AMPYRA,Urinary Tract Infections,Anaphylaxis Urinary Tract Infections,1,0.7768261432647705
AMPYRA,Urinary Tract Infections,Anaphylaxis Urinary Tract Infections EXCERPT The,1,0.76358562707901
AMPYRA,urinary tract infection,nausea asthenia back pain balance disorder,0,0.5328025817871094
AMPYRA,urinary tract infection,tract infection insomnia dizziness headache,1,0.671436607837677
AMPYRA,insomnia,insomnia dizziness headache,1,0.8504974246025085
AMPYRA,insomnia,insomnia dizziness headache nausea,1,0.8514883518218994
AMPYRA,insomnia,tract insomnia dizziness headache nausea asthenia,1,0.7562048435211182
AMPYRA,insomnia,placebo rate for AMPYRA were urinary,0,0.504010796546936
AMPYRA,dizziness,dizziness,1,0.9999998807907104
AMPYRA,dizziness,were urinary tract infection dizziness headache nausea asthenia,1,0.7286306619644165
AMPYRA,dizziness,asthenia back pain balance disorder multiple sclerosis relapse,0,0.6568819284439087
AMPYRA,dizziness,sclerosis relapse,0,0.5586576461791992
AMPYRA,dizziness,were urinary tract infection dizziness headache nausea asthenia back pain,1,0.705198347568512
AMPYRA,dizziness,were urinary tract infection dizziness headache,1,0.7619042992591858
AMPYRA,dizziness,urinary tract infection dizziness headache,1,0.7643425464630127
AMPYRA,headache,a rate greater than the placebo rate for AMPYRA were urinary,0,0.5500671863555908
AMPYRA,headache,headache nausea asthenia,1,0.8217108249664307
AMPYRA,headache,back pain balance disorder multiple sclerosis relapse,0,0.5476972460746765
AMPYRA,headache,headache nausea,1,0.8417852520942688
AMPYRA,nausea,insomnia dizziness headache,0,0.6571156978607178
AMPYRA,nausea,pain,0,0.6507443189620972
AMPYRA,nausea,nausea,1,1.0
AMPYRA,nausea,asthenia back pain balance disorder multiple sclerosis relapse,0,0.6064722537994385
AMPYRA,nausea,nausea asthenia back pain balance disorder,1,0.759967565536499
AMPYRA,asthenia,asthenia back pain balance,1,0.7415980100631714
AMPYRA,asthenia,asthenia,1,1.0000001192092896
AMPYRA,asthenia,rate for AMPYRA,0,0.5402044057846069
AMPYRA,asthenia,back pain balance disorder multiple,0,0.5254797339439392
AMPYRA,asthenia,relapse paresthesia nasopharyngitis constipatio,0,0.5803754329681396
AMPYRA,asthenia,asthenia back,1,0.8865198493003845
AMPYRA,back pain,back pain balance disorder multiple,1,0.7548647522926331
AMPYRA,back pain,nausea back pain,1,0.8290770649909973
AMPYRA,back pain,headache nausea back pain,1,0.7936947345733643
AMPYRA,back pain,back pain balance,1,0.8317116498947144
AMPYRA,back pain,ebo rate for AMPYRA were urinary,0,0.4967460334300995
AMPYRA,balance disorder,nausea asthenia back balance disorder multiple sclerosis relapse,1,0.7065219879150391
AMPYRA,balance disorder,ebo rate for AMPYRA were urinary,0,0.4523393213748932
AMPYRA,balance disorder,nausea asthenia back balance,1,0.7589433789253235
AMPYRA,balance disorder,tract,0,0.49298423528671265
AMPYRA,balance disorder,headache nausea asthenia back balance disorder multiple sclerosis relapse,1,0.6817055940628052
AMPYRA,multiple sclerosis relapse,pain balance multiple sclerosis relapse,1,0.8753989934921265
AMPYRA,multiple sclerosis relapse,paresthesia nasopharyngitis constipation dyspepsia and,0,0.5431290864944458
AMPYRA,multiple sclerosis relapse,balance multiple sclerosis relapse paresthesia nasopharyngitis constipation,1,0.8061690330505371
AMPYRA,multiple sclerosis relapse,infection insomnia dizziness headache nausea asthenia,0,0.5470809936523438
AMPYRA,multiple sclerosis relapse,pain balance multiple sclerosis relapse paresthesia nasopharyngitis constipation dyspepsia and,1,0.7553372383117676
AMPYRA,multiple sclerosis relapse,pharyngolaryngeal pain,0,0.47134339809417725
AMPYRA,multiple sclerosis relapse,asthenia back pain balance multiple sclerosis,1,0.7277361154556274
AMPYRA,paresthesia,back pain,0,0.5426315069198608
AMPYRA,nasopharyngitis,nasopharyngitis constipation dyspepsia,1,0.8362336158752441
AMPYRA,nasopharyngitis,multiple sclerosis relapse paresthesia,0,0.528023362159729
AMPYRA,nasopharyngitis,nausea asthenia back pain balance disorder multiple,0,0.5374412536621094
AMPYRA,nasopharyngitis,nasopharyngitis constipation dyspepsia and pharyngolaryngeal pain,1,0.7776088118553162
AMPYRA,nasopharyngitis,sclerosis relapse paresthesia,0,0.49186912178993225
AMPYRA,nasopharyngitis,nasopharyngitis,1,1.0000001192092896
AMPYRA,constipation,constipation dyspepsia and pharyngolaryngeal pain,1,0.7580547332763672
AMPYRA,constipation,constipation dyspepsia and,1,0.8119267225265503
AMPYRA,constipation,multiple sclerosis relapse paresthesia constipation dyspepsia and pharyngolaryngeal pain,1,0.6965179443359375
AMPYRA,constipation,nasopharyngitis,0,0.551152229309082
AMPYRA,constipation,pain To report SUSPECTED ADVERSE REACTIONS contact A,0,0.5351181030273438
AMPYRA,dyspepsia,relapse,0,0.5662283897399902
AMPYRA,dyspepsia,paresthesia nasopharyngitis constipation,0,0.6395658254623413
AMPYRA,dyspepsia,and pharyngolaryngeal pain To report,0,0.6441869735717773
AMPYRA,dyspepsia,pain balance disorder multiple sclerosis relapse paresthesia nasopharyngitis,0,0.5584356784820557
AMPYRA,dyspepsia,relapse paresthesia nasopharyngitis dyspepsia and pharyngolaryngeal,1,0.7425033450126648
AMPYRA,dyspepsia,multiple sclerosis relapse,0,0.5307418704032898
AMPYRA,dyspepsia,nasopharyngitis dyspepsia and pharyngolaryngeal pain To,1,0.7971504926681519
AMPYRA,dyspepsia,and pharyngolaryngeal pain To report SUSPECTED ADVERSE,0,0.62406986951828
AMPYRA,dyspepsia,pharyngolaryngeal pain To report SUSPECTED ADVERSE REACTIONS contact Acorda Thera,0,0.5930083990097046
AMPYRA,pharyngolaryngeal pain,dyspepsia pharyngolaryngeal pain,1,0.9059803485870361
AMPYRA,pharyngolaryngeal pain,pharyngolaryngeal pain To report SUSPECTED ADVERSE REACTIONS contact Acorda Thera,0,0.7813842296600342
AMPYRA,pharyngolaryngeal pain,pharyngolaryngeal pain,1,1.000000238418579
AMPYRA,pharyngolaryngeal pain,constipation dyspepsia pharyngolaryngeal pain To,1,0.8537970781326294
AMPYRA,pharyngolaryngeal pain,contact Acorda Therapeutics at or,0,0.4487733244895935
AMPYRA,headache,frequently compared to placebo headache AMPYRA placebo,1,0.7310771346092224
AMPYRA,headache,contact Acorda Therapeutics at or,0,0.4958518147468567
AMPYRA,headache,AMPYRA and that led to discontinuation more frequently compared to,0,0.5166000127792358
AMPYRA,dizziness,dizziness AMPYRA placebo and confusional,1,0.8008074164390564
AMPYRA,dizziness,placebo balance disorder,0,0.6612228155136108
AMPYRA,confusional state,confusional state AMPYRA placebo Table lists adverse,1,0.68332439661026
AMPYRA,confusional state,confusional state AMPYRA placebo Table lists,1,0.6812868714332581
AMPYRA,confusional state,confusional state AMPYRA placebo,1,0.76710045337677
AMPYRA,confusional state,confusional,1,0.8754180669784546
AMPYRA,confusional state,confusional state AMPYRA placebo Table,1,0.6966089010238647
AMPYRA,confusional state,AMPYRA placebo confusional,1,0.6331762075424194
AMPYRA,seizures,seizures has been observed in,1,0.9105416536331177
AMPYRA,seizures,seizures has been observed,1,0.9215134382247925
AMPYRA,seizures,openlabel,0,0.5220048427581787
AMPYRA,seizures,clinical trials As in controlled clinical trials,0,0.5242646932601929
AMPYRA,seizures,the,0,0.5440011024475098
AMPYRA,seizures,has,0,0.548740804195404
AMPYRA,seizures,seizures,1,0.9999998211860657
AMPYRA,seizures,"conducted under widely varying itions,  adverse reaction",1,0.5712498426437378
AMPYRA,anaphylaxis,label Seizures Anaphylaxis and,0,0.820054292678833
AMPYRA,anaphylaxis,rnings and,1,0.5381735563278198
AMPYRA,anaphylaxis,in the rnings and ,1,0.5357942581176758
AMPYRA,seizures,adverse events >=2%,1,0.5499448776245117
AMPYRA,seizures,events >=2%,1,0.5128491520881653
AMPYRA,seizures,"sia, nas",1,0.49139106273651123
AMPYRA,seizures,sclerosis,0,0.5511025786399841
AMPYRA,seizures,To report SUSPECTED AD,0,0.4850350022315979
AMPYRA,seizures,"sclerosis relapse sia, nas opharyngitis",1,0.5497339963912964
AMPYRA,seizures,iness headache nausea asthenia back pain,0,0.5438272953033447
AMPYRA,seizures,pain To report SUSPECTED,0,0.5226757526397705
AMPYRA,seizures,"multiple sclerosis relapse sia, nas opharyngitis",1,0.5595340132713318
AMPYRA,seizures,"sclerosis relapse sia,",1,0.5731345415115356
AMPYRA,seizures,FDA at FDA or ww.fda.g,1,0.4779033660888672
AMPYRA,seizures,ovmedwatch Controlled Clinical Trials,0,0.5338728427886963
AMPYRA,seizures,In three,0,0.5125720500946045
AMPYRA,seizures,ww.fda.g ovmedwatch Controlled,1,0.5240761041641235
AMPYRA,seizures,at FDA or ww.fda.g ovmedwatch Controlled Clinical Trials Experience,1,0.525168240070343
AMPYRA,seizures,ww.fda.g ovmedwatch Controlled Clinical,1,0.5316321849822998
AMPYRA,seizures,or wwwfdagovmedwatch  Clinica,1,0.5345069766044617
AMPYRA,seizures,In three placebocontrolled clinical trials of,0,0.5166789293289185
AMPYRA,seizures,placebocontrolled clinical trials,0,0.5169126391410828
AMPYRA,seizures,wwwfdagovmedwatch  Clinica,1,0.5417705774307251
AMPYRA,seizures,three,0,0.530550479888916
AMPYRA,seizures, Clinica l Trials Experience In three,1,0.5514179468154907
AMPYRA,seizures,or wwwfdagovmedwatch  Clinica l Trials Experience In,1,0.5445159673690796
AMPYRA,allergic reactions,Back pain,0,0.521726131439209
AMPYRA,allergic reactions,pain,0,0.5599273443222046
AMPYRA,allergic reactions,                   Balance,1,0.451244592666626
AMPYRA,allergic reactions,Back,0,0.5281118154525757
AMPYRA,allergic reactions,                   Balance disorder,1,0.49282222986221313
AMPYRA,respiratory compromise,Back                  5%    Balance disorder,1,0.5001044869422913
AMPYRA,respiratory compromise,Back,0,0.47765034437179565
AMPYRA,respiratory compromise,                 5%    Balance,1,0.47210127115249634
AMPYRA,respiratory compromise,                 5%    Balance disorder,1,0.5182729959487915
AMPYRA,urticaria,Back           Balance,1,0.45559853315353394
AMPYRA,urticaria,                 5%    Balance,1,0.47321927547454834
AMPYRA,urticaria,          Balance disorder,1,0.5059541463851929
AMPYRA,urticaria,Back pain,0,0.48510095477104187
AMPYRA,urticaria,          Balance,1,0.4888487756252289
AMPYRA,urticaria,         ,1,0.5866749882698059
SIRTURO,Increased mortality,the,0,0.494318425655365
SIRTURO,Increased mortality,Increased,1,0.7601650953292847
SIRTURO,Increased mortality,elsewhere in the Increased mortality,1,0.9328079223632812
SIRTURO,Increased mortality,following serious adverse reactions are discussed elsewhere in,0,0.5959900617599487
SIRTURO,Increased mortality,QT Prolongation see Warnings and,0,0.5495158433914185
SIRTURO,Increased mortality,following serious adverse,0,0.6262827515602112
SIRTURO,QT Prolongation,mortality see Warnings and QT Prolongation see Warnings and Precautions,1,0.7617565393447876
SIRTURO,QT Prolongation,following serious adverse,0,0.5485402345657349
SIRTURO,QT Prolongation,see Warnings and Precautions,0,0.484768271446228
SIRTURO,QT Prolongation,elsewhere in the labeling Increased mortality see Warnings and,0,0.505600094795227
SIRTURO,QT Prolongation,elsewhere in the labeling Increased mortality,0,0.506044328212738
SIRTURO,QT Prolongation,mortality see Warnings,0,0.47673726081848145
SIRTURO,QT Prolongation,QT Prolongation see Warnings and Precautions,1,0.8982313275337219
SIRTURO,QT Prolongation,Precautions,0,0.489068865776062
SIRTURO,QT Prolongation,QT Prolongation,1,1.0
SIRTURO,nausea,patients treated with SIRTURO nausea arthralgia headache hemoptysis and,1,0.6785202026367188
SIRTURO,nausea,QT Prolongation,1,0.5004582405090332
SIRTURO,nausea,patients treated with SIRTURO nausea arthralgia,1,0.7210054397583008
SIRTURO,nausea,To report,0,0.5185260772705078
SIRTURO,nausea,nausea arthralgia,1,0.827822208404541
SIRTURO,nausea,nausea,1,1.0
SIRTURO,nausea,headache hemoptysis and chest,0,0.6033691167831421
SIRTURO,nausea,nausea arthralgia headache hemoptysis and,1,0.773328959941864
SIRTURO,nausea,reported in or more of patients treated with SIRTURO,0,0.5302781462669373
SIRTURO,nausea,SIRTURO were,0,0.45056745409965515
SIRTURO,nausea,and chest pain,0,0.5852929949760437
SIRTURO,arthralgia,EXCERPT To,0,0.46753033995628357
SIRTURO,arthralgia,were,0,0.48943954706192017
SIRTURO,arthralgia,of patients,0,0.5111250877380371
SIRTURO,arthralgia,arthralgia headache hemoptysis and,1,0.7741339206695557
SIRTURO,arthralgia,treated with SIRTURO were arthralgia headache hemoptysis and,1,0.6839287281036377
SIRTURO,arthralgia,arthralgia headache hemoptysis,1,0.7649140954017639
SIRTURO,arthralgia,nausea,0,0.5610087513923645
SIRTURO,arthralgia,and,0,0.4762381911277771
SIRTURO,headache,headache hemoptysis,1,0.7855740785598755
SIRTURO,headache,headache hemoptysis and chest pain EXCERPT,1,0.7514579892158508
SIRTURO,hemoptysis,hemoptysis and,1,0.9576349854469299
SIRTURO,hemoptysis,actions reported in or more of patients treated,0,0.4886992275714874
SIRTURO,hemoptysis,arthralgia,0,0.46727681159973145
SIRTURO,hemoptysis,hemoptysis and chest,1,0.9195626974105835
SIRTURO,hemoptysis,were nausea arthralgia hemoptysis and,1,0.8192474842071533
SIRTURO,hemoptysis,hemoptysis and chest pain EXCERPT To,1,0.8629845380783081
SIRTURO,hemoptysis,nausea arthralgia headache,0,0.5316975116729736
SIRTURO,hemoptysis,arthralgia hemoptysis,1,0.8609740734100342
SIRTURO,hemoptysis,To report SUSPECTED,0,0.484988808631897
SIRTURO,hemoptysis,arthralgia hemoptysis and chest,1,0.818053126335144
SIRTURO,aminotransferase elevations,normal developed more,0,0.6237833499908447
SIRTURO,aminotransferase elevations,Studies,0,0.6001293659210205
SIRTURO,aminotransferase elevations,Study In both Studies aminotransferase elevations,1,0.9407515525817871
SIRTURO,aminotransferase elevations,Adverse Reactions were identified from the uncontrolled,0,0.6071194410324097
SIRTURO,increased mortality,increased mortality risk by Week in,1,0.8525504469871521
SIRTURO,increased mortality,there was a statistically increased mortality,1,0.9431028366088867
SIRTURO,increased mortality,treatment group compared to,0,0.5133254528045654
SIRTURO,deaths,Five of the deaths and the,1,0.8258283138275146
SIRTURO,deaths,treatment group compared to,0,0.46359604597091675
SIRTURO,deaths,deaths and the,1,0.8900558948516846
SIRTURO,deaths,difference Five of,0,0.5246566534042358
SIRTURO,deaths,deaths and the deaths were tuberculosisrelated One,1,0.7741644382476807
SIRTURO,deaths,deaths and the deaths were tuberculosisrelated One death occurred,1,0.7517588138580322
SIRTURO,deaths,deaths were tuberculosisrelated One death occurred,1,0.733719527721405
SIRTURO,deaths,of the difference Five of the SIRTURO deaths,0,0.7378384470939636
SIRTURO,deaths,deaths were tuberculosisrelated One,1,0.7517536878585815
SIRTURO,death,The median time to death,0,0.7391949892044067
SIRTURO,death,death,1,0.9999998807907104
SIRTURO,death,placebo deaths were tuberculosisrelated death,1,0.6318364143371582
SIRTURO,death,tuberculosisrelated death occurred during the,1,0.6635756492614746
SIRTURO,death,median time to,0,0.5127183198928833
SIRTURO,death,death occurred during the week SIRTURO,1,0.7248585820198059
SIRTURO,death,intake of S,0,0.5468788743019104
SIRTURO,deaths,unexplained,0,0.49522238969802856
SIRTURO,deaths,The imbalance deaths is unexplained no discernible pattern,1,0.6817787885665894
SIRTURO,deaths,last intake,0,0.5642207860946655
SIRTURO,deaths,deaths is,1,0.8486310243606567
SIRTURO,deaths,SIRTURO The imbalance deaths is unexplained no discernible,1,0.691766619682312
SIRTURO,deaths,in,0,0.5468313694000244
SIRTURO,deaths,deaths,1,0.9999999403953552
SIRTURO,death,treat tuberculosis HIV status,0,0.459514319896698
SIRTURO,death,unexplained no discernible pattern death and,1,0.6859139204025269
SIRTURO,death,death and sputum,1,0.7379856109619141
SIRTURO,death,discernible pattern death and sputum conversion relapse,1,0.6010275483131409
SIRTURO,death,death and sputum conversion relapse sensitivity,1,0.61116623878479
SIRTURO,death,drugs used,0,0.534765362739563
SIRTURO,died,observed In the openlabel,0,0.4982302784919739
SIRTURO,died,died The most common,1,0.7858095169067383
SIRTURO,died,died The,1,0.9422892332077026
SIRTURO,died,died,1,1.0000001192092896
SIRTURO,died,died The most,1,0.7976860404014587
SIRTURO,died,died The most common cause,1,0.770362377166748
SIRTURO,death,but,0,0.567886233329773
SIRTURO,death,one subject who died of TB,0,0.6295361518859863
SIRTURO,death,most common cause death,1,0.7321699857711792
SIRTURO,death,death as reported by the,1,0.7839335799217224
SIRTURO,death,death as reported by the investigator,1,0.734184741973877
SIRTURO,death,cause death as reported by the,1,0.7544882893562317
SIRTURO,death,died of TB had not con,0,0.6388129591941833
SIRTURO,died,not converted,0,0.49192529916763306
SIRTURO,died,subject,0,0.5337268114089966
SIRTURO,died,died of TB,1,0.7367535829544067
SIRTURO,death,causes death,1,0.8114820122718811
SIRTURO,death,died of TB,1,0.6540870666503906
SIRTURO,death,not,0,0.5553945302963257
SIRTURO,death,TB had not converted or,0,0.4637398421764374
SIRTURO,death,All but one subject who died of TB had not converted,0,0.5461101531982422
SIRTURO,death,remaining subjects varied,0,0.5319762229919434
SIRTURO,death,in,0,0.5595656633377075
SIRTURO,death,relapsed The causes death in the remaining,1,0.6901437044143677
SIRTURO,death,in the,0,0.580456018447876
SIRTURO,INCREASED MORTALITY,REACTIONS following serious a,1,0.5907692909240723
SIRTURO,INCREASED MORTALITY,ADVERSE REACTIONS following serious a,1,0.6229312419891357
SIRTURO,INCREASED MORTALITY,reactions are discussed elsewhere in,0,0.5258352160453796
SIRTURO,INCREASED MORTALITY,ADVERSE REACTIONS following serious a dverse reactions are,1,0.6027588248252869
SIRTURO,INCREASED MORTALITY,following serious a dverse reactions,1,0.5694460272789001
SIRTURO,INCREASED MORTALITY,following serious a dverse,1,0.5398192405700684
SIRTURO,INCREASED MORTALITY,ADVERSE REACTIONS following serious a dverse,1,0.6258665323257446
SIRTURO,INCREASED MORTALITY,dverse reactions,0,0.5109323859214783
SIRTURO,QT PROLONGATION,* In creased mortality,1,0.5128028392791748
SIRTURO,QT PROLONGATION,serious adverse,0,0.5148805975914001
SIRTURO,QT PROLONGATION,* In creased mortality see,1,0.5068594217300415
SIRTURO,QT PROLONGATION,discussed elsewhere in the ling: * In,1,0.5373247861862183
SIRTURO,QT PROLONGATION,"elsewhere in the ling:



 *  In creased mortality see Warnings and",1,0.502966582775116
SIRTURO,QT PROLONGATION,adverse reactions are discussed elsewhere in,0,0.5157197713851929
SIRTURO,QT PROLONGATION,"the ling:



 *  In creased mortality see",1,0.5198607444763184
SIRTURO,QT PROLONGATION,"the ling:



 *  In creased mortality",1,0.5444394946098328
SIRTURO,QT PROLONGATION,"in the ling:



 *  In creased mortality",1,0.540783166885376
SIRTURO,INCREASED MORTALITY,and Precaut ions QT,1,0.4667471647262573
SIRTURO,INCREASED MORTALITY,labeling Increased mortality see arnings and Precaut ions QT Prolongation see,1,0.7762216925621033
SIRTURO,INCREASED MORTALITY,and Clinical,0,0.5482299327850342
SIRTURO,INCREASED MORTALITY,see arnings and Precaut ions QT Prolongation see Warnings,1,0.551956832408905
SIRTURO,INCREASED MORTALITY,Warnings and Precautions,0,0.5752885341644287
SIRTURO,INCREASED MORTALITY,and Precautions and,0,0.545384407043457
SIRTURO,INCREASED MORTALITY,Increased mortality see arnings and Precaut ions QT Prolongation see,1,0.7840836048126221
SIRTURO,QT PROLONGATION,"mortality see Warnings and ns (5.1)  ]  
 ",1,0.4916941225528717
SIRTURO,QT PROLONGATION,and Precautions and,0,0.47816967964172363
SIRTURO,QT PROLONGATION,and ns (5.1),1,0.4897295832633972
SIRTURO,QT PROLONGATION,Prolongation,0,0.777242124080658
SIRTURO,death,nings and Precautions Drug Interactions,1,0.5120334625244141
SIRTURO,death,nings and,1,0.5528435707092285
SIRTURO,death,and,0,0.6179868578910828
SIRTURO,death,War,0,0.6370340585708618
SIRTURO,death,Clinical,0,0.5404825210571289
SIRTURO,death,Warnings and,0,0.5806009769439697
SIRTURO,death,Precautions Drug,0,0.49970459938049316
SIRTURO,death,nings,1,0.5217280387878418
SIRTURO,death,Hepatotoxicity see nings,1,0.5254029035568237
SIRTURO,QT prolongation,pain,0,0.49400293827056885
SIRTURO,QT prolongation,SUSPECTED ADVERSE REACTIONS contact Janssen Therapeutics Division of,0,0.4678915739059448
SIRTURO,QT prolongation,      EXCERPT: ,1,0.5138826370239258
SIRTURO,QT prolongation,chest       EXCERPT:  To report SUSPECTED,1,0.4554559290409088
SIRTURO,QT prolongation,Therapeutics Division,0,0.5314731597900391
SIRTURO,QT prolongation,"Janssen Therapeutics Division of ssen Products,  LP at JANSSEN or",1,0.48501265048980713
SIRTURO,QT prolongation,"Division of ssen Products,  LP at JANSSEN",1,0.46318596601486206
SIRTURO,QT prolongation,Therapeutics Division of ssen,1,0.5413371324539185
SIRTURO,QT prolongation,ssen,1,0.5141538381576538
SIRTURO,QT prolongation,"Division of ssen Products,",1,0.4923551678657532
SIRTURO,QT prolongation,"ssen Products, LP at JANSSEN or FDA",1,0.5041256546974182
SIRTURO,QT prolongation,"ssen Products, LP at JANSSEN",1,0.4690161645412445
SIRTURO,QT prolongation,FDA at FDA or wwwfdagovmedwatch,0,0.4623028039932251
SIRTURO,death,clinical studies are ducte d under,1,0.49802345037460327
SIRTURO,death,FDA at FDA or wwwfdagovmedwatch,0,0.49500900506973267
SIRTURO,death,ducte d under,1,0.4861009120941162
SIRTURO,death,ducte d under widely varying conditions,1,0.5057903528213501
SIRTURO,death,ducte,1,0.49802881479263306
SIRTURO,death,clinical,0,0.5404824614524841
SIRTURO,QT prolongation,from the pooled safety  from 335 SIRTU ROexposed patients who received,1,0.5733538866043091
SIRTURO,QT prolongation,clinical,0,0.5013034343719482
SIRTURO,QT prolongation,reactions for SIRTURO were identified from,0,0.5039494633674622
SIRTURO,QT prolongation,pooled,0,0.49116742610931396
SIRTURO,QT prolongation,335 SIRTU ROexposed patients who received weeks,1,0.6162640452384949
SIRTURO,QT prolongation,pooled safety from 335,1,0.5010405778884888
SIRTURO,QT prolongation,practice Adverse,0,0.4902563989162445
SIRTURO,QT prolongation,safety  from 335 SIRTU,1,0.5466052293777466
SIRTURO,QT prolongation,discussed,0,0.5018504858016968
SIRTURO,QT prolongation,discussed elsewhere,0,0.4891132116317749
SIRTURO,QT prolongation,erse reactions are discussed,1,0.5300233960151672
SIRTURO,QT prolongation,REACTIONS The following serious erse reactions ,1,0.5059710144996643
SIRTURO,QT prolongation,REACTIONS The following serious erse reactions  are,1,0.5005639791488647
SIRTURO,QT prolongation,adv,0,0.5523898005485535
SIRTURO,QT prolongation,erse reactions are discussed elsewhere in the,1,0.5165947675704956
SIRTURO,QT prolongation,erse reactions are discussed elsewhere,1,0.5118853449821472
SIRTURO,Hepatotoxicity,reased mortality see Warnings and Precautions QT Prolongation see Warnings and,0,0.5894681811332703
SIRTURO,Hepatotoxicity,ecautions,1,0.5059880614280701
SIRTURO,Hepatotoxicity,see Warnings and,0,0.575476348400116
SIRTURO,Hepatotoxicity,Prolongation see Warnings and ecautions (5.2 and,1,0.5617024302482605
SIRTURO,Hepatotoxicity,and Clinical,0,0.5229658484458923
SIRTURO,Hepatotoxicity,and ecautions (5.2,1,0.4696011543273926
SIRTURO,Hepatotoxicity,Pr,0,0.47122690081596375
SIRTURO,Hepatotoxicity,ecautions (5.2 and Clinical,1,0.5325067043304443
SIRTURO,Hepatotoxicity,Precautions QT Prolongation see Warnings and,0,0.5643975734710693
SIRTURO,Hepatotoxicity,Prolongation see Warnings and ecautions,1,0.5649571418762207
SIRTURO,death,ommon adverse reactions reported in or,1,0.500092089176178
SIRTURO,death,were,0,0.5811336040496826
SIRTURO,death,ommon adverse reactions,1,0.4987650513648987
SIRTURO,death,REACTIONS contact Janssen Therapeutics Division of Janssen Products LP,0,0.48648887872695923
SIRTURO,death,ECTED ADVERSE,1,0.5709326863288879
SIRTURO,death,report ECTED ADVERSE REACTIONS contact,1,0.4975757598876953
SIRTURO,death,To report ECTED ADVERSE REACTIONS contact Janssen Therapeutics,1,0.47660791873931885
SIRTURO,deaths,Product,0,0.4870041310787201
SIRTURO,deaths,"s, LP at JANSSEN or",1,0.4988331198692322
SIRTURO,deaths,ADVERSE REACTIONS contact Janssen Therapeutics,0,0.4637022316455841
SIRTURO,deaths,"s, LP  at JANSSEN or",1,0.4988331198692322
SIRTURO,deaths,"s, LP ",1,0.5187748670578003
SIRTURO,deaths,"s, LP  at JANSSEN or FDA",1,0.47413375973701477
SIRTURO,deaths,Therapeutics Division of Janssen Product,0,0.4442603588104248
SIRTURO,deaths,"Janssen s, LP",1,0.46367427706718445
SIRTURO,death,LP at JANSSEN or at 1-,1,0.4922367036342621
SIRTURO,death,at JANSSEN or at,1,0.509148120880127
SIRTURO,death,at 1- FDA or wwwfdagovmedwatch,1,0.5142037272453308
SIRTURO,death,at 1-,1,0.5130655765533447
SIRTURO,death,LP at JANSSEN or at 1- FDA or,1,0.4970714747905731
SIRTURO,prolongs the QT interval,another,0,0.4966326057910919
SIRTURO,prolongs the QT interval,clinical studies of another dr,0,0.5370330810546875
SIRTURO,prolongs the QT interval,not reflect t,1,0.47186243534088135
SIRTURO,prolongs the QT interval,reactions for SIRTURO,0,0.48470425605773926
SIRTURO,prolongs the QT interval,of another ug and may not reflect t he rates observed in,1,0.5367709398269653
SIRTURO,prolongs the QT interval,may not reflect t,1,0.4801509380340576
SIRTURO,prolongs the QT interval,Adverse drug reactions,0,0.5316545963287354
SIRTURO,prolongs the QT interval,reflect t he rates observed in,1,0.5034464597702026
SIRTURO,prolongs the QT interval,drug cannot be directly compared to the rates in the clinical,0,0.5668169260025024
ADREVIEW,hypersensitivity reactions,ADVERSE REACTIONS EXCERPT Serious,0,0.7321312427520752
ADREVIEW,hypersensitivity reactions,hypersensitivity,1,0.9332083463668823
ADREVIEW,hypersensitivity reactions,reported,0,0.5072222948074341
ADREVIEW,hypersensitivity reactions,Serious,0,0.5191116333007812
ADREVIEW,hypersensitivity reactions,REACTIONS EXCERPT Serious,0,0.6863544583320618
ADREVIEW,hypersensitivity reactions,REACTIONS EXCERPT,0,0.7113242149353027
ADREVIEW,hypersensitivity reactions,EXCERPT hypersensitivity reactions have been reported,1,0.9248032569885254
ADREVIEW,hypersensitivity reactions,following AdreView administration The most,0,0.44790714979171753
ADREVIEW,hypersensitivity reactions,EXCERPT Serious,0,0.5328457355499268
ADREVIEW,dizziness,site,0,0.5075662136077881
ADREVIEW,dizziness,dizziness,1,1.0
ADREVIEW,dizziness,The most common adverse dizziness rash pruritis flushing,1,0.7531728744506836
ADREVIEW,dizziness,dizziness rash pruritis flushing,1,0.7770593166351318
ADREVIEW,dizziness,The most common adverse reactions,0,0.5779491662979126
ADREVIEW,dizziness,hemorrhage occurred in of,0,0.5383667945861816
ADREVIEW,rash,rash pruritis flushing,1,0.8240506052970886
ADREVIEW,rash,rash pruritis flushing headache and,1,0.7937718033790588
ADREVIEW,rash,dizziness,0,0.5513002276420593
ADREVIEW,pruritis,hemorrhage occurred in of,0,0.46911686658859253
ADREVIEW,pruritis,pruritis,1,0.9999998807907104
ADREVIEW,pruritis,injection site hemorrhage occurred,0,0.5056018829345703
ADREVIEW,flushing,pruritis,0,0.5485849380493164
ADREVIEW,flushing,administration The most common,0,0.525783896446228
ADREVIEW,flushing,dizziness rash flushing headache and injection,1,0.6478603482246399
ADREVIEW,flushing,adverse reactions dizziness rash,0,0.5449010729789734
ADREVIEW,flushing,flushing,1,1.0
ADREVIEW,flushing,flushing headache,1,0.802191972732544
ADREVIEW,flushing,in of,0,0.5425071716308594
ADREVIEW,flushing,common,0,0.5338139533996582
ADREVIEW,injection site hemorrhage,rash pruritis flushing headache and,0,0.5291948318481445
ADREVIEW,injection site hemorrhage,injection site hemorrhage,1,1.0000001192092896
ADREVIEW,injection site hemorrhage,flushing headache injection site hemorrhage,1,0.867732048034668
ADREVIEW,injection site hemorrhage,ministration The most common adverse reactions dizziness rash pruritis flushing,0,0.5590012073516846
ADREVIEW,injection site hemorrhage,in,0,0.4750601649284363
ADREVIEW,injection site hemorrhage,injection site hemorrhage occurred in of patients To,1,0.9624841213226318
ADREVIEW,injection site hemorrhage,rash pruritis flushing headache injection site hemorrhage,1,0.773766279220581
ADREVIEW,injection site hemorrhage,flushing headache injection site hemorrhage occurred in of patients,1,0.8508021235466003
ADREVIEW,injection site hemorrhage,and,0,0.4275165796279907
ADREVIEW,injection site hemorrhage,headache injection,1,0.6718800663948059
ADREVIEW,dizziness,Congestive Heart Failure No,0,0.5723831653594971
ADREVIEW,dizziness,were predominantly isolated occurrences patients of one of the following reactions,0,0.5563039779663086
ADREVIEW,dizziness,following dizziness rash,1,0.8688163757324219
ADREVIEW,dizziness,dizziness rash pruritus flushing or,1,0.7718180418014526
ADREVIEW,rash,isolated,0,0.507418155670166
ADREVIEW,pruritus,patients of one of the following reactions dizziness rash,0,0.6436065435409546
ADREVIEW,flushing,flushing or injection,1,0.8409967422485352
ADREVIEW,injection site hemorrhage,flushing or injection,1,0.7168933153152466
ADREVIEW,injection site hemorrhage,injection site hemorrhage Congestive Heart Failure No,1,0.8877984285354614
ADREVIEW,injection site hemorrhage,currences patients of one of the following reactions dizziness rash pruritus flushing,0,0.5423275232315063
ADREVIEW,injection site hemorrhage,Heart Failure No serious adverse reactions to AdreView were,0,0.5376923084259033
ADREVIEW,injection site hemorrhage,flushing injection site hemorrhage,1,0.935577929019928
ADREVIEW,injection site hemorrhage,dizziness rash pruritus flushing injection site hemorrhage Congestive,1,0.7735871076583862
ADREVIEW,injection site hemorrhage,rash pruritus flushing injection,1,0.6311324834823608
ADREVIEW,injection site hemorrhage,injection site hemorrhage Congestive Heart Failure No serious,1,0.8747498393058777
ADREVIEW,headache,reactions were predominantly of mild to moderate intensity,0,0.5372627377510071
ADREVIEW,headache,mild to moderate intensity,0,0.5641688108444214
ADREVIEW,headache,headache The adverse,1,0.883115291595459
ADREVIEW,headache,other most,0,0.5099925994873047
ADREVIEW,headache,headache The adverse reactions were predominantly,1,0.7997210621833801
ADREVIEW,headache,headache,1,1.0
ADREVIEW,headache,of mild,0,0.5456595420837402
ADREVIEW,headache,mild,0,0.5618560314178467
ADREVIEW,headache,and bruising The other most common reactions were flushing,0,0.5399452447891235
ADREVIEW,Hypersensitivity reactions,Hypersensitivity reactions have,1,0.9594573974609375
ADREVIEW,Hypersensitivity reactions,drug exposure,0,0.5972369909286499
ADREVIEW,Hypersensitivity reactions,to drug Hypersensitivity reactions,1,0.880365252494812
ADREVIEW,Hypersensitivity reactions,to drug Hypersensitivity reactions have,1,0.8784396648406982
ADREVIEW,Hypersensitivity reactions,Serious,0,0.5191116333007812
ADREVIEW,Hypersensitivity reactions,adverse reactions,0,0.7704890966415405
ADREVIEW,Hypersensitivity reactions,ensitivity,1,0.6371151208877563
ADREVIEW,Hypersensitivity reactions,REACTIONS EXCERPT Serious ensitivity,1,0.710397481918335
ADREVIEW,Hypersensitivity reactions,EXCERPT Serious,0,0.5328457355499268
ADREVIEW,Hypersensitivity reactions,following AdreView administration The,0,0.4583887457847595
ADREVIEW,Hypersensitivity reactions,ensitivity reactions have been reported following AdreView administration,1,0.708966851234436
ADREVIEW,Hypersensitivity reactions,hypers,0,0.6050809025764465
ADREVIEW,Hypersensitivity reactions,EXCERPT Serious ensitivity reactions have,1,0.7655512690544128
ADREVIEW,Hypersensitivity reactions,"with heart ure, and 110 control patie nts All patients",1,0.5262161493301392
ADREVIEW,Hypersensitivity reactions,"neuroblastoma patients with heart ure, and 110 control patie nts",1,0.5371519327163696
ARCAPTA,asthma,asthma related death ARCAPTA NEOHALER is,1,0.7288659811019897
ARCAPTA,asthma,of asthma,0,0.902438759803772
ARCAPTA,asthma,risk,0,0.5603410005569458
ARCAPTA,asthma,asthma related death ARCAPTA NEOHALER,1,0.7404948472976685
ARCAPTA,asthma,of,0,0.5317946672439575
ARCAPTA,death,death,1,0.9999998807907104
ARCAPTA,death,treatment of asthma See B,0,0.48260343074798584
ARCAPTA,death,for the treatment of asthma See,0,0.4739040732383728
ARCAPTA,death,death ARCAPTA NEOHALER is not indicated,1,0.5867730379104614
ARCAPTA,death,the treatment of asthma See B oxed,0,0.517689049243927
ARCAPTA,death,the risk of death ARCAPTA,1,0.6799076795578003
ARCAPTA,death,of death ARCAPTA NEOHALER is not indicated,1,0.5922194719314575
ARCAPTA,death,treatment of asthma See B oxed,0,0.5159443020820618
ARCAPTA,oropharyngeal pain,oropharyngeal pain nasopharyngitis headache and nausea To,1,0.8453900814056396
ARCAPTA,oropharyngeal pain,nausea To report SUSPECTED ADVERSE REACTIONS,0,0.558808445930481
ARCAPTA,oropharyngeal pain,than placebo are oropharyngeal,1,0.7777244448661804
ARCAPTA,oropharyngeal pain,are oropharyngeal pain,1,0.986465573310852
ARCAPTA,oropharyngeal pain,EXCERPT,0,0.45537853240966797
ARCAPTA,oropharyngeal pain,oropharyngeal pain nasopharyngitis,1,0.8759450912475586
ARCAPTA,nasopharyngitis,are,0,0.49877679347991943
ARCAPTA,nasopharyngitis,report SUSPECTED ADVERSE REACTIONS contact,0,0.5617607831954956
ARCAPTA,nasopharyngitis,SUSPECTED ADVERSE REACTIONS contact Novartis,0,0.5550280809402466
ARCAPTA,nasopharyngitis,are cough oropharyngeal nasopharyngitis,1,0.8419872522354126
ARCAPTA,nasopharyngitis,nasopharyngitis headache and nausea To report,1,0.8532853126525879
ARCAPTA,nasopharyngitis,are cough oropharyngeal nasopharyngitis headache and nausea To,1,0.7925728559494019
ARCAPTA,headache,headache and nausea To report,1,0.7870804071426392
ARCAPTA,headache,cough oropharyngeal pain headache and,1,0.7478346228599548
ARCAPTA,headache,headache,1,0.9999998807907104
ARCAPTA,headache,and more common than placebo are,0,0.5492424368858337
ARCAPTA,headache,nausea To report SUSPECTED ADVERSE,0,0.5993645787239075
ARCAPTA,headache,cough oropharyngeal pain headache,1,0.75583815574646
ARCAPTA,nausea,pain nasopharyngitis headache nausea To report SUSPECTED ADVERSE REACTIONS,1,0.7203852534294128
ARCAPTA,nausea,nausea To report SUSPECTED ADVERSE,0,0.8329814672470093
ARCAPTA,nausea,pain nasopharyngitis headache nausea To report SUSPECTED,1,0.7195136547088623
ARCAPTA,nausea,nausea To report,1,0.8770608305931091
ARCAPTA,nausea,Novartis,0,0.5496560335159302
ARCAPTA,nausea,pain nasopharyngitis headache nausea To report,1,0.7440389394760132
ARCAPTA,nausea,headache nausea To report SUSPECTED ADVERSE,1,0.8038730025291443
ARCAPTA,nausea,nausea To report SUSPECTED,1,0.8313741087913513
ARCAPTA,nausea,common than,0,0.5454061031341553
ARCAPTA,nausea,nausea To report SUSPECTED ADVERSE REACTIONS,1,0.8234140872955322
ARCAPTA,COPD,of ARCAPTA NEOHALER COPD and dyspnea The,1,0.741104781627655
ARCAPTA,COPD,nausea To report SUSPECTED ADVERSE REACTIONS,1,0.49090680480003357
ARCAPTA,COPD,COPD,0,1.0000001192092896
ARCAPTA,COPD,d patients The most common,0,0.5994488596916199
ARCAPTA,COPD,NEOHALER COPD and dyspnea The most,1,0.7670835256576538
ARCAPTA,dyspnea,dyspnea The most,1,0.9156959056854248
ARCAPTA,dyspnea,The most common adverse reactions that lead to discontinuation of ARCAPTA NEOHALER were COPD,0,0.6185417771339417
ARCAPTA,dyspnea,COPD dyspnea The most common,1,0.7918007373809814
ARCAPTA,dyspnea,dyspnea The,1,0.9632712602615356
ARCAPTA,dyspnea,discontinuation of ARCAPTA,0,0.518218994140625
ARCAPTA,dyspnea,adverse reactions were COPD exacerbation pneumonia angina,0,0.6351784467697144
ARCAPTA,dyspnea,dyspnea The most common,1,0.8681252002716064
ARCAPTA,COPD exacerbation,ation of ARCAPTA NEOHALER were COPD and,0,0.716920018196106
ARCAPTA,pneumonia,adverse reactions were COPD pneumonia angina pectoris and atrial fibrillation,1,0.6608531475067139
ARCAPTA,pneumonia,ation of ARCAPTA NEOHALER were COPD and,0,0.5670409202575684
ARCAPTA,pneumonia,and dyspnea The most common serious adverse reactions were COPD,0,0.5584239959716797
ARCAPTA,angina pectoris,common serious adverse,0,0.5115138292312622
ARCAPTA,angina pectoris,at,0,0.5349905490875244
ARCAPTA,angina pectoris,angina,1,0.8910032510757446
ARCAPTA,angina pectoris,angina pectoris and atrial fibrillation,1,0.8655264377593994
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris atrial fibrillation which occurred at similar rates,1,0.7212635278701782
ARCAPTA,atrial fibrillation,angina pectoris and atrial fibrillation,1,0.7988595962524414
ARCAPTA,atrial fibrillation,common serious,0,0.5105389356613159
ARCAPTA,atrial fibrillation,adverse,0,0.5038586258888245
ARCAPTA,atrial fibrillation,treatment groups Table,0,0.5193276405334473
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris atrial fibrillation,1,0.7097922563552856
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris atrial fibrillation which,1,0.7242254018783569
ARCAPTA,atrial fibrillation,pneumonia angina pectoris atrial fibrillation which occurred,1,0.7605165243148804
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris and,0,0.55474853515625
ARCAPTA,atrial fibrillation,angina pectoris atrial fibrillation,1,0.8099402785301208
ARCAPTA,Cough,Cough Oropharyngeal pain,1,0.794522762298584
ARCAPTA,Nasopharyngitis,and Nasopharyngitis Nervous system disorders,1,0.8301975727081299
ARCAPTA,Nasopharyngitis,Cough Oropharyngeal pain,1,0.6246932148933411
ARCAPTA,Nasopharyngitis,Nasopharyngitis Nervous system disorders,1,0.8161153197288513
ARCAPTA,Nasopharyngitis,Nasopharyngitis,1,1.0000001192092896
ARCAPTA,Nasopharyngitis,system disorders,0,0.4853661060333252
ARCAPTA,Headache,system disorders,0,0.5078222751617432
ARCAPTA,Headache,Headache,1,0.9999998807907104
ARCAPTA,Nausea,Nausea,1,1.0
ARCAPTA,Nausea,disorders,0,0.5810480713844299
ARCAPTA,Nausea,Gastrointestinal Nausea In these trials the,1,0.7948352098464966
ARCAPTA,Nausea,Nausea In these trials the,1,0.8393428325653076
ARCAPTA,Nausea,Nausea In,1,0.9463655948638916
ARCAPTA,Nausea,Headache,0,0.668434739112854
ARCAPTA,muscle spasm,tissue muscle,1,0.7034552693367004
ARCAPTA,musculoskeletal pain,disorders muscle musculoskeletal,1,0.7973555326461792
ARCAPTA,musculoskeletal pain,muscle musculoskeletal pain General disorders and administration site,1,0.821020245552063
ARCAPTA,musculoskeletal pain,and administration site conditions edema peripheral Metabolism and,0,0.5498683452606201
ARCAPTA,musculoskeletal pain,musculoskeletal pain General disorders,1,0.8709133863449097
ARCAPTA,edema peripheral,and administration site edema peripheral,1,0.9084087014198303
ARCAPTA,edema peripheral,musculoskeletal pain General disorders,1,0.5722290277481079
ARCAPTA,edema peripheral,disorders and administration site edema peripheral,1,0.8842929005622864
ARCAPTA,edema peripheral,edema peripheral Metabolism and nutrition disorder diabetes,1,0.8253134489059448
ARCAPTA,edema peripheral,and administration site conditions,0,0.5191203355789185
ARCAPTA,edema peripheral,disorder diabetes mellitus,0,0.5510698556900024
ARCAPTA,edema peripheral,Infections and,0,0.5402926802635193
ARCAPTA,edema peripheral,musculoskeletal pain General disorders and administration site conditions,0,0.5839560031890869
ARCAPTA,edema peripheral,site edema peripheral,1,0.9422098398208618
ARCAPTA,edema peripheral,disorders and administration site edema,1,0.7733136415481567
ARCAPTA,diabetes mellitus,upper respiratory tract infection,0,0.5518208146095276
ARCAPTA,diabetes mellitus,and nutrition diabetes mellitus,1,0.8409408926963806
ARCAPTA,diabetes mellitus,nutrition diabetes mellitus,1,0.8329476714134216
ARCAPTA,diabetes mellitus,disorder,0,0.5815024375915527
ARCAPTA,diabetes mellitus,and administration,0,0.47838038206100464
ARCAPTA,diabetes mellitus,and infestations,0,0.518496036529541
ARCAPTA,hyperglycemia,upper respiratory tract,0,0.5114181041717529
ARCAPTA,hyperglycemia,hyperglycemia Infections and infestations,1,0.8091903924942017
ARCAPTA,hyperglycemia,and nutrition disorder diabetes mellitus,0,0.7070279121398926
ARCAPTA,hyperglycemia,mellitus,0,0.5418753027915955
ARCAPTA,hyperglycemia,tract infection C ough,0,0.5107712745666504
ARCAPTA,hyperglycemia,infection C,0,0.539975643157959
ARCAPTA,hyperglycemia,hyperglycemia Infections and infestations sinusitis,1,0.7593682408332825
ARCAPTA,hyperglycemia,hyperglycemia Infections,1,0.8591182231903076
ARCAPTA,sinusitis,experienced p ost,0,0.5158196687698364
ARCAPTA,sinusitis,sinusitis upper respiratory,1,0.8350242376327515
ARCAPTA,sinusitis,Infections and sinusitis upper respiratory,1,0.8181519508361816
ARCAPTA,sinusitis,sinusitis upper respiratory tract infection C,1,0.8135392665863037
ARCAPTA,sinusitis,and nutrition disorder diabetes mellitus hyperglycemia Infections and,0,0.5658770799636841
ARCAPTA,sinusitis,mellitus hyperglycemia Infections and sinusitis,1,0.793096661567688
ARCAPTA,upper respiratory tract infection,infestations upper respiratory tract infection,1,0.8321223258972168
ARCAPTA,upper respiratory tract infection,mellitus hyperglycemia Infections and infestations,0,0.5638712644577026
ARCAPTA,upper respiratory tract infection,upper respiratory tract infection C ough experienced p ost,1,0.8786922097206116
ARCAPTA,upper respiratory tract infection,infestations upper respiratory tract infection C ough experienced,1,0.80856853723526
ARCAPTA,cough,of,0,0.5623703598976135
ARCAPTA,cough,on at least of visits following inhalation of the,0,0.6078462600708008
ARCAPTA,cough,inhalation of the recommended mcg dose of,0,0.5722612142562866
ARCAPTA,cough,patients experienced cough on,1,0.8297064304351807
ARCAPTA,cough,dose of,0,0.5850158929824829
ARCAPTA,cough,to of,0,0.5841413736343384
ARCAPTA,cough,placebo cough usually occurred,1,0.8136652708053589
ARCAPTA,cough,cough usually occurred within,1,0.8451883792877197
ARCAPTA,cough,within seconds following inhalation and lasted for no more than seconds Cou,0,0.6078383326530457
ARCAPTA,cough,f,0,0.5427392721176147
ARCAPTA,cough,inhalation and lasted for no,0,0.6165586709976196
ARCAPTA,cough,cough usually occurred,1,0.8679718971252441
ARCAPTA,cough,cough usually,1,0.8894432187080383
ARCAPTA,Cough,within seconds following inhalation and lasted for no more than,0,0.5928305983543396
ARCAPTA,Cough,Cough,1,1.0
ARCAPTA,Cough,Cough following inhalation in clinical trials,1,0.7679169178009033
ARCAPTA,Cough,Cough following,1,0.8843218684196472
ARCAPTA,Cough,was not associated,0,0.4828893542289734
ARCAPTA,Cough,Cough following inhalation,1,0.808669924736023
ARCAPTA,bronchospasm,associated bronchospasm exacerbations deteriorations of,1,0.8078362345695496
ARCAPTA,bronchospasm,Cough following inhalation,1,0.659403920173645
ARCAPTA,bronchospasm,bronchospasm,1,1.0
ARCAPTA,bronchospasm,bronchospasm exacerbations,1,0.851838231086731
ARCAPTA,loss of efficacy,disease loss of efficacy Clinical Trials Experience,1,0.836974024772644
ARCAPTA,loss of efficacy,bronchospasm exacerbations,1,0.5964170694351196
ARCAPTA,loss of efficacy,exacerbations deteriorations of disease,0,0.6667687892913818
ARCAPTA,loss of efficacy,of efficacy Clinical Trials,1,0.740291953086853
ARCAPTA,loss of efficacy,n clinical trials was not associated with bronchospasm exacerbations deteriorations of,0,0.6352291107177734
ARCAPTA,loss of efficacy,deteriorations of disease loss of efficacy,1,0.9041592478752136
ARCAPTA,loss of efficacy,of efficacy Clinical Trials Experience in,1,0.7312259674072266
ARCAPTA,deaths,dose group There were deaths in the,1,0.8666433691978455
ARCAPTA,deaths,of efficacy Clinical Trials Experience in,1,0.47621411085128784
ARCAPTA,deaths,in the ARCAPTA NEOHALER mcg dose group or in the,0,0.4740927815437317
ARCAPTA,deaths,were deaths in,1,0.9116151332855225
ARCAPTA,deaths,dose group There were deaths in the ARCAPTA NEOHALER,1,0.6885519027709961
ARCAPTA,deaths,there were respiratoryrelated deaths in the ARCAPTA NEOHALER mcg,0,0.6835007071495056
ARCAPTA,deaths,respiratoryrelated deaths in the ARCAPTA NEOHALER mcg dose group There were no,0,0.6243054866790771
ARCAPTA,deaths,deaths,1,0.9999999403953552
ARCAPTA,deaths,deaths in the,1,0.9474966526031494
ARCAPTA,asthma exacerbation,asthma exacerbation,1,0.9999998807907104
ARCAPTA,asthma exacerbation,the indacaterol mcg group patients in,0,0.5185821652412415
ARCAPTA,asthma exacerbation,were reported for,0,0.49647781252861023
ARCAPTA,asthma exacerbation,adverse reactions related asthma exacerbation were reported,1,0.875952422618866
ARCAPTA,asthma exacerbation,mcg group,0,0.43221208453178406
ARCAPTA,deaths,inhaled corticosteroids deaths intubations or,1,0.6313333511352539
ARCAPTA,deaths,mcg group,0,0.4731592833995819
ARCAPTA,deaths,deaths intubations,1,0.7567803859710693
ARCAPTA,deaths,inhaled corticosteroids deaths intubations or serious adverse,1,0.6076643466949463
ARCAPTA,deaths,reactions related,0,0.5579634308815002
ARCAPTA,paradoxical bronchospasm,reactions are hypersensitivity paradoxical bronchospasm,1,0.9176288843154907
ARCAPTA,paradoxical bronchospasm,hypersensitivity paradoxical,1,0.7587103843688965
ARCAPTA,paradoxical bronchospasm,paradoxical bronchospasm tachycardiaheart,1,0.912073016166687
ARCAPTA,tachycardia,tachycardia heart rate increasepalpitations pruritusrash,1,0.798099160194397
ARCAPTA,tachycardia,tachycardia heart,1,0.8982356190681458
ARCAPTA,tachycardia,hypersensitivity reactions paradoxical tachycardia heart rate increasepalpitations,1,0.7827537059783936
ARCAPTA,tachycardia,tachycardia heart rate,1,0.9139612913131714
ARCAPTA,heart rate increase,heart rate increase palpitations pruritusrash and dizziness,1,0.7974013090133667
ARCAPTA,heart rate increase,tachycardia heart rate,1,0.80701744556427
ARCAPTA,palpitations,bronchospasm tachycardiaheart rate increase,0,0.6916221380233765
ARCAPTA,palpitations,rate palpitations,1,0.9254902601242065
ARCAPTA,palpitations,pruritusrash and dizziness,0,0.6090309619903564
ARCAPTA,palpitations,pruritusrash,0,0.5860748291015625
ARCAPTA,palpitations,palpitations pruritusrash,1,0.8238929510116577
ARCAPTA,palpitations,paradoxical bronchospasm,0,0.5673615336418152
ARCAPTA,palpitations,pruritusrash and,0,0.5886890888214111
ARCAPTA,palpitations,paradoxical bronchospasm tachycardiaheart rate palpitations pruritusrash and,1,0.731000542640686
ARCAPTA,pruritus,rash and dizziness,0,0.6455253958702087
ARCAPTA,pruritus,paradoxical bronchospasm,0,0.5108914375305176
ARCAPTA,pruritus,reactions paradoxical bronchospasm,0,0.5172516107559204
ARCAPTA,pruritus,tachycardiaheart rate pruritus,1,0.8126293420791626
ARCAPTA,pruritus,pruritus rash,1,0.9252881407737732
ARCAPTA,pruritus,pruritus,1,0.9999999403953552
ARCAPTA,rash,bronchospasm tachycardiaheart rate increasepalpitations rash and dizziness,1,0.6710679531097412
ARCAPTA,rash,pruritus rash,1,0.8591687083244324
ARCAPTA,rash,rash and,1,0.9337756037712097
ARCAPTA,rash,bronchospasm tachycardiaheart rate,0,0.5274231433868408
ARCAPTA,rash,tachycardiaheart rate increasepalpitations rash and,1,0.7104202508926392
ARCAPTA,rash,reactions paradoxical bronchospasm tachycardiaheart rate,0,0.5446888208389282
ARCAPTA,rash,tachycardiaheart rate,0,0.5047187209129333
ARCAPTA,DEATH,    -,1,0.5773090124130249
ARCAPTA,DEATH,REACTIONS L,0,0.5637325048446655
ARCAPTA,DEATH,REACTIONS L ong,0,0.5770105123519897
ARCAPTA,DEATH,ADVERSE REACTIONS,0,0.5449328422546387
ARCAPTA,DEATH,as A RCAPTA NEOHALER,0,0.49329590797424316
ARCAPTA,DEATH,    - acting beta,1,0.49118247628211975
ARCAPTA,DEATH,ong,0,0.5380093455314636
ARCAPTA,DEATH,acting,0,0.5456656217575073
ARCAPTA,DEATH,increase the risk,0,0.5126234889030457
ARCAPTA,DEATH,beta c ago nists such as,1,0.474190354347229
ARCAPTA,DEATH,acting beta c ago,1,0.5103364586830139
ARCAPTA,DEATH,ong acting beta c,1,0.5145925879478455
ARCAPTA,DEATH,ong acting beta c ago,1,0.5245834589004517
ARCAPTA,DEATH,c ago nists such as,1,0.4724692106246948
ARCAPTA,DEATH,acting beta c,1,0.4940393269062042
ARCAPTA,death,of asthma See,0,0.5082388520240784
ARCAPTA,death,is,1,0.5676156282424927
ARCAPTA,death,W,0,0.5490193367004395
ARCAPTA,deaths,yngeal pain nasopharyngitis headache and,1,0.5042321681976318
ARCAPTA,deaths,yngeal pain nasopharyngitis headache and nausea,1,0.5065282583236694
ARCAPTA,deaths,EXCERPT Most common adverse reactions and more common than placebo are cough orophar,0,0.5020313262939453
ARCAPTA,deaths,yngeal pain nasopharyngitis,1,0.4881797432899475
ARCAPTA,deaths,cough,0,0.5802087783813477
ARCAPTA,deaths,To report SUSPECTED ADVERSE REACTIONS,0,0.49673962593078613
ARCAPTA,deaths,yngeal,1,0.49663862586021423
ARCAPTA,DEATH,practice The ARCAPTA NEOHALER safety database reflects,0,0.5229799747467041
ARCAPTA,DEATH,The ARCAPTA NEOHALER,0,0.4936526417732239
ARCAPTA,death,ALER safety,0,0.5314130783081055
ARCAPTA,death,or eater for at,1,0.5254696607589722
ARCAPTA,death,or,0,0.5881109237670898
ARCAPTA,death,of mcg or eater,1,0.5419272184371948
ARCAPTA,death,and,0,0.6179868578910828
ARCAPTA,death,least weeks in,0,0.5316816568374634
ARCAPTA,death,weeks in six confirmatory randomized doubleblind placebo and activecontrolled,0,0.48201441764831543
ARCAPTA,deaths,see,0,0.5418784022331238
ARCAPTA,deaths,randomized,0,0.47302931547164917
ARCAPTA,deaths, trial s patients were exposed to,1,0.5353949069976807
ARCAPTA,deaths,placebo and,0,0.4675302505493164
ARCAPTA,deaths,doubleblind placebo and activecontrolled clinical trials see Section In these,0,0.4577067494392395
ARCAPTA,death,respectively Overall pa,0,0.5169781446456909
ARCAPTA,death,months and d 425 COPD patients were,1,0.4789893329143524
ARCAPTA,death,recommended,0,0.5520370006561279
ARCAPTA,death,were exposed to the recommended dose of mcg,0,0.5243040323257446
ARCAPTA,death,exposed to the recommended dose of mcg for up to months and,0,0.5124589204788208
ARCAPTA,death,d 425 COPD patients were exposed,1,0.4858497083187103
ARCAPTA,cardiovascular effects,nausea To report,0,0.5657042264938354
ARCAPTA,cardiovascular effects,"are cough, or",1,0.48613041639328003
ARCAPTA,cardiovascular effects,"cough, or opharyngeal pain nasopharyngitis",1,0.49851471185684204
ARCAPTA,cardiovascular effects,and more common placebo),1,0.538304328918457
ARCAPTA,cardiovascular effects,placebo),1,0.5517287254333496
ARCAPTA,cardiovascular effects,ecautions EXCERPT Most common adverse reactions and,0,0.6406570672988892
ARCAPTA,cardiovascular effects,than,0,0.4847319722175598
ARCAPTA,cardiovascular effects,"reactions and more common placebo) are cough, or opharyngeal",1,0.571832001209259
ARCAPTA,cardiovascular effects,reactions,0,0.6052613258361816
ARCAPTA,cardiovascular effects,"more common placebo) are cough, or opharyngeal",1,0.5337709188461304
ARCAPTA,hypersensitivity reactions,placebo are cough oropharyngeal pain nasopharyngitis,0,0.5298207998275757
ARCAPTA,hypersensitivity reactions,nasopharyngitis and,1,0.5845932960510254
ARCAPTA,hypersensitivity reactions," and nausea. (  6  ) 



  To",1,0.5498236417770386
ARCAPTA,hypersensitivity reactions,"oropharyngeal pain nasopharyngitis  and nausea. (  6  ) 



  To report SUSPECTED ADVERSE REACTIONS",1,0.6135638952255249
ARCAPTA,hypersensitivity reactions,oropharyngeal pain nasopharyngitis and nausea. (,1,0.5383903384208679
ARCAPTA,hypersensitivity reactions,SUSPECTED,0,0.49897080659866333
ARCAPTA,hypersensitivity reactions,placebo are cough oropharyngeal pain,0,0.49267247319221497
ARCAPTA,hypersensitivity reactions,eactions and more common than placebo are cough oropharyngeal pain nasopharyngitis,0,0.5707876682281494
ARCAPTA,paradoxical bronchospasm,REACTIONS contact Novartis cals Corporation at 1-88 or FDA at,1,0.5294190049171448
ARCAPTA,paradoxical bronchospasm,eactions and more common than placebo are cough oropharyngeal pain nasopharyngitis,0,0.577908456325531
ARCAPTA,death,EOHAL ER,1,0.5208777785301208
ARCAPTA,death,the rates observed in practice The ARCAPTA,0,0.4728586673736572
ARCAPTA,deaths,of or mcg,0,0.5119538307189941
ARCAPTA,deaths,were e xposed to a,1,0.4802854657173157
ARCAPTA,death,n age of patients,1,0.47867608070373535
ARCAPTA,death,of The n age of patients,1,0.49194473028182983
ARCAPTA,death,of The n age,1,0.5087838768959045
ARCAPTA,death,mea,0,0.5036314725875854
ARCAPTA,death,on,1,0.588549017906189
ARCAPTA,death,that,0,0.6206560134887695
ARCAPTA,death,and for placebotreated patients,0,0.5216371417045593
ARCAPTA,hypersensitivity reactions,"iated with bronchospasm, e",1,0.5983887910842896
ARCAPTA,hypersensitivity reactions,"not iated with bronchospasm, e",1,0.5596499443054199
ARCAPTA,hypersensitivity reactions,trials was not iated,1,0.4618925154209137
ARCAPTA,hypersensitivity reactions,"iated with bronchospasm, e xacerbations deteriorations",1,0.5959889888763428
ARCAPTA,hypersensitivity reactions,clinical trials was not,0,0.45331302285194397
ARCAPTA,hypersensitivity reactions,"with bronchospasm, e xacerbations deteriorations of disease",1,0.5854177474975586
ARCAPTA,hypersensitivity reactions,efficacy Clinical Trials,0,0.5043748021125793
ARCAPTA,hypersensitivity reactions,of efficacy,0,0.4923098087310791
ARCAPTA,paradoxical bronchospasm,Of these pati,1,0.4313296377658844
ARCAPTA,paradoxical bronchospasm,concomitant with inhaled corticosteroids which were,0,0.6583486795425415
ARCAPTA,paradoxical bronchospasm,andomized. Of these pati ents there,1,0.48622432351112366
ARCAPTA,paradoxical bronchospasm,n,0,0.4658967852592468
ARCAPTA,increases in pulse rate,in the indacaterol mcg,0,0.5899233818054199
ARCAPTA,increases in pulse rate,600 mcg gr oup and,1,0.5335444211959839
ARCAPTA,increases in pulse rate,600 mcg gr,1,0.5083312392234802
ARCAPTA,increases in pulse rate,mcg group patients in  indacaterol 600 mcg gr,1,0.5697794556617737
ARCAPTA,ECG changes,mild persistent asthma inhaled cor ticosteroids No deaths intubations or,1,0.4916219711303711
ARCAPTA,ECG changes,600 mcg gr,1,0.4898884892463684
ARCAPTA,ECG changes,with mild persistent asthma,0,0.4805845320224762
ARCAPTA,ECG changes,to asthma exacerbation,0,0.5137465000152588
ARCAPTA,ECG changes,asthma exacerbation we,0,0.5291135311126709
ARCAPTA,ECG changes,conducted in,0,0.5014010071754456
ARCAPTA,ECG changes,asthma inhaled cor ticosteroids,1,0.4843370318412781
ARCAPTA,flattening of the T wave,"taking inhaled ds. No deaths, intubatio ns or",1,0.4852907061576843
ARCAPTA,flattening of the T wave,conducted in,0,0.5500363111495972
ARCAPTA,flattening of the T wave,"asthma taking inhaled ds. No deaths, intubatio",1,0.4717376232147217
ARCAPTA,flattening of the T wave,taking inhaled ds. No,1,0.47933289408683777
ARCAPTA,flattening of the T wave,"No deaths, intubatio ns",1,0.5242778062820435
ARCAPTA,flattening of the T wave,serious adverse,0,0.5153164863586426
ARCAPTA,flattening of the T wave,reported,0,0.5177672505378723
ARCAPTA,flattening of the T wave,"inhaled ds. No deaths, intubatio ns or serious adverse reactions",1,0.4959338307380676
ARCAPTA,flattening of the T wave,"inhaled ds. No deaths, intubatio ns or serious adverse",1,0.49014461040496826
ARCAPTA,flattening of the T wave,adverse reactions,0,0.5159589052200317
ARCAPTA,flattening of the T wave,g trial was conducted in adult patients with mild persistent asthma,0,0.5360604524612427
ARCAPTA,prolongation of the QTc interval,"corticosteroids No deaths ,",1,0.48066940903663635
ARCAPTA,prolongation of the QTc interval,No deaths,0,0.5064390301704407
ARCAPTA,prolongation of the QTc interval,mild persistent asthma taking inhaled corticosteroids,0,0.4816538989543915
ARCAPTA,prolongation of the QTc interval,"corticosteroids No deaths , or serious adverse reactions r elated to asthma exacerbation",1,0.5087804794311523
ARCAPTA,prolongation of the QTc interval,corticosteroids No,0,0.44333386421203613
ARCAPTA,prolongation of the QTc interval,reactions r,1,0.5138574838638306
ARCAPTA,prolongation of the QTc interval,"inhaled corticosteroids No deaths , or serious adverse reactions r elated to asthma exacerbation were",1,0.5072742104530334
ARCAPTA,prolongation of the QTc interval,inhaled corticosteroids,0,0.4679660499095917
ARCAPTA,prolongation of the QTc interval,reactions r elated to asthma exacerbation were,1,0.4971338212490082
ARCAPTA,prolongation of the QTc interval,reactions r elated to asthma,1,0.4816093444824219
ARCAPTA,ST segment depression,serious adverse reactions to asthma,1,0.4896959662437439
INTELENCE,hypersensitivity reactions,reactions are described in greater detail in other sections Severe skin,0,0.7432944774627686
INTELENCE,hypersensitivity reactions,hypersensitivity reactions see Warnings,1,0.8669772744178772
INTELENCE,hypersensitivity reactions,hypersensitivity reactions see Warnings and Precautions EXCERPT,1,0.8635315895080566
INTELENCE,hypersensitivity reactions,hypersensitivity reactions,1,1.0
INTELENCE,hypersensitivity reactions,hypersensitivity,1,0.9332083463668823
INTELENCE,rash,than placebo in adults are,0,0.5228961706161499
INTELENCE,diarrhea,in at least,0,0.5268573760986328
INTELENCE,diarrhea,diarrhea To report SUSPECTED ADVERSE REACTIONS,1,0.7948397397994995
INTELENCE,diarrhea,rash diarrhea To report SUSPECTED,1,0.7787741422653198
INTELENCE,rash,Grade in,0,0.4864659905433655
INTELENCE,rash,rash StevensJohnson syndrome,1,0.8082630634307861
INTELENCE,rash,rash,1,1.0000001192092896
INTELENCE,rash,rash StevensJohnson syndrome drug hypersensitivity reaction,1,0.750908374786377
INTELENCE,rash,the placebo arm The most frequently reported ADR at least Grade in severity was,0,0.5369981527328491
INTELENCE,rash,rash StevensJohnson,1,0.757967472076416
INTELENCE,rash,and,0,0.5314319133758545
INTELENCE,rash,The most frequently reported ADR at,0,0.4751399755477905
INTELENCE,Stevens-Johnson syndrome,reported ADR at least Grade in severity was rash,0,0.6565930843353271
INTELENCE,Stevens-Johnson syndrome,Stevens-Johnson,1,0.8184363842010498
INTELENCE,Stevens-Johnson syndrome,in,0,0.5339440107345581
INTELENCE,Stevens-Johnson syndrome,rash,0,0.6669876575469971
INTELENCE,Stevens-Johnson syndrome,Stevens-Johnson syndrome drug hypersensitivity,1,0.8857159614562988
INTELENCE,Stevens-Johnson syndrome,Stevens-Johnson syndrome drug,1,0.886113166809082
INTELENCE,hypersensitivity,reaction and erythema multiforme were reported in less than,0,0.7058100700378418
INTELENCE,hypersensitivity,reported ADR at least Grade in severity was rash StevensJohnson syndrome,0,0.6199471354484558
INTELENCE,hypersensitivity,hypersensitivity reaction,1,0.9445638656616211
INTELENCE,hypersensitivity,hypersensitivity reaction and erythema multiforme,1,0.8215896487236023
INTELENCE,hypersensitivity,at least Grade in severity,0,0.5355350971221924
INTELENCE,erythema multiforme,than of subjects during clinical development with INTELENCE r,0,0.5183819532394409
INTELENCE,erythema multiforme,hypersensitivity reaction erythema multiforme were,1,0.8959078788757324
INTELENCE,rash,rash In general in,1,0.9114450216293335
INTELENCE,rash,rash In general in clinical trials,1,0.8135697841644287
INTELENCE,rash,r discontinued due,0,0.5064417719841003
INTELENCE,rash,was mild to moderate occurred primarily in the,0,0.5125722885131836
INTELENCE,rash,discontinued due rash In,1,0.8141273260116577
INTELENCE,rash,rash In general in clinical,1,0.856562614440918
INTELENCE,rash,trials,0,0.5345271825790405
INTELENCE,rash,discontinued due to rash In general in clinical trials,0,0.7508788108825684
INTELENCE,Rash,Rash generally resolved within to weeks,1,0.7817955613136292
INTELENCE,Rash,occurred primarily in the second week of therapy and was infrequent,0,0.5171933770179749
INTELENCE,Rash,was infrequent after Rash,1,0.8154326677322388
INTELENCE,Rash,and was infrequent after Rash generally resolved within to weeks,1,0.7379419207572937
INTELENCE,Rash,Rash generally resolved within to,1,0.8024064898490906
INTELENCE,Rash,in the second week of therapy and was infrequent,0,0.4947732090950012
INTELENCE,Rash,was,0,0.5342103242874146
INTELENCE,Rash,infrequent after Rash generally resolved within to,1,0.7738370895385742
INTELENCE,Rash,on continued therapy The incidence,0,0.5227762460708618
INTELENCE,rash,Week Rash generally resolved within to weeks on,0,0.7618036270141602
INTELENCE,rash,therapy The incidence rash was higher in,1,0.79010009765625
INTELENCE,rash,men in the INTELENCE r arm in,0,0.5078015327453613
INTELENCE,rash,rash was higher in,1,0.8594042062759399
INTELENCE,rash,within to weeks on continued therapy The incidence,0,0.5623630285263062
INTELENCE,rash,rash was higher in women compared,1,0.77866530418396
INTELENCE,rash,the Phase trials rash,0,0.7849668264389038
INTELENCE,rash,therapy The incidence rash was higher in women compared,1,0.7619953155517578
INTELENCE,rash,r arm in the Phase trials,0,0.5580816268920898
INTELENCE,rash,arm in the,0,0.5541384816169739
INTELENCE,rash,in the Phase rash,1,0.8186432123184204
INTELENCE,rash,rash Grade,1,0.8038485050201416
INTELENCE,rash,rash Grade was,1,0.7632381916046143
INTELENCE,rash,reported in,0,0.4963473379611969
INTELENCE,rash,rash Grade was reported,1,0.7293717265129089
INTELENCE,rash,rash Grade was reported in,1,0.7471117973327637
INTELENCE,rash,was higher in women compared to men,0,0.4537714123725891
INTELENCE,rash,in women versus men see Warnings and,0,0.5000531673431396
INTELENCE,rash,a history of rash did not appear to be,1,0.7733439207077026
INTELENCE,rash,be at increased risk for the development of INTELENCE,0,0.5418319702148438
INTELENCE,rash,r related rash,0,0.8284910917282104
INTELENCE,rash,a history of,0,0.46643000841140747
INTELENCE,rash,rash compared,1,0.887768030166626
INTELENCE,rash,did not appear,0,0.4554179608821869
INTELENCE,rash,rash compared to,1,0.8795567154884338
INTELENCE,rash,to be at increased risk for the development of INTELENCE r,0,0.5602917075157166
INTELENCE,rash,rash Common Adverse Reactions,1,0.8357322812080383
INTELENCE,rash,rash Common Adverse Reactions Clinical,1,0.816631019115448
INTELENCE,rash,greater,0,0.5185672044754028
INTELENCE,rash,without a history of rash Common Adverse Reactions Clinical ADRs,1,0.7169119715690613
INTELENCE,Peripheral neuropathy,System,0,0.45744138956069946
INTELENCE,Peripheral neuropathy,Peripheral neuropathy,1,1.0000001192092896
INTELENCE,Peripheral neuropathy,Disorders,0,0.5852333307266235
INTELENCE,Peripheral neuropathy,System Disorders,0,0.5382242202758789
INTELENCE,Peripheral neuropathy,Skin and,0,0.5604995489120483
INTELENCE,Peripheral neuropathy,System Peripheral,1,0.6208534836769104
INTELENCE,Peripheral neuropathy,ground regimen Nervous System Peripheral neuropathy,1,0.8584657907485962
INTELENCE,Peripheral neuropathy,Peripheral neuropathy Skin and,1,0.9142827391624451
INTELENCE,Peripheral neuropathy,regimen Nervous System Peripheral neuropathy,1,0.8605155944824219
INTELENCE,angina pectoris,Eye Disorders,0,0.4813482165336609
INTELENCE,angina pectoris,myocardial angina pectoris,1,0.947213351726532
INTELENCE,angina pectoris,angina pectoris atrial fibrillation Ear and,1,0.8323615193367004
INTELENCE,angina pectoris,fibrillation Ear and Labyrinth Disorders,0,0.5063742399215698
INTELENCE,angina pectoris,Disorders vertigo Eye Disorders blurred vi,0,0.5004326701164246
INTELENCE,atrial fibrillation,blurred,0,0.5337835550308228
INTELENCE,atrial fibrillation,atrial fibrillation Ear and,1,0.8625340461730957
INTELENCE,atrial fibrillation,atrial fibrillation Ear and Labyrinth,1,0.8224046230316162
INTELENCE,atrial fibrillation,infarction angina atrial fibrillation Ear and Labyrinth Disorders vertigo,1,0.6948025226593018
INTELENCE,atrial fibrillation,infarction,0,0.6317381858825684
INTELENCE,atrial fibrillation,Eye Disorders blurred,0,0.50816810131073
INTELENCE,atrial fibrillation,atrial fibrillation Ear and Labyrinth Disorders,1,0.7982014417648315
INTELENCE,atrial fibrillation,angina,0,0.6393884420394897
INTELENCE,atrial fibrillation,angina pectoris,0,0.6505557894706726
INTELENCE,vertigo,fibrillation Ear and Labyrinth,0,0.692358672618866
INTELENCE,vertigo,vertigo Eye Disorders blurred vision,1,0.807998776435852
INTELENCE,vertigo,vertigo,1,1.0
INTELENCE,vertigo,Ear and Labyrinth vertigo,1,0.8871376514434814
INTELENCE,vertigo,blurred vision Gastrointestinal Disorders gastroesophageal reflux,0,0.6162900924682617
INTELENCE,vertigo,Eye,0,0.6013036966323853
INTELENCE,vertigo,vertigo Eye,1,0.8862608671188354
INTELENCE,vertigo,vertigo Eye Disorders,1,0.8386784791946411
INTELENCE,vertigo,blurred vision Gastrointestinal Disorders gastroesophageal,0,0.6040976047515869
INTELENCE,blurred vision,Disorders,0,0.5856733322143555
INTELENCE,blurred vision,Disorders gastroesophageal,0,0.48360487818717957
INTELENCE,blurred vision,blurred vision Gastrointestinal,1,0.8450274467468262
INTELENCE,blurred vision,blurred vision Gastrointestinal Disorders gastroesophageal reflux,1,0.7660894393920898
INTELENCE,gastroesophageal reflux disease,gastroesophageal reflux disease,1,0.9999998211860657
INTELENCE,gastroesophageal reflux disease,Gastrointestinal gastroesophageal,1,0.8190053701400757
INTELENCE,gastritis,gastritis abdominal distension pancreatitis constipation,1,0.814083456993103
INTELENCE,gastritis,gastritis abdominal,1,0.8905201554298401
INTELENCE,gastritis,gastritis abdominal distension pancreatitis,1,0.8052108287811279
INTELENCE,pancreatitis,distension,0,0.5788906812667847
INTELENCE,pancreatitis,pancreatitis,1,0.9999998807907104
INTELENCE,pancreatitis,pancreatitis constipation dry mouth hematemesis retching,1,0.7755640745162964
INTELENCE,pancreatitis,pancreatitis constipation dry,1,0.7836641669273376
INTELENCE,constipation,abdominal distension constipation dry mouth,1,0.7892337441444397
INTELENCE,constipation,pancreatitis constipation dry,1,0.7745976448059082
INTELENCE,constipation,dry mouth hematemesis retching stomatitis General Disorders and,0,0.6252484917640686
INTELENCE,constipation,dry mouth hematemesis retching stomatitis General Disorders and Administration Site,0,0.6137077808380127
INTELENCE,constipation,flatulence gastritis abdominal distension constipation dry,1,0.7750303745269775
INTELENCE,constipation,stomatitis General Disorders and Administration,0,0.54648756980896
INTELENCE,constipation,gastritis abdominal distension constipation dry mouth,1,0.7422902584075928
INTELENCE,constipation,retching stomatitis,0,0.5971642732620239
INTELENCE,constipation,constipation dry mouth,1,0.8063317537307739
INTELENCE,constipation,flatulence gastritis abdominal,0,0.6311091184616089
INTELENCE,hematemesis,hematemesis,1,1.0
INTELENCE,hematemesis,dry hematemesis retching stomatitis General Disorders and,1,0.7231968641281128
INTELENCE,hematemesis,hematemesis retching stomatitis General,1,0.7727407813072205
INTELENCE,hematemesis,Disorders and Administration Site Conditions,0,0.5647863745689392
INTELENCE,hematemesis,hematemesis retching stomatitis General Disorders and,1,0.750514030456543
INTELENCE,hematemesis,distension pancreatitis constipation dry,0,0.5259759426116943
INTELENCE,retching,e flatulence,0,0.7071496248245239
INTELENCE,retching,Administration,0,0.49742981791496277
INTELENCE,retching,retching stomatitis General Disorders,1,0.803715705871582
INTELENCE,retching,retching stomatitis,1,0.8638132810592651
INTELENCE,retching,dry mouth retching stomatitis General Disorders and Administration,1,0.7697555422782898
INTELENCE,retching,Site,0,0.5019140243530273
INTELENCE,retching,retching stomatitis General Disorders and,1,0.8196443319320679
INTELENCE,retching,dry mouth retching stomatitis General Disorders and,1,0.774246335029602
INTELENCE,retching,constipation dry mouth retching,1,0.8306544423103333
INTELENCE,sluggishness,Hepatobiliary Disorders hepatic failure h,0,0.5111583471298218
INTELENCE,sluggishness,sluggishness,1,1.000000238418579
INTELENCE,sluggishness,Hepatobiliary Disorders,0,0.5400078296661377
INTELENCE,sluggishness,Administration Site sluggishness Hematologic Disorders hemolytic anemia Hepatobiliary,1,0.7163530588150024
INTELENCE,sluggishness,and Administration,0,0.5120667219161987
INTELENCE,hemolytic anemia,Conditions sluggishness Hematologic hemolytic anemia Hepatobiliary Disorders,1,0.7324197888374329
INTELENCE,hemolytic anemia,and Administration,0,0.414566308259964
INTELENCE,hemolytic anemia,and,0,0.47617673873901367
INTELENCE,hemolytic anemia,hemolytic anemia Hepatobiliary,1,0.8319713473320007
INTELENCE,hemolytic anemia,hepatitis hepatic steato,0,0.53792405128479
INTELENCE,hemolytic anemia,Hepatobiliary Disorders hepatic failure,0,0.5491068363189697
INTELENCE,hemolytic anemia,hemolytic anemia Hepatobiliary Disorders hepatic,1,0.8043454885482788
INTELENCE,hepatic failure,ns sluggishness,0,0.5251166820526123
INTELENCE,hepatic failure,hepatic failure hepatomegaly cytolytic hepatitis,1,0.8520075678825378
INTELENCE,hepatomegaly,Immune System Disorders drug hypersensi,0,0.5578708648681641
INTELENCE,cytolytic hepatitis,Hepatobiliary Disorders hepatic failure cytolytic hepatitis,1,0.8450130224227905
INTELENCE,cytolytic hepatitis,Disorders hepatic failure cytolytic,1,0.8414686322212219
INTELENCE,cytolytic hepatitis,logic Disorders hemolytic anemia Hepatobiliary Disorders,0,0.6268965005874634
INTELENCE,cytolytic hepatitis,Immune System Disorders drug hypersensitivity,0,0.5339670181274414
INTELENCE,cytolytic hepatitis,hepatic failure cytolytic hepatitis,1,0.9269952178001404
INTELENCE,cytolytic hepatitis,cytolytic hepatitis,1,0.9999997615814209
INTELENCE,hepatic steatosis,hepatic steatosis hepatitis Immune System Disorders drug,1,0.8202452659606934
INTELENCE,hepatic steatosis,hepatomegaly cytolytic,0,0.6251474618911743
INTELENCE,hepatic steatosis,failure hepatomegaly cytolytic hepatic steatosis hepatitis Immune System Disorders,1,0.7623993158340454
INTELENCE,hepatic steatosis,hepatic steatosis hepatitis Immune System Disorders,1,0.8239268064498901
INTELENCE,hepatitis,Disorders hepatic failure hepatomegaly cytolytic hepatitis,0,0.7147631645202637
INTELENCE,hepatitis,hepatitis,1,1.0
INTELENCE,hepatitis,System Disorders drug hypersensitivity immune reconstitution syndrome Metabo,0,0.5393761396408081
INTELENCE,hepatitis,hepatitis Immune System,1,0.8398236036300659
INTELENCE,hepatitis,hepatitis Immune System Disorders drug hypersensitivity,1,0.7202508449554443
INTELENCE,hepatitis,hepatic steatosis,0,0.717839241027832
INTELENCE,drug hypersensitivity,drug hypersensitivity immune reconstitution,1,0.8403265476226807
INTELENCE,drug hypersensitivity,drug hypersensitivity immune reconstitution syndrome Metabolism and,1,0.8006908893585205
INTELENCE,drug hypersensitivity,drug hypersensitivity immune reconstitution syndrome,1,0.8309289216995239
INTELENCE,drug hypersensitivity,drug,1,0.7220426201820374
INTELENCE,drug hypersensitivity,steatosis hepatitis Immune,0,0.47368040680885315
INTELENCE,drug hypersensitivity,immune reconstitution syndrome Metabolism and Nutrition Disorders diabetes mellitus anor,0,0.5469987392425537
INTELENCE,drug hypersensitivity,hepatomegaly cytolytic hepatitis hepatic steatosis hepatitis,0,0.5059429407119751
INTELENCE,drug hypersensitivity,drug hypersensitivity immune,1,0.9383025169372559
INTELENCE,immune reconstitution syndrome,Disorders drug immune reconstitution,1,0.8316702842712402
INTELENCE,immune reconstitution syndrome,diabetes mellitus anorexia dyslipidemia,0,0.5302937030792236
INTELENCE,immune reconstitution syndrome,Immune System Disorders drug immune reconstitution syndrome Metabolism and,1,0.8399747014045715
INTELENCE,immune reconstitution syndrome,reconstitution syndrome Metabolism and Nutrition Disorders,1,0.8155643939971924
INTELENCE,immune reconstitution syndrome,Disorders drug immune reconstitution syndrome,1,0.9036275148391724
INTELENCE,immune reconstitution syndrome,drug immune reconstitution syndrome,1,0.9095004200935364
INTELENCE,immune reconstitution syndrome,drug,0,0.46384817361831665
INTELENCE,immune reconstitution syndrome,drug immune reconstitution syndrome Metabolism and,1,0.851830005645752
INTELENCE,immune reconstitution syndrome,System Disorders drug hypersensitivity,0,0.5933711528778076
INTELENCE,diabetes mellitus,somnolence convulsion hyp,0,0.4698990285396576
INTELENCE,diabetes mellitus,Metabolism and Nutrition diabetes,1,0.7615371942520142
INTELENCE,diabetes mellitus,and Nutrition diabetes mellitus anorexia dyslipidemia Nervous System,1,0.7419751882553101
INTELENCE,diabetes mellitus,dyslipidemia Nervous System Disorders paraesthesia,0,0.6318778991699219
INTELENCE,diabetes mellitus,syndrome Metabolism and Nutrition diabetes mellitus anorexia dyslipidemia Nervous System Disorders,1,0.7018637657165527
INTELENCE,diabetes mellitus,Metabolism and Nutrition diabetes mellitus anorexia dyslipidemia Nervous System,1,0.7314050197601318
INTELENCE,diabetes mellitus,and Nutrition diabetes mellitus,1,0.8409408926963806
INTELENCE,diabetes mellitus,diabetes mellitus,1,0.9999998807907104
INTELENCE,diabetes mellitus,Nutrition diabetes mellitus,1,0.8329476714134216
INTELENCE,anorexia,diabetes anorexia dyslipidemia Nervous,1,0.7190868258476257
INTELENCE,anorexia,Nutrition diabetes mellitus,1,0.552912712097168
INTELENCE,anorexia,immune reconstitution syndrome Metabolism and,0,0.5744081139564514
INTELENCE,anorexia,anorexia dyslipidemia Nervous System Disorders,1,0.7509670257568359
INTELENCE,anorexia,anorexia dyslipidemia Nervous System Disorders paraesthesia,1,0.7480601072311401
INTELENCE,anorexia,Disorders diabetes,0,0.5711816549301147
INTELENCE,anorexia,dyslipidemia,0,0.5962452292442322
INTELENCE,anorexia,and Nutrition Disorders diabetes anorexia dyslipidemia,1,0.7424851059913635
INTELENCE,anorexia,immune reconstitution syndrome Metabolism and Nutrition Disorders diabetes,0,0.5937013626098633
INTELENCE,anorexia,and Nutrition,0,0.6280830502510071
INTELENCE,dyslipidemia,Disorders diabetes mellitus dyslipidemia Nervous,1,0.7777975797653198
INTELENCE,dyslipidemia,and Nutrition,0,0.6171470284461975
INTELENCE,dyslipidemia,Nervous System,0,0.5656660795211792
INTELENCE,paraesthesia,convulsion hypoesthesia amnesia syncope disturbance in attention,0,0.6285513043403625
INTELENCE,paraesthesia,paraesthesia somnolence convulsion hypoesthesia amnesia,1,0.8125187158584595
INTELENCE,paraesthesia,paraesthesia somnolence convulsion,1,0.8130956888198853
INTELENCE,paraesthesia,convulsion hypoesthesia amnesia syncope disturbance in attention hypersomnia tre,0,0.6400324106216431
INTELENCE,paraesthesia,paraesthesia,1,1.0
INTELENCE,paraesthesia,paraesthesia somnolence convulsion hypoesthesia amnesia syncope,1,0.8088635206222534
INTELENCE,paraesthesia,Disorders,0,0.5698867440223694
INTELENCE,paraesthesia,paraesthesia somnolence,1,0.8383642435073853
INTELENCE,somnolence,System Disorders somnolence convulsion hypoesthesia amnesia,1,0.7258683443069458
INTELENCE,somnolence,Disorders,0,0.5874348282814026
INTELENCE,somnolence,somnolence convulsion hypoesthesia,1,0.7638674974441528
INTELENCE,somnolence,convulsion,0,0.5253793001174927
INTELENCE,somnolence,somnolence convulsion hypoesthesia amnesia syncope,1,0.757466733455658
INTELENCE,somnolence,dyslipidemia Nervous System Disorders somnolence convulsion hypoesthesia amnesia,1,0.6713688373565674
INTELENCE,somnolence,Nervous System Disorders somnolence convulsion hypoesthesia amnesia syncope disturbance,1,0.7021488547325134
INTELENCE,somnolence,somnolence convulsion,1,0.8014227151870728
INTELENCE,somnolence,somnolence convulsion hypoesthesia amnesia,1,0.7608456611633301
INTELENCE,convulsion,attention hypersomnia,0,0.5485953688621521
INTELENCE,convulsion,paraesthesia,0,0.6293086409568787
INTELENCE,convulsion,convulsion,1,1.0000001192092896
INTELENCE,hypoesthesia,hypoesthesia,1,0.9999999403953552
INTELENCE,hypoesthesia,attention hypersomnia tremor,0,0.621049165725708
INTELENCE,hypoesthesia,hypoesthesia amnesia syncope disturbance in,1,0.8292851448059082
INTELENCE,hypoesthesia,hypoesthesia amnesia syncope disturbance,1,0.8359525203704834
INTELENCE,hypoesthesia,syncope disturbance in attention,0,0.613203763961792
INTELENCE,amnesia,attention hypersomnia,0,0.6210522651672363
INTELENCE,amnesia,in attention hypersomnia tremor Psychiatric Disorders,0,0.5918358564376831
INTELENCE,amnesia,Nervous System,0,0.5699729919433594
INTELENCE,amnesia,dyslipidemia Nervous System Disorders paraesthesia somnolence,0,0.5898240804672241
INTELENCE,amnesia,attention hypersomnia tremor Psychiatric Disorders anxiety sle,0,0.5855727195739746
INTELENCE,amnesia,amnesia,1,0.9999998807907104
INTELENCE,syncope,somnolence convulsion hypoesthesia syncope,1,0.7757407426834106
INTELENCE,syncope,attention hypersomnia tremor Psychiatric Disorders anxiety sle,0,0.5968671441078186
INTELENCE,syncope,syncope disturbance in attention hypersomnia tremor,1,0.8024827241897583
INTELENCE,syncope,syncope disturbance,1,0.902082085609436
INTELENCE,syncope,syncope,1,0.9999998807907104
INTELENCE,syncope,syncope disturbance in attention hypersomnia,1,0.7877339124679565
INTELENCE,syncope,amnesia,0,0.5306670665740967
INTELENCE,disturbance in attention,Disorders paraesthesia,0,0.637976884841919
INTELENCE,disturbance in attention,abnormal dreams,0,0.5961701273918152
INTELENCE,disturbance in attention,sleep,0,0.515844464302063
INTELENCE,disturbance in attention,sleep disorders abnormal,0,0.5983031988143921
INTELENCE,disturbance in attention,hypersomnia tremor Psychiatric Disorders anxiety sleep disorders abnormal dreams,0,0.6184805631637573
INTELENCE,disturbance in attention,disturbance in attention hypersomnia,1,0.8320993185043335
INTELENCE,disturbance in attention,in attention,1,0.8461825847625732
INTELENCE,disturbance in attention,hypoesthesia amnesia disturbance,1,0.6865500211715698
INTELENCE,disturbance in attention,convulsion hypoesthesia amnesia disturbance in,1,0.644728422164917
INTELENCE,hypersomnia,hypersomnia tremor,1,0.8529695868492126
INTELENCE,hypersomnia,hypersomnia tremor Psychiatric Disorders,1,0.8055992126464844
INTELENCE,tremor,tremor,1,0.9999998807907104
INTELENCE,tremor,syncope disturbance in attention tremor,1,0.7458465099334717
INTELENCE,tremor,disorders abnormal dreams confusional state,0,0.5346435904502869
INTELENCE,tremor,attention hypersomnia,0,0.5351701974868774
INTELENCE,anxiety,state disorientation nervousness nightmares,0,0.7176002264022827
INTELENCE,anxiety,attention,0,0.6081905364990234
INTELENCE,anxiety,anxiety sleep disorders abnormal dreams,1,0.688262939453125
INTELENCE,anxiety,disorders abnormal dreams confusional state,0,0.5836633443832397
INTELENCE,anxiety,disorientation nervousness,0,0.7726574540138245
INTELENCE,anxiety,anxiety sleep disorders abnormal dreams confusional,1,0.7106835842132568
INTELENCE,anxiety,confusional,0,0.6305356025695801
INTELENCE,anxiety,attention hypersomnia tremor Psychiatric anxiety sleep disorders abnormal dreams confusional,1,0.6873949766159058
INTELENCE,anxiety,anxiety sleep disorders,1,0.7588955163955688
INTELENCE,anxiety,anxiety,1,1.0
INTELENCE,sleep disorders,sleep disorders abnormal dreams,1,0.8452879190444946
INTELENCE,abnormal dreams,confusional,0,0.538440465927124
INTELENCE,abnormal dreams,Psychiatric,0,0.6107849478721619
INTELENCE,abnormal dreams,sleep abnormal dreams confusional state disorientation,1,0.8227381706237793
INTELENCE,abnormal dreams,Disorders anxiety sleep abnormal,1,0.7585142254829407
INTELENCE,abnormal dreams,nightmares,0,0.7814386487007141
INTELENCE,abnormal dreams,in attention hypersomnia tremor Psychiatric Disorders anxiety sleep disorders,0,0.6474323272705078
INTELENCE,abnormal dreams,abnormal dreams confusional state disorientation nervousness,1,0.8347681760787964
INTELENCE,abnormal dreams,abnormal dreams confusional,1,0.9179528951644897
INTELENCE,abnormal dreams,Disorders anxiety sleep abnormal dreams confusional state disorientation,1,0.7851993441581726
INTELENCE,abnormal dreams,abnormal dreams confusional state,1,0.8773217797279358
INTELENCE,confusional state,nervousness nightmares Renal and Urinary,0,0.6051782965660095
INTELENCE,confusional state,acute,0,0.5143634080886841
INTELENCE,confusional state,confusional state,1,1.000000238418579
INTELENCE,confusional state,confusional,1,0.8754180669784546
INTELENCE,confusional state,confusional state disorientation,1,0.8987767696380615
INTELENCE,confusional state,anxiety sleep disorders abnormal,0,0.5819917917251587
INTELENCE,confusional state,Disorders anxiety sleep disorders abnormal,0,0.5895283222198486
INTELENCE,confusional state,anxiety sleep disorders abnormal confusional state disorientation,1,0.7872695922851562
INTELENCE,confusional state,Renal,0,0.4973282814025879
INTELENCE,disorientation,disorientation nervousness nightmares Renal and Urinary,1,0.7592257261276245
INTELENCE,disorientation,Renal,0,0.4954938292503357
INTELENCE,disorientation,disorientation nervousness nightmares,1,0.8223644495010376
INTELENCE,disorientation,disorientation nervousness nightmares Renal and,1,0.7880029082298279
INTELENCE,disorientation,disorientation nervousness,1,0.8829545974731445
INTELENCE,disorientation,confusional disorientation nervousness nightmares Renal and,1,0.7893819808959961
INTELENCE,disorientation,disorientation,1,0.9999999403953552
INTELENCE,disorientation,abnormal dreams confusional disorientation,1,0.8284562230110168
INTELENCE,nervousness,failure Reproductive System,0,0.48509177565574646
INTELENCE,nervousness,nervousness,1,1.000000238418579
INTELENCE,nightmares,acute renal failure Reproductive,0,0.4285374581813812
INTELENCE,nightmares,nightmares Renal and,1,0.8221827149391174
INTELENCE,nightmares,disorders abnormal dreams confusional state,0,0.7134453058242798
INTELENCE,nightmares,nightmares Renal and Urinary Disorders acute,1,0.7562545537948608
INTELENCE,nightmares,rders anxiety sleep,0,0.6559051275253296
INTELENCE,nightmares,dreams confusional state disorientation nightmares Renal,1,0.7437108755111694
INTELENCE,acute renal failure,Urinary acute renal failure Reproductive,1,0.8256210088729858
INTELENCE,acute renal failure,rders anxiety sleep,0,0.3968822956085205
INTELENCE,acute renal failure,Breast,0,0.5182710886001587
INTELENCE,acute renal failure,acute renal,1,0.9240354299545288
INTELENCE,acute renal failure,Renal and Urinary acute renal failure Reproductive System and Breast Disorders,1,0.7863442897796631
INTELENCE,acute renal failure,Disorders gynecomastia RespiratoryThoracic,0,0.447323739528656
INTELENCE,acute renal failure,Breast Disorders,0,0.500579833984375
INTELENCE,acute renal failure,state disorientation nervousness,0,0.4264877438545227
INTELENCE,acute renal failure,Renal and Urinary acute,1,0.8600907325744629
INTELENCE,acute renal failure,renal failure,1,0.8923428654670715
INTELENCE,gynecomastia,gynecomastia RespiratoryThoracic,1,0.8648332357406616
INTELENCE,gynecomastia,and,0,0.4825253486633301
INTELENCE,gynecomastia,exertional dyspnea bronchospasm Skin,0,0.5117618441581726
INTELENCE,gynecomastia,gynecomastia RespiratoryThoracic and Mediastinal Disorders,1,0.8368511199951172
INTELENCE,gynecomastia,Reproductive System and Breast,0,0.7034376859664917
INTELENCE,gynecomastia,Disorders,0,0.5395137071609497
INTELENCE,gynecomastia,and Mediastinal,0,0.5885103344917297
INTELENCE,gynecomastia,Breast Disorders,0,0.6807926893234253
INTELENCE,gynecomastia,gynecomastia RespiratoryThoracic and,1,0.8748036623001099
INTELENCE,gynecomastia,gynecomastia,1,1.0000001192092896
INTELENCE,gynecomastia,Breast gynecomastia,1,0.9565889835357666
INTELENCE,gynecomastia,System and Breast Disorders,0,0.6618257761001587
INTELENCE,gynecomastia,dyspnea,0,0.5532407760620117
INTELENCE,exertional dyspnea,Mediastinal exertional dyspnea bronchospasm Skin and Subcutaneous,1,0.797356128692627
INTELENCE,exertional dyspnea,gynecomastia RespiratoryThoracic,1,0.5910055637359619
INTELENCE,exertional dyspnea,exertional dyspnea,1,1.0000001192092896
INTELENCE,exertional dyspnea,RespiratoryThoracic and Mediastinal exertional dyspnea,1,0.8980913162231445
INTELENCE,exertional dyspnea,gynecomastia RespiratoryThoracic and Mediastinal exertional dyspnea,1,0.8010342717170715
INTELENCE,exertional dyspnea,Tissue Disorders night sweats,0,0.5675326585769653
INTELENCE,exertional dyspnea,exertional dyspnea bronchospasm,1,0.882813572883606
INTELENCE,exertional dyspnea,System and Breast Disorders gynecomastia RespiratoryThoracic and Mediastinal,0,0.5921365022659302
INTELENCE,exertional dyspnea,exertional dyspnea bronchospasm Skin and Subcutaneous,1,0.8291937112808228
INTELENCE,exertional dyspnea,and Mediastinal exertional dyspnea bronchospasm Skin and Subcutaneous Tissue,1,0.78145432472229
INTELENCE,night sweats,lipohypertrophy prurigo,0,0.6352205276489258
INTELENCE,night sweats,Skin and Subcutaneous Tissue night,1,0.7644878625869751
INTELENCE,lipohypertrophy,exertional dyspnea bronchospasm Skin and,0,0.5050361156463623
INTELENCE,lipohypertrophy,sweats,0,0.5570758581161499
INTELENCE,lipohypertrophy,lipohypertrophy prurigo hyperhidrosis dry skin,1,0.8171889781951904
INTELENCE,lipohypertrophy,Disorders night lipohypertrophy,1,0.8707283735275269
INTELENCE,lipohypertrophy,lipohypertrophy prurigo hyperhidrosis dry,1,0.8108505010604858
INTELENCE,lipohypertrophy,Disorders night sweats,0,0.5581926107406616
INTELENCE,lipohypertrophy,Subcutaneous Tissue Disorders night lipohypertrophy prurigo hyperhidrosis,1,0.7403431534767151
INTELENCE,lipohypertrophy,Tissue Disorders night sweats,0,0.5964511036872864
INTELENCE,lipohypertrophy,hyperhidrosis dry skin swelling face Additional ADRs of at least moderate,0,0.6103311777114868
INTELENCE,prurigo,prurigo hyperhidrosis dry skin swelling face,1,0.7523616552352905
INTELENCE,prurigo,prurigo hyperhidrosis dry skin swelling,1,0.756583571434021
INTELENCE,prurigo,prurigo hyperhidrosis,1,0.8116493225097656
INTELENCE,hyperhidrosis,lipohypertrophy prurigo,0,0.7039341926574707
INTELENCE,swelling face,swelling face,1,0.9999998807907104
INTELENCE,swelling face,lipohypertrophy prurigo hyperhidrosis dry swelling face,1,0.7492622137069702
INTELENCE,swelling face,Tissue Disorders night sweats lipohypertrophy prurigo hyperhidrosis dry skin,0,0.616196870803833
INTELENCE,swelling face,lipohypertrophy prurigo hyperhidrosis dry,0,0.5813339948654175
INTELENCE,swelling face,hyperhidrosis,0,0.5836937427520752
INTELENCE,swelling face,Disorders night sweats lipohypertrophy prurigo hyperhidrosis dry skin,0,0.5850323438644409
INTELENCE,swelling face,d Subcutaneous Tissue Disorders night,0,0.6196756362915039
INTELENCE,acquired lipodystrophy,of at least moderate,0,0.5030598640441895
INTELENCE,acquired lipodystrophy,haemorrhagic stroke each reported in no,0,0.4861007034778595
INTELENCE,acquired lipodystrophy,observed in other trials acquired lipodystrophy angioneurotic edema erythema multiforme and,1,0.8366009593009949
INTELENCE,acquired lipodystrophy,stroke each reported in no,0,0.5170841217041016
INTELENCE,angioneurotic edema,were acquired angioneurotic edema erythema multiforme and haemorrhagic stroke,1,0.8145256042480469
INTELENCE,angioneurotic edema,stroke each reported in no,0,0.5630366802215576
INTELENCE,angioneurotic edema,observed in other trials were acquired,0,0.5613398551940918
INTELENCE,angioneurotic edema,stroke each reported in no more,0,0.5317413806915283
INTELENCE,angioneurotic edema,acquired angioneurotic edema,1,0.9479689598083496
INTELENCE,angioneurotic edema,angioneurotic edema erythema multiforme and,1,0.8997731804847717
INTELENCE,angioneurotic edema,other trials were acquired angioneurotic,1,0.7501548528671265
INTELENCE,angioneurotic edema,other trials were acquired angioneurotic edema,1,0.8865650296211243
INTELENCE,angioneurotic edema,angioneurotic edema erythema multiforme,1,0.9016417264938354
INTELENCE,erythema multiforme,were acquired lipodystrophy angioneurotic erythema multiforme,1,0.7994332313537598
INTELENCE,erythema multiforme,erythema multiforme and haemorrhagic stroke,1,0.8638705015182495
INTELENCE,erythema multiforme,no more than of subjects Laboratory Abnorma,0,0.49305567145347595
INTELENCE,erythema multiforme,observed in other trials were,0,0.5101520419120789
INTELENCE,erythema multiforme,observed in other trials were acquired lipodystrophy angioneurotic edema,0,0.6162240505218506
INTELENCE,erythema multiforme,erythema multiforme and haemorrhagic,1,0.9120903611183167
INTELENCE,erythema multiforme,erythema multiforme,1,1.0000001192092896
INTELENCE,ALT abnormalities,enroll AST,0,0.5445517897605896
INTELENCE,ALT abnormalities,ALT abnormalities occurred more frequently,1,0.9084738492965698
INTELENCE,ALT abnormalities,ALT abnormalities occurred more frequently in,1,0.9159950017929077
INTELENCE,ALT abnormalities,and,0,0.504222571849823
INTELENCE,ALT abnormalities,ALT abnormalities occurred more frequently in hepatitis,1,0.833836555480957
INTELENCE,ALT abnormalities,to enroll AST ALT abnormalities,1,0.8542170524597168
INTELENCE,rash,rash which was observed more,1,0.8582303524017334
INTELENCE,rash,subjects The most common adverse drug,0,0.5864399671554565
INTELENCE,rash,adult subjects except for,0,0.4975624680519104
INTELENCE,rash,least of pediatric subjects rash and diarrhea Rash,1,0.7382014393806458
INTELENCE,rash,rash and diarrhea Rash was reported,1,0.8017851710319519
INTELENCE,rash,subjects rash and diarrhea Rash was reported,1,0.790422797203064
INTELENCE,rash,subjects,0,0.5408451557159424
INTELENCE,rash,in male subjects rash,0,0.8269791603088379
INTELENCE,rash,more frequently in,0,0.5317059755325317
INTELENCE,diarrhea,Grade was,0,0.5013657212257385
INTELENCE,diarrhea,diarrhea Rash was,1,0.8074352741241455
INTELENCE,diarrhea,common adverse drug reactions in at least of pediatric subjects were,0,0.5465623140335083
INTELENCE,diarrhea,pediatric subjects were rash diarrhea Rash was reported more,1,0.7443576455116272
INTELENCE,diarrhea,diarrhea Rash was reported,1,0.8069332838058472
INTELENCE,diarrhea,male subjects,0,0.5002896189689636
INTELENCE,diarrhea,diarrhea Rash was reported more frequently,1,0.770561695098877
INTELENCE,diarrhea,diarrhea Rash was reported more,1,0.7893662452697754
INTELENCE,Rash,Rash,1,1.0000001192092896
INTELENCE,Rash,of pediatric subjects were,0,0.4966830313205719
INTELENCE,Rash,and Rash was reported more frequently,1,0.8108507394790649
INTELENCE,Rash,rash and Rash was reported more frequently,1,0.8316617012023926
INTELENCE,Rash,of pediatric subjects were rash and,0,0.7802643179893494
INTELENCE,rash,females versus males,0,0.45478492975234985
INTELENCE,rash,versus males discontinuations,0,0.4850797951221466
INTELENCE,rash,subjects than,0,0.521132230758667
INTELENCE,rash,rash Grade was reported in females,1,0.7682363390922546
INTELENCE,rash,diarrhea Rash was reported more frequently in female subjects than in male,0,0.7139343023300171
INTELENCE,rash,frequently in female subjects than in,0,0.47689324617385864
INTELENCE,rash,males discontinuations due,0,0.4688590168952942
INTELENCE,rash,rash were reported,1,0.9001861810684204
INTELENCE,Rash,in females versus Rash greater than or equal,1,0.7332397699356079
INTELENCE,Rash,rash were reported,1,0.9001861810684204
INTELENCE,Rash,versus Rash greater than or,1,0.7872236967086792
INTELENCE,Rash,Rash greater than,1,0.8663769960403442
INTELENCE,Rash,than or equal to Grade occurred,0,0.4782623052597046
INTELENCE,rash,of therapy Rash was,0,0.8420276641845703
INTELENCE,Rash,the second week of Rash was,1,0.8325059413909912
INTELENCE,Rash,rash,1,1.0000001192092896
INTELENCE,Rash,Rash was selflimiting,1,0.817533016204834
INTELENCE,Rash,Rash was selflimiting and generally resolved,1,0.7561105489730835
INTELENCE,Rash,week of Rash was,1,0.855299711227417
INTELENCE,Rash,mild to moderate of,0,0.5557186007499695
INTELENCE,hypersensitivity,hypersensitivity reactions including DRESS and cases,1,0.8328006267547607
INTELENCE,DRESS,DRESS and cases of,1,0.85886549949646
INTELENCE,DRESS,DRESS and,1,0.9032570123672485
INTELENCE,DRESS,see Warnings and Precautions,0,0.526214063167572
INTELENCE,DRESS,been reported,0,0.5240944623947144
INTELENCE,DRESS,reactions,0,0.5397524237632751
INTELENCE,DRESS,have been,0,0.5343717336654663
INTELENCE,DRESS,Severe hypersensitivity reactions including,0,0.46916598081588745
INTELENCE,hepatic failure,System,0,0.5266492962837219
INTELENCE,hepatic failure,including DRESS,0,0.4002937078475952
INTELENCE,hepatic failure,and cases hepatic,1,0.7717016935348511
INTELENCE,hepatic failure,including DRESS and cases hepatic failure have,1,0.8818293213844299
INTELENCE,hepatic failure,hepatic failure have been,1,0.9581758975982666
INTELENCE,rhabdomyolysis,Subcutaneous Tissue,0,0.5270471572875977
INTELENCE,rhabdomyolysis,rhabdomyolysis Skin,1,0.8626844882965088
INTELENCE,rhabdomyolysis,Tissue Disorders Fatal cases of toxic epidermal necrolysis have,0,0.560245156288147
INTELENCE,rhabdomyolysis,rhabdomyolysis Skin and Subcutaneous,1,0.8575267195701599
INTELENCE,Fatal,Fatal cases of toxic epidermal necrolysis,1,0.6743999719619751
INTELENCE,Fatal,been reported see Warnings and Precautions,0,0.5246270895004272
INTELENCE,Fatal,Skin and Subcutaneous Tissue Fatal cases of toxic,1,0.6936423182487488
INTELENCE,toxic epidermal necrolysis,toxic epidermal necrolysis have been,1,0.9748499393463135
INTELENCE,toxic epidermal necrolysis,toxic epidermal necrolysis have been reported,1,0.9592889547348022
INTELENCE,toxic epidermal necrolysis,Disorders Fatal cases toxic epidermal,1,0.8755983710289001
INTELENCE,toxic epidermal necrolysis,epidermal necrolysis have been reported see Warnings,1,0.8675975799560547
INTELENCE,toxic epidermal necrolysis,have been,0,0.43325263261795044
INTELENCE,fatal,are described in greater il,1,0.4512341022491455
INTELENCE,fatal,are described in greater il in other,1,0.44368869066238403
INTELENCE,fatal,described in,0,0.4938831925392151
INTELENCE,fatal,The following adverse reactions are,0,0.5621925592422485
INTELENCE,fatal,in greater il,1,0.4530389606952667
INTELENCE,skin reactions,reactions are described in greater,0,0.7186840772628784
INTELENCE,skin reactions,other sections Severe skin and hypersensitivity reactions,1,0.821556568145752
INTELENCE,skin reactions,described in greater detail in,0,0.4971161186695099
INTELENCE,skin reactions,in greater detail other sections Severe skin and hypersensitivity,1,0.7787927389144897
INTELENCE,skin reactions,greater detail other,1,0.5138330459594727
INTELENCE,skin reactions,in greater detail other sections,1,0.5048552751541138
INTELENCE,Stevens-Johnson syndrome,hypersensitivity actions [ see  Warnings  and Precautions EXCERPT,1,0.6380353569984436
INTELENCE,Stevens-Johnson syndrome,greater detail other,1,0.47511589527130127
INTELENCE,Stevens-Johnson syndrome,actions [ see Warnings and Precautions EXCERPT The,1,0.5725190043449402
INTELENCE,Stevens-Johnson syndrome,skin and hypersensitivity actions [ see  Warnings  and Precautions EXCERPT The most,1,0.6422767639160156
INTELENCE,Stevens-Johnson syndrome,[ see Warnings and Precautions,1,0.5775569677352905
INTELENCE,Stevens-Johnson syndrome,Precautions EXCERPT The most common adverse drug,0,0.6156529784202576
INTELENCE,Stevens-Johnson syndrome,other sections Severe skin and,0,0.6013137102127075
INTELENCE,Stevens-Johnson syndrome,Precautions EXCERPT,0,0.5846418142318726
INTELENCE,hypersensitivity reaction,d Precautions (5.1),1,0.5441696643829346
INTELENCE,hypersensitivity reaction,Precautions (5.1) ]. EXCERPT The most common,1,0.5420284867286682
INTELENCE,hypersensitivity reaction,an,0,0.5680986642837524
INTELENCE,hypersensitivity reaction,The most common,0,0.498015820980072
INTELENCE,hypersensitivity reaction,d Precautions (5.1) ]. EXCERPT The,1,0.5613684058189392
INTELENCE,hypersensitivity reaction,see Warnings d Precautions (5.1)   ]. ,1,0.5339562892913818
INTELENCE,hypersensitivity reaction,adverse drug reactions of moderate to severe,0,0.6832718849182129
INTELENCE,hypersensitivity reaction,sections Severe skin,0,0.5744063854217529
INTELENCE,hypersensitivity reaction,sections,0,0.47981691360473633
INTELENCE,hypersensitivity reaction,of moderate to severe intensity,0,0.5749911069869995
INTELENCE,toxic epidermal necrolysis,The most c,1,0.4625664949417114
INTELENCE,toxic epidermal necrolysis,skin and,0,0.6476134061813354
INTELENCE,toxic epidermal necrolysis,least which occurred at,0,0.467739462852478
INTELENCE,erythema multiforme,drug react ions of moderate to severe,1,0.5477628111839294
INTELENCE,erythema multiforme,adverse drug react ions of moderate to,1,0.5430636405944824
INTELENCE,erythema multiforme,EXCERPT The,0,0.47549718618392944
INTELENCE,erythema multiforme,adverse drug,1,0.5641599893569946
INTELENCE,erythema multiforme,reactions,0,0.5245171785354614
INTELENCE,erythema multiforme,Precautions EXCERPT The most common,0,0.5330249071121216
INTELENCE,fatal,"ts, L P at JANSSEN",1,0.5057564973831177
INTELENCE,fatal,"ts, L P",1,0.5383959412574768
INTELENCE,fatal,"ADVERSE REACTIONS contact Janssen ts,",1,0.5303409695625305
INTELENCE,skin reactions,report SUSPECTED ADVERSE REACTIONS contact,0,0.7104796171188354
INTELENCE,Stevens-Johnson syndrome,Products LP at JANSSEN or FDA at FDA,0,0.5817365646362305
INTELENCE,Stevens-Johnson syndrome,contact Janssen Products LP at JANSSEN or,0,0.5328996181488037
INTELENCE,Stevens-Johnson syndrome,clinical trials are conducted u,0,0.502475917339325
INTELENCE,toxic epidermal necrolysis,at FDA,0,0.5004639625549316
INTELENCE,toxic epidermal necrolysis,or tch . 6.1,1,0.46741870045661926
INTELENCE,toxic epidermal necrolysis,Experience Adults Because clinical trials are,0,0.5150452852249146
INTELENCE,toxic epidermal necrolysis,"or tch  .  



 

  6.1 Clini cal",1,0.518608570098877
INTELENCE,toxic epidermal necrolysis,"or tch  .  



 

  6.1 Clini cal Trials",1,0.5251626968383789
INTELENCE,toxic epidermal necrolysis,"or tch  .  



 

  6.1 Clini cal Trials Experience Adults Because",1,0.508563756942749
INTELENCE,toxic epidermal necrolysis,. 6.1 Clini cal Trials Experience,1,0.5295202732086182
INTELENCE,toxic epidermal necrolysis,"tch  .  



 

  6.1 Clini cal Trials Experience Adults",1,0.5180143117904663
INTELENCE,erythema multiforme,or FDA,0,0.49982762336730957
INTELENCE,erythema multiforme,Experience: A dults,1,0.520493745803833
INTELENCE,erythema multiforme,wwwfdagovmedwatch Clinical rials Experience: A,1,0.5353660583496094
INTELENCE,Hypersensitivity reactions,Experience lts Because clinical tr,1,0.5065063238143921
INTELENCE,Hypersensitivity reactions,Clinical Trials Experience,0,0.5390644073486328
INTELENCE,Hypersensitivity reactions,FDA or wwwfdagovmedwatch Clinical,0,0.4702887237071991
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"under widely varying conditions, adverse reaction rates observed",1,0.6255873441696167
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,are co,0,0.4553888142108917
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,drug cannot be directly compared,0,0.5643283724784851
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"are nducted under widely varying conditions, adverse ",1,0.5237702131271362
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,clinical trials are nducted under,1,0.4937608242034912
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"widely varying conditions, adverse reaction",1,0.6677486300468445
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"varying conditions, adverse reaction rates observed in",1,0.6346778273582458
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,Because clinical trials are nducted under widely,1,0.4913995862007141
INTELENCE,DRESS,adverse actio n rates observed in,1,0.45453107357025146
INTELENCE,DRESS,are co,0,0.5136632919311523
INTELENCE,rash,nnot be directly compared to rates,1,0.45929479598999023
INTELENCE,rash,nnot be directly compared to,1,0.4853528141975403
INTELENCE,rash,under widely varying,0,0.5234919786453247
INTELENCE,rash,nnot,1,0.5432395935058594
INTELENCE,rash,a drug nnot,1,0.5673772096633911
INTELENCE,rash,ca,0,0.5323941707611084
INTELENCE,hepatic failure,of another and may not ref lect the rates,1,0.40505266189575195
INTELENCE,hepatic failure,ca,0,0.4592968821525574
INTELENCE,hepatic failure,another and,1,0.4726369380950928
INTELENCE,hepatic failure,a drug cannot be directly compared to rates in the clinical trials of,0,0.5240228772163391
INTELENCE,hepatic failure,safety assessment is based on all data,0,0.5022029280662537
INTELENCE,hepatic failure,may not ref lect the rates observed in,1,0.4522864520549774
INTELENCE,hepatic failure,trials of another and may not ref lect the rates observed in,1,0.48740339279174805
INTELENCE,hepatic failure,trials of another and may not,1,0.49441462755203247
INTELENCE,rash,mg twice daily In these,0,0.5172099471092224
INTELENCE,rash,trials the median exposure,0,0.5627272129058838
INTELENCE,rash,whom received INTELENCE r mg twice daily In these pooled trials the,0,0.5202473402023315
INTELENCE,rash,twice daily,0,0.5244037508964539
INTELENCE,rash,HIVinfected,0,0.5325649976730347
INTELENCE,rash, of  whom received INTELENCE r mg,1,0.49902844429016113
INTELENCE,Rash,g tw ice daily,1,0.563432514667511
INTELENCE,Rash,INTELENCE r arm and,0,0.5355068445205688
INTELENCE,Rash,treatmentexperienced HIVinfected adult subjects of,0,0.5364888906478882
INTELENCE,Rash,g tw ice daily In these,1,0.48146626353263855
INTELENCE,rash,mg twice daily In these pooled trials the median exposure for,0,0.5805826783180237
INTELENCE,rash,TELE NCE r,1,0.5234966278076172
INTELENCE,rash,daily In these pooled trials the median exposure for,0,0.5636289715766907
INTELENCE,rash,the TELE NCE r arm,1,0.5392452478408813
INTELENCE,rash,r mg twice daily In these pooled trials the,0,0.5418446660041809
INTELENCE,accumulation of body fat,to weeks,0,0.5313528776168823
INTELENCE,accumulation of body fat,to moderate red primarily in the sec ond,1,0.48443174362182617
INTELENCE,accumulation of body fat,moderate red primarily in the,1,0.5153985619544983
INTELENCE,accumulation of body fat,to moderate red primarily in the sec,1,0.47474443912506104
INTELENCE,accumulation of body fat,in clinical trials rash was mild to moderate occur,0,0.5256556272506714
INTELENCE,accumulation of body fat,moderate,0,0.5002180933952332
INTELENCE,central obesity,"therapy, and",1,0.47277817130088806
INTELENCE,central obesity,"therapy, and wa s",1,0.4771837890148163
INTELENCE,central obesity,second week of,0,0.507314145565033
INTELENCE,central obesity,"second week therapy, and wa",1,0.5054194331169128
INTELENCE,central obesity,"the second week therapy, and wa s infrequent after",1,0.4910818934440613
INTELENCE,central obesity,"therapy, and wa s infrequent after",1,0.4528875946998596
INTELENCE,dorsocervical fat enlargement,incidence of rash was,0,0.5107395052909851
INTELENCE,dorsocervical fat enlargement,therapy The,0,0.4963650107383728
INTELENCE,dorsocervical fat enlargement,incidence of,0,0.548920750617981
INTELENCE,dorsocervical fat enlargement,The incidence of rash was higher,0,0.5403734445571899
INTELENCE,dorsocervical fat enlargement,and infrequent,1,0.454922080039978
INTELENCE,dorsocervical fat enlargement,4. Rash generally,1,0.5116730332374573
INTELENCE,dorsocervical fat enlargement,Week 4. Rash generally resolved within to,1,0.5131836533546448
INTELENCE,dorsocervical fat enlargement,mild to moderate occurred,0,0.536833643913269
INTELENCE,buffalo hump,enerally,1,0.46077218651771545
INTELENCE,buffalo hump,enerally res olved within to,1,0.4950369596481323
INTELENCE,buffalo hump,Week Rash enerally res olved within to weeks,1,0.4622369110584259
INTELENCE,buffalo hump,Week Rash enerally res,1,0.4681931734085083
INTELENCE,buffalo hump,higher,0,0.48455652594566345
INTELENCE,buffalo hump,Week Rash enerally res olved within to,1,0.4716477394104004
INTELENCE,facial wasting,within to ks on continue,1,0.4516225755214691
INTELENCE,facial wasting,generally resolved within to,0,0.4764972925186157
INTELENCE,facial wasting,ks on continue,1,0.4691307246685028
INTELENCE,breast enlargement,within to weeks on therapy. The,1,0.5229578018188477
INTELENCE,breast enlargement,on therapy. The incid ence of rash was higher,1,0.5813230276107788
INTELENCE,cushingoid appearance,continued therapy The incidence  rash was higher in w omen compared to men in,1,0.5585301518440247
INTELENCE,cushingoid appearance,within to weeks on therapy. The,1,0.4934166669845581
INTELENCE,cushingoid appearance,The incidence  rash was higher in w omen compared to men in,1,0.5586519241333008
INTELENCE,cushingoid appearance, rash was higher in w omen compared to men in,1,0.5970959663391113
INTELENCE,cushingoid appearance,therapy The incidence rash was higher in w,1,0.5309203267097473
INTELENCE,cushingoid appearance,rash was higher in,1,0.5645583868026733
INTELENCE,Immune reconstitution syndrome,Patients with a history of NNRTIrelated rash did,0,0.6364827156066895
INTELENCE,inflammatory response,"dverse Reactions  


",1,0.6150773763656616
INTELENCE,inflammatory response,Patients with a history of NNRTIrelated rash did,0,0.5552310943603516
INTELENCE,inflammatory response,rash Common dverse,1,0.5447043180465698
INTELENCE,inflammatory response,of NNRTIrelated rash Common dverse Reactions,1,0.6451561450958252
INTELENCE,opportunistic infections,te intensity or greater greater,1,0.5046436786651611
INTELENCE,opportunistic infections,Reactions Clinical ADRs of te intensity or greater,1,0.5595279335975647
INTELENCE,opportunistic infections,of te intensity or greater  greater than or equal to,1,0.5140634775161743
INTELENCE,opportunistic infections,history of,0,0.4903898239135742
INTELENCE,opportunistic infections,Grade and reported in at,0,0.4704720973968506
INTELENCE,opportunistic infections,of te intensity or,1,0.5027130246162415
INTELENCE,opportunistic infections,intensity or greater greater than or equal to,1,0.5039158463478088
INTELENCE,opportunistic infections,hout a history,0,0.4955872893333435
INTELENCE,Mycobacterium avium infection,r and occurring at a higher rate,0,0.5228973627090454
INTELENCE,Mycobacterium avium infection,or greater greater han or equal to Grade 2) and r eported in at least of,1,0.46246537566185
INTELENCE,cytomegalovirus,equal to Grade and orted in at lea st of,1,0.4528413414955139
INTELENCE,cytomegalovirus,r and occurring at a higher rate,0,0.48878076672554016
INTELENCE,cytomegalovirus,to Grade and orted in at lea st of,1,0.4662213921546936
INTELENCE,cytomegalovirus,to Grade and orted in at lea st of subjects treated with,1,0.5248430967330933
INTELENCE,cytomegalovirus,at lea st of,1,0.45927664637565613
INTELENCE,cytomegalovirus,equal to Grade and orted in at lea st of subjects,1,0.45257487893104553
INTELENCE,cytomegalovirus,equal,0,0.4783923923969269
INTELENCE,PCP,ENC,1,0.5879662036895752
INTELENCE,Autoimmune disorders,abnormalities considered ADRs are,0,0.6228355765342712
INTELENCE,Autoimmune disorders,excess of are esented in Table 1.  Laboratory abnormalities considered ADRs are,1,0.6305798292160034
INTELENCE,Autoimmune disorders,are esented in Table 1.  Laboratory,1,0.5541440844535828
INTELENCE,Autoimmune disorders,included in Table,0,0.5326941609382629
INTELENCE,Autoimmune disorders,to placebo excess of are,0,0.49416351318359375
INTELENCE,Autoimmune disorders,Table 1. Laboratory abnormalities,1,0.5993388891220093
INTELENCE,Autoimmune disorders,of are esented in Table 1. ,1,0.547429621219635
INTELENCE,Graves' disease,TreatmentEmergent Adverse,0,0.5610424280166626
INTELENCE,Graves' disease, abnormalities  considered ADRs,1,0.5721365213394165
INTELENCE,Graves' disease,Table Table TreatmentEmergent Adverse ReactionsIncludes,0,0.5405223369598389
INTELENCE,polymyositis,Table Laboratory abnormalities nsidered ADR s are included in,1,0.5248154997825623
INTELENCE,polymyositis, abnormalities  considered ADRs,1,0.5497620105743408
INTELENCE,polymyositis,nsidered ADR s,1,0.4948091506958008
INTELENCE,polymyositis,are presented in Table Laboratory abnormalities co,0,0.5032377243041992
INTELENCE,polymyositis,nsidered ADR,1,0.49651452898979187
INTELENCE,Guillain-Barre syndrome,to placebo excess of are presented in Table Laboratory abnormalities considered ADRs are,0,0.5551104545593262
INTELENCE,Guillain-Barre syndrome,Table TreatmentEmergent Adverse ReactionsIncludes adverse reactions at least possibly,0,0.5911765694618225
INTELENCE,Guillain-Barre syndrome,Table 2.,1,0.4892094135284424
INTELENCE,Guillain-Barre syndrome,abnormalities considered ADRs included,1,0.5661147832870483
INTELENCE,Guillain-Barre syndrome,adverse reactions at least,0,0.6235330700874329
INTELENCE,Guillain-Barre syndrome,are,0,0.4644402265548706
PICATO,Ophthalmic Adverse Reaction,discussed in more detail in other,0,0.43862849473953247
PICATO,Ophthalmic Adverse Reaction,other sections of the Ophthalmic Adverse Reaction see Warnings and Precautions,1,0.8568505048751831
PICATO,Ophthalmic Adverse Reaction,other sections of the Ophthalmic Adverse Reaction,1,0.8997007608413696
PICATO,Ophthalmic Adverse Reaction,Ophthalmic Adverse Reaction see Warnings,1,0.9326027631759644
PICATO,Ophthalmic Adverse Reaction,Adverse Reaction see,1,0.81552654504776
PICATO,Ophthalmic Adverse Reaction,the Ophthalmic Adverse Reaction,1,0.9876918196678162
PICATO,Ophthalmic Adverse Reaction,sections of the Ophthalmic Adverse Reaction see Warnings,1,0.8920121192932129
PICATO,Ophthalmic Adverse Reaction,sections of the Ophthalmic Adverse Reaction,1,0.9236698746681213
PICATO,Ophthalmic Adverse Reaction,the Ophthalmic Adverse,1,0.9126430749893188
PICATO,Ophthalmic Adverse Reaction,detail in,0,0.4577469825744629
PICATO,Hypersensitivity Reactions,EXCERPT The most common adverse reactions,0,0.718472421169281
PICATO,Hypersensitivity Reactions,and Precautions EXCERPT The most common adverse reactions,0,0.7045794725418091
PICATO,Hypersensitivity Reactions,Hypersensitivity Reactions see Warnings and,1,0.8730374574661255
PICATO,Hypersensitivity Reactions,and Hypersensitivity Reactions,1,0.948401689529419
PICATO,Hypersensitivity Reactions,EXCERPT The most common adverse,0,0.5750274658203125
PICATO,Hypersensitivity Reactions,and Precautions,0,0.5542477965354919
PICATO,local skin reactions,adverse reactions local skin,1,0.919562041759491
PICATO,local skin reactions,gs and Precautions EXCERPT The most,0,0.5591146349906921
PICATO,local skin reactions,skin reactions application site pain application,1,0.7886043787002563
PICATO,local skin reactions,local skin reactions application site pain application site,1,0.8501319885253906
PICATO,application site pain,EXCERPT The most common,0,0.5028440952301025
PICATO,application site pain,skin application site,1,0.7559909820556641
PICATO,application site pain,skin application site pain,1,0.8178383708000183
PICATO,application site pruritus,application site irritation application site infection periorbital edema nasopharyngitis,0,0.7766847610473633
PICATO,application site pruritus,reactions,0,0.5381360650062561
PICATO,application site pruritus,skin reactions application site application site pruritus,1,0.9297032356262207
PICATO,application site pruritus,application site pruritus application site irritation application,1,0.9507079124450684
PICATO,application site pruritus,infection periorbital,0,0.5302445292472839
PICATO,application site pruritus,skin reactions application site application site pruritus application site irritation application site,1,0.8955657482147217
PICATO,application site irritation,infection periorbital edema nasopharyngitis and,0,0.540451169013977
PICATO,application site irritation,application site irritation application site infection periorbital,1,0.863945722579956
PICATO,application site irritation,site irritation application,1,0.9460902810096741
PICATO,application site irritation,site irritation application site infection periorbital,1,0.806532621383667
PICATO,application site irritation,pain application site pruritus,0,0.8402395248413086
PICATO,application site infection,To report SUSPECTED ADVERSE R,0,0.5781947374343872
PICATO,periorbital edema,periorbital edema,1,1.0000001192092896
PICATO,nasopharyngitis,lication site pruritus application site irritation,0,0.5178934931755066
PICATO,nasopharyngitis,LEO Pharma Inc,0,0.4318413734436035
PICATO,nasopharyngitis,nasopharyngitis,1,1.0000001192092896
PICATO,nasopharyngitis,application site irritation application site,0,0.5169004797935486
PICATO,nasopharyngitis,and headache To report SUSPECTED ADVERSE REACTIONS contact LEO Pharma Inc at,0,0.533506453037262
PICATO,nasopharyngitis,nasopharyngitis and headache To,1,0.8743600249290466
PICATO,nasopharyngitis,SUSPECTED ADVERSE REACTIONS contact LEO Pharma Inc,0,0.48935556411743164
PICATO,headache,headache To,1,0.9336680173873901
PICATO,headache,REACTIONS contact LEO Pharma Inc,0,0.48042064905166626
PICATO,headache,nasopharyngitis,0,0.5994969606399536
PICATO,headache,periorbital edema nasopharyngitis headache To,1,0.7629778385162354
PICATO,Local skin reactions,consecutive Local skin reactions including,1,0.9375261664390564
PICATO,Local skin reactions,nasopharyngitis,0,0.5369217395782471
PICATO,Local skin reactions,Local skin reactions including erythema,1,0.9471831321716309
PICATO,Local Skin Reactions,Assessment of,0,0.5220491886138916
PICATO,Local Skin Reactions,Local Skin Reactions in the Treatment Area during,1,0.9136937856674194
PICATO,Local Skin Reactions,of Local,1,0.70294189453125
PICATO,Local Skin Reactions,Skin Reactions in,1,0.8929418325424194
PICATO,Local Skin Reactions,Area during,0,0.6026027202606201
PICATO,Local Skin Reactions,Investigator Assessment of Local,1,0.6156861782073975
PICATO,Local Skin Reactions,Table Investigator Assessment of Local Skin,1,0.7918601036071777
PICATO,Local Skin Reactions,Investigator Assessment of Local Skin,1,0.8070257902145386
PICATO,Local skin reactions,Severe Local skin reactions,1,0.9402748942375183
PICATO,Local skin reactions,Severe grade,0,0.5203149318695068
PICATO,Local skin reactions,within day of treatment initiation peaked in,0,0.5944424867630005
PICATO,Local skin reactions,Local skin reactions typically occurred within,1,0.9519592523574829
PICATO,Local skin reactions,Severe Local skin reactions typically occurred within day,1,0.8772549629211426
PICATO,Local skin reactions,peaked in intensity,0,0.549126148223877
PICATO,Application Site Pain,gel N Vehicle Application Site,1,0.6725196242332458
PICATO,Application Site Pain,Vehicle Application,1,0.6345904469490051
PICATO,Application Site Pain,Application Site Pain Application Site Pruritus,1,0.8646105527877808
PICATO,Application Site Pain,N,0,0.4904599189758301
PICATO,Application Site Pain,Vehicle Application Site Pain Application,1,0.8258674144744873
PICATO,Application Site Pruritus,Application Site Pruritus,1,0.9999998211860657
PICATO,Application Site Pruritus,N,0,0.4972567856311798
PICATO,Application Site Pruritus,Site Application Site Pruritus Application Site Infection,1,0.9308793544769287
PICATO,Application Site Pruritus,Application Site Application Site,1,0.7544722557067871
PICATO,Application Site Pruritus,Application,1,0.7305372953414917
PICATO,Application Site Pruritus,Application,0,0.7305372953414917
PICATO,Application Site Pruritus,Application Site Infection,0,0.8060576915740967
PICATO,Application Site Infection,Application Site Application,1,0.8041622638702393
PICATO,Application Site Infection,Application Site Application Site Infection Periorbital,1,0.8474965691566467
PICATO,Application Site Infection,Application Site Infection Periorbital,1,0.8301758766174316
PICATO,Headache,Headache,1,0.9999998807907104
PICATO,Headache,Headache Table,1,0.803139328956604
PICATO,Headache,Edema,0,0.5967940092086792
PICATO,Headache,Periorbital Headache Table Adver,1,0.7564821243286133
PICATO,Headache,Headache Table Adver,1,0.7711135149002075
PICATO,Headache,Periorbital Headache,1,0.8100504279136658
PICATO,Application Site Pruritus,Picator gel N Vehicle Application,1,0.5565155744552612
PICATO,Application Site Pruritus,Application Site,1,0.766069769859314
PICATO,Application Site Pruritus,Vehicle N,0,0.4536716938018799
PICATO,Application Site Pruritus,Picator gel N Vehicle N,0,0.5414981842041016
PICATO,Application Site Pruritus,N Vehicle Application Site,1,0.6818364262580872
PICATO,Nasopharyngitis,Application Site Pain,0,0.4880855977535248
PICATO,Nasopharyngitis,Nasopharyngitis Application,1,0.8901904821395874
PICATO,Nasopharyngitis,Application Site,0,0.46498072147369385
PICATO,Nasopharyngitis,Nasopharyngitis,1,1.0000001192092896
PICATO,Nasopharyngitis,Nasopharyngitis Application Site Pain,1,0.8196093440055847
PICATO,Nasopharyngitis,Application,0,0.5122858285903931
PICATO,Nasopharyngitis,Nasopharyngitis Application Site,1,0.8600252270698547
PICATO,eyelid edema,with Picato,0,0.4647703468799591
PICATO,eyelid edema,r eyelid edema eye pain conjunctivitis A,1,0.8792349100112915
PICATO,eyelid edema,Picato r eyelid edema,1,0.8823465704917908
PICATO,eyelid edema,eyelid edema eye pain conjunctivitis,1,0.8883482813835144
PICATO,eye pain,r included eyelid eye pain conjunctivitis A total of subjects,1,0.8308905959129333
PICATO,eye pain,eyelid edema eye pain conjunctivitis,1,0.8272586464881897
PICATO,eye pain,eyelid edema,0,0.7236387729644775
PICATO,eye pain,gel on,0,0.4992184340953827
PICATO,eye pain,included eyelid eye pain conjunctivitis,1,0.8683203458786011
PICATO,conjunctivitis,conjunctivitis A total,1,0.8777639269828796
PICATO,conjunctivitis,eyelid edema eye pain,0,0.7017257213592529
PICATO,conjunctivitis,conjunctivitis,1,1.0
PICATO,conjunctivitis,edema eye conjunctivitis,1,0.8432550430297852
PICATO,conjunctivitis,r,0,0.5249292850494385
PICATO,conjunctivitis,of subjects treated with Picato r,0,0.5188102722167969
PICATO,conjunctivitis,total of subjects treated with Picato,0,0.5086894035339355
PICATO,conjunctivitis,eye conjunctivitis A total of subjects treated,1,0.8406174182891846
PICATO,conjunctivitis,with Picato,0,0.4829205274581909
PICATO,hypersensitivity,hypersensitivity allergic contact dermatitis herpes,1,0.8131692409515381
PICATO,hypersensitivity,gel hypersensitivity allergic contact,1,0.7912269830703735
PICATO,hypersensitivity,mebutate,0,0.5488738417625427
PICATO,hypersensitivity,r ingenol mebutate gel hypersensitivity,1,0.7546953558921814
PICATO,allergic contact dermatitis,Picato r ingenol mebutate gel and,0,0.5685591697692871
PICATO,allergic contact dermatitis,zoster chemical conjunctivitis and corneal burn Because these,0,0.6357920169830322
PICATO,allergic contact dermatitis,allergic contact dermatitis herpes zoster chemical conjunctivitis,1,0.8036266565322876
PICATO,allergic contact dermatitis,uring post approval use of Picato r ingenol mebutate gel and,0,0.5659953355789185
PICATO,herpes zoster,allergic contact dermatitis,0,0.593727171421051
PICATO,herpes zoster,allergic contact herpes zoster,1,0.8541320562362671
PICATO,herpes zoster,contact herpes zoster,1,0.8924140930175781
PICATO,herpes zoster,these,0,0.5225263833999634
PICATO,herpes zoster,and hypersensitivity allergic contact herpes zoster chemical conjunctivitis and,1,0.7792421579360962
PICATO,herpes zoster,conjunctivitis and corneal burn Because,0,0.5763272643089294
PICATO,herpes zoster,herpes zoster chemical conjunctivitis and,1,0.8205252885818481
PICATO,herpes zoster,allergic contact herpes zoster chemical,1,0.8181407451629639
PICATO,herpes zoster,herpes,1,0.8254160284996033
PICATO,herpes zoster,hypersensitivity allergic contact herpes,1,0.7238335609436035
PICATO,chemical conjunctivitis,and corneal burn Because these reactions are reported voluntarily from a population of,0,0.6792546510696411
PICATO,chemical conjunctivitis,herpes chemical conjunctivitis,1,0.8959160447120667
PICATO,chemical conjunctivitis,are reported voluntarily from,0,0.46160173416137695
PICATO,chemical conjunctivitis,dermatitis herpes chemical conjunctivitis and corneal,1,0.8483445048332214
PICATO,chemical conjunctivitis,chemical conjunctivitis and corneal burn,1,0.9058695435523987
PICATO,chemical conjunctivitis,are reported voluntarily,0,0.45305684208869934
PICATO,chemical conjunctivitis,dermatitis herpes chemical conjunctivitis and,1,0.8555519580841064
PICATO,chemical conjunctivitis,allergic contact dermatitis herpes chemical conjunctivitis,1,0.8514162302017212
PICATO,chemical conjunctivitis,allergic contact dermatitis herpes chemical conjunctivitis and corneal burn Because these,1,0.8170771598815918
PICATO,corneal burn,conjunctivitis corneal burn,1,0.9124425053596497
PICATO,corneal burn,herpes zoster chemical conjunctivitis corneal burn Because these,1,0.8389555811882019
PICATO,corneal burn,from a,0,0.4928995668888092
PICATO,corneal burn,corneal burn Because these reactions are,1,0.8973331451416016
PICATO,corneal burn,chemical conjunctivitis,0,0.6578171253204346
PICATO,corneal burn,corneal burn,1,1.0
PICATO,corneal burn,a population,0,0.4521889090538025
PICATO,corneal burn,conjunctivitis,0,0.6708816289901733
PICATO,Eye disorders,are discus,0,0.47497129440307617
PICATO,Eye disorders,Reaction see Warnings a,0,0.4541194438934326
PICATO,Eye disorders,of the labeling Ophthalmic Adverse Reaction see,0,0.6544345617294312
PICATO,corneal burn,of the *,1,0.5119647979736328
PICATO,corneal burn,ious,0,0.498215913772583
PICATO,corneal burn,the * Ophthalmi,1,0.6479672789573669
PICATO,eyelid edema,other,0,0.5246907472610474
PICATO,eyelid edema,sections of the labeling Adverse Reac tion,1,0.5329580903053284
PICATO,eyelid ptosis,ngs and Precautions Hypersensitivity,0,0.49045658111572266
PICATO,eyelid ptosis,Adverse on [see Warni,1,0.5267117023468018
PICATO,eyelid ptosis,Ophthalmic Adverse on [see Warni ngs and Precautions Hypersensitivity Reactions,1,0.6381858587265015
PICATO,eyelid ptosis,Ophthalmic Adverse on [see,1,0.6772065162658691
PICATO,eyelid ptosis,in other sections of the labeling Ophthalmic,0,0.6309948563575745
PICATO,eyelid ptosis,detail in other sections of the labeling Ophthalmic,0,0.6237290501594543
PICATO,Eye disorders,Experience cause,1,0.5089747309684753
PICATO,Eye disorders,wwwfdagovmedwatch Clinical Trials Experience cause clinica l trials are conducted under,1,0.542293131351471
PICATO,Eye disorders,cause clinica,1,0.5736253261566162
PICATO,Eye disorders,cause clinica l trials are,1,0.5396853089332581
PICATO,Eye disorders,Trials Experience cause clinica,1,0.5486323237419128
PICATO,Eye disorders,cause clinica l trials,1,0.5621063113212585
PICATO,Eye disorders,Experience cause clinica,1,0.5456691980361938
PICATO,eye pain,Because,0,0.4247683882713318
PICATO,eye pain,ted unde r widely,1,0.40606069564819336
PICATO,eye pain,are ted unde r widely varying conditions,1,0.4257608652114868
PICATO,eye pain,ted unde r widely varying,1,0.4206887483596802
PICATO,chemical conjunctivitis,trials,0,0.5251894593238831
PICATO,chemical conjunctivitis,widely varying conditio,1,0.4893808364868164
PICATO,chemical conjunctivitis,varying conditio ns adverse,1,0.5371785759925842
PICATO,chemical conjunctivitis,varying conditio,1,0.48593461513519287
PICATO,chemical conjunctivitis,clinical trials are conducted widely varying conditio ns adverse,1,0.5264419317245483
PICATO,chemical conjunctivitis,medwatch Clinical Trials Experience,0,0.5218464732170105
PICATO,chemical conjunctivitis,varying conditio ns,1,0.48726916313171387
PICATO,chemical conjunctivitis,trials are conducted widely varying,1,0.5168534517288208
PICATO,corneal burn,adverse re,1,0.5170581340789795
PICATO,corneal burn,widely varying conditions,0,0.4814881682395935
PICATO,eyelid edema,varying,0,0.4618756175041199
PICATO,eyelid edema,tion rates o bserved in,1,0.452075719833374
PICATO,eyelid edema,rates o bserved in the clinical trials,1,0.48501813411712646
PICATO,eyelid edema,in the clinical trials of a drug cannot be directly,0,0.4738585948944092
PICATO,eyelid ptosis,erved in,1,0.48991885781288147
PICATO,eyelid ptosis,conditions adverse reaction rates erved in the  clinical,1,0.49719977378845215
PICATO,eyelid ptosis,rates erved in the ,1,0.4578286409378052
PICATO,eyelid ptosis,clinical trials of a drug cannot be directly compared to rates in the clinical,0,0.4396904706954956
PICATO,eyelid ptosis,erved in the clinical,1,0.49490517377853394
PICATO,eyelid ptosis,in the clinical,1,0.47741401195526123
PICATO,eyelid ptosis,under widely varying conditions adverse reaction rates,0,0.4911382794380188
PICATO,eyelid ptosis,reaction rates erved in the  clinical trials of,1,0.4792061448097229
PICATO,periorbital edema,inical trials of a drug cannot,1,0.483575701713562
PICATO,periorbital edema,the inical trials of  a drug cannot be directly,1,0.4949277639389038
PICATO,periorbital edema,inical trials of a drug,1,0.5160325765609741
PICATO,periorbital edema,rates in the clinical trials of another drug and,0,0.4960961937904358
PICATO,periorbital edema,inical trials of ,1,0.516244113445282
PICATO,periorbital edema,conditions adverse reaction rates observed in,0,0.5581817626953125
PICATO,periorbital edema,inical trials of,1,0.516244113445282
PICATO,Hypersensitivity reactions,"for 3 consecutive days,",1,0.45568960905075073
PICATO,Hypersensitivity reactions,"of once for 3 consecutive days, an",1,0.4552382826805115
PICATO,Hypersensitivity reactions,"for 3 consecutive days, an d subjects",1,0.5004662275314331
PICATO,Hypersensitivity reactions,for 3,1,0.46656954288482666
PICATO,Hypersensitivity reactions,treatment skin area,0,0.5570918917655945
PICATO,Hypersensitivity reactions,"for 3 consecutive days, an d subjects exposed",1,0.5659365653991699
PICATO,Hypersensitivity reactions,field treatment skin,0,0.5605610609054565
PICATO,Hypersensitivity reactions,"concentration of once for 3 consecutive days, an d subjects exposed",1,0.5616169571876526
PICATO,Hypersensitivity reactions,once for,1,0.4867287576198578
PICATO,anaphylaxis,scalp regions at a concentration of once daily for consecutive,0,0.5485372543334961
PICATO,anaphylaxis,trunk or,0,0.42489907145500183
PICATO,anaphylaxis,extremities regions at,0,0.49289485812187195
PICATO,anaphylaxis,cm in the trunk or extremities,0,0.49218934774398804
PICATO,allergic contact dermatitis,at a concentration of once,0,0.5417494177818298
PICATO,allergic contact dermatitis,trunk,0,0.39879530668258667
PICATO,allergic contact dermatitis,cato (r) gel field treatm ent skin,1,0.6541922092437744
PICATO,skin reactions in the treated area,were within the selected treatment,1,0.6690808534622192
PICATO,skin reactions in the treated area,of represented no,0,0.4943526089191437
PICATO,skin reactions in the treated area,treatment area and graded by,1,0.6870182752609253
PICATO,skin reactions in the treated area,erosionulceration,0,0.5845499038696289
PICATO,skin reactions in the treated area,investigator,0,0.4480355978012085
PICATO,skin reactions in the treated area,within,1,0.5022012591362
PICATO,skin reactions in the treated area,vesiculationpustulation and erosionulceration were within the selected,1,0.5988106727600098
PICATO,skin reactions in the treated area,swelling vesiculationpustulation and erosionulceration were assessed,0,0.6165479421615601
PICATO,skin reactions in the treated area,within the selected treatment area and graded by the investigator,1,0.646489143371582
VIZAMYL,flushing,flushing headache increased blood,1,0.715401828289032
VIZAMYL,flushing,flushing headache,1,0.802191972732544
VIZAMYL,flushing,dizziness To repor,0,0.5385112762451172
VIZAMYL,flushing,nausea,0,0.5387477874755859
VIZAMYL,headache,headache increased blood pressure nausea,1,0.7644773125648499
VIZAMYL,headache,headache increased,1,0.8815398216247559
VIZAMYL,headache,reactions were headache,1,0.7806242108345032
VIZAMYL,nausea,nausea and,1,0.9323806166648865
VIZAMYL,nausea,nausea and dizziness To report,1,0.8354691863059998
VIZAMYL,nausea,dizziness To report,0,0.6888065338134766
VIZAMYL,nausea,blood nausea and dizziness To,1,0.8216102123260498
VIZAMYL,nausea,ADVERSE REACTIONS contact GE Healthcare at,0,0.5633772611618042
VIZAMYL,dizziness,blood pressure nausea dizziness To report SUSPECTED ADVERSE REACTIONS,1,0.7080094814300537
VIZAMYL,dizziness,ADVERSE REACTIONS contact GE Healthcare at,0,0.5462013483047485
VIZAMYL,dizziness,blood pressure nausea dizziness To,1,0.8034457564353943
VIZAMYL,dizziness,increased,0,0.536552369594574
VIZAMYL,dizziness,contact,0,0.5121212005615234
VIZAMYL,dizziness,dizziness To,1,0.9522849917411804
VIZAMYL,dizziness,pressure nausea dizziness To report,1,0.7782506942749023
VIZAMYL,dizziness,and,0,0.5259379148483276
VIZAMYL,hypersensitivity reaction,experienced a hypersensitivity reaction with flushing dyspnea and chest,1,0.8201415538787842
VIZAMYL,hypersensitivity reaction,and,0,0.49199411273002625
VIZAMYL,hypersensitivity reaction,Vizamyl experienced a hypersensitivity reaction with flushing dyspnea,1,0.757411539554596
VIZAMYL,hypersensitivity reaction,dyspnea and chest pressure within minutes following Vizamyl administration and,0,0.557453989982605
VIZAMYL,hypersensitivity reaction,ed a dose,0,0.5433398485183716
VIZAMYL,flushing,experienced a serious hypersensitivity reaction,0,0.5462228059768677
VIZAMYL,flushing,administered Vizamyl experienced a serious hypersensitivity reaction with,0,0.5531245470046997
VIZAMYL,flushing,following Vizamyl administration and recovered with trea,0,0.5854024291038513
VIZAMYL,dyspnea,dyspnea,1,1.0
VIZAMYL,dyspnea,dyspnea and,1,0.9412474632263184
VIZAMYL,dyspnea,and recovered,0,0.5487048625946045
VIZAMYL,dyspnea,reaction with,0,0.5268700122833252
VIZAMYL,dyspnea,serious hypersensitivity reaction with dyspnea and chest pressure,1,0.7623313665390015
VIZAMYL,dyspnea,a,0,0.5649319887161255
VIZAMYL,dyspnea,dyspnea and chest pressure within,1,0.8597838878631592
VIZAMYL,dyspnea,with dyspnea and chest,1,0.8748241662979126
VIZAMYL,chest pressure,administration and,0,0.4694019854068756
VIZAMYL,chest pressure,chest pressure,1,0.9999999403953552
VIZAMYL,chest pressure,with treatment,0,0.5491189360618591
VIZAMYL,chest pressure,flushing dyspnea chest pressure within minutes following Vizamyl administration,1,0.7696858644485474
VIZAMYL,chest pressure,chest pressure within,1,0.9425030946731567
VIZAMYL,chest pressure,with flushing,0,0.5506553053855896
VIZAMYL,chest pressure,serious hypersensitivity reaction with flushing,0,0.5417829155921936
VIZAMYL,Hypersensitivity reactions,commonly,0,0.4973919689655304
VIZAMYL,Hypersensitivity reactions,reported adverse reactions were flushing headache increased,1,0.694728434085846
VIZAMYL,Hypersensitivity reactions,ADVERSE REACTIONS EXCERPT Most reported,1,0.6915991306304932
VIZAMYL,Radiation risk,Experience Clinical trials are conducted under,0,0.5154622197151184
VIZAMYL,Radiation risk,conducted under widely ying,1,0.4951869547367096
VIZAMYL,Radiation risk,trials are conducted under widely var,0,0.5533609390258789
VIZAMYL,long-term cumulative radiation exposure,trials of Vizamyl not be directly compared to,1,0.5187642574310303
VIZAMYL,long-term cumulative radiation exposure,conditions and adverse reaction rates observed in the clinical trials of Vizamyl can,0,0.5500277280807495
VIZAMYL,long-term cumulative radiation exposure,the rates observed in clinical practice,0,0.5891063213348389
VIZAMYL,long-term cumulative radiation exposure,not be directly,1,0.4727625846862793
VIZAMYL,long-term cumulative radiation exposure,not be directly compared to rates in,1,0.4779304563999176
VIZAMYL,Hypersensitivity reactions,and women Caucasian th a mean age of 62 years,1,0.46075373888015747
VIZAMYL,flushing,Most subjects received a dose of MBq mCi One,0,0.5116890668869019
VIZAMYL,flushing,of years -93 year,1,0.4390445947647095
VIZAMYL,flushing,mCi,0,0.5306799411773682
VIZAMYL,flushing,-93 year,1,0.45651960372924805
VIZAMYL,flushing,of years -93,1,0.4349597692489624
VIZAMYL,flushing,a mean age of years,0,0.4979524612426758
POTIGA,Retinal abnormalities,Warnings and Precautions section of the,0,0.46521425247192383
POTIGA,Retinal abnormalities,of the Retinal abnormalities and potential vision loss,1,0.9013384580612183
POTIGA,Retinal abnormalities,Retinal abnormalities,1,0.9999998807907104
POTIGA,Retinal abnormalities,potential vision loss see Warnings and Precautions Urinary retention,0,0.6175981163978577
POTIGA,Retinal abnormalities,Warnings,0,0.5121690034866333
POTIGA,Retinal abnormalities,and Precautions section,0,0.4490237832069397
POTIGA,Retinal abnormalities,more detail in,0,0.4667896628379822
POTIGA,vision loss,and Precautions Urinary retention see Warnings and Precautions,0,0.5309263467788696
POTIGA,vision loss,vision loss see Warnings and,1,0.8808625936508179
POTIGA,vision loss,and vision loss see Warnings and Precautions Urinary,1,0.8009692430496216
POTIGA,vision loss,and,0,0.52968430519104
POTIGA,vision loss,Warnings and Precautions section of the label Retinal abnormalities and,0,0.675658106803894
POTIGA,vision loss,of the label Retinal abnormalities and,0,0.6907683610916138
POTIGA,vision loss,vision loss see,1,0.9349348545074463
POTIGA,vision loss,and vision loss,1,0.9305849075317383
POTIGA,vision loss,and Precautions section of the,0,0.48074156045913696
POTIGA,Urinary retention,Urinary retention see Warnings,1,0.8843698501586914
POTIGA,Urinary retention,see Warnings and Precautions,0,0.48716410994529724
POTIGA,Urinary retention,Precautions Skin,0,0.48718586564064026
POTIGA,Urinary retention,and Urinary,1,0.7837041616439819
POTIGA,Urinary retention,Precautions,0,0.4967684745788574
POTIGA,Urinary retention,see Warnings and Urinary,1,0.7200270891189575
POTIGA,Urinary retention,see Warnings and Urinary retention,1,0.856735110282898
POTIGA,Urinary retention,and Precautions Skin discoloration see,0,0.5170823335647583
POTIGA,Skin discoloration,Warnings and Skin discoloration,1,0.8511772751808167
POTIGA,Skin discoloration,and Skin,1,0.729682207107544
POTIGA,Skin discoloration,Warnings and Precautions Neuropsychiatric,0,0.5400060415267944
POTIGA,Skin discoloration,retention see Warnings and Skin,1,0.6999355554580688
POTIGA,Skin discoloration,Skin discoloration see Warnings and Precautions Neuropsychiatric,1,0.8318685293197632
POTIGA,Skin discoloration,and Skin discoloration see Warnings,1,0.8815550804138184
POTIGA,Skin discoloration,and Precautions Neuropsychiatric symptoms see Warnings and Precaution,0,0.5420581102371216
POTIGA,Skin discoloration,retention see Warnings and Skin discoloration see,1,0.80701744556427
POTIGA,Neuropsychiatric symptoms,Warnings and Neuropsychiatric symptoms see,1,0.8874648809432983
POTIGA,Neuropsychiatric symptoms,and Precautions Neuropsychiatric symptoms see Warnings and Precaution,0,0.8690388202667236
POTIGA,Neuropsychiatric symptoms,Warnings and,0,0.5688421726226807
POTIGA,Neuropsychiatric symptoms,Neuropsychiatric symptoms see Warnings and Precautions,1,0.9119584560394287
POTIGA,Neuropsychiatric symptoms,discoloration see Warnings and Neuropsychiatric symptoms see Warnings and Precautions,1,0.788455605506897
POTIGA,Neuropsychiatric symptoms,see,0,0.49096953868865967
POTIGA,Neuropsychiatric symptoms,and somnolence see Warnings and Precautions,0,0.6256998181343079
POTIGA,Neuropsychiatric symptoms,see Warnings and Neuropsychiatric,1,0.8353127837181091
POTIGA,Dizziness,Dizziness and,1,0.9494887590408325
POTIGA,Dizziness,d Precautions,0,0.5372344851493835
POTIGA,Dizziness,and Precautions,0,0.4907934069633484
POTIGA,Dizziness,Warnings and Dizziness and,1,0.8531502485275269
POTIGA,somnolence,somnolence see Warnings and Precautions QT,1,0.7726835012435913
POTIGA,somnolence,see,0,0.46394896507263184
POTIGA,QT interval effect,QT interval effect see Warnings and,1,0.8594363331794739
POTIGA,QT interval effect,and QT interval effect see,1,0.9802498817443848
POTIGA,QT interval effect,Warnings,0,0.49393430352211
POTIGA,QT interval effect,QT interval effect see Warnings and Precautions,1,0.9076557159423828
POTIGA,QT interval effect,and Precautions,0,0.48727545142173767
POTIGA,QT interval effect,somnolence see Warnings and QT interval effect,1,0.815483570098877
POTIGA,QT interval effect,and ideation see Warnings,0,0.4980652928352356
POTIGA,QT interval effect,Warnings and,0,0.48982560634613037
POTIGA,Suicidal behavior,effect see Warnings and Suicidal behavior,1,0.8044626116752625
POTIGA,Suicidal behavior,Suicidal behavior and,1,0.9584693908691406
POTIGA,Suicidal behavior,see Warnings and Suicidal behavior,1,0.851421594619751
POTIGA,Suicidal behavior,see,0,0.4542023539543152
POTIGA,Suicidal behavior,Withdrawal seizures see Warnings,0,0.5218717455863953
POTIGA,Withdrawal seizures,Warnings and Withdrawal seizures see Warnings,1,0.7937387824058533
POTIGA,Withdrawal seizures,Withdrawal seizures see Warnings,0,0.8823246955871582
POTIGA,Withdrawal seizures,Warnings and Withdrawal seizures see Warnings and Precautions,1,0.7890385389328003
POTIGA,Withdrawal seizures,and Precautions,0,0.46379247307777405
POTIGA,Withdrawal seizures,ideation see Warnings and Withdrawal seizures,1,0.8024696111679077
POTIGA,Withdrawal seizures,and,0,0.46934783458709717
POTIGA,Withdrawal seizures,Withdrawal seizures see Warnings,1,0.8823246955871582
POTIGA,Withdrawal seizures,cautions Suicidal behavior and ideation see Warnings and Precautions,0,0.522511899471283
POTIGA,dizziness,common adverse reactions incidence and twice,0,0.5561279654502869
POTIGA,somnolence,confusional state vertigo tremor abnormal coordination diplopia,0,0.5428376197814941
POTIGA,somnolence,somnolence fatigue confusional,1,0.8432263135910034
POTIGA,somnolence,were somnolence fatigue confusional,1,0.8327264785766602
POTIGA,somnolence,and twice placebo were somnolence fatigue confusional state,1,0.7571016550064087
POTIGA,somnolence,placebo were somnolence fatigue confusional state,1,0.7712221145629883
POTIGA,somnolence,tremor abnormal coordination diplopia disturbance in,0,0.5154078602790833
POTIGA,somnolence,somnolence fatigue,1,0.8950692415237427
POTIGA,fatigue,placebo were dizziness fatigue,1,0.7644307613372803
POTIGA,fatigue,somnolence fatigue,1,0.8170138001441956
POTIGA,confusional state,confusional,1,0.8754180669784546
POTIGA,confusional state,were dizziness somnolence confusional state vertigo tremor abnormal coordination diplopia,1,0.6943880319595337
POTIGA,confusional state,were dizziness somnolence confusional state,1,0.8110727071762085
POTIGA,confusional state,twice placebo were dizziness,0,0.606829822063446
POTIGA,confusional state,abnormal,0,0.5803239941596985
POTIGA,confusional state,tremor abnormal coordination diplopia disturbance in attention memory impairment ast,0,0.5954968929290771
POTIGA,confusional state,confusional state vertigo tremor abnormal coordination,1,0.7876549959182739
POTIGA,confusional state,confusional state vertigo tremor abnormal coordination diplopia,1,0.7701435089111328
POTIGA,confusional state,vertigo tremor,0,0.5919908881187439
POTIGA,vertigo,vertigo tremor abnormal coordination,1,0.7811099290847778
POTIGA,vertigo,vertigo tremor abnormal coordination diplopia disturbance,1,0.7632390856742859
POTIGA,tremor,tremor,1,0.9999998807907104
POTIGA,tremor,tremor abnormal coordination,1,0.8208869695663452
POTIGA,tremor,tremor abnormal,1,0.8938937187194824
POTIGA,tremor,in attention memory impairment,0,0.4859127104282379
POTIGA,diplopia,diplopia disturbance in,1,0.9098042845726013
POTIGA,diplopia,in attention memory impairment,0,0.5213372111320496
POTIGA,diplopia,diplopia disturbance in attention memory,1,0.8077043890953064
POTIGA,diplopia,diplopia,1,1.0000001192092896
POTIGA,diplopia,diplopia disturbance,1,0.8927039504051208
POTIGA,disturbance in attention,coordination diplopia,0,0.6197037100791931
POTIGA,memory impairment,memory impairment asthenia blurred,1,0.8536971807479858
POTIGA,memory impairment,diplopia disturbance in memory impairment asthenia blurred vision,1,0.76511549949646
POTIGA,asthenia,asthenia blurred vision gait disturbance aphasia,1,0.7474890947341919
POTIGA,asthenia,asthenia blurred vision gait disturbance,1,0.7191892862319946
POTIGA,asthenia,asthenia blurred,1,0.8410073518753052
POTIGA,asthenia,asthenia blurred vision,1,0.7896018028259277
POTIGA,blurred vision,gait disturbance aphasia dysarthria,0,0.5452268719673157
POTIGA,gait disturbance,report SUSPECTED ADVERSE,0,0.6108912229537964
POTIGA,gait disturbance,report,0,0.548904538154602
POTIGA,gait disturbance,gait disturbance aphasia dysarthria and,1,0.8444805145263672
POTIGA,gait disturbance,impairment asthenia blurred gait,1,0.8350180387496948
POTIGA,aphasia,balance disorder To report SUSPECTED ADVERSE,0,0.5550572872161865
POTIGA,aphasia,aphasia dysarthria and balance disorder,1,0.8155587911605835
POTIGA,aphasia,SUSPECTED ADVERSE REACTIONS contact G,0,0.46738117933273315
POTIGA,aphasia,disorder To report SUSPECTED ADVERSE REACTIONS,0,0.5236865282058716
POTIGA,aphasia,aphasia,1,0.9999998807907104
POTIGA,aphasia,aphasia dysarthria and balance disorder To,1,0.8191086649894714
POTIGA,aphasia,REACTIONS contact G,0,0.49121230840682983
POTIGA,dysarthria,dysarthria and balance disorder,1,0.8682377934455872
POTIGA,balance disorder,disturbance aphasia dysarthria balance disorder,1,0.8336226940155029
POTIGA,balance disorder,balance disorder To,1,0.9618038535118103
POTIGA,dizziness,dizziness,1,1.0
POTIGA,dizziness,dizziness confusional state fatigue and somnolence,1,0.8001779317855835
POTIGA,dizziness,The most,0,0.528454601764679
POTIGA,dizziness,confusional state fatigue and somnolence Common Adverse Reactions,0,0.6755056381225586
POTIGA,dizziness,reactions leading to withdrawal,0,0.5670437812805176
POTIGA,confusional state,Adverse Reactions in,0,0.5230915546417236
POTIGA,confusional state,patients receiving POTIGA were confusional state fatigue and,1,0.723175048828125
POTIGA,confusional state,to withdrawal in patients receiving POTIGA were,0,0.5453805923461914
POTIGA,confusional state,patients receiving POTIGA were confusional,1,0.7109099626541138
POTIGA,confusional state,confusional state,1,1.000000238418579
POTIGA,fatigue,Adverse,0,0.5371894836425781
POTIGA,fatigue,fatigue and somnolence Common Adverse,1,0.7828845977783203
POTIGA,fatigue,confusional state,0,0.5483655333518982
POTIGA,somnolence,somnolence Common Adverse Reactions in All,1,0.8023564219474792
POTIGA,dizziness,dizziness somnolence fatigue confusional state vertigo,1,0.8344156742095947
POTIGA,dizziness,rate,0,0.5143170356750488
POTIGA,dizziness,dizziness somnolence,1,0.8632394075393677
POTIGA,dizziness,placebo rate dizziness somnolence,1,0.7790518999099731
POTIGA,dizziness,occurring approximately twice,0,0.5463956594467163
POTIGA,vertigo,placebo rate were,0,0.5321053266525269
POTIGA,vertigo,vertigo tremor abnormal coordination diplopia,1,0.763336181640625
POTIGA,vertigo,in attention memory,0,0.5469668507575989
POTIGA,vertigo,dizziness somnolence fatigue confusional vertigo,1,0.8231558799743652
POTIGA,vertigo,state,0,0.4560612142086029
POTIGA,vertigo,dizziness somnolence,0,0.7480804920196533
POTIGA,tremor,diplopia disturbance,0,0.5789706707000732
POTIGA,tremor,state tremor,1,0.8551185131072998
POTIGA,tremor,in attention memory,0,0.48144039511680603
POTIGA,tremor,state vertigo,0,0.6041562557220459
POTIGA,tremor,tremor abnormal coordination diplopia,1,0.7646151781082153
POTIGA,abnormal coordination,tremor,0,0.6355615258216858
POTIGA,abnormal coordination,abnormal coordination diplopia disturbance in,1,0.848078727722168
POTIGA,abnormal coordination,diplopia disturbance in attention,0,0.6456113457679749
POTIGA,abnormal coordination,vertigo,0,0.5972145795822144
POTIGA,abnormal coordination,in attention,0,0.5898265242576599
POTIGA,abnormal coordination,state vertigo abnormal coordination diplopia,1,0.8153475522994995
POTIGA,diplopia,diplopia disturbance in attention memory impairment,1,0.7813923358917236
POTIGA,disturbance in attention,blurred vision,0,0.6387239694595337
POTIGA,disturbance in attention,impairment,0,0.6854318976402283
POTIGA,disturbance in attention,in attention memory impairment asthenia,1,0.8155294060707092
POTIGA,disturbance in attention,tremor abnormal coordination disturbance,1,0.6959776282310486
POTIGA,disturbance in attention,vertigo tremor abnormal coordination disturbance,1,0.7039528489112854
POTIGA,disturbance in attention,vertigo tremor abnormal coordination disturbance in attention,1,0.8190860152244568
POTIGA,memory impairment,coordination diplopia disturbance in,0,0.6000809669494629
POTIGA,memory impairment,memory impairment asthenia,1,0.8662686944007874
POTIGA,asthenia,asthenia,1,1.0000001192092896
POTIGA,asthenia,memory asthenia blurred vision gait disturbance aphasia,1,0.6856961250305176
POTIGA,asthenia,in attention memory asthenia blurred vision gait,1,0.6228683590888977
POTIGA,asthenia,and balance,0,0.5254923701286316
POTIGA,asthenia,aphasia dysarthria and,0,0.586336076259613
POTIGA,asthenia,asthenia blurred vision gait,1,0.7302076816558838
POTIGA,blurred vision,attention memory impairment blurred vision gait disturbance aphasia dysarthria,1,0.6829560399055481
POTIGA,blurred vision,aphasia dysarthria and,0,0.5384573936462402
POTIGA,blurred vision,in attention memory impairment asthenia,0,0.5955645442008972
POTIGA,blurred vision,blurred vision,1,1.0
POTIGA,blurred vision,impairment,0,0.675049901008606
POTIGA,gait disturbance,ia disturbance in attention memory,0,0.6158390045166016
POTIGA,gait disturbance,memory impairment asthenia blurred gait disturbance,1,0.8200365900993347
POTIGA,gait disturbance,gait disturbance,1,1.0
POTIGA,gait disturbance,impairment asthenia blurred gait disturbance aphasia dysarthria and,1,0.7923902273178101
POTIGA,gait disturbance,blurred gait,1,0.8261772394180298
POTIGA,gait disturbance,impairment asthenia blurred gait disturbance aphasia dysarthria and balance,1,0.7998923063278198
POTIGA,gait disturbance,Table,0,0.5177626609802246
POTIGA,gait disturbance,attention memory impairment asthenia,0,0.6063152551651001
POTIGA,gait disturbance,gait disturbance aphasia dysarthria,1,0.8529230952262878
POTIGA,aphasia,cases the reactions were of,0,0.5202447175979614
POTIGA,aphasia,aphasia dysarthria,1,0.8541895151138306
POTIGA,aphasia,gait aphasia dysarthria and,1,0.8234020471572876
POTIGA,aphasia,reactions were,0,0.5030447244644165
POTIGA,dysarthria,the reactions were,0,0.46754875779151917
POTIGA,dysarthria,dysarthria and balance,1,0.873349666595459
POTIGA,dysarthria,dysarthria and,1,0.960985004901886
POTIGA,dysarthria,memory impairment asthenia blurred vision,0,0.5945119261741638
POTIGA,dysarthria,disturbance dysarthria and,1,0.9206910133361816
POTIGA,dysarthria,of mild,0,0.5225546956062317
POTIGA,dysarthria,disturbance dysarthria and balance disorder,1,0.8595706820487976
POTIGA,dysarthria,gait disturbance aphasia,0,0.6897603273391724
POTIGA,increased appetite,and,0,0.503643810749054
POTIGA,increased appetite,placebo increased,1,0.7050553560256958
POTIGA,increased appetite,dysphagia hyperhydrosis,0,0.6519840955734253
POTIGA,increased appetite,increased appetite hallucinations myoclonus peripheral edema,1,0.7966179847717285
POTIGA,increased appetite,POTIGA and numerically greater than placebo,0,0.6297207474708557
POTIGA,hallucinations,hallucinations myoclonus peripheral edema,1,0.792427659034729
POTIGA,hallucinations,n of patients treated,0,0.5158048272132874
POTIGA,hallucinations,placebo were increased appetite,0,0.5436329245567322
POTIGA,hallucinations,hypokinesia dry,0,0.5621989369392395
POTIGA,hallucinations,n of patients treated with POTIGA,0,0.5046367049217224
POTIGA,hallucinations,hallucinations myoclonus peripheral,1,0.7890955805778503
POTIGA,hallucinations,were increased hallucinations myoclonus peripheral edema hypokinesia dry,1,0.7915305495262146
POTIGA,myoclonus,myoclonus peripheral edema,1,0.8340697288513184
POTIGA,myoclonus,were increased appetite hallucinations,0,0.5606318712234497
POTIGA,myoclonus,mouth dysphagia hyperhydrosis urinary retention malaise an,0,0.5255390405654907
POTIGA,myoclonus,myoclonus peripheral edema hypokinesia dry mouth,1,0.7810639142990112
POTIGA,myoclonus,treated with,0,0.5080653429031372
POTIGA,myoclonus,myoclonus peripheral edema hypokinesia dry,1,0.7944567203521729
POTIGA,peripheral edema,appetite hallucinations peripheral edema hypokinesia dry,1,0.7287003993988037
POTIGA,peripheral edema,myoclonus peripheral edema hypokinesia dry,1,0.7735185623168945
POTIGA,peripheral edema,hallucinations peripheral edema,1,0.8389351963996887
POTIGA,peripheral edema,appetite hallucinations peripheral edema,1,0.8040542602539062
POTIGA,hypokinesia,dysphagia hyperhydrosis urinary,0,0.5643917918205261
POTIGA,hypokinesia,peripheral hypokinesia dry mouth,1,0.7630100250244141
POTIGA,hypokinesia,myoclonus peripheral,0,0.5505945086479187
POTIGA,hypokinesia,myoclonus peripheral hypokinesia dry mouth dysphagia,1,0.6851441264152527
POTIGA,hypokinesia,hypokinesia dry,1,0.9104136824607849
POTIGA,dry mouth,appetite hallucinations myoclonus peripheral edema hypokinesia,0,0.5834264755249023
POTIGA,dry mouth,dry mouth dysphagia hyperhydrosis urinary retention malaise,1,0.7703676223754883
POTIGA,dry mouth,myoclonus peripheral edema hypokinesia,0,0.5438576936721802
POTIGA,dry mouth,retention malaise and,0,0.5684080123901367
POTIGA,dry mouth,peripheral edema,0,0.5610426068305969
POTIGA,dysphagia,dysphagia hyperhydrosis,1,0.8071318864822388
POTIGA,dysphagia,Most of the adverse,0,0.5431246757507324
POTIGA,dysphagia,appetite hallucinations myoclonus peripheral,0,0.5654928088188171
POTIGA,hyperhydrosis,hallucinations myoclonus peripheral,0,0.5354535579681396
POTIGA,hyperhydrosis,hyperhydrosis urinary retention malaise,1,0.8273106217384338
POTIGA,hyperhydrosis,hyperhydrosis urinary,1,0.8705935478210449
POTIGA,hyperhydrosis,retention malaise and increased liver enzymes Most of the adverse reactions,0,0.5629163980484009
POTIGA,hyperhydrosis,peripheral edema hypokinesia,0,0.6559014916419983
POTIGA,hyperhydrosis,hyperhydrosis urinary retention malaise and increased,1,0.8364806175231934
POTIGA,hyperhydrosis,mouth hyperhydrosis urinary retention malaise and increased,1,0.8063094615936279
POTIGA,urinary retention,urinary retention malaise and increased liver enzymes,1,0.8330453634262085
POTIGA,urinary retention,hyperhydrosis urinary retention malaise and increased,1,0.8279296159744263
POTIGA,malaise,hyperhydrosis urinary malaise,1,0.6792354583740234
POTIGA,malaise,hyperhydrosis urinary retention malaise and increased,1,0.6399027109146118
POTIGA,malaise,malaise and increased liver enzymes Most,1,0.7598263621330261
POTIGA,malaise,malaise,1,0.9999999403953552
POTIGA,malaise,enzymes Most of the adverse reactions appear to be,0,0.5478012561798096
POTIGA,malaise,malaise and increased liver,1,0.7445560693740845
POTIGA,malaise,dysphagia hyperhydrosis urinary retention,0,0.5529530048370361
POTIGA,malaise,mouth dysphagia,0,0.5084165334701538
POTIGA,malaise,retention,0,0.5354015231132507
POTIGA,malaise,malaise and increased,1,0.8601542711257935
POTIGA,malaise,Most of the adverse reactions appear to,0,0.5645588040351868
POTIGA,increased liver enzymes,those classified as psychi,0,0.48190024495124817
POTIGA,increased liver enzymes,malaise increased,1,0.6095172166824341
POTIGA,increased liver enzymes,and,0,0.48114609718322754
POTIGA,increased liver enzymes,hypokinesia dry mouth dysphagia hyperhydrosis urinary retention malaise and,0,0.5203452110290527
POTIGA,increased liver enzymes,the adverse reactions appear to be dose related,0,0.6221291422843933
POTIGA,increased liver enzymes,reactions appear to be dose related especially,0,0.6302512884140015
POTIGA,increased liver enzymes,liver enzymes Most of,1,0.8392565846443176
POTIGA,dizziness,blurred,0,0.6117379665374756
POTIGA,dizziness,and nervous system symptoms dizziness somnolence confusional state,1,0.7859335541725159
POTIGA,dizziness,memory impairment blurred,0,0.6251651048660278
POTIGA,dizziness,dizziness somnolence confusional,1,0.8433336019515991
POTIGA,dizziness,and nervous system symptoms dizziness somnolence confusional state tremor,1,0.7742010354995728
POTIGA,dizziness,symptoms dizziness somnolence confusional state,1,0.8205422163009644
POTIGA,dizziness,dizziness somnolence confusional state,1,0.8069713115692139
POTIGA,dizziness,tremor abnormal coordination memory,0,0.5673275589942932
POTIGA,somnolence,nervous system symptoms including somnolence confusional state tremor abnormal coordination,1,0.7127945423126221
POTIGA,somnolence,tremor abnormal coordination memory,0,0.536186158657074
POTIGA,somnolence,as psychiatric,0,0.5609662532806396
POTIGA,somnolence,symptoms including dizziness,0,0.5629698038101196
POTIGA,somnolence,somnolence,1,1.0
POTIGA,somnolence,coordination memory impairment,0,0.5115741491317749
POTIGA,somnolence,system symptoms including dizziness,0,0.5704538822174072
POTIGA,somnolence,nervous system symptoms including somnolence confusional state tremor abnormal,1,0.7337603569030762
POTIGA,somnolence,somnolence confusional state,1,0.8497350811958313
POTIGA,somnolence,somnolence confusional state tremor abnormal coordination,1,0.7328096628189087
POTIGA,somnolence,coordination memory,0,0.5024391412734985
POTIGA,confusional state,symptoms including dizziness confusional state tremor,1,0.7536510229110718
POTIGA,confusional state,coordination memory,0,0.6090248823165894
POTIGA,confusional state,dizziness confusional state,1,0.881451427936554
POTIGA,confusional state,psychiatric and nervous system,0,0.613881528377533
POTIGA,confusional state,symptoms including dizziness confusional state,1,0.8115779161453247
POTIGA,tremor,tremor abnormal coordination memory impairment blurred,1,0.7816848754882812
POTIGA,tremor,somnolence confusional tremor abnormal coordination memory impairment,1,0.7444517612457275
POTIGA,tremor,abnormal coordination memory impairment blurred,0,0.5939007997512817
POTIGA,tremor,tremor abnormal coordination memory impairment,1,0.7848529815673828
POTIGA,abnormal coordination,somnolence confusional state,0,0.5804544687271118
POTIGA,abnormal coordination,balance disorder constipation dysu,0,0.6921372413635254
POTIGA,abnormal coordination,balance,0,0.5992876291275024
POTIGA,abnormal coordination,state abnormal coordination memory impairment blurred vision,1,0.8144301176071167
POTIGA,abnormal coordination,confusional,0,0.6088534593582153
POTIGA,abnormal coordination,abnormal coordination memory,1,0.9124906659126282
POTIGA,abnormal coordination,including dizziness,0,0.5784959197044373
POTIGA,abnormal coordination,state tremor,0,0.6364578008651733
POTIGA,abnormal coordination,aphasia balance disorder constipation,0,0.6715259552001953
POTIGA,memory impairment,memory,1,0.8451153039932251
POTIGA,memory impairment,memory impairment blurred vision,1,0.8476145267486572
POTIGA,memory impairment,tremor,0,0.547752857208252
POTIGA,memory impairment,aphasia balance,0,0.6288979053497314
POTIGA,blurred vision,blurred vision gait disturbance aphasia balance disorder,1,0.7403900623321533
POTIGA,blurred vision,abnormal coordination memory blurred vision gait disturbance aphasia,1,0.6870841979980469
POTIGA,blurred vision,blurred vision gait disturbance,1,0.8467690944671631
POTIGA,blurred vision,abnormal coordination memory blurred vision gait disturbance aphasia balance disorder,1,0.671294629573822
POTIGA,blurred vision,somnolence confusional state tremor abnormal coordination memory,0,0.5567805171012878
POTIGA,blurred vision,abnormal coordination memory blurred vision,1,0.8195053339004517
POTIGA,blurred vision,abnormal coordination memory blurred,1,0.6897532939910889
POTIGA,blurred vision,coordination memory blurred vision,1,0.8370802998542786
POTIGA,gait disturbance,coordination memory impairment blurred gait,1,0.7718592286109924
POTIGA,gait disturbance,vision,0,0.5037352442741394
POTIGA,gait disturbance,state tremor abnormal coordination memory impairment,0,0.6835328340530396
POTIGA,gait disturbance,gait disturbance aphasia,1,0.8631184101104736
POTIGA,gait disturbance,gait disturbance aphasia balance disorder,1,0.8456661701202393
POTIGA,gait disturbance,memory impairment blurred gait disturbance aphasia balance disorder,1,0.7966208457946777
POTIGA,gait disturbance,was,0,0.5288970470428467
POTIGA,gait disturbance,gait,1,0.8661473989486694
POTIGA,aphasia,memory impairment blurred,0,0.6753123998641968
POTIGA,aphasia,aphasia balance disorder,1,0.8280729055404663
POTIGA,balance disorder,balance disorder constipation dysuria and chromaturia,1,0.8052535057067871
POTIGA,balance disorder,aphasia balance disorder,1,0.8620420694351196
POTIGA,balance disorder,disturbance balance,1,0.7006446719169617
POTIGA,balance disorder,with doserelated weight,0,0.6024894714355469
POTIGA,balance disorder,disturbance balance disorder,1,0.9394359588623047
POTIGA,balance disorder,associated,0,0.5071008801460266
POTIGA,balance disorder,disturbance balance disorder constipation dysuria and chromaturia,1,0.780620276927948
POTIGA,balance disorder,balance disorder,1,0.9999998807907104
POTIGA,constipation,with mean weigh,0,0.5636863708496094
POTIGA,constipation,constipation dysuria and chromaturia,1,0.7821786403656006
POTIGA,constipation,constipation dysuria and chromaturia POTIGA,1,0.7762187123298645
POTIGA,constipation,constipation dysuria,1,0.7970339059829712
POTIGA,constipation,ormal coordination memory impairment blurred vision gait disturbance aphasia balance disorder,0,0.5584092140197754
POTIGA,constipation,gain with,0,0.5910830497741699
POTIGA,constipation,constipation dysuria and,1,0.8041266798973083
POTIGA,constipation,gait,0,0.5929766893386841
POTIGA,chromaturia,chromaturia POTIGA,1,0.7747859954833984
POTIGA,chromaturia,and,0,0.45659154653549194
POTIGA,chromaturia,associated with doserelated weight gain with mean weight,0,0.5267926454544067
POTIGA,chromaturia,chromaturia POTIGA was associated with doserelated,1,0.8282294273376465
POTIGA,chromaturia,mean weight increasing by kg,0,0.5024701356887817
POTIGA,chromaturia,chromaturia POTIGA was associated,1,0.8034353256225586
POTIGA,chromaturia,chromaturia,1,0.9999998807907104
POTIGA,chromaturia,with doserelated weight gain with mean weight increasing,0,0.5162613391876221
POTIGA,chromaturia,disturbance aphasia balance disorder constipation dysuria,0,0.6537313461303711
POTIGA,weight gain,POTIGA was associated with weight gain,1,0.8081690669059753
POTIGA,weight gain,disturbance aphasia balance disorder constipation dysuria,0,0.5546998977661133
POTIGA,weight gain,weight gain with mean weight increasing,1,0.9128590822219849
POTIGA,weight gain,associated with doserelated,0,0.5386844873428345
POTIGA,weight gain,weight gain with,1,0.9520342946052551
POTIGA,weight gain,was associated with weight,1,0.7701009511947632
POTIGA,weight increasing,per day,0,0.591672420501709
POTIGA,rash,syncope,0,0.5778658390045166
POTIGA,nystagmus,during all clinical trials nystagmus dyspnea leukopenia muscle spasms alopecia,1,0.7082638740539551
POTIGA,nystagmus,syncope,0,0.5891896486282349
POTIGA,nystagmus,nystagmus dyspnea leukopenia muscle,1,0.7692699432373047
POTIGA,nystagmus,rash,0,0.48819124698638916
POTIGA,nystagmus,dyspnea leukopenia muscle spasms alopecia,0,0.5449313521385193
POTIGA,nystagmus,nystagmus dyspnea leukopenia,1,0.7715393900871277
POTIGA,nystagmus,nystagmus dyspnea,1,0.8412879109382629
POTIGA,nystagmus,muscle,0,0.5026489496231079
POTIGA,dyspnea,neutropenia,0,0.537151575088501
POTIGA,dyspnea,alopecia nephrolithiasis syncope,0,0.558647632598877
POTIGA,dyspnea,dyspnea leukopenia muscle spasms,1,0.7384740114212036
POTIGA,dyspnea,dyspnea leukopenia muscle spasms alopecia,1,0.7486853003501892
POTIGA,leukopenia,leukopenia muscle spasms,1,0.7859481573104858
POTIGA,leukopenia,leukopenia muscle spasms alopecia nephrolithiasis syncope,1,0.7415841817855835
POTIGA,leukopenia,trials rash nystagmus leukopenia muscle spasms alopecia nephrolithiasis,1,0.6234345436096191
POTIGA,leukopenia,euphoric mood,0,0.4853173494338989
POTIGA,leukopenia,leukopenia muscle,1,0.8692938685417175
POTIGA,muscle spasms,dyspnea muscle spasms,1,0.8561626672744751
POTIGA,muscle spasms,trials rash nystagmus dyspnea muscle spasms alopecia nephrolithiasis syncope neutropenia,1,0.7147349119186401
POTIGA,alopecia,alopecia nephrolithiasis syncope,1,0.7456704378128052
POTIGA,alopecia,leukopenia muscle alopecia,1,0.7987796068191528
POTIGA,alopecia,alopecia nephrolithiasis,1,0.7768621444702148
POTIGA,alopecia,alopecia nephrolithiasis syncope neutropenia thrombocytopenia euphoric,1,0.7168900966644287
POTIGA,nephrolithiasis,nephrolithiasis syncope neutropenia,1,0.7976433038711548
POTIGA,nephrolithiasis,syncope neutropenia,0,0.5074613690376282
POTIGA,nephrolithiasis,clinical,0,0.559505820274353
POTIGA,nephrolithiasis,spasms nephrolithiasis,1,0.8711552619934082
POTIGA,nephrolithiasis,syncope neutropenia thrombocytopenia,0,0.5220131278038025
POTIGA,nephrolithiasis,nephrolithiasis syncope,1,0.8107671141624451
POTIGA,nephrolithiasis,nephrolithiasis syncope neutropenia thrombocytopenia,1,0.7772260308265686
POTIGA,nephrolithiasis,dyspnea leukopenia muscle spasms nephrolithiasis syncope neutropenia thrombocytopenia euphoric mood,1,0.6519724130630493
POTIGA,nephrolithiasis,thrombocytopenia euphoric mood renal colic,0,0.6457526683807373
POTIGA,syncope,syncope neutropenia thrombocytopenia euphoric mood renal,1,0.7354658842086792
POTIGA,syncope,syncope neutropenia thrombocytopenia euphoric mood,1,0.730736494064331
POTIGA,neutropenia,neutropenia thrombocytopenia,1,0.8478608727455139
POTIGA,neutropenia,neutropenia thrombocytopenia euphoric mood renal,1,0.7642638683319092
POTIGA,neutropenia,neutropenia thrombocytopenia euphoric mood renal colic,1,0.7740758657455444
POTIGA,neutropenia,neutropenia thrombocytopenia euphoric,1,0.783527672290802
POTIGA,neutropenia,neutropenia thrombocytopenia euphoric mood,1,0.7701494693756104
POTIGA,neutropenia,neutropenia,1,1.0000001192092896
POTIGA,neutropenia,rash nystagmus dyspnea leukopenia muscle spasms alopecia,0,0.591498076915741
POTIGA,thrombocytopenia,dyspnea leukopenia muscle spasms,0,0.5786004066467285
POTIGA,thrombocytopenia,thrombocytopenia euphoric mood renal colic coma,1,0.7959842681884766
POTIGA,thrombocytopenia,thrombocytopenia euphoric mood renal,1,0.7994968295097351
POTIGA,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
POTIGA,thrombocytopenia,syncope neutropenia,0,0.6521538496017456
POTIGA,thrombocytopenia,thrombocytopenia euphoric mood renal colic,1,0.7974389791488647
POTIGA,euphoric mood,spasms alopecia nephrolithiasis syncope,0,0.562771737575531
POTIGA,euphoric mood,syncope neutropenia euphoric mood renal colic,1,0.7323369383811951
POTIGA,euphoric mood,neutropenia thrombocytopenia,0,0.4784092903137207
POTIGA,euphoric mood,leukopenia muscle spasms alopecia nephrolithiasis syncope,0,0.5503814220428467
POTIGA,euphoric mood,euphoric mood renal colic coma encephalopathy,1,0.805681586265564
POTIGA,euphoric mood,The,0,0.5256234407424927
POTIGA,renal colic,syncope neutropenia thrombocytopenia euphoric renal,1,0.6569600105285645
POTIGA,renal colic,a muscle spasms alopecia nephrolithiasis syncope neutropenia thrombocytopenia euphoric mood,0,0.6350228786468506
POTIGA,renal colic,thrombocytopenia euphoric renal,1,0.6671848297119141
POTIGA,renal colic,overall adverse reaction,0,0.5700488686561584
POTIGA,renal colic,renal colic coma encephalopathy Comparison of,1,0.7943390607833862
POTIGA,renal colic,euphoric renal colic,1,0.91907799243927
POTIGA,renal colic,mood,0,0.5004957914352417
POTIGA,renal colic,neutropenia thrombocytopenia euphoric renal colic coma encephalopathy Comparison,1,0.6775301098823547
POTIGA,encephalopathy,encephalopathy Comparison,1,0.8952435255050659
POTIGA,encephalopathy,encephalopathy Comparison of Gender Age and,1,0.8397746086120605
POTIGA,encephalopathy,Comparison of,0,0.5022982358932495
POTIGA,encephalopathy,colic encephalopathy,1,0.8016195297241211
POTIGA,encephalopathy,encephalopathy Comparison of Gender Age,1,0.8265337347984314
POTIGA,encephalopathy,thrombocytopenia euphoric mood,0,0.5247335433959961
POTIGA,encephalopathy,and Race The overall,0,0.4651385545730591
POTIGA,encephalopathy,euphoric mood renal colic encephalopathy,1,0.7020764350891113
POTIGA,encephalopathy,overall adverse reaction profile of POTIGA was,0,0.5807603597640991
POTIGA,RETINAL ABNORMALITIES,REACTIONS,0,0.47307276725769043
POTIGA,RETINAL ABNORMALITIES,REACTIONS The,0,0.43130946159362793
POTIGA,RETINAL ABNORMALITIES,are described in more detail in the Warnings and Precautions section,0,0.45994508266448975
POTIGA,RETINAL ABNORMALITIES,The,0,0.46714723110198975
POTIGA,RETINAL ABNORMALITIES, following adverse re actions are described,1,0.5287172794342041
POTIGA,RETINAL ABNORMALITIES,ADVERSE REACTIONS  following adverse re actions are described in more,1,0.5415214896202087
POTIGA,RETINAL ABNORMALITIES,described in more detail,0,0.4798349142074585
POTIGA,RETINAL ABNORMALITIES,REACTIONS following adverse re,1,0.5590638518333435
POTIGA,VISION LOSS,reactions are cribed in m,1,0.48276352882385254
POTIGA,RETINAL ABNORMALITIES,the Warnings and,1,0.49006131291389465
POTIGA,RETINAL ABNORMALITIES, the  Warnings and Pr ecautions section of the,1,0.47938841581344604
POTIGA,RETINAL ABNORMALITIES,and Pr ecautions section,1,0.4774438142776489
POTIGA,RETINAL ABNORMALITIES,more detail,0,0.4649379253387451
POTIGA,RETINAL ABNORMALITIES,ecautions section of the label Retinal abnormalities,0,0.8644969463348389
POTIGA,RETINAL ABNORMALITIES,are described in more detail,0,0.4866044521331787
POTIGA,RETINAL ABNORMALITIES, the  Warnings and Pr ecautions,1,0.4945216774940491
POTIGA,RETINAL ABNORMALITIES,Warnings and Pr ecautions,1,0.4935130178928375
POTIGA,RETINAL ABNORMALITIES,the Warnings and Pr ecautions section of,1,0.49057987332344055
POTIGA,VISION LOSS,Warnings and Precautions ion,1,0.5590033531188965
POTIGA,retinal abnormalities,loss see Warnings and Precautions Urinary retention see,0,0.4914003610610962
POTIGA,retinal abnormalities,label Retinal,0,0.7581111788749695
POTIGA,retinal abnormalities,abnormalities and po tential vision loss,1,0.8443406820297241
POTIGA,retinal abnormalities,abnormalities and po,1,0.695454478263855
POTIGA,retinal abnormalities,abnormalities and po tential,1,0.7263089418411255
POTIGA,retinal abnormalities,section of the label  abnormalities and po tential vision,1,0.773409366607666
POTIGA,retinal abnormalities,and po tential,1,0.48403874039649963
POTIGA,retinal abnormalities,of,0,0.4628438949584961
POTIGA,retinal abnormalities,section of the label  abnormalities and po,1,0.650269091129303
POTIGA,retinal abnormalities,Retinal,0,0.8397958874702454
POTIGA,damage to the photoreceptors,* Skin disco loration see,1,0.5917267799377441
POTIGA,vision loss,Warnings and,0,0.5948982834815979
POTIGA,vision loss,Warnings and Precautions Skin ion [see,1,0.5430814027786255
POTIGA,vision loss,Skin ion,1,0.4972890019416809
POTIGA,vision loss,ion [see Wa rnings and Precautions,1,0.5090060234069824
POTIGA,retinal abnormalities,see Warnings an,0,0.5223541259765625
POTIGA,retinal abnormalities,* Neuropsychia,1,0.49949154257774353
POTIGA,abnormal visual acuity,Neuropsychiatric symptoms see Warnin,0,0.5745754241943359
POTIGA,abnormal visual acuity,and Precautions (5. Dizziness and somnolence see,1,0.5346217155456543
POTIGA,abnormal visual acuity,symptoms see gs and Precautions (5.,1,0.5658737421035767
POTIGA,abnormal visual acuity,Dizziness and somnolence see Warnings,0,0.5615921020507812
POTIGA,abnormal visual acuity,see Warnings and Precautions QT interval effect,0,0.5560436844825745
POTIGA,abnormal visual acuity,gs and Precautions (5. Dizziness and somnolence see,1,0.5305564999580383
POTIGA,abnormal visual acuity,QT interval effect,0,0.5170190930366516
POTIGA,decreased visual acuity,somnolence see,0,0.5082793831825256
POTIGA,retinal pigmentary abnormalities,adverse react,1,0.5063217282295227
POTIGA,retinal pigmentary abnormalities,adverse react ions incidence,1,0.5279953479766846
POTIGA,retinal pigmentary abnormalities,see Warnings and Precautions RPT:   Most common adverse react ions incidence,1,0.5132738947868347
POTIGA,retinal pigmentary abnormalities,RPT:   Most common adverse react ions incidence,1,0.5366204977035522
POTIGA,retinal abnormalities,"ce, fatigue, confusio",1,0.5135454535484314
POTIGA,retinal abnormalities,"ce, fatigue, confusio nal",1,0.5136010050773621
POTIGA,retinal abnormalities,abnormal,0,0.6605586409568787
POTIGA,retinal abnormalities,"placebo were dizziness ce, fatigue, confusio nal state",1,0.502261221408844
POTIGA,retinal abnormalities,coordination diplopia disturbance in attention,0,0.5796695947647095
POTIGA,retinal abnormalities,incidence and twice,0,0.5621739625930786
POTIGA,retinal abnormalities,"were dizziness ce, fatigue, confusio",1,0.5547125339508057
POTIGA,retinal abnormalities,tremor abnormal coordination diplopia disturbance in attention memory,0,0.5613821744918823
POTIGA,retinal abnormalities,"were dizziness ce, fatigue, confusio nal state vertigo tremor",1,0.5441741943359375
POTIGA,retinal abnormalities,"in  memory impairment, a sthenia blurred vision gait disturbance",1,0.6049774885177612
POTIGA,retinal abnormalities,igue confusional state vertigo tremor abnormal coordination diplopia disturbance in,0,0.5656311511993408
POTIGA,retinal abnormalities,disturbance,0,0.5555158853530884
POTIGA,retinal abnormalities,tremor abnormal coordination diplopia disturbance in attention,0,0.5751872062683105
POTIGA,retinal abnormalities,"disturbance in  memory impairment, a sthenia blurred vision",1,0.6221758127212524
POTIGA,retinal abnormalities,"memory impairment, a sthenia",1,0.525547444820404
POTIGA,RETINAL ABNORMALITIES,"Discontinuation in All Controlled  Studies  



 In the randomized",1,0.4932408630847931
POTIGA,RETINAL ABNORMALITIES,"memory impairment, a sthenia",1,0.525547444820404
POTIGA,RETINAL ABNORMALITIES,in All Controlled,0,0.4389389753341675
POTIGA,RETINAL ABNORMALITIES,for at least years Adverse Reactions Leading to Discontinuation,0,0.5252129435539246
POTIGA,RETINAL ABNORMALITIES,doubleblind placebocontrolled studies of patients receiving,0,0.6022067070007324
POTIGA,RETINAL ABNORMALITIES,Studies In the,1,0.5007115602493286
POTIGA,RETINAL ABNORMALITIES,Studies In the randomized doubleblind placebocontrolled,1,0.5914103984832764
POTIGA,VISION LOSS,All Controlled Clinical Studies In,0,0.4820817708969116
POTIGA,VISION LOSS,and,0,0.5296841859817505
POTIGA,VISION LOSS,double-blin d placebocontrolled studies of,1,0.4930729269981384
POTIGA,VISION LOSS,double-blin d,1,0.5048002004623413
POTIGA,VISION LOSS,In the double-blin d placebocontrolled studies of,1,0.49254220724105835
POTIGA,VISION LOSS,Clinical Studies In the double-blin d placebocontrolled studies of patients,1,0.49952661991119385
POTIGA,retinal abnormalities,and,0,0.4430163502693176
POTIGA,retinal abnormalities,receiving POTIGA and of ts (11%) receiving,1,0.4674365520477295
POTIGA,retinal abnormalities,ts (11%) receiving pl acebo,1,0.48380622267723083
POTIGA,retinal abnormalities,(11%) receiving pl acebo,1,0.4899466931819916
POTIGA,retinal abnormalities,reactions The most common adverse,0,0.5092204213142395
POTIGA,retinal abnormalities,reactions The most,0,0.41083359718322754
POTIGA,retinal abnormalities,(11%) receiving pl acebo discontinued,1,0.46762073040008545
POTIGA,retinal abnormalities,acebo discontinued treatment because of adverse reactions,0,0.4933186173439026
POTIGA,retinal abnormalities,and of,0,0.44528788328170776
POTIGA,damage to the photoreceptors,reactions The most common,0,0.5109356641769409
POTIGA,damage to the photoreceptors,reactions leading to awal in patients receiving P OTIGA were,1,0.5478842258453369
POTIGA,damage to the photoreceptors,adverse reactions leading to awal,1,0.5599855184555054
POTIGA,damage to the photoreceptors,withdr,0,0.5650373101234436
POTIGA,damage to the photoreceptors,state fatigue and,0,0.5210245251655579
POTIGA,damage to the photoreceptors,leading to awal in patients receiving P OTIGA were,1,0.5672773122787476
POTIGA,damage to the photoreceptors,awal in patients receiving P,1,0.5474365949630737
POTIGA,damage to the photoreceptors,OTIGA were dizziness confusional state fatigue and somnolence,0,0.5848568677902222
POTIGA,damage to the photoreceptors,awal in patients receiving P OTIGA,1,0.5560712218284607
POTIGA,damage to the photoreceptors,fatigue,0,0.5372364521026611
POTIGA,vision loss,Common Adverse,0,0.5438033938407898
POTIGA,vision loss,withdrawal in patients receiving were dizzi,1,0.48460277915000916
POTIGA,vision loss,in patients receiving were,1,0.5662564039230347
POTIGA,vision loss,receiving were dizzi,1,0.4968070685863495
POTIGA,vision loss,POTIGA,0,0.4685615301132202
POTIGA,vision loss,in patients receiving  were dizzi ness,1,0.5107195377349854
POTIGA,vision loss,receiving  were dizzi ness confusional state fatigue,1,0.5331171751022339
POTIGA,vision loss,leading,0,0.5249565839767456
POTIGA,Urinary retention,ions are describe d,1,0.5158095359802246
POTIGA,Urinary retention,leading,0,0.48873454332351685
POTIGA,skin discoloration,the label Retinal ities and potentia l vision loss see,1,0.5474519729614258
POTIGA,skin discoloration,leading,0,0.46481865644454956
POTIGA,skin discoloration,Warnings,0,0.5625072717666626
POTIGA,skin discoloration,Urinary retention see,0,0.5392965078353882
POTIGA,skin discoloration,label Retinal ities and potentia,1,0.5084118843078613
POTIGA,skin discoloration,ities and potentia l vision loss see Warnings,1,0.5838611125946045
POTIGA,skin discoloration,Warnings and Precautions section of,0,0.5443031787872314
POTIGA,skin discoloration,in the Warnings and Precautions section of,0,0.5303217172622681
POTIGA,Neuropsychiatric symptoms,s and Precautions Neuropsychiatric,0,0.8043539524078369
POTIGA,Neuropsychiatric symptoms,symptoms see Warnings,0,0.6873531341552734
POTIGA,Neuropsychiatric symptoms,retention see,0,0.5076805353164673
POTIGA,Neuropsychiatric symptoms,iscoloration [see Warning s and Precautions,1,0.5030890107154846
POTIGA,Neuropsychiatric symptoms,iscoloration [see Warning,1,0.4835672378540039
POTIGA,Neuropsychiatric symptoms,retention see Warnings,0,0.5681793689727783
POTIGA,Neuropsychiatric symptoms,symptoms see Warnings and,0,0.6879528760910034
POTIGA,Neuropsychiatric symptoms,iscoloration [see Warning s and Precautions Neuropsychiatric,1,0.7564147710800171
POTIGA,Neuropsychiatric symptoms,Skin iscoloration [see,1,0.46570512652397156
POTIGA,QT prolongation,an,0,0.5110714435577393
POTIGA,QT prolongation,Precautions ( QT interval effect see Warnings,1,0.7630182504653931
POTIGA,abnormalities of the retina,"were zziness, somnolence, fatigu e confusional state",1,0.5135601758956909
POTIGA,abnormalities of the retina,Precautions ( QT interval effect see Warnings,1,0.4926471412181854
POTIGA,abnormalities of the retina,were,0,0.4669891595840454
POTIGA,abnormalities of the retina,and twice placebo were di,0,0.49626368284225464
POTIGA,abnormalities of the retina,vertigo tremor abnormal coordination,0,0.5598377585411072
POTIGA,abnormalities of the retina,"twice placebo were zziness, somnolence, fatigu e confusional",1,0.4968233108520508
POTIGA,abnormalities of the retina,"somnolence, fatigu e",1,0.4816517233848572
POTIGA,abnormalities of the retina,"placebo were zziness, somnolence, fatigu e confusional state vertigo",1,0.5120011568069458
POTIGA,abnormalities of the retina,"zziness, somnolence, fatigu e confusional state",1,0.5136579275131226
POTIGA,damage to photoreceptors,"vision gait disturbance asia, dysarthria,",1,0.6325432062149048
POTIGA,damage to photoreceptors,To report,0,0.48956820368766785
POTIGA,damage to photoreceptors,"gait disturbance asia, dysarthria,",1,0.5524463653564453
POTIGA,damage to photoreceptors,"asia, dysarthria,",1,0.4954015016555786
POTIGA,vision loss,dysarthria and  disorder.  To,1,0.5187532305717468
POTIGA,vision loss,"asia, dysarthria,",1,0.495074063539505
POTIGA,vision loss,memory impairment asthenia blurred vision gait disturbance aphasia,0,0.650800883769989
POTIGA,vision loss, disorder.  To report SUSPECTED ADVERSE,1,0.5244312882423401
POTIGA,vision loss, disorder.  To report,1,0.5153837203979492
POTIGA,vision loss, disorder.  To,1,0.5408319234848022
POTIGA,vision loss,balance,0,0.5446997880935669
POTIGA,vision loss,dysarthria and  disorder. ,1,0.5068166255950928
POTIGA,vision loss, disorder.  To report SUSPECTED,1,0.49778860807418823
POTIGA,retinal abnormalities,"and balance  

   To report SUSPE CTED ADVERSE",1,0.48929041624069214
POTIGA,retinal abnormalities, disorder.  To report SUSPECTED,1,0.5589851140975952
POTIGA,retinal abnormalities,dysarthria and balance To report,1,0.5375191569328308
POTIGA,retinal abnormalities,balance disorder,0,0.5468533039093018
POTIGA,retinal abnormalities,To report SUSPE CTED ADVERSE REACTIONS,1,0.49292945861816406
POTIGA,retinal abnormalities,REACTIONS contact GlaxoSmithKline at,0,0.4354926347732544
POTIGA,retinal abnormalities,GlaxoSmithKline at or,0,0.474420428276062
POTIGA,retinal abnormalities,To,1,0.4612155258655548
POTIGA,retinal pigmentary abnormalities,of a drug cannot,0,0.4390334486961365
POTIGA,retinal abnormalities,POTIGA was nistered as adjunctiv e therapy to patients,1,0.5122414231300354
POTIGA,retinal abnormalities,of a drug cannot,0,0.4374466836452484
POTIGA,retinal abnormalities,practice POTIGA was nistered,1,0.48153218626976013
POTIGA,retinal abnormalities,drug and may not reflect the rates observed in,0,0.5120810270309448
POTIGA,retinal abnormalities,and may not reflect the rates observed in practice,0,0.4742565155029297
POTIGA,retinal abnormalities,in practice POTIGA was nistered as adjunctiv,1,0.44268831610679626
POTIGA,retinal abnormalities,practice POTIGA was nistered as,1,0.47446271777153015
POTIGA,retinal abnormalities,practice POTIGA was nistered as adjunctiv,1,0.45143288373947144
POTIGA,retinal abnormalities,nistered,1,0.4412950277328491
POTIGA,mucous membrane discoloration,clinical studies ng the premarketing developme,1,0.5204020738601685
POTIGA,mucous membrane discoloration,nistered,1,0.49623972177505493
POTIGA,mucous membrane discoloration,nt A,0,0.5131833553314209
POTIGA,discoloration,longer,0,0.5064867734909058
POTIGA,discoloration,treated for year,0,0.5740935802459717
POTIGA,discoloration,least months patients were treated for year or longer and patients,0,0.508104145526886
POTIGA,discoloration,of patients were reated for at least months patients were,1,0.5443710684776306
POTIGA,discoloration,patients were reated for at,1,0.5384079813957214
POTIGA,discoloration,during the premarketing development A total of patients,0,0.544259250164032
POTIGA,discoloration,t,0,0.537602424621582
POTIGA,retinal abnormalities,"at least , 585 patients were",1,0.4764346480369568
POTIGA,retinal abnormalities,months,0,0.49350348114967346
POTIGA,retinal pigmentary abnormalities,Reactions Lea ding,1,0.4352739453315735
POTIGA,retinal pigmentary abnormalities,at least ars. Adverse,1,0.49907076358795166
POTIGA,retinal pigmentary abnormalities,Adverse Reactions Lea ding,1,0.5145846009254456
POTIGA,retinal pigmentary abnormalities,ars. Adverse Reactions Lea,1,0.50469970703125
POTIGA,retinal pigmentary abnormalities,"least ars.



   Adverse Reactions Lea",1,0.4872809648513794
POTIGA,retinal pigmentary abnormalities,Studies In the randomized doubleblind,0,0.5985756516456604
POTIGA,retinal pigmentary abnormalities,for at least ars. Adverse Reactions,1,0.5033696889877319
POTIGA,retinal pigmentary abnormalities,ars.,1,0.47937506437301636
POTIGA,retinal pigmentary abnormalities,patients were treated for at least,0,0.5039455890655518
POTIGA,discoloration,were treated for at,0,0.6006271839141846
POTIGA,discoloration,ntinuation in All Controlled,1,0.5415199398994446
POTIGA,discoloration,to ntinuation in All Controlled,1,0.5411897897720337
POTIGA,discoloration,Reactions Leading to ntinuation,1,0.5505085587501526
POTIGA,discoloration,to ntinuation in,1,0.5647644400596619
POTIGA,discoloration,ntinuation in All Controlled Clinical Studies In,1,0.5391979813575745
POTIGA,discoloration,ntinuation in All,1,0.5461532473564148
POTIGA,discoloration,Reactions Leading to ntinuation in,1,0.5615559816360474
POTIGA,discoloration,were treated for at least years Adverse,0,0.6129245162010193
POTIGA,Funduscopic abnormalities,ontrolled Clinical Studie s,1,0.563531756401062
POTIGA,Funduscopic abnormalities,were treated for at least years Adverse,0,0.547735333442688
POTIGA,Funduscopic abnormalities,in All,0,0.44177526235580444
POTIGA,Funduscopic abnormalities,Clinical Studie,1,0.5668188333511353
POTIGA,Funduscopic abnormalities,ontrolled Clinical Studie s In,1,0.5611742734909058
POTIGA,focal retinal pigment epithelium clumping,of ients (11%) receiving,1,0.5020791292190552
POTIGA,focal retinal pigment epithelium clumping,ients (11%) receiving placebo discontinue,1,0.5056966543197632
POTIGA,retinal abnormalities,of adverse ons. The most,1,0.5588653087615967
POTIGA,retinal abnormalities,because of adverse reacti,0,0.5254521369934082
POTIGA,retinal abnormalities,leading to,0,0.4884897470474243
POTIGA,retinal abnormalities,of adverse ons. The most common  adverse reactions leading to,1,0.5371178984642029
POTIGA,retinal abnormalities,of adverse ons. The most common,1,0.5734818577766418
POTIGA,retinal abnormalities,receiving,0,0.4580296576023102
POTIGA,retinal abnormalities,treatment because of adverse ons. The most common  adverse reactions leading to withdrawal,1,0.5203801393508911
POTIGA,retinal abnormalities,adverse ons. The most,1,0.5645937919616699
POTIGA,abnormal visual acuity,receiving POTIGA were,0,0.45460808277130127
POTIGA,abnormal visual acuity,in pati ents receiving POTIGA were,1,0.4707489013671875
POTIGA,retinal abnormalities,"Overall, th e",1,0.44450557231903076
POTIGA,retinal abnormalities,"Clinical ies  



 Overall, th e most",1,0.510712206363678
POTIGA,retinal abnormalities,"in All Controlled Clinical ies Overall, th",1,0.5125023722648621
POTIGA,retinal dystrophy,occurring approximately  the placebo rate were dizziness,1,0.4648531675338745
POTIGA,retinal dystrophy,"in All Controlled Clinical ies Overall, th",1,0.4834456145763397
POTIGA,retinal dystrophy,POTIGA and,0,0.4429018795490265
POTIGA,retinal dystrophy,the placebo rate,1,0.42406558990478516
POTIGA,abnormalities in the electroretinogram,"somnolence (22%), fatigue confusional state vertigo tremor abnormal",1,0.5624250769615173
POTIGA,abnormalities in the electroretinogram,confusional state vertigo,0,0.5229581594467163
POTIGA,abnormalities in the electroretinogram,"placebo rate were ness (23%), somnolence (22%), fatigue  confusional state vertigo tremor abnormal",1,0.5160083174705505
POTIGA,abnormalities in the electroretinogram,"were ness (23%), somnolence (22%), fatigue  confusional state vertigo tremor abnormal",1,0.5669467449188232
POTIGA,abnormal fluorescein angiography,fatigue confusional state,0,0.5074601173400879
POTIGA,retinal abnormalities,asthenia ed,1,0.49502283334732056
POTIGA,retinal abnormalities,"ed vision (5%), gait disturbance aphasia dysarthria",1,0.6459362506866455
POTIGA,retinal abnormalities,disorder,0,0.5861616730690002
POTIGA,retinal abnormalities,see,0,0.5446200370788574
POTIGA,retinal abnormalities,"ed vision (5%), gait disturbance",1,0.6871861219406128
POTIGA,suicides,these studies  of pati,1,0.4830278158187866
POTIGA,suicides,"ed vision (5%), gait disturbance",1,0.44354233145713806
POTIGA,suicides,of pati ents treated,1,0.4838806688785553
POTIGA,suicides,reported in these studies  of pati ents treated with,1,0.49777474999427795
POTIGA,suicide,"dry uth, dy",1,0.512080729007721
POTIGA,suicide,"peripheral edema hypokinesia dry uth, dy",1,0.4415808916091919
POTIGA,suicide,"edema hypokinesia dry uth,",1,0.4514511823654175
POTIGA,suicide,liver enzymes Most of the adv,0,0.4389612376689911
POTIGA,suicidal thoughts,"ary retention, ma laise and",1,0.47795218229293823
POTIGA,suicidal thoughts,"ary retention, ma laise and increased",1,0.47823065519332886
POTIGA,suicidal thoughts,increased liver enzymes Most of the adverse,0,0.4810571074485779
POTIGA,suicidal thoughts,"mouth dysphagia hyperhydrosis ary retention,",1,0.4799157977104187
POTIGA,suicidal thoughts,hypokinesia dry mouth dysphagia hyperhydrosis,0,0.4616958498954773
POTIGA,suicidal thoughts,and increased liver enzymes Most of,0,0.45472902059555054
POTIGA,suicidal thoughts,"vision gait disturbance aphasia ance disorder,",1,0.4683186411857605
POTIGA,suicidal thoughts,was associated with doserelated weight gain with,0,0.45032548904418945
POTIGA,suicidal thoughts,"ance disorder, co",1,0.5240679979324341
POTIGA,suicidal thoughts,"vision gait disturbance aphasia ance disorder, co",1,0.461697518825531
POTIGA,suicidal thoughts,"ance disorder, co nstipation dysuria and chromaturia",1,0.5058759450912476
POTIGA,Suicidal Thoughts,by patients,0,0.505681037902832
POTIGA,Suicidal Thoughts,"rash, n ystagmus dyspnea leukopenia muscle",1,0.4892526865005493
POTIGA,Suicidal Thoughts,list of adverse reactions reported by patients treated with POTIGA during all clinica,0,0.4742121398448944
POTIGA,Suicidal Thoughts,Following is a list of adverse reactions reported by patients treated with POTIGA,0,0.48490479588508606
POTIGA,Suicidal Thoughts,"l trials: rash, n ystagmus",1,0.4663315415382385
POTIGA,Suicidal Thoughts,"trials: rash, n ystagmus dyspnea leukopenia",1,0.47600483894348145
BREO,death,death Currently available data are inadequate,1,0.6770581007003784
BREO,death,determine,0,0.5657300353050232
BREO,deaths,deaths in,1,0.9592404365539551
BREO,deaths,in deaths in subjects receiving salmeterol,1,0.698663592338562
BREO,deaths,in subjects,0,0.5444539785385132
BREO,deaths,Precautions,0,0.49517005681991577
BREO,deaths,in,0,0.5468313694000244
BREO,deaths,deaths in subjects receiving,1,0.7719959020614624
BREO,deaths,salmeterol See Warnings,0,0.4924628734588623
BREO,deaths,salmeterol or placebo added to usual,0,0.46689993143081665
BREO,deaths,in deaths in subjects receiving salmeterol See,1,0.7102851867675781
BREO,Candida albicans infection,pneumonia in COPD see Warnings and,0,0.49070024490356445
BREO,pneumonia,Warnings and,0,0.5696778297424316
BREO,pneumonia,pneumonia in COPD see,1,0.7650541067123413
BREO,pneumonia,Precautions Increased risk pneumonia in COPD,1,0.7214287519454956
BREO,pneumonia,pneumonia in COPD,1,0.7748327255249023
BREO,Immunosuppression,risk of pneumonia in COPD,0,0.5371441841125488
BREO,Immunosuppression,Immunosuppression see Warnings and Precautions Hypercorticism,1,0.7676386833190918
BREO,Immunosuppression,Warnings and Precautions,0,0.511005163192749
BREO,Immunosuppression,Immunosuppression,1,1.0
BREO,Immunosuppression,Hypercorticism and adrenal suppression,0,0.5566821098327637
BREO,Immunosuppression,Immunosuppression see,1,0.9370709657669067
BREO,Hypercorticism,Warnings and Precautions Reduction in bone,0,0.5064926147460938
BREO,adrenal suppression,ns Immunosuppression see Warnings and Precautions Hypercorticism and,0,0.6583049893379211
BREO,adrenal suppression,Precautions Hypercorticism adrenal,1,0.751683235168457
BREO,adrenal suppression,density see Warnings,0,0.5365538001060486
BREO,adrenal suppression,Warnings and Precautions Hypercorticism adrenal,1,0.736764132976532
BREO,adrenal suppression,Hypercorticism adrenal suppression,1,0.898419976234436
BREO,adrenal suppression,adrenal suppression see Warnings and,1,0.8966131210327148
BREO,adrenal suppression,Warnings and Precautions Hypercorticism adrenal suppression see Warnings and Precautions,1,0.7964539527893066
BREO,adrenal suppression,Hypercorticism adrenal,1,0.7718791961669922
BREO,adrenal suppression,see Warnings and Precautions,0,0.48687589168548584
BREO,Reduction in bone mineral density,bone mineral density see Warnings and Precautions Because,1,0.802944540977478
BREO,nasopharyngitis,nasopharyngitis upper respiratory tract infection headache,1,0.8306653499603271
BREO,upper respiratory tract infection,Most common,0,0.5089535713195801
BREO,headache,headache and,1,0.9235892295837402
BREO,headache,Most common,0,0.5427559018135071
BREO,headache,headache and oral candidiasis,1,0.758953332901001
BREO,headache,headache and oral candidiasis Asthma,1,0.7049292922019958
BREO,headache,headache and oral,1,0.8304895758628845
BREO,oral candidiasis,oral candidiasis Asthma,1,0.8119709491729736
BREO,oral candidiasis,oral candidiasis Asthma Most common,1,0.7870802879333496
BREO,oral candidiasis,upper respiratory tract infection headache,0,0.5064940452575684
BREO,nasopharyngitis,candidiasis headache influenza upper respiratory tract infection bronchitis sinusitis,0,0.6750098466873169
BREO,nasopharyngitis,adverse reactions incidence greater than or,0,0.5581191182136536
BREO,oral candidiasis,respiratory tract infection bronchitis sinusitis,0,0.5471459627151489
BREO,oral candidiasis,incidence greater than or equal,0,0.5036734342575073
BREO,oral candidiasis,nasopharyngitis,0,0.6354625821113586
BREO,oral candidiasis,influenza upper respiratory tract infection bronchitis,0,0.5260449647903442
BREO,oral candidiasis,sinusitis,0,0.6237460374832153
BREO,oral candidiasis,to are oral candidiasis,1,0.957316517829895
BREO,oral candidiasis,oral candidiasis headache,1,0.8393006324768066
BREO,oral candidiasis,reactions incidence,0,0.5162258744239807
BREO,headache,headache influenza,1,0.8169655203819275
BREO,headache,headache,1,0.9999998807907104
BREO,headache,headache influenza upper respiratory tract infection,1,0.7833501100540161
BREO,headache,headache influenza upper,1,0.786151111125946
BREO,influenza,respiratory tract infection bronchitis sinusitis oropharyngeal pain dysphonia and,0,0.6060270071029663
BREO,influenza,influenza upper respiratory tract infection bronchitis,1,0.738025426864624
BREO,influenza,nasopharyngitis oral candidiasis influenza upper,1,0.726763129234314
BREO,influenza,candidiasis influenza upper respiratory tract,1,0.7527419328689575
BREO,influenza,influenza upper respiratory tract,1,0.8020310401916504
BREO,influenza,oral candidiasis influenza upper respiratory tract,1,0.7478803396224976
BREO,upper respiratory tract infection,candidiasis headache upper respiratory tract infection bronchitis sinusitis oropharyngeal pain,1,0.7362496852874756
BREO,upper respiratory tract infection,influenza upper respiratory tract,1,0.8671712875366211
BREO,upper respiratory tract infection,candidiasis headache upper respiratory,1,0.7467728853225708
BREO,upper respiratory tract infection,nasopharyngitis oral candidiasis headache upper respiratory tract infection bronchitis sinusitis oropharyngeal,1,0.7496433258056641
BREO,upper respiratory tract infection,pain dysphonia and cough,0,0.619496762752533
BREO,upper respiratory tract infection,or,0,0.5173909068107605
BREO,upper respiratory tract infection,candidiasis headache upper,1,0.6754359006881714
BREO,bronchitis,To report SUSPECTED ADVERSE,0,0.5496004819869995
BREO,bronchitis,bronchitis sinusitis oropharyngeal pain dysphonia and,1,0.7394986152648926
BREO,bronchitis,bronchitis sinusitis oropharyngeal pain,1,0.7486716508865356
BREO,bronchitis,influenza upper respiratory tract,0,0.596386194229126
BREO,sinusitis,sinusitis oropharyngeal pain dysphonia and cough,1,0.8000115752220154
BREO,sinusitis,sinusitis oropharyngeal,1,0.841666579246521
BREO,sinusitis,sinusitis,1,0.9999998807907104
BREO,sinusitis,infection sinusitis,1,0.9350323677062988
BREO,sinusitis,infection sinusitis oropharyngeal pain dysphonia and cough,1,0.7878021001815796
BREO,oropharyngeal pain,oropharyngeal pain dysphonia and,1,0.8798279762268066
BREO,oropharyngeal pain,and cough To report SUSPECTED,0,0.5382221937179565
BREO,cough,sinusitis,0,0.6429142355918884
BREO,cough,infection bronchitis sinusitis,0,0.6650084257125854
BREO,cough,cough To report,1,0.826801061630249
BREO,cough,cough,1,1.0
BREO,cough,cough To report SUSPECTED ADVERSE,1,0.8133768439292908
BREO,cough,pain dysphonia cough,1,0.7928209900856018
BREO,cough,cough To report SUSPECTED,1,0.8173993825912476
BREO,cough,cough To report SUSPECTED ADVERSE REACTIONS,1,0.7878124713897705
BREO,cough,respiratory tract infection bronchitis sinusitis oropharyngeal,0,0.6670509576797485
BREO,oral candidiasis,a oral candidiasis,1,0.9734025597572327
BREO,oropharyngeal candidiasis,oropharyngeal,1,0.8143954277038574
BREO,oropharyngeal candidiasis,oral oropharyngeal candidiasis candidiasis and fungal oropharyngitis,1,0.9480670094490051
BREO,fungal oropharyngitis,candidiasis oropharyngeal candidiasis candidiasis fungal,1,0.900295615196228
BREO,fungal oropharyngitis,safety data is based,0,0.4164086580276489
BREO,fungal oropharyngitis,candidiasis fungal oropharyngitis,1,0.9567505121231079
BREO,fungal oropharyngitis,candidiasis oropharyngeal candidiasis candidiasis fungal oropharyngitis,1,0.916593611240387
BREO,fungal oropharyngitis,Includes oral candidiasis oropharyngeal,0,0.8717953562736511
BREO,back pain,back pain pneumonia see Warnings,1,0.7538106441497803
BREO,back pain,treated with BREO ELLIPTA n for months,0,0.515019416809082
BREO,back pain,cough oropharyngeal pai,0,0.4719063639640808
BREO,pneumonia,cough oropharyngeal pain,0,0.6251450777053833
BREO,pneumonia,sinusitis cough oropharyngeal,0,0.6202040910720825
BREO,bronchitis,oropharyngeal pain arthralgia,0,0.5518927574157715
BREO,bronchitis,bronchitis sinusitis cough oropharyngeal,1,0.78096604347229
BREO,bronchitis,see Warnings and bronchitis,1,0.8269587755203247
BREO,bronchitis,Warnings and bronchitis sinusitis,1,0.7436310052871704
BREO,bronchitis,see,0,0.5233020782470703
BREO,bronchitis,bronchitis sinusitis cough oropharyngeal pain arthralgia,1,0.7844622135162354
BREO,bronchitis,see Warnings and bronchitis sinusitis cough oropharyngeal,1,0.7542742490768433
BREO,bronchitis,Warnings and,0,0.5239542722702026
BREO,sinusitis,see Warnings,0,0.5220170021057129
BREO,sinusitis,pain arthralgia influenza pharyngitis and pyrexia,0,0.6118136644363403
BREO,cough,bronchitis cough oropharyngeal pain arthralgia influenza,1,0.7657231092453003
BREO,cough,pain arthralgia influenza pharyngitis and pyrexia,0,0.6640140414237976
BREO,cough,cough oropharyngeal,1,0.8377176523208618
BREO,cough,arthralgia influenza pharyngitis,0,0.6542370915412903
BREO,cough,cough oropharyngeal pain arthralgia,1,0.7856177091598511
BREO,cough,and Precautions bronchitis cough oropharyngeal pain arthralgia,1,0.7618499994277954
BREO,cough,oropharyngeal,0,0.5528545379638672
BREO,cough,pain pneumonia,0,0.7089605331420898
BREO,cough,bronchitis cough oropharyngeal,1,0.7925703525543213
BREO,oropharyngeal pain,bronchitis sinusitis,0,0.5366449356079102
BREO,oropharyngeal pain,and pyrexia Clinical Trials,0,0.5374976396560669
BREO,oropharyngeal pain,oropharyngeal pain,1,1.0
BREO,arthralgia,cough oropharyngeal arthralgia influenza,1,0.6908180713653564
BREO,arthralgia,oropharyngeal pain,1,0.6021764278411865
BREO,arthralgia,Trials Experience in,0,0.533990740776062
BREO,arthralgia,arthralgia influenza pharyngitis and pyrexia Clinical,1,0.7215595841407776
BREO,arthralgia,cough oropharyngeal pain,0,0.6000490188598633
BREO,arthralgia,cough oropharyngeal arthralgia influenza pharyngitis and,1,0.669653058052063
BREO,pharyngitis,pharyngitis and pyrexia Clinical,1,0.838128924369812
BREO,pyrexia,BREO ELLIPTA for the treatment of asthma,0,0.5405510067939758
BREO,pyrexia,pyrexia Clinical Trials Experience,1,0.8637065887451172
BREO,pyrexia,and,0,0.48467883467674255
BREO,oral candidiasis,Includes,0,0.5211175084114075
BREO,oral candidiasis,a,0,0.5007106065750122
BREO,oral candidiasis,a oral,1,0.7272247672080994
BREO,oral candidiasis,oral candidiasis and oropharyngeal candidiasis Trial was,1,0.8621602058410645
BREO,oral candidiasis,oral candidiasis and oropharyngeal,1,0.9003132581710815
BREO,oropharyngeal candidiasis,candidiasis oropharyngeal candidiasis Trial was a week trial,1,0.8818475604057312
BREO,oropharyngeal candidiasis,oral candidiasis and oropharyngeal candidiasis Trial was,1,0.8792374134063721
BREO,arthralgia,pharyngitis pyrexia arthralgia Month Trial Longterm safety,1,0.6888687610626221
BREO,arthralgia,oral candidiasis and oropharyngeal candidiasis Trial was,1,0.5180082321166992
BREO,pyrexia,pyrexia back,1,0.9239228963851929
BREO,pyrexia,pyrexia back pain extrasystoles,1,0.8074727654457092
BREO,back pain,pain respiratory tract infection allergic rhinitis,0,0.5990502834320068
BREO,back pain,tract infection allergic,0,0.4708520770072937
BREO,extrasystoles,rhinitis pharyngitis rhinitis,0,0.41912469267845154
BREO,extrasystoles,extrasystoles upper,1,0.9132291078567505
BREO,extrasystoles,upper abdominal pain respiratory tract infection allergic,0,0.5066646337509155
BREO,extrasystoles,rhinitis,0,0.4486352205276489
BREO,extrasystoles,pharyngitis rhinitis,0,0.432697057723999
BREO,extrasystoles,extrasystoles upper abdominal,1,0.8082343339920044
BREO,extrasystoles,extrasystoles upper abdominal pain respiratory tract,1,0.723563551902771
BREO,extrasystoles,back extrasystoles upper abdominal,1,0.7833552360534668
BREO,upper abdominal pain,upper abdominal pain respiratory tract infection,1,0.8650236129760742
BREO,upper abdominal pain,upper abdominal pain respiratory tract,1,0.8765548467636108
BREO,upper abdominal pain,pyrexia back pain upper,1,0.7058217525482178
BREO,upper abdominal pain,pyrexia back,0,0.5578713417053223
BREO,upper abdominal pain,upper abdominal pain respiratory,1,0.8969962000846863
BREO,upper abdominal pain,rhinitis,0,0.5164043307304382
BREO,upper abdominal pain,abdominal pain respiratory tract infection allergic rhinitis,1,0.7632689476013184
BREO,upper abdominal pain,pain upper,1,0.7751753330230713
BREO,upper abdominal pain,back pain upper abdominal pain,1,0.92337965965271
BREO,respiratory tract infection,upper abdominal,0,0.506424605846405
BREO,respiratory tract infection,allergic rhinitis pharyngitis,0,0.6690179109573364
BREO,respiratory tract infection,pain extrasystoles upper abdominal respiratory tract infection allergic rhinitis,1,0.6882232427597046
BREO,respiratory tract infection,ELLIPTA,0,0.45475584268569946
BREO,respiratory tract infection,allergic,0,0.5954270362854004
BREO,respiratory tract infection,abdominal pain,0,0.5150455832481384
BREO,respiratory tract infection,abdominal respiratory,1,0.6726855039596558
BREO,respiratory tract infection,respiratory tract infection allergic rhinitis pharyngitis rhinitis arthralgia,1,0.8231553435325623
BREO,respiratory tract infection,abdominal respiratory tract infection allergic,1,0.759568989276886
BREO,respiratory tract infection,extrasystoles,0,0.4835723042488098
BREO,allergic rhinitis,tract allergic rhinitis pharyngitis rhinitis,1,0.8136153221130371
BREO,allergic rhinitis,extrasystoles,0,0.45223212242126465
BREO,allergic rhinitis,pain respiratory tract allergic,1,0.7615498900413513
BREO,allergic rhinitis,rhinitis arthralgia supraventricular extrasystoles,0,0.6725462079048157
BREO,allergic rhinitis,nths included pyrexia back pain extrasystoles upper abdominal pain respiratory tract,0,0.5651497840881348
BREO,allergic rhinitis,abdominal pain respiratory tract allergic rhinitis pharyngitis rhinitis,1,0.7164440751075745
BREO,allergic rhinitis,tract allergic rhinitis pharyngitis,1,0.7938588857650757
BREO,allergic rhinitis,arthralgia supraventricular extrasystoles ventricular extrasystoles,0,0.47021037340164185
BREO,allergic rhinitis,allergic rhinitis pharyngitis rhinitis arthralgia supraventricular extrasystoles,1,0.7652711272239685
BREO,pharyngitis,pharyngitis rhinitis arthralgia,1,0.8345010280609131
BREO,pharyngitis,pharyngitis rhinitis arthralgia supraventricular extrasystoles ventricular,1,0.7539108991622925
BREO,pharyngitis,pharyngitis rhinitis,1,0.8790721893310547
BREO,pharyngitis,pharyngitis rhinitis arthralgia supraventricular,1,0.7937139272689819
BREO,pharyngitis,upper abdominal pain respiratory tract,0,0.5862427949905396
BREO,pharyngitis,back pain,0,0.46715688705444336
BREO,pharyngitis,pharyngitis,1,1.0
BREO,pharyngitis,arthralgia supraventricular extrasystoles ventricular,0,0.514274001121521
BREO,rhinitis,respiratory tract infection allergic rhinitis pharyngitis,0,0.7972357273101807
BREO,rhinitis,infection allergic rhinitis rhinitis arthralgia supraventricular extrasystoles ventricular extrasystoles,1,0.7047857046127319
BREO,rhinitis,allergic rhinitis rhinitis arthralgia supraventricular extrasystoles ventricular extrasystoles,1,0.7220953702926636
BREO,rhinitis,rhinitis arthralgia supraventricular extrasystoles,1,0.7007570266723633
BREO,rhinitis,upper abdominal pain respiratory,0,0.578893780708313
BREO,rhinitis,rhinitis arthralgia supraventricular extrasystoles ventricular,1,0.7152743339538574
BREO,rhinitis,rhinitis,1,1.0
BREO,arthralgia,arthralgia supraventricular extrasystoles ventricular,1,0.6977418661117554
BREO,arthralgia,rhinitis pharyngitis,0,0.4801824390888214
BREO,arthralgia,arthralgia supraventricular extrasystoles ventricular extrasystoles acute,1,0.6764237880706787
BREO,arthralgia,arthralgia supraventricular extrasystoles ventricular extrasystoles,1,0.675838828086853
BREO,supraventricular extrasystoles,Exacerbation Trial In a,0,0.5288702249526978
BREO,supraventricular extrasystoles,Trial,0,0.5112372636795044
BREO,supraventricular extrasystoles,rhinitis pharyngitis rhinitis supraventricular extrasystoles,1,0.822881817817688
BREO,supraventricular extrasystoles,rhinitis supraventricular extrasystoles,1,0.878064751625061
BREO,supraventricular extrasystoles,supraventricular extrasystoles ventricular,1,0.9273194074630737
BREO,supraventricular extrasystoles,supraventricular extrasystoles,1,0.9999999403953552
BREO,supraventricular extrasystoles,pain respiratory tract,0,0.49153491854667664
BREO,supraventricular extrasystoles,extrasystoles acute sinusitis and pneumonia Exacerbation Trial In a,0,0.6989246606826782
BREO,ventricular extrasystoles,ventricular extrasystoles acute sinusitis and,1,0.8470131158828735
BREO,acute sinusitis,rhinitis,0,0.6999145746231079
BREO,acute sinusitis,pharyngitis rhinitis arthralgia,0,0.6316909790039062
BREO,acute sinusitis,Exacerbation Trial In a to week trial subjects received BREO EL,0,0.5407364964485168
BREO,acute sinusitis,arthralgia supraventricular,0,0.5570077896118164
BREO,acute sinusitis,In a to week trial subjects received BREO,0,0.4878048896789551
BREO,pneumonia,ventricular extrasystoles acute sinusitis pneumonia,1,0.6982721090316772
BREO,pneumonia,In a to week trial subjects received BREO,0,0.5166561603546143
BREO,deaths,deaths or asthmarelated intubations,1,0.6951531171798706
BREO,deaths,trial,0,0.48416414856910706
BREO,deaths,were no,0,0.5576568841934204
BREO,deaths,with subjects treated with fluticasone furoate mcg n There were no,0,0.48055899143218994
BREO,Palpitations,Palpitations tachycardia Immune System Disorders,1,0.7863025665283203
BREO,Palpitations,Palpitations tachycardia,1,0.8869621157646179
BREO,Palpitations,Hypersensitivity,0,0.5640871524810791
BREO,Palpitations,tachycardia Immune System Disorders Hypersensitivity reactions including anaphylaxis,0,0.6750137805938721
BREO,tachycardia,tachycardia Immune System,1,0.8013172745704651
BREO,tachycardia,these factors Cardiac Disorders tachycardia Immune System Disorders,1,0.7408349514007568
BREO,tachycardia,tachycardia Immune System Disorders Hypersensitivity,1,0.7957957983016968
BREO,tachycardia,of these,0,0.5274817943572998
BREO,Hypersensitivity reactions,Hypersensitivity reactions,1,1.0
BREO,Hypersensitivity reactions,tachycardia Immune System Disorders,0,0.6599557399749756
BREO,Hypersensitivity reactions,Immune System Hypersensitivity reactions including anaphylaxis angioedema,1,0.8611112236976624
BREO,angioedema,Disorders Hypersensitivity reactions including angioedema,1,0.8574420809745789
BREO,angioedema,tachycardia Immune System Disorders,0,0.6225056052207947
BREO,angioedema,angioedema rash and urticaria Musculoskeletal,1,0.8249807357788086
BREO,rash,Musculoskeletal and Connective Tissue Disorders Muscle,0,0.5428388714790344
BREO,rash,rash and urticaria Musculoskeletal and,1,0.7891919612884521
BREO,rash,including anaphylaxis rash and urticaria Musculoskeletal and Connective,1,0.722439169883728
BREO,rash,rash,1,1.0000001192092896
BREO,rash,Hypersensitivity reactions including anaphylaxis angioedema,0,0.6247024536132812
BREO,urticaria,urticaria,1,1.0
BREO,urticaria,Connective Tissue Disorders Muscle,0,0.4914827346801758
BREO,urticaria,anaphylaxis angioedema rash urticaria Musculoskeletal and,1,0.805404782295227
BREO,urticaria,including anaphylaxis angioedema rash urticaria Musculoskeletal,1,0.8021532297134399
BREO,urticaria,rash urticaria Musculoskeletal and,1,0.8220587968826294
BREO,Muscle spasms,and urticaria Musculoskeletal and Connective,0,0.6652582883834839
BREO,Muscle spasms,Connective Tissue Muscle spasms Nervous System Disorders,1,0.8539155721664429
BREO,Tremor,Psychiatric Disorders Nervousness,0,0.5956605672836304
BREO,Tremor,Nervous System,0,0.6140187978744507
BREO,Tremor,spasms Nervous System Disorders,0,0.651767373085022
BREO,Tremor,Psychiatric Disorders,0,0.5674149990081787
BREO,Tremor,Nervous System Tremor Psychiatric Disorders Nervousness,1,0.7647988796234131
BREO,Tremor,Muscle spasms Nervous System Disorders,0,0.6660293340682983
BREO,Tremor,Tremor Psychiatric Disorders,1,0.8327067494392395
BREO,DEATH,lante rol one,1,0.538284182548523
BREO,DEATH,LABA such as lante rol one,1,0.5333237051963806
BREO,DEATH,lante,1,0.4925946593284607
BREO,DEATH,rol one of,0,0.5729656219482422
BREO,DEATH,lante rol,1,0.5333570837974548
BREO,DEATH,REACTIONS LABA such as lante rol one,1,0.5651884078979492
BREO,DEATH,death Currently available data are inadequat,0,0.6937114000320435
BREO,DEATH,increase the risk of,0,0.5124797821044922
BREO,DEATH,active,0,0.5386601090431213
BREO,DEATH,REACTIONS LABA such,0,0.5595284104347229
BREO,DEATH,ingre,0,0.5273842215538025
BREO,DEATH,the active dient s in BREO,1,0.5796923637390137
BREO,DEATH,REACTIONS LABA such as,0,0.5492867231369019
BREO,DEATH,such as vilanterol,0,0.47961437702178955
BREO,DEATH,one of,0,0.5558208227157593
BREO,death,oster oids or,1,0.5019482374191284
BREO,death,oster oids or other,1,0.4869624376296997
BREO,death,cortic,0,0.552811861038208
BREO,death,oids or other longterm asthma control drugs mitigates the increased,0,0.47964224219322205
BREO,death,use of inhaled oster oids or other longterm asthma,1,0.4875195026397705
BREO,death,oster oids,1,0.4977373480796814
BREO,death,oster,1,0.5008387565612793
BREO,death,of asthmarelated death,0,0.7237462997436523
BREO,death,to determine whether,0,0.5142014622688293
BREO,deaths,suggest that LABA  the r isk,1,0.497855007648468
BREO,deaths,to determine whether,0,0.4448283314704895
BREO,deaths,arelated death from LABA Available data from controlled,0,0.6892904043197632
BREO,deaths,LABA,0,0.48622480034828186
BREO,deaths,the r,1,0.5143440961837769
BREO,deaths,that,0,0.5232831239700317
BREO,death,salmeterol ee,1,0.4796530604362488
BREO,death,ee Wa rnings and Precautions Systemic and,1,0.5367558002471924
BREO,death,Systemic and local corticosteroid use,0,0.466657429933548
BREO,death,may result in,0,0.5719031691551208
BREO,death,subjects receiving,0,0.5218932628631592
BREO,death,increase in asthmarelated deaths in subjects receiving salmeterol,0,0.6204578280448914
BREO,death,salmeterol ee Wa,1,0.49514707922935486
BREO,death,in asthmarelated,0,0.5126075744628906
BREO,death,deaths,0,0.8624649047851562
BREO,death,and,0,0.6179868578910828
BREO,DEATH,and oral candidiasis Asthma,0,0.4835883677005768
BREO,DEATH,incidence greater than,0,0.5146960616111755
BREO,DEATH,eacti ons incidence greater,1,0.47432637214660645
BREO,DEATH,adverse r,0,0.5460706949234009
BREO,DEATH,eacti ons incidence greater than,1,0.486657977104187
BREO,DEATH,Asthma Most common adverse r,0,0.5020749568939209
BREO,death,report SUSPECTED ADVERSE REACTIONS contact,0,0.4911552965641022
BREO,death,"oropharyngeal n, dy",1,0.5142093896865845
BREO,death,bronchitis sinusitis oropharyngeal,0,0.4715692400932312
BREO,death,and cough To report SUSPECTED ADVERSE,0,0.5457503795623779
BREO,death,"bronchitis sinusitis oropharyngeal n, dy",1,0.4868531823158264
BREO,death,infection bronchitis sinusitis oropharyngeal pai,0,0.486519455909729
BREO,death,ADVERSE REACTIONS,0,0.5449328422546387
BREO,deaths,FDA at FDA or wwwfdagovmedwatch Clinical,0,0.4697444438934326
BREO,death,in BREO LIPTA increase,1,0.4743361473083496
BREO,death,FDA at FDA or wwwfdagovmedwatch Clinical,0,0.4905502498149872
BREO,Candida albicans infection of the mouth,from controlled clinical trials suggest,0,0.5189396739006042
BREO,Candida albicans infection of the mouth,LABA Available data from controlled clinical trials suggest that LABA increase the risk,0,0.5001948475837708
BREO,Candida albicans infection of the mouth,increase the risk f asthma-related hospitalization in ped iatric,1,0.44038188457489014
BREO,Candida albicans infection of the mouth,f asthma-related hospitalization,1,0.45295020937919617
BREO,Candida albicans infection of the mouth,suggest that LABA increase the risk,0,0.492168664932251
BREO,Candida albicans infection of the mouth,hospitalization in ped iatric,1,0.4789348840713501
BREO,Candida albicans infection of the mouth,the risk f asthma-related hospitalization in ped iatric and adolescent,1,0.4501904845237732
BREO,pneumonia,placebo added to usual asthma therapy showed an increase,0,0.5196353793144226
BREO,pneumonia,lated dea ths in subjects,1,0.5157220363616943
BREO,pneumonia,lated dea,1,0.5490739345550537
BREO,pneumonia,in asthmare,0,0.573889970779419
BREO,pneumonia,in lated dea,1,0.5645196437835693
BREO,pneumonia,f another LABA salmeterol or placebo added to usual asthma therapy showed an increase in,0,0.5243116021156311
BREO,worsening of infections,in the following Candida albicans infection see,0,0.6552419662475586
BREO,worsening of infections,albicans infection see Warnings and,0,0.6674603223800659
BREO,worsening of infections,the following Candida,0,0.5940424203872681
BREO,worsening of infections,Precautions Systemic and local orticosteroid use may r,1,0.5630685687065125
BREO,worsening of infections,albicans infection,0,0.6508634686470032
BREO,fatal," 
 *  Immunosuppression",1,0.5061215162277222
BREO,fatal,Warnings and,0,0.5715155005455017
BREO,fatal,and Precautions,0,0.47710418701171875
BREO,fatal,"see Warnings and  
 *  Immunosuppression see Warnings and",1,0.5239378213882446
BREO,fatal," 
 * ",1,0.6040569543838501
BREO,chickenpox,ppression ,1,0.535215437412262
BREO,chickenpox,ppression  see Warnings and Precautions Hypercorticism,1,0.5432136058807373
BREO,chickenpox,Precautions ppression ,1,0.5877066850662231
BREO,chickenpox,Precautions ppression  see Warnings,1,0.5811715126037598
BREO,chickenpox,of pneumonia in COPD see Warnings and,0,0.4886487126350403
BREO,chickenpox,adrenal suppression see Warnings an,0,0.5043027997016907
BREO,chickenpox,ppression  see,1,0.513184130191803
BREO,chickenpox,see Warnings and Precautions,0,0.5780190229415894
BREO,chickenpox,ppression  see Warnings and Precautions,1,0.5619007349014282
BREO,measles, Warnin gs and,1,0.530051052570343
BREO,measles, Warnin gs and Precautions Hypercorticism and,1,0.5465289354324341
BREO,measles,see,0,0.5443016290664673
BREO,measles,Precautions Immunosuppression  Warnin gs and Precautions,1,0.5651863813400269
BREO,measles, Warnin gs,1,0.5192343592643738
BREO,impaired adrenal function,Precautions Hypercorticism and suppression [see Warnings and Precautions Reduction in bone,1,0.667168378829956
BREO,impaired adrenal function, Warnin gs,1,0.4821332097053528
BREO,impaired adrenal function,suppression [see Warnings and Precautions Reduction,1,0.5288900136947632
BREO,impaired adrenal function,[see Warnings and Precautions Reduction in,1,0.5156785845756531
BREO,impaired adrenal function,suppression [see Warnings,1,0.5153558254241943
BREO,impaired adrenal function,in bone mineral density,0,0.5843642950057983
BREO,impaired adrenal function,and suppression [see,1,0.5153788328170776
BREO,impaired adrenal function,and Precautions Hypercorticism and,0,0.6706152558326721
BREO,Hypercorticism,reaction,0,0.5504749417304993
BREO,death,with COPD in,0,0.5376298427581787
BREO,death,function,0,0.5515226125717163
BREO,death,month exacerbation trials a,0,0.48417383432388306
BREO,death,nclud ed subjects with COPD in,1,0.48782020807266235
BREO,death,two month exacerbation,0,0.4994764029979706
BREO,death,month lung function trials two month exacerbation trials a,0,0.47610726952552795
BREO,death,received at 1 do,1,0.5101544260978699
BREO,death,COPD received at  1 do se of BREO ELLIPTA and,1,0.5444473028182983
BREO,death,1 do se,1,0.5343364477157593
BREO,death,a,0,0.5680289268493652
BREO,death,COPD received at 1,1,0.5327755212783813
BREO,death,COPD received at  1 do,1,0.5333547592163086
BREO,death,subjects received a higher,0,0.46816715598106384
BREO,death,subjects with COPD received at,0,0.5026399493217468
BREO,death,1 do se of BREO,1,0.5340032577514648
BREO,death,1,1,0.5460909008979797
BREO,deaths,ELLIPTA fluticasone erol 5,1,0.4571874141693115
BREO,deaths,ELLIPTA BREO ELLIPTA fluticasone erol 5 mcg mcg,1,0.48013538122177124
BREO,deaths,erol 5 mcg,1,0.46874457597732544
BREO,death,Obstructive,0,0.5430432558059692
BREO,death,Reactions with BREO,0,0.5417084693908691
BREO,death,ubjects with Chronic,0,0.5191946029663086
BREO,death,in S ubjects with,1,0.5421052575111389
BREO,death,BREO ELLIPTA with Incidence and More Common than,0,0.48968422412872314
BREO,death,than Placebo,0,0.5410250425338745
BREO,death, in S ubjects,1,0.550236701965332
BREO,death,Fluti casone Furoate mcg n Placebo,1,0.47412121295928955
BREO,death,n BREO,0,0.5506144762039185
BREO,death,Furoate mcg n,0,0.4814150929450989
BREO,death,Fluti casone Furoate mcg n,1,0.47916853427886963
BREO,death,Vilanterol,0,0.49465590715408325
BREO,death,n,0,0.5521928071975708
BREO,death,n Vilanterol mcg n,0,0.5165479183197021
BREO,fatalities,thma. BREO ELLIPTA was studied in,1,0.47357267141342163
BREO,fatalities,which enrolled subjects with thma.,1,0.5043343305587769
BREO,fatalities,enrolled subjects with thma. BREO ELLIPTA,1,0.5207014083862305
BREO,fatalities,studied in subjects,0,0.48918554186820984
BREO,pneumonia,Adverse Reaction,0,0.517890214920044
BREO,pneumonia,")  




  Adverse Reaction",1,0.5044313073158264
BREO,pneumonia,")  




  Adverse Reaction BREO ELLIPTA n",1,0.5123832821846008
BREO,pneumonia,")  




  Adverse Reaction BREO ELLIPTA",1,0.49657702445983887
BREO,pneumonia,ELLIPTA n,0,0.5119702219963074
BREO,pneumonia,than Placebo in Subjects with Asthma Trial,0,0.49495768547058105
BREO,pneumonia,Reaction BREO ELLIPTA n Fluticasone,0,0.5487453937530518
BREO,pneumonia,"with Asthma )  




  Adverse",1,0.5369311571121216
BREO,pneumonia,with Incidence and More,0,0.5418755412101746
BREO,pneumonias,  Placebo ,1,0.5067973732948303
BREO,pneumonias,  Placebo  n Infections and,1,0.6066237092018127
BREO,pneumonias,Furoate mcg,0,0.48582059144973755
BREO,infections,and mediastinal disorders,0,0.5886013507843018
BREO,infections,          ,1,0.6203988790512085
BREO,Chickenpox,           Oropharyngeal pain,1,0.5438098907470703
BREO,Chickenpox,          ,1,0.5970349311828613
BREO,Chickenpox,thoracic and,0,0.5451455116271973
BREO,Chickenpox,mediastinal            Oropharyngeal,1,0.49528002738952637
BREO,measles,ediastinal         Oropharyngeal,1,0.5067829489707947
BREO,measles,thoracic and,0,0.5306336283683777
BREO,measles,       ,1,0.5834546089172363
BREO,measles,        Oropharyngeal,1,0.5004031658172607
BREO,HPA dysfunction,and fluti casone,1,0.4614453911781311
BREO,HPA dysfunction,"ELLIPTA once daily 202), and fluti",1,0.5020406246185303
BREO,HPA dysfunction,"202), and fluti casone",1,0.42338690161705017
BREO,HPA dysfunction,"daily 202), and fluti casone propionate",1,0.4830693006515503
BREO,HPA dysfunction,daily n,0,0.477369487285614
BREO,HPA dysfunction,subjects with asthma,0,0.6068441271781921
BREO,hypercorticism,upper abdominal pain,0,0.5278336405754089
BREO,hypercorticism,act infection allergic rhinitis,0,0.5088786482810974
BREO,hypercorticism,pain extrasystoles upper abdominal respiratory tr act infection,1,0.5638937950134277
BREO,adrenal suppression,"pain respiratory tract nfection, allergic",1,0.514413595199585
BREO,adrenal suppression,supraventricular extrasystoles ventricular extrasystol,0,0.5487216114997864
BREO,adrenal suppression,"nfection, allergic",1,0.5218061208724976
BREO,adrenal suppression,"pain respiratory tract nfection, allergic  rhinitis pharyngitis rhinitis arthralgia supraventricular",1,0.5189670324325562
BREO,adrenal suppression,for months included pyrexia back pain,0,0.565110981464386
BREO,adrenal suppression,months,0,0.4889200031757355
BREO,adrenal crisis,"allergic rhinitis aryngitis,",1,0.49363642930984497
BREO,adrenal crisis,extrasystoles,0,0.5474817752838135
BREO,paradoxical bronchospasm,BREO ELLIPTA compared with jects (0.7%),1,0.5011029243469238
BREO,paradoxical bronchospasm,treated wit h fluticasone,1,0.6207325458526611
BREO,paradoxical bronchospasm,jects (0.7%) treated wit h fluticasone furoate,1,0.591710090637207
BREO,paradoxical bronchospasm,jects (0.7%) treated wit h,1,0.4991593658924103
BREO,paradoxical bronchospasm,jects (0.7%),1,0.47857511043548584
BREO,Hypersensitivity reactions,in this 6.3 Postmarketing,1,0.514178991317749
BREO,Hypersensitivity reactions,observed in this 6.3 Postmarketing Experien,1,0.5327944755554199
BREO,Hypersensitivity reactions,observed in this 6.3 Postmarketing Experien ce In addition to adverse,1,0.5804706811904907
BREO,Hypersensitivity reactions,intubations observed in this 6.3 Postmarketing Experien ce In addition,1,0.5220550298690796
BREO,Hypersensitivity reactions,this 6.3 Postmarketing,1,0.5062463283538818
BREO,Hypersensitivity reactions,were no asthmarelated deaths or asthmarelated intubations observed in this,0,0.5276241302490234
BREO,anaphylaxis,have been,0,0.514287531375885
BREO,anaphylaxis,trials the,0,0.5085996389389038
BREO,anaphylaxis,this trial Postmarketing Experience addition to adverse reactions reported from clinical,1,0.6356858015060425
BREO,anaphylaxis,Experience addition,1,0.5272434949874878
BREO,anaphylaxis,addition to adverse reactions reported,1,0.658402681350708
BREO,angioedema,addition to dverse rea ctions reported,1,0.5227518081665039
BREO,angioedema,addition to adverse reactions reported,1,0.6268618106842041
BREO,angioedema,have,0,0.5197470188140869
BREO,angioedema,In addition to dverse rea,1,0.5423674583435059
BREO,angioedema,in this trial,0,0.5219374895095825
BREO,angioedema,addition to dverse rea ctions reported from,1,0.535645604133606
BREO,angioedema,dverse rea ctions,1,0.535798192024231
BREO,angioedema,Experience In,0,0.5242273807525635
BREO,angioedema,dverse rea ctions reported from,1,0.5350889563560486
BREO,angioedema,clinical trials the following adverse reactions have been identified during po,0,0.5955079197883606
BREO,rash,ions reported from,1,0.4791804552078247
BREO,urticaria,In addition to adverse,0,0.559455394744873
BREO,urticaria,ted from clinical trials the following,1,0.529041051864624
BREO,urticaria,ted from,1,0.47141703963279724
BREO,urticaria,ted,1,0.49955618381500244
BREO,urticaria,ted from clinical,1,0.4890006184577942
BREO,urticaria,postapproval,0,0.45745575428009033
BREO,anaphylactic reactions,ELLIPTA Because,0,0.47961878776550293
BREO,anaphylactic reactions,to,0,0.5020766258239746
BREO,anaphylactic reactions,are reported voluntarily,1,0.46033355593681335
BREO,increases in pulse rate,"Palpitations .



   Immune System D isorders Hypersensitivity reactions including",1,0.733441948890686
BREO,increases in pulse rate,are reported voluntarily,1,0.4874281883239746
BREO,increases in pulse rate,Palpitations . Immune,1,0.7315153479576111
BREO,increases in pulse rate,Palpitations .,1,0.7807518243789673
BREO,increases in pulse rate,Immune System D isorders,1,0.5807111859321594
BREO,increases in pulse rate,"Cardiac Disorders Palpitations .



   Immune System D isorders Hypersensitivity",1,0.7312853932380676
BREO,increases in pulse rate,Disorders Palpitations . Immune,1,0.7141260504722595
BREO,increases in pulse rate,".



   Immune System D",1,0.5645992159843445
BREO,cardiac arrhythmias,Immune System Disorders Hypersensitivity reactions,0,0.49004095792770386
BREO,cardiac arrhythmias,Palpitations tachycardia,0,0.7644485235214233
BREO,cardiac arrhythmias,and urticaria Musculoskeletal and Connective Tissue Disorders,0,0.5180413722991943
BREO,cardiac arrhythmias,"System Disorders Hypersensitivity reactions ing anaphylaxis, an gioedema",1,0.5168716907501221
BREO,cardiac arrhythmias,tachycardia Immune System Disorders Hypersensitivity reactions includ,0,0.6478116512298584
BREO,cardiac arrhythmias,"Disorders Hypersensitivity reactions ing anaphylaxis, an gioedema rash",1,0.5093055963516235
BREO,cardiac arrhythmias,gioedema rash and urticaria Musculoskeletal and,0,0.4924634099006653
BREO,cardiac arrhythmias,"Disorders Hypersensitivity reactions ing anaphylaxis, an gioedema rash and urticaria Musculoskeletal",1,0.5271668434143066
BREO,supraventricular tachycardia,Tissue Disorders,0,0.523039698600769
BREO,supraventricular tachycardia,Muscle spasms Nervous System,0,0.582890510559082
BREO,supraventricular tachycardia,Nervous System Disorders,0,0.5239888429641724
BREO,supraventricular tachycardia,Immune System Disorders Hypersensitivity reactions,0,0.5299251675605774
BREO,extrasystoles,Connective Tissue Disorders Muscle,0,0.49216437339782715
BREO,extrasystoles,angioedema rash and urticaria oskeletal,1,0.5123544931411743
BREO,extrasystoles,and urticaria oskeletal,1,0.544749915599823
BREO,extrasystoles,Muscle spasms Nervous,0,0.6074668169021606
BREO,extrasystoles,Tissue Disorders Muscle,0,0.526560366153717
BREO,extrasystoles,and urticaria oskeletal and,1,0.5541238784790039
BREO,extrasystoles,oskeletal and Connective Tissue Disorders Muscle spasms,1,0.5857257843017578
BREO,extrasystoles,urticaria oskeletal,1,0.5396022796630859
DOTAREM,NSF,associated with a,0,0.48058146238327026
DOTAREM,NSF,has not been reported,0,0.486471951007843
DOTAREM,NSF,risk,0,0.5325477123260498
DOTAREM,NSF,associated with,0,0.4944331645965576
DOTAREM,NSF,NSF has not been reported,1,0.8271723985671997
DOTAREM,NSF,and NSF has,1,0.9392071962356567
DOTAREM,NSF,NSF has not been reported in,1,0.8357579708099365
DOTAREM,NSF,NSF,1,1.0
DOTAREM,NSF,a,0,0.5040678977966309
DOTAREM,NSF,and NSF,1,0.9430427551269531
DOTAREM,NSF,Warnings and NSF has,1,0.8259692192077637
DOTAREM,Hypersensitivity reactions,to DOTAREM Hypersensitivity reactions and,1,0.8752586245536804
DOTAREM,Hypersensitivity reactions,a,0,0.4917769432067871
DOTAREM,Hypersensitivity reactions,DOTAREM Hypersensitivity,1,0.8050919771194458
DOTAREM,Hypersensitivity reactions,alone,0,0.37700432538986206
DOTAREM,Hypersensitivity reactions,to DOTAREM Hypersensitivity reactions,1,0.8691906929016113
DOTAREM,acute kidney injury,alone Hypersensitivity reactions acute,1,0.6102960109710693
DOTAREM,acute kidney injury,in other sections of the labeling,0,0.46009397506713867
DOTAREM,acute kidney injury,reactions acute,1,0.6618925333023071
DOTAREM,acute kidney injury,acute kidney,1,0.877278208732605
DOTAREM,acute kidney injury,DOTAREM alone Hypersensitivity reactions acute,1,0.593132734298706
DOTAREM,nausea,nausea headache injection site,1,0.7868602275848389
DOTAREM,nausea,nausea headache injection site pain injection,1,0.7768552303314209
DOTAREM,nausea,nausea headache injection,1,0.8185336589813232
DOTAREM,nausea,sensation To report,0,0.5834634304046631
DOTAREM,nausea,adverse reactions in clinical studies were,0,0.5699502229690552
DOTAREM,headache,EXCERPT The most frequent,0,0.5130012631416321
DOTAREM,headache,headache,1,0.9999998807907104
DOTAREM,headache,most frequent adverse reactions in clinical studies were,0,0.5329083800315857
DOTAREM,headache,clinical studies were headache injection site,1,0.7464350461959839
DOTAREM,injection site pain,injection site coldness and burning,0,0.8181724548339844
DOTAREM,injection site pain,injection site pain injection,1,0.9721097946166992
DOTAREM,injection site pain,clinical studies were nausea injection site pain injection site,1,0.8511327505111694
DOTAREM,injection site pain,injection site pain injection site coldness,1,0.878426194190979
DOTAREM,injection site pain,clinical studies were nausea injection site pain,1,0.867419958114624
DOTAREM,injection site pain,were nausea injection site pain injection site coldness and,1,0.8438690900802612
DOTAREM,injection site pain,studies were nausea headache,0,0.5880362391471863
DOTAREM,injection site pain,SUSPECTED,0,0.4692685008049011
DOTAREM,injection site coldness,injection site injection site,1,0.8131468296051025
DOTAREM,injection site coldness,site coldness and,1,0.8282981514930725
DOTAREM,injection site coldness,sensation To report SUSPECTED ADVERSE REACTIONS contact GUERBET LLC,0,0.5647140741348267
DOTAREM,injection site coldness,headache injection site,0,0.7475964426994324
DOTAREM,injection site coldness,site pain,0,0.6220812201499939
DOTAREM,injection site coldness,injection site coldness and,1,0.9942998290061951
DOTAREM,injection site coldness,ADVERSE REACTIONS contact,0,0.5744644403457642
DOTAREM,injection site coldness,injection site coldness and burning sensation To,1,0.9052966833114624
DOTAREM,burning sensation,burning sensation To report SUSPECTED ADVERSE REACTIONS,1,0.8828548192977905
DOTAREM,burning sensation,injection site coldness and burning sensation To,1,0.8285431265830994
DOTAREM,burning sensation,burning sensation To report SUSPECTED ADVERSE,1,0.8958228230476379
DOTAREM,burning sensation,clinical,0,0.5111138820648193
DOTAREM,burning sensation,injection site coldness burning,1,0.7370532751083374
DOTAREM,burning sensation,injection site coldness burning sensation,1,0.8474467396736145
DOTAREM,feeling cold,patients who received DOTAREM feeling cold,1,0.8133938312530518
DOTAREM,feeling cold,injection site coldness burning,1,0.6901096105575562
DOTAREM,feeling cold,that occurred with a frequency in patients,0,0.4786600172519684
DOTAREM,rash,received DOTAREM,0,0.5460845232009888
DOTAREM,rash,rash somnolence fatigue dizziness,1,0.752958357334137
DOTAREM,somnolence,paresthesia dysgeusia pain in extremity anxiety hypert,0,0.5754991769790649
DOTAREM,somnolence,feeling cold somnolence fatigue dizziness vomiting,1,0.7240294814109802
DOTAREM,somnolence,received DOTAREM include feeling cold,0,0.5726962685585022
DOTAREM,somnolence,somnolence fatigue dizziness vomiting pruritus,1,0.7970536947250366
DOTAREM,somnolence,include feeling cold somnolence,1,0.7860474586486816
DOTAREM,somnolence,somnolence fatigue dizziness,1,0.799979031085968
DOTAREM,somnolence,vomiting pruritus paresthesia dysgeusia pain in,0,0.5802802443504333
DOTAREM,somnolence,a,0,0.5432611703872681
DOTAREM,somnolence,somnolence,1,1.0
DOTAREM,fatigue,pruritus paresthesia,0,0.5701518058776855
DOTAREM,fatigue,fatigue dizziness vomiting pruritus,1,0.7890276908874512
DOTAREM,fatigue,a frequency in patients who received DOTAREM include,0,0.5208920240402222
DOTAREM,fatigue,in,0,0.5335518717765808
DOTAREM,fatigue,cold,0,0.6058768033981323
DOTAREM,fatigue,dizziness vomiting pruritus,0,0.6159584522247314
DOTAREM,dizziness,extremity anxiety hypertension,0,0.5724271535873413
DOTAREM,dizziness,dizziness vomiting pruritus paresthesia,1,0.8111679553985596
DOTAREM,vomiting,vomiting pruritus paresthesia dysgeusia,1,0.7692346572875977
DOTAREM,vomiting,dizziness vomiting pruritus paresthesia,1,0.74947190284729
DOTAREM,vomiting,rash somnolence fatigue vomiting pruritus paresthesia,1,0.6702656149864197
DOTAREM,vomiting,DOTAREM include,0,0.4780001640319824
DOTAREM,vomiting,vomiting pruritus paresthesia dysgeusia pain,1,0.7517701387405396
DOTAREM,vomiting,vomiting pruritus,1,0.8158321976661682
DOTAREM,pruritus,pruritus paresthesia,1,0.9199062585830688
DOTAREM,pruritus,feeling cold rash somnolence,0,0.6658303737640381
DOTAREM,pruritus,in extremity anxiety hypertension palpitations,0,0.5852335095405579
DOTAREM,pruritus,pruritus paresthesia dysgeusia pain in,1,0.8474546670913696
DOTAREM,paresthesia,cold rash somnolence fatigue dizziness vomiting,0,0.6116883754730225
DOTAREM,paresthesia,fatigue dizziness,0,0.625458836555481
DOTAREM,paresthesia,dizziness vomiting paresthesia dysgeusia pain,1,0.7205463647842407
DOTAREM,paresthesia,paresthesia dysgeusia,1,0.8164641857147217
DOTAREM,paresthesia,paresthesia dysgeusia pain in,1,0.7672827243804932
DOTAREM,paresthesia,dysgeusia pain in extremity anxiety hypertension palpitations oropharyngeal discomfort,0,0.6250348091125488
DOTAREM,dysgeusia,anxiety hypertension palpitations oropharyngeal discomfort serum creatinine,0,0.5771637558937073
DOTAREM,dysgeusia,fatigue dizziness vomiting pruritus dysgeusia pain in extremity anxiety hypertension,1,0.6781411170959473
DOTAREM,dysgeusia,feeling cold rash somnolence fatigue dizziness vomiting pruritus,0,0.6180671453475952
DOTAREM,dysgeusia,dysgeusia pain,1,0.8972386717796326
DOTAREM,dysgeusia,dysgeusia pain in extremity,1,0.8337761163711548
DOTAREM,pain in extremity,discomfort serum creatinine increased and,0,0.5735964775085449
DOTAREM,hypertension,hypertension palpitations oropharyngeal discomfort serum,1,0.7228420972824097
DOTAREM,hypertension,discomfort serum creatinine,0,0.5721802115440369
DOTAREM,hypertension,site,0,0.5438633561134338
DOTAREM,hypertension,hypertension palpitations oropharyngeal,1,0.7480959892272949
DOTAREM,hypertension,vomiting pruritus paresthesia dysgeusia pain in,0,0.5240806937217712
DOTAREM,hypertension,hypertension,1,1.0
DOTAREM,hypertension,creatinine increased and injection site reactions,0,0.5658458471298218
DOTAREM,hypertension,discomfort serum creatinine increased and injection site reactions,0,0.5646172761917114
DOTAREM,palpitations,vomiting,0,0.48785853385925293
DOTAREM,palpitations,palpitations,1,0.9999999403953552
DOTAREM,palpitations,creatinine increased,0,0.5329341888427734
DOTAREM,palpitations,creatinine increased and injection site reactions including site,0,0.5083816051483154
DOTAREM,palpitations,dizziness vomiting pruritus paresthesia dysgeusia pain,0,0.5653191208839417
DOTAREM,oropharyngeal discomfort,oropharyngeal discomfort serum creatinine increased and injection,1,0.7570914030075073
DOTAREM,serum creatinine increased,hypertension palpitations oropharyngeal serum creatinine increased and injection site,1,0.8070303201675415
DOTAREM,serum creatinine increased,oropharyngeal discomfort serum creatinine increased and injection,1,0.8134881258010864
DOTAREM,serum creatinine increased,extravasation,0,0.5516379475593567
DOTAREM,serum creatinine increased,pruritus,0,0.5142161846160889
DOTAREM,serum creatinine increased,pain,0,0.4890996813774109
DOTAREM,injection site reactions,mity anxiety hypertension,0,0.5033940076828003
DOTAREM,injection site reactions,including site inflammation extravasation pruritus,0,0.7013442516326904
DOTAREM,injection site reactions,serum creatinine increased injection,1,0.6676685810089111
DOTAREM,injection site reactions,oropharyngeal,0,0.49767744541168213
DOTAREM,injection site reactions,palpitations oropharyngeal discomfort,0,0.49549779295921326
DOTAREM,injection site reactions,creatinine increased injection site reactions including,1,0.8380324840545654
DOTAREM,headache,reported adverse reaction headache,1,0.786407470703125
DOTAREM,headache,palpitations oropharyngeal discomfort,0,0.6055001020431519
DOTAREM,headache,frequently reported adverse reaction headache,1,0.783915638923645
DOTAREM,headache,headache Most adverse events were mild,1,0.7519376277923584
DOTAREM,headache,was,0,0.5374895334243774
DOTAREM,headache,headache Most,1,0.8950859308242798
DOTAREM,bradycardia,Cardiac,0,0.6990696787834167
DOTAREM,bradycardia,action Cardiac bradycardia tachycardia,1,0.7845499515533447
DOTAREM,bradycardia,bradycardia tachycardia arrhythmia Immune,1,0.7672879695892334
DOTAREM,bradycardia,bradycardia tachycardia arrhythmia,1,0.8093448877334595
DOTAREM,bradycardia,Cardiac Disorders,0,0.6948497295379639
DOTAREM,bradycardia,System Disorders hype,0,0.5183415412902832
DOTAREM,bradycardia,bradycardia tachycardia arrhythmia Immune System Disorders,1,0.7348413467407227
DOTAREM,tachycardia,tachycardia arrhythmia Immune System Disorders hypersensitivity,1,0.7869269847869873
DOTAREM,tachycardia,Disorders tachycardia arrhythmia Immune System Disorders hypersensitivity,1,0.7520632743835449
DOTAREM,tachycardia,Disorders tachycardia arrhythmia Immune System,1,0.7709983587265015
DOTAREM,tachycardia,tachycardia arrhythmia Immune System Disorders,1,0.7824110984802246
DOTAREM,tachycardia,Cardiac Disorders bradycardia,0,0.7340484261512756
DOTAREM,tachycardia,System Disorders hypersensitivity,0,0.5645997524261475
DOTAREM,arrhythmia,Disorders,0,0.5722936391830444
DOTAREM,arrhythmia,arrhythmia,1,0.9999998211860657
DOTAREM,arrhythmia,bradycardia,0,0.7699328064918518
DOTAREM,hypersensitivity,arrest respiratory arrest cyanosis pharyngeal edema,0,0.555659294128418
DOTAREM,hypersensitivity,hypersensitivity anaphylactoid,1,0.8392051458358765
DOTAREM,hypersensitivity,hypersensitivity,1,1.0
DOTAREM,hypersensitivity,arrhythmia Immune System hypersensitivity anaphylactoid reactions including,1,0.7832638025283813
DOTAREM,anaphylactoid reactions,arrest cyanosis,0,0.5379249453544617
DOTAREM,anaphylactoid reactions,anaphylactoid,1,0.9218830466270447
DOTAREM,anaphylactoid reactions,arrest cyanosis pharyngeal,0,0.5219556093215942
DOTAREM,anaphylactoid reactions,System Disorders anaphylactoid reactions including cardiac arrest respiratory,1,0.8655321598052979
DOTAREM,anaphylactoid reactions,hypersensitivity,0,0.7552152872085571
DOTAREM,anaphylactoid reactions,anaphylactoid reactions including,1,0.9688722491264343
DOTAREM,anaphylactoid reactions,arrhythmia Immune System Disorders anaphylactoid,1,0.8230702877044678
DOTAREM,anaphylactoid reactions,pharyngeal edema laryngospasm,0,0.6008006930351257
DOTAREM,anaphylactoid reactions,Immune System Disorders anaphylactoid reactions including cardiac,1,0.8653085231781006
DOTAREM,respiratory arrest,anaphylactoid reactions including cardiac respiratory arrest,1,0.7605816721916199
DOTAREM,respiratory arrest,anaphylactoid reactions,0,0.5560963749885559
DOTAREM,respiratory arrest,bronchospasm angioedema conjunctivitis ocular hyperemi,0,0.5592918992042542
DOTAREM,respiratory arrest,Disorders hypersensitivity anaphylactoid reactions,0,0.5239200592041016
DOTAREM,respiratory arrest,including cardiac respiratory arrest,1,0.9010884761810303
DOTAREM,respiratory arrest,anaphylactoid,0,0.5321195125579834
DOTAREM,cyanosis,cyanosis pharyngeal edema laryngospasm,1,0.7530450820922852
DOTAREM,cyanosis,cyanosis,1,0.9999998807907104
DOTAREM,cyanosis,bronchospasm angioedema conjunctivitis ocular hyperemia eyelid,0,0.6167094707489014
DOTAREM,cyanosis,ocular hyperemia,0,0.5843201875686646
DOTAREM,cyanosis,cardiac arrest respiratory arrest,0,0.5808395147323608
DOTAREM,pharyngeal edema,pharyngeal edema,1,1.0
DOTAREM,pharyngeal edema,pharyngeal edema laryngospasm bronchospasm angioedema conjunctivitis ocular,1,0.834393322467804
DOTAREM,pharyngeal edema,arrest cyanosis,0,0.5852059721946716
DOTAREM,pharyngeal edema,arrest respiratory arrest pharyngeal,1,0.7275264263153076
DOTAREM,pharyngeal edema,respiratory,0,0.6116915941238403
DOTAREM,pharyngeal edema,hyperemia eyelid edema,0,0.6834673881530762
DOTAREM,pharyngeal edema,reactions including cardiac,0,0.5480153560638428
DOTAREM,pharyngeal edema,laryngospasm bronchospasm angioedema conjunctivitis ocular hyperemia eyelid edema,0,0.711563229560852
DOTAREM,pharyngeal edema,pharyngeal edema laryngospasm bronchospasm angioedema conjunctivitis,1,0.8451910614967346
DOTAREM,pharyngeal edema,eyelid edema lacrimatio,0,0.6517192125320435
DOTAREM,laryngospasm,cyanosis pharyngeal laryngospasm bronchospasm,1,0.8392899632453918
DOTAREM,laryngospasm,eyelid edema lacrimatio,0,0.5236837863922119
DOTAREM,laryngospasm,laryngospasm bronchospasm angioedema conjunctivitis ocular hyperemia,1,0.7860684990882874
DOTAREM,laryngospasm,laryngospasm,1,1.0000001192092896
DOTAREM,laryngospasm,eyelid edema lacrimation increased h,0,0.5413345098495483
DOTAREM,bronchospasm,edema bronchospasm angioedema conjunctivitis,1,0.7651807069778442
DOTAREM,bronchospasm,eyelid edema lacrimation increased h,0,0.5270915031433105
DOTAREM,bronchospasm,bronchospasm angioedema conjunctivitis ocular,1,0.8302274942398071
DOTAREM,angioedema,angioedema,1,1.000000238418579
DOTAREM,conjunctivitis,pharyngeal edema laryngospasm bronchospasm conjunctivitis,1,0.7196155786514282
DOTAREM,conjunctivitis,angioedema,1,0.6678833365440369
DOTAREM,conjunctivitis,conjunctivitis,1,1.0
DOTAREM,conjunctivitis,laryngospasm bronchospasm conjunctivitis,1,0.7520826458930969
DOTAREM,conjunctivitis,diac arrest respiratory arrest cyanosis pharyngeal edema laryngospasm,0,0.47691887617111206
DOTAREM,conjunctivitis,ocular hyperemia eyelid edema,0,0.678230881690979
DOTAREM,conjunctivitis,conjunctivitis ocular,1,0.935411810874939
DOTAREM,ocular hyperemia,bronchospasm angioedema ocular hyperemia eyelid edema lacrimation,1,0.7182541489601135
DOTAREM,ocular hyperemia,ocular hyperemia eyelid edema,0,0.8935441374778748
DOTAREM,ocular hyperemia,conjunctivitis,0,0.6738409399986267
DOTAREM,ocular hyperemia,ocular hyperemia eyelid edema lacrimation increased,1,0.8457790017127991
DOTAREM,ocular hyperemia,angioedema conjunctivitis,0,0.6679341793060303
DOTAREM,ocular hyperemia,laryngospasm bronchospasm angioedema,0,0.5335589647293091
DOTAREM,ocular hyperemia,edema laryngospasm bronchospasm,0,0.5336271524429321
DOTAREM,ocular hyperemia,ocular hyperemia,1,1.0
DOTAREM,eyelid edema,Nervous,0,0.5180785655975342
DOTAREM,eyelid edema,eyelid edema lacrimation increased hyperhidrosis urticaria,1,0.8171385526657104
DOTAREM,lacrimation increased,coma convulsion syncope,0,0.544971227645874
DOTAREM,lacrimation increased,hyperemia eyelid lacrimation increased,1,0.8606259226799011
DOTAREM,hyperhidrosis,coma convulsion syncope,0,0.5025821328163147
DOTAREM,hyperhidrosis,hyperhidrosis urticaria Nervous System Disorders,1,0.8378291130065918
DOTAREM,hyperhidrosis,lacrimation hyperhidrosis urticaria Nervous System Disorders coma,1,0.7384604215621948
DOTAREM,hyperhidrosis,hyperhidrosis urticaria,1,0.901025652885437
DOTAREM,hyperhidrosis,coma,0,0.4613048732280731
DOTAREM,urticaria,urticaria Nervous System,1,0.8234292268753052
DOTAREM,urticaria,coma,0,0.49121561646461487
DOTAREM,urticaria,System Disorders coma convulsion syncope presyncope,0,0.5120671987533569
DOTAREM,urticaria,urticaria,1,1.0
DOTAREM,urticaria,urticaria Nervous,1,0.8463932275772095
DOTAREM,coma,coma convulsion syncope presyncope parosmia,1,0.7681411504745483
DOTAREM,coma,coma convulsion syncope,1,0.8081503510475159
DOTAREM,coma,coma convulsion syncope presyncope parosmia tremor,1,0.7759948968887329
DOTAREM,coma,urticaria Nervous System Disorders,0,0.5114712715148926
DOTAREM,coma,parosmia tremor Musculoskeletal,0,0.5240942239761353
DOTAREM,coma,System Disorders,0,0.5737197399139404
DOTAREM,convulsion,convulsion syncope presyncope parosmia,1,0.7758014798164368
DOTAREM,convulsion,convulsion syncope presyncope,1,0.7776157259941101
DOTAREM,convulsion,urticaria Nervous System Disorders coma,0,0.645172119140625
DOTAREM,convulsion,increased hyperhidrosis urticaria,0,0.5123302936553955
DOTAREM,convulsion,urticaria Nervous System Disorders convulsion syncope presyncope parosmia tremor,1,0.7169898748397827
DOTAREM,convulsion,presyncope parosmia tremor Musculoskeletal,0,0.5328479409217834
DOTAREM,convulsion,Musculoskeletal and,0,0.46963584423065186
DOTAREM,syncope,syncope presyncope parosmia,1,0.8121871948242188
DOTAREM,syncope,Musculoskeletal and,0,0.47334620356559753
DOTAREM,presyncope,Connective Tissue Disorders,0,0.5254477262496948
DOTAREM,presyncope,Disorders,0,0.5438745021820068
DOTAREM,presyncope,presyncope parosmia tremor Musculoskeletal,1,0.7218800783157349
DOTAREM,parosmia,coma convulsion syncope,0,0.505765438079834
DOTAREM,parosmia,syncope presyncope,0,0.5359020233154297
DOTAREM,parosmia,System Disorders coma convulsion syncope,0,0.5123641490936279
DOTAREM,parosmia,Musculoskeletal and,0,0.4874930679798126
DOTAREM,parosmia,muscle contracture,0,0.475553035736084
DOTAREM,parosmia,convulsion syncope parosmia tremor Musculoskeletal and Connective,1,0.6307165026664734
DOTAREM,parosmia,parosmia tremor Musculoskeletal,1,0.7297316789627075
DOTAREM,parosmia,convulsion syncope parosmia,1,0.7681002616882324
DOTAREM,tremor,tremor,1,0.9999998807907104
DOTAREM,tremor,tremor Musculoskeletal and Connective Tissue Disorders,1,0.7885318994522095
DOTAREM,tremor,Disorders coma,0,0.5340619683265686
DOTAREM,tremor,convulsion syncope presyncope tremor Musculoskeletal,1,0.7691216468811035
DOTAREM,tremor,and Connective,0,0.5572812557220459
DOTAREM,tremor,Disorders muscle contracture muscle,0,0.6070283055305481
DOTAREM,tremor,tremor Musculoskeletal and Connective Tissue,1,0.8052847385406494
DOTAREM,tremor,Musculoskeletal and Connective Tissue Disorders,0,0.5650827884674072
DOTAREM,tremor,coma convulsion syncope presyncope tremor Musculoskeletal and Connective,1,0.7291392087936401
DOTAREM,muscle contracture,Tissue,0,0.575782060623169
DOTAREM,muscle contracture,muscle contracture muscle,1,0.976806640625
DOTAREM,muscle contracture,Connective Tissue muscle contracture,1,0.8993335366249084
DOTAREM,muscle contracture,weakness Gastrointestinal Disorders diarrhea s,0,0.550818681716919
DOTAREM,muscle contracture,and Connective Tissue muscle contracture muscle weakness Gastrointestinal Disorders diarrhea,1,0.7535073757171631
DOTAREM,muscle contracture,muscle contracture,1,1.000000238418579
DOTAREM,muscle contracture,muscle contracture muscle weakness,1,0.9088225364685059
DOTAREM,muscle contracture,parosmia,0,0.475553035736084
DOTAREM,muscle weakness,Tissue Disorders muscle muscle,1,0.734359085559845
DOTAREM,muscle weakness,muscle weakness,1,1.0
DOTAREM,muscle weakness,muscle muscle,1,0.7507642507553101
DOTAREM,muscle weakness,Gastrointestinal Disorders,0,0.5387234687805176
DOTAREM,muscle weakness,Tissue Disorders muscle muscle weakness Gastrointestinal,1,0.7683122158050537
DOTAREM,muscle weakness,muscle weakness Gastrointestinal Disorders,1,0.7887858152389526
DOTAREM,salivary hypersecretion,and Administration Site Conditions,0,0.5094596743583679
DOTAREM,salivary hypersecretion,Gastrointestinal Disorders diarrhea,0,0.563785195350647
DOTAREM,salivary hypersecretion,muscle weakness Gastrointestinal Disorders diarrhea,0,0.5299309492111206
DOTAREM,salivary hypersecretion,Gastrointestinal Disorders salivary hypersecretion General Disorders and Administration Site,1,0.8464850187301636
DOTAREM,salivary hypersecretion,salivary,1,0.8319761157035828
DOTAREM,malaise,Site Conditions,0,0.5049111843109131
DOTAREM,malaise,malaise fever Skin and Subcutaneous Tissue,1,0.7390397787094116
DOTAREM,malaise,malaise fever Skin and,1,0.8021280169487
DOTAREM,malaise,Administration Site,0,0.5134810209274292
DOTAREM,malaise,Conditions,0,0.5999091863632202
DOTAREM,malaise,Subcutaneous,0,0.558677077293396
DOTAREM,malaise,malaise fever Skin,1,0.797702968120575
DOTAREM,malaise,malaise,1,0.9999999403953552
DOTAREM,fever,fever Skin and Subcutaneous Tissue,1,0.7858095765113831
DOTAREM,NSF,Tissue NSF in patients,1,0.7772552371025085
DOTAREM,NSF,fever Skin and Subcutaneous Tissue,1,0.5235533714294434
DOTAREM,NSF,Subcutaneous Tissue NSF,1,0.7835144996643066
DOTAREM,NSF,were confounded by the receipt of other GBCAs or in,0,0.4231056571006775
DOTAREM,NSF,NSF have been reported,1,0.9012769460678101
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,GBC,0,0.5284034013748169
DOTAREM,NSF,with a,0,0.48756980895996094
DOTAREM,NSF,with ris k for,1,0.5517075061798096
DOTAREM,NSF,have been associated with ris k for NSF see Warnings,1,0.7474666833877563
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,has not been reported,0,0.43339988589286804
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,e Warnings,1,0.498587429523468
DOTAREM,NSF,.1 ,1,0.5170490741729736
DOTAREM,NSF,Warnings and .1 ,1,0.5222877264022827
DOTAREM,NSF,of xpo sure to,1,0.5082123875617981
DOTAREM,NSF,xpo sure to DOTAREM alone Hypersensitivity,1,0.5228978991508484
DOTAREM,NSF,been reported in patients with,0,0.4417110085487366
DOTAREM,NSF,DOTAREM alone Hypersensitivity reactions,0,0.49296748638153076
DOTAREM,NSF,xpo sure to,1,0.512035608291626
DOTAREM,NSF,xpo sure to DOTAREM alone,1,0.5222533941268921
DOTAREM,NSF,xpo sure,1,0.5191224217414856
DOTAREM,NSF,are described in other,0,0.4978863596916199
DOTAREM,NSF,EXCERPT,0,0.4807640314102173
DOTAREM,NSF,Precautions and EXCERPT he  most frequent,1,0.49820828437805176
DOTAREM,NSF,frequent adverse,0,0.49051445722579956
DOTAREM,NSF,he  most frequent adverse,1,0.49472707509994507
DOTAREM,NSF,he  most frequent adverse reactions,1,0.4586733281612396
DOTAREM,NSF,in clinical studies,0,0.5188623070716858
DOTAREM,NSF,see Warnings and,0,0.5061442852020264
DOTAREM,NSF,he  most,1,0.4922696053981781
DOTAREM,fatal,>= 0. adverse reactions in clinical,1,0.5914091467857361
DOTAREM,fatal,Precautions,0,0.4998426139354706
DOTAREM,fatal,EXCERPT The most >= 0. adverse reactions in,1,0.5723781585693359
DOTAREM,fibrosis,and burning se,0,0.5479038953781128
DOTAREM,fibrosis,and EXCERPT,0,0.503781795501709
DOTAREM,fibrosis,Precautions and,0,0.5019934773445129
DOTAREM,NSF,clinical studies were nausea headache,0,0.5000051856040955
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,where ethnicity was recorded,1,0.4639762341976166
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,Black and,0,0.4695691168308258
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,and pediatric patients Overall of,0,0.5174480676651001
DOTAREM,NSF,he  ethnic distribution was Caucasian,1,0.4673738181591034
DOTAREM,NSF,he  ethnic distribution was Caucasian Asian,1,0.47735831141471863
DOTAREM,NSF,ethnicity was recorded,0,0.46903252601623535
DOTAREM,NSF,years,0,0.5318726897239685
DOTAREM,NSF,reaction,0,0.5034897923469543
DOTAREM,NSF,immediately,0,0.48211854696273804
DOTAREM,NSF,"to years l,  of patients reported at",1,0.4478904604911804
DOTAREM,NSF,and transient in Tab le lists adverse reactions that,1,0.44572463631629944
DOTAREM,NSF,Tab le lists,1,0.49028342962265015
DOTAREM,NSF,patients who,0,0.4360736310482025
DOTAREM,NSF,transient in Tab,1,0.49353569746017456
DOTAREM,Nephrogenic Systemic Fibrosis,REACTIONS GBCAs have been associated,0,0.5331599116325378
DOTAREM,Nephrogenic Systemic Fibrosis,have been with a,1,0.4541581869125366
DOTAREM,Nephrogenic Systemic Fibrosis,GBCAs have been with a risk for NSF [see War,1,0.5096638202667236
DOTAREM,Nephrogenic Systemic Fibrosis,REACTIONS GBCAs have been,0,0.474381685256958
DOTAREM,Nephrogenic Systemic Fibrosis,REACTIONS GBCAs have been with a risk for NSF  [see War nings and,1,0.5306412577629089
DOTAREM,Nephrogenic Systemic Fibrosis,NSF [see War nings and Precautions,1,0.5060901641845703
DOTAREM,Hypersensitivity,s and acute kidn ey,1,0.6036906242370605
DOTAREM,Hypersensitivity,clear history of exposure to DOTAREM alone Hypersensitivity,0,0.7474970817565918
DOTAREM,Hypersensitivity,the,0,0.5452110767364502
DOTAREM,Hypersensitivity,Hypersensitivity s,1,0.9179109334945679
DOTAREM,Hypersensitivity,to DOTAREM alone Hypersensitivity s and acute kidn ey injury are described in,1,0.7908198237419128
DOTAREM,anaphylactic reactions,are scribed in,1,0.44098952412605286
DOTAREM,anaphylactic reactions,injury are scribed,1,0.5124108791351318
DOTAREM,anaphylactic reactions,labeling see Warnings and Precautions and,0,0.5535550117492676
DOTAREM,anaphylactic reactions,other secti ons of,1,0.4975297152996063
DOTAREM,anaphylactic reactions,history of exposure to DOTAREM alone Hypersensitivity reactions and acute kidney injury are,0,0.6938316822052002
DOTAREM,death,st fr equent adverse reactions in clinical,1,0.5237987041473389
DOTAREM,death,st fr,1,0.5286351442337036
DOTAREM,death,st fr equent adverse,1,0.5615592002868652
DOTAREM,death,Precautions and EXCERPT The st fr,1,0.5327425599098206
DOTAREM,death,injection site,0,0.5238708257675171
DOTAREM,death,Precautions and EXCERPT The st fr equent,1,0.5357844233512878
DOTAREM,death,Warnings,0,0.5793666839599609
DOTAREM,nephrogenic systemic fibrosis,ADVERSE REACTIONS contact GUERBET LLC at,0,0.5090640187263489
DOTAREM,nephrogenic systemic fibrosis,at,0,0.50473952293396
DOTAREM,nephrogenic systemic fibrosis,wwwfdagovmedwatch Clinical Studies Experience Because clinical trials,0,0.537061333656311
DOTAREM,nephrogenic systemic fibrosis,trials are con,0,0.4600374400615692
DOTAREM,nephrogenic systemic fibrosis,REACTIONS contact GUERBET LLC,0,0.4790043830871582
DOTAREM,nephrogenic systemic fibrosis,GUERBET LLC 679 or,1,0.450530081987381
DOTAREM,nephrogenic systemic fibrosis,REACTIONS contact GUERBET LLC 679 or FDA at 1-800-FDA-1088  or wwwfdagovmedwatch Clinical Studies,1,0.5304019451141357
DOTAREM,NSF,SUSPECTED ADVERSE REACTIONS,0,0.4583595395088196
DOTAREM,NSF,Because clinical,0,0.4955822825431824
DOTAREM,NSF,at FDA  ww wfdagovmedwatch Clinical Studies,1,0.5459717512130737
DOTAREM,NSF, ww wfdagovmedwatch,1,0.5353317856788635
DOTAREM,NSF, ww wfdagovmedwatch Clinical Studies Experience,1,0.5430781841278076
DOTAREM,NSF,wfdagovmedwatch Clinical Studies Experience Because,0,0.5331817269325256
DOTAREM,NSF,asian Asian,0,0.49864456057548523
DOTAREM,NSF,auc asian Asian Black and,1,0.49815934896469116
DOTAREM,NSF,auc asian Asian,1,0.48720088601112366
DOTAREM,NSF,distribution was auc asian Asian Black,1,0.5066384077072144
DOTAREM,NSF,the ethnic distribution was auc asian,1,0.46045511960983276
DOTAREM,NSF,others The,0,0.46780937910079956
DOTAREM,NSF,ethnic distribution was,0,0.446795254945755
DOTAREM,NSF,auc asian Asian Black,1,0.4974537491798401
DOTAREM,fatal,"n, 4% Black and",1,0.5055301189422607
DOTAREM,fatal,"distribution was Caucasian n, 4% Black and others The average",1,0.47015655040740967
DOTAREM,fatal,others,0,0.525429368019104
DOTAREM,fatal,range from,0,0.4571504592895508
DOTAREM,fatal,others The average age was years range from to,0,0.4613625109195709
DOTAREM,fatal,others The average age was years range from to years Overall,0,0.45463258028030396
DOTAREM,fatal,was recorded the,0,0.464041531085968
DOTAREM,fatal,"Caucasian n,",1,0.4869921803474426
DOTAREM,fatal,average,0,0.5045982599258423
DOTAREM,fibrosis,ere,0,0.5166184306144714
DOTAREM,fibrosis,to years Overall of patients,0,0.5574594140052795
DOTAREM,fibrosis,thers. T,1,0.5534729957580566
DOTAREM,anaphylactoid reactions,received DOTAREM Overall pediatric patients re,0,0.5777870416641235
DOTAREM,anaphylactoid reactions,"aged 2 - 5 years, aged years and aged",1,0.5014638304710388
DOTAREM,anaphylactoid reactions,"pediatric patients aged s, 33 aged 2 - 5 years, aged years and aged",1,0.5226986408233643
DOTAREM,anaphylactoid reactions,"trials pediatric patients aged s, 33 aged 2 - 5 years, aged",1,0.5410230159759521
DOTAREM,anaphylactoid reactions,"patients aged s, 33 aged 2 - 5 years, aged years and",1,0.5334073305130005
DOTAREM,anaphylactoid reactions,"s, 33 aged 2 - 5 years, aged years and",1,0.47741931676864624
DOTAREM,anaphylactoid reactions,During,0,0.49867403507232666
DOTAREM,anaphylactoid reactions,pediatric patients,0,0.5452717542648315
DOTAREM,anaphylactoid reactions,"patients aged s, 33 aged 2",1,0.5263944268226624
DOTAREM,circulatory collapse,tion following DOTAR EM administration The,1,0.541279673576355
DOTAREM,circulatory collapse,adverse tion following DOTAR EM administration The most,1,0.5480729341506958
DOTAREM,circulatory collapse,EM administration The most frequently reported adverse,0,0.518040120601654
DOTAREM,circulatory collapse,one adverse tion following DOTAR,1,0.5617881417274475
DOTAREM,circulatory collapse,Most adverse e,0,0.5503501892089844
DOTAREM,died,pediatric patients reported at least one adverse reaction,0,0.4563747048377991
DOTAREM,died,Overall pediatric patients reported at least one adverse reaction,0,0.45492830872535706
DOTAREM,died,mini stration The most frequently,1,0.4632459580898285
DOTAREM,died,mini,1,0.521003246307373
DOTAREM,hypersensitivity reaction,reactions are ted voluntarily,1,0.6440352201461792
DOTAREM,hypersensitivity reaction,possible to reliably estimate their frequency or,0,0.4197721481323242
DOTAREM,hypersensitivity reaction,reactions are ted voluntarily from a po pulation of uncertain size it,1,0.6664226651191711
DOTAREM,hypersensitivity reaction,a po pulation of uncertain size it,1,0.48851442337036133
DOTAREM,hypersensitivity reaction,eactions have been identified during postmarketing use of DOTAREM Because these reactions are repor,0,0.6995857954025269
DOTAREM,hypersensitivity reaction,are repor,0,0.49369627237319946
DOTAREM,acute kidney injury,bradycardia,0,0.5069637298583984
DOTAREM,acute kidney injury,diac Disorders bradycardia tachycardia Immune System D,1,0.5343133807182312
DOTAREM,acute kidney injury,isorders hypersensitivity anaphylactoid reactions including,0,0.5402354001998901
DOTAREM,acute kidney injury,System D,1,0.47652333974838257
DOTAREM,acute kidney injury,Immune System D,1,0.5406593084335327
NESINA,headache,headache and,1,0.9235892295837402
NESINA,headache,in,0,0.5469978451728821
NESINA,pancreatitis,in of patients receiving,0,0.5259939432144165
NESINA,pancreatitis,NESINA,0,0.489050030708313
NESINA,pancreatitis,trial,0,0.5085395574569702
NESINA,pancreatitis,pancreatitis was reported,1,0.8841354250907898
NESINA,pancreatitis,pancreatitis was reported in of,1,0.8748421669006348
NESINA,pancreatitis,the clinical,0,0.5657058954238892
NESINA,pancreatitis,pancreatitis was reported in,1,0.879329264163971
NESINA,pancreatitis,to five of,0,0.48322826623916626
NESINA,hypersensitivity reactions,compared to with all comparators A single event of serum,0,0.5688546895980835
NESINA,hypersensitivity reactions,the overall incidence hypersensitivity reactions,1,0.8618261814117432
NESINA,serum sickness,event serum sickness,1,0.8721110820770264
NESINA,serum sickness,serum,1,0.8173142075538635
NESINA,serum sickness,mg Hypoglycemia,0,0.5195553302764893
NESINA,serum sickness,serum sickness was,1,0.9724574685096741
NESINA,serum sickness,serum sickness was reported in,1,0.9569989442825317
NESINA,serum sickness,A single event serum sickness was reported in,1,0.9027682542800903
NESINA,serum sickness,single event serum sickness,1,0.8911192417144775
NESINA,Hypoglycemic events,treated with NESINA mg Hypoglycemic events were documented based,1,0.8138045072555542
NESINA,Hypoglycemic events,serum sickness was,1,0.4745219945907593
NESINA,Hypoglycemic events,a blood,0,0.5263510942459106
NESINA,Hypoglycemic events,with NESINA mg Hypoglycemic events,1,0.8560997247695923
NESINA,Hypoglycemic events,mg Hypoglycemic events were documented based upon a,1,0.8584316372871399
NESINA,Hypoglycemic events,treated with NESINA mg Hypoglycemic events were documented based upon a,1,0.8091766834259033
NESINA,Hypoglycemic events,symptoms of,0,0.5670491456985474
NESINA,Hypoglycemic events,Hypoglycemic events were documented based upon a,1,0.9048986434936523
NESINA,Hypoglycemic events,were documented based upon a blood glucose value andor clinical signs,0,0.7001484632492065
NESINA,hypoglycemia,hypoglycemia In the monotherapy,1,0.8537054061889648
NESINA,hypoglycemia,hypoglycemia In the,1,0.9693946838378906
NESINA,hypoglycemia,hypoglycemia In the monotherapy study,1,0.8266613483428955
NESINA,hypoglycemia,hypoglycemia,0,1.0
NESINA,hypoglycemia,hypoglycemia In,1,0.9719533920288086
NESINA,hypoglycemia,hypoglycemia was in,1,0.9560443758964539
NESINA,hypoglycemia,the monotherapy study the incidence,0,0.49284881353378296
NESINA,hypoglycemia,in elderly patients,0,0.5120429396629333
NESINA,hypoglycemia,hypoglycemia compared to placebo In,1,0.8487628698348999
NESINA,hypoglycemia,as addon therapy to glyburide or insulin did not increase the,0,0.6410800218582153
NESINA,hypoglycemia,increase the incidence,0,0.505707323551178
NESINA,hypoglycemia,patients the incidence,0,0.511098325252533
NESINA,hypoglycemia,monotherapy study comparing NESINA,0,0.537058413028717
NESINA,hypoglycemia,hypoglycemia was with NESINA compared to,1,0.8201900720596313
NESINA,hypoglycemia,with glipizide Table,0,0.6169393658638
NESINA,Hypoglycemia,and,0,0.49946165084838867
NESINA,Hypoglycemia,NESINA compared to with glipizide Table Table,0,0.5780220031738281
NESINA,Hypoglycemia,compared to with glipizide,0,0.6007180213928223
NESINA,Hypoglycemia,Hypoglycemia Adverse reactions of,1,0.8561253547668457
NESINA,Hypoglycemia,Hypoglycemia Adverse reactions of hypoglycemia,1,0.8655056953430176
NESINA,Hypoglycemia,Hypoglycemia Adverse reactions of hypoglycemia were,1,0.862897515296936
NESINA,hypoglycemia,Rate of HypoglycemiaAdverse reactions hypoglycemia were,1,0.8463631868362427
NESINA,hypoglycemia,Hypoglycemia Adverse reactions of hypoglycemia were,1,0.862897515296936
NESINA,hypoglycemia,hypoglycemia were,1,0.9714431166648865
NESINA,hypoglycemia,hypoglycemia were based on,1,0.8830665946006775
NESINA,hypoglycemia,hypoglycemia a concurrent,1,0.9144660830497742
NESINA,hypoglycemia,symptomatic and hypoglycemia a concurrent glucose measurement,1,0.8091241121292114
NESINA,hypoglycemia,symptomatic and hypoglycemia a concurrent glucose measurement was,1,0.8152412176132202
NESINA,hypoglycemia,and,0,0.49946165084838867
NESINA,hypoglycemia,intenttotreat population in Placebo and,0,0.5305159091949463
NESINA,hypoglycemia,events requiring medical assistance or exhibiting,0,0.5234625339508057
NESINA,hypoglycemia,medical,0,0.5873774290084839
NESINA,hypoglycemia,Severe events hypoglycemia,1,0.8611459732055664
NESINA,hypoglycemia,hypoglycemia were defined as those events,1,0.8629103899002075
NESINA,changes in vital signs,observed in patients treated with NESINA Laboratory,0,0.6073637008666992
NESINA,changes in vital signs,changes in vital signs or in,1,0.9673038125038147
NESINA,changes in vital signs,Signs No,0,0.5334291458129883
NESINA,changes in vital signs,Signs No clinically changes in,1,0.732027530670166
NESINA,changes in vital signs,Vital Signs No clinically meaningful,0,0.7925992012023926
NESINA,changes in vital signs,observed in patients treated with NESINA,0,0.5945698022842407
NESINA,Hypersensitivity reactions,Hypersensitivity reactions including,1,0.9571927189826965
NESINA,Hypersensitivity reactions,adverse reactions,0,0.7704890966415405
NESINA,anaphylaxis,including StevensJohnson synd,0,0.4999516010284424
NESINA,anaphylaxis,anaphylaxis angioedema rash,1,0.8387706279754639
NESINA,anaphylaxis,or establish,0,0.4890117049217224
NESINA,anaphylaxis,anaphylaxis,1,0.9999999403953552
NESINA,anaphylaxis,anaphylaxis angioedema rash urticaria,1,0.8452139496803284
NESINA,angioedema,rash urticaria and severe cutaneous adverse reactions including StevensJohnson syndrome,0,0.6596584320068359
NESINA,angioedema,angioedema,1,1.000000238418579
NESINA,angioedema,including StevensJohnson,0,0.4998359978199005
NESINA,angioedema,exposure Hypersensitivity reactions including angioedema rash urticaria and,1,0.8028577566146851
NESINA,angioedema,rash urticaria and severe cutaneous adverse reactions,0,0.6400951147079468
NESINA,angioedema,exposure Hypersensitivity reactions including angioedema rash urticaria,1,0.8012597560882568
NESINA,urticaria,urticaria and severe,1,0.8673601150512695
NESINA,urticaria,urticaria and severe cutaneous adverse reactions,1,0.8340904712677002
NESINA,cutaneous adverse reactions,cutaneous adverse reactions including StevensJohnson syndrome,1,0.869260311126709
NESINA,cutaneous adverse reactions,StevensJohnson syndrome hepatic enzyme elevations fulminant hepatic failure severe,0,0.6088716983795166
NESINA,cutaneous adverse reactions,angioedema rash urticaria and cutaneous adverse reactions including StevensJohnson syndrome hepatic enzyme,1,0.7859705686569214
NESINA,cutaneous adverse reactions,osure Hypersensitivity reactions including anaphylaxis angioedema,0,0.716660737991333
NESINA,cutaneous adverse reactions,urticaria and cutaneous adverse reactions including StevensJohnson syndrome hepatic enzyme,1,0.7916721701622009
NESINA,cutaneous adverse reactions,adverse reactions including StevensJohnson syndrome hepatic,1,0.7465526461601257
NESINA,cutaneous adverse reactions,and cutaneous,1,0.7746375799179077
NESINA,cutaneous adverse reactions,enzyme,0,0.5093173980712891
NESINA,cutaneous adverse reactions,syndrome hepatic enzyme,0,0.535982608795166
NESINA,hepatic enzyme elevations,StevensJohnson hepatic enzyme elevations,1,0.9224810600280762
NESINA,hepatic enzyme elevations,StevensJohnson hepatic enzyme elevations fulminant hepatic failure,1,0.8330156803131104
NESINA,hepatic enzyme elevations,acute pancreatitis,0,0.6049320697784424
NESINA,hepatic enzyme elevations,hepatic enzyme elevations fulminant hepatic failure severe and,1,0.8637950420379639
NESINA,fulminant hepatic failure,fulminant hepatic failure severe,1,0.9620652794837952
NESINA,fulminant hepatic failure,fulminant hepatic failure severe and disabling arthralgia,1,0.8768117427825928
NESINA,fulminant hepatic failure,syndrome hepatic enzyme,0,0.7077631950378418
NESINA,fulminant hepatic failure,StevensJohnson syndrome hepatic enzyme fulminant hepatic,1,0.7914215326309204
NESINA,arthralgia,enzyme elevations fulminant hepatic failure,0,0.4972878694534302
NESINA,arthralgia,acute pancreatitis see Warnings and,0,0.5262634754180908
NESINA,arthralgia,arthralgia,1,1.0
NESINA,acute pancreatitis,hepatic enzyme elevations fulminant hepatic failure severe and disabling arthralgia,0,0.6024139523506165
NESINA,acute pancreatitis,see,0,0.5283825397491455
NESINA,acute pancreatitis,acute pancreatitis see Warnings and Precautions,1,0.8573296070098877
NESINA,acute pancreatitis,enzyme elevations fulminant hepatic,0,0.6391031742095947
NESINA,acute pancreatitis,acute pancreatitis,1,0.9999999403953552
NESINA,Acute pancreatitis,of patients treated with NESINA mg and more frequently than in patients who received,0,0.5076717734336853
NESINA,Acute pancreatitis,patients treated with NESINA mg and more frequently than in patients,0,0.5111761093139648
NESINA,Acute pancreatitis,reactions (report,1,0.5410270690917969
NESINA,Acute pancreatitis,reactions (report ed in of patients treated,1,0.5880415439605713
NESINA,Acute pancreatitis,Common reactions (report,1,0.5493003129959106
NESINA,Acute pancreatitis,ADVERSE REACTIONS EXCERPT Common  reactions (report ed in,1,0.5810130834579468
NESINA,Acute pancreatitis,EXCERPT Common  reactions (report ed in of patients,1,0.5796821713447571
NESINA,acute pancreatitis,adverse reactions reported in,0,0.6045986413955688
NESINA,acute pancreatitis,25 mg and more fre,1,0.5013370513916016
NESINA,acute pancreatitis,and more fre quently than,1,0.48598140478134155
NESINA,acute pancreatitis,patients treated with 25 mg and more fre quently,1,0.5062270760536194
NESINA,acute pancreatitis,patients treated with 25 mg and more fre quently than in,1,0.5065695643424988
NESINA,acute pancreatitis,received placebo,0,0.4933012127876282
NESINA,acute pancreatitis,patients treated with 25 mg and more fre quently than in patients,1,0.5030091404914856
NESINA,Hypersensitivity,upper re,1,0.5369826555252075
NESINA,Hypersensitivity,REACTIONS contact Takeda P,0,0.5760722756385803
NESINA,hypersensitivity reactions,ort SUSPECTED ADVERSE REAC TIONS contact Takeda Pharmaceuticals,1,0.54339599609375
NESINA,hypersensitivity reactions,ort SUSPECTED ADVERSE REAC,1,0.5412143468856812
NESINA,hypersensitivity reactions,infection To ort SUSPECTED ADVERSE REAC TIONS,1,0.5779203176498413
NESINA,hypersensitivity reactions,SUSPECTED ADVERSE REAC,1,0.5574670433998108
NESINA,hypersensitivity reactions,infection,0,0.5838252902030945
NESINA,hypersensitivity reactions,infection To ort SUSPECTED,1,0.5552495121955872
NESINA,hypersensitivity reactions,To ort SUSPECTED ADVERSE,1,0.5658799409866333
NESINA,hypersensitivity reactions,upper respiratory tract infection To,0,0.5591977834701538
NESINA,hypersensitivity reactions,upper respiratory tract,0,0.5305868983268738
NESINA,anaphylaxis,contact Takeda Pharmaceuticals 1-877-TAKED A,1,0.48031628131866455
NESINA,anaphylaxis,upper respiratory tract,0,0.523245096206665
NESINA,anaphylaxis,FDA or,0,0.5328362584114075
NESINA,anaphylaxis,at FDA or wwwfdagovmedwatch,0,0.5091381072998047
NESINA,anaphylaxis,1-877-TAKED A,1,0.4923385977745056
NESINA,anaphylaxis,FDA or wwwfdagovmedwatch,0,0.5144453048706055
NESINA,anaphylaxis,REACTIONS contact Takeda Pharmaceuticals at,0,0.5572081208229065
NESINA,anaphylaxis,at FDA,0,0.5068837404251099
NESINA,anaphylaxis,or wwwfdagovmedwatch Clini,0,0.5124917030334473
NESINA,angioedema,SUSPECTED ADVERSE REACTIONS contact,0,0.635358452796936
NESINA,angioedema,7 (1-877-8,1,0.4628840982913971
NESINA,cutaneous adverse reactions,FDA at 1-800-FDA-1088 or ww wfdagovmedwatch Clinical Studies Experience,1,0.5291487574577332
NESINA,cutaneous adverse reactions,7 (1-877-8,1,0.4749796390533447
NESINA,cutaneous adverse reactions,or ww wfdagovmedwatch Clinical Studies,1,0.48510682582855225
NESINA,cutaneous adverse reactions,at 1-800-FDA-1088 or ww wfdagovmedwatch Clinical,1,0.5156634449958801
NESINA,cutaneous adverse reactions,FDA at 1-800-FDA-1088 or,1,0.5135934352874756
NESINA,Hepatic effects,cal trials of a drug cannot be directly compared,1,0.5115443468093872
NESINA,Hepatic effects,observed in the cal trials of a drug cannot be directly,1,0.5562695860862732
NESINA,Hepatic effects,trials of a drug,1,0.5752724409103394
NESINA,Hepatic effects,cal trials,1,0.45466381311416626
NESINA,Hepatic effects,in,0,0.495016872882843
NESINA,hepatic failure,directly mpared to rates in the clinical trials,1,0.5139703154563904
NESINA,hepatic failure,in,0,0.516455888748169
NESINA,hepatic failure,trials,0,0.5206271409988403
NESINA,hepatic failure,not reflect the rates,0,0.4149738550186157
NESINA,hepatic failure,drug cannot be directly mpared,1,0.5496704578399658
NESINA,hepatic failure,and may not reflect the rates observed in clinical,0,0.5198590755462646
NESINA,hepatic failure,drug,0,0.5374237298965454
NESINA,fatal,ical  trials,1,0.4854523837566376
NESINA,fatal,ical  trials of another,1,0.4900222420692444
NESINA,fatal,ical  trials of another drug,1,0.4799354076385498
NESINA,fatal,ical ,1,0.500049889087677
NESINA,fatal,rates in the ical  trials of,1,0.4717237949371338
NESINA,fatal,the ical  trials of another,1,0.49331024289131165
NESINA,fatal,ical  trials of,1,0.49049854278564453
NESINA,arthralgia,"farction,  had a history of unstable",1,0.5050044059753418
NESINA,arthralgia,"farction, ",1,0.5071247816085815
NESINA,arthralgia,had a,0,0.5121445655822754
NESINA,acute pancreatitis,placebocontrolled addon combination therapy,0,0.5036992430686951
NESINA,hypersensitivity reactions,metformin therapy ee active-controlled trial s of weeks in,1,0.49213969707489014
NESINA,hypersensitivity reactions,placebocontrolled addon combination therapy,0,0.5434545278549194
NESINA,hypersensitivity reactions,ee active-controlled trial s of weeks in,1,0.4805726706981659
NESINA,hypersensitivity reactions,s of,0,0.5201069712638855
NESINA,hypersensitivity reactions,background of metformin therapy ee active-controlled trial s of,1,0.5064072012901306
NESINA,hypersensitivity reactions,therapy ee active-controlled,1,0.5336595773696899
NESINA,hypersensitivity reactions,ee active-controlled trial s of weeks in duration,1,0.48846280574798584
NESINA,angioedema,itazone an d,1,0.5811979174613953
NESINA,angioedema,itazone an d metformin in combination,1,0.5290567874908447
NESINA,angioedema,treated with itazone an d metformin,1,0.5603839159011841
NESINA,angioedema,in patients treated with itazone an d metformin in combination,1,0.5300769209861755
NESINA,cutaneous adverse reactions,pooled analysis of,0,0.5174680352210999
NESINA,cutaneous adverse reactions,treated with pioglitazone and  in combination with metfor min and as monotherapy,1,0.5689418315887451
NESINA,cutaneous adverse reactions,in patients,0,0.5374137759208679
NESINA,cutaneous adverse reactions,treated with pioglitazone and  in combination with metfor min and as monotherapy compared,1,0.5711592435836792
NESINA,Stevens-Johnson syndrome,metformin and as onotherapy compared to g lipizide,1,0.5173541307449341
NESINA,Stevens-Johnson syndrome,in patients,0,0.5664889812469482
NESINA,Stevens-Johnson syndrome,with metformin and as onotherapy compared to g lipizide In,1,0.5256969928741455
NESINA,Stevens-Johnson syndrome,and as onotherapy compared,1,0.5141669511795044
NESINA,Stevens-Johnson syndrome,onotherapy,1,0.5591947436332703
NESINA,Stevens-Johnson syndrome,combination with metformin and,0,0.5268629789352417
NESINA,Stevens-Johnson syndrome,onotherapy compared to g lipizide In a,1,0.5434528589248657
NESINA,Stevens-Johnson syndrome,pioglitazone and metformin in combination with,0,0.49913063645362854
NESINA,Stevens-Johnson syndrome,as onotherapy compared,1,0.5246136784553528
NESINA,fatal,of patients treated with NESINA mg and,0,0.5126042366027832
NESINA,fatal,treated with NESINA mg more  frequently than in patients,1,0.4968871474266052
NESINA,fatal,more  frequently than in,1,0.4521329402923584
NESINA,hepatic failure,frequently n in patients w ho received placebo are summarized,1,0.4705742597579956
NESINA,hepatic failure,more  frequently than in,1,0.4753289222717285
NESINA,hepatic failure,in patients w ho,1,0.5429097414016724
NESINA,hepatic failure,frequently n in patients w ho received,1,0.5250166654586792
NESINA,hepatic failure,and more frequently n in,1,0.5113470554351807
NESINA,hepatic failure,Adverse reactions reported,0,0.5881128311157227
NESINA,hepatic failure,n in patients w ho received placebo are,1,0.47016656398773193
NESINA,hepatic failure,n in patients w ho received placebo are summarized,1,0.46989843249320984
NESINA,hepatic failure,more frequently tha,0,0.5039774775505066
NESINA,hepatic failure,summarized in Table Table Adverse Reactions Reported,0,0.6012126803398132
NESINA,hepatic failure,mg and more frequently,0,0.5130399465560913
NESINA,arthralgia,y comparin,1,0.47627970576286316
NESINA,arthralgia,did not increase the,0,0.4503011107444763
NESINA,arthralgia,placebo In a monotherapy y,1,0.5155755281448364
NESINA,arthralgia,NESINA to a sulfonylurea in elderly patients the incidence of hypoglycemia was with NESINA c,0,0.4566360116004944
NESINA,arthralgia,sulfonylurea in elderly patients the,0,0.4725574851036072
NESINA,arthralgia,a monotherapy y comparin g NESINA to a,1,0.5273184776306152
NESINA,arthralgia,monotherapy y comparin g NESINA to,1,0.5155195593833923
NESINA,arthralgia,y comparin g,1,0.4937968850135803
NESINA,arthralgia,compared to placebo,0,0.5073674917221069
EYLEA,Endophthalmitis,intraocular pressure,0,0.6954959034919739
EYLEA,Endophthalmitis,Endophthalmitis and retinal detachments Increased intraocular,1,0.8234700560569763
EYLEA,Endophthalmitis,Endophthalmitis,1,1.0
EYLEA,retinal detachments,retinal detachments,1,0.9999998807907104
EYLEA,retinal detachments,Endophthalmitis,1,0.6570596694946289
EYLEA,retinal detachments,retinal detachments Increased intraocular pressure,1,0.8398398160934448
EYLEA,retinal detachments,the labeling Endophthalmitis retinal detachments,1,0.8430079221725464
EYLEA,retinal detachments,section of the labeling,0,0.4677480459213257
EYLEA,retinal detachments,retinal detachments Increased intraocular pressure Thromboembolic,1,0.7940771579742432
EYLEA,retinal detachments,retinal detachments Increased intraocular,1,0.8862088918685913
EYLEA,retinal detachments,of the labeling Endophthalmitis retinal detachments,1,0.84271240234375
EYLEA,retinal detachments,the labeling Endophthalmitis,0,0.6142310500144958
EYLEA,retinal detachments,intraocular pressure Thromboembolic,0,0.618526816368103
EYLEA,Increased intraocular pressure,and retinal Increased,1,0.8030973076820374
EYLEA,Increased intraocular pressure,Endophthalmitis and retinal Increased intraocular pressure Thromboembolic,1,0.8227384090423584
EYLEA,Thromboembolic events,detachments Increased intraocular Thromboembolic,1,0.7599762678146362
EYLEA,conjunctival hemorrhage,receiving EYLEA conjunctival hemorrhage eye pain cataract vitreous floaters,1,0.8159568905830383
EYLEA,conjunctival hemorrhage,detachments Increased intraocular Thromboembolic,1,0.6996966600418091
EYLEA,conjunctival hemorrhage,receiving EYLEA conjunctival hemorrhage eye,1,0.8861192464828491
EYLEA,eye pain,conjunctival eye pain cataract,1,0.8505603075027466
EYLEA,eye pain,detachments Increased intraocular Thromboembolic,1,0.6660854816436768
EYLEA,eye pain,eye pain cataract vitreous,1,0.83351069688797
EYLEA,eye pain,reported in patients receiving EYLEA were conjunctival hemorrhage,0,0.6548441648483276
EYLEA,eye pain,reactions reported in,0,0.4627460539340973
EYLEA,eye pain,eye pain cataract vitreous floaters,1,0.7672581076622009
EYLEA,cataract,cataract vitreous floaters intraocular pressure,1,0.7140359282493591
EYLEA,cataract,receiving EYLEA,0,0.5118054151535034
EYLEA,cataract,increased and vitreous,0,0.6252967119216919
EYLEA,cataract,pain,0,0.6044435501098633
EYLEA,cataract,cataract,1,0.9999998807907104
EYLEA,cataract,cataract vitreous floaters,1,0.7422419190406799
EYLEA,cataract,vitreous detachment To report,0,0.5967000722885132
EYLEA,cataract,verse reactions reported in patients,0,0.5177147388458252
EYLEA,intraocular pressure increased,vitreous intraocular pressure increased and vitreous detachment,1,0.861611008644104
EYLEA,intraocular pressure increased,verse reactions reported in patients,0,0.533276379108429
EYLEA,intraocular pressure increased,eye pain cataract vitreous intraocular pressure increased,1,0.8571757078170776
EYLEA,vitreous detachment,increased vitreous detachment,1,0.9287972450256348
EYLEA,vitreous detachment,REACTIONS,0,0.4748809337615967
EYLEA,vitreous detachment,intraocular pressure increased vitreous,1,0.7843204736709595
EYLEA,vitreous detachment,conjunctival hemorrhage,0,0.6491302251815796
EYLEA,vitreous detachment,vitreous detachment To report SUSPECTED,1,0.8905878067016602
EYLEA,vitreous detachment,vitreous detachment To report SUSPECTED ADVERSE REACTIONS,1,0.8417962193489075
EYLEA,vitreous detachment,report SUSPECTED ADVERSE REACTIONS contact Regeneron at or,0,0.5189652442932129
EYLEA,vitreous detachment,report SUSPECTED ADVERSE REACTIONS contact,0,0.48115795850753784
EYLEA,vitreous detachment,increased,0,0.4583587646484375
EYLEA,endophthalmitis,endophthalmitis and retinal,1,0.8813212513923645
EYLEA,endophthalmitis,adverse reactions,0,0.5886196494102478
EYLEA,retinal detachment,retinal detachment The most common adverse,1,0.8852468729019165
EYLEA,retinal detachment,in of intravitreal,0,0.7226623296737671
EYLEA,retinal detachment,including endophthalmitis retinal detachment The most,1,0.8602795600891113
EYLEA,conjunctival hemorrhage,EYLEA conjunctival hemorrhage,1,0.8890433311462402
EYLEA,conjunctival hemorrhage,conjunctival hemorrhage eye pain,1,0.9222476482391357
EYLEA,conjunctival hemorrhage,The most common adverse reactions reported in patients receiving EYLEA,0,0.5473953485488892
EYLEA,conjunctival hemorrhage,conjunctival,1,0.8505813479423523
EYLEA,conjunctival hemorrhage,intraocular pressure,0,0.6860954761505127
EYLEA,conjunctival hemorrhage,receiving EYLEA conjunctival,1,0.7547178268432617
EYLEA,conjunctival hemorrhage,receiving EYLEA conjunctival hemorrhage,1,0.8836057186126709
EYLEA,eye pain,reported in patients receiving EYLEA were,0,0.524550199508667
EYLEA,eye pain,eye pain cataract vitreous floaters intraocular pressure,1,0.7731060981750488
EYLEA,eye pain,EYLEA were conjunctival eye pain,1,0.8576791286468506
EYLEA,eye pain,eye pain,1,0.9999999403953552
EYLEA,eye pain,receiving EYLEA were conjunctival eye pain cataract vitreous floaters intraocular,1,0.7569402456283569
EYLEA,eye pain,conjunctival eye pain,1,0.8920866250991821
EYLEA,cataract,cataract vitreous floaters intraocular pressure increased,1,0.7169904112815857
EYLEA,cataract,intraocular pressure increased,0,0.6232020854949951
EYLEA,vitreous floaters,pain vitreous,1,0.7905974388122559
EYLEA,vitreous floaters,in patients,0,0.5304149389266968
EYLEA,vitreous floaters,EYLEA were conjunctival hemorrhage eye pain,0,0.6125841736793518
EYLEA,vitreous floaters,conjunctival hemorrhage eye pain vitreous floaters,1,0.8532999753952026
EYLEA,vitreous floaters,and,0,0.4549718499183655
EYLEA,vitreous floaters,Wet AgeRelated Mac,0,0.5154027938842773
EYLEA,vitreous floaters,cataract,0,0.6206834316253662
EYLEA,vitreous floaters,pain vitreous floaters intraocular pressure increased,1,0.8658381104469299
EYLEA,intraocular pressure increased,vitreous intraocular pressure increased and,1,0.9035352468490601
EYLEA,intraocular pressure increased,cataract,0,0.6232020854949951
EYLEA,intraocular pressure increased,Neovascular Wet AgeRelated Macular Degeneration,0,0.635011613368988
EYLEA,intraocular pressure increased,cataract vitreous intraocular pressure increased and vitreous,1,0.8792270421981812
EYLEA,intraocular pressure increased,pressure increased,1,0.7370283603668213
EYLEA,intraocular pressure increased,vitreous,0,0.590691089630127
EYLEA,intraocular pressure increased,pressure increased and vitreous,1,0.8284704685211182
EYLEA,intraocular pressure increased,intraocular pressure,1,0.9121530652046204
EYLEA,intraocular pressure increased,floaters,0,0.5972155332565308
EYLEA,intraocular pressure increased,cataract vitreous,0,0.6263677477836609
EYLEA,vitreous detachment,vitreous detachment Neovascular Wet AgeRelated,1,0.8426820039749146
EYLEA,vitreous detachment,described below,0,0.4877052903175354
EYLEA,Conjunctival hemorrhage,Active Control Conjunctival hemorrhage Eye,1,0.87494295835495
EYLEA,Conjunctival hemorrhage,described below,0,0.502520740032196
EYLEA,Conjunctival hemorrhage,Conjunctival hemorrhage,1,1.0000001192092896
EYLEA,Conjunctival hemorrhage,Conjunctival hemorrhage Eye,1,0.976710319519043
EYLEA,Conjunctival hemorrhage,EYLEAN Active Control Conjunctival hemorrhage,1,0.862019419670105
EYLEA,Conjunctival hemorrhage,Active Control Conjunctival hemorrhage Eye pain,1,0.8434286117553711
EYLEA,Detachment of the retinal pigment epithelium,pithelium,0,0.4704524278640747
EYLEA,Detachment of the retinal pigment epithelium,Detachment of,1,0.6243628263473511
EYLEA,Detachment of the retinal pigment epithelium,retinal pigment epithelium Injection,1,0.8213189840316772
EYLEA,Detachment of the retinal pigment epithelium,the retinal pigment epithelium Injection,1,0.820788562297821
EYLEA,Detachment of the retinal pigment epithelium,retinal pigment epithelium Injection site pain,1,0.7820076942443848
EYLEA,Detachment of the retinal pigment epithelium,pithelium Detachment of the retinal pigment epithelium Injection site,1,0.8739427328109741
EYLEA,Detachment of the retinal pigment epithelium,Injection site,0,0.5036740899085999
EYLEA,Detachment of the retinal pigment epithelium,Detachment of the retinal pigment epithelium Injection,1,0.9184736013412476
EYLEA,Injection site pain,site pain Foreign,1,0.7392195463180542
EYLEA,Injection site pain,epithelium,0,0.5256765484809875
EYLEA,Injection site pain,retinal pigment Injection site pain,1,0.818231999874115
EYLEA,Foreign body sensation in eyes,site Foreign body sensation in eyes,1,0.9812261462211609
EYLEA,Foreign body sensation in eyes,site Foreign body sensation in,1,0.8347538709640503
EYLEA,Foreign body sensation in eyes,site Foreign body sensation in eyes Lacrimation,1,0.9337803721427917
EYLEA,Lacrimation increased,in Lacrimation increased Vision,1,0.9208809733390808
EYLEA,Lacrimation increased,site Foreign body sensation in,1,0.5457022190093994
EYLEA,Lacrimation increased,in Lacrimation,1,0.9125840663909912
EYLEA,Lacrimation increased,ody sensation in Lacrimation increased,1,0.9205213785171509
EYLEA,Lacrimation increased,Lacrimation increased Vision blurr,1,0.873934268951416
EYLEA,Lacrimation increased,Lacrimation increased Vision,1,0.9059339165687561
EYLEA,Retinal pigment epithelium tear,Injection site hemorrh,0,0.5577446222305298
EYLEA,Retinal pigment epithelium tear,ar Retinal pigment epithelium tear Injection site,1,0.876477837562561
EYLEA,Retinal pigment epithelium tear,inflammation,0,0.5694164037704468
EYLEA,Retinal pigment epithelium tear,ar,0,0.5023840665817261
EYLEA,Retinal pigment epithelium tear,Retinal pigment epithelium tear,1,1.0
EYLEA,Retinal pigment epithelium tear,epithelium tear,1,0.8575640320777893
EYLEA,Retinal pigment epithelium tear,epithelium tear Injection site hemorrh,1,0.7566964030265808
EYLEA,Injection site hemorrhage,igment epithelium Injection site hemorrhage Eyelid,1,0.7970904111862183
EYLEA,Injection site hemorrhage,epithelium tear Injection site hemorrh,1,0.829965353012085
EYLEA,Injection site hemorrhage,igment epithelium tear,0,0.6161246299743652
EYLEA,Injection site hemorrhage,Injection site hemorrhage Eyelid edema,1,0.8461205959320068
EYLEA,hypersensitivity,Macular Edema Following Retinal,0,0.5532591938972473
EYLEA,hypersensitivity,serious adverse reactions reported in of,0,0.6542860269546509
EYLEA,hypersensitivity,and endophthalmitis Macular Edema Following Retinal,0,0.558226466178894
EYLEA,hypersensitivity,hypersensitivity retinal detachment retinal,1,0.7628124952316284
EYLEA,hypersensitivity,hypersensitivity retinal detachment retinal tear,1,0.746686577796936
EYLEA,hypersensitivity,hypersensitivity,1,1.0
EYLEA,hypersensitivity,endophthalmitis Macular Edema Following Retinal Vei,0,0.5465531349182129
EYLEA,hypersensitivity,reactions reported in of the,0,0.6462116241455078
EYLEA,hypersensitivity,hypersensitivity retinal detachment,1,0.7824022769927979
EYLEA,retinal detachment,Retinal Vein Occlusion RVO,0,0.6999562382698059
EYLEA,retinal detachment,endophthalmitis Macular Edema Following Retinal,0,0.7346619367599487
EYLEA,retinal detachment,retinal detachment retinal tear and endophthalmitis Macular,1,0.8382984399795532
EYLEA,retinal tear,retinal retinal,1,0.7849422693252563
EYLEA,retinal tear,hypersensitivity retinal detachment,0,0.7918870449066162
EYLEA,retinal tear,EYLEA were hypersensitivity retinal retinal,1,0.749626636505127
EYLEA,retinal tear,retinal,0,0.815656304359436
EYLEA,endophthalmitis,endophthalmitis Macular Edema Following Retinal,1,0.8139182329177856
EYLEA,endophthalmitis,Vein Occlusion RVO The data,0,0.5051848888397217
EYLEA,endophthalmitis,endophthalmitis Macular,1,0.8716262578964233
EYLEA,endophthalmitis,RVO The data described below,0,0.4828045666217804
EYLEA,endophthalmitis,EYLEA,0,0.4884093999862671
EYLEA,Corneal epithelium defect,ressure increased,0,0.512086808681488
EYLEA,Corneal epithelium defect,epithelium defect Vitreous flo,1,0.795259952545166
EYLEA,Corneal epithelium defect,increased,0,0.4822078347206116
EYLEA,Corneal epithelium defect,Corneal epithelium defect,1,1.0
EYLEA,Corneal epithelium defect,Corneal epithelium defect Vitreous flo,1,0.8735710978507996
EYLEA,corneal edema,corneal edema retinal tear,1,0.8216911554336548
EYLEA,corneal edema,CRVO studies corneal,1,0.719916820526123
EYLEA,corneal edema,corneal edema retinal tear hypersensitivity and endophthalmitis,1,0.8243758678436279
EYLEA,corneal edema,corneal edema retinal tear hypersensitivity and,1,0.8487423658370972
EYLEA,corneal edema,with,0,0.5271859169006348
EYLEA,corneal edema,studies corneal edema,1,0.9241437911987305
EYLEA,corneal edema,studies corneal,1,0.779625654220581
EYLEA,corneal edema,Diabetic,0,0.5502783060073853
EYLEA,retinal tear,corneal retinal tear hypersensitivity,1,0.8168838620185852
EYLEA,retinal tear,Diabetic,0,0.5260541439056396
EYLEA,retinal tear,the CRVO,0,0.4853837192058563
EYLEA,retinal tear,studies were corneal retinal tear hypersensitivity and endophthalmitis,1,0.7603091597557068
EYLEA,retinal tear,retinal tear hypersensitivity and,1,0.8649880886077881
EYLEA,retinal tear,retinal tear hypersensitivity,1,0.8724569082260132
EYLEA,retinal tear,retinal tear,1,1.0
EYLEA,retinal tear,studies were corneal retinal tear hypersensitivity and,1,0.7872854471206665
EYLEA,retinal tear,CRVO studies,0,0.48706546425819397
EYLEA,hypersensitivity,hypersensitivity and endophthalmitis Diabetic Macular,1,0.7496222257614136
EYLEA,hypersensitivity,CRVO studies,0,0.4836276173591614
EYLEA,hypersensitivity,hypersensitivity and,1,0.9473000764846802
EYLEA,hypersensitivity,The,0,0.5452110767364502
EYLEA,hypersensitivity,were corneal edema retinal hypersensitivity and endophthalmitis Diabetic,1,0.6817811727523804
EYLEA,hypersensitivity,were corneal edema retinal hypersensitivity,1,0.7243525981903076
EYLEA,hypersensitivity,edema retinal hypersensitivity,1,0.7369679808616638
EYLEA,hypersensitivity,below reflect e,0,0.5313489437103271
EYLEA,hypersensitivity,hypersensitivity and endophthalmitis Diabetic,1,0.7538937330245972
EYLEA,hypersensitivity,Diabetic Macular Edema,0,0.5488284826278687
EYLEA,endophthalmitis,treated with EYLEA in the,0,0.5737641453742981
EYLEA,endophthalmitis,studies were corneal,0,0.6139087080955505
EYLEA,endophthalmitis,endophthalmitis,1,1.0
EYLEA,endophthalmitis,endophthalmitis Diabetic Macular Edema DME The,1,0.8088642954826355
EYLEA,endophthalmitis,in,0,0.5493949055671692
EYLEA,endophthalmitis,Diabetic Macular,0,0.6342257857322693
EYLEA,endophthalmitis,endophthalmitis Diabetic Macular Edema DME,1,0.8029161095619202
EYLEA,endophthalmitis,hypersensitivity endophthalmitis Diabetic Macular Edema DME The,1,0.7537158131599426
EYLEA,endophthalmitis,and,0,0.5385932922363281
EYLEA,Conjunctival hemorrhage,Conjunctival hemorrhage Eye pain,1,0.9222476482391357
EYLEA,Conjunctival hemorrhage,ControlN,0,0.49682140350341797
EYLEA,Conjunctival hemorrhage,EYLEAN ControlN EYLEAN Conjunctival,1,0.7470442652702332
EYLEA,Intraocular pressure increased,Intraocular pressure increased,1,1.0
EYLEA,Intraocular pressure increased,Intraocular pressure increased Ocular hyperemia,1,0.8581318855285645
EYLEA,Lacrimation increased,sensation,0,0.6236757636070251
EYLEA,Lacrimation increased,Lacrimation increased Vision b,1,0.905554473400116
EYLEA,Lacrimation increased,in Lacrimation increased,1,0.9907382130622864
EYLEA,retinal detachment,retinal tear corneal edema and injection site hemorrhage Immunogenicity As with al,0,0.6376922726631165
EYLEA,retinal detachment,were retinal detachment retinal,1,0.9542343616485596
EYLEA,retinal detachment,As with al,0,0.4325755834579468
EYLEA,retinal detachment,retinal detachment retinal,1,0.9336622357368469
EYLEA,retinal detachment,were retinal detachment,1,0.973802387714386
EYLEA,retinal detachment,were retinal detachment retinal tear corneal,1,0.8332298994064331
EYLEA,retinal detachment,treated with EYLEA were retinal detachment retinal tear corneal edema and,1,0.7585581541061401
EYLEA,retinal tear,injection site hemorrhage Immunogenicity As with all,0,0.5120516419410706
EYLEA,retinal tear,hypersensitivity retinal retinal tear corneal edema and injection site,1,0.7790716886520386
EYLEA,retinal tear,corneal edema and injection site hemorrhage Immunogenicity,0,0.5967933535575867
EYLEA,retinal tear,EYLEA were hypersensitivity retinal,0,0.7307913899421692
EYLEA,corneal edema,corneal edema and,1,0.9760429859161377
EYLEA,corneal edema,treated with EYLEA were hypersensitivity,0,0.5813415050506592
EYLEA,injection site hemorrhage,and,0,0.4275165796279907
EYLEA,injection site hemorrhage,injection site hemorrhage,1,1.0000001192092896
EYLEA,injection site hemorrhage,injection site hemorrhage Immunogenicity As with all therapeutic,1,0.8491050004959106
EYLEA,injection site hemorrhage,therapeutic proteins there is a,0,0.5297796130180359
EYLEA,injection site hemorrhage,with all therapeutic proteins there is,0,0.539684534072876
EYLEA,injection site hemorrhage,proteins there is a potential for an,0,0.49967995285987854
EYLEA,injection site hemorrhage,retinal tear corneal edema injection site hemorrhage Immunogenicity As,1,0.7749409675598145
EYLEA,Endophthalmitis,adverse eactions,1,0.5299929976463318
EYLEA,Endophthalmitis,are di scussed in greater detail in,1,0.5109322667121887
EYLEA,Endophthalmitis,scussed in greater detail in the Warnings and Precautions section of,0,0.5306727886199951
EYLEA,Endophthalmitis,are di scussed in greater,1,0.5381665229797363
EYLEA,Endophthalmitis,ADVERSE REACTIONS The following adverse r,0,0.5513101816177368
EYLEA,Endophthalmitis,The following adverse eactions are,1,0.5515909194946289
EYLEA,retinal detachments,in greater detai l in the,1,0.4865726828575134
EYLEA,retinal detachments,are ed in greater,1,0.48479124903678894
EYLEA,retinal detachments,The following adverse reactions are discuss,0,0.48955708742141724
EYLEA,retinal detachments,reactions are ed in,1,0.4635947644710541
EYLEA,retinal detachments,in the Warnings and Precautions section of the labeling,0,0.43951934576034546
EYLEA,Increases in intraocular pressure,EXCERPT The most common rse reactions,1,0.4990701675415039
EYLEA,Increases in intraocular pressure,common rse reactions (>=5%),1,0.49381589889526367
EYLEA,Increases in intraocular pressure,most common rse reactions (>=5%) reported in  patients receiving EYLEA,1,0.5443980693817139
EYLEA,arterial thromboembolic events,pain cataract vitreous,0,0.45232051610946655
EYLEA,arterial thromboembolic events,and vitr eous,1,0.5110977292060852
EYLEA,arterial thromboembolic events,"pain cataract vitreous floaters r pressure increased,",1,0.49444326758384705
EYLEA,arterial thromboembolic events,ADVERSE REACTIONS contact Regeneron,0,0.5286539793014526
EYLEA,arterial thromboembolic events,pain cataract vitreous floaters r pressure,1,0.4848180115222931
EYLEA,endophthalmitis,wwwfdagovmedwatch Clinical Trials,0,0.5279637575149536
EYLEA,endophthalmitis,"Clinical Trials perience

  Bec ause",1,0.5455173254013062
EYLEA,endophthalmitis,Trials perience Bec,1,0.4981306195259094
EYLEA,endophthalmitis,"or wwwfdagovmedwatch Clinical Trials perience

  Bec ause clinical trials",1,0.5456778407096863
EYLEA,endophthalmitis,"Trials perience

  Bec ause clinical trials are conducted",1,0.5325489044189453
EYLEA,endophthalmitis,or wwwfdagovmedwatch Clinical Trials perience Bec,1,0.5433548092842102
EYLEA,endophthalmitis,perience Bec ause clinical trials,1,0.55331951379776
EYLEA,endophthalmitis,"Clinical Trials perience

  Bec ause clinical trials",1,0.5378942489624023
EYLEA,endophthalmitis,wwwfdagovmedwatch Clinical Trials perience Bec,1,0.5390802621841431
EYLEA,retinal detachments,trials are conducted under widely varying conditions,1,0.4917687177658081
EYLEA,retinal detachments,in the clinical trials o,0,0.501069962978363
EYLEA,Acute increases in intraocular pressure,patients were d with the recommended dose of 2 mg. Se rious adverse reactions related to,1,0.5736762285232544
EYLEA,Acute increases in intraocular pressure,in the clinical trials o,0,0.5380107164382935
EYLEA,Acute increases in intraocular pressure,Among those patients were d with,1,0.5472264885902405
EYLEA,Acute increases in intraocular pressure,recommended dose of 2 mg. Se rious,1,0.5379104614257812
EYLEA,Acute increases in intraocular pressure,dose of 2 mg. Se rious,1,0.5323164463043213
EYLEA,Acute increases in intraocular pressure,2 mg. Se rious adverse reactions related,1,0.589042603969574
EYLEA,Sustained increases in intraocular pressure,of intravitreal injections with LEA including endophthalmitis and retinal d etachment,1,0.6766819953918457
EYLEA,Sustained increases in intraocular pressure,2 mg. Se rious adverse reactions related,1,0.5664185881614685
EYLEA,Sustained increases in intraocular pressure,procedure have occurred,0,0.516247570514679
EYLEA,Sustained increases in intraocular pressure,adverse reactions reported in patients receiving EYLEA were conjun,0,0.5897753238677979
EYLEA,Sustained increases in intraocular pressure,adverse reactions reported,0,0.5570794939994812
EYLEA,arterial thromboembolic events,with wet AMD including patients treated with,1,0.5261685848236084
EYLEA,arterial thromboembolic events,The data described below reflect exposure to EYLEA,0,0.5446674227714539
EYLEA,arterial thromboembolic events,in 1824 patients,1,0.5077682733535767
EYLEA,arterial thromboembolic events,Wet AgeRelated Macular Degeneration AMD The data described below reflect exposure,0,0.5551841855049133
EYLEA,arterial thromboembolic events,below reflect exposure to in,1,0.4991685450077057
EYLEA,arterial thromboembolic events,to in 1824 patients with,1,0.5487571954727173
EYLEA,arterial thromboembolic events,reflect exposure to  in 1824 patients with wet AMD including patients treated with,1,0.5252397060394287
EYLEA,arterial thromboembolic events,Degeneration AMD,0,0.49331846833229065
EYLEA,arterial thromboembolic events,The,0,0.4840357303619385
EYLEA,ATEs,incl uding,1,0.5694118142127991
EYLEA,ATEs,incl uding patients treated with the,1,0.4929758906364441
EYLEA,ATEs,with wet incl uding patients,1,0.49891555309295654
EYLEA,thromboembolic events,Reactions,0,0.5822972059249878
EYLEA,thromboembolic events,Vitreous detachment,0,0.47837886214256287
EYLEA,thromboembolic events,                      Vitreous floaters,1,0.5251966118812561
EYLEA,thromboembolic events,detachment,0,0.47898367047309875
EYLEA,thromboembolic events,Vitreous                      ,1,0.4715625047683716
EYLEA,thromboembolic events,                     ,1,0.6082335710525513
EYLEA,thromboembolic events,                      Vitreous,1,0.4715625047683716
TECFIDERA,Anaphylaxis,Progressive,0,0.5229572653770447
TECFIDERA,Anaphylaxis,described elsewhere in Anaphylaxis and Angioedema see,1,0.8436728119850159
TECFIDERA,Anaphylaxis,Anaphylaxis,1,0.9999999403953552
TECFIDERA,Anaphylaxis,Anaphylaxis and Angioedema see Warnings,1,0.8419051170349121
TECFIDERA,Anaphylaxis,in labeling,0,0.48469892144203186
TECFIDERA,Progressive multifocal leukoencephalopathy,Warnings and Precautions Lymphopenia see Warnings and,0,0.5843517780303955
TECFIDERA,Progressive multifocal leukoencephalopathy,see Warnings and Progressive,1,0.5864977836608887
TECFIDERA,Progressive multifocal leukoencephalopathy,and,0,0.46081656217575073
TECFIDERA,Progressive multifocal leukoencephalopathy,Warnings,0,0.5201483368873596
TECFIDERA,Lymphopenia,Lymphopenia see,1,0.971963107585907
TECFIDERA,Lymphopenia,Lymphopenia see Warnings,1,0.8962830305099487
TECFIDERA,Lymphopenia,leukoencephalopathy see Warnings and Lymphopenia see,1,0.8260579109191895
TECFIDERA,Lymphopenia,and,0,0.4855990409851074
TECFIDERA,Flushing,Flushing see Warnings,1,0.8571864366531372
TECFIDERA,Flushing,Lymphopenia see Warnings,0,0.5029392242431641
TECFIDERA,Flushing,Flushing see Warnings and Precautions EXCERPT,1,0.8051363229751587
TECFIDERA,Flushing,Flushing,1,1.0
TECFIDERA,flushing,diarrhea and nausea To report,0,0.5631930232048035
TECFIDERA,flushing,common,0,0.5338139533996582
TECFIDERA,flushing,flushing abdominal pain diarrhea,1,0.7608883380889893
TECFIDERA,flushing,flushing abdominal pain,1,0.78000807762146
TECFIDERA,abdominal pain,report,0,0.49081283807754517
TECFIDERA,abdominal pain,abdominal pain diarrhea and nausea,1,0.8494037985801697
TECFIDERA,diarrhea,abdominal diarrhea and nausea To report,1,0.7936248779296875
TECFIDERA,diarrhea,report,0,0.5893527269363403
TECFIDERA,diarrhea,To report SUSPECTED ADVERSE,0,0.5814003944396973
TECFIDERA,diarrhea,and placebo were flushing,0,0.6208806037902832
TECFIDERA,diarrhea,diarrhea,1,0.9999999403953552
TECFIDERA,diarrhea,diarrhea and,1,0.9006589651107788
TECFIDERA,nausea,nausea,1,1.0
TECFIDERA,nausea,contact Biogen,0,0.4779086112976074
TECFIDERA,nausea,nausea To report,1,0.8770608305931091
TECFIDERA,nausea,nausea To report SUSPECTED,1,0.8313741087913513
TECFIDERA,flushing,flushing abdominal pain diarrhea and nausea,1,0.7305363416671753
TECFIDERA,flushing,pain diarrhea and,0,0.5567845702171326
TECFIDERA,flushing,flushing abdominal pain diarrhea and,1,0.7550172209739685
TECFIDERA,flushing,diarrhea and nausea Adverse Reactions in PlaceboControlled,0,0.5180020928382874
TECFIDERA,flushing,for TECFIDERA flushing,1,0.8147672414779663
TECFIDERA,flushing,flushing,1,1.0
TECFIDERA,flushing,flushing abdominal,1,0.8424788117408752
TECFIDERA,flushing,and more than placebo,0,0.5290913581848145
TECFIDERA,flushing,diarrhea and nausea Adverse Reactions,0,0.5360999703407288
TECFIDERA,abdominal pain,were abdominal pain diarrhea and nausea Adverse Reactions,1,0.7638382315635681
TECFIDERA,abdominal pain,diarrhea and nausea Adverse Reactions,0,0.6137519478797913
TECFIDERA,diarrhea,diarrhea and nausea,1,0.8338501453399658
TECFIDERA,diarrhea,in PlaceboControlled Trials,0,0.5233971476554871
TECFIDERA,nausea,diarrhea nausea Adverse Reactions in PlaceboControlled Trials,1,0.725074052810669
TECFIDERA,nausea,in PlaceboControlled Trials,0,0.5675185918807983
TECFIDERA,GI events,Gastrointestinal TECFIDERA GI events,1,0.8384617567062378
TECFIDERA,GI events,TECFIDERA caused,0,0.4817332625389099
TECFIDERA,GI events,TECFIDERA GI,1,0.670754611492157
TECFIDERA,GI events,TECFIDERA GI events,1,0.8265963196754456
TECFIDERA,nausea,nausea vomiting diarrhea abdominal pain and,1,0.7896491289138794
TECFIDERA,nausea,The incidence,0,0.6181822419166565
TECFIDERA,nausea,caused,0,0.557212233543396
TECFIDERA,nausea,eg,0,0.5338753461837769
TECFIDERA,nausea,events nausea vomiting diarrhea abdominal pain and,1,0.7641045451164246
TECFIDERA,nausea,TECFIDERA caused GI events,0,0.6309263706207275
TECFIDERA,vomiting,vomiting diarrhea abdominal pain and dyspepsia,1,0.7717804312705994
TECFIDERA,vomiting,higher early in,0,0.5253074169158936
TECFIDERA,vomiting,events was higher,0,0.49772536754608154
TECFIDERA,vomiting,vomiting diarrhea abdominal pain,1,0.7925930023193359
TECFIDERA,vomiting,vomiting diarrhea abdominal,1,0.8366195559501648
TECFIDERA,vomiting,events eg vomiting diarrhea,1,0.819188117980957
TECFIDERA,vomiting,abdominal,0,0.6077465415000916
TECFIDERA,vomiting,higher,0,0.5002936720848083
TECFIDERA,diarrhea,diarrhea abdominal pain and dyspepsia The,1,0.8048418760299683
TECFIDERA,abdominal pain,and dyspepsia The incidence of,0,0.6262149810791016
TECFIDERA,abdominal pain,abdominal pain and dyspepsia The incidence of,1,0.7944844961166382
TECFIDERA,abdominal pain,abdominal pain and,1,0.957221269607544
TECFIDERA,abdominal pain,abdominal pain,1,0.9999998807907104
TECFIDERA,abdominal pain,caused GI events eg nausea vomiting,0,0.6661074757575989
TECFIDERA,abdominal pain,vomiting abdominal pain and dyspepsia,1,0.815748929977417
TECFIDERA,abdominal pain,vomiting abdominal pain,1,0.8816165924072266
TECFIDERA,abdominal pain,dyspepsia The incidence of GI events was higher early in the course,0,0.6438649892807007
TECFIDERA,dyspepsia,events was higher early in the,0,0.4679017663002014
TECFIDERA,dyspepsia,pain,0,0.6120443344116211
TECFIDERA,dyspepsia,pain dyspepsia The incidence of GI,1,0.7869426012039185
TECFIDERA,dyspepsia,diarrhea abdominal,0,0.6394678354263306
TECFIDERA,dyspepsia,incidence of GI events was higher early in the course of treatment primarily in month,0,0.6108828783035278
TECFIDERA,dyspepsia,dyspepsia The incidence of GI events,1,0.8227367401123047
TECFIDERA,dyspepsia,abdominal pain dyspepsia The incidence of,1,0.8080216646194458
TECFIDERA,GI events,dyspepsia The incidence GI events,1,0.7877707481384277
TECFIDERA,GI events,GI,1,0.8630253672599792
TECFIDERA,GI events,diarrhea abdominal pain and dyspepsia The incidence,0,0.6434046030044556
TECFIDERA,GI events,The incidence,0,0.5498881340026855
TECFIDERA,GI events,GI events was,1,0.9267964959144592
TECFIDERA,GI events,incidence GI,1,0.7896265983581543
TECFIDERA,GI events,primarily in month and usually decreased,0,0.5144468545913696
TECFIDERA,GI events,early in the course of treatment,0,0.49124544858932495
TECFIDERA,GI events,of,0,0.5099319219589233
TECFIDERA,gastrointestinal events,patients discontinued due gastrointestinal events,1,0.7799538373947144
TECFIDERA,gastrointestinal events,of,0,0.5151370167732239
TECFIDERA,gastrointestinal events,placebo patients discontinued due gastrointestinal events The incidence of,1,0.7437127232551575
TECFIDERA,gastrointestinal events,TECFIDERA Hepatic,0,0.548052966594696
TECFIDERA,gastrointestinal events,placebo,0,0.5698509812355042
TECFIDERA,gastrointestinal events,was,0,0.5235689878463745
TECFIDERA,gastrointestinal events,incidence of serious GI events was in,0,0.8209671974182129
TECFIDERA,gastrointestinal events,discontinued due gastrointestinal,1,0.7566688060760498
TECFIDERA,gastrointestinal events,due gastrointestinal,1,0.8229122757911682
TECFIDERA,gastrointestinal events,of placebo patients discontinued due,0,0.49982351064682007
TECFIDERA,gastrointestinal events,gastrointestinal events,1,1.0
TECFIDERA,GI events,in,0,0.5504751205444336
TECFIDERA,GI events,patients treated with,0,0.465590238571167
TECFIDERA,GI events,was in patients,0,0.4889466166496277
TECFIDERA,GI events,to gastrointestinal events The incidence of,0,0.7750978469848633
TECFIDERA,GI events,in patients treated with TECFIDERA Hepatic Transaminases An increased inciden,0,0.4990372061729431
TECFIDERA,Elevations of alanine aminotransferase,to times the ULN occurred in,0,0.55521559715271
TECFIDERA,Elevations of alanine aminotransferase,ULN,0,0.5325887203216553
TECFIDERA,Elevations of alanine aminotransferase,Elevations of alanine aminotransferase,1,0.9999999403953552
TECFIDERA,Elevations of alanine aminotransferase,upper limit of normal Elevations of alanine aminotransferase and aspartate aminotransferase,1,0.9161732196807861
TECFIDERA,Elevations of alanine aminotransferase,normal Elevations of alanine aminotransferase and aspartate,1,0.9194620847702026
TECFIDERA,Elevations of alanine aminotransferase,small,0,0.47717705368995667
TECFIDERA,Elevations of alanine aminotransferase,upper limit of,0,0.5743804574012756
TECFIDERA,Elevations of alanine aminotransferase,ULN occurred in a,0,0.57069993019104
TECFIDERA,elevations in transaminases,elevations in transaminases,1,0.9999999403953552
TECFIDERA,elevations in transaminases,There were elevations in transaminases,1,0.9810380935668945
TECFIDERA,elevations in transaminases,were elevations,1,0.5775328874588013
TECFIDERA,elevations in transaminases,elevations in transaminases times the ULN,1,0.9082362651824951
TECFIDERA,elevations in transaminases,in total bilirubin,0,0.6465908288955688
TECFIDERA,elevations in transaminases,were elevations in transaminases,1,0.9892624616622925
TECFIDERA,elevations in transaminases,and,0,0.4933133125305176
TECFIDERA,elevations in transaminases,groups There were elevations in,1,0.5708305239677429
TECFIDERA,elevations in transaminases,elevations in transaminases times the,1,0.9775010347366333
TECFIDERA,elevations in total bilirubin,elevations in,0,0.622485876083374
TECFIDERA,elevations in total bilirubin,the,0,0.5116437673568726
TECFIDERA,elevations in total bilirubin,elevations in total bilirubin times the,1,0.9811447858810425
TECFIDERA,elevations in total bilirubin,total bilirubin times,1,0.8440185189247131
TECFIDERA,elevations in total bilirubin,elevations,1,0.626146674156189
TECFIDERA,elevations in total bilirubin,total bilirubin times the ULN Discontinuations due,1,0.7927442789077759
TECFIDERA,elevations in total bilirubin,in total bilirubin,1,0.8991560339927673
TECFIDERA,elevations in total bilirubin,ULN with elevations in total bilirubin,1,0.8931554555892944
TECFIDERA,elevations in total bilirubin,hepatic transaminases were and were simila,0,0.6427825689315796
TECFIDERA,elevated hepatic transaminases,Discontinuations due elevated hepatic transaminases,1,0.8843115568161011
TECFIDERA,elevated hepatic transaminases,elevated hepatic transaminases were and,1,0.9826442003250122
TECFIDERA,elevated hepatic transaminases,elevated hepatic transaminases,1,1.0
TECFIDERA,increase in mean eosinophil counts,in patients treated with TECFIDERA or placebo Eosinophilia A transient,0,0.706299901008606
TECFIDERA,increase in mean eosinophil counts,or placebo Eosinophilia A increase in mean eosinophil counts was seen,1,0.9171204566955566
TECFIDERA,increase in mean eosinophil counts,TECFIDERA,0,0.47269731760025024
TECFIDERA,increase in mean eosinophil counts,increase in mean,1,0.7278299927711487
TECFIDERA,increase in mean eosinophil counts,A increase,1,0.6856780052185059
TECFIDERA,increase in mean eosinophil counts,A increase in mean eosinophil counts was,1,0.9899212121963501
TECFIDERA,increase in mean eosinophil counts,or placebo Eosinophilia A increase in mean eosinophil counts was seen during the,1,0.9135729074478149
TECFIDERA,Anaphylaxis,described elsewhere in labeling Anaphylaxis and Angioedema see Warnings,0,0.7999095916748047
TECFIDERA,Anaphylaxis,important dverse reac,1,0.5436750650405884
TECFIDERA,Anaphylaxis,important dverse,1,0.535595178604126
TECFIDERA,Anaphylaxis,dverse reac,1,0.4967649579048157
TECFIDERA,angioedema,Angioedema,0,1.000000238418579
TECFIDERA,angioedema,see Warnings,0,0.5229176878929138
TECFIDERA,angioedema,important adverse are,1,0.5730226039886475
TECFIDERA,angioedema,adverse  are descr ibed,1,0.6120445728302002
TECFIDERA,angioedema,adverse,0,0.5974486470222473
TECFIDERA,Progressive multifocal leukoencephalopathy,ssive multifocal leukoencephalopathy see,0,0.8914077877998352
TECFIDERA,Progressive multifocal leukoencephalopathy,and Angioedema,0,0.5457005500793457
TECFIDERA,Progressive multifocal leukoencephalopathy,and Precautions ( 5.1 )]. * Progre ssive multifocal,1,0.6194939613342285
TECFIDERA,Progressive multifocal leukoencephalopathy,"Angioedema see s and Precautions (  5.1  )].  
 *  Progre ssive",1,0.5243792533874512
TECFIDERA,Progressive multifocal leukoencephalopathy,Precautions,0,0.48006510734558105
TECFIDERA,Progressive multifocal leukoencephalopathy,leukoencephalopathy,0,0.8446725606918335
TECFIDERA,Progressive multifocal leukoencephalopathy,labeling Anaphylaxis and Angioedema see Warning,0,0.5072449445724487
TECFIDERA,Progressive multifocal leukoencephalopathy,dverse,0,0.49767541885375977
TECFIDERA,Progressive multifocal leukoencephalopathy,and Angioedema see,0,0.5512209534645081
TECFIDERA,Progressive multifocal leukoencephalopathy,described elsewhere in labeling Anaphylaxis and Angioedema see Warning,0,0.5076082944869995
TECFIDERA,PML,see,0,0.5422948002815247
TECFIDERA,PML,ive multifocal,1,0.5263963341712952
TECFIDERA,Lymphopenia,Lymph,0,0.758355975151062
TECFIDERA,Lymphopenia,Precautions Flushing,0,0.47793102264404297
TECFIDERA,Lymphopenia,Precautions openia [see,1,0.5050779581069946
TECFIDERA,Lymphopenia,Warnings and,0,0.5335805416107178
TECFIDERA,Lymphopenia,Warnings and Precautions openia [see Warnings and,1,0.5143690705299377
TECFIDERA,Lymphopenia,openia [see Warnings and,1,0.5004034638404846
TECFIDERA,Lymphopenia,openia [see Warnings and Precautions Flushing,1,0.4997016191482544
TECFIDERA,Lymphopenia,and Precautions,0,0.46807605028152466
TECFIDERA,Lymphopenia,Flushing,0,0.5100892782211304
TECFIDERA,angioedema,Biogen at or FDA -800-FDA-1 or wwwfdagovmedwatch Clinical Trials Experience,1,0.5219497680664062
TECFIDERA,angioedema,Flushing,0,0.6291743516921997
TECFIDERA,angioedema,-800-FDA-1,1,0.5120463967323303
TECFIDERA,angioedema,Experience Because clinical,0,0.5072921514511108
TECFIDERA,angioedema,-800-FDA-1 or wwwfdagovmedwatch Clinical Trials Experience,1,0.506231427192688
TECFIDERA,angioedema,at or FDA -800-FDA-1 or wwwfdagovmedwatch Clinical,1,0.49582183361053467
TECFIDERA,angioedema,Because clinical trials,0,0.5401692986488342
TECFIDERA,angioedema,Clinical Trials Experience Because clinical,0,0.5408716201782227
TECFIDERA,angioedema,-800-FDA-1 or wwwfdagovmedwatch Clinical,1,0.48871177434921265
TECFIDERA,angioedema,clinical,0,0.547964334487915
TECFIDERA,difficulty breathing,rates observed,0,0.4770090579986572
TECFIDERA,difficulty breathing,or wwwfdagovmedwatch Clinical Trials,0,0.5113279819488525
TECFIDERA,difficulty breathing,varying conditions adverse,0,0.6327219009399414
TECFIDERA,difficulty breathing,l trials are conduct ed,1,0.5087528228759766
TECFIDERA,difficulty breathing,Because l trials are conduct ed under widely varying conditions,1,0.5277493000030518
TECFIDERA,difficulty breathing,Experience Because clinica,0,0.5190039873123169
TECFIDERA,difficulty breathing,Because clinica,0,0.5096452832221985
TECFIDERA,difficulty breathing,l trials are conduct ed under widely,1,0.5237793922424316
TECFIDERA,swelling of the throat,"arying conditions, adv",1,0.5750292539596558
TECFIDERA,swelling of the throat,"under widely arying conditions,",1,0.4761177897453308
TECFIDERA,swelling of the throat,"arying conditions, adv erse reaction rates observed",1,0.4801332950592041
TECFIDERA,swelling of the throat,Because,0,0.4327332377433777
TECFIDERA,swelling of the throat,cannot be directly,0,0.47333401441574097
TECFIDERA,swelling of the throat,"arying conditions, adv erse",1,0.5928747653961182
TECFIDERA,swelling of the throat,"under widely arying conditions, adv erse reaction rates observed in",1,0.4884558916091919
TECFIDERA,swelling of the throat,"widely arying conditions, adv",1,0.5768411159515381
TECFIDERA,fatal,than placebo for TECFIDERA were,0,0.45778942108154297
TECFIDERA,fatal,ence  and,1,0.4789887070655823
TECFIDERA,fatal,ence  and more than,1,0.5067751407623291
TECFIDERA,progressive multifocal leukoencephalopathy,in PlaceboControlled Tr,0,0.49186497926712036
TECFIDERA,progressive multifocal leukoencephalopathy,reactions incidence and,0,0.5011314153671265
TECFIDERA,progressive multifocal leukoencephalopathy,than placebo) for TECFIDERA wer e flushing abdominal pain,1,0.4736791253089905
TECFIDERA,progressive multifocal leukoencephalopathy,more than placebo) for TECFIDERA wer e,1,0.5136325359344482
TECFIDERA,progressive multifocal leukoencephalopathy,diarrhea,0,0.5150604844093323
TECFIDERA,progressive multifocal leukoencephalopathy,The most common adverse reactions incidence and,0,0.49003535509109497
TECFIDERA,progressive multifocal leukoencephalopathy,in clinical,0,0.5117391347885132
TECFIDERA,progressive multifocal leukoencephalopathy,clinical practice The most common,0,0.4803105890750885
TECFIDERA,progressive multifocal leukoencephalopathy,common adverse reactions incidence,0,0.49391961097717285
TECFIDERA,PML,than placebo for TECFIDERA flu shing abdominal pain diarrhea,1,0.49736487865448
TECFIDERA,PML,common adverse reactions incidence,0,0.48001551628112793
TECFIDERA,PML,pain diarrhea and nausea Adverse Reactions in PlaceboControlled Trials,0,0.4936399757862091
TECFIDERA,PML,TECFIDERA,0,0.4515025019645691
TECFIDERA,PML,flu shing abdominal,1,0.5235162377357483
TECFIDERA,PML,diarrhea,0,0.5395447015762329
TECFIDERA,PML,than placebo for TECFIDERA flu shing abdominal pain,1,0.4918254613876343
TECFIDERA,PML,flu,1,0.5617589950561523
TECFIDERA,PML,common adverse reactions incidence and more than,0,0.48402243852615356
TECFIDERA,PML,flu shing abdominal pain diarrhea and,1,0.522199809551239
TECFIDERA,lymphopenia,ation from  patients treated with TECFIDERA,1,0.5401208996772766
TECFIDERA,lymphopenia,flu shing abdominal pain diarrhea and,1,0.5196769833564758
TECFIDERA,lymphopenia,TECFIDERA mg,0,0.49661487340927124
TECFIDERA,lymphopenia,twice a,0,0.5244021415710449
TECFIDERA,lymphopenia,in Study and ed for TECF IDERA mg BID,1,0.48217856884002686
TECFIDERA,lymphopenia,ed for TECF IDERA mg BID at higher,1,0.43917226791381836
TECFIDERA,lymphopenia,ed for TECF,1,0.5229486227035522
TECFIDERA,prolonged lymphopenia,caused GI events (e.g nausea vomiting diarrhea abdominal pain,1,0.5447937250137329
TECFIDERA,prolonged lymphopenia,Gastrointestinal caused GI events (e.g nausea vomiting diarrhea abdominal,1,0.5414242744445801
TECFIDERA,lymphocyte counts <0.5 x 10 9 /L,TECFIDERA and less,0,0.5696880221366882
TECFIDERA,lymphocyte counts <0.5 x 10 9 /L,compared with placebo Four percent of patients treated with TECFIDERA and less than,0,0.56435227394104
TECFIDERA,flushing,ansient  increase in mean,1,0.5789154171943665
TECFIDERA,flushing,ansient  increase in,1,0.558141827583313
TECFIDERA,warmth,in me an eosinophil,1,0.5039109587669373
TECFIDERA,warmth,seen during the first,0,0.5059307217597961
TECFIDERA,redness,in  eosino phil counts was seen during,1,0.5400668978691101
TECFIDERA,redness,seen during the first,0,0.5268287062644958
TECFIDERA,redness, eosino phil counts was seen during,1,0.5439128279685974
TECFIDERA,redness, eosino phil,1,0.6044845581054688
TECFIDERA,redness, eosino phil counts was,1,0.5157210826873779
TECFIDERA,redness,of,0,0.5188126564025879
TECFIDERA,redness,Adverse,0,0.5761650204658508
TECFIDERA,redness, eosino,1,0.6754406094551086
TECFIDERA,redness, eosino phil counts was seen,1,0.556981086730957
TECFIDERA,itching,or placebo Eosinophilia A transient increase in mean,0,0.6342875957489014
TECFIDERA,itching,il,1,0.5541950464248657
TECFIDERA,itching,in mean il coun,1,0.5401923656463623
TECFIDERA,itching,Reactions in PlaceboControlled an,0,0.6050901412963867
TECFIDERA,itching,mean il coun ts was,1,0.5479893684387207
TECFIDERA,itching,il coun,1,0.5139077305793762
TECFIDERA,itching,mean il coun ts was seen during,1,0.559895396232605
TECFIDERA,itching,il coun ts,1,0.5595829486846924
TECFIDERA,burning sensation,was en during the fir,1,0.5359570980072021
TECFIDERA,burning sensation,in PlaceboControlled and,0,0.5928588509559631
TECFIDERA,burning sensation,during the fir st months of therapy Adverse,1,0.5623716115951538
TECFIDERA,burning sensation,en during,1,0.5423609018325806
TECFIDERA,burning sensation,counts was en,1,0.4740496575832367
TECFIDERA,burning sensation,and Uncontrolled,0,0.4717663526535034
TECFIDERA,burning sensation,en during the fir st months,1,0.4929506182670593
TECFIDERA,burning sensation,counts was en during the fir st months of therapy,1,0.5192034244537354
TECFIDERA,flushing,Studies In placebocontrolled and,0,0.5281858444213867
TECFIDERA,flushing,ed and U,1,0.5331151485443115
TECFIDERA,flushing,therapy Adverse Reactions in ed and U,1,0.5521938800811768
TECFIDERA,flushing,Adverse Reactions in ed and U ncontrolled,1,0.5719088315963745
TECFIDERA,flushing,In placebocontrolled and uncontrolled clinical,0,0.5131219625473022
TECFIDERA,flushing,ed,1,0.5589288473129272
TECFIDERA,flushing,Reactions in ed and,1,0.5975916385650635
TECFIDERA,Flushing,in PlaceboControlled and ontrolle d Studies In placebocontrolled and,1,0.5282423496246338
TECFIDERA,Flushing,Reactions in ed and,1,0.5975916385650635
TECFIDERA,Flushing,ontrolle d Studies In placebocontrolled,1,0.540277898311615
TECFIDERA,Flushing,ontrolle d,1,0.5422884225845337
TECFIDERA,Flushing,in PlaceboControlled and ontrolle d,1,0.5439091324806213
TECFIDERA,Flushing,uncontrolled clinical,0,0.5102016925811768
TECFIDERA,Flushing,a total of patients,0,0.5116057991981506
TECFIDERA,Flushing,ontrolle d Studies In placebocontrolled and,1,0.5352505445480347
TECFIDERA,Flushing,ontrolle d Studies In,1,0.5386214256286621
TECFIDERA,Flushing,In placebocontrolled,0,0.536634087562561
TECFIDERA,flushing,and been followed for riods up,1,0.5522592067718506
TECFIDERA,flushing,In placebocontrolled,0,0.536634087562561
TECFIDERA,flushing,followed for riods up,1,0.5657241344451904
TECFIDERA,flushing,clinical studies a total,0,0.5195258855819702
TECFIDERA,flushing,exposure of personyears,0,0.5154237747192383
TECFIDERA,flushing,riods up to years,1,0.5049037933349609
TECFIDERA,flushing,been followed for riods up to,1,0.537806510925293
TECFIDERA,flushing,TECFIDERA and been followed for pe,0,0.5473359823226929
TECFIDERA,flushing,for pe,0,0.5164541006088257
TECFIDERA,flushing,placebo- controlled,1,0.5233619213104248
TECFIDERA,flushing,placebo- controlled clinical,1,0.506474494934082
TECFIDERA,flushing,with the experience in placebo-,1,0.5121177434921265
TECFIDERA,flushing,studies was consistent with the,0,0.5140014290809631
TECFIDERA,flushing,the experience in placebo- controlled clinical,1,0.508762001991272
TECFIDERA,flushing,controlled clinical,0,0.5225433111190796
TECFIDERA,flushing,placebo-,1,0.5426848530769348
TECFIDERA,flushing,controlled clinical trials,0,0.5120723247528076
TREANDA,Myelosuppression,Precautions Infections see Warnings and,0,0.5541388988494873
TREANDA,Infections,Infections see Warnings,1,0.8066917657852173
TREANDA,Infections,Infections,1,0.9999999403953552
TREANDA,Infections,see Warnings and Infections see Warnings and,1,0.751417875289917
TREANDA,Infusion Reactions,Precautions Anaphylaxis Infusion Reactions see Warnings and,1,0.846131443977356
TREANDA,Infusion Reactions,Infections,1,0.5553957223892212
TREANDA,Infusion Reactions,see,0,0.4884057641029358
TREANDA,Infusion Reactions,Precautions Anaphylaxis Infusion,1,0.8068434596061707
TREANDA,Infusion Reactions,and Precautions Anaphylaxis Infusion Reactions see Warnings and Precautions Tumor,1,0.7784239053726196
TREANDA,Infusion Reactions,see Warnings and Precautions Tumor Lysis Syndrome see Warnings and Precauti,0,0.6157297492027283
TREANDA,Infusion Reactions,and Precautions Anaphylaxis Infusion Reactions,1,0.8700969219207764
TREANDA,Infusion Reactions,Warnings and Precautions Anaphylaxis Infusion Reactions,1,0.8595030307769775
TREANDA,Tumor Lysis Syndrome,Lysis Syndrome see,1,0.8291302919387817
TREANDA,Skin Reactions,Skin Reactions see,1,0.978790819644928
TREANDA,Skin Reactions,Syndrome see Warnings and Precautions,0,0.6016350388526917
TREANDA,Malignancies,Malignancies see Warnings and Precautions Extravasation,1,0.7245175838470459
TREANDA,Extravasation injury,Warnings and Precautions,0,0.5276220440864563
TREANDA,Extravasation injury,Extravasation injury see Warnings,1,0.8897663354873657
TREANDA,pyrexia,nonhematologic adverse reactions,0,0.5826390981674194
TREANDA,pyrexia,pyrexia nausea,1,0.9049828052520752
TREANDA,pyrexia,reactions for CLL frequency pyrexia nausea,1,0.7421679496765137
TREANDA,pyrexia,CLL frequency pyrexia nausea and,1,0.7616108655929565
TREANDA,pyrexia,Most common nonhematologic adverse reactions for NHL,0,0.5433515906333923
TREANDA,pyrexia,pyrexia nausea and vomiting Most,1,0.8535844087600708
TREANDA,pyrexia,for CLL frequency pyrexia nausea,1,0.7671973705291748
TREANDA,nausea,nausea and vomiting Most common nonhematologic,1,0.7809586524963379
TREANDA,vomiting,pyrexia nausea vomiting Most common nonhematologic adverse,1,0.7294286489486694
TREANDA,vomiting,nausea and vomiting Most common nonhematologic,1,0.7892756462097168
TREANDA,nausea,nausea,1,1.0
TREANDA,nausea,nausea fatigue vomiting,1,0.8803701400756836
TREANDA,fatigue,fatigue vomiting,1,0.7956310510635376
TREANDA,fatigue,nausea,1,0.684320867061615
TREANDA,fatigue,nausea,0,0.684320867061615
TREANDA,fatigue,headache weight decreased,0,0.6058610081672668
TREANDA,fatigue,fatigue vomiting diarrhea pyrexia constipation anorexia,1,0.7718281149864197
TREANDA,fatigue,fatigue vomiting diarrhea pyrexia constipation,1,0.7757079601287842
TREANDA,fatigue,frequency are nausea,0,0.6538993716239929
TREANDA,fatigue,weight,0,0.6190299987792969
TREANDA,fatigue,adverse reactions for NHL frequency,0,0.5294700860977173
TREANDA,vomiting,anorexia,0,0.667826235294342
TREANDA,vomiting,vomiting diarrhea pyrexia constipation anorexia cough,1,0.8011655211448669
TREANDA,vomiting,vomiting diarrhea pyrexia constipation,1,0.8142476081848145
TREANDA,vomiting,are nausea vomiting diarrhea pyrexia constipation anorexia,1,0.7475857138633728
TREANDA,vomiting,nausea vomiting,1,0.9408671855926514
TREANDA,vomiting,nonhematologic adverse reactions for NHL frequency are nausea,0,0.6710795164108276
TREANDA,diarrhea,diarrhea pyrexia constipation,1,0.7710871696472168
TREANDA,diarrhea,nonhematologic adverse reactions for NHL frequency are nausea,0,0.5526570081710815
TREANDA,pyrexia,pyrexia constipation anorexia cough headache weight,1,0.7666157484054565
TREANDA,pyrexia,headache weight decreased dyspnea rash and,0,0.6090365052223206
TREANDA,pyrexia,reactions for NHL frequency are nausea fatigue vomiting,0,0.5990421772003174
TREANDA,pyrexia,dyspnea rash and,0,0.5859797596931458
TREANDA,pyrexia,nhematologic adverse reactions for NHL frequency are nausea fatigue vomiting,0,0.5815339088439941
TREANDA,pyrexia,pyrexia,1,1.0000001192092896
TREANDA,pyrexia,pyrexia constipation,1,0.8204981088638306
TREANDA,pyrexia,nausea fatigue vomiting pyrexia constipation anorexia,1,0.737846314907074
TREANDA,pyrexia,headache weight decreased dyspnea rash and stomatitis,0,0.607954204082489
TREANDA,constipation,are nausea fatigue vomiting diarrhea pyrexia,0,0.5926388502120972
TREANDA,constipation,weight decreased dyspnea rash,0,0.5776240825653076
TREANDA,constipation,constipation anorexia,1,0.8106367588043213
TREANDA,constipation,are nausea fatigue vomiting,0,0.5660226345062256
TREANDA,constipation,diarrhea pyrexia,0,0.5930417776107788
TREANDA,constipation,fatigue vomiting diarrhea constipation anorexia cough headache,1,0.7384341359138489
TREANDA,constipation,nausea fatigue vomiting diarrhea constipation,1,0.7672642469406128
TREANDA,constipation,for NHL frequency,0,0.45576488971710205
TREANDA,anorexia,anorexia cough headache weight,1,0.7712842226028442
TREANDA,anorexia,for NHL frequency,0,0.44903117418289185
TREANDA,anorexia,anorexia,1,1.0
TREANDA,anorexia,constipation,0,0.6557490229606628
TREANDA,anorexia,pyrexia,0,0.6030768156051636
TREANDA,anorexia,NHL,0,0.4400267004966736
TREANDA,headache,constipation,0,0.6022411584854126
TREANDA,headache,headache weight decreased,1,0.8116089105606079
TREANDA,headache,dyspnea rash,0,0.4949836730957031
TREANDA,headache,constipation anorexia headache weight,1,0.6981477737426758
TREANDA,headache,Most common hematologic,0,0.4970463514328003
TREANDA,headache,headache weight decreased dyspnea rash,1,0.7347999811172485
TREANDA,headache,headache weight decreased dyspnea,1,0.7545300126075745
TREANDA,headache,vomiting,0,0.6014151573181152
TREANDA,weight decreased,anorexia cough weight decreased dyspnea rash and stomatitis,1,0.668326735496521
TREANDA,weight decreased,constipation,0,0.5610760450363159
TREANDA,weight decreased,pyrexia constipation anorexia cough weight decreased,1,0.7734706401824951
TREANDA,weight decreased,abnormalities for,0,0.511490523815155
TREANDA,weight decreased,weight decreased dyspnea rash and,1,0.7300584316253662
TREANDA,weight decreased,pyrexia constipation anorexia cough weight decreased dyspnea,1,0.7053817510604858
TREANDA,weight decreased,pyrexia constipation anorexia cough weight decreased dyspnea rash and stomatitis,1,0.6796510815620422
TREANDA,weight decreased,common,0,0.4636166989803314
TREANDA,weight decreased,weight decreased dyspnea,1,0.7871309518814087
TREANDA,weight decreased,cough weight,1,0.6697361469268799
TREANDA,rash,cough headache weight decreased rash and stomatitis,1,0.6982830762863159
TREANDA,rash,cough weight,1,0.5107930898666382
TREANDA,rash,vomiting diarrhea pyrexia constipation anorexia cough headache weight decreased dyspnea,0,0.5347433686256409
TREANDA,rash,weight decreased rash and stomatitis Most,1,0.7080219388008118
TREANDA,rash,decreased rash and stomatitis Most common,1,0.7172650098800659
TREANDA,stomatitis,weight decreased dyspnea rash stomatitis Most common hematologic abnormalities for,1,0.6641542911529541
TREANDA,stomatitis,vomiting diarrhea pyrexia constipation anorexia cough headache weight decreased dyspnea,0,0.4825463891029358
TREANDA,stomatitis,stomatitis,1,1.0
TREANDA,stomatitis,common hematologic abnormalities for both indications frequency,0,0.4674864411354065
TREANDA,stomatitis,stomatitis Most common hematologic abnormalities for,1,0.7700201869010925
TREANDA,stomatitis,stomatitis Most,1,0.877737283706665
TREANDA,stomatitis,hematologic abnormalities,0,0.4980928301811218
TREANDA,stomatitis,rash stomatitis,1,0.847495436668396
TREANDA,stomatitis,weight decreased dyspnea rash and,0,0.48975229263305664
TREANDA,stomatitis,both,0,0.46401283144950867
TREANDA,hematologic abnormalities,frequency are,0,0.5110333561897278
TREANDA,hematologic abnormalities,rash and stomatitis Most hematologic,1,0.7475358247756958
TREANDA,hematologic abnormalities,hematologic abnormalities for both,1,0.9315601587295532
TREANDA,hematologic abnormalities,leukopenia thrombocytopenia and,0,0.6981906890869141
TREANDA,hematologic abnormalities,and stomatitis Most hematologic abnormalities,1,0.8541637659072876
TREANDA,lymphopenia,abnormalities for both,0,0.5823734998703003
TREANDA,lymphopenia,lymphopenia anemia leukopenia,1,0.8813696503639221
TREANDA,lymphopenia,neutropenia EXCERPT To,0,0.6099838018417358
TREANDA,lymphopenia,lymphopenia anemia leukopenia thrombocytopenia,1,0.8584824800491333
TREANDA,lymphopenia,lymphopenia anemia leukopenia thrombocytopenia and neutropenia,1,0.8441605567932129
TREANDA,lymphopenia,and neutropenia,0,0.640899658203125
TREANDA,lymphopenia,lymphopenia anemia leukopenia thrombocytopenia and,1,0.8524788618087769
TREANDA,lymphopenia,both,0,0.49779704213142395
TREANDA,anemia,and neutropenia EXCERPT,0,0.6966063380241394
TREANDA,anemia,thrombocytopenia and neutropenia EXCERPT To report SUSPECTED A,0,0.6708296537399292
TREANDA,thrombocytopenia,thrombocytopenia and neutropenia EXCERPT To,1,0.8598955869674683
TREANDA,thrombocytopenia,frequency are lymphopenia anemia thrombocytopenia and,1,0.7850497961044312
TREANDA,thrombocytopenia,thrombocytopenia and neutropenia EXCERPT,1,0.8641150593757629
TREANDA,thrombocytopenia,thrombocytopenia and neutropenia,1,0.8865814208984375
TREANDA,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
TREANDA,thrombocytopenia,thrombocytopenia and neutropenia EXCERPT To report,1,0.8506203889846802
TREANDA,neutropenia,neutropenia EXCERPT,1,0.9186868071556091
TREANDA,neutropenia,neutropenia EXCERPT To report SUSPECTED,1,0.8519668579101562
TREANDA,neutropenia,anemia leukopenia thrombocytopenia neutropenia EXCERPT To report,1,0.790399432182312
TREANDA,neutropenia,SUSPECTED ADVERSE REACTIONS,0,0.5399051904678345
TREANDA,neutropenia,neutropenia EXCERPT To,1,0.9048851132392883
TREANDA,neutropenia,anemia leukopenia,0,0.7416390776634216
TREANDA,pyrexia,one or mo,0,0.5169106721878052
TREANDA,pyrexia,greater than pyrexia nausea and vomiting,1,0.8352185487747192
TREANDA,pyrexia,a frequency greater than pyrexia nausea,1,0.8161701560020447
TREANDA,nausea,frequency,0,0.5145185589790344
TREANDA,nausea,a frequency greater than were,0,0.5012378096580505
TREANDA,nausea,were nausea and,1,0.9364908933639526
TREANDA,vomiting,were pyrexia nausea vomiting Other,1,0.8061577081680298
TREANDA,vomiting,a frequency greater than were,0,0.4887391924858093
TREANDA,vomiting,or more,0,0.4998316466808319
TREANDA,asthenia,asthenia,1,1.0000001192092896
TREANDA,asthenia,asthenia fatigue,1,0.8543986082077026
TREANDA,asthenia,or more studies,0,0.5414274334907532
TREANDA,fatigue,fatigue malaise and weakness dry,1,0.8113574385643005
TREANDA,fatigue,or more studies included asthenia,0,0.5989841222763062
TREANDA,fatigue,mouth somnolence cough constipation headache mucosal inflammation,0,0.616806149482727
TREANDA,fatigue,more studies included fatigue malaise,1,0.7975883483886719
TREANDA,fatigue,weakness dry mouth somnolence cough constipation,0,0.6918220520019531
TREANDA,fatigue,fatigue malaise and,1,0.8720666170120239
TREANDA,fatigue,included fatigue malaise and,1,0.8537027835845947
TREANDA,malaise,headache mucosal inflammation and,0,0.5534701347351074
TREANDA,malaise,fatigue,0,0.6166409254074097
TREANDA,malaise,mucosal inflammation and,0,0.5125948786735535
TREANDA,weakness,weakness dry mouth somnolence cough constipation,1,0.7214505076408386
TREANDA,weakness,somnolence cough constipation headache mucosal inflammation,0,0.545610785484314
TREANDA,dry mouth,dry mouth,1,1.0
TREANDA,dry mouth,somnolence cough constipation headache mucosal inflammation,0,0.625959575176239
TREANDA,dry mouth,weakness,0,0.5686275959014893
TREANDA,dry mouth,dry mouth somnolence,1,0.8827464580535889
TREANDA,dry mouth,dry mouth somnolence cough constipation headache,1,0.7949924468994141
TREANDA,somnolence,frequently in one or more studies,0,0.529302179813385
TREANDA,somnolence,mucosal inflammation and,0,0.4917062520980835
TREANDA,cough,included asthenia fatigue,0,0.5805550813674927
TREANDA,cough,fatigue,0,0.6278507709503174
TREANDA,constipation,and stomatitis Worsening hypertension was reported,0,0.554099977016449
TREANDA,headache,cough headache mucosal inflammation and stomatitis,1,0.7149592638015747
TREANDA,headache,and stomatitis Worsening hypertension was reported,0,0.5515784025192261
TREANDA,headache,mouth somnolence cough headache,1,0.7566213607788086
TREANDA,headache,was reported in patients treate,0,0.5570418238639832
TREANDA,headache,mouth somnolence cough headache mucosal inflammation and stomatitis Worsening,1,0.6680028438568115
TREANDA,headache,hypertension was reported in,0,0.5766301155090332
TREANDA,headache,mouth somnolence cough headache mucosal inflammation and stomatitis,1,0.6763045787811279
TREANDA,headache,headache,1,0.9999998807907104
TREANDA,headache,cough headache mucosal,1,0.7508804202079773
TREANDA,mucosal inflammation,mucosal inflammation and,1,0.9673401117324829
TREANDA,mucosal inflammation,mucosal inflammation and stomatitis Worsening,1,0.8616483211517334
TREANDA,mucosal inflammation,mucosal inflammation,1,1.0
TREANDA,mucosal inflammation,reported in patients,0,0.5415932536125183
TREANDA,mucosal inflammation,mucosal inflammation and stomatitis Worsening hypertension,1,0.793236494064331
TREANDA,stomatitis,stomatitis Worsening hypertension was reported,1,0.7845361232757568
TREANDA,stomatitis,stomatitis Worsening hypertension,1,0.8024429678916931
TREANDA,stomatitis,inflammation,0,0.6345037221908569
TREANDA,stomatitis,and,0,0.4686421751976013
TREANDA,stomatitis,stomatitis Worsening hypertension was reported in,1,0.7824519872665405
TREANDA,stomatitis,constipation headache mucosal inflammation stomatitis Worsening,1,0.7472790479660034
TREANDA,Worsening hypertension,Worsening hypertension was reported,1,0.950586199760437
TREANDA,hypersensitivity,leading to study withdrawal for patients receiving TREANDA,0,0.5067344903945923
TREANDA,hypersensitivity,were,0,0.4843417704105377
TREANDA,hypersensitivity,contains the treatment emergent adverse,0,0.5812377333641052
TREANDA,hypersensitivity,pyrexia Table contains the treatment emergent adverse reactions,0,0.630010187625885
TREANDA,hypersensitivity,hypersensitivity and pyrexia Table contains the,1,0.7836039066314697
TREANDA,hypersensitivity,patients receiving TREANDA hypersensitivity and pyrexia,1,0.7341768741607666
TREANDA,hypersensitivity,receiving TREANDA hypersensitivity and pyrexia Table contains the,1,0.7321548461914062
TREANDA,hypersensitivity,hypersensitivity,1,1.0
TREANDA,hypersensitivity,receiving TREANDA hypersensitivity and pyrexia,1,0.7569582462310791
TREANDA,pyrexia,pyrexia Table contains,1,0.8877492547035217
TREANDA,pyrexia,pyrexia Table contains the treatment,1,0.8365667462348938
TREANDA,pyrexia,were,0,0.5141094923019409
TREANDA,pyrexia,emergent adverse reactions regardless of,0,0.606334388256073
TREANDA,pyrexia,Table contains the treatment emergent adverse reactions regardless of,0,0.5665165185928345
TREANDA,pyrexia,TREANDA were hypersensitivity pyrexia Table contains the treatment,1,0.782163143157959
TREANDA,pyrexia,receiving TREANDA were hypersensitivity pyrexia,1,0.775524377822876
TREANDA,myelosuppressive effects,myelosuppressive effects seen in patients treated with,1,0.9451815485954285
TREANDA,myelosuppressive effects,confirm myelosuppressive effects,1,0.9398139715194702
TREANDA,myelosuppressive effects,Table These findings confirm myelosuppressive,1,0.857761025428772
TREANDA,Hemoglobin Decreased,Grade n,0,0.4843018054962158
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased,1,0.9999999403953552
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased Platelets Decreased,1,0.9125480651855469
TREANDA,Platelets Decreased,Platelets Decreased Leukocytes,1,0.8841133117675781
TREANDA,Platelets Decreased,Hemoglobin Decreased Platelets Decreased,1,0.8827672004699707
TREANDA,Leukocytes Decreased,Leukocytes,1,0.8547206521034241
TREANDA,Leukocytes Decreased,Leukocytes Decreased Lymphocytes,1,0.9374855160713196
TREANDA,Leukocytes Decreased,Leukocytes Decreased,1,1.0
TREANDA,Leukocytes Decreased,Leukocytes Decreased Lymphocytes Decreased,1,0.9500919580459595
TREANDA,Leukocytes Decreased,Platelets Decreased,0,0.7895282506942749
TREANDA,Leukocytes Decreased,Decreased,0,0.7512873411178589
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased Neutrophils Decreased,1,0.9036984443664551
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased Neutrophils,1,0.8806977272033691
TREANDA,Lymphocytes Decreased,Leukocytes Lymphocytes,1,0.7677794694900513
TREANDA,bilirubin elevations,bilirubin elevations,1,0.9999998807907104
TREANDA,bilirubin elevations,trial of patients bilirubin,1,0.8033413290977478
TREANDA,bilirubin elevations,CLL trial of patients bilirubin elevations some without,1,0.8181076049804688
TREANDA,bilirubin elevations,of patients bilirubin,1,0.8431431651115417
TREANDA,bilirubin elevations,of patients bilirubin elevations some without associated significant,1,0.9012483358383179
TREANDA,bilirubin elevations,CLL,0,0.5032931566238403
TREANDA,bilirubin elevations,of patients bilirubin elevations some without associated significant elevations,1,0.8976871371269226
TREANDA,bilirubin elevations,patients bilirubin elevations some without associated significant elevations,1,0.9003872871398926
TREANDA,bilirubin elevations,CLL trial of patients bilirubin elevations,1,0.8231289386749268
TREANDA,elevations in AST,associated elevations,1,0.794293999671936
TREANDA,elevations in AST,elevations in AST and ALT Grade or increased,1,0.8479264974594116
TREANDA,increased bilirubin,increased bilirubin occurred in of,1,0.9647995829582214
TREANDA,increased bilirubin,AST and ALT Grade increased bilirubin,1,0.879453718662262
TREANDA,increased bilirubin,and ALT Grade increased,1,0.6082735061645508
TREANDA,increased bilirubin,AST and ALT Grade increased bilirubin occurred in of,1,0.8894184231758118
TREANDA,increased bilirubin,increased bilirubin,1,0.9999999403953552
TREANDA,increased bilirubin,increased bilirubin occurred in,1,0.9692555665969849
TREANDA,increased bilirubin,in of patients Increases in AST and ALT of,0,0.644812822341919
TREANDA,Increases in AST,Increases in AST and ALT of Grade or,1,0.8841733932495117
TREANDA,Increases in AST,Grade or increased,0,0.699694037437439
TREANDA,Increases in AST,in,0,0.550361692905426
TREANDA,Increases in AST,bilirubin occurred in of Increases in AST,1,0.8443578481674194
TREANDA,Increases in AST,occurred in of Increases in,1,0.7665650248527527
TREANDA,nausea,nonhematologic adverse reactions nausea fatigue vomiting diarrhea and,1,0.7307915687561035
TREANDA,nausea,occurred in of Increases in,1,0.5469933748245239
TREANDA,nausea,The most,0,0.49588459730148315
TREANDA,nausea,most common nonhemato,0,0.5141575336456299
TREANDA,nausea,nonhematologic adverse reactions nausea fatigue vomiting diarrhea and pyrexia,1,0.7350693345069885
TREANDA,nausea,nausea fatigue,1,0.8767740726470947
TREANDA,nausea,were,0,0.524542510509491
TREANDA,fatigue,fatigue vomiting diarrhea and,1,0.7518984079360962
TREANDA,fatigue,fatigue vomiting diarrhea,1,0.7457631826400757
TREANDA,fatigue,common nonhematologic,0,0.5537259578704834
TREANDA,fatigue,fatigue vomiting diarrhea and pyrexia The,1,0.7532347440719604
TREANDA,vomiting,vomiting diarrhea and pyrexia,1,0.8176817893981934
TREANDA,vomiting,vomiting,1,0.9999999403953552
TREANDA,vomiting,fatigue,0,0.539206326007843
TREANDA,vomiting,vomiting diarrhea and pyrexia The most,1,0.8013476729393005
TREANDA,diarrhea,fatigue diarrhea and pyrexia The,1,0.7538406848907471
TREANDA,diarrhea,vomiting diarrhea and pyrexia The most,1,0.7577837705612183
TREANDA,diarrhea,diarrhea,1,0.9999999403953552
TREANDA,diarrhea,were nausea fatigue diarrhea,1,0.7523813843727112
TREANDA,diarrhea,diarrhea and pyrexia The,1,0.7974404096603394
TREANDA,diarrhea,reactions were nausea fatigue,0,0.5795634984970093
TREANDA,diarrhea,diarrhea and pyrexia,1,0.8029703497886658
TREANDA,diarrhea,nausea,0,0.6490728855133057
TREANDA,pyrexia,common nonhematologic Grade or,0,0.557576060295105
TREANDA,pyrexia,adverse reactions were nausea fatigue vomiting diarrhea and,0,0.587893545627594
TREANDA,pyrexia,reactions were nausea fatigue vomiting diarrhea,0,0.6009502410888672
TREANDA,pyrexia,reactions,0,0.5825496912002563
TREANDA,pyrexia,vomiting diarrhea pyrexia The most common nonhematologic,1,0.7543043494224548
TREANDA,pyrexia,The most common nonhematologic Grade or adverse reactions were,0,0.5625236630439758
TREANDA,fatigue,febrile neutropenia and pneumonia,0,0.5436635613441467
TREANDA,fatigue,fatigue febrile neutropenia and,1,0.7895535230636597
TREANDA,fatigue,fatigue,1,1.0
TREANDA,febrile neutropenia,febrile,1,0.8051060438156128
TREANDA,febrile neutropenia,febrile neutropenia,1,1.0000001192092896
TREANDA,febrile neutropenia,and pneumonia hypokalemia and dehydration each,0,0.5984028577804565
TREANDA,febrile neutropenia,The most common nonhematologic Grade or adverse reactions were,0,0.5812637209892273
TREANDA,febrile neutropenia,adverse reactions were febrile neutropenia and,1,0.8770990371704102
TREANDA,febrile neutropenia,and pneumonia hypokalemia and,0,0.5791130065917969
TREANDA,pneumonia,pneumonia hypokalemia and dehydration each reported,1,0.7038193345069885
TREANDA,pneumonia,febrile neutropenia pneumonia hypokalemia and,1,0.6926554441452026
TREANDA,pneumonia,neutropenia pneumonia hypokalemia and dehydration each reported,1,0.6713793277740479
TREANDA,pneumonia,and dehydration each reported in,0,0.5436020493507385
TREANDA,pneumonia,fatigue febrile,0,0.6094212532043457
TREANDA,pneumonia,dehydration each reported in of patients Table,0,0.5083444714546204
TREANDA,hypokalemia,were fatigue febrile neutropenia and pneumonia,0,0.4734550714492798
TREANDA,dehydration,dehydration,1,1.0
TREANDA,dehydration,pneumonia hypokalemia dehydration each reported in of,1,0.7691982984542847
TREANDA,dehydration,dehydration each reported in of patients,1,0.863990068435669
TREANDA,dehydration,neutropenia and pneumonia hypokalemia and,0,0.5798317193984985
TREANDA,dehydration,dehydration each reported in of,1,0.8924335837364197
TREANDA,dehydration,dehydration each reported in,1,0.8943236470222473
TREANDA,Abdominal distension,Abdominal distension,1,1.0000001192092896
TREANDA,Abdominal distension,Abdominal distension General disorder,1,0.9093731641769409
TREANDA,Abdominal distension,l pain upper,0,0.6202490925788879
TREANDA,Abdominal distension,pain Abdominal distension General,1,0.9263108968734741
TREANDA,Abdominal distension,l pain Abdominal distension,1,0.9504255056381226
TREANDA,Hematologic toxicities,system organ class Hematologic,1,0.7415792942047119
TREANDA,Hematologic toxicities,values and CTC grade in NHL patients,0,0.6291454434394836
TREANDA,Hematologic toxicities,in each,0,0.5191728472709656
TREANDA,Hematologic toxicities,each system organ class Hematologic toxicities based on laboratory values,1,0.8692675828933716
TREANDA,Hematologic toxicities,nly once in each preferred term category and once,0,0.49868637323379517
TREANDA,Hematologic toxicities,each system organ class Hematologic toxicities,1,0.8930317163467407
TREANDA,Hematologic toxicities,once in each preferred term category and once in each system organ,0,0.5453570485115051
TREANDA,Hematologic toxicities,on laboratory values and CTC grade in NHL patients treated in both single arm,0,0.6396911144256592
TREANDA,Hematologic toxicities,organ class Hematologic toxicities based on laboratory values and,1,0.8819459676742554
TREANDA,hyperglycemia,at,0,0.5464295148849487
TREANDA,hyperglycemia,hyperglycemia elevated creatinine hyponatremia,1,0.7845392227172852
TREANDA,hyperglycemia,hyperglycemia elevated creatinine,1,0.8136603832244873
TREANDA,elevated creatinine,were elevated creatinine hyponatremia and hypocalcemia Table Incidence,1,0.7808005809783936
TREANDA,elevated creatinine,hyperglycemia elevated creatinine,1,0.9053372144699097
TREANDA,elevated creatinine,elevated creatinine hyponatremia and hypocalcemia Table Incidence,1,0.792337954044342
TREANDA,elevated creatinine,combined were elevated creatinine hyponatremia,1,0.8489359617233276
TREANDA,hyponatremia,elevated hyponatremia and hypocalcemia,1,0.8357012271881104
TREANDA,hyponatremia,elevated creatinine hyponatremia and hypocalcemia Table Incidence,1,0.7612442374229431
TREANDA,hyponatremia,hyponatremia and hypocalcemia Table,1,0.8292670249938965
TREANDA,hypocalcemia,hypocalcemia Table,1,0.8883441090583801
TREANDA,hypocalcemia,hyponatremia and hypocalcemia Table,1,0.8347072601318359
TREANDA,hypocalcemia,arm studies combined were hyperglycemia,0,0.5442948341369629
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased,1,0.9999998807907104
TREANDA,Lymphocytes Decreased,patients Hematology variable All Grades,0,0.5929554104804993
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased Leukocytes Decreased Hemog,1,0.8667114973068237
TREANDA,Lymphocytes Decreased,variable All Grades Lymphocytes Decreased,1,0.867855429649353
TREANDA,Lymphocytes Decreased,Percent,0,0.5098986625671387
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased Leukocytes,1,0.9221651554107666
TREANDA,Lymphocytes Decreased,Leukocytes,0,0.7006601691246033
TREANDA,Lymphocytes Decreased,Grades Lymphocytes Decreased Leukocytes,1,0.8736695051193237
TREANDA,Leukocytes Decreased,Hemoglobin Decreased,0,0.7356936931610107
TREANDA,Leukocytes Decreased,Grades Lymphocytes Leukocytes Decreased,1,0.9087697267532349
TREANDA,Leukocytes Decreased,Grades,0,0.4958575367927551
TREANDA,Leukocytes Decreased,Grades Grades Lymphocytes Leukocytes,1,0.7527337074279785
TREANDA,Leukocytes Decreased,Grades Grades Lymphocytes,0,0.6698148250579834
TREANDA,Leukocytes Decreased,Leukocytes Decreased Hemoglobin Decreased Neut,1,0.876329243183136
TREANDA,Leukocytes Decreased,Hemoglobin Decreased Neut,0,0.7438856363296509
TREANDA,Hemoglobin Decreased,Grades Grades Lymphocytes,0,0.5307140350341797
TREANDA,Hemoglobin Decreased,eased Leukocytes Hemoglobin Decreased Neutrophils,1,0.7957035303115845
TREANDA,Hemoglobin Decreased,Leukocytes Hemoglobin,1,0.7149222493171692
TREANDA,Hemoglobin Decreased,eased Leukocytes Hemoglobin Decreased,1,0.861893892288208
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased Neutrophils Decreased Plat,1,0.8440349102020264
TREANDA,Hemoglobin Decreased,Hemoglobin,1,0.839390754699707
TREANDA,Hemoglobin Decreased,Leukocytes Hemoglobin Decreased,1,0.8772610425949097
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased Neutrophils Decreased,1,0.8836461305618286
TREANDA,Neutrophils Decreased,Hemoglobin,0,0.5630844235420227
TREANDA,Neutrophils Decreased,Neutrophils Decreased Platelets Decreased,1,0.914145827293396
TREANDA,Platelets Decreased,In both studies serious adverse reactions regardless,0,0.4919700622558594
TREANDA,Platelets Decreased,Neutrophils,0,0.6090419292449951
TREANDA,Platelets Decreased,Platelets,1,0.8337002396583557
TREANDA,Platelets Decreased,Platelets Decreased In both studies,1,0.9074687957763672
TREANDA,Platelets Decreased,both studies serious adverse reactions,0,0.5151675939559937
TREANDA,Platelets Decreased,Platelets Decreased,1,1.0
TREANDA,febrile neutropenia,patients febrile neutropenia,1,0.9419192671775818
TREANDA,febrile neutropenia,febrile neutropenia and pneumonia,1,0.9064971208572388
TREANDA,febrile neutropenia,occurring in of patients febrile,1,0.7715475559234619
TREANDA,pneumonia,pneumonia,1,0.9999997615814209
TREANDA,pneumonia,pneumonia Other,1,0.865027904510498
TREANDA,pneumonia,pneumonia Other important serious adverse reactions,1,0.7319858074188232
TREANDA,pneumonia,pneumonia Other important,1,0.8550387620925903
TREANDA,pneumonia,adverse reactions occurring in of patients were febrile neutropenia,0,0.5710244178771973
TREANDA,pneumonia,pneumonia Other important serious adverse,1,0.7861683964729309
TREANDA,pneumonia,pneumonia Other important serious,1,0.8264516592025757
TREANDA,cardiac failure,acute renal cardiac,1,0.6588643193244934
TREANDA,cardiac failure,cardiac failure hypersensitivity skin reactions pulmonary fibrosis,1,0.721237063407898
TREANDA,cardiac failure,cardiac failure hypersensitivity,1,0.8219578266143799
TREANDA,cardiac failure,andor postmarketing experience were acute,0,0.5322127938270569
TREANDA,cardiac failure,pulmonary fibrosis and,0,0.5840644836425781
TREANDA,cardiac failure,cardiac failure hypersensitivity skin,1,0.7655333280563354
TREANDA,cardiac failure,andor postmarketing experience were acute renal failure,0,0.6244472861289978
TREANDA,hypersensitivity,fibrosis and myelodysplastic syndrome Serious drugrelated adverse,0,0.5601458549499512
TREANDA,hypersensitivity,acute renal failure cardiac hypersensitivity skin reactions pulmonary fibrosis,1,0.7424815893173218
TREANDA,hypersensitivity,renal failure cardiac hypersensitivity skin,1,0.7437108755111694
TREANDA,hypersensitivity,cardiac hypersensitivity,1,0.8243634104728699
TREANDA,hypersensitivity,skin reactions pulmonary fibrosis and myelodysplastic syndrome Serious,0,0.6718370914459229
TREANDA,hypersensitivity,hypersensitivity skin reactions pulmonary,1,0.7964791655540466
TREANDA,hypersensitivity,Serious drugrelated,0,0.5815774202346802
TREANDA,skin reactions,experience were acute renal failure,0,0.5307456254959106
TREANDA,skin reactions,cardiac failure skin reactions,1,0.8126606345176697
TREANDA,skin reactions,skin reactions pulmonary,1,0.8518881797790527
TREANDA,skin reactions,drugrelated,0,0.5494827628135681
TREANDA,skin reactions,failure cardiac failure skin reactions,1,0.7914586067199707
TREANDA,skin reactions,cardiac failure skin reactions pulmonary,1,0.7754669785499573
TREANDA,skin reactions,skin reactions pulmonary fibrosis and myelodysplastic syndrome,1,0.7395340204238892
TREANDA,skin reactions,skin reactions,1,1.0
TREANDA,pulmonary fibrosis,drugrelated adverse reactions reported,0,0.5304943323135376
TREANDA,pulmonary fibrosis,myelodysplastic syndrome Serious,0,0.5235767960548401
TREANDA,pulmonary fibrosis,pulmonary fibrosis and,1,0.9319888353347778
TREANDA,pulmonary fibrosis,pulmonary fibrosis and myelodysplastic syndrome Serious,1,0.7905847430229187
TREANDA,pulmonary fibrosis,cardiac failure hypersensitivity skin pulmonary fibrosis and myelodysplastic syndrome Serious,1,0.6878759860992432
TREANDA,pulmonary fibrosis,hypersensitivity skin pulmonary,1,0.6798174977302551
TREANDA,pulmonary fibrosis,cardiac failure hypersensitivity skin reactions,0,0.5427969694137573
TREANDA,myelodysplastic syndrome,fibrosis myelodysplastic,1,0.7927442789077759
TREANDA,myelodysplastic syndrome,pulmonary,0,0.506049394607544
TREANDA,myelodysplastic syndrome,reactions reported in clinical trials included myelosuppression,0,0.6686915159225464
TREANDA,myelodysplastic syndrome,hypersensitivity skin reactions pulmonary fibrosis and,0,0.48236382007598877
TREANDA,myelodysplastic syndrome,failure cardiac,0,0.4758686125278473
TREANDA,myelodysplastic syndrome,reactions pulmonary fibrosis myelodysplastic,1,0.7403554916381836
TREANDA,myelodysplastic syndrome,pulmonary fibrosis myelodysplastic syndrome Serious drugrelated adverse reactions,1,0.7539495229721069
TREANDA,myelodysplastic syndrome,myelodysplastic syndrome Serious drugrelated,1,0.8432722091674805
TREANDA,myelosuppression,included,0,0.5156885385513306
TREANDA,myelosuppression,pneumonia tumor lysis syndrome and,0,0.5842368006706238
TREANDA,myelosuppression,myelosuppression infection,1,0.9347956776618958
TREANDA,myelosuppression,reactions see Warnings and,0,0.5700064897537231
TREANDA,myelosuppression,syndrome Serious drugrelated adverse reactions reported in clinical,0,0.5719760656356812
TREANDA,infection,lysis syndrome,0,0.5571967363357544
TREANDA,infection,infection pneumonia tumor,1,0.7285316586494446
TREANDA,infection,clinical trials included infection pneumonia tumor lysis,1,0.6600380539894104
TREANDA,infection,and infusion reactions see Warnings and Precautions,0,0.6125354170799255
TREANDA,infection,syndrome and infusion reactions see Warnings and Precautions,0,0.6076307892799377
TREANDA,pneumonia,Precautions,0,0.5791901350021362
TREANDA,pneumonia,pneumonia tumor lysis,1,0.7406271696090698
TREANDA,pneumonia,pneumonia tumor lysis syndrome and infusion,1,0.6826281547546387
TREANDA,tumor lysis syndrome,reported in clinical,0,0.556115984916687
TREANDA,tumor lysis syndrome,included myelosuppression infection tumor lysis,1,0.8000800013542175
TREANDA,tumor lysis syndrome,myelosuppression infection tumor lysis,1,0.7986066937446594
TREANDA,infusion reactions,reactions occurring less,0,0.6635602712631226
TREANDA,infusion reactions,and,0,0.48085689544677734
TREANDA,infusion reactions,tumor lysis syndrome infusion reactions,1,0.8358112573623657
TREANDA,infusion reactions,infusion reactions,1,1.0000001192092896
TREANDA,infusion reactions,pneumonia tumor lysis syndrome infusion reactions see Warnings and Precautions Adverse,1,0.8010709285736084
TREANDA,infusion reactions,syndrome infusion,1,0.8140760660171509
TREANDA,hemolysis,Adverse reactions occurring,0,0.602405309677124
TREANDA,hemolysis,to TREANDA treatment hemolysis,1,0.857049822807312
TREANDA,hemolysis,hemolysis dysgeusiataste disorder,1,0.758670449256897
TREANDA,hemolysis,hemolysis dysgeusiataste,1,0.7865337133407593
TREANDA,hemolysis,hemolysis dysgeusiataste disorder atypical,1,0.7203937768936157
TREANDA,hemolysis,possibly related to TREANDA,0,0.5011254549026489
TREANDA,dysgeusia,dysgeusia taste disorder atypical pneumonia sepsis,1,0.7815474271774292
TREANDA,dysgeusia,TREANDA,0,0.529457688331604
TREANDA,taste disorder,herpes zoster,0,0.5385236740112305
TREANDA,taste disorder,hemolysis taste,1,0.7107552289962769
TREANDA,taste disorder,TREANDA treatment were hemolysis taste disorder,1,0.8112874627113342
TREANDA,taste disorder,taste disorder,1,1.0
TREANDA,atypical pneumonia,hemolysis dysgeusiataste atypical pneumonia sepsis,1,0.7737253904342651
TREANDA,atypical pneumonia,taste disorder,1,0.48231041431427
TREANDA,atypical pneumonia,skin necrosis Postmarketing,0,0.5134028196334839
TREANDA,atypical pneumonia,possibly related to TREANDA,0,0.5524306297302246
TREANDA,atypical pneumonia,treatment were hemolysis dysgeusiataste atypical pneumonia sepsis herpes zoster,1,0.693196177482605
TREANDA,atypical pneumonia,were hemolysis dysgeusiataste,0,0.48672938346862793
TREANDA,atypical pneumonia,were hemolysis dysgeusiataste atypical pneumonia,1,0.810075581073761
TREANDA,sepsis,zoster erythema dermatitis and skin necrosis Postmarketing Experience,0,0.5252195000648499
TREANDA,sepsis,sepsis herpes zoster erythema dermatitis,1,0.739871621131897
TREANDA,sepsis,disorder atypical sepsis herpes zoster erythema,1,0.7134489417076111
TREANDA,sepsis,and skin necrosis Postmarketing Experience,0,0.5647193193435669
TREANDA,herpes zoster,related to,0,0.5266166925430298
TREANDA,herpes zoster,and skin necrosis,0,0.5869375467300415
TREANDA,herpes zoster,pneumonia herpes zoster erythema dermatitis and skin,1,0.7339584827423096
TREANDA,herpes zoster,atypical pneumonia herpes zoster erythema,1,0.769887387752533
TREANDA,herpes zoster,pneumonia herpes,1,0.6663290858268738
TREANDA,erythema,erythema dermatitis and skin necrosis Postmarketing,1,0.7926212549209595
TREANDA,erythema,sepsis herpes zoster,0,0.6019061207771301
TREANDA,erythema,erythema dermatitis and,1,0.9133175611495972
TREANDA,erythema,dysgeusiataste disorder atypical pneumonia sepsis herpes,0,0.5369620323181152
TREANDA,erythema,pneumonia sepsis herpes erythema dermatitis and,1,0.7194985151290894
TREANDA,dermatitis,sepsis herpes zoster dermatitis and skin necrosis,1,0.7270851135253906
TREANDA,dermatitis,dysgeusiataste disorder atypical pneumonia sepsis herpes,0,0.5655319690704346
TREANDA,dermatitis,dermatitis and,1,0.9375846982002258
TREANDA,dermatitis,Postmarketing Experience The,0,0.5221853256225586
TREANDA,dermatitis,dermatitis and skin necrosis Postmarketing Experience,1,0.7694405913352966
TREANDA,anaphylaxis,to reliably estimate their,0,0.4436405897140503
TREANDA,anaphylaxis,establish a,0,0.48726755380630493
TREANDA,anaphylaxis,their frequency or,0,0.4587705731391907
TREANDA,anaphylaxis,anaphylaxis and injection or,1,0.856488049030304
TREANDA,anaphylaxis,anaphylaxis and injection or infusion,1,0.8311229944229126
TREANDA,anaphylaxis,or infusion site reactions including,0,0.6464338302612305
TREANDA,infusion site reactions,or,0,0.4918884336948395
TREANDA,infusion site reactions,injection,0,0.7007905840873718
TREANDA,infusion site reactions,injection infusion,1,0.8006207346916199
TREANDA,infusion site reactions,infusion site reactions including phlebitis pruritus irritation,1,0.8742573857307434
TREANDA,infusion site reactions,site reactions including,1,0.7514874935150146
TREANDA,pneumocystis jiroveci pneumonia,irritation,0,0.4558519721031189
TREANDA,pneumocystis jiroveci pneumonia,pneumocystis jiroveci pneumonia and pneumonitis Skin,1,0.888778805732727
TREANDA,pneumocystis jiroveci pneumonia,and pneumocystis jiroveci pneumonia and,1,0.9599052667617798
TREANDA,pneumonitis,when TREANDA was administered,0,0.42793598771095276
TREANDA,Skin reactions,pneumonia and Skin reactions including SJS and,1,0.7842334508895874
TREANDA,Skin reactions,when TREANDA was administered,0,0.45862865447998047
TREANDA,Skin reactions,Skin reactions including SJS and TEN have,1,0.8756731748580933
TREANDA,Skin reactions,Skin,1,0.7991300821304321
TREANDA,SJS,TEN have occurred when TREANDA was administered concomitantly with allopurinol and,0,0.42282548546791077
TREANDA,SJS,pneumocystis jiroveci pneumonia,0,0.4966219365596771
TREANDA,SJS,SJS,1,0.9999997615814209
TREANDA,SJS,SJS and TEN have occurred when,1,0.7997488975524902
TREANDA,SJS,swelling pneumocystis jiroveci,0,0.504366397857666
TREANDA,SJS,Skin reactions including,0,0.4924287796020508
TREANDA,TEN,TEN have,1,0.9012720584869385
TREANDA,TEN,Skin reactions including,0,0.5035288333892822
TREANDA,TEN,TEN have occurred when TREANDA,1,0.7555647492408752
TREANDA,TEN,and pneumonitis Skin,0,0.47656190395355225
TREANDA,Myelosuppression,REACTIONS The following serious se reactions hav,1,0.5848879218101501
TREANDA,myelosuppression,of the abel. *,1,0.49986889958381653
TREANDA,myelosuppression,Warnings,0,0.5409673452377319
TREANDA,death,label on [s,1,0.5090439915657043
TREANDA,death,label on,1,0.5184721350669861
TREANDA,death,of the label on [s,1,0.5209890007972717
TREANDA,death,on [s ee,1,0.552525520324707
TREANDA,Infections,see Warnings and ecautions ,1,0.5978332757949829
TREANDA,Infections,on [s ee,1,0.5453985929489136
TREANDA,Infections,Infections see Warnings and,0,0.8097579479217529
TREANDA,Infections,ecautions  Infections see,1,0.8227242827415466
TREANDA,Infections,see Warnings and,0,0.5886807441711426
TREANDA,Infections,ecautions  Infections,1,0.8141927719116211
TREANDA,Infections,ecautions  Infections see Warnings and,1,0.7636968493461609
TREANDA,Infections,other sections of,0,0.5557336211204529
TREANDA,Infections,ecautions ,1,0.572136402130127
TREANDA,Anaphylaxis,Warnings and Precautions ylaxis,1,0.6251834034919739
TREANDA,Anaphylaxis,see Warnings and Precautions ylaxis,1,0.6244789361953735
TREANDA,Anaphylaxis,ylaxis and Infusion Reactions see Warnings,1,0.6697932481765747
TREANDA,Anaphylaxis,ylaxis and  Infusion Reactions see Warnings and,1,0.6710845828056335
TREANDA,Anaphylaxis,ylaxis and Infusion Reactions see,1,0.6747345924377441
TREANDA,Anaphylaxis,Warnings and Precautions ylaxis and  Infusion Reactions see Warnings,1,0.6560091972351074
TREANDA,Infusion Reactions,and ion Reactions [see Warnings and Precautions,1,0.6889311075210571
TREANDA,Infusion Reactions,ylaxis and Infusion Reactions see,1,0.8729549050331116
TREANDA,Infusion Reactions,Infections see Warnings and Precautions Anaphylaxis and,0,0.6312456727027893
TREANDA,Infusion Reactions,and Precautions Tumor Lysis Syndrome see Warnings and,0,0.6092952489852905
TREANDA,Infusion Reactions,Anaphylaxis and ion Reactions [see Warnings and Precautions Tumor Lysis,1,0.7036908864974976
TREANDA,anaphylactic reactions,and Precautions Anaphylaxis and Infusion,0,0.7903133034706116
TREANDA,anaphylactic reactions,see Warnings d Precautions (,1,0.5641248226165771
TREANDA,anaphylactic reactions,see Warnings d Precautions  (  5.3  Tumor,1,0.5448768138885498
TREANDA,anaphylactic reactions,see Warnings,0,0.5530003905296326
TREANDA,anaphylactic reactions,Warnings an,0,0.5876686573028564
TREANDA,anaphylactic reactions,and Infusion Reactions see Warnings,0,0.6929867267608643
TREANDA,anaphylactic reactions,Warnings and Precautions Skin Reactions,0,0.7402142286300659
TREANDA,anaphylactic reactions,Precautions ( 5.3,1,0.5597587823867798
TREANDA,anaphylactic reactions,Precautions,0,0.5907171368598938
TREANDA,anaphylactic reactions,Warnings d Precautions,1,0.5762258768081665
TREANDA,Acute renal failure,Other,0,0.5045278668403625
TREANDA,Acute renal failure,Warnings and Precautions,0,0.4962143301963806
TREANDA,Acute renal failure,and Precautions Malignancies,1,0.472073495388031
TREANDA,Acute renal failure,Warnings and Precautions Malignancies [see   Warnings and Precautions Extravasation,1,0.5014538764953613
TREANDA,Acute renal failure,see Warnings and Precautions Malignancies [see,1,0.4857623279094696
TREANDA,death,ngs a nd Precautions Extravasation,1,0.49339964985847473
TREANDA,death,see Warnings and Precautions Malignancies [see,1,0.5552999377250671
TREANDA,death,and Precautions Other Malignancies see,0,0.5343470573425293
TREANDA,death,ngs a nd Precautions,1,0.5174197554588318
TREANDA,death,Precautions Other Malignancies see ngs a,1,0.5290714502334595
TREANDA,death,Warnings and,0,0.5806010365486145
TREANDA,death,Extravasation injury see Warnings and,0,0.5058972239494324
TREANDA,death,Other Malignancies see Warni,0,0.5524076223373413
TREANDA,death,nd Precautions Extravasation injury see Warnings and,0,0.4998014569282532
TREANDA,death,ngs a nd,1,0.5350002646446228
TREANDA,Skin Reactions,see Warnings and Precautions,0,0.5846994519233704
TREANDA,Skin Reactions,Extravasation injury e  Warnings an d Precautions,1,0.6272225975990295
TREANDA,Skin Reactions,e  Warnings an d Precautions,1,0.5749267339706421
TREANDA,Skin Reactions,e Warnings an d Precautions,1,0.5749267339706421
TREANDA,SJS,mon nonhematologic adverse reactions for,1,0.4721214175224304
TREANDA,SJS,Most com,0,0.4668485224246979
TREANDA,SJS,mon nonhematologic adverse reactions,1,0.4871196746826172
TREANDA,SJS,and Precautions Most mon,1,0.4974293112754822
TREANDA,SJS,nausea and vomiting,0,0.42883992195129395
TREANDA,SJS,CLL frequency are pyrexia,0,0.4950472116470337
TREANDA,TEN,Most common non,0,0.5643606185913086
TREANDA,TEN,atologic adverse reactions for CLL frequency are pyrexia,0,0.46093249320983887
TREANDA,TEN,hem atologic adverse,1,0.5186762809753418
TREANDA,fatal,c adv erse reactions for CLL frequency,1,0.5067535042762756
TREANDA,fatal,hem atologic adverse,1,0.6160390973091125
TREANDA,fatal,nausea and vomiting Most,0,0.5714003443717957
TREANDA,fatal,pyrexia nausea and vomiting Most,0,0.5687195062637329
TREANDA,fatal,CLL frequency are pyrexia nausea and vomiting Most,0,0.5612331628799438
TREANDA,fatal,erse reactions for,0,0.549028754234314
TREANDA,fatal,Precautions Most common c adv,1,0.5041201114654541
TREANDA,fatal,and,0,0.5288088321685791
TREANDA,Malignancies,y >=,1,0.4735289514064789
TREANDA,malignant diseases,"are nausea fatigue omiting,",1,0.50062096118927
TREANDA,malignant diseases,"frequency are nausea fatigue omiting,",1,0.49971839785575867
TREANDA,malignant diseases,"fatigue omiting, diarrhea, pyrexia constipation anorexia",1,0.5642332434654236
TREANDA,malignant diseases,nausea,0,0.5435717701911926
TREANDA,malignant diseases,Most common nonhematologic adverse reactions for NHL frequency are nausea,0,0.5333535671234131
TREANDA,malignant diseases,"omiting, diarrhea, pyrexia constipation",1,0.5327861309051514
TREANDA,Extravasation,"diarrhea pyrexia constipation anorexia h, headache,  weight decreased dyspnea",1,0.5380305051803589
TREANDA,Extravasation,"omiting, diarrhea, pyrexia constipation",1,0.5472773313522339
TREANDA,Extravasation,coug,0,0.4968078136444092
TREANDA,Extravasation,and stomatitis Most common,0,0.5223075151443481
TREANDA,Extravasation,weight decreased dyspnea rash and stomatitis Most common hematologic abnorma,0,0.5476508140563965
TREANDA,Embryo-fetal toxicity,stomatitis Most common hematologic es for both indicatio,1,0.4567345678806305
TREANDA,Embryo-fetal toxicity,leukopenia thrombocytopenia,0,0.481374591588974
TREANDA,Embryo-fetal toxicity,for both indicatio ns frequency are lymphopenia anemia,1,0.49670350551605225
TREANDA,Fetal harm,(frequency are lymphopenia anemia leukopenia thrombocytopenia,1,0.5046797394752502
TREANDA,Fetal harm,(frequency are lymphopenia anemia leukopenia,1,0.49903395771980286
TREANDA,Fetal harm,abnormalities for both (frequency are,1,0.5897834300994873
TREANDA,Fetal harm,(frequency are,1,0.4753855764865875
TREANDA,Fetal harm,both indications,0,0.5406990051269531
TREANDA,Fetal harm,(frequency are lymphopenia anemia,1,0.486707478761673
TREANDA,myelosuppression,at 1-800-FDA-108 or wwwfdagovmedwatch Clinical,1,0.47272056341171265
TREANDA,myelosuppression,(frequency are lymphopenia anemia,1,0.6252886652946472
TREANDA,myelosuppression,Teva Pharmaceuticals at or at,1,0.4862646758556366
TREANDA,myelosuppression,Teva Pharmaceuticals at or at 1-800-FDA-108 or wwwfdagovmedwatch,1,0.4384695887565613
TREANDA,myelosuppression,Because,0,0.4966531991958618
TREANDA,myelosuppression,at 1-800-FDA-108,1,0.45935994386672974
TREANDA,myelosuppression,SUSPECTED ADVERSE,0,0.5870943665504456
TREANDA,myelosuppression,at 1-800-FDA-108 or,1,0.44600996375083923
TREANDA,died,Clinical Trials Experience Because ical trials are conducted under,1,0.44174766540527344
TREANDA,died,SUSPECTED ADVERSE,0,0.5251326560974121
TREANDA,died,Clinical Trials Experience,0,0.44868016242980957
TREANDA,died,Because,0,0.5281459093093872
TREANDA,died,Clinical Trials Experience Because ical trials are conducted,1,0.4457505941390991
TREANDA,died,ical trials,1,0.4645836353302002
TREANDA,myelosuppression-related adverse reactions,clinical,0,0.5290589928627014
TREANDA,myelosuppression-related adverse reactions,Because clinical trial,0,0.5324395895004272
TREANDA,myelosuppression-related adverse reactions,s are conducted under widely varying condi tions adverse reaction,1,0.7279543280601501
TREANDA,myelosuppression-related adverse reactions,clinical s are conducted under widely varying condi tions,1,0.5143836736679077
TREANDA,myelosuppression-related adverse reactions,clinical s are conducted under widely varying condi,1,0.49051666259765625
TREANDA,neutropenic sepsis,conditions adverse eaction rates obse,1,0.5153989791870117
TREANDA,neutropenic sepsis,conditions adverse eaction rates obse rved in the,1,0.5187365412712097
TREANDA,diffuse alveolar hemorrhage,adverse,0,0.5154216885566711
TREANDA,thrombocytopenia,drug,0,0.5111945867538452
TREANDA,pneumonia,be directly  to rates,1,0.4862707853317261
TREANDA,pneumonia,drug,0,0.6047806739807129
TREANDA,opportunistic infection,in the linical trials of anoth er drug and,1,0.5080618858337402
TREANDA,opportunistic infection,drug,0,0.5239058136940002
TREANDA,opportunistic infection,trials of anoth er drug,1,0.507067084312439
TREANDA,opportunistic infection,of anoth er drug,1,0.5168036222457886
TREANDA,Infection,vomiting Other adverse ons seen  frequently in,1,0.5552719235420227
TREANDA,Infection,of anoth er drug,1,0.582292377948761
TREANDA,Infection,reacti,0,0.5658653974533081
TREANDA,Infection,Other adverse ons seen ,1,0.5791730880737305
TREANDA,Infection,vomiting Other,0,0.5562378168106079
TREANDA,Infection,dry mouth somn,0,0.5210159420967102
TREANDA,Infection,ons seen frequently in one or more,1,0.6009393930435181
TREANDA,pneumonia,more,0,0.5492346882820129
TREANDA,pneumonia,frequently i,0,0.5156264305114746
TREANDA,pneumonia,n one or more,1,0.5230026245117188
TREANDA,sepsis,weakness dry mouth somnolence cough constipation,0,0.5487031936645508
TREANDA,sepsis,re stu dies included asthenia fatigue,1,0.5699787735939026
TREANDA,sepsis,re stu dies,1,0.5181522369384766
TREANDA,sepsis,frequently in one or re stu dies included asthenia,1,0.5668271780014038
TREANDA,sepsis,frequently in one or re stu dies,1,0.5602210164070129
TREANDA,sepsis,and vomiting Other adverse reactions,0,0.5912641286849976
TREANDA,sepsis,asthenia fatigue malaise,0,0.5273287892341614
TREANDA,sepsis,one or re,1,0.538278341293335
TREANDA,sepsis,adverse reactions seen frequently,0,0.5753140449523926
TREANDA,septic shock,constipation,0,0.5686640739440918
TREANDA,septic shock,studi,0,0.5295801162719727
TREANDA,septic shock,cough constipation headache,0,0.5034682750701904
TREANDA,septic shock,mouth somnolence cough constipation headache muco,0,0.49471133947372437
TREANDA,septic shock,in one or more es included,1,0.49509018659591675
TREANDA,septic shock,more es included ,1,0.501621663570404
TREANDA,septic shock,or more es included  asthenia,1,0.5025810599327087
TREANDA,septic shock,es included asthenia,1,0.4955143630504608
TREANDA,death,"ia, f atigue",1,0.5402807593345642
TREANDA,death,"included ia, f atigue malaise and weakness",1,0.5554545521736145
TREANDA,death,"ia, f atigue malaise and",1,0.5318040251731873
TREANDA,death,"studies included ia, f atigue malaise",1,0.5193968415260315
TREANDA,death,reactions seen frequently in,0,0.5312055349349976
TREANDA,death,"more studies included ia, f",1,0.49660056829452515
TREANDA,death,"ia, f atigue malaise and weakness dry",1,0.5481672883033752
TREANDA,myelosuppression,in patients treated with TREANDA,0,0.5216741561889648
TREANDA,infections,with TREA NDA in,1,0.48022741079330444
TREANDA,infections,stomatitis Worsening hypertension was reported in patients,0,0.577656090259552
TREANDA,infections,with chlorambucil Three,0,0.5819724798202515
TREANDA,infections,and,0,0.5494766235351562
TREANDA,infections,with TREA NDA,1,0.4893419146537781
TREANDA,infections,in patients with TREA,1,0.5219491720199585
TREANDA,infections,with TREA NDA in the CLL trial,1,0.5143076181411743
TREANDA,infections,these adverse reactions,0,0.6412474513053894
TREANDA,Infusion reactions,The most freq uent adverse reactions leading,1,0.6865139007568359
TREANDA,fever,g TRE ANDA,1,0.522826611995697
TREANDA,fever,g TRE ANDA were,1,0.5050479173660278
TREANDA,fever,receivin,0,0.5669496059417725
TREANDA,fever,study withdrawal for patients g TRE,1,0.46526944637298584
TREANDA,chills,DA wer e,1,0.5289433598518372
TREANDA,chills,pyrexia Table contains the treatment emergent adverse,0,0.5646380186080933
TREANDA,chills,DA wer e hypersensitivity,1,0.5626196265220642
TREANDA,chills,DA wer,1,0.5273149609565735
TREANDA,chills,e hypersensitivity and pyrexia,0,0.6093155145645142
TREANDA,pruritus,emergent,0,0.5284367799758911
TREANDA,pruritus,for patients receiving TREANDA hypersen sitivity and pyrexia,1,0.6504175066947937
TREANDA,rash,TREANDA were ity  and pyrexia Table,1,0.5430009961128235
TREANDA,rash,emergent,0,0.5662424564361572
TREANDA,rash,ity  and pyrexia,1,0.608124852180481
TREANDA,rash,Table contains,0,0.49458175897598267
TREANDA,rash,were ity  and pyrexia Table contains,1,0.5215197801589966
TREANDA,anaphylactoid reactions,the,1,0.47717177867889404
TREANDA,anaphylactoid reactions,patients receiving TREANDA were hypersensitivity and pyrexia Table,0,0.6370418071746826
TREANDA,anaphylactoid reactions,the treatment emergent adverse reactions,1,0.6926376819610596
TREANDA,anaphylactoid reactions,treatment emergent adverse reactions regardless,1,0.6548237800598145
TREANDA,SJS,infestat,0,0.48532769083976746
TREANDA,SJS,Infections and ion,1,0.47888535261154175
TREANDA,SJS,ion,1,0.47637152671813965
TREANDA,myelodysplastic syndrome,5,1,0.48482656478881836
TREANDA,myelodysplastic syndrome,Weight   5 (3)         0        Metabolism and nutrition,1,0.5232745409011841
TREANDA,myelodysplastic syndrome,Weight decreased,0,0.47035568952560425
TREANDA,myelodysplastic syndrome,Metabolism,0,0.5549603700637817
TREANDA,myelodysplastic syndrome,Metabolism and,0,0.5524759292602539
TREANDA,myeloproliferative disorders,on,0,0.5555077791213989
ELIQUIS,thrombotic events,information Increased risk thrombotic events after premature,1,0.814521849155426
ELIQUIS,thrombotic events,on,0,0.5447491407394409
ELIQUIS,thrombotic events,prescribing information Increased risk thrombotic events,1,0.7804207801818848
ELIQUIS,thrombotic events,thrombotic,1,0.8530523777008057
ELIQUIS,thrombotic events,thrombotic events after premature discontinuation seeWarnings,1,0.7707617282867432
ELIQUIS,thrombotic events,the prescribing information Increased,0,0.5140877366065979
ELIQUIS,thrombotic events,Increased risk thrombotic events,1,0.9089743494987488
ELIQUIS,thrombotic events,premature discontinuation seeWarnings and,0,0.5326206684112549
ELIQUIS,Bleeding,or puncture seeWarnings,0,0.6049541234970093
ELIQUIS,Bleeding,or puncture,0,0.6807360649108887
ELIQUIS,Bleeding,Bleeding seeWarnings and Precautions Spinalepidural,1,0.7160621881484985
ELIQUIS,Bleeding,Bleeding seeWarnings,1,0.8233720064163208
ELIQUIS,bleeding-related adverse reactions,studies was bleeding-related adverse reactions in,1,0.9476507902145386
ELIQUIS,bleeding-related adverse reactions,Bleeding seeWarnings,1,0.7819539308547974
ELIQUIS,bleeding,least one,0,0.49913325905799866
ELIQUIS,bleeding,bleeding during,1,0.9444722533226013
ELIQUIS,bleeding,of patients experiencing bleeding during the treatment period and,1,0.8216667771339417
ELIQUIS,bleeding,bleeding during the treatment,1,0.8613460659980774
ELIQUIS,bleeding,and bleeding,1,0.9427608251571655
ELIQUIS,bleeding,bleeding rate,1,0.8771886825561523
ELIQUIS,bleeding,bleeding,1,1.0
ELIQUIS,bleeding,bleeding rate percentage of subjects with,1,0.8054799437522888
ELIQUIS,bleeding,of subjects with at least one bleeding event per,0,0.8333580493927002
ELIQUIS,bleeding,bleeding rate percentage of subjects,1,0.8039461374282837
ELIQUIS,bleeding,subjects with at least one bleeding event per patientyears in ARISTOTLE a,0,0.7712322473526001
ELIQUIS,bleeding,treatment period and bleeding rate percentage,1,0.7765186429023743
ELIQUIS,bleeding,bleeding event per patientyears,1,0.7789503335952759
ELIQUIS,bleeding,bleeding event,1,0.8621304035186768
ELIQUIS,bleeding,rate percentage of subjects with at least,0,0.4885025918483734
ELIQUIS,bleeding,at least,0,0.5137267112731934
ELIQUIS,bleeding,bleeding event per patientyears in ARISTOTLE,1,0.7679283618927002
ELIQUIS,Bleeding,Bleeding Events,1,0.845495343208313
ELIQUIS,Bleeding,Bleeding Events in Patients with,1,0.8312934637069702
ELIQUIS,Bleeding,Bleeding Events in Patients,1,0.8510037660598755
ELIQUIS,Bleeding,Ratio,0,0.5389237403869629
ELIQUIS,Bleeding,were counted once per subject but subjects may,0,0.5097886919975281
ELIQUIS,Bleeding,subject but subjects may have contributed,0,0.5086193084716797
ELIQUIS,Bleeding,Bleeding events were counted,1,0.8386632204055786
ELIQUIS,Bleeding,to,0,0.5197806358337402
ELIQUIS,Bleeding,Bleeding events were,1,0.836751401424408
ELIQUIS,Bleeding,treatment ontreatment per,0,0.5575820207595825
ELIQUIS,Bleeding,were counted during treatment or within days,0,0.5739595890045166
ELIQUIS,Bleeding,stopping,0,0.5380080938339233
ELIQUIS,Bleeding,treatment ontreatment,0,0.5661466121673584
ELIQUIS,bleeding,of stopping study treatment,0,0.5134472846984863
ELIQUIS,bleeding,ontreatment period Defined,0,0.5517573356628418
ELIQUIS,bleeding,period Defined as clinically bleeding accompanied,1,0.7551352977752686
ELIQUIS,bleeding,one or more of the following a decrease in hemoglobin of gdL a,0,0.5734198093414307
ELIQUIS,bleeding,decrease in hemoglobin of gdL a,0,0.5698103308677673
ELIQUIS,bleeding,of the following a decrease in hemoglobin of gdL a transfusion,0,0.5954039096832275
ELIQUIS,decrease in hemoglobin,in hemoglobin,1,0.8413786888122559
ELIQUIS,decrease in hemoglobin,following decrease in hemoglobin,1,0.9640492796897888
ELIQUIS,decrease in hemoglobin,a transfusion of or more units of packed red blood cells bleeding,0,0.6044987440109253
ELIQUIS,decrease in hemoglobin,in hemoglobin of,1,0.8358396291732788
ELIQUIS,decrease in hemoglobin,more of the following decrease in hemoglobin of gdL a transfusion,1,0.8629382848739624
ELIQUIS,decrease in hemoglobin,the following decrease in hemoglobin of gdL a transfusion of,1,0.8557828664779663
ELIQUIS,decrease in hemoglobin,of the following decrease in hemoglobin,1,0.9832407832145691
ELIQUIS,decrease in hemoglobin,following decrease in hemoglobin of gdL a transfusion of,1,0.8522262573242188
ELIQUIS,bleeding at a critical site,critical site intracranial intraspinal intraocular pericardial intraarticular,1,0.6917085647583008
ELIQUIS,bleeding at a critical site,bleeding at a critical site intracranial,1,0.870149552822113
ELIQUIS,bleeding at a critical site,of packed red blood,0,0.6766461730003357
ELIQUIS,bleeding at a critical site,of,0,0.4859306812286377
ELIQUIS,bleeding at a critical site,at a critical site intracranial intraspinal intraocular pericardial intraarticular,1,0.7097117900848389
ELIQUIS,bleeding at a critical site,bleeding at a critical site,1,1.000000238418579
ELIQUIS,bleeding at a critical site,red blood bleeding at a critical site intracranial,1,0.8486332893371582
ELIQUIS,bleeding at a critical site,of packed red blood bleeding at a critical site intracranial intraspinal intraocular,1,0.7794844508171082
ELIQUIS,compartment syndrome,pericardial intraarticular intramuscular compartment syndrome retroperitoneal or with fatal,1,0.7593290209770203
ELIQUIS,compartment syndrome,at a critical site intracranial intraspinal intraocular pericardial intraarticular,1,0.5199199318885803
ELIQUIS,compartment syndrome,intraocular pericardial intraarticular intramuscular compartment syndrome retroperitoneal or with fatal outcome,1,0.7371244430541992
ELIQUIS,compartment syndrome,compartment syndrome retroperitoneal or with fatal outcome,1,0.8296129703521729
ELIQUIS,fatal outcome,or fatal outcome Intracranial bleed includes intracerebral intraventricular,1,0.7040315270423889
ELIQUIS,fatal outcome,at a critical site intracranial intraspinal intraocular pericardial intraarticular,1,0.5828309059143066
ELIQUIS,fatal outcome,retroperitoneal,0,0.5124800205230713
ELIQUIS,fatal outcome,fatal outcome,1,1.0
ELIQUIS,Intracranial bleed,fatal Intracranial bleed includes intracerebral intraventricular subdural and,1,0.8399252891540527
ELIQUIS,Intracranial bleed,fatal outcome,1,0.5688456296920776
ELIQUIS,Intracranial bleed,fatal,0,0.5457818508148193
ELIQUIS,Intracranial bleed,intracerebral intraventricular subdural and subarachnoid bleeding,0,0.823165237903595
ELIQUIS,Intracranial bleed,subdural and,0,0.6557509303092957
ELIQUIS,Intracranial bleed,outcome,0,0.48815780878067017
ELIQUIS,Intracranial bleed,Intracranial bleed includes intracerebral,1,0.9072108864784241
ELIQUIS,Intracranial bleed,Intracranial bleed,1,1.0000001192092896
ELIQUIS,Intracranial bleed,with fatal Intracranial bleed includes intracerebral,1,0.8582085371017456
ELIQUIS,subarachnoid bleeding,hemorrhagic stroke was adjudicated and counted as an,0,0.638694167137146
ELIQUIS,subarachnoid bleeding,counted as an intracranial,0,0.6726264357566833
ELIQUIS,subarachnoid bleeding,intracerebral intraventricular subdural subarachnoid bleeding,1,0.8287479877471924
ELIQUIS,subarachnoid bleeding,intraventricular subdural subarachnoid bleeding Any type,1,0.8525387048721313
ELIQUIS,subarachnoid bleeding,subarachnoid bleeding Any type of hemorrhagic,1,0.8905080556869507
ELIQUIS,hemorrhagic stroke,and subarachnoid,0,0.5950197577476501
ELIQUIS,hemorrhagic stroke,Any type hemorrhagic,1,0.7952308058738708
ELIQUIS,hemorrhagic stroke,hemorrhagic,1,0.8603018522262573
ELIQUIS,hemorrhagic stroke,hemorrhagic stroke was adjudicated and counted as,1,0.846096396446228
ELIQUIS,hemorrhagic stroke,type hemorrhagic stroke was adjudicated and,1,0.8674529790878296
ELIQUIS,GI bleed,based on the safety population,0,0.4583624005317688
ELIQUIS,GI bleed,GI bleed,1,0.9999998807907104
ELIQUIS,GI bleed,Fatal bleeding is,0,0.6981344223022461
ELIQUIS,GI bleed,bleeding Fatal bleeding is an,0,0.6742373704910278
ELIQUIS,rectal bleeding,rectal bleeding Fatal,1,0.9151903390884399
ELIQUIS,rectal bleeding,GI rectal bleeding Fatal bleeding is an adjudicated,1,0.820355236530304
ELIQUIS,rectal bleeding,lower GI rectal bleeding Fatal bleeding is,1,0.8669606447219849
ELIQUIS,rectal bleeding,upper GI lower GI rectal bleeding,1,0.85252445936203
ELIQUIS,rectal bleeding,Section GI bleed includes upper GI lower,0,0.7190061807632446
ELIQUIS,rectal bleeding,lower GI,0,0.6006163358688354
ELIQUIS,rectal bleeding,death as intracranial,0,0.4952922463417053
ELIQUIS,Fatal,rectal Fatal bleeding is an,1,0.6831122040748596
ELIQUIS,Fatal,death as intracranial,0,0.6649022102355957
ELIQUIS,Fatal,GI and rectal bleeding,0,0.5369151830673218
ELIQUIS,Fatal,GI and rectal Fatal,1,0.716789186000824
ELIQUIS,Fatal,adjudicated death with the primary cause of death,0,0.6796599626541138
ELIQUIS,Fatal,Section GI bleed includes upper GI lower GI,0,0.5073796510696411
ELIQUIS,bleeding,GI and,0,0.5280201435089111
ELIQUIS,bleeding,GI and rectal bleeding bleeding is an,1,0.7716524004936218
ELIQUIS,bleeding,bleeding is an adjudicated death with,1,0.7888310551643372
ELIQUIS,death,is an death with the primary cause,1,0.7330573797225952
ELIQUIS,death,bleeding is an adjudicated death with,1,0.7216140031814575
ELIQUIS,death,Fatal bleeding is an death with the primary,1,0.6931939125061035
ELIQUIS,death,Fatal bleeding is an death with the primary cause,1,0.7102906703948975
ELIQUIS,death,death with the primary cause of,1,0.7730475664138794
ELIQUIS,death,death with,1,0.8613942861557007
ELIQUIS,death,death with the primary cause,1,0.7709286212921143
ELIQUIS,death,bleeding Fatal bleeding is an adjudicated,0,0.6502856612205505
ELIQUIS,death,death as intracranial,1,0.7878400683403015
ELIQUIS,death,death as,1,0.8728203773498535
ELIQUIS,death,and rectal bleeding Fatal bleeding is an adjudicated death with,0,0.6694982647895813
ELIQUIS,intracranial bleeding,primary cause of death intracranial bleeding or nonintracranial,1,0.7877624034881592
ELIQUIS,intracranial bleeding,and rectal bleeding Fatal bleeding is an adjudicated death with,0,0.6041600704193115
ELIQUIS,intracranial bleeding,intracranial bleeding or,1,0.959111213684082
ELIQUIS,intracranial bleeding,ontreatment period Major,0,0.5370324850082397
ELIQUIS,intracranial bleeding,primary cause of,0,0.5567835569381714
ELIQUIS,intracranial bleeding,of death intracranial bleeding,1,0.8920215368270874
ELIQUIS,intracranial bleeding,intracranial bleeding or nonintracranial bleeding during the,1,0.8903166651725769
ELIQUIS,intracranial bleeding,bleeding during the,0,0.8065980672836304
ELIQUIS,intracranial bleeding,intracranial bleeding or nonintracranial bleeding,1,0.8956624865531921
ELIQUIS,intracranial bleeding,the primary cause,0,0.5373505353927612
ELIQUIS,non-intracranial bleeding,as intracranial bleeding non-intracranial bleeding,1,0.9606012105941772
ELIQUIS,non-intracranial bleeding,the primary cause,0,0.5273949503898621
ELIQUIS,non-intracranial bleeding,bleeding non-intracranial bleeding during,1,0.9593628644943237
ELIQUIS,non-intracranial bleeding,non-intracranial bleeding during the ontreatment period Major,1,0.8930044174194336
ELIQUIS,bleeding,bleeding were generally consistent,1,0.833041787147522
ELIQUIS,bleeding,bleeding were,1,0.9790282249450684
ELIQUIS,bleeding,bleeding were generally consistent across,1,0.8351576328277588
ELIQUIS,bleeding,ARISTOTLE the results for major,0,0.5166929960250854
ELIQUIS,bleeding,bleeding were generally,1,0.9157817363739014
ELIQUIS,bled,apixaban with bled more per,1,0.6515926122665405
ELIQUIS,bled,bleeding were generally,1,0.6668777465820312
ELIQUIS,bled,Subjects treated with apixaban with,0,0.545177698135376
ELIQUIS,bled,bled more per,1,0.7276906967163086
ELIQUIS,bled,bled,1,1.0
ELIQUIS,bled,bled more per year than,1,0.6835342645645142
ELIQUIS,bled,region and,0,0.5223848819732666
ELIQUIS,bled,per year than did subjects without diabetes per year,0,0.4857443571090698
ELIQUIS,bled,Figure Subjects treated with,0,0.49888646602630615
ELIQUIS,Bleeding,Bleeding Hazard Ratios by,1,0.7914914488792419
ELIQUIS,Bleeding,Bleeding Hazard Ratios by Baseline,1,0.7758584022521973
ELIQUIS,Bleeding,Figure Bleeding Hazard Ratios by,1,0.7927654385566711
ELIQUIS,Bleeding,Bleeding,1,1.0
ELIQUIS,Bleeding,year Figure Bleeding Hazard Ratios,1,0.7397968769073486
ELIQUIS,Bleeding,Bleeding Hazard,1,0.8824865221977234
ELIQUIS,Bleeding,did subjects without diabetes per year Figure Major,0,0.46207231283187866
ELIQUIS,Bleeding,be,0,0.5177352428436279
ELIQUIS,Bleeding,overinterpreted Bleeding Events,1,0.7986478805541992
ELIQUIS,Bleeding,not be overinterpreted Bleeding Events in Patients with Nonvalvular,1,0.7529498338699341
ELIQUIS,Bleeding,pparent homogeneity or heterogeneity among groups should,0,0.5045421123504639
ELIQUIS,Bleeding,Bleeding Forest Plot Other Adverse Reactions,1,0.6750922203063965
ELIQUIS,Bleeding,Bleeding Forest Plot,1,0.7204509973526001
ELIQUIS,Bleeding,ARISTOTLE,0,0.5135409832000732
ELIQUIS,Bleeding,Major,0,0.5121725797653198
ELIQUIS,Hypersensitivity reactions,Hypersensitivity reactions including,1,0.9571927189826965
ELIQUIS,Hypersensitivity reactions,Hypersensitivity reactions including drug hypersensitivity such,1,0.8775635361671448
ELIQUIS,Hypersensitivity reactions,Adverse Hypersensitivity reactions including,1,0.8943520784378052
ELIQUIS,Hypersensitivity reactions,Reactions,0,0.7718844413757324
ELIQUIS,Hypersensitivity reactions,such,0,0.49570977687835693
ELIQUIS,drug hypersensitivity,and syncope were reported,0,0.504375696182251
ELIQUIS,drug hypersensitivity,Plot Other Adverse,0,0.5364259481430054
ELIQUIS,drug hypersensitivity,rash,0,0.6615039110183716
ELIQUIS,drug hypersensitivity,skin rash and anaphylactic reactions,0,0.7147877216339111
ELIQUIS,drug hypersensitivity,drug hypersensitivity such as skin rash and,1,0.9249929189682007
ELIQUIS,drug hypersensitivity,Reactions Hypersensitivity reactions drug,1,0.928013801574707
ELIQUIS,drug hypersensitivity,drug hypersensitivity such as skin rash,1,0.9149119853973389
ELIQUIS,drug hypersensitivity,including,0,0.5108115673065186
ELIQUIS,skin rash,reactions such as allergic edema and,0,0.6845999956130981
ELIQUIS,skin rash,such skin,1,0.6813961267471313
ELIQUIS,skin rash,skin rash and anaphylactic,1,0.86039799451828
ELIQUIS,skin rash,including drug,0,0.5554440021514893
ELIQUIS,skin rash,such as allergic edema and syncope were reported in of,0,0.6297738552093506
ELIQUIS,skin rash,skin rash,1,1.0
ELIQUIS,skin rash,hypersensitivity such skin,1,0.768756628036499
ELIQUIS,skin rash,in of patients r,0,0.526402473449707
ELIQUIS,skin rash,in,0,0.5109331607818604
ELIQUIS,anaphylactic reactions,as skin rash anaphylactic reactions,1,0.8725075721740723
ELIQUIS,anaphylactic reactions,anaphylactic reactions such,1,0.9489993453025818
ELIQUIS,allergic edema,syncope were reported in of patients receiving ELIQUIS Prophylaxis of,0,0.5452909469604492
ELIQUIS,allergic edema,anaphylactic reactions such allergic,1,0.7719427943229675
ELIQUIS,allergic edema,including drug hypersensitivity such as skin,0,0.6823388934135437
ELIQUIS,allergic edema,skin,0,0.6057983636856079
ELIQUIS,allergic edema,reactions,0,0.5903773307800293
ELIQUIS,syncope,syncope were reported in,1,0.9076400995254517
ELIQUIS,syncope,as allergic edema syncope,1,0.8376771211624146
ELIQUIS,syncope,in of patients receiving ELIQUIS Prophylaxis of Deep Vein,0,0.5411783456802368
ELIQUIS,syncope,were reported in of patients receiving ELIQUIS Prophylaxis of,0,0.5343970060348511
ELIQUIS,syncope,syncope were reported in of patients,1,0.8734461069107056
ELIQUIS,syncope,syncope were reported,1,0.9156457185745239
ELIQUIS,syncope,Vein Thrombosis,0,0.6332489252090454
ELIQUIS,Bleeding,Bleeding results,1,0.9011592864990234
ELIQUIS,Bleeding,patients treated with ELIQUIS mg twice daily experienced,0,0.6158791780471802
ELIQUIS,Bleeding,Bleeding results during,1,0.911276638507843
ELIQUIS,Bleeding,Bleeding results during the treatment,1,0.8537387847900391
ELIQUIS,Bleeding,adverse Bleeding results during the treatment,1,0.8116467595100403
ELIQUIS,Bleeding,in the Phase III studies are shown in Table,0,0.5072187781333923
ELIQUIS,Bleeding,patients,0,0.5812273621559143
ELIQUIS,Bleeding,Bleeding results during the,1,0.9022253751754761
ELIQUIS,Bleeding,mg twice daily experienced,0,0.5449662208557129
ELIQUIS,Bleeding,Bleeding was assessed,1,0.9061048626899719
ELIQUIS,Bleeding,are,0,0.5260499119758606
ELIQUIS,Bleeding,Replacement Surgery Ble,0,0.497979998588562
ELIQUIS,Bleeding,with the,0,0.5714250802993774
ELIQUIS,Bleeding,Table,0,0.5469434261322021
ELIQUIS,Bleeding,in each,0,0.5455365180969238
ELIQUIS,Bleeding,assessed in each study beginning with the first dose of,0,0.5141458511352539
ELIQUIS,bleeding,Surgery bleeding,1,0.8594610095024109
ELIQUIS,bleeding,assessed in each study beginning with the first dose of,0,0.5141458511352539
ELIQUIS,bleeding,Includes subjects with,0,0.49496614933013916
ELIQUIS,bleeding,bleeding criteria,1,0.8331339359283447
ELIQUIS,surgical site bleeding,Surgery All bleeding criteria surgical site bleeding,1,0.8935723304748535
ELIQUIS,surgical site bleeding,bleeding criteria,1,0.7079213857650757
ELIQUIS,surgical site bleeding,surgical site bleeding,1,0.9999999403953552
ELIQUIS,bleeding,bleeding events,1,0.845495343208313
ELIQUIS,bleeding,bleeding events that,1,0.8190796971321106
ELIQUIS,bleeding,bleeding events that occurred,1,0.8621811866760254
ELIQUIS,bleeding,bleeding events that occurred before the,1,0.7926645278930664
ELIQUIS,bleeding,bleeding Includes subjects with major,0,0.843797504901886
ELIQUIS,bleeding,subjects with major,0,0.4853101968765259
ELIQUIS,bleeding,hours post surgery,0,0.5240124464035034
ELIQUIS,bleeding,subjects with bleeding events that occurred,1,0.8712136149406433
ELIQUIS,bleeding,to hours,0,0.49175649881362915
ELIQUIS,bleeding,bleeding events that occurred before,1,0.8127458095550537
ELIQUIS,bleeding,hours,0,0.527387261390686
ELIQUIS,bleeding,of apixaban administered to hours post surgery,0,0.6157606840133667
ELIQUIS,Bleeding into an operated joint,this category of,0,0.4293827712535858
ELIQUIS,Bleeding into an operated joint,all patients with this category of bleeding,0,0.6986026763916016
ELIQUIS,bleeding,Events and event rates include one enoxaparintreated patient in ADVANCE who also,0,0.655610203742981
ELIQUIS,bleeding,was present,0,0.5536044836044312
ELIQUIS,bleeding,bleeding Events,1,0.845495343208313
ELIQUIS,bleeding,present in all patients with this category of,0,0.5584904551506042
ELIQUIS,bleeding,bleeding Events and event rates include,1,0.7951499223709106
ELIQUIS,bleeding,category of,0,0.4956900477409363
ELIQUIS,bleeding,and event rates,0,0.5188259482383728
ELIQUIS,bleeding,bleeding Events and event,1,0.7844893932342529
ELIQUIS,intracranial hemorrhage,also intracranial hemorrhage CRNM clinically,1,0.8399038314819336
ELIQUIS,intracranial hemorrhage,bleeding Events and event,1,0.6282992362976074
ELIQUIS,intracranial hemorrhage,mg po,0,0.4656584560871124
ELIQUIS,intracranial hemorrhage,relevant,0,0.5066143870353699
ELIQUIS,intracranial hemorrhage,include one enoxaparintreated patient in ADVANCE who,0,0.5729854106903076
ELIQUIS,hemorrhagic anemia,postoperative hemorrhagic,1,0.7403216361999512
ELIQUIS,hemorrhagic anemia,postoperative and,0,0.4684831500053406
ELIQUIS,hematoma,hematoma and vaginal and urethral hemorrhage,1,0.8144334554672241
ELIQUIS,hematoma,postoperative and,0,0.526871919631958
ELIQUIS,hematoma,Hemorrhage hematoma and vaginal and,1,0.810131311416626
ELIQUIS,hematoma,hematoma and,1,0.9583984017372131
ELIQUIS,urethral hemorrhage,Postprocedural hemorrhage including postpr,0,0.66020667552948
ELIQUIS,urethral hemorrhage,hematoma and vaginal urethral hemorrhage Postprocedural hemorrhage including,1,0.7938470244407654
ELIQUIS,urethral hemorrhage,and vaginal urethral hemorrhage Postprocedural,1,0.8088200092315674
ELIQUIS,urethral hemorrhage,vaginal urethral hemorrhage,1,0.9084516167640686
ELIQUIS,urethral hemorrhage,and vaginal urethral hemorrhage Postprocedural hemorrhage,1,0.8098362684249878
ELIQUIS,urethral hemorrhage,vaginal urethral hemorrhage Postprocedural hemorrhage including,1,0.8105123043060303
ELIQUIS,Postprocedural hemorrhage,vaginal,0,0.4813399016857147
ELIQUIS,Postprocedural hemorrhage,urethral Postprocedural,1,0.7342336773872375
ELIQUIS,Postprocedural hemorrhage,matoma and vaginal and urethral hemorrhage,0,0.6506924629211426
ELIQUIS,Postprocedural hemorrhage,and urethral Postprocedural hemorrhage including postprocedural hematoma,1,0.8824102878570557
ELIQUIS,Postprocedural hemorrhage,urethral Postprocedural hemorrhage including postprocedural hematoma wound hemorrhage,1,0.8762937784194946
ELIQUIS,Postprocedural hemorrhage,site hematoma and,0,0.6818665862083435
ELIQUIS,postprocedural hematoma,hemorrhage including,0,0.703582763671875
ELIQUIS,postprocedural hematoma,and catheter site,0,0.5971486568450928
ELIQUIS,wound hemorrhage,wound hemorrhage vessel,1,0.9225900173187256
ELIQUIS,wound hemorrhage,wound hemorrhage,1,1.0
ELIQUIS,wound hemorrhage,postprocedural wound,1,0.7390589118003845
ELIQUIS,wound hemorrhage,puncture site hematoma and catheter site,0,0.7127653360366821
ELIQUIS,wound hemorrhage,wound hemorrhage vessel puncture,1,0.8407156467437744
ELIQUIS,wound hemorrhage,wound hemorrhage vessel puncture site,1,0.8314087390899658
ELIQUIS,wound hemorrhage,hemorrhage including postprocedural wound hemorrhage vessel puncture,1,0.8017719984054565
ELIQUIS,catheter site hemorrhage,site hemorrhage Transaminases increased including,1,0.7158091068267822
ELIQUIS,catheter site hemorrhage,catheter site hemorrhage Transaminases increased including alanine,1,0.8105580806732178
ELIQUIS,catheter site hemorrhage,hematoma catheter site hemorrhage,1,0.9329261779785156
ELIQUIS,catheter site hemorrhage,increased,0,0.5055180191993713
ELIQUIS,catheter site hemorrhage,catheter site hemorrhage Transaminases increased,1,0.8443074226379395
ELIQUIS,catheter site hemorrhage,postprocedural hematoma,0,0.6936344504356384
ELIQUIS,catheter site hemorrhage,puncture site hematoma catheter,1,0.8199688792228699
ELIQUIS,catheter site hemorrhage,hemorrhage vessel puncture site hematoma and,0,0.7980059385299683
ELIQUIS,Transaminases increased,alanine aminotransferase,0,0.7129570245742798
ELIQUIS,Transaminases increased,and catheter site Transaminases,1,0.8109238743782043
ELIQUIS,Transaminases increased,Transaminases increased including alanine aminotransferase increased,1,0.949421226978302
ELIQUIS,Transaminases increased,including alanine,0,0.6672429442405701
ELIQUIS,Transaminases increased,hematoma and catheter site,0,0.5286339521408081
ELIQUIS,Transaminases increased,Transaminases increased including,1,0.9938533306121826
ELIQUIS,Transaminases increased,alanine,0,0.6222814917564392
ELIQUIS,Transaminases increased,Transaminases increased including alanine aminotransferase,1,0.9460565447807312
ELIQUIS,alanine aminotransferase increased,morrhage Transaminases increased,0,0.7734062075614929
ELIQUIS,alanine aminotransferase increased,and alanine aminotransferase abnormal Aspar,0,0.8208673000335693
ELIQUIS,alanine aminotransferase increased,alanine aminotransferase increased and alanine,1,0.9834208488464355
ELIQUIS,alanine aminotransferase increased,alanine,0,0.7473383545875549
ELIQUIS,alanine aminotransferase abnormal,alanine aminotransferase abnormal Aspartate,1,0.9246647357940674
ELIQUIS,alanine aminotransferase abnormal,aminotransferase,0,0.8425783514976501
ELIQUIS,alanine aminotransferase abnormal,including alanine aminotransferase increased and,0,0.8902523517608643
ELIQUIS,alanine aminotransferase abnormal,Aspartate,0,0.6003674268722534
ELIQUIS,alanine aminotransferase abnormal,alanine aminotransferase increased alanine aminotransferase abnormal,1,0.9565144181251526
ELIQUIS,Aspartate aminotransferase increased,eased and alanine aminotransferase Aspartate aminotransferase,1,0.8755042552947998
ELIQUIS,Aspartate aminotransferase increased,aminotransferase increased Gammaglutamyltransferase i,1,0.8333221673965454
ELIQUIS,Aspartate aminotransferase increased,and alanine aminotransferase Aspartate aminotransferase increased Gammaglutamyltransferase,1,0.8886436820030212
ELIQUIS,Aspartate aminotransferase increased,aminotransferase increased,1,0.9375388622283936
ELIQUIS,thrombocytopenia,system thrombocytopenia including platelet count decreases Vascular,1,0.7979832887649536
ELIQUIS,thrombocytopenia,aminotransferase increased,1,0.5441986918449402
ELIQUIS,thrombocytopenia,thrombocytopenia including platelet,1,0.9361592531204224
ELIQUIS,thrombocytopenia,disorders,0,0.5538288354873657
ELIQUIS,thrombocytopenia,Blood and lymphatic system thrombocytopenia including platelet count decreases Vascular,1,0.7690326571464539
ELIQUIS,thrombocytopenia,thrombocytopenia including platelet count decreases Vascular,1,0.8104408979415894
ELIQUIS,thrombocytopenia,and lymphatic,0,0.5209910869598389
ELIQUIS,thrombocytopenia,Blood and lymphatic system thrombocytopenia,1,0.8339110016822815
ELIQUIS,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
ELIQUIS,platelet count decreases,count decreases Vascular disorders hypotension including,1,0.7010965347290039
ELIQUIS,platelet count decreases,disorders thrombocytopenia platelet count decreases,1,0.8976324796676636
ELIQUIS,platelet count decreases,of to Blood and lymphatic system disorders,0,0.5763804912567139
ELIQUIS,platelet count decreases,thrombocytopenia platelet count decreases Vascular disorders,1,0.8256189227104187
ELIQUIS,platelet count decreases,platelet count decreases Vascular disorders hypotension including procedural,1,0.8024332523345947
ELIQUIS,platelet count decreases,thrombocytopenia platelet count decreases,1,0.9362144470214844
ELIQUIS,platelet count decreases,disorders,0,0.49721699953079224
ELIQUIS,platelet count decreases,platelet count decreases Vascular,1,0.9042595624923706
ELIQUIS,platelet count decreases,and lymphatic system,0,0.5077208280563354
ELIQUIS,platelet count decreases,to Blood and lymphatic,0,0.589614748954773
ELIQUIS,hypotension,hypotension including procedural hypotension Respiratory thoracic,1,0.8026672601699829
ELIQUIS,hypotension,thoracic and mediastinal disorders,0,0.5208820104598999
ELIQUIS,hypotension,hypotension including,1,0.9207078218460083
ELIQUIS,hypotension,Respiratory thoracic and mediastinal disorders epistax,0,0.5195061564445496
ELIQUIS,hypotension,and mediastinal disorders,0,0.5068891048431396
ELIQUIS,hypotension,decreases,0,0.5957416892051697
ELIQUIS,hypotension,Vascular hypotension including procedural hypotension Respiratory,1,0.8039484024047852
ELIQUIS,procedural hypotension,hypotension procedural hypotension Respiratory thoracic and mediastinal,1,0.8790932893753052
ELIQUIS,procedural hypotension,decreases,0,0.5693744421005249
ELIQUIS,procedural hypotension,procedural hypotension Respiratory,1,0.904510498046875
ELIQUIS,procedural hypotension,procedural hypotension,1,1.0
ELIQUIS,procedural hypotension,procedural hypotension Respiratory thoracic,1,0.8908846974372864
ELIQUIS,procedural hypotension,platelet count decreases,0,0.566073477268219
ELIQUIS,procedural hypotension,procedural hypotension Respiratory thoracic and mediastinal disorders,1,0.8560840487480164
ELIQUIS,procedural hypotension,decreases Vascular disorders hypotension procedural hypotension Respiratory thoracic and,1,0.8467297554016113
ELIQUIS,epistaxis,epistaxis Gastrointestinal disorders gastrointestinal hemorrhage,1,0.795554518699646
ELIQUIS,epistaxis,disorders,0,0.5312409400939941
ELIQUIS,epistaxis,epistaxis Gastrointestinal disorders gastrointestinal hemorrhage including,1,0.7957397699356079
ELIQUIS,gastrointestinal hemorrhage,disorders epistaxis Gastrointestinal disorders,0,0.7092102766036987
ELIQUIS,gastrointestinal hemorrhage,Hepatobiliary,0,0.6310166716575623
ELIQUIS,gastrointestinal hemorrhage,hematochezia Hepatobiliary disorders liver function tes,0,0.6476887464523315
ELIQUIS,gastrointestinal hemorrhage,and melena hematochezia Hepatobiliary disorders,0,0.6741510629653931
ELIQUIS,hematemesis,gastrointestinal hemorrhage hematemesis,1,0.8852989673614502
ELIQUIS,hematemesis,and melena hematochezia Hepatobiliary disorders,0,0.6525107622146606
ELIQUIS,hematemesis,hematemesis and melena hematochezia,1,0.8844908475875854
ELIQUIS,hematemesis,hematemesis and melena hematochezia Hepatobiliary disorders,1,0.8037725687026978
ELIQUIS,hematemesis,gastrointestinal hemorrhage hematemesis and,1,0.8557093143463135
ELIQUIS,hematemesis,hematemesis,1,1.0
ELIQUIS,melena,melena hematochezia Hepatobiliary disorders,1,0.7404607534408569
ELIQUIS,melena,hematemesis and melena hematochezia,1,0.7239350080490112
ELIQUIS,melena,hematemesis melena hematochezia Hepatobiliary disorders liver function,1,0.6661765575408936
ELIQUIS,melena,epistaxis Gastrointestinal disorders,0,0.5126971006393433
ELIQUIS,melena,melena,1,1.0
ELIQUIS,melena,melena hematochezia Hepatobiliary disorders liver function,1,0.7207534313201904
ELIQUIS,melena,melena hematochezia Hepatobiliary,1,0.7414525747299194
ELIQUIS,hematochezia,including hematemesis and melena,0,0.7569840550422668
ELIQUIS,liver function test abnormal,increased,0,0.5155770778656006
ELIQUIS,liver function test abnormal,and urinary,0,0.5459160804748535
ELIQUIS,liver function test abnormal,Renal and urinary disorders,0,0.5527342557907104
ELIQUIS,liver function test abnormal,melena hematochezia,0,0.4876410961151123
ELIQUIS,blood alkaline phosphatase increased,liver function test blood alkaline phosphatase increased,1,0.900672197341919
ELIQUIS,blood alkaline phosphatase increased,function test blood alkaline phosphatase increased,1,0.9307040572166443
ELIQUIS,blood alkaline phosphatase increased,phosphatase increased blood bilirubin increased Renal and,1,0.817566990852356
ELIQUIS,blood bilirubin increased,bilirubin increased Renal and urinary,1,0.8740609884262085
ELIQUIS,blood bilirubin increased,blood,1,0.6827642321586609
ELIQUIS,blood bilirubin increased,bilirubin increased,1,0.979468047618866
ELIQUIS,blood bilirubin increased,Hepatobiliary disorders liver function,0,0.7075384855270386
ELIQUIS,hematuria,blood bilirubin increased Renal,0,0.6496056318283081
ELIQUIS,hematuria,hematuria,1,1.0
ELIQUIS,wound secretion,procedural complications,0,0.5790013074874878
ELIQUIS,wound secretion,parameters Injury poisoning,0,0.6229842901229858
ELIQUIS,wound secretion,including incisionsite hematoma operative hemorrhage Less,0,0.5913142561912537
ELIQUIS,wound secretion,wound secretion,1,0.9999999403953552
ELIQUIS,incision-site hemorrhage,incision-site hemorrhage including incisionsite hematoma operative hemorrhage,1,0.9406798481941223
ELIQUIS,incision-site hemorrhage,wound secretion,1,0.6351640224456787
ELIQUIS,incision-site hemorrhage,and procedural complications wound incision-site hemorrhage,1,0.9170126914978027
ELIQUIS,incision-site hemorrhage,incision-site hemorrhage,1,0.9999999403953552
ELIQUIS,incision-site hemorrhage,incision-site hemorrhage including incisionsite hematoma,1,0.9446921944618225
ELIQUIS,incision-site hemorrhage,complications wound incision-site,1,0.8166227340698242
ELIQUIS,incision-site hematoma,incision-site hematoma operative,1,0.9696587920188904
ELIQUIS,incision-site hematoma,incision-site hematoma operative hemorrhage Less common,1,0.9028596878051758
ELIQUIS,incision-site hematoma,operative hemorrhage Less common,0,0.7071179151535034
ELIQUIS,incision-site hematoma,operative hemorrhage Less common adverse reactions in apixabantreated,0,0.6206463575363159
ELIQUIS,incision-site hematoma,common adverse reactions in apixabantreated patients undergoing hi,0,0.5397073030471802
ELIQUIS,incision-site hematoma,hemorrhage incision-site hematoma operative hemorrhage Less,1,0.9002785086631775
ELIQUIS,incision-site hematoma,incision-site hematoma operative hemorrhage Less,1,0.9255675077438354
ELIQUIS,incision-site hematoma,incision-site hematoma operative hemorrhage Less common adverse,1,0.8925087451934814
ELIQUIS,incision-site hematoma,secretion incisionsite hemorrhage,0,0.7897258400917053
ELIQUIS,operative hemorrhage,operative hemorrhage,1,1.0
ELIQUIS,operative hemorrhage,patients,0,0.5265306234359741
ELIQUIS,operative hemorrhage,hip or,0,0.5156159400939941
ELIQUIS,hemoptysis,hypersensitivity muscle hemorrhage ocular hemorrhage including,0,0.6287783980369568
ELIQUIS,hemoptysis,hypersensitivity,0,0.5439413785934448
ELIQUIS,hemoptysis,of Gingival bleeding,0,0.5726419687271118
ELIQUIS,hemoptysis,hemorrhage including conjunctival,0,0.6726980209350586
ELIQUIS,hemoptysis,of Gingival hemoptysis hypersensitivity muscle hemorrhage,1,0.7515021562576294
ELIQUIS,hemoptysis,of Gingival hemoptysis,1,0.8415248990058899
ELIQUIS,hypersensitivity,hypersensitivity,1,1.0
ELIQUIS,hypersensitivity,frequency of Gingival bleeding,0,0.49431341886520386
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage ocular,1,0.736725389957428
ELIQUIS,hypersensitivity,Gingival bleeding hypersensitivity,1,0.7815521955490112
ELIQUIS,muscle hemorrhage,Treatment,0,0.5414018034934998
ELIQUIS,muscle hemorrhage,hemoptysis muscle hemorrhage,1,0.846402645111084
ELIQUIS,muscle hemorrhage,muscle hemorrhage ocular hemorrhage including conjunctival,1,0.8334348201751709
ELIQUIS,muscle hemorrhage,hemoptysis muscle hemorrhage ocular hemorrhage including,1,0.8215701580047607
ELIQUIS,muscle hemorrhage,Gingival,0,0.4621119499206543
ELIQUIS,ocular hemorrhage,and PE,0,0.45483970642089844
ELIQUIS,ocular hemorrhage,ocular hemorrhage,1,1.0
ELIQUIS,ocular hemorrhage,ocular,1,0.7723380327224731
ELIQUIS,ocular hemorrhage,bleeding hemoptysis hypersensitivity muscle ocular,1,0.793578565120697
ELIQUIS,conjunctival hemorrhage,muscle hemorrhage ocular hemorrhage conjunctival hemorrhage rectal hemorrhage Treatment,1,0.8166437149047852
ELIQUIS,conjunctival hemorrhage,bleeding hemoptysis hypersensitivity muscle ocular,1,0.7787007093429565
ELIQUIS,conjunctival hemorrhage,ocular hemorrhage conjunctival hemorrhage rectal,1,0.8992936611175537
ELIQUIS,conjunctival hemorrhage,conjunctival hemorrhage,1,1.0000001192092896
ELIQUIS,conjunctival hemorrhage,ocular hemorrhage conjunctival,1,0.9699378609657288
ELIQUIS,conjunctival hemorrhage,Gingival bleeding hemoptysis hypersensitivity muscle hemorrhage ocular hemorrhage,0,0.7858275175094604
ELIQUIS,conjunctival hemorrhage,conjunctival hemorrhage rectal hemorrhage Treatment,1,0.8402025699615479
ELIQUIS,conjunctival hemorrhage,hemoptysis hypersensitivity muscle hemorrhage ocular,0,0.7889623641967773
ELIQUIS,conjunctival hemorrhage,hemorrhage conjunctival hemorrhage rectal hemorrhage Treatment of DVT,1,0.7940477728843689
ELIQUIS,conjunctival hemorrhage,Gingival bleeding hemoptysis hypersensitivity muscle hemorrhage ocular hemorrhage including,0,0.79388427734375
ELIQUIS,rectal hemorrhage,rectal hemorrhage Treatment of DVT,1,0.8029560446739197
ELIQUIS,rectal hemorrhage,muscle hemorrhage ocular hemorrhage,0,0.6844598650932312
ELIQUIS,rectal hemorrhage,including conjunctival,0,0.5005155205726624
ELIQUIS,epistaxis,epistaxis contusion,1,0.8640410900115967
ELIQUIS,epistaxis,including conjunctival,0,0.5736157298088074
ELIQUIS,epistaxis,to ELIQUIS mg twice daily Common adverse,0,0.5656559467315674
ELIQUIS,epistaxis,epistaxis contusion hematuria rectal hemorrhage,1,0.7799481749534607
ELIQUIS,contusion,epistaxis,0,0.5181949138641357
ELIQUIS,contusion,were gingival bleeding contusion,1,0.7793372869491577
ELIQUIS,contusion,hemoptysis AMPLIFY Study,0,0.5169278979301453
ELIQUIS,contusion,menorrhagia,0,0.5687727332115173
ELIQUIS,contusion,and,0,0.5130102634429932
ELIQUIS,contusion,contusion hematuria rectal hemorrhage,1,0.7756029367446899
ELIQUIS,hematuria,hematuria rectal hemorrhage hematoma menorrhagia,1,0.8284623622894287
ELIQUIS,hematuria,hemoptysis AMPLIFY Study The,0,0.5906119346618652
ELIQUIS,hematuria,epistaxis hematuria rectal hemorrhage hematoma,1,0.7434847354888916
ELIQUIS,hematuria,were gingival bleeding epistaxis,0,0.5423974990844727
ELIQUIS,rectal hemorrhage,bleeding epistaxis contusion hematuria,0,0.6667988300323486
ELIQUIS,rectal hemorrhage,Study The mean duration of,0,0.4812397062778473
ELIQUIS,rectal hemorrhage,rectal hemorrhage,1,1.0000001192092896
ELIQUIS,rectal hemorrhage,epistaxis contusion rectal hemorrhage,1,0.8561261892318726
ELIQUIS,rectal hemorrhage,were gingival bleeding,0,0.6517815589904785
ELIQUIS,rectal hemorrhage,hemoptysis AMPLIFY Study The mean duration of,0,0.5821890830993652
ELIQUIS,rectal hemorrhage,duration of exposure to ELI,0,0.4826599359512329
ELIQUIS,rectal hemorrhage,were,0,0.4858032464981079
ELIQUIS,rectal hemorrhage,rectal,1,0.8087302446365356
ELIQUIS,hematoma,epistaxis contusion hematuria rectal hemorrhage,0,0.66929030418396
ELIQUIS,menorrhagia,hematuria rectal,0,0.6093490123748779
ELIQUIS,menorrhagia,rectal hemorrhage,0,0.7025893926620483
ELIQUIS,menorrhagia,gingival bleeding epistaxis contusion hematuria rectal hemorrhage hematoma,0,0.687159538269043
ELIQUIS,menorrhagia,hemorrhage hematoma,0,0.7234817743301392
ELIQUIS,menorrhagia,contusion hematuria rectal hemorrhage menorrhagia and hemoptysis AMPLIFY,1,0.7609888315200806
ELIQUIS,menorrhagia,menorrhagia and hemoptysis AMPLIFY Study,1,0.8282887935638428
ELIQUIS,hemoptysis,menorrhagia,0,0.6153442859649658
ELIQUIS,hemoptysis,hemoptysis,1,0.9999998807907104
ELIQUIS,hemoptysis,epistaxis contusion hematuria rectal hemorrhage hematoma menorrhagia and,0,0.6728954911231995
ELIQUIS,hemoptysis,hemoptysis AMPLIFY Study,1,0.8392344117164612
ELIQUIS,bleeding,was days in,0,0.5250222682952881
ELIQUIS,bleeding,compared,0,0.4977337121963501
ELIQUIS,bleeding,in the AMPLIFY study Adverse reactions related to,0,0.5561174750328064
ELIQUIS,bleeding,reactions related bleeding occurred in ELIQUIStreated,1,0.8414119482040405
ELIQUIS,bleeding,occurred in ELIQUIStreated,0,0.5536857843399048
ELIQUIS,bleeding,Adverse reactions related bleeding occurred in,1,0.7962925434112549
ELIQUIS,bleeding,bleeding occurred in ELIQUIStreated patients compared,1,0.8512241840362549
ELIQUIS,bleeding,rate due to,0,0.5287325382232666
ELIQUIS,bleeding,the ELIQUIStreated,0,0.5241554975509644
ELIQUIS,bleeding,CI Pvalue,0,0.4737934470176697
ELIQUIS,Bleeding,Bleeding results from the AMPLIFY,1,0.8092044591903687
ELIQUIS,Bleeding,y safety endpoint of major bleeding relative risk CI Pvalue,0,0.7431846857070923
ELIQUIS,Bleeding,bleeding relative risk CI Bleeding results from the,1,0.7503901720046997
ELIQUIS,Bleeding,bleeding relative risk CI Bleeding results,1,0.7495990991592407
ELIQUIS,Bleeding,Bleeding Results in the AMPLIFY Study,1,0.7803215980529785
ELIQUIS,Bleeding,AMPLIFY Study,0,0.5382899641990662
ELIQUIS,Bleeding,Bleeding Results in,1,0.9010066390037537
ELIQUIS,Bleeding,Bleeding Results,1,0.9011592864990234
ELIQUIS,Bleeding,Table Bleeding Results,1,0.8108620643615723
ELIQUIS,Bleeding,in,0,0.5393304824829102
ELIQUIS,Bleeding,are summarized in Table Bleeding Results in,1,0.812389075756073
ELIQUIS,CRNM,Risk CI,0,0.5413126945495605
ELIQUIS,CRNM,CRNM clinically relevant nonmajor bleedingEvents associated,1,0.738746166229248
ELIQUIS,CRNM,ELIQUISNn EnoxaparinWarfarinNn Relative Risk CRNM clinically relevant,1,0.6841210722923279
ELIQUIS,CRNM,EnoxaparinWarfarinNn Relative Risk CRNM clinically relevant,1,0.7093917727470398
ELIQUIS,clinically relevant nonmajor bleeding,IQUISNn EnoxaparinWarfarinNn Relative Risk CI CRNM,0,0.6474829912185669
ELIQUIS,clinically relevant nonmajor bleeding,Relative Risk CI clinically,1,0.6188641786575317
ELIQUIS,clinically relevant nonmajor bleeding,clinically relevant nonmajor bleeding Events associated with each,1,0.9145841598510742
ELIQUIS,clinically relevant nonmajor bleeding,relevant nonmajor bleeding Events associated with each endpoint,1,0.8521924614906311
ELIQUIS,clinically relevant nonmajor bleeding,per,0,0.5141260623931885
ELIQUIS,clinically relevant nonmajor bleeding,once per subject but subjects may,0,0.5401859283447266
ELIQUIS,clinically relevant nonmajor bleeding,nonmajor bleeding Events associated,1,0.9049692153930664
ELIQUIS,clinically relevant nonmajor bleeding,Risk CI clinically relevant nonmajor,1,0.7610045671463013
ELIQUIS,bleeding,Adverse reactions related bleeding occurred in ELIQUIStreated patients compared,1,0.7772314548492432
ELIQUIS,bleeding,Risk CI clinically relevant nonmajor,1,0.48492932319641113
ELIQUIS,bleeding,in ELIQUIStreated patients compared to,0,0.547624409198761
ELIQUIS,bleeding,Adverse reactions related bleeding occurred in ELIQUIStreated,1,0.7954827547073364
ELIQUIS,bleeding,ELIQUIStreated patients compared to,0,0.5397894978523254
ELIQUIS,bleeding,occurred in ELIQUIStreated patients compared to placebotreated patients,0,0.5788842439651489
ELIQUIS,bleeding,bleeding events was approximately in,1,0.8087320923805237
ELIQUIS,bleeding,to,0,0.5197806358337402
ELIQUIS,bleeding,bleeding events was,1,0.8063675165176392
ELIQUIS,bleeding,approximately in the ELIQUIStreated patients compared to in those patients in,0,0.5509054660797119
ELIQUIS,bleeding,bleeding events was approximately,1,0.8076438903808594
ELIQUIS,bleeding,was,0,0.5299928188323975
ELIQUIS,Bleeding,Bleeding results from the,1,0.9017987251281738
ELIQUIS,Bleeding,Bleeding results from the AMPLIFYEXT study,1,0.7828183174133301
ELIQUIS,Bleeding,Table Table Bleeding,0,0.8091225624084473
ELIQUIS,Bleeding,results from the AMPLIFYEXT study are summarized in Table,0,0.5486649870872498
ELIQUIS,Bleeding,Table Bleeding Results in the AMPLIFYEXT Study,1,0.7601352334022522
ELIQUIS,Bleeding,the AMPLIFYEXT Study ELIQUIS mg bidNn,0,0.561693012714386
ELIQUIS,CRNM,bidNn,0,0.6095051169395447
ELIQUIS,CRNM,CRNM clinically relevant,1,0.8890078067779541
ELIQUIS,CRNM,counted,0,0.5029631853103638
ELIQUIS,CRNM,CRNM,1,1.0000001192092896
ELIQUIS,CRNM,CRNM clinically relevant nonmajor bleedingEvents,1,0.7384288311004639
ELIQUIS,clinically relevant nonmajor bleeding,may,0,0.48717862367630005
ELIQUIS,clinically relevant nonmajor bleeding,ELIQUIS mg bidNn PlaceboNn clinically relevant,1,0.6307529211044312
ELIQUIS,hemorrhagic anemia,system hemorrhagic anemia,1,0.9070963263511658
ELIQUIS,hematochezia,hemorrhagic anemia,0,0.733251690864563
ELIQUIS,hematochezia,hematochezia hemorrhoidal hemorrhage gastrointestinal,1,0.8441416025161743
ELIQUIS,hematochezia,hematochezia,1,1.0
ELIQUIS,hematochezia,hemorrhoidal hemorrhage gastrointestinal hemorrhage hematemesis melena anal,0,0.7253144979476929
ELIQUIS,hematochezia,hematochezia hemorrhoidal hemorrhage gastrointestinal hemorrhage,1,0.8388255834579468
ELIQUIS,hematochezia,hematochezia hemorrhoidal hemorrhage,1,0.8424545526504517
ELIQUIS,hematochezia,hemorrhagic anemia Gastrointestinal hematochezia hemorrhoidal hemorrhage gastrointestinal,1,0.8121055364608765
ELIQUIS,hematochezia,gastrointestinal hemorrhage hematemesis melena anal hemorrhage,0,0.7139943838119507
ELIQUIS,hemorrhoidal hemorrhage,hemorrhoidal hemorrhage,1,0.9999998807907104
ELIQUIS,gastrointestinal hemorrhage,gastrointestinal hemorrhage hematemesis melena,1,0.8461872339248657
ELIQUIS,gastrointestinal hemorrhage,anal,0,0.5336977243423462
ELIQUIS,hematemesis,hemorrhage,0,0.7272741198539734
ELIQUIS,melena,gastrointestinal hemorrhage melena anal hemorrhage,1,0.7229165434837341
ELIQUIS,melena,hemorrhage,0,0.5417894124984741
ELIQUIS,melena,melena anal hemorrhage Injury,1,0.7099369764328003
ELIQUIS,melena,melena anal hemorrhage Injury poisoning,1,0.689816951751709
ELIQUIS,melena,melena anal hemorrhage,1,0.7606393098831177
ELIQUIS,melena,Injury poisoning and procedural complications,0,0.4458087086677551
ELIQUIS,melena,melena anal,1,0.833320140838623
ELIQUIS,melena,hemorrhoidal hemorrhage gastrointestinal hemorrhage melena,1,0.7340031862258911
ELIQUIS,anal hemorrhage,anal hemorrhage Injury poisoning and,1,0.8724517226219177
ELIQUIS,anal hemorrhage,melena anal,1,0.7031183242797852
ELIQUIS,anal hemorrhage,gastrointestinal hemorrhage hematemesis anal,1,0.852285623550415
ELIQUIS,anal hemorrhage,gastrointestinal hemorrhage hematemesis anal hemorrhage,1,0.8558488488197327
ELIQUIS,anal hemorrhage,anal hemorrhage Injury poisoning and procedural complications,1,0.850085437297821
ELIQUIS,anal hemorrhage,hemorrhage gastrointestinal hemorrhage hematemesis anal hemorrhage Injury poisoning and procedural,1,0.7932312488555908
ELIQUIS,anal hemorrhage,anal hemorrhage Injury,1,0.9425793886184692
ELIQUIS,wound hemorrhage,poisoning and procedural,0,0.550885796546936
ELIQUIS,wound hemorrhage,hematoma periorbital hematoma Musculoskeletal and conn,0,0.6475971341133118
ELIQUIS,traumatic hematoma,tissue disorders,0,0.5769043564796448
ELIQUIS,traumatic hematoma,disorders muscle,0,0.4641198515892029
ELIQUIS,traumatic hematoma,traumatic hematoma periorbital hematoma,1,0.812964677810669
ELIQUIS,traumatic hematoma,postprocedural traumatic hematoma periorbital hematoma,1,0.8016413450241089
ELIQUIS,traumatic hematoma,complications wound hemorrhage postprocedural traumatic,1,0.7062778472900391
ELIQUIS,traumatic hematoma,traumatic hematoma periorbital,1,0.826080322265625
ELIQUIS,periorbital hematoma,hemorrhage postprocedural hemorrhage traumatic periorbital,1,0.8456667065620422
ELIQUIS,periorbital hematoma,disorders muscle hemorrhage,0,0.6037294864654541
ELIQUIS,muscle hemorrhage,connective tissue muscle,1,0.6854958534240723
ELIQUIS,muscle hemorrhage,and connective tissue muscle hemorrhage Reproductive system,1,0.8307003974914551
ELIQUIS,muscle hemorrhage,tissue muscle hemorrhage,1,0.9498276114463806
ELIQUIS,muscle hemorrhage,disorders vaginal,0,0.4840884208679199
ELIQUIS,muscle hemorrhage,tissue muscle hemorrhage Reproductive system and,1,0.8622629642486572
ELIQUIS,muscle hemorrhage,muscle hemorrhage Reproductive,1,0.8810882568359375
ELIQUIS,muscle hemorrhage,traumatic hematoma,0,0.6559593677520752
ELIQUIS,muscle hemorrhage,Musculoskeletal and connective tissue muscle hemorrhage Reproductive,1,0.8514310121536255
ELIQUIS,muscle hemorrhage,and breast disorders vaginal hemorrhage metrorrhagia menometrorrhagia,0,0.6356658935546875
ELIQUIS,vaginal hemorrhage,Reproductive system and breast vaginal hemorrhage metrorrhagia menometrorrhagia,1,0.7976523041725159
ELIQUIS,vaginal hemorrhage,and breast disorders vaginal hemorrhage metrorrhagia menometrorrhagia,0,0.8035789132118225
ELIQUIS,vaginal hemorrhage,breast vaginal hemorrhage,1,0.8690060973167419
ELIQUIS,vaginal hemorrhage,system and breast vaginal hemorrhage,1,0.8516346216201782
ELIQUIS,metrorrhagia,hemorrhage,0,0.6041842103004456
ELIQUIS,metrorrhagia,metrorrhagia menometrorrhagia genital hemorrhage Vascular,1,0.8024344444274902
ELIQUIS,metrorrhagia,metrorrhagia menometrorrhagia genital,1,0.8483814597129822
ELIQUIS,metrorrhagia,genital hemorrhage,0,0.6196853518486023
ELIQUIS,metrorrhagia,metrorrhagia menometrorrhagia genital hemorrhage,1,0.8281311988830566
ELIQUIS,menometrorrhagia,disorders vaginal hemorrhage,0,0.6646928787231445
ELIQUIS,menometrorrhagia,breast disorders vaginal hemorrhage menometrorrhagia genital hemorrhage Vascular,1,0.7280536890029907
ELIQUIS,menometrorrhagia,disorders vaginal hemorrhage menometrorrhagia genital hemorrhage Vascular,1,0.7223414778709412
ELIQUIS,menometrorrhagia,and subcutaneous tissue,0,0.5714973211288452
ELIQUIS,menometrorrhagia,subcutaneous,0,0.5606232285499573
ELIQUIS,menometrorrhagia,vaginal hemorrhage menometrorrhagia genital,1,0.8353981375694275
ELIQUIS,menometrorrhagia,uscle hemorrhage Reproductive system and breast,0,0.6624072194099426
ELIQUIS,menometrorrhagia,vaginal hemorrhage,0,0.6674306392669678
ELIQUIS,menometrorrhagia,menometrorrhagia genital hemorrhage Vascular disorders hemorrhage,1,0.7946059703826904
ELIQUIS,menometrorrhagia,menometrorrhagia,1,1.0
ELIQUIS,genital hemorrhage,and subcutaneous,0,0.5488672256469727
ELIQUIS,genital hemorrhage,genital hemorrhage Vascular disorders,1,0.8748828172683716
ELIQUIS,genital hemorrhage,vaginal hemorrhage metrorrhagia genital hemorrhage Vascular,1,0.8582843542098999
ELIQUIS,hemorrhage,hemorrhage,0,1.0
ELIQUIS,ecchymosis,tissue ecchymosis skin hemorrhage petechiae,1,0.815239667892456
ELIQUIS,ecchymosis,hemorrhage,0,0.704937756061554
ELIQUIS,ecchymosis,ecchymosis skin hemorrhage petechiae Eye,1,0.8035427331924438
ELIQUIS,skin hemorrhage,tissue disorders skin,1,0.7302823662757874
ELIQUIS,skin hemorrhage,disorders,0,0.5584949254989624
ELIQUIS,skin hemorrhage,and subcutaneous tissue disorders skin hemorrhage petechiae Eye disorders conjunctival hemorrhage,1,0.8011074066162109
ELIQUIS,skin hemorrhage,skin hemorrhage petechiae Eye disorders,1,0.8083876371383667
ELIQUIS,skin hemorrhage,tissue disorders skin hemorrhage petechiae Eye disorders conjunctival hemorrhage,1,0.7938365340232849
ELIQUIS,skin hemorrhage,e Vascular disorders hemorrhage Skin and subcutaneous,0,0.8748658895492554
ELIQUIS,skin hemorrhage,conjunctival hemorrhage retinal hemorrhage,0,0.7001242637634277
ELIQUIS,skin hemorrhage,tissue disorders skin hemorrhage,1,0.9117879271507263
ELIQUIS,petechiae,petechiae Eye disorders,1,0.8895351886749268
ELIQUIS,petechiae,Skin and subcutaneous tissue disorders ecchymosis,0,0.6732306480407715
ELIQUIS,conjunctival hemorrhage,tissue disorders ecchymosis skin hemorrhage petechiae,0,0.6725828051567078
ELIQUIS,conjunctival hemorrhage,urine,0,0.4998144209384918
ELIQUIS,conjunctival hemorrhage,eye hemorrhage,0,0.8876646757125854
ELIQUIS,conjunctival hemorrhage,conjunctival hemorrhage retinal,1,0.9060792922973633
ELIQUIS,conjunctival hemorrhage,and,0,0.46592003107070923
ELIQUIS,conjunctival hemorrhage,skin hemorrhage petechiae Eye conjunctival,1,0.8858111500740051
ELIQUIS,conjunctival hemorrhage,hemorrhage petechiae Eye conjunctival hemorrhage,1,0.9223314523696899
ELIQUIS,conjunctival hemorrhage,conjunctival hemorrhage retinal hemorrhage eye hemorrhage Investigations,1,0.876704752445221
ELIQUIS,conjunctival hemorrhage,Eye conjunctival,1,0.8319203853607178
ELIQUIS,retinal hemorrhage,hemorrhage,0,0.7958425283432007
ELIQUIS,eye hemorrhage,eye hemorrhage Investigations blood,1,0.8803918361663818
ELIQUIS,eye hemorrhage,hemorrhage retinal eye hemorrhage Investigations blood,1,0.8701673746109009
ELIQUIS,eye hemorrhage,eye hemorrhage Investigations,1,0.8884133696556091
ELIQUIS,blood urine present,urine present occult blood positive occult blood,1,0.8574747443199158
ELIQUIS,occult blood positive,disorders,0,0.5065011382102966
ELIQUIS,occult blood positive,Investigations blood urine occult blood positive occult blood red blood cells,1,0.8458189964294434
ELIQUIS,occult blood positive,present,0,0.5303207039833069
ELIQUIS,occult blood positive,Investigations blood urine occult blood positive occult blood,1,0.8683622479438782
ELIQUIS,occult blood positive,blood positive,1,0.8384355306625366
ELIQUIS,occult blood positive,red blood,0,0.6801015138626099
ELIQUIS,occult blood positive,blood,0,0.7281837463378906
ELIQUIS,occult blood positive,urine occult blood positive occult,1,0.901887059211731
ELIQUIS,occult blood,occult blood occult blood,1,0.9494307041168213
ELIQUIS,occult blood,blood,0,0.7947341203689575
ELIQUIS,occult blood,occult blood,1,1.0000001192092896
ELIQUIS,red blood cells urine positive,blood cells urine positive General disorders and,1,0.8902044296264648
ELIQUIS,injection-site hematoma,vessel,0,0.5334703922271729
ELIQUIS,injection-site hematoma,vessel puncturesite hematoma,0,0.8436745405197144
ELIQUIS,injection-site hematoma,and administrationsite injection-site hematoma,1,0.9792237281799316
ELIQUIS,injection-site hematoma,General disorders and administrationsite injection-site hematoma vessel puncturesite hematoma,1,0.9138261675834656
ELIQUIS,injection-site hematoma,disorders and,0,0.5021207332611084
ELIQUIS,injection-site hematoma,vessel puncturesite,0,0.7051064968109131
ELIQUIS,injection-site hematoma,injection-site hematoma vessel puncturesite hematoma,1,0.9269185066223145
ELIQUIS,injection-site hematoma,injection-site hematoma vessel puncturesite,1,0.9311585426330566
ELIQUIS,THROMBOTIC EVENTS,of,0,0.5072709321975708
ELIQUIS,THROMBOTIC EVENTS,discussed in greater etail in other,1,0.5141223073005676
ELIQUIS,THROMBOTIC EVENTS,other se ctions of the prescribing information,1,0.5172901153564453
ELIQUIS,THROMBOTIC EVENTS,in other se ctions of the,1,0.5398198366165161
ELIQUIS,THROMBOTIC EVENTS,in other se ctions,1,0.5597710609436035
ELIQUIS,THROMBOTIC EVENTS,etail in other se,1,0.4792407751083374
ELIQUIS,THROMBOTIC EVENTS,other se ctions of the,1,0.5558123588562012
ELIQUIS,THROMBOTIC EVENTS,d,0,0.507910966873169
ELIQUIS,EPIDURAL HEMATOMA,greater detail in,0,0.48636215925216675
ELIQUIS,EPIDURAL HEMATOMA,he prescribing in formation Increased,1,0.46101921796798706
ELIQUIS,THROMBOTIC EVENTS,premature,0,0.5368502140045166
ELIQUIS,THROMBOTIC EVENTS,after premature,0,0.5336591601371765
ELIQUIS,THROMBOTIC EVENTS,and Precautions Bleeding seeWarnings and Precautions Spina,0,0.6243551969528198
ELIQUIS,THROMBOTIC EVENTS,after premature continuation [see Warnings and Precautions Bleeding,1,0.6370421648025513
ELIQUIS,THROMBOTIC EVENTS,continuation [see Warnings and Precautions Bleeding seeWarnings,1,0.6355895400047302
ELIQUIS,THROMBOTIC EVENTS,after premature continuation,1,0.5225191712379456
ELIQUIS,EPIDURAL HEMATOMA,Precautions Spinalepidural anesthesia or,0,0.668735146522522
ELIQUIS,EPIDURAL HEMATOMA,risk of thrombotic events after premature discontinuation seeWarnings,0,0.511384904384613
ELIQUIS,EPIDURAL HEMATOMA,after premature discontinuation seeWarnings d,1,0.46121129393577576
ELIQUIS,EPIDURAL HEMATOMA,discontinuation seeWarnings d Precautions (5.,1,0.46188443899154663
ELIQUIS,EPIDURAL HEMATOMA,Precautions (5.,1,0.4740656018257141
ELIQUIS,THROMBOTIC EVENTS,inal/epidural ane sthesia or puncture seeWarnings,1,0.5837768316268921
ELIQUIS,THROMBOTIC EVENTS,Precautions EXCERPT,0,0.555108904838562
ELIQUIS,THROMBOTIC EVENTS,seeWarnings and Precautions inal/epidural ane,1,0.5649649500846863
ELIQUIS,thrombotic events,adverse s (>1%) are,1,0.5621759295463562
ELIQUIS,thrombotic events,s (>1%) are relat ed to,1,0.5327044725418091
ELIQUIS,thrombotic events,s,1,0.5280800461769104
ELIQUIS,thrombotic events,common adverse s (>1%) are relat,1,0.566696286201477
ELIQUIS,spinal hematomas,trials of a g,1,0.47943925857543945
ELIQUIS,spinal hematomas,of a g cannot be dire ctly compared to rates,1,0.45763683319091797
ELIQUIS,spinal hematomas,clinical,0,0.4970144033432007
ELIQUIS,hematomas,"

   Redu ction of",1,0.5306968688964844
ELIQUIS,hematomas,clinical,0,0.5186590552330017
ELIQUIS,hematomas,"

   Redu ction",1,0.5272074341773987
ELIQUIS,hematomas,"

   Redu ction of Risk of",1,0.535093367099762
ELIQUIS,hematomas,in Patients with Nonvalvular Atrial Fibrillation,0,0.48108580708503723
ELIQUIS,hematomas,in,0,0.5330528616905212
ELIQUIS,hematomas,reflect the rates observed,0,0.47480884194374084
ELIQUIS,hematomas,observed in,0,0.4998939037322998
ELIQUIS,hematomas,with Nonvalvular,0,0.5106639862060547
ELIQUIS,hematomas,Embolism in,0,0.6228361129760742
ELIQUIS,hematomas,of another drug and may not reflect the rates observed,0,0.44141677021980286
ELIQUIS,permanent paralysis,and,0,0.4358495771884918
ELIQUIS,permanent paralysis,Risk of Stroke Systemic Embolism i,1,0.5175240635871887
ELIQUIS,permanent paralysis,Embolism i,1,0.508509635925293
ELIQUIS,permanent paralysis,was evaluated in,0,0.48861849308013916
ELIQUIS,permanent paralysis,safety of ELIQUIS was evaluated,0,0.4644851088523865
ELIQUIS,permanent paralysis,ELIQUIS was evaluated,0,0.45860379934310913
ELIQUIS,permanent paralysis,The safety of,0,0.5018670558929443
ELIQUIS,permanent paralysis,of Stroke Systemic Embolism i n Patients with Nonvalvular Atrial,1,0.4937369227409363
ELIQUIS,spinal hematomas,seeCl,0,0.43169623613357544
ELIQUIS,spinal hematomas,ARISTOTLE and AVERROES studies inical Studies ( including patients exposed to ELIQUIS,1,0.5051499009132385
ELIQUIS,spinal hematomas,to ELIQUIS mg twice daily and patients,0,0.4704909920692444
ELIQUIS,spinal hematomas,daily and patients,0,0.4684634208679199
ELIQUIS,spinal hematomas,AVERROES studies inical Studies ( including patients exposed to,1,0.47306424379348755
ELIQUIS,spinal hematomas,twice daily and patients,0,0.47304055094718933
ELIQUIS,THROMBOTIC EVENTS,bleeding during the treatment period and the bleeding rate percentage,0,0.6507768630981445
ELIQUIS,THROMBOTIC EVENTS,and,0,0.4975603222846985
ELIQUIS,THROMBOTIC EVENTS,rate  of subjects with at,1,0.574539840221405
ELIQUIS,THROMBOTIC EVENTS,subjects with at least one bleeding event,1,0.7603104114532471
ELIQUIS,THROMBOTIC EVENTS,the bleeding rate of,1,0.6433232426643372
ELIQUIS,THROMBOTIC EVENTS,bleeding rate  of subjects with at least one,1,0.6440064907073975
ELIQUIS,THROMBOTIC EVENTS,of subjects with at least one,1,0.5329166650772095
ELIQUIS,EPIDURAL HEMATOMA,ne bleeding event,1,0.5933592319488525
ELIQUIS,EPIDURAL HEMATOMA,bleeding event per patientyears in ARISTOTLE,1,0.5466333627700806
ELIQUIS,EPIDURAL HEMATOMA,treatment period and the bleeding,0,0.5766713619232178
ELIQUIS,EPIDURAL HEMATOMA,with at least ne,1,0.4860803186893463
ELIQUIS,THROMBOTIC EVENTS,ARI,0,0.4867052435874939
ELIQUIS,THROMBOTIC EVENTS,"Fibrillation in STOTLE* 
         ELIQUISNn per ptyear WarfarinNn per",1,0.6387011408805847
ELIQUIS,THROMBOTIC EVENTS,Patients with,0,0.5926351547241211
ELIQUIS,thrombotic events,ELIQUISNn per ptyear,0,0.5547661781311035
ELIQUIS,thrombotic events,per ptyear Ratio(95%,1,0.4960275888442993
ELIQUIS,thrombotic events,ptyear Ratio(95% CI),1,0.4918060004711151
ELIQUIS,thrombotic events,WarfarinNn per ptyear Ratio(95% CI),1,0.5874646902084351
ELIQUIS,thrombotic events,per ptyear Hazard,0,0.602224588394165
ELIQUIS,thrombotic events,Ratio(95% CI) P-,1,0.5222944021224976
ELIQUIS,thrombotic events,per ptyear Ratio(95% CI)  P- value Bleeding events,1,0.7093704342842102
ELIQUIS,spinal hematomas,treatment or within days of stopping study treatment ontrea,0,0.5013009905815125
ELIQUIS,spinal hematomas,study treatment tment period).   Defined as clinically overt,1,0.4924159646034241
ELIQUIS,spinal hematomas,stopping study treatment tment period).,1,0.4775274693965912
ELIQUIS,spinal hematomas,more of the following a decrease,0,0.48602139949798584
ELIQUIS,spinal hematomas,treatment,0,0.5194319486618042
ELIQUIS,spinal hematomas,stopping study treatment tment period).   Defined as clinically overt,1,0.4868720769882202
ELIQUIS,spinal hematomas,tment period).   Defined as clinically overt,1,0.5206132531166077
ELIQUIS,spinal hematomas,tment period).,1,0.5029797554016113
ELIQUIS,spinal hematomas,tment period).   Defined as clinically overt bleeding,1,0.565601110458374
ELIQUIS,hematomas,units of packed red blood cells bleeding at a critical site intracranial,0,0.6691769361495972
ELIQUIS,hematomas,"hemoglobin of /dL, a tr",1,0.5884220600128174
ELIQUIS,hematomas,"decrease in hemoglobin of /dL,",1,0.5591081380844116
ELIQUIS,hematomas,"decrease in hemoglobin of /dL, a",1,0.5608325004577637
ELIQUIS,hematomas,"of /dL, a tr",1,0.4936090111732483
ELIQUIS,hematomas,at a critical,0,0.508934736251831
ELIQUIS,hematomas,a tr ansfusion of or more units,1,0.565240740776062
ELIQUIS,hematomas,"of /dL, a tr ansfusion of or",1,0.49365052580833435
ELIQUIS,permanent paralysis,transfusion of or more  of packed red bloo,1,0.48404765129089355
ELIQUIS,permanent paralysis,a tr ansfusion of or more units,1,0.5031569600105286
ELIQUIS,permanent paralysis,or more of packed,1,0.4397751986980438
ELIQUIS,permanent paralysis,of packed red bloo d cells bleeding at a,1,0.501712441444397
ELIQUIS,fatal,detai l in other sections of,1,0.5424258708953857
ELIQUIS,thrombotic events,ed to bleeding.(6,1,0.6484645009040833
ELIQUIS,stroke,PECTED ADVERSE REACTIONS,1,0.539975643157959
ELIQUIS,stroke,ed to bleeding.(6,1,0.6196739673614502
ELIQUIS,stroke,PECTED ADVERSE REACTIONS contact BristolMyers Squibb,1,0.5228438377380371
ELIQUIS,stroke,PECTED ADVERSE REACTIONS contact BristolMyers,1,0.5167097449302673
ELIQUIS,stroke,PECTED ADVERSE REACTIONS contact,1,0.5090181827545166
ELIQUIS,stroke,bleeding To report PECTED ADVERSE REACTIONS contact BristolMyers Squibb,1,0.5569992065429688
ELIQUIS,stroke,ADVERSE REACTIONS contact BristolMyers Squibb at or FDA at FDA or,0,0.5147657990455627
ELIQUIS,stroke,adverse reactions are related to bleeding To report SUS,0,0.5608175992965698
ELIQUIS,stroke,BristolMyers Squibb at,0,0.5155538320541382
ELIQUIS,stroke,To report PECTED ADVERSE REACTIONS contact BristolMyers,1,0.5077938437461853
ELIQUIS,stroke,BristolMyers Squibb at or FDA at FDA or ww,0,0.5157433152198792
ELIQUIS,bleeding,and may not ect the,1,0.5217729210853577
ELIQUIS,bleeding,ect the ,1,0.5403445959091187
ELIQUIS,bleeding,and may not ect the  rates observed in,1,0.4945463240146637
ELIQUIS,bleeding,refl,0,0.4837527573108673
ELIQUIS,fatal,   Re duction of Risk of Stroke,1,0.5694924592971802
ELIQUIS,fatal,   Re duction of Risk,1,0.5688652992248535
ELIQUIS,fatal,   Re duction of Risk of,1,0.5750835537910461
ELIQUIS,fatal,in,0,0.5502201914787292
ELIQUIS,fatal,observed in    Re,1,0.5511296987533569
ELIQUIS,fatal,rates,0,0.49251869320869446
ELIQUIS,bleeding,ction of Risk of Stroke and,1,0.5643404126167297
ELIQUIS,bleeding,Embolism in Patients with Nonvalvular Atrial,0,0.6082121133804321
ELIQUIS,bleeding,in practice ction,1,0.5283799171447754
ELIQUIS,bleeding,rates observed in practice ction of Risk of Stroke,1,0.5501682758331299
ELIQUIS,bleeding,rates observed in practice ction of,1,0.5186792016029358
ELIQUIS,bleeding,rates observed in practice Redu,0,0.5320947766304016
ELIQUIS,bleeding,ction of,1,0.5344868898391724
ELIQUIS,bleeding,exposed to ELIQUIS mg twice,0,0.5890063047409058
ELIQUIS,bleeding,and VERROES  studies seeClinical Studies including,1,0.5312714576721191
ELIQUIS,permanent paralysis,"intraarticular intramuscular with ent syndrome, retro peritoneal or with fatal",1,0.5445926785469055
ELIQUIS,permanent paralysis,exposed to ELIQUIS mg twice,0,0.49446576833724976
ELIQUIS,permanent paralysis,"syndrome, retro peritoneal or with",1,0.5006706714630127
ELIQUIS,permanent paralysis,"intraarticular intramuscular with ent syndrome,",1,0.5498218536376953
ELIQUIS,permanent paralysis,"intramuscular with ent syndrome, retro",1,0.5518869161605835
ELIQUIS,permanent paralysis,Intracranial bleed includes,0,0.5106016993522644
ELIQUIS,permanent paralysis,or with fatal,0,0.5871343612670898
ELIQUIS,permanent paralysis,ent,1,0.4891280233860016
ELIQUIS,permanent paralysis,outcome Intracranial bleed,0,0.5024628639221191
BOSULIF,Myelosuppression,Warnings and Precautions Hepatic toxici,0,0.5323812961578369
BOSULIF,Myelosuppression,Myelosuppression see Dosage and,1,0.8967297673225403
BOSULIF,Myelosuppression,and Warnings and Precautions,0,0.5283316969871521
BOSULIF,Myelosuppression,Myelosuppression see Dosage and Administration,1,0.8885372877120972
BOSULIF,Hepatic toxicity,Warnings and Hepatic toxicity see Dosage and,1,0.8494415879249573
BOSULIF,Hepatic toxicity,Myelosuppression see Dosage and Administration,1,0.5211477875709534
BOSULIF,Hepatic toxicity,Hepatic toxicity see,1,0.9693242907524109
BOSULIF,Hepatic toxicity,and Hepatic toxicity,1,0.9623929858207703
BOSULIF,Fluid retention,Fluid retention see Warnings and Precautions,1,0.8801795840263367
BOSULIF,Fluid retention,Precautions Renal,0,0.5897505283355713
BOSULIF,Fluid retention,and Fluid,1,0.7175133228302002
BOSULIF,Fluid retention,Fluid retention see Warnings and,1,0.8928858041763306
BOSULIF,Fluid retention,Warnings and Fluid retention,1,0.8593554496765137
BOSULIF,Renal toxicity,see Warnings and Precautions EXCERPT Most common adverse,0,0.5697211027145386
BOSULIF,Renal toxicity,and Renal toxicity,1,0.9618809223175049
BOSULIF,Renal toxicity,Renal toxicity see Warnings and,1,0.9164085388183594
BOSULIF,Renal toxicity,Renal toxicity see,1,0.970746636390686
BOSULIF,diarrhea,anemia,0,0.5841463804244995
BOSULIF,diarrhea,diarrhea nausea,1,0.8461776971817017
BOSULIF,diarrhea,abdominal pain rash anemia pyrexia and,0,0.6448626518249512
BOSULIF,nausea,fatigue To,0,0.64564049243927
BOSULIF,nausea,nausea,1,1.0
BOSULIF,nausea,are nausea,1,0.9338856339454651
BOSULIF,nausea,incidence greater than are nausea thrombocytopenia vomiting abdominal,1,0.7359389662742615
BOSULIF,nausea,common adverse reactions incidence greater than,0,0.6140371561050415
BOSULIF,nausea,nausea thrombocytopenia,1,0.7780146598815918
BOSULIF,nausea,incidence greater than are nausea thrombocytopenia vomiting,1,0.7387635707855225
BOSULIF,thrombocytopenia,thrombocytopenia vomiting abdominal pain,1,0.8462817072868347
BOSULIF,thrombocytopenia,incidence greater than are,0,0.5333961844444275
BOSULIF,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
BOSULIF,thrombocytopenia,fatigue To report SUSPECTED ADVE,0,0.5283780694007874
BOSULIF,thrombocytopenia,EXCERPT Most common,0,0.5019912719726562
BOSULIF,thrombocytopenia,vomiting abdominal,0,0.4993836283683777
BOSULIF,thrombocytopenia,than are diarrhea thrombocytopenia vomiting abdominal pain,1,0.7916166186332703
BOSULIF,vomiting,vomiting abdominal pain rash anemia,1,0.809843897819519
BOSULIF,vomiting,than are diarrhea nausea vomiting abdominal,1,0.79012131690979
BOSULIF,vomiting,are diarrhea nausea vomiting,1,0.7955501079559326
BOSULIF,abdominal pain,abdominal pain rash,1,0.8401690721511841
BOSULIF,abdominal pain,abdominal pain,1,0.9999998807907104
BOSULIF,rash,thrombocytopenia vomiting abdominal rash anemia pyrexia and fatigue,1,0.6673922538757324
BOSULIF,rash,abdominal pain,1,0.5441004037857056
BOSULIF,rash,pain,0,0.6062779426574707
BOSULIF,rash,rash anemia,1,0.8185510635375977
BOSULIF,rash,thrombocytopenia vomiting abdominal rash anemia pyrexia and fatigue To,1,0.6742304563522339
BOSULIF,rash,To report SUSPECTED ADVERSE REACTIONS,0,0.6098340749740601
BOSULIF,rash,rash anemia pyrexia and fatigue To,1,0.7235685586929321
BOSULIF,rash,rash,1,1.0000001192092896
BOSULIF,anemia,anemia pyrexia and,1,0.8232002258300781
BOSULIF,anemia,anemia,1,1.0
BOSULIF,anemia,abdominal pain anemia pyrexia and,1,0.7597178220748901
BOSULIF,anemia,anemia pyrexia and fatigue To,1,0.8046841025352478
BOSULIF,anemia,nausea thrombocytopenia vomiting,0,0.5753166079521179
BOSULIF,pyrexia,pyrexia and fatigue To,1,0.8708513975143433
BOSULIF,pyrexia,ADVERSE,0,0.5464146137237549
BOSULIF,pyrexia,fatigue To,0,0.5690171122550964
BOSULIF,pyrexia,pyrexia,1,1.0000001192092896
BOSULIF,pyrexia,vomiting abdominal pain rash pyrexia,1,0.8115408420562744
BOSULIF,pyrexia,anemia,0,0.5942764282226562
BOSULIF,pyrexia,abdominal pain rash pyrexia and fatigue To report,1,0.7749425768852234
BOSULIF,pyrexia,pyrexia and fatigue,1,0.8859043121337891
BOSULIF,pyrexia,pyrexia and,1,0.9570271968841553
BOSULIF,pyrexia,contact Pfizer,0,0.5599648356437683
BOSULIF,fatigue,vomiting abdominal pain rash anemia pyrexia,0,0.5841060876846313
BOSULIF,fatigue,fatigue To report SUSPECTED ADVERSE,1,0.8013911247253418
BOSULIF,fatigue,anemia pyrexia fatigue To,1,0.787535548210144
BOSULIF,fatigue,fatigue To report,1,0.8527353405952454
BOSULIF,anaphylactic shock,and may not reflect the,0,0.4229462444782257
BOSULIF,anaphylactic shock,see Contraindications myelosuppression,0,0.5460477471351624
BOSULIF,anaphylactic shock,reported anaphylactic,1,0.8621834516525269
BOSULIF,anaphylactic shock,anaphylactic shock,1,1.0000001192092896
BOSULIF,anaphylactic shock,adverse reactions reported anaphylactic shock see,1,0.8528696894645691
BOSULIF,anaphylactic shock,reported include,0,0.5157626867294312
BOSULIF,anaphylactic shock,reactions reported anaphylactic shock see Contraindications,1,0.8247361183166504
BOSULIF,anaphylactic shock,the rates,0,0.48563653230667114
BOSULIF,myelosuppression,shock see,0,0.5273627042770386
BOSULIF,myelosuppression,shock see myelosuppression gastrointestinal toxicity diarrhea fluid,1,0.7791308760643005
BOSULIF,myelosuppression,shock,0,0.5734385251998901
BOSULIF,gastrointestinal toxicity,of any toxicity grade r,0,0.687677800655365
BOSULIF,gastrointestinal toxicity,fluid retention hepatotoxicity and rash Adverse,0,0.7228716015815735
BOSULIF,gastrointestinal toxicity,shock see Contraindications gastrointestinal toxicity diarrhea fluid,1,0.782109260559082
BOSULIF,gastrointestinal toxicity,Adverse reactions of any toxicity grade r,0,0.6954522132873535
BOSULIF,gastrointestinal toxicity,gastrointestinal toxicity diarrhea fluid retention hepatotoxicity and,1,0.8560308218002319
BOSULIF,diarrhea,myelosuppression gastrointestinal diarrhea,1,0.7341330051422119
BOSULIF,diarrhea,gastrointestinal toxicity diarrhea fluid retention hepatotoxicity and,1,0.7210941314697266
BOSULIF,diarrhea,diarrhea fluid retention hepatotoxicity,1,0.7346662878990173
BOSULIF,diarrhea,myelosuppression gastrointestinal toxicity,0,0.6333565711975098
BOSULIF,diarrhea,anaphylactic shock,0,0.6167378425598145
BOSULIF,diarrhea,diarrhea fluid,1,0.8479992151260376
BOSULIF,diarrhea,of any toxicity grade reported,0,0.5666038990020752
BOSULIF,diarrhea,gastrointestinal diarrhea fluid retention,1,0.7752171158790588
BOSULIF,diarrhea,diarrhea fluid retention hepatotoxicity and,1,0.7489581108093262
BOSULIF,fluid retention,rash Adverse reactions of,0,0.47998976707458496
BOSULIF,fluid retention,hepatotoxicity and rash Adverse reactions of,0,0.4899786114692688
BOSULIF,fluid retention,toxicity fluid retention,1,0.8914293646812439
BOSULIF,fluid retention,fluid retention hepatotoxicity and rash Adverse,1,0.7310075163841248
BOSULIF,fluid retention,of any,0,0.49360591173171997
BOSULIF,fluid retention,fluid retention,1,1.000000238418579
BOSULIF,fluid retention,fluid retention hepatotoxicity,1,0.7836130857467651
BOSULIF,fluid retention,fluid retention hepatotoxicity and rash Adverse reactions,1,0.7286645770072937
BOSULIF,hepatotoxicity,hepatotoxicity and rash Adverse reactions,1,0.8255225419998169
BOSULIF,hepatotoxicity,hepatotoxicity,1,1.0
BOSULIF,hepatotoxicity,diarrhea fluid hepatotoxicity and,1,0.8121281862258911
BOSULIF,hepatotoxicity,diarrhea fluid,0,0.5171685814857483
BOSULIF,hepatotoxicity,toxicity grade reported for greater than,0,0.665972113609314
BOSULIF,rash,and,0,0.5314319133758545
BOSULIF,rash,rash Adverse reactions of any toxicity,1,0.8244129419326782
BOSULIF,rash,rash Adverse reactions of any,1,0.8325594067573547
BOSULIF,rash,toxicity diarrhea fluid retention,0,0.53617262840271
BOSULIF,rash,diarrhea,0,0.6233848333358765
BOSULIF,rash,rash Adverse,1,0.8992288112640381
BOSULIF,diarrhea,abdominal,0,0.6251316666603088
BOSULIF,nausea,were nausea thrombocytopenia vomiting abdominal pain,1,0.7612263560295105
BOSULIF,nausea,abdominal,0,0.5877907872200012
BOSULIF,nausea,population n were nausea thrombocytopenia,1,0.7227133512496948
BOSULIF,nausea,abdominal pain rash anemia,0,0.6747786998748779
BOSULIF,nausea,nausea thrombocytopenia vomiting,1,0.7685810327529907
BOSULIF,nausea,safety population n were nausea thrombocytopenia vomiting,1,0.7326737642288208
BOSULIF,nausea,population n were nausea,1,0.7918339967727661
BOSULIF,thrombocytopenia,rash,0,0.48084723949432373
BOSULIF,thrombocytopenia,abdominal,0,0.5161737203598022
BOSULIF,thrombocytopenia,anemia,0,0.6230168342590332
BOSULIF,thrombocytopenia,nausea,0,0.5370280742645264
BOSULIF,thrombocytopenia,anemia pyrexia,0,0.5870628356933594
BOSULIF,thrombocytopenia,pyrexia and,0,0.5681965947151184
BOSULIF,thrombocytopenia,thrombocytopenia vomiting abdominal pain rash,1,0.8465749025344849
BOSULIF,thrombocytopenia,Phase safety population,0,0.5107654333114624
BOSULIF,rash,rash anemia pyrexia and fatigue see,1,0.7294395565986633
BOSULIF,rash,rash anemia pyrexia and,1,0.7401039004325867
BOSULIF,rash,anemia pyrexia and fatigue see Clinical,0,0.5619335174560547
BOSULIF,rash,thrombocytopenia vomiting abdominal rash anemia pyrexia and fatigue see,1,0.6688965559005737
BOSULIF,rash,vomiting,0,0.6140508651733398
BOSULIF,anemia,rash,0,0.5674880146980286
BOSULIF,anemia,anemia pyrexia and fatigue see,1,0.8070010542869568
BOSULIF,anemia,pain,0,0.595651388168335
BOSULIF,pyrexia,pyrexia and fatigue see Clinical Studies,1,0.8249325156211853
BOSULIF,pyrexia,Studies Adverse,0,0.5114985704421997
BOSULIF,pyrexia,thrombocytopenia,0,0.5793038606643677
BOSULIF,pyrexia,and fatigue see Clinical Studies Adverse Reactions in,0,0.5718145966529846
BOSULIF,pyrexia,vomiting abdominal,0,0.6049642562866211
BOSULIF,fatigue,cytopenia vomiting abdominal pain rash anemia,0,0.5774112939834595
BOSULIF,fatigue,fatigue see,1,0.8969507217407227
BOSULIF,fatigue,fatigue see Clinical,1,0.8564440011978149
BOSULIF,fatigue,Studies Adverse,0,0.5226525664329529
BOSULIF,fatigue,see Clinical Studies Adverse Reactions in Patients,0,0.4913627803325653
BOSULIF,fatigue,fatigue see Clinical Studies Adverse,1,0.7853238582611084
BOSULIF,QTcF interval of greater than 500 milliseconds,disease including QT interval,0,0.729017972946167
BOSULIF,QTcF interval of greater than 500 milliseconds,one patient QTcF interval,1,0.8200812339782715
BOSULIF,QTcF interval of greater than 500 milliseconds,Phase clinical trial one,0,0.5495465993881226
BOSULIF,QTcF interval of greater than 500 milliseconds,interval of greater than 500 milliseconds,1,0.859014093875885
BOSULIF,QTcF interval of greater than 500 milliseconds,one patient QTcF interval of greater than,1,0.8299574851989746
BOSULIF,QTcF interval of greater than 500 milliseconds,trial,0,0.5463279485702515
BOSULIF,QTcF interval of greater than 500 milliseconds,clinical trial one patient QTcF interval of greater than 500 milliseconds Patients with uncontrolled or significant,1,0.869491457939148
BOSULIF,QTcF interval of greater than 500 milliseconds,500 milliseconds Patients,1,0.7542333006858826
BOSULIF,QTcF interval of greater than 500 milliseconds,trial one patient QTcF interval of greater than 500 milliseconds Patients with uncontrolled or,1,0.8649857640266418
BOSULIF,QTcF interval of greater than 500 milliseconds,trial one patient QTcF interval of greater than 500 milliseconds,1,0.8955681920051575
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,less than 1*10 9 /L Hemoglobin,1,0.7546696662902832
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,Low less than Absolute Neutrophil Count less than 1*10  9  /L Hemoglobin,1,0.9393609762191772
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,than Absolute Neutrophil Count less than 1*10  9  /L Hemoglobin,1,0.9508464336395264
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,Hemoglobin Low,0,0.6223725080490112
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,less than,0,0.6391990184783936
BOSULIF,ALT greater than 5.0*ULN,Biochemistry Parameters ALT greater than 5.0*ULN SGOTAST greater t,1,0.7298534512519836
BOSULIF,ALT greater than 5.0*ULN,less than,0,0.5625877380371094
BOSULIF,ALT greater than 5.0*ULN,Biochemistry,0,0.472292423248291
BOSULIF,AST greater than 5.0*ULN,ULN AST greater,1,0.8878877758979797
BOSULIF,Lipase greater than 2*ULN,Lipase greater than 2*ULN,1,1.0000001192092896
BOSULIF,Lipase greater than 2*ULN,than Lipase greater than,1,0.8678563237190247
BOSULIF,Lipase greater than 2*ULN,ULN,0,0.6432832479476929
BOSULIF,Lipase greater than 2*ULN,eater than ULN,0,0.6392155885696411
BOSULIF,Lipase greater than 2*ULN,greater than 2*ULN Phosphorus Lo,1,0.7442624568939209
BOSULIF,Total Bilirubin greater than 3.0*ULN,Low less than Total Bilirubin greater than 3.0*ULN Additional Adv,1,0.9246317744255066
BOSULIF,Total Bilirubin greater than 3.0*ULN,greater than 2*ULN Phosphorus Lo,1,0.6866313219070435
BOSULIF,Total Bilirubin greater than 3.0*ULN,mmolL,0,0.4652177095413208
BOSULIF,Total Bilirubin greater than 3.0*ULN,Low less than Total Bilirubin greater than 3.0*ULN,1,0.9444963335990906
BOSULIF,Total Bilirubin greater than 3.0*ULN,than Total Bilirubin greater than 3.0*ULN,1,0.9907984733581543
BOSULIF,Total Bilirubin greater than 3.0*ULN,Low less than Total Bilirubin greater than,1,0.8926941156387329
BOSULIF,Total Bilirubin greater than 3.0*ULN,than mmolL,0,0.5258870124816895
BOSULIF,febrile neutropenia,System Disorders and less febrile neutropenia Cardiac Disorders and less,1,0.7802190780639648
BOSULIF,febrile neutropenia,than mmolL,0,0.4559941291809082
BOSULIF,febrile neutropenia,System Disorders and,0,0.47296541929244995
BOSULIF,febrile neutropenia,System Disorders and less febrile,1,0.6615829467773438
BOSULIF,febrile neutropenia,less febrile neutropenia,1,0.9023580551147461
BOSULIF,febrile neutropenia,and less febrile neutropenia,1,0.8771089315414429
BOSULIF,febrile neutropenia,Disorders and less febrile neutropenia,1,0.8506802320480347
BOSULIF,febrile neutropenia,Disorders and less than,0,0.4874914586544037
BOSULIF,febrile neutropenia,System Disorders and less,0,0.46808016300201416
BOSULIF,febrile neutropenia,category Blood,0,0.5905702114105225
BOSULIF,pericardial effusion,pericardial effusion and,1,0.981122612953186
BOSULIF,pericardial effusion,and less than pericarditis Ear and,0,0.7077897787094116
BOSULIF,pericardial effusion,less than pericarditis Ear and Labyrinth Disorders and less than,0,0.6471476554870605
BOSULIF,pericardial effusion,less pericardial effusion,1,0.8995383381843567
BOSULIF,pericardial effusion,pericardial effusion,1,1.0000001192092896
BOSULIF,pericardial effusion,Disorders and less pericardial,1,0.7634425163269043
BOSULIF,pericardial effusion,less than pericarditis Ear and Labyrinth Disorders and,0,0.6436599493026733
BOSULIF,pericardial effusion,and,0,0.4755444824695587
BOSULIF,pericarditis,pericarditis Ear and Labyrinth,1,0.8086119890213013
BOSULIF,pericarditis,than tinnitus,0,0.5621844530105591
BOSULIF,tinnitus,tinnitus Gastrointestinal,1,0.7921942472457886
BOSULIF,tinnitus,and less tinnitus Gastrointestinal Disorders,1,0.7687723636627197
BOSULIF,gastritis,gastritis and,1,0.936227560043335
BOSULIF,gastritis,tinnitus Gastrointestinal,1,0.7103900909423828
BOSULIF,acute pancreatitis,acute pancreatitis gastrointestinal,1,0.894909143447876
BOSULIF,acute pancreatitis,acute pancreatitis gastrointestinal hemorrhage includes gastrointestinal hemorrhage,1,0.807153582572937
BOSULIF,acute pancreatitis,than gastritis and less than,0,0.6081179976463318
BOSULIF,acute pancreatitis,gastritis and less acute pancreatitis,1,0.7838361263275146
BOSULIF,acute pancreatitis,includes,0,0.5039716362953186
BOSULIF,acute pancreatitis,and less acute,1,0.5734587907791138
BOSULIF,gastrointestinal hemorrhage,and less than gastritis,0,0.6716742515563965
BOSULIF,gastrointestinal hemorrhage,less than gastritis and less than acute pancreatitis,0,0.694823682308197
BOSULIF,gastrointestinal hemorrhage,Disorders and,0,0.5517290234565735
BOSULIF,gastrointestinal hemorrhage,than acute gastrointestinal hemorrhage includes gastrointestinal,1,0.9063955545425415
BOSULIF,gastrointestinal hemorrhage,hemorrhage gastric,0,0.8885385394096375
BOSULIF,gastrointestinal hemorrhage,gastrointestinal,1,0.8296748399734497
BOSULIF,gastrointestinal hemorrhage,hemorrhage gastric hemorrhage upper gastrointestinal hemorrhage,0,0.8965078592300415
BOSULIF,gastrointestinal hemorrhage,acute pancreatitis gastrointestinal hemorrhage gastrointestinal hemorrhage,1,0.8829792737960815
BOSULIF,gastrointestinal hemorrhage,and less than acute pancreatitis gastrointestinal hemorrhage includes,0,0.8930057883262634
BOSULIF,gastrointestinal hemorrhage,pancreatitis gastrointestinal hemorrhage gastrointestinal hemorrhage gastric,1,0.8695915937423706
BOSULIF,gastric hemorrhage,and Administrative Site,0,0.44489288330078125
BOSULIF,gastric hemorrhage,hemorrhage includes gastrointestinal gastric hemorrhage,1,0.8982847929000854
BOSULIF,gastric hemorrhage,s than acute pancreatitis gastrointestinal hemorrhage includes gastrointestinal,0,0.8214538097381592
BOSULIF,gastric hemorrhage,gastric hemorrhage upper gastrointestinal,1,0.8918298482894897
BOSULIF,gastric hemorrhage,gastrointestinal hemorrhage General,0,0.8532459735870361
BOSULIF,gastric hemorrhage,gastrointestinal hemorrhage includes gastrointestinal gastric hemorrhage upper gastrointestinal,1,0.8507122993469238
BOSULIF,gastric hemorrhage,upper gastrointestinal hemorrhage General Disorders and Administrative,0,0.7934189438819885
BOSULIF,upper gastrointestinal hemorrhage,hemorrhage,0,0.7768571972846985
BOSULIF,upper gastrointestinal hemorrhage,gastrointestinal hemorrhage General,1,0.875338613986969
BOSULIF,chest pain,chest pain,1,0.9999999403953552
BOSULIF,chest pain,Disorders and,0,0.50502610206604
BOSULIF,chest pain,and less than,0,0.4233180284500122
BOSULIF,chest pain,chest pain and chest discomfort pain,1,0.8863559365272522
BOSULIF,chest pain,less than chest pain chest,1,0.8504215478897095
BOSULIF,chest pain,than chest pain chest,1,0.9420347213745117
BOSULIF,chest pain,than chest pain chest pain and chest discomfort,1,0.8852452039718628
BOSULIF,pain,pain Hepatobiliary Disorders and less,1,0.7054364085197449
BOSULIF,pain,and chest,0,0.5555598139762878
BOSULIF,pain,chest pain Hepatobiliary Disorders and less than,1,0.5991460084915161
BOSULIF,pain,than hepatotoxicity includes hepatotoxicity,0,0.49235016107559204
BOSULIF,hepatotoxicity,and less than,0,0.4526645243167877
BOSULIF,hepatotoxicity,hepatotoxicity includes,1,0.9372951984405518
BOSULIF,hepatotoxicity,hepatotoxicity toxic hepatitis and,0,0.9034487009048462
BOSULIF,hepatotoxicity,and,0,0.5135397911071777
BOSULIF,hepatotoxicity,hepatotoxicity includes hepatotoxicity,1,0.9108597040176392
BOSULIF,hepatotoxicity,hepatic function,0,0.761284351348877
BOSULIF,hepatotoxicity,Hepatobiliary Disorders and less hepatotoxicity includes,1,0.8092625141143799
BOSULIF,hepatotoxicity,chest pain,0,0.4797819256782532
BOSULIF,hepatotoxicity,cytolytic hepatitis,0,0.6774468421936035
BOSULIF,hepatotoxicity,hepatotoxicity toxic,1,0.9350632429122925
BOSULIF,hepatotoxicity,than hepatotoxicity hepatotoxicity toxic hepatitis and,1,0.8902065753936768
BOSULIF,hepatotoxicity,hepatotoxicity toxic hepatitis and cytolytic hepatitis,1,0.8480761051177979
BOSULIF,toxic hepatitis,hepatitis abnormal hepatic function includes abnormal hepatic,0,0.763093113899231
BOSULIF,cytolytic hepatitis,cytolytic,1,0.8425519466400146
BOSULIF,cytolytic hepatitis,hepatotoxicity toxic hepatitis cytolytic,1,0.873702347278595
BOSULIF,cytolytic hepatitis,abnormal hepatic function includes abnormal hepatic function liver,0,0.6532829999923706
BOSULIF,cytolytic hepatitis,cytolytic hepatitis abnormal hepatic,1,0.9065707325935364
BOSULIF,abnormal hepatic function,hepatic function includes,1,0.8656579852104187
BOSULIF,abnormal hepatic function,hepatic function abnormal,1,0.9839635491371155
BOSULIF,abnormal hepatic function,abnormal hepatic function,1,1.0
BOSULIF,abnormal hepatic function,than,0,0.49333932995796204
BOSULIF,abnormal hepatic function,hepatic,0,0.7998940944671631
BOSULIF,abnormal hepatic function,abnormal hepatic function abnormal,1,0.9864224791526794
BOSULIF,abnormal hepatic function,hepatitis abnormal hepatic function abnormal,1,0.9424270391464233
BOSULIF,abnormal hepatic function,abnormal hepatic function liver disorder,1,0.9505526423454285
BOSULIF,liver disorder,liver disorder and less,1,0.9143036603927612
BOSULIF,liver disorder,abnormal hepatic function liver disorder,1,0.8770613670349121
BOSULIF,liver disorder,includes abnormal hepatic,0,0.7925168871879578
BOSULIF,liver injury,disorder and,0,0.5238183736801147
BOSULIF,liver injury,liver injury Immune System Disorders and less,1,0.8252014517784119
BOSULIF,liver injury,drug hypersensitivity,0,0.5258743762969971
BOSULIF,drug hypersensitivity,Disorders and less drug hypersensitivity,1,0.8385337591171265
BOSULIF,drug hypersensitivity,than anaphylactic shock,0,0.664031445980072
BOSULIF,drug hypersensitivity,Infestations and less,0,0.4609472453594208
BOSULIF,drug hypersensitivity,than,0,0.5076379179954529
BOSULIF,drug hypersensitivity,drug hypersensitivity and less,1,0.9130303859710693
BOSULIF,drug hypersensitivity,drug hypersensitivity,1,0.9999998807907104
BOSULIF,anaphylactic shock,anaphylactic shock Infections and Infestations and,1,0.8081835508346558
BOSULIF,anaphylactic shock,than,0,0.49772220849990845
BOSULIF,anaphylactic shock,anaphylactic shock Infections and Infestations,1,0.8127340078353882
BOSULIF,anaphylactic shock,less than pneumonia includes pneumonia,0,0.4938843846321106
BOSULIF,anaphylactic shock,includes,0,0.5447455048561096
BOSULIF,anaphylactic shock,less anaphylactic,1,0.8384231328964233
BOSULIF,anaphylactic shock,and less anaphylactic shock Infections and Infestations and less,1,0.7774415016174316
BOSULIF,anaphylactic shock,less anaphylactic shock Infections,1,0.8248507976531982
BOSULIF,pneumonia,Infections,0,0.7223317623138428
BOSULIF,pneumonia,and Infestations and less than,0,0.5119634866714478
BOSULIF,pneumonia,pneumonia includes pneumonia bronchopneumonia lobar pneumonia,1,0.8220964074134827
BOSULIF,pneumonia,pneumonia includes pneumonia bronchopneumonia lobar,1,0.7923436164855957
BOSULIF,pneumonia,pneumonia includes,1,0.8873904943466187
BOSULIF,pneumonia,primary atypical pneumonia influenza bro,0,0.7098631262779236
BOSULIF,pneumonia,pneumonia includes pneumonia,1,0.8772344589233398
BOSULIF,pneumonia,lobar pneumonia,0,0.8584892749786377
BOSULIF,pneumonia,primary,0,0.5317889451980591
BOSULIF,pneumonia,and less than,0,0.47148728370666504
BOSULIF,pneumonia,pneumonia,1,0.9999997615814209
BOSULIF,pneumonia,shock Infections and Infestations and less than pneumonia,0,0.6663777232170105
BOSULIF,pneumonia,bronchopneumonia lobar pneumonia primary atypical pneumonia influenza bronchitis Invest,0,0.750562310218811
BOSULIF,lobar pneumonia,includes pneumonia lobar pneumonia,1,0.9101502895355225
BOSULIF,lobar pneumonia,lobar pneumonia,1,1.0
BOSULIF,lobar pneumonia,includes pneumonia bronchopneumonia,0,0.7579379081726074
BOSULIF,lobar pneumonia,and less,0,0.4613628387451172
BOSULIF,lobar pneumonia,lobar,1,0.774091362953186
BOSULIF,lobar pneumonia,atypical pneumonia influenza bronchitis Investigations and less,0,0.703905463218689
BOSULIF,lobar pneumonia,than pneumonia includes pneumonia lobar pneumonia primary atypical pneumonia influenza,1,0.8133375644683838
BOSULIF,lobar pneumonia,primary atypical pneumonia influenza bronchitis Investigations and,0,0.6697169542312622
BOSULIF,lobar pneumonia,pneumonia lobar,1,0.9312074184417725
BOSULIF,lobar pneumonia,lobar pneumonia primary atypical,1,0.7940250039100647
BOSULIF,primary atypical pneumonia,lobar primary atypical pneumonia,1,0.9383481740951538
BOSULIF,primary atypical pneumonia,primary atypical pneumonia influenza bronchitis Investigations and,1,0.8584120273590088
BOSULIF,primary atypical pneumonia,lobar primary,1,0.6538366079330444
BOSULIF,primary atypical pneumonia,bronchopneumonia lobar primary atypical pneumonia,1,0.8917136192321777
BOSULIF,primary atypical pneumonia,Investigations and less,0,0.4790589511394501
BOSULIF,bronchitis,bronchitis Investigations and less,1,0.8294763565063477
BOSULIF,bronchitis,bronchitis Investigations and less than,1,0.8256516456604004
BOSULIF,bronchitis,primary,0,0.515853226184845
BOSULIF,bronchitis,primary atypical pneumonia influenza,0,0.5740395784378052
BOSULIF,electrocardiogram QT prolonged,Metabolism,0,0.5210433006286621
BOSULIF,electrocardiogram QT prolonged,electrocardiogram QT prolonged,1,1.0
BOSULIF,electrocardiogram QT prolonged,influenza bronchitis Investigations and less than,0,0.4563811719417572
BOSULIF,electrocardiogram QT prolonged,less,0,0.43206587433815
BOSULIF,electrocardiogram QT prolonged,electrocardiogram QT prolonged increased blood creatine,1,0.8756636381149292
BOSULIF,electrocardiogram QT prolonged,Investigations and less electrocardiogram QT prolonged,1,0.8863370418548584
BOSULIF,increased blood creatine phosphokinase,electrocardiogram QT increased blood creatine,1,0.792251706123352
BOSULIF,increased blood creatine phosphokinase,increased blood,0,0.7450469732284546
BOSULIF,increased blood creatine phosphokinase,creatine phosphokinase increased blood creatinine,1,0.9583204388618469
BOSULIF,increased blood creatine phosphokinase,Metabolism and Nutrition Disorder,0,0.5852105617523193
BOSULIF,increased blood creatine phosphokinase,prolonged,0,0.5495826005935669
BOSULIF,increased blood creatine phosphokinase,than electrocardiogram QT increased blood creatine phosphokinase increased blood creatinine Metabolism,1,0.8563469052314758
BOSULIF,increased blood creatinine,increased blood creatinine Metabolism and Nutrition Disorder,1,0.8462947607040405
BOSULIF,increased blood creatinine,and less than electrocardiogram QT prolonged,0,0.5735728740692139
BOSULIF,dehydration,dehydration Musculoskeletal and Connective,1,0.7962965965270996
BOSULIF,dehydration,dehydration Musculoskeletal and Connective Tissue Disorder,1,0.7723482847213745
BOSULIF,dehydration,dehydration Musculoskeletal and,1,0.8138916492462158
BOSULIF,dehydration,less than,0,0.49717092514038086
BOSULIF,dehydration,than,0,0.5552163124084473
BOSULIF,myalgia,myalgia Nervous System Disorders,1,0.8437530994415283
BOSULIF,myalgia,myalgia Nervous System,1,0.8634004592895508
BOSULIF,myalgia,myalgia Nervous,1,0.8550747632980347
BOSULIF,myalgia,Tissue Disorder and less myalgia,1,0.7808109521865845
BOSULIF,myalgia,Tissue Disorder and less than,0,0.5815203785896301
BOSULIF,myalgia,Musculoskeletal and Connective,0,0.636276364326477
BOSULIF,myalgia,myalgia,1,0.9999996423721313
BOSULIF,myalgia,Disorder and less myalgia,1,0.7912845611572266
BOSULIF,dysgeusia,dysgeusia Renal and Urinary,1,0.848365843296051
BOSULIF,dysgeusia,dysgeusia Renal and Urinary Disorders and,1,0.8402279615402222
BOSULIF,acute renal failure,renal failure renal failure Respiratory Thoracic and,1,0.772651731967926
BOSULIF,acute renal failure,dysgeusia Renal and Urinary Disorders and less,0,0.6517703533172607
BOSULIF,acute renal failure,than,0,0.5171418786048889
BOSULIF,acute renal failure,acute renal failure renal,1,0.9478762149810791
BOSULIF,renal failure,acute renal,0,0.7815603017807007
BOSULIF,renal failure,than acute renal renal failure Respiratory Thoracic and Mediastinal Disorders,1,0.7811930179595947
BOSULIF,renal failure,than pleural,0,0.5349598526954651
BOSULIF,renal failure,renal failure Respiratory Thoracic and,1,0.8246217966079712
BOSULIF,pleural effusion,edema,0,0.6611123085021973
BOSULIF,pleural effusion,pleural effusion and,1,0.9502535462379456
BOSULIF,pleural effusion,pleural effusion and less than acute pulmonary,1,0.888632595539093
BOSULIF,pleural effusion,pleural effusion and less than acute,1,0.887642502784729
BOSULIF,pleural effusion,and less than acute pulmonary edema respiratory,0,0.6712114810943604
BOSULIF,pleural effusion,than,0,0.5260139107704163
BOSULIF,pleural effusion,Disorders and less pleural effusion and less than acute,1,0.8247748613357544
BOSULIF,pleural effusion,and,0,0.5172967314720154
BOSULIF,acute pulmonary edema,acute pulmonary edema respiratory failure pulmonary,1,0.8928959369659424
BOSULIF,acute pulmonary edema,and less acute pulmonary edema respiratory,1,0.8543503284454346
BOSULIF,acute pulmonary edema,pulmonary edema respiratory failure,1,0.8323705196380615
BOSULIF,acute pulmonary edema,less acute pulmonary edema,1,0.9029369950294495
BOSULIF,acute pulmonary edema,pulmonary edema respiratory failure pulmonary hypertension,1,0.8142909407615662
BOSULIF,acute pulmonary edema,Skin and Subcutaneous Disorders,0,0.5284178256988525
BOSULIF,acute pulmonary edema,c and Mediastinal Disorders and,0,0.579309344291687
BOSULIF,acute pulmonary edema,less acute pulmonary edema respiratory failure pulmonary hypertension Skin,1,0.8134365677833557
BOSULIF,respiratory failure,effusion and less than acute pulmonary edema,0,0.6418651938438416
BOSULIF,respiratory failure,less than,0,0.5186859369277954
BOSULIF,respiratory failure,Subcutaneous Disorders and,0,0.5117985010147095
BOSULIF,respiratory failure,respiratory failure,1,1.0000001192092896
BOSULIF,pulmonary hypertension,acute pulmonary edema respiratory,0,0.6465768218040466
BOSULIF,pulmonary hypertension,pulmonary hypertension Skin,1,0.8196437358856201
BOSULIF,pulmonary hypertension,respiratory pulmonary hypertension,1,0.8480556607246399
BOSULIF,pulmonary hypertension,acute pulmonary edema respiratory pulmonary hypertension Skin and,1,0.750924289226532
BOSULIF,pulmonary hypertension,Subcutaneous Disorders,0,0.505742073059082
BOSULIF,pulmonary hypertension,Skin and Subcutaneous Disorders and less than,0,0.5205820798873901
BOSULIF,pulmonary hypertension,pulmonary,0,0.739597737789154
BOSULIF,pulmonary hypertension,pulmonary edema respiratory pulmonary hypertension,1,0.7995806932449341
BOSULIF,pulmonary hypertension,failure,0,0.4975993037223816
BOSULIF,urticaria,urticaria pruritus acne and less,1,0.8118861317634583
BOSULIF,urticaria,urticaria pruritus acne and,1,0.8257185220718384
BOSULIF,urticaria,failure pulmonary hypertension Skin and Subcutaneous Disorders and less than,0,0.6104426383972168
BOSULIF,pruritus,less than pruritus acne,1,0.8305101990699768
BOSULIF,pruritus,urticaria pruritus acne and,1,0.8289074897766113
BOSULIF,erythema multiforme,pruritus acne and less erythema multiforme exfoliative rash drug eruption,1,0.7529166340827942
BOSULIF,erythema multiforme,urticaria pruritus acne and,1,0.6933085322380066
BOSULIF,exfoliative rash,exfoliative rash drug eruption,1,0.9263050556182861
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in,1,0.6350357532501221
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in g reater detail,1,0.6490567922592163
BOSULIF,Gastrointestinal Toxicity,adverse ctions are discussed in g reater,1,0.647461473941803
BOSULIF,Gastrointestinal Toxicity,REACTIONS The following adverse ctions are discussed in g reater,1,0.6696864366531372
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in g reater detail in other,1,0.639225959777832
BOSULIF,Gastrointestinal Toxicity,REACTIONS The following adverse ctions are discussed in g,1,0.6829571723937988
BOSULIF,Gastrointestinal Toxicity,ctions are discussed in g reater detail in other sections,1,0.5151880979537964
BOSULIF,Gastrointestinal Toxicity,REACTIONS The following adverse ctions are discussed in g reater detail in other sections,1,0.6588554382324219
BOSULIF,Gastrointestinal Toxicity,ctions are discussed,1,0.46796077489852905
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in g,1,0.6677583456039429
BOSULIF,Hepatic Toxicity,sage and Adminis tration and Warnings and,1,0.5341421365737915
BOSULIF,Hepatic Toxicity,The following adverse ctions are discussed in g,1,0.6008239388465881
BOSULIF,Hepatic Toxicity,sage and Adminis,1,0.4224279820919037
BOSULIF,Hepatic Toxicity,Precautions Myelosuppression see sage and,1,0.5231150388717651
BOSULIF,Hepatic Toxicity,Precautions Myelosuppression see sage and Adminis tration and,1,0.5237648487091064
BOSULIF,Hepatic Toxicity,Precautions Hepatic toxicity see Dosage and Admin,0,0.820580244064331
BOSULIF,Hepatic Toxicity,see sage and,1,0.43960994482040405
BOSULIF,Fluid Retention,Dosage and Administration and Warnings,0,0.5594415068626404
BOSULIF,Fluid Retention,] . *,1,0.5356359481811523
BOSULIF,Fluid Retention,Administration and Warnings and ] .,1,0.5161594748497009
BOSULIF,Fluid Retention,Hepatic toxicity see Dosage and Administration and Warnings and,0,0.5287696719169617
BOSULIF,Embryofetal Toxicity,vomiting dominal,1,0.5669004917144775
BOSULIF,Embryofetal Toxicity,"dominal pain, rash,  anemia pyrexia and fatigue",1,0.49971580505371094
BOSULIF,Embryofetal Toxicity,"dominal pain, rash,",1,0.4985637664794922
BOSULIF,Embryofetal Toxicity,thrombocytopenia vomiting ab,0,0.5552607774734497
BOSULIF,Embryofetal Toxicity,nausea thrombocytopenia vomiting dominal,1,0.5496299862861633
BOSULIF,fetal harm,"xia, and f atigue To report SUSPECTED",1,0.5088436007499695
BOSULIF,fetal harm,"xia, and f atigue To",1,0.49861496686935425
BOSULIF,fetal harm,contact Pfizer,0,0.47815361618995667
BOSULIF,fetal harm,and f,1,0.49411386251449585
BOSULIF,fetal harm,"pain rash anemia xia, and f atigue",1,0.5301988124847412
BOSULIF,fetal harm,"abdominal pain rash anemia xia, and f atigue",1,0.5387530326843262
BOSULIF,fetal harm,"pain rash anemia xia, and f",1,0.5255002379417419
BOSULIF,Diarrhea,"

  6.1 ",1,0.5009584426879883
BOSULIF,Diarrhea,"

  6.1  Clinical Trials Experience Because clinical",1,0.49527043104171753
BOSULIF,nausea,Trials Experience,0,0.5294314622879028
BOSULIF,nausea,or wwwfdagovmedwatch inical Trials Experience,1,0.5353107452392578
BOSULIF,nausea,inical Trials Experience,1,0.5437729358673096
BOSULIF,nausea,inical Trials,1,0.5262693166732788
BOSULIF,nausea,at FDA or wwwfdagovmedwatch inical Trials,1,0.522148847579956
BOSULIF,nausea,are conducted under widely varying conditions adverse,0,0.5366811752319336
BOSULIF,nausea,trials are conducted under widely,0,0.46882927417755127
BOSULIF,vomiting,or wwwfdagovmedwatch Clinical rials Ex perience Because clinical,1,0.5234866142272949
BOSULIF,vomiting,trials are conducted under widely,0,0.46464434266090393
BOSULIF,vomiting,rials Ex perience,1,0.5572325587272644
BOSULIF,vomiting,rials Ex,1,0.5031276345252991
BOSULIF,vomiting,perience Because clinical trials are,0,0.5057536363601685
BOSULIF,vomiting,FDA or wwwfdagovmedwatch Clinical rials Ex,1,0.49867916107177734
BOSULIF,abdominal pain,or,0,0.4825837016105652
BOSULIF,abdominal pain,or FDA at,0,0.46519559621810913
BOSULIF,abdominal pain,"wwwfdagovmedwatch Clinical Trials ce

  Because  clinical trials",1,0.46787720918655396
BOSULIF,abdominal pain,ce Because clinical trials,1,0.4729393422603607
BOSULIF,Thrombocytopenia,pain,0,0.5641842484474182
BOSULIF,Thrombocytopenia,"were diarrhea nausea thrombocytopenia ing (39%), abdom inal pain",1,0.7357437610626221
BOSULIF,Thrombocytopenia,"nausea thrombocytopenia ing (39%), abdom inal pain rash anemia pyrexia",1,0.77156662940979
BOSULIF,Thrombocytopenia,"were diarrhea nausea thrombocytopenia ing (39%), abdom inal",1,0.7444747686386108
BOSULIF,Thrombocytopenia,"ing (39%), abdom inal pain",1,0.5315831303596497
BOSULIF,Thrombocytopenia,"(39%), abdom inal pain rash",1,0.49786120653152466
BOSULIF,Thrombocytopenia,anemia pyrexia and,0,0.5904351472854614
BOSULIF,anemia,al pai n rash anemia pyrexia and,1,0.7328915596008301
BOSULIF,anemia,n were diarrhea nausea,0,0.5407766103744507
BOSULIF,anemia,vomiting al pai n rash,1,0.5358383655548096
BOSULIF,anemia,opulation n,0,0.5143576264381409
BOSULIF,anemia,al pai n rash anemia pyrexia,1,0.7213946580886841
BOSULIF,neutropenia,anemia pyrexia,0,0.6486103534698486
BOSULIF,neutropenia,Clinical Studies Adver,0,0.5148801803588867
BOSULIF,neutropenia,diarrhea nausea thrombocytopenia,0,0.6372088193893433
BOSULIF,neutropenia,anemia pyrexia and fatigue see,0,0.6612162590026855
BOSULIF,neutropenia,"%), rash",1,0.503872275352478
BOSULIF,neutropenia,diarrhea nausea thrombocytopenia vomiting abdominal,0,0.6216604709625244
BOSULIF,neutropenia,n were diarrhea nausea thrombocytopenia vomiting,0,0.624245285987854
BOSULIF,neutropenia,"nausea thrombocytopenia vomiting abdominal %), rash",1,0.6336604356765747
BOSULIF,neutropenia,rash (3 anemia pyrexia and fatigue,1,0.6255360245704651
BOSULIF,drug induced liver injury,ous leukemia (CML) and wi th resistance or intolerance,1,0.49869757890701294
BOSULIF,drug induced liver injury,blast phase chronic ous leukemia (CML) and wi th resistance or,1,0.4761196970939636
BOSULIF,drug induced liver injury,Study enrolled patients with Ph chronic,0,0.5333336591720581
BOSULIF,drug induced liver injury,blast phase chronic ous leukemia (CML) and wi th resistance or intolerance to,1,0.48262840509414673
BOSULIF,drug induced liver injury,therapy see Clinical Studies The,0,0.5062624216079712
BOSULIF,drug induced liver injury,chronic ous leukemia (CML) and,1,0.5022567510604858
BOSULIF,drug induced liver injury,blast phase chronic ous leukemia (CML) and,1,0.49113497138023376
BOSULIF,elevations in ALT,rapy see Clinical Studies The safety population received,0,0.48693975806236267
BOSULIF,elevations in ALT,Studies The safety population received at least,0,0.4642011523246765
BOSULIF,elevations in ALT,safety population received at,0,0.4800933599472046
BOSULIF,elevations in ALT,with resistance or ance to prior the,1,0.5174829959869385
BOSULIF,elevations in ALT,or blast phase chronic myelogenous leukemia CML and with,0,0.45062389969825745
BOSULIF,total bilirubin greater than 2*ULN,safety population (received at lea st dose of BOSULIF included,1,0.5704952478408813
BOSULIF,total bilirubin greater than 2*ULN,or blast phase chronic myelogenous leukemia CML and with,0,0.5391675233840942
BOSULIF,total bilirubin greater than 2*ULN,population (received at lea st dose of BOSULIF included,1,0.5567551851272583
BOSULIF,total bilirubin greater than 2*ULN,CML patients patients with CP CML,0,0.5333954691886902
BOSULIF,total bilirubin greater than 2*ULN,Clinical Studies safety population (received at lea st,1,0.5291488170623779
BOSULIF,total bilirubin greater than 2*ULN,safety population (received at lea st dose,1,0.5276637673377991
BOSULIF,total bilirubin greater than 2*ULN,at lea st dose of BOSULIF,1,0.5550763607025146
BOSULIF,total bilirubin greater than 2*ULN,therapy see Clinical Studies safety population,1,0.516261875629425
BOSULIF,total bilirubin greater than 2*ULN,Clinical Studies safety,1,0.5223836898803711
BOSULIF,total bilirubin greater than 2*ULN,safety population (received at lea st dose of BOSULIF,1,0.5678332448005676
BOSULIF,total bilirubin greater than 2*ULN,of BOSULIF,0,0.508892297744751
BOSULIF,alkaline phosphatase less than 2*ULN,dose of BOSULIF) included 546 CML pa tients patients with CP CML,1,0.5396215319633484
BOSULIF,alkaline phosphatase less than 2*ULN,of BOSULIF,0,0.48810985684394836
BOSULIF,alkaline phosphatase less than 2*ULN,received at dose of BOSULIF) included 546 CML pa tients,1,0.5553751587867737
BOSULIF,alkaline phosphatase less than 2*ULN,dose of BOSULIF) included 546 CML pa tients,1,0.5558969974517822
BOSULIF,alkaline phosphatase less than 2*ULN,had,0,0.5131001472473145
BOSULIF,alkaline phosphatase less than 2*ULN,BOSULIF) included 546 CML pa tients patients with CP CML,1,0.5092040300369263
BOSULIF,alkaline phosphatase less than 2*ULN,at dose of BOSULIF) included 546 CML pa tients patients,1,0.533493161201477
BOSULIF,alkaline phosphatase less than 2*ULN,CML pa tients patients,1,0.504118025302887
BOSULIF,alkaline phosphatase less than 2*ULN,population received at dose of BOSULIF) included 546,1,0.5598483085632324
BOSULIF,AST elevation,d,0,0.5009380578994751
BOSULIF,AST elevation,additional TKI who had,0,0.48185425996780396
BOSULIF,AST elevation,months,0,0.5364506244659424
BOSULIF,AST elevation,a median uration of BO SULIF treatment of months,1,0.5256094932556152
BOSULIF,AST elevation,uration of BO SULIF treatment,1,0.5074166655540466
BOSULIF,AST elevation,median d,0,0.5189896821975708
BOSULIF,AST elevation,had a median uration of,1,0.5889183282852173
BOSULIF,AST elevation,of BO SULIF treatment of months and,1,0.4931037127971649
BOSULIF,increased ALT,respectively The median dose nsity was 483,1,0.5337637066841125
BOSULIF,increased ALT,nsity was 483,1,0.5630881786346436
BOSULIF,increased ALT,respectively The median dose nsity was,1,0.5468287467956543
BOSULIF,increased ALT,nsity was 483 mgday and,1,0.5608080625534058
BOSULIF,increased ALT,nsity was,1,0.5343666672706604
BOSULIF,increased ALT,AP CML and,0,0.5389007925987244
BOSULIF,increased ALT,respectively The median dose nsity,1,0.5275593996047974
BOSULIF,increased ALT,months respectively The median dose inte,0,0.5518223643302917
BOSULIF,increased ALT,inte,0,0.5851410627365112
BOSULIF,Fluid retention,Advanced Phase CML includes patients with Accelerated Phase and Blast Phase,0,0.4901680052280426
BOSULIF,Fluid retention,CMLN All Grades,0,0.47199109196662903
BOSULIF,Fluid retention,CMLN,0,0.5025796294212341
BOSULIF,Fluid retention,All es(%)           Grade Advanced,1,0.4696059226989746
BOSULIF,pericardial effusion,Advanced Phase L includes patients,1,0.5263445973396301
BOSULIF,pericardial effusion,Phase L includes,1,0.47838762402534485
BOSULIF,pericardial effusion,includes patients,1,0.5245919823646545
BOSULIF,pericardial effusion,Grade Advanced Phase L includes patients  with Accelerated,1,0.5285782814025879
BOSULIF,pericardial effusion,es Grade All,0,0.4833125174045563
BOSULIF,pericardial effusion,Advanced Phase L includes,1,0.5039440393447876
BOSULIF,pericardial effusion,Grade Advanced Phase L includes patients  with Accelerated Phase and Blast,1,0.5409685969352722
BOSULIF,pericardial effusion,Grade Advanced Phase,0,0.5102472901344299
BOSULIF,pericardial effusion,Accelerated,0,0.47866904735565186
BOSULIF,pleural effusion,hase and Blast Phase CML,0,0.5530273914337158
BOSULIF,pleural effusion,th Accelerated P,1,0.5310614109039307
BOSULIF,pleural effusion,includes patients th,1,0.5520346760749817
BOSULIF,pleural effusion,Accelerated P hase,1,0.5433589220046997
BOSULIF,pleural effusion,th Accelerated P hase and,1,0.5346375703811646
BOSULIF,pulmonary edema,Pha,0,0.5878647565841675
BOSULIF,pulmonary edema,patients with Accelerated se and Blast Ph ase CML,1,0.5298128724098206
BOSULIF,fetal harm,the c,1,0.49400484561920166
BOSULIF,fetal harm,by protocol Table fies the c linically relevant or severe,1,0.5447410345077515
BOSULIF,fetal harm,including QT interval prolongation were excluded by protocol Table identi,0,0.4946458339691162
BOSULIF,embryofetal toxicities,laboratory test normalities for the,1,0.5379365086555481
BOSULIF,embryofetal toxicities,test normalities for the,1,0.5332520604133606
BOSULIF,embryofetal toxicities,safety,0,0.5718730688095093
BOSULIF,embryofetal toxicities,normalities for the Ph ase,1,0.5750045776367188
BOSULIF,embryofetal toxicities,Grade laboratory test normalities,1,0.5180965662002563
BOSULIF,embryofetal toxicities,the Ph ase,1,0.5537111759185791
BOSULIF,embryofetal toxicities,for the Ph ase CML safety population,1,0.5738827586174011
GILENYA,Bradyarrhythmia,described elsewhere in Bradyarrhythmia and Atrioventricular,1,0.8714472055435181
GILENYA,Bradyarrhythmia,for the Ph ase CML safety population,1,0.5115822553634644
GILENYA,Atrioventricular Blocks,and,0,0.49380365014076233
GILENYA,Atrioventricular Blocks,in labeling Bradyarrhythmia Atrioventricular Blocks see Warnings and Precautions Infections,1,0.793825626373291
GILENYA,Atrioventricular Blocks,labeling Bradyarrhythmia,0,0.6868050694465637
GILENYA,Atrioventricular Blocks,elsewhere,0,0.46568015217781067
GILENYA,Infections,see Warnings and Infections see Warnings and Precautions,1,0.7367923259735107
GILENYA,Infections,elsewhere,0,0.5428276062011719
GILENYA,Infections,Infections see,1,0.8875965476036072
GILENYA,Progressive multifocal leukoencephalopathy,multifocal leukoencephalopathy see Warnings and,1,0.8821462988853455
GILENYA,Progressive multifocal leukoencephalopathy,Warnings and Precautions Macular Edema see Warnings,0,0.573088526725769
GILENYA,Progressive multifocal leukoencephalopathy,Progressive multifocal leukoencephalopathy see Warnings and Precautions,1,0.9033548831939697
GILENYA,Progressive multifocal leukoencephalopathy,Infections see Warnings and Progressive multifocal leukoencephalopathy see Warnings and,1,0.856968879699707
GILENYA,Progressive multifocal leukoencephalopathy,multifocal leukoencephalopathy,1,0.9654580354690552
GILENYA,Progressive multifocal leukoencephalopathy,Infections see Warnings and Progressive multifocal leukoencephalopathy,1,0.8681700825691223
GILENYA,Progressive multifocal leukoencephalopathy,see Warnings,0,0.526826798915863
GILENYA,Progressive multifocal leukoencephalopathy,Macular Edema see Warnings and,0,0.578126072883606
GILENYA,Macular Edema,leukoencephalopathy see Warnings and Macular Edema see Warnings,1,0.813940167427063
GILENYA,Macular Edema,Macular Edema see Warnings and,0,0.8823482990264893
GILENYA,Macular Edema,Warnings and Macular Edema see Warnings,1,0.854623556137085
GILENYA,Macular Edema,Macular Edema see Warnings,1,0.8812650442123413
GILENYA,Macular Edema,Macular Edema see Warnings and,1,0.8823482990264893
GILENYA,Posterior Reversible Encephalopathy Syndrome,Warnings and,0,0.5229110717773438
GILENYA,Posterior Reversible Encephalopathy Syndrome,Precautions Respiratory Effects see Warnings and,0,0.5194017887115479
GILENYA,Posterior Reversible Encephalopathy Syndrome,Edema see Warnings and,0,0.5715465545654297
GILENYA,Posterior Reversible Encephalopathy Syndrome,and Precautions Respiratory Effects see,0,0.508468508720398
GILENYA,Posterior Reversible Encephalopathy Syndrome,see Warnings,0,0.5200099945068359
GILENYA,Respiratory Effects,Encephalopathy,0,0.5323238968849182
GILENYA,Respiratory Effects,and Respiratory Effects,1,0.973918080329895
GILENYA,Respiratory Effects,Warnings and Respiratory Effects see Warnings and,1,0.8810056447982788
GILENYA,Respiratory Effects,Respiratory Effects see Warnings and Precautions Liver,1,0.8153680562973022
GILENYA,Respiratory Effects,Respiratory Effects,1,0.9999999403953552
GILENYA,Respiratory Effects,Respiratory Effects see,1,0.9799644947052002
GILENYA,Respiratory Effects,see,0,0.5094783902168274
GILENYA,Liver Injury,Precautions EXCERPT Most common,0,0.4956245720386505
GILENYA,Liver Injury,Liver Injury,1,1.0
GILENYA,Liver Injury,Liver Injury see Warnings,1,0.8656759262084961
GILENYA,Liver Injury,adverse reactions,0,0.6014378070831299
GILENYA,Liver Injury,Precautions,0,0.5163127183914185
GILENYA,Liver Injury,and Precautions EXCERPT Most common,0,0.4934261739253998
GILENYA,Liver Injury,Warnings and,0,0.5076788663864136
GILENYA,Headache,adverse reactions incidence and Headache liver transaminase elevation diarrhea,1,0.6538456678390503
GILENYA,Headache,Warnings and,0,0.5771616101264954
GILENYA,Headache,incidence and placebo,0,0.5600213408470154
GILENYA,Headache,common adverse,0,0.5587698221206665
GILENYA,Headache,and,0,0.5308664441108704
GILENYA,Headache,Headache liver transaminase elevation diarrhea,1,0.7062312364578247
GILENYA,Headache,reactions incidence and Headache,1,0.7654592990875244
GILENYA,Headache,Most common,0,0.5427559018135071
GILENYA,Headache,incidence and Headache liver transaminase,1,0.7203134894371033
GILENYA,Headache,Headache liver transaminase,1,0.7442765831947327
GILENYA,liver transaminase elevation,reactions incidence and placebo liver,1,0.6998690962791443
GILENYA,liver transaminase elevation,and placebo liver transaminase elevation,1,0.9060324430465698
GILENYA,liver transaminase elevation,cough influenza sinusitis back pain abdominal pain and pain in,0,0.4994068145751953
GILENYA,liver transaminase elevation,EXCERPT Most common adverse reactions,0,0.5704078674316406
GILENYA,liver transaminase elevation,liver transaminase elevation diarrhea cough influenza sinusitis,1,0.8446372747421265
GILENYA,liver transaminase elevation,pain abdominal pain and pain in extremity,0,0.53512042760849
GILENYA,liver transaminase elevation,liver transaminase elevation diarrhea cough influenza sinusitis back,1,0.8387205600738525
GILENYA,liver transaminase elevation,transaminase elevation diarrhea cough influenza,1,0.8456278443336487
GILENYA,liver transaminase elevation,cough influenza sinusitis,0,0.4478719234466553
GILENYA,diarrhea,diarrhea cough influenza sinusitis back,1,0.7270243167877197
GILENYA,diarrhea,liver transaminase diarrhea cough influenza sinusitis back pain,1,0.6539470553398132
GILENYA,diarrhea,diarrhea cough influenza,1,0.7900263667106628
GILENYA,diarrhea,placebo Headache liver transaminase diarrhea cough influenza sinusitis back pain,1,0.5996626615524292
GILENYA,diarrhea,diarrhea cough influenza sinusitis back pain,1,0.7257959842681885
GILENYA,cough,cough influenza sinusitis back pain,1,0.7562447786331177
GILENYA,cough,back pain abdominal pain and,0,0.5661742687225342
GILENYA,cough,influenza,0,0.684150218963623
GILENYA,cough,incidence and placebo Headache liver,0,0.5583778619766235
GILENYA,cough,diarrhea,0,0.6073877811431885
GILENYA,cough,influenza sinusitis back pain abdominal pain,0,0.632021427154541
GILENYA,cough,pain,0,0.6599282026290894
GILENYA,influenza,influenza,1,0.9999998211860657
GILENYA,influenza,elevation diarrhea influenza sinusitis back pain abdominal,1,0.6849266886711121
GILENYA,influenza,influenza sinusitis,1,0.7776387333869934
GILENYA,influenza,influenza sinusitis back,1,0.7633036375045776
GILENYA,influenza,abdominal,0,0.5528031587600708
GILENYA,influenza,pain and pain in extremity To report SUSPECTED AD,0,0.52678382396698
GILENYA,sinusitis,elevation diarrhea,0,0.4808458089828491
GILENYA,sinusitis,sinusitis back pain abdominal,1,0.7979413270950317
GILENYA,back pain,back pain abdominal pain,1,0.8457180261611938
GILENYA,abdominal pain,contact,0,0.4733116328716278
GILENYA,abdominal pain,REACTIONS contact Novartis,0,0.5103403329849243
GILENYA,abdominal pain,SUSPECTED ADVERSE REACTIONS contact Novartis,0,0.5240463614463806
GILENYA,abdominal pain,influenza sinusitis back abdominal,1,0.6532795429229736
GILENYA,abdominal pain,back abdominal pain and pain in,1,0.8747735023498535
GILENYA,pain in extremity,pain abdominal pain pain in,1,0.6739519834518433
GILENYA,headache,adverse reactions incidence and placebo for GILENYA mg,0,0.5339750051498413
GILENYA,headache,headache,1,0.9999998807907104
GILENYA,headache,influenza sinusitis back pain abdominal pain an,0,0.5947797298431396
GILENYA,headache,influenza sinusitis back,0,0.5767849683761597
GILENYA,headache,headache liver,1,0.8065640926361084
GILENYA,headache,headache liver transaminase elevation,1,0.7337731122970581
GILENYA,headache,headache liver transaminase elevation diarrhea cough,1,0.7032362222671509
GILENYA,headache,for GILENYA,0,0.5009477734565735
GILENYA,headache,liver transaminase elevation diarrhea cough influenza sinusitis back,0,0.5751286149024963
GILENYA,liver transaminase elevation,mg were liver transaminase,1,0.8084338903427124
GILENYA,liver transaminase elevation,pain and,0,0.4656030237674713
GILENYA,liver transaminase elevation,pain and pain in extremity,0,0.48561370372772217
GILENYA,liver transaminase elevation,mg were liver transaminase elevation diarrhea cough influenza sinusitis,1,0.795112133026123
GILENYA,diarrhea,placebo for GILENYA mg were headache liver transaminase elevation,0,0.5302430391311646
GILENYA,diarrhea,and placebo for GILENYA mg were headache liver transaminase elevation,0,0.5300503373146057
GILENYA,diarrhea,influenza sinusitis back pain abdominal pain and,0,0.590303361415863
GILENYA,diarrhea,sinusitis back pain abdominal pain and pain in extremity Adverse events,0,0.5640653967857361
GILENYA,cough,dence and placebo for GILENYA mg were headache liver transaminase elevation,0,0.5297368764877319
GILENYA,cough,headache liver transaminase elevation cough influenza sinusitis back pain,1,0.647553563117981
GILENYA,cough,pain abdominal pain and pain,0,0.5901867151260376
GILENYA,cough,cough influenza sinusitis,1,0.7689071893692017
GILENYA,influenza,mg were headache liver transaminase elevation,0,0.4974963665008545
GILENYA,sinusitis,sinusitis back,1,0.8697009086608887
GILENYA,sinusitis,diarrhea cough sinusitis back pain abdominal pain,1,0.7360043525695801
GILENYA,sinusitis,back,0,0.5060973167419434
GILENYA,back pain,influenza back,1,0.558611273765564
GILENYA,back pain,in extremity Adverse events that led to treatment,0,0.5564844012260437
GILENYA,back pain,back,1,0.7162756323814392
GILENYA,abdominal pain,sinusitis back abdominal,1,0.7095999121665955
GILENYA,abdominal pain,sinusitis back abdominal pain and pain in,1,0.7602474689483643
GILENYA,abdominal pain,abdominal pain and,1,0.9572213888168335
GILENYA,abdominal pain,cough influenza sinusitis back abdominal pain and pain in extremity,1,0.7234944105148315
GILENYA,abdominal pain,mg were headache liver transaminase elevation,0,0.5808150768280029
GILENYA,abdominal pain,events that led to treatment discontinuation,0,0.4714053273200989
GILENYA,abdominal pain,cough influenza sinusitis back abdominal pain,1,0.7483240365982056
GILENYA,abdominal pain,abdominal pain,1,1.000000238418579
GILENYA,pain in extremity,pain abdominal pain pain in extremity Adverse events that led,1,0.8126696348190308
GILENYA,pain in extremity,abdominal pain,1,0.6397389769554138
GILENYA,pain in extremity,and,0,0.4899181127548218
GILENYA,pain in extremity,abdominal pain pain in extremity Adverse events that led to,1,0.7969570159912109
GILENYA,pain in extremity,pain in extremity Adverse events that,1,0.8757131099700928
GILENYA,pain in extremity,pain in extremity,1,1.000000238418579
GILENYA,pain in extremity,back pain,0,0.6894804835319519
GILENYA,serum transaminase elevations,taking GILENYA mg serum transaminase elevations,1,0.8447181582450867
GILENYA,serum transaminase elevations,back pain,0,0.48796164989471436
GILENYA,serum transaminase elevations,to on placebo,0,0.5272167921066284
GILENYA,basal cell carcinoma,cell carcinoma compared to on placebo Table,1,0.6521835923194885
GILENYA,basal cell carcinoma,basal cell carcinoma compared,1,0.900223970413208
GILENYA,basal cell carcinoma,transaminase elevations compared,0,0.4679338037967682
GILENYA,basal cell carcinoma,cell carcinoma compared to,1,0.6925752758979797
GILENYA,basal cell carcinoma,basal cell,1,0.781726598739624
GILENYA,basal cell carcinoma,ients taking GILENYA mg were serum transaminase elevations,0,0.48161959648132324
GILENYA,basal cell carcinoma,to on placebo basal cell,1,0.7420397996902466
GILENYA,basal cell carcinoma,basal cell carcinoma compared to on placebo Table,1,0.8072001338005066
GILENYA,Tinea versicolor,Herpes Tinea,1,0.7648302316665649
GILENYA,Tinea versicolor,Tinea versicolor Cardiac,1,0.8840752840042114
GILENYA,Tinea versicolor,Tinea versicolor,1,0.9999999403953552
GILENYA,Tinea versicolor,Herpes Tinea versicolor,1,0.9397178888320923
GILENYA,Bradycardia,Disorders,0,0.5772126913070679
GILENYA,Bradycardia,Cardiac,0,0.6990697383880615
GILENYA,Bradycardia,Nervous,0,0.6433433294296265
GILENYA,Bradycardia,Bradycardia Nervous system disorders,1,0.8361331224441528
GILENYA,Bradycardia,Nervous system,0,0.5773895978927612
GILENYA,Headache,Headache Migraine,1,0.9186675548553467
GILENYA,Headache,system disorders,0,0.5078222751617432
GILENYA,Headache,Nervous system,0,0.6036272048950195
GILENYA,Headache,disorders,0,0.5661548376083374
GILENYA,Asthenia,Asthenia,1,1.0000001192092896
GILENYA,Asthenia,Asthenia Musculoskeletal and connective tissue,1,0.7792454957962036
GILENYA,Asthenia,Asthenia Musculoskeletal,1,0.8219237923622131
GILENYA,Asthenia,and,0,0.5410805344581604
GILENYA,Pain in extremity,Pain in,1,0.7611168622970581
GILENYA,Pain in extremity,Pain in extremity Skin and subcutaneous tissue disorders,1,0.8488336801528931
GILENYA,Pain in extremity,in extremity Skin,1,0.8078881502151489
GILENYA,Pain in extremity,Back pain,0,0.6894804835319519
GILENYA,Pain in extremity,subcutaneous,0,0.6280099749565125
GILENYA,Pain in extremity,in extremity Skin and,1,0.7984265089035034
GILENYA,Pain in extremity,in extremity Skin and subcutaneous tissue disorders,1,0.7470343708992004
GILENYA,Pain in extremity,Back Pain in extremity,1,0.8981788158416748
GILENYA,Alopecia,Alopecia Actinic keratosis,1,0.7613843679428101
GILENYA,Alopecia,Back Pain in extremity,1,0.5035784244537354
GILENYA,Blood triglycerides increased,Blood triglycerides increased,1,0.9999999403953552
GILENYA,Blood triglycerides increased,transaminase elevations Blood triglycerides increased,1,0.9046875238418579
GILENYA,Blood triglycerides increased,thoracic and mediastinal disorders,0,0.5024428367614746
GILENYA,Blood triglycerides increased,transaminase elevations Blood triglycerides increased Respiratory thoracic and mediastinal disorders,1,0.8060637712478638
GILENYA,Blood triglycerides increased,Respiratory thoracic and mediastinal disorders,0,0.47638294100761414
GILENYA,Blood triglycerides increased,Blood,1,0.6713166236877441
GILENYA,Blood triglycerides increased,Liver transaminase elevations Blood triglycerides increased,1,0.8946036100387573
GILENYA,Blood triglycerides increased,triglycerides increased Respiratory thoracic,1,0.8266340494155884
GILENYA,Blood triglycerides increased,transaminase elevations Blood triglycerides increased Respiratory thoracic and,1,0.8521480560302734
GILENYA,Blood triglycerides increased,and mediastinal,0,0.4745680093765259
GILENYA,Cough,Cough Dyspnea,1,0.8331000804901123
GILENYA,Cough,Cough Dyspnea E,1,0.815666139125824
GILENYA,Cough,Respiratory thoracic and mediastinal Cough,1,0.8046773076057434
GILENYA,Cough,thoracic and,0,0.5946572422981262
GILENYA,Cough,mediastinal,0,0.6247513294219971
GILENYA,Cough,disorders,0,0.554822564125061
GILENYA,Vision blurred,disorders,0,0.5530133247375488
GILENYA,Vision blurred,Vision blurred Vascular,1,0.8825598359107971
GILENYA,Vision blurred,Vision blurred,1,1.0000001192092896
GILENYA,Vision blurred,Eye Vision blurred,1,0.9639312028884888
GILENYA,Hypertension,Hypertension Blood and lymphatic,1,0.8028604388237
GILENYA,Hypertension,Hypertension Blood and,1,0.8753935098648071
GILENYA,Hypertension,disorders,0,0.6091046929359436
GILENYA,Hypertension,Hypertension Blood and lymphatic system,1,0.7840471267700195
GILENYA,Hypertension,Vascular,0,0.6455401182174683
GILENYA,Hypertension,lymphatic system disorders,0,0.5303963422775269
GILENYA,Lymphopenia,and lymphatic system disorders,0,0.720903217792511
GILENYA,Lymphopenia,system,0,0.4887085556983948
GILENYA,Lymphopenia,Lymphopenia Leukopenia,1,0.89577317237854
GILENYA,Lymphopenia,Lymphopenia,1,1.000000238418579
GILENYA,Lymphopenia,and lymphatic system,0,0.7151936292648315
GILENYA,Lymphopenia,Lymphopenia Leukopenia Neop,1,0.8224526047706604
GILENYA,Basal cell carcinoma,papilloma,0,0.6475768089294434
GILENYA,Basal cell carcinoma,Adverse reactions,0,0.5213348865509033
GILENYA,Basal cell carcinoma,Basal cell carcinoma Adverse reactions of dizziness pneumonia,1,0.6937557458877563
GILENYA,Basal cell carcinoma,Basal cell carcinoma Adverse reactions of dizziness,1,0.7466311454772949
GILENYA,dizziness,reported in Studies and but,0,0.5104869604110718
GILENYA,dizziness,reactions of,0,0.5616838932037354
GILENYA,dizziness,dizziness pneumonia eczema and pruritus were,1,0.6730909943580627
GILENYA,dizziness,carcinoma Adverse reactions,0,0.5325139760971069
GILENYA,pneumonia,Adverse reactions of pneumonia eczema,1,0.7042846083641052
GILENYA,pneumonia,carcinoma Adverse reactions,0,0.5093541145324707
GILENYA,pneumonia,reactions of,0,0.5395629405975342
GILENYA,pneumonia,pneumonia eczema and pruritus were also,1,0.7167564630508423
GILENYA,pneumonia,pneumonia,1,0.9999997615814209
GILENYA,pneumonia,of pneumonia eczema and pruritus were also,1,0.7172683477401733
GILENYA,pneumonia,in Studies and but did not meet the reporting rate,0,0.46720147132873535
GILENYA,pneumonia,pneumonia eczema and pruritus were,1,0.7163398265838623
GILENYA,pneumonia,Basal cell,0,0.4604482650756836
GILENYA,eczema,not meet the reporting rate criteria for,0,0.44606149196624756
GILENYA,eczema,eczema and pruritus were,1,0.8462297916412354
GILENYA,eczema,eczema and pruritus were also reported,1,0.8184118270874023
GILENYA,eczema,eczema and pruritus were also,1,0.8323063254356384
GILENYA,eczema,eczema and pruritus,1,0.8623045682907104
GILENYA,pruritus,reporting rate criteria for inclusion in,0,0.462446391582489
GILENYA,pruritus,rate criteria for,0,0.49413836002349854
GILENYA,pruritus,pruritus were also reported,1,0.8898642063140869
GILENYA,pruritus,reactions of,0,0.5565363764762878
GILENYA,Vascular events,to those in Studies and,0,0.502360463142395
GILENYA,Vascular events,Vascular events including ischemic,1,0.9279928207397461
GILENYA,Vascular events,and hemorrhagic strokes and peripheral,0,0.697898268699646
GILENYA,Vascular events,those in Studies and,0,0.4930664896965027
GILENYA,Vascular events,generally similar to those in,0,0.5050225257873535
GILENYA,Vascular events,study were generally similar,0,0.4907252788543701
GILENYA,peripheral arterial occlusive disease,peripheral arterial occlusive disease were reported in premarketing clinical,1,0.8981748819351196
GILENYA,peripheral arterial occlusive disease,hemorrhagic strokes peripheral arterial occlusive disease were reported,1,0.8582463264465332
GILENYA,Bradycardia,in labeling Bradyarrhythmia and Atrioventricular Blocks,0,0.7374542951583862
GILENYA,Bradycardia,labeling Bradyarrhythmia and Atrioventricular Blocks see War,0,0.7282713055610657
GILENYA,Bradycardia,ons are described elsewhere in labeling Bradyarrhythmia and Atrioventricular,0,0.7262892723083496
GILENYA,Bradycardia,ADVERSE,0,0.5432173609733582
GILENYA,atrioventricular conduction,in labe ling Bradyarrhythmia and Atrioventricular,1,0.8360873460769653
GILENYA,atrioventricular conduction,elsewhere in labe ling Bradyarrhythmia,1,0.7116468548774719
GILENYA,atrioventricular conduction,REACTIONS The following serious adverse reactions are,0,0.49621155858039856
GILENYA,atrioventricular conduction,see Warnings and Precautions,0,0.5050799250602722
GILENYA,atrioventricular conduction,Atrioventricular Blocks see,0,0.866488516330719
GILENYA,atrioventricular conduction,see Warnings and,0,0.5062476396560669
GILENYA,atrioventricular conduction,serious adverse reactions described elsewhere in labe ling Bradyarrhythmia and,1,0.6508910655975342
GILENYA,atrioventricular conduction,serious adverse reactions,0,0.4793955385684967
GILENYA,atrioventricular conduction,following serious adverse reactions described elsewhere in labe ling Bradyarrhythmia and,1,0.649187445640564
GILENYA,Infections,described elsewhere in labeling Bradyarrhythmia and Atrioventricular Blocks,0,0.4952763020992279
GILENYA,infections,ections,1,0.5967586636543274
GILENYA,infections,Warnings,0,0.6218047142028809
GILENYA,infections,and Precautions ections [s,1,0.6138861179351807
GILENYA,infections,Precautions ections [s,1,0.6278778314590454
GILENYA,infections,ee Warnings and Precautions Progressive multifocal leukoencephalopathy see Warnings an,0,0.6031250953674316
GILENYA,infections,Precautions ections [s ee Warnings and Precautions Progressive,1,0.6209735870361328
GILENYA,infections,Precautions Progressive multifocal leukoencephalopathy,0,0.6158029437065125
GILENYA,Progressive multifocal leukoencephalopathy,and Pr ecautions,1,0.46836161613464355
GILENYA,Progressive multifocal leukoencephalopathy,cephalopathy Syndrome [see Warnings and Pr,1,0.6259182691574097
GILENYA,Progressive multifocal leukoencephalopathy,Respiratory Effects,0,0.4692925810813904
GILENYA,Progressive multifocal leukoencephalopathy,Effects see Warnings and Precautions Liver,0,0.5095826983451843
GILENYA,Progressive multifocal leukoencephalopathy,Precautions Liver Injury,0,0.46210378408432007
GILENYA,Progressive multifocal leukoencephalopathy,Warnings and Pr ecautions Respiratory Effects see Warnings,1,0.4992097318172455
GILENYA,Progressive multifocal leukoencephalopathy,Precautions Liver,0,0.4933847486972809
GILENYA,PML,Syndrome see Warnings and aut ions Respiratory Effects,1,0.4777064919471741
GILENYA,PML,Precautions Liver,0,0.5145507454872131
GILENYA,PML,aut ions Respiratory Effects,1,0.46820345520973206
GILENYA,PML,Respiratory Effects see Warnings and Precautions Liver Injury see,0,0.47775202989578247
GILENYA,Posterior reversible encephalopathy syndrome,pain in extremity ( To report SUSPECTED,1,0.4419025480747223
GILENYA,Posterior reversible encephalopathy syndrome,"back n, abdominal pain, and pain in extremity (  ",1,0.5420091152191162
GILENYA,Posterior reversible encephalopathy syndrome,"cough influenza sinusitis back n, abdominal pain, and pain in extremity (   To",1,0.560773491859436
GILENYA,PRES,1 ) To,1,0.5407741665840149
GILENYA,PRES,pain,0,0.47904443740844727
GILENYA,PRES,1 ),1,0.5213034749031067
GILENYA,PRES,1 ) To report SUSPECTED,1,0.5055415034294128
GILENYA,PRES,Pharmaceuticals Corporation at,0,0.4695464074611664
GILENYA,PRES,extremity,0,0.5319857001304626
GILENYA,PRES,in 1,1,0.49945321679115295
GILENYA,Decrease in pulmonary function tests,SUSPECTED ADVERSE,0,0.5576326847076416
GILENYA,Decrease in pulmonary function tests,report SUSPECTED ADVERSE REACTIONS Novartis Pharmaceuticals Corporatio,1,0.5115849375724792
GILENYA,Decrease in pulmonary function tests,report SUSPECTED ADVERSE REACTIONS  Novartis Pharmaceuticals Corporatio n,1,0.5192035436630249
GILENYA,Decrease in pulmonary function tests,Novartis Pharmaceuticals Corporatio n at,1,0.4787369966506958
GILENYA,Decrease in pulmonary function tests,n at or FDA at FDA,0,0.49299564957618713
GILENYA,Decrease in pulmonary function tests,report SUSPECTED ADVERSE REACTIONS  Novartis Pharmaceuticals Corporatio n at,1,0.5147264003753662
GILENYA,Liver injury,or medwatch,1,0.5051156282424927
GILENYA,Liver injury,at or FDA,0,0.5165215730667114
GILENYA,Liver injury,medwatch . Clinical Trials Experience Because clinical,1,0.47609376907348633
GILENYA,Liver injury,clinical,0,0.5570554733276367
GILENYA,Liver injury,or medwatch  .  Clinical Trials Experience Because,1,0.4811646342277527
GILENYA,Liver injury,at FDA or medwatch  .  Clinical,1,0.5015548467636108
GILENYA,Liver injury,Novartis Pharmaceuticals Corporation at,0,0.49092426896095276
GILENYA,Liver injury,or FDA at FDA or wwwfdagov,0,0.5060328245162964
GILENYA,heart rate decrease,lled trial (Study 2,1,0.5178548097610474
GILENYA,heart rate decrease,or FDA at FDA or wwwfdagov,0,0.4788382649421692
GILENYA,heart rate decrease,in,0,0.4782840311527252
GILENYA,heart rate decrease,mg in the year lled trial (Study 2 The overall exposure,1,0.5275021195411682
GILENYA,heart rate decrease,trials Studies and and,0,0.5241320729255676
GILENYA,heart rate decrease,who received,0,0.42282167077064514
GILENYA,heart rate decrease,year activecontro,0,0.4695683419704437
GILENYA,heart rate decrease,exposure in the,0,0.5268220901489258
GILENYA,heart rate decrease,mg in the year lled trial (Study 2 The,1,0.5233108401298523
GILENYA,heart rate decrease,lled trial (Study 2 The overall exposure in the,1,0.5330474376678467
GILENYA,heart rate decrease,the year lled trial (Study 2 The,1,0.5039461851119995
GILENYA,decline in heart rate,exposure in the,0,0.5272008180618286
GILENYA,decline in heart rate,equivalent to personyears Approximately patients received,1,0.4921789765357971
GILENYA,decline in heart rate,was equivalent to personyears,1,0.4650844633579254
GILENYA,decline in heart rate,was equivalent to personyears Approximately patients received,1,0.4951293468475342
GILENYA,decline in heart rate,activecontrolled trial Study The,0,0.5521212816238403
GILENYA,decline in heart rate,least years of treatment,0,0.5331371426582336
GILENYA,decline in heart rate,ls was equivalent to personyears,1,0.44192713499069214
GILENYA,heart rate decrease,the xposure to,1,0.5129976272583008
GILENYA,heart rate decrease,to GILENYA mg was,1,0.4834216833114624
GILENYA,heart rate decrease,mg In all clinical studies including uncontrolled extension studies the e,0,0.5033676624298096
GILENYA,heart rate decrease,to GILENYA,1,0.48601266741752625
GILENYA,heart rate decrease,placebo for GILENYA mg were headach,0,0.5649490356445312
GILENYA,heart rate decrease,adverse reactions incidence and placebo for GILENYA,0,0.5519208908081055
GILENYA,heart rate decrease,extension studies,0,0.471017450094223
GILENYA,heart rate decrease,personyears In o-controlled trials the most frequent adverse reactions,1,0.5191278457641602
GILENYA,heart rate decrease,o-controlled trials,1,0.5276769995689392
GILENYA,Heart rates below 40 beats per minute,back pain abdominal pain and pain in extremity Adverse e,0,0.5215451717376709
GILENYA,Heart rates below 40 beats per minute,and pain in extremity Adverse,0,0.5043517351150513
GILENYA,Heart rates below 40 beats per minute,sinusitis back pain abdominal pain and pain in extremity,0,0.5026456713676453
GILENYA,symptomatic bradycardia,pain and n in extremity. Adverse,1,0.5738030076026917
GILENYA,symptomatic bradycardia,sinusitis back pain abdominal pain and pain in extremity,0,0.5162667036056519
GILENYA,symptomatic bradycardia,and n in extremity. Adverse events that led,1,0.5670971274375916
GILENYA,symptomatic bradycardia,pain abdominal pain and n in extremity.,1,0.5500847101211548
GILENYA,symptomatic bradycardia,abdominal pain and n,1,0.5520602464675903
GILENYA,symptomatic bradycardia,elevation diarrhea cough influenza sinusitis,0,0.5139449834823608
GILENYA,symptomatic bradycardia,extremity. Adverse events that led to,1,0.537065863609314
GILENYA,symptomatic bradycardia,abdominal pain,0,0.5363948941230774
GILENYA,symptomatic bradycardia,n in extremity. Adverse events that led to,1,0.5560925006866455
GILENYA,bradycardia,transaminase .7%,1,0.5037252902984619
GILENYA,bradycardia,transaminase .7% compare,1,0.5044196248054504
GILENYA,bradycardia,mg were serum transaminase .7% compare d to,1,0.49846702814102173
GILENYA,bradycardia,d to on placebo and,0,0.5603156685829163
GILENYA,bradycardia,more than,0,0.452060341835022
GILENYA,bradycardia,patients taking GILENYA mg were serum transaminase,0,0.5288580060005188
GILENYA,bradycardia,.7%,1,0.47452282905578613
GILENYA,bradycardia,serum transaminase .7%,1,0.4979534149169922
GILENYA,hypotension,in of GILENYAtreated patients,0,0.5690876245498657
GILENYA,hypotension,compared 0.5%,1,0.5142297744750977
GILENYA,hypotension,that,0,0.52208411693573
GILENYA,hypotension,on pl acebo Table lists adverse,1,0.5170822739601135
GILENYA,dizziness,"ebo).



",1,0.461126446723938
GILENYA,dizziness,"compared to on ebo).



 Table lists adverse",1,0.5439809560775757
GILENYA,dizziness,and,0,0.5259379148483276
GILENYA,dizziness,"ebo).



 Table lists adverse reactions",1,0.5491526126861572
GILENYA,dizziness,"to on ebo).



 Table lists adverse reactions that",1,0.5633447766304016
GILENYA,dizziness,compared to on placebo and basal,0,0.5370208621025085
GILENYA,fatigue,able 1 lists,1,0.5080888271331787
GILENYA,fatigue,compared to on placebo able 1,1,0.5448527336120605
GILENYA,fatigue,able 1 lists adverse reactions that occurred,1,0.5331607460975647
GILENYA,fatigue,cell carcinoma compared to,0,0.4968477785587311
GILENYA,fatigue,reactions that occurred in,0,0.48990774154663086
GILENYA,palpitations,that occurred in of GILENYAtreated patients and higher rate than for placebo,0,0.5567672252655029
GILENYA,palpitations,compared to on placebo,0,0.5234705805778503
GILENYA,palpitations,to on placebo Table sts adverse  reactions,1,0.525327742099762
GILENYA,palpitations,patients and higher rate than,0,0.5533196926116943
GILENYA,chest pain,adverse that,1,0.48591136932373047
GILENYA,decrease in heart rate,for placebo Table Adverse tions Reported,1,0.5203677415847778
GILENYA,decrease in heart rate,Adverse tions Reported in Stud ies and Occurring in of,1,0.5240334272384644
GILENYA,decrease in heart rate,placebo Table Adverse tions Reported in Stud ies and Occurring in,1,0.5421557426452637
GILENYA,decrease in heart rate,ies and Occurring in of,0,0.48181313276290894
GILENYA,decrease in heart rate,at Higher Rate,0,0.5165958404541016
GILENYA,AV conduction delays,itis 11,1,0.48361092805862427
GILENYA,AV conduction delays,itis  11             Bronchitis Herpes zoster,1,0.5147906541824341
GILENYA,AV conduction delays,Influenza itis  11             Bronchitis,1,0.4886968731880188
GILENYA,AV conduction delays,itis 11 Bronchitis Herpes zoster,1,0.5147906541824341
GILENYA,AV conduction delays,Sinus,0,0.5482742190361023
GILENYA,AV conduction delays,Influenza itis 11,1,0.48304933309555054
GILENYA,AV conduction delays,itis 11 Bronchitis Herpes,1,0.5112403631210327
GILENYA,AV conduction delays,Influenza itis,1,0.49755069613456726
GILENYA,first-degree AV block,Herpes zoster Tinea versic,0,0.46986937522888184
GILENYA,first-degree AV block,chitis 8 Herpes zoster Tinea versic,1,0.45140063762664795
GILENYA,first-degree AV block,chitis  8             Herpes zoster Tinea versic,1,0.4514005780220032
GILENYA,first-degree AV block,chitis 8 Herpes zoster,1,0.46006864309310913
GILENYA,first-degree AV block,Herpes,0,0.4852135181427002
GILENYA,first-degree AV block,zoster,0,0.5093398690223694
GILENYA,second-degree AV blocks,"           
   Nervous  system disorders Headache",1,0.5387696027755737
GILENYA,second-degree AV blocks,"           
   Nervous ",1,0.5292620062828064
GILENYA,second-degree AV blocks,system disorders,0,0.5650850534439087
GILENYA,second-degree AV blocks,"           
   Nervous  system",1,0.5564319491386414
GILENYA,second-degree AV blocks,system disorders Headache,0,0.5531569719314575
GILENYA,second-degree AV blocks,"Disorders            
   Nervous ",1,0.5393862724304199
GILENYA,second-degree AV blocks,"           
   Nervous  system disorders",1,0.5660400390625
GILENYA,2:1 AV blocks,              Headache Migraine,1,0.4604257643222809
GILENYA,2:1 AV blocks,             ,1,0.599845290184021
GILENYA,2:1 AV blocks,disorders,0,0.48499658703804016
GILENYA,2:1 AV blocks,system               Headache Migraine,1,0.5207448601722717
GILENYA,2:1 AV block,ers         ,1,0.5101616978645325
GILENYA,2:1 AV block,Gastrointestinal ers         ,1,0.46380382776260376
GILENYA,conduction abnormalities,disorders an d,1,0.6424776315689087
GILENYA,conduction abnormalities,"Abdominal 
   General disorders an d",1,0.5598573088645935
GILENYA,conduction abnormalities,"Abdominal 
   General disorders an d administration site",1,0.5525433421134949
GILENYA,conduction abnormalities,disorders an d administration,1,0.6261664032936096
GILENYA,conduction abnormalities,d administration site conditions,0,0.5155317783355713
GILENYA,conduction abnormalities,"
   General disorders an",1,0.6296992301940918
GILENYA,conduction abnormalities,General,1,0.5324333310127258
GILENYA,third-degree AV block,tissue disorders,0,0.49920177459716797
GILENYA,third-degree AV block,in extremity,0,0.5425686836242676
GILENYA,third-degree AV block,               9      Pain in extremity Skin,1,0.5026102066040039
GILENYA,AV block,Back,0,0.5403977632522583
GILENYA,AV block,"       
 Pain in extremity",1,0.48671209812164307
GILENYA,AV block,ssue disorders Back,0,0.5173764824867249
GILENYA,AV block,and,0,0.5103535652160645
GILENYA,AV block,"ssue disorders Back        
 Pain in extremity",1,0.472261905670166
GILENYA,AV block,"       
",1,0.6269254684448242
GILENYA,AV block,"Back        
 Pain in",1,0.4963800609111786
GILENYA,AV block,"       
 Pain",1,0.5277596712112427
GILENYA,junctional escape,Pain in extremit,1,0.5148776769638062
GILENYA,junctional escape,Back Pain,1,0.42855995893478394
GILENYA,junctional escape,in extremit,1,0.5888459086418152
GILENYA,asystole,ia   3   Actinic keratosis In,1,0.42382457852363586
GILENYA,asystole,Pain in extremit,1,0.5479792356491089
GILENYA,asystole,subcutaneous tissue disorders Alopec,0,0.49017012119293213
GILENYA,asystole,tissue disorders Alopec,0,0.4782218039035797
GILENYA,asystole,tissue disorders ia,1,0.5133742094039917
GILENYA,asystole,ia 3 Actinic keratosis In,1,0.423824667930603
GILENYA,asystole,Actinic keratosis,0,0.41991937160491943
GILENYA,asystole,ia   3   Actinic,1,0.4772917628288269
GILENYA,asystole,and subcutaneous tissue disorders ia   3   Actinic keratosis,1,0.4513128995895386
GILENYA,death,      Actinic,1,0.5040364861488342
GILENYA,death,     ,1,0.6161128878593445
GILENYA,death,neous tissue disorders,0,0.500585675239563
GILENYA,syncope,        Blood triglycerides,1,0.5238798260688782
GILENYA,syncope,Blood,0,0.5830634832382202
GILENYA,syncope,transaminase elevations ALTGGTAST,0,0.5235904455184937
GILENYA,syncope,        Blood,1,0.5830634832382202
GILENYA,syncope,       ,1,0.5766812562942505
GILENYA,reduction in peripheral lymphocyte count,disorders                                Cough Dyspnea,1,0.4831862449645996
GILENYA,sequestration of lymphocytes in lymphoid tissues,9 7,1,0.46193355321884155
GILENYA,infections,Dyspnea Eye            Vision blurred Vascular,1,0.5044625401496887
GILENYA,infections,9 7,1,0.4745129942893982
GILENYA,infections,           Vision blurred Vascular disorders,1,0.5091869831085205
GILENYA,infections,          ,1,0.6203988790512085
GILENYA,infections,Table difference was,0,0.4761248528957367
GILENYA,infections,was less than Adverse reactions with GILENYA mg,0,0.5463287830352783
GILENYA,infections,reactions,0,0.5630025863647461
GILENYA,bronchitis,year activecontrolled versus,0,0.4660889506340027
GILENYA,bronchitis,in Study the year activecontrolled versus interferon beta,0,0.5430103540420532
GILENYA,bronchitis,). Adv erse,1,0.5033307075500488
GILENYA,bronchitis,reactions with GILENYA mg in,0,0.4769759476184845
GILENYA,bronchitis,difference was less ).,1,0.40439146757125854
GILENYA,herpes zoster,in Table,0,0.4665939211845398
GILENYA,herpes zoster,se reactions with,1,0.5396232008934021
GILENYA,herpes zoster,se reactions with GILENYA,1,0.5254272222518921
GILENYA,pneumonia,"in  2, the 1 year activecontrolled versus interferon",1,0.5572645664215088
GILENYA,pneumonia,se reactions with GILENYA,1,0.4882492125034332
GILENYA,herpetic infections,e disease,1,0.5567700862884521
GILENYA,herpetic infections,e disease were repo rted in premarketing clinical,1,0.5616152286529541
GILENYA,died,received GILENYA mg)  higher than recommended for use,1,0.4593203067779541
GILENYA,died,e disease,1,0.5097739100456238
GILENYA,died,mg)  higher than recommended for use,1,0.4568890929222107
GILENYA,died,received GILENYA mg)  higher than recommended,1,0.4664885401725769
GILENYA,died,mg)  higher,1,0.4876815676689148
GILENYA,died,mg)  higher than,1,0.4819222092628479
GILENYA,died,mg)  higher than recommended,1,0.46553945541381836
GILENYA,died,patients who received GILENYA doses,0,0.47883903980255127
GILENYA,died,premarketing clinical trials in patients,0,0.41302239894866943
GILENYA,herpetic infections,in patients who,0,0.5415681600570679
GILENYA,herpetic infections,mg er than recommended,1,0.5038174390792847
GILENYA,herpetic infections,doses mg er,1,0.5117245316505432
GILENYA,herpetic infections,Similar events have been,0,0.5091574788093567
GILENYA,herpetic infections,mg er than,1,0.5193583965301514
GILENYA,herpetic infections,er than recommended for,1,0.4963865876197815
GILENYA,herpetic infections,than recommended for use in,1,0.5041173696517944
GILENYA,herpetic infections,received GILENYA doses mg er than recommended,1,0.5256564617156982
GILENYA,herpetic infections,the postmarketing setting,0,0.4705280661582947
GILENYA,disseminated primary herpes zoster,not been established Lymphomas,0,0.5212541818618774
GILENYA,disseminated primary herpes zoster,the postm arketing setting although,1,0.48026609420776367
GILENYA,disseminated primary herpes zoster,been d with GILENYA 0.5 mg in the postm arketing,1,0.528273344039917
GILENYA,disseminated primary herpes zoster,doses mg higher than recommended for,0,0.5121262669563293
GILENYA,disseminated primary herpes zoster,been d with GILENYA 0.5 mg in the postm arketing setting although a,1,0.523160457611084
GILENYA,disseminated primary herpes zoster,for,0,0.5259482860565186
GILENYA,herpes simplex encephalitis,causal relationsh ip has,1,0.4778226613998413
GILENYA,herpes simplex encephalitis,in the postmarketing setting lthough a causal relationsh ip has not been established,1,0.47118914127349854
GILENYA,herpes simplex encephalitis,in MS Similar events have,0,0.5206485986709595
GILENYA,herpes simplex encephalitis,lthough a causal relationsh ip,1,0.501254677772522
GILENYA,herpes simplex encephalitis,setting lthough a causal relationsh ip has not been,1,0.46423280239105225
GILENYA,herpes simplex encephalitis,in premarketing,0,0.4404337704181671
GILENYA,herpes simplex encephalitis,setting a,0,0.44030308723449707
BENLYSTA,Mortality,Mortality see Warnings and Precautions,1,0.7970552444458008
BENLYSTA,Mortality,detail in the Warnings,0,0.5895170569419861
BENLYSTA,Mortality,Mortality see,1,0.8950119018554688
BENLYSTA,Mortality,with,0,0.5897895097732544
BENLYSTA,Mortality,section,0,0.551156759262085
BENLYSTA,Mortality,Mortality see Warnings,1,0.8328551650047302
BENLYSTA,Infections,Infections,1,1.000000238418579
BENLYSTA,Infections,Infections see Warnings and Precautions Malignancy,1,0.7470619678497314
BENLYSTA,Infections,see,0,0.5760005712509155
BENLYSTA,Infections,Precautions Infections see Warnings and,1,0.769990086555481
BENLYSTA,Infections,section Mortality see Warnings and,0,0.5871294140815735
BENLYSTA,Infections,Infections see Warnings and,1,0.8097580075263977
BENLYSTA,Malignancy,Serious Infections see,0,0.5753053426742554
BENLYSTA,Malignancy,Precautions Hypersensitivity Reactions,0,0.5161558389663696
BENLYSTA,Malignancy,Malignancy see Warnings,1,0.807492733001709
BENLYSTA,Malignancy,see Warnings and Precautions Hypersensitivity Reactions including Anaphylax,0,0.5284537076950073
BENLYSTA,Malignancy,Malignancy see Warnings and Precautions Hypersensitivity,1,0.7357386946678162
BENLYSTA,Malignancy,Hypersensitivity Reactions including Anaphylax,0,0.5309244394302368
BENLYSTA,Malignancy,see,0,0.5707535147666931
BENLYSTA,Anaphylaxis,Anaphylaxis see Warnings and,1,0.8716140985488892
BENLYSTA,Anaphylaxis,Anaphylaxis see,1,0.920531690120697
BENLYSTA,Anaphylaxis,and Precautions Infusion Reactions see Warnings and Precau,0,0.6667349934577942
BENLYSTA,Anaphylaxis,Infusion Reactions see Warnings and,0,0.6553128957748413
BENLYSTA,Anaphylaxis,Anaphylaxis see Warnings and Precautions,1,0.8584316968917847
BENLYSTA,Depression,Depression see,1,0.8992124795913696
BENLYSTA,Depression,EXCERPT Common adverse,0,0.530442476272583
BENLYSTA,Depression,Common adverse reactions,0,0.5266828536987305
BENLYSTA,Depression,Infusion Reactions see Warnings and Precautions,0,0.4622125029563904
BENLYSTA,Depression,Reactions see Warnings and Depression see Warnings and,1,0.7179405689239502
BENLYSTA,Depression,Depression see Warnings,1,0.8228039145469666
BENLYSTA,Depression,Depression,1,0.9999998807907104
BENLYSTA,Depression,and Precautions,0,0.47281891107559204
BENLYSTA,Depression,Depression see Warnings and Precautions,1,0.7940919399261475
BENLYSTA,nausea,trials were,0,0.48421236872673035
BENLYSTA,diarrhea,diarrhea pyrexia nasopharyngitis bronchitis insomnia,1,0.7261189222335815
BENLYSTA,diarrhea,diarrhea pyrexia nasopharyngitis,1,0.7452394366264343
BENLYSTA,diarrhea,diarrhea,1,0.9999999403953552
BENLYSTA,diarrhea,diarrhea pyrexia nasopharyngitis bronchitis,1,0.7333275079727173
BENLYSTA,diarrhea,clinical trials were,0,0.48944291472435
BENLYSTA,diarrhea,depression migraine and,0,0.5299383401870728
BENLYSTA,diarrhea,clinical trials were diarrhea pyrexia nasopharyngitis,1,0.7081236839294434
BENLYSTA,pyrexia,pyrexia nasopharyngitis,1,0.8121863007545471
BENLYSTA,pyrexia,pyrexia nasopharyngitis bronchitis insomnia pain,1,0.807378888130188
BENLYSTA,pyrexia,adverse,0,0.5464146137237549
BENLYSTA,pyrexia,were nausea diarrhea,0,0.600877046585083
BENLYSTA,nasopharyngitis,trials were nausea diarrhea nasopharyngitis bronchitis insomnia pain,1,0.662697434425354
BENLYSTA,nasopharyngitis,were nausea diarrhea,0,0.5849162340164185
BENLYSTA,nasopharyngitis,diarrhea nasopharyngitis bronchitis insomnia pain in,1,0.7396087646484375
BENLYSTA,bronchitis,bronchitis insomnia pain in,1,0.8049156665802002
BENLYSTA,bronchitis,in clinical trials were nausea diarrhea pyrexia,0,0.5272918939590454
BENLYSTA,bronchitis,nausea diarrhea pyrexia bronchitis,1,0.7895556688308716
BENLYSTA,bronchitis,nasopharyngitis,0,0.6154769062995911
BENLYSTA,bronchitis,bronchitis insomnia,1,0.7942401170730591
BENLYSTA,bronchitis,bronchitis insomnia pain in extremity depression,1,0.7198493480682373
BENLYSTA,bronchitis,nausea diarrhea pyrexia bronchitis insomnia pain in,1,0.6700719594955444
BENLYSTA,bronchitis,diarrhea,0,0.6088984608650208
BENLYSTA,insomnia,pyrexia,0,0.5275911092758179
BENLYSTA,insomnia,clinical trials were,0,0.4610109329223633
BENLYSTA,insomnia,in extremity depression migraine and,0,0.5960651636123657
BENLYSTA,insomnia,diarrhea pyrexia nasopharyngitis insomnia,1,0.6846461892127991
BENLYSTA,insomnia,pain in extremity depression migraine and pharyngitis To report SUSPECTED,0,0.5517364740371704
BENLYSTA,insomnia,clinical trials were nausea diarrhea pyrexia,0,0.5239351987838745
BENLYSTA,insomnia,pharyngitis To report SUSPECTED ADVE,0,0.4495537281036377
BENLYSTA,insomnia,e reactions in,0,0.45143935084342957
BENLYSTA,insomnia,pharyngitis To,0,0.4938342571258545
BENLYSTA,insomnia,pyrexia nasopharyngitis bronchitis,0,0.46450942754745483
BENLYSTA,pain in extremity,nausea diarrhea,0,0.4972655773162842
BENLYSTA,pain in extremity,in extremity depression migraine and pharyngitis,1,0.6803008317947388
BENLYSTA,pain in extremity,bronchitis pain in extremity depression migraine,1,0.7128399610519409
BENLYSTA,pain in extremity,diarrhea pyrexia,0,0.5210826992988586
BENLYSTA,pain in extremity,pain in,1,0.7611168622970581
BENLYSTA,pain in extremity,ADVERSE REACTIONS cont,0,0.5508902072906494
BENLYSTA,migraine,nasopharyngitis bronchitis insomnia pain in extremity,0,0.6166054010391235
BENLYSTA,migraine,migraine,1,0.9999998807907104
BENLYSTA,migraine,migraine and pharyngitis To report SUSPECTED,1,0.7568525671958923
BENLYSTA,migraine,pharyngitis To report SUSPECTED ADVERSE REACTIONS contact GlaxoSmithKline,0,0.5180976390838623
BENLYSTA,migraine,migraine and pharyngitis,1,0.768710196018219
BENLYSTA,migraine,depression,0,0.6696014404296875
BENLYSTA,pharyngitis,pain in extremity depression migraine and,0,0.46303170919418335
BENLYSTA,pharyngitis,depression migraine pharyngitis To report,1,0.7899929285049438
BENLYSTA,pharyngitis,pyrexia nasopharyngitis bronchitis insomnia pain in extremity,0,0.6210943460464478
BENLYSTA,pharyngitis,depression migraine pharyngitis To report SUSPECTED ADVERSE,1,0.7724453210830688
BENLYSTA,pharyngitis,nasopharyngitis bronchitis insomnia,0,0.6330350637435913
BENLYSTA,pharyngitis,depression migraine pharyngitis To report SUSPECTED,1,0.7841470241546631
BENLYSTA,pharyngitis,pharyngitis To report,1,0.902023434638977
BENLYSTA,pharyngitis,ADVERSE REACTIONS contact,0,0.5327228307723999
BENLYSTA,pharyngitis,pharyngitis To report SUSPECTED ADVERSE REACTIONS,1,0.8455381989479065
BENLYSTA,infections,with treated with placebo The most common serious adverse,0,0.5266523957252502
BENLYSTA,infections,and in the groups receiving BENLYSTA and placebo respectively see Warnings and,0,0.5412428975105286
BENLYSTA,infections,infections and in the,1,0.8950964212417603
BENLYSTA,infections,infections,1,1.000000238418579
BENLYSTA,nausea,nausea diarrhea,1,0.8622832298278809
BENLYSTA,nausea,infections,1,0.6117834448814392
BENLYSTA,nausea,nausea diarrhea pyrexia,1,0.8078976273536682
BENLYSTA,nausea,trials nausea diarrhea pyrexia,1,0.7668210864067078
BENLYSTA,nausea,clinical trials nausea diarrhea,1,0.7605410814285278
BENLYSTA,nausea,in clinical trials nausea diarrhea pyrexia,1,0.7413140535354614
BENLYSTA,nausea,nausea diarrhea pyrexia nasopharyngitis bronchitis insomnia,1,0.7544969320297241
BENLYSTA,nausea,patients in clinical trials nausea,1,0.7995018362998962
BENLYSTA,nausea,in clinical trials nausea diarrhea pyrexia nasopharyngitis,1,0.7247684001922607
BENLYSTA,nausea,bronchitis insomnia,0,0.5505690574645996
BENLYSTA,nausea,reactions occurring in of,0,0.5232346653938293
BENLYSTA,diarrhea,insomnia pain in extremity depression migraine,0,0.4819621443748474
BENLYSTA,diarrhea,diarrhea pyrexia,1,0.7626122236251831
BENLYSTA,pyrexia,were nausea pyrexia nasopharyngitis bronchitis insomnia pain,1,0.7529414296150208
BENLYSTA,pyrexia,diarrhea pyrexia,1,0.8972519636154175
BENLYSTA,pyrexia,pyrexia nasopharyngitis bronchitis insomnia,1,0.8017799854278564
BENLYSTA,pyrexia,pyrexia nasopharyngitis bronchitis,1,0.7643930912017822
BENLYSTA,nasopharyngitis,adverse reactions occurring in of patients in clinical trials were nausea,0,0.565396785736084
BENLYSTA,nasopharyngitis,reactions occurring in of patients in,0,0.5459402799606323
BENLYSTA,bronchitis,in extremity depression migraine,0,0.4570060074329376
BENLYSTA,bronchitis,bronchitis insomnia pain in extremity,1,0.7278728485107422
BENLYSTA,bronchitis,nausea diarrhea pyrexia bronchitis insomnia pain,1,0.6626075506210327
BENLYSTA,insomnia,patients who,0,0.47084885835647583
BENLYSTA,insomnia,insomnia,1,1.0000001192092896
BENLYSTA,insomnia,insomnia pain in extremity depression migraine,1,0.7708412408828735
BENLYSTA,insomnia,pharyngitis The proportion of,0,0.4602523446083069
BENLYSTA,insomnia,nasopharyngitis insomnia pain in extremity depression migraine,1,0.7010469436645508
BENLYSTA,insomnia,in extremity depression migraine and pharyngitis The proportion of patients,0,0.5621815919876099
BENLYSTA,insomnia,pain in extremity depression migraine and pharyngitis The proportion of patients who disco,0,0.5585049390792847
BENLYSTA,pain in extremity,bronchitis pain in extremity,1,0.7983493804931641
BENLYSTA,pain in extremity,pain in extremity depression migraine and pharyngitis The proportion of patients who disco,0,0.733765721321106
BENLYSTA,pain in extremity,The proportion of patients who discontinued treatment d,0,0.502205491065979
BENLYSTA,pain in extremity,migraine and pharyngitis The proportion of patients,0,0.5054121613502502
BENLYSTA,pain in extremity,who discontinued treatment,0,0.4929736256599426
BENLYSTA,pain in extremity,pyrexia nasopharyngitis bronchitis pain in extremity depression,1,0.7171881198883057
BENLYSTA,pain in extremity,insomnia,0,0.5106054544448853
BENLYSTA,pain in extremity,pyrexia nasopharyngitis bronchitis pain in extremity,1,0.7547115087509155
BENLYSTA,pain in extremity,who,0,0.48010945320129395
BENLYSTA,pain in extremity,nasopharyngitis bronchitis pain in extremity,1,0.7707667350769043
BENLYSTA,depression,depression migraine and pharyngitis The proportion,1,0.7205314040184021
BENLYSTA,depression,depression migraine and pharyngitis,1,0.7300057411193848
BENLYSTA,depression,bronchitis insomnia pain in depression migraine and pharyngitis The,1,0.6631077527999878
BENLYSTA,depression,depression migraine and pharyngitis The,1,0.7279476523399353
BENLYSTA,migraine,pain in extremity migraine and pharyngitis The,1,0.7583552598953247
BENLYSTA,migraine,depression migraine and pharyngitis The,1,0.7491490244865417
BENLYSTA,migraine,in extremity migraine and pharyngitis The proportion of,1,0.7458297610282898
BENLYSTA,migraine,migraine and,1,0.9101767539978027
BENLYSTA,pharyngitis,due to any adverse,0,0.5017712116241455
BENLYSTA,pharyngitis,who discontinued treatment due to any adverse reaction during the c,0,0.5024739503860474
BENLYSTA,pharyngitis,pyrexia nasopharyngitis bronchitis insomnia pain in,0,0.6493995785713196
BENLYSTA,pharyngitis,adverse reaction during the,0,0.5485856533050537
BENLYSTA,pharyngitis,pharyngitis The,1,0.9569201469421387
BENLYSTA,pharyngitis,pharyngitis The proportion,1,0.8945881128311157
BENLYSTA,pharyngitis,pharyngitis The proportion of,1,0.8739646673202515
BENLYSTA,pharyngitis,pharyngitis The proportion of patients who,1,0.8412442207336426
BENLYSTA,pharyngitis,patients who discontinued treatment due to any adverse,0,0.4675092101097107
BENLYSTA,infusion reactions,nephritis BENLYSTA and placebo and infections,0,0.5885372757911682
BENLYSTA,lupus nephritis,and infections BENLYSTA and,0,0.5498964190483093
BENLYSTA,lupus nephritis,BENLYSTA and lupus nephritis,1,0.8290221691131592
BENLYSTA,lupus nephritis,BENLYSTA or placebo were infusion reactions BENLYSTA,0,0.5181565880775452
BENLYSTA,infections,lists adverse reactions regardless,0,0.5933607816696167
BENLYSTA,infections,infections BENLYSTA,1,0.7983938455581665
BENLYSTA,infections,BENLYSTA and placebo,0,0.5209838151931763
BENLYSTA,infusion reactions,infusion reactions of nausea erythematous rash pruritus,1,0.8372350931167603
BENLYSTA,infusion reactions,patients receiving BENLYSTA mgkg Three patients with antibelimumab antibodies experienced,0,0.597500205039978
BENLYSTA,infusion reactions,experienced infusion reactions,1,0.958436906337738
BENLYSTA,infusion reactions,antibelimumab antibodies experienced infusion reactions,1,0.797559380531311
BENLYSTA,infusion reactions,and,0,0.48085689544677734
BENLYSTA,infusion reactions,pruritus eyelid edema headache and dyspnea none of the reactions,0,0.6407519578933716
BENLYSTA,infusion reactions,with antibelimumab antibodies experienced infusion,1,0.7485995292663574
BENLYSTA,nausea,nausea erythematous,1,0.8125246167182922
BENLYSTA,nausea,experienced mild infusion reactions nausea erythematous,1,0.7277087569236755
BENLYSTA,nausea,experienced mild infusion reactions nausea erythematous rash pruritus,1,0.6683741211891174
BENLYSTA,nausea,nausea erythematous rash,1,0.7901418805122375
BENLYSTA,nausea,nausea erythematous rash pruritus eyelid edema,1,0.7347102165222168
BENLYSTA,erythematous rash,headache and dyspnea none of the reactions was,0,0.49499833583831787
BENLYSTA,pruritus,nausea erythematous pruritus eyelid edema,1,0.7919586896896362
BENLYSTA,pruritus,headache and dyspnea none of the reactions was,0,0.5705024600028992
BENLYSTA,pruritus,pruritus,1,0.9999999403953552
BENLYSTA,pruritus,pruritus eyelid edema,1,0.8125222325325012
BENLYSTA,pruritus,pruritus eyelid,1,0.86060631275177
BENLYSTA,pruritus,pruritus eyelid edema headache and,1,0.8197344541549683
BENLYSTA,pruritus,erythematous rash,0,0.680880069732666
BENLYSTA,pruritus,mild infusion reactions of,0,0.5558030009269714
BENLYSTA,eyelid edema,eyelid edema headache and dyspnea none,1,0.8587309718132019
BENLYSTA,eyelid edema,eyelid edema headache and,1,0.9043872356414795
BENLYSTA,headache,and,0,0.5308664441108704
BENLYSTA,headache,headache and dyspnea none of,1,0.7614709138870239
BENLYSTA,headache,headache,1,0.9999998807907104
BENLYSTA,headache,experienced,0,0.5069901347160339
BENLYSTA,headache,infusion reactions of nausea erythematous,0,0.5557514429092407
BENLYSTA,headache,erythematous rash pruritus eyelid headache and dyspnea none of the,1,0.6366862058639526
BENLYSTA,headache,eyelid headache and dyspnea none of the,1,0.7329649925231934
BENLYSTA,headache,edema,0,0.5967940092086792
BENLYSTA,headache,was lifethreatening The,0,0.5034725666046143
BENLYSTA,headache,reactions of nausea erythematous rash pruritus eyelid edema,0,0.566872239112854
BENLYSTA,dyspnea,headache,0,0.533991277217865
BENLYSTA,dyspnea,of the presence,0,0.5070151090621948
BENLYSTA,dyspnea,headache dyspnea none of the,1,0.763290524482727
BENLYSTA,dyspnea,eyelid edema headache,0,0.520480751991272
BENLYSTA,dyspnea,the presence of,0,0.5249434113502502
BENLYSTA,dyspnea,none of the reactions was lifethreatening The clinical relevance of the,0,0.5347152352333069
BENLYSTA,dyspnea,edema headache dyspnea,1,0.7705149054527283
BENLYSTA,dyspnea,the reactions was lifethreatening The clinical relevance of the presence,0,0.5403493642807007
BENLYSTA,Fatal,see Warnings,0,0.5702261924743652
BENLYSTA,Fatal,frequency or establish a causal relationship to,0,0.5088393092155457
BENLYSTA,anaphylaxis,anaphylaxis see Warnings and,1,0.8716140985488892
BENLYSTA,anaphylaxis,drug exposure Fatal,0,0.5410549640655518
BENLYSTA,Mortality,conditions,0,0.6319893002510071
BENLYSTA,deaths,under widely ying c,1,0.5111120939254761
BENLYSTA,deaths,widely ying c onditions adverse reaction rates observed,1,0.5543969869613647
BENLYSTA,deaths,clinical trials are conducted under widely,0,0.4631730914115906
BENLYSTA,deaths,conducted under widely ying c onditions adverse reaction,1,0.5356467962265015
BENLYSTA,deaths,widely ying c,1,0.518027663230896
BENLYSTA,deaths,observed in the clinical trials of a drug,0,0.4710686206817627
BENLYSTA,Infections,n the clin ical,1,0.5586304664611816
BENLYSTA,Infections,the clin ical trials,1,0.563024640083313
BENLYSTA,Infections,n the clin ical trials of,1,0.5621583461761475
BENLYSTA,Infections,with rates n,1,0.5233221054077148
BENLYSTA,Infections,the clinical trials of a drug cannot be,0,0.4889097213745117
BENLYSTA,Infections,directly compared with rates,0,0.47348764538764954
BENLYSTA,fatal,rug a nd may not,1,0.4684178829193115
BENLYSTA,fatal,another rug a,1,0.4389660358428955
BENLYSTA,fatal,of another rug a,1,0.42354491353034973
BENLYSTA,fatal,of a drug,0,0.4977670907974243
BENLYSTA,fatal,practice The following have been observed with,0,0.4829786419868469
BENLYSTA,fatal,compared with rates in,0,0.46905717253685
BENLYSTA,infections,d,1,0.5440078973770142
BENLYSTA,infections,trials of another drug d may not  reflect the,1,0.5190151333808899
BENLYSTA,infections,may not reflect the,1,0.4332129955291748
BENLYSTA,infections,of another drug d may not  reflect the rates observed,1,0.5207440853118896
BENLYSTA,infections,rates observed in practice The following have,0,0.49507683515548706
BENLYSTA,infections,in practice The following have been,0,0.5093763470649719
BENLYSTA,PML,Precautions [ s,1,0.5069670677185059
BENLYSTA,PML,in practice The following have been,0,0.4744621515274048
BENLYSTA,PML,[ s ee Warnings and Precautions,1,0.44320744276046753
BENLYSTA,Hypersensitivity Reactions,XCERPT Common adverse,0,0.561206579208374
BENLYSTA,Hypersensitivity Reactions,trials,0,0.5489218235015869
BENLYSTA,Hypersensitivity Reactions,] E XCERPT Common adverse reactions in,1,0.6753952503204346
BENLYSTA,Hypersensitivity Reactions,autions (5.6) ],1,0.5289746522903442
BENLYSTA,Hypersensitivity Reactions,(5.6) ] E XCERPT Common adverse reactions,1,0.669363260269165
BENLYSTA,Hypersensitivity Reactions,clinical trials were nausea diarrhea,0,0.5299831628799438
BENLYSTA,Hypersensitivity Reactions,autions,1,0.5552884340286255
BENLYSTA,Hypersensitivity Reactions,Depression see Warnings and,0,0.4841940402984619
BENLYSTA,Hypersensitivity Reactions,Depression see Warnings and autions,1,0.4960358142852783
BENLYSTA,Anaphylaxis,mmon advers e reactions in,1,0.6425588726997375
BENLYSTA,Anaphylaxis,and Precautions,0,0.5631759166717529
BENLYSTA,Anaphylaxis,e reactions in,0,0.6392067074775696
BENLYSTA,Anaphylaxis,were nausea diarrhea,0,0.570104718208313
BENLYSTA,Anaphylaxis,reactions in clinical trials were nausea,0,0.6453428864479065
BENLYSTA,Anaphylaxis,mmon advers,1,0.4978484511375427
BENLYSTA,Anaphylaxis,mmon advers e reactions in clinical,1,0.6975714564323425
BENLYSTA,Anaphylaxis,Precautions EXCERPT,0,0.5957015752792358
BENLYSTA,Anaphylaxis,Warnings and Precautions EXCERPT mmon,1,0.5960310697555542
BENLYSTA,fatal,insomnia pain,0,0.4747353196144104
BENLYSTA,fatal,Common adverse =5%)  in,1,0.5346958637237549
BENLYSTA,Depression,report SUSPECTED ADVERSE REACTIONS,0,0.4814257025718689
BENLYSTA,Depression,REACTIONS contact,0,0.5082669854164124
BENLYSTA,Depression,ADVERSE REACTIONS contact,0,0.4997418522834778
BENLYSTA,Depression,REACTIONS contact GlaxoSmithKline -6597,1,0.514264702796936
BENLYSTA,Depression,SUSPECTED ADVERSE,0,0.5398173332214355
BENLYSTA,Depression,The data d,0,0.5459299683570862
BENLYSTA,Depression,GlaxoSmithKline -6597 or,1,0.5271265506744385
BENLYSTA,Depression,-6597 or F DA at,1,0.506955623626709
BENLYSTA,Depression,FDA or wwwfdagovmedwatch,0,0.5054572224617004
BENLYSTA,Depression,The data described,0,0.5146950483322144
BENLYSTA,Depression,REACTIONS contact GlaxoSmithKline at or FDA,0,0.510287880897522
BENLYSTA,Depression,at 1-800- FDA,1,0.4971555769443512
BENLYSTA,Depression,contact GlaxoSmithKline at or at 1-800-,1,0.5196824073791504
BENLYSTA,Depression,GlaxoSmithKline at or at 1-800-,1,0.5230385065078735
BENLYSTA,Depression,GlaxoSmithKline at or  at 1-800- FDA or wwwfdagovmedwatch,1,0.5075690746307373
BENLYSTA,Depression,or FDA,0,0.5638881921768188
BENLYSTA,suicidality,at or FDA at 088 or www.,1,0.47486698627471924
BENLYSTA,suicidality,FDA at 088,1,0.46501457691192627
BENLYSTA,suicidality,088,1,0.45424163341522217
BENLYSTA,suicidality,or www. fdagovmedwatch Clinical Trials,1,0.4623119533061981
BENLYSTA,suicidality,088 or,1,0.4461918771266937
BENLYSTA,deaths,= 675) intravenously over a,1,0.49903547763824463
BENLYSTA,deaths,= 675) intravenously over a hour period,1,0.5106328725814819
BENLYSTA,deaths,of the trials T,0,0.5316080451011658
BENLYSTA,deaths,at doses of mgkg N mgkg N Trial only or mgkg N or,0,0.4935944676399231
BENLYSTA,deaths,was given,0,0.4987866282463074
BENLYSTA,deaths,", whil e in the other",1,0.5143535137176514
BENLYSTA,deaths,in the,0,0.5595569610595703
BENLYSTA,deaths,no apparent ose-re lated,1,0.42518776655197144
BENLYSTA,deaths,ose-re lated increase in the majority,1,0.48156604170799255
BENLYSTA,deaths,ose-re lated,1,0.4800383150577545
BENLYSTA,deaths,see Clinical Studies Because there was no apparent,0,0.4821664094924927
BENLYSTA,deaths,the safety data,0,0.5480857491493225
BENLYSTA,deaths,BENLYSTA,0,0.492473304271698
BENLYSTA,death,data summarized below are presented for th,0,0.5071790814399719
BENLYSTA,death,3 d oses pooled,1,0.4980061650276184
BENLYSTA,death,presented for e 3,1,0.48157474398612976
BENLYSTA,death,for e 3 d,1,0.5238714814186096
BENLYSTA,death,e 3 d oses pooled,1,0.5091544389724731
BENLYSTA,death,for e 3 d oses pooled,1,0.5087254047393799
BENLYSTA,infection,ated; the adverse,1,0.5908385515213013
BENLYSTA,infection,e 3 d oses pooled,1,0.5042002201080322
BENLYSTA,infection,ated; the,1,0.5970523357391357
BENLYSTA,infection,ated; the adverse reaction table displays,1,0.586740255355835
BENLYSTA,infection,recommended dose of mgkg compared with plac,0,0.5215026140213013
BENLYSTA,infection,results for the recommended dose,0,0.5531901121139526
BENLYSTA,infection,of mgkg compared with plac,0,0.49623584747314453
BENLYSTA,infection,presented,0,0.5447969436645508
BENLYSTA,infection,ated; the adverse reaction table,1,0.5907855033874512
BENLYSTA,infection,unless otherwise ated; the,1,0.5603076219558716
BENLYSTA,cardiovascular disease,the dverse reaction table  displays the,1,0.5212522149085999
BENLYSTA,cardiovascular disease,unless otherwise ated; the,1,0.4954663813114166
BENLYSTA,cardiovascular disease,indicated the dverse reaction table  displays,1,0.5303880572319031
BENLYSTA,cardiovascular disease,doses pooled unless otherwise,0,0.534150242805481
BENLYSTA,suicide,reaction table,0,0.48963552713394165
BENLYSTA,fatal,place bo The population had a,1,0.4820762872695923
BENLYSTA,fatal,bo The population had a mean age of range to were,0,0.49095165729522705
BENLYSTA,fatal,compared place bo The population had,1,0.4884372353553772
BENLYSTA,fatal,dose of mgkg compared place bo The population,1,0.5378025770187378
BENLYSTA,fatal,place bo The population had,1,0.4788326919078827
BENLYSTA,infections,of mgkg compared with o.,1,0.4720025062561035
BENLYSTA,infections,with o. The,1,0.5365579128265381
BENLYSTA,infections,placeb,0,0.49890005588531494
BENLYSTA,infections,o. The population had,1,0.5115560293197632
BENLYSTA,infections,and,0,0.5494766235351562
BENLYSTA,infections,"with o.



 The population had a mean age",1,0.5240360498428345
BENLYSTA,infections,population had a mean age of range to were,0,0.5128226280212402
BENLYSTA,infections,o. The,1,0.525971531867981
BENLYSTA,infections,female,0,0.5157157778739929
BENLYSTA,infections,o. The population had a,1,0.511123776435852
BENLYSTA,infections,compared with o. The,1,0.49661985039711
BENLYSTA,infections,"diarrhea,  pyrexia",1,0.6489386558532715
BENLYSTA,infections,"in clinical trials were diarrhea,  pyrexia nasopharyngitis bronchitis",1,0.6198900938034058
BENLYSTA,infections,"diarrhea,  pyrexia nasopharyngitis bronchitis insomnia",1,0.6886104345321655
BENLYSTA,infections,reactions occurring in,0,0.5633715391159058
BENLYSTA,infections,clinical trials were nausea,0,0.5262887477874756
BENLYSTA,infections,and pharyngitis  proportio,1,0.5869193077087402
BENLYSTA,infections,pain in extremity depression migraine and pharyngitis,0,0.6068453192710876
BENLYSTA,infections,The,0,0.5522018074989319
BENLYSTA,infections,and pharyngitis The,0,0.6388705372810364
BENLYSTA,infections,discontinued treatment due to any adverse reaction during the controlled,0,0.5153385996818542
BENLYSTA,infections, proportio n of patients who,1,0.5571098327636719
BENLYSTA,infections, proportio n of patients,1,0.551456093788147
BENLYSTA,infections,discontinued treatment due to any adverse reaction during the,0,0.5129913091659546
BENLYSTA,infections,and pharyngitis,0,0.6548744440078735
BENLYSTA,upper respiratory tract infection,adverse reaction during,1,0.5619579553604126
BENLYSTA,upper respiratory tract infection,e to any adverse reaction during  the controlled clinical trials was,1,0.5327430367469788
BENLYSTA,upper respiratory tract infection,for patients,0,0.5367391705513
BENLYSTA,upper respiratory tract infection,pharyngitis The proportion of patients who discontinued,0,0.6434289813041687
BENLYSTA,upper respiratory tract infection,e to any adverse reaction during,1,0.5833362340927124
BENLYSTA,upper respiratory tract infection,reaction during the,1,0.49132227897644043
BENLYSTA,upper respiratory tract infection,discontinued treatment e to any adverse reaction during  the controlled clinical,1,0.5171504616737366
BENLYSTA,upper respiratory tract infection,discontinued treatment e to any adverse reaction during  the controlled,1,0.5283164978027344
BENLYSTA,upper respiratory tract infection,treatment e,1,0.5441027283668518
BENLYSTA,upper respiratory tract infection,proportion of patients who,0,0.4841322898864746
BENLYSTA,urinary tract infection,placebo The,0,0.5335696339607239
BENLYSTA,urinary tract infection,patients receiving placebo The most,0,0.46721088886260986
BENLYSTA,urinary tract infection,patients who discontinued,0,0.49004560708999634
BENLYSTA,urinary tract infection,e controlled clinical t rials was for patients,1,0.4970684051513672
BENLYSTA,urinary tract infection,patients receiving placebo The most com,0,0.47235307097435
BENLYSTA,urinary tract infection,BENLYSTA and for patients receiving placebo The,0,0.4944874048233032
BENLYSTA,urinary tract infection,reaction during e controlled clinical t rials was for patients,1,0.497416615486145
BENLYSTA,urinary tract infection,controlled clinical t rials was for patients receiving,1,0.5185943841934204
BENLYSTA,nasopharyngitis,was 6.2% fo r patients receiving,1,0.5088227391242981
BENLYSTA,nasopharyngitis,clinical als was,1,0.45887160301208496
BENLYSTA,nasopharyngitis,receiving placebo The most common adverse,0,0.5201503038406372
BENLYSTA,nasopharyngitis,treatment due,0,0.5422938466072083
BENLYSTA,nasopharyngitis,clinical tri,0,0.5017204880714417
BENLYSTA,nasopharyngitis,als was 6.2% fo r patients receiving,1,0.44426673650741577
BENLYSTA,nasopharyngitis,during the controlled clinical als was 6.2% fo r patients receiving BENLYSTA,1,0.4532405138015747
BENLYSTA,nasopharyngitis,als was 6.2% fo r,1,0.45343661308288574
BENLYSTA,bronchitis,receiving placebo The most common adverse,0,0.4668967127799988
BENLYSTA,bronchitis,patients ceiving BE NLYSTA,1,0.5308531522750854
BENLYSTA,bronchitis,the controlled clinical trials,0,0.5160174369812012
BENLYSTA,bronchitis,adverse reaction during the,0,0.5446147322654724
BENLYSTA,bronchitis,to any adverse reaction,0,0.540320098400116
BENLYSTA,bronchitis,ceiving BE,1,0.5812394618988037
BENLYSTA,influenza,trials was for,0,0.49007153511047363
BENLYSTA,influenza, and 7.1%,1,0.44012245535850525
BENLYSTA,influenza,receiving  and 7.1% for patients receiving placebo The,1,0.4785259962081909
BENLYSTA,influenza,was for patients receiving  and 7.1% for,1,0.4807434678077698
BENLYSTA,influenza,and 7.1% for,1,0.44872546195983887
BENLYSTA,influenza,was for patients receiving and,1,0.5207170844078064
BENLYSTA,influenza,controlled,0,0.5198863744735718
BENLYSTA,influenza,trials was for patients receiving,0,0.5108835101127625
BENLYSTA,infections,during the controlled,0,0.5319145917892456
BENLYSTA,infections,A or place bo were infusion reactions,1,0.5486469864845276
BENLYSTA,infections,mmon adverse reactions resulting in discontinuation,0,0.5553156137466431
BENLYSTA,infections,treatment of patients receiving A or,1,0.5749051570892334
BENLYSTA,infections,bo were infusion reactions BENLYSTA and placebo lupus nephritis BENLYSTA,0,0.5335521101951599
BENLYSTA,pneumonia,placebo were nfusion r,1,0.5488351583480835
BENLYSTA,pneumonia,in discontinuation of treatment,0,0.5432506203651428
BENLYSTA,bronchitis,and lupus neph,1,0.5187307000160217
BENLYSTA,bronchitis,BENLYSTA and lupus,1,0.5409383773803711
BENLYSTA,bronchitis,and placebo,0,0.5051630735397339
BENLYSTA,bronchitis,and,0,0.5355700254440308
BENLYSTA,bronchitis,ritis,0,0.5487496852874756
BENLYSTA,bronchitis,BENLYSTA,0,0.5179337859153748
BENLYSTA,bronchitis,BENLYSTA and,0,0.5258803367614746
BENLYSTA,bronchitis,reactions BENLYSTA and lupus neph,1,0.547817587852478
BENLYSTA,Infections,lupus tis (0.7%  BENLYSTA and placebo and,1,0.530605673789978
BENLYSTA,Infections,reactions BENLYSTA and lupus neph,1,0.5354045629501343
BENLYSTA,Infections,infections BENLYSTA and placebo Table lists ad,0,0.7070634365081787
BENLYSTA,Infections,tis (0.7% BENLYSTA,1,0.5365302562713623
BENLYSTA,Infections,lupus tis (0.7%  BENLYSTA and,1,0.5501319169998169
BENLYSTA,Infections,with SLE who,0,0.5708577036857605
BENLYSTA,Infections,lists adverse reactions regardless f causalit y occurring in,1,0.6015574932098389
BENLYSTA,Infections,adverse reactions regardless f causalit,1,0.5900342464447021
BENLYSTA,Infections,lists adverse reactions regardless f causalit y,1,0.599029541015625
BENLYSTA,Infections,f causalit y,1,0.5319361686706543
BENLYSTA,Infections,reactions regardless f causalit,1,0.545918345451355
BENLYSTA,Infections,received BENLYSTA mgkg and at an incidence,0,0.5405791997909546
BENLYSTA,Infections,f causalit y occurring in at least,1,0.5478307008743286
BENLYSTA,Infections,who,0,0.5307941436767578
BENLYSTA,JC virus,controlled studies,0,0.53463214635849
BENLYSTA,JC virus,studies Table Inciden,0,0.4715902507305145
BENLYSTA,JC virus,occurring in at Least of Patients Treated,0,0.5386249423027039
BENLYSTA,JC virus,of Ad verse,1,0.46760857105255127
BENLYSTA,JC virus,t least greater than that observed with placebo in the controlled studies,0,0.48388734459877014
BENLYSTA,JC virus,greater than that observed with placebo in the controlled,0,0.4989452362060547
BENLYSTA,JC virus,Table ce of,1,0.4822245240211487
BENLYSTA,JC virus,controlled studies Table ce of Ad,1,0.531053900718689
BENLYSTA,JC virus,controlled studies Table ce of Ad verse,1,0.5015267133712769
BENLYSTA,JC virus,controlled studies Table ce of,1,0.5076022148132324
BENLYSTA,PML,ons occurring in at Least,1,0.5265836715698242
BENLYSTA,PML,ons occurring,1,0.5390335321426392
BENLYSTA,PML,ons occurring in at Least of,1,0.5267943739891052
BENLYSTA,neurological deficits,mgkg plus Standard of Care and,0,0.5228239297866821
BENLYSTA,neurological deficits,Adverse Reactions occurring at,1,0.542160153388977
BENLYSTA,neurological deficits,ts Treated with BENLYSTA mgkg plus Standard of Care and at Least More Frequently than in,0,0.5103379487991333
BENLYSTA,fatal,Least,0,0.5304504632949829
BENLYSTA,fatal,Least of Patients Treated ith B,1,0.5276761651039124
BENLYSTA,fatal,Patients Treated ith B,1,0.5286675095558167
BENLYSTA,fatal,Treated,0,0.5667134523391724
BENLYSTA,fatal,of Adverse Reactions,0,0.5691142678260803
BENLYSTA,fatal,ith B ENLYSTA mgkg plus Standard of,1,0.5541924834251404
BENLYSTA,hypersensitivity reactions,in of patients receiving  mg/kg and in 27 of 559 (4 patients receiving BENLYSTA mgkg The,1,0.551677405834198
BENLYSTA,hypersensitivity reactions,of Adverse Reactions,0,0.7458202838897705
BENLYSTA,hypersensitivity reactions,for the group receiving mgkg ma,0,0.49970757961273193
BENLYSTA,hypersensitivity reactions,mg/kg and in,1,0.5328394174575806
BENLYSTA,hypersensitivity reactions,in of patients receiving BENLYSTA,0,0.5589887499809265
BENLYSTA,hypersensitivity reactions, mg/kg and in 27 of 559 (4 patients receiving BENLYSTA mgkg The,1,0.5460942387580872
BENLYSTA,hypersensitivity reactions,27 of 559 (4 patients,1,0.5240681171417236
BENLYSTA,hypersensitivity reactions,receiving,0,0.4878961443901062
BENLYSTA,hypersensitivity reactions,of patients receiving mg/kg and in,1,0.5426690578460693
BENLYSTA,hypersensitivity reactions,frequency for the group receiving,0,0.450516939163208
BENLYSTA,hypersensitivity reactions,patients receiving,0,0.5688093900680542
BENLYSTA,Anaphylaxis,ass,0,0.5152992010116577
BENLYSTA,Anaphylaxis,to lower ay,1,0.5213941335678101
BENLYSTA,Anaphylaxis,frequency due to lower ay sensitiv,1,0.5956203937530518
BENLYSTA,hypotension,patients wi th antibelimumab antibodies experienced mild,1,0.5179409980773926
BENLYSTA,hypotension,patients wi th antibelimumab,1,0.4875964820384979
BENLYSTA,hypotension,receiving BENLYSTA mgkg patients wi th,1,0.5593804121017456
BENLYSTA,hypotension,patients wi th,1,0.5591890811920166
BENLYSTA,hypotension,patients receiving BENLYSTA mgkg patients wi,1,0.5340603590011597
BENLYSTA,angioedema, anti-beli mumab antibodies experienced mild,1,0.6025655269622803
BENLYSTA,angioedema,antibodies were detected in patients,0,0.597995400428772
BENLYSTA,angioedema, anti-beli,1,0.5913383960723877
BENLYSTA,urticaria,rash pruritus eyelid edema,0,0.7000732421875
BENLYSTA,urticaria,in patients receiving BENLYSTA mgkg Three,0,0.5294259786605835
BENLYSTA,urticaria,mild infusion reactions of nausea erythematous rash pruritus eyelid,0,0.6579416990280151
BENLYSTA,urticaria,mab antib odies experienced mild,1,0.6228175759315491
BENLYSTA,rash,rien ced,1,0.5036885738372803
BENLYSTA,rash,rien ced mild infusion reactions,1,0.5455771088600159
BENLYSTA,rash,rien,1,0.5034928321838379
BENLYSTA,rash,mgkg Three patients with antibelimumab,0,0.5481604337692261
BENLYSTA,rash,antibelimumab antibodies rien ced mild,1,0.5676445364952087
BENLYSTA,rash,mild infusion reactions of nausea erythematous rash pruritus,0,0.7077298760414124
BENLYSTA,rash,edema headache and dysp,0,0.5373039245605469
BENLYSTA,rash,edema headache,0,0.5307396650314331
BENLYSTA,pruritus,edema headache,0,0.5466572046279907
BENLYSTA,pruritus,d mild i,1,0.5771560072898865
BENLYSTA,dyspnea,erythematous rash pruritus eyelid edema headache,0,0.49746373295783997
BENLYSTA,dyspnea,n react,1,0.5315980315208435
BENLYSTA,dyspnea,mild n react,1,0.5325455069541931
BENLYSTA,dyspnea,n react ions of,1,0.48615527153015137
BENLYSTA,hypersensitivity reactions,one of the reactions was l,1,0.7362333536148071
BENLYSTA,hypersensitivity reactions,of the reactions was l,1,0.7074918746948242
BENLYSTA,hypersensitivity reactions,the presence of antibelimumab antibodies is not known,0,0.5788284540176392
BENLYSTA,hypersensitivity reactions,ld infusion reactions of nausea erythematous rash pruritus eyelid edema headache and,0,0.7133336067199707
BENLYSTA,hypersensitivity reactions,presence of antibelimumab,0,0.5813654661178589
BENLYSTA,hypersensitivity reactions,of the reactions was l ifethreatening The clinical relevance,1,0.7071143388748169
BENLYSTA,infusion reactions,eyelid edema headache and dyspnea,0,0.5583897829055786
BENLYSTA,infusion reactions,reactions was,0,0.7362050414085388
BENLYSTA,infusion reactions,hreatening. The cl inical,1,0.5515323281288147
BENLYSTA,infusion reactions,hreatening. The cl inical relevance of the presence,1,0.5103936195373535
BENLYSTA,infusion reactions,reactions was hreatening. The,1,0.7078279256820679
BENLYSTA,infusion reactions,is not known The data reflect the,0,0.4571336507797241
BENLYSTA,adverse events associated with the infusion,a causal relationship to drug exp osure Fatal,1,0.6191155314445496
BENLYSTA,adverse events associated with the infusion,frequency establish a causal relationship to drug exp osure Fatal,1,0.5995982885360718
BENLYSTA,adverse events associated with the infusion,a causal relationship to drug exp,1,0.5946289896965027
BENLYSTA,adverse events associated with the infusion,their frequency,0,0.43975353240966797
BENLYSTA,adverse events associated with the infusion,reliably estimate their frequency establish a causal relationship to drug exp,1,0.5784881711006165
BENLYSTA,adverse events associated with the infusion,see Warnings and Precautions,0,0.6098291277885437
BENLYSTA,adverse events associated with the infusion,of uncertain size it is not,0,0.3999893069267273
XALKORI,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions,1,0.8759649395942688
XALKORI,Hepatotoxicity,of uncertain size it is not,0,0.42272722721099854
XALKORI,Hepatotoxicity,Hepatotoxicity see,1,0.9551874399185181
XALKORI,Hepatotoxicity,Hepatotoxicity,1,1.0
XALKORI,Hepatotoxicity,see Warnings and Precautions,0,0.5665377378463745
XALKORI,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions Interstitial,1,0.8202967047691345
XALKORI,Hepatotoxicity,sections of the Hepatotoxicity see Warnings and Precautions Interstitial,1,0.8198444247245789
XALKORI,Hepatotoxicity,Hepatotoxicity see Warnings and,1,0.9071921110153198
XALKORI,Hepatotoxicity,Hepatotoxicity see Warnings,1,0.8999106287956238
XALKORI,Interstitial Lung Disease,QT Interval,0,0.4706301987171173
XALKORI,Interstitial Lung Disease,sections of the labeling Hepatotoxicity,0,0.516769289970398
XALKORI,Interstitial Lung Disease,and Interstitial Lung Disease Pneumonitis see Warnings and,1,0.8371566534042358
XALKORI,Interstitial Lung Disease,and Interstitial,1,0.7156983613967896
XALKORI,Pneumonitis,see Warnings and,0,0.49198609590530396
XALKORI,Pneumonitis,Pneumonitis see Warnings,1,0.8605952262878418
XALKORI,Pneumonitis,Interstitial Lung Pneumonitis see Warnings and,1,0.783364474773407
XALKORI,Pneumonitis,Precautions Interstitial Lung Pneumonitis see Warnings and Precautions QT,1,0.7174948453903198
XALKORI,QT Interval Prolongation,DiseasePneumonitis see,0,0.42955246567726135
XALKORI,Bradycardia,Bradycardia see,1,0.9294329881668091
XALKORI,Bradycardia,and Precautions,0,0.49998268485069275
XALKORI,Bradycardia,see Warnings and Bradycardia see Warnings and Precautions Severe,1,0.7641474008560181
XALKORI,Visual Loss,The,0,0.5316243171691895
XALKORI,Visual Loss,Warnings and Precautions Visual Loss see Warnings and,1,0.8002750873565674
XALKORI,Visual Loss,Visual Loss see,1,0.9450551271438599
XALKORI,Visual Loss,Visual Loss,1,1.0
XALKORI,Visual Loss,and Precautions Visual Loss,1,0.8860874176025391
XALKORI,vision disorders,vision,1,0.7269545793533325
XALKORI,vision disorders,most common adverse reactions vision disorders,1,0.7948817014694214
XALKORI,vision disorders,vision disorders,1,0.9999998807907104
XALKORI,vision disorders,vision disorders diarrhea nausea,1,0.8352529406547546
XALKORI,vision disorders,EXCERPT The most common adverse,0,0.5440255403518677
XALKORI,diarrhea,edema elevated transaminases upper,0,0.5726349353790283
XALKORI,diarrhea,vision diarrhea nausea,1,0.7854014039039612
XALKORI,diarrhea,diarrhea nausea,1,0.8461776971817017
XALKORI,diarrhea,diarrhea nausea vomiting constipation,1,0.8422160148620605
XALKORI,diarrhea,vision diarrhea,1,0.807219386100769
XALKORI,diarrhea,transaminases upper respiratory,0,0.5526594519615173
XALKORI,diarrhea,vision diarrhea nausea vomiting constipation edema,1,0.7641879916191101
XALKORI,diarrhea,diarrhea nausea vomiting constipation edema elevated,1,0.7986817359924316
XALKORI,diarrhea,diarrhea nausea vomiting,1,0.8504341244697571
XALKORI,nausea,transaminases upper respiratory infection,0,0.5980450510978699
XALKORI,nausea,nausea vomiting constipation edema,1,0.802147626876831
XALKORI,nausea,vomiting constipation edema elevated transaminases upper respiratory infection decreased,0,0.7183656692504883
XALKORI,nausea,elevated transaminases,0,0.5561931729316711
XALKORI,nausea,nausea vomiting constipation edema elevated,1,0.7867721319198608
XALKORI,vomiting,disorders diarrhea vomiting constipation edema elevated transaminases,1,0.6848100423812866
XALKORI,vomiting,nausea vomiting constipation edema,1,0.7991191148757935
XALKORI,vomiting,vomiting,1,0.9999999403953552
XALKORI,vomiting,diarrhea vomiting constipation edema elevated transaminases upper,1,0.7051188945770264
XALKORI,vomiting,decreased,0,0.5053275227546692
XALKORI,vomiting,constipation edema elevated,0,0.5884318351745605
XALKORI,vomiting,are vision disorders diarrhea vomiting constipation edema elevated transaminases,1,0.650443434715271
XALKORI,vomiting,decreased appetite and,0,0.608761191368103
XALKORI,vomiting,transaminases upper respiratory infection,0,0.5714176297187805
XALKORI,vomiting,vomiting constipation edema elevated transaminases upper,1,0.7489760518074036
XALKORI,constipation,decreased appetite and dysgeusia,0,0.6385248899459839
XALKORI,edema,vomiting edema elevated transaminases,1,0.7049814462661743
XALKORI,edema,decreased appetite and dysgeusia,0,0.5813348293304443
XALKORI,edema,edema elevated transaminases upper respiratory,1,0.7204679846763611
XALKORI,edema,disorders diarrhea nausea vomiting edema elevated transaminases upper respiratory infection,1,0.6455185413360596
XALKORI,elevated transaminases,decreased appetite and dysgeusia,0,0.539143443107605
XALKORI,elevated transaminases,elevated transaminases upper respiratory infection decreased,1,0.8293657898902893
XALKORI,elevated transaminases,To,0,0.5473383665084839
XALKORI,elevated transaminases,vomiting,0,0.5343248248100281
XALKORI,elevated transaminases,diarrhea nausea vomiting constipation elevated transaminases,1,0.8751426935195923
XALKORI,elevated transaminases,constipation elevated transaminases upper,1,0.8799888491630554
XALKORI,elevated transaminases,elevated transaminases upper respiratory infection,1,0.8867300748825073
XALKORI,elevated transaminases,elevated transaminases,1,1.0
XALKORI,elevated transaminases,diarrhea nausea vomiting constipation elevated,1,0.6692448854446411
XALKORI,upper respiratory infection,diarrhea nausea vomiting constipation edema,0,0.5003005862236023
XALKORI,upper respiratory infection,and,0,0.5034056305885315
XALKORI,upper respiratory infection,upper respiratory infection decreased,1,0.8699272871017456
XALKORI,upper respiratory infection,upper respiratory infection,1,1.000000238418579
XALKORI,upper respiratory infection,upper respiratory infection decreased appetite and,1,0.796409547328949
XALKORI,upper respiratory infection,elevated,0,0.5769202709197998
XALKORI,upper respiratory infection,upper respiratory infection decreased appetite,1,0.7936381101608276
XALKORI,upper respiratory infection,disorders diarrhea nausea vomiting constipation edema elevated,0,0.49379563331604004
XALKORI,decreased appetite,decreased appetite and dysgeusia To report SUSPECTED,1,0.8494327068328857
XALKORI,decreased appetite,arrhea,0,0.4952632784843445
XALKORI,decreased appetite,edema elevated transaminases,0,0.5295804738998413
XALKORI,decreased appetite,decreased appetite,1,0.9999999403953552
XALKORI,decreased appetite,decreased appetite and dysgeusia To report,1,0.8569395542144775
XALKORI,decreased appetite,elevated transaminases upper respiratory decreased appetite and dysgeusia,1,0.7553296089172363
XALKORI,decreased appetite,REACTIONS contact Pfizer Inc at,0,0.47426390647888184
XALKORI,dysgeusia,dysgeusia To report SUSPECTED,1,0.8765252232551575
XALKORI,dysgeusia,report SUSPECTED ADVERSE,0,0.5515912771224976
XALKORI,dysgeusia,respiratory infection decreased appetite dysgeusia To report,1,0.7886891961097717
XALKORI,dysgeusia,infection decreased appetite and,0,0.6197617053985596
XALKORI,vision disorders,adverse reactions of XALKORI in,0,0.48804354667663574
XALKORI,vision disorders,Studies and vision,1,0.6932270526885986
XALKORI,vision disorders,transaminases upper respiratory infecti,0,0.4816354215145111
XALKORI,vision disorders,vision disorders diarrhea nausea vomiting constipation edema,1,0.8287532329559326
XALKORI,diarrhea,diarrhea,1,0.9999999403953552
XALKORI,diarrhea,reactions of XALKORI,0,0.5561986565589905
XALKORI,diarrhea,nausea vomiting constipation edema elevated transaminases upper,0,0.6460981965065002
XALKORI,diarrhea,nausea vomiting constipation edema elevated transaminases upper respiratory infection decrea,0,0.6636625528335571
XALKORI,diarrhea,diarrhea nausea vomiting constipation edema,1,0.8105849623680115
XALKORI,vomiting,vision disorders diarrhea nausea,0,0.6597223281860352
XALKORI,vomiting,nausea,0,0.8409453630447388
XALKORI,constipation,are vision disorders diarrhea nausea vomiting,0,0.6198482513427734
XALKORI,constipation,constipation edema elevated transaminases upper,1,0.7374326586723328
XALKORI,constipation,nausea vomiting,0,0.6057789325714111
XALKORI,constipation,vomiting,0,0.6330149173736572
XALKORI,constipation,appetite and,0,0.652055561542511
XALKORI,constipation,disorders diarrhea nausea constipation,1,0.7525356411933899
XALKORI,elevated transaminases,appetite and dysgeusia Previously,0,0.5794984102249146
XALKORI,elevated transaminases,elevated transaminases upper,1,0.9505391120910645
XALKORI,elevated transaminases,constipation elevated transaminases upper respiratory infection decreased appetite,1,0.7529224753379822
XALKORI,elevated transaminases,edema,0,0.5447943210601807
XALKORI,elevated transaminases,nausea vomiting constipation elevated transaminases upper respiratory infection decreased,1,0.7653146982192993
XALKORI,elevated transaminases,Studies and are vision,0,0.5084888935089111
XALKORI,upper respiratory infection,edema elevated upper respiratory infection decreased appetite and dysgeusia Previously,1,0.7426731586456299
XALKORI,upper respiratory infection,Studies and are vision,0,0.4782491624355316
XALKORI,upper respiratory infection,constipation edema elevated upper respiratory,1,0.6767120361328125
XALKORI,upper respiratory infection,constipation edema elevated upper,1,0.5600056648254395
XALKORI,upper respiratory infection,respiratory infection decreased appetite and,1,0.7153602838516235
XALKORI,dysgeusia,and,0,0.4908916652202606
XALKORI,dysgeusia,dysgeusia Previously Untreated,1,0.882559061050415
XALKORI,dyspnea,dyspnea and pulmonary embolism,1,0.844102144241333
XALKORI,dyspnea,treated with XALKORI dyspnea and pulmonary embolism Fatal adverse,1,0.7294789552688599
XALKORI,dyspnea,dyspnea and pulmonary embolism Fatal adverse,1,0.7946552634239197
XALKORI,pulmonary embolism,were dyspnea pulmonary embolism Fatal,1,0.8017227649688721
XALKORI,pulmonary embolism,dyspnea and pulmonary embolism Fatal adverse,1,0.8007593154907227
XALKORI,pulmonary embolism,pulmonary embolism Fatal adverse events,1,0.8276017904281616
XALKORI,pulmonary embolism,XALKORI were dyspnea pulmonary embolism Fatal,1,0.7793254256248474
XALKORI,pulmonary embolism,pulmonary,1,0.7724299430847168
XALKORI,pulmonary embolism,patients consisting of,0,0.5621620416641235
XALKORI,pulmonary embolism,pulmonary embolism Fatal adverse,1,0.8357512354850769
XALKORI,pulmonary embolism,serious adverse events,0,0.5782561302185059
XALKORI,pulmonary embolism,pulmonary embolism Fatal adverse events in,1,0.8333718776702881
XALKORI,pulmonary embolism,events reported in,0,0.5157034397125244
XALKORI,pulmonary embolism,Fatal adverse events in XALKORItreated patients occurred in patients,0,0.5581358671188354
XALKORI,Fatal,were dyspnea and pulmonary Fatal adverse,1,0.7031919956207275
XALKORI,Fatal,Fatal adverse events in XALKORItreated patients occurred in patients,0,0.6436813473701477
XALKORI,Fatal,Fatal adverse events in,1,0.7637103796005249
XALKORI,septic shock,septic shock,1,0.9999999403953552
XALKORI,septic shock,adverse events in XALKORItreated patients occurred in patients consisting of,0,0.49295634031295776
XALKORI,septic shock,Fatal adverse events in XALKORItreated patients occurred in,0,0.5107336044311523
XALKORI,septic shock,reductions due to adverse reactions,0,0.5671545267105103
XALKORI,septic shock,Fatal adverse events in XALKORItreated,0,0.5260294675827026
XALKORI,septic shock,occurred in patients consisting septic shock,1,0.8777986764907837
XALKORI,septic shock,septic shock acute respiratory,1,0.838067889213562
XALKORI,acute respiratory failure,of septic acute respiratory failure,1,0.8935037851333618
XALKORI,acute respiratory failure,septic shock acute respiratory,1,0.831180989742279
XALKORI,acute respiratory failure,and diabetic ketoacidosis Dose reductions due to adverse reactions were,0,0.5182980895042419
XALKORI,acute respiratory failure,patients consisting of,0,0.5600214004516602
XALKORI,diabetic ketoacidosis,diabetic ketoacidosis,1,1.0
XALKORI,diabetic ketoacidosis,respiratory failure diabetic ketoacidosis Dose reductions due to adverse,1,0.8026723861694336
XALKORI,diabetic ketoacidosis,diabetic ketoacidosis Dose reductions,1,0.8429121971130371
XALKORI,diabetic ketoacidosis,failure diabetic ketoacidosis,1,0.9087971448898315
XALKORI,diabetic ketoacidosis,shock acute respiratory failure diabetic,1,0.714042603969574
XALKORI,diabetic ketoacidosis,diabetic ketoacidosis Dose reductions due,1,0.8382458686828613
XALKORI,diabetic ketoacidosis,diabetic ketoacidosis Dose reductions due to,1,0.8330592513084412
XALKORI,diabetic ketoacidosis,diabetic ketoacidosis Dose,1,0.89243483543396
XALKORI,nausea,nausea and elevated transaminases,1,0.759287416934967
XALKORI,nausea,dose reduction in these patients,0,0.5288664698600769
XALKORI,nausea,discontinuation,0,0.525469183921814
XALKORI,nausea,nausea and,1,0.9323806762695312
XALKORI,elevated transaminases,discontinuation in XALKORItreated,0,0.46805042028427124
XALKORI,elevated transaminases,discontinuation in XALKORItreated patients elevated,1,0.6090952754020691
XALKORI,elevated transaminases,discontinuation in XALKORItreated patients elevated transaminases,1,0.7983967065811157
XALKORI,hepatotoxicity,hepatotoxicity and ILD Tables and,1,0.8496708869934082
XALKORI,hepatotoxicity,hepatotoxicity and ILD,1,0.8604732155799866
XALKORI,hepatotoxicity,in XALKORItreated patients,0,0.5397852659225464
XALKORI,hepatotoxicity,hepatotoxicity and ILD Tables and summarize,1,0.8437250256538391
XALKORI,nausea,neuropathy which,0,0.5433584451675415
XALKORI,nausea,nausea decreased appetite fatigue neuropathy,1,0.7474971413612366
XALKORI,nausea,at an overall incidence between and in patients treated with XALKORI included,0,0.5635842084884644
XALKORI,nausea,patients treated with XALKORI nausea decreased appetite fatigue,1,0.7076929807662964
XALKORI,nausea,an,0,0.5514737367630005
XALKORI,decreased appetite,decreased appetite fatigue neuropathy which included,1,0.8213087320327759
XALKORI,decreased appetite,treated with XALKORI included,0,0.5485981702804565
XALKORI,decreased appetite,with XALKORI included decreased,1,0.6073197722434998
XALKORI,decreased appetite,hypoaesthesia muscular,0,0.5608803033828735
XALKORI,decreased appetite,decreased,1,0.7124267816543579
XALKORI,decreased appetite,included gait disturbance hypoaesthesia muscular,0,0.602894127368927
XALKORI,decreased appetite,included,0,0.47366464138031006
XALKORI,decreased appetite,XALKORI included decreased appetite fatigue neuropathy which included,1,0.7542235851287842
XALKORI,fatigue,neuropathy which included gait disturbance hypoaesthesia,0,0.5590128898620605
XALKORI,fatigue,fatigue neuropathy which included,1,0.7969680428504944
XALKORI,fatigue,treated with,0,0.5520012378692627
XALKORI,fatigue,XALKORI included nausea,0,0.586956799030304
XALKORI,fatigue,included nausea decreased fatigue neuropathy,1,0.755610466003418
XALKORI,neuropathy,with XALKORI included nausea decreased appetite,0,0.5310038924217224
XALKORI,neuropathy,neuropathy which included gait disturbance,1,0.8245067596435547
XALKORI,neuropathy,gait disturbance hypoaesthesia muscular weakness,0,0.6578992605209351
XALKORI,neuropathy,hypoaesthesia muscular weakness neuralgia neuropathy peri,0,0.7478369474411011
XALKORI,hypoaesthesia,included gait hypoaesthesia muscular weakness neuralgia,1,0.7377365827560425
XALKORI,hypoaesthesia,hypoaesthesia muscular weakness neuralgia neuropathy peri,0,0.7900383472442627
XALKORI,hypoaesthesia,paraesthesia,0,0.7962000370025635
XALKORI,hypoaesthesia,hypoaesthesia muscular weakness neuralgia neuropathy peripheral,1,0.8044304847717285
XALKORI,hypoaesthesia,which,0,0.506859302520752
XALKORI,hypoaesthesia,hypoaesthesia muscular weakness neuralgia,1,0.8090645670890808
XALKORI,hypoaesthesia,included,0,0.4997660517692566
XALKORI,muscular weakness,muscular weakness,1,1.0000001192092896
XALKORI,muscular weakness,disturbance muscular weakness,1,0.9156513214111328
XALKORI,muscular weakness,sed appetite,0,0.5369566679000854
XALKORI,muscular weakness,which included gait disturbance muscular weakness neuralgia neuropathy,1,0.7348296642303467
XALKORI,muscular weakness,fatigue neuropathy which included,0,0.6497864723205566
XALKORI,muscular weakness,muscular weakness neuralgia neuropathy,1,0.8247482776641846
XALKORI,muscular weakness,peripheral,0,0.50108402967453
XALKORI,neuralgia,hypoaesthesia muscular neuralgia neuropathy peripheral,1,0.7545249462127686
XALKORI,neuralgia,muscular weakness,1,0.534259557723999
XALKORI,neuralgia,neuralgia neuropathy peripheral,1,0.813453733921051
XALKORI,neuralgia,neuralgia neuropathy peripheral paraesthesia peripheral,1,0.8040757775306702
XALKORI,neuralgia,disturbance hypoaesthesia muscular,0,0.5658842325210571
XALKORI,neuralgia,which included gait disturbance hypoaesthesia,0,0.5530894994735718
XALKORI,neuralgia,hypoaesthesia muscular neuralgia neuropathy peripheral paraesthesia peripheral sensory,1,0.7520043849945068
XALKORI,neuralgia,paraesthesia peripheral sensory neuropathy,0,0.6233521699905396
XALKORI,neuralgia,fatigue neuropathy which included gait disturbance,0,0.5992729067802429
XALKORI,neuralgia,peripheral sensory neuropathy polyneuropathy sensory distur,0,0.6382222771644592
XALKORI,neuropathy peripheral,neuropathy peripheral paraesthesia peripheral sensory neuropathy,1,0.8874049782752991
XALKORI,neuropathy peripheral,disturbance hypoaesthesia muscular weakness neuropathy peripheral,1,0.7277151346206665
XALKORI,neuropathy peripheral,disturbance rash ren,0,0.4692407250404358
XALKORI,neuropathy peripheral,peripheral sensory neuropathy polyneuropathy sensory,0,0.857050359249115
XALKORI,neuropathy peripheral,weakness neuropathy peripheral paraesthesia peripheral,1,0.8924887776374817
XALKORI,neuropathy peripheral,hypoaesthesia muscular weakness neuropathy peripheral,1,0.7748199701309204
XALKORI,paraesthesia,muscular weakness neuralgia neuropathy,0,0.5719832181930542
XALKORI,paraesthesia,neuralgia neuropathy peripheral,0,0.5934343934059143
XALKORI,paraesthesia,weakness neuralgia neuropathy,0,0.5918266773223877
XALKORI,paraesthesia,disturbance rash renal,0,0.5413215160369873
XALKORI,paraesthesia,paraesthesia,1,1.0
XALKORI,polyneuropathy,polyneuropathy,1,1.0
XALKORI,polyneuropathy,peripheral paraesthesia peripheral,0,0.6515669822692871
XALKORI,polyneuropathy,rash renal cyst,0,0.4872599244117737
XALKORI,polyneuropathy,sensory polyneuropathy sensory disturbance rash renal cyst,1,0.7294349074363708
XALKORI,polyneuropathy,polyneuropathy sensory,1,0.8838715553283691
XALKORI,polyneuropathy,ILD ILD,0,0.46985989809036255
XALKORI,sensory disturbance,sensory disturbance rash,1,0.8962905406951904
XALKORI,rash,disturbance,0,0.5284914970397949
XALKORI,rash,rash renal cyst,1,0.7631134986877441
XALKORI,rash,rash renal cyst ILD ILD,1,0.7330349683761597
XALKORI,renal cyst,renal cyst,1,0.9999998807907104
XALKORI,renal cyst,syncope,0,0.4280184507369995
XALKORI,renal cyst,renal cyst ILD ILD,1,0.8327040672302246
XALKORI,renal cyst,disturbance renal cyst ILD ILD pneumonitis,1,0.8157370090484619
XALKORI,renal cyst,sensory disturbance renal cyst ILD ILD pneumonitis,1,0.7616283893585205
XALKORI,renal cyst,pneumonitis,0,0.5119789838790894
XALKORI,renal cyst,peripheral sensory neuropathy,0,0.44853097200393677
XALKORI,ILD,ILD ILD pneumonitis,1,0.8234950304031372
XALKORI,ILD,sensory,0,0.5362767577171326
XALKORI,ILD,ILD pneumonitis and syncope,1,0.7079319953918457
XALKORI,ILD,renal,0,0.505372941493988
XALKORI,pneumonitis,rash renal cyst ILD pneumonitis and,1,0.727062463760376
XALKORI,pneumonitis,renal,0,0.5351470708847046
XALKORI,pneumonitis,rash renal cyst ILD,0,0.5245785713195801
XALKORI,pneumonitis,rash,0,0.534686803817749
XALKORI,pneumonitis,renal cyst ILD ILD,0,0.5379647016525269
XALKORI,pneumonitis,pneumonitis and syncope Table Summary of,1,0.7532410025596619
XALKORI,syncope,syncope Table,1,0.8729774951934814
XALKORI,syncope,TreatmentEmergent Laboratory,0,0.5230666399002075
XALKORI,syncope,ILD ILD pneumonitis syncope Table Summary of TreatmentEmergent,1,0.7618566751480103
XALKORI,syncope,syncope,1,0.9999998807907104
XALKORI,syncope,disturbance rash renal cyst ILD ILD,0,0.5164684057235718
XALKORI,syncope,cyst ILD ILD pneumonitis syncope Table Summary of,1,0.7311457991600037
XALKORI,syncope,Laboratory Abnormalities,0,0.5311282277107239
XALKORI,pneumonia,adverse reactions reported in patients,0,0.49474892020225525
XALKORI,pneumonia,adverse reactions,0,0.5477504730224609
XALKORI,pneumonia,pneumonia pulmonary embolism,1,0.8099209666252136
XALKORI,pneumonia,reactions in,0,0.5278002023696899
XALKORI,pulmonary embolism,reported in patients,0,0.5807641744613647
XALKORI,dyspnea,in XALKORItreated patients in Study,0,0.5466024875640869
XALKORI,dyspnea,dyspnea and ILD Fatal adverse reactions,1,0.770125687122345
XALKORI,dyspnea,were pneumonia pulmonary dyspnea,1,0.8441582918167114
XALKORI,ILD,were pneumonia pulmonary embolism,0,0.4368756115436554
XALKORI,ILD,ILD,1,1.0
XALKORI,Fatal,adverse reactions in XALKORItreated patients in,0,0.5432305335998535
XALKORI,Fatal,Fatal adverse,1,0.8618949055671692
XALKORI,Fatal,XALKORItreated patients in Study occurred,0,0.5357635021209717
XALKORI,Fatal,Fatal adverse reactions in,1,0.7593940496444702
XALKORI,Fatal,Fatal adverse reactions in XALKORItreated patients,1,0.638047456741333
XALKORI,Fatal,in Study,0,0.49971404671669006
XALKORI,Fatal,Fatal adverse reactions,1,0.7630990743637085
XALKORI,acute respiratory distress syndrome,occurred in patients consisting acute respiratory distress syndrome,1,0.8655275106430054
XALKORI,acute respiratory distress syndrome,consisting acute respiratory distress syndrome arrhythmia dyspnea pneumonia pneumonitis pulmonary,1,0.82518470287323
XALKORI,acute respiratory distress syndrome,of,0,0.5106322169303894
XALKORI,acute respiratory distress syndrome,patients consisting acute respiratory distress,1,0.841370701789856
XALKORI,acute respiratory distress syndrome,distress syndrome arrhythmia dyspnea,1,0.7129772901535034
XALKORI,acute respiratory distress syndrome,dyspnea pneumonia pneumonitis pulmonary embolism ILD respiratory,0,0.6480330228805542
XALKORI,acute respiratory distress syndrome,patients consisting acute respiratory distress syndrome arrhythmia dyspnea pneumonia,1,0.8045592308044434
XALKORI,acute respiratory distress syndrome,patients consisting acute respiratory distress syndrome arrhythmia dyspnea pneumonia pneumonitis,1,0.8008654117584229
XALKORI,acute respiratory distress syndrome,ILD respiratory failure,0,0.6623059511184692
XALKORI,acute respiratory distress syndrome,occurred in patients consisting acute respiratory,1,0.7313532829284668
XALKORI,arrhythmia,pneumonitis pulmonary embolism ILD,0,0.5451244115829468
XALKORI,arrhythmia,syndrome,0,0.5365278720855713
XALKORI,arrhythmia,arrhythmia,1,0.9999998211860657
XALKORI,arrhythmia,arrhythmia dyspnea,1,0.8271784782409668
XALKORI,pneumonia,pneumonia pneumonitis,1,0.8414096236228943
XALKORI,pneumonia,in patients consisting,0,0.541899561882019
XALKORI,pneumonia,pneumonia,1,0.9999997615814209
XALKORI,pneumonia,pneumonia pneumonitis pulmonary embolism ILD respiratory,1,0.7330644726753235
XALKORI,pneumonia,syndrome,0,0.5597255825996399
XALKORI,pneumonia,of acute,0,0.5648847818374634
XALKORI,pneumonia,pneumonia pneumonitis pulmonary embolism,1,0.7570587396621704
XALKORI,pneumonitis,pneumonitis pulmonary embolism ILD,1,0.7747129201889038
XALKORI,pneumonitis,pneumonitis pulmonary embolism,1,0.8306503295898438
XALKORI,pneumonitis,arrhythmia dyspnea pneumonia,0,0.6698706746101379
XALKORI,pneumonitis,dyspnea pneumonia,0,0.724544882774353
XALKORI,pneumonitis,reductions due,0,0.43581467866897583
XALKORI,pneumonitis,pneumonitis pulmonary embolism ILD respiratory failure,1,0.758551836013794
XALKORI,pneumonitis,due to,0,0.522498607635498
XALKORI,pulmonary embolism,pulmonary embolism,1,1.0
XALKORI,pulmonary embolism,pulmonary embolism ILD respiratory failure,1,0.7938498258590698
XALKORI,pulmonary embolism,distress syndrome arrhythmia,0,0.5295351147651672
XALKORI,pulmonary embolism,dyspnea pneumonia pulmonary embolism ILD respiratory failure and,1,0.7763360738754272
XALKORI,pulmonary embolism,pulmonary embolism ILD respiratory failure and sepsis,1,0.8101990818977356
XALKORI,pulmonary embolism,pneumonia pulmonary embolism ILD respiratory,1,0.7909106016159058
XALKORI,pulmonary embolism,pneumonia pulmonary embolism,1,0.880416214466095
XALKORI,pulmonary embolism,syndrome arrhythmia dyspnea pneumonia pulmonary embolism ILD respiratory failure and sepsis,1,0.7258507609367371
XALKORI,pulmonary embolism,to adverse,0,0.5168920159339905
XALKORI,ILD,ILD respiratory failure,1,0.8513669967651367
XALKORI,ILD,to adverse,0,0.5361642837524414
XALKORI,ILD,dyspnea pneumonia pneumonitis pulmonary ILD respiratory failure and sepsis,1,0.6983228921890259
XALKORI,ILD,ILD respiratory failure and sepsis,1,0.7919740080833435
XALKORI,ILD,pneumonia pneumonitis pulmonary,0,0.5026044249534607
XALKORI,ILD,ILD respiratory failure and,1,0.8392744064331055
XALKORI,ILD,pneumonia pneumonitis pulmonary ILD respiratory failure and sepsis Dose,1,0.7108224630355835
XALKORI,ILD,pneumonitis pulmonary ILD respiratory failure,1,0.7486754655838013
XALKORI,ILD,pneumonia pneumonitis pulmonary ILD respiratory,1,0.7694829702377319
XALKORI,respiratory failure,pneumonia pneumonitis pulmonary embolism respiratory failure,1,0.7884594202041626
XALKORI,respiratory failure,respiratory failure,1,1.0000001192092896
XALKORI,respiratory failure,dyspnea pneumonia pneumonitis pulmonary embolism ILD,0,0.6623583436012268
XALKORI,respiratory failure,pulmonary embolism respiratory failure and sepsis Dose reductions due,1,0.728744626045227
XALKORI,respiratory failure,pneumonia pneumonitis pulmonary embolism respiratory failure and,1,0.7866179943084717
XALKORI,respiratory failure,respiratory failure and,1,0.936090350151062
XALKORI,respiratory failure,respiratory failure and sepsis Dose reductions due,1,0.7606481313705444
XALKORI,sepsis,sepsis Dose reductions,1,0.7648377418518066
XALKORI,QTc prolongation,neutropenia XALKORI was discontinued for adverse reactions in,0,0.5351682901382446
XALKORI,QTc prolongation,concurrent aspartate aminotransferase,0,0.5990493893623352
XALKORI,QTc prolongation,QTc prolongation and neutropenia XALKORI was discontinued,1,0.7986758947372437
XALKORI,QTc prolongation,elevation,0,0.4940292239189148
XALKORI,neutropenia,elevation QTc prolongation neutropenia XALKORI was discontinued for adverse,1,0.7149443626403809
XALKORI,neutropenia,elevation,0,0.502406656742096
XALKORI,neutropenia,neutropenia XALKORI was discontinued for,1,0.7598078846931458
XALKORI,neutropenia,e patients with concurrent aspartate aminotransferase AST elevation QTc prolongation and,0,0.4843679368495941
XALKORI,ILD,ALT and AST elevation,0,0.5142934918403625
XALKORI,ILD,ILD ALT and AST elevation,1,0.7476798295974731
XALKORI,ILD,ILD ALT and,1,0.8720837831497192
XALKORI,ILD,AST elevation dyspnea and pulmonary embolism,0,0.48268604278564453
XALKORI,AST elevation,XALKORI were ILD ALT AST elevation dyspnea and pulmonary,1,0.6210013628005981
XALKORI,AST elevation,ILD ALT and AST elevation,1,0.8595961332321167
XALKORI,dyspnea,AST,0,0.5221964120864868
XALKORI,dyspnea,dyspnea and pulmonary embolism Tables and,1,0.8004271388053894
XALKORI,dyspnea,and AST,0,0.5323300957679749
XALKORI,dyspnea,ILD ALT and AST dyspnea and pulmonary,1,0.7820649147033691
XALKORI,dyspnea,were ILD ALT,0,0.5078363418579102
XALKORI,pulmonary embolism,pulmonary embolism Tables,1,0.844038724899292
XALKORI,pulmonary embolism,adverse,0,0.505284309387207
XALKORI,pulmonary embolism,pulmonary embolism Tables and summarize common,1,0.826650857925415
XALKORI,pulmonary embolism,common,0,0.5315424799919128
XALKORI,pulmonary embolism,discontinuation of XALKORI were ILD,0,0.46986740827560425
XALKORI,pulmonary embolism,AST elevation dyspnea pulmonary embolism Tables and,1,0.7756068110466003
XALKORI,Upper respiratory infection,Upper respiratory infection,1,1.000000238418579
XALKORI,Upper respiratory infection,discontinuation of XALKORI were ILD,0,0.5315249562263489
XALKORI,Upper respiratory infection,Upper,1,0.6612037420272827
XALKORI,Upper respiratory infection,Infestations,0,0.5481580495834351
XALKORI,Upper respiratory infection,d Infestations,0,0.5472779870033264
XALKORI,neuropathy,included neuropathy dysesthesia gait disturbance hypoesthesia muscular,1,0.7831113934516907
XALKORI,neuropathy,d Infestations,0,0.5226376056671143
XALKORI,neuropathy,XALKORI included neuropathy dysesthesia gait disturbance hypoesthesia muscular,1,0.7192888855934143
XALKORI,neuropathy,neuropathy dysesthesia gait disturbance,1,0.8000532984733582
XALKORI,neuropathy,neuropathy dysesthesia gait,1,0.8217481374740601
XALKORI,neuropathy,XALKORI included,0,0.464962363243103
XALKORI,neuropathy,patients treated with XALKORI included fatigue,0,0.5610944032669067
XALKORI,neuropathy,treated with XALKORI,0,0.5681682825088501
XALKORI,neuropathy,neuropathy dysesthesia gait disturbance hypoesthesia,1,0.7722668051719666
XALKORI,neuropathy,neuropathy dysesthesia,1,0.8465563654899597
XALKORI,neuropathy,with,0,0.5415923595428467
XALKORI,dysesthesia,dysesthesia gait,1,0.8504692316055298
XALKORI,dysesthesia,patients treated,0,0.5598907470703125
XALKORI,dysesthesia,weakness neuralgia peripheral neuropathy,0,0.5664622783660889
XALKORI,dysesthesia,neuralgia peripheral neuropathy parasthesia,0,0.6381219625473022
XALKORI,dysesthesia,with XALKORI,0,0.45319241285324097
XALKORI,dysesthesia,dysesthesia gait disturbance,1,0.8481714725494385
XALKORI,dysesthesia,dysesthesia,1,0.9999998211860657
XALKORI,dysesthesia,neuropathy,0,0.5712528824806213
XALKORI,hypoesthesia,hypoesthesia muscular weakness,1,0.8625110387802124
XALKORI,hypoesthesia,hypoesthesia muscular weakness neuralgia peripheral neuropathy,1,0.8322605490684509
XALKORI,hypoesthesia,dysesthesia gait disturbance,0,0.6424367427825928
XALKORI,muscular weakness,gait disturbance muscular weakness,1,0.8466441631317139
XALKORI,muscular weakness,dysesthesia gait disturbance muscular,1,0.6908353567123413
XALKORI,muscular weakness,disturbance muscular weakness neuralgia,1,0.8102645874023438
XALKORI,muscular weakness,dysesthesia gait disturbance muscular weakness neuralgia peripheral,1,0.7094408273696899
XALKORI,muscular weakness,muscular weakness neuralgia peripheral neuropathy parasthesia,1,0.7748814821243286
XALKORI,muscular weakness,muscular weakness neuralgia peripheral neuropathy,1,0.8258757591247559
XALKORI,muscular weakness,muscular,1,0.7599583864212036
XALKORI,neuralgia,neuralgia peripheral,1,0.8534468412399292
XALKORI,neuralgia,gait disturbance muscular weakness,1,0.5177692174911499
XALKORI,neuralgia,gait disturbance hypoesthesia muscular neuralgia peripheral,1,0.7350929975509644
XALKORI,neuralgia,peripheral neuropathy parasthesia peripheral sensory neuropathy polyneuropathy burning sensati,0,0.6684022545814514
XALKORI,neuralgia,disturbance hypoesthesia muscular weakness,0,0.5619438886642456
XALKORI,neuralgia,disturbance hypoesthesia,0,0.5590655207633972
XALKORI,neuralgia,hypoesthesia muscular neuralgia peripheral neuropathy,1,0.7558225393295288
XALKORI,neuralgia,sensory neuropathy polyneuropathy,0,0.6288777589797974
XALKORI,neuralgia,fatigue neuropathy,0,0.6267843246459961
XALKORI,neuralgia,neuralgia peripheral neuropathy,1,0.81241774559021
XALKORI,peripheral neuropathy,weakness peripheral,1,0.8105636835098267
XALKORI,peripheral neuropathy,muscular weakness peripheral,1,0.8286758661270142
XALKORI,peripheral neuropathy,neuralgia,0,0.6346161961555481
XALKORI,peripheral neuropathy,peripheral neuropathy parasthesia peripheral sensory neuropathy,1,0.8568339347839355
XALKORI,peripheral neuropathy,peripheral neuropathy,1,1.0000001192092896
XALKORI,peripheral neuropathy,hypoesthesia muscular,0,0.5372620820999146
XALKORI,parasthesia,muscular weakness neuralgia peripheral,0,0.5608324408531189
XALKORI,parasthesia,in skin rash,0,0.481508731842041
XALKORI,parasthesia,parasthesia peripheral sensory neuropathy,1,0.8211458921432495
XALKORI,parasthesia,parasthesia peripheral sensory,1,0.844192624092102
XALKORI,parasthesia,parasthesia,1,1.0
XALKORI,parasthesia,neuropathy polyneuropathy burning,0,0.5567148923873901
XALKORI,parasthesia,parasthesia peripheral sensory neuropathy polyneuropathy burning,1,0.7905800342559814
XALKORI,parasthesia,hypoesthesia muscular weakness neuralgia peripheral neuropathy,0,0.5906360745429993
XALKORI,peripheral sensory neuropathy,sensation in skin,0,0.7301191091537476
XALKORI,peripheral sensory neuropathy,sensory neuropathy polyneuropathy,1,0.8931884765625
XALKORI,peripheral sensory neuropathy,neuropathy peripheral sensory neuropathy polyneuropathy,1,0.9158291220664978
XALKORI,peripheral sensory neuropathy,polyneuropathy burning sensation,0,0.7681074738502502
XALKORI,polyneuropathy,skin rash ILD acute respiratory distress syndrome ILD pneumoni,0,0.5262942314147949
XALKORI,polyneuropathy,skin rash ILD acute respiratory,0,0.46753525733947754
XALKORI,polyneuropathy,polyneuropathy burning sensation,1,0.8557538390159607
XALKORI,polyneuropathy,parasthesia peripheral sensory polyneuropathy burning sensation,1,0.7717836499214172
XALKORI,polyneuropathy,neuropathy parasthesia peripheral,0,0.7983281016349792
XALKORI,polyneuropathy,skin rash ILD acute respiratory distress syndrome ILD,0,0.4938904643058777
XALKORI,burning sensation in skin,rash ILD,0,0.5904825329780579
XALKORI,burning sensation in skin,in skin rash ILD,1,0.6554738283157349
XALKORI,burning sensation in skin,ILD pneumonitis renal cyst and,0,0.48707643151283264
XALKORI,burning sensation in skin,neuropathy burning sensation in,1,0.8748157024383545
XALKORI,burning sensation in skin,burning sensation in skin,1,1.0
XALKORI,burning sensation in skin,parasthesia peripheral sensory neuropathy burning sensation in skin,1,0.8677128553390503
XALKORI,burning sensation in skin,rash ILD acute respiratory distress syndrome ILD pneumonitis,0,0.5611172318458557
XALKORI,rash,neuropathy polyneuropathy burning sensation,0,0.5831499099731445
XALKORI,rash,parasthesia peripheral sensory neuropathy,0,0.5235179662704468
XALKORI,rash,peripheral sensory neuropathy polyneuropathy burning sensation in,0,0.6015873551368713
XALKORI,rash,distress syndrome ILD,0,0.5357327461242676
XALKORI,ILD,ILD acute,1,0.8575029373168945
XALKORI,ILD,ILD acute respiratory,1,0.8374711275100708
XALKORI,ILD,rash,0,0.4992256462574005
XALKORI,ILD,peripheral sensory neuropathy polyneuropathy burning sensation in,0,0.4878620505332947
XALKORI,acute respiratory distress syndrome,sensation in skin rash acute respiratory distress syndrome ILD,1,0.7458087205886841
XALKORI,acute respiratory distress syndrome,ILD,1,0.48981064558029175
XALKORI,acute respiratory distress syndrome,sensation in skin rash acute respiratory distress syndrome ILD pneumonitis,1,0.7197169065475464
XALKORI,acute respiratory distress syndrome,rash acute respiratory distress,1,0.772631049156189
XALKORI,acute respiratory distress syndrome,sensory neuropathy polyneuropathy burning sensation in,0,0.4707910418510437
XALKORI,acute respiratory distress syndrome,neuropathy polyneuropathy burning sensation in skin rash,0,0.4673389792442322
XALKORI,acute respiratory distress syndrome,sensory,0,0.49751442670822144
XALKORI,acute respiratory distress syndrome,sensation in skin rash acute respiratory distress,1,0.7297673225402832
XALKORI,acute respiratory distress syndrome,acute respiratory distress syndrome,1,1.0000001192092896
XALKORI,ILD,syndrome,0,0.5057425498962402
XALKORI,ILD,ILD pneumonitis renal cyst and,1,0.6710354089736938
XALKORI,pneumonitis,acute respiratory distress syndrome pneumonitis renal cyst,1,0.7426358461380005
XALKORI,pneumonitis,ILD pneumonitis renal cyst and,1,0.7611150741577148
XALKORI,pneumonitis,pneumonitis renal cyst,1,0.7975326776504517
XALKORI,pneumonitis,syndrome,0,0.5279077887535095
XALKORI,pneumonitis,syndrome pneumonitis,1,0.8658648729324341
XALKORI,pneumonitis,pneumonitis,1,1.0
XALKORI,pneumonitis,and hepatic failure Table Summary of,0,0.4606870412826538
XALKORI,renal cyst,renal cyst and hepatic failure Table Summary,1,0.7836887836456299
XALKORI,renal cyst,TreatmentEmergent,0,0.49075746536254883
XALKORI,renal cyst,skin rash ILD,0,0.46264567971229553
XALKORI,renal cyst,skin rash ILD acute,0,0.46854275465011597
XALKORI,Vision disorders,Adverse Drug Reactions Vision Vision disorders,1,0.8161936402320862
XALKORI,Vision disorders,skin rash ILD acute,0,0.5069809556007385
XALKORI,Vision disorders,blurred vision or vitreous,0,0.7533245086669922
XALKORI,Vision disorders,Vision,1,0.7269545793533325
XALKORI,visual impairment,visual impairment photopsia blurred vision,1,0.8524396419525146
XALKORI,visual impairment,photopsia blurred vision or vitreous floaters occurred in of patients The majo,0,0.6532934904098511
XALKORI,visual impairment,visual impairment photopsia,1,0.8589618802070618
XALKORI,visual impairment,vision or,0,0.7224292755126953
XALKORI,photopsia,photopsia blurred,1,0.9109941720962524
XALKORI,vitreous floaters,vitreous floaters occurred in of,1,0.96909499168396
XALKORI,vitreous floaters,these,0,0.5410991907119751
XALKORI,visual adverse reactions,patients with Grade and patients with Grade visual impairment,0,0.6650650501251221
XALKORI,visual adverse reactions,these patients had visual,1,0.7525858283042908
XALKORI,visual adverse reactions,of these patients had visual adverse reactions,1,0.9347497820854187
XALKORI,visual adverse reactions,occurred in,0,0.568554699420929
XALKORI,visual adverse reactions,patients had visual adverse reactions There were,1,0.9416913390159607
XALKORI,visual adverse reactions,patients The majority of these,0,0.5513441562652588
XALKORI,visual impairment,Visual Symptom Assessment Questionnaire VSAQALK,0,0.7177830934524536
XALKORI,visual impairment,and patients with Grade,0,0.5542504191398621
XALKORI,visual impairment,and patients with visual impairment,1,0.8964440822601318
XALKORI,visual impairment,with Grade,0,0.5238017439842224
XALKORI,visual impairment,visual impairment Based on the,1,0.9113544225692749
XALKORI,visual impairment,patients treated with XALKORI,0,0.5129131078720093
XALKORI,visual impairment,and patients with visual impairment Based on the,1,0.8725041151046753
XALKORI,visual impairment,adverse reactions There were patients,0,0.5287750959396362
XALKORI,visual impairment,visual impairment Based,1,0.9186621308326721
XALKORI,visual impairment,patients with visual impairment,1,0.9018321633338928
XALKORI,visual impairment,with visual impairment,1,0.9571574926376343
XALKORI,visual disturbances,incidence visual,1,0.764051079750061
XALKORI,vision disorder,with chemotherapy The onset vision,1,0.6891688704490662
XALKORI,vision disorder,on the XALKORI,0,0.44034844636917114
XALKORI,vision disorder,vision disorder generally was within the first,1,0.8598648309707642
XALKORI,vision disorder,onset vision disorder,1,0.8799965977668762
XALKORI,vision disorder,vision disorder,1,1.0000001192092896
XALKORI,visual disturbances,Studies and visual,1,0.6391724348068237
XALKORI,visual disturbances,The majority of patients on the XALKORI arms in Studies and reported,0,0.5458447933197021
XALKORI,visual disturbances,Studies and visual disturbances,1,0.884599506855011
XALKORI,visual disturbances,patients on the XALKORI arms,0,0.5409783124923706
XALKORI,visual disturbances,visual,1,0.7323249578475952
XALKORI,visual disturbances,visual disturbances which occurred at,1,0.9456027746200562
XALKORI,visual disturbances,and visual disturbances,1,0.9781734943389893
XALKORI,Renal cysts,in patients,0,0.49764591455459595
XALKORI,Renal cysts,Grade in severity Renal,0,0.6625151634216309
XALKORI,Renal cysts,in severity Renal Renal cysts were experienced by of,1,0.8854020833969116
XALKORI,Renal cysts,Renal cysts were experienced by of,1,0.8943612575531006
XALKORI,Renal cysts,Renal cysts were experienced by of patients,1,0.8872424364089966
XALKORI,Renal cysts,in severity Renal Renal cysts,1,0.9163947105407715
XALKORI,Renal cysts,Grade in severity Renal Renal cysts,1,0.8699847459793091
XALKORI,Renal cysts,occurred in patients treated with XALKORI and patient treated with chemotherapy in St,0,0.5479147434234619
XALKORI,Renal cysts,Renal Cysts Renal cysts,0,0.9790763854980469
XALKORI,Renal cysts,were experienced by of Renal cysts,1,0.9207472801208496
XALKORI,Renal cysts,Renal cysts occurred,1,0.949073314666748
XALKORI,Renal cysts,with chemotherapy in St,0,0.4807175099849701
XALKORI,Renal cysts,Renal cysts occurred in patients treated,1,0.890181303024292
XALKORI,Renal cysts,in Renal cysts occurred,1,0.9506136178970337
XALKORI,Renal cysts,chemotherapy in Renal cysts,1,0.8624805212020874
XALKORI,Renal cysts,with chemotherapy in Renal cysts,1,0.8539454936981201
XALKORI,renal cysts,complex Local cystic invasion beyond the kidney occurred in some,0,0.7771162986755371
XALKORI,renal cysts,renal cysts in XALKORItreated,1,0.8396941423416138
XALKORI,Local cystic invasion beyond the kidney,Local cystic invasion beyond the kidney occurred,1,0.9898636341094971
XALKORI,Local cystic invasion beyond the kidney,the kidney occurred in some,1,0.7178313732147217
XALKORI,Local cystic invasion beyond the kidney,XALKORItreated patients were Local cystic invasion beyond the kidney occurred,1,0.9085925817489624
XALKORI,Local cystic invasion beyond the kidney,Local cystic invasion beyond the kidney occurred in some,1,0.9817578792572021
XALKORI,renal abscesses,trials no,0,0.45544230937957764
XALKORI,renal abscesses,by,0,0.4800785779953003
XALKORI,Hepatotoxicity,are dis cussed in greater detail in,1,0.45162805914878845
XALKORI,Hepatotoxicity,following adverse ctions are dis cussed in greater,1,0.5323570966720581
XALKORI,Hepatotoxicity,labeling,0,0.5012255311012268
XALKORI,Hepatotoxicity,are dis cussed in greater detail,1,0.4555214047431946
XALKORI,Hepatotoxicity,REACTIONS The following adverse ctions are dis,1,0.6498333215713501
XALKORI,Hepatotoxicity,The following adverse ctions are,1,0.6328727602958679
XALKORI,Hepatotoxicity,are dis cussed in greater,1,0.44759392738342285
XALKORI,Hepatotoxicity,of the labeling Hepatotoxicity see Warnings and,0,0.8729070425033569
XALKORI,Hepatotoxicity,ADVERSE REACTIONS,0,0.6700133085250854
XALKORI,Hepatotoxicity,in greater detail in other sections of the labeling Hepatotoxicity see Warnings and,0,0.8346412181854248
XALKORI,Fatal,of the labeling Hepatotoxicity see Warnings,0,0.5857958793640137
XALKORI,hepatotoxicity,in other sections,0,0.4807887673377991
XALKORI,hepatotoxicity,i,0,0.48627856373786926
XALKORI,hepatotoxicity,n greater,1,0.4852398633956909
XALKORI,hepatotoxicity,Hepatotoxicity,0,1.0
XALKORI,hepatotoxicity,following adverse,0,0.5705793499946594
XALKORI,hepatotoxicity,n greater deta il in,1,0.47073644399642944
XALKORI,Interstitial Lung Disease,Lung DiseasePneumonitis see nings and Precautions (5. QT Interval Prolongation see Warnings,1,0.683806836605072
XALKORI,Interstitial Lung Disease,following adverse,0,0.5215610265731812
XALKORI,Interstitial Lung Disease,and,0,0.5210820436477661
XALKORI,Interstitial Lung Disease,Interstitial Lung DiseasePneumonitis see nings and Precautions (5. QT,1,0.8096380829811096
XALKORI,Interstitial Lung Disease,Lung DiseasePneumonitis,0,0.7790857553482056
XALKORI,Interstitial Lung Disease,Precautions Bradycardia,0,0.4924381375312805
XALKORI,Interstitial Lung Disease,War,0,0.4889240264892578
XALKORI,ILD,  ] QT Interval Prolongation,1,0.5276929140090942
XALKORI,ILD,  ],1,0.56923907995224
XALKORI,ILD,QT,0,0.5545819997787476
XALKORI,ILD,and,0,0.5121333599090576
XALKORI,Pneumonitis,see Warnings and * QT,1,0.43794023990631104
XALKORI,Pneumonitis,"and 
 *  QT Int",1,0.4435211420059204
XALKORI,Pneumonitis,Precautions,0,0.5369132161140442
XALKORI,Pneumonitis,* QT Int erval Prolongation see Warnings and,1,0.4575335383415222
XALKORI,Pneumonitis,DiseasePneumonitis see Warnings and * QT Int,1,0.7433976531028748
XALKORI,Pneumonitis,and,0,0.48372557759284973
XALKORI,Pneumonitis,see Warnings,0,0.5032320022583008
XALKORI,QT Interval Prolongation,ns (5.4) ] * Severe,1,0.5532146692276001
XALKORI,QT Interval Prolongation,Bradycardia see Warnings and Precautio,0,0.6194496154785156
XALKORI,QT Interval Prolongation,"Bradycardia see Warnings and ns (5.4)  ]  
 *  Severe Visual Loss see",1,0.6186639070510864
XALKORI,QT Interval Prolongation,Warnings and ns (5.4) ] * Severe,1,0.5135805010795593
XALKORI,Bradycardia,decreased appetite and To report S USPECTED,1,0.5997264385223389
XALKORI,Bradycardia,Warnings and ns (5.4) ] * Severe,1,0.5151840448379517
XALKORI,Bradycardia,decreased appetite and To report S USPECTED ADVERSE,1,0.6038342714309692
XALKORI,Bradycardia,REACTIONS contact Pfizer Inc at or FDA at,0,0.5049834847450256
XALKORI,Bradycardia,decreased appetite and dysgeusia,0,0.5533480644226074
XALKORI,Bradycardia,FDA or wwwf,0,0.49847954511642456
XALKORI,Bradycardia,appetite and To report S USPECTED ADVERSE,1,0.5538079142570496
XALKORI,bradycardia,"report SUSPECTED ADVERSE CTIONS,",1,0.5136090517044067
XALKORI,bradycardia,"CTIONS, con tact",1,0.5142554044723511
XALKORI,Visual Loss,are conducted under widely varying conditions,0,0.47893863916397095
XALKORI,Visual Loss,conducted under widely varying conditions adverse reaction rates observed in the,0,0.49782484769821167
XALKORI,Visual Loss,or wwwfdagovmedwatch Clinical Trials Experience,0,0.5222783088684082
XALKORI,Visual Loss,Because nical trial s are conducted under widely,1,0.48255595564842224
XALKORI,Visual Loss,Experience Because nical trial s,1,0.530521035194397
XALKORI,Visual Loss,Because nical trial s are conducted under,1,0.46430933475494385
XALKORI,Visual Loss,nical trial s,1,0.4896423816680908
XALKORI,Embryofetal Toxicity,rates in the clinic al trials,1,0.5006737112998962
XALKORI,Embryofetal Toxicity,drug cannot be directly,0,0.5325584411621094
XALKORI,Embryofetal Toxicity,compared  rates in the clinic al,1,0.48256102204322815
XALKORI,Embryofetal Toxicity,in the clinic al trials,1,0.506227433681488
XALKORI,Embryofetal Toxicity,the clinic al,1,0.47444039583206177
XALKORI,Embryofetal Toxicity,compared  rates in the clinic al trials of another,1,0.49871087074279785
XALKORI,Embryofetal Toxicity, rates in the clinic al trials of another,1,0.5055496692657471
XALKORI,fetal harm, another d rug and may not reflect,1,0.4919186532497406
XALKORI,fetal harm,the clinic al,1,0.5339168310165405
XALKORI,fetal harm,not reflect the rates observed in clinical practice,0,0.48664194345474243
XALKORI,fetal harm,trials  another d,1,0.5171838998794556
XALKORI,hepatotoxicity,daily i n,1,0.5096056461334229
XALKORI,hepatotoxicity,twice,1,0.5009939670562744
XALKORI,hepatotoxicity,who,0,0.49076369404792786
XALKORI,hepatotoxicity,XALKORI twice,1,0.49529606103897095
XALKORI,hepatotoxicity,NSCLC who received XALKORI twice,1,0.5395610332489014
XALKORI,hepatotoxicity,XALKORI twice daily,1,0.5400043725967407
XALKORI,hepatotoxicity,based primarily on patients with ALKpositive,0,0.5096463561058044
XALKORI,hepatotoxicity, twice daily i n two openlabel randomized,1,0.4596271216869354
XALKORI,fatal,This,0,0.5786569714546204
XALKORI,fatal,in two,0,0.5174444913864136
XALKORI,fatal,trials,0,0.5179088711738586
XALKORI,fatal,open- label randomized,1,0.4980887770652771
XALKORI,fatal,open- label,1,0.5002948045730591
XALKORI,fatal,open- label randomized activecontrolled trials Studies,1,0.47466763854026794
XALKORI,fatal,twice daily in open- label randomized activecontrolled trials,1,0.48892349004745483
XALKORI,elevations in alanine aminotransferase,adverse drug reactions 1326 patients with,1,0.5823765993118286
XALKORI,elevations in alanine aminotransferase,Studies and,0,0.5633488297462463
XALKORI,elevations in alanine aminotransferase,on adverse drug reactions 1326 patients with ALK-positive,1,0.6112136840820312
XALKORI,elevations in alanine aminotransferase,on adverse drug reactions 1326 patients with ALK-positive metast atic,1,0.620018720626831
XALKORI,elevations in alanine aminotransferase,ALK-positive metast atic NSCLC who received XALKORI,1,0.5788938999176025
XALKORI,elevations in alanine aminotransferase,1326 patients with ALK-positive metast,1,0.5585557222366333
XALKORI,elevations in alanine aminotransferase,drug,0,0.5277519226074219
XALKORI,elevations in ALT,"constipation a, elevated trans aminases",1,0.5252654552459717
XALKORI,elevations in ALT,drug,0,0.4647897481918335
XALKORI,elevations in ALT,"nausea vomiting constipation a,",1,0.4766102135181427
XALKORI,elevations in ALT,constipation,0,0.4774516820907593
XALKORI,elevations in ALT,"a, elevated trans aminases",1,0.5767414569854736
XALKORI,elevations in ALT,"constipation a, elevated trans aminases upper",1,0.5598887801170349
XALKORI,elevations in ALT,and are vision disorders diarrhea,0,0.4586551785469055
XALKORI,elevations in ALT,"vomiting constipation a,",1,0.452140748500824
XALKORI,elevations in ALT,upper respiratory infection decreased appetite and,0,0.49117380380630493
XALKORI,elevations in ALT,and dysgeusia Previously,0,0.5028064846992493
XALKORI,elevations in ALT,diarrhea nausea,0,0.4770883321762085
XALKORI,elevated transaminases,are derived from 340 patients,1,0.5183775424957275
XALKORI,elevated transaminases, are derived from 340  patients with ALKpositive metastatic NSCLC,1,0.4684150218963623
XALKORI,elevated transaminases,data in are derived from,1,0.4992216229438782
XALKORI,Transaminase elevations,not received previous systemic treatment for advanced,0,0.5605509281158447
XALKORI,Transaminase elevations,with ALK-positiv e metastatic,1,0.5168685913085938
XALKORI,Transaminase elevations,tients with ALK-positiv e,1,0.5815556049346924
XALKORI,Transaminase elevations,are derived from tients with ALK-positiv e metastatic NSCLC who,1,0.4927777051925659
XALKORI,Transaminase elevations,Table are derived from tients with,1,0.5694811940193176
XALKORI,Transaminase elevations,Table are derived from tients with ALK-positiv e metastatic NSCLC,1,0.5462362766265869
XALKORI,fatal,UC) o f or,1,0.5446344614028931
XALKORI,fatal,UC) o f or mgminmL,1,0.4821711480617523
XALKORI,fatal,A,0,0.531038224697113
XALKORI,fatal,for up to,0,0.4938453137874603
XALKORI,fatal,the concentrationtime curve UC) o,1,0.5354744791984558
XALKORI,fatal,was given by intravenous infusion every weeks for up,0,0.4810835123062134
XALKORI,fatal,every,0,0.5584244132041931
XALKORI,fatal,under the concentrationtime curve UC) o f,1,0.5320830941200256
XALKORI,interstitial lung disease,concentrationtime curve AUC  5 or 6 mg?min/mL (n=78). Chemotherapy,1,0.5108665227890015
XALKORI,interstitial lung disease,was given by intravenous infusion every weeks for up,0,0.5243161916732788
XALKORI,interstitial lung disease,cycles in the absence of,0,0.5172204971313477
XALKORI,interstitial lung disease,6 mg?min/mL (n=78). Chemotherapy was given by,1,0.478371262550354
XALKORI,interstitial lung disease,was given by intravenous infusion every weeks,0,0.5262832641601562
XALKORI,interstitial lung disease,concentrationtime curve AUC  5 or 6 mg?min/mL (n=78). Chemotherapy was given,1,0.514894425868988
XALKORI,interstitial lung disease,curve AUC  5 or 6 mg?min/mL (n=78). Chemotherapy was given by intravenous,1,0.5034339427947998
XALKORI,interstitial lung disease,5 or 6 mg?min/mL (n=78). Chemotherapy was,1,0.485129714012146
XALKORI,interstitial lung disease,in the absence of,0,0.49432453513145447
XALKORI,interstitial lung disease,or 6 mg?min/mL (n=78). Chemotherapy was given by intravenous,1,0.48377299308776855
XALKORI,ILD,the absence of,0,0.48813456296920776
XALKORI,ILD,hem,1,0.514224648475647
XALKORI,ILD,hem otherapy was given by intravenous,1,0.5139023661613464
XALKORI,ILD,of or mgminmL n hem otherapy was given by,1,0.5647519826889038
XALKORI,ILD,curve AUC of or,0,0.5557887554168701
XALKORI,ILD,or mgminmL n hem otherapy was given by,1,0.5469893217086792
XALKORI,ILD,hem otherapy was,1,0.4911259412765503
XALKORI,ILD,hem otherapy was given by,1,0.5120434761047363
XALKORI,ILD,calculated to produce,0,0.5012138485908508
XALKORI,ILD,intravenous infusion every weeks for up to cycles in the absence,0,0.5323230028152466
XALKORI,ILD,cycles in the absence of dose,0,0.5237716436386108
XALKORI,ILD,or mgminmL n C,0,0.5345679521560669
XALKORI,ILD,of or mgminmL n hem otherapy was given by intravenous,1,0.5574266910552979
XALKORI,pneumonitis,of or mgminmL n,0,0.4788963198661804
XALKORI,pneumonitis,of,0,0.49069780111312866
XALKORI,pneumonitis,an area under the concentrationtime curve AUC of or mgminmL n Chemot,0,0.5580194592475891
XALKORI,pneumonitis,herapy was given by intravenous infusion,1,0.477828711271286
XALKORI,pneumonitis,mgminmL n herapy was  given by intravenous infusion,1,0.4861263036727905
XALKORI,pneumonitis,herapy,1,0.5080412030220032
XALKORI,pneumonitis,Chemot,0,0.5005742311477661
XALKORI,pneumonitis,herapy was given by intravenous,1,0.4872262477874756
XALKORI,pneumonitis,mgminmL n herapy,1,0.5037147402763367
XALKORI,pneumonitis,herapy was,1,0.4738979935646057
XALKORI,pneumonitis,or,0,0.47322529554367065
XALKORI,pneumonitis,n herapy was,1,0.4994933605194092
XALKORI,ILD,tox icities After cycles,1,0.5263891816139221
XALKORI,ILD,infusion every weeks for up to cycles in the absence of,0,0.5186263918876648
XALKORI,ILD,remained on study with,0,0.5047757625579834
XALKORI,ILD,patients remained on  wi th no additional anticancer,1,0.4366934895515442
XALKORI,ILD,on  wi,1,0.5957742929458618
XALKORI,ILD, wi th no,1,0.5477827191352844
XALKORI,ILD,absence,0,0.5480455160140991
XALKORI,ILD, wi,1,0.5758455991744995
XALKORI,ILD,doselimiting chemotherapyrelated toxicities After cycles patients remained,0,0.4743904769420624
XALKORI,ILD, wi th,1,0.558614194393158
XALKORI,ILD,treatment and tumor assessments continued until documented disease,0,0.515078067779541
XALKORI,ILD,treatment and tumor assessments continued until documented disease prog,0,0.5183870792388916
XALKORI,fatal,treat ment and tumor assessments continued,1,0.48931995034217834
XALKORI,fatal,no additional treat ment and tumor assessments continued,1,0.5028066635131836
XALKORI,fatal,treat ment and,1,0.5381038784980774
XALKORI,fatal,cycles patients remained on study,0,0.47630494832992554
XALKORI,ILD,ent and tumor assessments,1,0.47004300355911255
XALKORI,ILD,additional anticancer,0,0.4712211489677429
XALKORI,QTc prolongation,of patients were,1,0.5152630805969238
XALKORI,QTc prolongation,additional anticancer,0,0.550555944442749
XALKORI,QTc prolongation,than years A total of of patients were female and were Asian Serious adverse,0,0.49869656562805176
XALKORI,QTc prolongation,in,0,0.5253275036811829
XALKORI,QTc prolongation,were,0,0.45909953117370605
XALKORI,QTc prolongation,of,0,0.49341249465942383
XALKORI,Symptomatic bradycardia,for,0,0.5014814138412476
XALKORI,Symptomatic bradycardia,XALKORIN Chemotherapy PemetrexedCis,0,0.4591987729072571
XALKORI,Symptomatic bradycardia,than Chemotherapy in Study Adverse,1,0.5123991966247559
XALKORI,Symptomatic bradycardia,for Grades with KORI than Chemotherapy  in Study Adverse,1,0.5196935534477234
XALKORI,Symptomatic bradycardia,KORI than Chemotherapy in Study Adverse Reaction XALKORIN,1,0.5315024256706238
XALKORI,bradycardia,Adverse Reaction,0,0.5634706020355225
XALKORI,bradycardia,XALKORI,0,0.41293108463287354
XALKORI,bradycardia,or PemetrexedCarboplatinN All Grades,0,0.47780823707580566
XALKORI,bradycardia,71) Chemo therapy PemetrexedCisplatin or,1,0.4197755455970764
XALKORI,bradycardia,Reaction 71),1,0.4441118836402893
XALKORI,bradycardia,therapy PemetrexedCisplatin or PemetrexedCarboplatinN All,0,0.462870717048645
XALKORI,bradycardia,Study Adverse Reaction 71)   Chemo therapy PemetrexedCisplatin or PemetrexedCarboplatinN,1,0.4642984867095947
XALKORI,bradycardia,71) Chemo,1,0.41633889079093933
XALKORI,heart rate less than 50 beats per minute,PemetrexedCisplatin,0,0.4888545274734497
XALKORI,heart rate less than 50 beats per minute,PemetrexedCisplatin or PemetrexedCarboplatinN All Grade 3/4(%) All,1,0.5147683620452881
XALKORI,heart rate less than 50 beats per minute,PemetrexedCarboplatinN All Grade 3/4(%) All Grades(%),1,0.5123140811920166
XALKORI,syncope,All Grades Grade des,1,0.4720234274864197
XALKORI,syncope,des cas es,1,0.5339798927307129
XALKORI,syncope,Grade Inclu,0,0.4663202166557312
XALKORI,syncope,des cas es reported within the clustered,1,0.5022367238998413
XALKORI,syncope,reported within the clustered,0,0.48333901166915894
XALKORI,syncope,des cas es reported within,1,0.523311197757721
XALKORI,syncope,des cas es reported within the,1,0.5267311334609985
XALKORI,syncope,Grades Grade,0,0.48287686705589294
XALKORI,syncope,des cas es reported,1,0.543172299861908
XALKORI,embryotoxicity,increased,0,0.5289548635482788
XALKORI,embryotoxicity,"          
   ",1,0.5931857228279114
XALKORI,embryotoxicity,and Connective Tissue,0,0.5379554033279419
XALKORI,embryotoxicity,"Weight           
   ",1,0.4632382392883301
CLEVIPREX,Hypotension,Hypotension and Reflex Tachycardia see,1,0.8192000389099121
CLEVIPREX,Hypotension,in the,0,0.5439687371253967
CLEVIPREX,Hypotension,Tachycardia see Warnings and Precautions EXCERPT Most common adve,0,0.5931665897369385
CLEVIPREX,Hypotension,discussed elsewhere in the labeling,0,0.45228680968284607
CLEVIPREX,Hypotension,Warnings and Precautions EXCERPT Most common adve,0,0.5461857914924622
CLEVIPREX,Hypotension,the labeling,0,0.45745906233787537
CLEVIPREX,Reflex Tachycardia,Reflex Tachycardia see,1,0.9773381948471069
CLEVIPREX,Reflex Tachycardia,the labeling,0,0.4640376567840576
CLEVIPREX,Reflex Tachycardia,Hypotension Reflex Tachycardia,1,0.9164581298828125
CLEVIPREX,Reflex Tachycardia,Hypotension Reflex,1,0.7595654726028442
CLEVIPREX,headache,reactions headache nausea and vomiting To report,1,0.7349873781204224
CLEVIPREX,headache,Hypotension Reflex,1,0.531502366065979
CLEVIPREX,headache,see Warnings and Precautions EXCERPT Most common adverse reactions are,0,0.549160361289978
CLEVIPREX,headache,reactions headache nausea and vomiting To,1,0.7432624101638794
CLEVIPREX,headache,EXCERPT,0,0.47266167402267456
CLEVIPREX,headache,SUSPECTED ADVERSE REACTIONS,0,0.5619930028915405
CLEVIPREX,headache,headache nausea and vomiting To report,1,0.7661982774734497
CLEVIPREX,headache,Warnings and Precautions EXCERPT Most common,0,0.5569133758544922
CLEVIPREX,headache,nausea and vomiting To report,0,0.5849354863166809
CLEVIPREX,nausea,SUSPECTED ADVERSE REACTIONS contact The Medicines,0,0.5883116722106934
CLEVIPREX,nausea,nausea and,1,0.9323806762695312
CLEVIPREX,nausea,nausea and vomiting To report SUSPECTED,1,0.8078956604003906
CLEVIPREX,nausea,and vomiting To,0,0.8019907474517822
CLEVIPREX,nausea,reactions are nausea and vomiting To report,1,0.8013916015625
CLEVIPREX,vomiting,are headache nausea vomiting To report,1,0.8076666593551636
CLEVIPREX,vomiting,and vomiting To,0,0.9507140517234802
CLEVIPREX,vomiting,vomiting,1,0.9999999403953552
CLEVIPREX,vomiting,headache nausea vomiting To,1,0.8682835698127747
CLEVIPREX,vomiting,vomiting To report SUSPECTED ADVERSE REACTIONS,1,0.8437035083770752
CLEVIPREX,vomiting,are headache nausea and,0,0.6957142353057861
CLEVIPREX,vomiting,nausea,0,0.8409453630447388
CLEVIPREX,vomiting,headache nausea and,0,0.7408207654953003
CLEVIPREX,vomiting,vomiting To report SUSPECTED,1,0.8428542017936707
CLEVIPREX,headache,vomiting The incidence of adverse events,0,0.5431855916976929
CLEVIPREX,headache,incidence,0,0.5699205994606018
CLEVIPREX,headache,headache nausea and,1,0.8320519328117371
CLEVIPREX,headache,Cleviprex in severe hypertension headache nausea and vomiting The incidence,1,0.6552152037620544
CLEVIPREX,headache,headache nausea and vomiting The,1,0.7779074907302856
CLEVIPREX,headache,Cleviprex in severe hypertension headache nausea and,1,0.6842499375343323
CLEVIPREX,headache,incidence of adverse events,0,0.5219832062721252
CLEVIPREX,headache,in severe hypertension headache nausea and vomiting The incidence,1,0.6894581317901611
CLEVIPREX,headache,headache nausea and vomiting The incidence,1,0.7482108473777771
CLEVIPREX,nausea,included nausea and vomiting The incidence,1,0.8304623961448669
CLEVIPREX,nausea,headache nausea and vomiting The incidence,1,0.7999242544174194
CLEVIPREX,nausea,severe hypertension included nausea and,1,0.7496074438095093
CLEVIPREX,nausea,Cleviprex,0,0.4927259087562561
CLEVIPREX,nausea,vomiting The incidence of adverse events,0,0.7312394380569458
CLEVIPREX,nausea,severe hypertension included,0,0.5331826210021973
CLEVIPREX,nausea,severe hypertension included nausea and vomiting The,1,0.7488607168197632
CLEVIPREX,vomiting,incidence of adverse events,0,0.5395300388336182
CLEVIPREX,vomiting,in severe,0,0.6487270593643188
CLEVIPREX,vomiting,vomiting The incidence,1,0.8874285817146301
CLEVIPREX,vomiting,Cleviprex in,0,0.46919506788253784
CLEVIPREX,myocardial infarction,severe or essential hypertension myocardial infarction,1,0.7887565493583679
CLEVIPREX,myocardial infarction,Cleviprex in,0,0.4895450472831726
CLEVIPREX,myocardial infarction,or essential hypertension myocardial infarction,1,0.8181493282318115
CLEVIPREX,myocardial infarction,cardiac,0,0.7265621423721313
CLEVIPREX,myocardial infarction,syncopeRespiratory dyspnea PostMarketing and Other,0,0.5591429471969604
CLEVIPREX,myocardial infarction,cardiac arrestNervous,0,0.6394908428192139
CLEVIPREX,myocardial infarction,hypertension myocardial infarction,1,0.8504906892776489
CLEVIPREX,myocardial infarction,severe or essential hypertension myocardial infarction cardiac,1,0.7868829965591431
CLEVIPREX,myocardial infarction,or essential hypertension myocardial infarction cardiac arrestNervous system syncopeRespiratory,1,0.7514079213142395
CLEVIPREX,cardiac arrest,Nervous system syncopeRespiratory dyspnea PostMarketing and Other Clinical,0,0.6139137744903564
CLEVIPREX,cardiac arrest,myocardial cardiac arrest,1,0.9406133890151978
CLEVIPREX,cardiac arrest,dyspnea,0,0.5930426120758057
CLEVIPREX,cardiac arrest,hypertension includedCardiac myocardial cardiac arrest Nervous system syncopeRespiratory dyspnea PostMarketing,1,0.7449792623519897
CLEVIPREX,cardiac arrest,Nervous system syncopeRespiratory dyspnea PostMarketing and,0,0.6129631996154785
CLEVIPREX,syncope,essential hypertension includedCardiac myocardial infarction cardiac arrestNervous system,0,0.6430388689041138
CLEVIPREX,syncope,syncope Respiratory dyspnea PostMarketing and Other,1,0.7899381518363953
CLEVIPREX,syncope,cardiac arrestNervous,0,0.7235494256019592
CLEVIPREX,syncope,syncope Respiratory,1,0.8569322824478149
CLEVIPREX,syncope,syncope Respiratory dyspnea,1,0.8337349891662598
CLEVIPREX,syncope,re or essential hypertension includedCardiac myocardial infarction cardiac,0,0.577662467956543
CLEVIPREX,syncope,myocardial infarction cardiac arrestNervous,0,0.6941165924072266
CLEVIPREX,syncope,syncope,1,0.9999998807907104
CLEVIPREX,dyspnea,dyspnea PostMarketing and Other,1,0.8282922506332397
CLEVIPREX,dyspnea,syncope Respiratory,1,0.6554214358329773
CLEVIPREX,increased blood triglycerides,postapproval use of increased blood triglycerides ileus hypersensitivity hypotension nausea,1,0.8001847863197327
CLEVIPREX,increased blood triglycerides,dyspnea PostMarketing and Other,1,0.5513564944267273
CLEVIPREX,increased blood triglycerides,ileus hypersensitivity hypotension nausea,0,0.5246146321296692
CLEVIPREX,increased blood triglycerides,blood triglycerides ileus hypersensitivity hypotension,1,0.7707285284996033
CLEVIPREX,increased blood triglycerides,possible pulmonary,0,0.5396556854248047
CLEVIPREX,increased blood triglycerides,postapproval use of increased blood triglycerides,1,0.880262017250061
CLEVIPREX,increased blood triglycerides,increased blood triglycerides ileus hypersensitivity,1,0.8486350774765015
CLEVIPREX,ileus,hypersensitivity hypotension nausea decreased oxygen saturation possible pulmonary,0,0.5131354928016663
CLEVIPREX,ileus,ileus hypersensitivity hypotension nausea decreased,1,0.7062181830406189
CLEVIPREX,hypersensitivity,oxygen saturation possible pulmonary shunting and,0,0.5131903886795044
CLEVIPREX,hypersensitivity,increased blood,0,0.6185665130615234
CLEVIPREX,hypersensitivity,hypersensitivity hypotension nausea,1,0.7797334790229797
CLEVIPREX,hypotension,hypotension nausea decreased oxygen,1,0.8251205682754517
CLEVIPREX,hypotension,hypotension nausea decreased oxygen saturation possible,1,0.8241129517555237
CLEVIPREX,hypotension,triglycerides ileus hypotension,1,0.767315149307251
CLEVIPREX,nausea,nausea decreased oxygen saturation possible,1,0.7895089387893677
CLEVIPREX,nausea,nausea decreased oxygen saturation,1,0.7966964840888977
CLEVIPREX,nausea,nausea decreased,1,0.8272810578346252
CLEVIPREX,nausea,saturation possible,0,0.5402824878692627
CLEVIPREX,nausea,nausea,1,1.0
CLEVIPREX,nausea,hypersensitivity nausea decreased oxygen saturation possible pulmonary,1,0.722905695438385
CLEVIPREX,nausea,of Cleviprex increased blood triglycerides ileus,0,0.549943208694458
CLEVIPREX,nausea,possible pulmonary,0,0.5594232082366943
CLEVIPREX,nausea,oxygen,0,0.5484417676925659
CLEVIPREX,pulmonary shunting,nausea decreased oxygen saturation pulmonary,1,0.6761218309402466
CLEVIPREX,pulmonary shunting,pulmonary shunting,1,1.0
CLEVIPREX,pulmonary shunting,and reflex,0,0.48328685760498047
CLEVIPREX,pulmonary shunting,pulmonary shunting and reflex,1,0.8808393478393555
CLEVIPREX,Hypotension,Warnings and ecautions (,1,0.5307700634002686
CLEVIPREX,Hypotension,headache nausea and vomiting,0,0.5847885608673096
CLEVIPREX,reflex tachycardia,"    
      EXCERPT Most common adverse",1,0.5342402458190918
CLEVIPREX,reflex tachycardia,"    
      EXCERPT",1,0.49224942922592163
CLEVIPREX,reflex tachycardia,"    
      EXCERPT Most common",1,0.4775209426879883
CLEVIPREX,reflex tachycardia,"    
      EXCERPT Most",1,0.4739733636379242
CLEVIPREX,reflex tachycardia,Most common adverse reactions are,0,0.5574451684951782
CLEVIPREX,negative inotropic effects,report SUSPECTED ADVERSE REACTIONS ct The Medicines Company a t MDCO or FDA,1,0.554295003414154
CLEVIPREX,negative inotropic effects,Most common adverse reactions are,0,0.621307909488678
CLEVIPREX,negative inotropic effects,Company a t MDCO or FDA,1,0.5204961895942688
CLEVIPREX,negative inotropic effects,SUSPECTED ADVERSE REACTIONS ct The Medicines Company a t,1,0.5679658651351929
CLEVIPREX,negative inotropic effects,ct The Medicines Company a t MDCO or FDA,1,0.5046980381011963
CLEVIPREX,negative inotropic effects,ADVERSE REACTIONS ct The Medicines Company a t MDCO or FDA,1,0.5768932104110718
CLEVIPREX,negative inotropic effects,ADVERSE REACTIONS ct The Medicines,1,0.5982952117919922
CLEVIPREX,negative inotropic effects,ct The Medicines Company a t MDCO or,1,0.4995407164096832
CLEVIPREX,exacerbate heart failure,88-977-MDCO (6326) or FD A at FDA or,1,0.5289263725280762
CLEVIPREX,exacerbate heart failure,ADVERSE REACTIONS ct The Medicines,1,0.5530626177787781
CLEVIPREX,exacerbate heart failure,88-977-MDCO (6326) or FD,1,0.49729377031326294
CLEVIPREX,exacerbate heart failure,at FDA or wwwfdagovmedwatch,0,0.5472452044487
CLEVIPREX,exacerbate heart failure,contact The Medicines Company 88-977-MDCO (6326) or FD,1,0.5459380149841309
CLEVIPREX,exacerbate heart failure,or FD A at FDA or,1,0.5467305183410645
CLEVIPREX,exacerbate heart failure,wwwfdagovmedwatch Clinical Trials,0,0.5414000749588013
CLEVIPREX,exacerbate heart failure,Company 88-977-MDCO (6326) or FD A at FDA or wwwfdagovmedwatch,1,0.525546133518219
CLEVIPREX,exacerbate heart failure,contact The Medicines Company 88-977-MDCO (6326),1,0.5195376873016357
CLEVIPREX,reflex tachycardia,in an additional patients r durations betwee n and hours Because,1,0.5448054075241089
CLEVIPREX,reflex tachycardia,contact The Medicines Company 88-977-MDCO (6326),1,0.4817628264427185
CLEVIPREX,reflex tachycardia,additional patients r,1,0.5643594264984131
CLEVIPREX,reflex tachycardia,trials are conducted,0,0.5331310629844666
CLEVIPREX,reflex tachycardia,in an additional patients r durations betwee,1,0.5815099477767944
CLEVIPREX,reflex tachycardia,jority of patients n it was infused as a continuous infusion in,0,0.5348950624465942
CLEVIPREX,reflex tachycardia,conducted under widely varying conditions advers,0,0.5260233879089355
CLEVIPREX,reflex tachycardia,patients r durations betwee n and hours,1,0.5231367349624634
CLEVIPREX,reflex tachycardia,fo,0,0.48696619272232056
CLEVIPREX,negative inotropic effects,reactions Table Common adverse ctions in,1,0.6550785303115845
CLEVIPREX,negative inotropic effects,ctions in placebo-controll ed perioperative studies ESCAPE ESCAPE,1,0.5980730056762695
CLEVIPREX,negative inotropic effects,ctions in placebo-controll ed,1,0.5937260985374451
CLEVIPREX,negative inotropic effects,perioperative studies ESCAPE,0,0.5476253032684326
CLEVIPREX,negative inotropic effects,Common adverse ctions,1,0.6345254182815552
CLEVIPREX,negative inotropic effects,reactions Table Common adverse ctions in placebo-controll,1,0.6663846969604492
CLEVIPREX,negative inotropic effects,by at,0,0.47296178340911865
CLEVIPREX,negative inotropic effects,in placebo-controll ed perioperative studies ESCAPE,1,0.6056371331214905
CLEVIPREX,negative inotropic effects,ctions,1,0.48507994413375854
CLEVIPREX,exacerbate heart failure,in placebocontrolled rioperative,1,0.5235186815261841
CLEVIPREX,exacerbate heart failure,placebocontrolled,0,0.5200031995773315
CLEVIPREX,exacerbate heart failure,"reactions in placebocontrolled rioperative studies. 
   ESCAPE ESCAPE",1,0.5432226657867432
CLEVIPREX,exacerbate heart failure,rioperative studies.,1,0.5024638175964355
LUMIZYME,hypersensitivity reactions,trials hypersensitivity reactions and,1,0.8771133422851562
LUMIZYME,hypersensitivity reactions,rioperative studies.,1,0.5313515663146973
LUMIZYME,hypersensitivity reactions,EXCERPT The,0,0.49708765745162964
LUMIZYME,anaphylaxis,anaphylaxis rash,1,0.9015436172485352
LUMIZYME,anaphylaxis,hypersensitivity reactions and anaphylaxis rash pyrexia,1,0.7762044668197632
LUMIZYME,anaphylaxis,and anaphylaxis rash,1,0.8957959413528442
LUMIZYME,anaphylaxis,trials were,0,0.4865172207355499
LUMIZYME,anaphylaxis,urticaria headache hyperhidrosis,0,0.6434905529022217
LUMIZYME,rash,hyperhidrosis nausea cough,0,0.6380288600921631
LUMIZYME,rash,hypersensitivity reactions and,0,0.6320549249649048
LUMIZYME,rash,hyperhidrosis nausea cough decreased oxygen,0,0.5967707633972168
LUMIZYME,rash,reactions in clinical,0,0.5813705921173096
LUMIZYME,pyrexia,included anaphylaxis pyrexia flushingfeeling hot,1,0.749600350856781
LUMIZYME,pyrexia,reactions in clinical,0,0.5833333730697632
LUMIZYME,pyrexia,reactions,0,0.5825496912002563
LUMIZYME,pyrexia,nausea cough decreased oxygen saturati,0,0.6266709566116333
LUMIZYME,pyrexia,headache hyperhidrosis nausea cough decreased,0,0.6758700609207153
LUMIZYME,pyrexia,pyrexia flushingfeeling hot,1,0.90397709608078
LUMIZYME,pyrexia,reactions and included anaphylaxis pyrexia flushingfeeling,1,0.6958839297294617
LUMIZYME,pyrexia,cough decreased oxygen saturati,0,0.5945084691047668
LUMIZYME,pyrexia,included anaphylaxis,0,0.5556290149688721
LUMIZYME,pyrexia,pyrexia,1,1.0000001192092896
LUMIZYME,flushing,in clinical trials were hypersensitivity reactions,0,0.5173306465148926
LUMIZYME,flushing,flushing,1,1.0
LUMIZYME,flushing,pyrexia,0,0.5167732238769531
LUMIZYME,flushing,hypersensitivity reactions and included,0,0.5460359454154968
LUMIZYME,flushing,flushing feeling,1,0.830020546913147
LUMIZYME,flushing,flushing feeling hot urticaria headache hyperhidrosis,1,0.7032052874565125
LUMIZYME,feeling hot,nausea cough decreased,0,0.5190651416778564
LUMIZYME,feeling hot,headache hyperhidrosis nausea cough decreased oxygen saturation tachycardia tachy,0,0.6551358699798584
LUMIZYME,feeling hot,headache hyperhidrosis nausea cough decreased oxygen,0,0.6588459014892578
LUMIZYME,feeling hot,feeling hot urticaria headache hyperhidrosis,1,0.8329495191574097
LUMIZYME,feeling hot,rash,0,0.6129896640777588
LUMIZYME,feeling hot,reactions,0,0.603675127029419
LUMIZYME,feeling hot,pyrexia feeling hot,1,0.8691924810409546
LUMIZYME,urticaria,urticaria headache hyperhidrosis nausea cough decreased,1,0.7378464341163635
LUMIZYME,headache,hot headache hyperhidrosis nausea,1,0.7356878519058228
LUMIZYME,headache,urticaria headache hyperhidrosis nausea cough decreased,1,0.6652450561523438
LUMIZYME,headache,headache hyperhidrosis,1,0.7530339956283569
LUMIZYME,headache,headache,1,0.9999998807907104
LUMIZYME,headache,headache hyperhidrosis nausea cough,1,0.7313830852508545
LUMIZYME,hyperhidrosis,urticaria hyperhidrosis nausea cough decreased oxygen saturation,1,0.7557872533798218
LUMIZYME,hyperhidrosis,headache hyperhidrosis nausea cough,1,0.8331926465034485
LUMIZYME,hyperhidrosis,hyperhidrosis nausea cough decreased oxygen,1,0.7961856722831726
LUMIZYME,nausea,nausea cough,1,0.870718240737915
LUMIZYME,nausea,discomfort dizziness muscle,0,0.7092114686965942
LUMIZYME,cough,hyperhidrosis cough decreased oxygen,1,0.7130637168884277
LUMIZYME,cough,discomfort dizziness muscle,0,0.5724313855171204
LUMIZYME,cough,cough decreased oxygen saturation tachycardia,1,0.7458177804946899
LUMIZYME,cough,cough decreased,1,0.8415301442146301
LUMIZYME,cough,anaphylaxis rash pyrexia,0,0.5607969760894775
LUMIZYME,cough,oxygen saturation tachycardia tachypnea,0,0.5305997729301453
LUMIZYME,cough,cough decreased oxygen saturation tachycardia tachypnea,1,0.7664087414741516
LUMIZYME,cough,headache hyperhidrosis cough decreased oxygen saturation tachycardia tachypnea,1,0.6588401794433594
LUMIZYME,decreased oxygen saturation,urticaria headache hyperhidrosis nausea decreased,1,0.5524308681488037
LUMIZYME,decreased oxygen saturation,chest discomfort dizziness,0,0.5983067750930786
LUMIZYME,decreased oxygen saturation,decreased oxygen,1,0.9428279399871826
LUMIZYME,decreased oxygen saturation,tachycardia tachypnea chest discomfort dizziness muscle twitching agitation cyanosis erythe,0,0.6154780983924866
LUMIZYME,decreased oxygen saturation,hot urticaria headache,0,0.43582046031951904
LUMIZYME,decreased oxygen saturation,urticaria headache hyperhidrosis nausea decreased oxygen saturation,1,0.7329174280166626
LUMIZYME,decreased oxygen saturation,rash pyrexia flushingfeeling hot urticaria headache hyperhidrosis nausea cough,0,0.48736268281936646
LUMIZYME,decreased oxygen saturation,pyrexia flushingfeeling hot urticaria headache hyperhidrosis,0,0.5108751058578491
LUMIZYME,decreased oxygen saturation,discomfort dizziness muscle twitching agitation cyanosis erythe,0,0.5891309380531311
LUMIZYME,decreased oxygen saturation,headache hyperhidrosis nausea decreased oxygen saturation tachycardia tachypnea chest discomfort,1,0.709511399269104
LUMIZYME,tachycardia,tachycardia tachypnea,1,0.8234368562698364
LUMIZYME,tachycardia,muscle,0,0.5418107509613037
LUMIZYME,tachycardia,dizziness,0,0.5959216952323914
LUMIZYME,tachycardia,twitching,0,0.6047495603561401
LUMIZYME,tachycardia,tachycardia,1,0.9999999403953552
LUMIZYME,chest discomfort,cough decreased oxygen saturation tachycardia,0,0.6012699604034424
LUMIZYME,chest discomfort,decreased oxygen saturation tachycardia chest discomfort dizziness muscle twitching agitation cyanosis,1,0.6892220973968506
LUMIZYME,chest discomfort,saturation tachycardia tachypnea,0,0.616304337978363
LUMIZYME,chest discomfort,chest discomfort dizziness muscle twitching agitation,1,0.812443733215332
LUMIZYME,chest discomfort,agitation,0,0.5416207313537598
LUMIZYME,dizziness,chest dizziness muscle twitching agitation,1,0.7566478252410889
LUMIZYME,dizziness,agitation,0,0.5653581619262695
LUMIZYME,dizziness,dizziness muscle twitching,1,0.8320639133453369
LUMIZYME,dizziness,saturation tachycardia tachypnea chest dizziness muscle twitching agitation cyanosis,1,0.6920592784881592
LUMIZYME,dizziness,dizziness muscle,1,0.8772339820861816
LUMIZYME,dizziness,cyanosis,0,0.5698654651641846
LUMIZYME,dizziness,dizziness muscle twitching agitation cyanosis,1,0.7756008505821228
LUMIZYME,dizziness,oxygen saturation tachycardia tachypnea chest,0,0.5421494245529175
LUMIZYME,muscle twitching,dizziness,0,0.5561292767524719
LUMIZYME,muscle twitching,muscle twitching agitation cyanosis erythema,1,0.799994945526123
LUMIZYME,muscle twitching,tachypnea chest discomfort muscle twitching agitation cyanosis,1,0.7375756502151489
LUMIZYME,muscle twitching,tachypnea chest discomfort muscle twitching agitation cyanosis erythema hypertensionincreased blood,1,0.727735161781311
LUMIZYME,muscle twitching,tachypnea chest,0,0.5300291776657104
LUMIZYME,muscle twitching,chest discomfort,0,0.5969411134719849
LUMIZYME,muscle twitching,cough decreased oxygen saturation tachycardia tachypnea chest discomfort,0,0.5801775455474854
LUMIZYME,agitation,agitation cyanosis erythema hypertensionincreased blood,1,0.7954049706459045
LUMIZYME,agitation,agitation cyanosis erythema hypertensionincreased blood pressure,1,0.7872022986412048
LUMIZYME,agitation,agitation,1,1.0
LUMIZYME,cyanosis,cyanosis erythema hypertensionincreased blood pressure pallor,1,0.720139741897583
LUMIZYME,cyanosis,cyanosis erythema hypertensionincreased blood pressure,1,0.7313974499702454
LUMIZYME,cyanosis,cyanosis erythema,1,0.8290790319442749
LUMIZYME,erythema,erythema hypertensionincreased,1,0.8338484168052673
LUMIZYME,erythema,muscle twitching agitation erythema hypertensionincreased blood pressure pallor,1,0.6966854333877563
LUMIZYME,erythema,agitation erythema hypertensionincreased blood pressure pallor,1,0.7370032668113708
LUMIZYME,erythema,cyanosis,0,0.5669474601745605
LUMIZYME,erythema,erythema,1,1.0
LUMIZYME,hypertension,pressure pallor,0,0.5822028517723083
LUMIZYME,hypertension,hypertension increased blood pressure pallor,1,0.7929447889328003
LUMIZYME,hypertension,pallor rigors tremor,0,0.5631494522094727
LUMIZYME,hypertension,hypertension increased blood pressure pallor rigors,1,0.797163188457489
LUMIZYME,hypertension,hypertension increased blood,1,0.8358705043792725
LUMIZYME,hypertension,twitching agitation cyanosis hypertension increased blood pressure pallor,1,0.7012394666671753
LUMIZYME,increased blood pressure,blood pressure pallor rigors tremor,1,0.6944181323051453
LUMIZYME,increased blood pressure,SUSPECTED ADVERSE,0,0.5811339020729065
LUMIZYME,increased blood pressure,chest discomfort dizziness muscle,0,0.5749431848526001
LUMIZYME,pallor,blood pallor rigors tremor,1,0.7172386646270752
LUMIZYME,pallor,chest discomfort dizziness muscle,0,0.5217297077178955
LUMIZYME,pallor,and myalgia,0,0.5027448534965515
LUMIZYME,pallor,blood pallor rigors tremor vomiting fatigue and,1,0.7019058465957642
LUMIZYME,pallor,pallor rigors tremor vomiting,1,0.7076671123504639
LUMIZYME,pallor,pallor,1,1.0
LUMIZYME,pallor,pallor rigors tremor vomiting fatigue,1,0.7434887886047363
LUMIZYME,pallor,pallor rigors tremor vomiting fatigue and,1,0.735286295413971
LUMIZYME,pallor,erythema hypertensionincreased blood,0,0.5476493835449219
LUMIZYME,tremor,tremor vomiting fatigue and myalgia To,1,0.7770547866821289
LUMIZYME,tremor,tremor vomiting fatigue and,1,0.7965631484985352
LUMIZYME,tremor,tremor vomiting fatigue,1,0.7923089265823364
LUMIZYME,tremor,hypertensionincreased blood pressure pallor tremor vomiting fatigue,1,0.7048239707946777
LUMIZYME,tremor,tremor,1,0.9999998807907104
LUMIZYME,tremor,myalgia To report,0,0.573018491268158
LUMIZYME,tremor,blood pressure pallor tremor vomiting,1,0.7150121927261353
LUMIZYME,vomiting,vomiting fatigue and myalgia To,1,0.7905418872833252
LUMIZYME,vomiting,vomiting fatigue and,1,0.8590199947357178
LUMIZYME,vomiting,ADVERSE,0,0.5872194766998291
LUMIZYME,vomiting,vomiting fatigue and myalgia,1,0.7826904058456421
LUMIZYME,vomiting,erythema hypertensionincreased blood pressure pallor rigors tremor,0,0.5453280806541443
LUMIZYME,vomiting,agitation cyanosis erythema hypertensionincreased blood pressure pallor rigors tremor,0,0.5981730818748474
LUMIZYME,fatigue,report,0,0.5485293865203857
LUMIZYME,myalgia,myalgia,1,0.9999996423721313
LUMIZYME,myalgia,Genzyme at or,0,0.4954521059989929
LUMIZYME,myalgia,vomiting,0,0.5050665736198425
LUMIZYME,myalgia,myalgia To report SUSPECTED,1,0.8401591777801514
LUMIZYME,myalgia,rigors,0,0.5767223834991455
LUMIZYME,myalgia,myalgia To report,1,0.881942629814148
LUMIZYME,anaphylaxis,hypersensitivity reactions and anaphylaxis rash pyrexia flushingfeeling hot urticaria,1,0.7813295125961304
LUMIZYME,anaphylaxis,rigors,0,0.5111550092697144
LUMIZYME,anaphylaxis,pyrexia flushingfeeling hot urticaria,0,0.6828091144561768
LUMIZYME,anaphylaxis,anaphylaxis rash pyrexia flushingfeeling hot urticaria,1,0.7932523488998413
LUMIZYME,anaphylaxis,anaphylaxis rash pyrexia,1,0.7999825477600098
LUMIZYME,anaphylaxis,alglucosidase alfa treatment,0,0.5496813058853149
LUMIZYME,anaphylaxis,headache hyperhidrosis,0,0.590819776058197
LUMIZYME,anaphylaxis,and,0,0.5316504240036011
LUMIZYME,rash,nausea cough decreased oxygen,0,0.5123768448829651
LUMIZYME,rash,rash,1,1.0000001192092896
LUMIZYME,rash,cough decreased oxygen,0,0.48026061058044434
LUMIZYME,rash,rash pyrexia flushingfeeling,1,0.7867496013641357
LUMIZYME,rash,reactions and included rash pyrexia,1,0.7693663835525513
LUMIZYME,pyrexia,pyrexia flushingfeeling,1,0.8677436709403992
LUMIZYME,pyrexia,included anaphylaxis pyrexia,1,0.7830029726028442
LUMIZYME,pyrexia,reactions and included anaphylaxis rash,0,0.5495847463607788
LUMIZYME,pyrexia,and included anaphylaxis rash,0,0.5426288843154907
LUMIZYME,flushing,flushing feeling hot,1,0.773169219493866
LUMIZYME,flushing,decreased,0,0.5735843777656555
LUMIZYME,flushing,rash flushing feeling hot urticaria headache hyperhidrosis,1,0.6395978927612305
LUMIZYME,flushing,included anaphylaxis rash flushing feeling hot urticaria headache hyperhidrosis,1,0.6147855520248413
LUMIZYME,feeling hot,headache hyperhidrosis nausea cough decreased oxygen saturation tachycardia,0,0.6570974588394165
LUMIZYME,feeling hot,feeling hot urticaria,1,0.8757153749465942
LUMIZYME,feeling hot,anaphylaxis rash pyrexia feeling hot,1,0.8407734632492065
LUMIZYME,feeling hot,included anaphylaxis rash pyrexia feeling hot,1,0.8316630721092224
LUMIZYME,urticaria,urticaria,1,1.0
LUMIZYME,urticaria,cough decreased oxygen saturation tachycardia tachypnea chest,0,0.5253286361694336
LUMIZYME,urticaria,urticaria headache hyperhidrosis,1,0.7628034353256226
LUMIZYME,urticaria,urticaria headache hyperhidrosis nausea,1,0.7758563160896301
LUMIZYME,urticaria,hot,0,0.5611462593078613
LUMIZYME,urticaria,urticaria headache,1,0.8525415658950806
LUMIZYME,headache,urticaria,0,0.5657576322555542
LUMIZYME,headache,nausea cough decreased oxygen saturation tachycardia tachypnea,0,0.5376402139663696
LUMIZYME,headache,included anaphylaxis,0,0.5687183737754822
LUMIZYME,headache,persensitivity reactions and included anaphylaxis,0,0.5334711074829102
LUMIZYME,headache,hyperhidrosis nausea cough decreased,0,0.5400569438934326
LUMIZYME,headache,headache hyperhidrosis nausea,1,0.7349135875701904
LUMIZYME,headache,hot headache,1,0.8444100022315979
LUMIZYME,headache,oxygen saturation tachycardia tachypnea chest,0,0.44961807131767273
LUMIZYME,hyperhidrosis,headache,0,0.5383189916610718
LUMIZYME,hyperhidrosis,hyperhidrosis nausea cough,1,0.8678736686706543
LUMIZYME,hyperhidrosis,hyperhidrosis nausea,1,0.8499875664710999
LUMIZYME,hyperhidrosis,included anaphylaxis,0,0.5796469449996948
LUMIZYME,hyperhidrosis,chest discomfort,0,0.5470800399780273
LUMIZYME,hyperhidrosis,flushingfeeling hot urticaria,0,0.7263765335083008
LUMIZYME,hyperhidrosis,hyperhidrosis nausea cough decreased,1,0.8141913414001465
LUMIZYME,hyperhidrosis,hyperhidrosis nausea cough decreased oxygen saturation,1,0.7880657911300659
LUMIZYME,hyperhidrosis,oxygen saturation tachycardia tachypnea chest discomfort,0,0.5437252521514893
LUMIZYME,nausea,nausea cough decreased oxygen saturation,1,0.7560436725616455
LUMIZYME,nausea,hyperhidrosis,0,0.5016090869903564
LUMIZYME,nausea,anaphylaxis rash pyrexia flushingfeeling,0,0.649443507194519
LUMIZYME,cough,anaphylaxis rash pyrexia flushingfeeling,0,0.5764008164405823
LUMIZYME,cough,headache,0,0.6147438883781433
LUMIZYME,cough,cough decreased oxygen,1,0.7989382743835449
LUMIZYME,cough,flushingfeeling hot urticaria headache hyperhidrosis nausea,0,0.5549728274345398
LUMIZYME,cough,dizziness muscle twitching,0,0.5204029679298401
LUMIZYME,cough,anaphylaxis rash,0,0.5258668065071106
LUMIZYME,cough,nausea,0,0.6918084621429443
LUMIZYME,cough,cough,1,1.0
LUMIZYME,decreased oxygen saturation,oxygen saturation tachycardia tachypnea chest discomfort dizziness,1,0.7635096907615662
LUMIZYME,decreased oxygen saturation,nausea decreased oxygen,1,0.8153939843177795
LUMIZYME,decreased oxygen saturation,urticaria headache hyperhidrosis nausea decreased oxygen saturation tachycardia tachypnea chest discomfort dizziness,1,0.6866419911384583
LUMIZYME,decreased oxygen saturation,decreased oxygen saturation tachycardia tachypnea chest discomfort,1,0.8333449959754944
LUMIZYME,decreased oxygen saturation,hyperhidrosis nausea decreased oxygen saturation,1,0.78556889295578
LUMIZYME,decreased oxygen saturation,headache hyperhidrosis nausea decreased oxygen saturation tachycardia tachypnea chest discomfort dizziness,1,0.7115491032600403
LUMIZYME,decreased oxygen saturation,oxygen saturation tachycardia tachypnea,1,0.7805477380752563
LUMIZYME,decreased oxygen saturation,nausea cough,0,0.49688583612442017
LUMIZYME,tachycardia,nausea cough decreased oxygen tachycardia tachypnea chest,1,0.7468136548995972
LUMIZYME,tachycardia,hyperhidrosis nausea cough,0,0.5535749197006226
LUMIZYME,tachycardia,dizziness muscle twitching agitation cyanosis,0,0.6040013432502747
LUMIZYME,tachycardia,cyanosis,0,0.5774628520011902
LUMIZYME,tachycardia,decreased oxygen tachycardia tachypnea chest,1,0.7916842699050903
LUMIZYME,tachycardia,tachycardia tachypnea chest discomfort dizziness muscle,1,0.8423846960067749
LUMIZYME,tachycardia,cyanosis erythema hypertens,0,0.5853812098503113
LUMIZYME,tachycardia,cough decreased oxygen tachycardia tachypnea chest discomfort dizziness,1,0.7506711483001709
LUMIZYME,tachypnea,tachypnea chest discomfort,1,0.878746509552002
LUMIZYME,tachypnea,tachypnea chest discomfort dizziness muscle,1,0.8074239492416382
LUMIZYME,tachypnea,oxygen saturation tachypnea chest discomfort dizziness muscle twitching,1,0.7910817265510559
LUMIZYME,tachypnea,saturation tachycardia,0,0.7206968665122986
LUMIZYME,tachypnea,twitching,0,0.5676479935646057
LUMIZYME,tachypnea,tachypnea chest discomfort dizziness,1,0.818790078163147
LUMIZYME,chest discomfort,saturation tachycardia chest discomfort dizziness muscle twitching agitation,1,0.710961103439331
LUMIZYME,chest discomfort,twitching,0,0.5418952703475952
LUMIZYME,chest discomfort,decreased oxygen saturation tachycardia chest,1,0.6859951019287109
LUMIZYME,dizziness,dizziness muscle twitching agitation cyanosis erythema,1,0.7451256513595581
LUMIZYME,dizziness,hypertensionincreased blood pressure,0,0.5868159532546997
LUMIZYME,dizziness,dizziness,1,0.9999998807907104
LUMIZYME,dizziness,saturation,0,0.6051467061042786
LUMIZYME,muscle twitching,muscle twitching agitation,1,0.9069665670394897
LUMIZYME,muscle twitching,tachypnea chest discomfort muscle twitching agitation cyanosis erythema hypertensionincreased,1,0.7314518690109253
LUMIZYME,muscle twitching,blood pressure pallor rigors tremor,0,0.6895383596420288
LUMIZYME,muscle twitching,muscle twitching,1,0.9999999403953552
LUMIZYME,muscle twitching,muscle twitching agitation cyanosis,1,0.7972241640090942
LUMIZYME,muscle twitching,saturation tachycardia tachypnea,0,0.5474314093589783
LUMIZYME,agitation,agitation cyanosis,1,0.834700345993042
LUMIZYME,agitation,muscle agitation cyanosis erythema hypertensionincreased,1,0.7666527628898621
LUMIZYME,agitation,agitation cyanosis erythema,1,0.7940744161605835
LUMIZYME,agitation,dizziness muscle agitation cyanosis erythema hypertensionincreased blood pressure,1,0.7169378995895386
LUMIZYME,cyanosis,cyanosis erythema hypertensionincreased,1,0.750832200050354
LUMIZYME,cyanosis,agitation,0,0.5893077254295349
LUMIZYME,cyanosis,pressure pallor rigors tremor,0,0.6011735796928406
LUMIZYME,cyanosis,rigors tremor vomiting fatigue,0,0.5195223689079285
LUMIZYME,erythema,erythema hypertensionincreased blood pressure,1,0.8094350695610046
LUMIZYME,erythema,erythema hypertensionincreased blood,1,0.8168001174926758
LUMIZYME,erythema,ration tachycardia tachypnea chest discomfort dizziness,0,0.5129064321517944
LUMIZYME,erythema,muscle twitching agitation cyanosis,0,0.5374391078948975
LUMIZYME,erythema,dizziness muscle twitching agitation erythema hypertensionincreased blood,1,0.667693018913269
LUMIZYME,erythema,twitching agitation erythema hypertensionincreased blood pressure,1,0.7012481689453125
LUMIZYME,erythema,tremor vomiting fatigue and,0,0.5008177757263184
LUMIZYME,erythema,hypertensionincreased blood pressure pallor rigors tremor vomiting fatigue and myalgia,0,0.5529047250747681
LUMIZYME,erythema,discomfort dizziness muscle twitching,0,0.5053807497024536
LUMIZYME,hypertension,hypertension,1,1.0
LUMIZYME,hypertension,tachypnea,0,0.549156665802002
LUMIZYME,hypertension,cyanosis hypertension increased blood pressure pallor,1,0.7421731948852539
LUMIZYME,hypertension,and myalgia Clinical,0,0.5535709857940674
LUMIZYME,hypertension,cyanosis erythema,0,0.49596911668777466
LUMIZYME,hypertension,cyanosis hypertension increased blood,1,0.7320998907089233
LUMIZYME,hypertension,pallor rigors tremor vomiting fatigue and myalgia,0,0.5730607509613037
LUMIZYME,increased blood pressure,cyanosis erythema increased blood pressure pallor,1,0.7371236085891724
LUMIZYME,increased blood pressure,pallor rigors tremor vomiting fatigue and myalgia,0,0.5203278660774231
LUMIZYME,increased blood pressure,blood pressure pallor rigors tremor vomiting fatigue,1,0.6739683151245117
LUMIZYME,increased blood pressure,twitching agitation cyanosis erythema,0,0.5279955863952637
LUMIZYME,tremor,pressure pallor tremor vomiting fatigue and myalgia,1,0.7062930464744568
LUMIZYME,tremor,twitching agitation cyanosis erythema,0,0.64268958568573
LUMIZYME,tremor,Clinical Trials in InfantileOnset and JuvenileOnset,0,0.5131680965423584
LUMIZYME,tremor,twitching agitation cyanosis erythema hypertensionincreased blood,0,0.6598374247550964
LUMIZYME,tremor,and myalgia,0,0.5889043807983398
LUMIZYME,tremor,InfantileOnset and JuvenileOnset,0,0.5120500326156616
LUMIZYME,tremor,hypertensionincreased blood pressure,0,0.5439329147338867
LUMIZYME,fatigue,fatigue and myalgia,1,0.8366037607192993
LUMIZYME,anaphylaxis,anaphylaxis and acute cardiorespiratory failure The,1,0.8421131372451782
LUMIZYME,anaphylaxis,most serious,0,0.527014970779419
LUMIZYME,anaphylaxis,acute cardiorespiratory failure The most common adverse reactions,0,0.658037543296814
LUMIZYME,anaphylaxis,alfa treatment included,0,0.5658462047576904
LUMIZYME,anaphylaxis,alfa treatment anaphylaxis and acute cardiorespiratory failure The,1,0.7984945178031921
LUMIZYME,anaphylaxis,anaphylaxis and acute cardiorespiratory,1,0.8651342391967773
LUMIZYME,anaphylaxis,included,0,0.5414680242538452
LUMIZYME,anaphylaxis,anaphylaxis and acute cardiorespiratory failure,1,0.8382766246795654
LUMIZYME,anaphylaxis,anaphylaxis,1,0.9999998211860657
LUMIZYME,acute cardiorespiratory failure,included anaphylaxis acute cardiorespiratory,1,0.745989203453064
LUMIZYME,acute cardiorespiratory failure,most common adverse,0,0.5278258323669434
LUMIZYME,acute cardiorespiratory failure,cardiorespiratory failure The most common,1,0.8521689772605896
LUMIZYME,acute cardiorespiratory failure,reactions reported,0,0.521661639213562
LUMIZYME,acute cardiorespiratory failure,treatment included anaphylaxis acute cardiorespiratory failure The most common adverse reactions,1,0.7439558506011963
LUMIZYME,acute cardiorespiratory failure,treatment included anaphylaxis acute cardiorespiratory failure The,1,0.7962159514427185
LUMIZYME,acute cardiorespiratory failure,anaphylaxis acute cardiorespiratory failure The most common adverse,1,0.7990949749946594
LUMIZYME,hypersensitivity reactions,in clinical trials hypersensitivity,1,0.8049535155296326
LUMIZYME,hypersensitivity reactions,intervention in clinical trials hypersensitivity,1,0.776695728302002
LUMIZYME,hypersensitivity reactions,trials hypersensitivity reactions,1,0.8769360184669495
LUMIZYME,hypersensitivity reactions,atory failure The most,0,0.4536959230899811
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions,1,1.0
LUMIZYME,hypersensitivity reactions,alfa and included rash,0,0.6442220211029053
LUMIZYME,rash,pyrexia urticaria flushing decreased oxygen saturation cough tachypnea tachycardia hyperten,0,0.6366211175918579
LUMIZYME,rash,rash pyrexia urticaria flushing,1,0.7669224739074707
LUMIZYME,rash,rash pyrexia urticaria flushing decreased oxygen,1,0.7300397157669067
LUMIZYME,rash,cough tachypnea,0,0.4878162741661072
LUMIZYME,pyrexia,pyrexia urticaria flushing decreased,1,0.7776871919631958
LUMIZYME,pyrexia,cough tachypnea tachycardia hypertensionincr,0,0.6130067110061646
LUMIZYME,pyrexia,occurring in of patients treated with alglucosidase alfa and included rash,0,0.5294457077980042
LUMIZYME,pyrexia,and included pyrexia urticaria flushing decreased oxygen,1,0.7376564741134644
LUMIZYME,urticaria,urticaria flushing decreased,1,0.8249093890190125
LUMIZYME,flushing,of patients treated with alglucosidase alfa and included rash,0,0.5189281702041626
LUMIZYME,flushing,alfa and,0,0.48173633217811584
LUMIZYME,flushing,cough tachypnea,0,0.5217110514640808
LUMIZYME,decreased oxygen saturation,tachycardia hypertensionincreased blood pressure pallor rigors vomiting,0,0.575273871421814
LUMIZYME,decreased oxygen saturation,urticaria decreased oxygen saturation,1,0.8059600591659546
LUMIZYME,decreased oxygen saturation,decreased oxygen saturation,1,1.0
LUMIZYME,decreased oxygen saturation,pyrexia urticaria decreased oxygen saturation cough tachypnea tachycardia hypertensionincreased blood,1,0.71136873960495
LUMIZYME,decreased oxygen saturation,pressure pallor rigors vomiting cy,0,0.601362943649292
LUMIZYME,cough,cough tachypnea tachycardia,1,0.7376892566680908
LUMIZYME,cough,saturation,0,0.5004166960716248
LUMIZYME,cough,cough tachypnea tachycardia hypertensionincreased blood pressure,1,0.7147711515426636
LUMIZYME,cough,urticaria flushing decreased oxygen cough tachypnea tachycardia,1,0.6267507076263428
LUMIZYME,cough,oxygen,0,0.5901010036468506
LUMIZYME,cough,hypertensionincreased blood pressure pallor,0,0.5336557030677795
LUMIZYME,tachypnea,tachycardia hypertensionincreased blood pressure pallor rigors vomiting cyanosis agitation,0,0.6456551551818848
LUMIZYME,tachypnea,tachypnea tachycardia hypertensionincreased blood pressure,1,0.786996603012085
LUMIZYME,tachypnea,tachypnea tachycardia hypertensionincreased blood,1,0.7848269939422607
LUMIZYME,tachypnea,flushing,0,0.5362947583198547
LUMIZYME,tachypnea,decreased oxygen saturation tachypnea tachycardia hypertensionincreased,1,0.7830312252044678
LUMIZYME,tachycardia,tachycardia hypertensionincreased,1,0.8477425575256348
LUMIZYME,tachycardia,tachycardia hypertensionincreased blood pressure pallor rigors,1,0.7903876304626465
LUMIZYME,hypertension,hypertension increased,1,0.8728972673416138
LUMIZYME,increased blood pressure,vomiting,0,0.4840455651283264
LUMIZYME,increased blood pressure,tachycardia increased blood pressure pallor rigors,1,0.7799160480499268
LUMIZYME,increased blood pressure,oxygen saturation cough,0,0.5240079164505005
LUMIZYME,increased blood pressure,increased blood pressure pallor rigors vomiting,1,0.8054772615432739
LUMIZYME,increased blood pressure,saturation cough tachypnea tachycardia,0,0.5348101854324341
LUMIZYME,increased blood pressure,cough tachypnea tachycardia hypertension,0,0.6948382258415222
LUMIZYME,increased blood pressure,cough tachypnea tachycardia increased blood,1,0.6958869695663452
LUMIZYME,increased blood pressure,rigors vomiting cyanosis agitation and tremor These reactions were more likely,0,0.5983916521072388
LUMIZYME,increased blood pressure,rigors vomiting cyanosis agitation and,0,0.578275203704834
LUMIZYME,pallor,tachypnea tachycardia hypertensionincreased blood pallor rigors vomiting cyanosis,1,0.6331723928451538
LUMIZYME,pallor,rigors vomiting cyanosis agitation and,0,0.589202880859375
LUMIZYME,pallor,tachycardia hypertensionincreased blood pallor,1,0.7055157423019409
LUMIZYME,pallor,were more likely to occur,0,0.48832377791404724
LUMIZYME,pallor,saturation cough tachypnea,0,0.48679283261299133
LUMIZYME,pallor,hypertensionincreased blood pallor rigors vomiting,1,0.6501513719558716
LUMIZYME,pallor,pallor rigors vomiting cyanosis,1,0.7561162710189819
LUMIZYME,pallor,pallor rigors vomiting cyanosis agitation,1,0.7469022274017334
LUMIZYME,rigors,more,0,0.5561426877975464
LUMIZYME,rigors,tremor These reactions were more likely to occur with higher i,0,0.5702980160713196
LUMIZYME,rigors,rigors vomiting cyanosis agitation,1,0.7314563989639282
LUMIZYME,rigors,hypertensionincreased blood pressure rigors vomiting cyanosis agitation and,1,0.6284133195877075
LUMIZYME,rigors,likely,0,0.5308185815811157
LUMIZYME,rigors,rigors vomiting cyanosis,1,0.7304033041000366
LUMIZYME,rigors,pressure rigors,1,0.8592021465301514
LUMIZYME,rigors,were more likely to,0,0.5307693481445312
LUMIZYME,rigors,pressure rigors vomiting cyanosis,1,0.6959555149078369
LUMIZYME,vomiting,vomiting cyanosis,1,0.8105159997940063
LUMIZYME,vomiting,hypertensionincreased blood,0,0.4893757700920105
LUMIZYME,vomiting,vomiting,1,0.9999999403953552
LUMIZYME,vomiting,vomiting cyanosis agitation and tremor,1,0.76758873462677
LUMIZYME,vomiting,vomiting cyanosis agitation,1,0.7837516069412231
LUMIZYME,vomiting,vomiting cyanosis agitation and,1,0.7959932088851929
LUMIZYME,vomiting,n saturation cough tachypnea tachycardia hypertensionincreased blood,0,0.5733412504196167
LUMIZYME,vomiting,hypertensionincreased blood pressure pallor vomiting cyanosis agitation,1,0.6445037126541138
LUMIZYME,cyanosis,cyanosis agitation,1,0.8551218509674072
LUMIZYME,agitation,agitation and tremor These reactions were,1,0.842642068862915
LUMIZYME,tremor,tremor These reactions,1,0.8511320948600769
LUMIZYME,tremor,blood,0,0.5103500485420227
LUMIZYME,tremor,Some patients,0,0.49439603090286255
LUMIZYME,tremor,tremor These,1,0.8828330039978027
LUMIZYME,tremor,more likely to occur with higher infusion rates Some patients,0,0.4954908788204193
LUMIZYME,tremor,pallor rigors vomiting,0,0.5703631043434143
LUMIZYME,tremor,tremor These reactions were,1,0.8437924385070801
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions Table summarizes,1,0.8693541288375854
LUMIZYME,hypersensitivity reactions,Table summarizes all adverse reactions occurring in of patients or more patients,0,0.6721405982971191
LUMIZYME,hypersensitivity reactions,reactions occurring in of,0,0.6737921833992004
LUMIZYME,hypersensitivity reactions,of patients or more,0,0.5088061690330505
LUMIZYME,hypersensitivity reactions,corticosteroids still experienced,0,0.5802181959152222
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions Table summarizes all adverse,1,0.824357271194458
LUMIZYME,hypersensitivity reactions,all,0,0.5131107568740845
LUMIZYME,hypersensitivity reactions,patients or more patients,0,0.5147348642349243
LUMIZYME,rash erythematous,Rash including,0,0.8392832279205322
LUMIZYME,rash erythematous,including,0,0.49691832065582275
LUMIZYME,rash erythematous,rash,1,0.873319149017334
LUMIZYME,rash erythematous,rash macular and maculopapular,0,0.6972346305847168
LUMIZYME,rash erythematous,rash erythematous rash macular and,1,0.809414267539978
LUMIZYME,rash erythematous,Rash rash erythematous rash macular and maculopapular Pyrexia,1,0.7609571218490601
LUMIZYME,rash macular,and maculopapular,0,0.8131294846534729
LUMIZYME,rash macular,rash macular and maculopapular Pyrexia,1,0.8942769765853882
LUMIZYME,rash macular,Rash including rash rash,1,0.7328082323074341
LUMIZYME,rash macular,rash macular,1,0.9999999403953552
LUMIZYME,rash macular,and,0,0.47949641942977905
LUMIZYME,rash macular,including rash rash macular and maculopapular,1,0.9374755024909973
LUMIZYME,livedo reticularis,with alglucosidase alfa livedo,1,0.664945125579834
LUMIZYME,livedo reticularis,alglucosidase,0,0.4164596199989319
LUMIZYME,livedo reticularis,trials and expanded access programs with alglucosidase alfa included,0,0.4599142074584961
LUMIZYME,livedo reticularis,in other clinical trials and,0,0.5215571522712708
LUMIZYME,livedo reticularis,in other clinical trials and expanded access programs,0,0.4927660822868347
LUMIZYME,livedo reticularis,ventricular extrasystoles nodal rhythm rales,0,0.5726368427276611
LUMIZYME,irritability,irritability retching increased lacrimation,1,0.7914913296699524
LUMIZYME,irritability,included livedo irritability retching increased,1,0.7748978734016418
LUMIZYME,irritability,irritability retching increased lacrimation ventricular extrasystoles,1,0.7395691871643066
LUMIZYME,irritability,irritability,1,1.0000001192092896
LUMIZYME,irritability,irritability retching increased lacrimation ventricular,1,0.7737751007080078
LUMIZYME,irritability,irritability retching increased,1,0.8147890567779541
LUMIZYME,irritability,livedo irritability retching,1,0.7691232562065125
LUMIZYME,retching,and expanded access programs with alglucosidase alfa included,0,0.4833116829395294
LUMIZYME,retching,expanded access programs with alglucosidase alfa included livedo,0,0.46827635169029236
LUMIZYME,retching,and expanded access programs with,0,0.4640263319015503
LUMIZYME,retching,and expanded access programs with alglucosidase alfa included livedo,0,0.463367223739624
LUMIZYME,retching,rhythm rales respiratory tract,0,0.6297272443771362
LUMIZYME,retching,included livedo reticularis retching increased lacrimation ventricular extrasystoles,1,0.7775667309761047
LUMIZYME,ventricular extrasystoles,ventricular extrasystoles nodal rhythm rales respiratory tract,1,0.8250806331634521
LUMIZYME,ventricular extrasystoles,alfa included livedo,0,0.5395815372467041
LUMIZYME,ventricular extrasystoles,ventricular extrasystoles nodal rhythm rales respiratory,1,0.8407787084579468
LUMIZYME,ventricular extrasystoles,rales respiratory tract irritation and cold sweat,0,0.4877195358276367
LUMIZYME,ventricular extrasystoles,increased ventricular extrasystoles nodal rhythm rales respiratory tract,1,0.8151224851608276
LUMIZYME,nodal rhythm,nodal rhythm rales respiratory tract irritation and,1,0.8091355562210083
LUMIZYME,nodal rhythm,rales respiratory tract irritation and cold sweat,0,0.5034007430076599
LUMIZYME,nodal rhythm,increased lacrimation ventricular nodal rhythm rales respiratory tract,1,0.7374566793441772
LUMIZYME,nodal rhythm,cold,0,0.5045791268348694
LUMIZYME,nodal rhythm,sweat Safety was also evaluated,0,0.468845397233963
LUMIZYME,nodal rhythm,increased lacrimation ventricular nodal rhythm,1,0.7945112586021423
LUMIZYME,nodal rhythm,increased lacrimation,0,0.5077095031738281
LUMIZYME,nodal rhythm,lacrimation ventricular nodal rhythm rales respiratory,1,0.7819749116897583
LUMIZYME,nodal rhythm,retching increased lacrimation ventricular nodal,1,0.6406164169311523
LUMIZYME,rales,lacrimation ventricular extrasystoles nodal rales,1,0.6353530883789062
LUMIZYME,rales,retching increased lacrimation ventricular nodal,1,0.5536270141601562
LUMIZYME,rales,rales respiratory tract irritation and,1,0.7394822835922241
LUMIZYME,rales,rales,1,0.9999998807907104
LUMIZYME,rales,rales respiratory tract irritation and cold,1,0.7106459736824036
LUMIZYME,rales,rales respiratory tract irritation,1,0.7501490712165833
LUMIZYME,respiratory tract irritation,extrasystoles,0,0.4482003152370453
LUMIZYME,cold sweat,nodal rhythm rales respiratory tract,0,0.5053388476371765
LUMIZYME,cold sweat,cold sweat Safety was also evaluated,1,0.8265597820281982
LUMIZYME,cold sweat,rhythm rales respiratory tract irritation,0,0.5706053376197815
LUMIZYME,cold sweat,cold sweat,1,1.0
LUMIZYME,cold sweat,also evaluated in patients male females,0,0.5099093317985535
LUMIZYME,cold sweat,irritation,0,0.5977528095245361
LUMIZYME,cold sweat,females with Pompe disease in,0,0.4914560616016388
LUMIZYME,cold sweat,respiratory tract irritation cold sweat Safety,1,0.8057473301887512
LUMIZYME,cold sweat,tract irritation cold sweat,1,0.8653280138969421
LUMIZYME,anaphylactic reactions,anaphylactic reactions Serious adverse reactions reported,1,0.8621183633804321
LUMIZYME,anaphylactic reactions,Two patients receiving alglucosidase alfa discontinued the trial,0,0.5107752084732056
LUMIZYME,anaphylactic reactions,trial due anaphylactic reactions,1,0.8689048886299133
LUMIZYME,anaphylactic reactions,discontinued the trial due anaphylactic reactions,1,0.7865347266197205
LUMIZYME,anaphylaxis,anaphylaxis which presented as angioedema throat,1,0.8294574022293091
LUMIZYME,anaphylaxis,anaphylaxis which,1,0.9401992559432983
LUMIZYME,anaphylaxis,with alglucosidase alfa anaphylaxis which presented as angioedema throat,1,0.7834891080856323
LUMIZYME,anaphylaxis,alglucosidase alfa anaphylaxis which,1,0.8074508905410767
LUMIZYME,anaphylaxis,which presented,0,0.5315766930580139
LUMIZYME,anaphylaxis,paindiscomfort,0,0.5805903673171997
LUMIZYME,angioedema,alfa,0,0.544911801815033
LUMIZYME,angioedema,angioedema throat tightness and,1,0.8734497427940369
LUMIZYME,angioedema,angioedema throat tightness and chest paindiscomfort,1,0.830041766166687
LUMIZYME,angioedema,angioedema throat,1,0.8818337917327881
LUMIZYME,angioedema,which presented angioedema,1,0.917668342590332
LUMIZYME,angioedema,alfa included anaphylaxis,0,0.6990779638290405
LUMIZYME,angioedema,angioedema,1,1.000000238418579
LUMIZYME,angioedema,anaphylaxis which presented angioedema throat tightness and chest paindiscomfort,1,0.8058496713638306
LUMIZYME,throat tightness,which presented as throat tightness and chest paindiscomfort,1,0.8652434349060059
LUMIZYME,throat tightness,angioedema,1,0.6176294088363647
LUMIZYME,throat tightness,anaphylaxis which presented as throat tightness and chest paindiscomfort One patient,1,0.7864686846733093
LUMIZYME,chest pain,a serious,0,0.5366074442863464
LUMIZYME,chest pain,tightness chest pain discomfort One patient with,1,0.8351072072982788
LUMIZYME,chest pain,history of WolffParkinsonWhite,0,0.44988709688186646
LUMIZYME,chest pain,chest pain discomfort One patient,1,0.8622969388961792
LUMIZYME,chest pain,throat tightness and,0,0.6609036922454834
LUMIZYME,chest pain,of WolffParkinsonWhite syndrome experienced a serious,0,0.538582444190979
LUMIZYME,chest pain,chest,1,0.7111942172050476
LUMIZYME,chest pain,and,0,0.47974079847335815
LUMIZYME,chest pain,as angioedema throat tightness chest,1,0.7202147841453552
LUMIZYME,supraventricular tachycardia,a serious adverse reaction supraventricular,1,0.7875424027442932
LUMIZYME,supraventricular tachycardia,most common adverse reactions,0,0.518855631351471
LUMIZYME,hypersensitivity reactions,headache nausea urticaria,0,0.63747239112854
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions and included anaphylaxis,1,0.8795419931411743
LUMIZYME,anaphylaxis,and anaphylaxis headache nausea,1,0.8505443334579468
LUMIZYME,anaphylaxis,hypersensitivity reactions and included anaphylaxis,1,0.8613653779029846
LUMIZYME,anaphylaxis,anaphylaxis headache,1,0.8655441999435425
LUMIZYME,anaphylaxis,nausea,0,0.6407433748245239
LUMIZYME,anaphylaxis,nausea urticaria dizziness chest discomfort vomiting hyperhidrosis flushingfeelin,0,0.7210363745689392
LUMIZYME,anaphylaxis,hypersensitivity reactions,0,0.7580587267875671
LUMIZYME,anaphylaxis,anaphylaxis headache nausea urticaria dizziness chest,1,0.8307079076766968
LUMIZYME,anaphylaxis,anaphylaxis headache nausea,1,0.854272723197937
LUMIZYME,anaphylaxis,hypersensitivity reactions and included,0,0.7538776397705078
LUMIZYME,anaphylaxis,dizziness,0,0.6086536645889282
LUMIZYME,headache,anaphylaxis,0,0.5895000100135803
LUMIZYME,headache,reactions and,0,0.5196945071220398
LUMIZYME,headache,headache nausea urticaria dizziness,1,0.7812714576721191
LUMIZYME,dizziness,included anaphylaxis headache nausea dizziness chest discomfort,1,0.7012287378311157
LUMIZYME,dizziness,reactions and,0,0.5362515449523926
LUMIZYME,dizziness,dizziness chest discomfort vomiting,1,0.7840840816497803
LUMIZYME,dizziness,dizziness chest discomfort vomiting hyperhidrosis flushingfeeling,1,0.7745487689971924
LUMIZYME,chest discomfort,nausea urticaria chest discomfort vomiting hyperhidrosis flushingfeeling,1,0.7072634696960449
LUMIZYME,chest discomfort,dizziness chest discomfort vomiting hyperhidrosis flushingfeeling,1,0.7356188297271729
LUMIZYME,chest discomfort,hypersensitivity reactions and included anaphylaxis headache nausea,0,0.565505862236023
LUMIZYME,chest discomfort,urticaria chest discomfort vomiting hyperhidrosis flushingfeeling hot increased,1,0.7047964334487915
LUMIZYME,chest discomfort,chest discomfort vomiting hyperhidrosis flushingfeeling,1,0.8073141574859619
LUMIZYME,chest discomfort,chest discomfort vomiting hyperhidrosis flushingfeeling hot,1,0.7988872528076172
LUMIZYME,chest discomfort,nausea urticaria chest discomfort,1,0.7953488826751709
LUMIZYME,vomiting,pressure paresthesia pyrexia,0,0.5761071443557739
LUMIZYME,vomiting,vomiting hyperhidrosis flushingfeeling hot increased blood,1,0.7316702604293823
LUMIZYME,hyperhidrosis,nausea,0,0.5016090869903564
LUMIZYME,hyperhidrosis,discomfort hyperhidrosis flushingfeeling hot increased,1,0.8747923374176025
LUMIZYME,hyperhidrosis,hyperhidrosis flushingfeeling hot increased blood,1,0.8736512064933777
LUMIZYME,hyperhidrosis,dizziness chest,0,0.5585635900497437
LUMIZYME,hyperhidrosis,hyperhidrosis flushingfeeling,1,0.8848522305488586
LUMIZYME,flushing,dizziness chest,0,0.5123832821846008
LUMIZYME,flushing,anaphylaxis headache nausea urticaria dizziness chest discomfort,0,0.5494470596313477
LUMIZYME,feeling hot,chest discomfort vomiting hyperhidrosis feeling hot,1,0.8011654615402222
LUMIZYME,feeling hot,vomiting hyperhidrosis feeling,1,0.7667973637580872
LUMIZYME,feeling hot,chest discomfort vomiting hyperhidrosis feeling,1,0.7280375957489014
LUMIZYME,feeling hot,vomiting hyperhidrosis feeling hot,1,0.8531147241592407
LUMIZYME,feeling hot,vomiting hyperhidrosis feeling hot increased blood pressure paresthesia,1,0.7998125553131104
LUMIZYME,increased blood pressure,flushingfeeling increased blood pressure,1,0.8636706471443176
LUMIZYME,increased blood pressure,vomiting hyperhidrosis feeling hot,1,0.5586015582084656
LUMIZYME,increased blood pressure,blood pressure paresthesia,1,0.7526517510414124
LUMIZYME,increased blood pressure,and throat,0,0.5312200784683228
LUMIZYME,increased blood pressure,hyperhidrosis flushingfeeling increased blood pressure paresthesia pyrexia local,1,0.7555574178695679
LUMIZYME,increased blood pressure,hyperhidrosis flushingfeeling increased blood pressure paresthesia pyrexia,1,0.7620065212249756
LUMIZYME,increased blood pressure,chest discomfort vomiting hyperhidrosis,0,0.5523503422737122
LUMIZYME,paresthesia,paresthesia pyrexia,1,0.7964521646499634
LUMIZYME,paresthesia,increased blood paresthesia pyrexia local swelling,1,0.729286253452301
LUMIZYME,paresthesia,paresthesia,1,0.9999998807907104
LUMIZYME,paresthesia,paresthesia pyrexia local swelling diarrhea,1,0.7216353416442871
LUMIZYME,paresthesia,paresthesia pyrexia local swelling diarrhea pruritus,1,0.7621492743492126
LUMIZYME,paresthesia,pruritus rash and throat tightness Delayedonset,0,0.5946789979934692
LUMIZYME,paresthesia,discomfort vomiting hyperhidrosis flushingfeeling,0,0.6155521869659424
LUMIZYME,paresthesia,blood paresthesia pyrexia local,1,0.7463604211807251
LUMIZYME,pyrexia,pyrexia local swelling,1,0.8458987474441528
LUMIZYME,pyrexia,pressure pyrexia local,1,0.8023794889450073
LUMIZYME,local swelling,local swelling diarrhea pruritus,1,0.79356849193573
LUMIZYME,local swelling,local swelling diarrhea pruritus rash and,1,0.7759296894073486
LUMIZYME,local swelling,paresthesia local swelling,1,0.8691576719284058
LUMIZYME,local swelling,local swelling diarrhea,1,0.8342108726501465
LUMIZYME,local swelling,increased blood pressure paresthesia local swelling diarrhea pruritus rash and throat,1,0.7125623226165771
LUMIZYME,local swelling,local swelling diarrhea pruritus rash and throat,1,0.7484918832778931
LUMIZYME,pruritus,hot increased,0,0.5783737897872925
LUMIZYME,pruritus,Delayedonset reactions defined as,0,0.5210567712783813
LUMIZYME,pruritus,paresthesia pyrexia local swelling pruritus,1,0.8254901170730591
LUMIZYME,pruritus,reactions defined,0,0.5016281008720398
LUMIZYME,pruritus,Delayedonset reactions defined as adverse reactions occurring,0,0.5940476655960083
LUMIZYME,rash,rash and throat tightness Delayedonset,1,0.7501106262207031
LUMIZYME,rash,rash and throat,1,0.834172785282135
LUMIZYME,rash,rash and throat tightness,1,0.7916179895401001
LUMIZYME,throat tightness,swelling diarrhea pruritus rash throat tightness,1,0.7591351270675659
LUMIZYME,throat tightness,rash and throat tightness,1,0.880855917930603
LUMIZYME,throat tightness,throat tightness Delayedonset reactions,1,0.8568352460861206
LUMIZYME,throat tightness,paresthesia pyrexia local swelling,0,0.6070950031280518
LUMIZYME,throat tightness,throat tightness Delayedonset reactions defined as,1,0.79203861951828
LUMIZYME,throat tightness,diarrhea pruritus rash,0,0.5338470935821533
LUMIZYME,hyperhidrosis,the controlled trial hyperhidrosis Additional delayedonset reactions occurring in,1,0.8474650382995605
LUMIZYME,hyperhidrosis,diarrhea pruritus rash,0,0.6022865772247314
LUMIZYME,hyperhidrosis,hyperhidrosis Additional,1,0.9240472912788391
LUMIZYME,hyperhidrosis,hyperhidrosis Additional delayedonset reactions occurring in,1,0.842704176902771
LUMIZYME,fatigue,delayedonset reactions occurring in alglucosidase,0,0.4983413815498352
LUMIZYME,fatigue,in alglucosidase alfatreated patients fatigue myalgia and nausea,1,0.7154800295829773
LUMIZYME,fatigue,delayedonset,0,0.48393502831459045
LUMIZYME,fatigue,fatigue,1,1.0
LUMIZYME,fatigue,fatigue myalgia and nausea,1,0.8139486312866211
LUMIZYME,fatigue,in alglucosidase,0,0.49597132205963135
LUMIZYME,fatigue,about the,0,0.490706205368042
LUMIZYME,fatigue,fatigue myalgia and nausea Patients,1,0.7921466827392578
LUMIZYME,myalgia,possibility of delayedonset hypersensitivity r,0,0.5662723779678345
LUMIZYME,nausea,nausea Patients should be counseled about,1,0.8027634620666504
LUMIZYME,nausea,of delayedonset hypersensitivity reactions and,0,0.5510321855545044
LUMIZYME,anaphylaxis,anaphylaxis and hypersensitivity,1,0.8847521543502808
LUMIZYME,anaphylaxis,anaphylaxis and hypersensitivity reactions,1,0.8629916906356812
LUMIZYME,anaphylaxis,infusion interruption decreased infusion,0,0.5189860463142395
LUMIZYME,anaphylaxis,clinical trials,0,0.5469067692756653
LUMIZYME,anaphylaxis,anaphylaxis and hypersensitivity reactions were managed,1,0.8492373824119568
LUMIZYME,anaphylaxis,trials,0,0.5182522535324097
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions were,1,0.9541298151016235
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions were managed with infusion,1,0.8005218505859375
LUMIZYME,hypersensitivity reactions,In clinical trials anaphylaxis hypersensitivity reactions were managed with infusion,1,0.753226101398468
LUMIZYME,hypersensitivity reactions,trials anaphylaxis and,0,0.7281873226165771
LUMIZYME,hypersensitivity reactions,infusion rate administration of,0,0.4999045133590698
LUMIZYME,IgG antibody titers with inhibitory activity,IgG antibody titers with inhibitory activity Alglucosidase alfatreated,1,0.8806495666503906
LUMIZYME,IgG antibody titers with inhibitory activity,infusion rate administration of,0,0.5545871257781982
LUMIZYME,IgG antibody titers with inhibitory activity,inhibitory activity Alglucosidase alfatreated,1,0.715004026889801
LUMIZYME,IgG antibody titers with inhibitory activity,presence of high IgG,1,0.7577470541000366
LUMIZYME,IgG antibody titers with inhibitory activity,decrease in motor function should be,0,0.533109724521637
LUMIZYME,IgG antibody titers with inhibitory activity,the presence of high IgG antibody titers with inhibitory,1,0.9299275279045105
LUMIZYME,IgG antibody titers with inhibitory activity,sustained,0,0.47366756200790405
LUMIZYME,recurrent hypersensitivity reactions,to severe recurrent hypersensitivity reactions for which,1,0.9523205757141113
LUMIZYME,recurrent hypersensitivity reactions,sustained,0,0.5123547315597534
LUMIZYME,recurrent hypersensitivity reactions,for which mastcell activation was suspected Some of the patients who tested positive for,0,0.6210922002792358
LUMIZYME,recurrent hypersensitivity reactions,hypersensitivity reactions for which mastcell activation,1,0.7507530450820923
LUMIZYME,recurrent hypersensitivity reactions,hypersensitivity reactions for which,1,0.8347841501235962
LUMIZYME,recurrent hypersensitivity reactions,recurrent hypersensitivity reactions for which mastcell activation,1,0.858310341835022
LUMIZYME,recurrent hypersensitivity reactions,experienced moderate to severe recurrent hypersensitivity,1,0.9127532243728638
LUMIZYME,recurrent hypersensitivity reactions,recurrent hypersensitivity reactions for which mastcell,1,0.8486709594726562
LUMIZYME,recurrent hypersensitivity reactions,moderate to severe,0,0.5391635298728943
LUMIZYME,recurrent hypersensitivity reactions,hypersensitivity reactions for which mastcell activation was,1,0.7489169239997864
LUMIZYME,hypersensitivity reactions,hypersensitivity,1,0.9332083463668823
LUMIZYME,hypersensitivity reactions,moderate to severe or hypersensitivity reactions,1,0.8675374984741211
LUMIZYME,hypersensitivity reactions,to severe or hypersensitivity reactions for which mastcell activation,1,0.7954613566398621
LUMIZYME,hypersensitivity reactions,patients,0,0.5566474199295044
LUMIZYME,anaphylactic reactions,alglucosidase alfaspecific IgE antibodies anaphylactic reactions seeBoxed,1,0.7841252088546753
LUMIZYME,anaphylactic reactions,patients,0,0.5390959978103638
LUMIZYME,anaphylactic reactions,anaphylactic reactions,1,1.0000001192092896
LUMIZYME,anaphylactic reactions,anaphylactic reactions seeBoxed WarningandWarnings,1,0.8724677562713623
LUMIZYME,anaphylactic reactions,IgE antibodies anaphylactic reactions seeBoxed WarningandWarnings and,1,0.8282897472381592
LUMIZYME,anaphylactic reactions,the patients who tested positive for alglucosidase alfaspecific IgE antibodies experienced,0,0.7135001420974731
LUMIZYME,hypersensitivity reactions,using a slower infusion rate at,0,0.47360825538635254
LUMIZYME,hypersensitivity reactions,alfaspecific IgE antibodies and hypersensitivity reactions were able to,1,0.8168266415596008
LUMIZYME,hypersensitivity reactions,alfa using a slower infusion rate at lower,0,0.467947393655777
LUMIZYME,anaphylaxis,anaphylaxis seeBoxed WarningandWarnings and,1,0.8319181203842163
LUMIZYME,anaphylaxis,anaphylaxis seeBoxed WarningandWarnings,1,0.8278518319129944
LUMIZYME,Acute cardiorespiratory failure,Acute cardiorespiratory failure possibly,1,0.9538936018943787
LUMIZYME,Acute cardiorespiratory failure,in infantileonset Pompe disease patien,0,0.5253475308418274
LUMIZYME,Acute cardiorespiratory failure,cardiorespiratory failure possibly associated with,1,0.873460054397583
LUMIZYME,Acute cardiorespiratory failure,Acute cardiorespiratory failure possibly associated with,1,0.9283736348152161
LUMIZYME,Acute cardiorespiratory failure,infantileonset Pompe disease,0,0.535959005355835
LUMIZYME,Acute cardiorespiratory failure,anaphylaxis seeBoxed WarningandWarnings and Acute cardiorespiratory failure possibly associated with fluid,1,0.7301203012466431
LUMIZYME,Acute cardiorespiratory failure,WarningandWarnings and Acute,1,0.625619649887085
LUMIZYME,Acute cardiorespiratory failure,WarningandWarnings and Acute cardiorespiratory failure,1,0.8473430871963501
LUMIZYME,Acute cardiorespiratory failure,in infantileonset Pompe,0,0.552564263343811
LUMIZYME,fluid overload,with,0,0.5530402064323425
LUMIZYME,fluid overload,patients with preexisting hypertrophic cardiom,0,0.5791581273078918
LUMIZYME,fluid overload,fluid overload has,1,0.9844273328781128
LUMIZYME,fluid overload,cardiorespiratory failure possibly associated fluid overload has been reported,1,0.8320427536964417
LUMIZYME,fluid overload,failure possibly associated fluid overload has been,1,0.8785101771354675
LUMIZYME,flu-like illness,seeBoxed WarningandWarning and Precautions Recurrent reactions,0,0.6131849884986877
LUMIZYME,flu-like illness,Recurrent reactions consisting flu-like illness or a combination,1,0.8218051791191101
LUMIZYME,flu-like illness,flu-like illness or a combination,1,0.9168393611907959
LUMIZYME,flu-like illness,flu-like illness or a,1,0.9687868356704712
LUMIZYME,flu-like illness,flu-like,1,0.9569178819656372
LUMIZYME,pyrexia,pyrexia chills,1,0.9102816581726074
LUMIZYME,pyrexia,pyrexia chills myalgia arthralgia pain or,1,0.8585954308509827
LUMIZYME,pyrexia,pyrexia chills myalgia arthralgia pain,1,0.8617598414421082
LUMIZYME,pyrexia,after completion of infusions,0,0.5586897730827332
LUMIZYME,chills,consisting of flulike illness or a combination of events,0,0.5937575697898865
LUMIZYME,chills,chills myalgia arthralgia pain,1,0.7938547134399414
LUMIZYME,chills,chills myalgia arthralgia pain or fatigue,1,0.760947048664093
LUMIZYME,chills,events such,0,0.5093908905982971
LUMIZYME,chills,arthralgia pain or fatigue occurring after completion of,0,0.5171029567718506
LUMIZYME,chills,chills myalgia,1,0.7995564341545105
LUMIZYME,chills,infusions and,0,0.5249546766281128
LUMIZYME,myalgia,fatigue occurring after,0,0.6452819108963013
LUMIZYME,myalgia,myalgia arthralgia,1,0.8684595227241516
LUMIZYME,myalgia,such as pyrexia chills,0,0.5252256393432617
LUMIZYME,myalgia,occurring after completion of infusions and lasting,0,0.5230967402458191
LUMIZYME,myalgia,flulike illness or a combination of events such as,0,0.5627318620681763
LUMIZYME,myalgia,myalgia arthralgia pain or fatigue occurring,1,0.8193326592445374
LUMIZYME,myalgia,urrent reactions consisting of flulike illness or,0,0.5538042783737183
LUMIZYME,arthralgia,occurring after completion of infusions and lasting usually for days have b,0,0.5421992540359497
LUMIZYME,arthralgia,chills arthralgia,1,0.8245704174041748
LUMIZYME,arthralgia,arthralgia pain or,1,0.9548426866531372
LUMIZYME,arthralgia,arthralgia pain or fatigue occurring,1,0.8805229663848877
LUMIZYME,arthralgia,arthralgia,1,1.0
LUMIZYME,arthralgia,for days have b,0,0.5060728192329407
LUMIZYME,arthralgia,after completion of infusions,0,0.5132889747619629
LUMIZYME,pain,pain,1,0.9999999403953552
LUMIZYME,pain,have been ob,0,0.5249013900756836
LUMIZYME,pain,as pyrexia chills myalgia pain or fatigue occurring,1,0.6594972610473633
LUMIZYME,pain,events such as,0,0.4745712876319885
LUMIZYME,pain,as pyrexia chills myalgia pain,1,0.6911536455154419
LUMIZYME,pain,pyrexia chills myalgia arthralgia,0,0.6377373337745667
LUMIZYME,pain,or fatigue occurring after completion of infusions and lasting usually,0,0.5685878992080688
LUMIZYME,pain,pain or,1,0.8774235248565674
LUMIZYME,pain,chills myalgia pain or fatigue occurring after completion,1,0.6558161973953247
LUMIZYME,pain,pain or fatigue occurring after,1,0.7307940721511841
LUMIZYME,fatigue,fatigue occurring,1,0.9072326421737671
LUMIZYME,fatigue,such as pyrexia chills myalgia,0,0.6294315457344055
LUMIZYME,hypersensitivity reactions,in clinical trials seeAdverse Reactions the following hypersensitivity reactio,0,0.8320902585983276
LUMIZYME,hypersensitivity reactions,and,0,0.48918282985687256
LUMIZYME,hypersensitivity reactions,In addition to,0,0.5600805878639221
LUMIZYME,hypersensitivity reactions,addition to hypersensitivity,1,0.8663883209228516
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions reported in clinical trials seeAdverse,1,0.830926239490509
LUMIZYME,hypersensitivity reactions,In addition to hypersensitivity reactions,1,0.9121917486190796
LUMIZYME,hypersensitivity reactions,to the,0,0.5217874050140381
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions reported,1,0.9262576699256897
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions have been reported,1,0.9228438138961792
LUMIZYME,hypersensitivity reactions,trials seeAdverse Reactions the hypersensitivity reactions,1,0.8765196800231934
LUMIZYME,hypersensitivity reactions,Reactions the hypersensitivity reactions,1,0.959013819694519
LUMIZYME,hypersensitivity reactions,trials seeAdverse Reactions the,0,0.6431053876876831
LUMIZYME,hypersensitivity reactions,have been reported in at,0,0.5150082111358643
LUMIZYME,hypersensitivity reactions,the hypersensitivity reactions have,1,0.9537723064422607
LUMIZYME,anaphylactic shock,at least patients and anaphylactic shock,1,0.8670580387115479
LUMIZYME,anaphylactic shock,and anaphylactic shock respiratory failure respiratory,1,0.8327208161354065
LUMIZYME,respiratory failure,patients and included anaphylactic respiratory failure,1,0.7384713888168335
LUMIZYME,respiratory failure,at least patients and anaphylactic shock,1,0.5384036898612976
LUMIZYME,respiratory failure,anaphylactic respiratory failure,1,0.7730239033699036
LUMIZYME,respiratory failure,respiratory failure respiratory,1,0.9282745122909546
LUMIZYME,respiratory arrest,anaphylactic shock respiratory respiratory arrest,1,0.8633272647857666
LUMIZYME,respiratory arrest,anaphylactic shock respiratory respiratory arrest cardiac arrest hypoxia,1,0.8283402919769287
LUMIZYME,respiratory arrest,shock respiratory respiratory arrest,1,0.9248056411743164
LUMIZYME,respiratory arrest,have been reported in at least patients and,0,0.49325716495513916
LUMIZYME,respiratory arrest,respiratory respiratory arrest cardiac arrest hypoxia,1,0.8866583704948425
LUMIZYME,respiratory arrest,respiratory arrest cardiac arrest,1,0.9213079214096069
LUMIZYME,respiratory arrest,cardiac arrest hypoxia dyspnea wheezing convulsions peripheral coldness restlessness nervou,0,0.740646481513977
LUMIZYME,respiratory arrest,arrest hypoxia dyspnea wheezing convulsions peripheral coldness,0,0.716020941734314
LUMIZYME,respiratory arrest,included anaphylactic shock respiratory respiratory,1,0.7217051982879639
LUMIZYME,cardiac arrest,dyspnea wheezing convulsions,0,0.5913046598434448
LUMIZYME,cardiac arrest,respiratory cardiac,1,0.6790852546691895
LUMIZYME,cardiac arrest,wheezing convulsions,0,0.5913852453231812
LUMIZYME,cardiac arrest,cardiac arrest hypoxia dyspnea wheezing convulsions peripheral,1,0.7956124544143677
LUMIZYME,cardiac arrest,failure respiratory cardiac arrest,1,0.8345651626586914
LUMIZYME,cardiac arrest,in at least,0,0.5085153579711914
LUMIZYME,cardiac arrest,shock respiratory failure respiratory cardiac arrest hypoxia dyspnea wheezing,1,0.7554646134376526
LUMIZYME,cardiac arrest,least patients and included,0,0.45908427238464355
LUMIZYME,cardiac arrest,cardiac arrest hypoxia dyspnea wheezing,1,0.8096065521240234
LUMIZYME,hypoxia,hypoxia dyspnea wheezing convulsions peripheral,1,0.7222509384155273
LUMIZYME,hypoxia,hypoxia dyspnea wheezing convulsions peripheral coldness,1,0.7247117757797241
LUMIZYME,hypoxia,arrest cardiac arrest,0,0.6101982593536377
LUMIZYME,dyspnea,dyspnea,1,1.0
LUMIZYME,convulsions,convulsions,1,0.9999998807907104
LUMIZYME,convulsions,cardiac arrest hypoxia,0,0.5821398496627808
LUMIZYME,convulsions,pain,0,0.5733019709587097
LUMIZYME,convulsions,convulsions peripheral coldness restlessness nervousness,1,0.8293743133544922
LUMIZYME,peripheral coldness,peripheral coldness restlessness nervousness back,1,0.8624075651168823
LUMIZYME,peripheral coldness,arrest hypoxia dyspnea wheezing peripheral coldness restlessness nervousness,1,0.6800334453582764
LUMIZYME,restlessness,restlessness nervousness back,1,0.885584831237793
LUMIZYME,restlessness,back pain stridor pharyngeal edema abdominal pain apnea muscle spasm and,0,0.5483126640319824
LUMIZYME,restlessness,restlessness nervousness back pain stridor,1,0.7926782369613647
LUMIZYME,restlessness,nervousness back pain,0,0.6170741319656372
LUMIZYME,restlessness,restlessness nervousness,1,0.9200289249420166
LUMIZYME,restlessness,respiratory arrest,0,0.5044937133789062
LUMIZYME,restlessness,peripheral restlessness nervousness back,1,0.8410816192626953
LUMIZYME,nervousness,cardiac arrest hypoxia dyspnea wheezing convulsions,0,0.5606313943862915
LUMIZYME,nervousness,peripheral coldness nervousness back pain stridor,1,0.6893863677978516
LUMIZYME,nervousness,nervousness back,1,0.9129716157913208
LUMIZYME,back pain,coldness restlessness back pain,1,0.7621150612831116
LUMIZYME,back pain,nervousness back,1,0.5113614201545715
LUMIZYME,back pain,back pain stridor pharyngeal edema abdominal,1,0.7089952230453491
LUMIZYME,back pain,pharyngeal edema abdominal pain apnea muscle spasm and conjunctivitis,0,0.538262128829956
LUMIZYME,back pain,stridor pharyngeal edema abdominal pain apnea muscle spasm,0,0.5269050002098083
LUMIZYME,back pain,arrest hypoxia dyspnea wheezing convulsions peripheral,0,0.4702247381210327
LUMIZYME,back pain,apnea muscle spasm and conjunctivitis In addition,0,0.5153248310089111
LUMIZYME,back pain,apnea muscle spasm and,0,0.5333806276321411
LUMIZYME,stridor,nervousness back,0,0.4903351664543152
LUMIZYME,stridor,stridor,1,0.9999997615814209
LUMIZYME,stridor,stridor pharyngeal edema abdominal,1,0.6938936710357666
LUMIZYME,stridor,stridor pharyngeal edema abdominal pain,1,0.6836094260215759
LUMIZYME,pharyngeal edema,back pain pharyngeal,1,0.7442883253097534
LUMIZYME,pharyngeal edema,pharyngeal edema abdominal pain apnea,1,0.913948655128479
LUMIZYME,pharyngeal edema,pharyngeal edema abdominal pain apnea muscle,1,0.8858668208122253
LUMIZYME,pharyngeal edema,pain,0,0.5591764450073242
LUMIZYME,pharyngeal edema,dyspnea wheezing convulsions peripheral coldness restlessness nervousness back,0,0.5997100472450256
LUMIZYME,pharyngeal edema,pharyngeal edema,1,1.0
LUMIZYME,pharyngeal edema,conjunctivitis In addition one case of,0,0.5780777335166931
LUMIZYME,abdominal pain,of,0,0.464073121547699
LUMIZYME,abdominal pain,abdominal pain apnea muscle,1,0.7919110059738159
LUMIZYME,abdominal pain,convulsions peripheral coldness restlessness nervousness,0,0.4575248956680298
LUMIZYME,apnea,In addition one case of hyperparathyroidism has been reported,0,0.515618622303009
LUMIZYME,apnea,apnea muscle spasm and conjunctivitis,1,0.7639530897140503
LUMIZYME,apnea,nervousness back pain stridor,0,0.6196454167366028
LUMIZYME,apnea,abdominal,0,0.5208677053451538
LUMIZYME,apnea,apnea muscle,1,0.8576014041900635
LUMIZYME,conjunctivitis,conjunctivitis In addition one,1,0.9166333079338074
LUMIZYME,conjunctivitis,conjunctivitis,1,1.0
LUMIZYME,conjunctivitis,conjunctivitis In,1,0.9559459686279297
LUMIZYME,conjunctivitis,abdominal pain apnea muscle spasm,0,0.4658042788505554
LUMIZYME,conjunctivitis,pain apnea muscle,0,0.4732876420021057
LUMIZYME,conjunctivitis,conjunctivitis In addition,1,0.9088459610939026
LUMIZYME,hyperparathyroidism,hyperparathyroidism has been reported Systemic,1,0.8649163246154785
LUMIZYME,hyperparathyroidism,hyperparathyroidism,1,1.0
LUMIZYME,proteinuria,necrotizing skin lesions,0,0.5088962316513062
LUMIZYME,proteinuria,erparathyroidism has been reported Systemic and,0,0.5870645642280579
LUMIZYME,proteinuria,proteinuria and nephrotic,1,0.8916605710983276
LUMIZYME,proteinuria,proteinuria,1,1.000000238418579
LUMIZYME,proteinuria,and cutaneous immunemediated reactions proteinuria and nephrotic syndrome,1,0.7802286148071289
LUMIZYME,proteinuria,membranous glomerulonephritis,0,0.6911336183547974
LUMIZYME,proteinuria,Systemic,0,0.5281237363815308
LUMIZYME,proteinuria,immunemediated reactions proteinuria and nephrotic syndrome,1,0.7992798089981079
LUMIZYME,proteinuria,skin lesions,0,0.5405490398406982
LUMIZYME,proteinuria,reactions proteinuria and nephrotic syndrome secondary to,1,0.8076874017715454
LUMIZYME,nephrotic syndrome,proteinuria,0,0.7178252935409546
LUMIZYME,nephrotic syndrome,including proteinuria nephrotic,1,0.8434262275695801
LUMIZYME,nephrotic syndrome,nephrotic syndrome secondary,1,0.8884595632553101
LUMIZYME,nephrotic syndrome,to membranous glomerulonephritis and necrotizing skin lesions have been reported,0,0.7240779399871826
LUMIZYME,nephrotic syndrome,nephrotic syndrome secondary to membranous glomerulonephritis,1,0.881519079208374
LUMIZYME,nephrotic syndrome,nephrotic syndrome secondary to,1,0.9090439677238464
LUMIZYME,membranous glomerulonephritis,membranous glomerulonephritis and necrotizing skin,1,0.8721169233322144
LUMIZYME,membranous glomerulonephritis,and nephrotic syndrome secondary membranous,1,0.8195897340774536
LUMIZYME,membranous glomerulonephritis,postmarketing safety,0,0.48967379331588745
LUMIZYME,membranous glomerulonephritis,syndrome secondary to,0,0.5568076372146606
LUMIZYME,membranous glomerulonephritis,necrotizing skin lesions have been reported in postmarketing safety experience with alglucosid,0,0.5886062979698181
LUMIZYME,membranous glomerulonephritis,membranous glomerulonephritis and necrotizing skin lesions have,1,0.8809293508529663
LUMIZYME,membranous glomerulonephritis,syndrome secondary membranous glomerulonephritis,1,0.8842117786407471
LUMIZYME,membranous glomerulonephritis,and nephrotic syndrome secondary membranous glomerulonephritis and necrotizing skin,1,0.8274526596069336
LUMIZYME,necrotizing skin lesions,membranous glomerulonephritis necrotizing skin lesions,1,0.8385835886001587
LUMIZYME,necrotizing skin lesions,to membranous glomerulonephritis necrotizing skin lesions have been reported in postmarketing,1,0.8040111660957336
LUMIZYME,necrotizing skin lesions,secondary to membranous glomerulonephritis necrotizing skin,1,0.8032947778701782
LUMIZYME,ANAPHYLAXIS, *  The mos t,1,0.41080987453460693
LUMIZYME,ANAPHYLAXIS,secondary to membranous glomerulonephritis necrotizing skin,1,0.5367839336395264
LUMIZYME,ANAPHYLAXIS,clinical trials were hypersensitivity,0,0.6729950904846191
LUMIZYME,ANAPHYLAXIS,ADVERSE REACTIONS *,1,0.7171739339828491
LUMIZYME,ANAPHYLAXIS,REACTIONS  *  The mos t frequently reported adverse,1,0.6413453817367554
LUMIZYME,ANAPHYLAXIS,* The mos,1,0.41362953186035156
LUMIZYME,ANAPHYLAXIS,ADVERSE REACTIONS  *  The mos t frequently reported adverse,1,0.6273964643478394
LUMIZYME,ANAPHYLAXIS,ADVERSE REACTIONS * The mos,1,0.6289060115814209
LUMIZYME,ANAPHYLAXIS,REACTIONS EXCERPT,0,0.6265383958816528
LUMIZYME,HYPERSENSITIVITY,ADVERSE REACTIONS EXCERPT,0,0.6659689545631409
LUMIZYME,IMMUNE-MEDIATED REACTIONS,trials,0,0.5363116264343262
LUMIZYME,IMMUNE-MEDIATED REACTIONS,dverse reactions (>= 5%) in clinical trials were hypersensitivity,1,0.707744836807251
LUMIZYME,IMMUNE-MEDIATED REACTIONS,The most frequently reported,0,0.5255371332168579
LUMIZYME,IMMUNE-MEDIATED REACTIONS,frequently reported dverse,1,0.5411850214004517
LUMIZYME,ANAPHYLAXIS,reactions and : anaphylax is rash pyrexia flushingfeeling,1,0.8079784512519836
LUMIZYME,ANAPHYLAXIS,frequently reported dverse,1,0.5000129342079163
LUMIZYME,ANAPHYLAXIS,adverse reactions in clinical trials were hypersensitivity reactions,0,0.6946851015090942
LUMIZYME,ANAPHYLAXIS,y reported adverse reactions,0,0.6694928407669067
LUMIZYME,ANAPHYLAXIS,were hypersensitivity reactions and :,1,0.7372998595237732
LUMIZYME,ANAPHYLAXIS,hypersensitivity reactions and : anaphylax is rash pyrexia flushingfeeling,1,0.7898423671722412
LUMIZYME,ANAPHYLAXIS,: anaphylax is rash pyrexia flushingfeeling hot,1,0.8078451752662659
LUMIZYME,HYPERSENSITIVITY,hyperhidrosis nausea cough decreased oxygen saturatio,0,0.5978069305419922
LUMIZYME,HYPERSENSITIVITY,urticaria headache hyperhidrosis nausea cough decreased oxygen,0,0.6596370935440063
LUMIZYME,HYPERSENSITIVITY,hypersensitivity reactions,0,0.9332083463668823
LUMIZYME,HYPERSENSITIVITY,"rash, pyrexia, flushingfeeling hot urticaria headache hyperhidrosis",1,0.6941512823104858
LUMIZYME,HYPERSENSITIVITY,headache hyperhidrosis nausea,0,0.6426634192466736
LUMIZYME,HYPERSENSITIVITY,", rash, pyrexia, flushingfeeling hot",1,0.6811354160308838
LUMIZYME,HYPERSENSITIVITY,"included , rash, pyrexia, flushingfeeling hot urticaria headache hyperhidrosis",1,0.7047171592712402
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"hing/feeling hot, urticar ia headache",1,0.586247444152832
LUMIZYME,IMMUNE-MEDIATED REACTIONS,", rash, pyrexia, flushingfeeling hot",1,0.6135276556015015
LUMIZYME,IMMUNE-MEDIATED REACTIONS,clinical trials were hypersensitivity reactions and included,0,0.7029892206192017
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"hing/feeling hot, urticar",1,0.5974090099334717
LUMIZYME,IMMUNE-MEDIATED REACTIONS,decreased oxygen,0,0.5104896426200867
LUMIZYME,IMMUNE-MEDIATED REACTIONS,pyrexia flus,0,0.5860455632209778
LUMIZYME,IMMUNE-MEDIATED REACTIONS,rash pyrexia hing/feeling,1,0.5810917615890503
LUMIZYME,IMMUNE-MEDIATED REACTIONS,headache hyperhidrosis nausea cough decreased oxygen saturation,0,0.5635282397270203
LUMIZYME,hypersensitivity reactions,tachypnea,0,0.5344606041908264
LUMIZYME,hypersensitivity reactions,"st discomfort, dizziness,  muscle twitching agitation",1,0.5375542044639587
LUMIZYME,hypersensitivity reactions,saturation tachycardia tachypnea st,1,0.5631440877914429
LUMIZYME,hypersensitivity reactions,hypertensionincreased blood pressure pallor rigo,0,0.5538678765296936
LUMIZYME,hypersensitivity reactions,"st discomfort, dizziness, muscle twitching agitation cyanosis",1,0.5578970313072205
LUMIZYME,hypersensitivity reactions,hypertensionincreased blood pressure pallor,0,0.5541744828224182
LUMIZYME,hypersensitivity reactions,"st discomfort, dizziness, muscle twitching agitation cyanosis erythema",1,0.596032977104187
LUMIZYME,respiratory distress,"discomfort dizziness muscle , agitation, cyanosi s erythema",1,0.5804789066314697
LUMIZYME,respiratory distress,"st discomfort, dizziness, muscle twitching agitation cyanosis erythema",1,0.5926363468170166
LUMIZYME,respiratory distress,tremor vomiting,0,0.5420788526535034
LUMIZYME,respiratory distress,"discomfort dizziness muscle , agitation, cyanosi s erythema hypertensionincreased blood pressure",1,0.579317569732666
LUMIZYME,respiratory distress,"dizziness muscle , agitation, cyanosi",1,0.5649973154067993
LUMIZYME,respiratory distress,twitching,0,0.5316933393478394
LUMIZYME,respiratory distress,", agitation,",1,0.6064939498901367
LUMIZYME,respiratory distress,pressure pallor rigors tremor vomiting fatigue and m,0,0.6175726056098938
LUMIZYME,hypoxia,chest discomfort dizziness muscle twitching,0,0.5645390748977661
LUMIZYME,apnea,"twitching agitation cyanosis , hyp",1,0.6157261729240417
LUMIZYME,dyspnea,cyanosis erythema tension,1,0.6055442094802856
LUMIZYME,dyspnea,"twitching agitation cyanosis , hyp",1,0.6185269355773926
LUMIZYME,dyspnea,agitation cyanosis,0,0.6212831735610962
LUMIZYME,bradycardia,ncreased bl ood,1,0.48937273025512695
LUMIZYME,bradycardia,agitation cyanosis,0,0.602008044719696
LUMIZYME,bradycardia,ncreased bl,1,0.4777541160583496
LUMIZYME,bradycardia,tremor vomiting fatigue,0,0.6455832123756409
LUMIZYME,bradycardia,chest discomfort dizziness muscle twitching agitation,0,0.6713749170303345
LUMIZYME,bradycardia,rigors tremor vomiting fatigue and myalgia To report SUSPECT,0,0.624751627445221
LUMIZYME,bronchospasm,"hypertensionincreased blood pressure allor, rigor",1,0.5671234726905823
LUMIZYME,bronchospasm,"erythema hypertensionincreased blood pressure allor,",1,0.5457243919372559
LUMIZYME,bronchospasm,s tremor vomiting fatigue and myalgia To report SUSPECTED ADVERSE REACTIONS,0,0.5817288756370544
LUMIZYME,bronchospasm,"pressure allor,",1,0.5700417160987854
LUMIZYME,bronchospasm,"allor, rigor s",1,0.54933762550354
LUMIZYME,bronchospasm,agitation cyanosis erythema hypertensionincreased blood,0,0.6040425300598145
LUMIZYME,bronchospasm,"hypertensionincreased blood pressure allor, rigor s tremor vomiting",1,0.5931349992752075
LUMIZYME,bronchospasm,and myalgia To,0,0.5187099575996399
LUMIZYME,throat tightness,"hypertensionincreased blood pressure pallor  tremor, vomitin",1,0.5690879821777344
LUMIZYME,throat tightness,and myalgia To,0,0.5558327436447144
LUMIZYME,throat tightness,cyanosis erythema hypertensionincreased blood pressure,0,0.5641399621963501
LUMIZYME,throat tightness,rigors,0,0.5230095386505127
LUMIZYME,throat tightness,"blood pressure pallor tremor,",1,0.5425839424133301
LUMIZYME,throat tightness,"blood pressure pallor tremor, vomitin",1,0.5762104392051697
LUMIZYME,throat tightness,and myalgia To report SUSPECTED ADVERSE REACTIONS contact Genzyme at,0,0.5638520121574402
LUMIZYME,hypotension,"pallor rigors tremor fatigue, a",1,0.5282586812973022
LUMIZYME,hypotension,erythema,0,0.5176573991775513
LUMIZYME,hypotension,"pressure pallor rigors tremor fatigue,",1,0.5958600044250488
LUMIZYME,hypotension,"rigors tremor fatigue, a",1,0.5303300619125366
LUMIZYME,hypotension,"fatigue, a nd myalgia To report",1,0.5705910921096802
LUMIZYME,angioedema,contact Genzyme at,0,0.5248857736587524
LUMIZYME,angioedema,fatigue  myalgia ( To,1,0.5849440097808838
LUMIZYME,angioedema,myalgia (,1,0.5901616811752319
LUMIZYME,angioedema,tremor vomiting fatigue  myalgia (,1,0.55636066198349
LUMIZYME,angioedema,myalgia ( To report,1,0.5916571021080017
LUMIZYME,angioedema,ADVERSE REACTIONS contact Genzyme,0,0.6084120273590088
LUMIZYME,angioedema,fatigue,0,0.5736905932426453
LUMIZYME,angioedema,tremor vomiting fatigue  myalgia ( To report SUSPECTED ADVERSE REACTIONS,1,0.5932737588882446
LUMIZYME,angioedema,REACTIONS contact Genzyme,0,0.5678377151489258
LUMIZYME,lip swelling,DVERSE REACTIONS contact,0,0.5291368365287781
LUMIZYME,lip swelling,eased blood,0,0.5220238566398621
LUMIZYME,periorbital edema,at or FDA at FDA or wwwfdagovmedwatch Clin,0,0.521632194519043
LUMIZYME,periorbital edema,or FDA at FDA or wwwfdagovmedwatch Clin,0,0.5187063217163086
LUMIZYME,periorbital edema,"ERSE REACTIONS, c",1,0.5242397785186768
LUMIZYME,periorbital edema,rigors tremor vomiting fatigue and myalgia To report,0,0.5368260145187378
LUMIZYME,periorbital edema,"myalgia To report SUSPECTED ERSE REACTIONS,",1,0.5483149886131287
LUMIZYME,periorbital edema,"ERSE REACTIONS, c ontact Genzyme",1,0.5192111730575562
LUMIZYME,periorbital edema,FDA or wwwfdagovmedwatch,0,0.521988034248352
LUMIZYME,periorbital edema,vomiting fatigue and myalgia To report SUSPECTED ADV,0,0.5348158478736877
LUMIZYME,periorbital edema,"SUSPECTED ERSE REACTIONS, c ontact Genzyme at or FDA",1,0.5556877851486206
LUMIZYME,face edema,at FDA,0,0.49216604232788086
LUMIZYME,face edema,ADVERSE REACTIONS Genzyme a,1,0.5715194940567017
LUMIZYME,face edema, Genzyme a t or FDA at FDA,1,0.5192126035690308
LUMIZYME,Immune-mediated reactions,"wwwfdagovmedwatch Clinical Trials xperience

  Because clin ical trials are conducted",1,0.5530951023101807
LUMIZYME,Immune-mediated reactions,ADVERSE REACTIONS Genzyme a,1,0.6363565921783447
LUMIZYME,Immune-mediated reactions,"Trials xperience

  Because clin ical trials",1,0.5546178817749023
LUMIZYME,Immune-mediated reactions,Trials xperience Because,1,0.49983498454093933
LUMIZYME,Immune-mediated reactions,under widely varying conditions adverse reaction rates observed in the cl,0,0.6956188678741455
LUMIZYME,Immune-mediated reactions,xperience Because clin ical trials are conducted under,1,0.5658935308456421
LUMIZYME,Immune-mediated reactions,adverse,0,0.5608224868774414
LUMIZYME,Immune-mediated reactions,or FDA at FDA or wwwfdagovmedwatch Clinical Trials E,0,0.5044654607772827
LUMIZYME,Immune-mediated reactions,adverse reaction,0,0.703658401966095
LUMIZYME,Immune-mediated reactions,Because clin ical,1,0.5907172560691833
LUMIZYME,Immune-mediated reactions,Clinical Trials xperience Because,1,0.542751669883728
LUMIZYME,proteinuria, conducted  under widely varying,1,0.4738345444202423
LUMIZYME,proteinuria,of,0,0.49599602818489075
LUMIZYME,proteinuria,clinical trials,0,0.5415732860565186
LUMIZYME,proteinuria, conducted  under,1,0.49977874755859375
LUMIZYME,proteinuria, conducted  under widely,1,0.48569950461387634
LUMIZYME,nephrotic syndrome,Experience Because,0,0.4120919108390808
LUMIZYME,necrotizing skin lesions,Clinical Trials Experience Because clinical trials are conducted under widely,0,0.5028527975082397
LUMIZYME,necrotizing skin lesions,of a drug,0,0.4398743510246277
LUMIZYME,necrotizing skin lesions,"conducted under widely varying tions, adverse reaction  rates observed in the clinical",1,0.5753714442253113
LUMIZYME,necrotizing skin lesions,"tions, adverse reaction rates observed in",1,0.5764119029045105
LUMIZYME,necrotizing skin lesions,clinical trials of a drug,0,0.5001833438873291
LUMIZYME,necrotizing skin lesions,"tions, adverse reaction rates observed",1,0.5618730783462524
LUMIZYME,fluid overload,"saturation achycardia,",1,0.581031084060669
LUMIZYME,fluid overload,shingfeeling hot,0,0.5842279195785522
LUMIZYME,fluid overload,urticaria headache hyperhidrosis,0,0.5639017820358276
LUMIZYME,fluid overload,"saturation achycardia, ta chypnea chest discomfort dizziness muscle",1,0.5842715501785278
LUMIZYME,fluid overload,"achycardia, ta chypnea",1,0.5798647403717041
LUMIZYME,fluid overload,"achycardia, ta",1,0.5312858819961548
LUMIZYME,ANAPHYLAXIS,blood p ressure pallor rigors tremor,1,0.544524073600769
LUMIZYME,ANAPHYLAXIS,fatigue and myalgia,0,0.47996264696121216
LUMIZYME,ANAPHYLAXIS,erythema sed,1,0.566226601600647
LUMIZYME,ANAPHYLAXIS,cyanosis erythema hypertensionincrea,0,0.607254147529602
LUMIZYME,ANAPHYLAXIS,sed blood p ressure pallor rigors tremor vomiting,1,0.6013988256454468
LUMIZYME,HYPERSENSITIVITY,igors tremor vomiting fatigue and myalgia Clinical Trials,0,0.5275735855102539
LUMIZYME,HYPERSENSITIVITY,omfort dizziness muscle twitching agitation cyanosis erythema,0,0.6059098243713379
LUMIZYME,HYPERSENSITIVITY,"hypertensionincreased blood ssure, pallor, r",1,0.5790312886238098
LUMIZYME,HYPERSENSITIVITY,"blood ssure, pallor, r igors",1,0.5602998733520508
LUMIZYME,HYPERSENSITIVITY,"ssure, pallor, r",1,0.550168514251709
LUMIZYME,HYPERSENSITIVITY,hypertensionincreased blood pre,0,0.5693582892417908
LUMIZYME,HYPERSENSITIVITY,"ssure, pallor, r igors tremor",1,0.5061401128768921
LUMIZYME,HYPERSENSITIVITY,dizziness muscle twitching agitation cyanosis,0,0.5355178117752075
LUMIZYME,HYPERSENSITIVITY,"cyanosis erythema hypertensionincreased blood ssure, pallor, r",1,0.6192600727081299
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"hypertensionincreased blood pressure pallor , tremor, vomiting, fatig ue",1,0.5043385624885559
LUMIZYME,IMMUNE-MEDIATED REACTIONS,dizziness muscle twitching agitation cyanosis,0,0.5085645914077759
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"pressure pallor , tremor, vomiting, fatig",1,0.5251410007476807
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"hypertensionincreased blood pressure pallor ,",1,0.4989463686943054
LUMIZYME,IMMUNE-MEDIATED REACTIONS,blood,0,0.5976544618606567
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"blood pressure pallor , tremor, vomiting, fatig ue and myalgia Clinical",1,0.5086910724639893
LUMIZYME,IMMUNE-MEDIATED REACTIONS,",",1,0.5571564435958862
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"pallor , tremor,",1,0.4952751398086548
LUMIZYME,IMMUNE-MEDIATED REACTIONS,and JuvenileOnset Pompe,0,0.48885902762413025
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"vomiting, fatig ue",1,0.5589486360549927
LUMIZYME,IMMUNE-MEDIATED REACTIONS,and myalgia Clinical Trials in InfantileOnset and JuvenileOnset Pompe Disease T,0,0.5199032425880432
LUMIZYME,CARDIORESPIRATORY FAILURE,Clinical Trial s in InfantileOnset and JuvenileOnset,1,0.5184504985809326
LUMIZYME,anaphylactic reactions,Disease Two multicenter openlabel al,1,0.523080587387085
LUMIZYME,anaphylactic reactions,openlabel al trials were conduct,1,0.5008008480072021
LUMIZYME,hypersensitivity reactions,conducted in,0,0.49608999490737915
LUMIZYME,hypersensitivity reactions,conducted in antile-onset Pompe disease patients ages month to,1,0.5119109153747559
LUMIZYME,hypersensitivity reactions,Pompe disease patients ages month to,1,0.47019416093826294
LUMIZYME,hypersensitivity reactions,conducted in antile-onset,1,0.5788824558258057
LUMIZYME,hypersensitivity reactions,antile-onset Pompe disease,1,0.5146375298500061
LUMIZYME,hypersensitivity reactions,openlabel clinical trials were conducted in inf,0,0.5172793865203857
LUMIZYME,hypersensitivity reactions,antile-onset Pompe disease patients,1,0.5098364949226379
LUMIZYME,Immune-mediated reactions,Approximately half of the 4%) were male. Patients w,1,0.4771413207054138
LUMIZYME,Immune-mediated reactions,antile-onset Pompe disease patients,1,0.5335438847541809
LUMIZYME,Immune-mediated reactions,alfa or mgkg,0,0.4666215777397156
LUMIZYME,proteinuria,were treated h,1,0.5037589073181152
LUMIZYME,proteinuria,treated h alglucosi dase,1,0.5573581457138062
LUMIZYME,proteinuria,Patients were treated h alglucosi dase alfa or,1,0.5788817405700684
LUMIZYME,proteinuria,other,0,0.5014405250549316
LUMIZYME,nephrotic syndrome,were treated with se,1,0.5238969326019287
LUMIZYME,nephrotic syndrome,se alfa 20,1,0.47340068221092224
LUMIZYME,nephrotic syndrome,to weeks mean,0,0.4502938687801361
LUMIZYME,necrotizing skin lesions,alfa or mgkg very other week for peri ods ranging from to,1,0.48662543296813965
LUMIZYME,necrotizing skin lesions,se alfa 20,1,0.4594666063785553
LUMIZYME,necrotizing skin lesions,mgkg very other week,1,0.47969865798950195
LUMIZYME,necrotizing skin lesions,very other week for peri ods ranging from to,1,0.5307530164718628
LUMIZYME,necrotizing skin lesions,alglucosidase alfa or mgkg very other week for peri ods,1,0.5308573842048645
LUMIZYME,necrotizing skin lesions,for peri ods ranging from,1,0.5468456149101257
LUMIZYME,necrotizing skin lesions,very other week for,1,0.4697935879230499
LUMIZYME,necrotizing skin lesions,treated with alglucosidase alfa,0,0.5091762542724609
LUMIZYME,fluid overload,These reactions were more kely to occur,1,0.581998884677887
LUMIZYME,fluid overload,with higher infusion rates Some patients who were pretreated with antihistamines,0,0.6383994221687317
LUMIZYME,Hypersensitivity Reactions,most frequently rted adverse reactions (>= in clinical trials,1,0.6342184543609619
LUMIZYME,Hypersensitivity Reactions,with higher infusion rates Some patients who were pretreated with antihistamines,0,0.6607123613357544
LUMIZYME,Hypersensitivity Reactions,trials were hypersensitivity,0,0.8121812343597412
LUMIZYME,anaphylaxis,ials were h,1,0.531240701675415
LUMIZYME,anaphylaxis,trials were hypersensitivity,0,0.7092201709747314
LUMIZYME,anaphylaxis,in clinical ials were h,1,0.5474560856819153
LUMIZYME,anaphylaxis,and included anaphylaxis rash pyrexia flushingfeeling hot,0,0.8195499181747437
LUMIZYME,anaphylaxis,ypersensitivity reactions and included anaphylaxis rash pyrexia flushingfeeling hot,0,0.8100517988204956
LUMIZYME,anaphylaxis,reactions in clinical ials,1,0.6764233708381653
LUMIZYME,anaphylaxis,reported,0,0.5321630239486694
LUMIZYME,anaphylaxis,frequently reported,0,0.5169191956520081
LUMIZYME,hypersensitivity reactions,and i,1,0.4758564829826355
LUMIZYME,hypersensitivity reactions,reactions and i ncluded anaphylaxis rash pyrexia flushingfeeling,1,0.7821954488754272
LUMIZYME,hypersensitivity reactions,were hypers,0,0.6093871593475342
LUMIZYME,Immune-Mediated Reactions,myalgia To report SPECTED ADVERSE REACTIONS contact Genzyme at,1,0.6309940218925476
LUMIZYME,Immune-Mediated Reactions,were hypers,0,0.5262344479560852
LUMIZYME,Immune-Mediated Reactions,fatigue,0,0.4943198561668396
LUMIZYME,Immune-Mediated Reactions,ADVERSE REACTIONS contact Genzyme,1,0.6467324495315552
LUMIZYME,Immune-Mediated Reactions,report SPECTED ADVERSE,1,0.5592766404151917
LUMIZYME,Immune-Mediated Reactions,SPECTED ADVERSE REACTIONS contact Genzyme,1,0.647769033908844
LUMIZYME,Immune-Mediated Reactions,or wwwfdagovmedwatch,0,0.5112756490707397
LUMIZYME,Immune-Mediated Reactions,ADVERSE REACTIONS contact Genzyme at or,1,0.6532435417175293
LUMIZYME,acute cardiorespiratory failure,trials of a drug canno,1,0.5329415798187256
LUMIZYME,acute cardiorespiratory failure,inical,0,0.4987444281578064
LUMIZYME,acute cardiorespiratory failure,in,0,0.48575490713119507
LUMIZYME,acute cardiorespiratory failure,drug canno,1,0.4870847463607788
LUMIZYME,acute cardiorespiratory failure,drug canno t be directly,1,0.48932093381881714
LUMIZYME,acute cardiorespiratory failure,clinical,1,0.5714380741119385
LUMIZYME,acute cardiorespiratory failure,rates observed in clinical,1,0.5955191254615784
LUMIZYME,acute cardiorespiratory failure,clinical trials of a drug canno t be directly compared to,1,0.5167784690856934
LUMIZYME,acute cardiorespiratory failure,be directly compared to,0,0.4805149435997009
LUMIZYME,acute cardiorespiratory failure,drug canno t,1,0.5162925720214844
LUMIZYME,Cardiac Arrhythmia,Precautions In clinical,0,0.5546942353248596
LUMIZYME,Sudden Cardiac Death,the labeling Anaphylaxis hypersensitivity rea,1,0.49355348944664
LUMIZYME,Sudden Cardiac Death,Anaphylaxis hypersensitivity rea ctions seeWarnings and,1,0.5253644585609436
LUMIZYME,Sudden Cardiac Death,most common adverse reacti,0,0.5183857679367065
LUMIZYME,Sudden Cardiac Death,hypersensitivity rea ctions seeWarnings and Precautions In,1,0.5056343078613281
LUMIZYME,Sudden Cardiac Death,and Precautions In clinical trials the most common,0,0.5247746109962463
LUMIZYME,Sudden Cardiac Death,hypersensitivity rea,1,0.4800187349319458
LUMIZYME,Anaphylaxis,hot urticaria headache hyperhidrosis,0,0.6390329003334045
LUMIZYME,Anaphylaxis,"nausea, cou gh",1,0.5983179807662964
LUMIZYME,Anaphylaxis,"urticaria headache nausea, cou",1,0.683573305606842
LUMIZYME,Anaphylaxis,included,0,0.5414680242538452
LUMIZYME,Anaphylaxis,discomfort dizziness muscle,0,0.5435367822647095
LUMIZYME,hypersensitivity reactions,cough ecreased oxygen saturation tachycardia tachypnea,1,0.5627878904342651
LUMIZYME,hypersensitivity reactions,discomfort dizziness muscle,0,0.5036596059799194
LUMIZYME,hypersensitivity reactions,d,0,0.4869401454925537
LUMIZYME,hypersensitivity reactions,oxygen saturation tachycardia tachypnea chest,1,0.536069393157959
LUMIZYME,hypersensitivity reactions,nausea cough ecreased oxygen saturation tachycardia tachypnea chest discomfort,1,0.5615850687026978
LUMIZYME,hypersensitivity reactions,hyperhidrosis nausea cough ecreased oxygen,1,0.623552680015564
LUMIZYME,hypersensitivity reactions,hyperhidrosis nausea cough ecreased oxygen saturation,1,0.6266292333602905
LUMIZYME,hypersensitivity reactions,headache hyperhidrosis nausea cough ecreased oxygen,1,0.6353820562362671
LUMIZYME,anaphylactic shock,"rigors, tremor, vomiting",1,0.5670405030250549
LUMIZYME,anaphylactic shock,", rigors, tremor, vomiting fatigue",1,0.5346581935882568
LUMIZYME,anaphylactic shock,blood pressure,0,0.6275098323822021
LUMIZYME,anaphylactic shock,vomiting fatigue and myalgia Clinical Trials in,0,0.5411384105682373
LUMIZYME,anaphylactic shock,"pressure , rigors, tremor,  vomiting",1,0.6052098274230957
LUMIZYME,anaphylactic shock,",",1,0.5303857326507568
LUMIZYME,anaphylactic shock,erythema,0,0.6070326566696167
LUMIZYME,anaphylactic shock,in,0,0.5101061463356018
LUMIZYME,cardiac arrest,"miting,",1,0.4558302164077759
LUMIZYME,cardiac arrest,"pallor rigors tremor miting,",1,0.5045182704925537
LUMIZYME,cardiac arrest,JuvenileOnset Pompe Disease Tw,0,0.47464025020599365
LUMIZYME,cardiac arrest,"miting, fatigu e and",1,0.46722811460494995
LUMIZYME,cardiac arrest,myalgia Clinical Trials in InfantileOnset and JuvenileOnset Pompe Disease,0,0.46544477343559265
LUMIZYME,respiratory arrest,pallor rigors tremor vomiting and myalgia.,1,0.4806586503982544
LUMIZYME,respiratory arrest,and myalgia. Clinical Trials in InfantileOnset,1,0.4861429035663605
LUMIZYME,respiratory arrest,rigors tremor vomiting,0,0.5565872192382812
LUMIZYME,respiratory arrest," and myalgia.
 

  Clinical Trials in",1,0.4705716669559479
LUMIZYME,respiratory arrest,"pallor rigors tremor vomiting  and myalgia.
 

  Clinical Trials in InfantileOnset and",1,0.49912023544311523
LUMIZYME,respiratory arrest,"tremor vomiting  and myalgia.
 

  Clinical",1,0.48989197611808777
LUMIZYME,respiratory arrest,in,0,0.5122215747833252
LUMIZYME,respiratory arrest,and,0,0.48610860109329224
LUMIZYME,respiratory arrest,"rigors tremor vomiting  and myalgia.
 

  Clinical Trials in InfantileOnset and",1,0.5128961205482483
LUMIZYME,respiratory distress,pallor rigors tremor vomiting fatigue and,0,0.5824394822120667
LUMIZYME,respiratory distress,vomiting fatigue and,0,0.6080541610717773
LUMIZYME,respiratory distress,and   Clinical Trials in InfantileOnset and JuvenileOnset,1,0.513096272945404
LUMIZYME,respiratory distress,tremor vomiting fatigue and Clinical Trials,1,0.567188024520874
LUMIZYME,respiratory distress,Clinical Trials in,1,0.5297024250030518
LUMIZYME,hypoxia,and JuvenileOnset Pompe Disease,0,0.5498979091644287
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe,1,0.5434085130691528
LUMIZYME,hypoxia,in nfantil,1,0.5334675312042236
LUMIZYME,hypoxia,Disease Two multicenter openlabel clinical,0,0.5571881532669067
LUMIZYME,hypoxia,tremor vomiting fatigue and myalgia,0,0.5311592817306519
LUMIZYME,hypoxia,JuvenileOnset Pompe Disease Two multicenter,0,0.547964870929718
LUMIZYME,hypoxia,multicenter,0,0.5520781874656677
LUMIZYME,hypoxia,nfantil eOnset,1,0.5163402557373047
LUMIZYME,hypoxia,pallor rigors tremor vomiting fatigue and myalgia Clinical Trials in I,0,0.5813193321228027
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe Disease,1,0.5593907833099365
LUMIZYME,apnea,vomiting fatigue,0,0.5612095594406128
LUMIZYME,apnea,Disease Two multicenter openlabel clinical,0,0.5119329690933228
LUMIZYME,apnea,Trials in Onset and JuvenileOnset,1,0.4945513606071472
LUMIZYME,apnea,Onset,1,0.574779212474823
LUMIZYME,apnea,Onset and JuvenileOnset Pompe,1,0.539730429649353
LUMIZYME,dyspnea,nd,1,0.5470435619354248
LUMIZYME,dyspnea,in InfantileOnset nd Juve,1,0.5186349153518677
LUMIZYME,dyspnea,Clinical Trials in InfantileOnset nd Juve,1,0.54596346616745
LUMIZYME,dyspnea,in InfantileOnset nd Juve nileOnset Pompe Disease,1,0.5468199253082275
LUMIZYME,dyspnea,Clinical Trials in InfantileOnset nd,1,0.5429489016532898
LUMIZYME,dyspnea,Disease Two multicenter openlabel clinical trials were conducted,0,0.5457923412322998
LUMIZYME,dyspnea,Clinical Trials in InfantileOnset a,0,0.5388009548187256
LUMIZYME,dyspnea,nd Juve nileOnset Pompe,1,0.501139760017395
LUMIZYME,dyspnea,openlabel clinical trials were,0,0.5115340948104858
LUMIZYME,bradycardia,multicenter openlabel clinical trials were conducted in,0,0.5191948413848877
LUMIZYME,bradycardia,le-Onset Po,1,0.4699319899082184
LUMIZYME,bradycardia,and le-Onset Po mpe Disease,1,0.485297828912735
LUMIZYME,bradycardia,clinical trials were conducted in infantileonset P,0,0.492937833070755
LUMIZYME,bradycardia,le-Onset Po mpe,1,0.4831039309501648
LUMIZYME,bradycardia,Trials in InfantileOnset and le-Onset,1,0.5195733308792114
LUMIZYME,bradycardia,InfantileOnset and le-Onset Po mpe Disease Two multicenter,1,0.4798107445240021
LUMIZYME,bradycardia,and le-Onset Po,1,0.476360559463501
LUMIZYME,bradycardia,were conducted in,0,0.5278387069702148
LUMIZYME,bradycardia,and le-Onset,1,0.5178092122077942
LUMIZYME,tachycardia,vomiting,0,0.49183595180511475
LUMIZYME,tachycardia,InfantileOnset and JuvenileOnset e,1,0.5431869029998779
LUMIZYME,tachycardia,and JuvenileOnset e Disease,1,0.5621683597564697
LUMIZYME,tachycardia,JuvenileOnset e Disease  ,1,0.5686944723129272
LUMIZYME,tachycardia,in InfantileOnset and JuvenileOnset e Disease,1,0.5592626929283142
LUMIZYME,tachycardia,Clinical Trials in InfantileOnset and,0,0.5481517910957336
LUMIZYME,tachycardia,clinical trials were conducted in infantileonset Pompe disease,0,0.5224313139915466
LUMIZYME,tachycardia,e Disease Two multicenter openlabel,1,0.5609201192855835
LUMIZYME,tachycardia,and JuvenileOnset e Disease   Two multicenter openlabel,1,0.5322345495223999
LUMIZYME,bronchospasm,Clinical,0,0.531324565410614
LUMIZYME,bronchospasm,infantileonset Pompe disease patients,0,0.4270519018173218
LUMIZYME,bronchospasm,"JuvenileOnset Pompe 

 Two multi center openlabel clinical trials were",1,0.5191680192947388
LUMIZYME,bronchospasm,in infantileonset Pompe disease patients ages,0,0.4084954857826233
LUMIZYME,bronchospasm,Pompe,0,0.45610350370407104
LUMIZYME,bronchospasm,"

 Two multi center openlabel",1,0.45609015226364136
LUMIZYME,bronchospasm,Two multi center openlabel,1,0.45609015226364136
LUMIZYME,bronchospasm,"and JuvenileOnset Pompe 

 Two multi center openlabel clinical",1,0.5074672102928162
LUMIZYME,throat tightness,JuvenileOnset,0,0.4491274654865265
LUMIZYME,throat tightness,"nter, open-label clinical trials were",1,0.48479121923446655
LUMIZYME,throat tightness,in infantileonset Pompe,0,0.4791765809059143
LUMIZYME,throat tightness,"JuvenileOnset Pompe Disease Two nter, open-label",1,0.44178056716918945
LUMIZYME,throat tightness,in InfantileOnset and JuvenileOnset Pompe,0,0.4656628370285034
LUMIZYME,throat tightness,Pompe Disease Two multice,0,0.45407071709632874
LUMIZYME,hypotension,linical tri,1,0.45854833722114563
LUMIZYME,hypotension,linical tri als were conducted,1,0.5180454850196838
LUMIZYME,hypotension,linical tri als were conducted in infantileonset,1,0.5121904611587524
LUMIZYME,hypotension,Trials in InfantileOnset and,0,0.5233858823776245
LUMIZYME,hypotension,disease patients ages month to years,0,0.5268236398696899
LUMIZYME,hypotension,linical tri als,1,0.5068585872650146
LUMIZYME,hypotension,linical tri als were,1,0.49441975355148315
LUMIZYME,hypotension,Disease Two multicenter openlabel linical tri als were,1,0.4987662732601166
LUMIZYME,angioedema,openlabel clinical s were con,1,0.5353309512138367
LUMIZYME,angioedema,s were con,1,0.4907040596008301
LUMIZYME,angioedema,patients ages month to years old,0,0.532728374004364
LUMIZYME,lip swelling,patients ages month to years old Approximately half,0,0.535161018371582
LUMIZYME,lip swelling,-onset Pompe disease patients ages,1,0.4647098183631897
LUMIZYME,lip swelling,years old Approximately,0,0.4893344044685364
LUMIZYME,lip swelling,-onset Pompe disease patients,1,0.4692640006542206
LUMIZYME,lip swelling,in -onset,1,0.533510684967041
LUMIZYME,lip swelling,disease,0,0.5629382133483887
LUMIZYME,periorbital edema,sease Two,0,0.4963628053665161
LUMIZYME,periorbital edema,"isease patients,  ages month to years old",1,0.5704289674758911
LUMIZYME,periorbital edema,"conducted in infantileonset Pompe isease patients,",1,0.5416013598442078
LUMIZYME,periorbital edema,sease Two multicenter openlabel clinical trials were conducted in infantileonset Pompe d,0,0.5404399633407593
LUMIZYME,periorbital edema,"infantileonset Pompe isease patients,  ages month to years old",1,0.5460201501846313
LUMIZYME,periorbital edema,Pompe d,0,0.5099663734436035
LUMIZYME,periorbital edema,openlabel clinical trials were conducted,0,0.5245665907859802
LUMIZYME,periorbital edema,"infantileonset Pompe isease patients,",1,0.5473452806472778
LUMIZYME,periorbital edema,the patients were male Patients,0,0.5190483331680298
LUMIZYME,face edema,month to years,1,0.4397634267807007
LUMIZYME,face edema,years old Approximately half of the patients were male Patients,0,0.5125972032546997
LUMIZYME,face edema,Pompe,0,0.5237051248550415
LUMIZYME,face edema,trials were conducted in infantileonset Pompe,0,0.5350753664970398
LUMIZYME,face edema,the patients were male,0,0.5310635566711426
LUMIZYME,face edema,were treated,0,0.5519351363182068
LUMIZYME,face edema,patients ages,0,0.5434625148773193
LUMIZYME,face edema,month to years old Approximately half,1,0.510811448097229
LUMIZYME,face edema,month to,1,0.45218002796173096
LUMIZYME,face edema,the patients were male Patients were,0,0.5418734550476074
LUMIZYME,face edema,Patients were treated,0,0.5604853630065918
LUMIZYME,face edema,month to years old Approximately,1,0.5048036575317383
LUMIZYME,face edema,month to years old Approximately half of,1,0.5127074718475342
LUMIZYME,face edema,clinical trials were conducted in infantileonset Pompe disease,0,0.5297560691833496
LUMIZYME,face edema,disease patients month,1,0.5265617966651917
LUMIZYME,face edema,month to years old,1,0.498329222202301
LUMIZYME,urticaria,month to rs old. A,1,0.4818422496318817
LUMIZYME,urticaria,male Patients were treated with,0,0.4941618740558624
LUMIZYME,urticaria,treated with,0,0.5566986203193665
LUMIZYME,urticaria,to rs old. A,1,0.4992288053035736
LUMIZYME,urticaria,with alglucosidase alfa,0,0.5131462812423706
LUMIZYME,urticaria,month to rs old. A pproximately half,1,0.5025286674499512
LUMIZYME,urticaria,rs old. A,1,0.4927038252353668
LUMIZYME,urticaria,month to rs old. A pproximately half of the,1,0.5178527235984802
LUMIZYME,urticaria,month to rs old.,1,0.4825018048286438
LUMIZYME,urticaria,in infantileonset Pompe disease patients ages month,0,0.4716501235961914
LUMIZYME,urticaria,patients ages month to rs old.,1,0.4818485379219055
LUMIZYME,urticaria,rs old. A pproximately half of,1,0.5207672119140625
LUMIZYME,urticaria,pproximately half,0,0.5067509412765503
LUMIZYME,urticaria,to rs old. A pproximately,1,0.5415273904800415
LUMIZYME,chest discomfort,Pompe disease patients ages month to years old Approximately half,0,0.4473443031311035
LUMIZYME,chest discomfort,periods ranging from,0,0.5125219821929932
LUMIZYME,chest discomfort,Approximately half of the were male. Patie nts,1,0.4812115430831909
LUMIZYME,chest discomfort,half of the were male. Patie,1,0.4717453420162201
LUMIZYME,chest discomfort,the were male. Patie nts were treated with alglucosidase,1,0.46671411395072937
LUMIZYME,chest discomfort,patients,0,0.5480546951293945
LUMIZYME,chest discomfort,were male. Patie nts were treated,1,0.5457544326782227
LUMIZYME,chest discomfort,of the were male. Patie nts were,1,0.49915578961372375
LUMIZYME,chest discomfort,male. Patie nts were treated with,1,0.5548403263092041
LUMIZYME,chest discomfort,treated with alglucosidase alfa or,0,0.4310488998889923
LUMIZYME,wheezing,old Approximately half of the patients were male,0,0.4783321022987366
LUMIZYME,wheezing,wer,0,0.5502179861068726
LUMIZYME,wheezing,alglucosidase alfa or mgkg every other week for periods ranging from to weeks,0,0.5131266117095947
LUMIZYME,wheezing,Patients,0,0.5143405199050903
LUMIZYME,wheezing,the patients were male,0,0.4917137026786804
LUMIZYME,wheezing,patients were male Patients e treate,1,0.5052260160446167
LUMIZYME,wheezing,of,0,0.5287473201751709
LUMIZYME,wheezing,patients were male Patients e treate d,1,0.5075895190238953
LUMIZYME,tachypnea,Patients were,0,0.5338934659957886
LUMIZYME,tachypnea,the patients were,0,0.5403337478637695
LUMIZYME,tachypnea,or mgkg every other week for periods ranging,0,0.5226032137870789
LUMIZYME,tachypnea,with algl ucosidase alfa or mgkg every,1,0.5046154260635376
LUMIZYME,tachypnea,were male Patients were with algl,1,0.5436906814575195
LUMIZYME,tachypnea,to weeks mean,0,0.501477837562561
LUMIZYME,tachypnea,every other week for periods,0,0.5135200023651123
LUMIZYME,cyanosis,weeks,0,0.4897800385951996
LUMIZYME,cyanosis,years old Approximately half of the patients were male,0,0.4802406132221222
LUMIZYME,cyanosis,osidase  alfa or mgkg every,1,0.4993119239807129
LUMIZYME,cyanosis,osidase  alfa or mgkg,1,0.5049004554748535
LUMIZYME,cyanosis,were male Patients,0,0.5005759000778198
LUMIZYME,cyanosis,mgkg every other week for periods ranging from to,0,0.5054295659065247
LUMIZYME,decreased oxygen saturation,with alglucosidase fa 20 or 40 mg/kg every oth er week,1,0.5143038630485535
LUMIZYME,decreased oxygen saturation,mgkg every other week for periods ranging from to,0,0.49895453453063965
LUMIZYME,decreased oxygen saturation,were treated with alglucosidase fa 20 or 40 mg/kg every oth er week for periods ranging,1,0.5040969848632812
LUMIZYME,decreased oxygen saturation,with alglucosidase fa 20 or 40 mg/kg every oth er week for periods ranging,1,0.4987308979034424
LUMIZYME,decreased oxygen saturation,20 or 40 mg/kg every oth er week for periods ranging,1,0.5244526267051697
LUMIZYME,decreased oxygen saturation,treated with alglucosidase fa 20,1,0.538936972618103
LUMIZYME,decreased oxygen saturation,treated with alglucosidase fa,1,0.5074992179870605
LUMIZYME,convulsions,most serious,0,0.5386601686477661
LUMIZYME,convulsions,mgkg every  week for p eriods ranging from,1,0.505486011505127
LUMIZYME,convulsions,week,1,0.5163790583610535
LUMIZYME,convulsions,alglucosidase alfa or,0,0.47046971321105957
LUMIZYME,convulsions,for p eriods ranging from to weeks,1,0.5517710447311401
LUMIZYME,convulsions,week for p,1,0.46777403354644775
LUMIZYME,convulsions,weeks mean weeks The most serious,0,0.5553251504898071
LUMIZYME,pruritus,from to weeks mean weeks The most serious adverse reactions,0,0.6144475340843201
LUMIZYME,pruritus,other week for iods ran,1,0.48572468757629395
LUMIZYME,pruritus,for iods ran,1,0.48973548412323
LUMIZYME,pruritus,iods ran ging,1,0.5038577318191528
LUMIZYME,hyperhidrosis,to 106 we eks mean weeks,1,0.4793599247932434
LUMIZYME,hyperhidrosis,periods ranging m 1 to 106 we eks,1,0.5535106658935547
LUMIZYME,hyperhidrosis,1 to 106 we,1,0.46508121490478516
LUMIZYME,hyperhidrosis,weeks,0,0.4778282046318054
LUMIZYME,hyperhidrosis,periods ranging m 1 to 106,1,0.5585780739784241
LUMIZYME,hyperhidrosis,m 1 to 106 we eks mean weeks The,1,0.4952491521835327
LUMIZYME,hyperhidrosis,with alglucosidase,0,0.4923965334892273
LUMIZYME,nausea,periods ranging from to s (mea n,1,0.5163196325302124
LUMIZYME,nausea,with alglucosidase,0,0.5214973092079163
LUMIZYME,nausea,The most serious adverse reactions reported with alglucosidase alfa treatment incl,0,0.5681165456771851
LUMIZYME,nausea,week,0,0.5274800658226013
LUMIZYME,nausea,weeks The most serious adverse reactions reported with,0,0.6079204082489014
LUMIZYME,nausea,ranging from to s (mea,1,0.5306898355484009
LUMIZYME,nausea,adverse reactions reported with alglucosidase,0,0.571453332901001
LUMIZYME,dizziness,alglucosidase,0,0.45302221179008484
LUMIZYME,dizziness,ranging from,0,0.5265587568283081
LUMIZYME,dizziness,serious adverse reactions reported with,0,0.5588504076004028
LUMIZYME,dizziness,alfa,0,0.48910409212112427
LUMIZYME,dizziness,ranging from to weeks  61 weeks,1,0.4886881709098816
LUMIZYME,dizziness,61 weeks The most serious,1,0.5110093355178833
LUMIZYME,dizziness,61 weeks,1,0.47377264499664307
LUMIZYME,dizziness,reported with alglucosidase alfa treatment,0,0.5194722414016724
LUMIZYME,dizziness,treatment included,0,0.5480674505233765
LUMIZYME,hypertension,"to weeks mean 



 The mos t serious adverse reactions reported",1,0.5316599607467651
LUMIZYME,hypertension,treatment included,0,0.5974147915840149
LUMIZYME,hypertension,adverse reactions reported with alglucosidase alfa treatment included anaphylaxis and acut,0,0.49102672934532166
LUMIZYME,increased blood pressure,serious adverse reactio,1,0.5951204895973206
LUMIZYME,increased blood pressure,serious adverse reactio ns reported,1,0.5908966660499573
LUMIZYME,increased blood pressure,weeks The serious adverse reactio,1,0.5912108421325684
LUMIZYME,increased blood pressure,to weeks mean weeks The most,0,0.4488978981971741
LUMIZYME,flushing,periods ranging from,0,0.5295639038085938
LUMIZYME,flushing,The most serious adverse  reporte,1,0.5041694641113281
LUMIZYME,flushing,with alglucosidase alfa treatment included anaphylaxis and,0,0.5356608629226685
LUMIZYME,feeling hot,with alglu cosidase alfa treatment included,1,0.48896753787994385
LUMIZYME,feeling hot,serious adverse reactions  with alglu cosidase alfa,1,0.5084364414215088
LUMIZYME,feeling hot,most serious adverse reactions  with alglu cosidase,1,0.5056580305099487
LUMIZYME,erythema,sidase a lfa treatment,1,0.5428729057312012
LUMIZYME,erythema,most,0,0.4752783179283142
LUMIZYME,pallor,treatme,0,0.5219300985336304
LUMIZYME,pallor,nt inc luded anaphylaxis and,1,0.4657977819442749
LUMIZYME,pallor,with alglucosidase alfa nt inc luded anaphylaxis and,1,0.43784311413764954
LUMIZYME,pallor,alfa nt inc luded anaphylaxis and,1,0.4584391415119171
LUMIZYME,pallor,nt inc luded,1,0.5023036599159241
LUMIZYME,pallor,failure The,0,0.49652934074401855
LUMIZYME,restlessness,cute cardior,1,0.4885355830192566
LUMIZYME,restlessness,anaphylaxis and cute,1,0.43379196524620056
LUMIZYME,restlessness,intervention in,0,0.5258739590644836
LUMIZYME,restlessness,treatment,0,0.5297224521636963
LUMIZYME,restlessness,cute,1,0.4820200800895691
LUMIZYME,restlessness,included anaphylaxis and cute cardior,1,0.44523748755455017
LUMIZYME,restlessness,anaphylaxis and cute cardior,1,0.44369807839393616
LUMIZYME,nervousness,treatment included anaphylaxis and acute,0,0.5755854249000549
LUMIZYME,nervousness,and acute cardiores,0,0.5421289205551147
LUMIZYME,nervousness,requiring intervention in clinical trials were hypersen,0,0.5682234764099121
LUMIZYME,nervousness,anaphylaxis and acute piratory,1,0.5707482695579529
LUMIZYME,headache,"ure.



 The most common adverse reactions",1,0.5744410753250122
LUMIZYME,headache,"ure.



 The",1,0.5406671166419983
LUMIZYME,headache,"acute cardiorespiratory ure.



 The most common",1,0.5429540872573853
LUMIZYME,headache,"ure.



 The most common",1,0.5319741368293762
LUMIZYME,back pain,most c ommon adverse reactions requiring intervention,1,0.541231632232666
LUMIZYME,back pain,treatment included anaphylaxis and,0,0.4825611114501953
LUMIZYME,back pain,most c ommon adverse reactions requiring,1,0.5351415872573853
LUMIZYME,back pain,he most c,1,0.42380088567733765
LUMIZYME,back pain,he most c ommon,1,0.4347565770149231
LUMIZYME,back pain,ommon adverse reactions requiring intervention in clinical trials were hypersensitivity reactions,0,0.49276381731033325
LUMIZYME,paresthesia,most adverse,1,0.5519570112228394
LUMIZYME,paresthesia,cardiorespiratory failure The most adverse,1,0.5036858916282654
LUMIZYME,paresthesia,intervention in clinical trials were hypersensitivity reactions occurring,0,0.5403249263763428
LUMIZYME,paresthesia,common,0,0.5266990661621094
LUMIZYME,paresthesia,clinical trials were hypersensitivity reactions occurring in of,0,0.53510582447052
LUMIZYME,paresthesia,The most adverse rea ctions requiring intervention in,1,0.5381792783737183
LUMIZYME,paresthesia,acute,0,0.586341381072998
LUMIZYME,paresthesia,cardiorespiratory failure The most adverse rea ctions requiring intervention in clinical,1,0.49063897132873535
LUMIZYME,paresthesia,failure The most adverse rea,1,0.49640944600105286
LUMIZYME,Immune-mediated cutaneous reactions,ythematous rash macular and maculopapular,0,0.6538875102996826
LUMIZYME,Immune-mediated cutaneous reactions,Adverse Rash (including rash er,1,0.69969642162323
LUMIZYME,pyrexia,ensionIncreased Blood  Decrea,1,0.6163751482963562
LUMIZYME,pyrexia,Adverse Rash (including rash er,1,0.5727657675743103
LUMIZYME,pyrexia,sed,0,0.46072033047676086
LUMIZYME,pyrexia,sed Oxygen,0,0.48572513461112976
LUMIZYME,pyrexia,Pressure,0,0.5325169563293457
LUMIZYME,pyrexia,Blood  Decrea sed,1,0.5620152950286865
LUMIZYME,pyrexia, Decrea sed Oxygen Saturation,1,0.5328879356384277
LUMIZYME,pyrexia, Decrea sed Oxygen,1,0.5182738304138184
LUMIZYME,Acute cardiorespiratory failure,n infantile-onset Pompe disease patients treated in,1,0.5297709703445435
LUMIZYME,Acute cardiorespiratory failure,sed,0,0.48323482275009155
LUMIZYME,Acute cardiorespiratory failure,observed n,1,0.4926917552947998
LUMIZYME,Acute cardiorespiratory failure,Additional hypersensitivity reactions observed n,1,0.5095813274383545
LUMIZYME,Acute cardiorespiratory failure,infantile-onset Pompe disease patients,1,0.5362190008163452
LUMIZYME,Acute cardiorespiratory failure,expanded access programs,0,0.5126370787620544
LUMIZYME,Acute cardiorespiratory failure,Pompe disease patients treated in other clinical,1,0.5477281212806702
LUMIZYME,fluid overload,", irritability retching increased",1,0.564863920211792
LUMIZYME,fluid overload,"alfa included livedo , irritability",1,0.5611481666564941
LUMIZYME,fluid overload,", irritability retching increased lacrimation ventricular extrasystoles",1,0.5964133739471436
LUMIZYME,fluid overload,"alfa included livedo , irritability retching increased lacrimation",1,0.6112960577011108
LUMIZYME,fluid overload,"alglucosidase alfa included livedo , irritability retching increased",1,0.5888006687164307
LUMIZYME,fluid overload,and expanded access programs with alglucosidase alfa included livedo reticularis,0,0.5596644878387451
LUMIZYME,Ventricular arrhythmias,18 years with a m edian duration of treatment of,1,0.5215672254562378
LUMIZYME,Ventricular arrhythmias,with a m edian duration of,1,0.4980015456676483
LUMIZYME,Ventricular arrhythmias,alfa Patients were  1 to 18 years with a m edian duration of treatment,1,0.5389288067817688
LUMIZYME,bradycardia,years with a  duration o f treatment,1,0.5006597638130188
LUMIZYME,bradycardia,with a m edian duration of,1,0.5396400690078735
LUMIZYME,bradycardia,a duration,1,0.5716666579246521
LUMIZYME,bradycardia,days No,0,0.5211101174354553
LUMIZYME,cardiac arrest,duration of treatment 437 days (rang e,1,0.48971322178840637
LUMIZYME,cardiac arrest,days No,0,0.47640347480773926
LUMIZYME,cardiac arrest,437 days (rang,1,0.4614904522895813
LUMIZYME,cardiac arrest,Patients were aged to years with a median duration of treatment of,0,0.5017068982124329
LUMIZYME,cardiac arrest,of treatment 437 days (rang e to days,1,0.4745292663574219
LUMIZYME,cardiac arrest,a median duration of treatment,0,0.493561327457428
LUMIZYME,cardiac arrest,duration of treatment 437 days (rang,1,0.49179935455322266
LUMIZYME,cardiac arrest,e to days No new safety findings were,0,0.5312818288803101
LUMIZYME,cardiac arrest,437 days (rang e to days No,1,0.4619409739971161
LUMIZYME,cardiac arrest,median duration of treatment 437 days (rang,1,0.48572924733161926
LUMIZYME,cardiac arrest,of treatment 437,1,0.5057416558265686
LUMIZYME,death,to 4,1,0.5345196723937988
LUMIZYME,death,findings were,0,0.5484336614608765
LUMIZYME,death,treatment of days  to 4 days,1,0.48384585976600647
LUMIZYME,death,to,0,0.5820343494415283
LUMIZYME,death,to 4 days No new safety,1,0.4949326813220978
LUMIZYME,reduced clinical efficacy,years of age and the youngest placebotreated patient was years of,0,0.5676734447479248
LUMIZYME,reduced clinical efficacy,patients were,0,0.6690062284469604
LUMIZYME,reduced clinical efficacy,nai,0,0.4840565621852875
LUMIZYME,reduced clinical efficacy,to enzyme replacement therapy,1,0.5772607922554016
LUMIZYME,reduced clinical efficacy,All patients were ve to enzyme,1,0.6041840314865112
LUMIZYME,reduced clinical efficacy,ve to enzyme replacement  therapy Patients,1,0.5886305570602417
LUMIZYME,loss of motor function,received al glucosidase alfa or placebo,1,0.5092068910598755
LUMIZYME,loss of motor function,ratio and received al glucosidase alfa or,1,0.5144684314727783
LUMIZYME,death,every other week,1,0.5008044838905334
CERDELGA,fatigue,most common adverse reactions fatigue headache nausea diarrhea,1,0.6399379372596741
CERDELGA,fatigue,every other week,1,0.5494430661201477
CERDELGA,fatigue,fatigue headache nausea diarrhea back,1,0.7819837331771851
CERDELGA,fatigue,common adverse reactions fatigue headache nausea,1,0.7172642946243286
CERDELGA,fatigue,most common adverse reactions fatigue,1,0.7692773342132568
CERDELGA,fatigue,diarrhea back pain pain in extremities and upper abdominal,0,0.5320647358894348
CERDELGA,fatigue,fatigue,1,1.0
CERDELGA,fatigue,reactions,0,0.5019875168800354
CERDELGA,fatigue,adverse reactions,0,0.5466587543487549
CERDELGA,headache,common adverse reactions are headache nausea diarrhea,1,0.6752297878265381
CERDELGA,headache,adverse reactions,0,0.5783864259719849
CERDELGA,headache,headache nausea diarrhea back,1,0.7721348404884338
CERDELGA,headache,headache nausea diarrhea back pain,1,0.7685599327087402
CERDELGA,headache,are headache nausea diarrhea back,1,0.7398085594177246
CERDELGA,headache,adverse reactions are headache nausea diarrhea back pain pain,1,0.6768261194229126
CERDELGA,headache,in extremities,0,0.5053738951683044
CERDELGA,headache,diarrhea back pain pain in extremities and upper abdominal pain To report,0,0.5682734251022339
CERDELGA,headache,headache nausea,1,0.8417852520942688
CERDELGA,nausea,ADVERSE REACTIONS EXCERPT,0,0.6185684204101562
CERDELGA,nausea,fatigue nausea,1,0.8716872930526733
CERDELGA,nausea,To,0,0.5347014665603638
CERDELGA,nausea,nausea,1,1.0
CERDELGA,diarrhea,most common adverse reactions are fatigue headache,0,0.5462514758110046
CERDELGA,diarrhea,diarrhea back pain pain,1,0.7858574390411377
CERDELGA,diarrhea,diarrhea back,1,0.8574234247207642
CERDELGA,back pain,fatigue headache nausea back,1,0.6404099464416504
CERDELGA,back pain,back pain,1,1.0
CERDELGA,back pain,headache nausea back,1,0.6081812381744385
CERDELGA,back pain,diarrhea,0,0.5469861030578613
CERDELGA,back pain,fatigue headache nausea back pain,1,0.7574244737625122
CERDELGA,back pain,reactions are fatigue headache nausea,0,0.5749197602272034
CERDELGA,back pain,and upper abdominal pain To report SUSPECTED,0,0.6227253675460815
CERDELGA,back pain,nausea back pain,1,0.8290771245956421
CERDELGA,pain in extremities,back pain in extremities,1,0.9110747575759888
CERDELGA,pain in extremities,nausea back pain,1,0.6254020929336548
CERDELGA,pain in extremities,upper abdominal pain To report SUSPECTED,0,0.6174271702766418
CERDELGA,pain in extremities,contact,0,0.4713127017021179
CERDELGA,upper abdominal pain,diarrhea back pain,0,0.620130717754364
CERDELGA,upper abdominal pain,upper abdominal pain To,1,0.9724953770637512
CERDELGA,upper abdominal pain,extremities upper abdominal,1,0.8002789616584778
CERDELGA,upper abdominal pain,pain in extremities upper abdominal pain To report SUSPECTED ADVERSE,1,0.8373558521270752
CERDELGA,upper abdominal pain,abdominal pain To report SUSPECTED,1,0.7887085676193237
CERDELGA,upper abdominal pain,are,0,0.5038366317749023
CERDELGA,upper abdominal pain,report SUSPECTED ADVERSE REACTIONS contact Genzyme Corporation at or,0,0.5101454257965088
CERDELGA,upper abdominal pain,contact,0,0.4764385223388672
CERDELGA,upper abdominal pain,abdominal pain To report SUSPECTED ADVERSE REACTIONS,1,0.731298565864563
CERDELGA,upper abdominal pain,pain pain in extremities upper,1,0.7230762243270874
CERDELGA,headache,across Trials and were,0,0.4839872717857361
CERDELGA,nausea,nausea diarrhea,1,0.8622832298278809
CERDELGA,nausea,of the GD,0,0.4784613251686096
CERDELGA,nausea,across Trials and were fatigue,0,0.5934133529663086
CERDELGA,nausea,nausea diarrhea back pain pain in,1,0.7416713237762451
CERDELGA,diarrhea,nausea diarrhea,1,0.8369524478912354
CERDELGA,diarrhea,were fatigue headache diarrhea back pain pain in,1,0.6954076290130615
CERDELGA,diarrhea,the GD patients,0,0.5590221881866455
CERDELGA,diarrhea,diarrhea back pain pain in,1,0.7811388969421387
CERDELGA,diarrhea,fatigue headache diarrhea back,1,0.743155837059021
CERDELGA,back pain,Trials and were fatigue,0,0.5675067901611328
CERDELGA,back pain,were fatigue headache nausea back,1,0.5835680961608887
CERDELGA,back pain,nausea diarrhea,0,0.5177397727966309
CERDELGA,back pain,Trials and were fatigue headache nausea,0,0.5681459307670593
CERDELGA,back pain,back,1,0.716275691986084
CERDELGA,upper abdominal pain,two,0,0.4528343677520752
CERDELGA,upper abdominal pain,is based on two controlled,0,0.42766761779785156
CERDELGA,upper abdominal pain,Trials and were fatigue headache nausea diarrhea back pain pain in extremities and,0,0.6041960716247559
CERDELGA,upper abdominal pain,upper abdominal pain The adverse reaction profile of,1,0.8396387100219727
CERDELGA,upper abdominal pain,upper abdominal pain The,1,0.9898600578308105
CERDELGA,upper abdominal pain,upper abdominal pain The adverse reaction profile,1,0.840576171875
CERDELGA,upper abdominal pain,upper abdominal pain,1,1.0000001192092896
CERDELGA,upper abdominal pain,studies Trials and,0,0.47714686393737793
CERDELGA,upper abdominal pain,in extremities upper abdominal pain,1,0.909168004989624
CERDELGA,ECG Changes,adverse r,1,0.5190950632095337
CERDELGA,ECG Changes,EXCERPT The most n adverse r eactions are fatigue headache nausea,1,0.5150048732757568
CERDELGA,ECG Changes,pain in,0,0.5007926225662231
CERDELGA,ECG Changes,n adverse,1,0.5103427171707153
CERDELGA,Cardiac Arrhythmias,"most common adverse reactions e: fatigue, headach e nausea diarrhea back pain",1,0.48662489652633667
CERDELGA,Cardiac Arrhythmias,n adverse,1,0.4923706650733948
CERDELGA,Cardiac Arrhythmias,adverse,0,0.4664127230644226
CERDELGA,Cardiac Arrhythmias,extremities and,0,0.4923279881477356
CERDELGA,Cardiac Arrhythmias,"reactions e: fatigue,",1,0.5278887152671814
CERDELGA,Cardiac Arrhythmias,"reactions e: fatigue, headach e nausea diarrhea back pain",1,0.5079252123832703
CERDELGA,Cardiac Arrhythmias,EXCERPT The most common adverse,0,0.5072199106216431
CERDELGA,Cardiac Arrhythmias,extremities and upper abdominal pain To,0,0.5184047222137451
CERDELGA,Cardiac Arrhythmias,e:,1,0.5303548574447632
CERDELGA,Cardiac Arrhythmias,most common adverse reactions e:,1,0.5039840936660767
CERDELGA,cardiac arrhythmias, clinical trials of another drug,1,0.5677057504653931
CERDELGA,cardiac arrhythmias,most common adverse reactions e:,1,0.5039840936660767
CERDELGA,cardiac arrhythmias,and may,0,0.42036718130111694
CERDELGA,cardiac arrhythmias,clinical trials of another drug and may not,1,0.5398271083831787
NEURACEQ,injection site reaction,most commonly reported adverse reactions,0,0.6609936952590942
NEURACEQ,injection site reaction,pain To report SUSPECTED ADV,0,0.6165012717247009
NEURACEQ,injection site reaction,reactions,0,0.7354097366333008
NEURACEQ,injection site reaction,adverse reactions injection site reaction consisting of,1,0.9294655323028564
NEURACEQ,injection site reaction,injection site reaction consisting of erythema irritation and,1,0.8936916589736938
NEURACEQ,injection site reactions,mild to moderate in,0,0.540142297744751
NEURACEQ,application site erythema,application site erythema Injection site,1,0.9316689968109131
NEURACEQ,application site erythema,mild to moderate in,0,0.5227197408676147
NEURACEQ,application site erythema,in,0,0.5063602924346924
NEURACEQ,application site erythema,irritation Injection s,0,0.6165749430656433
NEURACEQ,application site erythema,application site erythema Injection,1,0.9372068047523499
NEURACEQ,Injection site irritation,site Injection site irritation Injection,1,0.9383407831192017
NEURACEQ,Injection site irritation,application site erythema Injection,1,0.7751029133796692
NEURACEQ,Injection site irritation,Injection,0,0.7715620994567871
NEURACEQ,Injection site irritation,Injection application site Injection site irritation,1,0.9737387895584106
NEURACEQ,Injection site irritation,n Injection application site Injection site irritation Injection site pain,1,0.9319766759872437
NEURACEQ,Injection site irritation,site irritation Injection,1,0.9512103796005249
NEURACEQ,Injection site irritation,site Injection site irritation Injection site,1,0.9603838920593262
NEURACEQ,Injection site irritation,Injection site,0,0.8731536865234375
NEURACEQ,long-term cumulative radiation exposure,of erythema irritation and pain,0,0.5512133240699768
NEURACEQ,long-term cumulative radiation exposure,tion consisting of erythema irritation and pain To report,0,0.58201003074646
NEURACEQ,long-term cumulative radiation exposure,"To report  ADVERSE REACTIONS, contact Piramal at  or FDA",1,0.5304163694381714
NEURACEQ,long-term cumulative radiation exposure,"and pain To report ADVERSE REACTIONS, contact Piramal at",1,0.5221580266952515
NEURACEQ,long-term cumulative radiation exposure,e drug,1,0.4851136803627014
NEURACEQ,long-term cumulative radiation exposure,Injection,0,0.504709005355835
NEURACEQ,long-term cumulative radiation exposure,n Administrations in Subjects e drug reaction      n (%)              Injection application site erythema Injection,1,0.5727806091308594
NEURACEQ,long-term cumulative radiation exposure,Injection application site erythema,0,0.5484185218811035
NEURACEQ,long-term cumulative radiation exposure,n (%) Injection,1,0.5301681756973267
NEURACEQ,long-term cumulative radiation exposure,erythema Injection,0,0.5151736736297607
NEURACEQ,long-term cumulative radiation exposure,e drug reaction      n (%)              Injection application site erythema,1,0.5483661890029907
NEURACEQ,Long-term cumulative radiation exposure,Administrations in Subjects Adverse drug,0,0.5454816818237305
NEURACEQ,Long-term cumulative radiation exposure,n,0,0.5282701849937439
NEURACEQ,Long-term cumulative radiation exposure,site irritation,0,0.5832182168960571
NEURACEQ,cancer,ection site irritation Injection site,1,0.519340991973877
NEURACEQ,cancer,site irritation,0,0.5366140007972717
NEURACEQ,cancer,n Injection application site erythema Inj,0,0.5099446773529053
NEURACEQ,cancer,ection site irritation,1,0.5518067479133606
NEURACEQ,cancer,ection site irritation Injection site pain,1,0.5360185503959656
NEURACEQ,cancer,ection,1,0.5588842630386353
NEURACEQ,cancer,site erythema ection,1,0.5434340238571167
NEURACEQ,cancer,irritation Injection,0,0.5281403660774231
PROLIA,Hypocalcemia,Hypocalcemia see Warnings and Precautions Serious,1,0.8637397885322571
PROLIA,Hypocalcemia,are discussed below and also,0,0.4787360727787018
PROLIA,Hypocalcemia,Hypocalcemia see Warnings,1,0.8764317035675049
PROLIA,Hypocalcemia,Hypocalcemia see Warnings and Precautions,1,0.8659399747848511
PROLIA,Infections,Infections see Warnings,1,0.8066918253898621
PROLIA,Infections,see,0,0.5760005712509155
PROLIA,Infections,Infections see Warnings and Precautions Dermatologic,1,0.7444183826446533
PROLIA,Infections,Warnings and Precautions Infections see Warnings and,1,0.7554160952568054
PROLIA,Infections,Warnings and,0,0.6020025610923767
PROLIA,Infections,Infections,1,1.000000238418579
PROLIA,Infections,Infections see Warnings and,1,0.8097580075263977
PROLIA,Dermatologic Adverse Reactions,see Warnings and Dermatologic Adverse Reactions see Warnings and Precautions Osteonecrosis,1,0.7637083530426025
PROLIA,Dermatologic Adverse Reactions,Infections see Warnings,1,0.6081110835075378
PROLIA,Dermatologic Adverse Reactions,Dermatologic Adverse Reactions see Warnings and Precautions,1,0.9198137521743774
PROLIA,Dermatologic Adverse Reactions,Dermatologic Adverse Reactions,1,1.0
PROLIA,Dermatologic Adverse Reactions,Infections see Warnings and Dermatologic Adverse Reactions see Warnings and Precautions,1,0.8299803137779236
PROLIA,Dermatologic Adverse Reactions,Adverse Reactions see,1,0.8066972494125366
PROLIA,Dermatologic Adverse Reactions,and Precautions Osteonecrosis of the Jaw,0,0.5159246325492859
PROLIA,Dermatologic Adverse Reactions,Precautions Serious Infections,0,0.5820935964584351
PROLIA,Dermatologic Adverse Reactions,Warnings and,0,0.5816600322723389
PROLIA,Osteonecrosis of the Jaw,Precautions,0,0.5113622546195984
PROLIA,back pain,The most common a,0,0.4643716812133789
PROLIA,back pain,patients,0,0.5673086643218994
PROLIA,pain in extremity,pain,0,0.7890955209732056
PROLIA,pain in extremity,in extremity musculoskeletal pain,1,0.9235168099403381
PROLIA,pain in extremity,in extremity musculoskeletal pain hypercholesterolemia,1,0.769993782043457
PROLIA,pain in extremity,osteoporosis are back pain in extremity,1,0.7839513421058655
PROLIA,pain in extremity,pain in extremity musculoskeletal pain,1,0.917290210723877
PROLIA,musculoskeletal pain,with,0,0.5335615873336792
PROLIA,musculoskeletal pain,pain pain in musculoskeletal pain hypercholesterolemia,1,0.7839617133140564
PROLIA,musculoskeletal pain,Prolia in patients with postmenopausal osteoporosis are back pain pain in extremity,0,0.67342209815979
PROLIA,musculoskeletal pain,in patients with postmenopausal osteoporosis are back pain,0,0.6774203777313232
PROLIA,musculoskeletal pain,musculoskeletal pain hypercholesterolemia and,1,0.8050179481506348
PROLIA,musculoskeletal pain,adverse reactions reported with Prolia,0,0.4898352026939392
PROLIA,musculoskeletal pain,and cystitis The,0,0.610895037651062
PROLIA,musculoskeletal pain,musculoskeletal pain hypercholesterolemia,1,0.7835856080055237
PROLIA,musculoskeletal pain,pain pain in musculoskeletal pain,1,0.9458404779434204
PROLIA,cystitis,osteoporosis are back pain,0,0.49854472279548645
PROLIA,cystitis,cystitis The most common adverse reactions,1,0.8239750266075134
PROLIA,cystitis,cystitis The most common adverse,1,0.8380361199378967
PROLIA,cystitis,cystitis The,1,0.9457411766052246
PROLIA,back pain,osteoporosis back pain arthralgia and nasopharyngitis,1,0.7245407104492188
PROLIA,back pain,cystitis The most common adverse reactions,1,0.5515035390853882
PROLIA,arthralgia,most common adverse reactions reported with Prolia in men with osteoporosis,0,0.5483732223510742
PROLIA,arthralgia,Prolia in men with osteoporosis are back pain,0,0.6077980399131775
PROLIA,arthralgia,and nasopharyngitis The most common,0,0.46605366468429565
PROLIA,arthralgia,per patient incidence adverse reactions reported,0,0.507027268409729
PROLIA,arthralgia,arthralgia,1,1.0
PROLIA,arthralgia,arthralgia and nasopharyngitis The most,1,0.7799839973449707
PROLIA,arthralgia,are back arthralgia and nasopharyngitis The,1,0.7576717138290405
PROLIA,arthralgia,with Prolia in men with,0,0.5263765454292297
PROLIA,arthralgia,reactions reported with Prolia,0,0.5362704396247864
PROLIA,nasopharyngitis,nasopharyngitis The,1,0.9566863775253296
PROLIA,nasopharyngitis,are back pain arthralgia nasopharyngitis,1,0.7973868250846863
PROLIA,nasopharyngitis,Prolia in,0,0.5072367191314697
PROLIA,nasopharyngitis,most common per patient incidence adverse reactions reported with Prolia in,0,0.5454772710800171
PROLIA,nasopharyngitis,nasopharyngitis The most common,1,0.8717905879020691
PROLIA,nasopharyngitis,pain arthralgia nasopharyngitis The most common per,1,0.788909912109375
PROLIA,nasopharyngitis,back pain arthralgia and,0,0.47785013914108276
PROLIA,nasopharyngitis,common,0,0.5190814733505249
PROLIA,arthralgia,been reported in clinical tria,0,0.5549201965332031
PROLIA,arthralgia,cancer are,0,0.511401355266571
PROLIA,arthralgia,arthralgia and back,1,0.8898096084594727
PROLIA,back pain,arthralgia and,0,0.635743260383606
PROLIA,musculoskeletal pain,musculoskeletal pain have also been reported in,1,0.9090715646743774
PROLIA,musculoskeletal pain,arthralgia and,0,0.7341423630714417
PROLIA,back pain,back pain and,1,0.9475376605987549
PROLIA,back pain,The Prolia Postmarketing Active Safety Surveillance,0,0.4696859121322632
PROLIA,back pain,are,0,0.47776031494140625
PROLIA,back pain,with,0,0.511995792388916
PROLIA,constipation,discontinuation of Prolia,0,0.5947998762130737
PROLIA,constipation,with postmenopausal osteoporosis,0,0.5335904359817505
PROLIA,constipation,to collect,0,0.5204648971557617
PROLIA,constipation,Prolia Postmarketing Active Safety Surveillance Program is available,0,0.5110366344451904
PROLIA,constipation,constipation,1,1.0000001192092896
PROLIA,constipation,constipation The Prolia,1,0.8406585454940796
PROLIA,constipation,patients with postmenopausal osteoporosis are back,0,0.4992308020591736
PROLIA,constipation,with postmenopausal osteoporosis are,0,0.5171607136726379
PROLIA,constipation,constipation The Prolia Postmarketing Active Safety,1,0.7884365916252136
PROLIA,pain in extremity,in extremity hypercholesterolemia,1,0.7120400667190552
PROLIA,hypercholesterolemia,hypercholesterolemia musculoskeletal pain and cystitis,1,0.7705562114715576
PROLIA,hypercholesterolemia,pain in hypercholesterolemia musculoskeletal pain and,1,0.785128653049469
PROLIA,hypercholesterolemia,back pain pain in hypercholesterolemia musculoskeletal pain and,1,0.7647398710250854
PROLIA,hypercholesterolemia,in hypercholesterolemia musculoskeletal,1,0.8314124345779419
PROLIA,hypercholesterolemia,more common than placebo were back pain pain in extremity,0,0.4999305307865143
PROLIA,hypercholesterolemia,in clinical trials,0,0.5724619030952454
PROLIA,hypercholesterolemia,been reported in clinical,0,0.5720157623291016
PROLIA,hypercholesterolemia,placebo were,0,0.5273786187171936
PROLIA,hypercholesterolemia,cystitis Pancreatitis,0,0.504501223564148
PROLIA,hypercholesterolemia,hypercholesterolemia musculoskeletal,1,0.8177065253257751
PROLIA,musculoskeletal pain,musculoskeletal pain and cystitis Pancreatitis has been,1,0.7615838050842285
PROLIA,musculoskeletal pain,extremity musculoskeletal pain and cystitis Pancreatitis has been,1,0.7435799837112427
PROLIA,musculoskeletal pain,pain in extremity,0,0.7793220281600952
PROLIA,musculoskeletal pain,extremity musculoskeletal pain and cystitis Pancreatitis has,1,0.7389876246452332
PROLIA,musculoskeletal pain,pain in extremity musculoskeletal pain and cystitis Pancreatitis has,1,0.7570345401763916
PROLIA,musculoskeletal pain,and more common than placebo were back,0,0.5180942416191101
PROLIA,cystitis,been,0,0.553064227104187
PROLIA,cystitis,cystitis Pancreatitis,1,0.8026679754257202
PROLIA,cystitis,cystitis,1,1.0000001192092896
PROLIA,Pancreatitis,Pancreatitis has been reported,1,0.8888047933578491
PROLIA,Pancreatitis,hypercholesterolemia musculoskeletal pain and Pancreatitis has,1,0.7336958646774292
PROLIA,Pancreatitis,Pancreatitis has been reported in,1,0.877774715423584
PROLIA,Pancreatitis,and cystitis,0,0.6248102784156799
PROLIA,Pancreatitis,Osteoporosis,0,0.586849570274353
PROLIA,Pancreatitis,Pancreatitis has been,1,0.9054376482963562
PROLIA,back pain,than placebo back,1,0.6273206472396851
PROLIA,back pain,ablation for cancer,0,0.48798102140426636
PROLIA,back pain,hormone,0,0.48594391345977783
PROLIA,back pain,placebo back pain arthralgia,1,0.7885581851005554
PROLIA,back pain,back pain arthralgia and nasopharyngitis Bone loss,1,0.7419483661651611
PROLIA,back pain,and more common than,0,0.4451308846473694
PROLIA,back pain,common than placebo back pain,1,0.8387224674224854
PROLIA,back pain,back pain arthralgia,1,0.8567788004875183
PROLIA,back pain,loss due to hormone ablation,0,0.496860146522522
PROLIA,arthralgia,cancer,0,0.5490374565124512
PROLIA,nasopharyngitis,nasopharyngitis Bone loss due,1,0.8035449385643005
PROLIA,nasopharyngitis,loss due to hormone ablation for cancer Most common adverse,0,0.4536510705947876
PROLIA,nasopharyngitis,nasopharyngitis Bone loss due to,1,0.7991449236869812
PROLIA,nasopharyngitis,nasopharyngitis,1,1.0000001192092896
PROLIA,nasopharyngitis,nasopharyngitis Bone loss,1,0.8099309206008911
PROLIA,nasopharyngitis,and more common than placebo,0,0.4982304275035858
PROLIA,nasopharyngitis,back pain arthralgia nasopharyngitis Bone loss due to,1,0.7015236616134644
PROLIA,nasopharyngitis,arthralgia,0,0.4893870949745178
PROLIA,arthralgia,extremity and musculoskeletal pain have,0,0.7001162767410278
PROLIA,arthralgia,placebo arthralgia and,1,0.82802414894104
PROLIA,arthralgia,arthralgia and back pain Pain,1,0.8768153190612793
PROLIA,arthralgia,extremity and musculoskeletal pain have also been reported in,0,0.6835517287254333
PROLIA,arthralgia,Pain in extremity and musculoskeletal pain have also been reported in,0,0.6821234822273254
PROLIA,arthralgia,common than placebo arthralgia and back pain,1,0.8076818585395813
PROLIA,arthralgia,extremity and musculoskeletal,0,0.6410855054855347
PROLIA,Pain in extremity,back Pain in extremity and musculoskeletal pain,1,0.8410532474517822
PROLIA,Pain in extremity,extremity and musculoskeletal,0,0.8233810067176819
PROLIA,Pain in extremity,and back Pain in extremity and musculoskeletal pain have,1,0.8457204103469849
PROLIA,Pain in extremity,Pain in extremity,1,1.000000238418579
PROLIA,Pain in extremity,Pain in extremity and musculoskeletal,1,0.922654390335083
PROLIA,mortality,incidence of mortality was n in,1,0.7808923721313477
PROLIA,mortality,Pain in extremity and musculoskeletal,1,0.517064094543457
PROLIA,mortality,mortality was n in,1,0.836409330368042
PROLIA,mortality,mortality was n,1,0.8658682703971863
PROLIA,mortality,and IU of vitamin D supplementation per day,0,0.5237566232681274
PROLIA,mortality,mortality,1,1.0000001192092896
PROLIA,Anemia,Anemia CARDIAC DISORDERS,1,0.8117865324020386
PROLIA,Anemia,Anemia,1,1.0
PROLIA,Anemia,CARDIAC DISORDERS,0,0.5500197410583496
PROLIA,Angina pectoris,EAR AND,0,0.4562029242515564
PROLIA,Angina pectoris,AND LABYRINTH D,0,0.4613533616065979
PROLIA,Angina pectoris,CARDIAC,0,0.726325511932373
PROLIA,Angina pectoris,Atrial fibrillation EAR,0,0.5640194416046143
PROLIA,Angina pectoris,AND,0,0.5192347764968872
PROLIA,Atrial fibrillation,LABYRINTH DISORDERS Vertigo,0,0.5430799722671509
PROLIA,Atrial fibrillation,Atrial fibrillation EAR AND LABYRINTH DISORDERS,1,0.7982014417648315
PROLIA,Atrial fibrillation,Angina Atrial fibrillation,1,0.8295889496803284
PROLIA,Atrial fibrillation,AND LABYRINTH,0,0.5241459608078003
PROLIA,Atrial fibrillation,Atrial fibrillation EAR AND,1,0.8625340461730957
PROLIA,Vertigo,Vertigo GASTROINTESTINAL,1,0.8002424240112305
PROLIA,Vertigo,AND LABYRINTH Vertigo GASTROINTESTINAL DISORDERS Abdominal,1,0.7209513783454895
PROLIA,Vertigo,AND LABYRINTH DISORDERS,0,0.7521781921386719
PROLIA,Vertigo,DISORDERS,0,0.588239312171936
PROLIA,Vertigo,LABYRINTH DISORDERS,0,0.7522449493408203
PROLIA,Vertigo,LABYRINTH Vertigo GASTROINTESTINAL DISORDERS,1,0.7540308237075806
PROLIA,Abdominal pain upper,Vertigo GASTROINTESTINAL Abdominal pain upper Flatulence Gastroesophageal reflux di,1,0.7720259428024292
PROLIA,Abdominal pain upper,LABYRINTH DISORDERS,0,0.46554237604141235
PROLIA,Abdominal pain upper,pain upper,1,0.7937817573547363
PROLIA,Abdominal pain upper,Flatulence Gastroesophageal reflux di,0,0.619369626045227
PROLIA,Flatulence,DISORDERS Abdominal pain upper,0,0.5995519757270813
PROLIA,Flatulence,GASTROINTESTINAL DISORDERS Abdominal pain Flatulence Gastroesophageal reflux disease,1,0.7294005155563354
PROLIA,Flatulence,Flatulence Gastroesophageal,1,0.8690727353096008
PROLIA,Flatulence,reflux disease,0,0.6913114786148071
PROLIA,Flatulence,GASTROINTESTINAL DISORDERS Abdominal pain Flatulence Gastroesophageal reflux disease GENERAL,1,0.7351037263870239
PROLIA,Gastroesophageal reflux disease,reflux disease GENERAL DISORDERS AND ADMINISTRATION,1,0.8309876918792725
PROLIA,Gastroesophageal reflux disease,upper Gastroesophageal,1,0.7933064103126526
PROLIA,Gastroesophageal reflux disease,upper Gastroesophageal reflux,1,0.890106201171875
PROLIA,Gastroesophageal reflux disease,Abdominal pain upper Flatulence,0,0.6467471718788147
PROLIA,Gastroesophageal reflux disease,Abdominal,0,0.5797979235649109
PROLIA,Gastroesophageal reflux disease,pain upper Gastroesophageal reflux disease GENERAL DISORDERS,1,0.830282986164093
PROLIA,Gastroesophageal reflux disease,upper Gastroesophageal reflux disease GENERAL DISORDERS,1,0.8803956508636475
PROLIA,Gastroesophageal reflux disease,upper Gastroesophageal reflux disease,1,0.9651959538459778
PROLIA,Edema peripheral,ADMINISTRATION SITE Edema peripheral Asthenia INFECTIONS AND INFESTATIONS,1,0.7994436621665955
PROLIA,Edema peripheral,upper Gastroesophageal reflux disease,1,0.5215801000595093
PROLIA,Edema peripheral,SITE Edema peripheral,1,0.9422098398208618
PROLIA,Edema peripheral,AND ADMINISTRATION SITE Edema peripheral,1,0.9084087610244751
PROLIA,Edema peripheral,Edema peripheral Asthenia,1,0.9143401384353638
PROLIA,Edema peripheral,Edema peripheral Asthenia INFECTIONS,1,0.8512503504753113
PROLIA,Edema peripheral,INFECTIONS,0,0.5435161590576172
PROLIA,Edema peripheral,DISORDERS AND ADMINISTRATION SITE Edema peripheral,1,0.8842929005622864
PROLIA,Asthenia,SITE CONDITIONS Edema,0,0.6036602854728699
PROLIA,Asthenia,peripheral,0,0.5436301231384277
PROLIA,Asthenia,INFECTIONS,0,0.5806547403335571
PROLIA,Asthenia,Asthenia INFECTIONS,1,0.8964083194732666
PROLIA,Asthenia,INFECTIONS AND INFESTATIONS,0,0.586624264717102
PROLIA,Cystitis,Cystitis,1,1.0000001192092896
PROLIA,Cystitis,AND INFESTATIONS,0,0.5334808230400085
PROLIA,Cystitis,Cystitis Upper respiratory tract infection P,1,0.78017258644104
PROLIA,Cystitis,Asthenia INFECTIONS AND Cystitis Upper respiratory tract,1,0.7046017050743103
PROLIA,Cystitis,tract,0,0.5279297232627869
PROLIA,Cystitis,INFECTIONS AND Cystitis Upper respiratory tract infection,1,0.75896155834198
PROLIA,Upper respiratory tract infection,AND INFESTATIONS Upper respiratory,1,0.7936054468154907
PROLIA,Upper respiratory tract infection,AND INFESTATIONS Cystitis,0,0.5458887219429016
PROLIA,Upper respiratory tract infection,Cystitis,0,0.5793309211730957
PROLIA,Upper respiratory tract infection,INFECTIONS AND INFESTATIONS Upper respiratory tract infection,1,0.8435384035110474
PROLIA,Upper respiratory tract infection,respiratory tract infection Pneumonia,1,0.8062055706977844
PROLIA,Upper respiratory tract infection,AND INFESTATIONS,0,0.5218372344970703
PROLIA,Pneumonia,Pneumonia Pharyngitis Herpes zoster,1,0.7425627708435059
PROLIA,Pneumonia,AND INFESTATIONS,0,0.5244228839874268
PROLIA,Pneumonia,respiratory tract Pneumonia Pharyngitis Herpes zoster,1,0.7374820709228516
PROLIA,Pneumonia,respiratory tract Pneumonia,1,0.8363109230995178
PROLIA,Pharyngitis,infection Pneumonia,0,0.6162951588630676
PROLIA,Pharyngitis,Pharyngitis Herpes zoster METABOLISM AND NUTRITION,1,0.7527348399162292
PROLIA,Pharyngitis,spiratory tract infection Pharyngitis Herpes zoster METABOLISM AND NUTRITION,1,0.7481141090393066
PROLIA,Pharyngitis,METABOLISM,0,0.4917888045310974
PROLIA,Pharyngitis,Pharyngitis Herpes zoster METABOLISM,1,0.7750625610351562
PROLIA,Pharyngitis,tract infection Pharyngitis,1,0.9019896984100342
PROLIA,Pharyngitis,tract,0,0.5159661769866943
PROLIA,Pharyngitis,Pharyngitis Herpes,1,0.8966853022575378
PROLIA,Pharyngitis,Pharyngitis,1,1.0
PROLIA,Pharyngitis,Pneumonia,0,0.6345750689506531
PROLIA,Hypercholesterolemia,AND NUTRITION Hypercholesterolemia MUSCULOSKELETAL AND,1,0.8335375189781189
PROLIA,Hypercholesterolemia,Pneumonia,0,0.5527954697608948
PROLIA,Hypercholesterolemia,Hypercholesterolemia MUSCULOSKELETAL AND CONNECTIVE TISSUE,1,0.7972902655601501
PROLIA,Hypercholesterolemia,Hypercholesterolemia MUSCULOSKELETAL AND CONNECTIVE,1,0.803431510925293
PROLIA,Hypercholesterolemia,CONNECTIVE,0,0.5360794067382812
PROLIA,Hypercholesterolemia,Hypercholesterolemia MUSCULOSKELETAL,1,0.8177065253257751
PROLIA,Hypercholesterolemia,DISORDERS,0,0.6115058660507202
PROLIA,Back pain,DISORDERS,0,0.54429692029953
PROLIA,Back pain,sterolemia MUSCULOSKELETAL AND CONNECTIVE,0,0.5591151714324951
PROLIA,Back pain,CONNECTIVE TISSUE Back,1,0.657030463218689
PROLIA,Back pain,TISSUE Back pain,1,0.8648338913917542
PROLIA,Back pain,Back pain,1,0.9999997615814209
PROLIA,Pain in extremity,TISSUE DISORDERS Back Pain in extremity Musculoskeletal pain Bone pain,1,0.7901023030281067
PROLIA,Pain in extremity,Back pain,1,0.6894804835319519
PROLIA,Pain in extremity,Musculoskeletal pain Bone pain,0,0.7641652822494507
PROLIA,Pain in extremity,Back pain,0,0.6894804835319519
PROLIA,Pain in extremity,in extremity Musculoskeletal pain,1,0.9235168099403381
PROLIA,Pain in extremity,Musculoskeletal pain,0,0.7793220281600952
PROLIA,Pain in extremity,DISORDERS Back Pain in extremity,1,0.8615988492965698
PROLIA,Pain in extremity,pain Bone,0,0.7857089042663574
PROLIA,Musculoskeletal pain,Bone,0,0.615245521068573
PROLIA,Musculoskeletal pain,in Musculoskeletal,1,0.899739682674408
PROLIA,Musculoskeletal pain,Back,0,0.5821495652198792
PROLIA,Musculoskeletal pain,extremity,0,0.607506275177002
PROLIA,Musculoskeletal pain,Musculoskeletal pain Bone,1,0.9091863036155701
PROLIA,Musculoskeletal pain,in Musculoskeletal pain Bone,1,0.8990263342857361
PROLIA,Musculoskeletal pain,Back pain Pain in Musculoskeletal pain,1,0.8979852199554443
PROLIA,Bone pain,extremity Musculoskeletal Bone pain,1,0.8440377712249756
PROLIA,Bone pain,Back pain Pain in Musculoskeletal pain,1,0.7101215124130249
PROLIA,Bone pain,Musculoskeletal Bone pain Myalgia,1,0.820734977722168
PROLIA,Bone pain,Bone pain Myalgia,1,0.8705761432647705
PROLIA,Bone pain,Bone pain Myalgia Spinal,1,0.865105926990509
PROLIA,Bone pain,Musculoskeletal Bone pain Myalgia Spinal osteoarthritis,1,0.8195571899414062
PROLIA,Myalgia,Myalgia Spinal osteoarthritis NERVOUS SYSTEM DI,1,0.7950608730316162
PROLIA,Myalgia,Myalgia Spinal osteoarthritis NERVOUS,1,0.7840203642845154
PROLIA,Myalgia,osteoarthritis,0,0.6360751390457153
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS SYSTEM DISORDERS,1,0.87428218126297
PROLIA,Spinal osteoarthritis,osteoarthritis,0,0.8530094027519226
PROLIA,Spinal osteoarthritis,Myalgia,0,0.6098963022232056
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS SYSTEM,1,0.8819800019264221
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS SYSTEM DISORDERS Sciatica,1,0.8414896726608276
PROLIA,Spinal osteoarthritis,pain Spinal osteoarthritis NERVOUS SYSTEM,1,0.8754079341888428
PROLIA,Spinal osteoarthritis,Bone pain Myalgia,0,0.6392707824707031
PROLIA,Spinal osteoarthritis,SYSTEM DISORDERS Sciatica,0,0.5943350791931152
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS,1,0.863123893737793
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis,1,1.0
PROLIA,Sciatica,SYSTEM Sciatica PSYCHIATRIC DISORDERS,1,0.7640693783760071
PROLIA,Sciatica,Spinal osteoarthritis,1,0.6350180506706238
PROLIA,Sciatica,PSYCHIATRIC DISORDERS Insomnia,0,0.5018022656440735
PROLIA,Sciatica,osteoarthritis NERVOUS SYSTEM DISORDERS,0,0.5888673067092896
PROLIA,Sciatica,Sciatica PSYCHIATRIC,1,0.8342593312263489
PROLIA,Rash,Pruritus,0,0.7443514466285706
PROLIA,Rash,Insomnia SKIN,0,0.6222954392433167
PROLIA,Rash,SUBCUTANEOUS,0,0.6418073177337646
PROLIA,Rash,SUBCUTANEOUS TISSUE Rash Pruritus,1,0.7831637263298035
PROLIA,Rash,Rash,1,1.0000001192092896
PROLIA,Rash,Pruritus Hypocalcemia Decreases,0,0.6180702447891235
PROLIA,Pruritus,Pruritus Hypocalcemia Decreases,1,0.7769461870193481
PROLIA,Hypocalcemia,Hypocalcemia Decreases in serum calcium,1,0.8651670813560486
PROLIA,Hypocalcemia,Rash,0,0.49392062425613403
PROLIA,Hypocalcemia,Decreases,0,0.5263791084289551
PROLIA,Hypocalcemia,Hypocalcemia Decreases in,1,0.888831615447998
PROLIA,Hypocalcemia,Rash Pruritus,0,0.4583317041397095
PROLIA,Decreases in serum calcium levels,visit were reported in women in the placebo group,0,0.5300153493881226
PROLIA,Decreases in serum calcium levels,Decreases in,1,0.7668285369873047
PROLIA,Decreases in serum calcium levels,Rash Pruritus Decreases in serum calcium levels to less,1,0.822462797164917
PROLIA,Decreases in serum calcium levels,Rash Pruritus Decreases in serum calcium levels to less than mgdL at,1,0.812615156173706
PROLIA,Decreases in serum calcium levels,Rash Pruritus Hypocalcemia,0,0.6957930326461792
PROLIA,Decreases in serum calcium levels,Decreases in serum calcium levels,1,1.0
PROLIA,Decreases in serum calcium levels,calcium levels to,1,0.8217368125915527
PROLIA,Decreases in serum calcium levels,Pruritus Decreases in serum calcium levels to less than mgdL,1,0.8234933018684387
PROLIA,Decreases in serum calcium levels,Decreases in serum calcium levels to,1,0.9881336688995361
PROLIA,infection,may increase the risk infection In the clinical,1,0.7517389059066772
PROLIA,infection,calcium levels to,1,0.5623435974121094
PROLIA,infection,risk infection In the,1,0.8055105209350586
PROLIA,infection,of postmenopausal women,0,0.46935033798217773
PROLIA,infections,postmenopausal women with osteoporosis the incidence of,0,0.4832051396369934
PROLIA,infections,with osteoporosis the incidence of,0,0.524827241897583
PROLIA,infections,infections resulting in death,1,0.7525054216384888
PROLIA,infections,the incidence infections resulting in,1,0.7723573446273804
PROLIA,infections,with osteoporosis the,0,0.5154235363006592
PROLIA,infections,infections resulting in,1,0.8410015106201172
PROLIA,death,the incidence of nonfatal,0,0.5386451482772827
PROLIA,death,incidence of infections resulting death,1,0.6875172853469849
PROLIA,death,incidence of infections resulting death was in both placebo and,1,0.6527236104011536
PROLIA,infections,due to,0,0.5586961507797241
PROLIA,infections,infections was in the,1,0.8896857500076294
PROLIA,infections,of nonfatal infections was in the placebo and,1,0.7112219333648682
PROLIA,infections,of nonfatal,0,0.5042087435722351
PROLIA,infections,the incidence of nonfatal infections was in,1,0.7430193424224854
PROLIA,infections,infections was in the placebo and,1,0.7486977577209473
PROLIA,Endocarditis,Prolia,0,0.4645121097564697
PROLIA,Endocarditis,Endocarditis was reported in no,1,0.8545942306518555
PROLIA,Endocarditis,receiving Prolia Skin infections,0,0.5689682960510254
PROLIA,Endocarditis,Endocarditis was reported,1,0.8806172609329224
PROLIA,Endocarditis,Endocarditis,1,0.9999997615814209
PROLIA,Endocarditis,Prolia were Endocarditis,1,0.8022050261497498
PROLIA,Endocarditis,Endocarditis was reported in,1,0.8831513524055481
PROLIA,Skin infections,Skin infections,1,1.0
PROLIA,Skin infections,Endocarditis was reported in no,1,0.5576890707015991
PROLIA,Skin infections,reported Endocarditis was reported in no placebo patients and,0,0.5166112780570984
PROLIA,Skin infections,Skin infections including erysipelas and cellulitis leading,1,0.8321816921234131
PROLIA,Skin infections,frequently in p,0,0.4963343143463135
PROLIA,Skin infections,Skin infections including erysipelas and cellulitis,1,0.8483389019966125
PROLIA,Skin infections,no placebo patients and,0,0.4389649033546448
PROLIA,Skin infections,reported Endocarditis was reported,0,0.567841649055481
PROLIA,Skin infections,receiving Skin infections including erysipelas and,1,0.8197966814041138
PROLIA,erysipelas,erysipelas and,1,0.9396289587020874
PROLIA,erysipelas,receiving Prolia Skin infections erysipelas,1,0.8218759298324585
PROLIA,erysipelas,Skin infections erysipelas and cellulitis,1,0.8513396978378296
PROLIA,erysipelas,Prolia Skin infections erysipelas and,1,0.831184446811676
PROLIA,cellulitis,cellulitis leading to hospitalization were,1,0.8213993906974792
PROLIA,cellulitis,cellulitis leading to,1,0.8970572352409363
PROLIA,cellulitis,infections,0,0.6985373497009277
PROLIA,cellulitis,and,0,0.520575761795044
PROLIA,cellulitis,and patients receiving Prolia Skin,0,0.5640044212341309
PROLIA,cellulitis,with Prolia p,0,0.5022211074829102
PROLIA,cellulitis,cellulitis leading to hospitalization were reported,1,0.817131757736206
PROLIA,dermal adverse events,eczema and rashes with these events reported in of the,0,0.7598406076431274
PROLIA,dermal adverse events,epidermal dermal adverse events,1,0.9432492256164551
PROLIA,dermal adverse events,in of the placebo and,0,0.5712898969650269
PROLIA,dermal adverse events,in,0,0.5048496723175049
PROLIA,dermal adverse events,events reported in of the placebo and,0,0.6208842992782593
PROLIA,dermatitis,events,0,0.5085732936859131
PROLIA,dermatitis,dermatitis eczema,1,0.8957030773162842
PROLIA,dermatitis,dermatitis eczema and rashes,1,0.8521298766136169
PROLIA,dermatitis,of the,0,0.5310567617416382
PROLIA,dermatitis,treated with Prolia developed epidermal and,0,0.6487830877304077
PROLIA,dermatitis,these events reported in of the,0,0.46878063678741455
PROLIA,dermatitis,and rashes with these events reported in of,0,0.6869016289710999
PROLIA,eczema,eczema and rashes,1,0.8801755905151367
PROLIA,eczema,eczema and rashes with these,1,0.8361086845397949
PROLIA,eczema,eczema and rashes with these events,1,0.8292168378829956
PROLIA,rashes,dermal adverse events such as dermatitis eczema,0,0.7095127701759338
PROLIA,rashes,rashes with,1,0.942325234413147
PROLIA,rashes,events,0,0.5256718397140503
PROLIA,rashes,with these events reported in of the placebo and of the Prolia groups p Mo,0,0.5328090190887451
PROLIA,rashes,rashes with these events reported,1,0.8725125789642334
PROLIA,rashes,rashes with these events reported in,1,0.8678939938545227
PROLIA,ONJ,Warnings and Precautions Osteonecrosis of the,0,0.554672360420227
PROLIA,ONJ,Jaw,0,0.5665775537490845
PROLIA,ONJ,been reported in the osteoporosis,0,0.5129616260528564
PROLIA,atypical femoral fractures,osteoporosis clinical trial atypical femoral,1,0.8258500099182129
PROLIA,atypical femoral fractures,trial atypical femoral fractures were,1,0.9359782338142395
PROLIA,atypical femoral fractures,atypical femoral fractures were,1,0.9887867569923401
PROLIA,atypical femoral fracture,atypical femoral fracture diagnosis,1,0.9439734220504761
PROLIA,atypical femoral fracture,was,0,0.4570593535900116
PROLIA,atypical femoral fracture,Prolia exposure,0,0.4921361804008484
PROLIA,atypical femoral fracture,early as years see Warnings and,0,0.48651689291000366
PROLIA,atypical femoral fracture,Prolia exposure to time atypical,1,0.6066591739654541
PROLIA,atypical femoral fracture,Prolia exposure to time atypical femoral fracture diagnosis was as early,1,0.819169819355011
PROLIA,Pancreatitis,Pancreatitis was reported,1,0.8841354250907898
PROLIA,Pancreatitis,Pancreatitis was,1,0.919313907623291
PROLIA,Pancreatitis,Pancreatitis,1,0.9999998807907104
PROLIA,Pancreatitis,Pancreatitis was reported in,1,0.8793293237686157
PROLIA,Pancreatitis,agnosis was,0,0.45977169275283813
PROLIA,Pancreatitis,as years,0,0.4631268382072449
PROLIA,death,in the placebo group and all patients in,0,0.457768976688385
PROLIA,malignancies,and in the Prolia,0,0.539878785610199
PROLIA,malignancies,placebo and in the Prolia groups New,0,0.5369422435760498
PROLIA,malignancies,occurrence was variable New Malignancies,0,0.7968706488609314
PROLIA,malignancies,malignancies,1,1.0
PROLIA,malignancies,malignancies was,1,0.9185260534286499
PROLIA,malignancies,was in the placebo and in the Prolia groups,0,0.532617449760437
PROLIA,malignancies,Prolia groups,0,0.5057100057601929
PROLIA,mortality,The incidence of allcause,0,0.5995880365371704
PROLIA,mortality,group The incidence of,0,0.6073907613754272
PROLIA,mortality,vitamin D supplementation per day The,0,0.5373508930206299
PROLIA,mortality,the placebo group and,0,0.5086709260940552
PROLIA,mortality,mortality was n in the placebo,1,0.7146397829055786
PROLIA,mortality,The incidence of mortality was n,1,0.7944601774215698
PROLIA,back pain,back pain,1,0.9999997615814209
PROLIA,back pain,back,1,0.7162756323814392
PROLIA,back pain,Prolia than,0,0.4793233275413513
PROLIA,back pain,with osteoporosis and more frequently with Prolia than,0,0.5536073446273804
PROLIA,back pain,arthralgia,0,0.6318295001983643
PROLIA,back pain,back pain placebo vs Prolia,1,0.7456014156341553
PROLIA,arthralgia,the placebotreated patients were back,0,0.4926309287548065
PROLIA,arthralgia,Prolia,0,0.5057591199874878
PROLIA,arthralgia,vs,0,0.46919870376586914
PROLIA,arthralgia,back pain placebo vs arthralgia,1,0.7719535827636719
PROLIA,arthralgia,arthralgia placebo vs Prolia and nasopharyngitis,1,0.7540780305862427
PROLIA,arthralgia,arthralgia placebo vs,1,0.8302682638168335
PROLIA,arthralgia,nasopharyngitis placebo vs Prolia,0,0.5156494379043579
PROLIA,nasopharyngitis,arthralgia placebo vs Prolia nasopharyngitis placebo vs Prolia Serious Infections,1,0.6715631484985352
PROLIA,nasopharyngitis,arthralgia,1,0.4893870949745178
PROLIA,nasopharyngitis,nasopharyngitis placebo vs Prolia Serious,1,0.7772773504257202
PROLIA,nasopharyngitis,vs Prolia nasopharyngitis placebo vs Prolia,1,0.7241910696029663
PROLIA,nasopharyngitis,was reported in,0,0.5151010155677795
PROLIA,nasopharyngitis,nasopharyngitis placebo vs Prolia Serious Infections,1,0.7675532102584839
PROLIA,infection,no,0,0.49499401450157166
PROLIA,infection,S infection was reported,1,0.7987300157546997
PROLIA,infection,infection was reported in patient in,1,0.8100899457931519
PROLIA,infection,Prolia,0,0.4865759015083313
PROLIA,infection,in patient in,0,0.6209025382995605
PROLIA,infection,Serious Infections S erious,0,0.7835049629211426
PROLIA,infection,infection was reported,1,0.854498028755188
PROLIA,infection,Prolia Serious Infections,0,0.6869548559188843
PROLIA,dermatitis,the Prolia group Dermatologic Reactions Epidermal and dermal adverse,0,0.7201215028762817
PROLIA,dermatitis,dermatitis,1,1.000000238418579
PROLIA,dermatitis,placebo group,0,0.527587890625
PROLIA,dermatitis,dermatitis eczema and rashes were reported,1,0.8346466422080994
PROLIA,dermatitis,dermatitis eczema and rashes were,1,0.8396087884902954
PROLIA,dermatitis,group and,0,0.49759534001350403
PROLIA,dermatitis,dermatitis eczema and,1,0.8815664649009705
PROLIA,dermatitis,Reactions Epidermal and,0,0.7181066274642944
PROLIA,eczema,eczema and rashes were,1,0.8605891466140747
PROLIA,rashes,as dermatitis eczema rashes were reported in,1,0.8336328268051147
PROLIA,rashes,eczema and rashes were,1,0.8691052198410034
PROLIA,rashes,dermal adverse events such as dermatitis eczema and,0,0.7104731798171997
PROLIA,rashes,rashes were reported in patients in,1,0.8847990036010742
PROLIA,rashes,as dermatitis,0,0.7431843280792236
PROLIA,rashes,the placebo group and patients in the Prolia,0,0.5032839775085449
PROLIA,rashes,the Prolia group,0,0.47980695962905884
PROLIA,rashes,rashes were reported in patients,1,0.8867642879486084
PROLIA,ONJ,the Jaw No cases ONJ were reported Pancreatitis Pancreatitis was,1,0.5530931949615479
PROLIA,ONJ,rashes were reported in patients,1,0.44710734486579895
PROLIA,Pancreatitis,patient in the,0,0.5583807229995728
PROLIA,Pancreatitis,Pancreatitis was reported in patient,1,0.861443281173706
PROLIA,malignancies,group New Malignancies malignancies were reported,1,0.824505090713501
PROLIA,malignancies,Pancreatitis was reported in patient,1,0.5311681032180786
PROLIA,malignancies,Prolia group New Malignancies,0,0.7400625348091125
PROLIA,malignancies,Prolia group New Malignancies malignancies,1,0.7423131465911865
PROLIA,malignancies,Malignancies malignancies were reported in no,1,0.8286611437797546
PROLIA,malignancies,group New,0,0.5156880021095276
PROLIA,malignancies,were reported in no patients in the placebo group,0,0.46231427788734436
PROLIA,prostate cancers,the placebo group and prostate,1,0.7091286182403564
PROLIA,prostate cancers,malignancies were reported in no patients in the placebo group and patients,0,0.6056254506111145
PROLIA,prostate cancers,of Bone,0,0.4833108186721802
PROLIA,prostate cancers,prostate cancers basal cell carcinoma in the,1,0.7521937489509583
PROLIA,prostate cancers,group,0,0.4922826588153839
PROLIA,basal cell carcinoma,Receiving Androgen,0,0.5517712831497192
PROLIA,basal cell carcinoma,and patients prostate basal,1,0.6543882489204407
PROLIA,basal cell carcinoma,prostate basal cell carcinoma in the Prolia group,1,0.7789720296859741
PROLIA,basal cell carcinoma,in the placebo,0,0.5065392255783081
PROLIA,basal cell carcinoma,of Bone Loss in Patients,0,0.5205826163291931
PROLIA,basal cell carcinoma,group and patients prostate basal,1,0.6483088731765747
PROLIA,arthralgia,therapy for breast cancer and more frequently than in the placebotreated patients,0,0.5000921487808228
PROLIA,back pain,equently than in the placebotreated patients were arthralgia placebo vs,0,0.6229498386383057
PROLIA,back pain,back pain placebo,1,0.8302505016326904
PROLIA,back pain,back pain placebo vs Prolia Pain,1,0.7671160697937012
PROLIA,back pain,than in the,0,0.4582928717136383
PROLIA,back pain,Prolia,0,0.45227956771850586
PROLIA,Pain in extremity,Prolia and musculoskeletal pain,0,0.7203863859176636
PROLIA,Pain in extremity,pain placebo vs Pain in extremity placebo vs Prolia and musculoskeletal,1,0.7677758932113647
PROLIA,Pain in extremity,and musculoskeletal,0,0.6784927248954773
PROLIA,Pain in extremity,pain,0,0.7890955209732056
PROLIA,Pain in extremity,in extremity placebo vs Prolia and musculoskeletal,1,0.7386671304702759
PROLIA,Pain in extremity,s were arthralgia placebo vs Prolia and back pain placebo vs,0,0.6462924480438232
PROLIA,Pain in extremity,Pain in extremity placebo,1,0.8562667369842529
PROLIA,Pain in extremity,back pain placebo vs Pain,1,0.6305102109909058
PROLIA,Pain in extremity,Pain in extremity placebo vs Prolia,1,0.7692289352416992
PROLIA,Pain in extremity,and musculoskeletal pain placebo vs Prolia have also be,0,0.6723388433456421
PROLIA,musculoskeletal pain,musculoskeletal pain,1,1.0000001192092896
PROLIA,musculoskeletal pain,extremity placebo vs Prolia musculoskeletal,1,0.6804100275039673
PROLIA,musculoskeletal pain,Prolia have also,0,0.4532517194747925
PROLIA,musculoskeletal pain,clinical trials Additionally in,0,0.5244226455688477
PROLIA,musculoskeletal pain,clinical trials Additionally in Proliat,0,0.4950597286224365
PROLIA,musculoskeletal pain,reported in,0,0.4795815050601959
PROLIA,musculoskeletal pain,back pain placebo vs Prolia Pain in extremity,0,0.6826997995376587
PROLIA,musculoskeletal pain,musculoskeletal pain placebo,1,0.8297412395477295
PROLIA,musculoskeletal pain,trials Additionally,0,0.5155787467956543
PROLIA,musculoskeletal pain,musculoskeletal pain placebo vs Prolia,1,0.7545478343963623
PROLIA,cataracts,serum calcium mgdL was,0,0.5907918810844421
PROLIA,cataracts,vs Prolia Hypocalcemia,0,0.5755085349082947
PROLIA,cataracts,cataracts was,1,0.9292140007019043
PROLIA,cataracts,ADT a greater incidence cataracts was observed placebo vs Prolia,1,0.7669485807418823
PROLIA,cataracts,serum calcium mgdL was reported,0,0.5947405099868774
PROLIA,Hypocalcemia,Hypocalcemia serum calcium,1,0.8573494553565979
PROLIA,Hypocalcemia,vs at,0,0.47006165981292725
PROLIA,Hypocalcemia,observed placebo vs Hypocalcemia serum calcium mgdL was reported,1,0.8006277084350586
PROLIA,Hypocalcemia,Hypocalcemia serum,1,0.8665881156921387
PROLIA,Hypocalcemia,Hypocalcemia serum calcium mgdL,1,0.8323447108268738
PROLIA,Hypocalcemia,calcium mgdL was reported only,0,0.688014805316925
PROLIA,Hypocalcemia,was observed placebo vs,0,0.5173840522766113
PROLIA,Hypocalcemia,vs Hypocalcemia serum,1,0.8430886268615723
PROLIA,hypersensitivity reactions,use,0,0.48837122321128845
PROLIA,hypersensitivity reactions,use of,0,0.487032413482666
PROLIA,hypersensitivity reactions,hypersensitivity reactions,1,1.0
PROLIA,hypersensitivity reactions,of Prolia hypersensitivity reactions anaphylaxis,1,0.7720345258712769
PROLIA,hypersensitivity reactions,wing adverse reactions have been identified during post approval use of,0,0.6554517149925232
PROLIA,hypersensitivity reactions,Prolia hypersensitivity,1,0.7486488819122314
PROLIA,hypersensitivity reactions,use of Prolia hypersensitivity reactions anaphylaxis rash,1,0.7576277852058411
PROLIA,hypersensitivity reactions,swelling,0,0.5810171365737915
PROLIA,anaphylaxis,anaphylaxis rash urticaria,1,0.8594182133674622
PROLIA,anaphylaxis,of Prolia Drugrelated hypersensitivity anaphylaxis,1,0.8026342391967773
PROLIA,anaphylaxis,Drugrelated hypersensitivity anaphylaxis rash urticaria facial swelling and,1,0.7617412805557251
PROLIA,anaphylaxis,hypersensitivity anaphylaxis rash,1,0.841580867767334
PROLIA,rash,rash urticaria facial,1,0.796320378780365
PROLIA,rash,reactions rash urticaria facial swelling and,1,0.7662709355354309
PROLIA,rash,of Prolia Drugrelated hypersensitivity reactions anaphylaxis,0,0.6230219006538391
PROLIA,rash,severe,0,0.5879839658737183
PROLIA,rash,Prolia Drugrelated hypersensitivity reactions rash urticaria facial swelling,1,0.677620530128479
PROLIA,rash,reactions rash urticaria facial swelling and erythema,1,0.7545221447944641
PROLIA,rash,urticaria facial swelling,0,0.6368057727813721
PROLIA,rash,Prolia Drugrelated hypersensitivity reactions rash urticaria,1,0.719030499458313
PROLIA,urticaria,severe symptomatic hypocalcemia,0,0.48786041140556335
PROLIA,urticaria,anaphylaxis,0,0.7659014463424683
PROLIA,facial swelling,urticaria,0,0.6021480560302734
PROLIA,facial swelling,rash facial swelling,1,0.8755477666854858
PROLIA,facial swelling,reactions anaphylaxis rash urticaria,0,0.5402265787124634
PROLIA,facial swelling,reactions anaphylaxis rash facial swelling,1,0.7863243818283081
PROLIA,facial swelling,facial swelling,1,1.0
PROLIA,facial swelling,facial swelling and,1,0.9769107103347778
PROLIA,facial swelling,reactions,0,0.5366828441619873
PROLIA,facial swelling,facial swelling and erythema Hypocalcemia severe,1,0.7877057790756226
PROLIA,erythema,swelling and,0,0.5913085341453552
PROLIA,erythema,facial swelling erythema,1,0.8245007991790771
PROLIA,erythema,erythema Hypocalcemia severe symptomatic hypocalcemia,1,0.7321114540100098
PROLIA,erythema,Hypocalcemia severe,0,0.5299230813980103
PROLIA,erythema,Musculoskeletal pain including severe,0,0.5752026438713074
PROLIA,erythema,erythema Hypocalcemia severe symptomatic hypocalcemia Musculoskeletal,1,0.7274612188339233
PROLIA,erythema,swelling erythema Hypocalcemia severe,1,0.7327773571014404
PROLIA,Hypocalcemia,facial swelling and Hypocalcemia severe symptomatic hypocalcemia,1,0.8210560083389282
PROLIA,Hypocalcemia,erythema Hypocalcemia severe symptomatic hypocalcemia Musculoskeletal,1,0.8045786619186401
PROLIA,symptomatic hypocalcemia,severe cases Parathyroid Hormone PTH,0,0.6960338950157166
PROLIA,symptomatic hypocalcemia,and erythema Hypocalcemia symptomatic hypocalcemia Musculoskeletal pain including,1,0.8713242411613464
PROLIA,symptomatic hypocalcemia,symptomatic hypocalcemia,1,0.9999998807907104
PROLIA,symptomatic hypocalcemia,pain including severe cases Parathyroid Hormone PTH,0,0.7012418508529663
PROLIA,symptomatic hypocalcemia,erythema Hypocalcemia symptomatic,1,0.883553683757782
PROLIA,symptomatic hypocalcemia,Hypocalcemia,0,0.9120277166366577
PROLIA,hypocalcemia,severe cases Parathyroid Hormone,0,0.6929869651794434
PROLIA,hypocalcemia,hypocalcemia,1,1.0
PROLIA,hypocalcemia,hypocalcemia Musculoskeletal pain including severe cases,1,0.8252122402191162
PROLIA,hypocalcemia,hypocalcemia Musculoskeletal pain including severe,1,0.8294458389282227
PROLIA,hypocalcemia,hypocalcemia Musculoskeletal,1,0.8558892011642456
PROLIA,hypocalcemia,severe,0,0.5173815488815308
PROLIA,hypocalcemia,cases Parathyroid Hormone PTH,0,0.6889697909355164
PROLIA,hypocalcemia,anaphylaxis rash,0,0.468264102935791
PROLIA,Musculoskeletal pain,Musculoskeletal pain including severe cases Parathyroid Hormone,1,0.8010822534561157
PROLIA,Musculoskeletal pain,Marked,0,0.535241425037384
PROLIA,Musculoskeletal pain,facial swelling and erythema Hypocalcemia severe symptomatic hypocalcemia,0,0.5313889980316162
PROLIA,Musculoskeletal pain,Musculoskeletal pain including severe,1,0.9022338390350342
PROLIA,Musculoskeletal pain,Hypocalcemia severe symptomatic Musculoskeletal pain including,1,0.7625846862792969
PROLIA,Musculoskeletal pain,symptomatic Musculoskeletal pain,1,0.9161316156387329
PROLIA,Musculoskeletal pain,facial swelling and,0,0.5614827871322632
PROLIA,elevation in serum PTH,elevation,1,0.6257998943328857
PROLIA,elevation in serum PTH,Hormone PTH elevation in serum PTH,1,0.956369936466217
PROLIA,elevation in serum PTH,Marked,0,0.4937955141067505
PROLIA,elevation in serum PTH,cases Parathyroid Hormone PTH elevation,1,0.9052021503448486
PROLIA,elevation in serum PTH,in patients with severe renal,0,0.536858320236206
PROLIA,elevation in serum PTH,elevation in serum PTH in patients,1,0.9646605253219604
PROLIA,elevation in serum PTH,Parathyroid Hormone,0,0.7886557579040527
PROLIA,elevation in serum PTH,Hormone PTH elevation in serum PTH in,1,0.9531919956207275
PROLIA,elevation in serum PTH,in serum PTH in patients with severe renal,1,0.8461480140686035
PROLIA,toxicity,altered pharmacokinetic toxicity profile or clinical,1,0.6926180124282837
PROLIA,toxicity,in serum PTH in patients with severe renal,1,0.5243883728981018
PROLIA,toxicity,toxicity,1,1.000000238418579
PROLIA,Hypersensitivity,Warnings and Pre cautions,1,0.537184476852417
PROLIA,Hypersensitivity,elsewhere in the labeling Hypocalcemia see,0,0.5380229949951172
PROLIA,Hypersensitivity,Warnings and Pre cautions Serious Infections,1,0.5544719696044922
PROLIA,Hypersensitivity,discussed below and also elsewhere in the labeling,0,0.5345346331596375
PROLIA,anaphylactic reactions,Adverse Reactions,0,0.7798902988433838
PROLIA,anaphylactic reactions,* Serious Infections see Warnings,1,0.5475926399230957
PROLIA,anaphylactic reactions,Hypocalcemia see Warnings and 5.3 )] *,1,0.5366041660308838
PROLIA,anaphylactic reactions,"and  5.3  )]  
 *  Serious",1,0.45204222202301025
PROLIA,anaphylactic reactions,)] * Serious Infections see Warnings,1,0.549788773059845
PROLIA,anaphylactic reactions,)] * Serious Infections,1,0.5442562103271484
PROLIA,anaphylactic reactions,5.3 )] *,1,0.4508694112300873
PROLIA,Hypocalcemia,Warnings and Precautions Osteonecrosis of,1,0.5423798561096191
PROLIA,Hypocalcemia,the Jaw see,0,0.5611975193023682
PROLIA,Hypocalcemia,rious Infections see Warnings and Precautions Dermatologic Adverse,0,0.4833475351333618
PROLIA,Hypocalcemia,Warnings and Precautions Dermatologic Adverse,0,0.486804723739624
PROLIA,Hypocalcemia,Adverse Reactions Warnings,1,0.5272074341773987
PROLIA,Osteonecrosis of the jaw,and Diaphyseal,0,0.573347806930542
PROLIA,Osteonecrosis of the jaw,see Warnings and,0,0.49806249141693115
PROLIA,Osteonecrosis of the jaw,with Prolia in patients with postmenopausal,0,0.5325741767883301
PROLIA,Osteonecrosis of the jaw,( 5.5 )] The most,1,0.402013897895813
PROLIA,Osteonecrosis of the jaw,Precautions ( 5.5 )] The most common adverse,1,0.5009851455688477
PROLIA,Atypical femoral fractures,with postmenopausal os teoporosis are,1,0.6376012563705444
PROLIA,Atypical femoral fractures,patie,0,0.46846652030944824
PROLIA,infections,men with osteoporosis are back pain arthralgia,0,0.49696534872055054
PROLIA,infections,mon advers e reactions reported,1,0.5508118867874146
PROLIA,infections,in men with osteoporosis are back pain arthralgia and nasopharyng,0,0.5485212802886963
PROLIA,infections,and cystitis The,0,0.6811821460723877
PROLIA,infections,mon advers e reactions reported with Prolia,1,0.5731879472732544
PROLIA,infections,The most mon,1,0.494705468416214
PROLIA,infections,and cystitis The most mon advers e reactions reported with Prolia,1,0.6125743389129639
PROLIA,infections,mon advers e reactions,1,0.552557110786438
PROLIA,skin infections,The most common adverse reported,1,0.5332376956939697
PROLIA,Dermatologic reactions,in patients with e loss receiving,1,0.5154048204421997
PROLIA,Dermatologic reactions,in patients with e loss receiving andro gen,1,0.5360901355743408
PROLIA,Dermatologic reactions,e loss receiving andro gen deprivation therapy for,1,0.5427712202072144
PROLIA,Dermatologic reactions,in patients with e loss receiving andro gen deprivation therapy for prostate,1,0.5163223743438721
PROLIA,Dermatologic reactions,with e loss receiving,1,0.4523065686225891
PROLIA,Dermatologic reactions,patients with bon,0,0.582440972328186
PROLIA,Dermatologic reactions,patients with e loss receiving andro gen deprivation therapy for prostate,1,0.5133790373802185
PROLIA,Dermatologic reactions,receiving andro gen deprivation therapy for,1,0.5483089089393616
PROLIA,Dermatologic reactions,loss receiving andro gen,1,0.4964165985584259
PROLIA,Dermatitis,n deprivat ion therapy,1,0.5231278538703918
PROLIA,Dermatitis,n deprivat ion,1,0.5797975063323975
PROLIA,Dermatitis,with bone loss receiving n deprivat ion therapy for prostate cancer,1,0.46261337399482727
PROLIA,Dermatitis,with bone loss receiving n,1,0.4834947884082794
PROLIA,Dermatitis,or adjuvant aromatase inhibitor,0,0.524519681930542
PROLIA,Dermatitis,receiving n deprivat ion therapy for,1,0.520026683807373
PROLIA,Dermatitis,loss receiving n deprivat ion therapy,1,0.523170530796051
PROLIA,Dermatitis,with bone loss receiving n deprivat ion,1,0.509116530418396
PROLIA,Dermatitis,ncidence adverse reactions,0,0.6356116533279419
PROLIA,rashes,n ther apy for,1,0.521889865398407
PROLIA,rashes,ncidence adverse reactions,0,0.6290217638015747
PROLIA,rashes,receiving androgen n ther apy,1,0.5300217866897583
PROLIA,rashes,bone loss receiving androgen,0,0.493819922208786
PROLIA,rashes,loss receiving androgen n ther,1,0.5345371961593628
PROLIA,eczema,androgen deprivation therapy r pros,1,0.4984126091003418
PROLIA,Muscle Pain,emity and m usculoskeletal pain have also been,1,0.7013362646102905
PROLIA,Muscle Pain,androgen deprivation therapy r pros,1,0.5016583204269409
PROLIA,Muscle Pain,pain Pain in emity and m usculoskeletal pain,1,0.7342994213104248
PROLIA,Muscle Pain,in clinical,0,0.49110713601112366
PROLIA,Muscle Pain,pain have also been reported in clinical trials The most,0,0.6248719096183777
PROLIA,Muscle Pain,pain Pain in emity and,1,0.7341703176498413
PROLIA,Muscle Pain,emity and m usculoskeletal pain have,1,0.7141304612159729
PROLIA,Muscle Pain,Pain in emity and m usculoskeletal pain have,1,0.7232692837715149
PROLIA,Suppression of bone turnover,he most common,1,0.44917577505111694
PROLIA,hypersensitivity,thi,0,0.5687249898910522
PROLIA,hypersensitivity,s program. EXCERPT Postmenopausal,1,0.5359728336334229
PROLIA,hypersensitivity,more information about s,1,0.5415442585945129
PROLIA,anaphylaxis,this program     *  Post,1,0.5370351076126099
PROLIA,anaphylaxis,more information about s,1,0.49297940731048584
PROLIA,anaphylaxis,* Post menopausal osteoporosis Most common,1,0.46674948930740356
PROLIA,hypotension,back pain pain in extremity hypercholesterolemia musculoskeletal,0,0.5271778106689453
PROLIA,hypotension,common adverse (> 5% and m ore common than placebo,1,0.5351918935775757
PROLIA,hypotension,and m ore common,1,0.4593181908130646
PROLIA,hypotension,adverse (> 5% and,1,0.5402806997299194
PROLIA,hypotension,5% and m ore common than placebo,1,0.5427510738372803
PROLIA,hypotension,out this program EXCERPT Postmenopausal osteoporosis Most common,0,0.49661052227020264
PROLIA,hypotension,were back pain pain,0,0.5358589887619019
PROLIA,dyspnea,e commo n,1,0.524058997631073
PROLIA,dyspnea,common adverse reactions and e commo n than placebo were,1,0.5210792422294617
PROLIA,dyspnea,and e,1,0.5391736626625061
PROLIA,dyspnea,e commo n than placebo,1,0.5193825364112854
PROLIA,throat tightness,more than placebo),1,0.5365525484085083
PROLIA,throat tightness,than placebo) we re back pain pain,1,0.5044195652008057
PROLIA,upper airway edema,Pancreatitis,0,0.526247501373291
PROLIA,upper airway edema,pain in extremit y,1,0.47887539863586426
PROLIA,upper airway edema,common adverse reactions and more common than placebo were back,0,0.5496972799301147
PROLIA,upper airway edema,common,0,0.4965643882751465
PROLIA,upper airway edema,in extremit,1,0.5033220052719116
PROLIA,upper airway edema,pain in extremit y hypercholesterolemia musculoskeletal pain,1,0.49344414472579956
PROLIA,upper airway edema,pain in extremit y hypercholesterolemia musculoskeletal pain and,1,0.49713167548179626
PROLIA,upper airway edema,"than placebo were back , pain",1,0.5060573816299438
PROLIA,pruritus,pain pain in  hyperch,1,0.6308501958847046
PROLIA,pruritus,"than placebo were back , pain",1,0.6246015429496765
PROLIA,pruritus, hyperch olesterolemia musculoskeletal pain and cystitis,1,0.6270439624786377
PROLIA,pruritus, hyperch olesterolemia musculoskeletal pain,1,0.6323606371879578
PROLIA,pruritus, hyperch olesterolemia,1,0.5841000080108643
PROLIA,urticaria,musculoskeletal pain and cystitis Pancreatitis has been,0,0.5075207352638245
PROLIA,urticaria,than placebo were back pain pain in extremity,0,0.4813464283943176
PROLIA,urticaria,"rolemia,  musculoskeletal pain",1,0.5023667812347412
PROLIA,urticaria,in clinical trials,0,0.5067300796508789
PROLIA,urticaria,"rolemia,  musculoskeletal pain and cystitis",1,0.49794477224349976
PROLIA,urticaria,"rolemia, ",1,0.4930570423603058
PROLIA,hypocalcemia,drug cannot be directly pared to rat es in the,1,0.49369001388549805
PROLIA,hypocalcemia,"rolemia, ",1,0.49416011571884155
PROLIA,hypocalcemia,be directly pared to rat es in the clinical studies,1,0.5108343362808228
PROLIA,hypocalcemia,the clinical studies,0,0.5050038695335388
PROLIA,hypocalcemia,to rat es,1,0.4426807761192322
PROLIA,Hypocalcemia,Women ith,1,0.5035649538040161
PROLIA,Hypocalcemia,not reflect the rates observed in clinical practice Treatment of Postmenopausal Women w,0,0.47131624817848206
PROLIA,Hypocalcemia,Women ith Osteopor osis,1,0.5469021797180176
PROLIA,Hypocalcemia,Treatment of Postmenopausal Women ith Osteopor,1,0.5664845108985901
PROLIA,Hypocalcemia,postmenopausal osteoporosis was assessed in a,0,0.5783205628395081
PROLIA,Hypocalcemia,Postmenopausal Women ith,1,0.5208606719970703
PROLIA,Hypocalcemia,practice Treatment of,0,0.5129412412643433
PROLIA,Hypocalcemia,Postmenopausal Women ith Osteopor,1,0.5788511633872986
PROLIA,Hypocalcemia,osteoporosis was assessed in,0,0.6145362854003906
PROLIA,elevations of serum parathyroid hormone,study of l women aged 60 to 91 years. A total of women were,1,0.5208672285079956
PROLIA,elevations of serum parathyroid hormone,osteoporosis was assessed in,0,0.6369278430938721
PROLIA,elevations of serum parathyroid hormone,doubleblind placebocontrolled multinational study,0,0.5162390470504761
PROLIA,elevations of serum parathyroid hormone,placebocontrolled multinational study of l women aged 60 to 91 years. A total of women were exposed,1,0.5525781512260437
PROLIA,elevations of serum parathyroid hormone,aged 60 to 91 years. A total of women were,1,0.4769192337989807
PROLIA,elevations of serum parathyroid hormone,were exposed,0,0.5392865538597107
PROLIA,elevations of serum parathyroid hormone,postmenopausa,0,0.5498125553131104
PROLIA,ONJ,adverse events was,0,0.5089640617370605
PROLIA,ONJ,events was and for,0,0.5333883762359619
PROLIA,ONJ,was and for the placebo and Prolia groups respectively Adverse reac,0,0.5142730474472046
PROLIA,ONJ,postmenopausal women with osteoporosis and more frequently,0,0.4773867428302765
PROLIA,ONJ,ns,0,0.5078195929527283
PROLIA,ONJ,tio ns,1,0.5850561261177063
PROLIA,ONJ,tio ns reported in of postmenopausal,1,0.49972158670425415
PROLIA,ONJ,tio ns reported in,1,0.56471848487854
PROLIA,Atypical femoral fractures,(2.0) Pruritus Hypocalcemia Decreases in serum calcium,1,0.49226874113082886
PROLIA,Atypical femoral fractures,"SUBCUTANEOUS TISSUE DISORDERS  (2.0)   
     Pruritus    Hypocalcemia Decreases in",1,0.5035427808761597
PROLIA,thigh pain,in  Prolia gr oup The nadir in serum,1,0.4249229431152344
PROLIA,thigh pain,(2.0) Pruritus Hypocalcemia Decreases in serum calcium,1,0.4844520092010498
PROLIA,thigh pain,the,0,0.4715937077999115
PROLIA,thigh pain,in the placebo group and,0,0.49368351697921753
PROLIA,thigh pain,nadir in serum calcium level occurs at approximately day after Prolia dosing in subjects,0,0.4379422962665558
PROLIA,thigh pain, Prolia gr oup The nadir,1,0.4428703784942627
PROLIA,thigh pain,group and women in Prolia gr,1,0.4292832016944885
PROLIA,thigh pain,women in Prolia gr,1,0.43209779262542725
PROLIA,thigh pain,in women in the,0,0.4692023694515228
PROLIA,skin infections,vs n subjects with,1,0.49012088775634766
PROLIA,skin infections,in women in the,0,0.481603741645813
PROLIA,skin infections,subjects with creatinine clearance mLmin Serious Infections,1,0.6272023916244507
PROLIA,skin infections,creatinine clearance mLmin vs n subjects,1,0.471266508102417
PROLIA,skin infections,n subjects with creatinine clearance mLmin Serious Infections,1,0.6253594160079956
PROLIA,skin infections,clearance,0,0.456500768661499
PROLIA,skin infections,n subjects with creatinine clearance,1,0.48851948976516724
PROLIA,skin infections,Prolia dosing was in subjects with creatinine clearance mLmin,0,0.47096124291419983
PROLIA,infections of the abdomen,RANKL is expressed,0,0.4444947838783264
PROLIA,infections of the abdomen,ligand RANKL is expressed on,0,0.4252413809299469
PROLIA,infections of the abdomen,with creatinine learance >=,1,0.4672068953514099
PROLIA,Endocarditis,kappaB RANKL) is ex,1,0.47750675678253174
PROLIA,Endocarditis,with creatinine learance >=,1,0.5138838291168213
PROLIA,Endocarditis,nuclear factor kappaB RANKL) is ex pressed on activated T and,1,0.5040505528450012
PROLIA,opportunistic infections,and B lymphocytes and,0,0.5548301935195923
PROLIA,infections,menopausal women with osteoporosis,1,0.47870323061943054
PROLIA,infections,the clinical study of,0,0.5504189729690552
PROLIA,infections,the,0,0.5522018074989319
PROLIA,infections,(0.7% pl acebo vs Prolia,1,0.5224030613899231
PROLIA,infections,in the n (0.7% pl acebo vs Prolia,1,0.5318665504455566
PROLIA,infections,n (0.7% pl acebo vs Prolia,1,0.5361324548721313
PROLIA,dermal adverse events,that reported with,0,0.506436824798584
PROLIA,dermal adverse events,(< 0.1% placebo vs Prolia The,1,0.5776864886283875
PROLIA,dermal adverse events,The incidence of opportunistic infections was,0,0.5716586112976074
PROLIA,dermal adverse events,to that reported with p,0,0.507297933101654
PROLIA,dermal adverse events,in patients treated with rolia (<,1,0.5926724076271057
PROLIA,dermal adverse events,rolia (< 0.1% placebo,1,0.5817012786865234
PROLIA,dermal adverse events,rolia,1,0.49756354093551636
PROLIA,dermal adverse events,The incidence of opportunistic infections was similar to that,0,0.5625728368759155
PROLIA,dermatitis," Prolia).
 The incidence of opportunistic",1,0.5264734029769897
PROLIA,dermatitis,vs,0,0.5169707536697388
PROLIA,dermatitis," Prolia).
",1,0.47589677572250366
PROLIA,dermatitis,"Prolia placebo  Prolia).
 The incidence of",1,0.5094462633132935
PROLIA,dermatitis," Prolia).
 The incidence of",1,0.5304667353630066
PROLIA,dermatitis,with Prolia placebo,0,0.5049523711204529
PROLIA,dermatitis,"treated with Prolia placebo  Prolia).
",1,0.49803388118743896
PROLIA,dermatitis,"with Prolia placebo  Prolia).
",1,0.496632844209671
PROLIA,eczema,frequently in patients treated,0,0.5331265926361084
PROLIA,eczema,of opportunistic infections was,0,0.5064150094985962
PROLIA,rashes,The nce,1,0.4805554151535034
PROLIA,muscle pain,events were not pecific to  the injection,1,0.4816685914993286
PROLIA,muscle pain,The nce,1,0.4292639195919037
PROLIA,muscle pain,were not pecific,1,0.44710856676101685
PROLIA,suppression of bone remodeling,Prolia The duration of ia exposure to time of atypica,1,0.5606604814529419
PROLIA,suppression of bone remodeling,Warnings and,0,0.5121355056762695
PROLIA,suppression of bone remodeling,treated with Prolia,0,0.5940136909484863
PROLIA,suppression of bone remodeling,ia exposure to time of atypica l femoral fracture,1,0.598831057548523
PROLIA,suppression of bone remodeling,was as early as years,0,0.5108697414398193
PROLIA,suppression of bone remodeling,of atypica l,1,0.4887171983718872
PROLIA,suppression of bone remodeling,in the Prolia group had serious,1,0.49408525228500366
PROLIA,suppression of bone remodeling,group and 8,1,0.43683937191963196
PROLIA,suppression of bone remodeling,in,0,0.4888277053833008
PROLIA,suppression of bone remodeling,and all,0,0.4610868990421295
PROLIA,osteonecrosis of the jaw,the,0,0.4605024456977844
PROLIA,osteonecrosis of the jaw,group eral,1,0.4659166634082794
PROLIA,osteonecrosis of the jaw,Prolia,0,0.4424898028373718
PROLIA,osteonecrosis of the jaw,group eral patients,1,0.5251642465591431
PROLIA,osteonecrosis of the jaw,history of pancreatitis The time from product administration to event,0,0.5005401372909546
PROLIA,osteonecrosis of the jaw,of pancreatitis The time from product,0,0.5091012716293335
PROLIA,atypical fractures,of pancrea titis The,1,0.506746768951416
PROLIA,atypical fractures,of pancrea titis The time,1,0.5171234011650085
PROLIA,atypical fractures,a history of pancrea titis The time,1,0.4974885880947113
PROLIA,delayed fracture healing,of The time,1,0.5072287321090698
PROLIA,delayed fracture healing,product a dministration to event occurrence,1,0.4731052815914154
PROLIA,delayed fracture healing,from product a dministration to event occurrence was,1,0.47462061047554016
PROLIA,delayed fracture healing,group Several patients had a prior history,0,0.5578035116195679
FANAPT,dizziness,fatigue nasal,0,0.6247996091842651
FANAPT,dizziness,adverse reactions incidence and fold greater than placebo were,0,0.5373733043670654
FANAPT,dizziness,tachycardia and weight,0,0.5739980936050415
FANAPT,dry mouth,dry mouth,1,1.0
FANAPT,dry mouth,greater than placebo,0,0.5659536123275757
FANAPT,dry mouth,than placebo were dry mouth fatigue nasal,1,0.8206683993339539
FANAPT,dry mouth,observed adverse reactions incidence and fold greater,0,0.5100470781326294
FANAPT,dry mouth,were dry mouth,1,0.9677225351333618
FANAPT,dry mouth,dry mouth fatigue nasal congestion orthostatic,1,0.8138527274131775
FANAPT,fatigue,dizziness dry fatigue nasal congestion,1,0.7360107898712158
FANAPT,fatigue,were dry mouth,1,0.6219240427017212
FANAPT,nasal congestion,and weight,0,0.4753263294696808
FANAPT,nasal congestion,dizziness dry mouth nasal,1,0.7528834939002991
FANAPT,nasal congestion,orthostatic hypotension somnolence tachycardia and,0,0.5206649303436279
FANAPT,nasal congestion,tachycardia and,0,0.4883737564086914
FANAPT,nasal congestion,and fold greater than placebo,0,0.5087530016899109
FANAPT,nasal congestion,increased,0,0.547440767288208
FANAPT,somnolence,somnolence tachycardia and weight,1,0.7677723169326782
FANAPT,somnolence,nasal congestion orthostatic somnolence tachycardia,1,0.7525057792663574
FANAPT,somnolence,somnolence tachycardia and weight increased,1,0.7484784722328186
FANAPT,tachycardia,tachycardia and weight increased To report,1,0.7997949123382568
FANAPT,weight increased,REACTIONS contact Novartis Pharmaceuticals Corporatio,0,0.4819794297218323
FANAPT,weight increased,Novartis Pharmaceuticals,0,0.45854631066322327
FANAPT,weight increased,weight increased,1,1.0
FANAPT,weight increased,somnolence,0,0.4688946008682251
FANAPT,Weight Increased,Musculoskeletal Weight Increased,1,0.8823972344398499
FANAPT,Weight Increased,somnolence,0,0.4688946008682251
FANAPT,Weight Increased,Weight Increased Cardiac,1,0.8383810520172119
FANAPT,Weight Increased,Musculoskeletal Stiffness,0,0.5666731595993042
FANAPT,Weight Increased,Weight Increased Cardiac Disorders,1,0.7615885138511658
FANAPT,Weight Increased,Weight Increased,1,1.0
FANAPT,Weight Increased,Musculoskeletal Weight Increased Cardiac Disorders,1,0.7375800609588623
FANAPT,Vision Blurred,Eye Vision Blurred Gastrointestinal,1,0.8147650957107544
FANAPT,Vision Blurred,Weight Increased Cardiac,1,0.48135384917259216
FANAPT,Vision Blurred,Vision Blurred,1,1.0000001192092896
FANAPT,Nausea,Gastrointestinal Nausea,1,0.8668369054794312
FANAPT,Nausea,Vision Blurred,1,0.553012490272522
FANAPT,Diarrhea,Dry Diarrhea,1,0.8499348163604736
FANAPT,Diarrhea,Vision Blurred,1,0.5416254997253418
FANAPT,Hypotension,Hypotension Table includes adverse,1,0.8232629895210266
FANAPT,Hypotension,Hypotension,1,1.0
FANAPT,Hypotension,Table includes adverse reactions,0,0.5368508100509644
FANAPT,Hypotension,Hypotension Table includes adverse reactions,1,0.8086941242218018
FANAPT,Hypotension,Hypotension Table,1,0.8738176822662354
FANAPT,Hypotension,Hypotension,0,1.0
FANAPT,Hypotension,Hypotension Table includes,1,0.8539503812789917
FANAPT,Hypotension,Orthostatic Hypotension,0,0.8801928758621216
FANAPT,Hypotension,includes adverse,0,0.5390233993530273
FANAPT,abdominal discomfort,to mgday abdominal discomfort dizziness hypotension,1,0.8048430681228638
FANAPT,abdominal discomfort,includes adverse,0,0.5440946817398071
FANAPT,dizziness,dizziness hypotension musculoskeletal stiffness tachycardia and,1,0.7618831992149353
FANAPT,dizziness,dizziness hypotension,1,0.8775063753128052
FANAPT,dizziness,Common and,0,0.4889354407787323
FANAPT,dizziness,stiffness tachycardia,0,0.5813823342323303
FANAPT,dizziness,dizziness hypotension musculoskeletal,1,0.7889190316200256
FANAPT,dizziness,dizziness,1,0.9999998807907104
FANAPT,hypotension,increased Common and DrugRelated,0,0.49567824602127075
FANAPT,hypotension,and DrugRelated,0,0.506671130657196
FANAPT,hypotension,hypotension musculoskeletal stiffness tachycardia and weight,1,0.7613946199417114
FANAPT,hypotension,weight increased Common,0,0.5189831852912903
FANAPT,musculoskeletal stiffness,musculoskeletal stiffness tachycardia,1,0.8607532382011414
FANAPT,musculoskeletal stiffness,musculoskeletal stiffness tachycardia and weight increased Common,1,0.8383976817131042
FANAPT,musculoskeletal stiffness,were abdominal discomfort dizziness musculoskeletal,1,0.7016862034797668
FANAPT,tachycardia,discomfort dizziness,0,0.5564854145050049
FANAPT,tachycardia,and DrugRelated Adverse Reactions in Clinical Trials Ba,0,0.5730756521224976
FANAPT,tachycardia,tachycardia and weight increased Common and,1,0.8146674633026123
FANAPT,tachycardia,abdominal discomfort dizziness hypotension musculoskeletal stiffness,0,0.5973209738731384
FANAPT,tachycardia,dizziness hypotension musculoskeletal tachycardia and weight increased,1,0.7250192165374756
FANAPT,tachycardia,tachycardia and weight increased,1,0.8087780475616455
FANAPT,tachycardia,tachycardia and,1,0.9360133409500122
FANAPT,tachycardia,weight increased Common and DrugRelated Adverse Reactions in,0,0.5236033797264099
FANAPT,weight increased,weight increased Common and,1,0.9045345187187195
FANAPT,weight increased,weight increased Common and DrugRelated Adverse,1,0.7891715168952942
FANAPT,weight increased,weight increased Common,1,0.9351149201393127
FANAPT,weight increased,day were abdominal discomfort dizziness hypotension musculoskeletal stiffness tachycardia,0,0.5595042705535889
FANAPT,weight increased,stiffness tachycardia weight,1,0.6696673631668091
FANAPT,weight increased,dizziness hypotension musculoskeletal,0,0.5450228452682495
FANAPT,dizziness,dizziness dry,1,0.8765573501586914
FANAPT,dizziness,dizziness hypotension musculoskeletal,0,0.7889190316200256
FANAPT,dizziness,dizziness dry mouth fatigue nasal,1,0.7917177081108093
FANAPT,dry mouth,for at least dose dry,1,0.7201703786849976
FANAPT,dry mouth,least dose dry mouth fatigue nasal congestion,1,0.8040722608566284
FANAPT,dry mouth,tachycardia orthostatic hypotension and weight increased,0,0.5007617473602295
FANAPT,fatigue,fatigue nasal congestion somnolence,1,0.775888979434967
FANAPT,fatigue,fatigue nasal congestion somnolence tachycardia orthostatic,1,0.7451276183128357
FANAPT,fatigue,orthostatic hypotension,0,0.5613559484481812
FANAPT,fatigue,somnolence,0,0.6411272287368774
FANAPT,fatigue,dry fatigue nasal congestion,1,0.7474855780601501
FANAPT,nasal congestion,nasal congestion somnolence tachycardia orthostatic hypotension and,1,0.7743123173713684
FANAPT,nasal congestion,nasal congestion somnolence tachycardia,1,0.794288158416748
FANAPT,nasal congestion,for at least dose dizziness dry mouth fatigue,0,0.6092225313186646
FANAPT,nasal congestion,dry mouth nasal congestion somnolence tachycardia orthostatic hypotension and,1,0.7331591248512268
FANAPT,nasal congestion,weight increased,0,0.5047615170478821
FANAPT,nasal congestion,dose dizziness dry mouth nasal congestion,1,0.800804853439331
FANAPT,somnolence,for,0,0.5322664380073547
FANAPT,somnolence,fatigue nasal somnolence,1,0.8229515552520752
FANAPT,somnolence,and weight increased Dizziness tachycardia and,0,0.5691182017326355
FANAPT,tachycardia,tachycardia orthostatic,1,0.8062753677368164
FANAPT,tachycardia,and weight increased Dizziness tachycardia and,0,0.7488620281219482
FANAPT,tachycardia,dose dizziness dry,0,0.5414804816246033
FANAPT,tachycardia,tachycardia orthostatic hypotension and,1,0.8178985118865967
FANAPT,tachycardia,hypotension and weight increased Dizziness tachycardia and weight increased were a,0,0.7204805016517639
FANAPT,tachycardia,tachycardia orthostatic hypotension,1,0.8024680614471436
FANAPT,tachycardia,placebo rate for,0,0.5659803152084351
FANAPT,tachycardia,mouth fatigue nasal congestion tachycardia orthostatic hypotension and weight increased,1,0.6817902326583862
FANAPT,tachycardia,congestion tachycardia orthostatic hypotension and,1,0.7776628732681274
FANAPT,orthostatic hypotension,nasal congestion somnolence orthostatic hypotension,1,0.8329264521598816
FANAPT,orthostatic hypotension,placebo rate for,0,0.5550867319107056
FANAPT,orthostatic hypotension,tachycardia,0,0.6326419115066528
FANAPT,orthostatic hypotension,for at least dose dizziness dry,0,0.6048487424850464
FANAPT,orthostatic hypotension,somnolence orthostatic hypotension,1,0.8955202698707581
FANAPT,weight increased,weight increased Dizziness,1,0.7706868648529053
FANAPT,weight increased,weight increased Dizziness tachycardia,1,0.7393911480903625
FANAPT,weight increased,hypotension weight increased Dizziness tachycardia and,1,0.6334124803543091
FANAPT,weight increased,somnolence tachycardia orthostatic hypotension weight,1,0.6017388105392456
FANAPT,weight increased,orthostatic hypotension weight increased,1,0.7549194693565369
FANAPT,weight increased,fatigue,0,0.5581046342849731
FANAPT,tachycardia,were at least twice as common on to mgday as on to,0,0.5009689927101135
FANAPT,tachycardia,weight increased,0,0.4790704846382141
FANAPT,tachycardia,tachycardia,1,0.9999999403953552
FANAPT,tachycardia,common on to mgday as on to,0,0.5245819091796875
FANAPT,tachycardia,were at least twice as common,0,0.49344170093536377
FANAPT,weight increased,increased Dizziness tachycardia weight increased,1,0.7629798650741577
FANAPT,weight increased,tachycardia weight increased,1,0.802052915096283
FANAPT,weight increased,increased Dizziness tachycardia,0,0.563734769821167
FANAPT,weight increased,to mgday as,0,0.5256503820419312
FANAPT,weight increased,weight increased were at least twice,1,0.9337682723999023
FANAPT,weight increased,weight increased Dizziness tachycardia weight increased,1,0.7874357104301453
FANAPT,EPS-related adverse events,event,0,0.5365232825279236
FANAPT,EPS-related adverse events,event data collected from those trials showed,0,0.6066814064979553
FANAPT,EPS-related adverse events,adverse events as shown in Table Table,1,0.7407711744308472
FANAPT,EPS-related adverse events,rates EPS-related adverse events as,1,0.9478603601455688
FANAPT,EPS-related adverse events,of,0,0.48483550548553467
FANAPT,EPS,EPSrelated adverse events as shown,0,0.6593658924102783
FANAPT,EPS,EPS Compared to,1,0.8809651136398315
FANAPT,anemia,anemia iron deficiency,1,0.8442137837409973
FANAPT,anemia,anemia iron deficiency anemia,1,0.8644252419471741
FANAPT,anemia,anemia iron,1,0.905601978302002
FANAPT,anemia,and Lymphatic Disorders,0,0.5441610217094421
FANAPT,anemia,and Lymphatic Disorders anemia iron deficiency,1,0.7287591695785522
FANAPT,anemia,anemia iron deficiency anemia Rare leukopenia,1,0.7683233022689819
FANAPT,anemia,Blood and,0,0.7049142122268677
FANAPT,iron deficiency anemia,Cardiac Disorders Frequent palpitations,0,0.42254191637039185
FANAPT,iron deficiency anemia,Disorders,0,0.5530179738998413
FANAPT,iron deficiency anemia,in fewer than patients Blood and,0,0.6280375719070435
FANAPT,iron deficiency anemia,iron deficiency anemia,1,0.9999998211860657
FANAPT,iron deficiency anemia,in fewer than patients Blood and Lymphatic Disorders Infrequent anemia,0,0.7331458330154419
FANAPT,iron deficiency anemia,iron deficiency anemia Rare leukopenia,1,0.8048924207687378
FANAPT,iron deficiency anemia,Frequent palpitations Rare arrhythmia atriov,0,0.46536433696746826
FANAPT,iron deficiency anemia,Infrequent iron deficiency anemia Rare leukopenia Cardiac Disorders,1,0.7674728631973267
FANAPT,iron deficiency anemia,in fewer than patients Blood and Lymphatic Disorders Infrequent,0,0.5882986783981323
FANAPT,leukopenia,leukopenia Cardiac Disorders,1,0.8234109878540039
FANAPT,palpitations,Cardiac Disorders palpitations,1,0.9227930307388306
FANAPT,palpitations,leukopenia Cardiac Disorders,1,0.5772263407707214
FANAPT,arrhythmia,arrhythmia atrioventricular block first degree,1,0.77353435754776
FANAPT,arrhythmia,deficiency anemia Rare leukopenia Cardiac Disorders Frequent palpitations,0,0.7029207944869995
FANAPT,arrhythmia,first degree cardiac failure including,0,0.621881365776062
FANAPT,arrhythmia,Rare leukopenia,0,0.47553154826164246
FANAPT,arrhythmia,Disorders Frequent palpitations arrhythmia atrioventricular block first,1,0.7835777997970581
FANAPT,atrioventricular block,Cardiac Disorders,0,0.6557111740112305
FANAPT,atrioventricular block,anemia,0,0.508106529712677
FANAPT,atrioventricular block,atrioventricular block first,1,0.920886754989624
FANAPT,vertigo,cardiac failure,0,0.5614496469497681
FANAPT,vertigo,vertigo tinnitus Endocrine Disorders,1,0.7638400197029114
FANAPT,vertigo,vertigo tinnitus Endocrine,1,0.7884963750839233
FANAPT,vertigo,Eye Disorders,0,0.5610060691833496
FANAPT,vertigo,acute Ear and Labyrinth,0,0.6984628438949585
FANAPT,vertigo,Eye,0,0.6013036966323853
FANAPT,vertigo,Labyrinth Disorders vertigo tinnitus Endocrine Disorders,1,0.7546796798706055
FANAPT,vertigo,tinnitus Endocrine Disorders,0,0.5752202868461609
FANAPT,vertigo,vertigo tinnitus Endocrine Disorders Infrequent hypothyroidism,1,0.7344830632209778
FANAPT,tinnitus,Endocrine Disorders Infrequent hypothyroidism,0,0.5490109324455261
FANAPT,tinnitus,Disorders Infrequent tinnitus Endocrine Disorders Infrequent hypothyroidism Eye,1,0.7644771933555603
FANAPT,tinnitus,Infrequent hypothyroidism Eye Disorders Frequent,0,0.5166743993759155
FANAPT,tinnitus,tinnitus Endocrine Disorders Infrequent hypothyroidism,1,0.7903088331222534
FANAPT,hypothyroidism,hypothyroidism Eye Disorders,1,0.8191321492195129
FANAPT,hypothyroidism,Endocrine Disorders hypothyroidism,1,0.895278811454773
FANAPT,hypothyroidism,hypothyroidism Eye Disorders Frequent conjunctivitis,1,0.7781097292900085
FANAPT,hypothyroidism,dry,0,0.5114455819129944
FANAPT,hypothyroidism,hypothyroidism Eye Disorders Frequent conjunctivitis including,1,0.7743430733680725
FANAPT,hypothyroidism,tinnitus Endocrine Disorders hypothyroidism,1,0.7928999662399292
FANAPT,hypothyroidism,Infrequent,0,0.5225160121917725
FANAPT,conjunctivitis,conjunctivitis including allergic Infrequent,1,0.8355656862258911
FANAPT,conjunctivitis,conjunctivitis including allergic,1,0.8683542013168335
FANAPT,conjunctivitis,Infrequent hypothyroidism,0,0.4692961275577545
FANAPT,conjunctivitis,conjunctivitis,1,1.0
FANAPT,dry eye,cataract hyperemia including,0,0.5410096049308777
FANAPT,dry eye,dry eye blepharitis eyelid edema,1,0.8394616842269897
FANAPT,dry eye,including allergic dry eye,1,0.8653198480606079
FANAPT,dry eye,conjunctivitis including allergic dry,1,0.8084390759468079
FANAPT,dry eye,Disorders,0,0.5422484278678894
FANAPT,dry eye,allergic dry eye,1,0.8822489976882935
FANAPT,dry eye,blepharitis eyelid,0,0.7542873620986938
FANAPT,blepharitis,eyelid edema eye,0,0.73126220703125
FANAPT,blepharitis,cataract hyperemia,0,0.5268665552139282
FANAPT,blepharitis,blepharitis eyelid edema eye,1,0.8773549795150757
FANAPT,eye swelling,conjunctivitis including allergic Infrequent dry eye blepharitis eyelid edema,0,0.7507224082946777
FANAPT,eye swelling,dry eye blepharitis eyelid eye swelling lenticular opacities,1,0.7821660041809082
FANAPT,eye swelling,cataract hyperemia including conjunctival,0,0.6669086217880249
FANAPT,lenticular opacities,lenticular opacities,1,1.000000238418579
FANAPT,lenticular opacities,Infrequent dry,0,0.5584993362426758
FANAPT,lenticular opacities,lenticular opacities cataract hyperemia including conjunctival,1,0.8073393106460571
FANAPT,lenticular opacities,hyperemia including conjunctival,0,0.6252801418304443
FANAPT,lenticular opacities,including conjunctival Gastrointestinal Disorders Infrequent gastr,0,0.6294821500778198
FANAPT,cataract,hyperemia including conjunctival Gastrointestinal Disorders Infrequent,0,0.5726931095123291
FANAPT,cataract,cataract hyperemia including conjunctival Gastrointestinal Disorders,1,0.7455702424049377
FANAPT,cataract,cataract hyperemia including conjunctival Gastrointestinal,1,0.7528485059738159
FANAPT,cataract,cataract hyperemia,1,0.8145764470100403
FANAPT,hyperemia,swelling lenticular opacities hyperemia including,1,0.7955969572067261
FANAPT,hyperemia,cataract hyperemia,1,0.77836012840271
FANAPT,gastritis,gastritis salivary hypersecretion fecal,1,0.789279580116272
FANAPT,gastritis,ities,0,0.5727119445800781
FANAPT,gastritis,gastritis salivary hypersecretion fecal incontinence,1,0.7749115228652954
FANAPT,gastritis,hypersecretion fecal,0,0.5834329128265381
FANAPT,salivary hypersecretion,Rare aphthous stomatitis,0,0.5823348760604858
FANAPT,salivary hypersecretion,salivary hypersecretion,1,1.0
FANAPT,salivary hypersecretion,ulceration Rare,0,0.5630150437355042
FANAPT,salivary hypersecretion,salivary hypersecretion fecal incontinence mouth ulceration,1,0.8493832945823669
FANAPT,salivary hypersecretion,Disorders Infrequent salivary hypersecretion fecal incontinence mouth ulceration,1,0.8274932503700256
FANAPT,salivary hypersecretion,ulcer,0,0.5720834732055664
FANAPT,salivary hypersecretion,conjunctival Gastrointestinal Disorders Infrequent salivary hypersecretion fecal incontinence,1,0.7550646066665649
FANAPT,salivary hypersecretion,conjunctival Gastrointestinal Disorders Infrequent salivary hypersecretion fecal incontinence mouth ulceration Rare,1,0.7477666735649109
FANAPT,fecal incontinence,conjunctival Gastrointestinal Disorders Infrequent,0,0.6441938877105713
FANAPT,fecal incontinence,duodenal,0,0.5618757009506226
FANAPT,fecal incontinence,stomatitis duodenal ulcer hiatus hernia,0,0.5562968850135803
FANAPT,fecal incontinence,Infrequent gastritis salivary hypersecretion,0,0.5251386761665344
FANAPT,fecal incontinence,fecal incontinence mouth,1,0.8852024674415588
FANAPT,fecal incontinence,hypersecretion,0,0.5876080989837646
FANAPT,fecal incontinence,stomatitis duodenal ulcer hiatus,0,0.5381918549537659
FANAPT,fecal incontinence,Gastrointestinal Disorders Infrequent,0,0.6530280113220215
FANAPT,fecal incontinence,salivary,0,0.4936205744743347
FANAPT,mouth ulceration,mouth ulceration Rare aphthous stomatitis,1,0.8715730309486389
FANAPT,mouth ulceration,salivary,0,0.6779130697250366
FANAPT,mouth ulceration,mouth ulceration Rare,1,0.9032950401306152
FANAPT,mouth ulceration,hypersecretion fecal incontinence,0,0.5372664928436279
FANAPT,mouth ulceration,mouth ulceration Rare aphthous,1,0.8523151874542236
FANAPT,mouth ulceration,mouth ulceration Rare aphthous stomatitis duodenal ulcer,1,0.8514536619186401
FANAPT,mouth ulceration,fecal mouth ulceration,1,0.8576117753982544
FANAPT,mouth ulceration,hyperchlorhydria lip ulceration,0,0.7637467384338379
FANAPT,aphthous stomatitis,mouth ulceration aphthous stomatitis,1,0.9161962270736694
FANAPT,aphthous stomatitis,hyperchlorhydria lip ulceration,0,0.6294628381729126
FANAPT,aphthous stomatitis,hyperchlorhydria lip,0,0.5536785125732422
FANAPT,aphthous stomatitis,ulceration aphthous,1,0.8597932457923889
FANAPT,aphthous stomatitis,hiatus hernia hyperchlorhydria lip ulceration reflux,0,0.6007073521614075
FANAPT,aphthous stomatitis,ulceration Rare,0,0.5979915261268616
FANAPT,aphthous stomatitis,incontinence mouth ulceration aphthous,1,0.82049560546875
FANAPT,aphthous stomatitis,incontinence mouth ulceration aphthous stomatitis,1,0.8473537564277649
FANAPT,duodenal ulcer,ulceration reflux esophagitis,0,0.7225121855735779
FANAPT,duodenal ulcer,mouth ulceration Rare aphthous duodenal,1,0.7954002022743225
FANAPT,duodenal ulcer,Rare aphthous duodenal ulcer,1,0.8551731109619141
FANAPT,duodenal ulcer,duodenal ulcer hiatus,1,0.8374221324920654
FANAPT,duodenal ulcer,hypersecretion,0,0.5608694553375244
FANAPT,duodenal ulcer,stomatitis,0,0.5717766880989075
FANAPT,hiatus hernia,duodenal hiatus hernia,1,0.891055703163147
FANAPT,hiatus hernia,ulceration Rare aphthous,0,0.5451183915138245
FANAPT,hiatus hernia,hiatus hernia hyperchlorhydria lip ulceration reflux,1,0.8306382298469543
FANAPT,hyperchlorhydria,stomatitis duodenal ulcer hiatus hyperchlorhydria,1,0.7823043465614319
FANAPT,hyperchlorhydria,hiatus hernia hyperchlorhydria lip ulceration reflux,1,0.7521259784698486
FANAPT,hyperchlorhydria,hyperchlorhydria lip,1,0.8845411539077759
FANAPT,hyperchlorhydria,stomatitis duodenal ulcer hiatus hyperchlorhydria lip ulceration,1,0.6888471841812134
FANAPT,lip ulceration,stomatitis duodenal ulcer,0,0.7486196756362915
FANAPT,lip ulceration,Rare aphthous stomatitis,0,0.6606180667877197
FANAPT,lip ulceration,duodenal ulcer hiatus hernia lip,1,0.7553537487983704
FANAPT,lip ulceration,duodenal ulcer hiatus hernia lip ulceration reflux esophagitis,1,0.7669529318809509
FANAPT,lip ulceration,lip ulceration,1,1.0
FANAPT,lip ulceration,stomatitis,0,0.7221904397010803
FANAPT,reflux esophagitis,reflux esophagitis stomatitis,1,0.8786194324493408
FANAPT,reflux esophagitis,stomatitis,0,0.5690742135047913
FANAPT,reflux esophagitis,hiatus hernia hyperchlorhydria lip reflux esophagitis stomatitis General Disorders and Administrative,1,0.7445294857025146
FANAPT,reflux esophagitis,reflux esophagitis stomatitis General Disorders,1,0.8400061130523682
FANAPT,reflux esophagitis,Conditions Infrequent edema genera,0,0.5782631039619446
FANAPT,reflux esophagitis,Site Conditions Infrequent edema genera,0,0.5695617198944092
FANAPT,reflux esophagitis,reflux esophagitis stomatitis General Disorders and Administrative,1,0.8283533453941345
FANAPT,reflux esophagitis,hiatus hernia hyperchlorhydria lip reflux esophagitis stomatitis General Disorders,1,0.7503495216369629
FANAPT,stomatitis,ulceration reflux stomatitis General Disorders,1,0.7691577076911926
FANAPT,stomatitis,reflux esophagitis stomatitis General Disorders,1,0.7352564334869385
FANAPT,edema,to cardiac disease difficulty in walking,0,0.5553283095359802
FANAPT,edema,thirst,0,0.6383786201477051
FANAPT,edema,edema general pitting due to cardiac,1,0.7773133516311646
FANAPT,edema,general pitting due to cardiac,0,0.5903654098510742
FANAPT,difficulty in walking,to cardiac difficulty in,1,0.6546392440795898
FANAPT,difficulty in walking,to cardiac difficulty,1,0.6544061303138733
FANAPT,difficulty in walking,due to cardiac disease,0,0.5885858535766602
FANAPT,difficulty in walking,difficulty in walking thirst Rare hyperthermia,1,0.7348055243492126
FANAPT,difficulty in walking,Infrequent cholelithiasis In,0,0.5194129943847656
FANAPT,difficulty in walking,difficulty in walking thirst Rare,1,0.8173233270645142
FANAPT,difficulty in walking,edema general pitting,0,0.5268383622169495
FANAPT,difficulty in walking,in walking thirst Rare hyperthermia,1,0.6419211626052856
FANAPT,thirst,thirst Rare,1,0.8625521659851074
FANAPT,thirst,in walking thirst Rare hyperthermia,1,0.736401379108429
FANAPT,thirst,thirst Rare hyperthermia Hepatobiliary Disorders Infrequent,1,0.6799702048301697
FANAPT,thirst,thirst,1,0.9999998211860657
FANAPT,thirst,Infrequent cholelithiasis,0,0.46039748191833496
FANAPT,thirst,walking,0,0.5178382396697998
FANAPT,thirst,Disorders,0,0.5561708807945251
FANAPT,thirst,hyperthermia Hepatobiliary Disorders Infrequent,0,0.5062140822410583
FANAPT,cholelithiasis,decreased Infrequent,0,0.5141947269439697
FANAPT,cholelithiasis,cholelithiasis Investigations,1,0.8829154968261719
FANAPT,cholelithiasis,difficulty in walking thirst Rare hyperthermia Hepatobiliary Disorders,0,0.6151783466339111
FANAPT,cholelithiasis,cholelithiasis Investigations Frequent weight,1,0.8408993482589722
FANAPT,cholelithiasis,Investigations Frequent,0,0.4980608820915222
FANAPT,cholelithiasis,Rare hyperthermia Hepatobiliary Disorders cholelithiasis Investigations Frequent weight,1,0.7615091800689697
FANAPT,cholelithiasis,cholelithiasis Investigations Frequent,1,0.8654106855392456
FANAPT,weight decreased,count increased hematocrit decreased,0,0.6015955805778503
FANAPT,weight decreased,cholelithiasis Investigations weight,1,0.6517278552055359
FANAPT,weight decreased,neutrophil,0,0.4596031904220581
FANAPT,weight decreased,Disorders Infrequent cholelithiasis Investigations weight,1,0.6471573710441589
FANAPT,weight decreased,weight decreased Infrequent hemoglobin decreased neutrophil,1,0.7651350498199463
FANAPT,weight decreased,count increased,0,0.4963764548301697
FANAPT,weight decreased,weight decreased Infrequent,1,0.9109127521514893
FANAPT,weight decreased,weight decreased Infrequent hemoglobin decreased,1,0.8112124800682068
FANAPT,hemoglobin decreased,decreased hemoglobin,1,0.9840918779373169
FANAPT,hemoglobin decreased,hemoglobin decreased neutrophil count increased,1,0.8213908672332764
FANAPT,hemoglobin decreased,rs Infrequent cholelithiasis Investigations Frequent weight,0,0.5432769060134888
FANAPT,hemoglobin decreased,decreased Metabolism and Nutrition,0,0.7289739847183228
FANAPT,hemoglobin decreased,count increased,0,0.5172988772392273
FANAPT,hemoglobin decreased,neutrophil count increased,0,0.5295478701591492
FANAPT,neutrophil count increased,neutrophil count increased hematocrit decreased,1,0.8499801158905029
FANAPT,neutrophil count increased,neutrophil count,1,0.9075433015823364
FANAPT,neutrophil count increased,hemoglobin neutrophil count,1,0.8474195003509521
FANAPT,neutrophil count increased,neutrophil count increased,1,0.9999998807907104
FANAPT,neutrophil count increased,hemoglobin neutrophil count increased hematocrit decreased Metabolism and Nutrition,1,0.789533257484436
FANAPT,neutrophil count increased,weight decreased Infrequent hemoglobin neutrophil count increased,1,0.8088353872299194
FANAPT,hematocrit decreased,neutrophil count hematocrit decreased Metabolism and Nutrition Disorders Infrequent,1,0.790906548500061
FANAPT,hematocrit decreased,neutrophil count increased,1,0.6113404035568237
FANAPT,hematocrit decreased,appetite,0,0.48934245109558105
FANAPT,hematocrit decreased,count hematocrit,1,0.8067365884780884
FANAPT,hematocrit decreased,count hematocrit decreased Metabolism and Nutrition,1,0.8741652965545654
FANAPT,increased appetite,and Nutrition Disorders increased appetite,1,0.8870853781700134
FANAPT,increased appetite,increased appetite,1,0.9999999403953552
FANAPT,increased appetite,fluid retention Musculoskeletal,0,0.5590150356292725
FANAPT,increased appetite,hematocrit decreased Metabolism and,0,0.6026124954223633
FANAPT,increased appetite,Nutrition Disorders Infrequent,0,0.6044539213180542
FANAPT,increased appetite,Connective,0,0.5201975703239441
FANAPT,dehydration,Infrequent increased dehydration hypokalemia fluid retention,1,0.7454822659492493
FANAPT,dehydration,Connective,0,0.526398777961731
FANAPT,dehydration,dehydration,1,0.9999998807907104
FANAPT,dehydration,dehydration hypokalemia,1,0.8189877271652222
FANAPT,dehydration,dehydration hypokalemia fluid,1,0.797714114189148
FANAPT,dehydration,dehydration hypokalemia fluid retention,1,0.7818647027015686
FANAPT,hypokalemia,hypokalemia fluid retention Musculoskeletal,1,0.8176537156105042
FANAPT,hypokalemia,hypokalemia fluid retention Musculoskeletal and Connective,1,0.8047876358032227
FANAPT,hypokalemia,hypokalemia,1,1.0
FANAPT,hypokalemia,hypokalemia fluid retention,1,0.854808509349823
FANAPT,fluid retention,fluid,1,0.7183349132537842
FANAPT,fluid retention,Nutrition Disorders Infrequent increased appetite dehydration,0,0.6580343246459961
FANAPT,fluid retention,appetite dehydration fluid retention Musculoskeletal and Connective Tissue,1,0.7685631513595581
FANAPT,fluid retention,fluid retention Musculoskeletal and,1,0.8626502752304077
FANAPT,myalgia,myalgia muscle spasms Rare torticollis Nervous,1,0.7643734812736511
FANAPT,myalgia,Infrequent paresthesia ps,0,0.5550521612167358
FANAPT,myalgia,myalgia muscle spasms Rare torticollis,1,0.7638177871704102
FANAPT,myalgia,myalgia muscle spasms,1,0.8342361450195312
FANAPT,myalgia,and Connective Tissue Disorders myalgia muscle spasms Rare torticollis,1,0.7515920400619507
FANAPT,myalgia,myalgia muscle spasms Rare,1,0.8028626441955566
FANAPT,myalgia,Disorders myalgia muscle spasms,1,0.8079503774642944
FANAPT,torticollis,torticollis Nervous System Disorders Infrequent,1,0.8453595638275146
FANAPT,torticollis,Disorders Infrequent paresthesia,0,0.5433014035224915
FANAPT,torticollis,torticollis Nervous System,1,0.9022060036659241
FANAPT,torticollis,myalgia muscle spasms torticollis Nervous System Disorders Infrequent,1,0.7464959621429443
FANAPT,torticollis,torticollis Nervous,1,0.88327556848526
FANAPT,torticollis,Disorders Frequent myalgia,0,0.562014639377594
FANAPT,paresthesia,Infrequent,0,0.5144984722137451
FANAPT,paresthesia,System Disorders paresthesia psychomotor hyperactivity,1,0.7590235471725464
FANAPT,paresthesia,paresthesia psychomotor,1,0.8538558483123779
FANAPT,paresthesia,System Disorders paresthesia psychomotor hyperactivity restlessness,1,0.7297905683517456
FANAPT,paresthesia,torticollis Nervous System Disorders paresthesia psychomotor hyperactivity restlessness amnesia nystagmus,1,0.6763232946395874
FANAPT,paresthesia,psychomotor hyperactivity restlessness amnesia nystagmus Rare restless,0,0.6306880712509155
FANAPT,paresthesia,paresthesia psychomotor hyperactivity restlessness,1,0.7859930992126465
FANAPT,psychomotor hyperactivity,torticollis Nervous System Disorders Infrequent,0,0.6201533079147339
FANAPT,restlessness,Rare restless legs,0,0.7794967293739319
FANAPT,restlessness,restlessness,1,1.0000001192092896
FANAPT,restlessness,restlessness amnesia nystagmus,1,0.8172708749771118
FANAPT,restlessness,restlessness amnesia nystagmus Rare restless legs,1,0.7851368188858032
FANAPT,restlessness,Disorders Infrequent paresthesia psychomotor restlessness amnesia nystagmus Rare restless,1,0.7680371403694153
FANAPT,amnesia,Psychiatric Disorders,0,0.5753143429756165
FANAPT,amnesia,paresthesia psychomotor hyperactivity amnesia nystagmus Rare restless,1,0.7026679515838623
FANAPT,amnesia,restlessness,0,0.5962613821029663
FANAPT,amnesia,Infrequent paresthesia psychomotor hyperactivity amnesia nystagmus Rare,1,0.686529278755188
FANAPT,amnesia,amnesia,1,0.9999998807907104
FANAPT,amnesia,psychomotor hyperactivity amnesia nystagmus Rare restless legs,1,0.6961790323257446
FANAPT,restless legs syndrome,restlessness amnesia nystagmus restless legs syndrome Psychiatric,1,0.8191087245941162
FANAPT,restless legs syndrome,amnesia,1,0.5368877649307251
FANAPT,restless legs syndrome,hyperactivity restlessness amnesia nystagmus restless,1,0.6846199035644531
FANAPT,restless legs syndrome,amnesia nystagmus restless legs syndrome Psychiatric Disorders Frequent,1,0.7683581709861755
FANAPT,restless legs syndrome,legs syndrome Psychiatric Disorders Frequent,1,0.7802273035049438
FANAPT,restless legs syndrome,restlessness amnesia nystagmus restless legs,1,0.8128469586372375
FANAPT,restless legs syndrome,nystagmus restless legs syndrome,1,0.8753757476806641
FANAPT,restless legs syndrome,restlessness amnesia nystagmus,0,0.6885035037994385
FANAPT,restless legs syndrome,restless,1,0.7238985300064087
FANAPT,restless legs syndrome,hyperactivity restlessness,0,0.7376416325569153
FANAPT,aggression,confusional state man,0,0.5281066298484802
FANAPT,aggression,Psychiatric Disorders Frequent aggression delusion Infrequent hostility,1,0.7429973483085632
FANAPT,aggression,aggression delusion Infrequent hostility,1,0.7829385995864868
FANAPT,delusion,delusion Infrequent hostility,1,0.7875305414199829
FANAPT,delusion,legs,0,0.5146104693412781
FANAPT,delusion,libido,0,0.5372432470321655
FANAPT,delusion,restless legs syndrome Psychiatric Disorders Frequent,0,0.564322292804718
FANAPT,delusion,delusion Infrequent hostility libido decreased,1,0.735687792301178
FANAPT,delusion,Disorders Frequent restlessness,0,0.5785006880760193
FANAPT,hostility,libido decreased paranoia anorgasmia confusional state,0,0.5585993528366089
FANAPT,hostility,hostility libido decreased,1,0.7547494173049927
FANAPT,hostility,hostility,1,0.9999998211860657
FANAPT,hostility,Frequent restlessness aggression delusion hostility libido decreased,1,0.70371413230896
FANAPT,hostility,hostility libido decreased paranoia,1,0.7304204106330872
FANAPT,hostility,delusion hostility libido decreased paranoia anorgasmia,1,0.6857677698135376
FANAPT,libido decreased,restlessness aggression delusion Infrequent libido decreased paranoia anorgasmia confusional state,1,0.7530965209007263
FANAPT,libido decreased,hostility libido decreased paranoia,1,0.7736075520515442
FANAPT,libido decreased,panic attack,0,0.4931420087814331
FANAPT,paranoia,attack obsessivecompulsive,0,0.6033787727355957
FANAPT,paranoia,paranoia anorgasmia,1,0.8182669281959534
FANAPT,paranoia,paranoia anorgasmia confusional state mania catatonia,1,0.774718165397644
FANAPT,anorgasmia,decreased anorgasmia confusional state,1,0.8116163015365601
FANAPT,anorgasmia,paranoia anorgasmia confusional state mania catatonia,1,0.6988011002540588
FANAPT,anorgasmia,equent restlessness aggression delusion Infrequent,0,0.561133623123169
FANAPT,confusional state,swings panic attack obsessivecompulsive,0,0.6140842437744141
FANAPT,confusional state,confusional state mania catatonia mood,1,0.8103739023208618
FANAPT,confusional state,stlessness aggression delusion Infrequent hostility,0,0.6338991522789001
FANAPT,confusional state,paranoia confusional state mania catatonia mood swings panic,1,0.7521616220474243
FANAPT,confusional state,bulimia nervosa delir,0,0.5424021482467651
FANAPT,confusional state,hostility libido decreased paranoia confusional state,1,0.7370607256889343
FANAPT,confusional state,anorgasmia,0,0.5470267534255981
FANAPT,confusional state,paranoia confusional state,1,0.8785344362258911
FANAPT,mania,mania catatonia mood swings panic attack,1,0.7382948398590088
FANAPT,mania,paranoia anorgasmia confusional mania catatonia mood swings panic,1,0.7058904767036438
FANAPT,mania,paranoia,0,0.5962134003639221
FANAPT,mania,mood swings panic attack obsessivecompulsive disorder bulimia nervosa delirium,0,0.6564123630523682
FANAPT,mania,delusion Infrequent hostility libido decreased paranoia anorgasmia,0,0.6216892004013062
FANAPT,catatonia,catatonia mood swings,1,0.8931318521499634
FANAPT,catatonia,libido decreased,0,0.5632981657981873
FANAPT,catatonia,catatonia,1,1.0
FANAPT,catatonia,confusional state catatonia,1,0.892605185508728
FANAPT,catatonia,mood swings panic attack obsessivecompulsive disorder,0,0.6315939426422119
FANAPT,catatonia,catatonia mood,1,0.9176934361457825
FANAPT,catatonia,lusion Infrequent hostility,0,0.5583927631378174
FANAPT,mood swings,delirium,0,0.5873866081237793
FANAPT,mood swings,mood swings panic,1,0.8805587887763977
FANAPT,mood swings,bulimia nervosa delirium,0,0.5990028381347656
FANAPT,mood swings,nervosa delirium polydipsia psychogenic,0,0.6255688667297363
FANAPT,mood swings,mood swings panic attack,1,0.8513011932373047
FANAPT,mood swings,polydipsia,0,0.5633823275566101
FANAPT,mood swings,delirium polydipsia psychogenic im,0,0.6018162965774536
FANAPT,mood swings,bulimia nervosa delirium polydipsia psychogenic im,0,0.624558687210083
FANAPT,panic attack,obsessivecompulsive disorder bulimia,0,0.5679559707641602
FANAPT,panic attack,panic attack obsessivecompulsive,1,0.8350625038146973
FANAPT,obsessive-compulsive disorder,obsessive-compulsive disorder bulimia nervosa,1,0.8694720268249512
FANAPT,obsessive-compulsive disorder,panic attack obsessivecompulsive,1,0.8032790422439575
FANAPT,obsessive-compulsive disorder,panic attack,0,0.5931272506713867
FANAPT,delirium,bulimia nervosa,0,0.5016032457351685
FANAPT,delirium,polydipsia psychogenic impulsecontrol disorder major depression Renal and Urinary Disorde,0,0.5957071781158447
FANAPT,delirium,impulsecontrol,0,0.47552889585494995
FANAPT,delirium,Renal,0,0.5348195433616638
FANAPT,delirium,state mania catatonia mood swings panic,0,0.6316508054733276
FANAPT,delirium,delirium polydipsia psychogenic impulsecontrol,1,0.7419687509536743
FANAPT,delirium,disorder major depression Renal and Urinary,0,0.5687214136123657
FANAPT,delirium,delirium polydipsia,1,0.8333041667938232
FANAPT,polydipsia psychogenic,bulimia nervosa polydipsia psychogenic impulsecontrol disorder,1,0.8292070627212524
FANAPT,polydipsia psychogenic,delirium polydipsia,1,0.8197830319404602
FANAPT,polydipsia psychogenic,disorder bulimia nervosa polydipsia psychogenic impulsecontrol disorder major,1,0.798882246017456
FANAPT,polydipsia psychogenic,and Urinary,0,0.580544114112854
FANAPT,polydipsia psychogenic,polydipsia psychogenic impulsecontrol disorder major,1,0.8918200731277466
FANAPT,polydipsia psychogenic,nervosa polydipsia,1,0.8320876359939575
FANAPT,polydipsia psychogenic,polydipsia psychogenic impulsecontrol disorder,1,0.8982787728309631
FANAPT,polydipsia psychogenic,disorder bulimia nervosa polydipsia psychogenic,1,0.8898617625236511
FANAPT,impulse-control disorder,bulimia nervosa delirium polydipsia impulse-control disorder major depression Renal,1,0.732463002204895
FANAPT,impulse-control disorder,disorder bulimia nervosa polydipsia psychogenic,1,0.6756678223609924
FANAPT,major depression,impulsecontrol major depression Renal and,1,0.6994835138320923
FANAPT,major depression,disorder bulimia nervosa polydipsia psychogenic,1,0.5593093633651733
FANAPT,major depression,psychogenic impulsecontrol major,1,0.565797746181488
FANAPT,major depression,major depression Renal and Urinary Disorders Frequent,1,0.7507071495056152
FANAPT,major depression,delirium polydipsia,0,0.5710742473602295
FANAPT,major depression,major depression Renal,1,0.8120217323303223
FANAPT,major depression,impulsecontrol major,1,0.5502558946609497
FANAPT,major depression,psychogenic impulsecontrol major depression Renal and Urinary Disorders Frequent,1,0.6704109907150269
FANAPT,major depression,Urinary Disorders Frequent urinary,0,0.5081629753112793
FANAPT,major depression,major depression Renal and,1,0.8197560906410217
FANAPT,major depression,Urinary Disorders Frequent urinary incontinence Infrequent dysuria,0,0.5115979909896851
FANAPT,urinary incontinence,depression Renal and,0,0.612472414970398
FANAPT,urinary incontinence,impulsecontrol disorder major depression,0,0.5089157819747925
FANAPT,urinary incontinence,Frequent,0,0.5386307835578918
FANAPT,dysuria,depression,0,0.5740677714347839
FANAPT,dysuria,incontinence dysuria pollakiuria,1,0.7976231575012207
FANAPT,dysuria,incontinence Infrequent,0,0.6065366268157959
FANAPT,dysuria,dysuria pollakiuria,1,0.8251609802246094
FANAPT,dysuria,urinary incontinence dysuria pollakiuria,1,0.8055094480514526
FANAPT,dysuria,dysuria pollakiuria enuresis nephrolithiasis,1,0.8463207483291626
FANAPT,pollakiuria,renal failure acute Reproductive,0,0.5071015357971191
FANAPT,pollakiuria,pollakiuria enuresis,1,0.8658245205879211
FANAPT,pollakiuria,urinary incontinence Infrequent pollakiuria enuresis nephrolithiasis Rare urinary retention,1,0.7348136901855469
FANAPT,pollakiuria,incontinence Infrequent pollakiuria enuresis nephrolithiasis,1,0.7613157033920288
FANAPT,pollakiuria,pollakiuria enuresis nephrolithiasis Rare urinary retention,1,0.7922605872154236
FANAPT,pollakiuria,pollakiuria enuresis nephrolithiasis,1,0.8257495760917664
FANAPT,pollakiuria,urinary incontinence Infrequent pollakiuria enuresis nephrolithiasis Rare,1,0.7466317415237427
FANAPT,enuresis,enuresis nephrolithiasis Rare urinary retention,1,0.7995538711547852
FANAPT,enuresis,enuresis nephrolithiasis,1,0.8280929327011108
FANAPT,enuresis,enuresis nephrolithiasis Rare urinary,1,0.7903852462768555
FANAPT,enuresis,failure acute Reproductive System and Bre,0,0.5840867161750793
FANAPT,enuresis,incontinence Infrequent dysuria enuresis nephrolithiasis Rare,1,0.7866603136062622
FANAPT,nephrolithiasis,retention renal,0,0.6714091300964355
FANAPT,nephrolithiasis,incontinence Infrequent dysuria pollakiuria nephrolithiasis Rare urinary retention renal,1,0.7661590576171875
FANAPT,nephrolithiasis,nephrolithiasis Rare,1,0.9018616080284119
FANAPT,nephrolithiasis,pollakiuria nephrolithiasis Rare urinary retention,1,0.7874227166175842
FANAPT,nephrolithiasis,nephrolithiasis Rare urinary retention renal,1,0.8728808164596558
FANAPT,urinary retention,dysuria pollakiuria enuresis nephrolithiasis urinary retention renal failure acute Reproductive,1,0.7687166929244995
FANAPT,urinary retention,nephrolithiasis Rare,1,0.6325390338897705
FANAPT,urinary retention,urinary retention,1,0.9999999403953552
FANAPT,urinary retention,pollakiuria enuresis nephrolithiasis urinary retention renal failure acute Reproductive System,1,0.7600185871124268
FANAPT,urinary retention,urinary retention renal failure,1,0.835689902305603
FANAPT,urinary retention,urinary retention renal failure acute Reproductive,1,0.7909724712371826
FANAPT,urinary retention,Frequent erectile dysfuncti,0,0.5925446152687073
FANAPT,urinary retention,Frequent erectile,0,0.5961581468582153
FANAPT,erectile dysfunction,pain amenorrhea breast pain,0,0.5207654237747192
FANAPT,erectile dysfunction,and Breast Disorders erectile dysfunction,1,0.8398057222366333
FANAPT,erectile dysfunction,erectile dysfunction Infrequent testicular pain amenorrhea breast,1,0.7727588415145874
FANAPT,erectile dysfunction,breast pain Rare,0,0.4545632004737854
FANAPT,erectile dysfunction,Breast Disorders erectile dysfunction Infrequent,1,0.7949409484863281
FANAPT,erectile dysfunction,failure acute Reproductive System and Breast,0,0.6160904169082642
FANAPT,erectile dysfunction,erectile dysfunction,1,0.9999998211860657
FANAPT,testicular pain,Frequent,0,0.48809951543807983
FANAPT,testicular pain,testicular pain amenorrhea breast,1,0.8709368705749512
FANAPT,testicular pain,testicular pain amenorrhea breast pain Rare,1,0.8489859104156494
FANAPT,testicular pain,Infrequent,0,0.47466862201690674
FANAPT,testicular pain,Disorders Frequent erectile dysfunction testicular pain amenorrhea breast pain Rare,1,0.7738926410675049
FANAPT,amenorrhea,amenorrhea breast pain Rare,1,0.7800815105438232
FANAPT,amenorrhea,amenorrhea breast pain,1,0.8047189116477966
FANAPT,amenorrhea,erectile dysfunction,0,0.6062605381011963
FANAPT,breast pain,testicular pain breast,1,0.8456559181213379
FANAPT,breast pain,metrorrhagia postmenopausal,0,0.5517194867134094
FANAPT,breast pain,menstruation irregular gynecomastia menorrhagia,0,0.600390613079071
FANAPT,breast pain,breast pain Rare menstruation irregular gynecomastia,1,0.7881664037704468
FANAPT,breast pain,dysfunction Infrequent testicular,0,0.4733668565750122
FANAPT,breast pain,Rare menstruation irregular gynecomastia menorrhagia metrorrhagia postmenopausal hemorrha,0,0.5835711359977722
FANAPT,breast pain,and Breast Disorders,0,0.7413807511329651
FANAPT,breast pain,Infrequent testicular pain breast pain,1,0.816163957118988
FANAPT,breast pain,testicular pain breast pain Rare menstruation irregular gynecomastia menorrhagia,1,0.7694355845451355
FANAPT,breast pain,dysfunction Infrequent testicular pain breast,1,0.7750357985496521
FANAPT,menstruation irregular,menstruation irregular gynecomastia menorrhagia,1,0.8543487787246704
FANAPT,menstruation irregular,menstruation irregular gynecomastia menorrhagia metrorrhagia postmenopausal hemorrhage,1,0.8122750520706177
FANAPT,menstruation irregular,pain amenorrhea breast pain menstruation irregular gynecomastia menorrhagia metrorrhagia,1,0.7611241340637207
FANAPT,menstruation irregular,menstruation,1,0.8640795946121216
FANAPT,menstruation irregular,pain amenorrhea breast pain,0,0.628543496131897
FANAPT,menstruation irregular,postmenopausal,0,0.583381175994873
FANAPT,menstruation irregular,menstruation irregular gynecomastia,1,0.8389667868614197
FANAPT,menstruation irregular,postmenopausal hemorrhage prostatitis,0,0.5823363065719604
FANAPT,menstruation irregular,menstruation irregular gynecomastia menorrhagia metrorrhagia,1,0.8538522720336914
FANAPT,gynecomastia,gynecomastia,1,1.0
FANAPT,gynecomastia,gynecomastia menorrhagia metrorrhagia postmenopausal,1,0.8123730421066284
FANAPT,gynecomastia,pain Rare menstruation gynecomastia,1,0.8090109825134277
FANAPT,gynecomastia,breast pain Rare menstruation gynecomastia,1,0.8060284852981567
FANAPT,metrorrhagia,menorrhagia,0,0.619823157787323
FANAPT,metrorrhagia,metrorrhagia postmenopausal hemorrhage,1,0.8217728137969971
FANAPT,metrorrhagia,postmenopausal,0,0.5706932544708252
FANAPT,metrorrhagia,Thoracic and Mediastinal Disorders Inf,0,0.4927704930305481
FANAPT,postmenopausal hemorrhage,Disorders Infrequent epistaxis,0,0.5329846739768982
FANAPT,postmenopausal hemorrhage,postmenopausal hemorrhage prostatitis Respiratory Thoracic,1,0.8286399841308594
FANAPT,postmenopausal hemorrhage,postmenopausal hemorrhage prostatitis Respiratory Thoracic and,1,0.82148677110672
FANAPT,prostatitis,prostatitis Respiratory,1,0.8185409903526306
FANAPT,prostatitis,Respiratory Thoracic and,0,0.45377326011657715
FANAPT,prostatitis,prostatitis Respiratory Thoracic and Mediastinal,1,0.7932792901992798
FANAPT,prostatitis,menorrhagia metrorrhagia postmenopausal prostatitis,1,0.763891875743866
FANAPT,prostatitis,Thoracic,0,0.4858642816543579
FANAPT,epistaxis,Disorders epistaxis asthma rhinorrhea sinus,1,0.774358868598938
FANAPT,epistaxis,Thoracic,0,0.5609666109085083
FANAPT,asthma,asthma rhinorrhea sinus congestion,1,0.7448839545249939
FANAPT,asthma,asthma,1,1.0
FANAPT,rhinorrhea,rhinorrhea sinus congestion nasal dryness Rare,1,0.7901480197906494
FANAPT,rhinorrhea,asthma rhinorrhea sinus congestion,1,0.7586154937744141
FANAPT,rhinorrhea,rhinorrhea sinus congestion nasal,1,0.857869029045105
FANAPT,rhinorrhea,rhinorrhea sinus,1,0.8935962915420532
FANAPT,sinus congestion,Infrequent epistaxis asthma sinus congestion nasal dryness Rare dry throat,1,0.7638304233551025
FANAPT,sinus congestion,rhinorrhea sinus,1,0.8157404661178589
FANAPT,sinus congestion,asthma sinus congestion nasal dryness Rare dry throat,1,0.7801015377044678
FANAPT,sinus congestion,Infrequent epistaxis asthma sinus congestion nasal dryness Rare dry,1,0.766638994216919
FANAPT,sinus congestion,sinus congestion nasal dryness Rare dry throat,1,0.8153419494628906
FANAPT,sinus congestion,epistaxis asthma sinus congestion,1,0.8475180268287659
FANAPT,sinus congestion,syndrome dyspnea,0,0.5582908391952515
FANAPT,sinus congestion,sleep,0,0.5028986930847168
FANAPT,sinus congestion,Thoracic,0,0.4836353063583374
FANAPT,sinus congestion,asthma sinus congestion,1,0.8923494815826416
FANAPT,nasal dryness,dry,0,0.7158881425857544
FANAPT,nasal dryness,dry throat sleep apnea syndrome dyspnea exertional Postmarketing,0,0.6646264791488647
FANAPT,dry throat,sinus congestion nasal dryness dry,1,0.7135953903198242
FANAPT,dry throat,dryness dry throat sleep apnea,1,0.852228045463562
FANAPT,dry throat,Experience The following a,0,0.5361889600753784
FANAPT,dry throat,nasal dryness dry throat sleep apnea syndrome,1,0.7621080279350281
FANAPT,sleep apnea syndrome,Infrequent epistaxis asthma,0,0.5601825714111328
FANAPT,sleep apnea syndrome,apnea syndrome dyspnea exertional Postmarketing Experience,1,0.748577892780304
FANAPT,sleep apnea syndrome,rhinorrhea sinus congestion nasal dryness Rare dry,0,0.5664648413658142
FANAPT,sleep apnea syndrome,adverse reactions,0,0.5564201474189758
FANAPT,sleep apnea syndrome,dry sleep apnea syndrome dyspnea exertional Postmarketing Experience The,1,0.7699184417724609
FANAPT,sleep apnea syndrome,following,0,0.4418233036994934
FANAPT,sleep apnea syndrome,dryness Rare dry sleep apnea,1,0.7520939707756042
FANAPT,sleep apnea syndrome,asthma rhinorrhea,0,0.5548213124275208
FANAPT,sleep apnea syndrome,dryness Rare dry sleep apnea syndrome,1,0.8113441467285156
FANAPT,sleep apnea syndrome,dryness Rare dry throat,0,0.5645337104797363
FANAPT,dyspnea exertional,throat sleep apnea dyspnea exertional Postmarketing Experience The following adverse,1,0.7685868740081787
FANAPT,dyspnea exertional,dryness Rare dry throat,0,0.5820357799530029
FANAPT,dyspnea exertional,Experience The following adverse reactions have been identified,0,0.551545262336731
FANAPT,dyspnea exertional,dry throat sleep apnea dyspnea exertional,1,0.8361257314682007
FANAPT,retrograde ejaculation,of FANAPT,0,0.511448860168457
FANAPT,retrograde ejaculation,use of,0,0.5107243061065674
FANAPT,retrograde ejaculation,of retrograde,1,0.816321611404419
FANAPT,retrograde ejaculation,identified during postapproval,0,0.5054168701171875
FANAPT,retrograde ejaculation,retrograde ejaculation Because these reactions were,1,0.9085910320281982
FANAPT,retrograde ejaculation,of,0,0.5136052966117859
FANAPT,MORTALITY,were: di zziness dry mouth fatigue,1,0.5541411638259888
FANAPT,death,erien ce Because clinical trials are,1,0.48675304651260376
FANAPT,death,clinical trial database for FANAPT consisting of patients exposed to FANAPT at,0,0.4959034323692322
FANAPT,death,ow is,1,0.5511842966079712
FANAPT,death,FANAPT consisting of patients exposed to,0,0.5098868608474731
FANAPT,death,ow,1,0.5691747069358826
FANAPT,deaths,a clinical rial d,1,0.5051241517066956
FANAPT,deaths,clinical rial d atabase for FANAPT,1,0.48728978633880615
FANAPT,sudden death,patients exposed to NAPT,1,0.5359120965003967
FANAPT,sudden death,of patients exposed to NAPT at dose s of mgday,1,0.5209490060806274
FANAPT,sudden death,of patients exposed to NAPT at dose s of mgday or,1,0.5195772051811218
FANAPT,sudden death,FANAPT for at,0,0.5223091244697571
FANAPT,sudden death,patients exposed to NAPT at dose s of mgday or,1,0.5217723250389099
FANAPT,sudden death,patients exposed to NAPT at dose,1,0.5259294509887695
FANAPT,sudden death,of patients exposed to NAPT at dose s of,1,0.5197327733039856
FANAPT,sudden death,of patients exposed to NAPT,1,0.5265003442764282
FANAPT,pneumonia,for,0,0.5838503837585449
FANAPT,pneumonia,database for FANAPT consisting of patients exposed to FANAPT at doses of mgday or,0,0.5460472702980042
FANAPT,MORTALITY,reactions during re were o btained by general inquiry and,1,0.47983092069625854
FANAPT,MORTALITY,database for FANAPT consisting of patients exposed to FANAPT at doses of mgday or,0,0.5563417077064514
FANAPT,MORTALITY,re were o,1,0.5542967915534973
FANAPT,MORTALITY,exposure Adverse reactions during re were o,1,0.5241221785545349
FANAPT,MORTALITY,investigators using their own terminology Conse,0,0.49408143758773804
FANAPT,MORTALITY,own terminology,0,0.5293352603912354
FANAPT,MORTALITY,and recorded by,0,0.4757393002510071
FANAPT,death, cate gories using MedDRA terminology The,1,0.5119791626930237
FANAPT,death,proportion of individuals experiencing adverse reactions,0,0.47144684195518494
FANAPT,death, cate gories using MedDRA,1,0.4926365911960602
FANAPT,death, cate gories using,1,0.49571800231933594
FANAPT,cerebrovascular-related adverse events,fold greater than placebo were dizziness dry mouth fatigue nasal,0,0.6139024496078491
FANAPT,cerebrovascular-related adverse events,"nasal congestion hypotension, somnolence,",1,0.5845780372619629
FANAPT,cerebrovascular-related adverse events,ADVERSE,0,0.6587576866149902
FANAPT,cerebrovascular-related adverse events,"somnolence, tachycardia, and weight",1,0.5648571252822876
FANAPT,cerebrovascular-related adverse events,"hypotension, somnolence, tachycardia,",1,0.5778592824935913
FANAPT,cerebrovascular-related adverse events,"somnolence, tachycardia, and weight increased",1,0.5801020860671997
FANAPT,cerebrovascular-related adverse events,"nasal congestion hypotension, somnolence, tachycardia,",1,0.5865812301635742
FANAPT,QT prolongation,and weight increased,0,0.5388592481613159
FANAPT,QT prolongation,or FDA at,0,0.5002967119216919
FANAPT,QT prolongation,contact Novartis,0,0.5241556167602539
FANAPT,Prolongs QT interval,ADVERSE REACTIO NS,1,0.5446494817733765
FANAPT,Prolongs QT interval,CTED ADVERSE REACTIO,1,0.5821879506111145
FANAPT,Prolongs QT interval,report CTED ADVERSE REACTIO NS contact Novartis,1,0.576022744178772
FANAPT,arrhythmia,euticals C orporation at or,1,0.5134128928184509
FANAPT,arrhythmia,CTED ADVERSE REACTIO,1,0.5781567096710205
FANAPT,arrhythmia,euticals C orporation at or FDA,1,0.5229320526123047
FANAPT,arrhythmia,ADVERSE REACTIONS contact Novartis euticals,1,0.5290636420249939
FANAPT,arrhythmia,euticals C orporation at,1,0.5155874490737915
FANAPT,arrhythmia,SUSPECTED ADVERSE REACTIONS,0,0.5426543951034546
FANAPT,arrhythmia,at or FDA at FDA or,0,0.5277461409568787
FANAPT,arrhythmia,weight increased To,0,0.4673415422439575
FANAPT,sudden death,Novartis Pharmaceuticals ation at 1-8 or,1,0.4860929250717163
FANAPT,sudden death,weight increased To,0,0.4976210594177246
FANAPT,sudden death,contact Novartis Pharmaceuticals ation at 1-8 or FDA at FDA or,1,0.4766322374343872
FANAPT,sudden death,contact Novartis Pharmaceuticals ation at 1-8 or FDA,1,0.4832199215888977
FANAPT,sudden death,contact Novartis Pharmaceuticals ation at 1-8,1,0.47088944911956787
FANAPT,sudden death,report SUSPECTED ADVERSE REACTIONS contact Novartis Pharmaceuticals,0,0.5248444080352783
FANAPT,sudden death,wwwfdagovmedwatch Clinical,0,0.5385048389434814
FANAPT,sudden death,or wwwfdagovmedwatch Clinical Studies,0,0.530494749546051
FANAPT,Neuroleptic Malignant Syndrome,patients exposed to FANAPT a,0,0.5479395389556885
FANAPT,Neuroleptic Malignant Syndrome,clinical actice. The information below,1,0.524280309677124
FANAPT,Neuroleptic Malignant Syndrome,clinical pr,0,0.5209747552871704
FANAPT,Tardive dyskinesia,trial database for FANAPT,0,0.473199725151062
FANAPT,Tardive dyskinesia,to FANAPT at do,1,0.5251868963241577
FANAPT,Tardive dyskinesia,FANAPT at do,1,0.5336253643035889
FANAPT,Tardive dyskinesia,received FANAPT for,0,0.47884291410446167
FANAPT,Tardive dyskinesia,consisting of patients ed to FANAPT at do ses of mgday,1,0.5291269421577454
FANAPT,Hyperglycemia,of nia. Of these received,1,0.48057031631469727
FANAPT,Hyperglycemia,received FANAPT for,0,0.4818226397037506
FANAPT,Hyperglycemia,treatment of nia.,1,0.5681725144386292
FANAPT,Hyperglycemia,nia. Of these received,1,0.477742075920105
FANAPT,Hyperglycemia,the treatment of nia. Of these received,1,0.5289728045463562
FANAPT,Hyperglycemia,Of these received FANAPT,1,0.48211660981178284
FANAPT,Hyperglycemia,nia. Of these,1,0.4807016849517822
FANAPT,Hyperglycemia,for the treatment of nia. Of,1,0.5737594366073608
FANAPT,Hyperglycemia,least,0,0.43512192368507385
FANAPT,Hyperglycemia,FANAPT for at,0,0.5221648812294006
FANAPT,diabetes mellitus,treatment of schizophrenia Of  received FANAPT ,1,0.47000598907470703
FANAPT,diabetes mellitus,FANAPT for at,0,0.5019000768661499
FANAPT,diabetes mellitus,received FANAPT for at least months,1,0.4836800992488861
FANAPT,diabetes mellitus,for the treatment,0,0.5562032461166382
FANAPT,diabetes mellitus,least,0,0.525239109992981
FANAPT,diabetes mellitus,Of  received FANAPT  for,1,0.4807707667350769
FANAPT,diabetes mellitus,of schizophrenia Of  received FANAPT  for,1,0.4917496144771576
FANAPT,diabetes mellitus,received FANAPT for at,1,0.4844833314418793
FANAPT,diabetes mellitus,months,0,0.5412843227386475
FANAPT,Dyslipidemia,categories openlabel and d,0,0.528976321220398
FANAPT,Dyslipidemia,trials The and,1,0.5020300149917603
FANAPT,Weight Gain,and flexibledose studies and shortterm and longer,0,0.5047579407691956
FANAPT,Weight Gain,phases of studies inpatients and outpatients fixeddose,1,0.5172865390777588
FANAPT,Weight Gain,phases of studies inpatients and outpatients,1,0.5226322412490845
FANAPT,Weight Gain,openlabel and  phases of  studies inpatients and,1,0.5062779784202576
FANAPT,Weight Gain,phases of studies inpatients,1,0.5124363899230957
FANAPT,Metabolic Changes,flexibledos,0,0.5682017803192139
FANAPT,Metabolic Changes,"e studies, and sh ortterm and longerterm exposure Adverse",1,0.5765655636787415
FANAPT,Metabolic Changes,fixeddose and e,1,0.5660184025764465
FANAPT,Metabolic Changes,outpatients fixeddose and flexibledos,0,0.626068115234375
FANAPT,Metabolic Changes,reactions during,0,0.6298216581344604
FANAPT,cerebrovascular risk,general inquiry d recorded by clinic al,1,0.4960052967071533
FANAPT,cerebrovascular risk,reactions during,0,0.4865048825740814
FANAPT,cerebrovascular risk,obtained by general inquiry d recorded by clinic al investigators using their own,1,0.49225449562072754
FANAPT,metabolic changes,clinical tigators using th eir own,1,0.5417622327804565
FANAPT,metabolic changes,reactions during,0,0.6298216581344604
FANAPT,metabolic changes,tigators using th eir own terminology Consequently,1,0.508094847202301
FANAPT,metabolic changes,Consequently to provide a meaningful,0,0.4802284836769104
FANAPT,metabolic changes,eir own terminology Consequently to provide a meaningful estimate of,0,0.5157928466796875
FANAPT,metabolic changes,by clinical,0,0.5586913228034973
FANAPT,metabolic changes,and recorded by clinical tigators using,1,0.5373184084892273
FANAPT,hyperglycemia,investigators using their own erminology.,1,0.449408620595932
FANAPT,hyperglycemia,own erminology.,1,0.4703769087791443
FANAPT,hyperglycemia,erminology. C onsequently to provide a meaningful,1,0.46686792373657227
FANAPT,hyperglycemia,own erminology. C onsequently to provide a meaningful,1,0.4450974464416504
FANAPT,hyperglycemia,obtained by general inquiry and recorded,0,0.491424560546875
FANAPT,hyperglycemia,erminology. C,1,0.4820713996887207
FANAPT,hyperglycemia,erminology.,1,0.49146905541419983
FANAPT,dyslipidemia,"sequently, t o provide a meaningful estimate",1,0.5242679119110107
FANAPT,dyslipidemia,investigators using their own erminology.,1,0.4866517186164856
FANAPT,dyslipidemia,their own terminology Con,0,0.4881521463394165
FANAPT,dyslipidemia,"their own terminology sequently, t o",1,0.48069366812705994
FANAPT,dyslipidemia,experiencing adverse reactions,0,0.5537890195846558
FANAPT,dyslipidemia,using their own terminology Con,0,0.49594491720199585
FANAPT,dyslipidemia,"own terminology sequently,",1,0.48396599292755127
FANAPT,weight gain,ide a meani,1,0.5402253866195679
FANAPT,weight gain,terminology Consequently to ide a meani,1,0.5306094884872437
FANAPT,weight gain,proportion of individuals experiencing adverse,0,0.5248994827270508
FANAPT,weight gain,own terminology Consequently to ide,1,0.4588700532913208
FANAPT,weight gain,estimate of the proportion of individuals,0,0.5181395411491394
FANAPT,Seizures,meaningful estimate the prop ortion of individuals,1,0.4877910912036896
FANAPT,Seizures,estimate of the proportion of individuals,0,0.4673299789428711
FANAPT,Seizures,the prop ortion of individuals,1,0.5072461366653442
FANAPT,Seizures,grouped,0,0.5077050924301147
FANAPT,Seizures,estimate of,0,0.4863572120666504
FANAPT,Orthostatic hypotension,categories using MedDRA inology.,1,0.5209205746650696
FANAPT,Orthostatic hypotension,"inology.



 The stated",1,0.4768565893173218
FANAPT,Orthostatic hypotension,grouped,0,0.45847246050834656
FANAPT,Orthostatic hypotension,standardized categories,0,0.4657161235809326
FANAPT,Dizziness,requencie,1,0.5139087438583374
FANAPT,Dizziness,requencie s of adverse reactions represent,1,0.5854312181472778
FANAPT,tachycardia,of adverse,1,0.5169951915740967
FANAPT,tachycardia,terminology The stated of,1,0.508419394493103
FANAPT,tachycardia,of adverse reactions represent the proportions of,1,0.5468913316726685
FANAPT,tachycardia,terminology The stated of adverse  reactions represent the proportions of,1,0.5514059066772461
FANAPT,tachycardia,of adverse reactions represent the proportions,1,0.547376275062561
FANAPT,tachycardia,The stated,0,0.5041322112083435
FANAPT,tachycardia,terminology The stated of adverse,1,0.5187098979949951
FANAPT,tachycardia,were grouped in standardized categories using MedDRA terminology The,0,0.5049939751625061
FANAPT,syncope,stated frequencies of adverse ons rep,1,0.49142229557037354
FANAPT,syncope,were grouped in standardized categories using MedDRA terminology The,0,0.4717962145805359
FANAPT,syncope,reacti,0,0.5227451324462891
FANAPT,syncope,stated frequencies of adverse ons rep resent the proportions of individuals,1,0.4873241186141968
FANAPT,syncope,of adverse ons rep,1,0.5137165784835815
FANAPT,syncope,ons rep,1,0.4793463349342346
FANAPT,syncope,terminology The stated frequencies,0,0.4839498996734619
FANAPT,syncope,treatmentemergent adverse reaction of,0,0.5611066818237305
FANAPT,syncope,adverse ons rep resent the proportions of,1,0.4660743176937103
FANAPT,syncope,ons rep resent the proportions of individuals,1,0.4425651729106903
FANAPT,syncope,treatmentemergent adverse,0,0.5542993545532227
FANAPT,Leukopenia,experience d a,1,0.504504382610321
FANAPT,Leukopenia,experience d a treatmentemergent adverse reaction,1,0.5168249607086182
FANAPT,Leukopenia,individuals experience d a treatmentemergent,1,0.5356822609901428
FANAPT,Leukopenia,treatmentemergent adverse reaction of the type listed A reaction,0,0.5218514204025269
FANAPT,Leukopenia,of individuals experience d a treatmentemergent adverse,1,0.531498908996582
FANAPT,Leukopenia,frequencies,0,0.5205832123756409
FANAPT,Neutropenia,who a treatment,1,0.5312892198562622
FANAPT,Neutropenia,frequencies,0,0.5201690196990967
FANAPT,Suicide,Adverse Reactions Occurring at an Incidence of or More,0,0.49485743045806885
FANAPT,Suicide,doses n,1,0.5050889849662781
FANAPT,Suicide,patients who received FANAPT at daily doses withi,0,0.4847188889980316
FANAPT,Suicide,ge of to mg n Adverse Reactions Occurring,0,0.5077887177467346
FANAPT,Suicide,Incidence of or More among,0,0.486339807510376
FANAPT,Suicide,fixed or flexibledose studies,0,0.5096737146377563
FANAPT,Priapism,eived FANAPT at daily doses within a range of to mg n Adverse Reactions,0,0.5683084726333618
FANAPT,Priapism,n Adverse Reactions g at an  Incidence of or More among,1,0.5125898122787476
FANAPT,Priapism,at an Incidence,1,0.5185952186584473
FANAPT,Priapism,mg n Adverse Reactions g,1,0.5056625604629517
FANAPT,Priapism,and More,0,0.4652900695800781
FANAPT,Priapism,g at an,1,0.5032396912574768
FANAPT,motor impairment,than Placebo able 7 enumerate s the,1,0.5512820482254028
FANAPT,motor impairment,g at an,1,0.513387143611908
FANAPT,motor impairment,able 7 enumerate s the pooled,1,0.5333291292190552
FANAPT,motor impairment,7 enumerate s the pooled,1,0.48594069480895996
FANAPT,motor impairment,More Frequent,0,0.5280656218528748
FANAPT,motor impairment,T,0,0.5442652702331543
FANAPT,motor impairment,Placebo able,1,0.5494598746299744
FANAPT,motor impairment,able,1,0.6425052881240845
FANAPT,cerebrovascular adverse events,Term    (N=483)          (N=391)    Body as a Whole Arthralgia,1,0.5021611452102661
FANAPT,cerebrovascular adverse events,able,1,0.49577921628952026
FANAPT,cerebrovascular adverse events,FANAPT mgday Dictionaryderived Term N,0,0.4740316569805145
FANAPT,cerebrovascular adverse events,   (N=483)          (N=391)    Body as a Whole,1,0.46344733238220215
FANAPT,cerebrovascular adverse events,N,0,0.4680200219154358
FANAPT,fatalities,N N Body as,0,0.5854834318161011
FANAPT,QTc prolongation,Cardiac Disorde rs Tachycardia,1,0.6580399870872498
FANAPT,QTcF increase,"Gastrointestinal   
       Nau sea Dry Mouth",1,0.4692252576351166
FANAPT,QTcF increase,Cardiac Disorde rs Tachycardia,1,0.5378714203834534
FANAPT,QTcF increase,sea,0,0.46924060583114624
FANAPT,QTcF increase,"  
       Nau sea Dry",1,0.42330294847488403
FANAPT,Neuroleptic Malignant Syndrome,patients,0,0.5056243538856506
FANAPT,Neuroleptic Malignant Syndrome,the incidence in patients reated with,1,0.5501223802566528
FANAPT,Neuroleptic Malignant Syndrome,abdominal discomfort dizziness hypotension,0,0.5084748268127441
FANAPT,Neuroleptic Malignant Syndrome,with FANAPT 10 to 16 mg day were,1,0.5470197200775146
FANAPT,Neuroleptic Malignant Syndrome,patients treated with FANAPT to mgday were twice than the incidence,0,0.5422937870025635
FANAPT,Neuroleptic Malignant Syndrome,stiffness tachycardia,0,0.49755051732063293
FANAPT,Neuroleptic Malignant Syndrome,incidence in patients reated with FANAPT 10 to 16 mg day were,1,0.557894229888916
FANAPT,Neuroleptic Malignant Syndrome,treated with FANAPT to mgday were twice,0,0.5510563850402832
FANAPT,NMS,ay  were abdominal discomfort,1,0.505547821521759
FANAPT,NMS,dizziness hypotension,0,0.46659648418426514
FANAPT,NMS,tachycardia,0,0.5064458847045898
FANAPT,NMS,FANAPT to ay  were abdominal discomfort dizziness hypotension,1,0.5142003297805786
FANAPT,hyperpyrexia,stiffness,0,0.5568246841430664
FANAPT,hyperpyrexia,Common nd,1,0.4581805169582367
FANAPT,hyperpyrexia,nd Drug-Rela ted Adverse Reactions in Clinical,1,0.5375889539718628
FANAPT,muscle rigidity,d Adverse React ions in Clinical Trials,1,0.5217275619506836
FANAPT,muscle rigidity,ions in Clinical Trials Based on the,0,0.5450712442398071
FANAPT,altered mental status,ns in Clinical Trials,1,0.4962102174758911
FANAPT,altered mental status,DrugRelated Adverse ns in Clinical Trials,1,0.5353522896766663
FANAPT,altered mental status,Common and DrugRelated Adverse ns in Clinical Trials,1,0.5202206373214722
FANAPT,altered mental status,ns in Clinical Trials Based on,1,0.514616847038269
FANAPT,altered mental status,DrugRelated Adverse ns in Clinical Trials Based on the pooled data,1,0.5313236713409424
FANAPT,altered mental status,the pooled,0,0.4954732656478882
FANAPT,altered mental status,tachycardia and weight,0,0.5486682057380676
FANAPT,altered mental status,the pooled data from placebocontrolled or week fixed or flexibledose,0,0.5818240642547607
FANAPT,catatonic signs,weight increased Common and DrugRelated Adverse Reactions in Clinical Trials Based,0,0.526823878288269
FANAPT,catatonic signs,in Clinical Trials on the pooled,1,0.4961022734642029
FANAPT,catatonic signs,on the pooled data,1,0.48005372285842896
FANAPT,catatonic signs,Reactions in Clinical Trials  on the pooled  data,1,0.5295174717903137
FANAPT,catatonic signs,Clinical Trials on,1,0.4979732632637024
FANAPT,catatonic signs,in Clinical Trials on,1,0.5051066875457764
FANAPT,autonomic instability,flexibledose studies the following adverse reactions occurred in incidence,0,0.6176145076751709
FANAPT,autonomic instability,"from o-controlled, 4-",1,0.5156686305999756
FANAPT,autonomic instability,"o-controlled, 4- or 6 week fixed or",1,0.565100371837616
FANAPT,autonomic instability,"the pooled data from o-controlled,",1,0.5303531885147095
FANAPT,autonomic instability,4- or 6 week fixed or,1,0.5300936698913574
FANAPT,autonomic instability,in,0,0.4964199662208557
FANAPT,autonomic instability,4- or 6 week fixed,1,0.5362251996994019
FANAPT,autonomic instability,adverse,0,0.5964787006378174
FANAPT,autonomic instability,4- or 6 week fixed or flexibledose studies,1,0.5725488662719727
FANAPT,irregular pulse,the following adverse reactions occurred in incidence,0,0.5430654287338257
FANAPT,irregular pulse,"data from placebocontrolled or eek, fixed- or ",1,0.5636801719665527
FANAPT,irregular pulse,"eek, fixed- or  flexibledose",1,0.5423382520675659
FANAPT,irregular pulse,"eek, fixed- or flexibledose studies the following",1,0.5469039678573608
FANAPT,irregular pulse,"eek, fixed- or flexibledose studies",1,0.5517376065254211
FANAPT,irregular pulse,placebocontrolled,0,0.532435417175293
FANAPT,tachycardia,Based on the pooled,0,0.47086724638938904
FANAPT,tachycardia,incidence in,0,0.5568584203720093
FANAPT,tachycardia,reactions occurred in incidence in the patients treated with FANAPT and at,0,0.6073973178863525
FANAPT,tachycardia,"week fixed or flexibledose s, the foll",1,0.5591312646865845
FANAPT,tachycardia,owing adverse reactions occurred in incidence in the,0,0.5446702241897583
FANAPT,tachycardia,"s, the foll owing adverse reactions occurred",1,0.5421195030212402
FANAPT,tachycardia,"fixed or flexibledose s, the foll owing adverse reactions occurred",1,0.5681024789810181
FANAPT,tachycardia,"s, the foll",1,0.4995613694190979
FANAPT,tachycardia,"flexibledose s, the foll owing adverse",1,0.5653111934661865
FANAPT,tachycardia,"fixed or flexibledose s, the",1,0.5504975318908691
FANAPT,diaphoresis,ing adverse reactions occurred,1,0.5264357328414917
FANAPT,diaphoresis,ing adverse,1,0.5421306490898132
FANAPT,diaphoresis,in incidence in the patients treated,0,0.5289486646652222
FANAPT,diaphoresis,studies the ing adverse,1,0.5736820101737976
FANAPT,diaphoresis,or flexibledose studies the ing adverse reactions occurred in,1,0.5391499996185303
FANAPT,diaphoresis,from placebocontrolled or week fixed or flexibledose studies the follow,0,0.516583263874054
FANAPT,diaphoresis,ing adverse reactions occurred in,1,0.5330185890197754
FANAPT,diaphoresis,ing adverse reactions,1,0.5380473732948303
FANAPT,diaphoresis,data from placebocontrolled or,0,0.5141345262527466
FANAPT,diaphoresis,ing adverse reactions occurred in incidence in,1,0.5323513746261597
FANAPT,cardiac dysrhythmia,occurred in >= incidence,1,0.5181469917297363
FANAPT,cardiac dysrhythmia,rom placebocontrolled or week fixed or flexibledose studies,0,0.5166912078857422
FANAPT,cardiac dysrhythmia,ions occurred in >= incidence in the patients,1,0.5629297494888306
FANAPT,cardiac dysrhythmia,with FANAPT and at least twice the placebo rate for at,0,0.5015982389450073
FANAPT,cardiac dysrhythmia,following adverse,0,0.5189486742019653
FANAPT,cardiac dysrhythmia,ions occurred in >= incidence in the,1,0.4921647012233734
FANAPT,myoglobinuria,ce the placeb,1,0.463290274143219
FANAPT,myoglobinuria,ions occurred in >= incidence in the,1,0.4444044232368469
FANAPT,myoglobinuria,adverse reactions occurred in incidence in the,0,0.5006235837936401
FANAPT,myoglobinuria,patients treated with FANAPT and,0,0.4882471561431885
FANAPT,myoglobinuria,FANAPT and at least ce the placeb,1,0.4645216763019562
FANAPT,myoglobinuria,at least ce the placeb,1,0.4795420169830322
FANAPT,myoglobinuria,the placeb o rate for at least,1,0.474397212266922
FANAPT,myoglobinuria,and at least ce the placeb o rate for at,1,0.4679119288921356
FANAPT,myoglobinuria,the patients treated with FANAPT and at,0,0.4893133342266083
FANAPT,myoglobinuria,the placeb,1,0.47869330644607544
FANAPT,myoglobinuria,fatigue nasal,0,0.5121048092842102
FANAPT,rhabdomyolysis,at least twice,0,0.5055867433547974
FANAPT,rhabdomyolysis,rate for at,1,0.43685945868492126
FANAPT,rhabdomyolysis,least twice the rate,1,0.47164297103881836
FANAPT,rhabdomyolysis,tions occurred in incidence in the patients treated with FANAPT and at,0,0.5340108871459961
FANAPT,rhabdomyolysis,rate for at le ast dose dizziness dry,1,0.551354169845581
FANAPT,rhabdomyolysis,for at le ast dose,1,0.5487051606178284
FANAPT,rhabdomyolysis,congestion somnolence tachycardia,0,0.47257256507873535
FANAPT,rhabdomyolysis,placebo,0,0.539846658706665
FANAPT,acute renal failure,"rate for at least ose: dizziness,",1,0.4864153265953064
FANAPT,acute renal failure,"rate for at least ose: dizziness, dry",1,0.4932761788368225
FANAPT,acute renal failure,"rate for at least ose: dizziness, dry mouth fatigue nasal congestion somnolence",1,0.47574329376220703
FANAPT,Tardive dyskinesia,     1.9           Adverse Reactions,1,0.5329344272613525
FANAPT,Tardive dyskinesia,     1.9           Adverse Reactions Associated,1,0.5305071473121643
FANAPT,Tardive dyskinesia,Parkinsonism      1.9          ,1,0.668054461479187
FANAPT,Tardive dyskinesia,Tremor,0,0.628791093826294
FANAPT,Tardive dyskinesia,Associated with,0,0.5066366195678711
FANAPT,Tardive dyskinesia,     1.9           Adverse,1,0.49386173486709595
FANAPT,Tardive dyskinesia,Parkinsonism,0,0.7093667387962341
FANAPT,"involuntary, dyskinetic movements",erse Reactions,1,0.5238083600997925
FANAPT,"involuntary, dyskinetic movements",Associated with Di scontinuation of,1,0.5859214067459106
FANAPT,"involuntary, dyskinetic movements",Treatment in Clinical Trials Based on,0,0.530121922492981
FANAPT,"involuntary, dyskinetic movements",Tremor erse Reactions Associated with Di scontinuation,1,0.7621818780899048
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated,1,0.5380221605300903
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated with Di scontinuation of Treatment in Clinical,1,0.6144561767578125
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated with Di scontinuation of Treatment in,1,0.6236838102340698
FANAPT,"involuntary, dyskinetic movements",with Di scontinuation of Treatment in,1,0.5961595773696899
FANAPT,hyperglycemia,listed in order of decreasing,0,0.47799408435821533
FANAPT,hyperglycemia,by it. R eactions,1,0.5116198062896729
FANAPT,hyperglycemia,"were not necessarily  by it.



 R eactions are further",1,0.46878254413604736
FANAPT,hyperglycemia,were not necessarily by,1,0.4809555411338806
FANAPT,hyperglycemia,necessarily by,1,0.5311298370361328
FANAPT,dyslipidemia,ctions are f urther categorized by MedDRA,1,0.5433164834976196
FANAPT,dyslipidemia,it ctions are,1,0.5556223392486572
FANAPT,dyslipidemia,in,0,0.556219220161438
FANAPT,dyslipidemia,necessarily caused by it ctions are f urther categorized by MedDRA system,1,0.5744925737380981
FANAPT,dyslipidemia,categorized by MedDRA system organ class and listed,0,0.4974368214607239
FANAPT,body weight gain,frequency according,0,0.5084247589111328
FANAPT,body weight gain,decreasing,0,0.5374179482460022
FANAPT,body weight gain,it Reactions are categorized,1,0.501462459564209
FANAPT,body weight gain,categorized by MedDRA system organ class and,1,0.5080836415290833
FANAPT,body weight gain,categorized by MedDRA system organ,1,0.5280449390411377
FANAPT,body weight gain,treatment with FANAPT they were not necessarily caused by,0,0.5133236050605774
FANAPT,body weight gain,further,0,0.5025798678398132
FANAPT,body weight gain, categorized by  MedDRA system organ class,1,0.5059118270874023
FANAPT,body weight gain,it Reactions are  categorized by  MedDRA system,1,0.5061901211738586
FANAPT,body weight gain,were not necessarily caused by it Reactions,0,0.5304818153381348
FANAPT,Hyperglycemia,requent adver se,1,0.519597053527832
FANAPT,Hyperglycemia,requent adver se reactions are,1,0.5328354835510254
FANAPT,Hyperglycemia,in Table appear in this,0,0.5338431000709534
FANAPT,Hyperglycemia,listed in Table appear in,0,0.520021915435791
FANAPT,Hyperglycemia,requent adver se reactions are those,1,0.5297751426696777
FANAPT,Hyperglycemia,appear in this listing requent,1,0.5136635899543762
FANAPT,ketoacidosis,those occurring in  1/1000 pati ents rare,1,0.5273388624191284
FANAPT,ketoacidosis,requent adver se,1,0.5107228755950928
FANAPT,ketoacidosis,events are those occurring,0,0.4656409025192261
FANAPT,ketoacidosis,those occurring in 1/1000 pati,1,0.5469552278518677
FANAPT,ketoacidosis,are those,0,0.4673525094985962
FANAPT,ketoacidosis,those,0,0.43317413330078125
FANAPT,ketoacidosis,1/1000 pati ents rare,1,0.47677505016326904
FANAPT,ketoacidosis,Blood and Lymphatic,0,0.5027944445610046
FANAPT,ketoacidosis,Blood,0,0.5349358916282654
FANAPT,ketoacidosis,in,0,0.4986613690853119
FANAPT,ketoacidosis, 1/1000 pati ents,1,0.49079760909080505
FANAPT,hyperosmolar coma,patients Blood,0,0.5393738746643066
FANAPT,hyperosmolar coma,in to ; rare events are,1,0.5202917456626892
FANAPT,hyperosmolar coma,; rare events are those occurring,1,0.5061659812927246
FANAPT,hyperosmolar coma,; rare events are those occurring in fewer,1,0.49753525853157043
FANAPT,hyperosmolar coma,Blood,0,0.5612239837646484
FANAPT,hyperosmolar coma,events are those occurring in fewer,1,0.503106415271759
FANAPT,hyperosmolar coma,occurring in to ; rare events are those occurring in fewer,1,0.5200421810150146
FANAPT,hyperosmolar coma,to ; rare events are those occurring in,1,0.5055257081985474
FANAPT,hyperosmolar coma,; rare events are those,1,0.4864412546157837
FANAPT,death,se oc curring,1,0.5563810467720032
FANAPT,death,se oc curring in,1,0.5532926321029663
FANAPT,death,rare events are se oc,1,0.513824462890625
FANAPT,death,se oc,1,0.5588517189025879
FANAPT,death,se oc curring in fewer than,1,0.5211480855941772
FANAPT,death,curring in fewer than patients,0,0.4723523259162903
FANAPT,death,patients rare events are se oc,1,0.507158637046814
FANAPT,death,those occurring in to patients rare events are,0,0.5155169367790222
FANAPT,hyperglycemia-related adverse events,"opacities cataract hyperemia ncluding conjunctival)



   Gastroi ntestinal Disorders Infrequent gastritis salivary",1,0.6335470676422119
FANAPT,hyperglycemia-related adverse events,those occurring in to patients rare events are,0,0.6734901666641235
FANAPT,hyperglycemia-related adverse events,cataract hyperemia ncluding,1,0.6112020015716553
FANAPT,hyperglycemia-related adverse events,"ncluding conjunctival)



   Gastroi ntestinal Disorders Infrequent gastritis salivary",1,0.5682092905044556
FANAPT,hyperglycemia-related adverse events,swelling lenticular,0,0.5713971853256226
FANAPT,hyperglycemia-related adverse events,"lenticular opacities cataract hyperemia ncluding conjunctival)



   Gastroi ntestinal Disorders Infrequent gastritis",1,0.6367764472961426
FANAPT,hyperglycemia-related adverse events,lenticular opacities cataract hyperemia ncluding,1,0.6322213411331177
FANAPT,hyperglycemia-related adverse events,"cataract hyperemia ncluding conjunctival)



   Gastroi ntestinal Disorders Infrequent gastritis salivary",1,0.6349500417709351
FULYZAQ,Upper respiratory tract infection,tract infection Bronchitis,1,0.7215487957000732
FULYZAQ,Upper respiratory tract infection,n PlaceboN Upper respiratory tract infection Bronchitis,1,0.8252293467521667
FULYZAQ,Upper respiratory tract infection,respiratory tract infection,1,0.9014788866043091
FULYZAQ,Bronchitis,Upper respiratory tract infection,0,0.6903374791145325
FULYZAQ,Bronchitis,n Upper respiratory tract infection,0,0.6542207598686218
FULYZAQ,Bronchitis,Upper respiratory tract Bronchitis,1,0.8477851152420044
FULYZAQ,Bronchitis,Bronchitis Cough,1,0.8921972513198853
FULYZAQ,Bronchitis,tract Bronchitis Cough,1,0.8175743818283081
FULYZAQ,Flatulence,Flatulence Increased bilirubin,1,0.7969125509262085
FULYZAQ,Flatulence,Bronchitis Cough,1,0.5322182178497314
FULYZAQ,Nausea,Nausea,1,1.0
FULYZAQ,Nausea,Bronchitis Cough,1,0.5574167966842651
FULYZAQ,Nausea,Nausea Back,1,0.8866218328475952
FULYZAQ,Nausea,Increased Nausea Back,1,0.8626737594604492
FULYZAQ,Nausea,bilirubin,0,0.5810256600379944
FULYZAQ,Nausea,Increased,0,0.5574426651000977
FULYZAQ,Back pain,Back pain,1,1.0
FULYZAQ,Back pain,Back pain Arthralgia,1,0.8567789196968079
FULYZAQ,Back pain,Nausea,0,0.5431005358695984
FULYZAQ,Arthralgia,Arthralgia Urinary tract infection,1,0.8100699186325073
FULYZAQ,Arthralgia,Arthralgia,1,1.0
FULYZAQ,Arthralgia,Urinary,0,0.5305094122886658
FULYZAQ,Arthralgia,Arthralgia Urinary,1,0.8486563563346863
FULYZAQ,Urinary tract infection,Urinary,1,0.8110286593437195
FULYZAQ,Urinary tract infection,n Urinary tract,1,0.7945590615272522
FULYZAQ,Urinary tract infection,n,0,0.5348697900772095
FULYZAQ,Nasopharyngitis,Urinary,0,0.5447673797607422
FULYZAQ,Nasopharyngitis,tract Nasopharyngitis,1,0.868354082107544
FULYZAQ,Nasopharyngitis,tract infection,0,0.6445010304450989
FULYZAQ,Nasopharyngitis,tract Nasopharyngitis Musculoskeletal,1,0.8199028968811035
FULYZAQ,Nasopharyngitis,Urinary tract,0,0.5664858818054199
FULYZAQ,Nasopharyngitis,Nasopharyngitis,1,1.0000001192092896
FULYZAQ,Nasopharyngitis,Nasopharyngitis Musculoskeletal,1,0.8380576372146606
FULYZAQ,Musculoskeletal pain,Musculoskeletal pain,1,1.0000001192092896
FULYZAQ,Musculoskeletal pain,Nasopharyngitis,0,0.5053642392158508
FULYZAQ,Musculoskeletal pain,Musculoskeletal pain Hemorrhoids Giard,1,0.7865113615989685
FULYZAQ,Hemorrhoids,Musculoskeletal Hemorrhoids Giardiasis,1,0.7512586712837219
FULYZAQ,Hemorrhoids,Musculoskeletal pain Hemorrhoids Giard,1,0.7664750814437866
FULYZAQ,Giardiasis,Giardiasis Anxiety In,1,0.8460500240325928
FULYZAQ,Giardiasis,Giardiasis,1,1.0
FULYZAQ,Giardiasis,pain Giardiasis Anxiety In,1,0.8224090337753296
FULYZAQ,Increased alanine aminotransferase,is Increased alanine aminotransferase Abdominal distension,1,0.8635436296463013
FULYZAQ,Increased alanine aminotransferase,Giardiasis,1,0.5484265089035034
FULYZAQ,Increased alanine aminotransferase,alanine aminotransferase Abdominal distension,1,0.8144482374191284
FULYZAQ,abdominal pain,bilirubin increased,0,0.4898976683616638
FULYZAQ,acne,FULYZAQ were abdominal acne increased aspartate aminotransferase,1,0.7319951057434082
FULYZAQ,acne,bilirubin increased,0,0.5028737783432007
FULYZAQ,increased aspartate aminotransferase,pain increased,1,0.6343452334403992
FULYZAQ,increased aspartate aminotransferase,abdominal pain acne,0,0.5188966393470764
FULYZAQ,increased aspartate aminotransferase,bilirubin increased unconjugated blood bilirubin constipation,0,0.6236159801483154
FULYZAQ,increased aspartate aminotransferase,abdominal pain increased aspartate aminotransferase increased conjugated,1,0.8582674264907837
FULYZAQ,increased aspartate aminotransferase,increased aspartate aminotransferase increased conjugated bilirubin increased,1,0.893102765083313
FULYZAQ,increased conjugated bilirubin,increased aspartate increased conjugated bilirubin,1,0.8982932567596436
FULYZAQ,increased conjugated bilirubin,increased aspartate aminotransferase increased conjugated bilirubin increased,1,0.8999873399734497
FULYZAQ,increased conjugated bilirubin,increased conjugated bilirubin increased unconjugated,1,0.9669686555862427
FULYZAQ,increased conjugated bilirubin,increased aspartate,0,0.6925609111785889
FULYZAQ,increased conjugated bilirubin,increased aspartate increased,1,0.6986932158470154
FULYZAQ,increased conjugated bilirubin,aspartate increased conjugated bilirubin,1,0.8822047710418701
FULYZAQ,increased conjugated bilirubin,blood bilirubin constipation depression dermatitis dizziness,0,0.7598028182983398
FULYZAQ,increased unconjugated blood bilirubin,increased unconjugated blood bilirubin constipation depression dermatitis dizziness dry,1,0.8901662826538086
FULYZAQ,increased unconjugated blood bilirubin,increased aspartate,0,0.6909294724464417
FULYZAQ,increased unconjugated blood bilirubin,increased unconjugated,1,0.8030210137367249
FULYZAQ,increased unconjugated blood bilirubin,were abdominal pain acne increased aspartate aminotransferase,0,0.5952511429786682
FULYZAQ,increased unconjugated blood bilirubin,conjugated increased,1,0.744389533996582
FULYZAQ,increased unconjugated blood bilirubin,aminotransferase increased conjugated bilirubin,0,0.842390775680542
FULYZAQ,increased unconjugated blood bilirubin,aspartate aminotransferase increased conjugated increased unconjugated,1,0.7351000308990479
FULYZAQ,depression,conjugated bilirubin increased unconjugated blood bilirubin constipation,0,0.533380389213562
FULYZAQ,depression,depression dermatitis dizziness dry,1,0.7854506969451904
FULYZAQ,depression,depression,1,0.9999998807907104
FULYZAQ,depression,bilirubin depression dermatitis,1,0.6587517857551575
FULYZAQ,dermatitis,depression,0,0.5617244243621826
FULYZAQ,dermatitis,unconjugated blood bilirubin constipation dermatitis dizziness dry mouth dyspepsia gastroenteritis,1,0.6212875843048096
FULYZAQ,dermatitis,constipation dermatitis dizziness dry mouth,1,0.735013484954834
FULYZAQ,dermatitis,blood bilirubin constipation dermatitis dizziness dry mouth dyspepsia gastroenteritis,1,0.6631262302398682
FULYZAQ,dermatitis,mouth dyspepsia gastroenteritis herpes,0,0.5756592154502869
FULYZAQ,dermatitis,conjugated bilirubin increased unconjugated,0,0.4856032133102417
FULYZAQ,dermatitis,dermatitis dizziness dry mouth,1,0.7983658313751221
FULYZAQ,dermatitis,unconjugated blood bilirubin constipation depression,0,0.49800512194633484
FULYZAQ,dermatitis,increased unconjugated blood bilirubin,0,0.4894799292087555
FULYZAQ,dermatitis,dermatitis dizziness dry mouth dyspepsia,1,0.7771114110946655
FULYZAQ,dry mouth,dermatitis dry mouth dyspepsia gastroenteritis herpes,1,0.7290830612182617
FULYZAQ,dry mouth,dermatitis dizziness dry mouth dyspepsia,1,0.718673586845398
FULYZAQ,dry mouth,constipation depression dermatitis dry mouth,1,0.7454323172569275
FULYZAQ,dyspepsia,dry dyspepsia gastroenteritis herpes zoster,1,0.7960354685783386
FULYZAQ,dyspepsia,constipation depression dermatitis dry mouth,1,0.6750236749649048
FULYZAQ,dyspepsia,gastroenteritis herpes zoster nephrolithiasis pain in extremity pollakiuria procedural,0,0.6228413581848145
FULYZAQ,gastroenteritis,gastroenteritis herpes zoster nephrolithiasis pain in,1,0.714202880859375
FULYZAQ,herpes zoster,mouth dyspepsia herpes zoster nephrolithiasis pain in extremity pollakiuria,1,0.7376301884651184
FULYZAQ,herpes zoster,gastroenteritis herpes zoster nephrolithiasis pain in,1,0.7694506645202637
FULYZAQ,herpes zoster,mouth dyspepsia herpes,1,0.7168445587158203
FULYZAQ,herpes zoster,mouth,0,0.5542392730712891
FULYZAQ,herpes zoster,dizziness dry mouth dyspepsia herpes,1,0.7027519941329956
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis,1,0.8107008934020996
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis pain,1,0.8043122291564941
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis pain in extremity,1,0.7938969731330872
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis pain in,1,0.7990906238555908
FULYZAQ,herpes zoster,depression dermatitis dizziness dry mouth,0,0.5949028730392456
FULYZAQ,nephrolithiasis,nephrolithiasis pain in extremity pollakiuria,1,0.8152101039886475
FULYZAQ,nephrolithiasis,nephrolithiasis pain in,1,0.8986425399780273
FULYZAQ,nephrolithiasis,allergy sinusitis and decreased white b,0,0.5483031868934631
FULYZAQ,nephrolithiasis,mouth dyspepsia gastroenteritis herpes nephrolithiasis pain in,1,0.6928352117538452
FULYZAQ,pain in extremity,dermatitis dizziness dry mouth dyspepsia gastroenteritis herpes zoster nephrolithiasis,0,0.598443865776062
FULYZAQ,pollakiuria,dry mouth dyspepsia gastroenteritis herpes zoster nephrolithiasis pain in,0,0.5179771780967712
FULYZAQ,pollakiuria,pain in pollakiuria procedural,1,0.7949854731559753
FULYZAQ,procedural pain,procedural pain,1,1.0000001192092896
FULYZAQ,procedural pain,seasonal allergy sinusitis and decreased white blood,0,0.5148077011108398
FULYZAQ,seasonal allergy,seasonal allergy sinusitis and decreased,1,0.8455730676651001
FULYZAQ,seasonal allergy,in extremity pollakiuria procedural seasonal allergy sinusitis and,1,0.7920511960983276
FULYZAQ,seasonal allergy,seasonal allergy sinusitis and,1,0.8819352388381958
FULYZAQ,seasonal allergy,decreased,0,0.4782164692878723
FULYZAQ,seasonal allergy,were similar,0,0.46420007944107056
FULYZAQ,sinusitis,patients who received d,0,0.5087337493896484
FULYZAQ,sinusitis,sinusitis and decreased white,1,0.8312524557113647
FULYZAQ,sinusitis,sinusitis and decreased white blood cell,1,0.818708062171936
FULYZAQ,sinusitis,sinusitis and decreased,1,0.8619544506072998
FULYZAQ,sinusitis,pollakiuria procedural pain seasonal sinusitis and decreased white blood cell,1,0.7490475177764893
FULYZAQ,sinusitis,sinusitis and,1,0.9340534806251526
FULYZAQ,decreased white blood cell count,pain in extremity pollakiuria procedural pain seasonal allergy sinusitis and,0,0.49662667512893677
FULYZAQ,upper respiratory tract infection,upper respiratory tract infection bronchitis,1,0.8733058571815491
FULYZAQ,upper respiratory tract infection,pain in extremity pollakiuria procedural pain seasonal allergy sinusitis and,0,0.6044522523880005
FULYZAQ,upper respiratory tract infection,tract infection bronchitis,1,0.7215487957000732
FULYZAQ,upper respiratory tract infection,mg daily EXCERPT Most common adverse,0,0.5271034240722656
FULYZAQ,upper respiratory tract infection,upper respiratory tract infection bronchitis cough flatulence,1,0.8471628427505493
FULYZAQ,upper respiratory tract infection,adverse reactions incidence upper respiratory tract infection bronchitis cough,1,0.7545703053474426
FULYZAQ,upper respiratory tract infection,common adverse reactions incidence,0,0.5536594390869141
FULYZAQ,upper respiratory tract infection,To report SUSPECTED ADVERSE R,0,0.5852383375167847
FULYZAQ,upper respiratory tract infection,reactions incidence upper respiratory tract infection bronchitis cough flatulence and,1,0.7602362036705017
FULYZAQ,bronchitis,bronchitis,1,0.9999999403953552
FULYZAQ,bronchitis,tract,0,0.5172674655914307
FULYZAQ,bronchitis,incidence are upper respiratory,0,0.588748037815094
FULYZAQ,bronchitis,bronchitis cough flatulence and,1,0.8276939392089844
FULYZAQ,bronchitis,report SUSPECTED ADVERSE,0,0.5504729151725769
FULYZAQ,bronchitis,adverse reactions incidence are upper respiratory tract infection,0,0.5858052968978882
FULYZAQ,bronchitis,are upper respiratory,0,0.5846274495124817
FULYZAQ,flatulence,flatulence and increased bilirubin To,1,0.8047906756401062
FULYZAQ,increased bilirubin,tract,0,0.4905773401260376
FULYZAQ,increased bilirubin,are upper respiratory tract infection bronchitis cough,0,0.535519003868103
FULYZAQ,increased bilirubin,contact Salix,0,0.43794238567352295
FULYZAQ,increased bilirubin,flatulence increased,1,0.6642671823501587
FULYZAQ,increased bilirubin,respiratory tract infection,0,0.5473694801330566
FULYZAQ,increased bilirubin,and,0,0.4916672110557556
FULYZAQ,increased bilirubin,infection bronchitis cough flatulence increased bilirubin To report SUSPECTED ADVERSE,1,0.7984001636505127
FULYZAQ,increased bilirubin,are upper,0,0.5490280985832214
EOVIST,Nephrogenic systemic fibrosis,elsewhere in the Nephrogenic,1,0.7871496081352234
EOVIST,Nephrogenic systemic fibrosis,in the Nephrogenic systemic fibrosis,1,0.9868634939193726
EOVIST,Nephrogenic systemic fibrosis,the,0,0.46334517002105713
EOVIST,Nephrogenic systemic fibrosis,and Warnings and Precautions Hypersensitivity,0,0.5025805830955505
EOVIST,Nephrogenic systemic fibrosis,reactionsare,0,0.5347449779510498
EOVIST,Nephrogenic systemic fibrosis,Warning and,0,0.4843359887599945
EOVIST,Nephrogenic systemic fibrosis,Boxed,0,0.459219366312027
EOVIST,Nephrogenic systemic fibrosis,elsewhere in the Nephrogenic systemic fibrosis,1,0.9613866806030273
EOVIST,NSF,NSF see Boxed Warning,1,0.7773100137710571
EOVIST,NSF,systemic NSF see Boxed,1,0.8301171660423279
EOVIST,NSF,NSF see Boxed Warning and,1,0.782315731048584
EOVIST,NSF,and Precautions,0,0.4767376184463501
EOVIST,Hypersensitivity reactions,and Hypersensitivity,1,0.8890628814697266
EOVIST,Hypersensitivity reactions,EXCERPT Most,0,0.4936469495296478
EOVIST,Hypersensitivity reactions,Hypersensitivity reactions see Contraindications,1,0.8384571075439453
EOVIST,Hypersensitivity reactions,fibrosis NSF,0,0.508462131023407
EOVIST,Hypersensitivity reactions,see Contraindications and Warnings and Precautions EXCERPT Most comm,0,0.5814356803894043
EOVIST,Hypersensitivity reactions,Warning and Warnings and Hypersensitivity reactions,1,0.8053289651870728
EOVIST,nausea,nausea headache feeling hot dizziness,1,0.8180807828903198
EOVIST,headache,headache feeling hot dizziness and back,1,0.7833293676376343
EOVIST,feeling hot,feeling hot,1,1.0000001192092896
EOVIST,feeling hot,feeling,1,0.6968855857849121
EOVIST,feeling hot,SUSPECTED ADVERSE REACTIONS contact,0,0.5664981603622437
EOVIST,feeling hot,feeling hot dizziness,1,0.8197260499000549
EOVIST,feeling hot,adverse reactions incidence are,0,0.5294952392578125
EOVIST,feeling hot,back pain,0,0.5274538993835449
EOVIST,feeling hot,are nausea feeling hot dizziness and back,1,0.7403964996337891
EOVIST,feeling hot,nausea feeling hot,1,0.8691933751106262
EOVIST,feeling hot,pain To report SUSPECTED ADVERSE REACTIONS contact,0,0.5687077641487122
EOVIST,dizziness,dizziness and,1,0.949488639831543
EOVIST,dizziness,common adverse reactions incidence,0,0.5399556159973145
EOVIST,back pain,reactions incidence are nausea headache feeling,0,0.5350936651229858
EOVIST,back pain,common,0,0.4872180223464966
EOVIST,back pain,feeling hot dizziness back,1,0.5795961022377014
EOVIST,back pain,dizziness back pain To,1,0.7987355589866638
EOVIST,back pain,dizziness back pain To report,1,0.789817214012146
EOVIST,back pain,headache feeling hot dizziness back pain To,1,0.7442673444747925
EOVIST,nausea,frequent adverse reactions,0,0.6078885793685913
EOVIST,nausea,mild to,0,0.5834618210792542
EOVIST,headache,with the use of,0,0.5272198915481567
EOVIST,headache,headache feeling,1,0.8759911060333252
EOVIST,dizziness,reactions were predominantly of mild to moderate severity,0,0.567328691482544
EOVIST,dizziness,feeling dizziness and back pain Adverse reactions,1,0.7933312654495239
EOVIST,dizziness,pain Adverse reactions,0,0.5438389778137207
EOVIST,dizziness,dizziness and back pain Adverse,1,0.8333250880241394
EOVIST,back pain,reactions were predominantly of mild to moderate severity Table lists adverse react,0,0.5123336315155029
EOVIST,Dizziness,Dizziness Back,1,0.9092365503311157
EOVIST,Vomiting,Vomiting Blood pressure,1,0.8139986395835876
EOVIST,Vomiting,Vomiting Blood,1,0.8887100219726562
EOVIST,Vomiting,Blood pressure,0,0.510667085647583
EOVIST,Vomiting,Blood pressure increased,0,0.4715287685394287
EOVIST,Vomiting,Back Vomiting,1,0.8598011136054993
EOVIST,Injection site reactions,pressure,0,0.5249931812286377
EOVIST,Injection site reactions,increased,0,0.5575982332229614
EOVIST,Injection site reactions,Blood pressure Injection site reactions pain burning,1,0.8075800538063049
EOVIST,Injection site reactions,coldness extravasation,0,0.5977697372436523
EOVIST,Injection site reactions,Blood pressure increased,0,0.5265601277351379
EOVIST,Injection site reactions,Injection site reactions,1,1.0
EOVIST,Injection site reactions,pressure Injection site reactions,1,0.8720662593841553
EOVIST,Rash,Rash Respiratory disorders dyspnea,1,0.7570743560791016
EOVIST,Rash,pressure Injection site reactions,1,0.536746084690094
EOVIST,dyspnea,dyspnea,1,1.0
EOVIST,dyspnea,respiratory distress Fatigue,0,0.6588156223297119
EOVIST,respiratory distress,disorders respiratory,1,0.7405039668083191
EOVIST,respiratory distress,Rash Respiratory disorders respiratory distress,1,0.871619701385498
EOVIST,respiratory distress,Rash Respiratory disorders respiratory distress Fatigue,1,0.8255718350410461
EOVIST,respiratory distress,Respiratory disorders,0,0.7696943879127502
EOVIST,respiratory distress,Respiratory disorders respiratory,1,0.7468500137329102
EOVIST,respiratory distress,respiratory distress Fatigue,1,0.898613691329956
EOVIST,Fatigue,Fatigue Chest,1,0.8092989921569824
EOVIST,Fatigue,Fatigue,1,1.0
EOVIST,Fatigue,Fatigue Chest pain,1,0.807784378528595
EOVIST,Vertigo,Vertigo Dry,1,0.8618506789207458
EOVIST,Vertigo,Fatigue Chest pain,1,0.5591928362846375
EOVIST,Vertigo,Chest,0,0.49182265996932983
EOVIST,Vertigo,Vertigo Dry mouth,1,0.8128640055656433
EOVIST,Vertigo,Vertigo,1,1.0
EOVIST,Vertigo,Chest pain,0,0.5096672773361206
EOVIST,Vertigo,Chest Vertigo,1,0.8580667972564697
EOVIST,Chills,Chills Feeling abnormal,1,0.8850536346435547
EOVIST,Chills,mouth,0,0.5159255266189575
EOVIST,Chills,Dry,0,0.5412601232528687
EOVIST,Chills,Chills,1,0.9999998807907104
EOVIST,Chills,Chills Feeling,1,0.9442722797393799
EOVIST,Chills,Dry mouth,0,0.5311006307601929
EOVIST,akathisia,EOVIST include akathisia bundle branch block palpitation oral,1,0.724851131439209
EOVIST,akathisia,Dry mouth,0,0.5162368416786194
EOVIST,akathisia,include akathisia,1,0.924270749092102
EOVIST,akathisia,discomfort salivary hypersecretion maculopapular rash,0,0.5838415622711182
EOVIST,akathisia,occurred with a,0,0.545391321182251
EOVIST,bundle branch block,include tremor akathisia,0,0.5460071563720703
EOVIST,bundle branch block,hypersecretion maculopapular,0,0.4644227921962738
EOVIST,bundle branch block,branch block palpitation oral discomfort salivary hypersecretion,1,0.6885548830032349
EOVIST,bundle branch block,bundle branch block,1,1.0
EOVIST,bundle branch block,palpitation oral discomfort salivary hypersecretion maculopapular rash,0,0.5407683849334717
EOVIST,bundle branch block,tremor bundle branch,1,0.733782172203064
EOVIST,bundle branch block,occurred with a frequency of,0,0.5354280471801758
EOVIST,bundle branch block,discomfort salivary,0,0.4201727509498596
EOVIST,palpitation,palpitation,1,1.0000001192092896
EOVIST,oral discomfort,akathisia bundle branch,0,0.4832318425178528
EOVIST,oral discomfort,hyperhidrosis,0,0.56529700756073
EOVIST,oral discomfort,oral discomfort salivary hypersecretion maculopapular rash hyperhidrosis,1,0.7876406311988831
EOVIST,oral discomfort,branch block oral discomfort salivary hypersecretion maculopapular rash,1,0.7452831864356995
EOVIST,oral discomfort,maculopapular rash hyperhidrosis discomfort and malaise,0,0.5953808426856995
EOVIST,oral discomfort,EOVIST include tremor akathisia bundle branch block,0,0.5243798494338989
EOVIST,oral discomfort,block,0,0.5054299831390381
EOVIST,oral discomfort,bundle branch block oral discomfort salivary hypersecretion maculopapular rash hyperhidrosis,1,0.68698650598526
EOVIST,oral discomfort,akathisia bundle branch block oral discomfort salivary hypersecretion maculopapular rash hyperhidrosis,1,0.6814498901367188
EOVIST,salivary hypersecretion,Elevation of serum iron,0,0.6219966411590576
EOVIST,salivary hypersecretion,include tremor akathisia bundle branch block,0,0.5262891054153442
EOVIST,salivary hypersecretion,discomfort and malaise Elevation of serum iron values and,0,0.639117956161499
EOVIST,salivary hypersecretion,discomfort,0,0.5419996976852417
EOVIST,salivary hypersecretion,hyperhidrosis discomfort and malaise Elevation of serum iron,0,0.6451610922813416
EOVIST,salivary hypersecretion,block palpitation oral salivary hypersecretion maculopapular rash hyperhidrosis discomfort and,1,0.7900108695030212
EOVIST,salivary hypersecretion,Elevation of serum iron values,0,0.6150310039520264
EOVIST,maculopapular rash,salivary,0,0.5267297625541687
EOVIST,maculopapular rash,maculopapular rash,1,1.0
EOVIST,maculopapular rash,serum iron,0,0.4742186963558197
EOVIST,maculopapular rash,oral discomfort salivary,0,0.5087589025497437
EOVIST,maculopapular rash,discomfort salivary maculopapular rash,1,0.8753762245178223
EOVIST,maculopapular rash,palpitation oral discomfort salivary maculopapular rash hyperhidrosis discomfort and malaise,1,0.7097954154014587
EOVIST,maculopapular rash,bundle branch block palpitation oral discomfort salivary,0,0.5385599136352539
EOVIST,maculopapular rash,bundle branch block palpitation,0,0.5080038905143738
EOVIST,discomfort,discomfort and malaise Elevation of,1,0.8251059651374817
EOVIST,discomfort,salivary hypersecretion maculopapular rash discomfort and malaise Elevation of,1,0.6201533079147339
EOVIST,discomfort,discomfort and malaise Elevation,1,0.8169986605644226
EOVIST,malaise,malaise Elevation of serum,1,0.7814510464668274
EOVIST,malaise,Elevation of serum iron values and serum bilirubin laboratory values,0,0.4866449236869812
EOVIST,Elevation of serum iron,malaise,0,0.5231113433837891
EOVIST,Hypersensitivity reactions,causal relationship to drug Hypersensitivity reactions anaphylacticshock hypotension pharyngolaryngeal,1,0.7611658573150635
EOVIST,Hypersensitivity reactions,malaise,0,0.5241677761077881
EOVIST,Hypersensitivity reactions,Hypersensitivity reactions,1,1.0
EOVIST,Hypersensitivity reactions,drug exposure,0,0.5972369909286499
EOVIST,Hypersensitivity reactions,to,0,0.5400255918502808
EOVIST,anaphylacticshock,anaphylacticshock hypotension pharyngolaryngeal edema,1,0.8148382306098938
EOVIST,hypotension,relationship,0,0.4723357558250427
EOVIST,hypotension,hypotension pharyngolaryngeal edema urticaria,1,0.755945086479187
EOVIST,hypotension,hypotension pharyngolaryngeal,1,0.8312453031539917
EOVIST,hypotension,drug exposure Hypersensitivity reactions hypotension pharyngolaryngeal edema urticaria face,1,0.6406063437461853
EOVIST,pharyngolaryngeal edema,Hypersensitivity reactions anaphylacticshock pharyngolaryngeal,1,0.7280128002166748
EOVIST,urticaria,reactions anaphylacticshock hypotension pharyngolaryngeal urticaria face edema rhinitis,1,0.7126076221466064
EOVIST,urticaria,Hypersensitivity reactions anaphylacticshock pharyngolaryngeal,1,0.649150013923645
EOVIST,face edema,face edema rhinitis conjunctivitis,1,0.8654731512069702
EOVIST,face edema,face edema,1,0.9999998807907104
EOVIST,rhinitis,rhinitis conjunctivitis abdominal pain,1,0.7437170743942261
EOVIST,rhinitis,cough and pallor see Warnings,0,0.591038703918457
EOVIST,conjunctivitis,conjunctivitis,1,1.0
EOVIST,conjunctivitis,pharyngolaryngeal,0,0.4677612781524658
EOVIST,conjunctivitis,cough and pallor,0,0.5810056924819946
EOVIST,abdominal pain,abdominal pain hypoesthesia sneezing cough,1,0.7792531251907349
EOVIST,abdominal pain,abdominal pain hypoesthesia,1,0.8012270927429199
EOVIST,hypoesthesia,conjunctivitis abdominal hypoesthesia sneezing cough and pallor see,1,0.688178300857544
EOVIST,hypoesthesia,abdominal pain hypoesthesia,1,0.874470055103302
EOVIST,hypoesthesia,hypoesthesia sneezing cough and,1,0.8296855092048645
EOVIST,hypoesthesia,hypoesthesia sneezing cough and pallor see,1,0.7953754663467407
EOVIST,hypoesthesia,pallor see Warnings and Precautions Tachycardia,0,0.5343226194381714
EOVIST,hypoesthesia,edema urticaria face edema,0,0.5678927302360535
EOVIST,hypoesthesia,Warnings and,0,0.5045197606086731
EOVIST,hypoesthesia,hypoesthesia sneezing,1,0.8528627157211304
EOVIST,hypoesthesia,conjunctivitis,0,0.47125136852264404
EOVIST,sneezing,and pallor,0,0.4996644854545593
EOVIST,sneezing,sneezing cough and pallor see,1,0.7915713787078857
EOVIST,sneezing,abdominal pain sneezing cough and pallor,1,0.718354344367981
EOVIST,sneezing,urticaria,0,0.67792809009552
EOVIST,cough,abdominal pain hypoesthesia cough and pallor see Warnings,1,0.699198305606842
EOVIST,cough,urticaria,0,0.5509262084960938
EOVIST,cough,cough and pallor see,1,0.8101641535758972
EOVIST,cough,cough and,1,0.9321798086166382
EOVIST,cough,and,0,0.5597959756851196
EOVIST,cough,hypoesthesia,0,0.4909229576587677
EOVIST,cough,pain hypoesthesia cough and pallor see Warnings and,1,0.7236247062683105
EOVIST,pallor,pallor,1,1.0
EOVIST,pallor,sneezing cough pallor see Warnings and,1,0.7013700008392334
EOVIST,pallor,hypoesthesia sneezing cough pallor see Warnings,1,0.6282253861427307
EOVIST,pallor,pain,0,0.5254408121109009
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,adverse re actionsare discussed,1,0.48670127987861633
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,elsewhere,0,0.5065984725952148
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,REACTIONS The,0,0.46464353799819946
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,ADVERSE REACTIONS  following serious adverse re actionsare discussed,1,0.5456057190895081
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,fibrosis,0,0.7606819868087769
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,labeling Nephrogenic systemic fibrosis,0,0.9344728589057922
EOVIST,NSF,tio nsare discussed elsewhere in the,1,0.5760743618011475
EOVIST,NSF,following serious adverse tio nsare discussed elsewhere,1,0.49079951643943787
EOVIST,NSF,tio nsare discussed elsewhere,1,0.581511378288269
EOVIST,NSF,serious adverse tio nsare,1,0.5230511426925659
EOVIST,NSF,The following serious adverse tio nsare discussed elsewhere in the,1,0.5024079084396362
EOVIST,NSF,REACTIONS The following serious,0,0.4864283800125122
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,see Boxed Warning and,0,0.48005130887031555
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,the labeling:,1,0.47658202052116394
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,"adverse reactionsare d elsewhere in the labeling:
 Nephrogenic",1,0.7321184277534485
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,discusse,0,0.4727533459663391
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,serious adverse reactionsare d,1,0.5755431652069092
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,in the labeling:,1,0.4674232006072998
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,serious adverse reactionsare d elsewhere in the labeling:,1,0.544914186000824
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,REACTIONS The following serious,0,0.5070765614509583
EOVIST,NSF,"
 * Nephrogenic",1,0.5439021587371826
EOVIST,NSF,in the labeling,0,0.4986867606639862
EOVIST,NSF,"
 * Nephrogenic systemic fibrosis",1,0.5777531862258911
EOVIST,NSF,"
 *",1,0.5887232422828674
EOVIST,NSF,"
 * Nephrogenic systemic fibrosis NSF",1,0.7539491653442383
EOVIST,NSF,"elsewhere in the 
 * Nephrogenic",1,0.5304250717163086
EOVIST,NSF,"the 
 *",1,0.5075194239616394
EOVIST,NSF,ERSE REACTIONS The following serious adverse reactionsare discussed,0,0.4570671319961548
EOVIST,NSF,"the 
 * Nephrogenic systemic fibrosis NSF",1,0.7300097942352295
EOVIST,NSF,see Boxed Warning and s a nd Precautions Hypersensitivity,1,0.5191293954849243
EOVIST,NSF,see,0,0.537940502166748
EOVIST,NSF,Precautions,0,0.4761228859424591
EOVIST,NSF,e n ausea headache feeling,1,0.45333850383758545
EOVIST,NSF,headache feeling hot dizziness and back pain To,0,0.42298486828804016
EOVIST,fatal,", fee ling hot dizziness and",1,0.562106728553772
EOVIST,fatal,"incidence are nausea ,",1,0.5723397731781006
EOVIST,fatal,"nausea , fee",1,0.5768371820449829
EOVIST,fatal,"are nausea ,",1,0.5518515110015869
EOVIST,fatal,"incidence are nausea , fee",1,0.5700450539588928
EOVIST,fibrosis,"ss, and back pain To report SUSPECTED",1,0.5062803626060486
EOVIST,fibrosis,"feeling hot ss, and",1,0.5035110116004944
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,", 22% Asian, 3% Hispanic, 2%  Black and of",1,0.46559014916419983
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,"feeling hot ss, and",1,0.5082115530967712
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,was years age,0,0.4784427285194397
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,were men and the ethnic distribution was,0,0.4693189263343811
EOVIST,NSF,ack,1,0.5251564383506775
EOVIST,NSF,ack and,1,0.5238232612609863
EOVIST,NSF,Hispanic ack and,1,0.48986443877220154
EOVIST,NSF,Caucasian Asian Hispanic ack and of,1,0.49760812520980835
EOVIST,NSF,Caucasian Asian Hispanic ack,1,0.4995361864566803
EOVIST,NSF,age range,0,0.5102012157440186
EOVIST,NSF,rea,1,0.48130613565444946
EOVIST,NSF,rea ctions,1,0.5080326199531555
EOVIST,Nephrogenic Systemic Fibrosis,The following serious,0,0.5285001397132874
EOVIST,Nephrogenic Systemic Fibrosis,systemic,0,0.6700531244277954
EOVIST,Nephrogenic Systemic Fibrosis,serious se reactionsare discussed els ewhere,1,0.4898024797439575
EOVIST,hypersensitivity reactions,incidence,0,0.5634609460830688
EOVIST,cutaneous manifestations,and Precautions EXCERPT ost common adverse react,1,0.6101313829421997
EOVIST,shock,ling  hot dizziness and back pain,1,0.5471116304397583
EOVIST,shock,hot dizziness and back,0,0.5591598749160767
EOVIST,shock,headache fee,0,0.5033633708953857
EOVIST,shock,ling  hot dizziness,1,0.5632403492927551
EOVIST,shock,ling  hot dizziness and,1,0.5637392997741699
EOVIST,shock,adverse reactions incidence are nausea headache fee,0,0.5394442677497864
EOVIST,shock,contact Bayer Healt,0,0.4860237240791321
EOVIST,nephrogenic systemic fibrosis,Clinical Trials E xperience Because clinical trials are,1,0.5110126733779907
EOVIST,nephrogenic systemic fibrosis,FDA at FDA or 6.1 Clinical,1,0.5170475244522095
EOVIST,nephrogenic systemic fibrosis,6.1,1,0.4770491123199463
EOVIST,nephrogenic systemic fibrosis,"or 


 

  6.1 Clinical Trials E xperience Because clinical trials",1,0.5350639224052429
EOVIST,nephrogenic systemic fibrosis,at,0,0.50473952293396
EOVIST,nephrogenic systemic fibrosis,6.1 Clinical Trials E xperience Because clinical,1,0.5371803045272827
EOVIST,NSF,eri ence,1,0.4612433910369873
EOVIST,NSF,6.1 Clinical Trials E xperience Because clinical,1,0.5471134185791016
EOVIST,NSF,eri ence Because clinical,1,0.49024537205696106
EOVIST,NSF,conducted under widely varying conditions adverse reaction,0,0.5133180618286133
EOVIST,NSF,reactions described in,0,0.5081439018249512
EOVIST,NSF,fle ct the,1,0.5075662136077881
EOVIST,NSF,in clinical practice The,0,0.48595499992370605
EOVIST,NSF,fle ct the rates,1,0.4757651388645172
EOVIST,NSF,fle ct the rates observed in,1,0.5315679907798767
EOVIST,NSF,fle ct the rates observed,1,0.5176783800125122
EOVIST,NSF, of other ethnic groups,1,0.44382792711257935
EOVIST,NSF,subjects,0,0.5315916538238525
EOVIST,NSF, of other,1,0.4773240089416504
EOVIST,NSF,average age was years age range,0,0.46979057788848877
EOVIST,NSF,was,0,0.5145812034606934
EOVIST,fatal,roups The average,1,0.4564046263694763
EOVIST,fatal,The average age was years age range from to years Overall of subjects,0,0.452150821685791
EOVIST,fatal,consisted of other ethnic roups The average age was years,1,0.4809967279434204
EOVIST,fatal,roups,1,0.4653632640838623
EOVIST,fatal,roups The,1,0.48121917247772217
EOVIST,fatal,roups The average age,1,0.4404619336128235
EOVIST,fatal,g,0,0.5301516652107239
EOVIST,fatal,other ethnic roups The average,1,0.4652538597583771
EOVIST,fatal,other,0,0.5389153957366943
EOVIST,fibrosis,average  was 57 ,1,0.49168044328689575
EOVIST,fibrosis,roups The average,1,0.5287135243415833
EOVIST,fibrosis,The average was 57,1,0.4856950342655182
EOVIST,fibrosis,average  was 57  years age range,1,0.51018226146698
EOVIST,fibrosis,was,1,0.5277785062789917
EOVIST,fibrosis,was 57 years age range,1,0.5035748481750488
EOVIST,fibrosis,Overall,0,0.5574089288711548
EOVIST,hypersensitivity reactions,n                         ,1,0.4788944125175476
EOVIST,hypersensitivity reactions,Vertigo,0,0.470439612865448
EOVIST,hypersensitivity reactions,n                          Vertigo,1,0.4687599241733551
EOVIST,hypersensitivity reactions,n                          Vertigo Dry,1,0.456664502620697
EOVIST,hypersensitivity reactions,Vertigo Dry mou,0,0.4859388470649719
EOVIST,hypersensitivity reactions,s Fatigue,0,0.5034310221672058
EOVIST,hypersensitivity reactions,n                          Vertigo Dry mou,1,0.48284706473350525
EOVIST,cutaneous manifestations,Dry,0,0.47076669335365295
EOVIST,cutaneous manifestations,Vertigo,0,0.4558408260345459
EOVIST,cutaneous manifestations,Chest pain Vertigo,0,0.4720390737056732
EOVIST,cutaneous manifestations,                        ,1,0.5840191841125488
EOVIST,cutaneous manifestations,                         Dry mouth Chill,1,0.48643290996551514
EOVIST,cutaneous manifestations,Dry mouth,0,0.5125081539154053
EOVIST,hypersensitivity reaction,"received EOVIST include  akathisia, bundle branch block palpitation",1,0.5412667393684387
EOVIST,hypersensitivity reaction,Dry mouth,0,0.5430461168289185
EOVIST,hypersensitivity reaction,"received EOVIST include akathisia, bundle branch",1,0.5360732674598694
EOVIST,hypersensitivity reaction,bundle branch block palpitation oral,1,0.5124786496162415
EOVIST,hypersensitivity reaction,"akathisia, bundle branch block palpitation oral",1,0.5096208453178406
EOVIST,hypersensitivity reaction,a frequency of in subjects who received EOVIST include tremor,0,0.516593337059021
EOVIST,hypersensitivity reaction,of in subjects who received EOVIST include tremor,0,0.5258780717849731
EOVIST,hypersensitivity reaction,occurred with a frequency of,0,0.5457277297973633
EOVIST,hypersensitivity reaction,bundle branch block palpitation oral discomfort salivary,1,0.5372258424758911
EOVIST,hypersensitivity reaction,"akathisia, bundle branch",1,0.4825555682182312
EOVIST,hypersensitivity reaction,"who received EOVIST include akathisia, bundle branch",1,0.5143267512321472
EOVIST,acute kidney injury,uncertain size it is not possible to,1,0.4222412109375
EOVIST,acute kidney injury,uncertain size it,1,0.42657938599586487
EOVIST,acute kidney injury,causal,0,0.4949856400489807
EOVIST,acute kidney injury,reported voluntarily from a n of uncertain size it,1,0.42558613419532776
EOVIST,acute kidney injury,from a n of uncertain size it is,1,0.4570261240005493
EOVIST,acute kidney injury,reported voluntarily from a n of,1,0.41573435068130493
EOVIST,acute kidney injury,hypotension pharyngolaryngeal edema,0,0.5597353577613831
EOVIST,acute kidney injury,ship to drug exposu re Hypersensitivity,1,0.5189383625984192
EOVIST,acute kidney injury,not possible to reliably estimate their frequency,0,0.40293651819229126
EOVIST,acute kidney injury,drug exposu re Hypersensitivity reactions anaphylacticshock hypotension,1,0.5552219748497009
ONFI,Somnolence,Somnolence,1,1.0
ONFI,Somnolence,Somnolence or Sedation see Warnings and,1,0.7795202732086182
ONFI,Somnolence,sections of the labeling include the following,0,0.5012267827987671
ONFI,Somnolence,other sections of the labeling include the,0,0.49323028326034546
ONFI,Somnolence,Precautions Potentiation of Sedation from Concomitan,0,0.6109049320220947
ONFI,Somnolence,Somnolence or Sedation see Warnings,1,0.7763677835464478
ONFI,Somnolence,icant adverse reactions that appear in other sections,0,0.5026127099990845
ONFI,Somnolence,Somnolence or,1,0.9631102681159973
ONFI,Sedation,Sedation,1,1.0000001192092896
ONFI,Sedation,Somnolence Sedation see Warnings and Precautions Potentiation,1,0.7815290689468384
ONFI,Sedation,Sedation see Warnings,1,0.863764762878418
ONFI,Potentiation of Sedation,with,0,0.534442663192749
ONFI,Potentiation of Sedation,Nervous System Depressants see Warnings and,0,0.611815333366394
ONFI,Dermatological Reactions,Contraindications Warnings,0,0.5777276754379272
ONFI,Dermatological Reactions,see Warnings and Precautions Serious,0,0.5825103521347046
ONFI,Dermatological Reactions,Precautions Dermatological,1,0.7629052400588989
ONFI,Dermatological Reactions,Dermatological Reactions see,1,0.9842400550842285
ONFI,Dermatological Reactions,Precautions Dermatological Reactions,1,0.9016437530517578
ONFI,Psychological Dependence,Warnings and Precautions Physical Psychological,1,0.6389883756637573
ONFI,Psychological Dependence,and Precautions Physical Psychological Dependence,1,0.8711099028587341
ONFI,Psychological Dependence,and Precautions Physical Psychological,1,0.6723428964614868
ONFI,Psychological Dependence,Warnings and Precautions Physical and,0,0.5210461616516113
ONFI,Psychological Dependence,see Warnings and,0,0.4685656428337097
ONFI,Suicidal Behavior,Suicidal Behavior and Ideation,1,0.9020045399665833
ONFI,Suicidal Behavior,Dependence see Warnings and Suicidal Behavior,1,0.8187680244445801
ONFI,Suicidal Behavior,Suicidal Behavior and,1,0.9584693908691406
ONFI,Suicidal Behavior,see Warnings and Suicidal Behavior,1,0.851421594619751
ONFI,Suicidal Behavior,and Precautions EXCERPT,0,0.5454157590866089
ONFI,constipation,in any ONFI dose constipation,1,0.8505822420120239
ONFI,constipation,and Precautions EXCERPT,0,0.5037012696266174
ONFI,constipation,constipation somnolence or sedation pyrexia lethargy,1,0.746544361114502
ONFI,constipation,in any ONFI dose constipation somnolence or sedation pyrexia lethargy,1,0.7272324562072754
ONFI,somnolence,somnolence or sedation,1,0.8502905964851379
ONFI,somnolence,somnolence or sedation pyrexia,1,0.8044251203536987
ONFI,somnolence,somnolence or,1,0.9631102681159973
ONFI,somnolence,included somnolence or sedation pyrexia lethargy and,1,0.7923111915588379
ONFI,somnolence,sedation,0,0.6407902836799622
ONFI,somnolence,constipation,0,0.5509151220321655
ONFI,sedation,dose included constipation somnolence sedation pyrexia lethargy and drooling,1,0.7107105851173401
ONFI,sedation,constipation,0,0.6230200529098511
ONFI,sedation,sedation pyrexia lethargy and drooling To,1,0.7321999073028564
ONFI,sedation,in any ONFI dose,0,0.6263562440872192
ONFI,pyrexia,pyrexia lethargy,1,0.853057861328125
ONFI,drooling,drooling To report SUSPECTED ADVERSE,1,0.8615479469299316
ONFI,drooling,pyrexia lethargy,1,0.5522578954696655
ONFI,drooling,any ONFI,0,0.5281301736831665
ONFI,lethargy,Common Adverse Reactions in an L,0,0.5240706205368042
ONFI,lethargy,lethargy somnolence ataxia aggression fatigue and,1,0.8234351277351379
ONFI,lethargy,fatigue and insomnia Most Common,0,0.6859692335128784
ONFI,somnolence,somnolence ataxia aggression fatigue and,1,0.7806262373924255
ONFI,somnolence,in an,0,0.490714967250824
ONFI,ataxia,ataxia aggression fatigue and,1,0.8196570873260498
ONFI,ataxia,ataxia aggression fatigue,1,0.8149936199188232
ONFI,ataxia,in an LGS,0,0.48488056659698486
ONFI,ataxia,Reactions,0,0.5589078664779663
ONFI,ataxia,order,0,0.5176044702529907
ONFI,aggression,aggression,1,1.0
ONFI,aggression,aggression fatigue,1,0.8365761041641235
ONFI,aggression,lethargy somnolence aggression fatigue and insomnia Most,1,0.7062935829162598
ONFI,fatigue,order of frequency,0,0.5342284440994263
ONFI,fatigue,frequency included lethargy somnolence,0,0.6951462030410767
ONFI,fatigue,fatigue and insomnia Most,1,0.843359112739563
ONFI,fatigue,lethargy somnolence ataxia fatigue and,1,0.7858046293258667
ONFI,fatigue,lethargy somnolence ataxia fatigue and insomnia Most Common,1,0.7861701250076294
ONFI,fatigue,order of frequency included lethargy somnolence,0,0.6797742247581482
ONFI,insomnia,Most,0,0.47356313467025757
ONFI,insomnia,insomnia Most Common Adverse Reactions,1,0.7609485387802124
ONFI,insomnia,insomnia Most Common Adverse,1,0.8187253475189209
ONFI,Somnolence,Nervous System Disorders,0,0.570435643196106
ONFI,Somnolence,Somnolence or Sedation,1,0.8502905964851379
ONFI,Somnolence,Nervous System Somnolence or,1,0.8503846526145935
ONFI,Anemia,Anemia eosinophilia leukopenia thrombocytopenia Eye Disorders,1,0.7194699048995972
ONFI,Anemia,Somnolence,1,0.5421806573867798
ONFI,Anemia,organ,0,0.5145490169525146
ONFI,Anemia,Anemia eosinophilia leukopenia thrombocytopenia Eye,1,0.740634560585022
ONFI,Anemia,Anemia eosinophilia leukopenia thrombocytopenia,1,0.7542237043380737
ONFI,Anemia,Disorders Diplopia vision blurred Gastro,0,0.5212568044662476
ONFI,Anemia,categorized by system organ class,0,0.5093827247619629
ONFI,eosinophilia,eosinophilia leukopenia,1,0.7722420692443848
ONFI,eosinophilia,eosinophilia leukopenia thrombocytopenia Eye Disorders,1,0.7464394569396973
ONFI,eosinophilia,Blood Disorders Anemia,0,0.6151032447814941
ONFI,eosinophilia,system organ class Blood Disorders Anemia,0,0.563637375831604
ONFI,eosinophilia,Disorders eosinophilia leukopenia,1,0.8118160963058472
ONFI,eosinophilia,eosinophilia leukopenia thrombocytopenia Eye Disorders Diplopia,1,0.7127518057823181
ONFI,leukopenia,leukopenia thrombocytopenia Eye Disorders,1,0.7775629758834839
ONFI,leukopenia,Eye Disorders Diplopia vision blurred,0,0.5520080327987671
ONFI,thrombocytopenia,thrombocytopenia Eye Disorders Diplopia vision blurred,1,0.7991853952407837
ONFI,Hepatic enzyme increased,enzyme increased Musculoskeletal Muscle spasms Psychiatric Disorders,1,0.6815277338027954
ONFI,Agitation,Agitation anxiety apathy,1,0.837348461151123
ONFI,Agitation,Agitation anxiety,1,0.9113702178001404
ONFI,Agitation,Hepatic enzyme increased Musculoskeletal Muscle spasms Psychiatric Disorders,0,0.6547825336456299
ONFI,Agitation,Disorders,0,0.6165855526924133
ONFI,Agitation,Agitation anxiety apathy confusional,1,0.8248515725135803
ONFI,Agitation,delusion hallucination,0,0.5899165272712708
ONFI,Agitation,Agitation,1,1.0
ONFI,anxiety,anxiety,1,1.0
ONFI,anxiety,and Urinary Diso,0,0.5537245869636536
ONFI,anxiety,anxiety apathy confusional state depression delirium,1,0.7395814061164856
ONFI,anxiety,anxiety apathy confusional state,1,0.7358791828155518
ONFI,confusional state,Musculoskeletal Muscle spasms Psychiatric Disorders Agitation,0,0.6171568632125854
ONFI,confusional state,confusional state depression delirium delusion,1,0.8476366400718689
ONFI,confusional state,Disorders Agitation anxiety confusional state depression delirium delusion hallucination Renal,1,0.726224422454834
ONFI,confusional state,Urinary Disorders Urinary retention,0,0.5564336180686951
ONFI,confusional state,confusional state depression delirium delusion hallucination,1,0.8263767957687378
ONFI,confusional state,Disorders Agitation anxiety confusional state depression delirium delusion,1,0.7561987638473511
ONFI,confusional state,anxiety,0,0.650446355342865
ONFI,confusional state,depression delirium delusion hallucination,0,0.6624186635017395
ONFI,confusional state,confusional state,1,1.000000238418579
ONFI,confusional state,delusion hallucination Renal and,0,0.6327530145645142
ONFI,depression,depression,1,0.9999998807907104
ONFI,depression,Urinary Disorders Urinary retention Respirat,0,0.5342099666595459
ONFI,delirium,anxiety apathy confusional state delirium,1,0.8247877359390259
ONFI,delirium,Urinary Disorders Urinary retention Respirat,0,0.5150411128997803
ONFI,delirium,hallucination Renal and,0,0.6281591653823853
ONFI,delirium,Agitation anxiety apathy,0,0.6123944520950317
ONFI,delirium,delirium delusion hallucination,1,0.828792929649353
ONFI,delirium,delirium delusion hallucination Renal and,1,0.7935868501663208
ONFI,delusion,delusion hallucination Renal,1,0.7856647968292236
ONFI,hallucination,hallucination Renal,1,0.8603435158729553
ONFI,hallucination,state depression delirium hallucination Renal and Urinary Disorders,1,0.710227370262146
ONFI,hallucination,depression delirium hallucination Renal and Urinary,1,0.749671459197998
ONFI,hallucination,hallucination,1,1.0000001192092896
ONFI,hallucination,Urinary,0,0.5537177920341492
ONFI,Aspiration,Aspiration respiratory depression Skin and,1,0.7661527395248413
ONFI,Aspiration,Aspiration,1,1.0000001192092896
ONFI,Aspiration,Disorders,0,0.5300408005714417
ONFI,Aspiration,and Subcutaneous Tissue Disorders Rash urticaria,0,0.44211262464523315
ONFI,Aspiration,Urinary retention Respiratory Aspiration respiratory depression Skin and,1,0.7015490531921387
ONFI,Aspiration,Rash urticaria,0,0.42250069975852966
ONFI,Aspiration,Aspiration respiratory,1,0.8468364477157593
ONFI,Aspiration,Respiratory Aspiration respiratory,1,0.8077247142791748
ONFI,respiratory depression,respiratory depression Skin and Subcutaneous Tissue,1,0.8487569093704224
ONFI,respiratory depression,Urinary retention Respiratory Disorders respiratory depression,1,0.8466296195983887
ONFI,respiratory depression,Urinary retention Respiratory Disorders respiratory,1,0.7322264313697815
ONFI,respiratory depression,angioedema,0,0.5519251823425293
ONFI,respiratory depression,respiratory depression Skin and Subcutaneous Tissue Disorders,1,0.8234304189682007
ONFI,respiratory depression,retention Respiratory Disorders respiratory,1,0.7314263582229614
ONFI,respiratory depression,Respiratory,0,0.8308204412460327
ONFI,respiratory depression,angioedema and,0,0.5548682808876038
ONFI,respiratory depression,Urinary retention Respiratory Disorders respiratory depression Skin and Subcutaneous Tissue Disorders,1,0.75201416015625
ONFI,Rash,Rash urticaria angioedema and facial,1,0.7755191326141357
ONFI,Rash,Tissue Rash urticaria angioedema and facial and,1,0.739708423614502
ONFI,Rash,Subcutaneous Tissue,0,0.6196359395980835
ONFI,Rash,Subcutaneous,0,0.6418073177337646
ONFI,Rash,Rash urticaria angioedema and,1,0.8079046010971069
ONFI,urticaria,Subcutaneous Tissue Disorders urticaria angioedema,1,0.7723207473754883
ONFI,urticaria,Rash urticaria angioedema and,1,0.8436484932899475
ONFI,urticaria,urticaria angioedema and,1,0.8673273324966431
ONFI,urticaria,urticaria angioedema and facial and,1,0.837135910987854
ONFI,angioedema,angioedema and facial and lip edema,1,0.8650597333908081
ONFI,angioedema,Subcutaneous Tissue Disorders Rash angioedema and facial,1,0.7899825572967529
ONFI,angioedema,Tissue Disorders Rash angioedema and facial and lip edema,1,0.8201429843902588
ONFI,angioedema,Subcutaneous Tissue Disorders Rash angioedema and facial and,1,0.7904870510101318
ONFI,angioedema,and,0,0.5059272646903992
ONFI,angioedema,angioedema,1,1.000000238418579
ONFI,angioedema,Rash,0,0.6317238807678223
ONFI,angioedema,facial,0,0.5864128470420837
ONFI,Sedation,ns that  appear in other sections,1,0.5035669803619385
ONFI,Sedation,facial,0,0.5520263910293579
ONFI,Dermatological Reactions,Warnings and Precautions Serious Dermatological Reactions see,0,0.8544172048568726
ONFI,Dermatological Reactions,Symptoms [see Warnings and Precautions Serious,1,0.5986801981925964
ONFI,Dermatological Reactions,Precautions ithdrawal,1,0.5720136165618896
ONFI,Dermatological Reactions,see Warnings and Precautions ithdrawal Symptoms [see  Warnings and Precautions Serious,1,0.6078329086303711
ONFI,Dermatological Reactions,ithdrawal Symptoms [see Warnings and Precautions Serious,1,0.5977848172187805
ONFI,Dermatological Reactions,Symptoms [see,1,0.6022235751152039
ONFI,Dermatological Reactions,ithdrawal Symptoms [see Warnings and Precautions,1,0.58840411901474
ONFI,Dermatological Reactions,Warnings and Precautions W,0,0.5595730543136597
ONFI,Dermatological Reactions,Precautions ithdrawal Symptoms,1,0.6049178838729858
ONFI,Dermatological Reactions,Warnings and Precautions ithdrawal Symptoms [see  Warnings and,1,0.5935351848602295
ONFI,Stevens-Johnson syndrome,Withdrawal Symptoms see Warnings d Precautions (    5.3   Serious Dermatological Reactions see Contraindications,1,0.6213318109512329
ONFI,Stevens-Johnson syndrome,Precautions ithdrawal Symptoms,1,0.5991697311401367
ONFI,Stevens-Johnson syndrome,Symptoms see Warnings,0,0.6161519289016724
ONFI,Stevens-Johnson syndrome,Serious,0,0.5217785835266113
ONFI,Stevens-Johnson syndrome,Symptoms see Warnings d Precautions (    5.3   Serious Dermatological,1,0.6145964860916138
ONFI,Stevens-Johnson syndrome,Symptoms,0,0.6154896020889282
ONFI,Stevens-Johnson syndrome,Symptoms see Warnings d Precautions (    5.3   Serious,1,0.5813578367233276
ONFI,Stevens-Johnson syndrome,Precautions Withdrawal Symptoms see Warnings,0,0.5798195600509644
ONFI,Stevens-Johnson syndrome,see Contraindications,0,0.5719143152236938
ONFI,Stevens-Johnson syndrome,Withdrawal Symptoms see Warnings d Precautions (    5.3   Serious Dermatological Reactions see,1,0.6300257444381714
ONFI,Stevens-Johnson syndrome,( 5.3 Serious,1,0.4894673228263855
ONFI,toxic epidermal necrolysis,Warnings and Precautions,0,0.5647960901260376
ONFI,toxic epidermal necrolysis," 
 *  Serious Dermatologic",1,0.6427711248397827
ONFI,toxic epidermal necrolysis,and Precautions Physical,0,0.5246008634567261
ONFI,toxic epidermal necrolysis,"Warnings and  
 *  Serious Dermatologic",1,0.677227795124054
ONFI,toxic epidermal necrolysis,s and Precautions,0,0.5368288159370422
ONFI,toxic epidermal necrolysis,Precautions,0,0.5332335233688354
ONFI,toxic epidermal necrolysis,"Warnings and  
 *  Serious Dermatologic al",1,0.6776613593101501
ONFI,toxic epidermal necrolysis,see Contraindications,0,0.5638192296028137
ONFI,toxic epidermal necrolysis,"and  
 *  Serious Dermatologic al Reactions",1,0.7118070125579834
ONFI,toxic epidermal necrolysis,"Warnings and  
 *  Serious Dermatologic al Reactions",1,0.7119253873825073
ONFI,Psychological Dependence,see,0,0.4511401653289795
ONFI,Psychological Dependence,and cal,1,0.4772754907608032
ONFI,Psychological Dependence,Warnings and,0,0.4937846064567566
ONFI,Psychological Dependence,see Contraindications Warnings and Precautions,0,0.47439756989479065
ONFI,Suicidal Behavior,and,0,0.46218615770339966
ONFI,Suicidal Behavior,EXCERPT: Ad,1,0.4778119921684265
ONFI,Suicidal Behavior,Warnings and EXCERPT: Ad,1,0.5251910090446472
ONFI,Suicidal Behavior,Ideation see Warnings and EXCERPT:,1,0.570378303527832
ONFI,Suicidal Behavior,    EXCERPT:   Ad verse reactions,1,0.46831217408180237
ONFI,somnolence,"edation, p",1,0.479201078414917
ONFI,somnolence,"edation, p yrexia lethargy and",1,0.6452981233596802
ONFI,somnolence,"sedation pyrexia lethargy and .1  )   
  To",1,0.668353796005249
ONFI,somnolence,"sedation pyrexia lethargy and .1  )   
 ",1,0.6657513380050659
ONFI,somnolence,pyrexia lethargy,0,0.6564392447471619
ONFI,somnolence,sedation pyrexia lethargy and .1,1,0.6645336747169495
ONFI,somnolence,lethargy and .1,1,0.6481949090957642
ONFI,somnolence,"pyrexia lethargy and .1  )   
  To report SUSPECTED",1,0.6191651821136475
ONFI,sedation,To repo rt SUSPECTED ADVERSE REACTIONS,1,0.5914517045021057
ONFI,sedation,and  To repo rt SUSPECTED,1,0.5251911878585815
ONFI,sedation,drooling,0,0.5385047197341919
ONFI,sedation,and To,1,0.5313424468040466
ONFI,sedation,FDA at FDA,0,0.5532799959182739
ONFI,somnolence,t 1-800-FD A,1,0.4577561616897583
ONFI,sedation,wwwfdagovmedwatch Clinical Trials Experience,0,0.5447680950164795
ONFI,sedation,8 or wwwfdagovmedwatch Clinical Trials,1,0.5587619543075562
ONFI,sedation,or FDA at 8 or     wwwfdagovmedwatch Clinical Trials,1,0.5661858320236206
ONFI,sedation,SUSPECTED ADVERSE REACTIONS contact Lundbeck at or FDA,0,0.5814247727394104
ONFI,sedation,at 8,1,0.5237312316894531
ONFI,sedation,at 8 or    ,1,0.5270774960517883
ONFI,skin reactions,dose of mg for g body weight; mg for,1,0.4920101761817932
ONFI,skin reactions,at 8,1,0.4771038889884949
ONFI,skin reactions,body weight; mg for,1,0.5000103712081909
ONFI,skin reactions,g body weight;,1,0.48308390378952026
ONFI,skin reactions,kg body weight mg for kg body weight c Maximum daily dose of,0,0.5247799158096313
ONFI,skin reactions,for kg body weight c Maximum daily dose,0,0.5282355546951294
ONFI,skin reactions,mg for g,1,0.5087289810180664
ONFI,skin reactions,for g body weight; mg for kg,1,0.512304961681366
ONFI,skin reactions,for g body weight;,1,0.4773200750350952
ONFI,Stevens-Johnson syndrome,All ONFI N,0,0.5345059037208557
ONFI,Stevens-Johnson syndrome,body weight Placebo N ONFI Dose,1,0.5241456031799316
ONFI,Stevens-Johnson syndrome,body weight,0,0.4972990155220032
ONFI,Stevens-Johnson syndrome,mg for kg body,0,0.5262055397033691
ONFI,SJS,    Placebo N ONFI Dose,1,0.4917048513889313
ONFI,SJS,   ,1,0.6164666414260864
ONFI,SJS,mg,0,0.49192267656326294
ONFI,SJS,kg body     Placebo N ONFI Dose,1,0.4918752610683441
ONFI,toxic epidermal necrolysis,for kg body Placebo N=59,1,0.49502938985824585
ONFI,toxic epidermal necrolysis,body           Placebo    N=59  ONFI Dose Level All ONFI,1,0.5223293304443359
ONFI,toxic epidermal necrolysis,mg for kg body Placebo,1,0.5003312230110168
ONFI,toxic epidermal necrolysis,Placebo N=59,1,0.5006479620933533
ONFI,toxic epidermal necrolysis,kg body weight mg,0,0.5111274719238281
ONFI,toxic epidermal necrolysis,Placebo N=59 ONFI Dose Level All,1,0.5054577589035034
ONFI,toxic epidermal necrolysis,body           Placebo    N=59  ONFI,1,0.5292294025421143
ONFI,toxic epidermal necrolysis,Low a N Medium b,0,0.4759098291397095
ONFI,TEN,body weight Placebo     ONFI Dose Level,1,0.5085684061050415
ONFI,TEN,Low a N Medium b,0,0.5553027391433716
ONFI,TEN,    ONFI Dose Level All ONFI,1,0.5301122665405273
ONFI,TEN,    ONFI,1,0.5586591958999634
ONFI,TEN,   ,1,0.6406887769699097
ONFI,TEN,body weight Placebo     ONFI Dose Level All,1,0.5166053771972656
ONFI,TEN,weight Placebo     ONFI Dose Level All,1,0.5230203866958618
ONFI,TEN,body weight Placebo     ONFI,1,0.5154948234558105
ONFI,TEN,for,0,0.5895606279373169
ONFI,TEN,    ONFI Dose Level,1,0.5260376334190369
ONFI,suicidal behavior,olence,0,0.43667760491371155
ONFI,suicidal behavior,"     
       Somn olence or Sedation",1,0.5283812284469604
ONFI,suicidal behavior,"     
       Somn olence",1,0.4983196258544922
ONFI,suicidal behavior,"     
       Somn",1,0.5290537476539612
ONFI,suicidal thoughts,Disorders Aspiration,0,0.47451654076576233
ONFI,suicidal thoughts,llucination Re nal and,1,0.5172784328460693
ONFI,suicidal thoughts,depression delirium,0,0.6319272518157959
ONFI,suicidal thoughts,state depression delirium delusion llucination    Re nal and Urinary,1,0.6286134719848633
ONFI,suicidal thoughts,and Urinary Disorders Urinary retention Respiratory,0,0.4554829001426697
ONFI,suicidal thoughts,llucination Re,1,0.5161101818084717
ONFI,suicidal thoughts,llucination Re nal,1,0.5181595087051392
COMETRIQ,Perforations,Boxed Warning Warnings and Precautions Hemorrhage see B,0,0.6264118552207947
COMETRIQ,Perforations,adverse reactions are discussed elsewhere in the label,0,0.519936203956604
COMETRIQ,Perforations,Fistula see,0,0.6428849697113037
COMETRIQ,Perforations,serious adverse reactions are discussed elsewhere in the,0,0.5622967481613159
COMETRIQ,Perforations,Hemorrhage see,0,0.6357086896896362
COMETRIQ,Perforations,and Fistula see Boxed Warning Warnings and Precautions Hemorrhage see B,0,0.6411640644073486
COMETRIQ,Perforations,Perforations,1,1.0000001192092896
COMETRIQ,Perforations,Fistula see Boxed Warning Warnings,0,0.6209906339645386
COMETRIQ,Perforations,Fistula see Boxed Warning,0,0.6297060251235962
COMETRIQ,Hemorrhage,Warnings and Hemorrhage see Boxed,1,0.7714877724647522
COMETRIQ,Hemorrhage,Fistula see Boxed Warning,0,0.5786179304122925
COMETRIQ,Hemorrhage,and,0,0.5080123543739319
COMETRIQ,Thromboembolic Events,Thromboembolic Events see Warnings and Precautions,1,0.8910256624221802
COMETRIQ,Thromboembolic Events,and Thromboembolic Events see,1,0.9703988432884216
COMETRIQ,Thromboembolic Events,Warning Warnings and Thromboembolic Events see Warnings and,1,0.8484025001525879
COMETRIQ,Thromboembolic Events,Thromboembolic Events,1,1.0
COMETRIQ,Thromboembolic Events,Precautions,0,0.5739678144454956
COMETRIQ,Thromboembolic Events,Complications see Warnings and,0,0.5935120582580566
COMETRIQ,Wound Complications,see Warnings and Wound Complications,1,0.8530543446540833
COMETRIQ,Hypertension,see Warnings and Hypertension see,1,0.8182255029678345
COMETRIQ,Hypertension,see Warnings and Wound Complications,1,0.5292575359344482
COMETRIQ,Hypertension,Precautions Wound Complications see Warnings and Precautions,0,0.5062380433082581
COMETRIQ,Hypertension,and,0,0.5626955032348633
COMETRIQ,Osteonecrosis of the Jaw,Warnings and Osteonecrosis,1,0.8220013976097107
COMETRIQ,Osteonecrosis of the Jaw,and Osteonecrosis of the Jaw see,1,0.9744389653205872
COMETRIQ,Osteonecrosis of the Jaw,gs and,0,0.4757547676563263
COMETRIQ,Osteonecrosis of the Jaw,and Precautions,0,0.4921557307243347
COMETRIQ,Osteonecrosis of the Jaw,Warnings and Osteonecrosis of the Jaw see Warnings and Precautions Palmarplantar,1,0.8312697410583496
COMETRIQ,Osteonecrosis of the Jaw,and Osteonecrosis of the,1,0.9031380414962769
COMETRIQ,Osteonecrosis of the Jaw,erythrodysesthesia syndrome see,0,0.5145753622055054
COMETRIQ,Osteonecrosis of the Jaw,Warnings,0,0.5026569962501526
COMETRIQ,Osteonecrosis of the Jaw,and,0,0.46184706687927246
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,Jaw see Warnings and Palmar-plantar,1,0.6979541778564453
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,see Warnings and Palmar-plantar erythrodysesthesia syndrome see Warnings and,1,0.9110690355300903
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome see Warnings and Precautions Proteinuria,1,0.8957703113555908
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,see Warnings and Palmar-plantar,1,0.7087894082069397
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome see Warnings,1,0.9458233714103699
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,and Palmar-plantar,1,0.7463282346725464
COMETRIQ,Proteinuria,Warnings and Proteinuria see Warnings and Precautions,1,0.8191803693771362
COMETRIQ,Proteinuria,and Palmar-plantar,1,0.4663940370082855
COMETRIQ,Proteinuria,Proteinuria,1,1.0
COMETRIQ,Proteinuria,and Proteinuria see Warnings,1,0.8631347417831421
COMETRIQ,Proteinuria,Precautions Reversible Posterior,0,0.4966837763786316
COMETRIQ,Proteinuria,see Warnings and Precautions Reversible Posterior,0,0.5005330443382263
COMETRIQ,Proteinuria,Proteinuria see Warnings,1,0.8657373785972595
COMETRIQ,Proteinuria,Proteinuria see Warnings and Precautions,1,0.8574901819229126
COMETRIQ,Proteinuria,Warnings and Proteinuria see Warnings and,1,0.8222780227661133
COMETRIQ,Proteinuria,syndrome see Warnings and Proteinuria see Warnings,1,0.794363796710968
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Reversible Posterior,1,0.7624326944351196
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Proteinuria see Warnings and Reversible Posterior Leukoencephalopathy Syndrome see Warnings and Precautions EXCERPT,1,0.8372446894645691
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Leukoencephalopathy Syndrome see Warnings and Precautions EXCERPT,1,0.8109023571014404
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Posterior Leukoencephalopathy Syndrome see Warnings,1,0.8811915516853333
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Leukoencephalopathy Syndrome see Warnings and,1,0.8258446455001831
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Proteinuria see Warnings and Reversible Posterior Leukoencephalopathy,1,0.8327121734619141
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Reversible Posterior Leukoencephalopathy Syndrome,1,1.0000001192092896
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,most commonly reported adverse,0,0.5427722930908203
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Reversible Posterior Leukoencephalopathy Syndrome see Warnings and Precautions EXCERPT,1,0.9347164630889893
COMETRIQ,diarrhea,syndrome PPES,0,0.5568298101425171
COMETRIQ,diarrhea,diarrhea stomatitis palmarplantar,1,0.744743287563324
COMETRIQ,diarrhea,reported adverse drug reactions diarrhea stomatitis palmarplantar erythrodysesthesia syndrome PPES,1,0.649687647819519
COMETRIQ,diarrhea,EXCERPT The most commonly reported adverse drug,0,0.5653997659683228
COMETRIQ,diarrhea,palmarplantar erythrodysesthesia syndrome PPES decreased,0,0.5187176465988159
COMETRIQ,diarrhea,EXCERPT The most commonly,0,0.5360386371612549
COMETRIQ,diarrhea,diarrhea,1,0.9999999403953552
COMETRIQ,diarrhea,commonly reported,0,0.547609806060791
COMETRIQ,diarrhea,diarrhea stomatitis,1,0.7623847723007202
COMETRIQ,stomatitis,adverse drug reactions are stomatitis palmarplantar erythrodysesthesia,1,0.6947919130325317
COMETRIQ,stomatitis,diarrhea stomatitis,1,0.8702546954154968
COMETRIQ,stomatitis,reactions are stomatitis palmarplantar erythrodysesthesia syndrome PPES decreased,1,0.6817989945411682
COMETRIQ,stomatitis,stomatitis,1,0.9999998807907104
COMETRIQ,stomatitis,erythrodysesthesia syndrome PPES decreased weight decreased appetite nausea,0,0.5136594772338867
COMETRIQ,stomatitis,weight decreased appetite nausea,0,0.47249144315719604
COMETRIQ,stomatitis,PPES decreased weight,0,0.47489869594573975
COMETRIQ,stomatitis,decreased appetite nausea f,0,0.4970446825027466
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,appetite nausea fatigue oral pain hair color,0,0.5909122228622437
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,reactions are diarrhea,0,0.5287024974822998
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,are diarrhea palmar-plantar erythrodysesthesia syndrome,1,0.9087657928466797
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,adverse drug reactions,0,0.5724546909332275
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,are diarrhea palmar-plantar,1,0.7059831023216248
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,appetite nausea fatigue oral pain hair color changes,0,0.5910006761550903
COMETRIQ,PPES,PPES decreased weight,1,0.823408305644989
COMETRIQ,decreased weight,syndrome,0,0.5001058578491211
COMETRIQ,decreased weight,drug reactions are diarrhea stomatitis,0,0.4736570715904236
COMETRIQ,decreased weight,decreased weight,1,0.9999997615814209
COMETRIQ,decreased weight,reactions are diarrhea stomatitis palmarplantar erythrodysesthesia syndrome PPES,0,0.48999297618865967
COMETRIQ,decreased weight,erythrodysesthesia syndrome PPES,0,0.505902111530304
COMETRIQ,decreased appetite,decreased appetite,1,0.9999999403953552
COMETRIQ,decreased appetite,erythrodysesthesia syndrome PPES,0,0.5350936651229858
COMETRIQ,nausea,decreased,0,0.5155445337295532
COMETRIQ,nausea,fatigue oral pain hair color changes dysgeusia hypertension abdominal pain and constipation,0,0.6611570119857788
COMETRIQ,fatigue,erythrodysesthesia syndrome PPES decreased,0,0.504317045211792
COMETRIQ,fatigue,abdominal pain and constipation,0,0.5311295986175537
COMETRIQ,fatigue,oral pain hair color,0,0.543938934803009
COMETRIQ,oral pain,oral pain hair color,1,0.8160953521728516
COMETRIQ,oral pain,oral pain hair color,0,0.8160953521728516
COMETRIQ,oral pain,oral pain hair color changes dysgeusia,1,0.7642089128494263
COMETRIQ,oral pain,oral pain hair color changes dysgeusia hypertension,1,0.7585972547531128
COMETRIQ,hair color changes,decreased weight decreased appetite nausea fatigue oral pain,0,0.5254515409469604
COMETRIQ,hair color changes,nausea fatigue oral hair color,1,0.7905652523040771
COMETRIQ,hair color changes,hair color changes dysgeusia hypertension abdominal pain,1,0.8206804990768433
COMETRIQ,hair color changes,decreased weight decreased appetite nausea fatigue,0,0.5412765741348267
COMETRIQ,hair color changes,hair color changes dysgeusia hypertension abdominal pain and,1,0.80370032787323
COMETRIQ,hair color changes,pain and constipation The most common laboratory abnormalitie,0,0.4986785650253296
COMETRIQ,dysgeusia,dysgeusia,1,1.0000001192092896
COMETRIQ,dysgeusia,dysgeusia hypertension abdominal,1,0.8161497116088867
COMETRIQ,hypertension,hypertension abdominal pain and constipation,1,0.7629860639572144
COMETRIQ,hypertension,hypertension,1,0.9999999403953552
COMETRIQ,hypertension,most common laboratory abnormalities,0,0.5562583208084106
COMETRIQ,hypertension,hypertension abdominal pain and constipation The,1,0.769714891910553
COMETRIQ,hypertension,appetite nausea fatigue,0,0.5390785932540894
COMETRIQ,hypertension,laboratory,0,0.5488651394844055
COMETRIQ,abdominal pain,abnormalities are increased,0,0.5675076842308044
COMETRIQ,abdominal pain,pain,0,0.7264407277107239
COMETRIQ,abdominal pain,color changes dysgeusia abdominal pain and,1,0.7420556545257568
COMETRIQ,abdominal pain,abdominal pain,1,0.9999998807907104
COMETRIQ,constipation,The most,0,0.5389691591262817
COMETRIQ,constipation,constipation The most common laboratory,1,0.8099457621574402
COMETRIQ,constipation,hair,0,0.6051011681556702
COMETRIQ,constipation,abnormalities are increased AST,0,0.5681126117706299
COMETRIQ,constipation,most common laboratory abnormalities are increased AST,0,0.5236091017723083
COMETRIQ,constipation,constipation The most common,1,0.8497157692909241
COMETRIQ,increased AST,abnormalities increased AST,1,0.9218679666519165
COMETRIQ,increased AST,constipation The most common,1,0.5172072649002075
COMETRIQ,increased AST,increased AST increased ALT,1,0.9307966232299805
COMETRIQ,increased AST,hypocalcemia neutropenia,0,0.492454469203949
COMETRIQ,increased AST,common laboratory abnormalities increased,1,0.7172980308532715
COMETRIQ,increased AST,increased AST,1,1.0
COMETRIQ,increased AST,phosphatase hypocalcemia neutropenia thrombocyto,0,0.5523974895477295
COMETRIQ,increased AST,laboratory abnormalities increased AST,1,0.9011095762252808
COMETRIQ,increased AST,abnormalities increased AST increased ALT lymphopenia increased alkaline,1,0.753799319267273
COMETRIQ,increased AST,increased AST increased ALT lymphopenia increased,1,0.8221032619476318
COMETRIQ,increased ALT,lymphopenia increased alkaline phosphatase hypocalcemia neutropenia thrombocytopenia,0,0.5807347297668457
COMETRIQ,increased ALT,common,0,0.520238995552063
COMETRIQ,increased ALT,neutropenia thrombocytopenia hypophos,0,0.470848023891449
COMETRIQ,increased ALT,increased increased ALT lymphopenia increased alkaline phosphatase,1,0.6708452701568604
COMETRIQ,increased ALT,constipation The most,0,0.5193609595298767
COMETRIQ,increased ALT,increased increased ALT,1,0.9900727868080139
COMETRIQ,increased ALT,phosphatase hypocalcemia neutropenia thrombocytopenia hypophos,0,0.48284873366355896
COMETRIQ,increased ALT,abnormalities,0,0.5653852224349976
COMETRIQ,increased ALT,are increased increased ALT lymphopenia,1,0.6989288926124573
COMETRIQ,lymphopenia,phosphatase,0,0.516338586807251
COMETRIQ,lymphopenia,lymphopenia increased alkaline phosphatase hypocalcemia neutropenia,1,0.822595477104187
COMETRIQ,lymphopenia,lymphopenia,1,1.000000238418579
COMETRIQ,lymphopenia,nd constipation The,0,0.5050038695335388
COMETRIQ,lymphopenia,The most common laboratory,0,0.4757307171821594
COMETRIQ,increased alkaline phosphatase,hypocalcemia neutropenia thrombocytopenia hypophosphatemia,0,0.6528629660606384
COMETRIQ,increased alkaline phosphatase,increased AST increased ALT increased alkaline phosphatase,1,0.9234883785247803
COMETRIQ,increased alkaline phosphatase,increased AST increased ALT increased,1,0.7155816555023193
COMETRIQ,increased alkaline phosphatase,neutropenia thrombocytopenia hypophosphatemia and,0,0.6580479741096497
COMETRIQ,increased alkaline phosphatase,increased,1,0.7091622948646545
COMETRIQ,increased alkaline phosphatase,increased AST increased ALT increased alkaline,1,0.8402119278907776
COMETRIQ,increased alkaline phosphatase,increased ALT increased,1,0.662749171257019
COMETRIQ,increased alkaline phosphatase,increased alkaline phosphatase hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1,0.8821066617965698
COMETRIQ,hypocalcemia,hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1,0.8023953437805176
COMETRIQ,hypocalcemia,hypocalcemia neutropenia,1,0.8194804191589355
COMETRIQ,hypocalcemia,bnormalities are increased AST increased ALT lymphopenia increased,0,0.5497289896011353
COMETRIQ,hypocalcemia,ALT lymphopenia increased alkaline,0,0.6379891633987427
COMETRIQ,hypocalcemia,lymphopenia increased,0,0.5793863534927368
COMETRIQ,hypocalcemia,alkaline hypocalcemia neutropenia thrombocytopenia hypophosphatemia and,1,0.7865744829177856
COMETRIQ,hypocalcemia,increased alkaline hypocalcemia neutropenia thrombocytopenia,1,0.7602803111076355
COMETRIQ,neutropenia,To report,0,0.5080041885375977
COMETRIQ,neutropenia,hypophosphatemia and hyperbilirubinemia To report SUSPECTED AD,0,0.5414860248565674
COMETRIQ,neutropenia,lymphopenia increased,0,0.6111495494842529
COMETRIQ,neutropenia,neutropenia thrombocytopenia,1,0.8478608727455139
COMETRIQ,neutropenia,increased ALT,0,0.45875096321105957
COMETRIQ,thrombocytopenia,phosphatase hypocalcemia thrombocytopenia,1,0.81927889585495
COMETRIQ,thrombocytopenia,increased ALT,0,0.4783850312232971
COMETRIQ,thrombocytopenia,thrombocytopenia hypophosphatemia and hyperbilirubinemia,1,0.7767132520675659
COMETRIQ,thrombocytopenia,phosphatase hypocalcemia thrombocytopenia hypophosphatemia and hyperbilirubinemia,1,0.7105593681335449
COMETRIQ,thrombocytopenia,thrombocytopenia hypophosphatemia and hyperbilirubinemia To,1,0.7768728733062744
COMETRIQ,hypophosphatemia,neutropenia,0,0.5636718273162842
COMETRIQ,hypophosphatemia,alkaline phosphatase hypocalcemia neutropenia hypophosphatemia and hyperbilirubinemia,1,0.7732384204864502
COMETRIQ,hypophosphatemia,hypophosphatemia and hyperbilirubinemia To report,1,0.8586667776107788
COMETRIQ,hypophosphatemia,hypophosphatemia and,1,0.9742427468299866
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia To report SUSPECTED ADVERSE REACTIONS,1,0.860421895980835
COMETRIQ,hyperbilirubinemia,SUSPECTED ADVERSE REACTIONS contact Exelixis,0,0.5537328720092773
COMETRIQ,hyperbilirubinemia,phosphatase hypocalcemia neutropenia thrombocytopenia hypophosphatemia and,0,0.5304949283599854
COMETRIQ,hyperbilirubinemia,To report SUSPECTED ADVERSE,0,0.5718792080879211
COMETRIQ,hyperbilirubinemia,alkaline phosphatase hypocalcemia neutropenia thrombocytopenia,0,0.5503997802734375
COMETRIQ,hyperbilirubinemia,ADVERSE,0,0.5376410484313965
COMETRIQ,hyperbilirubinemia,SUSPECTED ADVERSE REACTIONS contact,0,0.5676827430725098
COMETRIQ,diarrhea,diarrhea stomatitis palmarplantar erythrodysesthesia syndrome,1,0.6787869334220886
COMETRIQ,diarrhea,diarrhea stomatitis palmarplantar erythrodysesthesia,1,0.7149141430854797
COMETRIQ,diarrhea,decreasing diarrhea,1,0.7973725199699402
COMETRIQ,diarrhea,of decreasing diarrhea,1,0.7837715148925781
COMETRIQ,stomatitis,palmarplantar erythrodysesthesia syndrome PPES,0,0.5195306539535522
COMETRIQ,stomatitis,stomatitis palmarplantar erythrodysesthesia syndrome PPES decreased,1,0.6764571666717529
COMETRIQ,stomatitis,of decreasing,0,0.4341181516647339
COMETRIQ,stomatitis,order of decreasing frequency stomatitis palmarplantar erythrodysesthesia,1,0.7156703472137451
COMETRIQ,stomatitis,stomatitis palmarplantar,1,0.7612470388412476
COMETRIQ,stomatitis,of decreasing frequency stomatitis palmarplantar erythrodysesthesia,1,0.71583092212677
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome PPES decreased,1,0.8629430532455444
COMETRIQ,PPES,order of,0,0.533973753452301
COMETRIQ,PPES,order of decreasing frequency diarrhea stomatitis palmarplantar erythrodysesthesia,0,0.5435544848442078
COMETRIQ,PPES,PPES decreased,1,0.8582373261451721
COMETRIQ,PPES,erythrodysesthesia PPES decreased weight decreased,1,0.7402336597442627
COMETRIQ,PPES,PPES decreased weight decreased appetite,1,0.7871007919311523
COMETRIQ,PPES,pain hair color changes dysgeusia,0,0.48418372869491577
COMETRIQ,PPES,in,0,0.5344620943069458
COMETRIQ,PPES,decreased appetite nausea fatigue oral pain hair color changes dysgeusia,0,0.4989416003227234
COMETRIQ,PPES,palmarplantar erythrodysesthesia PPES,1,0.7609546780586243
COMETRIQ,decreased weight,decreasing frequency,0,0.6683345437049866
COMETRIQ,decreased weight,erythrodysesthesia syndrome decreased weight decreased appetite,1,0.693905234336853
COMETRIQ,decreased appetite,decreased appetite nausea fatigue oral pain hair,1,0.8361721038818359
COMETRIQ,decreased appetite,syndrome PPES decreased decreased appetite nausea fatigue oral,1,0.7633590698242188
COMETRIQ,nausea,weight decreased nausea fatigue,1,0.7719118595123291
COMETRIQ,nausea,decreased appetite nausea fatigue oral pain hair,1,0.7229814529418945
COMETRIQ,nausea,hair color changes dysgeusia,0,0.6237611770629883
COMETRIQ,nausea,oral pain,0,0.5605509281158447
COMETRIQ,fatigue,fatigue oral pain hair,1,0.7901449203491211
COMETRIQ,oral pain,appetite nausea oral pain,1,0.8535745739936829
COMETRIQ,hair color changes,color changes dysgeusia hypertension abdominal pain and,1,0.7232239842414856
COMETRIQ,hair color changes,common laboratory,0,0.5034525394439697
COMETRIQ,hair color changes,hair color changes dysgeusia,1,0.7933428287506104
COMETRIQ,hair color changes,The most common,0,0.5021237134933472
COMETRIQ,dysgeusia,color dysgeusia hypertension abdominal pain,1,0.7627174854278564
COMETRIQ,dysgeusia,The most common,0,0.5129597187042236
COMETRIQ,hypertension,color changes hypertension abdominal pain,1,0.7115882635116577
COMETRIQ,hypertension,The most common,0,0.5410904884338379
COMETRIQ,abdominal pain,color changes dysgeusia abdominal pain,1,0.7623558044433594
COMETRIQ,abdominal pain,The most common,0,0.4686545729637146
COMETRIQ,abdominal pain,changes,0,0.45563289523124695
COMETRIQ,abdominal pain,dysgeusia abdominal pain,1,0.7781164646148682
COMETRIQ,increased AST,common laboratory abnormalities increased AST increased ALT,1,0.8477932810783386
COMETRIQ,increased AST,most common laboratory,0,0.5564526319503784
COMETRIQ,increased AST,The,0,0.5336804986000061
COMETRIQ,increased AST,abnormalities increased,1,0.7094284296035767
COMETRIQ,increased AST,increased AST increased,1,0.9889861941337585
COMETRIQ,increased ALT,laboratory abnormalities were increased increased,1,0.6674716472625732
COMETRIQ,increased ALT,laboratory abnormalities were increased increased ALT lymphopenia increased ALP hypocalcemia,1,0.6175031065940857
COMETRIQ,increased ALT,abnormalities were increased increased ALT,1,0.8699227571487427
COMETRIQ,lymphopenia,lymphopenia increased ALP hypocalcemia neutropenia,1,0.8429923057556152
COMETRIQ,lymphopenia,lymphopenia increased ALP hypocalcemia,1,0.8369882106781006
COMETRIQ,lymphopenia,laboratory abnormalities,0,0.6013396978378296
COMETRIQ,lymphopenia,thrombocytopenia,0,0.6005550026893616
COMETRIQ,lymphopenia,lymphopenia increased ALP,1,0.8466049432754517
COMETRIQ,lymphopenia,ALT,0,0.49986493587493896
COMETRIQ,lymphopenia,increased AST increased lymphopenia increased ALP hypocalcemia neutropenia thrombocytopenia,1,0.7645606994628906
COMETRIQ,increased ALP,increased AST increased ALT increased ALP hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1,0.7949650883674622
COMETRIQ,increased ALP,lymphopenia increased ALP hypocalcemia,1,0.7221508622169495
COMETRIQ,increased ALP,increased ALP hypocalcemia,1,0.8220506310462952
COMETRIQ,increased ALP,laboratory abnormalities were increased,0,0.7101966142654419
COMETRIQ,increased ALP,increased,1,0.7943875789642334
COMETRIQ,increased ALP,increased ALT increased ALP hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1,0.7951452732086182
COMETRIQ,increased ALP,ALT increased ALP hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1,0.7932027578353882
COMETRIQ,increased ALP,increased ALP,1,1.0
COMETRIQ,increased ALP,increased AST increased ALT increased,1,0.818500280380249
COMETRIQ,increased ALP,increased ALP hypocalcemia neutropenia thrombocytopenia hypophosphatemia and,1,0.8028256893157959
COMETRIQ,increased ALP,increased ALT lymphopenia,0,0.6930223703384399
COMETRIQ,hypocalcemia,hypocalcemia,1,1.0
COMETRIQ,hypocalcemia,hypophosphatemia and,0,0.7184267044067383
COMETRIQ,hypocalcemia,mmon laboratory abnormalities were increased AST increased ALT lymphopenia,0,0.5755658745765686
COMETRIQ,neutropenia,hypocalcemia,0,0.5723409652709961
COMETRIQ,neutropenia,and hyperbilirubinemia,0,0.5114785432815552
COMETRIQ,neutropenia,ALT lymphopenia increased ALP neutropenia thrombocytopenia hypophosphatemia and,1,0.7003881931304932
COMETRIQ,neutropenia,neutropenia thrombocytopenia hypophosphatemia and,1,0.7912826538085938
COMETRIQ,neutropenia,hyperbilirubinemia Grade adverse reactions,0,0.48490339517593384
COMETRIQ,neutropenia,neutropenia thrombocytopenia hypophosphatemia,1,0.7863043546676636
COMETRIQ,neutropenia,lymphopenia increased ALP neutropenia thrombocytopenia hypophosphatemia and,1,0.7051241993904114
COMETRIQ,neutropenia,neutropenia thrombocytopenia hypophosphatemia and hyperbilirubinemia Grade,1,0.7190675735473633
COMETRIQ,thrombocytopenia,thrombocytopenia hypophosphatemia,1,0.8235663175582886
COMETRIQ,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
COMETRIQ,thrombocytopenia,thrombocytopenia hypophosphatemia and,1,0.8318876028060913
COMETRIQ,thrombocytopenia,Grade adverse,0,0.45897746086120605
COMETRIQ,thrombocytopenia,thrombocytopenia hypophosphatemia and hyperbilirubinemia Grade,1,0.7673256397247314
COMETRIQ,thrombocytopenia,and hyperbilirubinemia Grade adverse,0,0.4761090874671936
COMETRIQ,hypophosphatemia,hypophosphatemia and hyperbilirubinemia,1,0.864999532699585
COMETRIQ,hypophosphatemia,hypophosphatemia and hyperbilirubinemia Grade adverse reactions,1,0.8210106492042542
COMETRIQ,hypophosphatemia,hypophosphatemia and hyperbilirubinemia Grade adverse,1,0.8414797782897949
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia,1,0.9999998807907104
COMETRIQ,hyperbilirubinemia,occurred,0,0.5122754573822021
COMETRIQ,hyperbilirubinemia,abnormalities which occurred,0,0.5745320320129395
COMETRIQ,hyperbilirubinemia,hypophosphatemia hyperbilirubinemia Grade adverse reactions and,1,0.7797224521636963
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia Grade adverse reactions and,1,0.858659029006958
COMETRIQ,hyperbilirubinemia,hypophosphatemia hyperbilirubinemia Grade adverse reactions,1,0.7691144943237305
COMETRIQ,diarrhea,diarrhea PPES lymphopenia hypocalcemia,1,0.7753116488456726
COMETRIQ,diarrhea,of decreasing diarrhea PPES lymphopenia hypocalcemia fatigue,1,0.7398790121078491
COMETRIQ,diarrhea,asthenia increased ALT,0,0.5213572382926941
COMETRIQ,diarrhea,included,0,0.5803995728492737
COMETRIQ,diarrhea,difference of included in order of,0,0.5503792762756348
COMETRIQ,diarrhea,fatigue hypertension asthenia increased ALT,0,0.5340926647186279
COMETRIQ,diarrhea,diarrhea PPES lymphopenia,1,0.7652360200881958
COMETRIQ,diarrhea,in order of decreasing diarrhea PPES lymphopenia hypocalcemia,1,0.748581051826477
COMETRIQ,PPES,frequency PPES lymphopenia hypocalcemia,1,0.7196228504180908
COMETRIQ,PPES,diarrhea PPES lymphopenia,1,0.6921358704566956
COMETRIQ,lymphopenia,of decreasing frequency,0,0.5575578212738037
COMETRIQ,lymphopenia,lymphopenia hypocalcemia fatigue hypertension,1,0.8235435485839844
COMETRIQ,lymphopenia,ALT decreased weight stomatitis and de,0,0.5901448726654053
COMETRIQ,lymphopenia,a betweenarm difference of included in order of decreasing,0,0.5044577121734619
COMETRIQ,lymphopenia,decreasing frequency diarrhea lymphopenia hypocalcemia fatigue,1,0.7529866695404053
COMETRIQ,lymphopenia,lymphopenia hypocalcemia fatigue hypertension asthenia,1,0.8339890241622925
COMETRIQ,lymphopenia,of decreasing frequency diarrhea lymphopenia hypocalcemia fatigue,1,0.7582192420959473
COMETRIQ,hypocalcemia,diarrhea PPES hypocalcemia fatigue hypertension,1,0.7524008750915527
COMETRIQ,hypocalcemia,lymphopenia hypocalcemia fatigue hypertension asthenia,1,0.7833737134933472
COMETRIQ,hypocalcemia,diarrhea PPES hypocalcemia fatigue hypertension asthenia increased ALT,1,0.734647810459137
COMETRIQ,hypocalcemia,frequency diarrhea PPES hypocalcemia,1,0.7946169376373291
COMETRIQ,hypocalcemia,increased ALT decreased weight stomatitis and,0,0.5334234237670898
COMETRIQ,fatigue,fatigue hypertension asthenia increased ALT,1,0.7642134428024292
COMETRIQ,fatigue,fatigue,1,1.0
COMETRIQ,fatigue,frequency diarrhea PPES lymphopenia fatigue hypertension asthenia increased ALT decreased,1,0.7056187391281128
COMETRIQ,fatigue,order of decreasing frequency diarrhea PPES,0,0.511238157749176
COMETRIQ,fatigue,fatigue hypertension,1,0.8026680946350098
COMETRIQ,fatigue,fatigue hypertension asthenia increased,1,0.7804722785949707
COMETRIQ,fatigue,PPES lymphopenia fatigue hypertension asthenia increased ALT decreased,1,0.7202582955360413
COMETRIQ,fatigue,and decreased appetite,0,0.6492218375205994
COMETRIQ,fatigue,frequency diarrhea PPES lymphopenia fatigue hypertension asthenia increased ALT,1,0.6908684968948364
COMETRIQ,fatigue,in order of decreasing,0,0.5441613793373108
COMETRIQ,hypertension,weight,0,0.6531878709793091
COMETRIQ,hypertension,hypertension asthenia increased ALT decreased weight,1,0.8091546893119812
COMETRIQ,hypertension,hypocalcemia hypertension,1,0.7872253060340881
COMETRIQ,hypertension,hypertension asthenia increased ALT decreased,1,0.8099197745323181
COMETRIQ,hypertension,hypertension asthenia increased,1,0.8001970052719116
COMETRIQ,asthenia,order of,0,0.4737541377544403
COMETRIQ,asthenia,increased,0,0.5251404643058777
COMETRIQ,asthenia,increased ALT,0,0.5271093249320984
COMETRIQ,asthenia,asthenia increased ALT decreased weight stomatitis,1,0.739243745803833
COMETRIQ,increased ALT,increased ALT,1,1.0
COMETRIQ,increased ALT,increased ALT decreased weight stomatitis and decreased,1,0.7251016497612
COMETRIQ,stomatitis,stomatitis and decreased,1,0.8773223161697388
COMETRIQ,stomatitis,increased ALT decreased stomatitis,1,0.821730375289917
COMETRIQ,stomatitis,asthenia increased ALT decreased stomatitis and,1,0.8189220428466797
COMETRIQ,stomatitis,stomatitis and decreased appetite see Table,1,0.8225428462028503
COMETRIQ,decreased appetite,decreased appetite see,1,0.9758185148239136
COMETRIQ,decreased appetite,of patients receiving COME,0,0.5059888958930969
COMETRIQ,decreased appetite,decreased appetite see Table Table,1,0.9116411209106445
COMETRIQ,decreased appetite,weight stomatitis decreased appetite,1,0.8154096603393555
COMETRIQ,decreased appetite,decreased appetite see Table Table Fatal adverse,1,0.7967968583106995
COMETRIQ,Fatal,Fatal adverse reactions occurred,1,0.7463456988334656
COMETRIQ,Fatal,Table Fatal adverse reactions occurred in of,1,0.7141130566596985
COMETRIQ,Fatal,appetite see Table Fatal adverse reactions occurred,1,0.6828151941299438
COMETRIQ,Fatal,appetite see Table Fatal adverse reactions,1,0.6809672117233276
COMETRIQ,Fatal,see Table Fatal adverse reactions occurred in,1,0.7166969776153564
COMETRIQ,Fatal,decreased appetite see Table Fatal adverse reactions occurred in of,1,0.6805505156517029
COMETRIQ,Fatal,occurred in of patients receiving COMETRIQ,0,0.5260964632034302
COMETRIQ,Fatal,Table Fatal,1,0.786867618560791
COMETRIQ,Fatal,occurred in of patients receiving COMETRIQ and,0,0.5288845300674438
COMETRIQ,hemorrhage,septicemia fistulas,0,0.5761101245880127
COMETRIQ,hemorrhage,e Fatal adverse reactions occurred in of,0,0.5967615842819214
COMETRIQ,hemorrhage,receiving COMETRIQ and resulted hemorrhage pneumonia septicemia fistulas,1,0.6791253089904785
COMETRIQ,hemorrhage,COMETRIQ and resulted hemorrhage pneumonia septicemia fistulas cardiac,1,0.7303210496902466
COMETRIQ,hemorrhage,and,0,0.5080123543739319
COMETRIQ,hemorrhage,occurred in of patients receiving COMETRIQ and,0,0.5772157311439514
COMETRIQ,hemorrhage,resulted hemorrhage pneumonia,1,0.7900363802909851
COMETRIQ,hemorrhage,pneumonia septicemia fistulas cardiac,0,0.5644046068191528
COMETRIQ,hemorrhage,receiving COMETRIQ and,0,0.5026212930679321
COMETRIQ,pneumonia,fistulas cardiac arrest respiratory failure and unspecified death,0,0.5826464295387268
COMETRIQ,pneumonia,failure and unspecified death Fatal,0,0.5146619081497192
COMETRIQ,pneumonia,death,0,0.6104602813720703
COMETRIQ,pneumonia,pneumonia septicemia fistulas cardiac arrest,1,0.7278741598129272
COMETRIQ,pneumonia,COMETRIQ and resulted from pneumonia septicemia fistulas,1,0.7352636456489563
COMETRIQ,pneumonia,from pneumonia septicemia fistulas cardiac arrest,1,0.7279608249664307
COMETRIQ,pneumonia,pneumonia septicemia fistulas cardiac arrest respiratory,1,0.7419196963310242
COMETRIQ,septicemia,arrest respiratory,0,0.5234100818634033
COMETRIQ,septicemia,hemorrhage septicemia fistulas cardiac arrest,1,0.7393794655799866
COMETRIQ,septicemia,septicemia fistulas,1,0.8226355314254761
COMETRIQ,fistulas,fistulas,1,1.0
COMETRIQ,fistulas,fistulas cardiac arrest respiratory failure,1,0.7579780220985413
COMETRIQ,fistulas,of patients,0,0.580974817276001
COMETRIQ,fistulas,fistulas cardiac arrest respiratory failure and,1,0.7581830024719238
COMETRIQ,fistulas,failure and unspecified death Fatal adverse,0,0.508792519569397
COMETRIQ,cardiac arrest,cardiac arrest respiratory failure and unspecified death,1,0.8369550704956055
COMETRIQ,cardiac arrest,cardiac arrest respiratory,1,0.886608898639679
COMETRIQ,respiratory failure,respiratory failure and unspecified death Fatal,1,0.8122351169586182
COMETRIQ,respiratory failure,arrest,0,0.4923448860645294
COMETRIQ,respiratory failure,pneumonia septicemia fistulas cardiac respiratory failure,1,0.7588191032409668
COMETRIQ,respiratory failure,Fatal adverse reactions occurred in of patients receiving,0,0.5546613931655884
COMETRIQ,respiratory failure,cardiac respiratory failure,1,0.8701677322387695
COMETRIQ,respiratory failure,respiratory failure,1,1.0000001192092896
COMETRIQ,respiratory failure,fistulas cardiac,0,0.47708189487457275
COMETRIQ,death,death Fatal adverse reactions occurred,1,0.7221158742904663
COMETRIQ,death,fistulas cardiac,0,0.4672759771347046
COMETRIQ,death,death Fatal,1,0.8646934032440186
COMETRIQ,death,occurred in of patients receiving,0,0.5001550912857056
COMETRIQ,death,death Fatal adverse reactions occurred in,1,0.7293843030929565
COMETRIQ,death,reactions occurred in of patients receiving placebo and,0,0.47903117537498474
COMETRIQ,death,and death Fatal adverse reactions occurred,1,0.7105219960212708
COMETRIQ,death,occurred in of,0,0.5813376903533936
COMETRIQ,Fatal,Fatal adverse reactions occurred in of,1,0.7366756200790405
COMETRIQ,Fatal,respiratory failure,0,0.6214501261711121
COMETRIQ,Fatal,septicemia fistulas cardiac,0,0.47226595878601074
COMETRIQ,Fatal,Fatal adverse reactions occurred in,1,0.7391897439956665
COMETRIQ,Fatal,respiratory failure and unspecified Fatal adverse reactions occurred in,1,0.695768415927887
COMETRIQ,Fatal,receiving placebo and resulted,0,0.45003384351730347
COMETRIQ,Fatal,Fatal adverse reactions,1,0.7630990743637085
COMETRIQ,pneumonia,and resulted from septicemia,0,0.6353505253791809
COMETRIQ,pneumonia,pneumonia and,1,0.9008134603500366
COMETRIQ,pneumonia,pneumonia and general deterioration The,1,0.8167897462844849
COMETRIQ,pneumonia,from,0,0.557187020778656
COMETRIQ,pneumonia,and resulted from pneumonia and general deterioration The dose,1,0.7901443839073181
COMETRIQ,general deterioration,in of patients receiving COMETRIQ compared,0,0.5447431206703186
COMETRIQ,general deterioration,from septicemia pneumonia general deterioration The dose was reduced,1,0.6983691453933716
COMETRIQ,hypocalcemia,treated with COMETRIQ hypocalcemia increased lipase PPES,1,0.7455068230628967
COMETRIQ,hypocalcemia,hypocalcemia increased lipase PPES diarrhea fatigue,1,0.7601978778839111
COMETRIQ,hypocalcemia,hypocalcemia increased lipase,1,0.7910248041152954
COMETRIQ,hypocalcemia,hypocalcemia increased lipase PPES diarrhea,1,0.7519306540489197
COMETRIQ,increased lipase,increased lipase PPES diarrhea fatigue hypertension nausea,1,0.8489027619361877
COMETRIQ,increased lipase,patients treated with,0,0.5214805603027344
COMETRIQ,increased lipase,COMETRIQ were increased lipase PPES diarrhea fatigue hypertension nausea,1,0.7983903884887695
COMETRIQ,increased lipase,increased lipase,1,0.9999999403953552
COMETRIQ,PPES,fatigue hypertension,0,0.4706794321537018
COMETRIQ,PPES,tracheal,0,0.5798603296279907
COMETRIQ,PPES,discontinuation in patients treated with COMETRIQ were hypocalcemia increased lipase,0,0.5221437215805054
COMETRIQ,PPES,PPES diarrhea fatigue hypertension nausea pancreatitis,1,0.7629613876342773
COMETRIQ,PPES,PPES,1,1.0
COMETRIQ,diarrhea,diarrhea fatigue hypertension nausea pancreatitis tracheal,1,0.7604609727859497
COMETRIQ,diarrhea,increased lipase diarrhea,1,0.7570555210113525
COMETRIQ,diarrhea,were hypocalcemia increased,0,0.5583921670913696
COMETRIQ,diarrhea,diarrhea fatigue hypertension nausea,1,0.7776373624801636
COMETRIQ,fatigue,and vomiting Increased,0,0.5228688716888428
COMETRIQ,fatigue,increased,0,0.5325073003768921
COMETRIQ,fatigue,fatigue hypertension nausea,1,0.8155596256256104
COMETRIQ,fatigue,in patients treated with COMETRIQ were hypocalcemia increased lipase PPES,0,0.5041261911392212
COMETRIQ,fatigue,pancreatitis tracheal fistula formation and vomiting Increased,0,0.4826756417751312
COMETRIQ,fatigue,hypertension nausea pancreatitis tracheal fistula,0,0.5327553749084473
COMETRIQ,hypertension,increased lipase PPES diarrhea hypertension nausea pancreatitis tracheal fistula,1,0.5985755920410156
COMETRIQ,hypertension,fatigue hypertension nausea,1,0.757475733757019
COMETRIQ,hypertension,diarrhea hypertension nausea,1,0.7848018407821655
COMETRIQ,hypertension,hypertension nausea pancreatitis tracheal fistula formation,1,0.6626235246658325
COMETRIQ,hypertension,and vomiting Increased levels,0,0.512155294418335
COMETRIQ,hypertension,formation and,0,0.5300900936126709
COMETRIQ,hypertension,hypertension nausea pancreatitis tracheal,1,0.7488813400268555
COMETRIQ,nausea,nausea pancreatitis tracheal fistula formation and,1,0.6712862253189087
COMETRIQ,nausea,nausea pancreatitis tracheal,1,0.7370595932006836
COMETRIQ,nausea,vomiting Increased levels of thyroid stimulating,0,0.6784924268722534
COMETRIQ,nausea,and,0,0.5219222903251648
COMETRIQ,nausea,nausea pancreatitis,1,0.8117666244506836
COMETRIQ,nausea,formation and vomiting,0,0.764829158782959
COMETRIQ,nausea,PPES diarrhea fatigue nausea pancreatitis,1,0.7047644853591919
COMETRIQ,nausea,nausea pancreatitis tracheal fistula,1,0.6854842901229858
COMETRIQ,pancreatitis,pancreatitis tracheal fistula formation,1,0.6967964172363281
COMETRIQ,pancreatitis,pancreatitis tracheal fistula formation and,1,0.7087492942810059
COMETRIQ,tracheal fistula formation,were hypocalcemia increased lipase PPES,0,0.5033754110336304
COMETRIQ,Peripheral neuropathy,sensory Peripheral neuropathy,1,0.9237288236618042
COMETRIQ,Peripheral neuropathy,were hypocalcemia increased lipase PPES,0,0.5187431573867798
COMETRIQ,elevated blood pressure,COMETRIQtreated,0,0.5504399538040161
COMETRIQ,elevated blood pressure,blood pressure and there was a,1,0.8511260747909546
COMETRIQ,elevated blood pressure,in COMETRIQtreated patients,0,0.5608918070793152
COMETRIQ,hypertension,hypertension in,1,0.9312629699707031
COMETRIQ,hypertension,hypertension in COMETRIQtreated patients,1,0.7974479794502258
COMETRIQ,hypertension,of,0,0.5356321334838867
COMETRIQ,hypertension,COMETRIQtreated patients over placebotreated patients vs according to,0,0.5646177530288696
COMETRIQ,hypertension,overt,0,0.5797927379608154
COMETRIQ,hypertension,the incidence of hypertension in COMETRIQtreated patients over,1,0.7727373838424683
COMETRIQ,hypertension,was a doubling in the incidence,0,0.5850273370742798
COMETRIQ,hypertension,the incidence of hypertension in COMETRIQtreated patients,1,0.7688953280448914
COMETRIQ,malignant hypertension,patients malignant hypertension Table,1,0.9072991609573364
COMETRIQ,malignant hypertension,was a doubling in the incidence,0,0.5445433855056763
COMETRIQ,malignant hypertension,Table PerPatient Incidence of Hypertension in Protocol XL Hypertension,0,0.6786923408508301
COMETRIQ,malignant hypertension,PerPatient Incidence of Hypertension in Protocol,0,0.6930385231971741
COMETRIQ,malignant hypertension,and Treatment of High Blood Pressure JNC staging,0,0.7118138074874878
COMETRIQ,malignant hypertension,staging,0,0.48320910334587097
COMETRIQ,malignant hypertension,malignant hypertension Table PerPatient Incidence,1,0.8641178607940674
COMETRIQ,malignant hypertension,PerPatient Incidence,0,0.541232705116272
COMETRIQ,malignant hypertension,staging criteria No patients malignant hypertension,1,0.8436821699142456
COMETRIQ,Hypertension,in Protocol XL,0,0.4984548091888428
COMETRIQ,Hypertension,Hypertension in Protocol,1,0.8067888021469116
COMETRIQ,Pre-hypertension,Pre-hypertension Systolic,1,0.906933069229126
COMETRIQ,Pre-hypertension,Pre-hypertension Systolic mmHg or,1,0.8574371337890625
COMETRIQ,Pre-hypertension,mmHg and Diastolic Pre-hypertension Systolic,1,0.8117983937263489
COMETRIQ,Pre-hypertension,Diastolic,0,0.5989333391189575
COMETRIQ,Pre-hypertension,mmHg,0,0.5223633646965027
COMETRIQ,PERFORATIONS,following s erious,1,0.5304039716720581
COMETRIQ,FISTULAS,Perforations and,0,0.6716362237930298
COMETRIQ,HEMORRHAGE,The following serious adverse tions,1,0.615607738494873
COMETRIQ,HEMORRHAGE,ADVERSE REACTIONS The following serious adverse,0,0.5813018083572388
COMETRIQ,HEMORRHAGE,REACTIONS,0,0.5514365434646606
COMETRIQ,HEMORRHAGE,adverse,0,0.5697399377822876
COMETRIQ,PERFORATIONS,adverse reactions are discussed ewhere in,1,0.5615291595458984
COMETRIQ,PERFORATIONS,discussed ewhere in th e,1,0.5138837099075317
COMETRIQ,PERFORATIONS,ewhere,1,0.5107486248016357
COMETRIQ,PERFORATIONS,ewhere in th,1,0.5181828737258911
COMETRIQ,PERFORATIONS,discussed ewhere in th,1,0.5144288539886475
COMETRIQ,PERFORATIONS,Fistula see Boxed Warning Warnings and Precautions,0,0.6148313283920288
COMETRIQ,FISTULAS,Fistula see Boxed Warning Warnings and Precautions Hemo,0,0.7547353506088257
COMETRIQ,FISTULAS,"el:



  Perforations",1,0.6420770883560181
COMETRIQ,FISTULAS,serious adverse reactions are discussed elsewhere,0,0.5041154623031616
COMETRIQ,FISTULAS,"the el:



  Perforations and Fistula see Boxed",1,0.7871825695037842
COMETRIQ,FISTULAS,"elsewhere in the el:



 ",1,0.47605469822883606
COMETRIQ,FISTULAS,"el:



  Perforations and Fistula see Boxed",1,0.7904912233352661
COMETRIQ,FISTULAS,"in the el:



  Perforations",1,0.6549142599105835
COMETRIQ,FISTULAS,are discussed elsewhere in the lab,0,0.47698360681533813
COMETRIQ,HEMORRHAGE,Boxed Warning,0,0.5157018303871155
COMETRIQ,HEMORRHAGE,EACTIONS,0,0.5124499201774597
COMETRIQ,HEMORRHAGE,forations  and Fistula see Boxed,1,0.5851788520812988
COMETRIQ,HEMORRHAGE,and Fistula see Boxed Warning,0,0.5836782455444336
COMETRIQ,HEMORRHAGE,reactions are discussed,0,0.5316765904426575
COMETRIQ,HEMORRHAGE,see Boxed Warning,0,0.5260969400405884
COMETRIQ,Perforations,[ see,1,0.5644366145133972
COMETRIQ,Perforations,the label Perforations and stula [ see ,1,0.81724613904953
COMETRIQ,Perforations,Perforations and Fi,0,0.9193702936172485
COMETRIQ,fistulas,see Boxe,0,0.4956076741218567
COMETRIQ,fistulas,see,0,0.562623918056488
COMETRIQ,fistulas,d Warnin g,1,0.4820847511291504
COMETRIQ,fistulas,Fistula see d Warnin,1,0.8473047614097595
COMETRIQ,fistulas,d Warnin g Warnings,1,0.4986911118030548
COMETRIQ,fistulas,Boxe,0,0.48813366889953613
COMETRIQ,fistulas,elsewhere in the label Perforations and Fistula see,0,0.7766192555427551
COMETRIQ,fistulas,and Fistula see d Warnin g Warnings,1,0.8119208812713623
COMETRIQ,Gastrointestinal perforations,label Perforations and Fistula see Boxed,0,0.7365245819091797
COMETRIQ,Gastrointestinal perforations,"see Boxed  ,  Warnings and Precautions  Hemorrhage see",1,0.5871315598487854
COMETRIQ,Gastrointestinal perforations,the,0,0.5177944898605347
COMETRIQ,Gastrointestinal perforations,Fistula see,0,0.6074455380439758
COMETRIQ,Gastrointestinal perforations,Boxed,0,0.5107287168502808
COMETRIQ,Gastrointestinal perforations,see,0,0.508966326713562
COMETRIQ,fistula formation,Warnings and Precautions morrhage [ see  B oxed Warning,1,0.5852757096290588
COMETRIQ,fistula formation,see,0,0.513059675693512
COMETRIQ,Hemorrhage,Complications see ings and,1,0.5928704738616943
COMETRIQ,Hemorrhage,ings and P recautions Hypertension,1,0.5416368842124939
COMETRIQ,Hemorrhage,Warnings and Precautions Wound Complications see Warn,0,0.6014879941940308
COMETRIQ,Hemorrhage,Precautions Wound Complications see ings and P,1,0.5876767039299011
COMETRIQ,Hemorrhage,see ings and P,1,0.47539055347442627
COMETRIQ,Hemorrhage,and P recautions,1,0.48175716400146484
COMETRIQ,fatal,"Warnings and ) ] 
 Hypertension",1,0.5915855169296265
COMETRIQ,fatal,and P recautions,1,0.4601948857307434
COMETRIQ,fatal,Complications see Warnings and Precautions,0,0.5514415502548218
COMETRIQ,fatal,") ] 
 Hypertension",1,0.5663987398147583
COMETRIQ,fatal,the Jaw see W,0,0.5100153684616089
COMETRIQ,fatal,Wound Complications,0,0.5331080555915833
COMETRIQ,fatal,of,0,0.5430633425712585
COMETRIQ,fatal,Complications see Warnings and ),1,0.5699290037155151
COMETRIQ,fatal,) ] Hypertension,1,0.5663987398147583
COMETRIQ,hemorrhage,  Hyperten sion see Warnings and,1,0.6173259615898132
COMETRIQ,hemorrhage,Warnings and   Hyperten sion see Warnings and Precautions,1,0.5914696455001831
COMETRIQ,hemorrhage,and Precautions Osteonecrosis of the Jaw see Warnings and,0,0.5490807294845581
COMETRIQ,hemorrhage,of,0,0.5401743054389954
COMETRIQ,hemorrhage,Precautions Wound Complications,0,0.5975223779678345
COMETRIQ,hemorrhage,Warnings,0,0.5447796583175659
COMETRIQ,hemorrhage,  Hyperten sion see Warnings,1,0.6096497774124146
COMETRIQ,hemorrhage,Complications,0,0.6158410310745239
COMETRIQ,hemorrhage,the,0,0.5402138233184814
COMETRIQ,hemorrhage,d Precautions Wound Complications see Warnings,0,0.5911012887954712
COMETRIQ,hemoptysis, Warnings  and,1,0.4972538352012634
COMETRIQ,gastrointestinal hemorrhage,"and recautions  (  5.5  ) ] 
 * Osteonecrosis of",1,0.49338218569755554
COMETRIQ,gastrointestinal hemorrhage, Warnings  and,1,0.5261803865432739
COMETRIQ,gastrointestinal hemorrhage,of the Jaw see Warnings and Precautions Palmarplantar erythrod,0,0.5632442235946655
COMETRIQ,gastrointestinal hemorrhage,see Warnings,0,0.5191516876220703
COMETRIQ,gastrointestinal hemorrhage,"Warnings and recautions  (  5.5  ) ] 
 * Osteonecrosis of the",1,0.5045254826545715
COMETRIQ,PERFORATIONS,Reversible sterior Leuk,1,0.5685314536094666
COMETRIQ,FISTULAS,phalopat hy,1,0.4967716932296753
COMETRIQ,FISTULAS,and Precautions EXCERPT The most,0,0.5428784489631653
COMETRIQ,FISTULAS,Warnings,0,0.5326309204101562
COMETRIQ,FISTULAS,Precautions EXCERPT The most,0,0.5443409085273743
COMETRIQ,FISTULAS,phalopat hy Syndrome see,1,0.5594981908798218
COMETRIQ,FISTULAS,phalopat hy Syndrome see Warnings,1,0.5438321828842163
COMETRIQ,FISTULAS,Precautions Reversible Posterior phalopat hy Syndrome see Warnings and,1,0.5560435056686401
COMETRIQ,HEMORRHAGE,[ s ee Warnings and Precautions,1,0.4993816912174225
COMETRIQ,HEMORRHAGE,ndrome,1,0.5427794456481934
COMETRIQ,HEMORRHAGE,and Precautions,0,0.5195255279541016
COMETRIQ,HEMORRHAGE,Reversible Posterior Leukoencephalopathy ndrome [ s,1,0.5134221911430359
COMETRIQ,HEMORRHAGE,The,0,0.5402138233184814
COMETRIQ,HEMORRHAGE,Precautions Reversible Posterior Leukoencephalopathy Sy,0,0.5286712646484375
COMETRIQ,HEMORRHAGE,Leukoencephalopathy ndrome [ s ee Warnings and Precautions EXCERPT,1,0.508165180683136
COMETRIQ,HEMORRHAGE,ndrome [ s ee Warnings and,1,0.5251559615135193
COMETRIQ,Perforations,are diarrhea stomatitis palmarplantar erythrodysesthesia syndrome PPE,0,0.5599008798599243
COMETRIQ,Perforations,EXCERPT The most commonly eported adve rse,1,0.6004841923713684
COMETRIQ,Perforations,eported adve,1,0.6062808036804199
COMETRIQ,Fistulas,rug reac tions are diarrhea stomatitis palmarplantar,1,0.6077150106430054
COMETRIQ,Fistulas,eported adve,1,0.5713412761688232
COMETRIQ,Fistulas,most commonly reported adverse rug reac,1,0.5380706787109375
COMETRIQ,Fistulas,tions are diarrhea stomatitis palmarplantar erythrodysesthesia syndrome PPES,0,0.6533386707305908
COMETRIQ,Fistulas,rug reac tions are diarrhea,1,0.589111328125
COMETRIQ,Fistulas,erythrodysesthesia syndrome,0,0.5826504230499268
COMETRIQ,Fistulas,adverse rug reac,1,0.5362496972084045
COMETRIQ,Gastrointestinal perforations,"reported adverse drug ons (>=25%) are diarrhea, sto matitis palmarplantar erythrodysesthesia syndrome",1,0.6134850382804871
COMETRIQ,Gastrointestinal perforations,rug reac tions are diarrhea stomatitis palmarplantar,1,0.6082898378372192
COMETRIQ,Gastrointestinal perforations,"reported adverse drug ons (>=25%) are diarrhea, sto matitis palmarplantar erythrodysesthesia",1,0.6092019081115723
COMETRIQ,Gastrointestinal perforations,"commonly reported adverse drug ons (>=25%) are diarrhea,",1,0.6334384679794312
COMETRIQ,Gastrointestinal perforations,reported adverse drug,0,0.5573126077651978
COMETRIQ,Gastrointestinal perforations,syndrome PPES decreased weight,0,0.5580028295516968
COMETRIQ,Gastrointestinal perforations,reported adverse drug ons (>=25%),1,0.5744146108627319
COMETRIQ,Gastrointestinal perforations,palmarplantar erythrodysesthesia syndrome PPES decreased,0,0.5568236112594604
COMETRIQ,fistula formation,reactions are diarrhea stomatitis tar erythrodysest hesia syndrome PPES,1,0.5610254406929016
COMETRIQ,fistula formation,syndrome PPES decreased weight,0,0.5174112915992737
COMETRIQ,fistula formation,tar erythrodysest hesia syndrome PPES decreased,1,0.5803467035293579
COMETRIQ,fistula formation,are diarrhea stomatitis tar erythrodysest,1,0.5827645063400269
COMETRIQ,fistula formation,are diarrhea stomatitis,0,0.565424919128418
COMETRIQ,fistula formation,stomatitis tar erythrodysest hesia syndrome,1,0.5720064640045166
COMETRIQ,fistula formation,nausea fatigue oral,0,0.49100175499916077
COMETRIQ,fistula formation,tar erythrodysest hesia syndrome PPES,1,0.5914192795753479
COMETRIQ,fistula formation,tar,1,0.5024285912513733
COMETRIQ,fistula formation,tar erythrodysest,1,0.5507914423942566
COMETRIQ,fatal,changes dysgeusia hypertension nal p ain and constipation,1,0.5171364545822144
COMETRIQ,fatal,tar erythrodysest,1,0.5098286271095276
COMETRIQ,fatal,and constipation The most common laboratory abnormalities,0,0.5263107419013977
COMETRIQ,fatal,color changes dysgeusia hypertension nal p ain and constipation The,1,0.5309394001960754
COMETRIQ,fatal,and constipation The most common laboratory abnormalities are increased AST,0,0.5113357901573181
COMETRIQ,fatal,nal p ain and,1,0.5242233276367188
COMETRIQ,fatal,most common,0,0.5315134525299072
COMETRIQ,fatal,hair color changes,0,0.4665507972240448
COMETRIQ,fatal,dysgeusia hypertension nal p ain,1,0.556740939617157
COMETRIQ,hemorrhage,and con stipation The most common laboratory,1,0.5105072259902954
COMETRIQ,hemorrhage,"dysgeusia hypertension abdominal n, and con",1,0.6040656566619873
COMETRIQ,hemorrhage,"n,",1,0.5206187963485718
COMETRIQ,hemorrhage,"n, and con stipation The most common laboratory",1,0.5116533637046814
COMETRIQ,hemorrhage,hypertension abdominal,0,0.6305909156799316
COMETRIQ,hemorrhage,nausea fatigue,0,0.5768626928329468
COMETRIQ,hemorrhage,and con stipation The most,1,0.4963799715042114
COMETRIQ,hemorrhage,pain hair color changes dysgeusia hypertension abdominal pai,0,0.6344215869903564
COMETRIQ,hemorrhage,"hypertension abdominal n, and",1,0.6420481204986572
COMETRIQ,hemorrhage,hypertension abdominal pai,0,0.631012499332428
COMETRIQ,hemorrhage,"n, and con",1,0.4639721214771271
COMETRIQ,hemorrhage,"n, and con stipation The most common",1,0.5158902406692505
COMETRIQ,hemorrhage,sed appetite nausea,0,0.550568163394928
COMETRIQ,hemorrhage,common laboratory abnormalities are increased AST increased ALT,0,0.5608507394790649
COMETRIQ,hemorrhage,laboratory abnormalities are increased AST,0,0.5689976215362549
COMETRIQ,gastrointestinal hemorrhage,most  laboratory abnormalities ( are increased AST increased,1,0.5631069540977478
COMETRIQ,gastrointestinal hemorrhage,laboratory abnormalities are increased AST,0,0.5776572823524475
COMETRIQ,gastrointestinal hemorrhage,most laboratory abnormalities,1,0.5425201654434204
COMETRIQ,gastrointestinal hemorrhage,The most common,0,0.48590177297592163
COMETRIQ,gastrointestinal hemorrhage,constipation The most  laboratory abnormalities ( are increased AST,1,0.6119774580001831
COMETRIQ,Thrombotic Events,The following serious,0,0.5334060192108154
COMETRIQ,Thrombotic Events,erse reactions ar e discussed,1,0.5906481742858887
COMETRIQ,Thrombotic Events,REACTIONS The following serious erse reactions ar e,1,0.6152467727661133
COMETRIQ,Thrombotic Events,Perforations and Fistula,0,0.6025999784469604
COMETRIQ,Thrombotic Events,and Fistula see Boxed Warning Warning,0,0.5489739775657654
COMETRIQ,Wound Complications,[ see Boxed Warning Warnings,1,0.5333297252655029
COMETRIQ,Wound Complications,Precautions,0,0.621411919593811
COMETRIQ,Wound Complications,Hemorrhage [ see Boxed Warning,1,0.6146990060806274
COMETRIQ,Wound Complications,and  Hemorrhage [ see   Boxed Warning Warnings and,1,0.6250275373458862
COMETRIQ,Wound Complications,Thromboembolic Events see,0,0.5816337466239929
COMETRIQ,Wound Complications,see Boxed Warning,0,0.5247360467910767
COMETRIQ,Wound Complications,Fistula see,0,0.6520359516143799
COMETRIQ,Wound Complications,Hemorrhage [ see,1,0.6148315668106079
COMETRIQ,Wound Complications,Warning,0,0.5353609323501587
COMETRIQ,Wound Complications,[ see Boxed Warning Warnings and,1,0.5357450246810913
COMETRIQ,Hypertension,Warnings and Precautions,0,0.5530973672866821
COMETRIQ,Hypertension,Wound Complications,0,0.5029481649398804
COMETRIQ,Hypertension,Precautions Thromboembolic Events,0,0.5666389465332031
COMETRIQ,Hypertension,and Precauti,1,0.5362908840179443
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,Warnings and Precautions ecrosis of the,1,0.575152575969696
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,syndrome see Warnings and,0,0.6021032333374023
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,and Pre cautions Palmarplantar erythrodysesthesia,1,0.8647267818450928
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,and Precautions ecrosis of the Jaw [ see  Warnings and Pre cautions Palmarplantar erythrodysesthesia,1,0.7616044878959656
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,Warnings and Pre,1,0.5128558874130249
COMETRIQ,Proteinuria,a syndrome see Warnings and Precautions,1,0.49205586314201355
COMETRIQ,Proteinuria,a syndrome,1,0.5307785272598267
COMETRIQ,Proteinuria,the Jaw see Warnings and,0,0.45614373683929443
COMETRIQ,Proteinuria,a,1,0.5117894411087036
COMETRIQ,Proteinuria,Precautions Palmarplantar a,1,0.49506157636642456
COMETRIQ,Reversible posterior leukoencephalopathy syndrome,"s and Precautions  (  5.8  ) ] 
 *  Reversible Po sterior Leukoencephalopathy Syndrome see",1,0.854590654373169
COMETRIQ,Reversible posterior leukoencephalopathy syndrome,Precautions Palmarplantar a,1,0.5074470043182373
COMETRIQ,Reversible posterior leukoencephalopathy syndrome,Proteinuria see s and Precautions ( 5.8 ) ] *,1,0.529259443283081
COMETRIQ,RPLS,Precautions Reversible,0,0.5088239312171936
COMETRIQ,RPLS,see Warnings,0,0.5083366632461548
COMETRIQ,RPLS,ions,0,0.5477180480957031
COMETRIQ,RPLS,Precautions Reversible erio r,1,0.569080114364624
COMETRIQ,RPLS,erio r Leukoencephalopathy Syndrome see Warnings,1,0.5719666481018066
COMETRIQ,RPLS,erio,1,0.4992648959159851
COMETRIQ,RPLS,Leukoencephalopathy Syndrome see,0,0.5360511541366577
COMETRIQ,RPLS,Leukoencephalopathy Syndrome see Warnings and Precautions EXCERPT The mo,0,0.5252535343170166
COMETRIQ,Embryofetal toxicity,drug reactions,0,0.5518691539764404
COMETRIQ,Embryofetal toxicity,rnings and Precautio ns,1,0.5359780788421631
COMETRIQ,Embryofetal toxicity,and Precautio ns EXCERPT The most commonly,1,0.46997761726379395
COMETRIQ,Embryofetal toxicity,Posterior Leukoencephalopathy Syndrome see rnings and Precautio ns,1,0.5325988531112671
COMETRIQ,Embryofetal toxicity,Leukoencephalopathy Syndrome,0,0.5050182938575745
COMETRIQ,Embryofetal toxicity,and Precautio ns EXCERPT,1,0.5003499984741211
COMETRIQ,Embryofetal toxicity,The most commonly reported adverse drug reactions,0,0.5440170168876648
COMETRIQ,Embryofetal toxicity,most commonly reported adverse drug reactions are,0,0.5402078032493591
COMETRIQ,Embryofetal toxicity,and Precautions Reversible Posterior Leukoencephalopathy Syndrome see,0,0.5079659223556519
COMETRIQ,fetal harm,) ] EXCERPT,1,0.49222415685653687
COMETRIQ,fetal harm,Warnings and ) ],1,0.5654856562614441
COMETRIQ,fetal harm,Reversible Posterior Leukoencephalopathy Syndrome,0,0.5209172964096069
COMETRIQ,GI fistula,"hair color changes dysgeusia n,",1,0.5455276966094971
COMETRIQ,GI fistula,pain and constipation The most common laboratory abnormalities,0,0.526654839515686
COMETRIQ,GI fistula,"dysgeusia n, abdomin",1,0.6289671063423157
COMETRIQ,GI fistula,abnormalities,0,0.5333487391471863
COMETRIQ,GI fistula,"color changes dysgeusia n,",1,0.5421756505966187
COMETRIQ,GI fistula,are increased,0,0.45444145798683167
COMETRIQ,GI fistula,"n, abdomin al pain",1,0.5733878016471863
COMETRIQ,GI fistula,"n, abdomin al pain and constipation The",1,0.5706813335418701
COMETRIQ,GI fistula,"color changes dysgeusia n, abdomin",1,0.5872617363929749
COMETRIQ,fatal,"dysgeusia hypertension abdominal in, a nd constipation The most",1,0.564550518989563
COMETRIQ,fatal,"color changes dysgeusia n, abdomin",1,0.5034576058387756
COMETRIQ,fatal,"in, a",1,0.5027573108673096
COMETRIQ,fatal,common,0,0.5453147888183594
COMETRIQ,fatal,abdominal pa,0,0.5420444011688232
COMETRIQ,Non-GI fistulas,and pation. The mos t common laboratory abnormalities are,1,0.5321005582809448
COMETRIQ,Non-GI fistulas,abdominal pa,0,0.603806734085083
COMETRIQ,Non-GI fistulas,pain and,0,0.48351413011550903
COMETRIQ,Non-GI fistulas,pation.,1,0.48719751834869385
COMETRIQ,Non-GI fistulas,pain and consti,0,0.5596815347671509
COMETRIQ,Non-GI fistulas,The mos,1,0.4353756308555603
COMETRIQ,Non-GI fistulas,The mos t common,1,0.4718928635120392
COMETRIQ,Non-GI fistulas,dysgeusia hypertension abdominal,0,0.5923604965209961
COMETRIQ,Non-GI fistulas,The mos t common laboratory abnormalities,1,0.5401291847229004
COMETRIQ,Non-GI fistulas,abdominal pain and pation. The mos t common laboratory,1,0.5741820931434631
COMETRIQ,fatal,ALT lymphopenia increased ine,1,0.5335329174995422
COMETRIQ,fatal,ine p hosphatase hypocalcemia neutropenia thrombocytopenia,1,0.5263853073120117
COMETRIQ,fatal,Inc 935 o,1,0.4719031751155853
COMETRIQ,fatal,REACTIONS contact Exelixis Inc 935 o r FDA,1,0.5008001923561096
COMETRIQ,fatal,935 o r FDA at,1,0.4831836521625519
COMETRIQ,fatal,Inc,0,0.5409464836120605
COMETRIQ,hemorrhage,FDA at 1- FDA or wwwfdagovmedwatch Clinical Trial,1,0.4853852093219757
COMETRIQ,hemorrhage,contact Exelixis Inc at  FDA at 1- FDA,1,0.49039506912231445
COMETRIQ,hemorrhage,Exelixis Inc,0,0.5374374985694885
COMETRIQ,hemorrhage, FDA at 1- FDA or wwwfdagovmedwatch Clinical,1,0.4833863377571106
COMETRIQ,hemorrhage,at  FDA at 1- FDA or wwwfdagovmedwatch Clinical Trial,1,0.4882076680660248
COMETRIQ,hemorrhage,at 1-,1,0.48763465881347656
COMETRIQ,hemorrhage,at 1- FDA,1,0.4594271779060364
COMETRIQ,hemorrhage,at,0,0.5428693294525146
COMETRIQ,hemorrhage,FDA at 1- FDA or,1,0.43987366557121277
COMETRIQ,hemorrhage, FDA at 1- FDA or,1,0.43987366557121277
COMETRIQ,hemorrhagic events,Clinical Tr,1,0.5254477858543396
COMETRIQ,hemorrhagic events,or 6.1,1,0.44772493839263916
COMETRIQ,hemorrhagic events,clinical trials are conducted under widely varying conditions,0,0.5588337182998657
COMETRIQ,hemorrhagic events,FDA at FDA or 6.1,1,0.45098331570625305
COMETRIQ,hemorrhagic events,conducted under widely,0,0.5582132935523987
COMETRIQ,thrombotic events,of COMETRIQ was,0,0.48815205693244934
COMETRIQ,thrombotic events,ice The safety of COMETRIQ was evaluated in,0,0.5335057973861694
COMETRIQ,thrombotic events,not reflect the observed in,1,0.4643409252166748
COMETRIQ,venous thromboembolism,of C OMETRIQ,1,0.5238643884658813
COMETRIQ,venous thromboembolism,safety of C OMETRIQ was evaluated,1,0.5830079317092896
COMETRIQ,venous thromboembolism,rates observed in e. The,1,0.5443638563156128
COMETRIQ,venous thromboembolism,ed to,0,0.563618540763855
COMETRIQ,venous thromboembolism,rates observed in e. The safety,1,0.5490103960037231
COMETRIQ,venous thromboembolism,observed in practic,0,0.5002623200416565
COMETRIQ,arterial thromboembolism,330 patients wi th progressive metastatic medullary thyroid,1,0.48182210326194763
COMETRIQ,arterial thromboembolism,330 patients wi th progressive metastatic medullary,1,0.5209594964981079
COMETRIQ,arterial thromboembolism,COMETRIQ,0,0.4852331578731537
COMETRIQ,arterial thromboembolism,not reflect the rates,0,0.4543752670288086
COMETRIQ,Wound complications,See Clinical Studies,0,0.5441014170646667
COMETRIQ,Wound complications,Clinical 4) .] The,1,0.5597062110900879
COMETRIQ,Wound complications,Clinical 4) .],1,0.5609187483787537
COMETRIQ,Wound complications,below reflect a median,0,0.4373420178890228
COMETRIQ,hypertension,frequency diarrhea stomatitis palmarplantar sthesia synd rome PPES decreased weight decreased,1,0.557719349861145
COMETRIQ,hypertension,below reflect a median,0,0.5090835094451904
COMETRIQ,hypertension,fatigue oral,0,0.5444943904876709
COMETRIQ,hypertension,hair,0,0.6289719343185425
COMETRIQ,hypertension,sthesia synd rome,1,0.4801851511001587
COMETRIQ,hypertension,rome PPES decreased weight decreased appetite nausea fatigue oral pain hair color,0,0.5410650968551636
COMETRIQ,hypertension,diarrhea stomatitis palmarplantar sthesia,1,0.5223647952079773
COMETRIQ,hypertension,order of decreasing frequency diarrhea stomatitis palmarplantar erythrodyse,0,0.5584486722946167
COMETRIQ,hypertension,sthesia synd,1,0.4769326448440552
COMETRIQ,hypertension,petite nausea fatigue oral pain hair color changes dysgeusia,0,0.5488719344139099
COMETRIQ,hypertension, constipatio n The most,1,0.5639331936836243
COMETRIQ,hypertension, constipatio,1,0.6166667342185974
COMETRIQ,hypertension, constipatio n,1,0.5869356393814087
COMETRIQ,Osteonecrosis of the jaw,"PPES lymphopenia hypocalcemia fatigue ypertension, asthenia, i",1,0.50528883934021
COMETRIQ,Osteonecrosis of the jaw, constipatio n,1,0.4818841218948364
COMETRIQ,Osteonecrosis of the jaw,"asthenia, i ncreased ALT decreased weight stomatitis",1,0.6080774068832397
COMETRIQ,Osteonecrosis of the jaw,"asthenia, i",1,0.42726659774780273
COMETRIQ,Osteonecrosis of the jaw,"asthenia, i ncreased ALT decreased",1,0.47385677695274353
COMETRIQ,Osteonecrosis of the jaw,and decreased appetite see Table Table,0,0.5075463652610779
COMETRIQ,Osteonecrosis of the jaw,"ypertension, asthenia, i ncreased",1,0.48346182703971863
COMETRIQ,Osteonecrosis of the jaw,stomatitis and decreased appetite see Table Table,0,0.6023541688919067
COMETRIQ,ONJ,see Table Table Fata,0,0.48752114176750183
COMETRIQ,ONJ,rea sed ALT decreased weight,1,0.4970681667327881
COMETRIQ,ONJ,rea sed ALT decreased,1,0.4958348572254181
COMETRIQ,ONJ,fatigue hypertension asthenia inc,0,0.4715638756752014
COMETRIQ,ONJ,rea sed ALT decreased weight stomatitis,1,0.49896395206451416
COMETRIQ,ONJ,PPES lymphopenia,0,0.5093415379524231
COMETRIQ,ONJ,occurred in of patients,0,0.49670863151550293
COMETRIQ,ONJ,eas ed appetite,1,0.4909769892692566
COMETRIQ,ONJ,eas ed appetite see Table Table,1,0.4845274090766907
COMETRIQ,jaw pain,stomatitis and decreased appetite Table,1,0.6398160457611084
COMETRIQ,jaw pain,decreased appetite Table,1,0.5181503295898438
COMETRIQ,jaw pain,decreased appetite  Table 1 Table Fatal,1,0.4853781461715698
COMETRIQ,jaw pain,Fatal adverse reactions occurred in,0,0.4798896610736847
COMETRIQ,jaw pain, Table 1 Table Fatal adverse reactions,1,0.4829425811767578
COMETRIQ,jaw pain,Table 1 Table,1,0.44431447982788086
COMETRIQ,jaw pain,and decreased appetite Table 1,1,0.504338264465332
COMETRIQ,jaw pain,stomatitis and decreased appetite  Table 1 Table Fatal adverse,1,0.6032521724700928
COMETRIQ,jaw pain,Fatal adverse reactions occurred in of patients receiving COMETRIQ,0,0.4569404125213623
COMETRIQ,jaw pain,stomatitis and decreased appetite  Table 1 Table Fatal adverse reactions occurred,1,0.6054137945175171
COMETRIQ,osteomyelitis,"decreased appetite see ,  Table 2  ) Fatal",1,0.47158634662628174
COMETRIQ,osteomyelitis,Fatal adverse reactions occurred in of patients receiving COMETRIQ,0,0.4982064664363861
COMETRIQ,osteomyelitis,and,0,0.5017448663711548
COMETRIQ,osteomyelitis,"decreased appetite see , Table",1,0.4966738522052765
COMETRIQ,osteitis,"


 Fata",1,0.43691718578338623
COMETRIQ,osteitis,from,0,0.539867639541626
COMETRIQ,osteitis,decreased appetite see Table Table,0,0.503130316734314
COMETRIQ,bone erosion,adverse reac tions occurred in,1,0.614369809627533
COMETRIQ,bone erosion,occurred in of patients receiving COMETRIQ and resulted from,0,0.5578153133392334
COMETRIQ,bone erosion,see Table Table adverse reac tions occurred in of patients,1,0.5649275183677673
COMETRIQ,bone erosion,see Table Table adverse,1,0.5659312009811401
COMETRIQ,bone erosion,ALT decreased,0,0.4953427016735077
COMETRIQ,bone erosion,Table Table adverse reac tions occurred,1,0.5592055320739746
COMETRIQ,bone erosion,adverse reac,1,0.5728528499603271
COMETRIQ,bone erosion,Table Table adverse,1,0.5578476190567017
COMETRIQ,bone erosion,appetite see Table Table adverse reac tions occurred in of,1,0.5595637559890747
COMETRIQ,bone erosion,adverse reac tions occurred in of,1,0.6098067760467529
COMETRIQ,periodontal infection,6% of patients receiving COMETRIQ,1,0.5022225379943848
COMETRIQ,periodontal infection,stomatitis and,0,0.7318594455718994
COMETRIQ,periodontal infection,COMETRIQ,0,0.48392724990844727
COMETRIQ,periodontal infection,6% of patients receiving,1,0.502118706703186
COMETRIQ,periodontal infection,resulted from,0,0.5237998962402344
COMETRIQ,periodontal infection,reactions red in,1,0.528182327747345
COMETRIQ,periodontal infection,adverse reactions red in 6% of patients,1,0.5401211977005005
COMETRIQ,toothache,eceiving  COMETRIQ and resulted,1,0.4388643205165863
COMETRIQ,toothache,in of patients eceiving  COMETRIQ and resulted,1,0.497148722410202
COMETRIQ,toothache,COMETRIQ and resulted from hemorrhage pneumonia septicemia fistulas cardiac arrest respiratory,0,0.460218608379364
COMETRIQ,toothache,occurred in of patients eceiving  COMETRIQ,1,0.509757399559021
COMETRIQ,toothache,ased appetite see,0,0.5129626989364624
COMETRIQ,toothache,and resulted from hemorrhage pneumonia septicemia fistulas cardiac,0,0.4846351742744446
COMETRIQ,toothache,eceiving  COMETRIQ and resulted from,1,0.441391259431839
COMETRIQ,toothache,occurred in of patients eceiving  COMETRIQ and resulted from,1,0.5031177997589111
COMETRIQ,gingival ulceration,adverse reactions occurred in of patients receiving CO,0,0.5278010964393616
COMETRIQ,persistent jaw pain,"COMETRIQ and resulted from age, pneumonia, sep ticemia fistulas cardiac",1,0.4954376518726349
COMETRIQ,persistent jaw pain,adverse reactions occurred in of patients receiving CO,0,0.48308512568473816
COMETRIQ,persistent jaw pain,death Fatal adverse reactio,0,0.47146379947662354
COMETRIQ,persistent jaw pain,hemorrh,0,0.48059311509132385
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,discontinuation in,0,0.49227169156074524
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,receiving Q compared to none in patients receiving p lacebo Adverse,1,0.5802997350692749
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,in patients receiving p lacebo Adverse reactions led to,1,0.6199303269386292
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,receiving Q compared to none in patients,1,0.5517601370811462
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,led to study,0,0.48879605531692505
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,one in patients receiving Q compared to none in patients receiving p lacebo Adverse,1,0.5685039162635803
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,patients receiving Q compared to none in patients receiving p,1,0.5651051998138428
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,receiving placebo The median,0,0.5311972498893738
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,receiving COMETRI,0,0.4678099751472473
COMETRIQ,PPES,none in patients receiving cebo Adverse reactions led to study,1,0.5485391020774841
COMETRIQ,PPES,discontinuation in,0,0.513105571269989
COMETRIQ,PPES,patients,0,0.5580967664718628
COMETRIQ,PPES,patients receiving cebo Adverse,1,0.5606173276901245
COMETRIQ,PPES,of patients,0,0.5253307223320007
COMETRIQ,PPES,cebo Adverse reactions led to study,1,0.5676037669181824
COMETRIQ,PPES,cebo Adverse,1,0.5557576417922974
COMETRIQ,PPES,cebo,1,0.5074824690818787
COMETRIQ,PPES,compared to none in,0,0.5020937919616699
COMETRIQ,PPES,led to study treatment discontinuation in,0,0.5175369381904602
COMETRIQ,PPES,cebo Adverse reactions led,1,0.5764936208724976
COMETRIQ,PPES,r of dosing delays was one in patients receiving COMETRIQ compared,0,0.5162932276725769
COMETRIQ,Proteinuria,"increased ase, PPES, ",1,0.5126619338989258
COMETRIQ,Proteinuria,cebo Adverse,1,0.49889519810676575
COMETRIQ,Proteinuria,"were hypocalcemia increased ase, PPES,",1,0.5169974565505981
COMETRIQ,Proteinuria,"increased ase, PPES,  diarrhea fatigue hypertension nausea",1,0.5562617778778076
COMETRIQ,Proteinuria,pancreatitis tracheal fistula formation and vomiting,0,0.46166443824768066
COMETRIQ,Proteinuria,fistula formation and,0,0.5659373998641968
COMETRIQ,Proteinuria,"ase, PPES, diarrhea",1,0.5227965712547302
COMETRIQ,Proteinuria,"hypocalcemia increased ase, PPES,  diarrhea fatigue hypertension nausea pancreatitis",1,0.5171293616294861
COMETRIQ,Proteinuria,"were hypocalcemia increased ase, PPES,  diarrhea",1,0.521938145160675
COMETRIQ,Proteinuria,"increased ase, PPES,  diarrhea fatigue hypertension nausea pancreatitis",1,0.5539938807487488
COMETRIQ,RPLS,prior thyroidectomy d 89 were taking thyroid,1,0.38681602478027344
COMETRIQ,RPLS,"were hypocalcemia increased ase, PPES,",1,0.48170006275177
COMETRIQ,RPLS,d 89 were taking thyroid hormone replacement,1,0.43191635608673096
COMETRIQ,subcortical vasogenic edema,and,0,0.4770670533180237
COMETRIQ,subcortical vasogenic edema,of Selected Adverse Reactions,0,0.5942146182060242
COMETRIQ,subcortical vasogenic edema,arm had a prior thyroidectomy,0,0.4733595550060272
NULOJIX,PTLD,PTLD predominantly CNS PTLD and other,1,0.8019852638244629
NULOJIX,PTLD,PTLD predominantly,1,0.9228741526603699
NULOJIX,PTLD,reactions reported with NULOJIX PTLD,1,0.6623820066452026
NULOJIX,PTLD,with NULOJIX PTLD predominantly CNS PTLD,1,0.7097513675689697
NULOJIX,PTLD,NULOJIX,0,0.5104636549949646
NULOJIX,CNS PTLD,CNS PTLD and other malignancies,1,0.8355635404586792
NULOJIX,CNS PTLD,CNS PTLD and other malignancies see,1,0.8341814875602722
NULOJIX,CNS PTLD,are PTLD CNS PTLD and other malignancies see,1,0.8275189399719238
NULOJIX,CNS PTLD,CNS PTLD,1,0.9999999403953552
NULOJIX,CNS PTLD,malignancies see Boxed Warning and,0,0.5197210311889648
NULOJIX,CNS PTLD,malignancies see Boxed Warning and Warnings,0,0.5180147886276245
NULOJIX,CNS PTLD,CNS,1,0.8324081301689148
NULOJIX,malignancies,Boxed,0,0.5234063863754272
NULOJIX,malignancies,Precautions,0,0.5313975811004639
NULOJIX,malignancies,malignancies,1,1.0
NULOJIX,malignancies,malignancies see Boxed Warning,1,0.7879179120063782
NULOJIX,malignancies,Precautions Serious,0,0.5331631302833557
NULOJIX,malignancies,and malignancies see Boxed,1,0.802725076675415
NULOJIX,malignancies,malignancies see Boxed,1,0.7948611974716187
NULOJIX,malignancies,with NULOJIX are PTLD predominantly CNS PTLD and other,0,0.53093421459198
NULOJIX,infections,see,0,0.5760005712509155
NULOJIX,JC virus,JC virus associated PML,1,0.8199058175086975
NULOJIX,JC virus,and Precautions Serious,0,0.5137340426445007
NULOJIX,JC virus,see Warnings and Precautions,0,0.5351449847221375
NULOJIX,PML,Serious infections,0,0.5212820768356323
NULOJIX,PML,PML,1,0.9999998807907104
NULOJIX,PML,JC PML,1,0.8271657228469849
NULOJIX,PML,PML and,1,0.9436883926391602
NULOJIX,PML,PML and polyoma virus nephropathy,1,0.787989616394043
NULOJIX,PML,PML and polyoma,1,0.8482053279876709
NULOJIX,PML,and,0,0.48432987928390503
NULOJIX,PML,see Warnings,0,0.5118392705917358
NULOJIX,PML,infections including JC PML and polyoma virus,1,0.7376012206077576
NULOJIX,PML,Serious infections including,0,0.5291256904602051
NULOJIX,polyoma virus nephropathy,polyoma virus nephropathy see Warnings and Precautions EXCERPT,1,0.9081753492355347
NULOJIX,polyoma virus nephropathy,PML polyoma virus,1,0.7642278671264648
NULOJIX,polyoma virus nephropathy,PML polyoma,1,0.6936416625976562
NULOJIX,polyoma virus nephropathy,and,0,0.4587738811969757
NULOJIX,polyoma virus nephropathy,EXCERPT Most common adverse,0,0.48168736696243286
NULOJIX,polyoma virus nephropathy,Precautions EXCERPT Most common adverse rea,0,0.4735482931137085
NULOJIX,polyoma virus nephropathy,PML,0,0.5636958479881287
NULOJIX,polyoma virus nephropathy,polyoma virus nephropathy see Warnings and,1,0.9159010648727417
NULOJIX,anemia,anemia diarrhea urinary tract infection peripheral,1,0.7558938264846802
NULOJIX,diarrhea,treatment are diarrhea urinary tract infection peripheral edema,1,0.7267376184463501
NULOJIX,diarrhea,anemia diarrhea urinary tract infection peripheral,1,0.6979424953460693
NULOJIX,diarrhea,reactions on NULOJIX treatment are,0,0.5558315515518188
NULOJIX,diarrhea,NULOJIX,0,0.5605230331420898
NULOJIX,diarrhea,diarrhea urinary tract infection peripheral,1,0.7175049185752869
NULOJIX,diarrhea,urinary tract,0,0.633965015411377
NULOJIX,diarrhea,treatment,0,0.5861543416976929
NULOJIX,diarrhea,are diarrhea urinary tract infection peripheral,1,0.7034028768539429
NULOJIX,diarrhea,Most common adverse reactions on NULOJIX treatment,0,0.557755708694458
NULOJIX,urinary tract infection,NULOJIX treatment are anemia urinary tract infection,1,0.6992602348327637
NULOJIX,urinary tract infection,graft,0,0.5016772747039795
NULOJIX,urinary tract infection,dysfunction cough nausea,0,0.5613594055175781
NULOJIX,urinary tract infection,are anemia urinary tract infection peripheral,1,0.7326160669326782
NULOJIX,urinary tract infection,urinary tract infection,1,1.000000238418579
NULOJIX,urinary tract infection,reactions on,0,0.48458588123321533
NULOJIX,peripheral edema,peripheral edema constipation hypertension,1,0.8687418699264526
NULOJIX,peripheral edema,urinary tract peripheral edema constipation hypertension pyrexia,1,0.7928025722503662
NULOJIX,peripheral edema,peripheral edema,1,1.0000001192092896
NULOJIX,peripheral edema,urinary tract peripheral edema constipation hypertension,1,0.8121856451034546
NULOJIX,constipation,cough nausea vomiting,0,0.582162082195282
NULOJIX,constipation,constipation hypertension pyrexia graft dysfunction cough,1,0.7012526392936707
NULOJIX,constipation,constipation hypertension pyrexia,1,0.7662829160690308
NULOJIX,constipation,urinary tract infection peripheral constipation hypertension pyrexia graft dysfunction,1,0.6555798053741455
NULOJIX,hypertension,hypertension pyrexia graft dysfunction,1,0.6915287971496582
NULOJIX,hypertension,pyrexia,0,0.5447151064872742
NULOJIX,hypertension,hyperkalemia and leuk,0,0.6617367267608643
NULOJIX,hypertension,graft dysfunction cough,0,0.5235563516616821
NULOJIX,hypertension,hypertension,1,0.9999999403953552
NULOJIX,hypertension,hypertension pyrexia graft dysfunction cough nausea,1,0.691139280796051
NULOJIX,hypertension,hypertension pyrexia graft,1,0.7188397645950317
NULOJIX,hypertension,infection peripheral edema hypertension pyrexia graft,1,0.6553507447242737
NULOJIX,hypertension,tract infection peripheral edema hypertension pyrexia graft dysfunction,1,0.6254440546035767
NULOJIX,pyrexia,urinary tract infection peripheral edema,0,0.517207682132721
NULOJIX,pyrexia,hyperkalemia and leukopenia,0,0.5459110736846924
NULOJIX,pyrexia,tract infection peripheral edema,0,0.5526630878448486
NULOJIX,pyrexia,anemia diarrhea urinary tract,0,0.5617396831512451
NULOJIX,graft dysfunction,graft dysfunction,1,1.0
NULOJIX,graft dysfunction,hypertension graft dysfunction cough nausea vomiting,1,0.7884284257888794
NULOJIX,graft dysfunction,graft dysfunction cough,1,0.8736413717269897
NULOJIX,graft dysfunction,urinary tract infection peripheral edema constipation,0,0.5509583950042725
NULOJIX,graft dysfunction,graft,1,0.8284443616867065
NULOJIX,graft dysfunction,leukopenia,0,0.5217787027359009
NULOJIX,graft dysfunction,constipation hypertension graft dysfunction,1,0.8301752805709839
NULOJIX,graft dysfunction,hypertension graft dysfunction cough,1,0.7986865043640137
NULOJIX,cough,cough nausea vomiting,1,0.8236581683158875
NULOJIX,cough,cough nausea vomiting headache,1,0.8014163970947266
NULOJIX,cough,pyrexia graft cough nausea,1,0.7479645609855652
NULOJIX,cough,edema,0,0.5597254037857056
NULOJIX,cough,cough,1,1.0
NULOJIX,nausea,nausea vomiting headache hypokalemia,1,0.7720358967781067
NULOJIX,nausea,cough,1,0.6918084621429443
NULOJIX,nausea,headache hypokalemia hyperkalemia,0,0.5688376426696777
NULOJIX,nausea,nausea vomiting headache hypokalemia hyperkalemia,1,0.7593299746513367
NULOJIX,nausea,graft dysfunction nausea vomiting headache hypokalemia,1,0.6525672674179077
NULOJIX,nausea,y tract infection,0,0.5786498785018921
NULOJIX,nausea,nausea vomiting headache,1,0.8597691059112549
NULOJIX,nausea,leukopenia To,0,0.5497560501098633
NULOJIX,vomiting,pyrexia graft dysfunction cough vomiting,1,0.7231171131134033
NULOJIX,vomiting,leukopenia To,0,0.5138919353485107
NULOJIX,vomiting,headache hypokalemia hyperkalemia and leukopenia To report SUSPECTED,0,0.5678225159645081
NULOJIX,vomiting,vomiting headache hypokalemia,1,0.7548789978027344
NULOJIX,vomiting,pyrexia graft dysfunction cough vomiting headache hypokalemia,1,0.6507576704025269
NULOJIX,vomiting,vomiting,1,0.9999999403953552
NULOJIX,vomiting,pyrexia graft dysfunction cough vomiting headache hypokalemia hyperkalemia and leukopenia,1,0.6465103626251221
NULOJIX,hypokalemia,cough nausea vomiting hypokalemia hyperkalemia,1,0.8060880899429321
NULOJIX,hypokalemia,vomiting,1,0.5187711715698242
NULOJIX,hypokalemia,hypokalemia hyperkalemia and leukopenia To report,1,0.8119481801986694
NULOJIX,hypokalemia,vomiting hypokalemia hyperkalemia and leukopenia,1,0.7953925132751465
NULOJIX,hypokalemia,dysfunction cough nausea vomiting hypokalemia,1,0.7985249161720276
NULOJIX,hypokalemia,hypokalemia hyperkalemia and leukopenia To,1,0.8234478235244751
NULOJIX,hypokalemia,hypokalemia,1,1.0
NULOJIX,hyperkalemia,hypertension pyrexia graft dysfunction,0,0.6055461168289185
NULOJIX,hyperkalemia,hypertension pyrexia,0,0.625400185585022
NULOJIX,hyperkalemia,tipation hypertension pyrexia graft,0,0.6007320284843445
NULOJIX,hyperkalemia,leukopenia To report SUSPECTED,0,0.5439326763153076
NULOJIX,hyperkalemia,hyperkalemia and leukopenia To report SUSPECTED,1,0.8275935649871826
NULOJIX,hyperkalemia,report SUSPECTED ADVERSE REACTIONS,0,0.5523441433906555
NULOJIX,hyperkalemia,hyperkalemia and leukopenia,1,0.8640496730804443
NULOJIX,hyperkalemia,hyperkalemia and leukopenia To,1,0.8595596551895142
NULOJIX,leukopenia,leukopenia,1,1.0000001192092896
NULOJIX,leukopenia,leukopenia To report SUSPECTED,1,0.8656339645385742
NULOJIX,leukopenia,report SUSPECTED ADVERSE REACTIONS contact,0,0.5082820653915405
NULOJIX,leukopenia,and,0,0.45996373891830444
NULOJIX,leukopenia,leukopenia To report SUSPECTED ADVERSE REACTIONS,1,0.8225870728492737
NULOJIX,leukopenia,dysfunction cough nausea,0,0.4913552403450012
NULOJIX,leukopenia,nausea vomiting headache hypokalemia,0,0.515889048576355
NULOJIX,CNS PTLD,for CNS PTLD,1,0.981214165687561
NULOJIX,CNS PTLD,CNS PTLD PML and,1,0.8545732498168945
NULOJIX,CNS PTLD,treated and followed for CNS,1,0.7371141910552979
NULOJIX,CNS PTLD,and followed for CNS PTLD PML and other CNS infections,1,0.7786911129951477
NULOJIX,PML,PML and other CNS infections were,1,0.7790666818618774
NULOJIX,PML,CNS PML,1,0.8235917091369629
NULOJIX,PML,PML and other CNS,1,0.8309389352798462
NULOJIX,CNS infections,association with a NULOJIX regimen of,0,0.5188548564910889
NULOJIX,CNS infections,CNS infections were more frequently,1,0.8702285885810852
NULOJIX,anemia,and frequency of NULOJIX anemia diarrhea urinary tract,1,0.686560869216919
NULOJIX,anemia,association with a NULOJIX regimen of,0,0.5560410618782043
NULOJIX,anemia,anemia diarrhea urinary tract,1,0.7716865539550781
NULOJIX,anemia,anemia diarrhea urinary,1,0.7985000610351562
NULOJIX,anemia,anemia diarrhea,1,0.8181662559509277
NULOJIX,anemia,frequency of NULOJIX anemia diarrhea urinary tract,1,0.6791090965270996
NULOJIX,anemia,patients treated with the recommended dose and,0,0.5574356913566589
NULOJIX,diarrhea,infection peripheral edema,0,0.5781988501548767
NULOJIX,urinary tract infection,edema constipation hypertension pyrexia graft dysfunction,0,0.5860817432403564
NULOJIX,peripheral edema,recommended,0,0.537468671798706
NULOJIX,peripheral edema,NULOJIX were anemia diarrhea urinary,0,0.5549328923225403
NULOJIX,peripheral edema,diarrhea urinary tract peripheral edema constipation hypertension pyrexia graft,1,0.6921260356903076
NULOJIX,peripheral edema,graft dysfunction cough,0,0.5496684908866882
NULOJIX,peripheral edema,peripheral edema constipation,1,0.8653062582015991
NULOJIX,peripheral edema,diarrhea urinary tract peripheral,1,0.6874161958694458
NULOJIX,peripheral edema,cough nausea,0,0.4838847517967224
NULOJIX,peripheral edema,urinary tract infection,0,0.5604362487792969
NULOJIX,peripheral edema,cough nausea vomiting headache,0,0.49143311381340027
NULOJIX,constipation,constipation hypertension,1,0.8425655961036682
NULOJIX,constipation,infection peripheral constipation hypertension pyrexia graft,1,0.6720443964004517
NULOJIX,constipation,constipation hypertension pyrexia graft dysfunction,1,0.6735267639160156
NULOJIX,constipation,constipation hypertension pyrexia graft,1,0.7098848819732666
NULOJIX,hypertension,infection peripheral edema hypertension pyrexia graft dysfunction cough nausea,1,0.6542909741401672
NULOJIX,hypertension,constipation hypertension pyrexia graft dysfunction,1,0.6144044399261475
NULOJIX,hypertension,edema,0,0.6662336587905884
NULOJIX,hypertension,hypertension pyrexia,1,0.7560595273971558
NULOJIX,pyrexia,pyrexia graft dysfunction,1,0.7971885204315186
NULOJIX,pyrexia,hypertension pyrexia,1,0.8631398677825928
NULOJIX,pyrexia,hyperkalemia and,0,0.5275360941886902
NULOJIX,pyrexia,pyrexia graft dysfunction cough nausea,1,0.7734518051147461
NULOJIX,pyrexia,urinary tract infection,0,0.5598363876342773
NULOJIX,pyrexia,pyrexia graft dysfunction cough,1,0.7624479532241821
NULOJIX,pyrexia,LOJIX were anemia diarrhea urinary tract infection peripheral edema,0,0.5744394659996033
NULOJIX,pyrexia,LOJIX were anemia diarrhea urinary tract infection peripheral edema constipation hypertension,0,0.5728679895401001
NULOJIX,pyrexia,were,0,0.5141094923019409
NULOJIX,graft dysfunction,edema,0,0.6197232604026794
NULOJIX,cough,dysfunction,0,0.5290360450744629
NULOJIX,cough,hyperkalemia,0,0.49176180362701416
NULOJIX,cough,hypertension pyrexia graft cough nausea,1,0.7412749528884888
NULOJIX,cough,pyrexia graft cough nausea vomiting headache,1,0.6963827610015869
NULOJIX,cough,graft cough nausea,1,0.7603638768196106
NULOJIX,cough,and leukopenia The proportion,0,0.4935169219970703
NULOJIX,cough,pyrexia,0,0.6231146454811096
NULOJIX,cough,The proportion of,0,0.48820388317108154
NULOJIX,nausea,vomiting,0,0.8409453630447388
NULOJIX,nausea,infection peripheral,0,0.5226377844810486
NULOJIX,nausea,headache hypokalemia hyperkalemia and leukopenia The proportion of patients,0,0.580610990524292
NULOJIX,nausea,nausea vomiting headache hypokalemia hyperkalemia and,1,0.7552651166915894
NULOJIX,vomiting,headache hypokalemia,0,0.537166953086853
NULOJIX,vomiting,vomiting headache hypokalemia hyperkalemia,1,0.7570629715919495
NULOJIX,vomiting,vomiting headache hypokalemia hyperkalemia and leukopenia,1,0.7338778972625732
NULOJIX,vomiting,vomiting headache,1,0.8704005479812622
NULOJIX,vomiting,patients who,0,0.4855969548225403
NULOJIX,vomiting,cough vomiting headache hypokalemia hyperkalemia and leukopenia,1,0.7052076458930969
NULOJIX,vomiting,graft dysfunction cough vomiting,1,0.7391328811645508
NULOJIX,headache,of patients who,0,0.52898770570755
NULOJIX,headache,pyrexia graft,0,0.5280783176422119
NULOJIX,headache,headache hypokalemia,1,0.7838982939720154
NULOJIX,headache,dysfunction cough nausea headache hypokalemia hyperkalemia and leukopenia,1,0.5982856750488281
NULOJIX,headache,The proportion of patients who discontinued,0,0.48118728399276733
NULOJIX,headache,headache,1,0.9999998807907104
NULOJIX,headache,headache hypokalemia hyperkalemia and leukopenia,1,0.7221486568450928
NULOJIX,headache,who discontinued treatme,0,0.4813254475593567
NULOJIX,hypokalemia,headache,0,0.5310183167457581
NULOJIX,hypokalemia,leukopenia The proportion of patients who discontinued treatment due to adv,0,0.5296633243560791
NULOJIX,hypokalemia,dysfunction cough nausea vomiting hypokalemia hyperkalemia,1,0.7893689274787903
NULOJIX,hyperkalemia,hyperkalemia and leukopenia The,1,0.8664853572845459
NULOJIX,hyperkalemia,hyperkalemia and leukopenia The proportion of,1,0.821626603603363
NULOJIX,hyperkalemia,treatment due to,0,0.5663429498672485
NULOJIX,leukopenia,sion pyrexia graft dysfunction,0,0.5339460372924805
NULOJIX,leukopenia,sion,0,0.46074724197387695
NULOJIX,leukopenia,headache hypokalemia hyperkalemia leukopenia The proportion of,1,0.6951068043708801
NULOJIX,leukopenia,of patients who discontinued treatment due to adverse,0,0.5033437013626099
NULOJIX,leukopenia,was,0,0.49688634276390076
NULOJIX,leukopenia,dysfunction cough nausea vomiting headache hypokalemia hyperkalemia,0,0.51731938123703
NULOJIX,leukopenia,leukopenia The proportion of,1,0.8956353664398193
NULOJIX,leukopenia,nausea,0,0.532667875289917
NULOJIX,leukopenia,leukopenia The proportion of patients who,1,0.8677515983581543
NULOJIX,cytomegalovirus infection,cytomegalovirus infection and complications of transplanted kidney,1,0.795994758605957
NULOJIX,cytomegalovirus infection,leukopenia The proportion of patients who,1,0.5495643019676208
NULOJIX,cytomegalovirus infection,to discontinuation in NULOJIXtreated,0,0.46798238158226013
NULOJIX,cytomegalovirus infection,cytomegalovirus infection,1,1.0
NULOJIX,cytomegalovirus infection,transplanted kidney,0,0.5588908195495605
NULOJIX,cytomegalovirus infection,most common adverse reactions leading to discontinuation in NULOJIXtreated patients,0,0.5456093549728394
NULOJIX,cytomegalovirus infection,Information on selected,0,0.4989958703517914
NULOJIX,complications of transplanted kidney,patients were cytomegalovirus infection complications of transplanted kidney,1,0.8457907438278198
NULOJIX,complications of transplanted kidney,complications of transplanted kidney Information,1,0.9588648080825806
NULOJIX,complications of transplanted kidney,infection complications of transplanted kidney Information on selected,1,0.9085686802864075
NULOJIX,complications of transplanted kidney,clinical,0,0.5253300666809082
NULOJIX,complications of transplanted kidney,Information on selected significant adverse reactions observed during clinical trials i,0,0.5976052284240723
NULOJIX,complications of transplanted kidney,infection complications of,1,0.7044053077697754
NULOJIX,complications of transplanted kidney,transplanted kidney,1,0.8803827166557312
NULOJIX,complications of transplanted kidney,leading to discontinuation in NULOJIXtreated patients were cytomegalovirus,0,0.5705075860023499
NULOJIX,complications of transplanted kidney,cytomegalovirus infection complications of transplanted kidney Information on selected significant adverse,1,0.8547134399414062
NULOJIX,complications of transplanted kidney,patients were,0,0.5437300801277161
NULOJIX,post-transplant lymphoproliferative disorder,Disorder Reported cases,0,0.5719883441925049
NULOJIX,post-transplant lymphoproliferative disorder,PostTransplant Lymphoproliferative Disorder Reported cases of,0,0.9306591153144836
NULOJIX,post-transplant lymphoproliferative disorder,of,0,0.49952393770217896
NULOJIX,post-transplant lymphoproliferative disorder,were obtained for NULOJIX by,0,0.5202766060829163
NULOJIX,post-transplant lymphoproliferative disorder,Disorder Reported cases post-transplant lymphoproliferative disorder PTLD up,1,0.9208168387413025
NULOJIX,post-transplant lymphoproliferative disorder,Lymphoproliferative Disorder Reported cases post-transplant lymphoproliferative disorder PTLD,1,0.9296011924743652
NULOJIX,post-transplant lymphoproliferative disorder,Reported cases post-transplant lymphoproliferative disorder PTLD up to months,1,0.9164394736289978
NULOJIX,PTLD,Lymphoproliferative Disorder,0,0.6242688894271851
NULOJIX,PTLD,PTLD up to,1,0.9151290655136108
NULOJIX,PTLD,PTLD up to months post,1,0.8060137033462524
NULOJIX,PTLD,lymphoproliferative PTLD up to months post transplant,1,0.7294383645057678
NULOJIX,PTLD,for NULOJIX by pooling both dosage,0,0.5225456953048706
NULOJIX,PTLD,posttransplant lymphoproliferative PTLD up to months,1,0.724469006061554
NULOJIX,PTLD,there were cases PTLD in EBV seropositive,1,0.748812198638916
NULOJIX,PTLD,PTLD in EBV seropositive,1,0.76091468334198
NULOJIX,PTLD,PTLD in EBV seropositive patients and,1,0.7446263432502747
NULOJIX,PTLD,PTLD,1,0.9999998807907104
NULOJIX,PTLD,PTLD without,1,0.8625479340553284
NULOJIX,PTLD,treated with,0,0.5636047720909119
NULOJIX,PTLD,PTLD without CNS involvement All cases,1,0.7546179294586182
NULOJIX,PTLD,to,0,0.6076675653457642
NULOJIX,PTLD,PTLD reported up to months,1,0.815191924571991
NULOJIX,PTLD,All cases PTLD reported,1,0.8133101463317871
NULOJIX,PTLD,of,0,0.5800802707672119
NULOJIX,PTLD,PTLD reported up to,1,0.861575722694397
NULOJIX,PTLD,PTLD reported,1,0.9038372039794922
NULOJIX,PTLD,PTLD reported up to months post,1,0.8055452108383179
NULOJIX,PTLD,PTLD reported up,1,0.8514314889907837
NULOJIX,PTLD,PTLD in patients,1,0.8627108335494995
NULOJIX,PTLD,PTLD Reported,1,0.9038372039794922
NULOJIX,PTLD,Contraindications Table Summary PTLD,1,0.7620210647583008
NULOJIX,PTLD,Contraindications Table Summary PTLD Reported in Studies and,1,0.7442450523376465
NULOJIX,PTLD,Reported in Studies and Through Three,0,0.5205593109130859
NULOJIX,PTLD,PTLD Reported in Studies,1,0.8443468809127808
NULOJIX,PTLD,Reported in Studies and Through Three Years of Treatment NULOJIX No,0,0.49748486280441284
NULOJIX,PTLD,PTLD compared to of,1,0.8932884931564331
NULOJIX,PTLD,PTLD compared to of CMV seropositive,1,0.7382701635360718
NULOJIX,PTLD,PTLD compared to,1,0.9117417335510254
NULOJIX,PTLD,EBV seropositive recipients tr,0,0.5155668258666992
NULOJIX,PTLD,CMV seronegative,0,0.462263822555542
NULOJIX,PTLD,PTLD cases,1,0.897119402885437
NULOJIX,PTLD,regimen of NULOJIX three,0,0.5212987661361694
NULOJIX,PTLD,dosage regimen,0,0.5446521043777466
NULOJIX,PTLD,PTLD remains to be determined,1,0.858028769493103
NULOJIX,PTLD,a risk factor,0,0.5000099539756775
NULOJIX,PTLD,factor for,0,0.5046151876449585
NULOJIX,PTLD,risk factor PTLD remains to be determined however,1,0.7391870021820068
NULOJIX,PTLD,prescribing NULOJIX se,0,0.4988061189651489
NULOJIX,Malignancies,were reported in Study,0,0.5426924228668213
NULOJIX,Malignancies,Malignancies excluding nonmelanoma,1,0.809707760810852
NULOJIX,Malignancies,Malignancies,0,1.0
NULOJIX,Malignancies,skin cancer and PTLD were reported in Study and Study in,0,0.6763311624526978
NULOJIX,non-melanoma skin cancer,skin cancer,1,0.8570156097412109
NULOJIX,non-melanoma skin cancer,Precautions Other Malignancies Malignancies non-melanoma skin,1,0.8286981582641602
NULOJIX,non-melanoma skin cancer,non-melanoma,1,0.900564968585968
NULOJIX,non-melanoma skin cancer,Other Malignancies Malignancies non-melanoma skin cancer and PTLD,1,0.8360072374343872
NULOJIX,non-melanoma skin cancer,in Study and Study,0,0.3948217034339905
NULOJIX,non-melanoma skin cancer,skin cancer and,1,0.8267776966094971
NULOJIX,non-melanoma skin cancer,non-melanoma skin cancer,1,1.0
NULOJIX,PTLD,skin cancer PTLD were reported in,1,0.7566202878952026
NULOJIX,PTLD,non-melanoma skin cancer,1,0.46603521704673767
NULOJIX,PTLD,PTLD were,1,0.9735521674156189
NULOJIX,PTLD,PTLD were reported in,1,0.8740819692611694
NULOJIX,PTLD,utions,0,0.5659781694412231
NULOJIX,PTLD,cancer PTLD were reported in Study,1,0.7529110908508301
NULOJIX,PTLD,PTLD were reported in Study and,1,0.8576011657714844
NULOJIX,PTLD,excluding nonmelanoma skin,0,0.48046815395355225
NULOJIX,PTLD,PTLD were reported,1,0.8933517336845398
NULOJIX,Non-melanoma skin cancer,skin cancer was reported in of,1,0.7840765714645386
NULOJIX,Non-melanoma skin cancer,with the cyclosporine control Non-melanoma skin cancer,1,0.8033009767532349
NULOJIX,Non-melanoma skin cancer,with,0,0.4792630672454834
NULOJIX,Non-melanoma skin cancer,Non-melanoma skin cancer was reported in of,1,0.929100751876831
NULOJIX,Non-melanoma skin cancer,skin cancer was reported,1,0.8055483102798462
NULOJIX,fatal,fatal,1,1.0000001192092896
NULOJIX,fatal,reported among,0,0.5206996202468872
NULOJIX,fatal,progressive multifocal,0,0.4505571722984314
NULOJIX,fatal,Multifocal Leukoencephalopathy Two,0,0.4931432902812958
NULOJIX,progressive multifocal leukoencephalopathy,been reported among patients treated with a,0,0.5563753247261047
NULOJIX,progressive multifocal leukoencephalopathy,and Precautions Progressive Multifocal Leukoencephalopathy,0,0.919967770576477
NULOJIX,progressive multifocal leukoencephalopathy,progressive multifocal leukoencephalopathy PML have,1,0.9005656242370605
NULOJIX,PML,PML have been,1,0.928471565246582
NULOJIX,PML,cases of progressive,0,0.5765675902366638
NULOJIX,PML,PML have,1,0.9422945380210876
NULOJIX,PML,of progressive multifocal leukoencephalopathy,0,0.6496235132217407
NULOJIX,PML,PML have been reported among,1,0.9018544554710388
NULOJIX,PML,ve Multifocal Leukoencephalopathy Two fatal cases of progressive multifocal,0,0.600016713142395
NULOJIX,PML,cases of progressive multifocal,0,0.5622514486312866
NULOJIX,PML,liver transplant,0,0.5019276142120361
NULOJIX,PML,PML were reported,1,0.9067464470863342
NULOJIX,PML,PML were,1,0.9439325332641602
NULOJIX,PML,PML were reported in patients treated,1,0.8408454060554504
NULOJIX,PML,trial of,0,0.5121995806694031
NULOJIX,infectious etiology,infectious etiology were reported based,1,0.904556930065155
NULOJIX,infectious etiology,clinical assessment,0,0.5788956880569458
NULOJIX,infectious etiology,infectious etiology were reported based on clinical,1,0.887079656124115
NULOJIX,infectious etiology,Adverse reactions infectious,1,0.7110934257507324
NULOJIX,infectious etiology,organisms for,0,0.6007208824157715
NULOJIX,infectious etiology,reactions infectious etiology,1,0.8822437524795532
NULOJIX,infectious etiology,Viral and,0,0.6375178098678589
NULOJIX,infections,number infections serious infections and select,1,0.7823277711868286
NULOJIX,infections,Viral and,0,0.6401423215866089
NULOJIX,infections,patients treated,0,0.6029460430145264
NULOJIX,infections,in patients treated wi,0,0.5997947454452515
NULOJIX,infections,number of infections infections and select,1,0.8147084712982178
NULOJIX,infections,infections and select infections,1,0.8727993369102478
NULOJIX,infections,the NULOJIX,0,0.5271191596984863
NULOJIX,infections,of infections,0,0.898516058921814
NULOJIX,infections,and infections with identified etiology reported in,1,0.752198338508606
NULOJIX,infections,etiology reported in patients treated with the NULOJIX recommended regimen or the,0,0.5771384239196777
NULOJIX,infections,infections with,1,0.8962360620498657
NULOJIX,infections,when provided by,0,0.5227582454681396
NULOJIX,infections,serious infections and infections with,1,0.8424478769302368
NULOJIX,infections,select,0,0.5694471597671509
NULOJIX,Fungal infections,patients,0,0.5743026733398438
NULOJIX,Fungal infections,Fungal infections,1,1.0000001192092896
NULOJIX,Fungal infections,Fungal infections were,1,0.9421704411506653
NULOJIX,Fungal infections,to receiving cyclosporine,0,0.5599046349525452
NULOJIX,Fungal infections,receiving NULOJIX compared to receiving cyclosporine,0,0.5301694273948669
NULOJIX,Fungal infections,Fungal infections were reported,1,0.8963373899459839
NULOJIX,Fungal infections,in Fungal,1,0.7887521982192993
NULOJIX,Fungal infections,NULOJIX compared,0,0.4909307360649109
NULOJIX,Fungal infections,in Fungal infections were reported in,1,0.8672005534172058
NULOJIX,mucocutaneous fungal infections,due to skin mucocutaneous fungal infections Tuberculosis and herpes infections,1,0.8873987197875977
NULOJIX,mucocutaneous fungal infections,NULOJIX compared,0,0.49717360734939575
NULOJIX,mucocutaneous fungal infections,cyclosporine primarily due,0,0.5541068911552429
NULOJIX,mucocutaneous fungal infections,of,0,0.4715806841850281
NULOJIX,mucocutaneous fungal infections,reported more frequently in patients receiving,0,0.53555828332901
NULOJIX,mucocutaneous fungal infections,to skin and,0,0.5891892313957214
NULOJIX,herpes infections,fungal infections Tuberculosis herpes infections,1,0.8225148916244507
NULOJIX,herpes infections,receiving cyclosporine primarily,0,0.5539790391921997
NULOJIX,tuberculosis,but one NULOJIX patient lived in countries with a high prevalence,0,0.5152865648269653
NULOJIX,tuberculosis,the patients who,0,0.5277407169342041
NULOJIX,tuberculosis,rted more frequently in patients receiving NULOJIX than cyclosporine Of the,0,0.49534136056900024
NULOJIX,tuberculosis,than,0,0.5471099019050598
NULOJIX,tuberculosis,the patients who tuberculosis through years all,1,0.7507534027099609
NULOJIX,tuberculosis,than cyclosporine Of,0,0.5308999419212341
NULOJIX,tuberculosis,tuberculosis through years,1,0.8136525750160217
NULOJIX,Infections,Select Infections with,0,0.8158323764801025
NULOJIX,Infections,Infections and,1,0.91960608959198
NULOJIX,Infections,Three Years of,0,0.5318543314933777
NULOJIX,Infections,a high prevalence of tuberculosis see Warnings and,0,0.5830439925193787
NULOJIX,Infections,Infections with Identified Etiology by Treatment,1,0.7603555917739868
NULOJIX,Infections,Infections with Identified Etiology,1,0.7711759805679321
NULOJIX,Infections,Infections with,1,0.8962360620498657
NULOJIX,Infections,following One and Three Years of,0,0.5379211902618408
NULOJIX,Infections,and Three Years of Treatment,0,0.5539284944534302
NULOJIX,Infections,Overall Infections and Infections with Identified Etiology,1,0.793926477432251
NULOJIX,Infections,Table Overall Infections,0,0.7850214838981628
NULOJIX,Infections,Table Overall Infections and Infections with Identified Etiology,1,0.7543481588363647
NULOJIX,infections,reactions the,0,0.5068968534469604
NULOJIX,infectious adverse reactions,fungal and other organisms infectious adverse,1,0.806881844997406
NULOJIX,death,in,0,0.5595656633377075
NULOJIX,death,may be lifethreatening,0,0.5847527384757996
NULOJIX,death,death or hospitalization or prolongation of,1,0.7017496824264526
NULOJIX,death,or result in,0,0.5978600978851318
NULOJIX,Infections,Infections not meeting,1,0.7555453777313232
NULOJIX,Infections,are,0,0.540595531463623
NULOJIX,Infections,are considered nonserious BK virusassociated nephropathy was,0,0.5731583833694458
NULOJIX,Infections,meeting these criteria are considered nonserious BK virusassociated nephropathy was re,0,0.5759538412094116
NULOJIX,Infections,of,0,0.5444138050079346
NULOJIX,Infections,Infections not meeting these criteria are,1,0.7530509233474731
NULOJIX,BK virus-associated nephropathy,reported in NULOJIX patients of which resulted in,0,0.5338740348815918
NULOJIX,BK virus-associated nephropathy,BK virus-associated nephropathy was reported,1,0.9746719598770142
NULOJIX,BK virus-associated nephropathy,virus-associated nephropathy was reported in NULOJIX,1,0.7873166799545288
NULOJIX,BK virus-associated nephropathy,virus-associated nephropathy,1,0.8768339157104492
NULOJIX,BK virus-associated nephropathy,existing,0,0.4833480715751648
NULOJIX,herpes infections,discontinuation All infections,0,0.6299677491188049
NULOJIX,herpes infections,treatment discontinuation All infections,0,0.622333824634552
NULOJIX,herpes infections,in graft,0,0.48572075366973877
NULOJIX,herpes infections,nonserious and led to treatment discontinuation,0,0.5170058012008667
NULOJIX,herpes infections,herpes infections were,1,0.9249553680419922
NULOJIX,herpes infections,Year herpes infections,1,0.8824969530105591
NULOJIX,herpes infections,graft loss by Year herpes infections,1,0.7681154012680054
NULOJIX,herpes infections,and led to treatment discontinuation All,0,0.5016874074935913
NULOJIX,herpes infections,discontinuation,0,0.4761927127838135
NULOJIX,herpes infections,loss by Year herpes infections,1,0.8153411149978638
NULOJIX,herpes infections,nonserious,0,0.5111624598503113
NULOJIX,herpes infections,cyclosporine,0,0.5407453179359436
NULOJIX,cryptococcal meningitis,cryptococcal meningitis,1,0.9999999403953552
NULOJIX,cryptococcal meningitis,Infections Reported in the CNS Following three,0,0.6667919158935547
NULOJIX,cryptococcal meningitis,Studies cryptococcal meningitis,1,0.8998852968215942
NULOJIX,cryptococcal meningitis,cryptococcal meningitis was reported in,1,0.9228091239929199
NULOJIX,cryptococcal meningitis,cryptococcal,1,0.8645199537277222
NULOJIX,CNS infections,CNS infections including,1,0.9606797695159912
NULOJIX,CNS infections,Studies and were reported to have developed,0,0.5341172218322754
NULOJIX,CNS infections,case of Chagas encephalitis with,0,0.6371341347694397
NULOJIX,CNS infections,with cryptococcal,0,0.630616307258606
NULOJIX,CNS infections,were reported to have CNS infections including cases of cryptococcal,1,0.8339072465896606
NULOJIX,CNS infections,to have CNS infections,1,0.9230340719223022
NULOJIX,CNS infections,to have CNS infections including cases of,1,0.9078013896942139
NULOJIX,CNS infections,CNS infections including cases,1,0.9255351424217224
NULOJIX,cryptococcal meningitis,cryptococcal meningitis one case of Chagas encephalitis,1,0.8771475553512573
NULOJIX,cryptococcal meningitis,infections including cases cryptococcal meningitis,1,0.8790073394775391
NULOJIX,cryptococcal meningitis,one case of Chagas encephalitis,0,0.6399572491645813
NULOJIX,cryptococcal meningitis,cases cryptococcal meningitis,1,0.9317262172698975
NULOJIX,cryptococcal meningitis,encephalitis with cryptococcal meningitis one case of,0,0.8464000821113586
NULOJIX,cryptococcal meningitis,cryptococcal meningitis one case,1,0.9122231006622314
NULOJIX,Chagas encephalitis,meningitis one case Chagas encephalitis,1,0.8656934499740601
NULOJIX,cryptococcal meningitis,encephalitis cryptococcal meningitis one case of cerebral,1,0.8639909625053406
NULOJIX,cryptococcal meningitis,meningitis one case Chagas encephalitis,1,0.7702502012252808
NULOJIX,cryptococcal meningitis,of Chagas encephalitis cryptococcal meningitis one case of,1,0.8681998252868652
NULOJIX,cryptococcal meningitis,case of,0,0.5182790756225586
NULOJIX,cryptococcal meningitis,one case,0,0.48095864057540894
NULOJIX,cryptococcal meningitis,cases of cryptococcal,0,0.8317177891731262
NULOJIX,cryptococcal meningitis,of Chagas encephalitis cryptococcal meningitis,1,0.8792316913604736
NULOJIX,cryptococcal meningitis,of Chagas encephalitis cryptococcal meningitis one,1,0.8798158168792725
NULOJIX,cerebral aspergillosis,cerebral aspergillosis one case of West,1,0.9217406511306763
NULOJIX,cerebral aspergillosis,cerebral,1,0.7266948819160461
NULOJIX,cerebral aspergillosis,one case of West Nile encephalitis and one case of PML discussed above,0,0.5703949332237244
NULOJIX,cerebral aspergillosis,meningitis one case cerebral aspergillosis,1,0.9290609359741211
NULOJIX,cerebral aspergillosis,cerebral aspergillosis,1,0.9999999403953552
NULOJIX,PML,There were,0,0.4926959276199341
NULOJIX,PML,PML discussed above Infusion Reactions There,1,0.7634683847427368
NULOJIX,PML,above Infusion,0,0.4810326397418976
NULOJIX,anaphylaxis,PML discussed above,0,0.48763734102249146
NULOJIX,anaphylaxis,in,0,0.5257902145385742
NULOJIX,anaphylaxis,case of PML discussed,0,0.4708235263824463
NULOJIX,anaphylaxis,Studies and through three years,0,0.43776243925094604
NULOJIX,anaphylaxis,discussed above Infusion Reactions There were no reports,0,0.5584458112716675
NULOJIX,anaphylaxis,anaphylaxis,1,0.9999998211860657
NULOJIX,anaphylaxis,anaphylaxis or drug hypersensitivity in patients,1,0.8213307857513428
NULOJIX,anaphylaxis,anaphylaxis or,1,0.9278731346130371
NULOJIX,drug hypersensitivity,or,0,0.4366016983985901
NULOJIX,drug hypersensitivity,anaphylaxis drug,1,0.7720509767532349
NULOJIX,drug hypersensitivity,reports,0,0.4608287513256073
NULOJIX,drug hypersensitivity,three years,0,0.41416090726852417
NULOJIX,drug hypersensitivity,drug hypersensitivity,1,0.9999998807907104
NULOJIX,drug hypersensitivity,no reports of anaphylaxis drug hypersensitivity in patients,1,0.7828474044799805
NULOJIX,drug hypersensitivity,Reactions,0,0.6181821227073669
NULOJIX,drug hypersensitivity,drug hypersensitivity in patients treated,1,0.9246058464050293
NULOJIX,drug hypersensitivity,drug hypersensitivity in patients treated with NULOJIX,1,0.8165535926818848
NULOJIX,drug hypersensitivity,drug hypersensitivity in patients treated with,1,0.920014500617981
NULOJIX,Infusion-related reactions,Infusion-related reactions,1,1.000000238418579
NULOJIX,Infusion-related reactions,and through three Infusion-related reactions within,1,0.933968186378479
NULOJIX,Infusion-related reactions,through three Infusion-related reactions within one hour of infusion,1,0.894218921661377
NULOJIX,Infusion-related reactions,through three Infusion-related reactions,1,0.9506000280380249
NULOJIX,Infusion-related reactions,within,0,0.4959290325641632
NULOJIX,Infusion-related reactions,recommended,0,0.46579521894454956
NULOJIX,Infusion-related reactions,infusion were reported in of patients treated with the recommended dose,0,0.7634826898574829
NULOJIX,Infusion-related reactions,Infusion-related reactions within one,1,0.9646562933921814
NULOJIX,hypotension,hypotension and hypertension Proteinuria,1,0.7802422642707825
NULOJIX,hypotension,Year The most frequent reactions,0,0.49503958225250244
NULOJIX,proteinuria,the frequency proteinuria,1,0.8805851340293884
NULOJIX,proteinuria,Year The most frequent reactions,0,0.4966111481189728
NULOJIX,proteinuria,frequency proteinuria on urine dipstick,1,0.8292117118835449
NULOJIX,proteinuria,on urine dipstick in,0,0.6362951993942261
NULOJIX,proteinuria,proteinuria,1,1.000000238418579
NULOJIX,proteinuria,Studies and the frequency proteinuria on urine,1,0.8557155132293701
NULOJIX,proteinuria,ars after transplantation in,0,0.553124189376831
NULOJIX,proteinuria,The clinical,0,0.4911934435367584
NULOJIX,proteinuria,occurrence proteinuria in both,1,0.8857452869415283
NULOJIX,proteinuria,occurrence of,0,0.5160218477249146
NULOJIX,proteinuria,occurrence proteinuria,1,0.8953107595443726
NULOJIX,proteinuria,proteinuria in,1,0.966330349445343
NULOJIX,proteinuria,differences in the occurrence,0,0.49346283078193665
NULOJIX,proteinuria,in the occurrence,0,0.48106303811073303
NULOJIX,proteinuria,proteinuria The clinical,1,0.9021456837654114
NULOJIX,proteinuria,both studies at any,0,0.4566758871078491
NULOJIX,proteinuria,proteinuria The,1,0.9606549739837646
NULOJIX,early proteinuria,early proteinuria is unknown Immunogenicity Antibodies,1,0.8674914836883545
NULOJIX,early proteinuria,this increase early proteinuria,1,0.9405279159545898
NULOJIX,early proteinuria,against,0,0.4948396682739258
NULOJIX,early proteinuria,of this increase early proteinuria,1,0.9391048550605774
NULOJIX,early proteinuria,and no patients experienced,0,0.4201968014240265
NULOJIX,new-onset diabetes after transplantation,Transplantation The incidence new-onset diabetes after transplantation,1,0.963744580745697
NULOJIX,new-onset diabetes after transplantation,diabetes after transplantation NODAT was defined in Studies,1,0.8589009046554565
NULOJIX,NODAT,in,0,0.5512468218803406
NULOJIX,NODAT,NODAT by the end of one,1,0.6905908584594727
NULOJIX,NODAT,NULOJIX,0,0.5486235022544861
NULOJIX,NODAT,year compared to of patients on the cyclosporine control regimen Ho,0,0.4530561864376068
NULOJIX,NODAT,NODAT by the end,1,0.81512850522995
NULOJIX,NODAT,NULOJIX recommended regimen NODAT by the end,1,0.5802158117294312
NULOJIX,NODAT,NODAT by,1,0.9069192409515381
NULOJIX,NODAT,NODAT by the,1,0.8978604078292847
NULOJIX,NODAT,NULOJIX recommended regimen NODAT by the end of,1,0.577904462814331
NULOJIX,NODAT,patients treated with,0,0.4874059557914734
NULOJIX,NODAT,NODAT was,1,0.9694721102714539
NULOJIX,NODAT,NULOJIX recommended regimen and in,0,0.5325272083282471
NULOJIX,NODAT,incidence NODAT was in patients treated with,1,0.5715882778167725
NULOJIX,Hypertension,Hypertension was reported as an,1,0.8423471450805664
NULOJIX,Hypertension,were mmHg lower in NULOJIXtreated patients compared,0,0.6067385673522949
NULOJIX,Hypertension,and,0,0.5626955032348633
NULOJIX,Hypertension,compared to cyclosporinetreated Hypertension,1,0.7397119998931885
NULOJIX,Urinary tract infection,d Urinary,1,0.773436427116394
NULOJIX,Guillain-Barre syndrome,Infestations see Table,0,0.5185832977294922
NULOJIX,Guillain-Barre syndrome,listed below Immune System Guillain-Barre,1,0.8480225801467896
NULOJIX,stomatitis,see Table Gastrointestinal stomatitis including,1,0.8220611214637756
NULOJIX,stomatitis,listed below Immune System Guillain-Barre,1,0.4949968159198761
NULOJIX,stomatitis,Disorders,0,0.5536336302757263
NULOJIX,stomatitis,stomatitis including aphthous,1,0.8615497946739197
NULOJIX,stomatitis,stomatitis including aphthous stomatitis Injury,1,0.8454285264015198
NULOJIX,stomatitis,Complications,0,0.5447828769683838
NULOJIX,stomatitis,stomatitis,1,1.0
NULOJIX,aphthous stomatitis,including,0,0.5023980736732483
NULOJIX,aphthous stomatitis,aphthous stomatitis Injury Poisoning and,1,0.8719643950462341
NULOJIX,aphthous stomatitis,aphthous stomatitis,1,0.9999999403953552
NULOJIX,chronic allograft nephropathy,chronic allograft,1,0.8753440380096436
NULOJIX,chronic allograft nephropathy,Injury Poisoning and Procedural chronic allograft nephropathy complications of transplanted,1,0.8451995253562927
NULOJIX,complications of transplanted kidney,complications of transplanted kidney including wound dehiscence,1,0.8943953514099121
NULOJIX,complications of transplanted kidney,Complications chronic,0,0.6906492710113525
NULOJIX,complications of transplanted kidney,complications of transplanted kidney including wound dehiscence arteriovenous fistula,1,0.8958796262741089
NULOJIX,complications of transplanted kidney,complications of transplanted kidney,1,1.0
NULOJIX,complications of transplanted kidney,complications of,1,0.7607066631317139
NULOJIX,wound dehiscence,complications of transplanted,0,0.5929053425788879
NULOJIX,wound dehiscence,Lymphatic System,0,0.5657756328582764
NULOJIX,arteriovenous fistula thrombosis,allograft nephropathy complications of transplanted kidney including wound,0,0.6041302680969238
NULOJIX,arteriovenous fistula thrombosis,and,0,0.42405202984809875
NULOJIX,arteriovenous fistula thrombosis,arteriovenous fistula thrombosis,1,1.0000001192092896
NULOJIX,neutropenia,renal failure renal artery s,0,0.46856850385665894
NULOJIX,neutropenia,renal impairment including acute renal failure renal artery,0,0.4531607925891876
NULOJIX,neutropenia,Urinary Disorders renal impairment including acute renal failure renal artery s,0,0.46166178584098816
NULOJIX,neutropenia,Blood and Lymphatic System neutropenia Renal and Urinary Disorders,1,0.7519466876983643
NULOJIX,neutropenia,neutropenia Renal and,1,0.8574509024620056
NULOJIX,neutropenia,neutropenia Renal and Urinary,1,0.8373062014579773
NULOJIX,neutropenia,neutropenia Renal and Urinary Disorders renal,1,0.8035470843315125
NULOJIX,neutropenia,neutropenia,1,1.0
NULOJIX,neutropenia,Disorders renal impairment including acute renal failure renal artery,0,0.45269066095352173
NULOJIX,neutropenia,ing wound dehiscence arteriovenous,0,0.5284571051597595
NULOJIX,renal impairment,Urinary,0,0.7273985743522644
NULOJIX,renal artery stenosis,renal renal artery stenosis urinary incontinence hydronephrosis Vascular Disorders,1,0.8508045673370361
NULOJIX,renal artery stenosis,Urinary,0,0.6096697449684143
NULOJIX,renal artery stenosis,renal artery stenosis urinary,1,0.9146178960800171
NULOJIX,renal artery stenosis,including acute renal renal artery stenosis urinary incontinence,1,0.8466638326644897
NULOJIX,urinary incontinence,hydronephrosis Vascular,0,0.6133278608322144
NULOJIX,urinary incontinence,failure renal artery urinary incontinence,1,0.8035104274749756
NULOJIX,urinary incontinence,hydronephrosis,0,0.6692091226577759
NULOJIX,urinary incontinence,hematoma lymphocele Musculoskeletal and,0,0.5481942296028137
NULOJIX,urinary incontinence,urinary incontinence hydronephrosis Vascular,1,0.7621957659721375
NULOJIX,urinary incontinence,renal artery urinary,1,0.6671675443649292
NULOJIX,hydronephrosis,stenosis urinary hydronephrosis Vascular,1,0.8247684240341187
NULOJIX,hydronephrosis,renal artery urinary,1,0.6766983270645142
NULOJIX,hydronephrosis,artery stenosis urinary hydronephrosis Vascular Disorders hematoma lymphocele Musculoskeletal,1,0.7441335916519165
NULOJIX,hydronephrosis,hydronephrosis Vascular Disorders hematoma lymphocele Musculoskeletal,1,0.7696611285209656
NULOJIX,hydronephrosis,Disorders hematoma lymphocele Musculoskeletal,0,0.5152158737182617
NULOJIX,lymphocele,hydronephrosis,0,0.5119553804397583
NULOJIX,lymphocele,lymphocele,1,0.9999998807907104
NULOJIX,lymphocele,incontinence hydronephrosis Vascular Disorders lymphocele Musculoskeletal,1,0.7437285780906677
NULOJIX,lymphocele,and Connective Tissue Disorders musculoskeletal pain Skin and,0,0.503347635269165
NULOJIX,lymphocele,lymphocele Musculoskeletal and Connective Tissue Disorders,1,0.7999364733695984
NULOJIX,musculoskeletal pain,and Connective Tissue musculoskeletal,1,0.7841285467147827
NULOJIX,musculoskeletal pain,and Connective Tissue musculoskeletal pain,1,0.8862470388412476
NULOJIX,musculoskeletal pain,Connective Tissue musculoskeletal pain Skin and Subcutaneous Tissue Disorders,1,0.8095180988311768
NULOJIX,musculoskeletal pain,and Connective Tissue musculoskeletal pain Skin and Subcutaneous,1,0.8404582738876343
NULOJIX,musculoskeletal pain,Connective Tissue,0,0.6316365003585815
NULOJIX,musculoskeletal pain,hyperhidrosis Cardiac Disorders at,0,0.5060034394264221
NULOJIX,musculoskeletal pain,musculoskeletal pain Skin and Subcutaneous,1,0.8729194402694702
NULOJIX,alopecia,alopecia hyperhidrosis Cardiac Disorders atrial,1,0.7253495454788208
NULOJIX,alopecia,hyperhidrosis Cardiac Disorders atrial,0,0.5395941138267517
NULOJIX,alopecia,Skin and Subcutaneous Tissue alopecia hyperhidrosis Cardiac Disorders,1,0.7052813768386841
NULOJIX,hyperhidrosis,Cardiac,0,0.49110913276672363
NULOJIX,hyperhidrosis,Cardiac Disorders atrial fibrillation,0,0.514098048210144
NULOJIX,hyperhidrosis,hyperhidrosis Cardiac,1,0.8690289258956909
NULOJIX,hyperhidrosis,hyperhidrosis,1,0.9999998807907104
NULOJIX,hyperhidrosis,Disorders atrial fibrillation,0,0.524696409702301
NULOJIX,hyperhidrosis,hyperhidrosis Cardiac Disorders,1,0.8467264175415039
NULOJIX,hyperhidrosis,hyperhidrosis Cardiac Disorders atrial fibrillation,1,0.8161011338233948
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,most serious adverse reactions reported wit h NULOJIX are PTLD,1,0.5919414758682251
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,The,0,0.4555985927581787
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, most serious adverse reactions reported wit h,1,0.528785228729248
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,ADVERSE REACTIONS most serious adverse reactions,1,0.5360755920410156
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,REACTIONS most serious adverse reactions reported wit,1,0.5322762727737427
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,predominantly CNS,0,0.5145471096038818
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,h,0,0.4599045515060425
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,most,1,0.463293194770813
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,reactions reported wit h NULOJIX are,1,0.5406324863433838
NULOJIX,MALIGNANCIES,"reactions reported with X are:



 * PTLD predominantly CNS PTLD",1,0.5367303490638733
NULOJIX,MALIGNANCIES,reactions reported wit h NULOJIX are,1,0.5222846865653992
NULOJIX,MALIGNANCIES,reported with X are:,1,0.5189937353134155
NULOJIX,MALIGNANCIES,adverse reactions reported with,0,0.5613771677017212
NULOJIX,MALIGNANCIES,other malignancies see Boxed Warning,0,0.7657763957977295
NULOJIX,MALIGNANCIES,malignancies see Boxed Warning and Warnings and,0,0.7824339866638184
NULOJIX,MALIGNANCIES,CNS PTLD and other malignancies see Boxed Warning,0,0.7205312252044678
NULOJIX,MALIGNANCIES,"reactions reported with X are:



 * PTLD predominantly CNS PTLD and",1,0.5398712158203125
NULOJIX,INFECTIONS,ominantly  CNS PTLD,1,0.5574147701263428
NULOJIX,INFECTIONS,ominantly  CNS,1,0.5760425925254822
NULOJIX,INFECTIONS,ominantly  CNS PTLD and,1,0.5587823987007141
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,CNS PTLD  other malignancies [see   Boxed Warning   a,1,0.6128997802734375
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,ominantly  CNS PTLD,1,0.5672814846038818
NULOJIX,INFECTIONS,", 5.3) Serious infections including",1,0.7774794697761536
NULOJIX,INFECTIONS,Boxed Warning and,0,0.5540541410446167
NULOJIX,INFECTIONS,polyoma virus nephropathy see,0,0.5564529299736023
NULOJIX,INFECTIONS,and Warnings and Precautions,0,0.6065384745597839
NULOJIX,INFECTIONS,"  ,  5.3)  Serious infections",1,0.7715113759040833
NULOJIX,INFECTIONS,"Warning and Warnings and ,",1,0.5905930995941162
NULOJIX,INFECTIONS,"and ,",1,0.5187821388244629
NULOJIX,INFECTIONS,Serious infections including JC virusassociated PML and polyoma virus nephropathy,0,0.6606217622756958
NULOJIX,post-transplant lymphoproliferative disorder,ding JC virus-associated PML and polyoma,1,0.6539621949195862
NULOJIX,post-transplant lymphoproliferative disorder,polyoma vir us nephropathy see Warnings and,1,0.5721698999404907
NULOJIX,post-transplant lymphoproliferative disorder,Warning and Warnings and Precautions Serious infections inclu,0,0.5146646499633789
NULOJIX,post-transplant lymphoproliferative disorder,and Precautions EXCERPT,0,0.47387605905532837
NULOJIX,post-transplant lymphoproliferative disorder,infections ding JC virus-associated,1,0.605864405632019
NULOJIX,post-transplant lymphoproliferative disorder,PML and polyoma vir us nephropathy see,1,0.6298703551292419
NULOJIX,post-transplant lymphoproliferative disorder,Serious infections ding JC virus-associated PML and polyoma vir us nephropathy see,1,0.6494176387786865
NULOJIX,post-transplant lymphoproliferative disorder,Warnings and Precautions Serious,0,0.4949149787425995
NULOJIX,PTLD, nep hropathy see Warnings and Precautions,1,0.5117181539535522
NULOJIX,PTLD,see Warnings and Precautions EXCERPT Most,0,0.5286127328872681
NULOJIX,PTLD,hropathy see Warnings,0,0.5380744934082031
NULOJIX,PTLD, nep hropathy see Warnings,1,0.5230803489685059
NULOJIX,PTLD, nep hropathy see Warnings and,1,0.529463529586792
NULOJIX,PTLD, nep hropathy see,1,0.5281425714492798
NULOJIX,PTLD, nep hropathy,1,0.50904780626297
NULOJIX,Increased susceptibility to infection,a total of patients t,0,0.5596804618835449
NULOJIX,Increased susceptibility to infection,Administration in a total  patients compared to a cyclosporine  control,1,0.5762425661087036
NULOJIX,Increased susceptibility to infection,total patients compared to a cyclosporine,1,0.5460571646690369
NULOJIX,Increased susceptibility to infection,a total  patients compared to a cyclosporine  control regimen in a,1,0.5699620842933655
NULOJIX,Increased susceptibility to infection,frequency see Dosage,0,0.5331107378005981
NULOJIX,Increased susceptibility to infection,in a total patients,1,0.5596548318862915
NULOJIX,malignancies,in a total patients. T,1,0.5833579301834106
NULOJIX,malignancies,patients. T hese two trials also,1,0.6179208755493164
NULOJIX,malignancies,patients. T,1,0.6143926382064819
NULOJIX,malignancies,patients. T hese two,1,0.6160993576049805
NULOJIX,malignancies,two trials also included,0,0.5798580646514893
NULOJIX,malignancies,regimen in a total patients.,1,0.5671380758285522
NULOJIX,malignancies,regimen in a total patients. T,1,0.5627527236938477
NULOJIX,malignancies,in a total patients.,1,0.5831565856933594
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,"and corticosteroids ts were treated and followed for 3 years.


 CNS PTLD PML and",1,0.6131894588470459
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,in a total patients.,1,0.5129714012145996
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,mycophenolate mofetil and,0,0.6122056245803833
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,"ts were treated and followed for 3 years.


 CNS PTLD PML",1,0.6240342259407043
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,All patients also,0,0.5026132464408875
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,PTLD PML and other CNS infections were more frequently observed in association,0,0.6320867538452148
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,All,0,0.48794662952423096
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,followed for 3 years. CNS,1,0.5204759240150452
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,and corticosteroids ts were treated and followed for,1,0.5468146204948425
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,ts were treated and followed for 3 years.,1,0.5621019601821899
NULOJIX,MALIGNANCIES,"LD, PML, and other CNS",1,0.6203304529190063
NULOJIX,MALIGNANCIES,"LD, PML, and other",1,0.6526986360549927
NULOJIX,MALIGNANCIES,frequently observed in association with a,0,0.5531060695648193
NULOJIX,MALIGNANCIES,"LD, PML, and other CNS infections were",1,0.6120531558990479
NULOJIX,MALIGNANCIES,"years CNS LD, PML, and",1,0.6144511699676514
NULOJIX,MALIGNANCIES,"CNS LD, PML, and other CNS",1,0.6158136129379272
NULOJIX,MALIGNANCIES,were more frequently observed in association with a NULOJIX,0,0.5677032470703125
NULOJIX,MALIGNANCIES,in association,0,0.5538784265518188
NULOJIX,INFECTIONS,ections we re more frequently,1,0.557743489742279
NULOJIX,INFECTIONS,PML and other CNS ections we re more frequently,1,0.5837832689285278
NULOJIX,INFECTIONS,PML and other CNS ections we re more frequently observed,1,0.579448938369751
NULOJIX,INFECTIONS,NULOJIX regimen of higher cumulative dose and,0,0.5272806882858276
NULOJIX,post-transplant lymphoproliferative disorder,to the recommended regimen; t,1,0.513390839099884
NULOJIX,PTLD,more,0,0.5224711894989014
NULOJIX,PTLD,refo,1,0.5065858364105225
NULOJIX,PTLD,NULOJIX is,0,0.4975644052028656
NULOJIX,PTLD,the recommended regimen refo re,1,0.5211541652679443
NULOJIX,PTLD,dosing compared,0,0.5301929712295532
NULOJIX,PTLD,refo re,1,0.5303714871406555
NULOJIX,Increased susceptibility to infection,from the d States and 75% from other countries Because clinical trials are conducted,1,0.5112316608428955
NULOJIX,Increased susceptibility to infection,refo re,1,0.4614689350128174
NULOJIX,Increased susceptibility to infection,conducted under widely varying conditions the adverse,0,0.6208235025405884
NULOJIX,Increased susceptibility to infection,d States and 75% from other countries Because clinical,1,0.5427539348602295
NULOJIX,malignancies,trials are,0,0.5740792751312256
NULOJIX,malignancies,conducted u nder,1,0.5455629229545593
NULOJIX,malignancies,nder widely varying conditions the adverse reaction rates observed cannot be directly,0,0.5439829230308533
NULOJIX,malignancies,trials conducted,1,0.5952401161193848
NULOJIX,malignancies,Because clinical trials conducted u,1,0.610090970993042
NULOJIX,malignancies,directly,0,0.5362690687179565
NULOJIX,Post-Transplant Lymphoproliferative Disorder,with NULOJIX are: * P TLD predominantly,1,0.5225347280502319
NULOJIX,PTLD,"with NULOJIX are D, p",1,0.5728493928909302
NULOJIX,PTLD,with NULOJIX are: * P TLD predominantly,1,0.6630017757415771
NULOJIX,PTLD,"with NULOJIX are D, p redominantly",1,0.5878021717071533
NULOJIX,PTLD,"NULOJIX are D, p",1,0.5635631680488586
NULOJIX,PTLD,"D, p",1,0.6192286014556885
NULOJIX,malignancies, nephropathy,1,0.6059441566467285
NULOJIX,malignancies,polyoma,0,0.659416913986206
NULOJIX,malignancies,including JC virusassociated PML and polyoma virus,0,0.6386929750442505
NULOJIX,malignancies, nephropathy see Warnings and Precautions,1,0.5484534502029419
NULOJIX,malignancies,polyoma virus,0,0.6113306283950806
NULOJIX,malignancies,and Precautions EXCERPT,0,0.5230849981307983
NULOJIX,malignancies, nephropathy see,1,0.5805138349533081
NULOJIX,malignancies,and,0,0.5575416088104248
NULOJIX,Progressive Multifocal Leukoencephalopathy,"are anemia diarrhea  tract infection, peripheral edema, consti pation hypertension pyrexia graft dysfunction",1,0.5569571256637573
NULOJIX,Progressive Multifocal Leukoencephalopathy,and,0,0.46081656217575073
NULOJIX,Progressive Multifocal Leukoencephalopathy,"edema, consti pation hypertension pyrexia graft",1,0.5316364765167236
NULOJIX,Progressive Multifocal Leukoencephalopathy,"tract infection, peripheral",1,0.5436211824417114
NULOJIX,Progressive Multifocal Leukoencephalopathy," tract infection, peripheral edema, consti",1,0.5449665784835815
NULOJIX,Progressive Multifocal Leukoencephalopathy,cough nausea vomiting headache hypokalemia,0,0.5370093584060669
NULOJIX,Progressive Multifocal Leukoencephalopathy,anemia diarrhea,0,0.5007341504096985
NULOJIX,Progressive Multifocal Leukoencephalopathy,"anemia diarrhea tract infection, peripheral edema, consti",1,0.5480320453643799
NULOJIX,Progressive Multifocal Leukoencephalopathy,"edema, consti",1,0.5316598415374756
NULOJIX,Progressive Multifocal Leukoencephalopathy,"infection, peripheral edema, consti pation hypertension pyrexia graft dysfunction",1,0.5577163696289062
NULOJIX,PML,nausea vomiting headache hypokalemia,0,0.5186871290206909
NULOJIX,PML,tio n hypertension pyrexia graft,1,0.5350185632705688
NULOJIX,PML,tio n hypertension pyrexia graft dysfunction,1,0.5402917861938477
NULOJIX,PML,diarrhea urinary tract infection,0,0.43831467628479004
NULOJIX,PML,edema constipa,0,0.45535001158714294
NULOJIX,PML,treatment are anemia diarrhea urinary tract infection peripheral edema,0,0.49054357409477234
NULOJIX,PML,edema tio n,1,0.4691319167613983
NULOJIX,PML,infection peripheral edema tio n hypertension pyrexia graft,1,0.5299583673477173
NULOJIX,PML,tio n hypertension,1,0.45513826608657837
NULOJIX,infections,Experience The data described belo,0,0.5392645597457886
NULOJIX,infections,wwwfdagovmedwatch Clinical Studies Experience The data described belo,0,0.5565354824066162
NULOJIX,infections,-FDA-1088 ,1,0.49416452646255493
NULOJIX,infections,Squibb at,0,0.4878097474575043
NULOJIX,infections,-FDA-1088  or,1,0.476127952337265
NULOJIX,infections,Clinical Studies,0,0.5720214247703552
NULOJIX,infections,at or FDA at,0,0.5203942060470581
NULOJIX,infections,-FDA-1088  or wwwfdagovmedwatch,1,0.49187105894088745
NULOJIX,protozoal infections,cal Studies Experien,1,0.44306856393814087
NULOJIX,protozoal infections,at or FDA at,0,0.5076789259910583
NULOJIX,protozoal infections,wwwfdagovmedwatch cal,1,0.48099562525749207
NULOJIX,protozoal infections,wwwfdagovmedwatch cal Studies Experien,1,0.4994233548641205
NULOJIX,protozoal infections,FDA at FDA or wwwfdagovmedwatch Clini,0,0.4635626971721649
NULOJIX,protozoal infections,FDA at,0,0.49394938349723816
NULOJIX,protozoal infections,Studies Experien ce The data described,1,0.5200098156929016
NULOJIX,opportunistic infections,trials,0,0.5329614281654358
NULOJIX,opportunistic infections,ta described below prima rily derive from two randomized,1,0.5397962927818298
NULOJIX,opportunistic infections,trials of NULOJIX in,0,0.489063560962677
NULOJIX,opportunistic infections,below prima rily,1,0.48990148305892944
NULOJIX,opportunistic infections,described below prima,1,0.4927144944667816
NULOJIX,opportunistic infections,Experience The ta described below,1,0.5131645202636719
NULOJIX,opportunistic infections,Clinical Studies Experience The ta described below prima rily,1,0.5570924282073975
NULOJIX,tuberculosis,The data described below derive from,1,0.4938369691371918
NULOJIX,tuberculosis,below derive from ,1,0.5127117037773132
NULOJIX,tuberculosis,derive from two randomized activecontrolled threeyear trials,1,0.5288267135620117
NULOJIX,tuberculosis,below derive,1,0.5032627582550049
NULOJIX,tuberculosis,Experience The,0,0.507071852684021
NULOJIX,tuberculosis,data described below derive from,1,0.4957870841026306
NULOJIX,infections,in,0,0.5424151420593262
NULOJIX,infections,"derive from two domized, a ctivecontrolled threeyear trials",1,0.5430970191955566
NULOJIX,infections,de novo kidney transplant patients In,0,0.5307345986366272
NULOJIX,infections,trials of NULOJIX in de novo kidney transplant patients In Study,0,0.5291568040847778
NULOJIX,infections,Experience,0,0.5485423803329468
NULOJIX,infections,"domized, a",1,0.49908530712127686
NULOJIX,infections,derive from two ran,0,0.49792152643203735
NULOJIX,infections,data,0,0.5814281702041626
NULOJIX,infections,kidney transplant patients In Study,0,0.5119225382804871
NULOJIX,fatal,contr,1,0.5387874245643616
NULOJIX,fatal,contr olled threeyear trials of NULOJIX,1,0.46482282876968384
NULOJIX,fatal,derive from two randomized contr,1,0.473948210477829
NULOJIX,Polyoma virus-associated nephropathy,Experience The data described below primarily derive,0,0.4513055682182312
NULOJIX,Polyoma virus-associated nephropathy,below primarily derive from,0,0.44625014066696167
NULOJIX,Polyoma virus-associated nephropathy,kidney transplant patients In Study and Study NULOJIX was studied at the recommended,0,0.5819610357284546
NULOJIX,Polyoma virus-associated nephropathy,from two randomized led three-year,1,0.45610255002975464
NULOJIX,kidney graft loss,activecontrolled threeyear trials of NULOJIX in de novo kid,0,0.4972726106643677
NULOJIX,kidney graft loss,de novo ney transplant pa tients In Study and Study,1,0.6736962795257568
NULOJIX,kidney graft loss,threeyear trials of NULOJIX in de,0,0.49026936292648315
NULOJIX,kidney graft loss,novo ney transplant,1,0.6373674273490906
NULOJIX,Graft Loss,ulative,1,0.5197609663009644
NULOJIX,Graft Loss,ulative do se and more frequent dosing,1,0.4607679843902588
NULOJIX,post-transplant lymphoproliferative disorder,and more frequent dosing compared to the r ecommended,1,0.4504304528236389
NULOJIX,PTLD,omme nded regimen therefore administration of,1,0.5404983758926392
NULOJIX,PTLD,higher,0,0.5100549459457397
NULOJIX,PTLD,administration of higher than,0,0.5446093678474426
NULOJIX,PTLD,omme,1,0.49254217743873596
NULOJIX,PTLD,the,0,0.5665540099143982
NULOJIX,PTLD,regimen therefore administration,0,0.5311828851699829
NULOJIX,PTLD,may not reflect,0,0.513748049736023
NULOJIX,PTLD,ed c,1,0.5445770025253296
NULOJIX,PTLD,ed c annot be directly compared to,1,0.5831648111343384
NULOJIX,PTLD,ed c annot,1,0.5528035759925842
NULOJIX,PTLD,use clinical trials are conducted under widely varying conditions the adverse,0,0.49449992179870605
NULOJIX,PTLD,of PTLD in EBV seropositive,0,0.7541571259498596
NULOJIX,PTLD,PTLD in,0,0.9675897359848022
NULOJIX,PTLD,regimen of higher ativ e dose and more,1,0.5367435216903687
NULOJIX,PTLD,ativ e dose and more frequent,1,0.5307382345199585
NULOJIX,PTLD,ativ e,1,0.5370644330978394
NULOJIX,PML,patients treated with cyclosporine developed PTLD without CNS involvement,0,0.5842975378036499
NULOJIX,PML,l c ases of PTLD,1,0.6346797347068787
NULOJIX,PVAN,Amo,0,0.4764244556427002
NULOJIX,PVAN,Subpopulation Amo,0,0.4904661178588867
NULOJIX,PVAN,Subpopulation ng,1,0.47278672456741333
NULOJIX,PVAN,ng t he EBV seropositive,1,0.4917250871658325
NULOJIX,PVAN,Seropositive Subpopulation ng t,1,0.5139230489730835
NULOJIX,PVAN,EBV seropositive,0,0.47981494665145874
NULOJIX,PVAN,ng,1,0.48451337218284607
NULOJIX,deteriorating renal function,CMV seronegative patients deve,0,0.5328422784805298
NULOJIX,deteriorating renal function,serostatus treated with eith er NULOJIX regimen,1,0.5227729082107544
NULOJIX,deteriorating renal function,and,0,0.4512910842895508
NULOJIX,deteriorating renal function,CMV seronegative,0,0.510598361492157
NULOJIX,deteriorating renal function,serostatus treated with eith er NULOJIX regimen in,1,0.5214170217514038
NULOJIX,deteriorating renal function,seropositive patients with known serostatus treated with eith er NULOJIX regimen in Studies,1,0.5089318752288818
NULOJIX,deteriorating renal function,with eith er NULOJIX regimen in Studies,1,0.5310995578765869
NULOJIX,deteriorating renal function,with known serostatus treated with eith er NULOJIX regimen,1,0.5196731686592102
NULOJIX,graft loss,and Stu dy,1,0.4789292514324188
NULOJIX,graft loss,1 and,1,0.4800260066986084
NULOJIX,graft loss,1 and Stu dy in of patients treated,1,0.559104323387146
NULOJIX,graft loss,were reported in  1 and Stu dy,1,0.5027637481689453
NULOJIX,death,in Study and,0,0.5148959159851074
NULOJIX,death,reported in Study and,0,0.507269024848938
NULOJIX,death,with,0,0.6023277044296265
NULOJIX,death,Study and in,1,0.4987090229988098
NULOJIX,death,in Study and in 3. of patients treated,1,0.4935961365699768
NULOJIX,death,in 3.,1,0.5195499658584595
NULOJIX,death,reported in Study and in 3.,1,0.5071179270744324
NULOJIX,death,in 3. of,1,0.5040996074676514
NULOJIX,PTLD, and of patients treated,1,0.474173903465271
NULOJIX,PTLD, and of patients treated with the,1,0.48817819356918335
NULOJIX,PTLD, and,1,0.5178549289703369
NULOJIX,PTLD,with the recommended NULOJIX  and,1,0.5349354147911072
NULOJIX,fatal,skin cancer was,0,0.4977407157421112
NULOJIX,fatal,patients treated ith,1,0.5152233839035034
NULOJIX,fatal,treated ith t he cyclosporine,1,0.4841548502445221
NULOJIX,fatal,patients,0,0.5091433525085449
NULOJIX,fatal,and of patients treated ith t he cyclosporine control regimen Nonmelanoma,1,0.447582870721817
NULOJIX,fatal,ith t he cyclosporine control,1,0.45263034105300903
NULOJIX,fatal,orine control regimen Nonmelanoma skin,1,0.43864911794662476
NULOJIX,PML,reg,1,0.4787503778934479
NULOJIX,PTLD,patients,0,0.5038400888442993
NULOJIX,PTLD,of patients d,1,0.519481360912323
NULOJIX,PTLD,th the recommended NULOJIX regimen and in of patients treated,0,0.492281973361969
NULOJIX,PTLD,cancer was reported in of patients,0,0.4413696527481079
NULOJIX,fatal,ted with cyclosporine,0,0.4544526934623718
NULOJIX,fatal, trea ted with cyclosporine,1,0.48233309388160706
NULOJIX,fatal, trea ted,1,0.5020133256912231
NULOJIX,fatal,of patients,0,0.5013786554336548
NULOJIX,fatal,in,0,0.5502201914787292
NULOJIX,fatal, trea ted with cyclosporine see Warnings,1,0.5098634362220764
NULOJIX,PML,in of patients treated cyc losporine see,1,0.5420122146606445
NULOJIX,PML, trea ted with cyclosporine see Warnings,1,0.49637138843536377
NULOJIX,PML,treated with,0,0.515267014503479
NULOJIX,PML,Warnings and Precautions Progressive,0,0.5422206521034241
NULOJIX,PML,of patients treated cyc losporine see Warnings and,1,0.530880331993103
NULOJIX,PML,cyc losporine see Warnings and Precautions,1,0.5458590984344482
NULOJIX,PML,patients treated with the recommended NULOJIX regimen and in of patients,0,0.5239354372024536
NULOJIX,PML,in of patients treated cyc losporine,1,0.5339258313179016
NULOJIX,PML,Precautions Progressive Multifocal Leukoencephalopa,0,0.6572726964950562
NULOJIX,PML,cyc losporine,1,0.5518966913223267
NULOJIX,Graft loss,treated with the,0,0.5690233707427979
NULOJIX,Graft loss,nt recipie nt was treated with,1,0.5477850437164307
NULOJIX,Graft loss,nt recipie nt,1,0.515343189239502
NULOJIX,Graft loss,kidney nt recipie,1,0.6076278686523438
NULOJIX,Graft loss,trials The kidney nt recipie nt was treated,1,0.623741090297699
NULOJIX,Graft loss,regimen or the control regimen in these trials The kidney transpla,0,0.5951845645904541
GILOTRIF,Diarrhea,Diarrhea,1,0.9999999403953552
GILOTRIF,Diarrhea,Diarrhea see Warnings and Precautions,1,0.8089746236801147
GILOTRIF,Diarrhea,other sections of the Diarrhea see,1,0.804171085357666
GILOTRIF,Diarrhea,llowing adverse reactions are discussed in greater detail in other sections of the labeling,0,0.5695214867591858
GILOTRIF,Exfoliative Skin Disorders,Warnings and Precautions,0,0.5011227130889893
GILOTRIF,Exfoliative Skin Disorders,Bullous Exfoliative Skin Disorders see Warnings and Precautions,1,0.860832929611206
GILOTRIF,Exfoliative Skin Disorders,Precautions Bullous Exfoliative Skin,1,0.8167670369148254
GILOTRIF,Exfoliative Skin Disorders,and Precautions Bullous Exfoliative Skin Disorders see,1,0.8813610076904297
GILOTRIF,Exfoliative Skin Disorders,Precautions Bullous Exfoliative Skin Disorders see Warnings,1,0.8451568484306335
GILOTRIF,Exfoliative Skin Disorders,Skin Disorders see,1,0.803430438041687
GILOTRIF,Exfoliative Skin Disorders,Warnings,0,0.5260626077651978
GILOTRIF,Exfoliative Skin Disorders,Skin Disorders see Warnings and Precautions,1,0.7348580360412598
GILOTRIF,Interstitial Lung Disease,Bullous and Exfoliative Skin Disorders see Warnings and,0,0.5690929889678955
GILOTRIF,Interstitial Lung Disease,Precautions,0,0.49869322776794434
GILOTRIF,Interstitial Lung Disease,Skin Disorders,0,0.6265576481819153
GILOTRIF,Interstitial Lung Disease,Warnings and Precautions,0,0.5073807239532471
GILOTRIF,Interstitial Lung Disease,Precautions Hepatic Toxicity see Warnings and Precautions,0,0.5108151435852051
GILOTRIF,Interstitial Lung Disease,see,0,0.528469443321228
GILOTRIF,Hepatic Toxicity,Hepatic Toxicity,1,0.9999998807907104
GILOTRIF,Hepatic Toxicity,see Warnings and Hepatic Toxicity see Warnings and Precautions,1,0.8381321430206299
GILOTRIF,Hepatic Toxicity,and,0,0.5089246034622192
GILOTRIF,Hepatic Toxicity,Keratitis see,0,0.49929293990135193
GILOTRIF,Hepatic Toxicity,see Warnings and Hepatic Toxicity,1,0.8904967308044434
GILOTRIF,Hepatic Toxicity,and Hepatic,1,0.8169187903404236
GILOTRIF,Hepatic Toxicity,Keratitis see Warnings,0,0.5719817876815796
GILOTRIF,Keratitis,Keratitis see Warnings and Precautions EXCERPT,1,0.8284897804260254
GILOTRIF,Keratitis,Keratitis see Warnings and Precautions,1,0.8386080265045166
GILOTRIF,Keratitis,Keratitis,1,1.0
GILOTRIF,Keratitis,and Keratitis see Warnings and Precautions EXCERPT,1,0.8168520331382751
GILOTRIF,Keratitis,Precautions EXCERPT Most common adverse,0,0.5429667830467224
GILOTRIF,Keratitis,Warnings,0,0.5725084543228149
GILOTRIF,Keratitis,Warnings and Precautions EXCERPT Most common adverse,0,0.5499758124351501
GILOTRIF,Keratitis,Precautions,0,0.5581210851669312
GILOTRIF,Keratitis,and Precautions EXCERPT,0,0.5372086763381958
GILOTRIF,diarrhea,diarrhea rashdermatitis acneiform stomatitis paronychia dry,1,0.7609202861785889
GILOTRIF,diarrhea,decreased appetite nausea,0,0.557249903678894
GILOTRIF,diarrhea,common adverse reactions diarrhea rashdermatitis,1,0.7392274141311646
GILOTRIF,diarrhea,diarrhea rashdermatitis acneiform stomatitis,1,0.7650970220565796
GILOTRIF,diarrhea,diarrhea rashdermatitis,1,0.794660747051239
GILOTRIF,diarrhea,diarrhea rashdermatitis acneiform,1,0.7686198353767395
GILOTRIF,diarrhea,see Warnings and Precautions,0,0.5687434673309326
GILOTRIF,dermatitis acneiform,dermatitis acneiform stomatitis paronychia,1,0.8903828859329224
GILOTRIF,dermatitis acneiform,are diarrhea rash,0,0.6194940805435181
GILOTRIF,dermatitis acneiform,dermatitis acneiform,1,1.0
GILOTRIF,dermatitis acneiform,and Precautions EXCERPT Most common adverse reactions are diarrhea,0,0.555234968662262
GILOTRIF,dermatitis acneiform,nausea,0,0.522034764289856
GILOTRIF,paronychia,report SUSPECTED ADVERSE R,0,0.5043214559555054
GILOTRIF,paronychia,To report SUSPECTED ADVERSE,0,0.48596227169036865
GILOTRIF,paronychia,paronychia dry skin decreased appetite,1,0.7683751583099365
GILOTRIF,paronychia,paronychia dry,1,0.8594112396240234
GILOTRIF,paronychia,report SUSPECTED ADVERSE,0,0.4906374216079712
GILOTRIF,paronychia,paronychia dry skin,1,0.8705558776855469
GILOTRIF,paronychia,acneiform paronychia dry,1,0.8098418712615967
GILOTRIF,paronychia,acneiform,0,0.5409456491470337
GILOTRIF,dry skin,diarrhea rashdermatitis acneiform stomatitis dry skin decreased appetite nausea vomiting pruritus,1,0.72171950340271
GILOTRIF,dry skin,acneiform,0,0.609708845615387
GILOTRIF,dry skin,acneiform stomatitis paronychia,0,0.6216287612915039
GILOTRIF,decreased appetite,pruritus To report SUSPECTED ADVERSE REACTIONS contact,0,0.47799772024154663
GILOTRIF,decreased appetite,stomatitis paronychia dry decreased appetite,1,0.7869933843612671
GILOTRIF,decreased appetite,REACTIONS contact Boehringer I,0,0.4658762216567993
GILOTRIF,decreased appetite,report SUSPECTED ADVERSE REACTIONS contact,0,0.46756047010421753
GILOTRIF,decreased appetite,acneiform stomatitis paronychia dry decreased,1,0.590050995349884
GILOTRIF,decreased appetite,acneiform stomatitis paronychia dry decreased appetite,1,0.7624000310897827
GILOTRIF,decreased appetite,rashdermatitis,0,0.4319615364074707
GILOTRIF,decreased appetite,acneiform stomatitis paronychia dry decreased appetite nausea,1,0.7283660173416138
GILOTRIF,decreased appetite,dry decreased appetite,1,0.9379407167434692
GILOTRIF,nausea,decreased nausea vomiting pruritus,1,0.7524675130844116
GILOTRIF,nausea,rashdermatitis,0,0.5576024055480957
GILOTRIF,nausea,skin decreased,0,0.5272577404975891
GILOTRIF,nausea,vomiting pruritus To report SUSPECTED ADVERSE,0,0.7297414541244507
GILOTRIF,nausea,nausea vomiting pruritus,1,0.8099973797798157
GILOTRIF,nausea,paronychia dry skin decreased nausea vomiting pruritus To,1,0.68428635597229
GILOTRIF,nausea,SUSPECTED,0,0.52186119556427
GILOTRIF,nausea,nausea vomiting pruritus To,1,0.807496964931488
GILOTRIF,nausea,nausea vomiting pruritus To report SUSPECTED,1,0.7520539164543152
GILOTRIF,vomiting,Boehringer Ingelheim Pharmaceu,0,0.5109546184539795
GILOTRIF,vomiting,skin decreased appetite vomiting pruritus,1,0.6919971704483032
GILOTRIF,vomiting,vomiting pruritus To report SUSPECTED,1,0.7580165863037109
GILOTRIF,vomiting,To report SUSPECTED ADVERSE REACTIONS contact,0,0.5700007677078247
GILOTRIF,vomiting,decreased appetite vomiting pruritus To report SUSPECTED,1,0.7252063155174255
GILOTRIF,vomiting,ADVERSE REACTIONS,0,0.6298950910568237
GILOTRIF,vomiting,decreased appetite vomiting pruritus To,1,0.7435511946678162
GILOTRIF,pruritus,pruritus To report,1,0.8884772062301636
GILOTRIF,pruritus,SUSPECTED ADVERSE REACTIONS contact Boehringer Ingelheim Pharmaceuticals,0,0.5818591117858887
GILOTRIF,pruritus,pruritus To report SUSPECTED ADVERSE REACTIONS,1,0.8341944217681885
GILOTRIF,pruritus,acneiform stomatitis paronychia dry,0,0.6714385747909546
GILOTRIF,pruritus,pruritus To,1,0.944543182849884
GILOTRIF,pruritus,pruritus To report SUSPECTED,1,0.8672550916671753
GILOTRIF,pruritus,pruritus,1,0.9999999403953552
GILOTRIF,pruritus,pruritus To report SUSPECTED ADVERSE,1,0.8520089387893677
GILOTRIF,pruritus,acneiform stomatitis paronychia dry skin decreased,0,0.6787008047103882
GILOTRIF,diarrhea,adverse reactions reported in patients treated with,0,0.5201314687728882
GILOTRIF,diarrhea,diarrhea vomiting,1,0.8409132957458496
GILOTRIF,diarrhea,diarrhea vomiting and,1,0.8348865509033203
GILOTRIF,diarrhea,with GILOTRIF diarrhea vomiting and,1,0.757340669631958
GILOTRIF,vomiting,vomiting,1,0.9999999403953552
GILOTRIF,vomiting,treated with GILOTRIF were vomiting and dyspnea fatigue and hypokalemia,1,0.7119373083114624
GILOTRIF,vomiting,hypokalemia each Fatal adverse reactions,0,0.6020219922065735
GILOTRIF,vomiting,vomiting and dyspnea,1,0.8552656173706055
GILOTRIF,vomiting,reactions in GILOTRIFtrea,0,0.5564199686050415
GILOTRIF,vomiting,GILOTRIF were vomiting and dyspnea fatigue,1,0.7769694328308105
GILOTRIF,vomiting,reactions reported,0,0.6137822270393372
GILOTRIF,dyspnea,Fatal adverse,0,0.5735267400741577
GILOTRIF,dyspnea,dyspnea fatigue and hypokalemia each,1,0.7670109272003174
GILOTRIF,fatigue,fatigue and hypokalemia each Fatal,1,0.7579184770584106
GILOTRIF,fatigue,fatigue,1,1.0
GILOTRIF,fatigue,fatigue and hypokalemia,1,0.7916784286499023
GILOTRIF,fatigue,reactions in GILOTRIFtreated patients in,0,0.5661722421646118
GILOTRIF,fatigue,and fatigue,1,0.9284305572509766
GILOTRIF,Fatal,and dyspnea fatigue and,0,0.5261998176574707
GILOTRIF,Fatal,Fatal,1,1.0000001192092896
GILOTRIF,Fatal,Fatal adverse reactions in,1,0.7593940496444702
GILOTRIF,Fatal,pulmonary,0,0.5610833764076233
GILOTRIF,Fatal,dyspnea fatigue,0,0.5134900808334351
GILOTRIF,Fatal,dyspnea fatigue and hypokalemia Fatal adverse,1,0.6649019718170166
GILOTRIF,Fatal,each,0,0.5487604737281799
GILOTRIF,Fatal,Fatal adverse,1,0.8618949055671692
GILOTRIF,ILD-like adverse reactions,pulmonary ILD-like adverse reactions,1,0.9346637725830078
GILOTRIF,ILD-like adverse reactions,adverse reactions sepsis and pneumonia Dose,1,0.6813548803329468
GILOTRIF,ILD-like adverse reactions,to adverse reactions were re,0,0.7923662662506104
GILOTRIF,ILD-like adverse reactions,ILD-like adverse reactions sepsis and pneumonia Dose,1,0.8759405612945557
GILOTRIF,ILD-like adverse reactions,pulmonary ILD-like,1,0.8006685972213745
GILOTRIF,ILD-like adverse reactions,Dose reductions due to,0,0.5593733787536621
GILOTRIF,ILD-like adverse reactions,in Study included pulmonary ILD-like,1,0.7712005376815796
GILOTRIF,ILD-like adverse reactions,ILD-like adverse reactions sepsis and pneumonia,1,0.9042149782180786
GILOTRIF,sepsis,toxicityILDlike adverse sepsis and pneumonia Dose reductions due,1,0.7189329862594604
GILOTRIF,sepsis,in Study included pulmonary ILD-like,1,0.597103476524353
GILOTRIF,sepsis,to adverse reactions,0,0.5901065468788147
GILOTRIF,sepsis,reductions due to adverse,0,0.4822824001312256
GILOTRIF,sepsis,adverse sepsis and pneumonia,1,0.791332483291626
GILOTRIF,sepsis,GILOTRIFtreated patients in Study included,0,0.5599657297134399
GILOTRIF,sepsis,GILOTRIFtreated patients in,0,0.5807870626449585
GILOTRIF,sepsis,sepsis and pneumonia,1,0.8518863916397095
GILOTRIF,pneumonia,reactions sepsis pneumonia Dose,1,0.7715928554534912
GILOTRIF,pneumonia,sepsis and pneumonia,1,0.8171623945236206
GILOTRIF,pneumonia,and,0,0.5450941324234009
GILOTRIF,pneumonia,pneumonia Dose reductions,1,0.7847819924354553
GILOTRIF,pneumonia,pneumonia Dose,1,0.8392150402069092
GILOTRIF,pneumonia,pneumonia,1,0.9999997615814209
GILOTRIF,diarrhea,were,0,0.5706315040588379
GILOTRIF,diarrhea,diarrhea rashacne paronychia and stomatitis,1,0.7354868650436401
GILOTRIF,diarrhea,the,0,0.5906126499176025
GILOTRIF,diarrhea,diarrhea,1,0.9999999403953552
GILOTRIF,diarrhea,diarrhea rashacne paronychia and,1,0.762617826461792
GILOTRIF,rash,rash acne paronychia and stomatitis,1,0.7529321908950806
GILOTRIF,rash,GILOTRIF,0,0.5478593111038208
GILOTRIF,rash,with GILOTRIF were rash,1,0.6810681819915771
GILOTRIF,rash,rash acne paronychia and,1,0.7894864082336426
GILOTRIF,rash,rash acne paronychia and stomatitis Discontinuation,1,0.7039061784744263
GILOTRIF,rash,acne paronychia and stomatitis Discontinuation of therapy in,0,0.5929198265075684
GILOTRIF,rash,rash,1,1.0000001192092896
GILOTRIF,rash,and stomatitis Discontinuation of therapy,0,0.543144941329956
GILOTRIF,acne,acne paronychia and stomatitis Discontinuation,1,0.7199980616569519
GILOTRIF,acne,acne paronychia and,1,0.8013745546340942
GILOTRIF,acne,treated with GILOTRIF,0,0.559325635433197
GILOTRIF,acne,stomatitis Discontinuation of therapy in,0,0.5674717426300049
GILOTRIF,paronychia,of,0,0.5244898796081543
GILOTRIF,paronychia,diarrhea paronychia and stomatitis Discontinuation of therapy,1,0.74735426902771
GILOTRIF,paronychia,Discontinuation of therapy in GILOTRIFtreated,0,0.5378797650337219
GILOTRIF,paronychia,GILOTRIFtreated patients,0,0.5260955095291138
GILOTRIF,paronychia,paronychia and stomatitis,1,0.8479001522064209
GILOTRIF,paronychia,reduction in the patients treated with,0,0.48352497816085815
GILOTRIF,paronychia,stomatitis Discontinuation of therapy in,0,0.5325212478637695
GILOTRIF,paronychia,Discontinuation,0,0.501921534538269
GILOTRIF,paronychia,patients,0,0.5073555707931519
GILOTRIF,stomatitis,stomatitis,1,0.9999998807907104
GILOTRIF,stomatitis,of therapy in GILOTRIFtreated patients for adverse reactions was,0,0.5492355823516846
GILOTRIF,stomatitis,for adverse,0,0.5287989974021912
GILOTRIF,stomatitis,treated,0,0.5692291855812073
GILOTRIF,stomatitis,stomatitis Discontinuation of,1,0.8202112317085266
GILOTRIF,stomatitis,for,0,0.5133334398269653
GILOTRIF,stomatitis,stomatitis Discontinuation,1,0.8225999474525452
GILOTRIF,stomatitis,patients treated with GILOTRIF were diarrhea,0,0.5241701006889343
GILOTRIF,stomatitis,were diarrhea,0,0.5103689432144165
GILOTRIF,diarrhea,excluded patients with a,0,0.4914763569831848
GILOTRIF,diarrhea,diarrhea ILD,1,0.807790994644165
GILOTRIF,diarrhea,diarrhea ILD and paronychia,1,0.7458493709564209
GILOTRIF,diarrhea,in GILOTRIFtreated patients diarrhea ILD and paronychia Clinical,1,0.7159608602523804
GILOTRIF,ILD,that led to discontinuation in GILOTRIFtreated patients were diarrhea,0,0.5474526882171631
GILOTRIF,ILD,ILD and paronychia Clinical trials of,1,0.7396712303161621
GILOTRIF,ILD,Clinical,0,0.5598978996276855
GILOTRIF,ILD,an abnormal,0,0.5590214729309082
GILOTRIF,ILD,reactions that led to discontinuation in GILOTRIFtreated patients,0,0.560215413570404
GILOTRIF,paronychia,paronychia Clinical trials,1,0.8568992614746094
GILOTRIF,paronychia,ILD and,0,0.492279052734375
GILOTRIF,ventricular dysfunction,More GILOTRIFtreated patients n ventricular,1,0.766427755355835
GILOTRIF,diastolic dysfunction,defined diastolic,1,0.8329137563705444
GILOTRIF,diastolic dysfunction,or ventricular dilation all Grade compared,0,0.6503678560256958
GILOTRIF,diastolic dysfunction,Grade compared to chemotherapytre,0,0.4504549205303192
GILOTRIF,diastolic dysfunction,as,0,0.5372241735458374
GILOTRIF,diastolic dysfunction,dilation all,0,0.5872681736946106
GILOTRIF,diastolic dysfunction,diastolic dysfunction left ventricular dysfunction or ventricular,1,0.8960587978363037
GILOTRIF,diastolic dysfunction,diastolic dysfunction,1,1.0
GILOTRIF,left ventricular dysfunction,left,1,0.6140724420547485
GILOTRIF,left ventricular dysfunction,dysfunction defined as diastolic left,1,0.8472632765769958
GILOTRIF,stomatitis,stomatitis one patient on GILOTRIF were,1,0.8087180256843567
GILOTRIF,stomatitis,Patients in Study,0,0.5359101891517639
GILOTRIF,stomatitis,table stomatitis one patient,1,0.812267005443573
GILOTRIF,stomatitis,stomatitis one,1,0.8721786737442017
GILOTRIF,stomatitis,stomatitis one patient,1,0.8845468759536743
GILOTRIF,stomatitis,stomatitis one patient on,1,0.8889164924621582
GILOTRIF,stomatitis,this table stomatitis one patient,1,0.8428425788879395
GILOTRIF,stomatitis,in severity Includes stomatitis aphthous,0,0.7829602360725403
GILOTRIF,aphthous stomatitis,aphthous stomatitis mucosal,1,0.912396252155304
GILOTRIF,mucosal inflammation,on GILOTRIF were,0,0.5024281740188599
GILOTRIF,mucosal inflammation,mucosal inflammation mouth ulceration oral mucosa erosion,1,0.842178225517273
GILOTRIF,mucosal inflammation,stomatitis,0,0.6809722185134888
GILOTRIF,mucosal inflammation,Grade in severity Includes stomatitis aphthous,0,0.6514599919319153
GILOTRIF,mucosal inflammation,mucosal inflammation,1,1.0
GILOTRIF,mucosal inflammation,Includes stomatitis aphthous mucosal inflammation,1,0.8067018985748291
GILOTRIF,mucosal inflammation,stomatitis aphthous mucosal inflammation mouth ulceration oral mucosa erosion,1,0.7845371961593628
GILOTRIF,mucosal inflammation,on GILOTRIF were Grade in severity,0,0.5588499307632446
GILOTRIF,mouth ulceration,stomatitis mucosal mouth,1,0.8036664128303528
GILOTRIF,mouth ulceration,mucosal inflammation,0,0.7193599939346313
GILOTRIF,oral mucosa erosion,preferred,0,0.48532676696777344
GILOTRIF,oral mucosa erosion,mucosa erosion,1,0.9459257125854492
GILOTRIF,mucosal erosion,mucosal erosion mucosal ulceration,1,0.9173685312271118
GILOTRIF,mucosal erosion,oral mucosa erosion,0,0.9394590854644775
GILOTRIF,mucosal erosion,ulceration oral mucosa mucosal erosion mucosal,1,0.9053331613540649
GILOTRIF,mucosal erosion,mucosal erosion mucosal,1,0.9463234543800354
GILOTRIF,mucosal erosion,ulceration oral mucosa mucosal,1,0.8128868341445923
GILOTRIF,mucosal erosion,erosion,0,0.8179161548614502
GILOTRIF,mucosal erosion,oral mucosa mucosal,1,0.8020788431167603
GILOTRIF,mucosal ulceration,Includes group of rash preferred terms acne acne,0,0.5958237648010254
GILOTRIF,mucosal ulceration,oral mucosa erosion mucosal mucosal,1,0.8326729536056519
GILOTRIF,mucosal ulceration,preferred terms acne acne,0,0.5979859828948975
GILOTRIF,mucosal ulceration,mucosal ulceration Includes group of rash preferred,1,0.8736859560012817
GILOTRIF,mucosal ulceration,mucosal ulceration Includes group,1,0.9145221710205078
GILOTRIF,mucosal ulceration,mucosal ulceration Includes group of,1,0.9161206483840942
GILOTRIF,mucosal ulceration,mucosal,1,0.8478127717971802
GILOTRIF,mucosal ulceration,ulceration oral,0,0.8672490119934082
GILOTRIF,rash,ulceration Includes group rash preferred terms acne,1,0.766327440738678
GILOTRIF,rash,ulceration oral,0,0.5918087959289551
GILOTRIF,rash,rash preferred terms acne acne pustular,1,0.8134026527404785
GILOTRIF,rash,preferred terms acne,0,0.6116467118263245
GILOTRIF,acne,pustular dermatitis acneiform Includes paronychia nail,0,0.7214381098747253
GILOTRIF,acne,preferred acne,1,0.8629618883132935
GILOTRIF,acne,preferred acne acne,1,0.8720732927322388
GILOTRIF,acne pustular,acne pustular,1,0.9999997615814209
GILOTRIF,acne pustular,pustular dermatitis acneiform Includes paronychia nail,0,0.8331670761108398
GILOTRIF,acne pustular,nail,0,0.5098339915275574
GILOTRIF,acne pustular,acneiform Includes paronychia nail infection nail,0,0.7179993391036987
GILOTRIF,acne pustular,preferred terms acne pustular,1,0.9308295249938965
GILOTRIF,paronychia,paronychia nail infection nail bed,1,0.8394460678100586
GILOTRIF,nail infection,terms acne acne pustular dermatitis,0,0.530159056186676
GILOTRIF,nail infection,dermatitis acneiform Includes nail infection nail bed infection GILOTRIFn,1,0.7994899153709412
GILOTRIF,nail infection,acneiform Includes nail,1,0.76374351978302
GILOTRIF,nail infection,Includes nail infection nail bed infection,1,0.8867939710617065
GILOTRIF,nail infection,Includes nail infection nail,1,0.9233838319778442
GILOTRIF,nail infection,nail infection nail,1,0.9743127822875977
GILOTRIF,nail infection,group of rash preferred,0,0.5216293334960938
GILOTRIF,nail infection,infection,0,0.7536806464195251
GILOTRIF,nail bed infection,PemetrexedCisplatinn Adverse,0,0.5198562145233154
GILOTRIF,nail bed infection,GILOTRIFn,0,0.5119209289550781
GILOTRIF,Rash,disorders,0,0.5988904237747192
GILOTRIF,Rash,subcutaneous,0,0.6418073177337646
GILOTRIF,Pruritus,atitis Pruritus Dry,1,0.8207104206085205
GILOTRIF,Pruritus,subcutaneous,0,0.6404271721839905
GILOTRIF,Pruritus,Pruritus,1,0.9999999403953552
GILOTRIF,Pruritus,Pruritus Dry skin,1,0.8842805624008179
GILOTRIF,Decreased appetite,and nutrition,0,0.6309770941734314
GILOTRIF,Pyrexia,Pyrexia Eye,1,0.8683208227157593
GILOTRIF,Pyrexia,Pyrexia,1,1.0000001192092896
GILOTRIF,Pyrexia,Pyrexia Eye disorders,1,0.8318321704864502
GILOTRIF,Pyrexia,conditions,0,0.610844612121582
GILOTRIF,Pyrexia,and administration site Pyrexia Eye disorders,1,0.7942811250686646
GILOTRIF,Conjunctivitis,Table,0,0.5108861327171326
GILOTRIF,Conjunctivitis,Conjunctivitis Table Adverse Reactio,1,0.8149586915969849
GILOTRIF,blood potassium decreased,igations SOC Reported in,0,0.4705698788166046
GILOTRIF,blood potassium decreased,class GILOTRIFn PemetrexedCisplatinn,0,0.4868793487548828
GILOTRIF,Hypokalemia,Hypokalemia Aspartate aminotransfe,1,0.8344323635101318
GILOTRIF,Diarrhea,adverse reactions a,0,0.5856152772903442
GILOTRIF,Diarrhea,The following adverse reactions a,0,0.593616783618927
GILOTRIF,Diarrhea,re discu,1,0.5522291660308838
GILOTRIF,Diarrhea,re,1,0.5682826638221741
GILOTRIF,Diarrhea,see Warnings,0,0.5982129573822021
GILOTRIF,dehydration,other sections of the labeling Diarrhea,0,0.6043416261672974
GILOTRIF,dehydration,detail in,1,0.545071005821228
GILOTRIF,dehydration, detail in  other sections of the,1,0.507347583770752
GILOTRIF,renal failure,in,0,0.5239776968955994
GILOTRIF,renal failure,greater detail in sections,1,0.4653815031051636
GILOTRIF,renal failure,and,0,0.5150890350341797
GILOTRIF,Interstitial lung disease,ions Keratitis see Warnings and,0,0.515689492225647
GILOTRIF,Interstitial lung disease,common rse,1,0.4824058711528778
GILOTRIF,Interstitial lung disease,see Warnings and Precautions EXCERPT Most common adve,0,0.5191743969917297
GILOTRIF,Interstitial lung disease,common rse reactions (>=20%),1,0.5232911109924316
GILOTRIF,Interstitial lung disease,Precautions EXCERPT Most common rse,1,0.5029106736183167
GILOTRIF,Interstitial lung disease,Precautions EXCERPT Most common rse reactions (>=20%) are diarrhea,1,0.5054384469985962
GILOTRIF,ILD,iar rhea rashdermatitis acneiform,1,0.5524693727493286
GILOTRIF,ILD,dry skin,0,0.5103098154067993
GILOTRIF,ILD,common adverse reactions are iar rhea rashdermatitis acneiform stomatitis paronychia,1,0.5273318886756897
GILOTRIF,Hepatic toxicity,To report SUSPECTED ADVERSE,0,0.5858089923858643
GILOTRIF,Hepatic toxicity,"TIONS, contact",1,0.42075759172439575
GILOTRIF,Fatal,vomiting pruritus To report SUSPECTED ADVERSE REACTIONS contact,0,0.5398882627487183
GILOTRIF,Fatal,Boe,0,0.4983331561088562
GILOTRIF,Fatal,report SUSPECTED,0,0.4823165237903595
GILOTRIF,Fatal,Pharmaceuticals Inc at or,0,0.47595280408859253
GILOTRIF,Fatal,hring er Ingelheim Pharmaceuticals Inc at,1,0.508730411529541
GILOTRIF,Fatal,hring er Ingelheim Pharmaceuticals Inc,1,0.5088760852813721
GILOTRIF,hepatic impairment,contact,0,0.45868682861328125
GILOTRIF,hepatic impairment,r Ingelheim Pharma,1,0.52253258228302
GILOTRIF,hepatic impairment,SUSPECTED ADVERSE REACTIONS contact r Ingelheim Pharma ceuticals Inc,1,0.5393503308296204
GILOTRIF,hepatic impairment,pruritus To,0,0.5085574388504028
GILOTRIF,hepatic impairment,at,0,0.5516249537467957
GILOTRIF,hepatic impairment,Inc at or TTY or FDA at FDA orwwwfdagovmedwa,0,0.5219093561172485
GILOTRIF,hepatic impairment,ADVERSE REACTIONS contact r Ingelheim,1,0.5449095964431763
GILOTRIF,hepatic impairment,or,0,0.4910210967063904
GILOTRIF,Keratitis,FDA at FDA orwwwfdagovmedwatch Clinical Trials,0,0.5138857364654541
GILOTRIF,Keratitis,reaction rates observed,0,0.5430703163146973
GILOTRIF,Keratitis,reaction,0,0.539310097694397
GILOTRIF,Embryofetal toxicity,and may not reflect the rates observed in,0,0.4290122985839844
GILOTRIF,Embryofetal toxicity,es in the clinical t rials of another drug and,1,0.5571372509002686
GILOTRIF,Embryofetal toxicity,the rates observed in practice The,0,0.4439244866371155
GILOTRIF,Embryofetal toxicity,es in the clinical t rials,1,0.5712563395500183
GILOTRIF,Embryofetal toxicity,compared to es in the clinical t,1,0.5402281284332275
GILOTRIF,Embryofetal toxicity,in the clinical,0,0.5102367401123047
GILOTRIF,Embryofetal toxicity,es in the clinical,1,0.5473167300224304
GILOTRIF,fetal harm,compared to rates in the clinical trials of,0,0.5020568370819092
GILOTRIF,Diarrhea,more 00,1,0.5518133640289307
GILOTRIF,Diarrhea,from more 00 patie,1,0.5508496165275574
GILOTRIF,Diarrhea,the data from more 00 patie,1,0.5669071078300476
GILOTRIF,Diarrhea,is based on the data from,0,0.5178912281990051
GILOTRIF,Diarrhea,more 00 patie,1,0.5401526689529419
GILOTRIF,Diarrhea,data from more 00,1,0.571337103843689
GILOTRIF,Diarrhea,observed in practice,0,0.5092057585716248
GILOTRIF,Diarrhea,00 patie nts,1,0.5507659912109375
GILOTRIF,dehydration,at or above,0,0.4670957922935486
GILOTRIF,dehydration,from more than patients 35 NSCLC pa tients receiving,1,0.4379311501979828
GILOTRIF,dehydration,NSCLC pa tients receiving,1,0.4633810222148895
GILOTRIF,dehydration,at or above the recommended dose Controlled Study,0,0.5407582521438599
GILOTRIF,dehydration,35 NSCLC pa,1,0.4107193350791931
GILOTRIF,renal impairment,Tables and below refl,0,0.522722065448761
GILOTRIF,renal impairment,GILOTRIF monothe,1,0.4807968735694885
GILOTRIF,renal impairment,including NSCLC patients GILOTRIF monothe rapy at,1,0.4762687683105469
GILOTRIF,renal impairment,Tables and,0,0.48250991106033325
GILOTRIF,renal impairment,GILOTRIF monothe rapy at or,1,0.46482181549072266
GILOTRIF,fatal,n patients including NSCLC patients receiving,0,0.4460758566856384
GILOTRIF,fatal,n patients including NSCLC patients receiving GILOTRIF,0,0.5011012554168701
GILOTRIF,fatal,and below reflect,0,0.4849306344985962
GILOTRIF,fatal,ended dose Controlled,1,0.5521281361579895
GILOTRIF,diarrhea,ontrolle d Study The data in,1,0.5711305141448975
GILOTRIF,diarrhea,recommended dose ontrolle d Study The,1,0.576015830039978
GILOTRIF,diarrhea,ontrolle d Study,1,0.5744330286979675
GILOTRIF,diarrhea,ontrolle,1,0.5778235197067261
GILOTRIF,diarrhea,and below,0,0.5658831000328064
GILOTRIF,diarrhea,cluding NSCLC patients receiving GILOTRIF monotherapy at or above the,0,0.4336853623390198
GILOTRIF,diarrhea,C,0,0.5615123510360718
GILOTRIF,diarrhea,ontrolle d Study The,1,0.5684866905212402
GILOTRIF,diarrhea,reflect,0,0.5277163982391357
GILOTRIF,diarrhea,ontrolle d,1,0.5818005800247192
GILOTRIF,diarrhea,above the recommended dose ontrolle d Study The data in,1,0.5615466833114624
GILOTRIF,diarrhea,at or above the recommended dose,0,0.5348193049430847
GILOTRIF,diarrhea,above the recommended dose ontrolle d Study,1,0.565125584602356
GILOTRIF,Renal impairment,a ra ndomized multicenter openlabel trial Study,1,0.5309529900550842
GILOTRIF,Renal impairment,patients,0,0.5507089495658875
GILOTRIF,Renal impairment,enrolled,1,0.5045564770698547
GILOTRIF,Renal impairment,a ra ndomized,1,0.5334479808807373
GILOTRIF,Renal impairment,in a ra,1,0.5784071683883667
GILOTRIF,Renal impairment,enrolled in a ra ndomized multicenter,1,0.5492725372314453
GILOTRIF,Renal impairment,FRTKI naive GILOTRIFtreated patients with,0,0.5955367088317871
GILOTRIF,Renal impairment,naive GILOTRIFtreated patients with EGFR mutationpositive metastatic nonsquamous,0,0.5445155501365662
GILOTRIF,Renal impairment,mutationpositive metastatic nonsquamous enrolled in a,1,0.49290716648101807
GILOTRIF,Renal impairment,daily,0,0.5331925749778748
GILOTRIF,Renal impairment,Study Patients received GILOTRIF mg,0,0.5408487915992737
GILOTRIF,Renal impairment,EGFR mutationpositive metastatic nonsquamous enrolled in,1,0.5211296677589417
GILOTRIF,Renal impairment,ndomized multicenter openlabel trial Study Patients received GILOTRIF mg daily,0,0.530001163482666
GILOTRIF,Renal impairment,nonsquamous NSCLC,0,0.47320589423179626
GILOTRIF,Renal impairment,multicenter openlabel trial Study Patients,0,0.5149075984954834
GILOTRIF,cutaneous reactions,patients in the,0,0.541674792766571
GILOTRIF,cutaneous reactions,A total of of patients on GILOTRIF,1,0.5615999102592468
GILOTRIF,cutaneous reactions,A total of of,1,0.4908369779586792
GILOTRIF,cutaneous reactions,years. A total of of,1,0.43666690587997437
GILOTRIF,cutaneous reactions,were female More than,0,0.4607853889465332
GILOTRIF,cutaneous reactions,the pemetrexedcisplatin arm were younger than,0,0.5550453662872314
GILOTRIF,cutaneous reactions,of patients on GILOTRIF and,0,0.5684242248535156
GILOTRIF,cutaneous reactions,patients,0,0.5571280717849731
GILOTRIF,cutaneous reactions,arm were younger years.,1,0.5430909395217896
GILOTRIF,cutaneous reactions,years. A total,1,0.4510451555252075
GILOTRIF,exfoliating lesions,and,0,0.4970834255218506
GILOTRIF,exfoliating lesions,Asia GILOTRIF,0,0.5164068937301636
GILOTRIF,cutaneous reactions,reactions were reported % of patients treat ed with,1,0.6862497329711914
GILOTRIF,cutaneous reactions,Asia GILOTRIF,0,0.5101763010025024
GILOTRIF,cutaneous reactions,reported % of patients treat ed with GILOTRIF The most,1,0.5221057534217834
GILOTRIF,rash,F. T,1,0.522167444229126
GILOTRIF,rash,F. T he most frequent serious adverse,1,0.5920078754425049
GILOTRIF,rash,treated with F.,1,0.5504038333892822
GILOTRIF,erythema,patients treated with GILOTRIF were diarrhea,0,0.5138749480247498
GILOTRIF,erythema,reported in patients treated,0,0.5439138412475586
GILOTRIF,erythema,most fr equent serious adverse reactions reported,1,0.585532546043396
GILOTRIF,erythema,treated with GILOTRIF most fr,1,0.5747601985931396
GILOTRIF,erythema,reactions were reported,0,0.5353271961212158
GILOTRIF,erythema,reactions,0,0.5554845929145813
GILOTRIF,erythema,most fr equent serious adverse reactions,1,0.6063948273658752
GILOTRIF,erythema,with GILOTRIF  most fr equent,1,0.5185906887054443
GILOTRIF,acneiform rash,with GILOTRIF The most  serious adver se reactions reported in,1,0.565027117729187
GILOTRIF,acneiform rash,most fr equent serious adverse reactions,1,0.6151517629623413
GILOTRIF,acneiform rash,most  serious adver se reactions,1,0.5551277995109558
GILOTRIF,acneiform rash,reactions were reported in of patients treated with GILOTRIF,0,0.5741395950317383
GILOTRIF,acneiform rash,GILOTRIF The most serious,1,0.5353220701217651
GILOTRIF,acneiform rash,serious adver se,1,0.5286455154418945
GILOTRIF,acneiform rash,The most  serious adver se reactions reported,1,0.5461205244064331
GILOTRIF,acneiform rash,most serious,1,0.4804378151893616
GILOTRIF,cutaneous reactions,ed,1,0.4864530563354492
GILOTRIF,cutaneous reactions,reported in patients ed with GILOTRIF we re,1,0.582746684551239
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,"diarrhea vomiting and fatigue,",1,0.5111504793167114
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,and hypokalemia (1.7% each). Fata,1,0.5942704677581787
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,patients in Study included pulmonary toxicityILDlike,0,0.5326964855194092
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,"fatigue, and hypokalemia (1.7% each).",1,0.6098140478134155
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,"fatigue, and hypokalemia (1.7% each). Fata l adverse reactions in GILOTRIFtreated",1,0.6377236843109131
GILOTRIF,ILD,was The most,1,0.4889272451400757
GILOTRIF,ILD,"fatigue, and hypokalemia (1.7% each).",1,0.5131210088729858
GILOTRIF,ILD,was The most frequent adverse reactions,1,0.46256765723228455
GILOTRIF,ILD,patients for adverse was The,1,0.4894893765449524
GILOTRIF,ILD,Discontinuation of therapy in,0,0.5163167119026184
GILOTRIF,ILD,was The most frequent adverse,1,0.5199739336967468
GILOTRIF,ILD,adverse was The most frequent adverse,1,0.5176162719726562
GILOTRIF,lung infiltration,that led to discontinuation in GILOTRIFtreated patients,1,0.4926654100418091
GILOTRIF,lung infiltration,tions that led to discontinuation in GILOTRIFtreated,1,0.46817803382873535
GILOTRIF,pneumonitis,iscontinuat ion in GILOTRIFtreated patients,1,0.5576517581939697
GILOTRIF,pneumonitis,diarrhea,0,0.5284216403961182
GILOTRIF,pneumonitis,in GILOTRIFtreated patients were diarrhea ILD and,0,0.49080902338027954
GILOTRIF,pneumonitis,iscontinuat ion in,1,0.4985421597957611
GILOTRIF,acute respiratory distress syndrome,patients were diarrhea ILD and,1,0.4858004152774811
GILOTRIF,acute respiratory distress syndrome,ILD,0,0.4898105561733246
GILOTRIF,acute respiratory distress syndrome,reactions that led to n in GILOTRIF-treated patients were diarrhea ILD,1,0.4802340269088745
GILOTRIF,acute respiratory distress syndrome,led to discontinuatio,0,0.47767922282218933
GILOTRIF,acute respiratory distress syndrome,n in GILOTRIF-treated patients were diarrhea ILD,1,0.4670972228050232
GILOTRIF,fatal,LVEF ie below the institutional lower limit of,0,0.5106397867202759
GILOTRIF,fatal,icula r ejection,1,0.5363122224807739
GILOTRIF,ILD,ejection  (L VEF ie,1,0.5598008036613464
GILOTRIF,ILD,icula r ejection,1,0.6142699718475342
GILOTRIF,ILD, (L VEF ie below the,1,0.5227435231208801
GILOTRIF,ILD,fraction,0,0.5266916751861572
GILOTRIF,ILD,left ventricular ejection  (L VEF ie below,1,0.523955225944519
GILOTRIF,ILD, (L VEF ie below the institutional,1,0.5337479710578918
GILOTRIF,ILD,of GILOTRIF excluded patients,0,0.5709226131439209
GILOTRIF,ILD,excluded patients with an,0,0.5161198377609253
GILOTRIF,ILD,ejection  (L VEF,1,0.5347022414207458
GILOTRIF,ILD,patients with an abnormal left,0,0.5985925197601318
GILOTRIF,ILD,eek s,1,0.5207809805870056
GILOTRIF,ILD,eek s thereafter,1,0.5258232951164246
GILOTRIF,ILD,eek,1,0.5376174449920654
GILOTRIF,ILD,eek s thereafter in the,1,0.5396810173988342
GILOTRIF,ILD,eek s thereafter in the GILOTRIFtreated,1,0.6002817153930664
GILOTRIF,death,weeks thereafter in the IF-tr eated group and,1,0.5222993493080139
GILOTRIF,death,eek s thereafter in the,1,0.5918624401092529
GILOTRIF,death,group and as needed in the,0,0.5053719878196716
GILOTRIF,death,and as needed in the pemetrexedcisplatin group More GILOTRIFtreated patients,0,0.5070405006408691
GILOTRIF,death,in the IF-tr eated,1,0.585587739944458
GILOTRIF,death,IF-tr eated group and,1,0.5206431746482849
GILOTRIF,death,IF-tr eated group,1,0.519484281539917
GILOTRIF,death,thereafter in the IF-tr eated group and as,1,0.5448813438415527
GILOTRIF,death,pemetrexedcisplatin group More GILOTRIFtreated patients,0,0.4997120201587677
GILOTRIF,liver test abnormalities,chemotherapytreated patients n 1 Adverse Reactions Repo rted in of,1,0.5442043542861938
GILOTRIF,liver test abnormalities,pemetrexedcisplatin group More GILOTRIFtreated patients,0,0.50677889585495
GILOTRIF,liver test abnormalities,of GILOTRIFTreated Patients in Study None,0,0.5342347621917725
GILOTRIF,liver test abnormalities,all Grade compared to chemotherapytreated patients n,0,0.5033767223358154
GILOTRIF,liver test abnormalities,n 1 Adverse Reactions Repo,1,0.5056525468826294
GILOTRIF,fatal,GILOTRIF,0,0.5451952219009399
GILOTRIF,fatal,of the adverse reactions in this,0,0.5643124580383301
GILOTRIF,fatal,Reactions Reported in of Treat,1,0.5657352209091187
GILOTRIF,fatal,of GILOTRIF,0,0.5307906866073608
GILOTRIF,fatal,patients n Table Adverse Reactions Reported in,0,0.5255522131919861
GILOTRIF,fatal,in of Treat ed Patients in Study None,1,0.5242263674736023
GILOTRIF,fatal,Treat ed Patients in Study None,1,0.5298500061035156
GILOTRIF,fatal,Treat ed Patients in,1,0.5278889536857605
GILOTRIF,fatal,Treat ed,1,0.5225715637207031
GILOTRIF,fatal,Reported in of Treat ed Patients in Study None,1,0.5250653624534607
GILOTRIF,liver test abnormalities,GILOTRIFTreated Patients in,0,0.5537102222442627
GILOTRIF,liver test abnormalities,Study 1 *None of the adverse reactions,1,0.5251321792602539
GILOTRIF,liver test abnormalities,"in of GILOTRIFTreated Patients  Study 1 

 *None of the",1,0.5334594249725342
GILOTRIF,liver test abnormalities,of GILOTRIFTreated Patients Study,1,0.5367935299873352
GILOTRIF,liver test abnormalities,in of GILOTRIFTreated Patients,0,0.5577974319458008
GILOTRIF,liver test abnormalities,in of GILOTRIFTreated Patients Study 1 *None,1,0.5443369746208191
GILOTRIF,liver test abnormalities," Study 1 

 *None of the adverse reactions in this",1,0.517816424369812
GILOTRIF,worsening eye inflammation,acneiform Includes paronychia nail infection nail,0,0.5550605654716492
GILOTRIF,worsening eye inflammation,infection nail bed infection TRIFn=229      Pemetrexed/ Cisplatinn,1,0.509824812412262
GILOTRIF,light sensitivity,"    
   Adverse R eaction All Grades",1,0.576275110244751
GILOTRIF,light sensitivity,acneiform Includes paronychia nail infection nail,0,0.5336631536483765
GILOTRIF,light sensitivity,bed infection,0,0.46686747670173645
GILOTRIF,blurred vision,GILOTRIFn PemetrexedCisplatinn Adverse ction All,1,0.5398797392845154
GILOTRIF,blurred vision,Grade Gastrointestinal,0,0.48303234577178955
GILOTRIF,blurred vision,ction All Grades Grade,1,0.5070650577545166
GILOTRIF,blurred vision,ction All Grades Grade All Grades Grade,1,0.4934577941894531
GILOTRIF,eye pain,rades(%) Grade All,1,0.41668522357940674
GILOTRIF,eye pain,Grade,0,0.45637643337249756
GILOTRIF,red eye,de 3*(% All,1,0.4847964346408844
GILOTRIF,red eye,Grade,0,0.498160183429718
GILOTRIF,red eye,de 3*(% All Grades,1,0.47171664237976074
GILOTRIF,fetal harm,           Infections and infestations,1,0.5266926288604736
GILOTRIF,fetal harm,Infections and infestations,0,0.5266925096511841
GILOTRIF,fetal harm,Dry            Infections,1,0.4856959581375122
GILOTRIF,fetal harm,skin,0,0.5577759742736816
GILOTRIF,fetal harm,           Infections and infestations Paronychia,1,0.4600442349910736
GILOTRIF,embryotoxic,"   
       ",1,0.5953190326690674
GILOTRIF,embryotoxic,"   
        Paronychia Cystit",1,0.48212605714797974
GILOTRIF,embryotoxic,infestations,0,0.5216898918151855
GILOTRIF,embryotoxic,"   
        Paronychia",1,0.477832168340683
GILOTRIF,embryotoxic,and infestations,0,0.5002487301826477
GILOTRIF,abortions at late gestational stages,Paronychia,0,0.42740750312805176
GILOTRIF,abortions at late gestational stages,and,0,0.4642435908317566
DATSCAN,Hypersensitivity,EXCERPT,0,0.505143404006958
DATSCAN,Hypersensitivity,ADVERSE REACTIONS,0,0.7051181793212891
DATSCAN,Hypersensitivity,Hypersensitivity,1,1.0
DATSCAN,Hypersensitivity,Hypersensitivity and injection,1,0.8618366718292236
DATSCAN,Hypersensitivity,Hypersensitivity and injection site reactions,1,0.8032984733581543
DATSCAN,Hypersensitivity,Hypersensitivity and injection site reactions have,1,0.8146542906761169
DATSCAN,Hypersensitivity,REACTIONS Hypersensitivity,1,0.9034578800201416
DATSCAN,injection site reactions,Hypersensitivity injection site reactions,1,0.9180395603179932
DATSCAN,injection site reactions,injection site reactions have been reported following DaTscan,1,0.8480685949325562
DATSCAN,injection site reactions,ADVERSE REACTIONS EXCERPT Hypersensitivity injection site,1,0.8584606647491455
DATSCAN,headache,most common adverse headache nausea vertigo dry mouth,1,0.7302459478378296
DATSCAN,headache,ADVERSE REACTIONS EXCERPT Hypersensitivity injection site,1,0.5142433643341064
DATSCAN,headache,headache nausea,1,0.8417853116989136
DATSCAN,headache,headache nausea vertigo dry,1,0.7869594097137451
DATSCAN,headache,headache nausea vertigo dry mouth or,1,0.7556435465812683
DATSCAN,headache,the most common adverse headache nausea vertigo dry,1,0.751944899559021
DATSCAN,headache,common,0,0.5378744602203369
DATSCAN,headache,headache,1,0.9999998807907104
DATSCAN,vertigo,vertigo dry mouth or,1,0.8150773644447327
DATSCAN,vertigo,headache,1,0.6732674241065979
DATSCAN,vertigo,report,0,0.5063495635986328
DATSCAN,vertigo,vertigo dry mouth,1,0.8128640055656433
DATSCAN,vertigo,vertigo dry,1,0.8618506789207458
DATSCAN,vertigo,mouth or,0,0.5424791574478149
DATSCAN,vertigo,vertigo dry mouth or dizziness occurred,1,0.7687379121780396
DATSCAN,vertigo,reactions headache vertigo dry,1,0.7437257766723633
DATSCAN,vertigo,occurred,0,0.5278974175453186
DATSCAN,vertigo,dry mouth or dizziness occurred in of subjects To report SUSPECTED,0,0.6681208610534668
DATSCAN,dry mouth,dry mouth or dizziness occurred,1,0.8627704381942749
DATSCAN,dry mouth,report SUSPECTED ADVERSE REACTIONS,0,0.5406546592712402
DATSCAN,dry mouth,dry mouth,1,1.0
DATSCAN,dry mouth,dry mouth or dizziness,1,0.8788227438926697
DATSCAN,dry mouth,nausea dry mouth or dizziness occurred in,1,0.8267634510993958
DATSCAN,dizziness,headache,0,0.7131447196006775
DATSCAN,dizziness,adverse,0,0.5787200927734375
DATSCAN,dizziness,vertigo dry mouth dizziness occurred in of subjects,1,0.801592230796814
DATSCAN,dizziness,vertigo dry mouth dizziness occurred,1,0.8201305866241455
DATSCAN,dizziness,contact,0,0.5121212005615234
DATSCAN,headache,rate of or less and the,0,0.46082252264022827
DATSCAN,nausea,These reactions were of,0,0.5746707320213318
DATSCAN,nausea,of nausea vertigo,1,0.8846719861030579
DATSCAN,nausea,nausea vertigo dry mouth,1,0.8290671706199646
DATSCAN,nausea,the reported events consisted of,0,0.5189626216888428
DATSCAN,nausea,events consisted of nausea vertigo dry,1,0.8143028020858765
DATSCAN,nausea,reactions were of mild,0,0.5729503035545349
DATSCAN,nausea,nausea vertigo dry mouth or dizziness,1,0.8059277534484863
DATSCAN,nausea,of nausea vertigo dry mouth or dizziness,1,0.8136358261108398
DATSCAN,nausea,a rate of or less and the reported events consisted,0,0.511145830154419
DATSCAN,vertigo,vertigo dry mouth or dizziness These,1,0.7837618589401245
DATSCAN,vertigo,vertigo,1,1.0
DATSCAN,vertigo,mouth or dizziness,0,0.7611539363861084
DATSCAN,vertigo,e reactions,0,0.5253013372421265
DATSCAN,vertigo,events consisted of,0,0.4821481704711914
DATSCAN,vertigo,were of,0,0.5167927145957947
DATSCAN,dizziness,mild to,0,0.5921194553375244
DATSCAN,dizziness,to moderate severity Postmarketing Experience Because,0,0.5994812250137329
DATSCAN,dizziness,nausea vertigo dry mouth dizziness These reactions were,1,0.76043701171875
DATSCAN,dizziness,dizziness These reactions were of mild,1,0.8174903392791748
DATSCAN,hypersensitivity reactions,hypersensitivity reactions have been,1,0.939632773399353
DATSCAN,hypersensitivity reactions,dizziness These reactions were of mild,1,0.6322604417800903
DATSCAN,hypersensitivity reactions,the postmarketing hypersensitivity reactions have been reported The,1,0.809443473815918
DATSCAN,hypersensitivity reactions,eir frequency or,0,0.4363103210926056
DATSCAN,hypersensitivity reactions,exposure In the postmarketing hypersensitivity reactions have been reported The reactions,1,0.806986391544342
DATSCAN,rash,rash,1,1.0
DATSCAN,rash,pruritis within minutes of DaTscan administration,0,0.6678590774536133
DATSCAN,rash,The reactions either resolved,0,0.5092616081237793
DATSCAN,rash,rash and,1,0.9337756037712097
DATSCAN,pruritis,hypersensitivity reactions have been reported The,0,0.6603986024856567
DATSCAN,Hypersensitivity reactions,REACTIONS EXCERPT ty and injection site reac tions,1,0.6959980726242065
DATSCAN,Hypersensitivity reactions,hypersensitivity reactions have been reported The,0,0.9113994836807251
DATSCAN,Hypersensitivity reactions,Hypersensitivi,0,0.8519665002822876
DATSCAN,Hypersensitivity reactions,reported following DaTscan administration In,0,0.4934425950050354
DATSCAN,Hypersensitivity reactions,ADVERSE REACTIONS EXCERPT ty and injection site reac tions have been reported following,1,0.6800994277000427
DATSCAN,Hypersensitivity reactions,DaTscan administration In clinical trials the,0,0.4752042293548584
DATSCAN,Hypersensitivity reactions,clinical trials,0,0.553510308265686
DATSCAN,Hypersensitivity reactions,ADVERSE REACTIONS EXCERPT ty and injection site reac tions have been,1,0.6758139133453369
DATSCAN,Hypersensitivity reactions,DaTscan administration In clinical trials the most co,0,0.47693967819213867
DATSCAN,Hypersensitivity reactions,REACTIONS EXCERPT ty and injection site reac tions have been reported,1,0.7084049582481384
DATSCAN,Hypersensitivity reactions,118 or FDA at 1-800-FDA-10 or wwwfdagovmedwatch,1,0.4847322404384613
DATSCAN,Hypersensitivity reactions,or FDA at 1-800-FDA-10 or wwwfdagovmedwatch Clinical Study,1,0.47809898853302
DATSCAN,Hypersensitivity reactions,GE Healthcare 118 or FDA at 1-800-FDA-10 or wwwfdagovmedwatch,1,0.473115473985672
DATSCAN,Hypersensitivity reactions,contact GE Healthcare 118,1,0.460174560546875
DATSCAN,Hypersensitivity reactions,contact GE Healthcare 118 or FDA,1,0.5019618272781372
DATSCAN,skin erythema,with a mean age of years range to,0,0.4908214807510376
DATSCAN,pruritis,a mean,1,0.5368427038192749
DATSCAN,pruritis,Study Experience The data from,0,0.5136894583702087
DATSCAN,pruritis,DaTscan in subjects  a mean ,1,0.5205218195915222
DATSCAN,pruritis,in subjects a,1,0.5179576873779297
DATSCAN,pruritis, a mean ,1,0.5368427038192749
DATSCAN,pruritis,studies reflect exposure to DaTscan in subjects with,0,0.5537453889846802
DATSCAN,pruritis,years Among these subjects were,0,0.5053701400756836
DATSCAN,pruritis,subjects  a mean  age of years,1,0.501848578453064
DATSCAN,pruritis,subjects,0,0.5529302358627319
KALBITOR,Hypersensitivity,Hypersensitivity reactions including,1,0.9095338582992554
KALBITOR,Hypersensitivity,Hypersensitivity reactions,1,0.9332083463668823
KALBITOR,Hypersensitivity,Hypersensitivity reactions including anaphylaxis have occurred,1,0.8438518047332764
KALBITOR,Hypersensitivity,Hypersensitivity reactions including anaphylaxis have,1,0.8507847785949707
KALBITOR,Hypersensitivity,ADVERSE Hypersensitivity reactions including anaphylaxis,1,0.8206871747970581
KALBITOR,Hypersensitivity,Hypersensitivity,1,1.0
KALBITOR,anaphylaxis,anaphylaxis have occurred in patients treated,1,0.8539513349533081
KALBITOR,anaphylaxis,anaphylaxis,1,0.9999999403953552
KALBITOR,headache,placebo headache,1,0.8044212460517883
KALBITOR,headache,anaphylaxis,1,0.5894999504089355
KALBITOR,headache,headache,1,0.9999998807907104
KALBITOR,headache,headache nausea diarrhea,1,0.7836863994598389
KALBITOR,headache,headache nausea,1,0.8417852520942688
KALBITOR,headache,KALBITORtreated patients and greater than placebo are,0,0.5061901807785034
KALBITOR,headache,headache nausea diarrhea pyrexia injection,1,0.6952366828918457
KALBITOR,nausea,reactions occurring in of KALBITORtreated patients and greater than placebo are,0,0.5899583101272583
KALBITOR,nausea,nausea diarrhea pyrexia injection site,1,0.7384853363037109
KALBITOR,nausea,nausea diarrhea,1,0.8622832298278809
KALBITOR,nausea,headache,0,0.668434739112854
KALBITOR,nausea,patients,0,0.54615718126297
KALBITOR,nausea,nausea diarrhea pyrexia,1,0.8078977465629578
KALBITOR,nausea,greater than placebo are,0,0.590076744556427
KALBITOR,nausea,placebo are nausea diarrhea,1,0.7726845741271973
KALBITOR,nausea,greater than placebo are nausea diarrhea pyrexia injection,1,0.7496899366378784
KALBITOR,diarrhea,diarrhea pyrexia injection site reactions and,1,0.7098703980445862
KALBITOR,diarrhea,than placebo are headache nausea,0,0.5332812666893005
KALBITOR,pyrexia,headache nausea pyrexia injection site reactions and,1,0.807054877281189
KALBITOR,pyrexia,than placebo are headache nausea,0,0.5766642689704895
KALBITOR,pyrexia,pyrexia injection site reactions and nasopharyngitis,1,0.7477283477783203
KALBITOR,pyrexia,pyrexia injection site reactions and,1,0.8141068816184998
KALBITOR,injection site reactions,headache nausea diarrhea injection,1,0.7188590168952942
KALBITOR,injection site reactions,report SUSPECTED ADVERSE REACTIONS contact,0,0.6712801456451416
KALBITOR,injection site reactions,headache nausea,0,0.5218925476074219
KALBITOR,injection site reactions,REACTIONS contact Dyax Corp at,0,0.6626905202865601
KALBITOR,injection site reactions,diarrhea injection,1,0.6929701566696167
KALBITOR,injection site reactions,contact Dyax Corp at,0,0.5343919992446899
KALBITOR,injection site reactions,report,0,0.5222762227058411
KALBITOR,nasopharyngitis,injection site reactions,0,0.5323948264122009
KALBITOR,nasopharyngitis,nasopharyngitis To report,1,0.9002370834350586
KALBITOR,nasopharyngitis,reactions,0,0.5103693604469299
KALBITOR,nasopharyngitis,nasopharyngitis To report SUSPECTED ADVERSE REACTIONS,1,0.8508172035217285
KALBITOR,nasopharyngitis,injection site reactions nasopharyngitis To report SUSPECTED ADVERSE REACTIONS,1,0.7994897365570068
KALBITOR,headache,headache nausea fatigue,1,0.8013410568237305
KALBITOR,headache,reactions in,0,0.5197322368621826
KALBITOR,headache,the most common adverse reactions in patients,0,0.5602081418037415
KALBITOR,headache,headache nausea fatigue diarrhea,1,0.7512391805648804
KALBITOR,headache,diarrhea upper respiratory tract,0,0.5592767596244812
KALBITOR,headache,patients with HAE headache nausea fatigue diarrhea,1,0.7013565897941589
KALBITOR,headache,patients with HAE headache,1,0.7865842580795288
KALBITOR,headache,headache nausea fatigue diarrhea upper respiratory,1,0.734420120716095
KALBITOR,headache,patients with HAE headache nausea fatigue,1,0.7399172782897949
KALBITOR,nausea,injection site reacti,0,0.5499184131622314
KALBITOR,nausea,nausea fatigue diarrhea,1,0.7976186275482178
KALBITOR,nausea,tract infection injection site,0,0.5538650751113892
KALBITOR,nausea,patients with HAE were nausea fatigue diarrhea,1,0.7250317931175232
KALBITOR,nausea,nausea,1,1.0
KALBITOR,nausea,patients with HAE were nausea fatigue diarrhea upper respiratory,1,0.7302618026733398
KALBITOR,nausea,nausea fatigue diarrhea upper respiratory,1,0.7872797250747681
KALBITOR,fatigue,HAE were headache fatigue diarrhea upper respiratory,1,0.7110302448272705
KALBITOR,fatigue,nausea,1,0.684320867061615
KALBITOR,fatigue,fatigue diarrhea upper respiratory tract,1,0.7466451525688171
KALBITOR,diarrhea,infection injection site reactions nasopharyngitis,0,0.5682474374771118
KALBITOR,diarrhea,nausea fatigue,0,0.5714635848999023
KALBITOR,diarrhea,diarrhea upper,1,0.8197612762451172
KALBITOR,diarrhea,injection site reactions nasopharyngitis,0,0.5567845106124878
KALBITOR,diarrhea,reactions in patients with HAE,0,0.5479385852813721
KALBITOR,diarrhea,fatigue,0,0.5677722692489624
KALBITOR,diarrhea,diarrhea upper respiratory tract infection injection,1,0.7289903163909912
KALBITOR,diarrhea,were headache,0,0.5513623356819153
KALBITOR,diarrhea,tract infection,0,0.6595566868782043
KALBITOR,diarrhea,diarrhea upper respiratory tract infection,1,0.7599071860313416
KALBITOR,upper respiratory tract infection,upper respiratory tract infection injection site reactions nasopharyngitis vomiting,1,0.7760372161865234
KALBITOR,upper respiratory tract infection,diarrhea upper respiratory tract infection,1,0.8680696487426758
KALBITOR,upper respiratory tract infection,eactions in,0,0.5094689130783081
KALBITOR,upper respiratory tract infection,upper respiratory tract infection injection site reactions,1,0.791069507598877
KALBITOR,upper respiratory tract infection,fatigue upper respiratory tract infection,1,0.8513885736465454
KALBITOR,upper respiratory tract infection,respiratory tract infection injection site,1,0.754278302192688
KALBITOR,upper respiratory tract infection,headache nausea fatigue upper respiratory tract,1,0.7785306572914124
KALBITOR,upper respiratory tract infection,were headache nausea fatigue upper respiratory,1,0.7253726720809937
KALBITOR,upper respiratory tract infection,fatigue upper respiratory tract,1,0.8075733780860901
KALBITOR,injection site reactions,upper abdominal,0,0.5194137096405029
KALBITOR,injection site reactions,injection site reactions,1,1.0
KALBITOR,injection site reactions,tract injection site reactions,1,0.9283462166786194
KALBITOR,nasopharyngitis,upper abdominal pain,0,0.5209032893180847
KALBITOR,nasopharyngitis,nasopharyngitis vomiting pruritus upper abdominal,1,0.8004028797149658
KALBITOR,nasopharyngitis,nasopharyngitis vomiting,1,0.8619270324707031
KALBITOR,nasopharyngitis,pain and,0,0.5157642960548401
KALBITOR,nasopharyngitis,upper abdominal pain and pyrexia Anaphylaxis wa,0,0.5863973498344421
KALBITOR,nasopharyngitis,tract infection injection site nasopharyngitis vomiting pruritus,1,0.7769203186035156
KALBITOR,nasopharyngitis,nasopharyngitis,1,1.0000001192092896
KALBITOR,nasopharyngitis,respiratory tract,0,0.6248137950897217
KALBITOR,vomiting,pruritus upper abdominal pain and pyrexia Anaphylaxis,0,0.6360085010528564
KALBITOR,vomiting,vomiting,1,0.9999999403953552
KALBITOR,vomiting,site reactions nasopharyngitis,0,0.5923247337341309
KALBITOR,vomiting,upper abdominal pain,0,0.583964467048645
KALBITOR,vomiting,vomiting pruritus upper abdominal,1,0.755061149597168
KALBITOR,vomiting,vomiting pruritus,1,0.8158321976661682
KALBITOR,pruritus,tract infection injection site reactions,0,0.5643709301948547
KALBITOR,pruritus,pruritus upper abdominal,1,0.8300402164459229
KALBITOR,pruritus,nasopharyngitis vomiting,0,0.5326529741287231
KALBITOR,pruritus,was reported,0,0.5068460702896118
KALBITOR,pruritus,pruritus upper abdominal pain and,1,0.8408808708190918
KALBITOR,pruritus,tract,0,0.5189730525016785
KALBITOR,pruritus,injection site,0,0.5406883358955383
KALBITOR,pruritus,pruritus,1,0.9999999403953552
KALBITOR,upper abdominal pain,reactions nasopharyngitis,0,0.506726861000061
KALBITOR,upper abdominal pain,upper,1,0.7185947895050049
KALBITOR,upper abdominal pain,upper abdominal pain and,1,0.9823002815246582
KALBITOR,upper abdominal pain,nasopharyngitis vomiting upper,1,0.6484183073043823
KALBITOR,upper abdominal pain,nasopharyngitis vomiting upper abdominal pain and pyrexia Anaphylaxis was,1,0.7103756070137024
KALBITOR,pyrexia,pyrexia Anaphylaxis was reported,1,0.7891236543655396
KALBITOR,Anaphylaxis,Anaphylaxis was reported in of patients,1,0.8614095449447632
KALBITOR,Anaphylaxis,Injection,0,0.6036103963851929
KALBITOR,ANAPHYLAXIS,have occurred in patients treated,0,0.566510021686554
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions,1,0.7342389225959778
KALBITOR,ANAPHYLAXIS,with,0,0.5578500628471375
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions including anaphylaxis have,1,0.8692408800125122
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions including anaphylaxis,1,0.8673678636550903
KALBITOR,ANAPHYLAXIS,see Contraindications,0,0.5585809946060181
KALBITOR,ANAPHYLAXIS,reactions,0,0.6815289258956909
KALBITOR,ANAPHYLAXIS,"REACTIONS Hypersensitivity ,",1,0.7615903615951538
KALBITOR,ANAPHYLAXIS,"ADVERSE REACTIONS Hypersensitivity , including",1,0.7523934245109558
KALBITOR,ANAPHYLAXIS,"Hypersensitivity ,",1,0.7648999691009521
KALBITOR,ANAPHYLAXIS,", including",1,0.5454915761947632
KALBITOR,Anaphylaxis,"REACTIONS Hypersensitivity reactions including ylaxis, hav",1,0.7289348840713501
KALBITOR,Anaphylaxis,"Hypersensitivity reactions including ylaxis,",1,0.7491826415061951
KALBITOR,ANAPHYLAXIS,t the rates observed in practice The,1,0.44367483258247375
KALBITOR,ANAPHYLAXIS,not t,1,0.49469512701034546
KALBITOR,ANAPHYLAXIS,the rates observed in practice The,1,0.44256049394607544
KALBITOR,ANAPHYLAXIS,not t the rates,1,0.45109033584594727
KALBITOR,ANAPHYLAXIS,reflec,0,0.5080870389938354
KALBITOR,ANAPHYLAXIS,of another drug and,0,0.5416578054428101
KALBITOR,Anaphylaxis,data described below reflect exposure to KALBITOR in,0,0.5780925750732422
KALBITOR,Anaphylaxis,atients wit h HAE treated,1,0.5861214995384216
KALBITOR,Anaphylaxis,below,0,0.48820996284484863
KALBITOR,Hypersensitivity Reactions,occurred in patients treated,0,0.5914403200149536
KALBITOR,Hypersensitivity Reactions,ADVERSE REACTIONS Hypersensitivity reaction,0,0.9070731401443481
KALBITOR,Hypersensitivity Reactions,treated with KALBITOR see Contraindications,0,0.5873156785964966
KALBITOR,Hypersensitivity Reactions,"s, including anaphylaxis,",1,0.7535054087638855
KALBITOR,Hypersensitivity Reactions,"including anaphylaxis, have occurred in",1,0.7569912672042847
KALBITOR,Hypersensitivity Reactions,"REACTIONS Hypersensitivity s, including",1,0.9350026845932007
KALBITOR,Anaphylaxis,including anaphylaxis,0,0.9172511100769043
KALBITOR,Anaphylaxis,ed in,1,0.5702934861183167
KALBITOR,Anaphylaxis,reactions including anaphylaxis have ed in,1,0.8608448505401611
KALBITOR,Anaphylaxis,ed in patie nts treated with,1,0.5856841206550598
KALBITOR,Anaphylaxis,ed in patie,1,0.5668302774429321
KALBITOR,Anaphylaxis,anaphylaxis have occurr,0,0.9212749004364014
KALBITOR,Anaphylaxis,treated w ith KALBITOR,1,0.5995162725448608
KALBITOR,Anaphylaxis,anaphylaxis have occurred in,0,0.9117475748062134
KALBITOR,Anaphylaxis,treated w ith KALBITOR see Contraindications and,1,0.5774601697921753
KALBITOR,Anaphylaxis,and Warnings and Precautions,0,0.5619054436683655
KALBITOR,Anaphylaxis,anaphylaxis have occurred in s treated w,1,0.8781248331069946
KALBITOR,Anaphylaxis,have occurred in s,1,0.5717206001281738
KALBITOR,Anaphylaxis,in,0,0.5257902145385742
KALBITOR,Anaphylaxis,occurred,0,0.6156413555145264
KALBITOR,Anaphylaxis,have occurred,0,0.5980479717254639
KALBITOR,Anaphylaxis,s treated w ith KALBITOR see Contraindications and,1,0.5794925689697266
KALBITOR,hypersensitivity,tact Dyax Corp.  at or FDA,1,0.5741814970970154
KALBITOR,hypersensitivity,s treated w ith KALBITOR see Contraindications and,1,0.5865616798400879
KALBITOR,hypersensitivity,tact Dyax Corp. at or,1,0.5674942135810852
KALBITOR,hypersensitivity,Dyax Corp. at or FDA at,1,0.545693039894104
KALBITOR,hypersensitivity,con,0,0.5376651883125305
KALBITOR,hypersensitivity,Dyax Corp. at or FDA at FDA,1,0.5482690930366516
KALBITOR,hypersensitivity,SUSPECTED ADVERSE REACTIONS tact Dyax Corp. ,1,0.6320561170578003
KALBITOR,anaphylaxis,or DA at,1,0.5353326797485352
KALBITOR,anaphylaxis,or DA at 1-800 FDA or wwwfdagovmedwatch Clinical Trials,1,0.4888163208961487
KALBITOR,anaphylaxis,Corp at or DA,1,0.47887447476387024
KALBITOR,anaphylaxis,the clinical trials of an,0,0.55339115858078
KALBITOR,anaphylaxis,of other drug  and may not reflect the,1,0.4939059913158417
KALBITOR,anaphylaxis,clinical trials of,0,0.5298182964324951
KALBITOR,anaphylaxis,not reflect the rates observed in practice The safety,0,0.4869392514228821
KALBITOR,anaphylaxis,other drug and may not reflect,1,0.5000121593475342
KALBITOR,flushing,to KALBITOR,0,0.5431642532348633
KALBITOR,flushing,in patients,0,0.5177333354949951
KALBITOR,flushing,practice The safety data cribed b elow reflect exposure,1,0.5358400344848633
KALBITOR,flushing,cribed b elow,1,0.568539023399353
KALBITOR,flushing,The safety data cribed b elow,1,0.5085001587867737
KALBITOR,pharyngeal edema,described ow,1,0.5723495483398438
KALBITOR,pharyngeal edema,data described ow reflect,1,0.4953332543373108
KALBITOR,pharyngeal edema,described bel,0,0.5183731913566589
KALBITOR,pharyngeal edema,described,0,0.5100870132446289
KALBITOR,pharyngeal edema,in practice The safety data,0,0.46629878878593445
KALBITOR,pharyngeal edema,The safety data described ow reflect expos ure to KALBITOR in,1,0.49660271406173706
KALBITOR,pharyngeal edema,and may not reflect the rates observed,0,0.4291662573814392
KALBITOR,pruritus,described below reflect e to KAL BITOR in patients,1,0.5636976957321167
KALBITOR,pruritus,and may not reflect the rates observed,0,0.43097180128097534
KALBITOR,rhinorrhea,in 255,1,0.4317701458930969
KALBITOR,rhinorrhea,with HAE treated with either intravenous or subcutaneous KALBITOR Of the,0,0.5167858600616455
KALBITOR,rhinorrhea,TOR in 255 patients,1,0.5273467302322388
KALBITOR,rhinorrhea,rates observed in practice The safety,0,0.45596516132354736
KALBITOR,rhinorrhea,in 255 patients with HAE treated,1,0.5139972567558289
KALBITOR,rhinorrhea,to TOR in 255 patients with HAE,1,0.537073016166687
KALBITOR,sneezing,atients  with HAE treated,1,0.5406910181045532
KALBITOR,sneezing,practice,0,0.5325300693511963
KALBITOR,sneezing,in atients  with HAE treated with,1,0.5425954461097717
KALBITOR,sneezing,below reflect exposure,0,0.49946603178977966
KALBITOR,sneezing,KALBITOR in atients  with HAE treated,1,0.5271978378295898
KALBITOR,sneezing,atients  with HAE treated with either,1,0.5441318154335022
KALBITOR,sneezing,KALBITOR Of the patients of patie,0,0.512589156627655
KALBITOR,sneezing,intravenous or subcutaneous KALBITOR Of the patients,0,0.5408127903938293
KALBITOR,nasal congestion,to KALBITOR in patients th HAE treated w,1,0.5418306589126587
KALBITOR,nasal congestion,or subcutaneous KALBITOR Of the patients,0,0.5352334976196289
KALBITOR,nasal congestion,KALBITOR in patients th HAE treated w,1,0.529174268245697
KALBITOR,nasal congestion,in patients th HAE treated w,1,0.5494080781936646
KALBITOR,nasal congestion,treated w ith,1,0.5739538669586182
KALBITOR,nasal congestion,were,0,0.5036604404449463
KALBITOR,nasal congestion,ith either intravenous or subcutaneous KALBITOR Of the patients of patients were female,0,0.5241430997848511
KALBITOR,nasal congestion,described below reflect exposure to KALBITOR in patients,0,0.528899610042572
KALBITOR,throat irritation,either intraven ous or,1,0.5401328802108765
KALBITOR,throat irritation,exposure to KALBITOR in patients with HAE treated wit,0,0.55718994140625
KALBITOR,throat irritation,treated h either intraven ous or subcutaneous,1,0.5370204448699951
KALBITOR,throat irritation,Of the patients of patients were female and were,0,0.46432074904441833
KALBITOR,throat irritation,described below reflect exposure to KALBITOR in patients with HAE treated wit,0,0.5683315992355347
KALBITOR,throat irritation,treated h either intraven ous or,1,0.5232323408126831
KALBITOR,throat irritation,KALBITOR Of the patients of,0,0.490810364484787
KALBITOR,throat irritation,patients with HAE treated h,1,0.5017977952957153
KALBITOR,throat irritation,either intraven ous or subcutaneous,1,0.5511851906776428
KALBITOR,throat irritation,to KALBITOR,0,0.4598628282546997
KALBITOR,urticaria,either s or subc,1,0.49452507495880127
KALBITOR,urticaria,treated with either s or subc utaneous KALBITOR Of,1,0.5745977163314819
KALBITOR,urticaria,s or subc,1,0.4795886278152466
KALBITOR,wheezing,Of the,0,0.5069949626922607
KALBITOR,wheezing,aneous K ALBITOR Of the patients,1,0.5821008682250977
KALBITOR,wheezing,with HAE,0,0.5272908210754395
KALBITOR,wheezing,either intravenous or aneous K ALBITOR Of the patients of,1,0.5227051377296448
KALBITOR,wheezing,Of the patients of patients were female and were Caucasian Patients treated,0,0.4862729609012604
KALBITOR,wheezing,the patients of patients were female and were Caucasian,0,0.4914230704307556
KALBITOR,hypotension,with,0,0.5291465520858765
KALBITOR,hypotension,subcutaneous R. Of the 2 patients,1,0.5754783153533936
KALBITOR,hypotension,the 2 patients,1,0.5418967008590698
KALBITOR,hypotension,or subcutaneous R. Of the 2 patients of patients were female,1,0.5553150773048401
KALBITOR,hypotension,subcutaneous R. Of the 2,1,0.5740058422088623
KALBITOR,hypotension,KALBITO,0,0.4494676887989044
KALBITOR,hypotension,female,0,0.519945502281189
KALBITOR,hypotension,or subcutaneous R. Of the 2 patients of patients,1,0.5805082321166992
KALBITOR,hypotension,to KALBITOR in,0,0.46679866313934326
KALBITOR,hypersensitivity,treated with KALBITOR were een the ages,1,0.5847482681274414
KALBITOR,hypersensitivity,and years Overall the most common adverse reactions in patients with HAE were,0,0.6175442934036255
KALBITOR,pruritus,ost comm on adverse,1,0.5450490713119507
KALBITOR,pruritus,with HAE were,0,0.523446798324585
KALBITOR,pruritus,Overall the ost comm on adverse reactions in patients,1,0.5757029056549072
KALBITOR,pruritus,ost comm on adverse reactions,1,0.5943840742111206
KALBITOR,pruritus,the ost,1,0.47391241788864136
KALBITOR,pruritus,and years Overall the ost comm,1,0.4471021294593811
KALBITOR,pruritus,were headache,0,0.6193329095840454
KALBITOR,pruritus,were headache nausea fatigue diar,0,0.6296889185905457
KALBITOR,pruritus,and years Overall the ost comm on adverse reactions in,1,0.5888248682022095
KALBITOR,rash,ts treated with KALBITOR were between the ages,0,0.5830273628234863
KALBITOR,rash,rse  reactions in patients,1,0.6219273805618286
KALBITOR,rash,the most common rse  reactions in patients with,1,0.6219682097434998
KALBITOR,rash,in,0,0.5418816208839417
KALBITOR,rash,common rse  reactions in patients with,1,0.6279470920562744
KALBITOR,rash,rse ,1,0.5103550553321838
KALBITOR,rash,between the ages of,0,0.47565126419067383
KALBITOR,rash,rse  reactions in patients with,1,0.6234107613563538
KALBITOR,rash,Overall the most common rse ,1,0.5155729651451111
KALBITOR,urticaria,n 255 pat ients,1,0.4745076894760132
KALBITOR,urticaria,were headache nausea fatigue diarrhea,0,0.5235424637794495
KALBITOR,urticaria,reactions n,1,0.5376541614532471
KALBITOR,urticaria,reactions i,0,0.5362520217895508
KALBITOR,urticaria,upper respiratory t,0,0.5885078310966492
KALBITOR,urticaria,reactions n 255,1,0.5389870405197144
KALBITOR,urticaria,years Overall,0,0.4590485990047455
APTIOM,Suicidal Behavior,Suicidal Behavior and Ideation see Warnings and,1,0.8508774042129517
APTIOM,Suicidal Behavior,in more,0,0.45926743745803833
APTIOM,Suicidal Behavior,of the Suicidal Behavior,1,0.9485329389572144
APTIOM,Suicidal Behavior,see Warnings and Precautions Serious Dermatologic Reactions see War,0,0.5061544179916382
APTIOM,Suicidal Behavior,Suicidal Behavior and Ideation see Warnings,1,0.867552638053894
APTIOM,Suicidal Behavior,the Suicidal,1,0.8602626919746399
APTIOM,Suicidal Behavior,section of the Suicidal Behavior,1,0.9115369319915771
APTIOM,Suicidal Behavior,Suicidal Behavior and,1,0.9584693908691406
APTIOM,Suicidal Behavior,Precautions section of the Suicidal Behavior,1,0.8390016555786133
APTIOM,Suicidal Behavior,the Suicidal Behavior,1,0.9662112593650818
APTIOM,Dermatologic Reactions,Precautions Drug Reaction with,0,0.7136695384979248
APTIOM,Dermatologic Reactions,Dermatologic Reactions see,1,0.9886579513549805
APTIOM,Dermatologic Reactions,Precautions Dermatologic Reactions see Warnings and Precautions,1,0.8513294458389282
APTIOM,Dermatologic Reactions,and Precautions Dermatologic Reactions see Warnings and Precautions,1,0.8563187122344971
APTIOM,Dermatologic Reactions,Warnings and Precautions Drug Reaction,0,0.7095601558685303
APTIOM,Dermatologic Reactions,Dermatologic,1,0.8289058208465576
APTIOM,Dermatologic Reactions,see Warnings and Precautions Serious,0,0.5752224326133728
APTIOM,Dermatologic Reactions,Precautions Dermatologic Reactions,1,0.9114312529563904
APTIOM,Dermatologic Reactions,Warnings and Precautions Dermatologic Reactions see,1,0.8852035999298096
APTIOM,Dermatologic Reactions,see Warnings and Precautions Dermatologic Reactions,1,0.8862766027450562
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Warnings and Drug Reaction with Eosinophilia and Systemic Symptoms,1,0.943778395652771
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,see Warnings and Drug Reaction with Eosinophilia and Systemic Symptoms DRESSMultiorgan Hypersensitivity see Warnings,1,0.8950659036636353
APTIOM,DRESS,with Eosinophilia and Systemic DRESS Multiorgan,1,0.6557891368865967
APTIOM,DRESS,Warnings and Drug Reaction with Eosinophilia and Systemic Symptoms,1,0.49448198080062866
APTIOM,DRESS,DRESS,1,1.0
APTIOM,DRESS,ee Warnings and Precautions Drug Reaction with,0,0.5208372473716736
APTIOM,DRESS,Warnings and Precautions Anaphylactic,0,0.49516427516937256
APTIOM,DRESS,DRESS Multiorgan Hypersensitivity,1,0.6970919966697693
APTIOM,DRESS,DRESS Multiorgan,1,0.7976982593536377
APTIOM,DRESS,and Precautions Drug Reaction with Eosinophilia and,0,0.5180554986000061
APTIOM,Multiorgan Hypersensitivity,and Systemic Symptoms Multiorgan Hypersensitivity,1,0.9233577251434326
APTIOM,Multiorgan Hypersensitivity,Systemic Symptoms Multiorgan,1,0.7901386022567749
APTIOM,Multiorgan Hypersensitivity,and Systemic Symptoms Multiorgan,1,0.7915875315666199
APTIOM,Multiorgan Hypersensitivity,Symptoms Multiorgan Hypersensitivity see Warnings and Precautions Anaphylactic,1,0.879569947719574
APTIOM,Multiorgan Hypersensitivity,Drug Reaction with Eosinophilia and Systemic Symptoms DRESS,0,0.6801202297210693
APTIOM,Multiorgan Hypersensitivity,Multiorgan Hypersensitivity see Warnings,1,0.9195313453674316
APTIOM,Multiorgan Hypersensitivity,Anaphylactic Reactions and Angioedema see Warnings,0,0.7175185084342957
APTIOM,Multiorgan Hypersensitivity,Eosinophilia and Systemic Symptoms Multiorgan Hypersensitivity see,1,0.857524037361145
APTIOM,Multiorgan Hypersensitivity,Multiorgan Hypersensitivity see Warnings and,1,0.9184092283248901
APTIOM,Anaphylactic Reactions,Anaphylactic Reactions,1,1.0000001192092896
APTIOM,Angioedema,Angioedema,1,1.000000238418579
APTIOM,Angioedema,Reactions,0,0.5928596258163452
APTIOM,Angioedema,Angioedema see Warnings and,1,0.8779383897781372
APTIOM,Hyponatremia,see Warnings,0,0.5324622392654419
APTIOM,Hyponatremia,and Hyponatremia,1,0.9202337265014648
APTIOM,Hyponatremia,Precautions,0,0.5064534544944763
APTIOM,Hyponatremia,Warnings and Precautions Neurological Adverse Reactions see Warnings,0,0.5619155764579773
APTIOM,Hyponatremia,Hyponatremia,1,1.000000238418579
APTIOM,Hyponatremia,and Precautions Neurological Adverse Reactions see Warnings,0,0.5528064966201782
APTIOM,Hyponatremia,Hyponatremia see Warnings,1,0.8586117029190063
APTIOM,Hyponatremia,and Angioedema see Warnings,0,0.5433262586593628
APTIOM,Hyponatremia,and Hyponatremia see Warnings,1,0.8490514755249023
APTIOM,Hyponatremia,Precautions Neurological Adverse Reactions see,0,0.5511476993560791
APTIOM,Neurological Adverse Reactions,and Precautions Drug Induced Liver Injury,0,0.6058046817779541
APTIOM,Neurological Adverse Reactions,Hyponatremia see Warnings and Neurological Adverse,1,0.78312087059021
APTIOM,Neurological Adverse Reactions,see Warnings and Precautions,0,0.6355805397033691
APTIOM,Neurological Adverse Reactions,Neurological Adverse Reactions see Warnings and Precautions,1,0.9277764558792114
APTIOM,Neurological Adverse Reactions,Neurological,1,0.812767744064331
APTIOM,Neurological Adverse Reactions,and Neurological Adverse,1,0.8983272910118103
APTIOM,Drug Induced Liver Injury,and Drug Induced Liver Injury see Warnings and Precautions Abnormal,1,0.8878509998321533
APTIOM,Drug Induced Liver Injury,and Neurological Adverse,1,0.5305896997451782
APTIOM,Drug Induced Liver Injury,Drug Induced Liver Injury see Warnings and Precautions,1,0.9045528173446655
APTIOM,Drug Induced Liver Injury,Tests see Warnings and Pr,0,0.5104094743728638
APTIOM,Abnormal Thyroid Function Tests,see Warnings and Abnormal Thyroid,1,0.7937252521514893
APTIOM,dizziness,diplopia,0,0.6221114993095398
APTIOM,somnolence,placebo somnolence nausea,1,0.7681596875190735
APTIOM,somnolence,diplopia,0,0.46253567934036255
APTIOM,somnolence,greater than placebo,0,0.5352407097816467
APTIOM,somnolence,placebo,0,0.5680555701255798
APTIOM,somnolence,adverse reactions in patients receiving APTIOM and,0,0.5300462245941162
APTIOM,headache,fatigue vertigo ataxia blurred vision and tremor To,0,0.6358008980751038
APTIOM,diplopia,diplopia,1,1.0000001192092896
APTIOM,diplopia,nausea diplopia vomiting fatigue vertigo ataxia,1,0.7636168599128723
APTIOM,diplopia,and,0,0.45230233669281006
APTIOM,diplopia,diplopia vomiting,1,0.817193865776062
APTIOM,diplopia,diplopia vomiting fatigue vertigo ataxia blurred,1,0.8289965987205505
APTIOM,vomiting,vomiting fatigue vertigo ataxia blurred,1,0.7954223155975342
APTIOM,vomiting,dizziness somnolence nausea headache vomiting fatigue vertigo ataxia blurred,1,0.7202243804931641
APTIOM,vomiting,vomiting fatigue vertigo ataxia blurred vision,1,0.7887404561042786
APTIOM,vomiting,fatigue vertigo ataxia blurred vision and,0,0.5555065870285034
APTIOM,vomiting,nausea headache vomiting fatigue vertigo ataxia,1,0.7679802775382996
APTIOM,vomiting,vomiting,1,0.9999999403953552
APTIOM,vomiting,nausea headache vomiting,1,0.8686666488647461
APTIOM,fatigue,fatigue vertigo ataxia,1,0.8138988018035889
APTIOM,vertigo,d greater than placebo dizziness somnolence nausea,0,0.6768619418144226
APTIOM,vertigo,nausea headache diplopia vomiting vertigo ataxia blurred,1,0.7830613255500793
APTIOM,vertigo,vertigo ataxia,1,0.8561723232269287
APTIOM,vertigo,To report,0,0.4802637994289398
APTIOM,vertigo,vertigo ataxia blurred vision,1,0.8275582790374756
APTIOM,vertigo,headache diplopia vomiting vertigo ataxia blurred,1,0.774991512298584
APTIOM,vertigo,dizziness somnolence nausea headache diplopia vomiting,0,0.7403203845024109
APTIOM,vertigo,vertigo ataxia blurred vision and,1,0.8264928460121155
APTIOM,vertigo,vertigo,1,1.0
APTIOM,ataxia,ataxia,1,1.000000238418579
APTIOM,ataxia,diplopia vomiting fatigue ataxia blurred vision and tremor To,1,0.7436232566833496
APTIOM,ataxia,To report SUSPECTED ADVERSE REACTIONS contact Sunovio,0,0.47706735134124756
APTIOM,ataxia,ataxia blurred vision and,1,0.8494528532028198
APTIOM,ataxia,blurred,0,0.5493185520172119
APTIOM,ataxia,ataxia blurred vision and tremor,1,0.8402911424636841
APTIOM,ataxia,placebo dizziness somnolence nausea headache diplopia vomiting,0,0.5434964895248413
APTIOM,blurred vision,blurred vision and,1,0.9714990854263306
APTIOM,blurred vision,placebo dizziness somnolence nausea headache diplopia vomiting,0,0.5984996557235718
APTIOM,blurred vision,vertigo blurred vision,1,0.8915534019470215
APTIOM,blurred vision,blurred vision,1,0.9999999403953552
APTIOM,blurred vision,blurred vision and tremor,1,0.8637042045593262
APTIOM,blurred vision,blurred vision and tremor To report,1,0.8418229818344116
APTIOM,blurred vision,contact Sunovion,0,0.4722684323787689
APTIOM,blurred vision,vomiting fatigue vertigo ataxia,0,0.6269936561584473
APTIOM,blurred vision,diplopia vomiting fatigue vertigo blurred vision,1,0.7438787221908569
APTIOM,tremor,vision and,0,0.49710822105407715
APTIOM,tremor,tremor,1,0.9999998807907104
APTIOM,tremor,tremor To report SUSPECTED,1,0.8325891494750977
APTIOM,tremor,vertigo ataxia blurred vision tremor To report,1,0.7209893465042114
APTIOM,tremor,ADVERSE REACTIONS contact Sunovion at or,0,0.47114065289497375
APTIOM,tremor,tremor To,1,0.9375815987586975
APTIOM,tremor,ss,0,0.508476972579956
APTIOM,hyponatremia,hyponatremia Adverse reactions observed,1,0.840489387512207
APTIOM,hyponatremia,hyponatremia Adverse reactions observed in,1,0.8446432948112488
APTIOM,hyponatremia,hyponatremia Adverse,1,0.8618515729904175
APTIOM,Dizziness,Dizziness nausea somnolence and,1,0.8470260500907898
APTIOM,Dizziness,Dizziness nausea somnolence and fatigue were,1,0.7976799011230469
APTIOM,Dizziness,at,0,0.5329846143722534
APTIOM,Dizziness,Dizziness nausea somnolence and fatigue,1,0.8192712068557739
APTIOM,Dizziness,and fatigue were all reported at lower,0,0.6045005321502686
APTIOM,Dizziness,Dizziness,1,0.9999998807907104
APTIOM,nausea,established,0,0.4760114550590515
APTIOM,somnolence,somnolence,1,1.0
APTIOM,somnolence,established Dizziness somnolence and fatigue were,1,0.755198061466217
APTIOM,fatigue,Dizziness nausea somnolence,0,0.685289204120636
APTIOM,fatigue,fatigue were all reported at,1,0.8543644547462463
APTIOM,fatigue,nausea somnolence fatigue were all reported,1,0.7966771125793457
APTIOM,fatigue,not be established Dizziness nausea,0,0.5858025550842285
APTIOM,fatigue,fatigue,1,1.0
APTIOM,fatigue,Dizziness nausea somnolence fatigue were all reported at lower,1,0.7620863914489746
APTIOM,fatigue,and,0,0.5631532073020935
APTIOM,dizziness,dizziness,1,0.9999998807907104
APTIOM,dizziness,dizziness nausea vomiting ataxia diplopia,1,0.7947157621383667
APTIOM,vomiting,headache blurred vision vertigo,0,0.6092323064804077
APTIOM,vomiting,frequency were dizziness vomiting ataxia diplopia,1,0.7039459943771362
APTIOM,vomiting,vomiting ataxia diplopia,1,0.754845380783081
APTIOM,vomiting,ataxia diplopia somnolence headache blurred vision vertigo asthenia fatigue,0,0.5517147779464722
APTIOM,vomiting,somnolence headache blurred vision vertigo,0,0.5759321451187134
APTIOM,ataxia,ataxia diplopia somnolence headache blurred,1,0.7847887873649597
APTIOM,ataxia,ataxia diplopia somnolence headache blurred vision,1,0.806108832359314
APTIOM,ataxia,descending order of frequency were dizziness nausea vomiting,0,0.548965334892273
APTIOM,ataxia,ataxia diplopia somnolence,1,0.7809381484985352
APTIOM,ataxia,were dizziness nausea ataxia diplopia,1,0.7850428819656372
APTIOM,ataxia,leading to discontinuation in descending order of frequency were dizziness nausea vomiting,0,0.545596718788147
APTIOM,diplopia,diplopia somnolence headache blurred vision,1,0.8125290274620056
APTIOM,diplopia,vision vertigo asthenia fatigue rash,0,0.6394879817962646
APTIOM,diplopia,diplopia somnolence headache blurred vision vertigo,1,0.8352259993553162
APTIOM,diplopia,diplopia somnolence,1,0.794215738773346
APTIOM,diplopia,dizziness,0,0.6221114993095398
APTIOM,diplopia,vision vertigo asthenia fatigue rash dysarthria and tremor,0,0.6466493606567383
APTIOM,somnolence,somnolence headache blurred vision vertigo asthenia,1,0.8019607663154602
APTIOM,headache,vertigo asthenia fatigue rash dysarthria and tremor The most,0,0.634434700012207
APTIOM,headache,headache blurred vision vertigo,1,0.828288197517395
APTIOM,headache,blurred vision vertigo asthenia fatigue,0,0.6601482629776001
APTIOM,headache,headache blurred vision,1,0.8261648416519165
APTIOM,headache,diplopia,0,0.5790180563926697
APTIOM,blurred vision,blurred vision vertigo asthenia fatigue rash dysarthria,1,0.750705361366272
APTIOM,blurred vision,diplopia,0,0.6893560886383057
APTIOM,blurred vision,diplopia somnolence blurred vision,1,0.8177670240402222
APTIOM,blurred vision,most frequently reported adverse,0,0.5750537514686584
APTIOM,blurred vision,blurred vision vertigo,1,0.8896931409835815
APTIOM,blurred vision,diplopia somnolence blurred,1,0.7618028521537781
APTIOM,blurred vision,vomiting ataxia diplopia somnolence blurred vision vertigo asthenia fatigue,1,0.6604763269424438
APTIOM,vertigo,vertigo asthenia fatigue,1,0.8486261963844299
APTIOM,vertigo,most frequently reported adverse reaction,0,0.5193309783935547
APTIOM,asthenia,asthenia fatigue rash dysarthria and,1,0.7443004846572876
APTIOM,asthenia,most frequently reported adverse reaction,0,0.5213717818260193
APTIOM,fatigue,vision vertigo fatigue rash dysarthria and,1,0.7163912057876587
APTIOM,fatigue,most frequently reported adverse reaction,0,0.5056614875793457
APTIOM,fatigue,headache blurred vision vertigo fatigue rash dysarthria and,1,0.7142564058303833
APTIOM,fatigue,fatigue rash,1,0.8257787227630615
APTIOM,fatigue,fatigue rash dysarthria and tremor,1,0.7304360866546631
APTIOM,fatigue,fatigue rash dysarthria and tremor The,1,0.7388584613800049
APTIOM,fatigue,most frequently reported,0,0.5302006602287292
APTIOM,fatigue,ataxia diplopia somnolence headache,0,0.5970118045806885
APTIOM,fatigue,fatigue rash dysarthria and,1,0.753538191318512
APTIOM,dysarthria,adverse,0,0.5388253331184387
APTIOM,dysarthria,asthenia fatigue dysarthria and,1,0.8370709419250488
APTIOM,dysarthria,dysarthria and tremor,1,0.8886026740074158
APTIOM,dysarthria,vision vertigo asthenia fatigue dysarthria and tremor The most,1,0.7015979290008545
APTIOM,dysarthria,dysarthria and tremor The most frequently,1,0.8305850028991699
APTIOM,tremor,at doses of mg,0,0.5410140752792358
APTIOM,tremor,vertigo asthenia,0,0.6223784685134888
APTIOM,tremor,tremor The most frequently reported,1,0.8240993022918701
APTIOM,tremor,and,0,0.5268450975418091
APTIOM,tremor,doses of mg,0,0.5321337580680847
APTIOM,tremor,tremor The most frequently,1,0.8801069259643555
APTIOM,tremor,The most frequently reported adverse reactions in patients receiving APTIOM at doses of mg,0,0.5275141000747681
APTIOM,tremor,patients,0,0.5014742612838745
APTIOM,dizziness,diplopia vomiting fatigue vertigo ataxia blurred vision and tr,0,0.7446485161781311
APTIOM,dizziness,than placebo dizziness somnolence nausea headache diplopia,1,0.7708234190940857
APTIOM,dizziness,nausea headache diplopia vomiting fatigue vertigo ataxia blurred vision and tr,0,0.7560830116271973
APTIOM,dizziness,n patients receiving APTIOM at doses,0,0.5579139590263367
APTIOM,dizziness,n patients receiving APTIOM at,0,0.5536580085754395
APTIOM,dizziness,placebo dizziness somnolence nausea headache,1,0.7665309906005859
APTIOM,dizziness,and greater than placebo dizziness somnolence nausea headache diplopia vomiting,1,0.7508218288421631
APTIOM,somnolence,somnolence nausea,1,0.8681323528289795
APTIOM,somnolence,mg and greater than placebo were dizziness,0,0.5440715551376343
APTIOM,somnolence,nausea headache diplopia vomiting fatigue vertigo ataxia blurred vision,0,0.573818027973175
APTIOM,somnolence,placebo were,0,0.54430091381073
APTIOM,somnolence,at doses of mg or mg and greater,0,0.49072808027267456
APTIOM,somnolence,somnolence nausea headache diplopia,1,0.7612608671188354
APTIOM,somnolence,placebo were somnolence nausea headache diplopia vomiting fatigue,1,0.6879539489746094
APTIOM,somnolence,diplopia vomiting fatigue vertigo ataxia blurred vision and,0,0.5491046905517578
APTIOM,nausea,placebo were dizziness nausea headache,1,0.7636578679084778
APTIOM,nausea,diplopia vomiting fatigue vertigo ataxia blurred vision and,0,0.7262621521949768
APTIOM,nausea,nausea headache diplopia vomiting fatigue vertigo,1,0.8182653784751892
APTIOM,nausea,were dizziness nausea headache diplopia vomiting fatigue,1,0.7997574806213379
APTIOM,nausea,nausea headache,1,0.8831434845924377
APTIOM,nausea,headache diplopia vomiting fatigue vertigo ataxia blurred vision,0,0.7289990186691284
APTIOM,headache,headache diplopia vomiting fatigue vertigo,1,0.7629895210266113
APTIOM,headache,Table gives,0,0.48225075006484985
APTIOM,headache,doses,0,0.5656680464744568
APTIOM,headache,headache diplopia vomiting fatigue,1,0.7408553957939148
APTIOM,diplopia,fatigue,0,0.5223034620285034
APTIOM,diplopia,were dizziness somnolence nausea diplopia vomiting,1,0.7335944175720215
APTIOM,diplopia,headache,0,0.5790180563926697
APTIOM,vomiting,the incidence of,0,0.5885960459709167
APTIOM,vomiting,somnolence nausea headache vomiting fatigue vertigo ataxia blurred,1,0.7066161632537842
APTIOM,vomiting,greater than placebo were dizziness somnolence nausea,0,0.6432622075080872
APTIOM,vomiting,vomiting fatigue,1,0.8589359521865845
APTIOM,vomiting,vomiting fatigue vertigo ataxia,1,0.8020675778388977
APTIOM,vomiting,ataxia blurred vision,0,0.5283457040786743
APTIOM,vomiting,nausea headache vomiting fatigue vertigo,1,0.7823565006256104
APTIOM,fatigue,fatigue vertigo,1,0.8307110667228699
APTIOM,fatigue,headache diplopia fatigue vertigo ataxia,1,0.7236143350601196
APTIOM,fatigue,fatigue vertigo ataxia blurred vision,1,0.8054133653640747
APTIOM,fatigue,headache diplopia fatigue vertigo ataxia blurred vision,1,0.721788763999939
APTIOM,fatigue,fatigue vertigo ataxia blurred vision and,1,0.7919172048568726
APTIOM,vertigo,headache diplopia vomiting vertigo ataxia blurred vision and tremor,1,0.76143878698349
APTIOM,vertigo,nausea headache diplopia vomiting vertigo ataxia blurred vision,1,0.7726839780807495
APTIOM,vertigo,adverse reactions that o,0,0.5435922145843506
APTIOM,vertigo,and tremor Table,0,0.6138123273849487
APTIOM,vertigo,were dizziness somnolence nausea headache diplopia vomiting,0,0.7335737943649292
APTIOM,vertigo,and tremor Table gives the incidence,0,0.6386284828186035
APTIOM,blurred vision,in of,0,0.5164153575897217
APTIOM,blurred vision,reactions that occurred in,0,0.5084669589996338
APTIOM,blurred vision,vomiting fatigue vertigo blurred vision,1,0.7455612421035767
APTIOM,blurred vision,blurred vision and tremor Table gives the,1,0.8127013444900513
APTIOM,blurred vision,blurred vision and tremor Table,1,0.8201286196708679
APTIOM,blurred vision,fatigue vertigo blurred vision,1,0.8032698035240173
APTIOM,blurred vision,ataxia,0,0.5821406841278076
APTIOM,tremor,incidence of adverse reactions that occurred in,0,0.4998796880245209
APTIOM,tremor,nausea headache diplopia vomiting fatigue,0,0.5718644857406616
APTIOM,tremor,tremor Table gives the incidence,1,0.8087892532348633
APTIOM,tremor,tremor Table gives the,1,0.8333240747451782
APTIOM,Vertigo,Ear and labyrinth Vertigo Eye disorders,1,0.798828661441803
APTIOM,Vertigo,tremor Table gives the,1,0.6198300719261169
APTIOM,Vertigo,N Ear and labyrinth Vertigo Eye disorders,1,0.8095765709877014
APTIOM,Vertigo,Eye disorders,0,0.5610061287879944
APTIOM,Vertigo,Eye disorders Diplopia,0,0.6296515464782715
APTIOM,Vertigo,labyrinth,0,0.6716924905776978
APTIOM,Vertigo,Vertigo Eye,1,0.8862608671188354
APTIOM,Diplopia,Diplopia Blurred vision Visual impairment,1,0.8785342574119568
APTIOM,Diplopia,vision Visual,0,0.6402565836906433
APTIOM,Diplopia,Eye Diplopia Blurred vision Visual,1,0.8803358674049377
APTIOM,Diplopia,Blurred,0,0.5955060124397278
APTIOM,Diplopia,Diplopia Blurred vision Visual,1,0.8848198652267456
APTIOM,Diplopia,Vertigo Eye Diplopia Blurred vision Visual impairment,1,0.8288179636001587
APTIOM,Diplopia,Diplopia Blurred,1,0.9125785827636719
APTIOM,Blurred vision,Visual impairment Gastroint,0,0.675199031829834
APTIOM,Blurred vision,disorders Blurred,1,0.8021436929702759
APTIOM,Blurred vision,Diplopia,0,0.6893560886383057
APTIOM,Blurred vision,Eye disorders Blurred vision Visual impairment Gastroint,1,0.7747154235839844
APTIOM,Blurred vision,Visual,0,0.630926251411438
APTIOM,Blurred vision,Blurred vision Visual,1,0.9580404758453369
APTIOM,Blurred vision,Eye disorders Blurred vision Visual impairment,1,0.8580544590950012
APTIOM,Visual impairment,Visual impairment Gastrointestinal,1,0.8274803161621094
APTIOM,Visual impairment,Diplopia,0,0.6695765852928162
APTIOM,Visual impairment,Eye disorders Diplopia Blurred vision,0,0.7202688455581665
APTIOM,Visual impairment,Diplopia Blurred Visual,1,0.7339703440666199
APTIOM,Visual impairment,Visual impairment Gastrointestinal disorders,1,0.8198555707931519
APTIOM,Visual impairment,disorders,0,0.6321163773536682
APTIOM,Visual impairment,Diplopia Blurred Visual impairment Gastrointestinal,1,0.7664415836334229
APTIOM,Visual impairment,Visual impairment,1,1.0
APTIOM,Nausea,Nausea Vomiting Diarrhea Constipation,1,0.8159308433532715
APTIOM,Nausea,Nausea Vomiting Diarrhea,1,0.8330716490745544
APTIOM,Nausea,Nausea Vomiting Diarrhea Constipation Abdominal pain,1,0.7750250101089478
APTIOM,Nausea,disorders,0,0.5810480713844299
APTIOM,Nausea,Abdominal pain,0,0.6394764184951782
APTIOM,Vomiting,Diarrhea Constipation Abdominal pain,0,0.6030364632606506
APTIOM,Vomiting,Vomiting Diarrhea Constipation Abdominal pain Gastritis,1,0.7312273979187012
APTIOM,Diarrhea,Diarrhea Constipation Abdominal,1,0.7706781625747681
APTIOM,Diarrhea,Diarrhea,1,0.9999999403953552
APTIOM,Constipation,Constipation Abdominal,1,0.8175082206726074
APTIOM,Constipation,Constipation Abdominal pain Gastritis,1,0.7769585847854614
APTIOM,Abdominal pain,Nausea Vomiting Diarrhea Abdominal pain Gastritis,1,0.7584078311920166
APTIOM,Abdominal pain,Constipation Abdominal pain Gastritis,1,0.7975751161575317
APTIOM,Abdominal pain,Nausea Vomiting Diarrhea Abdominal pain Gastritis General disorders,1,0.722101628780365
APTIOM,Abdominal pain,Diarrhea Constipation,0,0.6322648525238037
APTIOM,Abdominal pain,Constipation,0,0.6521742939949036
APTIOM,Gastritis,Gastritis General disorders,1,0.8808908462524414
APTIOM,Gastritis,Gastritis General disorders and administr,1,0.8401151895523071
APTIOM,Gastritis,disorders and administr,0,0.5111886858940125
APTIOM,Gastritis,pain,0,0.6233971118927002
APTIOM,Fatigue,Fatigue Asthenia Gait,1,0.7715005874633789
APTIOM,Fatigue,Fatigue Asthenia Gait disturbance,1,0.7579355239868164
APTIOM,Fatigue,Fatigue Asthenia,1,0.8828307390213013
APTIOM,Fatigue,Gait disturbance Peripheral,0,0.5815749168395996
APTIOM,Fatigue,Fatigue Asthenia Gait disturbance Peripheral edema,1,0.7268836498260498
APTIOM,Fatigue,Fatigue,1,1.0
APTIOM,Asthenia,disturbance Peripheral,0,0.5627992153167725
APTIOM,Gait disturbance,Fatigue Gait,1,0.8071231842041016
APTIOM,Gait disturbance,Fatigue Gait disturbance Peripheral edema,1,0.7687364816665649
APTIOM,Gait disturbance,s Fatigue Gait disturbance Peripheral,1,0.8203245997428894
APTIOM,Gait disturbance,s,0,0.5097671747207642
APTIOM,Gait disturbance,Fatigue,0,0.5856010913848877
APTIOM,Gait disturbance,Fatigue Gait disturbance,1,0.9019073247909546
APTIOM,Gait disturbance,Gait,1,0.8661473989486694
APTIOM,Peripheral edema,Peripheral edema,1,1.0000001192092896
APTIOM,Dizziness,Ataxia Balance disorder,0,0.6366845369338989
APTIOM,Somnolence,Somnolence Headache Ataxia Balance,1,0.735844612121582
APTIOM,Somnolence,Ataxia Balance disorder,0,0.48697859048843384
APTIOM,Somnolence,Somnolence Headache Ataxia Balance disorder,1,0.7359226942062378
APTIOM,Somnolence,Somnolence Headache Ataxia,1,0.7437543869018555
APTIOM,Somnolence,disorder Tremor Dysarthria Memory impairment,0,0.5427646636962891
APTIOM,Somnolence,Tremor Dysarthria,0,0.5314247608184814
APTIOM,Headache,Headache Ataxia Balance,1,0.7335392236709595
APTIOM,Ataxia,Ataxia Balance disorder Tremor Dysarthria,1,0.8406180143356323
APTIOM,Ataxia,Ataxia Balance disorder Tremor Dysarthria Memory,1,0.8344619274139404
APTIOM,Ataxia,Headache,0,0.5697788000106812
APTIOM,Balance disorder,Balance disorder Tremor,1,0.8717464208602905
APTIOM,Balance disorder,Dysarthria Memory impairment Nystagmus,0,0.6250101327896118
APTIOM,Balance disorder,Headache Balance disorder,1,0.8391736149787903
APTIOM,Balance disorder,disorders Dizziness Somnolence Headache,0,0.6209337711334229
APTIOM,Tremor,Somnolence Headache Ataxia Balance Tremor,1,0.7133538126945496
APTIOM,Tremor,disorders Dizziness Somnolence Headache,0,0.533482551574707
APTIOM,Tremor,Tremor Dysarthria Memory impairment Nystagmus,1,0.7719399929046631
APTIOM,Dysarthria,Headache Ataxia Balance disorder Dysarthria,1,0.8055435419082642
APTIOM,Dysarthria,Tremor Dysarthria Memory impairment Nystagmus,1,0.7708133459091187
APTIOM,Dysarthria,Memory impairment Nystagmus,0,0.583334743976593
APTIOM,Dysarthria,Memory,0,0.53288733959198
APTIOM,Memory impairment,disorder Tremor Memory,1,0.7434995174407959
APTIOM,Memory impairment,disorder Tremor,0,0.5750387907028198
APTIOM,Memory impairment,Nystagmus Psychiatric disor,0,0.5435158014297485
APTIOM,Memory impairment,Tremor Dysarthria,0,0.5905874967575073
APTIOM,Nystagmus,Psychiatric,0,0.5368869304656982
APTIOM,Nystagmus,Nystagmus Psychiatric,1,0.8621341586112976
APTIOM,Depression,Psychiatric Depression,1,0.8625278472900391
APTIOM,Depression,Nystagmus Psychiatric,1,0.6080666780471802
APTIOM,Depression,agmus,0,0.44538745284080505
APTIOM,Insomnia,Insomnia,1,1.0000001192092896
APTIOM,Insomnia,thoracic and,0,0.43224430084228516
APTIOM,Insomnia,Psychiatric,0,0.5770912170410156
APTIOM,Insomnia,Insomnia Respiratory thoracic and,1,0.7735407948493958
APTIOM,Insomnia,Insomnia Respiratory thoracic,1,0.7731029987335205
APTIOM,Insomnia,Insomnia Respiratory,1,0.8202595710754395
APTIOM,Rash,Rash Vascular,1,0.8291141986846924
APTIOM,Rash,disorders,0,0.5988904237747192
APTIOM,Rash,Vascular disorders Hyperten,0,0.514392077922821
APTIOM,Hypertension,Hypertension Other,1,0.8915776014328003
APTIOM,Hypertension,disorders,0,0.6091046929359436
APTIOM,Hypertension,Hypertension,1,0.9999999403953552
APTIOM,Hypertension,Vascular disorders,0,0.6605312824249268
APTIOM,Hypertension,Vascular,0,0.6455400586128235
APTIOM,Suicidal Behavior,more detail in the Warnings and Precautions section,0,0.5663295388221741
APTIOM,Suicidal Behavior,The following adverse ctions are descri,1,0.5803024172782898
APTIOM,Suicidal Behavior,in the Warnings and Precautions section of the label,0,0.5438442230224609
APTIOM,Suicidal Behavior,adverse ctions are descri bed,1,0.6082013845443726
APTIOM,Suicidal Behavior,are descri bed in more detail,1,0.4765099883079529
APTIOM,Suicidal Behavior,of the,0,0.47941550612449646
APTIOM,Dermatologic Reactions,of the  Suicidal Behavior and Ideation see Warnings and Precautions,1,0.49624818563461304
APTIOM,Dermatologic Reactions,of the,0,0.48256897926330566
APTIOM,Dermatologic Reactions,section of the Suicidal Behavior,1,0.4781038761138916
APTIOM,Dermatologic Reactions,Serious Dermatologic,0,0.7873963117599487
APTIOM,Dermatologic Reactions,the  Suicidal Behavior and,1,0.4679156541824341
APTIOM,Dermatologic Reactions,more detail in the Warnings and Precautions section of,0,0.5609556436538696
APTIOM,Dermatologic Reactions,Suicidal Behavior and,1,0.46290695667266846
APTIOM,Dermatologic Reactions,Reactions,0,0.7650399208068848
APTIOM,Dermatologic Reactions,Suicidal Behavior and Ideation see Warnings and,1,0.48943763971328735
APTIOM,Dermatologic Reactions,the Suicidal Behavior,1,0.4708956778049469
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Serious Dermatologic Reactions see Warnings and Precautions Drug Reaction with,0,0.7716265916824341
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,"label Suicidal Behavior and deation [see Warnings and Precautions (  5.1  )]  
 *",1,0.5550214648246765
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,in the Warnings and Precautions section of the label Suicidal Behavior and,0,0.5637232661247253
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,and Precautions section of the label Suicidal Behavior and I,0,0.5626181364059448
APTIOM,DRESS,of the label Suicidal Behavior,0,0.4835498332977295
APTIOM,DRESS,see Warnings and Precautions,0,0.526214063167572
APTIOM,DRESS,Serio us Dermatologic Reactions,1,0.5393930077552795
APTIOM,Anaphylactic Reactions,and Systemic Symptom,0,0.5603095293045044
APTIOM,Anaphylactic Reactions,Warnings and Precautions Dermatologic,1,0.5822869539260864
APTIOM,Angioedema,Precautions Serious Dermatologic Reactions  Warnings  and Precautions Drug,1,0.5919387340545654
APTIOM,Angioedema,Warnings and Precautions Dermatologic,1,0.5748966932296753
APTIOM,Angioedema, Warnings  and Precautions Drug Reaction,1,0.5752609968185425
APTIOM,Angioedema,Warnings and,0,0.5275458693504333
APTIOM,Angioedema,and Ideation see Warnings and Precautions Serious Dermatologic,0,0.5599631071090698
APTIOM,Angioedema, Warnings  and,1,0.5275458693504333
APTIOM,Angioedema, Warnings  and Precautions,1,0.5282502770423889
APTIOM,Angioedema, Warnings  and Precautions Drug,1,0.5463293790817261
APTIOM,Angioedema,Precautions Serious Dermatologic Reactions  Warnings ,1,0.607881486415863
APTIOM,Angioedema,with Eosinophilia and Systemic Symptoms,0,0.611247718334198
APTIOM,Neurological Adverse Reactions,Precautions Neurological,0,0.8071604371070862
APTIOM,Neurological Adverse Reactions,see nings and Precautions (  5.4   Hyponatremia see Warnings,1,0.6195656061172485
APTIOM,Neurological Adverse Reactions,Hyponatremia see Warnings,0,0.6544255018234253
APTIOM,Neurological Adverse Reactions,Warnings and Precautions,0,0.6484099626541138
APTIOM,Neurological Adverse Reactions,Precautions Neurological Adverse,0,0.8539069890975952
APTIOM,Neurological Adverse Reactions,Angioedema see nings and Precautions,1,0.6230902671813965
APTIOM,Neurological Adverse Reactions,Precautions ( 5.4 Hyponatremia see Warnings and,1,0.6137471199035645
APTIOM,Neurological Adverse Reactions,see nings and Precautions (  5.4   Hyponatremia,1,0.596061646938324
APTIOM,Drug Induced Liver Injury,nausea,0,0.55060875415802
APTIOM,Drug Induced Liver Injury,common adverse ons in patients receiving APTIOM and,1,0.5829629898071289
APTIOM,Drug Induced Liver Injury,reacti,0,0.4980695843696594
APTIOM,Drug Induced Liver Injury,and greater than placebo dizziness somnolence nausea,0,0.5413886308670044
APTIOM,Drug Induced Liver Injury,greater than placebo dizziness somnolence nausea headache diplopia,0,0.5344966650009155
APTIOM,Drug Induced Liver Injury,somnolence nausea headache diplopia,0,0.47960788011550903
APTIOM,Drug Induced Liver Injury,patients receiving APTIOM and greater,1,0.5355060696601868
APTIOM,suicidal thoughts,report SUSPECTED ADVERSE,0,0.5487164855003357
APTIOM,suicidal thinking,"Clinical Studies patients received IOM, of whom 225",1,0.4552706480026245
APTIOM,suicidal thinking,whom 225,1,0.4621233344078064
APTIOM,suicidal thinking,"patients received IOM,",1,0.459555983543396
APTIOM,suicidal thinking,"Clinical Studies patients received IOM, of whom 225  were treated for longer than",1,0.46204063296318054
APTIOM,suicidal thinking,whom 225 were treated for,1,0.4864383637905121
APTIOM,suicidal thinking,Studies patients,0,0.4726692736148834
APTIOM,suicidal thinking,and for longer than months Of the patients,0,0.48043733835220337
APTIOM,suicidal thinking,longer,0,0.4872639775276184
APTIOM,suicidal thinking,were,1,0.4538954496383667
APTIOM,suicidal thinking,received APTIOM of were treated for,1,0.4762742817401886
APTIOM,suicidal thinking,were treated for  longer,1,0.5121329426765442
APTIOM,suicidal thinking,of were treated for  longer,1,0.5132128596305847
APTIOM,suicidal thinking,of were treated for,1,0.5111305713653564
APTIOM,suicidal thinking,treated for,1,0.5103300213813782
APTIOM,suicides,e placeb o,1,0.4869762659072876
APTIOM,suicides,treated for,1,0.5158734321594238
APTIOM,suicides,APTIOM of whom were treated,0,0.49794095754623413
APTIOM,suicides,longer than,0,0.47994405031204224
APTIOM,suicidal thoughts,in those trials approximately e between 18 and,1,0.4849701523780823
APTIOM,suicidal thoughts,approximately e between 18 and ,1,0.48385369777679443
APTIOM,suicidal thoughts,in those trials approximately e between 18 and  years old approximately were male,1,0.49371659755706787
APTIOM,suicidal thoughts,in those trials approximately e between 18 and  years old approximately,1,0.4916882812976837
APTIOM,suicidal thoughts,APTIOM Of,0,0.45895877480506897
APTIOM,suicidal thoughts,e between 18 and  years old approximately were male,1,0.5075318217277527
APTIOM,suicidal thoughts,between 18 and years old approximately were male,1,0.5153172016143799
APTIOM,suicidal thoughts,between 18 and years old approximately were,1,0.5123398303985596
APTIOM,suicidal thoughts,those trials approximately e between 18 and  years old approximately were,1,0.4973582327365875
APTIOM,suicidal thoughts,in those trials,0,0.48542287945747375
APTIOM,suicidal thoughts,at the recommend ed doses of,1,0.4902775287628174
APTIOM,suicidal thoughts,at the recommend ed doses of mg and,1,0.47982001304626465
APTIOM,suicidal thoughts,and mg once daily discontinued from the,0,0.46583953499794006
APTIOM,suicidal thoughts,randomized to receive at,1,0.4495569169521332
APTIOM,suicidal thoughts,APTIOM,0,0.4486704468727112
APTIOM,suicidal thoughts,of,0,0.48606008291244507
APTIOM,suicidal thoughts,as a result o f an adverse,1,0.5270345211029053
APTIOM,Suicidal Thoughts,fatigue were all reported at,0,0.5236810445785522
APTIOM,Suicidal Thoughts,Titration Phase,0,0.44543856382369995
APTIOM,Suicidal Thoughts,incidences durin g the AED Withdrawal,1,0.46237248182296753
APTIOM,Suicidal Thoughts,incidences durin g,1,0.4962884187698364
APTIOM,Suicidal Thoughts,Phase compared with the Titration,0,0.41710031032562256
APTIOM,Suicidal Thoughts,and fatigue were all reported at lower,0,0.5108318328857422
APTIOM,Suicidal Thoughts,Withdrawal Phase,0,0.47441527247428894
APTIOM,suicidal thoughts,than,0,0.5160808563232422
APTIOM,suicidal thoughts,than ebo) were dizzine ss somnolence nausea,1,0.5568139553070068
APTIOM,suicidal thoughts,ebo) were dizzine ss somnolence nausea,1,0.5539936423301697
APTIOM,suicidal thoughts,mg and greater than ebo),1,0.4542270302772522
APTIOM,suicidal thoughts,greater than,0,0.4679064154624939
APTIOM,suicidal thoughts,receiving,0,0.4589257538318634
APTIOM,mortality,initial dose mg for 1  week and,1,0.5033681988716125
APTIOM,mortality,receiving,0,0.509871244430542
APTIOM,mortality,for 1 week and then increased,1,0.49640804529190063
APTIOM,mortality,and then increased to mg compared to patients who initiated therapy at mg,0,0.5124199390411377
APTIOM,mortality,mg for 1 week and,1,0.5120881795883179
APTIOM,suicidal thoughts,and then increased  800 mg compared  to patients who,1,0.455939382314682
APTIOM,suicidal thoughts,mg for 1 week and,1,0.4600711762905121
APTIOM,suicidal thoughts,and,0,0.46735239028930664
APTIOM,suicidal thoughts,then increased 800 mg,1,0.45582956075668335
APTIOM,suicidal thoughts,patients who began therapy at an initial dose of mg for week,0,0.50559002161026
APTIOM,suicidal thoughts,then increased  800 mg compared  to patients who initiated therapy,1,0.4789423644542694
APTIOM,suicidal thoughts,dose of mg for week and,0,0.4583079218864441
APTIOM,suicidal thoughts,mg for week,0,0.4797859787940979
APTIOM,suicidal thoughts,800 mg compared,1,0.4458373486995697
APTIOM,suicidal thoughts,therapy at mg Table Adverse Reactions Incidence in Pooled,0,0.4769434928894043
APTIOM,dermatologic reactions,disorders Diplopia Blurred vision Visual,0,0.4803691804409027
APTIOM,dermatologic reactions,      1151             Gastrointestinal disorders,1,0.5298455953598022
APTIOM,dermatologic reactions,ye disorders Diplopia Blurred vision,0,0.49407535791397095
APTIOM,Stevens-Johnson Syndrome,Gastrointestinal disor,1,0.5745201110839844
APTIOM,Stevens-Johnson Syndrome,"rred vision Visual 
 Gastrointestinal disor ders",1,0.5147800445556641
APTIOM,Stevens-Johnson Syndrome,vision,0,0.4973388612270355
APTIOM,Stevens-Johnson Syndrome,Gastrointestinal disor ders,1,0.580154538154602
APTIOM,Stevens-Johnson Syndrome,Visual,0,0.5160164833068848
APTIOM,SJS,rs ,1,0.6383607387542725
APTIOM,fatal,Constipation,0,0.5441373586654663
APTIOM,fatal,      Nausea Vomiting Diarrhea Constipation Abdominal,1,0.5935158729553223
APTIOM,fatal,      Nausea Vomiting,1,0.6113756895065308
APTIOM,fatal,Nausea Vomiting Diarrhea Constipation,0,0.5769039988517761
APTIOM,fatal,Diarrhea Constipation,0,0.5431829690933228
APTIOM,fatal,strointestinal       Nausea Vomiting Diarrhea Constipation,1,0.5795998573303223
APTIOM,fatal,disorders,0,0.5877641439437866
APTIOM,fatal,Constipation Abdominal pain Gastritis,0,0.499239057302475
APTIOM,fatal,      Nausea,1,0.5998321771621704
APTIOM,fatal,Constipation Abdominal pain,0,0.4995255470275879
APTIOM,dermatologic reactions,Nausea Vomit,1,0.509722888469696
APTIOM,dermatologic reactions,testinal       Nausea     Vomit ing Diarrhea Constipation Abdominal pain,1,0.5698368549346924
APTIOM,dermatologic reactions,Diarrhea Constipation Abdominal,0,0.5031755566596985
APTIOM,dermatologic reactions,testinal       Nausea     Vomit,1,0.5470987558364868
APTIOM,dermatologic reactions,      Nausea     Vomit,1,0.509722888469696
APTIOM,dermatologic reactions,Nausea Vomit ing Diarrhea Constipation Abdominal,1,0.5408609509468079
APTIOM,toxic epidermal necrolysis,Nausea Vomiting rhea,1,0.5032617449760437
APTIOM,toxic epidermal necrolysis,rhea Constipation,1,0.4504440426826477
APTIOM,toxic epidermal necrolysis,Nausea Vomiting rhea     Constipation     ,1,0.5003483295440674
APTIOM,toxic epidermal necrolysis,Abdominal pain Gastritis,0,0.47769695520401
APTIOM,toxic epidermal necrolysis,Diar,0,0.4589160978794098
APTIOM,TEN,dom inal pain Gastritis General,1,0.5001054406166077
APTIOM,TEN,dom inal pain Gastritis,1,0.4954835772514343
APTIOM,TEN,Diarrhea,0,0.566009521484375
APTIOM,TEN,inal pain Gastritis General,0,0.5052951574325562
APTIOM,TEN,dom inal pain,1,0.5294411182403564
APTIOM,TEN,Diarrhea Constipation dom inal,1,0.5239702463150024
APTIOM,TEN,dom inal,1,0.5423887968063354
APTIOM,TEN,dom,1,0.5358923673629761
APTIOM,SJS,ain,1,0.4918859302997589
APTIOM,SJS,ain Gastritis General disorders,1,0.4777836799621582
APTIOM,SJS,Gastritis General,0,0.5103488564491272
APTIOM,SJS,ain Gastritis General,1,0.4878212511539459
APTIOM,SJS,Nausea Vomiting,0,0.4360569715499878
APTIOM,SJS,Diarrhea Constipation,0,0.46980780363082886
APTIOM,SJS,Gastritis General disorders,0,0.4896112084388733
APTIOM,SJS,Nausea Vomiting Diarrhea,0,0.4347303509712219
APTIOM,dermatologic reactions,           7321        Infections and Infestations Urinary tract,1,0.5207463502883911
APTIOM,dermatologic reactions,Peripheral            7321       ,1,0.4966028332710266
APTIOM,dermatologic reactions,           7321        Infections,1,0.5365248918533325
APTIOM,dermatologic reactions,Gait disturbance Peripheral            7321        Infections and,1,0.5298680067062378
APTIOM,dermatologic reactions,Urinary,0,0.5191172361373901
APTIOM,dermatologic reactions,Gait,0,0.47250866889953613
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,"and nutrition                                 
      Hyponatremia  ",1,0.45763278007507324
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Gait,0,0.456911563873291
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,"                                
      Hyponatremia   Nervous",1,0.5394562482833862
APTIOM,DRESS,      Nervous system di,1,0.4891018569469452
APTIOM,DRESS,ders,0,0.5437138676643372
APTIOM,DRESS,      Nervous system,1,0.4958363175392151
APTIOM,DRESS,      Nervous,1,0.5746495723724365
APTIOM,fatal,ers   Dizziness Somnolence Headache Ataxia,1,0.5292361974716187
APTIOM,fatal,ers   Dizziness Somnolence,1,0.49469873309135437
APTIOM,fatal,system disord,0,0.5055433511734009
APTIOM,fatal,ers   Dizziness Somnolence Headache Ataxia Balance,1,0.5281445384025574
APTIOM,DRESS,lence Headache Ataxia,1,0.43886131048202515
APTIOM,DRESS,Ataxia Balance disorder Tremor Dysarthria,0,0.4738820195198059
APTIOM,DRESS,Dysarthria,0,0.4981567859649658
APTIOM,DRESS,system disorders Dizziness Somno,0,0.41758856177330017
APTIOM,DRESS,system disorders Dizziness lence Headache Ataxia Balance disorder,1,0.44016143679618835
APTIOM,fever,emor ,1,0.4458830952644348
APTIOM,fever,emor  Dysarthria,1,0.44824516773223877
APTIOM,fever,emor  Dysarthria Memory,1,0.44154036045074463
APTIOM,fever,Dysarthria Memory,0,0.45244401693344116
APTIOM,fever,disorder Tr,0,0.5059816241264343
APTIOM,rash,Ataxia Balance disorder   Dy sarthria Memory,1,0.5340555310249329
APTIOM,rash,disorder Tr,0,0.5924281477928162
APTIOM,rash,Balance disorder   Dy sarthria Memory impairment Nystagmus,1,0.5275452136993408
APTIOM,lymphadenopathy,Balance disorder,0,0.5144054889678955
APTIOM,lymphadenopathy,disorder Tremor Memory impa,1,0.49697747826576233
APTIOM,hepatitis,Memory,0,0.5321188569068909
APTIOM,hepatitis,disorders Depression,0,0.5021283030509949
APTIOM,hepatitis,Dysarthria Memory impairment 181563422,1,0.4831189811229706
APTIOM,hepatitis,181563422 Psychiatric,1,0.5016587972640991
APTIOM,hepatitis,Memory impairment 181563422 Psychiatric disorders Depression,1,0.4937071204185486
APTIOM,hepatitis,181563422,1,0.47629767656326294
APTIOM,hepatitis,Psychiatric,0,0.5456954836845398
APTIOM,nephritis,          Psychiatric disorders,1,0.5484815835952759
APTIOM,nephritis,disorders Depression,0,0.5237594842910767
APTIOM,nephritis,Memory impairment           Psychiatric disorders Depression Insomnia,1,0.5014728307723999
APTIOM,nephritis,          Psychiatric,1,0.5314745903015137
APTIOM,nephritis,Memory impairment           Psychiatric disorders Depression,1,0.493742972612381
APTIOM,hematological abnormalities,Psychiatric disorders Depression Insomnia,1,0.6001501083374023
APTIOM,hematological abnormalities,"   
 Psychiatric disorders ",1,0.6216304302215576
APTIOM,myocarditis,disorders,0,0.5684393644332886
APTIOM,myocarditis,  Depressio n,1,0.4938315153121948
APTIOM,myocarditis,  Depressio n Insomnia Respiratory thor,1,0.4956878125667572
APTIOM,myocarditis,Psychiatric   Depressio n,1,0.45879480242729187
APTIOM,myocarditis,  Depressio,1,0.5060585141181946
APTIOM,myocarditis,stagmus Psychiatric,0,0.5038532018661499
APTIOM,myocarditis,  Depressio n Insomnia,1,0.47048452496528625
APTIOM,myocarditis,stagmus Psychiatric   Depressio n Insomnia,1,0.5035971403121948
APTIOM,myositis, Insomni,1,0.5426176190376282
APTIOM,myositis,  Depressio n,1,0.47857749462127686
APTIOM,myositis,Respiratory thoracic and,0,0.5125054121017456
APTIOM,myositis,Psychiatric disorders,0,0.5199262499809265
APTIOM,myositis,Depression,0,0.5368897914886475
APTIOM,myositis, Insomni a Respiratory thoracic,1,0.5452457070350647
APTIOM,myositis,a,0,0.4909389615058899
APTIOM,Eosinophilia,disorders Depression              Respiratory thoracic,1,0.5797338485717773
APTIOM,Eosinophilia,a,0,0.5396884083747864
APTIOM,Eosinophilia,Insomnia,0,0.4813581109046936
APTIOM,Eosinophilia,Psychiatric disorders Depression              Respiratory thoracic and mediastinal disorders,1,0.5672715902328491
APTIOM,Eosinophilia,             Respiratory thoracic and,1,0.5502575039863586
APTIOM,Eosinophilia,             Respiratory thoracic and mediastinal,1,0.526665210723877
APTIOM,Eosinophilia,and mediastinal,0,0.5065032243728638
APTIOM,Eosinophilia,             Respiratory thoracic,1,0.540550708770752
APTIOM,Eosinophilia,disorders,0,0.6449887752532959
APTIOM,Eosinophilia,and mediastinal disorders,0,0.5640449523925781
APTIOM,rash,sue disorders Rash Vascular,0,0.8027110695838928
APTIOM,angioedema,in creatin,1,0.5801039934158325
APTIOM,angioedema,in hemoglobin and,0,0.5526482462882996
APTIOM,angioedema,in creatin e phosphokinase Adverse Reactions Based,1,0.5963937044143677
APTIOM,angioedema,triglycerides and LDL and in creatin e phosphokinase Adverse Reactions,1,0.6073521375656128
APTIOM,angioedema,hemoglobin and hematocrit,0,0.534416675567627
APTIOM,angioedema,gender differences,0,0.47288277745246887
APTIOM,angioedema,reactions,0,0.5928596258163452
APTIOM,angioedema,"Race  



",1,0.5322344303131104
APTIOM,angioedema,phosphokinase Adverse Reactions Based on Gender and,0,0.5835225582122803
APTIOM,angioedema,"Based on Gender Race  



 No significant",1,0.44765838980674744
APTIOM,angioedema,"Race  



 No significant gender differences",1,0.4303159713745117
APTIOM,angioedema,"Race  



 No significant gender",1,0.47408491373062134
APTIOM,laryngeal edema,of adverse reactions Although there were few,0,0.5178331732749939
APTIOM,laryngeal edema,and Race No significant ender differenc,1,0.4303332567214966
APTIOM,laryngeal edema,in the incidence of adverse reactions Although there were few nonCaucasian,0,0.5297877192497253
APTIOM,laryngeal edema,ender,1,0.4607789218425751
APTIOM,fatal,Although there were few,0,0.44290298223495483
APTIOM,fatal,noted in,1,0.5129329562187195
APTIOM,fatal,noted in the incidence,1,0.5588775277137756
APTIOM,fatal,No significant,0,0.48911356925964355
DUAVEE,Cardiovascular Disorders,of the Cardiovascular Disorders see Warnings,1,0.8470690250396729
DUAVEE,Cardiovascular Disorders,No significant,0,0.4444068670272827
DUAVEE,Cardiovascular Disorders,discussed in greater,0,0.48689451813697815
DUAVEE,Cardiovascular Disorders,Cardiovascular Disorders see Warnings,1,0.8483214378356934
DUAVEE,Cardiovascular Disorders,in greater,0,0.49500784277915955
DUAVEE,Cardiovascular Disorders,see Warnings and Precautions Malignant,0,0.4929587244987488
DUAVEE,Malignant Neoplasms,Malignant,1,0.8336909413337708
DUAVEE,Malignant Neoplasms,and Malignant Neoplasms,1,0.9582087397575378
DUAVEE,Malignant Neoplasms,Precautions,0,0.5400277972221375
DUAVEE,Malignant Neoplasms,and Precautions Gallbladder Disease see,0,0.5544790625572205
DUAVEE,Malignant Neoplasms,and Precautions Gallbladder Disease see Warnings and Precautions,0,0.5497241020202637
DUAVEE,Malignant Neoplasms,Cardiovascular Disorders see,0,0.5402699708938599
DUAVEE,Malignant Neoplasms,Disorders see Warnings and Malignant Neoplasms,1,0.7971705198287964
DUAVEE,Malignant Neoplasms,Malignant Neoplasms,1,1.0
DUAVEE,Malignant Neoplasms,Warnings and Malignant,1,0.7312740087509155
DUAVEE,Gallbladder Disease,Warnings and Precautions,0,0.5293187499046326
DUAVEE,Gallbladder Disease,and Gallbladder,1,0.846670389175415
DUAVEE,Gallbladder Disease,Malignant Neoplasms,0,0.5812418460845947
DUAVEE,Gallbladder Disease,Precautions,0,0.5129282474517822
DUAVEE,Gallbladder Disease,Gallbladder Disease,1,1.0
DUAVEE,Gallbladder Disease,gs and Precautions Malignant Neoplasms see Warnings,0,0.5494873523712158
DUAVEE,Gallbladder Disease,see Warnings and Gallbladder Disease see Warnings and,1,0.840616762638092
DUAVEE,Hypertriglyceridemia,see Warnings and Precautions EXCERPT In four,0,0.4860514998435974
DUAVEE,muscle spasms,incidence were,0,0.5592315793037415
DUAVEE,muscle spasms,reactions incidence,0,0.5725011229515076
DUAVEE,muscle spasms,abdominal pain upper oropharyngeal,0,0.5334610939025879
DUAVEE,muscle spasms,incidence muscle spasms nausea diarrhea,1,0.8393439650535583
DUAVEE,muscle spasms,reactions incidence muscle spasms nausea diarrhea,1,0.8425018191337585
DUAVEE,nausea,nausea diarrhea dyspepsia abdominal pain,1,0.7658111453056335
DUAVEE,nausea,the common adverse reactions incidence were muscle spasms,0,0.6107094287872314
DUAVEE,nausea,incidence were muscle nausea diarrhea,1,0.7352384328842163
DUAVEE,nausea,pain upper,0,0.6144315004348755
DUAVEE,nausea,nausea diarrhea dyspepsia abdominal,1,0.7867685556411743
DUAVEE,nausea,incidence were muscle spasms,0,0.5762481689453125
DUAVEE,nausea,pain upper oropharyngeal pain dizziness and neck pain,0,0.6306226253509521
DUAVEE,diarrhea,diarrhea dyspepsia abdominal,1,0.7852596044540405
DUAVEE,diarrhea,muscle spasms,0,0.5709371566772461
DUAVEE,dyspepsia,dyspepsia,1,1.0000001192092896
DUAVEE,abdominal pain upper,nausea diarrhea abdominal pain,1,0.7883216738700867
DUAVEE,abdominal pain upper,als the common adverse reactions incidence were muscle spasms nausea,0,0.5508097410202026
DUAVEE,abdominal pain upper,diarrhea abdominal,1,0.7359679937362671
DUAVEE,abdominal pain upper,neck pain,0,0.5848252177238464
DUAVEE,abdominal pain upper,and neck,0,0.489216148853302
DUAVEE,abdominal pain upper,report SUSPECTED,0,0.4471587836742401
DUAVEE,abdominal pain upper,diarrhea abdominal pain upper oropharyngeal,1,0.807985782623291
DUAVEE,abdominal pain upper,diarrhea dyspepsia,0,0.622260570526123
DUAVEE,oropharyngeal pain,oropharyngeal pain dizziness and neck pain To,1,0.8289723992347717
DUAVEE,oropharyngeal pain,contact Pfizer Inc,0,0.4957852363586426
DUAVEE,oropharyngeal pain,report SUSPECTED,0,0.42293304204940796
DUAVEE,oropharyngeal pain,oropharyngeal pain,1,1.0
DUAVEE,oropharyngeal pain,abdominal pain oropharyngeal pain,1,0.8722161650657654
DUAVEE,oropharyngeal pain,abdominal pain oropharyngeal pain dizziness and neck pain,1,0.7699703574180603
DUAVEE,oropharyngeal pain,reactions incidence,0,0.4612330496311188
DUAVEE,dizziness,dizziness,1,0.9999998807907104
DUAVEE,dizziness,dizziness and neck pain,1,0.8512656688690186
DUAVEE,dizziness,dizziness and neck pain To,1,0.8641268014907837
DUAVEE,neck pain,dizziness and,0,0.5608567595481873
DUAVEE,mortality,was in the DUAVEE group and in the placebo group The incidence of,0,0.533340334892273
DUAVEE,mortality,was in the DUAVEE group and in the,0,0.48925715684890747
DUAVEE,hot flush,commonly observed adverse,0,0.5689547061920166
DUAVEE,hot flush,most commonly observed adverse,0,0.5649638175964355
DUAVEE,hot flush,observed adverse reactions,0,0.5584371089935303
DUAVEE,hot flush,The most common,0,0.5466947555541992
DUAVEE,hot flush,nausea,0,0.5594497919082642
DUAVEE,hot flush,and in the placebo group The most common adverse reactions leading to,0,0.5619412660598755
DUAVEE,hot flush,reactions leading to discontinuation hot flush,1,0.8545231819152832
DUAVEE,abdominal pain upper,most common adverse reactions leading to discontinuation were hot flush,0,0.5298044681549072
DUAVEE,abdominal pain upper,were hot abdominal pain upper,1,0.8940042853355408
DUAVEE,abdominal pain upper,leading to discontinuation were hot,0,0.47596898674964905
DUAVEE,abdominal pain upper,observed,0,0.4748396873474121
DUAVEE,abdominal pain upper,abdominal pain upper and nausea The,1,0.9149266481399536
DUAVEE,abdominal pain upper,pain upper and nausea,1,0.806472659111023
DUAVEE,abdominal pain upper,adverse reactions incidence,0,0.5328128337860107
DUAVEE,abdominal pain upper,discontinuation were hot,0,0.4772195518016815
DUAVEE,abdominal pain upper,abdominal pain upper and nausea,1,0.9204386472702026
DUAVEE,abdominal pain upper,hot abdominal pain,1,0.8102926015853882
DUAVEE,nausea,pain upper nausea The,1,0.8559227585792542
DUAVEE,nausea,hot abdominal pain,1,0.6159836649894714
DUAVEE,nausea,frequently reported in wom,0,0.5271188020706177
DUAVEE,nausea,upper,0,0.5147274136543274
DUAVEE,venous thromboembolism,venous thromboembolism deep venous thrombosis,1,0.9365399479866028
DUAVEE,venous thromboembolism,venous thromboembolism deep,1,0.882739782333374
DUAVEE,venous thromboembolism,venous thromboembolism deep venous,1,0.9004260301589966
DUAVEE,venous thromboembolism,Venous thromboembolism In the clinical studies,0,0.8717347383499146
DUAVEE,venous thromboembolism,embolism and retinal vein thrombosis were low in,0,0.7410731315612793
DUAVEE,venous thromboembolism,and retinal vein thrombosis were low in all,0,0.69700026512146
DUAVEE,venous thromboembolism,for,0,0.5417541265487671
DUAVEE,venous thromboembolism,the reporting rates venous thromboembolism deep,1,0.8545259237289429
DUAVEE,deep venous thrombosis,venous deep,1,0.7769657373428345
DUAVEE,deep venous thrombosis,deep venous,1,0.8492798805236816
DUAVEE,deep venous thrombosis,for venous deep venous thrombosis,1,0.9227796792984009
DUAVEE,deep venous thrombosis,rates for venous deep,1,0.7567346096038818
DUAVEE,deep venous thrombosis,thromboembolism,0,0.8285215497016907
DUAVEE,deep venous thrombosis,treatment groups Adverse reactio,0,0.5108039975166321
DUAVEE,deep venous thrombosis,groups,0,0.45981401205062866
DUAVEE,venous thromboembolism,treatment groups Adverse reactions venous thromboembolism,1,0.8109105825424194
DUAVEE,venous thromboembolism,Adverse reactions venous,1,0.7112157940864563
DUAVEE,venous thromboembolism,treatment groups,0,0.47528183460235596
DUAVEE,venous thromboembolism,that the risk venous thromboembolism,1,0.8806654810905457
DUAVEE,venous thromboembolism,not possible to conclude,0,0.45920330286026
DUAVEE,venous thromboembolism,venous thromboembolism with DUAVEE is different from,1,0.8365354537963867
DUAVEE,venous thromboembolism,risk venous thromboembolism with,1,0.8828490376472473
DUAVEE,venous thromboembolism,conclude that the risk venous thromboembolism with,1,0.8699032068252563
DUAVEE,venous thromboembolism,that seen with other estrogen therapies see Warnings,0,0.5487939119338989
DUAVEE,venous thromboembolism,the risk venous thromboembolism with DUAVEE is different from,1,0.8108974695205688
DUAVEE,ENDOMETRIAL CANCER,following adverse reactions are discussed in greater,1,0.49096590280532837
DUAVEE,ENDOMETRIAL CANCER,REACTIONS  following adverse,1,0.4668624997138977
DUAVEE,ENDOMETRIAL CANCER,are discussed in greater detail in other sections of the label Cardiovascular,0,0.5187673568725586
DUAVEE,ENDOMETRIAL CANCER, following adverse reactions,1,0.4917781949043274
DUAVEE,ENDOMETRIAL CANCER,detail in other sections of,0,0.5038424134254456
DUAVEE,CARDIOVASCULAR DISORDERS,following adverse eactions are discussed i n,1,0.5623159408569336
DUAVEE,CARDIOVASCULAR DISORDERS,detail in other sections of,0,0.5251799821853638
DUAVEE,CARDIOVASCULAR DISORDERS,REACTIONS The following adverse eactions are discussed i n greater detail,1,0.5545921325683594
DUAVEE,CARDIOVASCULAR DISORDERS,adverse eactions are discussed i n greater detail in,1,0.557292103767395
DUAVEE,CARDIOVASCULAR DISORDERS,the label Cardiovascular Disorders see Warnings and,0,0.8101567029953003
DUAVEE,CARDIOVASCULAR DISORDERS,adverse,0,0.5472041368484497
DUAVEE,CARDIOVASCULAR DISORDERS,following adverse eactions are,1,0.5676390528678894
DUAVEE,DEMENTIA,following adverse reactions are discussed,0,0.5289801359176636
DUAVEE,DEMENTIA,l in oth er sections of,1,0.5424498319625854
DUAVEE,DEMENTIA,in,0,0.5247114300727844
DUAVEE,DEMENTIA,REACTIONS The following adverse,0,0.5210354328155518
DUAVEE,DEMENTIA,in oth er sections,1,0.5196052193641663
DUAVEE,DEMENTIA,are discussed in greater l in oth er sections of the,1,0.5247758626937866
DUAVEE,DEMENTIA,l in oth,1,0.5006006360054016
DUAVEE,DEMENTIA,detai,0,0.5121197700500488
DUAVEE,ENDOMETRIAL CANCER,of he label:,1,0.4659764766693115
DUAVEE,CARDIOVASCULAR DISORDERS,the label,0,0.4622840881347656
DUAVEE,CARDIOVASCULAR DISORDERS,diovascular Disorders [s ee,1,0.7410506010055542
DUAVEE,DEMENTIA,see Warnings,0,0.5482370853424072
DUAVEE,DEMENTIA,d Precau,1,0.5323084592819214
DUAVEE,endometrial hyperplasia,"mized, placebo-controll",1,0.5126217603683472
DUAVEE,endometrial hyperplasia,"EXCERPT In four prospective mized, placebo-controll",1,0.5093183517456055
DUAVEE,endometrial hyperplasia,"mized, placebo-controll ed trials the common adverse",1,0.5325933694839478
DUAVEE,endometrial hyperplasia,ed,0,0.5677859783172607
DUAVEE,endometrial hyperplasia,"prospective mized,",1,0.465864360332489
DUAVEE,stroke,drug and may not reflect the rates observed in clinical practice The safety of conjug,0,0.4884209632873535
DUAVEE,stroke,safety of,0,0.529488742351532
DUAVEE,stroke,drug cannot be directly compared to rates in,0,0.5139437913894653
DUAVEE,stroke,and may not reflect the rates observed in clinical practice The safety of,0,0.5016226172447205
DUAVEE,stroke,the rates observed in clinical practice The,0,0.5210723876953125
DUAVEE,stroke,ials o f another drug,1,0.5704358816146851
DUAVEE,stroke,in the clinical trials of a drug cannot be directly compared,0,0.5059346556663513
DUAVEE,stroke,trials,0,0.5668254494667053
DUAVEE,stroke,observed in clinical practice The,0,0.5481683015823364
DUAVEE,deep vein thrombosis,in clinical practice The safety of,0,0.5639380216598511
DUAVEE,deep vein thrombosis,the clinical trials of ther drug and may no t reflect the rates,1,0.5491875410079956
DUAVEE,deep vein thrombosis,ther drug and may no t reflect the,1,0.5032877922058105
DUAVEE,deep vein thrombosis,ano,0,0.4779415428638458
DUAVEE,deep vein thrombosis,observed in clinical practice The safety of conjugated,0,0.566929280757904
DUAVEE,deep vein thrombosis,observed in clinical practice The safety,0,0.5337129831314087
DUAVEE,deep vein thrombosis,reflect the rates,0,0.5085813999176025
DUAVEE,DVT,ref lect the rates observed in,1,0.5352433919906616
DUAVEE,DVT,ref lect,1,0.5209472179412842
DUAVEE,dementia,treated ,1,0.5686284303665161
DUAVEE,dementia,treated  with DUAVEE and patients received,1,0.5633510947227478
DUAVEE,dementia,of patients treated  with DUAVEE and,1,0.5680216550827026
DUAVEE,dementia,treated  with,1,0.5800880193710327
DUAVEE,dementia,A total of patients treated  with DUAVEE and patients,1,0.545035183429718
DUAVEE,dementia,were,0,0.5476422905921936
DUAVEE,ENDOMETRIAL CANCER,upper and,0,0.48982810974121094
DUAVEE,ENDOMETRIAL CANCER,common adverse eactions leading t,1,0.5186837911605835
DUAVEE,ENDOMETRIAL CANCER,most common adverse eactions leading,1,0.5016880631446838
DUAVEE,CARDIOVASCULAR DISORDERS,reactions leading discontinuation were hot flush abdominal pain,1,0.5383260250091553
DUAVEE,CARDIOVASCULAR DISORDERS,most common adverse eactions leading,1,0.5710492134094238
DUAVEE,CARDIOVASCULAR DISORDERS,adverse reactions leading discontinuation were hot,1,0.5231332778930664
DUAVEE,CARDIOVASCULAR DISORDERS,discontinuation were hot flush,1,0.5619069337844849
DUAVEE,CARDIOVASCULAR DISORDERS,leading discontinuation were,1,0.4627409875392914
DUAVEE,CARDIOVASCULAR DISORDERS,common adverse reactions leading discontinuation were hot,1,0.5301781892776489
DUAVEE,CARDIOVASCULAR DISORDERS,were hot,1,0.49962812662124634
DUAVEE,CARDIOVASCULAR DISORDERS,common adverse reactions leading discontinuation were,1,0.5251861214637756
DUAVEE,DEMENTIA,adverse reactions,0,0.5352373123168945
DUAVEE,endometrial cancer,"in .



 Table 1: Adv erse",1,0.554915189743042
DUAVEE,endometrial cancer,adverse reactions,0,0.5194082260131836
DUAVEE,endometrial cancer,Table 1: Adv erse Reactions Incidence,1,0.5380668640136719
DUAVEE,endometrial cancer,DUAVEE than placebo are presented in,0,0.5048513412475586
DUAVEE,endometrial cancer,placebo are presented in Table,0,0.5330501198768616
DUAVEE,endometrial cancer,Group in Placebocontrolled,0,0.5070452094078064
DUAVEE,venous thromboembolism,Warnings a nd Precautions,1,0.5199414491653442
DUAVEE,venous thromboembolism,and Precautions Malignant,0,0.5188731551170349
DUAVEE,venous thromboembolism,Warnings and Precautions Malignant lasms [see,1,0.5496170520782471
DUAVEE,venous thromboembolism,and Precautions Malignant lasms [see,1,0.5449750423431396
DUAVEE,venous thromboembolism,Malignant lasms [see Warnings,1,0.5456608533859253
DUAVEE,pulmonary embolism,Malignant Neoplasms see Warnings Precautions (5.3),1,0.5643591284751892
DUAVEE,pulmonary embolism,cular Disorders see Warnings,0,0.5302722454071045
DUAVEE,pulmonary embolism,Precautions (5.3) Gallbladder Disease see Warnings,1,0.5578733086585999
DUAVEE,pulmonary embolism,Neoplasms see Warnings  Precautions (5.3) Gallbladder Disease,1,0.5729446411132812
DUAVEE,stroke,Warnings and Precautions Malignant Neoplasms see,0,0.5094304084777832
DUAVEE,stroke,Warnings and ] *,1,0.537015438079834
DUAVEE,stroke,and ],1,0.5478813648223877
DUAVEE,retinal vascular thrombosis,[see Warni ngs,1,0.4906741976737976
DUAVEE,retinal vascular thrombosis,Precautions bladder Disease [see  Warni,1,0.48303934931755066
DUAVEE,retinal vascular thrombosis,Warnings and Precautions bladder Disease [see  Warni ngs and Precautions,1,0.4963144361972809
DUAVEE,retinal vascular thrombosis,[see Warni ngs and Precautions Hypertriglyceridemia see,1,0.5509647130966187
DUAVEE,retinal vascular thrombosis,and Precautions bladder Disease [see  Warni ngs and,1,0.4856347143650055
DUAVEE,retinal vascular thrombosis,see Warnings and Precautions bladder Disease [see  Warni ngs and Precautions Hypertriglyceridemia see,1,0.5501218438148499
DUAVEE,retinal vascular thrombosis,bladder Disease [see  Warni ngs and Precautions Hypertriglyceridemia,1,0.5436573028564453
DUAVEE,Malignant neoplasms,"see Warnings and )  ]  
 *  Hypertri glyceridemia see",1,0.5752915143966675
DUAVEE,Malignant neoplasms,[see Warni ngs and Precautions Hypertriglyceridemia see,1,0.5841764807701111
DUAVEE,Malignant neoplasms,Warnings and,0,0.5532915592193604
DUAVEE,Malignant neoplasms,Disease,0,0.6444763541221619
DUAVEE,Malignant neoplasms,* Hypertri glyceridemia see Warnings and,1,0.5711008310317993
DUAVEE,Malignant neoplasms,"and )  ]  
 *  Hypertri glyceridemia see Warnings and Precautions",1,0.5690345764160156
DUAVEE,Malignant neoplasms,Warnings and Precautions EXCERPT In four,0,0.526930034160614
DUAVEE,Malignant neoplasms,Precautions Gallbladder,0,0.5353524684906006
DUAVEE,Malignant neoplasms,] * Hypertri glyceridemia see,1,0.566336452960968
DUAVEE,endometrial cancer,Warnings an d Precautions EXCERPT In,1,0.4787721633911133
DUAVEE,endometrial cancer,and Precautions  [see  Warnings an d Precautions EXCERPT In four,1,0.4850049912929535
DUAVEE,endometrial cancer,and Precautions Hypertriglyceridemia,0,0.5005673766136169
DUAVEE,endometrial cancer,Warnings an d Precautions EXCERPT In four,1,0.4731345772743225
DUAVEE,endometrial cancer,d Precautions EXCERPT In four,0,0.4726357161998749
DUAVEE,endometrial cancer,Precautions,0,0.48998820781707764
DUAVEE,endometrial cancer,Precautions EXCERPT In,0,0.48066362738609314
DUAVEE,endometrial cancer,Warnings an d Precautions EXCERPT,1,0.4754742383956909
DUAVEE,endometrial cancer,Warnings and Precautions [see Warnings an,1,0.4871183931827545
DUAVEE,breast cancer,Warnings Precautions (,1,0.4958864152431488
DUAVEE,breast cancer,Warnings and Precautions [see Warnings an,1,0.5051363706588745
DUAVEE,breast cancer,Precautions ( EXCERPT,1,0.49328309297561646
DUAVEE,ovarian cancer,] EXCE RPT,1,0.47012218832969666
DUAVEE,ovarian cancer,"Hypertriglyceridemia see Warnings and ]  
      EXCE",1,0.5346251726150513
DUAVEE,gallbladder disease,-controlled trials the,1,0.5297480821609497
DUAVEE,VTE,enrolling postmenopausal,0,0.5457093119621277
DUAVEE,VTE, 3  clinical trials ranging from,1,0.5152596235275269
DUAVEE,VTE,and enrolling,0,0.5000618100166321
DUAVEE,VTE, 3  clinical trials,1,0.5025303959846497
DUAVEE,VTE, 3  clinical trials ranging from weeks,1,0.5119609832763672
DUAVEE,VTE,was evaluated in four  3  clinical trials ranging from weeks,1,0.516484797000885
DUAVEE,VTE,in duration and enrolling postmenopausal,0,0.5319983959197998
DUAVEE,VTE, 3  clinical trials ranging,1,0.5197457075119019
DUAVEE,VTE, 3  clinical,1,0.5135310888290405
DUAVEE,stroke,in duration and enrolling postmenopausal women age,0,0.5115693211555481
DUAVEE,stroke,clinical trials ranging,0,0.5419975519180298
DUAVEE,stroke,Phase clinical trials ranging m 12 w eeks to,1,0.5599364638328552
DUAVEE,stroke,trials ranging m 12,1,0.5488604307174683
DUAVEE,stroke,12 w eeks to months in duration,1,0.4962875247001648
DUAVEE,stroke,of conjugated estrogensbazedoxifene was evaluated in four,0,0.4996302127838135
DUAVEE,stroke,m,1,0.5241509079933167
DUAVEE,DVT,duration and enrolling postmenopausal women age to years,0,0.5314135551452637
DUAVEE,DVT,njugated estrogensbazedoxifene was evaluated in four Phase,0,0.5208573341369629
DUAVEE,DVT,to ,1,0.5834106206893921
DUAVEE,DVT,to  months in duration,1,0.48559290170669556
DUAVEE,DVT,to  months in duration and enrolling,1,0.5088319182395935
DUAVEE,DVT,njugated estrogensbazedoxifene was evaluated in four,0,0.509630024433136
DUAVEE,stroke,The incidence,0,0.5469971895217896
DUAVEE,stroke,adverse reactions ce >=  more,1,0.5433504581451416
DUAVEE,stroke,than placebo are,0,0.5177114009857178
DUAVEE,stroke,ce >=,1,0.5400307178497314
DUAVEE,stroke,nausea The most commonly observed adverse reactions,0,0.4919640123844147
DUAVEE,stroke,commonly observed adverse reactions ce >= ,1,0.5325558185577393
DUAVEE,stroke,ce >= more frequently reported,1,0.4748326539993286
DUAVEE,VTE,10 ,1,0.5165756940841675
DUAVEE,PE,disorders Muscle spasms,0,0.4840269386768341
KALYDECO,Transaminase Elevations,Transaminase Elevations see Warnings and Precautions,1,0.929619312286377
KALYDECO,Transaminase Elevations,the Transaminase,1,0.8483449816703796
KALYDECO,Transaminase Elevations,label,0,0.4637184143066406
KALYDECO,Transaminase Elevations,other sections of the Transaminase Elevations,1,0.9064937829971313
KALYDECO,Transaminase Elevations,sections of the Transaminase Elevations,1,0.9190452098846436
KALYDECO,Transaminase Elevations,adverse reaction is discussed in greater detail in other sections of the label,0,0.6032588481903076
KALYDECO,Transaminase Elevations,sections of the Transaminase Elevations see Warnings and,1,0.8853144645690918
KALYDECO,Transaminase Elevations,most common adverse drug,0,0.5340796709060669
KALYDECO,Transaminase Elevations,sections of the Transaminase,1,0.8052483797073364
KALYDECO,headache,headache oropharyngeal,1,0.8358312845230103
KALYDECO,headache,headache oropharyngeal pain upper,1,0.8131541013717651
KALYDECO,headache,were,0,0.5297192335128784
KALYDECO,headache,congestion,0,0.6104447841644287
KALYDECO,oropharyngeal pain,were oropharyngeal pain upper respiratory tract infection,1,0.8861371874809265
KALYDECO,oropharyngeal pain,congestion,0,0.5105664730072021
KALYDECO,oropharyngeal pain,oropharyngeal pain upper respiratory tract infection nasal,1,0.8699798583984375
KALYDECO,oropharyngeal pain,oropharyngeal,1,0.8612298965454102
KALYDECO,oropharyngeal pain,gene were oropharyngeal pain,1,0.8925487995147705
KALYDECO,oropharyngeal pain,the CFTR gene were oropharyngeal pain,1,0.7828880548477173
KALYDECO,oropharyngeal pain,CFTR gene were oropharyngeal pain,1,0.7911142110824585
KALYDECO,oropharyngeal pain,upper respiratory tract infection nasal congestion abdominal pain nasopharyngitis diarrhea,0,0.6405892372131348
KALYDECO,upper respiratory tract infection,a GD mutation in,0,0.4746585190296173
KALYDECO,upper respiratory tract infection,tract infection nasal congestion abdominal,1,0.7136085629463196
KALYDECO,upper respiratory tract infection,gene were headache oropharyngeal upper respiratory tract infection nasal congestion abdominal pain nasopharyngitis,1,0.7289801836013794
KALYDECO,upper respiratory tract infection,tract infection nasal congestion,1,0.7578467130661011
KALYDECO,nasal congestion,respiratory tract nasal congestion abdominal pain nasopharyngitis diarrhea rash,1,0.7748233079910278
KALYDECO,nasal congestion,tract infection nasal congestion,1,0.9053680896759033
KALYDECO,nasal congestion,pain upper respiratory tract nasal congestion,1,0.8862299919128418
KALYDECO,nasal congestion,upper respiratory tract nasal,1,0.815643310546875
KALYDECO,nasal congestion,nasopharyngitis diarrhea rash,0,0.6132064461708069
KALYDECO,nasal congestion,rash nausea and dizziness To,0,0.5827877521514893
KALYDECO,nasal congestion,pain,0,0.5528784990310669
KALYDECO,nasal congestion,pain upper respiratory,0,0.6820738911628723
KALYDECO,nasal congestion,respiratory tract,0,0.6537541151046753
KALYDECO,nasal congestion,nasal congestion abdominal pain,1,0.8350515365600586
KALYDECO,abdominal pain,headache,0,0.6068118214607239
KALYDECO,abdominal pain,tract infection nasal abdominal pain nasopharyngitis,1,0.7108145952224731
KALYDECO,abdominal pain,respiratory tract infection nasal abdominal,1,0.6654877066612244
KALYDECO,abdominal pain,diarrhea rash,0,0.5959771871566772
KALYDECO,abdominal pain,abdominal pain,1,0.9999998807907104
KALYDECO,nasopharyngitis,tract infection nasal congestion,0,0.6935216188430786
KALYDECO,nasopharyngitis,nasopharyngitis diarrhea rash,1,0.8325768709182739
KALYDECO,nasopharyngitis,abdominal pain,0,0.5264430046081543
KALYDECO,nasopharyngitis,nasal congestion abdominal nasopharyngitis diarrhea rash nausea,1,0.778168797492981
KALYDECO,nasopharyngitis,nasopharyngitis diarrhea rash nausea and,1,0.8412312865257263
KALYDECO,nasopharyngitis,nasopharyngitis diarrhea,1,0.8949661254882812
KALYDECO,nasopharyngitis,report SUSPECTED ADVERSE,0,0.5613325834274292
KALYDECO,nasopharyngitis,and,0,0.5093782544136047
KALYDECO,nasopharyngitis,SUSPECTED ADVERSE REACTIONS,0,0.5972316265106201
KALYDECO,diarrhea,pain diarrhea rash nausea and dizziness To,1,0.7752702236175537
KALYDECO,diarrhea,nasopharyngitis diarrhea,1,0.7927175760269165
KALYDECO,diarrhea,nasal congestion,0,0.6016041040420532
KALYDECO,rash,congestion abdominal pain nasopharyngitis rash nausea and dizziness To report,1,0.6863551735877991
KALYDECO,rash,nasal congestion,0,0.5195406675338745
KALYDECO,rash,rash nausea and,1,0.858069658279419
KALYDECO,rash,nasal congestion abdominal pain nasopharyngitis diarrhea,0,0.5351036787033081
KALYDECO,rash,infection nasal congestion abdominal pain nasopharyngitis diarrhea,0,0.534784197807312
KALYDECO,rash,rash,1,1.0000001192092896
KALYDECO,nausea,nausea and dizziness To report,1,0.835469126701355
KALYDECO,dizziness,nasopharyngitis diarrhea rash,0,0.5085568428039551
KALYDECO,increased hepatic enzymes,KALYDECOtreated patients included abdominal increased hepatic enzymes,1,0.8356342911720276
KALYDECO,increased hepatic enzymes,adverse,0,0.5414687991142273
KALYDECO,increased hepatic enzymes,more frequently in,0,0.5990859866142273
KALYDECO,increased hepatic enzymes,hepatic enzymes and hypoglycemia The most,1,0.8154222369194031
KALYDECO,increased hepatic enzymes,in KALYDECOtreated patients included,0,0.5182797908782959
KALYDECO,increased hepatic enzymes,abdominal increased hepatic,1,0.8520925045013428
KALYDECO,hypoglycemia,increased hepatic enzymes,0,0.5365891456604004
KALYDECO,hypoglycemia,patients treated with KALYDECO were headache,0,0.5670511722564697
KALYDECO,hypoglycemia,KALYDECO were,0,0.5151320099830627
KALYDECO,hypoglycemia,the patients treated with KALYDECO were,0,0.5633776187896729
KALYDECO,hypoglycemia,hypoglycemia The most common adverse,1,0.8512014746665955
KALYDECO,hypoglycemia,KALYDECOtreated patients included abdominal pain increased hepatic,0,0.5461333990097046
KALYDECO,hypoglycemia,hypoglycemia,1,1.0
KALYDECO,hypoglycemia,hypoglycemia The most common,1,0.8680621385574341
KALYDECO,headache,headache upper respiratory tract infection,1,0.8152729272842407
KALYDECO,headache,with KALYDECO were,0,0.46387842297554016
KALYDECO,headache,the patients treated,0,0.5371448993682861
KALYDECO,headache,hypoglycemia,0,0.5590025186538696
KALYDECO,headache,headache upper respiratory tract,1,0.8161494731903076
KALYDECO,upper respiratory tract infection,upper respiratory tract infection nasal congestion nausea rash rhinitis,1,0.8631462454795837
KALYDECO,nasal congestion,dizziness arthralgia and bacteria,0,0.5965139269828796
KALYDECO,nasal congestion,upper respiratory tract nasal congestion,1,0.928787112236023
KALYDECO,nasal congestion,nasal congestion nausea rash rhinitis dizziness,1,0.8557089567184448
KALYDECO,nausea,nausea rash rhinitis dizziness arthralgia and,1,0.7971446514129639
KALYDECO,nausea,nausea rash rhinitis,1,0.7922086119651794
KALYDECO,nausea,KALYDECO were headache upper respiratory tract infection nasal congestion,0,0.6616932153701782
KALYDECO,rash,rash rhinitis dizziness,1,0.7341963052749634
KALYDECO,rash,infection nasal congestion rash rhinitis,1,0.7343995571136475
KALYDECO,rash,congestion nausea,0,0.5470724701881409
KALYDECO,rash,sputum The inciden,0,0.5489681959152222
KALYDECO,rash,rash rhinitis dizziness arthralgia and,1,0.7538838386535645
KALYDECO,rash,tract infection nasal congestion,0,0.5168650150299072
KALYDECO,rhinitis,rhinitis dizziness arthralgia and bacteria,1,0.7636740207672119
KALYDECO,rhinitis,dizziness arthralgia and bacteria,0,0.6061310768127441
KALYDECO,rhinitis,rhinitis dizziness arthralgia and,1,0.8153336048126221
KALYDECO,dizziness,dizziness,1,0.9999998807907104
KALYDECO,dizziness,The incidence of adverse reactions below is,0,0.5703414678573608
KALYDECO,dizziness,dizziness arthralgia and bacteria in sputum,1,0.7334780693054199
KALYDECO,dizziness,in sputum The incidence of adverse reactions below is,0,0.5021197199821472
KALYDECO,dizziness,and bacteria in sputum The incidence of adverse reactions below is,0,0.5052987337112427
KALYDECO,bacteria in sputum,in sputum The incidence of adverse,1,0.8127104043960571
KALYDECO,bacteria in sputum,rash rhinitis dizziness arthralgia bacteria in sputum The,1,0.7937663793563843
KALYDECO,bacteria in sputum,in sputum The incidence,1,0.8265153765678406
KALYDECO,rhinitis,rhinitis,1,1.0
KALYDECO,rhinitis,rhinitis Investigations aspartate aminotransferase increased bacteria,1,0.7259697914123535
KALYDECO,rhinitis,in the placebo group include Infections and infestations,0,0.5630161762237549
KALYDECO,rhinitis,exceeded that in the,0,0.4461209177970886
KALYDECO,bacteria in sputum,bacteria in sputum blood,1,0.9016121029853821
KALYDECO,bacteria in sputum,rhinitis,1,0.5410629510879517
KALYDECO,bacteria in sputum,connective,0,0.5260369181632996
KALYDECO,bacteria in sputum,glucose increased hepatic enzyme,0,0.45573753118515015
KALYDECO,bacteria in sputum,increased hepatic,0,0.5049726963043213
KALYDECO,bacteria in sputum,rhinitis Investigations aspartate,0,0.5495362281799316
KALYDECO,bacteria in sputum,aminotransferase,0,0.4694438874721527
KALYDECO,blood glucose increased,in blood,1,0.609362781047821
KALYDECO,blood glucose increased,enzyme increased Musculoskeletal,0,0.6449518203735352
KALYDECO,blood glucose increased,disorders,0,0.5383898019790649
KALYDECO,hepatic enzyme increased,and connective tissue disorders arthralgia musculoskeletal chest,0,0.4919332265853882
KALYDECO,hepatic enzyme increased,hepatic enzyme increased Musculoskeletal,1,0.8691807985305786
KALYDECO,hepatic enzyme increased,glucose increased,0,0.7317094802856445
KALYDECO,hepatic enzyme increased,enzyme increased Musculoskeletal and connective tissue disorders,1,0.7406319379806519
KALYDECO,hepatic enzyme increased,in sputum blood,0,0.5624043345451355
KALYDECO,hepatic enzyme increased,chest pain m,0,0.47060710191726685
KALYDECO,hepatic enzyme increased,sputum blood glucose hepatic enzyme increased,1,0.8414812684059143
KALYDECO,arthralgia,arthralgia musculoskeletal chest pain myalgia,1,0.811724066734314
KALYDECO,arthralgia,tissue disorders,0,0.5671525001525879
KALYDECO,arthralgia,Musculoskeletal and connective tissue,0,0.6329536437988281
KALYDECO,arthralgia,disorders,0,0.5670176148414612
KALYDECO,arthralgia,arthralgia musculoskeletal,1,0.9157119989395142
KALYDECO,arthralgia,connective,0,0.5797217488288879
KALYDECO,arthralgia,tissue arthralgia musculoskeletal chest pain,1,0.7826929092407227
KALYDECO,arthralgia,arthralgia musculoskeletal chest pain myalgia Nervous,1,0.8015676736831665
KALYDECO,musculoskeletal chest pain,and connective tissue disorders musculoskeletal chest pain myalgia Nervous,1,0.8393632173538208
KALYDECO,musculoskeletal chest pain,arthralgia musculoskeletal chest pain myalgia Nervous,1,0.8568234443664551
KALYDECO,musculoskeletal chest pain,musculoskeletal chest pain,1,0.9999998807907104
KALYDECO,musculoskeletal chest pain,sinus,0,0.5194385647773743
KALYDECO,musculoskeletal chest pain,musculoskeletal chest pain myalgia Nervous,1,0.8903757333755493
KALYDECO,musculoskeletal chest pain,myalgia Nervous system disorders sinus headache Respiratory,0,0.6305524110794067
KALYDECO,musculoskeletal chest pain,and,0,0.477210134267807
KALYDECO,musculoskeletal chest pain,and connective tissue disorders musculoskeletal chest pain,1,0.9230977296829224
KALYDECO,musculoskeletal chest pain,tissue disorders arthralgia,0,0.6691756844520569
KALYDECO,musculoskeletal chest pain,sinus headache,0,0.5205076932907104
KALYDECO,myalgia,musculoskeletal chest myalgia Nervous system disorders sinus headache,1,0.7445081472396851
KALYDECO,myalgia,sinus headache,0,0.5233708620071411
KALYDECO,myalgia,arthralgia musculoskeletal chest myalgia,1,0.8104233741760254
KALYDECO,sinus headache,Nervous system sinus headache Respiratory thoracic and mediastinal disorders,1,0.7653181552886963
KALYDECO,sinus headache,sinus headache,0,1.0000001192092896
KALYDECO,sinus headache,sinus headache,1,1.0000001192092896
KALYDECO,sinus headache,Nervous system sinus headache Respiratory thoracic and,1,0.8212621212005615
KALYDECO,pharyngeal erythema,Respiratory thoracic,0,0.5971447229385376
KALYDECO,pharyngeal erythema,sinus,0,0.5574138164520264
KALYDECO,pleuritic pain,pleuritic pain sinus congestion,1,0.8225524425506592
KALYDECO,pleuritic pain,tissue disorders acne The safety p,0,0.4904664158821106
KALYDECO,pleuritic pain,disorders pharyngeal pleuritic pain sinus,1,0.7870258092880249
KALYDECO,pleuritic pain,ders,0,0.5059446096420288
KALYDECO,pleuritic pain,pleuritic pain sinus,1,0.858428955078125
KALYDECO,pleuritic pain,and mediastinal disorders pharyngeal pleuritic,1,0.727851390838623
KALYDECO,sinus congestion,sinus congestion wheezing,1,0.8431231379508972
KALYDECO,sinus congestion,sinus congestion wheezing Skin and subcutaneous,1,0.7637046575546265
KALYDECO,sinus congestion,and mediastinal disorders pharyngeal erythema,0,0.5708781480789185
KALYDECO,wheezing,sinus wheezing,1,0.8698800206184387
KALYDECO,wheezing,and mediastinal disorders pharyngeal erythema,0,0.5922221541404724
KALYDECO,wheezing,pleuritic pain sinus wheezing Skin,1,0.7747377157211304
KALYDECO,acne,clinical,0,0.5426203012466431
KALYDECO,acne,and subcutaneous tissue acne,1,0.823293924331665
KALYDECO,elevated transaminases,to have serious adverse reactions,0,0.6067568063735962
KALYDECO,elevated transaminases,patients treated with KALYDECO,0,0.5518407821655273
KALYDECO,elevated transaminases,adverse,0,0.5381689071655273
KALYDECO,elevated transaminases,have serious,0,0.5426249504089355
KALYDECO,elevated transaminases,elevated transaminases all,1,0.9465775489807129
KALYDECO,elevated transaminases,elevated transaminases all ULN,1,0.9029014110565186
KALYDECO,elevated liver transaminases,elevated liver transaminases compared to none,1,0.9331597685813904
KALYDECO,elevated liver transaminases,have serious adverse reactions elevated,1,0.6477689743041992
KALYDECO,transaminase elevations,transaminase elevations ALT,1,0.9557625651359558
KALYDECO,transaminase elevations,incidence of patients,0,0.5376157760620117
KALYDECO,transaminase elevations,daily the incidence of patients experiencing,0,0.55791836977005
KALYDECO,transaminase elevations,of patients transaminase,1,0.866165280342102
KALYDECO,transaminase elevations,transaminase elevations ALT or AST,1,0.9149407148361206
KALYDECO,transaminase elevations,the incidence of patients transaminase elevations ALT or AST,1,0.9002948999404907
KALYDECO,AST levels >8 * ULN,which returned,0,0.5195668935775757
KALYDECO,AST levels >8 * ULN,baseline levels following interruption of KALYDECO dosing,0,0.5506247282028198
KALYDECO,AST levels >8 * ULN,g transaminase elevations ALT or AST ULN was All patients had maximum ALT,0,0.711979866027832
KALYDECO,AST levels >8 * ULN,had maximum ALT,0,0.6243909001350403
KALYDECO,AST levels >8 * ULN,* ULN which returned to baseline levels,1,0.7668426632881165
KALYDECO,Elevated transaminases,sections of the label Transaminase Elevations,0,0.8780449628829956
KALYDECO,Elevated transaminases,ction is,1,0.4631173312664032
KALYDECO,Elevated transaminases,REACTIONS The following adverse ction is discussed in  greater detail in,1,0.6187149882316589
KALYDECO,Elevated transaminases,rea,0,0.5062862038612366
KALYDECO,Elevated transaminases,ction is discussed in greater,1,0.5091671943664551
KALYDECO,Elevated transaminases,detail in other sections of the label,0,0.48804205656051636
KALYDECO,Elevated transaminases,The following adverse ction is discussed,1,0.5823441743850708
KALYDECO,Elevated transaminases,adverse rea,0,0.532711386680603
KALYDECO,Cataracts,practice. The,1,0.524670422077179
KALYDECO,Cataracts,practice. The overall,1,0.5299232006072998
KALYDECO,Cataracts,on pooled data from three,0,0.5211697816848755
KALYDECO,Non-congenital lens opacities,observed in,0,0.512691855430603
KALYDECO,Non-congenital lens opacities,overall safety profile of KALYDECO is,1,0.49222344160079956
KALYDECO,Elevated transaminases,GD mutation,0,0.501095175743103
KALYDECO,Elevated transaminases,for the Fdel n (Trial 3). In additi on,1,0.5120006799697876
KALYDECO,Elevated transaminases,n (Trial 3). In additi on the,1,0.5422844290733337
KALYDECO,Elevated transaminases,the Fdel n (Trial 3). In additi on the following clinical trials,1,0.5439860224723816
KALYDECO,Elevated transaminases,the Fdel n (Trial 3). In,1,0.4694620668888092
KALYDECO,Elevated transaminases,n (Trial 3). In,1,0.5020546317100525
KALYDECO,Elevated transaminases,n (Trial 3). In additi on,1,0.5422346591949463
KALYDECO,Elevated transaminases,were homozygous for the Fdel mutatio,0,0.5441338419914246
KALYDECO,non-congenital lens opacities,patients Serious adverse reactions,0,0.5120724439620972
KALYDECO,non-congenital lens opacities,and for placebotreated patients Serious adverse reactions,0,0.5017585158348083
AMYVID,headache,adverse reaction headache occurring in of,1,0.8176044225692749
AMYVID,headache,and for placebotreated patients Serious adverse reactions,0,0.5314183235168457
AMYVID,musculoskeletal pain,musculoskeletal,1,0.8928014039993286
AMYVID,musculoskeletal pain,increased fatigue,0,0.5903574228286743
AMYVID,musculoskeletal pain,patients followed musculoskeletal pain,1,0.8699508905410767
AMYVID,musculoskeletal pain,in of patients followed musculoskeletal pain blood pressure,1,0.8015958070755005
AMYVID,musculoskeletal pain,of patients followed musculoskeletal pain blood pressure,1,0.7980080842971802
AMYVID,musculoskeletal pain,in of pa,0,0.47175484895706177
AMYVID,musculoskeletal pain,followed,0,0.47002410888671875
AMYVID,musculoskeletal pain,followed musculoskeletal pain blood pressure increased fatigue nausea,1,0.7806270122528076
AMYVID,blood pressure increased,blood pressure increased fatigue nausea and injection,1,0.7625308036804199
AMYVID,blood pressure increased,followed,0,0.47034844756126404
AMYVID,fatigue,patients,0,0.5585906505584717
AMYVID,fatigue,pressure fatigue nausea and injection site reaction,1,0.6905777454376221
AMYVID,fatigue,fatigue nausea and injection site reaction,1,0.73292076587677
AMYVID,fatigue,pressure,0,0.572711706161499
AMYVID,fatigue,all occurring in of patients To report SUS,0,0.5632849931716919
AMYVID,fatigue,fatigue nausea,1,0.8762110471725464
AMYVID,fatigue,fatigue nausea and injection site,1,0.7608640193939209
AMYVID,fatigue,of patients To,0,0.5411142706871033
AMYVID,nausea,patients followed by musculoskeletal pain blood pressure increased fatigue,0,0.5726458430290222
AMYVID,nausea,of patients,0,0.525994062423706
AMYVID,nausea,nausea and injection site reaction all,1,0.7829689979553223
AMYVID,nausea,pressure increased fatigue,0,0.5728614330291748
AMYVID,nausea,followed by musculoskeletal pain blood pressure,0,0.5483219623565674
AMYVID,nausea,fatigue,0,0.684320867061615
AMYVID,injection site reaction,occurring,0,0.555268406867981
AMYVID,injection site reaction,and,0,0.4683077931404114
AMYVID,injection site reaction,in,0,0.5095956325531006
AMYVID,injection site reaction,nausea injection site reaction,1,0.8955067992210388
AMYVID,blood pressure increased,Includes the blood pressure,1,0.8347519636154175
AMYVID,blood pressure increased,the blood pressure,1,0.8473380208015442
AMYVID,blood pressure increased,pressure increased and hypertension b Includes the,1,0.8559715747833252
AMYVID,blood pressure increased,blood pressure increased and hypertension,1,0.9383748769760132
AMYVID,blood pressure increased,Table Adverse Reactions Reported in Clinical Trials N patients a Includes,0,0.5229952335357666
AMYVID,blood pressure increased,Reactions Reported in Clinical,0,0.569934606552124
AMYVID,hypertension,hypertension,1,1.0
AMYVID,hypertension,hypertension b Includes the terms,1,0.7997820377349854
AMYVID,hypertension,patients a Includes the terms blood pressure increased,0,0.7451077699661255
AMYVID,hypertension,hypertension b,1,0.8421128988265991
AMYVID,hypertension,a,0,0.5570000410079956
AMYVID,hypertension,hypertension b Includes the,1,0.8263013362884521
AMYVID,hypertension,terms blood pressure increased hypertension b Includes,1,0.796644389629364
AMYVID,hypertension,blood pressure increased,0,0.8084428310394287
AMYVID,hypertension,the terms injection,0,0.5196504592895508
AMYVID,injection site haemorrhage,the,0,0.4757813811302185
AMYVID,injection site haemorrhage,hypertension b Includes the injection,1,0.6976627707481384
AMYVID,injection site haemorrhage,injection site haemorrhage injection site irritation and,1,0.9371358752250671
AMYVID,injection site haemorrhage,the terms blood pressure increased,0,0.5557785034179688
AMYVID,injection site haemorrhage,cold and,0,0.4028645157814026
AMYVID,injection site haemorrhage,the terms,0,0.41115325689315796
AMYVID,injection site haemorrhage,Includes the terms,0,0.43219655752182007
AMYVID,injection site haemorrhage,Includes the injection site,1,0.8202400207519531
AMYVID,injection site haemorrhage,injection site haemorrhage injection site irritation and injection,1,0.9324373006820679
AMYVID,injection site haemorrhage,injection site,1,0.8582098484039307
AMYVID,injection site irritation,pain c Includes the terms feeling cold,0,0.5655802488327026
AMYVID,injection site irritation,injection site irritation and injection,1,0.9829602837562561
AMYVID,injection site irritation,injection site irritation and,1,0.9914489984512329
AMYVID,injection site irritation,blood pressure,0,0.5152311325073242
AMYVID,injection site irritation,b,0,0.5051963329315186
AMYVID,injection site irritation,site irritation and injection,1,0.9665919542312622
AMYVID,injection site irritation,injection,0,0.7715621590614319
AMYVID,injection site irritation,the terms injection site injection site irritation and,1,0.9413071870803833
AMYVID,injection site pain,haemorrhage,0,0.5206001400947571
AMYVID,injection site pain,hypertension b Includes,0,0.4991835355758667
AMYVID,injection site pain,haemorrhage injection site irritation injection site pain c Includes the,1,0.8578674793243408
AMYVID,injection site pain,Includes the terms injection site haemorrhage injection site irritation and,0,0.80559241771698
AMYVID,injection site pain,site pain c Includes the terms,1,0.6735728979110718
AMYVID,injection site pain,terms injection site,0,0.7500280737876892
AMYVID,injection site pain,the terms injection site haemorrhage injection site irritation,0,0.8181939125061035
AMYVID,injection site pain,terms injection site haemorrhage,0,0.7962615489959717
AMYVID,injection site pain,site pain c Includes,1,0.7360986471176147
AMYVID,feeling cold,Reactions N Percent of,0,0.43444108963012695
AMYVID,feeling cold,feeling cold and chills,1,0.9392162561416626
AMYVID,feeling cold,the feeling cold and chills Adverse Reactions,1,0.8397021889686584
AMYVID,feeling cold,feeling cold and chills Adverse Reactions,1,0.8327177166938782
AMYVID,feeling cold,feeling cold and chills Adverse,1,0.9252173900604248
AMYVID,feeling cold,c Includes the feeling cold,1,0.9223916530609131
AMYVID,chills,and injection site pain c Includes,0,0.5398480892181396
AMYVID,chills,chills,1,0.9999998807907104
AMYVID,chills,Reactions N Percent of,0,0.5134760737419128
AMYVID,chills,chills Adverse Reactions N,1,0.8185107707977295
AMYVID,chills,Percent,0,0.4925364851951599
AMYVID,chills,chills Adverse,1,0.9052522778511047
AMYVID,Blood pressure increased,pain,0,0.5263241529464722
AMYVID,infusion site rash,infusion site rash dysgeusia pruritis,1,0.8857636451721191
AMYVID,infusion site rash,and infusion site rash dysgeusia,1,0.8377759456634521
AMYVID,infusion site rash,and infusion site rash,1,0.9876505136489868
AMYVID,infusion site rash,infusion site rash dysgeusia pruritis urticaria and,1,0.9047805070877075
AMYVID,infusion site rash,occurred at lower frequencies and,0,0.47916945815086365
AMYVID,infusion site rash,infusion site rash dysgeusia,1,0.8569164276123047
AMYVID,infusion site rash,pruritis urticaria and,0,0.6409133672714233
AMYVID,infusion site rash,urticaria,0,0.6410610675811768
AMYVID,infusion site rash,infusion site rash dysgeusia pruritis urticaria and flushing,1,0.8998023271560669
AMYVID,pruritis,pruritis urticaria and flushing,1,0.808156430721283
AMYVID,pruritis,infusion,0,0.49680131673812866
AMYVID,urticaria,pruritis,0,0.6981722116470337
AMYVID,urticaria,dysgeusia urticaria and,1,0.8036487102508545
AMYVID,urticaria,site rash dysgeusia urticaria,1,0.788422703742981
AMYVID,urticaria,site rash dysgeusia urticaria and flushing,1,0.7874953746795654
AMYVID,Radiation risk,"of patients followed by eletal pain,",1,0.48982569575309753
AMYVID,Radiation risk,musculosk,0,0.50864577293396
AMYVID,Radiation risk,"pain, b lood",1,0.4775168001651764
AMYVID,Radiation risk,patients followed by eletal,1,0.5247233510017395
AMYVID,Radiation risk,of patients followed by eletal,1,0.5140340924263
AMYVID,Radiation risk,"eletal pain, b lood pressure increased fatigue",1,0.4855894446372986
AMYVID,long-term cumulative radiation exposure,"and injection site reaction  occurring in <1% of patients (  6  ).
 To report SUSPECTED ADVERSE REACTIONS",1,0.5173641443252563
AMYVID,long-term cumulative radiation exposure,"eletal pain, b lood pressure increased fatigue",1,0.5339824557304382
AMYVID,long-term cumulative radiation exposure,fatigue nausea and,0,0.5338629484176636
AMYVID,long-term cumulative radiation exposure,6 ). To report SUSPECTED,1,0.48492470383644104
AMYVID,long-term cumulative radiation exposure,patients ( 6 ).,1,0.496969610452652
AMYVID,long-term cumulative radiation exposure,site pain c,0,0.5594569444656372
AMYVID,long-term cumulative radiation exposure,injection site,0,0.5441203117370605
AMYVID,long-term cumulative radiation exposure,terms feel,0,0.5190206170082092
AMYVID,long-term cumulative radiation exposure,c Includes the terms,0,0.5378382205963135
AMYVID,long-term cumulative radiation exposure,e Reactions N Percent of patients He,0,0.5235432386398315
AMYVID,long-term cumulative radiation exposure,Percent of,0,0.5207698941230774
AMYVID,long-term cumulative radiation exposure,"Includes the terms ing cold and chills.      
  
   Advers",1,0.5123178362846375
AMYVID,long-term cumulative radiation exposure,Percent,0,0.5194344520568848
AMYVID,long-term cumulative radiation exposure,of patients He,0,0.4998275637626648
AMYVID,Long-term cumulative radiation exposure,chills Reactions                              ,1,0.4923485815525055
AMYVID,Long-term cumulative radiation exposure,of patients He,0,0.4998275637626648
AMYVID,Long-term cumulative radiation exposure,and chills Reactions                               N Percent,1,0.534563422203064
AMYVID,Long-term cumulative radiation exposure,Reactions                               N Percent of patients Headache,1,0.4966699779033661
AMYVID,Long-term cumulative radiation exposure,Reactions                               N,1,0.5010035634040833
TIVICAY,Hypersensitivity,biochemistries in,0,0.5615884065628052
TIVICAY,Hypersensitivity,Hypersensitivity reactions,1,0.9332083463668823
TIVICAY,Hypersensitivity,related by the investigator or ADRs are,0,0.5128467679023743
TIVICAY,Hypersensitivity,Warnings and Precautions,0,0.5578351020812988
TIVICAY,Fat Redistribution,coinfection see Warnings and Fat Redistribution see Warnings and Precautions Immune,1,0.7130135297775269
TIVICAY,Fat Redistribution,Warnings and Precautions,0,0.4927181303501129
TIVICAY,Fat Redistribution,and Precautions Immune Reconstitution,0,0.5475190877914429
TIVICAY,Immune Reconstitution Syndrome,Precautions,0,0.496658593416214
TIVICAY,Immune Reconstitution Syndrome,and Immune Reconstitution Syndrome see Warnings and Precautions,1,0.8822516202926636
TIVICAY,Immune Reconstitution Syndrome,under,0,0.47820258140563965
TIVICAY,Immune Reconstitution Syndrome,Reconstitution Syndrome see,1,0.8827064037322998
TIVICAY,insomnia,insomnia fatigue and,1,0.8822083473205566
TIVICAY,insomnia,one adult trial insomnia fatigue,1,0.8123074769973755
TIVICAY,insomnia,insomnia,1,1.0000001192092896
TIVICAY,fatigue,contact ViiV Healthcare,0,0.5024407505989075
TIVICAY,headache,headache To,1,0.9336679577827454
TIVICAY,headache,adult trial,0,0.4942401647567749
TIVICAY,headache,insomnia fatigue headache,1,0.782489538192749
TIVICAY,rash,rash rash generalized rash macular rash,1,0.7997088432312012
TIVICAY,rash,rash rash generalized,1,0.8674004077911377
TIVICAY,rash,pooled,0,0.542994499206543
TIVICAY,rash,eruption In,0,0.5601291656494141
TIVICAY,rash,rash maculopapular rash pruritic and,0,0.7914232015609741
TIVICAY,rash generalized,Includes pooled terms,0,0.5370879769325256
TIVICAY,rash generalized,rash generalized rash macular rash maculopapular,1,0.8086485862731934
TIVICAY,rash generalized,drug eruption In addition Grade inso,0,0.6346890926361084
TIVICAY,rash generalized,Includes pooled terms rash generalized,1,0.8043221831321716
TIVICAY,rash generalized,pooled terms rash,0,0.6995614767074585
TIVICAY,rash generalized,a Includes pooled terms rash generalized,1,0.7517075538635254
TIVICAY,rash generalized,rash generalized rash,1,0.9788112044334412
TIVICAY,rash macular,rash macular rash maculopapular rash,1,0.9236874580383301
TIVICAY,rash macular,rash rash,0,0.7413245439529419
TIVICAY,rash macular,pooled terms rash rash rash,1,0.6956079006195068
TIVICAY,rash macular,Grade,0,0.4949590563774109
TIVICAY,rash macular,rash macular,1,0.9999999403953552
TIVICAY,rash macular,rash macular rash maculopapular,1,0.925887942314148
TIVICAY,rash maculo-papular,rash rash generalized rash rash maculo-papular rash pruritic and drug,1,0.8691576719284058
TIVICAY,rash maculo-papular,rash macular rash maculopapular,1,0.9150696992874146
TIVICAY,rash maculo-papular,rash maculo-papular rash,1,0.9901909828186035
TIVICAY,rash maculo-papular,macular,0,0.7301161289215088
TIVICAY,rash maculo-papular,rash,1,0.7951656579971313
TIVICAY,rash maculo-papular,rash maculo-papular rash pruritic and,1,0.9360160827636719
TIVICAY,rash maculo-papular,rash generalized rash rash maculo-papular rash pruritic and drug eruption,1,0.8637909293174744
TIVICAY,rash maculo-papular,rash rash generalized rash rash maculo-papular,1,0.9382063150405884
TIVICAY,rash maculo-papular,by and less th,0,0.4560539126396179
TIVICAY,rash pruritic,macular rash rash,1,0.7269793152809143
TIVICAY,drug eruption,drug eruption,1,1.000000238418579
TIVICAY,drug eruption,addition Grade insomnia was reported by and less than of subjects,0,0.48036566376686096
TIVICAY,insomnia,insomnia was reported,1,0.8857535123825073
TIVICAY,insomnia,of subjects receiving TIVICAY and raltegravir,0,0.4897441267967224
TIVICAY,insomnia,insomnia was reported by,1,0.8760082125663757
TIVICAY,diarrhea,diarrhea,1,0.9999999403953552
TIVICAY,diarrhea,insomnia was reported by,1,0.5006785988807678
TIVICAY,diarrhea,diarrhea of in subjects receiving TIVICAY,1,0.7679201364517212
TIVICAY,diarrhea,diarrhea of in subjects receiving,1,0.8051999807357788
TIVICAY,diarrhea,severe intensity with at,0,0.5322290062904358
TIVICAY,diarrhea,mg once,0,0.5834329724311829
TIVICAY,diarrhea,at,0,0.5801942348480225
TIVICAY,Abdominal pain,Abdominal pain abdominal discomfort flatulence upper,1,0.8661003112792969
TIVICAY,abdominal discomfort,relationship Gastrointestinal Disorders Abdominal abdominal,1,0.7573350667953491
TIVICAY,abdominal discomfort,relationship Gastrointestinal Disorders Abdominal abdominal discomfort flatulence,1,0.7787319421768188
TIVICAY,abdominal discomfort,pain vomiting Hepatobiliary Disorders,0,0.6853381395339966
TIVICAY,abdominal discomfort,abdominal discomfort,1,1.000000238418579
TIVICAY,abdominal discomfort,relationship Gastrointestinal Disorders Abdominal abdominal discomfort flatulence upper abdominal pain vomiting,1,0.7702156901359558
TIVICAY,flatulence,flatulence upper abdominal pain vomiting,1,0.7928930521011353
TIVICAY,flatulence,pain vomiting Hepatobiliary Disorders,0,0.606838583946228
TIVICAY,flatulence,pain,0,0.6043051481246948
TIVICAY,flatulence,pain vomiting Hepatobiliary Disorders Hepatitis Musculoskeletal,0,0.5675805807113647
TIVICAY,flatulence,Hepatobiliary Disorders Hepatitis,0,0.5668882727622986
TIVICAY,upper abdominal pain,abdominal discomfort upper,1,0.9381985664367676
TIVICAY,vomiting,vomiting Hepatobiliary Disorders Hepatitis,1,0.7826664447784424
TIVICAY,vomiting,abdominal pain,0,0.6247491836547852
TIVICAY,vomiting,vomiting,1,0.9999999403953552
TIVICAY,vomiting,Disorders Hepatitis Musculoskeletal Disorders,0,0.5208866596221924
TIVICAY,vomiting,abdominal vomiting Hepatobiliary Disorders Hepatitis Musculoskeletal Disorders,1,0.7315747141838074
TIVICAY,vomiting,discomfort flatulence upper abdominal pain,0,0.5855380296707153
TIVICAY,vomiting,Disorders Abdominal,0,0.6081193685531616
TIVICAY,Hepatitis,discomfort flatulence upper,0,0.4677618741989136
TIVICAY,Hepatitis,pain vomiting Hepatobiliary Hepatitis Musculoskeletal Disorders Myositis Psychiatric,1,0.6971365213394165
TIVICAY,Hepatitis,flatulence upper abdominal pain vomiting,0,0.5271825790405273
TIVICAY,Myositis,ideation attempt behavior or completion,0,0.41819167137145996
TIVICAY,Myositis,Myositis Psychiatric Disorders Suicidal ideation,1,0.7911561727523804
TIVICAY,Myositis,Myositis Psychiatric Disorders Suicidal,1,0.7904366254806519
TIVICAY,Myositis,Myositis Psychiatric Disorders,1,0.8118622303009033
TIVICAY,Myositis,Disorders Suicidal ideation,0,0.48686906695365906
TIVICAY,Myositis,Myositis,1,1.0
TIVICAY,Myositis,Musculoskeletal,0,0.6456862688064575
TIVICAY,Myositis,Myositis Psychiatric,1,0.8340713977813721
TIVICAY,Suicidal ideation,Suicidal ideation attempt behavior or completion These,1,0.8582201600074768
TIVICAY,Suicidal ideation,Disorders Myositis Psychiatric Suicidal,1,0.6837476491928101
TIVICAY,Renal impairment,eexisting history of depression or other psychiatric illness Renal and Urinary,0,0.7480108737945557
TIVICAY,Renal impairment,Subcutaneous,0,0.5132538080215454
TIVICAY,Renal impairment,Renal impairment,1,1.0
TIVICAY,Renal impairment,Renal impairment Skin and,1,0.8822748064994812
TIVICAY,Renal impairment,Urinary Renal,1,0.7905000448226929
TIVICAY,Renal impairment,illness Renal and,0,0.8435076475143433
TIVICAY,Pruritus,Pruritus,1,0.9999999403953552
TIVICAY,Pruritus,Pruritus Laboratory Abnormalities Treatmentnaive Subjects,1,0.8087800741195679
TIVICAY,Pruritus,Tissue Pruritus Laboratory,1,0.830123782157898
TIVICAY,Pruritus,Subcutaneous Tissue Pruritus Laboratory Abnormalities Treatmentnaive Subjects Selected,1,0.8042680621147156
TIVICAY,Pruritus,Pruritus Laboratory Abnormalities,1,0.8150666952133179
TIVICAY,Pruritus,Selected laboratory abnormaliti,0,0.5504189729690552
TIVICAY,Pruritus,Renal and Urinary Disorders Renal impairment Skin and Subcutaneous Tissue Disorders,0,0.6008636355400085
TIVICAY,Pruritus,and Subcutaneous Tissue,0,0.624954342842102
TIVICAY,elevated ALT,combined observed in,0,0.5693199038505554
TIVICAY,hyperglycemia,ALT AST cholesterol creatine hyperglycemia and lipase Two,1,0.7237670421600342
TIVICAY,hyperglycemia,combined observed in,0,0.532670259475708
TIVICAY,hyperglycemia,of subjects had a Grade to treatmentemergent,0,0.5335313677787781
TIVICAY,hyperglycemia,creatine hyperglycemia and lipase,1,0.7447363138198853
TIVICAY,hyperglycemia,at Week were,0,0.4729248285293579
TIVICAY,hyperglycemia,AST cholesterol creatine hyperglycemia,1,0.769246518611908
TIVICAY,hyperglycemia,hyperglycemia and lipase Two,1,0.7968714237213135
TIVICAY,hyperglycemia,Grade,0,0.5012099146842957
TIVICAY,hyperglycemia,and lipase Two percent of of subjects had a Grade to treatmentemergent h,0,0.5712783932685852
TIVICAY,hyperglycemia,Two percent of of subjects had a Grade to treatmentemergent,0,0.5208525061607361
TIVICAY,neutropenia,hematology laboratory abnormality neutropenia of,1,0.8391092419624329
TIVICAY,neutropenia,Two percent of of subjects had a Grade to treatmentemergent,0,0.5148226022720337
TIVICAY,neutropenia,hematology,0,0.7305526733398438
TIVICAY,neutropenia,laboratory abnormality neutropenia,1,0.8558205962181091
TIVICAY,neutropenia,most frequently,0,0.5230697393417358
TIVICAY,ALT abnormalities,and,0,0.504222571849823
TIVICAY,ALT abnormalities,rates of AST ALT abnormalities were higher in the,1,0.8071088790893555
TIVICAY,ALT abnormalities,B andor C virus coinfection,0,0.5684131383895874
TIVICAY,ALT abnormalities,andor C virus coinfection for all treatment,0,0.5533694624900818
TIVICAY,ALT abnormalities,rates of AST ALT,1,0.6972392201423645
TIVICAY,ALT abnormalities,AST ALT abnormalities,1,0.8808301687240601
TIVICAY,ALT abnormalities,ALT abnormalities were,1,0.9745003581047058
TIVICAY,ALT abnormalities,that observed in subjects without hepatitis B or C coinfection,0,0.5818793773651123
TIVICAY,ALT abnormalities,ALT abnormalities,1,0.9999998807907104
TIVICAY,ALT abnormalities,subgroup with hepatitis B andor,0,0.5792858600616455
TIVICAY,Liver chemistry elevations,vs with,0,0.47952067852020264
TIVICAY,Liver chemistry elevations,Liver chemistry elevations consistent with immune,1,0.8983314037322998
TIVICAY,Liver chemistry elevations,immune,0,0.5284706354141235
TIVICAY,Liver chemistry elevations,with hepatitis B and,0,0.678852379322052
TIVICAY,Liver chemistry elevations,in,0,0.5106375813484192
TIVICAY,immune reconstitution syndrome,reconstitution syndrome,1,0.901359498500824
TIVICAY,immune reconstitution syndrome,chemistry elevations consistent immune reconstitution,1,0.7942385077476501
TIVICAY,immune reconstitution syndrome,consistent immune reconstitution syndrome,1,0.9333783388137817
TIVICAY,increase serum creatinine,has been shown increase serum creatinine due,1,0.9345088005065918
TIVICAY,increase serum creatinine,consistent immune reconstitution syndrome,1,0.5448790192604065
TIVICAY,increase serum creatinine,serum creatinine due to,1,0.860747218132019
TIVICAY,increase serum creatinine,increase serum creatinine,1,1.000000238418579
TIVICAY,increase serum creatinine,increase serum creatinine due to inhibition of tubular,1,0.8918097019195557
TIVICAY,increase serum creatinine,Dolutegravir has been shown increase serum,1,0.6924326419830322
TIVICAY,increase serum creatinine,increase serum creatinine due to inhibition of,1,0.9012986421585083
TIVICAY,increase serum creatinine,shown increase serum,1,0.8098019957542419
TIVICAY,increase serum creatinine,Dolutegravir has been shown to,0,0.5045871734619141
TIVICAY,Increases in serum creatinine,to,0,0.4810403883457184
TIVICAY,Creatinine increases,were comparable,0,0.4845743179321289
TIVICAY,Creatinine increases,weeks of Creatinine increases,1,0.9321713447570801
TIVICAY,Creatinine increases,weeks of Creatinine increases were comparable,1,0.8920608162879944
TIVICAY,Creatinine increases,by background NRTIs and,0,0.5181322693824768
TIVICAY,Creatinine increases,dL to mg per dL was observed after weeks of treatment,0,0.6560215950012207
TIVICAY,Creatinine increases,similar in treatmentexperienced subjects,0,0.5301698446273804
TIVICAY,Creatinine increases,Creatinine increases,1,0.9999998807907104
TIVICAY,rash,rash n abdominal pain n and,1,0.8329092860221863
TIVICAY,abdominal pain,ADRs reported in at least subject were rash n,0,0.5026459693908691
TIVICAY,abdominal pain,subject were rash n,0,0.5040166974067688
TIVICAY,diarrhea,abdominal pain,0,0.6398805975914001
TIVICAY,diarrhea,diarrhea n No Grade or,1,0.7876813411712646
TIVICAY,diarrhea,laboratory abnormalities were,0,0.5688906311988831
TIVICAY,diarrhea,were reported The Grade laboratory abnormalities,0,0.5652070045471191
TIVICAY,diarrhea,diarrhea n No Grade,1,0.7996764183044434
TIVICAY,diarrhea,diarrhea n No,1,0.8669116497039795
TIVICAY,diarrhea,Grade or ADRs were reported The Grade laboratory abnormalities were elevated,0,0.554646372795105
TIVICAY,diarrhea,Grade ADRs reported,0,0.5201866030693054
TIVICAY,diarrhea,laboratory abnormalities were elevated tot,0,0.5871897339820862
TIVICAY,elevated total bilirubin,The Grade laboratory abnormalities elevated total bilirubin,1,0.8981595039367676
TIVICAY,Hypersensitivity reactions,adverse reactions (adverse,1,0.7237132787704468
TIVICAY,Hypersensitivity reactions,REACTIONS The following adverse reactions (adverse events  assessed as causally,1,0.7087582349777222
TIVICAY,Hypersensitivity reactions,The following adverse reactions (adverse events ,1,0.6905555129051208
TIVICAY,Hypersensitivity reactions,reactions (adverse events,1,0.7657628059387207
TIVICAY,Hypersensitivity reactions,reactions (adverse events assessed as causally,1,0.7094826102256775
TIVICAY,Hypersensitivity reactions,(adverse events,1,0.5807086825370789
TIVICAY,rash,ly r elated by,1,0.5348289012908936
TIVICAY,rash,ly r,1,0.5380198359489441
TIVICAY,rash,as ly r,1,0.560235321521759
TIVICAY,rash,The following adverse drug,0,0.619105875492096
TIVICAY,rash,as ly r elated by the investigator or,1,0.48422300815582275
TIVICAY,rash,events assessed as ly r,1,0.5071141123771667
TIVICAY,organ dysfunction,in other sections of,1,0.5423620343208313
TIVICAY,liver injury,discussed in other sections the labelin,1,0.47580403089523315
TIVICAY,liver injury,other sections the labelin,1,0.47633787989616394
TIVICAY,liver injury,g Hypersensitivity reactions see Warnings and Precautions Effects on,0,0.514433741569519
TIVICAY,liver injury,the labelin,1,0.49002695083618164
TIVICAY,liver injury,Precautions,0,0.5163127779960632
TIVICAY,liver injury,other,0,0.5063201189041138
TIVICAY,liver injury,and,0,0.5149791240692139
TIVICAY,liver injury,in other sections the,1,0.4625195264816284
TIVICAY,liver injury,in other sections the labelin,1,0.4679226279258728
TIVICAY,liver injury,discussed in other sections  the labelin g Hypersensitivity reactions,1,0.502243161201477
TIVICAY,transaminase elevations,recautions (5.4)] . Because clinical trials are conducted,1,0.5303735733032227
TIVICAY,transaminase elevations,"Warnings and recautions (5.4)] . 
   Because clinical trials are",1,0.555166482925415
TIVICAY,transaminase elevations,"Warnings and recautions (5.4)] . 
   Because",1,0.5174985527992249
TIVICAY,transaminase elevations,see Warnings and recautions (5.4)] .,1,0.5241087675094604
TIVICAY,transaminase elevations,Warnings and recautions (5.4)] .,1,0.535927414894104
TIVICAY,transaminase elevations,widely varying conditions adverse reaction,0,0.6287243962287903
TIVICAY,transaminase elevations,see Warnings and recautions (5.4)],1,0.5252604484558105
TIVICAY,transaminase elevations,Warnings and recautions (5.4)],1,0.5267457365989685
TIVICAY,transaminase elevations,(5.4)] . Because clinical trials are conducted,1,0.5238922834396362
TIVICAY,accumulation of body fat,incidence at least in tho,0,0.5652249455451965
TIVICAY,accumulation of body fat,actice. EXCERPT: The most common adverse reactions,1,0.5278990864753723
TIVICAY,accumulation of body fat,actice. EXCERPT: The,1,0.5355669856071472
TIVICAY,accumulation of body fat,intensity and incidence at least,0,0.5509283542633057
TIVICAY,accumulation of body fat,actice. EXCERPT:,1,0.5342762470245361
TIVICAY,accumulation of body fat,in,0,0.5355721712112427
TIVICAY,accumulation of body fat,"observed in actice.
 

   EXCERPT:  ",1,0.5554503202438354
TIVICAY,Hypersensitivity,insomnia fatigue,0,0.4942241311073303
TIVICAY,Hypersensitivity,"fatigue and (  6.1  )



    To report SUSPECTED ADVERSE",1,0.5278793573379517
TIVICAY,Hypersensitivity,adult trial are insomnia fatigue and headache,0,0.5254636406898499
TIVICAY,Hypersensitivity,and ( 6.1,1,0.4817166328430176
TIVICAY,Hypersensitivity,(,1,0.5562083721160889
TIVICAY,Hypersensitivity,6.1 ) To report SUSPECTED ADVERSE,1,0.5135595798492432
TIVICAY,rash,thca re,1,0.5499889850616455
TIVICAY,rash,contact ViiV thca re at or FDA at,1,0.5042814016342163
TIVICAY,organ dysfunction,at 1088 or  www.fda. govmedwatch,1,0.49796468019485474
TIVICAY,organ dysfunction,thca re,1,0.5789220929145813
TIVICAY,organ dysfunction,at or FDA at 1088 or  www.fda.,1,0.4742337167263031
TIVICAY,organ dysfunction,Clinical Trials,0,0.5655511617660522
TIVICAY,organ dysfunction,at 1088 or,1,0.4364788830280304
TIVICAY,organ dysfunction,ViiV Healthcare at or FDA at,0,0.5200718641281128
TIVICAY,organ dysfunction,FDA,0,0.5483932495117188
TIVICAY,organ dysfunction,at or FDA at 1088 or www.fda.,1,0.4742337167263031
TIVICAY,liver injury,"    



 

  Clinical Trials",1,0.5555524230003357
TIVICAY,liver injury,FDA at,0,0.5033624172210693
TIVICAY,liver injury,"    



 

  Clinical Trials Experience",1,0.4993976354598999
TIVICAY,liver injury,"FDA at FDA or     



 

 ",1,0.4936029613018036
TIVICAY,transaminase elevations,dose of ther TIVICAY 50 mg with fixeddose,1,0.6116392612457275
TIVICAY,transaminase elevations,"    



 

  Clinical Trials Experience",1,0.5508172512054443
TIVICAY,transaminase elevations,50 mg with fixeddose,1,0.5794521570205688
TIVICAY,transaminase elevations,dose of ther TIVICAY 50 mg,1,0.6102361083030701
TIVICAY,transaminase elevations,ther,1,0.53727126121521
TIVICAY,transaminase elevations,daily or,0,0.5214878916740417
TIVICAY,transaminase elevations,TIVICAY 50 mg with fixeddose abacavir sulfate and lamivudine,1,0.5982251167297363
TIVICAY,transaminase elevations,mg with fixeddose,1,0.5469180345535278
TIVICAY,elevations in transaminases,either TIVICAY mg,0,0.5878139138221741
TIVICAY,elevations in transaminases,d-dose efavirenz/emtricitab inetenofovir,1,0.5755194425582886
TIVICAY,elevations in transaminases,sulfate and lamivudine EPZICOM once daily or fixe,0,0.5803877115249634
TIVICAY,elevations in transaminases,or d-dose efavirenz/emtricitab inetenofovir ATRIPLA r once,1,0.577792763710022
TIVICAY,immune reconstitution syndrome,discontinuation were in subjects receiving TIVICA,0,0.5242955684661865
TIVICAY,immune reconstitution syndrome,daily or fixeddose efavirenzemtricitabinetenofovir (r) ) once daily. Through,1,0.5766381025314331
TIVICAY,immune reconstitution syndrome,efavirenzemtricitabinetenofovir (r) ) once daily. Through,1,0.588472843170166
TIVICAY,immune reconstitution syndrome,Through 9 weeks,1,0.4821524918079376
TIVICAY,immune reconstitution syndrome,efavirenzemtricitabinetenofovir   (r)  ) once daily. Through 9 weeks,1,0.5840876698493958
TIVICAY,immune reconstitution syndrome,efavirenzemtricitabinetenofovir (r) ),1,0.5971919894218445
TIVICAY,immune reconstitution syndrome,) once daily. Through 9 weeks the,1,0.4968605041503906
TIVICAY,immune reconstitution syndrome,weeks the rates,0,0.44707655906677246
TIVICAY,immune reconstitution syndrome,subjects,0,0.4994794428348541
TIVICAY,immune reconstitution syndrome,  (r)  ) once daily. Through 9 weeks the rates of,1,0.4981050491333008
TIVICAY,hepatitis B reactivation,"daily Through eks, the rates of advers e events leading",1,0.46963363885879517
TIVICAY,hepatitis B reactivation,subjects,0,0.48424214124679565
TIVICAY,hepatitis B reactivation,events,0,0.5151190757751465
TIVICAY,hepatitis B reactivation,"daily Through eks, the rates",1,0.43872079253196716
TIVICAY,hepatitis B reactivation,"once daily Through eks, the rates",1,0.4653606414794922
TIVICAY,hepatitis B reactivation,"daily Through eks, the rates of",1,0.448546439409256
TIVICAY,central obesity,simplify resentation; di,1,0.5216678380966187
TIVICAY,central obesity,resentation; di,1,0.537533700466156
TIVICAY,central obesity,SPRING and SINGLE trials are provided,0,0.43501266837120056
TIVICAY,central obesity,resentation; di rect comparisons across trials,1,0.5415877103805542
TIVICAY,central obesity,resentation; di rect comparisons across trials should,1,0.5208402872085571
TIVICAY,central obesity,is to simplify resentation;,1,0.4888899624347687
TIVICAY,dorsocervical fat enlargement,designs Table,0,0.4503922760486603
TIVICAY,dorsocervical fat enlargement,across trials should not be made due,1,0.4461008906364441
TIVICAY,buffalo hump,direct comparisons across trials ould not be ,1,0.4485997259616852
TIVICAY,buffalo hump,across trials should not be made due,1,0.45678919553756714
TIVICAY,facial wasting,rial,1,0.5090699195861816
TIVICAY,facial wasting,Drug Reactions,0,0.49913710355758667
TIVICAY,facial wasting,differing t,0,0.542939305305481
TIVICAY,facial wasting,be,0,0.5143582820892334
TIVICAY,facial wasting,rial designs. Table Treatmentemergent Adverse Drug,1,0.513853132724762
TIVICAY,breast enlargement,"to differing trial 
 Table 2. Treatme ntemergent Adverse Drug",1,0.5275954008102417
TIVICAY,breast enlargement,rial designs. Table Treatmentemergent Adverse Drug,1,0.5232614278793335
TIVICAY,breast enlargement,at,0,0.5044454336166382
TIVICAY,breast enlargement,"due to differing trial 
 Table 2. Treatme ntemergent",1,0.5443509817123413
TIVICAY,breast enlargement,should not be made due to differing trial,0,0.4569172263145447
TIVICAY,breast enlargement,trials should not be made due,0,0.44975799322128296
TIVICAY,breast enlargement,trial designs,0,0.5271533727645874
TIVICAY,breast enlargement,"trial 
 Table 2. Treatme ntemergent Adverse Drug",1,0.5324996709823608
TIVICAY,Immune reconstitution syndrome,+ 2 NRTIs,1,0.5243936777114868
TIVICAY,Immune reconstitution syndrome,NRTIs n,0,0.5378479361534119
TIVICAY,Immune reconstitution syndrome,Preferred Term SPRING TIVICAY 50,1,0.4424045979976654
TIVICAY,Immune reconstitution syndrome,mg Once Daily + 2 NRTIs,1,0.5546561479568481
TIVICAY,Immune reconstitution syndrome,  TIVICAY 50 mg Once Daily + 2 NRTIs n Raltegravir,1,0.5312621593475342
TIVICAY,polymyositis,      <1%    Nervous System,1,0.5164991021156311
TIVICAY,Guillain-Barre syndrome,Abnormal            <1%         ,1,0.5365986227989197
TIVICAY,Guillain-Barre syndrome,      <1%    Nervous System,1,0.6179149150848389
TIVICAY,Guillain-Barre syndrome,           <1%         ,1,0.4806276261806488
TIVICAY,Guillain-Barre syndrome,           <1%          Nervous System,1,0.6179149150848389
TIVICAY,Guillain-Barre syndrome,dreams,0,0.5099428296089172
TIVICAY,Guillain-Barre syndrome,Abnormal            <1%          Nervous,1,0.5721137523651123
TIVICAY,Guillain-Barre syndrome,           <1%          Nervous,1,0.5107899904251099
TIVICAY,Guillain-Barre syndrome,Abnormal dreams,0,0.5240230560302734
ULESFIA,ocular irritation,with ocular irritation,1,0.9761489033699036
ULESFIA,ocular irritation,Abnormal dreams,0,0.4800158739089966
ULESFIA,ocular irritation,ocular irritation application site irritation and application,1,0.8764265775680542
ULESFIA,ocular irritation,than with ocular irritation application site,1,0.8937526345252991
ULESFIA,ocular irritation,ocular irritation application,1,0.9308886528015137
ULESFIA,ocular irritation,more common than with ocular irritation,1,0.8577780723571777
ULESFIA,ocular irritation,irritation and application site anesthesia and,0,0.7027562856674194
ULESFIA,ocular irritation,site irritation and application site anesthesia and hypoesthesia To re,0,0.643064558506012
ULESFIA,ocular irritation,application site anesthesia and hypoesthesia To re,0,0.5259730815887451
ULESFIA,application site irritation,application site irritation and application site anesthesia,1,0.8915053606033325
ULESFIA,application site irritation,application site anesthesia and hypoesthesia To re,0,0.7031862735748291
ULESFIA,application site irritation,site irritation and application,1,0.9289484024047852
ULESFIA,application site irritation,and application site anesthesia and hypoesthesia To report SUSPECTED ADVERSE REACTI,0,0.7416390180587769
ULESFIA,application site irritation,site irritation and application site anesthesia,1,0.8357336521148682
ULESFIA,application site irritation,placebo ocular application site irritation,1,0.804656982421875
ULESFIA,application site irritation,ocular application site,1,0.7485034465789795
ULESFIA,application site irritation,ocular irritation,0,0.7088038921356201
ULESFIA,application site irritation,application,1,0.741076648235321
ULESFIA,application site irritation,irritation,0,0.7875229120254517
ULESFIA,application site anesthesia,application site anesthesia,1,1.0
ULESFIA,application site anesthesia,with placebo ocular irritation application site irritation,0,0.6340630054473877
ULESFIA,application site anesthesia,contact,0,0.516119658946991
ULESFIA,application site anesthesia,and more common than with placebo,0,0.5418263673782349
ULESFIA,application site anesthesia,site irritation application site anesthesia and hypoesthesia To report SUSPECTED,1,0.7899735569953918
ULESFIA,Application site Irritation,Application,0,0.741076648235321
ULESFIA,Application site Irritation,Application site Irritation Application,1,0.9756994843482971
ULESFIA,Application site anesthesia,site anesthesia hypoesthesia Pain,1,0.7973541021347046
ULESFIA,Application site anesthesia,Lotion Vehicle Application site Application,1,0.6811767220497131
ULESFIA,Application site anesthesia,Vehicle,0,0.4658023715019226
ULESFIA,Application site anesthesia,Application site anesthesia hypoesthesia,1,0.8563140034675598
ULESFIA,Application site anesthesia,site Application site anesthesia,1,0.9682093262672424
ULESFIA,Pain,subjects who did not h,0,0.4625045657157898
ULESFIA,Pain,Pain The subset of,1,0.847669243812561
ULESFIA,Pain,Pain The subset of subjects,1,0.7572637796401978
ULESFIA,Pain,anesthesia hypoesthesia,0,0.5416858196258545
ULESFIA,Pain,hypoesthesia,0,0.5578529834747314
ULESFIA,Pain,did,0,0.5380679965019226
ULESFIA,Pruritus,Monitored Adverse Pruritus Erythema Pyoderma,1,0.8073716759681702
ULESFIA,Pruritus,did,0,0.5323495268821716
ULESFIA,Pruritus,Treatment,0,0.5841726064682007
ULESFIA,Pruritus,Table Monitored Adverse,0,0.5488535165786743
ULESFIA,Pruritus,Pruritus Erythema Pyoderma and Ocular Irritation,1,0.8023417592048645
ULESFIA,Pruritus,Irritation with,0,0.7516465187072754
ULESFIA,Erythema,Erythema Pyoderma and Ocular Irritation,1,0.7744652032852173
ULESFIA,Erythema,and Ocular Irritation with Onset After Treatment SignsSymptoms ULESFIA r,0,0.6246246099472046
ULESFIA,Erythema,Table Monitored Adverse Reactions Erythema Pyoderma and,1,0.7637233734130859
ULESFIA,Erythema,Erythema Pyoderma and Ocular Irritation with,1,0.7712092399597168
ULESFIA,Pyoderma,Pyoderma,1,1.0
ULESFIA,Pyoderma,After Treatment SignsSymptoms ULESFIA r,0,0.5550316572189331
ULESFIA,Ocular Irritation,Ocular Irritation,1,1.0
ULESFIA,Ocular Irritation,Pyoderma Ocular,1,0.7512600421905518
ULESFIA,Ocular Irritation,and,0,0.4958396553993225
ULESFIA,Ocular Irritation,Ocular Irritation with Onset After Treatment SignsSymptoms,1,0.8726434707641602
ULESFIA,Ocular Irritation,with Onset After Treatment SignsSymptoms ULESFIA r Lotion Vehicle Pruritu,0,0.6430264711380005
ULESFIA,Ocular Irritation,Ocular Irritation with,1,0.9815807938575745
ULESFIA,application site dryness,site dermatitis,0,0.671741783618927
ULESFIA,application site dryness,site dryness,1,0.9098842144012451
ULESFIA,application site dryness,order of application site dryness,1,0.9445356130599976
ULESFIA,application site dryness,of application site dryness,1,0.9794228076934814
ULESFIA,application site dryness,in decreasing order of application,1,0.6710715889930725
ULESFIA,application site dryness,were in decreasing order of,0,0.5477043986320496
ULESFIA,application site excoriation,application site excoriation paraesthesia application site,1,0.844962477684021
ULESFIA,application site excoriation,site excoriation paraesthesia application,1,0.7901663184165955
ULESFIA,application site excoriation,site excoriation paraesthesia,1,0.7736259698867798
ULESFIA,application site excoriation,excoriation thermal burn,0,0.6901060938835144
ULESFIA,application site excoriation,thermal,0,0.5187138915061951
ULESFIA,application site excoriation,application site application site excoriation,1,0.9875862002372742
ULESFIA,paraesthesia,paraesthesia application site dermatitis excoriation thermal,1,0.8098660707473755
ULESFIA,paraesthesia,site paraesthesia application,1,0.8427212238311768
ULESFIA,paraesthesia,paraesthesia application site,1,0.843559980392456
ULESFIA,application site dermatitis,dryness,0,0.6028760671615601
ULESFIA,application site dermatitis,site excoriation application site,1,0.7995908856391907
ULESFIA,application site dermatitis,excoriation application site,1,0.7691770195960999
ULESFIA,application site dermatitis,site dermatitis excoriation thermal burn,1,0.7530169486999512
ULESFIA,application site dermatitis,site excoriation application site dermatitis excoriation thermal burn dandruff,1,0.7850972414016724
ULESFIA,application site dermatitis,application site dermatitis excoriation thermal,1,0.8439610004425049
ULESFIA,application site dermatitis,thermal burn,0,0.5687583684921265
ULESFIA,excoriation,thermal burn dandruff erythema rash and skin,0,0.6172049045562744
ULESFIA,excoriation,excoriation thermal,1,0.8792639970779419
ULESFIA,excoriation,excoriation thermal burn dandruff,1,0.7804552912712097
ULESFIA,thermal burn,thermal burn dandruff erythema rash and skin,1,0.7944502830505371
ULESFIA,thermal burn,thermal burn dandruff erythema rash and,1,0.8040883541107178
ULESFIA,thermal burn,paraesthesia application site dermatitis thermal burn dandruff erythema rash and skin,1,0.685290515422821
ULESFIA,thermal burn,site dermatitis thermal burn dandruff erythema rash and,1,0.7379865646362305
ULESFIA,dandruff,dandruff erythema rash and skin,1,0.8268918991088867
ULESFIA,dandruff,erythema rash and skin,0,0.5696163773536682
ULESFIA,erythema,rash,0,0.7343558669090271
ULESFIA,erythema,dermatitis excoriation thermal,0,0.7123119831085205
ULESFIA,erythema,thermal burn,0,0.599992036819458
ULESFIA,erythema,erythema,1,1.000000238418579
ULESFIA,erythema,dermatitis excoriation thermal burn erythema rash and skin exfoliation,1,0.7743390798568726
ULESFIA,erythema,dermatitis excoriation thermal burn erythema rash and skin,1,0.7927917838096619
ULESFIA,erythema,thermal burn erythema rash and,1,0.7986749410629272
ULESFIA,erythema,dermatitis excoriation thermal burn erythema rash,1,0.7930159568786621
ULESFIA,erythema,dandruff,0,0.6222512125968933
ULESFIA,rash,rash,1,1.0
ULESFIA,rash,rash and,1,0.9337756037712097
ULESFIA,rash,rash and skin exfoliation,1,0.8277837634086609
ULESFIA,rash,paraesthesia application site dermatitis excoriation thermal burn dandruff,0,0.6863757371902466
ULESFIA,rash,excoriation thermal,0,0.5973902940750122
ULESFIA,rash,site dermatitis excoriation,0,0.6750987768173218
ULESFIA,Neonatal toxicity,common,0,0.485626757144928
ULESFIA,gasping syndrome,more common th an with,1,0.4996778666973114
ULESFIA,gasping syndrome,and application site anesthesia,0,0.5157755613327026
ULESFIA,gasping syndrome,irritation application site irritation and application site anesthesia,0,0.5134211778640747
ULESFIA,gasping syndrome,common th an with placebo ocular,1,0.4836925268173218
ULESFIA,gasping syndrome,an,0,0.5224555730819702
ULESFIA,Eye irritation,"irritation application site rritation, and application site anesthesia and hypoesthesia",1,0.672207236289978
ULESFIA,Eye irritation,an,0,0.5229580998420715
ULESFIA,Eye irritation,with placebo ocular irritation,0,0.8492207527160645
ULESFIA,Eye irritation,"rritation, and application site anesthesia and hypoesthesia",1,0.5269635915756226
ULESFIA,Eye irritation,"rritation,",1,0.505075216293335
ULESFIA,Eye irritation,placebo ocular irritation application site,0,0.8069766759872437
ULESFIA,Eye irritation,"rritation, and application site anesthesia and",1,0.5160800814628601
ULESFIA,Eye irritation,"irritation application site rritation,",1,0.7384685277938843
ULESFIA,Eye irritation,"rritation, and application site anesthesia",1,0.5161415338516235
ULESFIA,Eye irritation,"site rritation, and application site anesthesia and hypoesthesia",1,0.5181454420089722
ULESFIA,Contact dermatitis,at 1 or FDA,1,0.5347051620483398
ULESFIA,Contact dermatitis,and hypoesthesia To report,0,0.5626658201217651
ULESFIA,Contact dermatitis,"uticals, LLC. at 1",1,0.507635772228241
ULESFIA,neonatal gasping syndrome,to rates in the clinical trials of another drug and may not,0,0.4190322458744049
ULESFIA,neonatal gasping syndrome,observed in clini cal practice The,1,0.49384886026382446
ULESFIA,neonatal gasping syndrome,may not reflect e rates observed in clini,1,0.4610629677772522
ULESFIA,neonatal gasping syndrome,compared to rates in the clinical trials of another drug and may not reflect,0,0.4158608317375183
ULESFIA,neonatal gasping syndrome,not reflect e rates observed in,1,0.43155327439308167
ULESFIA,neonatal gasping syndrome,and may,0,0.4126012325286865
ULESFIA,neonatal gasping syndrome,and may not reflect e rates observed in clini cal practice The rates,1,0.45078131556510925
ULESFIA,metabolic acidosis,rates of adv,1,0.496107280254364
ULESFIA,metabolic acidosis,rates of adv erse reactions,1,0.5464416742324829
ULESFIA,metabolic acidosis,clinical The rates of,1,0.5234363079071045
ULESFIA,metabolic acidosis,clinical   The rates of adv erse reactions below were derived,1,0.54532790184021
ULESFIA,metabolic acidosis,rates of adv erse reactions below were,1,0.5431830883026123
ULESFIA,metabolic acidosis,of adv erse reactions below were derived,1,0.554664134979248
ULESFIA,progressive hypotension,of adverse reactions below e,1,0.6104958057403564
ULESFIA,seizures,trials and one openlabel study,0,0.5608947277069092
ULESFIA,seizures,"derived from two ized, mu lticenter vehiclecontrolled clinical trials and",1,0.5343713760375977
ULESFIA,seizures,The rates of adverse reactions,0,0.5762356519699097
ULESFIA,seizures,study in subjects,0,0.49301785230636597
ULESFIA,seizures,"ized, mu lticenter vehiclecontrolled clinical trials",1,0.5267561674118042
ULESFIA,seizures,with,0,0.5627552270889282
ULESFIA,seizures,clinical practice The rates of adverse reactions below,0,0.5658020973205566
ULESFIA,seizures,"two ized, mu lticenter vehiclecontrolled clinical trials and",1,0.5424920320510864
ULESFIA,central nervous system depression,rates of adverse reactions below,0,0.5198599696159363
ULESFIA,central nervous system depression,"i-center, vehicle-controlled clin ical trials",1,0.5814305543899536
ULESFIA,central nervous system depression,"i-center, vehicle-controlled clin ical",1,0.5440865755081177
ULESFIA,central nervous system depression,openlabel study in subjects with head lice infestation,0,0.5366518497467041
ULESFIA,central nervous system depression,"randomized i-center, vehicle-controlled clin",1,0.5496681928634644
ULESFIA,central nervous system depression,"i-center, vehicle-controlled",1,0.5272879600524902
ULESFIA,central nervous system depression,with head lice infestation Skin scalp,0,0.5076932907104492
ULESFIA,intraventricular hemorrhage,and one open-labe l study in subjects with,1,0.49464285373687744
ULESFIA,intraventricular hemorrhage,multicenter vehiclecontrolled al trials and one,1,0.4995782971382141
ULESFIA,intraventricular hemorrhage,two randomized multicenter vehiclecontrolled al trials and,1,0.5163663625717163
ULESFIA,death,y in,1,0.5317587852478027
ULESFIA,gasping syndrome,about the presence of n and scalp symp toms the results,1,0.5369203090667725
ULESFIA,gasping syndrome,y in,1,0.4794061779975891
ULESFIA,gasping syndrome,results are presented in Table Table Monitored Adverse,0,0.523088812828064
ULESFIA,gasping syndrome,n,1,0.4747329652309418
ULESFIA,gasping syndrome,scalp symp toms the,1,0.5366061925888062
ULESFIA,gasping syndrome,clinical trials All,0,0.48232826590538025
ULESFIA,gasping syndrome,presented,0,0.5051602125167847
ULESFIA,eye irritation,Application site /478),1,0.49041253328323364
ULESFIA,eye irritation,Lotion Vehicle Application site /478),1,0.5282442569732666
ULESFIA,eye irritation,Application site anesthesia,0,0.48610854148864746
ULESFIA,eye irritation,Lotion Vehicle Application site /478) 1%,1,0.5260446071624756
ULESFIA,eye irritation,/478) 1%,1,0.4773814082145691
ULESFIA,eye irritation,/478) 1% Application,1,0.5095999240875244
ULESFIA,eye irritation,/478)      1% ,1,0.4773814082145691
ULESFIA,eye irritation,Irritation,0,0.8283274173736572
ULESFIA,eye irritation,/478) 1% Application site anesthesia hypoesthesia,1,0.498075008392334
JUBLIA,ingrown toenails,ingrown toenails application site dermatitis application site,1,0.8504536151885986
JUBLIA,ingrown toenails,/478) 1% Application site anesthesia hypoesthesia,1,0.5127214193344116
JUBLIA,ingrown toenails,most common adverse reactions incidence,0,0.4868072271347046
JUBLIA,ingrown toenails,ingrown toenails application site dermatitis application,1,0.8666739463806152
JUBLIA,ingrown toenails,EXCERPT,0,0.4799203872680664
JUBLIA,ingrown toenails,ADVERSE REACTIONS,0,0.52001953125
JUBLIA,ingrown toenails,ingrown toenails,1,0.9999999403953552
JUBLIA,application site dermatitis,most common adverse reactions incidence were ingrown,0,0.6570035219192505
JUBLIA,application site dermatitis,most,0,0.4815695881843567
JUBLIA,application site vesicles,application site vesicles and application site pain To,1,0.9340487122535706
JUBLIA,application site vesicles,e most common adverse reactions incidence were ingrown toenails application site dermatitis,0,0.5427023768424988
JUBLIA,application site vesicles,site,0,0.6818658709526062
JUBLIA,Ingrown toenail,n JUBLIAN Ingrown,1,0.7956317067146301
JUBLIA,Ingrown toenail,JUBLIAN Ingrown toenail Application site dermatitis,1,0.8344471454620361
JUBLIA,Ingrown toenail,Adverse Event n,0,0.4892880916595459
JUBLIA,Ingrown toenail,Application site,0,0.4544250965118408
JUBLIA,Application site dermatitis,Application site dermatitis,1,0.9999998807907104
JUBLIA,Application site dermatitis,Application site dermatitis Application site vesicles,1,0.8584645390510559
JUBLIA,Application site dermatitis,Application site vesicles,0,0.704623818397522
JUBLIA,Application site dermatitis,Ingrown Application site dermatitis,1,0.8716409802436829
JUBLIA,Application site vesicles,Application site Application,1,0.7818683385848999
TRULICITY,Thyroid C-cell Tumors,prescribing information Risk Thyroid C-cell Tumors see Warnings and,1,0.8488595485687256
TRULICITY,Thyroid C-cell Tumors,Application site Application,1,0.4243479073047638
TRULICITY,Thyroid C-cell Tumors,C-cell Tumors see,1,0.8643975257873535
TRULICITY,Thyroid C-cell Tumors,Thyroid C-cell Tumors,1,1.0
TRULICITY,Thyroid C-cell Tumors,Thyroid C-cell Tumors see Warnings,1,0.9201205968856812
TRULICITY,Thyroid C-cell Tumors,are,0,0.46527257561683655
TRULICITY,Thyroid C-cell Tumors,see Warnings,0,0.501273512840271
TRULICITY,Pancreatitis,Warnings and Precautions Hypoglycemia with Concomitant Use,0,0.5540820360183716
TRULICITY,Pancreatitis,Pancreatitis,1,0.9999998211860657
TRULICITY,Pancreatitis,Use,0,0.5575299263000488
TRULICITY,Hypoglycemia,see Warnings and Precautions,0,0.5096666216850281
TRULICITY,Hypoglycemia,Hypoglycemia,1,1.0
TRULICITY,Hypoglycemia,Insulin see Warnings and Precautions,0,0.6700993776321411
TRULICITY,Hypersensitivity,impairment see Warnings,0,0.5695558786392212
TRULICITY,Hypersensitivity,and Precautions,0,0.5511589646339417
TRULICITY,Hypersensitivity,Hypersensitivity reactions see Warnings and,1,0.8364865779876709
TRULICITY,Hypersensitivity,Secretagogues or Insulin see Warnings,0,0.5838703513145447
TRULICITY,Hypersensitivity,Hypersensitivity reactions see Warnings and Precautions,1,0.8208584785461426
TRULICITY,Renal impairment,Renal impairment,1,1.0
TRULICITY,Renal impairment,Renal impairment see Warnings and Precautions,1,0.872637152671814
TRULICITY,Gastrointestinal Disease,Gastrointestinal Disease see,1,0.942840576171875
TRULICITY,Gastrointestinal Disease,Renal impairment see Warnings and Precautions,1,0.574622392654419
TRULICITY,Gastrointestinal Disease,and Precautions EXCERPT The most common adverse reactions repo,0,0.5500962734222412
TRULICITY,nausea,nausea diarrhea vomiting,1,0.8434498310089111
TRULICITY,nausea,and Precautions EXCERPT The most common adverse reactions repo,0,0.584143877029419
TRULICITY,nausea,nausea,1,1.0
TRULICITY,diarrhea,diarrhea,1,0.9999999403953552
TRULICITY,diarrhea,diarrhea vomiting abdominal,1,0.7952749729156494
TRULICITY,diarrhea,The most common adverse reactions reported in of patients treated,0,0.5391128063201904
TRULICITY,diarrhea,are diarrhea vomiting,1,0.7865201234817505
TRULICITY,diarrhea,common adverse reactions reported in of,0,0.5799802541732788
TRULICITY,diarrhea,nausea,0,0.6490728855133057
TRULICITY,diarrhea,treated with TRULICITY are diarrhea vomiting abdominal,1,0.7555837035179138
TRULICITY,diarrhea,The most common adverse reactions reported in,0,0.5770506858825684
TRULICITY,vomiting,reported in of patients treated with TRULICITY are,0,0.5628656148910522
TRULICITY,vomiting,ommon adverse reactions reported in of patients treated with TRULICITY are nausea,0,0.6882245540618896
TRULICITY,vomiting,reported in of patients,0,0.526640772819519
TRULICITY,abdominal pain,patients treated with,0,0.5302878022193909
TRULICITY,abdominal pain,are nausea diarrhea abdominal pain,1,0.8154393434524536
TRULICITY,decreased appetite,abdominal pain decreased appetite,1,0.8190599679946899
TRULICITY,decreased appetite,patients,0,0.5480929613113403
TRULICITY,decreased appetite,decreased appetite To,1,0.9723002910614014
TRULICITY,decreased appetite,Lilly and Company,0,0.4284226596355438
TRULICITY,decreased appetite,treated with TRULICITY are nausea diarrhea vomiting,0,0.6116966009140015
TRULICITY,decreased appetite,abdominal pain and,0,0.5319810509681702
TRULICITY,decreased appetite,abdominal pain decreased appetite To report,1,0.8117263913154602
TRULICITY,decreased appetite,decreased appetite To report SUSPECTED ADVERSE,1,0.873684287071228
TRULICITY,decreased appetite,and Company at Lill,0,0.45473745465278625
TRULICITY,hypoglycemia,common adverse reactions hypoglycemia,1,0.8556697964668274
TRULICITY,hypoglycemia,and Company at Lill,0,0.4855831563472748
TRULICITY,diarrhea,diarrhea fecal volume,1,0.7706276178359985
TRULICITY,diarrhea,a diarrhea fecal volume,1,0.7977777719497681
TRULICITY,diarrhea,Includes retching vomiting vomiting pr,0,0.6713510751724243
TRULICITY,diarrhea,increased frequent bowel movements b Includes retching vomiting,0,0.6704717874526978
TRULICITY,diarrhea,Reported in of TRULICITYTreated Patients a,0,0.5834405422210693
TRULICITY,diarrhea,diarrhea fecal volume increased frequent bowel,1,0.7466375827789307
TRULICITY,fecal volume increased,Includes fecal,1,0.826004683971405
TRULICITY,fecal volume increased,b Includes retching,0,0.668083667755127
TRULICITY,fecal volume increased,fecal volume increased,1,1.0000001192092896
TRULICITY,fecal volume increased,Patients,0,0.5046601891517639
TRULICITY,fecal volume increased,vomiting vomiting projectile,0,0.5671843886375427
TRULICITY,fecal volume increased,Includes fecal volume increased,1,0.9873543977737427
TRULICITY,fecal volume increased,in,0,0.48821210861206055
TRULICITY,fecal volume increased,in of TRULICITYTreated Patients a Includes,0,0.5538520812988281
TRULICITY,frequent bowel movements,Reported in,0,0.5356924533843994
TRULICITY,retching,movements b retching vomiting vomiting projectile c Includes,1,0.8619807958602905
TRULICITY,retching,Reported in,0,0.5264387726783752
TRULICITY,retching,retching vomiting vomiting projectile c Includes,1,0.8397971391677856
TRULICITY,retching,retching vomiting vomiting projectile c,1,0.8609243035316467
TRULICITY,retching,bowel movements b retching vomiting vomiting,1,0.862572968006134
TRULICITY,retching,retching,1,1.0
TRULICITY,retching,frequent bowel movements b retching vomiting vomiting,1,0.8337265253067017
TRULICITY,vomiting,Includes,0,0.506866455078125
TRULICITY,vomiting,vomiting vomiting projectile c Includes,1,0.8343874216079712
TRULICITY,vomiting,movements b Includes vomiting vomiting,1,0.851269006729126
TRULICITY,vomiting,projectile c Includes abdominal discomfort abdominal,0,0.6584585905075073
TRULICITY,vomiting,abdominal pain,0,0.6247491836547852
TRULICITY,vomiting,vomiting vomiting projectile c,1,0.8488838076591492
TRULICITY,vomiting,increased frequent bowel movements b Includes,0,0.5521414279937744
TRULICITY,vomiting,vomiting,1,0.9999999403953552
TRULICITY,vomiting projectile,abdominal pain abdominal pain lower abdominal pain upper,0,0.549496054649353
TRULICITY,vomiting projectile,abdominal discomfort abdominal pain abdominal pain lower abdominal,0,0.5465302467346191
TRULICITY,vomiting projectile,vomiting,1,0.8945611119270325
TRULICITY,vomiting projectile,abdominal discomfort abdominal pain abdominal pain lower,0,0.5460666418075562
TRULICITY,abdominal discomfort,abdominal discomfort abdominal pain,1,0.9709703922271729
TRULICITY,abdominal discomfort,abdominal discomfort abdominal pain abdominal pain lower,0,0.9080707430839539
TRULICITY,abdominal discomfort,upper,0,0.46227264404296875
TRULICITY,abdominal discomfort,abdominal discomfort abdominal pain abdominal,1,0.9575481414794922
TRULICITY,abdominal discomfort,vomiting vomiting projectile,0,0.5915348529815674
TRULICITY,abdominal discomfort,vomiting projectile c abdominal discomfort abdominal pain abdominal,1,0.8284603357315063
TRULICITY,abdominal discomfort,projectile c abdominal,1,0.6955398917198181
TRULICITY,abdominal discomfort,projectile c abdominal discomfort,1,0.8322500586509705
TRULICITY,abdominal discomfort,c abdominal discomfort abdominal pain abdominal pain,1,0.9217047691345215
TRULICITY,abdominal discomfort,c abdominal,1,0.80223548412323
TRULICITY,abdominal pain,gastrointestinal,0,0.7238667011260986
TRULICITY,abdominal pain,projectile c Includes abdominal abdominal pain,1,0.8047465085983276
TRULICITY,abdominal pain,abdominal pain,0,0.9999998807907104
TRULICITY,abdominal pain,abdominal abdominal,1,0.7627865076065063
TRULICITY,abdominal pain,abdominal pain abdominal,1,0.9777070879936218
TRULICITY,abdominal pain,abdominal pain abdominal pain,1,0.980596661567688
TRULICITY,abdominal pain,vomiting projectile c,0,0.5795236825942993
TRULICITY,abdominal pain lower,abdominal pain lower abdominal pain upper,1,0.8889849781990051
TRULICITY,abdominal pain lower,abdominal pain lower abdominal,1,0.9773297309875488
TRULICITY,abdominal pain lower,pain upper abdominal tenderness gastrointestinal,0,0.7842320799827576
TRULICITY,abdominal pain lower,abdominal discomfort,0,0.8683984279632568
TRULICITY,abdominal pain lower,discomfort abdominal abdominal pain lower,1,0.9640708565711975
TRULICITY,abdominal pain lower,Includes abdominal discomfort abdominal abdominal pain,1,0.8528643846511841
TRULICITY,abdominal pain lower,Includes abdominal discomfort abdominal abdominal,1,0.8298799991607666
TRULICITY,abdominal pain lower,abdominal pain lower abdominal pain upper abdominal tenderness,1,0.8439164161682129
TRULICITY,abdominal pain lower,abdominal abdominal pain lower abdominal pain upper abdominal,1,0.869286298751831
TRULICITY,abdominal pain lower,abdominal abdominal pain lower,1,0.9922524690628052
TRULICITY,abdominal pain upper,vomiting projectile c Includes abdominal,0,0.6602835655212402
TRULICITY,abdominal pain upper,fatigue,0,0.5241222977638245
TRULICITY,abdominal pain upper,abdominal pain abdominal pain upper abdominal tenderness gastrointestinal,1,0.8983901143074036
TRULICITY,abdominal tenderness,lower abdominal pain abdominal tenderness,1,0.9321354627609253
TRULICITY,abdominal tenderness,abdominal tenderness gastrointestinal pain d Includes,1,0.8976664543151855
TRULICITY,abdominal tenderness,malaise Note Percentages refl,0,0.49333369731903076
TRULICITY,abdominal tenderness,Includes fatigue asthenia malaise Note,0,0.5893914699554443
TRULICITY,abdominal tenderness,pain abdominal tenderness gastrointestinal pain d Includes fatigue,1,0.8486375212669373
TRULICITY,abdominal tenderness,abdominal pain abdominal tenderness gastrointestinal pain d,1,0.8915583491325378
TRULICITY,gastrointestinal pain,pain upper abdominal gastrointestinal pain d Includes,1,0.8522443771362305
TRULICITY,gastrointestinal pain,Includes fatigue asthenia malaise Note,0,0.5600621700286865
TRULICITY,gastrointestinal pain,pain upper abdominal gastrointestinal pain d Includes fatigue asthenia,1,0.8197002410888672
TRULICITY,gastrointestinal pain,d Includes fatigue asthenia malaise Note Percentages reflect the,0,0.5542711019515991
TRULICITY,gastrointestinal pain,upper abdominal gastrointestinal pain d Includes fatigue asthenia malaise,1,0.8113209009170532
TRULICITY,gastrointestinal pain,d Includes fatigue asthenia malaise Note Percentages reflect the number of patie,0,0.5630755424499512
TRULICITY,gastrointestinal pain,upper abdominal gastrointestinal pain d Includes,1,0.8435325622558594
TRULICITY,gastrointestinal pain,d Includes fatigue asthenia malaise Note,0,0.5681825280189514
TRULICITY,gastrointestinal pain,gastrointestinal pain d Includes fatigue,1,0.8548363447189331
TRULICITY,gastrointestinal pain,reflect the number,0,0.46002811193466187
TRULICITY,gastrointestinal pain,gastrointestinal pain d Includes fatigue asthenia malaise,1,0.8352919220924377
TRULICITY,fatigue,Includes,0,0.5379856824874878
TRULICITY,fatigue,pain lower,0,0.5977224707603455
TRULICITY,fatigue,pain upper abdominal tenderness gastrointestinal pain d,0,0.5841063857078552
TRULICITY,fatigue,d fatigue,1,0.851723313331604
TRULICITY,fatigue,fatigue,1,1.0
TRULICITY,fatigue,tenderness gastrointestinal pain d fatigue asthenia malaise,1,0.7277660369873047
TRULICITY,asthenia,asthenia malaise Note Percentages reflect the,1,0.7463627457618713
TRULICITY,asthenia,asthenia malaise Note Percentages reflect,1,0.7493410706520081
TRULICITY,asthenia,patients that,0,0.528329610824585
TRULICITY,asthenia,asthenia,1,1.0000001192092896
TRULICITY,malaise,fatigue malaise Note Percentages reflect the,1,0.6977163553237915
TRULICITY,malaise,asthenia,1,0.6103212833404541
TRULICITY,gastrointestinal adverse reactions,frequently among patients,0,0.5345682501792908
TRULICITY,gastrointestinal adverse reactions,pool of placebocontrolled gastrointestinal adverse,1,0.7961064577102661
TRULICITY,gastrointestinal adverse reactions,placebocontrolled gastrointestinal adverse,1,0.8188356161117554
TRULICITY,gastrointestinal adverse reactions,placebocontrolled gastrointestinal adverse reactions,1,0.8639442920684814
TRULICITY,gastrointestinal adverse reactions,discontinued treatment due gastrointestinal adverse reactions,1,0.8487540483474731
TRULICITY,gastrointestinal adverse reactions,discontinued treatment due gastrointestinal,1,0.7509729862213135
TRULICITY,gastrointestinal adverse reactions,due gastrointestinal,1,0.8321822285652161
TRULICITY,gastrointestinal adverse reactions,mg discontinued,0,0.5031192302703857
TRULICITY,gastrointestinal adverse reactions,gastrointestinal adverse,1,0.920128345489502
TRULICITY,gastrointestinal adverse reactions,of gastrointestinal,0,0.8299075365066528
TRULICITY,gastrointestinal adverse reactions,adverse reactions than patients,1,0.7396973967552185
TRULICITY,gastrointestinal adverse reactions,mg discontinued treatment due gastrointestinal adverse reactions than patients receiving,1,0.8006786108016968
TRULICITY,gastrointestinal adverse reactions,severity of,0,0.5920262932777405
TRULICITY,gastrointestinal adverse reactions,and TRULICITY mg discontinued treatment,0,0.5686134696006775
TRULICITY,gastrointestinal adverse reactions,adverse reactions occurring on mg,1,0.7722599506378174
TRULICITY,gastrointestinal adverse reactions,mg of TRULICITY as mild in and of cases respectively,0,0.6145931482315063
TRULICITY,gastrointestinal adverse reactions,Investigators graded the severity gastrointestinal adverse reactions occurring on,1,0.8906158208847046
TRULICITY,gastrointestinal adverse reactions,gastrointestinal adverse reactions occurring on,1,0.9535865783691406
TRULICITY,constipation,than placebo frequencies,0,0.5808993577957153
TRULICITY,constipation,constipation flatulence abdominal,1,0.7829061150550842
TRULICITY,constipation,than placebo frequencies listed respectively as placebo mg mg,0,0.5738359093666077
TRULICITY,constipation,respectively as placebo,0,0.5864682197570801
TRULICITY,constipation,frequencies listed respectively as placebo,0,0.576709508895874
TRULICITY,abdominal distension,as placebo mg mg constipation flatulence,0,0.6136442422866821
TRULICITY,abdominal distension,disease and eructation,0,0.6043216586112976
TRULICITY,abdominal distension,constipation abdominal distension gastroesophageal reflux disease,1,0.8135861158370972
TRULICITY,abdominal distension,disease,0,0.5528650283813477
TRULICITY,gastroesophageal reflux disease,distension,0,0.5988991260528564
TRULICITY,gastroesophageal reflux disease,abdominal gastroesophageal,1,0.7608628273010254
TRULICITY,eructation,eructation Pool of Placebo and,1,0.7249670028686523
TRULICITY,eructation,eructation Pool of Placebo,1,0.7215571403503418
TRULICITY,hypoglycemia,common adverse reactions,0,0.5195791721343994
TRULICITY,hypoglycemia,were similar to those listed in Table,0,0.4845712184906006
TRULICITY,hypoglycemia,hypoglycemia,1,1.0
TRULICITY,hypoglycemia,adverse reactions hypoglycemia were similar to those,1,0.8303773403167725
TRULICITY,hypoglycemia,similar to those listed in Table Other,0,0.48865222930908203
TRULICITY,hypoglycemia,hypoglycemia were similar to those listed,1,0.8694248795509338
TRULICITY,hypoglycemia,Table Other Adverse,0,0.4963853359222412
TRULICITY,hypoglycemia,hypoglycemia in the,1,0.9693946838378906
TRULICITY,hypoglycemia,glucose threshold and hypoglycemia,1,0.8264406323432922
TRULICITY,hypoglycemia,hypoglycemia in,1,0.9719533920288086
TRULICITY,Hypoglycemia,PlaceboControlled Trials Placebo,0,0.5658615231513977
TRULICITY,Hypoglycemia,Hypoglycemia Adverse Reactions,1,0.8638124465942383
TRULICITY,Hypoglycemia,Documented Symptomatic and Hypoglycemia Adverse Reactions in PlaceboControlled Trials,1,0.7744697332382202
TRULICITY,hypoglycemia,hypoglycemia occurred in and of,1,0.9075600504875183
TRULICITY,hypoglycemia,Hypoglycemia,1,1.0
TRULICITY,hypoglycemia,patients when TRULICITY mg and mg respectively was,0,0.5782861709594727
TRULICITY,hypoglycemia,coadministered with a sulfonylurea hypoglycemia occurred in,1,0.846464216709137
TRULICITY,hypoglycemia,hypoglycemia occurred in and of patients,1,0.881183922290802
TRULICITY,symptomatic hypoglycemia,mg and mg respectively was coadministered,0,0.5441927909851074
TRULICITY,symptomatic hypoglycemia,sulfonylurea symptomatic hypoglycemia,1,0.8881270885467529
TRULICITY,symptomatic hypoglycemia,symptomatic,1,0.7554289102554321
TRULICITY,symptomatic hypoglycemia,sulfonylurea symptomatic,1,0.7759999632835388
TRULICITY,symptomatic hypoglycemia,of patients when TRULICITY,0,0.5856656432151794
TRULICITY,hypoglycemia,insulin,0,0.7495182752609253
TRULICITY,hypoglycemia,prandial insulin hypoglycemia occurred in and of patients,1,0.819611668586731
TRULICITY,hypoglycemia,with prandial insulin hypoglycemia occurred in and of,1,0.8353885412216187
TRULICITY,increase in heart rate,in heart rate HR,1,0.8257967829704285
TRULICITY,increase in heart rate,a,0,0.5110164284706116
TRULICITY,increase in heart rate,have not b,0,0.4655708074569702
TRULICITY,increase in heart rate,increase in heart rate HR of beats per minute,1,0.9118107557296753
TRULICITY,increase in heart rate,increase in HR have,0,0.8066734671592712
TRULICITY,increase in heart rate,mg resulted in a increase in heart rate,1,0.8495105504989624
TRULICITY,increase in HR,rate HR of beats per minute bpm The longterm clinical effects of the,0,0.7001473903656006
TRULICITY,increase in HR,established see Warnings,0,0.5360908508300781
TRULICITY,increase in HR,clinical effects of increase in HR have not been established see,1,0.847956120967865
TRULICITY,increase in HR,of,0,0.46931856870651245
TRULICITY,increase in HR,increase in HR have not been established,1,0.8544830679893494
TRULICITY,increase in HR,longterm clinical effects of increase,1,0.7030024528503418
TRULICITY,increase in HR,longterm clinical effects of increase in HR,1,0.8607615232467651
TRULICITY,increase in HR,of increase in HR have not been established,1,0.8431680202484131
TRULICITY,Sinus tachycardia,with placebo TRULICITY mg and,0,0.5373378992080688
TRULICITY,Persistence of sinus tachycardia,TRULICITY mg Persistence of sinus tachycardia reported at more than,1,0.9145538806915283
TRULICITY,Persistence of sinus tachycardia,with placebo TRULICITY mg and,0,0.542112410068512
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity,1,1.0
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse reactions sometimes,1,0.8940032720565796
TRULICITY,Systemic hypersensitivity,other products Systemic,1,0.7089489698410034
TRULICITY,Systemic hypersensitivity,other products,0,0.5097590088844299
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse reactions,1,0.9238585829734802
TRULICITY,Systemic hypersensitivity,products Systemic hypersensitivity,1,0.9217796325683594
TRULICITY,Systemic hypersensitivity,products Systemic,1,0.7173224091529846
TRULICITY,Systemic hypersensitivity,other products Systemic hypersensitivity adverse,1,0.8573298454284668
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse reactions sometimes severe,1,0.8825607299804688
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse,1,0.9135558605194092
TRULICITY,urticaria,Systemic hypersensitivity adverse reactions sometimes severe,0,0.6884970664978027
TRULICITY,urticaria,in of patients on TRULICITY in,0,0.547219455242157
TRULICITY,urticaria,rash,0,0.7540437579154968
TRULICITY,urticaria,urticaria systemic rash,1,0.823824405670166
TRULICITY,urticaria,patients on TRULICITY in,0,0.5548779964447021
TRULICITY,urticaria,Hypersensitivity Systemic hypersensitivity adverse,0,0.6861207485198975
TRULICITY,systemic rash,eg severe systemic,1,0.7558504343032837
TRULICITY,systemic rash,severe eg severe urticaria,0,0.665023684501648
TRULICITY,systemic rash,severe systemic rash,1,0.936133861541748
TRULICITY,systemic rash,severe systemic rash facial,1,0.8810615539550781
TRULICITY,systemic rash,facial edema lip swelling occurred in,0,0.5728508234024048
TRULICITY,systemic rash,systemic rash facial,1,0.9149552583694458
TRULICITY,systemic rash,severe systemic,1,0.7694156169891357
TRULICITY,facial edema,urticaria,0,0.6157301664352417
TRULICITY,facial edema,facial,1,0.7774593830108643
TRULICITY,facial edema,adverse reactions sometimes severe eg,0,0.5833683013916016
TRULICITY,facial edema,adverse reactions sometimes severe eg severe urticaria systemic rash,0,0.5700125098228455
TRULICITY,facial edema,facial edema,1,1.0000001192092896
TRULICITY,facial edema,in of patients on TRULICITY,0,0.5732110142707825
TRULICITY,lip swelling,rash facial lip,1,0.7734248042106628
TRULICITY,injection-site reactions,the placebocontrolled injection-site reactions eg injectionsite rash erythema were,1,0.8089730739593506
TRULICITY,injection-site reactions,rash facial lip,1,0.5138201713562012
TRULICITY,injection-site reactions,patients and,0,0.5295854806900024
TRULICITY,injection-site reactions,five Phase studies Injectionsite Reactions In the placebocontrolled studies,0,0.8411798477172852
TRULICITY,injection-site reactions,injection-site reactions eg injectionsite rash,1,0.8831065893173218
TRULICITY,injection-site reactions,injection-site reactions eg injectionsite rash erythema were,1,0.8643752932548523
TRULICITY,injection-site reactions,injection-site reactions eg,1,0.9900600910186768
TRULICITY,injection-site reactions,injection-site reactions,1,0.9999997615814209
TRULICITY,injection-site reactions,patients,0,0.5450713634490967
TRULICITY,injection-site rash,reactions injection-site rash erythema were reported in,1,0.9143420457839966
TRULICITY,injection-site rash,patients,0,0.5597777962684631
TRULICITY,injection-site rash,and in of placebotreated patie,0,0.504909098148346
TRULICITY,PR interval increase,and of patients,0,0.49970000982284546
TRULICITY,PR interval increase,respectively On electrocardiograms PR interval increase to at least,1,0.9044623970985413
TRULICITY,PR interval increase,patients treated with placebo,0,0.5401233434677124
TRULICITY,PR interval increase,PR interval increase to at least milliseconds was,1,0.9271420240402222
TRULICITY,PR interval increase,patients,0,0.5327836275100708
TRULICITY,PR interval increase,PR interval increase to,1,0.9905051589012146
TRULICITY,PR interval increase,On electrocardiograms PR interval,1,0.8263587355613708
TRULICITY,PR interval increase,of,0,0.494364857673645
TRULICITY,THYROID C-CELL TUMORS,the prescribing,0,0.4694671034812927
TRULICITY,THYROID C-CELL TUMORS,Thyroid Ccell Tumor,0,0.8929890990257263
TRULICITY,THYROID C-CELL TUMORS,REACTIONS The ng serious,1,0.4782382845878601
TRULICITY,THYROID C-CELL TUMORS,REACTIONS The ng serious reactions  are described below or,1,0.4962541460990906
TRULICITY,THYROID C-CELL TUMORS,information Risk of Thyroid Ccell,0,0.7535908222198486
TRULICITY,THYROID C-CELL TUMORS,reactions are described below elsewhere in the pres cribing,1,0.4615657925605774
TRULICITY,THYROID C-CELL TUMORS,described below,0,0.4841134548187256
TRULICITY,THYROID C-CELL TUMORS,information Risk of,0,0.47811174392700195
TRULICITY,THYROID C-CELL TUMORS,elsewhere in the pres cribing information Risk of,1,0.4797421395778656
TRULICITY,thyroid C-cell tumors,( 5. Hypoglycemia with Concomitant Use,1,0.543897271156311
TRULICITY,thyroid C-cell tumors,( 5. Hypoglycemia,1,0.5564520359039307
TRULICITY,thyroid C-cell tumors,see and Precautions,1,0.46125707030296326
TRULICITY,thyroid C-cell tumors,and Precautions Hypersensitivity reactions see Warnings and,1,0.49896687269210815
TRULICITY,thyroid C-cell tumors,Insulin Secretagogues,0,0.5648351907730103
TRULICITY,thyroid C-cell tumors,Hypersensitivity reactions see Warnings and,0,0.5194334983825684
TRULICITY,thyroid C-cell tumors,with Concomitant Use,0,0.48704642057418823
TRULICITY,thyroid C-cell tumors,Insulin see ings,1,0.5021936893463135
TRULICITY,thyroid C-cell tumors,see ings and Precautions,1,0.47472110390663147
TRULICITY,thyroid C-cell tumors,see,0,0.47908246517181396
TRULICITY,thyroid C-cell tumors,ings and Precautions Hypersensitivity reactions,1,0.48247653245925903
TRULICITY,thyroid C-cell tumors,ings and Precautions  Hypersensitivity reactions,1,0.48247653245925903
TRULICITY,medullary thyroid carcinoma,ions see,0,0.4805442690849304
TRULICITY,medullary thyroid carcinoma,and Precautions,0,0.4326207637786865
TRULICITY,medullary thyroid carcinoma,"Insulin see Warnings and 
 *  Hypersensitivity react ions see Warnings",1,0.5313068628311157
TRULICITY,medullary thyroid carcinoma,or,0,0.4665083885192871
TRULICITY,MTC,ns  see Warnings and,1,0.4861048460006714
TRULICITY,MTC,and Precautions Renal impairment,0,0.47808384895324707
TRULICITY,MTC,Secretagogues or Insulin see Warnings and Precautions Hypersensitivity reactio,0,0.4855800271034241
TRULICITY,MTC,ns  see Warnings and Precautions,1,0.47774559259414673
TRULICITY,MTC,ns  see Warnings,1,0.48028087615966797
TRULICITY,MTC,Secretagogues or Insulin,0,0.48090410232543945
TRULICITY,MTC,and Precautions Hypersensitivity,0,0.49790284037590027
TRULICITY,thyroid C-cell tumors,and Precautions Renal t [see Warnings,1,0.5160977840423584
TRULICITY,thyroid C-cell tumors,and P recautions,1,0.45784974098205566
TRULICITY,thyroid C-cell tumors,and Precautions Renal t [see Warnings and P recautions Severe,1,0.5049214363098145
TRULICITY,thyroid C-cell tumors,Warnings and Precautions,0,0.4896591901779175
TRULICITY,thyroid C-cell tumors,t [see Warnings and P recautions,1,0.5247620344161987
TRULICITY,thyroid C-cell tumors,t [see Warnings and P recautions Severe,1,0.5317794680595398
TRULICITY,thyroid C-cell tumors,Renal t [see Warnings and P recautions Severe Gastrointestinal,1,0.5452715754508972
TRULICITY,thyroid C-cell tumors,in able,1,0.4642656743526459
TRULICITY,thyroid C-cell tumors,from the placebocontrolled trials see Clinical,0,0.5251831412315369
TRULICITY,thyroid C-cell tumors,)] . These,1,0.48718342185020447
TRULICITY,thyroid C-cell tumors,patients to TRULICITY and a,0,0.5425869226455688
TRULICITY,thyroid C-cell tumors,Studies ( 14 )] . These,1,0.4870010316371918
TRULICITY,medullary thyroid carcinoma,These ta reflect exposure of,1,0.4511432647705078
TRULICITY,medullary thyroid carcinoma,exposure of 1670 patients to TRULICITY and,1,0.5308628678321838
TRULICITY,medullary thyroid carcinoma,see Clinical Studies These ta reflect exposure of,1,0.5106967091560364
TRULICITY,medullary thyroid carcinoma,see Clinical Studies These ta reflect exposure of 1670 patients to TRULICITY and,1,0.5292144417762756
TRULICITY,MTC,ati ents to TRULICITY and a,1,0.5426363348960876
TRULICITY,MTC,data,0,0.532950222492218
TRULICITY,MTC,ati,1,0.5116060972213745
TRULICITY,thyroid C-cell tumors,exposure to TRULICITY of,0,0.5427365303039551
TRULICITY,Thyroid C-cell Tumors,tions are described b elow or elsewhere in,1,0.47536689043045044
TRULICITY,Thyroid C-cell Tumors,are described b elow,1,0.4602680206298828
TRULICITY,Thyroid C-cell Tumors,tions are described b elow or elsewhere in the,1,0.4683840274810791
TRULICITY,Thyroid C-cell Tumors,following serious tions,1,0.48736006021499634
TRULICITY,Thyroid C-cell Tumors,serious tions are described b elow or elsewhere,1,0.4941258430480957
TRULICITY,Thyroid C-cell Tumors,serious tions are described b elow or,1,0.4852575361728668
TRULICITY,Thyroid C-cell Tumors,tions are described b elow or elsewhere,1,0.4768998622894287
TRULICITY,Thyroid C-cell Tumors,The following serious tions are,1,0.5096050500869751
TRULICITY,Pancreatitis,information: Risk of Thyroid Ccell,1,0.5277163982391357
TRULICITY,Hypoglycemia, Precautions Hypersensitivity reactions see,1,0.4999293088912964
TRULICITY,Hypoglycemia,see Warnings  Precautions,1,0.514264702796936
TRULICITY,Hypoglycemia, Precautions Hypersensitivity reactions see Warnings,1,0.5018556118011475
TRULICITY,Hypoglycemia,Insulin see Warnings  Precautions Hypersensitivity reactions see,1,0.6413977146148682
TRULICITY,Hypoglycemia,and Precautions,0,0.5047518014907837
TRULICITY,Hypoglycemia,see Warnings and,0,0.5102573037147522
TRULICITY,Hypoglycemia, Precautions Hypersensitivity reactions,1,0.49665701389312744
TRULICITY,Hypoglycemia,Concomitant Use,0,0.48209983110427856
TRULICITY,Hypersensitivity,Disease see gs and Precautio ns EXCERPT The most common,1,0.5577980279922485
TRULICITY,Hypersensitivity,Concomitant Use,0,0.5648705363273621
TRULICITY,Hypersensitivity,Precautions,0,0.579883337020874
TRULICITY,Hypersensitivity,Disease see gs,1,0.5524696111679077
TRULICITY,Hypersensitivity,Gastrointestinal Disease see gs and Precautio,1,0.5682772397994995
TRULICITY,Hypersensitivity,reactions reported in,0,0.6612502336502075
TRULICITY,Hypersensitivity,Severe Gastrointestinal Disease,0,0.5758540630340576
TRULICITY,Renal Impairment,decreased appetite To report SUSPECTED ADVERSE REACTIONS contact,0,0.5596157908439636
TRULICITY,Renal Impairment,"nausea diarrhea iting,",1,0.5808824300765991
TRULICITY,Renal Impairment,"iting, abdominal pain and decreased appetite",1,0.5225799083709717
TRULICITY,Renal Impairment,"are nausea diarrhea iting, abdominal",1,0.5841343998908997
TRULICITY,Renal Impairment,"TRULICITY are nausea diarrhea iting,",1,0.5515952110290527
TRULICITY,Renal Impairment,vom,0,0.46939483284950256
TRULICITY,thyroid C-cell adenomas,Clinical,0,0.4953041970729828
TRULICITY,thyroid C-cell adenomas,The data in Table are derived,0,0.48226141929626465
TRULICITY,thyroid C-cell adenomas,( 14 )] . These data reflect exposure of patients,1,0.4783751964569092
TRULICITY,thyroid C-cell adenomas,Clinical (,1,0.49377012252807617
TRULICITY,thyroid C-cell adenomas,placebocontrolled trials see Clinical ( 14 )] . These,1,0.5057119131088257
TRULICITY,thyroid C-cell adenomas,placebocontrolled trials,0,0.5049453973770142
TRULICITY,thyroid C-cell adenomas,trials see Clinical ( 14,1,0.5037633180618286
TRULICITY,thyroid C-cell tumors,exposure,0,0.5114864110946655
TRULICITY,thyroid C-cell tumors,. Across the treatmen,1,0.46136730909347534
TRULICITY,thyroid C-cell tumors,TRULICITY of . Across the treatmen t arms the mean,1,0.5071755647659302
TRULICITY,thyroid C-cell tumors,to TRULICITY of,0,0.5112580060958862
TRULICITY,thyroid C-cell tumors,the treatmen,1,0.46230214834213257
TRULICITY,thyroid C-cell tumors,exposure to TRULICITY of . Across the,1,0.5107142329216003
TRULICITY,medullary thyroid carcinoma,population in these,0,0.43472468852996826
TRULICITY,medullary thyroid carcinoma,of patients was 56 years were years,1,0.47180235385894775
TRULICITY,medullary thyroid carcinoma,age of patients was 56 years were years or older,1,0.4839601516723633
TRULICITY,medullary thyroid carcinoma,mean age of patients was 56 years,1,0.4799247980117798
TRULICITY,medullary thyroid carcinoma,age of patients was 56 years,1,0.4918718636035919
TRULICITY,medullary thyroid carcinoma,were years or older and,0,0.41719868779182434
TRULICITY,MTC,ear s were years or older,1,0.49284714460372925
TRULICITY,MTC,ear s were,1,0.48706942796707153
TRULICITY,MTC,ear,1,0.5076817274093628
TRULICITY,thyroid C-cell tumors,hese studies,1,0.42915791273117065
TRULICITY,thyroid C-cell tumors,in hese studies was 69%  White Black or,1,0.4140927791595459
TRULICITY,thyroid C-cell tumors,of Hispanic or Latino ethnicity At baselin,0,0.4834691286087036
TRULICITY,thyroid C-cell tumors,Black or African American Asian were of Hispanic or Latino ethnicity At baselin,0,0.4567165672779083
TRULICITY,thyroid C-cell tumors,was 69% White Black,1,0.3828067183494568
TRULICITY,thyroid C-cell tumors,studies was 69% White Black or African American,1,0.3946682810783386
TRULICITY,thyroid C-cell tumors,hese studies was 69%  White Black,1,0.4007701575756073
TRULICITY,thyroid C-cell tumors,of patients was years were years or older and were male The population in,0,0.5118498802185059
TRULICITY,thyroid C-cell tumors,The population in hese studies,1,0.4528564512729645
TRULICITY,MTC,n;  were of Hispanic or Latino,1,0.4848523736000061
TRULICITY,MTC,or African American n;  were of Hispanic or Latino,1,0.47297900915145874
TRULICITY,MTC,n;  were of Hispanic or,1,0.4871513843536377
TRULICITY,MTC,n;  were of,1,0.5278558731079102
TRULICITY,MTC,n; ,1,0.5269531011581421
TRULICITY,MTC,studies was White Black or African American,0,0.4862201511859894
TRULICITY,MTC,n;  were of Hispanic,1,0.4891359806060791
TRULICITY,MTC,Black or African American n;  were,1,0.47584208846092224
TRULICITY,MTC,retinopathy Baseline,0,0.4734448492527008
TRULICITY,MTC,he  population reported retinopathy,1,0.4758482575416565
TRULICITY,MTC,he ,1,0.4910997152328491
TRULICITY,MTC,he  population reported retinopathy Baseline estimated,1,0.47887104749679565
TRULICITY,MTC,estimated renal function was normal or mildly impaired eG,0,0.4692264199256897
TRULICITY,MTC,he  population reported,1,0.4932631254196167
TRULICITY,MTC,of he  population reported,1,0.4970771074295044
TRULICITY,MTC,lud ing hypoglycemia,1,0.46117058396339417
TRULICITY,MTC,lud ing hypoglycemia associated with the,1,0.4690132141113281
TRULICITY,MTC,lud ing hypoglycemia associated,1,0.468826562166214
TRULICITY,MTC,lud ing,1,0.5229233503341675
TRULICITY,MTC,lud,1,0.4954202473163605
TRULICITY,pancreatitis,             Vomiting,1,0.5849286317825317
TRULICITY,pancreatitis,lud,1,0.44387075304985046
TRULICITY,pancreatitis,a,0,0.5043290257453918
TRULICITY,pancreatitis,Diarrhea,0,0.6981860399246216
TRULICITY,pancreatitis,             Vomiting b,1,0.5888242721557617
TRULICITY,hypoglycemia,ULICITY 1.5 mg discontinued treatment due to,1,0.5578838586807251
TRULICITY,hypoglycemia,TRULICITY mg and ULICITY 1.5 ,1,0.5285563468933105
TRULICITY,hypoglycemia,gastrointestinal adverse reactions,0,0.5475730299949646
TRULICITY,hypoglycemia,ULICITY 1.5 mg discontinued treatment due,1,0.5614860653877258
TRULICITY,hypoglycemia,receiving TRULICITY,0,0.5507616400718689
TRULICITY,hypoglycemia,ULICITY 1.5 mg,1,0.5658876895904541
TRULICITY,hypoglycemia,receiving TRULICITY mg and ULICITY,1,0.5514827966690063
TRULICITY,hypoglycemia,TRULICITY mg and,0,0.5617892742156982
TRULICITY,hypoglycemia,TRULICITY mg and ULICITY 1.5  mg discontinued treatment due to,1,0.5640778541564941
TRULICITY,Systemic hypersensitivity,"of cases, respectively, or severe in and",1,0.5601930618286133
TRULICITY,Systemic hypersensitivity,"cases respectively moderate in % of cases, respectively, or severe",1,0.5345532298088074
TRULICITY,Systemic hypersensitivity,"of cases, respectively, or severe in and of",1,0.5693387985229492
TRULICITY,Systemic hypersensitivity,cases respectively In addition to the,0,0.5354608297348022
TRULICITY,Systemic hypersensitivity,%,1,0.49545109272003174
TRULICITY,Systemic hypersensitivity,"cases respectively moderate in % of cases,",1,0.49070724844932556
TRULICITY,Systemic hypersensitivity,in %,1,0.5061607360839844
TRULICITY,Systemic hypersensitivity,"in % of cases, respectively, or severe in",1,0.5507683753967285
TRULICITY,Systemic hypersensitivity,"respectively moderate in % of cases,",1,0.48059141635894775
TRULICITY,acute renal failure,abdominal disten,0,0.566440999507904
TRULICITY,chronic renal failure,distension gastroesopha,0,0.4978288412094116
TRULICITY,chronic renal failure,reflux disease ( and,1,0.5393624901771545
TRULICITY,chronic renal failure,geal reflux,1,0.5246556997299194
TRULICITY,chronic renal failure,Pool of Placebo and,0,0.505736231803894
TRULICITY,chronic renal failure,disease ( and,1,0.538040280342102
TRULICITY,chronic renal failure,abdominal,0,0.5305284261703491
TRULICITY,chronic renal failure,flatulence,0,0.49927380681037903
TRULICITY,nausea, type ,1,0.5041987299919128
TRULICITY,nausea, type  diabetes participating in placebo,1,0.5471455454826355
TRULICITY,nausea, type  diabetes participating in,1,0.5259792804718018
TRULICITY,nausea, type  diabetes participating in placebo and,1,0.551261305809021
TRULICITY,nausea,use of,0,0.5220773220062256
TRULICITY,vomiting,a larger,0,0.47234106063842773
TRULICITY,vomiting,diabetes participating in placebo,1,0.5004922151565552
TRULICITY,vomiting,diabetes participating,1,0.5228027701377869
TRULICITY,diarrhea,evaluated in a larger pool of patients with type diabetes,0,0.5208139419555664
TRULICITY,diarrhea,use of TRULICITY as monotherapy,0,0.5597593784332275
TRULICITY,diarrhea,articipa,1,0.5319560766220093
TRULICITY,dehydration,patients with type diabetes in 6 placeb o and activecontrolled trials,1,0.5222547650337219
TRULICITY,dehydration,articipa,1,0.5054489374160767
TRULICITY,dehydration,type diabetes in 6 placeb o and activecontrolled,1,0.5128646492958069
TRULICITY,gastrointestinal adverse reactions,"American, 11% Asian; 32% w ere of Hispanic",1,0.4701917767524719
TRULICITY,gastrointestinal adverse reactions,"African American, 11% Asian; 32% w ere of Hispanic",1,0.46543338894844055
TRULICITY,gastrointestinal adverse reactions,"studies was White Black African American,",1,0.41705965995788574
TRULICITY,gastrointestinal adverse reactions,"African American, 11% Asian; 32% w ere of Hispanic or",1,0.46820786595344543
TRULICITY,gastrointestinal adverse reactions,The population in these studies was White Black or,0,0.4614574909210205
TRULICITY,gastrointestinal adverse reactions,Asian; 32% w,1,0.5112820267677307
TRULICITY,gastrointestinal adverse reactions,"American, 11% Asian; 32% w ere",1,0.46429234743118286
TRULICITY,gastrointestinal adverse reactions,"American, 11% Asian; 32% w ere of Hispanic or Latino",1,0.4630868434906006
TRULICITY,gastrointestinal adverse reactions,Asian; 32% w ere of Hispanic or Latino,1,0.4754665791988373
TRULICITY,gastrointestinal adverse reactions,population had diabetes,0,0.48791444301605225
TRULICITY,gastrointestinal adverse reactions,"Black African American, 11% Asian; 32%",1,0.4545642137527466
TRULICITY,gastrointestinal adverse reactions,Black or,0,0.45389097929000854
TRULICITY,gastrointestinal adverse reactions,"was White Black African American, 11% Asian; 32% w ere of Hispanic or Latino",1,0.44557833671569824
TRULICITY,gastrointestinal adverse reactions,Latino ethnicity At baseline the population had diabetes for,0,0.4865815043449402
TRULICITY,gastrointestinal adverse reactions,"studies was White Black African American, 11% Asian;",1,0.448768675327301
TRULICITY,gastrointestinal adverse reactions,ethnicity At baseline the population,0,0.4504833221435547
TEFLARO,Hypersensitivity Reactions,and Precautions Hypersensitivity,1,0.8403257131576538
TEFLARO,Hypersensitivity Reactions,Hypersensitivity,1,0.9332083463668823
TEFLARO,Hypersensitivity Reactions,diarrhea see War,0,0.5221486687660217
TEFLARO,Hypersensitivity Reactions,and Precautions Hypersensitivity Reactions see Warnings and Precautions,1,0.8224754929542542
TEFLARO,Hypersensitivity Reactions,Hypersensitivity Reactions see,1,0.9621642827987671
TEFLARO,Hypersensitivity Reactions,difficile Associated,0,0.5431538820266724
TEFLARO,Hypersensitivity Reactions,Hypersensitivity Reactions,1,1.0
TEFLARO,Clostridium difficile -Associated diarrhea,Seroconversion see,0,0.5046869516372681
TEFLARO,Clostridium difficile -Associated diarrhea,Reactions see Warnings and Clostridium,1,0.6575611233711243
TEFLARO,Clostridium difficile -Associated diarrhea,see Warnings and Clostridium,1,0.6752976179122925
TEFLARO,Clostridium difficile -Associated diarrhea,see Warnings and Clostridium difficile -Associated,1,0.8313776850700378
TEFLARO,Clostridium difficile -Associated diarrhea,Hypersensitivity Reactions see,0,0.5282002091407776
TEFLARO,Clostridium difficile -Associated diarrhea,Reactions see Warnings and Precautions,0,0.5263145565986633
TEFLARO,nausea,nausea,1,1.0
TEFLARO,rash,rash To,1,0.9322768449783325
TEFLARO,rash,occurring in of patients are diarrhea nausea and,0,0.5602297782897949
TEFLARO,rash,rash To report SUSPECTED ADVERSE REACTIONS,1,0.8133967518806458
TEFLARO,rash,To report SUSPECTED ADVERSE REACTIONS,0,0.6098340749740601
TEFLARO,rash,of patients are,0,0.5030257701873779
TEFLARO,rash,rash To report SUSPECTED ADVERSE,1,0.8174117803573608
TEFLARO,rash,patients are diarrhea nausea rash To report,1,0.7303934097290039
TEFLARO,rash,patients are diarrhea nausea rash,1,0.7314757108688354
TEFLARO,diarrhea,diarrhea nausea and rash,1,0.8003908395767212
TEFLARO,diarrhea,diarrhea nausea and,1,0.834321141242981
TEFLARO,diarrhea,diarrhea,1,0.9999999403953552
TEFLARO,diarrhea,trials diarrhea nausea,1,0.7657086849212646
TEFLARO,diarrhea,reactions occurring in,0,0.5586336851119995
TEFLARO,diarrhea,lists,0,0.5333841443061829
TEFLARO,nausea,the pooled,0,0.4989754557609558
TEFLARO,nausea,were nausea and,1,0.9364908933639526
TEFLARO,nausea,of patients receiving Teflaro in the pooled phase clinical trials were diarrhea,0,0.5797439813613892
TEFLARO,nausea,trials were nausea,1,0.8022152781486511
TEFLARO,nausea,lists,0,0.47487661242485046
TEFLARO,nausea,nausea and rash Table lists adverse,1,0.7544495463371277
TEFLARO,nausea,phase clinical trials were nausea and rash Table lists adverse,1,0.6895965337753296
TEFLARO,nausea,and rash Table lists adverse reactions occurring,0,0.6118237972259521
TEFLARO,rash,receiving Teflaro in the pooled phase clinical trials,0,0.5240764617919922
TEFLARO,rash,phase clinical trials were diarrhea nausea,0,0.5599007606506348
TEFLARO,rash,nausea rash Table lists,1,0.7447969317436218
TEFLARO,Increased transaminases,Increased transaminases Metabolism,1,0.9630915522575378
TEFLARO,Increased transaminases,Increased transaminases,1,0.9999998807907104
TEFLARO,Increased transaminases,Laboratory,0,0.5253318548202515
TEFLARO,Increased transaminases,Increased transaminases Metabolism and,1,0.9627857208251953
TEFLARO,Anemia,Thrombocytopenia Cardiac,0,0.584149181842804
TEFLARO,Eosinophilia,Eosinophilia Neutropenia Thrombocytopenia Cardiac disorders Bradycardia,1,0.7292903661727905
TEFLARO,Eosinophilia,Thrombocytopenia Cardiac,0,0.49394702911376953
TEFLARO,Eosinophilia,and lymphatic system disorders,0,0.5816031694412231
TEFLARO,Eosinophilia,system disorders Eosinophilia Neutropenia,1,0.7776355147361755
TEFLARO,Eosinophilia,Eosinophilia Neutropenia Thrombocytopenia Cardiac,1,0.7680946588516235
TEFLARO,Neutropenia,Blood and lymphatic system disorders Anemia Eosinophilia,0,0.6202932596206665
TEFLARO,Neutropenia,and lymphatic system disorders Anemia Eosinophilia,0,0.6031180024147034
TEFLARO,Neutropenia,Thrombocytopenia Cardiac disorders,0,0.6005329489707947
TEFLARO,Thrombocytopenia,disorders Anemia Eosinophilia Thrombocytopenia,1,0.7423873543739319
TEFLARO,Thrombocytopenia,Thrombocytopenia Cardiac disorders,0,0.8567137718200684
TEFLARO,Thrombocytopenia,Thrombocytopenia,1,0.9999998807907104
TEFLARO,Thrombocytopenia,Thrombocytopenia Cardiac,1,0.885087788105011
TEFLARO,Thrombocytopenia,system disorders Anemia Eosinophilia,0,0.5503392219543457
TEFLARO,Bradycardia,Neutropenia Thrombocytopenia Cardiac Bradycardia Palpitations,1,0.7484896183013916
TEFLARO,Bradycardia,system disorders Anemia Eosinophilia,0,0.4882770776748657
TEFLARO,Bradycardia,Bradycardia,1,1.000000238418579
TEFLARO,Bradycardia,pain General disorders and,0,0.5333090424537659
TEFLARO,Bradycardia,Cardiac disorders,0,0.6948497295379639
TEFLARO,Palpitations,Palpitations Gastrointestinal disorders Abdominal pain,1,0.7819517850875854
TEFLARO,Palpitations,Bradycardia,1,0.7568186521530151
TEFLARO,Palpitations,disorders Palpitations Gastrointestinal,1,0.8298277258872986
TEFLARO,Palpitations,Gastrointestinal,0,0.5162229537963867
TEFLARO,Palpitations,Palpitations Gastrointestinal disorders,1,0.8009198904037476
TEFLARO,Palpitations,Eosinophilia,0,0.5415526628494263
TEFLARO,Palpitations,Thrombocytopenia Cardiac disorders Palpitations Gastrointestinal disorders,1,0.7497380971908569
TEFLARO,Palpitations,Palpitations Gastrointestinal,1,0.8299798369407654
TEFLARO,Palpitations,Cardiac disorders Palpitations Gastrointestinal,1,0.8294850587844849
TEFLARO,Palpitations,and administration site,0,0.4300522804260254
TEFLARO,Abdominal pain,administration site conditions,0,0.43168890476226807
TEFLARO,Abdominal pain,Gastrointestinal Abdominal,1,0.7905943393707275
TEFLARO,Abdominal pain,Bradycardia Palpitations Gastrointestinal Abdominal pain,1,0.7959099411964417
TEFLARO,Abdominal pain,disorders Bradycardia,0,0.47385698556900024
TEFLARO,Abdominal pain,Abdominal pain,1,0.9999998807907104
TEFLARO,Abdominal pain,Gastrointestinal,0,0.7238667011260986
TEFLARO,Abdominal pain,Gastrointestinal Abdominal pain,1,0.9289349317550659
TEFLARO,Abdominal pain,disorders Bradycardia Palpitations,0,0.4830654263496399
TEFLARO,Abdominal pain,Bradycardia Palpitations Gastrointestinal Abdominal pain General disorders and administration,1,0.7485287189483643
TEFLARO,Pyrexia,Hepatitis Immune system disorders Hypersensitivity,0,0.5645335912704468
TEFLARO,Pyrexia,site Pyrexia Hepatobiliary disorders Hepatitis Immune system,1,0.7423945665359497
TEFLARO,Hepatitis,disorders Hypersensitivity Anaphylaxis Infections and infestations,0,0.5128952264785767
TEFLARO,Hepatitis,Immune system,0,0.6453820466995239
TEFLARO,Hypersensitivity,conditions Pyrexia,0,0.5913633704185486
TEFLARO,Hypersensitivity,difficile colitis,0,0.5765904188156128
TEFLARO,Hypersensitivity,difficile,0,0.5800654888153076
TEFLARO,Hypersensitivity,Hepatitis Immune,0,0.5894178152084351
TEFLARO,Anaphylaxis,and infestations Clostridium,0,0.5428476333618164
TEFLARO,Anaphylaxis,disorders Anaphylaxis Infections,1,0.8012910485267639
TEFLARO,Anaphylaxis,system disorders Anaphylaxis Infections and infestations Clostridium difficile,1,0.7270253896713257
TEFLARO,Anaphylaxis,Anaphylaxis Infections and infestations Clostridium,1,0.7808230519294739
TEFLARO,Clostridium difficile colitis,Clostridium,1,0.7385569214820862
TEFLARO,Clostridium difficile colitis,and Clostridium,1,0.7143163681030273
TEFLARO,Clostridium difficile colitis,difficile colitis Metabolism,1,0.8553098440170288
TEFLARO,Clostridium difficile colitis,and Clostridium difficile  colitis Metabolism and,1,0.8965975642204285
TEFLARO,Clostridium difficile colitis,Immune system disorders Hypersensitivity Anaphylaxis Infections and infestations,0,0.5408475399017334
TEFLARO,Clostridium difficile colitis,Clostridium difficile  colitis Metabolism and nutrition disorders,1,0.869016170501709
TEFLARO,Clostridium difficile colitis,Anaphylaxis Infections and Clostridium difficile colitis,1,0.831461489200592
TEFLARO,Hyperglycemia,and,0,0.5175440907478333
TEFLARO,Hyperglycemia,Hyperglycemia Hyperkalemia Nervous system,1,0.8033581972122192
TEFLARO,Hyperglycemia,Hyperglycemia Hyperkalemia,1,0.8534127473831177
TEFLARO,Hyperkalemia,disorders Dizziness Convulsion Renal and urinary disorders,0,0.602791428565979
TEFLARO,Hyperkalemia,Convulsion Renal,0,0.5867551565170288
TEFLARO,Hyperkalemia,tions Clostridium difficile colitis Metabolism,0,0.5150567889213562
TEFLARO,Hyperkalemia,disorders,0,0.5528538227081299
TEFLARO,Hyperkalemia,Hyperkalemia Nervous system disorders,1,0.854852557182312
TEFLARO,Dizziness,Dizziness Convulsion Renal,1,0.8083916902542114
TEFLARO,Dizziness,Nervous system Dizziness Convulsion Renal and urinary disorders,1,0.7609102725982666
TEFLARO,Dizziness,Dizziness Convulsion Renal and urinary disorders,1,0.7778511047363281
TEFLARO,Dizziness,Dizziness Convulsion Renal and,1,0.8112579584121704
TEFLARO,Dizziness,Dizziness,1,0.9999998807907104
TEFLARO,Dizziness,failure Skin and subcutaneous,0,0.4787067770957947
TEFLARO,Convulsion,Convulsion Renal and urinary,1,0.8291817307472229
TEFLARO,Convulsion,Dizziness,0,0.6371114253997803
TEFLARO,Convulsion,Nervous system disorders Convulsion Renal and urinary,1,0.7757273316383362
TEFLARO,Convulsion,Convulsion,1,1.0000001192092896
TEFLARO,Renal failure,Renal and urinary disorders,0,0.7994338274002075
TEFLARO,Renal failure,and,0,0.5150890350341797
TEFLARO,Renal failure,Renal failure Skin and subcutaneous,1,0.8160193562507629
TEFLARO,Renal failure,urinary Renal failure,1,0.9344077110290527
TEFLARO,Renal failure,Convulsion Renal and urinary Renal failure Skin and subcutaneous tissue,1,0.7466564774513245
TEFLARO,Renal failure,Convulsion Renal and urinary,0,0.7264165282249451
TEFLARO,Renal failure,Skin and,0,0.4976089894771576
TEFLARO,Renal failure,urinary Renal,1,0.7904121279716492
TEFLARO,Urticaria,Experience The following adverse reaction has been,0,0.6197710633277893
TEFLARO,Urticaria,reaction,0,0.5624832510948181
TEFLARO,Urticaria,Skin and subcutaneous tissue Urticaria Postmarketing Experience The following,1,0.7853697538375854
TEFLARO,Urticaria,Skin and,0,0.6405042409896851
TEFLARO,Urticaria,Urticaria Postmarketing Experience,1,0.8009032011032104
TEFLARO,Urticaria,Urticaria,1,1.0
TEFLARO,Urticaria,tissue Urticaria,1,0.8415663242340088
TEFLARO,Urticaria,Urticaria Postmarketing Experience The,1,0.7892757654190063
TEFLARO,Urticaria,adverse reaction has,0,0.6118581891059875
TEFLARO,Clostridium difficile -associated diarrhea,diarrhea [see Warnings and Precautions (,1,0.708958625793457
TEFLARO,Clostridium difficile -associated diarrhea,Warnings and Precautions E,0,0.5198266506195068
TEFLARO,Clostridium difficile -associated diarrhea,and Precautions E,0,0.4999229907989502
TEFLARO,Clostridium difficile -associated diarrhea,[see Warnings and Precautions (,1,0.5209221839904785
TEFLARO,CDAD,.2   Direct Coombs Test Seroconversion,1,0.5173287987709045
TEFLARO,CDAD,.2   Direct,1,0.5804424285888672
TEFLARO,fatal,idely varying,1,0.5147991180419922
TEFLARO,fatal,drug cannot,0,0.550682783126831
TEFLARO,fatal,Experience Because clinical trials are conducted under w,0,0.4626207947731018
TEFLARO,fatal,conducted under idely varying conditions adverse,1,0.5631392002105713
TEFLARO,fatal,idely varying conditions adverse reaction rates,1,0.5793663263320923
TEFLARO,skin reactions,conducted under widely varying conditions adverse reaction,0,0.7186435461044312
TEFLARO,skin reactions,clinical tria ls of,1,0.5366512537002563
TEFLARO,skin reactions,adverse reaction rates observed clinical tria,1,0.6710668802261353
TEFLARO,skin reactions,reaction rates observed  clinical tria,1,0.6856774091720581
TEFLARO,skin reactions,clinical,0,0.5378653407096863
TEFLARO,skin reactions,rates observed clinical,1,0.506273627281189
TEFLARO,skin reactions,directly to rates from clinical trials of,0,0.5354957580566406
TEFLARO,skin reactions,directly,0,0.5259659290313721
TEFLARO,skin reactions,ls of a drug cannot be,0,0.4960215985774994
TEFLARO,CDAD,Caucasian Serious Adverse s,1,0.48985302448272705
TEFLARO,CDAD,s an d Adverse Reactions,1,0.5731696486473083
TEFLARO,diarrhea,in of patients receiving Teflaro and of patients receiving,0,0.5288606882095337
TEFLARO,diarrhea,Teflaro and of,0,0.5748707056045532
TEFLARO,diarrhea,s (SARs),1,0.5636545419692993
TEFLARO,diarrhea,clinical trials serious adverse s (SARs) occurred in of,1,0.5290480852127075
TEFLARO,diarrhea,serious adverse s (SARs) occurred in of patients,1,0.5187025666236877
TEFLARO,diarrhea,s (SARs) occurred in of patients receiving,1,0.528471052646637
TEFLARO,fatal,of patients receiving Teflaro and of patients receiving comparato,0,0.48037174344062805
TEFLARO,fatal,patients receiving comparato,0,0.4802064299583435
TEFLARO,fatal,reactions SARs urred in of,1,0.5537530183792114
TEFLARO,fatal,pooled Phase clinical trials serious adverse reactions SARs,0,0.5577747821807861
TEFLARO,fatal,urred in of patients receiving Teflaro,1,0.48473018407821655
TEFLARO,fatal,urred in of patients receiving,1,0.47793149948120117
TEFLARO,fatal,In the four,0,0.5006375312805176
TEFLARO,fatal,adverse,0,0.6163619756698608
TEFLARO,colitis,reactions SARs in,1,0.5301499366760254
TEFLARO,colitis,in 98/1,1,0.48257267475128174
TEFLARO,colitis,Phase,0,0.5295807123184204
TEFLARO,colitis,patients receiving,0,0.5469086170196533
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,h in the Phase CABP trials Adverse,0,0.5828772783279419
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,gram IV very 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI,1,0.5395681858062744
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,Phase,0,0.5400217175483704
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,IV very 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI trial s and ceftriaxone,1,0.5538721680641174
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,included vancomycin gram IV very 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI trial s and ceftriaxone gram IV,1,0.5467286705970764
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,IV very 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI,1,0.5395981073379517
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,in the Phase CABP trials Adverse,0,0.5797748565673828
JARDIANCE,Hypotension,Renal Function see Warnings and Preca,0,0.5761726498603821
JARDIANCE,Hypotension,Hypotension see Warnings and Precautions Impairment,1,0.8233239650726318
JARDIANCE,Hypotension,Hypotension see Warnings and Precautions,1,0.8548194766044617
JARDIANCE,Hypotension,the Hypotension,1,0.9641364216804504
JARDIANCE,Impairment in Renal Function,Precautions,0,0.48572030663490295
JARDIANCE,Impairment in Renal Function,and elsewhere in the,0,0.45865941047668457
JARDIANCE,Hypoglycemia,Warnings,0,0.5464382767677307
JARDIANCE,Genital Mycotic Infections,Genital Mycotic Infections see Warnings and,1,0.9088178873062134
JARDIANCE,Genital Mycotic Infections,Mycotic Infections see Warnings,1,0.7737369537353516
JARDIANCE,Urinary Tract Infections,Warnings and Urinary,1,0.7463489770889282
JARDIANCE,Urinary Tract Infections,Warnings and Urinary Tract,1,0.759675920009613
JARDIANCE,Urinary Tract Infections,Urinary Tract Infections see Warnings and Precautions Increased,1,0.8194068670272827
JARDIANCE,Urinary Tract Infections,Infections see Warnings and,0,0.6687301397323608
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,see Warnings and Increased Low-Density Lipoprotein,1,0.8684149980545044
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,Increased Low-Density Lipoprotein Cholesterol LDLC see Warnings,1,0.889980673789978
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,and Increased Low-Density Lipoprotein,1,0.9663404822349548
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,recautions Urinary Tract,0,0.5161139369010925
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,see Warnings and Precautions The most common adverse,0,0.5402494072914124
JARDIANCE,urinary tract infections,greater incidence urinary tract infections,1,0.815401554107666
JARDIANCE,urinary tract infections,The most common adverse reactions associated with JARDIANCE or,0,0.5454496145248413
JARDIANCE,urinary tract infections,or greater,0,0.494537889957428
JARDIANCE,genital mycotic infections,To report SUSPECTED ADVERSE REACTIONS,0,0.5411896705627441
JARDIANCE,genital mycotic infections,and genital mycotic infections EXCERPT To report,1,0.9173221588134766
JARDIANCE,genital mycotic infections,incidence were urinary tract infections,0,0.5984632968902588
JARDIANCE,genital mycotic infections,mycotic infections,1,0.8683234453201294
JARDIANCE,genital mycotic infections,tract infections and genital mycotic,1,0.9192203879356384
JARDIANCE,genital mycotic infections,genital mycotic infections,1,0.9999997615814209
JARDIANCE,genital mycotic infections,ADVERSE REACTIONS contact,0,0.5382336974143982
JARDIANCE,hypoglycemia,eGFR mLmin m,0,0.5050731301307678
JARDIANCE,urinary tract infection,but not limited urinary,1,0.7191651463508606
JARDIANCE,urinary tract infection,tract infection asymptomatic bacteriuria cystitis b,1,0.7554166316986084
JARDIANCE,urinary tract infection,infections,0,0.7285875082015991
JARDIANCE,asymptomatic bacteriuria,limited to urinary tract asymptomatic,1,0.8569384813308716
JARDIANCE,asymptomatic bacteriuria,urinary tract,0,0.7089539766311646
JARDIANCE,asymptomatic bacteriuria,infections include the following,0,0.6015845537185669
JARDIANCE,asymptomatic bacteriuria,asymptomatic bacteriuria cystitis b Female genital,1,0.858161449432373
JARDIANCE,asymptomatic bacteriuria,asymptomatic bacteriuria cystitis,1,0.9416242837905884
JARDIANCE,cystitis,cystitis,1,1.0000001192092896
JARDIANCE,Female genital mycotic infections,genital mycotic infections include the following adverse reactions,1,0.8665300607681274
JARDIANCE,Female genital mycotic infections,Female genital mycotic infections include the following,1,0.9807965755462646
JARDIANCE,Female genital mycotic infections,cystitis,0,0.6372672319412231
JARDIANCE,Female genital mycotic infections,cystitis Female genital mycotic infections include the following adverse reactions,1,0.8897404670715332
JARDIANCE,Female genital mycotic infections,vulvovaginal mycotic,0,0.846588134765625
JARDIANCE,Female genital mycotic infections,vulvovaginal,0,0.6343909502029419
JARDIANCE,Female genital mycotic infections,asymptomatic bacteriuria cystitis b,0,0.6123571395874023
JARDIANCE,vulvovaginal mycotic infection,include,0,0.45594286918640137
JARDIANCE,vulvovaginal mycotic infection,infections include the following,0,0.6851980686187744
JARDIANCE,vulvovaginal mycotic infection,adverse vulvovaginal mycotic infection,1,0.9554652571678162
JARDIANCE,vulvovaginal mycotic infection,the,0,0.457389235496521
JARDIANCE,vulvovaginal mycotic infection,Female genital mycotic infections include the following,0,0.8578492999076843
JARDIANCE,vulvovaginal mycotic infection,adverse,0,0.5019011497497559
JARDIANCE,vulvovaginal mycotic infection,vulvovaginal mycotic infection vaginal infection vulvitis,1,0.969785213470459
JARDIANCE,vulvovaginal mycotic infection,vulvovaginal mycotic infection vaginal infection,1,0.9834537506103516
JARDIANCE,vulvovaginal mycotic infection,infection genital candidiasis gen,0,0.7702703475952148
JARDIANCE,vulvitis,ections include the following adverse reactions vulvovaginal,0,0.7572391629219055
JARDIANCE,vulvovaginal candidiasis,vulvovaginal candidiasis genital,1,0.9122565984725952
JARDIANCE,vulvovaginal candidiasis,vulvovaginal candidiasis genital infection genital,1,0.9188846349716187
JARDIANCE,vulvovaginal candidiasis,vaginal infection vulvovaginal candidiasis genital infection,1,0.9256826639175415
JARDIANCE,vulvovaginal candidiasis,genital infection fungal genitourinary tract,0,0.7717759609222412
JARDIANCE,vulvovaginal candidiasis,fungal genitourinary tract infection,0,0.7570027112960815
JARDIANCE,vulvovaginal candidiasis,infection fungal genitourinary tract,0,0.7456836700439453
JARDIANCE,vulvovaginal candidiasis,mycotic infection vaginal infection vulvovaginal,1,0.8828814029693604
JARDIANCE,vulvovaginal candidiasis,mycotic infection,0,0.6512026786804199
JARDIANCE,vulvovaginal candidiasis,vulvovaginal candidiasis genital infection,1,0.9380366802215576
JARDIANCE,genital infection,genital infection fungal genitourinary tract infection vulvovaginitis cerv,0,0.8320093750953674
JARDIANCE,genital infection,infection fungal genitourinary,0,0.7903972864151001
JARDIANCE,genital infection,vulvitis vulvovaginal genital infection genital candidiasis genital infection fungal,1,0.8116028308868408
JARDIANCE,genital infection,vulvitis vulvovaginal genital infection genital candidiasis genital,1,0.825253427028656
JARDIANCE,genital infection,infection vulvovaginitis,0,0.8159568309783936
JARDIANCE,genital infection,genital infection,1,1.0
JARDIANCE,genital infection,vaginal infection vulvitis vulvovaginal genital infection,1,0.836439311504364
JARDIANCE,genital infection,e reactions vulvovaginal mycotic infection vaginal infection vulvitis vulvovaginal candidiasis,0,0.7357674837112427
JARDIANCE,genital infection,genital infection genital candidiasis genital infection,1,0.8803160190582275
JARDIANCE,genital candidiasis,genital,1,0.8089237809181213
JARDIANCE,genital candidiasis,genital candidiasis genital infection fungal genitourinary tract,1,0.9065181016921997
JARDIANCE,genital candidiasis,vulvovaginal candidiasis genital genital candidiasis genital infection fungal genitourinary,1,0.8903900384902954
JARDIANCE,genital candidiasis,genital candidiasis genital infection fungal,1,0.9472309350967407
JARDIANCE,genital infection fungal,candidiasis,0,0.7494568824768066
JARDIANCE,genital infection fungal,genital infection fungal genitourinary tract infection vulvovaginitis,1,0.922544002532959
JARDIANCE,genital infection fungal,genital infection fungal,1,1.000000238418579
JARDIANCE,genital infection fungal,genitourinary tract infection vulvovaginitis cervicitis urogenital infection fungal vaginitis,0,0.8399803638458252
JARDIANCE,genital infection fungal,infection fungal genitourinary,1,0.906353235244751
JARDIANCE,genitourinary tract infection,genitourinary tract infection vulvovaginitis cervicitis urogenital infection fungal,1,0.8703373670578003
JARDIANCE,genitourinary tract infection,genital infection genitourinary tract infection,1,0.9684039354324341
JARDIANCE,vulvovaginitis,vaginitis bacterial Percentages calculated with,0,0.716431736946106
JARDIANCE,vulvovaginitis,infection genital candidiasis genital,0,0.7031643390655518
JARDIANCE,vulvovaginitis,genitourinary tract,0,0.6139299869537354
JARDIANCE,vulvovaginitis,vulvovaginitis cervicitis urogenital infection fungal,1,0.8429156541824341
JARDIANCE,vulvovaginitis,vulvovaginitis cervicitis urogenital,1,0.8483781814575195
JARDIANCE,vulvovaginitis,genitourinary tract vulvovaginitis,1,0.8784043192863464
JARDIANCE,vulvovaginitis,vaginitis,0,0.8897047638893127
JARDIANCE,vulvovaginitis,genital infection fungal genitourinary tract,0,0.6737322807312012
JARDIANCE,vulvovaginitis,infection fungal genitourinary tract vulvovaginitis cervicitis urogenital,1,0.7821816205978394
JARDIANCE,vulvovaginitis,genital,0,0.6594094038009644
JARDIANCE,cervicitis,cervicitis urogenital infection fungal vaginitis,1,0.8481716513633728
JARDIANCE,cervicitis,fungal genitourinary tract infection vulvovaginitis,0,0.6631010174751282
JARDIANCE,cervicitis,cervicitis,1,1.0
JARDIANCE,cervicitis,urogenital infection fungal,0,0.6331679821014404
JARDIANCE,cervicitis,cervicitis urogenital infection fungal,1,0.8216437697410583
JARDIANCE,cervicitis,calculated with the number,0,0.44220632314682007
JARDIANCE,urogenital infection fungal,urogenital infection fungal,1,1.0
JARDIANCE,urogenital infection fungal,calculated with the number,0,0.44192302227020264
JARDIANCE,urogenital infection fungal,l candidiasis genital,0,0.8217947483062744
JARDIANCE,urogenital infection fungal,vulvovaginitis,0,0.661226749420166
JARDIANCE,urogenital infection fungal,infection fungal vaginitis bacterial Percentages,1,0.794715404510498
JARDIANCE,urogenital infection fungal,vulvovaginitis urogenital infection fungal,1,0.9205942749977112
JARDIANCE,urogenital infection fungal,genital infection,0,0.7661054134368896
JARDIANCE,urogenital infection fungal,genitourinary tract infection vulvovaginitis cervicitis,0,0.747411847114563
JARDIANCE,urogenital infection fungal,group,0,0.47029152512550354
JARDIANCE,vaginitis bacterial,urogenital infection vaginitis,1,0.8522917628288269
JARDIANCE,vaginitis bacterial,infection vaginitis bacterial,1,0.9554992914199829
JARDIANCE,polyuria,polyuria,1,0.9999998807907104
JARDIANCE,polyuria,polyuria pollakiuria and nocturia d,1,0.8162003755569458
JARDIANCE,polyuria,polyuria pollakiuria and nocturia,1,0.8215725421905518
JARDIANCE,pollakiuria,pollakiuria and nocturia,1,0.8353419303894043
JARDIANCE,pollakiuria,pollakiuria,1,1.0
JARDIANCE,pollakiuria,pollakiuria and nocturia d Male,1,0.7910897731781006
JARDIANCE,pollakiuria,limited to pollakiuria and nocturia,1,0.7724080085754395
JARDIANCE,pollakiuria,to pollakiuria and nocturia,1,0.8018835783004761
JARDIANCE,pollakiuria,pollakiuria and nocturia d Male genital,1,0.7814850211143494
JARDIANCE,balanoposthitis,candida scrotal ab,0,0.5408308506011963
JARDIANCE,balanoposthitis,include the following adverse balanoposthitis,1,0.799628496170044
JARDIANCE,balanoposthitis,balanoposthitis balanitis genital infections fungal genitourinary,1,0.7585089206695557
JARDIANCE,balanoposthitis,balanoposthitis balanitis genital infections fungal,1,0.7769647836685181
JARDIANCE,balanoposthitis,include the following adverse balanoposthitis balanitis genital infections fungal genitourinary,1,0.7098593711853027
JARDIANCE,balanoposthitis,infections fungal genitourinary tract infection balanitis,0,0.6213793754577637
JARDIANCE,balanoposthitis,genital infections fungal genitourinary tract infection balanitis,0,0.5943081378936768
JARDIANCE,balanoposthitis,adverse balanoposthitis balanitis genital infections,1,0.7752358913421631
JARDIANCE,balanoposthitis,reactions,0,0.48079314827919006
JARDIANCE,balanitis,balanitis,1,0.9999999403953552
JARDIANCE,balanitis,balanitis genital infections fungal genitourinary tract,1,0.7951906323432922
JARDIANCE,balanitis,the following adverse reactions balanitis,1,0.8577841520309448
JARDIANCE,genital infections fungal,ale genital mycotic infections include,0,0.8866214752197266
JARDIANCE,genital infections fungal,adverse reactions balanoposthitis genital,1,0.6815012693405151
JARDIANCE,genitourinary tract infection,candida scrotal abscess,0,0.6956263780593872
JARDIANCE,genitourinary tract infection,penile,0,0.6499478816986084
JARDIANCE,genitourinary tract infection,infections genitourinary tract infection balanitis,1,0.8688286542892456
JARDIANCE,genitourinary tract infection,with the,0,0.5360512733459473
JARDIANCE,genitourinary tract infection,genitourinary tract infection balanitis,1,0.8701760768890381
JARDIANCE,genitourinary tract infection,genitourinary tract infection,1,1.0000001192092896
JARDIANCE,genitourinary tract infection,balanitis genital infections genitourinary tract,1,0.8551375865936279
JARDIANCE,balanitis candida,Percentages calculated with the number of male subjects in each,0,0.4751782715320587
JARDIANCE,balanitis candida,genitourinary tract balanitis candida,1,0.8972795009613037
JARDIANCE,balanitis candida,infection,0,0.6333631873130798
JARDIANCE,balanitis candida,balanitis candida scrotal abscess penile infection,1,0.8640972375869751
JARDIANCE,balanitis candida,with,0,0.5200246572494507
JARDIANCE,balanitis candida,genitourinary tract balanitis candida scrotal abscess penile infection Percentages,1,0.8096579909324646
JARDIANCE,scrotal abscess,scrotal abscess penile infection Percentages,1,0.8971309065818787
JARDIANCE,scrotal abscess,genitourinary tract infection balanitis candida,0,0.6718880534172058
JARDIANCE,scrotal abscess,tract,0,0.48192036151885986
JARDIANCE,scrotal abscess,genitourinary tract,0,0.6167030334472656
JARDIANCE,scrotal abscess,scrotal,1,0.8256584405899048
JARDIANCE,scrotal abscess,balanitis candida,0,0.5696462392807007
JARDIANCE,scrotal abscess,balanitis scrotal abscess penile infection Percentages,1,0.8489341139793396
JARDIANCE,scrotal abscess,candida,0,0.5084106922149658
JARDIANCE,penile infection,penile infection Percentages calculated with,1,0.8524563312530518
JARDIANCE,penile infection,scrotal penile infection Percentages calculated,1,0.8134900331497192
JARDIANCE,penile infection,infections fungal genitourinary tract infection,0,0.6980092525482178
JARDIANCE,penile infection,Percentages calculated,0,0.4572914242744446
JARDIANCE,penile infection,scrotal penile infection Percentages calculated with the,1,0.8087044954299927
JARDIANCE,penile infection,penile infection Percentages calculated,1,0.8580545783042908
JARDIANCE,penile infection,balanitis candida scrotal penile,1,0.8139222264289856
JARDIANCE,Urinary tract infection,PlaceboN JARDIANCE mgN JARDIANCE mgN,0,0.4852261245250702
JARDIANCE,Urinary tract infection,JARDIANCE mgN JARDIANCE Urinary tract infection,1,0.7646881341934204
JARDIANCE,Urinary tract infection,tract infection a Female genit,1,0.7012227177619934
JARDIANCE,Urinary tract infection,JARDIANCE Urinary tract,1,0.7388845682144165
JARDIANCE,Urinary tract infection,tract infection,1,0.8207153677940369
JARDIANCE,Urinary tract infection,JARDIANCE mgN JARDIANCE,0,0.4843149185180664
JARDIANCE,Female genital mycotic infections,Female genital mycotic infections b Upper,1,0.9254603385925293
JARDIANCE,Female genital mycotic infections,JARDIANCE mgN JARDIANCE,0,0.4374659061431885
JARDIANCE,Female genital mycotic infections,b,0,0.462846040725708
JARDIANCE,Female genital mycotic infections,infection a,0,0.6588925123214722
JARDIANCE,Upper respiratory tract infection,mycotic infections Upper respiratory tract infection,1,0.8677060008049011
JARDIANCE,Upper respiratory tract infection,infections b,0,0.6196032762527466
JARDIANCE,Upper respiratory tract infection,Upper respiratory tract infection,1,1.0000001192092896
JARDIANCE,Upper respiratory tract infection,infections Upper respiratory tract,1,0.9239954948425293
JARDIANCE,Upper respiratory tract infection,infections Upper respiratory,1,0.9022699594497681
JARDIANCE,Upper respiratory tract infection,Upper respiratory tract infection Increased urination,1,0.7994257211685181
JARDIANCE,Increased urination,ratory tract,0,0.5583447813987732
JARDIANCE,Increased urination,tract Increased urination,1,0.9357618689537048
JARDIANCE,Increased urination,Increased urination,1,1.0000001192092896
JARDIANCE,Increased urination,infection,0,0.5783275365829468
JARDIANCE,Increased urination,Increased urination c Dyslipid,1,0.8357521295547485
JARDIANCE,polydipsia,in and for placebo JARDIANCE mg and,0,0.5356369018554688
JARDIANCE,polydipsia,and,0,0.4998475909233093
JARDIANCE,polydipsia,JARDIANCE mg,0,0.5109484791755676
JARDIANCE,polydipsia,JARDIANCE mg respectively,0,0.5095345973968506
JARDIANCE,polydipsia,polydipsia was reported in,1,0.9409959316253662
JARDIANCE,polydipsia,polydipsia was reported in and for,1,0.9169501662254333
JARDIANCE,osmotic diuresis,JARDIANCE causes osmotic diuresis which may lead to,1,0.7878810167312622
JARDIANCE,osmotic diuresis,polydipsia was reported in and for,1,0.6777157187461853
JARDIANCE,osmotic diuresis,JARDIANCE,0,0.5038312077522278
JARDIANCE,osmotic diuresis,osmotic diuresis which may lead to intravascular,1,0.8475121259689331
JARDIANCE,osmotic diuresis,Volume Depletion JARDIANCE causes osmotic diuresis which may lead,1,0.7915841341018677
JARDIANCE,volume depletion,volume depletion In the,1,0.9861198663711548
JARDIANCE,volume depletion,to volume,0,0.8104422092437744
JARDIANCE,volume depletion,of five placebocontrolled clinical trials adverse,0,0.46840256452560425
JARDIANCE,volume depletion,volume depletion eg blood pressure,1,0.8716927766799927
JARDIANCE,volume depletion,reactions related volume depletion,1,0.8537206649780273
JARDIANCE,volume depletion,blood pressure systolic decreased dehydration,0,0.6104687452316284
JARDIANCE,volume depletion,volume depletion eg,1,0.9851341843605042
JARDIANCE,volume depletion,adverse reactions related volume depletion,1,0.8319907188415527
JARDIANCE,volume depletion,pressure ambulatory,0,0.5410583019256592
JARDIANCE,volume depletion,related volume depletion eg blood pressure,1,0.8533236980438232
JARDIANCE,volume depletion,decreased,0,0.6760643124580383
JARDIANCE,volume depletion,related volume depletion,1,0.9406325817108154
JARDIANCE,blood pressure systolic decreased,related to,0,0.507682204246521
JARDIANCE,blood pressure systolic decreased,ambulatory blood pressure,1,0.7182596921920776
JARDIANCE,blood pressure systolic decreased,volume depletion eg blood,0,0.678308367729187
JARDIANCE,blood pressure systolic decreased,depletion eg blood pressure,0,0.7798485159873962
JARDIANCE,blood pressure systolic decreased,eg blood,0,0.5450115203857422
JARDIANCE,blood pressure systolic decreased,depletion eg,0,0.5898300409317017
JARDIANCE,blood pressure systolic decreased,dehydration hypotension,0,0.734117865562439
JARDIANCE,dehydration,eg,0,0.5335046648979187
JARDIANCE,dehydration,hypotension hypovolemia orthostatic hypotension and syncope,0,0.5776731967926025
JARDIANCE,hypotension,ambulatory decreased blood pressure systolic,0,0.7203435897827148
JARDIANCE,hypotension,decreased hypotension hypovolemia orthostatic hypotension and syncope,1,0.7928338050842285
JARDIANCE,hypotension,blood pressure systolic decreased,0,0.7876870632171631
JARDIANCE,hypotension,hypotension hypovolemia orthostatic hypotension and,1,0.8104895353317261
JARDIANCE,hypotension,reported by and of patien,0,0.4932902157306671
JARDIANCE,hypotension,pressure systolic decreased,0,0.7922437191009521
JARDIANCE,hypotension,hypotension hypovolemia orthostatic hypotension,1,0.8164386749267578
JARDIANCE,hypotension,orthostatic hypotension,0,0.8801928758621216
JARDIANCE,hypotension,pressure systolic decreased hypotension hypovolemia orthostatic hypotension and,1,0.8158324956893921
JARDIANCE,hypotension,pressure systolic decreased hypotension hypovolemia orthostatic hypotension,1,0.8143445253372192
JARDIANCE,hypovolemia,blood pressure,0,0.6559898257255554
JARDIANCE,hypovolemia,pressure systolic decreased dehydration hypotension,0,0.7289813756942749
JARDIANCE,hypovolemia,hypotension,0,0.8091295957565308
JARDIANCE,hypovolemia,blood pressure systolic,0,0.6042112112045288
JARDIANCE,hypovolemia,decreased,0,0.6163825988769531
JARDIANCE,hypovolemia,decreased dehydration hypovolemia orthostatic hypotension and,1,0.7999368906021118
JARDIANCE,hypovolemia,hypovolemia orthostatic hypotension and,1,0.8650749921798706
JARDIANCE,orthostatic hypotension,orthostatic hypotension and syncope were reported,1,0.9027206897735596
JARDIANCE,orthostatic hypotension,orthostatic hypotension and,1,0.9693670868873596
JARDIANCE,orthostatic hypotension,hypotension orthostatic hypotension,1,0.970612108707428
JARDIANCE,orthostatic hypotension,and of patients treated with placebo,0,0.5458205938339233
JARDIANCE,orthostatic hypotension,hypotension,0,0.8801928758621216
JARDIANCE,orthostatic hypotension,systolic,0,0.588932454586029
JARDIANCE,orthostatic hypotension,decreased blood pressure systolic decreased dehydration hypotension,0,0.7445982694625854
JARDIANCE,orthostatic hypotension,and of patients treated with placebo JARDIANCE,0,0.5280019044876099
JARDIANCE,orthostatic hypotension,decreased dehydration,0,0.6146665215492249
JARDIANCE,orthostatic hypotension,orthostatic,1,0.8745036721229553
JARDIANCE,syncope,syncope were reported,1,0.9156457185745239
JARDIANCE,syncope,hypovolemia orthostatic hypotension,0,0.6981568336486816
JARDIANCE,syncope,by and,0,0.47467905282974243
JARDIANCE,hypotension,hypotension in patients at,1,0.9030219912528992
JARDIANCE,hypotension,hypotension in patients at risk for,1,0.841253399848938
JARDIANCE,hypotension,and JARDIANCE mg respectively JARDIANCE may increase,0,0.4882626533508301
JARDIANCE,hypotension,respectively,0,0.48944810032844543
JARDIANCE,hypotension,contraction,0,0.5929569005966187
JARDIANCE,hypotension,hypotension in,1,0.9647535085678101
JARDIANCE,hypotension,hypotension in patients at risk,1,0.8560585975646973
JARDIANCE,hypotension,hypotension in patients,1,0.9076245427131653
JARDIANCE,hypotension,increase the risk,0,0.5255955457687378
JARDIANCE,Increased Urination,Use in Specific,0,0.514415979385376
JARDIANCE,Increased Urination,Specific Increased Urination,1,0.9451376795768738
JARDIANCE,Increased Urination,Increased Urination In,1,0.9885136485099792
JARDIANCE,increased urination,increased urination eg polyuria pollakiuria and nocturia,1,0.8737510442733765
JARDIANCE,increased urination,eg polyuria pollakiuria and nocturia,0,0.7231960296630859
JARDIANCE,increased urination,JARDIANCE than,0,0.49418026208877563
JARDIANCE,increased urination,trials adverse reactions increased,1,0.6138001680374146
JARDIANCE,increased urination,increased urination eg,1,0.9849134683609009
JARDIANCE,increased urination,increased urination,1,1.0000001192092896
JARDIANCE,polyuria,polyuria pollakiuria and nocturia occurred,1,0.8256874084472656
JARDIANCE,polyuria,pool of five placebocontrolled clinical trials adverse reactions,0,0.5258506536483765
JARDIANCE,polyuria,on JARDIANCE,0,0.48424187302589417
JARDIANCE,polyuria,on JARDIANCE than,0,0.4830116033554077
JARDIANCE,pollakiuria,urination eg pollakiuria and,1,0.8473182916641235
JARDIANCE,nocturia,nocturia,1,0.9999998807907104
JARDIANCE,nocturia,adverse reactions of increased urination,0,0.6093877553939819
JARDIANCE,nocturia,nocturia occurred more frequently on,1,0.879379153251648
JARDIANCE,nocturia,polyuria pollakiuria and,0,0.6384421586990356
JARDIANCE,nocturia,adverse reactions of increased urination eg polyuria pollakiuria and,0,0.6233888864517212
JARDIANCE,nocturia,nocturia was reported by and of,1,0.8942673206329346
JARDIANCE,nocturia,placebo see Table nocturia,1,0.8717764616012573
JARDIANCE,nocturia,and of patients treated,0,0.4935086965560913
JARDIANCE,Impairment in Renal Function,Impairment in Renal Function Use,1,0.9530420303344727
JARDIANCE,Impairment in Renal Function,nocturia was reported by and of,1,0.5436360836029053
JARDIANCE,Impairment in Renal Function,in serum creatinine,0,0.6795526742935181
JARDIANCE,Impairment in Renal Function,eGFR,0,0.5880820751190186
JARDIANCE,Impairment in Renal Function,patients treated with placebo JARDIANCE mg,0,0.5049651265144348
JARDIANCE,Impairment in Renal Function,and JARDIANCE mg Impairment,1,0.6789200305938721
JARDIANCE,Impairment in Renal Function,associated with increases in,0,0.5671670436859131
JARDIANCE,Impairment in Renal Function,creatinine and decreases,0,0.6980124711990356
JARDIANCE,Impairment in Renal Function,and,0,0.469149112701416
JARDIANCE,Impairment in Renal Function,with,0,0.4937397539615631
JARDIANCE,increases in serum creatinine,JARDIANCE,0,0.42629075050354004
JARDIANCE,increases in serum creatinine,Impairment in,0,0.5306644439697266
JARDIANCE,decreases in eGFR,decreases in eGFR see Table Patients with moderate,1,0.9064967632293701
JARDIANCE,decreases in eGFR,renal impairment at baseline had larger mean,0,0.611111044883728
JARDIANCE,eGFR 30 to less than 60 mL/min/1.73 m 2,study eGFR 30 to less than 60 mL/min/1.73 m  2 Pool,1,0.9177954196929932
JARDIANCE,eGFR 30 to less than 60 mL/min/1.73 m 2,renal impairment at baseline had larger mean,0,0.6025503873825073
JARDIANCE,eGFR 30 to less than 60 mL/min/1.73 m 2,less than 60 mL/min/1.73 m 2 Pool of Week PlaceboControlled,1,0.7466424703598022
JARDIANCE,Hypoglycemia,Hypoglycemia The incidence of hypoglycemia,1,0.8793474435806274
JARDIANCE,Hypoglycemia,Hypoglycemia,1,1.0
JARDIANCE,Hypoglycemia,R mLmin,0,0.533121645450592
JARDIANCE,Hypoglycemia,R mLmin Hypoglycemia The,1,0.8984988331794739
JARDIANCE,hypoglycemia,hypoglycemia,1,1.0
JARDIANCE,hypoglycemia,was administered with,0,0.4994712471961975
JARDIANCE,hypoglycemia,by study is shown in Table,0,0.4822879433631897
JARDIANCE,Hypoglycemic Events,and Precautions Table Incidence of Overalla,0,0.5509783029556274
JARDIANCE,Hypoglycemic Events,and Hypoglycemic Events in PlaceboControlled Clinical Studies,1,0.8191118240356445
JARDIANCE,Hypoglycemic Events,hypoglycemic events plasma or capillary,0,0.8465147018432617
JARDIANCE,Hypoglycemic Events,of,0,0.49043506383895874
JARDIANCE,Hypoglycemic Events,Overall,0,0.506696879863739
JARDIANCE,Hypoglycemic Events,Incidence of Overalla and Hypoglycemic Events,1,0.8806701898574829
JARDIANCE,Hypoglycemic Events,or capillary,0,0.47329181432724
JARDIANCE,Hypoglycemic Events,and Hypoglycemic Events,1,0.9788092970848083
JARDIANCE,Hypoglycemic Events,of Overalla and Hypoglycemic,1,0.8003039360046387
JARDIANCE,Hypoglycemic Events,Overalla and Severeb,0,0.5369725227355957
JARDIANCE,Hypoglycemic Events,Hypoglycemic Events in PlaceboControlled Clinical Studies,1,0.831099808216095
JARDIANCE,Hypoglycemic Events,Hypoglycemic Events in PlaceboControlled,1,0.8426140546798706
JARDIANCE,hypoglycemic events,Studies,0,0.5309115648269653
JARDIANCE,hypoglycemic events,Studies a hypoglycemic events,1,0.9517824053764343
JARDIANCE,hypoglycemic events,hypoglycemic events plasma,1,0.8679376840591431
JARDIANCE,hypoglycemic events,and Severeb Hypoglycemic Events in,0,0.9328452348709106
JARDIANCE,hypoglycemic events,hypoglycemic events plasma or capillary glucose of,1,0.8384578227996826
JARDIANCE,hypoglycemic events,Clinical Studies a hypoglycemic events plasma or,1,0.8567805290222168
JARDIANCE,hypoglycemic events,Overalla and Severeb Hypoglycemic Events in PlaceboControlled Clinical,0,0.8462900519371033
JARDIANCE,hypoglycemic events,Studies a hypoglycemic events plasma or capillary,1,0.8290075063705444
JARDIANCE,hypoglycemic events,hypoglycemic,1,0.8656071424484253
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,Overall hypoglycemic events plasma capillary,1,0.7876526713371277
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,glucose c Insu,0,0.707585334777832
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,70 mg/dL b Severe hypoglycemic,1,0.7704527378082275
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,requiring assistance regardless,0,0.4952840209007263
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,than or equal to 70 mg/dL b,1,0.7296798229217529
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,events plasma capillary glucose of less than or equal to 70 mg/dL,1,0.9495352506637573
JARDIANCE,hypoglycemic events,Severe,0,0.5196400880813599
JARDIANCE,hypoglycemic events,to mgdL b hypoglycemic,1,0.7627055644989014
JARDIANCE,hypoglycemic events,equal to mgdL b hypoglycemic,1,0.7530843019485474
JARDIANCE,hypoglycemic events,hypoglycemic events requiring,1,0.9474965929985046
JARDIANCE,genital mycotic infections,infection vaginal infection genital infection fungal vulvovaginal candidi,0,0.8416601419448853
JARDIANCE,genital mycotic infections,genital infection fungal,0,0.9120677709579468
JARDIANCE,genital mycotic infections,clinical trials the incidence genital,1,0.6917112469673157
JARDIANCE,genital mycotic infections,incidence,0,0.5242009162902832
JARDIANCE,genital mycotic infections,vaginal mycotic infection vaginal infection genital infection fungal vulvovaginal,0,0.8779201507568359
JARDIANCE,genital mycotic infections,mycotic infections eg vaginal mycotic,1,0.8903894424438477
JARDIANCE,vaginal mycotic infection,vaginal mycotic infection,1,0.9999998807907104
JARDIANCE,vaginal mycotic infection,mycotic infections vaginal mycotic infection vaginal infection genital,1,0.9525002837181091
JARDIANCE,vaginal mycotic infection,infections vaginal mycotic infection,1,0.9762487411499023
JARDIANCE,vaginal mycotic infection,mycotic infection vaginal infection genital infection fungal,1,0.9449814558029175
JARDIANCE,vaginal infection,genital infection fungal vulvovaginal candidiasis and vulvitis,0,0.7967693209648132
JARDIANCE,vaginal infection,mycotic infection,0,0.7503612637519836
JARDIANCE,vaginal infection,was,0,0.49290990829467773
JARDIANCE,vaginal infection,vaginal mycotic vaginal,1,0.8407789468765259
JARDIANCE,vaginal infection,infections eg vaginal mycotic vaginal,1,0.876396894454956
JARDIANCE,genital infection fungal,vaginal mycotic infection vaginal genital infection,1,0.8721053600311279
JARDIANCE,genital infection fungal,treated with JARDIANCE,0,0.5257681012153625
JARDIANCE,genital infection fungal,mycotic,0,0.7111502885818481
JARDIANCE,genital infection fungal,vaginal mycotic infection vaginal,0,0.8322741985321045
JARDIANCE,genital infection fungal,vaginal mycotic infection vaginal genital infection fungal,1,0.9471595287322998
JARDIANCE,genital infection fungal,candidiasis and vulvitis was increased in patients treated,0,0.7493360042572021
JARDIANCE,genital infection fungal,vaginal mycotic infection,0,0.8542160987854004
JARDIANCE,genital infection fungal,genital infection fungal vulvovaginal candidiasis and vulvitis,1,0.9121406078338623
JARDIANCE,vulvovaginal candidiasis,infection vulvovaginal candidiasis and,1,0.9396268129348755
JARDIANCE,vulvovaginal candidiasis,genital infection fungal vulvovaginal candidiasis and vulvitis,1,0.9028409123420715
JARDIANCE,vulvovaginal candidiasis,eg vaginal mycotic infection,0,0.8093273639678955
JARDIANCE,vulvovaginal candidiasis,and vulvitis was increased in patients treated,0,0.6840156316757202
JARDIANCE,vulvovaginal candidiasis,mycotic infections eg vaginal mycotic infection vaginal infection genital infection,0,0.756575882434845
JARDIANCE,vulvitis,vulvitis was,1,0.9521237015724182
JARDIANCE,vulvitis,fungal vulvovaginal candidiasis vulvitis was,1,0.8341114521026611
JARDIANCE,vulvitis,vulvitis was increased in patients treated,1,0.8222339749336243
JARDIANCE,genital infection,Discontinuation from study due genital infection occurred in of placebotreated patients,1,0.7610903978347778
JARDIANCE,genital infection,occurred in of placebotreated patients and of patients treated with,0,0.527030885219574
JARDIANCE,genital infection,JARDIANCE mg respectively Discontinuation from study due to,0,0.504713773727417
JARDIANCE,genital infection,Discontinuation from study due genital infection,1,0.7791268825531006
JARDIANCE,genital infection,from study due genital infection,1,0.8653454184532166
JARDIANCE,genital infection,genital infection occurred in of placebotreated patients,1,0.8271785974502563
JARDIANCE,Phimosis,less,0,0.5386162996292114
JARDIANCE,Phimosis,Phimosis occurred more,1,0.885376513004303
JARDIANCE,Phimosis,male patients see Phimosis occurred more,1,0.8426214456558228
JARDIANCE,Phimosis,Phimosis occurred,1,0.9254534244537354
JARDIANCE,Phimosis,see,0,0.5369268655776978
JARDIANCE,Phimosis,occurred more frequently,0,0.49413204193115234
JARDIANCE,Urinary Tract Infections,Urinary Tract,1,0.8227918148040771
JARDIANCE,Urinary Tract Infections,less than,0,0.46188682317733765
JARDIANCE,Urinary Tract Infections,JARDIANCE mg than Urinary,1,0.6550540924072266
JARDIANCE,Urinary Tract Infections,Urinary Tract Infections In,1,0.9429824352264404
JARDIANCE,Urinary Tract Infections,mg than Urinary Tract Infections,1,0.8234544992446899
JARDIANCE,Urinary Tract Infections,clinical trials the,0,0.584746241569519
JARDIANCE,Urinary Tract Infections,Urinary Tract Infections In the pool of five,1,0.8424907326698303
JARDIANCE,Urinary Tract Infections,JARDIANCE mg than Urinary Tract Infections In,1,0.7743270993232727
JARDIANCE,Urinary Tract Infections,Tract Infections In the pool of,1,0.7297487258911133
JARDIANCE,urinary tract infections,Urinary Tract Infections In the pool,0,0.7745064496994019
JARDIANCE,urinary tract infections,trials the incidence urinary,1,0.701261043548584
JARDIANCE,urinary tract infections,clinical trials the incidence urinary tract infections eg urinary tract,1,0.7886033058166504
JARDIANCE,urinary tract infections,urinary,1,0.7966906428337097
JARDIANCE,urinary tract infections,the incidence urinary tract infections eg urinary tract,1,0.8240511417388916
JARDIANCE,urinary tract infections,bacteriuria and cystitis was increased in patients,0,0.7704421281814575
JARDIANCE,urinary tract infections,clinical trials the incidence urinary,1,0.6815425753593445
JARDIANCE,urinary tract infections,increased in,0,0.528598427772522
JARDIANCE,urinary tract infection,bacteriuria and cystitis was increased in patients treated,0,0.7422970533370972
JARDIANCE,urinary tract infection,patients,0,0.5518239736557007
JARDIANCE,urinary tract infection,e pool of five placebocontrolled,0,0.5282593965530396
JARDIANCE,urinary tract infection,infections urinary tract infection asymptomatic bacteriuria and cystitis was,1,0.8154025673866272
JARDIANCE,urinary tract infection,tract infections urinary tract infection asymptomatic bacteriuria and cystitis,1,0.8254678845405579
JARDIANCE,asymptomatic bacteriuria,asymptomatic bacteriuria,1,1.0
JARDIANCE,asymptomatic bacteriuria,asymptomatic bacteriuria and cystitis was increased,1,0.8932129740715027
JARDIANCE,asymptomatic bacteriuria,treated with JARDIANCE compared to placebo see Table,0,0.5120760798454285
JARDIANCE,asymptomatic bacteriuria,eg urinary tract asymptomatic,1,0.8653628826141357
JARDIANCE,cystitis,patients treated with JARDIANCE compared to placebo see Table,0,0.5150759220123291
JARDIANCE,cystitis,compared to placebo see,0,0.5275033712387085
JARDIANCE,cystitis,to placebo see Table Patients,0,0.49013519287109375
JARDIANCE,cystitis,to placebo see Table,0,0.5145131349563599
JARDIANCE,cystitis,cystitis was increased in patients treated,1,0.831670880317688
JARDIANCE,urinary tract infection,experience urinary tract,1,0.7663809061050415
JARDIANCE,urinary tract infection,urinary tract infection The,1,0.9402253031730652
JARDIANCE,urinary tract infection,urinary tract infection The rate of treatment,1,0.8077082633972168
JARDIANCE,urinary tract infection,likely to experience urinary tract infection,1,0.8340623378753662
JARDIANCE,urinary tract infections,treatment discontinuation due to,0,0.528250515460968
JARDIANCE,urinary tract infections,urinary,0,0.7966906428337097
JARDIANCE,urinary tract infections,urinary tract infections was and for placebo,1,0.8171789646148682
JARDIANCE,urinary tract infections,infection,0,0.7042419910430908
JARDIANCE,urinary tract infections,treatment discontinuation due urinary tract infections was and for placebo,1,0.7539921998977661
JARDIANCE,Urinary tract infections,mg Urinary tract infections occurred more frequently in female,1,0.7703549265861511
JARDIANCE,Urinary tract infections,infection,0,0.7042419910430908
JARDIANCE,Urinary tract infections,tract infections,1,0.8144137859344482
JARDIANCE,Urinary tract infections,and for placebo JARDIANCE mg and JARDIANCE,0,0.5499217510223389
JARDIANCE,Urinary tract infections,tract infections occurred more frequently in female,1,0.6843999624252319
JARDIANCE,urinary tract infections,patients The incidence urinary tract infections,1,0.8078625798225403
JARDIANCE,urinary tract infections,placebo,0,0.5327656269073486
JARDIANCE,urinary tract infections,Urinary tract infections occurred more frequently in female patients,0,0.7887157201766968
JARDIANCE,urinary tract infections,patients The incidence urinary,1,0.7077332735061646
JARDIANCE,urinary tract infections,tract infections in,1,0.7799884080886841
JARDIANCE,urinary tract infections,urinary tract infections,1,0.9999999403953552
JARDIANCE,urinary tract infections,JARDIANCE mg,0,0.5092735290527344
JARDIANCE,urinary tract infections,of,0,0.5250772833824158
JARDIANCE,Increase in Low-Density Lipoprotein Cholesterol,Tests,0,0.5240140557289124
JARDIANCE,Increase in Low-Density Lipoprotein Cholesterol,Specific Populations Laboratory Increase in,1,0.6374497413635254
JARDIANCE,Increase in Low-Density Lipoprotein Cholesterol,Specific Populations Laboratory Increase in Low-Density Lipoprotein Cholesterol,1,0.8935844898223877
JARDIANCE,increases in low-density lipoprotein cholesterol,LowDensity Lipoprotein Cholesterol LDLC increases in low-density lipoprotein cholesterol LDLC were observed in,1,0.9023781418800354
JARDIANCE,increases in low-density lipoprotein cholesterol,Specific Populations Laboratory Increase in,1,0.63667893409729
JARDIANCE,increases in low-density lipoprotein cholesterol,increases in low-density lipoprotein cholesterol LDLC were observed in patients,1,0.9189760684967041
JARDIANCE,increases in low-density lipoprotein cholesterol,LowDensity,0,0.6275115609169006
JARDIANCE,increases in low-density lipoprotein cholesterol,in LowDensity Lipoprotein Cholesterol LDLC Doserelated,0,0.8118250370025635
JARDIANCE,Increase in Hematocrit,to mgdL across treatment Increase in,1,0.6170823574066162
JARDIANCE,hematocrit decreased,hematocrit decreased by,1,0.9824087619781494
JARDIANCE,hematocrit decreased,groups Increase in Hematocrit In a pool of four placebocontrolled studies,0,0.7506240010261536
JARDIANCE,hematocrit decreased,placebocontrolled studies hematocrit decreased by in placebo and,1,0.8585580587387085
JARDIANCE,hematocrit decreased,placebocontrolled studies,0,0.5761839747428894
JARDIANCE,hematocrit decreased,studies hematocrit decreased,1,0.9654157161712646
JARDIANCE,hematocrit decreased,of four placebocontrolled studies hematocrit decreased,1,0.8578667640686035
JARDIANCE,Hypotension,important verse react ions,1,0.510185956954956
JARDIANCE,Hypotension,of four placebocontrolled studies hematocrit decreased,1,0.6028008460998535
JARDIANCE,Hypotension,The following,0,0.5365250706672668
JARDIANCE,Hypotension,following important verse react,1,0.5045157670974731
JARDIANCE,Hypotension,and elsewhere in the labeling Hypotension see Warnings and,0,0.8093154430389404
JARDIANCE,Hypotension,the labeling Hypotension see Warnings,0,0.8292860388755798
JARDIANCE,Hypotension,labeling Hypotension see Warnings and,0,0.8256821036338806
JARDIANCE,Hypotension,in the labeling Hypotension see,0,0.8648316860198975
JARDIANCE,Hypotension,important verse react,1,0.5130987763404846
JARDIANCE,Hypotension,below and,0,0.5925480127334595
JARDIANCE,Hypotension,The following important verse react ions are described below,1,0.5002890825271606
JARDIANCE,Impairment in renal function,Precautions Genital Mycotic Infections see Warnings and,0,0.4816949963569641
JARDIANCE,Impairment in renal function,Precautions Hypoglycemia with Concomitant Use with Insulin and,0,0.5090583562850952
JARDIANCE,Impairment in renal function,Genital Mycotic Infections see,0,0.501157283782959
JARDIANCE,Impairment in renal function,Mycotic Infections see Warnings,0,0.49926310777664185
JARDIANCE,Impairment in renal function,see Warnings and Precautions,0,0.4894644021987915
JARDIANCE,Impairment in renal function,Precautions,0,0.48572030663490295
JARDIANCE,Impairment in renal function,[see Wa rnings and Precautions Genital Mycotic,1,0.49338090419769287
JARDIANCE,Impairment in renal function,nsulin,1,0.46326690912246704
JARDIANCE,Genital mycotic infections,ommon adverse reactions as sociated with JARDIANCE or greater,1,0.5483976602554321
JARDIANCE,Genital mycotic infections,most ommon adverse,1,0.49834907054901123
JARDIANCE,Urinary tract infections,ere urinary tract infect,1,0.820076048374176
JARDIANCE,Urinary tract infections,or greater incidence ere urinary,1,0.7064226865768433
JARDIANCE,Urinary tract infections,incidence ere urinary tract infect ions and female,1,0.7698692083358765
JARDIANCE,Urinary tract infections,female genital mycotic infections EXCERPT To report SUSPECTED,0,0.607151985168457
JARDIANCE,Urinary tract infections,EXCERPT To report,0,0.5103789567947388
JARDIANCE,Urinary tract infections,ere urinary tract infect ions,1,0.805881142616272
JARDIANCE,Urinary tract infections,ere,1,0.48607757687568665
JARDIANCE,Urinary tract infections,greater incidence ere urinary tract infect ions and female genital,1,0.7523626089096069
JARDIANCE,Urinary tract infections,EXCERPT To report SUSPECTED,0,0.5085539817810059
JARDIANCE,Urinary tract infections,incidence,0,0.5359894037246704
JARDIANCE,Increased LDL-C,female genital,0,0.45677316188812256
JARDIANCE,Increased LDL-C,) EXCERP T To report SUSPECTED,1,0.5551840662956238
JARDIANCE,intravascular volume contraction,Trials Experience Because clinical ials,1,0.5397871732711792
JARDIANCE,Symptomatic hypotension,Because,0,0.4620665907859802
JARDIANCE,Symptomatic hypotension,"rying conditions, adver se reaction rates observed in",1,0.483673095703125
JARDIANCE,Symptomatic hypotension,"under widely rying conditions, adver",1,0.5048152804374695
JARDIANCE,Symptomatic hypotension,"conditions, adver se reaction",1,0.5289161205291748
JARDIANCE,Symptomatic hypotension,the clinical trials,0,0.531790018081665
JARDIANCE,Symptomatic hypotension,in the clinical trials of,0,0.5238767862319946
JARDIANCE,Symptomatic hypotension,"rying conditions,",1,0.5878618955612183
JARDIANCE,Symptomatic hypotension,"rying conditions, adver se reaction rates observed",1,0.48730534315109253
JARDIANCE,decreases eGFR,received,0,0.48066654801368713
JARDIANCE,decreases eGFR,JARDIANCE mg,0,0.580368161201477
JARDIANCE,impaired renal function,placebo (N=995) JARDIANCE mg N or,1,0.49895960092544556
JARDIANCE,impaired renal function,of approximately weeks Patients eceived placebo (N=995),1,0.45792460441589355
JARDIANCE,impaired renal function,eceived placebo (N=995) JARDIANCE mg N or JARDIANCE,1,0.5069633722305298
JARDIANCE,impaired renal function,of the population,0,0.46151062846183777
JARDIANCE,impaired renal function,of approximately weeks,0,0.4572067856788635
JARDIANCE,hypoglycemia,"nephropathy pathy (8%),",1,0.4801994860172272
JARDIANCE,hypoglycemia,"pathy (8%), or neuropathy Baseline renal function",1,0.5019892454147339
JARDIANCE,hypoglycemia,"included diabetic nephropathy pathy (8%), ",1,0.5654409527778625
JARDIANCE,hypoglycemia,in of patients and,0,0.5065022706985474
JARDIANCE,hypoglycemia,nephropathy retino,0,0.46126097440719604
JARDIANCE,hypoglycemia,diabetes at baseline included,0,0.654000997543335
JARDIANCE,hypoglycemia,pathy,1,0.459273099899292
JARDIANCE,hypoglycemia,neuropathy Baseline renal function was normal or mildly impaired,0,0.506832480430603
JARDIANCE,genital mycotic infections,occurred in greate r than or,1,0.5042327642440796
JARDIANCE,genital mycotic infections,JARDIANCE mg Table,0,0.46936529874801636
JARDIANCE,genital mycotic infections,r than or equal to of patients treated with JARDIANCE mg or JARDIANCE,0,0.5116862058639526
JARDIANCE,genital mycotic infections,ebo and,1,0.4814627170562744
JARDIANCE,mycotic genital infections,or JARDIANCE mg Table Adverse Reactions Reported in of,0,0.5254783630371094
JARDIANCE,mycotic genital infections,with JARDIANCE an d Greater than Placebo in,1,0.48091211915016174
JARDIANCE,mycotic genital infections,Reported in of Treated,1,0.5352761745452881
JARDIANCE,mycotic genital infections,in of  Treated with JARDIANCE an d Greater than,1,0.530526876449585
JARDIANCE,mycotic genital infections,Treated,1,0.5509678721427917
JARDIANCE,mycotic genital infections,Reported in of Treated with,1,0.550301730632782
JARDIANCE,mycotic genital infections,Reactions Reported in of  Treated with JARDIANCE an d Greater than Placebo,1,0.504695475101471
JARDIANCE,mycotic genital infections,than Placebo in Pooled PlaceboControlled Clinical Studies of JARDIANCE Monotherapy,0,0.48617032170295715
JARDIANCE,mycotic genital infections,with JARDIANCE an d Greater,1,0.48099789023399353
JARDIANCE,urinary tract infections,"Combination herapy 
   a  Predefined adverse event grouping including",1,0.5371299386024475
JARDIANCE,urinary tract infections,with JARDIANCE an d Greater,1,0.5051501393318176
JARDIANCE,urinary tract infections,Monotherapy or Combination herapy a Predefined,1,0.546534538269043
JARDIANCE,urinary tract infections,limited to urinary tract,0,0.7624817490577698
JARDIANCE,urinary tract infections,tract,0,0.5814784169197083
JARDIANCE,urinary tract infections,JARDIANCE Monotherapy or Combination herapy a Predefined,1,0.5488327145576477
JARDIANCE,urinary tract infections,herapy a Predefined adverse,1,0.4963001012802124
JARDIANCE,urinary tract infections,of JARDIANCE,0,0.44378530979156494
JARDIANCE,urinary tract infections,Placebo in Pooled,0,0.5389919281005859
JARDIANCE,Increases in LDL-C,genital cotic infections i nclude the following adverse,1,0.525604248046875
JARDIANCE,Increases in LDL-C,Placebo in Pooled,0,0.5548146963119507
JARDIANCE,Increases in LDL-C,Female genital cotic infections i nclude the following adverse,1,0.515459418296814
JARDIANCE,Increases in LDL-C,cystitis b,0,0.47928252816200256
JARDIANCE,Increases in LDL-C,cotic,1,0.5386237502098083
JARDIANCE,Increases in LDL-C,cystitis b Female genital cotic,1,0.47686219215393066
ULORIC,liver function abnormalities,least greater than placebo liver function abnormalities nausea arthralgia and rash To,1,0.777473509311676
ULORIC,liver function abnormalities,cystitis b Female genital cotic,1,0.479106068611145
ULORIC,liver function abnormalities,greater than placebo liver function abnormalities nausea arthralgia and,1,0.8260695338249207
ULORIC,nausea,nausea,1,1.0
ULORIC,nausea,nausea arthralgia and rash To report,1,0.7715504169464111
ULORIC,nausea,nausea arthralgia and rash To,1,0.794758677482605
ULORIC,arthralgia,abnormalities nausea,0,0.5179513692855835
ULORIC,arthralgia,arthralgia and,1,0.9559702277183533
ULORIC,arthralgia,arthralgia and rash To,1,0.8543016910552979
ULORIC,arthralgia,at least greater,0,0.48827868700027466
ULORIC,arthralgia,arthralgia,1,1.0
ULORIC,arthralgia,rash To report SUSPECTED ADVERSE,0,0.5492019653320312
ULORIC,arthralgia,function abnormalities arthralgia and rash To,1,0.7956904172897339
ULORIC,arthralgia,greater than placebo are,0,0.5166125297546387
ULORIC,rash,To report SUSPECTED ADVERSE REACTIONS contact Takeda Pharmaceuticals,0,0.580316424369812
ULORIC,rash,Takeda,0,0.49184858798980713
ULORIC,rash,SUSPECTED ADVERSE REACTIONS,0,0.6345202922821045
ULORIC,liver function abnormalities,liver function abnormalities in of,1,0.9537809491157532
ULORIC,liver function abnormalities,was,0,0.4596778154373169
ULORIC,liver function abnormalities,to discontinuation from therapy liver function abnormalities,1,0.8525304794311523
ULORIC,liver function abnormalities,liver,1,0.7659165263175964
ULORIC,liver function abnormalities,discontinuation from therapy liver function abnormalities in of ULORIC mg,1,0.7596912980079651
ULORIC,liver function abnormalities,from therapy liver function abnormalities,1,0.9289207458496094
ULORIC,liver function abnormalities,reaction,0,0.5004119277000427
ULORIC,liver function abnormalities,in of ULORIC mg of ULORIC mg and in of allopurinoltreated subjects In,0,0.5305399894714355
ULORIC,liver function abnormalities,function abnormalities in of ULORIC,1,0.7365424633026123
ULORIC,dizziness,presented in dizziness was reported in,1,0.8724650740623474
ULORIC,dizziness,function abnormalities in of ULORIC,1,0.5827252864837646
ULORIC,dizziness,rate more than,0,0.5209209322929382
ULORIC,dizziness,dizziness,1,0.9999998807907104
ULORIC,dizziness,Table,0,0.501779317855835
ULORIC,dizziness,reactions presented in dizziness was reported in more,1,0.818398654460907
ULORIC,dizziness,of allopurinoltreated subjects In addition,0,0.5018680095672607
ULORIC,dizziness,dizziness was reported in more than,1,0.8860113620758057
ULORIC,dizziness,dizziness was reported,1,0.9301130771636963
ULORIC,anemia,anemia idiopathic,1,0.832642674446106
ULORIC,anemia,thrombocytopenic purpura leukocytosisleukopenia neutropenia pancytopenia splenomeg,0,0.6099162101745605
ULORIC,anemia,and Lymphatic System anemia idiopathic thrombocytopenic,1,0.7159768342971802
ULORIC,anemia,from Warnings and Precautions Blood,0,0.6694805026054382
ULORIC,idiopathic thrombocytopenic purpura,System Disorders idiopathic thrombocytopenic,1,0.8642445802688599
ULORIC,idiopathic thrombocytopenic purpura,neutropenia pancytopenia,0,0.6805247068405151
ULORIC,idiopathic thrombocytopenic purpura,idiopathic thrombocytopenic purpura,1,1.0000001192092896
ULORIC,leukocytosis,Cardiac,0,0.4302298426628113
ULORIC,leukocytosis,splenomegaly thrombocytopenia,0,0.5718002319335938
ULORIC,leukocytosis,and Lymphatic System Disorders anemia,0,0.6003959774971008
ULORIC,leukocytosis,leukocytosis leukopenia,1,0.8605605363845825
ULORIC,leukocytosis,leukocytosis leukopenia neutropenia pancytopenia splenomegaly,1,0.8099842071533203
ULORIC,leukocytosis,leukocytosis leukopenia neutropenia pancytopenia,1,0.8351176977157593
ULORIC,leukocytosis,Cardiac Disorders,0,0.46711134910583496
ULORIC,leukopenia,idiopathic thrombocytopenic purpura leukopenia,1,0.8233941197395325
ULORIC,leukopenia,leukocytosis leukopenia neutropenia pancytopenia splenomegaly,1,0.820011556148529
ULORIC,leukopenia,leukopenia neutropenia pancytopenia splenomegaly,1,0.8251519799232483
ULORIC,leukopenia,and Lymphatic System Disorders anemia idiopathic thrombocytopenic,0,0.6359332799911499
ULORIC,leukopenia,anemia,0,0.6550049185752869
ULORIC,leukopenia,Blood and,0,0.6264069080352783
ULORIC,leukopenia,thrombocytopenia Cardiac Disorders angina,0,0.5608571767807007
ULORIC,leukopenia,leukopenia,1,1.0000001192092896
ULORIC,leukopenia,leukopenia neutropenia,1,0.9149845838546753
ULORIC,leukopenia,idiopathic thrombocytopenic purpura,0,0.5513268709182739
ULORIC,neutropenia,neutropenia pancytopenia,1,0.8512123227119446
ULORIC,neutropenia,System Disorders anemia,0,0.6107955574989319
ULORIC,neutropenia,neutropenia pancytopenia splenomegaly,1,0.7782320976257324
ULORIC,pancytopenia,tem Disorders anemia idiopathic thrombocytopenic,0,0.7335272431373596
ULORIC,pancytopenia,Disorders angina,0,0.4960513114929199
ULORIC,pancytopenia,pancytopenia splenomegaly thrombocytopenia,1,0.8599302768707275
ULORIC,pancytopenia,angina pectoris atrial fibrillationfl,0,0.5183490514755249
ULORIC,splenomegaly,atrial fibrillationflutter cardiac,0,0.4863737225532532
ULORIC,splenomegaly,angina pectoris atrial,0,0.47781267762184143
ULORIC,splenomegaly,purpura leukocytosisleukopenia neutropenia splenomegaly thrombocytopenia,1,0.7225195169448853
ULORIC,splenomegaly,splenomegaly thrombocytopenia Cardiac Disorders angina,1,0.7531102895736694
ULORIC,splenomegaly,thrombocytopenia Cardiac Disorders angina pectoris,0,0.5636770725250244
ULORIC,splenomegaly,splenomegaly thrombocytopenia Cardiac Disorders angina pectoris,1,0.7482339143753052
ULORIC,thrombocytopenia,neutropenia pancytopenia thrombocytopenia Cardiac,1,0.8045589327812195
ULORIC,thrombocytopenia,splenomegaly thrombocytopenia Cardiac Disorders angina pectoris,1,0.7351064682006836
ULORIC,angina pectoris,fibrillationflutter cardiac murmur ECG,0,0.6270300149917603
ULORIC,angina pectoris,pancytopenia splenomegaly thrombocytopenia Cardiac angina pectoris,1,0.7536805868148804
ULORIC,angina pectoris,ECG abnormal palpitations,0,0.6312811374664307
ULORIC,angina pectoris,Cardiac angina pectoris,1,0.9629313349723816
ULORIC,angina pectoris,angina pectoris atrial fibrillationflutter cardiac murmur ECG,1,0.8369574546813965
ULORIC,atrial fibrillation,tachycardia,0,0.7388362884521484
ULORIC,atrial fibrillation,atrial fibrillation,1,1.0
ULORIC,atrial fibrillation,tachycardia Ear,0,0.6629636287689209
ULORIC,atrial fibrillation,Cardiac Disorders angina atrial fibrillation,1,0.7982374429702759
ULORIC,atrial fibrillation,angina atrial fibrillation,1,0.8295889496803284
ULORIC,atrial fibrillation,splenomegaly thrombocytopenia Cardiac Disorders angina,0,0.607006311416626
ULORIC,atrial fibrillation,atrial fibrillation flutter,1,0.8332930207252502
ULORIC,cardiac murmur,atrial,0,0.6750679016113281
ULORIC,cardiac murmur,cardiac murmur ECG abnormal palpitations sinus bradycardia,1,0.8084670305252075
ULORIC,cardiac murmur,palpitations sinus bradycardia tachycardia Ear and Labyrinth Disorders,0,0.6418642401695251
ULORIC,cardiac murmur,pectoris atrial cardiac murmur ECG abnormal palpitations,1,0.7949749231338501
ULORIC,cardiac murmur,cardiac murmur ECG abnormal palpitations sinus,1,0.823818027973175
ULORIC,cardiac murmur,Ear and Labyrinth Disorders d,0,0.550299882888794
ULORIC,ECG abnormal,pectoris atrial fibrillationflutter cardiac ECG,1,0.7302393913269043
ULORIC,ECG abnormal,ECG abnormal palpitations sinus bradycardia tachycardia,1,0.8131871223449707
ULORIC,ECG abnormal,sinus bradycardia tachycardia Ear and Labyrinth Disorders deafness,0,0.6234054565429688
ULORIC,ECG abnormal,Cardiac,0,0.6876983642578125
ULORIC,ECG abnormal,ECG abnormal palpitations,1,0.8816947340965271
ULORIC,ECG abnormal,ECG abnormal,1,0.9999999403953552
ULORIC,ECG abnormal,angina pectoris atrial,0,0.6254655122756958
ULORIC,ECG abnormal,cytopenia,0,0.51945960521698
ULORIC,ECG abnormal,Disorders deafness,0,0.5452998876571655
ULORIC,palpitations,palpitations sinus bradycardia tachycardia Ear,1,0.8386328816413879
ULORIC,sinus bradycardia,Labyrinth Disorders deafness,0,0.5471344590187073
ULORIC,sinus bradycardia,angina pectoris atrial fibrillationflutter cardiac murmur,0,0.6374803185462952
ULORIC,sinus bradycardia,ECG abnormal sinus bradycardia,1,0.9216703772544861
ULORIC,sinus bradycardia,murmur ECG,0,0.6266148686408997
ULORIC,sinus bradycardia,cardiac murmur ECG abnormal sinus,1,0.7789463400840759
ULORIC,sinus bradycardia,Disorders deafness tinnitus,0,0.5603722929954529
ULORIC,sinus bradycardia,murmur ECG abnormal sinus bradycardia tachycardia Ear,1,0.7854945659637451
ULORIC,sinus bradycardia,abnormal sinus bradycardia tachycardia Ear,1,0.8511130213737488
ULORIC,tachycardia,ECG abnormal,0,0.690690279006958
ULORIC,tachycardia,deafness tinnitus vertigo Eye Disorders,0,0.5434714555740356
ULORIC,tachycardia,tinnitus vertigo Eye Disorders vision bl,0,0.5598589181900024
ULORIC,tachycardia,abnormal palpitations sinus tachycardia Ear and Labyrinth Disorders deafness,1,0.7340720891952515
ULORIC,tachycardia,sinus,0,0.5671221017837524
ULORIC,tachycardia,ctoris atrial,0,0.6675774455070496
ULORIC,deafness,deafness,1,0.9999998807907104
ULORIC,deafness,deafness tinnitus vertigo Eye Disorders vision,1,0.8103728294372559
ULORIC,deafness,Gastrointestinal,0,0.4707876443862915
ULORIC,deafness,and,0,0.5065765976905823
ULORIC,tinnitus,blurred,0,0.52324378490448
ULORIC,tinnitus,Disorders tinnitus vertigo Eye Disorders vision,1,0.750855565071106
ULORIC,tinnitus,tinnitus vertigo Eye Disorders,1,0.7933709025382996
ULORIC,tinnitus,tinnitus vertigo,1,0.8587486147880554
ULORIC,vertigo,deafness vertigo Eye,1,0.8560295104980469
ULORIC,vertigo,tinnitus vertigo,1,0.8603940010070801
ULORIC,vertigo,Disorders deafness vertigo Eye,1,0.8098517656326294
ULORIC,vision blurred,vertigo Eye,0,0.6884215474128723
ULORIC,vision blurred,Eye vision,1,0.76678466796875
ULORIC,vision blurred,Labyrinth Disorders deafness,0,0.5495703816413879
ULORIC,vision blurred,vision blurred Gastrointestinal Disorders,1,0.7953082323074341
ULORIC,vision blurred,pain constipation dry,0,0.4877742528915405
ULORIC,vision blurred,constipation,0,0.5308362245559692
ULORIC,vision blurred,vision blurred Gastrointestinal Disorders abdominal,1,0.7692715525627136
ULORIC,vision blurred,distention abdominal pain constipation dry mouth,0,0.4601615071296692
ULORIC,vision blurred,tinnitus vertigo Eye vision,1,0.6584118008613586
ULORIC,abdominal distention,abdominal pain constipation dry mouth dyspepsia flatulence frequent stools,0,0.6598571538925171
ULORIC,abdominal distention,abdominal,1,0.8263062238693237
ULORIC,abdominal distention,Disorders vision blurred Gastrointestinal abdominal,1,0.6705338358879089
ULORIC,abdominal distention,abdominal distention abdominal pain constipation dry,1,0.8526355624198914
ULORIC,abdominal distention,constipation dry,0,0.5804975628852844
ULORIC,abdominal distention,Disorders vision,0,0.48009711503982544
ULORIC,constipation,flatulence,0,0.7536705136299133
ULORIC,constipation,constipation dry,1,0.8619378209114075
ULORIC,constipation,abdominal distention abdominal constipation dry,1,0.798434853553772
ULORIC,constipation,dry mouth dyspepsia flatulence frequent,0,0.7026108503341675
ULORIC,dry mouth,Disorders abdominal distention abdominal pain constipation,0,0.49074551463127136
ULORIC,dyspepsia,frequent stools gastritis,0,0.6929633021354675
ULORIC,dyspepsia,abdominal pain constipation dry dyspepsia,1,0.7961910963058472
ULORIC,flatulence,dry mouth flatulence frequent stools gastritis gastroesophageal,1,0.7521153688430786
ULORIC,flatulence,frequent stools gastritis,0,0.6536092162132263
ULORIC,flatulence,constipation dry mouth flatulence frequent stools,1,0.731629490852356
ULORIC,flatulence,flatulence frequent stools gastritis gastroesophageal reflux,1,0.784214973449707
ULORIC,flatulence,flatulence,1,1.0000001192092896
ULORIC,flatulence,constipation dry mouth flatulence,1,0.7811483144760132
ULORIC,flatulence,rointestinal Disorders abdominal distention abdominal pain,0,0.6488332748413086
ULORIC,flatulence,abdominal,0,0.6304095983505249
ULORIC,flatulence,dry mouth flatulence frequent stools,1,0.7588728666305542
ULORIC,flatulence,Disorders,0,0.6078671216964722
ULORIC,frequent stools,gingival pain haematemes,0,0.4927635192871094
ULORIC,frequent stools,frequent stools,1,1.0
ULORIC,gastritis,stools,0,0.5678955316543579
ULORIC,gastritis,mouth dyspepsia flatulence frequent gastritis gastroesophageal reflux,1,0.7927509546279907
ULORIC,gastritis,dyspepsia flatulence frequent gastritis gastroesophageal reflux disease,1,0.787595272064209
ULORIC,gastritis,gastrointestinal discomfort gingival pain,0,0.7090736627578735
ULORIC,gastritis,constipation dry mouth dyspepsia flatulence,0,0.6557974815368652
ULORIC,gastritis,frequent gastritis gastroesophageal reflux disease gastrointestinal,1,0.8215750455856323
ULORIC,gastritis,gastroesophageal reflux disease gastrointestinal,0,0.7307775616645813
ULORIC,gastritis,gastritis gastroesophageal,1,0.9032442569732666
ULORIC,gastritis,pain haematemesis,0,0.5512771010398865
ULORIC,gastritis,gastritis gastroesophageal reflux disease gastrointestinal discomfort,1,0.8343032598495483
ULORIC,gastroesophageal reflux disease,reflux disease gastrointestinal discomfort,1,0.8643009662628174
ULORIC,gastroesophageal reflux disease,gastroesophageal reflux disease gastrointestinal discomfort gingival pain,1,0.8291195034980774
ULORIC,gastroesophageal reflux disease,mouth dyspepsia flatulence frequent,0,0.6815609931945801
ULORIC,gastrointestinal discomfort,gastritis gastroesophageal reflux gastrointestinal,1,0.8123948574066162
ULORIC,gastrointestinal discomfort,disease,0,0.5688960552215576
ULORIC,gingival pain,gingival pain,1,1.0
ULORIC,gingival pain,gastroesophageal reflux disease gastrointestinal gingival pain,1,0.8502547740936279
ULORIC,gingival pain,discomfort,0,0.6398617029190063
ULORIC,gingival pain,hematochezia mouth ulceration pancreatitis,0,0.6152853965759277
ULORIC,haematemesis,ent stools gastritis gastroesophageal reflux disease,0,0.5099343061447144
ULORIC,haematemesis,mouth ulceration,0,0.5295282006263733
ULORIC,haematemesis,hematochezia mouth ulceration pancreatitis peptic,0,0.6604822874069214
ULORIC,haematemesis,pain,0,0.5357522964477539
ULORIC,haematemesis,haematemesis hyperchlorhydria hematochezia,1,0.8495890498161316
ULORIC,haematemesis,haematemesis hyperchlorhydria hematochezia mouth ulceration,1,0.8105679750442505
ULORIC,haematemesis,discomfort gingival,0,0.49327975511550903
ULORIC,hyperchlorhydria,ulceration pancreatitis peptic ulcer vomiting,0,0.528018593788147
ULORIC,mouth ulceration,mouth ulceration,1,1.0000001192092896
ULORIC,mouth ulceration,hyperchlorhydria hematochezia,0,0.5325738191604614
ULORIC,mouth ulceration,Administration Site,0,0.5020128488540649
ULORIC,mouth ulceration,pancreatitis peptic ulcer vomiting General Disorders,0,0.6234647035598755
ULORIC,pancreatitis,pancreatitis peptic ulcer vomiting General Disorders,1,0.7308868169784546
ULORIC,pancreatitis,pancreatitis peptic ulcer vomiting General Disorders,0,0.7308868169784546
ULORIC,pancreatitis,and Administration,0,0.42624324560165405
ULORIC,pancreatitis,hematochezia mouth,0,0.5039706230163574
ULORIC,peptic ulcer,peptic ulcer,1,0.9999999403953552
ULORIC,peptic ulcer,hematochezia mouth,0,0.5370082855224609
ULORIC,peptic ulcer,ulceration peptic ulcer vomiting General Disorders and Administration,1,0.7695825695991516
ULORIC,peptic ulcer,hyperchlorhydria hematochezia mouth ulceration peptic ulcer vomiting General Disorders and,1,0.7076694965362549
ULORIC,vomiting,pancreatitis peptic vomiting General Disorders and,1,0.7748683094978333
ULORIC,vomiting,peptic ulcer,1,0.6159234046936035
ULORIC,vomiting,vomiting General Disorders and,1,0.8673593997955322
ULORIC,vomiting,pancreatitis peptic vomiting General Disorders and Administration,1,0.7754169702529907
ULORIC,vomiting,vomiting General Disorders,1,0.8577778339385986
ULORIC,vomiting,haematemesis hyperchlorhydria hematochezia,0,0.613402247428894
ULORIC,vomiting,and Administration Site Conditions asthenia chest,0,0.5532804727554321
ULORIC,vomiting,hyperchlorhydria hematochezia mouth ulceration pancreatitis peptic,0,0.6257820129394531
ULORIC,vomiting,mouth ulceration pancreatitis,0,0.5565310120582581
ULORIC,vomiting,pancreatitis peptic vomiting General,1,0.7841964960098267
ULORIC,asthenia,vomiting,0,0.5399789214134216
ULORIC,asthenia,ulcer vomiting General Disorders and Administration Site,0,0.49819719791412354
ULORIC,asthenia,asthenia chest paindiscomfort edema,1,0.7836658358573914
ULORIC,asthenia,Administration Site asthenia chest paindiscomfort edema fatigue feeling,1,0.6923795342445374
ULORIC,asthenia,gait,0,0.5415695309638977
ULORIC,asthenia,asthenia chest paindiscomfort edema fatigue feeling,1,0.756359338760376
ULORIC,asthenia,Disorders and Administration Site asthenia chest,1,0.7352548837661743
ULORIC,chest pain,chest pain discomfort,1,0.9325345754623413
ULORIC,chest pain,asthenia chest paindiscomfort edema fatigue feeling,1,0.7725987434387207
ULORIC,chest pain,Site Conditions asthenia,0,0.5201877951622009
ULORIC,chest pain,chest pain,1,0.9999999403953552
ULORIC,chest pain,gait,0,0.5008277893066406
ULORIC,chest pain,Administration Site Conditions chest pain discomfort edema,1,0.7365929484367371
ULORIC,chest pain,chest pain discomfort edema fatigue feeling,1,0.820493221282959
ULORIC,chest pain,Site Conditions chest pain discomfort,1,0.8425397872924805
ULORIC,chest pain,Administration Site Conditions chest,1,0.6754099130630493
ULORIC,chest pain,Administration Site Conditions chest pain,1,0.8070256114006042
ULORIC,edema,edema fatigue feeling abnormal gait,1,0.8054906129837036
ULORIC,edema,edema fatigue feeling,1,0.8570436239242554
ULORIC,fatigue,asthenia chest,0,0.593672513961792
ULORIC,fatigue,fatigue feeling abnormal,1,0.8298850059509277
ULORIC,fatigue,paindiscomfort,0,0.639660120010376
ULORIC,fatigue,fatigue feeling,1,0.8827975988388062
ULORIC,fatigue,fatigue feeling abnormal gait disturbance,1,0.7828493714332581
ULORIC,fatigue,fatigue feeling abnormal gait,1,0.7913885116577148
ULORIC,feeling abnormal,edema feeling abnormal gait,1,0.7420445680618286
ULORIC,feeling abnormal,fatigue feeling,1,0.690739631652832
ULORIC,feeling abnormal,influenzalike symptoms,0,0.6453976631164551
ULORIC,feeling abnormal,edema fatigue,0,0.5630457401275635
ULORIC,feeling abnormal,feeling abnormal gait disturbance influenzalike symptoms mass,1,0.7497761249542236
ULORIC,gait disturbance,thirst Hepatobiliary Disorders,0,0.5544298887252808
ULORIC,influenza-like symptoms,chest paindiscomfort edema fatigue feeling abnormal gait,0,0.6100668907165527
ULORIC,influenza-like symptoms,influenza-like symptoms mass pain,1,0.844731330871582
ULORIC,mass,mass pain thirst Hepatobiliary,1,0.5761593580245972
ULORIC,pain,disturbance influenzalike symptoms pain thirst Hepatobiliary Disorders cholelithiasischolecystitis hepatic,1,0.5974739789962769
ULORIC,pain,mass pain thirst Hepatobiliary,1,0.668961763381958
ULORIC,pain,pain thirst Hepatobiliary Disorders,1,0.6509201526641846
ULORIC,pain,pain,1,0.9999999403953552
ULORIC,pain,pain thirst Hepatobiliary,1,0.6829227209091187
ULORIC,thirst,hepatic steatosis hepatitis,0,0.5239394903182983
ULORIC,thirst,disturbance influenzalike symptoms mass thirst Hepatobiliary,1,0.7077629566192627
ULORIC,thirst,thirst Hepatobiliary,1,0.798215925693512
ULORIC,thirst,pain,0,0.5468119382858276
ULORIC,thirst,disturbance influenzalike symptoms mass thirst Hepatobiliary Disorders,1,0.7057175636291504
ULORIC,thirst,thirst Hepatobiliary Disorders cholelithiasischolecystitis,1,0.7454671859741211
ULORIC,cholelithiasis,hepatomegaly Immune,0,0.5375227928161621
ULORIC,cholelithiasis,Immune System Disorder hypersen,0,0.47361302375793457
ULORIC,cholelithiasis,cholelithiasis cholecystitis,1,0.8890780806541443
ULORIC,cholelithiasis,Immune System,0,0.5362067222595215
ULORIC,cholelithiasis,hepatomegaly Immune System Disorder hypersen,0,0.5318946838378906
ULORIC,cholelithiasis,Hepatobiliary cholelithiasis,1,0.8909115791320801
ULORIC,cholelithiasis,thirst Hepatobiliary cholelithiasis,1,0.8312280178070068
ULORIC,cholelithiasis,thirst Hepatobiliary cholelithiasis cholecystitis hepatic steatosis hepatitis hepatomegaly,1,0.7179349064826965
ULORIC,cholecystitis,System,0,0.45601582527160645
ULORIC,cholecystitis,Disorders cholecystitis hepatic steatosis hepatitis hepatomegaly Immune,1,0.7325435876846313
ULORIC,cholecystitis,hepatomegaly Immune System Disorder,0,0.5144560933113098
ULORIC,hepatic steatosis,thirst Hepatobiliary Disorders hepatic steatosis hepatitis hepatomegaly Immune,1,0.7746561765670776
ULORIC,hepatic steatosis,hepatomegaly Immune System Disorder,0,0.6617995500564575
ULORIC,hepatic steatosis,Immune,0,0.4765464663505554
ULORIC,hepatic steatosis,thirst Hepatobiliary Disorders hepatic steatosis,1,0.852863073348999
ULORIC,hepatic steatosis,Disorder,0,0.549552321434021
ULORIC,hepatic steatosis,pain thirst Hepatobiliary Disorders hepatic steatosis,1,0.8479166030883789
ULORIC,hepatic steatosis,pain thirst Hepatobiliary Disorders hepatic steatosis hepatitis hepatomegaly Immune,1,0.750813364982605
ULORIC,hepatitis,hepatitis hepatomegaly Immune System Disorder hypersensitivity,1,0.7286198139190674
ULORIC,hepatomegaly,hepatomegaly Immune System Disorder hypersensitivity Infections,1,0.7996222972869873
ULORIC,hepatomegaly,hepatomegaly,1,0.9999998807907104
ULORIC,hepatomegaly,hepatic steatosis hepatomegaly Immune,1,0.8261946439743042
ULORIC,hepatomegaly,cholelithiasischolecystitis hepatic steatosis hepatitis,0,0.6757044792175293
ULORIC,hepatomegaly,cholelithiasischolecystitis hepatic steatosis hepatomegaly Immune System Disorder,1,0.7199742794036865
ULORIC,hepatomegaly,hepatic steatosis,0,0.7062798142433167
ULORIC,hypersensitivity,hypersensitivity Infections and Infestations herpes,1,0.7968777418136597
ULORIC,hypersensitivity,and Infestations,0,0.554233193397522
ULORIC,hypersensitivity,hypersensitivity,1,1.0
ULORIC,hypersensitivity,herpes zoster,0,0.640674352645874
ULORIC,hypersensitivity,hepatic steatosis hepatitis hepatomegaly Immune System,0,0.5815202593803406
ULORIC,hypersensitivity,hepatitis hepatomegaly Immune System,0,0.6054112911224365
ULORIC,hypersensitivity,Immune System hypersensitivity Infections,1,0.8225597739219666
ULORIC,hypersensitivity,hypersensitivity Infections,1,0.8709668517112732
ULORIC,contusion,contusion Metabolism,1,0.8490136861801147
ULORIC,contusion,zoster Procedural contusion Metabolism,1,0.7015506029129028
ULORIC,contusion,Infections and Infestations herpes,0,0.5376167893409729
ULORIC,contusion,contusion,1,0.9999998211860657
ULORIC,contusion,Complications,0,0.5780739188194275
ULORIC,contusion,zoster Procedural Complications,0,0.5610634088516235
ULORIC,anorexia,anorexia appetite,1,0.8762049674987793
ULORIC,anorexia,contusion,0,0.5184361934661865
ULORIC,anorexia,anorexia,1,1.0
ULORIC,anorexia,mellitus hypercholesterolemia,0,0.4968459904193878
ULORIC,anorexia,anorexia appetite decreasedincreased dehydration diabetes,1,0.7656219005584717
ULORIC,anorexia,anorexia appetite decreasedincreased dehydration diabetes mellitus,1,0.7614582180976868
ULORIC,anorexia,and,0,0.5424877405166626
ULORIC,appetite decreased,Nutrition Disorders appetite decreased increased dehydration diabetes mellitus,1,0.7829233407974243
ULORIC,appetite decreased,and,0,0.480785071849823
ULORIC,appetite decreased,Nutrition,0,0.6671997308731079
ULORIC,appetite decreased,appetite decreased increased dehydration diabetes mellitus,1,0.7958134412765503
ULORIC,appetite decreased,Metabolism and Nutrition Disorders appetite decreased increased dehydration diabetes mellitus,1,0.7859851717948914
ULORIC,dehydration,anorexia appetite dehydration diabetes mellitus hypercholesterolemia,1,0.7001932263374329
ULORIC,dehydration,appetite decreased increased dehydration diabetes mellitus,1,0.7310115694999695
ULORIC,diabetes mellitus,Disorders anorexia,0,0.5451462864875793
ULORIC,diabetes mellitus,diabetes mellitus hypercholesterolemia hyperglycemia hyperlipidemia hypertriglyceridemia hypokalemia,1,0.8012919425964355
ULORIC,diabetes mellitus,hyperlipidemia hypertriglyceridemia hypokalemia,0,0.6379948854446411
ULORIC,diabetes mellitus,Disorders anorexia appetite decreasedincreased diabetes,1,0.7129300832748413
ULORIC,diabetes mellitus,diabetes mellitus hypercholesterolemia hyperglycemia,1,0.8311735987663269
ULORIC,diabetes mellitus,hyperglycemia hyperlipidemia,0,0.7650357484817505
ULORIC,diabetes mellitus,n Metabolism and Nutrition,0,0.5455480813980103
ULORIC,hypercholesterolemia,hypercholesterolemia hyperglycemia hyperlipidemia hypertriglyceridemia hypokalemia,1,0.8373748660087585
ULORIC,hypercholesterolemia,diabetes,0,0.6538106799125671
ULORIC,hypercholesterolemia,hypercholesterolemia,1,0.9999999403953552
ULORIC,hyperglycemia,hyperglycemia hyperlipidemia hypertriglyceridemia hypokalemia,1,0.7978537678718567
ULORIC,hyperglycemia,rs anorexia appetite decreasedincreased dehydration diabetes mellitus hypercholesterolemia,0,0.676496148109436
ULORIC,hyperglycemia,dehydration diabetes,0,0.7451029419898987
ULORIC,hyperlipidemia,hyperlipidemia,1,1.000000238418579
ULORIC,hyperlipidemia,hypokalemia weight decreasedincreased Musculoskeletal and,0,0.5565836429595947
ULORIC,hyperlipidemia,hyperlipidemia hypertriglyceridemia,1,0.8967205286026001
ULORIC,hyperlipidemia,hyperlipidemia hypertriglyceridemia hypokalemia,1,0.8180282711982727
ULORIC,hyperlipidemia,hyperlipidemia hypertriglyceridemia hypokalemia weight,1,0.8040502071380615
ULORIC,hyperlipidemia,diabetes mellitus hypercholesterolemia hyperlipidemia,1,0.8507745862007141
ULORIC,hyperlipidemia,decreasedincreased Musculoskeletal and Connectiv,0,0.5409449338912964
ULORIC,hypertriglyceridemia,dehydration diabetes mellitus hypercholesterolemia hyperglycemia,0,0.715998649597168
ULORIC,hypertriglyceridemia,and,0,0.4683174788951874
ULORIC,hypertriglyceridemia,mellitus hypercholesterolemia hyperglycemia hyperlipidemia,0,0.8072879314422607
ULORIC,hypertriglyceridemia,decreasedincreased Musculoskeletal and Connective,0,0.49740535020828247
ULORIC,hypertriglyceridemia,weight decreasedincreased Musculoskeletal and Connective,0,0.5214811563491821
ULORIC,hypertriglyceridemia,hypertriglyceridemia,1,1.0
ULORIC,hypertriglyceridemia,hyperglycemia hyperlipidemia,0,0.8476051092147827
ULORIC,hypertriglyceridemia,diabetes mellitus hypercholesterolemia hyperglycemia hypertriglyceridemia hypokalemia weight decreasedincreased,1,0.7611998915672302
ULORIC,hypokalemia,hypokalemia weight decreasedincreased Musculoskeletal and Connective,1,0.8260531425476074
ULORIC,hypokalemia,and Connective,0,0.49760007858276367
ULORIC,hypokalemia,decreasedincreased Musculoskeletal and Connective Tissue Disorders arthritis jo,0,0.5194896459579468
ULORIC,hypokalemia,hyperlipidemia hypokalemia weight decreasedincreased Musculoskeletal,1,0.7985787987709045
ULORIC,hypokalemia,hyperglycemia,0,0.5904508829116821
ULORIC,hypokalemia,Disorders arthritis,0,0.47865232825279236
ULORIC,hypokalemia,hypokalemia,1,1.0
ULORIC,hypokalemia,mellitus,0,0.5278359651565552
ULORIC,arthritis,joint stiffness joint swelling muscle,0,0.6818822622299194
ULORIC,arthritis,stiffness joint,0,0.6669705510139465
ULORIC,arthritis,and Connective Tissue arthritis joint stiffness joint swelling muscle,1,0.7601256370544434
ULORIC,arthritis,joint,0,0.7127888202667236
ULORIC,arthritis,Disorders,0,0.6095662117004395
ULORIC,arthritis,stiffness joint swelling muscle,0,0.6777034997940063
ULORIC,arthritis,arthritis joint,1,0.8727884888648987
ULORIC,arthritis,and Connective Tissue arthritis joint stiffness joint,1,0.7674570679664612
ULORIC,arthritis,arthritis joint stiffness joint swelling muscle,1,0.7834349274635315
ULORIC,joint stiffness,arthritis,0,0.7192771434783936
ULORIC,joint stiffness,Tissue,0,0.569554328918457
ULORIC,joint stiffness,Connective Tissue Disorders joint stiffness joint swelling muscle spasmstwitchingtightnessweakness musculoskeletal,1,0.8153782486915588
ULORIC,joint stiffness,Connective Tissue Disorders joint stiffness joint swelling muscle spasmstwitchingtightnessweakness,1,0.8146718740463257
ULORIC,joint stiffness,and Connective Tissue Disorders joint,1,0.7726732492446899
ULORIC,joint swelling,joint swelling muscle,1,0.9223138093948364
ULORIC,joint swelling,Tissue Disorders arthritis joint joint swelling muscle spasmstwitchingtightnessweakness musculoskeletal painstiffness myalgia,1,0.7821997404098511
ULORIC,joint swelling,joint swelling,1,0.9999998211860657
ULORIC,joint swelling,muscle,0,0.6216593384742737
ULORIC,joint swelling,arthritis joint stiffness,0,0.7828084230422974
ULORIC,joint swelling,arthritis joint joint swelling muscle spasmstwitchingtightnessweakness,1,0.8473769426345825
ULORIC,joint swelling,Tissue Disorders arthritis joint,0,0.8003177642822266
ULORIC,joint swelling,painstiffness myalgia Nervous,0,0.5898739099502563
ULORIC,muscle spasms,painstiffness myalgia Nervous System,0,0.681541383266449
ULORIC,muscle spasms,joint muscle spasms twitchingtightnessweakness musculoskeletal painstiffness myalgia,1,0.8717780709266663
ULORIC,muscle spasms,musculoskeletal painstiffness myalgia,0,0.6751000285148621
ULORIC,muscle spasms,muscle spasms twitchingtightnessweakness musculoskeletal painstiffness myalgia,1,0.8904500603675842
ULORIC,muscle spasms,stiffness joint muscle spasms,1,0.8964051008224487
ULORIC,musculoskeletal pain,musculoskeletal,1,0.8928014039993286
ULORIC,musculoskeletal pain,musculoskeletal pain stiffness myalgia,1,0.8821085691452026
ULORIC,myalgia,myalgia Nervous System Disorders,1,0.8437530994415283
ULORIC,myalgia,myalgia Nervous System Disorders altered taste,1,0.7386972308158875
ULORIC,myalgia,ffness joint,0,0.5848934054374695
ULORIC,altered taste,altered taste balance,1,0.9199948310852051
ULORIC,altered taste,musculoskeletal painstiffness myalgia Nervous System,0,0.45244550704956055
ULORIC,altered taste,altered taste,1,0.9999999403953552
ULORIC,altered taste,GuillainBarre,0,0.5035815238952637
ULORIC,altered taste,musculoskeletal,0,0.43724608421325684
ULORIC,balance disorder,headache hemiparesis,0,0.593593955039978
ULORIC,balance disorder,balance disorder cerebrovascular accident GuillainBarre syndrome,1,0.7611137628555298
ULORIC,balance disorder,syndrome headache hemiparesis,0,0.5959877967834473
ULORIC,balance disorder,Disorders altered balance disorder cerebrovascular accident GuillainBarre,1,0.7836493253707886
ULORIC,cerebrovascular accident,hypoesthesia hyposmia lacunar infarction,0,0.682296872138977
ULORIC,cerebrovascular accident,Nervous System Disorders altered,0,0.5770946741104126
ULORIC,cerebrovascular accident,altered taste balance cerebrovascular accident GuillainBarre syndrome headache,1,0.7350823283195496
ULORIC,cerebrovascular accident,Disorders altered taste balance cerebrovascular accident GuillainBarre syndrome,1,0.7098819613456726
ULORIC,Guillain-Barre syndrome,taste balance disorder cerebrovascular Guillain-Barre,1,0.7508821487426758
ULORIC,Guillain-Barre syndrome,altered taste balance disorder cerebrovascular accident,0,0.5674290657043457
ULORIC,Guillain-Barre syndrome,cerebrovascular Guillain-Barre syndrome headache hemiparesis hypoesthesia hyposmia lacunar,1,0.8047323226928711
ULORIC,Guillain-Barre syndrome,cerebrovascular Guillain-Barre syndrome,1,0.8538089990615845
ULORIC,Guillain-Barre syndrome,cerebrovascular,0,0.5354127883911133
ULORIC,Guillain-Barre syndrome,balance disorder cerebrovascular Guillain-Barre syndrome,1,0.80516517162323
ULORIC,Guillain-Barre syndrome,Guillain-Barre syndrome headache hemiparesis hypoesthesia hyposmia lacunar,1,0.8315428495407104
ULORIC,headache,headache hemiparesis hypoesthesia hyposmia,1,0.7715955376625061
ULORIC,headache,Disorders altered taste balance,0,0.5210404396057129
ULORIC,headache,headache,1,0.9999998807907104
ULORIC,headache,balance disorder cerebrovascular accident GuillainBarre,0,0.572755753993988
ULORIC,headache,hypoesthesia hyposmia lacunar infarction lethargy mental impairment migraine pa,0,0.6668500304222107
ULORIC,headache,cerebrovascular accident,0,0.6448606252670288
ULORIC,headache,infarction lethargy mental impairment migraine pa,0,0.6955912113189697
ULORIC,headache,headache hemiparesis hypoesthesia hyposmia lacunar,1,0.7632421255111694
ULORIC,headache,em Disorders altered taste balance disorder cerebrovascular,0,0.5741808414459229
ULORIC,hemiparesis,accident GuillainBarre,0,0.5698577761650085
ULORIC,hemiparesis,rs altered taste balance disorder cerebrovascular,0,0.6461769938468933
ULORIC,hemiparesis,lethargy mental impairment migraine,0,0.5800093412399292
ULORIC,hemiparesis,hemiparesis hypoesthesia,1,0.8663231134414673
ULORIC,hemiparesis,syndrome,0,0.5531148910522461
ULORIC,hemiparesis,headache,0,0.5846899151802063
ULORIC,hypoesthesia,taste balance disorder cerebrovascular accident GuillainBarre syndrome,0,0.5735524296760559
ULORIC,hyposmia,hemiparesis hyposmia lacunar,1,0.7608156204223633
ULORIC,hyposmia,taste balance disorder cerebrovascular accident GuillainBarre syndrome,0,0.6262147426605225
ULORIC,hyposmia,hyposmia lacunar,1,0.8321208357810974
ULORIC,hyposmia,paresthesia somnolence,0,0.6467024683952332
ULORIC,hyposmia,GuillainBarre syndrome headache hemiparesis hyposmia lacunar infarction lethargy,1,0.6305660009384155
ULORIC,hyposmia,hyposmia,1,1.0
ULORIC,hyposmia,hyposmia lacunar infarction lethargy mental impairment,1,0.7720954418182373
ULORIC,hyposmia,mental impairment migraine paresthesia somnolence transient,0,0.6389871835708618
ULORIC,lacunar infarction,hemiparesis hypoesthesia lacunar infarction,1,0.8776611685752869
ULORIC,lacunar infarction,headache hemiparesis hypoesthesia lacunar infarction,1,0.8260685801506042
ULORIC,lacunar infarction,syndrome headache hemiparesis hypoesthesia lacunar infarction lethargy mental,1,0.716951847076416
ULORIC,lacunar infarction,syndrome headache hemiparesis hypoesthesia lacunar infarction lethargy mental impairment migraine,1,0.7005396485328674
ULORIC,lacunar infarction,migraine paresthesia,0,0.546781599521637
ULORIC,lacunar infarction,impairment migraine paresthesia somnolence transient ischemic attack tremor,0,0.6470819711685181
ULORIC,lacunar infarction,syndrome headache hemiparesis hypoesthesia lacunar infarction,1,0.7759823799133301
ULORIC,lacunar infarction,hypoesthesia lacunar infarction,1,0.8849334716796875
ULORIC,lacunar infarction,headache hemiparesis,0,0.6358380317687988
ULORIC,lacunar infarction,lacunar infarction lethargy mental impairment migraine paresthesia,1,0.8467959761619568
ULORIC,lethargy,lethargy mental impairment,1,0.8864497542381287
ULORIC,lethargy,lethargy mental,1,0.9249813556671143
ULORIC,lethargy,GuillainBarre syndrome headache hemiparesis hypoesthesia hyposmia,0,0.575901210308075
ULORIC,lethargy,lethargy mental impairment migraine,1,0.7978188991546631
ULORIC,lethargy,headache hemiparesis hypoesthesia hyposmia lacunar,0,0.5991880893707275
ULORIC,mental impairment,hyposmia lacunar infarction mental impairment migraine paresthesia somnolence transient ischemic,1,0.5726161003112793
ULORIC,mental impairment,headache hemiparesis hypoesthesia hyposmia lacunar,0,0.5587713718414307
ULORIC,mental impairment,hemiparesis,0,0.5745800137519836
ULORIC,mental impairment,hypoesthesia hyposmia lacunar infarction mental impairment,1,0.725007951259613
ULORIC,mental impairment,lethargy,0,0.5930020809173584
ULORIC,mental impairment,hyposmia lacunar infarction,0,0.5181122422218323
ULORIC,mental impairment,hypoesthesia hyposmia lacunar infarction mental impairment migraine paresthesia somnolence transient ischemic,1,0.5771526098251343
ULORIC,mental impairment,mental impairment migraine paresthesia somnolence,1,0.7465388774871826
ULORIC,mental impairment,mental,1,0.8217368125915527
ULORIC,migraine,migraine,1,0.9999998807907104
ULORIC,migraine,mental,1,0.5518500804901123
ULORIC,migraine,impairment,0,0.5135399103164673
ULORIC,migraine,ischemic,0,0.5684569478034973
ULORIC,migraine,migraine paresthesia,1,0.8632365465164185
ULORIC,migraine,lethargy,0,0.5401785969734192
ULORIC,migraine,transient ischemic attack,0,0.6137282848358154
ULORIC,migraine,attack tremor,0,0.5934847593307495
ULORIC,migraine,migraine paresthesia somnolence transient,1,0.7989029884338379
ULORIC,paresthesia,infarction lethargy mental impairment paresthesia somnolence transient,1,0.6807836294174194
ULORIC,paresthesia,migraine paresthesia somnolence transient,1,0.7426642179489136
ULORIC,paresthesia,paresthesia,1,0.9999998807907104
ULORIC,paresthesia,transient,0,0.5670746564865112
ULORIC,paresthesia,lethargy mental impairment paresthesia somnolence transient ischemic attack tremor,1,0.6529947519302368
ULORIC,paresthesia,paresthesia somnolence,1,0.8318253755569458
ULORIC,transient ischemic attack,infarction lethargy mental,0,0.6682102680206299
ULORIC,transient ischemic attack,paresthesia,0,0.5227136015892029
ULORIC,transient ischemic attack,ischemic attack tremor,1,0.7713162302970886
ULORIC,transient ischemic attack,hyposmia lacunar infarction lethargy mental impairment migraine paresthesia,0,0.6405365467071533
ULORIC,transient ischemic attack,Disorders agitation,0,0.5467796921730042
ULORIC,tremor,ischemic tremor,1,0.8151453733444214
ULORIC,tremor,Disorders agitation,0,0.6202080249786377
ULORIC,tremor,insomnia irritability libido,0,0.5474828481674194
ULORIC,tremor,ischemic tremor Psychiatric,1,0.7722189426422119
ULORIC,tremor,tremor Psychiatric Disorders,1,0.8327067494392395
ULORIC,tremor,mental impairment migraine,0,0.509843111038208
ULORIC,tremor,impairment migraine paresthesia somnolence,0,0.5346947312355042
ULORIC,tremor,Disorders,0,0.6066813468933105
ULORIC,tremor,tremor Psychiatric Disorders agitation anxiety,1,0.8092756867408752
ULORIC,tremor,attack,0,0.5865007638931274
ULORIC,agitation,ischemic attack tremor Psychiatric agitation,1,0.7827754020690918
ULORIC,agitation,attack,0,0.6033426523208618
ULORIC,agitation,insomnia,0,0.5266743898391724
ULORIC,agitation,Psychiatric agitation,1,0.8951237201690674
ULORIC,agitation,agitation,1,1.0
ULORIC,agitation,irritability libido decreased nervousness panic attack,0,0.6645078659057617
ULORIC,agitation,anxiety depression,0,0.6135821342468262
ULORIC,agitation,tremor Psychiatric agitation anxiety depression,1,0.7709647417068481
ULORIC,agitation,anxiety depression insomnia irritability libido decreased,0,0.5884816646575928
ULORIC,agitation,attack tremor,0,0.6522326469421387
ULORIC,anxiety,attack tremor Psychiatric Disorders anxiety depression insomnia,1,0.6759397983551025
ULORIC,anxiety,attack tremor,0,0.5649042725563049
ULORIC,anxiety,tremor,0,0.5979763269424438
ULORIC,depression,depression,1,0.9999998807907104
ULORIC,depression,anxiety,0,0.7022079229354858
ULORIC,depression,panic attack personality,0,0.5390568375587463
ULORIC,insomnia,insomnia irritability libido decreased nervousness,1,0.7120954990386963
ULORIC,insomnia,Disorders agitation anxiety insomnia irritability libido decreased nervousness panic,1,0.642842173576355
ULORIC,irritability,personality change,0,0.6014942526817322
ULORIC,irritability,irritability libido decreased nervousness panic,1,0.7558738589286804
ULORIC,irritability,attack,0,0.5606166124343872
ULORIC,irritability,irritability,1,1.0000001192092896
ULORIC,irritability,attack tremor Psychiatric Disorders agitation anxiety depression,0,0.6392656564712524
ULORIC,irritability,Renal and Urinary Disorders,0,0.5246856808662415
ULORIC,libido decreased,insomnia libido decreased,1,0.9120457172393799
ULORIC,libido decreased,anxiety depression insomnia libido decreased,1,0.9087173342704773
ULORIC,libido decreased,libido decreased,1,1.0
ULORIC,libido decreased,depression insomnia,0,0.6155740022659302
ULORIC,libido decreased,depression insomnia libido decreased,1,0.9179699420928955
ULORIC,libido decreased,Disorders hematuria,0,0.5228873491287231
ULORIC,libido decreased,libido decreased nervousness panic attack,1,0.8116054534912109
ULORIC,nervousness,panic attack personality change Renal and Urinary,0,0.6732223033905029
ULORIC,nervousness,change Renal and Urinary,0,0.5060184597969055
ULORIC,nervousness,and,0,0.5123417377471924
ULORIC,nervousness,nervousness panic attack,1,0.8702512383460999
ULORIC,panic attack,nervousness,0,0.6870136260986328
ULORIC,panic attack,irritability libido decreased panic attack personality change Renal and,1,0.6701691150665283
ULORIC,panic attack,Disorders hematuria,0,0.4441133141517639
ULORIC,personality change,personality change Renal and Urinary Disorders hematuria,1,0.784719705581665
ULORIC,personality change,nervousness panic personality change Renal,1,0.7649244666099548
ULORIC,personality change,hematuria nephrolithiasis pollakiuria proteinuria,0,0.5042484402656555
ULORIC,personality change,Renal and Urinary Disorders hematuria,0,0.48678648471832275
ULORIC,personality change,decreased nervousness panic,0,0.6195312142372131
ULORIC,hematuria,Urinary hematuria nephrolithiasis pollakiuria proteinuria,1,0.8071461915969849
ULORIC,hematuria,decreased nervousness panic,0,0.4773104190826416
ULORIC,hematuria,hematuria nephrolithiasis,1,0.8718064427375793
ULORIC,hematuria,renal insufficiency,0,0.6186913251876831
ULORIC,hematuria,hematuria nephrolithiasis pollakiuria,1,0.8165442943572998
ULORIC,hematuria,hematuria nephrolithiasis pollakiuria proteinuria,1,0.7995330095291138
ULORIC,hematuria,hematuria,1,1.0
ULORIC,hematuria,pollakiuria proteinuria renal,0,0.6505104303359985
ULORIC,hematuria,pollakiuria,0,0.6085575222969055
ULORIC,nephrolithiasis,nephrolithiasis,1,1.0
ULORIC,nephrolithiasis,urgency,0,0.504934549331665
ULORIC,nephrolithiasis,and Urinary Disorders nephrolithiasis pollakiuria proteinuria renal,1,0.8248187303543091
ULORIC,nephrolithiasis,change Renal and Urinary,0,0.726021409034729
ULORIC,nephrolithiasis,urgency incontinence Reprodu,0,0.5732465982437134
ULORIC,nephrolithiasis,renal,0,0.7442145347595215
ULORIC,nephrolithiasis,nephrolithiasis pollakiuria proteinuria renal failure,1,0.8352124094963074
ULORIC,nephrolithiasis,panic attack,0,0.48360615968704224
ULORIC,pollakiuria,pollakiuria proteinuria renal failure,1,0.7911484241485596
ULORIC,pollakiuria,pollakiuria proteinuria,1,0.8263367414474487
ULORIC,pollakiuria,nephrolithiasis,0,0.5868470072746277
ULORIC,pollakiuria,Disorders,0,0.5150067210197449
ULORIC,pollakiuria,Urinary Disorders hematuria,0,0.5997216105461121
ULORIC,pollakiuria,Renal and Urinary,0,0.5888501405715942
ULORIC,proteinuria,Urinary Disorders,0,0.6965397596359253
ULORIC,proteinuria,nephrolithiasis proteinuria renal failure renal insufficiency,1,0.7875902652740479
ULORIC,proteinuria,pollakiuria,0,0.6020244359970093
ULORIC,proteinuria,Urinary Disorders hematuria nephrolithiasis proteinuria renal failure,1,0.7834914922714233
ULORIC,proteinuria,proteinuria renal failure renal insufficiency,1,0.861579179763794
ULORIC,proteinuria,renal insufficiency urgency incontinence Reproductive System and Breast Ch,0,0.6357718110084534
ULORIC,proteinuria,nephrolithiasis,0,0.6540536880493164
ULORIC,proteinuria,Renal and,0,0.6989358067512512
ULORIC,renal failure,renal failure renal insufficiency urgency incontinence Reproductive,1,0.8057177662849426
ULORIC,renal failure,renal,1,0.8547980785369873
ULORIC,renal failure,Renal and Urinary,0,0.7955842018127441
ULORIC,renal failure,pollakiuria renal failure,1,0.7945866584777832
ULORIC,renal failure,hematuria nephrolithiasis pollakiuria renal failure renal insufficiency,1,0.769675612449646
ULORIC,renal failure,Reproductive System and Breast,0,0.5172034502029419
ULORIC,renal failure,renal failure renal insufficiency,1,0.8953218460083008
ULORIC,renal failure,pollakiuria,0,0.5214872360229492
ULORIC,renal insufficiency,pollakiuria proteinuria renal failure,0,0.7214417457580566
ULORIC,renal insufficiency,pollakiuria proteinuria renal renal insufficiency urgency incontinence Reproductive System and,1,0.7628233432769775
ULORIC,renal insufficiency,renal insufficiency urgency incontinence Reproductive System and,1,0.8361651301383972
ULORIC,renal insufficiency,Renal and Urinary Disorders hematuria nephrolithiasis pollakiuria proteinuria renal failure,0,0.7159844040870667
ULORIC,renal insufficiency,breast pain erectile,0,0.5051605105400085
ULORIC,breast pain,and Breast breast,1,0.758431077003479
ULORIC,breast pain,and Breast Changes,0,0.6782527565956116
ULORIC,breast pain,Mediastinal Disorders bronc,0,0.4934018850326538
ULORIC,breast pain,System and Breast breast pain,1,0.9075733423233032
ULORIC,breast pain,dysfunction gynecomastia Respiratory Thoracic and,0,0.5786207914352417
ULORIC,breast pain,Breast breast pain,1,0.9919182062149048
ULORIC,breast pain,System and Breast breast,1,0.7309317588806152
ULORIC,breast pain,gynecomastia Respiratory Thoracic and Mediastinal Disorders,0,0.5659464001655579
ULORIC,breast pain,ailure renal insufficiency urgency incontinence Reproductive System and,0,0.49045658111572266
ULORIC,breast pain,Changes,0,0.44429048895835876
ULORIC,erectile dysfunction,Respiratory Thoracic and,0,0.43659740686416626
ULORIC,erectile dysfunction,Respiratory Thoracic and Mediastinal,0,0.43988603353500366
ULORIC,erectile dysfunction,Thoracic and Mediastinal Disorders bronchitis,0,0.4481094479560852
ULORIC,erectile dysfunction,breast erectile dysfunction gynecomastia,1,0.7712920904159546
ULORIC,erectile dysfunction,Changes breast erectile dysfunction,1,0.8179129958152771
ULORIC,erectile dysfunction,Thoracic and Mediastinal Disorders bronchitis cough,0,0.4402611255645752
ULORIC,erectile dysfunction,erectile dysfunction,1,0.9999998211860657
ULORIC,gynecomastia,dysfunction,0,0.5267975330352783
ULORIC,bronchitis,bronchitis cough dyspnea epistaxis,1,0.7974921464920044
ULORIC,bronchitis,Disorders,0,0.5645221471786499
ULORIC,bronchitis,Respiratory Thoracic and Mediastinal Disorders,0,0.6115133762359619
ULORIC,bronchitis,Mediastinal,0,0.5912686586380005
ULORIC,bronchitis,bronchitis cough,1,0.8921972513198853
ULORIC,bronchitis,bronchitis cough dyspnea epistaxis nasal dryness,1,0.7833524942398071
ULORIC,cough,cough dyspnea epistaxis nasal,1,0.7519378662109375
ULORIC,dyspnea,dyspnea epistaxis nasal dryness,1,0.7311255931854248
ULORIC,dyspnea,and Mediastinal Disorders bronchitis dyspnea epistaxis nasal dryness paranasal,1,0.6964101195335388
ULORIC,dyspnea,dyspnea epistaxis nasal dryness paranasal,1,0.741502046585083
ULORIC,dyspnea,dyspnea epistaxis nasal dryness paranasal sinus,1,0.7217704057693481
ULORIC,dyspnea,hypersecretion pharyngeal edema,0,0.6468522548675537
ULORIC,dyspnea,and Mediastinal Disorders bronchitis dyspnea epistaxis nasal dryness,1,0.7049248218536377
ULORIC,dyspnea,bronchitis cough,0,0.5504039525985718
ULORIC,epistaxis,pharyngeal edema respiratory tract congestion sne,0,0.5960673093795776
ULORIC,epistaxis,tract,0,0.5107336640357971
ULORIC,epistaxis,epistaxis,1,1.000000238418579
ULORIC,epistaxis,epistaxis nasal dryness paranasal sinus hypersecretion,1,0.7795813083648682
ULORIC,epistaxis,bronchitis cough epistaxis nasal dryness paranasal sinus,1,0.7145033478736877
ULORIC,epistaxis,epistaxis nasal dryness paranasal,1,0.8144571781158447
ULORIC,epistaxis,Mediastinal Disorders bronchitis cough epistaxis nasal dryness paranasal,1,0.6523096561431885
ULORIC,epistaxis,Disorders bronchitis cough epistaxis nasal dryness paranasal sinus hypersecretion,1,0.6775484085083008
ULORIC,nasal dryness,Disorders bronchitis cough dyspnea nasal dryness,1,0.771696925163269
ULORIC,paranasal sinus hypersecretion,paranasal sinus hypersecretion pharyngeal,1,0.9247715473175049
ULORIC,paranasal sinus hypersecretion,upper respiratory,0,0.6122049689292908
ULORIC,pharyngeal edema,nasal,0,0.5989475250244141
ULORIC,pharyngeal edema,paranasal sinus pharyngeal edema respiratory tract congestion sneezing,1,0.8082990646362305
ULORIC,respiratory tract congestion,paranasal sinus hypersecretion pharyngeal respiratory tract congestion sneezing,1,0.7848184108734131
ULORIC,respiratory tract congestion,nasal,0,0.6574999094009399
ULORIC,respiratory tract congestion,pharyngeal respiratory tract congestion sneezing throat irritation upper respiratory,1,0.8481354117393494
ULORIC,sneezing,pharyngeal edema respiratory tract sneezing throat,1,0.7788260579109192
ULORIC,sneezing,nasal,0,0.7150155901908875
ULORIC,sneezing,respiratory tract sneezing throat irritation upper respiratory tract,1,0.7652997970581055
ULORIC,sneezing,sneezing throat irritation upper respiratory,1,0.7921295166015625
ULORIC,sneezing,hypersecretion pharyngeal edema,0,0.6069846153259277
ULORIC,sneezing,sneezing throat irritation,1,0.8132796883583069
ULORIC,sneezing,sneezing throat irritation upper respiratory tract,1,0.7896654605865479
ULORIC,sneezing,sneezing throat,1,0.8688833713531494
ULORIC,sneezing,irritation upper respiratory tract infection Skin and Subcutaneous,0,0.633769154548645
ULORIC,sneezing,congestion,0,0.5950006246566772
ULORIC,throat irritation,Tissue Disorders,0,0.5047013759613037
ULORIC,throat irritation,congestion throat irritation upper respiratory tract,1,0.8331692218780518
ULORIC,upper respiratory tract infection,tract infection Skin and Subcutaneous Tissue Disorders,1,0.6225089430809021
ULORIC,upper respiratory tract infection,throat,0,0.6773558855056763
ULORIC,alopecia,alopecia,1,1.0
ULORIC,alopecia,alopecia angioedema dermatitis dermographism ecchymosis eczema,1,0.7628346681594849
ULORIC,alopecia,eczema hair,0,0.7686663866043091
ULORIC,alopecia,tract infection Skin and Subcutaneous,0,0.5404795408248901
ULORIC,alopecia,alopecia angioedema dermatitis dermographism ecchymosis,1,0.7663142085075378
ULORIC,alopecia,changes hair growth,0,0.7490694522857666
ULORIC,angio-edema,angio-edema dermatitis dermographism,1,0.8228926658630371
ULORIC,angio-edema,color changes hair growth abnormal,0,0.5252153277397156
ULORIC,angio-edema,angio-edema dermatitis dermographism ecchymosis eczema hair,1,0.8167128562927246
ULORIC,angio-edema,and Subcutaneous,0,0.5946964025497437
ULORIC,angio-edema,Skin and,0,0.5835548639297485
ULORIC,angio-edema,alopecia,0,0.580410361289978
ULORIC,angio-edema,Disorders,0,0.5848202705383301
ULORIC,dermatitis,abnormal hyperhidrosis,0,0.5939546823501587
ULORIC,dermatitis,Tissue Disorders alopecia dermatitis dermographism ecchymosis eczema hair color,1,0.7021222114562988
ULORIC,dermatitis,dermatitis dermographism ecchymosis eczema hair color,1,0.805246889591217
ULORIC,dermatitis,changes hair growth,0,0.5284879207611084
ULORIC,dermatitis,ecchymosis eczema,0,0.7094452977180481
ULORIC,dermatitis,hair growth abnormal,0,0.5413740277290344
ULORIC,dermatitis,dermatitis,1,1.000000238418579
ULORIC,dermatitis,dermatitis dermographism ecchymosis,1,0.7773901224136353
ULORIC,dermographism,dermographism ecchymosis eczema hair color,1,0.8308300971984863
ULORIC,dermographism,dermatitis,1,0.654848575592041
ULORIC,dermographism,dermographism ecchymosis,1,0.8827686905860901
ULORIC,dermographism,dermographism ecchymosis eczema,1,0.8894548416137695
ULORIC,dermographism,angioedema dermographism,1,0.8276045322418213
ULORIC,dermographism,eczema,0,0.5726422667503357
ULORIC,ecchymosis,ecchymosis eczema,1,0.8608468770980835
ULORIC,eczema,dermatitis dermographism eczema hair color changes hair growth,1,0.7332623600959778
ULORIC,eczema,ecchymosis eczema,1,0.8714038133621216
ULORIC,eczema,angioedema dermatitis dermographism eczema hair,1,0.7986745238304138
ULORIC,eczema,eczema hair color changes hair growth,1,0.8092831373214722
ULORIC,eczema,eczema hair,1,0.8900952935218811
ULORIC,eczema,eczema hair color changes,1,0.839513897895813
ULORIC,eczema,growth abnormal,0,0.5467240810394287
ULORIC,eczema,changes hair growth abnormal hyperhidrosis peeling,0,0.6326313614845276
ULORIC,eczema,Disorders alopecia angioedema dermatitis,0,0.7352066040039062
ULORIC,eczema,eczema,1,1.0000001192092896
ULORIC,hair color changes,ecchymosis hair color changes,1,0.8298636674880981
ULORIC,hair color changes,eczema,1,0.5664529204368591
ULORIC,hair color changes,skin petechiae,0,0.6068730354309082
ULORIC,hair color changes,photosensitivity,0,0.6072855591773987
ULORIC,hair color changes,hair color,1,0.9011573195457458
ULORIC,hair color changes,growth abnormal hyperhidrosis peeling skin,0,0.527414083480835
ULORIC,hair color changes,dermatitis dermographism ecchymosis,0,0.5348890423774719
ULORIC,hair color changes,hair color changes hair growth,1,0.8966202735900879
ULORIC,hair color changes,cutaneous,0,0.567705512046814
ULORIC,hyperhidrosis,hyperhidrosis peeling skin petechiae,1,0.8406243324279785
ULORIC,hyperhidrosis,hyperhidrosis peeling skin petechiae photosensitivity,1,0.7905291318893433
ULORIC,hyperhidrosis,pruritus purpura skin discolorationaltered pigmen,0,0.5925345420837402
ULORIC,hyperhidrosis,hyperhidrosis peeling,1,0.8717018365859985
ULORIC,hyperhidrosis,hyperhidrosis peeling skin,1,0.8633677959442139
ULORIC,peeling skin,peeling skin petechiae photosensitivity pruritus,1,0.7936389446258545
ULORIC,peeling skin,peeling skin petechiae photosensitivity,1,0.8004568815231323
ULORIC,peeling skin,discolorationaltered pigmentation skin,0,0.6728869676589966
ULORIC,peeling skin,peeling,1,0.9175536632537842
ULORIC,petechiae,petechiae photosensitivity,1,0.8448752760887146
ULORIC,petechiae,hism ecchymosis eczema hair color changes hair,0,0.6340667009353638
ULORIC,petechiae,pigmentation,0,0.6717689037322998
ULORIC,petechiae,hyperhidrosis peeling skin,0,0.6070561408996582
ULORIC,petechiae,purpura skin discolorationaltered pigmentation skin,0,0.6612340211868286
ULORIC,petechiae,growth abnormal hyperhidrosis peeling petechiae photosensitivity pruritus,1,0.7161075472831726
ULORIC,petechiae,photosensitivity,0,0.5943307876586914
ULORIC,petechiae,abnormal hyperhidrosis peeling petechiae photosensitivity pruritus purpura skin discolorationaltered,1,0.7089234590530396
ULORIC,pruritus,skin petechiae pruritus purpura,1,0.8100457191467285
ULORIC,pruritus,photosensitivity,0,0.6055101156234741
ULORIC,pruritus,pruritus purpura skin discolorationaltered pigmentation skin,1,0.8128453493118286
ULORIC,pruritus,petechiae pruritus,1,0.8717474937438965
ULORIC,purpura,purpura,1,1.0
ULORIC,skin discoloration,petechiae photosensitivity pruritus skin,1,0.6709389686584473
ULORIC,skin discoloration,skin discoloration altered,1,0.924648642539978
ULORIC,skin discoloration,skin discoloration altered pigmentation skin lesion,1,0.8831443786621094
ULORIC,skin lesion,pigmentation,0,0.6767852306365967
ULORIC,skin lesion,discolorationaltered skin,1,0.7272728681564331
ULORIC,skin lesion,flush hypertension,0,0.4952356517314911
ULORIC,skin odor abnormal,skin odor abnormal urticaria,1,0.8782939910888672
ULORIC,skin odor abnormal,discolorationaltered pigmentation skin skin odor abnormal urticaria Vascular Disorders,1,0.8199361562728882
ULORIC,skin odor abnormal,pigmentation skin skin odor abnormal,1,0.9043475389480591
ULORIC,skin odor abnormal,skin lesion,0,0.6410877704620361
ULORIC,skin odor abnormal,flush hypertension hypotension Labor,0,0.4979049861431122
ULORIC,skin odor abnormal,urticaria Vascular Disorders flushing,0,0.6139178276062012
ULORIC,skin odor abnormal,purpura skin discolorationaltered pigmentation skin,0,0.6325421333312988
ULORIC,skin odor abnormal,discolorationaltered,0,0.5873663425445557
ULORIC,skin odor abnormal,pruritus purpura skin discolorationaltered pigmentation skin,0,0.6848825812339783
ULORIC,urticaria,skin lesion skin odor urticaria Vascular Disorders flushing hot,1,0.7188786864280701
ULORIC,urticaria,pruritus purpura skin discolorationaltered pigmentation skin,0,0.6766616106033325
ULORIC,urticaria,odor urticaria Vascular Disorders flushing,1,0.7645090222358704
ULORIC,hot flush,urticaria Vascular Disorders hot flush,1,0.8091646432876587
ULORIC,hot flush,urticaria Vascular Disorders,0,0.5679852962493896
ULORIC,hot flush,Disorders hot,1,0.7119401693344116
ULORIC,hot flush,Disorders hot flush,1,0.9022501111030579
ULORIC,hot flush,Parameters activated partial thromboplastin time pro,0,0.5432792901992798
ULORIC,hot flush,abnormal urticaria Vascular Disorders hot flush hypertension hypotension Laboratory Parameters,1,0.7288384437561035
ULORIC,hot flush,hot flush hypertension,1,0.9149208068847656
ULORIC,hypertension,flushing,0,0.6818193197250366
ULORIC,hypertension,hypertension hypotension Laboratory Parameters activated partial,1,0.7430909872055054
ULORIC,hypertension,hypertension hypotension Laboratory Parameters,1,0.7600487470626831
ULORIC,hypertension,hypertension hypotension Laboratory Parameters activated,1,0.7455242872238159
ULORIC,hypertension,hot flush,0,0.7014439105987549
ULORIC,hypertension,hypertension hypotension Laboratory,1,0.7784106731414795
ULORIC,hypotension,time prolonged creatine increased,0,0.5116453170776367
ULORIC,hypotension,prolonged,0,0.5251582860946655
ULORIC,hypotension,hypotension Laboratory Parameters activated partial thromboplastin,1,0.7413529753684998
ULORIC,hypotension,hypotension,1,1.0
ULORIC,hypotension,Parameters activated,0,0.5028491616249084
ULORIC,hypotension,hypotension Laboratory Parameters activated,1,0.8096963167190552
ULORIC,activated partial thromboplastin time prolonged,Parameters,0,0.5073049068450928
ULORIC,activated partial thromboplastin time prolonged,flushing hot flush hypertension hypotension Laboratory,0,0.5491646528244019
ULORIC,activated partial thromboplastin time prolonged,Laboratory,0,0.5245606899261475
ULORIC,activated partial thromboplastin time prolonged,activated partial thromboplastin time prolonged creatine increased bicarbonate,1,0.8456376791000366
ULORIC,activated partial thromboplastin time prolonged,partial thromboplastin time prolonged creatine increased bicarbonate decreased,1,0.830062210559845
ULORIC,activated partial thromboplastin time prolonged,activated partial thromboplastin time prolonged creatine increased,1,0.8941962718963623
ULORIC,activated partial thromboplastin time prolonged,Laboratory activated partial thromboplastin time,1,0.9107047319412231
ULORIC,activated partial thromboplastin time prolonged,hypertension hypotension Laboratory activated partial thromboplastin time prolonged creatine increased bicarbonate decreased,1,0.7941756248474121
ULORIC,activated partial thromboplastin time prolonged,increased bicarbonate decreased,0,0.5174750089645386
ULORIC,creatine increased,decreased sodium increased EEG abnormal glucose,0,0.5360426306724548
ULORIC,bicarbonate decreased,glucose increased cholesterol increased triglycerides increased,0,0.5080647468566895
ULORIC,bicarbonate decreased,cholesterol increased triglycerides,0,0.5062087178230286
ULORIC,bicarbonate decreased,creatine,0,0.5569572448730469
ULORIC,bicarbonate decreased,time prolonged creatine bicarbonate decreased,1,0.8149446249008179
ULORIC,bicarbonate decreased,time prolonged creatine bicarbonate,1,0.7135394811630249
ULORIC,bicarbonate decreased,cholesterol increased triglycerides increased,0,0.5100434422492981
ULORIC,sodium increased,creatine increased bicarbonate sodium increased,1,0.780177891254425
ULORIC,sodium increased,cholesterol increased triglycerides increased,0,0.6687970161437988
ULORIC,EEG abnormal,EEG abnormal,1,1.0000001192092896
ULORIC,EEG abnormal,increased bicarbonate decreased sodium EEG abnormal,1,0.7776135206222534
ULORIC,EEG abnormal,partial thromboplastin,0,0.41854748129844666
ULORIC,EEG abnormal,EEG abnormal glucose increased,1,0.8439278602600098
ULORIC,EEG abnormal,EEG abnormal glucose increased cholesterol,1,0.8130507469177246
ULORIC,EEG abnormal,bicarbonate,0,0.47485411167144775
ULORIC,glucose increased,sodium increased EEG glucose increased cholesterol increased triglycerides increased,1,0.7709344625473022
ULORIC,glucose increased,bicarbonate,0,0.525935173034668
ULORIC,glucose increased,glucose increased cholesterol,1,0.8549407720565796
ULORIC,glucose increased,glucose increased cholesterol increased,1,0.883393406867981
ULORIC,glucose increased,increased amylase increased potassium increased,0,0.7854574918746948
ULORIC,cholesterol increased,cholesterol increased,1,0.9999997615814209
ULORIC,cholesterol increased,cholesterol,1,0.8552542924880981
ULORIC,cholesterol increased,EEG abnormal glucose cholesterol increased,1,0.7460083961486816
ULORIC,cholesterol increased,EEG abnormal glucose cholesterol increased triglycerides increased amylase,1,0.6770966053009033
ULORIC,cholesterol increased,abnormal glucose cholesterol increased,1,0.8623670935630798
ULORIC,cholesterol increased,sodium increased EEG abnormal,0,0.5560265183448792
ULORIC,cholesterol increased,cholesterol increased triglycerides increased amylase increased,1,0.8458921909332275
ULORIC,cholesterol increased,increased EEG abnormal glucose cholesterol increased triglycerides increased amylase increased,1,0.7294252514839172
ULORIC,cholesterol increased,increased platelet,0,0.6913687586784363
ULORIC,triglycerides increased,bicarbonate decreased sodium increased EEG abnormal glucose increased cholesterol increased,0,0.6507436037063599
ULORIC,triglycerides increased,platelet count decreased hematocrit decrea,0,0.5131993293762207
ULORIC,triglycerides increased,triglycerides increased amylase increased,1,0.8779309988021851
ULORIC,amylase increased,increased triglycerides increased,0,0.7154721021652222
ULORIC,amylase increased,amylase,1,0.885936975479126
ULORIC,amylase increased,amylase increased potassium increased,1,0.8901407718658447
ULORIC,amylase increased,increased cholesterol increased,0,0.7315446138381958
ULORIC,amylase increased,triglycerides amylase increased,1,0.8853342533111572
ULORIC,amylase increased,EEG abnormal glucose increased cholesterol increased triglycerides increased,0,0.6564227342605591
ULORIC,amylase increased,increased platelet count decreased hematocrit decreased,0,0.5876821279525757
ULORIC,potassium increased,potassium,1,0.8531337976455688
ULORIC,potassium increased,increased triglycerides increased amylase potassium,1,0.7436281442642212
ULORIC,potassium increased,potassium increased TSH increased,1,0.8722838759422302
ULORIC,potassium increased,amylase potassium increased,1,0.8357948064804077
ULORIC,potassium increased,amylase potassium increased TSH increased,1,0.7448292970657349
ULORIC,potassium increased,EEG abnormal glucose increased cholesterol increased triglycerides,0,0.5797147750854492
ULORIC,platelet count decreased,increased TSH platelet count,1,0.733095645904541
ULORIC,hematocrit decreased,hematocrit decreased hemoglobin decreased MCV,1,0.8842481970787048
ULORIC,hematocrit decreased,hemoglobin decreased MCV increased RBC decreased creatinine increased blood urea increased,0,0.7725135087966919
ULORIC,hematocrit decreased,increased platelet count hematocrit,1,0.8110126256942749
ULORIC,hematocrit decreased,platelet count hematocrit,1,0.8334363698959351
ULORIC,hematocrit decreased,blood urea increased BU,0,0.6042357683181763
ULORIC,hematocrit decreased,count hematocrit decreased hemoglobin decreased MCV,1,0.8816477060317993
ULORIC,hematocrit decreased,hematocrit decreased hemoglobin decreased,1,0.9323553442955017
ULORIC,hemoglobin decreased,hematocrit hemoglobin,1,0.7546722292900085
ULORIC,hemoglobin decreased,increased,0,0.51612788438797
ULORIC,hemoglobin decreased,increased BUNcreatinine,0,0.5374924540519714
ULORIC,hemoglobin decreased,hemoglobin decreased,1,0.9999999403953552
ULORIC,hemoglobin decreased,hemoglobin decreased MCV increased RBC decreased,1,0.87980055809021
ULORIC,MCV increased,MCV increased RBC decreased creatinine increased,1,0.8324305415153503
ULORIC,MCV increased,MCV increased RBC decreased creatinine,1,0.8025335669517517
ULORIC,MCV increased,MCV increased,1,0.9999999403953552
ULORIC,MCV increased,hemoglobin MCV increased RBC decreased creatinine increased,1,0.8021441698074341
ULORIC,MCV increased,increased blood,0,0.7655013203620911
ULORIC,RBC decreased,decreased,0,0.773273229598999
ULORIC,creatinine increased,MCV increased RBC creatinine increased blood urea increased,1,0.7785971164703369
ULORIC,creatinine increased,decreased,0,0.49269574880599976
ULORIC,creatinine increased,creatinine increased blood urea increased,1,0.8982295989990234
ULORIC,blood urea increased,decreased creatinine,0,0.6110703945159912
ULORIC,blood urea increased,blood urea increased BUNcreatinine ratio increased,1,0.8705949187278748
ULORIC,blood urea increased,decreased,0,0.5062499046325684
ULORIC,blood urea increased,increased,0,0.7131444811820984
ULORIC,BUN/creatinine ratio increased,hemoglobin decreased MCV increased,0,0.6523582935333252
ULORIC,BUN/creatinine ratio increased,hemoglobin decreased MCV increased RBC decreased creatinine,0,0.7120610475540161
ULORIC,BUN/creatinine ratio increased,hemoglobin decreased MCV increased RBC decreased creatinine increased,0,0.7242157459259033
ULORIC,BUN/creatinine ratio increased,creatinine increased blood urea BUN/creatinine ratio,1,0.9362984895706177
ULORIC,BUN/creatinine ratio increased,BUN/creatinine ratio increased,1,1.000000238418579
ULORIC,BUN/creatinine ratio increased,phosphokinase CPK,0,0.5438129901885986
ULORIC,alkaline phosphatase increased,increased creatine phosphokinase CPK alkaline phosphatase increased LDH increased,1,0.8313788175582886
ULORIC,alkaline phosphatase increased,phosphokinase CPK,0,0.5876448154449463
ULORIC,alkaline phosphatase increased,increased urine,0,0.6880691647529602
ULORIC,urine output increased,decreased lymphocyte count,0,0.49794524908065796
ULORIC,urine output increased,eatine phosphokinase CPK increased alkaline phosphatase increased,0,0.6199910640716553
ULORIC,urine output increased,decreased WBC increaseddecreased coagula,0,0.5829226970672607
ULORIC,urine output increased,increased PSA urine output increased decreased lymphocyte count,1,0.7534801363945007
ULORIC,urine output increased,PSA increased,0,0.6756843328475952
ULORIC,urine output increased,urine output increased decreased lymphocyte count decreased neutrophil,1,0.7968701124191284
ULORIC,urine output increased,urine output increased decreased lymphocyte,1,0.8030405044555664
ULORIC,urine output increased,increased PSA urine output,1,0.8755724430084229
ULORIC,lymphocyte count decreased,increased LDH increased,0,0.5756320953369141
ULORIC,lymphocyte count decreased,neutrophil count decreased WBC increaseddecreased,0,0.7899172306060791
ULORIC,lymphocyte count decreased,ed alkaline phosphatase increased LDH increased PSA increased urine output increaseddecreased,0,0.5468075275421143
ULORIC,lymphocyte count decreased,abnormal low,0,0.6270760893821716
ULORIC,lymphocyte count decreased,lymphocyte count decreased,1,1.0
ULORIC,lymphocyte count decreased,urine output lymphocyte count decreased neutrophil count decreased WBC,1,0.8369939923286438
ULORIC,WBC increased,WBC increased,1,0.9999998807907104
ULORIC,WBC increased,test abnormal low density lipoprotein LDL,0,0.5292338728904724
ULORIC,WBC increased,WBC increased decreased coagulation test abnormal,1,0.74019455909729
ULORIC,WBC increased,output increaseddecreased lymphocyte count decreased,0,0.7653480768203735
ULORIC,WBC increased,decreased neutrophil count WBC,1,0.7626044750213623
ULORIC,WBC increased,count decreased neutrophil count WBC increased,1,0.8464186191558838
ULORIC,WBC increased,WBC increased decreased,1,0.9034571647644043
ULORIC,coagulation test abnormal,creaseddecreased lymphocyte,0,0.5078578591346741
ULORIC,coagulation test abnormal,density lipoprotein LDL increased prothrombin time prolonged urinary casts urine positive,0,0.6770813465118408
ULORIC,coagulation test abnormal,prothrombin time prolonged urinary casts urine positive,0,0.7092829942703247
ULORIC,coagulation test abnormal,decreased WBC coagulation test abnormal low density lipoprotein,1,0.7800878286361694
ULORIC,coagulation test abnormal,test abnormal low density lipoprotein,1,0.6813379526138306
ULORIC,prothrombin time prolonged,prothrombin time prolonged urinary casts urine positive for,1,0.8359291553497314
ULORIC,urine positive for white blood cells,test abnormal low density lipoprotein LDL increased prothrombin time prolonged urinary casts,0,0.6525790691375732
ULORIC,Cardiovascular events,Cardiovascular,1,0.8389431238174438
ULORIC,Cardiovascular events,were adjudicated to one of the predefined endpoints from the AntiPlatelet Trialists,0,0.6227554678916931
ULORIC,Cardiovascular events,protein Cardiovascular Cardiovascular events,1,0.8485617637634277
ULORIC,Cardiovascular events,the predefined endpoints from the AntiPlatelet Trialists,0,0.6284343004226685
ULORIC,cardiovascular death,cardiovascular death nonfatal myocardial infarction and,1,0.8424299359321594
ULORIC,cardiovascular death,Trialists Collaborations cardiovascular death,1,0.8212769031524658
ULORIC,cardiovascular death,from the AntiPlatelet Trialists Collaborations APTC,0,0.5499184131622314
ULORIC,cardiovascular death,myocardial infarction,0,0.693625807762146
ULORIC,cardiovascular death,cardiovascular death,1,0.9999998807907104
ULORIC,cardiovascular death,Trialists Collaborations APTC,0,0.4751547873020172
ULORIC,cardiovascular death,to one,0,0.5026830434799194
ULORIC,myocardial infarction,APTC cardiovascular death myocardial infarction,1,0.7839505672454834
ULORIC,myocardial infarction,and,0,0.5323652029037476
ULORIC,myocardial infarction,cardiovascular death myocardial infarction and,1,0.8192912340164185
ULORIC,myocardial infarction,myocardial infarction and nonfatal stroke in,1,0.7849964499473572
ULORIC,myocardial infarction,myocardial infarction and nonfatal stroke,1,0.7831695675849915
ULORIC,myocardial infarction,myocardial infarction and nonfatal stroke in the,1,0.7873954772949219
ULORIC,myocardial infarction,myocardial infarction and,1,0.9392371773719788
ULORIC,myocardial infarction,longterm extension studies,0,0.4760478436946869
ULORIC,myocardial infarction,studies In,0,0.5271227955818176
ULORIC,stroke,and,0,0.5547710657119751
ULORIC,stroke,stroke in the randomized controlled and,1,0.7909014225006104
ULORIC,stroke,randomized controlled and,0,0.5180262327194214
ULORIC,stroke,stroke in the,1,0.9402909278869629
ULORIC,stroke,alists Collaborations APTC cardiovascular death,0,0.5950342416763306
ULORIC,stroke,stroke,1,1.0
ULORIC,stroke,myocardial infarction and stroke in the,1,0.7969610691070557
ULORIC,hepatic failure,hepatic failure some fatal jaundice serious cases,1,0.8511137962341309
ULORIC,hepatic failure,function test results liver disorder,0,0.6899263858795166
ULORIC,hepatic failure,causal relationship Hepatobiliary hepatic failure some fatal jaundice serious cases,1,0.8015905618667603
ULORIC,hepatic failure,liably estimate their frequency or establish,0,0.4441390633583069
ULORIC,hepatic failure,frequency or establish a causal relationship Hepatobiliary Disorders,0,0.6825264692306519
ULORIC,hepatic failure,results liver,0,0.7335840463638306
ULORIC,hepatic failure,hepatic failure,1,0.9999999403953552
ULORIC,fatal,fatal jaundice serious cases of abnormal,1,0.6999882459640503
ULORIC,fatal,fatal,1,1.0000001192092896
ULORIC,fatal,disorder,0,0.5903191566467285
ULORIC,fatal,Hepatobiliary Disorders hepatic failure fatal jaundice serious cases of abnormal,1,0.6396833658218384
ULORIC,fatal,fatal jaundice serious cases,1,0.7056808471679688
ULORIC,jaundice,jaundice serious cases of abnormal,1,0.8367122411727905
ULORIC,jaundice,jaundice serious cases of,1,0.8592705726623535
ULORIC,jaundice,jaundice serious,1,0.8897932767868042
ULORIC,jaundice,jaundice,1,1.0
ULORIC,abnormal liver function,fatal,0,0.5484862327575684
ULORIC,liver disorder,function test liver,1,0.7714852094650269
ULORIC,liver disorder,results,0,0.5250550508499146
ULORIC,liver disorder,System Disorders anaphylaxis,0,0.5758794546127319
ULORIC,liver disorder,liver disorder Immune System Disorders anaphylaxis anaphylactic,1,0.783327043056488
ULORIC,liver disorder,anaphylactic reaction Musculoskeletal and Conn,0,0.49410009384155273
ULORIC,liver disorder,test liver disorder Immune,1,0.7995632886886597
ULORIC,anaphylaxis,Musculoskeletal and Connective Tissue Disorders,0,0.46681028604507446
ULORIC,anaphylaxis,reaction Musculoskeletal and Connective Tissue Disorders,0,0.5302104949951172
ULORIC,anaphylaxis,Tissue Disorders,0,0.5030652284622192
ULORIC,anaphylactic reaction,Immune System Disorders anaphylactic reaction Musculoskeletal and Connective,1,0.7761242389678955
ULORIC,anaphylactic reaction,Tissue Disorders,0,0.49996471405029297
ULORIC,anaphylactic reaction,Disorders anaphylactic reaction Musculoskeletal,1,0.8218121528625488
ULORIC,anaphylactic reaction,disorder Immune,0,0.560882568359375
ULORIC,anaphylactic reaction,results liver disorder Immune System Disorders anaphylaxis,0,0.7495101690292358
ULORIC,anaphylactic reaction,rhabdomyolysis,0,0.5626180171966553
ULORIC,rhabdomyolysis,Musculoskeletal and Connective Tissue rhabdomyolysis Psychiatric Disorders psychotic behavior,1,0.7411577701568604
ULORIC,rhabdomyolysis,rhabdomyolysis,0,0.9999999403953552
ULORIC,rhabdomyolysis,Connective Tissue rhabdomyolysis Psychiatric,1,0.7841125726699829
ULORIC,rhabdomyolysis,rhabdomyolysis Psychiatric Disorders psychotic behavior,1,0.7619761228561401
ULORIC,rhabdomyolysis,rhabdomyolysis Psychiatric Disorders,1,0.8003108501434326
ULORIC,rhabdomyolysis,rhabdomyolysis,1,0.9999999403953552
ULORIC,rhabdomyolysis,Connective Tissue Disorders,0,0.5816076993942261
ULORIC,rhabdomyolysis,rhabdomyolysis Psychiatric Disorders psychotic,1,0.7769862413406372
ULORIC,psychotic behavior,Tissue Disorders rhabdomyolysis Psychiatric psychotic behavior,1,0.7476966381072998
ULORIC,psychotic behavior,psychotic behavior,1,0.9999999403953552
ULORIC,psychotic behavior,rhabdomyolysis Psychiatric psychotic behavior including aggressive thoughts Renal and,1,0.7437272071838379
ULORIC,psychotic behavior,psychotic,1,0.884156346321106
ULORIC,psychotic behavior,Tissue Disorders rhabdomyolysis Psychiatric psychotic,1,0.6654710173606873
ULORIC,psychotic behavior,rhabdomyolysis Psychiatric,0,0.6006327867507935
ULORIC,psychotic behavior,aggressive thoughts Renal and Urinary,0,0.6254541873931885
ULORIC,psychotic behavior,Tissue Disorders rhabdomyolysis Psychiatric psychotic behavior including aggressive thoughts,1,0.7547199130058289
ULORIC,psychotic behavior,Renal and,0,0.4786815941333771
ULORIC,tubulointerstitial nephritis,tubulointerstitial nephritis Skin and Subcutaneous Tissue,1,0.9072186350822449
ULORIC,tubulointerstitial nephritis,Renal and Urinary,0,0.7474086284637451
ULORIC,tubulointerstitial nephritis,tubulointerstitial nephritis,1,1.0
ULORIC,tubulointerstitial nephritis,tubulointerstitial nephritis Skin and Subcutaneous,1,0.9186190366744995
ULORIC,tubulointerstitial nephritis,tubulointerstitial nephritis Skin and,1,0.9468799829483032
ULORIC,tubulointerstitial nephritis,Renal and Urinary tubulointerstitial nephritis,1,0.9683087468147278
ULORIC,tubulointerstitial nephritis,Johnson,0,0.4914093613624573
ULORIC,tubulointerstitial nephritis,Urinary tubulointerstitial nephritis Skin and Subcutaneous Tissue Disorders,1,0.8801465630531311
ULORIC,tubulointerstitial nephritis,Disorders psychotic behavior including aggressive thoughts Renal and Urinary Disorders,0,0.631442666053772
ULORIC,tubulointerstitial nephritis,Subcutaneous Tissue Disorders generalized rash Stevens Johnson,0,0.6027933359146118
ULORIC,generalized rash,generalized rash Stevens Johnson Syndrome hypersensitivity skin,1,0.8375884294509888
ULORIC,generalized rash,Stevens,0,0.5208753943443298
ULORIC,generalized rash,Skin and Subcutaneous Tissue generalized rash Stevens Johnson,1,0.847531259059906
ULORIC,generalized rash,generalized rash Stevens Johnson Syndrome hypersensitivity,1,0.8434196710586548
ULORIC,generalized rash,Skin and Subcutaneous Tissue generalized,1,0.7759572863578796
ULORIC,generalized rash,generalized rash Stevens,1,0.8575882911682129
ULORIC,generalized rash,Skin and Subcutaneous Tissue generalized rash Stevens Johnson Syndrome hypersensitivity skin,1,0.8079743385314941
ULORIC,Stevens Johnson Syndrome,hypersensitivity skin,0,0.6283475160598755
ULORIC,Stevens Johnson Syndrome,hypersensitivity,0,0.6584352254867554
ULORIC,Stevens Johnson Syndrome,and Subcutaneous Tissue,0,0.582505464553833
ULORIC,Gout Flare,Adverse  occurring in at least of ULORICtreated,1,0.609109103679657
ULORIC,Gout Flare,and Subcutaneous Tissue,0,0.5247887969017029
ULORIC,Gout Flare, occurring in at least of,1,0.5083671808242798
ULORIC,Gout Flare,EXCERPT Adverse  occurring in at least of,1,0.5375809073448181
ULORIC,Gout Flare, occurring in at least,1,0.49609842896461487
ULORIC,Gout Flare,are liver,0,0.48198211193084717
ULORIC,Gout Flare,least greater than placebo are liver,0,0.5254231691360474
ULORIC,Gout Flare,of ULORICtreated patients and at,0,0.5889372825622559
ULORIC,Gout Flare, occurring in at,1,0.542058527469635
ULORIC,Gout Flare,ADVERSE REACTIONS EXCERPT Adverse  occurring in at least of,1,0.5485888719558716
ULORIC,gout flares, ULORIC-tre,1,0.5476088523864746
ULORIC,gout flares, ULORIC-tre ated patients,1,0.6151661276817322
ULORIC,gout flares,least  ULORIC-tre,1,0.47008174657821655
ULORIC,gout flares, ULORIC-tre ated patients and at least,1,0.6107478141784668
ULORIC,Cardiovascular Events,wwwfdagovmedwatch Clinical Trials Experience ause clinical trials  are,1,0.6348966360092163
ULORIC,Cardiovascular Events, ULORIC-tre ated patients and at least,1,0.5934532880783081
ULORIC,Cardiovascular Events,ause clinical,1,0.5636518597602844
ULORIC,Cardiovascular Events,Clinical Trials Experience ause clinical,1,0.6247043609619141
ULORIC,Cardiovascular Events,Clinical Trials Experience ause clinical trials,1,0.6390355229377747
ULORIC,Cardiovascular Events,wwwfdagovmedwatch Clinical Trials Experience ause clinical,1,0.6197463274002075
ULORIC,Cardiovascular Events,observed in the clinical trial,0,0.583774983882904
ULORIC,cardiovascular thromboembolic events,"conditions, adverse r",1,0.5493776798248291
ULORIC,Hepatic Effects,to rates in the,0,0.45913922786712646
ULORIC,Hepatic Effects,the rates obs erved in practice,1,0.4849450886249542
ULORIC,Hepatic Effects,total of subjects with hyperuricemia and gout were treated with ULORIC,0,0.5910971164703369
ULORIC,Hepatic Effects,clinical trials of another drug,0,0.5719171762466431
ULORIC,Hepatic Effects,drug and may not t the rates obs erved in practice A total,1,0.5475233793258667
ULORIC,hepatic failure,tal of 2757 sub jects with hyperuricemia and gout,1,0.5352902412414551
ULORIC,hepatic failure,observed in practice A to,0,0.4517759084701538
ULORIC,hepatic failure,practice A tal of,1,0.4331255555152893
ULORIC,hepatic failure,in practice A tal,1,0.4667162001132965
ULORIC,fatal,yperu ricemia and gout were,1,0.5307869911193848
ULORIC,fatal,in practice A tal,1,0.48796963691711426
ULORIC,fatal,another drug and may not reflect the rates observed in practice A total of subjects with,0,0.48168814182281494
ULORIC,fatal,and gout were treated with ULORIC mg or mg daily in clinical studies For ULORIC,0,0.48716723918914795
ULORIC,gout flares,controlled linical stu,1,0.4763716459274292
ULORIC,gout flares,linical stu,1,0.5053131580352783
ULORIC,gout flares,In three randomized controlled linical stu dies Studies,1,0.5042107701301575
ULORIC,cardiovascular thromboembolic events,Placebo ULORIC allopurinolO,0,0.49132978916168213
ULORIC,cardiovascular thromboembolic events,Greater than Seen in Receiving Placebo in Controlled Stud ies Adverse,1,0.534153163433075
ULORIC,cardiovascular thromboembolic events,Greater than Seen in Receiving Placebo,1,0.505868136882782
ULORIC,cardiovascular deaths,Controlled s Adverse React,1,0.5257174372673035
ULORIC,cardiovascular deaths,ions Placebo ULORIC allopurinolOf,0,0.44150230288505554
ULORIC,cardiovascular deaths,in Controlled s,1,0.48264825344085693
ULORIC,cardiovascular deaths,s Adverse React,1,0.5321418046951294
ULORIC,myocardial infarctions,Studies Adverse       Placebo          ULORIC allopurinolOf the subjects,1,0.4888511896133423
ULORIC,myocardial infarctions,s Adverse React,1,0.5560592412948608
ULORIC,myocardial infarctions,ULORIC allopurinolOf,0,0.4609203338623047
ULORIC,myocardial infarctions,allopurinolOf,0,0.467631995677948
ULORIC,myocardial infarctions,      Placebo          ULORIC,1,0.47558555006980896
ULORIC,myocardial infarctions,Patients Receiving,0,0.5515269041061401
ULORIC,myocardial infarctions,      Placebo          ULORIC allopurinolOf the subjects,1,0.48103880882263184
ULORIC,myocardial infarctions,Adverse,0,0.5191641449928284
ULORIC,myocardial infarctions,      Placebo          ULORIC allopurinolOf the,1,0.4781712591648102
ULORIC,myocardial infarctions,Placebo in Controlled,0,0.48354071378707886
ULORIC,strokes,Placebo LORIC   allopurinolOf,1,0.5057928562164307
ULORIC,strokes,Placebo in Controlled,0,0.5364461541175842
ULORIC,strokes,Controlled Studies Adverse Reactions,0,0.5468901991844177
ULORIC,strokes,Adverse Reactions Placebo LORIC   allopurinolOf the subjects who,1,0.4961284399032593
ULORIC,strokes,allopurinol received mg received,0,0.47757911682128906
ULORIC,strokes,U,0,0.5770211219787598
ULORIC,strokes,received mg received mg,0,0.49933603405952454
ULORIC,strokes,allopurinol,0,0.5022335052490234
ULORIC,strokes,received allopurinol received mg,0,0.4805825352668762
ULORIC,strokes,LORIC  ,1,0.5236262679100037
KYPROLIS,Cardiac Toxicities,Cardiac Toxicities see Warnings and,1,0.9410356879234314
KYPROLIS,Cardiac Toxicities,other sections of the Cardiac Toxicities see Warnings and Precautions Acute,1,0.8688796758651733
KYPROLIS,Cardiac Toxicities,sections of the,0,0.5031667351722717
KYPROLIS,Cardiac Toxicities,in other,0,0.4825277328491211
KYPROLIS,Cardiac Toxicities,other sections of the Cardiac Toxicities,1,0.9296427965164185
KYPROLIS,Cardiac Toxicities,Cardiac Toxicities see,1,0.9856284856796265
KYPROLIS,Cardiac Toxicities,Cardiac,1,0.7687764167785645
KYPROLIS,Cardiac Toxicities,the Cardiac,1,0.7585630416870117
KYPROLIS,Cardiac Toxicities,sections of the Cardiac Toxicities,1,0.9414185285568237
KYPROLIS,Acute Renal Failure,Toxicities see Warnings and Acute Renal Failure,1,0.8165676593780518
KYPROLIS,Acute Renal Failure,the Cardiac,1,0.5053067207336426
KYPROLIS,Acute Renal Failure,Renal Failure see Warnings,1,0.7908329367637634
KYPROLIS,Acute Renal Failure,Warnings and Acute Renal Failure see,1,0.8555277585983276
KYPROLIS,Acute Renal Failure,Acute Renal Failure see Warnings and Precautions,1,0.8694925308227539
KYPROLIS,Acute Renal Failure,Precautions,0,0.49089860916137695
KYPROLIS,Acute Renal Failure,see Warnings and Precautio,0,0.4938596189022064
KYPROLIS,Tumor Lysis Syndrome,and Tumor Lysis Syndrome see Warnings and Precautions,1,0.8518725037574768
KYPROLIS,Tumor Lysis Syndrome,see Warnings and Precautio,0,0.47313109040260315
KYPROLIS,Tumor Lysis Syndrome,Warnings and Precautions,0,0.4706181287765503
KYPROLIS,Tumor Lysis Syndrome,Warnings and Tumor Lysis Syndrome see,1,0.8706787824630737
KYPROLIS,Tumor Lysis Syndrome,and,0,0.4305259883403778
KYPROLIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings,1,0.9096418619155884
KYPROLIS,Pulmonary Toxicity,Warnings and Pulmonary Toxicity see,1,0.8632348775863647
KYPROLIS,Pulmonary Toxicity,Hypertension see Warnings and Precaut,0,0.4885140657424927
KYPROLIS,Pulmonary Toxicity,see Warnings and,0,0.5704491138458252
KYPROLIS,Pulmonary Toxicity,Syndrome see Warnings and Pulmonary Toxicity,1,0.8164620399475098
KYPROLIS,Pulmonary Toxicity,see Warnings and Pulmonary,1,0.7457107901573181
KYPROLIS,Pulmonary Toxicity,Syndrome see Warnings and Pulmonary,1,0.7081825733184814
KYPROLIS,Pulmonary Toxicity,Pulmonary,1,0.7798680067062378
KYPROLIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings and Precautions,1,0.8760800361633301
KYPROLIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings and,1,0.9051858186721802
KYPROLIS,Pulmonary Hypertension,Toxicity see Warnings and Pulmonary,1,0.6376234889030457
KYPROLIS,Pulmonary Hypertension,and Pulmonary Hypertension,1,0.9140945672988892
KYPROLIS,Pulmonary Hypertension,Pulmonary Hypertension see Warnings and,1,0.8378696441650391
KYPROLIS,Pulmonary Hypertension,Pulmonary Hypertension see Warnings and Precautions,1,0.8226867914199829
KYPROLIS,Pulmonary Hypertension,Precautions Dyspnea see Warnings and,0,0.6011484861373901
KYPROLIS,Pulmonary Hypertension,and Pulmonary,1,0.7253941893577576
KYPROLIS,Pulmonary Hypertension,Warnings,0,0.5356436967849731
KYPROLIS,Dyspnea,Dyspnea see Warnings and,1,0.8749547600746155
KYPROLIS,Dyspnea,Hypertension,0,0.5871384143829346
KYPROLIS,Dyspnea,Dyspnea see,1,0.9446259140968323
KYPROLIS,Hypertension,Hypertension see,1,0.9015195369720459
KYPROLIS,Hypertension,Warnings and Precautions,0,0.5530973672866821
KYPROLIS,Hypertension,Dyspnea see Warnings and Hypertension see Warnings and Precautions Venous,1,0.7177554368972778
KYPROLIS,Hypertension,Hypertension,1,1.0
KYPROLIS,Hypertension,Dyspnea see,0,0.5807529091835022
KYPROLIS,Hypertension,Hypertension see Warnings and Precautions,1,0.8228535056114197
KYPROLIS,Hypertension,Hypertension see Warnings and,1,0.8397073745727539
KYPROLIS,Hypertension,Hypertension see Warnings and Precautions Venous,1,0.7662267684936523
KYPROLIS,Venous Thrombosis,see Warnings and Venous Thrombosis,1,0.8261579871177673
KYPROLIS,Venous Thrombosis,Hypertension see Warnings and,1,0.5328741073608398
KYPROLIS,Venous Thrombosis,Venous Thrombosis,1,0.9999998807907104
KYPROLIS,Infusion Reactions,see Warnings,0,0.5517964363098145
KYPROLIS,Infusion Reactions,Venous Thrombosis see Warnings and,0,0.5249028205871582
KYPROLIS,Thrombocytopenia,Reactions see Warnings and Thrombocytopenia see Warnings and Precautions,1,0.8015273809432983
KYPROLIS,Thrombocytopenia,Venous Thrombosis see Warnings and,0,0.5897078514099121
KYPROLIS,Thrombocytopenia,Thrombocytopenia see Warnings,1,0.8765190839767456
KYPROLIS,Hepatic Toxicity,Hepatic Toxicity and Hepatic Failure,1,0.907593846321106
KYPROLIS,Hepatic Toxicity,see Warnings and Hepatic,1,0.8154404759407043
KYPROLIS,Hepatic Toxicity,see Warnings and Hepatic Toxicity and Hepatic Failure,1,0.865691065788269
KYPROLIS,Hepatic Toxicity,Warnings and Hepatic Toxicity,1,0.8965432643890381
KYPROLIS,Hepatic Toxicity,Hepatic Toxicity and Hepatic,1,0.9572010636329651
KYPROLIS,Hepatic Toxicity,cautions Thrombocytopenia see Warnings and Precautions,0,0.5824905633926392
KYPROLIS,Hepatic Toxicity,Thrombocytopenia see Warnings and Hepatic Toxicity,1,0.8052903413772583
KYPROLIS,Hepatic Failure,Toxicity Hepatic Failure,1,0.9426469206809998
KYPROLIS,Hepatic Failure,Toxicity,0,0.6059131026268005
KYPROLIS,Hepatic Failure,see Warnings and,0,0.50482577085495
KYPROLIS,Thrombotic Thrombocytopenic Purpura,see Warnings and Thrombotic Thrombocytopenic Purpura,1,0.8845824599266052
KYPROLIS,Thrombotic Thrombocytopenic Purpura,see Warnings and,0,0.47813406586647034
KYPROLIS,Hemolytic Uremic Syndrome,see Warnings and Precautions Thrombotic Thrombocytopenic Purpura,0,0.6851350665092468
KYPROLIS,Hemolytic Uremic Syndrome,and Precautions Posterior Reversible,0,0.48430222272872925
KYPROLIS,Hemolytic Uremic Syndrome,Warnings and,0,0.5342506766319275
KYPROLIS,Hemolytic Uremic Syndrome,Thrombocytopenic Hemolytic Uremic,1,0.839626133441925
KYPROLIS,Hemolytic Uremic Syndrome,Hemolytic Uremic Syndrome see,1,0.9478089213371277
KYPROLIS,Hemolytic Uremic Syndrome,Hemolytic Uremic,1,0.9230145215988159
KYPROLIS,Hemolytic Uremic Syndrome,and Precautions Thrombotic Thrombocytopenic Hemolytic Uremic Syndrome see Warnings and Precautions,1,0.8269457221031189
KYPROLIS,Hemolytic Uremic Syndrome,Failure see Warnings and Precautions,0,0.5044623613357544
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,most common adverse event,0,0.557701826095581
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,The,0,0.46229010820388794
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,Precautions,0,0.49309098720550537
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,and Precautions,0,0.4771344065666199
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,The most common adverse,0,0.5612873435020447
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,Posterior Reversible Encephalopathy,1,0.9572980403900146
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,Syndrome see Warnings and Posterior Reversible Encephalopathy Syndrome,1,0.9061803817749023
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,Posterior Reversible Encephalopathy Syndrome PRES see Warnings and,1,0.9175294637680054
KYPROLIS,PRES,common adverse events occu,0,0.45789074897766113
KYPROLIS,fatigue,fatigue thrombocytopenia,1,0.7774362564086914
KYPROLIS,fatigue,common adverse events occu,0,0.5263797044754028
KYPROLIS,fatigue,fatigue,1,1.0
KYPROLIS,fatigue,thrombocytopenia nausea pyrexia decreased platelets dyspnea diarrhea,0,0.6150205731391907
KYPROLIS,fatigue,fatigue thrombocytopenia nausea pyrexia,1,0.7868195176124573
KYPROLIS,thrombocytopenia,thrombocytopenia nausea pyrexia decreased platelets dyspnea,1,0.7958602905273438
KYPROLIS,thrombocytopenia,nausea pyrexia decreased platelets dyspnea diarrhea decreased lymphocyte headache decreased,0,0.639252781867981
KYPROLIS,thrombocytopenia,thrombocytopenia nausea pyrexia decreased,1,0.7967930436134338
KYPROLIS,thrombocytopenia,thrombocytopenia nausea,1,0.8761627078056335
KYPROLIS,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
KYPROLIS,thrombocytopenia,anemia thrombocytopenia,1,0.893404483795166
KYPROLIS,nausea,nausea pyrexia decreased platelets dyspnea diarrhea,1,0.7264992594718933
KYPROLIS,nausea,nausea pyrexia,1,0.838968813419342
KYPROLIS,nausea,monotherapy trials anemia fatigue nausea pyrexia decreased platelets,1,0.6705654263496399
KYPROLIS,nausea,nausea,1,1.0
KYPROLIS,nausea,diarrhea decreased lymphocyte,0,0.5391300916671753
KYPROLIS,pyrexia,anemia fatigue thrombocytopenia pyrexia decreased platelets dyspnea diarrhea,1,0.713054895401001
KYPROLIS,pyrexia,diarrhea decreased lymphocyte,0,0.5503842234611511
KYPROLIS,pyrexia,headache,0,0.5772687196731567
KYPROLIS,pyrexia,lymphocyte headache,0,0.5950866937637329
KYPROLIS,decreased platelets,hemoglobin cough edema,0,0.5474423170089722
KYPROLIS,decreased platelets,dyspnea diarrhea decreased,0,0.6079777479171753
KYPROLIS,decreased platelets,thrombocytopenia nausea decreased platelets dyspnea diarrhea decreased lymphocyte headache,1,0.790279746055603
KYPROLIS,decreased platelets,Kyprolis,0,0.4834727644920349
KYPROLIS,decreased platelets,decreased platelets dyspnea diarrhea decreased lymphocyte,1,0.8057675957679749
KYPROLIS,decreased platelets,thrombocytopenia nausea decreased platelets dyspnea diarrhea decreased,1,0.8226701617240906
KYPROLIS,decreased platelets,decreased platelets dyspnea diarrhea decreased lymphocyte headache,1,0.8060154914855957
KYPROLIS,decreased platelets,hemoglobin cough,0,0.5402520298957825
KYPROLIS,decreased platelets,decreased platelets dyspnea diarrhea,1,0.8114020228385925
KYPROLIS,dyspnea,dyspnea diarrhea decreased,1,0.7773886322975159
KYPROLIS,dyspnea,pyrexia decreased dyspnea diarrhea,1,0.7124248743057251
KYPROLIS,dyspnea,decreased dyspnea diarrhea decreased lymphocyte,1,0.7364673614501953
KYPROLIS,dyspnea,pyrexia,0,0.5781912803649902
KYPROLIS,diarrhea,thrombocytopenia nausea pyrexia decreased platelets dyspnea,0,0.5748315453529358
KYPROLIS,diarrhea,decreased hemoglobin cough edema peripheral The,0,0.5188930630683899
KYPROLIS,diarrhea,notherapy trials anemia fatigue thrombocytopenia nausea pyrexia,0,0.5279197096824646
KYPROLIS,diarrhea,edema peripheral The,0,0.5531920194625854
KYPROLIS,diarrhea,diarrhea decreased lymphocyte headache,1,0.7428440451622009
KYPROLIS,diarrhea,diarrhea decreased lymphocyte headache decreased hemoglobin,1,0.7376185655593872
KYPROLIS,diarrhea,pyrexia decreased platelets diarrhea decreased lymphocyte headache decreased,1,0.656866192817688
KYPROLIS,decreased lymphocyte,headache decreased hemoglobin cough edema,0,0.6032576560974121
KYPROLIS,decreased lymphocyte,decreased lymphocyte headache,1,0.837243914604187
KYPROLIS,decreased lymphocyte,common adverse even,0,0.5380908846855164
KYPROLIS,decreased lymphocyte,decreased lymphocyte,1,1.0
KYPROLIS,decreased lymphocyte,decreased lymphocyte headache decreased hemoglobin cough edema,1,0.8160410523414612
KYPROLIS,decreased lymphocyte,most common adverse even,0,0.5194612741470337
KYPROLIS,decreased lymphocyte,platelets dyspnea decreased lymphocyte headache,1,0.7557854652404785
KYPROLIS,headache,headache decreased hemoglobin cough edema,1,0.7503631711006165
KYPROLIS,headache,decreased headache decreased hemoglobin,1,0.7443164587020874
KYPROLIS,headache,headache,1,0.9999998807907104
KYPROLIS,headache,decreased,0,0.5219336152076721
KYPROLIS,headache,adverse,0,0.5728578567504883
KYPROLIS,headache,edema peripheral The most common,0,0.577641487121582
KYPROLIS,decreased hemoglobin,at least of,0,0.497810959815979
KYPROLIS,decreased hemoglobin,edema peripheral The most common adverse,0,0.5621795058250427
KYPROLIS,decreased hemoglobin,lymphocyte decreased hemoglobin cough edema,1,0.7356960773468018
KYPROLIS,decreased hemoglobin,decreased hemoglobin cough edema peripheral The most,1,0.7659841775894165
KYPROLIS,cough,headache decreased cough edema peripheral The,1,0.7376347184181213
KYPROLIS,cough,decreased hemoglobin cough edema peripheral The most,1,0.7084159851074219
KYPROLIS,cough,cough edema peripheral The most,1,0.7546546459197998
KYPROLIS,edema peripheral,decreased hemoglobin edema peripheral,1,0.8750638365745544
KYPROLIS,edema peripheral,decreased hemoglobin cough edema peripheral The most,1,0.781639814376831
KYPROLIS,edema peripheral,hemoglobin edema peripheral The most common,1,0.8658748865127563
KYPROLIS,edema peripheral,The most common adverse events occurring in at least of,0,0.5411674976348877
KYPROLIS,decreased lymphocytes,neutropenia decreased total,0,0.7269542813301086
KYPROLIS,decreased absolute neutrophil count,the combination therapy trial decreased,0,0.6331555843353271
KYPROLIS,decreased absolute neutrophil count,patients treated with Kyprolis in,0,0.55268794298172
KYPROLIS,decreased phosphorus,platelets diarrhea fatigu,0,0.5793007612228394
KYPROLIS,decreased phosphorus,decreased phosphorus,1,1.0000001192092896
KYPROLIS,decreased phosphorus,lymphocytes decreased absolute neutrophil decreased phosphorus anemia neutropenia,1,0.7701452970504761
KYPROLIS,decreased phosphorus,decreased phosphorus anemia neutropenia decreased total,1,0.8454853892326355
KYPROLIS,decreased phosphorus,decreased total white blood cell count decreased platelets,0,0.6896349191665649
KYPROLIS,decreased phosphorus,neutropenia decreased total white blood cell count,0,0.620728075504303
KYPROLIS,decreased phosphorus,decreased,1,0.7517616748809814
KYPROLIS,anemia,anemia neutropenia decreased total white,1,0.7580876350402832
KYPROLIS,anemia,decreased,1,0.5402147769927979
KYPROLIS,anemia,count decreased anemia neutropenia decreased total white blood,1,0.738150417804718
KYPROLIS,neutropenia,anemia,0,0.7147143483161926
KYPROLIS,neutropenia,count decreased,0,0.550166130065918
KYPROLIS,decreased total white blood cell count,neutrophil count decreased phosphorus anemia neutropenia,0,0.7220643758773804
KYPROLIS,decreased platelets,decreased platelets,1,0.9999998211860657
KYPROLIS,decreased platelets,neutrophil count decreased phosphorus anemia neutropenia,0,0.7394128441810608
KYPROLIS,decreased platelets,cell decreased platelets diarrhea fatigue,1,0.7957677841186523
KYPROLIS,decreased platelets,total white blood cell decreased,1,0.7546866536140442
KYPROLIS,decreased platelets,eutrophil,0,0.5380620956420898
KYPROLIS,decreased platelets,cell decreased platelets diarrhea fatigue thrombocytopenia,1,0.830930769443512
KYPROLIS,decreased platelets,count,0,0.5059089660644531
KYPROLIS,decreased platelets,cough upper respiratory tract infecti,0,0.4420230984687805
KYPROLIS,decreased platelets,decreased platelets diarrhea,1,0.8578588366508484
KYPROLIS,decreased platelets,blood cell decreased,1,0.8260038495063782
KYPROLIS,decreased platelets,cell decreased,1,0.7739257216453552
KYPROLIS,diarrhea,decreased,0,0.537799596786499
KYPROLIS,diarrhea,count decreased,0,0.5437418222427368
KYPROLIS,diarrhea,diarrhea fatigue thrombocytopenia,1,0.7467906475067139
KYPROLIS,diarrhea,diarrhea fatigue,1,0.8042935729026794
KYPROLIS,fatigue,cough,0,0.6278507709503174
KYPROLIS,fatigue,fatigue thrombocytopenia pyrexia,1,0.7470644116401672
KYPROLIS,fatigue,thrombocytopenia pyrexia muscle spasm cough upper respiratory tract infection,0,0.5870915651321411
KYPROLIS,fatigue,respiratory tract infection decreased hemog,0,0.58270263671875
KYPROLIS,fatigue,cough upper respiratory,0,0.5370000600814819
KYPROLIS,thrombocytopenia,thrombocytopenia pyrexia muscle spasm,1,0.7582986354827881
KYPROLIS,thrombocytopenia,count decreased platelets diarrhea thrombocytopenia pyrexia muscle,1,0.7356696724891663
KYPROLIS,thrombocytopenia,decreased platelets diarrhea thrombocytopenia pyrexia muscle spasm,1,0.721424400806427
KYPROLIS,thrombocytopenia,decreased hemoglobin hypokalemia,0,0.5679336786270142
KYPROLIS,pyrexia,pyrexia muscle,1,0.8764241933822632
KYPROLIS,pyrexia,cough upper respiratory,0,0.5946056842803955
KYPROLIS,pyrexia,platelets diarrhea fatigue pyrexia muscle spasm cough,1,0.7324851155281067
KYPROLIS,pyrexia,pyrexia muscle spasm,1,0.8339792490005493
KYPROLIS,pyrexia,decreased platelets diarrhea fatigue thrombocytopenia,0,0.6106519103050232
KYPROLIS,pyrexia,muscle spasm cough upper respiratory tract infection decreased hemoglobin hypokalemia,0,0.6115632057189941
KYPROLIS,muscle spasm,muscle spasm,1,1.0
KYPROLIS,muscle spasm,diarrhea fatigue thrombocytopenia muscle spasm cough upper respiratory,1,0.6735075116157532
KYPROLIS,muscle spasm,diarrhea fatigue thrombocytopenia muscle spasm cough,1,0.6943670511245728
KYPROLIS,muscle spasm,hemoglobin,0,0.5073966979980469
KYPROLIS,muscle spasm,muscle spasm cough upper respiratory tract,1,0.78759765625
KYPROLIS,muscle spasm,diarrhea fatigue thrombocytopenia muscle spasm,1,0.7587968111038208
KYPROLIS,cough,To report,0,0.526266872882843
KYPROLIS,cough,cough upper,1,0.8412541151046753
KYPROLIS,cough,diarrhea fatigue thrombocytopenia pyrexia muscle spasm,0,0.5673525929450989
KYPROLIS,cough,cough upper respiratory,1,0.8498309850692749
KYPROLIS,cough,count decreased platelets diarrhea fatigue thrombocytopenia pyrexia muscle,0,0.5643970966339111
KYPROLIS,upper respiratory tract infection,muscle spasm upper respiratory tract infection decreased,1,0.7690290808677673
KYPROLIS,upper respiratory tract infection,count decreased platelets diarrhea fatigue thrombocytopenia pyrexia muscle,0,0.48665693402290344
KYPROLIS,upper respiratory tract infection,thrombocytopenia pyrexia muscle spasm upper respiratory tract infection,1,0.7309433221817017
KYPROLIS,upper respiratory tract infection,muscle spasm upper respiratory tract infection,1,0.7866149544715881
KYPROLIS,upper respiratory tract infection,thrombocytopenia pyrexia muscle spasm upper respiratory tract infection decreased hemoglobin hypokalemia To,1,0.6738067865371704
KYPROLIS,upper respiratory tract infection,upper respiratory,1,0.857993483543396
KYPROLIS,upper respiratory tract infection,decreased hemoglobin,0,0.49119502305984497
KYPROLIS,upper respiratory tract infection,diarrhea fatigue,0,0.4975716471672058
KYPROLIS,upper respiratory tract infection,SUSPECTED ADVERSE REACTIONS contact,0,0.5573166608810425
KYPROLIS,upper respiratory tract infection,thrombocytopenia pyrexia muscle spasm upper respiratory tract infection decreased,1,0.7255787253379822
KYPROLIS,decreased hemoglobin,spasm cough,0,0.5138720273971558
KYPROLIS,hypokalemia,hypokalemia To report SUSPECTED ADVERSE REACTIONS,1,0.8418624401092529
KYPROLIS,hypokalemia,hypokalemia To report,1,0.9048933982849121
KYPROLIS,Deaths,Rd Deaths due to,1,0.7964035272598267
KYPROLIS,Deaths,hypokalemia To report,1,0.5145341157913208
KYPROLIS,Deaths,Deaths due,1,0.8530093431472778
KYPROLIS,Deaths,Deaths due to,1,0.8684725761413574
KYPROLIS,Deaths,Deaths due to adverse,1,0.8066239356994629
KYPROLIS,died,died due to,1,0.8786733150482178
KYPROLIS,died,with patients died due to adverse events,1,0.6526230573654175
KYPROLIS,died,died due to adverse,1,0.8143406510353088
KYPROLIS,died,died,1,1.0000001192092896
KYPROLIS,died,who,0,0.5952916741371155
KYPROLIS,died,arm occurred in patients,0,0.49941664934158325
KYPROLIS,died,patients died,1,0.714131236076355
KYPROLIS,deaths,the last dose of any Rd therapy The,0,0.5301743745803833
KYPROLIS,deaths,deaths occurring,1,0.9024759531021118
KYPROLIS,deaths,of,0,0.5323759913444519
KYPROLIS,deaths,cause deaths occurring,1,0.7909295558929443
KYPROLIS,deaths,deaths occurring in patients in the,1,0.7677699327468872
KYPROLIS,deaths,any Rd therapy The most,0,0.4767325520515442
KYPROLIS,deaths,of the last dose of,0,0.5848715305328369
KYPROLIS,deaths,Rd therapy The most common,0,0.4575216472148895
KYPROLIS,pneumonia,pneumonia versus respiratory tract infection versus,1,0.8057170510292053
KYPROLIS,pneumonia,arm pneumonia versus,1,0.763918399810791
KYPROLIS,pneumonia,pneumonia versus respiratory tract infection,1,0.798009991645813
KYPROLIS,pneumonia,events reported in the KRd arm as compared with the Rd,0,0.47050169110298157
KYPROLIS,pneumonia,common serious adverse events reported in,0,0.4961681365966797
KYPROLIS,pneumonia,arm pneumonia versus respiratory,1,0.7390575408935547
KYPROLIS,pneumonia,tract infection versus,0,0.6469719409942627
KYPROLIS,pneumonia,pneumonia versus,1,0.847044825553894
KYPROLIS,pneumonia,infection versus pyrexia,0,0.622868001461029
KYPROLIS,respiratory tract infection,respiratory tract infection versus,1,0.8975047469139099
KYPROLIS,pyrexia,infection,0,0.6292355060577393
KYPROLIS,pyrexia,infection pyrexia versus and pulmonary,1,0.8298445343971252
KYPROLIS,pyrexia,tract,0,0.5179157257080078
KYPROLIS,pyrexia,pyrexia,1,1.0000001192092896
KYPROLIS,pyrexia,infection pyrexia versus and,1,0.8635193705558777
KYPROLIS,pyrexia,pyrexia versus and pulmonary embolism,1,0.7940351963043213
KYPROLIS,pyrexia,tract infection pyrexia versus and pulmonary,1,0.8049947023391724
KYPROLIS,pyrexia,pyrexia versus and pulmonary,1,0.8475919961929321
KYPROLIS,pulmonary embolism,event occurred in,0,0.5138524174690247
KYPROLIS,pulmonary embolism,pulmonary embolism versus Discontinuation due to,1,0.8163066506385803
KYPROLIS,pulmonary embolism,infection versus pyrexia versus pulmonary,1,0.6426869630813599
KYPROLIS,pulmonary embolism,infection versus pyrexia versus pulmonary embolism,1,0.7688003778457642
KYPROLIS,pulmonary embolism,versus,0,0.5281320214271545
KYPROLIS,pneumonia,pneumonia myocardial,1,0.8059980869293213
KYPROLIS,pneumonia,pneumonia myocardial infarction and,1,0.7922284603118896
KYPROLIS,myocardial infarction,myocardial infarction and upper respiratory,1,0.791533350944519
KYPROLIS,myocardial infarction,pneumonia myocardial infarction and,1,0.7833567261695862
KYPROLIS,myocardial infarction,myocardial infarction and upper,1,0.8307377099990845
KYPROLIS,myocardial infarction,of Kyprolis occurred,0,0.4456935524940491
KYPROLIS,myocardial infarction,common events included myocardial infarction,1,0.826666533946991
KYPROLIS,myocardial infarction,included myocardial infarction and upper respiratory,1,0.805493175983429
KYPROLIS,myocardial infarction,and the most common events included pneumonia,0,0.5468055605888367
KYPROLIS,myocardial infarction,most common events included myocardial infarction and upper respiratory,1,0.7718484997749329
KYPROLIS,myocardial infarction,tract infection Common,0,0.5052989721298218
KYPROLIS,upper respiratory tract infection,and,0,0.4904365837574005
KYPROLIS,upper respiratory tract infection,included pneumonia myocardial infarction upper respiratory tract,1,0.737395167350769
KYPROLIS,upper respiratory tract infection,patients,0,0.5316616892814636
KYPROLIS,upper respiratory tract infection,respiratory tract infection Common Adverse Events The adverse,1,0.7477227449417114
KYPROLIS,upper respiratory tract infection,most,0,0.4741694927215576
KYPROLIS,upper respiratory tract infection,upper respiratory tract infection Common,1,0.8787370920181274
KYPROLIS,Pneumonia,lenalidomide and,0,0.5436792969703674
KYPROLIS,Pneumonia,Pneumonia,1,0.9999997615814209
KYPROLIS,Pneumonia,Pneumonia includes preferred terms,1,0.8054980039596558
KYPROLIS,Pneumonia,Pneumonia includes preferred,1,0.8308287262916565
KYPROLIS,Pneumonia,Pneumonia includes,1,0.8873904943466187
KYPROLIS,Pneumonia,dexamethasone Pneumonia includes preferred terms of pneumonia,1,0.7844212055206299
KYPROLIS,Pneumonia,lenalidomide and lowdose dexamethasone a,0,0.5520490407943726
KYPROLIS,Pneumonia,Pneumonia includes preferred terms of,1,0.8115744590759277
KYPROLIS,Pneumonia,includes preferred,0,0.5375626683235168
KYPROLIS,pneumonia,Pneumonia includes preferred terms pneumonia bronchopneumonia,1,0.8003352880477905
KYPROLIS,pneumonia,includes preferred,0,0.5375626683235168
KYPROLIS,pneumonia,Rd lenalidomide and lowdose dexamethasone a Pneumonia includes,0,0.7477338910102844
KYPROLIS,pneumonia,pneumonia bronchopneumonia b Peripheral,1,0.7365995645523071
KYPROLIS,pneumonia,pneumonia bronchopneumonia,1,0.8340162038803101
KYPROLIS,pneumonia,pneumonia bronchopneumonia b,1,0.7728846669197083
KYPROLIS,bronchopneumonia,includes preferred terms of bronchopneumonia,1,0.8500264883041382
KYPROLIS,bronchopneumonia,pneumonia bronchopneumonia b,1,0.8912004828453064
KYPROLIS,Peripheral neuropathies NEC,neuropathies NEC includes preferred terms,1,0.8723002076148987
KYPROLIS,Peripheral neuropathies NEC,terms,0,0.47964388132095337
KYPROLIS,Peripheral neuropathies NEC,peripheral neuropathies NEC,0,1.0
KYPROLIS,Peripheral neuropathies NEC,pneumonia bronchopneumonia Peripheral neuropathies,1,0.7875022888183594
KYPROLIS,Peripheral neuropathies NEC,pneumonia bronchopneumonia Peripheral,1,0.659907877445221
KYPROLIS,Peripheral neuropathies NEC,Peripheral neuropathies NEC includes preferred terms under HLT,1,0.8779149651527405
KYPROLIS,Peripheral neuropathies NEC,Peripheral neuropathies NEC includes preferred terms under,1,0.9217901229858398
KYPROLIS,Peripheral neuropathies NEC,Peripheral neuropathies NEC includes,1,0.9771958589553833
KYPROLIS,Peripheral neuropathies NEC,pneumonia,0,0.4808521866798401
KYPROLIS,Peripheral neuropathies NEC,terms of pneumonia bronchopneumonia Peripheral neuropathies NEC,1,0.8060541152954102
KYPROLIS,peripheral neuropathies NEC,b Peripheral neuropathies NEC,0,0.9794958233833313
KYPROLIS,peripheral neuropathies NEC,d Embolic,0,0.5290216207504272
KYPROLIS,peripheral neuropathies NEC,includes preferred terms under,0,0.49576759338378906
KYPROLIS,peripheral neuropathies NEC,neuropathies NEC c Dyspnea includes,1,0.8225353956222534
KYPROLIS,peripheral neuropathies NEC,includes preferred terms of dyspnea dyspnea exertional,0,0.501181960105896
KYPROLIS,Dyspnea,d,0,0.6927800178527832
KYPROLIS,Dyspnea,Dyspnea includes preferred terms of,1,0.8755264282226562
KYPROLIS,Dyspnea,Dyspnea includes,1,0.9314980506896973
KYPROLIS,Dyspnea,includes preferred terms under HLT peripheral neuropathies,0,0.5333071947097778
KYPROLIS,Dyspnea,terms of dyspnea dyspnea exertional d Embolic and thrombotic events,0,0.8229228258132935
KYPROLIS,Dyspnea,peripheral neuropathies,0,0.48929888010025024
KYPROLIS,Dyspnea,preferred terms under HLT peripheral neuropathies NEC c,0,0.5531651377677917
KYPROLIS,Dyspnea,Dyspnea,1,1.0
KYPROLIS,dyspnea,preferred terms under HLT peripheral neuropathies NEC c Dyspnea includes preferred,0,0.7430111169815063
KYPROLIS,dyspnea,events venous include,0,0.5652461051940918
KYPROLIS,dyspnea,dyspnea dyspnea exertional d Embolic and,1,0.8251028060913086
KYPROLIS,dyspnea,dyspnea dyspnea exertional,1,0.8530833125114441
KYPROLIS,dyspnea exertional,NEC c Dyspnea includes preferred,0,0.742100179195404
KYPROLIS,dyspnea exertional,thrombotic events venous include preferred terms,0,0.5652287006378174
KYPROLIS,dyspnea exertional,terms of dyspnea exertional d,1,0.9555529356002808
KYPROLIS,dyspnea exertional,dyspnea exertional d Embolic and thrombotic events,1,0.8618860840797424
KYPROLIS,dyspnea exertional,terms of dyspnea exertional d Embolic,1,0.8945893049240112
KYPROLIS,"Embolic and thrombotic events, venous",Embolic and thrombotic,1,0.883651614189148
KYPROLIS,"embolic and thrombotic events, venous",terms in MedDRA,0,0.547943115234375
KYPROLIS,"embolic and thrombotic events, venous",hypertensive,0,0.5432615280151367
KYPROLIS,"embolic and thrombotic events, venous",preferred terms,0,0.5010581612586975
KYPROLIS,"embolic and thrombotic events, venous","events, venous e",1,0.8147854208946228
KYPROLIS,"embolic and thrombotic events, venous","thrombotic events, venous e Hypertension includes preferred",1,0.8716388940811157
KYPROLIS,"embolic and thrombotic events, venous","embolic and thrombotic events, venous e Hypertension includes",1,0.9242355823516846
KYPROLIS,Hypertension,venous Hypertension includes preferred terms of hypertension,1,0.7400651574134827
KYPROLIS,Hypertension,"thrombotic events, venous e Hypertension includes preferred",1,0.7051882147789001
KYPROLIS,Hypertension,of hypertension hypertensive,0,0.8887157440185547
KYPROLIS,Hypertension,events venous Hypertension includes preferred terms of,1,0.6814768314361572
KYPROLIS,Hypertension,venous Hypertension includes preferred,1,0.6985626220703125
KYPROLIS,Hypertension,preferred terms in MedDRA SMQ,0,0.5372500419616699
KYPROLIS,Hypertension,crisis,0,0.540151834487915
KYPROLIS,Hypertension,hypertensive,0,0.9238433837890625
KYPROLIS,Hypertension,Hypertension includes preferred terms of,1,0.8220572471618652
KYPROLIS,hypertensive crisis,venous e,0,0.5016113519668579
KYPROLIS,hypertensive emergency,ArmN Rd ArmN,0,0.49536189436912537
KYPROLIS,hypertensive emergency,hypertensive emergency System Organ Class KRd ArmN,1,0.8168752789497375
KYPROLIS,hypertensive emergency,hypertensive emergency,1,0.9999998211860657
KYPROLIS,hypertensive emergency,hypertensive hypertensive,1,0.8253929018974304
KYPROLIS,hypertensive emergency,venous e,0,0.5290443897247314
KYPROLIS,hypertensive emergency,preferred,0,0.4692143201828003
KYPROLIS,hypertensive emergency,Class,0,0.5059931874275208
KYPROLIS,hypertensive emergency,KRd ArmN Rd,0,0.5002725720405579
KYPROLIS,hypertensive emergency,hypertension hypertensive crisis,0,0.9107859134674072
KYPROLIS,lymphopenia,failure cardiac failure congestive,0,0.5097401738166809
KYPROLIS,cardiac arrest,Cardiac cardiac arrest cardiac failure cardiac,1,0.8414533138275146
KYPROLIS,cardiac arrest,failure cardiac failure congestive,0,0.6653698682785034
KYPROLIS,cardiac arrest,lymphopenia Cardiac cardiac arrest cardiac failure cardiac failure,1,0.7583321928977966
KYPROLIS,cardiac failure,myocardial ischemia,0,0.6990947723388672
KYPROLIS,cardiac failure,cardiac cardiac failure cardiac failure congestive myocardial infarction,1,0.8505006432533264
KYPROLIS,cardiac failure,cardiac cardiac failure cardiac failure congestive,1,0.884848952293396
KYPROLIS,cardiac failure congestive,cardiac arrest cardiac cardiac,1,0.7142142057418823
KYPROLIS,cardiac failure congestive,arrest,0,0.45335936546325684
KYPROLIS,myocardial infarction,arrest,0,0.4904809594154358
KYPROLIS,myocardial infarction,cardiac failure cardiac failure congestive,0,0.6550405621528625
KYPROLIS,myocardial infarction,cardiac failure myocardial,1,0.781417965888977
KYPROLIS,myocardial infarction,cardiac failure,0,0.6944059133529663
KYPROLIS,myocardial infarction,cardiac arrest cardiac failure,0,0.65438312292099
KYPROLIS,myocardial infarction,blurred Gastrointestinal,0,0.5291632413864136
KYPROLIS,myocardial infarction,ischemia,0,0.710768461227417
KYPROLIS,myocardial infarction,failure cardiac failure myocardial infarction,1,0.8352962136268616
KYPROLIS,myocardial infarction,lymphopenia Cardiac disorders cardiac arrest cardiac failure cardiac,0,0.6520388126373291
KYPROLIS,myocardial ischemia,myocardial,0,0.8381392359733582
KYPROLIS,myocardial ischemia,myocardial ischemia Eye disorders cataract,1,0.7869988679885864
KYPROLIS,myocardial ischemia,myocardial ischemia Eye disorders cataract vision,1,0.7830826640129089
KYPROLIS,myocardial ischemia,Eye disorders cataract vision blurred Gastrointestinal,0,0.5007888674736023
KYPROLIS,myocardial ischemia,cataract,0,0.5550358295440674
KYPROLIS,myocardial ischemia,myocardial ischemia Eye disorders cataract vision blurred,1,0.7858409881591797
KYPROLIS,myocardial ischemia,vision blurred Gastrointestinal disorders,0,0.5132421255111694
KYPROLIS,cataract,lure cardiac failure congestive myocardial infarction myocardial ischemia Eye disorders,0,0.6046517491340637
KYPROLIS,cataract,ischemia Eye cataract vision blurred Gastrointestinal disorders abdominal,1,0.7377912402153015
KYPROLIS,cataract,cataract vision blurred Gastrointestinal disorders abdominal,1,0.7691272497177124
KYPROLIS,vision blurred,vision blurred Gastrointestinal disorders,1,0.7953082323074341
KYPROLIS,abdominal pain upper,abdominal pain upper dyspepsia toothache,1,0.823525071144104
KYPROLIS,abdominal pain upper,vision blurred Gastrointestinal disorders,1,0.635420560836792
KYPROLIS,abdominal pain upper,abdominal abdominal pain upper,1,0.9926161766052246
KYPROLIS,abdominal pain upper,disorders abdominal abdominal pain,1,0.8334944844245911
KYPROLIS,abdominal pain upper,abdominal pain,1,0.8900389671325684
KYPROLIS,abdominal pain upper,Gastrointestinal disorders abdominal abdominal pain upper dyspepsia toothache General,1,0.7914289832115173
KYPROLIS,abdominal pain upper,Gastrointestinal disorders abdominal abdominal pain upper,1,0.9198789596557617
KYPROLIS,abdominal pain upper,conditions,0,0.554914653301239
KYPROLIS,abdominal pain upper,and administration,0,0.49540776014328003
KYPROLIS,dyspepsia,dyspepsia toothache General,1,0.7941012978553772
KYPROLIS,toothache,upper toothache,1,0.8531321883201599
KYPROLIS,toothache,dyspepsia toothache General,1,0.8053133487701416
KYPROLIS,toothache,toothache,1,0.9999998807907104
KYPROLIS,toothache,toothache General disorders and administration site,1,0.8231902718544006
KYPROLIS,chills,chills infusion site reaction,1,0.7790893316268921
KYPROLIS,chills,and administration site chills infusion site reaction,1,0.6898159384727478
KYPROLIS,chills,and infestations influenza,0,0.5564658641815186
KYPROLIS,chills,conditions,0,0.551891565322876
KYPROLIS,chills,chills infusion,1,0.8285605907440186
KYPROLIS,infusion site reaction,infusion site reaction,1,1.0000001192092896
KYPROLIS,infusion site reaction,site reaction,1,0.7927250862121582
KYPROLIS,infusion site reaction,infusion site reaction multiorgan failure pain Infections and,1,0.8612557649612427
KYPROLIS,infusion site reaction,and administration site conditions infusion site reaction multiorgan,1,0.9188504219055176
KYPROLIS,infusion site reaction,conditions infusion site reaction multiorgan failure,1,0.8676302433013916
KYPROLIS,infusion site reaction,urinary tract in,0,0.5706241130828857
KYPROLIS,infusion site reaction,conditions infusion site reaction,1,0.9745302796363831
KYPROLIS,infusion site reaction,administration site conditions infusion site reaction multiorgan failure,1,0.8816422820091248
KYPROLIS,multi-organ failure,chills infusion site multi-organ failure pain Infections and infestations,1,0.7171000242233276
KYPROLIS,multi-organ failure,conditions infusion site reaction,1,0.5337265729904175
KYPROLIS,pain,pain Infections and,1,0.7947683334350586
KYPROLIS,pain,conditions infusion site reaction,1,0.5443159341812134
KYPROLIS,pain,pain Infections,1,0.8046690225601196
KYPROLIS,pain,multiorgan pain Infections and infestations influenza sepsis,1,0.704339861869812
KYPROLIS,pain,failure,0,0.5809663534164429
KYPROLIS,influenza,influenza sepsis urinary tract infection viral,1,0.7700916528701782
KYPROLIS,influenza,Infections and influenza sepsis urinary tract,1,0.7344869375228882
KYPROLIS,influenza,influenza sepsis urinary tract,1,0.7403205633163452
KYPROLIS,influenza,infusion site reaction multiorgan failure pain,0,0.5074254870414734
KYPROLIS,influenza,Infections and influenza sepsis urinary,1,0.744094729423523
KYPROLIS,sepsis,Infections and infestations sepsis urinary tract infection,1,0.7397190928459167
KYPROLIS,sepsis,infusion site reaction multiorgan failure pain,0,0.6184947490692139
KYPROLIS,sepsis,urinary tract infection viral infection Metabolism,0,0.579736590385437
KYPROLIS,sepsis,infestations sepsis urinary tract,1,0.738579273223877
KYPROLIS,sepsis,site,0,0.5437574982643127
KYPROLIS,sepsis,sepsis urinary tract infection viral infection,1,0.7519797086715698
KYPROLIS,sepsis,site reaction,0,0.5241507291793823
KYPROLIS,viral infection,viral infection Metabolism and nutrition disorders dehydration,1,0.7300012707710266
KYPROLIS,viral infection,viral infection Metabolism and nutrition disorders,1,0.7427951097488403
KYPROLIS,viral infection,dehydration,0,0.5914919376373291
KYPROLIS,viral infection,nutrition disorders dehydration hyperkalemia hyperuricemia,0,0.502927303314209
KYPROLIS,viral infection,sepsis,0,0.6669458150863647
KYPROLIS,viral infection,pain Infections and infestations influenza sepsis urinary tract infection,0,0.6702576875686646
KYPROLIS,viral infection,and nutrition disorders dehydration,0,0.5278887748718262
KYPROLIS,viral infection,infestations influenza sepsis urinary tract,0,0.650192379951477
KYPROLIS,viral infection,hyperkalemia hyperuricemia hypoalbuminem,0,0.49261945486068726
KYPROLIS,dehydration,dehydration hyperkalemia hyperuricemia hypoalbuminemia,1,0.7601800560951233
KYPROLIS,dehydration,hypoalbuminemia,0,0.6038814783096313
KYPROLIS,dehydration,dehydration,1,1.0
KYPROLIS,dehydration,dehydration hyperkalemia,1,0.7965446710586548
KYPROLIS,dehydration,nutrition,0,0.6588160991668701
KYPROLIS,dehydration,nutrition dehydration,1,0.8938748836517334
KYPROLIS,dehydration,dehydration hyperkalemia hyperuricemia hypoalbuminemia hyponatremia,1,0.7767332792282104
KYPROLIS,dehydration,tumor,0,0.5329750776290894
KYPROLIS,dehydration,hyperkalemia hyperuricemia,0,0.5358176231384277
KYPROLIS,hyperkalemia,tumor lysis syndrome Musculoskeletal and,0,0.5791329741477966
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia hypoalbuminemia hyponatremia tumor lysis,1,0.782799482345581
KYPROLIS,hyperkalemia,urinary tract infection viral,0,0.4989756941795349
KYPROLIS,hyperkalemia,tract infection viral infection,0,0.45368194580078125
KYPROLIS,hyperkalemia,Musculoskeletal and con,0,0.5135636329650879
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia,1,0.8759612441062927
KYPROLIS,hyperuricemia,disorders dehydration hyperuricemia hypoalbuminemia,1,0.7968663573265076
KYPROLIS,hyperuricemia,dehydration hyperkalemia,0,0.6302452087402344
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hyponatremia tumor lysis syndrome,1,0.7765733003616333
KYPROLIS,hyperuricemia,disorders dehydration hyperuricemia hypoalbuminemia hyponatremia tumor lysis,1,0.7355657815933228
KYPROLIS,hyperuricemia,and connective tissue,0,0.520919680595398
KYPROLIS,hyperuricemia,lysis syndrome Musculoskeletal and connective tissue,0,0.5685281753540039
KYPROLIS,hyperuricemia,and nutrition disorders dehydration hyperuricemia,1,0.8415147066116333
KYPROLIS,hypoalbuminemia,hypoalbuminemia hyponatremia tumor lysis syndrome Musculoskeletal,1,0.7676988840103149
KYPROLIS,hypoalbuminemia,and connective,0,0.5249921083450317
KYPROLIS,hyponatremia,syndrome Musculoskeletal and connective tissue,0,0.4372694194316864
KYPROLIS,hyponatremia,hyponatremia tumor lysis,1,0.8068474531173706
KYPROLIS,hyponatremia,Musculoskeletal and connective tissue disorders muscular,0,0.4520643949508667
KYPROLIS,hyponatremia,hyponatremia tumor,1,0.8537852764129639
KYPROLIS,tumor lysis syndrome,tumor lysis syndrome,1,0.9999999403953552
KYPROLIS,tumor lysis syndrome,hyperuricemia hypoalbuminemia tumor,1,0.6548627614974976
KYPROLIS,tumor lysis syndrome,weakness myalgia,0,0.5010716915130615
KYPROLIS,tumor lysis syndrome,hyperuricemia hypoalbuminemia tumor lysis syndrome Musculoskeletal and connective,1,0.7830504179000854
KYPROLIS,tumor lysis syndrome,tumor lysis syndrome Musculoskeletal and connective tissue,1,0.8310664892196655
KYPROLIS,muscular weakness,Nervous system disorders,0,0.5878545045852661
KYPROLIS,muscular weakness,disorders,0,0.5955802798271179
KYPROLIS,muscular weakness,connective tissue muscular,1,0.680942177772522
KYPROLIS,myalgia,myalgia Nervous system disorders hypoesthesia,1,0.7709667086601257
KYPROLIS,myalgia,connective tissue disorders muscular myalgia Nervous,1,0.7699278593063354
KYPROLIS,myalgia,myalgia Nervous system,1,0.8634004592895508
KYPROLIS,myalgia,connective tissue disorders muscular myalgia,1,0.8131746053695679
KYPROLIS,hypoesthesia,and connective tissue disorders muscular weakness myalgia Nervous system disorders,0,0.5990057587623596
KYPROLIS,hypoesthesia,hypoesthesia paresthesia deafness Psychiatric,1,0.833152174949646
KYPROLIS,hypoesthesia,hypoesthesia paresthesia deafness,1,0.8512532711029053
KYPROLIS,paresthesia,paresthesia deafness Psychiatric disorders anxiety,1,0.7864868640899658
KYPROLIS,paresthesia,paresthesia deafness,1,0.8772947192192078
KYPROLIS,paresthesia,paresthesia,1,0.9999998807907104
KYPROLIS,paresthesia,ective tissue disorders muscular weakness myalgia Nervous system disorders hypoesthesia,0,0.586492657661438
KYPROLIS,paresthesia,weakness myalgia Nervous,0,0.5899677872657776
KYPROLIS,paresthesia,ective tissue disorders muscular weakness myalgia,0,0.546744704246521
KYPROLIS,paresthesia,paresthesia deafness Psychiatric,1,0.8049677610397339
KYPROLIS,anxiety,Nervous system disorders hypoesthesia,0,0.5792578458786011
KYPROLIS,renal failure,and urinary renal,1,0.7717349529266357
KYPROLIS,renal failure acute,thoracic,0,0.48229527473449707
KYPROLIS,renal impairment,Renal,0,0.8530256748199463
KYPROLIS,renal impairment,renal impairment,1,1.0
KYPROLIS,renal impairment,renal failure renal,1,0.8661607503890991
KYPROLIS,renal impairment,renal impairment Respiratory thoracic and,1,0.8587019443511963
KYPROLIS,renal impairment,thoracic,0,0.505041241645813
KYPROLIS,renal impairment,disorders dysphonia epistaxis oropharyngeal,0,0.5132178068161011
KYPROLIS,renal impairment,renal impairment Respiratory,1,0.8735557794570923
KYPROLIS,epistaxis,epistaxis oropharyngeal pain pulmonary,1,0.784540593624115
KYPROLIS,epistaxis,epistaxis oropharyngeal pain,1,0.8293244242668152
KYPROLIS,epistaxis,epistaxis oropharyngeal pain pulmonary embolism pulmonary,1,0.7688296437263489
KYPROLIS,epistaxis,impairment Respiratory thoracic and mediastinal disorders dysphonia,0,0.4918292760848999
KYPROLIS,oropharyngeal pain,and mediastinal disorders dysphonia oropharyngeal pain pulmonary,1,0.7615725994110107
KYPROLIS,oropharyngeal pain,epistaxis oropharyngeal pain,1,0.8418254852294922
KYPROLIS,oropharyngeal pain,te renal impairment Respiratory thoracic and mediastinal disorders,0,0.5368593335151672
KYPROLIS,oropharyngeal pain,thoracic and mediastinal disorders dysphonia,0,0.5712652206420898
KYPROLIS,oropharyngeal pain,dysphonia oropharyngeal pain,1,0.879727840423584
KYPROLIS,oropharyngeal pain,thoracic,0,0.5132726430892944
KYPROLIS,oropharyngeal pain,oropharyngeal pain pulmonary embolism pulmonary edema,1,0.8271521329879761
KYPROLIS,oropharyngeal pain,mediastinal disorders dysphonia oropharyngeal pain pulmonary embolism pulmonary edema,1,0.7123846411705017
KYPROLIS,oropharyngeal pain,dysphonia oropharyngeal pain pulmonary embolism,1,0.7541462182998657
KYPROLIS,oropharyngeal pain,disorders dysphonia oropharyngeal pain pulmonary embolism pulmonary edema Skin,1,0.7188581824302673
KYPROLIS,pulmonary embolism,oropharyngeal pulmonary embolism,1,0.816301167011261
KYPROLIS,pulmonary edema,pain,0,0.567312479019165
KYPROLIS,pulmonary edema,subcutaneous tissue disorders erythema hyperhidrosis pruritus Vascular,0,0.5559388399124146
KYPROLIS,erythema,and subcutaneous tissue erythema hyperhidrosis pruritus Vascular disorders deep,1,0.7711240649223328
KYPROLIS,erythema,subcutaneous tissue disorders erythema hyperhidrosis pruritus Vascular,0,0.7494350075721741
KYPROLIS,erythema,disorders deep vein,0,0.5313438177108765
KYPROLIS,erythema,erythema hyperhidrosis pruritus Vascular disorders deep,1,0.7745750546455383
KYPROLIS,erythema,erythema hyperhidrosis pruritus Vascular disorders,1,0.779315710067749
KYPROLIS,erythema,and subcutaneous,0,0.6590012311935425
KYPROLIS,hyperhidrosis,hyperhidrosis pruritus,1,0.8890409469604492
KYPROLIS,hyperhidrosis,disorders erythema,0,0.6133905649185181
KYPROLIS,hyperhidrosis,and,0,0.49371418356895447
KYPROLIS,hyperhidrosis,deep vein thrombosis hypotension,0,0.5518791675567627
KYPROLIS,hyperhidrosis,hyperhidrosis pruritus Vascular disorders deep,1,0.8486964702606201
KYPROLIS,hyperhidrosis,hyperhidrosis pruritus Vascular disorders,1,0.8337699174880981
KYPROLIS,hyperhidrosis,disorders deep vein thrombosis hypotension Grade,0,0.5496266484260559
KYPROLIS,pruritus,pruritus Vascular,1,0.8466490507125854
KYPROLIS,deep vein thrombosis,occurred during Cycles with a subs,0,0.5528196096420288
KYPROLIS,deep vein thrombosis,vein thrombosis hypotension Grade and,1,0.7915352582931519
KYPROLIS,deep vein thrombosis,disorders erythema hyperhidrosis pruritus Vascular,0,0.5410642027854919
KYPROLIS,hypotension,hypotension Grade and higher,1,0.843241274356842
KYPROLIS,hypotension,and higher adverse reactions that occurred during,0,0.5480598211288452
KYPROLIS,neutropenia,difference between the two,0,0.44331276416778564
KYPROLIS,neutropenia,arms,0,0.5155141949653625
KYPROLIS,neutropenia,neutropenia thrombocytopenia,1,0.8478608727455139
KYPROLIS,neutropenia,two arms neutropenia thrombocytopenia hypokalemia and hypophosphatemia Laboratory,1,0.7475986480712891
KYPROLIS,thrombocytopenia,thrombocytopenia hypokalemia and,1,0.8438242077827454
KYPROLIS,thrombocytopenia,thrombocytopenia hypokalemia and hypophosphatemia Laboratory,1,0.7902899980545044
KYPROLIS,hypophosphatemia,the,0,0.45997440814971924
KYPROLIS,hypophosphatemia,Grade laboratory abnormalities r,0,0.5702056884765625
KYPROLIS,Decreased Lymphocytes,Decreased Lymphocytes Decreased Ab,1,0.9023138284683228
KYPROLIS,Decreased Lymphocytes,Decreased Lymphocytes Decreased,1,0.9786463975906372
KYPROLIS,Decreased Lymphocytes,y Abnormality KRd N Decreased Lymphocytes Decreased Ab,1,0.7997314929962158
KYPROLIS,Decreased Lymphocytes,N Decreased Lymphocytes Decreased,1,0.9505360722541809
KYPROLIS,Decreased Lymphocytes,Abnormality KRd N Decreased Lymphocytes,1,0.8543500304222107
KYPROLIS,Decreased Lymphocytes,N RdN,0,0.4808650612831116
KYPROLIS,Decreased Lymphocytes,KRd N,0,0.4625091552734375
KYPROLIS,Decreased Phosphorus,Neutrophil Count,0,0.5249635577201843
KYPROLIS,Decreased Phosphorus,Neutrophil Decreased,1,0.6957627534866333
KYPROLIS,Decreased Phosphorus,Decreased Phosphorus,1,1.0000001192092896
KYPROLIS,Decreased Hemoglobin,Blood Cell Decreased Hemoglobin,1,0.9376997947692871
KYPROLIS,Decreased Hemoglobin,Decreased Hemoglobin,1,1.000000238418579
KYPROLIS,Decreased Hemoglobin,White Blood Cell Decreased Hemoglobin,1,0.9032686948776245
KYPROLIS,Decreased Hemoglobin,White Blood Cell Decreased,1,0.7989165782928467
KYPROLIS,Decreased Hemoglobin,Decreased Hemoglobin Decreased,1,0.9793208837509155
KYPROLIS,Decreased Hemoglobin,Blood Cell,0,0.6603320837020874
KYPROLIS,Decreased Hemoglobin,White Blood Cell,0,0.6215310096740723
KYPROLIS,pneumonia,pneumonia acute renal failure,1,0.7854241132736206
KYPROLIS,pneumonia,pneumonia acute renal failure disease,1,0.7768139839172363
KYPROLIS,pneumonia,progression pyrexia hypercalcemia congest,0,0.5698860883712769
KYPROLIS,pneumonia,pneumonia acute renal,1,0.7903414368629456
KYPROLIS,acute renal failure,acute renal failure disease,1,0.930861234664917
KYPROLIS,acute renal failure,pneumonia acute renal,1,0.8307687044143677
KYPROLIS,acute renal failure,were acute renal failure,1,0.9781731963157654
KYPROLIS,disease progression,pneumonia acute renal disease,1,0.5656938552856445
KYPROLIS,pyrexia,failure multiple,0,0.478279709815979
KYPROLIS,pyrexia,pyrexia hypercalcemia congestive,1,0.7851459980010986
KYPROLIS,pyrexia,failure disease pyrexia hypercalcemia congestive heart,1,0.7330565452575684
KYPROLIS,pyrexia,failure multiple myeloma,0,0.49497145414352417
KYPROLIS,pyrexia,were pneumonia acute renal,0,0.546275794506073
KYPROLIS,congestive heart failure,disease,0,0.5961675047874451
KYPROLIS,congestive heart failure,progression pyrexia congestive heart failure,1,0.7668271064758301
KYPROLIS,congestive heart failure,pyrexia congestive heart failure multiple myeloma anemia and,1,0.6833801865577698
KYPROLIS,multiple myeloma,incidence of,0,0.531098484992981
KYPROLIS,anemia,anemia and dyspnea,1,0.8121531009674072
KYPROLIS,anemia,anemia and dyspnea In,1,0.8157523274421692
KYPROLIS,anemia,pyrexia,0,0.5942764282226562
KYPROLIS,Deaths,Deaths due to adverse events within,1,0.7431203126907349
KYPROLIS,Deaths,years old and in those years old see,0,0.5214123725891113
KYPROLIS,Deaths,events within,0,0.5427703857421875
KYPROLIS,Deaths,Geriatric Deaths due to adverse events,1,0.6890245676040649
KYPROLIS,Deaths,old see Geriatric Deaths due to adverse events,1,0.6977638006210327
KYPROLIS,Deaths,of Kyprolis occurred in patients,0,0.5467778444290161
KYPROLIS,Deaths,see Geriatric Deaths,1,0.7808962464332581
KYPROLIS,Deaths,and in those,0,0.5529268383979797
KYPROLIS,cardiac disorders,These,0,0.5384074449539185
KYPROLIS,cardiac disorders,events were related cardiac disorders in,1,0.8247264623641968
KYPROLIS,cardiac disorders,patients renal disorders in patients and,0,0.6237397193908691
KYPROLIS,cardiac disorders,related cardiac disorders,1,0.8860661387443542
KYPROLIS,cardiac disorders,in,0,0.5328332185745239
KYPROLIS,cardiac disorders,patients,0,0.6102755069732666
KYPROLIS,renal disorders,renal disorders,1,1.0
KYPROLIS,renal disorders,patients infections in renal disorders,1,0.8263880014419556
KYPROLIS,renal disorders,in renal,1,0.8379217982292175
KYPROLIS,renal disorders,in renal disorders in patients and other adverse,1,0.8674027323722839
KYPROLIS,renal disorders,in renal disorders in patients,1,0.9059135913848877
KYPROLIS,renal disorders,in renal disorders,1,0.9561278820037842
KYPROLIS,mortality,mortality was higher in the patients,1,0.7330610752105713
KYPROLIS,mortality,the control,0,0.4996316730976105
KYPROLIS,mortality,and refractory multiple mortality,1,0.7009668350219727
KYPROLIS,mortality,mortality was,1,0.9256629347801208
KYPROLIS,acute renal failure,renal failure The common adverse,1,0.8013877272605896
KYPROLIS,acute renal failure,adverse event acute renal failure,1,0.89324951171875
KYPROLIS,acute renal failure,greater with Kyprolis,0,0.5068473815917969
KYPROLIS,acute renal failure,adverse events occurring at a rate,0,0.5728034377098083
KYPROLIS,acute renal failure,event acute renal failure The common,1,0.8865376114845276
KYPROLIS,acute renal failure,acute,1,0.6979737877845764
KYPROLIS,Pneumonia,Pneumonia includes the preferred terms,1,0.8249907493591309
KYPROLIS,Pneumonia,a,0,0.5570367574691772
KYPROLIS,Pneumonia,Kyprolis Monotherapy Pneumonia includes the preferred,1,0.7529236674308777
KYPROLIS,pneumonia,neuropathies NEC includes,0,0.47830456495285034
KYPROLIS,Peripheral neuropathies NEC,terms of pneumonia bronchopneumonia Peripheral neuropathies NEC includes,1,0.8167308568954468
KYPROLIS,Peripheral neuropathies NEC,neuropathies NEC includes,0,0.937272846698761
KYPROLIS,peripheral neuropathies NEC,eumonia,0,0.4707593321800232
KYPROLIS,peripheral neuropathies NEC,exertional d Hypertension,0,0.46512293815612793
KYPROLIS,peripheral neuropathies NEC,includes the preferred terms under HLT,0,0.4761293828487396
KYPROLIS,peripheral neuropathies NEC,peripheral neuropathies,1,0.932127833366394
KYPROLIS,peripheral neuropathies NEC,NEC includes,0,0.6581919193267822
KYPROLIS,peripheral neuropathies NEC,HLT,0,0.46997106075286865
KYPROLIS,Dyspnea,neuropathies,0,0.5118910074234009
KYPROLIS,Dyspnea,of dyspnea dyspnea exertional d Hypertension includes,0,0.8191513419151306
KYPROLIS,Dyspnea,the preferred terms,0,0.5224301815032959
KYPROLIS,Dyspnea,includes the preferred,0,0.5207885503768921
KYPROLIS,Dyspnea,NEC includes the preferred terms under HLT,0,0.5125124454498291
KYPROLIS,Dyspnea,Dyspnea includes the preferred,1,0.893963098526001
KYPROLIS,dyspnea,exertional d Hypertension includes the preferred terms of hypertension hypertensive,0,0.6007731556892395
KYPROLIS,dyspnea exertional,the preferred terms of dyspnea,1,0.7957265377044678
KYPROLIS,dyspnea exertional,preferred terms of dyspnea exertional d Hypertension includes,1,0.8784947991371155
KYPROLIS,dyspnea exertional,dyspnea exertional d Hypertension includes the,1,0.8895037174224854
KYPROLIS,dyspnea exertional,the preferred,0,0.458976149559021
KYPROLIS,dyspnea exertional,HLT peripheral neuropathies NEC c Dyspnea includes the preferred terms of dyspnea,0,0.7289139032363892
KYPROLIS,Hypertension,Hypertension includes the preferred terms,1,0.8323796987533569
KYPROLIS,Hypertension,HLT peripheral neuropathies NEC c Dyspnea includes the preferred terms of dyspnea,0,0.566876232624054
KYPROLIS,Hypertension,preferred terms of dyspnea dyspnea,0,0.5432658195495605
KYPROLIS,Hypertension,and,0,0.5626955032348633
KYPROLIS,Hypertension,preferred,0,0.5484855771064758
KYPROLIS,Hypertension,dyspnea dyspnea exertional Hypertension,1,0.7341500520706177
KYPROLIS,Hypertension,preferred terms of hypertension hypertensive crisis and hypertensive,0,0.7849137783050537
KYPROLIS,Hypertension,hypertensive crisis and hypertensive,0,0.8024488091468811
KYPROLIS,Hypertension,neuropathies NEC c Dyspnea,0,0.540838897228241
KYPROLIS,hypertension,hypertension hypertensive crisis and hypertensive,1,0.8045589327812195
KYPROLIS,hypertensive crisis,hypertensive crisis and hypertensive emergency Kyprol,1,0.8678479194641113
KYPROLIS,hypertensive crisis,hypertension hypertensive crisis and hypertensive,1,0.9287872314453125
KYPROLIS,hypertensive crisis,hypertensive crisis,1,0.9999998807907104
KYPROLIS,hypertensive crisis,hypertensive crisis and hypertensive,1,0.9590861797332764
KYPROLIS,hypertensive crisis,dyspnea exertional d Hypertension includes the,0,0.6958612203598022
KYPROLIS,hypertensive crisis,hypertensive crisis and hypertensive emergency,1,0.9430323839187622
KYPROLIS,hypertensive crisis,terms of hypertensive crisis,1,0.9423726201057434
KYPROLIS,hypertensive crisis,preferred terms of hypertensive,1,0.7478529214859009
KYPROLIS,hypertensive emergency,d Hypertension includes the,0,0.7705612778663635
KYPROLIS,hypertensive emergency,of hypertension hypertensive crisis hypertensive emergency Kyprolis,1,0.8885691165924072
KYPROLIS,hypertensive emergency,Kyprolis,0,0.4710228443145752
KYPROLIS,hypertensive emergency,hypertensive crisis hypertensive,1,0.9181550741195679
KYPROLIS,hypertensive emergency,of hypertension hypertensive crisis hypertensive,1,0.906969428062439
KYPROLIS,hypertensive emergency,hypertension hypertensive crisis and,0,0.888197124004364
KYPROLIS,Pneumonia,Pneumonia a,1,0.8633357286453247
KYPROLIS,Pneumonia,hypertension hypertensive crisis and,0,0.5042957067489624
KYPROLIS,Pneumonia,piratory,0,0.5026147961616516
KYPROLIS,Pneumonia,piratory Tract Pneumonia a Met,1,0.7724246978759766
KYPROLIS,febrile neutropenia,febrile neutropenia,1,1.0000001192092896
KYPROLIS,febrile neutropenia,Reactions Occurring at a Frequency of Blood and lymphatic,0,0.5829792022705078
KYPROLIS,febrile neutropenia,Reactions,0,0.5120879411697388
KYPROLIS,febrile neutropenia,disorders cardiac arrest cardiac failure congestive myocardial,0,0.43787282705307007
KYPROLIS,febrile neutropenia,at a Frequency of Blood and lymphatic system,0,0.5755107998847961
KYPROLIS,febrile neutropenia,febrile neutropenia Cardiac,1,0.8432244062423706
KYPROLIS,febrile neutropenia,arrest cardiac failure congestive myocardial,0,0.4310457110404968
KYPROLIS,febrile neutropenia,febrile neutropenia Cardiac disorders,1,0.8204890489578247
KYPROLIS,febrile neutropenia,and lymphatic system febrile neutropenia,1,0.8612264394760132
KYPROLIS,cardiac arrest,Blood and lymphatic system disorders febrile,0,0.4662152826786041
KYPROLIS,cardiac arrest,disorders febrile neutropenia Cardiac cardiac arrest cardiac failure congestive myocardial infarction,1,0.6963413953781128
KYPROLIS,cardiac arrest,disorders,0,0.4899047017097473
KYPROLIS,cardiac arrest,cardiac arrest cardiac failure congestive,1,0.8700509667396545
KYPROLIS,cardiac arrest,congestive myocardial,0,0.7000621557235718
KYPROLIS,cardiac arrest,neutropenia Cardiac cardiac arrest cardiac,1,0.8102145195007324
KYPROLIS,cardiac arrest,disorders febrile neutropenia Cardiac cardiac arrest,1,0.7685360908508301
KYPROLIS,cardiac arrest,lymphatic system,0,0.4423781931400299
KYPROLIS,cardiac arrest,disorders febrile neutropenia Cardiac cardiac,1,0.5946160554885864
KYPROLIS,cardiac arrest,ischemia,0,0.6978744268417358
KYPROLIS,cardiac failure congestive,Eye disorders cataract,0,0.5009118318557739
KYPROLIS,cardiac failure congestive,disorders cardiac cardiac failure,1,0.8390800356864929
KYPROLIS,cardiac failure congestive,disorders cardiac cardiac failure congestive myocardial infarction,1,0.8721283674240112
KYPROLIS,cardiac failure congestive,cardiac failure congestive,1,1.0000001192092896
KYPROLIS,cardiac failure congestive,neutropenia Cardiac disorders cardiac cardiac failure congestive,1,0.7840674519538879
KYPROLIS,cardiac failure congestive,myocardial infarction myocardial,0,0.6856067180633545
KYPROLIS,cardiac failure congestive,Cardiac disorders cardiac cardiac failure congestive myocardial infarction,1,0.8732870221138
KYPROLIS,cardiac failure congestive,failure congestive myocardial infarction myocardial,1,0.8338719606399536
KYPROLIS,cardiac failure congestive,disorders cardiac cardiac failure congestive myocardial infarction myocardial ischemia,1,0.8269575238227844
KYPROLIS,myocardial ischemia,congestive myocardial myocardial ischemia,1,0.8901697397232056
KYPROLIS,myocardial ischemia,cardiac arrest cardiac failure,0,0.669708788394928
KYPROLIS,blurred vision,blurred vision Gastrointestinal disorders abdominal pain,1,0.7698329091072083
KYPROLIS,blurred vision,Eye disorders blurred,1,0.8863009214401245
KYPROLIS,blurred vision,failure congestive myocardial infarction,0,0.5215811729431152
KYPROLIS,blurred vision,Eye disorders blurred vision Gastrointestinal disorders,1,0.7819169759750366
KYPROLIS,blurred vision,myocardial ischemia Eye disorders blurred vision,1,0.830405592918396
KYPROLIS,blurred vision,disorders blurred vision Gastrointestinal disorders abdominal,1,0.7727885842323303
KYPROLIS,blurred vision,myocardial ischemia Eye disorders blurred,1,0.7784746885299683
KYPROLIS,blurred vision,disorders blurred vision Gastrointestinal,1,0.8103951215744019
KYPROLIS,blurred vision,Gastrointestinal disorders abdominal pain,0,0.4570385217666626
KYPROLIS,blurred vision,blurred,1,0.8454651236534119
KYPROLIS,abdominal pain,Gastrointestinal disorders,0,0.7160562872886658
KYPROLIS,abdominal pain,abdominal pain abdominal pain upper dyspepsia,1,0.8517147302627563
KYPROLIS,abdominal pain,and administration,0,0.43640315532684326
KYPROLIS,abdominal pain upper,vision Gastrointestinal,0,0.6547834873199463
KYPROLIS,abdominal pain upper,vision Gastrointestinal disorders abdominal abdominal pain upper dyspepsia toothache General disorders,1,0.7599796056747437
KYPROLIS,abdominal pain upper,Eye disorders cataract blurred vision Gastrointestinal disorders abdominal,0,0.670911431312561
KYPROLIS,abdominal pain upper,Gastrointestinal disorders abdominal abdominal pain upper dyspepsia toothache General disorders,1,0.7706719040870667
KYPROLIS,abdominal pain upper,blurred,0,0.44064807891845703
KYPROLIS,abdominal pain upper,vision Gastrointestinal disorders abdominal abdominal pain upper dyspepsia toothache,1,0.7766454219818115
KYPROLIS,abdominal pain upper,abdominal,0,0.7627829909324646
KYPROLIS,abdominal pain upper,abdominal pain upper,1,1.0000001192092896
KYPROLIS,abdominal pain upper,cataract blurred vision Gastrointestinal disorders,0,0.6492279767990112
KYPROLIS,dyspepsia,dyspepsia,1,1.0000001192092896
KYPROLIS,toothache,infusion site reaction multiorgan f,0,0.49667447805404663
KYPROLIS,toothache,reaction multiorgan,0,0.46508079767227173
KYPROLIS,toothache,pain abdominal pain upper toothache General disorders and administration,1,0.7688339352607727
KYPROLIS,toothache,toothache General disorders and,1,0.865007221698761
KYPROLIS,toothache,site,0,0.4952406585216522
KYPROLIS,toothache,site reaction multiorgan f,0,0.4923008680343628
KYPROLIS,toothache,disorders abdominal pain,0,0.5817316174507141
KYPROLIS,infusion site reaction,hepatic,0,0.5539771914482117
KYPROLIS,infusion site reaction,site reaction multiorgan failure,1,0.7667694687843323
KYPROLIS,infusion site reaction,administration site infusion site reaction,1,0.9660875797271729
KYPROLIS,multi-organ failure,and administration site conditions infusion,0,0.5588939785957336
KYPROLIS,multi-organ failure,site multi-organ,1,0.7510600090026855
KYPROLIS,multi-organ failure,multi-organ failure pain,1,0.8969661593437195
KYPROLIS,multi-organ failure,site conditions infusion site multi-organ failure,1,0.8126171827316284
KYPROLIS,multi-organ failure,site multi-organ failure,1,0.9356278777122498
KYPROLIS,multi-organ failure,multi-organ failure,1,1.0
KYPROLIS,multi-organ failure,multi-organ failure pain Hepatobiliary,1,0.8078900575637817
KYPROLIS,multi-organ failure,infusion site multi-organ failure,1,0.8571776151657104
KYPROLIS,pain,disorders hepatic failure Infections and infestations bronchitis i,0,0.4678700566291809
KYPROLIS,pain,multiorgan pain Hepatobiliary disorders,1,0.6813950538635254
KYPROLIS,bronchitis,Hepatobiliary disorders hepatic failure Infections and,0,0.5510331392288208
KYPROLIS,bronchitis,Hepatobiliary disorders hepatic failure Infections,0,0.5465002655982971
KYPROLIS,bronchitis,bronchitis influenza nasopharyngitis respiratory,1,0.8076033592224121
KYPROLIS,bronchitis,tract,0,0.5172675251960754
KYPROLIS,nasopharyngitis,nasopharyngitis respiratory,1,0.8757400512695312
KYPROLIS,respiratory tract infection,respiratory tract infection sepsis urinary tract infection,1,0.8290535807609558
KYPROLIS,respiratory tract infection,influenza respiratory tract infection,1,0.8994682431221008
KYPROLIS,respiratory tract infection,influenza,0,0.7394532561302185
KYPROLIS,sepsis,nasopharyngitis respiratory tract sepsis urinary tract,1,0.7100363373756409
KYPROLIS,sepsis,influenza,0,0.6695708632469177
KYPROLIS,sepsis,and nutrition,0,0.5582880973815918
KYPROLIS,sepsis,urinary tract infection Metabolism and nutrition disorders hyperglycemia,0,0.6224240660667419
KYPROLIS,sepsis,nutrition disorders hyperglycemia,0,0.5449597835540771
KYPROLIS,sepsis,sepsis urinary tract infection,1,0.8316673040390015
KYPROLIS,sepsis,nasopharyngitis respiratory tract infection,0,0.5622889995574951
KYPROLIS,sepsis,and infestations bronchitis influenza nasopharyngitis respiratory tract infection,0,0.5565155744552612
KYPROLIS,sepsis,sepsis urinary,1,0.8521502017974854
KYPROLIS,urinary tract infection,tract infection urinary tract infection,1,0.9326914548873901
KYPROLIS,urinary tract infection,ions and,0,0.5404846668243408
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia,1,0.7782850861549377
KYPROLIS,hyperglycemia,Metabolism and nutrition hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia,1,0.7084496021270752
KYPROLIS,hyperglycemia,nutrition disorders,0,0.5745131969451904
KYPROLIS,hyperglycemia,ratory tract infection sepsis urinary tract infection,0,0.5146366357803345
KYPROLIS,hyperglycemia,and nutrition hyperglycemia hyperkalemia hyperuricemia,1,0.762010931968689
KYPROLIS,hyperglycemia,hypoalbuminemia hypocalcemia hypomagnesemia,0,0.5975022315979004
KYPROLIS,hyperglycemia,tract infection,0,0.5236645936965942
KYPROLIS,hyperkalemia,urinary tract,0,0.5350593328475952
KYPROLIS,hyperkalemia,hyperkalemia,1,1.0000001192092896
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia,1,0.8402321338653564
KYPROLIS,hyperkalemia,hyperuricemia hypoalbuminemia,0,0.632864773273468
KYPROLIS,hyperkalemia,hypomagnesemia hyponatremia hypophosphatemia tumo,0,0.6413789391517639
KYPROLIS,hyperkalemia,fection,0,0.5196080803871155
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia hypomagnesemia hyponatremia,1,0.8198714256286621
KYPROLIS,hyperuricemia,hypocalcemia hypomagnesemia hyponatremia,0,0.5796857476234436
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hypocalcemia hypomagnesemia hyponatremia,1,0.8144828081130981
KYPROLIS,hyperuricemia,urinary tract infection Metabolism and nutrition,0,0.6801444292068481
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hypocalcemia hypomagnesemia hyponatremia hypophosphatemia,1,0.8057619333267212
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hypocalcemia,1,0.847298264503479
KYPROLIS,hyperuricemia,hypophosphatemia tumor lysis,0,0.5746185779571533
KYPROLIS,hypoalbuminemia,hypoalbuminemia hypocalcemia,1,0.8597993850708008
KYPROLIS,hypoalbuminemia,hypomagnesemia hyponatremia hypophosphatemia tumor lysis,0,0.6037154197692871
KYPROLIS,hypoalbuminemia,hypocalcemia hypomagnesemia hyponatremia hypophosphatemia,0,0.623062252998352
KYPROLIS,hypoalbuminemia,hypomagnesemia hyponatremia hypophosphatemia tumor lysis syndrome,0,0.6084647178649902
KYPROLIS,hypocalcemia,syndrome,0,0.5080115795135498
KYPROLIS,hypocalcemia,hypocalcemia hypomagnesemia hyponatremia hypophosphatemia tumor lysis,1,0.8102452158927917
KYPROLIS,hypocalcemia,lysis,0,0.5055657625198364
KYPROLIS,hypomagnesemia,hypomagnesemia hyponatremia hypophosphatemia tumor lysis,1,0.8387008905410767
KYPROLIS,hypomagnesemia,and connective tissue,0,0.48183688521385193
KYPROLIS,hypomagnesemia,hypomagnesemia hyponatremia,1,0.8922773599624634
KYPROLIS,hypomagnesemia,hypomagnesemia hyponatremia hypophosphatemia tumor lysis syndrome,1,0.8223903179168701
KYPROLIS,hypomagnesemia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypomagnesemia hyponatremia,1,0.7661967277526855
KYPROLIS,hypomagnesemia,hypomagnesemia hyponatremia hypophosphatemia,1,0.8635648488998413
KYPROLIS,hyponatremia,and connective tissue,0,0.47444504499435425
KYPROLIS,hyponatremia,hyponatremia hypophosphatemia,1,0.8037502765655518
KYPROLIS,hyponatremia,hyponatremia hypophosphatemia tumor lysis,1,0.7720714807510376
KYPROLIS,hyponatremia,Musculoskeletal and connective tissue,0,0.4400617778301239
KYPROLIS,hyponatremia,hypophosphatemia tumor lysis syndrome Musculoskeletal and,0,0.5758658647537231
KYPROLIS,hyponatremia,hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia hyponatremia hypophosphatemia tumor,1,0.7254501581192017
KYPROLIS,hyponatremia,syndrome Musculoskeletal and connective tissue disorders,0,0.4336295425891876
KYPROLIS,tumor lysis syndrome,hypoalbuminemia hypocalcemia hypomagnesemia hyponatremia tumor lysis syndrome Musculoskeletal and connective tissue,1,0.7441063523292542
KYPROLIS,tumor lysis syndrome,syndrome Musculoskeletal and connective tissue disorders,0,0.5455888509750366
KYPROLIS,tumor lysis syndrome,tumor lysis syndrome Musculoskeletal and connective,1,0.8492661714553833
KYPROLIS,tumor lysis syndrome,hyponatremia tumor lysis,1,0.8178586959838867
KYPROLIS,tumor lysis syndrome,hypomagnesemia,0,0.585893988609314
KYPROLIS,musculoskeletal chest pain,disorders,0,0.5536579489707947
KYPROLIS,musculoskeletal chest pain,disorders hypoesthesia paresthesia Psychiatric,0,0.5065428614616394
KYPROLIS,musculoskeletal chest pain,hypophosphatemia tumor lysis syndrome Musculoskeletal and connective,0,0.6644495725631714
KYPROLIS,musculoskeletal chest pain,Musculoskeletal and connective tissue musculoskeletal,1,0.7591172456741333
KYPROLIS,myalgia,myalgia Nervous system disorders hypoesthesia paresthesia,1,0.8105449080467224
KYPROLIS,myalgia,chest pain,0,0.6428908109664917
KYPROLIS,myalgia,chest myalgia Nervous system disorders hypoesthesia paresthesia,1,0.7667683362960815
KYPROLIS,myalgia,myalgia,1,0.9999996423721313
KYPROLIS,myalgia,musculoskeletal chest myalgia Nervous system,1,0.7774412631988525
KYPROLIS,myalgia,tissue disorders musculoskeletal chest myalgia Nervous system disorders hypoesthesia,1,0.7359155416488647
KYPROLIS,myalgia,musculoskeletal chest myalgia Nervous,1,0.7671919465065002
KYPROLIS,hypoesthesia,hypoesthesia paresthesia Psychiatric,1,0.8734402656555176
KYPROLIS,paresthesia,paresthesia Psychiatric disorders anxiety Renal,1,0.7874975204467773
KYPROLIS,paresthesia,paresthesia Psychiatric disorders,1,0.8266928791999817
KYPROLIS,paresthesia,paresthesia Psychiatric,1,0.8680555820465088
KYPROLIS,paresthesia,myalgia Nervous system,0,0.5837485194206238
KYPROLIS,paresthesia,system,0,0.5340288877487183
KYPROLIS,paresthesia,Psychiatric disorders anxiety Renal,0,0.5228308439254761
KYPROLIS,paresthesia,chest pain myalgia,0,0.4864843785762787
KYPROLIS,anxiety,and urinary disorders renal impairment,0,0.512133777141571
KYPROLIS,dysphonia,and,0,0.48670703172683716
KYPROLIS,dysphonia,mediastinal dysphonia oropharyngeal pain pulmonary edema Skin,1,0.7522945404052734
KYPROLIS,dysphonia,disorders renal impairment Respiratory thoracic and,0,0.5537121295928955
KYPROLIS,dysphonia,mediastinal dysphonia oropharyngeal pain pulmonary,1,0.7529704570770264
KYPROLIS,dysphonia,urinary disorders renal impairment Respiratory thoracic and,0,0.5521835088729858
KYPROLIS,dysphonia,subcutaneous tissue disorders erythema hype,0,0.5126486420631409
KYPROLIS,dysphonia,dysphonia oropharyngeal pain pulmonary,1,0.7889351844787598
KYPROLIS,dysphonia,dysphonia oropharyngeal pain pulmonary edema Skin,1,0.8019737601280212
KYPROLIS,dysphonia,pain pulmonary edema Skin and subcutaneous tissue disorders erythema,0,0.5149359107017517
KYPROLIS,oropharyngeal pain,disorders,0,0.5452293753623962
KYPROLIS,pulmonary edema,oropharyngeal pulmonary edema Skin and subcutaneous tissue,1,0.8021638989448547
KYPROLIS,pulmonary edema,disorders,0,0.5848894119262695
KYPROLIS,pulmonary edema,erythema hyperhidrosis,0,0.5324968099594116
KYPROLIS,pulmonary edema,subcutaneous tissue disorders erythema hyperhidrosis pruritus rash Vas,0,0.5497878789901733
KYPROLIS,pulmonary edema,mediastinal disorders dysphonia oropharyngeal pulmonary,1,0.6012669801712036
KYPROLIS,pulmonary edema,oropharyngeal pulmonary edema Skin and subcutaneous tissue disorders,1,0.7809270620346069
KYPROLIS,pulmonary edema,mediastinal disorders dysphonia oropharyngeal,0,0.5397967100143433
KYPROLIS,pulmonary edema,disorders dysphonia oropharyngeal pulmonary edema,1,0.7744326591491699
KYPROLIS,pulmonary edema,pulmonary edema Skin,1,0.9002714157104492
KYPROLIS,pulmonary edema,disorders dysphonia oropharyngeal pulmonary edema Skin,1,0.7412968277931213
KYPROLIS,erythema,erythema hyperhidrosis pruritus,1,0.7884811162948608
KYPROLIS,pruritus,pruritus rash,1,0.9252880811691284
KYPROLIS,pruritus,disorders embolic and thrombotic events venous including deep vein thromb,0,0.45635879039764404
KYPROLIS,pruritus,pruritus rash Vascular disorders embolic,1,0.7549072504043579
KYPROLIS,pruritus,tissue disorders erythema pruritus rash Vascular,1,0.734670877456665
KYPROLIS,pruritus,disorders erythema pruritus rash Vascular disorders embolic,1,0.7241294384002686
KYPROLIS,pruritus,pruritus rash Vascular disorders,1,0.7955848574638367
KYPROLIS,pruritus,tissue disorders erythema pruritus,1,0.779404878616333
KYPROLIS,rash,rash Vascular disorders embolic and thrombotic,1,0.7515484094619751
KYPROLIS,rash,edema Skin,0,0.6324204206466675
KYPROLIS,rash,pruritus,0,0.7443514466285706
KYPROLIS,rash,thrombotic events venous including deep vein,0,0.5073187947273254
KYPROLIS,rash,rash,1,1.0000001192092896
KYPROLIS,rash,and,0,0.5314319133758545
KYPROLIS,rash,tissue disorders,0,0.5597127676010132
KYPROLIS,"embolic and thrombotic events, venous","embolic and thrombotic events, venous",1,0.9999999403953552
KYPROLIS,deep vein thrombosis,drosis pruritus rash Vascular disorders,0,0.6247158050537109
KYPROLIS,deep vein thrombosis,vein thrombosis and pulmonary,1,0.841058611869812
KYPROLIS,deep vein thrombosis,and higher adverse reactions occurring at an,0,0.5241497755050659
KYPROLIS,deep vein thrombosis,thrombotic events venous deep vein thrombosis,1,0.8646863698959351
KYPROLIS,deep vein thrombosis,events venous deep vein thrombosis and,1,0.8803306818008423
KYPROLIS,deep vein thrombosis,deep,1,0.561368465423584
KYPROLIS,deep vein thrombosis,vein thrombosis and,1,0.8858629465103149
KYPROLIS,deep vein thrombosis,deep vein,1,0.8429165482521057
KYPROLIS,pulmonary embolism,pulmonary embolism hypotension Grade,1,0.8022549152374268
KYPROLIS,pulmonary embolism,deep vein,1,0.632358193397522
KYPROLIS,pulmonary embolism,including deep vein thrombosis pulmonary,1,0.8401552438735962
KYPROLIS,pulmonary embolism,thrombosis,0,0.8041780591011047
KYPROLIS,pulmonary embolism,at an incidence of include,0,0.5748866200447083
KYPROLIS,pulmonary embolism,pulmonary embolism hypotension Grade and higher,1,0.8120895624160767
KYPROLIS,pulmonary embolism,deep vein,0,0.632358193397522
KYPROLIS,pulmonary embolism,pulmonary,1,0.7724299430847168
KYPROLIS,pulmonary embolism,including deep vein thrombosis pulmonary embolism hypotension Grade and,1,0.7859432697296143
KYPROLIS,pulmonary embolism,deep vein thrombosis pulmonary embolism hypotension Grade and,1,0.7954663634300232
KYPROLIS,hypotension,hypotension Grade,1,0.8730683326721191
KYPROLIS,febrile neutropenia,cardiac arrest cardiac failure congestive pain sepsis urinary tract infection hyperglycemia,0,0.5598381757736206
KYPROLIS,febrile neutropenia,febrile neutropenia cardiac arrest cardiac,1,0.8090722560882568
KYPROLIS,febrile neutropenia,at an incidence of febrile neutropenia cardiac,1,0.8350989818572998
KYPROLIS,cardiac failure congestive,include febrile neutropenia cardiac cardiac failure congestive,1,0.7585822343826294
KYPROLIS,pain,arrest cardiac failure pain,1,0.7143734693527222
KYPROLIS,pain,include febrile neutropenia cardiac cardiac failure congestive,1,0.5447525382041931
KYPROLIS,pain,pain sepsis urinary tract,1,0.6989227533340454
KYPROLIS,pain,pain,1,0.9999999403953552
KYPROLIS,pain,sepsis urinary tract,0,0.5341974496841431
KYPROLIS,pain,febrile neutropenia cardiac arrest cardiac,0,0.5071802735328674
KYPROLIS,sepsis,hyperuricemia hypoalbuminemia,0,0.5217401385307312
KYPROLIS,sepsis,infection hyperglycemia hyperkalemia hyperuricemia,0,0.642785906791687
KYPROLIS,sepsis,sepsis urinary tract,1,0.80903559923172
KYPROLIS,urinary tract infection,congestive pain urinary tract infection,1,0.8494694232940674
KYPROLIS,urinary tract infection,failure congestive pain,0,0.5740147829055786
KYPROLIS,urinary tract infection,sepsis,0,0.6921728849411011
KYPROLIS,urinary tract infection,pain urinary tract infection,1,0.8798749446868896
KYPROLIS,urinary tract infection,tract infection hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia,1,0.7168809771537781
KYPROLIS,urinary tract infection,pain urinary,1,0.7748380303382874
KYPROLIS,hyperglycemia,hyperglycemia,1,1.0000001192092896
KYPROLIS,hyperglycemia,urinary tract hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia,1,0.7227272987365723
KYPROLIS,hyperglycemia,urinary tract hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia hyponatremia,1,0.7112672924995422
KYPROLIS,hyperglycemia,tract hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia,1,0.7572766542434692
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia,1,0.782376766204834
KYPROLIS,hyperkalemia,hyponatremia hypophosphatemia renal failure,0,0.6083183884620667
KYPROLIS,hyperkalemia,hypophosphatemia renal failure renal,0,0.5999948978424072
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia hyponatremia hypophosphatemia,1,0.8192599415779114
KYPROLIS,hyperuricemia,urinary tract,0,0.6116815805435181
KYPROLIS,hyperuricemia,cardiac failure congestive pain sepsis urinary,0,0.5804481506347656
KYPROLIS,hyperuricemia,renal failure acute,0,0.5797454714775085
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hypocalcemia hyponatremia hypophosphatemia renal,1,0.8153584003448486
KYPROLIS,hyperuricemia,hypoalbuminemia hypocalcemia hyponatremia,0,0.6271793842315674
KYPROLIS,hypoalbuminemia,tract infection,0,0.49273067712783813
KYPROLIS,hyponatremia,pulmonary,0,0.5175647139549255
KYPROLIS,hyponatremia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hyponatremia,1,0.7375025749206543
KYPROLIS,hyponatremia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hyponatremia hypophosphatemia renal,1,0.7256067395210266
KYPROLIS,hyponatremia,hyponatremia,1,1.0
KYPROLIS,hyponatremia,hyponatremia hypophosphatemia renal failure renal failure,1,0.7644221782684326
KYPROLIS,hyponatremia,hypoalbuminemia hyponatremia hypophosphatemia renal failure renal failure,1,0.7170688509941101
KYPROLIS,hypophosphatemia,hyperuricemia hypoalbuminemia hypocalcemia hypophosphatemia renal failure,1,0.7682797312736511
KYPROLIS,hypophosphatemia,hyponatremia hypophosphatemia renal failure renal failure,1,0.8296616673469543
KYPROLIS,hypophosphatemia,hypophosphatemia renal failure,1,0.8806707859039307
KYPROLIS,hypophosphatemia,hypophosphatemia renal,1,0.8850807547569275
KYPROLIS,hypophosphatemia,acute renal,0,0.4857977628707886
KYPROLIS,hypophosphatemia,infection hyperglycemia hyperkalemia hyperuricemia,0,0.5640053153038025
KYPROLIS,renal failure,hypoalbuminemia hypocalcemia hyponatremia renal failure renal,1,0.7595303058624268
KYPROLIS,renal failure,infection hyperglycemia hyperkalemia hyperuricemia,0,0.5945764183998108
KYPROLIS,renal failure,renal impairment pulmonary edema and,0,0.7883315086364746
KYPROLIS,renal failure,renal failure renal failure,1,0.9255394339561462
KYPROLIS,renal failure,and hypotension,0,0.6050000190734863
KYPROLIS,renal failure,hyperuricemia hypoalbuminemia hypocalcemia hyponatremia hypophosphatemia,0,0.6085143685340881
KYPROLIS,renal failure,renal failure renal failure acute,1,0.8526483774185181
KYPROLIS,renal failure,renal,1,0.8547980785369873
KYPROLIS,renal failure acute,renal failure acute renal impairment pulmonary,1,0.8649524450302124
KYPROLIS,renal failure acute,renal failure acute renal impairment pulmonary edema and,1,0.8413794040679932
KYPROLIS,renal impairment,failure renal failure renal impairment pulmonary,1,0.8461915850639343
KYPROLIS,renal impairment,renal failure acute renal impairment pulmonary edema and,1,0.8244636654853821
KYPROLIS,renal impairment,failure,0,0.5319516658782959
KYPROLIS,renal impairment,renal impairment pulmonary edema and hypotension Laboratory,1,0.8108443021774292
KYPROLIS,renal impairment,failure renal failure renal impairment,1,0.9365440607070923
KYPROLIS,pulmonary edema,pulmonary edema and hypotension Laboratory Abnormalities Table,1,0.8105205297470093
KYPROLIS,pulmonary edema,describes,0,0.520329475402832
KYPROLIS,pulmonary edema,and hypotension Laboratory Abnormalities Table describes,0,0.5600918531417847
KYPROLIS,pulmonary edema,pulmonary edema and hypotension,1,0.8944522738456726
KYPROLIS,pulmonary edema,renal failure,0,0.5965025424957275
KYPROLIS,pulmonary edema,Laboratory Abnormalities Table describes,0,0.5276359915733337
KYPROLIS,pulmonary edema,impairment,0,0.5698208808898926
KYPROLIS,hypotension,Table describes Grade laboratory abnormalities,0,0.532049834728241
KYPROLIS,hypotension,Laboratory Abnormalities Table describes Grade laboratory abnormalities,0,0.5362522602081299
KYPROLIS,hypotension,failure renal failure acute renal impairment pulmonary edema and,0,0.6236182451248169
KYPROLIS,hypotension,edema hypotension Laboratory Abnormalities Table describes Grade,1,0.7513293027877808
KYPROLIS,hypotension,hypotension Laboratory Abnormalities Table,1,0.8011392951011658
KYPROLIS,hypotension,hypotension Laboratory Abnormalities,1,0.8157252073287964
KYPROLIS,hypotension,hypotension,1,1.0
KYPROLIS,hypotension,Laboratory,0,0.5150481462478638
KYPROLIS,hypotension,Abnormalities Table describes Grade laboratory abnormalities r,0,0.5387294888496399
KYPROLIS,Decreased Platelets,Reaction KyprolisN,0,0.5544593334197998
KYPROLIS,Decreased Hemoglobin,Lymphocytes,0,0.5348401069641113
KYPROLIS,Decreased Total White Blood Cell Count,Decreased Decreased Total White Blood Cell Count Decreased Sodium,1,0.89361572265625
KYPROLIS,Decreased Total White Blood Cell Count,Lymphocytes,0,0.6717709302902222
KYPROLIS,Decreased Total White Blood Cell Count,Decreased Hemoglobin,0,0.7331706881523132
KYPROLIS,Decreased Total White Blood Cell Count,Total White Blood Cell Count Decreased Sodium,1,0.8661205768585205
KYPROLIS,Decreased Total White Blood Cell Count,Hemoglobin,0,0.5887278914451599
KYPROLIS,Decreased Total White Blood Cell Count,Decreased Decreased Total White Blood,1,0.9056251645088196
KYPROLIS,Decreased Total White Blood Cell Count,Decreased Total White Blood Cell Count Decreased,1,0.9847590327262878
KYPROLIS,Decreased Total White Blood Cell Count,Decreased Total White Blood Cell Count,1,1.0
KYPROLIS,Decreased Sodium,White Blood Cell Decreased Sodium Decreased Absolute,1,0.8364590406417847
KYPROLIS,Decreased Sodium,Decreased Total White Blood Cell Count,1,0.6522367000579834
KYPROLIS,Decreased Sodium,Decreased Sodium,1,1.0
KYPROLIS,Decreased Sodium,Decreased Absolute Neu,0,0.6823131442070007
KYPROLIS,Decreased Sodium,Decreased Absolute,0,0.7123328447341919
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased,0,0.6823714971542358
KYPROLIS,Decreased Absolute Neutrophil Count,Sodium,0,0.5086312294006348
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Decreased Absolute Neutrophil,1,0.9497416019439697
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Absolute Neutrophil Count Postmarketing Experience,1,0.8962170481681824
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Decreased Absolute Neutrophil Count,1,0.9908990859985352
KYPROLIS,Decreased Absolute Neutrophil Count,Neutrophil Count Postmarketing Experience,1,0.7832951545715332
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Decreased Absolute Neutrophil Count Postmarketing,1,0.9089943766593933
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Absolute,1,0.7310076951980591
KYPROLIS,dehydration,dehydration thrombotic thrombocytopenic purpurahemolytic uremic,1,0.753090500831604
KYPROLIS,dehydration,or establish a causal relationship to,0,0.5131381750106812
KYPROLIS,dehydration,exposure,0,0.5678253173828125
KYPROLIS,dehydration,dehydration thrombotic,1,0.8030081391334534
KYPROLIS,thrombotic thrombocytopenic purpura,establish a causal relationship,0,0.45062607526779175
KYPROLIS,thrombotic thrombocytopenic purpura,or establish a causal relationship to,0,0.4475224018096924
KYPROLIS,thrombotic thrombocytopenic purpura,causal relationship to drug exposure dehydration,0,0.4748290777206421
KYPROLIS,thrombotic thrombocytopenic purpura,thrombocytopenic purpura hemolytic uremic,1,0.8609511852264404
KYPROLIS,thrombotic thrombocytopenic purpura,thrombotic thrombocytopenic,1,0.9159977436065674
KYPROLIS,thrombotic thrombocytopenic purpura,relationship to drug exposure thrombotic,1,0.7056399583816528
KYPROLIS,hemolytic uremic syndrome,syndrome including fatal outcomes and posterior reversible encephalopathy,0,0.6285254955291748
KYPROLIS,hemolytic uremic syndrome,dehydration thrombotic thrombocytopenic hemolytic uremic,1,0.7732037305831909
KYPROLIS,hemolytic uremic syndrome,exposure dehydration thrombotic thrombocytopenic hemolytic,1,0.7310305833816528
KYPROLIS,hemolytic uremic syndrome,to drug,0,0.36835968494415283
KYPROLIS,hemolytic uremic syndrome,exposure dehydration thrombotic thrombocytopenic hemolytic uremic syndrome TTPHUS tumor lysis syndrome,1,0.7677263021469116
KYPROLIS,hemolytic uremic syndrome,thrombocytopenic hemolytic uremic,1,0.839626133441925
KYPROLIS,TTP,syndrome,0,0.472883939743042
KYPROLIS,TTP,TTP HUS,1,0.8263855576515198
KYPROLIS,TTP,drug exposure dehydration thrombotic,0,0.5337821245193481
KYPROLIS,TTP,TTP,1,1.0000001192092896
KYPROLIS,TTP,dehydration thrombotic thrombocytopenic purpurahemolytic uremic,0,0.5591026544570923
KYPROLIS,TTP,purpurahemolytic uremic TTP HUS tumor lysis syndrome including,1,0.5690851211547852
KYPROLIS,TTP,TTP HUS tumor lysis,1,0.6706435680389404
KYPROLIS,tumor lysis syndrome,uremic,0,0.5827794075012207
KYPROLIS,tumor lysis syndrome,lysis syndrome including fatal,1,0.7991961240768433
KYPROLIS,tumor lysis syndrome,purpurahemolytic uremic syndrome tumor lysis syndrome including fatal outcomes and,1,0.8363574743270874
KYPROLIS,tumor lysis syndrome,rug exposure dehydration thrombotic,0,0.5888252258300781
KYPROLIS,tumor lysis syndrome,lysis syndrome including fatal outcomes and posterior,1,0.7959346175193787
KYPROLIS,tumor lysis syndrome,purpurahemolytic uremic syndrome tumor lysis syndrome,1,0.8659498691558838
KYPROLIS,tumor lysis syndrome,lysis syndrome including fatal outcomes and,1,0.7972568273544312
KYPROLIS,fatal,fatal outcomes and posterior,1,0.7187615633010864
KYPROLIS,fatal,thrombocytopenic purpurahemolytic uremic syndrome TTPHUS tumor,0,0.5257317423820496
KYPROLIS,fatal,outcomes and posterior reversible encephalopathy syndrome,0,0.5247982740402222
KYPROLIS,fatal,and posterior reversible encephalopathy syndrome PRES,0,0.5153766870498657
KYPROLIS,fatal,reversible encephalopathy syndrome,0,0.5554689764976501
KYPROLIS,fatal,uremic syndrome TTPHUS,0,0.5317777991294861
KYPROLIS,Cardiac toxicities,ions are discussed,1,0.5932447910308838
KYPROLIS,Cardiac toxicities,ions are discussed in,1,0.5930081605911255
KYPROLIS,Cardiac toxicities,sections of the labeling,0,0.494403213262558
KYPROLIS,Cardiac toxicities,are discussed in,1,0.4969088137149811
KYPROLIS,Cardiac toxicities,ions are discussed in greater detail in other,1,0.5773296356201172
KYPROLIS,cardiac failure,adverse reactions are discussed in great,0,0.5445115566253662
KYPROLIS,myocardial infarction,ections,1,0.5402529239654541
KYPROLIS,myocardial infarction,detail in other ections of the,1,0.5318945646286011
KYPROLIS,myocardial infarction,and Precautions,0,0.4955967664718628
KYPROLIS,myocardial infarction,ections of the labeli,1,0.4911900460720062
KYPROLIS,myocardial infarction,Precautions Acute,0,0.547477662563324
KYPROLIS,myocardial infarction,discussed in,0,0.49892905354499817
KYPROLIS,myocardial infarction,other ections of the labeli ng Cardiac Toxicities,1,0.6526432037353516
KYPROLIS,myocardial infarction,detail in other ections of the labeli ng Cardiac Toxicities see Warnings,1,0.6380084753036499
KYPROLIS,myocardial infarction,see Warnings and Precautions Acute,0,0.5508006811141968
KYPROLIS,fatal,"
 *   Cardiac Toxicities see Warnings and",1,0.6390817165374756
KYPROLIS,fatal,labeling,0,0.49907711148262024
KYPROLIS,fatal,"other sections of the 
 *   Cardiac Toxicities see Warnings and",1,0.6343958973884583
KYPROLIS,fatal,"
 *   Cardiac Toxicities see",1,0.6588987708091736
KYPROLIS,fatal,the labeling,0,0.5040940046310425
KYPROLIS,myocardial ischemia,Precautions Acute Renal Failure see Warnings and,0,0.5304039716720581
KYPROLIS,myocardial ischemia,of the labeling Cardiac cities [ see Warnin,1,0.5832964777946472
KYPROLIS,myocardial ischemia,labeling Cardiac cities [ see Warnin gs and Precautions,1,0.6049332022666931
KYPROLIS,myocardial ischemia,Renal Failure see Warnings,0,0.5204969048500061
KYPROLIS,myocardial ischemia,gs and Precautions Acute Renal Failure,0,0.5300552248954773
KYPROLIS,Acute Renal Failure,Failure,0,0.587551474571228
KYPROLIS,Acute Renal Failure,Lysis Syndrome see Warnings and,0,0.5702828764915466
KYPROLIS,Acute Renal Failure,Syndrome see Warnings and Precautions,0,0.49940967559814453
KYPROLIS,Acute Renal Failure,Renal see Warnings and Pr ecautions Tumor,1,0.6558761596679688
KYPROLIS,Acute Renal Failure,and Pr ecautions Tumor Lysis Syndrome see,1,0.5868769288063049
KYPROLIS,Acute Renal Failure,see Warnings and Precautions,0,0.4823707342147827
KYPROLIS,Tumor Lysis Syndrome,Precautions Tumor Lysis Syndrome e,1,0.8700923919677734
KYPROLIS,Tumor Lysis Syndrome,utions Pulmonary Toxicity see Warnings and,0,0.51206374168396
KYPROLIS,Tumor Lysis Syndrome,Precautions Tumor Lysis Syndrome e Warnings and Preca utions Pulmonary Toxicity see,1,0.8033621311187744
KYPROLIS,Tumor Lysis Syndrome,Renal,0,0.5736534595489502
KYPROLIS,Tumor Lysis Syndrome,and Preca utions Pulmonary Toxicity see Warnings,1,0.5037816762924194
KYPROLIS,Tumor Lysis Syndrome,and Precautions Pulmo,0,0.45764172077178955
KYPROLIS,Tumor Lysis Syndrome,Syndrome e Warnings and Preca utions,1,0.5566831827163696
KYPROLIS,Tumor Lysis Syndrome,Syndrome se,0,0.6160001754760742
KYPROLIS,Tumor Lysis Syndrome,Tumor Lysis Syndrome e Warnings and Preca utions,1,0.8801466226577759
KYPROLIS,Tumor Lysis Syndrome,Renal Failure see Warnings and Precautions Tumor Lysis Syndrome,0,0.8562681674957275
KYPROLIS,TLS,ion,1,0.5516356825828552
KYPROLIS,TLS,s Pulmonary,0,0.5304319262504578
KYPROLIS,Pulmonary Toxicity,Hypertension see Warnings d Precautions (,1,0.4981870651245117
KYPROLIS,Pulmonary Toxicity,Warnings d Precautions (  5 Dyspnea see,1,0.611953854560852
KYPROLIS,Acute Respiratory Distress Syndrome,[ see Warnings and Preca utions Hypertension see Warnings and,1,0.5135521292686462
KYPROLIS,Acute Respiratory Distress Syndrome,utions Hypertension see Warnings and Precautions Venous Thro,0,0.5232865810394287
KYPROLIS,Acute Respiratory Distress Syndrome,see Warnings and Preca utions Hypertension see Warnings,1,0.5024806261062622
KYPROLIS,Acute Respiratory Distress Syndrome,Dyspnea [ see Warnings and Preca utions,1,0.6184486150741577
KYPROLIS,Acute Respiratory Distress Syndrome,Warnings and    Dyspnea [ see Warnings and Preca utions Hypertension,1,0.597521185874939
KYPROLIS,Acute Respiratory Distress Syndrome,see,0,0.5355579257011414
KYPROLIS,Acute Respiratory Distress Syndrome,Warnings and    Dyspnea [ see Warnings and Preca utions Hypertension see,1,0.6024347543716431
KYPROLIS,acute respiratory failure,* H ypertension,1,0.4985277056694031
KYPROLIS,acute respiratory failure,] * H ypertension,1,0.5017369985580444
KYPROLIS,acute respiratory failure,) ] * H ypertension see Warnings and,1,0.5027981400489807
KYPROLIS,acute respiratory failure,Warnings,0,0.5115850567817688
KYPROLIS,acute respiratory failure,Warnings and ions ( 5.6 ),1,0.49391958117485046
KYPROLIS,acute respiratory failure,* H ypertension see Warnings,1,0.5027421116828918
KYPROLIS,acute respiratory failure,"see Warnings and ions (  5.6  ) ] 
 *    H ypertension",1,0.4814830422401428
KYPROLIS,acute respiratory failure,* H,1,0.5296289920806885
KYPROLIS,acute respiratory failure,ions ( 5.6 ) ],1,0.4814146161079407
KYPROLIS,acute diffuse infiltrative pulmonary disease,nsion,1,0.47460663318634033
KYPROLIS,acute diffuse infiltrative pulmonary disease,and Precautions ( 5.7 Venous Thrombosis,1,0.5275633931159973
KYPROLIS,Pulmonary Hypertension,nfusion Reactions see Warnings and,0,0.5419749021530151
KYPROLIS,Pulmonary Hypertension,Warnings and,0,0.5357515215873718
KYPROLIS,Pulmonary Hypertension,"s (  5.8  ) ] 
 *    I nfusion",1,0.572540283203125
KYPROLIS,Pulmonary Hypertension,Warnings and s ( 5.8,1,0.5128760933876038
KYPROLIS,Pulmonary Hypertension,"see Warnings and s (  5.8  ) ] 
 *    I nfusion Reactions",1,0.558294415473938
KYPROLIS,Pulmonary Hypertension,"s (  5.8  ) ] 
 *    I nfusion Reactions see Warnings",1,0.5568816661834717
KYPROLIS,Pulmonary Hypertension,Warnings and s ( 5.8 ),1,0.5108517408370972
KYPROLIS,Pulmonary Hypertension,see Warnings,0,0.5317903757095337
KYPROLIS,Pulmonary Hypertension,s ( 5.8 ) ] * I,1,0.5303008556365967
KYPROLIS,Hypertension,and Precautions Toxicity and Hepatic Failure,1,0.5195627212524414
KYPROLIS,Hypertension,s ( 5.8 ) ] * I,1,0.5316993594169617
KYPROLIS,hypertensive crisis,and Hepatic,0,0.5243993401527405
KYPROLIS,hypertensive crisis,Warnings,0,0.5207235813140869
KYPROLIS,Infusion Reactions,5.13 )],1,0.4714716076850891
KYPROLIS,Infusion Reactions,Warnings and Precaution,0,0.5691949129104614
KYPROLIS,Infusion Reactions,PRES see Warnings and Precaution,0,0.5358757376670837
KYPROLIS,Infusion Reactions,most common adverse events occurring in at least of patients treated with Ky,0,0.6262750029563904
KYPROLIS,Thrombocytopenia,anemia,0,0.6230168342590332
KYPROLIS,Thrombocytopenia,common adverse events occurring at least 20%,1,0.4745372235774994
KYPROLIS,Hepatic Toxicity,"d platelets, dys pnea",1,0.48434165120124817
KYPROLIS,Hepatic Toxicity,"thrombocytopenia nausea pyrexia d platelets, dys",1,0.5799206495285034
KYPROLIS,Hepatic Toxicity,pnea diarrhea decreased lymphocyte headache decreased hemoglobin cough edema,0,0.5240451693534851
KYPROLIS,Hepatic Toxicity,"d platelets, dys",1,0.5269706845283508
KYPROLIS,Hepatic Toxicity,"fatigue thrombocytopenia nausea pyrexia d platelets, dys",1,0.5711227655410767
KYPROLIS,Hepatic Toxicity,anemia,0,0.5564637780189514
KYPROLIS,Hepatic Toxicity,pyrexia,0,0.5391828417778015
KYPROLIS,Hepatic Toxicity,pnea,0,0.4390323758125305
KYPROLIS,Hepatic Failure,lymphocyte headache decreased hemoglobin cough,0,0.5187854766845703
KYPROLIS,Hepatic Failure,"nausea pyrexia decreased platelets  diarrhea, decr",1,0.5738372206687927
KYPROLIS,Hepatic Failure,anemia fatigue thrombocytopenia nausea pyrexia decreased,0,0.5926737785339355
KYPROLIS,Hepatic Failure,onotherapy trials anemia fatigue thrombocytopenia nausea pyrexia decreased platelets,0,0.5815060138702393
KYPROLIS,Thrombotic thrombocytopenic purpura,patients treated,0,0.560248613357544
KYPROLIS,Thrombotic thrombocytopenic purpura,6 ) The most common advers e events occurring in,1,0.4871080219745636
KYPROLIS,Thrombotic thrombocytopenic purpura,dyspnea diarrhea decreased,0,0.517496645450592
KYPROLIS,Thrombotic thrombocytopenic purpura,cough edema,0,0.48691993951797485
KYPROLIS,Thrombotic thrombocytopenic purpura,The most common advers e events occurring,1,0.48462653160095215
KYPROLIS,Thrombotic thrombocytopenic purpura,most common advers e events occurring in at,1,0.5103644132614136
KYPROLIS,Thrombotic thrombocytopenic purpura,dyspnea diarrhea decreased lymphocyte headache decreased hemoglobin cough,0,0.55577552318573
KYPROLIS,Thrombotic thrombocytopenic purpura,in the combination therapy tria,0,0.5685750842094421
KYPROLIS,hemolytic uremic syndrome,peripheral The most common events,1,0.47095948457717896
KYPROLIS,hemolytic uremic syndrome,The most common  events occurring in at l east,1,0.48969531059265137
KYPROLIS,hemolytic uremic syndrome,most common events occurring in,1,0.4974786639213562
KYPROLIS,hemolytic uremic syndrome,with Kyprolis in the combination,0,0.4918556809425354
KYPROLIS,hemolytic uremic syndrome,in at l east of,1,0.4689635932445526
KYPROLIS,hemolytic uremic syndrome,events,1,0.5039989948272705
KYPROLIS,hemolytic uremic syndrome,The most common events,1,0.48004719614982605
KYPROLIS,hemolytic uremic syndrome,headache decreased hemoglobin cough edema peripheral The most,0,0.55318284034729
KYPROLIS,HUS,at 0%  of patients treated with Kyprolis,1,0.47617679834365845
KYPROLIS,HUS,headache decreased hemoglobin cough edema peripheral The most,0,0.5309147238731384
KYPROLIS,Posterior reversible encephalopathy syndrome,therapy trial decreased lymphocytes d absolute neutrophil,1,0.5090746283531189
KYPROLIS,Posterior reversible encephalopathy syndrome,decreased total white blood cell count,0,0.5131556987762451
KYPROLIS,PRES,white blood,0,0.4828779101371765
KYPROLIS,PRES,"rus, anemia neutropenia decreased total",1,0.46355319023132324
KYPROLIS,PRES,"rus, anemia neutropenia decreased",1,0.465273380279541
KYPROLIS,PRES,"decreased rus, anemia neutropenia",1,0.4691518247127533
KYPROLIS,PRES,"rus, anemia neutropenia",1,0.45734912157058716
KYPROLIS,PRES,"decreased rus, anemia",1,0.46583932638168335
KYPROLIS,PRES,ination,0,0.5189162492752075
KYPROLIS,PRES,phospho,0,0.5366430878639221
KYPROLIS,PRES,total white blood cell count decreased,0,0.4287322461605072
KYPROLIS,Embryo-fetal Toxicity,"pyrexia muscle spasm ough, upper respirato ry tract infection decreased hemoglobin",1,0.49421966075897217
KYPROLIS,Embryo-fetal Toxicity,total white blood cell count decreased,0,0.47184446454048157
KYPROLIS,worsening of pre-existing cardiac failure,conducted under widely varying,0,0.5298559665679932
KYPROLIS,worsening of pre-existing cardiac failure,AMGEN or FDA at A-1088 or,1,0.5044345259666443
KYPROLIS,congestive heart failure,6.1 Clinical Trials Expe rience Because clinical trials are,1,0.5473835468292236
KYPROLIS,congestive heart failure,AMGEN or FDA at A-1088 or,1,0.5104245543479919
KYPROLIS,congestive heart failure,6.1 Clinical Trials Expe rience Because clinical trials,1,0.5481748580932617
KYPROLIS,congestive heart failure,AMGEN or FDA at FDA,0,0.5158019661903381
KYPROLIS,congestive heart failure,6.1 Clinical Trials Expe rience Because,1,0.548934280872345
KYPROLIS,pulmonary edema,Clinical,0,0.562352180480957
KYPROLIS,pulmonary edema,"ence

  Because",1,0.5157161951065063
KYPROLIS,pulmonary edema,adverse reaction rates observed,0,0.5288578271865845
KYPROLIS,pulmonary edema,at FDA or wwwfdagovmedwatch,0,0.5038028955459595
KYPROLIS,pulmonary edema,clinical trials are conducted under,0,0.5058268904685974
KYPROLIS,pulmonary edema,"Trials ence

  Because clinical trials are conducted",1,0.5507268309593201
KYPROLIS,pulmonary edema,Clinical Trials ence Because,1,0.5533090829849243
KYPROLIS,pulmonary edema,at FDA or wwwfdagovmedwatch Clinical,0,0.5069453716278076
KYPROLIS,pulmonary edema,ence Because clinical trials are,1,0.5679657459259033
KYPROLIS,pulmonary edema,"Trials ence

  Because clinical trials are conducted under",1,0.5530461668968201
KYPROLIS,decreased ejection fraction,d under widely,0,0.515643835067749
KYPROLIS,myocardial ischemia,Experience,0,0.49814704060554504
KYPROLIS,myocardial ischemia,of a drug cannot be directly compared with rates,0,0.5023449063301086
KYPROLIS,myocardial ischemia,adverse reactio n rates observed in the,1,0.5598345994949341
KYPROLIS,myocardial ischemia,adverse reactio,1,0.5769677758216858
KYPROLIS,myocardial ischemia,"under widely varying ns, adverse",1,0.5305756330490112
KYPROLIS,myocardial ischemia,adverse reactio n,1,0.5664674639701843
KYPROLIS,myocardial ischemia,"ns, adverse reactio",1,0.5743175745010376
KYPROLIS,myocardial ischemia,rates in the clin,0,0.5432069301605225
KYPROLIS,myocardial infarction,reaction s observed in the cli,1,0.5348845720291138
KYPROLIS,myocardial infarction,widely,0,0.47218388319015503
KYPROLIS,myocardial infarction,trials are conducted under widely varying conditions adverse,0,0.550675630569458
KYPROLIS,myocardial infarction,be directly compared with rates in the clinical trials of another drug,0,0.560871958732605
KYPROLIS,myocardial infarction,drug cannot be directly compared with rates in the clinical trials of another drug,0,0.5056056976318359
KYPROLIS,myocardial infarction,s observed in the cli nical trials,1,0.5524755716323853
KYPROLIS,myocardial infarction,in the cli nical trials of a drug,1,0.5666526556015015
KYPROLIS,myocardial infarction,reaction s observed in the cli nical trials of a drug,1,0.5847965478897095
KYPROLIS,myocardial infarction,in the cli nical trials of a,1,0.5422871112823486
KYPROLIS,fatalities,rates in the clinical trials of another drug,0,0.5053214430809021
KYPROLIS,fatalities,observed in the clinical s of a dru g,1,0.5456783771514893
KYPROLIS,fatalities,of another drug and may,0,0.48536378145217896
KYPROLIS,fatalities,s of a dru,1,0.5000866651535034
KYPROLIS,Death,Safety Experience ith K yprolis in Combination with Lenalidomide,1,0.5352224111557007
KYPROLIS,Death,s of a dru,1,0.5295369029045105
KYPROLIS,Death,Patients with Multiple Myeloma,0,0.47724929451942444
KYPROLIS,Death,ith K yprolis in Combination,1,0.554602861404419
KYPROLIS,Death,ith K,1,0.5590950846672058
KYPROLIS,Death,practice Safety Experience ith K,1,0.5386389493942261
KYPROLIS,cardiac arrest,Multiple Myeloma The,0,0.418470561504364
KYPROLIS,acute renal failure,arm were pneumoni a,1,0.5351430773735046
KYPROLIS,acute renal failure,in the Rd arm The most common,0,0.513881266117096
KYPROLIS,acute renal failure,the KRd arm as,0,0.5002724528312683
KYPROLIS,acute renal failure,with the d arm,1,0.5000209808349609
KYPROLIS,acute renal failure,with the d arm were pneumoni a,1,0.5294215679168701
KYPROLIS,acute renal failure,infection versus,0,0.5409245491027832
KYPROLIS,acute renal failure,events reported in the KRd arm as,0,0.5047528743743896
KYPROLIS,acute renal failure,tract infection versus pyrexia,0,0.5676531195640564
KYPROLIS,Renal insufficiency adverse events,arm as compared with the Rd arm were pneumonia versus respiratory tract infection,0,0.5477313995361328
KYPROLIS,Renal insufficiency adverse events,embolism versus Discontinuation due to any,0,0.548225462436676
KYPROLIS,Renal insufficiency adverse events,pyrexia (4% ver sus and pulmonary embolism,1,0.5390030145645142
KYPROLIS,Renal insufficiency adverse events,"versus respiratory tract (4% versus 1.5%), pyrexia (4%",1,0.496334046125412
KYPROLIS,Renal insufficiency adverse events,infection,0,0.5265412330627441
KYPROLIS,Renal insufficiency adverse events,tract (4% versus,1,0.4960291385650635
KYPROLIS,Renal insufficiency adverse events,event,0,0.5134352445602417
KYPROLIS,renal impairment,"s 2%), and pulmo nary embolism versus Discontinuation due",1,0.5290019512176514
KYPROLIS,renal impairment,event,0,0.5122528076171875
KYPROLIS,renal impairment,respiratory tract,0,0.5866470336914062
KYPROLIS,renal impairment,versus pyrexia s,1,0.49320775270462036
KYPROLIS,renal impairment,respiratory tract infection,0,0.5969393253326416
KYPROLIS,acute renal failure,(3% ver sus,1,0.4931045174598694
KYPROLIS,acute renal failure,versus pyrexia versus and ry embolism,1,0.5742044448852539
KYPROLIS,acute renal failure,embolism (3% ver sus,1,0.539695143699646
KYPROLIS,acute renal failure,infection,0,0.572745680809021
KYPROLIS,acute renal failure,versus respiratory tract infection versus pyrexia versus,0,0.5559540390968323
KYPROLIS,acute renal failure,arm,0,0.5381685495376587
KYPROLIS,acute renal failure,ry embolism (3% ver sus Discontinuation,1,0.5211658477783203
KYPROLIS,acute renal failure,ry embolism (3% ver sus Discontinuation due to,1,0.5157722234725952
KYPROLIS,acute renal failure,versus pyrexia versus and ry embolism (3% ver,1,0.5730479955673218
KYPROLIS,acute renal failure,versus pyrexia versus and ry embolism (3%,1,0.5731832981109619
KYPROLIS,renal failure,infection versus pyrexia versus,0,0.5347459316253662
KYPROLIS,renal failure,embolism,0,0.5639684200286865
KYPROLIS,renal failure,event occurred in in the KRd arm,0,0.5143306255340576
KYPROLIS,renal failure,embolism s 2%). Discon tinuation due to any,1,0.5270717144012451
KYPROLIS,renal failure,s 2%). Discon tinuation due to any,1,0.5057725310325623
KYPROLIS,renal failure,2%). Discon tinuation,1,0.4791601300239563
KYPROLIS,renal failure,s 2%). Discon,1,0.5040366649627686
KYPROLIS,renal failure,arm versus in,0,0.5169264078140259
KYPROLIS,renal failure,and pulmonary embolism s 2%). Discon tinuation due to any adverse,1,0.5493422746658325
KYPROLIS,Acute renal failure,versus in the Rd rm. Adverse events  leading to discontinuation of,1,0.5368639230728149
KYPROLIS,Acute renal failure,arm versus in,0,0.5136452913284302
KYPROLIS,Acute renal failure,Rd rm. Adverse,1,0.5659540295600891
KYPROLIS,Acute renal failure,patients and the most common,0,0.5065667629241943
KYPROLIS,Acute renal failure,the KRd arm versus,0,0.5188379883766174
KYPROLIS,Acute renal failure,the Rd rm.,1,0.47103509306907654
KYPROLIS,Acute renal failure,any adverse event occurred in in the KRd arm versus in the Rd,0,0.5875899791717529
KYPROLIS,Acute renal failure,rm. Adverse events leading to discontinuation,1,0.5257881879806519
KYPROLIS,TLS,lenalidomideand lowdose,0,0.5494500994682312
KYPROLIS,TLS,Kyprolis lenalidomideand lowdose has one Rd lenalidomide,1,0.560453474521637
KYPROLIS,TLS,has one Rd lenalidomide and,1,0.5551948547363281
KYPROLIS,TLS,has one Rd lenalidomide and lowdose,1,0.5602931976318359
KYPROLIS,TLS,has one Rd lenalidomide,1,0.5543660521507263
KYPROLIS,fatal,Pneumonia includes preferred terms,0,0.5174632668495178
KYPROLIS,fatal,alido mide and lowdose,1,0.5044791102409363
KYPROLIS,fatal,lenalidomideand lowdose dexamethasone Rd len,0,0.46667107939720154
KYPROLIS,fatal,alido mide and lowdose dexamethasone a,1,0.4816437363624573
KYPROLIS,fatal,of,0,0.5430633425712585
KYPROLIS,Acute Respiratory Distress Syndrome,Grade Grade Any,0,0.4490697681903839
KYPROLIS,Acute Respiratory Distress Syndrome,Preferred Term Any Grade Grade Any Grade,1,0.46156734228134155
KYPROLIS,Acute Respiratory Distress Syndrome,Class KRd ArmN Rd 389),1,0.5069961547851562
KYPROLIS,Acute Respiratory Distress Syndrome,Any Grade Grade Any Grade,0,0.44864386320114136
KYPROLIS,Acute Respiratory Distress Syndrome,"389)    
  Preferred Term           Any",1,0.46700578927993774
KYPROLIS,Acute Respiratory Distress Syndrome,Organ Class,0,0.5000884532928467
KYPROLIS,Acute Respiratory Distress Syndrome,Preferred Term Any Grade,1,0.4618292450904846
KYPROLIS,Acute Respiratory Distress Syndrome,"KRd ArmN Rd 389)    
  Preferred Term           Any Grade Grade",1,0.48377132415771484
KYPROLIS,Acute Respiratory Distress Syndrome,Rd 389) Preferred Term,1,0.49506041407585144
KYPROLIS,ARDS,Grade,0,0.513401448726654
KYPROLIS,ARDS,     Any,1,0.5366314649581909
KYPROLIS,ARDS,    ,1,0.5926731824874878
KYPROLIS,ARDS,Grade Grade,0,0.4933922290802002
KYPROLIS,ARDS,Any Grade Grade Blood,0,0.5336353778839111
KYPROLIS,acute respiratory failure,ArmN Preferred,0,0.5517889857292175
KYPROLIS,acute respiratory failure,Any Grad e,1,0.4777515232563019
KYPROLIS,acute respiratory failure,Preferred Term,0,0.4878820776939392
KYPROLIS,acute respiratory failure,Any Grad e Grade Any,1,0.4748278260231018
KYPROLIS,acute respiratory failure,Any Grad,1,0.4650420844554901
KYPROLIS,acute respiratory failure,Any Grade Grade Blood and Lymphatic,0,0.486861914396286
KYPROLIS,acute respiratory failure,Rd ArmN Preferred                  Any Grad,1,0.5161879658699036
KYPROLIS,acute respiratory failure,Rd ArmN,0,0.5727282762527466
KYPROLIS,acute respiratory failure,Grade Any Grade Grade Blood and Lymphatic System,0,0.477817565202713
KYPROLIS,acute respiratory failure,Grade Any Grade Grade Blood and Lymphatic,0,0.4773038625717163
KYPROLIS,acute diffuse infiltrative pulmonary disease,Term,0,0.5132991671562195
KYPROLIS,acute diffuse infiltrative pulmonary disease,Term Any >=,1,0.4569360613822937
KYPROLIS,acute diffuse infiltrative pulmonary disease,>= Grade 3 Any Grade >= Grade Blood and Lymphatic System,1,0.4989890456199646
KYPROLIS,acute diffuse infiltrative pulmonary disease,Grade 3 Any Grade >=,1,0.4416924715042114
KYPROLIS,acute diffuse infiltrative pulmonary disease,and Lymphatic,0,0.5303672552108765
KYPROLIS,pneumonitis,"Grade Any Grade      
  Blo od and Lymphatic System",1,0.525074303150177
KYPROLIS,pneumonitis,and Lymphatic,0,0.5592010021209717
KYPROLIS,interstitial lung disease,d Lymphatic System Disord ers,1,0.6030337810516357
KYPROLIS,interstitial lung disease,Any,0,0.4724361300468445
KYPROLIS,syncope,Tissue Disorders Muscle,0,0.48165807127952576
KYPROLIS,syncope,onnecti ve Tissue Disorders Muscle,1,0.5184761881828308
KYPROLIS,syncope,onnecti,1,0.5035585165023804
KYPROLIS,syncope,and onnecti ve,1,0.5170469284057617
KYPROLIS,syncope,onnecti ve,1,0.5170138478279114
KYPROLIS,syncope,C,0,0.518979012966156
KYPROLIS,syncope,onnecti ve Tissue,1,0.5350750684738159
KYPROLIS,syncope,and onnecti ve Tissue Disorders,1,0.5523037910461426
KYPROLIS,syncope,Musculoskeletal and C,0,0.4773835241794586
KYPROLIS,chest tightness,Musculoskeletal and Tissue Disorde,1,0.5579919815063477
KYPROLIS,chest tightness,Musculoskeletal and  Tissue Disorde rs,1,0.5553035736083984
KYPROLIS,chest tightness,Tissue Disorde rs,1,0.5604119300842285
KYPROLIS,chest tightness,rs Muscle Spasms,0,0.5847554206848145
KYPROLIS,angina,       Muscle Spasms,1,0.5859314799308777
KYPROLIS,angina,       Muscle,1,0.604909360408783
KYPROLIS,angina,and Connective Tissue        Muscle Spasms,1,0.5979017019271851
KYPROLIS,PRES,neutropenia lymphopenia Cardiac s: c,1,0.4784695506095886
KYPROLIS,PRES,ardiac arrest cardiac failure cardiac failure,0,0.45036935806274414
KYPROLIS,PRES,s: c ardiac arrest,1,0.5233107805252075
KYPROLIS,PRES,cardiac failure cardiac failure congestive myocardial infarction myocardial,0,0.41973453760147095
KYPROLIS,PRES,neutropenia lymphopenia Cardiac s: c ardiac arrest cardiac,1,0.4882300794124603
KYPROLIS,PRES,Cardiac s: c ardiac arrest cardiac,1,0.4850989580154419
KYPROLIS,PRES,febrile neutropenia lymphopenia Cardiac s: c,1,0.488859087228775
KYPROLIS,PRES,s: c ardiac arrest cardiac failure cardiac,1,0.4776706099510193
KYPROLIS,fetal harm,and connective tissue disorders lar,1,0.538149893283844
KYPROLIS,embryo-fetal toxicity,"failure te, renal impairment  Respiratory thoracic",1,0.560245156288147
KYPROLIS,embryo-fetal toxicity,and connective tissue disorders lar,1,0.5288264751434326
KYPROLIS,embryo-fetal toxicity,"renal failure te, renal impairment",1,0.5714882612228394
KYPROLIS,embryo-fetal toxicity,"renal failure renal failure te,",1,0.5503169298171997
KYPROLIS,embryo-fetal toxicity,"te, renal impairment  Respiratory",1,0.5644506812095642
KYPROLIS,embryo-fetal toxicity,"renal failure renal failure te, renal impairment",1,0.5619280338287354
KYPROLIS,embryo-fetal toxicity,"failure renal failure te, renal impairment ",1,0.5759741067886353
KYPROLIS,embryo-fetal toxicity,acu,0,0.46818071603775024
KYPROLIS,embryo-fetal toxicity,renal impairment Respiratory thoracic and,1,0.5416353940963745
KYPROLIS,embryo-fetal toxicity,mediastinal disorders dysphonia,0,0.47176802158355713
YERVOY,Immune-mediated hepatitis,Immune-mediated hepatitis see,1,0.9571781158447266
YERVOY,Immune-mediated hepatitis,Immune-mediated hepatitis see Warnings and Precautions Immunemediated,1,0.9001704454421997
YERVOY,Immune-mediated hepatitis,Immune-mediated hepatitis,1,0.9999998211860657
YERVOY,Immune-mediated hepatitis,Immunemediated dermatitis see Warnings,0,0.661554217338562
YERVOY,Immune-mediated hepatitis,labeling Immunemediated enterocolitis see,0,0.6594508290290833
YERVOY,Immune-mediated hepatitis,Warnings and Immune-mediated hepatitis see Warnings and Precautions,1,0.8551751375198364
YERVOY,Immune-mediated neuropathies,Immune-mediated neuropathies see Warnings and Precautions Immunemediated,1,0.908317506313324
YERVOY,Immune-mediated neuropathies,ons Immunemediated dermatitis see Warnings and Precautions,0,0.6219019293785095
YERVOY,Immune-mediated neuropathies,see Warnings and,0,0.48835039138793945
YERVOY,Immune-mediated neuropathies,see Warnings and Immune-mediated,1,0.6597988605499268
YERVOY,Immune-mediated neuropathies,Precautions Immunemediated endocrinopathies,0,0.6764609217643738
YERVOY,Immune-mediated neuropathies,Warnings and Precautions Immunemediated,0,0.6009560823440552
YERVOY,Immune-mediated neuropathies,Precautions Immunemediated endocrinopathies see Warnings,0,0.6640350818634033
YERVOY,Immune-mediated neuropathies,dermatitis see Warnings and Immune-mediated,1,0.6526764631271362
YERVOY,Immune-mediated endocrinopathies,and Precautions,0,0.4399966895580292
YERVOY,Immune-mediated endocrinopathies,Precautions,0,0.4627012610435486
YERVOY,Immune-mediated endocrinopathies,Other immunemediated adverse reactions,0,0.6706595420837402
YERVOY,Immune-mediated endocrinopathies,see Warnings and Immune-mediated endocrinopathies,1,0.8992873430252075
YERVOY,Immune-mediated endocrinopathies,Immune-mediated endocrinopathies see Warnings,1,0.93950355052948
YERVOY,Immune-mediated endocrinopathies,neuropathies see Warnings and Immune-mediated endocrinopathies,1,0.8490252494812012
YERVOY,Immune-mediated endocrinopathies,Warnings and,0,0.483110249042511
YERVOY,immune-mediated adverse reactions,and Precautions immune-mediated adverse reactions,1,0.9331722259521484
YERVOY,immune-mediated adverse reactions,Precautions immune-mediated adverse reactions,1,0.9266265630722046
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions including ocular,1,0.9150891304016113
YERVOY,immune-mediated adverse reactions,Precautions immune-mediated adverse reactions including,1,0.9141188859939575
YERVOY,immune-mediated adverse reactions,and Precautions immune-mediated adverse reactions including,1,0.9254999160766602
YERVOY,immune-mediated adverse reactions,Warnings and Precautions immune-mediated adverse reactions,1,0.9257681369781494
YERVOY,immune-mediated adverse reactions,and Precautions,0,0.5414035320281982
YERVOY,ocular manifestations,ocular manifestations see Warnings and Precautions,1,0.8766681551933289
YERVOY,ocular manifestations,ocular manifestations see,1,0.9852832555770874
YERVOY,ocular manifestations,Other immunemediated adverse reactions,0,0.6025477647781372
YERVOY,ocular manifestations,ocular manifestations see Warnings,1,0.8884940147399902
YERVOY,ocular manifestations,adverse,0,0.5586425065994263
YERVOY,ocular manifestations,adverse reactions ocular manifestations,1,0.8929558992385864
YERVOY,ocular manifestations,immunemediated adverse reactions ocular manifestations see Warnings,1,0.7939642667770386
YERVOY,ocular manifestations,Precautions EXCERPT Most common adverse reactions ar,0,0.5706304907798767
YERVOY,ocular manifestations,immunemediated adverse reactions ocular,1,0.7731084823608398
YERVOY,fatigue,fatigue diarrhea pruritus rash and,1,0.7372663021087646
YERVOY,fatigue,immunemediated adverse reactions ocular,1,0.5177990794181824
YERVOY,fatigue,fatigue,1,1.0
YERVOY,fatigue,fatigue diarrhea pruritus rash and colitis,1,0.7159832715988159
YERVOY,diarrhea,diarrhea pruritus rash and colitis To,1,0.7799537181854248
YERVOY,diarrhea,EXCERPT Most,0,0.5260341167449951
YERVOY,rash,rash and colitis To,1,0.8114414811134338
YERVOY,rash,EXCERPT Most,0,0.4855673313140869
YERVOY,rash,fatigue diarrhea,0,0.5391923189163208
YERVOY,rash,report SUSPECTED ADVERSE REACTIONS,0,0.6191276907920837
YERVOY,rash,rash and colitis To report SUSPECTED,1,0.7872581481933594
YERVOY,rash,reactions are fatigue diarrhea rash and colitis To report,1,0.7196599841117859
YERVOY,rash,rash and colitis To report,1,0.794980525970459
YERVOY,rash,report,0,0.5214495658874512
YERVOY,rash,reactions are fatigue diarrhea rash and colitis To,1,0.7155919075012207
YERVOY,colitis,colitis,1,0.9999999403953552
YERVOY,colitis,colitis To report SUSPECTED ADVERSE REACTIONS,1,0.7943666577339172
YERVOY,colitis,and,0,0.5257613658905029
YERVOY,colitis,pruritus rash colitis To report SUSPECTED,1,0.7584859132766724
YERVOY,colitis,fatigue diarrhea,0,0.6728120446205139
YERVOY,colitis,colitis To report SUSPECTED,1,0.8159855604171753
YERVOY,colitis,rash colitis To,1,0.8303564786911011
YERVOY,fatigue,common adverse,0,0.540793776512146
YERVOY,fatigue,most common adverse,0,0.540101170539856
YERVOY,fatigue,at mgkg fatigue diarrhea,1,0.717780590057373
YERVOY,diarrhea,mgkg were diarrhea pruritus,1,0.7632288932800293
YERVOY,diarrhea,most common adverse,0,0.5680344700813293
YERVOY,diarrhea,The,0,0.5906126499176025
YERVOY,pruritus,pruritus rash and,1,0.9158989191055298
YERVOY,pruritus,Table presents selected adverse reactions from,0,0.5917518138885498
YERVOY,pruritus,pruritus rash,1,0.9252880811691284
YERVOY,pruritus,who received,0,0.4901595115661621
YERVOY,pruritus,and colitis Table,0,0.5344879627227783
YERVOY,pruritus,mgkg were,0,0.4861077666282654
YERVOY,rash,rash,1,1.0000001192092896
YERVOY,rash,rash and colitis,1,0.8217179179191589
YERVOY,rash,rash and colitis Table,1,0.7613846063613892
YERVOY,rash,were fatigue diarrhea pruritus,0,0.65761399269104
YERVOY,rash,were fatigue diarrhea rash and colitis Table presents,1,0.6909777522087097
YERVOY,rash,rash and colitis Table presents selected,1,0.7417290210723877
YERVOY,rash,colitis Table presents selected adverse reactions from Study which occurred in at le,0,0.5871952772140503
YERVOY,rash,were fatigue diarrhea rash,1,0.7544348835945129
YERVOY,colitis,diarrhea,0,0.7265864014625549
YERVOY,fatal,severe lifethreatening fatal immunemediated adverse reactions,1,0.6918435096740723
YERVOY,fatal,diarrhea,0,0.613457441329956
YERVOY,fatal,lifethreatening or,0,0.5619451999664307
YERVOY,fatal,lifethreatening,0,0.5342761278152466
YERVOY,fatal,fatal immunemediated,1,0.7764497399330139
YERVOY,fatal,fatal immunemediated adverse,1,0.7356051206588745
YERVOY,fatal,severe lifethreatening fatal immunemediated adverse reactions from,1,0.6849942207336426
YERVOY,fatal,of severe lifethreatening fatal immunemediated,1,0.7342202067375183
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions from Study Table Severe,1,0.8639239072799683
YERVOY,immune-mediated adverse reactions,of severe lifethreatening or immune-mediated adverse reactions,1,0.8650965690612793
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions from Study Table,1,0.8889570236206055
YERVOY,immune-mediated adverse reactions,Fatal Immunemediated Adverse Reactions in Study,0,0.8436741828918457
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions,1,1.0
YERVOY,immune-mediated adverse reactions,severe lifethreatening or immune-mediated adverse reactions from,1,0.8659178018569946
YERVOY,Fatal,Adverse Reactions,0,0.5793318748474121
YERVOY,Fatal,to,0,0.5677997469902039
YERVOY,Fatal,Fatal Immunemediated Adverse Reactions,1,0.6829992532730103
YERVOY,Fatal,adverse reactions from Study Table,0,0.5468847751617432
YERVOY,Fatal,fethreatening or fatal immunemediated,0,0.7293223142623901
YERVOY,Fatal,Study Table Severe Fatal Immunemediated Adverse Reactions,1,0.6707636117935181
YERVOY,Fatal,from Study Table,0,0.47500425577163696
YERVOY,Fatal,Table,0,0.5100602507591248
YERVOY,Fatal,Including fatal outcome b,0,0.7743474245071411
YERVOY,Immune-mediated Adverse Reactions,adverse,0,0.6707263588905334
YERVOY,Immune-mediated Adverse Reactions,Adverse Reactions in Study,1,0.7797057628631592
YERVOY,Immune-mediated Adverse Reactions,in Study a,0,0.5022565126419067
YERVOY,Immune-mediated Adverse Reactions,Table,0,0.47281837463378906
YERVOY,Immune-mediated Adverse Reactions,in Study a Including fatal outcome b Including intestinal perforation c,0,0.5939162969589233
YERVOY,Immune-mediated Adverse Reactions,Severe to Immune-mediated Adverse,1,0.893064022064209
YERVOY,Immune-mediated Adverse Reactions,Study Table Severe,0,0.4945984482765198
YERVOY,Immune-mediated Adverse Reactions,from Study Table Severe to Fatal,0,0.5588030219078064
YERVOY,Immune-mediated Adverse Reactions,Fatal,0,0.536278486251831
YERVOY,fatal,a fatal outcome b Including intestinal perforation,1,0.7427854537963867
YERVOY,fatal,Fatal,0,1.0000001192092896
YERVOY,fatal,Reactions in,0,0.5728217363357544
YERVOY,fatal,fatal outcome b,1,0.8048999309539795
YERVOY,fatal,Severe to Fatal Immunemediated Adverse Reactions in Study,0,0.6497201919555664
YERVOY,fatal,fatal outcome b Including,1,0.8086201548576355
YERVOY,fatal,Reactions in Study a fatal outcome b Including intestinal perforation,1,0.7012926340103149
YERVOY,fatal,fatal outcome b Including intestinal,1,0.7464253902435303
YERVOY,fatal,Reactions,0,0.5744270086288452
YERVOY,fatal,to Fatal Immunemediated Adverse,0,0.7185739278793335
YERVOY,intestinal perforation,b intestinal perforation c Underlying,1,0.8785519599914551
YERVOY,intestinal perforation,to Fatal Immunemediated Adverse,0,0.6065859198570251
YERVOY,intestinal perforation,intestinal perforation c Underlying,1,0.8870588541030884
YERVOY,intestinal perforation,etiology not established Perc,0,0.6157132387161255
YERVOY,intestinal perforation,intestinal perforation c Underlying etiology not established,1,0.856322169303894
YERVOY,intestinal perforation,outcome b intestinal,1,0.718956470489502
YERVOY,intestinal perforation,intestinal perforation c Underlying etiology,1,0.8675000667572021
YERVOY,Enterocolitis,Adverse Reaction,0,0.5852684378623962
YERVOY,Enterocolitis,Adverse Enterocolitis ab,1,0.8421711921691895
YERVOY,Enterocolitis,Adverse Enterocolitis ab Hepa,1,0.7765566110610962
YERVOY,Enterocolitis,Enterocolitis ab Hepa,1,0.8041094541549683
YERVOY,Enterocolitis,Enterocolitis ab,1,0.8800428509712219
YERVOY,Enterocolitis,Enterocolitis,1,1.0
YERVOY,Enterocolitis,emediated Adverse Reaction,0,0.5989804267883301
YERVOY,Enterocolitis,Reaction,0,0.5346893668174744
YERVOY,urticaria,urticaria large intestinal,1,0.8077155351638794
YERVOY,urticaria,urticaria large intestinal ulcer,1,0.7702353000640869
YERVOY,esophagitis,noted urticaria large intestinal ulcer,0,0.6069167256355286
YERVOY,esophagitis,esophagitis acute respiratory distress,1,0.8241382837295532
YERVOY,esophagitis,and infusion reaction Based on the,0,0.5245158672332764
YERVOY,acute respiratory distress syndrome,ulcer acute respiratory,1,0.6771889925003052
YERVOY,acute respiratory distress syndrome,large intestinal ulcer acute respiratory distress,1,0.7088913321495056
YERVOY,acute respiratory distress syndrome,distress syndrome,1,0.7811665534973145
YERVOY,acute respiratory distress syndrome,distress syndrome renal failure and infusion reaction,1,0.6943104863166809
YERVOY,acute respiratory distress syndrome,urticaria large intestinal ulcer acute respiratory,1,0.603264570236206
YERVOY,acute respiratory distress syndrome,urticaria large intestinal ulcer acute respiratory distress syndrome renal failure,1,0.6966822147369385
YERVOY,acute respiratory distress syndrome,respiratory distress syndrome renal failure and infusion reaction,1,0.7576989531517029
YERVOY,infusion reaction,the incidence and,0,0.533092737197876
YERVOY,enterocolitis,enterocolitis and hepatitis,1,0.8539391160011292
YERVOY,hepatitis,appear to be,0,0.4946625232696533
YERVOY,Drug reaction with eosinophilia and systemic symptoms,DRESS,0,0.4820236563682556
YERVOY,Drug reaction with eosinophilia and systemic symptoms,reaction with eosinophilia and systemic symptoms DRESS,1,0.8681480288505554
YERVOY,Drug reaction with eosinophilia and systemic symptoms,Skin and Subcutaneous Tissue Drug reaction with eosinophilia and systemic symptoms,1,0.9239659905433655
YERVOY,Drug reaction with eosinophilia and systemic symptoms,and Subcutaneous Tissue Drug reaction with eosinophilia and systemic symptoms DRESS syndrome Immunogenicity,1,0.8182015419006348
YERVOY,Drug reaction with eosinophilia and systemic symptoms,Drug reaction with eosinophilia and systemic symptoms DRESS syndrome,1,0.9059993028640747
YERVOY,Drug reaction with eosinophilia and systemic symptoms,clinical studies of,0,0.561814546585083
YERVOY,DRESS syndrome,and systemic DRESS,1,0.7711403965950012
YERVOY,DRESS syndrome,Drug reaction with eosinophilia and,0,0.608296811580658
YERVOY,DRESS syndrome,eosinophilia and systemic DRESS syndrome Immunogenicity,1,0.7921204566955566
YERVOY,peri-infusional reactions,peri-infusional reactions,1,0.9999998807907104
YERVOY,peri-infusional reactions,peri-infusional reactions consistent with hypersensitivity,1,0.9380301237106323
YERVOY,peri-infusional reactions,ipilimumab Infusionrelated peri-infusional,1,0.7953286170959473
YERVOY,peri-infusional reactions,ipilimumab Infusionrelated peri-infusional reactions consistent with,1,0.8621215224266052
YERVOY,peri-infusional reactions,peri-infusional reactions consistent with hypersensitivity or anaphylaxis,1,0.9181262254714966
YERVOY,peri-infusional reactions,in these patients,0,0.6075536608695984
YERVOY,hypersensitivity,or periinfusional reactions consistent,0,0.6498883366584778
YERVOY,hypersensitivity,periinfusional reactions consistent with,0,0.6825581789016724
YERVOY,anaphylaxis,anaphylaxis were not,1,0.8181702494621277
YERVOY,anaphylaxis,periinfusional reactions consistent with,0,0.6890246868133545
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,of the labeling Immunemediated,0,0.7078423500061035
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,The following adverse reactions a re discussed in greater,1,0.7840360403060913
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,detail in,0,0.47437161207199097
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,The following adverse reactions a,1,0.7885180711746216
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,other sections,0,0.4819459319114685
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,The following adverse,1,0.7046241760253906
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,Warnings and Precautions,0,0.6302578449249268
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,in other sectio ns,1,0.4830665588378906
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,in greater detail in other sectio ns,1,0.483961820602417
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,adverse reactions are in greater detail in other sectio ns of the,1,0.7731561660766602
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,are in greater detail in,1,0.45537641644477844
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,in greater detail in other sectio,1,0.48494279384613037
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,in greater detail in other sectio ns of the,1,0.4643048644065857
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,The following adverse,0,0.7046241760253906
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,reactions are in greater detail in other sectio ns of the labeling,1,0.6044028997421265
YERVOY,immune-mediated adverse reactions,the labeling d enterocolitis [see Warnings,1,0.6095137596130371
YERVOY,immune-mediated adverse reactions,the labeling d enterocolitis,1,0.5539833307266235
YERVOY,immune-mediated adverse reactions,sections of the labeling Immunemediate,0,0.693587601184845
YERVOY,immune-mediated adverse reactions,of the labeling d enterocolitis [see  Warnings an d,1,0.6149232387542725
YERVOY,immune-mediated adverse reactions,labeling d enterocolitis [see  Warnings an d Precautions Immunemediated hepatitis,1,0.6570303440093994
YERVOY,immune-mediated adverse reactions,other sections,0,0.4819459319114685
YERVOY,immune-mediated adverse reactions,d enterocolitis [see,1,0.575973391532898
YERVOY,immune-mediated reactions,patitis [see Warnings an,1,0.5898833870887756
YERVOY,immune-mediated reactions,Immunemediated dermatitis see Warnings,0,0.7213205695152283
YERVOY,immune-mediated reactions,Precautions Immunemediated patitis [see,1,0.7072447538375854
YERVOY,immune-mediated reactions,and Precautions Immunemediated patitis [see Warnings an,1,0.7025046944618225
YERVOY,immune-mediated reactions,Precautions Immunemediated,0,0.7253954410552979
YERVOY,immune-mediated reactions,d Precautions Immunemediated dermatitis,0,0.7089071869850159
YERVOY,immune-mediated reactions,Warnings and,0,0.5566842555999756
YERVOY,immune-mediated reactions,see Warnings and,0,0.5454585552215576
YERVOY,immune-mediated reactions,see Warnings,0,0.5575336813926697
YERVOY,immune-mediated adverse reactions,Precautions (5.3) Immunemediated neuropathies see,1,0.6628237366676331
YERVOY,immune-mediated adverse reactions,Immunemediated,0,0.7271584868431091
YERVOY,immune-mediated adverse reactions,Warnings,0,0.6625305414199829
YERVOY,immune-mediated adverse reactions,see Warnings,0,0.6416037082672119
YERVOY,immune-mediated adverse reactions,Immunemediated dermatitis e  Warnings and Precautions (5.3) Immunemediated,1,0.7370089292526245
YERVOY,immune-mediated adverse reactions,and Precautions (5.3),1,0.556918740272522
YERVOY,immune-mediated adverse reactions,Precautions Immunemediated,0,0.7138546705245972
YERVOY,immune-mediated adverse reactions,and Precautions (5.3) Immunemediated neuropathies see Warnings and,1,0.6831484436988831
YERVOY,enterocolitis,"Warnings and  
 *  ?  Immu nemediated neuropathies see Warnings",1,0.5341048240661621
YERVOY,enterocolitis,and Precautions (5.3) Immunemediated neuropathies see Warnings and,1,0.5523157119750977
YERVOY,enterocolitis,and Precautions Immunemediated,0,0.57367342710495
YERVOY,enterocolitis,dermatitis see Warnings and,0,0.5702222585678101
YERVOY,hepatitis,-mediated neuropathies see Warnings,1,0.5071188807487488
YERVOY,hepatitis,see Warnings and Precautions Immunemediated,0,0.583712100982666
YERVOY,hepatitis,Warnings,0,0.5583553314208984
YERVOY,hepatitis,Warnings and Precautions,0,0.5411527156829834
YERVOY,dermatitis,Warnings and Precautions Immunemediated europathie s see Warnings and Precautions,1,0.6050671339035034
YERVOY,dermatitis,Warnings and Precautions,0,0.574573278427124
YERVOY,dermatitis,n,0,0.5112662315368652
YERVOY,dermatitis,and Precautions Immunemediated europathie s,1,0.6018210053443909
YERVOY,dermatitis,see Warnings and,0,0.5621591806411743
YERVOY,dermatitis,europathie s see Warnings and Precautions,1,0.5813689231872559
YERVOY,dermatitis,Precautions,0,0.5835760831832886
YERVOY,dermatitis,europathie s see,1,0.532889723777771
YERVOY,toxic epidermal necrolysis,ings and,1,0.4924168884754181
YERVOY,toxic epidermal necrolysis,and Precautions Immunemediated neuropathies,0,0.5973033905029297
YERVOY,toxic epidermal necrolysis,ings and Precautions (5.4) Immunemediated endocrinopathies see Warnings and,1,0.6303064823150635
YERVOY,toxic epidermal necrolysis,Precautions Immunemediated neuropathies see ings,1,0.6310920715332031
YERVOY,toxic epidermal necrolysis,and,0,0.43400847911834717
YERVOY,neuropathy,"see Warnings and  . 
 *  ?  Immunemediated endocrinopathies see Warnings",1,0.5879894495010376
YERVOY,neuropathy,and,0,0.5167378187179565
YERVOY,neuropathy,and Precautions Other,0,0.5080549120903015
YERVOY,neuropathy,* ? Immunemediated endocrinopathies see,1,0.5969849824905396
YERVOY,neuropathy,Precautions Other,0,0.5225846767425537
YERVOY,neuropathy,. * ? Immunemediated endocrinopathies see,1,0.5953741669654846
YERVOY,neuropathy,and .,1,0.5184962749481201
YERVOY,neuropathy,"and  . 
 *  ?  Immunemediated endocrinopathies see",1,0.6018112897872925
YERVOY,endocrinopathy,see Warnings,0,0.48332804441452026
YERVOY,endocrinopathy,e-mediated end ocrinopathies see Warnings and Precautions,1,0.6089720726013184
YERVOY,endocrinopathy,neuropathies see Warnings and Precautions,0,0.583928108215332
YERVOY,endocrinopathy,neuropathies see Warnings and Precautions Immun,0,0.5956165194511414
YERVOY,endocrinopathy,and Precautions e-mediated end ocrinopathies see Warnings,1,0.5989515781402588
YERVOY,endocrinopathy,Precautions e-mediated end ocrinopathies see Warnings and Precautions,1,0.601684033870697
YERVOY,endocrinopathy,immunemediated adverse,0,0.5460378527641296
YERVOY,endocrinopathy,Warnings and Precautions e-mediated end ocrinopathies,1,0.6018106937408447
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,experience with therapeutics n the same class and may not,1,0.6240149736404419
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,the same class and may not refl,1,0.5091824531555176
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,and may not refl ect the rates,1,0.4440762400627136
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,n the,1,0.5431766510009766
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,or experience with therapeutics n the same class and may not refl,1,0.6240036487579346
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,practice The,0,0.4282871186733246
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,directly compared with rates in other clinical trials or,0,0.555584192276001
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,experience with therapeutics n the same class and may not refl,1,0.6285480856895447
YERVOY,fatal,program,0,0.5019216537475586
YERVOY,fatal,ive a utoimmune disease or those receiving,1,0.49197131395339966
YERVOY,fatal,for organ transplantation Exposure,0,0.4926668405532837
YERVOY,fatal,organ transplantation,0,0.5393889546394348
YERVOY,fatal,with,0,0.5621656179428101
YERVOY,fatal,those receiving systemic immunosuppression for organ transplantation Exposure,0,0.4636057913303375
YERVOY,fatal,ive a utoimmune disease or those,1,0.5157715082168579
YERVOY,immune-mediated adverse reactions,toimmune disease or those receivi ng,1,0.7013469934463501
YERVOY,immune-mediated adverse reactions,those receiving systemic immunosuppression for organ transplantation Exposure,0,0.692455530166626
YERVOY,immune-mediated adverse reactions,ng systemic immunosuppression for organ transplantation Exposure to YERVOY,0,0.6731313467025757
YERVOY,immune-mediated adverse reactions,or those receivi ng systemic immunosuppression for,1,0.654714047908783
YERVOY,immune-mediated adverse reactions,in clinical practice The clinical development program excluded patients with active au,0,0.5621960759162903
YERVOY,immune-mediated adverse reactions,or those receivi ng systemic immunosuppression for organ,1,0.6393704414367676
YERVOY,immune-mediated adverse reactions,patients with active toimmune disease or those receivi ng systemic immunosuppression,1,0.6865097880363464
YERVOY,immune-mediated adverse reactions,mgkg,0,0.5046647787094116
YERVOY,immune-mediated adverse reactions,toimmune disease or those receivi ng systemic,1,0.7091059684753418
YERVOY,immune-mediated adverse reactions,Exposure to YERVOY mgkg for doses given by intravenous,0,0.6504018306732178
YERVOY,immune-mediated adverse reactions,study,0,0.47610700130462646
YERVOY,enterocolitis,unresectable metastatic,1,0.5006163120269775
YERVOY,enterocolitis,in previously treated patients with,0,0.5431103110313416
YERVOY,enterocolitis,unresectable metastatic m,1,0.5005233287811279
YERVOY,enterocolitis,metastatic m elanoma was assessed,1,0.515833854675293
YERVOY,enterocolitis,previously,0,0.5152329802513123
YERVOY,enterocolitis,treated patients with unresectable  metastatic m elanoma was assessed,1,0.4832627773284912
YERVOY,enterocolitis,with unresectable metastatic,1,0.5061557292938232
YERVOY,enterocolitis,metastatic m elanoma was assessed in a,1,0.5192073583602905
YERVOY,enterocolitis,randomized doubleblind clinical study,0,0.5074074864387512
YERVOY,hepatitis,anoma was assessed in a randomized,1,0.4692994952201843
YERVOY,hepatitis,with unresectable or metastatic anoma was,1,0.4714307188987732
YERVOY,hepatitis,or metastatic anoma was assessed in,1,0.4799521565437317
YERVOY,dermatitis,previously treated patients with unresectable or metastatic melanoma,0,0.523894190788269
YERVOY,dermatitis,ssessed in a randomized doubleblind,1,0.5046297311782837
YERVOY,dermatitis,metastatic melanoma was ssessed in,1,0.5770254731178284
YERVOY,dermatitis,melanoma was ssessed,1,0.6058540344238281
YERVOY,toxic epidermal necrolysis,double-blind clinical s tudy Study See Clinical Studies,1,0.5308104157447815
YERVOY,endocrinopathy,ee,1,0.49731677770614624
YERVOY,endocrinopathy,or metastatic melanoma was assessed in a randomized doubleblind,0,0.5097779035568237
YERVOY,endocrinopathy,One hundred thirtyone patients median age,0,0.5405398011207581
YERVOY,endocrinopathy,Study,0,0.5143096446990967
YERVOY,endocrinopathy,clinical study Study ee  Clinical S,1,0.5319421887397766
YERVOY,endocrinopathy,study Study ee,1,0.46869662404060364
YERVOY,endocrinopathy,study Study ee  Clinical S tudies One hundred,1,0.5420786142349243
YERVOY,immune-mediated reactions,See Clinical Studies One dred thirty-one patients  median age years male,1,0.5272319912910461
YERVOY,immune-mediated reactions,study Study ee,1,0.46041080355644226
YERVOY,immune-mediated reactions,agent patients median age,0,0.49350523948669434
YERVOY,immune-mediated reactions,as,0,0.5328773856163025
YERVOY,immune-mediated reactions,randomized doubleblind clinical study Study See Clinical Studies,0,0.5628504753112793
YERVOY,fatal,adverse reactions are ssed  in greater detail in other,1,0.5737064480781555
YERVOY,fatal,randomized doubleblind clinical study Study See Clinical Studies,0,0.4921152591705322
YERVOY,fatal,ssed  in,1,0.5219643115997314
YERVOY,fatal,the labeling Immunemediated enterocolitis see W,0,0.49470096826553345
YERVOY,fatal,ssed  in greater detail in,1,0.4985213875770569
YERVOY,fatal,ssed  in greater detail in other,1,0.48670482635498047
YERVOY,fatal,in other sections of,0,0.4903756082057953
YERVOY,immune-mediated reactions,reactions are discussed n greater detail in other,1,0.7087610960006714
YERVOY,immune-mediated reactions,reactions are discussed n,1,0.7278860807418823
YERVOY,immune-mediated reactions,ADVERSE REACTIONS The following adverse reactions are discussed,0,0.674958348274231
YERVOY,immune-mediated reactions,n greater detail in other,1,0.49748510122299194
YERVOY,immune-mediated reactions,reactions are,0,0.7760890126228333
YERVOY,immune-mediated reactions,adverse reactions are,0,0.7097402811050415
YERVOY,Immune-mediated hepatitis,fatigue diarrhea,0,0.5516675710678101
YERVOY,Immune-mediated endocrinopathies,(6.1) To report SU SPECTED,1,0.4560777544975281
YERVOY,Immune-mediated endocrinopathies,diarrhea pruritus rash and tis. (6.1) To,1,0.5506356358528137
YERVOY,diarrhea,varying conditions the,0,0.5263255834579468
YERVOY,diarrhea,cannot be directly pared wi th rates in other,1,0.4934055209159851
YERVOY,diarrhea,under widely varying conditions the adverse reaction rates observed cannot,0,0.5331908464431763
YERVOY,diarrhea,with therapeutics in the same class and may,0,0.5391846895217896
YERVOY,diarrhea,clinical trials or experience with therapeutics in the same class and may,0,0.5094881057739258
YERVOY,diarrhea,in the same,0,0.5546044111251831
YERVOY,diarrhea,conditions the adverse reaction rates observed cannot be directly com,0,0.5548141002655029
YERVOY,fever,other clinical trials exper ience with,1,0.5112687349319458
YERVOY,fever,conditions the adverse reaction rates observed cannot be directly com,0,0.5724526047706604
YERVOY,fever,in other clinical trials exper ience,1,0.5018003582954407
YERVOY,fever,exper ience,1,0.5319691300392151
YERVOY,fever,not reflect the rates observed in clinical practic,0,0.5091099143028259
YERVOY,fever,exper,1,0.5266433954238892
YERVOY,fever,observed in clinical,0,0.568151593208313
YERVOY,fever,in clinical,0,0.5729908347129822
YERVOY,fever,observed,0,0.5540614128112793
YERVOY,fever,the rates observed,0,0.5180913209915161
YERVOY,ileus,the rates observed,0,0.48266398906707764
YERVOY,ileus,or nce w ith,1,0.5729162693023682
YERVOY,ileus,nce w,1,0.5278158187866211
YERVOY,ileus,in clinical practice,0,0.5603251457214355
YERVOY,ileus,other clinical trials or nce w ith therapeutics in the,1,0.533005952835083
YERVOY,peritoneal signs,or experience h therapeutics i n the,1,0.48495936393737793
YERVOY,peritoneal signs,in clinical practice,0,0.5642249584197998
YERVOY,immune-mediated enterocolitis,same ass and may not,1,0.4650672674179077
YERVOY,immune-mediated enterocolitis,therapeutics in the same ass and may not reflect the r,1,0.526141881942749
YERVOY,immune-mediated enterocolitis,may not reflect the r ates observed in clinical,1,0.531778872013092
YERVOY,immune-mediated enterocolitis,same ass and may not reflect the r ates observed in,1,0.5242649912834167
YERVOY,immune-mediated enterocolitis,same ass and may not reflect the r ates,1,0.48635023832321167
YERVOY,immune-mediated enterocolitis,ass and may not reflect the,1,0.4818284511566162
YERVOY,immune-mediated enterocolitis,in the same ass and may not reflect the r ates observed in clinical practice,1,0.5435303449630737
YERVOY,immune-mediated enterocolitis,experience with therapeutics in,0,0.534232497215271
YERVOY,immune-mediated enterocolitis,therapeutics in the same ass and may not reflect the r ates observed in clinical practice,1,0.518297016620636
YERVOY,immune-mediated enterocolitis,therapeutics in the same ass and may not reflect the r ates observed,1,0.5222331285476685
YERVOY,diarrhea,ment,1,0.5818456411361694
YERVOY,diarrhea,ment pro,1,0.5695836544036865
YERVOY,diarrhea,practice The clinical ment pro gram excluded patients with active,1,0.5451697707176208
YERVOY,diarrhea,ment pro gram excluded patients with,1,0.5770222544670105
YERVOY,diarrhea,ment pro gram excluded patients,1,0.5577231645584106
YERVOY,diarrhea,patients with active autoimmune disease,0,0.5234777927398682
YERVOY,diarrhea,practice The clinical ment pro gram,1,0.564816951751709
YERVOY,abdominal pain,to YERVOY,0,0.4549506902694702
YERVOY,abdominal pain,program excluded patients,0,0.44810229539871216
YERVOY,abdominal pain,toimmune disea se or,1,0.508952796459198
YERVOY,abdominal pain,toimmune disea,1,0.5168206691741943
YERVOY,abdominal pain,clinical development program excluded patients with active au,0,0.4521809220314026
YERVOY,abdominal pain,organ transplantation Exposure to,0,0.4481940269470215
YERVOY,abdominal pain,development,0,0.48128384351730347
YERVOY,abdominal pain,toimmune disea se or those receiving,1,0.4973719120025635
YERVOY,abdominal pain,clinical,0,0.53324955701828
YERVOY,abdominal pain,patients with active toimmune disea se or,1,0.4856395721435547
YERVOY,blood in stool,development program,0,0.42638468742370605
YERVOY,blood in stool,receiving sys temic immunosuppression for,1,0.49756288528442383
YERVOY,blood in stool,receiving sys temic immunosuppression for organ,1,0.5115810036659241
YERVOY,blood in stool,tice The,0,0.5217864513397217
YERVOY,blood in stool,active autoimmune disease or receiving,1,0.4996492862701416
YERVOY,blood in stool,active autoimmune disease or  receiving sys temic immunosuppression for,1,0.502961277961731
YERVOY,blood in stool,active autoimmune disease or receiving sys,1,0.5193595886230469
YERVOY,enterocolitis,receiving systemic osuppression  for,1,0.5566152930259705
YERVOY,enterocolitis,active autoimmune disease or receiving sys,1,0.5405576229095459
YERVOY,enterocolitis,transplantation Exposure to,0,0.5519144535064697
YERVOY,enterocolitis,osuppression  for organ transplantation Exposure,1,0.5424357652664185
YERVOY,enterocolitis,osuppression  for organ transplantation Exposure to,1,0.5553338527679443
YERVOY,enterocolitis,organ transplantation Exposure to YERVOY mgkg for doses given by intravenous infusion in p,0,0.5191882252693176
YERVOY,intestinal perforation,patients with unrese ctable or,1,0.540825605392456
YERVOY,intestinal perforation,clinical,0,0.5606193542480469
YERVOY,intestinal perforation,lantation Exposure to YERVOY mgkg for doses given by intravenous infusion in previously,0,0.5510571599006653
YERVOY,died,metastatic,0,0.5592646598815918
YERVOY,enterocolitis,Clinical Stu dies,1,0.5164438486099243
YERVOY,enterocolitis,One hundred thirtyone,0,0.48375093936920166
YERVOY,enterocolitis,hundred thirtyone patients,0,0.4983225464820862
YERVOY,enterocolitis,with an investigational gp peptide vaccine gp and patients,0,0.5254034996032715
YERVOY,enterocolitis,with an investigational gp,0,0.5305850505828857
YERVOY,enterocolitis,received YERVOY as a single,0,0.45514774322509766
YERVOY,enterocolitis,an investigational,0,0.5438036918640137
YERVOY,enterocolitis,ale) received YERVOY with an investigational,1,0.5034250617027283
YERVOY,enterocolitis,median age years ale) received,1,0.5088472366333008
YERVOY,enterocolitis,ale) received YERVOY with,1,0.4910600781440735
YERVOY,enterocolitis,vestigational gp peptide,1,0.5471930503845215
YERVOY,enterocolitis,years,0,0.5356189012527466
YERVOY,enterocolitis,vestigational gp peptide vaccine,1,0.549531102180481
YERVOY,enterocolitis,male received gp pept,0,0.5334510207176208
YERVOY,enterocolitis,vestigational gp peptide vaccine gp and,1,0.5447162985801697
YERVOY,enterocolitis,patients median age years male received,0,0.5078129768371582
YERVOY,enterocolitis,with an vestigational gp peptide vaccine gp and,1,0.5450907945632935
YERVOY,enterocolitis,the study received,0,0.5269985198974609
YERVOY,enterocolitis,male received gp peptide vaccine alone Patients in the study received a median of doses,0,0.5422905087471008
YERVOY,enterocolitis,"7 years, 54% male received gp peptide vaccine",1,0.5225040912628174
YERVOY,enterocolitis,"median 7 years,",1,0.5101017355918884
YERVOY,enterocolitis,age,0,0.5557551383972168
YERVOY,enterocolitis,"patients median 7 years,",1,0.506665825843811
YERVOY,enterocolitis,median of doses,0,0.5030562281608582
YERVOY,enterocolitis,patients who received,0,0.5212671756744385
YERVOY,enterocolitis,"hea, pruritus",1,0.5563005805015564
YERVOY,enterocolitis,"hea, pruritus rash",1,0.5494366884231567
YERVOY,enterocolitis,"were fatigue hea, pruritus rash and colitis",1,0.6591233015060425
YERVOY,enterocolitis,reactions,0,0.5519174337387085
YERVOY,enterocolitis,fatigue diarr,0,0.6797717809677124
YERVOY,immune-mediated enterocolitis,regardless of,0,0.4638350009918213
YERVOY,immune-mediated enterocolitis,events regardless,0,0.46319711208343506
YERVOY,immune-mediated enterocolitis,Reactions in 1 a,1,0.5255306959152222
YERVOY,immune-mediated enterocolitis,"1 
   a     Incidences presen ted in this table are",1,0.5312055349349976
YERVOY,immune-mediated enterocolitis,"in 1 
   a     Incidences presen ted in",1,0.5234445333480835
YERVOY,immune-mediated enterocolitis,1 a Incidences presen ted in,1,0.5274630784988403
YERVOY,enterocolitis,are based,0,0.5026597380638123
YERVOY,enterocolitis,              Percentage of Patientsa YERVOY,1,0.49655628204345703
YERVOY,enterocolitis,of Patientsa YERVOY,0,0.5104566812515259
YERVOY,enterocolitis,              Percentage of Patientsa,1,0.46950066089630127
YERVOY,enterocolitis,             ,1,0.5868257284164429
YERVOY,enterocolitis,presented in this,0,0.555701732635498
YERVOY,enterocolitis,adverse events,0,0.5692582130432129
YERVOY,enterocolitis,ntsa YERVOY,0,0.46487611532211304
YERVOY,enterocolitis,"YERVOY mgkggpn 00n=132    
 ",1,0.45594358444213867
YERVOY,enterocolitis,"00n=132    
  System",1,0.4601961374282837
YERVOY,enterocolitis,"mgkgn YERVOY mgkggpn 00n=132    
  System Organ",1,0.5385302305221558
YERVOY,hepatotoxicity,n. c Unde rlying etiology not established,1,0.4996221959590912
YERVOY,hepatotoxicity,rlying,0,0.5077974796295166
YERVOY,hepatotoxicity,intestinal n.  c     Unde rlying etiology not established,1,0.5238208770751953
YERVOY,hepatotoxicity,n. c,1,0.43387532234191895
YERVOY,hepatotoxicity,outcome b Including intestinal n. c,1,0.5591903328895569
YERVOY,hepatotoxicity,outcome b Including intestinal n. c Unde,1,0.5615392923355103
YERVOY,hepatotoxicity,outcome b Including intestinal n.  c     Unde,1,0.5615392923355103
YERVOY,hepatotoxicity,intestinal n.  c     Unde rlying etiology not,1,0.5236713886260986
YERVOY,ALT elevations,perforation c Underlying iology not est,1,0.5273616313934326
YERVOY,ALT elevations,outcome b Including intestinal n. c Unde,1,0.5089536309242249
YERVOY,ALT elevations,ablished Percentage of,0,0.5076553225517273
YERVOY,ALT elevations,Percentage of,0,0.4735412895679474
YERVOY,ALT elevations,iology not est ablished,1,0.5661113262176514
YERVOY,ALT elevations,Percentage,0,0.48787131905555725
YERVOY,ALT elevations,iology not est ablished Percentage of,1,0.5387381315231323
YERVOY,total bilirubin elevations,c Underlying etiology not          Percentage (%) of Patients YERVOY,1,0.5239652991294861
YERVOY,total bilirubin elevations,Percentage,0,0.5269434452056885
YERVOY,total bilirubin elevations,(%) of Patients YERVOY,1,0.5008312463760376
YERVOY,total bilirubin elevations,(%) of Patients YERVOY mgkgn,1,0.49957093596458435
YERVOY,hepatic failure,mgkgn YERVOY mgkggpn,0,0.47140514850616455
YERVOY,hepatic failure,Any Immunemediated,0,0.5141732096672058
YERVOY,hepatic failure,"=380        
   Any Immunemediated",1,0.5094148516654968
YERVOY,hepatic failure,"YERVOY =380        
   Any Immunemediated Adverse",1,0.5202116966247559
YERVOY,increases in transaminases,s were also reported (inci dence less than unless,1,0.547586977481842
YERVOY,increases in transaminases,from to mgkg the following adverse reaction,0,0.6038312911987305
YERVOY,increases in transaminases,unless otherwise noted urticaria large,0,0.5415754318237305
YERVOY,increases in transaminases,less than unless otherwise noted urticaria large intestinal,0,0.6007034778594971
YERVOY,increases in transaminases,were also reported (inci dence,1,0.5129825472831726
YERVOY,increases in transaminases,s were also reported (inci dence,1,0.5328247547149658
YERVOY,increases in transaminases,s were also reported (inci dence less than unless otherwise,1,0.5410982370376587
YERVOY,increases in transaminases,less than unless otherwise noted urticaria,0,0.5544570088386536
YERVOY,increases in transaminases,dence less than unless otherwise noted urticaria large intestinal ulcer esophagitis acu,0,0.5952523946762085
YERVOY,increases in transaminases,were also reported (inci dence less than unless otherwise,1,0.5371739864349365
YERVOY,increases in total bilirubin,noted): urticaria (2% large intestinal ulcer esophagitis acute,1,0.576994001865387
YERVOY,increases in total bilirubin,intestinal ulcer esophagitis acute respiratory,0,0.5645105242729187
YERVOY,increases in total bilirubin,urticaria (2% large intestinal,1,0.5617949962615967
YERVOY,increases in total bilirubin,reactions were also reported incidence less than unless,0,0.5587398409843445
YERVOY,increases in total bilirubin,unless erwise noted): urticaria (2% large intestinal ulcer,1,0.5531888604164124
YERVOY,increases in total bilirubin,urticaria (2% large,1,0.5581424236297607
YERVOY,fatal, and  severity of enterocolitis,1,0.5663704872131348
YERVOY,immune-mediated dermatitis,melanoma the incidence and everity of enterocolitis a,1,0.564916729927063
YERVOY,immune-mediated dermatitis, and  severity of enterocolitis,1,0.47659096121788025
YERVOY,Stevens-Johnson syndrome,severity of enterocolitis and atitis appear to be dose dependent Postmarketing Experience The,1,0.5717788934707642
YERVOY,Stevens-Johnson syndrome, and  severity of enterocolitis,1,0.5333027839660645
YERVOY,Stevens-Johnson syndrome,Postmarketing Experience The,0,0.5193082094192505
YERVOY,Stevens-Johnson syndrome,for melanoma the incidence and severity,0,0.5110394358634949
YERVOY,Stevens-Johnson syndrome,and atitis appear to be dose dependent Postmarketing Experience,1,0.5587271451950073
YERVOY,toxic epidermal necrolysis,enterocolitis and hepatitis,0,0.5596396923065186
YERVOY,toxic epidermal necrolysis,"appear to be dose ependent.



   6.2   Post",1,0.5649882555007935
YERVOY,toxic epidermal necrolysis,identified during postapproval,0,0.5108888745307922
YERVOY,rash,be dose dependent ting Experience The following adverse,1,0.5803549885749817
YERVOY,rash,identified during postapproval,0,0.5186307430267334
YERVOY,rash,following adverse reactions have been identified during postapproval use of YERVO,0,0.6016420722007751
YERVOY,rash,ting Experience The following adverse reactions,1,0.6355577707290649
YERVOY,rash,The following adverse reactions have been identified during,0,0.5946598052978516
YERVOY,rash,to be dose dependent ting Experience The following adverse,1,0.5717831254005432
YERVOY,rash,enterocolitis and hepatitis appear,0,0.5548899173736572
YERVOY,rash,to be dose dependent ting Experience The following,1,0.5513389110565186
YERVOY,rash,severity of enterocolitis and hepatitis appear to be dose dependent,0,0.5330787897109985
YERVOY,rash,ting,1,0.5451531410217285
YERVOY,dermal ulceration,following,0,0.45772266387939453
YERVOY,dermal ulceration,verse reactions h,1,0.4858981966972351
YERVOY,dermal ulceration,following ad,0,0.45225727558135986
YERVOY,dermal ulceration,The following verse reactions h ave been,1,0.4884515404701233
YERVOY,dermal ulceration,identified,0,0.4837258458137512
YERVOY,dermal ulceration,hepatitis appear to be dose dependent Postmarketing Experience The following,0,0.514872670173645
YERVOY,died,of YERVOY Because these reactions are reported voluntarily from,0,0.4810277223587036
YERVOY,died,of in,1,0.543203592300415
YERVOY,died,use of YERVOY Because these reactions are reported voluntarily,0,0.47691741585731506
YERVOY,died,estimate their frequency or establish a causal,0,0.4558217525482178
YERVOY,died,in s ize it is not always,1,0.49928227066993713
YERVOY,died,in,1,0.553626537322998
YERVOY,died,uncerta,0,0.4897875487804413
YERVOY,died,population of in,1,0.48471754789352417
YERVOY,died,these reactions are reported voluntarily from a population of,0,0.4749374985694885
YERVOY,toxic epidermal necrolysis,not lways possible to reliably estimate their,1,0.437072217464447
YERVOY,toxic epidermal necrolysis,these reactions are reported voluntarily from a population of,0,0.5454449653625488
YERVOY,toxic epidermal necrolysis,not lways possible to reliably estimate,1,0.4407472312450409
YERVOY,toxic epidermal necrolysis,a population of uncertain,0,0.434321790933609
YERVOY,toxic epidermal necrolysis,size it is not lways,1,0.42019981145858765
YERVOY,toxic epidermal necrolysis,or establish a causal relationship to drug exposure Skin,0,0.6321759819984436
YERVOY,toxic epidermal necrolysis,or establish a causal relationship to drug exposure Skin and Subcut,0,0.6110278964042664
YERVOY,toxic epidermal necrolysis,possible to reliably,1,0.44741103053092957
YERVOY,dermatitis,relationship drug expos ure Skin and Subcutaneous Tissue,1,0.6868352890014648
YERVOY,dermatitis,possible to reliably,1,0.4583916664123535
YERVOY,dermatitis,ure Skin and Subcutaneous Tissue Disorders Drug reaction,0,0.7219803333282471
YERVOY,dermatitis,causal relationship drug expos ure Skin,1,0.6845493316650391
YERVOY,dermatitis,a causal relationship drug expos,1,0.5251156687736511
YERVOY,dermatitis,drug expos ure Skin and Subcutaneous,1,0.6916317343711853
YERVOY,dermatitis,and systemic,0,0.5729259848594666
YERVOY,dermatitis,Immunogenicity In,0,0.5439575910568237
YERVOY,dermatitis,and,0,0.5252739787101746
YERVOY,dermatitis,g reaction with eosinophilia and,1,0.6235290169715881
YERVOY,dermatitis,to drug exposure,0,0.5884515643119812
YERVOY,dermatitis,Disorders g reaction,1,0.5987609624862671
YERVOY,dermatitis,and Subcutaneous Tissue Disorders g reaction with eosinophilia and systemic,1,0.7074671983718872
YERVOY,dermatitis,Tissue Disorders g reaction with eosinophilia and systemic,1,0.645778238773346
YERVOY,dermatitis,and systemic symptoms DRESS,0,0.6454312801361084
YERVOY,dermatitis,Subcutaneous Tissue Disorders g reaction with eosinophilia and systemic symptoms,1,0.6898189783096313
YERVOY,immune-mediated dermatitis,"symptoms DRESS syndrome munogenicity

  In clinica l studies",1,0.6022567749023438
YERVOY,immune-mediated dermatitis,Disorders g reaction,1,0.5725333094596863
YERVOY,immune-mediated dermatitis,binding,0,0.5016655921936035
YERVOY,immune-mediated dermatitis,Drug reaction with eosinophilia,0,0.6071295142173767
YERVOY,immune-mediated dermatitis,syndrome munogenicity,1,0.5565847158432007
YERVOY,immune-mediated dermatitis,munogenicity In clinica l studies of evaluable patients,1,0.5585412383079529
YERVOY,immune-mediated dermatitis,In clinica l studies of evaluable,1,0.5288853645324707
YERVOY,immune-mediated dermatitis,"systemic symptoms DRESS syndrome munogenicity

  In clinica l studies of evaluable patients",1,0.6150553822517395
YERVOY,immune-mediated dermatitis,l,0,0.5106582641601562
YERVOY,dermatitis,against ipilimumab in an cent (ECL),1,0.571648120880127
YERVOY,dermatitis,based assay This assay has substantial limitations in detecting,0,0.5232528448104858
YERVOY,dermatitis,cent (ECL) based,1,0.5097070932388306
YERVOY,dermatitis,cent (ECL),1,0.5165703892707825
YERVOY,dermatitis,an cent (ECL),1,0.506794810295105
YERVOY,dermatitis,interfere with,0,0.5540513396263123
YERVOY,dermatitis,tralizing  antibodies against ipilimumab detected Because,1,0.5749343633651733
YERVOY,dermatitis,were not reported in these patients nor were,0,0.42077404260635376
YERVOY,dermatitis,tralizing ,1,0.5112264156341553
YERVOY,dermatitis,were,0,0.5000673532485962
YERVOY,dermatitis,nor were tralizing ,1,0.41112393140792847
YERVOY,dermatitis,tralizing  antibodies against ipilimumab detected,1,0.5708698034286499
YERVOY,dermatitis,of ipilimumab interfere with the,0,0.5929258465766907
GADAVIST,Nephrogenic Systemic Fibrosis,reactions are discussed elsewhere in labeling,0,0.5029940605163574
GADAVIST,Nephrogenic Systemic Fibrosis,following serious adverse reactions are discussed elsewhere in,0,0.5438193082809448
GADAVIST,Nephrogenic Systemic Fibrosis,in Nephrogenic Systemic Fibrosis NSF see,1,0.9381372928619385
GADAVIST,Nephrogenic Systemic Fibrosis,Nephrogenic Systemic Fibrosis NSF see Boxed,1,0.9199129939079285
GADAVIST,Nephrogenic Systemic Fibrosis,see Boxed Warning and Warnings and,0,0.4855538606643677
GADAVIST,Nephrogenic Systemic Fibrosis,Nephrogenic Systemic Fibrosis NSF see Boxed Warning,1,0.8827133178710938
GADAVIST,Nephrogenic Systemic Fibrosis,are,0,0.4773833751678467
GADAVIST,Nephrogenic Systemic Fibrosis,are discussed elsewhere in Nephrogenic,1,0.7624610662460327
GADAVIST,NSF,in labeling Nephrogenic Systemic NSF see Boxed Warning,1,0.7084083557128906
GADAVIST,NSF,are discussed elsewhere in Nephrogenic,1,0.5376432538032532
GADAVIST,NSF,NSF see Boxed Warning,1,0.7773100137710571
GADAVIST,NSF,adverse,0,0.4609730839729309
GADAVIST,NSF,NSF see Boxed Warning and,1,0.782315731048584
GADAVIST,NSF,are,0,0.511907696723938
GADAVIST,NSF,NSF see,1,0.9209843277931213
GADAVIST,Hypersensitivity reactions,see Boxed Warning and Warnings and,0,0.5602368116378784
GADAVIST,Hypersensitivity reactions,Warning,0,0.53556227684021
GADAVIST,headache,REACTIONS contact,0,0.4985228180885315
GADAVIST,headache,reactions incidence headache nausea and dizziness To report,1,0.7380048036575317
GADAVIST,headache,headache,1,0.9999998807907104
GADAVIST,headache,incidence headache nausea and dizziness To,1,0.7690420746803284
GADAVIST,headache,reactions incidence,0,0.5198880434036255
GADAVIST,headache,headache nausea and dizziness To,1,0.8092151284217834
GADAVIST,headache,SUSPECTED ADVERSE REACTIONS,0,0.5619930624961853
GADAVIST,headache,common adverse reactions incidence are,0,0.5387369394302368
GADAVIST,headache,reactions incidence headache nausea and dizziness To,1,0.7401804327964783
GADAVIST,nausea,nausea,1,1.0
GADAVIST,nausea,incidence,0,0.6217743158340454
GADAVIST,nausea,are nausea,1,0.9338856339454651
GADAVIST,nausea,are,0,0.5310268998146057
GADAVIST,nausea,nausea and,1,0.9323806762695312
GADAVIST,dizziness,reactions incidence are headache nausea and,0,0.649582028388977
GADAVIST,dizziness,dizziness,1,0.9999998807907104
GADAVIST,dizziness,Most common adverse reactions incidence are headache nausea,0,0.6323016881942749
GADAVIST,dizziness,dizziness To,1,0.9522849321365356
GADAVIST,dizziness,SUSPECTED ADVERSE REACTIONS contact Bayer HealthCare Pharmaceuticals In,0,0.5383332371711731
GADAVIST,dizziness,dizziness To report SUSPECTED ADVERSE REACTIONS,1,0.8249813914299011
GADAVIST,dizziness,headache nausea dizziness To report SUSPECTED ADVERSE REACTIONS,1,0.7223095893859863
GADAVIST,dizziness,REACTIONS contact Bayer HealthCare Pharmaceuticals In,0,0.5211615562438965
GADAVIST,Pruritus,Pruritus,1,0.9999999403953552
GADAVIST,Pruritus,includes generalized Erythe,0,0.6111927628517151
GADAVIST,hypotension,anaphylactoid reaction,0,0.5757373571395874
GADAVIST,hypotension,hypotension,1,1.0
GADAVIST,hypotension,hypotension urticaria,1,0.7879893779754639
GADAVIST,hypotension,hypotension urticaria face edema eyelid,1,0.7295592427253723
GADAVIST,hypotension,face edema eyelid edema,0,0.5106191635131836
GADAVIST,hypotension,reactions for hypotension urticaria face,1,0.7623504400253296
GADAVIST,hypotension,for example,0,0.5060803890228271
GADAVIST,hypotension,the following,0,0.5365250706672668
GADAVIST,hypotension,hypotension urticaria face edema eyelid edema,1,0.7289590835571289
GADAVIST,urticaria,adverse reactions for example hypotension,0,0.5709459781646729
GADAVIST,urticaria,urticaria face edema eyelid edema,1,0.77126145362854
GADAVIST,urticaria,eyelid edema,0,0.5683890581130981
GADAVIST,face edema,occurred with a frequency of in,0,0.5078229904174805
GADAVIST,face edema,adverse reactions for example,0,0.5893374681472778
GADAVIST,face edema,of the following adverse reactions for example,0,0.5907284021377563
GADAVIST,face edema,hypotension face,1,0.7222152352333069
GADAVIST,face edema,of,0,0.5215542316436768
GADAVIST,face edema,for example hypotension face edema,1,0.9055118560791016
GADAVIST,face edema,hypotension face edema eyelid edema flushing,1,0.8571736812591553
GADAVIST,face edema,for example hypotension face,1,0.7246559858322144
GADAVIST,face edema,reactions for example hypotension,0,0.5981383919715881
GADAVIST,eyelid edema,eyelid edema flushing Adverse reactions that,1,0.8480506539344788
GADAVIST,eyelid edema,face eyelid edema,1,0.9723255634307861
GADAVIST,eyelid edema,eyelid edema,1,1.0000001192092896
GADAVIST,flushing,flushing Adverse reactions that occurred,1,0.8099422454833984
GADAVIST,flushing,eyelid edema,1,0.5784786343574524
GADAVIST,flushing,of the following,0,0.5566298365592957
GADAVIST,flushing,flushing Adverse reactions that,1,0.8185093998908997
GADAVIST,flushing,in subjects who,0,0.4932671785354614
GADAVIST,loss of consciousness,of consciousness convulsion parosmia tachycardia palpitation,1,0.7256078124046326
GADAVIST,loss of consciousness,with a frequency of,0,0.5363303422927856
GADAVIST,loss of consciousness,subjects who received Gadavist loss of consciousness convulsion parosmia tachycardia palpitation dry,1,0.7471778988838196
GADAVIST,loss of consciousness,occurred with a frequency of in subjects who received,0,0.5651798248291016
GADAVIST,loss of consciousness,of consciousness convulsion,1,0.7788337469100952
GADAVIST,loss of consciousness,who received Gadavist loss of consciousness convulsion parosmia tachycardia palpitation,1,0.7417802810668945
GADAVIST,loss of consciousness,Gadavist loss of,1,0.5596768260002136
GADAVIST,loss of consciousness,frequency of in subjects who,0,0.5125476121902466
GADAVIST,loss of consciousness,loss of consciousness convulsion parosmia tachycardia palpitation dry,1,0.7916208505630493
GADAVIST,convulsion,tachycardia palpitation dry mouth,0,0.5689789056777954
GADAVIST,convulsion,palpitation dry mouth malaise and,0,0.5896662473678589
GADAVIST,convulsion,Gadavist include loss of convulsion,1,0.8434632420539856
GADAVIST,convulsion,convulsion parosmia tachycardia palpitation,1,0.7761112451553345
GADAVIST,parosmia,include loss of consciousness parosmia tachycardia palpitation dry,1,0.6681195497512817
GADAVIST,parosmia,convulsion parosmia tachycardia palpitation,1,0.69155353307724
GADAVIST,parosmia,parosmia tachycardia palpitation dry,1,0.6865088939666748
GADAVIST,parosmia,parosmia tachycardia,1,0.7838134765625
GADAVIST,parosmia,parosmia tachycardia palpitation dry mouth malaise,1,0.7212283611297607
GADAVIST,parosmia,consciousness parosmia tachycardia palpitation dry mouth,1,0.691658079624176
GADAVIST,parosmia,parosmia,1,1.0
GADAVIST,parosmia,tachycardia palpitation dry mouth,0,0.5192223787307739
GADAVIST,parosmia,mouth malaise and feeling cold Postmarketing,0,0.5316499471664429
GADAVIST,parosmia,loss,0,0.5251419544219971
GADAVIST,tachycardia,subjects who received Gadavist include loss of consciousness convulsion,0,0.5658011436462402
GADAVIST,tachycardia,tachycardia palpitation dry mouth malaise,1,0.786794900894165
GADAVIST,tachycardia,tachycardia palpitation,1,0.8941612243652344
GADAVIST,tachycardia,tachycardia,1,0.9999999403953552
GADAVIST,tachycardia,tachycardia palpitation dry,1,0.8249257206916809
GADAVIST,tachycardia,parosmia,0,0.488849401473999
GADAVIST,tachycardia,Experience The,0,0.5314868092536926
GADAVIST,palpitation,Postmarketing Experience The following additiona,0,0.5071600079536438
GADAVIST,palpitation,include,0,0.5085772275924683
GADAVIST,dry mouth,The following additional,0,0.5134719610214233
GADAVIST,dry mouth,consciousness convulsion parosmia tachycardia dry mouth malaise and feeling cold Postmarketing,1,0.7192015647888184
GADAVIST,malaise,dry mouth,0,0.5244370698928833
GADAVIST,malaise,malaise and feeling cold Postmarketing,1,0.6975405216217041
GADAVIST,malaise,malaise and feeling cold,1,0.7596402168273926
GADAVIST,malaise,malaise and,1,0.9599540829658508
GADAVIST,malaise,tachycardia,0,0.5498515963554382
GADAVIST,malaise,cold Postmarketing Experience,0,0.5299067497253418
GADAVIST,malaise,malaise,1,0.9999999403953552
GADAVIST,malaise,dry malaise and feeling cold Postmarketing Experience,1,0.6921544075012207
GADAVIST,feeling cold,feeling cold Postmarketing Experience The,1,0.8161314725875854
GADAVIST,feeling cold,malaise,1,0.5623645186424255
GADAVIST,feeling cold,feeling cold Postmarketing Experience,1,0.8001735210418701
GADAVIST,feeling cold,feeling cold,1,0.9999998807907104
GADAVIST,feeling cold,consciousness convulsion parosmia,0,0.5254719257354736
GADAVIST,feeling cold,adverse reactions have been reporte,0,0.48275822401046753
GADAVIST,feeling cold,palpitation dry mouth malaise feeling cold Postmarketing Experience The following,1,0.743301272392273
GADAVIST,feeling cold,parosmia tachycardia palpitation dry mouth malaise,0,0.5807876586914062
GADAVIST,feeling cold,palpitation dry mouth malaise feeling cold Postmarketing Experience,1,0.7455089092254639
GADAVIST,Cardiac arrest,Cardiac arrest Nephrogenic Systemic Fibrosis,1,0.7440157532691956
GADAVIST,Cardiac arrest,Systemic Fibrosis NSF Hypersensitivity,0,0.4872390627861023
GADAVIST,Cardiac arrest,to reliably estimate their frequency or establish,0,0.46596065163612366
GADAVIST,Cardiac arrest,Cardiac arrest Nephrogenic Systemic,1,0.7940621376037598
GADAVIST,Nephrogenic Systemic Fibrosis,exposure Cardiac Nephrogenic Systemic Fibrosis,1,0.9049075841903687
GADAVIST,Nephrogenic Systemic Fibrosis,Cardiac arrest Nephrogenic Systemic,1,0.7825984954833984
GADAVIST,Nephrogenic Systemic Fibrosis,Cardiac Nephrogenic Systemic Fibrosis NSF Hypersensitivity reactions,1,0.851926326751709
GADAVIST,Nephrogenic Systemic Fibrosis,drug exposure Cardiac Nephrogenic Systemic Fibrosis,1,0.8750203847885132
GADAVIST,Nephrogenic Systemic Fibrosis,Nephrogenic Systemic Fibrosis NSF Hypersensitivity reactions anaphylactic,1,0.8511245250701904
GADAVIST,Nephrogenic Systemic Fibrosis,drug exposure Cardiac Nephrogenic Systemic Fibrosis NSF,1,0.8607981204986572
GADAVIST,Nephrogenic Systemic Fibrosis,exposure Cardiac Nephrogenic Systemic Fibrosis NSF,1,0.8829885721206665
GADAVIST,Nephrogenic Systemic Fibrosis,Cardiac Nephrogenic Systemic Fibrosis NSF Hypersensitivity reactions anaphylactic,1,0.8232969045639038
GADAVIST,NSF,collapse respiratory arrest p,0,0.4702775776386261
GADAVIST,NSF,Nephrogenic Systemic NSF Hypersensitivity reactions,1,0.65053391456604
GADAVIST,NSF,NSF Hypersensitivity,1,0.8160197138786316
GADAVIST,NSF,Nephrogenic Systemic NSF Hypersensitivity reactions anaphylactic shock,1,0.6429048180580139
GADAVIST,NSF,Systemic NSF Hypersensitivity reactions anaphylactic,1,0.7143657207489014
GADAVIST,NSF,NSF Hypersensitivity reactions anaphylactic shock,1,0.734022855758667
GADAVIST,NSF,NSF Hypersensitivity reactions,1,0.7826018929481506
GADAVIST,Hypersensitivity reactions,Fibrosis Hypersensitivity reactions,1,0.8107631802558899
GADAVIST,Hypersensitivity reactions,Fibrosis Hypersensitivity reactions anaphylactic shock circulatory,1,0.7722055912017822
GADAVIST,Hypersensitivity reactions,edema bronchospasm cyano,0,0.6073851585388184
GADAVIST,anaphylactic shock,pulmonary edema,0,0.5645334720611572
GADAVIST,anaphylactic shock,NSF Hypersensitivity anaphylactic,1,0.806839108467102
GADAVIST,anaphylactic shock,anaphylactic shock circulatory collapse,1,0.8307616710662842
GADAVIST,circulatory collapse,Hypersensitivity reactions anaphylactic circulatory collapse respiratory arrest pulmonary edema bronchospasm,1,0.6871204972267151
GADAVIST,circulatory collapse,anaphylactic shock circulatory collapse,1,0.8674609661102295
GADAVIST,circulatory collapse,NSF Hypersensitivity reactions anaphylactic circulatory collapse respiratory,1,0.685456395149231
GADAVIST,circulatory collapse,NSF Hypersensitivity reactions,0,0.4863685965538025
GADAVIST,circulatory collapse,circulatory collapse,1,1.0
GADAVIST,circulatory collapse,Fibrosis NSF Hypersensitivity reactions anaphylactic,0,0.5369760990142822
GADAVIST,circulatory collapse,circulatory collapse respiratory arrest pulmonary edema bronchospasm,1,0.8164787292480469
GADAVIST,circulatory collapse,anaphylactic circulatory collapse,1,0.8508941531181335
GADAVIST,circulatory collapse,circulatory collapse respiratory,1,0.8602200746536255
GADAVIST,respiratory arrest,bronchospasm cyanosis oropharyngeal,0,0.6380829811096191
GADAVIST,respiratory arrest,circulatory respiratory arrest pulmonary edema bronchospasm cyanosis,1,0.818035364151001
GADAVIST,respiratory arrest,respiratory arrest pulmonary edema bronchospasm cyanosis oropharyngeal,1,0.8430945873260498
GADAVIST,respiratory arrest,reactions anaphylactic shock circulatory respiratory arrest,1,0.7961877584457397
GADAVIST,respiratory arrest,respiratory arrest pulmonary edema,1,0.8238339424133301
GADAVIST,respiratory arrest,respiratory arrest pulmonary edema bronchospasm,1,0.8407409191131592
GADAVIST,respiratory arrest,anaphylactic shock circulatory respiratory arrest,1,0.8188027143478394
GADAVIST,pulmonary edema,pulmonary edema bronchospasm cyanosis oropharyngeal swelling laryngeal,1,0.7669326066970825
GADAVIST,pulmonary edema,shock circulatory collapse respiratory,0,0.5706962943077087
GADAVIST,pulmonary edema,Hypersensitivity,0,0.5986902117729187
GADAVIST,pulmonary edema,anaphylactic shock circulatory collapse respiratory,0,0.5792415738105774
GADAVIST,pulmonary edema,F Hypersensitivity reactions anaphylactic shock circulatory,0,0.554279088973999
GADAVIST,pulmonary edema,shock circulatory collapse respiratory pulmonary edema bronchospasm cyanosis,1,0.6710048913955688
GADAVIST,pulmonary edema,pulmonary edema bronchospasm,1,0.8233480453491211
GADAVIST,pulmonary edema,collapse respiratory arrest,0,0.5841203927993774
GADAVIST,bronchospasm,bronchospasm cyanosis oropharyngeal,1,0.8232357501983643
GADAVIST,bronchospasm,pulmonary,0,0.6045706868171692
GADAVIST,bronchospasm,shock circulatory,0,0.5320124626159668
GADAVIST,bronchospasm,bronchospasm cyanosis oropharyngeal swelling,1,0.7843142747879028
GADAVIST,bronchospasm,bronchospasm cyanosis oropharyngeal swelling laryngeal,1,0.7842043042182922
GADAVIST,bronchospasm,edema blood pressure increased,0,0.5166157484054565
GADAVIST,bronchospasm,nsitivity reactions anaphylactic,0,0.649924635887146
GADAVIST,bronchospasm,bronchospasm cyanosis oropharyngeal swelling laryngeal edema,1,0.7835777401924133
GADAVIST,cyanosis,cyanosis oropharyngeal swelling,1,0.7570462822914124
GADAVIST,cyanosis,laryngeal edema blood pressure increased,0,0.5395941734313965
GADAVIST,cyanosis,respiratory arrest pulmonary edema cyanosis oropharyngeal swelling laryngeal,1,0.6595635414123535
GADAVIST,cyanosis,arrest,0,0.4963141977787018
GADAVIST,cyanosis,blood pressure increased,0,0.4883766174316406
GADAVIST,cyanosis,cyanosis oropharyngeal swelling laryngeal,1,0.7363685369491577
GADAVIST,cyanosis,cyanosis oropharyngeal swelling laryngeal edema blood,1,0.7373554110527039
GADAVIST,oropharyngeal swelling,circulatory collapse respiratory arrest,0,0.5050462484359741
GADAVIST,oropharyngeal swelling,circulatory collapse respiratory arrest pulmonary edema bronchospasm,0,0.5238161087036133
GADAVIST,oropharyngeal swelling,edema,0,0.6579598784446716
GADAVIST,oropharyngeal swelling,bronchospasm cyanosis,0,0.4858999252319336
GADAVIST,oropharyngeal swelling,arrest pulmonary edema bronchospasm oropharyngeal,1,0.7063332200050354
GADAVIST,oropharyngeal swelling,oropharyngeal swelling laryngeal edema blood pressure increased,1,0.8332014083862305
GADAVIST,oropharyngeal swelling,bronchospasm,0,0.5009980201721191
GADAVIST,oropharyngeal swelling,oropharyngeal swelling laryngeal edema,1,0.888127326965332
GADAVIST,oropharyngeal swelling,pulmonary edema,0,0.5896215438842773
GADAVIST,laryngeal edema,bronchospasm cyanosis oropharyngeal laryngeal,1,0.6926699876785278
GADAVIST,laryngeal edema,oropharyngeal laryngeal,1,0.7400679588317871
GADAVIST,laryngeal edema,hyperhidrosis,0,0.5319718718528748
GADAVIST,laryngeal edema,collapse respiratory arrest pulmonary edema bronchospasm cyanosis oropharyngeal swelling,0,0.7239595651626587
GADAVIST,laryngeal edema,pressure,0,0.5597743988037109
GADAVIST,laryngeal edema,arrest pulmonary edema bronchospasm cyanosis,0,0.6703035235404968
GADAVIST,laryngeal edema,oropharyngeal laryngeal edema blood pressure increased,1,0.8299045562744141
GADAVIST,laryngeal edema,laryngeal edema blood,1,0.9024022817611694
GADAVIST,blood pressure increased,blood pressure increased chest pain angioedema,1,0.8199458718299866
GADAVIST,blood pressure increased,cyanosis oropharyngeal swelling,0,0.5190904140472412
GADAVIST,blood pressure increased,swelling laryngeal blood pressure increased chest pain angioedema conjunctivitis hyperhidrosis,1,0.729215145111084
GADAVIST,blood pressure increased,pressure increased chest pain angioedema,1,0.7286312580108643
GADAVIST,blood pressure increased,blood pressure,1,0.8599449396133423
GADAVIST,blood pressure increased,laryngeal edema,0,0.5216432809829712
GADAVIST,blood pressure increased,pressure increased chest pain,1,0.7628480792045593
GADAVIST,blood pressure increased,sneezing burning sensation and pal,0,0.5103500485420227
GADAVIST,chest pain,pressure chest pain,1,0.882694661617279
GADAVIST,chest pain,sneezing burning sensation and pal,0,0.5322732925415039
GADAVIST,chest pain,bronchospasm cyanosis oropharyngeal swelling laryngeal edema blood,0,0.5876764059066772
GADAVIST,chest pain,chest pain,1,0.9999999403953552
GADAVIST,chest pain,hyperhidrosis cough sneezing burning sensation and pallor see,0,0.5192206501960754
GADAVIST,chest pain,edema blood pressure chest,1,0.7042771577835083
GADAVIST,chest pain,burning sensation,0,0.5755060911178589
GADAVIST,chest pain,cyanosis oropharyngeal swelling laryngeal edema blood pressure increased,0,0.5812051892280579
GADAVIST,angioedema,angioedema conjunctivitis hyperhidrosis cough,1,0.807772159576416
GADAVIST,angioedema,see Warnings and,0,0.5127228498458862
GADAVIST,angioedema,angioedema conjunctivitis hyperhidrosis,1,0.8257758617401123
GADAVIST,angioedema,increased chest angioedema,1,0.8450149297714233
GADAVIST,angioedema,angioedema conjunctivitis hyperhidrosis cough sneezing,1,0.7993589639663696
GADAVIST,angioedema,angioedema conjunctivitis hyperhidrosis cough sneezing burning,1,0.7985819578170776
GADAVIST,conjunctivitis,Warnings,0,0.56447434425354
GADAVIST,hyperhidrosis,hyperhidrosis cough sneezing burning sensation and,1,0.8101683855056763
GADAVIST,hyperhidrosis,hyperhidrosis cough sneezing burning,1,0.8235034942626953
GADAVIST,cough,cough sneezing burning sensation and pallor,1,0.7272031307220459
GADAVIST,cough,cough sneezing burning sensation and,1,0.7304188013076782
GADAVIST,cough,cough sneezing,1,0.8523238897323608
GADAVIST,cough,cough sneezing burning sensation,1,0.727986216545105
GADAVIST,burning sensation,cough burning sensation and pallor see Warnings and,1,0.8028868436813354
GADAVIST,burning sensation,cough sneezing burning sensation,1,0.8246500492095947
GADAVIST,burning sensation,and pallor see,0,0.5415696501731873
GADAVIST,burning sensation,cough burning sensation,1,0.870711624622345
GADAVIST,burning sensation,hyperhidrosis cough,0,0.602103590965271
GADAVIST,burning sensation,conjunctivitis hyperhidrosis cough sneezing,0,0.5823872089385986
GADAVIST,burning sensation,pain angioedema conjunctivitis hyperhidrosis cough,0,0.6574834585189819
GADAVIST,pallor,Warnings,0,0.520215630531311
GADAVIST,pallor,pain angioedema conjunctivitis hyperhidrosis cough,0,0.5251145362854004
GADAVIST,pallor,pallor see Warnings and Precautions,1,0.8144009709358215
GADAVIST,pallor,pallor see Warnings,1,0.8482570648193359
GADAVIST,pallor,pallor see Warnings and,1,0.8404277563095093
GADAVIST,pallor,see Warnings,0,0.5210665464401245
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,The following serious,1,0.5285001397132874
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,The following serious adv,1,0.582942008972168
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,The following serious adv erse reactions are,1,0.5522412061691284
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,ADVERSE The following serious adv,1,0.584741473197937
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,discussed elsewhere in labeling Nephrogenic Systemic,1,0.8166364431381226
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,following serious adverse s are discussed elsewhere in ,1,0.5241884589195251
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,Nephrogenic Systemic Fibrosis NSF see Boxed Warning,0,0.8827133178710938
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,serious adverse s are discussed elsewhere in  labeling Nephrogenic Systemic,1,0.7910302877426147
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,Boxed Warning and Warnings,0,0.48716115951538086
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,serious adverse s are discussed elsewhere in,1,0.5214195251464844
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,are discussed elsewhere in labeling Nephrogenic Systemic,1,0.8104500770568848
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,adverse s are discussed elsewhere in  labeling Nephrogenic Systemic Fibrosis NSF,1,0.8572642803192139
GADAVIST,NSF,nin g and,1,0.5266470909118652
GADAVIST,NSF,adverse reactions nci dence are headache nausea,1,0.5387254953384399
GADAVIST,NSF,nci,1,0.6385387778282166
GADAVIST,NSF,nci dence are headache nausea,1,0.5543985962867737
GADAVIST,NSF,and dizziness,0,0.45490163564682007
GADAVIST,NSF,nci dence,1,0.6105189919471741
GADAVIST,NSF,and Warnings and,0,0.5116357207298279
GADAVIST,NSF,nci dence are,1,0.6168299317359924
GADAVIST,NSF,Precautions EXCERPT Most common adverse,0,0.47055548429489136
GADAVIST,fatal,common adverse reactions are h,1,0.5849137306213379
GADAVIST,fatal,are h,1,0.5270994305610657
GADAVIST,fatal,are h eadache nausea,1,0.5547763705253601
GADAVIST,fatal,reactions are,1,0.5728986263275146
GADAVIST,fatal,Most common adverse reactions are h eadache nausea and,1,0.5679539442062378
GADAVIST,fatal,are h eadache nausea and dizziness,1,0.5295858383178711
GADAVIST,fatal,report SUSPECTED ADVERSE REACTIONS contact,0,0.5414437055587769
GADAVIST,fatal,are h eadache nausea and,1,0.5584114789962769
GADAVIST,fatal,nausea and dizziness To report SUSPECTED,0,0.5432961583137512
GADAVIST,fibrosis,and dizz iness To report,1,0.5448079109191895
GADAVIST,fibrosis,reactions incidence are headache and dizz,1,0.5301302671432495
GADAVIST,fibrosis,headache and,1,0.4833676218986511
GADAVIST,fibrosis,nausea,0,0.5642482042312622
GADAVIST,fibrosis,incidence are headache and,1,0.503623366355896
GADAVIST,fibrosis,are headache and,1,0.46594032645225525
GADAVIST,NSF, Ba yer HealthCare,1,0.4529639482498169
GADAVIST,NSF, Ba yer HealthCare Pharmaceuticals,1,0.4716687500476837
GADAVIST,NSF, Ba yer,1,0.49678826332092285
GADAVIST,NSF,ADVERSE REACTIONS  Ba,1,0.45364099740982056
GADAVIST,NSF,REACTIONS contact,0,0.5169466733932495
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,Hispanic Black and patients of other ethnic groups The,0,0.5573291778564453
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,subjects,0,0.4787900447845459
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,subjects were male nd the ethnic distribution wa s,1,0.4874228537082672
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,male nd the ethnic,1,0.488247275352478
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,the majority receiving the recommended dose Approximately of the subjects were male,0,0.50548255443573
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,subjects were male nd the ethnic distribution wa s Caucasian,1,0.4882192015647888
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,male nd the ethnic distribution wa,1,0.4830883741378784
GADAVIST,NSF,60% Caucasian Asian Hispanic Black and,1,0.4930684268474579
GADAVIST,NSF,the majority receiving the recommended dose Approximately of the subjects were male,0,0.5032905340194702
GADAVIST,NSF,ethnic groups The average ag,0,0.45917582511901855
GADAVIST,NSF,distribution 60% Caucasian Asian Hispanic Black,1,0.5085539817810059
GADAVIST,NSF,60% Caucasian Asian Hispanic,1,0.48670244216918945
GADAVIST,NSF,60% Caucasian Asian,1,0.4897700548171997
GADAVIST,NSF,the ethnic distribution 60% Caucasian Asian Hispanic Black,1,0.47996729612350464
GADAVIST,NSF,week yea rs Overall approximately,1,0.5401874780654907
GADAVIST,NSF,from,0,0.5354965925216675
GADAVIST,NSF,yea rs,1,0.5475760698318481
GADAVIST,NSF,week yea rs Overall approximately of subjects,1,0.5529813766479492
GADAVIST,NSF,week,0,0.5262681245803833
GADAVIST,NSF,groups The average age was years range from week to,0,0.47247353196144104
GADAVIST,NSF,reactions associated with,0,0.4843118190765381
GADAVIST,NSF,Table,0,0.55284184217453
GADAVIST,NSF,of  Gadavist were usually mild,1,0.4874308705329895
GADAVIST,NSF,of  Gadavist,1,0.5096692442893982
GADAVIST,NSF,of  Gadavist were usually,1,0.49026256799697876
GADAVIST,NSF,moderate in severity and transient in nature Table lists,0,0.51728755235672
GADAVIST,NSF,the of ,1,0.49846741557121277
GADAVIST,NSF,of ,1,0.5237915515899658
GADAVIST,NSF,transient in nature Table,0,0.5386453866958618
GADAVIST,Nephrogenic Systemic Fibrosis,The following s,1,0.4845939576625824
GADAVIST,Nephrogenic Systemic Fibrosis,ADVERSE REACTIONS The following s adverse reactions are discu ssed elsewhere in labeling,1,0.5245931148529053
GADAVIST,Nephrogenic Systemic Fibrosis,REACTIONS The following s adverse reactions are discu ssed elsewhere in,1,0.5448446273803711
GADAVIST,Nephrogenic Systemic Fibrosis,REACTIONS The following,0,0.5022467374801636
GADAVIST,hypersensitivity reactions,Hypersensitivity reactions,0,1.0
GADAVIST,hypersensitivity reactions,ations (4) and Warnings an d Precautions EXCERPT Most,1,0.5728003978729248
GADAVIST,hypersensitivity reactions,Precautions EXCERPT Most common,0,0.5726959705352783
GADAVIST,hypersensitivity reactions,and Warnings and Precautions,0,0.5480787754058838
GADAVIST,hypersensitivity reactions,and Precautions Hypersensitivity reactions,0,0.8861771821975708
GADAVIST,hypersensitivity reactions,see ations (4) and Warnings an,1,0.5532124638557434
GADAVIST,hypersensitivity reactions,Contraindic,0,0.5622503757476807
GADAVIST,cutaneous manifestations,* Most comm on adverse reactions incidence,1,0.5966291427612305
GADAVIST,cutaneous manifestations,Most comm on adverse reactions incidence,1,0.6016043424606323
GADAVIST,cutaneous manifestations,CERPT:    *    Most comm,1,0.4718044102191925
GADAVIST,cutaneous manifestations,Warnings and,0,0.5952399969100952
GADAVIST,cutaneous manifestations,Contraindications and Warnings,0,0.5869542956352234
GADAVIST,death,reactions are h eadache nausea and dizziness To,1,0.5517436861991882
GADAVIST,death,Contraindications and Warnings,0,0.5171365737915039
GADAVIST,death,are h,1,0.5116665363311768
GADAVIST,death,are h eadache nausea and,1,0.5405279994010925
GADAVIST,death,common adverse reactions are,1,0.5029628276824951
GADAVIST,death,common adverse reactions are h,1,0.5137323141098022
GADAVIST,nephrogenic systemic fibrosis,"at FDA or 
  6.1 Clinical Trials Experi",1,0.5174925327301025
GADAVIST,nephrogenic systemic fibrosis,common adverse reactions are,1,0.5310421586036682
GADAVIST,nephrogenic systemic fibrosis,Inc at or FDA at,0,0.5155300498008728
GADAVIST,nephrogenic systemic fibrosis,6.1 Clinical Trials Experi,1,0.5298333764076233
GADAVIST,nephrogenic systemic fibrosis,Because clinical trials are conducted,0,0.49983203411102295
GADAVIST,nephrogenic systemic fibrosis,Trials Experi,1,0.48726367950439453
GADAVIST,nephrogenic systemic fibrosis,"at FDA or 
  6.1 Clinical Trials Experi ence Because clinical",1,0.5179325938224792
GADAVIST,NSF,"ce
",1,0.5059219002723694
GADAVIST,NSF,conditions,0,0.5159381628036499
GADAVIST,NSF,or FDA at FDA or wwwfdagovmedwatch,0,0.5388633608818054
GADAVIST,NSF,"ce
 Because clinical trials",1,0.5322772264480591
GADAVIST,NSF,"ce
 Because",1,0.4858730733394623
GADAVIST,NSF,"wwwfdagovmedwatch Clinical Trials ce
 Because clinical trials are conducted",1,0.5623512268066406
GADAVIST,NSF,drug and may t,1,0.4697744846343994
GADAVIST,NSF,and,0,0.49894896149635315
GADAVIST,NSF,t r,1,0.509234607219696
GADAVIST,NSF,rates in the clinical,0,0.5167122483253479
GADAVIST,NSF,His panic Black,1,0.4600962996482849
GADAVIST,NSF,His panic Black and,1,0.46286433935165405
GADAVIST,NSF,His panic Black and patients of,1,0.43798670172691345
GADAVIST,NSF,The average age was years range from w,0,0.4714175760746002
GADAVIST,NSF,patients of other ethnic groups The average age was years range,0,0.44971659779548645
GADAVIST,NSF,range,0,0.5018606781959534
GADAVIST,NSF,of other ethnic groups The average age was years range from,0,0.454054594039917
GADAVIST,NSF,ethnic distribution was Caucasian His panic Black and patients,1,0.45336320996284485
GADAVIST,NSF,ethnic distribution was Caucasian His panic,1,0.46007004380226135
GADAVIST,fatal,e subjects were male and the ethnic distribution was,0,0.4998118281364441
GADAVIST,fatal,"was Caucasian Asian Hispanic ,",1,0.48647385835647583
GADAVIST,fatal,"Caucasian Asian Hispanic , and",1,0.47744402289390564
GADAVIST,fatal,"Caucasian Asian Hispanic ,",1,0.4889312982559204
GADAVIST,fatal,week to years,0,0.4531046748161316
GADAVIST,fatal,Hispanic Black,0,0.5397181510925293
GADAVIST,fibrosis,week to years Overall approximately,0,0.5191777944564819
GADAVIST,fibrosis,and patients of ther,1,0.5620867013931274
GADAVIST,acute kidney injury,genic Systemic Fibr,1,0.5299884080886841
GADAVIST,acute kidney injury,and patients of ther,1,0.5281801223754883
GADAVIST,acute kidney injury,arrest genic Systemic Fibr osis NSF Hypersensitivity,1,0.5067070722579956
GADAVIST,acute kidney injury,osis NSF,0,0.421715646982193
GADAVIST,acute kidney injury,Systemic Fibr osis NSF Hypersensitivity,1,0.4881438612937927
GADAVIST,acute kidney injury,Cardiac arrest genic Systemic Fibr osis NSF Hypersensitivity,1,0.5319385528564453
GADAVIST,acute kidney injury,relationship to drug,0,0.46555155515670776
GADAVIST,acute kidney injury,genic Systemic,1,0.5082542300224304
GADAVIST,acute kidney injury,circulatory,0,0.5785257816314697
OTEZLA,diarrhea,most common,0,0.5459122061729431
OTEZLA,diarrhea,reactions diarrhea nausea and headache Psoriasis,1,0.7474050521850586
OTEZLA,diarrhea,diarrhea,1,0.9999999403953552
OTEZLA,diarrhea,The most common adverse reactions are,0,0.5654026865959167
OTEZLA,diarrhea,headache Psoriasis The,0,0.5662851929664612
OTEZLA,diarrhea,diarrhea nausea and headache Psoriasis,1,0.7756803035736084
OTEZLA,diarrhea,adverse,0,0.5763810873031616
OTEZLA,nausea,nausea,1,1.0
OTEZLA,nausea,adverse reactions are diarrhea nausea,0,0.7598929405212402
OTEZLA,diarrhea,common adverse reactions diarrhea nausea upper,1,0.7249103784561157
OTEZLA,diarrhea,adverse reactions are diarrhea nausea,0,0.7578040957450867
OTEZLA,diarrhea,diarrhea nausea and headache Psoriasis The most common,0,0.7491674423217773
OTEZLA,diarrhea,Psoriasis The most,0,0.570702314376831
OTEZLA,diarrhea,tract infection and headache including tension,0,0.5785776972770691
OTEZLA,diarrhea,tract infection and headache including tension headache,0,0.5686249136924744
OTEZLA,nausea,nausea upper,1,0.8930381536483765
OTEZLA,nausea,nausea upper respiratory tract infection,1,0.8189057111740112
OTEZLA,nausea,nausea upper respiratory,1,0.8315922021865845
OTEZLA,nausea,are,0,0.5310268998146057
OTEZLA,nausea,common adverse reactions are diarrhea,0,0.6203227043151855
OTEZLA,nausea,including tension,0,0.5930757522583008
OTEZLA,nausea,most common adverse,0,0.5731617212295532
OTEZLA,upper respiratory tract infection,diarrhea nausea,0,0.5773810148239136
OTEZLA,upper respiratory tract infection,headache To report SUSPECTED ADVERSE,0,0.591938316822052
OTEZLA,upper respiratory tract infection,upper respiratory tract infection and headache including tension headache,1,0.8123806118965149
OTEZLA,upper respiratory tract infection,diarrhea upper respiratory tract,1,0.8168327212333679
OTEZLA,upper respiratory tract infection,adverse reactions are diarrhea upper respiratory tract infection,1,0.7631117701530457
OTEZLA,upper respiratory tract infection,adverse reactions are,0,0.5652891397476196
OTEZLA,upper respiratory tract infection,headache including tension headache To report SUSPECTED ADVERSE,0,0.5734649300575256
OTEZLA,upper respiratory tract infection,tract infection and,1,0.7333716154098511
OTEZLA,upper respiratory tract infection,most common adverse reactions are diarrhea,0,0.5301432013511658
OTEZLA,upper respiratory tract infection,tract infection and headache,1,0.7031418681144714
OTEZLA,headache,infection headache including tension headache To,1,0.8174940347671509
OTEZLA,headache,tract infection and headache,1,0.7885328531265259
OTEZLA,headache,headache including tension,1,0.8664688467979431
OTEZLA,headache,respiratory tract infection,0,0.5784865617752075
OTEZLA,headache,REACTIONS contact,0,0.4985228180885315
OTEZLA,headache,e most common adverse reactions,0,0.5825827121734619
OTEZLA,headache,headache including tension headache To,1,0.8548575043678284
OTEZLA,headache,headache including tension headache To report,1,0.8255648612976074
OTEZLA,headache,headache including,1,0.9300044775009155
OTEZLA,tension headache,infection and headache tension,1,0.8578802943229675
OTEZLA,tension headache,tension headache To report,1,0.9201610088348389
OTEZLA,tension headache,e reactions are diarrhea nausea upper respiratory,0,0.5296940803527832
OTEZLA,tension headache,report SUSPECTED ADVERSE REACTIONS contact,0,0.5173430442810059
OTEZLA,tension headache,infection and headache tension headache To report SUSPECTED,1,0.8380154371261597
OTEZLA,tension headache,report SUSPECTED,0,0.44696444272994995
OTEZLA,Diarrhea,treatment and tended to resolve over time with,0,0.5255743861198425
OTEZLA,Diarrhea,time with,0,0.5218196511268616
OTEZLA,Diarrhea,the first weeks of treatment,0,0.5114446878433228
OTEZLA,Diarrhea,time with continued dosing,0,0.5086934566497803
OTEZLA,headache,tended to resolve over time with,0,0.5405449867248535
OTEZLA,headache,Diarrhea,0,0.5687179565429688
OTEZLA,headache,headache and,1,0.9235891103744507
OTEZLA,headache,headache,1,0.9999998807907104
OTEZLA,headache,and nausea were the,0,0.6278948783874512
OTEZLA,headache,headache and nausea were,1,0.8108267784118652
OTEZLA,headache,headache and nausea were the,1,0.8105168342590332
OTEZLA,headache,The most common adverse reactions,0,0.5772163271903992
OTEZLA,headache,time with continued dosing headache and nausea,1,0.7199293971061707
OTEZLA,nausea,and tended to resolve over time with continued dosing Diarrhea headache,0,0.6422651410102844
OTEZLA,nausea,nausea were,1,0.9634414911270142
OTEZLA,nausea,tended,0,0.5470339059829712
OTEZLA,nausea,nausea were the most,1,0.8990409970283508
OTEZLA,nausea,nausea were the most commonly reported,1,0.833876371383667
OTEZLA,nausea,continued dosing Diarrhea headache nausea,1,0.7299349308013916
OTEZLA,nausea,headache nausea were,1,0.8746798038482666
OTEZLA,nausea,reactions The most common adverse reactions,0,0.600496232509613
OTEZLA,nausea,for patients taking OTEZLA nausea diarrhea,1,0.7200495004653931
OTEZLA,nausea,discontinuation for patients,0,0.5049941539764404
OTEZLA,nausea,adverse reactions leading to discontinuation for patients,0,0.5596309304237366
OTEZLA,headache,were nausea diarrhea headache The,1,0.7595961093902588
OTEZLA,headache,adverse reactions leading to discontinuation for patients,0,0.5263306498527527
OTEZLA,headache,headache The proportion of,1,0.8426023721694946
OTEZLA,headache,diarrhea headache The proportion of patients,1,0.7391178607940674
OTEZLA,headache,who discontinued treatment,0,0.49468544125556946
OTEZLA,headache,headache The proportion of patients with,1,0.8038718104362488
OTEZLA,headache,headache The proportion,1,0.8601986169815063
OTEZLA,headache,were nausea diarrhea headache,1,0.7682548761367798
OTEZLA,gastrointestinal adverse reactions,Patients on Placebo for up to Day Week,0,0.5256712436676025
OTEZLA,gastrointestinal adverse reactions,up to Day Week a Of the reported,0,0.47425493597984314
OTEZLA,gastrointestinal adverse reactions,Of the gastrointestinal adverse reactions,1,0.969348669052124
OTEZLA,gastrointestinal adverse reactions,on Placebo for,0,0.5514487028121948
OTEZLA,gastrointestinal adverse reactions,the gastrointestinal adverse reactions,1,0.986772358417511
OTEZLA,gastrointestinal adverse reactions,Of the gastrointestinal adverse,1,0.9135434627532959
OTEZLA,gastrointestinal adverse reactions,a serious adverse reaction of,0,0.7662439942359924
OTEZLA,gastrointestinal adverse reactions,gastrointestinal adverse reactions subject experienced a serious,1,0.916141152381897
OTEZLA,gastrointestinal adverse reactions,Week a Of the gastrointestinal adverse reactions,1,0.8842605352401733
OTEZLA,nausea,nausea and vomiting in,1,0.8789523243904114
OTEZLA,nausea,nausea and vomiting in OTEZLA mg,1,0.7852872610092163
OTEZLA,nausea,reaction nausea,1,0.8731347322463989
OTEZLA,nausea,a serious adverse reaction nausea and vomiting in OTEZLA,1,0.7673474550247192
OTEZLA,nausea,twice daily,0,0.502702534198761
OTEZLA,nausea,nausea and,1,0.9323806762695312
OTEZLA,nausea,and vomiting in OTEZLA mg,0,0.754317045211792
OTEZLA,vomiting,vomiting in OTEZLA mg twice,1,0.7985830903053284
OTEZLA,vomiting,vomiting in OTEZLA mg twice daily,1,0.7659523487091064
OTEZLA,vomiting,of nausea vomiting in OTEZLA mg,1,0.7981898784637451
OTEZLA,vomiting,vomiting in OTEZLA mg,1,0.8179198503494263
OTEZLA,vomiting,gastrointestinal adverse reactions subject,0,0.6717133522033691
OTEZLA,vomiting,of nausea vomiting in OTEZLA mg twice,1,0.7893245220184326
OTEZLA,vomiting,adverse reaction of nausea vomiting in OTEZLA mg twice daily,1,0.7458864450454712
OTEZLA,diarrhea,adverse reaction of headache,0,0.5313782691955566
OTEZLA,diarrhea,subject treated with OTEZLA mg twice daily experienced a serious adverse reaction,0,0.5675299167633057
OTEZLA,diarrhea,a,0,0.5636927485466003
OTEZLA,diarrhea,diarrhea patient treated with,1,0.7982989549636841
OTEZLA,diarrhea,serious adverse reaction of headache,0,0.5369938611984253
OTEZLA,diarrhea,diarrhea patient treated with OTEZLA mg,1,0.750716507434845
OTEZLA,headache,a serious adverse reaction headache b Of,1,0.8145302534103394
OTEZLA,headache,diarrhea patient treated with,1,0.4866521656513214
OTEZLA,headache,headache b,1,0.8420788049697876
OTEZLA,headache,headache b Of the reported,1,0.8545104265213013
OTEZLA,headache,reported adverse drug reactions none were serious c n indicates number,0,0.5290557146072388
OTEZLA,Hypersensitivity,Hypersensitivity Investigations Weight decrease Gastrointestinal Disorders,1,0.7401940226554871
OTEZLA,Hypersensitivity,clinical,0,0.5620430111885071
OTEZLA,Hypersensitivity,Disorders Frequent bowel movement gastroesop,0,0.5431257486343384
OTEZLA,Hypersensitivity,clinical studies,0,0.5331980586051941
OTEZLA,Weight decrease,Weight decrease Gastrointestinal Disorders Frequent bowel,1,0.7367031574249268
OTEZLA,Weight decrease,Frequent bowel movement,0,0.554267942905426
OTEZLA,Frequent bowel movement,Nutrition,0,0.5135776996612549
OTEZLA,Frequent bowel movement,decrease Gastrointestinal Frequent bowel,1,0.8410303592681885
OTEZLA,Frequent bowel movement,Disorders Decreased appetit,0,0.597578763961792
OTEZLA,Frequent bowel movement,Frequent bowel movement gastroesophageal,1,0.8858742713928223
OTEZLA,Frequent bowel movement,Investigations Weight decrease Gastrointestinal Frequent bowel movement gastroesophageal,1,0.8098186254501343
OTEZLA,Frequent bowel movement,Disorders,0,0.6187081933021545
OTEZLA,Frequent bowel movement,bowel movement gastroesophageal reflux disease dyspepsia,1,0.7886637449264526
OTEZLA,Frequent bowel movement,Gastrointestinal Frequent bowel movement gastroesophageal reflux disease dyspepsia Metabolism,1,0.8345953226089478
OTEZLA,Frequent bowel movement,Hypersensitivity Investigations Weight,0,0.5353772640228271
OTEZLA,gastroesophageal reflux disease,Disorders Decreased appetite,0,0.5779048800468445
OTEZLA,gastroesophageal reflux disease,ensitivity Investigations Weight decrease,0,0.534918487071991
OTEZLA,gastroesophageal reflux disease,Gastrointestinal Disorders Frequent bowel gastroesophageal reflux disease dyspepsia Metabolism,1,0.8047069311141968
OTEZLA,gastroesophageal reflux disease,reflux disease dyspepsia Metabolism and,1,0.8219538927078247
OTEZLA,gastroesophageal reflux disease,gastroesophageal reflux disease dyspepsia Metabolism and,1,0.8676421642303467
OTEZLA,gastroesophageal reflux disease,reflux disease dyspepsia,1,0.8502845168113708
OTEZLA,gastroesophageal reflux disease,Frequent bowel,0,0.6141642332077026
OTEZLA,dyspepsia,gastroesophageal reflux dyspepsia,1,0.8873637318611145
OTEZLA,dyspepsia,Frequent bowel,0,0.6250337362289429
OTEZLA,dyspepsia,Disorders Migraine Res,0,0.5972478985786438
OTEZLA,dyspepsia,gastroesophageal reflux,0,0.7467129230499268
OTEZLA,dyspepsia,bowel movement gastroesophageal,0,0.6781308650970459
OTEZLA,dyspepsia,reflux dyspepsia Metabolism and Nutrition Disorders,1,0.7899346351623535
OTEZLA,dyspepsia,reflux,0,0.7113787531852722
OTEZLA,Migraine,Migraine Respiratory Thoracic,1,0.7697581052780151
OTEZLA,Migraine,Migraine Respiratory,1,0.8095424771308899
OTEZLA,Migraine,appetite Nervous System Migraine Respiratory Thoracic and Mediastinal Disorders,1,0.6791727542877197
OTEZLA,Cough,Cough Skin and Subcutaneous,1,0.8063957691192627
OTEZLA,Cough,Migraine Respiratory,1,0.6498483419418335
OTEZLA,Cough,System Disorders Migraine Respiratory,0,0.5989142656326294
OTEZLA,Cough,treated with OTEZLA mg twice daily,0,0.540661633014679
OTEZLA,Cough,Cough Skin,1,0.8409528732299805
OTEZLA,Cough,Mediastinal Cough Skin and Subcutaneous Tissue,1,0.7620863318443298
OTEZLA,Cough,and Subcutaneous Tissue Disorders Rash,0,0.5071516633033752
OTEZLA,Cough,OTEZLA mg,0,0.4997421205043793
OTEZLA,Cough,Nervous System Disorders Migraine Respiratory,0,0.5920596718788147
OTEZLA,Cough,Cough Skin and,1,0.8488839864730835
OTEZLA,Diarrhea,overall median,0,0.5523599982261658
OTEZLA,Diarrhea,Diarrhea nausea and upper respiratory,1,0.7622110247612
OTEZLA,Diarrhea,Diarrhea nausea,1,0.8461776971817017
OTEZLA,Diarrhea,of Diarrhea nausea,1,0.8107573986053467
OTEZLA,Diarrhea,overall median age of Diarrhea,1,0.774523138999939
OTEZLA,Diarrhea,an overall median age of years,0,0.5158617496490479
OTEZLA,Diarrhea,commonly reported,0,0.547609806060791
OTEZLA,nausea,of years nausea and upper,1,0.8167366981506348
OTEZLA,nausea,commonly reported,0,0.5409419536590576
OTEZLA,nausea,nausea and upper,1,0.8787270784378052
OTEZLA,nausea,years nausea and upper,1,0.8208580613136292
OTEZLA,nausea,Diarrhea,0,0.6490728855133057
OTEZLA,nausea,and upper respiratory tract,0,0.634989321231842
OTEZLA,nausea,reactions leading to discontinuation for,0,0.5295901894569397
OTEZLA,nausea,subjects taking OTEZLA,0,0.5350631475448608
OTEZLA,nausea,nausea diarrhea,1,0.8622832298278809
OTEZLA,diarrhea,nausea,0,0.6490728855133057
OTEZLA,diarrhea,subjects taking OTEZLA,0,0.5400882959365845
OTEZLA,diarrhea,discontinued,0,0.5382083654403687
OTEZLA,diarrhea,with psoriasis,0,0.5786781907081604
OTEZLA,diarrhea,diarrhea and headache The proportion of,1,0.7900078296661377
OTEZLA,diarrhea,discontinued treatment d,0,0.5669201612472534
OTEZLA,headache,diarrhea headache,1,0.794334888458252
OTEZLA,headache,discontinued treatment d,0,0.5307730436325073
OTEZLA,headache,who discontinued,0,0.4376142919063568
OTEZLA,headache,headache The proportion of subjects with,1,0.7951754331588745
OTEZLA,headache,headache The proportion of subjects,1,0.7943251132965088
OTEZLA,headache,nausea diarrhea,0,0.5784451365470886
OTEZLA,headache,ions leading to discontinuation for subjects taking OTEZLA were nausea diarrhea and,0,0.5618847012519836
OTEZLA,headache,with,0,0.5505115985870361
OTEZLA,abdominal pain,reaction abdominal pain,1,0.893409252166748
OTEZLA,abdominal pain,abdominal pain Preferred Term Placebo Nn OTEZLA,1,0.7730363607406616
OTEZLA,abdominal pain,adverse reaction abdominal pain,1,0.8498656749725342
OTEZLA,abdominal pain,Placebo Nn OTEZLA mg BID Nn Diarrhea,0,0.596582293510437
OTEZLA,abdominal pain,abdominal pain Preferred,1,0.9068493843078613
OTEZLA,abdominal pain,Placebo Nn OTEZLA,0,0.5114848613739014
OTEZLA,Nausea,Nausea Upper,1,0.8930381536483765
OTEZLA,Nausea,Upper,0,0.5147274136543274
OTEZLA,Nausea,Nn Nausea Upper,1,0.8445310592651367
OTEZLA,Nausea,Nausea,1,1.0
OTEZLA,Nausea,Diarrhea,0,0.6490728855133057
OTEZLA,Nausea,mg BID Nn Diarrhea,0,0.6133149266242981
OTEZLA,Nausea,Nn Nausea Upper respiratory tract,1,0.8013755083084106
OTEZLA,Headache,headache,0,0.9999998807907104
OTEZLA,Headache,Headache,1,0.9999998807907104
OTEZLA,Headache,Tension,0,0.6046638488769531
OTEZLA,Headache,Headache Abdominal pain,1,0.8202846050262451
OTEZLA,Headache,Tension Headache Abdominal pain,1,0.7682173252105713
OTEZLA,Insomnia,Insomnia Back,1,0.8978735208511353
OTEZLA,Insomnia,Insomnia Back pain,1,0.8158684968948364
OTEZLA,Migraine,Frequent bowel,0,0.5135846138000488
OTEZLA,Folliculitis,Folliculitis,1,1.0
OTEZLA,Folliculitis,Tooth,0,0.4683876037597656
OTEZLA,Folliculitis,Folliculitis Sinus headache,1,0.796623706817627
OTEZLA,Weight Decrease,at FDA r www.fda.gov/m edwatch Clinical Trials,1,0.4875619411468506
OTEZLA,Weight Decrease,Folliculitis Sinus headache,1,0.4671474099159241
OTEZLA,Weight Decrease,trials are conducted,0,0.5144141316413879
OTEZLA,Weight Decrease,Celgene Corporation at or FDA at FDA,0,0.4694003760814667
OTEZLA,Weight Decrease,r www.fda.gov/m edwatch,1,0.49024832248687744
OTEZLA,Weight Decrease,or FDA at FDA r,1,0.4902387857437134
OTEZLA,Weight Decrease,are conducted under widely,0,0.4685262441635132
OTEZLA,Weight Decrease,FDA at FDA,0,0.45673370361328125
OTEZLA,Weight Decrease,are conducted,0,0.5043806433677673
OTEZLA,depression,doubleblind placebocontrolled [Studies P sA PsA,1,0.5385304689407349
OTEZLA,depression,are conducted,0,0.47534480690956116
OTEZLA,depression,placebocontrolled [Studies P,1,0.5392628908157349
OTEZLA,depression,arthritis see Cl,0,0.548714816570282
OTEZLA,depression,common e reaction,1,0.5219817161560059
OTEZLA,depression,resolve,0,0.5363370180130005
OTEZLA,depression,e reaction s presented inTable occurred,1,0.5231648087501526
OTEZLA,depression,of the most,0,0.49692779779434204
OTEZLA,depression,e reaction,1,0.5120558142662048
OTEZLA,depression,inTable occurred,0,0.5229078531265259
OTEZLA,depressed mood,adverse reactions esented inTabl e occurred within,1,0.49344637989997864
OTEZLA,depressed mood,inTable occurred,0,0.48998895287513733
OTEZLA,depressed mood,common adverse reactions esented inTabl e occurred,1,0.5057739615440369
OTEZLA,depressed mood,of treatment and tended to,0,0.5150887966156006
OTEZLA,depressed mood,reactions esented,1,0.5325619578361511
OTEZLA,depressed mood,reactions esented inTabl e occurred within,1,0.5028033256530762
OTEZLA,depressed mood,common adverse reactions esented inTabl e occurred within,1,0.49423450231552124
OTEZLA,depressed mood,an overall median age of years The majority of the most common,0,0.5014539957046509
OTEZLA,depressed mood,common adverse reactions esented inTabl,1,0.5075394511222839
OTEZLA,depressed mood,esented inTabl,1,0.5404634475708008
OTEZLA,depressed mood,most common adverse reactions esented,1,0.49110281467437744
OTEZLA,depression,mmonly rep orted adverse reactions The,1,0.5148946642875671
OTEZLA,depression,mmonly,1,0.5394201278686523
OTEZLA,depression,nausea were the most mmonly rep,1,0.6291308403015137
OTEZLA,depression,tended to resolve over time with continued dosing Diarrhea headache,0,0.5853083729743958
OTEZLA,depression,common adverse,0,0.5418399572372437
OTEZLA,depression,mmonly rep orted adverse reactions,1,0.5138677954673767
OTEZLA,depression,the most mmonly,1,0.5505320429801941
OTEZLA,depression,the most mmonly rep,1,0.494911253452301
OTEZLA,depression,mmonly rep orted adverse reactions The most,1,0.5229284763336182
OTEZLA,depressed mood,for patients,0,0.5133191347122192
OTEZLA,depressed mood,were the most commonly d adverse,1,0.5402846336364746
OTEZLA,depressed mood,Diarrhea headache and nausea were,0,0.5885869264602661
OTEZLA,depressed mood,d,1,0.531644344329834
OTEZLA,depressed mood,most commonly d adverse reac,1,0.537950336933136
OTEZLA,depressed mood,were the most commonly d,1,0.49305304884910583
OTEZLA,depressed mood,d adverse reac tions The most common adverse,1,0.5251965522766113
OTEZLA,depressed mood,and,0,0.4852595031261444
OTEZLA,depressed mood,adverse reac tions The most common,1,0.5275771617889404
OTEZLA,depressed mood,commonly d,1,0.5364933609962463
OTEZLA,Depression,common adverse reactions leading to disco,0,0.5546098947525024
OTEZLA,Depression,ntinuation for,1,0.523590624332428
OTEZLA,Depression,were nausea diarrhea and,0,0.5883644819259644
OTEZLA,Depression,ntinuation for patients taking OTEZLA were,1,0.572884202003479
OTEZLA,Depression,ntinuation for patients taking OTEZLA,1,0.5621360540390015
OTEZLA,Depression,ntinuation,1,0.5146536827087402
OTEZLA,suicidal ideation,The proportion of patients with psoriatic,0,0.4429205060005188
OTEZLA,suicide,on OTEZLA mg wice Da,1,0.5098004341125488
OTEZLA,suicide,Reported in of Patients,0,0.47967588901519775
OTEZLA,suicide,wice Da ily and Than That Observed,1,0.4957522749900818
OTEZLA,suicide,wice Da ily and,1,0.5059218406677246
OTEZLA,depression,miting in  OTEZLA mg,1,0.5384131073951721
OTEZLA,depression,Reported in of Patients,0,0.5268023014068604
OTEZLA,depression,of nausea and miting in  OTEZLA mg,1,0.6046521067619324
OTEZLA,depression,of nausea and miting,1,0.6571834087371826
OTEZLA,depression,twice daily,0,0.5603091716766357
OTEZLA,depression,twice daily experienced a serious adve,0,0.6235305070877075
OTEZLA,depression,and miting in ,1,0.5230789184570312
OTEZLA,depression,miting in OTEZLA mg twice daily,1,0.5612621307373047
OTEZLA,depression,miting in  OTEZLA mg twice daily subject,1,0.5796976089477539
OTEZLA,depression,and miting in,1,0.5230789184570312
OTEZLA,depression,ZLA 30 mg,1,0.5386528968811035
OTEZLA,Depression,patient treated with OTEZLA mg twice daily experienced a serious adverse,0,0.562057614326477
OTEZLA,Depression,arrhea patient treated with,0,0.4606245160102844
OTEZLA,Depression,twice daily experienced a,0,0.5678263902664185
OTEZLA,Depression,serious adverse reaction of adache.   ,1,0.48766326904296875
OTEZLA,Depression,of he,0,0.5182948112487793
OTEZLA,Depression,patient treated with OTEZLA mg twice daily experienced a,0,0.5698246955871582
OTEZLA,Depression,adache.    b Of the reported,1,0.48141372203826904
OTEZLA,Depression,adache.    b Of the reported adverse,1,0.4935852289199829
OTEZLA,Depression,adache.    b Of,1,0.47028738260269165
OTEZLA,Depression,adverse reaction of adache.    b Of the,1,0.47225552797317505
OTEZLA,suicidal behavior,patients and                 P lacebo OTEZLA mg BID,1,0.4986262023448944
OTEZLA,suicidal behavior,adache.    b Of,1,0.44628220796585083
OTEZLA,attempted suicide,12(N=493)n (%) Diarrhea a,1,0.44385796785354614
OTEZLA,attempted suicide,Day to Nn c Day to Day Nn Day to Nn Day,0,0.4554297924041748
OTEZLA,suicide,        Nausea,1,0.5751622915267944
OTEZLA,suicide,        Nausea a,1,0.5322900414466858
OTEZLA,suicide,       ,1,0.5677441954612732
OTEZLA,weight decrease,spiratory tract infection b,1,0.47504401206970215
OTEZLA,weight decrease,spiratory,1,0.4734559953212738
DYSPORT,Distant Spread of Toxin Effect,in Distant Spread of,1,0.7727252244949341
DYSPORT,Spread of Effects from Toxin,Toxin Products seeWarnings,0,0.7835907340049744
DYSPORT,Spread of Effects from Toxin,Toxin Products seeWarnings and Spread of Effects from Toxin seeWarnings and,1,0.8874399662017822
DYSPORT,Spread of Effects from Toxin,Products seeWarnings and Spread of Effects from Toxin seeWarnings and Precautions,1,0.8445701003074646
DYSPORT,Spread of Effects from Toxin,between Botulinum,0,0.6241273283958435
DYSPORT,Spread of Effects from Toxin,Effects from Toxin seeWarnings and,1,0.8403550386428833
DYSPORT,Spread of Effects from Toxin,Difficulties seeWarnings and,0,0.5750285387039185
DYSPORT,Spread of Effects from Toxin,ck of Interchangeability between Botulinum Toxin Products seeWarnings,0,0.6747397780418396
DYSPORT,Dysphagia,from Toxin seeWarnings and,0,0.5577628016471863
DYSPORT,Dysphagia,Toxin seeWarnings and Dysphagia and Breathing Difficulties seeWarnings and,1,0.7576794028282166
DYSPORT,Dysphagia,from Toxin seeWarnings and Precautions,0,0.547387957572937
DYSPORT,Dysphagia,from Toxin seeWarnings and Dysphagia and Breathing Difficulties seeWarnings,1,0.7571277618408203
DYSPORT,Dysphagia,Dysphagia and Breathing Difficulties,1,0.8525875806808472
DYSPORT,Dysphagia,Toxin seeWarnings and Precautions,0,0.5323634147644043
DYSPORT,Dysphagia,Spread of,0,0.5627319812774658
DYSPORT,Dysphagia,Dysphagia,1,1.0
DYSPORT,Breathing Difficulties,Dysphagia Breathing Difficulties,1,0.8801100850105286
DYSPORT,Breathing Difficulties,Spread of,0,0.5002505779266357
DYSPORT,Breathing Difficulties,Toxin seeWarnings and Precautions Dysphagia and,0,0.6170199513435364
DYSPORT,Breathing Difficulties,Precautions,0,0.5658935308456421
DYSPORT,Breathing Difficulties,Breathing Difficulties seeWarnings and Precautions Facial Anatomy,1,0.7907865643501282
DYSPORT,Breathing Difficulties,Dysphagia,0,0.6551220417022705
DYSPORT,Breathing Difficulties,Precautions Dysphagia Breathing,1,0.7521582841873169
DYSPORT,Breathing Difficulties,Breathing Difficulties seeWarnings and Precautions,1,0.8647527098655701
DYSPORT,Intradermal Immune Reaction,Albumin seeWarnings,0,0.5851120352745056
DYSPORT,muscular weakness,dysphagia dry mouth injection site discomfort,0,0.551801323890686
DYSPORT,muscular weakness,of patients muscular weakness,1,0.9201737642288208
DYSPORT,muscular weakness,reactions of patients muscular weakness dysphagia,1,0.7963165044784546
DYSPORT,muscular weakness,muscular weakness dysphagia dry mouth,1,0.82003253698349
DYSPORT,muscular weakness,muscular weakness dysphagia dry mouth injection site,1,0.7433222532272339
DYSPORT,muscular weakness,adverse reactions of patients muscular,1,0.7601388692855835
DYSPORT,muscular weakness,mouth injection site discomfort fatigue headache neck pain musculoskeletal,0,0.5839077234268188
DYSPORT,dysphagia,are muscular dysphagia dry,1,0.7971903085708618
DYSPORT,dysphagia,mouth injection site discomfort fatigue headache neck pain musculoskeletal,0,0.6080597639083862
DYSPORT,dysphagia,injection site discomfort fatigue headache,0,0.5159385800361633
DYSPORT,dysphagia,pain,0,0.6062299013137817
DYSPORT,dysphagia,neck pain musculoskeletal,0,0.5308891534805298
DYSPORT,dysphagia,are muscular dysphagia dry mouth,1,0.7846806049346924
DYSPORT,dysphagia,weakness,0,0.5866508483886719
DYSPORT,dysphagia,of patients are muscular weakness,0,0.5647087097167969
DYSPORT,dysphagia,dysphagia dry mouth injection site discomfort,1,0.7595506906509399
DYSPORT,dysphagia,of patients are muscular dysphagia dry mouth,1,0.7829388976097107
DYSPORT,dry mouth,are muscular,0,0.47616660594940186
DYSPORT,injection site discomfort,of patients are muscular weakness,0,0.5215004682540894
DYSPORT,injection site discomfort,pain musculoskeletal pain dysphonia injection site pain,0,0.7937771081924438
DYSPORT,injection site discomfort,pain dysphonia injection site pain and,0,0.8056603670120239
DYSPORT,fatigue,fatigue headache,1,0.8497189283370972
DYSPORT,headache,headache neck pain musculoskeletal pain,1,0.7970864772796631
DYSPORT,headache,headache neck pain musculoskeletal pain dysphonia,1,0.7356109619140625
DYSPORT,headache,are muscular,0,0.474109947681427
DYSPORT,headache,headache neck,1,0.8620351552963257
DYSPORT,neck pain,neck pain musculoskeletal pain dysphonia injection,1,0.7925422191619873
DYSPORT,neck pain,fatigue neck pain musculoskeletal pain dysphonia injection site,1,0.7737817168235779
DYSPORT,neck pain,discomfort fatigue neck pain musculoskeletal pain,1,0.827548623085022
DYSPORT,neck pain,fatigue neck pain musculoskeletal pain,1,0.8123012781143188
DYSPORT,neck pain,discomfort fatigue,0,0.5990906953811646
DYSPORT,neck pain,injection site discomfort fatigue neck pain,1,0.7822315692901611
DYSPORT,musculoskeletal pain,musculoskeletal pain,1,1.0000001192092896
DYSPORT,musculoskeletal pain,discomfort,0,0.6897512674331665
DYSPORT,musculoskeletal pain,Lines,0,0.47217410802841187
DYSPORT,musculoskeletal pain,discomfort fatigue headache neck musculoskeletal pain,1,0.7955589294433594
DYSPORT,musculoskeletal pain,musculoskeletal pain dysphonia injection site pain and,1,0.8004741072654724
DYSPORT,musculoskeletal pain,headache neck,0,0.6316543221473694
DYSPORT,musculoskeletal pain,fatigue headache neck musculoskeletal pain,1,0.7836655974388123
DYSPORT,dysphonia,headache neck pain musculoskeletal dysphonia injection site,1,0.7006024718284607
DYSPORT,dysphonia,fatigue headache neck musculoskeletal pain,1,0.49760857224464417
DYSPORT,dysphonia,dysphonia injection site pain and eye,1,0.761765718460083
DYSPORT,dysphonia,dysphonia injection site pain,1,0.7778483629226685
DYSPORT,dysphonia,Glabellar Lines The most,0,0.577173113822937
DYSPORT,injection site pain,injection site pain and eye,1,0.8944625854492188
DYSPORT,injection site pain,Glabellar Lines The most,0,0.4983224868774414
DYSPORT,injection site pain,pain injection,1,0.8687548637390137
DYSPORT,injection site pain,pain dysphonia,0,0.6018102169036865
DYSPORT,injection site pain,pain musculoskeletal pain injection site pain and eye disorders Glabellar,1,0.7980241775512695
DYSPORT,injection site pain,injection site pain and eye disorders,1,0.8695318698883057
DYSPORT,eye disorders,eye disorders Glabellar,1,0.8122587203979492
DYSPORT,nasopharyngitis,are,0,0.49877679347991943
DYSPORT,headache,frequently reported adverse reactions are nasopharyngitis,0,0.5694363117218018
DYSPORT,headache,headache injection site pain,1,0.771121621131897
DYSPORT,headache,are headache injection site pain injection site,1,0.7273719906806946
DYSPORT,headache,headache injection,1,0.8200616836547852
DYSPORT,headache,The most frequently reported adverse reactions,0,0.5690523386001587
DYSPORT,headache,nasopharyngitis,0,0.5994969606399536
DYSPORT,injection site pain,are nasopharyngitis injection site pain injection,1,0.8190115094184875
DYSPORT,injection site pain,nasopharyngitis,0,0.5083861351013184
DYSPORT,injection site pain,site pain injection site reaction,1,0.9183182716369629
DYSPORT,injection site pain,Lines The most,0,0.47904831171035767
DYSPORT,injection site reaction,nasopharyngitis headache injection site injection site,1,0.749070405960083
DYSPORT,injection site reaction,nasopharyngitis headache injection site injection site reaction upper,1,0.8084741830825806
DYSPORT,injection site reaction,site,0,0.6729443073272705
DYSPORT,injection site reaction,site injection site reaction upper respiratory tract infection,1,0.8587443232536316
DYSPORT,injection site reaction,ptosis sinusitis,0,0.48067015409469604
DYSPORT,injection site reaction,sinusitis,0,0.5250515937805176
DYSPORT,injection site reaction,headache injection site injection site reaction upper respiratory tract,1,0.8279880285263062
DYSPORT,injection site reaction,reactions are nasopharyngitis headache injection site,0,0.7776320576667786
DYSPORT,injection site reaction,injection site injection site reaction upper,1,0.9287061095237732
DYSPORT,injection site reaction,site injection site,1,0.9055963754653931
DYSPORT,upper respiratory tract infection,pain injection site upper respiratory tract infection,1,0.7885288596153259
DYSPORT,upper respiratory tract infection,site injection site,1,0.5070511102676392
DYSPORT,eyelid edema,respiratory tract,0,0.5089443325996399
DYSPORT,eyelid edema,reaction upper respiratory tract eyelid edema,1,0.8833504319190979
DYSPORT,eyelid edema,eyelid edema eyelid ptosis sinusitis,1,0.8688673973083496
DYSPORT,eyelid edema,upper respiratory tract eyelid edema eyelid ptosis sinusitis and,1,0.8308948278427124
DYSPORT,eyelid edema,ptosis sinusitis and nausea Upper Limb Spasticity The most,0,0.6126692891120911
DYSPORT,eyelid edema,tract infection,0,0.5588695406913757
DYSPORT,sinusitis,most frequently reported adverse reactions,0,0.5728098154067993
DYSPORT,sinusitis,sinusitis and nausea Upper,1,0.8321185111999512
DYSPORT,urinary tract infection,reactions urinary tract infection nasopharyngitis muscular,1,0.783470094203949
DYSPORT,urinary tract infection,sinusitis and nausea Upper,1,0.5774974822998047
DYSPORT,nasopharyngitis,nasopharyngitis muscular weakness,1,0.8214186429977417
DYSPORT,nasopharyngitis,musculoskeletal pain dizziness fall,0,0.513126015663147
DYSPORT,nasopharyngitis,nasopharyngitis muscular weakness musculoskeletal,1,0.7982053160667419
DYSPORT,nasopharyngitis,The most frequently reported adverse,0,0.5628325939178467
DYSPORT,nasopharyngitis,muscular weakness musculoskeletal pain dizziness fall and depression To report SUSP,0,0.500075101852417
DYSPORT,nasopharyngitis,nasopharyngitis muscular weakness musculoskeletal pain,1,0.7919033765792847
DYSPORT,muscular weakness,frequently reported adverse reactions are,0,0.5104990005493164
DYSPORT,muscular weakness,are urinary tract infection muscular weakness musculoskeletal pain dizziness,1,0.7153464555740356
DYSPORT,muscular weakness,muscular weakness musculoskeletal pain dizziness,1,0.8464475870132446
DYSPORT,muscular weakness,muscular weakness musculoskeletal,1,0.8766641616821289
DYSPORT,muscular weakness,SUSPECTED ADVERSE REACT,0,0.5397928357124329
DYSPORT,dizziness,SUSPECTED ADVERSE REACTIONS contact Ipsen Biopharmaceut,0,0.5030947923660278
DYSPORT,dizziness,dizziness,1,0.9999998807907104
DYSPORT,dizziness,dizziness fall,1,0.9033907055854797
DYSPORT,dizziness,musculoskeletal dizziness fall,1,0.8271734118461609
DYSPORT,dizziness,dizziness fall and,1,0.9078974723815918
DYSPORT,dizziness,dizziness fall and depression To,1,0.8774502277374268
DYSPORT,dizziness,REACTIONS contact Ipsen Biopharmaceut,0,0.48489439487457275
DYSPORT,dizziness,musculoskeletal dizziness,1,0.8358209729194641
DYSPORT,dizziness,SUSPECTED,0,0.5135259628295898
DYSPORT,fall,fall and depression To,1,0.8096052408218384
DYSPORT,fall,SUSPECTED,0,0.5089154243469238
DYSPORT,fall,and depression To report SUSPECTED ADVERSE,0,0.5157919526100159
DYSPORT,fall,muscular weakness musculoskeletal,0,0.5217230916023254
DYSPORT,fall,fall and depression To report SUSPECTED,1,0.6700007915496826
DYSPORT,muscular weakness,muscular weakness dysphagia,1,0.84349524974823
DYSPORT,muscular weakness,fall and depression To report SUSPECTED,1,0.5801362991333008
DYSPORT,muscular weakness,site discomfort fatigue headache neck pain musculoskeletal pai,0,0.5909571051597595
DYSPORT,muscular weakness,dry mouth injection site discomfort fatigue headache neck,0,0.5752352476119995
DYSPORT,muscular weakness,cervical dystonia patients muscular weakness,1,0.7929743528366089
DYSPORT,muscular weakness,of DYSPORT r in the placebo controlled clinical trials in cervical dystonia,0,0.5906089544296265
DYSPORT,muscular weakness,muscular weakness dysphagia dry mouth injection,1,0.7688963413238525
DYSPORT,dysphagia,patients were,0,0.5339266657829285
DYSPORT,dry mouth,pain musculoskeletal pain dysphonia,0,0.5216414928436279
DYSPORT,dry mouth,in cervical dystonia patients were muscular weakness,0,0.5432306528091431
DYSPORT,fatigue,site fatigue headache neck pain musculoskeletal pain,1,0.7613629102706909
DYSPORT,fatigue,in cervical dystonia patients were muscular weakness,0,0.5802416205406189
DYSPORT,fatigue,mouth injection site fatigue headache,1,0.7087451815605164
DYSPORT,fatigue,fatigue headache neck,1,0.7755588293075562
DYSPORT,fatigue,dry mouth injection site fatigue headache neck pain musculoskeletal,1,0.6763100624084473
DYSPORT,headache,eye disorders consisting,0,0.5035834312438965
DYSPORT,neck pain,pain dysphonia,0,0.636710524559021
DYSPORT,neck pain,injection site discomfort fatigue neck pain musculoskeletal,1,0.7701550126075745
DYSPORT,neck pain,discomfort fatigue neck pain,1,0.8646645545959473
DYSPORT,musculoskeletal pain,dry mouth injection site,0,0.48441094160079956
DYSPORT,musculoskeletal pain,musculoskeletal pain dysphonia injection site pain,1,0.8029924631118774
DYSPORT,dysphonia,dry mouth injection,0,0.5540338754653931
DYSPORT,dysphonia,dysphonia,1,1.0
DYSPORT,dysphonia,dysphonia injection site,1,0.8297038078308105
DYSPORT,dysphonia,pain musculoskeletal pain,0,0.4589969515800476
DYSPORT,dysphonia,dysphonia injection site pain and,1,0.7963034510612488
DYSPORT,dysphonia,disorders,0,0.6353222727775574
DYSPORT,dysphonia,eye disorders consisting of,0,0.5046123266220093
DYSPORT,injection site pain,pain musculoskeletal pain injection site pain and eye disorders consisting,1,0.8132489919662476
DYSPORT,injection site pain,eye disorders consisting of,0,0.43618783354759216
DYSPORT,injection site pain,disorders consisting of blurred vision diplopia and reduced visual,0,0.4409114718437195
DYSPORT,injection site pain,of blurred vision diplopia and reduced,0,0.4365793466567993
DYSPORT,injection site pain,and reduced visual acuity and,0,0.4473267197608948
DYSPORT,injection site pain,headache neck,0,0.560533881187439
DYSPORT,injection site pain,neck pain musculoskeletal pain injection site pain and eye disorders consisting of,1,0.7708469033241272
DYSPORT,eye disorders,pain eye disorders consisting of blurred vision,1,0.7927840352058411
DYSPORT,eye disorders,headache neck,0,0.46374598145484924
DYSPORT,eye disorders,pain eye disorders,1,0.8466310501098633
DYSPORT,eye disorders,site pain eye disorders,1,0.8013530373573303
DYSPORT,eye disorders,injection site pain eye disorders consisting,1,0.7712869644165039
DYSPORT,eye disorders,eye disorders consisting of blurred,1,0.8566704988479614
DYSPORT,eye disorders,fatigue headache neck pain musculoskeletal pain dysphonia,0,0.5272989273071289
DYSPORT,eye disorders,eye disorders consisting,1,0.944508969783783
DYSPORT,diplopia,of blurred vision,0,0.7022773027420044
DYSPORT,diplopia,and accommodation Other than,0,0.49055957794189453
DYSPORT,diplopia,diplopia and reduced visual acuity and,1,0.8768234252929688
DYSPORT,diplopia,blurred diplopia and reduced visual,1,0.8774423599243164
DYSPORT,diplopia,and eye disorders consisting of blurred,0,0.6588274240493774
DYSPORT,reduced visual acuity,of blurred vision diplopia and,0,0.7445340156555176
DYSPORT,reduced visual acuity,reduced visual acuity,1,1.0
DYSPORT,reduced visual acuity,blurred vision diplopia reduced visual acuity,1,0.8626278638839722
DYSPORT,reduced visual acuity,Other than injection site,0,0.5269812345504761
DYSPORT,reduced visual acuity,reduced visual acuity and accommodation Other than injection,1,0.8352665901184082
DYSPORT,reduced visual acuity,diplopia reduced visual acuity and accommodation,1,0.8326109647750854
DYSPORT,injection site reactions,accommodation Other injection site reactions most adverse reactions,1,0.8667743802070618
DYSPORT,injection site reactions,reduced visual acuity and accommodation Other than injection,1,0.6424299478530884
DYSPORT,injection site reactions,and accommodation Other injection,1,0.7425576448440552
DYSPORT,injection site reactions,injection site reactions most adverse reactions became,1,0.8923394680023193
DYSPORT,injection site reactions,injection,1,0.7913292646408081
DYSPORT,injection site reactions,and accommodation Other injection site reactions most adverse reactions became,1,0.8728992938995361
DYSPORT,injection site reactions,injection site reactions,1,1.0
DYSPORT,injection site reactions,became noticeable about one week after treatment and lasted several weeks,0,0.6025657653808594
DYSPORT,injection site reactions,reactions became noticeable about one,0,0.6793731451034546
DYSPORT,disturbance in attention,patient,0,0.5396245718002319
DYSPORT,disturbance in attention,One patient,0,0.5361055731773376
DYSPORT,disturbance in attention,withdrawal One,0,0.49109429121017456
DYSPORT,disturbance in attention,disorder feeling abnormal and headache and one patient experienced dysphagia Table,0,0.6273109316825867
DYSPORT,disturbance in attention,adverse reactions leading to,0,0.5271376371383667
DYSPORT,disturbance in attention,to,0,0.5179140567779541
DYSPORT,disturbance in attention,feeling abnormal and headache,0,0.6008497476577759
DYSPORT,eyelid disorder,one patient experienced dysphagia Table compares the inc,0,0.493137925863266
DYSPORT,eyelid disorder,experienced disturbance in eyelid disorder feeling abnormal and headache,1,0.799972653388977
DYSPORT,feeling abnormal,feeling abnormal and headache and one,1,0.8509701490402222
DYSPORT,feeling abnormal,disturbance in attention eyelid feeling,1,0.6800942420959473
DYSPORT,feeling abnormal,eyelid feeling abnormal and headache,1,0.7205256819725037
DYSPORT,feeling abnormal,feeling abnormal and headache,1,0.8626787066459656
DYSPORT,feeling abnormal,attention eyelid feeling,1,0.638475775718689
DYSPORT,feeling abnormal,disorder,0,0.7052721977233887
DYSPORT,feeling abnormal,experienced disturbance,0,0.6686016321182251
DYSPORT,feeling abnormal,eyelid feeling abnormal,1,0.7730762958526611
DYSPORT,feeling abnormal,headache and one patient experienced dysphagia Table compares the,0,0.5559493899345398
DYSPORT,headache,One patient,0,0.5599111914634705
DYSPORT,headache,headache and,1,0.9235891103744507
DYSPORT,headache,headache and one patient,1,0.8622860908508301
DYSPORT,headache,dysphagia Table,0,0.47967302799224854
DYSPORT,headache,feeling abnormal,0,0.5309566259384155
DYSPORT,headache,disorder feeling abnormal headache and,1,0.7838798761367798
DYSPORT,headache,most frequent adv,0,0.5149691104888916
DYSPORT,headache,disorder feeling abnormal headache and one patient,1,0.795979380607605
DYSPORT,headache,feeling abnormal headache,1,0.8476678133010864
DYSPORT,dysphagia,compares the incidence of,0,0.5292532444000244
DYSPORT,dysphagia,dysphagia Table compares the,1,0.8440287113189697
DYSPORT,dysphagia,dysphagia,1,1.0
DYSPORT,dysphagia,dysphagia Table compares the incidence of,1,0.8147303462028503
DYSPORT,dysphagia,and one patient dysphagia Table compares the incidence,1,0.7937495708465576
DYSPORT,Injection site discomfort,Injection site discomfort and injection site,1,0.9798221588134766
DYSPORT,Injection site discomfort,Injection,1,0.763262152671814
DYSPORT,Injection site discomfort,Site Injection site discomfort and injection site,1,0.9632502198219299
DYSPORT,Injection site discomfort,Injection Site Injection site discomfort and injection,1,0.9760990142822266
DYSPORT,Injection site discomfort,Injection Site Reactions,0,0.8594226241111755
DYSPORT,injection site pain,site discomfort injection site pain were common,1,0.9249674081802368
DYSPORT,injection site pain,Injection Site Reactions,0,0.8547797799110413
DYSPORT,injection site pain,Reactions Injection site discomfort injection site pain,1,0.9463133811950684
DYSPORT,injection site pain,Injection site discomfort injection site,1,0.9244213104248047
DYSPORT,injection site pain,discomfort injection site pain were common adverse reactions following,1,0.888945460319519
DYSPORT,injection site pain,following DYSPORT r administration Less Common,0,0.5961891412734985
DYSPORT,injection site pain,Injection Site,0,0.8863976001739502
DYSPORT,injection site pain,site pain were common adverse reactions following,1,0.7802285552024841
DYSPORT,injection site pain,Injection site discomfort injection site pain were common adverse,1,0.9120882749557495
DYSPORT,injection site pain,site discomfort,0,0.6950927972793579
DYSPORT,dyspnea,mainly dyspnea,1,0.9117869138717651
DYSPORT,dyspnea,site discomfort,0,0.5622367858886719
DYSPORT,dyspnea,dyspnea The median,1,0.8777941465377808
DYSPORT,dyspnea,dyspnea,1,1.0
DYSPORT,dyspnea,from last dose of DYSPORT r was approximately one week and the m,0,0.6495199203491211
DYSPORT,dyspnea,of,0,0.5646697878837585
DYSPORT,dyspnea,These consisted mainly dyspnea The median,1,0.8446760177612305
DYSPORT,dyspnea,time,0,0.518066942691803
DYSPORT,dizziness,dizziness in of DYSPORT r,1,0.8437422513961792
DYSPORT,dizziness,phase of clinical trials dizziness in of DYSPORT r treated,1,0.798186182975769
DYSPORT,muscle atrophy,muscle atrophy in of,1,0.971439003944397
DYSPORT,muscle atrophy,of the placebotreated patients L,0,0.4860319495201111
DYSPORT,muscle atrophy,muscle atrophy in of DYSPORT r,1,0.852168083190918
DYSPORT,muscle atrophy,muscle atrophy,1,0.9999997019767761
DYSPORT,muscle atrophy,r,0,0.5335037708282471
DYSPORT,muscle atrophy,patients muscle atrophy in of DYSPORT r,1,0.8378127813339233
DYSPORT,reduction in heart rate,study showed a statistically reduction in heart rate compared to baseline averaging,1,0.8723466396331787
DYSPORT,reduction in heart rate,r,0,0.521316647529602
DYSPORT,reduction in heart rate,heart rate compared to baseline,1,0.7796079516410828
DYSPORT,reduction in heart rate,showed a statistically reduction in,1,0.7111568450927734
DYSPORT,reduction in heart rate,thirty minutes after injecti,0,0.5770844221115112
DYSPORT,nasopharyngitis,nasopharyngitis headache injection site,1,0.8087217211723328
DYSPORT,nasopharyngitis,injection,0,0.5609104037284851
DYSPORT,nasopharyngitis,following injection of DYSPORT,0,0.5452356934547424
DYSPORT,nasopharyngitis,nasopharyngitis headache injection site pain,1,0.7874783277511597
DYSPORT,nasopharyngitis,of DYSPORT r nasopharyngitis headache injection site pain injection,1,0.7800532579421997
DYSPORT,nasopharyngitis,injection of DYSPORT r nasopharyngitis headache injection site,1,0.7850964069366455
DYSPORT,headache,headache injection site,1,0.7753393054008484
DYSPORT,headache,of DYSPORT,0,0.5069806575775146
DYSPORT,headache,headache injection site pain injection,1,0.7412819862365723
DYSPORT,injection site pain,headache,0,0.5937337875366211
DYSPORT,injection site pain,DYSPORT,0,0.5143797397613525
DYSPORT,injection site reaction,respiratory tract infection eyelid edema eyelid ptosis sinusitis and,0,0.5298248529434204
DYSPORT,injection site reaction,site pain,0,0.6955969333648682
DYSPORT,injection site reaction,injection,1,0.7873796224594116
DYSPORT,upper respiratory tract infection,site pain injection site,0,0.4977624714374542
DYSPORT,upper respiratory tract infection,to DYSPORT r,0,0.5341535210609436
DYSPORT,upper respiratory tract infection,tract infection,1,0.7573648691177368
DYSPORT,upper respiratory tract infection,site pain injection site upper respiratory,1,0.7276896238327026
DYSPORT,upper respiratory tract infection,eyelid edema eyelid ptosis sinusitis and nausea Table reflects exposure to,0,0.6180546879768372
DYSPORT,upper respiratory tract infection,upper respiratory tract infection eyelid edema eyelid,1,0.765221118927002
DYSPORT,upper respiratory tract infection,r were,0,0.57054603099823
DYSPORT,upper respiratory tract infection,upper respiratory tract infection eyelid edema eyelid ptosis,1,0.746597409248352
DYSPORT,eyelid edema,tract eyelid edema eyelid ptosis sinusitis,1,0.8584858775138855
DYSPORT,eyelid edema,r were,0,0.4715160131454468
DYSPORT,eyelid ptosis,eyelid ptosis sinusitis and nausea,1,0.8113034963607788
DYSPORT,sinusitis,eyelid edema eyelid sinusitis and,1,0.7866438627243042
DYSPORT,sinusitis,eyelid ptosis sinusitis and nausea,1,0.7689054608345032
DYSPORT,sinusitis,infection eyelid edema eyelid sinusitis and nausea Table reflects,1,0.7610523700714111
DYSPORT,nausea,years,0,0.4565931558609009
DYSPORT,nausea,nausea Table reflects,1,0.8022472262382507
DYSPORT,nausea,nausea,1,1.0
DYSPORT,nausea,sinusitis nausea Table,1,0.7479784488677979
DYSPORT,nausea,nausea Table,1,0.826574444770813
DYSPORT,nausea,exposure to DYSPORT r in patients to years,0,0.5634894967079163
DYSPORT,nausea,nausea Table reflects exposure to,1,0.7998193502426147
DYSPORT,nausea,DYSPORT r in patients to years of age,0,0.5268155336380005
DYSPORT,nausea,ptosis,0,0.5708803534507751
DYSPORT,Injection Site Reaction,Site Injection Site Reaction,1,0.9607086181640625
DYSPORT,Injection Site Reaction,ptosis,0,0.4738003611564636
DYSPORT,headache,headache nasopharyngitis injection,1,0.7631345987319946
DYSPORT,headache,reported of these adverse reactions were,0,0.5558573007583618
DYSPORT,headache,headache,1,0.9999998807907104
DYSPORT,headache,these adverse reactions headache nasopharyngitis injection site pain sinusitis,1,0.6914620995521545
DYSPORT,sinusitis,these adverse reactions were headache nasopharyngitis injection site,0,0.6135244965553284
DYSPORT,sinusitis,nasopharyngitis injection site sinusitis URI injection site,1,0.7350438237190247
DYSPORT,sinusitis,sinusitis,1,0.9999998807907104
DYSPORT,sinusitis,headache nasopharyngitis injection site sinusitis URI injection site,1,0.7262348532676697
DYSPORT,sinusitis,site pain,0,0.589461088180542
DYSPORT,sinusitis,nasopharyngitis,0,0.690142810344696
DYSPORT,sinusitis,sinusitis URI injection,1,0.7729952931404114
DYSPORT,URI,discomfort erythema tenderness,0,0.4968603253364563
DYSPORT,URI,URI injection site bruising and injection,1,0.7133249044418335
DYSPORT,URI,discomfort erythema,0,0.4983642101287842
DYSPORT,URI,URI injection,1,0.8386431932449341
DYSPORT,URI,bruising,0,0.5042279362678528
DYSPORT,URI,were,0,0.5575060844421387
DYSPORT,URI,nasopharyngitis injection site pain URI injection,1,0.6810280084609985
DYSPORT,URI,numbness discomfort erythema tenderness,0,0.48671019077301025
DYSPORT,URI,of these adverse reactions were headache,0,0.45414111018180847
DYSPORT,injection site bruising,injection site bruising and injection site reaction,1,0.9671189785003662
DYSPORT,injection site bruising,pain sinusitis injection site bruising,1,0.8637953996658325
DYSPORT,injection site reaction,injection site reaction,1,0.9999999403953552
DYSPORT,injection site reaction,injection site reaction numbness discomfort erythema tenderness tingling,1,0.8563376665115356
DYSPORT,injection site reaction,injection site reaction numbness discomfort erythema tenderness,1,0.8607136011123657
DYSPORT,bronchitis,pain cough contact dermatitis,0,0.6109963059425354
DYSPORT,bronchitis,of the population bronchitis influenza pharyngolaryngeal pain,1,0.721133828163147
DYSPORT,bronchitis,bronchitis influenza,1,0.8561975955963135
DYSPORT,bronchitis,of the population bronchitis influenza pharyngolaryngeal pain cough contact,1,0.7689358592033386
DYSPORT,bronchitis,the,0,0.5154281854629517
DYSPORT,bronchitis,of the population,0,0.47028854489326477
DYSPORT,bronchitis,bronchitis influenza pharyngolaryngeal,1,0.7228397130966187
DYSPORT,bronchitis,bronchitis influenza pharyngolaryngeal pain cough contact,1,0.7883980870246887
DYSPORT,bronchitis,repeated injections in of the population,0,0.49457961320877075
DYSPORT,influenza,influenza pharyngolaryngeal pain,1,0.754856288433075
DYSPORT,influenza,swelling,0,0.5923172235488892
DYSPORT,influenza,influenza pharyngolaryngeal pain cough,1,0.7554656267166138
DYSPORT,influenza,pharyngolaryngeal,0,0.5732887983322144
DYSPORT,influenza,influenza pharyngolaryngeal pain cough contact,1,0.7556509971618652
DYSPORT,influenza,site swelling and injection,0,0.5760538578033447
DYSPORT,influenza,included influenza pharyngolaryngeal pain cough contact,1,0.755544900894165
DYSPORT,pharyngolaryngeal pain,dermatitis injection site swelling and injection site,0,0.5126648545265198
DYSPORT,pharyngolaryngeal pain,bronchitis pharyngolaryngeal pain cough contact dermatitis injection site,1,0.7675100564956665
DYSPORT,pharyngolaryngeal pain,pharyngolaryngeal pain cough,1,0.919420063495636
DYSPORT,pharyngolaryngeal pain,influenza,0,0.5558747053146362
DYSPORT,pharyngolaryngeal pain,included bronchitis pharyngolaryngeal,1,0.7639023065567017
DYSPORT,pharyngolaryngeal pain,contact dermatitis injection site swelling and injection site discomfort The,0,0.5235335230827332
DYSPORT,pharyngolaryngeal pain,bronchitis pharyngolaryngeal pain cough contact,1,0.7752323150634766
DYSPORT,pharyngolaryngeal pain,injection site swelling and injection site,0,0.5417022705078125
DYSPORT,cough,included bronchitis influenza pharyngolaryngeal cough contact dermatitis injection site,1,0.7121672630310059
DYSPORT,cough,injection site swelling and injection site,0,0.563204824924469
DYSPORT,contact dermatitis,population included bronchitis influenza pharyngolaryngeal pain,0,0.48434263467788696
DYSPORT,contact dermatitis,bronchitis,0,0.577924370765686
DYSPORT,contact dermatitis,contact,1,0.6045767664909363
DYSPORT,contact dermatitis,contact dermatitis injection site swelling and injection,1,0.7955957055091858
DYSPORT,contact dermatitis,influenza pharyngolaryngeal pain contact dermatitis injection site swelling and,1,0.6854171752929688
DYSPORT,contact dermatitis,contact dermatitis injection,1,0.8539119958877563
DYSPORT,injection site swelling,incidence of,0,0.5461156368255615
DYSPORT,injection site swelling,The,0,0.5000354647636414
DYSPORT,injection site swelling,site swelling and injection site discomfort,1,0.9522019028663635
DYSPORT,injection site swelling,injection site discomfort The incidence of eyelid ptosis did not,0,0.7231398820877075
DYSPORT,injection site swelling,population included bronchitis influenza,0,0.4852455258369446
DYSPORT,eyelid ptosis,of,0,0.5230700373649597
DYSPORT,eyelid ptosis,The incidence,0,0.5982146263122559
DYSPORT,eyelid ptosis,eyelid ptosis did not increase in the,1,0.8525476455688477
DYSPORT,eyelid ptosis,dermatitis injection,0,0.4792857766151428
DYSPORT,eyelid ptosis,The incidence eyelid ptosis,1,0.9372420907020569
DYSPORT,eyelid ptosis,discomfort The incidence eyelid ptosis,1,0.9020041227340698
DYSPORT,eyelid ptosis,site discomfort The incidence eyelid,1,0.7508208155632019
DYSPORT,eyelid ptosis,h contact,0,0.49182820320129395
DYSPORT,eyelid ptosis,eyelid ptosis,1,1.000000238418579
DYSPORT,eyelid ptosis,moderate in severity and resolved over,0,0.5029594898223877
DYSPORT,eyelid ptosis,multiple retreatments at intervals three months The majority of the reports of,0,0.5234101414680481
DYSPORT,eyelid ptosis,ty studies with multiple,0,0.49510347843170166
DYSPORT,eyelid ptosis,eyelid ptosis were mild,1,0.9088658690452576
DYSPORT,eyelid ptosis,retreatments at,0,0.4935283958911896
DYSPORT,eyelid ptosis,eyelid ptosis were mild to,1,0.9143414497375488
DYSPORT,eyelid ptosis,intervals,0,0.502255916595459
DYSPORT,eyelid ptosis,eyelid,1,0.851814866065979
DYSPORT,eyelid ptosis,ty studies with multiple retreatments at intervals,0,0.5320450067520142
DYSPORT,eyelid ptosis,eyelid ptosis were mild to moderate,1,0.9071276187896729
DYSPORT,eyelid ptosis,to moderate in severity and resolved over several weeks,0,0.5083627104759216
DYSPORT,Muscular weakness,and connective tissue disorders,0,0.5800912380218506
DYSPORT,Muscular weakness,etal and connective tissue Muscular weakness Pain i,1,0.7596613168716431
DYSPORT,Muscular weakness,Muscular weakness Pain i,1,0.9003589153289795
DYSPORT,Muscular weakness,Muscular weakness Pain,1,0.9198431968688965
DYSPORT,Muscular weakness,tissue Muscular weakness,1,0.8964281678199768
DYSPORT,Injection site reactions,Injection site reactions eg,1,0.9910240769386292
DYSPORT,Injection site reactions,Reactions,0,0.7671623229980469
DYSPORT,Injection site reactions,Injection Site Injection site reactions,1,0.9593799114227295
DYSPORT,Injection site reactions,site reactions eg pain bruising haemorrhage injection,1,0.8399431705474854
DYSPORT,Injection site reactions,Injection site reactions eg pain bruising haemorrhage,1,0.8765367865562439
DYSPORT,Injection site reactions,Site Injection site,1,0.8870558738708496
DYSPORT,injection site erythema,haematoma etc have occurred,0,0.5910657048225403
DYSPORT,injection site erythema,pain bruising haemorrhage,0,0.6014687418937683
DYSPORT,injection site erythema,Injection Site Reactions Injection site,0,0.8347284197807312
DYSPORT,injection site erythema,reactions eg pain bruising injection site,1,0.7849457859992981
DYSPORT,dysphagia,treatment groups dysphagia gait disturbance hypertonia,1,0.7497678995132446
DYSPORT,dysphagia,reactions eg pain bruising injection site,1,0.49903935194015503
DYSPORT,gait disturbance,included gait,1,0.8241018056869507
DYSPORT,gait disturbance,r treatment groups included,0,0.5440804362297058
DYSPORT,gait disturbance,groups included gait,1,0.7881051301956177
DYSPORT,gait disturbance,sensation of,0,0.5710835456848145
DYSPORT,gait disturbance,Postmarketing,0,0.5067851543426514
DYSPORT,gait disturbance,incidence of less than reported,0,0.5854744911193848
DYSPORT,gait disturbance,gait disturbance,1,1.0
DYSPORT,gait disturbance,heaviness,0,0.5737310647964478
DYSPORT,hypertonia,dysphagia gait hypertonia and sensation of heaviness Postmarketing,1,0.7314295768737793
DYSPORT,hypertonia,heaviness,0,0.6225883960723877
DYSPORT,hypertonia,dysphagia gait hypertonia and sensation of,1,0.7499912977218628
DYSPORT,hypertonia,hypertonia and sensation of heaviness,1,0.876207709312439
DYSPORT,hypertonia,hypertonia,1,1.000000238418579
DYSPORT,sensation of heaviness,gait disturbance hypertonia sensation of heaviness Postmarketing Experience Because,1,0.806865930557251
DYSPORT,sensation of heaviness,hypertonia,1,0.6769800782203674
DYSPORT,sensation of heaviness,gait disturbance hypertonia sensation of heaviness Postmarketing Experience Because adverse reactions,1,0.7740386724472046
DYSPORT,sensation of heaviness,adverse reactions are,0,0.5359004735946655
DYSPORT,sensation of heaviness,included dysphagia gait disturbance hypertonia,0,0.6380130052566528
DYSPORT,sensation of heaviness,included dysphagia gait disturbance hypertonia and,0,0.636138379573822
DYSPORT,sensation of heaviness,reported voluntarily,0,0.4799405336380005
DYSPORT,sensation of heaviness,are reported voluntarily from,0,0.4726974368095398
DYSPORT,sensation of heaviness,sensation of,1,0.78452467918396
DYSPORT,vertigo,use of DYSPORT vertigo,1,0.8341289758682251
DYSPORT,vertigo,sensation of,1,0.6734871864318848
DYSPORT,vertigo,facial paresis,0,0.6226264238357544
DYSPORT,photophobia,paresis hypoesthesia,0,0.546008825302124
DYSPORT,photophobia,paresis hypoesthesia erythema and,0,0.6139986515045166
DYSPORT,photophobia,r vertigo,0,0.5629982948303223
DYSPORT,photophobia,photophobia influenzalike illness amyotrophy burning,1,0.8015091419219971
DYSPORT,photophobia,during postapproval use of DYSPORT,0,0.5595319867134094
DYSPORT,photophobia,DYSPORT r photophobia influenzalike illness,1,0.7957485318183899
DYSPORT,photophobia,photophobia,1,0.9999998807907104
DYSPORT,photophobia,DYSPORT r photophobia,1,0.8632869720458984
DYSPORT,influenza-like illness,of DYSPORT r vertigo influenza-like illness amyotrophy burning,1,0.7503005862236023
DYSPORT,influenza-like illness,photophobia,1,0.5111067295074463
DYSPORT,amyotrophy,amyotrophy burning sensation,1,0.7883149981498718
DYSPORT,amyotrophy,use of,0,0.5464097261428833
DYSPORT,amyotrophy,photophobia influenzalike,0,0.5431602001190186
DYSPORT,amyotrophy,amyotrophy burning,1,0.8394477367401123
DYSPORT,amyotrophy,amyotrophy burning sensation facial,1,0.7621250152587891
DYSPORT,amyotrophy,amyotrophy,1,1.0000001192092896
DYSPORT,amyotrophy,facial paresis hypoesthesia erythema,0,0.6036633253097534
DYSPORT,amyotrophy,paresis hypoesthesia,0,0.633430004119873
DYSPORT,burning sensation,illness burning sensation,1,0.9407509565353394
DYSPORT,burning sensation,paresis hypoesthesia,0,0.5767664313316345
DYSPORT,burning sensation,excessive granulation,0,0.5429778099060059
DYSPORT,burning sensation,excessive granulation tissue,0,0.5617887377738953
DYSPORT,burning sensation,hypoesthesia erythema and excessive,0,0.6169148683547974
DYSPORT,burning sensation,photophobia influenzalike illness burning sensation facial paresis hypoesthesia erythema,1,0.7506309747695923
DYSPORT,facial paresis,burning sensation,0,0.5442975759506226
DYSPORT,facial paresis,amyotrophy burning facial paresis hypoesthesia erythema and,1,0.7531529068946838
DYSPORT,hypoesthesia,amyotrophy burning sensation facial hypoesthesia erythema and excessive granulation tissue,1,0.7070580720901489
DYSPORT,hypoesthesia,burning sensation,0,0.5947664976119995
DYSPORT,hypoesthesia,paresis,0,0.6190659999847412
DYSPORT,hypoesthesia,tissue Immunogenicity As with all therapeutic pr,0,0.5293142795562744
DYSPORT,hypoesthesia,hypoesthesia erythema and,1,0.8581761717796326
DYSPORT,hypoesthesia,photophobia influenzalike illness amyotrophy burning sensation facial paresis,0,0.5867100358009338
DYSPORT,hypoesthesia,amyotrophy burning sensation facial hypoesthesia erythema,1,0.7357112169265747
DYSPORT,hypoesthesia,hypoesthesia,1,1.0000001192092896
DYSPORT,hypoesthesia,with,0,0.5259763598442078
DYSPORT,erythema,illness amyotrophy burning,0,0.5867315530776978
DYSPORT,erythema,tissue Immunogenicity As,0,0.5794850587844849
DYSPORT,erythema,erythema and excessive granulation tissue Immunogenicity,1,0.7646781206130981
DYSPORT,erythema,erythema,1,1.0
DYSPORT,erythema,erythema and excessive granulation,1,0.805665135383606
DYSPORT,erythema,erythema and excessive,1,0.8773808479309082
DYSPORT,erythema,and excessive granulation,0,0.5516597032546997
DYSPORT,erythema,facial paresis erythema and excessive granulation,1,0.7494235038757324
DYSPORT,erythema,erythema and excessive granulation tissue,1,0.8007808923721313
DYSPORT,excessive granulation tissue,hypoesthesia erythema excessive granulation tissue,1,0.8829682469367981
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,elsewhere in labeling Distant Spread of Toxin Effect seeBoxe,0,0.9104058146476746
DYSPORT,generalized muscle weakness,utions (5.2) ] * Dysphag,1,0.5309445858001709
DYSPORT,generalized muscle weakness,] * Dysphag ia and Breathing Difficulties seeWarnings,1,0.5242499709129333
DYSPORT,generalized muscle weakness,from Toxin seeWarnings and utions (5.2) ] *,1,0.5314860343933105
DYSPORT,generalized muscle weakness,Precautions,0,0.5057955980300903
DYSPORT,generalized muscle weakness,Toxin seeWarnings and utions,1,0.5519281029701233
DYSPORT,generalized muscle weakness,seeWarnings and utions (5.2) ] *,1,0.4771319627761841
DYSPORT,diplopia,Precautions Facial Anatomy in the,0,0.5090022087097168
DYSPORT,diplopia,seeWarnings and Precautions  and Bre athing,1,0.4933053255081177
DYSPORT,blurred vision,hing Difficult,1,0.5586405992507935
DYSPORT,blurred vision,and Precautions Dysphagia and hing Difficult ies,1,0.5345765352249146
DYSPORT,blurred vision,Precautions Dysphagia,0,0.517949640750885
DYSPORT,blurred vision,Breat,0,0.5026810169219971
DYSPORT,blurred vision,Precautions Dysphagia and hing,1,0.5112735033035278
DYSPORT,blurred vision,Treatment of Glabellar Lines,0,0.5453746318817139
DYSPORT,ptosis,s [see,1,0.5588220953941345
DYSPORT,ptosis,Precautions Dysphagia and Breathing s [see Warnings and Precautions Facial,1,0.5237014889717102
DYSPORT,ptosis,Breathing Difficultie,0,0.5135257244110107
DYSPORT,ptosis,Precautions Dysphagia and Breathing,0,0.49308764934539795
DYSPORT,ptosis,the Treatment of Glabellar Lines,0,0.6372249126434326
DYSPORT,ptosis,Precautions Dysphagia and Breathing s,1,0.5002408623695374
DYSPORT,dysphagia,Breathing Difficulties seeWa,0,0.6126925945281982
DYSPORT,dysphagia,Breathing Difficulties rnings,1,0.6383194923400879
DYSPORT,dysphonia,Precautio ns Facial Anatomy in,1,0.5084183216094971
DYSPORT,dysphonia,Precautio,1,0.4829470217227936
DYSPORT,dysarthria,"seeWarnings and  (5.3)]  
 Facial Anatomy in the Treatment",1,0.5594030022621155
DYSPORT,dysarthria,Precautio,1,0.4834936261177063
DYSPORT,dysarthria," (5.3)]  
 Facial Anatomy",1,0.5144891738891602
DYSPORT,dysarthria,"Difficulties seeWarnings and  (5.3)]  
 Facial",1,0.5702145099639893
DYSPORT,dysarthria," (5.3)]  
 Facial Anatomy in the Treatment",1,0.5142831206321716
DYSPORT,dysarthria,"Difficulties seeWarnings and  (5.3)]  
 Facial Anatomy in the Treatment",1,0.5735378861427307
DYSPORT,dysarthria,"Breathing Difficulties seeWarnings and  (5.3)]  
 Facial Anatomy in the Treatment",1,0.5738105773925781
DYSPORT,urinary incontinence,Glabellar Lines seeWarnings,0,0.5095934867858887
DYSPORT,urinary incontinence,Difficulties seeWarnings and Facial Anatomy in,1,0.4982792139053345
DYSPORT,urinary incontinence,Facial Anatomy in the,1,0.4958788752555847
DYSPORT,urinary incontinence,Breathing Difficulties seeWarnings and,0,0.5512564778327942
DYSPORT,urinary incontinence,  Facial Anatomy in ,1,0.502876341342926
DYSPORT,urinary incontinence,Anatomy in the Treatment of Glabellar,1,0.5246293544769287
DYSPORT,urinary incontinence,Glabellar Lines seeWarnings and Precautions,0,0.533726692199707
DYSPORT,urinary incontinence,Anatomy in,1,0.572901725769043
DYSPORT,breathing difficulties,Disorders seeWarnings an,0,0.629953145980835
DYSPORT,breathing difficulties,the,0,0.49745312333106995
DYSPORT,breathing difficulties,Lines seeWarnings and Precautions Preexisting Neuromuscular Disorders seeWarnings,0,0.627010703086853
DYSPORT,breathing difficulties,Facial Anatomy in the reatment,1,0.5248401761054993
DYSPORT,breathing difficulties,Anatomy in the reatment of Glabellar  Lines seeWarnings and Precautions Preexisting,1,0.5699263215065002
DYSPORT,breathing difficulties,Preexisting,0,0.5120208263397217
DYSPORT,breathing difficulties,Precautions Preexisting Neuromuscular s [seeWarnings and Pre cautions Human Albumin,1,0.5697307586669922
DYSPORT,breathing difficulties,and Precautions Preexisting Neuromuscular s [seeWarnings and Pre cautions,1,0.5981920957565308
DYSPORT,death,cauti ons Intradermal,1,0.48635876178741455
DYSPORT,death,Human Albumin,0,0.5381438732147217
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,respiratory tract infect ion eyelid,1,0.5420412421226501
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,reactions are nasopharyngitis headache injection site pain,0,0.5747737884521484
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,site upper respiratory tract,1,0.5329235792160034
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,reaction,0,0.6413280963897705
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,ion eyelid edema eyelid ptosis sinusitis and nausea Upper Limb Spasticity,0,0.5660395622253418
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,injection,0,0.5741130113601685
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,site,0,0.5336898565292358
DYSPORT,breathing difficulties,"SUSPECTED ADVERSE IONS, contact Ipsen Bi",1,0.5615841150283813
DYSPORT,breathing difficulties,"SUSPECTED ADVERSE IONS,",1,0.6106352210044861
DYSPORT,breathing difficulties,or,0,0.48563849925994873
DYSPORT,death,DA-10,1,0.5078191161155701
DYSPORT,death,REACTIONS contact Ipsen Biopharmaceuticals,0,0.4980250597000122
DYSPORT,death,DA-10 or wwwfdagovmedwatch Clinical Trials Experience,1,0.507905900478363
DYSPORT,death,Because clinical trials are c,0,0.48736572265625
DYSPORT,death,Biopharmaceuticals Inc at or,0,0.48210638761520386
DYSPORT,death,USPECTED ADVERSE REACTIONS contact Ipsen Biopharmaceuticals Inc,0,0.4936120808124542
DYSPORT,Creutzfeldt-Jakob disease,observed,0,0.5173293948173523
DYSPORT,CJD,ion s EXCERPT Cervical,1,0.5044267773628235
DYSPORT,CJD,observed,0,0.5228475332260132
DYSPORT,CJD,ion s EXCERPT,1,0.47315990924835205
DYSPORT,CJD,Dystonia Most,0,0.5202956199645996
DYSPORT,CJD,ion s EXCERPT Cervical Dystonia Most,1,0.53584223985672
DYSPORT,CJD,ion,1,0.4767247140407562
DYSPORT,CJD,Immune Reaction seeWarnings and ion s EXCERPT Cervical Dystonia Most,1,0.5566540360450745
DYSPORT,CJD,and Precaut,0,0.47121208906173706
DYSPORT,viral diseases,patients are muscular weakness dysphagia dry,0,0.5008917450904846
DYSPORT,viral diseases,Precautions,0,0.5470561385154724
DYSPORT,viral diseases," Dystonia  
 
",1,0.5166972875595093
DYSPORT,viral diseases,muscular weakness dysphagia,0,0.5162997841835022
DYSPORT,viral diseases,weakness,0,0.5366511344909668
DYSPORT,viral diseases,seeWarnings and Precautions EXCERPT,0,0.5363160967826843
DYSPORT,viral diseases,Cervical,0,0.5965630412101746
DYSPORT,viral diseases," Dystonia  
 
 Most commonly observed adverse reactions",1,0.5050607919692993
DYSPORT,CJD,st ,1,0.4878021478652954
DYSPORT,CJD,st  commonly observed adverse reactions of,1,0.5132251977920532
DYSPORT,CJD,st  commonly observed adverse,1,0.5202805995941162
DYSPORT,CJD,seeWarnings and Precautions,0,0.5054571628570557
DYSPORT,CJD,st  commonly observed,1,0.5229858160018921
DYSPORT,CJD,st  commonly,1,0.5057919025421143
DYSPORT,CJD,Precautions EXCERPT Cervical Dystonia st ,1,0.5625025033950806
DYSPORT,asthenia,conducted under,0,0.5139082670211792
DYSPORT,asthenia,at FDA or .fda.gov medwatch Clinical Trials,1,0.4980202317237854
DYSPORT,asthenia,FDA or .fda.gov medwatch Clinical Trials Experience Because,1,0.509750485420227
DYSPORT,asthenia,FDA or .fda.gov,1,0.49074476957321167
DYSPORT,asthenia,.fda.gov medwatch,1,0.48416340351104736
DYSPORT,asthenia,.fda.gov medwatch Clinical,1,0.4804670512676239
DYSPORT,asthenia,or .fda.gov medwatch,1,0.5012204647064209
DYSPORT,generalized muscle weakness,or,0,0.48541373014450073
DYSPORT,generalized muscle weakness,6.1 Clini,1,0.49044427275657654
DYSPORT,generalized muscle weakness,FDA at FDA or edwatch 6.1,1,0.44884803891181946
DYSPORT,generalized muscle weakness,under widely varying conditions,0,0.5461032390594482
DYSPORT,generalized muscle weakness,FDA or wwwfdagovm,0,0.5298342704772949
DYSPORT,generalized muscle weakness,at or FDA at FDA,0,0.4767419099807739
DYSPORT,generalized muscle weakness,Trials Experience Because clinical trials are,0,0.4781878590583801
DYSPORT,diplopia,at FDA or wwwfdagovmedwatch l Trials,1,0.4974544644355774
DYSPORT,diplopia,at FDA or wwwfdagovmedwatch l Trials Experience Because clinical trials are,1,0.48496362566947937
DYSPORT,diplopia,wwwfdagovmedwatch l Trials,1,0.5299092531204224
DYSPORT,diplopia,at FDA or wwwfdagovmedwatch l,1,0.48921382427215576
DYSPORT,diplopia,l Trials,1,0.5293405055999756
DYSPORT,diplopia,FDA or wwwfdagovmedwatch l Trials Experience Because clinical,1,0.48979830741882324
DYSPORT,diplopia,or FDA at FDA,0,0.4542897939682007
DYSPORT,diplopia,FDA at FDA,0,0.43509018421173096
DYSPORT,diplopia,at FDA or wwwfdagovmedwatch,0,0.479978084564209
DYSPORT,blurred vision,clinical trials are conducted under widely varying conditions adverse reaction rates,0,0.5541408658027649
DYSPORT,blurred vision,xperience B ecause clinical trials are conducted,1,0.5381671190261841
DYSPORT,blurred vision,"xperience

  B ecause",1,0.5524076223373413
DYSPORT,ptosis,Experience ause c linical trials are,1,0.4910486936569214
DYSPORT,ptosis,xperience B ecause clinical trials are conducted,1,0.5192077159881592
DYSPORT,ptosis,Trials Experience,0,0.46341583132743835
DYSPORT,ptosis,FDA or wwwfdagovmedwatch Clinical Trials Experience,0,0.46900492906570435
DYSPORT,ptosis,Experience ause c,1,0.47836869955062866
DYSPORT,ptosis,Clinical Trials Experience ause c,1,0.4763749837875366
DYSPORT,ptosis,Clinical Trials,0,0.48849695920944214
DYSPORT,ptosis,are conducted under widely varying conditions,0,0.47661978006362915
DYSPORT,ptosis,Experience ause,1,0.4817729890346527
DYSPORT,ptosis,ause c,1,0.47108209133148193
DYSPORT,ptosis,reaction rates observed in,0,0.48407310247421265
DYSPORT,dysphagia,Clinical Trials Experience Because nical tri als,1,0.5180085897445679
DYSPORT,dysphagia,reaction rates observed in,0,0.49964070320129395
DYSPORT,dysphagia,at FDA or wwwfdagovmedwatch Clinical Trials,0,0.4961185157299042
DYSPORT,dysphagia,nical tri als are conducted under,1,0.5160454511642456
DYSPORT,dysphonia,Experience Because clinical trial,0,0.4731808602809906
DYSPORT,dysphonia,are con ducted under,1,0.5004963278770447
DYSPORT,dysphonia,Because clinical s are con ducted,1,0.5434539318084717
DYSPORT,dysphonia,trials,0,0.48531249165534973
DYSPORT,dysarthria,clinical trials are cted under,1,0.5066092014312744
DYSPORT,dysarthria,trials are cted under,1,0.5118957757949829
DYSPORT,urinary incontinence,cannot be directly compared t,0,0.4441746473312378
DYSPORT,urinary incontinence,conducted under idely varying condit ions adverse,1,0.5609686970710754
DYSPORT,breathing difficulties,under widely varying conditions,0,0.5496288537979126
DYSPORT,breathing difficulties,reaction rate s observed in the,1,0.4907253384590149
DYSPORT,breathing difficulties,reaction rate s observed,1,0.4849470853805542
DYSPORT,breathing difficulties,compared to rates in,0,0.4693322479724884
DYSPORT,breathing difficulties,directly compared to rates the clinical,1,0.5155856013298035
DYSPORT,breathing difficulties,may not reflect the rates observed in practice Cervical Dystonia T,0,0.559983491897583
DYSPORT,death,described below reflect exposure to DYSPORT,0,0.5070319175720215
DYSPORT,death,another drug and may not reflect the rates observed,0,0.4953683614730835
DYSPORT,spread of toxin effects,the,0,0.5473284721374512
DYSPORT,spread of toxin effects,to DYSPORT,0,0.5523691177368164
DYSPORT,spread of toxin effects,"  Cervical Dystonia  

",1,0.5111469030380249
DYSPORT,spread of toxin effects,"observed in   Cervical Dystonia  

",1,0.5290254354476929
DYSPORT,spread of toxin effects,data described below reflect exposure,0,0.6207406520843506
DYSPORT,spread of toxin effects,"in   Cervical Dystonia  

 The data",1,0.5297739505767822
DYSPORT,spread of toxin effects,es in the clinical trials of another drug and may not reflect the,0,0.5441510677337646
DYSPORT,spread of toxin effects,The data described,0,0.5383919477462769
DYSPORT,spread of toxin effect,y Caucasian with a median age of years range years Most,0,0.4659982919692993
DYSPORT,spread of toxin effect,Caucasian with a median age of years range years Most,0,0.470194548368454
DYSPORT,breathing difficulties,reactions occurring in re than 5% of patients who received Units of,1,0.5541393756866455
DYSPORT,breathing difficulties,Caucasian with a median age of years range years Most,0,0.4673634171485901
DYSPORT,breathing difficulties,the placebo controlled clinical,0,0.4748134911060333
DYSPORT,breathing difficulties,received Units of DYSPORT r in the placebo,0,0.5279113054275513
DYSPORT,breathing difficulties,adverse reactions occurring in re than 5%,1,0.588935136795044
DYSPORT,breathing difficulties,reactions occurring in re than 5% of patients,1,0.5800089240074158
DYSPORT,breathing difficulties,adverse reactions occurring in re than 5% of patients who received Units,1,0.5588864684104919
DYSPORT,breathing difficulties,DYSPORT r in the placebo controlled,0,0.5390535593032837
DYSPORT,Deaths,injection site reactions most adverse reactions became noticeable,0,0.5361708998680115
DYSPORT,Deaths,commod ation Other,1,0.4797974228858948
DYSPORT,Deaths,disorders,0,0.5808999538421631
DYSPORT,Deaths,commod ation Other than,1,0.4635688066482544
DYSPORT,Deaths,visual acuity and ac,0,0.4303854703903198
DYSPORT,Deaths,and commod ation Other,1,0.4894624948501587
DYSPORT,Deaths,of blurred vision diplopia and,0,0.46232226490974426
DYSPORT,Deaths,commod ation Other than injection site,1,0.44876959919929504
DYSPORT,dysphagia,of blurred vision diplopia and reduced visual acuity,0,0.5182026624679565
DYSPORT,dysphagia,after treatment,0,0.5640585422515869
DYSPORT,dysphagia,Other than site reac tions most adverse,1,0.5456756353378296
DYSPORT,dysphagia,noticeable about one week after treatment and,0,0.5125057697296143
DYSPORT,dysphagia,about one,0,0.48276883363723755
DYSPORT,dysphagia,vision diplopia and reduced visual acuity,0,0.5092894434928894
DYSPORT,dysphagia,tions most adverse reactions became noticeable about one,0,0.5144675970077515
DYSPORT,dysphagia,acuity and accommodation Other,0,0.5416197180747986
DYSPORT,Dysphagia,reactions became noticeable about,0,0.4831584095954895
DYSPORT,Dysphagia,reactions became noticeable about week afte,1,0.47178784012794495
DYSPORT,Dysphagia,week afte r treatment and,1,0.5678515434265137
DYSPORT,Dysphagia,noticeable about week,1,0.5254761576652527
DYSPORT,Dysphagia,and lasted several weeks The rates,0,0.4973248243331909
DYSPORT,Dysphagia,week afte r treatment and lasted,1,0.5653893351554871
DYSPORT,Dysphagia,weeks The rates of adverse,0,0.5267132520675659
DYSPORT,Dysphagia,about week,1,0.4928944408893585
DYSPORT,Aspiration,than in the placebocontrolled trials During the clinical,0,0.5044772624969482
DYSPORT,Aspiration,and open-l,1,0.5756967663764954
DYSPORT,Aspiration,the combined and open-l abel experience than in,1,0.5722395181655884
DYSPORT,Aspiration,the clinical studies,0,0.5347697734832764
DYSPORT,dysphagia,experienced adverse reactions,0,0.5203881859779358
DYSPORT,dysphagia,the place bocontrolled trials During the clinical,1,0.5085214376449585
DYSPORT,dysphagia,and openlabel experience,0,0.4881894290447235
DYSPORT,dysphagia,the clinical studies two patients experienced adverse reactions,0,0.5061962604522705
DYSPORT,dysphagia,than in,0,0.5413884520530701
DYSPORT,weaken neck muscles,"id disorder, feelin",1,0.5263672471046448
DYSPORT,weaken neck muscles,than in,0,0.45479434728622437
DYSPORT,weaken neck muscles,in attention id,1,0.5028083324432373
DYSPORT,weaken neck muscles,"attention id disorder, feelin g abnormal and",1,0.46739819645881653
DYSPORT,weaken neck muscles,to withdrawal One patient,0,0.5088391304016113
DYSPORT,weaken neck muscles,"id disorder, feelin g abnormal and headache",1,0.5376901626586914
DYSPORT,weaken neck muscles,"disturbance in attention id disorder, feelin g abnormal and headache and",1,0.49619513750076294
DYSPORT,loss of breathing capacity,pares the incidence of,1,0.5468647480010986
DYSPORT,loss of breathing capacity,elid disorder feeling abnormal and headache and,0,0.5212526321411133
DYSPORT,loss of breathing capacity,from a single,0,0.4693582355976105
DYSPORT,loss of breathing capacity,patient experienced dysphagia Table pares the incidence of the most frequent,1,0.6082066893577576
DYSPORT,loss of breathing capacity,disorder feeling abnormal and headache and one patient experienced dysphagia Table,0,0.590724766254425
DYSPORT,loss of breathing capacity,Table pares the incidence of the,1,0.5349100828170776
DYSPORT,loss of breathing capacity,dysphagia Table pares the incidence of the most frequent adverse reactions from,1,0.5603160858154297
DYSPORT,breathing difficulties,placebo seeClinical Table 3: Most,1,0.4938129484653473
DYSPORT,breathing difficulties,placebo seeClinical Table,1,0.48951974511146545
DYSPORT,breathing difficulties,3: Most Com mon Adverse Reactions and,1,0.5782378315925598
DYSPORT,breathing difficulties,placebo,0,0.47101545333862305
DYSPORT,breathing difficulties,of Clinical T,0,0.5241912007331848
DYSPORT,breathing difficulties,seeClinical Studies,0,0.5519613027572632
DYSPORT,breathing difficulties,Table 3: Most Com mon Adverse,1,0.5841900110244751
DYSPORT,breathing difficulties,"compared to placebo seeClinical 



 Table 3: Most Com mon",1,0.5055481195449829
DYSPORT,respiratory failure,Reactions (>5%) and Greater than Placebo in the,1,0.5050655007362366
DYSPORT,respiratory failure,Table 3: Most Com mon Adverse,1,0.5305181741714478
DYSPORT,respiratory failure,Studies Table Most Common Reactions (>5%) and,1,0.5247365236282349
DYSPORT,respiratory failure,Studies Table Most Common Adverse,0,0.5163523554801941
DYSPORT,respiratory failure,(>5%) and Greater than Placebo in,1,0.502676248550415
DYSPORT,dysphagia,      7   Nervous system,1,0.522165060043335
DYSPORT,dysphagia,(>5%) and Greater than Placebo in,1,0.5190444588661194
DYSPORT,dysphagia,Nervous system,0,0.5705482363700867
DYSPORT,respiratory compromise,Nervous sy,1,0.599553108215332
DYSPORT,respiratory compromise,"        
   Nervous sy stem disorders",1,0.5474938750267029
DYSPORT,respiratory compromise,stem disorders H,0,0.5125725269317627
DYSPORT,respiratory compromise,mouth,0,0.5251957178115845
DYSPORT,respiratory compromise,Nervous sy stem disorders H,1,0.5514180660247803
DYSPORT,respiratory compromise,Nervous sy stem disorders,1,0.5474938750267029
DYSPORT,viral diseases,       9       Respiratory thoracic and mediastinal,1,0.5431597232818604
DYSPORT,viral diseases,       9       Respiratory thoracic and mediastinal disorders,1,0.600083589553833
DYSPORT,CJD,ders    ,1,0.5392136573791504
DYSPORT,CJD,       9       Respiratory thoracic and mediastinal disorders,1,0.4901087284088135
DYSPORT,CJD,    Eye Disorders,1,0.5482200980186462
DYSPORT,CJD,ders,0,0.5392136573791504
FIRAZYR,injection site reactions,reported adverse reactions injection site reactions,1,0.9245918393135071
FIRAZYR,injection site reactions,adverse reactions injection site reactions which occurred,1,0.9276496171951294
FIRAZYR,injection site reactions,injection site reactions which,1,0.9859357476234436
FIRAZYR,injection site reactions,site reactions which occurred in almost,1,0.7747653722763062
FIRAZYR,injection site reactions,injection site reactions which occurred in almost all,1,0.9397386908531189
FIRAZYR,injection site reactions,commonly reported adverse reactions injection site reactions which,1,0.900670051574707
FIRAZYR,injection site reactions,adverse reactions injection site reactions,1,0.9382110834121704
FIRAZYR,injection site reactions,in almost all patients in clinical trials,0,0.5572119355201721
FIRAZYR,injection site reactions,reported adverse reactions injection site reactions which occurred,1,0.9173187613487244
FIRAZYR,injection site reactions,commonly reported adverse reactions injection site reactions which occurred in,1,0.9011640548706055
FIRAZYR,transaminase increase,patients included transaminase,1,0.8522733449935913
FIRAZYR,transaminase increase,included transaminase increase,1,0.9762297868728638
FIRAZYR,rash,rash To report SUSPECTED,1,0.8175097703933716
FIRAZYR,rash,included transaminase increase,1,0.5232453346252441
FIRAZYR,rash,ADVERSE REACTIONS contact Shire Human Genetic,0,0.5992833971977234
FIRAZYR,rash,rash To,1,0.9322768449783325
FIRAZYR,rash,reactions reported rash nausea and,1,0.7878245711326599
FIRAZYR,nausea,nausea and headache,1,0.8670237064361572
FIRAZYR,nausea,reactions reported included nausea and headache,1,0.7678129076957703
FIRAZYR,nausea,controlled phase of the trials Other adverse reactions reported included,0,0.5941379070281982
FIRAZYR,headache,in the controlled phase of the trials Other adverse reactions reported included rash nausea,0,0.5360196828842163
FIRAZYR,headache,was evaluated in a separate,0,0.48929715156555176
FIRAZYR,headache,to FIRAZYR The safety of,0,0.49332237243652344
FIRAZYR,headache,was,0,0.5374895334243774
FIRAZYR,headache,headache,1,0.9999998807907104
FIRAZYR,headache,evaluated in a,0,0.4977991580963135
FIRAZYR,headache,nausea and,0,0.6214805841445923
FIRAZYR,headache,headache in,1,0.9522649049758911
FIRAZYR,hypersensitivity,hypersensitivity or anaphylactic,1,0.8657038807868958
FIRAZYR,hypersensitivity,hypersensitivity or anaphylactic reactions,1,0.8606661558151245
FIRAZYR,hypersensitivity,hypersensitivity or anaphylactic reactions were reported,1,0.8279962539672852
FIRAZYR,hypersensitivity,antiicatibant antibodies Three of these patients,0,0.6094729900360107
FIRAZYR,anaphylactic reactions,No hypersensitivity anaphylactic reactions were reported,1,0.7971355319023132
FIRAZYR,anaphylactic reactions,antiicatibant antibodies Three of these patients,0,0.6453529596328735
FIRAZYR,anaphylactic reactions,had subsequent tests which were negative No hypersensitivity or,0,0.6680100560188293
INVOKANA,Hypotension,Function see Warnings and,0,0.49996018409729004
INVOKANA,Hypotension,Hypotension see Warnings and,1,0.8647934198379517
INVOKANA,Hypotension,Hypotension,1,1.0
INVOKANA,Hypotension,Warnings and,0,0.5397686958312988
INVOKANA,Hypotension,elsewhere in the Hypotension see,1,0.8966618776321411
INVOKANA,Hypotension,the labeling,0,0.45745909214019775
INVOKANA,Impairment in Renal Function,Warnings and Impairment in Renal Function,1,0.8789450526237488
INVOKANA,Impairment in Renal Function,Hypotension see Warnings and,1,0.536283016204834
INVOKANA,Impairment in Renal Function,Impairment in Renal Function see Warnings and Precautions Hyperkalemia,1,0.8403233885765076
INVOKANA,Impairment in Renal Function,Warnings and Precautions,0,0.4991263151168823
INVOKANA,Impairment in Renal Function,Impairment in Renal Function,1,1.0
INVOKANA,Impairment in Renal Function,see Warnings and Impairment in Renal Function see Warnings and Precautions,1,0.8300945162773132
INVOKANA,Impairment in Renal Function,and Impairment,1,0.7204668521881104
INVOKANA,Hyperkalemia,Warnings and Hyperkalemia see Warnings and,1,0.8412047624588013
INVOKANA,Hyperkalemia,and Impairment,1,0.5198118686676025
INVOKANA,Hyperkalemia,see Warnings and Precautions Hypoglycemia with Concomitant Use with Insulin and In,0,0.5874261856079102
INVOKANA,Hyperkalemia,Warnings and Precautions Hypoglycemia with Concomitant Use with,0,0.5957865715026855
INVOKANA,Hyperkalemia,and Hyperkalemia see,1,0.9612273573875427
INVOKANA,Hyperkalemia,Hypoglycemia with Concomitant Use with,0,0.5854455232620239
INVOKANA,Hyperkalemia,Precautions,0,0.5267794132232666
INVOKANA,Hyperkalemia,Hyperkalemia see Warnings and,1,0.8795768022537231
INVOKANA,Hypoglycemia,Secretagogues see Warnings and,0,0.516309916973114
INVOKANA,Hypoglycemia,Use with Insulin and Insulin Secretagogues see Warnings and,0,0.6752686500549316
INVOKANA,Genital Mycotic Infections,Warnings and Genital Mycotic,1,0.857916533946991
INVOKANA,Genital Mycotic Infections,Warnings and Precautions Hypersensitivity Reactions,0,0.5448533296585083
INVOKANA,Genital Mycotic Infections,Reactions see Warnings,0,0.4874105751514435
INVOKANA,Genital Mycotic Infections,and Genital Mycotic Infections,1,0.9665748476982117
INVOKANA,Genital Mycotic Infections,see Warnings and Genital,1,0.6792964339256287
INVOKANA,Genital Mycotic Infections,Warnings,0,0.5335286855697632
INVOKANA,Genital Mycotic Infections,see Warnings and Precautions Hypersensitivity Reactions see Warnings and,0,0.5435659885406494
INVOKANA,Hypersensitivity Reactions,and Hypersensitivity Reactions see Warnings and Precautions,1,0.8313297033309937
INVOKANA,Hypersensitivity Reactions,Warnings and Genital Mycotic,1,0.5507056713104248
INVOKANA,Hypersensitivity Reactions,see Warnings and Hypersensitivity Reactions,1,0.8284075856208801
INVOKANA,Hypersensitivity Reactions,Hypersensitivity Reactions see Warnings and Precautions,1,0.8611944913864136
INVOKANA,Hypersensitivity Reactions,Fracture,0,0.43430793285369873
INVOKANA,Hypersensitivity Reactions,Hypersensitivity Reactions see,1,0.9621642827987671
INVOKANA,Hypersensitivity Reactions,Warnings and Precautions,0,0.5751934051513672
INVOKANA,Bone Fracture,Warnings and Precautions,0,0.4906262755393982
INVOKANA,Bone Fracture,LowDensity,0,0.4468894600868225
INVOKANA,Bone Fracture,Bone Fracture see Warnings and Precautions Increases,1,0.8035878539085388
INVOKANA,Bone Fracture,Bone,1,0.8272392749786377
INVOKANA,Bone Fracture,see Warnings,0,0.4732360243797302
INVOKANA,Bone Fracture,Precautions Hypersensitivity Reactions see Warnings and,0,0.4588676989078522
INVOKANA,Bone Fracture,and,0,0.5053144097328186
INVOKANA,Bone Fracture,Bone Fracture see Warnings and Precautions,1,0.8252884745597839
INVOKANA,Bone Fracture,LDLC,0,0.44080573320388794
INVOKANA,Increases in Low-Density Lipoprotein,in Low-Density Lipoprotein LDLC see Warnings,1,0.7941679954528809
INVOKANA,Increases in Low-Density Lipoprotein,Increases in Low-Density Lipoprotein LDLC see,1,0.9373127222061157
INVOKANA,Increases in Low-Density Lipoprotein,Low-Density Lipoprotein LDLC see,1,0.8098270893096924
INVOKANA,Increases in Low-Density Lipoprotein,LDLC see Warnings and Precautions Most,0,0.6147469282150269
INVOKANA,Increases in Low-Density Lipoprotein,adverse reactions,0,0.5892171263694763
INVOKANA,Increases in Low-Density Lipoprotein,Bone Fracture see,0,0.4469003677368164
INVOKANA,female genital mycotic infections,female,1,0.6694971323013306
INVOKANA,female genital mycotic infections,tract infection and increased,0,0.6250744462013245
INVOKANA,female genital mycotic infections,infection and increased urination EXCERPT To,0,0.6293390989303589
INVOKANA,female genital mycotic infections,greater,0,0.48974162340164185
INVOKANA,female genital mycotic infections,or greater female genital mycotic infections urinary tract infection and,1,0.8999085426330566
INVOKANA,female genital mycotic infections,tract infection and increased urination EXCERPT To report SUSPECTED,0,0.6108351349830627
INVOKANA,female genital mycotic infections,greater female genital mycotic infections urinary tract,1,0.8861474990844727
INVOKANA,female genital mycotic infections,mycotic infections urinary,1,0.7626222372055054
INVOKANA,female genital mycotic infections,EXCERPT To report,0,0.466164231300354
INVOKANA,urinary tract infection,urinary tract infection and increased urination,1,0.8231171369552612
INVOKANA,urinary tract infection,reactions,0,0.5369783639907837
INVOKANA,urinary tract infection,associated with INVOKANA,0,0.5231759548187256
INVOKANA,urinary tract infection,mycotic,0,0.6051746010780334
INVOKANA,urinary tract infection,urinary tract infection and increased urination EXCERPT To,1,0.8083152770996094
INVOKANA,urinary tract infection,reactions associated,0,0.5604908466339111
INVOKANA,urinary tract infection,ADVERSE REACTIONS,0,0.6117699146270752
INVOKANA,increased urination,ADVERSE REACTIONS contact Janssen,0,0.5272876620292664
INVOKANA,increased urination,infections urinary tract infection increased urination EXCERPT To report SUSPECTED ADVERSE,1,0.8501282930374146
INVOKANA,increased urination,infections urinary tract infection increased urination,1,0.87030029296875
INVOKANA,increased urination,contact Janssen,0,0.4608811140060425
INVOKANA,increased urination,greater incidence female genital mycotic infections urinary tract infection,0,0.6983641386032104
INVOKANA,increased urination,urinary tract infection increased,1,0.82002854347229
INVOKANA,Female genital mycotic infections,mgN INVOKANA Female genital,1,0.7148693799972534
INVOKANA,Female genital mycotic infections,INVOKANA Female genital mycotic infections,1,0.8981719017028809
INVOKANA,Female genital mycotic infections,PlaceboN INVOKANA mgN INVOKANA Female genital mycotic,1,0.8695418834686279
INVOKANA,Female genital mycotic infections,Urinary tract infectio,0,0.5968797206878662
INVOKANA,Female genital mycotic infections,PlaceboN INVOKANA mgN INVOKANA Female genital mycotic infections,1,0.8766448497772217
INVOKANA,Female genital mycotic infections,mgN INVOKANA,0,0.5210715532302856
INVOKANA,Female genital mycotic infections,INVOKANA mgN INVOKANA Female genital mycotic infections,1,0.8662819266319275
INVOKANA,Female genital mycotic infections,mgN INVOKANA Female genital mycotic,1,0.8738285303115845
INVOKANA,Urinary tract infections,mycotic Urinary tract infections,1,0.8645336627960205
INVOKANA,Urinary tract infections,mgN INVOKANA Female genital mycotic,1,0.5660053491592407
INVOKANA,Urinary tract infections,mycotic Urinary,1,0.7743004560470581
INVOKANA,Urinary tract infections,tract infections,1,0.8144137859344482
INVOKANA,Urinary tract infections,mycotic,0,0.5819008350372314
INVOKANA,Urinary tract infections,Urinary tract infections,1,0.9999999403953552
INVOKANA,Urinary tract infections,infections,0,0.7741572856903076
INVOKANA,Increased urination,ct Increased,1,0.6652624011039734
INVOKANA,Increased urination,Increased urination Male,1,0.9455850124359131
INVOKANA,fatigue,fatigue,1,1.0
INVOKANA,fatigue,INVOKANA,0,0.5061043500900269
INVOKANA,fatigue,fatigue with comparator with INVOKANA,1,0.7120723128318787
INVOKANA,fatigue,those listed in,0,0.5095251798629761
INVOKANA,fatigue,fatigue with,1,0.9335335493087769
INVOKANA,fatigue,reactions fatigue with comparator with INVOKANA,1,0.7182239890098572
INVOKANA,fatigue,loss,0,0.6054539680480957
INVOKANA,fatigue,with comparator with INVOKANA,0,0.4921311140060425
INVOKANA,loss of strength,loss,1,0.6887620091438293
INVOKANA,loss of strength,mg loss,1,0.6645587682723999
INVOKANA,loss of strength,INVOKANA mg loss of strength or energy,1,0.7636938095092773
INVOKANA,asthenia,asthenia,1,1.0000001192092896
INVOKANA,asthenia,mg loss,1,0.5574113130569458
INVOKANA,asthenia,asthenia with comparator with INVOKANA,1,0.697166919708252
INVOKANA,asthenia,with INVOKANA,0,0.6041275262832642
INVOKANA,asthenia,INVOKANA mg and loss of,0,0.5709093809127808
INVOKANA,asthenia,of strength or energy asthenia with comparator with INVOKANA,1,0.5902318954467773
INVOKANA,asthenia,asthenia with comparator with INVOKANA mg,1,0.6842526197433472
INVOKANA,asthenia,asthenia with comparator with,1,0.713124692440033
INVOKANA,asthenia,with comparator with INVOKANA mg and,0,0.5316588878631592
INVOKANA,hypersensitivity-related adverse reactions,occurred in,0,0.5887258052825928
INVOKANA,hypersensitivity-related adverse reactions,eight clinical hypersensitivity-related adverse reactions,1,0.9097145199775696
INVOKANA,hypersensitivity-related adverse reactions,and INVOKANA,0,0.5707255601882935
INVOKANA,erythema,erythema rash pruritus urticaria and angioedema,1,0.82969069480896
INVOKANA,erythema,erythema rash,1,0.9134859442710876
INVOKANA,erythema,hypersensitivityrelated adverse reactions erythema rash,1,0.7955101728439331
INVOKANA,erythema,hypersensitivityrelated adverse reactions erythema rash pruritus,1,0.7586290240287781
INVOKANA,erythema,and of,0,0.49802568554878235
INVOKANA,erythema,hypersensitivityrelated,0,0.6516121029853821
INVOKANA,erythema,reactions erythema rash pruritus urticaria and angioedema,1,0.7831977605819702
INVOKANA,erythema,erythema rash pruritus urticaria and,1,0.8466417193412781
INVOKANA,rash,rash pruritus urticaria and angioedema,1,0.7940617799758911
INVOKANA,pruritus,erythema pruritus,1,0.8701344132423401
INVOKANA,pruritus,rash pruritus urticaria and angioedema,1,0.795270562171936
INVOKANA,pruritus,and angioedema,0,0.6215389966964722
INVOKANA,pruritus,pruritus urticaria and angioedema occurred,1,0.8040359020233154
INVOKANA,pruritus,pruritus urticaria and angioedema occurred in,1,0.8037126660346985
INVOKANA,pruritus,pruritus urticaria,1,0.896393895149231
INVOKANA,urticaria,receiving comparator,0,0.4451832175254822
INVOKANA,urticaria,urticaria and,1,0.9184768795967102
INVOKANA,urticaria,erythema,0,0.7253542542457581
INVOKANA,urticaria,clinical trials hypersensitivityrelated adverse,0,0.6615610122680664
INVOKANA,urticaria,rash,0,0.7540437579154968
INVOKANA,angioedema,angioedema occurred in and of,1,0.9206815958023071
INVOKANA,angioedema,hypersensitivityrelated adverse reactions including erythema rash pruritus,0,0.6784642934799194
INVOKANA,angioedema,angioedema occurred in and of patients,1,0.8976718783378601
INVOKANA,hypersensitivity,adverse reactions of,0,0.6951189041137695
INVOKANA,hypersensitivity,hypersensitivity with INVOKANA which,1,0.7859705686569214
INVOKANA,hypersensitivity,hypersensitivity with INVOKANA which included patients,1,0.7584115862846375
INVOKANA,hypersensitivity,adverse reactions hypersensitivity with INVOKANA which,1,0.7551150321960449
INVOKANA,hypersensitivity,hypersensitivity,1,1.0
INVOKANA,hypersensitivity,hypersensitivity with INVOKANA which included,1,0.780880331993103
INVOKANA,urticaria,urticaria and patient with a,1,0.8803682327270508
INVOKANA,urticaria,included patients urticaria and patient,1,0.8371261358261108
INVOKANA,urticaria,with,0,0.5361298322677612
INVOKANA,urticaria,INVOKANA which included patients urticaria and patient,1,0.7556471824645996
INVOKANA,urticaria,INVOKANA which included patients urticaria and patient with,1,0.7538881301879883
INVOKANA,urticaria,urticaria occurring within hours of exposure,0,0.8286974430084229
INVOKANA,urticaria,INVOKANA which included,0,0.5100846290588379
INVOKANA,urticaria,rash and urticaria occurring within hours of exposure to,0,0.7814902067184448
INVOKANA,diffuse rash,diffuse rash,1,1.0
INVOKANA,diffuse rash,and patient with diffuse rash,1,0.9001153707504272
INVOKANA,diffuse rash,and patient with diffuse rash and,1,0.9036380052566528
INVOKANA,diffuse rash,exposure to INVOKANA,0,0.608240008354187
INVOKANA,urticaria,to INVOKANA Among these patients patients,0,0.49254584312438965
INVOKANA,urticaria,of exposure to INVOKANA Among these patients patients discontinued,0,0.5085406303405762
INVOKANA,urticaria,urticaria and patient with a diffuse rash,0,0.8329025506973267
INVOKANA,urticaria,rash urticaria,1,0.8945996761322021
INVOKANA,urticaria,urticaria occurring within,1,0.863702118396759
INVOKANA,urticaria,reinitiated,0,0.5309950113296509
INVOKANA,urticaria,to INVOKANA,0,0.5207632184028625
INVOKANA,urticaria,was reinitiated,0,0.5321139097213745
INVOKANA,Photosensitivity-related adverse reactions,patient with,0,0.5519117116928101
INVOKANA,photosensitivity reaction,photosensitivity reaction polymorphic,1,0.8948866128921509
INVOKANA,photosensitivity reaction,INVOKANA was reinitiated Photosensitivityrelated adverse reactions including,0,0.8021129369735718
INVOKANA,photosensitivity reaction,light eruption and sunburn occurred in and of patients receiving co,0,0.6722050905227661
INVOKANA,photosensitivity reaction,photosensitivity reaction polymorphic light eruption and sunburn,1,0.8397302627563477
INVOKANA,polymorphic light eruption,photosensitivity polymorphic,1,0.8158130645751953
INVOKANA,polymorphic light eruption,including photosensitivity polymorphic,1,0.8094091415405273
INVOKANA,polymorphic light eruption,light eruption and,1,0.9126566052436829
INVOKANA,polymorphic light eruption,of patients receiving comparator INVOKANA mg a,0,0.49534058570861816
INVOKANA,polymorphic light eruption,photosensitivity reaction,0,0.6771002411842346
INVOKANA,polymorphic light eruption,Photosensitivityrelated adverse reactions including photosensitivity reaction,0,0.7004390358924866
INVOKANA,sunburn,eruption sunburn occurred in and of,1,0.8817310333251953
INVOKANA,sunburn,Photosensitivityrelated adverse reactions including photosensitivity reaction,0,0.6515572667121887
INVOKANA,sunburn,comparator INVOKANA mg,0,0.4735637903213501
INVOKANA,sunburn,sunburn occurred in and of,1,0.9259470105171204
INVOKANA,sunburn,sunburn occurred in,1,0.9468101859092712
INVOKANA,sunburn,receiving,0,0.5010994672775269
INVOKANA,sunburn,sunburn occurred,1,0.954491913318634
INVOKANA,sunburn,light eruption sunburn,1,0.873708963394165
INVOKANA,osmotic diuresis,results in osmotic diuresis which,1,0.9541432857513428
INVOKANA,osmotic diuresis,sunburn occurred,1,0.46076449751853943
INVOKANA,osmotic diuresis,in osmotic,1,0.8514602184295654
INVOKANA,osmotic diuresis,intravascular volume In clinical studies,0,0.5638163089752197
INVOKANA,osmotic diuresis,in osmotic diuresis which may lead to,1,0.9110854864120483
INVOKANA,osmotic diuresis,INVOKANA results in osmotic,1,0.7560645937919617
INVOKANA,osmotic diuresis,treatment with INVOKANA,0,0.540557861328125
INVOKANA,reductions in intravascular volume,reductions in intravascular volume In,1,0.9950108528137207
INVOKANA,reductions in intravascular volume,treatment with INVOKANA,0,0.6438448429107666
INVOKANA,reductions in intravascular volume,may lead reductions in intravascular volume In clinical studies treatment,1,0.9170675277709961
INVOKANA,reductions in intravascular volume,osmotic diuresis which,0,0.5548546314239502
INVOKANA,reductions in intravascular volume,studies treatment with INVOKANA was associated with,0,0.6352537870407104
INVOKANA,reductions in intravascular volume,Adverse Reactions INVOKANA results in an,0,0.5873014330863953
INVOKANA,reductions in intravascular volume,may lead reductions in intravascular volume In clinical,1,0.9482300877571106
INVOKANA,reductions in intravascular volume,intravascular volume In clinical studies treatment with,1,0.8544789552688599
INVOKANA,hypotension,hypotension,1,1.0
INVOKANA,hypotension,volume depletionrelated adverse reactions hypotension postural dizziness orthostatic,1,0.7500856518745422
INVOKANA,postural dizziness,syncope and dehydration An increased incidence was,0,0.6617034673690796
INVOKANA,postural dizziness,postural dizziness orthostatic hypotension syncope,1,0.9078192710876465
INVOKANA,postural dizziness,reactions eg postural dizziness,1,0.8728513717651367
INVOKANA,postural dizziness,increased incidence was,0,0.4867098927497864
INVOKANA,postural dizziness,depletionrelated adverse reactions eg postural dizziness,1,0.8316932320594788
INVOKANA,postural dizziness,postural dizziness orthostatic,1,0.9384390115737915
INVOKANA,postural dizziness,eg postural dizziness,1,0.9758034944534302
INVOKANA,orthostatic hypotension,eg hypotension postural orthostatic hypotension,1,0.9138257503509521
INVOKANA,orthostatic hypotension,eg hypotension postural orthostatic hypotension syncope,1,0.8948073983192444
INVOKANA,orthostatic hypotension,orthostatic hypotension,1,0.9999999403953552
INVOKANA,orthostatic hypotension,patients on the,0,0.5580724477767944
INVOKANA,orthostatic hypotension,dizziness,0,0.6502772569656372
INVOKANA,orthostatic hypotension,postural dizziness,0,0.7284886837005615
INVOKANA,orthostatic hypotension,of,0,0.48648369312286377
INVOKANA,orthostatic hypotension,adverse reactions eg hypotension,0,0.7648166418075562
INVOKANA,dehydration,dehydration An increased,1,0.8857510685920715
INVOKANA,dehydration,dehydration An,1,0.9566048383712769
INVOKANA,dehydration,An increased incidence was observed,0,0.5449190139770508
INVOKANA,dehydration,the mg dose The,0,0.5719366669654846
INVOKANA,dehydration,dehydration,1,1.0
INVOKANA,dehydration,mg,0,0.5701233148574829
INVOKANA,volume depletion-related adverse reactions,increase,0,0.5708423256874084
INVOKANA,volume depletion-related adverse reactions,volume depletion-related adverse reactions were the use of,1,0.9821199774742126
INVOKANA,volume depletion-related adverse reactions,moderate renal impairment eGFR to less than mLmin,0,0.5894285440444946
INVOKANA,volume depletion-related adverse reactions,to less,0,0.5353322625160217
INVOKANA,volume depletion-related adverse reactions,adverse reactions,1,0.7682397961616516
INVOKANA,volume depletion-related adverse reactions,the largest increase volume,1,0.6660538911819458
INVOKANA,volume depletion-related adverse reactions,the largest,0,0.5051334500312805
INVOKANA,volume depletion-related adverse reactions,increase in,0,0.5946757197380066
INVOKANA,Volume Depletion-Related Adverse Reaction,and Table Proportion of Patients,0,0.5628195405006409
INVOKANA,Volume Depletion-Related Adverse Reaction,Trials Baseline Characteristic Comparator Gro,0,0.5325307846069336
INVOKANA,Volume Depletion-Related Adverse Reaction,Trials Baseline,0,0.5020509958267212
INVOKANA,Volume Depletion-Related Adverse Reaction,Results from Clinical Trials Baseline Characteristic Comparator Gro,0,0.5701151490211487
INVOKANA,Volume Depletion-Related Adverse Reaction,at Least Volume Depletion-Related Adverse Reaction,1,0.986369252204895
INVOKANA,Volume Depletion-Related Adverse Reaction,Patients With at Least Volume Depletion-Related Adverse Reaction,1,0.9600906372070312
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,less than 60 mL/min/1.73 m 2 Use of,1,0.8081194758415222
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,of,0,0.5061200261116028
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,eGFR less than 60 mL/min/1.73 m  2 Use of,1,0.9779622554779053
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,Use of loop,0,0.46209070086479187
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,Use of loop diuretic,0,0.5696862936019897
INVOKANA,falls,falls was and with,1,0.9242298603057861
INVOKANA,falls,falls was,1,0.9534422159194946
INVOKANA,falls,proportion of patients who falls was and with comparator,1,0.6643571853637695
INVOKANA,falls,falls was and with comparator,1,0.7502347230911255
INVOKANA,falls,who experienced,0,0.5126522183418274
INVOKANA,falls,falls was and with comparator INVOKANA,1,0.7365672588348389
INVOKANA,falls,of patients who falls was and with,1,0.746605396270752
INVOKANA,falls,falls for patients,1,0.5431627035140991
INVOKANA,increase in serum creatinine,increase,1,0.679589033126831
INVOKANA,fall in estimated GFR,renal impairment at,0,0.7136064767837524
INVOKANA,renal function decline,patients who experienced at least one,0,0.4898572564125061
INVOKANA,renal function decline,renal function decline defined as an,1,0.9479524493217468
INVOKANA,renal function decline,least one event of renal function,1,0.8143541812896729
INVOKANA,renal function decline,and lower than baseline was,0,0.5477169752120972
INVOKANA,renal function decline,of renal function,1,0.86704421043396
INVOKANA,eGFR below 80 mL/min/1.73 m 2,mL/min/1.73 m 2 and,1,0.7649908065795898
INVOKANA,eGFR below 80 mL/min/1.73 m 2,mg and with INVOK,0,0.585558295249939
INVOKANA,eGFR below 80 mL/min/1.73 m 2,as eGFR below 80 mL/min/1.73 m,1,0.9888563752174377
INVOKANA,eGFR below 80 mL/min/1.73 m 2,function decline defined as eGFR below 80 mL/min/1.73 m  2 and lower than,1,0.8928372859954834
INVOKANA,eGFR below 80 mL/min/1.73 m 2,m 2 and lower than,1,0.6416608095169067
INVOKANA,eGFR below 80 mL/min/1.73 m 2,decline defined as eGFR below 80 mL/min/1.73 m  2 and,1,0.9244891405105591
INVOKANA,eGFR below 80 mL/min/1.73 m 2,eGFR below 80 mL/min/1.73 m  2 and lower,1,0.9958192706108093
INVOKANA,eGFR below 80 mL/min/1.73 m 2,function decline defined as eGFR below 80 mL/min/1.73 m  2,1,0.9001225233078003
INVOKANA,renal function decline,renal function decline,1,1.0
INVOKANA,renal function decline,m 2 and lower than,1,0.5058309435844421
INVOKANA,renal function decline,INVOKANA mg had a renal function,1,0.7200164198875427
INVOKANA,renal function decline,renal function decline In a trial,1,0.9034576416015625
INVOKANA,renal function decline,out in patients with moderate renal impairment with a baseline eGFR of,0,0.7472412586212158
INVOKANA,renal function decline,event of renal function decline defined as an,1,0.9008080363273621
INVOKANA,renal function decline,experienced at least,0,0.4259781837463379
INVOKANA,renal function decline,function decline defined as an eGFR,1,0.7758287191390991
INVOKANA,renal function decline,of renal function decline defined as an eGFR,1,0.860048770904541
INVOKANA,renal function decline,one event of renal function decline,1,0.9283926486968994
INVOKANA,renal function decline,of renal function decline,1,0.9844121932983398
INVOKANA,eGFR 30% lower than baseline,with INVOKANA mg and with INVOKANA,0,0.512768030166626
INVOKANA,eGFR 30% lower than baseline,function decline defined as eGFR,1,0.7900103330612183
INVOKANA,eGFR 30% lower than baseline,function decline defined as eGFR 30% lower than baseline was with placebo,1,0.864458441734314
INVOKANA,eGFR 30% lower than baseline,function decline defined as eGFR 30%,1,0.8503769636154175
INVOKANA,eGFR 30% lower than baseline,lower than baseline was with placebo with INVOKANA,1,0.6260367631912231
INVOKANA,eGFR 30% lower than baseline,patients who experienced at least one event of significant renal function decline defined as,0,0.6034789681434631
INVOKANA,eGFR 30% lower than baseline,defined as eGFR,1,0.7902346253395081
INVOKANA,eGFR 30% lower than baseline,decline defined,0,0.5237523317337036
INVOKANA,renal function decline,with INVOKANA mg and with,0,0.5294109582901001
INVOKANA,renal function decline,a renal function decline In a,1,0.9650830030441284
INVOKANA,renal function decline,significant,0,0.48628687858581543
INVOKANA,renal function decline,a,0,0.4827892482280731
INVOKANA,renal function decline,INVOKANA mg had a renal function decline In,1,0.7903213500976562
INVOKANA,renal function decline,had,0,0.5023488402366638
INVOKANA,renal function decline,renal function decline In a pooled population,1,0.8860136270523071
INVOKANA,renal function decline,of significant,0,0.4812058210372925
INVOKANA,renal function decline,episodes of renal,1,0.7293219566345215
INVOKANA,renal-related adverse reactions,with,0,0.47566092014312744
INVOKANA,renal-related adverse reactions,renal-related adverse reactions eg increased blood creatinine,1,0.8987630605697632
INVOKANA,renal-related adverse reactions,glomerular,0,0.7021044492721558
INVOKANA,renal-related adverse reactions,renal-related,1,0.8482992649078369
INVOKANA,renal-related adverse reactions,filtration rate,0,0.5280617475509644
INVOKANA,renal-related adverse reactions,Use of,0,0.49534082412719727
INVOKANA,renal-related adverse reactions,incidence renal-related adverse reactions eg increased blood creatinine decreased,1,0.8825567960739136
INVOKANA,increased blood creatinine,reactions increased blood,1,0.7214689254760742
INVOKANA,decreased glomerular filtration rate,decreased glomerular filtration rate renal impairment and acute renal,1,0.8806557655334473
INVOKANA,decreased glomerular filtration rate,incidence of renalrelated adverse reactions,0,0.6705712080001831
INVOKANA,decreased glomerular filtration rate,increased blood decreased glomerular filtration rate renal impairment and acute renal,1,0.8305152654647827
INVOKANA,decreased glomerular filtration rate,of renalrelated adverse reactions,0,0.691687285900116
INVOKANA,decreased glomerular filtration rate,decreased glomerular filtration rate,1,1.0
INVOKANA,decreased glomerular filtration rate,decreased,1,0.6778883934020996
INVOKANA,decreased glomerular filtration rate,reactions eg increased blood decreased glomerular filtration rate renal impairment and,1,0.83024001121521
INVOKANA,decreased glomerular filtration rate,increased blood decreased,1,0.7068759799003601
INVOKANA,decreased glomerular filtration rate,decreased glomerular filtration rate renal,1,0.9681522250175476
INVOKANA,decreased glomerular filtration rate,renalrelated adverse reactions eg increased blood creatinine,0,0.6835814118385315
INVOKANA,renal impairment,increased blood creatinine decreased glomerular filtration rate,0,0.7455812692642212
INVOKANA,renal impairment,in patients with moderate renal impairment In the,0,0.8563257455825806
INVOKANA,acute renal failure,blood creatinine decreased glomerular filtration rate renal impairment and,0,0.6886255741119385
INVOKANA,acute renal failure,filtration rate renal impairment acute renal failure particularly,1,0.8411477208137512
INVOKANA,acute renal failure,acute renal failure,1,0.9999998807907104
INVOKANA,acute renal failure,particularly in patients with moderate renal impairment,0,0.7412608861923218
INVOKANA,acute renal failure,renal failure particularly in patients with,1,0.8277360200881958
INVOKANA,acute renal failure,renal impairment In,0,0.8100787997245789
INVOKANA,acute renal failure,eg increased blood creatinine decreased glomerular filtration,0,0.6866800785064697
INVOKANA,renal-related adverse reactions,was with,0,0.4646889567375183
INVOKANA,renal-related adverse reactions,adverse reactions was,1,0.7761197686195374
INVOKANA,renal-related adverse reactions,with placebo with,0,0.4899870753288269
INVOKANA,renal-related adverse events,with INVOKANA mg Discontinuations due,0,0.5423451662063599
INVOKANA,renal-related adverse events,mg Discontinuations due renal-related adverse events occurred in,1,0.7888633012771606
INVOKANA,female genital mycotic infections,vulvovaginal mycotic,0,0.846588134765625
INVOKANA,female genital mycotic infections,female genital mycotic infections eg vulvovaginal mycotic infection vulvovaginal,1,0.9389162659645081
INVOKANA,female genital mycotic infections,female genital mycotic infections eg vulvovaginal,1,0.9387633800506592
INVOKANA,female genital mycotic infections,female genital mycotic infections eg vulvovaginal mycotic infection,1,0.9458744525909424
INVOKANA,vulvovaginal mycotic infection,pool of four placebocontrolled clinical trials female,0,0.4954979419708252
INVOKANA,vulvovaginal mycotic infection,vulvovaginitis occurred in and of females treate,0,0.7663629651069641
INVOKANA,vulvovaginal mycotic infection,genital mycotic infections,0,0.8548480272293091
INVOKANA,vulvovaginal candidiasis,infections eg vulvovaginal mycotic vulvovaginal candidiasis and vulvovaginitis occurred,1,0.8616381287574768
INVOKANA,vulvovaginal candidiasis,genital mycotic infections,0,0.75661301612854
INVOKANA,vulvovaginitis,mycotic infection vulvovaginal,0,0.8294849395751953
INVOKANA,vulvovaginitis,vulvovaginal candidiasis vulvovaginitis,1,0.880805253982544
INVOKANA,vulvovaginitis,ale genital mycotic infections eg vulvovaginal mycotic infection vulvovaginal candidiasis,0,0.7652039527893066
INVOKANA,vulvovaginitis,vulvovaginitis occurred in and,1,0.9030746221542358
INVOKANA,genital mycotic infections,more likely to,0,0.4479326605796814
INVOKANA,genital mycotic infections,likely to genital,1,0.7171787023544312
INVOKANA,candidal balanitis,mycotic infections candidal balanitis,1,0.9414256811141968
INVOKANA,candidal balanitis,likely to genital,1,0.5867617130279541
INVOKANA,candidal balanitis,candidal balanitis balanoposthitis occurred in and,1,0.927635908126831
INVOKANA,candidal balanitis,candidal balanitis balanoposthitis occurred in and of,1,0.9224299192428589
INVOKANA,candidal balanitis,candidal balanitis balanoposthitis occurred,1,0.9283867478370667
INVOKANA,candidal balanitis,male genital mycotic infections candidal balanitis balanoposthitis occurred in,1,0.8727071285247803
INVOKANA,candidal balanitis,infections candidal balanitis balanoposthitis,1,0.9336975812911987
INVOKANA,candidal balanitis,infections candidal balanitis,1,0.9659558534622192
INVOKANA,candidal balanitis,male genital mycotic infections candidal,1,0.7721737623214722
INVOKANA,balanoposthitis,balanoposthitis occurred in,1,0.9392881393432617
INVOKANA,balanoposthitis,balanoposthitis occurred in and of males,1,0.8545163869857788
INVOKANA,balanoposthitis,balanoposthitis occurred,1,0.9388360381126404
INVOKANA,balanoposthitis,treated with,0,0.5304136276245117
INVOKANA,Male genital mycotic infections,and INVOKANA mg Male genital mycotic infections,1,0.908024787902832
INVOKANA,Male genital mycotic infections,males with,0,0.6637439727783203
INVOKANA,Male genital mycotic infections,prior history of balanitis or bal,0,0.5830812454223633
INVOKANA,phimosis,phimosis was reported in of,1,0.9052717685699463
INVOKANA,phimosis,analysis of controlled phimosis,1,0.8578025102615356
INVOKANA,phimosis,pooled analysis of controlled phimosis was reported in,1,0.8197473287582397
INVOKANA,phimosis,phimosis was reported,1,0.9091370105743408
INVOKANA,phimosis,Precautions Hypoglycemia,0,0.45772916078567505
INVOKANA,phimosis,phimosis see Warnings and Precautions Hypoglycemia,1,0.7674875259399414
INVOKANA,phimosis,In all clinical trials,0,0.476385235786438
INVOKANA,phimosis,circumcision to treat phimosis see Warnings and,1,0.8344483375549316
INVOKANA,phimosis,phimosis,1,1.000000238418579
INVOKANA,phimosis,circumcision to treat phimosis see,1,0.8665276765823364
INVOKANA,phimosis,treat,0,0.5559133887290955
INVOKANA,phimosis,phimosis see Warnings,1,0.863215446472168
INVOKANA,phimosis,all clinical trials hypo,0,0.4787895381450653
INVOKANA,hypoglycemia,hypoglycemia occurred at a higher rate,1,0.8605276346206665
INVOKANA,Hypoglycemia,Table Incidence,0,0.48734337091445923
INVOKANA,Hypoglycemia,Hypoglycemia Number,1,0.9095245599746704
INVOKANA,hypoglycemia,hypoglycemia based on either biochemically documented,1,0.8135195970535278
INVOKANA,hypoglycemic events,biochemically documented episodes or hypoglycemic events,1,0.8827534914016724
INVOKANA,hypoglycemic events,hypoglycemic,1,0.8656071424484253
INVOKANA,hypoglycemic events,hypoglycemic events in the,1,0.9790786504745483
INVOKANA,hypoglycemic events,intenttotreat,0,0.5084692239761353
INVOKANA,hypoglycemic events,documented episodes or hypoglycemic,1,0.8751134276390076
INVOKANA,hypoglycemic events,episodes or hypoglycemic,1,0.8714807033538818
INVOKANA,hypoglycemic events,the intenttotreat population in,0,0.4954608082771301
INVOKANA,bone fractures,rates of bone fractures,1,0.8550251722335815
INVOKANA,bone fractures,The,0,0.5191268920898438
INVOKANA,bone fractures,incidence rates of bone,1,0.7266514897346497
INVOKANA,bone fractures,INVOKANA mg,0,0.4926782250404358
INVOKANA,bone fractures,bone fractures were and per,1,0.9292657971382141
INVOKANA,bone fractures,of exposure to INVOKANA of weeks,0,0.5309047698974609
INVOKANA,bone fractures,bone fractures were and,1,0.9309619665145874
INVOKANA,Fractures,Fractures were,1,0.9498265981674194
INVOKANA,Fractures,bone fractures were and,1,0.8831007480621338
INVOKANA,Fractures,entyears of exposure in the comparator INVOKANA mg and INVOKANA mg,0,0.4840484857559204
INVOKANA,Fractures,observed as,0,0.5122435092926025
INVOKANA,Fractures,weeks after treatment initiation and were more likely,0,0.5336500406265259
INVOKANA,Fractures,mg groups Fractures were observed,1,0.7852857708930969
INVOKANA,Fractures,Fractures were observed as early,1,0.8237999677658081
INVOKANA,Fractures,Fractures were observed as,1,0.8977022171020508
INVOKANA,Fractures,INVOKANA mg groups,0,0.5094684362411499
INVOKANA,Fractures,respectively,0,0.5566461086273193
INVOKANA,Fractures,Fractures were observed as early as,1,0.8214539885520935
INVOKANA,Fractures,in the comparator,0,0.47303152084350586
INVOKANA,Fractures,observed as early as weeks after treatment initiation and were,0,0.5394346714019775
INVOKANA,Fractures,observed,0,0.5212625861167908
INVOKANA,Fractures,INVOKANA mg groups Fractures were observed,1,0.7625880837440491
INVOKANA,Fractures,exposure in the comparator INVOKANA,0,0.4930347502231598
INVOKANA,Fractures,Fractures,1,0.9999998807907104
INVOKANA,Fractures,initiation and were more,0,0.5018224120140076
INVOKANA,increases in serum potassium,than mLmin increases in serum potassium to greater than mEqL,1,0.8834854960441589
INVOKANA,increases in serum potassium,initiation and were more,0,0.5377298593521118
INVOKANA,increases in serum potassium,and of patients,0,0.5062531232833862
INVOKANA,increases in serum potassium,than mLmin increases,1,0.7061909437179565
INVOKANA,increases in serum potassium,than mLmin increases in serum potassium,1,0.8994663953781128
INVOKANA,increases in serum potassium,mLmin increases in,1,0.6964933276176453
INVOKANA,increases in serum potassium,to less than mLmin increases in,1,0.6851444244384766
INVOKANA,increases in serum potassium,less than mLmin increases in serum potassium to greater than mEqL,1,0.8829383254051208
INVOKANA,increases in serum potassium,increases,1,0.7128884792327881
INVOKANA,increases in serum potassium,and above baseline occurred in and of patients treat,0,0.6186659336090088
INVOKANA,increases in serum potassium,above baseline occurred in,0,0.6160471439361572
INVOKANA,increases in serum potassium,than mLmin increases in serum,1,0.7532272934913635
INVOKANA,increases in serum potassium,greater than mEqL and above baseline occurred in and,0,0.5982012748718262
INVOKANA,increases in serum potassium,to less than mLmin increases in serum potassium to greater than mEqL and,1,0.8852640986442566
INVOKANA,increases in potassium,potassium at baseline Among patients with,0,0.8095061779022217
INVOKANA,increases in potassium,INVOKANA mg In these increases in potassium were more commonly,1,0.8850368857383728
INVOKANA,increases in serum magnesium,in serum magnesium were,1,0.9012694954872131
INVOKANA,increases in serum magnesium,serum magnesium were observed,1,0.9292871356010437
INVOKANA,serum magnesium levels increased,levels increased by and,1,0.7784208059310913
INVOKANA,serum magnesium levels increased,impairment see Clinical serum magnesium,1,0.8276370763778687
INVOKANA,serum magnesium levels increased,magnesium levels increased by,1,0.9485650062561035
INVOKANA,serum magnesium levels increased,see Clinical serum,1,0.6297427415847778
INVOKANA,serum magnesium levels increased,Clinical serum,1,0.6245720386505127
INVOKANA,serum magnesium levels increased,In a trial,0,0.4926426112651825
INVOKANA,serum magnesium levels increased,impairment see Clinical serum magnesium levels increased,1,0.9273733496665955
INVOKANA,serum magnesium levels increased,renal impairment see Clinical serum magnesium,1,0.8144242763519287
INVOKANA,serum magnesium levels increased,renal impairment see Clinical serum magnesium levels increased by and with placebo INVOKANA,1,0.8385922908782959
INVOKANA,increases in serum phosphate,INVOKANA mg respectively Increases in Serum Phosphate Doserelated,0,0.8306498527526855
INVOKANA,increases in serum phosphate,increases in serum phosphate,1,0.9999999403953552
INVOKANA,increases in serum phosphate,increases in serum phosphate levels,1,0.990742564201355
INVOKANA,increases in serum phosphate,serum phosphate levels,1,0.9205986261367798
INVOKANA,increases in serum phosphate,Phosphate increases in serum,1,0.9796800017356873
INVOKANA,increases in serum phosphate,were observed with INVOKANA,0,0.5319462418556213
INVOKANA,increases in serum phosphate,Increases in Serum Phosphate increases in serum phosphate levels were,1,0.9822533130645752
INVOKANA,change in serum phosphate levels,the mean change in serum phosphate levels were and with INVOKANA,1,0.8698218464851379
INVOKANA,change in serum phosphate levels,were observed with INVOKANA,0,0.5300941467285156
INVOKANA,change in serum phosphate levels,mean change in serum phosphate levels were and,1,0.954384446144104
INVOKANA,change in serum phosphate levels,serum phosphate levels were and with INVOKANA,1,0.8347938060760498
INVOKANA,change in serum phosphate levels,controlled trials the mean change,1,0.6054350137710571
INVOKANA,change in serum phosphate levels,in serum phosphate levels,1,0.942143440246582
INVOKANA,change in serum phosphate levels,in serum phosphate levels were and with INVOKANA,1,0.8387458920478821
INVOKANA,change in serum phosphate levels,phosphate levels,1,0.8859858512878418
INVOKANA,change in serum phosphate levels,controlled trials the mean change in serum,1,0.7180531620979309
INVOKANA,increases in LDL-C,Cholesterol nonHDLC In the pool of four placebocontrolled trials doserelated,0,0.690554141998291
INVOKANA,increases in LDL-C,increases in LDL-C with,1,0.9834073781967163
INVOKANA,increases in non-HDL-C,percent changes,0,0.603061318397522
INVOKANA,hemoglobin above the upper limit of normal,and INVOKANA mg respectively had,0,0.5209897756576538
INVOKANA,hemoglobin above the upper limit of normal,INVOKANA mg respectively hemoglobin above the upper limit of normal Decreases in,1,0.838201105594635
INVOKANA,hemoglobin above the upper limit of normal,had,0,0.5485255122184753
INVOKANA,hemoglobin above the upper limit of normal,Density Bone mineral density BMD was,0,0.5745041370391846
INVOKANA,hemoglobin above the upper limit of normal,upper limit of normal Decreases in Bone Mineral Density,1,0.6637024879455566
INVOKANA,declines in BMD at the total hip,and respectively Additionall,0,0.48299992084503174
INVOKANA,declines in BMD at the total hip,mg had declines in,1,0.6606107950210571
INVOKANA,Hypotension,dverse reac tions,1,0.5172861814498901
INVOKANA,Hypotension,following important dverse reac,1,0.500844419002533
INVOKANA,Hypotension,The following,0,0.5365250706672668
INVOKANA,Hypotension,are described below and elsewhere in the labeling,0,0.47442635893821716
INVOKANA,Impairment in Renal Function,emia,1,0.45622682571411133
INVOKANA,Impairment in Renal Function,Hypoglyc,0,0.48981961607933044
INVOKANA,Impairment in Renal Function,s and Precautions Hyperkalemia see Warnings and,0,0.5732231140136719
INVOKANA,Impairment in Renal Function,Use wi th Insulin,1,0.5326763987541199
INVOKANA,Impairment in Renal Function,and Precautions emia with Concomitant,1,0.516310453414917
INVOKANA,Impairment in Renal Function,Insulin Secretagogues,0,0.4955122470855713
INVOKANA,Impairment in Renal Function,Warnings and Precautions Genital Mycotic I,0,0.4915841519832611
INVOKANA,Impairment in Renal Function,and Precautions,0,0.47426173090934753
INVOKANA,Impairment in Renal Function,Precautions Hyperkalemia see Warnings and Precautions,0,0.5623085498809814
INVOKANA,Hyperkalemia,Genital Mycotic,0,0.45029759407043457
INVOKANA,Hyperkalemia,] * H ypersensitivity Reactions,1,0.5721455216407776
INVOKANA,Hyperkalemia,and ),1,0.48283037543296814
INVOKANA,Hyperkalemia,and Precautions Genital Mycotic Infections see,0,0.45182573795318604
INVOKANA,Hyperkalemia,"and )  ]  
 *  H ypersensitivity Reactions see",1,0.5623328685760498
INVOKANA,Hyperkalemia,"Warnings and )  ]  
 *  H ypersensitivity Reactions see",1,0.5498929023742676
INVOKANA,Hyperkalemia,* H ypersensitivity Reactions see,1,0.5670678615570068
INVOKANA,Hyperkalemia,* H ypersensitivity,1,0.5732486248016357
INVOKANA,Hypoglycemia,Precautions Increases in nsity Lipopr,1,0.536695122718811
INVOKANA,Hypoglycemia,in nsity Lipopr,1,0.5399155616760254
INVOKANA,Hypoglycemia,nsity Lipopr otein LDLC see Warnings,1,0.5604488849639893
INVOKANA,Hypoglycemia,adverse,0,0.4924910366535187
INVOKANA,Hypoglycemia,Bone Fracture see,0,0.5075454711914062
INVOKANA,Hypoglycemia,nsity Lipopr otein,1,0.5251489877700806
INVOKANA,Hypoglycemia,LowDe,0,0.5561515688896179
INVOKANA,Hypoglycemia,and Precautions Increases in nsity Lipopr,1,0.5326868295669556
INVOKANA,Hypoglycemia,otein LDLC see Warnings and,0,0.563773512840271
INVOKANA,Genital mycotic infections,reactions associated with,0,0.5410842299461365
INVOKANA,Genital mycotic infections,"or greater incidence female enital mycotic infections,",1,0.8572343587875366
INVOKANA,Genital mycotic infections,enital,1,0.645728349685669
INVOKANA,Genital mycotic infections,tract,0,0.5158007144927979
INVOKANA,Genital mycotic infections,infection and increased urination EXCERPT,0,0.6709622144699097
INVOKANA,Genital mycotic infections,associated with INVOKANA,0,0.5262261033058167
INVOKANA,Genital mycotic infections,increased urination EXCERPT To,0,0.5686198472976685
INVOKANA,Hypersensitivity reactions,"infection and increased n (  6.1  ) 
      EXCERPT To report SUSPECTED ADVERSE",1,0.6063901782035828
INVOKANA,Hypersensitivity reactions,increased urination EXCERPT To,0,0.5524716973304749
INVOKANA,Hypersensitivity reactions,eater incidence female genital mycotic infections urinary tract,0,0.4988740384578705
INVOKANA,Hypersensitivity reactions,tract infection and increased n ( 6.1,1,0.581902265548706
INVOKANA,Hypersensitivity reactions,REACTIONS contact Janssen,0,0.6608929634094238
INVOKANA,Hypersensitivity reactions,) EXCERPT,1,0.4892297685146332
INVOKANA,Hypersensitivity reactions,"increased n (  6.1  ) 
      EXCERPT To",1,0.5401341319084167
INVOKANA,Hypersensitivity reactions,"increased n (  6.1  ) 
      EXCERPT To report",1,0.5427335500717163
INVOKANA,Hypersensitivity reactions,"n (  6.1  ) 
      EXCERPT To report SUSPECTED ADVERSE",1,0.5388480424880981
INVOKANA,Hypersensitivity reactions,"n (  6.1  ) 
      EXCERPT To report",1,0.4934306740760803
INVOKANA,Hypersensitivity reactions,infection and increased n (,1,0.6174322366714478
INVOKANA,Bone fracture,Pharmaceuticals at,1,0.43519073724746704
INVOKANA,Bone fracture,Pharmaceuticals Inc,0,0.42086511850357056
INVOKANA,Bone fracture,at 1-800-526- or,1,0.4384373724460602
INVOKANA,Bone fracture,Janssen Pharmaceuticals at,1,0.39007019996643066
INVOKANA,Bone fracture,or FDA at FDA or wwwfdagovmedwatch Clinical,0,0.4765314757823944
INVOKANA,Bone fracture,contact Janssen Pharmaceuticals at 1-800-526-,1,0.4151060879230499
INVOKANA,Bone fracture,Pharmaceuticals at 1-800-526- or FDA,1,0.44295406341552734
INVOKANA,Increased LDL-C,Clinical Studies ience,1,0.553234875202179
INVOKANA,Increased LDL-C,"ience

  Becaus e",1,0.5124258399009705
INVOKANA,Increased LDL-C,wwwfdagovmedwatch Clinical,0,0.5507986545562744
INVOKANA,Increased LDL-C,Studies ience,1,0.5281928181648254
INVOKANA,intravascular volume contraction,widely varying conditions adverse reaction rates,0,0.5631278157234192
INVOKANA,intravascular volume contraction,the clinical trials of a drug ca nnot be,1,0.5195454955101013
INVOKANA,intravascular volume contraction,varying conditions adverse reaction rates,0,0.5802283883094788
INVOKANA,Symptomatic hypotension,drug ot be directly compared,1,0.4989111125469208
INVOKANA,Symptomatic hypotension,varying conditions adverse reaction rates,0,0.597692608833313
INVOKANA,Symptomatic hypotension,be directly compared,1,0.44497573375701904
INVOKANA,Symptomatic hypotension,a drug ot,1,0.5298921465873718
INVOKANA,Symptomatic hypotension,trials of a drug ot be,1,0.5297738909721375
INVOKANA,Symptomatic hypotension,be directly compared to the,1,0.44157838821411133
INVOKANA,increases serum creatinine,years and were older than,0,0.4829670488834381
INVOKANA,increases serum creatinine,. Fifty percent (50%),1,0.43189042806625366
INVOKANA,decreases eGFR,age Fifty percent of the po,0,0.4555273652076721
INVOKANA,decreases eGFR,and were Black or African American At,0,0.39719539880752563
INVOKANA,decreases eGFR,pulation was m ale and were Caucasian were,1,0.47646358609199524
INVOKANA,Renal function abnormalities,of,0,0.4797589182853699
INVOKANA,Renal function abnormalities,population was male and were Caucasian were Asian and were Black,0,0.4574461579322815
INVOKANA,Renal function abnormalities,were Black or an American. At baseline the population had,1,0.4640473425388336
INVOKANA,hyperkalemia,f diabetes Baseline renal,0,0.5667257308959961
INVOKANA,hyperkalemia,INVOKANA mg or 300,1,0.5539939403533936
INVOKANA,hyperkalemia,either INVOKANA mg or 300,1,0.5606338977813721
INVOKANA,hyperkalemia," 300 mg.



 Table Adverse Reactions From Pool",1,0.5702465772628784
INVOKANA,hyperkalemia,300 mg. Table Adverse Reactions,1,0.5513975024223328
INVOKANA,hyperkalemia,Pool of Four Week PlaceboControlled Studies,0,0.5173974633216858
INVOKANA,hyperkalemia,treated,0,0.5674050450325012
INVOKANA,hyperkalemia,at least of patients treated with either INVOKANA mg or INVOKANA,0,0.5887167453765869
INVOKANA,hyperkalemia,Pool of Four Week PlaceboControlled,0,0.5379084348678589
INVOKANA,hyperkalemia,Table Adverse Reactions From,0,0.5430081486701965
INVOKANA,hypoglycemia,2%           Urinary tract infections,1,0.50249183177948
INVOKANA,hypoglycemia,2%           Urinary,1,0.5647218227386475
INVOKANA,hypoglycemia,2%          ,1,0.5149909257888794
INVOKANA,hypoglycemia,Female genital mycotic infections,0,0.46236854791641235
INVOKANA,hypoglycemia,Urinary tract,0,0.5157767534255981
INVOKANA,hypoglycemia,Female genital mycotic 2%           Urinary tract,1,0.4792768955230713
INVOKANA,genital mycotic infections,infections,0,0.7496839165687561
INVOKANA,genital mycotic infections,genital,0,0.7642450928688049
INVOKANA,bone fracture,than in patients taking placebo Pool of Placebo and,0,0.4530593156814575
INVOKANA,bone fracture,of,0,0.5032013058662415
INVOKANA,bone fracture,for canagliflozin was evaluated in a larger pool of,0,0.4483356177806854
INVOKANA,bone fracture,rolled Trials The occurrence of adverse reactions,1,0.4735451340675354
INVOKANA,bone fracture,Placebo,0,0.5180589556694031
INVOKANA,increases in LDL-C,Studies and,0,0.5617341995239258
INVOKANA,increases in LDL-C,was weeks,0,0.4877486824989319
INVOKANA,increases in LDL-C,to INVOKANA The ean,1,0.5375052094459534
XTANDI,Seizure,Seizure see,1,0.9302836656570435
XTANDI,Seizure,Seizure see Warnings and Precautions EXCERPT,1,0.79803866147995
XTANDI,fatigue,are fatigue back pain decreased appetite,1,0.696699857711792
XTANDI,fatigue,Seizure see Warnings and Precautions EXCERPT,1,0.5314631462097168
XTANDI,fatigue,appetite constipation,0,0.5849324464797974
XTANDI,fatigue,fatigue back pain,1,0.8186784386634827
XTANDI,back pain,back pain decreased appetite,1,0.7881724238395691
XTANDI,back pain,reactions are back pain,1,0.8685857653617859
XTANDI,back pain,common adverse reactions are back pain decreased appetite,1,0.7605406045913696
XTANDI,back pain,hot flush upper respiratory tract,0,0.4977492690086365
XTANDI,back pain,astheniafatigue,0,0.5351806282997131
XTANDI,back pain,are back pain decreased appetite constipation,1,0.7624512910842896
XTANDI,back pain,back pain decreased appetite constipation arthralgia,1,0.7743889093399048
XTANDI,back pain,arthralgia diarrhea hot flush,0,0.607587456703186
XTANDI,decreased appetite,back decreased appetite,1,0.895503044128418
XTANDI,decreased appetite,decreased appetite constipation arthralgia,1,0.8094272017478943
XTANDI,decreased appetite,reactions are astheniafatigue back decreased,1,0.6781874299049377
XTANDI,decreased appetite,are astheniafatigue back decreased appetite constipation arthralgia,1,0.7740951776504517
XTANDI,decreased appetite,decreased appetite constipation arthralgia diarrhea hot flush,1,0.8042874336242676
XTANDI,decreased appetite,decreased appetite constipation,1,0.8846323490142822
XTANDI,decreased appetite,common adverse reactions are astheniafatigue back,0,0.5183149576187134
XTANDI,decreased appetite,reactions are astheniafatigue back decreased appetite constipation arthralgia,1,0.7785943746566772
XTANDI,constipation,constipation arthralgia diarrhea hot flush upper,1,0.7713965177536011
XTANDI,constipation,back pain decreased,0,0.5811612010002136
XTANDI,constipation,upper respiratory tract infection peripheral,0,0.535496175289154
XTANDI,constipation,decreased constipation arthralgia diarrhea hot flush,1,0.7615241408348083
XTANDI,arthralgia,arthralgia diarrhea hot flush upper,1,0.7320547103881836
XTANDI,diarrhea,diarrhea hot flush,1,0.7987829446792603
XTANDI,diarrhea,peripheral edema dyspnea,0,0.5524828433990479
XTANDI,diarrhea,diarrhea hot,1,0.8519715070724487
XTANDI,hot flush,tract infection peripheral edema dyspnea musculoskeletal pain,0,0.534590482711792
XTANDI,hot flush,astheniafatigue back pain decreased appetite constipation arthralgia diarrhea,0,0.5773615837097168
XTANDI,hot flush,pain,0,0.5105605721473694
XTANDI,hot flush,decreased appetite constipation arthralgia hot flush,1,0.75831139087677
XTANDI,hot flush,upper respiratory tract infection peripheral edema dyspnea musculoskeletal pain weight decreas,0,0.5320241451263428
XTANDI,hot flush,pain decreased,0,0.5232037901878357
XTANDI,hot flush,back pain decreased appetite constipation arthralgia diarrhea,0,0.5542457103729248
XTANDI,hot flush,peripheral edema dyspnea,0,0.571652889251709
XTANDI,hot flush,s are,0,0.4928176999092102
XTANDI,hot flush,infection peripheral edema dyspnea musculoskeletal pain weight,0,0.5414498448371887
XTANDI,upper respiratory tract infection,diarrhea hot,0,0.5185800790786743
XTANDI,upper respiratory tract infection,decreased appetite constipation arthralgia diarrhea,0,0.498430460691452
XTANDI,upper respiratory tract infection,diarrhea hot upper respiratory tract infection peripheral edema dyspnea musculoskeletal pain,1,0.6854499578475952
XTANDI,upper respiratory tract infection,constipation arthralgia diarrhea hot upper respiratory tract infection peripheral edema dyspnea musculoskeletal pain,1,0.6648206114768982
XTANDI,upper respiratory tract infection,upper respiratory tract infection peripheral edema dyspnea musculoskeletal pain,1,0.7705380320549011
XTANDI,upper respiratory tract infection,hot upper respiratory,1,0.7654175758361816
XTANDI,upper respiratory tract infection,flush,0,0.5112285614013672
XTANDI,upper respiratory tract infection,arthralgia diarrhea hot upper,1,0.6053096652030945
XTANDI,peripheral edema,peripheral edema dyspnea,1,0.8934094905853271
XTANDI,peripheral edema,tract peripheral edema dyspnea musculoskeletal pain weight,1,0.7989016771316528
XTANDI,peripheral edema,flush upper respiratory tract peripheral,1,0.6991897821426392
XTANDI,dyspnea,dyspnea musculoskeletal pain,1,0.8306965231895447
XTANDI,dyspnea,dyspnea musculoskeletal pain weight decreased headache,1,0.7303586602210999
XTANDI,dyspnea,dyspnea musculoskeletal pain weight decreased,1,0.7426823973655701
XTANDI,dyspnea,edema,0,0.6395735740661621
XTANDI,dyspnea,infection peripheral dyspnea musculoskeletal,1,0.7761431932449341
XTANDI,dyspnea,musculoskeletal pain weight decreased headache,0,0.4960392415523529
XTANDI,musculoskeletal pain,peripheral edema musculoskeletal pain,1,0.8270979523658752
XTANDI,musculoskeletal pain,musculoskeletal pain,1,1.0000001192092896
XTANDI,musculoskeletal pain,headache hypertension and dizzinessvertigo To report SUSPECT,0,0.5193789601325989
XTANDI,musculoskeletal pain,decreased headache hypertension and dizzinessvertigo To,0,0.49609729647636414
XTANDI,musculoskeletal pain,arthralgia diarrhea hot,0,0.5919657945632935
XTANDI,weight decreased,hot flush,0,0.5344820022583008
XTANDI,weight decreased,dizzinessvertigo,0,0.5416903495788574
XTANDI,headache,headache,1,0.9999998807907104
XTANDI,hypertension,pain,0,0.6344354748725891
XTANDI,hypertension,hypertension and,1,0.920141339302063
XTANDI,hypertension,hypertension and dizzinessvertigo,1,0.815743088722229
XTANDI,hypertension,tract infection peripheral edema dyspnea musculoskeletal pain weight decreased,0,0.6071537733078003
XTANDI,hypertension,pain weight decreased hypertension and dizzinessvertigo To report,1,0.7491370439529419
XTANDI,hypertension,headache,0,0.6403322815895081
XTANDI,hypertension,REACTIONS contact Astellas Pha,0,0.5507258176803589
XTANDI,hypertension,weight decreased hypertension and dizzinessvertigo To report,1,0.7548381090164185
XTANDI,hypertension,hypertension and dizzinessvertigo To report,1,0.8024035692214966
XTANDI,dizziness,dizziness vertigo To report SUSPECTED,1,0.8600414991378784
XTANDI,dizziness,dizziness vertigo,1,0.9634802341461182
XTANDI,dizziness,weight decreased headache,0,0.678398072719574
XTANDI,dizziness,decreased headache hypertension dizziness,1,0.7747963666915894
XTANDI,dizziness,weight decreased headache hypertension and,0,0.647580623626709
XTANDI,vertigo,and vertigo To report SUSPECTED,1,0.8291082382202148
XTANDI,vertigo,weight decreased headache hypertension and,0,0.5956608057022095
XTANDI,vertigo,pain weight decreased,0,0.5442416667938232
XTANDI,vertigo,vertigo To report SUSPECTED,1,0.8463826179504395
XTANDI,vertigo,vertigo,1,1.0
XTANDI,vertigo,US Inc at,0,0.4571007490158081
XTANDI,vertigo,dyspnea musculoskeletal pain weight decreased headache,0,0.5809007883071899
XTANDI,vertigo,vertigo To,1,0.9445028305053711
XTANDI,vertigo,musculoskeletal pain weight,0,0.48416468501091003
XTANDI,vertigo,vertigo To report SUSPECTED ADVERSE,1,0.8327776789665222
XTANDI,asthenia,over placebo in the XTANDItreated patients,0,0.5594316720962524
XTANDI,asthenia,asthenia fatigue back pain decreased appetite,1,0.7493290305137634
XTANDI,asthenia,asthenia,1,1.0000001192092896
XTANDI,asthenia,asthenia fatigue back pain decreased,1,0.7126688957214355
XTANDI,asthenia,decreased appetite constipation arthralgia diarrhea hot,0,0.5810403227806091
XTANDI,fatigue,clinical trials were fatigue,1,0.7912474870681763
XTANDI,fatigue,decreased appetite constipation arthralgia diarrhea hot,0,0.6173442006111145
XTANDI,fatigue,fatigue back pain decreased appetite constipation,1,0.741407573223114
XTANDI,back pain,clinical trials were back pain,1,0.7874662280082703
XTANDI,back pain,fatigue back pain decreased appetite constipation,1,0.7523937225341797
XTANDI,back pain,back pain,1,1.0
XTANDI,back pain,were back,1,0.542091429233551
XTANDI,back pain,back pain decreased appetite constipation,1,0.7873003482818604
XTANDI,back pain,trials were back pain,1,0.8337092995643616
XTANDI,back pain,the two randomized clinical trials were astheniafatigue,0,0.5301773548126221
XTANDI,decreased appetite,were astheniafatigue back decreased,1,0.680221438407898
XTANDI,decreased appetite,infection peripheral,0,0.5147809386253357
XTANDI,decreased appetite,e XTANDItreated patients from the two randomized clinical trials were astheniafatigue back pain,0,0.5352835059165955
XTANDI,decreased appetite,flush upper respiratory tract infection peripheral,0,0.511350154876709
XTANDI,constipation,back pain decreased constipation arthralgia diarrhea hot flush upper,1,0.7059774398803711
XTANDI,constipation,flush upper respiratory tract infection peripheral,0,0.575941801071167
XTANDI,constipation,edema,0,0.6246553659439087
XTANDI,constipation,decreased,0,0.5425675511360168
XTANDI,constipation,constipation arthralgia diarrhea hot flush,1,0.7805730104446411
XTANDI,constipation,constipation arthralgia,1,0.8044120669364929
XTANDI,constipation,arthralgia diarrhea hot flush upper respiratory tract infection peripheral edema dyspnea mus,0,0.6375024318695068
XTANDI,arthralgia,arthralgia,1,1.0
XTANDI,arthralgia,trials,0,0.5585536956787109
XTANDI,arthralgia,two randomized clinical trials were,0,0.5086502432823181
XTANDI,arthralgia,diarrhea hot flush upper respiratory tract infection peripheral edema,0,0.5184425115585327
XTANDI,arthralgia,arthralgia diarrhea hot flush upper respiratory,1,0.736457347869873
XTANDI,hot flush,astheniafatigue back,0,0.6174498796463013
XTANDI,hot flush,musculoskeletal,0,0.45544102787971497
XTANDI,hot flush,arthralgia hot flush upper,1,0.792309582233429
XTANDI,hot flush,appetite constipation arthralgia hot,1,0.6856140494346619
XTANDI,hot flush,appetite constipation arthralgia hot flush upper respiratory tract,1,0.7397305965423584
XTANDI,upper respiratory tract infection,arthralgia diarrhea hot upper respiratory tract infection peripheral edema dyspnea,1,0.7129687070846558
XTANDI,upper respiratory tract infection,appetite constipation arthralgia hot,1,0.5444726943969727
XTANDI,upper respiratory tract infection,diarrhea hot upper,1,0.5914757251739502
XTANDI,upper respiratory tract infection,tract infection peripheral edema,1,0.6278336048126221
XTANDI,upper respiratory tract infection,hypertension and,0,0.5363209247589111
XTANDI,upper respiratory tract infection,diarrhea hot upper respiratory tract infection,1,0.7848210334777832
XTANDI,upper respiratory tract infection,astheniafatigue,0,0.49561411142349243
XTANDI,upper respiratory tract infection,diarrhea hot upper respiratory,1,0.7295073866844177
XTANDI,upper respiratory tract infection,constipation arthralgia diarrhea hot upper,1,0.5861584544181824
XTANDI,upper respiratory tract infection,upper respiratory tract infection peripheral edema dyspnea,1,0.797736406326294
XTANDI,peripheral edema,tract infection,0,0.5898821353912354
XTANDI,peripheral edema,respiratory tract peripheral edema dyspnea musculoskeletal pain weight,1,0.7537540793418884
XTANDI,peripheral edema,musculoskeletal pain weight decreased headache hypertension and,0,0.5992928147315979
XTANDI,peripheral edema,pain weight decreased headache,0,0.5707803964614868
XTANDI,peripheral edema,hot flush upper respiratory,0,0.55169278383255
XTANDI,peripheral edema,upper respiratory tract,0,0.5161360502243042
XTANDI,peripheral edema,peripheral,1,0.7205731272697449
XTANDI,peripheral edema,peripheral edema,1,1.0000001192092896
XTANDI,peripheral edema,diarrhea hot flush,0,0.5722904801368713
XTANDI,dyspnea,dyspnea musculoskeletal,1,0.8541164398193359
XTANDI,dyspnea,flush upper respiratory tract infection peripheral edema,0,0.5896283388137817
XTANDI,musculoskeletal pain,edema,0,0.5883647799491882
XTANDI,weight decreased,weight decreased headache hypertension and dizzinessvertigo Study,1,0.7117159962654114
XTANDI,weight decreased,weight decreased,1,1.0000001192092896
XTANDI,headache,dyspnea musculoskeletal pain weight,0,0.5507155060768127
XTANDI,headache,headache hypertension and,1,0.8235738277435303
XTANDI,headache,weight,0,0.5442156791687012
XTANDI,headache,edema dyspnea,0,0.542296290397644
XTANDI,headache,weight headache hypertension,1,0.7834932804107666
XTANDI,hypertension,Prostate Cancer,0,0.6092919111251831
XTANDI,hypertension,hypertension and dizzinessvertigo Study Metastatic CastrationResistant,1,0.75032639503479
XTANDI,hypertension,decreased hypertension and,1,0.8055347204208374
XTANDI,hypertension,Study Metastatic,0,0.5341629981994629
XTANDI,hypertension,pain weight decreased hypertension and,1,0.769668698310852
XTANDI,dizziness,dizziness vertigo Study Metastatic,1,0.8105112910270691
XTANDI,dizziness,CastrationResistant,0,0.4579532742500305
XTANDI,vertigo,headache,0,0.6732674241065979
XTANDI,vertigo,vertigo Study Metastatic CastrationResistant Prostate,1,0.7495088577270508
XTANDI,vertigo,Chemotherapy,0,0.5300279855728149
XTANDI,vertigo,vertigo Study Metastatic CastrationResistant,1,0.7640878558158875
XTANDI,vertigo,pain weight,0,0.5622704029083252
XTANDI,vertigo,headache hypertension and,0,0.5882418155670166
XTANDI,vertigo,hypertension and,0,0.5249673128128052
XTANDI,vertigo,vertigo Study Metastatic CastrationResistant Prostate Cancer,1,0.7445662021636963
XTANDI,seizure,seizure which occurred,1,0.9258930087089539
XTANDI,seizure,seizure which occurred in,1,0.9181808233261108
XTANDI,seizure,which occurred in of the XTANDItreated patients compared to,0,0.5750797390937805
XTANDI,seizure,treatment discontinuation,0,0.5238666534423828
XTANDI,seizure,leading to treatment discontinuation seizure which occurred in,1,0.7800452709197998
XTANDI,seizure,patients compared to none of the,0,0.4874069392681122
XTANDI,seizure,adverse,0,0.5677260756492615
XTANDI,seizure,seizure,1,1.0
XTANDI,Asthenic Conditions,Grade Grade General Disorders,0,0.6446421146392822
XTANDI,Asthenic Conditions,Asthenic Conditions b,1,0.9239693880081177
XTANDI,Asthenic Conditions,Grade Grade Grade General Asthenic Conditions b,1,0.8125490546226501
XTANDI,Asthenic Conditions,Asthenic,1,0.8476686477661133
XTANDI,Asthenic Conditions,Grade Grade General Asthenic Conditions b Peripher,1,0.8196941614151001
XTANDI,Asthenic Conditions,General Asthenic Conditions,1,0.9225119352340698
XTANDI,Upper Respiratory Tract Infection,e,0,0.5206472277641296
XTANDI,Upper Respiratory Tract Infection,Upper Respiratory Tract,1,0.8921869993209839
XTANDI,Upper Respiratory Tract Infection,Tract Infection e Lower,1,0.6858283281326294
XTANDI,Upper Respiratory Tract Infection,Infestations,0,0.544488787651062
XTANDI,Upper Respiratory Tract Infection,Tract Infection e Lower Respir,1,0.725051760673523
XTANDI,Lung Infection,Lower Respiratory Tract Lung Infection,1,0.8630286455154419
XTANDI,asthenia,and vertigod Includes amnesia memory,0,0.5532485246658325
XTANDI,fatigue,fatigue c Includes dizziness,1,0.7903698086738586
XTANDI,fatigue,and vertigod Includes amnesia memory,0,0.56842041015625
XTANDI,fatigue,c Includes dizziness and vertigod,0,0.6149961948394775
XTANDI,fatigue,Includes amnesia memory impairment cognitive disorder,0,0.5627351999282837
XTANDI,fatigue,fatigue c Includes dizziness and vertigod,1,0.7980598211288452
XTANDI,fatigue,amnesia memory impairment cognitive disorder a,0,0.5568591952323914
XTANDI,fatigue,CTCAE vb Includes,0,0.4840146601200104
XTANDI,fatigue,fatigue c Includes dizziness and,1,0.7973846197128296
XTANDI,fatigue,CTCAE vb Includes asthenia fatigue c Includes dizziness and,1,0.7512845993041992
XTANDI,fatigue,a CTCAE vb Includes,0,0.4969075620174408
XTANDI,dizziness,dizziness,1,0.9999998807907104
XTANDI,dizziness,a CTCAE vb Includes,0,0.4592133164405823
XTANDI,dizziness,asthenia and fatiguec dizziness and vertigod Includes amnesia,1,0.8087069392204285
XTANDI,dizziness,asthenia and fatiguec dizziness and vertigod Includes,1,0.8409208655357361
XTANDI,dizziness,memory impairment cognitive disorder,0,0.5286045074462891
XTANDI,dizziness,disturbance in attent,0,0.6003139019012451
XTANDI,dizziness,fatiguec,0,0.5845987796783447
XTANDI,dizziness,asthenia and fatiguec dizziness and vertigod Includes amnesia memory,1,0.7983918190002441
XTANDI,dizziness,CTCAE vb Includes asthenia and,0,0.5054001212120056
XTANDI,dizziness,a CTCAE vb Includes asthenia and fatiguec,0,0.5895199775695801
XTANDI,vertigo,Includes asthenia and fatiguec Includes dizziness,0,0.7420768141746521
XTANDI,vertigo,and fatiguec Includes dizziness vertigo d Includes,1,0.7941813468933105
XTANDI,vertigo,vertigo d Includes amnesia memory impairment,1,0.8026823401451111
XTANDI,vertigo,Includes dizziness vertigo d Includes amnesia memory,1,0.7895933985710144
XTANDI,vertigo,Includes amnesia,0,0.6087303757667542
XTANDI,vertigo,vb Includes asthenia and,0,0.5398560166358948
XTANDI,amnesia,disturbance in attentione Includes nasopharyngitis,0,0.6088144779205322
XTANDI,amnesia,memory impairment cognitive disorder,0,0.7054382562637329
XTANDI,amnesia,Includes,0,0.5117040872573853
XTANDI,amnesia,and vertigod Includes,0,0.591407060623169
XTANDI,amnesia,amnesia memory impairment cognitive disorder and,1,0.858857274055481
XTANDI,amnesia,amnesia memory impairment cognitive disorder,1,0.8494552969932556
XTANDI,amnesia,amnesia memory impairment cognitive,1,0.868362307548523
XTANDI,memory impairment,Includes memory impairment,1,0.9376035928726196
XTANDI,cognitive disorder,cognitive disorder and disturbance in attentione Includes,1,0.8767789006233215
XTANDI,cognitive disorder,nasopharyngitis upper respiratory tract infection,0,0.48276665806770325
XTANDI,cognitive disorder,cognitive disorder and disturbance in,1,0.9152374267578125
XTANDI,cognitive disorder,vertigod Includes,0,0.5900102853775024
XTANDI,cognitive disorder,cognitive disorder and,1,0.9626835584640503
XTANDI,cognitive disorder,attentione Includes nasopharyngitis upper respiratory,0,0.5785977840423584
XTANDI,cognitive disorder,vertigod Includes amnesia memory cognitive disorder and disturbance in attentione Includes,1,0.7642337083816528
XTANDI,cognitive disorder,amnesia memory,0,0.6050536632537842
XTANDI,disturbance in attention,impairment cognitive disorder disturbance in attention e Includes,1,0.8532576560974121
XTANDI,disturbance in attention,amnesia memory,0,0.5878545045852661
XTANDI,disturbance in attention,disturbance in attention,1,0.9999998807907104
XTANDI,disturbance in attention,Includes nasopharyngitis upper respiratory tract infection sinusitis rhinitis pharyngitis,0,0.4605361223220825
XTANDI,disturbance in attention,tract infection sinusitis rhinitis,0,0.4770103096961975
XTANDI,nasopharyngitis,disturbance in attentione nasopharyngitis upper,1,0.8040814399719238
XTANDI,nasopharyngitis,tract infection sinusitis rhinitis,0,0.6757498383522034
XTANDI,nasopharyngitis,and disturbance,0,0.48921316862106323
XTANDI,nasopharyngitis,nasopharyngitis upper respiratory tract infection sinusitis,1,0.8345705270767212
XTANDI,nasopharyngitis,nasopharyngitis upper respiratory tract infection,1,0.8865516781806946
XTANDI,nasopharyngitis,amnesia,0,0.5221275687217712
XTANDI,nasopharyngitis,and,0,0.5093783140182495
XTANDI,nasopharyngitis,nasopharyngitis upper respiratory tract,1,0.8730809092521667
XTANDI,nasopharyngitis,respiratory tract infection sinusitis rhinitis pharyngitis and,0,0.6903560161590576
XTANDI,nasopharyngitis,nasopharyngitis upper respiratory,1,0.8476746082305908
XTANDI,nasopharyngitis,disorder and disturbance in attentione,0,0.47412097454071045
XTANDI,upper respiratory tract infection,disturbance in attentione Includes,0,0.4818735122680664
XTANDI,sinusitis,pneumonia lower respiratory,0,0.5442865490913391
XTANDI,sinusitis,and disturbance in attentione Includes nasopharyngitis upper respiratory,0,0.6175259351730347
XTANDI,sinusitis,respiratory tract sinusitis rhinitis pharyngitis and,1,0.815791130065918
XTANDI,sinusitis,upper respiratory tract sinusitis rhinitis pharyngitis and laryngitisf Includes,1,0.7773603200912476
XTANDI,sinusitis,sinusitis rhinitis pharyngitis and laryngitisf,1,0.801547110080719
XTANDI,sinusitis,tract sinusitis rhinitis pharyngitis,1,0.80710369348526
XTANDI,sinusitis,sinusitis rhinitis pharyngitis and laryngitisf Includes,1,0.7988446354866028
XTANDI,sinusitis,Includes,0,0.49543753266334534
XTANDI,sinusitis,tract sinusitis rhinitis pharyngitis and laryngitisf Includes,1,0.7823192477226257
XTANDI,rhinitis,respiratory tract infection,0,0.6994647979736328
XTANDI,rhinitis,rhinitis,1,1.0
XTANDI,rhinitis,rhinitis pharyngitis and laryngitisf Includes,1,0.8011825084686279
XTANDI,rhinitis,upper,0,0.5124251842498779
XTANDI,rhinitis,rhinitis pharyngitis and,1,0.8446959853172302
XTANDI,pharyngitis,pharyngitis and,1,0.9423642754554749
XTANDI,pharyngitis,pharyngitis and laryngitisf Includes pneumonia lower,1,0.827337384223938
XTANDI,pharyngitis,nasopharyngitis upper respiratory tract infection,0,0.6956471800804138
XTANDI,laryngitis,upper respiratory tract infection sinusitis rhinitis pharyngitis,0,0.6408870220184326
XTANDI,laryngitis,laryngitis f Includes pneumonia lower respiratory,1,0.8173754215240479
XTANDI,laryngitis,laryngitis,1,0.9999999403953552
XTANDI,laryngitis,tract infection sinusitis rhinitis pharyngitis and,0,0.642779529094696
XTANDI,laryngitis,laryngitis f Includes,1,0.8905497789382935
XTANDI,pneumonia,pneumonia lower respiratory tract infection,1,0.8374005556106567
XTANDI,pneumonia,lung infection Study Chemo,0,0.65279221534729
XTANDI,pneumonia,pharyngitis and laryngitisf pneumonia lower respiratory,1,0.7133029103279114
XTANDI,pneumonia,sinusitis rhinitis pharyngitis,0,0.5662586688995361
XTANDI,pneumonia,upper,0,0.4979442059993744
XTANDI,pneumonia,upper respiratory tract infection sinusitis rhinitis pharyngitis and,0,0.6174448728561401
XTANDI,pneumonia,pneumonia lower respiratory tract,1,0.8163923621177673
XTANDI,pneumonia,pneumonia,1,0.9999997615814209
XTANDI,pneumonia,rhinitis pharyngitis and laryngitisf pneumonia lower respiratory tract infection,1,0.6826460957527161
XTANDI,bronchitis,lung infection Study Chemotherapynaive Metastatic CastrationResistant,0,0.6567510366439819
XTANDI,lung infection,lung infection Study Chemotherapynaive,1,0.7948845624923706
XTANDI,lung infection,lung infection Study Chemotherapynaive Metastatic CastrationResistant,0,0.748130202293396
XTANDI,fatigue,treatment discontinuation fatigue asthenia which occurred in,1,0.7642661929130554
XTANDI,fatigue,lung infection Study Chemotherapynaive Metastatic CastrationResistant,0,0.5442476272583008
XTANDI,fatigue,leading to treatment discontinuation fatigue asthenia which occurred,1,0.7783321142196655
XTANDI,fatigue,fatigue asthenia which,1,0.8681544661521912
XTANDI,fatigue,reaction leading to,0,0.47228187322616577
XTANDI,fatigue,in of patients on each treatment arm,0,0.5281733870506287
XTANDI,fatigue,fatigue,1,1.0
XTANDI,fatigue,fatigue asthenia which occurred in,1,0.8462737202644348
XTANDI,asthenia,asthenia which,1,0.9824248552322388
XTANDI,asthenia,to treatment discontinuation was asthenia which,1,0.7752269506454468
XTANDI,asthenia,common,0,0.5315069556236267
XTANDI,asthenia,in of patients on each treatment arm Table includes adverse reactions repor,0,0.5413068532943726
XTANDI,Asthenic Conditions,Asthenic Conditions b Periphe,1,0.8920028209686279
XTANDI,Restless Legs Syndrome,Restless Legs Syndrome,1,1.0
XTANDI,Restless Legs Syndrome,Asthenic Conditions b Periphe,1,0.5781611204147339
XTANDI,Restless Legs Syndrome,Disordersd,0,0.6383192539215088
XTANDI,Restless Legs Syndrome,nt Restless Legs Syndrome,1,0.9167653322219849
XTANDI,Restless Legs Syndrome,Restless Legs Syndrome Respiratory,1,0.8869277238845825
XTANDI,Restless Legs Syndrome,nt,0,0.5248793363571167
XTANDI,Upper Respiratory Tract Infection,Upper Respiratory Tract Infection f Lower,1,0.8631235957145691
XTANDI,Upper Respiratory Tract Infection,Infections And Upper Respiratory Tract     Infection f,1,0.8573712706565857
XTANDI,Upper Respiratory Tract Infection,Tract Infection f,1,0.6832970380783081
XTANDI,Upper Respiratory Tract Infection,And Upper Respiratory Tract,1,0.860675573348999
XTANDI,Upper Respiratory Tract Infection,Infections And Infestations,0,0.6294549107551575
XTANDI,Upper Respiratory Tract Infection,Upper,1,0.6525404453277588
XTANDI,Upper Respiratory Tract Infection,f Lower Respir,0,0.6204566359519958
XTANDI,Upper Respiratory Tract Infection,f,0,0.48158514499664307
XTANDI,Upper Respiratory Tract Infection,And Upper Respiratory,1,0.8441941142082214
XTANDI,asthenia,fatiguec Includes dizziness and vertigod Includes,0,0.5930136442184448
XTANDI,asthenia,a CTCAE vb asthenia and fatiguec Includes dizziness,1,0.6971414685249329
XTANDI,fatigue,c,0,0.5628566145896912
XTANDI,fatigue,fatigue c Includes,1,0.8143606781959534
XTANDI,fatigue,CTCAE vb Includes asthenia fatigue c Includes dizziness,1,0.744020938873291
XTANDI,fatigue,vertigod Includes amnesia memory impairment cognitive disorder,0,0.5751456022262573
XTANDI,dizziness,dizziness and vertigod,1,0.9279495477676392
XTANDI,vertigo,Includes dizziness,0,0.8252270221710205
XTANDI,vertigo,disorder and disturbance,0,0.5704582333564758
XTANDI,vertigo,a CTCAE vb Includes asthenia,0,0.5719133019447327
XTANDI,vertigo,dizziness vertigo d,1,0.8582881689071655
XTANDI,vertigo,vertigo d,1,0.8884595632553101
XTANDI,vertigo,Includes dizziness vertigo d Includes amnesia,1,0.8037196397781372
XTANDI,vertigo,fatiguec,0,0.5839503407478333
XTANDI,vertigo,Includes,0,0.522483229637146
XTANDI,amnesia,dizziness and vertigod amnesia,1,0.7848926782608032
XTANDI,amnesia,amnesia memory,1,0.9558194875717163
XTANDI,amnesia,and fatiguec Includes dizziness and vertigod,0,0.5841158628463745
XTANDI,amnesia,vb Includes asthenia and fatiguec Includes dizziness,0,0.5897548198699951
XTANDI,amnesia,Includes dizziness and vertigod amnesia memory,1,0.8058948516845703
XTANDI,amnesia,attentione,0,0.5874435305595398
XTANDI,amnesia,and vertigod amnesia memory,1,0.8590245246887207
XTANDI,memory impairment,vertigod Includes memory impairment,1,0.8100512623786926
XTANDI,memory impairment,attentione,0,0.6105781197547913
XTANDI,memory impairment,in attentione Includes dyspnea exertional,0,0.6248953938484192
XTANDI,memory impairment,vertigod Includes memory impairment cognitive disorder,1,0.7908763885498047
XTANDI,memory impairment,and vertigod Includes memory impairment,1,0.8143575191497803
XTANDI,memory impairment,memory impairment cognitive disorder and disturbance,1,0.8992813229560852
XTANDI,memory impairment,memory impairment cognitive disorder and,1,0.9186028242111206
XTANDI,memory impairment,and disturbance in attentione Includes,0,0.6778072118759155
XTANDI,exertional dyspnea,exertional dyspnea and dyspnea at,1,0.9563760757446289
XTANDI,exertional dyspnea,disturbance in attentione Includes exertional dyspnea,1,0.8344226479530334
XTANDI,exertional dyspnea,memory impairment cognitive disorder and disturbance in,0,0.5045957565307617
XTANDI,exertional dyspnea,in attentione Includes exertional,1,0.7148303985595703
XTANDI,dyspnea at rest,upper respiratory tract infection sinusitis,0,0.5061385631561279
XTANDI,dyspnea at rest,exertional dyspnea dyspnea at rest f Includes nasopharyngitis upper,1,0.8293590545654297
XTANDI,nasopharyngitis,at restf nasopharyngitis upper,1,0.8645613193511963
XTANDI,nasopharyngitis,upper respiratory tract infection sinusitis,0,0.6910189986228943
XTANDI,nasopharyngitis,restf nasopharyngitis upper,1,0.8262125253677368
XTANDI,upper respiratory tract infection,at restf Includes upper respiratory tract infection sinusitis rhinitis pharyngitis,1,0.832430362701416
XTANDI,upper respiratory tract infection,upper respiratory tract infection sinusitis,0,0.8891236186027527
XTANDI,upper respiratory tract infection,tract infection,1,0.7573648691177368
XTANDI,rhinitis,respiratory tract infection bronchitis,0,0.6357297897338867
XTANDI,rhinitis,pneumonia lower respiratory,0,0.5305157899856567
XTANDI,rhinitis,rhinitis pharyngitis and laryngitisg,1,0.8047464489936829
XTANDI,rhinitis,rhinitis pharyngitis and laryngitisg Includes,1,0.80191570520401
XTANDI,pharyngitis,infection,0,0.665919303894043
XTANDI,pharyngitis,pharyngitis and laryngitisg Includes pneumonia,1,0.848240315914154
XTANDI,laryngitis,laryngitis g Includes pneumonia,1,0.8280124068260193
XTANDI,laryngitis,respiratory tract infection bronchitis and,0,0.6110592484474182
XTANDI,laryngitis,laryngitis g Includes pneumonia lower,1,0.8128554821014404
XTANDI,laryngitis,upper respiratory tract,0,0.636939287185669
XTANDI,laryngitis,laryngitis g Includes,1,0.8883500099182129
XTANDI,pneumonia,and,0,0.5450941324234009
XTANDI,pneumonia,pneumonia lower respiratory tract infection bronchitis,1,0.7578518986701965
XTANDI,lower respiratory tract infection,and laryngitisg Includes lower respiratory tract infection,1,0.8838374614715576
XTANDI,lower respiratory tract infection,laryngitisg,0,0.6177393198013306
XTANDI,lower respiratory tract infection,the two randomized,0,0.44036665558815
XTANDI,lower respiratory tract infection,lung infection Laboratory,0,0.6555262804031372
XTANDI,lower respiratory tract infection,tract infection bronchitis and lung,1,0.7611160278320312
XTANDI,lower respiratory tract infection,sinusitis rhinitis pharyngitis,0,0.6565160155296326
XTANDI,lower respiratory tract infection,Laboratory Abnormalities In the two randomized,0,0.5063334703445435
XTANDI,bronchitis,bronchitis and,1,0.9222213625907898
XTANDI,bronchitis,bronchitis and lung infection Laboratory Abnormalities,1,0.7691354751586914
XTANDI,bronchitis,lower respiratory tract,0,0.6226651668548584
XTANDI,bronchitis,bronchitis and lung infection Laboratory,1,0.7962924242019653
XTANDI,bronchitis,respiratory tract bronchitis and,1,0.8248107433319092
XTANDI,bronchitis,and lung infection Laboratory Abnormalities,0,0.6546374559402466
XTANDI,bronchitis,bronchitis and lung infection,1,0.8779009580612183
XTANDI,neutropenia,neutropenia occurred in of patients,1,0.877630352973938
XTANDI,neutropenia,neutropenia occurred in,1,0.909941554069519
XTANDI,neutropenia,neutropenia,1,1.0000001192092896
XTANDI,neutropenia,trials neutropenia,1,0.8665258288383484
XTANDI,neutropenia,neutropenia occurred in of patients treated,1,0.8583692908287048
XTANDI,neutropenia,with XTANDI Grade and in of patients,0,0.4548439383506775
XTANDI,neutropenia,clinical trials neutropenia occurred in of patients treated,1,0.8296657800674438
XTANDI,neutropenia,treated with,0,0.5678842067718506
XTANDI,neutropenia,patients,0,0.5187681913375854
XTANDI,neutropenia,In the two randomized clinical trials Grade,0,0.521975040435791
XTANDI,neutropenia,trials neutropenia occurred in,1,0.8508937358856201
XTANDI,thrombocytopenia,thrombocytopenia was of patients,1,0.9173255562782288
XTANDI,thrombocytopenia,with placebo Grade,0,0.5173304080963135
XTANDI,thrombocytopenia,XTANDI,0,0.473438560962677
XTANDI,thrombocytopenia,treated with XTANDI Grade and of patients treated,0,0.5167781710624695
XTANDI,thrombocytopenia,The incidence of thrombocytopenia was of,1,0.8741519451141357
XTANDI,thrombocytopenia,thrombocytopenia was of patients treated with,1,0.8921773433685303
XTANDI,thrombocytopenia,with XTANDI Grade and of patients,0,0.5135334730148315
XTANDI,thrombocytopenia,Grade,0,0.4718240201473236
XTANDI,thrombocytopenia,treated with placebo,0,0.527094841003418
XTANDI,thrombocytopenia,of,0,0.5465577244758606
XTANDI,elevations in ALT,elevations in ALT occurred,1,0.9583661556243896
XTANDI,elevations in ALT,XTANDI Grade and of patients treated,0,0.5143567323684692
XTANDI,elevations in ALT,placebo Grade Grade,0,0.5059937834739685
XTANDI,elevations in ALT,in ALT occurred in of,1,0.7314550876617432
XTANDI,elevations in ALT,placebo Grade elevations in ALT occurred in,1,0.7533597350120544
XTANDI,elevations in ALT,and of patients treated with p,0,0.4358479380607605
XTANDI,elevations in ALT,Grade elevations in ALT occurred in of patients treated,1,0.7479923963546753
XTANDI,elevations in ALT,and of,0,0.5077596306800842
XTANDI,elevations in ALT,placebo,0,0.4724554419517517
XTANDI,elevations in ALT,placebo Grade elevations,1,0.666115403175354
XTANDI,elevations in ALT,in ALT occurred in,1,0.7443749904632568
XTANDI,elevations in ALT,treated,0,0.456926167011261
XTANDI,elevations in ALT,treated with placebo Grade elevations in ALT,1,0.7365041971206665
XTANDI,elevations in ALT,placebo Grade elevations in ALT,1,0.779744029045105
XTANDI,elevations in ALT,placebo Grade elevations in ALT occurred in of,1,0.747854471206665
XTANDI,elevations in bilirubin,in bilirubin occurred in,1,0.8819032907485962
XTANDI,elevations in bilirubin,with placebo Grade elevations in bilirubin occurred in of patients treated,1,0.8520743250846863
XTANDI,elevations in bilirubin,elevations in bilirubin,1,1.0
XTANDI,elevations in bilirubin,patients treated with XTANDI Grade and of,0,0.5305926203727722
XTANDI,elevations in bilirubin,and of patients treated with placebo Grade Grade,0,0.5163727402687073
XTANDI,elevations in bilirubin,in bilirubin occurred in of patients,1,0.85154128074646
XTANDI,elevations in bilirubin,elevations,1,0.6504623889923096
XTANDI,elevations in bilirubin,placebo Grade elevations in bilirubin occurred in,1,0.8687653541564941
XTANDI,elevations in bilirubin,of patients treated with pla,0,0.47897422313690186
XTANDI,elevations in bilirubin,in bilirubin occurred in of,1,0.8750475645065308
XTANDI,elevations in bilirubin,placebo Grade elevations in bilirubin occurred,1,0.8730231523513794
XTANDI,elevations in bilirubin,elevations in bilirubin occurred in of patients,1,0.933902382850647
XTANDI,elevations in bilirubin,patients treated with,0,0.5308072566986084
XTANDI,elevations in bilirubin,Grade,0,0.5049328207969666
XTANDI,elevations in bilirubin,treated with,0,0.5328958034515381
XTANDI,elevations in bilirubin,XTANDI Grade,0,0.5186949968338013
XTANDI,elevations in bilirubin,of patients treated with placebo Grade,0,0.5126290917396545
XTANDI,elevations in bilirubin,elevations in bilirubin occurred in of patients treated,1,0.9091713428497314
XTANDI,elevations in bilirubin,treated with placebo Grade elevations in bilirubin,1,0.8630983829498291
XTANDI,died,in each treatment group had an infection re,0,0.4743267595767975
XTANDI,died,patients treated with died from infections or sepsis In,1,0.6706153154373169
XTANDI,infections,infections or sepsis In,1,0.8202621936798096
XTANDI,infections,infections or sepsis In Study patient,1,0.7352962493896484
XTANDI,infections,placebo died infections or sepsis,1,0.6749824285507202
XTANDI,infections,XTANDI compared,0,0.5007736682891846
XTANDI,infections,patients treated with XTANDI,0,0.5248445868492126
XTANDI,infections,infections or sepsis,1,0.8122133016586304
XTANDI,sepsis,from,0,0.5571455359458923
XTANDI,sepsis,group had an infection resulting in death,0,0.6599322557449341
XTANDI,sepsis,compared to,0,0.526453971862793
XTANDI,sepsis,sepsis In Study,1,0.853304386138916
XTANDI,sepsis,treated with placebo died from infections,0,0.6226989030838013
XTANDI,sepsis,sepsis In Study patient in,1,0.8111055493354797
XTANDI,infection,infection resulting in death Falls,1,0.7020805478096008
XTANDI,infection,group had,0,0.5042813420295715
XTANDI,infection,infection resulting in death,1,0.7522929906845093
XTANDI,death,death Falls and Fallrelated Injuries,1,0.6885730028152466
XTANDI,death,had an infection resulting death,1,0.7555546760559082
XTANDI,death,an infection resulting death Falls and,1,0.7333067655563354
XTANDI,death,resulting death Falls and Fallrelated Injuries,1,0.6807483434677124
XTANDI,death,two randomized clinical trials falls,0,0.5064378380775452
XTANDI,death,randomized clinical trials falls,0,0.5059000849723816
XTANDI,death,an infection resulting death Falls and Fallrelated Injuries In,1,0.6469058990478516
XTANDI,death,death Falls and Fallrelated,1,0.7088491916656494
XTANDI,death,two randomized clinical trials,0,0.4969804584980011
XTANDI,falls,falls including fallrelated injuries occurred,1,0.7593502402305603
XTANDI,falls,falls,1,1.000000238418579
XTANDI,falls,falls including,1,0.9425122737884521
XTANDI,falls,two randomized,0,0.5163945555686951
XTANDI,falls,compared,0,0.519098699092865
XTANDI,falls,trials,0,0.5766500234603882
XTANDI,fall-related injuries,the two randomized clinical trials falls including,0,0.5561134219169617
XTANDI,fall-related injuries,compared to of patients treated with placebo,0,0.4538269639015198
XTANDI,fall-related injuries,clinical trials falls fall-related injuries occurred in of patients treated,1,0.8432562351226807
XTANDI,fall-related injuries,fall-related injuries occurred in of patients,1,0.9157957434654236
XTANDI,fall-related injuries,falls fall-related injuries,1,0.9699729681015015
XTANDI,fall-related injuries,and Fallrelated Injuries In the two randomized clinical trials falls,0,0.8035266399383545
XTANDI,loss of consciousness,loss of consciousness,1,1.0000001192092896
XTANDI,loss of consciousness,associated loss of consciousness or seizure Fallrelated,1,0.8449162840843201
XTANDI,loss of consciousness,seizure Fallrelated injuries were more severe in patients treated with XTANDI and,0,0.6477093696594238
XTANDI,loss of consciousness,of consciousness or seizure Fallrelated injuries were,1,0.7930416464805603
XTANDI,loss of consciousness,of consciousness,1,0.7025762796401978
XTANDI,loss of consciousness,were more severe in patients,0,0.5977303981781006
XTANDI,seizure,Falls were not associated with loss,0,0.5238234996795654
XTANDI,seizure,treated with XTANDI and included nonpathologic,0,0.5320038795471191
XTANDI,seizure,with placebo Falls were not associated with loss of consciousness or,0,0.5338634252548218
XTANDI,seizure,consciousness seizure,1,0.8545888662338257
XTANDI,seizure,injuries were more severe in patients treated with XTANDI and included,0,0.5540533065795898
XTANDI,seizure,severe in patients treated with XTANDI and included nonpathologic,0,0.5531877279281616
XTANDI,seizure,in patients treated with XTANDI,0,0.536435604095459
XTANDI,Fall-related injuries,Fall-related injuries were more,1,0.9260528683662415
XTANDI,Fall-related injuries,of consciousness or,0,0.47878360748291016
XTANDI,Fall-related injuries,or Fall-related,1,0.7696646451950073
XTANDI,non-pathologic fractures,non-pathologic fractures joint injuries and hematomas,1,0.8877811431884766
XTANDI,non-pathologic fractures,XTANDI and non-pathologic fractures,1,0.7857673764228821
XTANDI,non-pathologic fractures,non-pathologic fractures joint injuries,1,0.9258617162704468
XTANDI,non-pathologic fractures,patients,0,0.542908787727356
XTANDI,non-pathologic fractures,randomized trials hypertension was,0,0.47093120217323303
XTANDI,non-pathologic fractures,and hematomas Hypertension In the,0,0.5160543918609619
XTANDI,non-pathologic fractures,XTANDI and non-pathologic,1,0.6615942716598511
XTANDI,joint injuries,joint injuries and hematomas Hypertension In,1,0.7852883338928223
XTANDI,joint injuries,XTANDI and non-pathologic,1,0.4746226370334625
XTANDI,joint injuries,more severe in patients,0,0.589698076248169
XTANDI,joint injuries,joint injuries,1,0.9999999403953552
XTANDI,joint injuries,and,0,0.4955011010169983
XTANDI,joint injuries,XTANDI and included nonpathologic,0,0.4683980941772461
XTANDI,joint injuries,included nonpathologic,0,0.5299118757247925
XTANDI,joint injuries,and included nonpathologic joint injuries and,1,0.834079384803772
XTANDI,Hypertension,Hypertension In the two randomized trials,1,0.7880822420120239
XTANDI,Hypertension,and,0,0.5626955032348633
XTANDI,Hypertension,hypertension was reported in of,0,0.8543813228607178
XTANDI,Hypertension,Hypertension,1,0.9999999403953552
XTANDI,Hypertension,trials hypertension was reported in of patients receiving XTANDI and,0,0.7367926836013794
XTANDI,Hypertension,Hypertension In the,1,0.9211750030517578
XTANDI,hypertension,hypertension was reported in of patients,1,0.8273321390151978
XTANDI,hypertension,hypertension,1,0.9999999403953552
XTANDI,hypertension,hypertension was reported in of,1,0.8543813228607178
XTANDI,hypertension,placebo No patients,0,0.4938739538192749
XTANDI,hypertensive crisis,receiving placebo No patients hypertensive,1,0.6562817096710205
XTANDI,hypertensive crisis,Hypertension led to,0,0.8181448578834534
XTANDI,hypertensive crisis,hypertensive crisis,1,0.9999998807907104
XTANDI,hypertensive crisis,hypertensive crisis Medical history,1,0.8964741230010986
XTANDI,hypertensive crisis,hypertensive crisis Medical history of hypertension,1,0.8875337243080139
XTANDI,hypertensive crisis,to study discontinuati,0,0.4868156909942627
XTANDI,Seizure,cussed  in more,1,0.49700796604156494
XTANDI,Seizure,cussed ,1,0.5068599581718445
XTANDI,Seizure,The following is cussed ,1,0.489683598279953
XTANDI,seizure,"NS, con tact Astellas",1,0.5609204173088074
XTANDI,seizure,"report SUSPECTED ADVERSE NS,",1,0.5198773145675659
XTANDI,seizure,Pharma US Inc at or FDA at FDA,0,0.4624292850494385
XTANDI,seizure,"report SUSPECTED ADVERSE NS, con",1,0.5228264927864075
XTANDI,seizure,"ADVERSE NS, con",1,0.5712124109268188
XTANDI,seizure,"NS, con tact Astellas Pharma",1,0.5473971962928772
XTANDI,seizure,"NS, con tact Astellas Pharma US",1,0.5411564111709595
XTANDI,seizure,DA at 1 FDA or wwwfdagovmedwatch Clinical Trial,1,0.5130958557128906
XTANDI,Seizure,Because clinical tri,0,0.5201078653335571
XTANDI,Seizure,Inc at or FDA,0,0.5088015198707581
XTANDI,Seizure,Experience,0,0.5526048541069031
XTANDI,Seizure,wwwfdagovmedwatch,0,0.527311384677887
XTANDI,Seizure,00-FDA- or wwwfdagovmedwatch,1,0.5187624096870422
XTANDI,Seizure,00-FDA- or wwwfdagovmedwatch Clinical Trial,1,0.5171118378639221
XTANDI,Seizure,at or FDA at,0,0.5407346487045288
XTANDI,Seizure,00-FDA-,1,0.5114345550537109
XTANDI,Seizure,Because clinical,0,0.5383092164993286
XTANDI,seizure, trials of a drug cannot,1,0.5381085872650146
XTANDI,seizure, trials of a drug,1,0.5304920673370361
XTANDI,seizure,reaction rates observed in,0,0.473001629114151
XTANDI,seizure,the  trials of a drug cannot,1,0.5355379581451416
XTANDI,seizure, trials of,1,0.5148971080780029
XTANDI,seizure, trials,1,0.5449642539024353
XTANDI,seizure,rates observed in the  trials of a drug cannot be,1,0.5138023495674133
XTANDI,seizure,drug cannot be ectly c ompared,1,0.5784921646118164
XTANDI,seizure,cannot be ectly c ompared to rates in the,1,0.5023535490036011
XTANDI,seizure,observed in pr,0,0.48618924617767334
XTANDI,seizure,a drug cannot be ectly c ompared to rates,1,0.5566020011901855
XTANDI,seizure,cannot be ectly c,1,0.564842700958252
XTANDI,seizure,ectly c ompared to rates,1,0.5018762350082397
XTANDI,seizure,a drug cannot be ectly c,1,0.5633175373077393
AFINITOR,Infections,Infections see Warnings,1,0.8066918253898621
AFINITOR,Infections,see Warnings and Infections see Warnings and,1,0.7514179348945618
AFINITOR,Infections,Warnings and Infections see Warnings and Precautions Angioedema,1,0.7290617227554321
AFINITOR,Infections,and Infections see Warnings and,1,0.7981624007225037
AFINITOR,Infections,see Warnings and Infections see Warnings and Precautions,1,0.7367923259735107
AFINITOR,Infections,Infections see,1,0.887596607208252
AFINITOR,Angioedema,Angioedema,1,1.000000238418579
AFINITOR,Oral ulceration,Warnings,0,0.5198214054107666
AFINITOR,Impaired wound healing,Impaired wound healing,1,1.0
AFINITOR,Impaired wound healing,Impaired wound healing see Warnings and Precautions,1,0.8954294919967651
AFINITOR,Impaired wound healing,Because clinical trials are conducted,0,0.5257669687271118
AFINITOR,Impaired wound healing,Impaired,1,0.7129428386688232
AFINITOR,Impaired wound healing,see Warnings and Precautions,0,0.5033054351806641
AFINITOR,Impaired wound healing,Renal failure,0,0.5589326620101929
AFINITOR,Impaired wound healing,wound healing see Warnings and Precautions Because,1,0.7762974500656128
AFINITOR,Impaired wound healing,Impaired wound healing see Warnings and Precautions Because,1,0.8955459594726562
AFINITOR,stomatitis,stomatitis infections rash,1,0.8304790258407593
AFINITOR,stomatitis,stomatitis infections rash fatigue diarrhea,1,0.7981765270233154
AFINITOR,stomatitis,stomatitis,1,1.0
AFINITOR,stomatitis,reactions,0,0.5407161712646484
AFINITOR,stomatitis,stomatitis infections,1,0.911358118057251
AFINITOR,stomatitis,stomatitis infections rash fatigue,1,0.7877389192581177
AFINITOR,stomatitis,adverse reactions incidence stomatitis infections rash fatigue,1,0.7531358003616333
AFINITOR,stomatitis,fatigue,0,0.5325690507888794
AFINITOR,infections,infections rash fatigue diarrhea edema,1,0.7430276274681091
AFINITOR,infections,infections rash,1,0.7870267033576965
AFINITOR,infections,cough,0,0.6442767977714539
AFINITOR,infections,infections rash fatigue diarrhea edema abdominal,1,0.7290648221969604
AFINITOR,rash,adverse,0,0.614707887172699
AFINITOR,rash,include,0,0.5241231918334961
AFINITOR,rash,include stomatitis rash fatigue diarrhea edema abdominal pain,1,0.7457423210144043
AFINITOR,rash,abdominal pain nausea fever asthenia cough headache,0,0.5560429096221924
AFINITOR,fatigue,fatigue diarrhea edema abdominal pain nausea,1,0.74516361951828
AFINITOR,fatigue,fatigue,1,1.0
AFINITOR,diarrhea,cough headache and,0,0.5381615161895752
AFINITOR,diarrhea,RCC Most common adverse reactions,0,0.5279757976531982
AFINITOR,edema,nausea fever asthenia cough headache and decreased appetite,0,0.5654824376106262
AFINITOR,edema,include stomatitis infections,0,0.5317896604537964
AFINITOR,edema,edema abdominal pain nausea,1,0.8325013518333435
AFINITOR,edema,fatigue edema abdominal pain nausea,1,0.7826753258705139
AFINITOR,edema,infections rash fatigue edema abdominal pain nausea,1,0.7094855904579163
AFINITOR,edema,diarrhea,0,0.6077092885971069
AFINITOR,edema,edema abdominal pain nausea fever asthenia,1,0.8410130739212036
AFINITOR,edema,common adverse,0,0.5668702125549316
AFINITOR,edema,stomatitis infections rash fatigue edema abdominal pain nausea fever asthenia,1,0.6813409328460693
AFINITOR,abdominal pain,abdominal pain nausea fever asthenia cough,1,0.842485785484314
AFINITOR,abdominal pain,diarrhea edema,0,0.5816043019294739
AFINITOR,abdominal pain,fatigue diarrhea edema,0,0.6104003190994263
AFINITOR,abdominal pain,fatigue diarrhea abdominal pain,1,0.8244003057479858
AFINITOR,nausea,nausea fever asthenia cough headache,1,0.8154058456420898
AFINITOR,nausea,rash fatigue diarrhea edema,0,0.6771075129508972
AFINITOR,nausea,nausea fever,1,0.8722633123397827
AFINITOR,nausea,abdominal nausea fever asthenia,1,0.8159056305885315
AFINITOR,nausea,diarrhea edema,0,0.5950754880905151
AFINITOR,nausea,nausea fever asthenia cough headache and,1,0.7960150241851807
AFINITOR,nausea,pain,0,0.6507443189620972
AFINITOR,nausea,fatigue diarrhea edema abdominal nausea fever,1,0.7430817484855652
AFINITOR,nausea,asthenia cough headache and decreased appetite Renal,0,0.6797218322753906
AFINITOR,asthenia,and decreased appetite,0,0.5840007662773132
AFINITOR,asthenia,angiomyolipoma,0,0.43220287561416626
AFINITOR,asthenia,asthenia cough,1,0.8440523147583008
AFINITOR,cough,diarrhea edema abdominal pain nausea fever asthenia,0,0.5667895674705505
AFINITOR,cough,nausea fever cough,1,0.8125807046890259
AFINITOR,headache,with,0,0.5505115985870361
AFINITOR,headache,headache and decreased appetite,1,0.79313063621521
AFINITOR,headache,headache and decreased appetite Renal angiomyolipoma,1,0.6995618343353271
AFINITOR,headache,atitis infections rash fatigue diarrhea edema abdominal pain nausea fever asthenia cough,0,0.5864837169647217
AFINITOR,headache,fatigue diarrhea edema abdominal pain nausea fever,0,0.6116050481796265
AFINITOR,headache,diarrhea edema abdominal pain nausea fever,0,0.604625940322876
AFINITOR,stomatitis,adverse reactions incidence,0,0.5350319147109985
AFINITOR,stomatitis,stomatitis SEGA with,1,0.8910280466079712
AFINITOR,stomatitis,with TSC Most,0,0.5007710456848145
AFINITOR,stomatitis,stomatitis SEGA,1,0.8415852785110474
AFINITOR,stomatitis,Renal angiomyolipoma with TSC Most common adverse reaction,0,0.511336088180542
AFINITOR,stomatitis,incidence stomatitis SEGA,1,0.8062950372695923
AFINITOR,stomatitis,SEGA with TSC Most common adverse,0,0.5357930660247803
AFINITOR,stomatitis,respiratory tract infection To,0,0.5461204648017883
AFINITOR,stomatitis,adverse reactions incidence stomatitis and respiratory tract,1,0.7753953337669373
AFINITOR,stomatitis,stomatitis and respiratory tract infection,1,0.8431262969970703
AFINITOR,respiratory tract infection,REACTIONS contact,0,0.5262155532836914
AFINITOR,stomatitis,stomatitis infections rash fatigue diarrhea and,1,0.788161039352417
AFINITOR,stomatitis,of approximately months The most,0,0.4787473678588867
AFINITOR,infections,infections rash fatigue,1,0.7260411977767944
AFINITOR,infections,infections rash fatigue diarrhea and decreased,1,0.6940704584121704
AFINITOR,infections,common Grade,0,0.4991092383861542
AFINITOR,infections,adverse,0,0.5383040904998779
AFINITOR,rash,stomatitis infections,0,0.5187903642654419
AFINITOR,rash,rash,1,1.0000001192092896
AFINITOR,rash,rash fatigue diarrhea and decreased appetite,1,0.7215370535850525
AFINITOR,rash,reactions incidence were stomatitis infections,0,0.5644809007644653
AFINITOR,rash,rash fatigue diarrhea,1,0.7737464904785156
AFINITOR,rash,were stomatitis rash fatigue diarrhea and decreased,1,0.6944600343704224
AFINITOR,rash,rash fatigue,1,0.8455263376235962
AFINITOR,rash,reactions incidence were stomatitis rash fatigue diarrhea,1,0.7120202779769897
AFINITOR,fatigue,fatigue diarrhea and decreased appetite The,1,0.7327413558959961
AFINITOR,diarrhea,diarrhea and decreased,1,0.8227272033691406
AFINITOR,diarrhea,diarrhea and decreased appetite,1,0.7990113496780396
AFINITOR,diarrhea,diarrhea and decreased appetite The,1,0.7968898415565491
AFINITOR,diarrhea,common adverse reactions incidence,0,0.5654752850532532
AFINITOR,diarrhea,were stomatitis infections rash diarrhea and decreased appetite The most,1,0.6945847272872925
AFINITOR,diarrhea,stomatitis infections rash diarrhea and decreased appetite The most,1,0.7096421718597412
AFINITOR,diarrhea,Grade,0,0.5262745022773743
AFINITOR,decreased appetite,reactions incidence were stomatitis,0,0.540399432182312
AFINITOR,decreased appetite,rash fatigue diarrhea decreased appetite The most common Grade adverse,1,0.7411489486694336
AFINITOR,decreased appetite,decreased appetite The most common,1,0.8895325660705566
AFINITOR,decreased appetite,decreased appetite The most common Grade adverse,1,0.8340017795562744
AFINITOR,decreased appetite,fatigue diarrhea decreased appetite The most common Grade adverse,1,0.7806049585342407
AFINITOR,decreased appetite,and,0,0.46837252378463745
AFINITOR,decreased appetite,The most common Grade adverse reactions incidence,0,0.4622013568878174
AFINITOR,stomatitis,The most common Grade adverse reactions incidence,0,0.5268951058387756
AFINITOR,stomatitis,stomatitis infections hyperglycemia fatigue,1,0.7870286107063293
AFINITOR,stomatitis,The most common,0,0.4762633442878723
AFINITOR,stomatitis,pneumonitis and diarrhea The most common,0,0.5256408452987671
AFINITOR,infections,pneumonitis and diarrhea The most common laboratory abnormaliti,0,0.6145696043968201
AFINITOR,infections,infections hyperglycemia,1,0.7570916414260864
AFINITOR,infections,fatigue dyspnea pneumonitis and diarrhea,0,0.6101783514022827
AFINITOR,infections,decreased appetite The most,0,0.5029999613761902
AFINITOR,infections,decreased appetite The most common Grade adverse reactions incidence,0,0.5679898262023926
AFINITOR,infections,most common Grade,0,0.5123200416564941
AFINITOR,infections,and diarrhea The most common laboratory abnormaliti,0,0.5720105171203613
AFINITOR,infections,pneumonitis and diarrhea The,0,0.6597363948822021
AFINITOR,hyperglycemia,hyperglycemia fatigue dyspnea,1,0.8090039491653442
AFINITOR,hyperglycemia,were stomatitis hyperglycemia fatigue dyspnea pneumonitis and,1,0.7296971678733826
AFINITOR,hyperglycemia,hyperglycemia fatigue,1,0.8634402751922607
AFINITOR,hyperglycemia,were stomatitis hyperglycemia fatigue,1,0.7790929079055786
AFINITOR,hyperglycemia,common laboratory,0,0.5131762623786926
AFINITOR,hyperglycemia,hyperglycemia fatigue dyspnea pneumonitis and diarrhea,1,0.7621832489967346
AFINITOR,hyperglycemia,were stomatitis hyperglycemia fatigue dyspnea pneumonitis,1,0.7274390459060669
AFINITOR,hyperglycemia,laboratory abnormalities,0,0.5838689804077148
AFINITOR,dyspnea,hyperglycemia,0,0.5306602120399475
AFINITOR,dyspnea,infections,0,0.5542159676551819
AFINITOR,pneumonitis,pneumonitis and diarrhea The most common,1,0.7601238489151001
AFINITOR,pneumonitis,laboratory abnormalities incidence were,0,0.4989977777004242
AFINITOR,diarrhea,abnormalities,0,0.5844370126724243
AFINITOR,diarrhea,diarrhea,1,0.9999999403953552
AFINITOR,diarrhea,fatigue dyspnea pneumonitis diarrhea The most common laboratory,1,0.7022125720977783
AFINITOR,diarrhea,diarrhea The,1,0.9120277166366577
AFINITOR,diarrhea,fatigue dyspnea pneumonitis diarrhea The most,1,0.7429624795913696
AFINITOR,diarrhea,hyperglycemia fatigue dyspnea pneumonitis diarrhea The most common laboratory,1,0.6938652992248535
AFINITOR,diarrhea,diarrhea The most common laboratory abnormalities,1,0.7667323350906372
AFINITOR,diarrhea,diarrhea The most common laboratory,1,0.783409833908081
AFINITOR,hypercholesterolemia,common laboratory abnormalities incidence were,0,0.5856684446334839
AFINITOR,hypercholesterolemia,aspartate transaminase AST,0,0.5140930414199829
AFINITOR,hypercholesterolemia,hypercholesterolemia hyperglycemia,1,0.8872829675674438
AFINITOR,hypercholesterolemia,transaminase AST,0,0.5244194269180298
AFINITOR,hypercholesterolemia,hypercholesterolemia hyperglycemia increased aspartate transaminase AST,1,0.7260390520095825
AFINITOR,hyperglycemia,leukopenia thrombocytopenia lymphopenia,0,0.5132811069488525
AFINITOR,hyperglycemia,hypercholesterolemia,0,0.7315106987953186
AFINITOR,increased aspartate transaminase,e most common laboratory,0,0.5362435579299927
AFINITOR,anemia,transaminase anemia leukopenia thrombocytopenia lymphopenia,1,0.6683405637741089
AFINITOR,anemia,e most common laboratory,0,0.543542742729187
AFINITOR,anemia,aspartate transaminase,0,0.55961012840271
AFINITOR,anemia,hyperglycemia increased aspartate transaminase,0,0.5657559633255005
AFINITOR,anemia,thrombocytopenia lymphopenia,0,0.6013222336769104
AFINITOR,anemia,anemia leukopenia thrombocytopenia,1,0.7729839086532593
AFINITOR,anemia,AST,0,0.5400708317756653
AFINITOR,anemia,aspartate,0,0.5741814374923706
AFINITOR,anemia,anemia,1,1.0
AFINITOR,leukopenia,leukopenia,1,0.9999998807907104
AFINITOR,leukopenia,transaminase AST leukopenia thrombocytopenia lymphopenia increased alanine,1,0.7307096719741821
AFINITOR,leukopenia,leukopenia thrombocytopenia,1,0.8635249733924866
AFINITOR,leukopenia,leukopenia thrombocytopenia lymphopenia increased,1,0.8456814885139465
AFINITOR,leukopenia,aspartate transaminase AST leukopenia thrombocytopenia lymphopenia,1,0.734260082244873
AFINITOR,thrombocytopenia,thrombocytopenia lymphopenia increased,1,0.8057060837745667
AFINITOR,thrombocytopenia,aspartate transaminase AST anemia thrombocytopenia lymphopenia,1,0.7244200706481934
AFINITOR,thrombocytopenia,most common Grade,0,0.4673755168914795
AFINITOR,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
AFINITOR,thrombocytopenia,thrombocytopenia lymphopenia,1,0.8228369951248169
AFINITOR,lymphopenia,and hypertriglyceridemia The most common,0,0.5475703477859497
AFINITOR,lymphopenia,lymphopenia increased alanine transaminase ALT and,1,0.8041829466819763
AFINITOR,lymphopenia,lymphopenia increased alanine,1,0.8543099164962769
AFINITOR,lymphopenia,lymphopenia increased,1,0.9250192046165466
AFINITOR,lymphopenia,most common,0,0.4929860234260559
AFINITOR,lymphopenia,lymphopenia increased alanine transaminase ALT,1,0.8055441975593567
AFINITOR,lymphopenia,transaminase AST anemia leukopenia lymphopenia increased alanine transaminase,1,0.746431827545166
AFINITOR,increased alanine transaminase,ALT and,0,0.5586656928062439
AFINITOR,increased alanine transaminase,laboratory abnormalities incidence,0,0.6112121343612671
AFINITOR,increased alanine transaminase,alanine transaminase ALT and hypertriglyceridemia The,1,0.8540581464767456
AFINITOR,increased alanine transaminase,AST anemia leukopenia thrombocytopenia increased alanine transaminase ALT and hypertriglyceridemia The,1,0.8183808326721191
AFINITOR,lymphopenia,were,0,0.4752873182296753
AFINITOR,lymphopenia,potassium increased AST increased ALT and,0,0.5455821752548218
AFINITOR,lymphopenia,incidence lymphopenia hyperglycemia,1,0.8319717645645142
AFINITOR,lymphopenia,AST increased ALT and thrombocytopenia,0,0.5866606831550598
AFINITOR,lymphopenia,Grade laboratory abnormalities incidence lymphopenia hyperglycemia anemia decreased potassium,1,0.76862633228302
AFINITOR,lymphopenia,AST increased,0,0.529608964920044
AFINITOR,lymphopenia,Grade laboratory,0,0.5064195990562439
AFINITOR,hyperglycemia,abnormalities incidence were hyperglycemia anemia decreased potassium increased,1,0.7449355721473694
AFINITOR,hyperglycemia,Grade laboratory,0,0.4976091980934143
AFINITOR,hyperglycemia,ALT and thrombocytopenia,0,0.5363349914550781
AFINITOR,hyperglycemia,were,0,0.5193837881088257
AFINITOR,hyperglycemia,hyperglycemia anemia decreased potassium increased,1,0.7921015024185181
AFINITOR,hyperglycemia,hyperglycemia anemia decreased potassium,1,0.7672238349914551
AFINITOR,hyperglycemia,anemia decreased potassium increased AST,0,0.5729449391365051
AFINITOR,anemia,abnormalities,0,0.5558170080184937
AFINITOR,anemia,anemia decreased,1,0.8454160094261169
AFINITOR,anemia,lymphopenia anemia decreased potassium increased AST increased,1,0.735929012298584
AFINITOR,anemia,increased AST increased ALT and,0,0.5417518019676208
AFINITOR,anemia,ALT and thrombocytopenia Fatal adverse reactio,0,0.5881739854812622
AFINITOR,anemia,anemia decreased potassium increased,1,0.7928346991539001
AFINITOR,anemia,AST increased ALT and,0,0.5170620679855347
AFINITOR,decreased potassium,lymphopenia hyperglycemia decreased potassium increased AST increased ALT,1,0.7381476163864136
AFINITOR,decreased potassium,AST increased ALT and,0,0.4979860782623291
AFINITOR,decreased potassium,decreased potassium,1,0.9999998807907104
AFINITOR,decreased potassium,reactions occurred,0,0.5105167627334595
AFINITOR,decreased potassium,AST,0,0.48068615794181824
AFINITOR,decreased potassium,decreased potassium increased AST,1,0.8373857736587524
AFINITOR,decreased potassium,decreased potassium increased,1,0.9311898946762085
AFINITOR,decreased potassium,ommon Grade,0,0.48849695920944214
AFINITOR,decreased potassium,adverse reactions occurred more,0,0.5143393278121948
AFINITOR,increased AST,hyperglycemia anemia decreased increased AST increased ALT,1,0.7748082876205444
AFINITOR,increased AST,adverse reactions occurred more,0,0.6456268429756165
AFINITOR,increased AST,hyperglycemia anemia decreased increased AST,1,0.8094322681427002
AFINITOR,increased AST,anemia,0,0.5650382041931152
AFINITOR,increased AST,atory abnormalities incidence were,0,0.5832101702690125
AFINITOR,increased AST,thrombocytopenia Fatal,0,0.5200367569923401
AFINITOR,increased ALT,patients who,0,0.49945080280303955
AFINITOR,increased ALT,increased ALT,1,1.0000001192092896
AFINITOR,increased ALT,decreased potassium increased increased ALT,1,0.7666266560554504
AFINITOR,increased ALT,anemia decreased potassium increased increased ALT and thrombocytopenia Fatal adverse reactions,1,0.5802295804023743
AFINITOR,increased ALT,decreased potassium increased increased ALT and thrombocytopenia,1,0.6373094320297241
AFINITOR,thrombocytopenia,Fatal adverse reactions occurred,0,0.49826937913894653
AFINITOR,thrombocytopenia,thrombocytopenia Fatal adverse reactions occurred more,1,0.8168072700500488
AFINITOR,thrombocytopenia,increased AST increased ALT thrombocytopenia Fatal adverse,1,0.783017635345459
AFINITOR,thrombocytopenia,potassium increased AST increased ALT,0,0.5642468929290771
AFINITOR,thrombocytopenia,thrombocytopenia Fatal adverse reactions,1,0.8315920829772949
AFINITOR,thrombocytopenia,decreased potassium,0,0.5265064835548401
AFINITOR,thrombocytopenia,decreased potassium increased AST increased,0,0.5562953352928162
AFINITOR,thrombocytopenia,thrombocytopenia Fatal adverse,1,0.8646771311759949
AFINITOR,thrombocytopenia,AST increased ALT thrombocytopenia,1,0.8268253207206726
AFINITOR,Fatal,received AFINITOR plus exemestane c,0,0.4561208486557007
AFINITOR,Fatal,AFINITOR plus exemestane,0,0.4842544198036194
AFINITOR,Fatal,Fatal adverse reactions,1,0.7630990743637085
AFINITOR,stomatitis,b stomatitis,1,0.8718670606613159
AFINITOR,stomatitis,Fatal adverse reactions,1,0.5228959321975708
AFINITOR,stomatitis,stomatitis mouth ulceration aphthous stomatitis glossodynia,1,0.8376388549804688
AFINITOR,stomatitis,stomatitis mouth ulceration aphthous,1,0.8669639825820923
AFINITOR,stomatitis,gingival pain glossitis and lip,0,0.7406470775604248
AFINITOR,stomatitis,stomatitis mouth ulceration,1,0.9070593118667603
AFINITOR,aphthous stomatitis,a period of weeks a Exemestane mgday b Includes stomatitis mouth ulceration,0,0.6748908758163452
AFINITOR,aphthous stomatitis,ulceration c Includes,0,0.5775754451751709
AFINITOR,aphthous stomatitis,aphthous stomatitis glossodynia gingival,1,0.8653203248977661
AFINITOR,aphthous stomatitis,y for a period,0,0.4919789433479309
AFINITOR,aphthous stomatitis,Includes stomatitis mouth aphthous stomatitis glossodynia gingival pain glossitis,1,0.8411985635757446
AFINITOR,aphthous stomatitis,aphthous stomatitis glossodynia,1,0.8437471389770508
AFINITOR,aphthous stomatitis,aphthous stomatitis glossodynia gingival pain,1,0.8415142297744751
AFINITOR,aphthous stomatitis,gingival,0,0.6590468883514404
AFINITOR,aphthous stomatitis,Includes stomatitis mouth aphthous stomatitis glossodynia gingival pain,1,0.8349452614784241
AFINITOR,aphthous stomatitis,ulceration,0,0.6337196826934814
AFINITOR,glossodynia,Includes stomatitis,0,0.6067339181900024
AFINITOR,glossodynia,ulceration aphthous glossodynia gingival pain glossitis and,1,0.7846935987472534
AFINITOR,glossodynia,b Includes stomatitis mouth,0,0.6104594469070435
AFINITOR,glossodynia,glossodynia gingival pain glossitis and,1,0.8624955415725708
AFINITOR,glossodynia,a Exemestane,0,0.5487810373306274
AFINITOR,glossodynia,Includes,0,0.4869391918182373
AFINITOR,glossodynia,mgday b Includes stomatitis,0,0.603705644607544
AFINITOR,glossodynia,glossodynia gingival pain glossitis and lip,1,0.8409521579742432
AFINITOR,glossodynia,stomatitis mouth ulceration aphthous glossodynia gingival,1,0.7266013622283936
AFINITOR,gingival pain,gingival pain glossitis and lip ulceration c,1,0.8123210072517395
AFINITOR,gingival pain,aphthous stomatitis gingival,1,0.7798411846160889
AFINITOR,gingival pain,stomatitis mouth ulceration aphthous stomatitis,0,0.6451138257980347
AFINITOR,gingival pain,ulceration c Includes all preferred terms within the infections and,0,0.5495278835296631
AFINITOR,gingival pain,preferred terms within the infections and,0,0.5135992765426636
AFINITOR,gingival pain,gingival pain glossitis and lip ulceration,1,0.8169416785240173
AFINITOR,gingival pain,stomatitis gingival pain,1,0.9316771030426025
AFINITOR,gingival pain,mouth,0,0.6416127681732178
AFINITOR,gingival pain,and lip,0,0.554695725440979
AFINITOR,glossitis,and,0,0.4779917895793915
AFINITOR,glossitis,gingival glossitis and lip ulceration c,1,0.8305813074111938
AFINITOR,glossitis,glossitis,1,1.0
AFINITOR,lip ulceration,aphthous stomatitis,0,0.6876293420791626
AFINITOR,lip ulceration,glossitis lip,1,0.7739183902740479
AFINITOR,lip ulceration,and infestations system organ class the,0,0.4940335750579834
AFINITOR,lip ulceration,stomatitis glossodynia,0,0.6417992115020752
AFINITOR,lip ulceration,pain glossitis lip ulceration c,1,0.836427628993988
AFINITOR,lip ulceration,glossodynia gingival pain glossitis lip,1,0.6939122080802917
AFINITOR,lip ulceration,pain glossitis lip ulceration,1,0.8638824820518494
AFINITOR,lip ulceration,lip ulceration c Includes all preferred terms,1,0.834237813949585
AFINITOR,nasopharyngitis,urinary tract infection upper,0,0.5530450344085693
AFINITOR,nasopharyngitis,nasopharyngitis urinary tract infection,1,0.8545644283294678
AFINITOR,nasopharyngitis,the most,0,0.4791553020477295
AFINITOR,nasopharyngitis,nasopharyngitis urinary tract infection upper respiratory,1,0.7969646453857422
AFINITOR,nasopharyngitis,class,0,0.5052735209465027
AFINITOR,nasopharyngitis,nasopharyngitis urinary tract,1,0.8420907258987427
AFINITOR,nasopharyngitis,nasopharyngitis urinary tract infection upper,1,0.7896267771720886
AFINITOR,urinary tract infection,being,0,0.5317478179931641
AFINITOR,urinary tract infection,being urinary tract infection upper respiratory tract infection,1,0.8276820778846741
AFINITOR,urinary tract infection,common being urinary tract,1,0.7676194310188293
AFINITOR,urinary tract infection,infections and infestations system organ class,0,0.6236757040023804
AFINITOR,urinary tract infection,urinary tract infection upper respiratory tract infection,1,0.8362135291099548
AFINITOR,upper respiratory tract infection,the most common being nasopharyngitis urinary tract,0,0.6846908330917358
AFINITOR,upper respiratory tract infection,being,0,0.5044246912002563
AFINITOR,upper respiratory tract infection,organ class the most,0,0.517095148563385
AFINITOR,upper respiratory tract infection,upper,1,0.6525404453277588
AFINITOR,upper respiratory tract infection,being nasopharyngitis urinary tract upper respiratory tract infection,1,0.845787525177002
AFINITOR,upper respiratory tract infection,cystitis sinusitis and also including candidiasi,0,0.628250241279602
AFINITOR,upper respiratory tract infection,tract upper respiratory,1,0.8404788374900818
AFINITOR,upper respiratory tract infection,system organ class the most common being nasopharyngitis,0,0.6866101622581482
AFINITOR,upper respiratory tract infection,nasopharyngitis urinary tract upper,1,0.7554116249084473
AFINITOR,pneumonia,pneumonia bronchitis cystitis,1,0.7642618417739868
AFINITOR,pneumonia,infection upper respiratory tract pneumonia bronchitis,1,0.7304033637046814
AFINITOR,pneumonia,infection upper,0,0.6081801056861877
AFINITOR,pneumonia,tract pneumonia,1,0.783480167388916
AFINITOR,pneumonia,infection,0,0.7058889269828796
AFINITOR,pneumonia,pneumonia bronchitis cystitis sinusitis,1,0.7499249577522278
AFINITOR,pneumonia,infection upper respiratory tract pneumonia bronchitis cystitis sinusitis and,1,0.7104633450508118
AFINITOR,pneumonia,and also including,0,0.5407336950302124
AFINITOR,bronchitis,bronchitis cystitis sinusitis and also including,1,0.7893779277801514
AFINITOR,bronchitis,bronchitis cystitis sinusitis and also,1,0.797692060470581
AFINITOR,bronchitis,including,0,0.5311071872711182
AFINITOR,cystitis,tract infection pneumonia cystitis sinusitis and also including,1,0.7247762084007263
AFINITOR,cystitis,including,0,0.5087651014328003
AFINITOR,cystitis,upper respiratory tract infection pneumonia,0,0.5240774154663086
AFINITOR,cystitis,pneumonia bronchitis,0,0.5084874629974365
AFINITOR,cystitis,candidiasis and,0,0.6630685925483704
AFINITOR,cystitis,cystitis sinusitis and,1,0.8300289511680603
AFINITOR,cystitis,cystitis sinusitis and also including,1,0.8186904788017273
AFINITOR,cystitis,cystitis sinusitis,1,0.8279706239700317
AFINITOR,sinusitis,sinusitis and also including candidiasis and,1,0.8578717112541199
AFINITOR,sinusitis,cystitis,0,0.668096125125885
AFINITOR,sinusitis,pneumonia,0,0.6165457963943481
AFINITOR,sinusitis,hepatitis C d,0,0.5114449858665466
AFINITOR,sinusitis,C,0,0.5149262547492981
AFINITOR,sinusitis,pneumonia bronchitis cystitis,0,0.6041312217712402
AFINITOR,sinusitis,also including candidiasis and sepsis and hepatitis,0,0.557216227054596
AFINITOR,candidiasis,also candidiasis,1,0.8805994987487793
AFINITOR,candidiasis,pneumonia,0,0.666426956653595
AFINITOR,candidiasis,also candidiasis and sepsis and,1,0.8191053867340088
AFINITOR,candidiasis,candidiasis and,1,0.9199600219726562
AFINITOR,candidiasis,hepatitis,0,0.6448322534561157
AFINITOR,candidiasis,sinusitis and also candidiasis and sepsis and hepatitis C,1,0.6992039680480957
AFINITOR,sepsis,candidiasis sepsis and hepatitis C d,1,0.7420490980148315
AFINITOR,sepsis,hepatitis,0,0.6158810257911682
AFINITOR,sepsis,including candidiasis sepsis and hepatitis,1,0.7499983906745911
AFINITOR,sepsis,including candidiasis sepsis and,1,0.7909741401672363
AFINITOR,sepsis,sepsis and hepatitis,1,0.8242701292037964
AFINITOR,sepsis,interstitial,0,0.583013653755188
AFINITOR,sepsis,sepsis and hepatitis C d,1,0.7912894487380981
AFINITOR,sepsis,and hepatitis C d Includes pneumonitis interstitial lung disease,0,0.5770460963249207
AFINITOR,hepatitis C,lung,0,0.540571391582489
AFINITOR,pneumonitis,pneumonitis interstitial lung,1,0.8411365747451782
AFINITOR,pneumonitis,lung,0,0.6759146451950073
AFINITOR,pneumonitis,d pneumonitis interstitial lung,1,0.8367040753364563
AFINITOR,pneumonitis,C d pneumonitis interstitial,1,0.8031823635101318
AFINITOR,pneumonitis,interstitial lung disease lung infiltration and,0,0.6766805648803711
AFINITOR,pneumonitis,sepsis and,0,0.5751519203186035
AFINITOR,pneumonitis,and also including candidiasis and sepsis and hepatitis C,0,0.5635696649551392
AFINITOR,pneumonitis,pneumonitis interstitial lung disease lung,1,0.8277050852775574
AFINITOR,pneumonitis,Exposure,0,0.549731433391571
AFINITOR,interstitial lung disease,interstitial lung disease lung,1,0.9441280364990234
AFINITOR,interstitial lung disease,Includes interstitial lung disease lung infiltration and,1,0.8756047487258911
AFINITOR,interstitial lung disease,interstitial lung,1,0.8930478692054749
AFINITOR,interstitial lung disease,d Includes interstitial lung,1,0.8447431325912476
AFINITOR,interstitial lung disease,Includes interstitial lung disease lung infiltration and pulmonary,1,0.8788858652114868
AFINITOR,interstitial lung disease,C d Includes interstitial,1,0.7270945310592651
AFINITOR,interstitial lung disease,lung infiltration and pulmonary,0,0.7261084914207458
AFINITOR,interstitial lung disease,interstitial lung disease lung infiltration and,1,0.8701568841934204
AFINITOR,interstitial lung disease,hepatitis C d Includes interstitial,1,0.6942672729492188
AFINITOR,lung infiltration,Includes pneumonitis interstitial lung lung infiltration,1,0.8841402530670166
AFINITOR,lung infiltration,hepatitis C d Includes interstitial,1,0.5998358726501465
AFINITOR,lung infiltration,lung infiltration and pulmonary fibrosis e,1,0.9027136564254761
AFINITOR,lung infiltration,lung disease,0,0.7366841435432434
AFINITOR,lung infiltration,lung infiltration,1,1.0
AFINITOR,lung infiltration,lung infiltration and pulmonary,1,0.9650041460990906
AFINITOR,lung infiltration,interstitial lung lung infiltration,1,0.9495145082473755
AFINITOR,lung infiltration,lung lung infiltration,1,0.9858310222625732
AFINITOR,pulmonary fibrosis,pulmonary fibrosis,1,0.9999998211860657
AFINITOR,pulmonary fibrosis,infiltration and,0,0.533338189125061
AFINITOR,pulmonary fibrosis,disease lung infiltration pulmonary fibrosis,1,0.8303470611572266
AFINITOR,pulmonary fibrosis,pulmonary,1,0.7944067716598511
AFINITOR,pulmonary fibrosis,pneumonitis,0,0.7147719264030457
AFINITOR,pulmonary fibrosis,pneumonitis interstitial lung disease lung infiltration,0,0.7277894020080566
AFINITOR,pulmonary fibrosis,infiltration pulmonary,1,0.715701162815094
AFINITOR,anemia,reports of,0,0.5306334495544434
AFINITOR,anemia,Reflects corresponding adverse drug,0,0.5384026169776917
AFINITOR,anemia,collectively as pancytopenia,0,0.6623805165290833
AFINITOR,anemia,reports anemia leukopenia lymphopenia neutropenia and,1,0.7776676416397095
AFINITOR,anemia,and thrombocytopenia,0,0.652958333492279
AFINITOR,anemia,anemia leukopenia lymphopenia neutropenia and thrombocytopenia,1,0.7513371109962463
AFINITOR,anemia,anemia leukopenia lymphopenia neutropenia and,1,0.7946706414222717
AFINITOR,anemia,and thrombocytopenia collectively as pancytopenia which,0,0.636111855506897
AFINITOR,anemia,thrombocytopenia collectively as pancytopenia which o,0,0.615991473197937
AFINITOR,leukopenia,leukopenia lymphopenia,1,0.895672082901001
AFINITOR,leukopenia,as pancytopenia which occurred at l,0,0.689302921295166
AFINITOR,leukopenia,leukopenia lymphopenia neutropenia and thrombocytopenia,1,0.844366192817688
AFINITOR,leukopenia,anemia,0,0.6550047993659973
AFINITOR,leukopenia,neutropenia and thrombocytopenia collectively as pancytopenia which,0,0.6743932962417603
AFINITOR,leukopenia,reports,0,0.49948275089263916
AFINITOR,leukopenia,reports of leukopenia lymphopenia neutropenia and,1,0.8651184439659119
AFINITOR,leukopenia,neutropenia and thrombocytopenia collectively,0,0.6808578968048096
AFINITOR,lymphopenia,reports of anemia lymphopenia,1,0.8632876873016357
AFINITOR,lymphopenia,neutropenia and thrombocytopenia collectively,0,0.6047837734222412
AFINITOR,lymphopenia,pancytopenia which,0,0.6197795867919922
AFINITOR,lymphopenia,Reflects corresponding adverse drug reaction reports,0,0.48437491059303284
AFINITOR,lymphopenia,lymphopenia neutropenia and thrombocytopenia collectively,1,0.8272799253463745
AFINITOR,lymphopenia,lymphopenia neutropenia and thrombocytopenia,1,0.8567008972167969
AFINITOR,neutropenia,neutropenia and thrombocytopenia collectively as,1,0.834710955619812
AFINITOR,neutropenia,occurred at lower frequency,0,0.5123485326766968
AFINITOR,neutropenia,b Reflects corresponding adverse drug reaction reports,0,0.5183045268058777
AFINITOR,neutropenia,reports of,0,0.5158388614654541
AFINITOR,neutropenia,anemia leukopenia neutropenia and thrombocytopenia collectively as,1,0.7953141927719116
AFINITOR,neutropenia,at lower frequency,0,0.49550074338912964
AFINITOR,neutropenia,at lower frequency L,0,0.49487319588661194
AFINITOR,neutropenia,gday b Reflects corresponding adverse drug reaction,0,0.5197043418884277
AFINITOR,neutropenia,neutropenia and thrombocytopenia collectively,1,0.8454586267471313
AFINITOR,thrombocytopenia,anemia leukopenia lymphopenia neutropenia thrombocytopenia collectively as pancytopenia which,1,0.7265626192092896
AFINITOR,thrombocytopenia,neutropenia and thrombocytopenia collectively,1,0.8530920147895813
AFINITOR,thrombocytopenia,thrombocytopenia collectively,1,0.918791651725769
AFINITOR,thrombocytopenia,leukopenia lymphopenia neutropenia and,0,0.630448579788208
AFINITOR,thrombocytopenia,which occurred,0,0.4816102385520935
AFINITOR,thrombocytopenia,thrombocytopenia collectively as pancytopenia,1,0.8564130067825317
AFINITOR,thrombocytopenia,thrombocytopenia collectively as,1,0.9055345058441162
AFINITOR,pancytopenia,pancytopenia which occurred at,1,0.9238452911376953
AFINITOR,pancytopenia,pancytopenia which occurred at lower,1,0.8773242831230164
AFINITOR,pancytopenia,thrombocytopenia collectively pancytopenia which occurred at,1,0.8749309778213501
AFINITOR,rash,headache The most common Grade,0,0.5059190988540649
AFINITOR,rash,rash diarrhea fatigue edema abdominal pain,1,0.7845514416694641
AFINITOR,diarrhea,and headache The most common Grade adverse rea,0,0.546697199344635
AFINITOR,diarrhea,nausea fever,0,0.6183898448944092
AFINITOR,diarrhea,diarrhea fatigue edema,1,0.7815728783607483
AFINITOR,diarrhea,stomatitis diarrhea fatigue edema abdominal pain nausea,1,0.7276654839515686
AFINITOR,diarrhea,nausea fever and headache The most common,0,0.5968295931816101
AFINITOR,diarrhea,The most common adverse reactions incidence,0,0.5713119506835938
AFINITOR,diarrhea,diarrhea fatigue edema abdominal pain nausea,1,0.7905684113502502
AFINITOR,diarrhea,diarrhea fatigue edema abdominal,1,0.7711358070373535
AFINITOR,fatigue,fatigue edema abdominal pain nausea,1,0.767052412033081
AFINITOR,fatigue,abdominal pain nausea fever,0,0.5895283222198486
AFINITOR,fatigue,adverse reactions incidence,0,0.5470182299613953
AFINITOR,fatigue,rash,0,0.5751873254776001
AFINITOR,fatigue,fatigue edema abdominal pain,1,0.7280406951904297
AFINITOR,edema,fatigue,0,0.6157312393188477
AFINITOR,abdominal pain,abdominal,1,0.7878189086914062
AFINITOR,abdominal pain,reactions incidence,0,0.49017858505249023
AFINITOR,abdominal pain,stomatitis rash diarrhea fatigue abdominal pain nausea fever and headache,1,0.6464460492134094
AFINITOR,abdominal pain,Grade adverse reactions,0,0.5469999313354492
AFINITOR,abdominal pain,diarrhea fatigue abdominal pain,1,0.8101983070373535
AFINITOR,abdominal pain,most common Grade adverse reactions incidence,0,0.5271347761154175
AFINITOR,abdominal pain,rash diarrhea fatigue abdominal,1,0.7206062078475952
AFINITOR,nausea,nausea fever and,1,0.8529201745986938
AFINITOR,nausea,incidence were,0,0.6237236857414246
AFINITOR,nausea,nausea,1,1.0
AFINITOR,nausea,fatigue edema abdominal nausea fever and headache The most,1,0.7451866865158081
AFINITOR,nausea,edema abdominal nausea,1,0.7962197661399841
AFINITOR,nausea,nausea fever and headache The most,1,0.7867326736450195
AFINITOR,nausea,diarrhea fatigue edema abdominal nausea fever and headache,1,0.7168716192245483
AFINITOR,nausea,edema abdominal nausea fever and headache The most,1,0.7378882169723511
AFINITOR,fever,Grade,0,0.5326350927352905
AFINITOR,fever,fever,1,1.0
AFINITOR,fever,were stomatitis rash diarrhea fatigue edema,0,0.591862678527832
AFINITOR,fever,fatigue edema abdominal pain fever and headache The most,1,0.7119640111923218
AFINITOR,fever,fever and headache,1,0.826650857925415
AFINITOR,fever,fever and headache The most,1,0.7825360894203186
AFINITOR,headache,headache The,1,0.9590147733688354
AFINITOR,headache,pain nausea fever and,0,0.6860713362693787
AFINITOR,headache,fever,0,0.6312446594238281
AFINITOR,headache,adverse,0,0.5728578567504883
AFINITOR,headache,abdominal pain nausea,0,0.6171289086341858
AFINITOR,diarrhea,er and headache The most common Grade adverse reactions,0,0.547374427318573
AFINITOR,diarrhea,diarrhea The most,1,0.8665586113929749
AFINITOR,diarrhea,were stomatitis and,0,0.5543414354324341
AFINITOR,decreased hemoglobin,were stomatitis and,0,0.47678279876708984
AFINITOR,decreased hemoglobin,decreased hemoglobin hyperglycemia alkaline phosphatase increased,1,0.7588742971420288
AFINITOR,decreased hemoglobin,decreased hemoglobin hyperglycemia alkaline phosphatase,1,0.7766121625900269
AFINITOR,hyperglycemia,hyperglycemia alkaline phosphatase,1,0.7614182233810425
AFINITOR,hyperglycemia,abnormalities incidence were decreased hyperglycemia alkaline phosphatase increased hypercholesterolemia bicarbonate,1,0.6900909543037415
AFINITOR,hyperglycemia,common laboratory abnormalities incidence were decreased,0,0.5301703810691833
AFINITOR,hyperglycemia,hyperglycemia alkaline phosphatase increased,1,0.7751755118370056
AFINITOR,hyperglycemia,hyperglycemia alkaline,1,0.7969017028808594
AFINITOR,hyperglycemia,bicarbonate decreased,0,0.49785760045051575
AFINITOR,hyperglycemia,abnormalities incidence were decreased hyperglycemia,1,0.7789732813835144
AFINITOR,hyperglycemia,hyperglycemia,1,1.0000001192092896
AFINITOR,hypercholesterolemia,phosphatase hypercholesterolemia,1,0.8317849040031433
AFINITOR,hypercholesterolemia,hyperglycemia,1,0.7315106987953186
AFINITOR,hypercholesterolemia,decreased hemoglobin hyperglycemia alkaline phosphatase,0,0.6284865736961365
AFINITOR,hypercholesterolemia,alkaline phosphatase increased,0,0.5727304220199585
AFINITOR,hypercholesterolemia,hypercholesterolemia bicarbonate,1,0.7876736521720886
AFINITOR,hypercholesterolemia,lities incidence were decreased hemoglobin hyperglycemia,0,0.6579456329345703
AFINITOR,hypercholesterolemia,hypercholesterolemia,1,0.9999999403953552
AFINITOR,increased aspartate transaminase,hypercholesterolemia bicarbonate decreased increased aspartate transaminase AST The most common Grade,1,0.7757824063301086
AFINITOR,increased aspartate transaminase,hypercholesterolemia,1,0.5777133703231812
AFINITOR,increased aspartate transaminase,abnormalities,0,0.5501972436904907
AFINITOR,increased aspartate transaminase,hypercholesterolemia bicarbonate decreased increased aspartate transaminase AST The most common,1,0.7918920516967773
AFINITOR,increased aspartate transaminase,aspartate transaminase,1,0.9148328304290771
AFINITOR,increased aspartate transaminase,increased aspartate transaminase AST The most common Grade,1,0.8975843191146851
AFINITOR,increased aspartate transaminase,increased aspartate transaminase AST The,1,0.9881011247634888
AFINITOR,increased aspartate transaminase,phosphatase increased,0,0.7174636125564575
AFINITOR,increased aspartate transaminase,aspartate transaminase AST,1,0.8555585741996765
AFINITOR,increased aspartate transaminase,decreased increased aspartate transaminase,1,0.9291899800300598
AFINITOR,hyperglycemia,hyperglycemia lymphopenia decreased hemoglobin hypophosphatemia,1,0.7344598770141602
AFINITOR,hyperglycemia,hyperglycemia lymphopenia decreased hemoglobin,1,0.7580901980400085
AFINITOR,lymphopenia,were lymphopenia decreased hemoglobin hypophosphatemia increased,1,0.8130262494087219
AFINITOR,lymphopenia,hyperglycemia lymphopenia decreased hemoglobin,1,0.8071430325508118
AFINITOR,lymphopenia,lymphopenia decreased hemoglobin hypophosphatemia increased alkaline,1,0.8154237866401672
AFINITOR,lymphopenia,lymphopenia,1,1.000000238418579
AFINITOR,decreased hemoglobin,increased aspartate,0,0.5589732527732849
AFINITOR,decreased hemoglobin,laboratory,0,0.5621036887168884
AFINITOR,decreased hemoglobin,were hyperglycemia lymphopenia,0,0.6300768852233887
AFINITOR,decreased hemoglobin,lymphopenia,0,0.6177047491073608
AFINITOR,decreased hemoglobin,decreased hemoglobin,1,1.000000238418579
AFINITOR,decreased hemoglobin,were hyperglycemia decreased hemoglobin hypophosphatemia,1,0.7771947979927063
AFINITOR,hypophosphatemia,hypophosphatemia,1,1.0000001192092896
AFINITOR,hypophosphatemia,hypophosphatemia increased alkaline phosphatase neutropenia increased,1,0.8061078786849976
AFINITOR,hypophosphatemia,hypophosphatemia increased alkaline phosphatase neutropenia,1,0.8211902379989624
AFINITOR,hypophosphatemia,decreased hypophosphatemia increased alkaline phosphatase neutropenia increased,1,0.8046897649765015
AFINITOR,hypophosphatemia,hyperglycemia lymphopenia decreased hypophosphatemia increased alkaline phosphatase neutropenia increased,1,0.7405451536178589
AFINITOR,hypophosphatemia,lymphopenia decreased hypophosphatemia increased alkaline phosphatase neutropenia increased,1,0.7807641625404358
AFINITOR,hypophosphatemia,were hyperglycemia lymphopenia decreased hypophosphatemia increased alkaline phosphatase neutropenia,1,0.7457174062728882
AFINITOR,increased alkaline phosphatase,increased alkaline phosphatase neutropenia increased aspartate transaminase,1,0.8545981049537659
AFINITOR,increased alkaline phosphatase,hypophosphatemia increased alkaline phosphatase neutropenia,1,0.8262952566146851
AFINITOR,increased alkaline phosphatase,hemoglobin increased alkaline,1,0.7706204652786255
AFINITOR,increased alkaline phosphatase,increased alkaline phosphatase neutropenia increased,1,0.8929048776626587
AFINITOR,increased alkaline phosphatase,hemoglobin increased,1,0.6827870607376099
AFINITOR,increased alkaline phosphatase,increased aspartate transaminase,0,0.7427520751953125
AFINITOR,increased alkaline phosphatase,decreased,0,0.49548184871673584
AFINITOR,increased alkaline phosphatase,incidence were,0,0.5395711660385132
AFINITOR,increased alkaline phosphatase,AST potassium decreased,0,0.596165657043457
AFINITOR,increased alkaline phosphatase,lymphopenia decreased hemoglobin increased,1,0.6186444759368896
AFINITOR,neutropenia,hypophosphatemia increased alkaline,0,0.5476356744766235
AFINITOR,neutropenia,neutropenia increased aspartate transaminase,1,0.7717779874801636
AFINITOR,neutropenia,decreased hemoglobin hypophosphatemia,0,0.5975081920623779
AFINITOR,neutropenia,decreased hemoglobin,0,0.5973868370056152
AFINITOR,neutropenia,thrombocytopenia,0,0.6994499564170837
AFINITOR,neutropenia,and thrombocytopenia Deaths during,0,0.666431188583374
AFINITOR,increased aspartate transaminase,increased aspartate transaminase AST potassium decreased,1,0.8685296773910522
AFINITOR,increased aspartate transaminase,phosphatase,0,0.5824973583221436
AFINITOR,increased aspartate transaminase,decreased and thrombocytopenia Deaths during doubleblind treatment where an ad,0,0.5793452262878418
AFINITOR,increased aspartate transaminase,increased aspartate transaminase AST potassium decreased and thrombocytopenia,1,0.8321050405502319
AFINITOR,thrombocytopenia,potassium decreased thrombocytopenia Deaths during doubleblind,1,0.7701835036277771
AFINITOR,thrombocytopenia,increased aspartate transaminase AST potassium decreased and thrombocytopenia,1,0.7829385995864868
AFINITOR,thrombocytopenia,potassium decreased thrombocytopenia Deaths during doubleblind treatment where,1,0.7655267715454102
AFINITOR,death,death on the,1,0.8028093576431274
AFINITOR,death,placebo Causes death on,1,0.6708290576934814
AFINITOR,death,death on the AFINITOR arm,1,0.6943091750144958
AFINITOR,death,death on,1,0.8468190431594849
AFINITOR,death,death on the AFINITOR arm included,1,0.6927791833877563
AFINITOR,acute renal failure,of the acute renal failure acute respiratory distress cardiac,1,0.853495717048645
AFINITOR,acute renal failure,death on the AFINITOR arm,1,0.5513392090797424
AFINITOR,acute renal failure,the following,0,0.5146306157112122
AFINITOR,acute renal failure,acute,1,0.6979737877845764
AFINITOR,acute renal failure,renal failure,1,0.8923428058624268
AFINITOR,acute renal failure,renal failure acute respiratory,1,0.8948463201522827
AFINITOR,acute respiratory distress,acute renal,0,0.6853498220443726
AFINITOR,acute respiratory distress,respiratory distress cardiac,1,0.8298266530036926
AFINITOR,acute respiratory distress,on the AFINITOR arm included one case,0,0.44441837072372437
AFINITOR,acute respiratory distress,case,0,0.49107953906059265
AFINITOR,acute respiratory distress,following acute renal failure,0,0.6898463368415833
AFINITOR,acute respiratory distress,following acute renal acute respiratory distress cardiac arrest,1,0.7845926284790039
AFINITOR,acute respiratory distress,and sepsis There,0,0.6700879335403442
AFINITOR,acute respiratory distress,pneumonia and sepsis There,0,0.6771886348724365
AFINITOR,acute respiratory distress,auses of death on the AFINITOR,0,0.5729104280471802
AFINITOR,cardiac arrest,failure pneumonia and sepsis There,0,0.5600753426551819
AFINITOR,death,due to,0,0.5772066116333008
AFINITOR,death,death cause,1,0.8193022012710571
AFINITOR,death,pneumonia and sepsis There was one death due to,0,0.6639922261238098
AFINITOR,death,death cause unknown hepatic,1,0.6760208606719971
AFINITOR,death,to pulmonary embol,0,0.5447289943695068
AFINITOR,hepatic failure,distress cardiac,0,0.5338207483291626
AFINITOR,hepatic failure,and sepsis There was one death due to pulmonary embolism on,0,0.5771186351776123
AFINITOR,hepatic failure,renal,0,0.5642827153205872
AFINITOR,hepatic failure,hepatic failure pneumonia,1,0.8488748073577881
AFINITOR,hepatic failure,cause hepatic,1,0.798211932182312
AFINITOR,hepatic failure,was one,0,0.4940008521080017
AFINITOR,pneumonia,unknown hepatic,0,0.5194793939590454
AFINITOR,pneumonia,death,0,0.6104602813720703
AFINITOR,pneumonia,cause unknown hepatic pneumonia and sepsis There was one,1,0.7061041593551636
AFINITOR,pneumonia,pneumonia and,1,0.9008133411407471
AFINITOR,sepsis,sepsis There was one death,1,0.8295847773551941
AFINITOR,sepsis,on the placebo arm After crossover,0,0.4938242435455322
AFINITOR,sepsis,pneumonia and,0,0.6459786891937256
AFINITOR,death,crossover to openlabel AFINITOR there,0,0.4601534307003021
AFINITOR,death,cardiac arrest death cause unknown hepatic failure pneumonia and,0,0.604080855846405
AFINITOR,death,and sepsis There was death due to pulmonary embolism on,1,0.6484595537185669
AFINITOR,death,There was death,1,0.8722158670425415
AFINITOR,deaths,there were three,0,0.6057455539703369
AFINITOR,deaths,patient with insulinoma,0,0.43178674578666687
AFINITOR,deaths,deaths one due,1,0.8255040645599365
AFINITOR,deaths,deaths one due to hypoglycemia and,1,0.7432957887649536
AFINITOR,hypoglycemia,hypoglycemia and cardiac,1,0.8715183138847351
AFINITOR,hypoglycemia,three additional deaths one due to,0,0.507161557674408
AFINITOR,hypoglycemia,hypoglycemia,1,1.0
AFINITOR,hypoglycemia,were three additional deaths,0,0.48354995250701904
AFINITOR,hypoglycemia,hypoglycemia and cardiac arrest,1,0.8374019861221313
AFINITOR,hypoglycemia,to,0,0.5124176144599915
AFINITOR,hypoglycemia,AFINITOR there were three additional,0,0.42165783047676086
AFINITOR,hypoglycemia,hypoglycemia and cardiac arrest in,1,0.8385236263275146
AFINITOR,cardiac arrest,cardiac arrest in,1,0.9715728163719177
AFINITOR,cardiac arrest,openlabel AFINITOR there were three additional deaths one due to,0,0.6329421997070312
AFINITOR,cardiac arrest,due to,0,0.5078161954879761
AFINITOR,cardiac arrest,hypoglycemia cardiac arrest in a,1,0.822948694229126
AFINITOR,cardiac arrest,to hypoglycemia cardiac arrest in,1,0.8321933746337891
AFINITOR,cardiac arrest,patient with insulinoma one due to myocardial infarction with congestive heart failure and,0,0.5831706523895264
AFINITOR,myocardial infarction,in a patient with insulinoma,0,0.5214956402778625
AFINITOR,myocardial infarction,insulinoma one due myocardial infarction,1,0.7769483327865601
AFINITOR,myocardial infarction,myocardial infarction with congestive,1,0.8742104172706604
AFINITOR,myocardial infarction,The rates of treatmentemergent,0,0.5375620126724243
AFINITOR,myocardial infarction,due,0,0.526407778263092
AFINITOR,myocardial infarction,congestive heart,0,0.6557179689407349
AFINITOR,congestive heart failure,congestive heart failure and the,1,0.9598935842514038
AFINITOR,congestive heart failure,congestive heart,0,0.8908698558807373
AFINITOR,congestive heart failure,other due to sudden death The rates of treatmentemergent,0,0.6135539412498474
AFINITOR,sudden death,of treatmentemergent,0,0.5375316143035889
AFINITOR,sudden death,sudden death The rates,1,0.8465667963027954
AFINITOR,sudden death,congestive heart failure and,0,0.6430286169052124
AFINITOR,sudden death,treatmentemergent adverse events resulting,0,0.5780709981918335
AFINITOR,renal failure,placebo patients renal failure,1,0.7870709896087646
AFINITOR,renal failure,renal failure occurred in six patients,1,0.8119034767150879
AFINITOR,renal failure,everolimus patients,0,0.5776424407958984
AFINITOR,renal failure,of placebo patients renal,1,0.7000654935836792
AFINITOR,renal failure,renal failure occurred in six,1,0.8332551717758179
AFINITOR,renal failure,renal,1,0.8547979593276978
AFINITOR,renal failure,renal failure occurred,1,0.9300718307495117
AFINITOR,renal failure,and of placebo patients renal failure occurred in six,1,0.7605200409889221
AFINITOR,renal failure,placebo patients renal,1,0.7045414447784424
AFINITOR,pulmonary embolus,pulmonary embolus in the,1,0.9326447248458862
AFINITOR,thrombosis,thrombosis in the everolimus arm and,1,0.7809432744979858
AFINITOR,thrombosis,patients with,0,0.6239563822746277
AFINITOR,thrombosis,compares,0,0.5159415006637573
AFINITOR,thrombosis,thrombosis in the everolimus,1,0.8070096373558044
AFINITOR,thrombosis,patients thrombosis,1,0.8630977869033813
AFINITOR,thrombosis,arm and two in the placebo arm Table compares the incidence of treatmente,0,0.5236282348632812
AFINITOR,thrombosis,in the placebo arm,0,0.5195637941360474
AFINITOR,thrombosis,arm as,0,0.5241661071777344
AFINITOR,stomatitis,gingival,0,0.6668239831924438
AFINITOR,stomatitis,lip,0,0.6311966180801392
AFINITOR,stomatitis,stomatitis aphthous stomatitis,1,0.8488844633102417
AFINITOR,stomatitis,Version a stomatitis aphthous stomatitis,1,0.8225014209747314
AFINITOR,stomatitis,stomatitis aphthous stomatitis gingival painswellingulceration,1,0.8210623264312744
AFINITOR,stomatitis,Patients with Advanced PNET Grading according,0,0.49421656131744385
AFINITOR,stomatitis,stomatitis aphthous stomatitis gingival painswellingulceration glossitis,1,0.8323495388031006
AFINITOR,aphthous stomatitis,PNET Grading according to,0,0.4911366403102875
AFINITOR,aphthous stomatitis,Version a,0,0.4920996427536011
AFINITOR,aphthous stomatitis,a Includes aphthous stomatitis gingival painswellingulceration glossitis glossodynia lip,1,0.8509114980697632
AFINITOR,aphthous stomatitis,aphthous stomatitis gingival painswellingulceration glossitis,1,0.8782387971878052
AFINITOR,aphthous stomatitis,ulceration mouth,0,0.7177821397781372
AFINITOR,aphthous stomatitis,Version a Includes aphthous stomatitis gingival painswellingulceration glossitis glossodynia,1,0.8242297768592834
AFINITOR,gingival pain,aphthous,0,0.6493657827377319
AFINITOR,gingival pain,gingival pain swellingulceration glossitis glossodynia lip ulceration,1,0.8514770269393921
AFINITOR,glossitis,ulceration mouth ulceration tongue ulceration and,0,0.7571703195571899
AFINITOR,glossitis,stomatitis aphthous stomatitis gingival painswellingulceration,0,0.6633790731430054
AFINITOR,glossitis,gingival glossitis glossodynia lip,1,0.8236466646194458
AFINITOR,glossitis,glossitis glossodynia,1,0.8533192276954651
AFINITOR,glossitis,aphthous stomatitis gingival glossitis glossodynia lip ulceration mouth,1,0.7695926427841187
AFINITOR,glossitis,mouth ulceration tongue ulceration and mucosal inflammation,0,0.779251754283905
AFINITOR,glossitis,stomatitis aphthous stomatitis gingival glossitis glossodynia lip,1,0.7729759812355042
AFINITOR,glossitis,glossitis glossodynia lip,1,0.830115795135498
AFINITOR,glossodynia,painswellingulceration glossitis,0,0.7244257926940918
AFINITOR,glossodynia,ulceration mouth,0,0.5770812034606934
AFINITOR,glossodynia,inflammation b Includes diarr,0,0.5343506932258606
AFINITOR,glossodynia,glossodynia lip ulceration mouth ulceration,1,0.8273707628250122
AFINITOR,glossodynia,glossodynia lip,1,0.8859336972236633
AFINITOR,glossodynia,glossodynia lip ulceration mouth ulceration tongue,1,0.844350278377533
AFINITOR,glossodynia,Includes stomatitis aphthous stomatitis gingival,0,0.5884528756141663
AFINITOR,glossodynia,glossodynia lip ulceration mouth,1,0.8563174605369568
AFINITOR,glossodynia,gingival painswellingulceration glossitis,0,0.7397725582122803
AFINITOR,lip ulceration,stomatitis gingival painswellingulceration,0,0.7025563716888428
AFINITOR,lip ulceration,lip ulceration mouth,1,0.9613405466079712
AFINITOR,lip ulceration,painswellingulceration glossitis lip,1,0.8235037326812744
AFINITOR,lip ulceration,ncludes stomatitis aphthous stomatitis,0,0.681767463684082
AFINITOR,lip ulceration,lip ulceration mouth ulceration,1,0.9505974054336548
AFINITOR,lip ulceration,lip ulceration mouth ulceration tongue ulceration,1,0.8869847059249878
AFINITOR,lip ulceration,ulceration,0,0.8425407409667969
AFINITOR,lip ulceration,gingival painswellingulceration glossitis lip ulceration,1,0.829350471496582
AFINITOR,mouth ulceration,painswellingulceration,0,0.7124220728874207
AFINITOR,mouth ulceration,mouth ulceration tongue ulceration,1,0.9124191999435425
AFINITOR,tongue ulceration,lip ulceration mouth tongue ulceration,1,0.9418460130691528
AFINITOR,tongue ulceration,mouth ulceration tongue ulceration,1,0.9734048843383789
AFINITOR,tongue ulceration,tongue ulceration and mucosal inflammation b Includes,1,0.8889745473861694
AFINITOR,tongue ulceration,mouth tongue ulceration,1,0.9734698534011841
AFINITOR,tongue ulceration,mouth tongue ulceration and mucosal inflammation,1,0.9230802655220032
AFINITOR,tongue ulceration,tongue ulceration,1,0.9999998807907104
AFINITOR,tongue ulceration,ulceration mouth tongue,1,0.9672468900680542
AFINITOR,mucosal inflammation,mucosal inflammation b Includes diarrhea,1,0.8480113744735718
AFINITOR,mucosal inflammation,ulceration mucosal inflammation b,1,0.8570519685745239
AFINITOR,mucosal inflammation,mucosal inflammation b Includes diarrhea enteritis enterocolitis,1,0.8548711538314819
AFINITOR,mucosal inflammation,ulceration tongue ulceration mucosal inflammation b,1,0.8159201741218567
AFINITOR,mucosal inflammation,glossitis glossodynia,0,0.6489329934120178
AFINITOR,mucosal inflammation,and,0,0.4714685082435608
AFINITOR,mucosal inflammation,mouth ulceration tongue ulceration mucosal inflammation,1,0.8366804122924805
AFINITOR,enteritis,enteritis enterocolitis,1,0.9182478189468384
AFINITOR,enteritis,enteritis enterocolitis colitis,1,0.9077725410461426
AFINITOR,enteritis,steatorrhea c Includes pneumonitis,0,0.5398154258728027
AFINITOR,enteritis,enteritis enterocolitis colitis defecation urgency and,1,0.8111166954040527
AFINITOR,enteritis,ulceration tongue ulceration and mucosal inflammation b,0,0.6380261182785034
AFINITOR,enteritis,Includes enteritis enterocolitis colitis defecation,1,0.8042704463005066
AFINITOR,enterocolitis,steatorrhea c,0,0.590253472328186
AFINITOR,enterocolitis,Includes diarrhea enteritis,0,0.7483766078948975
AFINITOR,enterocolitis,and,0,0.5423958897590637
AFINITOR,enterocolitis,steatorrhea c Includes pneumonitis,0,0.5903019905090332
AFINITOR,enterocolitis,enterocolitis colitis defecation urgency,1,0.7957794070243835
AFINITOR,enterocolitis,colitis defecation,0,0.7003219723701477
AFINITOR,colitis,colitis defecation urgency,1,0.7721154093742371
AFINITOR,colitis,colitis defecation,1,0.8274866938591003
AFINITOR,colitis,c Includes pneumonitis,0,0.5888463258743286
AFINITOR,colitis,colitis defecation urgency and,1,0.7790319919586182
AFINITOR,colitis,interstitial lung,0,0.5937033891677856
AFINITOR,colitis,colitis,1,0.9999999403953552
AFINITOR,defecation urgency,and steatorrhea c Includes pneumonitis interstitial lung disease,0,0.511142909526825
AFINITOR,defecation urgency,enteritis enterocolitis defecation urgency,1,0.893142819404602
AFINITOR,steatorrhea,steatorrhea c Includes pneumonitis,1,0.7684190273284912
AFINITOR,steatorrhea,steatorrhea c Includes pneumonitis interstitial,1,0.7691695690155029
AFINITOR,steatorrhea,steatorrhea c,1,0.8617957830429077
AFINITOR,steatorrhea,urgency,0,0.5634765625
AFINITOR,steatorrhea,colitis,0,0.5399638414382935
AFINITOR,steatorrhea,steatorrhea,1,0.9999999403953552
AFINITOR,pneumonitis,pneumonitis interstitial lung disease,1,0.8322185277938843
AFINITOR,pneumonitis,and steatorrhea c pneumonitis interstitial lung,1,0.7555348873138428
AFINITOR,pneumonitis,interstitial,0,0.5313053131103516
AFINITOR,pneumonitis,disease pulmonary fibrosis and,0,0.6701955199241638
AFINITOR,pneumonitis,pneumonitis,1,1.0000001192092896
AFINITOR,pneumonitis,pneumonitis interstitial lung disease pulmonary,1,0.8376653790473938
AFINITOR,pneumonitis,steatorrhea c pneumonitis interstitial lung disease pulmonary fibrosis,1,0.7165312170982361
AFINITOR,pneumonitis,udes diarrhea enteritis enterocolitis colitis defecation urgency and steatorrhea,0,0.4912309944629669
AFINITOR,interstitial lung disease,Includes interstitial lung disease pulmonary fibrosis and restrictive pulmonary,1,0.8753728270530701
AFINITOR,interstitial lung disease,udes diarrhea enteritis enterocolitis colitis defecation urgency and steatorrhea,0,0.5434896349906921
AFINITOR,interstitial lung disease,interstitial,1,0.7247503399848938
AFINITOR,interstitial lung disease,pulmonary disease,0,0.8263731002807617
AFINITOR,pulmonary fibrosis,N Placebo N,0,0.5172452330589294
AFINITOR,pulmonary fibrosis,pulmonary fibrosis and restrictive,1,0.8470360040664673
AFINITOR,pulmonary fibrosis,steatorrhea c Includes pneumonitis interstitial lung disease,0,0.6881591081619263
AFINITOR,restrictive pulmonary disease,lung disease pulmonary fibrosis restrictive pulmonary disease,1,0.9221161603927612
AFINITOR,restrictive pulmonary disease,fibrosis restrictive pulmonary disease,1,0.9149520993232727
AFINITOR,Cough,Cough productive,1,0.8452561497688293
AFINITOR,Cough,Cough productive cough,1,0.8548974990844727
AFINITOR,irregular menstruation,irregular menstruation occurred in of AFINITORtreated,1,0.9358333349227905
AFINITOR,irregular menstruation,patients aged to irregular,1,0.6978931427001953
AFINITOR,irregular menstruation,none of,0,0.4317159950733185
AFINITOR,irregular menstruation,of AFINITORtreated females and none of the females in,0,0.5788449048995972
AFINITOR,irregular menstruation,patients aged to years,0,0.5266717076301575
AFINITOR,irregular menstruation,aged to irregular menstruation occurred in,1,0.8994764685630798
AFINITOR,irregular menstruation,female patients aged to irregular menstruation occurred in,1,0.8953489065170288
AFINITOR,Lymphocytes decreased,decreased,0,0.7507877349853516
AFINITOR,Lymphocytes decreased,Hemoglobin decreased,0,0.732375979423523
AFINITOR,Lymphocytes decreased,Hemoglobin Lymphocytes decreased,1,0.8890606164932251
AFINITOR,Lymphocytes decreased,Lymphocytes decreased Platelets,1,0.865298867225647
AFINITOR,Lymphocytes decreased,Hemoglobin,0,0.5505038499832153
AFINITOR,Lymphocytes decreased,Lymphocytes decreased Platelets decreased,1,0.894149899482727
AFINITOR,Lymphocytes decreased,Hemoglobin Lymphocytes decreased Platelets,1,0.7954325079917908
AFINITOR,Platelets decreased,Lymphocytes Platelets decreased,1,0.9036957621574402
AFINITOR,WBC decreased,WBC decreased,1,1.000000238418579
AFINITOR,WBC decreased,WBC decreased Neutrophils,1,0.8989295959472656
AFINITOR,Alkaline phosphatase increased,nical Alkaline phosphatase,1,0.8500872850418091
AFINITOR,Alkaline phosphatase increased,Alkaline phosphatase increased Glucose fasting inc,1,0.8592789173126221
AFINITOR,Alkaline phosphatase increased,Alkaline phosphatase increased,1,1.0
AFINITOR,Alkaline phosphatase increased,Glucose fasting inc,0,0.4915669560432434
AFINITOR,Alkaline phosphatase increased,nical Alkaline phosphatase increased Glucose fasting,1,0.8329510688781738
AFINITOR,Alkaline phosphatase increased,Glucose fasting,0,0.5304641723632812
AFINITOR,Alkaline phosphatase increased,phosphatase increased Glucose fasting inc,1,0.7743973731994629
AFINITOR,Cholesterol increased,e fasting Cholesterol,1,0.767754077911377
AFINITOR,Cholesterol increased,fasting increased,0,0.6768692135810852
AFINITOR,Cholesterol increased,e fasting Cholesterol increased Bicarbonate decreased,1,0.7483640909194946
AFINITOR,Cholesterol increased,Cholesterol increased Bicarbonate,1,0.8324870467185974
AFINITOR,Cholesterol increased,increased,0,0.738486647605896
AFINITOR,Cholesterol increased,Cholesterol increased Bicarbonate decreased,1,0.7819037437438965
AFINITOR,Cholesterol increased,fasting Cholesterol,1,0.7941842675209045
AFINITOR,Cholesterol increased,Cholesterol increased,1,0.9999997615814209
AFINITOR,Bicarbonate decreased,Bicarbonate decreased,1,1.000000238418579
AFINITOR,Phosphate decreased,increased,0,0.5291976928710938
AFINITOR,Phosphate decreased,ALT,0,0.4701351523399353
AFINITOR,Phosphate decreased,Phosphate decreased Triglycerides increas,1,0.8102846145629883
AFINITOR,Phosphate decreased,Phosphate decreased,1,0.9999999403953552
AFINITOR,Triglycerides increased,Phosphate Triglycerides increased,1,0.8720508217811584
AFINITOR,Triglycerides increased,decreased,0,0.47621962428092957
AFINITOR,Triglycerides increased,Phosphate decreased,0,0.47221511602401733
AFINITOR,Triglycerides increased,Triglycerides,1,0.8782468438148499
AFINITOR,Calcium decreased,Calcium decreased,1,1.0000001192092896
AFINITOR,Calcium decreased,Triglycerides,1,0.5070992708206177
AFINITOR,Calcium decreased,Calcium decreased Potassium,1,0.8901567459106445
AFINITOR,Calcium decreased,Calcium,1,0.8159812092781067
AFINITOR,Potassium decreased,Calcium Potassium,1,0.7328763008117676
AFINITOR,Potassium decreased,Calcium Potassium decreased Creatinine increased,1,0.7945693135261536
AFINITOR,Potassium decreased,Calcium,0,0.5595667362213135
AFINITOR,Potassium decreased,decreased,0,0.7782597541809082
AFINITOR,Creatinine increased,Potassium decreased,0,0.6061359643936157
AFINITOR,Creatinine increased,Creatinine increased Sodium decreased,1,0.8321418762207031
AFINITOR,Creatinine increased,Creatinine increased Sodium,1,0.8844039440155029
AFINITOR,Albumin decreased,Sodium Albumin decreased,1,0.948006272315979
AFINITOR,Albumin decreased,Creatinine increased Sodium,1,0.5952523946762085
AFINITOR,Albumin decreased,Albumin decreased,1,0.9999998807907104
AFINITOR,Bilirubin increased,Albumin Bilirubin increased,1,0.9458785057067871
AFINITOR,Bilirubin increased,Albumin decreased,1,0.5910343527793884
AFINITOR,Bilirubin increased,Bilirubin,1,0.8944711685180664
AFINITOR,Bilirubin increased,Albumin decreased,0,0.5910343527793884
AFINITOR,stomatitis,stomatitis infections asthenia fatigue cough and,1,0.8174782395362854
AFINITOR,stomatitis,stomatitis infections asthenia fatigue,1,0.802380383014679
AFINITOR,stomatitis,placebo The most common adverse,0,0.5276454091072083
AFINITOR,stomatitis,most common Grade adverse reactions,0,0.5297290086746216
AFINITOR,stomatitis,common adverse reactions incidence stomatitis infections,1,0.8206943273544312
AFINITOR,infections,asthenia fatigue cough and,0,0.6014816761016846
AFINITOR,infections,incidence were infections asthenia fatigue cough and diarrhea,1,0.710322380065918
AFINITOR,infections,reactions incidence were infections asthenia,1,0.7221341133117676
AFINITOR,asthenia,incidence,0,0.578122615814209
AFINITOR,asthenia,asthenia fatigue cough and,1,0.7484970092773438
AFINITOR,asthenia,asthenia fatigue,1,0.8543986082077026
AFINITOR,asthenia,asthenia fatigue cough and diarrhea,1,0.7253689765930176
AFINITOR,asthenia,asthenia fatigue cough and diarrhea The,1,0.7242287397384644
AFINITOR,fatigue,fatigue cough and diarrhea The,1,0.771748960018158
AFINITOR,cough,reactions incidence were infections,0,0.5715522170066833
AFINITOR,cough,were stomatitis infections asthenia cough and diarrhea The most,1,0.7025917768478394
AFINITOR,cough,and diarrhea,0,0.5745305418968201
AFINITOR,cough,The most common Grade,0,0.48115673661231995
AFINITOR,diarrhea,asthenia fatigue cough diarrhea The most common Grade adverse,1,0.6941933631896973
AFINITOR,diarrhea,The most common Grade,0,0.499578058719635
AFINITOR,diarrhea,diarrhea The most common,1,0.8175173997879028
AFINITOR,infections,infections dyspnea,1,0.7497371435165405
AFINITOR,infections,infections dyspnea fatigue stomatitis dehydration pneumonitis,1,0.7183746099472046
AFINITOR,infections,most common Grade adverse reactions incidence,0,0.5769739151000977
AFINITOR,dyspnea,adverse reactions incidence were dyspnea fatigue stomatitis,1,0.7023778557777405
AFINITOR,dyspnea,infections dyspnea fatigue stomatitis dehydration pneumonitis,1,0.7383594512939453
AFINITOR,dyspnea,dyspnea fatigue stomatitis,1,0.7810519933700562
AFINITOR,dyspnea,dyspnea fatigue,1,0.8910001516342163
AFINITOR,dyspnea,diarrhea The most common Grade adverse reactions incidence,0,0.5134949088096619
AFINITOR,dyspnea,fatigue stomatitis dehydration pneumonitis abdominal pain and asthenia,0,0.6098436117172241
AFINITOR,fatigue,infections dyspnea,0,0.5895488262176514
AFINITOR,fatigue,fatigue stomatitis dehydration,1,0.7555906772613525
AFINITOR,fatigue,infections fatigue stomatitis,1,0.7638758420944214
AFINITOR,fatigue,abdominal pain and asthenia,0,0.6260661482810974
AFINITOR,fatigue,fatigue stomatitis dehydration pneumonitis,1,0.7565406560897827
AFINITOR,fatigue,The,0,0.5721358060836792
AFINITOR,stomatitis,adverse,0,0.5392824411392212
AFINITOR,stomatitis,dyspnea stomatitis dehydration pneumonitis abdominal pain and,1,0.6988239288330078
AFINITOR,stomatitis,stomatitis dehydration pneumonitis abdominal pain,1,0.7537389993667603
AFINITOR,stomatitis,stomatitis dehydration,1,0.8363314867019653
AFINITOR,stomatitis,were infections dyspnea fatigue,0,0.5268392562866211
AFINITOR,stomatitis,pneumonitis abdominal pain and asthenia The most common,0,0.5344483852386475
AFINITOR,dehydration,dyspnea fatigue dehydration pneumonitis abdominal,1,0.7592477798461914
AFINITOR,dehydration,pneumonitis abdominal pain and asthenia The most common,0,0.507664680480957
AFINITOR,dehydration,laboratory,0,0.538512110710144
AFINITOR,dehydration,were,0,0.5734970569610596
AFINITOR,dehydration,dehydration pneumonitis abdominal pain and,1,0.7652536034584045
AFINITOR,dehydration,dehydration pneumonitis abdominal pain,1,0.7611041069030762
AFINITOR,dehydration,and asthenia The most common laboratory,0,0.5322557687759399
AFINITOR,pneumonitis,abdominal pain,0,0.5119515657424927
AFINITOR,pneumonitis,stomatitis pneumonitis abdominal,1,0.7473965883255005
AFINITOR,asthenia,anemia hypercholesterolemia,0,0.5412584543228149
AFINITOR,asthenia,pneumonitis abdominal pain asthenia,1,0.7150661945343018
AFINITOR,asthenia,pain asthenia The,1,0.824270486831665
AFINITOR,asthenia,pneumonitis abdominal pain asthenia The most common laboratory,1,0.6657260656356812
AFINITOR,asthenia,anemia,0,0.6054657697677612
AFINITOR,asthenia,asthenia The most common,1,0.8552014231681824
AFINITOR,asthenia,asthenia The,1,0.9730668067932129
AFINITOR,asthenia,asthenia,1,1.0000001192092896
AFINITOR,asthenia,common laboratory abnormalities incidence were,0,0.5193628072738647
AFINITOR,anemia,anemia hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and,1,0.7399755716323853
AFINITOR,anemia,anemia hypercholesterolemia hypertriglyceridemia,1,0.7660443186759949
AFINITOR,anemia,and,0,0.5601953864097595
AFINITOR,anemia,anemia hypercholesterolemia hypertriglyceridemia hyperglycemia,1,0.7670913934707642
AFINITOR,anemia,tis abdominal pain and asthenia The most common laboratory abnormalities,0,0.6054019331932068
AFINITOR,anemia,hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and,0,0.6036946773529053
AFINITOR,anemia,and asthenia The most common laboratory,0,0.5858088135719299
AFINITOR,hypercholesterolemia,The most common,0,0.5410475730895996
AFINITOR,hypercholesterolemia,abnormalities incidence were hypercholesterolemia,1,0.8510770797729492
AFINITOR,hypercholesterolemia,and,0,0.5229741334915161
AFINITOR,hypercholesterolemia,hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and increased,1,0.8147323131561279
AFINITOR,hypercholesterolemia,were anemia,0,0.5580772161483765
AFINITOR,hypercholesterolemia,incidence were hypercholesterolemia hypertriglyceridemia hyperglycemia,1,0.8030295372009277
AFINITOR,hypercholesterolemia,were hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and,1,0.797716498374939
AFINITOR,hypercholesterolemia,hypercholesterolemia hypertriglyceridemia,1,0.8665739297866821
AFINITOR,hyperglycemia,anemia hypercholesterolemia hyperglycemia lymphopenia and increased creatinine,1,0.7069331407546997
AFINITOR,hyperglycemia,hypercholesterolemia hypertriglyceridemia,1,0.728018045425415
AFINITOR,hyperglycemia,hyperglycemia lymphopenia and increased,1,0.7833232879638672
AFINITOR,hyperglycemia,aboratory,0,0.5154708027839661
AFINITOR,hyperglycemia,laboratory abnormalities inciden,0,0.5798776149749756
AFINITOR,hyperglycemia,creatinine The most common Grade laboratory abnormalities inciden,0,0.560096263885498
AFINITOR,lymphopenia,lymphopenia and increased,1,0.9378566741943359
AFINITOR,lymphopenia,lymphopenia and increased creatinine The,1,0.8529843091964722
AFINITOR,lymphopenia,anemia,0,0.6239705085754395
AFINITOR,lymphopenia,lymphopenia and,1,0.9717342853546143
AFINITOR,lymphopenia,creatinine The,0,0.5445739030838013
AFINITOR,lymphopenia,creatinine The most common Grade laboratory abnormalities,0,0.5704958438873291
AFINITOR,increased creatinine,anemia hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and,0,0.6191273331642151
AFINITOR,increased creatinine,lymphopenia increased creatinine The most,1,0.8261212110519409
AFINITOR,increased creatinine,hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia increased creatinine The most common Grade laboratory,1,0.7529428601264954
AFINITOR,increased creatinine,increased creatinine,1,1.0000001192092896
AFINITOR,increased creatinine,increased creatinine The,1,0.988703727722168
AFINITOR,increased creatinine,hyperglycemia lymphopenia increased creatinine,1,0.8251782655715942
AFINITOR,increased creatinine,lymphopenia increased,1,0.644530177116394
AFINITOR,lymphopenia,lymphopenia hyperglycemia,1,0.8472102284431458
AFINITOR,lymphopenia,incidence lymphopenia,1,0.9299557209014893
AFINITOR,lymphopenia,lymphopenia hyperglycemia anemia,1,0.8550528287887573
AFINITOR,hyperglycemia,due to acute respiratory failure,0,0.5091551542282104
AFINITOR,anemia,and hypercholesterolemia Deaths due,0,0.5475214719772339
AFINITOR,anemia,and hypercholesterolemia Deaths due to acute,0,0.5340452194213867
AFINITOR,anemia,Deaths due to acute respiratory failure infect,0,0.5002912878990173
AFINITOR,anemia,abnormalities incidence were lymphopenia anemia hypophosphatemia and,1,0.6700252890586853
AFINITOR,hypophosphatemia,due to acute respiratory failure infection and,0,0.47431161999702454
AFINITOR,hypophosphatemia,incidence were lymphopenia hyperglycemia hypophosphatemia and hypercholesterolemia Deaths due,1,0.7467519044876099
AFINITOR,hypophosphatemia,were,0,0.4896843433380127
AFINITOR,hypercholesterolemia,hypercholesterolemia Deaths due to,1,0.8594375252723694
AFINITOR,hypercholesterolemia,were,0,0.4802931845188141
AFINITOR,hypercholesterolemia,lymphopenia hyperglycemia anemia hypophosphatemia hypercholesterolemia Deaths due to acute respiratory,1,0.7296668291091919
AFINITOR,Deaths,Deaths due,1,0.8530093431472778
AFINITOR,acute respiratory failure,hypercholesterolemia Deaths due acute,1,0.6044939756393433
AFINITOR,acute respiratory failure,acute respiratory failure infection,1,0.925251841545105
AFINITOR,acute respiratory failure,lymphopenia hyperglycemia anemia hypophosphatemia and hypercholesterolemia,0,0.4977629780769348
AFINITOR,acute respiratory failure,acute respiratory failure,1,0.9999998807907104
AFINITOR,acute respiratory failure,respiratory failure infection and,1,0.8135701417922974
AFINITOR,acute respiratory failure,hypercholesterolemia Deaths due acute respiratory failure infection and acute renal,1,0.7316401600837708
AFINITOR,acute respiratory failure,hyperglycemia anemia hypophosphatemia and hypercholesterolemia,0,0.4591526985168457
AFINITOR,infection,infection and,1,0.9140372276306152
AFINITOR,infection,hyperglycemia anemia hypophosphatemia and hypercholesterolemia,0,0.5196571946144104
AFINITOR,infection,infection and acute renal,1,0.733667254447937
AFINITOR,infection,infection and acute,1,0.8196486830711365
AFINITOR,infection,infection and acute renal failure,1,0.696869969367981
AFINITOR,infection,infection,1,0.9999999403953552
AFINITOR,acute renal failure,renal failure were observed on the AFINITOR,1,0.8337281942367554
AFINITOR,acute renal failure,rates,0,0.4902653098106384
AFINITOR,acute renal failure,on the AFINITOR arm but none on the placebo arm The,0,0.4577464461326599
AFINITOR,acute renal failure,respiratory failure infection acute renal failure,1,0.8856931924819946
AFINITOR,acute renal failure,acute renal failure were,1,0.9790278673171997
AFINITOR,acute renal failure,respiratory failure infection acute renal,1,0.8710116147994995
AFINITOR,pneumonitis,and dyspnea Infections stomatitis,0,0.6324236392974854
AFINITOR,dyspnea,for treatment delay or,0,0.5622109770774841
AFINITOR,dyspnea,dyspnea,1,1.0
AFINITOR,dyspnea,pneumonitis and,0,0.6596224308013916
AFINITOR,dyspnea,discontinuation were,0,0.5134174823760986
AFINITOR,dyspnea,dyspnea Infections stomatitis,1,0.7957203388214111
AFINITOR,dyspnea,and,0,0.5204545855522156
AFINITOR,dyspnea,dyspnea Infections stomatitis and,1,0.8038942217826843
AFINITOR,dyspnea,of,0,0.5646697878837585
AFINITOR,dyspnea,pneumonitis dyspnea Infections stomatitis,1,0.7363660931587219
AFINITOR,dyspnea,dyspnea Infections stomatitis and pneumonitis were,1,0.768997073173523
AFINITOR,Infections,Infections stomatitis,1,0.7699317932128906
AFINITOR,Infections,of causality leading to,0,0.5139411687850952
AFINITOR,Infections,Infections stomatitis and pneumonitis,1,0.7521086931228638
AFINITOR,Infections,reasons for treatment delay or dose,0,0.5501031279563904
AFINITOR,Infections,Infections stomatitis and,1,0.7885596752166748
AFINITOR,Infections,pneumonitis and Infections stomatitis and,1,0.7230783104896545
AFINITOR,Infections,discontinuation were pneumonitis and Infections,1,0.702377200126648
AFINITOR,Infections,pneumonitis were the most common reasons for treatment,0,0.5936025381088257
AFINITOR,stomatitis,pneumonitis were the most common reasons for treatment,0,0.5270799398422241
AFINITOR,stomatitis,stomatitis and pneumonitis,1,0.8447583317756653
AFINITOR,stomatitis,stomatitis and,1,0.9514771699905396
AFINITOR,infections,infections anemia,1,0.8100423216819763
AFINITOR,infections,infections anemia and stomatitis,1,0.7421634197235107
AFINITOR,infections,were infections anemia and stomatitis Table,1,0.7227189540863037
AFINITOR,infections,the incidence of treatmentemergent,0,0.5841898918151855
AFINITOR,infections,during AFINITOR treatment were infections,1,0.7785420417785645
AFINITOR,anemia,anemia and stomatitis,1,0.8222808241844177
AFINITOR,anemia,infections anemia and stomatitis,1,0.7987829446792603
AFINITOR,anemia,anemia and stomatitis Table compares the,1,0.7820762991905212
AFINITOR,anemia,interventions required during,0,0.552935004234314
AFINITOR,stomatitis,adverse reactions reported with an,0,0.5631733536720276
AFINITOR,stomatitis,stomatitis Table compares,1,0.8554769158363342
AFINITOR,stomatitis,were,0,0.4880203604698181
AFINITOR,Stomatitis,than in the Placebo Arm Grading according to CTCAE Version a,0,0.49646228551864624
AFINITOR,Stomatitis,Stomatitis including aphthous stomatitis and mouth,1,0.870110034942627
AFINITOR,aphthous stomatitis,according to CTCAE Version a Stomatitis including,0,0.7605408430099487
AFINITOR,aphthous stomatitis,Version a Stomatitis aphthous stomatitis and mouth and tongue,1,0.8880405426025391
AFINITOR,aphthous stomatitis,Stomatitis,0,0.8407280445098877
AFINITOR,aphthous stomatitis,aphthous stomatitis and mouth and,1,0.9484126567840576
AFINITOR,aphthous stomatitis,the Placebo Arm Grading according to CTCAE Version a Stomatitis including,0,0.6960773468017578
AFINITOR,aphthous stomatitis,Stomatitis including,0,0.826001763343811
AFINITOR,aphthous stomatitis,aphthous stomatitis,1,0.9999999403953552
AFINITOR,aphthous stomatitis,aphthous stomatitis and mouth and tongue ulceration,1,0.8981845378875732
AFINITOR,aphthous stomatitis,CTCAE Version a Stomatitis aphthous,1,0.8473731279373169
AFINITOR,tongue ulceration,a Stomatitis including aphthous,0,0.7558185458183289
AFINITOR,tongue ulceration,a Stomatitis including aphthous stomatitis and,0,0.748788058757782
AFINITOR,tongue ulceration,mouth,0,0.6922023296356201
AFINITOR,tongue ulceration,stomatitis and mouth and,0,0.7269402146339417
AFINITOR,nasopharyngitis,being,0,0.5013643503189087
AFINITOR,nasopharyngitis,the most common nasopharyngitis pneumonia urinary tract infection bronchitis,1,0.7429910898208618
AFINITOR,nasopharyngitis,nasopharyngitis pneumonia urinary,1,0.8089317083358765
AFINITOR,nasopharyngitis,and,0,0.5093783140182495
AFINITOR,nasopharyngitis,nasopharyngitis pneumonia urinary tract,1,0.7926958799362183
AFINITOR,nasopharyngitis,urinary tract,0,0.5664858222007751
AFINITOR,nasopharyngitis,nasopharyngitis,1,1.0000001192092896
AFINITOR,pneumonia,the most common being pneumonia urinary tract infection,1,0.752096951007843
AFINITOR,pneumonia,nasopharyngitis,1,0.6376098394393921
AFINITOR,pneumonia,pneumonia urinary tract infection bronchitis,1,0.7432732582092285
AFINITOR,pneumonia,most common being pneumonia urinary tract,1,0.7526026964187622
AFINITOR,pneumonia,organ class the most common,0,0.4879366457462311
AFINITOR,pneumonia,class the,0,0.5022310614585876
AFINITOR,urinary tract infection,urinary tract infection bronchitis and,1,0.8143665790557861
AFINITOR,urinary tract infection,being nasopharyngitis urinary,1,0.7236908078193665
AFINITOR,urinary tract infection,urinary,1,0.8110286593437195
AFINITOR,urinary tract infection,nasopharyngitis urinary tract infection bronchitis and,1,0.7602245807647705
AFINITOR,urinary tract infection,tract infection,1,0.8207153677940369
AFINITOR,bronchitis,bronchitis and sinusitis and also,1,0.8206539154052734
AFINITOR,bronchitis,bronchitis and sinusitis and also including,1,0.8171464800834656
AFINITOR,bronchitis,urinary tract bronchitis and sinusitis and,1,0.7822867035865784
AFINITOR,bronchitis,urinary tract bronchitis and sinusitis and also,1,0.7748619318008423
AFINITOR,bronchitis,being nasopharyngitis pneumonia urinary tract,0,0.5639808773994446
AFINITOR,sinusitis,being nasopharyngitis pneumonia urinary tract infection,0,0.5899145603179932
AFINITOR,sinusitis,pneumonia urinary tract infection bronchitis and,0,0.5626116991043091
AFINITOR,sinusitis,sinusitis and,1,0.9340534806251526
AFINITOR,aspergillosis,and also aspergillosis candidiasis,1,0.8421487808227539
AFINITOR,aspergillosis,pneumonia urinary tract infection bronchitis and,0,0.5962709784507751
AFINITOR,aspergillosis,aspergillosis candidiasis and sepsis c,1,0.7691004276275635
AFINITOR,aspergillosis,and sinusitis and also aspergillosis candidiasis,1,0.7606202960014343
AFINITOR,aspergillosis,and also aspergillosis candidiasis and sepsis,1,0.7975872755050659
AFINITOR,aspergillosis,tract infection bronchitis and,0,0.5955973863601685
AFINITOR,aspergillosis,aspergillosis candidiasis and sepsis c Includes,1,0.7559274435043335
AFINITOR,aspergillosis,and also aspergillosis candidiasis and sepsis c Includes,1,0.7593145966529846
AFINITOR,candidiasis,candidiasis and sepsis c,1,0.7981288433074951
AFINITOR,candidiasis,also including candidiasis and,1,0.8548728227615356
AFINITOR,sepsis,also including aspergillosis candidiasis sepsis c Includes,1,0.7459094524383545
AFINITOR,sepsis,candidiasis and sepsis c,1,0.7806884050369263
AFINITOR,sepsis,c Includes pneumonitis interstitial lung disease lung infiltration pulmonary,0,0.5865340828895569
AFINITOR,sepsis,sepsis c,1,0.8540989756584167
AFINITOR,sepsis,pneumonitis interstitial lung disease lung infiltration pulmonary alveolar,0,0.5684162974357605
AFINITOR,sepsis,sepsis c Includes,1,0.8172168731689453
AFINITOR,sepsis,pulmonary alveolar h,0,0.534896731376648
AFINITOR,sepsis,aspergillosis candidiasis sepsis c Includes pneumonitis interstitial lung,1,0.7093824148178101
AFINITOR,lung infiltration,and sepsis c Includes,0,0.5735488533973694
AFINITOR,lung infiltration,pneumonitis interstitial lung lung infiltration,1,0.897270679473877
AFINITOR,lung infiltration,interstitial lung lung infiltration pulmonary alveolar hemorrhage pulmonary toxicity,1,0.8033144474029541
AFINITOR,lung infiltration,pneumonitis interstitial lung,0,0.7460759282112122
AFINITOR,lung infiltration,interstitial lung lung infiltration pulmonary alveolar hemorrhage,1,0.8481036424636841
AFINITOR,lung infiltration,toxicity and alveolitis,0,0.6562821865081787
AFINITOR,pulmonary alveolar hemorrhage,interstitial,0,0.49349072575569153
AFINITOR,pulmonary alveolar hemorrhage,alveolar hemorrhage pulmonary toxicity and alveolitis,1,0.8605717420578003
AFINITOR,pulmonary alveolar hemorrhage,pulmonary alveolar hemorrhage,1,1.0
AFINITOR,pulmonary alveolar hemorrhage,lung pulmonary alveolar hemorrhage pulmonary toxicity and alveolitis AFINITOR,1,0.8565443754196167
AFINITOR,pulmonary alveolar hemorrhage,lung pulmonary alveolar hemorrhage pulmonary toxicity and alveolitis,1,0.868710994720459
AFINITOR,pulmonary toxicity,alveolar,0,0.6725093126296997
AFINITOR,pulmonary toxicity,lung infiltration pulmonary alveolar hemorrhage,0,0.6807152628898621
AFINITOR,pulmonary toxicity,pulmonary alveolar pulmonary toxicity,1,0.934023380279541
AFINITOR,pulmonary toxicity,AFINITOR,0,0.45947808027267456
AFINITOR,pulmonary toxicity,pulmonary toxicity and alveolitis AFINITOR mgday,1,0.8338172435760498
AFINITOR,pulmonary toxicity,pulmonary toxicity and alveolitis AFINITOR,1,0.8674677610397339
AFINITOR,pulmonary toxicity,infiltration pulmonary alveolar,0,0.6830065846443176
AFINITOR,alveolitis,alveolitis,1,0.9999997615814209
AFINITOR,alveolitis,pulmonary toxicity alveolitis AFINITOR mgday N Placebo N,1,0.758131742477417
AFINITOR,Abdominal pain,Abdominal pain,1,0.9999998807907104
AFINITOR,Abdominal pain,Gastrointestinal Abdominal pain dry mouth hemorrhoids,1,0.7990254163742065
AFINITOR,Abdominal pain,incidence of include Gastrointestinal disorders,0,0.6759933233261108
AFINITOR,Abdominal pain,General disorders and administrati,0,0.514083981513977
AFINITOR,Abdominal pain,include Gastrointestinal Abdominal,1,0.7586777210235596
AFINITOR,Abdominal pain,an incidence of,0,0.5618102550506592
AFINITOR,Abdominal pain,Abdominal,1,0.7878189086914062
AFINITOR,Abdominal pain,include Gastrointestinal Abdominal pain,1,0.8829920291900635
AFINITOR,Abdominal pain,of include Gastrointestinal Abdominal,1,0.7738145589828491
AFINITOR,dry mouth,dry mouth hemorrhoids dysphagia General disorders and,1,0.7773714065551758
AFINITOR,dry mouth,Abdominal dry mouth,1,0.8438864946365356
AFINITOR,dry mouth,dysphagia General disorders and administration,0,0.6333242058753967
AFINITOR,dry mouth,Gastrointestinal disorders Abdominal dry mouth hemorrhoids,1,0.7376457452774048
AFINITOR,dry mouth,disorders Abdominal,0,0.4367351531982422
AFINITOR,dry mouth,dry mouth,1,1.0
AFINITOR,hemorrhoids,administration site conditions Weight,0,0.5071859359741211
AFINITOR,hemorrhoids,hemorrhoids dysphagia General disorders and administration,1,0.7923702001571655
AFINITOR,hemorrhoids,hemorrhoids,1,0.9999998807907104
AFINITOR,hemorrhoids,dry hemorrhoids,1,0.8554234504699707
AFINITOR,hemorrhoids,dysphagia General disorders,0,0.5211251974105835
AFINITOR,hemorrhoids,mouth,0,0.5599876642227173
AFINITOR,hemorrhoids,hemorrhoids dysphagia,1,0.8377953767776489
AFINITOR,dysphagia,Weight decreased,0,0.5598608255386353
AFINITOR,dysphagia,dysphagia General disorders and,1,0.8601815700531006
AFINITOR,dysphagia,Weight decreased chest,0,0.587565541267395
AFINITOR,dysphagia,dysphagia General disorders and administration site,1,0.8243070840835571
AFINITOR,dysphagia,dysphagia General disorders and administration,1,0.8354200720787048
AFINITOR,dysphagia,dysphagia General,1,0.9027729034423828
AFINITOR,dysphagia,Gastrointestinal disorders Abdominal pain dry,0,0.5941331386566162
AFINITOR,Weight decreased,pain chills impaired wound healing Respiratory thoracic a,0,0.5123716592788696
AFINITOR,Weight decreased,administration site Weight,1,0.6459001302719116
AFINITOR,Weight decreased,site Weight decreased chest pain chills,1,0.714030385017395
AFINITOR,Weight decreased,site Weight decreased,1,0.8310699462890625
AFINITOR,chest pain,thoracic,0,0.6729534268379211
AFINITOR,chest pain,chest pain chills impaired wound healing,1,0.7386482954025269
AFINITOR,chest pain,thoracic and,0,0.6721431612968445
AFINITOR,chest pain,chest pain,1,0.9999999403953552
AFINITOR,chest pain,conditions Weight chest pain chills,1,0.799550473690033
AFINITOR,chills,General disorders,0,0.47157496213912964
AFINITOR,chills,chills impaired wound healing,1,0.7397858500480652
AFINITOR,chills,chest,0,0.5035308599472046
AFINITOR,chills,chills impaired wound healing Respiratory,1,0.7169997692108154
AFINITOR,chills,chills impaired wound healing Respiratory thoracic,1,0.7133278250694275
AFINITOR,chills,Weight decreased chest chills impaired wound,1,0.6689417362213135
AFINITOR,impaired wound healing,disorders and administration site conditions Weight decreased chest pain chills,0,0.5341957211494446
AFINITOR,impaired wound healing,and mediastinal disorders Pleural effusion pharyngola,0,0.5222532749176025
AFINITOR,impaired wound healing,impaired wound healing Respiratory thoracic and mediastinal,1,0.8353886604309082
AFINITOR,impaired wound healing,disorders and administration,0,0.5762619972229004
AFINITOR,impaired wound healing,decreased chest pain,0,0.5270068049430847
AFINITOR,Pleural effusion,Pleural effusion pharyngolaryngeal pain rhinorrhea,1,0.8024195432662964
AFINITOR,Pleural effusion,Respiratory thoracic,0,0.6389650106430054
AFINITOR,Pleural effusion,Respiratory thoracic and mediastinal disorders,0,0.6145743131637573
AFINITOR,Pleural effusion,Respiratory thoracic and mediastinal Pleural effusion pharyngolaryngeal pain,1,0.7388849854469299
AFINITOR,Pleural effusion,subcutaneous,0,0.574832558631897
AFINITOR,Pleural effusion,Respiratory thoracic and mediastinal Pleural effusion,1,0.8469680547714233
AFINITOR,Pleural effusion,mediastinal Pleural effusion pharyngolaryngeal pain,1,0.76070237159729
AFINITOR,Pleural effusion,Pleural effusion pharyngolaryngeal pain,1,0.7982598543167114
AFINITOR,Pleural effusion,Pleural,1,0.8603163957595825
AFINITOR,Pleural effusion,and mediastinal Pleural,1,0.7926123142242432
AFINITOR,pharyngolaryngeal pain,disorders Handfoot syndrome reporte,0,0.4399937391281128
AFINITOR,pharyngolaryngeal pain,and,0,0.4455067217350006
AFINITOR,pharyngolaryngeal pain,and subcutaneous tissue disorders Handfoot syndrome,0,0.44565901160240173
AFINITOR,pharyngolaryngeal pain,pharyngolaryngeal,1,0.875046968460083
AFINITOR,rhinorrhea,rhinorrhea Skin and subcutaneous tissue,1,0.8270021677017212
AFINITOR,rhinorrhea,effusion pharyngolaryngeal rhinorrhea Skin and subcutaneous,1,0.7805471420288086
AFINITOR,rhinorrhea,and mediastinal disorders Pleural effusion pharyngolaryngeal pain,0,0.5684159994125366
AFINITOR,Hand-foot syndrome,nail disorder erythema,0,0.6175887584686279
AFINITOR,Hand-foot syndrome,subcutaneous tissue Hand-foot syndrome,1,0.904920220375061
AFINITOR,Hand-foot syndrome,syndrome nail disorder,0,0.6877820491790771
AFINITOR,Hand-foot syndrome,and subcutaneous tissue disorders,0,0.6453366279602051
AFINITOR,Hand-foot syndrome,Hand-foot syndrome reported as palmarplantar erythrodysesthesia syndrome,1,0.8763357400894165
AFINITOR,Hand-foot syndrome,Hand-foot,1,0.8778023719787598
AFINITOR,Hand-foot syndrome,palmarplantar,0,0.555720329284668
AFINITOR,Hand-foot syndrome,and subcutaneous tissue Hand-foot syndrome,1,0.9058786630630493
AFINITOR,palmar-plantar erythrodysesthesia syndrome,Handfoot syndrome reported palmar-plantar erythrodysesthesia syndrome,1,0.9597949981689453
AFINITOR,palmar-plantar erythrodysesthesia syndrome,reported palmar-plantar erythrodysesthesia syndrome,1,0.9934413433074951
AFINITOR,palmar-plantar erythrodysesthesia syndrome,erythrodysesthesia syndrome,1,0.8774869441986084
AFINITOR,palmar-plantar erythrodysesthesia syndrome,reported palmar-plantar erythrodysesthesia syndrome nail disorder erythema,1,0.9005393981933594
AFINITOR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome nail disorder erythema onychoclasis skin,1,0.9034701585769653
AFINITOR,palmar-plantar erythrodysesthesia syndrome,Handfoot syndrome reported palmar-plantar erythrodysesthesia,1,0.9413650035858154
AFINITOR,palmar-plantar erythrodysesthesia syndrome,subcutaneous tissue,0,0.584445059299469
AFINITOR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome nail disorder,1,0.9019722938537598
AFINITOR,nail disorder,reported as palmarplantar erythrodysesthesia nail disorder erythema onychoclasis,1,0.811442494392395
AFINITOR,nail disorder,palmar-plantar erythrodysesthesia syndrome nail disorder,1,0.8629713654518127
AFINITOR,nail disorder,nail disorder,1,1.0
AFINITOR,erythema,palmarplantar erythrodysesthesia syndrome nail erythema onychoclasis skin lesion acneiform,1,0.709786057472229
AFINITOR,erythema,nail disorder,1,0.569782018661499
AFINITOR,onychoclasis,angioedema Metabolism and,0,0.49284428358078003
AFINITOR,onychoclasis,disorder,0,0.5975140929222107
AFINITOR,onychoclasis,nail disorder onychoclasis skin lesion,1,0.8877965807914734
AFINITOR,onychoclasis,onychoclasis skin lesion acneiform dermatitis,1,0.8476048707962036
AFINITOR,onychoclasis,as palmarplantar erythrodysesthesia syndrome nail disorder,0,0.7189604640007019
AFINITOR,onychoclasis,onychoclasis skin,1,0.9345616698265076
AFINITOR,skin lesion,erythema skin lesion,1,0.8912557363510132
AFINITOR,skin lesion,skin lesion,1,1.0
AFINITOR,acneiform dermatitis,syndrome nail disorder erythema onychoclasis,0,0.5953810214996338
AFINITOR,acneiform dermatitis,and nutrition disorders Exacerbation of preexisting d,0,0.5701388120651245
AFINITOR,acneiform dermatitis,acneiform dermatitis angioedema Metabolism and,1,0.8477083444595337
AFINITOR,acneiform dermatitis,and,0,0.45533668994903564
AFINITOR,acneiform dermatitis,onychoclasis skin,0,0.6573506593704224
AFINITOR,acneiform dermatitis,skin acneiform dermatitis,1,0.9882908463478088
AFINITOR,acneiform dermatitis,erythema onychoclasis skin acneiform,1,0.8364923000335693
AFINITOR,angioedema,skin lesion acneiform angioedema,1,0.8003363609313965
AFINITOR,angioedema,erythema onychoclasis skin acneiform,1,0.5577894449234009
AFINITOR,angioedema,lesion acneiform angioedema Metabolism and nutrition,1,0.7851159572601318
AFINITOR,angioedema,skin lesion acneiform angioedema Metabolism and,1,0.7850955724716187
AFINITOR,angioedema,and nutrition disorders Exacerbation of,0,0.5619651079177856
AFINITOR,angioedema,angioedema Metabolism,1,0.8590134382247925
AFINITOR,new onset of diabetes mellitus,Exacerbation of preexisting diabetes new onset of diabetes mellitus Psychiatric disorders,1,0.8310574293136597
AFINITOR,new onset of diabetes mellitus,angioedema Metabolism,1,0.5610074996948242
AFINITOR,new onset of diabetes mellitus,new onset of diabetes mellitus Psychiatric,1,0.8780202865600586
AFINITOR,new onset of diabetes mellitus,preexisting diabetes new,1,0.8290939927101135
AFINITOR,new onset of diabetes mellitus,Exacerbation of preexisting diabetes new onset of,1,0.86024010181427
AFINITOR,new onset of diabetes mellitus,mellitus,0,0.5741115808486938
AFINITOR,new onset of diabetes mellitus,Insomnia Nervous system,0,0.47150179743766785
AFINITOR,new onset of diabetes mellitus,of preexisting diabetes new onset,1,0.8822678327560425
AFINITOR,Insomnia,Insomnia Nervous,1,0.848321795463562
AFINITOR,Insomnia,Insomnia Nervous system,1,0.8314417004585266
AFINITOR,Insomnia,system disorders,0,0.49011626839637756
AFINITOR,Insomnia,system disorders Dizziness paresthesia Eye,0,0.5595213770866394
AFINITOR,Insomnia,Insomnia Nervous system disorders,1,0.801825761795044
AFINITOR,Insomnia,system disorders Dizziness paresthesia,0,0.5402625799179077
AFINITOR,Insomnia,Insomnia Nervous system disorders Dizziness,1,0.7876400947570801
AFINITOR,Insomnia,of diabetes mellitus Psychiatric Insomnia Nervous,1,0.7334795594215393
AFINITOR,Dizziness,Dizziness paresthesia,1,0.9077486991882324
AFINITOR,Dizziness,Dizziness paresthesia Eye,1,0.8732166290283203
AFINITOR,paresthesia,Insomnia Nervous system disorders paresthesia Eye disorders Eyelid edema,1,0.6855617761611938
AFINITOR,paresthesia,Dizziness paresthesia Eye,1,0.7889052629470825
AFINITOR,paresthesia,paresthesia,1,1.0000001192092896
AFINITOR,paresthesia,system disorders paresthesia Eye disorders Eyelid edema,1,0.7223267555236816
AFINITOR,paresthesia,paresthesia Eye,1,0.8687468767166138
AFINITOR,Eyelid edema,disorders,0,0.5518007278442383
AFINITOR,Eyelid edema,disorders Dizziness paresthesia,0,0.5433067083358765
AFINITOR,Eyelid edema,disorders Dizziness paresthesia Eye Eyelid edema conjunctivitis Vascular disorders Hypertension deep,1,0.7326160669326782
AFINITOR,conjunctivitis,conjunctivitis,1,1.0
AFINITOR,conjunctivitis,conjunctivitis Vascular disorders Hypertension,1,0.7947766780853271
AFINITOR,conjunctivitis,Eye disorders Eyelid conjunctivitis,1,0.8396437168121338
AFINITOR,conjunctivitis,Dizziness paresthesia,0,0.5338126420974731
AFINITOR,conjunctivitis,conjunctivitis Vascular disorders Hypertension deep vein,1,0.7696318030357361
AFINITOR,conjunctivitis,Hypertension deep vein,0,0.5118408203125
AFINITOR,conjunctivitis,disorders Dizziness,0,0.5398770570755005
AFINITOR,Hypertension,Hypertension deep,1,0.8568974733352661
AFINITOR,Hypertension,disorders,0,0.6091046929359436
AFINITOR,Hypertension,Hypertension,1,0.9999999403953552
AFINITOR,Hypertension,edema conjunctivitis Vascular,0,0.6112959980964661
AFINITOR,Hypertension,Hypertension deep vein thrombosis Renal,1,0.7975661754608154
AFINITOR,Hypertension,Eyelid edema conjunctivitis Vascular disorders,0,0.5875852704048157
AFINITOR,Hypertension,vein thrombosis,0,0.5707638263702393
AFINITOR,Tachycardia,Tachycardia congestive,1,0.8808356523513794
AFINITOR,congestive cardiac failure,urinary disorders Renal,0,0.5668724179267883
AFINITOR,congestive cardiac failure,disorders,0,0.5685839653015137
AFINITOR,congestive cardiac failure,failure Cardiac disorders congestive cardiac failure,1,0.9207726120948792
AFINITOR,congestive cardiac failure,disorders congestive cardiac failure Musculoskeletal and connective tissue,1,0.7762129306793213
AFINITOR,Hemorrhage,Hematologic Hemorrhage Key,1,0.7929454445838928
AFINITOR,Hemorrhage,disorders,0,0.5901208519935608
AFINITOR,Hemorrhage,Table Key,0,0.5086013078689575
AFINITOR,Hemorrhage,Hemorrhage,1,1.0
AFINITOR,Hemorrhage,Hemorrhage Key laboratory abnormalities,1,0.7849875688552856
AFINITOR,Hemorrhage,Jaw pain Hematologic Hemorrhage Key laboratory abnormalities are presented,1,0.6941511631011963
AFINITOR,Hemorrhage,pain Hematologic Hemorrhage Key,1,0.766149640083313
AFINITOR,Hemorrhage,Hemorrhage Key laboratory,1,0.805158793926239
AFINITOR,Hemorrhage,Jaw pain Hematologic disorders,0,0.5877273082733154
AFINITOR,anemia,reports anemia leukopenia lymphopenia neutropenia and thrombocytopenia,1,0.7514691352844238
AFINITOR,anemia,Jaw pain Hematologic disorders,0,0.6449127793312073
AFINITOR,anemia,pancytopenia which occu,0,0.6763184070587158
AFINITOR,anemia,anemia leukopenia lymphopenia,1,0.7754612565040588
AFINITOR,anemia,reports anemia leukopenia lymphopenia,1,0.7717494964599609
AFINITOR,anemia,of,0,0.5677421689033508
AFINITOR,anemia,drug reaction reports anemia leukopenia lymphopenia,1,0.687279462814331
AFINITOR,leukopenia,leukopenia lymphopenia neutropenia and,1,0.8832687139511108
AFINITOR,leukopenia,of leukopenia lymphopenia neutropenia and thrombocytopenia,1,0.857886791229248
AFINITOR,leukopenia,of leukopenia lymphopenia,1,0.898551344871521
AFINITOR,leukopenia,leukopenia lymphopenia neutropenia,1,0.8903487920761108
AFINITOR,leukopenia,reports of leukopenia,1,0.9304670095443726
AFINITOR,leukopenia,occurred,0,0.4725106954574585
AFINITOR,lymphopenia,of anemia lymphopenia neutropenia and thrombocytopenia,1,0.8160743713378906
AFINITOR,lymphopenia,leukopenia,0,0.8166248202323914
AFINITOR,lymphopenia,reaction reports of anemia lymphopenia neutropenia and thrombocytopenia collectively pancytopenia,1,0.7393542528152466
AFINITOR,neutropenia,leukopenia,0,0.7395179271697998
AFINITOR,neutropenia,thrombocytopenia collectively,0,0.6758639812469482
AFINITOR,neutropenia,neutropenia and,1,0.938434362411499
AFINITOR,neutropenia,neutropenia and thrombocytopenia,1,0.8689904808998108
AFINITOR,neutropenia,pancytopenia which occurred,0,0.734031081199646
AFINITOR,neutropenia,drug,0,0.5227756500244141
AFINITOR,neutropenia,anemia leukopenia neutropenia and,1,0.8410332202911377
AFINITOR,neutropenia,anemia leukopenia neutropenia and thrombocytopenia collectively,1,0.7998915910720825
AFINITOR,pancytopenia,arameter,0,0.4999217987060547
AFINITOR,stomatitis,incidence stomatitis The most common Grade adverse,1,0.806446373462677
AFINITOR,stomatitis,arameter,0,0.47943276166915894
AFINITOR,stomatitis,for AFINITOR,0,0.508586049079895
AFINITOR,stomatitis,adverse reactions incidence were stomatitis and amenorrhea The,0,0.7171145677566528
AFINITOR,stomatitis,were stomatitis and amenorrhea The,0,0.7802202701568604
AFINITOR,stomatitis,stomatitis The most common,1,0.8687252998352051
AFINITOR,stomatitis,stomatitis The most common Grade adverse,1,0.8223172426223755
AFINITOR,stomatitis,adverse reaction reported for AFINITOR,0,0.5548812747001648
AFINITOR,stomatitis,Grade adverse reactions incidence,0,0.5288151502609253
AFINITOR,stomatitis,stomatitis and amenorrhea,1,0.7991374135017395
AFINITOR,amenorrhea,common laboratory abnormalities incidence,0,0.5536683201789856
AFINITOR,amenorrhea,incidence,0,0.5881654024124146
AFINITOR,hypertriglyceridemia,hypertriglyceridemia and anemia The most common,1,0.8392155170440674
AFINITOR,hypertriglyceridemia,amenorrhea The most common laboratory abnormalities incidence,0,0.592467188835144
AFINITOR,anemia,anemia The most common Grade,1,0.7782734632492065
AFINITOR,anemia,anemia The most common,1,0.8224117755889893
AFINITOR,anemia,were,0,0.57362961769104
AFINITOR,anemia,laboratory abnormalities,0,0.6141215562820435
AFINITOR,anemia,The most,0,0.5145248174667358
AFINITOR,anemia,laboratory abnormality incidence was hypophosphatemia The r,0,0.5827303528785706
AFINITOR,anemia,hypertriglyceridemia anemia The most,1,0.7582813501358032
AFINITOR,anemia,The most common Grade laboratory abnormality incidence was hypophosphatemia The,0,0.5783140659332275
AFINITOR,anemia,hypertriglyceridemia anemia The most common,1,0.7352167367935181
AFINITOR,hypophosphatemia,triglyceridemia and anemia The most common Grade laboratory abnormality incidence,0,0.5464650392532349
AFINITOR,hypophosphatemia,hypophosphatemia The,1,0.973795473575592
AFINITOR,hypophosphatemia,hypophosphatemia The rate of,1,0.9008392095565796
AFINITOR,hypophosphatemia,hypophosphatemia The rate of adverse reactions,1,0.8382070064544678
AFINITOR,hypophosphatemia,discontinuation,0,0.48383045196533203
AFINITOR,hypophosphatemia,The most common Grade laboratory abnormality incidence was,0,0.5583815574645996
AFINITOR,hypersensitivity,convulsion and hypophosphatemia Dose adjustments interruptions or reduc,0,0.5087627172470093
AFINITOR,hypersensitivity,hypersensitivity angioedemabronchospasm convulsion,1,0.7734354138374329
AFINITOR,hypersensitivity,patients Adverse reactions leading to permanent discontinuation,0,0.6159498691558838
AFINITOR,hypersensitivity,interruptions or,0,0.4839884042739868
AFINITOR,hypersensitivity,patients Adverse,0,0.5701919794082642
AFINITOR,hypersensitivity,hypersensitivity angioedemabronchospasm convulsion and hypophosphatemia Dose,1,0.7455089092254639
AFINITOR,hypersensitivity,hypersensitivity angioedemabronchospasm,1,0.8106529712677002
AFINITOR,hypersensitivity,and hypophosphatemia Dose adjustments,0,0.5200342535972595
AFINITOR,angioedema,convulsion and hypophosphatemia Dose adjustments interruptions or reductions,0,0.4662123918533325
AFINITOR,angioedema,hypophosphatemia Dose,0,0.42925751209259033
AFINITOR,bronchospasm,bronchospasm convulsion and hypophosphatemia,1,0.7897335290908813
AFINITOR,bronchospasm,permanent discontinuation,0,0.4548470377922058
AFINITOR,bronchospasm,bronchospasm convulsion and hypophosphatemia Dose adjustments,1,0.7924916744232178
AFINITOR,bronchospasm,AFINITOR,0,0.44924265146255493
AFINITOR,bronchospasm,bronchospasm convulsion,1,0.859015703201294
AFINITOR,bronchospasm,bronchospasm convulsion and hypophosphatemia Dose,1,0.7953861355781555
AFINITOR,bronchospasm,bronchospasm convulsion and,1,0.8614158630371094
AFINITOR,convulsion,ing to,0,0.5382590889930725
AFINITOR,convulsion,were convulsion and,1,0.9286731481552124
AFINITOR,convulsion,the AFINITOR arm were convulsion and hypophosphatemia,1,0.7868202924728394
AFINITOR,convulsion,hypersensitivityangioedemabronchospasm,0,0.53575199842453
AFINITOR,convulsion,convulsion and hypophosphatemia Dose adjustments interruptions,1,0.7347280979156494
AFINITOR,convulsion,the AFINITOR arm were convulsion and,1,0.857204258441925
AFINITOR,convulsion,arm were convulsion and hypophosphatemia Dose,1,0.7679637670516968
AFINITOR,convulsion,adjustments interruptions or reductions,0,0.492195188999176
AFINITOR,convulsion,discontinuation in the AFINITOR,0,0.5117140412330627
AFINITOR,convulsion,convulsion and hypophosphatemia Dose adjustments,1,0.7439379692077637
AFINITOR,hypophosphatemia,hypersensitivityangioedemabronchospasm,0,0.4877241849899292
AFINITOR,hypophosphatemia,hypophosphatemia Dose adjustments interruptions or,1,0.8489385843276978
AFINITOR,hypophosphatemia,hypophosphatemia Dose adjustments,1,0.8779599070549011
AFINITOR,hypophosphatemia,hypophosphatemia Dose,1,0.9079651832580566
AFINITOR,stomatitis,stomatitis Table compares the incidence,1,0.8233586549758911
AFINITOR,aphthous stomatitis,Angiomyolipoma Grading according to,0,0.4797290563583374
AFINITOR,aphthous stomatitis,and glossodynia,0,0.5901548862457275
AFINITOR,aphthous stomatitis,CTCAE Version a Includes aphthous stomatitis mouth,1,0.8147932291030884
AFINITOR,aphthous stomatitis,aphthous,1,0.905167281627655
AFINITOR,aphthous stomatitis,stomatitis,0,0.8407280445098877
AFINITOR,aphthous stomatitis,aphthous stomatitis mouth ulceration gingival pain glossitis,1,0.8838851451873779
AFINITOR,mouth ulceration,and glossodynia AFINITOR N,0,0.5971719622612
AFINITOR,mouth ulceration,glossitis and glossodynia AFINITOR,0,0.674640953540802
AFINITOR,gingival pain,N,0,0.4734363853931427
AFINITOR,gingival pain,a,0,0.47172999382019043
AFINITOR,gingival pain,stomatitis aphthous stomatitis mouth gingival pain glossitis and glossodynia,1,0.7929750084877014
AFINITOR,gingival pain,AFINITOR N Placebo N,0,0.5769295692443848
AFINITOR,gingival pain,stomatitis aphthous stomatitis mouth gingival,1,0.7637647986412048
AFINITOR,gingival pain,mouth gingival pain,1,0.9721091985702515
AFINITOR,gingival pain,gingival pain,1,1.0
AFINITOR,gingival pain,aphthous stomatitis mouth gingival pain glossitis and glossodynia,1,0.7937429547309875
AFINITOR,glossitis,ulceration gingival glossitis and,1,0.8552401065826416
AFINITOR,glossitis,gingival pain,1,0.6027448177337646
AFINITOR,glossitis,glossitis and,1,0.9584686160087585
AFINITOR,glossitis,stomatitis mouth,0,0.7074704170227051
AFINITOR,glossitis,glossitis and glossodynia AFINITOR N Placebo,1,0.8188754320144653
AFINITOR,glossitis,aphthous,0,0.6313971281051636
AFINITOR,glossitis,Includes stomatitis aphthous stomatitis mouth ulceration gingival,0,0.6617928147315979
AFINITOR,glossitis,glossitis and glossodynia AFINITOR N,1,0.8594669103622437
AFINITOR,glossodynia,stomatitis aphthous stomatitis mouth,0,0.5888925790786743
AFINITOR,glossodynia,Includes stomatitis aphthous stomatitis mouth,0,0.5965902209281921
AFINITOR,glossodynia,glossodynia AFINITOR N Placebo,1,0.8571779131889343
AFINITOR,glossodynia,Includes stomatitis aphthous stomatitis,0,0.5957550406455994
AFINITOR,glossodynia,gingival pain glossitis and,0,0.7749484777450562
AFINITOR,glossodynia,glossodynia AFINITOR,1,0.8554163575172424
AFINITOR,glossodynia,glossodynia AFINITOR N,1,0.8487608432769775
AFINITOR,menorrhagia,menorrhagia,1,1.0
AFINITOR,menorrhagia,menorrhagia menstrual irregularities and vaginal,1,0.8515039682388306
AFINITOR,menorrhagia,the placebo group Other adverse reactions involving the,0,0.5054143667221069
AFINITOR,menorrhagia,in the placebo group Other adverse reactions involving the female reproductive,0,0.5972190499305725
AFINITOR,menorrhagia,system menorrhagia menstrual irregularities,1,0.8608657121658325
AFINITOR,menorrhagia,following,0,0.4814259707927704
AFINITOR,menorrhagia,reactions involving the female,0,0.6009061336517334
AFINITOR,menorrhagia,females in the placebo,0,0.5819470882415771
AFINITOR,menstrual irregularities,menstrual irregularities and vaginal hemorrhage,1,0.8860782384872437
AFINITOR,menstrual irregularities,were menstrual irregularities and,1,0.953571081161499
AFINITOR,menstrual irregularities,menstrual irregularities and vaginal,1,0.9122213125228882
AFINITOR,menstrual irregularities,reactions occurred in less,0,0.5104682445526123
AFINITOR,menstrual irregularities,involving the,0,0.5384228229522705
AFINITOR,vaginal hemorrhage,vaginal,1,0.7918858528137207
AFINITOR,vaginal hemorrhage,The following additional,0,0.5053859949111938
AFINITOR,vaginal hemorrhage,irregularities vaginal hemorrhage The following additional,1,0.899732232093811
AFINITOR,vaginal hemorrhage,additional adverse reactions occurred,0,0.5310848951339722
AFINITOR,epistaxis,epistaxis decreased,1,0.8953817486763
AFINITOR,epistaxis,abnormal,0,0.5216017961502075
AFINITOR,epistaxis,epistaxis decreased appetite otitis media,1,0.7969557046890259
AFINITOR,epistaxis,than of AFINITOR treated epistaxis decreased appetite otitis media depression,1,0.7665513753890991
AFINITOR,epistaxis,epistaxis decreased appetite otitis media depression,1,0.7952960729598999
AFINITOR,epistaxis,epistaxis decreased appetite,1,0.8338956236839294
AFINITOR,epistaxis,treated epistaxis,1,0.9247671365737915
AFINITOR,decreased appetite,decreased appetite otitis media depression abnormal taste,1,0.793857216835022
AFINITOR,decreased appetite,AFINITOR treated patients decreased,1,0.6238415241241455
AFINITOR,decreased appetite,decreased appetite otitis media depression abnormal,1,0.7930924296379089
AFINITOR,otitis media,otitis media depression abnormal taste increased,1,0.7449631690979004
AFINITOR,otitis media,otitis,1,0.8944963216781616
AFINITOR,otitis media,decreased otitis media,1,0.8612896203994751
AFINITOR,otitis media,otitis media,1,1.0
AFINITOR,otitis media,hormone LH levels,0,0.46519139409065247
AFINITOR,depression,AFINITOR treated patients epistaxis decreased appetite otitis,0,0.5058281421661377
AFINITOR,depression,depression abnormal taste increased blood luteinizing,1,0.705643892288208
AFINITOR,depression,abnormal taste,0,0.501556932926178
AFINITOR,depression,increased blood fo,0,0.5084414482116699
AFINITOR,depression,depression,1,0.9999998807907104
AFINITOR,abnormal taste,abnormal taste increased blood luteinizing hormone LH,1,0.7947275638580322
AFINITOR,abnormal taste,depression,0,0.501556932926178
AFINITOR,abnormal taste,abnormal taste increased blood luteinizing hormone,1,0.8110173940658569
AFINITOR,abnormal taste,abnormal taste,1,0.9999998807907104
AFINITOR,abnormal taste,increased blood follicle stimulating,0,0.5238757133483887
AFINITOR,abnormal taste,appetite otitis media abnormal taste increased blood luteinizing hormone LH,1,0.7307442426681519
AFINITOR,abnormal taste,media abnormal taste increased,1,0.8639202117919922
AFINITOR,abnormal taste,otitis media abnormal taste increased blood luteinizing,1,0.7755500078201294
AFINITOR,hypersensitivity,teinizing hormone LH levels increased blood follicle stimulating hormone,0,0.5555461645126343
AFINITOR,hypersensitivity,hypersensitivity ovarian cyst,1,0.7752674221992493
AFINITOR,hypersensitivity,angioedema Table Key Laboratory Abnorma,0,0.6462913155555725
AFINITOR,hypersensitivity,hormone FSH hypersensitivity ovarian,1,0.7158172726631165
AFINITOR,hypersensitivity,hypersensitivity ovarian,1,0.8230600953102112
AFINITOR,hypersensitivity,hypersensitivity ovarian cyst pneumonitis and angioedema,1,0.7361106872558594
AFINITOR,hypersensitivity,ovarian cyst,0,0.4945067763328552
AFINITOR,hypersensitivity,hormone FSH hypersensitivity ovarian cyst,1,0.6770210862159729
AFINITOR,ovarian cyst,levels ovarian cyst pneumonitis and angioedema Table,1,0.7659607529640198
AFINITOR,ovarian cyst,ovarian cyst,0,1.0000001192092896
AFINITOR,ovarian cyst,angioedema Table Key Laboratory Abnormalities Reported,0,0.4735383093357086
AFINITOR,ovarian cyst,levels ovarian cyst,1,0.8697969317436218
AFINITOR,ovarian cyst,FSH levels ovarian,1,0.6915693283081055
AFINITOR,ovarian cyst,ovarian cyst,1,1.0000001192092896
AFINITOR,ovarian cyst,Abnormalities Reported,0,0.5437244176864624
AFINITOR,ovarian cyst,angioedema Table,0,0.4819367229938507
AFINITOR,ovarian cyst,Key,0,0.45478013157844543
AFINITOR,pneumonitis,levels hypersensitivity,0,0.5348919630050659
AFINITOR,pneumonitis,hormone FSH levels,0,0.4072762727737427
AFINITOR,pneumonitis,hypersensitivity ovarian pneumonitis and angioedema,1,0.716152548789978
AFINITOR,pneumonitis,FSH levels hypersensitivity ovarian pneumonitis and angioedema Table Key Laboratory,1,0.6384682655334473
AFINITOR,pneumonitis,pneumonitis and angioedema Table,1,0.8055353164672852
AFINITOR,angioedema,levels hypersensitivity ovarian cyst pneumonitis,0,0.6270241737365723
AFINITOR,angioedema,angioedema Table Key,1,0.8788347244262695
AFINITOR,angioedema,Reported in,0,0.5248537063598633
AFINITOR,stomatitis,for,0,0.5133334398269653
AFINITOR,stomatitis,incidence,0,0.5140981674194336
AFINITOR,stomatitis,tract infection The most common,0,0.5669715404510498
AFINITOR,stomatitis,stomatitis and respiratory,1,0.8527621030807495
AFINITOR,stomatitis,The,0,0.49580514430999756
AFINITOR,stomatitis,and respiratory tract infection,0,0.5631837844848633
AFINITOR,stomatitis,tract infection The most common Grade adverse reactions,0,0.5750417709350586
AFINITOR,respiratory tract infection,were stomatitis pyrexia pneumonia,0,0.650009036064148
AFINITOR,respiratory tract infection,respiratory tract infection The most common Grade adverse,1,0.7899618148803711
AFINITOR,respiratory tract infection,incidence were stomatitis and,0,0.5406509637832642
AFINITOR,respiratory tract infection,AFINITOR incidence were stomatitis respiratory tract infection,1,0.7747782468795776
AFINITOR,respiratory tract infection,stomatitis,0,0.5712025165557861
AFINITOR,respiratory tract infection,respiratory tract infection The,1,0.952947199344635
AFINITOR,respiratory tract infection,most common adverse reactions reported for AFINITOR incidence were stomatitis,0,0.5435596704483032
AFINITOR,stomatitis,stomatitis pyrexia pneumonia,1,0.7320243120193481
AFINITOR,stomatitis,most common adverse reactions reported for AFINITOR incidence were stomatitis,0,0.7721563577651978
AFINITOR,stomatitis,pneumonia gastroenteritis aggression agitation and,0,0.49068641662597656
AFINITOR,stomatitis,stomatitis pyrexia pneumonia gastroenteritis aggression agitation,1,0.6796132326126099
AFINITOR,stomatitis,stomatitis pyrexia pneumonia gastroenteritis aggression,1,0.692571759223938
AFINITOR,stomatitis,adverse reactions incidence stomatitis pyrexia pneumonia,1,0.6857922077178955
AFINITOR,pyrexia,most common key laboratory,0,0.528002917766571
AFINITOR,pyrexia,adverse reactions incidence were pyrexia pneumonia gastroenteritis aggression agitation and,1,0.7478567361831665
AFINITOR,pyrexia,pyrexia pneumonia gastroenteritis,1,0.7950223088264465
AFINITOR,pyrexia,most,0,0.489400714635849
AFINITOR,pyrexia,aggression agitation and,0,0.6310053467750549
AFINITOR,pyrexia,adverse,0,0.5464146137237549
AFINITOR,pneumonia,pneumonia gastroenteritis aggression agitation and amenorrhea,1,0.7124706506729126
AFINITOR,gastroenteritis,The most common,0,0.4744236171245575
AFINITOR,gastroenteritis,key laboratory abnormalities incidence,0,0.5290135741233826
AFINITOR,gastroenteritis,gastroenteritis aggression agitation and amenorrhea,1,0.773007869720459
AFINITOR,gastroenteritis,gastroenteritis aggression agitation and,1,0.8123197555541992
AFINITOR,gastroenteritis,gastroenteritis,1,0.9999998211860657
AFINITOR,gastroenteritis,most common,0,0.48876065015792847
AFINITOR,gastroenteritis,were stomatitis pyrexia pneumonia,0,0.5890268087387085
AFINITOR,gastroenteritis,Grade,0,0.5025903582572937
AFINITOR,gastroenteritis,amenorrhea The most common key,0,0.44991379976272583
AFINITOR,aggression,Grade adverse,0,0.5766794681549072
AFINITOR,aggression,aggression agitation and,1,0.8777139186859131
AFINITOR,aggression,The,0,0.5474703311920166
AFINITOR,agitation,agitation and amenorrhea The most common,1,0.7368531227111816
AFINITOR,agitation,abnormalities incidence were hypercholeste,0,0.5808792114257812
AFINITOR,amenorrhea,amenorrhea The most,1,0.8892345428466797
AFINITOR,amenorrhea,amenorrhea The most common,1,0.8540544509887695
AFINITOR,amenorrhea,aggression agitation amenorrhea The most common,1,0.7950438261032104
AFINITOR,amenorrhea,gastroenteritis aggression agitation amenorrhea The most common,1,0.7239437103271484
AFINITOR,amenorrhea,amenorrhea,1,1.0
AFINITOR,amenorrhea,amenorrhea The,1,0.9447834491729736
AFINITOR,amenorrhea,most,0,0.521114706993103
AFINITOR,amenorrhea,key laboratory,0,0.46814069151878357
AFINITOR,amenorrhea,hypercholesterolemia and,0,0.5455304980278015
AFINITOR,hypercholesterolemia,on agitation and amenorrhea The,0,0.5413254499435425
AFINITOR,hypercholesterolemia,incidence hypercholesterolemia and,1,0.8615357875823975
AFINITOR,hypercholesterolemia,The,0,0.5533469915390015
AFINITOR,hypercholesterolemia,The most common Grade laboratory abnormality inciden,0,0.5914056301116943
AFINITOR,hypercholesterolemia,hypercholesterolemia and elevated partial thromboplastin,1,0.8064836263656616
AFINITOR,hypercholesterolemia,hypercholesterolemia and elevated,1,0.9060755372047424
AFINITOR,elevated partial thromboplastin time,common key laboratory abnormalities,0,0.5514966249465942
AFINITOR,elevated partial thromboplastin time,rhea The most common key laboratory abnormalities incidence were hypercholesterolemia,0,0.5837525129318237
AFINITOR,elevated partial thromboplastin time,rhea The most common key laboratory abnormalities incidence were hypercholesterolemia and,0,0.5833812952041626
AFINITOR,elevated partial thromboplastin time,rhea The most common key laboratory abnormalities,0,0.5516700744628906
AFINITOR,elevated partial thromboplastin time,The most common key laboratory abnormalities incidence were hypercholesterolemia and,0,0.5943096280097961
AFINITOR,elevated partial thromboplastin time,common key,0,0.4622567296028137
AFINITOR,elevated partial thromboplastin time,abnormalities incidence were hypercholesterolemia elevated partial thromboplastin time The,1,0.8534422516822815
AFINITOR,elevated partial thromboplastin time,key laboratory abnormalities incidence were hypercholesterolemia,0,0.5988656282424927
AFINITOR,elevated partial thromboplastin time,elevated partial thromboplastin time The most common Grade laboratory,1,0.8959717750549316
AFINITOR,elevated partial thromboplastin time,elevated partial thromboplastin time The most,1,0.9657340049743652
AFINITOR,neutropenia,permanent discontinuation Dose adjustments inte,0,0.5502233505249023
AFINITOR,neutropenia,There were no,0,0.45397311449050903
AFINITOR,neutropenia,no adverse reactions resulting in permanent discontinuation Dose adjustments,0,0.5134967565536499
AFINITOR,neutropenia,incidence neutropenia There,1,0.8824247121810913
AFINITOR,neutropenia,in permanent discontinuation Dose adjustments,0,0.5364962816238403
AFINITOR,stomatitis,stomatitis Table,1,0.8814517855644226
AFINITOR,stomatitis,of adverse reactions,0,0.5623916983604431
AFINITOR,stomatitis,the,0,0.49580514430999756
AFINITOR,stomatitis,stomatitis Table compares the,1,0.8480056524276733
AFINITOR,mouth ulceration,mouth ulceration stomatitis and lip ulceration b,1,0.8816841840744019
AFINITOR,mouth ulceration,Version a mouth ulceration stomatitis and lip ulceration,1,0.8944648504257202
AFINITOR,mouth ulceration,mouth ulceration stomatitis and lip ulceration,1,0.8954300880432129
AFINITOR,mouth ulceration,to CTCAE Version,0,0.44039127230644226
AFINITOR,mouth ulceration,Grading according to CTCAE Version,0,0.4597717523574829
AFINITOR,mouth ulceration,Version a mouth ulceration,1,0.9543724060058594
AFINITOR,stomatitis,stomatitis and lip ulceration b Includes,1,0.846704363822937
AFINITOR,stomatitis,stomatitis and lip ulceration,1,0.8791371583938599
AFINITOR,stomatitis,Includes mouth stomatitis and lip ulceration b Includes,1,0.8439782857894897
AFINITOR,lip ulceration,stomatitis lip,1,0.8151068687438965
AFINITOR,respiratory tract infection,lip ulceration b respiratory tract infection upper respiratory tract,1,0.7098346948623657
AFINITOR,respiratory tract infection,stomatitis lip,1,0.5228188037872314
AFINITOR,respiratory tract infection,respiratory tract infection upper,1,0.8327628374099731
AFINITOR,respiratory tract infection,ulceration b respiratory tract infection,1,0.7654855251312256
AFINITOR,respiratory tract infection,lip ulceration b Includes,0,0.5163575410842896
AFINITOR,respiratory tract infection,lip ulceration b respiratory tract infection upper respiratory,1,0.7102115154266357
AFINITOR,respiratory tract infection,ulceration stomatitis and lip,0,0.5072592496871948
AFINITOR,respiratory tract infection,respiratory tract infection upper respiratory tract,1,0.8281524181365967
AFINITOR,upper respiratory tract infection,and lip,0,0.5355625152587891
AFINITOR,upper respiratory tract infection,stomatitis and lip ulceration b Includes,0,0.5456058382987976
AFINITOR,upper respiratory tract infection,Includes mouth ulceration stomatitis and lip ulceration,0,0.5736929178237915
AFINITOR,upper respiratory tract infection,c Includes gastroenteritis gastroenteritis viral and gas,0,0.608249843120575
AFINITOR,respiratory tract infection viral,infection respiratory tract infection,1,0.8913199305534363
AFINITOR,respiratory tract infection viral,respiratory tract infection viral c Includes gastroenteritis gastroenteritis,1,0.7757998704910278
AFINITOR,respiratory tract infection viral,respiratory tract infection respiratory tract infection viral,1,0.9812140464782715
AFINITOR,respiratory tract infection viral,tract infection viral c Includes,1,0.7583835124969482
AFINITOR,respiratory tract infection viral,tract infection viral c,1,0.7735936641693115
AFINITOR,respiratory tract infection viral,respiratory tract infection viral c,1,0.8717062473297119
AFINITOR,respiratory tract infection viral,infection viral c Includes gastroenteritis gastroenteritis,1,0.6502040028572083
AFINITOR,respiratory tract infection viral,c Includes gastroenteritis gastroenteritis viral and,0,0.641954243183136
AFINITOR,gastroenteritis,gastroenteritis gastroenteritis viral and,1,0.8708359599113464
AFINITOR,gastroenteritis,gastroenteritis gastroenteritis viral and gastrointestinal,1,0.8577781915664673
AFINITOR,gastroenteritis,gastroenteritis gastroenteritis,1,0.9351868033409119
AFINITOR,gastroenteritis,and gastrointestinal infection d,0,0.7832480669021606
AFINITOR,gastroenteritis,gastroenteritis viral and gastrointestinal infection d Includes agitation anxiety panic attac,0,0.8151114583015442
AFINITOR,gastroenteritis,infection viral c Includes,0,0.5894129276275635
AFINITOR,gastroenteritis,c Includes,0,0.5102953910827637
AFINITOR,gastroenteritis viral,gastroenteritis viral and gastrointestinal infection,1,0.8874288201332092
AFINITOR,gastroenteritis viral,gastroenteritis viral and gastrointestinal infection d,1,0.856374979019165
AFINITOR,gastroenteritis viral,c Includes gastroenteritis viral and gastrointestinal,1,0.8315533399581909
AFINITOR,gastroenteritis viral,gastroenteritis viral and gastrointestinal,1,0.903207540512085
AFINITOR,gastroenteritis viral,gastroenteritis viral,1,1.0
AFINITOR,gastroenteritis viral,d,0,0.5065419673919678
AFINITOR,gastrointestinal infection,tract infection viral c Includes gastroenteritis gastroenteritis viral and,0,0.7230965495109558
AFINITOR,gastrointestinal infection,gastrointestinal infection,1,1.0000001192092896
AFINITOR,gastrointestinal infection,anxiety panic attack aggression abnormal behavior and,0,0.4926477074623108
AFINITOR,gastrointestinal infection,Includes gastroenteritis gastroenteritis viral gastrointestinal infection,1,0.848387598991394
AFINITOR,gastrointestinal infection,Includes gastroenteritis gastroenteritis viral gastrointestinal infection d Includes agitation anxiety panic,1,0.7709548473358154
AFINITOR,gastrointestinal infection,gastroenteritis gastroenteritis viral gastrointestinal infection,1,0.8747074604034424
AFINITOR,agitation,agitation anxiety panic,1,0.8932132720947266
AFINITOR,agitation,agitation anxiety panic attack,1,0.8675596714019775
AFINITOR,agitation,anxiety panic attack,0,0.6474024057388306
AFINITOR,agitation,and gastrointestinal infection d agitation,1,0.8027480840682983
AFINITOR,agitation,agitation anxiety panic attack aggression,1,0.8497680425643921
AFINITOR,anxiety,anxiety panic attack aggression,1,0.7476710081100464
AFINITOR,anxiety,panic attack,0,0.7706077098846436
AFINITOR,anxiety,aggression abnormal behavior and,0,0.5621483325958252
AFINITOR,anxiety,anxiety,1,1.0
AFINITOR,anxiety,anxiety panic attack,1,0.8274631500244141
AFINITOR,anxiety,viral and gastrointestinal infection d,0,0.527831494808197
AFINITOR,anxiety,infection d Includes anxiety panic attack aggression abnormal behavior,1,0.7253866195678711
AFINITOR,anxiety,and obsessive,0,0.6139066219329834
AFINITOR,anxiety,anxiety panic attack aggression abnormal behavior,1,0.7286412119865417
AFINITOR,panic attack,infection d Includes agitation panic,1,0.7396680116653442
AFINITOR,panic attack,d Includes agitation panic attack,1,0.8133453130722046
AFINITOR,panic attack,infection d Includes agitation panic attack,1,0.7779699563980103
AFINITOR,panic attack,gastrointestinal,0,0.4956170916557312
AFINITOR,panic attack,panic attack aggression,1,0.8752602338790894
AFINITOR,panic attack,abnormal behavior and obsessive compulsive disorder e Includes rash rash,0,0.5968735218048096
AFINITOR,panic attack,behavior and obsessive compulsive disorder,0,0.5307232737541199
AFINITOR,panic attack,panic attack aggression abnormal behavior,1,0.7907278537750244
AFINITOR,aggression,Includes agitation anxiety panic aggression,1,0.8097976446151733
AFINITOR,aggression,panic attack aggression abnormal behavior,1,0.7675765156745911
AFINITOR,aggression,Includes agitation anxiety panic aggression abnormal behavior and obsessive,1,0.7461709976196289
AFINITOR,aggression,aggression,1,1.0
AFINITOR,aggression,anxiety panic attack,0,0.568405270576477
AFINITOR,abnormal behavior,abnormal behavior and obsessive compulsive,1,0.8772902488708496
AFINITOR,abnormal behavior,Includes rash rash generalized,0,0.5259174704551697
AFINITOR,abnormal behavior,is viral and gastrointestinal infection d,0,0.5239582061767578
AFINITOR,obsessive compulsive disorder,generalized rash macular rash maculopapular rash papular dermatitis al,0,0.5056008100509644
AFINITOR,obsessive compulsive disorder,abnormal behavior obsessive compulsive disorder e Includes rash rash,1,0.7956738471984863
AFINITOR,obsessive compulsive disorder,compulsive disorder e,1,0.8306716084480286
AFINITOR,obsessive compulsive disorder,abnormal behavior obsessive compulsive disorder e Includes rash rash generalized,1,0.798772931098938
AFINITOR,obsessive compulsive disorder,and,0,0.528085470199585
AFINITOR,obsessive compulsive disorder,Includes rash rash generalized rash macular rash,0,0.5137050151824951
AFINITOR,obsessive compulsive disorder,rash rash generalized rash macular,0,0.4961385428905487
AFINITOR,obsessive compulsive disorder,obsessive compulsive disorder,1,1.0000001192092896
AFINITOR,obsessive compulsive disorder,estinal infection d Includes agitation anxiety panic,0,0.6324906349182129
AFINITOR,rash,rash rash,1,0.9747189283370972
AFINITOR,rash,rash rash generalized rash,1,0.8608335256576538
AFINITOR,rash,disorder e rash rash generalized rash,1,0.8387873768806458
AFINITOR,rash,rash rash generalized rash macular,1,0.7890965938568115
AFINITOR,rash,rash rash generalized rash macular rash,1,0.7997088432312012
AFINITOR,rash generalized,papular dermatitis,0,0.6812599301338196
AFINITOR,rash generalized,Includes,0,0.5523736476898193
AFINITOR,rash generalized,e Includes rash generalized rash,1,0.9257798194885254
AFINITOR,rash generalized,panic attack aggression abnormal behavior,0,0.5590669512748718
AFINITOR,rash macular,rash rash macular rash maculopapular rash papular dermatitis,1,0.8842581510543823
AFINITOR,rash macular,panic attack aggression abnormal behavior,0,0.5142673254013062
AFINITOR,rash macular,e Includes rash rash rash macular rash maculopapular rash papular dermatitis,1,0.8620721697807312
AFINITOR,rash macular,behavior and obsessive compulsive disorder e Includes,0,0.5016293525695801
AFINITOR,rash macular,maculopapular rash papular dermatitis allergic and,0,0.8062634468078613
AFINITOR,rash macular,Includes rash rash rash macular rash maculopapular rash papular,1,0.8838895559310913
AFINITOR,rash maculo-papular,disorder e Includes rash rash,0,0.7302464246749878
AFINITOR,rash maculo-papular,rash rash generalized rash rash maculo-papular rash,1,0.9308212399482727
AFINITOR,rash maculo-papular,rash maculo-papular rash,1,0.9901909828186035
AFINITOR,rash maculo-papular,and obsessive compulsive disorder e Includes,0,0.5222278833389282
AFINITOR,rash maculo-papular,rash macular,0,0.9009200930595398
AFINITOR,rash maculo-papular,rash maculo-papular,1,0.9999999403953552
AFINITOR,rash maculo-papular,rash rash generalized rash rash,1,0.7177766561508179
AFINITOR,rash maculo-papular,rash rash,1,0.7652450799942017
AFINITOR,rash papular,rash papular dermatitis allergic and urticaria AFINITOR,1,0.8786442875862122
AFINITOR,rash papular,rash rash,1,0.8327125906944275
AFINITOR,rash papular,rash macular rash rash papular dermatitis allergic and urticaria AFINITOR,1,0.8271759748458862
AFINITOR,rash papular,rash papular,1,0.9999998807907104
AFINITOR,rash papular,rash papular dermatitis,1,0.9480376243591309
AFINITOR,rash papular,generalized rash macular rash rash papular,1,0.8620764017105103
AFINITOR,rash papular,rash macular rash rash papular,1,0.8797691464424133
AFINITOR,dermatitis allergic,rash dermatitis allergic,1,0.9146747589111328
AFINITOR,dermatitis allergic,rash papular,1,0.6827129125595093
AFINITOR,urticaria,urticaria AFINITOR N Placebo N All,1,0.8109316825866699
AFINITOR,urticaria,N All,0,0.5166912078857422
AFINITOR,urticaria,allergic urticaria AFINITOR,1,0.8545005321502686
AFINITOR,menstrual abnormalities,the menstrual abnormalities were reported dysmenorrhea menorrhagia,1,0.8876584768295288
AFINITOR,menstrual abnormalities,N All,0,0.48873990774154663
AFINITOR,dysmenorrhea,abnormalities were dysmenorrhea menorrhagia metrorrhagia and unspecified menstrual,1,0.8167224526405334
AFINITOR,dysmenorrhea,N All,0,0.5088252425193787
AFINITOR,dysmenorrhea,dysmenorrhea menorrhagia metrorrhagia and unspecified menstrual,1,0.8231391906738281
AFINITOR,dysmenorrhea,r this same group of AFINITORtreated females the following menstrual,0,0.6699858903884888
AFINITOR,dysmenorrhea,dysmenorrhea menorrhagia metrorrhagia,1,0.8494968414306641
AFINITOR,menorrhagia,menorrhagia metrorrhagia,1,0.8700560331344604
AFINITOR,menorrhagia,f AFINITORtreated females the,0,0.6511002779006958
AFINITOR,menorrhagia,abnormalities were reported menorrhagia metrorrhagia,1,0.8572625517845154
AFINITOR,metrorrhagia,were reported dysmenorrhea metrorrhagia and unspecified,1,0.8039743304252625
AFINITOR,metrorrhagia,f AFINITORtreated females the,0,0.6327779293060303
AFINITOR,metrorrhagia,were reported dysmenorrhea metrorrhagia and unspecified menstrual irregularity The,1,0.7777896523475647
AFINITOR,metrorrhagia,abnormalities were reported dysmenorrhea menorrhagia,0,0.6113708019256592
AFINITOR,metrorrhagia,metrorrhagia and unspecified,1,0.9075711369514465
AFINITOR,metrorrhagia,menorrhagia,0,0.6198230981826782
AFINITOR,metrorrhagia,the following,0,0.5408225059509277
AFINITOR,metrorrhagia,reported dysmenorrhea metrorrhagia and,1,0.8292504549026489
AFINITOR,unspecified menstrual irregularity,adverse reactions occurred in less than,0,0.5583257675170898
AFINITOR,unspecified menstrual irregularity,metrorrhagia unspecified,1,0.724297046661377
AFINITOR,unspecified menstrual irregularity,unspecified,1,0.7190899848937988
AFINITOR,unspecified menstrual irregularity,menstrual irregularity The,1,0.9082401990890503
AFINITOR,unspecified menstrual irregularity,dysmenorrhea menorrhagia metrorrhagia unspecified,1,0.8078742027282715
AFINITOR,unspecified menstrual irregularity,menstrual abnormalities were reported dysmenorrhea menorrhagia metrorrhagia and,0,0.8371589183807373
AFINITOR,unspecified menstrual irregularity,unspecified menstrual irregularity The following,1,0.9831570386886597
AFINITOR,unspecified menstrual irregularity,unspecified menstrual irregularity,1,0.9999999403953552
AFINITOR,unspecified menstrual irregularity,menstrual irregularity The following additional adverse reactions,1,0.8044452667236328
AFINITOR,nausea,nausea pain in extremity,1,0.7862388491630554
AFINITOR,nausea,patients,0,0.54615718126297
AFINITOR,nausea,adverse reactions occurred in less than of AFINITORtreated,0,0.6193121671676636
AFINITOR,nausea,nausea pain,1,0.8864089250564575
AFINITOR,nausea,nausea pain in extremity insomnia,1,0.7426064610481262
AFINITOR,pain in extremity,insomnia pneumonia epistaxis hypersensitivity increased blood luteini,0,0.48635947704315186
AFINITOR,pain in extremity,insomnia pneumonia epistaxis hypersensitivity,0,0.48087573051452637
AFINITOR,pain in extremity,of AFINITORtreated patients pain in extremity,1,0.909369945526123
AFINITOR,insomnia,insomnia pneumonia epistaxis hypersensitivity,1,0.6886237263679504
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity,1,0.7018749713897705
AFINITOR,pneumonia,nausea pain in extremity pneumonia epistaxis hypersensitivity,1,0.7089451551437378
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity increased blood,1,0.6803454160690308
AFINITOR,pneumonia,extremity pneumonia,1,0.7562246322631836
AFINITOR,pneumonia,hypersensitivity increased blood luteinizing hormone LH,0,0.46708208322525024
AFINITOR,pneumonia,luteinizing hormone,0,0.524828314781189
AFINITOR,epistaxis,hormone LH levels and pneumonitis,0,0.4512985348701477
AFINITOR,hypersensitivity,hypersensitivity increased,1,0.8974180221557617
AFINITOR,hypersensitivity,hormone LH levels and pneumonitis Table,0,0.5619899034500122
AFINITOR,hypersensitivity,levels and pneumonitis Table,0,0.5527645349502563
AFINITOR,hypersensitivity,hypersensitivity increased blood luteinizing,1,0.8008133172988892
AFINITOR,hypersensitivity,hormone LH levels and pneumonitis,0,0.5614058971405029
AFINITOR,hypersensitivity,pneumonia hypersensitivity increased blood luteinizing hormone LH,1,0.703144371509552
AFINITOR,hypersensitivity,in extremity insomnia pneumonia epistaxis,0,0.49022290110588074
AFINITOR,hypersensitivity,hypersensitivity increased blood luteinizing hormone,1,0.7997380495071411
AFINITOR,pneumonitis,Table,0,0.4791463017463684
AFINITOR,pneumonitis,Laboratory Abnormalities Reported in AFINITORtreated,0,0.5422462821006775
AFINITOR,pneumonitis,pneumonitis Table Key Laboratory Abnormalities Reported,1,0.7586942911148071
AFINITOR,pneumonitis,Abnormalities Reported in AFINITORtreated Patients with SEGA in,0,0.5029717683792114
AFINITOR,cellulitis,cellulitis hyperglycemia and elevated creatinine,1,0.7796764373779297
AFINITOR,cellulitis,and elevated creatinine,0,0.5443300008773804
AFINITOR,cellulitis,cellulitis hyperglycemia and elevated,1,0.8127063512802124
AFINITOR,cellulitis,cellulitis hyperglycemia and elevated creatinine Postmarketing,1,0.7604141235351562
AFINITOR,cellulitis,key laboratory cellulitis,1,0.8058992624282837
AFINITOR,cellulitis,laboratory cellulitis hyperglycemia and,1,0.7900985479354858
AFINITOR,elevated creatinine,key laboratory abnormalities cellulitis,0,0.596092939376831
AFINITOR,elevated creatinine,elevated creatinine Postmarketing Experience The following adverse,1,0.8546997308731079
AFINITOR,elevated creatinine,hyperglycemia elevated creatinine,1,0.9053372144699097
AFINITOR,elevated creatinine,abnormalities cellulitis,0,0.5335522294044495
AFINITOR,elevated creatinine,elevated creatinine Postmarketing,1,0.8910494446754456
AFINITOR,acute pancreatitis,to drug acute,1,0.6818773746490479
AFINITOR,acute pancreatitis,acute pancreatitis cholecystitis cholelithiasis arterial,1,0.8115696907043457
AFINITOR,acute pancreatitis,arterial thrombotic,0,0.5442721843719482
AFINITOR,acute pancreatitis,to reliably estimate frequency,0,0.4355863928794861
AFINITOR,acute pancreatitis,causal,0,0.4994078278541565
AFINITOR,acute pancreatitis,reflex sympathetic,0,0.5318869948387146
AFINITOR,acute pancreatitis,drug acute pancreatitis cholecystitis,1,0.8208585977554321
AFINITOR,acute pancreatitis,causal relationship to drug acute,1,0.6075011491775513
AFINITOR,cholelithiasis,thrombotic events and,0,0.5338655710220337
AFINITOR,cholelithiasis,cholelithiasis arterial thrombotic events and reflex,1,0.7798037528991699
AFINITOR,cholelithiasis,cholelithiasis,1,0.9999998211860657
AFINITOR,cholelithiasis,cholelithiasis arterial thrombotic events and,1,0.8088643550872803
AFINITOR,arterial thrombotic events,thrombotic events and reflex,1,0.8514857292175293
AFINITOR,Non-infectious pneumonitis,reactions are discuss ed in,1,0.4937524199485779
AFINITOR,Non-infectious pneumonitis,reactions are discuss,1,0.49927568435668945
AFINITOR,Non-infectious pneumonitis,serious adv,0,0.5517392158508301
AFINITOR,Non-infectious pneumonitis,serious erse reactions are discuss ed,1,0.5230406522750854
AFINITOR,Non-infectious pneumonitis,following serious erse reactions are discuss ed,1,0.5168419480323792
AFINITOR,fatal,of the label e War nings and Precautions Noninfectious,1,0.4967230260372162
AFINITOR,fatal,serious adv,0,0.6218959093093872
AFINITOR,fatal,in greater,0,0.506556510925293
AFINITOR,Infections,utions (5. Angioedema with concomitant use,1,0.6014866828918457
AFINITOR,Infections,utions (5. Angioedema with concomitant use of,1,0.6001375317573547
AFINITOR,Infections,Infections see Warnings and utions (5.,1,0.7812670469284058
AFINITOR,Infections,see Warnings and utions (5.,1,0.5876954197883606
AFINITOR,Infections,see Warnings and utions (5. Angioedema with concomitant use of,1,0.6082978248596191
AFINITOR,Infections,utions (5. Angioedema with,1,0.6118658781051636
AFINITOR,Infections,Warnings and Preca,0,0.5714938640594482
AFINITOR,Infections,Precautions Infections see Warnings and,0,0.769990086555481
AFINITOR,Infections,with concomitant use,0,0.5759662985801697
AFINITOR,infections,Warnings and Precautions a,1,0.6190095543861389
AFINITOR,infections,with con comitant use of,1,0.5834554433822632
AFINITOR,infections,Precautions Infections,0,0.8154463768005371
AFINITOR,infections,Precautions a with con,1,0.6104538440704346
AFINITOR,infections,see,0,0.5760005116462708
AFINITOR,infections,see Warnings and Precautions Oral ulceration see Warn,0,0.6003713607788086
AFINITOR,Angioedema,lceration  see Warnings,1,0.530381441116333
AFINITOR,Angioedema,Precautions Oral lceration  see,1,0.5972028970718384
AFINITOR,Angioedema,failure see,0,0.5062874555587769
AFINITOR,Angioedema,u,0,0.5147534608840942
AFINITOR,Angioedema,see Warnings and Precautions Renal,0,0.5420193672180176
AFINITOR,Angioedema,lceration  see Warnings and,1,0.5266226530075073
AFINITOR,Angioedema,see,0,0.5217977166175842
AFINITOR,Oral ulceration,wound healin,1,0.6462585926055908
AFINITOR,Mouth ulcers,and Precautions Impaired wound,0,0.6339106559753418
AFINITOR,Mouth ulcers,Precautions Because clinical trials are conducted,0,0.5106151103973389
AFINITOR,Mouth ulcers,clinical trials are conducted under widely varying,0,0.5002366900444031
AFINITOR,stomatitis,wound healing see and Precau tions Because clinical trials,1,0.5682668685913086
AFINITOR,stomatitis,clinical trials are conducted under widely varying,0,0.49354949593544006
AFINITOR,stomatitis,and Precau tions Because clinical trials,1,0.5116915702819824
AFINITOR,stomatitis,and Precau tions Because clinical trials are,1,0.4911940097808838
AFINITOR,stomatitis,and Precau tions,1,0.4886248707771301
AFINITOR,stomatitis,wound healing see and Precau tions Because clinical,1,0.5660572648048401
AFINITOR,stomatitis,wound healing see and Precau,1,0.5749595165252686
AFINITOR,Renal failure,Because clinical trials,0,0.5355874300003052
AFINITOR,Renal failure,may not reflect the rates,0,0.42025771737098694
AFINITOR,Renal failure,eaction rates observed cannot,1,0.49174392223358154
AFINITOR,Renal failure,are conducted under widely varying conditions the adverse,0,0.5225508809089661
AFINITOR,renal failure,may not reflect the rates observed,0,0.4461607038974762
AFINITOR,renal failure,reaction rates observed c,0,0.5086759328842163
AFINITOR,renal failure,to rates in other trials and may,0,0.4962524473667145
AFINITOR,renal failure,annot be dire ctly compared to,1,0.5445523858070374
AFINITOR,fatal, not  reflect the rates observed,1,0.43966197967529297
AFINITOR,fatal,in other trials and  not  reflect the rates,1,0.45059770345687866
AFINITOR,fatal,the,0,0.5483651161193848
AFINITOR,fatal, not  reflect the,1,0.4535895884037018
AFINITOR,fatal, not ,1,0.5371623039245605
AFINITOR,fatal, not  reflect the rates observed in,1,0.4413190484046936
AFINITOR,fatal,compared to rates,0,0.4488981366157532
AFINITOR,fatal,directly compared to rates in other trials and may,0,0.48500412702560425
AFINITOR,fatal,trials and  not  reflect the rates observed,1,0.45801109075546265
AFINITOR,Impaired wound healing,EXCERPT: A dvanced HR BC advanced PNET,1,0.5382288694381714
AFINITOR,Impaired wound healing,reactions incidence include,0,0.5268518328666687
AFINITOR,Impaired wound healing,PNET,0,0.5528329610824585
AFINITOR,Impaired wound healing,clinical ce.,1,0.5398223996162415
AFINITOR,Impaired wound healing,may not reflect the rates observed in,0,0.5101475715637207
AFINITOR,Impaired wound healing,ce. EXCERPT: A dvanced HR BC,1,0.5130606889724731
AFINITOR,wound-related complications,reflect the rates observed in clinical practice EXCERPT Advanced,0,0.5380970239639282
AFINITOR,wound-related complications,"PNET, advanced RCC: Mo st common adverse reactions incidence",1,0.6067272424697876
AFINITOR,wound-related complications,advanced RCC: Mo st common adverse,1,0.5910367965698242
AFINITOR,wound-related complications,common adverse reactions incidence include stomatitis infections,0,0.6708611249923706
AFINITOR,wound-related complications,rash fatigue diarrhe,0,0.5227512121200562
AFINITOR,Elevations of serum creatinine,cough,0,0.49791738390922546
AFINITOR,Elevations of serum creatinine,headache and decreased,0,0.45884379744529724
AFINITOR,Elevations of serum creatinine,"nausea, fever, asthenia, cough",1,0.5157512426376343
AFINITOR,Elevations of serum creatinine,rash fatigue diarrhea edema,0,0.5352423191070557
AFINITOR,Elevations of serum creatinine,"edema pain, nausea, fever,",1,0.5360454320907593
AFINITOR,Elevations of serum creatinine,rash fatigue diarrhea,0,0.5026344656944275
AFINITOR,Decreases in hemoglobin,", 6.3 ) Renal an giomyolipoma with TSC Most",1,0.5035241842269897
AFINITOR,Decreases in hemoglobin,"cough headache and decreased  ,  6.3  )



 Renal an giomyolipoma with",1,0.5930765867233276
AFINITOR,Decreases in hemoglobin,nausea fever asthenia cough,0,0.5755892992019653
AFINITOR,Decreases in hemoglobin,adverse reaction incidence is,0,0.564822793006897
AFINITOR,Embryo-fetal toxicity,To report SUSPECTED ADVERSE REACTIONS contact Novartis Pharmaceut,0,0.5952427387237549
AFINITOR,Embryo-fetal toxicity,contact Novartis icals Corporation at ,1,0.5243643522262573
AFINITOR,Embryo-fetal toxicity,icals Corporation at ,1,0.4786149263381958
AFINITOR,Embryo-fetal toxicity,ADVERSE REACTIONS contact Novartis,0,0.5985052585601807
AFINITOR,Embryo-fetal toxicity,REACTIONS contact Novartis icals Corporation at ,1,0.5642926692962646
AFINITOR,Embryo-fetal toxicity,ADVERSE REACTIONS contact Novartis icals Corporation at  or FDA at FDA or,1,0.5961389541625977
AFINITOR,Non-infectious pneumonitis,AFINITOR mgday plus exemestane mgday n versus,0,0.4755667746067047
AFINITOR,Non-infectious pneumonitis,Breast,0,0.5034982562065125
AFINITOR,Non-infectious pneumonitis,placebo plus exemestane,0,0.4669512212276459
AFINITOR,Non-infectious pneumonitis,ancer The efficacy and safety,0,0.5137701034545898
AFINITOR,non-infectious pneumonitis,hormone receptorpositive  breast cancer. The median age of patients was,1,0.39511430263519287
AFINITOR,non-infectious pneumonitis,ancer The efficacy and safety,0,0.5137701034545898
AFINITOR,non-infectious pneumonitis,hormone receptorpositive  breast cancer. The median,1,0.4085671305656433
AFINITOR,non-infectious pneumonitis,or metastatic hormone receptorpositive  breast cancer. The median age of patients was years,1,0.4231385886669159
AFINITOR,non-infectious pneumonitis,in patients with advanced or metastatic hormone receptorpositive HERnegative,0,0.4771113991737366
AFINITOR,non-infectious pneumonitis,or metastatic hormone receptorpositive  breast cancer. The median,1,0.4289347529411316
AFINITOR,non-infectious pneumonitis,receptorpositive breast cancer.,1,0.4669700562953949
AFINITOR,non-infectious pneumonitis,metastatic hormone receptorpositive  breast cancer. The median age of patients was years,1,0.4146958589553833
AFINITOR,non-infectious pneumonitis,receptorpositive  breast cancer. The median,1,0.4387718439102173
AFINITOR,non-infectious pneumonitis,cancer. The median age of patients,1,0.42239442467689514
AFINITOR,non-infectious pneumonitis,controlled trial in patients with advanced or metastatic hormone receptorpositive,0,0.46803367137908936
AFINITOR,non-infectious pneumonitis,hormone receptorpositive  breast cancer. The median age,1,0.404887855052948
AFINITOR,non-infectious pneumonitis,or metastatic hormone receptorpositive breast cancer. The,1,0.4491173326969147
AFINITOR,pneumonitis, stomatitis,1,0.5781590938568115
AFINITOR,pneumonitis,lip ulceration c,0,0.519463062286377
AFINITOR,pneumonitis,and,0,0.4837256073951721
AFINITOR,pneumonitis,mouth ulceration aphthous stomatitis glossodynia gingival pain glossitis and lip ulceration c,0,0.5166257619857788
AFINITOR,pneumonitis, stomatitis mouth ulceration aphthous,1,0.5210022926330566
AFINITOR,pneumonitis,a Exemestane mgday b  stomatitis mouth ulceration aphthous stomatitis,1,0.5272833108901978
AFINITOR,pneumonitis,mgday b  stomatitis,1,0.5184206962585449
AFINITOR,pneumonitis, stomatitis mouth,1,0.5172646045684814
AFINITOR,pneumonitis,Exemestane mgday b  stomatitis,1,0.5060141086578369
AFINITOR,protozoal infections,tract infection upper respiratory tract infe,0,0.5715068578720093
AFINITOR,protozoal infections,em,1,0.5325280427932739
AFINITOR,protozoal infections,and,0,0.4929191470146179
AFINITOR,protozoal infections,tract infection upper respiratory tract,0,0.5715879201889038
AFINITOR,protozoal infections,and infestations em,1,0.6444191932678223
AFINITOR,protozoal infections,within the infections,0,0.7414568066596985
AFINITOR,protozoal infections,"em organ class,",1,0.48565393686294556
AFINITOR,protozoal infections,infection upper respiratory,0,0.5987377762794495
AFINITOR,infections with opportunistic pathogens,upper,0,0.46035462617874146
AFINITOR,infections with opportunistic pathogens,"being nasopharyngitis (10%), urinary tr act infection upper respiratory",1,0.6165595054626465
AFINITOR,infections with opportunistic pathogens,"organ class the most being nasopharyngitis (10%), urinary tr act infection upper",1,0.6021242141723633
AFINITOR,infections with opportunistic pathogens,infections and infestations,0,0.7532240748405457
AFINITOR,infections with opportunistic pathogens,act infection upper respiratory tract infection pneumonia bronchitis,0,0.621700644493103
AFINITOR,pneumonia,and sepsis and,0,0.6711397171020508
AFINITOR,pneumonia,candidiasis and,0,0.620138943195343
AFINITOR,pneumonia,tract infection,0,0.6878365278244019
AFINITOR,mycobacterial infections,"bronchitis cystitis inusitis (3%), and also  including",1,0.5865195989608765
AFINITOR,mycobacterial infections,tract infection,0,0.6662826538085938
AFINITOR,mycobacterial infections,C d Includes pneumonitis inte,0,0.6408032178878784
AFINITOR,mycobacterial infections,cystitis s,0,0.5903157591819763
AFINITOR,mycobacterial infections,"bronchitis cystitis inusitis (3%), and also  including candidiasis",1,0.6050333976745605
AFINITOR,mycobacterial infections,d Includes pneumonitis inte,0,0.6485596299171448
AFINITOR,mycobacterial infections,"pneumonia bronchitis cystitis inusitis (3%), and also  including candidiasis and sepsis and",1,0.6037014126777649
AFINITOR,mycobacterial infections,"infection pneumonia bronchitis cystitis inusitis (3%), and also  including candidiasis and sepsis and",1,0.6234698295593262
AFINITOR,mycobacterial infections,bronchitis,0,0.6265341639518738
AFINITOR,mycobacterial infections,infection pneumonia bronchitis cystitis inusitis,1,0.6419683694839478
AFINITOR,bacterial infections,"g candidiasis (<1%), and sepsis and hepatitis C",1,0.6206383109092712
AFINITOR,bacterial infections,"g candidiasis (<1%),",1,0.5905989408493042
AFINITOR,bacterial infections,"also g candidiasis (<1%), and sepsis",1,0.6778830289840698
AFINITOR,bacterial infections,"also g candidiasis (<1%), and",1,0.6069377660751343
AFINITOR,bacterial infections,cystitis sinusitis and also,0,0.621955156326294
AFINITOR,invasive fungal infections,"also including candidiasis nd sepsis (<1%), and hepat itis C d Includes",1,0.7530860900878906
AFINITOR,invasive fungal infections,cystitis sinusitis and also,0,0.6009482145309448
AFINITOR,invasive fungal infections,"including candidiasis nd sepsis (<1%), and hepat itis C",1,0.7554779052734375
AFINITOR,invasive fungal infections,candidiasis a,0,0.7580955028533936
AFINITOR,aspergillosis,d Inclu des,1,0.5538743734359741
AFINITOR,aspergillosis,des pneumonitis interstitial lung disease lung infiltration and pulmonary fibrosis e Exposure,0,0.5978053212165833
AFINITOR,aspergillosis,%). d,1,0.5434269905090332
AFINITOR,candidiasis,s pneumonit,1,0.5659044981002808
AFINITOR,candidiasis,s pneumonit is,1,0.5552616715431213
AFINITOR,candidiasis,s pneumonit is interstitial lung disease,1,0.5586691498756409
AFINITOR,candidiasis,d s pneumonit is interstitial lung disease lung,1,0.5555828809738159
AFINITOR,pneumocystis jiroveci pneumonia,"disease, lung",1,0.6204643249511719
AFINITOR,pneumocystis jiroveci pneumonia,"Includes pneumonitis nterstitial lung disease,",1,0.6505812406539917
AFINITOR,pneumocystis jiroveci pneumonia,i,0,0.492120623588562
AFINITOR,pneumocystis jiroveci pneumonia,so including candidiasis and,0,0.6388038396835327
AFINITOR,pneumocystis jiroveci pneumonia,pneumonitis,0,0.6941218376159668
AFINITOR,pneumocystis jiroveci pneumonia,nterstitial lung,1,0.5683896541595459
AFINITOR,pneumocystis jiroveci pneumonia,pulmonary,0,0.6474786996841431
AFINITOR,PJP,fil,1,0.5066654086112976
AFINITOR,PJP,nd sepsis and hepatitis C d Includes,0,0.4512885510921478
AFINITOR,PJP,pulmonary fibrosis,0,0.48596566915512085
AFINITOR,PJP,fil tration and pulmonary,1,0.48542606830596924
AFINITOR,PJP,and pulmonary,0,0.46728143095970154
AFINITOR,viral infections,"disease lung n, and pulmonary fibrosis e Exposure to AFINITOR",1,0.519745945930481
AFINITOR,viral infections,and pulmonary,0,0.5379334688186646
AFINITOR,viral infections,and pulmonary,1,0.5379334688186646
AFINITOR,viral infections,or placebo AFINITOR mgday ex,0,0.5151760578155518
AFINITOR,reactivation of hepatitis B virus,infiltration and pulmonary e Exposure to AFINITOR,1,0.5303982496261597
AFINITOR,reactivation of hepatitis B virus,or placeb o AFINITOR mgday,1,0.514947772026062
AFINITOR,sepsis,mgday exemestane,0,0.48667919635772705
AFINITOR,sepsis,exemestane a N Placebo ane  a,1,0.48525649309158325
AFINITOR,sepsis,ane a N All grades,1,0.5254009366035461
AFINITOR,sepsis,Grade Grade All grades,0,0.49312824010849
AFINITOR,sepsis,ane a,1,0.501674473285675
AFINITOR,sepsis,mgday exemestane a,0,0.48542600870132446
AFINITOR,sepsis,Grade Grade All,0,0.5078390836715698
AFINITOR,hepatic failure,a                 All grades Grade,1,0.4340773820877075
AFINITOR,hepatic failure,Grade Grade All,0,0.4549728035926819
AFINITOR,fatal,rades Grade Grade All grades,0,0.4851004481315613
AFINITOR,fatal,Placebo exemestane a All g rades Grade Grade All grades,1,0.46729016304016113
AFINITOR,angioedema,and administration site condi,0,0.47438323497772217
AFINITOR,angioedema,       7   General disorders,1,0.528138279914856
AFINITOR,angioedema,       7   General disorders and administration,1,0.5503738522529602
AFINITOR,angioedema,mouth,0,0.5397066473960876
AFINITOR,angioedema,       7   General disorders and,1,0.522547721862793
AFINITOR,angioedema,and administration,0,0.4566602110862732
AFINITOR,swelling of the airways,site,0,0.4865254759788513
AFINITOR,swelling of the airways,      0                 General disorders,1,0.5104312896728516
AFINITOR,swelling of the airways,      0                 General,1,0.48381277918815613
AFINITOR,swelling of the airways,      0                ,1,0.5287531018257141
AFINITOR,swelling of the airways,Dry       0                 General disorders,1,0.5368518233299255
AFINITOR,swelling of the airways,mouth,0,0.5467214584350586
AFINITOR,swelling of the airways,Dry,0,0.49068641662597656
AFINITOR,angioedema,site conditions      27    Edema peripheral,1,0.6967234015464783
AFINITOR,angioedema,Dry,0,0.5434998273849487
AFINITOR,angioedema,     27    Edema peripheral,1,0.7035562992095947
AFINITOR,angioedema,     27   ,1,0.5092153549194336
AFINITOR,angioedema,Fatigue,0,0.5736905932426453
AFINITOR,renal failure,and,0,0.5150890350341797
AFINITOR,renal failure,and nutrition disorders,0,0.518702507019043
AFINITOR,renal failure,disorders,0,0.5889327526092529
AFINITOR,renal failure,and nutrition,0,0.5118221044540405
AFINITOR,renal failure,nutrition disorders,0,0.5236462950706482
AFINITOR,renal failure,"  
       Dec reased appetite",1,0.48874109983444214
AFINITOR,wound-related complications,Musculoskeletal d connective tissue,1,0.5274554491043091
AFINITOR,wound-related complications,d connective tissue disorde,1,0.5745896100997925
AFINITOR,incisional hernia,   0.8           ,1,0.46104520559310913
AFINITOR,incisional hernia,   0.8            Back,1,0.4672849774360657
AFINITOR,lymphocele, 0        ,1,0.5337502956390381
AFINITOR,seroma,disorders   17   Back pain,1,0.4823949337005615
AFINITOR,seroma, 0        ,1,0.5399645566940308
AFINITOR,seroma,  17  ,1,0.5014544129371643
AFINITOR,Decreased hemoglobin,weeks weeks Key observed laboratory abnormalities are,0,0.6242073774337769
AFINITOR,Decreased hemoglobin,abnormalities are resented in,1,0.5301263332366943
AFINITOR,Decreased hemoglobin,Key observed laboratory abnormalities,0,0.644095242023468
AFINITOR,Decreased hemoglobin,are resented in,1,0.4781293570995331
AFINITOR,Decreased hemoglobin,Table 3. Table,1,0.4822314977645874
AFINITOR,Decreased hemoglobin,resented in Table 3. Table Key Laboratory Abnormalities Reported,1,0.5965796113014221
AFINITOR,Decreased hemoglobin,in Table 3. Table Key Laboratory Abnormalities Reported,1,0.6097824573516846
AFINITOR,Decreased hemoglobin,observed laboratory abnormalities are resented in Table 3. Table Key Laboratory,1,0.5696507692337036
AFINITOR,hepatic impairment,          5       ,1,0.4492027163505554
AFINITOR,hepatic impairment,in Table 3. Table Key Laboratory Abnormalities Reported,1,0.6569045782089233
AFINITOR,hepatic impairment,decreased,0,0.5571749806404114
AFINITOR,hepatic impairment,          5        Platelets,1,0.496509850025177
AFINITOR,hepatic impairment,WBC           5        Platelets,1,0.49386441707611084
AFINITOR,hepatic impairment,          5        Platelets decreased,1,0.5393083691596985
AFINITOR,hepatic impairment,WBC           5       ,1,0.46346086263656616
AFINITOR,fetal harm,AFINITOR,0,0.48845791816711426
AFINITOR,fetal harm,with advanced PNET the,0,0.43844470381736755
AFINITOR,fetal harm,a random ized controlled trial,1,0.5155102014541626
AFINITOR,embryo-fetal toxicities,AFINITOR (n=204) versus placebo n in,1,0.5092731714248657
AFINITOR,embryo-fetal toxicities,with,0,0.538812518119812
AFINITOR,embryo-fetal toxicities,al of AFINITOR (n=204),1,0.4703267812728882
AFINITOR,embryo-fetal toxicities,controlled al of,1,0.4883696436882019
AFINITOR,embryo-fetal toxicities,randomized controlled al of AFINITOR (n=204) ,1,0.4970276355743408
AFINITOR,embryo-fetal toxicities,al of AFINITOR (n=204)  versus placebo n in patients,1,0.4927816390991211
AFINITOR,embryo-fetal toxicities,a randomized controlled al of AFINITOR (n=204)  versus placebo n in patients,1,0.5011638402938843
AFINITOR,embryo-fetal toxicities,of AFINITOR (n=204) versus placebo,1,0.5161605477333069
ENTEREG,dyspepsia,dyspepsia To report SUSPECTED ADVERSE REACTIONS,1,0.8403024673461914
ENTEREG,dyspepsia,included a bowel resection dyspepsia To report SUSPECTED,1,0.7846717834472656
ENTEREG,dyspepsia,dyspepsia To,1,0.9393608570098877
ENTEREG,dyspepsia,Sharp Dohme,0,0.5116976499557495
ENTEREG,dyspepsia,after the first dose,0,0.5164046287536621
ENTEREG,dyspepsia,that occurred after the first,0,0.4523855745792389
ENTEREG,MYOCARDIAL INFARCTION,c,0,0.5507176518440247
ENTEREG,MYOCARDIAL INFARCTION,REACTIONS EXCERPT The most ommon,1,0.47515010833740234
ENTEREG,MYOCARDIAL INFARCTION,most ommon adverse reactio n,1,0.562650740146637
ENTEREG,myocardial infarction,"dyspepsia To report SUSPECTED VERSE REACTIONS,",1,0.5050172805786133
ENTEREG,myocardial infarction,"To report SUSPECTED VERSE REACTIONS, cont",1,0.5061435699462891
ENTEREG,myocardial infarction,VERSE,1,0.5130497217178345
ENTEREG,myocardial infarction,varying co nditions adverse,1,0.5316708087921143
ENTEREG,MYOCARDIAL INFARCTION,reflect e to ENTEREG 12 mg,1,0.5483759641647339
ENTEREG,MYOCARDIAL INFARCTION,e to ENTEREG 12 mg in patients,1,0.5643666982650757
ENTEREG,myocardial infarction,a ery that,1,0.5209301710128784
ENTEREG,myocardial infarction,Caucasian were undergoing a ery,1,0.5071054697036743
ENTEREG,myocardial infarctions,common adverse n (incidence >=1.5%) o ccurring with a,1,0.5791365504264832
ENTEREG,myocardial infarctions,Caucasian were undergoing a ery,1,0.49758946895599365
ENTEREG,abdominal pain,or wwwfdagovmedwatch Clinical Trials,0,0.4567263126373291
ENTEREG,abdominal pain,varying conditions adverse reaction rates observed,0,0.5196541547775269
ENTEREG,abdominal pain,wwwfdagovmedwatch Clinical Trials Experience clinical,1,0.4830974340438843
ENTEREG,abdominal pain,FDA or wwwfdagovmedwatch Clinical Trials,0,0.45088911056518555
ENTEREG,abdominal pain,clinical,1,0.5332494974136353
ENTEREG,abdominal pain,rates observed in the,0,0.46157968044281006
ENTEREG,abdominal pain,clinical tria ls are conducted under widely,1,0.5123507976531982
ENTEREG,abdominal pain,Experience clinical,1,0.5216067433357239
ENTEREG,abdominal pain,conditions,0,0.5600994825363159
ENTEREG,vomiting,are ted unde r,1,0.48405683040618896
ENTEREG,vomiting,conditions,0,0.5763915777206421
ENTEREG,vomiting,widely varying conditions adverse,0,0.5638691186904907
ENTEREG,vomiting,ted unde r widely varying conditions,1,0.5210036635398865
ENTEREG,vomiting,Clinical Trials Experience Because,0,0.4900451898574829
ENTEREG,vomiting,are ted unde,1,0.46268242597579956
ENTEREG,vomiting,wwwfdagovmedwatch Clinical Trials Experience Because,0,0.49555355310440063
ENTEREG,vomiting,trials are ted unde,1,0.4838879108428955
ENTEREG,vomiting,clinical trials are ted,1,0.4720298647880554
ENTEREG,myocardial infarctions,exposure to ENTEREG mg patients in 10 placebo,1,0.5552080273628235
ENTEREG,myocardial infarctions,clinical trials are ted,1,0.5608314871788025
ENTEREG,myocardial infarctions,daily until hospital discharge or for a maximum of days,0,0.5090409517288208
ENTEREG,myocardial infarctions,or for a maximum of days of,0,0.496598482131958
ENTEREG,myocardial infarctions,the scheduled of surgery and,1,0.5291353464126587
ENTEREG,myocardial infarctions,surgery and then t wice,1,0.5049703121185303
ENTEREG,myocardial infarctions,of surgery and then t,1,0.5188658237457275
ENTEREG,myocardial infarctions,a maximum,0,0.4829855263233185
ENTEREG,myocardial infarctions,or for a maximum of,0,0.48483508825302124
ENTEREG,myocardial infarctions,the scheduled  of surgery and then t,1,0.5330785512924194
COARTEM,anorexia,anorexia dizziness asthenia arthralgia and,1,0.810674250125885
COARTEM,anorexia,reactions in adults are anorexia dizziness asthenia,1,0.7745339870452881
COARTEM,anorexia,anorexia dizziness asthenia,1,0.8228088617324829
COARTEM,anorexia,most common adverse,0,0.521452784538269
COARTEM,anorexia,asthenia,0,0.6222578287124634
COARTEM,anorexia,most common adverse reactions in,0,0.4971412718296051
COARTEM,anorexia,arthralgia,0,0.5054241418838501
COARTEM,anorexia,anorexia dizziness asthenia arthralgia and myalgia,1,0.7711386680603027
COARTEM,anorexia,and myalgia The most common adverse,0,0.5363482236862183
COARTEM,anorexia,anorexia dizziness asthenia arthralgia,1,0.8068694472312927
COARTEM,dizziness,adults are headache dizziness asthenia,1,0.7726176977157593
COARTEM,dizziness,anorexia dizziness asthenia arthralgia,1,0.7069480419158936
COARTEM,asthenia,adverse reactions in adults,0,0.5687199831008911
COARTEM,asthenia,children,0,0.4875093102455139
COARTEM,asthenia,headache anorexia dizziness,0,0.6139886379241943
COARTEM,asthenia,asthenia arthralgia and myalgia,1,0.7760459184646606
COARTEM,asthenia,adults are headache anorexia asthenia arthralgia and myalgia The most,1,0.6742736101150513
COARTEM,asthenia,in adults are,0,0.5690889358520508
COARTEM,asthenia,asthenia arthralgia,1,0.805220365524292
COARTEM,arthralgia,arthralgia,1,1.0
COARTEM,arthralgia,arthralgia and myalgia The most,1,0.8551204800605774
COARTEM,arthralgia,headache anorexia dizziness arthralgia and myalgia The,1,0.7653181552886963
COARTEM,myalgia,myalgia The,1,0.9557672142982483
COARTEM,myalgia,myalgia,1,0.9999996423721313
COARTEM,myalgia,myalgia The most common adverse,1,0.835605263710022
COARTEM,myalgia,myalgia The most,1,0.9058788418769836
COARTEM,myalgia,most common,0,0.5153620839118958
COARTEM,pyrexia,and myalgia The most common adverse reactions in children are,0,0.539736270904541
COARTEM,pyrexia,reactions in children pyrexia cough vomiting anorexia and,1,0.7684690952301025
COARTEM,pyrexia,adverse,0,0.5464146137237549
COARTEM,cough,cough vomiting anorexia and headache,1,0.692461371421814
COARTEM,cough,cough vomiting anorexia and headache To,1,0.6973127126693726
COARTEM,cough,REACTIONS,0,0.5365242958068848
COARTEM,cough,cough vomiting anorexia,1,0.704896092414856
COARTEM,cough,The most common adverse reactions in,0,0.5500230193138123
COARTEM,cough,and headache To,0,0.6231464147567749
COARTEM,anorexia,pyrexia,0,0.6030768156051636
COARTEM,anorexia,pyrexia cough anorexia,1,0.7925945520401001
COARTEM,anorexia,To report SUSPECTED ADVERSE REACTIONS contact,0,0.4677585959434509
COARTEM,anorexia,To report SUSPECTED ADVERSE REACTIONS contact Novartis Pharmaceuticals,0,0.44521239399909973
COARTEM,anorexia,anorexia and headache To,1,0.8315936326980591
COARTEM,anorexia,common adverse reactions in children,0,0.5118931531906128
COARTEM,Hypersensitivity Reactions,Hypersensitivity Reactions see Contraindications and Adverse Reactions,1,0.8553438186645508
COARTEM,Hypersensitivity Reactions,Hypersensitivity Reactions see Contraindications,1,0.8384571075439453
COARTEM,anorexia,adverse reactions were anorexia dizziness and asthenia,1,0.760141134262085
COARTEM,anorexia,Hypersensitivity Reactions see Contraindications,1,0.47227269411087036
COARTEM,dizziness,the most frequently reported,0,0.5034363269805908
COARTEM,dizziness,were headache dizziness and asthenia In children,1,0.776556134223938
COARTEM,dizziness,reactions,0,0.5572818517684937
COARTEM,dizziness,children the adverse,0,0.548251211643219
COARTEM,dizziness,adverse reactions were headache dizziness and,1,0.7909877300262451
COARTEM,dizziness,dizziness and asthenia In children the,1,0.8270082473754883
COARTEM,dizziness,dizziness and,1,0.9494887590408325
COARTEM,dizziness,headache,0,0.7131447196006775
COARTEM,asthenia,dizziness asthenia In children,1,0.6873155832290649
COARTEM,asthenia,headache,0,0.5504732728004456
COARTEM,asthenia,frequently reported adverse reactions,0,0.5255787372589111
COARTEM,asthenia,reactions were headache anorexia,0,0.6055482625961304
COARTEM,asthenia,asthenia In children the,1,0.8126733899116516
COARTEM,asthenia,cough vomiting anorexia and headache Most adv,0,0.6085470914840698
COARTEM,asthenia,anorexia dizziness asthenia In children the adverse,1,0.698991060256958
COARTEM,asthenia,asthenia In children,1,0.8215150833129883
COARTEM,asthenia,headache anorexia dizziness asthenia In,1,0.7280547618865967
COARTEM,pyrexia,lead to,0,0.48624616861343384
COARTEM,pyrexia,reactions were headache anorexia dizziness and asthenia In children the adverse reactions were,0,0.5968685150146484
COARTEM,cough,adverse reactions were mild did not,0,0.5352963209152222
COARTEM,cough,reactions were cough vomiting anorexia and headache,1,0.6619232296943665
COARTEM,cough,mild did not lead to discontinuatio,0,0.5338070392608643
COARTEM,cough,were cough vomiting anorexia and,1,0.6747651696205139
COARTEM,cough,were headache anorexia dizziness and asthenia In children,0,0.47541213035583496
COARTEM,cough,anorexia and headache Most adverse reactions were mild did not lead,0,0.49258267879486084
COARTEM,vomiting,asthenia In children the adverse,0,0.5774247646331787
COARTEM,vomiting,vomiting,1,0.9999999403953552
COARTEM,vomiting,pyrexia vomiting anorexia and,1,0.8089727759361267
COARTEM,vomiting,were pyrexia,0,0.5745189785957336
COARTEM,anorexia,not,0,0.4763532280921936
COARTEM,anorexia,anorexia and,1,0.9305618405342102
COARTEM,headache,medication and,0,0.5731072425842285
COARTEM,headache,ness and asthenia In children the adverse,0,0.5813939571380615
COARTEM,headache,headache Most adverse reactions,1,0.8008595705032349
COARTEM,headache,reactions were mild did not lead to discontinuation,0,0.4820253849029541
COARTEM,headache,vomiting anorexia headache Most adverse,1,0.7278093099594116
COARTEM,headache,pyrexia cough vomiting anorexia headache Most adverse,1,0.680569052696228
COARTEM,headache,headache Most adverse reactions were mild,1,0.7624492645263672
COARTEM,Headache,N Nervous system Headache,1,0.8262896537780762
COARTEM,Headache,headache Most adverse reactions were mild,1,0.7624492645263672
COARTEM,Headache,Metabolism,0,0.5090700387954712
COARTEM,Headache,N Nervous system,0,0.5690109729766846
COARTEM,Headache,Headache Dizziness,1,0.8505905866622925
COARTEM,Arthralgia,Arthralgia,1,1.0
COARTEM,Arthralgia,and connective tissue Arthralgia Myalgia,1,0.8079473376274109
COARTEM,Arthralgia,Arthralgia Myalgia Gastrointestinal,1,0.8179479837417603
COARTEM,Arthralgia,tissue Arthralgia,1,0.8645145297050476
COARTEM,Arthralgia,and connective tissue disorders,0,0.6323078870773315
COARTEM,Arthralgia,Myalgia Gastrointestinal di,0,0.6272110939025879
COARTEM,Myalgia,tissue disorders Myalgia Gastrointestinal,1,0.7901161313056946
COARTEM,Myalgia,Myalgia Gastrointestinal di,0,0.8117473125457764
COARTEM,Myalgia,connective tissue disorders Myalgia Gastrointestinal disorders Nausea,1,0.7290115356445312
COARTEM,Vomiting,Gastrointestinal disorders Vomiting Abdominal pain,1,0.7815945744514465
COARTEM,Vomiting,Myalgia Gastrointestinal di,0,0.5459821224212646
COARTEM,Vomiting,Vomiting Abdominal,1,0.9126685261726379
COARTEM,Vomiting,Nausea,0,0.8409453630447388
COARTEM,Diarrhea,Diarrhea Psychiatric disorders Sleep,1,0.7200649976730347
COARTEM,Diarrhea,Diarrhea Psychiatric,1,0.7912807464599609
COARTEM,Diarrhea,Abdominal Diarrhea Psychiatric disorders Sleep,1,0.6917760968208313
COARTEM,Diarrhea,Abdominal,0,0.6251316666603088
COARTEM,Sleep disorder,Psychiatric Sleep disorder Insomnia Cardiac disorders Palp,1,0.7717780470848083
COARTEM,Sleep disorder,Abdominal,0,0.45655715465545654
COARTEM,Sleep disorder,Sleep disorder,1,1.0
COARTEM,Sleep disorder,Cardiac disorders Palp,0,0.5455418825149536
COARTEM,Sleep disorder,Psychiatric Sleep disorder,1,0.89754718542099
COARTEM,Sleep disorder,Diarrhea,0,0.4967486262321472
COARTEM,Sleep disorder,disorders,0,0.7285581827163696
COARTEM,Sleep disorder,Sleep disorder Insomnia Cardiac disorders,1,0.8015380501747131
COARTEM,Insomnia,Palpitations,0,0.4772157669067383
COARTEM,Insomnia,Insomnia Cardiac disorders Palpitations Hepatobiliary,1,0.6943910121917725
COARTEM,Insomnia,Sleep Insomnia Cardiac disorders Palpitations,1,0.6949582099914551
COARTEM,Insomnia,Sleep Insomnia,1,0.9422217011451721
COARTEM,Insomnia,Sleep,0,0.8139724731445312
COARTEM,Insomnia,Insomnia,1,1.0000001192092896
COARTEM,Insomnia,Insomnia Cardiac disorders Palpitations Hepatobiliary d,1,0.7014602422714233
COARTEM,Palpitations,Palpitations Hepatobiliary disorders Hepatomegaly Blood and,1,0.7634264230728149
COARTEM,Palpitations,Insomnia Cardiac disorders Palpitations Hepatobiliary d,1,0.7544023990631104
COARTEM,Palpitations,Insomnia,0,0.4772157669067383
COARTEM,Palpitations,rder Insomnia Cardiac,0,0.652216374874115
COARTEM,Palpitations,Hepatobiliary disorders Hepatomegaly Blood and,0,0.5243752002716064
COARTEM,Palpitations,Palpitations,1,0.9999999403953552
COARTEM,Palpitations,Hepatobiliary disorders Hepatomegaly Blood,0,0.5102533102035522
COARTEM,Hepatomegaly,Hepatomegaly,1,0.9999998807907104
COARTEM,Hepatomegaly,Hepatobiliary,0,0.7151542901992798
COARTEM,Hepatomegaly,Hepatomegaly Blood,1,0.9107931852340698
COARTEM,Hepatomegaly,Hepatomegaly Blood and,1,0.9196285009384155
COARTEM,Hepatomegaly,system,0,0.480273574590683
COARTEM,Hepatomegaly,Hepatomegaly Blood and lymphatic,1,0.8665329217910767
COARTEM,Splenomegaly,Anemia,0,0.6263025999069214
COARTEM,Splenomegaly,Anemia Respiratory thoracic,0,0.5791914463043213
COARTEM,Splenomegaly,Splenomegaly,1,1.0
COARTEM,Splenomegaly,system disorders,0,0.5404807329177856
COARTEM,Splenomegaly,Anemia Respiratory,0,0.5689894556999207
COARTEM,Anemia,system,0,0.5619195699691772
COARTEM,Anemia,Anemia Respiratory thoracic and mediastinal,1,0.7921386957168579
COARTEM,Anemia,Anemia Respiratory thoracic and mediastinal disorders,1,0.769526481628418
COARTEM,Anemia,lymphatic system disorders Anemia,1,0.784597635269165
COARTEM,Anemia,Anemia Respiratory,1,0.8255499601364136
COARTEM,Anemia,and lymphatic,0,0.5834556221961975
COARTEM,Anemia,and,0,0.5601954460144043
COARTEM,Cough,Cough Skin and,1,0.8488839864730835
COARTEM,Cough,Cough Skin,1,0.8409528732299805
COARTEM,Cough,Cough Skin and subcutaneous tissue disorders,1,0.7441216707229614
COARTEM,Cough,and subcutaneous tissue disorders,0,0.5054402351379395
COARTEM,Cough,and mediastinal Cough Skin and subcutaneous,1,0.7846524715423584
COARTEM,Cough,Respiratory thoracic and mediastinal Cough,1,0.8046773076057434
COARTEM,Pruritus,Pruritus Rash,1,0.9252881407737732
COARTEM,Pruritus,Cough Skin and subcutaneous tissue disorders,1,0.6493116617202759
COARTEM,Rash,Rash,1,1.0000001192092896
COARTEM,Rash,Rash Ear and labyrinth,1,0.7758162021636963
COARTEM,Rash,Pruritus,0,0.7443514466285706
COARTEM,Rash,subcutaneous,0,0.6418073177337646
COARTEM,Rash,and subcutaneous tissue disorders Rash Ear and labyrinth,1,0.7523876428604126
COARTEM,Vertigo,and labyrinth disorders,0,0.7521781921386719
COARTEM,Vertigo,Vertigo Infections and infestations,1,0.8137874603271484
COARTEM,Vertigo,Ear and labyrinth Vertigo,1,0.8871376514434814
COARTEM,Vertigo,Infections and,0,0.505409300327301
COARTEM,Vertigo,Ear and labyrinth Vertigo Infections and infestations Malaria,1,0.7749898433685303
COARTEM,Vertigo,Vertigo Infections and,1,0.8582848906517029
COARTEM,Vertigo,labyrinth Vertigo Infections and infestations Malaria,1,0.7929332256317139
COARTEM,Malaria,disorders Vertigo Infections and Malaria Nasopharyngitis Adult,1,0.6996965408325195
COARTEM,Malaria,Vertigo Infections and,1,0.5730939507484436
COARTEM,Malaria,and infestations,0,0.5682296752929688
COARTEM,Nasopharyngitis,Infections and infestations Malaria,0,0.5365306735038757
COARTEM,Nasopharyngitis,Infections and infestations Nasopharyngitis,1,0.8511794805526733
COARTEM,Nasopharyngitis,Table Adverse,0,0.5259196162223816
COARTEM,Nasopharyngitis,infestations Nasopharyngitis Adult patients,1,0.803937554359436
COARTEM,Nasopharyngitis,Nasopharyngitis Adult patients defined as years,1,0.806535005569458
COARTEM,Nasopharyngitis,and infestations Nasopharyngitis Adult patients defined as years,1,0.7851502299308777
COARTEM,Nasopharyngitis,and infestations Nasopharyngitis,1,0.8554208278656006
COARTEM,Nasopharyngitis,Malaria,0,0.5619860291481018
COARTEM,Nasopharyngitis,Nasopharyngitis Adult patients defined as,1,0.8221721649169922
COARTEM,Cough,Cough Gastrointestinal disorders Vomiting,1,0.7289625406265259
COARTEM,Cough,Cough,1,1.0
COARTEM,Cough,mediastinal Cough Gastrointestinal disorders Vomiting,1,0.7131698727607727
COARTEM,Cough,and,0,0.5597959756851196
COARTEM,Cough,and mediastinal Cough Gastrointestinal,1,0.7865058183670044
COARTEM,Vomiting,Vomiting Abdominal pain,1,0.8537113070487976
COARTEM,Vomiting,Vomiting,1,0.9999999403953552
COARTEM,Vomiting,mediastinal disorders Cough,0,0.5357241034507751
COARTEM,Vomiting,Cough,0,0.6370449066162109
COARTEM,Abdominal pain,Abdominal pain,1,0.9999998807907104
COARTEM,Diarrhea,Infections and in,0,0.6278116106987
COARTEM,Diarrhea,Diarrhea Nausea Infections,1,0.8112388253211975
COARTEM,Diarrhea,Diarrhea Nausea Infections and,1,0.804800271987915
COARTEM,Diarrhea,Abdominal pain,0,0.6398805975914001
COARTEM,Diarrhea,Nausea Infections,0,0.6130011677742004
COARTEM,Diarrhea,Diarrhea Nausea,1,0.8461776971817017
COARTEM,Nausea,Nausea,1,1.0
COARTEM,Nausea,Nausea Infections and,1,0.8638800382614136
COARTEM,Nausea,Plasmodium,0,0.4924831688404083
COARTEM,Nausea,Nausea Infections and infestations Plasmodium falciparum,1,0.7599242925643921
COARTEM,Plasmodium falciparum infection,Metabolism and,0,0.5137889385223389
COARTEM,Plasmodium falciparum infection,and infestations,0,0.5278462171554565
COARTEM,Plasmodium falciparum infection,Rhinitis Metabolism and,0,0.5023177862167358
COARTEM,Plasmodium falciparum infection,Infections and Plasmodium falciparum,1,0.8820103406906128
COARTEM,Plasmodium falciparum infection,Nausea Infections and Plasmodium falciparum  infection Rhinitis Metabolism and,1,0.7546759843826294
COARTEM,Plasmodium falciparum infection,and Plasmodium falciparum  infection,1,0.9065819978713989
COARTEM,Plasmodium falciparum infection,Nausea Infections and Plasmodium,1,0.7564931511878967
COARTEM,Rhinitis,Plasmodium falciparum Rhinitis Metabolism and,1,0.735689103603363
COARTEM,Rhinitis,Nausea Infections and Plasmodium,1,0.5633151531219482
COARTEM,Rhinitis,infestations Plasmodium falciparum Rhinitis,1,0.7596679329872131
COARTEM,Rhinitis,infestations Plasmodium falciparum Rhinitis Metabolism and nutrition,1,0.6938410997390747
COARTEM,Rhinitis,Metabolism,0,0.5032625198364258
COARTEM,Rhinitis,Rhinitis Metabolism and,1,0.8309671878814697
COARTEM,Rhinitis,and infestations,0,0.5078575611114502
COARTEM,Rhinitis,infestations Plasmodium falciparum Rhinitis Metabolism and nutrition disorders,1,0.6716444492340088
COARTEM,Dizziness,lymphatic system,0,0.4994647204875946
COARTEM,Dizziness,Dizziness,1,0.9999998807907104
COARTEM,Dizziness,Nervous system disorders Headache,0,0.6031279563903809
COARTEM,Dizziness,disorders Dizziness Blood and lymphatic system disorders,1,0.7747836112976074
COARTEM,Dizziness,Dizziness Blood,1,0.9081859588623047
COARTEM,Splenomegaly,lymphatic system Splenomegaly Anemia Hepatobiliary disorde,1,0.7896557450294495
COARTEM,Splenomegaly,Dizziness Blood,1,0.5218775272369385
COARTEM,Splenomegaly,Splenomegaly Anemia Hepatobiliary disorde,1,0.7960742712020874
COARTEM,Splenomegaly,Splenomegaly Anemia,1,0.8872582316398621
COARTEM,Splenomegaly,Splenomegaly Anemia Hepatobiliary,1,0.8048679232597351
COARTEM,Splenomegaly,system Splenomegaly Anemia Hepatobiliary,1,0.7909685373306274
COARTEM,Splenomegaly,lymphatic system disorders,0,0.6374796032905579
COARTEM,Anemia,Anemia Hepatobiliary,1,0.7709998488426208
COARTEM,Anemia,Anemia,1,1.0
COARTEM,Anemia,and lymphatic system disorders Anemia Hepatobiliary disorders Hepatomegaly,1,0.6797102689743042
COARTEM,Anemia,Anemia Hepatobiliary disorders,1,0.761986494064331
COARTEM,Anemia,Anemia Hepatobiliary disorders Hepatomegaly Investi,1,0.7447609901428223
COARTEM,Anemia,Hepatobiliary disorders Hepatomegaly,0,0.5369881391525269
COARTEM,Anemia,Blood,0,0.7706857919692993
COARTEM,Anemia,system disorders Anemia Hepatobiliary disorders Hepatomegaly,1,0.7083078026771545
COARTEM,Anemia,and lymphatic system disorders,0,0.5324105024337769
COARTEM,Anemia,lymphatic system disorders Anemia Hepatobiliary disorders Hepatomegaly,1,0.6650182008743286
COARTEM,Hepatomegaly,Hepatomegaly Investigations,1,0.9075644016265869
COARTEM,Aspartate aminotransferase increased,Aspartate aminotransferase increased Musculoskeletal and,1,0.8868552446365356
COARTEM,Arthralgia,Arthralgia Myalgia Skin,1,0.8356857299804688
COARTEM,Arthralgia,Musculoskeletal and connective tissue Arthralgia Myalgia Skin and,1,0.8067156672477722
COARTEM,Arthralgia,Arthralgia Myalgia,1,0.8964070677757263
COARTEM,Arthralgia,Arthralgia Myalgia Skin and,1,0.8430213928222656
COARTEM,Arthralgia,increased Musculoskeletal and,0,0.6490294933319092
COARTEM,Arthralgia,Musculoskeletal and connective tissue,0,0.6329536437988281
COARTEM,Arthralgia,Skin and,0,0.5388871431350708
COARTEM,Arthralgia,Myalgia,0,0.7334238290786743
COARTEM,Arthralgia,Arthralgia Myalgia Skin and subcutaneo,1,0.8036261200904846
COARTEM,Myalgia,tissue disorders Rash,0,0.5712034702301025
COARTEM,Myalgia,and,0,0.5113794803619385
COARTEM,Myalgia,Skin and subcutaneous tissue,0,0.5375134944915771
COARTEM,Myalgia,Myalgia Skin and subcutaneous,1,0.8377435207366943
COARTEM,Myalgia,Arthralgia,0,0.7334238290786743
COARTEM,Myalgia,Myalgia Skin and subcutaneous tissue,1,0.8307993412017822
COARTEM,Myalgia,Myalgia Skin,1,0.8769147396087646
COARTEM,Myalgia,Myalgia Skin and subcutaneous tissue disorders,1,0.8224430680274963
COARTEM,Myalgia,tissue disorders,0,0.5905206203460693
COARTEM,Rash,Rash Children defined as patients years,1,0.7587438225746155
COARTEM,Rash,Myalgia,0,0.5832322835922241
COARTEM,Rash,patients years of,0,0.489855021238327
COARTEM,eosinophilia,and lymphatic system eosinophilia Ear and labyrinth disorders,1,0.7444443106651306
COARTEM,eosinophilia,Myalgia,0,0.5323499441146851
COARTEM,tinnitus,tinnitus Eye disorders conjunctivitis Gastrointestinal,1,0.7624715566635132
COARTEM,tinnitus,lymphatic system,0,0.4905495047569275
COARTEM,tinnitus,tinnitus Eye disorders conjunctivitis,1,0.7934125065803528
COARTEM,conjunctivitis,constipation dyspepsia dysphagia peptic ulcer,0,0.5160213112831116
COARTEM,conjunctivitis,conjunctivitis Gastrointestinal disorders constipation dyspepsia,1,0.765892744064331
COARTEM,conjunctivitis,conjunctivitis Gastrointestinal,1,0.8203968405723572
COARTEM,conjunctivitis,tinnitus Eye conjunctivitis Gastrointestinal disorders constipation dyspepsia dysphagia,1,0.6699415445327759
COARTEM,constipation,constipation,1,1.0
COARTEM,dyspepsia,innitus Eye disorders conjunctivitis,0,0.5353336930274963
COARTEM,peptic ulcer,peptic,1,0.7619142532348633
COARTEM,peptic ulcer,Gastrointestinal disorders constipation dyspepsia peptic,1,0.6836069822311401
COARTEM,peptic ulcer,peptic ulcer,1,0.9999999403953552
COARTEM,peptic ulcer,disorders gait,0,0.47692951560020447
COARTEM,abscess,abscess acrodermatitis bronchitis ear,1,0.7581381797790527
COARTEM,abscess,acrodermatitis bronchitis ear infection gastroenteritis helminthic,0,0.6287395358085632
COARTEM,abscess,abscess acrodermatitis,1,0.7641316056251526
COARTEM,abscess,ear infection,0,0.6734222769737244
COARTEM,abscess,and abscess,1,0.9210801720619202
COARTEM,abscess,abscess acrodermatitis bronchitis ear infection gastroenteritis,1,0.743514895439148
COARTEM,abscess,disorders gait,0,0.5256150960922241
COARTEM,bronchitis,bronchitis ear infection,1,0.8403774499893188
COARTEM,bronchitis,abscess bronchitis ear infection gastroenteritis helminthic,1,0.7326986789703369
COARTEM,bronchitis,helminthic infection hookworm infection impetigo influenza,0,0.5693979263305664
COARTEM,bronchitis,bronchitis ear infection gastroenteritis,1,0.7701137065887451
COARTEM,bronchitis,Infections and infestations abscess acrodermatitis,0,0.5689573884010315
COARTEM,bronchitis,bronchitis,1,0.9999999403953552
COARTEM,bronchitis,Infections and infestations abscess bronchitis ear infection gastroenteritis helminthic,1,0.6976159811019897
COARTEM,bronchitis,bronchitis ear,1,0.8373700976371765
COARTEM,bronchitis,infestations abscess bronchitis,1,0.8015213012695312
COARTEM,ear infection,ear infection gastroenteritis helminthic infection hookworm,1,0.7816112637519836
COARTEM,ear infection,abscess acrodermatitis ear,1,0.7713818550109863
COARTEM,ear infection,infestations abscess,0,0.5995769500732422
COARTEM,ear infection,infestations abscess acrodermatitis ear infection gastroenteritis helminthic infection hookworm,1,0.7099664211273193
COARTEM,ear infection,infection impetigo influenza,0,0.6071797609329224
COARTEM,ear infection,ear infection gastroenteritis helminthic,1,0.7900580763816833
COARTEM,ear infection,abscess acrodermatitis,0,0.5833786129951477
COARTEM,ear infection,abscess acrodermatitis ear infection,1,0.801507294178009
COARTEM,ear infection,gait disturbance Infections and infestations abscess,0,0.5799857378005981
COARTEM,gastroenteritis,Infections and infestations abscess acrodermatitis bronchitis,0,0.5755808353424072
COARTEM,gastroenteritis,acrodermatitis bronchitis ear gastroenteritis helminthic,1,0.6939334273338318
COARTEM,gastroenteritis,gastroenteritis helminthic infection,1,0.8723818063735962
COARTEM,gastroenteritis,ear gastroenteritis helminthic infection,1,0.7931471467018127
COARTEM,gastroenteritis,gastroenteritis,1,0.9999998211860657
COARTEM,gastroenteritis,bronchitis ear infection,0,0.5382654070854187
COARTEM,gastroenteritis,ear gastroenteritis helminthic infection hookworm infection impetigo,1,0.7432175874710083
COARTEM,gastroenteritis,Infections and infestations,0,0.6199222803115845
COARTEM,gastroenteritis,infection,0,0.6742861270904541
COARTEM,helminthic infection,helminthic infection hookworm infection impetigo influenza,1,0.8451772928237915
COARTEM,helminthic infection,lower respiratory tract infection malaria,0,0.6141800880432129
COARTEM,helminthic infection,and infestations abscess acrodermatitis bronchitis ear,0,0.6753018498420715
COARTEM,helminthic infection,bronchitis ear infection helminthic      infection hookworm infection impetigo influenza lower,1,0.7609175443649292
COARTEM,helminthic infection,ear infection helminthic,1,0.8451437950134277
COARTEM,hookworm infection,lower respiratory tract,0,0.5159140825271606
COARTEM,hookworm infection,impetigo influenza lower respiratory tract infection malaria nasopharyngitis,0,0.5823094844818115
COARTEM,impetigo,hookworm impetigo,1,0.8195762634277344
COARTEM,impetigo,impetigo influenza lower respiratory tract infection malaria nasopharyngitis,0,0.7444003224372864
COARTEM,impetigo,impetigo influenza lower respiratory tract infection,1,0.7785341739654541
COARTEM,impetigo,ear,0,0.55255126953125
COARTEM,impetigo,infection,0,0.6312170028686523
COARTEM,impetigo,impetigo influenza lower respiratory,1,0.7867142558097839
COARTEM,impetigo,respiratory tract infection malaria,0,0.49866560101509094
COARTEM,impetigo,gastroenteritis helminthic infection hookworm impetigo influenza,1,0.6896055936813354
COARTEM,impetigo,impetigo influenza lower,1,0.8245651721954346
COARTEM,influenza,influenza lower respiratory tract,1,0.8098517656326294
COARTEM,influenza,influenza lower respiratory tract infection malaria,1,0.7562174797058105
COARTEM,influenza,ronchitis ear infection gastroenteritis helminthic infection hookworm infection,0,0.5558876395225525
COARTEM,influenza,infection hookworm,0,0.540921151638031
COARTEM,influenza,respiratory tract infection malaria nasopharyngitis oral herpes,0,0.6625951528549194
COARTEM,lower respiratory tract infection,infection impetigo lower respiratory tract infection malaria nasopharyngitis oral herpes pneumonia,1,0.7649903893470764
COARTEM,lower respiratory tract infection,respiratory tract infection malaria nasopharyngitis oral herpes,0,0.7215832471847534
COARTEM,lower respiratory tract infection,influenza,0,0.7023804783821106
COARTEM,lower respiratory tract infection,malaria nasopharyngitis oral herpes pneumonia respiratory,0,0.6617604494094849
COARTEM,lower respiratory tract infection,nasopharyngitis oral herpes,0,0.5966072082519531
COARTEM,malaria,malaria nasopharyngitis,1,0.7716889381408691
COARTEM,malaria,pneumonia respiratory,0,0.5741507411003113
COARTEM,malaria,tract,0,0.5012863278388977
COARTEM,malaria,malaria nasopharyngitis oral,1,0.7530475854873657
COARTEM,malaria,nasopharyngitis oral herpes pneumonia respiratory tract infection subcutaneous abscess,0,0.5211011171340942
COARTEM,malaria,malaria,1,1.0000001192092896
COARTEM,malaria,hookworm infection impetigo influenza lower respiratory tract,0,0.5841695070266724
COARTEM,malaria,infection hookworm infection impetigo influenza lower respiratory tract,0,0.587898850440979
COARTEM,malaria,minthic infection hookworm infection impetigo,0,0.5692479610443115
COARTEM,nasopharyngitis,oral herpes pneumonia respiratory tract infection subcutaneous abscess upper,0,0.6640435457229614
COARTEM,nasopharyngitis,subcutaneous abscess upper,0,0.5500862002372742
COARTEM,nasopharyngitis,nasopharyngitis oral herpes pneumonia respiratory tract,1,0.8114364147186279
COARTEM,nasopharyngitis,pneumonia,0,0.6376098394393921
COARTEM,nasopharyngitis,hookworm infection impetigo influenza lower respiratory,0,0.5840638875961304
COARTEM,nasopharyngitis,influenza lower respiratory tract infection,0,0.6676865816116333
COARTEM,pneumonia,oral,0,0.54884272813797
COARTEM,pneumonia,pneumonia respiratory tract infection,1,0.8640451431274414
COARTEM,pneumonia,pneumonia respiratory tract infection subcutaneous abscess,1,0.7272137403488159
COARTEM,pneumonia,influenza lower respiratory tract,0,0.6704206466674805
COARTEM,pneumonia,tract infection,0,0.6878365278244019
COARTEM,respiratory tract infection,oral herpes respiratory tract infection,1,0.8225419521331787
COARTEM,respiratory tract infection,subcutaneous abscess,0,0.5275384783744812
COARTEM,respiratory tract infection,malaria nasopharyngitis oral herpes respiratory tract,1,0.7168399095535278
COARTEM,respiratory tract infection,nfluenza lower respiratory tract infection,0,0.7868277430534363
COARTEM,respiratory tract infection,pneumonia,0,0.7647327184677124
COARTEM,respiratory tract infection,herpes respiratory tract infection subcutaneous abscess upper respiratory,1,0.7351075410842896
COARTEM,respiratory tract infection,respiratory tract infection subcutaneous abscess,1,0.7431987524032593
COARTEM,subcutaneous abscess,herpes pneumonia respiratory tract subcutaneous abscess,1,0.8072519898414612
COARTEM,subcutaneous abscess,herpes pneumonia respiratory tract subcutaneous abscess upper respiratory tract,1,0.7644084692001343
COARTEM,subcutaneous abscess,subcutaneous abscess upper respiratory,1,0.8707682490348816
COARTEM,upper respiratory tract infection,respiratory,0,0.7307553291320801
COARTEM,upper respiratory tract infection,respiratory tract infection urinary,1,0.8003244996070862
COARTEM,upper respiratory tract infection,a nasopharyngitis oral herpes pneumonia respiratory,0,0.7458668351173401
COARTEM,upper respiratory tract infection,infection,0,0.710341215133667
COARTEM,urinary tract infection,urinary tract infection Investigations alanine aminotransferase increased,1,0.766480565071106
COARTEM,urinary tract infection,urinary tract,1,0.8359100818634033
COARTEM,urinary tract infection,infection subcutaneous abscess upper,0,0.627104640007019
COARTEM,urinary tract infection,tract infection Investigations alanine aminotransferase,1,0.6698610782623291
COARTEM,urinary tract infection,upper respiratory,0,0.562444806098938
COARTEM,urinary tract infection,abscess upper respiratory tract urinary tract,1,0.7839075326919556
COARTEM,urinary tract infection,infection subcutaneous abscess upper respiratory tract infection,0,0.6433878540992737
COARTEM,urinary tract infection,respiratory tract urinary tract infection Investigations alanine aminotransferase,1,0.754703164100647
COARTEM,urinary tract infection,tract urinary tract infection Investigations,1,0.8302091360092163
COARTEM,urinary tract infection,tract infection Investigations alanine aminotransferase increased aspartate,1,0.661065399646759
COARTEM,alanine aminotransferase increased,upper respiratory,0,0.5119457840919495
COARTEM,alanine aminotransferase increased,infection,0,0.5518571138381958
COARTEM,alanine aminotransferase increased,infection Investigations,0,0.5338644981384277
COARTEM,aspartate aminotransferase increased,urinary tract infection,0,0.5525124073028564
COARTEM,aspartate aminotransferase increased,ct infection urinary tract infection,0,0.5284988880157471
COARTEM,aspartate aminotransferase increased,aspartate aminotransferase increased hematocrit,1,0.875090479850769
COARTEM,aspartate aminotransferase increased,count decreased platelet,0,0.5206302404403687
COARTEM,aspartate aminotransferase increased,alanine aminotransferase aspartate aminotransferase increased hematocrit decreased lymphocyte morphology abnormal,1,0.8321987390518188
COARTEM,aspartate aminotransferase increased,hematocrit decreased lymphocyte morphology,0,0.5322506427764893
COARTEM,hematocrit decreased,Investigations,0,0.4676266014575958
COARTEM,hematocrit decreased,increased,0,0.5474828481674194
COARTEM,hematocrit decreased,abnormal platelet,0,0.6069896221160889
COARTEM,hematocrit decreased,aspartate aminotransferase hematocrit      decreased lymphocyte morphology abnormal,1,0.7450046539306641
COARTEM,hematocrit decreased,hematocrit      decreased lymphocyte morphology abnormal platelet,1,0.8160367608070374
COARTEM,hematocrit decreased,aminotransferase increased aspartate aminotransferase hematocrit      decreased lymphocyte morphology,1,0.7205833196640015
COARTEM,hematocrit decreased,aspartate aminotransferase,0,0.5127158164978027
COARTEM,lymphocyte morphology abnormal,decreased,0,0.5142778158187866
COARTEM,lymphocyte morphology abnormal,lymphocyte morphology abnormal,1,0.9999998211860657
COARTEM,lymphocyte morphology abnormal,lymphocyte morphology,1,0.9349260330200195
COARTEM,lymphocyte morphology abnormal,increased white blood cell count decreased,0,0.6496286392211914
COARTEM,lymphocyte morphology abnormal,aminotransferase increased hematocrit lymphocyte,1,0.6696208119392395
COARTEM,platelet count increased,count increased,0,0.7723956108093262
COARTEM,platelet count increased,cell count decreased,0,0.6477580666542053
COARTEM,platelet count increased,abnormal platelet,0,0.8026778697967529
COARTEM,platelet count increased,cell count decreased white blood cell count increased,0,0.7639936208724976
COARTEM,white blood cell count decreased,white blood cell count increased Metabolism and nutrition disorders hypokalemia,0,0.7154419422149658
COARTEM,white blood cell count decreased,white,1,0.6313557624816895
COARTEM,white blood cell count decreased,cell count decreased white,1,0.9336622953414917
COARTEM,white blood cell count decreased,blood cell count decreased white blood cell count,1,0.9461675882339478
COARTEM,white blood cell count decreased,decreased platelet count white blood cell,1,0.8720353841781616
COARTEM,white blood cell count decreased,increased Metabolism and nutrition,0,0.504557728767395
COARTEM,white blood cell count decreased,Metabolism and,0,0.5297914147377014
COARTEM,white blood cell count decreased,decreased platelet,0,0.7603271007537842
COARTEM,white blood cell count increased,hypokalemia Musculoskeletal and,0,0.5243036150932312
COARTEM,white blood cell count increased,white blood,1,0.7755248546600342
COARTEM,hypokalemia,hypokalemia Musculoskeletal and connective,1,0.8388875722885132
COARTEM,back pain,nutrition disorders hypokalemia Musculoskeletal and connective tissue disorders,0,0.5514228343963623
COARTEM,back pain,disorders,0,0.5442969799041748
COARTEM,back pain,connective tissue back pain Nervous system,1,0.7586091756820679
COARTEM,back pain,connective tissue back pain Nervous,1,0.7406327724456787
COARTEM,back pain,tissue back pain,1,0.8648339509963989
COARTEM,back pain,back pain Nervous system,1,0.8289434909820557
COARTEM,back pain,back pain Nervous system disorders,1,0.790052592754364
COARTEM,ataxia,connective tissue disorders back pain,0,0.4955546259880066
COARTEM,ataxia,ataxia clonus,1,0.8388718962669373
COARTEM,ataxia,ataxia clonus fine motor,1,0.8107774257659912
COARTEM,ataxia,and connective,0,0.5141319632530212
COARTEM,ataxia,motor delay,0,0.5687474608421326
COARTEM,ataxia,hyperreflexia hypoesthesia nystagmus tremor Psychiatri,0,0.6184896230697632
COARTEM,ataxia,system,0,0.5250524282455444
COARTEM,ataxia,back pain,0,0.4876392185688019
COARTEM,ataxia,ataxia clonus fine,1,0.8238224387168884
COARTEM,ataxia,fine motor delay hyperreflexia hypoesthesia,0,0.6598660945892334
COARTEM,clonus,clonus,1,0.9999999403953552
COARTEM,fine motor delay,disorders ataxia fine motor delay hyperreflexia,1,0.7708351612091064
COARTEM,fine motor delay,clonus,1,0.48246556520462036
COARTEM,fine motor delay,clonus,0,0.48246556520462036
COARTEM,fine motor delay,motor delay hyperreflexia,1,0.8250555992126465
COARTEM,fine motor delay,fine,1,0.6080005764961243
COARTEM,hyperreflexia,system disorders ataxia clonus fine,0,0.6085330247879028
COARTEM,hyperreflexia,Psychiatric,0,0.533606231212616
COARTEM,hyperreflexia,agitation,0,0.5950355529785156
COARTEM,hyperreflexia,hyperreflexia hypoesthesia nystagmus,1,0.8179287910461426
COARTEM,hyperreflexia,disorders agitation mood,0,0.5566898584365845
COARTEM,hyperreflexia,ataxia clonus fine motor hyperreflexia hypoesthesia nystagmus tremor Psychiatric,1,0.6945469379425049
COARTEM,hyperreflexia,hyperreflexia hypoesthesia nystagmus tremor Psychiatric,1,0.7803505659103394
COARTEM,hyperreflexia,hyperreflexia,1,0.9999999403953552
COARTEM,hypoesthesia,motor delay,0,0.5767725706100464
COARTEM,hypoesthesia,pain Nervous system disorders ataxia,0,0.5879033207893372
COARTEM,hypoesthesia,hypoesthesia nystagmus tremor Psychiatric,1,0.7991013526916504
COARTEM,nystagmus,nystagmus tremor,1,0.9084956645965576
COARTEM,nystagmus,nystagmus tremor Psychiatric disorders agitation,1,0.779755711555481
COARTEM,nystagmus,delay hyperreflexia,0,0.5593620538711548
COARTEM,nystagmus,system disorders ataxia clonus fine motor delay hyperreflexia hypoesthesia,0,0.5742736458778381
COARTEM,tremor,and,0,0.5268451571464539
COARTEM,tremor,tremor Psychiatric disorders,1,0.8327067494392395
COARTEM,tremor,disorders agitation mood,0,0.5757030248641968
COARTEM,agitation,motor delay,0,0.5860787034034729
COARTEM,agitation,agitation mood swings Renal and urinary,1,0.7800734043121338
COARTEM,agitation,disorders hematuria proteinuria,0,0.47344720363616943
COARTEM,mood swings,hyperreflexia hypoesthesia nystagmus tremor Psychiatric disorders,0,0.643843412399292
COARTEM,mood swings,mood swings Renal and urinary,1,0.8170065879821777
COARTEM,mood swings,mood swings Renal and urinary disorders hematuria,1,0.786151647567749
COARTEM,mood swings,mood swings Renal and,1,0.8577271699905396
COARTEM,mood swings,nystagmus tremor Psychiatric disorders mood swings,1,0.8028197884559631
COARTEM,mood swings,agitation,0,0.6250193119049072
COARTEM,mood swings,disorders mood swings,1,0.9199602007865906
COARTEM,mood swings,Psychiatric disorders mood swings,1,0.9201505184173584
COARTEM,hematuria,Renal and urinary hematuria,1,0.9007166624069214
COARTEM,hematuria,disorders mood swings,1,0.482332706451416
COARTEM,hematuria,swings Renal and urinary hematuria,1,0.8639423847198486
COARTEM,hematuria,and urinary hematuria proteinuria,1,0.8270289301872253
COARTEM,hematuria,urinary,0,0.7470715045928955
COARTEM,hematuria,thoracic and,0,0.5026537179946899
COARTEM,hematuria,Respiratory thoracic and mediastinal disorders,0,0.4365599751472473
COARTEM,hematuria,agitation mood swings Renal and urinary,0,0.6293647289276123
COARTEM,hematuria,thoracic and mediastinal disorders,0,0.47999024391174316
COARTEM,hematuria,hematuria proteinuria,1,0.8294060230255127
COARTEM,hematuria,disorders,0,0.5488576889038086
COARTEM,asthma,asthma pharyngolaryngeal pain Skin and subcutaneous,1,0.7298016548156738
COARTEM,asthma,pharyngolaryngeal pain Skin and subcutaneous tissue,0,0.5606091618537903
COARTEM,pharyngo-laryngeal pain,urticaria,0,0.466768741607666
COARTEM,pharyngo-laryngeal pain,pharyngo-laryngeal pain Skin and subcutaneous tissue disorders,1,0.8386228084564209
COARTEM,pharyngo-laryngeal pain,disorders,0,0.5407412648200989
COARTEM,pharyngo-laryngeal pain,subcutaneous,0,0.4804893732070923
COARTEM,urticaria,and subcutaneous tissue urticaria Postmarketing Experience The,1,0.7820978164672852
COARTEM,urticaria,subcutaneous,0,0.6306431889533997
COARTEM,urticaria,been identified,0,0.4995875060558319
COARTEM,urticaria,have,0,0.4975612759590149
COARTEM,urticaria,Skin and,0,0.6405042409896851
COARTEM,anaphylaxis,Hypersensitivity,0,0.7709716558456421
COARTEM,anaphylaxis,drug exposure Hypersensitivity anaphylaxis urticaria angioedema and serious,1,0.7655559778213501
COARTEM,anaphylaxis,Hypersensitivity anaphylaxis urticaria angioedema and serious,1,0.8188709616661072
COARTEM,anaphylaxis,bullous eruption,0,0.6150423288345337
COARTEM,urticaria,urticaria angioedema and serious skin,1,0.8155754208564758
COARTEM,urticaria,Hypersensitivity reactions,0,0.6896200776100159
COARTEM,urticaria,to drug exposure Hypersensitivity reactions,0,0.6419888734817505
COARTEM,urticaria,urticaria angioedema and serious,1,0.8453243970870972
COARTEM,urticaria,urticaria angioedema and serious skin reactions,1,0.8075072765350342
COARTEM,urticaria,urticaria angioedema,1,0.8915119171142578
COARTEM,urticaria,and serious skin,0,0.5903007984161377
COARTEM,urticaria,urticaria,1,1.0
COARTEM,urticaria,skin reactions bullous eruption have been reported,0,0.6710947751998901
COARTEM,angioedema,angioedema and serious skin,1,0.8788528442382812
COARTEM,angioedema,relationship to drug exposure,0,0.5324127674102783
COARTEM,angioedema,Hypersensitivity,0,0.726775586605072
COARTEM,angioedema,angioedema and serious skin reactions bullous,1,0.8399397730827332
COARTEM,skin reactions,and skin,1,0.7681795954704285
COARTEM,skin reactions,urticaria angioedema and skin,1,0.7781662940979004
COARTEM,skin reactions,angioedema and,0,0.6648279428482056
COARTEM,skin reactions,skin reactions,1,1.0
COARTEM,bullous eruption,bullous,1,0.8774082660675049
COARTEM,bullous eruption,skin bullous,1,0.8736779093742371
COARTEM,bullous eruption,skin bullous eruption,1,0.9481908082962036
COARTEM,bullous eruption,have,0,0.5352615118026733
COARTEM,bullous eruption,angioedema and serious skin bullous eruption,1,0.8153828382492065
COARTEM,bullous eruption,angioedema and serious skin bullous eruption have,1,0.8258236646652222
COARTEM,bullous eruption,have been reported,0,0.5068883895874023
COARTEM,prolongation of the QT interval,sure to a 6-dose regimen of Coa,1,0.5687507390975952
COARTEM,prolongation of the QT interval,have been reported,0,0.49055546522140503
COARTEM,prolongation of the QT interval,data described below reflect,0,0.4968754053115845
COARTEM,prolongation of the QT interval,of Coa rtem Tablets in patients,1,0.5671190023422241
COARTEM,prolongation of the QT interval,sure,1,0.4379875063896179
COARTEM,prolongation of the QT interval,described below reflect sure to a 6-dose regimen of Coa rtem Tablets,1,0.5584290623664856
COARTEM,prolongation of the QT interval,and children,0,0.4557839334011078
COARTEM,QT prolongation,Hepatomegaly,0,0.49095237255096436
COARTEM,QT prolongation,Blood and ly,1,0.4782900810241699
COARTEM,QT prolongation,"disorders  
 Blood and ly mphatic system",1,0.5045049786567688
COARTEM,QT prolongation,system disorders Splenomegaly Anemia,0,0.5039153099060059
COARTEM,QT prolongation,Blood and ly mphatic system,1,0.5157267451286316
COARTEM,QT prolongation,Hepatobiliary disorders Hepatomegaly,0,0.51659095287323
COARTEM,QT prolongation,disorders Blood and ly,1,0.5015053749084473
COARTEM,QT prolongation,and ly mphatic system,1,0.5340571403503418
DALVANCE,nausea,nausea,1,0.9999999403953552
DALVANCE,nausea,with DALVANCE nausea headache,1,0.8223423957824707
DALVANCE,nausea,nausea headache and diarrhea,1,0.7835811376571655
DALVANCE,headache,headache and diarrhea,1,0.7775858640670776
DALVANCE,diarrhea,were nausea headache and,0,0.5645678043365479
DALVANCE,diarrhea,reactions in patients treated with DALVANCE were,0,0.5611660480499268
DALVANCE,diarrhea,REACTIONS,0,0.5872282385826111
DALVANCE,diarrhea,diarrhea To report SUSPECTED ADVERSE,1,0.8081265091896057
DALVANCE,diarrhea,and,0,0.5738846063613892
DALVANCE,diarrhea,diarrhea To report,1,0.8629391193389893
DALVANCE,nausea,with DALVANCE nausea headache and,1,0.8212757110595703
DALVANCE,nausea,diarrhea To report,1,0.599738597869873
DALVANCE,nausea,patients treated with,0,0.5386413931846619
DALVANCE,nausea,nausea headache,1,0.883143424987793
DALVANCE,headache,headache and diarrhea The,1,0.7781510353088379
DALVANCE,headache,with DALVANCE were headache and diarrhea,1,0.743638277053833
DALVANCE,headache,DALVANCE were headache and diarrhea,1,0.7639592885971069
DALVANCE,headache,headache,1,1.0
DALVANCE,headache,with DALVANCE,0,0.5546649694442749
DALVANCE,headache,were headache and diarrhea,1,0.7755491137504578
DALVANCE,headache,headache and diarrhea The median,1,0.7606260776519775
DALVANCE,headache,with DALVANCE were headache and,1,0.8041670322418213
DALVANCE,headache,headache and diarrhea The median duration,1,0.7525134682655334
DALVANCE,diarrhea,were nausea headache diarrhea The median duration of,1,0.7069114446640015
DALVANCE,diarrhea,headache,1,0.5687180757522583
DALVANCE,diarrhea,diarrhea The,1,0.9120277762413025
DALVANCE,diarrhea,diarrhea The median duration,1,0.8090323805809021
DALVANCE,diarrhea,nausea headache diarrhea The,1,0.795200526714325
DALVANCE,anemia,anemia hemorrhagic,1,0.8241956233978271
DALVANCE,anemia,anemia,1,1.0
DALVANCE,hemorrhagic anemia,trials Blood and lymphatic system disorders,0,0.6146038174629211
DALVANCE,hemorrhagic anemia,hemorrhagic anemia,1,0.9999998211860657
DALVANCE,hemorrhagic anemia,hemorrhagic anemia leucopenia neutropenia thrombocytopenia,1,0.8304585814476013
DALVANCE,hemorrhagic anemia,Blood and,0,0.713225245475769
DALVANCE,leucopenia,lymphatic system,0,0.5695178508758545
DALVANCE,leucopenia,eosinophilia thrombocytosis Gastrointestinal diso,0,0.5972598195075989
DALVANCE,leucopenia,anemia hemorrhagic leucopenia neutropenia thrombocytopenia petechiae eosinophilia,1,0.7656477093696594
DALVANCE,leucopenia,hemorrhagic leucopenia neutropenia thrombocytopenia petechiae eosinophilia,1,0.7807334661483765
DALVANCE,neutropenia,Blood and lymphatic system,0,0.5948613286018372
DALVANCE,thrombocytopenia,thrombocytopenia petechiae eosinophilia thrombocytosis Gastrointestinal,1,0.7763658165931702
DALVANCE,thrombocytopenia,disorders anemia,0,0.5737508535385132
DALVANCE,thrombocytopenia,thrombocytopenia petechiae eosinophilia thrombocytosis Gastrointestinal disorders,1,0.7585277557373047
DALVANCE,thrombocytopenia,thrombocytosis Gastrointestinal disorders,0,0.763787567615509
DALVANCE,thrombocytopenia,thrombocytopenia petechiae,1,0.8577165603637695
DALVANCE,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
DALVANCE,petechiae,petechiae eosinophilia thrombocytosis Gastrointestinal disorders gastrointestinal,1,0.7685032486915588
DALVANCE,eosinophilia,eosinophilia thrombocytosis Gastrointestinal disorders gastrointestinal hemorrhage,1,0.7615830898284912
DALVANCE,eosinophilia,hemorrhage melena,0,0.5570107698440552
DALVANCE,eosinophilia,eosinophilia thrombocytosis Gastrointestinal,1,0.779091477394104
DALVANCE,eosinophilia,anemia,0,0.5873605012893677
DALVANCE,eosinophilia,eosinophilia thrombocytosis Gastrointestinal disorders gastrointestinal,1,0.7626118659973145
DALVANCE,eosinophilia,anemia hemorrhagic anemia leucopenia neutropenia thrombocytopenia petechiae,0,0.6070082187652588
DALVANCE,thrombocytosis,hemorrhage melena,0,0.5073133707046509
DALVANCE,thrombocytosis,thrombocytosis Gastrointestinal disorders gastrointestinal hemorrhage melena,1,0.785751223564148
DALVANCE,thrombocytosis,thrombocytosis,1,0.9999999403953552
DALVANCE,thrombocytosis,thrombocytosis Gastrointestinal,1,0.8479202389717102
DALVANCE,thrombocytosis,thrombocytosis Gastrointestinal disorders gastrointestinal hemorrhage,1,0.8188724517822266
DALVANCE,gastrointestinal hemorrhage,Gastrointestinal gastrointestinal hemorrhage melena hematochezia abdominal pain General,1,0.8509347438812256
DALVANCE,gastrointestinal hemorrhage,thrombocytosis Gastrointestinal disorders gastrointestinal hemorrhage,1,0.8419079780578613
DALVANCE,gastrointestinal hemorrhage,petechiae eosinophilia thrombocytosis,0,0.5783461332321167
DALVANCE,gastrointestinal hemorrhage,administration site,0,0.4571799635887146
DALVANCE,gastrointestinal hemorrhage,gastrointestinal hemorrhage,1,1.0
DALVANCE,gastrointestinal hemorrhage,petechiae eosinophilia thrombocytosis Gastrointestinal gastrointestinal hemorrhage melena,1,0.7636822462081909
DALVANCE,gastrointestinal hemorrhage,eosinophilia thrombocytosis Gastrointestinal gastrointestinal hemorrhage melena hematochezia abdominal,1,0.7746090888977051
DALVANCE,gastrointestinal hemorrhage,hematochezia abdominal pain General disorders,0,0.7282171249389648
DALVANCE,melena,melena,1,1.0
DALVANCE,hematochezia,hematochezia abdominal pain General disorders,1,0.8503950834274292
DALVANCE,abdominal pain,melena,0,0.5417267084121704
DALVANCE,abdominal pain,hemorrhage melena abdominal pain General disorders,1,0.7749103307723999
DALVANCE,abdominal pain,melena abdominal pain,1,0.8404921293258667
DALVANCE,infusion-related reactions,infusion-related reactions,1,1.000000238418579
DALVANCE,infusion-related reactions,disorders anaphylactoid reac,0,0.6073563098907471
DALVANCE,infusion-related reactions,administration site infusion-related,1,0.754629373550415
DALVANCE,infusion-related reactions,General disorders and,0,0.5330390930175781
DALVANCE,infusion-related reactions,site,0,0.4950243830680847
DALVANCE,infusion-related reactions,and administration site infusion-related,1,0.7937978506088257
DALVANCE,infusion-related reactions,infusion-related reactions Hepatobiliary disorders,1,0.8551849126815796
DALVANCE,infusion-related reactions,site infusion-related reactions Hepatobiliary disorders,1,0.8442535400390625
DALVANCE,infusion-related reactions,and administration site infusion-related reactions Hepatobiliary disorders,1,0.8369325995445251
DALVANCE,hepatotoxicity,and,0,0.5135397911071777
DALVANCE,anaphylactoid reaction,anaphylactoid reaction Infections and infestations Clostridium,1,0.8331432342529297
DALVANCE,anaphylactoid reaction,and infestations Clostridium difficile,0,0.5195528268814087
DALVANCE,oral candidiasis,and,0,0.48967432975769043
DALVANCE,oral candidiasis,and infestations Clostridium difficile,0,0.5750038027763367
DALVANCE,oral candidiasis,and infestations Clostridium difficile oral candidiasis,1,0.8221875429153442
DALVANCE,oral candidiasis,Clostridium difficile oral candidiasis,1,0.8186212778091431
DALVANCE,oral candidiasis,difficile oral candidiasis,1,0.8311530351638794
DALVANCE,oral candidiasis,difficile oral candidiasis vulvovaginal mycotic infection Investigations,1,0.7477484345436096
DALVANCE,oral candidiasis,Clostridium difficile,0,0.5691308379173279
DALVANCE,oral candidiasis,Investigations hepatic transaminases increased blood,0,0.4913806915283203
DALVANCE,oral candidiasis,infestations,0,0.566031813621521
DALVANCE,vulvovaginal mycotic infection,vulvovaginal mycotic infection Investigations hepatic transaminases increased,1,0.8295848369598389
DALVANCE,vulvovaginal mycotic infection,mycotic infection Investigations hepatic,1,0.6850693225860596
DALVANCE,vulvovaginal mycotic infection,colitis oral vulvovaginal,1,0.7110322713851929
DALVANCE,vulvovaginal mycotic infection,vulvovaginal mycotic,1,0.9829071760177612
DALVANCE,vulvovaginal mycotic infection,and infestations,0,0.5577231645584106
DALVANCE,vulvovaginal mycotic infection,blood alkaline phosphatase,0,0.4396544098854065
DALVANCE,vulvovaginal mycotic infection,difficile colitis oral vulvovaginal mycotic infection Investigations hepatic transaminases,1,0.7365924715995789
DALVANCE,hepatic transaminases increased,candidiasis vulvovaginal mycotic infection hepatic transaminases increased,1,0.8050317168235779
DALVANCE,hepatic transaminases increased,blood alkaline phosphatase,0,0.6135345697402954
DALVANCE,hepatic transaminases increased,transaminases increased blood alkaline phosphatase increased international,1,0.8381809592247009
DALVANCE,hepatic transaminases increased,ridium difficile colitis oral candidiasis,0,0.5402275323867798
DALVANCE,hepatic transaminases increased,normalized ratio,0,0.49100568890571594
DALVANCE,hepatic transaminases increased,mycotic infection hepatic transaminases increased blood alkaline,1,0.8088122606277466
DALVANCE,blood alkaline phosphatase increased,alkaline phosphatase increased international normalized ratio increased,1,0.8835217952728271
DALVANCE,blood alkaline phosphatase increased,infection,0,0.5330020785331726
DALVANCE,blood alkaline phosphatase increased,alkaline phosphatase increased international normalized ratio,1,0.8772857785224915
DALVANCE,international normalized ratio increased,Metabolism and nutrition disorders hypoglycemia,0,0.5284059047698975
DALVANCE,international normalized ratio increased,tion,0,0.5230542421340942
DALVANCE,international normalized ratio increased,phosphatase international normalized ratio increased Metabolism and nutrition disorders hypoglycemia,1,0.7176381945610046
DALVANCE,international normalized ratio increased,increased blood alkaline phosphatase international normalized ratio increased Metabolism and,1,0.7177697420120239
DALVANCE,international normalized ratio increased,phosphatase international normalized ratio increased,1,0.8146509528160095
DALVANCE,international normalized ratio increased,ratio increased,1,0.8279653191566467
DALVANCE,hypoglycemia,hypoglycemia,1,1.0
DALVANCE,hypoglycemia,and mediastinal,0,0.4332370162010193
DALVANCE,hypoglycemia,international normalized ratio increased Metabolism,0,0.5827850699424744
DALVANCE,hypoglycemia,hypoglycemia Nervous System,1,0.8768143057823181
DALVANCE,dizziness,dizziness Respiratory thoracic and mediastinal disorders,1,0.7911381721496582
DALVANCE,dizziness,disorders hypoglycemia,0,0.5714930891990662
DALVANCE,bronchospasm,bronchospasm Skin,1,0.8726831674575806
DALVANCE,bronchospasm,bronchospasm Skin and Subcutaneous,1,0.8387254476547241
DALVANCE,bronchospasm,bronchospasm,1,1.0000001192092896
DALVANCE,bronchospasm,and mediastinal bronchospasm Skin,1,0.8223887085914612
DALVANCE,bronchospasm,disorders flushing phl,0,0.5302467346191406
DALVANCE,bronchospasm,bronchospasm Skin and,1,0.8753921985626221
DALVANCE,bronchospasm,disorders,0,0.538914144039154
DALVANCE,urticaria,Subcutaneous Tissue urticaria,1,0.8305941820144653
DALVANCE,urticaria,bronchospasm Skin and Subcutaneous,1,0.6819939613342285
DALVANCE,urticaria,disorders,0,0.5612454414367676
DALVANCE,urticaria,urticaria,1,1.0
DALVANCE,urticaria,Tissue urticaria Vascular,1,0.8067222833633423
DALVANCE,urticaria,disorders bronchospasm Skin and Subcutaneous,0,0.6729195713996887
DALVANCE,urticaria,thoracic,0,0.5528421401977539
DALVANCE,urticaria,urticaria Vascular disorders flushing phlebitis wound,1,0.7670167684555054
DALVANCE,urticaria,urticaria Vascular,1,0.8448926210403442
DALVANCE,urticaria,urticaria Vascular disorders,1,0.8157597780227661
DALVANCE,urticaria,Subcutaneous Tissue urticaria Vascular disorders flushing phlebitis wound,1,0.7623403072357178
DALVANCE,flushing,spontaneous hematoma Alanine Aminotransferase,0,0.5099865794181824
DALVANCE,flushing,flushing,1,1.0
DALVANCE,flushing,flushing phlebitis wound hemorrhage spontaneous,1,0.673915684223175
DALVANCE,flushing,Vascular flushing phlebitis wound hemorrhage,1,0.7004015445709229
DALVANCE,phlebitis,urticaria Vascular disorders phlebitis wound,1,0.8187100291252136
DALVANCE,phlebitis,flushing,1,0.5602070093154907
DALVANCE,phlebitis,Alanine Aminotransferase,0,0.4783506691455841
DALVANCE,wound hemorrhage,Vascular disorders flushing wound hemorrhage,1,0.8238216638565063
DALVANCE,wound hemorrhage,disorders flushing wound hemorrhage spontaneous hematoma Alanine Aminotransferase ALT,1,0.7486350536346436
DALVANCE,wound hemorrhage,urticaria Vascular disorders flushing wound hemorrhage spontaneous hematoma,1,0.7396209239959717
DALVANCE,wound hemorrhage,urticaria Vascular disorders flushing wound hemorrhage spontaneous hematoma Alanine Aminotransferase,1,0.7061959505081177
DALVANCE,wound hemorrhage,wound hemorrhage spontaneous hematoma Alanine Aminotransferase,1,0.7644416093826294
DALVANCE,wound hemorrhage,Vascular disorders flushing wound,1,0.7651838064193726
DALVANCE,wound hemorrhage,flushing phlebitis,0,0.6144576668739319
DALVANCE,wound hemorrhage,spontaneous hematoma Alanine Aminotransferase ALT,0,0.63591468334198
DALVANCE,spontaneous hematoma,Vascular disorders,0,0.5899344682693481
DALVANCE,spontaneous hematoma,wound spontaneous hematoma,1,0.9405966997146606
DALVANCE,spontaneous hematoma,disorders flushing phlebitis wound spontaneous hematoma,1,0.8439445495605469
DALVANCE,spontaneous hematoma,disorders flushing phlebitis wound spontaneous hematoma Alanine Aminotransferase ALT Elevations,1,0.7337197065353394
DALVANCE,spontaneous hematoma,flushing phlebitis wound spontaneous hematoma Alanine Aminotransferase,1,0.7618870735168457
DALVANCE,spontaneous hematoma,spontaneous hematoma,1,1.0000001192092896
DALVANCE,spontaneous hematoma,with normal baseline,0,0.5300160646438599
DALVANCE,spontaneous hematoma,Elevations Among patients with,0,0.5604397058486938
DALVANCE,ALT elevations,patients had ALT,1,0.6626275181770325
DALVANCE,ALT elevations,ALT,1,0.7938967943191528
DALVANCE,ALT elevations,than comparatortreated patients had,0,0.4838210940361023
DALVANCE,ALT elevations,ALT elevations greater than times the,1,0.9095363616943359
DALVANCE,ALT values greater than 10 times ULN,Eight of patients treated with,0,0.5221237540245056
DALVANCE,ALT values greater than 10 times ULN,than 10 times ULN Eight of patients,1,0.6604381799697876
DALVANCE,ALT values greater than 10 times ULN,had underlying conditions,0,0.4904962480068207
DALVANCE,ALT values greater than 10 times ULN,respectively including three subjects,0,0.5043653249740601
DALVANCE,ALT values greater than 10 times ULN,10 times ULN Eight of patients,1,0.6603291630744934
DALVANCE,ALT values greater than 10 times ULN,ALT values greater than 10 times ULN Eight of,1,0.9647470116615295
DALVANCE,ALT values greater than 10 times ULN,three subjects with ALT values greater than 10 times ULN Eight of patients,1,0.7348451614379883
DALVANCE,ALT values greater than 10 times ULN,subjects with ALT values,1,0.733823299407959
DALVANCE,ALT values greater than 10 times ULN,ULN vs respectively including,0,0.6726992130279541
DALVANCE,ALT values greater than 10 times ULN,including three subjects,0,0.5096600651741028
DALVANCE,ALT elevations,ALT elevations greater than,1,0.9326317310333252
DALVANCE,ALT elevations,ALT elevations were reversible in all subjects No comparatortreated,0,0.7620000839233398
DALVANCE,ALT elevations,addition one DALVANCEtreated subject in,0,0.5152519345283508
DALVANCE,ALT elevations,alcohol abuse In addition one DALVANCEtreated subject in a,0,0.4652497470378876
DALVANCE,ALT elevations,Phase trial had ALT elevations greater than times ULN,1,0.6985621452331543
DALVANCE,ALT elevations,ALT elevations,0,0.9999998807907104
DALVANCE,ALT elevations,ALT elevations were reversible,1,0.8348029851913452
DALVANCE,ALT elevations,a Phase,0,0.5017531514167786
DALVANCE,ALT elevations,ALT elevations were reversible in,1,0.846074104309082
DALVANCE,ALT elevations,elevations greater than times ALT elevations,1,0.8813461065292358
DALVANCE,ALT elevations,times ULN,0,0.5410555601119995
DALVANCE,ALT elevations,ALT elevations were reversible in all subjects,1,0.7635351419448853
DALVANCE,ALT elevations,comparatortreated subject with normal,0,0.548346757888794
DALVANCE,ALT elevation,baseline transaminases had ALT elevation,1,0.7109019160270691
DALVANCE,ALT elevation,had,0,0.47721779346466064
DALVANCE,skin reactions,rates in the clini,0,0.5004061460494995
DALVANCE,skin reactions,rates observed in clinical trials of DALVANCE cannot,0,0.4878753125667572
DALVANCE,skin reactions,"under widely varying ,",1,0.4839455187320709
DALVANCE,skin reactions,", adverse reac tion",1,0.5619069337844849
DALVANCE,skin reactions,", adverse",1,0.5702690482139587
DALVANCE,skin reactions,"varying , adverse reac tion rates observed in",1,0.50977623462677
DALVANCE,skin reactions,widely,0,0.4705874025821686
DALVANCE,ALT elevations,"with DALVANCE were a (5.5%), head",1,0.5157386064529419
DALVANCE,ALT elevations,"treated with DALVANCE were a (5.5%), head",1,0.4976041913032532
DALVANCE,ALT elevations,REACTIONS contact,0,0.4878491759300232
DALVANCE,Clostridium difficile -associated diarrhea,"SUSPECTED ADVERSE ACTIONS,",1,0.4881572425365448
DALVANCE,Clostridium difficile -associated diarrhea,"SUSPECTED ADVERSE ACTIONS, contact Durata Therapeutics, Inc.",1,0.5309650897979736
DALVANCE,Clostridium difficile -associated diarrhea,To report,0,0.5029467940330505
DALVANCE,Clostridium difficile -associated diarrhea,"SUSPECTED ADVERSE ACTIONS, contact Durata Therapeutics, Inc. at or FDA",1,0.538091778755188
DALVANCE,Red-Man Syndrome,patients and comparator was,1,0.4983977675437927
DALVANCE,Red-Man Syndrome,an adverse,0,0.5581159591674805
DALVANCE,Red-Man Syndrome,and comparator,1,0.4281139373779297
DALVANCE,Red-Man Syndrome,comparator was discontinued due to an,1,0.44838404655456543
DALVANCE,Red-Man Syndrome,in patients and comparator was,1,0.5061031579971313
DALVANCE,flushing of the upper body,the comparator was due to an adverse reaction in patients Most Common,1,0.5933661460876465
DALVANCE,flushing of the upper body,in patients and comparator was,1,0.5119544863700867
DALVANCE,urticaria,n 35/1224 patients Most Common,1,0.4980812668800354
DALVANCE,urticaria,in patients and comparator was,1,0.4774838984012604
DALVANCE,urticaria,reaction n 35/1224 patients Most Common Adverse Reactions,1,0.5897423028945923
DALVANCE,pruritus,2.8%) pa tients Most,1,0.5119690299034119
DALVANCE,pruritus,reaction 2.8%) pa tients Most Common Adverse,1,0.6041444540023804
DALVANCE,pruritus,reactions in patients,0,0.5784184336662292
DALVANCE,pruritus,common adverse reactions in patients trea,0,0.552412748336792
DALVANCE,pruritus,an adverse reaction 2.8%) pa,1,0.6207411289215088
DALVANCE,pruritus,2.8%) pa tients Most Common Adverse,1,0.5718149542808533
DALVANCE,rash,discontinued due to an,0,0.4511512517929077
DALVANCE,rash,due to an,0,0.5217900276184082
DALVANCE,rash,"

   Most Common Adverse Reactions The",1,0.5996806621551514
DALVANCE,rash,"

   Most Common",1,0.5171011686325073
DALVANCE,rash,atients and the comparator was discontinued due to an adverse reaction,0,0.542708158493042
DALVANCE,rash,in,0,0.5418816208839417
DALVANCE,rash,Adverse Reactions The most common,0,0.6008968353271484
DALVANCE,Clostridium difficile -associated diarrhea,N a           98 (5.5)         78 (6.4)       Vomiting,1,0.5529544949531555
DALVANCE,Clostridium difficile -associated diarrhea,Adverse Reactions The most common,0,0.5525550842285156
DALVANCE,Clostridium difficile -associated diarrhea,a           98 (5.5)         78 (6.4)      ,1,0.4251602292060852
DALVANCE,Clostridium difficile -associated diarrhea,Comparator N N a           98 (5.5)         78 (6.4)      ,1,0.4497026801109314
DALVANCE,Clostridium difficile -associated diarrhea,Dalbavancin Comparator N N a,1,0.5777159929275513
DALVANCE,Clostridium difficile -associated diarrhea,78 (6.4) Vomiting Diarrhea,1,0.6733404994010925
DALVANCE,Clostridium difficile -associated diarrhea,Nause,0,0.521202564239502
DALVANCE,Clostridium difficile -associated diarrhea,N N a 98,1,0.42642921209335327
DALVANCE,CDAD," 
   Vomiting Diarrhea",1,0.4929446578025818
DALVANCE,CDAD," 
  ",1,0.6182198524475098
DALVANCE,diarrhea,Headache,0,0.5687180757522583
DALVANCE,diarrhea,Diarrhea 83 (4.7),1,0.8037452697753906
DALVANCE,fatal,Diarrhea Headache,0,0.548324465751648
DALVANCE,colitis,Headache,0,0.5060923099517822
DALVANCE,colitis,9 (4.8) Rash Pruritus,1,0.5879847407341003
DALVANCE,colitis,9 (4.8),1,0.4925481081008911
FERRIPROX,chromaturia,pain alanine aminotransferase increased,0,0.5004165768623352
FERRIPROX,chromaturia,The most common adverse reactions are incidence,0,0.5010362863540649
FERRIPROX,chromaturia,chromaturia,1,0.9999999403953552
FERRIPROX,chromaturia,REACTIONS EXCERPT,0,0.4684753715991974
FERRIPROX,chromaturia,chromaturia nausea vomiting and abdominal,1,0.8478211164474487
FERRIPROX,vomiting,vomiting and,1,0.9646890163421631
FERRIPROX,vomiting,vomiting and abdominal pain alanine aminotransferase,1,0.7335556745529175
FERRIPROX,vomiting,reactions are incidence chromaturia vomiting and,1,0.7578054070472717
FERRIPROX,vomiting,most common adverse reactions are incidence chromaturia nausea,0,0.6449085474014282
FERRIPROX,abdominal pain,vomiting abdominal pain alanine,1,0.7868013381958008
FERRIPROX,abdominal pain,most common adverse reactions are incidence chromaturia nausea,0,0.583921492099762
FERRIPROX,abdominal pain,abdominal pain alanine aminotransferase increased arthralgia and,1,0.7561078667640686
FERRIPROX,alanine aminotransferase increased,SUSPECTED ADVERSE REACTIONS,0,0.581541895866394
FERRIPROX,alanine aminotransferase increased,alanine aminotransferase increased arthralgia and neutropenia To,1,0.8612504005432129
FERRIPROX,alanine aminotransferase increased,abdominal alanine aminotransferase increased arthralgia and neutropenia To,1,0.8468019366264343
FERRIPROX,alanine aminotransferase increased,alanine aminotransferase increased arthralgia,1,0.870627760887146
FERRIPROX,alanine aminotransferase increased,vomiting and abdominal alanine aminotransferase increased arthralgia and neutropenia To report,1,0.8111649751663208
FERRIPROX,alanine aminotransferase increased,abdominal alanine aminotransferase increased arthralgia and neutropenia,1,0.8443351984024048
FERRIPROX,alanine aminotransferase increased,ADVERSE,0,0.5407620668411255
FERRIPROX,alanine aminotransferase increased,arthralgia and neutropenia To report SUSPECTED,0,0.5697667598724365
FERRIPROX,arthralgia,arthralgia and,1,0.9559702277183533
FERRIPROX,arthralgia,arthralgia,1,1.0
FERRIPROX,arthralgia,arthralgia and neutropenia To report SUSPECTED,1,0.7764546871185303
FERRIPROX,arthralgia,arthralgia and neutropenia,1,0.8208678364753723
FERRIPROX,arthralgia,aminotransferase arthralgia,1,0.8446996212005615
FERRIPROX,neutropenia,neutropenia To report SUSPECTED ADVERSE,1,0.8429145812988281
FERRIPROX,neutropenia,neutropenia,1,1.0
FERRIPROX,Agranulocytosis,other sections of the Agranulocytosis Neutropenia see Warnings,1,0.8056211471557617
FERRIPROX,Agranulocytosis,neutropenia,1,0.7406491637229919
FERRIPROX,Agranulocytosis,sections of the Agranulocytosis,1,0.8901292085647583
FERRIPROX,Agranulocytosis,ALT,0,0.49255457520484924
FERRIPROX,Agranulocytosis,are also discussed in other sections,0,0.4586799740791321
FERRIPROX,Agranulocytosis,Agranulocytosis Neutropenia see Warnings,1,0.8389861583709717
FERRIPROX,Agranulocytosis,Neutropenia,0,0.7406491637229919
FERRIPROX,Agranulocytosis,Agranulocytosis Neutropenia see Warnings and,1,0.8434309363365173
FERRIPROX,Neutropenia,discussed in other sections,0,0.48021817207336426
FERRIPROX,Neutropenia,sections of the labeling Neutropenia see Warnings and Precautions,1,0.8058112263679504
FERRIPROX,Neutropenia,Elevated,0,0.5089081525802612
FERRIPROX,Neutropenia,Neutropenia see Warnings and Precautions,1,0.8538450002670288
FERRIPROX,Neutropenia,also discussed in other sections of the labeling Agranulocytosis,0,0.6925756931304932
FERRIPROX,Neutropenia,in,0,0.5025935173034668
FERRIPROX,Neutropenia,labeling Neutropenia,1,0.8697823882102966
FERRIPROX,Elevated ALT,Elevated ALT Decreased plasma zinc,1,0.7366050481796265
FERRIPROX,Elevated ALT,see Warnings and Elevated ALT Decreased plasma zinc concentrations,1,0.6967321634292603
FERRIPROX,Elevated ALT,see Warnings and Elevated ALT,1,0.8222309350967407
FERRIPROX,Elevated ALT,zinc concentrations Because,0,0.526091992855072
FERRIPROX,Elevated ALT,trials,0,0.49334031343460083
FERRIPROX,Elevated ALT,Precautions,0,0.5309628248214722
FERRIPROX,Elevated ALT,AgranulocytosisNeutropenia see Warnings and Elevated ALT Decreased plasma zinc,1,0.6039093732833862
FERRIPROX,Elevated ALT,Elevated ALT Decreased plasma zinc concentrations Because,1,0.7366925477981567
FERRIPROX,Decreased plasma zinc concentrations,Precautions Elevated Decreased plasma zinc concentrations,1,0.9277768731117249
FERRIPROX,Decreased plasma zinc concentrations,Elevated ALT Decreased plasma zinc concentrations Because,1,0.8947768211364746
FERRIPROX,agranulocytosis,Ferriprox agranulocytosis see Warnings and Precautions The,1,0.7748852968215942
FERRIPROX,agranulocytosis,Elevated ALT Decreased plasma zinc concentrations Because,1,0.5401122570037842
FERRIPROX,agranulocytosis,with Ferriprox agranulocytosis see,1,0.8027243614196777
FERRIPROX,agranulocytosis,agranulocytosis see,1,0.9314473271369934
FERRIPROX,agranulocytosis,agranulocytosis see Warnings and Precautions The,1,0.8664429187774658
FERRIPROX,agranulocytosis,agranulocytosis see Warnings,1,0.8815860748291016
FERRIPROX,agranulocytosis,agranulocytosis see Warnings and Precautions,1,0.8684870004653931
FERRIPROX,agranulocytosis,clinical trials with Ferriprox agranulocytosis see,1,0.770795464515686
FERRIPROX,chromaturia,during clinical,0,0.49132969975471497
FERRIPROX,chromaturia,chromaturia nausea vomiting,1,0.8774032592773438
FERRIPROX,chromaturia,reported during clinical trials chromaturia nausea vomiting abdominal,1,0.8033164739608765
FERRIPROX,nausea,reactions reported during clinical,0,0.5882151126861572
FERRIPROX,nausea,alanine aminotransferase increased,0,0.5609875917434692
FERRIPROX,nausea,adverse reactions,0,0.6473151445388794
FERRIPROX,nausea,aminotransferase increased,0,0.5661424398422241
FERRIPROX,vomiting,vomiting abdominal,1,0.9126685261726379
FERRIPROX,vomiting,vomiting,1,0.9999999403953552
FERRIPROX,vomiting,were chromaturia vomiting,1,0.7616610527038574
FERRIPROX,abdominal pain,abdominal pain alanine aminotransferase increased,1,0.7746490240097046
FERRIPROX,abdominal pain,The,0,0.48343634605407715
FERRIPROX,abdominal pain,most common adverse reactions reported,0,0.5331557989120483
FERRIPROX,abdominal pain,nausea vomiting,0,0.6341216564178467
FERRIPROX,abdominal pain,abdominal pain alanine aminotransferase increased arthralgia,1,0.7545381188392639
FERRIPROX,arthralgia,abdominal pain alanine aminotransferase,0,0.5847232341766357
FERRIPROX,neutropenia,nausea,0,0.5792617797851562
FERRIPROX,neutropenia,pain alanine aminotransferase increased,0,0.5183245539665222
FERRIPROX,neutropenia,neutropenia The table below,1,0.8768792748451233
FERRIPROX,neutropenia,the,0,0.5061156749725342
FERRIPROX,neutropenia,increased arthralgia neutropenia The table below lists the,1,0.7976981997489929
FERRIPROX,Nausea,Nausea Abdominal paindiscomf,1,0.8151184320449829
FERRIPROX,Neutrophil count decreased,Alanine Aminotransferase Neutrophil count,1,0.7523763179779053
FERRIPROX,Neutrophil count decreased,Aminotransferase Neutrophil count decreased Weight increased,1,0.804729700088501
FERRIPROX,Neutrophil count decreased,Neutrophil count decreased,1,1.0
FERRIPROX,Neutrophil count decreased,count decreased Weight increased,1,0.690505862236023
FERRIPROX,Weight increased,Weight increased Aspartate Aminotransferase incre,1,0.7752344608306885
FERRIPROX,Aspartate Aminotransferase increased,Weight Aspartate Aminotransferase,1,0.8801239728927612
FERRIPROX,Aspartate Aminotransferase increased,AND,0,0.5095244646072388
FERRIPROX,Aspartate Aminotransferase increased,AND NUTRITION DISORDERS,0,0.5578198432922363
FERRIPROX,Aspartate Aminotransferase increased,Weight,0,0.5474275350570679
FERRIPROX,Aspartate Aminotransferase increased,Aspartate Aminotransferase increased METABOLISM AND,1,0.9487850666046143
FERRIPROX,Aspartate Aminotransferase increased,METABOLISM AND,0,0.6540817022323608
FERRIPROX,Increased appetite,Increased appetite Decreased,1,0.8657887578010559
FERRIPROX,Increased appetite,NUTRITION Increased appetite Decreased,1,0.8326785564422607
FERRIPROX,Increased appetite,Increased appetite Decreased appetite,1,0.8781917691230774
FERRIPROX,Increased appetite,NUTRITION,0,0.6860775351524353
FERRIPROX,Increased appetite,AND NUTRITION Increased,1,0.7770058512687683
FERRIPROX,Increased appetite,METABOLISM AND NUTRITION,0,0.6919423937797546
FERRIPROX,Increased appetite,Increased appetite,1,0.9999999403953552
FERRIPROX,Decreased appetite,AND CONNECTIVE TISSUE,0,0.47023439407348633
FERRIPROX,Decreased appetite,appetite,0,0.8036579489707947
FERRIPROX,Decreased appetite,Decreased appetite MUSCULOSKELETAL,1,0.8353739976882935
FERRIPROX,Decreased appetite,Decreased appetite MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1,0.764265775680542
FERRIPROX,Decreased appetite,Increased,0,0.5270181894302368
FERRIPROX,Decreased appetite,Decreased appetite MUSCULOSKELETAL AND,1,0.8344218730926514
FERRIPROX,Decreased appetite,Decreased appetite MUSCULOSKELETAL AND CONNECTIVE,1,0.7923375368118286
FERRIPROX,Arthropathy,Arthropathy NERVOUS SYSTEM,1,0.8521169424057007
FERRIPROX,Arthropathy,NERVOUS,0,0.5094643235206604
FERRIPROX,Arthropathy,Arthropathy NERVOUS SYSTEM DISORDERS,1,0.8595615029335022
FERRIPROX,Arthropathy,NERVOUS SYSTEM DISORDERS,0,0.579413890838623
FERRIPROX,Arthropathy,Pain in Arthropathy NERVOUS,1,0.8161550164222717
FERRIPROX,Arthropathy,in,0,0.550417423248291
FERRIPROX,Headache,Headache URINARY,1,0.8333123922348022
FERRIPROX,Headache,in,0,0.5469977855682373
FERRIPROX,Headache,Headache,1,0.9999998807907104
FERRIPROX,Headache,SYSTEM Headache,1,0.774387001991272
FERRIPROX,Headache,Headache URINARY DISORDERS,1,0.7909299731254578
FERRIPROX,Headache,DISORDERS,0,0.5661548376083374
FERRIPROX,Chromaturia,Chromaturia,1,0.9999999403953552
FERRIPROX,nausea,nausea vomiting and abdominal pain,1,0.8212697505950928
FERRIPROX,nausea,symptoms,0,0.6900825500488281
FERRIPROX,nausea,symptoms such nausea vomiting and abdominal,1,0.8054441809654236
FERRIPROX,nausea,nausea,1,1.0
FERRIPROX,nausea,the most frequent adverse reactions reported by patients,0,0.5939946174621582
FERRIPROX,nausea,nausea vomiting,1,0.9235453605651855
FERRIPROX,nausea,such,0,0.5057132840156555
FERRIPROX,nausea,Chromaturia Gastrointestinal symptoms such,0,0.6170554161071777
FERRIPROX,nausea,Chromaturia Gastrointestinal symptoms such nausea vomiting and,1,0.7169101238250732
FERRIPROX,vomiting,maturia Gastrointestinal,0,0.5994856357574463
FERRIPROX,vomiting,as nausea,0,0.7955376505851746
FERRIPROX,abdominal pain,nausea vomiting abdominal pain,1,0.880584716796875
FERRIPROX,abdominal pain,vomiting,1,0.6247491836547852
FERRIPROX,abdominal pain,abdominal,1,0.7878189086914062
FERRIPROX,abdominal pain,as,0,0.4947966933250427
FERRIPROX,abdominal pain,nausea vomiting abdominal,1,0.7897743582725525
FERRIPROX,abdominal pain,abdominal pain were the most,1,0.8981386423110962
FERRIPROX,abdominal pain,were the most frequent adverse reactions reported by patients,0,0.5096209049224854
FERRIPROX,abdominal pain,Gastrointestinal symptoms such as nausea vomiting,0,0.7261008024215698
FERRIPROX,abdominal pain,abdominal pain,1,0.9999998807907104
FERRIPROX,abdominal pain,nausea,0,0.6394764184951782
FERRIPROX,Chromaturia,in the,0,0.4980792999267578
FERRIPROX,Chromaturia,urine is a result,0,0.7017343044281006
FERRIPROX,Chromaturia,of the urine is,0,0.6929494738578796
FERRIPROX,Chromaturia,Chromaturia reddishbrown discoloration of,1,0.8892093896865845
FERRIPROX,Chromaturia,of,0,0.4964712858200073
FERRIPROX,Chromaturia,in of Chromaturia reddishbrown discoloration of,1,0.8915685415267944
FERRIPROX,Chromaturia,Chromaturia reddishbrown discoloration,1,0.880012035369873
FERRIPROX,thrombocytosis,thrombocytosis pancytopenia,1,0.8842902183532715
FERRIPROX,thrombocytosis,Blood and lymphatic system thrombocytosis,1,0.8733257055282593
FERRIPROX,thrombocytosis,Blood and,0,0.6097793579101562
FERRIPROX,thrombocytosis,fibrillation cardiac failure,0,0.5037146210670471
FERRIPROX,thrombocytosis,thrombocytosis pancytopenia Cardiac disorders atrial fibrillation,1,0.7894753217697144
FERRIPROX,pancytopenia,pancytopenia Cardiac disorders atrial fibrillation,1,0.8186231851577759
FERRIPROX,atrial fibrillation,disorders thrombocytosis pancytopenia Cardiac atrial fibrillation cardiac failure Congenital familial and,1,0.7139745950698853
FERRIPROX,atrial fibrillation,pancytopenia Cardiac disorders atrial fibrillation,1,0.7639975547790527
FERRIPROX,atrial fibrillation,atrial fibrillation,1,1.0
FERRIPROX,atrial fibrillation,Cardiac atrial fibrillation,1,0.9475014209747314
FERRIPROX,atrial fibrillation,atrial,1,0.8164797425270081
FERRIPROX,atrial fibrillation,atrial fibrillation cardiac failure Congenital familial,1,0.7776129245758057
FERRIPROX,atrial fibrillation,pancytopenia Cardiac atrial fibrillation,1,0.762146532535553
FERRIPROX,atrial fibrillation,Cardiac disorders,0,0.7084046006202698
FERRIPROX,atrial fibrillation,cardiac failure,0,0.6939050555229187
FERRIPROX,cardiac failure,disorders,0,0.5996291637420654
FERRIPROX,cardiac failure,and genetic,0,0.4898184537887573
FERRIPROX,cardiac failure,disorders atrial,0,0.6380559802055359
FERRIPROX,hypospadias,hypospadias Eye disorders,1,0.8575647473335266
FERRIPROX,hypospadias,papilledema,0,0.5487912893295288
FERRIPROX,hypospadias,familial and genetic disorders,0,0.5478525161743164
FERRIPROX,hypospadias,hypospadias Eye disorders diplopia papilledema,1,0.8105045557022095
FERRIPROX,hypospadias,orders atrial fibrillation cardiac,0,0.45615464448928833
FERRIPROX,diplopia,Eye diplopia papilledema retinal toxicity,1,0.7533516883850098
FERRIPROX,diplopia,orders atrial fibrillation cardiac,0,0.3853212594985962
FERRIPROX,diplopia,enterocolitis rectal hemorrhag,0,0.4370548129081726
FERRIPROX,diplopia,and genetic disorders,0,0.5145875215530396
FERRIPROX,diplopia,diplopia papilledema,1,0.8566712141036987
FERRIPROX,diplopia,and,0,0.45230233669281006
FERRIPROX,diplopia,disorders,0,0.5359938144683838
FERRIPROX,diplopia,genetic disorders hypospadias Eye diplopia papilledema,1,0.711859405040741
FERRIPROX,papilledema,papilledema retinal,1,0.8926430940628052
FERRIPROX,papilledema,Congenital familial and genetic disorders,0,0.5521596670150757
FERRIPROX,retinal toxicity,diplopia retinal,1,0.7204082012176514
FERRIPROX,retinal toxicity,disorders diplopia retinal,1,0.711007833480835
FERRIPROX,retinal toxicity,hypospadias Eye disorders diplopia retinal toxicity,1,0.7839490175247192
FERRIPROX,retinal toxicity,retinal toxicity Gastrointestinal disorders enterocolitis,1,0.8191525936126709
FERRIPROX,retinal toxicity,retinal toxicity Gastrointestinal disorders,1,0.8476362824440002
FERRIPROX,enterocolitis,enterocolitis rectal hemorrhage gastric,1,0.8133977651596069
FERRIPROX,enterocolitis,enterocolitis,1,1.0
FERRIPROX,enterocolitis,enterocolitis rectal,1,0.8304678201675415
FERRIPROX,enterocolitis,enterocolitis rectal hemorrhage gastric ulcer,1,0.7819007635116577
FERRIPROX,enterocolitis,Gastrointestinal enterocolitis rectal hemorrhage,1,0.7715727090835571
FERRIPROX,enterocolitis,papilledema retinal toxicity Gastrointestinal enterocolitis rectal hemorrhage gastric,1,0.6767131090164185
FERRIPROX,rectal hemorrhage,pancreatitis parotid gland enlargement,0,0.5107985734939575
FERRIPROX,rectal hemorrhage,parotid gland enlargement,0,0.4886886477470398
FERRIPROX,rectal hemorrhage,rectal hemorrhage gastric ulcer pancreatitis parotid gland,1,0.811536967754364
FERRIPROX,rectal hemorrhage,rectal hemorrhage gastric ulcer pancreatitis,1,0.8349552154541016
FERRIPROX,rectal hemorrhage,rectal hemorrhage gastric,1,0.8564407825469971
FERRIPROX,rectal hemorrhage,papilledema retinal,0,0.5355514883995056
FERRIPROX,rectal hemorrhage,Gastrointestinal disorders rectal hemorrhage gastric ulcer pancreatitis,1,0.7507723569869995
FERRIPROX,rectal hemorrhage,retinal,0,0.5838937759399414
FERRIPROX,rectal hemorrhage,retinal toxicity Gastrointestinal disorders rectal hemorrhage gastric,1,0.775653600692749
FERRIPROX,rectal hemorrhage,toxicity Gastrointestinal disorders rectal hemorrhage,1,0.8546716570854187
FERRIPROX,gastric ulcer,gastric ulcer pancreatitis parotid gland,1,0.8014906644821167
FERRIPROX,gastric ulcer,enlargement General,0,0.46887296438217163
FERRIPROX,gastric ulcer,toxicity Gastrointestinal disorders enterocolitis rectal hemorrhage,0,0.6162595748901367
FERRIPROX,pancreatitis,pancreatitis parotid gland enlargement General,1,0.794176459312439
FERRIPROX,pancreatitis,rectal hemorrhage gastric ulcer,0,0.5707783102989197
FERRIPROX,pancreatitis,hemorrhage gastric pancreatitis,1,0.7682719826698303
FERRIPROX,pancreatitis,pancreatitis parotid,1,0.8063310384750366
FERRIPROX,pancreatitis,pancreatitis parotid gland enlargement General disorders,1,0.749351441860199
FERRIPROX,pancreatitis,disorders and,0,0.5554628968238831
FERRIPROX,pancreatitis,gland enlargement General disorders and administration site conditions,0,0.5418617129325867
FERRIPROX,parotid gland enlargement,gastric ulcer parotid gland enlargement General disorders and administration site,1,0.8092269897460938
FERRIPROX,parotid gland enlargement,gland enlargement General disorders and administration site conditions,0,0.79242342710495
FERRIPROX,parotid gland enlargement,rectal hemorrhage gastric ulcer parotid gland enlargement General disorders and,1,0.7417420148849487
FERRIPROX,parotid gland enlargement,pyrexia edema peripheral m,0,0.5499866008758545
FERRIPROX,parotid gland enlargement,conditions chills pyrexia edema peripheral m,0,0.5354470014572144
FERRIPROX,chills,failure,0,0.4529736340045929
FERRIPROX,chills,and administration site chills pyrexia edema peripheral,1,0.7083110213279724
FERRIPROX,chills,and administration site,0,0.47203224897384644
FERRIPROX,chills,disorders,0,0.5195738077163696
FERRIPROX,chills,chills pyrexia edema peripheral,1,0.7515764236450195
FERRIPROX,chills,conditions,0,0.551891565322876
FERRIPROX,chills,edema peripheral multiorgan failure,0,0.43850988149642944
FERRIPROX,edema peripheral,edema peripheral,1,1.0
FERRIPROX,edema peripheral,conditions chills edema peripheral multiorgan failure Hepatobiliary disorders,1,0.702555239200592
FERRIPROX,edema peripheral,chills edema,1,0.7331029176712036
FERRIPROX,edema peripheral,edema peripheral multiorgan failure Hepatobiliary disorders jaundice,1,0.7596539258956909
FERRIPROX,jaundice,anaphylactic shock hypersensitivity,0,0.5020526051521301
FERRIPROX,jaundice,shock hypersensitivity,0,0.4951924681663513
FERRIPROX,hepatomegaly,Hepatobiliary disorders,0,0.7346471548080444
FERRIPROX,hepatomegaly,jaundice,0,0.6044712066650391
FERRIPROX,hepatomegaly,hepatomegaly Immune system disorders anaphylactic shock,1,0.7776665687561035
FERRIPROX,hepatomegaly,hepatomegaly Immune,1,0.8869252800941467
FERRIPROX,hepatomegaly,hepatomegaly,1,0.9999998807907104
FERRIPROX,hepatomegaly,hepatomegaly Immune system disorders anaphylactic,1,0.7994063496589661
FERRIPROX,hepatomegaly,disorders hepatomegaly Immune system disorders,1,0.8285611867904663
FERRIPROX,hepatomegaly,peripheral multiorgan failure Hepatobiliary disorders,0,0.6966766715049744
FERRIPROX,anaphylactic shock,Immune system anaphylactic,1,0.881373405456543
FERRIPROX,anaphylactic shock,system anaphylactic shock hypersensitivity I nfections and infestations,1,0.7895165681838989
FERRIPROX,anaphylactic shock,jaundice hepatomegaly Immune system anaphylactic shock hypersensitivity I nfections and infestations,1,0.6825370192527771
FERRIPROX,anaphylactic shock,system anaphylactic shock,1,0.9003300666809082
FERRIPROX,hypersensitivity,hypersensitivity I nfections and infestations,1,0.8150550127029419
FERRIPROX,cryptococcal cutaneous infection,and,0,0.46760550141334534
FERRIPROX,enteroviral encephalitis,cryptococcal cutaneous enteroviral encephalitis,1,0.805377721786499
FERRIPROX,enteroviral encephalitis,pharyngitis pneumonia sepsis furuncle infectious hepatitis,0,0.5487326979637146
FERRIPROX,enteroviral encephalitis,enteroviral,1,0.8310469388961792
FERRIPROX,enteroviral encephalitis,enteroviral encephalitis pharyngitis pneumonia sepsis,1,0.8282971978187561
FERRIPROX,pharyngitis,furuncle infectious hepatitis rash pustular subcutaneous abscess Inve,0,0.5795316696166992
FERRIPROX,pharyngitis,infection enteroviral pharyngitis pneumonia sepsis furuncle infectious hepatitis,1,0.7114559412002563
FERRIPROX,pharyngitis,pharyngitis pneumonia sepsis furuncle infectious,1,0.7696794867515564
FERRIPROX,pneumonia,ctions and infestations cryptococcal cutaneous infection enteroviral,0,0.5465070009231567
FERRIPROX,pneumonia,pneumonia sepsis furuncle infectious hepatitis rash,1,0.7421708106994629
FERRIPROX,pneumonia,encephalitis pneumonia sepsis furuncle infectious hepatitis rash,1,0.71367347240448
FERRIPROX,pneumonia,pneumonia sepsis,1,0.8518068790435791
FERRIPROX,pneumonia,enteroviral encephalitis pneumonia sepsis,1,0.7156641483306885
FERRIPROX,pneumonia,pneumonia,1,0.9999997615814209
FERRIPROX,pneumonia,pneumonia sepsis furuncle,1,0.7563464641571045
FERRIPROX,sepsis,sepsis furuncle infectious hepatitis rash pustular,1,0.7236262559890747
FERRIPROX,sepsis,pneumonia sepsis furuncle,1,0.771367609500885
FERRIPROX,sepsis,sepsis furuncle infectious hepatitis rash,1,0.7505369782447815
FERRIPROX,sepsis,sepsis furuncle infectious,1,0.8320956826210022
FERRIPROX,sepsis,cryptococcal cutaneous infection enteroviral encephalitis,0,0.5572681427001953
FERRIPROX,furuncle,furuncle infectious hepatitis rash pustular subcutaneous,1,0.6061160564422607
FERRIPROX,furuncle,furuncle infectious hepatitis rash,1,0.6552936434745789
FERRIPROX,furuncle,enteroviral encephalitis pharyngitis pneumonia furuncle infectious hepatitis rash pustular,1,0.5293040871620178
FERRIPROX,furuncle,enteroviral encephalitis pharyngitis pneumonia furuncle infectious,1,0.6142369508743286
FERRIPROX,furuncle,hepatitis rash pustular,0,0.4925198554992676
FERRIPROX,infectious hepatitis,increased blood crea,0,0.5107487440109253
FERRIPROX,infectious hepatitis,rash pustular,0,0.48238179087638855
FERRIPROX,infectious hepatitis,infectious hepatitis rash,1,0.8319354057312012
FERRIPROX,infectious hepatitis,infectious hepatitis rash pustular,1,0.7550517916679382
FERRIPROX,infectious hepatitis,infectious hepatitis,1,1.0
FERRIPROX,infectious hepatitis,infectious hepatitis rash pustular subcutaneous abscess Investigations,1,0.7136125564575195
FERRIPROX,infectious hepatitis,sepsis furuncle,0,0.5275828838348389
FERRIPROX,infectious hepatitis,subcutaneous abscess Investigations blood bilirubin increased,0,0.5938203930854797
FERRIPROX,rash pustular,rash pustular subcutaneous abscess Investigations blood bilirubin,1,0.7737369537353516
FERRIPROX,rash pustular,infectious hepatitis,1,0.48238179087638855
FERRIPROX,rash pustular,blood,0,0.5076648592948914
FERRIPROX,rash pustular,infectious rash pustular subcutaneous abscess Investigations blood bilirubin,1,0.7580520510673523
FERRIPROX,rash pustular,Investigations blood bilirubin increased,0,0.45446527004241943
FERRIPROX,rash pustular,furuncle infectious rash pustular,1,0.899387001991272
FERRIPROX,rash pustular,abscess Investigations blood bilirubin increased blood creatinine phosphok,0,0.46564215421676636
FERRIPROX,rash pustular,rash pustular subcutaneous abscess Investigations,1,0.848522424697876
FERRIPROX,subcutaneous abscess,subcutaneous abscess,1,1.0000001192092896
FERRIPROX,subcutaneous abscess,infectious,0,0.6378529667854309
FERRIPROX,subcutaneous abscess,infectious hepatitis rash subcutaneous,1,0.7078089714050293
FERRIPROX,blood creatinine phosphokinase increased,Investigations blood bilirubin blood creatinine phosphokinase increased Metabolism,1,0.8491370677947998
FERRIPROX,blood creatinine phosphokinase increased,infectious hepatitis rash subcutaneous,1,0.493181973695755
FERRIPROX,blood creatinine phosphokinase increased,blood,1,0.6622306704521179
FERRIPROX,blood creatinine phosphokinase increased,blood creatinine phosphokinase increased,1,1.0
FERRIPROX,blood creatinine phosphokinase increased,disorders metabolic acidosis dehydration,0,0.529788613319397
FERRIPROX,blood creatinine phosphokinase increased,and,0,0.4841318428516388
FERRIPROX,blood creatinine phosphokinase increased,disorders,0,0.5212504267692566
FERRIPROX,metabolic acidosis,nutrition disorders,0,0.6025769710540771
FERRIPROX,metabolic acidosis,Musculoskeletal and,0,0.5274422764778137
FERRIPROX,metabolic acidosis,nutrition metabolic,1,0.7418333292007446
FERRIPROX,metabolic acidosis,metabolic acidosis dehydration Musculoskeletal and connective tissue,1,0.7659552693367004
FERRIPROX,metabolic acidosis,and nutrition metabolic acidosis dehydration Musculoskeletal and connective,1,0.7622616291046143
FERRIPROX,dehydration,phosphokinase increased Metabolism and nutrition disorders,0,0.540718674659729
FERRIPROX,dehydration,dehydration Musculoskeletal,1,0.8137772083282471
FERRIPROX,dehydration,connective tissue disorders,0,0.5057221055030823
FERRIPROX,dehydration,Musculoskeletal and connective tissue disorders myositis chondropathy trismus Ne,0,0.49283069372177124
FERRIPROX,dehydration,dehydration Musculoskeletal and connective tissue disorders,1,0.7732110023498535
FERRIPROX,dehydration,dehydration Musculoskeletal and connective tissue,1,0.7898908257484436
FERRIPROX,myositis,and connective,0,0.5602371096611023
FERRIPROX,myositis,myositis chondropathy trismus,1,0.7852798700332642
FERRIPROX,myositis,system disorders cerebellar syndrome,0,0.5427831411361694
FERRIPROX,myositis,and connective tissue myositis chondropathy trismus Nervous,1,0.7586170434951782
FERRIPROX,myositis,myositis,1,1.0
FERRIPROX,myositis,myositis chondropathy,1,0.8471252918243408
FERRIPROX,myositis,connective,0,0.5877866744995117
FERRIPROX,chondropathy,chondropathy trismus Nervous,1,0.7820307612419128
FERRIPROX,chondropathy,tissue,0,0.602962851524353
FERRIPROX,chondropathy,chondropathy trismus Nervous system,1,0.7545270919799805
FERRIPROX,chondropathy,metabolic acidosis dehydration Musculoskeletal,0,0.6392207145690918
FERRIPROX,trismus,convulsion gait distu,0,0.49071991443634033
FERRIPROX,cerebellar syndrome,system disorders,0,0.6412894129753113
FERRIPROX,cerebral hemorrhage,cerebral hemorrhage,1,1.000000238418579
FERRIPROX,cerebral hemorrhage,system disorders,0,0.5351670980453491
FERRIPROX,cerebral hemorrhage,disorders cerebellar cerebral hemorrhage convulsion,1,0.7573434710502625
FERRIPROX,cerebral hemorrhage,Nervous system,0,0.5930548906326294
FERRIPROX,cerebral hemorrhage,isorders myositis chondropathy trismus Nervous system,0,0.48024076223373413
FERRIPROX,gait disturbance,gait disturbance intracranial pressure increased psychomotor skills,1,0.741040825843811
FERRIPROX,gait disturbance,intracranial pressure increased psychomotor skills impaired pyramidal tract syndrome somnolence,0,0.5931973457336426
FERRIPROX,gait disturbance,hemorrhage convulsion,0,0.5721069574356079
FERRIPROX,gait disturbance,syndrome cerebral hemorrhage gait disturbance intracranial pressure increased,1,0.7666247487068176
FERRIPROX,intracranial pressure increased,gait intracranial pressure,1,0.8288185596466064
FERRIPROX,intracranial pressure increased,intracranial pressure increased psychomotor skills impaired pyramidal,1,0.8073845505714417
FERRIPROX,intracranial pressure increased,psychomotor skills impaired pyramidal tract syndrome somnolence Psychiatric disorders,0,0.5318385362625122
FERRIPROX,intracranial pressure increased,tract syndrome somnolence Psychiatric,0,0.5074054002761841
FERRIPROX,intracranial pressure increased,convulsion gait,0,0.5771455764770508
FERRIPROX,intracranial pressure increased,skills impaired pyramidal,0,0.52222740650177
FERRIPROX,intracranial pressure increased,convulsion gait intracranial,1,0.6968373656272888
FERRIPROX,pyramidal tract syndrome,bruxism,0,0.5389076471328735
FERRIPROX,pyramidal tract syndrome,pyramidal tract,1,0.9250648021697998
FERRIPROX,pyramidal tract syndrome,disorders,0,0.6349431276321411
FERRIPROX,somnolence,somnolence,1,1.0
FERRIPROX,somnolence,Psychiatric,0,0.5855460166931152
FERRIPROX,somnolence,somnolence Psychiatric disorders bruxism,1,0.7974587678909302
FERRIPROX,somnolence,somnolence Psychiatric disorders,1,0.8884694576263428
FERRIPROX,somnolence,impaired pyramidal tract somnolence Psychiatric disorders,1,0.7564321756362915
FERRIPROX,somnolence,pyramidal tract somnolence,1,0.8039389848709106
FERRIPROX,somnolence,pressure increased psychomotor skills impaired pyramidal tract,0,0.5128862857818604
FERRIPROX,somnolence,disorders,0,0.5874348282814026
FERRIPROX,bruxism,Psychiatric bruxism depression,1,0.8699805736541748
FERRIPROX,bruxism,disorders,0,0.645173192024231
FERRIPROX,bruxism,disorders glycosuria,0,0.5046430826187134
FERRIPROX,bruxism,bruxism depression obsessivecompulsive disorder Renal,1,0.8420908451080322
FERRIPROX,bruxism,disorder Renal,0,0.5203536748886108
FERRIPROX,bruxism,somnolence Psychiatric bruxism depression obsessivecompulsive disorder Renal,1,0.7942228317260742
FERRIPROX,bruxism,Renal disorders glycosuria,0,0.4757959246635437
FERRIPROX,bruxism,disorders glycosuria hemoglobinuria,0,0.5057367086410522
FERRIPROX,bruxism,bruxism depression obsessivecompulsive disorder Renal disorders,1,0.8322310447692871
FERRIPROX,depression,depression obsessivecompulsive disorder Renal,1,0.710616946220398
FERRIPROX,obsessive-compulsive disorder,obsessive-compulsive disorder,1,0.9999997615814209
FERRIPROX,obsessive-compulsive disorder,obsessive-compulsive disorder Renal disorders glycosuria,1,0.7573387622833252
FERRIPROX,obsessive-compulsive disorder,Renal disorders,0,0.5379071235656738
FERRIPROX,obsessive-compulsive disorder,Psychiatric disorders,0,0.7299082279205322
FERRIPROX,obsessive-compulsive disorder,syndrome somnolence Psychiatric disorders bruxism,0,0.6539371013641357
FERRIPROX,obsessive-compulsive disorder,Psychiatric disorders bruxism obsessive-compulsive disorder,1,0.7980149388313293
FERRIPROX,obsessive-compulsive disorder,bruxism depression,0,0.6526302099227905
FERRIPROX,glycosuria,glycosuria,1,1.000000238418579
FERRIPROX,glycosuria,glycosuria hemoglobinuria Respiratory,1,0.8309991955757141
FERRIPROX,glycosuria,glycosuria hemoglobinuria Respiratory thoracic and mediastinal,1,0.7952544689178467
FERRIPROX,glycosuria,glycosuria hemoglobinuria Respiratory thoracic and,1,0.811560869216919
FERRIPROX,glycosuria,hemoglobinuria Respiratory thoracic and mediastinal disorders acute respiratory,0,0.6038559675216675
FERRIPROX,hemoglobinuria,hemoglobinuria Respiratory,1,0.8465467691421509
FERRIPROX,hemoglobinuria,hemoglobinuria Respiratory thoracic and,1,0.8216436505317688
FERRIPROX,acute respiratory distress syndrome,respiratory distress syndrome epistaxis hemoptysis pulmonary embolism Skin,1,0.7545092105865479
FERRIPROX,acute respiratory distress syndrome,mediastinal acute,1,0.5997268557548523
FERRIPROX,acute respiratory distress syndrome,acute respiratory distress syndrome epistaxis,1,0.7919508218765259
FERRIPROX,acute respiratory distress syndrome,acute respiratory distress syndrome epistaxis hemoptysis,1,0.7872554063796997
FERRIPROX,acute respiratory distress syndrome,respiratory distress syndrome epistaxis hemoptysis pulmonary embolism,1,0.7626269459724426
FERRIPROX,acute respiratory distress syndrome,mediastinal disorders,0,0.5777699947357178
FERRIPROX,acute respiratory distress syndrome,hemoglobinuria Respiratory thoracic,0,0.5823065042495728
FERRIPROX,acute respiratory distress syndrome,respiratory distress syndrome epistaxis hemoptysis,1,0.7585846185684204
FERRIPROX,acute respiratory distress syndrome,thoracic and mediastinal acute respiratory distress syndrome epistaxis hemoptysis pulmonary embolism,1,0.7425345778465271
FERRIPROX,acute respiratory distress syndrome,glycosuria hemoglobinuria Respiratory thoracic and mediastinal,0,0.5614399313926697
FERRIPROX,epistaxis,disorders acute respiratory distress epistaxis hemoptysis pulmonary embolism Skin,1,0.7000826597213745
FERRIPROX,epistaxis,glycosuria hemoglobinuria Respiratory thoracic and mediastinal,0,0.534305989742279
FERRIPROX,epistaxis,disorders acute respiratory distress epistaxis hemoptysis pulmonary embolism Skin subcutaneous,1,0.6878380179405212
FERRIPROX,epistaxis,embolism Skin,0,0.5608922839164734
FERRIPROX,epistaxis,epistaxis hemoptysis pulmonary embolism Skin subcutaneous,1,0.7681705355644226
FERRIPROX,epistaxis,thoracic and mediastinal disorders acute respiratory distress,0,0.5303297638893127
FERRIPROX,epistaxis,respiratory distress epistaxis hemoptysis pulmonary embolism,1,0.7316712141036987
FERRIPROX,hemoptysis,Respiratory thoracic and mediastinal disorders acute respiratory distress,0,0.631233274936676
FERRIPROX,hemoptysis,hemoptysis pulmonary embolism Skin subcutaneous,1,0.7769731879234314
FERRIPROX,pulmonary embolism,syndrome epistaxis,0,0.5420914888381958
FERRIPROX,pulmonary embolism,pulmonary embolism Skin,1,0.8312922120094299
FERRIPROX,pulmonary embolism,respiratory distress syndrome epistaxis pulmonary embolism,1,0.7860170006752014
FERRIPROX,pulmonary embolism,epistaxis pulmonary,1,0.6819314360618591
FERRIPROX,pulmonary embolism,Skin subcutaneous tissue,0,0.49484944343566895
FERRIPROX,hyperhidrosis,ss syndrome epistaxis hemoptysis pulmonary,0,0.4815727472305298
FERRIPROX,hyperhidrosis,hyperhidrosis periorbital edema photosensitivity reaction pruritis,1,0.7964842915534973
FERRIPROX,hyperhidrosis,photosensitivity reaction pruritis urticaria,0,0.6345762014389038
FERRIPROX,hyperhidrosis,hyperhidrosis periorbital edema photosensitivity reaction,1,0.7833925485610962
FERRIPROX,hyperhidrosis,hyperhidrosis periorbital edema,1,0.817833662033081
FERRIPROX,hyperhidrosis,edema photosensitivity reaction pruritis urticaria rash HenochSchonlein,0,0.6635607481002808
FERRIPROX,hyperhidrosis,subcutaneous tissue hyperhidrosis periorbital edema photosensitivity,1,0.8076686263084412
FERRIPROX,photosensitivity reaction,photosensitivity reaction,1,1.0
FERRIPROX,photosensitivity reaction,disorders,0,0.4830913841724396
FERRIPROX,photosensitivity reaction,hyperhidrosis periorbital,0,0.5386176109313965
FERRIPROX,photosensitivity reaction,hyperhidrosis periorbital photosensitivity,1,0.7546354532241821
FERRIPROX,photosensitivity reaction,disorders hypotension,0,0.4296626150608063
FERRIPROX,pruritis,Vascular disorders hypotension,0,0.45480671525001526
FERRIPROX,pruritis,Skin subcutaneous tissue disorders hyperhidrosis,0,0.6605268716812134
FERRIPROX,pruritis,periorbital edema photosensitivity pruritis urticaria rash HenochSchonlein,1,0.7324080467224121
FERRIPROX,pruritis,edema photosensitivity pruritis urticaria,1,0.7706177234649658
FERRIPROX,pruritis,HenochSchonlein purpura Vascular disorders hypotension hypertension,0,0.5095415711402893
FERRIPROX,urticaria,Vascular disorders hypotension,0,0.49724081158638
FERRIPROX,urticaria,periorbital edema photosensitivity reaction urticaria rash HenochSchonlein,1,0.7191816568374634
FERRIPROX,rash,reaction pruritis rash HenochSchonlein purpura Vascular disorders hypotension,1,0.6943339109420776
FERRIPROX,rash,Vascular disorders hypotension,0,0.48387500643730164
FERRIPROX,rash,reaction pruritis rash HenochSchonlein purpura Vascular,1,0.7108454704284668
FERRIPROX,rash,rash HenochSchonlein purpura Vascular,1,0.6926037073135376
FERRIPROX,rash,pruritis rash HenochSchonlein purpura Vascular,1,0.7059611082077026
FERRIPROX,rash,photosensitivity reaction,0,0.5688498616218567
FERRIPROX,rash,pruritis rash HenochSchonlein,1,0.7426832914352417
FERRIPROX,rash,rash HenochSchonlein,1,0.6992197036743164
FERRIPROX,Henoch-Schonlein purpura,pruritis urticaria Henoch-Schonlein,1,0.813590407371521
FERRIPROX,Henoch-Schonlein purpura,pruritis urticaria Henoch-Schonlein purpura,1,0.8545096516609192
FERRIPROX,Henoch-Schonlein purpura,urticaria Henoch-Schonlein purpura,1,0.9062762260437012
FERRIPROX,Henoch-Schonlein purpura,disorders hypotension,0,0.5179151296615601
FERRIPROX,Henoch-Schonlein purpura,Henoch-Schonlein purpura Vascular,1,0.9168039560317993
FERRIPROX,Henoch-Schonlein purpura,Henoch-Schonlein purpura Vascular disorders hypotension hypertension,1,0.8620720505714417
FERRIPROX,Henoch-Schonlein purpura,Henoch-Schonlein purpura,1,1.000000238418579
FERRIPROX,AGRANULOCYTOSIS,ADVERSE EXCERPT:    *   The most common,1,0.4796466827392578
FERRIPROX,AGRANULOCYTOSIS,Henoch-Schonlein purpura,1,0.5461537837982178
FERRIPROX,AGRANULOCYTOSIS,ADVERSE EXCERPT:    *   The most common adverse reactions,1,0.4971870481967926
FERRIPROX,NEUTROPENIA,T,0,0.4868319630622864
FERRIPROX,NEUTROPENIA,and abdominal,0,0.5308654308319092
FERRIPROX,NEUTROPENIA,EXCERPT he most com mon adverse reactions,1,0.5355231761932373
FERRIPROX,NEUTROPENIA,reactions are incidence,0,0.5366377830505371
FERRIPROX,NEUTROPENIA,he most com mon adverse,1,0.49224036931991577
FERRIPROX,NEUTROPENIA,ADVERSE REACTIONS EXCERPT he most com,1,0.5369077324867249
FERRIPROX,NEUTROPENIA,EXCERPT he most com mon,1,0.4798426926136017
FERRIPROX,AGRANULOCYTOSIS,adverse eactions are (i,1,0.46767014265060425
FERRIPROX,AGRANULOCYTOSIS,reactions are incidence,0,0.5490009784698486
FERRIPROX,AGRANULOCYTOSIS,alanine aminotransferase increased,0,0.5903666019439697
FERRIPROX,NEUTROPENIA,ADVERSE REACTIONS EXCERPT The,0,0.5349623560905457
FERRIPROX,NEUTROPENIA,adverse reactions are cidence,1,0.5322751998901367
FERRIPROX,NEUTROPENIA,are cidence >=  chromaturia,1,0.5161552429199219
FERRIPROX,NEUTROPENIA,cidence >=,1,0.5209343433380127
FERRIPROX,NEUTROPENIA,cidence >= chromaturia nausea vomiting,1,0.5570664405822754
FERRIPROX,agranulocytosis,pain alanine aminotransferase increased arthralgia,0,0.5624213218688965
FERRIPROX,agranulocytosis,nal,0,0.553119421005249
FERRIPROX,agranulocytosis,pain alanine aminotransferase increased,0,0.551411509513855
FERRIPROX,infections,abdominal pain alanine nsferase i ncreased arthralgia and,1,0.5613179206848145
FERRIPROX,infections,pain alanine aminotransferase increased,0,0.5365028381347656
FERRIPROX,Neutropenia,aminotransferase increased thralgia,1,0.4971119165420532
FERRIPROX,Neutropenia,thralgia an,1,0.46682244539260864
FERRIPROX,Neutropenia,nausea vomiting and abdominal,0,0.5495902895927429
FERRIPROX,Neutropenia,alanine aminotransferase increased,0,0.5248154997825623
FERRIPROX,Neutropenia,increased thralgia an,1,0.4865358769893646
FERRIPROX,Neutropenia,thralgia an d neutropenia To report SUSPECTED,1,0.806986927986145
FERRIPROX,Neutropenia,and,0,0.4978025257587433
FERRIPROX,agranulocytosis,ADVERSE REACTIONS contact,0,0.5043749213218689
FERRIPROX,agranulocytosis,To re,1,0.4472454786300659
FERRIPROX,AGRANULOCYTOSIS,varying conditions e reaction rate s observed in the clinical,1,0.5371958613395691
FERRIPROX,AGRANULOCYTOSIS,To re,1,0.4472454786300659
FERRIPROX,AGRANULOCYTOSIS,Because clinical,0,0.5029710531234741
FERRIPROX,AGRANULOCYTOSIS,under widely varying conditions e reaction rate,1,0.4938393533229828
FERRIPROX,AGRANULOCYTOSIS,e reaction rate s observed in,1,0.49901166558265686
FERRIPROX,AGRANULOCYTOSIS,under widely varying conditions e reaction rate s observed in the,1,0.49625423550605774
FERRIPROX,NEUTROPENIA,the clinical trials of another d,0,0.554719090461731
FERRIPROX,NEUTROPENIA,erved in th,1,0.49961477518081665
FERRIPROX,NEUTROPENIA,erved,1,0.4719427824020386
FERRIPROX,NEUTROPENIA,adverse reaction rates erved in th e clinical trials of a,1,0.5216970443725586
FERRIPROX,NEUTROPENIA,adverse,0,0.49466508626937866
FERRIPROX,NEUTROPENIA,rates erved in,1,0.428250789642334
FERRIPROX,agranulocytosis,rug and may not reflect the rates observed,1,0.4252290725708008
FERRIPROX,agranulocytosis,rates erved in,1,0.4271138608455658
FERRIPROX,agranulocytosis,may not,1,0.40780407190322876
FERRIPROX,agranulocytosis,of another rug and may not reflect the rates observed,1,0.42109712958335876
FERRIPROX,agranulocytosis,and may not reflect the rates observed in,1,0.42881470918655396
FERRIPROX,agranulocytosis,rug and may not,1,0.4112864136695862
FERRIPROX,agranulocytosis,Ferriprox represents,0,0.5186240673065186
FERRIPROX,agranulocytosis,another rug and may not reflect the rates observed in,1,0.4317026734352112
FERRIPROX,agranulocytosis,the clinical trials of,0,0.4986341595649719
FERRIPROX,infections,d in pract ice Adverse reaction,1,0.5388584733009338
FERRIPROX,infections,not reflect the rates d in pract ice Adverse reaction information for,1,0.5356183648109436
FERRIPROX,infections,and may not reflect the rates,0,0.42671677470207214
FERRIPROX,infections,drug and may not reflect the rates observe,0,0.5089544653892517
FERRIPROX,infections,d in,1,0.5529597997665405
FERRIPROX,infections,Ferriprox represents the pooled data,0,0.5468761920928955
FERRIPROX,infections,rates d in,1,0.5430848598480225
FERRIPROX,infections,reaction information,0,0.5106532573699951
FERRIPROX,death,rates in the clinical trials of another drug and may not reflect the rates,0,0.4765092134475708
FERRIPROX,Neutropenia,Ferriprox represents the pooled data collected from patients,0,0.5589002370834351
FERRIPROX,Neutropenia,rates observed in practice erse reacti on information for,1,0.4989156126976013
FERRIPROX,Neutropenia,practice erse,1,0.5112195014953613
FERRIPROX,Neutropenia,data collected from patients,0,0.4921284019947052
FERRIPROX,Neutropenia,observed in practice erse reacti,1,0.476468950510025
FERRIPROX,Neutropenia,erse reacti,1,0.4982962906360626
FERRIPROX,Neutropenia,observed in practice erse,1,0.48583561182022095
FERRIPROX,agranulocytosis,for Ferriprox resents the poo led,1,0.4871593117713928
FERRIPROX,agranulocytosis,observed in practice erse,1,0.4607733488082886
FERRIPROX,agranulocytosis,information for Ferriprox resents the poo,1,0.49911224842071533
FERRIPROX,agranulocytosis,or activecontrolled clinical,0,0.5040098428726196
FERRIPROX,fetal harm,ADVERSE REACTIONS contact A,0,0.5691216588020325
FERRIPROX,Fatal,REACTIONS contact ApoPharma Inc at Telephone Email,0,0.4951799213886261
FERRIPROX,Fatal,medic alsafetyapopharmacom or FDA,1,0.537370502948761
FERRIPROX,Fatal,medic alsafetyapopharmacom or FDA at,1,0.5305768251419067
FERRIPROX,Fatal,medic alsafetyapopharmacom or FDA at FDA,1,0.5264878273010254
FERRIPROX,Fatal,at Telephone medic alsafetyapopharmacom or,1,0.5289363861083984
FERRIPROX,agranulocytosis,lsafety@apophar macom or FDA,1,0.5475627183914185
FERRIPROX,agranulocytosis,lsafety@apophar macom,1,0.5601659417152405
FERRIPROX,agranulocytosis,ApoPharma,0,0.5464274883270264
FERRIPROX,agranulocytosis,lsafety@apophar,1,0.5769203901290894
FERRIPROX,agranulocytosis,Email medica,0,0.47136634588241577
FERRIPROX,agranulocytosis,Inc at,0,0.4613439440727234
FERRIPROX,agranulocytosis,CTED,0,0.4697740972042084
FERRIPROX,agranulocytosis,lsafety@apophar macom or FDA at FDA,1,0.5348979830741882
FERRIPROX,neutropenia,/medwatch   Clinical Trial,1,0.4931357800960541
FERRIPROX,neutropenia,wwwfdagov,0,0.4283190965652466
FERRIPROX,neutropenia,adverse reactions are also discussed in o,0,0.517239511013031
FERRIPROX,neutropenia,Experience The following adverse reactions are,0,0.5110584497451782
FERRIPROX,neutropenia,or /medwatch   Clinical Trial Experience,1,0.482485294342041
FERRIPROX,neutropenia,FDA at FDA or,0,0.4563385248184204
FERRIPROX,agranulocytosis,adverse,0,0.4876333475112915
FERRIPROX,agranulocytosis,at FDA or wwwfdagovmedwatch l Trial,1,0.45180854201316833
FERRIPROX,agranulocytosis,FDA or wwwfdagovmedwatch Clinica,0,0.45740437507629395
FERRIPROX,agranulocytosis,Trial Experie,1,0.4328950345516205
FERRIPROX,agranulocytosis,or FDA at,0,0.45930176973342896
FERRIPROX,agranulocytosis,reactions are,0,0.5053260326385498
FERRIPROX,agranulocytosis,l,1,0.5119093656539917
FERRIPROX,agranulocytosis,l Trial Experie nce The following adverse reactions,1,0.4951014518737793
FERRIPROX,agranulocytosis,the rates observed,0,0.43736720085144043
FERRIPROX,agranulocytosis,pooled data collected from,0,0.4786328077316284
FERRIPROX,agranulocytosis,pooled data col lected,1,0.4827558398246765
FERRIPROX,agranulocytosis,from patients who participated in single arm or activecontrolled,0,0.4737972319126129
FERRIPROX,agranulocytosis,information for Ferriprox represents pooled data,1,0.5102637410163879
FERRIPROX,agranulocytosis,clinical,0,0.5469424724578857
FERRIPROX,agranulocytosis,who participated in single arm or,0,0.4478945732116699
FERRIPROX,agranulocytosis,information for Ferriprox represents pooled data col,1,0.5187080502510071
FERRIPROX,agranulocytosis,in,0,0.4994876980781555
FERRIPROX,Agranulocytosis,data collected from,0,0.48018285632133484
FERRIPROX,neutropenia,represents the pooled data collected from patients who,0,0.5101096630096436
FERRIPROX,agranulocytosis,studies The,0,0.4852137565612793
FERRIPROX,agranulocytosis,clinical trials with Ferriprox was agranulocytosis see,0,0.7751208543777466
FERRIPROX,agranulocytosis,or activecontrolled clinical studies The most serious adverse rea,0,0.492605060338974
FERRIPROX,agranulocytosis,rea,0,0.42918020486831665
FERRIPROX,agranulocytosis,serious adverse ction,1,0.5036903023719788
FERRIPROX,agranulocytosis,serious adverse ction reported  in clinical trials with,1,0.504320502281189
FERRIPROX,agranulocytosis,see,0,0.4980379343032837
FERRIPROX,agranulocytosis,participated in single arm or activecontrolled clinical studies The most serious adverse,0,0.5038547515869141
FERRIPROX,agranulocytosis,ction reported in,1,0.5176360011100769
FERRIPROX,agranulocytosis,ction reported in clinical trials with,1,0.5212458372116089
FERRIPROX,death,trial s,1,0.540643572807312
FERRIPROX,death,trial,1,0.5536686182022095
FERRIPROX,death,trial s with Ferriprox,1,0.5026333332061768
FERRIPROX,death,trial s with Ferriprox was,1,0.5018144845962524
FERRIPROX,embryofetal death,                  INVESTIGATIONS Alanine Amino,1,0.5196706056594849
FERRIPROX,embryofetal death,Diarrhea Dyspepsia,0,0.4877764582633972
FERRIPROX,embryofetal death,INVESTIGATIONS Alanine Amino,0,0.5196706056594849
FERRIPROX,embryofetal death,INVESTIGATIONS Alanine,0,0.5299568772315979
FERRIPROX,embryofetal death,Diarrhea,0,0.546898603439331
FERRIPROX,embryofetal death,                  INVESTIGATIONS,1,0.5009170770645142
FERRIPROX,increased serum ALT,NECTIVE TISSUE DISO,1,0.530329167842865
FERRIPROX,increased serum ALT,AND,0,0.5038557052612305
FERRIPROX,increased serum ALT,AND CON,0,0.5236520767211914
FERRIPROX,increased serum ALT,MUSCULOSKELETAL AND CON,0,0.5415931344032288
FERRIPROX,increased serum ALT,appetite MUSCULOSKELETAL AND NECTIVE TISSUE DISO RDERS,1,0.5459327101707458
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy          NERVOUS SYSTEM DISORDERS,1,0.548311710357666
FERRIPROX,Decreased plasma zinc concentrations,NERVOUS SYSTEM,0,0.5430514216423035
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy          NERVOUS SYSTEM DISORDERS Hea,1,0.5413525104522705
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy          NERVOUS,1,0.569070041179657
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy         ,1,0.5468782186508179
FERRIPROX,Decreased plasma zinc concentrations,in,0,0.5167790651321411
FERRIPROX,Decreased plasma zinc concentrations,Pain in                 Arthropathy          NERVOUS SYSTEM DISORDERS Hea,1,0.511771023273468
PRADAXA,bleeding,reactions reported,0,0.5417027473449707
PRADAXA,bleeding,bleeding see Warnings and,1,0.833770751953125
PRADAXA,bleeding,PRADAXA were related bleeding see Warnings,1,0.7641592621803284
PRADAXA,bleeding,common adverse reactions a,0,0.5566660165786743
PRADAXA,bleeding,and Precautions EXCERPT Most,0,0.5696192979812622
PRADAXA,bleeding,bleeding see,1,0.8743306398391724
PRADAXA,bleeding,bleeding see Warnings and Precautions,1,0.842707097530365
PRADAXA,bleeding,ADVERSE REACTIONS The most serious adverse reactions reported with PRADAXA were related,0,0.5440253019332886
PRADAXA,bleeding,The most serious adverse reactions reported with PRADAXA were,0,0.5434337854385376
PRADAXA,bleeding,EXCERPT Most,0,0.5079054832458496
PRADAXA,gastritis,and,0,0.47076740860939026
PRADAXA,gastritis,reactions gastritis like symptoms,1,0.8371373414993286
PRADAXA,gastritis,gastritis like symptoms and,1,0.8583897948265076
PRADAXA,gastritis,gastritis,1,1.000000238418579
PRADAXA,gastritis,adverse reactions gastritis like symptoms and bleeding To,1,0.8037598729133606
PRADAXA,gastritis,Warnings and Precautions EXCERPT Most,0,0.4753609299659729
PRADAXA,gastritis,ADVERSE REACTIONS contact Boehring,0,0.560177206993103
PRADAXA,gastritis,reactions gastritis like symptoms and,1,0.8385640382766724
PRADAXA,bleeding,To,0,0.5197806358337402
PRADAXA,bleeding,contact,0,0.4894242584705353
PRADAXA,bleeding,bleeding To report SUSPECTED ADVERSE,1,0.8211443424224854
PRADAXA,bleeding,are gastritislike symptoms bleeding To report SUSPECTED,1,0.7085121870040894
PRADAXA,bleeding,bleeding,1,1.0
PRADAXA,bleeding,symptoms bleeding To report SUSPECTED ADVERSE REACTIONS,1,0.7759833335876465
PRADAXA,bleeding,bleeding To,1,0.9191856384277344
PRADAXA,bleeding,SUSPECTED ADVERSE REACTIONS contact Boehringer Ingelheim Pharmaceutical,0,0.5671539306640625
PRADAXA,bleeding,To report SUSPECTED ADVERSE REACTIONS contact Boehringer,0,0.5517482757568359
PRADAXA,bleeding,bleeding and gastrointestinal events,1,0.7644675970077515
PRADAXA,bleeding,bleeding and gastrointestinal,1,0.8154147267341614
PRADAXA,bleeding,gastrointestinal events ie dyspepsia nausea upper abdominal pain gastrointestinal,0,0.5433993339538574
PRADAXA,bleeding,to discontinuation of PRADAXA bleeding and gastrointestinal events,1,0.6870973110198975
PRADAXA,bleeding,for warfarin The most frequent adverse,0,0.6158207654953003
PRADAXA,bleeding,nausea upper abdominal pain,0,0.598487138748169
PRADAXA,bleeding,nausea upper abdominal pain gastrointestinal hemorr,0,0.6752885580062866
PRADAXA,gastrointestinal events,gastrointestinal events ie dyspepsia nausea upper,1,0.9179572463035583
PRADAXA,gastrointestinal events,nausea upper abdominal pain gastrointestinal hemorr,0,0.7235095500946045
PRADAXA,gastrointestinal events,gastrointestinal,0,0.8638891577720642
PRADAXA,gastrointestinal events,to discontinuation of PRADAXA were bleeding and,0,0.5150137543678284
PRADAXA,gastrointestinal events,of PRADAXA were bleeding gastrointestinal events ie,1,0.7411242723464966
PRADAXA,gastrointestinal events,of PRADAXA were bleeding gastrointestinal events,1,0.726448655128479
PRADAXA,gastrointestinal events,were bleeding and,0,0.5407153964042664
PRADAXA,dyspepsia,bleeding and gastrointestinal events dyspepsia nausea,1,0.7857058048248291
PRADAXA,dyspepsia,were bleeding and,0,0.5242189168930054
PRADAXA,dyspepsia,upper abdominal pain,0,0.6354795694351196
PRADAXA,dyspepsia,dyspepsia nausea upper abdominal pain gastrointestinal,1,0.8653579950332642
PRADAXA,dyspepsia,dyspepsia nausea upper,1,0.8722617030143738
PRADAXA,dyspepsia,leading to discontinuation of,0,0.4964866042137146
PRADAXA,dyspepsia,dyspepsia nausea upper abdominal,1,0.8520100116729736
PRADAXA,dyspepsia,abdominal pain gastrointestinal,0,0.6941778659820557
PRADAXA,dyspepsia,and diarrhea Bleeding,0,0.6155307292938232
PRADAXA,dyspepsia,dyspepsia,1,1.0000001192092896
PRADAXA,nausea,events ie nausea upper abdominal pain,1,0.7696666717529297
PRADAXA,nausea,dyspepsia,1,0.67365962266922
PRADAXA,nausea,ie nausea,1,0.9048534631729126
PRADAXA,nausea,and diarrhea Bleeding,0,0.6041058897972107
PRADAXA,nausea,nausea upper,1,0.8930381536483765
PRADAXA,nausea,nausea upper abdominal pain gastrointestinal,1,0.7845317125320435
PRADAXA,nausea,discontinuation of PRADAXA were bleeding and,0,0.5515071749687195
PRADAXA,nausea,leading to discontinuation of PRADAXA were,0,0.5218759775161743
PRADAXA,nausea,of PRADAXA were bleeding and gastrointestinal events ie,0,0.6424246430397034
PRADAXA,upper abdominal pain,gastrointestinal events ie dyspepsia upper,1,0.7574350833892822
PRADAXA,upper abdominal pain,gastrointestinal events ie,0,0.6476030349731445
PRADAXA,gastrointestinal hemorrhage,ie dyspepsia nausea upper abdominal,0,0.689536452293396
PRADAXA,gastrointestinal hemorrhage,Warnings and Precautions T,0,0.5544806122779846
PRADAXA,gastrointestinal hemorrhage,Bleeding see Warnings and Precautions T,0,0.6665632724761963
PRADAXA,diarrhea,dyspepsia nausea upper abdominal pain gastrointestinal hemorrhage,0,0.6441627740859985
PRADAXA,bleeding,events during the,0,0.4969795346260071
PRADAXA,bleeding,bleeding events during the treatment period,1,0.8125516176223755
PRADAXA,bleeding,see Warnings and Precautions Table shows the number of adjudicated major,0,0.5533562898635864
PRADAXA,bleeding,events during the treatment period in the RELY study with the,0,0.5287309885025024
PRADAXA,bleeding,bleeding events during,1,0.8991684913635254
PRADAXA,bleeding,the,0,0.549575924873352
PRADAXA,bleeding,bleeding rate per subjectyears Major bleeding,1,0.7923495769500732
PRADAXA,bleeding,bleeding rate per subjectyears Major,1,0.7726489305496216
PRADAXA,bleeding,the RELY study with bleeding,1,0.8038539290428162
PRADAXA,bleeding,bleeding rate,1,0.8771886825561523
PRADAXA,bleeding,per,0,0.530096173286438
PRADAXA,bleeding,in,0,0.5393304824829102
PRADAXA,bleeding,the RELY study with,0,0.5057615041732788
PRADAXA,bleeding,gdL a transfusion of,0,0.5993242263793945
PRADAXA,bleeding,gdL a transfusion,0,0.6053946018218994
PRADAXA,bleeding,bleeding accompanied,1,0.9481565356254578
PRADAXA,bleeding,the bleeding rate per subjectyears,0,0.7783650159835815
PRADAXA,bleeding at a critical site,packed,0,0.5116472244262695
PRADAXA,bleeding at a critical site,blood bleeding at,1,0.8506218791007996
PRADAXA,bleeding at a critical site,bleeding at a critical site or with a fatal outcome,1,0.9158122539520264
PRADAXA,bleeding at a critical site,a transfusion of,0,0.6043481230735779
PRADAXA,bleeding at a critical site,a critical site or with a fatal outcome,1,0.8202429413795471
PRADAXA,bleeding at a critical site,of packed red blood bleeding at a critical site,1,0.9134116768836975
PRADAXA,bleeding at a critical site,cells,0,0.5327163934707642
PRADAXA,fatal,bleeding at a,0,0.5811257362365723
PRADAXA,Intracranial hemorrhage,Intracranial hemorrhage included intracerebral,1,0.8983226418495178
PRADAXA,Intracranial hemorrhage,fatal Intracranial hemorrhage included intracerebral hemorrhagic,1,0.8631800413131714
PRADAXA,Intracranial hemorrhage,or,0,0.500402569770813
PRADAXA,hemorrhagic stroke,critical site or with a fatal outcome,0,0.5946334600448608
PRADAXA,subdural bleeds,subdural bleeds Table Adjudicated Major Bleeding,1,0.8604353666305542
PRADAXA,subdural bleeds,subdural bleeds Table,1,0.9096742868423462
PRADAXA,subdural bleeds,subarachnoid subdural,1,0.7798383235931396
PRADAXA,subdural bleeds,aPatients during treatment o,0,0.5316301584243774
PRADAXA,subdural bleeds,Table Adjudicated Major,0,0.5058466792106628
PRADAXA,subdural bleeds,subdural bleeds Table Adjudicated Major,1,0.8580389618873596
PRADAXA,subdural bleeds,tal outcome Intracranial hemorrhage included intracerebral hemorrhagic stroke,0,0.6556721329689026
PRADAXA,subdural bleeds,Events in Treated Patientsa aPatients during,0,0.571736216545105
PRADAXA,subdural bleeds,in Treated,0,0.5391080379486084
PRADAXA,subdural bleeds,hemorrhagic stroke subarachnoid subdural bleeds,1,0.8895401954650879
PRADAXA,Bleeding,Bleeding,1,1.0
PRADAXA,Bleeding,bleeds Table Adjudicated Bleeding Events,1,0.7869501709938049
PRADAXA,Bleeding,bleeds Table Adjudicated Bleeding Events in Treated,1,0.7909834384918213
PRADAXA,Bleeding,subdural bleeds Table Adjudicated Bleeding Events in,1,0.7113990187644958
PRADAXA,Bleeding,Bleeding Events in Treated Patientsa,1,0.8279394507408142
PRADAXA,Bleeding,bleeds Table Adjudicated,0,0.7493634223937988
PRADAXA,Bleeding,Bleeding Events in Treated,1,0.8490617871284485
PRADAXA,Bleeding,bleeds Table Adjudicated Bleeding Events in,1,0.7973934412002563
PRADAXA,Bleeding,stroke subarachnoid,0,0.5603505373001099
PRADAXA,Bleeding,ntracerebral hemorrhagic stroke subarachnoid,0,0.6140369176864624
PRADAXA,decrease in hemoglobin,was considered cDefined as bleeding accompanied by one or more of the,0,0.5601335763931274
PRADAXA,decrease in hemoglobin,in hemoglobin of gdL a transfusion of,1,0.7225990295410156
PRADAXA,decrease in hemoglobin,was considered cDefined as bleeding accompanied,0,0.5753705501556396
PRADAXA,decrease in hemoglobin,the following decrease in hemoglobin,1,0.9855523109436035
PRADAXA,decrease in hemoglobin,or more units of,0,0.473858118057251
PRADAXA,decrease in hemoglobin,following decrease in,1,0.7455669641494751
PRADAXA,decrease in hemoglobin,of the following decrease in hemoglobin of gdL,1,0.9082977771759033
PRADAXA,decrease in hemoglobin,of the following decrease,1,0.734907329082489
PRADAXA,decrease in hemoglobin,bleeding accompanied,0,0.5890483856201172
PRADAXA,bleeding at a critical site,packed red blood bleeding,1,0.7626452445983887
PRADAXA,bleeding at a critical site,blood bleeding at a critical,1,0.9007814526557922
PRADAXA,bleeding at a critical site,bleeding,1,0.8397039175033569
PRADAXA,bleeding at a critical site,bleeding at a critical,1,0.9143919348716736
PRADAXA,bleeding at a critical site,a critical site or with fatal outcome,1,0.8260577917098999
PRADAXA,fatal,or fatal outcome dIntracranial bleed included,1,0.7133746147155762
PRADAXA,fatal,a critical site or with fatal outcome,1,0.7216416597366333
PRADAXA,fatal,fatal outcome dIntracranial,1,0.7590030431747437
PRADAXA,fatal,dL a transfusion of or more units of packed red blood cells,0,0.5253820419311523
PRADAXA,fatal,or more units of packed red blood,0,0.5008094906806946
PRADAXA,fatal,a critical site or fatal outcome,1,0.7262395620346069
PRADAXA,fatal,a critical,0,0.5656789541244507
PRADAXA,fatal,critical site or fatal outcome dIntracranial bleed included intracerebral,1,0.6586635708808899
PRADAXA,Intracranial bleed,outcome Intracranial bleed included intracerebral,1,0.87407386302948
PRADAXA,Intracranial bleed,fatal outcome dIntracranial,1,0.7092713713645935
PRADAXA,Intracranial bleed,with fatal outcome Intracranial,1,0.8020616769790649
PRADAXA,Intracranial bleed,fatal outcome Intracranial,1,0.7940027117729187
PRADAXA,Intracranial bleed,Intracranial bleed included intracerebral hemorrhagic stroke subarachnoid,1,0.8861929178237915
PRADAXA,Intracranial bleed,Intracranial bleed included intracerebral,1,0.9095407724380493
PRADAXA,Intracranial bleed,outcome Intracranial bleed included,1,0.8824363350868225
PRADAXA,hemorrhagic stroke,on the,0,0.4898751974105835
PRADAXA,hemorrhagic stroke,intracerebral,0,0.6539873480796814
PRADAXA,hemorrhagic stroke,bleed included hemorrhagic,1,0.8173330426216125
PRADAXA,hemorrhagic stroke,analysis based on the,0,0.4830681085586548
PRADAXA,hemorrhagic stroke,on the safety population,0,0.4645862579345703
PRADAXA,hemorrhagic stroke,hemorrhagic,1,0.8603018522262573
PRADAXA,hemorrhagic stroke,dIntracranial bleed included hemorrhagic stroke,1,0.9034751057624817
PRADAXA,subdural bleeds,stroke subarachnoid subdural bleeds eOntreatment analysis based on the,1,0.8318724632263184
PRADAXA,subdural bleeds,dIntracranial bleed included hemorrhagic stroke,1,0.7809843420982361
PRADAXA,subdural bleeds,subdural bleeds eOntreatment analysis based,1,0.8892202377319336
PRADAXA,subdural bleeds,subdural bleeds eOntreatment analysis,1,0.9013839364051819
PRADAXA,subdural bleeds,safety population,0,0.4751036763191223
PRADAXA,subdural bleeds,subdural,1,0.874552309513092
PRADAXA,Fatal,Studies Fatal bleed Adjudicated,1,0.679157018661499
PRADAXA,Fatal,subdural bleeds eOntreatment analysis,1,0.5246024131774902
PRADAXA,Fatal,as defined above with investigator,0,0.4933043122291565
PRADAXA,Fatal,Fatal,1,1.0000001192092896
PRADAXA,Fatal,in Section Clinical Studies Fatal,1,0.7357302904129028
PRADAXA,Fatal,Fatal bleed,1,0.8035207986831665
PRADAXA,Fatal,Fatal bleed Adjudicated major bleed,1,0.680698573589325
PRADAXA,Fatal,in Section Clinical Studies Fatal bleed Adjudicated major bleed as,1,0.673838198184967
PRADAXA,bleed,bleed Adjudicated major bleed,1,0.755735456943512
PRADAXA,bleed,Fatal bleed Adjudicated major bleed,1,0.7205402851104736
PRADAXA,bleed,in Section Clinical Studies bleed Adjudicated major bleed,1,0.7264305353164673
PRADAXA,bleed,bleed,1,1.0
PRADAXA,bleed,as defined above with investigator reported,0,0.5155722498893738
PRADAXA,bleed,ITT analysis presented in Section Clinical Studies fFatal bleed Adjudicated major,0,0.7029559016227722
PRADAXA,bleed,fFatal bleed,0,0.7910974621772766
PRADAXA,bleed,bleed as defined above with investigator,1,0.8090223073959351
PRADAXA,bleed,bleed as defined above with,1,0.885844349861145
PRADAXA,bleed,fFatal bleed Adjudicated bleed as defined above,1,0.7032126784324646
PRADAXA,bleed,bleed as defined,1,0.8966376185417175
PRADAXA,bleed,fatal outcome and,0,0.6052849292755127
PRADAXA,bleed,bleed as,1,0.9069676399230957
PRADAXA,death,fatal outcome and death with primary cause from,1,0.735387921333313
PRADAXA,death,bleed as,1,0.5936798453330994
PRADAXA,death,death with primary cause from bleeding,1,0.7337429523468018
PRADAXA,death,death with,1,0.8613942861557007
PRADAXA,death,reported fatal outcome and death with primary cause from bleeding,1,0.6965008974075317
PRADAXA,bleeding,bleeding gNonintracranial fatal bleed,1,0.7641907930374146
PRADAXA,bleeding,as,0,0.5616402626037598
PRADAXA,bleeding,and,0,0.5245391130447388
PRADAXA,bleeding,bleeding gNonintracranial fatal bleed Adjudicated major,1,0.7382436990737915
PRADAXA,bleeding,with investigator reported fatal outcome and adjudicated death with primary cause from,0,0.5452995300292969
PRADAXA,fatal,fatal bleed Adjudicated,1,0.7027155160903931
PRADAXA,fatal,primary cause from bleeding gNonintracranial,0,0.5645536184310913
PRADAXA,fatal,above and adjudicated death,0,0.6292882561683655
PRADAXA,fatal,primary cause from bleeding fatal bleed Adjudicated major bleed,1,0.6649158000946045
PRADAXA,fatal,fatal bleed Adjudicated major,1,0.7067720890045166
PRADAXA,fatal,from bleeding fatal bleed Adjudicated major,1,0.714475154876709
PRADAXA,fatal,fatal bleed Adjudicated major bleed as,1,0.6920945644378662
PRADAXA,fatal,bleeding fatal bleed Adjudicated major bleed as,1,0.6821935176849365
PRADAXA,bleed,from bleeding gNonintracranial fatal,0,0.7304280996322632
PRADAXA,death,above and death with primary cause from bleeding,1,0.7149957418441772
PRADAXA,death,from bleeding gNonintracranial fatal,0,0.6643304228782654
PRADAXA,death,without symptomatic,0,0.5233554840087891
PRADAXA,death,death with primary cause from,1,0.7725918292999268
PRADAXA,death,gNonintracranial fatal bleed Adjudicated major,0,0.62041836977005
PRADAXA,death,fatal bleed Adjudicated major,0,0.6410584449768066
PRADAXA,death,major bleed as defined above,0,0.5358514189720154
PRADAXA,bleeding,cause bleeding,1,0.9023579359054565
PRADAXA,bleeding,death with,1,0.5824173092842102
PRADAXA,bleeding,bleed,0,0.9319367408752441
PRADAXA,bleeding,bleeding but without symptomatic intracranial,1,0.7780300378799438
PRADAXA,bleeding,bleeding but without symptomatic intracranial bleed,1,0.7790417075157166
PRADAXA,bleeding,bleeding but,1,0.9324839115142822
PRADAXA,bleeding,death with primary cause bleeding but,1,0.7727099657058716
PRADAXA,bleeding,bleeding but without symptomatic,1,0.8111087083816528
PRADAXA,symptomatic intracranial bleed,symptomatic intracranial bleed,1,0.9999998807907104
PRADAXA,ICH,ICH,1,0.9999999403953552
PRADAXA,Hemorrhagic Stroke,CH Hemorrhagic Stroke e,1,0.9372507929801941
PRADAXA,Hemorrhagic Stroke,ICH,1,0.48619502782821655
PRADAXA,Hemorrhagic Stroke,Hemorrhagic Stroke e Oth,1,0.9654485583305359
PRADAXA,Hemorrhagic Stroke,CH Hemorrhagic,1,0.8275471925735474
PRADAXA,gastrointestinal bleeds,a higher rate of gastrointestinal,1,0.7896485328674316
PRADAXA,gastrointestinal bleeds,of gastrointestinal,1,0.8185228109359741
PRADAXA,gastrointestinal bleeds,than,0,0.46291953325271606
PRADAXA,gastrointestinal bleeds,patients receiving,0,0.5684975385665894
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in,1,0.9822511672973633
PRADAXA,gastrointestinal bleeds,any,0,0.4616566300392151
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients,1,0.9492273330688477
PRADAXA,bleeds,major subgroups defined by,0,0.5146545767784119
PRADAXA,bleeds,bleeds was similar with PRADAXA,1,0.7893113493919373
PRADAXA,bleeds,receiving warfarin vs respectively The risk,0,0.577796995639801
PRADAXA,bleeds,risk of bleeds was similar with,1,0.7801212072372437
PRADAXA,bleeding,bleeding on PRADAXA hazard ratio,1,0.7585236430168152
PRADAXA,bleeding,bleeding on PRADAXA hazard ratio CI,1,0.7432765960693359
PRADAXA,bleeding,to for,0,0.5104688405990601
PRADAXA,bleeding,ratio CI to for patients years of age Figure Ad,0,0.5122892260551453
PRADAXA,bleeding,bleeding on PRADAXA hazard,1,0.7754539847373962
PRADAXA,bleeding,higher incidence,0,0.620646595954895
PRADAXA,bleeding,bleeding on PRADAXA,1,0.8031976222991943
PRADAXA,Bleeding,Major,0,0.5121725797653198
PRADAXA,Bleeding,age Figure Adjudicated Bleeding by Baseline Characteristics Including Hemorrhagic,1,0.7853944301605225
PRADAXA,Bleeding,Adjudicated Bleeding,1,0.8379985690116882
PRADAXA,gastrointestinal adverse reactions,incidence gastrointestinal,1,0.831095278263092
PRADAXA,gastrointestinal adverse reactions,on,0,0.5120408535003662
PRADAXA,gastrointestinal adverse reactions,gastrointestinal adverse reactions vs on warfarin These were,1,0.8582825660705566
PRADAXA,gastrointestinal adverse reactions,increased incidence gastrointestinal adverse reactions vs on warfarin These were,1,0.8473811149597168
PRADAXA,gastrointestinal adverse reactions,incidence gastrointestinal adverse,1,0.8966152667999268
PRADAXA,gastrointestinal adverse reactions,adverse reactions,1,0.8465213775634766
PRADAXA,dyspepsia,dyspepsia including abdominal pain upper,1,0.8729015588760376
PRADAXA,dyspepsia,on warfarin These were dyspepsia including abdominal pain upper abdominal,1,0.761693000793457
PRADAXA,abdominal pain upper,abdominal pain upper abdominal pain,1,0.9677271246910095
PRADAXA,abdominal pain upper,abdominal pain upper,1,1.0000001192092896
PRADAXA,abdominal pain upper,abdominal pain upper abdominal pain abdominal discomfort and,1,0.9387959241867065
PRADAXA,abdominal pain upper,discomfort and gastritislike symptoms incl,0,0.6992490291595459
PRADAXA,abdominal pain upper,abdominal,1,0.7627829909324646
PRADAXA,abdominal pain,commonly dyspepsia including abdominal,0,0.7406970858573914
PRADAXA,abdominal pain,abdominal pain abdominal pain,1,0.980596661567688
PRADAXA,abdominal pain,abdominal pain abdominal discomfort and,1,0.9314187169075012
PRADAXA,abdominal pain,and gastritislike,0,0.691557765007019
PRADAXA,abdominal pain,dyspepsia including abdominal pain abdominal pain,1,0.8107613921165466
PRADAXA,abdominal pain,pain upper,0,0.6695013046264648
PRADAXA,abdominal pain,abdominal pain abdominal,1,0.9777070879936218
PRADAXA,abdominal discomfort,abdominal discomfort and epigastric,1,0.8858771324157715
PRADAXA,abdominal discomfort,abdominal discomfort and epigastric discomfort and,1,0.8882952928543091
PRADAXA,abdominal discomfort,abdominal discomfort and,1,0.9710015058517456
PRADAXA,abdominal discomfort,upper abdominal abdominal,1,0.7300848364830017
PRADAXA,abdominal discomfort,s on warfarin,0,0.4464312195777893
PRADAXA,gastritis,discomfort and,0,0.5441992282867432
PRADAXA,gastritis,symptoms including GERD esophagitis erosive gastritis gastric hemorrhage hemorrhagic gast,0,0.7761023640632629
PRADAXA,gastritis,gastritis like symptoms including,1,0.8499596118927002
PRADAXA,gastritis,discomfort and epigastric discomfort gastritis like symptoms,1,0.8034728765487671
PRADAXA,gastritis,and epigastric discomfort gastritis like symptoms including GERD esophagitis,1,0.7930001020431519
PRADAXA,gastritis,discomfort gastritis like symptoms including,1,0.834318995475769
PRADAXA,gastritis,and epigastric discomfort,0,0.6444048881530762
PRADAXA,GERD,gastritis,0,0.7147395014762878
PRADAXA,GERD,gastritislike symptoms including,0,0.6796222925186157
PRADAXA,GERD,GERD esophagitis,1,0.914290189743042
PRADAXA,GERD,GERD esophagitis erosive gastritis gastric hemorrhage,1,0.7937924861907959
PRADAXA,esophagitis,gastritis,0,0.7151142358779907
PRADAXA,esophagitis,hemorrhagic erosive gastritis and,0,0.6315823793411255
PRADAXA,esophagitis,esophagitis erosive gastritis gastric,1,0.82720947265625
PRADAXA,esophagitis,abdominal discomfort and epigastric,0,0.6318185925483704
PRADAXA,esophagitis,erosive gastritis gastric hemorrhage hemorrhagic,0,0.6329677700996399
PRADAXA,esophagitis,gastritislike symptoms including esophagitis erosive gastritis gastric hemorrhage,1,0.73209547996521
PRADAXA,erosive gastritis,erosive gastritis gastric hemorrhage,1,0.9159736037254333
PRADAXA,erosive gastritis,gastric hemorrhage,0,0.7397948503494263
PRADAXA,erosive gastritis,including GERD esophagitis,0,0.6819034814834595
PRADAXA,erosive gastritis,erosive gastritis,1,0.9999998807907104
PRADAXA,erosive gastritis,hemorrhagic gastritis hemorrhagic,0,0.8325080275535583
PRADAXA,erosive gastritis,erosive gastritis gastric,1,0.9743047952651978
PRADAXA,erosive gastritis,symptoms including GERD erosive gastritis gastric hemorrhage hemorrhagic gastritis,1,0.8276246786117554
PRADAXA,erosive gastritis,and epigastric,0,0.6157666444778442
PRADAXA,erosive gastritis,symptoms including GERD erosive gastritis gastric,1,0.8717856407165527
PRADAXA,erosive gastritis,and,0,0.42077159881591797
PRADAXA,gastric hemorrhage,hemorrhagic,0,0.7536522746086121
PRADAXA,gastric hemorrhage,esophagitis erosive gastric,1,0.7523746490478516
PRADAXA,gastric hemorrhage,gastric hemorrhage hemorrhagic gastritis hemorrhagic,1,0.9087095260620117
PRADAXA,gastric hemorrhage,gastric hemorrhage hemorrhagic gastritis hemorrhagic erosive gastritis,1,0.8749264478683472
PRADAXA,gastric hemorrhage,gastric hemorrhage hemorrhagic,1,0.9414269924163818
PRADAXA,gastric hemorrhage,gastritis hemorrhagic erosive,0,0.8480231761932373
PRADAXA,gastric hemorrhage,symptoms including GERD esophagitis erosive gastritis,0,0.696858286857605
PRADAXA,gastric hemorrhage,gastritislike symptoms including,0,0.7217962741851807
PRADAXA,gastric hemorrhage,erosive,0,0.5301440358161926
PRADAXA,hemorrhagic gastritis,hemorrhagic gastritis hemorrhagic,1,0.9883784651756287
PRADAXA,hemorrhagic gastritis,hemorrhagic gastritis hemorrhagic erosive gastritis,1,0.9493148326873779
PRADAXA,hemorrhagic gastritis,hemorrhagic gastritis hemorrhagic erosive gastritis and gastrointestinal,1,0.9213571548461914
PRADAXA,hemorrhagic erosive gastritis,gastritis gastric hemorrhage hemorrhagic hemorrhagic erosive gastritis,1,0.9514844417572021
PRADAXA,hemorrhagic erosive gastritis,hemorrhagic gastritis hemorrhagic erosive gastritis,1,0.9864902496337891
PRADAXA,hemorrhagic erosive gastritis,gastric hemorrhage,0,0.8431800603866577
PRADAXA,hemorrhagic erosive gastritis,gastric hemorrhage hemorrhagic hemorrhagic erosive gastritis and gastrointestinal,1,0.9360384345054626
PRADAXA,hemorrhagic erosive gastritis,gastritis gastric hemorrhage hemorrhagic hemorrhagic erosive gastritis and gastrointestinal ulcer Hypersensitivity Reactions,1,0.9062826633453369
PRADAXA,hemorrhagic erosive gastritis,hemorrhage hemorrhagic hemorrhagic erosive gastritis and gastrointestinal ulcer,1,0.9247381687164307
PRADAXA,hemorrhagic erosive gastritis,ulcer Hypersensitivity Reactions In the,0,0.6842894554138184
PRADAXA,hemorrhagic erosive gastritis,hemorrhagic erosive gastritis and gastrointestinal ulcer Hypersensitivity Reactions,1,0.9276580810546875
PRADAXA,hemorrhagic erosive gastritis,hemorrhage hemorrhagic hemorrhagic erosive,1,0.8075475692749023
PRADAXA,gastrointestinal ulcer,gastrointestinal ulcer Hypersensitivity Reactions In the,1,0.8195306062698364
PRADAXA,gastrointestinal ulcer,the RELY,0,0.5055461525917053
PRADAXA,urticaria,hypersensitivity including,0,0.7179465293884277
PRADAXA,urticaria,urticaria rash and pruritus,1,0.8397608995437622
PRADAXA,urticaria,urticaria,1,1.0
PRADAXA,urticaria,edema anaphylactic reaction and anaphylactic shock were,0,0.6622313261032104
PRADAXA,urticaria,were reported i,0,0.4662950038909912
PRADAXA,urticaria,urticaria rash and pruritus allergic edema,1,0.8170086145401001
PRADAXA,urticaria,urticaria rash and pruritus allergic,1,0.8397952318191528
PRADAXA,rash,were reported in,0,0.48256608843803406
PRADAXA,rash,including,0,0.541157603263855
PRADAXA,rash,rash and pruritus allergic edema,1,0.7802759408950806
PRADAXA,rash,drug hypersensitivity including,0,0.6544950604438782
PRADAXA,rash,drug hypersensitivity,0,0.6615039110183716
PRADAXA,rash,drug hypersensitivity including rash and pruritus allergic edema,1,0.7369451522827148
PRADAXA,pruritus,reported in,0,0.5257764458656311
PRADAXA,pruritus,rash pruritus allergic edema,1,0.8112534880638123
PRADAXA,pruritus,pruritus allergic edema anaphylactic,1,0.8097996711730957
PRADAXA,pruritus,reaction and,0,0.5446875691413879
PRADAXA,pruritus,including urticaria rash pruritus allergic edema anaphylactic reaction,1,0.7704272270202637
PRADAXA,pruritus,pruritus allergic edema anaphylactic reaction and,1,0.7985273599624634
PRADAXA,allergic edema,allergic edema anaphylactic,1,0.9441708326339722
PRADAXA,allergic edema,rash,0,0.6597069501876831
PRADAXA,anaphylactic reaction,and pruritus allergic anaphylactic,1,0.8197793364524841
PRADAXA,anaphylactic reaction,rash and pruritus allergic edema,0,0.6929985880851746
PRADAXA,anaphylactic reaction,including urticaria rash,0,0.6994225382804871
PRADAXA,anaphylactic reaction,anaphylactic reaction and anaphylactic shock,1,0.9157065153121948
PRADAXA,anaphylactic reaction,receiving PRADAXA,0,0.5318048596382141
PRADAXA,anaphylactic reaction,including urticaria rash and pruritus allergic edema,0,0.6977479457855225
PRADAXA,anaphylactic shock,receiving PRADAXA,0,0.5290701985359192
PRADAXA,anaphylactic shock,PRADAXA Treatment and,0,0.4932454526424408
PRADAXA,anaphylactic shock,allergic edema,0,0.7163200378417969
PRADAXA,anaphylactic shock,rash,0,0.6471325159072876
PRADAXA,bleeding,the following criteria applied fatal,0,0.5736018419265747
PRADAXA,bleeding,CrCl of mLmin Bleeding events,0,0.7466768026351929
PRADAXA,fatal,fatal bleeding,1,0.7836610078811646
PRADAXA,fatal,fatal bleeding symptomatic bleeding in a,1,0.7214698791503906
PRADAXA,fatal,critical area or,0,0.538146436214447
PRADAXA,fatal,fatal bleeding symptomatic bleeding in,1,0.7214679718017578
PRADAXA,fatal,at least one,0,0.5384345054626465
PRADAXA,fatal,fatal bleeding symptomatic,1,0.7392528057098389
PRADAXA,fatal,the following criteria fatal bleeding,1,0.7302164435386658
PRADAXA,fatal,bleeding,0,0.6126900911331177
PRADAXA,bleeding,applied fatal,0,0.6133716106414795
PRADAXA,bleeding,the following criteria applied bleeding symptomatic bleeding in a critical,1,0.7908007502555847
PRADAXA,symptomatic bleeding in a critical area,critical area or organ,1,0.7593328356742859
PRADAXA,symptomatic bleeding in a critical area,fatal symptomatic bleeding in a critical area or organ intraocular intracranial intraspinal,1,0.8207448720932007
PRADAXA,compartment syndrome,in a,0,0.5174089074134827
PRADAXA,retroperitoneal bleeding,intramuscular with compartment retroperitoneal,1,0.7168288230895996
PRADAXA,retroperitoneal bleeding,bleeding causing a fall in hemoglobin level,0,0.6609975695610046
PRADAXA,retroperitoneal bleeding,retroperitoneal,1,0.8777728080749512
PRADAXA,retroperitoneal bleeding,or organ intraocular intracranial intraspinal or intramuscular with compartment syndrome,0,0.5562564730644226
PRADAXA,retroperitoneal bleeding,or pericardial bleeding bleeding,0,0.7102359533309937
PRADAXA,retroperitoneal bleeding,compartment retroperitoneal bleeding intraarticular bleeding or pericardial,1,0.8341585397720337
PRADAXA,retroperitoneal bleeding,retroperitoneal bleeding intraarticular bleeding or,1,0.8866243958473206
PRADAXA,intra-articular bleeding,retroperitoneal,0,0.5409820079803467
PRADAXA,intra-articular bleeding,bleeding,0,0.770022451877594
PRADAXA,intra-articular bleeding,with compartment syndrome retroperitoneal intra-articular bleeding or pericardial bleeding bleeding,1,0.7764456272125244
PRADAXA,pericardial bleeding,syndrome retroperitoneal bleeding intraarticular bleeding or,0,0.66591477394104
PRADAXA,pericardial bleeding,or leading to trans,0,0.46694040298461914
PRADAXA,pericardial bleeding,pericardial bleeding,1,0.9999999403953552
PRADAXA,pericardial bleeding,retroperitoneal bleeding intraarticular bleeding pericardial,1,0.8330753445625305
PRADAXA,pericardial bleeding,pericardial bleeding bleeding causing a fall in,1,0.8566953539848328
PRADAXA,pericardial bleeding,bleeding intraarticular bleeding pericardial,1,0.8731786012649536
PRADAXA,bleeding,mmolL,0,0.5631729364395142
PRADAXA,bleeding,gdL,0,0.44179463386535645
PRADAXA,bleeding,or,0,0.5513760447502136
PRADAXA,fall in hemoglobin level,or,0,0.4841369390487671
PRADAXA,fall in hemoglobin level,in hemoglobin level of,1,0.8547570705413818
PRADAXA,fall in hemoglobin level,causing fall in hemoglobin level,1,0.9648219347000122
PRADAXA,fall in hemoglobin level,bleeding causing fall in hemoglobin level of gdL,1,0.8589193820953369
PRADAXA,fall in hemoglobin level,fall in hemoglobin level,1,0.9999999403953552
PRADAXA,fall in hemoglobin level,pericardial bleeding bleeding causing fall in hemoglobin level of gdL mmolL,1,0.8364965319633484
PRADAXA,fall in hemoglobin level,fall in hemoglobin level of gdL,1,0.9010798931121826
PRADAXA,bleeding,the number of patients bleeding events in the pooled,1,0.7827798128128052
PRADAXA,bleeding,fall in hemoglobin level,1,0.602962851524353
PRADAXA,bleeding,studies,0,0.5281075239181519
PRADAXA,bleeding,during the full treatment includi,0,0.5805750489234924
PRADAXA,Bleeding,Note MBE can belong to more,0,0.48054689168930054
PRADAXA,Bleeding,treatment periods,0,0.5886920690536499
PRADAXA,Bleeding,Bleeding Events in RECOVER,1,0.809715747833252
PRADAXA,Bleeding,RECOVER II Treated Patients Note MBE can belong to more,0,0.5010656118392944
PRADAXA,Bleeding,randomization,0,0.558329701423645
PRADAXA,MBE,MBE b,1,0.9206568598747253
PRADAXA,MBE,than one site of,0,0.5302400588989258
PRADAXA,MBE,MBE,1,0.9999996423721313
PRADAXA,MBE,MBE b Bleeding site based,1,0.7398216724395752
PRADAXA,MBE,MBE b Bleeding site based on,1,0.723603367805481
PRADAXA,MBE,one,0,0.52138352394104
PRADAXA,MBE,MBE b Bleeding,1,0.7719964981079102
PRADAXA,Bleeding,based on investigator assessment Patients can have more than one site,0,0.5019464492797852
PRADAXA,Bleeding,one MBE Bleeding site based,1,0.7558096051216125
PRADAXA,Bleeding,with at least one MBE b,0,0.4847928285598755
PRADAXA,bleeding,than one site,0,0.4795146584510803
PRADAXA,bleeding,ne MBE b Bleeding site based on investigator assessment Patients can have more than,0,0.7531284093856812
PRADAXA,bleeding,bleeding c Confidence interval Patients Major,1,0.7671641111373901
PRADAXA,bleeding,bleeding c Confidence interval Patients,1,0.7731179594993591
PRADAXA,bleeding,Confidence interval Patients bleeding,1,0.8135238885879517
PRADAXA,bleeding,bleeding event a Bleeding sites,1,0.8215903043746948
PRADAXA,bleeding,bleeding event a Bleeding sites for,1,0.8163259029388428
PRADAXA,bleeding,c Confidence interval Patients,0,0.5118454098701477
PRADAXA,bleeding,event,0,0.5222747325897217
PRADAXA,bleeding,interval Patients bleeding event a,1,0.7830193638801575
PRADAXA,bleeding,Patients,0,0.5812273621559143
PRADAXA,Bleeding,Bleeding sites for MBE,1,0.7757848501205444
PRADAXA,Bleeding,bleeding,0,1.0
PRADAXA,bleeding,bleeding The rate of any gastrointestinal bleeds,0,0.7355031967163086
PRADAXA,bleeding,Clinically,0,0.5809694528579712
PRADAXA,bleeding,bleeding The rate,0,0.8259376287460327
PRADAXA,bleeding,bleeding Any bleeding The,1,0.8948850631713867
PRADAXA,bleeding,bleeding Any bleeding The rate,1,0.8396671414375305
PRADAXA,bleeding,bleeding Any bleeding,1,0.884300708770752
PRADAXA,bleeding,relevant nonmajor,0,0.469014048576355
PRADAXA,bleeding,Clinically relevant nonmajor bleeding bleeding,1,0.7679009437561035
PRADAXA,bleeding,bleeding The rate of any,1,0.8225282430648804
PRADAXA,bleeding,nonmajor,0,0.4313881993293762
PRADAXA,bleeding,bleeding The,1,0.9657289981842041
PRADAXA,bleeding,any gastrointestinal bleeds in patients receiving,0,0.7360947132110596
PRADAXA,bleeding,gastrointestinal bleeds,0,0.7867625951766968
PRADAXA,bleeding,rate of any gastrointestinal bleeds in patients receiving PRADAXA mg in the full,0,0.691472053527832
PRADAXA,gastrointestinal bleeds,The rate of gastrointestinal bleeds in patients,1,0.899627685546875
PRADAXA,gastrointestinal bleeds,rate of any gastrointestinal bleeds in patients receiving PRADAXA mg in the full,0,0.777767539024353
PRADAXA,bleeding,bleeding events,1,0.845495343208313
PRADAXA,bleeding,bleeding events in the,1,0.8712440729141235
PRADAXA,bleeding,bleeding events in,1,0.8574225902557373
PRADAXA,bleeding,days Table shows the,0,0.4807831645011902
PRADAXA,bleeding,number of patients bleeding events in the study Table,1,0.7744845747947693
PRADAXA,bleeding,of days Table shows the number of patients experiencing,0,0.5499833226203918
PRADAXA,bleeding,mean exposure of days Table shows,0,0.507728636264801
PRADAXA,Bleeding,Note MBE can belong to more than one criterion,0,0.4606771469116211
PRADAXA,Bleeding,belong to more,0,0.5278045535087585
PRADAXA,Bleeding,investigator assessment Patients,0,0.5114612579345703
PRADAXA,bleeding,bleeding c Confidence interval,1,0.7832906246185303
PRADAXA,bleeding,bleeding c Confidence,1,0.7344284057617188
PRADAXA,bleeding,Confidence interval Patients Major,0,0.5253043174743652
PRADAXA,bleeding,sites for MBE,0,0.4759414792060852
PRADAXA,bleeding,bleeding event a Bleeding,1,0.8661477565765381
PRADAXA,bleeding,event a Bleeding,0,0.8916823863983154
PRADAXA,bleeding,bleeding Any,0,0.9122560024261475
PRADAXA,bleeding,bleeding In the REMEDY study the,1,0.8027993440628052
PRADAXA,bleeding,bleeding In the REMEDY,1,0.8521304130554199
PRADAXA,bleeding,bleeding In the,1,0.9683496952056885
PRADAXA,bleeding,Clinically relevant nonmajor bleeding bleeding In,1,0.769556999206543
PRADAXA,bleeding,REMEDY study the,0,0.5208004713058472
PRADAXA,bleeding,bleeding bleeding In the,1,0.9477764368057251
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients receiving,1,0.8945041298866272
PRADAXA,gastrointestinal bleeds,rate of gastrointestinal bleeds,1,0.914806067943573
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients receiving PRADAXA,1,0.8023509979248047
PRADAXA,gastrointestinal bleeds,PRADAXA mg,0,0.5030236840248108
PRADAXA,bleeding,of patients bleeding events in the,1,0.861799955368042
PRADAXA,bleeding,PRADAXA mg,0,0.5304895639419556
PRADAXA,bleeding,bleeding events in the study,1,0.8180856704711914
PRADAXA,Bleeding,study Bleeding Events in RESONATE Treated,1,0.7456778287887573
PRADAXA,Bleeding,bleeding events,1,0.845495343208313
PRADAXA,Bleeding,can,0,0.508385419845581
PRADAXA,Bleeding,Bleeding Events in RESONATE Treated,1,0.7520136833190918
PRADAXA,MBE,MBE can belong to,1,0.9094650149345398
PRADAXA,MBE,MBE b Bleeding site,1,0.7538121938705444
PRADAXA,MBE,on investigator assessment Patients can have more than one site,0,0.5154179334640503
PRADAXA,MBE,on investigator assessment Patients can have more than one,0,0.5054881572723389
PRADAXA,MBE,one site of,0,0.5292930603027344
PRADAXA,MBE,can belong,0,0.572352945804596
PRADAXA,Bleeding,based on investigator assessment Patients can have more,0,0.5194857120513916
PRADAXA,Bleeding,investigator assessment Patients can have more than one site,0,0.48937326669692993
PRADAXA,Bleeding,Bleeding site based on,1,0.8163701891899109
PRADAXA,bleeding,site bleeding c Confidence interval Patients,1,0.7490884065628052
PRADAXA,bleeding,Bleeding site based on,1,0.8163701891899109
PRADAXA,bleeding,interval Patients Major bleeding,0,0.8054081201553345
PRADAXA,bleeding,interval Patients bleeding event a Clinically,1,0.7981855869293213
PRADAXA,bleeding,Clinically relevant,0,0.5709012746810913
PRADAXA,bleeding,bleeding event a Clinically,1,0.8408454656600952
PRADAXA,bleeding,Patients bleeding event a Clinically relevant,1,0.807216465473175
PRADAXA,bleeding,bleeding event,1,0.8621304035186768
PRADAXA,bleeding,bleeding Any,1,0.9122560024261475
PRADAXA,bleeding,bleeding Any bleeding In the,1,0.8879208564758301
PRADAXA,bleeding,bleeding In the RESONATE,1,0.8245722651481628
PRADAXA,bleeding,bleeding In the RESONATE study,1,0.7511038780212402
PRADAXA,bleeding,nonmajor bleeding bleeding In,1,0.8010761737823486
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients receiving PRADAXA mg,1,0.7945753335952759
PRADAXA,gastrointestinal bleeds,the rate of gastrointestinal bleeds,1,0.9103854894638062
PRADAXA,gastrointestinal bleeds,nonmajor bleeding Any bleeding In the RESONATE study the rate of any,0,0.6480062007904053
PRADAXA,gastrointestinal bleeds,rate of gastrointestinal,1,0.765401303768158
PRADAXA,gastrointestinal bleeds,study the rate of gastrointestinal,1,0.7495911121368408
PRADAXA,gastrointestinal bleeds,in patients receiving PRADAXA mg was,0,0.5255461931228638
PRADAXA,myocardial infarction,myocardial infarction was reported,1,0.906358003616333
PRADAXA,myocardial infarction,gastrointestinal bleeds in patients,1,0.50290447473526
PRADAXA,myocardial infarction,myocardial infarction was reported in patients who,1,0.8393080234527588
PRADAXA,fatal,myocardial infarction was reported,0,0.5966821908950806
PRADAXA,fatal,the placebocontrolled study a similar rate of,0,0.47526323795318604
PRADAXA,fatal,fatal clinical myocardial infarction was reported,1,0.714851438999176
PRADAXA,fatal,rate of nonfatal fatal clinical myocardial infarction,1,0.6407483220100403
PRADAXA,fatal,was reported in patients,0,0.5161916017532349
PRADAXA,fatal,of,0,0.5430633425712585
PRADAXA,fatal,infarction was reported in patients who received PRADAXA per patie,0,0.5461519956588745
PRADAXA,fatal,fatal clinical myocardial infarction,1,0.7196469306945801
PRADAXA,fatal,patients who,0,0.4664340615272522
PRADAXA,myocardial infarction,nonfatal and fatal myocardial infarction,1,0.8210167288780212
PRADAXA,myocardial infarction,fatal myocardial infarction was reported in patients,1,0.8063677549362183
PRADAXA,myocardial infarction,of nonfatal and fatal myocardial infarction,1,0.8173552751541138
PRADAXA,myocardial infarction,was reported in patients who received PRADAXA per patientyears and in those who,0,0.5438045859336853
PRADAXA,myocardial infarction,in those who,0,0.5291343331336975
PRADAXA,gastrointestinal adverse reactions,gastrointestinal adverse reactions vs on,1,0.923650324344635
PRADAXA,gastrointestinal adverse reactions,had a similar incidence gastrointestinal adverse reactions,1,0.9129853844642639
PRADAXA,gastrointestinal adverse reactions,a similar incidence gastrointestinal adverse reactions,1,0.9253503084182739
PRADAXA,gastrointestinal adverse reactions,gastrointestinal adverse reactions,1,0.9999999403953552
PRADAXA,gastrointestinal adverse reactions,had,0,0.48548874258995056
PRADAXA,gastrointestinal adverse reactions,incidence gastrointestinal adverse reactions,1,0.9513744115829468
PRADAXA,gastrointestinal adverse reactions,gastrointestinal adverse reactions vs on warfarin Dyspepsia,1,0.840243935585022
PRADAXA,Dyspepsia,discomfort and epigastric discomfort o,0,0.7002722024917603
PRADAXA,Dyspepsia,Dyspepsia including abdominal pain upper abdominal,1,0.8546938300132751
PRADAXA,Dyspepsia,Dyspepsia including abdominal pain,1,0.8936449289321899
PRADAXA,abdominal pain upper,Dyspepsia abdominal pain upper,1,0.8986501693725586
PRADAXA,abdominal pain,abdominal pain abdominal discomfort and epigastric,1,0.8684990406036377
PRADAXA,abdominal discomfort,abdominal,0,0.8028988838195801
PRADAXA,abdominal discomfort,on PRADAXA in vs,0,0.45384272933006287
PRADAXA,abdominal discomfort,patients on PRADAXA in vs on warfarin and gastr,0,0.48966506123542786
PRADAXA,epigastric discomfort,gastritislike symptoms includi,0,0.7031832933425903
PRADAXA,epigastric discomfort,and,0,0.47245287895202637
PRADAXA,epigastric discomfort,abdominal pain upper abdominal pain,0,0.7256906032562256
PRADAXA,epigastric discomfort,epigastric discomfort,1,1.0
PRADAXA,gastritis,on PRADAXA in,0,0.5127444267272949
PRADAXA,gastritis,gastritis like symptoms including gastritis,1,0.8345568180084229
PRADAXA,gastritis,mfort and epigastric discomfort occurred in patients on,0,0.645436704158783
PRADAXA,gastritis,gastritis like,1,0.8917449116706848
PRADAXA,gastritis,gastritis and gastric,0,0.9131685495376587
PRADAXA,gastritis,gastritis like symptoms including gastritis GERD,1,0.8197226524353027
PRADAXA,gastritis,warfarin gastritis,1,0.8329950571060181
PRADAXA,gastritis,esophagitis,0,0.7151142358779907
PRADAXA,gastritis,gastritis and gastric hemorrhage occurred,0,0.8450020551681519
PRADAXA,gastritis,gastritis GERD esophagitis erosive gastritis and,1,0.8548630475997925
PRADAXA,gastritis,in patients,0,0.5382423400878906
PRADAXA,gastritis,including,0,0.5047604441642761
PRADAXA,gastritis,and gastritislike symptoms gastritis GERD esophagitis erosive gastritis and,1,0.8275342583656311
PRADAXA,gastritis,hemorrhage occurred at,0,0.5223941802978516
PRADAXA,GERD,GERD,1,1.0000001192092896
PRADAXA,GERD,gastritislike,0,0.6953854560852051
PRADAXA,esophagitis,esophagitis erosive,1,0.8472563028335571
PRADAXA,esophagitis,occurred,0,0.5451256036758423
PRADAXA,esophagitis,gastritislike symptoms including gastritis esophagitis,1,0.7569092512130737
PRADAXA,esophagitis,on PRADAXA in vs on warfarin and gastritislike,0,0.625460147857666
PRADAXA,esophagitis,esophagitis erosive gastritis and gastric,1,0.8017899990081787
PRADAXA,esophagitis,occurred at vs respectively Hypersens,0,0.6291938424110413
PRADAXA,esophagitis,esophagitis erosive gastritis,1,0.8135000467300415
PRADAXA,esophagitis,esophagitis,1,1.000000238418579
PRADAXA,erosive gastritis,and gastric hemorrhage occurred at,0,0.7146183848381042
PRADAXA,erosive gastritis,erosive gastritis and gastric hemorrhage occurred,1,0.9150780439376831
PRADAXA,erosive gastritis,on warfarin and gastritislike symptoms including gastritis,0,0.7160446047782898
PRADAXA,erosive gastritis,gastric hemorrhage occurred,0,0.7070631980895996
PRADAXA,erosive gastritis,GERD erosive gastritis and gastric hemorrhage occurred,1,0.8766963481903076
PRADAXA,erosive gastritis,erosive gastritis and gastric hemorrhage occurred at,1,0.9141967296600342
PRADAXA,erosive gastritis,gastric,0,0.7412109971046448
PRADAXA,hypersensitivity,studies,0,0.5291889905929565
PRADAXA,hypersensitivity,the pivotal studies hypersensitivity,1,0.8400483131408691
PRADAXA,hypersensitivity,hypersensitivity including urticaria rash,1,0.8664441108703613
PRADAXA,hypersensitivity,hypersensitivity including,1,0.9393411874771118
PRADAXA,hypersensitivity,hypersensitivity including urticaria rash and,1,0.8776242136955261
PRADAXA,hypersensitivity,pruritus allergic edema,0,0.7392232418060303
PRADAXA,urticaria,pivotal studies drug hypersensitivity urticaria rash and pruritus,1,0.750068724155426
PRADAXA,urticaria,pruritus allergic edema,0,0.7399899959564209
PRADAXA,urticaria,urticaria rash and,1,0.897344708442688
PRADAXA,urticaria,pivotal studies drug,0,0.5039547681808472
PRADAXA,urticaria,pivotal studies drug hypersensitivity urticaria rash and pruritus allergic edema,1,0.7523540258407593
PRADAXA,urticaria,Hypersensitivity Reactions In the pivotal,0,0.6766358017921448
PRADAXA,rash,and pruritus,0,0.7286311984062195
PRADAXA,rash,rash and pruritus allergic edema anaphylactic,1,0.7778878211975098
PRADAXA,rash,rash and pruritus allergic,1,0.8275542259216309
PRADAXA,rash,shock,0,0.6445159912109375
PRADAXA,rash,anaphylactic shock were,0,0.6166282892227173
PRADAXA,rash,rash and pruritus,1,0.8640639185905457
PRADAXA,rash,drug hypersensitivity including rash and pruritus allergic,1,0.7467577457427979
PRADAXA,rash,studies,0,0.5045089721679688
PRADAXA,pruritus,urticaria rash pruritus,1,0.867594301700592
PRADAXA,pruritus,studies,0,0.5299493074417114
PRADAXA,pruritus,pruritus,1,0.9999999403953552
PRADAXA,pruritus,pruritus allergic,1,0.8982860445976257
PRADAXA,pruritus,reported in of,0,0.523694634437561
PRADAXA,pruritus,rash and,0,0.7205100059509277
PRADAXA,pruritus,including urticaria rash pruritus allergic edema,1,0.7988970279693604
PRADAXA,pruritus,including urticaria rash pruritus allergic edema anaphylactic reaction and,1,0.7790931463241577
PRADAXA,pruritus,were reported in of patients,0,0.5304640531539917
PRADAXA,pruritus,pruritus allergic edema anaphylactic reaction,1,0.7889406681060791
PRADAXA,pruritus,were reported in,0,0.5189006924629211
PRADAXA,allergic edema,allergic edema anaphylactic reaction and,1,0.9245855808258057
PRADAXA,anaphylactic reaction,pruritus allergic anaphylactic reaction and anaphylactic shock were reported,1,0.8429567813873291
PRADAXA,anaphylactic reaction,allergic edema anaphylactic reaction and,1,0.8545588254928589
PRADAXA,anaphylactic reaction,rash and pruritus allergic anaphylactic reaction and anaphylactic,1,0.8282856941223145
PRADAXA,anaphylactic reaction,rash and pruritus allergic anaphylactic,1,0.8020051717758179
PRADAXA,anaphylactic reaction,and pruritus allergic anaphylactic reaction and anaphylactic shock,1,0.8438349366188049
PRADAXA,anaphylactic reaction,anaphylactic reaction,1,0.9999998807907104
PRADAXA,anaphylactic reaction,rash and pruritus allergic anaphylactic reaction,1,0.8420119285583496
PRADAXA,anaphylactic shock,allergic edema anaphylactic reaction anaphylactic,1,0.8032259941101074
PRADAXA,anaphylactic shock,allergic edema anaphylactic reaction anaphylactic shock,1,0.8530663251876831
PRADAXA,anaphylactic shock,anaphylactic,1,0.9406040906906128
PRADAXA,anaphylactic shock,rash and pruritus,0,0.6274275183677673
PRADAXA,anaphylactic shock,allergic edema anaphylactic reaction,0,0.807857871055603
PRADAXA,anaphylactic shock,were,0,0.4631515145301819
PRADAXA,angioedema,angioedema thrombocytopenia,1,0.818018913269043
PRADAXA,angioedema,post approval use of angioedema thrombocytopenia,1,0.7671961784362793
PRADAXA,thrombocytopenia,thrombocytopenia esophageal ulcer,1,0.7937505841255188
PRADAXA,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
PRADAXA,thrombocytopenia,approval use of PRADAXA thrombocytopenia,1,0.7876540422439575
PRADAXA,thrombocytopenia,of PRADAXA thrombocytopenia esophageal ulcer,1,0.7597576975822449
PRADAXA,thrombocytopenia,use of PRADAXA thrombocytopenia,1,0.8113524913787842
PRADAXA,thrombocytopenia,thrombocytopenia esophageal,1,0.82558673620224
PRADAXA,EPIDURAL HEMATOMA,bleeding see and Precautions,1,0.5761407613754272
PRADAXA,EPIDURAL HEMATOMA,bleeding see  and Precautions  EXCERPT Most common,1,0.5617474317550659
PRADAXA,EPIDURAL HEMATOMA,to bleeding see and,1,0.5861827731132507
PRADAXA,EPIDURAL HEMATOMA,see  and Precautions  EXCERPT,1,0.4911854863166809
PRADAXA,EPIDURAL HEMATOMA,to bleeding see  and Precautions  EXCERPT,1,0.5712614059448242
PRADAXA,EPIDURAL HEMATOMA,reactions are gastritislike symptoms and,0,0.4448234438896179
PRADAXA,EPIDURAL HEMATOMA,see  and Precautions ,1,0.4797128438949585
PRADAXA,EPIDURAL HEMATOMA,see and,1,0.44417911767959595
PRADAXA,EPIDURAL HEMATOMA,to bleeding see and Precautions,1,0.5759193301200867
PRADAXA,EPIDURAL HEMATOMA,are,0,0.46853190660476685
PRADAXA,EPIDURAL HEMATOMA,"  (6.1)  



    ",1,0.4688449800014496
PRADAXA,EPIDURAL HEMATOMA,"  (6.1)  



     To report SUSPECTED ADVERSE",1,0.5061100721359253
PRADAXA,EPIDURAL HEMATOMA,"  (6.1)  



     To report SUSPECTED",1,0.4677823483943939
PRADAXA,spinal hematomas,and System ic,1,0.40094250440597534
PRADAXA,spinal hematomas,reflect the rates observed in practice Reduction of Risk of,0,0.4917929172515869
PRADAXA,spinal hematomas,Nonvalvular Atrial Fibrillation The,0,0.44133931398391724
PRADAXA,spinal hematomas,and System ic Embolism in Nonvalvular Atrial,1,0.5151253938674927
PRADAXA,spinal hematomas,and System ic Embolism,1,0.564886212348938
PRADAXA,hematomas,y) study,1,0.44747215509414673
PRADAXA,hematomas,Anticoagulant y) study  provided,1,0.5126011371612549
PRADAXA,hematomas,y) study  provided safety information on the,1,0.4728333652019501
PRADAXA,hematomas,Anticoagulant y) study,1,0.5215880870819092
PRADAXA,hematomas,y),1,0.4630574882030487
PRADAXA,hematomas,Therap,0,0.5720211267471313
PRADAXA,hematomas,Longterm Anticoagulant y),1,0.5113241076469421
PRADAXA,permanent paralysis,use of two do ses of PRADAXA and warfarin,1,0.49512597918510437
PRADAXA,permanent paralysis,of patients and their e,0,0.5069162249565125
PRADAXA,EPIDURAL HEMATOMA,discontinuation were for XA 150,1,0.436084508895874
PRADAXA,EPIDURAL HEMATOMA,were for XA 150 mg,1,0.48713037371635437
PRADAXA,EPIDURAL HEMATOMA,treatment discontinuation were for XA 150 mg,1,0.47331494092941284
PRADAXA,EPIDURAL HEMATOMA,and 16% for warfarin The most,1,0.46677783131599426
PRADAXA,EPIDURAL HEMATOMA,discontinuation were for XA 150 mg and 16% ,1,0.4589230418205261
PRADAXA,EPIDURAL HEMATOMA,150 mg and 16% for warfarin,1,0.5158145427703857
PRADAXA,EPIDURAL HEMATOMA,and 16% for,1,0.4293211102485657
PRADAXA,spinal hematomas,or of the following,1,0.4945191740989685
PRADAXA,spinal hematomas,and 16% for,1,0.457401305437088
PRADAXA,spinal hematomas,accompanied by one or of the following a decrease in hemoglobin,1,0.5749127864837646
PRADAXA,spinal hematomas,or of the following a decrease,1,0.46355241537094116
PRADAXA,spinal hematomas,of the following a decrease,1,0.4639609456062317
PRADAXA,spinal hematomas,one or of the,1,0.47498393058776855
PRADAXA,spinal hematomas,transfusion of units of packed red blood cells,0,0.5508590936660767
PRADAXA,spinal hematomas,units,0,0.4723987579345703
PRADAXA,hematomas,outcome Intracranial hemorrhage included intracerebral hemorrhagic stroke,0,0.6232138872146606
PRADAXA,hematomas,fatal outcome Intracranial,0,0.5508695840835571
PRADAXA,permanent paralysis,and subdural bleeds Table Adjudicated,0,0.5116416215896606
PRADAXA,permanent paralysis,fatal,0,0.5894466042518616
PRADAXA,permanent paralysis,hemorrhage included,1,0.5128141641616821
PRADAXA,permanent paralysis,hemorrhagic stroke subarachnoid and subdural bleeds,0,0.513759434223175
PRADAXA,permanent paralysis,hemorrhage included intracerebral hemorrhagic stroke subarachnoid,1,0.526401698589325
PRADAXA,permanent paralysis,and subdural bleeds Table Adjudicated Majo,0,0.5145299434661865
PRADAXA,Bleeding,reaction s reported with,1,0.5462890863418579
PRADAXA,Bleeding,most serious,0,0.5847265720367432
PRADAXA,Bleeding,serious reaction s reported,1,0.6006186008453369
PRADAXA,Bleeding,reaction,1,0.5514813661575317
PRADAXA,Bleeding,most serious reaction s reported with PRADAXA,1,0.569412350654602
PRADAXA,fatal,to bleeding see,0,0.5907421112060547
PRADAXA,fatal,adverse reactions reported with PRADAXA were rel,0,0.5488426685333252
PRADAXA,fatal,most serious adverse reactions reported with PRADAXA were,0,0.5690436363220215
PRADAXA,fatal,most serious adverse reactions reported,0,0.62376868724823
PRADAXA,fatal,reported with PRADAXA were ated ,1,0.5569773316383362
PRADAXA,fatal,with PRADAXA,0,0.5073773860931396
PRADAXA,fatal,ated  to bleeding,1,0.6257607340812683
PRADAXA,bleeding,o bleedi ng see,1,0.8085848093032837
PRADAXA,bleeding,adverse,0,0.5555755496025085
PRADAXA,bleeding,o bleedi ng see Warnings,1,0.7691564559936523
PRADAXA,bleeding,common adverse reactions,0,0.5556801557540894
PRADAXA,bleeding,with PRADAXA were related o bleedi ng see Warnings,1,0.7205759286880493
PRADAXA,bleeding,see Warnings,0,0.5458295345306396
PRADAXA,bleeding,o bleedi,1,0.8155521154403687
PRADAXA,bleeding,PRADAXA were related o bleedi ng see Warnings,1,0.7325377464294434
PRADAXA,bleeding, reflect the rates observed in,1,0.4948025941848755
PRADAXA,fatal,of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation The RELY Ra,0,0.533191978931427
PRADAXA,fatal,The RELY,0,0.5354483723640442
PRADAXA,fatal,practice ducti,1,0.4966987371444702
PRADAXA,fatal,ducti on of Risk,1,0.564284086227417
PRADAXA,fatal,Risk,0,0.6106657981872559
PRADAXA,fatal,ducti on,1,0.5161072015762329
PRADAXA,fatal,ducti on of Risk of Stroke,1,0.5591993927955627
PRADAXA,bleeding,n of Ris k of Stroke and Systemic,1,0.5900486707687378
PRADAXA,bleeding,in practice n of Ris,1,0.5035876631736755
PRADAXA,bleeding,of Ris k of,1,0.5376244783401489
PRADAXA,bleeding,of Stroke and Systemic Embolism in Nonvalvular,0,0.612257182598114
PRADAXA,bleeding,observed in practice n of Ris,1,0.5070897340774536
PRADAXA,bleeding,n of Ris,1,0.4944920241832733
PRADAXA,bleeding,reflect,0,0.5138034820556641
PRADAXA,bleeding,Nonvalvular Atrial Fibrillation,0,0.5604844093322754
PRADAXA,bleeding,may not reflect the rates observed in,0,0.4765394628047943
PRADAXA,bleeding,rates observed in practice n of Ris,1,0.5154976844787598
PRADAXA,spinal hematoma, gastrointestin al hemorrhage,1,0.5527093410491943
PRADAXA,spinal hematoma,nausea upper abdominal  gastrointestin,1,0.44295135140419006
PRADAXA,spinal hematoma,see,0,0.4720103144645691
PRADAXA,spinal hematoma,and gastrointestinal events ie dyspepsia nausea upper,0,0.47104281187057495
PRADAXA,spinal hematoma, gastrointestin al hemorrhage and diarrhea,1,0.514277994632721
PRADAXA,spinal hematoma, gastrointestin,1,0.44878101348876953
PRADAXA,spinal hematoma,nausea upper abdominal,0,0.4594643712043762
PRADAXA,spinal hematoma, gastrointestin al hemorrhage and diarrhea Bleeding,1,0.5288641452789307
PRADAXA,permanent paralysis,"and   

        Bleedin g",1,0.4817456007003784
PRADAXA,permanent paralysis, gastrointestin al hemorrhage and diarrhea Bleeding,1,0.4680652916431427
PRADAXA,permanent paralysis,ie dyspepsia nausea upper abdominal pain gastrointestinal hemorrhage,0,0.45637190341949463
PRADAXA,permanent paralysis,"hemorrhage and   

        Bleedin",1,0.4780937731266022
PRADAXA,permanent paralysis,and,0,0.4358495771884918
PRADAXA,permanent paralysis,"  

        Bleedin",1,0.5113240480422974
PRADAXA,permanent paralysis,"pain gastrointestinal hemorrhage and   

        Bleedin g see",1,0.45524370670318604
PRADAXA,permanent paralysis,"pain gastrointestinal hemorrhage and   

        Bleedin g",1,0.45168665051460266
PRADAXA,permanent paralysis,ie dyspepsia nausea upper abdominal pain gastrointestinal,0,0.4562367796897888
PRADAXA,permanent paralysis,and Precautions Table shows the number,0,0.46313273906707764
PRADAXA,permanent paralysis,"  

        Bleedin g see Warnings and",1,0.5008786916732788
PRADAXA,paralysis,  Bleedin g,1,0.4982907176017761
PRADAXA,paralysis,shows the number of,0,0.45156586170196533
PRADAXA,paralysis,  Bleedin g see Warnings,1,0.5103047490119934
PRADAXA,paralysis,  Bleedin g see,1,0.5271872878074646
PRADAXA,paralysis,  Bleedin,1,0.5181753635406494
PRADAXA,paralysis,hemorrhage and   Bleedin g see,1,0.5083456635475159
PRADAXA,paralysis,gastrointestinal hemorrhage and,0,0.4655808210372925
PRADAXA,thromboembolic events,above with or reported,1,0.5296039581298828
PRADAXA,thromboembolic events,as defined above with or reported,1,0.5365664958953857
PRADAXA,thromboembolic events,above,0,0.4824432134628296
PRADAXA,thromboembolic events,fatal out come and,1,0.5797842741012573
PRADAXA,thromboembolic events,bleed as,0,0.6506044268608093
PRADAXA,transient ischemic attack,adjudicated death ith primary cause from bl eeding gNonintracranial fatal bleed,1,0.5695006251335144
PRADAXA,transient ischemic attack,bleed as,0,0.5586817860603333
PRADAXA,transient ischemic attack,cause from bl eeding gNonintracranial fatal bleed,1,0.5837271213531494
PRADAXA,transient ischemic attack,cause from bl eeding,1,0.5968152284622192
PRADAXA,transient ischemic attack,and adjudicated death ith primary cause from bl,1,0.5687392950057983
PRADAXA,transient ischemic attack,investigator reported fatal,0,0.4862651526927948
PRADAXA,transient ischemic attack,above,0,0.4813620448112488
PRADAXA,transient ischemic attack,death ith primary cause from bl eeding gNonintracranial fatal bleed,1,0.5613994598388672
PRADAXA,transient ischemic attack,with,0,0.5090327262878418
PRADAXA,transient ischemic attack,bleed Adjudicated major bleed as,0,0.5622345209121704
PRADAXA,bleeding,cause from bleeding but,0,0.8679854869842529
PRADAXA,pericardial effusions,fatal bleed Adjudicated major bleed as defined above,0,0.5895169973373413
PRADAXA,pericardial effusions,bleed Adjudicated major bleed as defined above,0,0.5921735167503357
PRADAXA,pericardial effusions,with prim ary cause from bleeding,1,0.6161180734634399
PRADAXA,pericardial effusions,e from bleeding gNonintracranial fatal bleed Adjudicated major bleed as defined above,0,0.5751932859420776
PRADAXA,pericardial effusions,above and cated death with prim,1,0.49990659952163696
PRADAXA,pericardial effusions,defined above and cated death with prim ary cause from bleeding but,1,0.594750165939331
PRADAXA,pericardial effusions,above and cated death with,1,0.5142356157302856
PRADAXA,pericardial effusions,from bleeding gNonintracranial fatal bleed Adjudicated,0,0.5793112516403198
PRADAXA,pericardial effusions,above and cated death with prim ary,1,0.5223079323768616
PRADAXA,pericardial effusions,bleed based,0,0.5951600074768066
PRADAXA,bleeding,         PRADAXA mgN,1,0.5323188304901123
PRADAXA,bleeding,assessment,0,0.5370386838912964
VORAXAZE,allergic reactions,allergic reactions,1,1.0000001192092896
VORAXAZE,allergic reactions,REACTIONS Serious,0,0.6707207560539246
VORAXAZE,allergic reactions,allergic reactions including anaphylactic,1,0.9093101024627686
VORAXAZE,allergic reactions,allergic reactions including,1,0.9507283568382263
VORAXAZE,anaphylactic reactions,most common adverse reactions incidence with VORAXAZE are paraesthesias,0,0.6123157143592834
VORAXAZE,anaphylactic reactions,anaphylactic reactions may occur,1,0.9445083141326904
VORAXAZE,anaphylactic reactions,anaphylactic reactions may occur The most,1,0.9029315710067749
VORAXAZE,anaphylactic reactions,anaphylactic reactions,1,1.0000001192092896
VORAXAZE,anaphylactic reactions,anaphylactic reactions may occur The most common,1,0.8852028846740723
VORAXAZE,anaphylactic reactions,anaphylactic reactions may occur The,1,0.9335678219795227
VORAXAZE,anaphylactic reactions,Serious allergic reactions anaphylactic reactions may occur The most,1,0.866407036781311
VORAXAZE,paraesthesias,flushing nausea andor,0,0.5994868278503418
VORAXAZE,paraesthesias,The most,0,0.5132089853286743
VORAXAZE,paraesthesias,paraesthesias flushing nausea andor,1,0.8277933597564697
VORAXAZE,flushing,with VORAXAZE are flushing,1,0.7884335517883301
VORAXAZE,flushing,The most,0,0.5003947615623474
VORAXAZE,flushing,flushing nausea andor vomiting,1,0.7681493163108826
VORAXAZE,nausea,nausea andor vomiting hypotension and,1,0.8141503930091858
VORAXAZE,nausea,nausea andor vomiting,1,0.8912792801856995
VORAXAZE,nausea,paraesthesias nausea andor vomiting,1,0.8263565301895142
VORAXAZE,nausea,nausea andor,1,0.923078179359436
VORAXAZE,headache,headache EXCERPT,1,0.8737919330596924
VORAXAZE,headache,vomiting hypotension headache EXCERPT,1,0.7627764940261841
VORAXAZE,headache,nausea andor vomiting hypotension headache EXCERPT,1,0.7487788200378418
VORAXAZE,headache,headache EXCERPT In,1,0.8736007213592529
VORAXAZE,headache,In clinical trials the most common related adverse events occurring in of p,0,0.5381566286087036
VORAXAZE,headache,headache EXCERPT In clinical,1,0.8185208439826965
VORAXAZE,headache,headache EXCERPT In clinical trials the,1,0.7869802713394165
VORAXAZE,headache,headache,1,0.9999998807907104
VORAXAZE,headache,are paraesthesias flushing nausea andor vomiting,0,0.5892656445503235
VORAXAZE,headache,headache EXCERPT In clinical trials,1,0.7816786170005798
VORAXAZE,paraesthesia,paraesthesia,1,1.0
VORAXAZE,paraesthesia,patients paraesthesia flushing nausea,1,0.820136308670044
VORAXAZE,paraesthesia,related adverse events occurring,0,0.5501559972763062
VORAXAZE,paraesthesia,paraesthesia flushing nausea andor vomiting,1,0.7952814102172852
VORAXAZE,paraesthesia,and headache To report,0,0.6114470362663269
VORAXAZE,paraesthesia,occurring in of patients paraesthesia flushing nausea andor vomiting hypotension,1,0.754177451133728
VORAXAZE,paraesthesia,paraesthesia flushing nausea,1,0.8407231569290161
VORAXAZE,paraesthesia,paraesthesia flushing nausea andor vomiting hypotension,1,0.7810788750648499
VORAXAZE,flushing,flushing nausea,1,0.7943637371063232
VORAXAZE,flushing,flushing,1,1.0
VORAXAZE,flushing,flushing nausea andor vomiting hypotension,1,0.7390902042388916
VORAXAZE,flushing,were,0,0.5194940567016602
VORAXAZE,nausea,and headache To report SUSPECTED,0,0.6311914920806885
VORAXAZE,nausea,nausea andor vomiting hypotension and headache,1,0.8048423528671265
VORAXAZE,nausea,were paraesthesia nausea andor vomiting hypotension and headache,1,0.7816514372825623
VORAXAZE,nausea,flushing,0,0.5387477278709412
VORAXAZE,nausea,and headache,0,0.6768844127655029
VORAXAZE,nausea,related adverse events occurring in of patients were,0,0.536620020866394
VORAXAZE,vomiting,paraesthesia flushing nausea,0,0.7274562120437622
VORAXAZE,vomiting,vomiting hypotension,1,0.8382202386856079
VORAXAZE,vomiting,and headache To report SUSPECTED ADVERSE,0,0.6200156211853027
VORAXAZE,vomiting,SUSPECTED ADVERSE REACTIONS call,0,0.5915089249610901
VORAXAZE,vomiting,andor,0,0.47789615392684937
VORAXAZE,vomiting,vomiting hypotension and headache To,1,0.8206456899642944
VORAXAZE,vomiting,were paraesthesia flushing,0,0.6044537425041199
VORAXAZE,vomiting,To report SUSPECTED,0,0.5072811841964722
VORAXAZE,hypotension,hypotension and headache To report,1,0.8332748413085938
VORAXAZE,hypotension,hypotension,1,1.0
VORAXAZE,headache,headache To report SUSPECTED,1,0.8286822438240051
VORAXAZE,headache,contact FDA at,0,0.48302558064460754
VORAXAZE,headache,report SUSPECTED ADVERSE REACTIONS call or contact,0,0.5121891498565674
VORAXAZE,headache,headache To,1,0.9336679577827454
VORAXAZE,headache,REACTIONS,0,0.5280338525772095
VORAXAZE,headache,headache To report,1,0.8183112144470215
VORAXAZE,headache,nausea andor vomiting hypotension headache To,1,0.7714314460754395
VORAXAZE,flushing,experienced related flushing The most common,1,0.8272643685340881
VORAXAZE,flushing,headache To report,1,0.5350354909896851
VORAXAZE,flushing,or renal events were,0,0.6446584463119507
VORAXAZE,flushing,flushing The most common related,1,0.8584144115447998
VORAXAZE,paresthesia,each occurred,0,0.5362560153007507
VORAXAZE,flushing,flushing and nausea andor vomiting which,1,0.7361198663711548
VORAXAZE,flushing,events were flushing and nausea,1,0.7402923107147217
VORAXAZE,vomiting,vomiting which each occurred in of,1,0.895683765411377
VORAXAZE,vomiting,vomiting which each occurred,1,0.9084255695343018
VORAXAZE,vomiting,of,0,0.5198577642440796
VORAXAZE,vomiting,occurred in of patients,0,0.562069833278656
VORAXAZE,vomiting,or renal events were paresthesia flushing and,0,0.6104073524475098
VORAXAZE,vomiting,ns that were not hematologic hepatic or renal events were paresthesia flushing,0,0.5764372944831848
VORAXAZE,vomiting,vomiting which each,1,0.946996808052063
VORAXAZE,flushing,classified as Grade in,0,0.449715793132782
VORAXAZE,flushing,the following flushing feeling hot burning sensation One,1,0.7432292699813843
VORAXAZE,feeling hot,Hepatic or Renal,0,0.5246663093566895
VORAXAZE,feeling hot,feeling hot burning sensation One of these,1,0.8598012924194336
VORAXAZE,feeling hot,following terms feeling,1,0.6545676589012146
VORAXAZE,feeling hot,or Renal Adverse Reactions This incidence,0,0.5114250779151917
VORAXAZE,burning sensation,following terms flushing feeling burning sensation One of these reactions,1,0.8685163259506226
VORAXAZE,burning sensation,or Renal Adverse Reactions This incidence,0,0.5765607357025146
VORAXAZE,burning sensation,This incidence includes the following terms flushing feeling,0,0.7505029439926147
VORAXAZE,burning sensation,terms flushing feeling burning sensation One of these reactions,1,0.8731827735900879
VORAXAZE,burning sensation,One of,0,0.5122419595718384
VORAXAZE,burning sensation,Adverse Reactions This incidence includes the following terms flushing feeling,0,0.7448898553848267
VORAXAZE,burning sensation,terms flushing feeling hot,0,0.7724437713623047
VORAXAZE,burning sensation,burning sensation,1,1.0
VORAXAZE,burning sensation,flushing feeling burning sensation,1,0.8987867832183838
VORAXAZE,burning sensation,feeling burning sensation One of these,1,0.9396424293518066
VORAXAZE,Vomiting,Vomiting Headache H,1,0.8179574012756348
VORAXAZE,Vomiting,Nausea,0,0.8409453630447388
VORAXAZE,Vomiting,Flushing,0,0.5910892486572266
VORAXAZE,Vomiting,Flushing Vomiting Headache,1,0.814541757106781
VORAXAZE,Vomiting,Vomiting Headache,1,0.8704005479812622
VORAXAZE,Hypotension,Hypotension Blurred Vision,1,0.8191010355949402
VORAXAZE,Hypotension,Hypotension,1,1.0
VORAXAZE,Hypotension,Hypotension Blurred,1,0.863515317440033
VORAXAZE,Rash,Rash,1,1.0000001192092896
VORAXAZE,Rash,Hypotension Blurred,1,0.5233649015426636
VORAXAZE,Rash,Rash Throat irritationThroat,1,0.8126158118247986
VORAXAZE,Rash,Throat irritationThroat,0,0.6127984523773193
VORAXAZE,Rash,Rash Throat irritationThroat tightness,1,0.7682802677154541
VORAXAZE,Rash,ty Rash Throat,1,0.813690185546875
VORAXAZE,Rash,ty,0,0.5902162790298462
VORAXAZE,Rash,Hypertension,0,0.5665625929832458
VORAXAZE,Tremor,Immunogenicity As with all th,0,0.465084969997406
VORAXAZE,Tremor,Tremor Immunogenicity As,1,0.7724995017051697
VORAXAZE,Tremor,Tremor Immunogenicity,1,0.7745140790939331
VORAXAZE,Tremor,Tremor Immunogenicity As with all th,1,0.7684736251831055
VORAXAZE,Tremor,tightness,0,0.5656306743621826
VORAXAZE,Tremor,Immunogenicity As with,0,0.45990562438964844
VORAXAZE,Tremor,Immunogenicity As,0,0.4424794614315033
VORAXAZE,Tremor,irritationThroat Tremor Immunogenicity As with all,1,0.7777670621871948
VORAXAZE,allergic reactions,with VORAXAZE are paraesthesi,0,0.48814713954925537
VORAXAZE,allergic reactions,most common adverse,0,0.5915061235427856
VORAXAZE,allergic reactions,common adverse reactions incidence with VORAXAZE,0,0.6236881613731384
VORAXAZE,allergic reactions,REACTIONS Serious allergic reactions ing anaphylactic r eactions may,1,0.8681315183639526
VORAXAZE,allergic reactions,reactions ing anaphylactic r eactions may occur The,1,0.8544183969497681
VORAXAZE,allergic reactions,ing anaphylactic r,1,0.7702726125717163
VORAXAZE,anaphylactic reactions,anaphylactic reactions y occur. The most comm on adverse reactions incidence,1,0.8397487998008728
VORAXAZE,anaphylactic reactions,ing anaphylactic r,1,0.8559741973876953
VORAXAZE,anaphylactic reactions,VORAXAZE are paraesthesias flushing nausea andor vomiti,0,0.6072592735290527
VORAXAZE,anaphylactic reactions,are paraesthesias flushing nausea,0,0.6185790300369263
VORAXAZE,anaphylactic reactions,y occur. The most comm on,1,0.5294748544692993
VORAXAZE,anaphylactic reactions,The most comm on,1,0.47673577070236206
VORAXAZE,anaphylactic reactions,reactions y occur. The most comm,1,0.6740601658821106
VORAXAZE,anaphylactic reactions,incidence with VORAXAZE are paraesthesias flushing nausea andor,0,0.5840491056442261
VORAXAZE,anaphylactic reactions,y occur. The most,1,0.5468178987503052
VORAXAZE,allergic reactions,drugs,0,0.5879834294319153
HORIZANT,Somnolence,Somnolence sedation and dizziness see Warnings,1,0.7357544898986816
HORIZANT,Somnolence,and dizziness see Warnings and Precautions,0,0.5645011067390442
HORIZANT,Somnolence,in more detail in the Warnings and Precautions,0,0.4935944676399231
HORIZANT,Somnolence,ctions are described in,0,0.5067628026008606
HORIZANT,sedation,sedation and dizziness see,1,0.8318065404891968
HORIZANT,sedation,section of the label sedation and dizziness see Warnings,1,0.7678496837615967
HORIZANT,sedation,and,0,0.5297682881355286
HORIZANT,sedation,sedation,1,1.0000001192092896
HORIZANT,sedation,the label Somnolence,0,0.6234085559844971
HORIZANT,dizziness,see Warnings and Precautions RLS Most common adverse,0,0.5969455242156982
HORIZANT,dizziness,dizziness,1,0.9999998807907104
HORIZANT,dizziness,the label Somnolencesedation dizziness see Warnings and Precautions,1,0.7652969360351562
HORIZANT,dizziness,label Somnolencesedation,0,0.591018557548523
HORIZANT,dizziness,dizziness see,1,0.9351365566253662
HORIZANT,somnolence,somnolence,1,1.0
HORIZANT,somnolence,of placebo somnolence sedation and,1,0.7683560252189636
HORIZANT,somnolence,adverse reactions,0,0.5239142179489136
HORIZANT,somnolence,somnolence sedation and,1,0.8751116394996643
HORIZANT,somnolence,sedation and dizziness PHN Most common adverse reactions and,0,0.5863149166107178
HORIZANT,somnolence,somnolence sedation and dizziness,1,0.7654438018798828
HORIZANT,sedation,were,0,0.5450856685638428
HORIZANT,sedation,somnolence,0,0.6407902836799622
HORIZANT,sedation,placebo were sedation and dizziness,1,0.7953554391860962
HORIZANT,sedation,common adverse,0,0.5149699449539185
HORIZANT,dizziness,Most common adverse reactions and greater than placebo,0,0.5661819577217102
HORIZANT,dizziness,dizziness somnolence and headache EXCERPT To,1,0.8060781955718994
HORIZANT,dizziness,To,0,0.5241683721542358
HORIZANT,dizziness,dizziness somnolence and headache,1,0.8271253108978271
HORIZANT,dizziness,and greater than placebo dizziness somnolence,1,0.7969779372215271
HORIZANT,dizziness,reactions and greater,0,0.5272734761238098
HORIZANT,dizziness,placebo,0,0.61080402135849
HORIZANT,somnolence,dizziness,0,0.5886321067810059
HORIZANT,somnolence,greater than placebo,0,0.5352407097816467
HORIZANT,somnolence,placebo were somnolence and headache EXCERPT To report,1,0.7404158115386963
HORIZANT,somnolence,REACTIONS contact XenoP,0,0.5012249946594238
HORIZANT,somnolence,were somnolence,1,0.9598312377929688
HORIZANT,somnolence,somnolence and headache,1,0.8504665493965149
HORIZANT,headache,PHN Most common adverse reactions and greater than,0,0.5524218082427979
HORIZANT,headache,headache EXCERPT,1,0.8737919330596924
HORIZANT,headache,Most common adverse,0,0.5778596997261047
HORIZANT,headache,reactions and greater than placebo,0,0.5399181842803955
HORIZANT,somnolence,somnolence sedation and dizziness see,1,0.7742903232574463
HORIZANT,somnolence,dose of HORIZANT somnolence sedation and,1,0.7786401510238647
HORIZANT,sedation,sedation and dizziness,1,0.8281848430633545
HORIZANT,sedation,sedation and,1,0.9342280626296997
HORIZANT,sedation,mg,0,0.5496175289154053
HORIZANT,sedation,placebo in these trials for the,0,0.6398176550865173
HORIZANT,sedation,mg dose of HORIZANT were somnolence,0,0.6478689312934875
HORIZANT,dizziness,were somnolencesedation and,0,0.5883028507232666
HORIZANT,balance disorder,greater than placebo balance disorder blurred,1,0.8195297718048096
HORIZANT,balance disorder,were somnolencesedation and,0,0.5241854786872864
HORIZANT,blurred vision,following,0,0.49940913915634155
HORIZANT,blurred vision,atients treated with,0,0.5593271255493164
HORIZANT,blurred vision,vertigo The,0,0.6357362270355225
HORIZANT,blurred vision,feeling drunk lethargy and vertigo,0,0.5972563624382019
HORIZANT,blurred vision,than placebo were balance blurred vision,1,0.8177264332771301
HORIZANT,blurred vision,and numerically greater than placebo were,0,0.49089017510414124
HORIZANT,blurred vision,numerically greater than placebo were balance disorder,0,0.540624737739563
HORIZANT,blurred vision,following adverse reactions were dos,0,0.617121696472168
HORIZANT,disorientation,disorder blurred disorientation,1,0.8829669952392578
HORIZANT,disorientation,following adverse reactions were dos,0,0.5801732540130615
HORIZANT,disorientation,were balance disorder blurred disorientation feeling drunk lethargy and,1,0.7988749742507935
HORIZANT,disorientation,blurred vision,0,0.6751657724380493
HORIZANT,disorientation,disorientation,1,0.9999999403953552
HORIZANT,disorientation,disorientation feeling drunk lethargy and,1,0.8014176487922668
HORIZANT,disorientation,disorientation feeling drunk,1,0.8310957551002502
HORIZANT,disorientation,disorientation feeling drunk lethargy,1,0.8069217801094055
HORIZANT,disorientation,vertigo The following adverse reactions were doserelated somno,0,0.6657589673995972
HORIZANT,feeling drunk,than placebo were balance disorder blurred vision,0,0.5309145450592041
HORIZANT,lethargy,lethargy and vertigo The following adverse,1,0.8092174530029297
HORIZANT,lethargy,lethargy,1,0.9999998807907104
HORIZANT,lethargy,disorientation feeling lethargy and vertigo The following,1,0.7105038166046143
HORIZANT,lethargy,placebo were balance disorder blurred,0,0.5562937259674072
HORIZANT,vertigo,feeling drunk lethargy vertigo The following adverse reactions were,1,0.7019214630126953
HORIZANT,vertigo,lethargy and vertigo The following adverse,1,0.7870457172393799
HORIZANT,vertigo,vertigo The following adverse,1,0.8645011782646179
HORIZANT,vertigo,vertigo,1,1.0
HORIZANT,vertigo,than placebo,0,0.5539435148239136
HORIZANT,somnolence,somnolence sedation dizziness feeling drunk libido,1,0.7390053272247314
HORIZANT,somnolence,reactions were somnolence sedation dizziness feeling,1,0.7334098219871521
HORIZANT,somnolence,reactions,0,0.5094771385192871
HORIZANT,somnolence,decreased depression headache,0,0.6082351207733154
HORIZANT,somnolence,somnolence sedation dizziness feeling,1,0.751822292804718
HORIZANT,somnolence,feeling,0,0.5763622522354126
HORIZANT,sedation,sedation dizziness feeling drunk libido,1,0.7206045985221863
HORIZANT,dizziness,vertigo,0,0.8601921200752258
HORIZANT,dizziness,edema,0,0.6331124305725098
HORIZANT,dizziness,dizziness feeling drunk libido decreased,1,0.7658014893531799
HORIZANT,dizziness,drunk libido decreased depression headache peripheral edema and,0,0.6448363065719604
HORIZANT,feeling drunk,and vertigo Postherpetic,0,0.5398240089416504
HORIZANT,feeling drunk,depression headache peripheral edema and vertigo,0,0.5814686417579651
HORIZANT,feeling drunk,headache,0,0.5608747005462646
HORIZANT,feeling drunk,depression headache,0,0.5465512275695801
HORIZANT,feeling drunk,feeling drunk libido decreased depression headache peripheral,1,0.8037948608398438
HORIZANT,feeling drunk,peripheral,0,0.44385743141174316
HORIZANT,libido decreased,somnolencesedation dizziness feeling libido decreased,1,0.8657448291778564
HORIZANT,libido decreased,peripheral,0,0.48908400535583496
HORIZANT,libido decreased,edema and vertigo Postherpetic Neuralgia,0,0.48544374108314514
HORIZANT,libido decreased,libido decreased,1,1.0
HORIZANT,depression,depression headache peripheral edema and vertigo,1,0.765485405921936
HORIZANT,depression,and vertigo Postherpetic Neuralgia The,0,0.5434861779212952
HORIZANT,depression,depression,1,0.9999998807907104
HORIZANT,headache,drunk libido decreased,0,0.49753499031066895
HORIZANT,headache,decreased headache peripheral,1,0.7736353874206543
HORIZANT,headache,Postherpetic Neuralgia The exposure to HORIZANT,0,0.5894001722335815
HORIZANT,headache,headache peripheral edema and vertigo,1,0.7656320333480835
HORIZANT,headache,somnolencesedation dizziness feeling drunk libido decreased,0,0.5818407535552979
HORIZANT,headache,depression,0,0.6358321905136108
HORIZANT,peripheral edema,Postherpetic Neuralgia The exposure to HORIZANT,0,0.5929742455482483
HORIZANT,peripheral edema,dizziness feeling drunk,0,0.5233344435691833
HORIZANT,peripheral edema,peripheral edema and vertigo Postherpetic,1,0.756614625453949
HORIZANT,peripheral edema,peripheral,1,0.7205731272697449
HORIZANT,peripheral edema,decreased depression peripheral edema and vertigo Postherpetic Neuralgia The,1,0.7209526300430298
HORIZANT,peripheral edema,depression peripheral,1,0.7272374033927917
HORIZANT,vertigo,peripheral edema vertigo Postherpetic Neuralgia The exposure,1,0.6998313665390015
HORIZANT,vertigo,depression peripheral,1,0.6299511194229126
HORIZANT,vertigo,libido decreased,0,0.48591119050979614
HORIZANT,vertigo,headache peripheral edema vertigo Postherpetic Neuralgia The exposure,1,0.6764910221099854
HORIZANT,vertigo,with PHN,0,0.5194557905197144
HORIZANT,vertigo,vertigo Postherpetic Neuralgia The exposure to,1,0.7895301580429077
HORIZANT,vertigo,libido decreased depression headache peripheral edema,0,0.5578904151916504
HORIZANT,vertigo,and,0,0.5135843753814697
HORIZANT,vertigo,vertigo Postherpetic Neuralgia,1,0.8045623302459717
HORIZANT,dizziness,for the mg,0,0.5347418785095215
HORIZANT,dizziness,of,0,0.5306555032730103
HORIZANT,dizziness,dizziness somnolence,1,0.8632392883300781
HORIZANT,dizziness,dizziness somnolence and headache see,1,0.8176956176757812
HORIZANT,somnolence,for the mg dose of HORIZANT were dizziness,0,0.556792140007019
HORIZANT,somnolence,somnolence and,1,0.9676932096481323
HORIZANT,somnolence,for,0,0.5322664380073547
HORIZANT,headache,headache,1,0.9999998807907104
HORIZANT,headache,Table lists treatmentemergent adverse reactions that occurred in of,0,0.538221538066864
HORIZANT,confusional state,dry mouth flatulence,0,0.49173519015312195
HORIZANT,confusional state,balance,0,0.5992090702056885
HORIZANT,confusional state,mgday balance confusional,1,0.6107915639877319
HORIZANT,confusional state,dry,0,0.5566824078559875
HORIZANT,confusional state,flatulence increased,0,0.486390084028244
HORIZANT,dry mouth,confusional state dry mouth flatulence increased appetite irritability,1,0.7171204090118408
HORIZANT,dry mouth,flatulence increased,0,0.5415765047073364
HORIZANT,dry mouth,mgday balance disorder confusional,0,0.4842135012149811
HORIZANT,dry mouth,dry mouth flatulence,1,0.8688181042671204
HORIZANT,dry mouth,appetite irritability and,0,0.5963666439056396
HORIZANT,dry mouth,but were,0,0.4766101837158203
HORIZANT,dry mouth,balance disorder confusional state dry mouth flatulence increased appetite irritability and,1,0.6813944578170776
HORIZANT,dry mouth,dry,1,0.7593775987625122
HORIZANT,dry mouth,confusional state dry,1,0.662742018699646
HORIZANT,dry mouth,dry mouth flatulence increased,1,0.8269604444503784
HORIZANT,increased appetite,mouth increased appetite,1,0.9137973785400391
HORIZANT,increased appetite,increased appetite,1,0.9999999403953552
HORIZANT,increased appetite,vertigo Dizziness somnolence,0,0.5418621301651001
HORIZANT,increased appetite,dry mouth,0,0.5874136686325073
HORIZANT,increased appetite,dry mouth flatulence,0,0.6122562885284424
HORIZANT,increased appetite,mouth increased appetite irritability and,1,0.8450289964675903
HORIZANT,increased appetite,increased appetite irritability and,1,0.8714711666107178
HORIZANT,irritability,irritability and vertigo Dizziness,1,0.8314956426620483
HORIZANT,irritability,mouth flatulence increased irritability and vertigo Dizziness somnolence fatigue,1,0.7739583253860474
HORIZANT,irritability,flatulence increased irritability and vertigo Dizziness somnolence fatigue,1,0.7722941040992737
HORIZANT,irritability,mouth flatulence increased irritability,1,0.8431776762008667
HORIZANT,irritability,irritability and vertigo Dizziness somnolence,1,0.822539210319519
HORIZANT,irritability,flatulence increased irritability and vertigo,1,0.7765660285949707
HORIZANT,irritability,flatulence increased irritability,1,0.8599077463150024
HORIZANT,irritability,and insomnia appeared to,0,0.5950334072113037
HORIZANT,vertigo,vertigo Dizziness somnolence,1,0.8082133531570435
HORIZANT,vertigo,and insomnia appeared to show a,0,0.554394006729126
HORIZANT,Dizziness,Dizziness,1,0.9999998807907104
HORIZANT,Dizziness,relationship Adverse Events A,0,0.5017282962799072
HORIZANT,Dizziness,a dose relationship Adverse Events A,0,0.5413187146186829
HORIZANT,somnolence,somnolence fatigue and insomnia,1,0.8505629301071167
HORIZANT,somnolence,irritability and vertigo somnolence fatigue and,1,0.7627942562103271
HORIZANT,somnolence,depression dry mouth flatulence increased appetite,0,0.6110993027687073
HORIZANT,somnolence,somnolence fatigue,1,0.8950692415237427
HORIZANT,somnolence,irritability and vertigo somnolence fatigue and insomnia appeared,1,0.7386504411697388
HORIZANT,insomnia,insomnia appeared to,1,0.8965886831283569
HORIZANT,insomnia,somnolence fatigue insomnia appeared to,1,0.8508269786834717
HORIZANT,insomnia,insomnia appeared,1,0.9188246726989746
HORIZANT,insomnia,and vertigo Dizziness,0,0.5627822875976562
HORIZANT,insomnia,Adverse Events Associated,0,0.4629511833190918
HORIZANT,insomnia,insomnia appeared to show a dose,1,0.8415210843086243
HORIZANT,insomnia,and,0,0.5087255239486694
HORIZANT,insomnia,irritability and vertigo Dizziness somnolence,0,0.6470568180084229
HORIZANT,insomnia,Events Associated With Gabapentin The,0,0.5329856872558594
HORIZANT,insomnia,insomnia appeared to show a,1,0.874890923500061
HORIZANT,breast enlargement,have been,0,0.4785670340061188
HORIZANT,breast enlargement,breast enlargement gynecomastia and elevated creatine kinase,1,0.7940784692764282
HORIZANT,gynecomastia,and elevated,0,0.521263837814331
HORIZANT,gynecomastia,in clinical,0,0.5068188905715942
HORIZANT,gynecomastia,gynecomastia,1,1.0
HORIZANT,gynecomastia,trials or postmarketing breast gynecomastia and elevated creatine kinase,1,0.8025224208831787
HORIZANT,gynecomastia,gynecomastia and elevated,1,0.9097659587860107
HORIZANT,Driving impairment,REACTIONS The following adverse ons,1,0.5399762988090515
HORIZANT,Driving impairment,the label,0,0.48028141260147095
HORIZANT,Driving impairment,and Precautions section of,0,0.5000159740447998
HORIZANT,Driving impairment,label Somnolencesedation a,0,0.5040935277938843
HORIZANT,Somnolence,RLS: Mos t common adverse reactions,1,0.526442289352417
HORIZANT,Somnolence,dizziness see Warnings and   RLS: Mos,1,0.5691457986831665
HORIZANT,Somnolence,Warnings and RLS: Mos,1,0.5052769780158997
HORIZANT,Somnolence,placebo,0,0.5680555701255798
HORIZANT,Somnolence,dizziness see Warnings and RLS: Mos,1,0.5691457986831665
HORIZANT,Somnolence,RLS: Mos t common,1,0.508783221244812
HORIZANT,Somnolence,Warnings and   RLS: Mos t common,1,0.5127503871917725
HORIZANT,sedation,see,0,0.5449472665786743
HORIZANT,sedation,RLS Most,0,0.5293809771537781
HORIZANT,sedation, common  adverse,1,0.5149699449539185
HORIZANT,sedation,times the rate of placebo were,0,0.5937463641166687
HORIZANT,sedation,Warnings and Precautions RLS  common  adverse,1,0.5810117125511169
HORIZANT,dizziness,times the rate of placebo,0,0.5616002082824707
HORIZANT,Suicidal thoughts,and greater,0,0.44067251682281494
HORIZANT,suicidal thoughts,ADVERSE REACTIO,0,0.482263445854187
HORIZANT,suicidal thoughts,"NS, contact XenoP ort",1,0.4571341872215271
HORIZANT,suicidal thoughts,To,0,0.49211838841438293
HORIZANT,suicidal thoughts,somnolence and headache EXCERPT To report SUSPECTED ADVERSE REACTIO,0,0.5246784687042236
HORIZANT,suicidal thoughts,"ADVERSE NS, contact XenoP ort at XENOPRT or",1,0.481961727142334
HORIZANT,driving impairment,reaction rates observed in the clinical trials of a,0,0.5029149055480957
HORIZANT,driving impairment,or wwwfdagovmedwatch Clinical Trials Experience,0,0.5197880268096924
HORIZANT,driving impairment,clinical trials,0,0.5209236145019531
HORIZANT,driving impairment,trials are co nducted under widely varying,1,0.5137755870819092
HORIZANT,driving impairment,ical trials are co nducted under widely varying conditions,1,0.520978569984436
HORIZANT,driving impairment,Experience Because ical trials are co,1,0.5191428661346436
HORIZANT,driving impairment,varying conditions,0,0.5539686679840088
HORIZANT,driving impairment,are co,1,0.4795800447463989
HORIZANT,driving impairment,Because ical trials are co,1,0.4934365153312683
HORIZANT,driving impairment,with rates in the clinical trials of,0,0.5185093879699707
HORIZANT,somnolence,for at least year HORIZANT in the treatment,0,0.47680166363716125
HORIZANT,somnolence,included,0,0.4911242127418518
HORIZANT,somnolence,at least year HORIZANT in the treatment of RLS was studied p,0,0.5208994746208191
HORIZANT,somnolence,osed for a t least months and,1,0.5258220434188843
HORIZANT,somnolence,least months and exposed for at least year HORIZANT in the,0,0.4980715811252594
HORIZANT,somnolence,RLS included osed for a t least,1,0.5099124908447266
HORIZANT,somnolence,t least,0,0.4914189577102661
HORIZANT,somnolence,patients with RLS included osed for a,1,0.5510267615318298
HORIZANT,somnolence,trials n nd in long,1,0.48542559146881104
HORIZANT,somnolence,was studied primarily in placebocontrolled,0,0.577953577041626
HORIZANT,somnolence,nd in long term followup studies The population,1,0.4763113856315613
HORIZANT,somnolence,in long term followup studies The population,1,0.4615458846092224
HORIZANT,somnolence,in placebocontrolled trials n nd in long term followup,1,0.5112395882606506
HORIZANT,sedation,population with RLS ranged,0,0.5128713846206665
HORIZANT,sedation,and in term fol lowup studies,1,0.5538630485534668
HORIZANT,sedation,RLS ranged from to years,0,0.537581741809845
HORIZANT,sedation,ranged from,0,0.485873818397522
HORIZANT,sedation,term fol lowup studies The,1,0.5422946810722351
HORIZANT,sedation,in term fol,1,0.5878087282180786
HORIZANT,sedation,term fol lowup,1,0.5661756992340088
HORIZANT,dizziness,in longterm p studies,1,0.48433905839920044
HORIZANT,somnolence,treated with mg of HORIZANT disconti,0,0.5343152284622192
HORIZANT,somnolence,with RLS in double blind placebocontrolled week clinical trials The,0,0.5336391925811768
HORIZANT,sedation,ied in,1,0.5106803774833679
HORIZANT,sedation,in 2 of the studies Eleven out,1,0.5098090171813965
HORIZANT,sedation,in 2 of the studies Eleven,1,0.5058301687240601
HORIZANT,sedation,The mg dose was ied in,1,0.5740286111831665
HORIZANT,sedation,dose was ied in,1,0.5129889249801636
HORIZANT,sedation,mg dose was ied in 2 of,1,0.5856695175170898
HORIZANT,sedation,Eleven out of patients treated with mg of,0,0.5835534930229187
HORIZANT,sedation,trials,0,0.5878188610076904
HORIZANT,sedation,ied in 2 of the studies Eleven out,1,0.5143071413040161
HORIZANT,somnolence,who received ebo.,1,0.4408608675003052
HORIZANT,somnolence,patients who received ebo.,1,0.4475060999393463
HORIZANT,somnolence,ebo. T he most commonly,1,0.5062863826751709
HORIZANT,somnolence,"ebo.



 T he most commonly observed adverse",1,0.5331840515136719
HORIZANT,Dizziness,of placebo in these for the 6 mg dose of,1,0.5556631684303284
HORIZANT,Dizziness,ebo. T he most commonly,1,0.491210013628006
HORIZANT,Dizziness,observed adverse reactions and at least times the rate,0,0.5556678771972656
HORIZANT,Dizziness,in these for the 6 mg dose of HORIZANT,1,0.5714216232299805
HORIZANT,Dizziness,in these for the 6 mg,1,0.5556102991104126
HORIZANT,Dizziness,reactions and at least times,0,0.5469198226928711
HORIZANT,Dizziness,of placebo in these for,1,0.5802770853042603
HORIZANT,Dizziness,for the 6 mg dose,1,0.5548887252807617
HORIZANT,dizziness,LS treate d with HORIZANT and numerically,1,0.5288693308830261
HORIZANT,dizziness,in of patients with LS treate d with HORIZANT and numerically,1,0.5818179845809937
HORIZANT,dizziness,in of patients with LS treate d with HORIZANT,1,0.5809403657913208
HORIZANT,Somnolence,than . Tabl,1,0.47129178047180176
HORIZANT,Somnolence,occurred in of patients with RLS treated with,0,0.5106964111328125
HORIZANT,Somnolence,.,1,0.5745638608932495
HORIZANT,Somnolence,. Tabl e Incidence,1,0.5260430574417114
HORIZANT,Somnolence,. Tabl,1,0.45236051082611084
HORIZANT,Somnolence,of Patients Treated With,0,0.4842418432235718
HORIZANT,Somnolence,with HORIZANT and numerically greater than,0,0.47960731387138367
HORIZANT,sedation,4. Inci dence of Adverse,1,0.5501842498779297
HORIZANT,sedation,numerically,0,0.5271037220954895
HORIZANT,Dizziness,Reactions in Week RLS Studies Reported,0,0.551697850227356
HORIZANT,Dizziness,Patie,0,0.43759411573410034
HORIZANT,Dizziness,nts Treat ed With,1,0.5140681266784668
HORIZANT,Dizziness, administ ration,1,0.4727628231048584
HORIZANT,Dizziness, administ ration site conditions,1,0.46996545791625977
HORIZANT,Dizziness,ration,0,0.4927166700363159
HORIZANT,Dizziness, administ ration site,1,0.4497092366218567
HORIZANT,Dizziness,General disorders  administ ration,1,0.553756058216095
HORIZANT,suicidal thoughts,                  Weight,1,0.5005666017532349
HORIZANT,suicidal thoughts,nutritional disorders,0,0.44721025228500366
HORIZANT,suicidal behavior,Libido                 2 a Placebo was a treatment,1,0.5166915059089661
HORIZANT,suicidal behavior,nutritional disorders,0,0.5341359376907349
HORIZANT,suicidal thinking,ment arm in of the doubleblind placebocontrolled week,0,0.47908222675323486
HORIZANT,suicidal thinking,trials b The mg dose of,0,0.4515780508518219
HORIZANT,suicidal thinking,was a treat,1,0.39229071140289307
HORIZANT,suicidal thinking,The mg d,0,0.4340873956680298
HORIZANT,suicidal thinking,IZANT was a treat ment arm in of the,1,0.47426319122314453
HORIZANT,suicidal thinking,in of the doubleblind placebocontrolled week clinical trials c The,0,0.4656131863594055
HORIZANT,suicidal thinking,c The,0,0.49824124574661255
HORIZANT,suicidal thinking,trials c,0,0.46097302436828613
HORIZANT,suicidal thinking,of IZANT was a treat,1,0.40360480546951294
HORIZANT,suicidal thoughts,12 wee k studies,1,0.4505072236061096
HORIZANT,suicidal thoughts,in t,0,0.4465561509132385
HORIZANT,suicidal thoughts,hese three 12 wee k studies in,1,0.465603232383728
HORIZANT,suicidal thoughts,reactions reported in hese,1,0.4749947190284729
HORIZANT,suicidal thoughts,12 wee k studies in of,1,0.4550911784172058
HORIZANT,suicidal thoughts,"headache, periphe ral edema and",1,0.5123814344406128
HORIZANT,suicidal thoughts,in,0,0.4908948540687561
HORIZANT,suicidal thoughts,"headache, periphe ral",1,0.5559304356575012
HORIZANT,suicidal thoughts,exposure,0,0.4949871599674225
HORIZANT,suicidal thoughts,"feeling drunk libido decreased headache, periphe ral edema and vertigo Postherpetic",1,0.4962221682071686
HORIZANT,suicidal thoughts,"decreased headache, periphe",1,0.5093239545822144
HORIZANT,suicidal thoughts,edema and vertigo Postherpetic,0,0.45726799964904785
HORIZANT,suicidal thoughts,"libido decreased headache, periphe ral edema and",1,0.48549899458885193
HORIZANT,suicidal thoughts,Numerically r Than the Placeb o Rate Reported in,1,0.4326488971710205
HORIZANT,suicidal thoughts,Reactions in At Least,0,0.4979572594165802
HORIZANT,suicidal thoughts,Body SystemAdverse Reaction PlaceboN,0,0.4757820963859558
HORIZANT,suicidal thoughts,r Than,1,0.4831973910331726
HORIZANT,suicidal thoughts,Numerically r Than the Placeb o Rate Reported in All,1,0.4349426031112671
HORIZANT,suicidal thoughts,of HORIZANT and Numerically r,1,0.45286130905151367
HORIZANT,suicidal thoughts,the Placeb o Rate Reported in,1,0.43840646743774414
HORIZANT,suicidal thoughts,With mgday of HORIZANT and,0,0.46834975481033325
HORIZANT,suicidal thoughts,PHN Study Body SystemAdverse Reaction PlaceboN,0,0.47621092200279236
HORIZANT,suicidal thoughts,SystemAdverse,0,0.4349384903907776
HORIZANT,myositis,nd nutri,1,0.49235981702804565
HORIZANT,myositis,SystemAdverse,0,0.44795751571655273
HORIZANT,Eosinophilia,             Weight,1,0.4679622948169708
HORIZANT,Eosinophilia,            ,1,0.5851094722747803
HORIZANT,Eosinophilia,nutritional             ,1,0.45276737213134766
HORIZANT,Eosinophilia,Metabolism and nutritional disorders,0,0.5294851660728455
HORIZANT,Eosinophilia,nutritional              Weight,1,0.43587344884872437
HORIZANT,rash,disorders,0,0.5988904237747192
STENDRA,headache,back pain To report SUSPECTED,0,0.588334858417511
STENDRA,headache,greater than or equal to include,0,0.4876014292240143
STENDRA,headache,headache flushing,1,0.8183545470237732
STENDRA,flushing,equal to include flushing nasal congestion nasopharyngitis and back,1,0.7181811332702637
STENDRA,flushing,headache flushing,1,0.8152972459793091
STENDRA,flushing,nasal congestion nasopharyngitis and back pain To,0,0.5302603840827942
STENDRA,flushing,flushing nasal congestion nasopharyngitis and,1,0.7308899164199829
STENDRA,flushing,equal to include flushing nasal congestion nasopharyngitis,1,0.7220144271850586
STENDRA,nasal congestion,equal to include headache nasal congestion nasopharyngitis and,1,0.8321280479431152
STENDRA,nasal congestion,flushing nasal congestion nasopharyngitis and,1,0.8458071947097778
STENDRA,nasal congestion,nasal congestion nasopharyngitis and,1,0.8903383016586304
STENDRA,nasal congestion,to include headache nasal,1,0.8100464940071106
STENDRA,nasal congestion,nasal congestion,1,1.0
STENDRA,nasal congestion,to include headache nasal congestion nasopharyngitis and,1,0.836524248123169
STENDRA,nasal congestion,or,0,0.5287147164344788
STENDRA,nasopharyngitis,ADVERSE REACTIONS contact,0,0.5660415887832642
STENDRA,nasopharyngitis,nasopharyngitis,1,1.0000001192092896
STENDRA,nasopharyngitis,report SUSPECTED ADVERSE,0,0.5613325834274292
STENDRA,nasopharyngitis,to include headache flushing nasal congestion,0,0.6671487092971802
STENDRA,nasopharyngitis,pain,0,0.5401082634925842
STENDRA,nasopharyngitis,report SUSPECTED ADVERSE REACTIONS contact or,0,0.5653997659683228
STENDRA,nasopharyngitis,nasopharyngitis and back,1,0.8727863430976868
STENDRA,nasopharyngitis,contact or FDA at,0,0.4845593273639679
STENDRA,nasopharyngitis,SUSPECTED ADVERSE REACTIONS,0,0.5972316265106201
STENDRA,nasopharyngitis,headache flushing nasal nasopharyngitis and back pain To,1,0.7878665328025818
STENDRA,back pain,back pain To report SUSPECTED ADVERSE,1,0.8387304544448853
STENDRA,back pain,congestion nasopharyngitis back pain To report,1,0.7266029119491577
STENDRA,back pain,FDA at,0,0.45685145258903503
STENDRA,back pain,or FDA,0,0.4838600754737854
STENDRA,back pain,nasopharyngitis back,1,0.6411874890327454
STENDRA,upper respiratory infection,bronchitis influenza,0,0.6920621991157532
STENDRA,URI,URI bronchitis influenza,1,0.7683084011077881
STENDRA,URI,upper respiratory URI bronchitis influenza sinusitis sinus congestion,1,0.6571365594863892
STENDRA,bronchitis,bronchitis influenza sinusitis sinus,1,0.7598512172698975
STENDRA,bronchitis,influenza sinusitis sinus congestion hypertension dyspepsia nausea constipation and,0,0.6029546856880188
STENDRA,bronchitis,infection bronchitis influenza sinusitis,1,0.7808467745780945
STENDRA,bronchitis,upper respiratory infection bronchitis influenza sinusitis sinus,1,0.7583851218223572
STENDRA,influenza,upper respiratory infection URI influenza sinusitis sinus congestion hypertension dyspepsia,1,0.6838301420211792
STENDRA,influenza,bronchitis influenza sinusitis sinus,1,0.7160806059837341
STENDRA,sinusitis,infection URI bronchitis sinusitis sinus congestion,1,0.7707604169845581
STENDRA,sinusitis,bronchitis influenza sinusitis sinus,1,0.807054877281189
STENDRA,sinusitis,sinusitis sinus,1,0.9366528987884521
STENDRA,sinusitis,sinusitis,1,0.9999998807907104
STENDRA,sinus congestion,sinus congestion hypertension dyspepsia nausea constipation and,1,0.8566051721572876
STENDRA,hypertension,sinusitis sinus hypertension,1,0.7476001977920532
STENDRA,hypertension,sinus congestion hypertension dyspepsia nausea constipation and,1,0.6805967092514038
STENDRA,hypertension,an,0,0.571048378944397
STENDRA,hypertension,hypertension dyspepsia,1,0.7677685618400574
STENDRA,hypertension,hypertension,1,0.9999999403953552
STENDRA,hypertension,rash In an openlabel longterm extension study,0,0.5396337509155273
STENDRA,hypertension,sinusitis sinus hypertension dyspepsia nausea constipation,1,0.6580796241760254
STENDRA,hypertension,and,0,0.5626955032348633
STENDRA,dyspepsia,dyspepsia nausea constipation and rash In,1,0.8394820690155029
STENDRA,dyspepsia,URI bronchitis,0,0.497268408536911
STENDRA,dyspepsia,nausea constipation and rash In an openlabel longterm extension study of two of these,0,0.6520766019821167
STENDRA,dyspepsia,dyspepsia nausea,1,0.9084006547927856
STENDRA,dyspepsia,constipation and,0,0.694894552230835
STENDRA,constipation,influenza sinusitis sinus congestion hypertension dyspepsia,0,0.6013147234916687
STENDRA,constipation,constipation and rash In an openlabel,1,0.790570080280304
STENDRA,constipation,extension study of two of these randomized doubleblind,0,0.48897677659988403
STENDRA,constipation,fection URI bronchitis influenza sinusitis sinus congestion hypertension dyspepsia,0,0.623456597328186
STENDRA,constipation,constipation and,1,0.913962185382843
STENDRA,upper respiratory infection,than of,0,0.5024023056030273
STENDRA,URI,pain arthralgia hypertension and diarrhea,0,0.503896951675415
STENDRA,URI,sinusitis bronchitis dizziness back pain arthralgia,0,0.5169714689254761
STENDRA,URI,URI influenza sinusitis bronchitis,1,0.7030820250511169
STENDRA,URI,patients,0,0.4795410633087158
STENDRA,URI,study,0,0.5398528575897217
STENDRA,URI,included upper respiratory URI influenza sinusitis bronchitis dizziness,1,0.625996470451355
STENDRA,URI,URI,1,1.0000001192092896
STENDRA,URI,patients in the openlabel extension study included upper respiratory infection,0,0.5709710717201233
STENDRA,URI,upper respiratory URI influenza sinusitis bronchitis dizziness,1,0.6518576145172119
STENDRA,URI,arthralgia hypertension and,0,0.47926267981529236
STENDRA,influenza,than of patients in the openlabel extension study,0,0.46978068351745605
STENDRA,influenza,arthralgia,0,0.517956554889679
STENDRA,influenza,influenza sinusitis bronchitis dizziness back pain,1,0.7323234677314758
STENDRA,influenza,influenza,1,0.9999999403953552
STENDRA,sinusitis,sinusitis bronchitis dizziness back pain,1,0.7996393442153931
STENDRA,sinusitis,URI sinusitis bronchitis dizziness,1,0.748248815536499
STENDRA,sinusitis,dizziness back,0,0.5445997714996338
STENDRA,sinusitis,URI,0,0.5224626064300537
STENDRA,bronchitis,events occurred in,0,0.49293309450149536
STENDRA,bronchitis,included upper respiratory infection,0,0.6717637181282043
STENDRA,bronchitis,respiratory infection URI influenza sinusitis,0,0.6215665340423584
STENDRA,bronchitis,bronchitis dizziness,1,0.8150148391723633
STENDRA,bronchitis,bronchitis dizziness back,1,0.8121961951255798
STENDRA,bronchitis,influenza,0,0.6567248702049255
STENDRA,bronchitis,infection URI influenza bronchitis dizziness,1,0.7437151670455933
STENDRA,bronchitis,bronchitis dizziness back pain,1,0.8278101682662964
STENDRA,bronchitis,bronchitis dizziness back pain arthralgia,1,0.8243020176887512
STENDRA,back pain,sinusitis bronchitis back pain,1,0.7335205078125
STENDRA,back pain,study included upper respiratory infection URI influenza,0,0.4543229341506958
STENDRA,hypertension,hypertension and diarrhea,1,0.8122624754905701
STENDRA,hypertension,er respiratory,0,0.5340024828910828
STENDRA,diarrhea,diarrhea The following events,1,0.8310441970825195
STENDRA,diarrhea,diarrhea,1,0.9999999403953552
STENDRA,diarrhea,ection URI influenza sinusitis bronchitis dizziness back pain,0,0.5770761966705322
STENDRA,diarrhea,diarrhea The,1,0.9120277166366577
STENDRA,diarrhea,diarrhea The following events occurred in,1,0.8207858204841614
STENDRA,diarrhea,diarrhea The following,1,0.8770276308059692
STENDRA,diarrhea,occurred in less than of patients in the,0,0.5295407772064209
STENDRA,edema peripheral,Cardiovascular angina unstable angina deep vein,0,0.5597134232521057
STENDRA,edema peripheral,as a edema peripheral fatigue Cardiovascular angina unstable angina,1,0.7809190154075623
STENDRA,edema peripheral,a edema,1,0.8437900543212891
STENDRA,edema peripheral,lausible relation to drug use and reports too imprecise to be meaningful Body as a whole,0,0.5222119092941284
STENDRA,edema peripheral,edema peripheral fatigue Cardiovascular,1,0.8511624932289124
STENDRA,edema peripheral,edema peripheral,1,1.0
STENDRA,edema peripheral,as a edema peripheral,1,0.9712993502616882
STENDRA,edema peripheral,edema peripheral fatigue Cardiovascular angina unstable,1,0.7735470533370972
STENDRA,edema peripheral,a edema peripheral,1,0.9757122993469238
STENDRA,fatigue,fatigue Cardiovascular,1,0.8460115790367126
STENDRA,fatigue,as a whole edema fatigue Cardiovascular angina,1,0.7246597409248352
STENDRA,fatigue,as a,0,0.5397597551345825
STENDRA,angina,angina unstable angina,1,0.8459869027137756
STENDRA,angina,as a,0,0.5122014284133911
STENDRA,angina,a whole,0,0.5619361400604248
STENDRA,angina,a whole edema peripheral fatigue Cardiovascular,0,0.6628420352935791
STENDRA,deep vein thrombosis,edema peripheral fatigue,0,0.6011577844619751
STENDRA,deep vein thrombosis,angina unstable deep vein thrombosis palpitations,1,0.76070636510849
STENDRA,deep vein thrombosis,vein thrombosis palpitations,1,0.7774223685264587
STENDRA,deep vein thrombosis,as a whole edema peripheral fatigue,0,0.6056027412414551
STENDRA,deep vein thrombosis,angina unstable deep vein thrombosis,1,0.8413363695144653
STENDRA,deep vein thrombosis,deep vein thrombosis palpitations Digestive gastritis gastroesophageal,1,0.764248251914978
STENDRA,deep vein thrombosis,palpitations,0,0.5499177575111389
STENDRA,deep vein thrombosis,gastritis,0,0.5308022499084473
STENDRA,deep vein thrombosis,a whole edema,0,0.595200777053833
STENDRA,palpitations,palpitations Digestive gastritis gastroesophageal reflux,1,0.805607795715332
STENDRA,palpitations,palpitations,1,0.9999999403953552
STENDRA,palpitations,palpitations Digestive gastritis,1,0.7931729555130005
STENDRA,gastritis,hypoglycemia,0,0.551716685295105
STENDRA,gastritis,vein thrombosis palpitations,0,0.4902024269104004
STENDRA,gastritis,Cardiovascular angina unstable angina,0,0.5300750136375427
STENDRA,gastritis,gastritis gastroesophageal reflux,1,0.8824454545974731
STENDRA,gastritis,unstable angina deep vein,0,0.5061123967170715
STENDRA,gastritis,gastritis gastroesophageal reflux disease hypoglycemia,1,0.8092272281646729
STENDRA,gastritis,unstable angina,0,0.5358994603157043
STENDRA,gastroesophageal reflux disease,thrombosis palpitations,0,0.502934992313385
STENDRA,gastroesophageal reflux disease,gastroesophageal reflux disease hypoglycemia,1,0.8179575204849243
STENDRA,gastroesophageal reflux disease,Digestive gastroesophageal reflux disease hypoglycemia blood glucose increased alanine,1,0.7710486650466919
STENDRA,gastroesophageal reflux disease,oropharyngeal pain sto,0,0.5851521492004395
STENDRA,gastroesophageal reflux disease,Digestive gastroesophageal,1,0.8214319944381714
STENDRA,gastroesophageal reflux disease,thrombosis palpitations Digestive gastroesophageal reflux disease hypoglycemia blood,1,0.7336137294769287
STENDRA,hypoglycemia,palpitations,0,0.5125958919525146
STENDRA,hypoglycemia,reflux hypoglycemia blood glucose increased alanine aminotransferase,1,0.748127818107605
STENDRA,hypoglycemia,palpitations Digestive,0,0.49965769052505493
STENDRA,hypoglycemia,gastroesophageal reflux disease,0,0.5276210904121399
STENDRA,hypoglycemia,vein thrombosis palpitations Digestive gastritis gastroesophageal,0,0.497292697429657
STENDRA,blood glucose increased,glucose increased alanine aminotransferase,1,0.7903985977172852
STENDRA,blood glucose increased,blood glucose increased alanine aminotransferase increased,1,0.8544591665267944
STENDRA,blood glucose increased,glucose increased alanine aminotransferase increased oropharyngeal,1,0.7881407141685486
STENDRA,blood glucose increased,reflux disease blood glucose increased,1,0.8097236752510071
STENDRA,blood glucose increased,rombosis palpitations,0,0.5033690333366394
STENDRA,blood glucose increased,Digestive,0,0.5430450439453125
STENDRA,blood glucose increased,gastroesophageal reflux disease,0,0.4975360333919525
STENDRA,blood glucose increased,pain stomach discomfort vomiting Musculo,0,0.5114782452583313
STENDRA,blood glucose increased,gastritis gastroesophageal reflux disease blood glucose increased,1,0.7810627222061157
STENDRA,alanine aminotransferase increased,disease hypoglycemia blood glucose alanine aminotransferase,1,0.8183995485305786
STENDRA,alanine aminotransferase increased,oropharyngeal pain stomach discomfort vomiting,0,0.523037850856781
STENDRA,alanine aminotransferase increased,hypoglycemia blood glucose alanine aminotransferase increased oropharyngeal pain stomach discomfort,1,0.7786554098129272
STENDRA,alanine aminotransferase increased,aminotransferase increased,1,0.9549258947372437
STENDRA,oropharyngeal pain,alanine aminotransferase oropharyngeal,1,0.7169345617294312
STENDRA,oropharyngeal pain,oropharyngeal pain,1,1.0
STENDRA,oropharyngeal pain,aminotransferase increased,0,0.4866803288459778
STENDRA,oropharyngeal pain,aminotransferase oropharyngeal pain,1,0.8459815382957458
STENDRA,oropharyngeal pain,ophageal,0,0.652868390083313
STENDRA,oropharyngeal pain,aminotransferase oropharyngeal pain stomach discomfort vomiting Musculoskeletal muscle,1,0.7274038195610046
STENDRA,oropharyngeal pain,hypoglycemia,0,0.5034139156341553
STENDRA,oropharyngeal pain,aminotransferase oropharyngeal pain stomach discomfort vomiting Musculoskeletal,1,0.7374320030212402
STENDRA,stomach discomfort,stomach discomfort vomiting,1,0.8808026909828186
STENDRA,stomach discomfort,aminotransferase increased oropharyngeal stomach,1,0.629705548286438
STENDRA,stomach discomfort,blood glucose increased alanine aminotransferase increased oropharyngeal,0,0.5261490345001221
STENDRA,vomiting,vomiting,1,0.9999999403953552
STENDRA,vomiting,vomiting Musculoskeletal muscle spasms musculoskeletal,1,0.7381137013435364
STENDRA,vomiting,oropharyngeal pain,0,0.545263409614563
STENDRA,vomiting,stomach vomiting Musculoskeletal muscle spasms musculoskeletal pain,1,0.7238805294036865
STENDRA,vomiting,vomiting Musculoskeletal muscle,1,0.7836229205131531
STENDRA,vomiting,vomiting Musculoskeletal muscle spasms musculoskeletal pain,1,0.7157633304595947
STENDRA,muscle spasms,extremity,0,0.5845990180969238
STENDRA,muscle spasms,discomfort vomiting muscle spasms musculoskeletal pain,1,0.8081921339035034
STENDRA,muscle spasms,in extremity Nervous depression,0,0.6274887323379517
STENDRA,muscle spasms,vomiting muscle spasms musculoskeletal pain,1,0.8336901068687439
STENDRA,muscle spasms,Nervous,0,0.6169251203536987
STENDRA,muscle spasms,pain myalgia,0,0.6525603532791138
STENDRA,muscle spasms,pain stomach discomfort vomiting,0,0.571459174156189
STENDRA,muscle spasms,pain stomach discomfort vomiting muscle spasms,1,0.799121618270874
STENDRA,musculoskeletal pain,depression insomnia somnolence,0,0.5122994184494019
STENDRA,musculoskeletal pain,discomfort vomiting Musculoskeletal muscle musculoskeletal pain,1,0.8297073841094971
STENDRA,myalgia,musculoskeletal,0,0.6581206321716309
STENDRA,myalgia,discomfort vomiting Musculoskeletal muscle spasms musculoskeletal pain,0,0.6697391271591187
STENDRA,myalgia,muscle spasms musculoskeletal myalgia pain in extremity Nervous depression,1,0.7807084321975708
STENDRA,myalgia,myalgia pain in extremity,1,0.8645379543304443
STENDRA,myalgia,myalgia pain,1,0.9669764637947083
STENDRA,myalgia,myalgia pain in,1,0.9353629350662231
STENDRA,pain in extremity,spasms musculoskeletal pain myalgia,0,0.6952944993972778
STENDRA,pain in extremity,pain in extremity Nervous depression insomnia somnolence,1,0.822927713394165
STENDRA,pain in extremity,musculoskeletal pain pain,1,0.7682112455368042
STENDRA,pain in extremity,Nervous depression insomnia somnolence vertigo Respiratory cough dyspnea exer,0,0.5543544292449951
STENDRA,depression,spasms musculoskeletal pain myalgia pain in,0,0.5490926504135132
STENDRA,depression,pain in extremity depression insomnia somnolence vertigo,1,0.730270504951477
STENDRA,depression,pain in extremity depression insomnia,1,0.7268575429916382
STENDRA,depression,depression insomnia somnolence vertigo Respiratory,1,0.7882697582244873
STENDRA,depression,depression insomnia somnolence,1,0.7963029146194458
STENDRA,insomnia,Nervous depression,0,0.5848994255065918
STENDRA,insomnia,insomnia somnolence,1,0.8790011405944824
STENDRA,insomnia,Nervous insomnia,1,0.8462061285972595
STENDRA,insomnia,pain in extremity Nervous insomnia,1,0.7797837257385254
STENDRA,insomnia,epistaxis,0,0.43031346797943115
STENDRA,insomnia,exertional epistaxis wheezing Skin,0,0.41183120012283325
STENDRA,insomnia,insomnia,1,1.0000001192092896
STENDRA,insomnia,spasms musculoskeletal pain myalgia pain in extremity,0,0.5083914399147034
STENDRA,insomnia,insomnia somnolence vertigo Respiratory cough,1,0.7880099415779114
STENDRA,somnolence,extremity Nervous depression insomnia,0,0.6809727549552917
STENDRA,somnolence,somnolence vertigo Respiratory cough dyspnea exertional,1,0.7419595718383789
STENDRA,somnolence,vertigo Respiratory cough dyspnea exertional epistaxis,0,0.5437403917312622
STENDRA,somnolence,somnolence vertigo Respiratory cough dyspnea,1,0.7523725032806396
STENDRA,somnolence,depression somnolence,1,0.8683881759643555
STENDRA,somnolence,pain myalgia pain in extremity Nervous,0,0.5497760772705078
STENDRA,somnolence,depression somnolence vertigo Respiratory cough,1,0.7076873779296875
STENDRA,somnolence,somnolence vertigo,1,0.8040940165519714
STENDRA,somnolence,Respiratory,0,0.5777020454406738
STENDRA,somnolence,Skin,0,0.5333840847015381
STENDRA,cough,somnolence vertigo cough,1,0.7529230117797852
STENDRA,cough,Skin,0,0.5675919651985168
STENDRA,dyspnea exertional,insomnia somnolence vertigo Respiratory dyspnea exertional,1,0.7622895836830139
STENDRA,dyspnea exertional,dyspnea exertional,1,1.0000001192092896
STENDRA,dyspnea exertional,pruritus Urogenital balanitis,0,0.5219785571098328
STENDRA,dyspnea exertional,Respiratory dyspnea exertional epistaxis wheezing Skin and,1,0.8142589926719666
STENDRA,dyspnea exertional,Skin and Appendages,0,0.5462547540664673
STENDRA,dyspnea exertional,Respiratory,0,0.6420998573303223
STENDRA,dyspnea exertional,Respiratory dyspnea,1,0.8170298337936401
STENDRA,dyspnea exertional,dyspnea,1,0.8652383089065552
STENDRA,epistaxis,epistaxis wheezing Skin and Appendages,1,0.7498252987861633
STENDRA,epistaxis,epistaxis wheezing Skin and Appendages pruritus,1,0.7399742007255554
STENDRA,epistaxis,cough dyspnea epistaxis wheezing,1,0.7657074332237244
STENDRA,epistaxis,epistaxis wheezing,1,0.8387374877929688
STENDRA,wheezing,wheezing Skin and Appendages pruritus,1,0.7689685821533203
STENDRA,wheezing,wheezing Skin and,1,0.8898434638977051
STENDRA,wheezing,pruritus Urogenital balanitis erection,0,0.5423721075057983
STENDRA,wheezing,pruritus Urogenital balanitis,0,0.5119954347610474
STENDRA,pruritus,cough dyspnea exertional epistaxis,0,0.5507274866104126
STENDRA,pruritus,pruritus Urogenital balanitis,1,0.8080540299415588
STENDRA,pruritus,epistaxis wheezing Skin and pruritus Urogenital balanitis erection,1,0.7193650007247925
STENDRA,pruritus,Skin and pruritus Urogenital balanitis,1,0.8048477172851562
STENDRA,pruritus,pruritus Urogenital balanitis erection increased hematuria,1,0.7483431100845337
STENDRA,pruritus,Skin and pruritus,1,0.9154893159866333
STENDRA,pruritus,Skin and pruritus Urogenital,1,0.8351319432258606
STENDRA,balanitis,balanitis erection increased hematuria nephrolithiasis,1,0.7975043058395386
STENDRA,balanitis,balanitis,1,0.9999999403953552
STENDRA,balanitis,pruritus Urogenital,0,0.6098413467407227
STENDRA,balanitis,tract infection In,0,0.5770981311798096
STENDRA,balanitis,infection In an,0,0.6568422317504883
STENDRA,balanitis,and Appendages,0,0.4872385561466217
STENDRA,balanitis,Appendages pruritus balanitis,1,0.7804507613182068
STENDRA,balanitis,Urogenital,0,0.5289250016212463
STENDRA,balanitis,exertional epistaxis wheezing Skin,0,0.5569992661476135
STENDRA,erection increased,pruritus Urogenital erection,1,0.7941324710845947
STENDRA,erection increased,erection increased hematuria nephrolithiasis,1,0.7772231101989746
STENDRA,erection increased,tract infection,0,0.5082557201385498
STENDRA,erection increased,Skin and,0,0.5446128845214844
STENDRA,erection increased,Urogenital erection increased,1,0.9368022680282593
STENDRA,erection increased,tract infection In an additional randomized,0,0.514014482498169
STENDRA,erection increased,and Appendages pruritus Urogenital erection increased hematuria nephrolithiasis pollakiuria urinary,1,0.7215574979782104
STENDRA,erection increased,Urogenital erection,1,0.8847202062606812
STENDRA,hematuria,nephrolithiasis pollakiuria urinary tract infection In an additional randomized doubleblin,0,0.6782504320144653
STENDRA,hematuria,hematuria nephrolithiasis pollakiuria urinary tract,1,0.8273186683654785
STENDRA,hematuria,Urogenital,0,0.6867579221725464
STENDRA,hematuria,hematuria nephrolithiasis pollakiuria urinary,1,0.831264853477478
STENDRA,hematuria,hematuria nephrolithiasis pollakiuria,1,0.8165442943572998
STENDRA,hematuria,infection In an additional randomized,0,0.5274873971939087
STENDRA,hematuria,In an,0,0.5016451478004456
STENDRA,nephrolithiasis,nephrolithiasis pollakiuria urinary tract,1,0.8566041588783264
STENDRA,nephrolithiasis,nephrolithiasis pollakiuria,1,0.8594003915786743
STENDRA,nephrolithiasis,nephrolithiasis pollakiuria urinary tract infection In,1,0.834667444229126
STENDRA,nephrolithiasis,Urogenital balanitis erection increased nephrolithiasis pollakiuria urinary,1,0.7522593140602112
STENDRA,nephrolithiasis,nephrolithiasis,1,1.0
STENDRA,nephrolithiasis,an additional randomized,0,0.504913330078125
STENDRA,nephrolithiasis,increased nephrolithiasis pollakiuria urinary tract infection In,1,0.8195998668670654
STENDRA,pollakiuria,pollakiuria,1,1.0
STENDRA,urinary tract infection,urinary tract infection,1,1.000000238418579
STENDRA,urinary tract infection,pollakiuria,1,0.5497326850891113
STENDRA,urinary tract infection,tract infection,1,0.8207153677940369
STENDRA,urinary tract infection,urinary tract infection In an,1,0.9151351451873779
STENDRA,urinary tract infection,tract infection In,1,0.7904148101806641
STENDRA,urinary tract infection,randomized,0,0.44957053661346436
STENDRA,urinary tract infection,increased hematuria nephrolithiasis urinary tract,1,0.6895287036895752
STENDRA,change in color vision,STENDRA dose subject reported change in color,1,0.7387723922729492
STENDRA,change in color vision,in color vision Postmarketing Experience Ophthalmologic Nonarteritic anterior,1,0.7642549872398376
STENDRA,change in color vision,a,0,0.49051541090011597
STENDRA,change in color vision,STENDRA dose subject reported change in,1,0.5970137119293213
STENDRA,change in color vision,change in color vision,1,1.000000238418579
STENDRA,change in color vision,Postmarketing Experience Ophthalmologic Nonarteritic anterior ischemic optic ne,0,0.6219631433486938
STENDRA,change in color vision,change in color vision Postmarketing Experience Ophthalmologic,1,0.8526030778884888
STENDRA,Non-arteritic anterior ischemic optic neuropathy,Non-arteritic anterior ischemic optic neuropathy NAION,1,0.9770604968070984
STENDRA,Non-arteritic anterior ischemic optic neuropathy,Non-arteritic anterior ischemic optic neuropathy,1,1.0
STENDRA,Non-arteritic anterior ischemic optic neuropathy,a cause of decreased vision including permanent loss of vision has been reported rarely,0,0.6767207384109497
STENDRA,Non-arteritic anterior ischemic optic neuropathy,of vision has been,0,0.5604002475738525
STENDRA,Non-arteritic anterior ischemic optic neuropathy,Postmarketing Experience Non-arteritic anterior ischemic optic neuropathy NAION a,1,0.8932664394378662
STENDRA,Non-arteritic anterior ischemic optic neuropathy,optic neuropathy NAION a cause of decreased,1,0.7497992515563965
STENDRA,Non-arteritic anterior ischemic optic neuropathy,Non-arteritic anterior ischemic,1,0.8315482139587402
STENDRA,Non-arteritic anterior ischemic optic neuropathy,permanent loss,0,0.48409056663513184
STENDRA,NAION,Ophthalmologic Nonarteritic anterior,0,0.493294894695282
STENDRA,decreased vision,ischemic optic neuropathy NAION,0,0.6990584135055542
STENDRA,permanent loss of vision,permanent loss of vision,1,1.0
STENDRA,permanent loss of vision,permanent loss of vision has been reported rarely postmarketing,1,0.8051576018333435
STENDRA,permanent loss of vision,decreased vision permanent,1,0.9016017913818359
STENDRA,permanent loss of vision,the use of,0,0.49314719438552856
STENDRA,permanent loss of vision,permanent loss of vision has,1,0.9717292785644531
STENDRA,permanent loss of vision,cause of decreased vision permanent loss of vision has,1,0.8442058563232422
STENDRA,hypotension,the clinical trials f another,1,0.5353127717971802
STENDRA,hypotension,administered to men dur,0,0.584053635597229
STENDRA,hypotension,clinical trials of a drug cannot be directly compared to,0,0.4898236095905304
STENDRA,hypotension,clinical trials f another d,1,0.5488775372505188
STENDRA,hypotension,directly compared to rates in the clinical trials,0,0.5377804636955261
STENDRA,hypotension,in the clinical trials f another d,1,0.5473065972328186
STENDRA,hypotension,trials f,1,0.492268443107605
STENDRA,hypotension,another d rug and may not,1,0.48129209876060486
STENDRA,hypotension,f,1,0.4888807535171509
STENDRA,hypotension,another d rug and may,1,0.47825634479522705
STENDRA,cardiac risk,"patients treated with RA 50 mg, 10 mg or mg was and",1,0.47710147500038147
STENDRA,cardiac risk,another d rug and may,1,0.4660072326660156
STENDRA,cardiac risk,respectively compared,0,0.4785073697566986
STENDRA,cardiac risk,discontinuation rate due to adverse reactions for patients,0,0.5413129329681396
STENDRA,cardiac risk,due to adverse reactions for patients treated,0,0.5566134452819824
STENDRA,cardiac risk,"RA 50 mg, 10 mg",1,0.5172483921051025
STENDRA,cardiac risk,"RA 50 mg, 10",1,0.5111410021781921
STENDRA,cardiac risk,or mg was and respectively compared to for placebotreated,0,0.453479528427124
STENDRA,cardiac risk,"50 mg, 10 mg or mg was and",1,0.4858109951019287
STENDRA,cardiac risk,RA,1,0.48880112171173096
STENDRA,cardiac risk,"for patients treated with RA 50 mg, 10",1,0.4914432168006897
STENDRA,non-arteritic anterior ischemic optic neuropathy,STENDRA is uncertain. Excluded from this li,1,0.4764454662799835
STENDRA,non-arteritic anterior ischemic optic neuropathy,this li st,1,0.4403355121612549
STENDRA,non-arteritic anterior ischemic optic neuropathy,A causal p to STENDRA is uncertain. Excluded,1,0.4986809492111206
STENDRA,non-arteritic anterior ischemic optic neuropathy,events that,0,0.4339991807937622
STENDRA,non-arteritic anterior ischemic optic neuropathy,uncertain. Excluded from this li st are those events that,1,0.4851548671722412
STENDRA,NAION,lasting months A causal relationship to STENDRA is,0,0.4705633521080017
STENDRA,NAION, are  those events that,1,0.5030896663665771
STENDRA,NAION, are  those events that were,1,0.5105229020118713
STENDRA,NAION, are  those,1,0.528561532497406
STENDRA,NAION,A,0,0.5782680511474609
STENDRA,NAION, are ,1,0.5598365068435669
STENDRA,NAION,reports too,0,0.4995032548904419
STENDRA,NAION,relationship to STENDRA is uncertain Excluded from this list,0,0.4803839921951294
STENDRA,NAION, are  those events that were minor,1,0.5025526881217957
STENDRA,decreased vision,with no plausib,1,0.453199565410614
STENDRA,decreased vision,minor,0,0.5373722314834595
STENDRA,permanent loss of vision,imprecise to be meaningful Body as a,0,0.44454893469810486
STENDRA,permanent loss of vision,"no plausible  to drug use, and report s too imprecise to be",1,0.4665732681751251
STENDRA,permanent loss of vision,"no plausible to drug use, and report",1,0.49419865012168884
STENDRA,permanent loss of vision,those,0,0.47140997648239136
STENDRA,NAION,pain,0,0.5274214744567871
STENDRA,NAION,"rt, v omiting Musculoskeletal muscle",1,0.48083147406578064
STENDRA,NAION,"rt, v omiting Musculoskeletal",1,0.50652015209198
STENDRA,NAION,"pain stomach rt, v omiting Musculoskeletal muscle spasms musculoskeletal",1,0.4691687226295471
STENDRA,NAION,Musculoskeletal muscle spasms musculoskeletal,0,0.4446735978126526
STENDRA,NAION,increased,0,0.5064919590950012
STENDRA,NAION,muscle spasms musculoskeletal,0,0.46509629487991333
STENDRA,NAION,"increased oropharyngeal pain stomach rt, v",1,0.46833154559135437
STENDRA,NAION,"musculoskeletal , mya",1,0.49564966559410095
STENDRA,NAION,Musculoskeletal muscle spasms,0,0.45786768198013306
STENDRA,symptomatic hypotension,of an erection sufficient,0,0.5727261304855347
STENDRA,symptomatic hypotension,"time to onset of of STENDRA, defined",1,0.549151599407196
STENDRA,dizziness,defined as the e to the,1,0.48693376779556274
STENDRA,dizziness,STENDRA defined as the e to the  first occurrence of an,1,0.4941243529319763
STENDRA,lightheadedness,of an erection sufficient for sexual intercourse Table presents the adverse reactions,0,0.5865304470062256
STENDRA,lightheadedness,of STENDRA defined as the time to the,0,0.5074005126953125
STENDRA,lightheadedness,for sexual intercourse Table presents the adverse reactions,0,0.5845082998275757
STENDRA,lightheadedness,to the rst occurrence,1,0.4889216423034668
STENDRA,fainting,to the first occurrence an,1,0.5185514688491821
STENDRA,symptomatic hypotension,Lasting Months o Determine the Time to,1,0.44596290588378906
STENDRA,symptomatic hypotension,Determine the Time to Onset of Effect Study Adverse,1,0.555077075958252
ADCETRIS,Peripheral Neuropathy,the prescribing Peripheral Neuropathy,1,0.8705597519874573
ADCETRIS,Peripheral Neuropathy,Peripheral,1,0.7185572385787964
ADCETRIS,Peripheral Neuropathy,of the prescribing information,0,0.481831818819046
ADCETRIS,Peripheral Neuropathy,of the prescribing Peripheral,1,0.7235270738601685
ADCETRIS,Anaphylaxis,Anaphylaxis and,1,0.9257369637489319
ADCETRIS,Anaphylaxis,Infusion,0,0.5476686954498291
ADCETRIS,Infusion Reactions,Infusion Reactions see Warnings and Precautions Hematologic,1,0.8632137775421143
ADCETRIS,Infusion Reactions,Neuropathy see,0,0.5487325191497803
ADCETRIS,Infusion Reactions,Anaphylaxis and,0,0.6684918403625488
ADCETRIS,Infusion Reactions,Warnings and Precautions,0,0.5853530764579773
ADCETRIS,Infusion Reactions,Neuropathy see Warnings and,0,0.5735033750534058
ADCETRIS,Hematologic Toxicities,Hematologic Toxicities see Warnings and Precautions Serious,1,0.9352569580078125
ADCETRIS,Infections,and Precautions Infections and Opportunistic Infections see Warnings,1,0.7552826404571533
ADCETRIS,Infections,Hematologic Toxicities see Warnings and Precautions Serious,1,0.5937991142272949
ADCETRIS,Infections,Infections,1,1.000000238418579
ADCETRIS,Infections,Infections and Opportunistic Infections see,1,0.8233639001846313
ADCETRIS,Infections,Infections and Opportunistic Infections,1,0.826484203338623
ADCETRIS,Infections,Toxicities see Warnings and Precautions Serious,0,0.5931051969528198
ADCETRIS,Opportunistic Infections,Opportunistic Infections,1,0.9999997615814209
ADCETRIS,Opportunistic Infections,Opportunistic Infections see Warnings and Precautions,1,0.8691237568855286
ADCETRIS,Opportunistic Infections,Precautions Tumor Lysis Syndrome see Warnings and P,0,0.5703915953636169
ADCETRIS,Opportunistic Infections,Precautions Serious Infections,0,0.6705445647239685
ADCETRIS,Opportunistic Infections,Precautions Serious Infections Opportunistic Infections,1,0.870570182800293
ADCETRIS,Opportunistic Infections,see Warnings,0,0.5360846519470215
ADCETRIS,Tumor Lysis Syndrome,see Warnings and Tumor Lysis Syndrome see Warnings and Precautions,1,0.8138195276260376
ADCETRIS,Tumor Lysis Syndrome,see Warnings,0,0.4917941689491272
ADCETRIS,Tumor Lysis Syndrome,Presence of,0,0.5005651712417603
ADCETRIS,Tumor Lysis Syndrome,and Tumor,1,0.6769051551818848
ADCETRIS,Tumor Lysis Syndrome,and Tumor Lysis Syndrome see Warnings and,1,0.8748478293418884
ADCETRIS,Tumor Lysis Syndrome,Tumor Lysis Syndrome see,1,0.9741637110710144
ADCETRIS,Tumor Lysis Syndrome,see Warnings and Precautions,0,0.4524320363998413
ADCETRIS,Tumor Lysis Syndrome,Warnings and Tumor Lysis,1,0.7930456399917603
ADCETRIS,Increased Toxicity,and Increased Toxicity in the,1,0.9683244824409485
ADCETRIS,Increased Toxicity,Warnings and Tumor Lysis,1,0.6184883713722229
ADCETRIS,Increased Toxicity,Syndrome see Warnings and Increased Toxicity in the Presence,1,0.8102242350578308
ADCETRIS,Increased Toxicity,Impairment see,0,0.5806020498275757
ADCETRIS,Increased Toxicity,Syndrome see Warnings,0,0.6124751567840576
ADCETRIS,Increased Toxicity,Tumor Lysis Syndrome see,0,0.5600830316543579
ADCETRIS,Increased Toxicity,Presence of Severe Renal,0,0.5950981378555298
ADCETRIS,Increased Toxicity,Syndrome see Warnings and Increased Toxicity in the Presence of,1,0.797812819480896
ADCETRIS,Increased Toxicity,Lysis Syndrome see,0,0.5614708065986633
ADCETRIS,Increased Toxicity,see Warnings and Increased Toxicity,1,0.9011096954345703
ADCETRIS,Increased Toxicity,Increased Toxicity,1,0.9999999403953552
ADCETRIS,Increased Toxicity,see Warnings,0,0.6212691068649292
ADCETRIS,Increased Toxicity,Severe Hepatic Impairment,0,0.6331139802932739
ADCETRIS,Increased Toxicity,and Increased Toxicity,1,0.9809359908103943
ADCETRIS,Increased Toxicity,Increased Toxicity in the Presence of Moderate,1,0.8962833881378174
ADCETRIS,Increased Toxicity,of Moderate or,0,0.47207111120224
ADCETRIS,Increased Toxicity,Increased Toxicity in the,1,0.9776396751403809
ADCETRIS,Increased Toxicity,Increased Toxicity in,1,0.9811060428619385
ADCETRIS,Increased Toxicity,of Moderate,0,0.4545288383960724
ADCETRIS,Hepatotoxicity,Warnings and Hepatotoxicity,1,0.8649801015853882
ADCETRIS,Hepatotoxicity,Severe Hepatic Impairment,0,0.7514182925224304
ADCETRIS,Hepatotoxicity,Impairment see Warnings,0,0.6069595813751221
ADCETRIS,Hepatotoxicity,Progressive,0,0.49284231662750244
ADCETRIS,Hepatotoxicity,see Warnings and Precautions Progressive,0,0.5598060488700867
ADCETRIS,Hepatotoxicity,and Hepatotoxicity see Warnings and,1,0.8921557664871216
ADCETRIS,Hepatotoxicity,Warnings and Hepatotoxicity see Warnings and Precautions Progressive,1,0.8204652070999146
ADCETRIS,Hepatotoxicity,of Moderate or Severe Hepatic Impairment see Warnings and Precautions,0,0.7269864082336426
ADCETRIS,Hepatotoxicity,Hepatotoxicity,1,1.0
ADCETRIS,Hepatotoxicity,see Warnings and Precautions,0,0.5665377378463745
ADCETRIS,Hepatotoxicity,see Warnings and Hepatotoxicity see Warnings,1,0.8653007745742798
ADCETRIS,Progressive Multifocal Leukoencephalopathy,see Warnings and Progressive Multifocal Leukoencephalopathy see,1,0.8963165283203125
ADCETRIS,Progressive Multifocal Leukoencephalopathy,see Warnings and Precautions,0,0.501007080078125
ADCETRIS,Progressive Multifocal Leukoencephalopathy,see Warnings,0,0.526826798915863
ADCETRIS,Progressive Multifocal Leukoencephalopathy,Multifocal Leukoencephalopathy see Warnings and Precautions Pulmonary,1,0.8307547569274902
ADCETRIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings and,1,0.9051858186721802
ADCETRIS,Pulmonary Toxicity,Warnings and Pulmonary Toxicity,1,0.8648669123649597
ADCETRIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings and Precautions Serious,1,0.8800075054168701
ADCETRIS,Pulmonary Toxicity,and Pulmonary Toxicity see Warnings and Precautions,1,0.8581411242485046
ADCETRIS,Pulmonary Toxicity,see Warnings and Pulmonary Toxicity,1,0.8625991344451904
ADCETRIS,Pulmonary Toxicity,and,0,0.471709668636322
ADCETRIS,Pulmonary Toxicity,Leukoencephalopathy see Warnings and Pulmonary Toxicity see Warnings and Precautions Serious,1,0.7668893337249756
ADCETRIS,Dermatologic Reactions,see Warnings and Precautions Dermatologic Reactions see Warnings,1,0.8600436449050903
ADCETRIS,Dermatologic Reactions,and,0,0.4670735001564026
ADCETRIS,Dermatologic Reactions,Warnings and Precautions Dermatologic,1,0.7795931100845337
ADCETRIS,Dermatologic Reactions,Dermatologic Reactions see Warnings and Precautions,1,0.8924001455307007
ADCETRIS,Dermatologic Reactions,Warnings and Precautions,0,0.5564755201339722
ADCETRIS,Dermatologic Reactions,and Precautions EXCERPT The most common adverse reactions,0,0.6816275119781494
ADCETRIS,Dermatologic Reactions,Warnings and Precautions Dermatologic Reactions,1,0.9006989002227783
ADCETRIS,Dermatologic Reactions,Precautions,0,0.5633094310760498
ADCETRIS,Dermatologic Reactions,Dermatologic Reactions see,1,0.9886579513549805
ADCETRIS,Dermatologic Reactions,Serious,0,0.5572972893714905
ADCETRIS,neutropenia,neutropenia,1,1.0
ADCETRIS,neutropenia,Serious,0,0.5266036987304688
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue,1,0.780876874923706
ADCETRIS,neutropenia,neutropenia peripheral,1,0.8545266389846802
ADCETRIS,neutropenia,HL and relapsed neutropenia peripheral sensory,1,0.7652086615562439
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue nausea,1,0.8124300241470337
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy,1,0.8228118419647217
ADCETRIS,neutropenia,neutropenia peripheral sensory,1,0.8049640655517578
ADCETRIS,neutropenia,sensory neuropathy fatigue nausea anemia upper respiratory,0,0.6074879765510559
ADCETRIS,peripheral sensory neuropathy,HL and relapsed sALCL peripheral,1,0.6139564514160156
ADCETRIS,peripheral sensory neuropathy,diarrhea pyrexia,0,0.527115523815155
ADCETRIS,peripheral sensory neuropathy,relapsed,0,0.48287543654441833
ADCETRIS,peripheral sensory neuropathy,sALCL peripheral sensory neuropathy,1,0.9266974925994873
ADCETRIS,fatigue,pyrexia rash,0,0.5563708543777466
ADCETRIS,fatigue,respiratory,0,0.5713639259338379
ADCETRIS,fatigue,rash,0,0.5751873254776001
ADCETRIS,fatigue,sensory fatigue nausea anemia upper respiratory tract,1,0.7575631141662598
ADCETRIS,fatigue,fatigue nausea anemia,1,0.8388357162475586
ADCETRIS,nausea,nausea anemia upper respiratory tract,1,0.7967519760131836
ADCETRIS,nausea,fatigue nausea anemia,1,0.7842794060707092
ADCETRIS,nausea,nausea,1,1.0
ADCETRIS,anemia,sensory neuropathy fatigue anemia upper,1,0.7482711672782898
ADCETRIS,anemia,nausea,1,0.6042536497116089
ADCETRIS,anemia,sALCL neutropenia peripheral sensory neuropathy fatigue nausea,0,0.6487738490104675
ADCETRIS,anemia,anemia,1,1.0
ADCETRIS,anemia,anemia upper respiratory tract infection diarrhea,1,0.7553746700286865
ADCETRIS,anemia,anemia upper respiratory,1,0.7799080610275269
ADCETRIS,anemia,neuropathy fatigue nausea,0,0.5966442823410034
ADCETRIS,upper respiratory tract infection,peripheral sensory neuropathy,0,0.49575284123420715
ADCETRIS,upper respiratory tract infection,cough and vomiting,0,0.6538978815078735
ADCETRIS,upper respiratory tract infection,pyrexia rash thrombocytopenia,0,0.5340122580528259
ADCETRIS,upper respiratory tract infection,pyrexia rash thrombocytopenia cough,0,0.6014503240585327
ADCETRIS,upper respiratory tract infection,neuropathy fatigue nausea upper respiratory tract infection diarrhea pyrexia rash,1,0.6767760515213013
ADCETRIS,upper respiratory tract infection,upper respiratory tract infection diarrhea,1,0.8611465096473694
ADCETRIS,upper respiratory tract infection,diarrhea pyrexia rash thrombocytopenia cough,0,0.5945557355880737
ADCETRIS,upper respiratory tract infection,upper respiratory tract,1,0.8921869993209839
ADCETRIS,upper respiratory tract infection,upper respiratory tract infection diarrhea pyrexia rash thrombocytopenia cough,1,0.7930673360824585
ADCETRIS,diarrhea,diarrhea pyrexia rash thrombocytopenia cough and,1,0.7285429239273071
ADCETRIS,diarrhea,ropenia peripheral sensory neuropathy,0,0.5104750394821167
ADCETRIS,diarrhea,tract diarrhea,1,0.8040386438369751
ADCETRIS,diarrhea,HL,0,0.5431876182556152
ADCETRIS,diarrhea,diarrhea pyrexia,1,0.7626122236251831
ADCETRIS,diarrhea,infection,0,0.6666979789733887
ADCETRIS,pyrexia,diarrhea,0,0.5893706679344177
ADCETRIS,pyrexia,pyrexia rash thrombocytopenia cough,1,0.8053949475288391
ADCETRIS,pyrexia,pyrexia,1,1.0000001192092896
ADCETRIS,pyrexia,tract infection pyrexia rash thrombocytopenia cough and,1,0.7721649408340454
ADCETRIS,pyrexia,nausea anemia upper respiratory,0,0.6468911170959473
ADCETRIS,pyrexia,infection pyrexia rash thrombocytopenia cough and vomiting,1,0.7805532217025757
ADCETRIS,pyrexia,pyrexia rash,1,0.8880088329315186
ADCETRIS,pyrexia,thrombocytopenia cough and vomiting Classical,0,0.6181721687316895
ADCETRIS,rash,rash thrombocytopenia cough,1,0.6885972023010254
ADCETRIS,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
ADCETRIS,thrombocytopenia,pyrexia thrombocytopenia,1,0.8389698266983032
ADCETRIS,thrombocytopenia,thrombocytopenia cough and vomiting Classical,1,0.8233520984649658
ADCETRIS,thrombocytopenia,respiratory tract infection,0,0.4903469383716583
ADCETRIS,thrombocytopenia,pyrexia,0,0.5793038606643677
ADCETRIS,thrombocytopenia,HL,0,0.5176900029182434
ADCETRIS,thrombocytopenia,infection diarrhea pyrexia thrombocytopenia cough and vomiting Classical HL,1,0.6677738428115845
ADCETRIS,thrombocytopenia,thrombocytopenia cough and,1,0.8661165237426758
ADCETRIS,thrombocytopenia,infection diarrhea pyrexia thrombocytopenia,1,0.7932244539260864
ADCETRIS,cough,cough and vomiting Classical,1,0.7710344195365906
ADCETRIS,cough,cough and,1,0.9321798086166382
ADCETRIS,vomiting,postautoHSCT consolidation neutropenia peripheral sensory neuropath,0,0.4997406601905823
ADCETRIS,neutropenia,sh thrombocytopenia cough and vomiting Classical HL,0,0.66954505443573
ADCETRIS,neutropenia,thrombocytopenia cough and vomiting Classical HL,0,0.6682194471359253
ADCETRIS,neutropenia,vomiting Classical HL,0,0.6015714406967163
ADCETRIS,neutropenia,upper respiratory tract,0,0.4926103353500366
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy thrombocytopenia,1,0.8008016347885132
ADCETRIS,neutropenia,upper respiratory tract infection,0,0.5429164171218872
ADCETRIS,neutropenia,thrombocytopenia cough and vomiting,0,0.6467880010604858
ADCETRIS,peripheral sensory neuropathy,Classical HL postautoHSCT consolidation peripheral sensory,1,0.709410548210144
ADCETRIS,peripheral sensory neuropathy,HL postautoHSCT consolidation neutropenia,0,0.4900607466697693
ADCETRIS,thrombocytopenia,HL postautoHSCT consolidation neutropenia,0,0.6181787252426147
ADCETRIS,thrombocytopenia,thrombocytopenia anemia upper respiratory tract,1,0.786179780960083
ADCETRIS,anemia,motor neuropathy nausea,0,0.5209053754806519
ADCETRIS,anemia,anemia upper,1,0.8311767578125
ADCETRIS,upper respiratory tract infection,neuropathy thrombocytopenia upper respiratory tract,1,0.6956000328063965
ADCETRIS,upper respiratory tract infection,peripheral motor neuropathy nausea cough and,0,0.5965874195098877
ADCETRIS,upper respiratory tract infection,upper respiratory tract infection fatigue peripheral motor,1,0.7768290638923645
ADCETRIS,upper respiratory tract infection,neuropathy thrombocytopenia anemia,0,0.46196621656417847
ADCETRIS,upper respiratory tract infection,upper,1,0.6525404453277588
ADCETRIS,upper respiratory tract infection,thrombocytopenia upper respiratory tract,1,0.72051602602005
ADCETRIS,upper respiratory tract infection,tract infection fatigue peripheral,1,0.6413953304290771
ADCETRIS,upper respiratory tract infection,sensory neuropathy thrombocytopenia anemia,0,0.4861449897289276
ADCETRIS,upper respiratory tract infection,diarrhea To,0,0.5668466091156006
ADCETRIS,fatigue,respiratory tract fatigue peripheral motor neuropathy nausea cough,1,0.7402480244636536
ADCETRIS,fatigue,diarrhea To,0,0.5515000820159912
ADCETRIS,fatigue,fatigue peripheral motor,1,0.7775874137878418
ADCETRIS,fatigue,openia,0,0.4703805446624756
ADCETRIS,fatigue,fatigue peripheral,1,0.8139448165893555
ADCETRIS,fatigue,To report,0,0.5489730834960938
ADCETRIS,peripheral motor neuropathy,fatigue,0,0.5687844753265381
ADCETRIS,peripheral motor neuropathy,peripheral motor neuropathy nausea cough and diarrhea,1,0.8535140752792358
ADCETRIS,nausea,nausea cough and,1,0.8609613180160522
ADCETRIS,nausea,nausea cough and diarrhea To report,1,0.7899281978607178
ADCETRIS,nausea,fatigue peripheral motor neuropathy,0,0.5454703569412231
ADCETRIS,nausea,nausea cough and diarrhea To,1,0.8013186454772949
ADCETRIS,nausea,infection fatigue peripheral motor nausea cough and diarrhea To report,1,0.7165405750274658
ADCETRIS,nausea,nausea cough,1,0.870718240737915
ADCETRIS,cough,cough and diarrhea To report,1,0.7702441215515137
ADCETRIS,cough,respiratory tract infection fatigue peripheral motor,0,0.6306301951408386
ADCETRIS,cough,tract infection fatigue,0,0.6101710796356201
ADCETRIS,cough,cough and diarrhea,1,0.8000437617301941
ADCETRIS,cough,cough and diarrhea To report SUSPECTED,1,0.7481822967529297
ADCETRIS,cough,cough and diarrhea To,1,0.8066924810409546
ADCETRIS,cough,diarrhea To report SUSPECTED ADVERSE REACTIONS contact Seattle,0,0.554915189743042
ADCETRIS,diarrhea,diarrhea,1,0.9999999403953552
ADCETRIS,diarrhea,SUSPECTED ADVERSE REACTIONS,0,0.5718289017677307
ADCETRIS,diarrhea,diarrhea To,1,0.9007161855697632
ADCETRIS,diarrhea,neuropathy,0,0.577670693397522
ADCETRIS,neutropenia,regardless of,0,0.4804241955280304
ADCETRIS,neutropenia,regardless of causality neutropenia peripheral,1,0.8132383823394775
ADCETRIS,neutropenia,causality were,0,0.4663998484611511
ADCETRIS,neutropenia,regardless of causality neutropenia,1,0.8457685708999634
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy,1,1.000000238418579
ADCETRIS,peripheral sensory neuropathy,causality were peripheral sensory neuropathy,1,0.9109201431274414
ADCETRIS,peripheral sensory neuropathy,fatigue nausea anemia upper,0,0.559093177318573
ADCETRIS,peripheral sensory neuropathy,diarrhea pyrexia rash thrombocytope,0,0.5526918172836304
ADCETRIS,peripheral sensory neuropathy,causality were,0,0.48788443207740784
ADCETRIS,peripheral sensory neuropathy,the most common adverse reactions regardless,0,0.5301719307899475
ADCETRIS,peripheral sensory neuropathy,causality were neutropenia,0,0.5455873608589172
ADCETRIS,peripheral sensory neuropathy,anemia upper respiratory tract,0,0.5250389575958252
ADCETRIS,peripheral sensory neuropathy,were peripheral sensory neuropathy,1,0.9863841533660889
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy fatigue nausea anemia,1,0.8424142599105835
ADCETRIS,fatigue,of causality,0,0.510026216506958
ADCETRIS,fatigue,neutropenia peripheral sensory fatigue,1,0.7437745332717896
ADCETRIS,fatigue,fatigue nausea anemia upper,1,0.805420994758606
ADCETRIS,fatigue,dverse reactions regardless of causality were neutropenia peripheral sensory,0,0.5298433899879456
ADCETRIS,fatigue,fatigue nausea anemia upper respiratory tract,1,0.7776836156845093
ADCETRIS,fatigue,sensory fatigue nausea anemia,1,0.7858328819274902
ADCETRIS,fatigue,pyrexia,0,0.5931437611579895
ADCETRIS,fatigue,fatigue nausea,1,0.8762108683586121
ADCETRIS,nausea,nausea anemia upper respiratory,1,0.7961645722389221
ADCETRIS,nausea,fatigue,0,0.684320867061615
ADCETRIS,anemia,neuropathy fatigue anemia upper respiratory tract infection diarrhea,1,0.6806584596633911
ADCETRIS,anemia,fatigue,0,0.6574997901916504
ADCETRIS,anemia,regardless of causality were neutropenia peripheral sensory,0,0.640608012676239
ADCETRIS,anemia,anemia upper respiratory tract,1,0.7776696681976318
ADCETRIS,anemia,causality,0,0.5613227486610413
ADCETRIS,anemia,infection diarrhea pyrexia rash thrombocytopenia cough,0,0.5781958103179932
ADCETRIS,upper respiratory tract infection,regardless of causality were neutropenia peripheral sensory neuropathy fatigue nausea,0,0.535914957523346
ADCETRIS,diarrhea,fatigue nausea anemia upper,0,0.565423309803009
ADCETRIS,diarrhea,diarrhea pyrexia rash thrombocytopenia cough,1,0.7307207584381104
ADCETRIS,diarrhea,thrombocytopenia cough and vomiting The most common,0,0.5709279775619507
ADCETRIS,pyrexia,tract,0,0.5179157257080078
ADCETRIS,pyrexia,pyrexia rash thrombocytopenia,1,0.8038715124130249
ADCETRIS,pyrexia,tract infection pyrexia rash thrombocytopenia cough,1,0.7686363458633423
ADCETRIS,pyrexia,The most,0,0.48278361558914185
ADCETRIS,rash,tract,0,0.5458565950393677
ADCETRIS,rash,pyrexia,0,0.5958070158958435
ADCETRIS,rash,diarrhea rash,1,0.8103918433189392
ADCETRIS,rash,diarrhea rash thrombocytopenia cough and,1,0.6995327472686768
ADCETRIS,rash,rash thrombocytopenia cough and,1,0.7095651626586914
ADCETRIS,rash,rash,1,1.0000001192092896
ADCETRIS,rash,rash thrombocytopenia cough and vomiting,1,0.6894445419311523
ADCETRIS,thrombocytopenia,thrombocytopenia cough and vomiting The most,1,0.8122896552085876
ADCETRIS,thrombocytopenia,respiratory tract infection diarrhea pyrexia rash,0,0.4823046326637268
ADCETRIS,thrombocytopenia,thrombocytopenia cough and vomiting The,1,0.8314996361732483
ADCETRIS,thrombocytopenia,thrombocytopenia cough,1,0.8650206327438354
ADCETRIS,thrombocytopenia,diarrhea pyrexia thrombocytopenia cough,1,0.7532294988632202
ADCETRIS,thrombocytopenia,infection diarrhea pyrexia thrombocytopenia cough and,1,0.7405726909637451
ADCETRIS,cough,cough and vomiting The,1,0.8130465149879456
ADCETRIS,cough,anemia upper respiratory tract infection,0,0.6198613047599792
ADCETRIS,cough,least of patients in,0,0.49204105138778687
ADCETRIS,cough,cough and vomiting The most common,1,0.7621781826019287
ADCETRIS,cough,adverse reactions occurring in at least of patients in either,0,0.5352790951728821
ADCETRIS,cough,cough and vomiting,1,0.8239437341690063
ADCETRIS,cough,rash thrombocytopenia,0,0.5176033973693848
ADCETRIS,vomiting,infection diarrhea pyrexia rash thrombocytopenia cough,0,0.6396136283874512
ADCETRIS,vomiting,vomiting The most common adverse reactions,1,0.833771288394928
ADCETRIS,vomiting,vomiting The,1,0.9778169393539429
ADCETRIS,vomiting,most common adverse reactions occurring in at least of patients in either Study or re,0,0.5649027228355408
ADCETRIS,vomiting,occurring in at least of patients,0,0.5877382755279541
ADCETRIS,vomiting,infection diarrhea pyrexia rash,0,0.6184113025665283
ADCETRIS,vomiting,vomiting The most common adverse,1,0.868133544921875
ADCETRIS,vomiting,anemia upper respiratory tract infection diarrhea pyrexia rash thrombocytopenia,0,0.6240049600601196
ADCETRIS,neutropenia,peripheral sensory neuropathy thrombocytopenia anemia upper respiratory,0,0.6712626218795776
ADCETRIS,peripheral sensory neuropathy,regardless of causality were peripheral sensory neuropathy,1,0.8759088516235352
ADCETRIS,peripheral sensory neuropathy,fatigue peripheral motor,0,0.6910257339477539
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy thrombocytopenia anemia,1,0.8735820651054382
ADCETRIS,peripheral sensory neuropathy,tract infection fatigue peripheral motor,0,0.6947805881500244
ADCETRIS,thrombocytopenia,thrombocytopenia anemia upper respiratory tract infection,1,0.7912688851356506
ADCETRIS,thrombocytopenia,peripheral motor neuropathy nausea cough,0,0.5092903971672058
ADCETRIS,thrombocytopenia,anemia upper respiratory tract infection fatigue peripheral motor neuropathy,0,0.5523165464401245
ADCETRIS,thrombocytopenia,thrombocytopenia anemia,1,0.9114134311676025
ADCETRIS,thrombocytopenia,fatigue peripheral,0,0.5360837578773499
ADCETRIS,anemia,neutropenia,0,0.7147142291069031
ADCETRIS,anemia,peripheral sensory neuropathy anemia,1,0.7931691408157349
ADCETRIS,anemia,nt arm,0,0.5269131660461426
ADCETRIS,anemia,of causality,0,0.5254379510879517
ADCETRIS,anemia,arm regardless of causality,0,0.5219146013259888
ADCETRIS,anemia,arm regardless of causality were neutropenia,0,0.6540514826774597
ADCETRIS,upper respiratory tract infection,respiratory tract infection fatigue,1,0.7670494318008423
ADCETRIS,fatigue,fatigue peripheral motor neuropathy nausea cough,1,0.794693112373352
ADCETRIS,fatigue,diarrhea,0,0.5677722692489624
ADCETRIS,fatigue,and diarrhea The most common,0,0.5381283760070801
ADCETRIS,peripheral motor neuropathy,infection peripheral motor neuropathy,1,0.9102129936218262
ADCETRIS,peripheral motor neuropathy,motor neuropathy nausea cough and diarrhea,1,0.7996323108673096
ADCETRIS,nausea,nausea cough and diarrhea,1,0.8038415312767029
ADCETRIS,nausea,infection fatigue peripheral motor nausea cough and,1,0.7279818058013916
ADCETRIS,nausea,occurring in at least of patients,0,0.6021009683609009
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue upper,1,0.785365641117096
ADCETRIS,peripheral sensory neuropathy,causality were peripheral sensory neuropathy fatigue upper,1,0.8670540452003479
ADCETRIS,peripheral sensory neuropathy,neutropenia peripheral sensory neuropathy fatigue upper,1,0.8109555244445801
ADCETRIS,peripheral sensory neuropathy,peripheral sensory,1,0.8515010476112366
ADCETRIS,peripheral sensory neuropathy,infection nausea,0,0.49545952677726746
ADCETRIS,peripheral sensory neuropathy,upper respiratory tract infection nausea,0,0.48679319024086
ADCETRIS,peripheral sensory neuropathy,reactions regardless of causality,0,0.4778250455856323
ADCETRIS,peripheral sensory neuropathy,were peripheral sensory neuropathy fatigue upper respiratory tract infection,1,0.8270320892333984
ADCETRIS,peripheral sensory neuropathy,of causality,0,0.4768333435058594
ADCETRIS,peripheral sensory neuropathy,infection nausea diarrhea anemia pyrexia thrombocytopenia,0,0.5447872281074524
ADCETRIS,fatigue,fatigue,1,1.0
ADCETRIS,fatigue,thrombocytopenia,0,0.5307615995407104
ADCETRIS,fatigue,neutropenia peripheral sensory,0,0.5534656047821045
ADCETRIS,fatigue,neutropenia peripheral sensory neuropathy,0,0.5514814853668213
ADCETRIS,fatigue,were neutropenia peripheral sensory fatigue upper respiratory tract infection,1,0.7140800952911377
ADCETRIS,fatigue,reactions regardless of causality were neutropenia peripheral sensory neuropathy,0,0.5178974866867065
ADCETRIS,fatigue,diarrhea anemia,0,0.5649365782737732
ADCETRIS,upper respiratory tract infection,abdominal pain,0,0.5089872479438782
ADCETRIS,upper respiratory tract infection,neuropathy upper respiratory tract infection nausea diarrhea anemia pyrexia,1,0.7191275358200073
ADCETRIS,upper respiratory tract infection,anemia pyrexia thrombocytopenia,0,0.5153367519378662
ADCETRIS,nausea,respiratory tract nausea diarrhea anemia pyrexia,1,0.7574944496154785
ADCETRIS,nausea,anemia pyrexia thrombocytopenia,0,0.6004815101623535
ADCETRIS,diarrhea,diarrhea anemia pyrexia,1,0.76073157787323
ADCETRIS,anemia,anemia pyrexia thrombocytopenia rash abdominal pain,1,0.7520604729652405
ADCETRIS,anemia,pain cough and vomiting,0,0.4987086057662964
ADCETRIS,anemia,anemia pyrexia thrombocytopenia,1,0.7354720830917358
ADCETRIS,anemia,cough and vomiting,0,0.5041800737380981
ADCETRIS,anemia,Summary of Clinical,0,0.5447808504104614
ADCETRIS,anemia,anemia pyrexia thrombocytopenia rash,1,0.7410445213317871
ADCETRIS,anemia,anemia pyrexia thrombocytopenia rash abdominal,1,0.7292822599411011
ADCETRIS,anemia,respiratory tract,0,0.504143476486206
ADCETRIS,pyrexia,vomiting Summary of Clinical Trial Exp,0,0.5923958420753479
ADCETRIS,pyrexia,sensory neuropathy fatigue upper respiratory tract,0,0.585539698600769
ADCETRIS,pyrexia,pyrexia thrombocytopenia rash abdominal,1,0.789188027381897
ADCETRIS,pyrexia,diarrhea pyrexia thrombocytopenia rash abdominal,1,0.7344105243682861
ADCETRIS,pyrexia,nausea diarrhea pyrexia thrombocytopenia,1,0.7629421949386597
ADCETRIS,thrombocytopenia,thrombocytopenia rash abdominal pain cough and,1,0.802343487739563
ADCETRIS,thrombocytopenia,tract infection nausea diarrhea,0,0.4792358875274658
ADCETRIS,thrombocytopenia,fatigue upper respiratory tract infection,0,0.48389387130737305
ADCETRIS,thrombocytopenia,nausea diarrhea anemia thrombocytopenia,1,0.7958799600601196
ADCETRIS,thrombocytopenia,and vomiting Summary of Clinical,0,0.5394454598426819
ADCETRIS,rash,of Clinical Trial Experience,0,0.5030400156974792
ADCETRIS,rash,respiratory tract infection nausea diarrhea anemia,0,0.5843566060066223
ADCETRIS,rash,diarrhea anemia pyrexia,0,0.5785953998565674
ADCETRIS,abdominal pain,abdominal pain cough and,1,0.8763765692710876
ADCETRIS,abdominal pain,pyrexia thrombocytopenia abdominal pain cough and,1,0.7148072719573975
ADCETRIS,abdominal pain,anemia pyrexia thrombocytopenia abdominal pain cough and vomiting Summary of,1,0.6872479915618896
ADCETRIS,abdominal pain,abdominal pain cough and vomiting,1,0.8410482406616211
ADCETRIS,cough,cough,1,1.0
ADCETRIS,cough,diarrhea anemia,0,0.5053057670593262
ADCETRIS,cough,tract infection,0,0.6290634870529175
ADCETRIS,cough,nausea diarrhea,0,0.617611289024353
ADCETRIS,cough,cough and vomiting Summary of,1,0.7822592258453369
ADCETRIS,cough,thrombocytopenia rash abdominal cough and vomiting Summary of,1,0.684491753578186
ADCETRIS,vomiting,vomiting,1,0.9999999403953552
ADCETRIS,vomiting,rash abdominal pain cough and,0,0.6684892177581787
ADCETRIS,vomiting,vomiting Summary of Clinical Trial Experience,1,0.8057253360748291
ADCETRIS,vomiting,cough vomiting,1,0.8782721757888794
ADCETRIS,vomiting,and,0,0.5051023960113525
ADCETRIS,neutropenia,of causality neutropenia anemia,1,0.8160279989242554
ADCETRIS,neutropenia,and,0,0.4978025257587433
ADCETRIS,neutropenia,neutropenia anemia,1,0.9147777557373047
ADCETRIS,neutropenia,neutropenia anemia peripheral,1,0.8108049631118774
ADCETRIS,neutropenia,most common,0,0.5093619227409363
ADCETRIS,anemia,peripheral sensory neuropathy fatigue nausea pyrexia rash diarrhea and,0,0.6182219386100769
ADCETRIS,anemia,anemia peripheral sensory neuropathy,1,0.7978466749191284
ADCETRIS,anemia,regardless of causality were anemia peripheral sensory neuropathy fatigue nausea,1,0.7550395131111145
ADCETRIS,anemia,anemia peripheral sensory,1,0.7826392650604248
ADCETRIS,anemia,anemia peripheral sensory neuropathy fatigue nausea,1,0.7862462997436523
ADCETRIS,anemia,of causality were,0,0.5227763056755066
ADCETRIS,anemia,anemia peripheral sensory neuropathy fatigue,1,0.7714439034461975
ADCETRIS,anemia,neuropathy fatigue nausea pyrexia rash diarrhea and pain Table,0,0.6250613927841187
ADCETRIS,peripheral sensory neuropathy,neutropenia peripheral sensory neuropathy,1,0.8496860861778259
ADCETRIS,peripheral sensory neuropathy,causality were neutropenia peripheral sensory neuropathy,1,0.8208114504814148
ADCETRIS,peripheral sensory neuropathy,Commonly Reported Ad,0,0.5436618328094482
ADCETRIS,peripheral sensory neuropathy,causality were neutropenia anemia,0,0.5537031888961792
ADCETRIS,peripheral sensory neuropathy,neutropenia,0,0.5477359294891357
ADCETRIS,peripheral sensory neuropathy,were neutropenia peripheral,1,0.6749205589294434
ADCETRIS,peripheral sensory neuropathy,were neutropenia peripheral sensory neuropathy fatigue,1,0.8235665559768677
ADCETRIS,peripheral sensory neuropathy,most common adverse reactions regardless of,0,0.5390142202377319
ADCETRIS,peripheral sensory neuropathy,pain Table,0,0.5511038303375244
ADCETRIS,peripheral sensory neuropathy,Commonly,0,0.49270355701446533
ADCETRIS,fatigue,peripheral sensory neuropathy,0,0.5830788612365723
ADCETRIS,fatigue,anemia peripheral sensory fatigue nausea pyrexia rash diarrhea,1,0.7224655747413635
ADCETRIS,fatigue,anemia peripheral sensory,0,0.5947020053863525
ADCETRIS,fatigue,anemia peripheral sensory fatigue,1,0.7691933512687683
ADCETRIS,nausea,anemia peripheral sensory,0,0.5675570964813232
ADCETRIS,nausea,neuropathy nausea pyrexia rash,1,0.7278823852539062
ADCETRIS,nausea,nausea pyrexia,1,0.838968813419342
ADCETRIS,pyrexia,pyrexia rash diarrhea and pain Table,1,0.8189569711685181
ADCETRIS,pyrexia,anemia,0,0.5942764282226562
ADCETRIS,pyrexia,sensory neuropathy fatigue pyrexia rash diarrhea and pain,1,0.712777853012085
ADCETRIS,pyrexia,Adverse Reactions in,0,0.5673201084136963
ADCETRIS,pyrexia,neuropathy fatigue pyrexia,1,0.8084020018577576
ADCETRIS,pyrexia,peripheral,0,0.54638671875
ADCETRIS,rash,neuropathy fatigue nausea,0,0.5756312608718872
ADCETRIS,rash,ss,0,0.5361595153808594
ADCETRIS,rash,nausea,0,0.6423230171203613
ADCETRIS,rash,Adverse Reactions in,0,0.6398450136184692
ADCETRIS,rash,rash diarrhea and pain Table Most,1,0.7436691522598267
ADCETRIS,rash,rash diarrhea and pain,1,0.8026643991470337
ADCETRIS,rash,neuropathy fatigue nausea rash diarrhea and,1,0.6818591356277466
ADCETRIS,diarrhea,diarrhea and pain Table Most,1,0.7790811061859131
ADCETRIS,diarrhea,diarrhea and,1,0.9006589651107788
ADCETRIS,diarrhea,pyrexia diarrhea and pain,1,0.7334795594215393
ADCETRIS,diarrhea,pain Table Most Commonly Reported Adverse Reactions in Studies and,0,0.5418894290924072
ADCETRIS,diarrhea,diarrhea and pain Table,1,0.7624770998954773
ADCETRIS,pain,diarrhea pain Table Most Commonly,1,0.6494812965393066
ADCETRIS,pain,diarrhea and pain Table,1,0.6702059507369995
ADCETRIS,pain,anemia peripheral sensory neuropathy fatigue nausea pyrexia,0,0.5950844287872314
ADCETRIS,pain,pain,1,0.9999999403953552
ADCETRIS,pain,Most Commonly Reported Adverse Reactions,0,0.5647298097610474
ADCETRIS,pain,and,0,0.5745763778686523
ADCETRIS,pain,pyrexia rash diarrhea pain,1,0.6391751766204834
ADCETRIS,neuropathy,experienced any grade neuropathy Of these patients,1,0.8118315935134888
ADCETRIS,neuropathy,and,0,0.5167378187179565
ADCETRIS,neuropathy,any,0,0.5255672931671143
ADCETRIS,neuropathy,neuropathy Of these,1,0.8919436931610107
ADCETRIS,neuropathy,neuropathy,1,1.0000001192092896
ADCETRIS,neuropathy,neuropathy Of these patients had,1,0.8773193955421448
ADCETRIS,neuropathy,who neuropathy had residual neuropathy at the,1,0.8293514251708984
ADCETRIS,neuropathy,Of the patients who neuropathy,1,0.8706791400909424
ADCETRIS,neuropathy,neuropathy had residual neuropathy at the,1,0.8660479187965393
ADCETRIS,neuropathy,the,0,0.5444921851158142
ADCETRIS,neuropathy,residual,0,0.5136470794677734
ADCETRIS,neuropathy,of patients treated with,0,0.5422582626342773
ADCETRIS,neuropathy,In Study of patients treated with ADCETRIS experienced any grade,0,0.5293059349060059
ADCETRIS,neuropathy,patients who neuropathy had complete resolution,1,0.7843815088272095
ADCETRIS,neuropathy,neuropathy had complete resolution and,1,0.8249112963676453
ADCETRIS,neuropathy,had residual neuropathy partial improvement,0,0.8135300874710083
ADCETRIS,neuropathy,improvement no,0,0.4856172800064087
ADCETRIS,neuropathy,had complete resolution and had residual neuropathy partial improvement,0,0.7575302720069885
ADCETRIS,residual neuropathy,the,0,0.5073912143707275
ADCETRIS,residual neuropathy,last evaluation Infusion,0,0.579499363899231
ADCETRIS,residual neuropathy,and residual neuropathy partial improvement,1,0.8953464031219482
ADCETRIS,infusion-related reactions,no Grade infusion-related reactions reported,1,0.8512266874313354
ADCETRIS,infusion-related reactions,last evaluation Infusion,0,0.7214946746826172
ADCETRIS,infusion-related reactions,no Grade infusion-related reactions,1,0.8978917002677917
ADCETRIS,infusion-related reactions,infusion-related reactions reported in Studies and,1,0.957038164138794
ADCETRIS,infusion-related reactions,of anaphylaxis,0,0.6566586494445801
ADCETRIS,infusion-related reactions,most common adverse,0,0.5719043016433716
ADCETRIS,infusion-related reactions,reactions associated infusion-related,1,0.9794706106185913
ADCETRIS,chills,most common adverse reactions associated,0,0.5289662480354309
ADCETRIS,chills,chills nausea dyspnea pruritus pyrexia,1,0.8259158730506897
ADCETRIS,chills,chills,1,0.9999998807907104
ADCETRIS,chills,pruritus pyrexia and cough,0,0.6177363395690918
ADCETRIS,chills,dyspnea pruritus pyrexia and cough In,0,0.6043553352355957
ADCETRIS,chills,chills nausea,1,0.8787863254547119
ADCETRIS,nausea,and,0,0.5219222903251648
ADCETRIS,nausea,nausea dyspnea pruritus pyrexia and,1,0.7431246042251587
ADCETRIS,nausea,pruritus pyrexia and cough In Study,0,0.6393944025039673
ADCETRIS,nausea,with infusionrelated reactions were nausea,1,0.8063612580299377
ADCETRIS,nausea,In Study infusionrelated r,0,0.5711268186569214
ADCETRIS,nausea,nausea dyspnea pruritus pyrexia,1,0.7653932571411133
ADCETRIS,nausea,common adverse reactions associated with infusionrelated,0,0.623951256275177
ADCETRIS,nausea,reactions were nausea dyspnea pruritus pyrexia and cough,1,0.7293798923492432
ADCETRIS,dyspnea,infusionrelated reactions were chills,0,0.5049929618835449
ADCETRIS,dyspnea,adverse reactions associated with infusionrelated reactions were,0,0.4962503910064697
ADCETRIS,dyspnea,with infusionrelated reactions were chills,0,0.5048094987869263
ADCETRIS,dyspnea,reactions were chills dyspnea pruritus pyrexia and,1,0.6632781028747559
ADCETRIS,dyspnea,dyspnea pruritus pyrexia and,1,0.7761692404747009
ADCETRIS,dyspnea,dyspnea,1,1.0
ADCETRIS,dyspnea,dyspnea pruritus pyrexia and cough,1,0.7561156153678894
ADCETRIS,pruritus,pruritus,1,0.9999999403953552
ADCETRIS,pruritus,were chills nausea pruritus pyrexia,1,0.7718228697776794
ADCETRIS,pruritus,were reported in,0,0.5189006924629211
ADCETRIS,pyrexia,pyrexia and cough In Study infusionrelated,1,0.8015373945236206
ADCETRIS,pyrexia,pyrexia and cough In,1,0.8828820586204529
ADCETRIS,pyrexia,pyrexia and cough,1,0.8833788633346558
ADCETRIS,pyrexia,pyrexia and,1,0.9570273160934448
ADCETRIS,pyrexia,pyrexia and cough In Study,1,0.8363139033317566
ADCETRIS,pyrexia,reactions were chills nausea dyspnea,0,0.6187153458595276
ADCETRIS,pyrexia,nausea dyspnea pyrexia and cough,1,0.8094182014465332
ADCETRIS,pyrexia,chills,0,0.6368893384933472
ADCETRIS,cough,cough In Study infusionrelated reactions were,1,0.7529916763305664
ADCETRIS,cough,cough In Study infusionrelated,1,0.7934122085571289
ADCETRIS,cough,cough In,1,0.9071601033210754
ADCETRIS,cough,cough In Study,1,0.809152364730835
ADCETRIS,cough,dyspnea pruritus,0,0.6210967898368835
ADCETRIS,cough,In Study infusionrelated reactions were reported in patients,0,0.5330590605735779
ADCETRIS,cough,and,0,0.5597959756851196
ADCETRIS,cough,pruritus pyrexia cough In,1,0.7712486982345581
ADCETRIS,infusion-related reactions,pyrexia and cough In infusion-related reactions were reported in,1,0.8612852096557617
ADCETRIS,infusion-related reactions,and,0,0.47052037715911865
ADCETRIS,infusion-related reactions,In infusion-related reactions were reported in patients in,1,0.9565967321395874
ADCETRIS,infusion-related reactions,In infusion-related reactions were reported,1,0.968929648399353
ADCETRIS,infusion-related reactions,patients in the ADCETRIStreated arm,0,0.575919508934021
ADCETRIS,infusion-related reactions,pyrexia and cough In infusion-related reactions,1,0.8585422039031982
ADCETRIS,infusion-related reactions,infusion-related reactions were,1,0.9879865646362305
ADCETRIS,infusion-related reactions,cough In infusion-related reactions,1,0.8972233533859253
ADCETRIS,infusion-related reactions,dyspnea pruritus pyrexia and cough In,0,0.5555259585380554
ADCETRIS,infusion-related reactions,the ADCETRIStreated arm and patients in the,0,0.5676884055137634
ADCETRIS,infusion-related reactions,infusion-related reactions,1,1.000000238418579
ADCETRIS,infusion-related reactions,the,0,0.4682292342185974
ADCETRIS,infusion-related reactions,infusionrelated reactions No infusion-related reactions,1,0.9032696485519409
ADCETRIS,infusion-related reactions,who experienced,0,0.5105094909667969
ADCETRIS,infusion-related reactions,reactions No infusion-related reactions,1,0.8777955174446106
ADCETRIS,infusion-related reactions,infusion-related reactions were reported The,1,0.9734746217727661
ADCETRIS,infusion-related reactions,common adverse,0,0.5806788206100464
ADCETRIS,infusion-related reactions,reactions No infusion-related,1,0.8811542391777039
ADCETRIS,infusion-related reactions,experienced infusionrelated reactions No infusion-related reactions,1,0.8866926431655884
ADCETRIS,infusion-related reactions,No infusion-related,1,0.7445119619369507
ADCETRIS,infusion-related reactions,infusion-related reactions were reported The most common,1,0.9182964563369751
ADCETRIS,infusion-related reactions,infusion-related reactions were nausea chills,1,0.8837095499038696
ADCETRIS,infusion-related reactions,infusion-related,1,0.8695873022079468
ADCETRIS,infusion-related reactions,adverse reactions associated infusion-related reactions were nausea chills,1,0.8878169655799866
ADCETRIS,infusion-related reactions,reactions associated infusion-related reactions were nausea chills dyspnea,1,0.9020193219184875
ADCETRIS,infusion-related reactions,most common,0,0.47779643535614014
ADCETRIS,nausea,nausea chills dyspnea,1,0.8060848712921143
ADCETRIS,nausea,nausea chills dyspnea headache pruritus,1,0.7734310626983643
ADCETRIS,nausea,associated with infusionrelated reactions nausea chills dyspnea headache pruritus rash,1,0.7088587284088135
ADCETRIS,nausea,infusionrelated,0,0.5969308614730835
ADCETRIS,dyspnea,rash back pain and vomiting,0,0.45754656195640564
ADCETRIS,headache,headache pruritus,1,0.785503089427948
ADCETRIS,headache,headache pruritus rash,1,0.7530930042266846
ADCETRIS,headache,headache,1,0.9999998807907104
ADCETRIS,headache,pruritus rash back pain and vomiting Pulmonary,0,0.5545176267623901
ADCETRIS,pruritus,headache,0,0.6132181882858276
ADCETRIS,pruritus,pruritus rash back pain and vomiting,1,0.8188039064407349
ADCETRIS,pruritus,chills,0,0.6065500974655151
ADCETRIS,pruritus,pruritus rash,1,0.9252880811691284
ADCETRIS,pruritus,pruritus rash back pain,1,0.8675904870033264
ADCETRIS,pruritus,pain and vomiting,0,0.5743393301963806
ADCETRIS,rash,rash back pain and vomiting,1,0.7669835090637207
ADCETRIS,rash,pruritus rash,1,0.8591687679290771
ADCETRIS,rash,headache pruritus,0,0.6615909337997437
ADCETRIS,rash,nausea chills dyspnea headache pruritus,0,0.6360176801681519
ADCETRIS,rash,rash back pain,1,0.8135764598846436
ADCETRIS,back pain,patients with classical HL th,0,0.4795597195625305
ADCETRIS,back pain,back pain and vomiting Pulmonary Toxicity In,1,0.7062590718269348
ADCETRIS,back pain,pruritus back pain and vomiting,1,0.7500249147415161
ADCETRIS,back pain,patients with,0,0.5565602779388428
ADCETRIS,back pain,trial in patients,0,0.5283458828926086
ADCETRIS,back pain,back pain,1,1.0
ADCETRIS,back pain,reactions were nausea chills,0,0.46030712127685547
ADCETRIS,vomiting,vomiting Pulmonary Toxicity In,1,0.8135998249053955
ADCETRIS,non-infectious pulmonary toxicity,the rate,0,0.40710175037384033
ADCETRIS,non-infectious pulmonary toxicity,rate non-infectious pulmonary toxicity,1,0.9451460838317871
ADCETRIS,non-infectious pulmonary toxicity,rate of,0,0.42686280608177185
ADCETRIS,non-infectious pulmonary toxicity,ABVD adriamycin,0,0.5571277737617493
ADCETRIS,non-infectious pulmonary toxicity,ABVD adriamycin bleomycin vinblastine,0,0.5675084590911865
ADCETRIS,non-infectious pulmonary toxicity,regimen the rate non-infectious pulmonary toxicity,1,0.9021296501159668
ADCETRIS,non-infectious pulmonary toxicity,non-infectious pulmonary toxicity was higher than,1,0.9325135946273804
ADCETRIS,cough,with ABVD adriamycin bleomycin vinblastine dacarbazine Patients,0,0.5251705050468445
ADCETRIS,cough,cough and dyspnea Interstitial infiltration,1,0.7495822906494141
ADCETRIS,cough,Patients typically cough,1,0.8155993223190308
ADCETRIS,cough,bleomycin vinblastine dacarbazine Patients,0,0.5156162977218628
ADCETRIS,cough,vinblastine dacarbazine Patients typically cough and,1,0.7389776706695557
ADCETRIS,dyspnea,dyspnea Interstitial infiltration andor inflammation were,1,0.826299786567688
ADCETRIS,dyspnea,reported,0,0.5063847899436951
ADCETRIS,dyspnea,cough,0,0.6503340005874634
ADCETRIS,dyspnea,reported cough dyspnea Interstitial,1,0.7897984981536865
ADCETRIS,dyspnea,adriamycin bleomycin vinblastine dacarbazine Patients,0,0.5355565547943115
ADCETRIS,pulmonary toxicity,contraindicated see Contraindications Cases pulmonary toxicity,1,0.8330506086349487
ADCETRIS,pulmonary toxicity,adriamycin bleomycin vinblastine dacarbazine Patients,0,0.5321674346923828
ADCETRIS,pulmonary toxicity,see Contraindications Cases pulmonary toxicity have also,1,0.8376911878585815
ADCETRIS,pulmonary toxicity,patients,0,0.4948267936706543
ADCETRIS,pulmonary toxicity,see Contraindications Cases pulmonary toxicity have also been,1,0.8377695083618164
ADCETRIS,pulmonary toxicity,contraindicated see Contraindications Cases pulmonary,1,0.7055889368057251
ADCETRIS,pulmonary toxicity,pulmonary toxicity have also,1,0.9581520557403564
ADCETRIS,pulmonary toxicity,with bleomycin is contraindicated see,0,0.5672303438186646
ADCETRIS,pulmonary toxicity,toxicity have also been,0,0.6800800561904907
ADCETRIS,pulmonary toxicity,pulmonary toxicity,1,0.9999998211860657
ADCETRIS,pulmonary toxicity,ADCETRIS In pulmonary toxicity,1,0.8186106085777283
ADCETRIS,pulmonary toxicity,in,0,0.4822888970375061
ADCETRIS,pulmonary toxicity,pulmonary,1,0.7798680067062378
ADCETRIS,pulmonary toxicity,the placebo,0,0.45622390508651733
ADCETRIS,peripheral motor neuropathy,motor neuropathy abdominal pain pulmonary embolism,1,0.8063182234764099
ADCETRIS,abdominal pain,abdominal pain pulmonary embolism pneumonitis,1,0.7908401489257812
ADCETRIS,abdominal pain,motor neuropathy abdominal pain pulmonary embolism,1,0.6967116594314575
ADCETRIS,abdominal pain,embolism,0,0.5420575141906738
ADCETRIS,abdominal pain,peripheral motor abdominal pain pulmonary embolism pneumonitis pneumothorax pyelonephritis,1,0.7411453723907471
ADCETRIS,abdominal pain,peripheral motor abdominal pain,1,0.8062505722045898
ADCETRIS,abdominal pain,HL include peripheral motor abdominal,1,0.6622203588485718
ADCETRIS,pulmonary embolism,peripheral motor,0,0.5225606560707092
ADCETRIS,pulmonary embolism,abdominal pulmonary embolism pneumonitis pneumothorax pyelonephritis and,1,0.7727416157722473
ADCETRIS,pulmonary embolism,HL include peripheral motor neuropathy,0,0.5355690717697144
ADCETRIS,pulmonary embolism,neuropathy abdominal pulmonary,1,0.6163081526756287
ADCETRIS,pulmonary embolism,with,0,0.5684696435928345
ADCETRIS,pulmonary embolism,pulmonary embolism pneumonitis pneumothorax pyelonephritis,1,0.8088352680206299
ADCETRIS,pneumonitis,lassical,0,0.5052304863929749
ADCETRIS,pneumonitis,pulmonary embolism,0,0.660535454750061
ADCETRIS,pneumonitis,pneumonitis pneumothorax pyelonephritis and,1,0.8113032579421997
ADCETRIS,pneumonitis,abdominal pain pulmonary pneumonitis pneumothorax pyelonephritis and pyrexia The,1,0.721839427947998
ADCETRIS,pneumonitis,abdominal pain pulmonary pneumonitis pneumothorax pyelonephritis and pyrexia,1,0.7129777669906616
ADCETRIS,pneumonitis,embolism,0,0.5568639636039734
ADCETRIS,pneumonitis,common serious adverse rea,0,0.5217223167419434
ADCETRIS,pneumonitis,pneumonitis pneumothorax pyelonephritis and pyrexia The,1,0.7672280669212341
ADCETRIS,pneumothorax,pneumothorax,1,0.9999997615814209
ADCETRIS,pneumothorax,most,0,0.4731639623641968
ADCETRIS,pneumothorax,abdominal pain pulmonary embolism pneumothorax pyelonephritis and,1,0.6836620569229126
ADCETRIS,pneumothorax,pneumothorax pyelonephritis and,1,0.8137725591659546
ADCETRIS,pneumothorax,abdominal pain pulmonary embolism pneumothorax pyelonephritis,1,0.6807379722595215
ADCETRIS,pneumothorax,pneumothorax pyelonephritis and pyrexia The most,1,0.746320903301239
ADCETRIS,pyelonephritis,adverse reactions,0,0.5823802351951599
ADCETRIS,pyrexia,pneumothorax pyelonephritis and,0,0.5438892245292664
ADCETRIS,pyrexia,pyrexia The most common serious adverse,1,0.8272506594657898
ADCETRIS,pyrexia,pyrexia The most common serious,1,0.8737504482269287
ADCETRIS,pyrexia,experienced by patients,0,0.5220873355865479
ADCETRIS,pyrexia,and,0,0.48467883467674255
ADCETRIS,pyrexia,pneumothorax pyelonephritis,0,0.5447810292243958
ADCETRIS,septic shock,septic shock supraventricular,1,0.829473078250885
ADCETRIS,septic shock,extremity and urinary tract infection O,0,0.5774539709091187
ADCETRIS,septic shock,with sALCL,0,0.5108367204666138
ADCETRIS,septic shock,most common serious adverse reactions,0,0.5893740653991699
ADCETRIS,septic shock,patients with sALCL septic,1,0.7567096948623657
ADCETRIS,supraventricular arrhythmia,infection,0,0.5326327681541443
ADCETRIS,supraventricular arrhythmia,most common serious adverse reactions experienced by patients,0,0.539084792137146
ADCETRIS,supraventricular arrhythmia,important serious,0,0.5155084133148193
ADCETRIS,supraventricular arrhythmia,supraventricular arrhythmia,1,1.0
ADCETRIS,supraventricular arrhythmia,with sALCL were septic supraventricular arrhythmia,1,0.8235117197036743
ADCETRIS,supraventricular arrhythmia,were septic supraventricular arrhythmia,1,0.8488240242004395
ADCETRIS,supraventricular arrhythmia,supraventricular arrhythmia pain in,1,0.8917668461799622
ADCETRIS,supraventricular arrhythmia,reactions experienced by patients with sALCL were septic,0,0.5424908399581909
ADCETRIS,supraventricular arrhythmia,with,0,0.5265740752220154
ADCETRIS,pain in extremity,in extremity and urinary tract,1,0.7572017908096313
ADCETRIS,pain in extremity,in extremity and urinary tract infection Other,1,0.7591668963432312
ADCETRIS,pain in extremity,supraventricular pain in extremity and urinary tract infection Other,1,0.7714517116546631
ADCETRIS,pain in extremity,serious adverse reactions,0,0.5440312027931213
ADCETRIS,pain in extremity,septic shock supraventricular pain,1,0.6114857792854309
ADCETRIS,pain in extremity,shock supraventricular pain in extremity and urinary tract infection,1,0.72963947057724
ADCETRIS,pain in extremity,septic shock supraventricular pain in extremity and urinary tract,1,0.7083672285079956
ADCETRIS,pain in extremity,pain in extremity,1,1.000000238418579
ADCETRIS,urinary tract infection,urinary tract infection Other important serious adverse reactions,1,0.7722640037536621
ADCETRIS,urinary tract infection,pain in extremity,1,0.5332338809967041
ADCETRIS,urinary tract infection,pain in extremity urinary,1,0.6958456039428711
ADCETRIS,urinary tract infection,extremity and,0,0.4885505139827728
ADCETRIS,urinary tract infection,shock supraventricular arrhythmia pain in extremity,0,0.5217294096946716
ADCETRIS,urinary tract infection,urinary tract,1,0.8359100818634033
ADCETRIS,urinary tract infection,pain in extremity urinary tract,1,0.713779091835022
ADCETRIS,urinary tract infection,arrhythmia,0,0.5941805839538574
ADCETRIS,urinary tract infection,extremity urinary tract infection,1,0.7866109609603882
ADCETRIS,PML,PML StevensJohnson syndrome and,1,0.791731595993042
ADCETRIS,PML,In Study serious adverse,0,0.5061022043228149
ADCETRIS,PML,PML StevensJohnson,1,0.7102649211883545
ADCETRIS,PML,PML StevensJohnson syndrome and tumor lysis,1,0.7273280620574951
ADCETRIS,PML,PML StevensJohnson syndrome and tumor,1,0.7687435150146484
ADCETRIS,PML,PML StevensJohnson syndrome,1,0.7952572703361511
ADCETRIS,Stevens-Johnson syndrome,reported include Stevens-Johnson syndrome,1,0.925084114074707
ADCETRIS,Stevens-Johnson syndrome,Stevens-Johnson syndrome and tumor lysis,1,0.8687677383422852
ADCETRIS,Stevens-Johnson syndrome,In Study serious,0,0.46640723943710327
ADCETRIS,Stevens-Johnson syndrome,reactions reported include Stevens-Johnson,1,0.7868150472640991
ADCETRIS,Stevens-Johnson syndrome,serious adverse reactions reported include,0,0.6644817590713501
ADCETRIS,Stevens-Johnson syndrome,In Study serious adverse reactions regardless of,0,0.6259540915489197
ADCETRIS,Stevens-Johnson syndrome,Stevens-Johnson syndrome,1,1.0
ADCETRIS,Stevens-Johnson syndrome,and urinary tract infection Other important serious adverse reactions,0,0.6402287483215332
ADCETRIS,tumor lysis syndrome,include PML StevensJohnson syndrome tumor lysis syndrome In Study serious adverse,1,0.8335121273994446
ADCETRIS,tumor lysis syndrome,and urinary tract infection Other important serious adverse reactions,0,0.5506442189216614
ADCETRIS,tumor lysis syndrome,reported,0,0.4958898723125458
ADCETRIS,tumor lysis syndrome,StevensJohnson syndrome tumor lysis syndrome,1,0.9057923555374146
ADCETRIS,tumor lysis syndrome,and,0,0.4305259883403778
ADCETRIS,tumor lysis syndrome,In Study serious adverse reactions,0,0.5322139263153076
ADCETRIS,pneumonia,nausea hepatotoxicity and peripheral,0,0.5435158014297485
ADCETRIS,pneumonia,reactions were,0,0.47817057371139526
ADCETRIS,pyrexia,pyrexia vomiting nausea hepatotoxicity and,1,0.8062620162963867
ADCETRIS,vomiting,were pneumonia vomiting nausea,1,0.8149120211601257
ADCETRIS,vomiting,pyrexia vomiting nausea hepatotoxicity and,1,0.7445484399795532
ADCETRIS,vomiting,vomiting nausea hepatotoxicity and peripheral sensory,1,0.7503526210784912
ADCETRIS,vomiting,pneumonia vomiting nausea,1,0.8263518810272217
ADCETRIS,vomiting,sensory neuropathy,0,0.5224132537841797
ADCETRIS,hepatotoxicity,pyrexia,0,0.5390020608901978
ADCETRIS,hepatotoxicity,hepatotoxicity and,1,0.955235481262207
ADCETRIS,hepatotoxicity,hepatotoxicity and peripheral,1,0.8673202991485596
ADCETRIS,hepatotoxicity,hepatotoxicity and peripheral sensory,1,0.8354036211967468
ADCETRIS,hepatotoxicity,hepatotoxicity and peripheral sensory neuropathy Dose,1,0.7961162328720093
ADCETRIS,hepatotoxicity,vomiting,0,0.5720875263214111
ADCETRIS,peripheral sensory neuropathy,hepatotoxicity peripheral,1,0.6880478858947754
ADCETRIS,neutropenia,neutropenia and peripheral sensory,1,0.8346174955368042
ADCETRIS,neutropenia,in Studies and neutropenia and peripheral sensory neuropathy,1,0.8106064796447754
ADCETRIS,peripheral sensory neuropathy,neutropenia peripheral sensory,1,0.815769374370575
ADCETRIS,peripheral sensory neuropathy,and,0,0.4446223974227905
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy see,1,0.9685338735580444
ADCETRIS,peripheral sensory neuropathy,reactions that led,0,0.4983484148979187
ADCETRIS,peripheral sensory neuropathy,more than of patients in,0,0.4890996217727661
ADCETRIS,peripheral sensory neuropathy,were neutropenia peripheral sensory neuropathy see,1,0.8447633385658264
ADCETRIS,peripheral sensory neuropathy,were neutropenia peripheral sensory neuropathy see Dosage,1,0.7940108776092529
ADCETRIS,neutropenia,of,0,0.5153184533119202
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy upper,1,0.8023092746734619
ADCETRIS,neutropenia,dose delays in more than of ADCETRIStreated patients in Study,0,0.5466223955154419
ADCETRIS,neutropenia,infection and peripheral,0,0.596709132194519
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy upper respiratory tract infection and,1,0.8030450344085693
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy upper,1,0.8466626405715942
ADCETRIS,peripheral sensory neuropathy,patients in Study were,0,0.5344911813735962
ADCETRIS,peripheral sensory neuropathy,delays in more than,0,0.4685095250606537
ADCETRIS,peripheral sensory neuropathy,tract infection and peripheral,0,0.6921471357345581
ADCETRIS,peripheral sensory neuropathy,Study were peripheral sensory neuropathy upper respiratory tract infection,1,0.8148565292358398
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy upper respiratory,1,0.845776379108429
ADCETRIS,peripheral sensory neuropathy,in Study were peripheral sensory neuropathy,1,0.9290865659713745
ADCETRIS,peripheral sensory neuropathy,motor neuropathy see,0,0.7186170220375061
ADCETRIS,upper respiratory tract infection,upper respiratory tract infection and,1,0.9463592767715454
ADCETRIS,upper respiratory tract infection,motor neuropathy see,0,0.5051478147506714
ADCETRIS,upper respiratory tract infection,neuropathy,0,0.512194037437439
ADCETRIS,upper respiratory tract infection,were neutropenia peripheral sensory upper respiratory tract infection and,1,0.7613861560821533
ADCETRIS,upper respiratory tract infection,Study were neutropenia peripheral,0,0.5156673192977905
ADCETRIS,upper respiratory tract infection,peripheral motor neuropathy see Dosage and Administration,0,0.49031323194503784
ADCETRIS,upper respiratory tract infection,tract infection and peripheral motor,1,0.6250385046005249
ADCETRIS,upper respiratory tract infection,neutropenia peripheral sensory upper respiratory tract infection and peripheral motor neuropathy,1,0.7143666744232178
ADCETRIS,upper respiratory tract infection,were neutropenia peripheral sensory upper respiratory tract,1,0.7304458618164062
ADCETRIS,peripheral motor neuropathy,peripheral,1,0.6450098752975464
ADCETRIS,peripheral motor neuropathy,peripheral sensory neuropathy upper respiratory,0,0.742823600769043
ADCETRIS,peripheral motor neuropathy,infection peripheral motor neuropathy see Dosage and Administration Discontinuations,1,0.8328832983970642
ADCETRIS,peripheral motor neuropathy,Administration Discontinuations Adve,0,0.49275773763656616
ADCETRIS,peripheral motor neuropathy,see Dosage and Administration Discontinuations,0,0.5145949125289917
ADCETRIS,peripheral motor neuropathy,tract infection peripheral motor,1,0.8208673000335693
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy and peripheral motor neuropathy Adverse,1,0.8888912796974182
ADCETRIS,peripheral sensory neuropathy,led to treatment,0,0.5445762872695923
ADCETRIS,peripheral sensory neuropathy,and peripheral motor neuropathy Adverse reactions led to treatment discontinuation i,0,0.7559202313423157
ADCETRIS,peripheral motor neuropathy,motor neuropathy Adverse,1,0.8724132180213928
ADCETRIS,peripheral motor neuropathy,patients with classical HL or sALCL were,0,0.5087699294090271
ADCETRIS,peripheral motor neuropathy,were peripheral sensory neuropathy peripheral motor neuropathy Adverse reactions led to,1,0.8772794008255005
ADCETRIS,peripheral motor neuropathy,sensory neuropathy peripheral motor,1,0.9486962556838989
ADCETRIS,peripheral sensory neuropathy,in or more patients peripheral sensory neuropathy peripheral motor neuropathy,1,0.8684619665145874
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy peripheral motor,1,0.9006364941596985
ADCETRIS,peripheral motor neuropathy,at led to treatment discontinuation in or more patients were peripheral sensory neuropathy,0,0.7423551082611084
ADCETRIS,peripheral motor neuropathy,to treatment discontinuation,0,0.5319246649742126
ADCETRIS,peripheral motor neuropathy,motor neuropathy acute,1,0.8548673391342163
ADCETRIS,peripheral motor neuropathy,peripheral sensory peripheral motor neuropathy acute respiratory,1,0.8409546613693237
ADCETRIS,acute respiratory distress syndrome,motor acute respiratory distress syndrome,1,0.8322404623031616
ADCETRIS,acute respiratory distress syndrome,motor neuropathy acute,1,0.534998893737793
ADCETRIS,acute respiratory distress syndrome,peripheral motor acute respiratory distress syndrome paraesthesia and vomiting,1,0.7521152496337891
ADCETRIS,acute respiratory distress syndrome,respiratory distress syndrome paraesthesia and vomiting Post,1,0.7473103404045105
ADCETRIS,acute respiratory distress syndrome,distress syndrome paraesthesia and vomiting Post Marketing,1,0.6527100205421448
ADCETRIS,acute respiratory distress syndrome,respiratory distress syndrome paraesthesia and,1,0.7802213430404663
ADCETRIS,paraesthesia,paraesthesia and vomiting Post,1,0.7893408536911011
ADCETRIS,paraesthesia,paraesthesia and vomiting Post Marketing,1,0.7595890760421753
ADCETRIS,paraesthesia,paraesthesia and,1,0.9433287382125854
ADCETRIS,vomiting,Post Marketing Experience The following adverse reactions have,0,0.5842694640159607
ADCETRIS,vomiting,neuropathy,0,0.5064269304275513
ADCETRIS,vomiting,vomiting Post Marketing Experience,1,0.7893122434616089
ADCETRIS,vomiting,distress syndrome paraesthesia vomiting Post,1,0.7844425439834595
ADCETRIS,vomiting,acute respiratory distress,0,0.6010874509811401
ADCETRIS,vomiting,acute respiratory distress syndrome paraesthesia,0,0.5535479784011841
ADCETRIS,vomiting,syndrome paraesthesia vomiting Post Marketing Experience The following,1,0.7461944818496704
ADCETRIS,vomiting,vomiting Post Marketing,1,0.8069853186607361
ADCETRIS,febrile neutropenia,system febrile neutropenia see Warnings,1,0.8580225110054016
ADCETRIS,febrile neutropenia,vomiting Post Marketing,1,0.5226024389266968
ADCETRIS,febrile neutropenia,Hepatobiliary,0,0.5017674565315247
ADCETRIS,febrile neutropenia,drug exposure Blood and lymphatic system,0,0.5576906204223633
ADCETRIS,PML,Warning Warnings and Precautions serious infections,0,0.5075294971466064
ADCETRIS,infections,infections and opportunistic infections see,1,0.8233639001846313
ADCETRIS,infections,infections and opportunistic,1,0.786155641078949
ADCETRIS,infections,infections and opportunistic infections,1,0.826484203338623
ADCETRIS,infections,Infections PML see Boxed Warning Warnings and,0,0.6842741370201111
ADCETRIS,infections,Warning Warnings and Precautions serious,0,0.6025112867355347
ADCETRIS,infections,Precautions serious,0,0.6089475154876709
ADCETRIS,opportunistic infections,Warnings and Precautions,0,0.5520157814025879
ADCETRIS,opportunistic infections,opportunistic infections see Warnings,1,0.8812873363494873
ADCETRIS,opportunistic infections,infections opportunistic,1,0.9680138826370239
ADCETRIS,opportunistic infections,and,0,0.4792117476463318
ADCETRIS,opportunistic infections,opportunistic infections see Warnings and Precautions,1,0.8691237568855286
ADCETRIS,opportunistic infections,see Warnings and Precautions Metabolism,0,0.5120477080345154
ADCETRIS,opportunistic infections,infections opportunistic infections see Warnings and,1,0.8911919593811035
ADCETRIS,Pancreatitis,outcomes Consider the,0,0.4793013334274292
ADCETRIS,Pancreatitis,Pancreatitis including fatal,1,0.8446006178855896
ADCETRIS,Pancreatitis,the diagnosis of pancreatitis for patients presenting,0,0.8008959889411926
ADCETRIS,fatal,fatal,1,1.0000001192092896
ADCETRIS,fatal,with severe,0,0.684425950050354
ADCETRIS,noninfectious pulmonary toxicity,some with fatal outcomes see,0,0.6123006939888
ADCETRIS,noninfectious pulmonary toxicity,thoracic and mediastinal noninfectious,1,0.7616227269172668
ADCETRIS,noninfectious pulmonary toxicity,Respiratory thoracic and mediastinal noninfectious pulmonary,1,0.7862054109573364
ADCETRIS,noninfectious pulmonary toxicity,pulmonary toxicity including pneumonitis interstitial lung disease,1,0.8211896419525146
ADCETRIS,pneumonitis,with fatal outcomes,0,0.4925888776779175
ADCETRIS,pneumonitis,pneumonitis interstitial lung,1,0.8411366939544678
ADCETRIS,pneumonitis,Respiratory thoracic and mediastinal disorders noninfectious,0,0.6308480501174927
ADCETRIS,pneumonitis,fatal outcomes see Warnings and,0,0.4922308325767517
ADCETRIS,pneumonitis,pneumonitis,1,1.0
ADCETRIS,pneumonitis,pneumonitis interstitial,1,0.8475720882415771
ADCETRIS,pneumonitis,toxicity pneumonitis interstitial lung disease and,1,0.7686620950698853
ADCETRIS,pneumonitis,disease and ARDS some with fatal outcomes see,0,0.6170055866241455
ADCETRIS,pneumonitis,noninfectious pulmonary toxicity pneumonitis interstitial lung disease and ARDS,1,0.7425456047058105
ADCETRIS,interstitial lung disease,and mediastinal,0,0.5910755395889282
ADCETRIS,interstitial lung disease,with fatal outcomes see Warnings and Precautions and Adverse Reactions,0,0.5060473084449768
ADCETRIS,interstitial lung disease,Warnings and Precautions and,0,0.49755966663360596
ADCETRIS,ARDS,ARDS some with fatal outcomes,1,0.8301976919174194
ADCETRIS,ARDS,ARDS some with fatal,1,0.8645470142364502
ADCETRIS,ARDS,outcomes see Warnings,0,0.5117232799530029
ADCETRIS,ARDS,lung disease ARDS some with fatal outcomes see,1,0.7887517213821411
ADCETRIS,ARDS,ARDS some with,1,0.9139093160629272
ADCETRIS,ARDS,fatal outcomes see Warnings and,0,0.5260358452796936
ADCETRIS,ARDS,and Adverse Reactions,0,0.5381913185119629
ADCETRIS,fatal,and ARDS some fatal outcomes,1,0.6977765560150146
ADCETRIS,fatal,and Adverse Reactions,0,0.5648455619812012
ADCETRIS,fatal,some fatal outcomes see,1,0.7764649391174316
ADCETRIS,fatal,and ARDS,0,0.5553466081619263
ADCETRIS,fatal,fatal outcomes see Warnings,1,0.7658518552780151
ADCETRIS,Toxic epidermal necrolysis,Adverse Reactions Skin,0,0.7682510018348694
ADCETRIS,Toxic epidermal necrolysis,and subcutaneous tissue Toxic,1,0.7464889287948608
ADCETRIS,Toxic epidermal necrolysis,Adverse,0,0.594222366809845
ADCETRIS,Toxic epidermal necrolysis,subcutaneous tissue Toxic,1,0.7603721022605896
ADCETRIS,Toxic epidermal necrolysis,disorders,0,0.5791814923286438
ADCETRIS,Toxic epidermal necrolysis,tissue Toxic epidermal necrolysis including fatal outcomes,1,0.9349086284637451
ADCETRIS,Toxic epidermal necrolysis,fatal outcomes see Warnings and,0,0.588337242603302
ADCETRIS,Toxic epidermal necrolysis,Toxic epidermal necrolysis,1,1.0000001192092896
ADCETRIS,fatal,Precautions Immunogenicity,0,0.45745763182640076
ADCETRIS,fatal,fatal outcomes,1,0.8159129619598389
ADCETRIS,fatal,disorders Toxic epidermal necrolysis fatal outcomes see,1,0.6539756655693054
ADCETRIS,fatal,fatal outcomes see Warnings and,1,0.7542406916618347
ADCETRIS,infusion reactions,patients with,0,0.5676603317260742
ADCETRIS,infusion reactions,reactions consistent infusion reactions,1,0.9148699045181274
ADCETRIS,infusion reactions,infusion reactions that,1,0.9767802953720093
ADCETRIS,infusion reactions,led to discontinuation of treatment Overall a higher incidence,0,0.5546644926071167
ADCETRIS,infusion reactions,positive antibodies experienced adverse reactions consistent,0,0.6969444751739502
ADCETRIS,infusion reactions,higher incidence of infusion related reactions,0,0.9103893041610718
ADCETRIS,infusion related reactions,with infusion reactions that led to,0,0.9526239633560181
ADCETRIS,infusion related reactions,a higher incidence of,0,0.5732033252716064
ADCETRIS,infusion related reactions,infusion related reactions was observed in,1,0.9815303087234497
ADCETRIS,infusion related reactions,incidence,0,0.5346372127532959
ADCETRIS,infusion related reactions,a higher incidence infusion related reactions was observed in patients,1,0.9233466386795044
ADCETRIS,infusion related reactions,infusion reactions that led to discontinuation,0,0.8700103759765625
ADCETRIS,infusion related reactions,higher incidence infusion related reactions was observed in patients who,1,0.9231042861938477
ADCETRIS,infusion related reactions,higher incidence infusion related reactions was observed,1,0.9279473423957825
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,following serious adverse reactions are d iscussed in,1,0.5421494841575623
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,ADVERSE REACTIONS following serious adverse,1,0.524847149848938
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,are d,1,0.5075592398643494
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,are d iscussed in greater,1,0.5283061861991882
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,ADVERSE REACTIONS following serious adverse reactions are d,1,0.5059390068054199
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, following serious adverse reactions are d iscussed in greater detail,1,0.5506700277328491
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,ADVERSE REACTIONS following serious,1,0.5183048248291016
ADCETRIS,PML,cus sed in greater detail in,1,0.443381130695343
ADCETRIS,PML,cus sed in,1,0.4329076409339905
ADCETRIS,PML,reactions are cus sed,1,0.4633476436138153
ADCETRIS,PML,dis,0,0.5041153430938721
ADCETRIS,PML,other sections of the prescribing information Peripheral Neuropathy,0,0.5101171731948853
ADCETRIS,PML,sections of,0,0.5034038424491882
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,etail in other sections of the prescribing information Peripheral,1,0.5154246091842651
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,sections of,0,0.5537638664245605
ADCETRIS,PML,in greater detail,0,0.4904536008834839
ADCETRIS,PML,the prescribing nfo rmation Peripheral,1,0.4984096884727478
ADCETRIS,PML,nfo rmation Peripheral Neuropathy see,1,0.5302151441574097
ADCETRIS,JC virus infection,* Peripheral Neuropathy see Warnings and Precautions,1,0.5495387315750122
ADCETRIS,JC virus infection,discussed in greater detail in,0,0.49282437562942505
ADCETRIS,JC virus infection,the prescribing *,1,0.4887579083442688
ADCETRIS,JC virus infection,of the prescribing * Peripheral,1,0.5028554201126099
ADCETRIS,death,see ngs a nd,1,0.5269402265548706
ADCETRIS,death,of the prescribing * Peripheral,1,0.5062368512153625
ADCETRIS,death,Peripheral Neuropathy see ngs,1,0.4943619966506958
ADCETRIS,death,ngs a nd,1,0.5350002646446228
ADCETRIS,death,see ngs,1,0.5261874794960022
ADCETRIS,death,detail in other sections of,0,0.5170999765396118
ADCETRIS,death,sections of the,0,0.5225017070770264
ADCETRIS,death,nd Precautions Anaphylaxis and Infusion Reactions see,0,0.49537068605422974
ADCETRIS,death,Peripheral Neuropathy see ngs a nd Precautions Anaphylaxis,1,0.5036605596542358
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,Infections and Opportunistic,0,0.5739545822143555
ADCETRIS,PML,rio,1,0.44372987747192383
ADCETRIS,PML,rio us Infections and Opportunistic Infections,1,0.5083543062210083
ADCETRIS,PML,rio us,1,0.42186206579208374
ADCETRIS,JC virus infection,"and 4      )  ]  
 *  ",1,0.44926542043685913
ADCETRIS,JC virus infection,rio us,1,0.44409066438674927
ADCETRIS,JC virus infection,"Warnings and 4      )  ]  
 *  ",1,0.5086569786071777
ADCETRIS,JC virus infection,Infections see,0,0.6161749362945557
ADCETRIS,JC virus infection,Infections see Warnings and Precautions,0,0.5912593007087708
ADCETRIS,death,see   Warnings and Precautions,1,0.5253603458404541
ADCETRIS,death,see   Warnings and Precautions Increased,1,0.5130369663238525
ADCETRIS,death,see   Warnings and Precautions Increased Toxicity,1,0.5653657913208008
ADCETRIS,Peripheral neuropathy,REACTIONS The following serious e reactions are discu,1,0.524530291557312
ADCETRIS,Peripheral neuropathy,e reactions are discu ssed in greater detail in,1,0.5044763684272766
ADCETRIS,Peripheral neuropathy,REACTIONS The following serious e,1,0.5105727314949036
ADCETRIS,Peripheral neuropathy,following serious e,1,0.5121279954910278
ADCETRIS,Peripheral neuropathy,REACTIONS The following serious e reactions are discu ssed in,1,0.5226578712463379
ADCETRIS,Peripheral neuropathy,other sections of the prescribing,0,0.5235393047332764
ADCETRIS,Anaphylaxis,pathy [see Warnings,1,0.5209543108940125
ADCETRIS,infusion reactions,ings,1,0.5402997136116028
ADCETRIS,infusion reactions,information Peripheral Neuropathy see ings and Precautio,1,0.5783296823501587
ADCETRIS,infusion reactions,ter detail in other,0,0.5237808227539062
ADCETRIS,infusion reactions,detail in other sections of,0,0.5406148433685303
ADCETRIS,infusion reactions,information Peripheral Neuropathy see ings,1,0.5740680694580078
ADCETRIS,infusion reactions,see ings and Precautio,1,0.5504904985427856
ADCETRIS,infusion reactions,and Precautio ns Anaphylaxis,1,0.6662251949310303
ADCETRIS,Hematologic toxicities,Warnings and Precautions,0,0.6124455332756042
ADCETRIS,Hematologic toxicities,Precautions,0,0.543830156326294
ADCETRIS,Hematologic toxicities,gs and Precautions Serious Infections,0,0.5578304529190063
ADCETRIS,Hematologic toxicities,gs and Precautions Serious Infections and Opportunistic Infections,0,0.5557359457015991
ADCETRIS,Hematologic toxicities,and Precautions Hematologic oxicities [see  Warnin gs and,1,0.7807282209396362
ADCETRIS,Hematologic toxicities,Precautions Serious Infections and Opportunistic Infections see,0,0.5617460012435913
ADCETRIS,infections,Warnings and Precautions,0,0.6236245036125183
ADCETRIS,infections,Increased,0,0.5575659871101379
ADCETRIS,Tumor lysis syndrome,Moderate or,0,0.4894958734512329
ADCETRIS,Tumor lysis syndrome,in the,0,0.46453189849853516
ADCETRIS,Tumor lysis syndrome,the Presence of,0,0.4779103994369507
ADCETRIS,Tumor lysis syndrome,Increased Toxicity in the,0,0.5628498196601868
ADCETRIS,Tumor lysis syndrome,of Moderate Severe Hepatic Impai,1,0.5610769987106323
ADCETRIS,Tumor lysis syndrome,and Precautions Hepatotoxicity see,0,0.5009235739707947
ADCETRIS,Tumor lysis syndrome,see Warnings,0,0.4917941689491272
ADCETRIS,Tumor lysis syndrome,Toxicity in the Presence,0,0.5341356992721558
ADCETRIS,Tumor lysis syndrome,Hepatotoxicity see Warnings,0,0.5219343900680542
ADCETRIS,Hepatotoxicity,see Warnings,0,0.5925098657608032
ADCETRIS,Hepatotoxicity,Precautions Hepatotoxicity see Warnings Precautions (  Progressive Multifocal,1,0.7736266851425171
ADCETRIS,Hepatotoxicity,Hepatotoxicity see Warnings Precautions,1,0.8641818165779114
ADCETRIS,Pulmonary Toxicity,atotoxicity see Warnings and Precautions Progressive,0,0.655368447303772
ADCETRIS,Pulmonary Toxicity,Leukoen,0,0.5062962770462036
ADCETRIS,Pulmonary Toxicity,Precautions Progressive Multifocal cephalopathy,1,0.514029324054718
ADCETRIS,dermatologic reactions,and Precau tions Serious Dermatologic Reactions see,1,0.9268612861633301
ADCETRIS,dermatologic reactions,Warnings and Precau,1,0.534038782119751
ADCETRIS,dermatologic reactions,Precautions Pulmonary Toxicity e,1,0.5593008399009705
ADCETRIS,dermatologic reactions,Warnings and Precautions Pulmonary,0,0.5181053876876831
ADCETRIS,dermatologic reactions,e Warnings and Precau tions Serious Dermatologic Reactions,1,0.8578149080276489
ADCETRIS,dermatologic reactions,Warnings and Precau tions Serious Dermatologic Reactions see,1,0.859353244304657
ADCETRIS,Fetal harm,ost common,1,0.4274367392063141
ADCETRIS,Fetal harm,The ost common adverse reactions were Relapsed classical,1,0.5205436944961548
ADCETRIS,Fetal harm,Dermatologic Reactions see Warnings and Precautions EXCERPT,0,0.5256242752075195
ADCETRIS,Fetal harm,classical HL and relapsed,0,0.5075090527534485
ADCETRIS,peripheral neuropathy,er respiratory tract infection diarrhea pyrexia rash thrombocytopenia,1,0.5179224014282227
ADCETRIS,peripheral neuropathy,pyrexia rash thrombocytopenia,0,0.5160534977912903
ADCETRIS,peripheral neuropathy,nausea anemia er respiratory tract  infection diarrhea pyrexia,1,0.5282172560691833
ADCETRIS,peripheral neuropathy,respiratory tract infection,1,0.4869638681411743
ADCETRIS,peripheral motor neuropathy,"diarrhea pyrexia rash bocytopenia, cough, and vom",1,0.5112735629081726
ADCETRIS,peripheral motor neuropathy,HL postautoHSCT consolidation,0,0.5276409387588501
ADCETRIS,peripheral motor neuropathy,"rash bocytopenia,",1,0.5098516345024109
ADCETRIS,peripheral motor neuropathy,tract infection diarrhea pyrexia,0,0.4967467486858368
ADCETRIS,peripheral motor neuropathy,"bocytopenia, cough,",1,0.47539496421813965
ADCETRIS,peripheral motor neuropathy,fatigue nausea anemia upper,0,0.524378776550293
ADCETRIS,peripheral neuropathy,-HSCT consolidation: neutropenia peripheral sensory,1,0.6762167811393738
ADCETRIS,neuropathy, periphera l motor neuropathy,1,0.7317296862602234
ADCETRIS,neuropathy, periphera l,1,0.43320590257644653
ADCETRIS,neuropathy, periphera l motor,1,0.4783114194869995
ADCETRIS,neuropathy,neuropathy thrombocytopenia,0,0.8160772323608398
ADCETRIS,neuropathy,tract infection  periphera l motor neuropathy,1,0.697842001914978
ADCETRIS,neuropathy,thrombocytopenia anemia,0,0.524486780166626
ADCETRIS,neuropathy,contact Seattle Genetics Inc t 1-855-47,1,0.5082575082778931
ADCETRIS,neuropathy,Seattle Genetics Inc t 1-855-47 or FDA at,1,0.5207484364509583
ADCETRIS,neuropathy,Clinical Trial Experience,0,0.5336729884147644
ADCETRIS,neuropathy,t 1-855-47 or FDA at,1,0.5365701913833618
ADCETRIS,neuropathy,t 1-855-47 or FDA at FDA,1,0.5168353319168091
ADCETRIS,neuropathy,t 1-855-47 or FDA at FDA or,1,0.5170233845710754
ADCETRIS,neuropathy,Seattle Genetics Inc t 1-855-47,1,0.513857364654541
ADCETRIS,neuropathy,at FDA or wwwfdagovmedwatch Clinical Trial Experience,0,0.48620903491973877
ADCETRIS,neuropathy,Inc t 1-855-47,1,0.5308436155319214
ADCETRIS,residual neuropathy,Genetics Inc at FDA at,1,0.47293952107429504
ADCETRIS,Infusion-related reactions,in two uncontrolled singlearm,0,0.47925621271133423
ADCETRIS,Infusion-related reactions,HL and systemic stic large cell lymphoma ( sALCL including patients in two,1,0.5036371946334839
ADCETRIS,Infusion-related reactions,cell lymphoma ( sALCL including patients,1,0.498344361782074
ADCETRIS,Infusion-related reactions,and systemic stic,1,0.5798578262329102
ADCETRIS,anaphylaxis,atients in,0,0.5084172487258911
ADCETRIS,anaphylaxis,large cell lymphoma sALCL uding 160 p atients,1,0.4718363285064697
ADCETRIS,anaphylaxis,sALCL uding 160 p atients in two uncontrolled,1,0.5165005326271057
ADCETRIS,anaphylaxis,and and patients,0,0.49703332781791687
ADCETRIS,anaphylaxis,160 p atients in,1,0.5121099948883057
ADCETRIS,anaphylaxis,uding 160 p atients,1,0.5140575170516968
ADCETRIS,anaphylaxis,sALCL uding 160 p atients in two,1,0.5195343494415283
ADCETRIS,neutropenia,in,0,0.5025935173034668
ADCETRIS,neutropenia,Toxicity Criteria CTC Version shown in,1,0.5405318737030029
ADCETRIS,neutropenia,Toxicity Criteria,0,0.5128081440925598
ADCETRIS,neutropenia,Toxicity Criteria CTC Version  shown in   Table In Study,1,0.5421448349952698
ADCETRIS,neutropenia,CTC Version  shown in   Table In Study the most,1,0.5407395362854004
ADCETRIS,neutropenia,CTC Version  shown in  ,1,0.508288562297821
ADCETRIS,neutropenia,Study the most common,0,0.4928508996963501
ADCETRIS,neutropenia,shown in Table In Study the most,1,0.5081164240837097
ADCETRIS,thrombocytopenia,In,0,0.49923771619796753
ADCETRIS,thrombocytopenia,"In 3, the most",1,0.43725836277008057
ADCETRIS,thrombocytopenia,causality were,0,0.48623859882354736
ADCETRIS,thrombocytopenia,"shown in Table In  3, the most com mon",1,0.4921499192714691
ADCETRIS,thrombocytopenia,"3, the most com mon adverse reactions in the",1,0.5185947418212891
ADCETRIS,thrombocytopenia,the most com mon adverse reactions in the,1,0.5215924382209778
ADCETRIS,thrombocytopenia,regardless of,0,0.4585514962673187
ADCETRIS,anemia,advers e,1,0.5219327211380005
ADCETRIS,anemia,advers e reactions in the ADCETRIStreatment,1,0.5614429712295532
ADCETRIS,anemia,advers e reactions,1,0.5044649839401245
ADCETRIS,anemia,advers,1,0.5089923143386841
ADCETRIS,Febrile neutropenia,Study the most common,0,0.4840850830078125
ADCETRIS,Febrile neutropenia,the,0,0.4793252944946289
ADCETRIS,Febrile neutropenia, ADCETRIS-treatment,1,0.5238162279129028
ADCETRIS,Febrile neutropenia, ADCETRIS-treatment arm regardless of,1,0.5178365707397461
ADCETRIS,Febrile neutropenia,common adverse reactions in  ADCETRIS-treatment arm,1,0.5533638000488281
ADCETRIS,Febrile neutropenia,arm regardless,0,0.4438350796699524
ADCETRIS,Febrile neutropenia, ADCETRIS-treatment arm regardless,1,0.5199750065803528
ADCETRIS,Febrile neutropenia,causality were neutropenia peripheral sensory,0,0.7441078424453735
ADCETRIS,Febrile neutropenia,in  ADCETRIS-treatment,1,0.5217214822769165
ADCETRIS,infections,was mgkg,0,0.491181880235672
ADCETRIS,infections,lassical H L in a single arm,1,0.523936927318573
ADCETRIS,infections,studied in patients with lassical,1,0.5525132417678833
ADCETRIS,infections,lassical H,1,0.4989446997642517
ADCETRIS,infections,in Relapsed Classical HL,0,0.5714894533157349
ADCETRIS,opportunistic infections,HL a,1,0.49844491481781006
ADCETRIS,opportunistic infections,clinical tr ial in which,1,0.5557408332824707
ADCETRIS,opportunistic infections,ADCETRIS was studied,0,0.5577157139778137
ADCETRIS,opportunistic infections,classical HL a single arm clinical,1,0.5369338989257812
ADCETRIS,pneumonia,with,0,0.5643700361251831
ADCETRIS,pneumonia,in ich the,1,0.5110589265823364
ADCETRIS,pneumonia,intravenously every weeks,0,0.5531993508338928
ADCETRIS,pneumonia,the r ecommended starting dose,1,0.5802388191223145
ADCETRIS,pneumonia,in ich,1,0.5147591233253479
ADCETRIS,pneumonia,the r,1,0.5088992714881897
ADCETRIS,pneumonia,clinical trial in ich,1,0.5170642733573914
ADCETRIS,pneumonia,ich the r ecommended starting,1,0.5102853775024414
ADCETRIS,pneumonia,clinical trial in ich the,1,0.5186870098114014
ADCETRIS,sepsis,g dose and,1,0.4962174594402313
ADCETRIS,sepsis,which the recommended g dose and schedule was,1,0.4853959083557129
ADCETRIS,sepsis,g dose and schedule was mgkg,1,0.4914500117301941
ADCETRIS,sepsis,in which the recommended g dose and schedule was mgkg,1,0.4964700937271118
ADCETRIS,sepsis,recommended g,1,0.5109493732452393
ADCETRIS,sepsis,recommended g dose,1,0.49305397272109985
ADCETRIS,sepsis,in a single arm clinical trial in which the,0,0.5570012927055359
ADCETRIS,sepsis,the recommended g dose and,1,0.4959897994995117
ADCETRIS,sepsis,which the recommended g dose and schedule was mgkg,1,0.48729878664016724
ADCETRIS,septic shock,arm clinical trial in which the,0,0.4948936104774475
ADCETRIS,septic shock,of treatment was,0,0.5785404443740845
ADCETRIS,septic shock,weeks Median duration of treatment was cycles range,0,0.5046831965446472
ADCETRIS,septic shock,s mgkg intravenously every weeks Median duration of treatment was cycles range s,0,0.5234991312026978
ADCETRIS,septic shock,treatment,0,0.5850721597671509
ADCETRIS,septic shock,schedule wa s mgkg intravenously,1,0.5789927244186401
ADCETRIS,septic shock,starting dose schedule wa,1,0.4428715705871582
ADCETRIS,septic shock,which the,0,0.47923025488853455
ADCETRIS,septic shock,schedule wa s mgkg,1,0.4676845073699951
ADCETRIS,septic shock,recommended starting dose  schedule wa s mgkg,1,0.4647800922393799
ADCETRIS,tumor lysis syndrome,"infection nausea diarrhea emia, pyrexia, throm bocytopenia rash",1,0.5678010582923889
ADCETRIS,tumor lysis syndrome,schedule wa s mgkg,1,0.5040913820266724
ADCETRIS,tumor lysis syndrome,neuropathy fatigue upper respiratory tract infection,0,0.4862656593322754
ADCETRIS,deaths,with classical HL at high risk of relapse or progression postautoHSCT in a randomiz,0,0.45215266942977905
ADCETRIS,deaths,died i n patients with classical,1,0.6901531219482422
ADCETRIS,deaths,Study ADCETRIS was died i,1,0.7232275009155273
ADCETRIS,deaths,Consolidation Study ADCETRIS was died,1,0.6350377798080444
ADCETRIS,deaths,HL PostautoHSCT,0,0.4905555546283722
ADCETRIS,deaths,at high risk of relapse or progression postautoHSCT,0,0.4536404013633728
ADCETRIS,deaths,died,1,0.8617929220199585
ADCETRIS,deaths,in Classical HL PostautoHSCT Consolidation Study ADCETRIS was stu,0,0.49087581038475037
ADCETRIS,deaths,classical HL at,0,0.4886922836303711
ADCETRIS,deaths,n patients with classical HL at high risk of relapse or,0,0.4596516788005829
ADCETRIS,deaths,  [see,1,0.5755661129951477
ADCETRIS,deaths,  [see Clinical Studies Standard international guidelines,1,0.4630807638168335
ADCETRIS,deaths,ADCETRIStreatment arm received cycles,0,0.4595336318016052
ADCETRIS,deaths,  [see Clinical Studies Standard international,1,0.4650880694389343
ADCETRIS,deaths,  [see Clinical,1,0.5102421641349792
ADCETRIS,deaths,Studies Standard international guidelines,0,0.47231775522232056
ADCETRIS,deaths,Studies Standard international guidelines were followed,0,0.48157474398612976
ADCETRIS,fatal,VZV prophylaxis with,0,0.4560229182243347
ADCETRIS,fatal,tient s received PCP,1,0.5130476951599121
ADCETRIS,fatal,a median duration of months,0,0.464850515127182
ADCETRIS,fatal,a median duration,0,0.5059245824813843
ADCETRIS,fatal,tient s received,1,0.5140811800956726
ADCETRIS,fatal,tient,1,0.535070538520813
ADCETRIS,hepatocellular injury,months range,0,0.4225321412086487
ADCETRIS,hepatocellular injury,"of months 



   Experience in  Systemic",1,0.5459505915641785
ADCETRIS,hepatocellular injury,median duration,0,0.47434157133102417
ADCETRIS,hepatocellular injury,of months Experience,1,0.4860208034515381
ADCETRIS,elevations of transaminases,Systemic,0,0.5677434206008911
ADCETRIS,elevations of transaminases,Cell Lymphoma Summary of,1,0.4759100675582886
ADCETRIS,elevations of transaminases,Experience in Systemic plastic,1,0.5462372303009033
ADCETRIS,elevations of transaminases,Systemic plastic Large,1,0.5478830933570862
ADCETRIS,elevations of transaminases,ADCETRIS,0,0.534355878829956
ADCETRIS,JC virus infection,"of causality were , anemia, peripher al sensory neuropathy",1,0.5474888682365417
ADCETRIS,JC virus infection,ADCETRIS,0,0.5169323682785034
ADCETRIS,JC virus infection,"regardless of causality were , anemia, peripher al sensory",1,0.5294705629348755
ADCETRIS,JC virus infection,most common adverse reactions,0,0.5336811542510986
ADCETRIS,JC virus infection,"causality were , anemia, peripher al",1,0.5369318723678589
ADCETRIS,JC virus infection,Table,0,0.4610157608985901
ADCETRIS,JC virus infection,regardless of causality were,0,0.48941704630851746
ADCETRIS,JC virus infection,", anemia, peripher",1,0.5327015519142151
ADCETRIS,JC virus infection,The most common,0,0.4725382328033447
ADCETRIS,PML,neutropenia anemia peripheral sensory rop athy fatigue nausea,1,0.5910989046096802
ADCETRIS,PML,The most common,0,0.5066877603530884
ADCETRIS,PML,Table,0,0.5208297371864319
ADCETRIS,PML,peripheral sensory rop athy fatigue nausea,1,0.5392773151397705
ADCETRIS,PML,neutropenia anemia,0,0.5776016712188721
ADCETRIS,PML,peripheral sensory neu,0,0.517878532409668
ADCETRIS,PML,neutropenia,0,0.6136506199836731
ADCETRIS,PML,rop athy fatigue nausea pyrexia,1,0.5670955181121826
ADCETRIS,PML,rop,1,0.514009952545166
ADCETRIS,Stevens-Johnson syndrome,Peripheral sensory neuropathy,0,0.584892213344574
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral sensory,1,0.5368438959121704
ADCETRIS,Stevens-Johnson syndrome,                        ,1,0.6094120740890503
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral,1,0.48290878534317017
ADCETRIS,Stevens-Johnson syndrome,Nervous system                         ,1,0.5451773405075073
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral sensory neuropathy,1,0.5848921537399292
ADCETRIS,SJS,    Peripheral sensory,1,0.48783400654792786
ADCETRIS,SJS,                         Peripheral sensory neuropathy,1,0.4634662866592407
ADCETRIS,SJS,   ,1,0.6164666414260864
ADCETRIS,SJS,stem     Peripheral sensory,1,0.494884192943573
ADCETRIS,SJS,Peripheral sensory,0,0.48783400654792786
ADCETRIS,SJS,    Peripheral,1,0.4855042099952698
ADCETRIS,SJS,Peripheral,0,0.48550426959991455
ADCETRIS,TEN,y   Peripheral,1,0.5258660316467285
ADCETRIS,TEN,neuropath,0,0.4754166603088379
ADCETRIS,TEN,y   Peripheral mot,1,0.5449074506759644
ADCETRIS,TEN,sensory neuropath,0,0.4716344177722931
ADCETRIS,TEN,sensory y   Peripheral,1,0.5290043354034424
ADCETRIS,fatal,sensory 52    Peripheral motor neuropathy,1,0.459144651889801
ADCETRIS,fatal,y   Peripheral mot,1,0.48299652338027954
ZERBAXA,Hypersensitivity reactions,in the Warnings and,0,0.5299489498138428
ZERBAXA,Hypersensitivity reactions,Hypersensitivity reactions see Warnings and Precautions,1,0.8611944913864136
ZERBAXA,Hypersensitivity reactions,Hypersensitivity reactions,1,1.0
ZERBAXA,Hypersensitivity reactions,Precautions Hypersensitivity reactions,1,0.8767232894897461
ZERBAXA,Hypersensitivity reactions,the Warnings and Precautions Hypersensitivity,1,0.8108158111572266
ZERBAXA,Hypersensitivity reactions,Hypersensitivity reactions see Warnings and,1,0.873037576675415
ZERBAXA,Hypersensitivity reactions,and Precautions section,0,0.5725700855255127
ZERBAXA,Hypersensitivity reactions,Warnings and Precautions Hypersensitivity reactions see Warnings,1,0.8283080458641052
ZERBAXA,Clostridium difficile -associated diarrhea,see Warnings and Clostridium difficile -associated diarrhea,1,0.8755958080291748
ZERBAXA,Clostridium difficile -associated diarrhea,and Precautions section,0,0.5030237436294556
ZERBAXA,nausea,adverse reactions in either indication,0,0.6237905621528625
ZERBAXA,nausea,in either indication nausea diarrhea headache and,1,0.7698435187339783
ZERBAXA,diarrhea,diarrhea headache,1,0.8032464981079102
ZERBAXA,headache,headache and pyrexia To report SUSPECTED,1,0.7554789781570435
ZERBAXA,pyrexia,report SUSPECTED ADVERSE REACTIONS contact Merck Sharp Dohme Corp,0,0.5567442178726196
ZERBAXA,pyrexia,diarrhea headache pyrexia To report,1,0.7872291207313538
ZERBAXA,pyrexia,pyrexia,1,1.0
ZERBAXA,pyrexia,nausea diarrhea headache pyrexia,1,0.8253398537635803
ZERBAXA,pyrexia,pyrexia To report SUSPECTED,1,0.8487449884414673
ZERBAXA,pyrexia,pyrexia To report,1,0.8917522430419922
ZERBAXA,nausea,nausea diarrhea headache and pyrexia,1,0.7627934217453003
ZERBAXA,nausea,adverse reactions or greater in either indication,0,0.615510106086731
ZERBAXA,nausea,nausea diarrhea headache and pyrexia Table,1,0.7497309446334839
ZERBAXA,nausea,in patients receiving ZERBAXA,0,0.5884928703308105
ZERBAXA,nausea,nausea,1,0.9999999403953552
ZERBAXA,nausea,indication occurring in patients receiving,0,0.5987875461578369
ZERBAXA,nausea,were,0,0.524542510509491
ZERBAXA,diarrhea,diarrhea headache and,1,0.813287615776062
ZERBAXA,diarrhea,adverse reactions occurring in or greater of patients rece,0,0.5675511956214905
ZERBAXA,diarrhea,headache and pyrexia Table lists adverse reactions occurring in or,0,0.5786927938461304
ZERBAXA,diarrhea,diarrhea headache and pyrexia Table lists,1,0.734424352645874
ZERBAXA,headache,occurring in or greater of,0,0.5241761207580566
ZERBAXA,headache,either indication occurring in patients receiving ZERBAXA were nausea diarrhea,0,0.533374547958374
ZERBAXA,headache,headache and pyrexia Table lists adverse,1,0.7272446155548096
ZERBAXA,headache,nausea headache,1,0.8364165425300598
ZERBAXA,headache,were nausea headache,1,0.8258686065673828
ZERBAXA,headache,headache and pyrexia Table lists,1,0.7376998662948608
ZERBAXA,headache,receiving ZERBAXA were,0,0.5203977227210999
ZERBAXA,pyrexia,were nausea diarrhea headache pyrexia Table lists adverse reactions,1,0.7629744410514832
ZERBAXA,pyrexia,headache and pyrexia Table lists adverse,1,0.7784618139266968
ZERBAXA,pyrexia,nausea,0,0.6547590494155884
ZERBAXA,pyrexia,headache,0,0.5772688388824463
ZERBAXA,Renal impairment,receiving comparator Renal impairment,1,0.8723117113113403
ZERBAXA,Renal impairment,comparator drugs,0,0.5381885766983032
ZERBAXA,Renal impairment,receiving comparator Renal impairment including the terms renal,1,0.8730113506317139
ZERBAXA,Renal impairment,patients receiving comparator drugs,0,0.5490520000457764
ZERBAXA,Renal impairment,receiving comparator Renal impairment including the terms,1,0.8337923288345337
ZERBAXA,Renal impairment,comparator Renal impairment including the,1,0.8674485087394714
ZERBAXA,Renal impairment,patients receiving comparator Renal impairment including,1,0.8370063900947571
ZERBAXA,Renal impairment,Renal,1,0.8530256748199463
ZERBAXA,renal impairment,renal impairment renal failure and renal,1,0.9003498554229736
ZERBAXA,renal impairment,patients receiving comparator drugs,0,0.5490520000457764
ZERBAXA,renal impairment,the terms,0,0.4347940683364868
ZERBAXA,renal impairment,impairment,0,0.7787888050079346
ZERBAXA,renal impairment,of patients receiving,0,0.5468555688858032
ZERBAXA,renal impairment,renal impairment renal failure and,1,0.9308056831359863
ZERBAXA,renal impairment,renal impairment renal failure,1,0.9071639180183411
ZERBAXA,renal impairment,to discontinuation,0,0.4535374343395233
ZERBAXA,renal impairment,treatment in,0,0.5502057075500488
ZERBAXA,renal failure,renal renal failure,1,0.9636938571929932
ZERBAXA,renal failure,renal failure and,1,0.9442847371101379
ZERBAXA,renal failure,of,0,0.5258084535598755
ZERBAXA,renal failure acute,renal failure acute,1,0.9999998211860657
ZERBAXA,death,death occurred in of,1,0.8349825739860535
ZERBAXA,death,death occurred in,1,0.8451774716377258
ZERBAXA,death,death occurred in of patients,1,0.6990238428115845
ZERBAXA,death,death varied and,1,0.7842695713043213
ZERBAXA,death,death varied and included worsening andor,1,0.7166832089424133
ZERBAXA,death,death varied and included,1,0.780504584312439
ZERBAXA,death,death varied and included worsening,1,0.7158520221710205
ZERBAXA,complications of infection,complications of infection,1,1.0000001192092896
ZERBAXA,complications of infection,varied and included worsening complications,1,0.7895780801773071
ZERBAXA,complications of infection,included worsening andor,0,0.6090325117111206
ZERBAXA,complications of infection,varied and included worsening complications of infection surgery and underlying,1,0.8642343282699585
ZERBAXA,complications of infection,varied and included worsening complications of,1,0.7989855408668518
ZERBAXA,complications of infection,Reactions The,0,0.49602192640304565
ZERBAXA,tachycardia,Cardiac tachycardia,1,0.9585098624229431
ZERBAXA,tachycardia,Reactions The,0,0.5421823263168335
ZERBAXA,tachycardia,in ZERBAXAtreated subjects at a rate of less,0,0.6037154197692871
ZERBAXA,tachycardia,less than Cardiac tachycardia angina pectoris Gastrointestinal disorders ileus,1,0.7606654167175293
ZERBAXA,angina pectoris,than Cardiac disorders angina pectoris,1,0.9294638633728027
ZERBAXA,angina pectoris,in ZERBAXAtreated subjects at a rate of less,0,0.5275001525878906
ZERBAXA,angina pectoris,angina pectoris,1,0.9999998807907104
ZERBAXA,angina pectoris,Cardiac disorders angina,1,0.8475568294525146
ZERBAXA,angina pectoris,than Cardiac disorders angina pectoris Gastrointestinal disorders,1,0.8146616220474243
ZERBAXA,ileus,ileus gastritis abdominal distension dyspepsia flatulence,1,0.7633674144744873
ZERBAXA,ileus,ileus paralytic General,0,0.8075101375579834
ZERBAXA,ileus,abdominal,0,0.6985695362091064
ZERBAXA,ileus,ileus,0,0.9999998807907104
ZERBAXA,ileus,tachycardia angina pectoris Gastrointestinal ileus gastritis abdominal distension dyspepsia,1,0.6758272647857666
ZERBAXA,ileus,Cardiac disorders tachycardia,0,0.5119436979293823
ZERBAXA,abdominal distension,tachycardia angina pectoris Gastrointestinal disorders ileus,0,0.6104269027709961
ZERBAXA,abdominal distension,ileus paralytic General disorders and,0,0.5959130525588989
ZERBAXA,abdominal distension,tachycardia angina pectoris Gastrointestinal disorders ileus gastritis,0,0.6054261922836304
ZERBAXA,abdominal distension,abdominal distension dyspepsia flatulence ileus,1,0.8301529288291931
ZERBAXA,abdominal distension,abdominal distension dyspepsia flatulence ileus paralytic,1,0.797831654548645
ZERBAXA,abdominal distension,abdominal distension dyspepsia flatulence ileus paralytic General,1,0.8011276721954346
ZERBAXA,abdominal distension,gastritis,0,0.6050310134887695
ZERBAXA,abdominal distension,disorders ileus abdominal distension dyspepsia flatulence ileus paralytic General,1,0.7342847585678101
ZERBAXA,abdominal distension,ileus,0,0.653958797454834
ZERBAXA,dyspepsia,Gastrointestinal disorders ileus gastritis abdominal,0,0.6475410461425781
ZERBAXA,dyspepsia,ileus paralytic General disorders and administration,0,0.575115442276001
ZERBAXA,dyspepsia,dyspepsia flatulence ileus paralytic General,1,0.7817949652671814
ZERBAXA,dyspepsia,angina pectoris Gastrointestinal disorders ileus gastritis abdominal,0,0.6446614861488342
ZERBAXA,dyspepsia,abdominal,0,0.5967363119125366
ZERBAXA,dyspepsia,disorders ileus gastritis abdominal dyspepsia flatulence ileus paralytic,1,0.7135597467422485
ZERBAXA,dyspepsia,gastritis abdominal dyspepsia flatulence ileus paralytic,1,0.7451638579368591
ZERBAXA,dyspepsia,ileus paralytic,0,0.5542556047439575
ZERBAXA,flatulence,na pectoris Gastrointestinal disorders ileus,0,0.615378201007843
ZERBAXA,flatulence,disorders ileus gastritis abdominal,0,0.6201761960983276
ZERBAXA,ileus paralytic,ileus paralytic,1,0.9999999403953552
ZERBAXA,ileus paralytic,ileus paralytic General disorders and administration site,1,0.8725950717926025
ZERBAXA,ileus paralytic,gastritis abdominal distension dyspepsia ileus paralytic,1,0.7960008382797241
ZERBAXA,ileus paralytic,Gastrointestinal disorders ileus,0,0.7833622694015503
ZERBAXA,ileus paralytic,ileus paralytic General disorders and administration,1,0.8870078325271606
ZERBAXA,infusion site reactions,conditions,0,0.5593827962875366
ZERBAXA,infusion site reactions,and infestations candidiasis,0,0.5604599714279175
ZERBAXA,candidiasis,and administration site conditions infusion,0,0.5535174608230591
ZERBAXA,candidiasis,infection Investigations increased serum gammagluta,0,0.6080163717269897
ZERBAXA,candidiasis,candidiasis oropharyngeal fungal urinary tract,1,0.760367751121521
ZERBAXA,fungal urinary tract infection,candidiasis fungal urinary tract infection Investigations increased serum gammaglutamyl,1,0.7724400758743286
ZERBAXA,fungal urinary tract infection,infection Investigations increased serum gammagluta,0,0.582067608833313
ZERBAXA,fungal urinary tract infection,GGT increased serum,0,0.5274753570556641
ZERBAXA,fungal urinary tract infection,tract infection Investigations increased,1,0.6249833106994629
ZERBAXA,fungal urinary tract infection,gammaglutamyl transpeptidase GGT increased serum,0,0.5092559456825256
ZERBAXA,fungal urinary tract infection,transpeptidase GGT increased serum,0,0.5038499236106873
ZERBAXA,fungal urinary tract infection,fungal,1,0.7778780460357666
ZERBAXA,increased serum gamma-glutamyl transpeptidase,phosphatase positive Coombs test,0,0.5967307686805725
ZERBAXA,increased serum gamma-glutamyl transpeptidase,tract infection increased serum gamma-glutamyl transpeptidase GGT,1,0.8948653340339661
ZERBAXA,increased serum gamma-glutamyl transpeptidase,fungal urinary tract infection Investigations,0,0.541301429271698
ZERBAXA,increased serum gamma-glutamyl transpeptidase,infection increased serum,1,0.6993804574012756
ZERBAXA,increased serum gamma-glutamyl transpeptidase,infection increased serum gamma-glutamyl transpeptidase,1,0.9325885772705078
ZERBAXA,increased serum gamma-glutamyl transpeptidase,gamma-glutamyl transpeptidase GGT increased serum alkaline,1,0.897060751914978
ZERBAXA,increased serum alkaline phosphatase,transpeptidase GGT,0,0.5703826546669006
ZERBAXA,increased serum alkaline phosphatase,tract,0,0.46774762868881226
ZERBAXA,increased serum alkaline phosphatase,increased serum alkaline phosphatase,1,1.0
ZERBAXA,increased serum alkaline phosphatase,increased serum alkaline phosphatase positive Coombs test Metabolism and,1,0.8850109577178955
ZERBAXA,increased serum alkaline phosphatase,increased serum alkaline phosphatase positive Coombs,1,0.9141678214073181
ZERBAXA,positive Coombs test,serum alkaline,0,0.544975221157074
ZERBAXA,positive Coombs test,positive Coombs test Metabolism and nutrition disorders hyperglycemia,1,0.840327262878418
ZERBAXA,positive Coombs test,positive Coombs test Metabolism and nutrition disorders,1,0.84797203540802
ZERBAXA,positive Coombs test,gations increased serum gammaglutamyl transpeptidase GGT increased serum alkaline phosphatase,0,0.575778067111969
ZERBAXA,positive Coombs test,GGT,0,0.561187744140625
ZERBAXA,hyperglycemia,hyperglycemia,1,1.0000001192092896
ZERBAXA,hyperglycemia,test Metabolism and nutrition hyperglycemia hypomagnesemia hypophosphatemia,1,0.6950958967208862
ZERBAXA,hyperglycemia,eased serum alkaline,0,0.4979169964790344
ZERBAXA,hyperglycemia,ischemic stroke Renal,0,0.5282167196273804
ZERBAXA,hyperglycemia,hyperglycemia hypomagnesemia,1,0.8082759380340576
ZERBAXA,hyperglycemia,hyperglycemia hypomagnesemia hypophosphatemia Nervous,1,0.7663522362709045
ZERBAXA,hypomagnesemia,hypomagnesemia,1,1.0
ZERBAXA,hypomagnesemia,hyperglycemia hypomagnesemia hypophosphatemia Nervous,1,0.8034744262695312
ZERBAXA,ischemic stroke,Nervous system ischemic stroke Renal,1,0.7927164435386658
ZERBAXA,ischemic stroke,hyperglycemia hypomagnesemia hypophosphatemia Nervous,1,0.5509518384933472
ZERBAXA,ischemic stroke,hypomagnesemia hypophosphatemia Nervous system ischemic stroke Renal and urinary system,1,0.7040106058120728
ZERBAXA,ischemic stroke,Renal and urinary system,0,0.5645252466201782
ZERBAXA,ischemic stroke,system renal impairment renal failure,0,0.5274132490158081
ZERBAXA,ischemic stroke,hypophosphatemia Nervous system ischemic stroke,1,0.7703549861907959
ZERBAXA,ischemic stroke,ischemic stroke Renal,1,0.8183727264404297
ZERBAXA,ischemic stroke,ischemic,1,0.8428610563278198
ZERBAXA,renal impairment,renal impairment renal failure Respiratory thoracic and,1,0.8530992865562439
ZERBAXA,renal failure,impairment,0,0.5875930190086365
ZERBAXA,renal failure,thoracic and mediastinal disorders dyspnea Skin and,0,0.5138978958129883
ZERBAXA,renal failure,renal renal failure Respiratory thoracic,1,0.8191553950309753
ZERBAXA,dyspnea,dyspnea Skin and,1,0.8810621500015259
ZERBAXA,dyspnea,dyspnea Skin and subcutaneous tissue disorders,1,0.8168855905532837
ZERBAXA,dyspnea,and subcutaneous tissue disorders urticaria Vascular disorders,0,0.5282067656517029
ZERBAXA,dyspnea,disorders urticaria Vascular disorders,0,0.5283136963844299
ZERBAXA,dyspnea,dyspnea Skin,1,0.8889379501342773
ZERBAXA,dyspnea,disorders urticaria Vascular disorders venous thro,0,0.5466923713684082
ZERBAXA,dyspnea,tissue disorders urticaria Vascular,0,0.508534848690033
ZERBAXA,dyspnea,and mediastinal,0,0.6193438172340393
ZERBAXA,dyspnea,urticaria Vascular disorders,0,0.5259038209915161
ZERBAXA,urticaria,Vascular disorders,0,0.5273141860961914
ZERBAXA,Clostridium difficile -associated diarrhea,"To report SUSPECTED ADVERSE S, contact Merck Sharp & Dohme Corp., a su",1,0.510229229927063
ZERBAXA,Clostridium difficile -associated diarrhea,Vascular disorders,0,0.47366803884506226
ZERBAXA,Clostridium difficile -associated diarrhea,"S, contact Merck Sharp & Dohme Corp., a su bsidiary of Merck Co Inc",1,0.4944823682308197
ZERBAXA,Clostridium difficile -associated diarrhea,REACTION,0,0.4884291887283325
ZERBAXA,Clostridium difficile -associated diarrhea,bsidiary of Merck Co,0,0.48853468894958496
ZERBAXA,Clostridium difficile -associated diarrhea,"S, contact Merck Sharp & Dohme",1,0.4690555930137634
ZERBAXA,CDAD,idia ry of Merck,1,0.529689610004425
ZERBAXA,CDAD,"S, contact Merck Sharp & Dohme",1,0.4823867678642273
ZERBAXA,CDAD,or FDA,0,0.5748104453086853
ZERBAXA,CDAD,idia,1,0.6150631308555603
ZERBAXA,CDAD,ADVERSE REACTIONS contact Merck Sharp Dohme Corp a,0,0.482890248298645
ZERBAXA,fatal,patients receiving ZERBAXA in Phase clinical,0,0.4836818277835846
ZERBAXA,fatal,g in or,1,0.5087891221046448
ZERBAXA,fatal,ZERBAXA in Phase,0,0.497136652469635
ZERBAXA,fatal,reactions g,1,0.5388140082359314
ZERBAXA,fatal,of patients receiving ZERBAXA in Phase clinical trials Table,0,0.46283817291259766
ZYDELIG,Hepatotoxicity,and are,0,0.49865469336509705
ZYDELIG,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions Severe,1,0.8674767017364502
ZYDELIG,Hepatotoxicity,sections of the prescribing Hepatotoxicity see Warnings and Precautions Severe,1,0.8104254007339478
ZYDELIG,Hepatotoxicity,Hepatotoxicity see Warnings and,1,0.9071921110153198
ZYDELIG,Hepatotoxicity,sections of the prescribing Hepatotoxicity,1,0.8506510257720947
ZYDELIG,Hepatotoxicity,sections,0,0.4990241527557373
ZYDELIG,Hepatotoxicity,the prescribing Hepatotoxicity see Warnings and,1,0.8506027460098267
ZYDELIG,Diarrhea,Diarrhea,1,1.0
ZYDELIG,Diarrhea,Pneumonitis see,0,0.5009602308273315
ZYDELIG,Diarrhea,and Precautions Diarrhea or Colitis see Warnings,1,0.7558242082595825
ZYDELIG,Colitis,Colitis see,1,0.8998700380325317
ZYDELIG,Colitis,Colitis see Warnings and Precautions Pneumonitis,1,0.7832717895507812
ZYDELIG,Colitis,Precautions Severe Diarrhea Colitis see Warnings,1,0.752149224281311
ZYDELIG,Colitis,information Hepatotoxicity see Warnings and,0,0.5522382259368896
ZYDELIG,Colitis,Colitis see Warnings,1,0.8344046473503113
ZYDELIG,Colitis,and Precautions Severe Diarrhea Colitis see Warnings,1,0.7565523982048035
ZYDELIG,Colitis,Colitis see Warnings and,1,0.8362724781036377
ZYDELIG,Pneumonitis,Pneumonitis,1,1.0
ZYDELIG,Intestinal Perforation,Pneumonitis see Warnings and Intestinal,1,0.6503836512565613
ZYDELIG,Cutaneous Reactions,Cutaneous Reactions see Warnings and Precautions Anaphylaxis,1,0.8588436841964722
ZYDELIG,Cutaneous Reactions,Perforation see Warnings and Precautions Severe,0,0.579785168170929
ZYDELIG,Cutaneous Reactions,Precautions Severe,0,0.5802184343338013
ZYDELIG,Cutaneous Reactions,Warnings and,0,0.5601975917816162
ZYDELIG,Cutaneous Reactions,see Warnings and Precautions Cutaneous Reactions see,1,0.8717920780181885
ZYDELIG,Cutaneous Reactions,see Warnings and Precautions Cutaneous Reactions,1,0.873275637626648
ZYDELIG,Cutaneous Reactions,Anaphylaxis see Warnings and,0,0.6912937164306641
ZYDELIG,Anaphylaxis,see Warnings and Precautions Neutropenia see Warnings,0,0.5474573373794556
ZYDELIG,Anaphylaxis,Anaphylaxis,1,0.9999998211860657
ZYDELIG,Anaphylaxis,and Precautions,0,0.5631759166717529
ZYDELIG,Anaphylaxis,Anaphylaxis see Warnings and Precautions Neutropenia,1,0.7904301881790161
ZYDELIG,Anaphylaxis,Reactions see Warnings and Anaphylaxis see Warnings and Precautions Neutropenia,1,0.7720829844474792
ZYDELIG,Neutropenia,see Warnings,0,0.5192054510116577
ZYDELIG,Neutropenia,Warnings and Precautions EXCERPT The,0,0.5446453094482422
ZYDELIG,diarrhea,common adverse reactions incidence diarrhea pyrexia fatigue,1,0.6894574165344238
ZYDELIG,diarrhea,Warnings and Precautions EXCERPT The,0,0.5741189122200012
ZYDELIG,diarrhea,nausea cough pneumonia,0,0.5481928586959839
ZYDELIG,diarrhea,incidence,0,0.5940293073654175
ZYDELIG,diarrhea,common adverse reactions incidence are,0,0.5545367002487183
ZYDELIG,diarrhea,diarrhea pyrexia fatigue nausea,1,0.758004903793335
ZYDELIG,diarrhea,adverse reactions incidence,0,0.5747090578079224
ZYDELIG,pyrexia,diarrhea,0,0.5893707275390625
ZYDELIG,pyrexia,EXCERPT The most common adverse,0,0.5332965850830078
ZYDELIG,pyrexia,chills and,0,0.6000276803970337
ZYDELIG,pyrexia,pyrexia fatigue nausea,1,0.8742327094078064
ZYDELIG,fatigue,rash The most common laborato,0,0.5576004385948181
ZYDELIG,fatigue,fatigue nausea cough pneumonia abdominal,1,0.7659902572631836
ZYDELIG,fatigue,fatigue nausea cough pneumonia,1,0.7926285266876221
ZYDELIG,fatigue,chills,0,0.531925618648529
ZYDELIG,nausea,diarrhea pyrexia nausea cough pneumonia abdominal,1,0.7621643543243408
ZYDELIG,nausea,chills,0,0.6362448930740356
ZYDELIG,nausea,nausea,1,1.0
ZYDELIG,nausea,chills and rash,0,0.6522557735443115
ZYDELIG,nausea,diarrhea pyrexia nausea,1,0.7940409183502197
ZYDELIG,nausea,pain chills and rash The most common laboratory,0,0.6072516441345215
ZYDELIG,nausea,nausea cough pneumonia abdominal,1,0.7792527675628662
ZYDELIG,nausea,reactions incidence,0,0.5829264521598816
ZYDELIG,nausea,most,0,0.5011175870895386
ZYDELIG,nausea,common adverse,0,0.5723273754119873
ZYDELIG,cough,cough pneumonia abdominal pain chills and,1,0.7616000771522522
ZYDELIG,cough,adverse reactions incidence are diarrhea pyrexia fatigue nausea,0,0.5604102611541748
ZYDELIG,cough,The most,0,0.5171912908554077
ZYDELIG,cough,cough,1,1.0
ZYDELIG,cough,cough pneumonia abdominal pain chills,1,0.7632054090499878
ZYDELIG,cough,pneumonia abdominal pain chills and rash The most common laboratory,0,0.6386421918869019
ZYDELIG,cough,chills and rash The most common,0,0.553727924823761
ZYDELIG,cough,common laboratory,0,0.5081402063369751
ZYDELIG,cough,and rash The most common,0,0.5435585379600525
ZYDELIG,pneumonia,pneumonia abdominal pain chills and rash,1,0.7714038491249084
ZYDELIG,pneumonia,reactions incidence are,0,0.4887998104095459
ZYDELIG,pneumonia,laboratory abnormalities,0,0.5505695343017578
ZYDELIG,abdominal pain,abdominal pain chills and rash The,1,0.813654899597168
ZYDELIG,abdominal pain,fatigue nausea cough abdominal pain chills and,1,0.7273679971694946
ZYDELIG,abdominal pain,pyrexia fatigue nausea,0,0.5759451985359192
ZYDELIG,abdominal pain,nausea cough abdominal pain,1,0.8721297383308411
ZYDELIG,abdominal pain,cough abdominal,1,0.7888228893280029
ZYDELIG,abdominal pain,abdominal pain chills and rash,1,0.811043918132782
ZYDELIG,abdominal pain,abdominal pain chills and,1,0.8696017861366272
ZYDELIG,chills,diarrhea pyrexia fatigue nausea cough,0,0.6007419228553772
ZYDELIG,chills,fatigue nausea,0,0.5410305261611938
ZYDELIG,chills,chills and rash The most,1,0.8429592847824097
ZYDELIG,chills,nausea cough pneumonia abdominal chills and rash,1,0.7016851305961609
ZYDELIG,chills,diarrhea pyrexia fatigue nausea cough pneumonia abdominal pain,0,0.5976245403289795
ZYDELIG,chills,chills and,1,0.9623491764068604
ZYDELIG,rash,abdominal pain,0,0.5441004037857056
ZYDELIG,rash,abdominal pain chills rash The most common laboratory,1,0.7160178422927856
ZYDELIG,rash,rash The most common,1,0.8459761142730713
ZYDELIG,rash,common laboratory abnormalities incidence are neutropenia hypertri,0,0.5041579008102417
ZYDELIG,rash,pain chills rash The most,1,0.7840293645858765
ZYDELIG,neutropenia,neutropenia,1,1.0000001192092896
ZYDELIG,neutropenia,common laboratory abnormalities incidence are neutropenia hypertri,0,0.7480812072753906
ZYDELIG,neutropenia,common laboratory abnormalities incidence neutropenia,1,0.8184221982955933
ZYDELIG,neutropenia,elevations,0,0.49687469005584717
ZYDELIG,neutropenia,common laboratory abnormalities incidence neutropenia hypertriglyceridemia hyperglycemia,1,0.6979151368141174
ZYDELIG,neutropenia,incidence neutropenia hypertriglyceridemia hyperglycemia,1,0.752485990524292
ZYDELIG,neutropenia,common laboratory abnormalities incidence neutropenia hypertriglyceridemia hyperglycemia ALT elevations,1,0.6846827268600464
ZYDELIG,neutropenia,neutropenia hypertriglyceridemia hyperglycemia,1,0.7703125476837158
ZYDELIG,hypertriglyceridemia,laboratory abnormalities incidence are hypertriglyceridemia hyperglycemia,1,0.83160400390625
ZYDELIG,hypertriglyceridemia,neutropenia hypertriglyceridemia hyperglycemia,1,0.8088871240615845
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia ALT elevations and AST,1,0.8234468698501587
ZYDELIG,hypertriglyceridemia,laboratory abnormalities incidence are hypertriglyceridemia hyperglycemia ALT elevations,1,0.8266531229019165
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia ALT elevations and,1,0.8642776012420654
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia ALT elevations,1,0.8517357110977173
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia,1,0.9175441861152649
ZYDELIG,hypertriglyceridemia,most common,0,0.5162882804870605
ZYDELIG,hyperglycemia,hyperglycemia,1,1.0000001192092896
ZYDELIG,hyperglycemia,SUSPECTED ADVERSE REACTIONS contact,0,0.5359010696411133
ZYDELIG,hyperglycemia,incidence are neutropenia hypertriglyceridemia,0,0.620772123336792
ZYDELIG,hyperglycemia,hyperglycemia ALT,1,0.8875863552093506
ZYDELIG,ALT elevations,incidence are neutropenia,0,0.4690532982349396
ZYDELIG,AST elevations,and,0,0.5299937129020691
ZYDELIG,AST elevations,incidence are neutropenia hypertriglyceridemia,0,0.49690213799476624
ZYDELIG,AST elevations,Inc,0,0.5219980478286743
ZYDELIG,AST elevations,SUSPECTED ADVERSE REACTIONS contact,0,0.5136045813560486
ZYDELIG,AST elevations,AST elevations To report SUSPECTED ADVERSE REACTIONS,1,0.7863452434539795
ZYDELIG,AST elevations,hyperglycemia ALT elevations AST elevations To report,1,0.779371976852417
ZYDELIG,AST elevations,hyperglycemia ALT elevations AST elevations,1,0.8123209476470947
ZYDELIG,AST elevations,contact,0,0.5168542861938477
ZYDELIG,AST elevations,AST elevations,1,1.0
ZYDELIG,pyrexia,were pyrexia,1,0.9577805995941162
ZYDELIG,pyrexia,AST elevations,1,0.4956304430961609
ZYDELIG,pyrexia,treated with Zydelig were pyrexia sepsis,1,0.7456321716308594
ZYDELIG,pyrexia,febrile neutropenia and diarrhea Adverse reactions that led to discon,0,0.598506510257721
ZYDELIG,pyrexia,reported for subjects treated with,0,0.5390537977218628
ZYDELIG,sepsis,were pneumonia sepsis febrile neutropenia,1,0.7512461543083191
ZYDELIG,sepsis,reported for subjects treated with,0,0.5540884733200073
ZYDELIG,sepsis,us adverse reactions reported for subjects treated with Zydelig,0,0.4977530241012573
ZYDELIG,sepsis,Zydelig were pneumonia sepsis,1,0.7843946814537048
ZYDELIG,sepsis,sepsis,1,1.0
ZYDELIG,sepsis,for subjects treated,0,0.5744798183441162
ZYDELIG,sepsis,led,0,0.55397629737854
ZYDELIG,sepsis,pneumonia,0,0.7199350595474243
ZYDELIG,sepsis,Zydelig were pneumonia sepsis febrile neutropenia,1,0.749445915222168
ZYDELIG,sepsis,Adverse reactions that led to discontinuation,0,0.5456292033195496
ZYDELIG,sepsis,sepsis febrile neutropenia,1,0.8073252439498901
ZYDELIG,diarrhea,febrile neutropenia diarrhea Adverse reactions,1,0.6742851734161377
ZYDELIG,diarrhea,sepsis febrile neutropenia,1,0.5396621227264404
ZYDELIG,diarrhea,with,0,0.5974210500717163
ZYDELIG,diarrhea,diarrhea Adverse reactions that led,1,0.7830038666725159
ZYDELIG,diarrhea,pyrexia sepsis febrile neutropenia and,0,0.5851137638092041
ZYDELIG,diarrhea,diarrhea Adverse reactions that,1,0.7910159826278687
ZYDELIG,diarrhea,diarrhea Adverse reactions,1,0.7996008396148682
ZYDELIG,diarrhea,diarrhea,1,1.0
ZYDELIG,diarrhea,Zydelig were pneumonia pyrexia sepsis,0,0.6140239834785461
ZYDELIG,hepatotoxicity,hepatotoxicity and diarrheacolitis Thirtynine subjects had,1,0.8268994092941284
ZYDELIG,hepatotoxicity,Zydelig were pneumonia pyrexia sepsis,0,0.5322409272193909
ZYDELIG,hepatotoxicity,discontinuations hepatotoxicity and diarrheacolitis Thirtynine,1,0.780815839767456
ZYDELIG,diarrhea,diarrhea colitis Thirtynine subjects had dose,1,0.7502249479293823
ZYDELIG,diarrhea,common adverse reactions that led to,0,0.5792973041534424
ZYDELIG,colitis,dose,0,0.5794552564620972
ZYDELIG,colitis,and colitis Thirtynine,1,0.8131335973739624
ZYDELIG,colitis,to treatment discontinuations were hepatotoxicity and,0,0.5454442501068115
ZYDELIG,colitis,and colitis,1,0.9067327380180359
ZYDELIG,elevated transaminases,adverse reactions,0,0.6177718043327332
ZYDELIG,elevated transaminases,to adverse reactions or laboratory abnormalities The most common reasons for dose reductions were,0,0.561713457107544
ZYDELIG,elevated transaminases,reductions elevated transaminases diarrhea or colitis and rash,1,0.8419914245605469
ZYDELIG,elevated transaminases,adverse reactions and labo,0,0.5743408203125
ZYDELIG,elevated transaminases,elevated transaminases diarrhea,1,0.9316891431808472
ZYDELIG,elevated transaminases,elevated transaminases diarrhea or colitis,1,0.9080938100814819
ZYDELIG,elevated transaminases,elevated transaminases diarrhea or,1,0.928898274898529
ZYDELIG,colitis,or,0,0.5204747915267944
ZYDELIG,colitis,colitis and rash Table and Table,1,0.7740598320960999
ZYDELIG,colitis,and Table summarize common adverse reactions,0,0.5761984586715698
ZYDELIG,rash,common reasons for dose reductions were,0,0.49592238664627075
ZYDELIG,rash,or colitis rash,1,0.8255314826965332
ZYDELIG,rash,rash Table and Table,1,0.7296828031539917
ZYDELIG,rash,rash Table and Table summarize,1,0.697502851486206
ZYDELIG,rash,abnormalities reported,0,0.5016530752182007
ZYDELIG,rash,abnormalities reported f,0,0.496934175491333
ZYDELIG,rash,Table summarize,0,0.49459347128868103
ZYDELIG,rash,colitis rash Table and,1,0.7655601501464844
ZYDELIG,neutrophil count decreased,neutrophil count decreased lymphocyte,1,0.9029324650764465
ZYDELIG,neutrophil count decreased,neutrophil count decreased,1,1.0
ZYDELIG,neutrophil count decreased,neutrophil count decreased lymphocyte co,1,0.8902809619903564
ZYDELIG,neutrophil count decreased,version R rituximab Hematology neutrophil count decreased lymphocyte co,1,0.7742739915847778
ZYDELIG,neutrophil count decreased,R,0,0.49164730310440063
ZYDELIG,lymphocyte count decreased,unt,0,0.43990790843963623
ZYDELIG,lymphocyte count increased,lymphocyte count,1,0.9033122658729553
ZYDELIG,lymphocyte count increased,lymphocyte count increased,1,1.0
ZYDELIG,lymphocyte count increased,lymphocyte,1,0.8316217064857483
ZYDELIG,lymphocyte count increased,unt lymphocyte count,1,0.8194619417190552
ZYDELIG,lymphocyte count increased,decreased,0,0.4713190793991089
ZYDELIG,lymphocyte count increased,count increased Serum,1,0.7298436760902405
ZYDELIG,lymphocyte count increased,lymphocyte count increased Serum,1,0.9294049739837646
ZYDELIG,pneumonia,pneumonia diarrhea and pyrexia Adverse,1,0.7570760250091553
ZYDELIG,pneumonia,pneumonia diarrhea,1,0.8426756262779236
ZYDELIG,pneumonia,pneumonia,1,0.9999997615814209
ZYDELIG,pneumonia,reactions that occurred pneumonia,1,0.7894019484519958
ZYDELIG,pneumonia,The,0,0.5524052977561951
ZYDELIG,pneumonia,pneumonia diarrhea and pyrexia Adverse reactions,1,0.7229891419410706
ZYDELIG,diarrhea,pneumonia,0,0.6291286945343018
ZYDELIG,diarrhea,diarrhea and pyrexia Adverse reactions resulted,1,0.7545322179794312
ZYDELIG,diarrhea,reactions that occurred were diarrhea,1,0.8156325817108154
ZYDELIG,diarrhea,diarrhea and,1,0.9006589651107788
ZYDELIG,diarrhea,diarrhea and pyrexia Adverse,1,0.7668960690498352
ZYDELIG,diarrhea,in interruption,0,0.5055346488952637
ZYDELIG,diarrhea,that occurred were diarrhea and pyrexia Adverse,1,0.7623633146286011
ZYDELIG,diarrhea,occurred were diarrhea and,1,0.8807530403137207
ZYDELIG,pyrexia,adverse reactions,0,0.5673512816429138
ZYDELIG,pyrexia,most frequent serious,0,0.5404036641120911
ZYDELIG,pyrexia,interruption or discontinuation for,0,0.4857555627822876
ZYDELIG,pyrexia,pyrexia Adverse reactions resulted in interruption,1,0.8155876398086548
ZYDELIG,diarrhea,for interruption or discontinuations diarrhea pneumonia and elevated,1,0.7076544761657715
ZYDELIG,diarrhea,pyrexia Adverse reactions resulted in interruption,1,0.5807279944419861
ZYDELIG,diarrhea,diarrhea pneumonia and elevated,1,0.753818690776825
ZYDELIG,diarrhea,discontinuations diarrhea pneumonia and elevated,1,0.7184668779373169
ZYDELIG,diarrhea,or,0,0.5481347441673279
ZYDELIG,diarrhea,diarrhea pneumonia,1,0.7832856774330139
ZYDELIG,diarrhea,Table provides the adverse reaction,0,0.5878993272781372
ZYDELIG,diarrhea,for interruption or discontinuations were,0,0.48661136627197266
ZYDELIG,diarrhea,ntinuation,0,0.5457379221916199
ZYDELIG,diarrhea,subjects The most common reasons for interruption,0,0.4903962016105652
ZYDELIG,elevated transaminases,pneumonia elevated transaminases Table provides the adverse reactions,1,0.838323712348938
ZYDELIG,elevated transaminases,diarrhea pneumonia,1,0.503404974937439
ZYDELIG,elevated transaminases,elevated transaminases Table provides,1,0.904753565788269
ZYDELIG,elevated transaminases,elevated transaminases Table provides the,1,0.9008430242538452
ZYDELIG,elevated transaminases,or discontinuations were diarrhea pneumonia,0,0.5054235458374023
ZYDELIG,elevated transaminases,were diarrhea pneumonia,0,0.5059479475021362
ZYDELIG,elevated transaminases,elevated transaminases Table,1,0.9341878294944763
ZYDELIG,upper respiratory tract infection,Respiratory thoracic,0,0.6743854880332947
ZYDELIG,FATAL,ADVERSE REACTIONS The,0,0.5748103260993958
ZYDELIG,FATAL, foll owing serious adverse reactions,1,0.6183257102966309
ZYDELIG,FATAL,REACTIONS The,0,0.5555377006530762
ZYDELIG,FATAL,The,0,0.5483651161193848
ZYDELIG,FATAL,REACTIONS  foll owing serious,1,0.6312242746353149
ZYDELIG,FATAL, foll owing serious,1,0.6736274361610413
ZYDELIG,FATAL,ADVERSE REACTIONS  foll owing,1,0.5719163417816162
ZYDELIG,FATAL, foll owing serious adverse,1,0.6893491744995117
ZYDELIG,TOXICITIES,serious,0,0.5634379386901855
ZYDELIG,TOXICITIES,The following,0,0.5749998688697815
ZYDELIG,TOXICITIES,following adverse r,1,0.620714008808136
ZYDELIG,TOXICITIES,REACTIONS The following  adverse r,1,0.681550920009613
ZYDELIG,TOXICITIES,following  adverse r eactions have,1,0.6951947212219238
ZYDELIG,TOXICITIES,adverse r eactions have,1,0.6740561723709106
ZYDELIG,TOXICITIES,REACTIONS The following adverse r,1,0.6815509796142578
ZYDELIG,COLITIS,been d with,1,0.5666990280151367
ZYDELIG,COLITIS,are discussed in greater detail in other sections of the,0,0.48814430832862854
ZYDELIG,COLITIS,have been d with  Zydelig in,1,0.5492920279502869
ZYDELIG,COLITIS,and are discussed in greater detail in,0,0.4887898564338684
ZYDELIG,COLITIS,d with Zydelig in clinical trials and,1,0.591316282749176
ZYDELIG,COLITIS,reactions have been d with  Zydelig in,1,0.5397337675094604
ZYDELIG,COLITIS,d with,1,0.5834630727767944
ZYDELIG,COLITIS,greater detail in,0,0.5195269584655762
ZYDELIG,COLITIS,have been,0,0.5299893617630005
ZYDELIG,PNEUMONITIS,discussed in,0,0.48980966210365295
ZYDELIG,PNEUMONITIS,the prescribing,0,0.49798381328582764
ZYDELIG,PNEUMONITIS,The following serious adverse reactions have been associated,0,0.5622341632843018
ZYDELIG,PNEUMONITIS,adverse reactions have,0,0.5589108467102051
ZYDELIG,PNEUMONITIS,and are discussed in,0,0.47157466411590576
ZYDELIG,PNEUMONITIS,The following serious adverse reactions have been,0,0.5608329176902771
ZYDELIG,INTESTINAL PERFORATION,clinical,0,0.5606193542480469
ZYDELIG,INTESTINAL PERFORATION,trials and are discuss ed,1,0.5194950699806213
ZYDELIG,INTESTINAL PERFORATION,detail in,0,0.5358444452285767
ZYDELIG,INTESTINAL PERFORATION,and are discuss ed,1,0.5033777356147766
ZYDELIG,INTESTINAL PERFORATION,associated with Zydelig in trials and,1,0.5042555332183838
ZYDELIG,INTESTINAL PERFORATION,associated with Zydelig in trials and are,1,0.4961398243904114
ZYDELIG,INTESTINAL PERFORATION,associated with Zydelig in clinical,0,0.5351357460021973
ZYDELIG,INTESTINAL PERFORATION,reactions have been associated with,0,0.5137278437614441
ZYDELIG,INTESTINAL PERFORATION,sections of the prescribing information Hepatotoxicity,0,0.5249521732330322
ZYDELIG,FATAL, deta,1,0.5321704149246216
ZYDELIG,FATAL,sections of the prescribing information Hepatotoxicity,0,0.5606730580329895
ZYDELIG,FATAL,sections of the prescribing information Hepatotoxicity see Warnings and,0,0.5596508979797363
ZYDELIG,FATAL,clinical trials and are discussed in greater,0,0.4677477777004242
ZYDELIG,FATAL,clinical trials and are discussed,0,0.45639005303382874
ZYDELIG,FATAL,information Hepatotoxicity see Warnings and,0,0.5873637199401855
ZYDELIG,FATAL, deta il in other,1,0.565610945224762
ZYDELIG,FATAL,greater,0,0.5033320784568787
ZYDELIG,FATAL,are discussed in  deta il in other sections,1,0.49620485305786133
ZYDELIG,DIARRHEA,on Hepatotoxicity see Warnings and Precautions Severe,0,0.5583983659744263
ZYDELIG,DIARRHEA,nformati on Hepatotoxicity see Warnings and,1,0.5871309638023376
ZYDELIG,DIARRHEA,in other sections of,0,0.5172865986824036
ZYDELIG,DIARRHEA,detail in other sections of,0,0.5118474960327148
ZYDELIG,DIARRHEA,nformati on Hepatotoxicity see Warnings,1,0.5831251740455627
ZYDELIG,DIARRHEA,of the prescribing nformati on,1,0.5465379953384399
ZYDELIG,DIARRHEA,Hepatotoxicity see Warnings and Precautions,0,0.5601508021354675
ZYDELIG,COLITIS,"the prescribing .



 * Hepatotoxicity see Warnings and",1,0.5496945381164551
ZYDELIG,COLITIS,Hepatotoxicity see Warnings and Precautions,0,0.5476807355880737
ZYDELIG,PNEUMONITIS,Hepatotoxic ity,1,0.5050193071365356
ZYDELIG,PNEUMONITIS,see Warnings and Prec,0,0.5208745002746582
ZYDELIG,PNEUMONITIS,Hepatotoxic,1,0.48550036549568176
ZYDELIG,PNEUMONITIS,Diarrhea or Colitis see,0,0.5180269479751587
ZYDELIG,PNEUMONITIS,discussed in greater detail in other,0,0.4839424788951874
ZYDELIG,INTESTINAL PERFORATION,the prescribing information Hepatotoxicity,0,0.5274754762649536
ZYDELIG,INTESTINAL PERFORATION,Hepatotoxicity e Warnings,1,0.550511360168457
ZYDELIG,INTESTINAL PERFORATION,or,0,0.49622300267219543
ZYDELIG,INTESTINAL PERFORATION,Hepatotoxicity e  Warnings and Precau tions Severe Diarrhea or,1,0.6083593368530273
ZYDELIG,INTESTINAL PERFORATION,greater,0,0.4928183853626251
ZYDELIG,INTESTINAL PERFORATION,prescribing information Hepatotoxicity e  Warnings and Precau tions Severe Diarrhea,1,0.598135769367218
ZYDELIG,Fatal,see,0,0.5040662884712219
ZYDELIG,Fatal,1) ] Severe Diarrhea or Colitis,1,0.5980183482170105
ZYDELIG,Fatal,Precautions Pneumonitis see,0,0.49620547890663147
ZYDELIG,Fatal,and 1),1,0.5155128836631775
ZYDELIG,Fatal,see Warnings and 1)  ],1,0.5484615564346313
ZYDELIG,hepatotoxicity,Warnings and,0,0.5879274606704712
ZYDELIG,hepatotoxicity,Warnings and Precautions Severe arrhea or Coli tis see Warnings and,1,0.5517587661743164
ZYDELIG,hepatotoxicity,and,0,0.5135397911071777
ZYDELIG,hepatotoxicity,or Coli tis see Warnings and,1,0.580340564250946
ZYDELIG,hepatotoxicity,or Coli tis,1,0.5240968465805054
ZYDELIG,hepatotoxicity,Hepatotoxicity,0,1.0
ZYDELIG,hepatotoxicity,arrhea or Coli tis,1,0.5032204389572144
ZYDELIG,hepatotoxicity,Warnings and Precautions Pneumonitis,0,0.5279430150985718
ZYDELIG,hepatotoxicity,Precautions Pneumonitis see Warnings and,0,0.5276819467544556
ZYDELIG,hepatotoxicity,escribing information Hepatotoxicity see Warnings and Precautions Severe Di,0,0.8400930166244507
ZYDELIG,Fatal,"]  
 ",1,0.6085816621780396
ZYDELIG,Fatal,"Warnings and ]  
  Anaphylaxis see Warnings and Precautions",1,0.5254032015800476
ZYDELIG,Fatal,"see Warnings and ]  
  Anaphylaxis see Warnings and",1,0.5559011697769165
ZYDELIG,Fatal,"]  
  Anaphylaxis see",1,0.5326783061027527
ZYDELIG,diarrhea,gs and P recautions Neutropenia see,1,0.5202761292457581
ZYDELIG,diarrhea,"]  
  Anaphylaxis see",1,0.6174541711807251
ZYDELIG,diarrhea,Warnings and Precautions EXCERPT,0,0.567152738571167
ZYDELIG,diarrhea,Anaphylaxis see gs and P,1,0.6010842323303223
ZYDELIG,diarrhea,and P recautions Neutropenia see Warnings,1,0.5550306439399719
ZYDELIG,diarrhea,recautions Neutropenia,0,0.532806396484375
ZYDELIG,diarrhea,and P,1,0.571854293346405
ZYDELIG,diarrhea,Warnings and Precautions,0,0.5735007524490356
ZYDELIG,colitis,see,0,0.5613054037094116
ZYDELIG,Fatal,pneumonia,0,0.5695408582687378
ZYDELIG,Fatal,pain chills and rash he mo,1,0.5526365041732788
ZYDELIG,Fatal,abnormalities incidence,0,0.5184910297393799
ZYDELIG,Fatal,rrhea pyrexia fatigue nausea cough pneumonia abdominal pain,0,0.544228196144104
ZYDELIG,Fatal,rash he mo st common laboratory,1,0.5362319946289062
ZYDELIG,pneumonitis,tigue nausea cough pneumonia abdominal pain chills and rash The most common,0,0.6076119542121887
ZYDELIG,pneumonitis,oratory abn,1,0.41673654317855835
ZYDELIG,pneumonitis,The most common oratory abn ormalities incidence are neutropenia,1,0.5239791870117188
ZYDELIG,pneumonitis,oratory abn ormalities incidence are neutropenia hypertriglyceridemia,1,0.5034937858581543
ZYDELIG,pneumonitis,oratory,1,0.4397778809070587
ZYDELIG,pneumonitis,are neutropenia hypertriglyceridemia,0,0.49400103092193604
ZYDELIG,pneumonitis,rash The most common oratory,1,0.45878326892852783
ZYDELIG,pneumonitis,most common oratory abn ormalities incidence are neutropenia hypertriglyceridemia,1,0.5017101764678955
ZYDELIG,pneumonitis,neutropenia,0,0.5653868913650513
ZYDELIG,Fatal,To report SUSPECTED,0,0.5342185497283936
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch Clinical,1,0.5169723629951477
ZYDELIG,Fatal,contact Gilead Sciences Inc at,0,0.4516730308532715
ZYDELIG,Fatal,or FDA,0,0.5609563589096069
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch,1,0.5154650807380676
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch Clinical Trial,1,0.49601098895072937
ZYDELIG,intestinal perforation,conducted,0,0.5236009359359741
ZYDELIG,intestinal perforation,".fda.gov/medwatch  


 Clinical Trial",1,0.463398814201355
ZYDELIG,intestinal perforation,".fda.gov/medwatch  


 Clinical",1,0.4799855947494507
ZYDELIG,FATAL,and may,0,0.4860110282897949
ZYDELIG,FATAL,t be directly compared to rates,0,0.4647217392921448
ZYDELIG,FATAL,rates observed,0,0.46831217408180237
ZYDELIG,FATAL,compared to rates in the clinical trials of another drug and may,0,0.47192078828811646
ZYDELIG,FATAL,be directly compared,0,0.5106629133224487
ZYDELIG,FATAL,widely varying conditions adverse reaction rates observed in the clinical trials of,0,0.5242255926132202
ZYDELIG,FATAL,varying conditions adverse reaction rates observed in the clinical trials of,0,0.5282280445098877
ZYDELIG,FATAL,trials of a canno t be directly,1,0.5395822525024414
ZYDELIG,FATAL,the clinical,0,0.5621991753578186
ZYDELIG,FATAL,clinical trials of another drug and,0,0.478914737701416
ZYDELIG,TOXICITIES,reflect the rates observed in,0,0.4777930974960327
ZYDELIG,TOXICITIES, compared  to rates,1,0.4573538899421692
ZYDELIG,TOXICITIES, compared  to rates in,1,0.4632432460784912
ZYDELIG,TOXICITIES,ying conditions adverse reaction rates observed in the clinical trials of a drug cannot be,0,0.5939464569091797
ZYDELIG,TOXICITIES,ying conditions adverse reaction rates,0,0.6688454151153564
ZYDELIG,TOXICITIES,cannot be  compared  to,1,0.5075652599334717
ZYDELIG,DIARRHEA,to rates in the inical t rials of another drug and,1,0.5579493641853333
ZYDELIG,DIARRHEA,ying conditions adverse reaction rates,0,0.5658317804336548
ZYDELIG,DIARRHEA,ction rates observed in the clinical trials of a drug cannot be directly compared to,0,0.4982866048812866
ZYDELIG,DIARRHEA,directly compared to rates in the,0,0.5061366558074951
ZYDELIG,DIARRHEA,a drug cannot be directly compared to rates in,0,0.5041182041168213
ZYDELIG,DIARRHEA,rates in the inical,1,0.5296834707260132
ZYDELIG,DIARRHEA,to rates in the inical t,1,0.5569783449172974
ZYDELIG,DIARRHEA,trials of a drug cannot be directly compared to rates in,0,0.49085378646850586
ZYDELIG,DIARRHEA,in the inical t rials,1,0.5666395425796509
ZYDELIG,DIARRHEA,inical t,1,0.5814982652664185
ZYDELIG,COLITIS,rates observed in practice,0,0.5213567018508911
ZYDELIG,COLITIS,the clinical als of ,1,0.5013959407806396
ZYDELIG,COLITIS,als of  another drug and,1,0.532638669013977
ZYDELIG,COLITIS,als of  another,1,0.5335512161254883
ZYDELIG,COLITIS,in the clinical als,1,0.5047069191932678
ZYDELIG,COLITIS,rates in the clinical als of  another drug,1,0.5367661714553833
ZYDELIG,PNEUMONITIS,clinical trials of other drug  and may not reflect the,1,0.501038134098053
ZYDELIG,PNEUMONITIS,in the clinical als,1,0.526110053062439
ZYDELIG,INTESTINAL PERFORATION,drug cannot be directly compared to rates in the clinical trials of another drug,0,0.4483446776866913
ZYDELIG,INTESTINAL PERFORATION,and y,1,0.4786824584007263
ZYDELIG,INTESTINAL PERFORATION,Clinical Trials in,0,0.5316029787063599
ZYDELIG,Fatal,Trials in Chronic ic Le ukemia The safety data reflect,1,0.5549659729003906
ZYDELIG,Fatal,Clinical Trials in,0,0.48738551139831543
ZYDELIG,Fatal,ic Le,1,0.5175846219062805
ZYDELIG,Fatal,in,0,0.5502201914787292
ZYDELIG,hepatotoxicity,observed in practice Summary of Clinical Trials in,0,0.5330767631530762
ZYDELIG,hepatotoxicity,Chronic Lymphocytic Leukemia he,1,0.5360473394393921
ZYDELIG,hepatotoxicity,Clinical Trials in Chronic Lymphocytic Leukemia T,0,0.5366268754005432
ZYDELIG,hepatotoxicity,he safety data,1,0.6145141124725342
ZYDELIG,hepatotoxicity,of Clinical Trials in,0,0.5378993153572083
ZYDELIG,hepatotoxicity,T,0,0.582110583782196
ZYDELIG,hepatotoxicity,in Chronic Lymphocytic Leukemia,0,0.48744967579841614
ZYDELIG,Fatal,mg daily The median,1,0.4990580677986145
ZYDELIG,Fatal,of Clinical Trials in,0,0.4670501947402954
ZYDELIG,Fatal,Serious adverse reactions were,0,0.6182745695114136
ZYDELIG,diarrhea,were reported in subjects treated,0,0.5435723066329956
ZYDELIG,diarrhea,of posure,1,0.5306245684623718
ZYDELIG,diarrhea,were reported,0,0.5658438205718994
ZYDELIG,diarrhea,The median duration of posure t o Zydelig was months,1,0.5591572523117065
ZYDELIG,diarrhea,The median duration of posure,1,0.5340299010276794
ZYDELIG,diarrhea,duration of posure,1,0.5118303894996643
ZYDELIG,diarrhea,of posure t o Zydelig was months,1,0.5679137706756592
ZYDELIG,colitis,delig w,1,0.5218489766120911
ZYDELIG,colitis,without Zydelig mg twice daily The median duration of exposure to Zy,0,0.5461188554763794
ZYDELIG,colitis,reactions were reported in subjects treated with Zydelig,0,0.5374833345413208
ZYDELIG,colitis,to,0,0.5822467803955078
ZYDELIG,Fatal,subjects treated with Zydelig were pneumonia pyrexia sepsis,0,0.5508241653442383
ZYDELIG,Fatal,rted  for,1,0.5218876004219055
ZYDELIG,Fatal,adverse reactions rted  for subjects treated,1,0.5542572736740112
ZYDELIG,Fatal,rted  for subjects,1,0.4944586753845215
ZYDELIG,Fatal,rted  for subjects treated,1,0.5200626850128174
ZYDELIG,pneumonitis,adverse reactions reported for treated wit,1,0.5254353880882263
ZYDELIG,pneumonitis,for treated wit h Zydelig,1,0.5760932564735413
ZYDELIG,Fatal,ig oc,1,0.49523472785949707
ZYDELIG,Fatal,to discontinuation of Zydel,0,0.4992526173591614
ZYDELIG,Fatal,led to discontinuation of ig oc,1,0.475827157497406
ZYDELIG,intestinal perforation,Zydelig occurred (10%) subjects. The mo st common,1,0.5109098553657532
ZYDELIG,intestinal perforation,led to discontinuation of ig oc,1,0.48621514439582825
ZYDELIG,intestinal perforation,The mo st,1,0.4548564851284027
ZYDELIG,intestinal perforation,of Zydelig occurred (10%),1,0.508398175239563
ZYDELIG,intestinal perforation,diarrhea Adverse reactions that led to discontinuation of Zydelig occurred,0,0.5939358472824097
ZYDELIG,intestinal perforation,occurred,0,0.5594657063484192
ZYDELIG,cutaneous reactions,adverse actions have been a ssociated with,1,0.5405223369598389
ZYDELIG,cutaneous reactions,occurred,0,0.5637480020523071
ZYDELIG,Anaphylaxis,of the ibing infor,1,0.5537039041519165
ZYDELIG,Neutropenia,see Warnings and Severe Dia,1,0.5236282348632812
ZYDELIG,Neutropenia,Hepatotoxicity see Warnings and Severe,1,0.5268876552581787
ZYDELIG,Neutropenia,Severe Dia rrhea or Colitis,1,0.5205298066139221
ZYDELIG,Neutropenia,and  Severe Dia rrhea or Colitis see,1,0.5244121551513672
ZYDELIG,Neutropenia,rrhea or Colitis see,0,0.569915235042572
ZYDELIG,Embryo-fetal toxicity,see Warnings and,0,0.585249662399292
ZYDELIG,Embryo-fetal toxicity,and,0,0.4758637547492981
ZYDELIG,Embryo-fetal toxicity,(5.2) ] Pneumonitis see Warnings and Precautions,1,0.5063696503639221
ZYDELIG,Embryo-fetal toxicity,(5.2) ] Pneumonitis,1,0.4663633406162262
ZYDELIG,fetal harm,and Precautions Pneumonit,0,0.49613773822784424
ZYDELIG,fetal harm,and Precautions Intestinal Perforation see,0,0.5701947212219238
ZYDELIG,fetal harm,and Precautions,0,0.5215631127357483
ZYDELIG,fetal harm,is [see  W arnings and,1,0.4821581244468689
ZYDELIG,Fatal,Precautions Severe Cutaneous [see  Warnings and Precautions Anaphylaxis,1,0.5150739550590515
ZYDELIG,Fatal,and Precautions,0,0.47710418701171875
ZYDELIG,Fatal,Cutaneous [see  Warnings,1,0.5126036405563354
ZYDELIG,Fatal,and Precautions Severe Cutaneous [see  Warnings and Precautions,1,0.5432568192481995
ZYDELIG,Fatal,[see  Warnings and,1,0.5570968389511108
ZYDELIG,Fatal,[see  Warnings and Precautions Anaphylaxis,1,0.5154955983161926
ZYDELIG,Fatal,Severe Cutaneous [see  Warnings and Precautions,1,0.5567338466644287
ZYDELIG,hepatotoxicity,see Warnings and ecautions (5.5,1,0.5548444986343384
ZYDELIG,hepatotoxicity,ecautions,1,0.5059881210327148
ZYDELIG,hepatotoxicity,ecautions (5.5,1,0.4765212833881378
ZYDELIG,hepatotoxicity,Warnings and Pr,0,0.5503342151641846
ZYDELIG,hepatotoxicity,Reactions see,0,0.5495535135269165
ZYDELIG,Elevations in ALT,Anaphylaxis see Warnings,0,0.5056570768356323
ZYDELIG,Elevations in ALT,ns (5.6) ] * Neutropenia see Warnings and,1,0.4961735010147095
ZYDELIG,Elevations in ALT,Precautio,0,0.5133119821548462
ZYDELIG,Elevations in ALT,"Anaphylaxis see Warnings and ns (5.6)  ]  
 *  Neutropenia see Warnings",1,0.503143846988678
ZYDELIG,Elevations in ALT,Reactions see Warnings and Precautions Anaphylaxis see Warnings,0,0.49795371294021606
ZYDELIG,Elevations in ALT,ns (5.6),1,0.531150221824646
ZYDELIG,Elevations in ALT,ns (5.6) ] * Neutropenia see Warnings and Precautions,1,0.4910571873188019
ZYDELIG,Elevations in ALT,ous Reactions see Warnings and Precautions,0,0.5038391351699829
ZYDELIG,Elevations in ALT,Warnings and ns (5.6) ] *,1,0.5170620679855347
ZYDELIG,diarrhea,with relapsed LL recei,1,0.5564830303192139
ZYDELIG,diarrhea,relapsed LL,1,0.563888430595398
ZYDELIG,diarrhea,LL recei ved up,1,0.5746735334396362
ZYDELIG,diarrhea,to Zydelig,0,0.5528280138969421
ZYDELIG,diarrhea,ved up to doses of,0,0.5834532976150513
ZYDELIG,diarrhea,relapsed LL recei ved up to,1,0.5809921026229858
ZYDELIG,diarrhea,or without Zydelig mg twice daily The median duration of ex,0,0.562840461730957
ZYDELIG,diarrhea,which subjects with relapsed LL recei ved,1,0.5600593090057373
ZYDELIG,diarrhea,LL recei,1,0.5803738236427307
ZYDELIG,diarrhea,rituximab,0,0.5421010851860046
ZYDELIG,colitis,up to 8 doses of rituximab with,1,0.5472933053970337
ZYDELIG,colitis,in,0,0.5464116334915161
ZYDELIG,colitis,relapsed CLL up to 8 doses of rituximab,1,0.5610744953155518
ZYDELIG,colitis,subjects with relapsed CLL up to 8 doses of rituximab,1,0.54899001121521
ZYDELIG,Diarrhea,median duration of exposure to Zydelig was,0,0.5732167959213257
ZYDELIG,Diarrhea,treated with Zydelig were,0,0.6008584499359131
ZYDELIG,Diarrhea,most fre quent,1,0.5212798118591309
ZYDELIG,Diarrhea,with Zydelig rituximab most fre quent serious adverse,1,0.5561778545379639
ZYDELIG,Diarrhea,most fre,1,0.5335850715637207
ZYDELIG,Diarrhea,with Zydelig rituximab most fre,1,0.5501736402511597
ZYDELIG,Diarrhea,Zydelig rituximab most fre,1,0.5570392608642578
ZYDELIG,Diarrhea,in subjects treated with,0,0.5551043152809143
ZYDELIG,Diarrhea,most fre quent serious adverse reactions,1,0.5828158855438232
ZYDELIG,Diarrhea,reactions were reported in,0,0.5728162527084351
ZYDELIG,Fatal,tions that led to treatment,1,0.5016971230506897
ZYDELIG,Fatal,reac,0,0.48522940278053284
ZYDELIG,Fatal,that led to treatment discontinuations were hepatotoxicity and diarrheacolitis,0,0.5635455846786499
ZYDELIG,Fatal,tions that led to treatment discontinuations,1,0.477308988571167
ZYDELIG,Fatal,tions,1,0.544770359992981
ZYDELIG,pneumonitis,were hepatotoxicity and diarrheacolitis Thirtynine subjects had dose in,0,0.49126529693603516
ZYDELIG,pneumonitis,that led treatment,1,0.526195764541626
ZYDELIG,pneumonitis,adverse reactions that led treatment d,1,0.5410214066505432
ZYDELIG,pneumonitis,and diarrheacolitis Thirtynine subjects,0,0.5247839093208313
ZYDELIG,pneumonitis,ontinuation of Zydelig occurred in subjects The most common adverse reactions that led,0,0.5520220994949341
ZYDELIG,Fatal,at Higher Incidence n Sub jects Receiving Zydelig Zydelig,1,0.554810643196106
ZYDELIG,Fatal,ontinuation of Zydelig occurred in subjects The most common adverse reactions that led,0,0.5853291153907776
ZYDELIG,Fatal,Incidence n Sub jects Receiving Zydelig Zydelig RN,1,0.5567023754119873
ZYDELIG,Fatal,at Higher Incidence n Sub,1,0.53753662109375
ZYDELIG,Fatal,Table Adverse Reactions Reported in of CLL Patients and Occurred,0,0.5138291120529175
ZYDELIG,Fatal,n Sub jects Receiving Zydelig,1,0.5175557136535645
ZYDELIG,Fatal,n Sub jects Receiving Zydelig Zydelig RN,1,0.5345293283462524
ZYDELIG,Fatal,n Sub jects,1,0.4931301474571228
ZYDELIG,Fatal,at Higher Incidence n,1,0.5328481197357178
ZYDELIG,intestinal perforation,Higher Incidence in Subjects ng Zydelig,1,0.5788583755493164
ZYDELIG,intestinal perforation,"in Subjects ng Zydelig 
          ",1,0.4964790940284729
ZYDELIG,intestinal perforation,in Subjects ng Zydelig,1,0.4964790642261505
ZYDELIG,diarrhea,         Any Grade,1,0.503311276435852
ZYDELIG,diarrhea,RN Adverse          Any Grade Grade Any Grade,1,0.5235318541526794
ZYDELIG,diarrhea,Reaction,0,0.5857597589492798
ZYDELIG,diarrhea,         Any Grade Grade Any,1,0.5007678270339966
ZYDELIG,diarrhea,Grade Grade Any Grade Grade R rituximab,0,0.515562891960144
ZYDELIG,anaphylaxis,disorders headache,0,0.5155922770500183
ZYDELIG,anaphylaxis,           ,1,0.5877662897109985
ZYDELIG,anaphylaxis,            General,1,0.537010908126831
ZYDELIG,anaphylaxis,General,0,0.537010908126831
ZYDELIG,anaphylaxis,            General disorders and,1,0.5027167797088623
ZYDELIG,teratogenic,            nasal congesti,1,0.5222176313400269
SIMPONI,Infections,Infections see Warnings and Precautions,1,0.7936474084854126
SIMPONI,Infections,serious adverse reactions were Infections,1,0.7629809379577637
SIMPONI,Infections,Malignancies see Warnings and Precautions,0,0.5847984552383423
SIMPONI,Infections,Infections see Warnings,1,0.8066918253898621
SIMPONI,Infections,adverse reactions were Infections,1,0.7858105897903442
SIMPONI,Infections,Precautions,0,0.6308221220970154
SIMPONI,Infections,ADVERSE REACTIONS The most serious,0,0.5938858389854431
SIMPONI,Malignancies,Malignancies,1,1.0
SIMPONI,Malignancies,Most common,0,0.5354639887809753
SIMPONI,upper respiratory tract infection,viral infection bronchitis hypertension and rash,0,0.6401710510253906
SIMPONI,upper respiratory tract infection,reactions,0,0.49790120124816895
SIMPONI,upper respiratory tract infection,upper respiratory tract infection,1,1.0
SIMPONI,upper respiratory tract infection,bronchitis,0,0.6903374791145325
SIMPONI,upper respiratory tract infection,upper respiratory tract infection viral infection bronchitis,1,0.8409786224365234
SIMPONI,upper respiratory tract infection,upper respiratory tract infection viral infection,1,0.903597354888916
SIMPONI,upper respiratory tract infection,common adverse reactions incidence upper respiratory tract infection viral infection,1,0.7812004089355469
SIMPONI,upper respiratory tract infection,adverse reactions incidence upper respiratory tract,1,0.7866747379302979
SIMPONI,upper respiratory tract infection,reactions incidence upper respiratory tract infection,1,0.8420366048812866
SIMPONI,viral infection,common adverse reactions incidence are,0,0.5425961017608643
SIMPONI,viral infection,viral infection bronchitis hypertension and,1,0.7345093488693237
SIMPONI,viral infection,viral infection bronchitis hypertension,1,0.7341874837875366
SIMPONI,viral infection,tract viral infection bronchitis hypertension and rash,1,0.6651917099952698
SIMPONI,viral infection,Most common adverse reactions incidence are upper,0,0.54197096824646
SIMPONI,viral infection,tract viral infection,1,0.769234299659729
SIMPONI,viral infection,bronchitis,0,0.6466093063354492
SIMPONI,viral infection,common adverse reactions incidence are upper,0,0.5459060668945312
SIMPONI,viral infection,upper respiratory tract,0,0.6046282052993774
SIMPONI,bronchitis,bronchitis hypertension and rash,1,0.7729108929634094
SIMPONI,bronchitis,infection viral bronchitis hypertension and,1,0.7823286652565002
SIMPONI,bronchitis,respiratory tract infection viral bronchitis hypertension and rash To report,1,0.7457272410392761
SIMPONI,hypertension,hypertension and,1,0.920141339302063
SIMPONI,hypertension,To report SUSPECTED,0,0.5167905688285828
SIMPONI,rash,rash,1,1.0000001192092896
SIMPONI,rash,rash To report SUSPECTED ADVERSE REACTIONS,1,0.8133968710899353
SIMPONI,rash,rash To,1,0.9322768449783325
SIMPONI,rash,rash To report,1,0.8124811053276062
SIMPONI,rash,rash To report SUSPECTED,1,0.8175097107887268
SIMPONI,Upper respiratory tract infection,patients and for,0,0.49848735332489014
SIMPONI,Upper respiratory tract infection,placebotreated Upper respiratory tract infection was the most,1,0.8293185830116272
SIMPONI,Upper respiratory tract infection,Upper respiratory tract infection was the most,1,0.887198805809021
SIMPONI,Upper respiratory tract infection,patients and for placebotreated,0,0.493668794631958
SIMPONI,Upper respiratory tract infection,for placebotreated Upper respiratory tract infection was the,1,0.8532872200012207
SIMPONI,Upper respiratory tract infection,placebotreated Upper respiratory tract infection was the,1,0.8494634032249451
SIMPONI,infections,infections observed in SIMPONI ARIAtreated patients,1,0.7171749472618103
SIMPONI,infections,SIMPONI ARIAtreated patients included sepsis pneumonia cellulitis abscess,0,0.6727669835090637
SIMPONI,infections,infections observed in,1,0.8662548661231995
SIMPONI,infections,infections observed in SIMPONI,1,0.7255830764770508
SIMPONI,sepsis,Infections Serious infections observed in,0,0.6581379771232605
SIMPONI,sepsis,sepsis pneumonia,1,0.8528244495391846
SIMPONI,sepsis,ARIAtreated patients,0,0.5575579404830933
SIMPONI,sepsis,sepsis pneumonia cellulitis abscess opportunistic,1,0.7747570872306824
SIMPONI,pneumonia,opportunistic infections tuberculosis TB and invasive,0,0.5794083476066589
SIMPONI,cellulitis,cellulitis abscess opportunistic infections tuberculosis TB,1,0.8020962476730347
SIMPONI,cellulitis,patients included sepsis cellulitis abscess,1,0.7901684045791626
SIMPONI,cellulitis,cellulitis abscess opportunistic infections tuberculosis,1,0.8077995777130127
SIMPONI,cellulitis,ions Serious infections observed in SIMPONI ARIAtreated patients included,0,0.582374632358551
SIMPONI,cellulitis,cellulitis abscess opportunistic,1,0.8223451375961304
SIMPONI,cellulitis,cellulitis abscess opportunistic infections,1,0.8136557936668396
SIMPONI,cellulitis,sepsis pneumonia,0,0.586652934551239
SIMPONI,cellulitis,cellulitis abscess,1,0.8856198787689209
SIMPONI,abscess,patients included sepsis pneumonia abscess opportunistic infections,1,0.6991410851478577
SIMPONI,abscess,cellulitis abscess opportunistic infections tuberculosis,1,0.7500039339065552
SIMPONI,abscess,infections tuberculosis TB and invasive,0,0.6355208158493042
SIMPONI,abscess,of TB,0,0.5305726528167725
SIMPONI,opportunistic infections,included sepsis pneumonia cellulitis opportunistic infections,1,0.8113212585449219
SIMPONI,opportunistic infections,opportunistic infections tuberculosis,1,0.9055718183517456
SIMPONI,opportunistic infections,cellulitis abscess,0,0.6120111346244812
SIMPONI,opportunistic infections,pneumonia cellulitis opportunistic,1,0.7930185198783875
SIMPONI,opportunistic infections,cellulitis opportunistic,1,0.8159935474395752
SIMPONI,opportunistic infections,in SIMPONI ARIAtreated,0,0.5214002728462219
SIMPONI,opportunistic infections,opportunistic infections,1,0.9999997615814209
SIMPONI,opportunistic infections,fungal infections Cases of TB included,0,0.6820382475852966
SIMPONI,tuberculosis,abscess,0,0.600965678691864
SIMPONI,tuberculosis,extrapulmonary TB The maj,0,0.7480686902999878
SIMPONI,tuberculosis,tuberculosis TB and invasive fungal,1,0.7884310483932495
SIMPONI,tuberculosis,TB,0,0.9546085596084595
SIMPONI,tuberculosis,included pulmonary and extrapulmonary TB The maj,0,0.7823200821876526
SIMPONI,tuberculosis,infections,0,0.6540960073471069
SIMPONI,tuberculosis,and extrapulmonary TB,0,0.7811331748962402
SIMPONI,TB,TB included pulmonary and extrapulmonary,1,0.811789333820343
SIMPONI,TB,TB included pulmonary and extrapulmonary TB,1,0.8166893720626831
SIMPONI,TB,TB included,1,0.8546151518821716
SIMPONI,TB,TB included pulmonary and,1,0.8397604823112488
SIMPONI,extrapulmonary TB,infections Cases,0,0.5410684943199158
SIMPONI,extrapulmonary TB,incidence rate,0,0.5098442435264587
SIMPONI,extrapulmonary TB,of the TB,0,0.8026673197746277
SIMPONI,extrapulmonary TB,extrapulmonary TB The majority of,1,0.9362293481826782
SIMPONI,extrapulmonary TB,extrapulmonary TB The,1,0.9863077402114868
SIMPONI,TB,the,0,0.5614744424819946
SIMPONI,TB,TB cases occurred in countries,1,0.7821798324584961
SIMPONI,TB,see Warnings and,0,0.5240220427513123
SIMPONI,TB,Cases of TB included pulmonary and extrapulmonary,0,0.7764072418212891
SIMPONI,TB,The majority of TB cases occurred in countries with,1,0.7567697167396545
SIMPONI,TB,in countries with a high,0,0.5070304274559021
SIMPONI,TB,majority of TB cases,1,0.7627794742584229
SIMPONI,TB,TB The,0,0.9005109071731567
SIMPONI,TB,cases occurred in countries with a high incidence rate of TB,0,0.7268768548965454
SIMPONI,TB,occurred in countries with a high incidence rate of TB,0,0.7421058416366577
SIMPONI,infections,infections were observed,1,0.8679201602935791
SIMPONI,infections,compared with of controltreated,0,0.5404590964317322
SIMPONI,infections,infections were observed in of SIMPONI,1,0.7352105975151062
SIMPONI,infections,SIMPONI ARIAtreated patients compared with of,0,0.549345850944519
SIMPONI,infections,patients compared with of controltreated,0,0.5558875799179077
SIMPONI,infections,Precautions In the controlled phase,0,0.5836215019226074
SIMPONI,infections,infections,1,1.000000238418579
SIMPONI,infections,patients,0,0.5940079689025879
SIMPONI,infections,controltreated patients and infections,1,0.7575298547744751
SIMPONI,infections,controltreated patients and infections were observed in of SIMPONI,1,0.7280154228210449
SIMPONI,infections,controltreated patients and infections were,1,0.7595235109329224
SIMPONI,infections,receiving,0,0.5305773615837097
SIMPONI,infections,patients receiving SIMPONI ARIA,0,0.5807089805603027
SIMPONI,infections,infections was CI in patients,1,0.8028299808502197
SIMPONI,infections,infections was,1,0.9014167785644531
SIMPONI,infections,infections was CI in patients receiving,1,0.7658383846282959
SIMPONI,infections,per patientyears of all infections was CI in patients receiving,1,0.7152690291404724
SIMPONI,active TB,was CI and,0,0.48700982332229614
SIMPONI,active TB,incidence active TB per,1,0.8802155256271362
SIMPONI,opportunistic infections,opportunistic infections per patientyears was CI Malignancies,1,0.8277680277824402
SIMPONI,opportunistic infections,was CI and,0,0.45752206444740295
SIMPONI,opportunistic infections,opportunistic infections per patientyears,1,0.8780699968338013
SIMPONI,opportunistic infections,per patientyears was,0,0.537718653678894
SIMPONI,opportunistic infections,opportunistic,1,0.8156602382659912
SIMPONI,opportunistic infections,was,0,0.46372729539871216
SIMPONI,malignancy,with SIMPONI ARIA was reported through Week,0,0.5172212719917297
SIMPONI,malignancy,Malignancies One case malignancy other,1,0.8258126378059387
SIMPONI,malignancy,CI Malignancies One case malignancy other than,1,0.7118368744850159
SIMPONI,malignancy,SIMPONI ARIA,0,0.4810803532600403
SIMPONI,lymphoma,lymphoma,1,1.0
SIMPONI,lymphoma,lymphoma and,1,0.9186431169509888
SIMPONI,lymphoma,lymphoma and NMSC,1,0.7931451201438904
SIMPONI,lymphoma,other,0,0.5606272220611572
SIMPONI,lymphoma,through Week during,0,0.5060891509056091
SIMPONI,lymphoma,lymphoma and NMSC with SIMPONI ARIA,1,0.7433018684387207
SIMPONI,NMSC,Malignancies One,0,0.46763378381729126
SIMPONI,malignancies,malignancies per,1,0.8984370827674866
SIMPONI,malignancies,malignancies,1,1.0
SIMPONI,malignancies,ial In the controlled and uncontrolled portions through approximately weeks the incidence,0,0.5683732032775879
SIMPONI,malignancies,than lymphoma and NMSC,0,0.6942036747932434
SIMPONI,malignancies,malignancies per patientyears other,1,0.8067850470542908
SIMPONI,malignancies,approximately weeks the incidence malignancies per patientyears other than,1,0.7692850828170776
SIMPONI,malignancies,NMSC,0,0.4813709259033203
SIMPONI,lymphoma,per patientyears other lymphoma and,1,0.8124879002571106
SIMPONI,lymphoma,NMSC,0,0.4468190371990204
SIMPONI,lymphoma,lymphoma and NMSC in SIMPONI,1,0.754886269569397
SIMPONI,lymphoma,per patientyears other,0,0.5151562690734863
SIMPONI,lymphoma,the incidence of NMSC,0,0.4968565106391907
SIMPONI,lymphoma,lymphoma and NMSC in,1,0.7833282947540283
SIMPONI,lymphoma,SIMPONI ARIAtreated patients was CI and the,0,0.5136969089508057
SIMPONI,NMSC,NMSC in SIMPONI ARIAtreated,1,0.8123949766159058
SIMPONI,NMSC,CI Liver Enzyme Elevations There have been,0,0.4696636199951172
SIMPONI,NMSC,NMSC was CI,1,0.9185649156570435
SIMPONI,NMSC,incidence,0,0.49033379554748535
SIMPONI,NMSC,There have,0,0.44931280612945557
SIMPONI,NMSC,reports of,0,0.4954391121864319
SIMPONI,NMSC,CI Liver Enzyme Elevations There have,0,0.4649556577205658
SIMPONI,NMSC,NMSC was,1,0.971796452999115
SIMPONI,NMSC,have,0,0.47185462713241577
SIMPONI,NMSC,Enzyme Elevations,0,0.49481433629989624
SIMPONI,hepatic reactions,s CI Liver Enzyme Elevations There have,0,0.763410210609436
SIMPONI,hepatic reactions,failure in patients receiving TNFblockers In the controlled phase,0,0.5188509225845337
SIMPONI,acute liver failure,acute liver failure,1,1.0
SIMPONI,acute liver failure,in patients receiving TNFblockers In,0,0.5319933891296387
SIMPONI,acute liver failure,patients receiving TNFblockers In the controlled phase of,0,0.5353942513465881
SIMPONI,acute liver failure,severe hepatic reactions acute liver failure in,1,0.9114546179771423
SIMPONI,acute liver failure,hepatic reactions acute,1,0.818581223487854
SIMPONI,acute liver failure,acute liver failure in,1,0.9842512607574463
SIMPONI,acute liver failure,of severe hepatic reactions acute liver failure in patients receiving TNFblockers In,1,0.7970770001411438
SIMPONI,acute liver failure,acute liver failure in patients receiving TNFblockers In,1,0.7874487638473511
SIMPONI,ALT elevations,receiving TNFblockers In the controlled phase,0,0.48776453733444214
SIMPONI,ALT elevations,ALT elevations,1,0.9999998807907104
SIMPONI,ALT elevations,ALT elevations ULN occurred,1,0.8959615230560303
SIMPONI,ALT elevations,of controltreated patients ALT elevations,1,0.7386292219161987
SIMPONI,ALT elevations,ALT elevations ULN occurred in of,1,0.8837873339653015
SIMPONI,ALT elevations,and,0,0.51124107837677
SIMPONI,ALT elevations,patients,0,0.451951265335083
SIMPONI,ALT elevations,ARIAtreated patients and,0,0.4942946434020996
SIMPONI,lupus-like syndrome,lupus-like syndrome At Week in Trial,1,0.9005709290504456
SIMPONI,lupus-like syndrome,of control patients were n,0,0.4946932792663574
SIMPONI,lupus-like syndrome,associated with the formation of autoantibodies and rarely,0,0.6907069683074951
SIMPONI,lupus-like syndrome,of,0,0.48427289724349976
SIMPONI,lupus-like syndrome,the development of lupus-like,1,0.8817374110221863
SIMPONI,lupus-like syndrome,of lupus-like syndrome At Week in Trial,1,0.8906702399253845
SIMPONI,lupus-like syndrome,development,0,0.5049264430999756
SIMPONI,newly ANA-positive,patients,0,0.6003589630126953
SIMPONI,newly positive anti-dsDNA antibodies,no controltreated patients newly positive anti-dsDNA antibodies Administration Reactions,1,0.8790206909179688
SIMPONI,newly positive anti-dsDNA antibodies,patients,0,0.5440822243690491
SIMPONI,infusion reaction,were associated with infusion reaction compared,1,0.9077596664428711
SIMPONI,infusion reaction,patients,0,0.552312433719635
SIMPONI,infusion reaction,infusions were associated with infusion reaction,1,0.9371806979179382
SIMPONI,infusion reaction,infusions were,0,0.8227901458740234
SIMPONI,infusion reaction,of infusions,0,0.8155790567398071
SIMPONI,infusion reaction,associated,0,0.5382533073425293
SIMPONI,rash,patients rash No serious infusion reactions,1,0.6728971004486084
SIMPONI,rash,associated,0,0.5350056886672974
SIMPONI,rash,SIMPONI ARIA treated patients rash No serious,1,0.664804220199585
SIMPONI,rash,rash No serious,1,0.8421972990036011
SIMPONI,rash,Immunogenicity Antibodies to,0,0.5193812847137451
SIMPONI,rash,rash No,1,0.8869713544845581
SIMPONI,rash,was,0,0.5342103242874146
SIMPONI,infusion reactions,was rash No infusion,1,0.6828373670578003
SIMPONI,infusion reactions,was rash No infusion reactions were reported Immunogenicity Antibodies,1,0.7710542678833008
SIMPONI,infusion reactions,ARIA were detected,0,0.5115512609481812
SIMPONI,infusion reactions,rash No infusion reactions were reported Immunogenicity,1,0.742486834526062
SIMPONI,infusion reactions,group The most common infusion reaction in SIMPONI ARIA treated,0,0.8029919862747192
SIMPONI,infusion reactions,infusion reactions were reported Immunogenicity Antibodies,1,0.8784976005554199
SIMPONI,infusion reactions,No serious,0,0.47977977991104126
SIMPONI,infusion reactions,infusion reactions were,1,0.9844766855239868
SIMPONI,Upper respiratory tract infection,and Upper respiratory tract infection,1,0.930793285369873
SIMPONI,Upper respiratory tract infection,Upper respiratory tract infection such as upper respiratory tract,1,0.9138513207435608
SIMPONI,upper respiratory tract infection,pharyngitis laryngitis,0,0.6774532198905945
SIMPONI,upper respiratory tract infection,respiratory tract infection such upper,1,0.9044592380523682
SIMPONI,upper respiratory tract infection,respiratory tract infection such upper respiratory tract infection nasopharyngitis pharyngitis laryngitis,1,0.8548474311828613
SIMPONI,upper respiratory tract infection,upper respiratory tract infection nasopharyngitis,1,0.9009209871292114
SIMPONI,upper respiratory tract infection,such upper respiratory tract infection,1,0.9125441908836365
SIMPONI,upper respiratory tract infection,upper respiratory tract infection nasopharyngitis pharyngitis laryngitis and,1,0.8538634181022644
SIMPONI,upper respiratory tract infection,respiratory tract infection such upper respiratory tract infection nasopharyngitis pharyngitis laryngitis and rhinitis,1,0.8520615100860596
SIMPONI,upper respiratory tract infection,infection such upper respiratory,1,0.9085030555725098
SIMPONI,upper respiratory tract infection,such as,0,0.48217636346817017
SIMPONI,upper respiratory tract infection,Upper,0,0.6525404453277588
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis and rhinitis,1,0.8154641389846802
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis,1,0.8384560942649841
SIMPONI,nasopharyngitis,pharyngitis,0,0.6990917921066284
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis and,1,0.8429598212242126
SIMPONI,nasopharyngitis,respiratory tract infection such as upper respiratory,0,0.6805357336997986
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis,1,0.8785302639007568
SIMPONI,pharyngitis,respiratory,0,0.6286070346832275
SIMPONI,pharyngitis,pharyngitis laryngitis and,1,0.8803441524505615
SIMPONI,pharyngitis,laryngitis and rhinitis Viral infec,0,0.6990606784820557
SIMPONI,pharyngitis,and rhinitis Viral,0,0.653661847114563
SIMPONI,pharyngitis,pharyngitis laryngitis and rhinitis,1,0.836480975151062
SIMPONI,pharyngitis,pharyngitis laryngitis and rhinitis Viral,1,0.8241143822669983
SIMPONI,pharyngitis,tract infection pharyngitis laryngitis and rhinitis Viral,1,0.8217167258262634
SIMPONI,laryngitis,respiratory tract infection nasopharyngitis laryngitis and rhinitis,1,0.7523494958877563
SIMPONI,laryngitis,pharyngitis laryngitis and rhinitis Viral,1,0.7698151469230652
SIMPONI,laryngitis,laryngitis and,1,0.9457718729972839
SIMPONI,rhinitis,and,0,0.4623573422431946
SIMPONI,rhinitis,rhinitis Viral infections such as,1,0.8384090065956116
SIMPONI,rhinitis,infection nasopharyngitis pharyngitis laryngitis and,0,0.6558365821838379
SIMPONI,rhinitis,as,0,0.5065973997116089
SIMPONI,rhinitis,rhinitis Viral infections such,1,0.8321173191070557
SIMPONI,rhinitis,nasopharyngitis pharyngitis laryngitis rhinitis Viral infections,1,0.749787449836731
SIMPONI,Viral infections,laryngitis and Viral infections,1,0.7849963307380676
SIMPONI,Viral infections,Viral infections such,1,0.8910447359085083
SIMPONI,Viral infections,and,0,0.5167860984802246
SIMPONI,Viral infections,and herpes Bacteri,0,0.7301958799362183
SIMPONI,Viral infections,Viral infections such as influenza,1,0.8754538893699646
SIMPONI,Viral infections,pharyngitis laryngitis,0,0.6337296962738037
SIMPONI,Viral infections,pharyngitis laryngitis and Viral infections,1,0.7772157788276672
SIMPONI,Viral infections,Viral infections such as influenza and,1,0.87164306640625
SIMPONI,Viral infections,and rhinitis,0,0.5980764627456665
SIMPONI,influenza,herpes Bacterial,0,0.6265431642532349
SIMPONI,influenza,influenza,1,0.9999999403953552
SIMPONI,influenza,nd rhinitis Viral infections,0,0.6376298666000366
SIMPONI,herpes,influenza herpes Bacterial infections,1,0.750994861125946
SIMPONI,herpes,nd rhinitis Viral infections,0,0.6109071969985962
SIMPONI,herpes,herpes Bacterial infections,1,0.8091204166412354
SIMPONI,Superficial fungal infection,respiratory tract infection pneumonia pyelonephritis,0,0.5165654420852661
SIMPONI,Superficial fungal infection,respiratory tract infection,0,0.5661112070083618
SIMPONI,Superficial fungal infection,fungal infection sinusitis abscess lower,1,0.728888988494873
SIMPONI,Superficial fungal infection,respiratory tract,0,0.4971086382865906
SIMPONI,sinusitis,sinusitis abscess lower respiratory tract infection,1,0.809124767780304
SIMPONI,sinusitis,abscess lower respiratory tract infection pneumonia,0,0.6059303879737854
SIMPONI,sinusitis,pneumonia pyelonephritis,0,0.5464935302734375
SIMPONI,sinusitis,and Infestations Superficial fungal sinusitis abscess,1,0.7809042930603027
SIMPONI,sinusitis,and Infestations Superficial fungal sinusitis,1,0.7873066663742065
SIMPONI,sinusitis,sinusitis abscess,1,0.8748822808265686
SIMPONI,sinusitis,abscess lower,0,0.5570998787879944
SIMPONI,sinusitis,sinusitis abscess lower respiratory,1,0.7988120317459106
SIMPONI,sinusitis,and Infestations Superficial fungal sinusitis abscess lower,1,0.7730776071548462
SIMPONI,abscess,Infestations Superficial fungal infection abscess lower,1,0.7561259269714355
SIMPONI,abscess,sinusitis abscess lower respiratory,1,0.7411527633666992
SIMPONI,abscess,pneumonia pyelonephritis,0,0.5402770638465881
SIMPONI,lower respiratory tract infection,Alanine aminotransferase increased aspartate,0,0.4756074845790863
SIMPONI,lower respiratory tract infection,sinusitis lower respiratory tract infection,1,0.8879899382591248
SIMPONI,lower respiratory tract infection,respiratory tract infection pneumonia pyelonephritis Investigations,1,0.7507818937301636
SIMPONI,lower respiratory tract infection,fungal infection sinusitis lower respiratory tract infection,1,0.8264462947845459
SIMPONI,pneumonia,Superficial,0,0.49059057235717773
SIMPONI,pneumonia,aminotransferase increased aspartate,0,0.4660274386405945
SIMPONI,pneumonia,pneumonia pyelonephritis Investigations Alanine aminotransferase increased,1,0.6927694082260132
SIMPONI,pneumonia,pneumonia pyelonephritis Investigations Alanine,1,0.7214444279670715
SIMPONI,pneumonia,Superficial fungal infection sinusitis abscess lower respiratory,0,0.611136794090271
SIMPONI,pneumonia,sinusitis abscess lower,0,0.5484920740127563
SIMPONI,pneumonia,tract pneumonia pyelonephritis Investigations,1,0.7392279505729675
SIMPONI,pyelonephritis,increased aspartate aminotransferase increased n,0,0.5023989081382751
SIMPONI,pyelonephritis,aminotransferase increased n,0,0.5093140602111816
SIMPONI,Alanine aminotransferase increased,infection pneumonia pyelonephritis Alanine aminotransferase,1,0.7971023321151733
SIMPONI,Alanine aminotransferase increased,pyelonephritis Alanine aminotransferase increased,1,0.8745827078819275
SIMPONI,Alanine aminotransferase increased,Alanine aminotransferase increased aspartate aminotransferase increased neutrophil,1,0.886873722076416
SIMPONI,Alanine aminotransferase increased,Alanine aminotransferase increased aspartate aminotransferase,1,0.9539878368377686
SIMPONI,Alanine aminotransferase increased,aspartate aminotransferase increased neutrophil count decreased Nervous system disorders,0,0.7773987650871277
SIMPONI,aspartate aminotransferase increased,pyelonephritis Investigations Alanine aminotransferase aspartate,1,0.776574432849884
SIMPONI,aspartate aminotransferase increased,pyelonephritis Investigations Alanine,0,0.6411442756652832
SIMPONI,aspartate aminotransferase increased,disorders Dizziness,0,0.4907625615596771
SIMPONI,aspartate aminotransferase increased,Dizziness,0,0.5272724032402039
SIMPONI,aspartate aminotransferase increased,neutrophil count,0,0.5506194829940796
SIMPONI,aspartate aminotransferase increased,Alanine aminotransferase,0,0.8167411684989929
SIMPONI,aspartate aminotransferase increased,aspartate aminotransferase increased neutrophil count decreased Nervous system,1,0.8451013565063477
SIMPONI,aspartate aminotransferase increased,Alanine aminotransferase increased,0,0.9163910150527954
SIMPONI,aspartate aminotransferase increased,aspartate aminotransferase increased neutrophil count decreased Nervous,1,0.8507493138313293
SIMPONI,neutrophil count decreased,aminotransferase,0,0.4631883502006531
SIMPONI,neutrophil count decreased,aspartate aminotransferase neutrophil count decreased,1,0.8532983064651489
SIMPONI,Dizziness,Dizziness,1,0.9999998807907104
SIMPONI,Dizziness,paresthesia,0,0.6622305512428284
SIMPONI,Dizziness,Dizziness paresthesia,1,0.9077486991882324
SIMPONI,Dizziness,neutrophil count decreased,0,0.5092895030975342
SIMPONI,paresthesia,Experience There is,0,0.545590877532959
SIMPONI,paresthesia,paresthesia Gastrointestinal,1,0.8159306645393372
SIMPONI,paresthesia,paresthesia Gastrointestinal disorders,1,0.7923340797424316
SIMPONI,paresthesia,decreased Nervous system disorders paresthesia Gastrointestinal disorders,1,0.7220108509063721
SIMPONI,paresthesia,Gastrointestinal,0,0.5424463748931885
SIMPONI,paresthesia,Constipation Postmarketing Experience There is no,0,0.5296958684921265
SIMPONI,paresthesia,disorders paresthesia Gastrointestinal disorders Constipation Postmarketing Experience,1,0.6865817308425903
SIMPONI,paresthesia,decreased Nervous system disorders paresthesia Gastrointestinal disorders Constipation Postmarketing Experience,1,0.6604009866714478
SIMPONI,Constipation,Constipation Postmarketing Experience There is no,1,0.7543063759803772
SIMPONI,Constipation,disorders Dizziness paresthesia,0,0.5800783634185791
SIMPONI,Constipation,no postmarketing experience,0,0.4645846486091614
SIMPONI,Constipation,Gastrointestinal Constipation Postmarketing Experience There,1,0.7866582274436951
SIMPONI,Melanoma,Melanoma see,1,0.8649958372116089
SIMPONI,Melanoma,no postmarketing experience,0,0.4693557620048523
SIMPONI,Melanoma,Neoplasm Benign and Melanoma see Warnings and Precautions,1,0.7528672814369202
SIMPONI,Melanoma,Malignant,0,0.6389132142066956
SIMPONI,Melanoma,exposure Neoplasm Benign and Melanoma see Warnings and Precautions Immune,1,0.7379263639450073
SIMPONI,Melanoma,exposure Neoplasm Benign and Melanoma see Warnings and,1,0.7528954148292542
SIMPONI,Melanoma,System Disorders Serious systemic,0,0.5157954096794128
SIMPONI,systemic hypersensitivity reactions,reaction see,0,0.6492178440093994
SIMPONI,systemic hypersensitivity reactions,Disorders systemic hypersensitivity reactions including anaphylactic reaction,1,0.9014648795127869
SIMPONI,systemic hypersensitivity reactions,Disorders systemic hypersensitivity reactions including anaphylactic reaction see Warnings,1,0.8760827779769897
SIMPONI,anaphylactic reaction,hypersensitivity reactions,0,0.8185365796089172
SIMPONI,anaphylactic reaction,hypersensitivity reactions anaphylactic,1,0.9247018694877625
SIMPONI,anaphylactic reaction,hypersensitivity reactions anaphylactic reaction see Warnings and Precautions,1,0.836213231086731
SIMPONI,anaphylactic reaction,Respiratory thoracic and,0,0.47505220770835876
SIMPONI,anaphylactic reaction,anaphylactic reaction see Warnings and,1,0.8784435987472534
SIMPONI,anaphylactic reaction,reactions anaphylactic reaction,1,0.9661741256713867
SIMPONI,sarcoidosis,sarcoidosis Respiratory thoracic and,1,0.8003789186477661
SIMPONI,sarcoidosis,sarcoidosis Respiratory thoracic and mediastinal,1,0.7792867422103882
SIMPONI,sarcoidosis,Skin and s,0,0.5346844792366028
SIMPONI,Interstitial lung disease,thoracic and mediastinal Interstitial,1,0.745133638381958
SIMPONI,Interstitial lung disease,Respiratory thoracic and mediastinal Interstitial lung disease Skin and,1,0.7985736727714539
SIMPONI,Interstitial lung disease,Interstitial lung disease Skin and subcutaneous,1,0.8520535230636597
SIMPONI,Interstitial lung disease,and Precautions sarcoidosis,0,0.6280567646026611
SIMPONI,Interstitial lung disease,Skin,0,0.5761833190917969
SIMPONI,Interstitial lung disease,and mediastinal Interstitial lung disease Skin and subcutaneous tissue disorders,1,0.8001158833503723
SIMPONI,Interstitial lung disease,and mediastinal Interstitial lung disease Skin and,1,0.8155465126037598
SIMPONI,Skin exfoliation,Skin exfoliation bullous skin,1,0.8743780851364136
SIMPONI,Skin exfoliation,bullous,0,0.5669906139373779
SIMPONI,Skin exfoliation,tissue Skin,1,0.7349110841751099
SIMPONI,Skin exfoliation,Skin exfoliation,1,1.000000238418579
SIMPONI,Skin exfoliation,Skin and subcutaneous tissue,0,0.7292255163192749
SIMPONI,INFECTIONS,ADVERSE REACTIONS The most rious adve rse reactions were Serious Infections,1,0.7370737195014954
SIMPONI,INFECTIONS,Skin and subcutaneous tissue,0,0.5795272588729858
SIMPONI,INFECTIONS,ections [s,1,0.6051030158996582
SIMPONI,INFECTIONS,Serious ections [s,1,0.5936331748962402
SIMPONI,INFECTIONS,reactions were Serious ections [s ee Warnings and,1,0.5273837447166443
SIMPONI,INFECTIONS,ections [s ee,1,0.5608676671981812
SIMPONI,MALIGNANCY,arnings an d Precautions Malignancies,1,0.7492150068283081
SIMPONI,MALIGNANCY,Precautions Malignancies see Warnings,0,0.7574077844619751
SIMPONI,MALIGNANCY,Serious Infections see arnings an,1,0.5785825252532959
SIMPONI,MALIGNANCY,Infections see arnings an d Precautions Malignancies see Warnings,1,0.7155264019966125
SIMPONI,MALIGNANCY,Precautions Malignancies,0,0.7911466956138611
SIMPONI,MALIGNANCY,arnings an d,1,0.5167348980903625
SIMPONI,INFECTIONS,ancies [se,1,0.5699975490570068
SIMPONI,INFECTIONS,Infections see Warnings and Precautions Malign,0,0.7701234817504883
SIMPONI,MALIGNANCY,rnings and Precautions EXCERPT Most,1,0.5255805253982544
SIMPONI,MALIGNANCY,Infections see Warnings and Precautions Malign,0,0.5671807527542114
SIMPONI,MALIGNANCY,Malignancies see rnings,1,0.8400266170501709
SIMPONI,MALIGNANCY,rnings and Precautions EXCERPT Most common adverse,1,0.5459500551223755
SIMPONI,MALIGNANCY,Precautions EXCERPT Most common adverse,0,0.5275101065635681
SIMPONI,infections,common adverse reactions %) are:,1,0.5736737251281738
SIMPONI,infections,are: up,1,0.5388817191123962
SIMPONI,infections,%) are: up per respiratory,1,0.5515227317810059
SIMPONI,death,", vir al",1,0.5274757742881775
SIMPONI,death,upper respiratory,0,0.5023149251937866
SIMPONI,death,"upper respiratory tract , vir al",1,0.5012840032577515
SIMPONI,death,bronchitis hypertension and rash,0,0.51212477684021
SIMPONI,death,"are upper respiratory tract , vir",1,0.478057324886322
SIMPONI,tuberculosis,"n, bronchiti s hypertension and rash To",1,0.5533014535903931
SIMPONI,tuberculosis,"n, bronchiti s",1,0.5584576725959778
SIMPONI,tuberculosis,"n, bronchiti s hypertension and rash",1,0.5457020998001099
SIMPONI,tuberculosis,tract infection,0,0.6283178329467773
SIMPONI,TB,reactions,0,0.5321304798126221
SIMPONI,TB,viral infection  h,1,0.5031395554542542
SIMPONI,TB,rash To report SUSPECTED ADVERSE REACTIONS contactJanssen Biotech,0,0.5087060928344727
SIMPONI,TB, h ypertension and rash To report,1,0.519382119178772
SIMPONI,TB,infection viral infection  h ypertension and,1,0.49985384941101074
SIMPONI,TB,viral infection  h ypertension and rash To report,1,0.500445544719696
SIMPONI,bacterial sepsis,and ra,1,0.47977423667907715
SIMPONI,bacterial sepsis,"infection bronchitis rtension, and",1,0.6033018827438354
SIMPONI,bacterial sepsis,"infection bronchitis rtension,",1,0.5922995805740356
SIMPONI,bacterial sepsis,contactJanssen Biotech Inc,0,0.5072162747383118
SIMPONI,bacterial sepsis,and ra sh,1,0.49442869424819946
SIMPONI,bacterial sepsis,"infection viral infection bronchitis rtension, and ra sh To",1,0.5532738566398621
SIMPONI,bacterial sepsis,contactJanssen Biotech Inc at,0,0.5047714114189148
SIMPONI,opportunistic infections,contactJanssen Biot ech Inc at JANSSEN or,1,0.4515555799007416
SIMPONI,Lymphoma,and may,0,0.459538072347641
SIMPONI,Lymphoma,are based on,0,0.47795340418815613
SIMPONI,Lymphoma,eflect t he,1,0.5453224182128906
SIMPONI,Lymphoma,in the clinical trials of another drug and may,0,0.559705376625061
SIMPONI,Lymphoma,not eflect,1,0.4858110547065735
SIMPONI,Lymphoma,and may not,0,0.4612583518028259
SIMPONI,Lymphoma,may not eflect t,1,0.5254664421081543
SIMPONI,Lymphoma,eflect t,1,0.5481390953063965
SIMPONI,malignancies,the rates served in cl inical practice The safety,1,0.5114831328392029
SIMPONI,malignancies,eflect t,1,0.5120452642440796
SIMPONI,malignancies,rates served in cl,1,0.48138877749443054
SIMPONI,malignancies,The safety data described,0,0.5450766086578369
SIMPONI,fatal,observed in pract ice The safety,1,0.5459333062171936
SIMPONI,fatal,The safety data described,0,0.5819915533065796
SIMPONI,fatal,pract,1,0.5183008313179016
SIMPONI,fatal,observed in clinical,0,0.5777376294136047
SIMPONI,fatal,The safety data described below are based on one,0,0.5881568193435669
SIMPONI,fatal,pract ice The safety data,1,0.5544219017028809
SIMPONI,fatal,rates observed in pract ice The safety data,1,0.545267641544342
SIMPONI,infections,patients taking ebo to rec eive treatment,1,0.5101428627967834
SIMPONI,infections,pract ice The safety data,1,0.4810847043991089
SIMPONI,infections,eive treatment with SIMPONI ARIA at Week or,0,0.5703309774398804
SIMPONI,infections,The protocol included provisions for patients taking,0,0.553473949432373
SIMPONI,infections,provisions for patients taking ebo to rec eive treatment with,1,0.5190967917442322
SIMPONI,death,with SIMPONI ARIA at eek,1,0.47652822732925415
SIMPONI,death,by design so,0,0.5285343527793884
SIMPONI,death,receive treatment with SIMPONI ARIA,0,0.4579135477542877
SIMPONI,death,eek 1 or Week either,1,0.5245924592018127
SIMPONI,death,with,0,0.6023277044296265
SIMPONI,death,with SIMPONI ARIA at eek 1 or Week either by patient,1,0.4954623579978943
SIMPONI,death,with SIMPONI ARIA at eek 1 or,1,0.4717973470687866
SIMPONI,infections,ONI ARIA at Week or Week either,0,0.5103732347488403
SIMPONI,infections,on uncontrolled disease activity r by desig n so that adverse,1,0.5957801342010498
SIMPONI,infections,disease activity r by desig,1,0.6088817119598389
SIMPONI,infections,by desig,1,0.5556440353393555
SIMPONI,infections,uncontrolled disease activity r by,1,0.5905812978744507
SIMPONI,infections,Week or Week,0,0.5032182931900024
SIMPONI,Active tuberculosis,(which incl udes controltreated patients,1,0.5241253972053528
SIMPONI,Active tuberculosis,atients (which incl udes controltreated patients who switched,1,0.5215027928352356
SIMPONI,Active tuberculosis,atients (which incl udes controltreated,1,0.5155419707298279
SIMPONI,Active tuberculosis,patients and SIMPONI ARIAtreated atients (which incl udes controltreated patients,1,0.5423896312713623
SIMPONI,Active tuberculosis,of exposure,0,0.5372543334960938
SIMPONI,tuberculosis,patients who discontinued treatment due to,0,0.510812520980835
SIMPONI,tuberculosis,to SIMPONI ARIA at eek 16).,1,0.4862930476665497
SIMPONI,tuberculosis,adverse reactions in,0,0.5557078719139099
SIMPONI,tuberculosis,to SIMPONI ARIA at eek,1,0.513744056224823
SIMPONI,tuberculosis,reactions in the,0,0.5321844816207886
SIMPONI,tuberculosis,at eek 16).,1,0.49080634117126465
SIMPONI,Invasive fungal infections,respiratory act infection was the,1,0.5468788146972656
SIMPONI,Invasive fungal infections,respiratory act infection was the most common adverse reaction reported,1,0.5770439505577087
SIMPONI,Invasive fungal infections,Upper respiratory act infection was the most,1,0.5671061277389526
SIMPONI,Invasive fungal infections,was the most common,1,0.4890151023864746
SIMPONI,Invasive fungal infections,patients Upper,0,0.555627167224884
SIMPONI,Invasive fungal infections,for SIMPONI ARIAtreated patients and for placebotreated patients Upper respiratory tr,0,0.5608394145965576
SIMPONI,Invasive fungal infections,through Week occurring in of,0,0.48920243978500366
SIMPONI,histoplasmosis,the most common rse,1,0.46880483627319336
SIMPONI,histoplasmosis,rse reaction r eported in,1,0.5128072500228882
SIMPONI,histoplasmosis,ts and for placebotreated,0,0.5389808416366577
SIMPONI,histoplasmosis,reaction r eported in the trial through,1,0.5314832925796509
SIMPONI,histoplasmosis,the most common rse reaction r eported in the,1,0.5287044644355774
SIMPONI,histoplasmosis,the most common rse reaction r,1,0.49954283237457275
SIMPONI,histoplasmosis,Week,0,0.48419392108917236
SIMPONI,histoplasmosis,rse reaction r,1,0.4934425950050354
SIMPONI,histoplasmosis,the most,0,0.4634440541267395
SIMPONI,coccidioidomycosis,reaction orted in,1,0.47536492347717285
SIMPONI,coccidioidomycosis,rep,0,0.47909092903137207
SIMPONI,coccidioidomycosis,most common adverse reaction orted in the,1,0.4942253828048706
SIMPONI,candidiasis,hrough Week occurring in of,1,0.4843537211418152
SIMPONI,candidiasis,as compared with of,0,0.44884103536605835
SIMPONI,aspergillosis,4 occurring i,1,0.5253232717514038
SIMPONI,aspergillosis,as compared with of,0,0.5029664635658264
SIMPONI,aspergillosis,the trial through Week,0,0.5087884664535522
SIMPONI,aspergillosis,the trial through 4 occurring i n of SIMPONI ARIAtreated,1,0.5456784963607788
SIMPONI,aspergillosis,patients,0,0.5458899140357971
SIMPONI,aspergillosis,the trial through 4 occurring i,1,0.5058265924453735
SIMPONI,aspergillosis,infection was,0,0.6731172800064087
SIMPONI,aspergillosis,was the most common adverse reaction reported in,0,0.5690609812736511
SIMPONI,aspergillosis,4 occurring i n of,1,0.5293630957603455
SIMPONI,aspergillosis,SIMPONI ARIAtreated patients as compared with of,0,0.5138605833053589
SIMPONI,blastomycosis,of SIMPO NI ARIAtreated,1,0.5344874858856201
SIMPONI,blastomycosis,through Week occurring 6.5% of SIMPO NI ARIAtreated patients,1,0.5189927220344543
SIMPONI,blastomycosis,ARIAtreated patients as compared with,0,0.516485333442688
SIMPONI,blastomycosis,of SIMPO NI ARIAtreated patients as compared,1,0.5226263999938965
SIMPONI,blastomycosis,Week occurring 6.5% of SIMPO NI ARIAtreated patients as,1,0.512906551361084
SIMPONI,blastomycosis,as compared,0,0.45637160539627075
SIMPONI,blastomycosis,trial through Week occurring 6.5% of SIMPO,1,0.5084827542304993
SIMPONI,blastomycosis,reaction reported in the,0,0.526951253414154
SIMPONI,pneumocystosis,adverse reaction reported in,0,0.5238016247749329
SIMPONI,pneumocystosis,IA-treated pat ients as compared with of,1,0.4970928430557251
SIMPONI,pneumocystosis,IA-treated pat,1,0.5210031270980835
SIMPONI,pneumocystosis,IA-treated pat ients as,1,0.46375590562820435
SIMPONI,pneumocystosis,trial through,0,0.4723537862300873
SIMPONI,pneumocystosis,of controltreated patients respectively Infections,0,0.5492615103721619
SIMPONI,Lymphoma,ortions  of Trial total patientyears of,1,0.5297949910163879
SIMPONI,Lymphoma,of Trial total patientyears of followup with a median followup of approximately weeks,0,0.5120788216590881
SIMPONI,Lymphoma,placebo group In the controlled and uncontrolled p,0,0.4858610928058624
SIMPONI,Lymphoma,patientyears of followup with,0,0.5279026031494141
SIMPONI,Lymphoma,uncontrolled ortions  of Trial,1,0.4885358214378357
SIMPONI,malignancies,and uncontrolled portions of  958 total p,1,0.5125526189804077
SIMPONI,malignancies,patientyears of followup with,0,0.5741197466850281
SIMPONI,malignancies,portions of  958 total p atientyears of,1,0.531334400177002
SIMPONI,fatal,Trial total years of followup with,1,0.476560115814209
SIMPONI,fatal,patientyears of followup with,0,0.44207054376602173
SIMPONI,fatal,years of followup with a median,1,0.4497954547405243
SIMPONI,fatal,Trial total years,1,0.47752341628074646
SIMPONI,fatal,of Trial total,0,0.5123339891433716
SIMPONI,fatal,years of followup,1,0.4424784183502197
SIMPONI,fatal,total years of followup with a median,1,0.45816418528556824
SIMPONI,fatal,In the controlled,0,0.5087461471557617
SIMPONI,fatal,of Trial total years of followup with,1,0.4689812958240509
SIMPONI,infections,see Warnings and Precautions Malignancies see Warnings an,0,0.6077938079833984
SIMPONI,infections,most,0,0.5234867930412292
SIMPONI,infections,"serious adverse s were:


 Serious Infections see Warnings",1,0.7355408072471619
SIMPONI,infections,serious adverse s were:,1,0.5761744976043701
SIMPONI,infections,"most serious adverse s were:


 Serious Infections see",1,0.7622339725494385
SIMPONI,infections,reaction,0,0.4934256672859192
SIMPONI,infections,adverse s were:,1,0.5722171664237976
SIMPONI,Invasive fungal infections,infection viral infection bronchitis hypertension and,0,0.549627423286438
SIMPONI,Invasive fungal infections,Most common adverse ns,1,0.5275375247001648
SIMPONI,Invasive fungal infections,ns (incidence >=3%) are: u pper respiratory tract,1,0.5503674745559692
SIMPONI,Invasive fungal infections,are: u,1,0.4767697751522064
SIMPONI,Invasive fungal infections,tract infection viral infection bronchitis hypertension and,0,0.5566797852516174
SIMPONI,Hepatitis B reactivation,or FDA at,1,0.5222975015640259
SIMPONI,Hepatitis B reactivation,SUSPECTED ADVERSE REACTIONS contactJanssen Biotech Inc,0,0.5532330274581909
SIMPONI,Hepatitis B reactivation,(1-800-526-7736) or FDA at,1,0.5035510063171387
SIMPONI,Hepatitis B reactivation,REACTIONS contactJanssen Biotech Inc,0,0.5611875057220459
SIMPONI,Hepatitis B reactivation,SUSPECTED ADVERSE,0,0.5142345428466797
SIMPONI,Hepatitis B reactivation,Inc at  (1-800-526-7736) or FDA at,1,0.5078498721122742
SIMPONI,Hepatitis B reactivation,Experience Because c,0,0.47231629490852356
SIMPONI,Hepatitis B reactivation,(1-800-526-7736) or FDA,1,0.5095653533935547
SIMPONI,Malignancies,the clinical trials of a drug cannot be directly compared to rates,0,0.5618659257888794
SIMPONI,Malignancies,"nditions, ad",1,0.5989368557929993
SIMPONI,Malignancies,"nditions, ad verse reaction",1,0.5350804328918457
SIMPONI,Malignancies,clinical trials are conducted under widely varying,0,0.5750426054000854
SIMPONI,Malignancies,"nditions, ad verse",1,0.5899155139923096
SIMPONI,Malignancies,verse reaction rates observed,0,0.5253386497497559
SIMPONI,Malignancies,varying,0,0.5246405005455017
SIMPONI,Malignancies,"varying nditions, ad",1,0.5584539175033569
SIMPONI,lymphoma,varying conditions adverse reaction tes obse,1,0.530271053314209
SIMPONI,lymphoma,tes,1,0.4832596778869629
SIMPONI,lymphoma,adverse reaction tes obse rved,1,0.5430382490158081
SIMPONI,lymphoma,in the clinical trials of a drug cannot be directly,0,0.5068867802619934
SIMPONI,lymphoma,tes obse rved in the clinical,1,0.518520712852478
SIMPONI,lymphoma,to rates in the clinical,0,0.4849867522716522
SIMPONI,lymphoma,under widely varying conditions,0,0.4954853057861328
SIMPONI,lymphoma,reaction tes obse,1,0.5207258462905884
SIMPONI,malignancies,ay not refle ct the rates observed in,1,0.5106433033943176
SIMPONI,malignancies,ay not refle ct the rates,1,0.4805525243282318
SIMPONI,malignancies,another drug and ay not refle ct the rates,1,0.5745946764945984
SIMPONI,malignancies,another drug and ay not refle,1,0.5532398819923401
SIMPONI,malignancies,ay not refle ct,1,0.5431913137435913
SIMPONI,malignancies,practice,0,0.5482591986656189
SIMPONI,malignancies,clinical trials of another drug,0,0.6102009415626526
SIMPONI,Heart failure,described,0,0.50529944896698
SIMPONI,Heart failure,not reflect the rates observed in clinical,0,0.5299598574638367
SIMPONI,Heart failure,below are bas ed on,1,0.50761878490448
SIMPONI,Heart failure,safety data below,1,0.5278210639953613
SIMPONI,Heart failure,clinical practice The safety data,0,0.52516770362854
SIMPONI,Heart failure,data below,1,0.5230725407600403
SIMPONI,Heart failure,below are bas ed on one randomized doubleblind,1,0.46817994117736816
SIMPONI,Heart failure,data below are bas ed on one randomized doubleblind,1,0.488473117351532
SIMPONI,Hypersensitivity reactions,Week either by patient response based on,0,0.5066657066345215
SIMPONI,systemic hypersensitivity reactions,uncontrolled disease activity or by design so that adv,0,0.5297547578811646
SIMPONI,systemic hypersensitivity reactions,Week 16 or W,1,0.44566476345062256
SIMPONI,systemic hypersensitivity reactions,based,0,0.46639010310173035
SIMPONI,systemic hypersensitivity reactions,to receive treatmen,0,0.5377952456474304
SIMPONI,systemic hypersensitivity reactions,taking placebo to receive t with SIMPONI ARIA at Week 16 or W,1,0.5450559854507446
SIMPONI,systemic hypersensitivity reactions,16 or W eek either by,1,0.4504881501197815
SIMPONI,systemic hypersensitivity reactions,to receive t with SIMPONI ARIA at Week,1,0.5445719957351685
SIMPONI,anaphylaxis,Week or Week er by patie nt response based on,1,0.5363092422485352
SIMPONI,anaphylaxis,to receive t with SIMPONI ARIA at Week,1,0.5416793823242188
SIMPONI,anaphylaxis,receive,0,0.5272815227508545
SIMPONI,anaphylaxis,isions for patients,0,0.4966870844364166
SIMPONI,anaphylaxis,er by patie,1,0.5502225160598755
SIMPONI,anaphylaxis,Week or Week er by patie,1,0.5322840809822083
SIMPONI,anaphylaxis,activity,0,0.5261448621749878
SIMPONI,anaphylaxis,by patie nt response based on uncontrolled,1,0.5536752939224243
SIMPONI,anaphylaxis,by patie nt response based,1,0.5562712550163269
SIMPONI,anaphylaxis,placebo to receive treatment with,0,0.5456266403198242
SIMPONI,infections,to a treatment. Comparisons,1,0.5548551678657532
SIMPONI,infections,by patie nt response based,1,0.5320876836776733
SIMPONI,infections,treatment. Comparisons between placebo and SIMPONI,1,0.5286076068878174
SIMPONI,death,first of ex,1,0.5439335107803345
SIMPONI,death,first of ex posure Trial included controltreated,1,0.5123186111450195
SIMPONI,death,based,0,0.5533384084701538
SIMPONI,death,the first,0,0.5360271334648132
SIMPONI,Opportunistic infections,. Trial 1 included 1,1,0.47751572728157043
SIMPONI,Opportunistic infections,.,1,0.5718246698379517
SIMPONI,Opportunistic infections,includes,0,0.5352808237075806
SIMPONI,aspergillosis,includes reated patien,1,0.5527386665344238
SIMPONI,aspergillosis,includes reated,1,0.5398915410041809
SIMPONI,aspergillosis,SIMPONI ARIAtreated patients,0,0.5251480340957642
SIMPONI,aspergillosis,of patients who discontinued treatment,0,0.47693169116973877
SIMPONI,aspergillosis,reated patien ts,1,0.5452081561088562
SIMPONI,aspergillosis,controltreated patients and SIMPONI ARIAtreated patients,0,0.5461934804916382
SIMPONI,candidiasis,ARIAtreated patients which includes controltreated patients who switched,0,0.539699375629425
SIMPONI,candidiasis,o SIMPONI A,1,0.48780912160873413
SIMPONI,candidiasis,controltreated patients who switched o SIMPONI,1,0.5351322293281555
SIMPONI,candidiasis,controltreated patients who switched o SIMPONI A RIA at Week The proportion,1,0.5212407112121582
SIMPONI,candidiasis,switched o SIMPONI A,1,0.5031676888465881
SIMPONI,candidiasis,tients and SIMPONI,0,0.528235137462616
SIMPONI,coccidioidomycosis,who switched to SIMPONI,0,0.4521567225456238
SIMPONI,coccidioidomycosis,SIMPONI A at Week 16). The,1,0.5115587115287781
SIMPONI,coccidioidomycosis,switched to SIMPONI A at Week 16). The proportion of patients who discontinued,1,0.47631675004959106
SIMPONI,coccidioidomycosis,switched to,0,0.4383689761161804
SIMPONI,coccidioidomycosis,SIMPONI A,1,0.48287612199783325
SIMPONI,coccidioidomycosis,SIMPONI A at Week 16). The proportion of,1,0.5035008788108826
SIMPONI,coccidioidomycosis,who switched to SIMPONI A at Week 16). The proportion of,1,0.46092909574508667
SIMPONI,histoplasmosis,who switched to SIMPONI ARIA,0,0.4461384415626526
SIMPONI,histoplasmosis,The,0,0.5086636543273926
SIMPONI,listeriosis,of patients who ntinued,1,0.4871909022331238
SIMPONI,listeriosis,patients who ntinued tre,1,0.5038278102874756
SIMPONI,listeriosis,Trial through Week was for SIMP,0,0.4347652196884155
SIMPONI,listeriosis,of patients who ntinued tre,1,0.5074923634529114
SIMPONI,listeriosis,who switched to SIMPONI ARIA at Week,0,0.47316300868988037
SIMPONI,pneumocystosis,of patients,0,0.5089656114578247
SIMPONI,pneumocystosis,patients who,0,0.5043801069259644
SIMPONI,pneumocystosis,of patients who discontinued ment,1,0.47545337677001953
SIMPONI,tuberculosis,adverse,0,0.5245485305786133
SIMPONI,tuberculosis,reactions in the controlled phase,1,0.5288870334625244
SIMPONI,tuberculosis,The proportion of patients who discontinued treatment due to,0,0.5024542808532715
SIMPONI,tuberculosis,discontinued,0,0.506553053855896
SIMPONI,tuberculosis,SIMPONI ARIA at Week The proportion,0,0.48460477590560913
SIMPONI,tuberculosis,SIMPONI ARIAtreated,0,0.5445164442062378
SIMPONI,reactivation of tuberculosis,other opportunistic infections patient-years was 0.42 (95%  CI Malignancies,1,0.5423409342765808
SIMPONI,reactivation of tuberculosis,SIMPONI ARIAtreated,0,0.564581573009491
SIMPONI,reactivation of tuberculosis,patient-years,1,0.5123850703239441
SIMPONI,reactivation of tuberculosis,patient-years was 0.42 (95% CI Malignancies One case,1,0.4846299886703491
SIMPONI,reactivation of tuberculosis,other opportunistic infections patient-years was,1,0.589124321937561
SIMPONI,reactivation of tuberculosis,patient-years was 0.42 (95% CI Malignancies,1,0.4815061092376709
SIMPONI,reactivation of tuberculosis,case,0,0.4949680268764496
SIMPONI,reactivation of tuberculosis,patient-years was 0.42 (95%,1,0.49844861030578613
SIMPONI,new tuberculosis infections,"patientyears was 0.11, 1.07).



     Malign ancies",1,0.5080848932266235
SIMPONI,new tuberculosis infections,patient-years was 0.42 (95%,1,0.4737289547920227
SIMPONI,new tuberculosis infections,"0.11, 1.07).",1,0.4803251624107361
SIMPONI,new tuberculosis infections,lymphoma and NMSC with SIMPONI ARIA was,0,0.5557655096054077
SIMPONI,new tuberculosis infections,"0.11, 1.07). Malign ancies One case",1,0.5252183079719543
SIMPONI,reactivation of hepatitis B virus,by,0,0.5097779035568237
SIMPONI,reactivation of hepatitis B virus,golimumab and thus results are an underestimate of t he rate of product,1,0.481166273355484
SIMPONI,reactivation of hepatitis B virus,The ELISA,0,0.5934180021286011
SIMPONI,reactivation of hepatitis B virus,and thus results are an underestimate of t he rate of product immunogenicity,1,0.5383168458938599
SIMPONI,reactivation of hepatitis B virus,results are an underestimate of t he,1,0.45389485359191895
SIMPONI,reactivation of hepatitis B virus,the sensitivity and specif,0,0.5051733255386353
SIMPONI,reactivation of hepatitis B virus,underestimate of t he,1,0.4524672329425812
SIMPONI,reactivation of hepatitis B virus,copresent golimumab and thus results are an underestimate of t he rate of product immunogenicity,1,0.5404543876647949
SIMPONI,HBV reactivation,the assay. Addit,1,0.5458794832229614
SIMPONI,HBV reactivation,underestimate of t he,1,0.45526042580604553
SIMPONI,HBV reactivation,and,0,0.4777812063694
SIMPONI,HBV reactivation,of antibody positivity in an,0,0.5755017995834351
SIMPONI,HBV reactivation,dependent on the sensitivity,0,0.49650877714157104
SIMPONI,HBV reactivation,the assay.,1,0.5453758239746094
SIMPONI,HBV reactivation,positivity in an assay,0,0.5604578852653503
SIMPONI,HBV reactivation,specificity,0,0.504474401473999
SIMPONI,Malignancies,herpes,0,0.6173796653747559
SIMPONI,Malignancies,             Bacterial,1,0.5312172770500183
SIMPONI,Malignancies,such as influenza and              Bacterial infections,1,0.5940204858779907
SIMPONI,fatal,      Bacterial,1,0.5512723922729492
SIMPONI,fatal,     ,1,0.6033680438995361
SIMPONI,fatal,Viral infections,0,0.5006623268127441
SIMPONI,lymphoma,not appear in,0,0.46503302454948425
SIMPONI,lymphoma,section included the lowing e,1,0.5017240047454834
SIMPONI,lymphoma,lowing e vents,1,0.4723849892616272
SIMPONI,lymphoma,section included,0,0.5166894793510437
SIMPONI,lymphoma,through Week that do not,0,0.4819190502166748
SIMPONI,lymphoma,There is,0,0.5781645774841309
SIMPONI,lymphoma,"


   Ga",1,0.5193204283714294
SIMPONI,lymphoma,"disorders Dizziness 


   Ga strointestinal disorders Constipation",1,0.49820229411125183
SIMPONI,lymphoma,Nervous system,0,0.56025230884552
SIMPONI,lymphoma,increased neutrophil count,0,0.5489071011543274
SIMPONI,chronic leukemia,Experience Th ere,1,0.46510571241378784
SIMPONI,chronic leukemia,Gastrointestinal disorders Constipation Experience Th,1,0.503383457660675
SIMPONI,hepatosplenic T-cell lymphoma,estimate ir frequency or establish a c,1,0.479309618473053
SIMPONI,hepatosplenic T-cell lymphoma,Gastrointestinal disorders Constipation Experience Th,1,0.4870794415473938
SIMPONI,hepatosplenic T-cell lymphoma,to golimumab exposure Neoplasm Benign and,0,0.5931711792945862
SIMPONI,hepatosplenic T-cell lymphoma,to reliably estimate ir,1,0.4442296326160431
SIMPONI,hepatosplenic T-cell lymphoma,to reliably estimate ir frequency or establish a c ausal relationship to golimumab,1,0.5292099118232727
SIMPONI,hepatosplenic T-cell lymphoma,establish a c ausal,1,0.47215041518211365
SIMPONI,hepatosplenic T-cell lymphoma,ir frequency or establish a c,1,0.4716888666152954
SIMPONI,hepatosplenic T-cell lymphoma,reliably estimate ir frequency or establish,1,0.4580196142196655
SIMPONI,HSTCL,sal r elationship to golimumab exposure,1,0.4634959101676941
SIMPONI,HSTCL,is not always possible,0,0.4803621470928192
SIMPONI,rare type of T-cell lymphoma,: Melanoma  [see  Warnings a nd Precautions Immune System Disorders,1,0.5800542831420898
SIMPONI,rare type of T-cell lymphoma,is not always possible,0,0.5062577724456787
SIMPONI,rare type of T-cell lymphoma,Benign and,0,0.5001718997955322
SIMPONI,rare type of T-cell lymphoma,System Disorders Serious systemic hypersensitivity,0,0.5333845615386963
SIMPONI,fatal,System rs :,1,0.4855758547782898
SIMPONI,fatal,Serious systemic hypersensitivity reactions including anaphylactic reaction see Warnings,0,0.5738219022750854
SIMPONI,fatal,rs :,1,0.5526842474937439
SIMPONI,fatal,rs : Serious systemic hypersensitivity reactions including,1,0.5709273815155029
BLINCYTO,Cytokine Release Syndrome,Release Syndrome see,1,0.8064988851547241
BLINCYTO,Cytokine Release Syndrome,the label,0,0.48076993227005005
BLINCYTO,Cytokine Release Syndrome,see Warnings,0,0.5448322296142578
BLINCYTO,Cytokine Release Syndrome,Release Syndrome see Warnings and,1,0.7554894089698792
BLINCYTO,Cytokine Release Syndrome,Release Syndrome,1,0.8251874446868896
BLINCYTO,Cytokine Release Syndrome,of the Cytokine,1,0.7312049865722656
BLINCYTO,Cytokine Release Syndrome,discussed in,0,0.5057831406593323
BLINCYTO,Cytokine Release Syndrome,Warnings and,0,0.547001838684082
BLINCYTO,Cytokine Release Syndrome,the Cytokine Release Syndrome,1,0.983642041683197
BLINCYTO,Neurological Toxicities,Warnings and Neurological Toxicities,1,0.9232977032661438
BLINCYTO,Neurological Toxicities,and Neurological Toxicities see Warnings and Precautions,1,0.9124020338058472
BLINCYTO,Neurological Toxicities,Warnings,0,0.66206294298172
BLINCYTO,Neurological Toxicities,see Warnings and Precautions Infections see Warnings and,0,0.5838037729263306
BLINCYTO,Neurological Toxicities,Syndrome see Warnings and Neurological Toxicities,1,0.8633591532707214
BLINCYTO,Neurological Toxicities,Cytokine Release Syndrome see Warnings,0,0.6237353086471558
BLINCYTO,Tumor Lysis Syndrome,Warnings,0,0.5197386741638184
BLINCYTO,Tumor Lysis Syndrome,Tumor Lysis Syndrome see,1,0.9741637110710144
BLINCYTO,Tumor Lysis Syndrome,Precautions,0,0.45718148350715637
BLINCYTO,Tumor Lysis Syndrome,Warnings and Tumor Lysis Syndrome see Warnings and,1,0.8428092002868652
BLINCYTO,Tumor Lysis Syndrome,Warnings and Tumor Lysis Syndrome,1,0.8889235854148865
BLINCYTO,Tumor Lysis Syndrome,and Febrile Neutropenia see Warnings,0,0.5485442876815796
BLINCYTO,Tumor Lysis Syndrome,Febrile Neutropenia see,0,0.566057562828064
BLINCYTO,Neutropenia,Syndrome see Warnings and Neutropenia and Febrile Neutropenia,1,0.7889456152915955
BLINCYTO,Neutropenia,Febrile Neutropenia see,0,0.8529484272003174
BLINCYTO,Neutropenia,Febrile Neutropenia see Warnings and Precautions Effects on Ability,0,0.7715355157852173
BLINCYTO,Neutropenia,Effects on Ability to Drive,0,0.4813286066055298
BLINCYTO,Neutropenia,and Precautions,0,0.5304017066955566
BLINCYTO,Neutropenia,Syndrome,0,0.5373554229736328
BLINCYTO,Neutropenia,Neutropenia and,1,0.938434362411499
BLINCYTO,Neutropenia,Neutropenia and Febrile Neutropenia see,1,0.8681967854499817
BLINCYTO,Neutropenia,Lysis,0,0.5680786371231079
BLINCYTO,Neutropenia,Syndrome see,0,0.5219577550888062
BLINCYTO,Neutropenia,Precautions,0,0.5516342520713806
BLINCYTO,Febrile Neutropenia,Warnings and Precautions Neutropenia Febrile Neutropenia,1,0.8927879333496094
BLINCYTO,Effects on Ability to Drive,Neutropenia and Febrile Neutropenia see Warnings,0,0.5229191184043884
BLINCYTO,Effects on Ability to Drive,and Effects on Ability to,1,0.8606350421905518
BLINCYTO,Effects on Ability to Drive,on Ability to Drive and Use Machines,1,0.720876157283783
BLINCYTO,Effects on Ability to Drive,Warnings and Effects on,1,0.7076106071472168
BLINCYTO,Effects on Ability to Drive,Enzymes,0,0.5212081670761108
BLINCYTO,Effects on Ability to Drive,Neutropenia see Warnings and Effects on Ability to Drive and Use Machines,1,0.759585440158844
BLINCYTO,Elevated Liver Enzymes,Use Machines see,0,0.4929302930831909
BLINCYTO,Elevated Liver Enzymes,on Ability to Drive and Use Machines see Warnings,0,0.5130823254585266
BLINCYTO,Elevated Liver Enzymes,Leukoencephalopathy,0,0.5208885073661804
BLINCYTO,Elevated Liver Enzymes,see Warnings and Elevated Liver Enzymes,1,0.8722171783447266
BLINCYTO,Elevated Liver Enzymes,Warnings and Precautions Leukoencephalopathy see,0,0.5566564202308655
BLINCYTO,Elevated Liver Enzymes,Warnings and Precautions,0,0.5554449558258057
BLINCYTO,Elevated Liver Enzymes,Drive and Use Machines see,0,0.4736438989639282
BLINCYTO,Elevated Liver Enzymes,Elevated Liver Enzymes see Warnings,1,0.9154367446899414
BLINCYTO,Elevated Liver Enzymes,Elevated Liver Enzymes,1,1.0
BLINCYTO,Leukoencephalopathy,and Leukoencephalopathy,1,0.9566080570220947
BLINCYTO,Leukoencephalopathy,Leukoencephalopathy,0,0.9999997615814209
BLINCYTO,Leukoencephalopathy,Preparation and Administration Errors,0,0.5170016884803772
BLINCYTO,pyrexia,pyrexia,1,1.0000001192092896
BLINCYTO,pyrexia,Preparation and Administration Errors,0,0.521684467792511
BLINCYTO,pyrexia,and Precautions The most common adverse reactions were,0,0.5578478574752808
BLINCYTO,headache,common adverse reactions were headache peripheral edema,1,0.73611980676651
BLINCYTO,headache,and Precautions The most common adverse reactions were,0,0.5554277896881104
BLINCYTO,peripheral edema,common adverse reactions,0,0.5781377553939819
BLINCYTO,peripheral edema,were,0,0.4628344774246216
BLINCYTO,peripheral edema,peripheral edema febrile,1,0.892227828502655
BLINCYTO,peripheral edema,peripheral edema febrile neutropenia,1,0.8512099385261536
BLINCYTO,peripheral edema,peripheral edema,1,1.0000001192092896
BLINCYTO,peripheral edema,common adverse reactions were pyrexia,0,0.567590594291687
BLINCYTO,febrile neutropenia,headache peripheral febrile neutropenia,1,0.8354950547218323
BLINCYTO,febrile neutropenia,common adverse reactions were pyrexia,0,0.6499470472335815
BLINCYTO,febrile neutropenia,were pyrexia headache peripheral febrile neutropenia nausea hypokalemia tremor rash,1,0.7118759155273438
BLINCYTO,febrile neutropenia,hypokalemia tremor rash and constipation EXCERPT To r,0,0.5098625421524048
BLINCYTO,febrile neutropenia,febrile neutropenia nausea hypokalemia,1,0.8294141292572021
BLINCYTO,febrile neutropenia,febrile neutropenia nausea hypokalemia tremor,1,0.7966196537017822
BLINCYTO,nausea,nausea,1,1.0
BLINCYTO,hypokalemia,n adverse reactions were pyrexia headache peripheral edema,0,0.5436568856239319
BLINCYTO,hypokalemia,neutropenia hypokalemia tremor rash,1,0.7434583902359009
BLINCYTO,hypokalemia,peripheral edema febrile neutropenia hypokalemia tremor rash and constipation EXCERPT,1,0.7359713315963745
BLINCYTO,hypokalemia,and constipation EXCERPT To report,0,0.509138822555542
BLINCYTO,hypokalemia,febrile,0,0.5330244302749634
BLINCYTO,hypokalemia,headache,0,0.5310183167457581
BLINCYTO,hypokalemia,hypokalemia tremor rash,1,0.8110920786857605
BLINCYTO,hypokalemia,hypokalemia tremor rash and constipation EXCERPT,1,0.7878744602203369
BLINCYTO,hypokalemia,hypokalemia,1,1.0
BLINCYTO,tremor,neutropenia nausea tremor rash and constipation,1,0.6519903540611267
BLINCYTO,tremor,hypokalemia,1,0.6097348928451538
BLINCYTO,rash,edema febrile neutropenia nausea hypokalemia tremor,0,0.6226097345352173
BLINCYTO,rash,febrile neutropenia,0,0.5495184659957886
BLINCYTO,rash,tremor,0,0.6276923418045044
BLINCYTO,rash,febrile neutropenia nausea hypokalemia rash and,1,0.7127119302749634
BLINCYTO,constipation,constipation EXCERPT To report SUSPECTED,1,0.8357706069946289
BLINCYTO,constipation,REACTIONS contact Amgen,0,0.47256630659103394
BLINCYTO,constipation,constipation EXCERPT To,1,0.8706003427505493
BLINCYTO,constipation,constipation EXCERPT,1,0.8816150426864624
BLINCYTO,pyrexia,pyrexia headache peripheral edema febrile neutropenia,1,0.7918660640716553
BLINCYTO,pyrexia,pyrexia headache,1,0.8879539966583252
BLINCYTO,pyrexia,Black or African,0,0.5075104832649231
BLINCYTO,headache,edema febrile neutropenia nausea hypokalemia and,0,0.5741472244262695
BLINCYTO,headache,hypokalemia and,0,0.5120804905891418
BLINCYTO,headache,febrile,0,0.6039026379585266
BLINCYTO,headache,adverse,0,0.5728578567504883
BLINCYTO,headache,African American The most,0,0.4607352614402771
BLINCYTO,headache,were,0,0.5297192335128784
BLINCYTO,headache,headache peripheral,1,0.8324973583221436
BLINCYTO,peripheral edema,were pyrexia peripheral edema febrile,1,0.7968963384628296
BLINCYTO,peripheral edema,pyrexia peripheral,1,0.7028489708900452
BLINCYTO,peripheral edema,reactions were pyrexia peripheral edema febrile,1,0.7589033246040344
BLINCYTO,febrile neutropenia,pyrexia headache peripheral febrile neutropenia nausea hypokalemia and constipation,1,0.7341671586036682
BLINCYTO,febrile neutropenia,pyrexia peripheral,1,0.6325356960296631
BLINCYTO,febrile neutropenia,most common adverse,0,0.5134265422821045
BLINCYTO,febrile neutropenia,pyrexia headache peripheral febrile neutropenia nausea hypokalemia and,1,0.7476168274879456
BLINCYTO,febrile neutropenia,febrile neutropenia nausea,1,0.8994521498680115
BLINCYTO,nausea,febrile nausea hypokalemia and constipation Serious,1,0.708498477935791
BLINCYTO,nausea,febrile neutropenia nausea hypokalemia,1,0.6871646046638489
BLINCYTO,nausea,nausea hypokalemia and constipation,1,0.7222903370857239
BLINCYTO,nausea,nausea hypokalemia and constipation Serious adverse,1,0.7181702852249146
BLINCYTO,nausea,were,0,0.524542510509491
BLINCYTO,nausea,were pyrexia headache peripheral edema febrile,0,0.6545988321304321
BLINCYTO,hypokalemia,ere pyrexia headache peripheral edema febrile,0,0.5430397987365723
BLINCYTO,hypokalemia,edema febrile neutropenia hypokalemia and constipation Serious adverse reactions,1,0.7276355028152466
BLINCYTO,hypokalemia,were reported in,0,0.487174391746521
BLINCYTO,hypokalemia,adverse reactions were,0,0.5132253170013428
BLINCYTO,hypokalemia,febrile neutropenia hypokalemia and constipation Serious adverse reactions,1,0.7248579263687134
BLINCYTO,hypokalemia,febrile neutropenia hypokalemia,1,0.8325104117393494
BLINCYTO,hypokalemia,hypokalemia and,1,0.952055037021637
BLINCYTO,hypokalemia,hypokalemia and constipation Serious,1,0.8172047138214111
BLINCYTO,hypokalemia,in of,0,0.47729426622390747
BLINCYTO,febrile neutropenia,common serious adverse reactions,0,0.5711811780929565
BLINCYTO,pyrexia,febrile pyrexia pneumonia sepsis neutropenia,1,0.7707209587097168
BLINCYTO,pyrexia,common serious adverse reactions,0,0.5482757687568665
BLINCYTO,pyrexia,reactions included febrile pyrexia pneumonia sepsis neutropenia devicerelated,1,0.7203697562217712
BLINCYTO,pyrexia,pneumonia sepsis neutropenia,0,0.5974762439727783
BLINCYTO,pyrexia,infection,0,0.6292355060577393
BLINCYTO,pyrexia,encephalopathy,0,0.5339599847793579
BLINCYTO,pyrexia,reactions included febrile pyrexia,1,0.8101942539215088
BLINCYTO,pyrexia,patients The most common serious adverse reactions included febrile neutropenia,0,0.5863835215568542
BLINCYTO,pyrexia,The most common serious adverse reactions included febrile neutropenia,0,0.5987427234649658
BLINCYTO,pyrexia,in of patients The most common serious adverse reactions included febrile,0,0.6148278117179871
BLINCYTO,pneumonia,sepsis,0,0.7199350595474243
BLINCYTO,pneumonia,neutropenia pneumonia sepsis neutropenia devicerelated,1,0.7210626006126404
BLINCYTO,pneumonia,pneumonia sepsis,1,0.8518068790435791
BLINCYTO,sepsis,sepsis neutropenia devicerelated infection,1,0.7605123519897461
BLINCYTO,sepsis,sepsis neutropenia devicerelated,1,0.7698180675506592
BLINCYTO,sepsis,encephalopathy infection,0,0.6136903166770935
BLINCYTO,sepsis,infection overdose confusion St,0,0.655093789100647
BLINCYTO,sepsis,sepsis neutropenia,1,0.8392083644866943
BLINCYTO,sepsis,sepsis,1,1.0
BLINCYTO,neutropenia,neutropenia pyrexia pneumonia sepsis,0,0.8133041858673096
BLINCYTO,neutropenia,neutropenia devicerelated infection tremor encephalopathy infection,1,0.7746416330337524
BLINCYTO,neutropenia,infection,0,0.618166983127594
BLINCYTO,neutropenia,neutropenia devicerelated infection tremor encephalopathy,1,0.7722821235656738
BLINCYTO,neutropenia,neutropenia pyrexia,0,0.8106894493103027
BLINCYTO,neutropenia,devicerelated infection tremor encephalopathy infection overdose confusion Staphylococcal,0,0.5617348551750183
BLINCYTO,device-related infection,infection overdose,0,0.6728031635284424
BLINCYTO,device-related infection,device-related infection tremor encephalopathy infection overdose,1,0.7930666208267212
BLINCYTO,device-related infection,overdose,0,0.49878254532814026
BLINCYTO,device-related infection,neutropenia pyrexia pneumonia sepsis device-related infection tremor,1,0.7492889165878296
BLINCYTO,device-related infection,Staphylococcal bacteremia and,0,0.5882104635238647
BLINCYTO,tremor,sepsis neutropenia devicerelated tremor encephalopathy infection overdose,1,0.6753898859024048
BLINCYTO,tremor,Staphylococcal bacteremia and,0,0.3967311680316925
BLINCYTO,tremor,sepsis neutropenia,0,0.4312015771865845
BLINCYTO,tremor,confusion Staphylococcal bacteremia and,0,0.4297237992286682
BLINCYTO,encephalopathy,pyrexia pneumonia sepsis neutropenia devicerelated,0,0.5325896739959717
BLINCYTO,encephalopathy,pneumonia sepsis neutropenia devicerelated infection,0,0.5260260105133057
BLINCYTO,encephalopathy,overdose confusion Staphylococcal bacteremia and headache,0,0.6228175163269043
BLINCYTO,encephalopathy,encephalopathy infection overdose,1,0.8418076634407043
BLINCYTO,infection,infection,1,0.9999999403953552
BLINCYTO,infection,infection overdose,1,0.7804975509643555
BLINCYTO,overdose,Adverse,0,0.5485159158706665
BLINCYTO,overdose,overdose confusion Staphylococcal,1,0.7484297752380371
BLINCYTO,overdose,overdose confusion Staphylococcal bacteremia and,1,0.7354003190994263
BLINCYTO,overdose,tremor encephalopathy overdose confusion Staphylococcal,1,0.6761161684989929
BLINCYTO,overdose,Adverse reactions of Grade,0,0.5835936665534973
BLINCYTO,overdose,overdose confusion Staphylococcal bacteremia and headache,1,0.6967456936836243
BLINCYTO,overdose,devicerelated infection tremor encephalopathy overdose confusion Staphylococcal,1,0.654109537601471
BLINCYTO,overdose,overdose confusion,1,0.8541940450668335
BLINCYTO,overdose,and headache Adverse reactions,0,0.5663261413574219
BLINCYTO,Staphylococcal bacteremia,infection overdose Staphylococcal  bacteremia and headache Adverse reactions,1,0.8004107475280762
BLINCYTO,Staphylococcal bacteremia,and headache Adverse reactions,0,0.49452459812164307
BLINCYTO,headache,overdose confusion Staphylococcal bacteremia,0,0.4955718517303467
BLINCYTO,encephalopathy,treatment encephalopathy and sepsis Fatal,1,0.7952452898025513
BLINCYTO,encephalopathy,overdose confusion Staphylococcal bacteremia,0,0.6020168662071228
BLINCYTO,encephalopathy,reported most,0,0.4633299708366394
BLINCYTO,sepsis,sepsis Fatal adverse,1,0.834169864654541
BLINCYTO,sepsis,of,0,0.5486863851547241
BLINCYTO,sepsis,sepsis Fatal adverse events occurred in,1,0.7945556640625
BLINCYTO,Fatal,Fatal adverse events occurred in of,1,0.7439362406730652
BLINCYTO,Fatal,Fatal adverse events occurred,1,0.7574949264526367
BLINCYTO,Fatal,and Fatal adverse,1,0.8459285497665405
BLINCYTO,Fatal,Fatal adverse events occurred in,1,0.7461051940917969
BLINCYTO,infections,among patients in remission,0,0.5786744356155396
BLINCYTO,infections,events infections No fatal,1,0.7177932262420654
BLINCYTO,infections,infections No fatal adverse,1,0.7323563098907471
BLINCYTO,infections,infections No fatal,1,0.7628263235092163
BLINCYTO,infections,Fatal adverse events occurred in of patients,0,0.532983124256134
BLINCYTO,infections,The,0,0.5522018074989319
BLINCYTO,infections,infections No,1,0.8379439115524292
BLINCYTO,infections,infections No fatal adverse events,1,0.7235990762710571
BLINCYTO,fatal,fatal adverse events occurred on,1,0.7428997159004211
BLINCYTO,fatal,adverse,0,0.6163619756698608
BLINCYTO,fatal,these events were infections fatal adverse events,1,0.6955897808074951
BLINCYTO,fatal,fatal adverse events occurred,1,0.7574949264526367
BLINCYTO,fatal,fatal,1,1.0000001192092896
BLINCYTO,Febrile neutropenia,or Higher Blood and lymphatic,0,0.5713369846343994
BLINCYTO,Febrile neutropenia,Anemia Neutropenia Thrombocytopenia,0,0.743536114692688
BLINCYTO,Febrile neutropenia,Grade or Higher Blood and,0,0.5803742408752441
BLINCYTO,Febrile neutropenia,Blood and lymphatic system Febrile neutropenia,1,0.872600257396698
BLINCYTO,Anemia,system disorders Febrile,0,0.5452080965042114
BLINCYTO,Neutropenia,Neutropenia Thrombocytopenia,1,0.8478608131408691
BLINCYTO,Neutropenia,Leukopenia Gastrointestinal d,0,0.6816260814666748
BLINCYTO,Neutropenia,Thrombocytopenia Leukopenia Gastrointestinal,0,0.720512330532074
BLINCYTO,Neutropenia,Thrombocytopenia Leukopenia Gastrointestinal d,0,0.7042688131332397
BLINCYTO,Neutropenia,Anemia,0,0.7147142291069031
BLINCYTO,Neutropenia,Thrombocytopenia,0,0.699449896812439
BLINCYTO,Neutropenia,lymphatic,0,0.5353875756263733
BLINCYTO,Neutropenia,disorders Febrile neutropenia Neutropenia Thrombocytopenia Leukopenia,1,0.790758490562439
BLINCYTO,Thrombocytopenia,Thrombocytopenia Leukopenia Gastrointestinal disorders,1,0.7982873916625977
BLINCYTO,Thrombocytopenia,Thrombocytopenia,1,0.9999998807907104
BLINCYTO,Thrombocytopenia,Leukopenia,0,0.6112263202667236
BLINCYTO,Thrombocytopenia,disorders Febrile neutropenia,0,0.5995979309082031
BLINCYTO,Thrombocytopenia,neutropenia Anemia Neutropenia,0,0.6451374292373657
BLINCYTO,Thrombocytopenia,Gastrointestinal disorders Nausea,0,0.5236247777938843
BLINCYTO,Leukopenia,Gastrointestinal,0,0.5365731716156006
BLINCYTO,Leukopenia,Leukopenia,1,1.0000001192092896
BLINCYTO,Leukopenia,Anemia Neutropenia Leukopenia Gastrointestinal,1,0.7866913080215454
BLINCYTO,Leukopenia,disorders Nausea,0,0.5201239585876465
BLINCYTO,Leukopenia,neutropenia,0,0.7395179867744446
BLINCYTO,Nausea,Nausea Constipation DiarrheaDiarrhea includes,1,0.7474373579025269
BLINCYTO,Nausea,Nausea Constipation,1,0.8314429521560669
BLINCYTO,Nausea,Gastrointestinal,0,0.6377835273742676
BLINCYTO,Nausea,Nausea Constipation DiarrheaDiarrhea includes the,1,0.7414878606796265
BLINCYTO,Nausea,disorders,0,0.5810480713844299
BLINCYTO,Nausea,Nausea Constipation DiarrheaDiarrhea,1,0.794098436832428
BLINCYTO,Nausea,openia,0,0.4355589747428894
BLINCYTO,Constipation,disorders Constipation DiarrheaDiarrhea includes the,1,0.7743269205093384
BLINCYTO,Constipation,openia,0,0.48014381527900696
BLINCYTO,Constipation,Leukopenia Gastrointestinal disorders Constipation DiarrheaDiarrhea includes the,1,0.7172137498855591
BLINCYTO,Diarrhea,Nausea Diarrhea Diarrhea includes,1,0.8112315535545349
BLINCYTO,Diarrhea,openia,0,0.5079737305641174
BLINCYTO,Diarrhea,Gastrointestinal disorders Nausea Constipation,0,0.678814172744751
BLINCYTO,Diarrhea,Gastrointestinal disorders Nausea Diarrhea,1,0.7677400708198547
BLINCYTO,Diarrhea,Diarrhea Diarrhea includes the,1,0.8626015186309814
BLINCYTO,Diarrhea,Gastrointestinal,0,0.701007604598999
BLINCYTO,Diarrhea,Nausea Constipation,0,0.6489224433898926
BLINCYTO,Diarrhea,Diarrhea Diarrhea includes the following,1,0.8584127426147461
BLINCYTO,Diarrhea,Constipation,0,0.7511695623397827
BLINCYTO,Diarrhea,the following terms colitis,0,0.6830956339836121
BLINCYTO,Diarrhea,Constipation Diarrhea,0,0.8703753352165222
BLINCYTO,Diarrhea,the following terms colitis diarrhea enteritis and neutropenic colitis Abdominal,0,0.7091516256332397
BLINCYTO,Diarrhea,disorders Nausea,0,0.5882007479667664
BLINCYTO,Diarrhea,Diarrhea includes,1,0.8730261325836182
BLINCYTO,Diarrhea,Diarrhea includes the,1,0.873638927936554
BLINCYTO,Diarrhea,colitis diarrhea,0,0.8405827283859253
BLINCYTO,colitis,the following colitis diarrhea enteritis and neutropenic,1,0.8021673560142517
BLINCYTO,colitis,colitis diarrhea,0,0.900517463684082
BLINCYTO,colitis,colitis,1,0.9999999403953552
BLINCYTO,diarrhea,Abdominal pain Vomiting,0,0.6214364171028137
BLINCYTO,diarrhea,diarrhea enteritis and,1,0.8157097697257996
BLINCYTO,diarrhea,includes the following terms diarrhea,1,0.8452327847480774
BLINCYTO,diarrhea,diarrhea enteritis and neutropenic colitis,1,0.7322770357131958
BLINCYTO,enteritis,following terms colitis enteritis and neutropenic,1,0.7800570130348206
BLINCYTO,enteritis,diarrhea enteritis and neutropenic colitis,1,0.8045996427536011
BLINCYTO,enteritis,and neutropenic colitis,0,0.6780573129653931
BLINCYTO,enteritis,enteritis and neutropenic colitis,1,0.8293288946151733
BLINCYTO,enteritis,Abdominal pain Vomiting,0,0.6346278190612793
BLINCYTO,enteritis,enteritis and,1,0.9313192963600159
BLINCYTO,neutropenic colitis,neutropenic,1,0.8506028652191162
BLINCYTO,neutropenic colitis,diarrhea enteritis and,0,0.6131278872489929
BLINCYTO,neutropenic colitis,diarrhea enteritis neutropenic colitis Abdominal pain Vomiting General disorders,1,0.7568403482437134
BLINCYTO,neutropenic colitis,neutropenic colitis Abdominal pain Vomiting General disorders,1,0.8666236996650696
BLINCYTO,neutropenic colitis,diarrhea enteritis neutropenic,1,0.8430083990097046
BLINCYTO,Abdominal pain,Abdominal pain Vomiting General disorders and,1,0.8021622896194458
BLINCYTO,Abdominal pain,disorders and administration,0,0.517699122428894
BLINCYTO,Abdominal pain,enteritis and neutropenic Abdominal pain Vomiting General disorders and administration,1,0.7145702838897705
BLINCYTO,Abdominal pain,diarrhea enteritis and neutropenic Abdominal pain,1,0.7613357305526733
BLINCYTO,Vomiting,General disorders and,0,0.5801523923873901
BLINCYTO,Vomiting,Vomiting General disorders,1,0.8577778339385986
BLINCYTO,Vomiting,General disorders,0,0.5867813229560852
BLINCYTO,Vomiting,Vomiting General disorders and,1,0.8673593997955322
BLINCYTO,Pyrexia,Fatigue Chills,0,0.6394361853599548
BLINCYTO,Peripheral edema,and,0,0.4866998493671417
BLINCYTO,Peripheral edema,General disorders and administration site conditions,0,0.6003708839416504
BLINCYTO,Peripheral edema,Peripheral edema,1,1.0000001192092896
BLINCYTO,Peripheral edema,Chills Chest pain Immune,0,0.5351705551147461
BLINCYTO,Fatigue,Fatigue Chills Chest pain,1,0.75440514087677
BLINCYTO,Fatigue,Pyrexia Peripheral Fatigue Chills Chest pain Immune system,1,0.709653377532959
BLINCYTO,Fatigue,Immune,0,0.5776635408401489
BLINCYTO,Fatigue,site conditions,0,0.49991869926452637
BLINCYTO,Chills,Chills Chest pain Immune system,1,0.7996580600738525
BLINCYTO,Chills,Chills,1,0.9999998807907104
BLINCYTO,Chills,ral disorders and administration,0,0.4721052050590515
BLINCYTO,Chills,Chills Chest pain Immune system disorders,1,0.7609535455703735
BLINCYTO,Chest pain,rs and administration site conditions Pyrexia Peripheral edema,0,0.501426100730896
BLINCYTO,Chest pain,disorders Cytokine release,0,0.5063968300819397
BLINCYTO,Chest pain,Chest pain Immune system disorders Cytokine release,1,0.7569999694824219
BLINCYTO,Chest pain,Chest pain Immune system disorders Cytokine,1,0.7569893002510071
BLINCYTO,Chest pain,Fatigue Chest,1,0.7081115245819092
BLINCYTO,Chest pain,Pyrexia Peripheral,0,0.4722984731197357
BLINCYTO,Chest pain,system disorders Cytokine release syndrom,0,0.5004945993423462
BLINCYTO,Chest pain,Pyrexia Peripheral edema Fatigue Chest pain,1,0.703560471534729
BLINCYTO,Chest pain,edema Fatigue Chest pain Immune,1,0.7293409109115601
BLINCYTO,Cytokine release syndrome,pain Immune system Cytokine release syndrome,1,0.9092416167259216
BLINCYTO,Cytokine release syndrome,system Cytokine release,1,0.8486286401748657
BLINCYTO,Cytokine release syndrome,system Cytokine release syndrome Infections and infestations,1,0.8745117783546448
BLINCYTO,Cytokine release syndrome,pain Immune system disorders,0,0.6676921844482422
BLINCYTO,Cytokine release syndrome,infestations,0,0.55318683385849
BLINCYTO,Cytokine release syndrome,release syndrome Infections,1,0.8273751139640808
BLINCYTO,Cytokine release syndrome,Cytokine release syndrome,1,1.0
BLINCYTO,Cytokine release syndrome,system disorders,0,0.6040794849395752
BLINCYTO,Cytokine release syndrome,Cytokine release syndrome Infections and infestations,1,0.8942880034446716
BLINCYTO,Fungal infections,Bacterial,0,0.5377625226974487
BLINCYTO,Fungal infections,pathogen infections Bacterial Fungal infections Viral infections Pneumonia Sepsis Investigation,1,0.7691639065742493
BLINCYTO,Fungal infections,infections,0,0.8289825916290283
BLINCYTO,Fungal infections,pathogen infections Bacterial Fungal infections,1,0.8338242769241333
BLINCYTO,Fungal infections,pathogen infections Bacterial Fungal infections Viral,1,0.831194281578064
BLINCYTO,Fungal infections,Fungal infections Viral infections Pneumonia Sepsis Investigation,1,0.8209255337715149
BLINCYTO,Fungal infections,Pneumonia Sepsis,0,0.6125622987747192
BLINCYTO,Viral infections,Sepsis,0,0.6423746347427368
BLINCYTO,Viral infections,infections Bacterial infections Fungal Viral infections Pneumonia Sepsis Investigations Increased,1,0.7246083617210388
BLINCYTO,Viral infections,Viral infections Pneumonia Sepsis Investigations Increased alani,1,0.7034735679626465
BLINCYTO,Viral infections,pathogen infections Bacterial,0,0.7221658229827881
BLINCYTO,Viral infections,Bacterial infections Fungal Viral infections,1,0.7848669290542603
BLINCYTO,Viral infections,Fungal infections,0,0.7556708455085754
BLINCYTO,Viral infections,infections Fungal Viral infections Pneumonia,1,0.7351120710372925
BLINCYTO,Pneumonia,Pneumonia Sepsis Investigations Increased alanine,1,0.701503336429596
BLINCYTO,Pneumonia,Fungal infections Viral Pneumonia Sepsis Investigations,1,0.7071173191070557
BLINCYTO,Pneumonia,Pneumonia Sepsis Investigations,1,0.7601185441017151
BLINCYTO,Pneumonia,Sepsis,0,0.7199350595474243
BLINCYTO,Pneumonia,Pneumonia,1,0.9999997615814209
BLINCYTO,Pneumonia,infections Bacterial infections Fungal infections,0,0.6396781206130981
BLINCYTO,Pneumonia,Sepsis Investigations Increased alanine,0,0.5554009675979614
BLINCYTO,Sepsis,Sepsis Investigations,1,0.8441672325134277
BLINCYTO,Sepsis,Sepsis Investigations Increased alanine,0,0.7797932028770447
BLINCYTO,Sepsis,Fungal infections Viral infections Sepsis Investigations,1,0.7334757447242737
BLINCYTO,Sepsis,Sepsis Investigations Increased alanine aminotransferase I,1,0.7499022483825684
BLINCYTO,Sepsis,Sepsis,1,1.0
BLINCYTO,Sepsis,Sepsis Investigations Increased alanine aminotransferase,1,0.7589309215545654
BLINCYTO,Increased alanine aminotransferase,Investigations,0,0.49365806579589844
BLINCYTO,Increased alanine aminotransferase,Pneumonia Sepsis Increased alanine,1,0.7445955872535706
BLINCYTO,Increased aspartate aminotransferase,Metabolism and nutrition disorders,0,0.6375939846038818
BLINCYTO,Increased aspartate aminotransferase,aminotransferase,0,0.8239412903785706
BLINCYTO,Increased aspartate aminotransferase,Increased aspartate aminotransferase Increased weight,1,0.9299579858779907
BLINCYTO,Increased aspartate aminotransferase,Investigations Increased alanine Increased aspartate aminotransferase Increased,1,0.9449706077575684
BLINCYTO,Increased weight,and nutrition disorders Hypokalemia Hypomagnese,0,0.5648316144943237
BLINCYTO,Increased weight,Metabolism,0,0.6543870568275452
BLINCYTO,Increased weight,Increased aspartate aminotransferase,0,0.6823599934577942
BLINCYTO,Increased weight,Increased aspartate Increased weight,1,0.8319841623306274
BLINCYTO,Increased weight,Increased weight Metabolism and nutrition disorders,1,0.8042854070663452
BLINCYTO,Increased weight,Increased weight,1,1.0
BLINCYTO,Hypokalemia,Hyperglycemia Decreased appetite Hypophosphatemia,0,0.6477623581886292
BLINCYTO,Hypokalemia,Hypokalemia Hypomagnesemia Hyperglycemia Decreased appetite Hypophosphatemia,1,0.804298996925354
BLINCYTO,Hypomagnesemia,Metabolism and nutrition,0,0.6142492294311523
BLINCYTO,Hypomagnesemia,Hyperglycemia,0,0.6086356043815613
BLINCYTO,Hypomagnesemia,nutrition disorders Hypomagnesemia Hyperglycemia Decreased appetite Hypophosphatemia,1,0.8185335397720337
BLINCYTO,Hypomagnesemia,Hypomagnesemia Hyperglycemia Decreased appetite,1,0.8249456882476807
BLINCYTO,Hypomagnesemia,Hypomagnesemia Hyperglycemia Decreased appetite Hypophosphatemia,1,0.8319379687309265
BLINCYTO,Hypomagnesemia,Hypomagnesemia Hyperglycemia,1,0.8599717617034912
BLINCYTO,Hyperglycemia,appetite Hypophosphatemia Musculoske,0,0.5670528411865234
BLINCYTO,Hyperglycemia,nutrition disorders Hypokalemia Hypomagnesemia,0,0.6133049130439758
BLINCYTO,Hyperglycemia,Decreased,0,0.4861595332622528
BLINCYTO,Hyperglycemia,appetite,0,0.5937840938568115
BLINCYTO,Hyperglycemia,Hyperglycemia Decreased appetite Hypophosphatemia,1,0.7454703450202942
BLINCYTO,Hyperglycemia,Hyperglycemia Decreased appetite,1,0.7999600768089294
BLINCYTO,Hyperglycemia,Hyperglycemia Decreased appetite Hypophosphatemia Musculoske,1,0.7611022591590881
BLINCYTO,Decreased appetite,nutrition disorders Hypokalemia Hypomagnesemia Decreased,1,0.6946378350257874
BLINCYTO,Decreased appetite,nutrition disorders Hypokalemia Hypomagnesemia Decreased appetite,1,0.7980249524116516
BLINCYTO,Decreased appetite,and connective,0,0.4635734558105469
BLINCYTO,Decreased appetite,Hypokalemia Hypomagnesemia Decreased appetite Hypophosphatemia Musculoskeletal,1,0.7475961446762085
BLINCYTO,Decreased appetite,Hypokalemia Hypomagnesemia Decreased appetite Hypophosphatemia Musculoskeletal and connective,1,0.7349563837051392
BLINCYTO,Decreased appetite,Decreased appetite Hypophosphatemia Musculoskeletal,1,0.7828302979469299
BLINCYTO,Decreased appetite,and connective ti,0,0.481773316860199
BLINCYTO,Decreased appetite,Decreased appetite Hypophosphatemia Musculoskeletal and connective ti,1,0.7629885673522949
BLINCYTO,Back pain,and,0,0.48877817392349243
BLINCYTO,Back pain,tissue Back pain,1,0.8648339509963989
BLINCYTO,Back pain,Musculoskeletal and connective tissue Back pain Pain in extremity Bone pain,1,0.7596877813339233
BLINCYTO,Back pain,Bone,0,0.5645508170127869
BLINCYTO,Back pain,connective tissue Back pain Pain,1,0.7951982617378235
BLINCYTO,Back pain,disorders,0,0.5442969799041748
BLINCYTO,Back pain,Back pain,1,1.0
BLINCYTO,Back pain,connective tissue Back,1,0.657030463218689
BLINCYTO,Back pain,Back pain Pain in extremity,1,0.8384119272232056
BLINCYTO,Back pain,Back,1,0.716275691986084
BLINCYTO,Pain in extremity,connective tissue disorders Back Pain,1,0.6454898715019226
BLINCYTO,Pain in extremity,Back Pain in extremity Bone pain,1,0.8576579093933105
BLINCYTO,Bone pain,pain Pain in Bone,1,0.9612082242965698
BLINCYTO,Arthralgia,Arthralgia Nervous system,1,0.8602156043052673
BLINCYTO,Arthralgia,Headache,0,0.5750669240951538
BLINCYTO,Arthralgia,extremity Bone Arthralgia Nervous system disorders Headache,1,0.7319132685661316
BLINCYTO,Arthralgia,Headache TremorTremor,0,0.568773627281189
BLINCYTO,Arthralgia,system disorders Headache TremorTremor inc,0,0.5642014741897583
BLINCYTO,Arthralgia,pain Pain in extremity Bone pain,0,0.6697952747344971
BLINCYTO,Arthralgia,Arthralgia Nervous system disorders Headache,1,0.7984195351600647
BLINCYTO,Arthralgia,in extremity Bone Arthralgia Nervous system disorders Headache TremorTremor,1,0.7298243045806885
BLINCYTO,Arthralgia,Arthralgia Nervous,1,0.8522399663925171
BLINCYTO,Headache,system Headache TremorTremor includes the following,1,0.7528629302978516
BLINCYTO,Headache,Arthralgia Nervous,1,0.5746210813522339
BLINCYTO,Headache,Arthralgia Nervous system Headache TremorTremor includes,1,0.7556122541427612
BLINCYTO,Headache,Headache TremorTremor includes,1,0.7876250743865967
BLINCYTO,Headache,Headache TremorTremor includes the following,1,0.7774085402488708
BLINCYTO,Headache,Arthralgia Nervous system Headache,1,0.7978615164756775
BLINCYTO,Headache,Headache TremorTremor,1,0.7993552088737488
BLINCYTO,Headache,Arthralgia Nervous system disorders,0,0.5772036910057068
BLINCYTO,Headache,tremor and tremor,0,0.5534766912460327
BLINCYTO,Headache,pain Arthralgia Nervous system disorders,0,0.5967015624046326
BLINCYTO,Headache,Headache TremorTremor includes the,1,0.7804867029190063
BLINCYTO,Tremor,Nervous system,0,0.6140187978744507
BLINCYTO,Tremor,system disorders Tremor Tremor,1,0.848780632019043
BLINCYTO,Tremor,Tremor Tremor,1,0.9848256707191467
BLINCYTO,Tremor,Tremor Tremor includes the,1,0.9262017011642456
BLINCYTO,Tremor,Tremor Tremor includes the following terms,1,0.8582817316055298
BLINCYTO,Tremor,Nervous system disorders Tremor,1,0.8357794284820557
BLINCYTO,Tremor,Tremor,1,0.9999998807907104
BLINCYTO,Tremor,system disorders Tremor Tremor includes the following terms,1,0.8231754899024963
BLINCYTO,Tremor,Tremor Tremor includes the following,1,0.8983546495437622
BLINCYTO,Tremor,disorders,0,0.6066813468933105
BLINCYTO,Tremor,disorders Headache Tremor,1,0.8168081641197205
BLINCYTO,resting tremor,following resting,1,0.6516098976135254
BLINCYTO,resting tremor,TremorTremor,0,0.8131512999534607
BLINCYTO,resting tremor,resting tremor and tremor Dizziness Psychiatric,1,0.8569966554641724
BLINCYTO,resting tremor,terms,0,0.4930167496204376
BLINCYTO,resting tremor,the following resting tremor,1,0.961118221282959
BLINCYTO,tremor,terms,0,0.49783986806869507
BLINCYTO,tremor,Dizziness,0,0.6202985048294067
BLINCYTO,tremor,Psychiatric disorders,0,0.5674149990081787
BLINCYTO,tremor,tremor Dizziness Psychiatric,1,0.7993969917297363
BLINCYTO,tremor,resting tremor tremor Dizziness,1,0.8098617196083069
BLINCYTO,tremor,TremorTremor,0,0.8739430904388428
BLINCYTO,tremor,and,0,0.5268450975418091
BLINCYTO,Dizziness,Psychiatric disorders,0,0.5844172239303589
BLINCYTO,Dizziness,and Dizziness Psychiatric disorders Insomnia,1,0.7876372337341309
BLINCYTO,Insomnia,mediastinal disorders Cough,0,0.4658120274543762
BLINCYTO,Insomnia,thoracic and mediastinal disorders,0,0.4543140232563019
BLINCYTO,Insomnia,Insomnia Respiratory,1,0.8202595710754395
BLINCYTO,Cough,Cough DyspneaDyspnea includes the following terms,1,0.7444869875907898
BLINCYTO,Dyspnea,disorders Dyspnea,1,0.9190622568130493
BLINCYTO,Dyspnea,Cough DyspneaDyspnea includes the following terms,1,0.8368679881095886
BLINCYTO,Dyspnea,omnia Respiratory thoracic and mediastinal disorders Cough,0,0.6105353832244873
BLINCYTO,Dyspnea,mediastinal disorders Dyspnea,1,0.8580870628356934
BLINCYTO,Dyspnea,Dyspnea Dyspnea includes,1,0.9225578904151917
BLINCYTO,Dyspnea,mediastinal,0,0.6144552230834961
BLINCYTO,Dyspnea,bronchial hyperactivity,0,0.598535418510437
BLINCYTO,Dyspnea,Cough,0,0.6503340005874634
BLINCYTO,Dyspnea,mediastinal disorders Dyspnea Dyspnea includes the,1,0.855437159538269
BLINCYTO,Dyspnea,thoracic and mediastinal disorders Dyspnea,1,0.8611943125724792
BLINCYTO,Dyspnea,Dyspnea includes,1,0.9314980506896973
BLINCYTO,Dyspnea,thoracic and mediastinal disorders,0,0.647355318069458
BLINCYTO,acute respiratory failure,DyspneaDyspnea includes the following acute respiratory failure bronchial hyperactivity,1,0.7605820298194885
BLINCYTO,acute respiratory failure,thoracic and mediastinal disorders,0,0.5962615609169006
BLINCYTO,acute respiratory failure,following,0,0.4413621425628662
BLINCYTO,acute respiratory failure,respiratory failure bronchial hyperactivity bronchospasm,1,0.737356424331665
BLINCYTO,acute respiratory failure,mediastinal,0,0.5617241859436035
BLINCYTO,bronchial hyperactivity,failure and,0,0.4730988144874573
BLINCYTO,bronchial hyperactivity,bronchial hyperactivity,1,0.9999998807907104
BLINCYTO,bronchial hyperactivity,respiratory distress respiratory,0,0.5939068794250488
BLINCYTO,bronchial hyperactivity,following terms acute respiratory bronchial hyperactivity bronchospasm dyspnea dyspnea exertional,1,0.8442217111587524
BLINCYTO,bronchospasm,failure bronchial hyperactivity,0,0.7377299070358276
BLINCYTO,dyspnea,failure bronchial hyperactivity dyspnea dyspnea exertional respiratory distress respiratory,1,0.7524005770683289
BLINCYTO,dyspnea,failure bronchial hyperactivity,0,0.6119895577430725
BLINCYTO,dyspnea exertional,failure bronchial hyperactivity bronchospasm dyspnea,1,0.7036466002464294
BLINCYTO,dyspnea exertional,dyspnea exertional respiratory distress respiratory failure and,1,0.8822216391563416
BLINCYTO,respiratory distress,bronchospasm dyspnea dyspnea respiratory distress,1,0.823930561542511
BLINCYTO,respiratory distress,exertional,0,0.5485899448394775
BLINCYTO,respiratory distress,bronchospasm dyspnea dyspnea respiratory,1,0.7420940399169922
BLINCYTO,respiratory distress,bronchial hyperactivity bronchospasm,0,0.6135100722312927
BLINCYTO,respiratory distress,dyspnea respiratory,1,0.7738490104675293
BLINCYTO,respiratory distress,acute respiratory failure bronchial hyperactivity,0,0.7238019108772278
BLINCYTO,respiratory distress,respiratory distress,1,1.0
BLINCYTO,respiratory distress,failure and wheezing Skin and subcutaneous,0,0.6711429357528687
BLINCYTO,respiratory failure,bronchospasm dyspnea dyspnea,0,0.6564209461212158
BLINCYTO,respiratory failure,and subcutaneous tissue disorders,0,0.5106412172317505
BLINCYTO,respiratory failure,hyperactivity bronchospasm dyspnea dyspnea,0,0.6339998841285706
BLINCYTO,respiratory failure,tissue disorders,0,0.5360001921653748
BLINCYTO,respiratory failure,respiratory failure and wheezing Skin and,1,0.7950121760368347
BLINCYTO,respiratory failure,respiratory failure and wheezing,1,0.8474572896957397
BLINCYTO,respiratory failure,respiratory respiratory failure,1,0.9734885692596436
BLINCYTO,respiratory failure,subcutaneous,0,0.5183429718017578
BLINCYTO,respiratory failure,respiratory distress,0,0.8200391530990601
BLINCYTO,respiratory failure,and wheezing Skin and subcutaneous tissue,0,0.61436527967453
BLINCYTO,wheezing,disorders RashRash includes,0,0.5319578051567078
BLINCYTO,wheezing,wheezing Skin and subcutaneous,1,0.8275080919265747
BLINCYTO,wheezing,wheezing,1,0.9999998807907104
BLINCYTO,wheezing,wheezing Skin and subcutaneous tissue,1,0.8318163752555847
BLINCYTO,Rash,Skin and subcutaneous tissue Rash Rash includes the following terms,1,0.8109560012817383
BLINCYTO,Rash,wheezing Skin and subcutaneous tissue,1,0.6274686455726624
BLINCYTO,Rash,Rash,1,1.0000001192092896
BLINCYTO,Rash,Rash includes the following terms,1,0.8794745206832886
BLINCYTO,Rash,Rash includes the,1,0.9328352212905884
BLINCYTO,Rash,the,0,0.5526965856552124
BLINCYTO,Rash,and subcutaneous tissue disorders Rash,1,0.8155445456504822
BLINCYTO,Rash,subcutaneous tissue disorders Rash includes the following terms erythema,1,0.7810122966766357
BLINCYTO,Rash,erythema rash erythematous rash generalized rash,0,0.8216633796691895
BLINCYTO,Rash,Skin and subcutaneous tissue,0,0.6503642797470093
BLINCYTO,erythema,erythema rash,1,0.9134859442710876
BLINCYTO,erythema,the following erythema rash erythematous rash generalized,1,0.8131011724472046
BLINCYTO,erythema,erythema,1,1.0
BLINCYTO,rash,following terms erythema,0,0.7151455879211426
BLINCYTO,rash,tissue disorders,0,0.5597127676010132
BLINCYTO,rash,rash papular rash and,0,0.841162919998169
BLINCYTO,erythematous rash,Skin,0,0.6524683237075806
BLINCYTO,erythematous rash,erythema erythematous rash generalized rash macular rash,1,0.8162927627563477
BLINCYTO,erythematous rash,Skin and subcutaneous tissue disorders RashRash includes the following,0,0.6588542461395264
BLINCYTO,erythematous rash,erythema erythematous rash,1,0.9728192687034607
BLINCYTO,erythematous rash,erythematous rash generalized rash macular rash,1,0.8037569522857666
BLINCYTO,generalized rash,rash erythematous generalized rash,1,0.9156675338745117
BLINCYTO,generalized rash,erythematous rash generalized rash macular rash,1,0.8063579797744751
BLINCYTO,generalized rash,terms erythema rash erythematous generalized rash,1,0.8841555118560791
BLINCYTO,generalized rash,erythematous generalized rash,1,0.9203344583511353
BLINCYTO,generalized rash,generalized rash macular,1,0.818231999874115
BLINCYTO,generalized rash,generalized rash,1,1.0
BLINCYTO,macular rash,papular rash,0,0.7259846925735474
BLINCYTO,macular rash,rash erythematous rash generalized macular rash maculopapular,1,0.9058306217193604
BLINCYTO,maculo-papular rash,maculo-papular rash,1,1.0000001192092896
BLINCYTO,maculo-papular rash,papular rash,0,0.858761727809906
BLINCYTO,maculo-papular rash,maculo-papular,1,0.934683084487915
BLINCYTO,maculo-papular rash,maculo-papular rash papular rash and vesicular rash,1,0.8829579949378967
BLINCYTO,maculo-papular rash,rash generalized rash,0,0.6942969560623169
BLINCYTO,maculo-papular rash,rash and vesicular rash,0,0.7242065072059631
BLINCYTO,papular rash,rash maculopapular papular,1,0.9087406992912292
BLINCYTO,papular rash,papular,1,0.8998901844024658
BLINCYTO,papular rash,rash maculopapular papular rash,1,0.8959152698516846
BLINCYTO,papular rash,erythema rash,0,0.7655377388000488
BLINCYTO,papular rash,rash macular rash maculopapular papular,1,0.8626731634140015
BLINCYTO,papular rash,rash,0,0.843501627445221
BLINCYTO,papular rash,vesicular rash Vascular disorders,0,0.6698253750801086
BLINCYTO,papular rash,maculopapular papular rash,1,0.9057102203369141
BLINCYTO,Hypotension,Hypotension Hypertension Additional important,1,0.8615334033966064
BLINCYTO,Hypotension,maculopapular papular rash,1,0.4581822156906128
BLINCYTO,Hypotension,reactions that,0,0.5322742462158203
BLINCYTO,Hypotension,Hypertension Additional important adverse reactions,0,0.6488887071609497
BLINCYTO,leukocytosis,and lymphatic system,0,0.5745302438735962
BLINCYTO,leukocytosis,lymphopenia Cardiac disorders tachycardia General disorders and admin,0,0.5851296782493591
BLINCYTO,leukocytosis,leukocytosis lymphopenia Cardiac disorders tachycardia,1,0.7352609634399414
BLINCYTO,leukocytosis,leukocytosis lymphopenia,1,0.8412712216377258
BLINCYTO,leukocytosis,General disorders and,0,0.5087752938270569
BLINCYTO,leukocytosis,disorders,0,0.5496386885643005
BLINCYTO,leukocytosis,lymphatic system leukocytosis lymphopenia Cardiac disorders,1,0.7235241532325745
BLINCYTO,leukocytosis,Cardiac disorders tachycardia General disorders,0,0.4627874791622162
BLINCYTO,leukocytosis,leukocytosis,1,1.000000238418579
BLINCYTO,lymphopenia,lymphopenia Cardiac disorders,1,0.8296923041343689
BLINCYTO,lymphopenia,system disorders lymphopenia Cardiac disorders tachycardia,1,0.750427782535553
BLINCYTO,lymphopenia,and lymphatic system disorders lymphopenia Cardiac disorders tachycardia,1,0.7509753704071045
BLINCYTO,lymphopenia,Table were Blood and lymphatic system disorders,0,0.7274988889694214
BLINCYTO,lymphopenia,disorders lymphopenia Cardiac disorders tachycardia,1,0.7781988382339478
BLINCYTO,lymphopenia,Cardiac disorders tachycardia General,0,0.4808109402656555
BLINCYTO,lymphopenia,disorders lymphopenia,1,0.9468173384666443
BLINCYTO,lymphopenia,tachycardia General disorders,0,0.5081783533096313
BLINCYTO,tachycardia,tachycardia General disorders and administration,1,0.845634937286377
BLINCYTO,tachycardia,tachycardia General disorders and administration site,1,0.8342571258544922
BLINCYTO,edema,disorders and administration site edema Immune system disorders cytokine storm,1,0.7604167461395264
BLINCYTO,edema,tachycardia General disorders and administration site,1,0.5421320199966431
BLINCYTO,edema,edema Immune system disorders cytokine,1,0.7949904799461365
BLINCYTO,edema,edema,1,1.0
BLINCYTO,cytokine storm,edema Immune system disorders,0,0.5679326057434082
BLINCYTO,cytokine storm,cytokine storm Investigations decreased,1,0.8536339998245239
BLINCYTO,cytokine storm,Investigations decreased immunoglobulins increased blood,0,0.5823747515678406
BLINCYTO,cytokine storm,administration site conditions edema Immune system disorders,0,0.5468146800994873
BLINCYTO,cytokine storm,cytokine,1,0.8072446584701538
BLINCYTO,cytokine storm,Investigations,0,0.4522634744644165
BLINCYTO,cytokine storm,system cytokine storm,1,0.9459585547447205
BLINCYTO,cytokine storm,system cytokine storm Investigations decreased immunoglobulins increased blood,1,0.8437539339065552
BLINCYTO,cytokine storm,cytokine storm Investigations decreased immunoglobulins increased blood,1,0.8399451971054077
BLINCYTO,cytokine storm,cytokine storm,1,0.9999998807907104
BLINCYTO,decreased immunoglobulins,cytokine,0,0.6192288398742676
BLINCYTO,decreased immunoglobulins,cytokine storm decreased immunoglobulins increased blood bilirubin,1,0.7779182195663452
BLINCYTO,decreased immunoglobulins,increased,0,0.5195767879486084
BLINCYTO,decreased immunoglobulins,disorders cytokine storm,0,0.5920372009277344
BLINCYTO,decreased immunoglobulins,increased gammaglutamyltransferase increased liver,0,0.5784308314323425
BLINCYTO,decreased immunoglobulins,decreased immunoglobulins increased blood,1,0.90465247631073
BLINCYTO,increased blood bilirubin,Investigations decreased,0,0.41026562452316284
BLINCYTO,increased blood bilirubin,storm Investigations,0,0.4373812675476074
BLINCYTO,increased gamma-glutamyl-transferase,blood increased gamma-glutamyl-transferase,1,0.9473352432250977
BLINCYTO,increased gamma-glutamyl-transferase,storm Investigations,0,0.41990506649017334
BLINCYTO,increased gamma-glutamyl-transferase,increased gamma-glutamyl-transferase increased liver enzymes Metabolism and,1,0.9510887265205383
BLINCYTO,increased gamma-glutamyl-transferase,storm Investigations decreased immunoglobulins increased,0,0.5812287330627441
BLINCYTO,increased gamma-glutamyl-transferase,increased gamma-glutamyl-transferase increased liver enzymes Metabolism,1,0.9499571323394775
BLINCYTO,increased gamma-glutamyl-transferase,increased gamma-glutamyl-transferase increased liver enzymes,1,0.9534611701965332
BLINCYTO,increased gamma-glutamyl-transferase,liver enzymes,0,0.7248778343200684
BLINCYTO,increased gamma-glutamyl-transferase,blood increased gamma-glutamyl-transferase increased,1,0.9499655365943909
BLINCYTO,increased gamma-glutamyl-transferase,increased liver enzymes Metabolism and nutrition disorders,0,0.7499322891235352
BLINCYTO,increased liver enzymes,bilirubin,0,0.6481155157089233
BLINCYTO,increased liver enzymes,bilirubin increased increased liver enzymes Metabolism,1,0.8494733572006226
BLINCYTO,increased liver enzymes,blood bilirubin increased increased liver enzymes Metabolism and nutrition,1,0.8026458024978638
BLINCYTO,increased liver enzymes,bilirubin increased increased,1,0.7925283908843994
BLINCYTO,increased liver enzymes,increased liver enzymes Metabolism and nutrition,1,0.8904159069061279
BLINCYTO,increased liver enzymes,increased liver enzymes Metabolism,1,0.9587007761001587
BLINCYTO,increased liver enzymes,gammaglutamyltransferase,0,0.5658808350563049
BLINCYTO,increased liver enzymes,blood bilirubin increased increased,1,0.7858335375785828
BLINCYTO,increased liver enzymes,increased liver enzymes Metabolism and nutrition disorders,1,0.8662508726119995
BLINCYTO,tumor lysis syndrome,nutrition tumor lysis syndrome hypoalbuminemia Nervous system disorders encephalopathy,1,0.7830333709716797
BLINCYTO,tumor lysis syndrome,blood bilirubin increased increased,1,0.5067253112792969
BLINCYTO,tumor lysis syndrome,lysis syndrome hypoalbuminemia Nervous system disorders,1,0.7667862176895142
BLINCYTO,tumor lysis syndrome,liver enzymes Metabolism,0,0.5289011597633362
BLINCYTO,tumor lysis syndrome,and nutrition tumor lysis syndrome,1,0.9024591445922852
BLINCYTO,hypoalbuminemia,tumor lysis hypoalbuminemia Nervous,1,0.8025776147842407
BLINCYTO,hypoalbuminemia,liver enzymes Metabolism,0,0.5513191223144531
BLINCYTO,hypoalbuminemia,disorders tumor lysis hypoalbuminemia Nervous system disorders encephalopathy paresthesia,1,0.7182451486587524
BLINCYTO,hypoalbuminemia,paresthesia,0,0.48658037185668945
BLINCYTO,hypoalbuminemia,paresthesia aphasia,0,0.4778416156768799
BLINCYTO,hypoalbuminemia,tumor,0,0.5261369943618774
BLINCYTO,hypoalbuminemia,hypoalbuminemia Nervous,1,0.8698514699935913
BLINCYTO,hypoalbuminemia,hypoalbuminemia Nervous system disorders encephalopathy paresthesia,1,0.8270560503005981
BLINCYTO,encephalopathy,syndrome hypoalbuminemia Nervous system encephalopathy paresthesia aphasia convulsion memory impairment,1,0.6945254802703857
BLINCYTO,encephalopathy,hypoalbuminemia Nervous system disorders encephalopathy paresthesia,1,0.7255458831787109
BLINCYTO,encephalopathy,system,0,0.5242521166801453
BLINCYTO,encephalopathy,encephalopathy paresthesia,1,0.8531991839408875
BLINCYTO,encephalopathy,system encephalopathy paresthesia aphasia,1,0.7542192935943604
BLINCYTO,paresthesia,disorders,0,0.575940728187561
BLINCYTO,paresthesia,memory impairment cognitive,0,0.5183504223823547
BLINCYTO,paresthesia,paresthesia aphasia,1,0.8708063960075378
BLINCYTO,paresthesia,cognitive disorder speech,0,0.5184547305107117
BLINCYTO,paresthesia,paresthesia aphasia convulsion memory impairment,1,0.7604013681411743
BLINCYTO,paresthesia,lysis,0,0.4647911489009857
BLINCYTO,convulsion,encephalopathy paresthesia,0,0.5847136974334717
BLINCYTO,convulsion,paresthesia convulsion memory impairment cognitive,1,0.7352681159973145
BLINCYTO,convulsion,convulsion,1,1.0000001192092896
BLINCYTO,convulsion,memory impairment,0,0.537019670009613
BLINCYTO,convulsion,speech disorder Psychiatric dis,0,0.5395949482917786
BLINCYTO,convulsion,convulsion memory impairment cognitive disorder speech,1,0.7717082500457764
BLINCYTO,convulsion,convulsion memory impairment,1,0.7965637445449829
BLINCYTO,cognitive disorder,speech disorder,0,0.7216657400131226
BLINCYTO,cognitive disorder,cognitive disorder speech,1,0.882847785949707
BLINCYTO,cognitive disorder,disorder Psychiatric disorders confusion,0,0.7397757768630981
BLINCYTO,speech disorder,disorientation Vascular disorders,0,0.6146378517150879
BLINCYTO,speech disorder,memory impairment cognitive speech,1,0.7568772435188293
BLINCYTO,speech disorder,impairment cognitive speech disorder,1,0.8389818668365479
BLINCYTO,speech disorder,speech disorder Psychiatric disorders,1,0.9032041430473328
BLINCYTO,speech disorder,confusion disorientation Vascular,0,0.5691432952880859
BLINCYTO,speech disorder,convulsion,0,0.5481343269348145
BLINCYTO,confusion,confusion disorientation Vascular disorders,1,0.7325904369354248
BLINCYTO,confusion,disorders,0,0.5654016733169556
BLINCYTO,confusion,impairment cognitive,0,0.5685304999351501
BLINCYTO,confusion,confusion disorientation Vascular disorders capillary,1,0.7276415824890137
BLINCYTO,disorientation,syndrome Hypersensitivity,0,0.4823452830314636
BLINCYTO,disorientation,disorientation Vascular disorders capillary leak syndrome,1,0.7560515403747559
BLINCYTO,capillary leak syndrome,confusion disorientation Vascular disorders,0,0.6067785024642944
BLINCYTO,capillary leak syndrome,leak syndrome,1,0.888024628162384
BLINCYTO,capillary leak syndrome,Vascular capillary leak syndrome,1,0.956275224685669
BLINCYTO,capillary leak syndrome,disorders confusion disorientation Vascular capillary leak syndrome,1,0.8641924858093262
BLINCYTO,capillary leak syndrome,disorientation Vascular disorders,0,0.6127752661705017
BLINCYTO,capillary leak syndrome,capillary leak syndrome,1,0.9999998807907104
BLINCYTO,Hypersensitivity reactions,Hypersensitivity reactions related to BLINCYTO treatment,1,0.7930605411529541
BLINCYTO,Hypersensitivity reactions,capillary leak Hypersensitivity,1,0.741043210029602
BLINCYTO,Hypersensitivity reactions,leak Hypersensitivity,1,0.7637832760810852
BLINCYTO,Hypersensitivity reactions,and,0,0.48918282985687256
BLINCYTO,Hypersensitivity reactions,treatment were hypersensitivity and bronchospasm,0,0.7661857604980469
BLINCYTO,Hypersensitivity reactions,Vascular disorders capillary leak Hypersensitivity reactions,1,0.7410026788711548
BLINCYTO,Hypersensitivity reactions,disorders capillary leak Hypersensitivity reactions related to BLINCYTO treatment,1,0.7262173295021057
BLINCYTO,hypersensitivity,to BLINCYTO treatment,0,0.5701940059661865
BLINCYTO,hypersensitivity,hypersensitivity,1,1.0
BLINCYTO,bronchospasm,bronchospasm,1,1.0
BLINCYTO,bronchospasm,therapeutic proteins there is potential,0,0.49409598112106323
BLINCYTO,bronchospasm,bronchospasm Immunogenicity As with all,1,0.8387925624847412
BLINCYTO,bronchospasm,proteins there is potential for im,0,0.5455381870269775
BLINCYTO,bronchospasm,proteins there,0,0.5207374095916748
BLINCYTO,bronchospasm,BLINCYTO treatment were hypersensitivity,0,0.6169618368148804
BLINCYTO,CYTOKINE RELEASE SYNDROME,REACTIONS e following adverse react ions,1,0.5785560607910156
BLINCYTO,CYTOKINE RELEASE SYNDROME,BLINCYTO treatment were hypersensitivity,0,0.6027337312698364
BLINCYTO,CYTOKINE RELEASE SYNDROME,adverse react ions are discussed,1,0.600605845451355
BLINCYTO,CYTOKINE RELEASE SYNDROME,adverse react,1,0.603776752948761
BLINCYTO,CYTOKINE RELEASE SYNDROME,of the label Cytokine Release Syn,0,0.8105552196502686
BLINCYTO,NEUROLOGICAL TOXICITIES,The following adverse reactions re discussed,1,0.6745548844337463
BLINCYTO,NEUROLOGICAL TOXICITIES,following adverse,0,0.6251694560050964
BLINCYTO,NEUROLOGICAL TOXICITIES,reactions re,1,0.5395883917808533
BLINCYTO,NEUROLOGICAL TOXICITIES,Cytokine,0,0.5400162935256958
BLINCYTO,NEUROLOGICAL TOXICITIES,re discussed,1,0.47712624073028564
BLINCYTO,NEUROLOGICAL TOXICITIES,of the label Cytokine,0,0.5267201662063599
BLINCYTO,NEUROLOGICAL TOXICITIES,adverse reactions a,0,0.642791748046875
BLINCYTO,CYTOKINE RELEASE SYNDROME,in r sections of the label:  Cytokine Release Syndrome see,1,0.8918048143386841
BLINCYTO,CYTOKINE RELEASE SYNDROME,adverse reactions a,0,0.6117132902145386
BLINCYTO,CYTOKINE RELEASE SYNDROME,sections of the label: Cytokine,1,0.7100533246994019
BLINCYTO,CYTOKINE RELEASE SYNDROME,see Warnings and Precautions Neurological,0,0.5260460376739502
BLINCYTO,CYTOKINE RELEASE SYNDROME,the label: Cytokine Release,1,0.8100483417510986
BLINCYTO,CYTOKINE RELEASE SYNDROME,see Warnings,0,0.5448322296142578
BLINCYTO,CYTOKINE RELEASE SYNDROME,Cytokine Release Syndrome see Warnings and Precautions Neurological Tox,0,0.8288518786430359
BLINCYTO,CYTOKINE RELEASE SYNDROME,the label: Cytokine Release Syndrome see Warnings,1,0.873140811920166
BLINCYTO,CYTOKINE RELEASE SYNDROME,see Warnings and Precautions Neurological Tox,0,0.5231917500495911
BLINCYTO,CYTOKINE RELEASE SYNDROME,detail in r sections of the label: ,1,0.5084359645843506
BLINCYTO,Cytokine Release Syndrome,Release Syndrome e Warnings and,1,0.7549228072166443
BLINCYTO,CRS,(   Neurological Toxicities,1,0.45602068305015564
BLINCYTO,CRS,(   Neurological Toxicities see,1,0.4475930333137512
BLINCYTO,CRS,(   Neurological Toxicities see Warnings,1,0.45152249932289124
BLINCYTO,CRS,Warnings and Precautions Infections see,0,0.5012063980102539
BLINCYTO,CRS,and Precautions Infections see,0,0.48525893688201904
BLINCYTO,Neurological toxicities,Warnings and Precautions Effects on Ability to Drive and Use,0,0.6762122511863708
BLINCYTO,Neurological toxicities,Febrile Ne utropenia see Warnings and Precautions,1,0.567676305770874
BLINCYTO,Neurological toxicities,tropenia and Febrile Ne utropenia see,1,0.5321817398071289
BLINCYTO,Neurological toxicities,tropenia and Febrile Ne,1,0.550140380859375
BLINCYTO,Neurological toxicities,Tumor Lysis Syndrome see,0,0.5271869897842407
BLINCYTO,Neurological toxicities,Warnings and,0,0.6394968032836914
BLINCYTO,Neurological toxicities,tropenia and Febrile Ne utropenia see Warnings and,1,0.596739649772644
BLINCYTO,Neurological toxicities,see Warnings and Precautions tropenia and Febrile Ne utropenia see Warnings and,1,0.5886555910110474
BLINCYTO,Neurological toxicities,Warnings and Precautions tropenia,1,0.6134238243103027
BLINCYTO,Neurological toxicities,Precautions tropenia,1,0.5673028826713562
BLINCYTO,Neurological toxicities,Febrile Ne utropenia see,1,0.5092089176177979
BLINCYTO,Neurological toxicities,Febrile Ne,1,0.5246102213859558
BLINCYTO,Neurological toxicities,and,0,0.48229676485061646
BLINCYTO,fatal,Warnings and .5  ),1,0.5566000938415527
BLINCYTO,fatal,and,0,0.5288088321685791
BLINCYTO,fatal,Ability to Drive and Use Machines see Warnings and,0,0.5132561922073364
BLINCYTO,fatal,Drive,0,0.5636390447616577
BLINCYTO,fatal,Precautions,0,0.4998426139354706
BLINCYTO,fatal,Neutropenia see Warnings and .5  ),1,0.4982783794403076
BLINCYTO,fatal,Warnings and .5  ) Effects on Ability,1,0.5421816110610962
BLINCYTO,fatal,Neutropenia see Warnings and .5  ) Effects on Ability,1,0.508587658405304
BLINCYTO,fatal,.5 ),1,0.49931973218917847
BLINCYTO,fatal,Neutropenia and,0,0.47995099425315857
BLINCYTO,CYTOKINE RELEASE SYNDROME,Leukoencephalopathy e,1,0.5121736526489258
BLINCYTO,CYTOKINE RELEASE SYNDROME,Enzymes see Warnings and,0,0.5481598377227783
BLINCYTO,CYTOKINE RELEASE SYNDROME,e Warnings and Precaution,1,0.5339980125427246
BLINCYTO,CYTOKINE RELEASE SYNDROME,and Precautions Leukoencephalopathy e Warnings and Precaution s Preparation,1,0.5435461401939392
BLINCYTO,CYTOKINE RELEASE SYNDROME,Leukoencephalopathy e Warnings,1,0.5542903542518616
BLINCYTO,CYTOKINE RELEASE SYNDROME,Warnings and Precautions Leukoencephalopathy e Warnings,1,0.5487775802612305
BLINCYTO,CYTOKINE RELEASE SYNDROME,Warnings and Precaution s Preparation and Administration Errors,1,0.5332826375961304
BLINCYTO,NEUROLOGICAL TOXICITIES,see Warnings and,0,0.6233251094818115
BLINCYTO,NEUROLOGICAL TOXICITIES,* Preparati on,1,0.46159863471984863
BLINCYTO,Cytokine Release Syndrome,The,1,0.5102906823158264
BLINCYTO,Cytokine Release Syndrome,see Warnings and The most,1,0.5284619927406311
BLINCYTO,Cytokine Release Syndrome,most common adverse,1,0.5522192716598511
BLINCYTO,Cytokine Release Syndrome,see Warnings and  The most common adverse  reactions were pyrexia headache,1,0.6014707088470459
BLINCYTO,Cytokine Release Syndrome,Errors see Warnings,0,0.525507390499115
BLINCYTO,Cytokine Release Syndrome,most common adverse reactions were pyrexia,1,0.6210757493972778
BLINCYTO,Cytokine Release Syndrome,see Warnings and The most common adverse,1,0.5593527555465698
BLINCYTO,Cytokine Release Syndrome,The most common adverse reactions were pyrexia,1,0.6218989491462708
BLINCYTO,Cytokine Release Syndrome,and The,1,0.48362475633621216
BLINCYTO,Cytokine Release Syndrome,reactions were pyrexia headache peripheral edema,0,0.6213285326957703
BLINCYTO,Cytokine Release Syndrome,Errors see Warnings and  The most common adverse  reactions were,1,0.5743879079818726
BLINCYTO,CRS,act ions were pyrexia,1,0.5325281620025635
BLINCYTO,CRS,act,1,0.523826003074646
BLINCYTO,CRS,Errors see Warnings and Precautions The most,0,0.4917106628417969
BLINCYTO,CRS,act ions were,1,0.5318447351455688
BLINCYTO,CRS,The most common adverse act ions were,1,0.49730825424194336
BLINCYTO,CRS,most common adverse act ions were,1,0.5073552131652832
BLINCYTO,CRS,febrile neutropenia,0,0.4797576665878296
BLINCYTO,CRS,act ions were pyrexia headache peripheral,1,0.5203837156295776
BLINCYTO,CRS,act ions were pyrexia headache,1,0.5151904821395874
BLINCYTO,CRS,re,0,0.6181811094284058
BLINCYTO,fatal,", per ipheral edema febrile neutropenia",1,0.506196916103363
BLINCYTO,fatal,headache,0,0.5944652557373047
BLINCYTO,fatal,"adverse reactions were pyrexia , per",1,0.5592742562294006
BLINCYTO,fatal,hypokalemia tremor rash,0,0.5282173156738281
BLINCYTO,Neurological toxicities,REACTIONS,0,0.5638195276260376
BLINCYTO,Neurological toxicities,"tremor rash and constipation RPT:   

}}        To r eport SUSPECTED ADVERSE REACTIONS",1,0.68354332447052
BLINCYTO,Neurological toxicities,at AMGEN or FDA at,0,0.500484824180603
BLINCYTO,Neurological toxicities,Inc at,0,0.4752475619316101
BLINCYTO,Neurological toxicities,SUSPECTED ADVERSE REACTIONS contact Amgen Inc at AMGEN or,0,0.5498207807540894
BLINCYTO,Neurological toxicities,}} To r eport SUSPECTED ADVERSE REACTIONS contact,1,0.6115553975105286
BLINCYTO,Neurological toxicities,constipation RPT: }} To,1,0.5324336290359497
BLINCYTO,Neurological toxicities,To r eport SUSPECTED ADVERSE REACTIONS,1,0.628860592842102
BLINCYTO,Neurological toxicities,RPT: }} To r eport SUSPECTED ADVERSE REACTIONS contact,1,0.6044353246688843
BLINCYTO,Neurological toxicities,To r eport SUSPECTED,1,0.5190892219543457
BLINCYTO,Neurological toxicities,tremor rash and constipation RPT:,1,0.6369792222976685
BLINCYTO,Neurological toxicities,at AMGEN,0,0.4792853593826294
BLINCYTO,fatal,mgen  Inc at,1,0.47936439514160156
BLINCYTO,fatal,A,0,0.531038224697113
BLINCYTO,fatal,SUSPECTED ADVERSE REACTIONS contact mgen  Inc at AMGEN,1,0.5097801685333252
BLINCYTO,fatal,Inc at AMGEN or FDA at FDA or wwwfdagovmedwatch,0,0.4900028705596924
BLINCYTO,fatal,mgen  Inc,1,0.4726963937282562
BLINCYTO,fatal,stipation EXCERPT To report SUSPECTED ADVERSE REACTIONS contact,0,0.528303861618042
BLINCYTO,fatal,EXCERPT To report SUSPECTED ADVERSE,0,0.5680325031280518
BLINCYTO,fatal,ADVERSE REACTIONS contact mgen  Inc at AMGEN or,1,0.5111154317855835
BLINCYTO,Infections,rea,0,0.5011211633682251
BLINCYTO,Infections,The following adverse rea,0,0.5455394983291626
BLINCYTO,Infections,label Cytokine Release Syndrome s,0,0.6149783134460449
BLINCYTO,Infections,adverse ctions,1,0.6025360226631165
BLINCYTO,Effects on Ability to Drive,Cytokine,0,0.49421608448028564
BLINCYTO,Cytokine Release Syndrome,Machines see Warnings and Elevated Liver Enzymes [s ee Warnings and Precautions Leukoencephalopathy,1,0.5514922142028809
BLINCYTO,Cytokine Release Syndrome,Cytokine,0,0.7552402019500732
BLINCYTO,Cytokine Release Syndrome,Warnings and Elevated Liver Enzymes,1,0.577904224395752
BLINCYTO,Cytokine Release Syndrome,see,0,0.502776026725769
BLINCYTO,Cytokine Release Syndrome,Warnings and Elevated Liver Enzymes [s,1,0.5884418487548828
BLINCYTO,Cytokine Release Syndrome,Elevated Liver Enzymes [s ee,1,0.5704848766326904
BLINCYTO,Cytokine Release Syndrome,Elevated Liver Enzymes [s ee Warnings and Precautions,1,0.5531518459320068
BLINCYTO,Cytokine Release Syndrome,Warnings,0,0.572739839553833
BLINCYTO,Cytokine Release Syndrome,and,0,0.4648241102695465
BLINCYTO,Cytokine Release Syndrome,Elevated Liver Enzymes [s ee Warnings,1,0.5645206570625305
BLINCYTO,Cytokine Release Syndrome,Liver Enzymes [s,1,0.5666989088058472
BLINCYTO,Cytokine Release Syndrome,Machines see Warnings and Elevated Liver Enzymes [s ee Warnings and Precautions,1,0.544925332069397
BLINCYTO,CRS,to Drive and Use Machines see Warnings and Precautions Elevated Liver,0,0.49635228514671326
BLINCYTO,CRS,Use Machines see Warnings and,0,0.4991569519042969
BLINCYTO,CRS, Wa rnings and Precautions,1,0.49820178747177124
BLINCYTO,CRS, Wa rnings and,1,0.569952130317688
BLINCYTO,CRS, Wa,1,0.5087937116622925
BLINCYTO,fatal,* L eukoencephalopathy see Warnings and Precautions,1,0.5542193651199341
BLINCYTO,fatal,Enzymes see Warnings and Precautions,0,0.5376273393630981
BLINCYTO,Infusion reactions,Warnings and ( 5.8 )] *,1,0.5307679176330566
BLINCYTO,CRS,peripheral,0,0.581821084022522
BLINCYTO,CRS,"peripheral ma, febrile neutropenia nausea",1,0.47420012950897217
BLINCYTO,CRS,rash,0,0.5146849155426025
BLINCYTO,pyrexia,febrile eutrope nia nausea,1,0.6634232997894287
BLINCYTO,pyrexia,rash,0,0.5958070158958435
BLINCYTO,pyrexia,common adverse reactions were pyrexia headache peripheral,0,0.7639880180358887
BLINCYTO,pyrexia,eutrope nia nausea,1,0.600757360458374
BLINCYTO,pyrexia,pyrexia headache peripheral edema febrile n,0,0.7965329885482788
BLINCYTO,pyrexia,edema febrile eutrope nia nausea hypokalemia tremor,1,0.625677227973938
BLINCYTO,headache,"a, nause a hypokalemia tremor rash",1,0.5396289825439453
BLINCYTO,headache,"edema febrile a, nause",1,0.5969420671463013
BLINCYTO,headache,tremor rash and constipation EXCERPT To,0,0.520302414894104
BLINCYTO,headache,"a, nause",1,0.6208028793334961
BLINCYTO,headache,"febrile a, nause a",1,0.5756674408912659
BLINCYTO,headache,"headache peripheral edema febrile a,",1,0.7764266133308411
BLINCYTO,headache,"febrile a,",1,0.5686603784561157
BLINCYTO,nausea,adverse reactions,0,0.6473151445388794
BLINCYTO,nausea, hypok alemia tremor rash and,1,0.6155250668525696
BLINCYTO,nausea,edema febrile neutropenia  hypok alemia tremor,1,0.6529879570007324
BLINCYTO,nausea,tremor rash and constipation EXCERPT,0,0.6269504427909851
BLINCYTO,nausea,neutropenia,0,0.5792617797851562
BLINCYTO,asthenia,and constipation,0,0.5599148273468018
BLINCYTO,asthenia,"nausea emia, tr",1,0.6065358519554138
BLINCYTO,asthenia,"emia, tr emor rash and constipation",1,0.5790319442749023
BLINCYTO,asthenia,hypokal,0,0.4902728497982025
BLINCYTO,asthenia,and constipation EXCERPT To report SUSPECTED ADVERSE R,0,0.5610865950584412
BLINCYTO,asthenia,"emia, tr emor rash and",1,0.5862857103347778
BLINCYTO,asthenia,"neutropenia nausea emia, tr emor rash and constipation EXCERPT",1,0.5954601168632507
BLINCYTO,asthenia,nausea,0,0.5804386734962463
BLINCYTO,hypotension,"or, rash,",1,0.5121821761131287
BLINCYTO,hypotension,"or, rash, a nd constipation EXCERPT To report",1,0.5289162397384644
BLINCYTO,hypotension,"hypokalemia or,",1,0.6872595548629761
BLINCYTO,hypotension,neutropenia,0,0.5262643098831177
BLINCYTO,hypotension,edema,0,0.6448710560798645
BLINCYTO,increased alanine aminotransferase,constipation. ( 6.1 ) E,1,0.5467749834060669
BLINCYTO,increased alanine aminotransferase,constipation. ( 6.1 ),1,0.5336970686912537
BLINCYTO,increased alanine aminotransferase,hypokalemia tremor rash constipation. (,1,0.5648201704025269
BLINCYTO,increased alanine aminotransferase,6.1 ) E XCERPT To report SUSPECTED,1,0.5053245425224304
BLINCYTO,increased alanine aminotransferase,Amgen Inc at AMGEN,0,0.5729644894599915
BLINCYTO,increased aspartate aminotransferase,To report SUSPEC,1,0.5066215991973877
BLINCYTO,increased aspartate aminotransferase,To report SUSPEC TED ADVERSE REACTIONS contact,1,0.5512439608573914
BLINCYTO,increased aspartate aminotransferase,To report SUSPEC TED ADVERSE REACTIONS,1,0.5775682926177979
BLINCYTO,increased aspartate aminotransferase,ERPT: }} To report SUSPEC TED,1,0.5265592336654663
BLINCYTO,increased aspartate aminotransferase,"rash and constipation ERPT:   

}}        To report SUSPEC",1,0.5852066874504089
BLINCYTO,increased aspartate aminotransferase,report SUSPEC TED ADVERSE REACTIONS,1,0.5875316858291626
BLINCYTO,increased aspartate aminotransferase,febrile neutropenia nausea,0,0.5319638252258301
BLINCYTO,fatal,.gov/ medwatch,1,0.5102328062057495
BLINCYTO,fatal,at FDA,0,0.44910624623298645
BLINCYTO,fatal,contact Amgen Inc at,0,0.45499539375305176
BLINCYTO,fatal,trials,0,0.5179088711738586
BLINCYTO,fatal,or .gov/ medwatch Clinical Trials Experience Because,1,0.46669596433639526
BLINCYTO,fatal,FDA at FDA or .gov/ medwatch Clinical Trials Experience Because,1,0.4698196053504944
BLINCYTO,fatal,FDA at FDA or .gov/ medwatch Clinical Trials Experience,1,0.4602614939212799
BLINCYTO,fatal,REACTIONS contact Amgen Inc at AMGEN or FDA at FDA,0,0.48816561698913574
BLINCYTO,CRS,edw atch Clinical Trials Experience,1,0.4896358847618103
BLINCYTO,CRS,edw,1,0.48808830976486206
BLINCYTO,CRS,clinical trials,0,0.5220195055007935
BLINCYTO,CRS,edw atch Clinical Trials,1,0.4843963384628296
BLINCYTO,CRS,FDA or edw atch Clinical Trials Experience Because,1,0.4596673548221588
BLINCYTO,CRS,edw atch,1,0.4830416738986969
BLINCYTO,CRS,Trials Experience Because clinical trials are conducted un,0,0.47826865315437317
BLINCYTO,CRS,clinical,0,0.5473541021347046
BLINCYTO,disseminated intravascular coagulation,Experience,0,0.45631179213523865
BLINCYTO,disseminated intravascular coagulation,Trials Experience Because al trials are conducted under widely v arying conditions adverse reaction rates,1,0.5648689270019531
BLINCYTO,disseminated intravascular coagulation,trials of a drug cannot,0,0.48180362582206726
BLINCYTO,disseminated intravascular coagulation,Because al trials are conducted under widely v arying conditions adverse,1,0.552157461643219
BLINCYTO,disseminated intravascular coagulation,al trials are conducted under widely v arying conditions adverse,1,0.5665910243988037
BLINCYTO,disseminated intravascular coagulation,clinical trials of a drug cannot,0,0.46953004598617554
BLINCYTO,disseminated intravascular coagulation,Clinical Trials Experience Because al trials are conducted under widely v,1,0.511275589466095
BLINCYTO,DIC,yin g conditions adverse reaction,1,0.4871899485588074
BLINCYTO,DIC,Clinical Trials Experience Because al trials are conducted under widely v,1,0.49038952589035034
BLINCYTO,DIC,under,0,0.5517456531524658
BLINCYTO,DIC,clinical trials are conducted,0,0.49168506264686584
BLINCYTO,DIC,yin g conditions,1,0.5095181465148926
BLINCYTO,DIC,yin g conditions adverse reaction rates,1,0.49670225381851196
BLINCYTO,DIC,reaction rates observed in the clinical trials of a drug,0,0.502967894077301
BLINCYTO,DIC,adverse reaction rates observed in the clinical trials of,0,0.47014451026916504
BLINCYTO,DIC,conducted under widely yin g conditions adverse reaction,1,0.5072357058525085
BLINCYTO,DIC,yin,1,0.5232783555984497
BLINCYTO,capillary leak syndrome,varying c,0,0.4829713702201843
BLINCYTO,capillary leak syndrome,"onditions, adverse reac tion rates observed in the",1,0.5494006872177124
BLINCYTO,capillary leak syndrome,"widely varying onditions, adverse",1,0.531571626663208
BLINCYTO,capillary leak syndrome,"under widely varying onditions, adverse reac tion rates observed",1,0.5239446759223938
BLINCYTO,capillary leak syndrome,"under widely varying onditions, adverse reac",1,0.5189449787139893
BLINCYTO,capillary leak syndrome,varying,0,0.474822998046875
BLINCYTO,CLS,on  rates,1,0.47965794801712036
BLINCYTO,hemophagocytic lymphohistiocytosis,rates bserved in the clinical,1,0.48089706897735596
BLINCYTO,hemophagocytic lymphohistiocytosis,clinical trials are conducted under widely varying conditions adverse reaction,0,0.519096314907074
BLINCYTO,hemophagocytic lymphohistiocytosis,bserved in the clinical trials of a drug,1,0.48375624418258667
BLINCYTO,hemophagocytic lymphohistiocytosis,rates,0,0.45814645290374756
BLINCYTO,hemophagocytic lymphohistiocytosis,bserved in the clinical trials of,1,0.5259935855865479
BLINCYTO,hemophagocytic lymphohistiocytosis,e Because clinical trials are conducted under widely varying conditions adverse reaction rates,0,0.5268656611442566
BLINCYTO,macrophage activation syndrome,of drug cannot be directly compa,1,0.4715876579284668
BLINCYTO,macrophage activation syndrome,clinical trials of  drug cannot be directly compa red to,1,0.4749208092689514
BLINCYTO,macrophage activation syndrome,cannot be directly compa red to rates in the,1,0.45038843154907227
BLINCYTO,macrophage activation syndrome,clinical trials of  drug cannot be directly compa red,1,0.4736163020133972
BLINCYTO,HLH,directly d,1,0.48604410886764526
BLINCYTO,HLH,d,1,0.5049896240234375
BLINCYTO,HLH,d t o,1,0.46001243591308594
BLINCYTO,MAS,clinical trials of another drug and may not reflect the rates observed in practice T,0,0.4756513833999634
BLINCYTO,CRS,rug and,1,0.49348917603492737
BLINCYTO,CRS,rug and may not,1,0.490325927734375
BLINCYTO,CRS,clinical trials of another rug and may,1,0.5239172577857971
BLINCYTO,CRS,The safety data described in this section r,0,0.5713295340538025
BLINCYTO,CRS,rug,1,0.5169793367385864
BLINCYTO,CRS,rug and may not reflect,1,0.4959537982940674
BLINCYTO,neurological toxicities,study,0,0.5117348432540894
BLINCYTO,neurological toxicities, 37 years (range: 18 to years were male,1,0.47772496938705444
BLINCYTO,neurological toxicities,(range: 18 to years were male were White,1,0.4425555169582367
BLINCYTO,neurological toxicities,population 37 years (range: 18 to,1,0.47148531675338745
BLINCYTO,neurological toxicities,White were Asian and were Black,0,0.4194045662879944
BLINCYTO,neurological toxicities,population,0,0.4719926118850708
BLINCYTO,neurological toxicities,18 to years were male were White,1,0.4348449110984802
BLINCYTO,neurological toxicities,study population  37 years (range: 18 to,1,0.5221643447875977
BLINCYTO,neurological toxicities,37 years (range: 18 to,1,0.48326462507247925
BLINCYTO,neurological toxicities,years (range: 18 to,1,0.4666978716850281
BLINCYTO,fatal,The,0,0.5483651161193848
BLINCYTO,fatal,", hea dache",1,0.519239068031311
BLINCYTO,encephalopathy,reported in of patients The most common serious,0,0.5400854349136353
BLINCYTO,encephalopathy,Seri,0,0.5183490514755249
BLINCYTO,encephalopathy,and,0,0.5151092410087585
BLINCYTO,encephalopathy,constipation ous adverse re actions were reported in of,1,0.5497796535491943
BLINCYTO,speech disorders,patients The most common serious adverse reactions,0,0.4840593636035919
BLINCYTO,speech disorders,reactions were ported in,1,0.5214438438415527
BLINCYTO,speech disorders,Serious adverse reactions were ported in 65% of patients The,1,0.4596003293991089
BLINCYTO,speech disorders,patients The most common serious adverse reactions included,0,0.4845634698867798
BLINCYTO,speech disorders,re,0,0.4851464629173279
BLINCYTO,speech disorders,were ported,1,0.5207430124282837
BLINCYTO,speech disorders,reactions were ported in 65% of patients The,1,0.4971376359462738
BLINCYTO,speech disorders,adverse reactions included,0,0.5075452923774719
BLINCYTO,speech disorders,65% of patients The most common,1,0.49705272912979126
BLINCYTO,disturbances in consciousness,atients.,1,0.5562499761581421
BLINCYTO,disturbances in consciousness,in of atients. The most common seri,1,0.5546077489852905
BLINCYTO,disturbances in consciousness,most common seri,1,0.5072866678237915
BLINCYTO,disturbances in consciousness,atients. The,1,0.5465393662452698
BLINCYTO,disturbances in consciousness,pyrexia pneumonia,0,0.5374153256416321
BLINCYTO,disturbances in consciousness,common seri ous adverse reactions,1,0.5453475713729858
BLINCYTO,disturbances in consciousness,constipation Serious adverse reactions,0,0.5663864612579346
BLINCYTO,confusion,febrile neutropenia pyrexia pneumonia sepsis neutropenia devicerel,0,0.49108225107192993
BLINCYTO,confusion,adverse reactions were reported in,0,0.5135742425918579
BLINCYTO,confusion,s,1,0.5399999618530273
BLINCYTO,disorientation,common serious adverse tions (>=,1,0.5475901365280151
BLINCYTO,disorientation,tions (>= 2%) included febrile neutropenia,1,0.5159398913383484
BLINCYTO,disorientation,sepsis neutropenia,0,0.4597139358520508
BLINCYTO,disorientation,The most common serious,0,0.5283297300338745
BLINCYTO,disorientation,common serious adverse,0,0.5432682633399963
BLINCYTO,disorientation,tions (>= 2%),1,0.5466256141662598
BLINCYTO,disorientation,febrile neutropenia,0,0.49571433663368225
BLINCYTO,balance disorders,"adverse reactions included febrile penia, pyrexia,",1,0.48804548382759094
BLINCYTO,balance disorders,"pyrexia, p neumonia sepsis",1,0.47150546312332153
BLINCYTO,balance disorders,"penia, pyrexia, p neumonia sepsis",1,0.48215603828430176
BLINCYTO,balance disorders,neutropenia devicerelated infection tremor encephalopathy infection overdose,0,0.6013054847717285
BLINCYTO,balance disorders,"febrile penia, pyrexia, p neumonia",1,0.5190296769142151
BLINCYTO,balance disorders,neutro,0,0.4700470566749573
BLINCYTO,infections,as the reason discontinu,1,0.4640939235687256
BLINCYTO,infections,neutro,0,0.511106014251709
BLINCYTO,infections,adverse reactions reported,0,0.609387218952179
BLINCYTO,infections,as the reason discontinu ation of treatment,1,0.5333860516548157
BLINCYTO,sepsis,for discontinuation treatm ent included encephalopathy,1,0.5264747738838196
BLINCYTO,sepsis,adverse reactions reported,0,0.580878734588623
BLINCYTO,sepsis,Fatal adverse events,0,0.5634398460388184
BLINCYTO,sepsis,most frequently,0,0.5277837514877319
BLINCYTO,sepsis,as the reason for discontinuation,0,0.46890753507614136
BLINCYTO,sepsis,frequently as the reason,0,0.5113130807876587
BLINCYTO,sepsis,adverse reactions reported most,0,0.5755096673965454
BLINCYTO,sepsis,treatm ent included encephalopathy,1,0.5522043704986572
BLINCYTO,sepsis,reason for discontinuation treatm ent included encephalopathy and sepsis,1,0.7051786184310913
BLINCYTO,pneumonia,of t include d encephalopathy and sepsis,1,0.6299377679824829
BLINCYTO,pneumonia,treatm ent included encephalopathy,1,0.5811387300491333
BLINCYTO,pneumonia,discontinuation of t include d encephalopathy and sepsis,1,0.6034221649169922
BLINCYTO,pneumonia,INCYTO The adverse reactions reported most frequently as the reason for discontinuation of treatmen,0,0.4922926425933838
BLINCYTO,pneumonia,in of patients The majority of these,0,0.5040079951286316
BLINCYTO,pneumonia,for discontinuation of t include d encephalopathy and sepsis Fatal,1,0.5840128660202026
BLINCYTO,pneumonia,most frequently as the reason for discontinuation of,0,0.5101884007453918
BLINCYTO,pneumonia,of t include d encephalopathy,1,0.5708425045013428
BLINCYTO,pneumonia,discontinuation of t include,1,0.5274350643157959
BLINCYTO,pneumonia,of t include d encephalopathy and sepsis Fatal,1,0.6219260692596436
BLINCYTO,pneumonia,t include d encephalopathy and sepsis,1,0.6308832168579102
BLINCYTO,pneumonia,reason for discontinuation of t include,1,0.4943583011627197
BLINCYTO,pneumonia,encephalopathy and,0,0.5637090802192688
BLINCYTO,pneumonia,for discontinuation of t include,1,0.5345189571380615
BLINCYTO,pneumonia,t include d encephalopathy,1,0.5709296464920044
BLINCYTO,bacteremia,encephalop athy and,1,0.5297631025314331
BLINCYTO,opportunistic infections,for discontinuation of treatment included,0,0.4945918917655945
BLINCYTO,opportunistic infections,included hy and,1,0.4617815613746643
BLINCYTO,opportunistic infections,of treatment included hy and,1,0.5201161503791809
BLINCYTO,opportunistic infections,frequently as the reason for,0,0.5195267796516418
BLINCYTO,catheter-site infections,vents occurred in,1,0.5267872214317322
BLINCYTO,catheter-site infections,occurred in 15% of patients The majority,1,0.5818493366241455
BLINCYTO,catheter-site infections,vents occurred,1,0.5184313058853149
BLINCYTO,catheter-site infections,the reason,0,0.4531899094581604
BLINCYTO,catheter-site infections,e,0,0.47843295335769653
BLINCYTO,catheter-site infections,events occurred,0,0.4630230963230133
BLINCYTO,catheter-site infections,Fatal adverse vents occurred,1,0.4994746446609497
BLINCYTO,catheter-site infections,vents occurred in 15% of,1,0.5383232831954956
BLINCYTO,catheter-site infections,Fatal adverse vents occurred in 15% of patients The,1,0.5805338621139526
BLINCYTO,catheter-site infections,15% of,1,0.49502599239349365
BLINCYTO,fatal,for any grade,0,0.4814828038215637
BLINCYTO,fatal,in of,0,0.5261666774749756
BLINCYTO,fatal,No fatal adverse events d on,1,0.640825092792511
BLINCYTO,fatal,No fatal adverse events d on  treatment among patients in remission,1,0.5812023878097534
BLINCYTO,fatal,No fatal adverse events d on  treatment among,1,0.6139618158340454
BLINCYTO,fatal,remission The adverse reactions with,0,0.5185566544532776
BLINCYTO,Tumor lysis syndrome,>= 5% Incidence for Grade or Higher N Adverse,1,0.5240620970726013
BLINCYTO,Tumor lysis syndrome,her are summarized in Table Table Adverse Reactions With Incidence for,0,0.5367185473442078
BLINCYTO,Tumor lysis syndrome,>= 5% Incidence,1,0.4970148205757141
BLINCYTO,Tumor lysis syndrome,Any GradeGrading based on NCI Common,0,0.479871928691864
BLINCYTO,Tumor lysis syndrome,on NCI,0,0.5094338059425354
BLINCYTO,Tumor lysis syndrome,Any Grade  >= 5% Incidence for Grade or Higher,1,0.4904264211654663
BLINCYTO,Tumor lysis syndrome,>= 5%,1,0.4510577321052551
BLINCYTO,Tumor lysis syndrome,Incidence for,1,0.49098047614097595
BLINCYTO,Tumor lysis syndrome,>= 5% Incidence for Grade or Higher,1,0.49779245257377625
BLINCYTO,Tumor lysis syndrome,Grade,0,0.4498928189277649
BLINCYTO,TLS,rad e,1,0.47886306047439575
BLINCYTO,TLS,rad e or Higher,1,0.48096880316734314
BLINCYTO,TLS,for rad e or,1,0.49111276865005493
BLINCYTO,TLS,Reaction Any,0,0.5370938777923584
BLINCYTO,fatal,eacti on,1,0.4820666015148163
BLINCYTO,fatal,Grade or Incidence for,0,0.5281391739845276
BLINCYTO,fatal,R,0,0.5551168918609619
BLINCYTO,fatal,based on NCI Common Terminology Criteria,0,0.5139185190200806
BLINCYTO,fatal,NCI Common Terminology Criteria,0,0.5111469626426697
BLINCYTO,fatal,eacti on Any,1,0.49205464124679565
BLINCYTO,fatal,eacti on Any GradeGrading based,1,0.4485509395599365
BLINCYTO,fatal,or Higher N Adverse eacti on Any GradeGrading based on,1,0.5311517715454102
BLINCYTO,Neutropenia,neutropenic tis.     Ab dominal pain Vomiting General disorders,1,0.7713208198547363
BLINCYTO,Neutropenia,eacti on Any,1,0.48458218574523926
BLINCYTO,Neutropenia,diarrhea,0,0.5387132167816162
BLINCYTO,Neutropenia,dominal pain Vomiting General,0,0.5164577960968018
BLINCYTO,Neutropenia,tis. Ab dominal pain Vomiting General,1,0.5182279944419861
BLINCYTO,Neutropenia,enteritis and neutropenic tis.     Ab dominal,1,0.7902909517288208
BLINCYTO,Neutropenia,tis. Ab,1,0.46983879804611206
BLINCYTO,Neutropenia,General,0,0.5155736207962036
BLINCYTO,Neutropenia,General disorders and,0,0.5089633464813232
BLINCYTO,Neutropenia,tis.,1,0.4820421636104584
BLINCYTO,Neutropenia,colitis,0,0.6084756851196289
BLINCYTO,Neutropenia,the following terms colitis diarrhea,0,0.5170000791549683
BLINCYTO,Neutropenia,disorders and,0,0.5363789796829224
BLINCYTO,Neutropenia,tis. Ab dominal pain Vomiting,1,0.5139626264572144
BLINCYTO,Neutropenia,pain Vomiting General disorders and administ,0,0.5240075588226318
BLINCYTO,Neutropenia,dominal pain Vomiting General disorders and,0,0.512205958366394
BLINCYTO,febrile neutropenia,g General disorders,0,0.5058398842811584
BLINCYTO,febrile neutropenia,al pain     Vomitin g,1,0.5478209257125854
BLINCYTO,febrile neutropenia,and,0,0.4605851471424103
BLINCYTO,febrile neutropenia,disorders,0,0.5265211462974548
BLINCYTO,febrile neutropenia,General disorders and,0,0.49770110845565796
BLINCYTO,febrile neutropenia,and neutropenic colitis al pain     Vomitin g,1,0.7293922901153564
BLINCYTO,febrile neutropenia,and neutropenic colitis al pain,1,0.7356559038162231
BLINCYTO,neurologic events,Fungal infections,0,0.5444968342781067
BLINCYTO,neurologic events,and infestations Other pathogen infections Bacte,0,0.552676796913147
BLINCYTO,neurologic events,Bacte,0,0.4921196401119232
BLINCYTO,seizures,infections Pneumonia,0,0.473468154668808
BLINCYTO,seizures,Fungal fections Viral infections Pneumonia Sepsis,1,0.5024570822715759
BLINCYTO,seizures,fections Viral infections Pneumonia,1,0.4634721875190735
BLINCYTO,loss of consciousness,aminotransferase Increased,0,0.5018504858016968
BLINCYTO,loss of consciousness,alanine aminotransferase Increased aspartate,0,0.5142859816551208
BLINCYTO,loss of consciousness,        4419151397   ,1,0.4843901991844177
BLINCYTO,loss of consciousness,infections Pneumonia Sepsis,0,0.5298336744308472
BLINCYTO,loss of consciousness,        4419151397    Investigations Increased alanine aminotransferase,1,0.497779905796051
BLINCYTO,loss of consciousness,infections,0,0.5273241996765137
BLINCYTO,elevations in liver enzymes,appetite 60735 Musculoskelet,1,0.5311672687530518
BLINCYTO,CRS,connective,0,0.580893874168396
BLINCYTO,CRS,    Bone pain Arthralgia Nervous,1,0.49299710988998413
BLINCYTO,CRS,    Bone pain Arthralgia Nervous system,1,0.540123462677002
BLINCYTO,CRS,   ,1,0.6317907571792603
BLINCYTO,CRS,pain Arthralgia Nervous system disorders,0,0.5553896427154541
BLINCYTO,CRS,Nervous,0,0.48771172761917114
BLINCYTO,CRS,disorders Back,0,0.5279726386070251
BLINCYTO,CRS,Arthralgia Nervous,0,0.4892638325691223
BLINCYTO,CRS,Back pain Pain in     Bone pain Arthralgia Nervous,1,0.5011605024337769
BLINCYTO,elevations in liver enzymes,tremor and remor. Dizziness,1,0.5282149910926819
BLINCYTO,elevations in liver enzymes,resting tremor and remor.     Dizziness        Psychiatric disorders,1,0.518071174621582
BLINCYTO,CRS,a   Respiratory,1,0.5246821641921997
BLINCYTO,CRS,tremor and remor. Dizziness,1,0.5194952487945557
BLINCYTO,leukoencephalopathy,rash and vesicular .        21       2 Vascular disorders,1,0.5421149134635925
BLINCYTO,leukoencephalopathy,tremor and remor. Dizziness,1,0.555684506893158
BLINCYTO,leukoencephalopathy,disorders Hypotension,0,0.5046730637550354
NATAZIA,cardiovascular events,cardiovascular events and stroke see,1,0.8905829191207886
NATAZIA,cardiovascular events,labeling Serious,0,0.5403671264648438
NATAZIA,cardiovascular events,and stroke see Boxed,0,0.5416839122772217
NATAZIA,cardiovascular events,elsewhere in the labeling cardiovascular events and,1,0.8703123927116394
NATAZIA,stroke,events stroke see Boxed Warning and Warnings,1,0.6862220764160156
NATAZIA,stroke,cardiovascular events and stroke see,1,0.8067274689674377
NATAZIA,stroke,Warnings,0,0.5358586311340332
NATAZIA,stroke,stroke see Boxed,1,0.7807885408401489
NATAZIA,stroke,Boxed Warning and Warnings and Precautions Vascular events see Warnings,0,0.6379889249801636
NATAZIA,stroke,Warnings and Precautions Vascular events see,0,0.6582687497138977
NATAZIA,stroke,stroke see,1,0.9003218412399292
NATAZIA,stroke,stroke,1,1.0
NATAZIA,stroke,Warning and Warnings,0,0.5275149345397949
NATAZIA,stroke,stroke see Boxed Warning and Warnings,1,0.7745078802108765
NATAZIA,Irregular uterine bleeding,uterine bleeding Nausea,1,0.8330397605895996
NATAZIA,Irregular uterine bleeding,Nausea Breast tenderness Headache EXCERPT,0,0.5925236940383911
NATAZIA,Irregular uterine bleeding,reported by COC users Irregular uterine,1,0.8223832249641418
NATAZIA,Irregular uterine bleeding,tenderness Headache EXCERPT The,0,0.5121502876281738
NATAZIA,Irregular uterine bleeding,reactions commonly reported by COC users,0,0.49533504247665405
NATAZIA,Nausea,Nausea Breast tenderness Headache EXCERPT,1,0.762603759765625
NATAZIA,Nausea,EXCERPT The most,0,0.48636695742607117
NATAZIA,Nausea,COC users are Irregular uterine,0,0.5263760685920715
NATAZIA,Nausea,Nausea Breast,1,0.8432179689407349
NATAZIA,Nausea,The most,0,0.49588459730148315
NATAZIA,Nausea,reactions,0,0.5885443687438965
NATAZIA,Nausea,Adverse reactions commonly reported by COC users are,0,0.5792326331138611
NATAZIA,Nausea,Nausea Breast tenderness,1,0.7769022583961487
NATAZIA,Headache,Headache EXCERPT,1,0.8737919330596924
NATAZIA,Headache,common adverse reactions in clinical trials for,0,0.5354301929473877
NATAZIA,Headache,most common adverse reactions in clinical trials for,0,0.5395199060440063
NATAZIA,Headache,uterine bleeding Nausea Breast Headache EXCERPT,1,0.6998216509819031
NATAZIA,Headache,reactions,0,0.5280338525772095
NATAZIA,Headache,reactions in clinical,0,0.5380038022994995
NATAZIA,Headache,Nausea Breast Headache,1,0.7762675285339355
NATAZIA,headaches,common adverse reactions in clinical trials for Natazia,0,0.5623816847801208
NATAZIA,headaches,breast tendernesspain,0,0.5285958051681519
NATAZIA,headaches,uterine bleedingheadache including migraines breast,0,0.7290736436843872
NATAZIA,headaches,headaches irregular uterine,1,0.7909876704216003
NATAZIA,headaches,for Natazia headaches irregular uterine,1,0.7583680748939514
NATAZIA,headaches,Natazia are,0,0.5071772336959839
NATAZIA,headaches,Natazia headaches irregular uterine,1,0.7607887983322144
NATAZIA,headache,headache including,1,0.9300044775009155
NATAZIA,headache,irregular uterine headache including migraines,1,0.777117133140564
NATAZIA,headache,menstrual disorders nausea or,0,0.5950088500976562
NATAZIA,headache,headache including migraines breast tendernesspain menstrual,1,0.7825769782066345
NATAZIA,headache,headache including migraines breast tendernesspain,1,0.7814185619354248
NATAZIA,headache,nausea or,0,0.6387162804603577
NATAZIA,headache,bleeding,0,0.6346873044967651
NATAZIA,migraines,migraines breast tendernesspain,1,0.7774229049682617
NATAZIA,migraines,uterine bleedingheadache migraines,1,0.7802044153213501
NATAZIA,breast tenderness,uterine bleedingheadache including breast tenderness pain menstrual,1,0.7607058882713318
NATAZIA,breast tenderness,migraines breast tendernesspain,1,0.8714451789855957
NATAZIA,breast tenderness,al trials for Natazia are headaches irregular uterine bleedingheadache including migraines,0,0.5534973740577698
NATAZIA,breast tenderness,irregular uterine bleedingheadache including breast tenderness,1,0.7832597494125366
NATAZIA,breast tenderness,bleedingheadache including breast tenderness pain menstrual disorders nausea,1,0.7443976402282715
NATAZIA,breast tenderness,uterine bleedingheadache including,0,0.6089645624160767
NATAZIA,breast tenderness,pain,0,0.6515480279922485
NATAZIA,breast tenderness,trials for Natazia are,0,0.5104644298553467
NATAZIA,breast tenderness,uterine bleedingheadache including breast tenderness pain,1,0.7916979789733887
NATAZIA,menstrual disorders,menstrual disorders nausea or vomiting acne,1,0.838115930557251
NATAZIA,menstrual disorders,migraines breast menstrual disorders,1,0.8331423997879028
NATAZIA,nausea,vomiting acne mood changes and increased weight,0,0.72320556640625
NATAZIA,nausea,tendernesspain menstrual disorders,0,0.5664584040641785
NATAZIA,nausea,nausea,1,1.0
NATAZIA,nausea,changes and increased weight To report,0,0.566026508808136
NATAZIA,nausea,increased weight,0,0.5944631099700928
NATAZIA,nausea,nausea or vomiting,1,0.8949248790740967
NATAZIA,acne,acne,1,0.9999998807907104
NATAZIA,acne,acne mood changes and,1,0.8298149108886719
NATAZIA,acne,menstrual disorders nausea or acne mood,1,0.7159353494644165
NATAZIA,acne,acne mood changes and increased,1,0.8261301517486572
NATAZIA,acne,acne mood changes,1,0.8307941555976868
NATAZIA,acne,changes,0,0.5612398386001587
NATAZIA,mood changes,report,0,0.5125951766967773
NATAZIA,mood changes,mood changes,1,1.0
NATAZIA,mood changes,or vomiting mood changes and,1,0.8163809776306152
NATAZIA,mood changes,mood,1,0.8552095890045166
NATAZIA,mood changes,disorders nausea or vomiting mood,1,0.7060034275054932
NATAZIA,mood changes,mood changes and increased weight To,1,0.8628353476524353
NATAZIA,mood changes,disorders nausea,0,0.5863699913024902
NATAZIA,mood changes,weight To report,0,0.5139197111129761
NATAZIA,increased weight,increased weight To,1,0.9802334904670715
NATAZIA,increased weight,acne mood,0,0.5021691918373108
NATAZIA,increased weight,mood changes increased weight To report SUSPECTED,1,0.8049712777137756
NATAZIA,increased weight,mood changes increased weight To report SUSPECTED ADVERSE REACTIONS,1,0.7732988595962524
NATAZIA,increased weight,vomiting acne mood changes and,0,0.5595182776451111
NATAZIA,increased weight,or vomiting acne,0,0.5612266063690186
NATAZIA,increased weight,increased weight To report SUSPECTED ADVERSE REACTIONS,1,0.8166637420654297
NATAZIA,increased weight,increased weight,1,1.0
NATAZIA,menstrual disorder,reactions leading,0,0.4959082305431366
NATAZIA,menstrual disorder,genital hemorrhage vaginal,0,0.6444352865219116
NATAZIA,menstrual disorder,menstrual disorder metrorrhagia,1,0.8435065746307373
NATAZIA,menstrual disorder,reactions leading to discontinuation menstrual disorder metrorrhagia menorrhagia menstruation,1,0.8170609474182129
NATAZIA,menstrual disorder,reactions leading to discontinuation menstrual disorder,1,0.8331650495529175
NATAZIA,metrorrhagia,metrorrhagia menorrhagia menstruation irregular,1,0.8067693710327148
NATAZIA,metrorrhagia,metrorrhagia menorrhagia menstruation,1,0.8184865713119507
NATAZIA,metrorrhagia,menstrual,0,0.6164015531539917
NATAZIA,metrorrhagia,the most frequent adverse reactions leading to discontinuation were menstrual,0,0.571993350982666
NATAZIA,menorrhagia,menorrhagia menstruation irregular genital hemorrhage,1,0.8598545789718628
NATAZIA,menstruation irregular,menstruation irregular genital hemorrhage,1,0.8799803256988525
NATAZIA,menstruation irregular,menstrual disorder metrorrhagia menorrhagia,0,0.8087409734725952
NATAZIA,menstruation irregular,were menstrual disorder metrorrhagia menstruation irregular genital,1,0.8466973304748535
NATAZIA,menstruation irregular,menstrual disorder metrorrhagia menstruation irregular genital hemorrhage vaginal,1,0.8305435180664062
NATAZIA,menstruation irregular,were menstrual disorder metrorrhagia menstruation irregular genital hemorrhage vaginal,1,0.8177639245986938
NATAZIA,menstruation irregular,leading to discontinuation were,0,0.5112167596817017
NATAZIA,genital hemorrhage,mood changes depression,0,0.4785751402378082
NATAZIA,genital hemorrhage,ding to,0,0.47787556052207947
NATAZIA,genital hemorrhage,genital hemorrhage vaginal hemorrhage dysfunctional,1,0.8523805737495422
NATAZIA,genital hemorrhage,metrorrhagia menorrhagia menstruation genital hemorrhage,1,0.8616499900817871
NATAZIA,genital hemorrhage,ding to discontinuation,0,0.42810308933258057
NATAZIA,genital hemorrhage,genital hemorrhage,1,1.0
NATAZIA,genital hemorrhage,menstruation,0,0.7024692893028259
NATAZIA,genital hemorrhage,menorrhagia menstruation genital hemorrhage vaginal hemorrhage dysfunctional uterine,1,0.8546150922775269
NATAZIA,vaginal hemorrhage,genital vaginal hemorrhage dysfunctional uterine bleeding mood,1,0.8473671674728394
NATAZIA,vaginal hemorrhage,genital hemorrhage,1,0.8774363994598389
NATAZIA,vaginal hemorrhage,changes depression mood swings mood altered,0,0.4871882498264313
NATAZIA,vaginal hemorrhage,menorrhagia menstruation,0,0.7298395037651062
NATAZIA,vaginal hemorrhage,changes depression mood,0,0.4627421498298645
NATAZIA,vaginal hemorrhage,disorder metrorrhagia menorrhagia menstruation,0,0.6996865272521973
NATAZIA,dysfunctional uterine bleeding,uterine bleeding mood changes,1,0.8438373804092407
NATAZIA,dysfunctional uterine bleeding,uterine bleeding mood,1,0.8548883199691772
NATAZIA,dysfunctional uterine bleeding,dysfunctional uterine bleeding mood,1,0.9285239577293396
NATAZIA,dysfunctional uterine bleeding,mood,0,0.5194480419158936
NATAZIA,dysfunctional uterine bleeding,vaginal dysfunctional uterine bleeding,1,0.9411742091178894
NATAZIA,mood changes,dysfunctional uterine mood changes depression mood,1,0.7384313344955444
NATAZIA,mood changes,vaginal dysfunctional uterine bleeding,1,0.5192851424217224
NATAZIA,mood changes,dysfunctional uterine mood changes,1,0.7721257209777832
NATAZIA,mood changes,mood swings mood altered depressed mood dysthymic disorder,0,0.7760840654373169
NATAZIA,mood changes,disorder crying acne,0,0.5979771018028259
NATAZIA,mood changes,hemorrhage dysfunctional uterine mood changes depression mood swings,1,0.7523866891860962
NATAZIA,depression,dysthymic,0,0.6803908348083496
NATAZIA,depression,depression,1,0.9999998807907104
NATAZIA,depression,uterine bleeding mood,0,0.6206536889076233
NATAZIA,mood swings,mood swings mood,1,0.9784054756164551
NATAZIA,mood swings,bleeding mood changes mood,1,0.8153033256530762
NATAZIA,mood swings,uterine bleeding mood changes mood swings mood altered depressed mood,1,0.8226222991943359
NATAZIA,mood swings,vaginal hemorrhage dysfunctional uterine,0,0.5162488222122192
NATAZIA,mood altered,mood altered depressed mood dysthymic disorder crying,1,0.7052468061447144
NATAZIA,mood altered,mood mood altered,1,0.9914461374282837
NATAZIA,mood altered,depressed mood dysthymic disorder crying acne headache including migraines,0,0.6638556122779846
NATAZIA,depressed mood,mood depressed,1,0.9831969738006592
NATAZIA,crying,crying,1,0.9999997019767761
NATAZIA,crying,crying acne,1,0.8323386907577515
NATAZIA,crying,crying acne headache including,1,0.7881752252578735
NATAZIA,crying,crying acne headache including migraines and,1,0.7823511362075806
NATAZIA,crying,including migraines,0,0.5456314086914062
NATAZIA,crying,migraines,0,0.5533322691917419
NATAZIA,crying,g mood changes depression mood swings mood altered depressed mood dysthymic disorder,0,0.6083354949951172
NATAZIA,crying,crying acne headache,1,0.8080805540084839
NATAZIA,crying,depressed mood dysthymic crying acne,1,0.7397546768188477
NATAZIA,crying,migraines and weight,0,0.492178738117218
NATAZIA,acne,disorder crying,0,0.5024956464767456
NATAZIA,weight increased,including migraines weight increased Common Adverse,1,0.7247880697250366
NATAZIA,weight increased,disorder crying,0,0.4563080668449402
NATAZIA,headache,Common Adverse headache including migraines breast,1,0.7864311337471008
NATAZIA,headache,disorder crying,0,0.5102301836013794
NATAZIA,migraines,Common Adverse Reactions headache,0,0.7243826985359192
NATAZIA,migraines,discomfort or tenderness menstrual disorders,0,0.6198894381523132
NATAZIA,migraines,increased Common,0,0.5273818969726562
NATAZIA,migraines,migraines breast pain discomfort or tenderness,1,0.7657121419906616
NATAZIA,breast pain,breast,1,0.8062633872032166
NATAZIA,breast pain,breast pain discomfort or,1,0.9400477409362793
NATAZIA,breast pain,Reactions headache including breast pain,1,0.8113836050033569
NATAZIA,metrorrhagia,menstrual disorders,0,0.6009484529495239
NATAZIA,menstruation irregular,or tenderness menstrual disorders menstruation irregular menorrhagia vaginal hemorrhage,1,0.8093315362930298
NATAZIA,menstruation irregular,menstrual disorders,0,0.861900269985199
NATAZIA,menstruation irregular,bleeding genital hemorrhage,0,0.6688623428344727
NATAZIA,menstruation irregular,tenderness menstrual disorders menstruation irregular,1,0.8655951619148254
NATAZIA,menstruation irregular,or tenderness menstrual disorders menstruation irregular menorrhagia,1,0.8476172089576721
NATAZIA,menstruation irregular,dysfunctional uterine bleeding genital hemorrhage abnormal,0,0.741889476776123
NATAZIA,menstruation irregular,menstruation irregular menorrhagia vaginal hemorrhage dysfunctional uterine,1,0.8400928974151611
NATAZIA,menstruation irregular,menstrual disorders menstruation,1,0.8620143532752991
NATAZIA,menstruation irregular,or tenderness menstrual disorders menstruation irregular,1,0.8801738023757935
NATAZIA,menorrhagia,menorrhagia vaginal hemorrhage dysfunctional,1,0.8114203214645386
NATAZIA,menorrhagia,or tenderness menstrual disorders menstruation irregular,1,0.7180598974227905
NATAZIA,menorrhagia,disorders metrorrhagia menstruation menorrhagia vaginal hemorrhage,1,0.7852448225021362
NATAZIA,menorrhagia,pain discomfort or,0,0.547627329826355
NATAZIA,menorrhagia,disorders metrorrhagia menstruation menorrhagia vaginal hemorrhage dysfunctional uterine bleeding,1,0.7813951969146729
NATAZIA,menorrhagia,hemorrhage abnormal withdrawal bleedi,0,0.7263005971908569
NATAZIA,menorrhagia,menstruation irregular,0,0.762610673904419
NATAZIA,vaginal hemorrhage,disorders metrorrhagia menstruation irregular vaginal,1,0.7435817718505859
NATAZIA,vaginal hemorrhage,vaginal hemorrhage dysfunctional uterine,1,0.862541913986206
NATAZIA,vaginal hemorrhage,disorders metrorrhagia menstruation irregular menorrhagia,0,0.7062574625015259
NATAZIA,vaginal hemorrhage,genital hemorrhage abnormal,0,0.8321171998977661
NATAZIA,vaginal hemorrhage,metrorrhagia menstruation irregular vaginal hemorrhage dysfunctional uterine,1,0.8131219148635864
NATAZIA,vaginal hemorrhage,abnormal withdrawal bleeding uterine hemorrha,0,0.7116485834121704
NATAZIA,dysfunctional uterine bleeding,hemorrhage,0,0.6875220537185669
NATAZIA,dysfunctional uterine bleeding,menorrhagia vaginal dysfunctional uterine bleeding,1,0.912574291229248
NATAZIA,dysfunctional uterine bleeding,dysfunctional uterine bleeding genital hemorrhage abnormal,1,0.9187663793563843
NATAZIA,genital hemorrhage,bleeding,0,0.759224534034729
NATAZIA,genital hemorrhage,uterine genital,1,0.7672333717346191
NATAZIA,abnormal withdrawal bleeding,hemorrhage nausea or vomiting acne mood changes depression,0,0.6329874992370605
NATAZIA,abnormal withdrawal bleeding,abnormal withdrawal bleeding,1,1.0
NATAZIA,abnormal withdrawal bleeding,genital abnormal withdrawal bleeding,1,0.9141303896903992
NATAZIA,uterine hemorrhage,uterine,1,0.8098225593566895
NATAZIA,uterine hemorrhage,hemorrhage abnormal withdrawal uterine hemorrhage nausea or vomiting,1,0.8261540532112122
NATAZIA,uterine hemorrhage,genital hemorrhage abnormal withdrawal uterine hemorrhage nausea,1,0.8163254857063293
NATAZIA,uterine hemorrhage,abnormal withdrawal uterine,1,0.7374283075332642
NATAZIA,uterine hemorrhage,genital hemorrhage abnormal withdrawal uterine hemorrhage,1,0.8245666027069092
NATAZIA,uterine hemorrhage,uterine hemorrhage,1,0.9999998807907104
NATAZIA,uterine hemorrhage,vomiting acne mood changes depression,0,0.481741726398468
NATAZIA,uterine hemorrhage,uterine hemorrhage nausea,1,0.8851876258850098
NATAZIA,uterine hemorrhage,bleeding,0,0.7680302858352661
NATAZIA,nausea,abnormal withdrawal bleeding uterine nausea or vomiting acne,1,0.6701563000679016
NATAZIA,nausea,bleeding,0,0.6030348539352417
NATAZIA,nausea,nausea or vomiting acne,1,0.7936532497406006
NATAZIA,nausea,nausea or vomiting acne mood,1,0.7849161624908447
NATAZIA,nausea,withdrawal bleeding uterine nausea,1,0.7190525531768799
NATAZIA,nausea,uterine bleeding genital hemorrhage abnormal withdrawal,0,0.5262001752853394
NATAZIA,nausea,nausea or vomiting acne mood changes,1,0.7641918659210205
NATAZIA,nausea,nausea or,1,0.9240811467170715
NATAZIA,vomiting,vomiting acne mood changes,1,0.741509199142456
NATAZIA,vomiting,vomiting acne mood changes depression,1,0.7159042358398438
NATAZIA,vomiting,bleeding uterine hemorrhage nausea vomiting acne mood changes,1,0.6349208354949951
NATAZIA,acne,or vomiting,0,0.49820640683174133
NATAZIA,acne,hemorrhage nausea or acne mood changes depression,1,0.7002331018447876
NATAZIA,mood changes,mood swings depressed,0,0.8132299780845642
NATAZIA,mood changes,depression mood swings,0,0.827446699142456
NATAZIA,mood changes,hemorrhage nausea or vomiting mood changes,1,0.7947357892990112
NATAZIA,mood changes,acne,0,0.563965916633606
NATAZIA,mood changes,vomiting acne,0,0.5237959623336792
NATAZIA,depression,disorder crying and,0,0.6354695558547974
NATAZIA,depression,acne mood depression mood swings depressed mood,1,0.7221642732620239
NATAZIA,depression,depression mood swings depressed mood,1,0.8030503988265991
NATAZIA,depression,depression mood,1,0.8819817304611206
NATAZIA,depression,uterine hemorrhage nausea or,0,0.5579012036323547
NATAZIA,mood swings,mood changes mood,1,0.8551194071769714
NATAZIA,mood swings,vomiting acne mood changes mood swings,1,0.8203861713409424
NATAZIA,mood swings,changes mood swings,1,0.9240256547927856
NATAZIA,mood swings,mood changes,0,0.873473584651947
NATAZIA,mood swings,ding uterine hemorrhage nausea,0,0.5670132040977478
NATAZIA,mood swings,mood,1,0.829024076461792
NATAZIA,mood swings,vomiting acne mood changes mood swings depressed mood mood altered,1,0.8176219463348389
NATAZIA,depressed mood,depressed mood,1,1.0000001192092896
NATAZIA,depressed mood,lability dysthymic disorder crying,0,0.645672082901001
NATAZIA,depressed mood,and increased weight,0,0.49986109137535095
NATAZIA,depressed mood,depressed mood mood altered affect,1,0.8575831055641174
NATAZIA,depressed mood,disorder,0,0.5910460948944092
NATAZIA,depressed mood,affect lability dysthymic disorder crying and,0,0.6887071132659912
NATAZIA,depressed mood,mood altered affect,0,0.7986006736755371
NATAZIA,depressed mood,mood changes depression mood depressed mood mood,1,0.8842092752456665
NATAZIA,depressed mood,dysthymic,0,0.7133350968360901
NATAZIA,mood altered,increased weight Serious,0,0.6020689010620117
NATAZIA,mood altered,disorder crying,0,0.5745376348495483
NATAZIA,mood altered,swings depressed mood altered affect lability,1,0.7914999723434448
NATAZIA,mood altered,mood altered affect,1,0.949471116065979
NATAZIA,mood altered,crying,0,0.5791642069816589
NATAZIA,affect lability,Serious,0,0.5933274030685425
NATAZIA,affect lability,mood mood affect,1,0.7370990514755249
NATAZIA,affect lability,affect lability dysthymic disorder crying,1,0.7193108201026917
NATAZIA,affect lability,affect lability dysthymic disorder crying and increased,1,0.725775420665741
NATAZIA,affect lability,disorder crying and increased weight Serious,0,0.5338147282600403
NATAZIA,crying,Serious Adverse Reactions myocardial infarction,0,0.4892939329147339
NATAZIA,crying,lability dysthymic crying and increased weight,1,0.7726139426231384
NATAZIA,increased weight,lability dysthymic disorder crying,0,0.46584728360176086
NATAZIA,increased weight,disorder crying increased weight Serious Adverse Reactions myocardial,1,0.6847068071365356
NATAZIA,increased weight,increased weight Serious Adverse Reactions myocardial,1,0.7932605147361755
NATAZIA,increased weight,myocardial infarction cases,0,0.493177205324173
NATAZIA,increased weight,dysthymic disorder crying increased weight Serious Adverse Reactions myocardial infarction,1,0.6442114114761353
NATAZIA,myocardial infarction,myocardial infarction cases ruptured ovarian cyst,1,0.7261128425598145
NATAZIA,ruptured ovarian cyst,infarction ruptured ovarian cyst cases deep vein thrombosis,1,0.8244616389274597
NATAZIA,ruptured ovarian cyst,myocardial infarction cases ruptured ovarian cyst,1,0.8732070922851562
NATAZIA,ruptured ovarian cyst,Reactions myocardial infarction ruptured ovarian cyst,1,0.8619188070297241
NATAZIA,ruptured ovarian cyst,liver,0,0.5024595856666565
NATAZIA,ruptured ovarian cyst,the liver uterine leiomyoma acute,0,0.6140141487121582
NATAZIA,ruptured ovarian cyst,Adverse Reactions myocardial infarction ruptured ovarian cyst,1,0.8163948059082031
NATAZIA,ruptured ovarian cyst,Adverse Reactions myocardial,0,0.45430850982666016
NATAZIA,ruptured ovarian cyst,ovarian cyst,1,0.8630415797233582
NATAZIA,ruptured ovarian cyst,hyperplasia of the liver uterine leiomyoma,0,0.5394610166549683
NATAZIA,deep vein thrombosis,uterine leiomyoma acute cholecystitis and chronic,0,0.5184189677238464
NATAZIA,deep vein thrombosis,cases ruptured ovarian cyst deep vein thrombosis focal nodular hyperplasia of,1,0.7314807176589966
NATAZIA,deep vein thrombosis,liver uterine,0,0.4985065460205078
NATAZIA,deep vein thrombosis,ruptured ovarian cyst deep vein thrombosis,1,0.7960628271102905
NATAZIA,deep vein thrombosis,deep vein thrombosis focal nodular,1,0.8535643815994263
NATAZIA,deep vein thrombosis,infarction cases ruptured ovarian cyst,0,0.565964937210083
NATAZIA,deep vein thrombosis,cyst deep vein,1,0.7714669704437256
NATAZIA,deep vein thrombosis,deep vein thrombosis,1,1.0
NATAZIA,deep vein thrombosis,ovarian cyst deep vein thrombosis focal nodular hyperplasia of,1,0.7593175172805786
NATAZIA,focal nodular hyperplasia of the liver,the liver uterine leiomyoma,1,0.7351211309432983
NATAZIA,focal nodular hyperplasia of the liver,and chronic acalculous cholecystitis Postmarket,0,0.5375871658325195
NATAZIA,focal nodular hyperplasia of the liver,cases deep vein focal nodular hyperplasia of the liver,1,0.9179348349571228
NATAZIA,focal nodular hyperplasia of the liver,deep vein focal nodular hyperplasia of the liver uterine leiomyoma acute cholecystitis and,1,0.850457489490509
NATAZIA,focal nodular hyperplasia of the liver,vein focal nodular hyperplasia of,1,0.8404026031494141
NATAZIA,uterine leiomyoma,the uterine leiomyoma acute cholecystitis,1,0.7917065024375916
NATAZIA,uterine leiomyoma,vein focal nodular hyperplasia of,1,0.5724596977233887
NATAZIA,uterine leiomyoma,uterine leiomyoma acute cholecystitis and chronic,1,0.8007289171218872
NATAZIA,uterine leiomyoma,Postmarketing Experience,0,0.47280704975128174
NATAZIA,uterine leiomyoma,cholecystitis and chronic acalculous cholecystitis,0,0.5344110131263733
NATAZIA,uterine leiomyoma,nodular hyperplasia of,0,0.6173257231712341
NATAZIA,uterine leiomyoma,hyperplasia of the uterine leiomyoma,1,0.871498703956604
NATAZIA,acute cholecystitis,liver uterine acute,1,0.6828355193138123
NATAZIA,acute cholecystitis,focal nodular,0,0.49767038226127625
NATAZIA,acute cholecystitis,the liver uterine acute cholecystitis,1,0.8327491283416748
NATAZIA,acute cholecystitis,deep vein thrombosis focal nodular hyperplasia of the liver uterine leiomyoma,0,0.5146437883377075
NATAZIA,acute cholecystitis,acute cholecystitis and chronic acalculous,1,0.8790101408958435
NATAZIA,chronic acalculous cholecystitis,chronic acalculous cholecystitis Postmarketing Experience The following,1,0.8913779854774475
NATAZIA,chronic acalculous cholecystitis,The following adverse reactions have been identified,0,0.5261570811271667
NATAZIA,chronic acalculous cholecystitis,Experience The,0,0.4544735848903656
NATAZIA,chronic acalculous cholecystitis,uterine leiomyoma acute cholecystitis chronic acalculous,1,0.8475573062896729
NATAZIA,chronic acalculous cholecystitis,acalculous cholecystitis,1,0.9521239995956421
NATAZIA,chronic acalculous cholecystitis,acute cholecystitis chronic acalculous cholecystitis,1,0.941392719745636
NATAZIA,chronic acalculous cholecystitis,acute cholecystitis chronic acalculous cholecystitis Postmarketing Experience,1,0.8807128667831421
NATAZIA,arterial thromboembolic events,thromboembolic events,1,0.9181861877441406
NATAZIA,arterial thromboembolic events,disorders Venous arterial thromboembolic events including pulmonary emboli deep,1,0.8827157020568848
NATAZIA,arterial thromboembolic events,drug exposure Vascular disorders Venous and,0,0.6658095121383667
NATAZIA,arterial thromboembolic events,myocardial,0,0.5506243109703064
NATAZIA,arterial thromboembolic events,thrombosis cerebral thrombosis myocardial,0,0.7078675031661987
NATAZIA,arterial thromboembolic events,arterial thromboembolic events,1,0.9999999403953552
NATAZIA,arterial thromboembolic events,thromboembolic events including pulmonary emboli deep,1,0.8523694276809692
NATAZIA,arterial thromboembolic events,Venous arterial thromboembolic events including pulmonary emboli deep,1,0.898996114730835
NATAZIA,pulmonary emboli,pulmonary emboli,1,1.0
NATAZIA,pulmonary emboli,thromboembolic events including pulmonary emboli deep,1,0.8374748229980469
NATAZIA,pulmonary emboli,pulmonary emboli deep vein thrombosis,1,0.8942474126815796
NATAZIA,pulmonary emboli,arterial thromboembolic events pulmonary,1,0.8473747372627258
NATAZIA,pulmonary emboli,and arterial thromboembolic events pulmonary emboli deep vein thrombosis cerebral,1,0.7772679924964905
NATAZIA,pulmonary emboli,events pulmonary,1,0.7053037285804749
NATAZIA,pulmonary emboli,and arterial thromboembolic events pulmonary emboli,1,0.8599448800086975
NATAZIA,pulmonary emboli,including,0,0.5357223153114319
NATAZIA,pulmonary emboli,exposure Vascular disorders Venous and arterial thromboembolic,0,0.7080204486846924
NATAZIA,deep vein thrombosis,stroke hypertension Hepatobiliary disorders,0,0.5799096822738647
NATAZIA,deep vein thrombosis,arterial,0,0.5169960856437683
NATAZIA,cerebral thrombosis,deep vein cerebral thrombosis myocardial infarction and stroke hypertension,1,0.8319616317749023
NATAZIA,cerebral thrombosis,arterial,0,0.5488119125366211
NATAZIA,cerebral thrombosis,pulmonary emboli,0,0.7065405249595642
NATAZIA,cerebral thrombosis,cerebral thrombosis myocardial infarction and stroke,1,0.871964693069458
NATAZIA,cerebral thrombosis,emboli deep vein cerebral thrombosis,1,0.8796853423118591
NATAZIA,cerebral thrombosis,stroke hypertension Hepatobiliary disorders Gallbladder disease,0,0.6475199460983276
NATAZIA,cerebral thrombosis,emboli deep vein cerebral thrombosis myocardial infarction and stroke,1,0.824455738067627
NATAZIA,myocardial infarction,myocardial infarction and stroke hypertension Hepatobiliary disorders,1,0.7391852736473083
NATAZIA,myocardial infarction,thrombosis cerebral myocardial infarction,1,0.7902869582176208
NATAZIA,myocardial infarction,emboli deep,0,0.5414027571678162
NATAZIA,myocardial infarction,myocardial infarction and stroke hypertension Hepatobiliary,1,0.7601404190063477
NATAZIA,stroke,Immune,0,0.5539278388023376
NATAZIA,stroke,stroke hypertension Hepatobiliary disorders,1,0.7419536113739014
NATAZIA,stroke,thrombosis,0,0.7331550121307373
NATAZIA,hepatitis,hypertension,0,0.6138534545898438
NATAZIA,hepatitis,hepatitis Immune,1,0.8462759256362915
NATAZIA,Fluid retention,system disorders Dizziness Skin and subcutaneous tissue,0,0.5833598375320435
NATAZIA,Fluid retention,Fluid retention hypertriglyceridemia Nervous system disorders Dizziness,1,0.754698634147644
NATAZIA,Fluid retention,Dizziness,0,0.6020100116729736
NATAZIA,Fluid retention,disorders Hypersensitivity Metabolism and nutrition disorders,0,0.520638108253479
NATAZIA,Fluid retention,system disorders Dizziness,0,0.5908077955245972
NATAZIA,Fluid retention,Fluid retention hypertriglyceridemia Nervous system,1,0.7594739198684692
NATAZIA,Fluid retention,and nutrition Fluid retention hypertriglyceridemia Nervous system disorders Dizziness,1,0.7349175214767456
NATAZIA,hypertriglyceridemia,hypertriglyceridemia Nervous,1,0.8685656785964966
NATAZIA,hypertriglyceridemia,disorders Fluid retention,0,0.5673841238021851
NATAZIA,hypertriglyceridemia,hypertriglyceridemia Nervous system disorders Dizziness,1,0.8217877149581909
NATAZIA,hypertriglyceridemia,nutrition disorders Fluid hypertriglyceridemia,1,0.8537212610244751
NATAZIA,hypertriglyceridemia,Fluid hypertriglyceridemia Nervous system,1,0.8215539455413818
NATAZIA,hypertriglyceridemia,Immune system disorders Hypersensitivity Metabolism and nutrition disorders Fluid retention,0,0.615201473236084
NATAZIA,hypertriglyceridemia,Metabolism and nutrition disorders,0,0.6523125171661377
NATAZIA,hypertriglyceridemia,hypertriglyceridemia Nervous system disorders Dizziness Skin,1,0.8212054967880249
NATAZIA,hypertriglyceridemia,hypertriglyceridemia Nervous system,1,0.8574051856994629
NATAZIA,Dizziness,tissue disorders Chloasma angioedema erythema nodosum erythema multif,0,0.4935406446456909
NATAZIA,Dizziness,Dizziness Skin and,1,0.8785176277160645
NATAZIA,Dizziness,Fluid retention hypertriglyceridemia,0,0.5234825611114502
NATAZIA,Chloasma,Chloasma angioedema,1,0.8457782864570618
NATAZIA,Chloasma,Chloasma angioedema erythema,1,0.8453707695007324
NATAZIA,Chloasma,Chloasma angioedema erythema nodosum erythema multiforme,1,0.7811484336853027
NATAZIA,Chloasma,angioedema erythema nodosum erythema multiforme Gastrointestinal disorders,0,0.5702886581420898
NATAZIA,Chloasma,multiforme Gastrointestinal disorders Gastrointestinal,0,0.4713616967201233
NATAZIA,Chloasma,Chloasma angioedema erythema nodosum erythema,1,0.7976464033126831
NATAZIA,Chloasma,triglyceridemia Nervous system disorders Dizziness Skin,0,0.5115927457809448
NATAZIA,Chloasma,system disorders Dizziness Skin and subcutaneous tissue disorders,0,0.5460408926010132
NATAZIA,angioedema,angioedema,1,1.000000238418579
NATAZIA,angioedema,angioedema erythema,1,0.9081182479858398
NATAZIA,erythema nodosum,Gastrointestinal symptoms for,0,0.5210158228874207
NATAZIA,erythema multiforme,erythema multiforme Gastrointestinal disorders Gastrointestinal,1,0.8438643217086792
NATAZIA,erythema multiforme,disorders Chloasma angioedema erythema erythema,1,0.7394524812698364
NATAZIA,erythema multiforme,erythema erythema,1,0.8478594422340393
NATAZIA,erythema multiforme,erythema,1,0.8613466024398804
NATAZIA,erythema multiforme,erythema erythema multiforme,1,0.9898635149002075
NATAZIA,erythema multiforme,Gastrointestinal,0,0.5233086347579956
NATAZIA,erythema multiforme,disorders Chloasma angioedema erythema erythema multiforme,1,0.8017109036445618
NATAZIA,CARDIOVASCULAR EVENTS,ctions with the use o f COCs are discussed elsewhere,1,0.5391362309455872
NATAZIA,CARDIOVASCULAR EVENTS,disorders Chloasma angioedema erythema erythema multiforme,1,0.558093786239624
NATAZIA,CARDIOVASCULAR EVENTS,are,0,0.5357875823974609
NATAZIA,CARDIOVASCULAR EVENTS,ing: * Serious cardiovascular,1,0.7229139804840088
NATAZIA,CARDIOVASCULAR EVENTS,elsewhere in the ing: *,1,0.5016229152679443
NATAZIA,CARDIOVASCULAR EVENTS,"in the ing:



 *    Serious cardiovascular events and stroke",1,0.8441855907440186
NATAZIA,CARDIOVASCULAR EVENTS,"the ing:



 *    Serious cardiovascular",1,0.7477639317512512
NATAZIA,CARDIOVASCULAR EVENTS,Boxed Warning and Warnings and,0,0.5234496593475342
NATAZIA,CARDIOVASCULAR EVENTS,discussed elsewhere in the ing: *,1,0.5204253196716309
NATAZIA,CARDIOVASCULAR EVENTS,elsewhere in the ing: * Serious,1,0.5172017812728882
NATAZIA,cardiovascular events,utions Vascular events see Warnings and,0,0.8133545517921448
NATAZIA,cardiovascular events,see Boxed Warning nd Warnings,1,0.5222881436347961
NATAZIA,cardiovascular events,and Preca utions Vascular events,1,0.8653713464736938
NATAZIA,cardiovascular events,nd Warnings and Preca,1,0.5525684356689453
NATAZIA,cardiovascular events,the labeling Serious cardiovascular events,0,0.8457041382789612
NATAZIA,cardiovascular events,see Boxed,0,0.5150856375694275
NATAZIA,cardiovascular events,and Preca utions Vascular events see Warnings,1,0.8072078227996826
NATAZIA,cardiovascular events,Boxed Warning nd,1,0.5024299025535583
NATAZIA,cardiovascular events,Warning nd Warnings and Preca,1,0.5499122142791748
NATAZIA,CARDIOVASCULAR EVENTS,common adverse (>= 2%) in,1,0.582353413105011
NATAZIA,CARDIOVASCULAR EVENTS,trials for Natazia are headaches irregular,0,0.5692172050476074
NATAZIA,CARDIOVASCULAR EVENTS,in clinical trials for Natazia are,1,0.5872169137001038
NATAZIA,CARDIOVASCULAR EVENTS,EXCERPT The,0,0.49267569184303284
NATAZIA,CARDIOVASCULAR EVENTS,adverse (>= 2%),1,0.5671625733375549
NATAZIA,CARDIOVASCULAR EVENTS,2%) in clinical,1,0.5124273896217346
NATAZIA,CARDIOVASCULAR EVENTS,including migraines bre,0,0.6076799035072327
NATAZIA,CARDIOVASCULAR EVENTS,(>= 2%) in clinical trials for Natazia are,1,0.5756505727767944
NATAZIA,cardiovascular events,(3%) and increased weight To report,1,0.5496081113815308
NATAZIA,cardiovascular events,mood es (3%) and increased,1,0.5526485443115234
NATAZIA,cardiovascular events,vomiting acne mood es (3%) and increased weight,1,0.5055074095726013
NATAZIA,cardiovascular events,(3%) and increased,1,0.5173118710517883
NATAZIA,cardiovascular events,contact Bayer HealthCare Pharmac,0,0.5054225921630859
NATAZIA,cardiovascular events,Bayer HealthCare Pharmac,0,0.5228895545005798
NATAZIA,Liver disease,] *,1,0.5394974946975708
NATAZIA,Liver disease,Precautions,0,0.5093284845352173
NATAZIA,Liver disease,reported by,0,0.5262002944946289
NATAZIA,Liver disease,"see Warnings and ]  
 *    Liv er disease",1,0.6418197154998779
NATAZIA,Liver disease,events see Warnings and ] * Liv,1,0.5059157609939575
NATAZIA,Liver disease,Precautions Adverse reactions commonly,0,0.49761518836021423
NATAZIA,Liver disease,Precautions Vascular events,0,0.5262245535850525
NATAZIA,Liver disease,disease see Warnings and Precautions Adverse reactions commonly reported,0,0.5817674398422241
NATAZIA,Liver disease,Warnings and ] *,1,0.5320749878883362
NATAZIA,Liver disease,Warnings and Precautions Vascular events see Warnings and,0,0.5412354469299316
NATAZIA,lipid metabolic effects,The most common adverse,1,0.5383062362670898
NATAZIA,lipid metabolic effects,Breast tenderness,0,0.48940348625183105
NATAZIA,lipid metabolic effects,most common adverse reactions in clinical trials,1,0.5513814687728882
NATAZIA,lipid metabolic effects,most common adverse reactions in,1,0.5606839656829834
NATAZIA,lipid metabolic effects,tenderness Headache The most common adverse reactions in clinical,1,0.5209449529647827
NATAZIA,lipid metabolic effects,common adverse reactions in clinical trials,1,0.5685790777206421
NATAZIA,lipid metabolic effects,Headache The most common adverse reactions,1,0.5188857316970825
NATAZIA,Headache,breast tendernesspain ual diso rders nausea or,1,0.5878473520278931
NATAZIA,Headache,common adverse reactions in clinical trials,1,0.5341022610664368
NATAZIA,Headache,ual diso rders nausea or vomiting,1,0.5825459957122803
NATAZIA,Headache,including migraines breast tendernesspain ual diso rders nausea or,1,0.6822924613952637
NATAZIA,Headache,migraines breast tendernesspain ual,1,0.7116637229919434
NATAZIA,Headache,mood changes and increased,0,0.526762068271637
NATAZIA,Headache,including migraines breast tendernesspain ual,1,0.7060716152191162
NATAZIA,Uterine bleeding,mood changes,0,0.5184345841407776
NATAZIA,Uterine bleeding,report SU,1,0.5351804494857788
NATAZIA,Uterine bleeding,mood changes and increased To report,1,0.531893789768219
NATAZIA,Uterine bleeding,changes,0,0.4903208017349243
NATAZIA,Uterine bleeding,report SU SPECTED ADVERSE,1,0.5220292210578918
NATAZIA,Uterine bleeding,changes and increased,0,0.5137784481048584
NATAZIA,Uterine bleeding,To report SU SPECTED ADVERSE REACTIONS contact,1,0.4870150685310364
NATAZIA,venous thromboembolism,Bleeding Studies,0,0.6273095607757568
NATAZIA,venous thromboembolism,and Heavy Menstrual Bleeding A total,1,0.5745803713798523
NATAZIA,venous thromboembolism,"Heavy Menstrual Bleeding  A total of 2,131 wome n to years of",1,0.5709718465805054
NATAZIA,venous thromboembolism,"Menstrual Bleeding A total of 2,131 wome",1,0.5656991004943848
NATAZIA,venous thromboembolism,Menstrual Bleeding A total of,1,0.5912269353866577
NATAZIA,venous thromboembolism,"Menstrual Bleeding  A total of 2,131 wome n to years of age",1,0.5761655569076538
NATAZIA,venous thromboembolism,one dose,1,0.5328024625778198
NATAZIA,venous thromboembolism,dose of Natazia w ere,1,0.5218097567558289
NATAZIA,venous thromboembolism,age who took at one dose,1,0.512755274772644
NATAZIA,venous thromboembolism,age who took at one dose of Natazia w,1,0.5052588582038879
NATAZIA,venous thromboembolism,ere enrolled in four clinical phase,0,0.5544969439506531
NATAZIA,venous thromboembolism,age who took at one dose of,1,0.5153601765632629
NATAZIA,venous thromboembolism,of age who took,0,0.5014317035675049
NATAZIA,venous thromboembolism,subjects were included in,0,0.5021035671234131
NATAZIA,venous thromboembolism,trials A total of subjects,0,0.5362288951873779
NATAZIA,venous thromboembolism,of Natazia w ere,1,0.45461052656173706
NATAZIA,VTE,two,0,0.4690910279750824
NATAZIA,VTE,al ,1,0.4306976795196533
NATAZIA,VTE,of Natazia were enrolled,0,0.5207704305648804
NATAZIA,VTE,al  of subjects were included in,1,0.5063006281852722
NATAZIA,VTE, up to cycles with,1,0.5868300199508667
NATAZIA,VTE,a treatment  up to cycles,1,0.547722578048706
NATAZIA,VTE,studies with a treatment  up,1,0.5218427181243896
NATAZIA,VTE,  1 Adverse,1,0.5101479291915894
NATAZIA,VTE,Clinical,0,0.5521048307418823
NATAZIA,VTE,frequent menstrual bleeding in,0,0.46974122524261475
NATAZIA,VTE,pathology See Clinical,0,0.5278306007385254
NATAZIA,VTE,menstrual bleeding in women without organic pathology See Clinical,0,0.48140519857406616
NATAZIA,VTE,  1 Adverse Reactions Leading,1,0.48783764243125916
NATAZIA,arterial thromboses,nt adverse reaction s leading to,1,0.520057201385498
NATAZIA,arterial thromboses,  1 Adverse Reactions Leading,1,0.5418333411216736
NATAZIA,arterial thromboses,metrorrhagia,0,0.5202206373214722
NATAZIA,arterial thromboses,the most nt adverse reaction s leading to discontinuation were,1,0.5151612758636475
NATAZIA,arterial thromboses,were menstrual disorder metrorrhagia menorrhagia menstruation irregu,0,0.5670264363288879
NATAZIA,arterial thromboses,an adverse,0,0.5190329551696777
NATAZIA,arterial thromboses,most nt adverse reaction,1,0.49821358919143677
NATAZIA,arterial thromboses,reaction the most nt,1,0.460621178150177
NATAZIA,arterial thromboses,to discontinuation were menstrual disorder metrorrhagia menorrhagia menstruation irregu,0,0.5529832243919373
NATAZIA,strokes,continuation were menstrual disorder metrorrhagia menorrhagia menstruation irregular,0,0.5976385474205017
NATAZIA,strokes,frequent adverse reactions  to dis continuation were,1,0.5390825271606445
NATAZIA,strokes,most frequent adverse reactions to dis,1,0.5197502374649048
NATAZIA,thromboembolic disease,"vaginal hemorrhage,",1,0.5386137962341309
NATAZIA,cerebrovascular events,"uterine hemorrhage nausea or (6.0%), acne",1,0.5354057550430298
NATAZIA,cerebrovascular events,"(6.0%), acne",1,0.44157642126083374
NATAZIA,cerebrovascular events,withdrawal bleeding uterine,0,0.5384184122085571
NATAZIA,cerebrovascular events,"nausea or  (6.0%), acne (3.9%),  mood changes depression",1,0.5192537307739258
NATAZIA,cerebrovascular events,mood changes depression mood swings,0,0.5359983444213867
NATAZIA,cerebrovascular events,uterine hemorrhage nausea,0,0.5421435832977295
NATAZIA,cerebrovascular events,"or (6.0%),",1,0.4535452723503113
NATAZIA,hemorrhagic strokes,affect lability dysthymic disorder crying and increased,0,0.5393940806388855
NATAZIA,stroke,increased weight Serious Adverse :  myo cardial infarction cases,1,0.5949089527130127
NATAZIA,stroke,affect lability dysthymic disorder crying and increased,0,0.5244396924972534
NATAZIA,stroke,increased weight Serious Adverse :  myo,1,0.5199624300003052
NATAZIA,stroke,cardial,0,0.5764262676239014
NATAZIA,stroke,: myo,1,0.555652379989624
NATAZIA,stroke,Serious Adverse,0,0.5674421787261963
NATAZIA,breast cancer,"events including pulmonary , deep vein t hrombosis cerebral",1,0.5089033842086792
NATAZIA,breast cancer,Serious Adverse,0,0.49562570452690125
NATAZIA,breast cancer,Vascular disorders Venous and arterial thromboembolic events including,0,0.4499630331993103
NATAZIA,breast cancer,vein t hrombosis,1,0.4659731388092041
NATAZIA,breast cancer,"including pulmonary , deep vein",1,0.5300585031509399
NATAZIA,breast cancer,"including pulmonary , deep vein t hrombosis cerebral thrombosis myocardial",1,0.5214745402336121
NATAZIA,breast cancer,disorders Venous and arterial thromboembolic events including,0,0.4582160711288452
NATAZIA,breast cancer,"events including pulmonary , deep vein t hrombosis cerebral thrombosis myocardial",1,0.5367095470428467
NATAZIA,breast cancer,and stroke hypertension patobiliary d,1,0.5628068447113037
NATAZIA,breast cancer,disorders Hypersensitivity Metabolis,0,0.4570678472518921
NATAZIA,breast cancer,patobiliary d,1,0.525833785533905
NATAZIA,breast cancer,He,0,0.4587671160697937
NATAZIA,breast cancer,infarction and stroke hypertension patobiliary d,1,0.5581377744674683
NATAZIA,breast cancer,patobiliary d isorders Gallbladder,1,0.5293315649032593
NATAZIA,breast cancer,infarction and stroke hypertension patobiliary,1,0.5438345670700073
NATAZIA,breast cancer,thrombosis cerebral thrombosis myocardial infarction,0,0.5304282903671265
NATAZIA,breast cancer,myocardial infarction and stroke hypertension,0,0.5346938371658325
NATAZIA,breast cancer,disease hepatitis Immune,0,0.446401983499527
NATAZIA,cervical cancer,"and nutrition disorders Fluid tion, hypertrig",1,0.475722074508667
NATAZIA,cervical cancer,"nutrition disorders Fluid tion,",1,0.455936074256897
NATAZIA,cervical cancer,disorders Dizziness Skin and subcutaneous tissue,0,0.4883982539176941
NATAZIA,cervical cancer,"tion, hypertrig lyceridemia Nervous",1,0.4964372515678406
NATAZIA,cervical cancer,"nutrition disorders Fluid tion, hypertrig lyceridemia Nervous system disorders",1,0.4739953875541687
NATAZIA,cervical cancer,"tion, hypertrig",1,0.49611419439315796
NATAZIA,cervical cancer,Fluid reten,0,0.5222408175468445
NATAZIA,cervical cancer,"tion, hypertrig lyceridemia Nervous system disorders",1,0.5000417828559875
NATAZIA,cervical cancer,"disorders Fluid tion, hypertrig",1,0.5084954500198364
NATAZIA,cervical cancer,"disorders Fluid tion, hypertrig lyceridemia Nervous",1,0.5003215074539185
DIFICID,nausea,adverse reactions nausea vomiting,1,0.8044742941856384
DIFICID,nausea,"disorders Fluid tion, hypertrig",1,0.5449479222297668
DIFICID,nausea,nausea vomiting,1,0.9235453009605408
DIFICID,nausea,adverse reactions nausea,1,0.8528498411178589
DIFICID,nausea,nausea vomiting abdominal pain,1,0.8348536491394043
DIFICID,vomiting,are vomiting abdominal pain,1,0.8358045816421509
DIFICID,vomiting,nausea vomiting abdominal pain,1,0.8152579069137573
DIFICID,vomiting,EXCERPT,0,0.4779292047023773
DIFICID,vomiting,vomiting abdominal pain gastrointestinal hemorrhage,1,0.7970166206359863
DIFICID,vomiting,vomiting abdominal,1,0.9126684665679932
DIFICID,vomiting,vomiting abdominal pain,1,0.8537112474441528
DIFICID,abdominal pain,gastrointestinal hemorrhage anemia,0,0.6618373394012451
DIFICID,abdominal pain,abdominal pain gastrointestinal hemorrhage anemia and,1,0.8189940452575684
DIFICID,gastrointestinal hemorrhage,gastrointestinal hemorrhage anemia and neutropenia To report,1,0.8520914316177368
DIFICID,gastrointestinal hemorrhage,nausea vomiting abdominal gastrointestinal,1,0.7749900817871094
DIFICID,anemia,anemia and neutropenia To,1,0.8478977680206299
DIFICID,anemia,nausea vomiting abdominal pain gastrointestinal hemorrhage,0,0.6055778861045837
DIFICID,anemia,gastrointestinal,0,0.5570145845413208
DIFICID,anemia,anemia and,1,0.9244571924209595
DIFICID,neutropenia,neutropenia To,1,0.9222820401191711
DIFICID,neutropenia,neutropenia To report,1,0.8860704898834229
DIFICID,neutropenia,report SUSPECTED ADVERSE,0,0.5264301300048828
DIFICID,abdominal distension,trials,0,0.5365137457847595
DIFICID,abdominal distension,flatulence intestinal,0,0.6855409145355225
DIFICID,abdominal distension,abdominal distension abdominal,1,0.9595749378204346
DIFICID,abdominal distension,Gastrointestinal abdominal,1,0.7645406126976013
DIFICID,abdominal distension,controlled trials Gastrointestinal abdominal,1,0.7238693237304688
DIFICID,abdominal distension,abdominal distension,1,1.0000001192092896
DIFICID,abdominal distension,Gastrointestinal abdominal distension,1,0.9390403032302856
DIFICID,abdominal tenderness,distension,0,0.6180505752563477
DIFICID,abdominal tenderness,intestinal obstruction megacolon Investigations,0,0.6160191297531128
DIFICID,abdominal tenderness,Gastrointestinal Disorders abdominal,0,0.7557141780853271
DIFICID,abdominal tenderness,Gastrointestinal Disorders abdominal abdominal tenderness dyspepsia dysphagia flatulence intestinal,1,0.7859377861022949
DIFICID,abdominal tenderness,dysphagia flatulence intestinal obstruction megacolon Investigations incre,0,0.6104496717453003
DIFICID,abdominal tenderness,dyspepsia dysphagia,0,0.5883690714836121
DIFICID,abdominal tenderness,Gastrointestinal Disorders abdominal abdominal tenderness dyspepsia,1,0.8501680493354797
DIFICID,dyspepsia,dyspepsia dysphagia,1,0.9216462969779968
DIFICID,dyspepsia,abdominal tenderness,0,0.6346349120140076
DIFICID,dyspepsia,Gastrointestinal Disorders abdominal distension abdominal tenderness,0,0.6697005033493042
DIFICID,dyspepsia,abdominal distension abdominal dyspepsia dysphagia flatulence intestinal obstruction megacolon,1,0.7313942313194275
DIFICID,dyspepsia,dyspepsia dysphagia flatulence intestinal obstruction megacolon,1,0.7856964468955994
DIFICID,dyspepsia,dyspepsia,1,1.0
DIFICID,dysphagia,Investigations,0,0.5177736878395081
DIFICID,dysphagia,obstruction megacolon Investigations increased blood alkaline,0,0.5623072385787964
DIFICID,flatulence,flatulence intestinal obstruction megacolon,1,0.7529683113098145
DIFICID,flatulence,abdominal tenderness dyspepsia,0,0.6495028734207153
DIFICID,flatulence,flatulence intestinal,1,0.8468306064605713
DIFICID,flatulence,alkaline phosphatase,0,0.5286120176315308
DIFICID,flatulence,tenderness,0,0.570101261138916
DIFICID,flatulence,flatulence intestinal obstruction,1,0.829325795173645
DIFICID,flatulence,flatulence intestinal obstruction megacolon Investigations increased,1,0.7479565143585205
DIFICID,intestinal obstruction,abdominal tenderness dyspepsia dysphagia intestinal obstruction,1,0.7516958713531494
DIFICID,intestinal obstruction,intestinal obstruction megacolon Investigations increased blood,1,0.7609372735023499
DIFICID,intestinal obstruction,Disorders abdominal,0,0.7216129302978516
DIFICID,intestinal obstruction,dyspepsia dysphagia intestinal obstruction megacolon Investigations increased blood alkaline,1,0.6867890357971191
DIFICID,intestinal obstruction,intestinal obstruction megacolon Investigations,1,0.7724441289901733
DIFICID,intestinal obstruction,dyspepsia dysphagia intestinal,1,0.7163249850273132
DIFICID,megacolon,megacolon,1,1.0000001192092896
DIFICID,megacolon,dyspepsia dysphagia intestinal,1,0.6263679265975952
DIFICID,megacolon,increased blood alkaline phosphatase decreased blood bicarbonate,0,0.4989633858203888
DIFICID,megacolon,flatulence intestinal,0,0.6450584530830383
DIFICID,megacolon,phosphatase decreased blood bicarbonate increas,0,0.5051636695861816
DIFICID,megacolon,dysphagia flatulence,0,0.5894008874893188
DIFICID,megacolon,dominal distension abdominal tenderness dyspepsia dysphagia flatulence intestinal obstruction,0,0.6174127459526062
DIFICID,megacolon,megacolon Investigations increased blood,1,0.8191676735877991
DIFICID,megacolon,dysphagia flatulence intestinal megacolon Investigations,1,0.8221420049667358
DIFICID,increased blood alkaline phosphatase,dyspepsia dysphagia flatulence intestinal,0,0.5070527195930481
DIFICID,increased blood alkaline phosphatase,alkaline phosphatase decreased,1,0.8280484676361084
DIFICID,increased blood alkaline phosphatase,rness dyspepsia dysphagia flatulence,0,0.51457679271698
DIFICID,increased blood alkaline phosphatase,obstruction megacolon increased blood alkaline phosphatase,1,0.8490752577781677
DIFICID,increased blood alkaline phosphatase,increased blood alkaline phosphatase decreased blood bicarbonate increased,1,0.8910752534866333
DIFICID,increased blood alkaline phosphatase,decreased,0,0.49253544211387634
DIFICID,increased blood alkaline phosphatase,platelet count Metabolism,0,0.6276240944862366
DIFICID,increased blood alkaline phosphatase,blood alkaline phosphatase decreased blood,1,0.8617615699768066
DIFICID,decreased blood bicarbonate,decreased platelet count,0,0.6611487865447998
DIFICID,decreased blood bicarbonate,e intestinal,0,0.5081506967544556
DIFICID,decreased blood bicarbonate,blood alkaline decreased blood bicarbonate increased hepatic enzymes decreased,1,0.8750920295715332
DIFICID,increased hepatic enzymes,Disorders hyperglycemia metabolic aci,0,0.6124939918518066
DIFICID,increased hepatic enzymes,Metabolism,0,0.6262112855911255
DIFICID,increased hepatic enzymes,hepatic enzymes decreased,1,0.8253511786460876
DIFICID,increased hepatic enzymes,increased hepatic enzymes decreased,1,0.8798449039459229
DIFICID,increased hepatic enzymes,platelet count Metabolism and Nutrition Disorders hyperglycemia,0,0.6164374351501465
DIFICID,increased hepatic enzymes,phosphatase,0,0.6075719594955444
DIFICID,increased hepatic enzymes,platelet count Metabolism,0,0.608302116394043
DIFICID,increased hepatic enzymes,phosphatase decreased blood increased hepatic,1,0.7914954423904419
DIFICID,increased hepatic enzymes,decreased blood increased hepatic enzymes,1,0.86280357837677
DIFICID,decreased platelet count,bicarbonate increased hepatic decreased platelet count Metabolism and,1,0.7392464876174927
DIFICID,decreased platelet count,decreased blood increased hepatic enzymes,1,0.6724863052368164
DIFICID,decreased platelet count,Metabolism and Nutrition,0,0.5147740840911865
DIFICID,decreased platelet count,blood bicarbonate increased hepatic decreased platelet count Metabolism and Nutrition Disorders,1,0.7109038829803467
DIFICID,decreased platelet count,acidosis Skin and Subcu,0,0.4987747371196747
DIFICID,decreased platelet count,bicarbonate increased hepatic decreased platelet count Metabolism and Nutrition,1,0.7299091815948486
DIFICID,decreased platelet count,blood bicarbonate increased hepatic,0,0.49942702054977417
DIFICID,decreased platelet count,Nutrition Disorders hyperglycemia metabolic acidosis Skin and,0,0.48182401061058044
DIFICID,hyperglycemia,count Metabolism and Nutrition,0,0.5833755731582642
DIFICID,hyperglycemia,hyperglycemia,1,1.0000001192092896
DIFICID,hyperglycemia,hyperglycemia metabolic acidosis Skin,1,0.7523590922355652
DIFICID,hyperglycemia,acidosis Skin and Subcutaneous Tissue Disorders drug eruption,0,0.5212364196777344
DIFICID,hyperglycemia,hyperglycemia metabolic,1,0.8847392797470093
DIFICID,hyperglycemia,e increased hepatic enzymes decreased platelet count,0,0.5506900548934937
DIFICID,hyperglycemia,hyperglycemia metabolic acidosis Skin and,1,0.7601311802864075
DIFICID,hyperglycemia,enzymes,0,0.6217259168624878
DIFICID,hyperglycemia,and Subcutaneous Tissue,0,0.5100312232971191
DIFICID,hyperglycemia,Tissue Disorders drug,0,0.5269090533256531
DIFICID,metabolic acidosis,metabolic acidosis Skin,1,0.864368736743927
DIFICID,metabolic acidosis,Disorders metabolic acidosis Skin and Subcutaneous,1,0.8381023406982422
DIFICID,metabolic acidosis,and Nutrition Disorders metabolic acidosis,1,0.9144010543823242
DIFICID,metabolic acidosis,Skin and,0,0.5219507813453674
DIFICID,metabolic acidosis,Nutrition Disorders metabolic acidosis,1,0.9134585857391357
DIFICID,metabolic acidosis,metabolic acidosis,1,1.0
DIFICID,metabolic acidosis,Nutrition Disorders metabolic,1,0.7364687919616699
DIFICID,drug eruption,drug eruption pruritus rash Post,1,0.8676695227622986
DIFICID,drug eruption,Experience,0,0.5190185308456421
DIFICID,rash,rash Post Marketing Experience Adverse reactions,1,0.7698546648025513
DIFICID,rash,eruption rash Post Marketing Experience Adverse reactions,1,0.7663446664810181
DIFICID,rash,rash Post Marketing,1,0.7351356148719788
DIFICID,rash,eruption rash Post Marketing Experience Adverse,1,0.7553185820579529
DIFICID,rash,marketing setting ari,0,0.4829270839691162
DIFICID,rash,rash Post Marketing Experience Adverse,1,0.7235846519470215
DIFICID,angioedema,have,0,0.5197468996047974
DIFICID,angioedema,angioedema rash and,1,0.8962804079055786
DIFICID,rash,always possible Hypersensitivity,0,0.6426082849502563
DIFICID,rash,rash and pruritus have been,1,0.8419377207756042
DIFICID,rash,rash and,1,0.9337756037712097
DIFICID,rash,rash and pruritus have been reported,1,0.8404961228370667
DIFICID,rash,have been reported,0,0.4968920648097992
DIFICID,rash,not always possible Hypersensitivity,0,0.6266154050827026
DIFICID,rash,possible,0,0.5114014148712158
DIFICID,pruritus,possible Hypersensitivity,0,0.6839339137077332
DIFICID,pruritus,pruritus,1,1.0000001192092896
DIFICID,pruritus,rash pruritus,1,0.9031826257705688
DIFICID,pruritus,pruritus have been reported,1,0.9152218103408813
DIFICID,Acute hypersensitivity reactions,ge anemia,0,0.5249844789505005
DIFICID,Acute hypersensitivity reactions,"nausea vomiting abdominal  (6%), gastrointestinal hemorrha ge anemia and",1,0.5604035258293152
DIFICID,Acute hypersensitivity reactions,"(6%), gastrointestinal hemorrha",1,0.5546705722808838
DIFICID,angioedema,are nausea vomiting abdominal pain,0,0.5139662027359009
DIFICID,angioedema,"(4%), ane",1,0.5338476896286011
DIFICID,angioedema,"pain gastrointestinal (4%),",1,0.5503101348876953
DIFICID,angioedema,ADVERSE REACTIONS,0,0.6705965995788574
DIFICID,angioedema,"gastrointestinal  (4%), ane mia and",1,0.5930280685424805
DIFICID,angioedema,"(4%), ane mia and neutropenia",1,0.5550349950790405
DIFICID,angioedema,"gastrointestinal (4%),",1,0.5540648102760315
DIFICID,angioedema,"vomiting abdominal pain gastrointestinal (4%), ane",1,0.5685528516769409
DIFICID,dyspnea,ctions are nausea vomiting abdominal pain gastrointestinal hemorrhage,0,0.545223593711853
DIFICID,dyspnea,report SUSPECTED ADVERSE,0,0.5615421533584595
DIFICID,dyspnea,SUSPECTED ADVERSE,0,0.5958888530731201
DIFICID,dyspnea,contact,0,0.5198546648025513
DIFICID,dyspnea,"a (2%), and neutropenia To report",1,0.5540229082107544
DIFICID,pruritus,hemorrhage anemia nd neutr openia To report SUSPECTED,1,0.5130179524421692
DIFICID,pruritus,"a (2%), and neutropenia To report",1,0.5551532506942749
DIFICID,pruritus,gastrointestinal hemorrhage anemia nd neutr openia To report SUSPECTED,1,0.5165507793426514
DIFICID,pruritus,hemorrhage anemia nd neutr openia To report,1,0.5021976232528687
DIFICID,rash,hemorrhage anemia and  (2% To report SUSPECTED ADVERSE,1,0.5362669229507446
DIFICID,rash,"a (2%), and neutropenia To report",1,0.5439311265945435
DIFICID,rash, (2% To,1,0.5206862092018127
DIFICID,rash,gastrointestinal hemorrhage anemia and  (2% To,1,0.5300856232643127
DIFICID,rash, (2% To report SUSPECTED,1,0.5137568712234497
DIFICID,rash,and  (2% To,1,0.5134798288345337
DIFICID,rash,REACTIONS contact,0,0.5905740261077881
DIFICID,rash, (2% To report SUSPECTED ADVERSE REACTIONS,1,0.5943325757980347
DIFICID,rash, (2% To report SUSPECTED ADVERSE,1,0.5526826977729797
DIFICID,Acute hypersensitivity reactions,not ect the rates observed in,1,0.4914020895957947
DIFICID,Acute hypersensitivity reactions,ect the rates observed in practi ce The,1,0.5248360633850098
DIFICID,Acute hypersensitivity reactions,for days was evaluated,0,0.48561668395996094
DIFICID,Acute hypersensitivity reactions,and may not ect the rates observed in practi,1,0.4694540202617645
DIFICID,Acute hypersensitivity reactions,not ect the,1,0.46311748027801514
DIFICID,Acute hypersensitivity reactions,in practi,1,0.5364091396331787
DIFICID,dyspnea,safety  of,1,0.5258617401123047
DIFICID,dyspnea,safety  of DIFICID mg tablets,1,0.5316542983055115
DIFICID,dyspnea,reflect the,0,0.49520865082740784
DIFICID,dyspnea,rates observed in practice safety  of,1,0.5104604959487915
DIFICID,rash,rates,0,0.5268455743789673
DIFICID,rash, DIF ICID mg tablets taken twice,1,0.5534945130348206
DIFICID,angioedema of the mouth,of DIFICID mg lets,1,0.5709534883499146
DIFICID,hypersensitivity reactions,ithdrew from trials as a r esult of adverse reactions,1,0.660624623298645
DIFICID,hypersensitivity reactions,of DIFICID mg lets,1,0.5585715770721436
DIFICID,hypersensitivity reactions,ithdrew from trials,1,0.5422348976135254
DIFICID,hypersensitivity reactions,patients receiving DIFICID ithdrew from trials as a r esult of adverse,1,0.5686639547348022
EDARBI,diarrhea,Pharmaceuticals LLC at,0,0.505441427230835
EDARBI,diarrhea,diarrhea To report SUSPECTED ADVERSE REACTIONS,1,0.7948397397994995
EDARBI,diarrhea,diarrhea To report,1,0.8629391193389893
EDARBI,diarrhea,diarrhea To,1,0.9007161855697632
EDARBI,diarrhea,diarrhea,1,0.9999999403953552
EDARBI,diarrhea,diarrhea To report SUSPECTED ADVERSE,1,0.8081265091896057
EDARBI,diarrhea,Arbor Pharmaceuticals LLC,0,0.4881199598312378
EDARBI,hypotension,to hypotension orthostatic hypotension was reported,1,0.8590283393859863
EDARBI,hypotension,Arbor Pharmaceuticals LLC,0,0.4488152265548706
EDARBI,hypotension,hypotension orthostatic hypotension was reported,1,0.8491992950439453
EDARBI,hypotension,hypotension orthostatic hypotension was,1,0.8446310758590698
EDARBI,hypotension,by patients randomized to Edarbi mg,0,0.5389325618743896
EDARBI,hypotension,hypotension orthostatic hypotension,1,0.8484514355659485
EDARBI,hypotension,hypotension orthostatic hypotension was reported by,1,0.8207893371582031
EDARBI,hypotension,by patients randomized,0,0.5426674485206604
EDARBI,hypotension,event leading to hypotension orthostatic hypotension was,1,0.8275021314620972
EDARBI,orthostatic hypotension,leading to discontinuation orthostatic,1,0.822049617767334
EDARBI,orthostatic hypotension,orthostatic,1,0.8745035529136658
EDARBI,orthostatic hypotension,orthostatic hypotension was reported by patients,1,0.9154977798461914
EDARBI,orthostatic hypotension,discontinuation orthostatic hypotension was reported,1,0.8922268152236938
EDARBI,orthostatic hypotension,Edarbi,0,0.4192255437374115
EDARBI,orthostatic hypotension,leading to discontinuation orthostatic hypotension was reported by,1,0.8746221661567688
EDARBI,diarrhea,similar regardless of,0,0.52716064453125
EDARBI,diarrhea,placebocontrolled,0,0.555478036403656
EDARBI,diarrhea,treated with Edarbi mg,0,0.5708087086677551
EDARBI,diarrhea,and similar regardless of age gender and race In,0,0.5001258254051208
EDARBI,diarrhea,to in patients,0,0.5293512344360352
EDARBI,diarrhea,diarrhea was,1,0.910380482673645
EDARBI,diarrhea,diarrhea was reported,1,0.8749850988388062
EDARBI,diarrhea,age gender and race,0,0.49085885286331177
EDARBI,diarrhea,diarrhea was reported up,1,0.8463751077651978
EDARBI,diarrhea,placebocontrolled monotherapy,0,0.5271106958389282
EDARBI,nausea,listed below Gastrointestinal Disorders,0,0.6041558980941772
EDARBI,nausea,Gastrointestinal nausea General,1,0.8243340253829956
EDARBI,asthenia,Site asthenia,1,0.8844621181488037
EDARBI,asthenia,listed below Gastrointestinal Disorders,0,0.5346217155456543
EDARBI,muscle spasm,Musculoskeletal and Connective Tissue muscle,1,0.6918120384216309
EDARBI,muscle spasm,Site Conditions asthenia fatigue Musculoskeletal and Connective,0,0.6372581720352173
EDARBI,muscle spasm,and Connective Tissue muscle spasm Nervous,1,0.8461132645606995
EDARBI,muscle spasm,Musculoskeletal and Connective Tissue muscle spasm,1,0.9066532850265503
EDARBI,muscle spasm,muscle spasm Nervous System Disorders,1,0.8432332277297974
EDARBI,muscle spasm,muscle spasm,1,1.0
EDARBI,muscle spasm,and Connective Tissue Disorders,0,0.5800855159759521
EDARBI,dizziness,dizziness dizziness postural Respiratory Thoracic,1,0.8106184005737305
EDARBI,dizziness,dizziness dizziness postural Respiratory Thoracic and,1,0.8077539801597595
EDARBI,dizziness,dizziness dizziness postural Respiratory,1,0.8390374779701233
EDARBI,dizziness,Musculoskeletal and Connective Tissue Disorders muscle,0,0.4422146677970886
EDARBI,dizziness,dizziness,1,0.9999998807907104
EDARBI,dizziness postural,Nervous System Disorders dizziness postural Respiratory Thoracic,1,0.8215408325195312
EDARBI,dizziness postural,dizziness,1,0.8697164058685303
EDARBI,dizziness postural,spasm Nervous System Disorders dizziness,1,0.7654792070388794
EDARBI,dizziness postural,Disorders cough,0,0.4890398383140564
EDARBI,dizziness postural,cough Clinical Laboratory Findin,0,0.4898889362812042
EDARBI,dizziness postural,System Disorders dizziness,0,0.7832266092300415
EDARBI,dizziness postural,Respiratory,0,0.5065195560455322
EDARBI,dizziness postural,Nervous System Disorders dizziness postural,1,0.8818218111991882
EDARBI,dizziness postural,System Disorders dizziness postural,1,0.898735761642456
EDARBI,cough,cough Clinical,1,0.8457497954368591
EDARBI,cough,cough Clinical Laboratory,1,0.8002657890319824
EDARBI,cough,dizziness postural,0,0.5343949794769287
EDARBI,cough,cough Clinical Laboratory Findings,1,0.7769548892974854
EDARBI,cough,Thoracic and Mediastinal,0,0.5941849946975708
EDARBI,cough,Disorders,0,0.554822564125061
EDARBI,cough,Findings In controlled clinical trials clinically relevant,0,0.5244359970092773
EDARBI,cough,cough,1,1.0
EDARBI,increases in serum creatinine,creatinine Small increases in serum creatinine,1,0.944222092628479
EDARBI,increases in serum creatinine,Edarbi The increase,0,0.6345378160476685
EDARBI,increases in serum creatinine,seen in patients receiving mg of Edarbi The increase may,0,0.6969274282455444
EDARBI,increases in serum creatinine,larger when coadministered with,0,0.5137860774993896
EDARBI,increases in serum creatinine,Serum creatinine Small increases in serum creatinine are seen in patients,1,0.9346698522567749
EDARBI,increases in serum creatinine,Small increases,1,0.6347776055335999
EDARBI,serum creatinine increases,more likely to serum creatinine increases HemoglobinHematocrit Low,1,0.839914083480835
EDARBI,serum creatinine increases,Small increases,1,0.635833740234375
EDARBI,serum creatinine increases,serum creatinine increases,1,0.9999998807907104
EDARBI,serum creatinine increases,more likely to serum,1,0.6781142950057983
EDARBI,serum creatinine increases,serum creatinine increases HemoglobinHematocrit Low hemoglobin,1,0.8332107067108154
EDARBI,serum creatinine increases,serum,1,0.6818093061447144
EDARBI,serum creatinine increases,serum creatinine increases HemoglobinHematocrit,1,0.8500998020172119
EDARBI,serum creatinine increases,creatinine increases HemoglobinHematocrit Low hemoglobin,1,0.795953631401062
EDARBI,serum creatinine increases,hematocrit and RBC counts were,0,0.6327202320098877
EDARBI,Low hemoglobin,Low hemoglobin hematocrit and RBC,1,0.870497465133667
EDARBI,Low hemoglobin,report serum creatinine increases Low hemoglobin,1,0.7941338419914246
EDARBI,Low hemoglobin,creatinine increases Low,1,0.632075309753418
EDARBI,Low hemoglobin,in and of Edarbitreated subjects,0,0.48475801944732666
EDARBI,Low hemoglobin,serum creatinine increases,0,0.5064196586608887
EDARBI,Low hemoglobin,creatinine increases Low hemoglobin hematocrit and RBC counts were,1,0.7556475400924683
EDARBI,Low hemoglobin,to report serum creatinine increases,0,0.5075267553329468
EDARBI,Nausea,relationship to,0,0.4524661600589752
EDARBI,Nausea,Nausea Muscle spasms Rash Pruritus Angioedema,1,0.7331329584121704
EDARBI,Nausea,spasms Rash,0,0.5956686735153198
EDARBI,Nausea,Nausea Muscle spasms Rash Pruritus,1,0.7391701936721802
EDARBI,Nausea,Nausea Muscle,1,0.8330925703048706
EDARBI,Nausea,Nausea Muscle spasms Rash,1,0.7586823105812073
EDARBI,Nausea,drug Nausea Muscle spasms Rash,1,0.7370281219482422
EDARBI,Nausea,to drug Nausea Muscle spasms,1,0.7682251930236816
EDARBI,Muscle spasms,exposure Muscle spasms,1,0.9080133438110352
EDARBI,FETAL TOXICITY,REACTIONS ERPT:,1,0.5444976091384888
EDARBI,FETAL TOXICITY,REACTIONS ERPT:   The mo st common,1,0.5091977715492249
EDARBI,FETAL TOXICITY,REACTIONS ERPT:   The mo st,1,0.5088123083114624
EDARBI,FETAL TOXICITY,ADVERSE,0,0.5499141216278076
EDARBI,FETAL TOXICITY,common adverse reaction in adults was diarrhea To,0,0.569807231426239
EDARBI,FETAL TOXICITY,The mo,1,0.43196868896484375
EDARBI,FETAL TOXICITY,common se reaction in adults was diarrhea To report,1,0.5245155692100525
EDARBI,FETAL TOXICITY,se reaction in adults was diarrhea To,1,0.5404888987541199
EDARBI,FETAL TOXICITY,contact Arbor Pharmace,0,0.4491727948188782
EDARBI,FETAL TOXICITY,EXCERPT The most common se reaction in adults was diarrhea,1,0.5170568227767944
EDARBI,FETAL TOXICITY,REACTIONS contact Arbor,0,0.533993124961853
EDARBI,FETAL TOXICITY,To report SUSPECTED ADVERSE REACTIONS contact,0,0.5853052735328674
EDARBI,FETAL TOXICITY,report SUSPECTED ADVERSE REACTIONS contact Arbor,0,0.5837899446487427
EDARBI,FETAL TOXICITY,EXCERPT The most common se reaction in,1,0.5242127180099487
EDARBI,FETAL TOXICITY,most common se reaction in,1,0.526130199432373
EDARBI,death to the developing fetus,"FDA or wwwfdagovmedwatch nical Trials Experience

  Be cause clinical trials",1,0.4739387035369873
EDARBI,death to the developing fetus,most common se reaction in,1,0.4661432206630707
EDARBI,death to the developing fetus,are conducted under widely,0,0.46271437406539917
EDARBI,death to the developing fetus,"nical Trials Experience

  Be cause clinical",1,0.4840867221355438
EDARBI,death to the developing fetus,Experience Be cause clinical trials,1,0.485809326171875
EDARBI,death to the developing fetus,at,0,0.47172653675079346
EDARBI,death to the developing fetus,wwwfdagovmedwatch nical Trials,1,0.505313515663147
EDARBI,death to the developing fetus,"FDA or wwwfdagovmedwatch nical Trials Experience

  Be cause",1,0.48620158433914185
EDARBI,death to the developing fetus,adverse reaction,0,0.49014198780059814
EDARBI,death to the developing fetus,"wwwfdagovmedwatch nical Trials Experience

  Be",1,0.4908848702907562
EDARBI,death to the developing fetus,"nical Trials Experience

  Be cause clinical trials are conducted",1,0.47322720289230347
EDARBI,FETAL TOXICITY,"conditions, ad",1,0.48546284437179565
EDARBI,death to the developing fetus,for safety when treated with Edarbi at doses,1,0.511086106300354
EDARBI,death to the developing fetus,patients,0,0.4383316934108734
EDARBI,death to the developing fetus,A total of,0,0.49937641620635986
EDARBI,death to the developing fetus,total of patients were for safety when treated with  Edarbi at doses of,1,0.4890373945236206
EDARBI,death to the developing fetus,mg in clinical,0,0.48626774549484253
EDARBI,death to the developing fetus,safety when treated with Edarbi at,1,0.5080388784408569
EDARBI,death to the developing fetus,treated with Edarbi at doses of,1,0.49168771505355835
EDARBI,death to the developing fetus,treated for at,0,0.4508229196071625
EDARBI,death to the developing fetus,for safety when treated with  Edarbi at,1,0.5187321305274963
EDARBI,reduces fetal renal function,"conditions, adv erse reaction rates observed in",1,0.49621450901031494
EDARBI,reduces fetal renal function,"dely varying conditions, adv erse reaction rates",1,0.5346511602401733
EDARBI,reduces fetal renal function,the clinical trials of a drug cannot be directly compared to rates i,0,0.5027415156364441
EDARBI,reduces fetal renal function,Because clinical trials,0,0.48989731073379517
EDARBI,reduces fetal renal function,"under dely varying conditions, adv",1,0.5257658958435059
EDARBI,reduces fetal renal function,"under dely varying conditions, adv erse reaction rates",1,0.5215007066726685
EDARBI,reduces fetal renal function,"trials are conducted under dely varying conditions, adv erse reaction",1,0.5064138174057007
EDARBI,reduces fetal renal function,wi,0,0.4556730091571808
EDARBI,reduces fetal renal function,the clinical trials of a drug cannot be directly compared,0,0.5099242329597473
EDARBI,reduces fetal renal function,compared to,0,0.48123082518577576
EDARBI,neonatal morbidity,in the clinica l trials,1,0.5105893611907959
EDARBI,neonatal morbidity,conditions adverse reaction rates ved in the clinica,1,0.5640041828155518
EDARBI,neonatal morbidity,rates ved,1,0.45321059226989746
EDARBI,oligohydramnios,be directly compared to rates in the,1,0.3898952007293701
EDARBI,oligohydramnios,drug and may not reflect,0,0.4628700017929077
EDARBI,oligohydramnios,be directly compared to rates,1,0.39411383867263794
EDARBI,oligohydramnios,a drug,0,0.48052874207496643
EDARBI,oligohydramnios,the clinical trials of a drug can,0,0.4565761387348175
EDARBI,oligohydramnios,not be directly compared to,1,0.42828887701034546
EDARBI,oligohydramnios,not be directly,1,0.4289494454860687
EDARBI,oligohydramnios,not be,1,0.45666003227233887
EDARBI,fetal lung hypoplasia,e clinical trials of another drug and,1,0.4636966586112976
EDARBI,fetal lung hypoplasia,trials of another drug,1,0.46076273918151855
EDARBI,fetal lung hypoplasia,reaction rates observed in the clinical trials of a drug cannot be directly compared to rates,0,0.4224362373352051
EDARBI,fetal lung hypoplasia,in e clinical trials of,1,0.47877901792526245
EDARBI,fetal lung hypoplasia,the clinical trials of a drug cannot,0,0.45408615469932556
EDARBI,fetal lung hypoplasia,directly compared to,0,0.4264005422592163
EDARBI,fetal lung hypoplasia,to rates in e clinical trials of  another drug and may,1,0.45136553049087524
EDARBI,fetal lung hypoplasia,rates in e,1,0.3827313184738159
EDARBI,fetal lung hypoplasia,patients,0,0.44912683963775635
EDARBI,neonatal adverse effects,ates observed in practic e A,1,0.5296643972396851
EDARBI,neonatal adverse effects,Edarbi,0,0.4699096977710724
EDARBI,neonatal adverse effects,not reflect the r,0,0.46206310391426086
EDARBI,neonatal adverse effects,not reflect the ates observed in practic e,1,0.5144098997116089
EDARBI,neonatal adverse effects,trials of another drug and may not reflect the,0,0.5529599189758301
EDARBI,neonatal adverse effects,the ates observed in practic e,1,0.5192776918411255
EDARBI,neonatal adverse effects,e A total of patients were evaluated for safety when,0,0.5743852257728577
EDARBI,neonatal adverse effects,trials of another drug and,0,0.5492546558380127
EDARBI,symptomatic hypotension,acebo-controlled monoth erapy and combination therapy,1,0.538643479347229
EDARBI,symptomatic hypotension,for Edarbi,0,0.46343064308166504
EDARBI,symptomatic hypotension,adverse reactions similar,0,0.588981568813324
EDARBI,changes in renal function,Other adverse reactions,0,0.5461243987083435
EDARBI,changes in renal function,treated th Edarbi 80 mg,1,0.5617855787277222
EDARBI,changes in renal function,wi,0,0.44434797763824463
EDARBI,changes in renal function,to in patients treated th Edarbi 80 mg daily com pared with,1,0.5722910165786743
EDARBI,oliguria,fatigue Musculoskeletal and Connective Tissue,0,0.500344455242157
EDARBI,oliguria,nia fatigue Musculoskeletal and Connective Tissue Disorders muscle spasm Nervous,0,0.5265653133392334
EDARBI,oliguria,and Connective Tissue Disorders,0,0.4859858453273773
EDARBI,oliguria,: asthe nia fatigue,1,0.5236440896987915
EDARBI,oliguria,Disorders and Administration Site :  asthe,1,0.5230735540390015
EDARBI,oliguria,Disorders and Administration Site :,1,0.5352572202682495
EDARBI,oliguria,: asthe nia fatigue Musculoskeletal and,1,0.5260451436042786
EDARBI,oliguria,and Connective Tissue,0,0.48820576071739197
EDARBI,progressive azotemia,Site Conditions,0,0.5079696178436279
EDARBI,progressive azotemia,Conditions fatigue,1,0.5595147609710693
EDARBI,progressive azotemia,and,0,0.4472661018371582
EDARBI,progressive azotemia,"Administration Site Conditions  fatigue



   Muscu loskeletal and",1,0.5215885043144226
EDARBI,progressive azotemia,Site Conditions fatigue Muscu,1,0.5094276666641235
EDARBI,progressive azotemia,Connective Tissue Disorders muscle spasm Nervous,0,0.4990055561065674
EDARBI,progressive azotemia,Administration Site Conditions fatigue,1,0.524610161781311
EDARBI,progressive azotemia,and Connective Tissue Disorders,0,0.48941436409950256
EDARBI,acute renal failure,and,0,0.4783390760421753
EDARBI,acute renal failure,fatigue Musculoskeletal and nnective Tissue Dis,1,0.4824490249156952
EDARBI,acute renal failure,spasm Nervous System,0,0.5138056874275208
EDARBI,acute renal failure,and nnective Tissue Dis,1,0.5319434404373169
EDARBI,acute renal failure,nnective Tissue Dis,1,0.5311416387557983
EDARBI,acute renal failure,orders,0,0.47508126497268677
EDARBI,acute renal failure,and nnective Tissue Dis orders muscle spasm Nervous,1,0.49135369062423706
EDARBI,acute renal failure,Musculoskeletal and nnective Tissue,1,0.49991095066070557
EDARBI,acute renal failure,nnective Tissue Dis orders,1,0.5307066440582275
EDARBI,death,Tissue,0,0.5989238619804382
EDARBI,increases in serum creatinine,uncommon with a dministration of Edarbi,1,0.5005232095718384
EDARBI,increases in serum creatinine,standard laboratory rameters,1,0.6025185585021973
EDARBI,increases in serum creatinine,Small reversible increases in,0,0.6550279855728149
EDARBI,increases in serum creatinine,in serum creatini,0,0.8845421671867371
EDARBI,increases in serum creatinine,In controlled clinical trials clinically relevant,0,0.5978214740753174
EDARBI,increases in serum creatinine,in standard laboratory rameters were uncommon with a dministration,1,0.5659544467926025
EDARBI,increases in serum creatinine,with a dministration,1,0.4578700661659241
EDARBI,increases in serum creatinine,trials clinically relevant changes in standard laboratory,0,0.657461404800415
EDARBI,increases in serum creatinine,rameters were uncommon with a dministration of Edarbi Serum creatinine,1,0.775544285774231
IMBRUVICA,Infections,and,0,0.5494766235351562
IMBRUVICA,Infections,the labeling Hemorrhage see Warnings and Precautions,0,0.5491158366203308
IMBRUVICA,Infections,and Infections,1,0.9098659157752991
IMBRUVICA,Infections,Infections see Warnings,1,0.8066917657852173
IMBRUVICA,Infections,Infections see Warnings and Precautions,1,0.7936474680900574
IMBRUVICA,Infections,Cytopenias see Warnings and Precautions,0,0.6512600183486938
IMBRUVICA,Infections,Warnings and,0,0.6020026206970215
IMBRUVICA,Infections,Infections see Warnings and,1,0.8097579479217529
IMBRUVICA,Cytopenias,Cytopenias see Warnings and Precautions,1,0.879557728767395
IMBRUVICA,Cytopenias,Warnings and,0,0.5119965076446533
IMBRUVICA,Cytopenias,Cytopenias see Warnings and,1,0.8878805637359619
IMBRUVICA,Cytopenias,and Precautions,0,0.49279552698135376
IMBRUVICA,Atrial Fibrillation,Warnings and Atrial Fibrillation see Warnings and Precautions Second,1,0.8083223700523376
IMBRUVICA,Atrial Fibrillation,and Precautions,0,0.5054295659065247
IMBRUVICA,Atrial Fibrillation,Primary Malignancies see Warnings,0,0.5257385969161987
IMBRUVICA,Atrial Fibrillation,Atrial,1,0.8164797425270081
IMBRUVICA,Atrial Fibrillation,see Warnings and Atrial Fibrillation,1,0.827587902545929
IMBRUVICA,Atrial Fibrillation,Cytopenias see Warnings and Atrial Fibrillation,1,0.7458261251449585
IMBRUVICA,Atrial Fibrillation,Warnings,0,0.5457383990287781
IMBRUVICA,Second Primary Malignancies,and Second Primary Malignancies,1,0.9878110885620117
IMBRUVICA,Second Primary Malignancies,Warnings,0,0.5269155502319336
IMBRUVICA,Second Primary Malignancies,Warnings and Second Primary Malignancies see,1,0.8876095414161682
IMBRUVICA,Second Primary Malignancies,Second Primary Malignancies,1,1.0
IMBRUVICA,Second Primary Malignancies,Second Primary Malignancies see Warnings,1,0.9226838946342468
IMBRUVICA,Tumor Lysis Syndrome,Tumor Lysis Syndrome see Warnings and,1,0.8842268586158752
IMBRUVICA,Tumor Lysis Syndrome,Second Primary Malignancies see Warnings,1,0.6134026646614075
IMBRUVICA,Tumor Lysis Syndrome,Warnings,0,0.5197386741638184
IMBRUVICA,Tumor Lysis Syndrome,trials are conducted under,0,0.4874265789985657
IMBRUVICA,Tumor Lysis Syndrome,Lysis Syndrome see Warnings,1,0.7658588886260986
IMBRUVICA,Tumor Lysis Syndrome,clinical trials are conducted under,0,0.5149914026260376
IMBRUVICA,thrombocytopenia,MCL CLL WM were,0,0.428694486618042
IMBRUVICA,thrombocytopenia,anemia fatigue musculoskeletal pain bruising,0,0.5950008034706116
IMBRUVICA,thrombocytopenia,thrombocytopenia neutropenia,1,0.8732267618179321
IMBRUVICA,thrombocytopenia,nausea upper respiratory,0,0.46851855516433716
IMBRUVICA,neutropenia,neutropenia diarrhea,1,0.8280078768730164
IMBRUVICA,neutropenia,reactions in patients with,0,0.5267257690429688
IMBRUVICA,neutropenia,neutropenia diarrhea anemia fatigue,1,0.8074823617935181
IMBRUVICA,neutropenia,with Bcell malignancies MCL CLL WM were,0,0.5657951831817627
IMBRUVICA,neutropenia,reactions in patients with Bcell malignancies MCL CLL WM,0,0.5926942229270935
IMBRUVICA,neutropenia,fatigue musculoskeletal pain bruising nausea upper respiratory tract,0,0.5640974044799805
IMBRUVICA,neutropenia,CLL WM were neutropenia diarrhea,1,0.746376633644104
IMBRUVICA,neutropenia,patients,0,0.5187681913375854
IMBRUVICA,diarrhea,nausea upper respiratory,0,0.532340407371521
IMBRUVICA,diarrhea,infection,0,0.6666979789733887
IMBRUVICA,diarrhea,respiratory tract,0,0.5492244362831116
IMBRUVICA,anemia,neutropenia,0,0.7147143483161926
IMBRUVICA,anemia,malignancies MCL CLL WM,0,0.5038260221481323
IMBRUVICA,anemia,anemia fatigue musculoskeletal,1,0.8105220794677734
IMBRUVICA,anemia,were thrombocytopenia neutropenia anemia fatigue musculoskeletal pain,1,0.7053931951522827
IMBRUVICA,anemia,neutropenia diarrhea,0,0.5997434854507446
IMBRUVICA,anemia,bruising nausea upper respiratory tract infection and,0,0.5667292475700378
IMBRUVICA,anemia,tract infection,0,0.5476434826850891
IMBRUVICA,anemia,malignancies MCL CLL WM were thrombocytopenia neutropenia diarrhea,0,0.5465198755264282
IMBRUVICA,fatigue,malignancies MCL CLL WM were thrombocytopenia neutropenia diarrhea anemia,0,0.5309034585952759
IMBRUVICA,fatigue,thrombocytopenia neutropenia diarrhea fatigue musculoskeletal pain bruising nausea upper,1,0.6825867891311646
IMBRUVICA,fatigue,diarrhea anemia,0,0.5649365782737732
IMBRUVICA,fatigue,WM were thrombocytopenia neutropenia,0,0.5644923448562622
IMBRUVICA,fatigue,neutropenia,0,0.5645427703857422
IMBRUVICA,fatigue,fatigue musculoskeletal pain bruising,1,0.765894889831543
IMBRUVICA,musculoskeletal pain,musculoskeletal pain bruising nausea upper respiratory,1,0.8420181274414062
IMBRUVICA,nausea,nausea upper respiratory tract infection,1,0.8189057111740112
IMBRUVICA,nausea,nausea upper,1,0.8930381536483765
IMBRUVICA,upper respiratory tract infection,upper respiratory tract,1,0.8921869993209839
IMBRUVICA,upper respiratory tract infection,pain bruising upper respiratory,1,0.7199375629425049
IMBRUVICA,upper respiratory tract infection,bruising upper respiratory,1,0.7223370671272278
IMBRUVICA,upper respiratory tract infection,ADVERSE REACTIONS,0,0.5950426459312439
IMBRUVICA,upper respiratory tract infection,upper respiratory tract infection and rash To report,1,0.825965404510498
IMBRUVICA,upper respiratory tract infection,rash To report SUSPECTED,0,0.5523086786270142
IMBRUVICA,upper respiratory tract infection,To report SUSPECTED ADVERSE REACTIONS contact Pharmacyclics,0,0.5340721607208252
IMBRUVICA,upper respiratory tract infection,musculoskeletal pain bruising upper,1,0.5161523818969727
IMBRUVICA,upper respiratory tract infection,pain bruising upper respiratory tract,1,0.744152307510376
IMBRUVICA,rash,rash To report SUSPECTED,1,0.8175097107887268
IMBRUVICA,rash,rash To report SUSPECTED ADVERSE,1,0.8174117803573608
IMBRUVICA,rash,rash To report,1,0.8124811053276062
IMBRUVICA,rash,upper respiratory tract infection rash To report SUSPECTED ADVERSE,1,0.7749404907226562
IMBRUVICA,rash,tract infection rash To report SUSPECTED ADVERSE REACTIONS,1,0.7670795321464539
IMBRUVICA,rash,tract infection rash To report,1,0.7816769480705261
IMBRUVICA,diarrhea,diarrhea neutropenia anemia,1,0.7765846848487854
IMBRUVICA,diarrhea,diarrhea,1,0.9999999403953552
IMBRUVICA,diarrhea,adverse reactions were thrombocytopenia,0,0.5401151180267334
IMBRUVICA,diarrhea,diarrhea neutropenia anemia fatigue musculoskeletal pain,1,0.7261873483657837
IMBRUVICA,diarrhea,adverse,0,0.5763810873031616
IMBRUVICA,diarrhea,peripheral edema upper respiratory tract infe,0,0.5379693508148193
IMBRUVICA,neutropenia,edema,0,0.565549373626709
IMBRUVICA,neutropenia,anemia,0,0.7147143483161926
IMBRUVICA,neutropenia,commonly occurring,0,0.5542303919792175
IMBRUVICA,neutropenia,adverse reactions were thrombocytopenia diarrhea,0,0.5955504775047302
IMBRUVICA,neutropenia,neutropenia anemia fatigue musculoskeletal pain,1,0.8073346614837646
IMBRUVICA,anemia,anemia fatigue,1,0.8668901920318604
IMBRUVICA,anemia,anemia fatigue musculoskeletal pain peripheral edema,1,0.7909220457077026
IMBRUVICA,anemia,upper respiratory,0,0.4911803901195526
IMBRUVICA,anemia,anemia fatigue musculoskeletal pain peripheral,1,0.7937426567077637
IMBRUVICA,anemia,reactions were,0,0.48663997650146484
IMBRUVICA,anemia,diarrhea anemia fatigue,1,0.7721468210220337
IMBRUVICA,anemia,commonly occurring adverse reactions were,0,0.5077532529830933
IMBRUVICA,anemia,adverse reactions were,0,0.5255929231643677
IMBRUVICA,anemia,pain peripheral edema upper respiratory tract infection,0,0.5347206592559814
IMBRUVICA,fatigue,diarrhea neutropenia fatigue musculoskeletal pain,1,0.7139760255813599
IMBRUVICA,fatigue,pain peripheral edema upper respiratory tract infection,0,0.5716044902801514
IMBRUVICA,musculoskeletal pain,thrombocytopenia diarrhea neutropenia anemia musculoskeletal,1,0.676690936088562
IMBRUVICA,musculoskeletal pain,thrombocytopenia diarrhea,0,0.4501252770423889
IMBRUVICA,musculoskeletal pain,neutropenia,0,0.4960572123527527
IMBRUVICA,musculoskeletal pain,edema upper respiratory tract,0,0.47877830266952515
IMBRUVICA,musculoskeletal pain,fatigue,0,0.6200509071350098
IMBRUVICA,musculoskeletal pain,thrombocytopenia diarrhea neutropenia anemia,0,0.4734974503517151
IMBRUVICA,musculoskeletal pain,musculoskeletal pain peripheral edema upper respiratory,1,0.8232035636901855
IMBRUVICA,peripheral edema,peripheral,1,0.7205730080604553
IMBRUVICA,peripheral edema,neutropenia anemia fatigue musculoskeletal peripheral edema upper respiratory tract infection,1,0.7058476209640503
IMBRUVICA,peripheral edema,anemia fatigue musculoskeletal peripheral edema upper respiratory tract infection,1,0.7064870595932007
IMBRUVICA,upper respiratory tract infection,upper respiratory tract infection nausea bruising dyspnea constipation,1,0.8159714937210083
IMBRUVICA,upper respiratory tract infection,peripheral,0,0.46741437911987305
IMBRUVICA,upper respiratory tract infection,e thrombocytopenia diarrhea neutropenia anemia fatigue musculoskeletal pain peripheral edema,0,0.5039407014846802
IMBRUVICA,upper respiratory tract infection,musculoskeletal pain peripheral upper respiratory tract,1,0.7298676371574402
IMBRUVICA,upper respiratory tract infection,anemia fatigue musculoskeletal pain peripheral,0,0.47705593705177307
IMBRUVICA,upper respiratory tract infection,constipation rash abdominal pain vomiting and decreased appetite,0,0.5258299112319946
IMBRUVICA,upper respiratory tract infection,respiratory tract infection nausea bruising dyspnea constipation,1,0.7226398587226868
IMBRUVICA,upper respiratory tract infection,bruising dyspnea constipation rash,0,0.5047398209571838
IMBRUVICA,upper respiratory tract infection,upper respiratory tract infection nausea,1,0.8740664720535278
IMBRUVICA,bruising,pain peripheral edema upper respiratory,0,0.598299503326416
IMBRUVICA,bruising,respiratory tract infection bruising dyspnea,1,0.7313520312309265
IMBRUVICA,bruising,rash abdominal pain vomiting and decreased,0,0.6028723120689392
IMBRUVICA,bruising,peripheral edema upper respiratory tract,0,0.5632858276367188
IMBRUVICA,bruising,bruising dyspnea constipation rash abdominal pain,1,0.770599365234375
IMBRUVICA,bruising,pain vomiting and decreased appetite see Tables,0,0.602118968963623
IMBRUVICA,bruising,and decreased,0,0.5190907716751099
IMBRUVICA,bruising,respiratory tract infection bruising dyspnea constipation rash abdominal,1,0.698333740234375
IMBRUVICA,dyspnea,decreased appetite see,0,0.5267952680587769
IMBRUVICA,dyspnea,musculoskeletal pain peripheral edema upper respiratory tract infection nausea,0,0.5587415099143982
IMBRUVICA,dyspnea,tract infection nausea dyspnea,1,0.7935693264007568
IMBRUVICA,dyspnea,musculoskeletal pain peripheral edema upper respiratory,0,0.5989009141921997
IMBRUVICA,dyspnea,dyspnea constipation rash abdominal pain vomiting,1,0.7706698179244995
IMBRUVICA,dyspnea,dyspnea constipation rash abdominal,1,0.7372264862060547
IMBRUVICA,dyspnea,infection nausea dyspnea constipation,1,0.75589919090271
IMBRUVICA,constipation,respiratory tract infection nausea bruising,0,0.506828248500824
IMBRUVICA,constipation,and The most comm,0,0.49165821075439453
IMBRUVICA,constipation,constipation rash abdominal pain,1,0.7743812203407288
IMBRUVICA,constipation,constipation rash,1,0.8136494755744934
IMBRUVICA,constipation,and,0,0.5457766056060791
IMBRUVICA,constipation,vomiting and decreased appetite see Tables and The,0,0.6208440661430359
IMBRUVICA,constipation,tract infection nausea bruising constipation,1,0.7315178513526917
IMBRUVICA,constipation,and decreased,0,0.5268406867980957
IMBRUVICA,constipation,tract infection nausea bruising dyspnea,0,0.594077467918396
IMBRUVICA,rash,infection nausea bruising dyspnea rash abdominal pain vomiting and decreased,1,0.6841158866882324
IMBRUVICA,rash,tract infection nausea bruising dyspnea,0,0.6108713150024414
IMBRUVICA,rash,bruising dyspnea rash,1,0.7429166436195374
IMBRUVICA,rash,respiratory tract infection nausea bruising dyspnea,0,0.6197949647903442
IMBRUVICA,rash,vomiting and decreased appetite see Tables and The,0,0.5163206458091736
IMBRUVICA,rash,rash abdominal pain vomiting,1,0.8148338198661804
IMBRUVICA,rash,Tables and The most common Gra,0,0.500390350818634
IMBRUVICA,rash,rash abdominal pain vomiting and,1,0.8135840892791748
IMBRUVICA,rash,rash abdominal pain,1,0.8334870338439941
IMBRUVICA,abdominal pain,abdominal pain vomiting and,1,0.882712721824646
IMBRUVICA,abdominal pain,bruising dyspnea constipation abdominal,1,0.715973973274231
IMBRUVICA,abdominal pain,Grade or nonhe,0,0.48186755180358887
IMBRUVICA,abdominal pain,abdominal pain vomiting,1,0.8824350833892822
IMBRUVICA,vomiting,vomiting and decreased appetite see,1,0.8414040207862854
IMBRUVICA,vomiting,vomiting and decreased appetite,1,0.8438305854797363
IMBRUVICA,vomiting,and The most common Grade or nonhematologica,0,0.4904688596725464
IMBRUVICA,vomiting,rash abdominal,0,0.6431030035018921
IMBRUVICA,vomiting,vomiting,1,0.9999999403953552
IMBRUVICA,vomiting,constipation rash abdominal vomiting and,1,0.7781648635864258
IMBRUVICA,decreased appetite,nonhematological adverse reactions,0,0.515801191329956
IMBRUVICA,decreased appetite,vomiting decreased appetite,1,0.8594292402267456
IMBRUVICA,decreased appetite,infection nausea bruising dyspnea,0,0.5798045992851257
IMBRUVICA,decreased appetite,decreased,1,0.7124267816543579
IMBRUVICA,decreased appetite,ratory tract infection nausea bruising,0,0.5802471041679382
IMBRUVICA,decreased appetite,infection nausea bruising,0,0.586021900177002
IMBRUVICA,decreased appetite,decreased appetite,1,0.9999999403953552
IMBRUVICA,pneumonia,pneumonia abdominal pain,1,0.7980747818946838
IMBRUVICA,pneumonia,atrial fibrillation diarrhea,0,0.551300585269928
IMBRUVICA,pneumonia,nonhematological adverse reactions pneumonia,1,0.7536450624465942
IMBRUVICA,pneumonia,fibrillation diarrhea fatigue and skin infections Fatal and,0,0.5796821713447571
IMBRUVICA,pneumonia,abdominal pain atrial fibrillation diarrhea fatigue and skin infections Fatal and serious,0,0.5987608432769775
IMBRUVICA,pneumonia,adverse reactions,0,0.5477504730224609
IMBRUVICA,pneumonia,nonhematological adverse reactions,0,0.5292936563491821
IMBRUVICA,pneumonia,pneumonia abdominal pain atrial fibrillation diarrhea,1,0.7668296098709106
IMBRUVICA,abdominal pain,were,0,0.48507949709892273
IMBRUVICA,abdominal pain,atrial fibrillation diarrhea fatigue and skin,0,0.5541738271713257
IMBRUVICA,abdominal pain,nonhematological adverse reactions were abdominal pain atrial fibrillation diarrhea fatigue and,1,0.6638363599777222
IMBRUVICA,abdominal pain,most common Grade or,0,0.4762866795063019
IMBRUVICA,abdominal pain,most common Grade or nonhematological adverse reactions were pneumonia,0,0.510857343673706
IMBRUVICA,abdominal pain,abdominal,1,0.7878189086914062
IMBRUVICA,abdominal pain,nonhematological adverse reactions were abdominal pain,1,0.776993453502655
IMBRUVICA,abdominal pain,adverse reactions were abdominal pain atrial fibrillation diarrhea fatigue and,1,0.6881144046783447
IMBRUVICA,abdominal pain,abdominal pain atrial fibrillation diarrhea fatigue,1,0.7541307210922241
IMBRUVICA,abdominal pain,adverse reactions were abdominal,1,0.743401050567627
IMBRUVICA,diarrhea,of renal failure have occurred with,0,0.5774586200714111
IMBRUVICA,fatigue,adverse reactions were pneumonia abdominal pain atrial fibrillation,0,0.5210542678833008
IMBRUVICA,skin infections,diarrhea fatigue skin,1,0.6664252281188965
IMBRUVICA,skin infections,of,0,0.48409298062324524
IMBRUVICA,skin infections,atrial fibrillation diarrhea fatigue skin infections Fatal and serious cases,1,0.7006595730781555
IMBRUVICA,skin infections,skin,1,0.7582346796989441
IMBRUVICA,skin infections,atrial fibrillation diarrhea fatigue skin infections,1,0.7204947471618652
IMBRUVICA,Fatal,cases of renal failure,0,0.6140695214271545
IMBRUVICA,Fatal,and serious cases of renal failure have occurred with IMBRUVICA therapy,0,0.5636661052703857
IMBRUVICA,Fatal,Fatal and serious cases of,1,0.7966707348823547
IMBRUVICA,Fatal,Fatal,1,1.0000001192092896
IMBRUVICA,Fatal,Fatal and serious cases,1,0.792728066444397
IMBRUVICA,renal failure,serious cases renal failure have occurred,1,0.8847240209579468
IMBRUVICA,renal failure,Fatal and serious cases,1,0.5808390974998474
IMBRUVICA,renal failure,have occurred with IMBRUVICA therapy Increases in,0,0.4707332253456116
IMBRUVICA,renal failure,and,0,0.5150890350341797
IMBRUVICA,renal failure,fibrillation diarrhea fatigue and skin infections Fatal,0,0.5743227005004883
IMBRUVICA,renal failure,skin infections Fatal and serious cases,0,0.5495331883430481
IMBRUVICA,renal failure,fibrillation diarrhea fatigue and skin infections Fatal and serious,0,0.5840529203414917
IMBRUVICA,renal failure,Fatal and serious cases renal failure have,1,0.8642457723617554
IMBRUVICA,renal failure,the upper limit of,0,0.5002319812774658
IMBRUVICA,Increases in creatinine,Increases in creatinine to times the upper limit,1,0.922515869140625
IMBRUVICA,Increases in creatinine,have occurred,0,0.5524262189865112
IMBRUVICA,Increases in creatinine,times the upper limit of,0,0.5297262668609619
IMBRUVICA,Increases in creatinine,have occurred with IMBRUVICA Increases in creatinine to times the,1,0.8664779663085938
IMBRUVICA,Increases in creatinine,in creatinine to times the upper,1,0.8608527779579163
IMBRUVICA,Increases in creatinine,times the upper limit,0,0.5495271682739258
IMBRUVICA,Increases in creatinine,in creatinine to times the,1,0.8577322363853455
IMBRUVICA,Increases in creatinine,have occurred with IMBRUVICA Increases in creatinine,1,0.8655589818954468
IMBRUVICA,Upper respiratory tract infection,respiratory tract infection,1,0.9014788866043091
IMBRUVICA,Pneumonia,Pneumonia Skin infections,1,0.7900518178939819
IMBRUVICA,Sinusitis,Sinusitis General disorders,1,0.8520358204841614
IMBRUVICA,Sinusitis,Sinusitis General disorders and a,1,0.8613681793212891
IMBRUVICA,Fatigue,disorders and administrative site Fatigue Peripheral,1,0.7449386119842529
IMBRUVICA,Fatigue,Sinusitis General disorders and a,1,0.5223259925842285
IMBRUVICA,Fatigue,Fatigue,1,1.0
IMBRUVICA,Fatigue,Fatigue Peripheral,1,0.8139448165893555
IMBRUVICA,Fatigue,Fatigue Peripheral edema,1,0.7775026559829712
IMBRUVICA,Musculoskeletal pain,Musculoskeletal and connective tissue Musculoskeletal pain,1,0.9062875509262085
IMBRUVICA,Musculoskeletal pain,disorders,0,0.5771771669387817
IMBRUVICA,Musculoskeletal pain,Musculoskeletal pain Muscle spasms,1,0.848371148109436
IMBRUVICA,Musculoskeletal pain,Musculoskeletal and connective tissue Musculoskeletal,1,0.8017520308494568
IMBRUVICA,Arthralgia,spasms,0,0.5606762170791626
IMBRUVICA,Headache,Headache,1,0.9999998807907104
IMBRUVICA,Headache,disorders,0,0.5661548376083374
IMBRUVICA,Headache,em disorders,0,0.5335632562637329
IMBRUVICA,Headache,Dizziness,0,0.7131447196006775
IMBRUVICA,Headache,Headache Table Treatme,1,0.7944883108139038
IMBRUVICA,Decrease of Hemoglobin,or Neutrophils,0,0.5402421355247498
IMBRUVICA,Decrease of Hemoglobin,adverse Decrease of Hemoglobin,1,0.9572036862373352
IMBRUVICA,subdural hematoma,reduction occurred,0,0.5168391466140747
IMBRUVICA,subdural hematoma,discontinuation subdural hematoma Adverse reactions leading,1,0.8088523149490356
IMBRUVICA,elevated uric acid levels,Forty percent of patients elevated uric acid,1,0.851647138595581
IMBRUVICA,elevated uric acid levels,Forty percent of patients elevated uric acid levels,1,0.8778650760650635
IMBRUVICA,elevated uric acid levels,elevated uric acid levels on study,1,0.9248839020729065
IMBRUVICA,elevated uric acid levels,percent of patients elevated uric acid levels on study including,1,0.8808532953262329
IMBRUVICA,elevated uric acid levels,percent of patients elevated uric acid,1,0.8860936164855957
IMBRUVICA,elevated uric acid levels,Adverse reaction of hyperuricemia was,0,0.7994717359542847
IMBRUVICA,hyperuricemia,elevated uric acid levels on study including with values above mgdL,0,0.7739064693450928
IMBRUVICA,hyperuricemia,hyperuricemia,1,1.0000001192092896
IMBRUVICA,hyperuricemia,reaction hyperuricemia was reported for,1,0.883983850479126
IMBRUVICA,hyperuricemia,levels on study including with values above mgdL Adverse reaction of,0,0.5629054307937622
IMBRUVICA,hyperuricemia,hyperuricemia was reported for of,1,0.9187932014465332
IMBRUVICA,hyperuricemia,mgdL Adverse reaction hyperuricemia was reported for,1,0.8222627639770508
IMBRUVICA,thrombocytopenia,thrombocytopenia neutropenia diarrhea anemia fatigue musculoskeletal,1,0.7752352952957153
IMBRUVICA,thrombocytopenia,most commonly occurring adverse reactions in Study,0,0.49496161937713623
IMBRUVICA,thrombocytopenia,thrombocytopenia neutropenia diarrhea,1,0.8263903856277466
IMBRUVICA,neutropenia,neutropenia diarrhea anemia fatigue musculoskeletal pain,1,0.7777224183082581
IMBRUVICA,diarrhea,thrombocytopenia diarrhea anemia fatigue musculoskeletal,1,0.6864966750144958
IMBRUVICA,diarrhea,diarrhea anemia fatigue musculoskeletal pain,1,0.7429501414299011
IMBRUVICA,diarrhea,were thrombocytopenia diarrhea anemia fatigue musculoskeletal pain,1,0.6558468341827393
IMBRUVICA,diarrhea,reactions,0,0.5872281789779663
IMBRUVICA,diarrhea,diarrhea anemia,1,0.7949967384338379
IMBRUVICA,diarrhea,anemia fatigue musculoskeletal pain upper respiratory,0,0.509517252445221
IMBRUVICA,diarrhea,diarrhea anemia fatigue musculoskeletal pain upper,1,0.7296288013458252
IMBRUVICA,diarrhea,were thrombocytopenia diarrhea anemia fatigue,1,0.6835646629333496
IMBRUVICA,anemia,anemia,1,1.0
IMBRUVICA,anemia,adverse reactions in Study and Study were thrombocytopenia neutropenia diarrhea,0,0.5909794569015503
IMBRUVICA,anemia,rash,0,0.5674880146980286
IMBRUVICA,anemia,anemia fatigue musculoskeletal pain upper respiratory,1,0.767242431640625
IMBRUVICA,anemia,thrombocytopenia neutropenia anemia fatigue musculoskeletal pain,1,0.7171578407287598
IMBRUVICA,fatigue,fatigue,1,1.0
IMBRUVICA,fatigue,and,0,0.5631532073020935
IMBRUVICA,fatigue,fatigue musculoskeletal pain upper,1,0.8102351427078247
IMBRUVICA,fatigue,thrombocytopenia neutropenia diarrhea fatigue musculoskeletal pain upper,1,0.6957528591156006
IMBRUVICA,fatigue,diarrhea,0,0.5677722692489624
IMBRUVICA,fatigue,upper respiratory tract infection rash nausea and,0,0.5608910322189331
IMBRUVICA,fatigue,rse reactions in Study and Study were thrombocytopenia neutropenia diarrhea,0,0.5141770839691162
IMBRUVICA,fatigue,fatigue musculoskeletal,1,0.845801591873169
IMBRUVICA,musculoskeletal pain,and Study were,0,0.45852336287498474
IMBRUVICA,musculoskeletal pain,musculoskeletal pain,1,1.0000001192092896
IMBRUVICA,musculoskeletal pain,upper respiratory tract infection rash nausea and pyrexia,0,0.484170138835907
IMBRUVICA,musculoskeletal pain,musculoskeletal pain upper,1,0.8952468633651733
IMBRUVICA,musculoskeletal pain,diarrhea anemia musculoskeletal pain upper respiratory tract infection,1,0.7218220233917236
IMBRUVICA,musculoskeletal pain,thrombocytopenia neutropenia diarrhea anemia musculoskeletal pain upper respiratory tract infection,1,0.6958327293395996
IMBRUVICA,musculoskeletal pain,upper,0,0.45228543877601624
IMBRUVICA,musculoskeletal pain,infection rash nausea,0,0.5151647329330444
IMBRUVICA,musculoskeletal pain,Study were thrombocytopenia neutropenia diarrhea,0,0.4584968686103821
IMBRUVICA,upper respiratory tract infection,respiratory tract infection,1,0.9014788866043091
IMBRUVICA,upper respiratory tract infection,anemia fatigue,0,0.4797411859035492
IMBRUVICA,upper respiratory tract infection,of patients receiving IMBRUVICA in Study,0,0.5197968482971191
IMBRUVICA,upper respiratory tract infection,rash nausea and pyrexia Approximately five percent of patients receiving IMBRUVICA,0,0.5770386457443237
IMBRUVICA,upper respiratory tract infection,diarrhea anemia fatigue musculoskeletal upper respiratory tract infection rash nausea,1,0.6716719269752502
IMBRUVICA,upper respiratory tract infection,diarrhea anemia fatigue musculoskeletal upper,1,0.569161593914032
IMBRUVICA,upper respiratory tract infection,upper respiratory tract infection rash nausea and pyrexia,1,0.8033292293548584
IMBRUVICA,upper respiratory tract infection,thrombocytopenia neutropenia diarrhea,0,0.5015158653259277
IMBRUVICA,rash,rash,1,1.0000001192092896
IMBRUVICA,rash,anemia fatigue musculoskeletal pain upper respiratory,0,0.5425985455513
IMBRUVICA,rash,rash nausea and,1,0.858069658279419
IMBRUVICA,nausea,IMBRUVICA in Study and,0,0.433258980512619
IMBRUVICA,infections,infections subdural hematomas and diarrhea,1,0.7258893251419067
IMBRUVICA,infections,infections subdural hematomas,1,0.7119535207748413
IMBRUVICA,infections,infections subdural,1,0.7313156127929688
IMBRUVICA,infections,These included,0,0.595184326171875
IMBRUVICA,infections,infections subdural hematomas and diarrhea Adverse,1,0.7215234041213989
IMBRUVICA,infections,discontinued treatment due to adverse,0,0.5095076560974121
IMBRUVICA,infections,events These infections,1,0.8227792978286743
IMBRUVICA,subdural hematomas,events These included subdural hematomas,1,0.9046430587768555
IMBRUVICA,subdural hematomas,to dose reduction occurred in approximately of,0,0.5328726172447205
IMBRUVICA,subdural hematomas,treatment due to adverse events These included infections,0,0.5318435430526733
IMBRUVICA,subdural hematomas,Study and Study discontinued treatment due to,0,0.46717706322669983
IMBRUVICA,subdural hematomas,These included subdural hematomas,1,0.9404579401016235
IMBRUVICA,subdural hematomas,subdural,1,0.8593801259994507
IMBRUVICA,subdural hematomas,adverse events These included subdural hematomas,1,0.8554840087890625
IMBRUVICA,subdural hematomas,subdural hematomas and diarrhea Adverse events,1,0.8090536594390869
IMBRUVICA,diarrhea,Adverse events leading,0,0.5664921998977661
IMBRUVICA,diarrhea,diarrhea Adverse events leading to,1,0.7923673391342163
IMBRUVICA,diarrhea,hematomas,0,0.5098997354507446
IMBRUVICA,diarrhea,diarrhea Adverse,1,0.8244174718856812
IMBRUVICA,diarrhea,to dose reduction occurred in approximately of patients Study,0,0.4917747974395752
IMBRUVICA,diarrhea,diarrhea Adverse events,1,0.8013460636138916
IMBRUVICA,Dyspepsia,Abdominal,0,0.5967363119125366
IMBRUVICA,Dyspepsia,Abdominal Dyspepsia Infections,1,0.8240347504615784
IMBRUVICA,Dyspepsia,Abdominal Dyspepsia,1,0.9086225628852844
IMBRUVICA,Dyspepsia,Infections,0,0.54640793800354
IMBRUVICA,Sinusitis,Upper respiratory tract infection,0,0.7119446992874146
IMBRUVICA,Sinusitis,Sinusitis Skin infection,1,0.8533576726913452
IMBRUVICA,Pneumonia,Pneumonia,1,0.9999997615814209
IMBRUVICA,Pyrexia,Pyrexia,1,1.0000001192092896
IMBRUVICA,Cough,Cough Oropharyngeal,1,0.8377176523208618
IMBRUVICA,Arthralgia,disorders Musculoskeletal Arthralgia Muscle spasms,1,0.7543346285820007
IMBRUVICA,Arthralgia,Cough Oropharyngeal,1,0.5493524074554443
IMBRUVICA,Arthralgia,Musculoskeletal Arthralgia Muscle spasms,1,0.7719760537147522
IMBRUVICA,Arthralgia,Arthralgia,1,1.0
IMBRUVICA,Arthralgia,disorders Musculoskeletal Arthralgia Muscle,1,0.8256418704986572
IMBRUVICA,Headache,Headache Peripheral neuropat,1,0.7703162431716919
IMBRUVICA,Headache,Headache Peripheral,1,0.8324973583221436
IMBRUVICA,Decreased appetite,Metabolism and nutrition Decreased appetite,1,0.8800652623176575
IMBRUVICA,Second malignancies,Neoplasms benign malignant Second,1,0.8618299961090088
IMBRUVICA,Laceration,Laceration Psychiatric,1,0.8451105952262878
IMBRUVICA,Laceration,Injury poisoning and procedural complications,0,0.6373870968818665
IMBRUVICA,Laceration,Laceration Psychiatric disorders,1,0.7914389967918396
IMBRUVICA,Insomnia,ic disorders Insomnia Vascular disorder,1,0.7615060806274414
IMBRUVICA,Insomnia,Laceration Psychiatric disorders,1,0.4919769763946533
IMBRUVICA,Insomnia,Anxiety,0,0.5916969776153564
IMBRUVICA,Insomnia,ic disorders,0,0.5165057182312012
IMBRUVICA,Insomnia,Insomnia,1,1.0000001192092896
IMBRUVICA,Insomnia,Insomnia Vascular,1,0.822135329246521
IMBRUVICA,Hypertension,Hypertension,1,0.9999999403953552
IMBRUVICA,Hypertension,Insomnia,1,0.5306167602539062
IMBRUVICA,Hypertension,Hypertension Table TreatmentEmerge,1,0.8013037443161011
IMBRUVICA,Decrease of Hemoglobin,and adverse Decrease of Hemoglobin,1,0.957507312297821
IMBRUVICA,Decrease of Hemoglobin,Hypertension Table TreatmentEmerge,1,0.5722254514694214
IMBRUVICA,Decrease of Hemoglobin,Patients with CLL N in,0,0.513150691986084
IMBRUVICA,Decrease of Hemoglobin,Study IMBRUVICAN Ofatumu,0,0.5103222727775574
IMBRUVICA,Decrease of Hemoglobin,TreatmentEmergentBased on laboratory measurements per IWCLL criteria,0,0.5859559774398804
IMBRUVICA,Decrease of Hemoglobin,Decrease of Hemoglobin Platelets,1,0.9046369791030884
IMBRUVICA,neutropenia,trial,0,0.48924747109413147
IMBRUVICA,neutropenia,trial neutropenia,1,0.8706415891647339
IMBRUVICA,neutropenia,neutropenia thrombocytopenia diarrhea rash nausea muscle,1,0.7673919200897217
IMBRUVICA,neutropenia,the WM trial neutropenia thrombocytopenia diarrhea rash nausea muscle,1,0.7006762623786926
IMBRUVICA,neutropenia,neutropenia thrombocytopenia,1,0.8478608727455139
IMBRUVICA,neutropenia,muscle,0,0.4913818836212158
IMBRUVICA,thrombocytopenia,thrombocytopenia diarrhea rash nausea muscle spasms,1,0.7840927839279175
IMBRUVICA,thrombocytopenia,thrombocytopenia,1,0.9999998807907104
IMBRUVICA,thrombocytopenia,thrombocytopenia diarrhea rash nausea,1,0.8150012493133545
IMBRUVICA,thrombocytopenia,thrombocytopenia diarrhea,1,0.8459816575050354
IMBRUVICA,thrombocytopenia,of patients,0,0.5218892097473145
IMBRUVICA,thrombocytopenia,neutropenia,0,0.6994499564170837
IMBRUVICA,diarrhea,neutropenia diarrhea,1,0.7739923000335693
IMBRUVICA,diarrhea,neutropenia,0,0.538713276386261
IMBRUVICA,diarrhea,in the,0,0.5838408470153809
IMBRUVICA,diarrhea,diarrhea rash nausea muscle,1,0.7970095276832581
IMBRUVICA,diarrhea,in the W,0,0.537712574005127
IMBRUVICA,rash,rash nausea muscle spasms and,1,0.7777856588363647
IMBRUVICA,rash,trial were neutropenia thrombocytopenia rash nausea muscle spasms and,1,0.6872605085372925
IMBRUVICA,rash,rash nausea muscle,1,0.7917903065681458
IMBRUVICA,nausea,nausea,1,1.0
IMBRUVICA,nausea,nausea muscle spasms and fatigue,1,0.80047208070755
IMBRUVICA,nausea,reactions in the WM,0,0.5639667510986328
IMBRUVICA,nausea,thrombocytopenia diarrhea nausea,1,0.743679404258728
IMBRUVICA,nausea,muscle spasms and fatigue Six percent of patients receiving IMBRUVICA in the,0,0.5733702182769775
IMBRUVICA,nausea,nausea muscle spasms,1,0.7960348129272461
IMBRUVICA,nausea,rash,0,0.6423230171203613
IMBRUVICA,muscle spasms,rash muscle,1,0.7522758841514587
IMBRUVICA,muscle spasms,receiving IMBRUVICA,0,0.5327470302581787
IMBRUVICA,muscle spasms,muscle spasms and fatigue Six percent,1,0.8498932123184204
IMBRUVICA,muscle spasms,reactions,0,0.60328608751297
IMBRUVICA,fatigue,neutropenia thrombocytopenia diarrhea,0,0.5205497741699219
IMBRUVICA,Fatigue,Fatigue Musculoskeletal,1,0.845801591873169
IMBRUVICA,Fatigue,disorders and administrative site Fatigue,1,0.7148680686950684
IMBRUVICA,Fatigue,Musculoskeletal and connecti,0,0.568801999092102
IMBRUVICA,Fatigue,and administrative site Fatigue Musculoskeletal and connecti,1,0.7611657381057739
IMBRUVICA,Fatigue,disorders,0,0.5902048349380493
IMBRUVICA,Arthropathy,Arthropathy Infections and infesta,1,0.8252115249633789
IMBRUVICA,Arthropathy,disorders Muscle Arthropathy Infections,1,0.8290907740592957
IMBRUVICA,Arthropathy,disorders,0,0.6479846239089966
IMBRUVICA,Arthropathy,Arthropathy Infections,1,0.9082557559013367
IMBRUVICA,Arthropathy,tissue,0,0.5620085597038269
IMBRUVICA,Arthropathy,Muscle Arthropathy Infections and,1,0.8440576195716858
IMBRUVICA,Cough,Epistaxis,0,0.5342017412185669
IMBRUVICA,Cough,Nervous system,0,0.5376706719398499
IMBRUVICA,Cough,diastinal disorders Epistaxis,0,0.5638676285743713
IMBRUVICA,Cough,Cough Nervous system d,1,0.7808501720428467
IMBRUVICA,Cough,disorders Epistaxis,0,0.5129164457321167
IMBRUVICA,Cough,Nervous system d,0,0.5051591396331787
IMBRUVICA,Skin cancer,Neoplasms benign malignant and unspecified including cysts and polyps,0,0.6103502511978149
IMBRUVICA,Skin cancer,and Skin cancer,1,0.9211357831954956
IMBRUVICA,Skin cancer,Skin cancer Table TreatmentEmerg,1,0.7848315238952637
IMBRUVICA,Skin cancer,including cysts,0,0.6106813549995422
IMBRUVICA,Skin cancer,Skin cancer,1,1.000000238418579
IMBRUVICA,Decrease of Hemoglobin,WM N Perc,0,0.5010005831718445
IMBRUVICA,Hypersensitivity reactions,angioedema,0,0.6895657777786255
IMBRUVICA,Hypersensitivity reactions,to drug Hypersensitivity,1,0.8351714611053467
IMBRUVICA,anaphylactic shock,reactions anaphylactic shock fatal urticaria and,1,0.8677653670310974
IMBRUVICA,anaphylactic shock,to drug Hypersensitivity,1,0.6651824712753296
IMBRUVICA,anaphylactic shock,Hypersensitivity reactions anaphylactic,1,0.8707009553909302
IMBRUVICA,anaphylactic shock,establish a causal relationship to,0,0.43720895051956177
IMBRUVICA,anaphylactic shock,reactions anaphylactic shock fatal urticaria and angioedema,1,0.8552381992340088
IMBRUVICA,anaphylactic shock,drug exposure Hypersensitivity reactions,0,0.6687185764312744
IMBRUVICA,anaphylactic shock,Hypersensitivity reactions anaphylactic shock,1,0.9068956971168518
IMBRUVICA,anaphylactic shock,drug exposure Hypersensitivity reactions anaphylactic shock fatal urticaria and angioedema have,1,0.7805490493774414
IMBRUVICA,fatal,fatal urticaria and angioedema have been,1,0.6513923406600952
IMBRUVICA,fatal,fatal,1,1.0000001192092896
IMBRUVICA,fatal,and angioedema have been reported,0,0.508276104927063
IMBRUVICA,angioedema,angioedema,1,1.000000238418579
IMBRUVICA,angioedema,have,0,0.5197469592094421
IMBRUVICA,Hemorrhage,adverse,0,0.5697399377822876
IMBRUVICA,Hemorrhage,rea,0,0.5636887550354004
IMBRUVICA,Hemorrhage,ctions are discussed,1,0.5061236619949341
IMBRUVICA,Hemorrhage,labeling Hemorrhage see Warnings and Pr,0,0.7787182331085205
IMBRUVICA,Hemorrhage,ctions are discussed in more,1,0.5098187923431396
IMBRUVICA,Hemorrhage,in other sections of the,0,0.5178354382514954
IMBRUVICA,Hemorrhage,following adverse ctions are,1,0.5898667573928833
IMBRUVICA,Hemorrhage,adverse ctions,1,0.5880996584892273
IMBRUVICA,Hemorrhage,ctions are discussed in more detail,1,0.5014867186546326
IMBRUVICA,Infections,detail in other ions of th,1,0.5489722490310669
IMBRUVICA,Infections,ctions are discussed in more detail,1,0.5307012796401978
IMBRUVICA,Infections,other ions of th e labeling,1,0.5691220760345459
IMBRUVICA,Infections,Warnings and Precautions,0,0.6236244440078735
IMBRUVICA,Infections,in other ions of th e labeling Hemorrhage,1,0.5432404279708862
IMBRUVICA,Infections,ions of th,1,0.5487270355224609
IMBRUVICA,Atrial Fibrillation,Atrial Fibrillation see Warnings and,0,0.8473317623138428
IMBRUVICA,Atrial Fibrillation,Cytopenias ee Warnings,1,0.518681526184082
IMBRUVICA,Second Primary Malignancies,see and Precautions (5.4) ],1,0.47332245111465454
IMBRUVICA,Second Primary Malignancies,Fibrillation,0,0.5283726453781128
IMBRUVICA,Second Primary Malignancies,Atrial Fibrillation,0,0.5289084911346436
IMBRUVICA,Second Primary Malignancies,and Precautions Tumor Lysis,0,0.6226199865341187
IMBRUVICA,Second Primary Malignancies,Atrial Fibrillation see and Precautions,1,0.4850134551525116
IMBRUVICA,Second Primary Malignancies,see  and Precautions (5.4)  ]   Second Primary Malignancies see Warnings,1,0.8563394546508789
IMBRUVICA,Second Primary Malignancies,Fibrillation see  and Precautions (5.4)  ]   Second Primary Malignancies see Warnings,1,0.8046410083770752
IMBRUVICA,skin cancers,Precautions Second Primary Malignancies,0,0.6579223275184631
IMBRUVICA,skin cancers,Warnings and Precautions,0,0.5204447507858276
IMBRUVICA,skin cancers,and tions (5.5),1,0.4678582549095154
IMBRUVICA,skin cancers,tions (5.5) Tumor Lysis Syndrome,1,0.5486570596694946
IMBRUVICA,skin cancers,tions (5.5) Tumor Lysis Syndrome see,1,0.5498659610748291
IMBRUVICA,skin cancers,Warnings and tions (5.5)  Tumor Lysis Syndrome see,1,0.5575432777404785
IMBRUVICA,skin cancers,Warnings and tions (5.5)  Tumor,1,0.6275634765625
IMBRUVICA,skin cancers,tions (5.5) Tumor,1,0.6368722319602966
IMBRUVICA,skin cancers,Tumor Lysis Syndrome,0,0.5709800720214844
IMBRUVICA,Tumor Lysis Syndrome,nings and Precaution s Because clinical trials are,1,0.5252751111984253
IMBRUVICA,Tumor Lysis Syndrome,see nings and Precaution s Because clinical trials,1,0.5344740152359009
IMBRUVICA,Tumor Lysis Syndrome,see nings and Precaution s Because clinical,1,0.5146030187606812
IMBRUVICA,TLS,and,0,0.5326210260391235
IMBRUVICA,TLS,adverse,0,0.5125336647033691
IMBRUVICA,TLS,and (5. Because,1,0.47004708647727966
IMBRUVICA,TLS,(5.,1,0.4867384433746338
IMBRUVICA,fetal harm,ed in clin,1,0.5559127330780029
IMBRUVICA,fetal harm,(5.,1,0.45999765396118164
IMBRUVICA,fetal harm,under widely variable conditions adverse event rates,0,0.559792160987854
IMBRUVICA,fetal harm,be directly compared with rates of clinical trials of,0,0.49461978673934937
IMBRUVICA,Fatal, prac tice EXCERPT The most common,1,0.5103341341018677
IMBRUVICA,Fatal,observed  prac tice EXCERPT The most,1,0.5124390125274658
IMBRUVICA,Fatal, prac tice EXCERPT,1,0.49696841835975647
IMBRUVICA,Fatal,drug and may not reflect,0,0.47212308645248413
IMBRUVICA,Fatal,The most common adverse reactions in patients,0,0.5443100333213806
IMBRUVICA,Fatal, prac tice EXCERPT The most,1,0.4920131266117096
IMBRUVICA,Fatal,reflect the rates observed  prac tice EXCERPT The,1,0.47495752573013306
IMBRUVICA,bleeding events,and may not reflect the rates observed in pract,0,0.5416698455810547
IMBRUVICA,bleeding events,"the rates observed in ice.
 

   EXCE RPT The most",1,0.5750564336776733
IMBRUVICA,bleeding events,in ice. EXCE,1,0.5613471269607544
IMBRUVICA,bleeding events,in patients with ell malignancie,1,0.5428744554519653
IMBRUVICA,bleeding events,WM,0,0.4702455401420593
IMBRUVICA,bleeding events,CLL WM were thrombocytopenia,0,0.6013246178627014
IMBRUVICA,bleeding events,anemia,0,0.5746582746505737
IMBRUVICA,subdural hematoma,"Bcell (MCL,",1,0.4444013833999634
IMBRUVICA,subdural hematoma,"patients with Bcell (MCL, CLL, WM) we",1,0.44918280839920044
IMBRUVICA,subdural hematoma,pain bruising nausea,0,0.5330801010131836
IMBRUVICA,subdural hematoma,WM) we re thrombocytopenia neutropenia diarrhea,1,0.5288399457931519
IMBRUVICA,subdural hematoma,EXCERPT The most,0,0.4385048449039459
IMBRUVICA,subdural hematoma,in,0,0.5071010589599609
IMBRUVICA,gastrointestinal bleeding,"MCL CLL WM thrombocytopenia,",1,0.5732620358467102
IMBRUVICA,gastrointestinal bleeding,"thrombocytopenia, neutro penia diarrhea anemia",1,0.6873278617858887
IMBRUVICA,gastrointestinal bleeding,"thrombocytopenia, neutro penia diarrhea",1,0.693722665309906
IMBRUVICA,gastrointestinal bleeding,were,0,0.4880180358886719
IMBRUVICA,hematuria,musculoskeletal pain bruising,0,0.48855555057525635
IMBRUVICA,hematuria,"were thrombocytopenia nia, diar",1,0.5575516223907471
IMBRUVICA,post procedural hemorrhage,"fatigue, musculos keletal pain bruising nausea upper",1,0.5559670925140381
IMBRUVICA,post procedural hemorrhage,malignancies MCL CLL WM were,0,0.47097069025039673
IMBRUVICA,Bleeding,pain bruising nausea upper piratory tract,1,0.6932367086410522
IMBRUVICA,Bleeding,malignancies MCL CLL WM were,0,0.49926847219467163
IMBRUVICA,Bleeding,REACTIONS contact,0,0.5237553715705872
IMBRUVICA,Bleeding,piratory tract infection,1,0.5298553705215454
IMBRUVICA,Bleeding,upper,0,0.4997900128364563
IMBRUVICA,Bleeding,upper piratory,1,0.49045971035957336
IMBRUVICA,Bleeding,fatigue musculoskeletal,0,0.50398188829422
IMBRUVICA,Bleeding,upper res,0,0.5113894939422607
IMBRUVICA,Bleeding,piratory tract infection and rash To,1,0.510413408279419
IMBRUVICA,bruising,tract infection and   To rep ort SUSPECTED ADVERSE REACTIONS,1,0.5056262612342834
IMBRUVICA,bruising,piratory tract infection and rash To,1,0.5789295434951782
IMBRUVICA,bruising,ort SUSPECTED ADVERSE REACTIONS contact,0,0.5901010036468506
IMBRUVICA,bruising,Pharmacyclics at or FDA,0,0.47096899151802063
IMBRUVICA,bruising,infection and   To rep ort,1,0.5887047648429871
IMBRUVICA,bruising,REACTIONS contact,0,0.5974489450454712
IMBRUVICA,petechiae,To report USPECTED  ADVERSE REACTIONS contact Pharmacyclics at,1,0.5305734872817993
IMBRUVICA,petechiae,REACTIONS contact,0,0.5283793210983276
IMBRUVICA,hemorrhage,"Mantle Cell ma  



 T he data",1,0.5220704078674316
IMBRUVICA,hemorrhage,REACTIONS contact,0,0.5227738618850708
IMBRUVICA,hemorrhage,ma T he data described below,1,0.5010563731193542
IMBRUVICA,hemorrhage,Experience Mantle Cell ma,1,0.508026123046875
IMBRUVICA,hemorrhage,IMBRUVICA in a clinical trial that,0,0.5382378101348877
IMBRUVICA,hemorrhage,ma T he data described,1,0.4882810711860657
IMBRUVICA,hemorrhage,clinical trial,0,0.5561789274215698
IMBRUVICA,hemorrhage,"Cell ma  



 T he data described below",1,0.5235382318496704
IMBRUVICA,hemorrhage,in a clinical trial that included patients,0,0.5247851610183716
IMBRUVICA,hemorrhage,a clinical trial that included,0,0.5504412651062012
IMBRUVICA,hemorrhage,exposure,0,0.5703436136245728
IMBRUVICA,Fatal,iarrh ea,1,0.49203360080718994
IMBRUVICA,Fatal,upper respiratory,0,0.4877685308456421
IMBRUVICA,Fatal,months The most commonly occurring adverse reactions were thrombocytopenia,0,0.5329216718673706
IMBRUVICA,Fatal,iarrh ea neutropenia anemia fatigue,1,0.4697515368461609
IMBRUVICA,Fatal,The most commonly,0,0.49979913234710693
IMBRUVICA,Fatal,edema upper respiratory tract in,0,0.5050067901611328
IMBRUVICA,Fatal,anemia fatigue musculoskeletal pain peripheral edema upper,0,0.48979300260543823
IMBRUVICA,Fatal,thrombocytopenia iarrh ea neutropenia anemia fatigue musculoskeletal,1,0.49674469232559204
IMBRUVICA,infections,"thrombocytopenia diarrhea , anemia,  fatigue musculoskeletal pain peripheral edema",1,0.6312953233718872
IMBRUVICA,infections,anemia fatigue musculoskeletal pain peripheral edema upper,0,0.5720020532608032
IMBRUVICA,infections,"were thrombocytopenia diarrhea , anemia,  fatigue",1,0.6292739510536194
IMBRUVICA,infections,commonly occurring adverse reactions,0,0.5929093360900879
IMBRUVICA,infections,", anemia,  fatigue musculoskeletal",1,0.5773874521255493
IMBRUVICA,infections,"diarrhea , anemia,  fatigue musculoskeletal",1,0.6427009105682373
IMBRUVICA,infections,occurring adverse reactions,0,0.5991991758346558
IMBRUVICA,infections,"diarrhea , anemia,  fatigue",1,0.6365604996681213
IMBRUVICA,infections,"were thrombocytopenia diarrhea ,",1,0.603847324848175
IMBRUVICA,infections,edema upper respiratory,0,0.5307167172431946
IMBRUVICA,infections,diarrhea,0,0.6685535907745361
IMBRUVICA,infections,neutropenia anemia,0,0.574957013130188
IMBRUVICA,infections,cytopenia diarrhea neutropenia anemia fatigue musculoskeletal pain peripheral,0,0.6407817602157593
IMBRUVICA,infections,bruising dyspnea constipation rash abdominal,0,0.5747866630554199
IMBRUVICA,PML,rash abdominal pain vomiting and decreased appetite,0,0.5129958391189575
IMBRUVICA,PML,most common Grade or nonhematological adverse reactions were,0,0.4922682046890259
IMBRUVICA,PML, an d The most common Grade,1,0.49293631315231323
IMBRUVICA,PML,decreased appetite see  an d The most common Grade,1,0.534583330154419
IMBRUVICA,cytopenias,"fatigue and skin s.



 Fat",1,0.535171389579773
IMBRUVICA,cytopenias, an d The most common Grade,1,0.4579591751098633
IMBRUVICA,cytopenias,s. Fat al and,1,0.39251694083213806
IMBRUVICA,cytopenias,"and skin s.



 Fat al and",1,0.4444841146469116
IMBRUVICA,cytopenias,s.,1,0.4964423179626465
IMBRUVICA,cytopenias,"fatigue and skin s.



 Fat al and serious cases of",1,0.5538985729217529
IMBRUVICA,cytopenias,IMBRUVICA therapy Increases,0,0.5300270318984985
IMBRUVICA,cytopenias,pain atrial fibrillation diarrhea fatigue and skin,0,0.5764541625976562
IMBRUVICA,cytopenias,"diarrhea fatigue and skin s.



 Fat al and serious cases",1,0.531442403793335
IMBRUVICA,cytopenias,fatigue and skin s. Fat,1,0.535171389579773
IMBRUVICA,cytopenias,"diarrhea fatigue and skin s.



 Fat al",1,0.5204563140869141
IMBRUVICA,neutropenia,and ous cases,1,0.5054327249526978
IMBRUVICA,neutropenia,in creatinine to times the upp,0,0.5088958144187927
IMBRUVICA,neutropenia,infections Fatal and ous,1,0.5646272897720337
IMBRUVICA,neutropenia,ous cases,1,0.4966263771057129
IMBRUVICA,neutropenia,ous cases o,1,0.48800909519195557
IMBRUVICA,neutropenia,Fatal and seri,0,0.4613495469093323
IMBRUVICA,neutropenia,IMBRUVICA therapy Increases in creatinine to times the,0,0.5129960179328918
IMBRUVICA,neutropenia,Fatal and ous,1,0.46680915355682373
IMBRUVICA,anemia,to times the upper limit of,0,0.50977623462677
IMBRUVICA,anemia,times the upper limit of normal occurred in of patients,0,0.5363883376121521
IMBRUVICA,anemia,es in creatinine to times,1,0.6086133122444153
IMBRUVICA,anemia,es in creatinine,1,0.6288203597068787
IMBRUVICA,Atrial fibrillation,using agent IMBRUVICA 560 mg daily occurring at a,1,0.5310717225074768
IMBRUVICA,Atrial fibrillation,es in creatinine,1,0.5333240628242493
IMBRUVICA,Atrial fibrillation,trial N using agent IMBRUVICA 560 mg daily occurring at a,1,0.5466599464416504
IMBRUVICA,Atrial fibrillation,occurred in of patients Adverse reactions from the MCL trial N,0,0.511920154094696
IMBRUVICA,Atrial fibrillation,IMBRUVICA 560,1,0.4809904098510742
IMBRUVICA,Atrial fibrillation,MCL trial N using agent IMBRUVICA 560,1,0.5143194198608398
IMBRUVICA,Atrial fibrillation,agent IMBRUVICA 560 mg,1,0.493524968624115
IMBRUVICA,Atrial fibrillation,MCL trial N using agent,1,0.5291571617126465
IMBRUVICA,atrial flutter,IMBRUVICA mg aily occurring,1,0.5055528879165649
IMBRUVICA,atrial flutter,agent IMBRUVICA mg aily occurring,1,0.4806686043739319
IMBRUVICA,atrial flutter,Table Table NonHematologic Adverse Reactions,0,0.5308935642242432
IMBRUVICA,atrial flutter,aily occurring,1,0.5771998167037964
IMBRUVICA,atrial flutter,IMBRUVICA mg aily occurring at a,1,0.5267359614372253
IMBRUVICA,Reduced fetal weights,administrative site conditions,0,0.4380072057247162
IMBRUVICA,Reduced fetal weights,conditions,0,0.5141657590866089
DUREZOL,elevated intraocular pressure,ophthalmic steroids elevated intraocular pressure which may be associated with,1,0.8422485589981079
DUREZOL,elevated intraocular pressure,conditions,0,0.5283951759338379
DUREZOL,elevated intraocular pressure,elevated intraocular,1,0.9322293996810913
DUREZOL,elevated intraocular pressure,steroids elevated intraocular pressure which may be associated,1,0.8377400040626526
DUREZOL,elevated intraocular pressure,with ophthalmic steroids elevated intraocular pressure which may be associated,1,0.8382887840270996
DUREZOL,elevated intraocular pressure,associated with ophthalmic steroids elevated,1,0.7526425123214722
DUREZOL,elevated intraocular pressure,elevated intraocular pressure,1,1.0
DUREZOL,optic nerve damage,cataract formation,0,0.5723375678062439
DUREZOL,optic nerve damage,associated,0,0.4709460139274597
DUREZOL,optic nerve damage,posterior,0,0.5657026171684265
DUREZOL,optic nerve damage,may be associated optic nerve damage visual acuity,1,0.8705223798751831
DUREZOL,optic nerve damage,secondary,0,0.4570178687572479
DUREZOL,posterior subcapsular cataract formation,posterior subcapsular cataract formation secondary,1,0.9532068371772766
DUREZOL,posterior subcapsular cataract formation,acuity and field posterior subcapsular cataract formation secondary,1,0.906427264213562
DUREZOL,secondary ocular infection,optic nerve damage visual acuity and field defects posterior,0,0.6125348806381226
DUREZOL,secondary ocular infection,defects posterior subcapsular cataract secondary,1,0.709621787071228
DUREZOL,secondary ocular infection,ocular infection from,1,0.8691461086273193
DUREZOL,secondary ocular infection,subcapsular cataract secondary ocular infection,1,0.86701899766922
DUREZOL,secondary ocular infection,subcapsular cataract formation,0,0.6297106742858887
DUREZOL,perforation of the globe,pathogens including herpes,0,0.4969232678413391
DUREZOL,perforation of the globe,cataract,0,0.6041337251663208
DUREZOL,perforation of the globe,including herpes simplex perforation of the globe,1,0.8209140300750732
DUREZOL,Ocular adverse reactions,Ocular adverse reactions occurring in,1,0.9772754311561584
DUREZOL,Ocular adverse reactions,cornea or sclera Ocular Ocular adverse reactions,1,0.8865092992782593
DUREZOL,Ocular adverse reactions,the cornea or sclera Ocular,0,0.6908278465270996
DUREZOL,Ocular adverse reactions,adverse reactions occurring in of,1,0.8157317638397217
DUREZOL,Ocular adverse reactions,Surgery,0,0.4980699419975281
DUREZOL,Ocular adverse reactions,Ocular Ocular adverse reactions,1,0.992861270904541
DUREZOL,Ocular adverse reactions,Ocular adverse reactions occurring in of,1,0.9586419463157654
DUREZOL,Ocular adverse reactions,cornea or sclera,0,0.647270679473877
DUREZOL,corneal edema,hyperemia eye pain,0,0.6827684640884399
DUREZOL,corneal edema,studies with DUREZOL corneal edema ciliary,1,0.8018894195556641
DUREZOL,corneal edema,corneal edema,1,0.9999999403953552
DUREZOL,corneal edema,and conjunctival hyperemia eye pain photophobia,0,0.6751424670219421
DUREZOL,conjunctival hyperemia,edema ciliary conjunctival hyperemia eye pain photophobia,1,0.8192195892333984
DUREZOL,conjunctival hyperemia,and conjunctival hyperemia eye pain photophobia,0,0.8757150769233704
DUREZOL,conjunctival hyperemia,corneal edema ciliary conjunctival hyperemia,1,0.9041349291801453
DUREZOL,conjunctival hyperemia,anterior chamber cells anterior,0,0.5725957155227661
DUREZOL,conjunctival hyperemia,edema ciliary conjunctival hyperemia,1,0.9158274531364441
DUREZOL,conjunctival hyperemia,conjunctival hyperemia eye pain photophobia,1,0.8863982558250427
DUREZOL,conjunctival hyperemia,conjunctival hyperemia eye pain,1,0.9128011465072632
DUREZOL,conjunctival hyperemia,included corneal edema ciliary conjunctival,1,0.7563999891281128
DUREZOL,eye pain,eye pain photophobia posterior capsule opacification anterior,1,0.7886993885040283
DUREZOL,eye pain,corneal edema ciliary and,0,0.665740430355072
DUREZOL,eye pain,hyperemia,0,0.4545831084251404
DUREZOL,eye pain,anterior chamber cells,0,0.6129227876663208
DUREZOL,photophobia,opacification anterior chamber cells anterior chamber flare,0,0.5741835832595825
DUREZOL,photophobia,conjunctival hyperemia eye photophobia posterior capsule opacification anterior chamber,1,0.7472500801086426
DUREZOL,photophobia,photophobia,1,0.9999998807907104
DUREZOL,photophobia,studies with DUREZOL included corneal edema,0,0.5465508103370667
DUREZOL,photophobia,photophobia posterior capsule,1,0.8376007080078125
DUREZOL,photophobia,and conjunctival hyperemia eye photophobia posterior capsule opacification anterior chamber,1,0.7574076056480408
DUREZOL,posterior capsule opacification,eye pain posterior,1,0.6727100014686584
DUREZOL,posterior capsule opacification,anterior chamber cells anterior chamber flare conjunctival edema and blepharitis Other,0,0.6519951820373535
DUREZOL,anterior chamber cells,conjunctival hyperemia eye pain photophobia,0,0.568943977355957
DUREZOL,anterior chamber flare,adverse,0,0.5794371366500854
DUREZOL,anterior chamber flare,unctival hyperemia eye pain photophobia posterior capsule opacification,0,0.6951806545257568
DUREZOL,anterior chamber flare,chamber cells,0,0.6180479526519775
DUREZOL,anterior chamber flare,anterior chamber anterior chamber flare,1,0.9879242777824402
DUREZOL,anterior chamber flare,reactions occurring in of subjects,0,0.5590806603431702
DUREZOL,anterior chamber flare,chamber flare,1,0.7991534471511841
DUREZOL,anterior chamber flare,chamber anterior chamber flare,1,0.978009045124054
DUREZOL,conjunctival edema,anterior chamber conjunctival edema and blepharitis,1,0.8898281455039978
DUREZOL,conjunctival edema,reactions occurring in of subjects,0,0.5027655363082886
DUREZOL,conjunctival edema,occurring in of,0,0.5532205104827881
DUREZOL,blepharitis,blepharitis Other,1,0.9123433828353882
DUREZOL,blepharitis,blepharitis Other ocular adverse reactions,1,0.8388128280639648
DUREZOL,blepharitis,chamber,0,0.5026853084564209
DUREZOL,blepharitis,blepharitis,1,0.9999998211860657
DUREZOL,reduced visual acuity,and blepharitis Other ocular adverse reactions occurring in of,0,0.616750955581665
DUREZOL,reduced visual acuity,blepharitis Other ocular adverse reactions occurring in of,0,0.6117715835571289
DUREZOL,reduced visual acuity,subjects reduced visual acuity punctate keratitis,1,0.8073427677154541
DUREZOL,punctate keratitis,inflammation,0,0.5629711151123047
DUREZOL,punctate keratitis,included reduced visual punctate keratitis,1,0.8807655572891235
DUREZOL,punctate keratitis,adverse reactions occurring in of subjects included app,0,0.5228374004364014
DUREZOL,punctate keratitis,subjects included reduced visual punctate keratitis eye inflammation and,1,0.8345421552658081
DUREZOL,punctate keratitis,punctate keratitis eye inflammation and iritis,1,0.9158315658569336
DUREZOL,punctate keratitis,subjects included reduced visual punctate keratitis,1,0.8525592088699341
DUREZOL,punctate keratitis,punctate keratitis eye inflammation and iritis Ocular,1,0.9091929197311401
DUREZOL,eye inflammation,acuity punctate eye inflammation,1,0.8273285627365112
DUREZOL,eye inflammation,eye inflammation and iritis Ocular adverse reactions,1,0.8381871581077576
DUREZOL,eye inflammation,punctate eye inflammation,1,0.8771904110908508
DUREZOL,eye inflammation,subjects included,0,0.4856739640235901
DUREZOL,eye inflammation,in of subjects included reduced visual acuity punctate keratitis,0,0.6866034269332886
DUREZOL,eye inflammation,of subjects included application,0,0.45527970790863037
DUREZOL,eye inflammation,eye inflammation and iritis Ocular,1,0.8808671236038208
DUREZOL,eye inflammation,visual acuity punctate eye inflammation,1,0.8291161060333252
DUREZOL,eye inflammation,acuity punctate eye inflammation and iritis Ocular adverse,1,0.7757428884506226
DUREZOL,iritis,iritis Ocular adverse reactions occurring in,1,0.8558986186981201
DUREZOL,iritis,in of subjects included reduced,0,0.5222916007041931
DUREZOL,iritis,iritis Ocular adverse reactions,1,0.8532791137695312
DUREZOL,application site discomfort,of subjects application site discomfort or,1,0.9360650777816772
DUREZOL,application site discomfort,iritis Ocular adverse reactions,1,0.5452187061309814
DUREZOL,application site discomfort,irritation and c,0,0.6441843509674072
DUREZOL,application site discomfort,subjects application site discomfort or irritation,1,0.8675763010978699
DUREZOL,application site discomfort,in of subjects application,1,0.6264427900314331
DUREZOL,application site discomfort,site discomfort,1,0.8804333209991455
DUREZOL,application site discomfort,in of subjects application site discomfort or irritation corneal,1,0.7691259384155273
DUREZOL,application site discomfort,site discomfort or irritation corneal,1,0.7312283515930176
DUREZOL,application site discomfort,and striae episcleritis eye pruritis eyelid irritation and c,0,0.6052870750427246
DUREZOL,corneal pigmentation,discomfort or corneal pigmentation,1,0.8826314210891724
DUREZOL,corneal pigmentation,corneal pigmentation and striae episcleritis,1,0.8495837450027466
DUREZOL,corneal pigmentation,corneal pigmentation and striae episcleritis eye,1,0.8368926048278809
DUREZOL,corneal pigmentation,discomfort or corneal,1,0.7381175756454468
DUREZOL,corneal pigmentation,or corneal,1,0.780860185623169
DUREZOL,corneal pigmentation,corneal pigmentation,1,1.0000001192092896
DUREZOL,corneal pigmentation,discomfort or corneal pigmentation and,1,0.882866382598877
DUREZOL,episcleritis,corneal pigmentation,0,0.5013836026191711
DUREZOL,episcleritis,corneal pigmentation and episcleritis,1,0.8056296706199646
DUREZOL,eye pruritis,irritation corneal pigmentation and,0,0.7080098390579224
DUREZOL,eye pruritis,eye pruritis eyelid,1,0.9344065189361572
DUREZOL,eye pruritis,pigmentation and striae eye pruritis eyelid irritation and crusting,1,0.8403592705726624
DUREZOL,eye pruritis,corneal pigmentation and striae eye pruritis eyelid irritation and crusting,1,0.8175934553146362
DUREZOL,eye pruritis,increased lacrimation macular edema scle,0,0.6878156661987305
DUREZOL,eye pruritis,and crusting foreign body sensation,0,0.6045418977737427
DUREZOL,eyelid irritation,eyelid irritation and crusting foreign body,1,0.876759946346283
DUREZOL,eyelid irritation,striae episcleritis eye eyelid irritation,1,0.8598573207855225
DUREZOL,foreign body sensation,these,0,0.5494247078895569
DUREZOL,foreign body sensation,and foreign body,1,0.8229202032089233
DUREZOL,foreign body sensation,foreign,1,0.5499774813652039
DUREZOL,foreign body sensation,pruritis eyelid irritation and foreign body,1,0.7124784588813782
DUREZOL,foreign body sensation,body sensation increased lacrimation macular edema sclera,1,0.6498979330062866
DUREZOL,foreign body sensation,macular edema sclera hyperemia and uveitis Most of these reactions,0,0.5323247909545898
DUREZOL,foreign body sensation,body sensation increased lacrimation macular edema,1,0.6615288257598877
DUREZOL,foreign body sensation,uveitis Most of these reactions,0,0.5360847115516663
DUREZOL,increased lacrimation,body increased lacrimation macular edema sclera hyperemia and,1,0.8395717740058899
DUREZOL,increased lacrimation,uveitis Most of these reactions,0,0.6716787219047546
DUREZOL,increased lacrimation,foreign body increased,1,0.6356898546218872
DUREZOL,increased lacrimation,increased lacrimation macular edema,1,0.8752351999282837
DUREZOL,increased lacrimation,these,0,0.5340912342071533
DUREZOL,increased lacrimation,been,0,0.5377926826477051
DUREZOL,increased lacrimation,increased lacrimation macular,1,0.8968187570571899
DUREZOL,increased lacrimation,and crusting foreign body increased lacrimation macular edema sclera hyperemia,1,0.7775405645370483
DUREZOL,increased lacrimation,increased lacrimation,1,1.0
DUREZOL,macular edema,foreign body sensation increased macular edema,1,0.8373991250991821
DUREZOL,macular edema,of these reactions may have,0,0.5049325823783875
DUREZOL,sclera hyperemia,Most of these reactions may have been,0,0.4715009331703186
DUREZOL,sclera hyperemia,sclera hyperemia and uveitis Most of these,1,0.9103960990905762
DUREZOL,sclera hyperemia,sclera,1,0.8100153803825378
DUREZOL,sclera hyperemia,increased lacrimation macular sclera,1,0.7571842670440674
DUREZOL,sclera hyperemia,reactions may have been the consequence of the surgical procedure,0,0.5362821817398071
DUREZOL,sclera hyperemia,sclera hyperemia,1,1.0
DUREZOL,uveitis,Most of these reactions may have been the consequence,0,0.44773879647254944
DUREZOL,uveitis,uveitis Most of these,1,0.8987388014793396
DUREZOL,uveitis,have been,0,0.4854620099067688
DUREZOL,uveitis,sclera hyperemia,0,0.6367027759552002
DUREZOL,uveitis,uveitis Most of these reactions may,1,0.8237355351448059
DUREZOL,blurred vision,eye pain headache increased IOP iritis limbal and conjunctival hyperemia punc,0,0.6451996564865112
DUREZOL,blurred vision,of subjects,0,0.4951523542404175
DUREZOL,eye irritation,eye irritation eye pain,1,0.9382297992706299
DUREZOL,eye irritation,included blurred eye irritation,1,0.8596063852310181
DUREZOL,eye irritation,eye irritation,1,1.0
DUREZOL,eye irritation,increased IOP iritis limbal and conjunctival,0,0.7481957077980042
DUREZOL,eye irritation,and conjunctival,0,0.7323850989341736
DUREZOL,eye irritation,limbal and,0,0.7118542790412903
DUREZOL,eye irritation,of subjects included blurred eye,1,0.6423686146736145
DUREZOL,eye pain,vision eye eye,1,0.6882858276367188
DUREZOL,eye pain,to,0,0.4964051842689514
DUREZOL,eye pain,eye pain headache increased,1,0.8602548241615295
DUREZOL,eye pain,eye pain headache increased IOP,1,0.8423512578010559
DUREZOL,eye pain,eye pain headache increased IOP iritis limbal,1,0.8132596611976624
DUREZOL,eye pain,occurring in of subjects included blurred vision,0,0.6277519464492798
DUREZOL,eye pain,vision eye eye pain,1,0.9385443329811096
DUREZOL,headache,blurred vision eye irritation eye pain,0,0.6882595419883728
DUREZOL,headache,headache increased IOP iritis,1,0.7509878873825073
DUREZOL,headache,headache increased IOP iritis limbal and,1,0.7649714946746826
DUREZOL,headache,headache increased IOP,1,0.7622277140617371
DUREZOL,headache,eye irritation eye headache,1,0.8118847608566284
DUREZOL,headache,and uveitis,0,0.5821352601051331
DUREZOL,headache,keratitis and uveitis,0,0.5384421944618225
DUREZOL,headache,in of subjects included blurred,0,0.5305994749069214
DUREZOL,increased IOP,DUREZOL occurring in of,0,0.553855299949646
DUREZOL,increased IOP,increased IOP iritis,1,0.8840445280075073
DUREZOL,increased IOP,conjunctival hyperemia punctate,0,0.7074066996574402
DUREZOL,iritis,IOP,0,0.7232249975204468
DUREZOL,iritis,conjunctival hyperemia punctate keratitis and uveitis Adverse,0,0.648364245891571
DUREZOL,iritis,blurred vision eye irritation,0,0.6983675360679626
DUREZOL,iritis,uveitis Adverse reactions occurring,0,0.6679655313491821
DUREZOL,conjunctival hyperemia,increased IOP iritis limbal conjunctival hyperemia punctate keratitis and,1,0.8253217935562134
DUREZOL,conjunctival hyperemia,uveitis Adverse reactions occurring,0,0.6364946365356445
DUREZOL,conjunctival hyperemia,iritis limbal conjunctival,1,0.7179735898971558
DUREZOL,conjunctival hyperemia,IOP iritis limbal conjunctival hyperemia,1,0.8897767066955566
DUREZOL,conjunctival hyperemia,iritis limbal conjunctival hyperemia punctate keratitis and,1,0.8557529449462891
DUREZOL,conjunctival hyperemia,keratitis and uveitis Adverse,0,0.6452376842498779
DUREZOL,conjunctival hyperemia,limbal conjunctival hyperemia,1,0.9592087864875793
DUREZOL,conjunctival hyperemia,eye irritation eye,0,0.657855749130249
DUREZOL,punctate keratitis,subjects included anterior chamber flare,0,0.659640908241272
DUREZOL,punctate keratitis,conjunctival punctate,1,0.8441647291183472
DUREZOL,uveitis,uveitis,1,1.0
DUREZOL,uveitis,IOP,0,0.6634754538536072
DUREZOL,uveitis,keratitis uveitis Adverse,1,0.8283693194389343
DUREZOL,uveitis,uveitis Adverse reactions occurring in of,1,0.8332409858703613
DUREZOL,uveitis,e pain headache increased IOP iritis limbal and conjunctival hyperemia punctate,0,0.6614837646484375
DUREZOL,uveitis,reactions occurring in of subjects included anterior chamber flare corneal edema d,0,0.6787049174308777
DUREZOL,uveitis,uveitis Adverse,1,0.8741347193717957
DUREZOL,corneal edema,included anterior chamber corneal edema dry,1,0.8526679277420044
DUREZOL,corneal edema,uveitis Adverse,1,0.6266601085662842
DUREZOL,corneal edema,occurring in of subjects included anterior chamber flare,0,0.6557697653770447
DUREZOL,corneal edema,eye iridocyclitis photophobia and reduced,0,0.5860238075256348
DUREZOL,corneal edema,flare,0,0.5298420786857605
DUREZOL,dry eye,chamber flare corneal dry eye,1,0.7984042167663574
DUREZOL,dry eye,flare corneal dry eye,1,0.8220701217651367
DUREZOL,dry eye,anterior chamber flare corneal dry eye iridocyclitis,1,0.7603622674942017
DUREZOL,dry eye,anterior chamber flare corneal dry eye,1,0.8046191930770874
DUREZOL,dry eye,and reduced visual acuity,0,0.5900285243988037
DUREZOL,photophobia,eye photophobia and reduced visual,1,0.869211733341217
DUREZOL,photophobia,and reduced visual acuity,0,0.6395099759101868
DUREZOL,photophobia,eye,0,0.5853936076164246
DUREZOL,glaucoma,ciated w ith optic nerve damage,1,0.7425297498703003
DUREZOL,glaucoma,ciated w,1,0.5230178833007812
DUREZOL,glaucoma,pressure which may be ciated w,1,0.5754967927932739
DUREZOL,glaucoma,ciated w ith optic nerve,1,0.758965015411377
DUREZOL,damage to the optic nerve,"associated with tic nerve damage, visual  acuity and field defects posterior",1,0.7432849407196045
DUREZOL,damage to the optic nerve,ciated w ith optic nerve,1,0.8844483494758606
DUREZOL,damage to the optic nerve,"may be associated with tic nerve damage, visual",1,0.7081958055496216
DUREZOL,damage to the optic nerve,"may be associated with tic nerve damage,",1,0.6290074586868286
DUREZOL,damage to the optic nerve,"tic nerve damage,",1,0.692780077457428
DUREZOL,damage to the optic nerve,secondary ocular,0,0.6417098045349121
DUREZOL,damage to the optic nerve,"tic nerve damage, visual",1,0.7557001113891602
DUREZOL,damage to the optic nerve,"tic nerve damage, visual  acuity and",1,0.7794255614280701
DUREZOL,defects in visual acuity,cataract formation secondary ocular infection,0,0.6225755214691162
DUREZOL,defects in visual acuity,"optic nerve damage visual uity and field defects,  posterior",1,0.7948541641235352
DUREZOL,defects in visual acuity,"and field defects, posterior subcapsular cataract",1,0.7089164853096008
DUREZOL,posterior subcapsular cataract,or sclera. 6.1 O cular Surgery Ocular,1,0.6216697692871094
DUREZOL,posterior subcapsular cataract,"of  cornea or sclera.



   6.1 O cular Surgery",1,0.6201731562614441
DUREZOL,posterior subcapsular cataract,where there is thinning,0,0.5054835081100464
DUREZOL,posterior subcapsular cataract,"thinning of  cornea or sclera.



   6.1 O cular Surgery Ocular",1,0.5904473066329956
DUREZOL,posterior subcapsular cataract,of cornea or sclera. 6.1 O,1,0.6368452310562134
DUREZOL,posterior subcapsular cataract,sclera. 6.1 O cular Surgery Ocular adverse reactions,1,0.6003625392913818
DUREZOL,posterior subcapsular cataract,adverse reactions occurring in of,0,0.5332284569740295
DUREZOL,delay healing,adverse,0,0.5795764923095703
DUREZOL,delay healing,in clinical studies h DUREZOL,1,0.5458449125289917
DUREZOL,secondary ocular infections,Most of these reactions may have been,0,0.4745860695838928
DUREZOL,secondary ocular infections,"foreign body sensation creased lacrimation, macula",1,0.6782689094543457
DUREZOL,secondary ocular infections,"sensation creased lacrimation, macula r edema sclera hyperemia and",1,0.6380133032798767
DUREZOL,secondary ocular infections,and striae episcleritis eye pruritis eyelid irritation and crusting foreign body sensation in,0,0.701532781124115
DUREZOL,secondary ocular infections,"body sensation creased lacrimation, macula r",1,0.6218925714492798
DUREZOL,secondary ocular infections,"body sensation creased lacrimation, macula",1,0.6235629320144653
DUREZOL,secondary ocular infections,edema sclera hyperemia and uveitis Most of these reactions may have been the,0,0.6335223913192749
DUREZOL,Fungal infections of the cornea,punctate and uveitis. Adverse reaction,1,0.6637059450149536
DUREZOL,Fungal infections of the cornea,conjunctival hyperemia punctate  and uveitis.  Adverse reaction s occurring,1,0.6418248414993286
DUREZOL,Fungal infections of the cornea,eye pain headache increased IOP,0,0.6099088191986084
ZYKADIA,Gastrointestinal Toxicity,see Warnings and Precautions Hepatotoxicity,0,0.7142537236213684
ZYKADIA,Gastrointestinal Toxicity,the labeling Severe or Gastrointestinal Toxicity see Warnings and Precautions Hepatotoxicity,1,0.8481493592262268
ZYKADIA,Gastrointestinal Toxicity,sections of the labeling Severe or,0,0.5643880367279053
ZYKADIA,Gastrointestinal Toxicity,Gastrointestinal Toxicity,1,0.9999998807907104
ZYKADIA,Gastrointestinal Toxicity,Severe or Gastrointestinal,1,0.7944955825805664
ZYKADIA,Gastrointestinal Toxicity,the labeling Severe or Gastrointestinal Toxicity see,1,0.8887166380882263
ZYKADIA,Gastrointestinal Toxicity,labeling,0,0.519623875617981
ZYKADIA,Gastrointestinal Toxicity,or Gastrointestinal,1,0.8071898221969604
ZYKADIA,Hepatotoxicity,Persistent Gastrointestinal Toxicity see Warnings and,0,0.6947735548019409
ZYKADIA,Hepatotoxicity,Warnings and,0,0.5879274606704712
ZYKADIA,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions Interstitial,1,0.8202967047691345
ZYKADIA,Hepatotoxicity,Hepatotoxicity,1,1.0
ZYKADIA,Hepatotoxicity,see Warnings and Hepatotoxicity see Warnings and Precautions Interstitial,1,0.8020578622817993
ZYKADIA,Hepatotoxicity,Warnings and Hepatotoxicity see,1,0.8737565875053406
ZYKADIA,Interstitial Lung Disease,and Precautions Hepatotoxicity see Warnings and Precautions,0,0.5153957009315491
ZYKADIA,Interstitial Lung Disease,Interstitial,1,0.7247503399848938
ZYKADIA,Interstitial Lung Disease,Pneumonitis,0,0.6998368501663208
ZYKADIA,Interstitial Lung Disease,Interval Prolongation see Warnings and P,0,0.48248395323753357
ZYKADIA,Pneumonitis,Pneumonitis see Warnings,1,0.8605952262878418
ZYKADIA,Pneumonitis,Precautions QT Interval Prolongation,0,0.4609837532043457
ZYKADIA,Pneumonitis,and Precautions,0,0.5070801973342896
ZYKADIA,Pneumonitis,Pneumonitis see Warnings and Precautions,1,0.8458632230758667
ZYKADIA,Pneumonitis,Interstitial Lung Pneumonitis see Warnings and Precautions,1,0.780849814414978
ZYKADIA,Pneumonitis,Pneumonitis see,1,0.9235252737998962
ZYKADIA,Pneumonitis,Warnings and Precautions QT Interval Prolongation see Warnings and Precautions,0,0.4770963490009308
ZYKADIA,Pneumonitis,Pneumonitis see Warnings and,1,0.8645514249801636
ZYKADIA,QT Interval Prolongation,Interval Prolongation see Warnings and Precautions,1,0.7602829933166504
ZYKADIA,QT Interval Prolongation,Warnings and Precautions,0,0.5159308910369873
ZYKADIA,Hyperglycemia,Hyperglycemia,1,1.0000001192092896
ZYKADIA,Hyperglycemia,and Precautions and Clinical Hyperglycemia see,1,0.8288038372993469
ZYKADIA,Hyperglycemia,Warnings and,0,0.5181525945663452
ZYKADIA,Bradycardia,and Bradycardia see Warnings,1,0.8539385795593262
ZYKADIA,Bradycardia,Warnings and,0,0.5191369652748108
ZYKADIA,Bradycardia,see Warnings and,0,0.49417179822921753
ZYKADIA,Bradycardia,Bradycardia,1,1.000000238418579
ZYKADIA,Bradycardia,Pancreatitis see,0,0.49064433574676514
ZYKADIA,Bradycardia,Hyperglycemia see,0,0.5216571092605591
ZYKADIA,Bradycardia,and Precautions and Clinical Pharmacology Pancreatitis see Warni,0,0.5128268003463745
ZYKADIA,Bradycardia,Clinical Pharmacology Hyperglycemia see Warnings and,0,0.5558305978775024
ZYKADIA,Pancreatitis,and Clinical Pancreatitis see Warnings and Precautions,1,0.7963901162147522
ZYKADIA,Pancreatitis,Clinical Pharmacology Hyperglycemia see Warnings and,0,0.561305582523346
ZYKADIA,Pancreatitis,and Precautions EXCERPT The most,0,0.49100738763809204
ZYKADIA,Pancreatitis,Pancreatitis see Warnings and,1,0.8424047231674194
ZYKADIA,Pancreatitis,Pancreatitis see Warnings,1,0.8354299068450928
ZYKADIA,Pancreatitis,Warnings and Precautions and Clinical Pharmacology,0,0.5247465372085571
ZYKADIA,diarrhea,diarrhea nausea,1,0.8461776971817017
ZYKADIA,diarrhea,diarrhea nausea elevated,1,0.796993613243103
ZYKADIA,diarrhea,vomiting abdominal,0,0.6573269367218018
ZYKADIA,nausea,nausea elevated,1,0.8966104984283447
ZYKADIA,nausea,nausea elevated transaminases vomiting,1,0.7721595168113708
ZYKADIA,nausea,transaminases vomiting abdominal pain fatigue,0,0.725503146648407
ZYKADIA,nausea,vomiting abdominal pain fatigue decreased appetite and,0,0.7532560229301453
ZYKADIA,nausea,of at least are nausea elevated transaminases,1,0.7586551308631897
ZYKADIA,elevated transaminases,appetite and constipation To,0,0.5805193185806274
ZYKADIA,elevated transaminases,are diarrhea nausea,0,0.5582761764526367
ZYKADIA,elevated transaminases,To report,0,0.5306698083877563
ZYKADIA,elevated transaminases,diarrhea elevated,1,0.7113775014877319
ZYKADIA,elevated transaminases,elevated transaminases vomiting abdominal,1,0.8791964650154114
ZYKADIA,elevated transaminases,at least are diarrhea elevated transaminases vomiting abdominal pain,1,0.8512629270553589
ZYKADIA,vomiting,report SUSPECTED A,0,0.4895850419998169
ZYKADIA,vomiting,elevated transaminases,0,0.5343247652053833
ZYKADIA,vomiting,vomiting abdominal pain fatigue decreased appetite,1,0.7613325119018555
ZYKADIA,vomiting,are diarrhea nausea elevated vomiting,1,0.7860760688781738
ZYKADIA,vomiting,are diarrhea nausea elevated vomiting abdominal pain fatigue decreased appetite,1,0.6895643472671509
ZYKADIA,fatigue,are diarrhea nausea elevated transaminases vomiting,0,0.5189998149871826
ZYKADIA,fatigue,fatigue decreased appetite and,1,0.7964380979537964
ZYKADIA,fatigue,fatigue decreased,1,0.8332653641700745
ZYKADIA,fatigue,vomiting abdominal fatigue decreased appetite and,1,0.7037605047225952
ZYKADIA,fatigue,fatigue,1,1.0
ZYKADIA,fatigue,abdominal fatigue decreased appetite and constipation To,1,0.7141783237457275
ZYKADIA,fatigue,abdominal fatigue decreased appetite and,1,0.728468656539917
ZYKADIA,fatigue,fatigue decreased appetite,1,0.7925516366958618
ZYKADIA,decreased appetite,transaminases vomiting abdominal pain decreased appetite and constipation,1,0.7511430978775024
ZYKADIA,decreased appetite,fatigue,1,0.6335309743881226
ZYKADIA,decreased appetite,decreased appetite and,1,0.9714775085449219
ZYKADIA,decreased appetite,contact,0,0.46227699518203735
ZYKADIA,decreased appetite,vomiting abdominal pain decreased appetite and,1,0.8091663122177124
ZYKADIA,decreased appetite,decreased appetite and constipation To report SUSPECTED,1,0.8605419993400574
ZYKADIA,decreased appetite,REACTIONS,0,0.5234577655792236
ZYKADIA,decreased appetite,decreased appetite and constipation To,1,0.897565484046936
ZYKADIA,decreased appetite,decreased appetite,1,0.9999999403953552
ZYKADIA,decreased appetite,pain decreased appetite and,1,0.8264461159706116
ZYKADIA,constipation,constipation To,1,0.9169237613677979
ZYKADIA,constipation,constipation To report SUSPECTED ADVERSE,1,0.8439298272132874
ZYKADIA,constipation,constipation,1,1.0000001192092896
ZYKADIA,increased ALT,increased ALT nausea increased AST diarrhea and,1,0.7294766902923584
ZYKADIA,increased ALT,increased AST diarrhea and vomiting Serious adverse drug,0,0.6197314262390137
ZYKADIA,increased ALT,nausea increased AST diarrhea and,0,0.6058675050735474
ZYKADIA,increased ALT,interruptions increased ALT nausea increased AST diarrhea,1,0.667129397392273
ZYKADIA,increased ALT,of patients that led to dose reductions or interruptions,0,0.5263709425926208
ZYKADIA,nausea,adverse,0,0.5926717519760132
ZYKADIA,nausea,nausea increased AST,1,0.8336952328681946
ZYKADIA,nausea,were increased nausea,1,0.8944152593612671
ZYKADIA,nausea,reductions or interruptions,0,0.4877685308456421
ZYKADIA,nausea,were,0,0.524542510509491
ZYKADIA,increased AST,or interruptions were increased,0,0.6414047479629517
ZYKADIA,increased AST,patients that led to dose reductions or interruptions were increased,0,0.638212263584137
ZYKADIA,increased AST,increased AST diarrhea,1,0.8519673347473145
ZYKADIA,increased AST,ALT increased AST,1,0.9135114550590515
ZYKADIA,increased AST,were increased ALT increased AST,1,0.9114806652069092
ZYKADIA,diarrhea,increased ALT nausea increased AST,0,0.5921280384063721
ZYKADIA,diarrhea,diarrhea,1,1.0
ZYKADIA,diarrhea,interruptions were increased ALT nausea,0,0.5804599523544312
ZYKADIA,vomiting,ALT nausea increased,0,0.7535727024078369
ZYKADIA,vomiting,Serious adverse drug reactions reported in or more of,0,0.5966081619262695
ZYKADIA,pneumonia,pneumonia ILDpneumonitis dyspnea dehydration hyperglycemia and,1,0.7311593890190125
ZYKADIA,pneumonia,pneumonia ILDpneumonitis dyspnea dehydration,1,0.7575591802597046
ZYKADIA,pneumonia,pneumonia,1,0.9999997615814209
ZYKADIA,pneumonia,adverse reactions,0,0.5477505326271057
ZYKADIA,pneumonia,Study were pneumonia ILDpneumonitis dyspnea dehydration hyperglycemia,1,0.7173390984535217
ZYKADIA,ILD,ILD pneumonitis dyspnea dehydration hyperglycemia,1,0.7206150889396667
ZYKADIA,ILD,convulsion ILD pneumonitis dyspnea,1,0.5669044256210327
ZYKADIA,pneumonitis,pneumonitis dyspnea dehydration hyperglycemia and nausea,1,0.7214096784591675
ZYKADIA,pneumonitis,pneumonitis dyspnea,1,0.8786547183990479
ZYKADIA,pneumonitis,pneumonitis dyspnea dehydration hyperglycemia,1,0.7447977066040039
ZYKADIA,dyspnea,pneumonia dyspnea dehydration hyperglycemia and,1,0.7448164820671082
ZYKADIA,dyspnea,pneumonitis dyspnea,1,0.8721741437911987
ZYKADIA,dyspnea,convulsion,0,0.5184553861618042
ZYKADIA,dyspnea,in or more,0,0.5401852130889893
ZYKADIA,dyspnea,were convulsion pneumonia dyspnea dehydration hyperglycemia,1,0.6695349812507629
ZYKADIA,dehydration,pneumonia ILDpneumonitis dehydration hyperglycemia and nausea,1,0.7122851014137268
ZYKADIA,dehydration,in or more,0,0.5042228698730469
ZYKADIA,dehydration,reported in or more of patients in Study were convulsion pneumonia ILDpneumonitis,0,0.4894014000892639
ZYKADIA,dehydration,dehydration hyperglycemia and nausea Fatal,1,0.7898996472358704
ZYKADIA,dehydration,in Study were convulsion,0,0.5856539607048035
ZYKADIA,dehydration,reported in or more of patients in,0,0.5366408824920654
ZYKADIA,dehydration,in patients treated with ZYKADIA occurred,0,0.5952869653701782
ZYKADIA,dehydration,dehydration hyperglycemia,1,0.8308514356613159
ZYKADIA,dehydration,were convulsion pneumonia ILDpneumonitis dehydration hyperglycemia and nausea Fatal adverse,1,0.6808804273605347
ZYKADIA,dehydration,or more of patients in Study were convulsion pneumonia,0,0.4950793385505676
ZYKADIA,hyperglycemia,hyperglycemia,1,1.0000001192092896
ZYKADIA,hyperglycemia,hyperglycemia and nausea Fatal,1,0.802739143371582
ZYKADIA,hyperglycemia,were convulsion pneumonia ILDpneumonitis dyspnea dehydration,0,0.5027822256088257
ZYKADIA,hyperglycemia,dyspnea dehydration,0,0.5609878897666931
ZYKADIA,nausea,nausea Fatal adverse reactions in patients,1,0.7869736552238464
ZYKADIA,nausea,ILDpneumonitis dyspnea dehydration hyperglycemia nausea,1,0.6676616072654724
ZYKADIA,nausea,nausea Fatal adverse reactions,1,0.8029536008834839
ZYKADIA,nausea,patients consisting of,0,0.5344607830047607
ZYKADIA,nausea,were convulsion pneumonia,0,0.5851783752441406
ZYKADIA,nausea,dyspnea dehydration hyperglycemia,0,0.5652722120285034
ZYKADIA,nausea,ts in,0,0.5304261445999146
ZYKADIA,nausea,of patients consisting of,0,0.5288636088371277
ZYKADIA,Fatal,Fatal adverse reactions,1,0.7630990743637085
ZYKADIA,Fatal,consisting of,0,0.5439304113388062
ZYKADIA,Fatal,hyperglycemia and nausea,0,0.5306111574172974
ZYKADIA,Fatal,udy were convulsion pneumonia ILDpneumonitis dyspnea dehydration hyperglycemia and,0,0.593783974647522
ZYKADIA,pneumonia,patients treated with ZYKADIA occurred in of patients consisting of,0,0.5662005543708801
ZYKADIA,pneumonia,pneumonia patients respiratory failure ILDpneumonitis,1,0.7410658597946167
ZYKADIA,respiratory failure,of,0,0.5361261367797852
ZYKADIA,respiratory failure,pneumonia respiratory failure,1,0.9095504283905029
ZYKADIA,respiratory failure,physical health deterioration,0,0.5797790288925171
ZYKADIA,ILD,ILD pneumonitis pneumothorax,1,0.7665477395057678
ZYKADIA,ILD,physical health deterioration pulmonary,0,0.5014661550521851
ZYKADIA,ILD,respiratory ILD pneumonitis,1,0.7868696451187134
ZYKADIA,ILD,pneumonia patients respiratory ILD pneumonitis pneumothorax gastric hemorrhage general,1,0.6303129196166992
ZYKADIA,ILD,pneumonia patients respiratory ILD,1,0.7607122659683228
ZYKADIA,pneumonitis,pneumonitis pneumothorax gastric hemorrhage general,1,0.7789281606674194
ZYKADIA,pneumothorax,pneumothorax gastric,1,0.8524810075759888
ZYKADIA,pneumothorax,pulmonary tuberculosis,0,0.6522396802902222
ZYKADIA,pneumothorax,respiratory failure,0,0.6680760383605957
ZYKADIA,pneumothorax,pneumonia patients respiratory,0,0.6012542247772217
ZYKADIA,gastric hemorrhage,respiratory failure ILDpneumonitis gastric hemorrhage general,1,0.7644650936126709
ZYKADIA,gastric hemorrhage,pneumothorax gastric,1,0.7641707062721252
ZYKADIA,gastric hemorrhage,gastric,1,0.8085796236991882
ZYKADIA,gastric hemorrhage,failure ILDpneumonitis gastric,1,0.6889826059341431
ZYKADIA,gastric hemorrhage,tuberculosis,0,0.5246667861938477
ZYKADIA,gastric hemorrhage,general physical health deterioration pulmonary tuberculosis cardiac tamponade and sepsis pa,0,0.5759434700012207
ZYKADIA,gastric hemorrhage,patients,0,0.5353832244873047
ZYKADIA,gastric hemorrhage,gastric hemorrhage general,1,0.9414832592010498
ZYKADIA,pulmonary tuberculosis,each Discontinuation of therapy due to adverse,0,0.4874119758605957
ZYKADIA,pulmonary tuberculosis,health pulmonary tuberculosis,1,0.8937482237815857
ZYKADIA,pulmonary tuberculosis,and sepsis patient each Discontinuation of,0,0.5015909671783447
ZYKADIA,pulmonary tuberculosis,deterioration,0,0.49964436888694763
ZYKADIA,pulmonary tuberculosis,pulmonary tuberculosis cardiac tamponade and sepsis patient,1,0.7355654239654541
ZYKADIA,pulmonary tuberculosis,physical health pulmonary tuberculosis,1,0.8431453704833984
ZYKADIA,pulmonary tuberculosis,health pulmonary,1,0.7593668103218079
ZYKADIA,pulmonary tuberculosis,pneumothorax,0,0.6522396802902222
ZYKADIA,cardiac tamponade,physical health deterioration pulmonary cardiac tamponade and sepsis patient,1,0.791684627532959
ZYKADIA,cardiac tamponade,pneumothorax,0,0.6207071542739868
ZYKADIA,cardiac tamponade,to adverse reactions occurred,0,0.555283784866333
ZYKADIA,cardiac tamponade,pulmonary cardiac tamponade,1,0.920036256313324
ZYKADIA,cardiac tamponade,cardiac tamponade and sepsis patient each Discontinuation,1,0.7859423160552979
ZYKADIA,cardiac tamponade,patient each Discontinuation,0,0.4938526153564453
ZYKADIA,cardiac tamponade,s,0,0.4838007688522339
ZYKADIA,cardiac tamponade,Discontinuation,0,0.4789918065071106
ZYKADIA,cardiac tamponade,each Discontinuation of therapy due to adverse reactions occurred in,0,0.5289907455444336
ZYKADIA,cardiac tamponade,cardiac tamponade,1,0.9999998807907104
ZYKADIA,pneumonia,patients,0,0.5424351692199707
ZYKADIA,pneumonia,were,0,0.5527466535568237
ZYKADIA,pneumonia,ILDpneumonitis and decreased appetite Tables,0,0.6623442769050598
ZYKADIA,ILD,ILD,1,1.0
ZYKADIA,ILD,Tables and summarize the common,0,0.48366284370422363
ZYKADIA,ILD,patients in Study were ILD pneumonitis,1,0.6986991167068481
ZYKADIA,ILD,ILD pneumonitis and decreased appetite Tables,1,0.6968443393707275
ZYKADIA,ILD,ILD pneumonitis,1,0.8217249512672424
ZYKADIA,pneumonitis,Tables and summarize the common adverse reactions and,0,0.5326677560806274
ZYKADIA,pneumonitis,pneumonitis and decreased,1,0.8650873303413391
ZYKADIA,pneumonitis,pneumonitis and decreased appetite Tables,1,0.7821502089500427
ZYKADIA,pneumonitis,and decreased appetite Tables,0,0.4342902898788452
ZYKADIA,decreased appetite,ILDpneumonitis decreased appetite,1,0.7962401509284973
ZYKADIA,decreased appetite,and summarize,0,0.4929567873477936
ZYKADIA,decreased appetite,and summarize the common adverse,0,0.4842754304409027
ZYKADIA,decreased appetite,decreased appetite Tables and summarize the,1,0.8326882123947144
ZYKADIA,decreased appetite,of patients,0,0.5040320158004761
ZYKADIA,decreased appetite,reactions,0,0.5234577655792236
ZYKADIA,decreased appetite,summarize the common adverse reactions and laboratory abnormalities observed in,0,0.5091306567192078
ZYKADIA,decreased appetite,at led to discontinuation in or more of patients in Study were pneumonia ILDpneumonitis and,0,0.5566296577453613
ZYKADIA,decreased appetite,Study were pneumonia ILDpneumonitis decreased appetite Tables,1,0.7687283754348755
ZYKADIA,Abdominal pain,National Cancer Institute Common Terminology Criteria for Adverse Events version,0,0.5212311148643494
ZYKADIA,Abdominal pain,Events version Abdominal,1,0.7098712921142578
ZYKADIA,abdominal pain,Abdominal abdominal pain upper abdominal pain,1,0.8814827799797058
ZYKADIA,abdominal pain,Events version Abdominal,1,0.7098712921142578
ZYKADIA,abdominal pain,abdominal pain upper abdominal pain abdominal,1,0.8918347954750061
ZYKADIA,abdominal pain,a Abdominal abdominal,1,0.7945201396942139
ZYKADIA,abdominal pain,discomfort b Esophageal disorder dyspep,0,0.6151995658874512
ZYKADIA,abdominal pain,Terminology,0,0.4841393828392029
ZYKADIA,abdominal pain,abdominal pain upper,1,0.8900389671325684
ZYKADIA,abdominal pain,discomfort b,0,0.609519898891449
ZYKADIA,abdominal pain,abdominal pain,1,0.9999998807907104
ZYKADIA,upper abdominal pain,a Abdominal pain abdominal upper abdominal,1,0.9707092642784119
ZYKADIA,upper abdominal pain,upper,1,0.7185947895050049
ZYKADIA,upper abdominal pain,discomfort epigastric discomfort b Esophageal disorder,0,0.655483603477478
ZYKADIA,upper abdominal pain,Abdominal pain abdominal upper abdominal pain,1,0.9742664098739624
ZYKADIA,upper abdominal pain,Events version,0,0.44703975319862366
ZYKADIA,abdominal discomfort,reflux disease dyspha,0,0.5680643320083618
ZYKADIA,abdominal discomfort,pain abdominal pain upper abdominal pain,0,0.8408963680267334
ZYKADIA,abdominal discomfort,disorder dyspepsia gastroesophageal reflux disease,0,0.5972670316696167
ZYKADIA,abdominal discomfort,upper abdominal abdominal,1,0.7300848364830017
ZYKADIA,abdominal discomfort,upper abdominal abdominal discomfort epigastric discomfort b Esophageal disorder,1,0.8028122186660767
ZYKADIA,abdominal discomfort,abdominal discomfort epigastric discomfort b Esophageal disorder,1,0.8081457614898682
ZYKADIA,abdominal discomfort,abdominal discomfort,1,1.000000238418579
ZYKADIA,abdominal discomfort,Adverse,0,0.5451247692108154
ZYKADIA,abdominal discomfort,abdominal discomfort epigastric discomfort b Esophageal,1,0.833889901638031
ZYKADIA,epigastric discomfort,upper abdominal pain abdominal epigastric,1,0.8620903491973877
ZYKADIA,Esophageal disorder,Esophageal disorder dyspepsia,1,0.873539924621582
ZYKADIA,dyspepsia,l pain upper abdominal pain abdominal discomfort,0,0.6736004948616028
ZYKADIA,dyspepsia,dyspepsia gastroesophageal reflux disease dysphagia c,1,0.8278061151504517
ZYKADIA,dyspepsia,b,0,0.5254991054534912
ZYKADIA,dyspepsia,Rash,0,0.5597295761108398
ZYKADIA,dyspepsia,disease dysphagia c Fatigue fatigue asthenia d,0,0.68500816822052
ZYKADIA,gastroesophageal reflux disease,rash maculopapular rash acneiform dermatiti,0,0.5086401104927063
ZYKADIA,gastroesophageal reflux disease,dyspepsia,0,0.7263026237487793
ZYKADIA,gastroesophageal reflux disease,b Esophageal disorder gastroesophageal,1,0.8328006863594055
ZYKADIA,gastroesophageal reflux disease,gastroesophageal reflux disease dysphagia c Fatigue,1,0.8185150623321533
ZYKADIA,gastroesophageal reflux disease,abdominal pain abdominal discomfort epigastric discomfort b Esophageal disorder dyspepsia,0,0.727594256401062
ZYKADIA,gastroesophageal reflux disease,gastroesophageal,1,0.8459291458129883
ZYKADIA,dysphagia,asthenia d,0,0.5980502367019653
ZYKADIA,dysphagia,c Fatigue fatigue asthenia d,0,0.6025168895721436
ZYKADIA,dysphagia,dysphagia c Fatigue fatigue,1,0.7981176376342773
ZYKADIA,dysphagia,disorder dyspepsia gastroesophageal reflux dysphagia c Fatigue fatigue asthenia d,1,0.7666945457458496
ZYKADIA,dysphagia,reflux,0,0.7017363905906677
ZYKADIA,Fatigue,rash,0,0.5751873254776001
ZYKADIA,Fatigue,reflux disease dysphagia Fatigue fatigue,1,0.7393125295639038
ZYKADIA,Fatigue,Fatigue fatigue asthenia d Rash rash,1,0.800525426864624
ZYKADIA,fatigue,fatigue asthenia,1,0.8828307390213013
ZYKADIA,fatigue,mfort b Esophageal disorder dyspepsia,0,0.48571133613586426
ZYKADIA,asthenia,asthenia d,1,0.8387727737426758
ZYKADIA,asthenia,rash maculopapular rash,0,0.514501690864563
ZYKADIA,asthenia,fatigue,0,0.6107423901557922
ZYKADIA,asthenia,rash acneiform dermatitis,0,0.519729495048523
ZYKADIA,asthenia,asthenia d Rash rash,1,0.7488754987716675
ZYKADIA,asthenia,asthenia,1,1.000000238418579
ZYKADIA,asthenia,reflux,0,0.5403264760971069
ZYKADIA,asthenia,disease dysphagia c Fatigue asthenia d Rash rash,1,0.6820471882820129
ZYKADIA,Rash,rash,0,1.0000001192092896
ZYKADIA,Rash,acneiform dermatitis,0,0.7067416310310364
ZYKADIA,Rash,Rash rash maculopapular rash,1,0.7861650586128235
ZYKADIA,Rash,Rash rash,1,0.9747189879417419
ZYKADIA,Rash,acneiform dermatitis ZYKADIAN,0,0.6556289196014404
ZYKADIA,Rash,Fatigue fatigue asthenia Rash rash maculopapular,1,0.7585959434509277
ZYKADIA,rash,fatigue asthenia d rash maculopapular rash acneiform dermatitis ZYKADIAN,1,0.7492461204528809
ZYKADIA,rash,Rash rash maculopapular rash,1,0.7861650586128235
ZYKADIA,rash,rash maculopapular rash acneiform,1,0.7842152118682861
ZYKADIA,rash,rash,1,1.0000001192092896
ZYKADIA,rash,acneiform dermatitis,0,0.7067416310310364
ZYKADIA,rash,fatigue asthenia d rash maculopapular rash acneiform,1,0.7613261938095093
ZYKADIA,rash,Fatigue fatigue asthenia d rash maculopapular rash acneiform dermatitis,1,0.7573173642158508
ZYKADIA,rash,dysphagia c Fatigue,0,0.5211461782455444
ZYKADIA,maculopapular rash,maculopapular rash acneiform dermatitis,1,0.8991685509681702
ZYKADIA,maculopapular rash,d Rash rash,0,0.7237944602966309
ZYKADIA,maculopapular rash,asthenia d Rash maculopapular rash acneiform dermatitis ZYKADIAN All,1,0.8138179779052734
ZYKADIA,maculopapular rash,acneiform dermatitis,0,0.691092848777771
ZYKADIA,maculopapular rash,ZYKADIAN,0,0.4892842173576355
ZYKADIA,Constipation,a,0,0.5316193103790283
ZYKADIA,Constipation,Constipation,1,1.0000001192092896
ZYKADIA,Constipation,Abdominal pain Constipation Esophageal,1,0.7817597985267639
ZYKADIA,Constipation,pain Constipation Esophageal disorder b,1,0.7416934967041016
ZYKADIA,Constipation,Abdominal pain Constipation,1,0.8253918886184692
ZYKADIA,Constipation,Abdominal pain a,0,0.6387098431587219
ZYKADIA,Constipation,pain Constipation Esophageal disorder,1,0.7568939328193665
ZYKADIA,Constipation,Esophageal disorder,0,0.6356669664382935
ZYKADIA,Fatigue,and administration site,0,0.4320339858531952
ZYKADIA,Fatigue,Fatigue c Metabolism,1,0.8116453886032104
ZYKADIA,Decreased appetite,Metabolism,0,0.639786958694458
ZYKADIA,Decreased appetite,Decreased appetite,1,0.9999999403953552
ZYKADIA,Decreased appetite,Skin and,0,0.49516770243644714
ZYKADIA,Decreased appetite,disorders,0,0.5750875473022461
ZYKADIA,Decreased appetite,Skin and subcutaneous tissue,0,0.5004894733428955
ZYKADIA,Decreased appetite,Skin and subcutaneous tissue disorders,0,0.4937949776649475
ZYKADIA,Decreased appetite,nutrition Decreased appetite Skin and subcutaneous tissue disorders,1,0.7841308116912842
ZYKADIA,Rash,and subcutaneous tissue Rash,1,0.809320330619812
ZYKADIA,Rash,Decreased appetite,1,0.47027289867401123
ZYKADIA,Rash,Rash d Respiratory thoracic and,1,0.7976863980293274
ZYKADIA,Rash,disorders,0,0.5988904237747192
ZYKADIA,Rash,Rash d Respiratory thoracic and mediastinal,1,0.7822370529174805
ZYKADIA,Rash,and subcutaneous,0,0.6512484550476074
ZYKADIA,Interstitial lung disease,clinically significant adverse,0,0.5578028559684753
ZYKADIA,Interstitial lung disease,mediastinal disorders,0,0.6657739877700806
ZYKADIA,Interstitial lung disease,thoracic and mediastinal Interstitial lung disease pneumonitis Additional clinically,1,0.8140459656715393
ZYKADIA,Interstitial lung disease,Respiratory thoracic and mediastinal Interstitial lung disease,1,0.8520365953445435
ZYKADIA,Interstitial lung disease,Respiratory thoracic and mediastinal Interstitial,1,0.7312607169151306
ZYKADIA,Interstitial lung disease,Additional,0,0.5299143195152283
ZYKADIA,pneumonitis,Interstitial lung pneumonitis Additional,1,0.8031562566757202
ZYKADIA,pneumonitis,Additional,0,0.508358895778656
ZYKADIA,pneumonitis,adverse reactions,0,0.5882508158683777
ZYKADIA,pneumonitis,disorders Interstitial lung pneumonitis Additional,1,0.7757619619369507
ZYKADIA,pneumonitis,clinically significant adverse reactions,0,0.538506031036377
ZYKADIA,pneumonitis,pneumonitis Additional clinically significant adverse,1,0.8018608689308167
ZYKADIA,pneumonitis,mediastinal disorders Interstitial lung,0,0.6450985670089722
ZYKADIA,pneumonitis,mediastinal disorders,0,0.6164331436157227
ZYKADIA,neuropathy,paresthesia,0,0.665299654006958
ZYKADIA,neuropathy,lly,0,0.5168193578720093
ZYKADIA,paresthesia,paresthesia muscular,1,0.8754794597625732
ZYKADIA,paresthesia,paresthesia muscular weakness gait disturbance,1,0.7627242803573608
ZYKADIA,paresthesia,comprised of,0,0.522097110748291
ZYKADIA,muscular weakness,muscular weakness,1,1.0000001192092896
ZYKADIA,muscular weakness,muscular weakness gait disturbance peripheral,1,0.7975842952728271
ZYKADIA,muscular weakness,of patients treated with,0,0.49623194336891174
ZYKADIA,gait disturbance,gait disturbance peripheral neuropathy hypoesthesia peripheral sensory,1,0.8355370163917542
ZYKADIA,gait disturbance,sensory neuropathy dysesthesia neuralgia,0,0.5588967800140381
ZYKADIA,peripheral neuropathy,included,0,0.4942988455295563
ZYKADIA,peripheral neuropathy,muscular weakness gait peripheral neuropathy hypoesthesia peripheral sensory neuropathy,1,0.8046939373016357
ZYKADIA,peripheral neuropathy,peripheral neuropathy hypoesthesia peripheral sensory,1,0.8422861099243164
ZYKADIA,peripheral neuropathy,peripheral neuropathy hypoesthesia,1,0.8328925371170044
ZYKADIA,peripheral neuropathy,peripheral neuropathy,1,1.0000001192092896
ZYKADIA,peripheral neuropathy,gait,0,0.5624595880508423
ZYKADIA,hypoesthesia,peripheral hypoesthesia peripheral sensory neuropathy dysesthesia,1,0.8210041522979736
ZYKADIA,hypoesthesia,gait,0,0.5560575723648071
ZYKADIA,hypoesthesia,hypoesthesia peripheral sensory neuropathy dysesthesia neuralgia,1,0.8193479180335999
ZYKADIA,peripheral sensory neuropathy,peripheral neuropathy peripheral sensory neuropathy dysesthesia neuralgia peripheral motor neuropathy,1,0.8730388879776001
ZYKADIA,peripheral sensory neuropathy,hypoesthesia peripheral sensory neuropathy dysesthesia neuralgia,1,0.7924771308898926
ZYKADIA,peripheral sensory neuropathy,paresthesia muscular weakness gait disturbance peripheral,0,0.7921111583709717
ZYKADIA,peripheral sensory neuropathy,disturbance peripheral neuropathy peripheral sensory neuropathy dysesthesia,1,0.844711184501648
ZYKADIA,peripheral sensory neuropathy,neuropathy peripheral sensory neuropathy dysesthesia neuralgia peripheral,1,0.8830813765525818
ZYKADIA,peripheral sensory neuropathy,peripheral sensory neuropathy dysesthesia neuralgia,1,0.8693585395812988
ZYKADIA,peripheral sensory neuropathy,peripheral sensory neuropathy dysesthesia,1,0.875465989112854
ZYKADIA,peripheral sensory neuropathy,neuropathy peripheral sensory,1,0.9756069779396057
ZYKADIA,dysesthesia,dysesthesia neuralgia peripheral motor neuropathy,1,0.7862963676452637
ZYKADIA,neuralgia,neuralgia peripheral motor neuropathy hypotonia,1,0.7504367232322693
ZYKADIA,neuralgia,motor neuropathy hypotonia or polyneuropathy vision disorder comprised,0,0.5130372643470764
ZYKADIA,neuralgia,neuralgia peripheral motor neuropathy,1,0.7508948445320129
ZYKADIA,neuralgia,dysesthesia,0,0.6475173830986023
ZYKADIA,peripheral motor neuropathy,or polyneuropathy vision disorder,0,0.6782070398330688
ZYKADIA,peripheral motor neuropathy,peripheral motor neuropathy hypotonia or,1,0.9012675285339355
ZYKADIA,peripheral motor neuropathy,neuropathy dysesthesia peripheral motor neuropathy hypotonia or,1,0.8392594456672668
ZYKADIA,peripheral motor neuropathy,peripheral motor neuropathy hypotonia or polyneuropathy vision,1,0.8538229465484619
ZYKADIA,peripheral motor neuropathy,motor neuropathy,1,0.9357932806015015
ZYKADIA,peripheral motor neuropathy,dysesthesia peripheral motor neuropathy,1,0.872382402420044
ZYKADIA,peripheral motor neuropathy,hypotonia or polyneuropathy vision disorder,0,0.6702482104301453
ZYKADIA,polyneuropathy,polyneuropathy vision,1,0.8630706071853638
ZYKADIA,vision disorder,or vision disorder comprised of,1,0.914630115032196
ZYKADIA,vision disorder,polyneuropathy vision,1,0.7314911484718323
ZYKADIA,vision disorder,or polyneuropathy,0,0.5617474913597107
ZYKADIA,vision disorder,polyneuropathy,0,0.5299506187438965
ZYKADIA,vision impairment,disorder presbyopia or reduced,0,0.7331467866897583
ZYKADIA,vision impairment,polyneuropathy vision disorder comprised vision impairment blurred vision photopsia accommodation disorder,1,0.7763971090316772
ZYKADIA,vision impairment,vision impairment blurred vision photopsia accommodation,1,0.8391234278678894
ZYKADIA,blurred vision,prolonged QT interval,0,0.5092082023620605
ZYKADIA,blurred vision,disorder comprised of vision impairment,0,0.7779315710067749
ZYKADIA,photopsia,photopsia,1,1.000000238418579
ZYKADIA,accommodation disorder,vision impairment blurred vision accommodation,1,0.811394989490509
ZYKADIA,accommodation disorder,visual,0,0.5050395727157593
ZYKADIA,accommodation disorder,impairment blurred vision accommodation,1,0.8191481828689575
ZYKADIA,accommodation disorder,accommodation disorder presbyopia or,1,0.8956016898155212
ZYKADIA,accommodation disorder,accommodation disorder presbyopia or reduced visual acuity,1,0.8486276268959045
ZYKADIA,accommodation disorder,vision impairment blurred vision accommodation disorder presbyopia or reduced visual,1,0.8039178848266602
ZYKADIA,accommodation disorder,presbyopia or,0,0.6484975814819336
ZYKADIA,accommodation disorder,accommodation disorder presbyopia,1,0.8897743821144104
ZYKADIA,accommodation disorder,acuity prolonged QT interval and bradycardia Table,0,0.5493972301483154
ZYKADIA,presbyopia,presbyopia or reduced visual acuity prolonged,1,0.8713293671607971
ZYKADIA,presbyopia,presbyopia or reduced,1,0.9103069305419922
ZYKADIA,presbyopia,presbyopia,1,1.0
ZYKADIA,presbyopia,disorder,0,0.5225465297698975
ZYKADIA,presbyopia,presbyopia or reduced visual,1,0.9051541090011597
ZYKADIA,reduced visual acuity,visual acuity prolonged QT interval and,1,0.7467184066772461
ZYKADIA,reduced visual acuity,visual acuity prolonged QT interval and bradycardia,1,0.744820237159729
ZYKADIA,reduced visual acuity,of vision impairment blurred vision,0,0.7998125553131104
ZYKADIA,reduced visual acuity,presbyopia reduced,1,0.7810953259468079
ZYKADIA,reduced visual acuity,blurred vision photopsia accommodation disorder presbyopia,0,0.7254083156585693
ZYKADIA,reduced visual acuity,impairment blurred vision photopsia accommodation,0,0.7519384026527405
ZYKADIA,reduced visual acuity,reduced visual acuity,1,1.0
ZYKADIA,reduced visual acuity,photopsia accommodation disorder presbyopia reduced,1,0.7209646701812744
ZYKADIA,prolonged QT interval,visual prolonged,1,0.6604000926017761
ZYKADIA,prolonged QT interval,bradycardia,0,0.667341947555542
ZYKADIA,prolonged QT interval,Key Laboratory Abnormalities Occurring in All NCI,0,0.5531030893325806
ZYKADIA,prolonged QT interval,visual prolonged QT interval and bradycardia Table,1,0.8563559055328369
ZYKADIA,prolonged QT interval,prolonged QT,1,0.9465363025665283
ZYKADIA,prolonged QT interval,reduced visual prolonged QT,1,0.854600191116333
ZYKADIA,prolonged QT interval,QT interval and bradycardia Table Key Laboratory,1,0.7798694372177124
ZYKADIA,prolonged QT interval,disorder presbyopia or,0,0.45628681778907776
ZYKADIA,prolonged QT interval,Abnormalities Occurring in All NCI CT,0,0.5283629298210144
ZYKADIA,Hemoglobin decreased,transaminase,0,0.5419906973838806
ZYKADIA,Creatinine increased,Creatinine,1,0.8818321824073792
ZYKADIA,Creatinine increased,Aspartate transaminase AST Creatinine increased Glucose increased,1,0.8013215065002441
ZYKADIA,Creatinine increased,Aspartate,0,0.5933640003204346
ZYKADIA,Creatinine increased,transaminase AST Creatinine,1,0.7824462652206421
ZYKADIA,Creatinine increased,Creatinine increased Glucose,1,0.8744537830352783
ZYKADIA,Creatinine increased,transaminase,0,0.5631846189498901
ZYKADIA,Creatinine increased,transaminase AST Creatinine increased,1,0.861478328704834
ZYKADIA,Creatinine increased,Creatinine increased,1,0.9999999403953552
ZYKADIA,Phosphate decreased,Glucose,0,0.5578814744949341
ZYKADIA,Phosphate decreased,Phosphate decreased,1,0.9999999403953552
ZYKADIA,Phosphate decreased,Glucose Phosphate,1,0.7176563143730164
ZYKADIA,Phosphate decreased,increased,0,0.5291976928710938
ZYKADIA,Lipase increased,Phosphate,0,0.5196298956871033
ZYKADIA,Lipase increased,Lipase increased Bilirubin,1,0.8374083042144775
ZYKADIA,Lipase increased,decreased,0,0.5203607678413391
ZYKADIA,Lipase increased,Bilirubin total,0,0.5441858768463135
ZYKADIA,Lipase increased,Lipase increased Bilirubin total,1,0.8352975845336914
ZYKADIA,diarrhea,other sections of the g: *,1,0.5105270743370056
ZYKADIA,diarrhea,Persistent Gastrointestinal Toxicity,0,0.6654025316238403
ZYKADIA,diarrhea,"other sections of the g:



 * Severe or Persistent Gastrointestinal",1,0.6226823925971985
ZYKADIA,diarrhea,"sections of the g:



 * Severe",1,0.5504220128059387
ZYKADIA,diarrhea,Persistent Gastrointestinal,0,0.6559349894523621
ZYKADIA,nausea,Severe or Persistent Gastrointestinal Toxicity see,1,0.62325119972229
ZYKADIA,nausea,Persistent Gastrointestinal,0,0.5734343528747559
ZYKADIA,nausea,other sections of the Severe or,1,0.5453968048095703
ZYKADIA,vomiting,r Persis tent Gastrointestinal Toxicity see,1,0.6560734510421753
ZYKADIA,vomiting,r Persis tent Gastrointestinal Toxicity see Warnings,1,0.636772632598877
ZYKADIA,vomiting,Gastrointestinal Toxicity see Warnings and Precautions Hepatotoxicity,0,0.6214658617973328
ZYKADIA,vomiting,Severe r,1,0.603632926940918
ZYKADIA,vomiting,labeling Severe o,0,0.5970354676246643
ZYKADIA,vomiting,adverse reactions are discussed,0,0.6299610137939453
ZYKADIA,vomiting,r Persis tent,1,0.4776414632797241
ZYKADIA,vomiting,Warnings and Precautions,0,0.5539659261703491
ZYKADIA,vomiting,greater detail in other sections of the labeling,0,0.4744059443473816
ZYKADIA,vomiting,r Persis tent Gastrointestinal Toxicity,1,0.6489704847335815
ZYKADIA,abdominal pain,labeling Severe or Persistent,0,0.5334685444831848
ZYKADIA,abdominal pain, Gastrointesti nal Toxicity see Warnings and,1,0.6255552768707275
ZYKADIA,abdominal pain,or,0,0.4825837016105652
ZYKADIA,abdominal pain, Gastrointesti nal Toxicity see Warnings,1,0.632889986038208
ZYKADIA,abdominal pain,are discussed in,0,0.4157640337944031
ZYKADIA,abdominal pain,labeling Severe or  Gastrointesti nal Toxicity,1,0.6146817207336426
ZYKADIA,abdominal pain,discussed,0,0.4325893521308899
ZYKADIA,Hepatotoxicity,umonitis [see,1,0.49937301874160767
ZYKADIA,Hepatotoxicity,Interval Prolongation see Warnings and Precautions a,0,0.5519061088562012
ZYKADIA,hepatotoxicity,"see Warnings and ons (5.3)]  
  QT Interval",1,0.5440250039100647
ZYKADIA,hepatotoxicity,umonitis [see,1,0.49937301874160767
ZYKADIA,hepatotoxicity,ons (5.3)] QT Interval Prolongation see Warnings,1,0.5269289016723633
ZYKADIA,hepatotoxicity,see Warnings,0,0.5925098657608032
ZYKADIA,hepatotoxicity,ons (5.3)] QT Interval Prolongation,1,0.5223269462585449
ZYKADIA,hepatotoxicity,and Precautions Interstitial Lung DiseasePneumonitis see Warnings,0,0.5691335201263428
ZYKADIA,hepatotoxicity,QT Interval Prolongation see Warnings and Precautions and Clinical,0,0.5593470335006714
ZYKADIA,hepatotoxicity,"see Warnings and ons (5.3)]  
  QT Interval Prolongation",1,0.5731891393661499
ZYKADIA,hepatotoxicity,"Warnings and ons (5.3)]  
  QT",1,0.5086492300033569
ZYKADIA,Interstitial Lung Disease,and ecautions,1,0.4775877594947815
ZYKADIA,Interstitial Lung Disease,Hyperglycemia see Warnings and ecautions (5.5)],1,0.49952268600463867
ZYKADIA,Interstitial Lung Disease,"Hyperglycemia see Warnings and ecautions (5.5)]  
 *  Br adycardia see Warnings and",1,0.5253863334655762
ZYKADIA,Interstitial Lung Disease,"Hyperglycemia see Warnings and ecautions (5.5)]  
 *  Br",1,0.5028715133666992
ZYKADIA,Interstitial Lung Disease,see Warnings and ecautions (5.5)] *,1,0.49314627051353455
ZYKADIA,ILD,Warnings and Precautions yca rdia see Warnings and,1,0.5390982627868652
ZYKADIA,ILD,Hyperglycemia see Warnings and ecautions (5.5)],1,0.5215483903884888
ZYKADIA,ILD,yca rdia see,1,0.5656677484512329
ZYKADIA,ILD,yca,1,0.47470492124557495
ZYKADIA,ILD,yca rdia see Warnings and Precautions,1,0.5434471964836121
ZYKADIA,ILD,Warnings and Precautions Brad,0,0.5058717131614685
ZYKADIA,ILD,Clinical Pharmacology Hyperglycemia see Warnings and Precautions Brad,0,0.4973292350769043
ZYKADIA,ILD,yca rdia see Warnings,1,0.5535421371459961
ZYKADIA,Pneumonitis,inical Pharmacology Hyperglycemia see,0,0.4731224775314331
ZYKADIA,Pneumonitis,Hyperglycemia see,0,0.47034192085266113
ZYKADIA,Pneumonitis,ia [see War nings and Precautions,1,0.5079091787338257
ZYKADIA,Pneumonitis,[see War nings and Precautions and,1,0.5249912738800049
ZYKADIA,Pneumonitis,Warnings and Precautions ia [see War nings,1,0.530022144317627
ZYKADIA,Pneumonitis,Precautions ia [see War nings,1,0.5282754898071289
ZYKADIA,Pneumonitis,see Warnings and P,0,0.5601438879966736
ZYKADIA,Pneumonitis,ia [see War nings and,1,0.5061417818069458
ZYKADIA,Pneumonitis,Warnings and Precautions ia [see War,1,0.521975576877594
ZYKADIA,Pneumonitis,and Clinical Pharmacology Pancreatitis see Warnings and P,0,0.5429251790046692
ZYKADIA,QT Interval Prolongation,EXCERPT The most mon,1,0.44996148347854614
ZYKADIA,QTc interval prolongation,"25%) are diarrhea, nausea elevated transaminases vomiting abdominal pain",1,0.48386919498443604
ZYKADIA,QTc interval prolongation,decreased,0,0.490340918302536
ZYKADIA,QTc interval prolongation,reactions incidence of at 25%) are,1,0.5282413363456726
ZYKADIA,QTc interval prolongation,"are diarrhea, nausea elevated",1,0.47574999928474426
ZYKADIA,QTc interval prolongation,least,0,0.44005677103996277
ZYKADIA,QTc interval prolongation,vomiting abdominal pain,0,0.4259115159511566
ZYKADIA,QTc interval prolongation,elevated transaminases vomiting abdominal pain fatigue decreased appetite and,0,0.5236068964004517
ZYKADIA,QTc interval prolongation,"diarrhea, nausea elevated transaminases vomiting abdominal",1,0.49415212869644165
ZYKADIA,Hyperglycemia,Clinical Trials,0,0.5686120986938477
ZYKADIA,Hyperglycemia,"or wwwfdagovmedwatch Clinical  Experience

 Because clinical trials are",1,0.5061179399490356
ZYKADIA,Hyperglycemia," Experience

 Because clinical",1,0.49132239818573
ZYKADIA,Hyperglycemia," Experience

 Because",1,0.44811204075813293
ZYKADIA,hyperglycemia,Trials Experience Because clinical ials are,1,0.5090620517730713
ZYKADIA,hyperglycemia,clinical ials are cond,1,0.5264103412628174
ZYKADIA,hyperglycemia,Trials Experience Because clinical ials are cond ucted under widely varying conditions,1,0.5242701172828674
ZYKADIA,hyperglycemia,Because clinical ials are cond ucted under widely varying conditions,1,0.5350313782691956
ZYKADIA,hyperglycemia,ials are cond ucted under widely,1,0.48549628257751465
ZYKADIA,hyperglycemia,Trials Experience Because clinical ials,1,0.509547233581543
ZYKADIA,hyperglycemia,the clinical trials of a,0,0.5465662479400635
ZYKADIA,hyperglycemia,in the,0,0.5693898797035217
ZYKADIA,Bradycardia,observed in practice The,0,0.4967699646949768
ZYKADIA,Bradycardia,eval,0,0.47457772493362427
ZYKADIA,Bradycardia,another drug and,0,0.5322376489639282
ZYKADIA,Bradycardia,reflect the rates,0,0.4749470353126526
ZYKADIA,Bradycardia,The safety eval,0,0.5226746201515198
ZYKADIA,bradycardia,ZYKADIA is based 5 ALK-posit ive patients in,1,0.4750080108642578
ZYKADIA,bradycardia,The safety eval,0,0.5226746201515198
ZYKADIA,bradycardia,5 ALK-posit ive patients in,1,0.4767199158668518
ZYKADIA,bradycardia,5 ALK-posit,1,0.4714145362377167
ZYKADIA,bradycardia,not reflect the rates observed,0,0.5205536484718323
ZYKADIA,bradycardia,evaluation of ZYKADIA is,0,0.5171535015106201
ZYKADIA,bradycardia,patients in Study patients with NSCLC and patients with other cancers who,0,0.48749491572380066
ZYKADIA,bradycardia,is based 5,1,0.4490694999694824
ZYKADIA,bradycardia,safety evaluation of,0,0.5373344421386719
ZYKADIA,Pancreatitis,of mg daily The dian,1,0.54475998878479
ZYKADIA,Pancreatitis,mg daily The dian duratio,1,0.5525864362716675
ZYKADIA,Pancreatitis,population characteristics were,0,0.4127417504787445
ZYKADIA,Elevations of lipase,duration f exposure to ZYKADI,1,0.5576514601707458
ZYKADIA,Elevations of lipase,population characteristics were,0,0.48025840520858765
ZYKADIA,Elevations of lipase,daily,0,0.5118986964225769
ZYKADIA,Elevations of lipase,f exposure to ZYKADI,1,0.5640403628349304
ZYKADIA,Elevations of lipase,f exposure to ZYKADI A was months The study,1,0.5611371994018555
ZYKADIA,Elevations of lipase,median duration f exposure to ZYKADI,1,0.5639609098434448
ZYKADIA,Elevations of lipase,The median duration f exposure to,1,0.5550833940505981
ZYKADIA,Elevations of lipase,The median duration f exposure to ZYKADI A was months The study,1,0.5535721778869629
ZYKADIA,Elevations of lipase,patients with other cancers who received ZYKADIA at a dose of mg daily The,0,0.5259945392608643
ZYKADIA,Elevations of lipase,median duration f exposure,1,0.5329756736755371
ZYKADIA,Elevations of lipase,daily The median duration f exposure to ZYKADI,1,0.5564818382263184
ZYKADIA,pancreatitis,ZYKADIA was months study popula tion,1,0.5240268707275391
ZYKADIA,pancreatitis,median duration f exposure,1,0.4785962402820587
ZYKADIA,pancreatitis,ZYKADIA was months study popula tion characteristics were median,1,0.5266637802124023
ZYKADIA,pancreatitis,were median age years age less,0,0.4802260398864746
ZYKADIA,pancreatitis,was months study popula tion characteristics,1,0.47579246759414673
ZYKADIA,pancreatitis,months study popula tion characteristics were median,1,0.4957420229911804
ZYKADIA,Embryofetal Toxicity,less than female Caucasian Asian NSCLC adenocarcinom,0,0.515204906463623
ZYKADIA,Embryofetal Toxicity,"a histology (90%),",1,0.5207109451293945
ZYKADIA,Embryofetal Toxicity,less,0,0.4421629309654236
ZYKADIA,Embryofetal Toxicity,"female Caucasian Asian NSCLC a histology (90%), n",1,0.5082542300224304
ZYKADIA,Embryofetal Toxicity,"histology (90%), n ever or",1,0.5236639976501465
ZYKADIA,Embryofetal Toxicity,Asian,0,0.4721793532371521
ZYKADIA,Embryofetal Toxicity,"a histology (90%), n ever or former smoker",1,0.5175861716270447
ZYKADIA,Embryofetal Toxicity,female Caucasian Asian NSCLC a histology,1,0.5241461992263794
ZYKADIA,fetal harm,Caucasian Asian NSCLC adenocarcinoma histology,0,0.4564833641052246
ZYKADIA,fetal harm,or brain metastasis and number of prior therapies or more,0,0.505794882774353
ZYKADIA,fetal harm,"(97%), EC",1,0.47707441449165344
ZYKADIA,fetal harm,or former smoker,0,0.46358007192611694
ZYKADIA,fetal harm,"former (97%), EC",1,0.4705770015716553
ZYKADIA,fetal harm," (97%), EC OG",1,0.48326408863067627
ZYKADIA,fetal harm,Caucasian Asian NSCLC adenocarcinoma histology never or former,0,0.44550490379333496
ZYKADIA,fetal harm,le,0,0.4971790313720703
ZYKADIA,Diarrhea,h ZYKADI A The most frequent,1,0.5780810117721558
ZYKADIA,Diarrhea,h ZYKADI,1,0.5378730893135071
ZYKADIA,Diarrhea,adverse reactions occurred in of patients treated wit,0,0.5283285975456238
ZYKADIA,Diarrhea,wit,0,0.5351263284683228
ZYKADIA,Diarrhea,treated h,1,0.5677343606948853
ZYKADIA,Diarrhea,h ZYKADI A The most,1,0.5599812269210815
ZYKADIA,Diarrhea,due to adverse reactions occurred in,0,0.5857549905776978
ZYKADIA,nausea,The m ost,1,0.48812395334243774
ZYKADIA,nausea,The m ost frequent adverse,1,0.5770175457000732
ZYKADIA,nausea,least of patients that led to,0,0.5214420557022095
ZYKADIA,nausea, The m ost frequent adverse reactions reported,1,0.6226074695587158
ZYKADIA,nausea,dose reductions,0,0.5460112690925598
ZYKADIA,nausea,ost frequent adverse reactions reported,0,0.6013510227203369
ZYKADIA,nausea,patients treated with  The m ost frequent adverse,1,0.5661917924880981
ZYKADIA,nausea,of patients treated with The m,1,0.5196473598480225
ZYKADIA,vomiting,The t,1,0.5094517469406128
ZYKADIA,vomiting,t freque nt adverse reactions reported,1,0.6137278079986572
ZYKADIA,vomiting,t freque nt adverse reactions,1,0.6134978532791138
ZYKADIA,vomiting,The mos,0,0.45732414722442627
ZYKADIA,vomiting,treated with ZYKADIA The t freque,1,0.5805248618125916
ZYKADIA,vomiting,ZYKADIA The mos,0,0.4870111346244812
ZYKADIA,abdominal pain,adverse reactions occurred in of patients treated with ZYKADIA,0,0.5143773555755615
ZYKADIA,abdominal pain,ZYKADIA The most frequent verse reaction s,1,0.5013530850410461
ZYKADIA,abdominal pain,verse reaction s reported in at,1,0.4892791211605072
ZYKADIA,diarrhea,sed AST diarrhea and,1,0.8057924509048462
ZYKADIA,diarrhea,in or more,0,0.5276591777801514
ZYKADIA,diarrhea,sed,1,0.5353270769119263
ZYKADIA,diarrhea,sed AST,1,0.514312744140625
ZYKADIA,nausea,"6%), d iarrhea and",1,0.5840279459953308
ZYKADIA,vomiting,AST rrhea,1,0.5145368576049805
ZYKADIA,vomiting,rrhea (1,1,0.4935876727104187
ZYKADIA,vomiting,dia,0,0.465032696723938
ZYKADIA,vomiting,ALT nausea increased AST rrhea (1,1,0.7072657346725464
ZYKADIA,vomiting,of,0,0.5198577046394348
ZYKADIA,vomiting,nausea increased AST rrhea (1 and,1,0.7196130752563477
ZYKADIA,vomiting,in or more,0,0.4754272401332855
ZYKADIA,vomiting,increased ALT nausea increased AST dia,0,0.706775963306427
ZYKADIA,vomiting,ALT nausea increased AST rrhea (1 and vomiting Serious adverse,1,0.763407289981842
ZYKADIA,abdominal pain,AST,0,0.48015642166137695
ZYKADIA,abdominal pain,and vomiting,1,0.6104130148887634
ZYKADIA,abdominal pain,and vomiting ( Serious adverse,1,0.6055641174316406
ZYKADIA,abdominal pain,vomiting (,1,0.6078587770462036
ZYKADIA,abdominal pain,vomiting ( Serious adverse drug reactions reported,1,0.5958139896392822
ZYKADIA,abdominal pain,nausea,0,0.6394764184951782
ZYKADIA,hepatotoxicity,"ion,",1,0.4961613118648529
ZYKADIA,hepatotoxicity,gastric hemorrhage,0,0.5393078327178955
ZYKADIA,hepatotoxicity,"ion, pulmonary",1,0.5168299674987793
ZYKADIA,Elevations in alanine aminotransferase,and (1 patient each). Discontinuation of,1,0.48802903294563293
ZYKADIA,Elevations in alanine aminotransferase,sepsis,0,0.5678747892379761
ZYKADIA,Elevations in alanine aminotransferase,tuberculosis cardiac tamponade and (1 patient each). Discontinuation of,1,0.5016793608665466
ZYKADIA,Elevations in alanine aminotransferase,and sepsis,0,0.5719956159591675
ZYKADIA,Elevations in alanine aminotransferase,each). Discontinuation of therapy due to,1,0.5189679265022278
ZYKADIA,Elevations in alanine aminotransferase,Discontinuation of therapy due,1,0.502829909324646
ZYKADIA,Elevations in alanine aminotransferase,cardiac tamponade and  (1 patient each). Discontinuation of  therapy due to adverse,1,0.531578540802002
ZYKADIA,Elevations in alanine aminotransferase,patient each). Discontinuation of therapy due to,1,0.5092724561691284
ZYKADIA,elevated transaminases,of,1,0.5071386098861694
ZYKADIA,elevated transaminases,decreased appetite Tables and summarize the common,0,0.5401313304901123
ZYKADIA,elevated transaminases,or  of patients in Study  were pneumonia,1,0.4898144006729126
ZYKADIA,elevated transaminases,led to,0,0.5249773263931274
ZYKADIA,jaundice, pneumon ia ILDpneumonitis,1,0.5323361158370972
ZYKADIA,jaundice,ILDpneumonitis and decreased appetite,0,0.5408929586410522
ZYKADIA,jaundice, pneumon ia ILDpneumonitis and decreased,1,0.5353935360908508
ZYKADIA,jaundice, pneumon,1,0.5037156939506531
ZYKADIA,jaundice,appetite Tables and summarize the common adverse reactio,0,0.5910917520523071
ZYKADIA,elevations in ALT,"onitis, and decre ased appetite Tables",1,0.5016125440597534
ZYKADIA,elevations in ALT,adverse reactions and laboratory,0,0.4803265929222107
ZYKADIA,elevations in ALT,"Study were pneumonia onitis, and decre ased appetite Tables and summarize",1,0.48220008611679077
ZYKADIA,ILD,rad,1,0.5982683300971985
ZYKADIA,ILD,dermatitis ZYKADIAN All Grades rad,1,0.5736421346664429
ZYKADIA,ILD,e Gastrointestinal disorders,0,0.5610551238059998
ZYKADIA,ILD,rad e Gastrointestinal,1,0.5876701474189758
ZYKADIA,ILD,e,0,0.5679211616516113
ZYKADIA,ILD,All Grades rad,1,0.5648793578147888
ZYKADIA,ILD,All Grades rad e Gastrointestinal,1,0.6074091196060181
ZYKADIA,ILD,dermatitis ZYKADIAN All Grades rad e Gastrointestinal disorders,1,0.5860579013824463
ZYKADIA,ILD,ZYKADIAN All Grades rad e Gastrointestinal disorders,1,0.591533899307251
ZYKADIA,ILD,rad e Gastrointestinal disorders,1,0.5907347202301025
ZYKADIA,pneumonitis, 3-4       ,1,0.4626840353012085
ZYKADIA,pneumonitis, 3-4        Gastrointestinal,1,0.46717000007629395
ZYKADIA,pneumonitis,m dermatitis ZYKADIAN All Grades Grade,0,0.5433351993560791
ZYKADIA,pneumonitis,All Grades Grade,0,0.47018831968307495
ZYKADIA,pneumonitis,dermatitis ZYKADIAN,0,0.5391731262207031
ZYKADIA,pneumonitis,m dermatitis ZYKADIAN All Grades,0,0.5455837845802307
ZYKADIA,pneumonitis,dermatitis,0,0.6142311096191406
ZYKADIA,pneumonitis,Grade,0,0.4843607544898987
ZYKADIA,pneumonitis, Gastrointe stinal disorders,1,0.5371626615524292
ZYKADIA,pneumonitis,All Grades  Gastrointe stinal disorders,1,0.5249594449996948
ZYKADIA,pneumonitis,Grades,0,0.4701130986213684
ZYKADIA,ILD,    Nausea Vomiting,1,0.4577908515930176
ZYKADIA,ILD,Grades,0,0.5026009678840637
ZYKADIA,ILD,   ,1,0.6133712530136108
ZYKADIA,ILD,Gastrointestinal,0,0.5443317890167236
ZYKADIA,pneumonitis,Gastrointestinal disorders           6,1,0.4949103593826294
ZYKADIA,pneumonitis,Gastrointestinal,0,0.4901772737503052
ZYKADIA,pneumonitis,          6 Nausea Vomiting,1,0.480960875749588
ZYKADIA,pneumonitis,Diarrhea,0,0.5284216403961182
ZYKADIA,fatal,Diarrhea Nausea,0,0.5711853504180908
ZYKADIA,fatal,Diarrhea 0     Vomiting Abdominal p,1,0.5958527326583862
ZYKADIA,fatal,0     Vomiting Abdominal,1,0.6393895745277405
ZYKADIA,fatal,0     Vomiting,1,0.621121883392334
ZYKADIA,fatal,0     Vomiting Abdominal p,1,0.6413235068321228
ZYKADIA,fatal,Vomiting Abdominal,0,0.6440024971961975
ZYKADIA,fatal,Diarrhea 0     Vomiting Abdominal,1,0.5859655141830444
ZYKADIA,ILD,    Vomiting,1,0.4894057810306549
ZYKADIA,ILD,    Vomiting Abdominal pain,1,0.44688886404037476
ZYKADIA,ILD,    Vomiting Abdominal,1,0.488567590713501
ZYKADIA,ILD,Constipation,0,0.4954695403575897
ZYKADIA,ILD,pain    ,1,0.4853403568267822
ZYKADIA,ILD,Abdominal pain     Constipation,1,0.44780027866363525
ZYKADIA,ILD,    Constipation Esophageal disorder,1,0.5397352576255798
ZYKADIA,ILD,Vomiting Abdominal,0,0.488567590713501
ZYKADIA,ILD,Esophageal,0,0.5245239734649658
ZYKADIA,ILD,a,0,0.5255967378616333
ZYKADIA,ILD,    Constipation Esophageal disorder b,1,0.5366957187652588
ZYKADIA,pneumonitis,            Constipation Esophageal disorder b,1,0.4753834009170532
ZYKADIA,pneumonitis,a,0,0.5209025740623474
ZYKADIA,QTc interval prolongation,nutrition disorders,0,0.47428417205810547
ZYKADIA,QTc interval prolongation,"Metabolism and nutrition            
     Decrease d appetite Skin and subcutaneous",1,0.5081708431243896
ZYKADIA,QTc interval prolongation,subcutaneous,0,0.529020369052887
ZYKADIA,QTc interval prolongation,"           
     Decrease d appetite Skin and",1,0.4977475106716156
ZYKADIA,ventricular tachyarrhythmias,rders Decreased Skin,1,0.4678213894367218
ZYKADIA,Torsade de pointes,appetite Skin and subcutaneous tissu,0,0.5004374384880066
ZYKADIA,Torsade de pointes,appetite Skin and subcutaneous e disorders       ,1,0.49848753213882446
ZYKADIA,Torsade de pointes,Skin and subcutaneous e,1,0.5353266000747681
ZYKADIA,Torsade de pointes,Skin and subcutaneous e disorders,1,0.5481977462768555
ZYKADIA,Torsade de pointes,e disorders Rash d Respirator,1,0.5530308485031128
ZYKADIA,sudden death,tissue              Rash d Respiratory,1,0.5320287942886353
ZYKADIA,sudden death,e disorders Rash d Respirator,1,0.5555187463760376
ZYKADIA,sudden death,             Rash d Respiratory thoracic,1,0.5048685669898987
ZYKADIA,QTc interval increase,sorders               Interstitial lung,1,0.4581272602081299
ZYKADIA,QTc interval increase,sorders               Interstitial,1,0.4986210763454437
ZYKADIA,increase from baseline QTc,ZYKADIA included neuropathy omprised of,1,0.524384617805481
ZYKADIA,increase from baseline QTc,"of paresthesia, m uscular",1,0.5231232643127441
ZYKADIA,increase from baseline QTc,in or more of patients treated with,0,0.5236383676528931
ZYKADIA,increase from baseline QTc,included,0,0.49295806884765625
ZYKADIA,increase from baseline QTc,included neuropathy,0,0.49946388602256775
ZYKADIA,increase from baseline QTc,"neuropathy omprised of paresthesia, m uscular weakness gait",1,0.49384456872940063
ZYKADIA,increase from baseline QTc,hypoesthesia,0,0.5817456245422363
ZYKADIA,increase from baseline QTc,occurring in or more,0,0.5555095076560974
ZYKADIA,increases in the QTc interval,"hypoesthesia peripheral sensory dysesthesia, neuralgia,",1,0.5067930221557617
ZYKADIA,increases in the QTc interval,"dysesthesia, neuralgia, perip",1,0.49951720237731934
ZYKADIA,Hyperglycemia,ase,0,0.5120711922645569
ZYKADIA,Hyperglycemia,ase increased Bilirubin total increased,0,0.5931835174560547
ZYKADIA,Hyperglycemia,"    
     Lip ase increased Bilirubin total increased",1,0.5777245759963989
ZYKADIA,Hyperglycemia,"    
     Lip",1,0.4963531792163849
ZYKADIA,Hyperglycemia,"    
     Lip ase increased",1,0.5872306823730469
ZYKADIA,Hyperglycemia,"    
     Lip ase",1,0.518576979637146
CHOLINE,injection site reaction,adverse reactions to Ccholine have been reported,0,0.6097849607467651
CHOLINE,injection site reaction,an uncommon injection,1,0.7257087230682373
CHOLINE,injection site reaction,uncommon injection,1,0.719636082649231
CHOLINE,injection site reaction,injection site reaction,1,0.9999999403953552
CHOLINE,injection site reaction,of an uncommon injection site reaction no,1,0.9312375783920288
CHOLINE,injection site reaction,rse reactions to Ccholine have been reported,0,0.6592676639556885
CHOLINE,injection site reaction,uncommon injection site reaction no other,1,0.8955807685852051
CHOLINE,Allergic reactions,reaction no other adverse reactions have been reported To,0,0.7119415998458862
CHOLINE,Radiation risk,been,0,0.5481659173965454
CHOLINE,Radiation risk,adverse reactions have,0,0.5900018215179443
CHOLINE,Radiation risk,mild injection site reaction no other adverse reactions have been reported To report,0,0.5558185577392578
CHOLINE,Radiation risk,Department of,0,0.5095588564872742
CHOLINE,Radiation risk,To SUSPECTED ADV,1,0.5443083047866821
ERWINAZE,Hypersensitivity reactions,the Hypersensitivity reactions,1,0.9706787467002869
ERWINAZE,Hypersensitivity reactions,Hypersensitivity,1,0.9332083463668823
ERWINAZE,Pancreatitis,Pancreatitis,1,0.9999998211860657
ERWINAZE,Glucose intolerance,Pancreatitis see Warnings and Glucose intolerance see Warnings and Precautions Thrombosis,1,0.7325395941734314
ERWINAZE,Glucose intolerance,Pancreatitis,1,0.623830258846283
ERWINAZE,Glucose intolerance,hemorrhage see Warnings and Precauti,0,0.48645931482315063
ERWINAZE,Glucose intolerance,Pancreatitis see Warnings and Glucose intolerance see Warnings,1,0.776423454284668
ERWINAZE,Glucose intolerance,see Warnings and Glucose,1,0.7355504035949707
ERWINAZE,Thrombosis,Warnings and Precautions,0,0.5647372007369995
ERWINAZE,Thrombosis,Precautions The most common,0,0.568463921546936
ERWINAZE,Thrombosis,and Precautions The most,0,0.5258986949920654
ERWINAZE,Thrombosis,Warnings and Thrombosis and hemorrhage,1,0.7620487809181213
ERWINAZE,Thrombosis,see,0,0.5639217495918274
ERWINAZE,Thrombosis,common,0,0.5620590448379517
ERWINAZE,Thrombosis,Thrombosis and hemorrhage see,1,0.8328776359558105
ERWINAZE,Thrombosis,Thrombosis and hemorrhage see Warnings,1,0.7884741425514221
ERWINAZE,hemorrhage,hemorrhage,1,1.0
ERWINAZE,hemorrhage,most,0,0.48157036304473877
ERWINAZE,hemorrhage,common adverse reactions incidence or,0,0.5604395866394043
ERWINAZE,hemorrhage,hemorrhage see,1,0.9332196712493896
ERWINAZE,hemorrhage,hemorrhage see Warnings and Precautions,1,0.8189400434494019
ERWINAZE,hemorrhage,Warnings and Precautions The,0,0.5381650328636169
ERWINAZE,systemic hypersensitivity,reactions vomiting nausea thr,0,0.605644941329956
ERWINAZE,systemic hypersensitivity,greater with ERWINAZE treatment systemic,1,0.6946392059326172
ERWINAZE,systemic hypersensitivity,ERWINAZE treatment systemic hypersensitivity,1,0.8198915719985962
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity hyperglycemia transaminases abnormal,1,0.7847574949264526
ERWINAZE,systemic hypersensitivity,greater with ERWINAZE treatment systemic hypersensitivity hyperglycemia,1,0.7627555131912231
ERWINAZE,systemic hypersensitivity,ERWINAZE treatment systemic hypersensitivity hyperglycemia transaminases abnormal fever pancreatitis,1,0.6995508670806885
ERWINAZE,systemic hypersensitivity,ERWINAZE,0,0.5152314305305481
ERWINAZE,systemic hypersensitivity,abnormal fever pancreatitis local,0,0.5452290773391724
ERWINAZE,hyperglycemia,abnormal fever pancreatitis local reactions,0,0.5535812973976135
ERWINAZE,hyperglycemia,systemic hyperglycemia transaminases,1,0.7800083160400391
ERWINAZE,hyperglycemia,greater with ERWINAZE,0,0.5774048566818237
ERWINAZE,hyperglycemia,are systemic hyperglycemia transaminases abnormal,1,0.7600693106651306
ERWINAZE,hyperglycemia,systemic hypersensitivity,0,0.6040825247764587
ERWINAZE,hyperglycemia,hyperglycemia transaminases abnormal fever pancreatitis local,1,0.7319063544273376
ERWINAZE,hyperglycemia,treatment are systemic hyperglycemia transaminases,1,0.7739216089248657
ERWINAZE,transaminases abnormal,transaminases abnormal,1,0.9999999403953552
ERWINAZE,transaminases abnormal,hyperglycemia transaminases abnormal fever pancreatitis local,1,0.7687829732894897
ERWINAZE,transaminases abnormal,local reactions vomiting,0,0.561467707157135
ERWINAZE,fever,local reactions vomiting nausea thrombosis,0,0.6019085645675659
ERWINAZE,fever,fever pancreatitis local,1,0.7031756043434143
ERWINAZE,fever,fever pancreatitis local reactions,1,0.69178307056427
ERWINAZE,fever,fever pancreatitis local reactions vomiting nausea,1,0.7118804454803467
ERWINAZE,fever,fever,1,1.0
ERWINAZE,fever,pancreatitis local reactions vomiting nausea thrombosis hyperbilirubinemia abdominal paindi,0,0.5670492649078369
ERWINAZE,fever,pancreatitis local reactions vomiting nausea thrombosis hyperbilirubinemia abdominal,0,0.5649691820144653
ERWINAZE,pancreatitis,pancreatitis local,1,0.8551428318023682
ERWINAZE,pancreatitis,thrombosis,0,0.6292437314987183
ERWINAZE,pancreatitis,hypersensitivity hyperglycemia transaminases abnormal pancreatitis local reactions vomiting nausea thrombosis,1,0.6845030784606934
ERWINAZE,pancreatitis,pancreatitis local reactions,1,0.8273061513900757
ERWINAZE,pancreatitis,thrombosis hyperbilirubinemia,0,0.5325844883918762
ERWINAZE,pancreatitis,nausea,0,0.5981712341308594
ERWINAZE,pancreatitis,transaminases,0,0.5764552354812622
ERWINAZE,pancreatitis,abnormal,0,0.5399790406227112
ERWINAZE,pancreatitis,hypersensitivity hyperglycemia transaminases abnormal pancreatitis local,1,0.7400112152099609
ERWINAZE,local reactions,fever local reactions vomiting nausea thrombosis,1,0.7237213850021362
ERWINAZE,local reactions,abnormal,0,0.531691312789917
ERWINAZE,local reactions,transaminases abnormal fever local reactions vomiting nausea thrombosis,1,0.6540474891662598
ERWINAZE,local reactions,abnormal fever local reactions vomiting nausea,1,0.7093222141265869
ERWINAZE,local reactions,hyperglycemia transaminases abnormal fever local reactions vomiting,1,0.6600232124328613
ERWINAZE,vomiting,vomiting nausea thrombosis hyperbilirubinemia abdominal paindiscomfort,1,0.7346925735473633
ERWINAZE,vomiting,and diarrhea,0,0.6619996428489685
ERWINAZE,vomiting,reactions,0,0.6171008348464966
ERWINAZE,vomiting,vomiting,1,0.9999999403953552
ERWINAZE,vomiting,local,0,0.5070443153381348
ERWINAZE,vomiting,vomiting nausea thrombosis,1,0.8343051671981812
ERWINAZE,vomiting,vomiting nausea thrombosis hyperbilirubinemia,1,0.7612587809562683
ERWINAZE,vomiting,abnormal fever pancreatitis local vomiting nausea thrombosis hyperbilirubinemia abdominal,1,0.6882082223892212
ERWINAZE,nausea,pancreatitis local reactions nausea thrombosis hyperbilirubinemia abdominal,1,0.6582465171813965
ERWINAZE,nausea,vomiting,1,0.8409453630447388
ERWINAZE,nausea,nausea,1,1.0
ERWINAZE,nausea,vomiting,0,0.8409453630447388
ERWINAZE,nausea,nausea thrombosis hyperbilirubinemia,1,0.7349156737327576
ERWINAZE,nausea,diarrhea EXCERPT,0,0.5827667713165283
ERWINAZE,nausea,EXCERPT Most com,0,0.5044016242027283
ERWINAZE,nausea,diarrhea EXCERPT Most com,0,0.5716806054115295
ERWINAZE,thrombosis,fever pancreatitis local reactions,0,0.5303625464439392
ERWINAZE,thrombosis,reactions vomiting thrombosis hyperbilirubinemia,1,0.7055244445800781
ERWINAZE,thrombosis,thrombosis hyperbilirubinemia,1,0.7737889289855957
ERWINAZE,thrombosis,thrombosis hyperbilirubinemia abdominal,1,0.7456321716308594
ERWINAZE,thrombosis,local reactions vomiting thrombosis hyperbilirubinemia abdominal paindiscomfort,1,0.6695917844772339
ERWINAZE,hyperbilirubinemia,ycemia transaminases abnormal fever pancreatitis local,0,0.6419293880462646
ERWINAZE,abdominal pain,vomiting nausea thrombosis abdominal pain,1,0.780328094959259
ERWINAZE,abdominal pain,ycemia transaminases abnormal fever pancreatitis local,0,0.6151698231697083
ERWINAZE,abdominal pain,hyperbilirubinemia,0,0.4942162036895752
ERWINAZE,abdominal pain,reactions vomiting nausea thrombosis abdominal,1,0.713971734046936
ERWINAZE,abdominal pain,nausea thrombosis abdominal pain discomfort and diarrhea EXCERPT Most,1,0.7410356402397156
ERWINAZE,abdominal pain,incidence or greater,0,0.48608243465423584
ERWINAZE,abdominal pain,local reactions vomiting nausea,0,0.6137305498123169
ERWINAZE,abdominal pain,thrombosis abdominal,1,0.7173495888710022
ERWINAZE,abdominal pain,abdominal pain discomfort,1,0.9578940868377686
ERWINAZE,diarrhea,diarrhea EXCERPT Most common adverse reactions,1,0.7771317958831787
ERWINAZE,diarrhea,diarrhea EXCERPT Most common,1,0.804295539855957
ERWINAZE,systemic hypersensitivity,abnormal fever pancreatitis,0,0.5490713715553284
ERWINAZE,systemic hypersensitivity,greater systemic hypersensitivity hyperglycemia transaminases abnormal fever pancreatitis,1,0.7879058122634888
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity,1,1.0
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity hyperglycemia transaminases abnormal fever pancreatitis,1,0.7849054336547852
ERWINAZE,systemic hypersensitivity,fever pancreatitis local reactions vomiting nausea,0,0.5901403427124023
ERWINAZE,systemic hypersensitivity,or greater systemic hypersensitivity hyperglycemia transaminases abnormal,1,0.7915337681770325
ERWINAZE,systemic hypersensitivity,greater,0,0.5670456886291504
ERWINAZE,hyperglycemia,transaminases abnormal fever pancreatitis local reactions vomiting,0,0.5589417219161987
ERWINAZE,hyperglycemia,pancreatitis local,0,0.5200273990631104
ERWINAZE,hyperglycemia,hyperglycemia transaminases abnormal,1,0.7816495895385742
ERWINAZE,hyperglycemia,hyperglycemia,1,1.0000001192092896
ERWINAZE,hyperglycemia,hyperglycemia transaminases abnormal fever pancreatitis,1,0.7337539792060852
ERWINAZE,hyperglycemia,reactions,0,0.5497577786445618
ERWINAZE,hyperglycemia,hyperglycemia transaminases,1,0.7953473925590515
ERWINAZE,hyperglycemia,nausea thrombosis,0,0.521648645401001
ERWINAZE,transaminases abnormal,vomiting nausea thrombosis hyperbilirubinemia,0,0.6635557413101196
ERWINAZE,transaminases abnormal,transaminases abnormal fever pancreatitis local reactions,1,0.7847508192062378
ERWINAZE,transaminases abnormal,transaminases abnormal fever pancreatitis local reactions vomiting,1,0.7917335033416748
ERWINAZE,transaminases abnormal,hypersensitivity hyperglycemia,0,0.5519571900367737
ERWINAZE,transaminases abnormal,systemic hypersensitivity transaminases,1,0.785160481929779
ERWINAZE,transaminases abnormal,adverse reactions incidence or,0,0.5768734216690063
ERWINAZE,transaminases abnormal,or greater are systemic hypersensitivity,0,0.5572065114974976
ERWINAZE,transaminases abnormal,fever,0,0.5139316320419312
ERWINAZE,fever,vomiting nausea thrombosis hyperbilirubinemia abdominal paindi,0,0.5901461243629456
ERWINAZE,fever,greater are systemic hypersensitivity hyperglycemia transaminases,0,0.5490115880966187
ERWINAZE,fever,reactions vomiting nausea thrombosis hyperbilirubinemia abdominal paindi,0,0.59541255235672
ERWINAZE,fever,hyperglycemia transaminases,0,0.5050501823425293
ERWINAZE,pancreatitis,idence or greater are systemic hypersensitivity hyperglycemia transaminases,0,0.5764076709747314
ERWINAZE,pancreatitis,hyperglycemia transaminases abnormal pancreatitis local,1,0.7466959357261658
ERWINAZE,pancreatitis,pancreatitis,1,0.9999998211860657
ERWINAZE,pancreatitis,pancreatitis local reactions vomiting,1,0.7857890129089355
ERWINAZE,pancreatitis,pancreatitis local reactions vomiting nausea thrombosis,1,0.7992496490478516
ERWINAZE,pancreatitis,transaminases abnormal,0,0.5648133754730225
ERWINAZE,pancreatitis,vomiting nausea thrombosis,0,0.5645132660865784
ERWINAZE,pancreatitis,fever,0,0.5925562381744385
ERWINAZE,local reactions,thrombosis hyperbilirubinemia abdominal paindiscomfort,0,0.5168969035148621
ERWINAZE,local reactions,transaminases abnormal fever local reactions vomiting nausea,1,0.672350287437439
ERWINAZE,local reactions,and diarrhea To,0,0.5566624999046326
ERWINAZE,vomiting,abnormal fever pancreatitis local vomiting nausea thrombosis hyperbilirubinemia abdominal paindiscomfort,1,0.674384593963623
ERWINAZE,vomiting,and diarrhea To,0,0.6533207297325134
ERWINAZE,vomiting,pancreatitis local reactions,0,0.563331127166748
ERWINAZE,vomiting,abdominal paindiscomfort and diarrhea,0,0.6343506574630737
ERWINAZE,vomiting,vomiting nausea,1,0.9458823204040527
ERWINAZE,nausea,nausea thrombosis hyperbilirubinemia abdominal paindiscomfort,1,0.7328747510910034
ERWINAZE,nausea,nausea thrombosis hyperbilirubinemia abdominal,1,0.7240452766418457
ERWINAZE,nausea,local reactions nausea thrombosis,1,0.7483890652656555
ERWINAZE,nausea,nausea thrombosis,1,0.8067858219146729
ERWINAZE,nausea,reactions,0,0.5885443687438965
ERWINAZE,thrombosis,nausea thrombosis,1,0.8100530505180359
ERWINAZE,thrombosis,thrombosis,1,0.9999998211860657
ERWINAZE,thrombosis,local reactions vomiting thrombosis hyperbilirubinemia abdominal paindiscomfort and,1,0.6740562319755554
ERWINAZE,thrombosis,hyperbilirubinemia abdominal paindiscomfort and diarrhea To report SUSPECTED ADVERSE,0,0.5325199365615845
ERWINAZE,thrombosis,hyperbilirubinemia abdominal paindiscomfort and diarrhea To,0,0.5389672517776489
ERWINAZE,thrombosis,hyperbilirubinemia,0,0.585426390171051
ERWINAZE,hyperbilirubinemia,nausea,0,0.5667246580123901
ERWINAZE,hyperbilirubinemia,SUSPECTED ADVERSE REACTIONS contact Jazz,0,0.5952982902526855
ERWINAZE,hyperbilirubinemia,vomiting nausea,0,0.5195550918579102
ERWINAZE,hyperbilirubinemia,transaminases abnormal,0,0.6469093561172485
ERWINAZE,hyperbilirubinemia,To report SUSPECTED ADVERSE REACTIONS,0,0.5876712203025818
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia abdominal,1,0.8349874019622803
ERWINAZE,hyperbilirubinemia,REACTIONS contact,0,0.5066550970077515
ERWINAZE,abdominal pain,abdominal pain discomfort and,1,0.9424288272857666
ERWINAZE,abdominal pain,abnormal fever pancreatitis local,0,0.6139962673187256
ERWINAZE,abdominal pain,vomiting nausea thrombosis abdominal,1,0.7313902378082275
ERWINAZE,abdominal pain,abdominal pain,1,0.9999998807907104
ERWINAZE,allergic reactions,allergic reactions,1,1.0
ERWINAZE,allergic reactions,to completion seven due allergic reactions five due to physician or,1,0.8082485198974609
ERWINAZE,allergic reactions,due to,0,0.5829477906227112
ERWINAZE,allergic reactions,allergic reactions five due to,1,0.8753359317779541
ERWINAZE,allergic reactions,eted all planned therapy Fourteen patients stopped therapy prior to,0,0.4859412908554077
ERWINAZE,allergic reactions,allergic reactions five due to physician,1,0.7915314435958862
ERWINAZE,allergic reactions,allergic reactions five due to physician or,1,0.7984637022018433
ERWINAZE,allergic reactions,completion seven due allergic reactions,1,0.8645769357681274
ERWINAZE,allergic reactions,allergic reactions five,1,0.9048722982406616
ERWINAZE,allergy,interest,0,0.5477213859558105
ERWINAZE,allergy,or,0,0.5281662940979004
ERWINAZE,allergy,allergy pancreatitis,1,0.7838195562362671
ERWINAZE,allergy,allergy pancreatitis coagulopathy hemorrhage,1,0.7464251518249512
ERWINAZE,allergy,allergy,1,1.0000001192092896
ERWINAZE,allergy,events of special allergy pancreatitis coagulopathy hemorrhage,1,0.730391800403595
ERWINAZE,pancreatitis,events of special interest pancreatitis coagulopathy hemorrhage thrombosis or infarct,1,0.7515170574188232
ERWINAZE,pancreatitis,allergy pancreatitis,1,0.819528341293335
ERWINAZE,pancreatitis,pancreatitis coagulopathy hemorrhage,1,0.7900592088699341
ERWINAZE,pancreatitis,events of special interest,0,0.49576807022094727
ERWINAZE,pancreatitis,pancreatitis coagulopathy hemorrhage thrombosis or infarct,1,0.7808228135108948
ERWINAZE,pancreatitis,hyperbilirubinemia,0,0.5893465280532837
ERWINAZE,pancreatitis,pancreatitis coagulopathy,1,0.7947014570236206
ERWINAZE,pancreatitis,adverse events of,0,0.5938892364501953
ERWINAZE,coagulopathy,hyperglycemia,0,0.538308322429657
ERWINAZE,coagulopathy,coagulopathy hemorrhage thrombosis or infarct,1,0.8155540227890015
ERWINAZE,coagulopathy,or infarct hyperbilirubinemia hyperglycemia hyperlipidemia ketoacidosi,0,0.5888246297836304
ERWINAZE,coagulopathy,interest allergy coagulopathy,1,0.8074371814727783
ERWINAZE,coagulopathy,e events were,0,0.45682448148727417
ERWINAZE,coagulopathy,coagulopathy hemorrhage thrombosis or,1,0.8509703278541565
ERWINAZE,hemorrhage,infarct hyperbilirubinemia hyperglycemia hyperlipidemia ketoacidosis and,0,0.5869394540786743
ERWINAZE,hemorrhage,the following adverse events of special interest allergy pancreatitis,0,0.5380626320838928
ERWINAZE,hemorrhage,thrombosis or infarct,0,0.667412281036377
ERWINAZE,thrombosis,coagulopathy,0,0.7771072387695312
ERWINAZE,infarct,thrombosis or,0,0.6672232151031494
ERWINAZE,infarct,infarct hyperbilirubinemia hyperglycemia hyperlipidemia,1,0.7491794228553772
ERWINAZE,hyperbilirubinemia,events hemorrhage thrombosis or infarction,0,0.5413227081298828
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia hyperglycemia,1,0.8775550127029419
ERWINAZE,hyperbilirubinemia,or hyperbilirubinemia hyperglycemia hyperlipidemia,1,0.8434956073760986
ERWINAZE,hyperglycemia,infarct hyperglycemia hyperlipidemia ketoacidosis,1,0.7568138241767883
ERWINAZE,hyperglycemia,hyperbilirubinemia hyperglycemia,1,0.854701042175293
ERWINAZE,hyperlipidemia,hyperlipidemia ketoacidosis and CNS,1,0.7875409126281738
ERWINAZE,hyperlipidemia,hyperbilirubinemia hyperglycemia,1,0.7067115902900696
ERWINAZE,hyperlipidemia,hyperlipidemia,1,1.000000238418579
ERWINAZE,hyperlipidemia,hyperglycemia,0,0.7591366171836853
ERWINAZE,hyperlipidemia,hyperlipidemia ketoacidosis and CNS events,1,0.7685978412628174
ERWINAZE,hyperlipidemia,hyperbilirubinemia hyperlipidemia ketoacidosis and,1,0.7913211584091187
ERWINAZE,hyperlipidemia,hemorrhage thrombosis or infarct,0,0.5781438946723938
ERWINAZE,hyperlipidemia,hyperlipidemia ketoacidosis and,1,0.8197305202484131
ERWINAZE,ketoacidosis,cerebral,0,0.544806957244873
ERWINAZE,ketoacidosis,and CNS events hemorrhage,0,0.4911647439002991
ERWINAZE,ketoacidosis,venous,0,0.4875202178955078
ERWINAZE,ketoacidosis,ketoacidosis and CNS events,1,0.8312005996704102
ERWINAZE,ketoacidosis,thrombosis or infarct,0,0.5501229763031006
ERWINAZE,CNS events,ketoacidosis and,0,0.4923962950706482
ERWINAZE,CNS events,CNS,1,0.8857292532920837
ERWINAZE,CNS events,hyperlipidemia ketoacidosis CNS events hemorrhage thrombosis or,1,0.6126770973205566
ERWINAZE,CNS events,CNS events hemorrhage thrombosis,1,0.7036187648773193
ERWINAZE,CNS events,and,0,0.4329172372817993
ERWINAZE,CNS events,hyperglycemia hyperlipidemia ketoacidosis CNS events hemorrhage thrombosis or,1,0.6133233308792114
ERWINAZE,CNS events,hyperlipidemia ketoacidosis and,0,0.499628484249115
ERWINAZE,CNS events,rhage thrombosis or infarct hyperbilirubinemia hyperglycemia hyperlipidemia,0,0.480540007352829
ERWINAZE,cerebral venous thrombosis,adverse events In,0,0.5578395128250122
ERWINAZE,cerebral venous thrombosis,for other,0,0.4678504467010498
ERWINAZE,cerebral venous thrombosis,and events,0,0.43346571922302246
ERWINAZE,cerebral venous thrombosis,cerebral venous thrombosis and only,1,0.9515761137008667
ERWINAZE,cerebral venous thrombosis,cerebral venous thrombosis and only Grade,1,0.9125059843063354
ERWINAZE,cerebral venous thrombosis,hyperlipidemia ketoacidosis and CNS events hemorrhage thrombosis,0,0.6931726932525635
ERWINAZE,cerebral venous thrombosis,venous thrombosis and only Grade and events,1,0.7396036386489868
ERWINAZE,cerebral venous thrombosis,cerebral venous thrombosis,1,0.9999999403953552
ERWINAZE,allergic reactions,information on occurrence allergic reactions thrombotic events hemorrhagic events hepatobiliary,1,0.7408425211906433
ERWINAZE,allergic reactions,cerebral venous thrombosis,1,0.4764126241207123
ERWINAZE,allergic reactions,requested information on occurrence allergic reactions thrombotic events hemorrhagic events,1,0.7472367286682129
ERWINAZE,allergic reactions,on occurrence allergic reactions thrombotic,1,0.8034346103668213
ERWINAZE,allergic reactions,allergic reactions thrombotic,1,0.8148854970932007
ERWINAZE,allergic reactions,on occurrence of,0,0.5275558829307556
ERWINAZE,allergic reactions,on occurrence allergic reactions,1,0.8869094848632812
ERWINAZE,allergic reactions,requested information on occurrence allergic,1,0.7923871278762817
ERWINAZE,allergic reactions,events hemorrhagic events hepatobiliary disorders,0,0.5443822145462036
ERWINAZE,thrombotic events,disorders and,0,0.5768705606460571
ERWINAZE,thrombotic events,allergic,0,0.5463337898254395
ERWINAZE,thrombotic events,on occurrence of allergic thrombotic events,1,0.840481162071228
ERWINAZE,thrombotic events,information on occurrence of allergic reactions,0,0.5969191789627075
ERWINAZE,thrombotic events,reactions,0,0.6045393943786621
ERWINAZE,thrombotic events,thrombotic,1,0.8530523777008057
ERWINAZE,thrombotic events,thrombotic events hemorrhagic events hepatobiliary disorders pancreatic,1,0.8324432373046875
ERWINAZE,hemorrhagic events,reactions thrombotic hemorrhagic events hepatobiliary disorders,1,0.7513049840927124
ERWINAZE,hemorrhagic events,thrombotic events hemorrhagic events hepatobiliary disorders pancreatic,1,0.7947773933410645
ERWINAZE,hemorrhagic events,The,0,0.5164719223976135
ERWINAZE,hemorrhagic events,on,0,0.5519297122955322
ERWINAZE,hepatobiliary disorders,hepatobiliary disorders pancreatic disorders and,1,0.9266115427017212
ERWINAZE,hepatobiliary disorders,events hemorrhagic events,0,0.5494452118873596
ERWINAZE,hepatobiliary disorders,events hemorrhagic hepatobiliary disorders pancreatic disorders and hyperglycemia The,1,0.8341450691223145
ERWINAZE,hepatobiliary disorders,hepatobiliary disorders pancreatic,1,0.8983185887336731
ERWINAZE,hepatobiliary disorders,hemorrhagic events,0,0.562178909778595
ERWINAZE,hepatobiliary disorders,hepatobiliary disorders,1,1.0000001192092896
ERWINAZE,pancreatic disorders,hemorrhagic events hepatobiliary pancreatic disorders,1,0.7812204360961914
ERWINAZE,pancreatic disorders,events hepatobiliary pancreatic disorders,1,0.8283969759941101
ERWINAZE,pancreatic disorders,thrombotic,0,0.5461186170578003
ERWINAZE,pancreatic disorders,adverse events all,0,0.5671359896659851
ERWINAZE,pancreatic disorders,pancreatic disorders and hyperglycemia,1,0.8984073400497437
ERWINAZE,pancreatic disorders,pancreatic disorders and hyperglycemia The incidence of,1,0.8450450897216797
ERWINAZE,hyperglycemia,hyperglycemia The incidence of,1,0.8616493344306946
ERWINAZE,hypersensitivity reactions,patients who developed,0,0.5620518326759338
ERWINAZE,hypersensitivity reactions,hypersensitivity reactions in,1,0.9634740948677063
ERWINAZE,hypersensitivity reactions,a higher risk hypersensitivity reactions,1,0.8772027492523193
ERWINAZE,hypersensitivity reactions,with a higher risk hypersensitivity reactions,1,0.8647500276565552
ERWINAZE,hypersensitivity reactions,neutralizing antibodiesThe presence of ADA to ERWINAZE is associated with,0,0.6017050743103027
ERWINAZE,hypersensitivity reactions,er sections of the label: Hypersensitivity,1,0.7811028957366943
ERWINAZE,hypersensitivity reactions,greater,0,0.5280673503875732
ERWINAZE,hypersensitivity reactions,"in er sections of the label:
 Hypersensitivity",1,0.788939893245697
ERWINAZE,hypersensitivity reactions,greater detail in er sections,1,0.5191503167152405
ERWINAZE,hypersensitivity reactions,in greater detail,0,0.5143886804580688
ERWINAZE,hypersensitivity reactions,Warnings and Precautions Pancreatitis see,0,0.5685685873031616
ERWINAZE,hypersensitivity reactions,oth,0,0.5168112516403198
ERWINAZE,hypersensitivity reactions,and Precautions Pancreatitis see,0,0.569415271282196
ERWINAZE,hypersensitivity reactions,sections of the label: Hypersensitivity reactions see,1,0.8830463886260986
ERWINAZE,hypersensitivity reactions,see Warnings,0,0.5517011880874634
ERWINAZE,anaphylaxis,ersensitivi,1,0.6011916399002075
ERWINAZE,anaphylaxis,Precautions,0,0.5991293787956238
ERWINAZE,anaphylaxis,ersensitivi ty reactions see Warnings,1,0.728060245513916
ERWINAZE,anaphylaxis,the label ersensitivi ty,1,0.6307656764984131
ERWINAZE,anaphylaxis,rious adverse reactions are discussed in greater detail,0,0.6702877879142761
ERWINAZE,hemorrhagic pancreatitis,see Warnings and Precautions Glucose,0,0.532757043838501
ERWINAZE,hemorrhagic pancreatitis,and Precautions,0,0.4597833752632141
ERWINAZE,hemorrhagic pancreatitis,the label Hypersensitivity reactions s,0,0.5235607624053955
ERWINAZE,hemorrhagic pancreatitis,Warnings and Precauti ons Pancreatitis see,1,0.7359501123428345
ERWINAZE,hemorrhagic pancreatitis,Warnings and Precauti ons Pancreatitis,1,0.7396474480628967
ERWINAZE,hemorrhagic pancreatitis,the label Hypersensitivity reactions ee,1,0.5244042873382568
ERWINAZE,hemorrhagic pancreatitis,ee Warnings and Precauti,1,0.4567559063434601
ERWINAZE,hemorrhagic pancreatitis,ee Warnings and Precauti ons Pancreatitis see Warnings,1,0.7124329209327698
ERWINAZE,pancreatitis,and Precauti,1,0.48432213068008423
ERWINAZE,Glucose intolerance,Warnings and Precautions,0,0.5118967294692993
ERWINAZE,Glucose intolerance,intolerance see Warnings,0,0.645505964756012
ERWINAZE,Glucose intolerance,see,0,0.49127745628356934
ERWINAZE,Glucose intolerance,Warnings and *,1,0.5026487112045288
ERWINAZE,Glucose intolerance,* Pancreatitis [ see Warnings,1,0.6017181873321533
ERWINAZE,Glucose intolerance,see Warnings and Precautions Glucose intolerance see Warnings and,0,0.8276461362838745
ERWINAZE,Glucose intolerance,*    Pancreatitis [ see,1,0.6197550296783447
ERWINAZE,Glucose intolerance,reactions see Warnings and *    Pancreatitis [ see,1,0.6078927516937256
ERWINAZE,Glucose intolerance,*,1,0.5337156057357788
ERWINAZE,Glucose intolerance,*    Pancreatitis [ see Warnings and Precautions,1,0.593067467212677
ERWINAZE,Glucose intolerance,and *    Pancreatitis [ see Warnings and,1,0.602064311504364
ERWINAZE,Glucose intolerance,see Warnings and Precautions,0,0.5059600472450256
ERWINAZE,Glucose intolerance,see Warnings and,0,0.507256269454956
ERWINAZE,Glucose intolerance,Precautions,0,0.5050501227378845
ERWINAZE,Glucose intolerance,reactions see Warnings and * Pancreatitis,1,0.6044638156890869
ERWINAZE,Glucose intolerance,Warnings and * Pancreatitis,1,0.595456600189209
ERWINAZE,Glucose intolerance,* Pancreatitis [ see Warnings and Precautions Glucose,1,0.7281008362770081
ERWINAZE,Glucose intolerance,see Warnings and Precautions Glucose intolerance see Warnings,0,0.8319896459579468
ERWINAZE,Glucose intolerance,Pancreatitis [ see Warnings and Precautions,1,0.5849575400352478
ERWINAZE,Glucose intolerance,and * Pancreatitis,1,0.6289004683494568
ERWINAZE,Thrombosis,ings and P recautions The,1,0.5302468538284302
ERWINAZE,Thrombosis,with ERWINAZE tr,0,0.5340356230735779
ERWINAZE,Thrombosis,hemorrhage see ings and P recautions The most,1,0.6283980011940002
ERWINAZE,Thrombosis,with ERWINAZE,0,0.5177446603775024
ERWINAZE,Thrombosis,ings and P recautions The most common adverse,1,0.5780611634254456
ERWINAZE,Thrombosis,and hemorrhage see ings and P recautions The most common adverse,1,0.636062741279602
ERWINAZE,Thrombosis,hemorrhage see Warn,0,0.6266580820083618
ERWINAZE,hemorrhage,cautions ( The most,1,0.4987780749797821
ERWINAZE,hemorrhage,or,0,0.5675545930862427
ERWINAZE,hemorrhage,cautions ( The most common,1,0.5127692222595215
ERWINAZE,hemorrhage,see Warnings and cautions (,1,0.5148458480834961
ERWINAZE,hypersensitivity reactions,"temic hypersensitivity, hy perglycemia transaminases abnormal",1,0.7437835931777954
ERWINAZE,hypersensitivity reactions,treatment are,0,0.5683714747428894
ERWINAZE,hypersensitivity reactions,pancreatitis,0,0.5618563890457153
ERWINAZE,Pancreatitis,hyperbilirubinemia,0,0.5893465280532837
ERWINAZE,Pancreatitis,hyperbilirubinemia abdominal paindiscomfort and,0,0.6317049264907837
ERWINAZE,glucose intolerance,EMTP an d access,1,0.47903990745544434
ERWINAZE,glucose intolerance,EMTP an d access program (b,1,0.46435797214508057
ERWINAZE,glucose intolerance,and,0,0.4891487658023834
ERWINAZE,glucose intolerance,Treatment Protocol EMTP an d access program (b oth intramuscular,1,0.5140751600265503
ERWINAZE,thrombotic events,ERWINAZEStudy enrolled,0,0.5035688281059265
ERWINAZE,thrombotic events,study trial of intravenous administration of ERWINAZEStudy enrolled patie,0,0.5722674131393433
ERWINAZE,thrombotic events,Cancer Institute NCIsponsored,0,0.5227919816970825
ERWINAZE,thrombotic events,of intravenous,0,0.6034692525863647
ERWINAZE,thrombotic events,ALL protocols who were,0,0.5654028654098511
ERWINAZE,thrombotic events,on Na tional Cancer Institute,1,0.5370047092437744
ERWINAZE,thrombotic events,nts treated on Na tional Cancer,1,0.5083422660827637
ERWINAZE,thrombotic events,ALL protocols who,0,0.5702695846557617
ERWINAZE,thrombotic events,ERWINAZEStudy enrolled nts,1,0.5262011289596558
ERWINAZE,sagittal sinus thrombosis,Institute (NCI)-sponsor ed cooperative group ALL protocols,1,0.469498872756958
ERWINAZE,sagittal sinus thrombosis,Institute (NCI)-sponsor ed cooperative group,1,0.4336686134338379
ERWINAZE,sagittal sinus thrombosis,enrolled patients treated on National,0,0.5280212163925171
ERWINAZE,sagittal sinus thrombosis,treated on National,0,0.5185940861701965
ERWINAZE,sagittal sinus thrombosis,National r Institute,1,0.44311273097991943
ERWINAZE,sagittal sinus thrombosis,unable to continue to,0,0.5219494104385376
ERWINAZE,sagittal sinus thrombosis,ed cooperative group ALL protocols who were unable,0,0.46425047516822815
ERWINAZE,sagittal sinus thrombosis,r Institute (NCI)-sponsor ed,1,0.4270555377006531
ERWINAZE,pulmonary embolism,on National Cancer Institute,0,0.5027787089347839
ERWINAZE,pulmonary embolism,Cancer Institute NCIsponsored co,0,0.5151419639587402
ERWINAZE,pulmonary embolism,Cancer Institute NCIsponsored operative,1,0.5045623183250427
SAPHRIS,Neuroleptic Malignant Syndrome,and,0,0.4392763376235962
SAPHRIS,Neuroleptic Malignant Syndrome,with DementiaRelated Psychosis,0,0.6767213344573975
SAPHRIS,Neuroleptic Malignant Syndrome,see Warnings and,0,0.5146127939224243
SAPHRIS,Neuroleptic Malignant Syndrome,Warningand Warnings and Precautions Neuroleptic Malignant Syndrome,1,0.9123361110687256
SAPHRIS,Neuroleptic Malignant Syndrome,Malignant Syndrome see Warnings and,1,0.7638360261917114
SAPHRIS,Neuroleptic Malignant Syndrome,Psychosis seeBoxed Warningand Warnings and,0,0.6648949384689331
SAPHRIS,Neuroleptic Malignant Syndrome,and Precautions and,0,0.48390889167785645
SAPHRIS,Neuroleptic Malignant Syndrome,Malignant Syndrome see Warnings and Precautions,1,0.7510641813278198
SAPHRIS,Tardive Dyskinesia,Warnings and Tardive,1,0.7198095917701721
SAPHRIS,Tardive Dyskinesia,Tardive Dyskinesia see,1,0.9638863801956177
SAPHRIS,Tardive Dyskinesia,Warnings and,0,0.46987485885620117
SAPHRIS,Tardive Dyskinesia,and Precautions,0,0.4317657947540283
SAPHRIS,Tardive Dyskinesia,Precautions Metabolic Changes see Warnings and Precautions,0,0.5056062936782837
SAPHRIS,Tardive Dyskinesia,Tardive Dyskinesia see Warnings,1,0.8978410363197327
SAPHRIS,Tardive Dyskinesia,Warnings and Tardive Dyskinesia,1,0.8887863159179688
SAPHRIS,Tardive Dyskinesia,Tardive Dyskinesia see Warnings and,1,0.8954099416732788
SAPHRIS,Tardive Dyskinesia,Tardive Dyskinesia,1,1.000000238418579
SAPHRIS,Metabolic Changes,Hypersensitivity Reactions see,0,0.5757910013198853
SAPHRIS,Hypersensitivity Reactions,Warnings and Precautions Metabolic Changes see Warnings and Precautions,0,0.5715506076812744
SAPHRIS,Orthostatic Hypotension,Orthostatic Hypotension Syncope and other Hemodynamic,1,0.8870694637298584
SAPHRIS,Orthostatic Hypotension,see Adverse Orthostatic,1,0.8609822988510132
SAPHRIS,Orthostatic Hypotension,and other Hemodynamic Effects see Warnings and Precautions Leukopenia Neut,0,0.593964695930481
SAPHRIS,Syncope,Reactions,0,0.5595884323120117
SAPHRIS,Syncope,and inflammation see,0,0.47397756576538086
SAPHRIS,Syncope,Syncope,1,0.9999998807907104
SAPHRIS,Syncope,and,0,0.5105896592140198
SAPHRIS,Syncope,Syncope and other Hemodynamic,1,0.8544108271598816
SAPHRIS,Syncope,Syncope and other Hemodynamic Effects,1,0.8327653408050537
SAPHRIS,Syncope,Adverse Reactions Orthostatic Syncope and other Hemodynamic Effects,1,0.7766505479812622
SAPHRIS,Syncope,Syncope and other Hemodynamic Effects see,1,0.8305952548980713
SAPHRIS,Hemodynamic Effects,Hemodynamic Effects,1,1.000000238418579
SAPHRIS,Hemodynamic Effects,Agranulocytosis see Warnin,0,0.47871315479278564
SAPHRIS,Hemodynamic Effects,Hemodynamic Effects see Warnings and Precautions Leukopenia,1,0.8074369430541992
SAPHRIS,Hemodynamic Effects,Reactions Orthostatic Hypotension,0,0.6835907697677612
SAPHRIS,Hemodynamic Effects,and Hemodynamic,1,0.8813326954841614
SAPHRIS,Hemodynamic Effects,Orthostatic Hypotension Syncope and Hemodynamic Effects see Warnings and,1,0.8206566572189331
SAPHRIS,Hemodynamic Effects,and Hemodynamic Effects see Warnings and,1,0.9173420667648315
SAPHRIS,Hemodynamic Effects,and,0,0.48818954825401306
SAPHRIS,Neutropenia,Neutropenia and Agranulocytosis see Warnings,1,0.8252594470977783
SAPHRIS,Neutropenia,Neutropenia and Agranulocytosis see,1,0.877835750579834
SAPHRIS,Neutropenia,Neutropenia and Agranulocytosis see Warnings and,1,0.8241981267929077
SAPHRIS,Neutropenia,Warnings,0,0.5334770679473877
SAPHRIS,Neutropenia,sion Syncope and other Hemodynamic Effects see Warnings and,0,0.49738967418670654
SAPHRIS,Neutropenia,Neutropenia and,1,0.938434362411499
SAPHRIS,Neutropenia,Neutropenia,1,1.0000001192092896
SAPHRIS,Agranulocytosis,and Precautions Leukopenia,0,0.6769914627075195
SAPHRIS,Agranulocytosis,Neutropenia Agranulocytosis,1,0.9100590944290161
SAPHRIS,QT Interval Prolongation,Warnings,0,0.5046653747558594
SAPHRIS,QT Interval Prolongation,QT Interval Prolongation,1,0.9999998807907104
SAPHRIS,QT Interval Prolongation,Warnings and QT Interval Prolongation see,1,0.8738915920257568
SAPHRIS,QT Interval Prolongation,Interval Prolongation see,1,0.7873832583427429
SAPHRIS,QT Interval Prolongation,Neutropenia and Agranulocytosis see,0,0.46958667039871216
SAPHRIS,QT Interval Prolongation,QT Interval Prolongation see Warnings and Precautions,1,0.910836935043335
SAPHRIS,QT Interval Prolongation,Agranulocytosis see Warnings and QT Interval Prolongation,1,0.7574641704559326
SAPHRIS,QT Interval Prolongation,see Warnings and,0,0.47113895416259766
SAPHRIS,Hyperprolactinemia,Warnings and Precautions,0,0.5133588910102844
SAPHRIS,Hyperprolactinemia,see Warnings and Hyperprolactinemia,1,0.863187313079834
SAPHRIS,Hyperprolactinemia,Warnings and Hyperprolactinemia see Warnings and Precautions Seizures,1,0.8132789731025696
SAPHRIS,Hyperprolactinemia,Prolongation see Warnings and Hyperprolactinemia see Warnings,1,0.8471286296844482
SAPHRIS,Hyperprolactinemia,and,0,0.46582555770874023
SAPHRIS,Hyperprolactinemia,Precautions Seizures,0,0.5297583341598511
SAPHRIS,Hyperprolactinemia,see Warnings and Hyperprolactinemia see,1,0.8690850734710693
SAPHRIS,Seizures,Seizures,1,0.9999998211860657
SAPHRIS,Seizures,and Precautions Potential for Cognitive and Motor Impairment,0,0.5779247283935547
SAPHRIS,Seizures,see Warnings and Precautions Potential for,0,0.5510870218276978
SAPHRIS,Seizures,Precautions Hyperprolactinemia,0,0.5584716200828552
SAPHRIS,Suicide,Suicide see,1,0.8589403629302979
SAPHRIS,Suicide,Suicide see Warnings and,1,0.7986450791358948
SAPHRIS,Suicide,Precautions,0,0.5250180959701538
SAPHRIS,Suicide,Temperature Regulation see Warnings,0,0.46764856576919556
SAPHRIS,Suicide,Suicide see Warnings,1,0.803124725818634
SAPHRIS,Suicide,Regulation see Warnings and Suicide,1,0.7298955917358398
SAPHRIS,Suicide,Regulation see Warnings and Suicide see,1,0.7060319781303406
SAPHRIS,Suicide,Dysphagia see Warnings and,0,0.5033619403839111
SAPHRIS,Dysphagia,Dysphagia see Warnings,1,0.8467980623245239
SAPHRIS,Dysphagia,Dysphagia see Warnings and Precautions Use,1,0.8167212009429932
SAPHRIS,Dysphagia,see Warnings and Dysphagia see Warnings and Precautions,1,0.7907141447067261
SAPHRIS,Dysphagia,and,0,0.5502547025680542
SAPHRIS,Dysphagia,Warnings and Dysphagia see Warnings and Precautions Use,1,0.7921624183654785
SAPHRIS,Dysphagia,Warnings and Dysphagia see Warnings,1,0.823635458946228
SAPHRIS,akathisia,akathisia oral hypoesthesia and somnolence,1,0.8219066858291626
SAPHRIS,akathisia,akathisia,1,0.9999998807907104
SAPHRIS,akathisia,adults with schizophrenia akathisia oral hypoesthesia and somnolence,1,0.7719097137451172
SAPHRIS,akathisia,schizophrenia akathisia oral,1,0.8385775089263916
SAPHRIS,akathisia,in adults with schizophrenia akathisia oral hypoesthesia and,1,0.7929959893226624
SAPHRIS,akathisia,safety profile of SAPHRIS in the maintenance treatment of,0,0.5291673541069031
SAPHRIS,oral hypoesthesia,were oral hypoesthesia and somnolence The,1,0.8669896721839905
SAPHRIS,oral hypoesthesia,safety profile of SAPHRIS in the maintenance treatment of,0,0.5714088082313538
SAPHRIS,oral hypoesthesia,oral,1,0.750699520111084
SAPHRIS,oral hypoesthesia,oral hypoesthesia and somnolence,1,0.8890175819396973
SAPHRIS,oral hypoesthesia,oral hypoesthesia and,1,0.9931439161300659
SAPHRIS,oral hypoesthesia,in adults with schizophrenia were akathisia,0,0.5354936718940735
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1,1.0000001192092896
SAPHRIS,oral hypoesthesia,with schizophrenia were oral hypoesthesia and somnolence The safety,1,0.785408616065979
SAPHRIS,oral hypoesthesia,oral hypoesthesia and somnolence The,1,0.8900296688079834
SAPHRIS,somnolence,of schizophrenia in,0,0.5164881348609924
SAPHRIS,somnolence,somnolence The safety profile of,1,0.8370429277420044
SAPHRIS,somnolence,somnolence The safety profile,1,0.8367961645126343
SAPHRIS,somnolence,somnolence The,1,0.9730949997901917
SAPHRIS,somnolence,and,0,0.49241912364959717
SAPHRIS,somnolence,were akathisia oral hypoesthesia,0,0.6083458662033081
SAPHRIS,somnolence,oral hypoesthesia somnolence The safety profile of SAPHRIS,1,0.741862416267395
SAPHRIS,somnolence,somnolence dizziness extrapyramidal,1,0.7202381491661072
SAPHRIS,somnolence,other than akathisia and increased weight and during the,0,0.5822104215621948
SAPHRIS,somnolence,than,0,0.5110822916030884
SAPHRIS,somnolence,somnolence dizziness,1,0.823455274105072
SAPHRIS,somnolence,bipolar I,0,0.5297687649726868
SAPHRIS,somnolence,adults were,0,0.4846380352973938
SAPHRIS,dizziness,dizziness extrapyramidal symptoms other than,1,0.7497589588165283
SAPHRIS,dizziness,dizziness extrapyramidal symptoms other than akathisia,1,0.7305957078933716
SAPHRIS,dizziness,dizziness extrapyramidal,1,0.8110082149505615
SAPHRIS,extrapyramidal symptoms,bipolar I disorder,0,0.5921488404273987
SAPHRIS,extrapyramidal symptoms,in adults were somnolence dizziness,0,0.5920575857162476
SAPHRIS,extrapyramidal symptoms,in,0,0.4799808859825134
SAPHRIS,akathisia,akathisia and,1,0.9612738490104675
SAPHRIS,akathisia,I,0,0.4734339118003845
SAPHRIS,akathisia,trial in bipolar I disorder in adults,0,0.5498577356338501
SAPHRIS,akathisia,akathisia and increased,1,0.9096719026565552
SAPHRIS,akathisia,the adjunctive,0,0.46515655517578125
SAPHRIS,akathisia,dizziness extrapyramidal symptoms,0,0.6610468626022339
SAPHRIS,akathisia,during the adjunctive therapy trial in bipolar I disorder in adults,0,0.5527448058128357
SAPHRIS,increased weight,symptoms other than akathisia increased,1,0.6531185507774353
SAPHRIS,increased weight,symptoms other than akathisia,0,0.5370769500732422
SAPHRIS,increased weight,somnolence and oral hy,0,0.5208772420883179
SAPHRIS,increased weight,akathisia increased,1,0.648298978805542
SAPHRIS,increased weight,than,0,0.5624191761016846
SAPHRIS,increased weight,than akathisia increased weight,1,0.7918405532836914
SAPHRIS,increased weight,were somnolence dizziness,0,0.5115252137184143
SAPHRIS,somnolence,hypoesthesia The adult,0,0.6155939102172852
SAPHRIS,somnolence,weight and during the adjunctive therapy trial in bipolar,0,0.5112724304199219
SAPHRIS,somnolence,during the adjunctive therapy trial in bipolar I disorder,0,0.5103403925895691
SAPHRIS,somnolence,hypoesthesia The adult information below is derived from a clinical trial,0,0.5864313840866089
SAPHRIS,oral hypoesthesia,oral hypoesthesia The adult information,1,0.9319835901260376
SAPHRIS,somnolence,somnolence dizziness dysgeusia oral paresthesia nausea,1,0.7767606973648071
SAPHRIS,somnolence,somnolence dizziness dysgeusia,1,0.781843364238739
SAPHRIS,somnolence,paresthesia nausea increased appetite fatigue and increased weight,0,0.6215417385101318
SAPHRIS,somnolence,increased,0,0.49132397770881653
SAPHRIS,dizziness,reported in pediatric patients,0,0.5332081317901611
SAPHRIS,dizziness,dizziness dysgeusia,1,0.864585280418396
SAPHRIS,dizziness,No new maj,0,0.43361276388168335
SAPHRIS,dizziness,dizziness dysgeusia oral,1,0.8184455037117004
SAPHRIS,dizziness,were,0,0.5186750888824463
SAPHRIS,dizziness,oral paresthesia nausea increased,0,0.6732195615768433
SAPHRIS,dizziness,fatigue and increased,0,0.6284100413322449
SAPHRIS,oral paresthesia,SAPHRIS were somnolence dizziness oral,1,0.6896531581878662
SAPHRIS,oral paresthesia,somnolence dizziness oral paresthesia nausea increased appetite fatigue and,1,0.7531904578208923
SAPHRIS,oral paresthesia,dizziness oral paresthesia nausea increased appetite fatigue,1,0.793199360370636
SAPHRIS,oral paresthesia,somnolence dizziness dysgeusia,0,0.6968306303024292
SAPHRIS,nausea,nausea increased appetite,1,0.818932056427002
SAPHRIS,fatigue,safety findings were reported,0,0.531095564365387
SAPHRIS,fatigue,SAPHRIS,0,0.48766669631004333
SAPHRIS,increased weight,increased weight No new major,1,0.8240095973014832
SAPHRIS,akathisia,Bipolar Disorder Adults,0,0.5362198352813721
SAPHRIS,oral hypoesthesia,Bipolar Disorder Adults Monotherapy somnolence dizziness,0,0.5658872723579407
SAPHRIS,oral hypoesthesia,Schizophrenia Adults oral hypoesthesia somnolence Bipolar Disorder Adults,1,0.7467719316482544
SAPHRIS,oral hypoesthesia,placebo were Schizophrenia,0,0.5848900079727173
SAPHRIS,oral hypoesthesia,Schizophrenia Adults oral hypoesthesia,1,0.8909826874732971
SAPHRIS,oral hypoesthesia,dizziness extrapyramidal sym,0,0.5951959490776062
SAPHRIS,oral hypoesthesia,placebo were Schizophrenia Adults oral hypoesthesia,1,0.8721632957458496
SAPHRIS,oral hypoesthesia,Monotherapy somnolence dizziness extrapyramidal,0,0.5749925374984741
SAPHRIS,oral hypoesthesia,Adults,0,0.5317345857620239
SAPHRIS,oral hypoesthesia,Adults oral hypoesthesia,1,0.9541710615158081
SAPHRIS,somnolence,Bipolar Disorder,0,0.5505073070526123
SAPHRIS,somnolence,hypoesthesia somnolence,0,0.8888794183731079
SAPHRIS,somnolence,increased weight Bipolar,0,0.5107876658439636
SAPHRIS,dizziness,somnolence,0,0.5886321067810059
SAPHRIS,dizziness,increased weight Bipolar Disorder Pediatric P,0,0.5237035751342773
SAPHRIS,dizziness,than akathisia,0,0.5892645120620728
SAPHRIS,dizziness,extrapyramidal symptoms other than akathisia increased weight Bipolar Disorder,0,0.5786873698234558
SAPHRIS,dizziness,Monotherapy dizziness extrapyramidal symptoms other,1,0.7222949862480164
SAPHRIS,dizziness,Adults Monotherapy dizziness extrapyramidal symptoms other than,1,0.6977694034576416
SAPHRIS,dizziness,dizziness,1,0.9999998807907104
SAPHRIS,dizziness,Bipolar Disorder Adults,0,0.5497346520423889
SAPHRIS,dizziness,Disorder Pediatric P,0,0.5066347122192383
SAPHRIS,akathisia,akathisia increased,1,0.9127742648124695
SAPHRIS,akathisia,dizziness extrapyramidal symptoms other akathisia increased,1,0.8191208839416504
SAPHRIS,akathisia,Pediatric,0,0.5167383551597595
SAPHRIS,akathisia,akathisia increased weight Bipolar Disorder,1,0.8350118398666382
SAPHRIS,akathisia,dizziness extrapyramidal symptoms other akathisia increased weight Bipolar Disorder,1,0.7677614688873291
SAPHRIS,akathisia,increased weight,0,0.4965788722038269
SAPHRIS,increased weight,than increased weight Bipolar Disorder Pediatric Patients,1,0.7487000226974487
SAPHRIS,increased weight,increased weight,0,1.0
SAPHRIS,increased weight,extrapyramidal symptoms,0,0.5632506012916565
SAPHRIS,increased weight,dizziness extrapyramidal symptoms other than akathisia,0,0.5517194271087646
SAPHRIS,increased weight,Pediatric Patients Monotherapy somnolence dizziness dysgeusia oral pa,0,0.5066717267036438
SAPHRIS,somnolence,fatigue increased weight,0,0.5814536809921265
SAPHRIS,somnolence,somnolence dizziness dysgeusia oral,1,0.7650852203369141
SAPHRIS,dizziness,dizziness dysgeusia oral paresthesia,1,0.8285508751869202
SAPHRIS,dizziness,Monotherapy somnolence,0,0.588320255279541
SAPHRIS,dizziness,Bipolar Disorder Pediatric,0,0.49328750371932983
SAPHRIS,dizziness,Disorder Pediatric Patients Monotherapy dizziness,1,0.7807531952857971
SAPHRIS,dizziness,Patients,0,0.5751866698265076
SAPHRIS,dizziness,dizziness dysgeusia oral paresthesia nausea increased,1,0.7970274686813354
SAPHRIS,dysgeusia,dysgeusia,1,1.0000001192092896
SAPHRIS,dysgeusia,dysgeusia oral paresthesia nausea increased appetite,1,0.8614420890808105
SAPHRIS,dysgeusia,dizziness,0,0.6838171482086182
SAPHRIS,dysgeusia,nausea increased appetite fatigue increased weight Bipolar Disorder,0,0.604799211025238
SAPHRIS,oral paresthesia,Patients Monotherapy somnolence dizziness oral paresthesia,1,0.7605586051940918
SAPHRIS,oral paresthesia,dizziness oral paresthesia nausea increased appetite,1,0.8100904226303101
SAPHRIS,oral paresthesia,Pediatric Patients Monotherapy somnolence dizziness dysgeusia,0,0.6771456003189087
SAPHRIS,oral paresthesia,oral,1,0.787158191204071
SAPHRIS,nausea,nausea,1,1.0
SAPHRIS,nausea,nausea increased appetite fatigue,1,0.8011879920959473
SAPHRIS,nausea,dysgeusia oral paresthesia,0,0.6163138151168823
SAPHRIS,increased appetite,increased appetite,1,0.9999999403953552
SAPHRIS,increased appetite,paresthesia increased appetite,1,0.8843026161193848
SAPHRIS,fatigue,fatigue increased,1,0.8774076104164124
SAPHRIS,fatigue,Adults,0,0.5682432651519775
SAPHRIS,fatigue,fatigue,1,1.0
SAPHRIS,increased weight,dizziness dysgeusia oral paresthesia nausea increased appetite fatigue,0,0.625691294670105
SAPHRIS,increased weight,paresthesia nausea increased appetite increased weight,1,0.7691789269447327
SAPHRIS,increased weight,oral hypoesthesia To,0,0.5247560739517212
SAPHRIS,increased weight,nausea increased,0,0.7004356980323792
SAPHRIS,increased weight,increased weight,1,1.0
SAPHRIS,increased weight,appetite,0,0.6461011171340942
SAPHRIS,increased weight,increased weight Bipolar Disorder,1,0.8129740357398987
SAPHRIS,somnolence,somnolence oral hypoesthesia To report SUSPECTED,1,0.8021514415740967
SAPHRIS,somnolence,Disorder Adults somnolence oral hypoesthesia To,1,0.8001339435577393
SAPHRIS,somnolence,Bipolar Disorder Adults somnolence oral hypoesthesia To report,1,0.7434587478637695
SAPHRIS,somnolence,weight Bipolar Disorder Adults,0,0.498553991317749
SAPHRIS,somnolence,Disorder Adults somnolence oral,1,0.8096125721931458
SAPHRIS,somnolence,increased weight Bipolar Disorder,0,0.4953024685382843
SAPHRIS,somnolence,contact Forest Laboratories LLC,0,0.462863564491272
SAPHRIS,oral hypoesthesia,increased,0,0.5234358310699463
SAPHRIS,oral hypoesthesia,To report SUSPECTED ADVERSE REACTIONS contact Forest Laboratories LLC,0,0.5104931592941284
SAPHRIS,oral hypoesthesia,oral hypoesthesia To report,1,0.9529901742935181
SAPHRIS,oral hypoesthesia,Adults Adjunctive oral hypoesthesia,1,0.9236871004104614
SAPHRIS,Akathisia,Akathisia includes,1,0.932929277420044
SAPHRIS,Akathisia,Extrapyramidal,0,0.686612606048584
SAPHRIS,Akathisia,Akathisia includes akathisia and,1,0.9032845497131348
SAPHRIS,Akathisia,Trials,0,0.5270707607269287
SAPHRIS,akathisia,Trials,0,0.5270707607269287
SAPHRIS,hyperkinesia,akathisia hyperkinesia,1,0.9100082516670227
SAPHRIS,hyperkinesia,Trials,0,0.5317240953445435
SAPHRIS,hyperkinesia,in Week Schizophrenia Trials Akathisia includes,0,0.6659849286079407
SAPHRIS,hyperkinesia,in the Placebo Group,0,0.535332202911377
SAPHRIS,hyperkinesia,hyperkinesia Extrapyramidal symptoms included dystonia oculogyration,1,0.7978653311729431
SAPHRIS,hyperkinesia,includes akathisia hyperkinesia Extrapyramidal,1,0.8231750130653381
SAPHRIS,hyperkinesia,Akathisia includes akathisia hyperkinesia Extrapyramidal symptoms included,1,0.7566472291946411
SAPHRIS,Extrapyramidal symptoms,Akathisia includes akathisia and Extrapyramidal,1,0.8234834671020508
SAPHRIS,Extrapyramidal symptoms,Extrapyramidal symptoms included dystonia oculogyration,1,0.9093055725097656
SAPHRIS,Extrapyramidal symptoms,and hyperkinesia,0,0.6517818570137024
SAPHRIS,Extrapyramidal symptoms,rigidity,0,0.5352065563201904
SAPHRIS,Extrapyramidal symptoms,Extrapyramidal symptoms included dystonia oculogyration dyskinesia,1,0.9193707704544067
SAPHRIS,Extrapyramidal symptoms,Akathisia includes akathisia and Extrapyramidal symptoms,1,0.8721608519554138
SAPHRIS,Extrapyramidal symptoms,Extrapyramidal symptoms included dystonia,1,0.931244969367981
SAPHRIS,Extrapyramidal symptoms,dyskinesia,0,0.686900794506073
SAPHRIS,Extrapyramidal symptoms,akathisia and Extrapyramidal symptoms,1,0.9092514514923096
SAPHRIS,dystonia,dystonia oculogyration,1,0.8396871089935303
SAPHRIS,dystonia,dystonia oculogyration dyskinesia tardive,1,0.8118022680282593
SAPHRIS,dystonia,dyskinesia muscle rigidity parkinsonism tremor and extrapyr,0,0.7592408657073975
SAPHRIS,dystonia,tardive dyskinesia muscle rigidity parkinsonism tremor,0,0.7195886373519897
SAPHRIS,dystonia,oculogyration dyskinesia tardive dyskinesia muscle rigidity parkinsonism tremor,0,0.7295620441436768
SAPHRIS,dystonia,rigidity parkinsonism tremor and,0,0.7202659249305725
SAPHRIS,dystonia,Extrapyramidal symptoms dystonia oculogyration dyskinesia tardive dyskinesia,1,0.7514892816543579
SAPHRIS,dystonia,hyperkinesia Extrapyramidal symptoms,0,0.6692688465118408
SAPHRIS,dystonia,symptoms,0,0.5726558566093445
SAPHRIS,oculogyration,hyperkinesia Extrapyramidal symptoms included,0,0.5420119762420654
SAPHRIS,oculogyration,Extrapyramidal symptoms included oculogyration dyskinesia tardive dyskinesia muscle,1,0.6393458247184753
SAPHRIS,dyskinesia,dyskinesia tardive dyskinesia,1,0.8476265072822571
SAPHRIS,tardive dyskinesia,tardive dyskinesia,1,1.000000238418579
SAPHRIS,tardive dyskinesia,oculogyration tardive dyskinesia muscle,1,0.8577415943145752
SAPHRIS,tardive dyskinesia,parkinsonism tremor and extrapyramidal,0,0.7454460859298706
SAPHRIS,tardive dyskinesia,and,0,0.4579055607318878
SAPHRIS,tardive dyskinesia,tardive dyskinesia muscle rigidity parkinsonism tremor,1,0.9127752780914307
SAPHRIS,muscle rigidity,dyskinesia,0,0.6340988874435425
SAPHRIS,muscle rigidity,tardive muscle rigidity,1,0.81855708360672
SAPHRIS,muscle rigidity,included,0,0.4819428324699402
SAPHRIS,muscle rigidity,muscle rigidity parkinsonism tremor and extrapyramidal disorder,1,0.7701489925384521
SAPHRIS,muscle rigidity,oculogyration dyskinesia tardive muscle,1,0.6150369644165039
SAPHRIS,muscle rigidity,included dystonia oculogyration dyskinesia tardive,0,0.5790983438491821
SAPHRIS,parkinsonism,parkinsonism tremor and,1,0.9124155044555664
SAPHRIS,tremor,muscle rigidity tremor and extrapyramidal disorder excluding,1,0.7565301656723022
SAPHRIS,tremor,parkinsonism tremor and,1,0.8467806577682495
SAPHRIS,extrapyramidal disorder,muscle rigidity parkinsonism tremor extrapyramidal disorder excluding akathisia Somnolence includes,1,0.820127546787262
SAPHRIS,extrapyramidal disorder,parkinsonism tremor and,1,0.7021924257278442
SAPHRIS,extrapyramidal disorder,extrapyramidal disorder excluding akathisia Somnolence,1,0.8889079093933105
SAPHRIS,extrapyramidal disorder,extrapyramidal disorder excluding,1,0.9313497543334961
SAPHRIS,extrapyramidal disorder,Somnolence includes,0,0.549038827419281
SAPHRIS,extrapyramidal disorder,akathisia Somnolence includes the following,0,0.6314889788627625
SAPHRIS,extrapyramidal disorder,includes the following events,0,0.5140768885612488
SAPHRIS,akathisia,and hypersomnia S,0,0.5760887861251831
SAPHRIS,akathisia,dyskinesia muscle rigidity parkinsonism tremor and extrapyramidal disorder excluding,0,0.6344100832939148
SAPHRIS,akathisia,extrapyramidal disorder excluding,0,0.6895488500595093
SAPHRIS,akathisia,excluding,0,0.5219706296920776
SAPHRIS,akathisia,tremor and extrapyramidal disorder akathisia Somnolence includes the,1,0.8098779320716858
SAPHRIS,akathisia,rigidity,0,0.5144155621528625
SAPHRIS,akathisia,akathisia Somnolence includes the following events,1,0.7973119020462036
SAPHRIS,akathisia,parkinsonism,0,0.6109848022460938
SAPHRIS,akathisia,muscle rigidity,0,0.5191673040390015
SAPHRIS,Somnolence,extrapyramidal disorder excluding Somnolence includes the,1,0.6758750677108765
SAPHRIS,Somnolence,muscle rigidity,0,0.5158361792564392
SAPHRIS,Somnolence,Somnolence includes the,1,0.9548037052154541
SAPHRIS,Somnolence,Somnolence includes,1,0.9313420057296753
SAPHRIS,Somnolence,Somnolence,1,1.0
SAPHRIS,Somnolence,somnolence sedation and hypersomnia S Also includes,0,0.8071407079696655
SAPHRIS,somnolence,somnolence sedation and,1,0.8751116394996643
SAPHRIS,somnolence,somnolence sedation and hypersomnia,1,0.8123128414154053
SAPHRIS,somnolence,disorder excluding akathisia Somnolence includes the following events,0,0.8078888654708862
SAPHRIS,somnolence,includes the Flexibledose trial,0,0.5040990114212036
SAPHRIS,somnolence,the following events,0,0.5070545673370361
SAPHRIS,somnolence,somnolence sedation and hypersomnia S,1,0.8117307424545288
SAPHRIS,somnolence,events,0,0.5115439295768738
SAPHRIS,somnolence,Somnolence includes the following somnolence sedation and,1,0.8825758695602417
SAPHRIS,sedation,sedation and,1,0.9342281222343445
SAPHRIS,sedation,trial,0,0.5770635604858398
SAPHRIS,sedation,sedation and hypersomnia S Also includes,1,0.8248295783996582
SAPHRIS,sedation,disorder excluding akathisia,0,0.5394622087478638
SAPHRIS,hypersomnia,hypersomnia S Also,1,0.9333297610282898
SAPHRIS,hypersomnia,disorder excluding akathisia,0,0.5526052713394165
SAPHRIS,akathisia,the incidence akathisia appeared to be,1,0.882641077041626
SAPHRIS,akathisia,disorder excluding akathisia,0,0.8394144177436829
SAPHRIS,akathisia,akathisia appeared to be doserelated,1,0.9013581275939941
SAPHRIS,akathisia,schizophrenia trials the incidence akathisia appeared to be doserelated seeTable,1,0.8235375285148621
SAPHRIS,akathisia,Reactions In the short term schizophrenia trials the,0,0.5580242872238159
SAPHRIS,akathisia,akathisia appeared to be,1,0.9258692264556885
SAPHRIS,anxiety,oral hypoesthesia compared to placebo Adverse Reactions Occurring,0,0.5764251947402954
SAPHRIS,anxiety,the placebo rate anxiety and,1,0.769530177116394
SAPHRIS,anxiety,treated with SAPHRIS rates,0,0.5044132471084595
SAPHRIS,anxiety,the,0,0.6229487657546997
SAPHRIS,anxiety,placebo Adverse Reactions Occurring a,0,0.5799008011817932
SAPHRIS,anxiety,anxiety and oral,1,0.7908792495727539
SAPHRIS,anxiety,anxiety and,1,0.9080883264541626
SAPHRIS,anxiety,placebo rate anxiety and oral hypoesthesia,1,0.7077974081039429
SAPHRIS,oral hypoesthesia,least and at least twice the placebo rate were anxiety,0,0.5588724613189697
SAPHRIS,Extrapyramidal symptoms,twice daily with flexible Extrapyramidal symptoms included,1,0.8873010873794556
SAPHRIS,Extrapyramidal symptoms,least and at least twice the placebo rate were anxiety,0,0.5633527040481567
SAPHRIS,dystonia,muscle rigidity,0,0.6545348167419434
SAPHRIS,dystonia,with flexible dosing Extrapyramidal,0,0.6103765964508057
SAPHRIS,dystonia,Extrapyramidal symptoms dystonia blepharospasm torticollis dyskinesia tardive,1,0.7586577534675598
SAPHRIS,dystonia,dystonia blepharospasm torticollis dyskinesia,1,0.8672896027565002
SAPHRIS,blepharospasm,dosing Extrapyramidal symptoms included blepharospasm torticollis,1,0.7875272035598755
SAPHRIS,blepharospasm,dystonia blepharospasm torticollis dyskinesia,1,0.8193590044975281
SAPHRIS,blepharospasm,daily with flexible dosing,0,0.5256491899490356
SAPHRIS,blepharospasm,blepharospasm torticollis dyskinesia tardive,1,0.8571780323982239
SAPHRIS,torticollis,disturbance masked facies,0,0.49141594767570496
SAPHRIS,torticollis,flexible,0,0.5084666013717651
SAPHRIS,torticollis,symptoms included dystonia torticollis dyskinesia,1,0.728356122970581
SAPHRIS,torticollis,torticollis dyskinesia tardive,1,0.7882068753242493
SAPHRIS,torticollis,included dystonia torticollis dyskinesia tardive dyskinesia,1,0.727394700050354
SAPHRIS,torticollis,included dystonia torticollis dyskinesia tardive dyskinesia muscle rigidity,1,0.7300140261650085
SAPHRIS,tardive dyskinesia,torticollis tardive dyskinesia,1,0.9003447890281677
SAPHRIS,tardive dyskinesia,blepharospasm torticollis tardive dyskinesia muscle rigidity parkinsonism gait,1,0.8298752307891846
SAPHRIS,tardive dyskinesia,tardive dyskinesia muscle rigidity parkinsonism,1,0.9077960252761841
SAPHRIS,tardive dyskinesia,tremor excluding akathisia,0,0.7025802135467529
SAPHRIS,muscle rigidity,symptoms included dystonia blepharospasm torticollis dyskinesia tardive dyskinesia,0,0.5887826681137085
SAPHRIS,muscle rigidity,blepharospasm torticollis dyskinesia tardive muscle rigidity parkinsonism gait,1,0.6825917363166809
SAPHRIS,parkinsonism,rigidity,0,0.5841275453567505
SAPHRIS,parkinsonism,tardive dyskinesia muscle parkinsonism gait disturbance,1,0.7555640935897827
SAPHRIS,parkinsonism,and tremor excluding akathisia,0,0.711797833442688
SAPHRIS,parkinsonism,parkinsonism gait disturbance masked facies,1,0.7981729507446289
SAPHRIS,parkinsonism,parkinsonism gait disturbance,1,0.8284537196159363
SAPHRIS,parkinsonism,muscle,0,0.5815935134887695
SAPHRIS,gait disturbance,gait disturbance masked facies and tremor excluding,1,0.8355779647827148
SAPHRIS,gait disturbance,gait disturbance masked facies,1,0.8246095180511475
SAPHRIS,gait disturbance,gait disturbance masked facies and,1,0.8509756922721863
SAPHRIS,masked facies,rigidity parkinsonism,0,0.5119837522506714
SAPHRIS,masked facies,muscle rigidity parkinsonism gait disturbance,0,0.45428991317749023
SAPHRIS,masked facies,and tremor excluding akathisia Somnolence includes the following events,0,0.4838973879814148
SAPHRIS,masked facies,muscle rigidity parkinsonism gait masked facies,1,0.6940996646881104
SAPHRIS,masked facies,masked facies,1,0.9999998211860657
SAPHRIS,masked facies,parkinsonism gait masked facies,1,0.7387682795524597
SAPHRIS,masked facies,excluding,0,0.5290707349777222
SAPHRIS,tremor,somnolence,0,0.5576401948928833
SAPHRIS,tremor,tremor excluding akathisia Somnolence,1,0.7988862991333008
SAPHRIS,tremor,tremor,1,0.9999998807907104
SAPHRIS,tremor,gait disturbance masked facies tremor excluding,1,0.7887849807739258
SAPHRIS,tremor,tremor excluding akathisia Somnolence includes the,1,0.7569218873977661
SAPHRIS,akathisia,akathisia Somnolence includes,1,0.8255479335784912
SAPHRIS,akathisia,akathisia Somnolence includes the following,1,0.8165410757064819
SAPHRIS,akathisia,disturbance masked facies and tremor,0,0.6178362369537354
SAPHRIS,akathisia,events somnolence sedation,0,0.5718460083007812
SAPHRIS,akathisia,akathisia Somnolence includes the,1,0.8287099599838257
SAPHRIS,akathisia,tremor akathisia,1,0.8852787017822266
SAPHRIS,akathisia,somnolence sedation and hypersomnia,0,0.5731073021888733
SAPHRIS,Somnolence,facies and tremor excluding akathisia,0,0.5658407211303711
SAPHRIS,Somnolence,Somnolence includes the following events,1,0.8879724740982056
SAPHRIS,Somnolence,rigidity,0,0.5309891700744629
SAPHRIS,somnolence,somnolence,1,1.0
SAPHRIS,somnolence,somnolence sedation,1,0.871126651763916
SAPHRIS,somnolence,somnolence sedation and hypersomnia System,1,0.795478105545044
SAPHRIS,somnolence,facies and tremor excluding akathisia Somnolence includes,0,0.7336908578872681
SAPHRIS,sedation,and hypersomnia System Organ ClassPreferred,0,0.5993666052818298
SAPHRIS,sedation,sedation and hypersomnia System,1,0.8129827976226807
SAPHRIS,sedation,and tremor excluding akathisia Somnolence includes the following,0,0.5862351655960083
SAPHRIS,hypersomnia,hypersomnia System Organ ClassPreferred,1,0.8070352077484131
SAPHRIS,hypersomnia,events,0,0.48539483547210693
SAPHRIS,hypersomnia,somnolence sedation hypersomnia System Organ ClassPreferred Term Placebo,1,0.7546862363815308
SAPHRIS,hypersomnia,sedation hypersomnia System Organ ClassPreferred Term Placebo,1,0.749222993850708
SAPHRIS,hypersomnia,Organ,0,0.4387950897216797
SAPHRIS,hypersomnia,sedation and,0,0.5907553434371948
SAPHRIS,abdominal pain,in the mg twice daily group and nausea in the mg twice daily,0,0.5618612766265869
SAPHRIS,abdominal pain,mg twice daily abdominal pain in the mg twice,1,0.8023519515991211
SAPHRIS,abdominal pain,in the mg twice daily group and in the mg twice daily,0,0.49382567405700684
SAPHRIS,abdominal pain,abdominal pain,1,0.9999998807907104
SAPHRIS,tachycardia,terms oral hypoesthesia oral paresthesia,0,0.5649850368499756
SAPHRIS,tachycardia,oral hypoesthesia oral,0,0.5709042549133301
SAPHRIS,tachycardia,a,0,0.5718467235565186
SAPHRIS,tachycardia,tachycardia and heart,1,0.9273319244384766
SAPHRIS,tachycardia,Placebo Group,0,0.5516058206558228
SAPHRIS,heart rate increased,tachycardia heart,1,0.7533853054046631
SAPHRIS,heart rate increased,rate increased Includes the,1,0.646924614906311
SAPHRIS,heart rate increased,heart rate increased Includes,1,0.9669004082679749
SAPHRIS,heart rate increased,rate increased Includes the preferred,1,0.5941779613494873
SAPHRIS,heart rate increased,and,0,0.4705480933189392
SAPHRIS,heart rate increased,rate increased Includes,1,0.6473352313041687
SAPHRIS,heart rate increased,the Placebo Group in a Week Bipolar Mania Trial Includes the,0,0.5103227496147156
SAPHRIS,heart rate increased,heart rate increased Includes the preferred terms oral,1,0.8592883348464966
SAPHRIS,heart rate increased,Includes the preferred,0,0.4704945683479309
SAPHRIS,oral hypoesthesia,terms,0,0.5109962224960327
SAPHRIS,oral hypoesthesia,increased Includes the preferred terms,0,0.5040576457977295
SAPHRIS,oral hypoesthesia,tachycardia and heart rate increased Includes the preferred terms,0,0.5478552579879761
SAPHRIS,oral hypoesthesia,Includes the,0,0.49785077571868896
SAPHRIS,oral hypoesthesia,Includes the preferred oral hypoesthesia oral paresthesia,1,0.8929073810577393
SAPHRIS,oral paresthesia,oral oral paresthesia and oral dysesthesia Includes,1,0.895117461681366
SAPHRIS,oral paresthesia,oral hypoesthesia,1,0.7957625389099121
SAPHRIS,oral paresthesia,the preferred terms oral oral paresthesia and oral dysesthesia Includes the,1,0.8709710836410522
SAPHRIS,oral paresthesia,terms oral oral paresthesia,1,0.9625074863433838
SAPHRIS,oral paresthesia,hypoesthesia,0,0.6729649305343628
SAPHRIS,oral dysesthesia,oral paresthesia and,0,0.7831346988677979
SAPHRIS,oral dysesthesia,oral dysesthesia Includes the preferred terms abdominal,1,0.8645439147949219
SAPHRIS,oral dysesthesia,paresthesia oral dysesthesia Includes the preferred,1,0.87952721118927
SAPHRIS,oral dysesthesia,paresthesia oral dysesthesia,1,0.9141000509262085
SAPHRIS,oral dysesthesia,oral paresthesia oral dysesthesia Includes the,1,0.914567232131958
SAPHRIS,oral dysesthesia,paresthesia oral dysesthesia Includes the preferred terms,1,0.8691754341125488
SAPHRIS,oral dysesthesia,preferred terms oral hypoesthesia oral,0,0.751645565032959
SAPHRIS,abdominal pain,erms oral hypoesthesia oral paresthesia and oral dysesthesia Includes,0,0.4969383180141449
SAPHRIS,abdominal pain,and abdominal,0,0.770221471786499
SAPHRIS,abdominal pain,discomfort Includes,0,0.6273717880249023
SAPHRIS,abdominal pain,lower,0,0.47569525241851807
SAPHRIS,abdominal pain,preferred abdominal pain,1,0.8864245414733887
SAPHRIS,abdominal pain,Includes the,0,0.454085111618042
SAPHRIS,abdominal pain,oral,0,0.4728153347969055
SAPHRIS,abdominal pain upper,preferred terms,0,0.4343430995941162
SAPHRIS,abdominal pain upper,abdominal abdominal,1,0.7378206849098206
SAPHRIS,abdominal pain upper,Includes the,0,0.4647841453552246
SAPHRIS,abdominal pain upper,terms abdominal abdominal pain upper,1,0.9589027166366577
SAPHRIS,abdominal pain upper,abdominal pain upper abdominal pain lower and abdominal,1,0.9108707904815674
SAPHRIS,abdominal pain upper,the preferred terms abdominal abdominal pain upper abdominal,1,0.8782787919044495
SAPHRIS,abdominal pain upper,terms abdominal abdominal pain upper abdominal,1,0.9333524703979492
SAPHRIS,abdominal pain upper,pain upper abdominal pain lower and abdominal,1,0.9136475324630737
SAPHRIS,abdominal pain lower,pain,0,0.6443053483963013
SAPHRIS,abdominal pain lower,oral dysesthesia Includes,0,0.49350041151046753
SAPHRIS,abdominal pain lower,pain lower,1,0.8379349112510681
SAPHRIS,abdominal pain lower,pain abdominal pain lower and abdominal discomfort,1,0.9452094435691833
SAPHRIS,abdominal pain lower,Includes the,0,0.4466979205608368
SAPHRIS,abdominal pain lower,abdominal discomfort Includes,0,0.8357253670692444
SAPHRIS,abdominal pain lower,Includes the preferred terms abdominal,0,0.6681073904037476
SAPHRIS,abdominal discomfort,and,0,0.4665776789188385
SAPHRIS,abdominal discomfort,abdominal discomfort Includes the preferred,1,0.8747134804725647
SAPHRIS,abdominal discomfort,abdominal discomfort Includes the preferred terms,1,0.8709425926208496
SAPHRIS,abdominal discomfort,abdominal discomfort Includes,1,0.9494108557701111
SAPHRIS,abdominal discomfort,preferred terms abdominal pain abdominal pain,0,0.8420919179916382
SAPHRIS,abdominal discomfort,pain lower abdominal discomfort Includes the,1,0.8844077587127686
SAPHRIS,abdominal discomfort,abdominal pain,0,0.9482358694076538
SAPHRIS,abdominal discomfort,upper abdominal pain lower abdominal discomfort Includes the preferred terms fatigue,1,0.8198251128196716
SAPHRIS,abdominal discomfort,abdominal pain lower abdominal discomfort,1,0.9214261174201965
SAPHRIS,fatigue,fatigue and,1,0.9332207441329956
SAPHRIS,fatigue,discomfort Includes the preferred fatigue and lethargy Includes the preferred,1,0.8041597604751587
SAPHRIS,fatigue,preferred fatigue,1,0.8576081991195679
SAPHRIS,lethargy,the preferred terms fatigue lethargy Includes the preferred terms,1,0.8519361019134521
SAPHRIS,lethargy,fatigue,1,0.7723743319511414
SAPHRIS,lethargy,lethargy,1,0.9999998807907104
SAPHRIS,lethargy,the preferred terms fatigue lethargy Includes the preferred terms hyperinsulinemia,1,0.8092362880706787
SAPHRIS,lethargy,preferred terms fatigue lethargy Includes,1,0.8780062794685364
SAPHRIS,lethargy,insulin,0,0.5384483337402344
SAPHRIS,lethargy,terms fatigue lethargy Includes,1,0.9002128839492798
SAPHRIS,lethargy,lethargy Includes the preferred terms,1,0.8938086032867432
SAPHRIS,lethargy,lethargy Includes,1,0.9541918039321899
SAPHRIS,lethargy,terms fatigue,0,0.7366572022438049
SAPHRIS,hyperinsulinemia,hyperinsulinemia and blood,1,0.9021720290184021
SAPHRIS,hyperinsulinemia,lethargy Includes the preferred hyperinsulinemia and blood insulin increased,1,0.7901404500007629
SAPHRIS,hyperinsulinemia,hyperinsulinemia and blood insulin,1,0.9136432409286499
SAPHRIS,hyperinsulinemia,preferred,0,0.47026944160461426
SAPHRIS,hyperinsulinemia,hyperinsulinemia and blood insulin increased Includes,1,0.8946453332901001
SAPHRIS,hyperinsulinemia,hyperinsulinemia and blood insulin increased,1,0.8946306109428406
SAPHRIS,blood insulin increased,blood insulin increased Includes the,1,0.9721429347991943
SAPHRIS,blood insulin increased,blood insulin increased Includes the preferred,1,0.9094952344894409
SAPHRIS,blood insulin increased,hyperinsulinemia blood insulin increased,1,0.9373656511306763
SAPHRIS,blood insulin increased,the preferred terms hyperinsulinemia blood,1,0.7923386693000793
SAPHRIS,blood insulin increased,the preferred terms somnolence sedation,0,0.4783252477645874
SAPHRIS,sedation,increased Includes the,0,0.5006154775619507
SAPHRIS,sedation,terms somnolence,0,0.6419748067855835
SAPHRIS,sedation,the preferred,0,0.5266798734664917
SAPHRIS,sedation,insulin increased Includes the preferred,0,0.5136069059371948
SAPHRIS,sedation,System Organ,0,0.5325614809989929
SAPHRIS,sedation,and blood insulin,0,0.5383682250976562
SAPHRIS,sedation,Includes the preferred terms sedation and hypersomnia System,1,0.8131269216537476
SAPHRIS,fatigue,bipolar trials the incidence fatigue appeared to be doserelated see,1,0.7870796918869019
SAPHRIS,fatigue,and blood insulin,0,0.5602802634239197
SAPHRIS,fatigue,be doserelated,0,0.5530041456222534
SAPHRIS,depression,ideation bipolar,0,0.5922226309776306
SAPHRIS,depression,depression suicidal ideation bipolar I disorder,1,0.7455177307128906
SAPHRIS,depression,disorder insomnia,0,0.6120660305023193
SAPHRIS,depression,depression,1,0.9999998807907104
SAPHRIS,suicidal ideation,and at least,0,0.431216835975647
SAPHRIS,suicidal ideation,disorder insomnia and depressive symptoms,0,0.5998243093490601
SAPHRIS,suicidal ideation,suicidal ideation,1,0.9999998807907104
SAPHRIS,suicidal ideation,suicidal ideation bipolar I disorder insomnia and,1,0.8289469480514526
SAPHRIS,bipolar I disorder,rate were depression suicidal bipolar I disorder,1,0.7915473580360413
SAPHRIS,bipolar I disorder,suicidal ideation bipolar I disorder insomnia and,1,0.787664532661438
SAPHRIS,bipolar I disorder,rate were depression suicidal bipolar I disorder insomnia and depressive,1,0.7277593016624451
SAPHRIS,bipolar I disorder,bipolar,1,0.8320964574813843
SAPHRIS,bipolar I disorder,at least twice the placebo,0,0.4871130883693695
SAPHRIS,bipolar I disorder,bipolar I disorder insomnia and depressive,1,0.8480508327484131
SAPHRIS,insomnia,ideation bipolar I disorder,0,0.5163987874984741
SAPHRIS,insomnia,insomnia,1,1.0000001192092896
SAPHRIS,insomnia,insomnia and depressive symptoms,1,0.8160101771354675
SAPHRIS,insomnia,at an Incidence,0,0.49898573756217957
SAPHRIS,insomnia,insomnia and depressive symptoms Adverse Reactions,1,0.7447487115859985
SAPHRIS,depressive symptoms,depressive symptoms Adverse,1,0.9049772024154663
SAPHRIS,depressive symptoms,bipolar I disorder insomnia depressive symptoms Adverse Reactions Occurring,1,0.7397931814193726
SAPHRIS,depressive symptoms,and,0,0.5041884779930115
SAPHRIS,depressive symptoms,Incidence of,0,0.5574614405632019
SAPHRIS,depressive symptoms,disorder insomnia depressive,1,0.7803358435630798
SAPHRIS,depressive symptoms,or More Among SAPHRISTreated,0,0.515218198299408
SAPHRIS,depressive symptoms,depressive symptoms Adverse Reactions Occurring at,1,0.8249636888504028
SAPHRIS,dystonia,mg to mg twice daily,0,0.5041495561599731
SAPHRIS,dystonia,dystonia parkinsonism oculogyration and tremor excluding,1,0.8188010454177856
SAPHRIS,dystonia,flexible dosing Extrapyramidal symptoms included,0,0.6378039717674255
SAPHRIS,dystonia,Extrapyramidal symptoms dystonia parkinsonism oculogyration and,1,0.778460681438446
SAPHRIS,dystonia,dystonia,1,0.9999998807907104
SAPHRIS,dystonia,flexible dosing Extrapyramidal symptoms dystonia parkinsonism,1,0.7500914335250854
SAPHRIS,dystonia,flexible dosing,0,0.5019608736038208
SAPHRIS,dystonia,dystonia parkinsonism oculogyration and tremor,1,0.8305560350418091
SAPHRIS,dystonia,oculogyration,0,0.5449636578559875
SAPHRIS,dystonia,oculogyration and,0,0.5527518391609192
SAPHRIS,parkinsonism,parkinsonism oculogyration and,1,0.8476221561431885
SAPHRIS,parkinsonism,parkinsonism oculogyration and tremor excluding,1,0.8420768976211548
SAPHRIS,parkinsonism,parkinsonism oculogyration and tremor,1,0.8540012240409851
SAPHRIS,parkinsonism,dosing Extrapyramidal symptoms included dystonia,0,0.6745832562446594
SAPHRIS,parkinsonism,parkinsonism oculogyration,1,0.846368670463562
SAPHRIS,parkinsonism,Extrapyramidal symptoms included dystonia,0,0.6952533721923828
SAPHRIS,parkinsonism,with flexible dosing Extrapyramidal,0,0.6535395979881287
SAPHRIS,oculogyration,oculogyration and,1,0.9827555418014526
SAPHRIS,oculogyration,with flexible dosing Extrapyramidal,0,0.5655237436294556
SAPHRIS,oculogyration,oculogyration,1,1.000000238418579
SAPHRIS,oculogyration,oculogyration and tremor excluding akathisia,1,0.7701476812362671
SAPHRIS,oculogyration,Extrapyramidal symptoms included dystonia oculogyration and,1,0.6606449484825134
SAPHRIS,oculogyration,flexible dosing Extrapyramidal symptoms included dystonia,0,0.5416069030761719
SAPHRIS,oculogyration,Somnolence includes the,0,0.5596592426300049
SAPHRIS,oculogyration,dosing Extrapyramidal symptoms included,0,0.5412904024124146
SAPHRIS,oculogyration,included dystonia oculogyration and tremor excluding akathisia Somnolence,1,0.6616467237472534
SAPHRIS,oculogyration,excluding akathisia Somnolence includes the,0,0.5527450442314148
SAPHRIS,tremor,excluding akathisia Somnolence includes the following,0,0.535537838935852
SAPHRIS,tremor,tremor excluding akathisia,1,0.826431155204773
SAPHRIS,akathisia,and sedation System Organ,0,0.5105724930763245
SAPHRIS,akathisia,Somnolence includes the,0,0.5962376594543457
SAPHRIS,akathisia,parkinsonism oculogyration and tremor excluding,0,0.5930064916610718
SAPHRIS,akathisia,oculogyration,0,0.5728471279144287
SAPHRIS,Somnolence,and tremor excluding Somnolence includes the following events,1,0.7065844535827637
SAPHRIS,Somnolence,oculogyration,0,0.5625999569892883
SAPHRIS,Somnolence,System,0,0.5105592012405396
SAPHRIS,Somnolence,includes the following events,0,0.49522215127944946
SAPHRIS,Somnolence,Somnolence includes the following events somnolence,1,0.8765853047370911
SAPHRIS,somnolence,the following somnolence and sedation,1,0.8587231636047363
SAPHRIS,somnolence,sedation System Organ ClassPreferred Term Placebo N,0,0.5689653158187866
SAPHRIS,somnolence,somnolence and sedation System Organ ClassPreferred,1,0.7871412634849548
SAPHRIS,somnolence,the following somnolence and sedation System,1,0.818396806716919
SAPHRIS,somnolence,Term Placebo,0,0.5454715490341187
SAPHRIS,sedation,events somnolence,0,0.6275421977043152
SAPHRIS,sedation,sedation System Organ ClassPreferred Term,1,0.7751001119613647
SAPHRIS,sedation,Organ ClassPreferred Term Placebo,0,0.6353148818016052
SAPHRIS,sedation,following,0,0.4938594400882721
SAPHRIS,sedation,ClassPreferred Term Placebo N SAPHRIS,0,0.6382754445075989
SAPHRIS,sedation,somnolence sedation System Organ ClassPreferred,1,0.7560283541679382
SAPHRIS,sedation,the following events somnolence sedation,1,0.815632700920105
SAPHRIS,sedation,and tremor,0,0.5936987400054932
SAPHRIS,sedation,tremor excluding akathisia Somnolence includes,0,0.585506021976471
SAPHRIS,dystonia,dystonia prolonged,1,0.8931844234466553
SAPHRIS,dystonia,of,0,0.5346921682357788
SAPHRIS,prolonged abnormal contractions of muscle groups,prolonged abnormal contractions of muscle groups may occur in,1,0.989427387714386
SAPHRIS,prolonged abnormal contractions of muscle groups,of,0,0.5109485387802124
SAPHRIS,prolonged abnormal contractions of muscle groups,contractions of muscle groups may occur,1,0.8583589792251587
SAPHRIS,prolonged abnormal contractions of muscle groups,Dystonia Symptoms of,0,0.6397409439086914
SAPHRIS,prolonged abnormal contractions of muscle groups,Dystonia Symptoms of dystonia,0,0.6298199892044067
SAPHRIS,prolonged abnormal contractions of muscle groups,individuals during the first few days of treatment,0,0.5134685039520264
SAPHRIS,prolonged abnormal contractions of muscle groups,in susceptible individuals during the first few days of treatment Dystonic,0,0.5959381461143494
SAPHRIS,Dystonic symptoms,of muscle groups may occur in susceptible individuals during the first,0,0.6118321418762207
SAPHRIS,Dystonic symptoms,treatment,0,0.5370276570320129
SAPHRIS,Dystonic symptoms,Dystonic symptoms include spasm of the neck,1,0.9217209815979004
SAPHRIS,Dystonic symptoms,Dystonic symptoms include spasm of the,1,0.9514991044998169
SAPHRIS,spasm of the neck muscles,symptoms spasm of the,1,0.8038926124572754
SAPHRIS,spasm of the neck muscles,spasm of the neck muscles sometimes progressing to tightness of,1,0.9244997501373291
SAPHRIS,spasm of the neck muscles,of treatment Dystonic symptoms spasm of the neck muscles,1,0.8605517148971558
SAPHRIS,spasm of the neck muscles,neck muscles sometimes,1,0.8523880839347839
SAPHRIS,spasm of the neck muscles,the first few days of treatment Dystonic symptoms include,0,0.6363054513931274
SAPHRIS,spasm of the neck muscles,of treatment Dystonic symptoms spasm of,1,0.7411941885948181
SAPHRIS,spasm of the neck muscles,difficulty,0,0.4685697555541992
SAPHRIS,spasm of the neck muscles,Dystonic symptoms spasm of the neck muscles sometimes progressing to tightness of,1,0.8544737696647644
SAPHRIS,spasm of the neck muscles,spasm of,1,0.8179378509521484
SAPHRIS,tightness of the throat,andor protrusion of the tongue While these,0,0.604485034942627
SAPHRIS,tightness of the throat,muscles sometimes,0,0.5366045236587524
SAPHRIS,tightness of the throat,tightness of the throat swallowing difficulty difficulty,1,0.8996673226356506
SAPHRIS,tightness of the throat,swallowing difficulty difficulty breathing andor protrusion of the tongue While,0,0.7246191501617432
SAPHRIS,tightness of the throat,progressing tightness,1,0.7190418839454651
SAPHRIS,swallowing difficulty,of the neck,0,0.6019759774208069
SAPHRIS,swallowing difficulty,swallowing difficulty difficulty breathing,1,0.9457208514213562
SAPHRIS,swallowing difficulty,swallowing difficulty difficulty breathing andor protrusion of,1,0.8774961829185486
SAPHRIS,swallowing difficulty,symptoms,0,0.5703089237213135
SAPHRIS,swallowing difficulty,swallowing difficulty difficulty breathing andor protrusion,1,0.8866433501243591
SAPHRIS,swallowing difficulty,tightness of the swallowing difficulty,1,0.9158215522766113
SAPHRIS,swallowing difficulty,of the swallowing difficulty difficulty breathing andor,1,0.9259195923805237
SAPHRIS,swallowing difficulty,tightness of the swallowing difficulty difficulty breathing andor protrusion,1,0.8809617757797241
SAPHRIS,difficulty breathing,difficulty breathing,1,1.0000001192092896
SAPHRIS,difficulty breathing,symptoms can occur,0,0.6411450505256653
SAPHRIS,difficulty breathing,of the throat swallowing difficulty,0,0.711471438407898
SAPHRIS,protrusion of the tongue,the throat swallowing difficulty difficulty breathing,0,0.6619368195533752
SAPHRIS,protrusion of the tongue,of the tongue,1,0.849515438079834
SAPHRIS,protrusion of the tongue,occur at low,0,0.5027758479118347
SAPHRIS,protrusion of the tongue,andor,0,0.48376914858818054
SAPHRIS,acute dystonia,is observed in males and younger age groups see Dosage and Administration Use in Specific,0,0.5404266119003296
SAPHRIS,extrapyramidal symptoms,Simpson Angus Rating Scale extrapyramidal,1,0.803308367729187
SAPHRIS,extrapyramidal symptoms,Scale extrapyramidal,1,0.8484956622123718
SAPHRIS,extrapyramidal symptoms,akathisia and the,0,0.719585657119751
SAPHRIS,EPS,EPS,1,0.9999998807907104
SAPHRIS,EPS,the Assessments of Involuntary,0,0.5612314939498901
SAPHRIS,EPS,EPS the Barnes Akathisia Scale,1,0.6510899066925049
SAPHRIS,EPS,collected on the,0,0.5680109262466431
SAPHRIS,EPS,for akathisia and the Assessments of,0,0.5695102214813232
SAPHRIS,EPS,extrapyramidal symptoms,0,0.541534960269928
SAPHRIS,EPS,EPS the Barnes Akathisia,1,0.6434767246246338
SAPHRIS,EPS,akathisia and the Assessments of Involuntary,0,0.552272617816925
SAPHRIS,akathisia,symptoms EPS the Barnes,0,0.582893967628479
SAPHRIS,akathisia,Barnes Akathisia Scale for,0,0.8490102291107178
SAPHRIS,akathisia,change from,0,0.47997385263442993
SAPHRIS,akathisia,akathisia and the,1,0.96284019947052
SAPHRIS,dyskinesias,dyskinesias The,1,0.9650583267211914
SAPHRIS,dyskinesias,Scales dyskinesias The mean change,1,0.854971170425415
SAPHRIS,EPS-related events,placebocontrolled schizophrenia adult trials the incidence of,0,0.5011717677116394
SAPHRIS,EPS-related events,the incidence,0,0.5713872909545898
SAPHRIS,EPS-related events,excluding events,0,0.6855700612068176
SAPHRIS,akathisia,akathisia related events for,1,0.8803519606590271
SAPHRIS,EPS-related events,In shortterm placebocontrolled bipolar mania adult trials,0,0.515326738357544
SAPHRIS,EPS-related events,was,0,0.5637648701667786
SAPHRIS,EPS-related events,shortterm placebocontrolled bipolar mania adult trials the incidence,0,0.5276033878326416
SAPHRIS,EPS-related events,placebo In shortterm placebocontrolled bipolar mania adult trials the,0,0.5050906538963318
SAPHRIS,EPS-related events,the,0,0.5016911625862122
SAPHRIS,EPS-related events,EPS-related events excluding events related to akathisia,1,0.8355134725570679
SAPHRIS,EPS-related events,adult trials the incidence,0,0.565752387046814
SAPHRIS,EPS-related events,EPS-related events,1,1.000000238418579
SAPHRIS,akathisia,versus for,0,0.49860522150993347
SAPHRIS,akathisia,versus for placebo and the,0,0.5040885210037231
SAPHRIS,akathisia,akathisia for SAPHRIStreated patients was,1,0.8748120665550232
SAPHRIS,akathisia,akathisia for,1,0.9598599672317505
SAPHRIS,akathisia,EPSrelated events excluding events related,0,0.5237613916397095
SAPHRIS,akathisia,the incidence akathisia related events for SAPHRIStreated patients,1,0.8353858590126038
SAPHRIS,akathisia,and the incidence,0,0.5428381562232971
SAPHRIS,akathisia,SAPHRIStreated patients,0,0.5524259805679321
SAPHRIS,akathisia,In a week,0,0.4707213044166565
SAPHRIS,akathisia,placebo and the incidence akathisia related events,1,0.8156663775444031
SAPHRIS,akathisia,akathisia related events for SAPHRIStreated patients,1,0.8466073274612427
SAPHRIS,EPS-related events,with SAPHRIS m,0,0.563530683517456
SAPHRIS,akathisia,mg twice daily,0,0.5522165894508362
SAPHRIS,akathisia,excluding events related akathisia were and for patients treated,1,0.8315210342407227
SAPHRIS,EPS-related events,respectively as compared to for placebotreated,0,0.512506365776062
SAPHRIS,EPS-related events,to for placebotreated EPS-related events,1,0.8244228363037109
SAPHRIS,EPS-related events,daily respectively as,0,0.5213243961334229
SAPHRIS,bradykinesia,bradykinesia dyskinesia dystonia oromandibular,1,0.8290396332740784
SAPHRIS,bradykinesia,oromandibular dystonia muscle contractions,0,0.6666056513786316
SAPHRIS,bradykinesia,to for placebotreated patients,0,0.5059382915496826
SAPHRIS,bradykinesia,placebotreated patients EPSrelated events bradykinesia dyskinesia dystonia oromandibular dystonia muscle,1,0.730857253074646
SAPHRIS,dyskinesia,dyskinesia dystonia oromandibular dystonia muscle contractions,1,0.7998074293136597
SAPHRIS,dyskinesia,dyskinesia dystonia oromandibular dystonia muscle,1,0.8046507835388184
SAPHRIS,dyskinesia,include bradykinesia,0,0.7533725500106812
SAPHRIS,dyskinesia,patients EPSrelated events include bradykinesia,0,0.7351375818252563
SAPHRIS,dyskinesia,include dyskinesia dystonia oromandibular,1,0.8485049605369568
SAPHRIS,dyskinesia,EPSrelated events include dyskinesia dystonia,1,0.8202870488166809
SAPHRIS,dyskinesia,as compared to for placebotreated patients EPSrelated events include,0,0.5482380986213684
SAPHRIS,dyskinesia,involuntary muscle twitching,0,0.6614675521850586
SAPHRIS,dyskinesia,dyskinesia,1,1.0
SAPHRIS,dyskinesia,dyskinesia dystonia oromandibular,1,0.8472239971160889
SAPHRIS,dystonia,dystonia oromandibular dystonia muscle contractions involuntary,1,0.8337939977645874
SAPHRIS,dystonia,dyskinesia,0,0.7939889430999756
SAPHRIS,dystonia,dystonia oromandibular,1,0.833244264125824
SAPHRIS,dystonia,dystonia muscle contractions,0,0.8787569403648376
SAPHRIS,dystonia,oromandibular dystonia muscle,0,0.8199419975280762
SAPHRIS,oromandibular dystonia,oromandibular dystonia muscle,1,0.9688085913658142
SAPHRIS,oromandibular dystonia,events include bradykinesia dyskinesia oromandibular dystonia muscle contractions,1,0.8346728086471558
SAPHRIS,oromandibular dystonia,events include bradykinesia dyskinesia oromandibular dystonia,1,0.84295654296875
SAPHRIS,oromandibular dystonia,oromandibular dystonia,1,0.9999997615814209
SAPHRIS,oromandibular dystonia,oromandibular,1,0.8227092027664185
SAPHRIS,muscle contractions involuntary,oromandibular,0,0.4867323935031891
SAPHRIS,muscle contractions involuntary,bradykinesia dyskinesia dystonia oromandibular muscle contractions,1,0.7408164739608765
SAPHRIS,muscle contractions involuntary,muscle contractions involuntary,1,1.0000001192092896
SAPHRIS,muscle contractions involuntary,contractions involuntary,1,0.8695665597915649
SAPHRIS,muscle twitching,dystonia muscle contractions muscle twitching,1,0.8706344962120056
SAPHRIS,muscle twitching,contractions involuntary,1,0.6913898587226868
SAPHRIS,muscle twitching,muscle twitching musculoskeletal stiffness parkinsonism protrusion tongue,1,0.8251328468322754
SAPHRIS,muscle twitching,muscle twitching musculoskeletal,1,0.922762393951416
SAPHRIS,muscle twitching,muscle twitching musculoskeletal stiffness parkinsonism protrusion,1,0.8222343325614929
SAPHRIS,muscle twitching,contractions muscle twitching musculoskeletal stiffness parkinsonism protrusion tongue,1,0.8355768918991089
SAPHRIS,muscle twitching,dystonia muscle contractions muscle,1,0.7668392062187195
SAPHRIS,muscle twitching,and tremor,0,0.7478040456771851
SAPHRIS,muscle twitching,oromandibular dystonia muscle contractions muscle,1,0.7273257374763489
SAPHRIS,musculoskeletal stiffness,protrusion tongue resting tremor and tremor For events,0,0.5606239438056946
SAPHRIS,musculoskeletal stiffness,parkinsonism protrusion tongue resting tremor and tremor For events of akathisia,0,0.524103045463562
SAPHRIS,musculoskeletal stiffness,musculoskeletal stiffness parkinsonism protrusion,1,0.8264304399490356
SAPHRIS,musculoskeletal stiffness,events of,0,0.46774768829345703
SAPHRIS,musculoskeletal stiffness,dystonia muscle contractions involuntary muscle twitching,0,0.5849780440330505
SAPHRIS,musculoskeletal stiffness,involuntary muscle musculoskeletal stiffness,1,0.9202998876571655
SAPHRIS,musculoskeletal stiffness,muscle contractions involuntary muscle musculoskeletal stiffness parkinsonism protrusion tongue resting,1,0.7509994506835938
SAPHRIS,musculoskeletal stiffness,contractions involuntary muscle musculoskeletal stiffness,1,0.9023505449295044
SAPHRIS,musculoskeletal stiffness,musculoskeletal,1,0.8681606650352478
SAPHRIS,musculoskeletal stiffness,involuntary muscle musculoskeletal stiffness parkinsonism protrusion,1,0.7990494966506958
SAPHRIS,parkinsonism,parkinsonism protrusion tongue resting,1,0.7904238700866699
SAPHRIS,parkinsonism,parkinsonism protrusion tongue resting tremor and,1,0.805914044380188
SAPHRIS,parkinsonism,parkinsonism protrusion,1,0.8505530953407288
SAPHRIS,parkinsonism,parkinsonism protrusion tongue,1,0.8053165674209595
SAPHRIS,protrusion tongue,muscle twitching musculoskeletal stiffness protrusion tongue resting,1,0.7882466316223145
SAPHRIS,protrusion tongue,parkinsonism protrusion tongue,1,0.8891217708587646
SAPHRIS,resting tremor,resting tremor and tremor For events of,1,0.920967698097229
SAPHRIS,resting tremor,resting tremor and tremor,1,0.9685487747192383
SAPHRIS,resting tremor,protrusion resting,1,0.6239316463470459
SAPHRIS,resting tremor,twitching musculoskeletal stiffness parkinsonism protrusion tongue,0,0.7281351685523987
SAPHRIS,resting tremor,ractions involuntary muscle,0,0.6336331367492676
SAPHRIS,resting tremor,protrusion resting tremor and tremor For events,1,0.8705323934555054
SAPHRIS,resting tremor,musculoskeletal stiffness parkinsonism protrusion resting tremor,1,0.8181171417236328
SAPHRIS,tremor,tremor For events of akathisia incidences,1,0.7872652411460876
SAPHRIS,tremor,treated,0,0.5251004695892334
SAPHRIS,akathisia,For events akathisia incidences were and for,1,0.8634880781173706
SAPHRIS,akathisia,treated,0,0.5726039409637451
SAPHRIS,akathisia,akathisia incidences were and,1,0.8868876695632935
SAPHRIS,akathisia,akathisia incidences were and for,1,0.8841889500617981
SAPHRIS,Oral hypoesthesia,usually resolves wit,0,0.5614455938339233
SAPHRIS,Oral hypoesthesia,administration,0,0.5310206413269043
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia andor oral,1,0.9700413942337036
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia,1,1.0000001192092896
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia andor oral paresthesia may,1,0.9479252696037292
SAPHRIS,Oral hypoesthesia,patients Other,0,0.5665137767791748
SAPHRIS,Oral hypoesthesia,for placebotreated patients Other Findings,0,0.6454912424087524
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia andor oral paresthesia may occur,1,0.9314507246017456
SAPHRIS,oral paresthesia,andor,0,0.4806516170501709
SAPHRIS,increase in transaminase levels,transaminase levels for,1,0.9113176465034485
SAPHRIS,increase in transaminase levels,mania trials the increase in transaminase levels for SAPHRIStreated patients was,1,0.8624154329299927
SAPHRIS,increase in transaminase levels,in transaminase levels,1,0.9186702966690063
SAPHRIS,increase in transaminase levels,increase in transaminase levels for,1,0.9920215010643005
SAPHRIS,increase in transaminase levels,the increase in transaminase levels for SAPHRIStreated patients was unitsL,1,0.9067366719245911
SAPHRIS,increase in transaminase levels,adult mania trials the increase,1,0.6246538758277893
SAPHRIS,increase in transaminase levels,mean,0,0.5076067447662354
SAPHRIS,increase in transaminase levels,in transaminase levels for,1,0.9193891286849976
SAPHRIS,increase in transaminase levels,the increase in transaminase levels,1,0.994337260723114
SAPHRIS,transaminase elevations,of patients transaminase elevations times upper limit of normal,1,0.9277421236038208
SAPHRIS,transaminase elevations,in transaminase levels for,1,0.8959893584251404
SAPHRIS,transaminase elevations,of unitsL in placebotreated,0,0.47379276156425476
SAPHRIS,transaminase elevations,ULN at,0,0.5346301794052124
SAPHRIS,transaminase elevations,for SAPHRIStreated patients,0,0.5230069756507874
SAPHRIS,transaminase elevations,unitsL in placebotreated patients,0,0.5482584238052368
SAPHRIS,transaminase elevations,The proportion of patients transaminase elevations times upper limit of normal,1,0.9063526391983032
SAPHRIS,transaminase elevations,patients transaminase elevations times upper limit,1,0.9196639060974121
SAPHRIS,elevations in serum transaminases,I disorder,0,0.4772549569606781
SAPHRIS,elevations in serum transaminases,elevations in serum transaminases primarily ALT were,1,0.9455614686012268
SAPHRIS,elevations in serum transaminases,bipolar I disorder elevations in serum transaminases primarily ALT were more common,1,0.8622933626174927
SAPHRIS,elevations in serum transaminases,In a week placebocontrolled pediatric,0,0.5057506561279297
SAPHRIS,elevations in serum transaminases,disorder elevations in serum transaminases primarily ALT were more,1,0.9204721450805664
SAPHRIS,elevations in serum transaminases,patients with,0,0.5515472292900085
SAPHRIS,ALT elevations,ALT elevations times upper limit of normal,1,0.8841509819030762
SAPHRIS,decreases in prolactin levels,prolactin levels were ngmL,1,0.7950737476348877
SAPHRIS,decreases in prolactin levels,ngmL for placebotreated,0,0.3624468445777893
SAPHRIS,decreases in prolactin levels,schizophrenia trials the decreases,1,0.6720974445343018
SAPHRIS,decreases in prolactin levels,decreases in prolactin levels,1,0.9999998807907104
SAPHRIS,decreases in prolactin levels,decreases in prolactin levels were,1,0.98997563123703
SAPHRIS,decreases in prolactin levels,decreases in prolactin levels were ngmL for,1,0.896730363368988
SAPHRIS,decreases in prolactin levels,in prolactin levels were,1,0.8893226385116577
SAPHRIS,decreases in prolactin levels,patients compared to,0,0.49778980016708374
SAPHRIS,decreases in prolactin levels,trials the decreases in prolactin levels,1,0.9410358667373657
SAPHRIS,decreases in prolactin levels,trials the decreases in prolactin levels were ngmL,1,0.8910737037658691
SAPHRIS,prolactin elevations,eated patients compared to ngmL for placebotreated,0,0.48037654161453247
SAPHRIS,increase in prolactin levels,to a decrease,0,0.4367738962173462
SAPHRIS,increase in prolactin levels,mania adult trials the increase in prolactin levels was ngmL,1,0.8413654565811157
SAPHRIS,increase in prolactin levels,for SAPHRIStreated patients compared to a decrease of ngmL,0,0.5454055070877075
SAPHRIS,increase in prolactin levels,increase in prolactin levels was ngmL for,1,0.8836443424224854
SAPHRIS,increase in prolactin levels,patients compared to a decrease,0,0.4826633334159851
SAPHRIS,increase in prolactin levels,adult,0,0.5264618396759033
SAPHRIS,increase in prolactin levels,mania adult trials the increase in,1,0.6740010976791382
SAPHRIS,increase in prolactin levels,adult trials the increase in prolactin levels,1,0.9146317839622498
SAPHRIS,increase in prolactin levels,adult trials,0,0.5027676820755005
SAPHRIS,increase in prolactin levels,trials the increase in prolactin levels,1,0.9378933310508728
SAPHRIS,prolactin elevations,of patients prolactin elevations times ULN,1,0.9080219268798828
SAPHRIS,prolactin elevations,trials the increase in prolactin levels,1,0.9051716327667236
SAPHRIS,prolactin elevations,of patients prolactin elevations times,1,0.9267422556877136
SAPHRIS,prolactin elevations,prolactin elevations times ULN at,1,0.8873112797737122
SAPHRIS,prolactin elevations,prolactin elevations times ULN,1,0.8811795711517334
SAPHRIS,decrease in prolactin,decrease in prolactin from baseline for SAPHRIStreated,1,0.8711333274841309
SAPHRIS,decrease in prolactin,patients with schizophrenia the mean,0,0.5316042900085449
SAPHRIS,decrease in prolactin,included primarily patients,0,0.4766286611557007
SAPHRIS,decrease in prolactin,trial that included,0,0.4249234199523926
SAPHRIS,decrease in prolactin,that included,0,0.4315034747123718
SAPHRIS,decrease in prolactin,with schizophrenia the decrease in prolactin from,1,0.8662086725234985
SAPHRIS,prolactin elevations,There were no reports prolactin,1,0.7587515115737915
SAPHRIS,prolactin elevations,reports prolactin elevations times ULN,1,0.8875859379768372
SAPHRIS,prolactin elevations,There were no reports prolactin elevations times ULN at Endpoint for,1,0.8312541842460632
SAPHRIS,Galactorrhea,Galactorrhea or dysmenorrhea,1,0.8599242568016052
SAPHRIS,Galactorrhea,Galactorrhea,1,1.0000001192092896
SAPHRIS,Galactorrhea,Galactorrhea or dysmenorrhea were reported,1,0.8323311805725098
SAPHRIS,Galactorrhea,Galactorrhea or,1,0.9771955013275146
SAPHRIS,Galactorrhea,or Galactorrhea or dysmenorrhea were reported in,1,0.826511025428772
SAPHRIS,Galactorrhea,with SAPHRIS or placebo,0,0.5437881946563721
SAPHRIS,Galactorrhea,Galactorrhea or dysmenorrhea were,1,0.8632587194442749
SAPHRIS,dysmenorrhea,patients treated with SAPHRIS or placebo Galactorrhea,0,0.6474106311798096
SAPHRIS,dysmenorrhea,or placebo Galactorrhea or,0,0.6424727439880371
SAPHRIS,dysmenorrhea,patients treated with SAPHRIS or,0,0.5536883473396301
SAPHRIS,dysmenorrhea,dysmenorrhea were reported,1,0.9328603744506836
SAPHRIS,dysmenorrhea,or placebo Galactorrhea dysmenorrhea were,1,0.8112788200378418
SAPHRIS,dysmenorrhea,dysmenorrhea,1,0.9999998807907104
SAPHRIS,dysmenorrhea,placebo Galactorrhea dysmenorrhea were reported,1,0.8160377740859985
SAPHRIS,gynecomastia,gynecomastia in this trial Creatine,1,0.8293033838272095
SAPHRIS,gynecomastia,gynecomastia in this trial,1,0.8889423608779907
SAPHRIS,gynecomastia,There were no reports gynecomastia in,1,0.8640226125717163
SAPHRIS,gynecomastia,gynecomastia in this trial Creatine Kinase,1,0.8146876096725464
SAPHRIS,gynecomastia,placebotreated patients There were no reports,0,0.4790716767311096
SAPHRIS,gynecomastia,patients with,0,0.5190063714981079
SAPHRIS,CK elevations,patients,0,0.49454760551452637
SAPHRIS,CK elevations,with,0,0.5667229890823364
SAPHRIS,CK elevations,CK elevations times ULN at any time,1,0.8296818733215332
SAPHRIS,CK elevations,times ULN at any time were,0,0.5055408477783203
SAPHRIS,CK elevations,of gynecomastia in this trial Creatine Kinase CK,0,0.6683855056762695
SAPHRIS,CK elevations,adult patients CK elevations times ULN,1,0.7737722396850586
SAPHRIS,CK elevations,CK elevations,1,1.0000001192092896
SAPHRIS,CK elevations,treated,0,0.4800475835800171
SAPHRIS,CK elevations,this finding is unknown The,0,0.5200216174125671
SAPHRIS,CK elevations,during a,0,0.5170170068740845
SAPHRIS,CK elevations,disorder at any,0,0.5030327439308167
SAPHRIS,CK elevations,ULN,0,0.48044419288635254
SAPHRIS,CK elevations,of patients CK elevations times ULN during a,1,0.7698684930801392
SAPHRIS,CK elevations,of patients with,0,0.5100969672203064
SAPHRIS,CK elevations,trial in pediatric bipolar I disorder at any time,0,0.47789862751960754
SAPHRIS,CK elevations,at any,0,0.5403214693069458
SAPHRIS,anemia,temporary bundle,0,0.509666919708252
SAPHRIS,anemia,Blood and lymphatic disorders anemia rare thrombocytopenia Cardiac disorders infrequent,1,0.7087301015853882
SAPHRIS,anemia,anemia rare thrombocytopenia Cardiac,1,0.7609871625900269
SAPHRIS,anemia,thrombocytopenia Cardiac,0,0.5841492414474487
SAPHRIS,thrombocytopenia,bundle,0,0.5037326216697693
SAPHRIS,thrombocytopenia,Blood and,0,0.637811541557312
SAPHRIS,thrombocytopenia,Eye disorders inf,0,0.48947763442993164
SAPHRIS,thrombocytopenia,thrombocytopenia Cardiac disorders infrequent temporary,1,0.8234477639198303
SAPHRIS,thrombocytopenia,thrombocytopenia Cardiac disorders infrequent temporary bundle,1,0.8092761635780334
SAPHRIS,thrombocytopenia,r,0,0.4904942214488983
SAPHRIS,thrombocytopenia,Blood and lymphatic disorders infrequent,0,0.5793625116348267
SAPHRIS,thrombocytopenia,disorders infrequent anemia rare,0,0.554750919342041
SAPHRIS,temporary bundle branch block,thrombocytopenia Cardiac disorders temporary bundle branch block,1,0.8742516040802002
SAPHRIS,temporary bundle branch block,Eye disorders infrequent accommodation disorder Gastrointestinal disorders,0,0.44372308254241943
SAPHRIS,temporary bundle branch block,infrequent,0,0.5368032455444336
SAPHRIS,accommodation disorder,infrequent temporary bundle,0,0.47397497296333313
SAPHRIS,accommodation disorder,accommodation disorder Gastrointestinal disorders infrequent swollen tongue,1,0.7916578054428101
SAPHRIS,accommodation disorder,Eye disorders,0,0.6979727745056152
SAPHRIS,accommodation disorder,accommodation disorder Gastrointestinal disorders infrequent swollen,1,0.8026631474494934
SAPHRIS,swollen tongue,accommodation disorder Gastrointestinal disorders swollen,1,0.6802384853363037
SAPHRIS,swollen tongue,accommodation disorder Gastrointestinal disorders swollen tongue General disorders rare,1,0.7589259147644043
SAPHRIS,swollen tongue,swollen tongue General disorders rare idiosyncratic,1,0.8700964450836182
SAPHRIS,swollen tongue,disorder Gastrointestinal disorders swollen tongue General disorders,1,0.8340849876403809
SAPHRIS,swollen tongue,Gastrointestinal disorders swollen tongue,1,0.8813420534133911
SAPHRIS,swollen tongue,disorder Gastrointestinal disorders swollen tongue General disorders rare idiosyncratic drug,1,0.8041706085205078
SAPHRIS,swollen tongue,Gastrointestinal disorders,0,0.5790010094642639
SAPHRIS,swollen tongue,disorder Gastrointestinal disorders swollen tongue,1,0.8521919250488281
SAPHRIS,idiosyncratic drug reaction,infrequent swollen tongue General,0,0.5720508098602295
SAPHRIS,idiosyncratic drug reaction,idiosyncratic drug reaction Investigations infrequent hyponatremia Nervous system,1,0.8210708498954773
SAPHRIS,idiosyncratic drug reaction,drug reaction,1,0.8538130521774292
SAPHRIS,idiosyncratic drug reaction,swollen tongue General disorders idiosyncratic drug reaction Investigations infrequent hyponatremia,1,0.7415732145309448
SAPHRIS,hyponatremia,hyponatremia,1,1.000000238418579
SAPHRIS,hyponatremia,reaction Investigations hyponatremia Nervous system disorders,1,0.7961341738700867
SAPHRIS,hyponatremia,drug reaction Investigations infrequent,0,0.5087258219718933
SAPHRIS,hyponatremia,hyponatremia Nervous,1,0.8397656679153442
SAPHRIS,hyponatremia,rare idiosyncratic drug,0,0.5435661673545837
SAPHRIS,hyponatremia,infrequent,0,0.47366058826446533
SAPHRIS,dysarthria,dysarthria Following is a,1,0.913999080657959
SAPHRIS,dysarthria,adults or pediatric patients,0,0.5057948231697083
SAPHRIS,dysarthria,already,0,0.5028787851333618
SAPHRIS,dysarthria,terms not,0,0.4846753478050232
SAPHRIS,dysarthria,dysarthria Following is a list,1,0.8982596397399902
SAPHRIS,dysarthria,dysarthria Following is,1,0.9370730519294739
SAPHRIS,dysarthria,disorders infrequent,0,0.5809534788131714
SAPHRIS,dysarthria,hyponatremia Nervous system disorders,0,0.5360157489776611
SAPHRIS,diplopia,diplopia,1,1.0000001192092896
SAPHRIS,diplopia,diplopia vision blurred Gastrointestinal disorders,1,0.8286641836166382
SAPHRIS,vision blurred,Eye disorders infrequent vision blurred Gastrointestinal disorders infrequent gastroesophageal,1,0.6884291172027588
SAPHRIS,vision blurred,diplopia vision blurred Gastrointestinal disorders,1,0.7378316521644592
SAPHRIS,vision blurred,Eye disorders infrequent vision blurred Gastrointestinal disorders infrequent,1,0.7220802307128906
SAPHRIS,vision blurred,vision blurred Gastrointestinal disorders,1,0.7953082323074341
SAPHRIS,vision blurred,Eye disorders infrequent vision blurred,1,0.8369861841201782
SAPHRIS,vision blurred,reflux disease,0,0.48591098189353943
SAPHRIS,vision blurred,Eye disorders infrequent vision,1,0.6982293128967285
SAPHRIS,gastroesophageal reflux disease,reflux disease Injury Poisoning and Procedural,1,0.7495874166488647
SAPHRIS,gastroesophageal reflux disease,vision blurred Gastrointestinal disorders infrequent,0,0.6853451728820801
SAPHRIS,gastroesophageal reflux disease,vision blurred Gastrointestinal,0,0.6560553908348083
SAPHRIS,gastroesophageal reflux disease,vision blurred Gastrointestinal disorders gastroesophageal reflux,1,0.820419192314148
SAPHRIS,gastroesophageal reflux disease,Gastrointestinal disorders gastroesophageal,1,0.8647882342338562
SAPHRIS,gastroesophageal reflux disease,blurred,0,0.4601670503616333
SAPHRIS,gastroesophageal reflux disease,gastroesophageal,1,0.8459291458129883
SAPHRIS,gastroesophageal reflux disease,gastroesophageal reflux disease Injury Poisoning,1,0.8405656814575195
SAPHRIS,gastroesophageal reflux disease,vision blurred Gastrointestinal disorders gastroesophageal reflux disease,1,0.8364972472190857
SAPHRIS,gastroesophageal reflux disease,reflux disease,1,0.9063660502433777
SAPHRIS,fall,and Procedural Complications fall Skin,1,0.5417584180831909
SAPHRIS,fall,reflux disease,1,0.5154524445533752
SAPHRIS,fall,infrequent,0,0.5767302513122559
SAPHRIS,fall,Poisoning and Procedural Complications fall Skin and,1,0.5009679794311523
SAPHRIS,fall,fall Skin and,1,0.8271158933639526
SAPHRIS,fall,fall Skin and subcutaneous tissue,1,0.7643812894821167
SAPHRIS,fall,Injury,0,0.6033993363380432
SAPHRIS,photosensitivity reaction,disorders photosensitivity reaction Renal and urinary disorders infrequent,1,0.7917266488075256
SAPHRIS,photosensitivity reaction,Injury,0,0.48181354999542236
SAPHRIS,photosensitivity reaction,disorders photosensitivity,1,0.8405723571777344
SAPHRIS,photosensitivity reaction,photosensitivity reaction Renal and urinary disorders infrequent,1,0.8161298036575317
SAPHRIS,photosensitivity reaction,tissue disorders photosensitivity,1,0.8370212912559509
SAPHRIS,photosensitivity reaction,tissue disorders photosensitivity reaction Renal and,1,0.8308327198028564
SAPHRIS,photosensitivity reaction,photosensitivity,1,0.9297028183937073
SAPHRIS,photosensitivity reaction,and subcutaneous tissue disorders photosensitivity reaction,1,0.8656216263771057
SAPHRIS,photosensitivity reaction,subcutaneous tissue disorders photosensitivity reaction,1,0.8616108894348145
SAPHRIS,photosensitivity reaction,tissue disorders photosensitivity reaction Renal,1,0.822857141494751
SAPHRIS,enuresis,urinary disorders enuresis Postmarketing Experience The following,1,0.8128253221511841
SAPHRIS,enuresis,subcutaneous tissue disorders photosensitivity reaction,1,0.48279866576194763
SAPHRIS,enuresis,disorders,0,0.6290231347084045
SAPHRIS,enuresis,enuresis Postmarketing Experience The following,1,0.8103148341178894
SAPHRIS,enuresis,Renal and urinary disorders enuresis Postmarketing,1,0.813329815864563
SAPHRIS,enuresis,enuresis Postmarketing,1,0.8267115354537964
SAPHRIS,enuresis,enuresis Postmarketing Experience The following adverse,1,0.8008485436439514
SAPHRIS,Application site reactions,of Application,1,0.729409396648407
SAPHRIS,Application site reactions,area have been reported These application,0,0.6995164155960083
SAPHRIS,Application site reactions,Application site reactions primarily,1,0.9622879028320312
SAPHRIS,Application site reactions,Application site reactions,1,0.9999998807907104
SAPHRIS,Application site reactions,to discontinuation of Application,1,0.612565279006958
SAPHRIS,Application site reactions,site reactions primarily in the sublingual area,1,0.6940897107124329
SAPHRIS,Application site reactions,reported These application site reactions,0,0.9283560514450073
SAPHRIS,Application site reactions,of Application site reactions primarily in the,1,0.8322787284851074
SAPHRIS,Application site reactions,occurrence of these adverse reactions led to discontinuation,0,0.5686399936676025
SAPHRIS,Application site reactions,application site reactions included,0,0.9717916250228882
SAPHRIS,application site reactions,peelingsloughing and inflammation Choking has,0,0.533125102519989
SAPHRIS,application site reactions,application site reactions included oral ulcers blisters,1,0.7779233455657959
SAPHRIS,application site reactions,has been,0,0.4829707145690918
SAPHRIS,application site reactions,area have been reported application site,1,0.7937368154525757
SAPHRIS,application site reactions,reported application site reactions,1,0.963118851184845
SAPHRIS,application site reactions,application site reactions,1,0.9999999403953552
SAPHRIS,Choking,blisters peelingsloughing and Choking has been reported,1,0.7166601419448853
SAPHRIS,Choking,area have been reported application site,1,0.43064767122268677
SAPHRIS,oropharyngeal muscular dysfunction,nd inflammation Choking has been reported by patients,0,0.6204908490180969
SAPHRIS,oropharyngeal muscular dysfunction,muscular dysfunction,1,0.7725138664245605
SAPHRIS,oropharyngeal muscular dysfunction,inflammation Choking has been reported by patients some of whom may have,0,0.625717043876648
SAPHRIS,oropharyngeal muscular dysfunction,whom may have also oropharyngeal muscular,1,0.8906385898590088
SAPHRIS,oropharyngeal muscular dysfunction,have also oropharyngeal muscular,1,0.8950653076171875
SAPHRIS,oropharyngeal muscular dysfunction,have also oropharyngeal muscular dysfunction,1,0.9717366695404053
SAPHRIS,INCREASED MORTALITY,REACTIONS  following adverse  reactions are discussed in more,1,0.5812186002731323
SAPHRIS,INCREASED MORTALITY,have also oropharyngeal muscular,1,0.49442023038864136
SAPHRIS,INCREASED MORTALITY,following adverse reactions,1,0.5723429918289185
SAPHRIS,INCREASED MORTALITY,REACTIONS,0,0.5423349142074585
SAPHRIS,INCREASED MORTALITY,The,0,0.494318425655365
SAPHRIS,INCREASED MORTALITY,"eling:



 *  Use i n Elderly Patients with",1,0.5924111008644104
SAPHRIS,INCREASED MORTALITY,"eling:



 *  Use i n Elderly Patients with DementiaRelated",1,0.5708111524581909
SAPHRIS,INCREASED MORTALITY,* Use i n Elderly,1,0.5747189521789551
SAPHRIS,death,see Warnings and Precautions Metabolic,0,0.522849977016449
SAPHRIS,death,and ution s Tardive Dyskinesia see Warnings,1,0.5033311247825623
SAPHRIS,INCREASED MORTALITY,"Reactions see ations, Warnings an",1,0.5580445528030396
SAPHRIS,INCREASED MORTALITY,"see ations, Warnings an",1,0.5342749357223511
SAPHRIS,death,Syncope and r Hem odynamic,1,0.5453698635101318
SAPHRIS,death,"Reactions see ations, Warnings an",1,0.5635054707527161
SAPHRIS,stroke,ts wit h DementiaRelated,1,0.5714040994644165
SAPHRIS,transient ischemic attack,Elderly Patients Dementia-Related Psychosi,1,0.49392372369766235
SAPHRIS,transient ischemic attack,Dementia-Related,1,0.5200957655906677
SAPHRIS,Neuroleptic Malignant Syndrome,Warnings and ions (5.3)],1,0.5305899381637573
SAPHRIS,Neuroleptic Malignant Syndrome,inesia see Warnings,0,0.5354750156402588
SAPHRIS,Neuroleptic Malignant Syndrome,see Warnings,0,0.5367438793182373
SAPHRIS,Neuroleptic Malignant Syndrome,ions (5.3)] * Tardive Dysk inesia see Warnings,1,0.6597900390625
SAPHRIS,Neuroleptic Malignant Syndrome,and ions (5.3)] * Tardive Dysk,1,0.6456445455551147
SAPHRIS,Neuroleptic Malignant Syndrome,inesia see Warnings and Precautions Metabolic Changes see Warnings,0,0.5694026947021484
SAPHRIS,Neuroleptic Malignant Syndrome,Warnings and Precautions and Neuroleptic Malignant Syndrome,0,0.8874586820602417
SAPHRIS,Neuroleptic Malignant Syndrome,ions (5.3)] * Tardive Dysk,1,0.6401581168174744
SAPHRIS,Neuroleptic Malignant Syndrome,Warnings and Precautions,0,0.525895893573761
SAPHRIS,Neuroleptic Malignant Syndrome,ions (5.3)] * Tardive,1,0.6107757091522217
SAPHRIS,Tardive Dyskinesia,Contraindications Warnings and,0,0.486179381608963
SAPHRIS,Tardive Dyskinesia,arnings and Precau tions Hypersensitivity Reactions see Contraindications,1,0.4730624854564667
SAPHRIS,Metabolic Changes,"blisters, peeling sloughing and",1,0.5519217252731323
SAPHRIS,Metabolic Changes,"oral blisters, peeling",1,0.5156566500663757
SAPHRIS,Metabolic Changes,Counseling Information Application site reactions,0,0.49985575675964355
SAPHRIS,Metabolic Changes,Orthostatic Hypotension,0,0.5277052521705627
SAPHRIS,Metabolic Changes,and inflammation see,0,0.6018580198287964
SAPHRIS,Metabolic Changes,inflammation see Adverse Reactions,0,0.6049985885620117
SAPHRIS,Metabolic Changes,Application site reactions including oral,0,0.5745126605033875
SAPHRIS,Metabolic Changes,Reactions Orthostatic Hypotension Syncope,0,0.5364950895309448
SAPHRIS,Metabolic Changes,"reactions including oral blisters, peeling",1,0.5899984240531921
SAPHRIS,metabolic changes,* Orthostati c Hypotension,1,0.5244013071060181
SAPHRIS,metabolic changes,* Orthostati,1,0.5746166706085205
SAPHRIS,metabolic changes,"Adverse   
 *  Orthostati c Hypotension Syncope and other",1,0.536689281463623
SAPHRIS,metabolic changes,"see Adverse   
 *  Orthostati c",1,0.5774399042129517
SAPHRIS,metabolic changes,and,0,0.5234094262123108
SAPHRIS,metabolic changes,* Orthostati c Hypotension Syncope and,1,0.5381962656974792
SAPHRIS,cerebrovascular risk,and Hemodynamic Effects,1,0.6538326740264893
SAPHRIS,cerebrovascular risk,Syncope and Hemodynamic Effects,1,0.6357857584953308
SAPHRIS,cerebrovascular risk,Hemodynamic Effects see Warnings,1,0.6981061697006226
SAPHRIS,metabolic changes,Agranulocytosis see,0,0.5562289953231812
SAPHRIS,hyperglycemia,and other Hemodynamic Effects see,0,0.5487075448036194
SAPHRIS,hyperglycemia,"and )]  
 *  Leuk openia Neutropenia and",1,0.5255547165870667
SAPHRIS,dyslipidemia,"Precautions enia, Neutro",1,0.5123019814491272
SAPHRIS,dyslipidemia,and other Hemodynamic Effects see,0,0.5355992913246155
SAPHRIS,dyslipidemia,"enia, Neutro",1,0.44461655616760254
SAPHRIS,dyslipidemia,Warnings and Precautions QT Interval,0,0.5399972200393677
SAPHRIS,dyslipidemia,and Precautions Leukop,0,0.5150367617607117
SAPHRIS,dyslipidemia,Warnings and Precautions QT Interval Prolongation see,0,0.5662692785263062
SAPHRIS,dyslipidemia,see Warnings and Precautions QT Interval,0,0.5397568345069885
SAPHRIS,weight gain,Precautions Leukopenia and,1,0.5242435932159424
SAPHRIS,weight gain,other Hemodynamic Effects see Warnings and Precautions Leukopenia,0,0.5613186955451965
SAPHRIS,weight gain,and Precautions Leukopenia and Agranu,1,0.525955319404602
SAPHRIS,weight gain,see Warnings and,0,0.5248766541481018
SAPHRIS,Hypersensitivity reactions,* QT Interval Pro,1,0.4266396760940552
SAPHRIS,Hypersensitivity reactions,"Warnings and .8)]  
 *  QT Interval Pro longation see",1,0.49805277585983276
SAPHRIS,Hypersensitivity reactions,Warnings and Precautions,0,0.5751934051513672
SAPHRIS,anaphylaxis,Precautions QT Interval Prolongation s,0,0.574263334274292
SAPHRIS,anaphylaxis,s,0,0.5342448949813843
SAPHRIS,anaphylaxis,Warnings and Precautions,0,0.5864318013191223
SAPHRIS,anaphylaxis,Interval Prolongation ee Warnings and Precautions Hyperprolactinemia see Warnings,1,0.5493752360343933
SAPHRIS,anaphylaxis,QT Interval Prolongation ee Warnings and Precautions,1,0.5521650314331055
SAPHRIS,anaphylaxis,Interval Prolongation ee,1,0.47674691677093506
SAPHRIS,anaphylaxis,Precautions QT Interval Prolongation ee Warnings,1,0.5708435773849487
SAPHRIS,angioedema,see Warnings and,0,0.5127228498458862
SAPHRIS,Orthostatic Hypotension,Prolongation see Warnings and,0,0.5097030997276306
SAPHRIS,Orthostatic Hypotension,and Precautions [see Warnings and Preca utions Seizures,1,0.5290745496749878
SAPHRIS,Orthostatic Hypotension,Warnings and Preca utions Seizures see Warnings and,1,0.5125629901885986
SAPHRIS,Orthostatic Hypotension,Potential for Cognitive,0,0.4762929677963257
SAPHRIS,Syncope,Warnings,0,0.5441508889198303
SAPHRIS,Syncope,and Precautions Potential for Cognitive,0,0.5117335319519043
SAPHRIS,Syncope,see Warnings and ions (5,1,0.5128416419029236
SAPHRIS,Hemodynamic Effects,arnings and Precautions Hyperprolactinemia see,0,0.5301382541656494
SAPHRIS,Hemodynamic Effects,and Seizures [see Warni ngs,1,0.5350944399833679
SAPHRIS,Hemodynamic Effects,[see Warni,1,0.46460849046707153
SAPHRIS,Hemodynamic Effects,Hyperprolactinemia see Warnings and Seizures [see Warni ngs and Precautions Potential,1,0.522528886795044
SAPHRIS,Hemodynamic Effects,Seizures [see Warni,1,0.5260077118873596
SAPHRIS,Dizziness,Precautions Seizures see s and Pre,1,0.5628017783164978
SAPHRIS,Dizziness,Potential for,0,0.513141393661499
SAPHRIS,Dizziness,Seizures see s,1,0.6035090088844299
SAPHRIS,Dizziness,s and,1,0.5098211765289307
SAPHRIS,Dizziness,and Pre cautions Potential for,1,0.5525089502334595
SAPHRIS,Dizziness,see s and Pre,1,0.4913923740386963
SAPHRIS,Dizziness,Seizures see s and Pre cautions Potential,1,0.6187541484832764
SAPHRIS,Dizziness,and Precautions Seizures see s and,1,0.5781696438789368
SAPHRIS,tachycardia,utions (5.1 Potential,1,0.5156309008598328
SAPHRIS,tachycardia,and Motor Impairment see,0,0.5017726421356201
SAPHRIS,bradycardia,see Warnings and,0,0.4941718280315399
SAPHRIS,bradycardia,Precautions,0,0.5190410614013672
SAPHRIS,bradycardia," 
 *  Poten tial for",1,0.5202114582061768
SAPHRIS,bradycardia,"Seizures see Warnings and  
 *  Poten tial for Cognitive and Motor",1,0.5522564053535461
SAPHRIS,bradycardia,"Warnings and  
 *  Poten",1,0.5144472122192383
SAPHRIS,bradycardia," 
 *  Poten tial for Cognitive and",1,0.5242772102355957
SAPHRIS,bradycardia,* Poten tial for Cognitive,1,0.5307555198669434
SAPHRIS,bradycardia,Warnings and * Poten,1,0.5144472122192383
SAPHRIS,bradycardia,* Poten tial for Cognitive and,1,0.5242772102355957
SAPHRIS,syncope,or Cogn itive,1,0.5355114936828613
SAPHRIS,syncope,or Cogn itive and Motor Impairment,1,0.5404934883117676
SAPHRIS,syncope,Potential f,0,0.50704026222229
SAPHRIS,Leukopenia,Precau,0,0.4901684522628784
SAPHRIS,Leukopenia,tions (5.1 Dysphagia,1,0.5475364923477173
SAPHRIS,Leukopenia,Suicide see Warnings and tions,1,0.4442715048789978
SAPHRIS,Leukopenia,and tions (5.1 Dysphagia see Warnings and,1,0.5377914905548096
SAPHRIS,Leukopenia,see Warnings and Precautions Use in Patients with Concomitant,0,0.534939169883728
SAPHRIS,Leukopenia,tions (5.1 Dysphagia see,1,0.5570096373558044
SAPHRIS,Leukopenia,see Warnings and tions (5.1,1,0.5023676753044128
SAPHRIS,Leukopenia,see Warnings and tions,1,0.49901604652404785
SAPHRIS,Neutropenia,Concomitant Illness see,0,0.5628154277801514
SAPHRIS,Neutropenia,Suicide see Warnings and ] *,1,0.4780394434928894
SAPHRIS,Agranulocytosis,Patients with Concomitant Illness,0,0.521155834197998
SAPHRIS,Agranulocytosis,in Patients with Concomitant Illness,0,0.5237538814544678
SAPHRIS,Agranulocytosis,Precautions [see,1,0.5254809856414795
SAPHRIS,Agranulocytosis,Precautions,0,0.5283382534980774
SAPHRIS,Agranulocytosis,[see Warnings and,1,0.5152938961982727
SAPHRIS,Agranulocytosis,[see Warnings and Precautions Use in,1,0.5325652956962585
SAPHRIS,Agranulocytosis,Precautions  [see Warnings  and Precautions,1,0.5231028199195862
SAPHRIS,QT Prolongation,in adults was similar to,1,0.47657227516174316
SAPHRIS,QT Prolongation,renia in,1,0.4534772038459778
SAPHRIS,QT Prolongation,most common adverse reactions,0,0.4843185245990753
SAPHRIS,QT Prolongation,most common adverse,0,0.4845770001411438
SAPHRIS,QT Prolongation,treatment of renia in,1,0.5056580305099487
SAPHRIS,QT Prolongation,the maintenance,0,0.5004199743270874
SAPHRIS,Increases in QT interval,treatment The most common adverse reactions and at least twice,0,0.5505051016807556
SAPHRIS,Increases in QT interval,w,0,0.47187697887420654
SAPHRIS,Increases in QT interval,rate of pla,0,0.47379612922668457
SAPHRIS,Increases in QT interval,with acute treatment The most common adverse reactions and at least twice the rate of,0,0.6093078851699829
SAPHRIS,Increases in QT interval,of schizophrenia in adults as similar to that seen  with,1,0.49622803926467896
SAPHRIS,Increases in QT interval,similar to that seen with acute treatment The most,1,0.5696371793746948
SAPHRIS,Increases in QT interval,to that seen with acute treatment The,1,0.5782228708267212
SAPHRIS,Increases in QT interval,adults as similar,1,0.4678151607513428
SAPHRIS,Increases in QT interval,schizophrenia in adults as similar to that seen  with acute treatment,1,0.5258615016937256
SAPHRIS,Increases in QT interval,SAPHRIS in the maintenance treatment of,0,0.5025408267974854
SAPHRIS,Seizures,reported with acute herapy,1,0.5453623533248901
SAPHRIS,Seizures,acute herapy t reatment of,1,0.567179799079895
SAPHRIS,Seizures,with acute,0,0.5686404705047607
SAPHRIS,Seizures,herapy t reatment of manic or mixed,1,0.5511727929115295
SAPHRIS,Seizures,herapy t reatment of manic,1,0.551490068435669
SAPHRIS,Seizures,herapy t,1,0.5329955816268921
SAPHRIS,Seizures,mixed episodes associated with bipolar I disorder in adults,0,0.5886722803115845
SAPHRIS,Motor Impairment,"sia, and",1,0.46674424409866333
SAPHRIS,Suicide,bipolar I disorder in adults were,1,0.5001136064529419
SAPHRIS,Suicide,akathisia and increased weight and during the adjunctive therapy,0,0.5087445974349976
SAPHRIS,Suicide,bipolar I disorder in,1,0.5246795415878296
SAPHRIS,death,APHRI Streated patients had,1,0.4959423840045929
SAPHRIS,death,es of SAPHRIS A total of SAPHRIStreated patients were treated for at least weeks and,0,0.4834930896759033
SAPHRIS,death, and  at least twice the,1,0.5326647758483887
SAPHRIS,death,adverse reactions,0,0.5449328422546387
SAPHRIS,death,"sia, ",1,0.5139375329017639
SAPHRIS,death,weight No new,0,0.4875822961330414
SAPHRIS,deaths,"rial.
",1,0.5164620876312256
SAPHRIS,deaths,"safety rial.
 A total of pediatric",1,0.5389344096183777
SAPHRIS,deaths,"rial.
 A total of pediatric",1,0.5211039781570435
SAPHRIS,deaths,"rial.
 A total",1,0.5187990665435791
SAPHRIS,deaths,were treated with SAPHRIS Of,0,0.5078043341636658
SAPHRIS,heart failure,with SA PHRIS Of these patients,1,0.5648773908615112
SAPHRIS,heart failure,of pediatric patients were eated with SA,1,0.49045321345329285
SAPHRIS,heart failure,pediatric patients were eated with SA,1,0.4930165410041809
SAPHRIS,heart failure,safety trial A,0,0.5057693719863892
SAPHRIS,heart failure,eated with SA PHRIS Of these patients pediatric,1,0.5062000751495361
SAPHRIS,sudden death,patients were treated with RIS. Of thes e patients,1,0.5537168979644775
SAPHRIS,sudden death,with SA PHRIS Of these patients,1,0.5359500646591187
SAPHRIS,sudden death,treated with RIS. Of thes e patients pediatric patients,1,0.5123276114463806
SAPHRIS,sudden death,pediatric patients were treated with SAPHRIS for at least days and pediatric,0,0.5078401565551758
SAPHRIS,sudden death,treated with SAPHRIS for at least days,0,0.49708443880081177
SAPHRIS,sudden death,were treated with RIS. Of thes e patients pediatric patients were,1,0.5164264440536499
SAPHRIS,sudden death,with RIS. Of,1,0.5510715842247009
SAPHRIS,sudden death,patients were,0,0.5488567352294922
SAPHRIS,sudden death,patients were treated with RIS. Of,1,0.5545130372047424
SAPHRIS,sudden death,patients were treated with RIS. Of thes e patients pediatric,1,0.5201220512390137
SAPHRIS,pneumonia,ic patien ts were treated with,1,0.5940464735031128
SAPHRIS,pneumonia,Of these patients ic,1,0.5460188388824463
SAPHRIS,pneumonia,ic patien ts were,1,0.5788767337799072
SAPHRIS,pneumonia,pediatr,0,0.5196722745895386
SAPHRIS,pneumonia,patients were treated with SAPHRIS Of,0,0.5224987268447876
SAPHRIS,pneumonia,ic patien,1,0.5583525896072388
SAPHRIS,increased mortality,in pediatric patients bipolar,1,0.4577232599258423
SAPHRIS,increased mortality,pediatric patients bipolar,1,0.46627452969551086
SAPHRIS,increased mortality,who participated in,0,0.5198144316673279
SAPHRIS,cerebrovascular adverse reactions,least twice that for placebo),1,0.5040173530578613
SAPHRIS,cerebrovascular adverse reactions,evaluation,0,0.4963679015636444
SAPHRIS,cerebrovascular adverse reactions,incidence and least twice that for placebo),1,0.5688161849975586
SAPHRIS,cerebrovascular adverse reactions,oral hypoesthesia somnolence,0,0.5710091590881348
SAPHRIS,cerebrovascular adverse reactions,reactions incidence and least twice that for placebo) wer e Schizophrenia,1,0.6003677845001221
SAPHRIS,cerebrovascular adverse reactions,placebo) wer e,1,0.544084906578064
SAPHRIS,cerebrovascular adverse reactions,Adults akathisia oral hypoesthesia somnolence Bipolar,0,0.5529173016548157
SAPHRIS,cerebrovascular adverse reactions,hypoesthesia somnolence Bipolar,0,0.5187065601348877
SAPHRIS,cerebrovascular adverse reactions,and least twice,1,0.4698576033115387
SAPHRIS,cerebrovascular accidents,incidence and at least twice that for,0,0.54963219165802
SAPHRIS,cerebrovascular accidents,twice that for placebo (6.1): *,1,0.4506820738315582
SAPHRIS,cerebrovascular accidents,Disorder Adults Monotherapy s,0,0.5214168429374695
SAPHRIS,cerebrovascular accidents,akathisia oral hypoesthesia somnolence Bipolar Disorder Adults Monotherapy s,0,0.5355292558670044
SAPHRIS,cerebrovascular accidents,* Schizophre nia Adults,1,0.5065878629684448
SAPHRIS,cerebrovascular accidents,placebo (6.1):,1,0.47634923458099365
SAPHRIS,transient ischemic attacks,"for placebo were Schizophrenia dults: akathisia, oral hyp oesthesia somnolence Bipolar Disorder",1,0.5373339653015137
SAPHRIS,transient ischemic attacks,placebo (6.1):,1,0.5239973068237305
SAPHRIS,transient ischemic attacks,oral hyp oesthesia somnolence Bipolar Disorder Adults,1,0.5586221218109131
SAPHRIS,transient ischemic attacks,"Schizophrenia dults: akathisia, oral hyp oesthesia somnolence",1,0.5462232828140259
SAPHRIS,transient ischemic attacks,"Schizophrenia dults: akathisia, oral hyp",1,0.5448538064956665
SAPHRIS,fatalities,akathisia oral hypoesthesia omnolence. Bipolar Disorder Adults Monotherapy,1,0.451294869184494
SAPHRIS,fatalities,"Schizophrenia dults: akathisia, oral hyp",1,0.500147819519043
SAPHRIS,fatalities,omnolence.,1,0.5516268014907837
SAPHRIS,fatalities,hypoesthesia,0,0.43291276693344116
SAPHRIS,fatalities,were Schizophrenia Adults akathisia,0,0.49144214391708374
SAPHRIS,fatalities,omnolence. Bipolar Disorder Adults Monotherapy somnolence,1,0.4802429676055908
SAPHRIS,fatalities,omnolence. Bipolar,1,0.5289832353591919
SAPHRIS,Neuroleptic Malignant Syndrome,hypoesthesia To report SUSPECTED,0,0.5367820262908936
SAPHRIS,Neuroleptic Malignant Syndrome,appetite fatigue increased Bipolar Disorder Adults (Ad,1,0.5705031752586365
SAPHRIS,Neuroleptic Malignant Syndrome,fatigue increased weight,0,0.48266464471817017
SAPHRIS,Neuroleptic Malignant Syndrome,paresthesia nausea increased appetite fatigue increased,0,0.547313928604126
SAPHRIS,Neuroleptic Malignant Syndrome,SUSPECTED ADVERSE REACTIONS contact,0,0.5313379168510437
SAPHRIS,NMS,weight Bipolar Disorder Adults,0,0.4034003019332886
SAPHRIS,NMS,Disorder Adults nct ive,1,0.5031127333641052
SAPHRIS,NMS,SUSPECTED,0,0.5096575021743774
SAPHRIS,NMS,-67 or FDA at,1,0.48814114928245544
SAPHRIS,NMS,contact Forest Laboratories LLC -67,1,0.4524023234844208
SAPHRIS,NMS,LLC -67 or FDA at FDA,1,0.47626587748527527
SAPHRIS,NMS,ADVERSE REACTIONS,0,0.4940372705459595
SAPHRIS,NMS,at FDA or wwwfdagovmedwatch Clinical Trials Experience,0,0.4839323163032532
SAPHRIS,hyperpyrexia,FDA or wwwfdagovmedwatch Clinical Trials Experience,0,0.48858213424682617
SAPHRIS,hyperpyrexia,or wwwfdagovmedwatch Clinical Trials,0,0.4796435236930847
SAPHRIS,hyperpyrexia,contact Forest Laboratories LLC 5 or FDA at  FDA or wwwfdagovmedwatch,1,0.4953393042087555
SAPHRIS,hyperpyrexia,contact Forest Laboratories LLC at,0,0.465749591588974
SAPHRIS,hyperpyrexia,Experience Because clinical,0,0.5053845643997192
SAPHRIS,hyperpyrexia,Forest Laboratories LLC 5,1,0.47352373600006104
SAPHRIS,hyperpyrexia,Trials Experience,0,0.5090235471725464
SAPHRIS,muscle rigidity,800-FDA-1088 or wwwfdagovmedwatch Clinical Trials Experience,1,0.4768756031990051
SAPHRIS,muscle rigidity,at,0,0.5318331122398376
SAPHRIS,muscle rigidity,800-FDA-1088 or wwwfdagovmedwatch Clinical Trials Experience Because,1,0.4780416488647461
SAPHRIS,muscle rigidity,ADVERSE REACTIONS contact Forest,0,0.5094289779663086
SAPHRIS,muscle rigidity,800-FDA-1088 or wwwfdagovmedwatch Clinical Trials,1,0.47755610942840576
SAPHRIS,muscle rigidity,800-FDA-1088 or wwwfdagovmedwatch Clinical,1,0.4730193018913269
SAPHRIS,muscle rigidity,wwwfdagovmedwatch Clinical Trials,0,0.4831898808479309
SAPHRIS,altered mental status,LLC at,0,0.5164307355880737
SAPHRIS,altered mental status,under widely varyi,0,0.5729334354400635
SAPHRIS,altered mental status,ww.fda.gov/medwatch. ,1,0.530204713344574
SAPHRIS,altered mental status,Clinical Trials Experience Because clinical trials are conducted,0,0.5317404866218567
SAPHRIS,altered mental status,ww.fda.gov/medwatch.  Clinical Trials Experience Because,1,0.5266568660736084
SAPHRIS,altered mental status,Clinical Trials Experience Because,0,0.535574197769165
SAPHRIS,altered mental status,LLC at or FDA at FDA,0,0.49890732765197754
SAPHRIS,autonomic instability,or wwwfdagovmedwatch ical Trials Experienc e Because clinical,1,0.5656599402427673
SAPHRIS,autonomic instability,LLC at or FDA at FDA,0,0.486203134059906
SAPHRIS,autonomic instability,Clin,0,0.5077945590019226
SAPHRIS,autonomic instability,wwwfdagovmedwatch ical Trials,1,0.5588992834091187
SAPHRIS,autonomic instability,FDA,0,0.5225669145584106
SAPHRIS,autonomic instability,wwwfdagovmedwatch ical Trials Experienc,1,0.5711866617202759
SAPHRIS,autonomic instability,ical Trials Experienc,1,0.5451315641403198
SAPHRIS,autonomic instability,FDA or wwwfdagovmedwatch ical Trials Experienc e Because clinical,1,0.5632346868515015
SAPHRIS,autonomic instability,ical Trials Experienc e Because clinical trials are,1,0.5708820819854736
SAPHRIS,irregular pulse,at FDA or wwwfdagovmedwatch Clinical Trials,0,0.5285974144935608
SAPHRIS,irregular pulse,conducted under widely varying conditions,0,0.5984843969345093
SAPHRIS,irregular pulse,"or wwwfdagovmedwatch Clinical Trials 
  Because clin",1,0.5448732376098633
SAPHRIS,irregular pulse,"or wwwfdagovmedwatch Clinical Trials 
  Because clin ical trials are conducted",1,0.5502862334251404
SAPHRIS,irregular pulse,"Trials 
  Because clin ical trials",1,0.515845775604248
SAPHRIS,irregular pulse,Because clin ical trials are conducted,1,0.5098893642425537
SAPHRIS,irregular pulse,Trials Experience,0,0.5141644477844238
SAPHRIS,tachycardia,trials are ucted under,1,0.5441995859146118
SAPHRIS,tachycardia,ucted under,1,0.5479397773742676
SAPHRIS,tachycardia,clinical trials of a,0,0.5864400267601013
SAPHRIS,tachycardia,Because clinical trials are ucted under,1,0.5327674150466919
SAPHRIS,elevated creatine phosphokinase,rates observed in the nical trials of a drug cannot,1,0.5424643754959106
SAPHRIS,elevated creatine phosphokinase,under widely varying conditions adverse,0,0.5546045303344727
SAPHRIS,elevated creatine phosphokinase,reflect the rates,0,0.49320217967033386
SAPHRIS,elevated creatine phosphokinase,trials of a drug cannot b e directly compared,1,0.534912109375
SAPHRIS,elevated creatine phosphokinase,drug cannot b e,1,0.5017770528793335
SAPHRIS,myoglobinuria,directly comp,1,0.4865995943546295
SAPHRIS,myoglobinuria,directly,1,0.4659078121185303
SAPHRIS,myoglobinuria,cannot,0,0.4681735634803772
SAPHRIS,myoglobinuria,rates observed in,0,0.46846362948417664
SAPHRIS,myoglobinuria,reflect the,0,0.4453248977661133
SAPHRIS,myoglobinuria,observed,0,0.4555085301399231
SAPHRIS,myoglobinuria,clinical trials of another drug,0,0.5039479732513428
SAPHRIS,myoglobinuria,directly comp ared to rates in,1,0.4453504979610443
SAPHRIS,myoglobinuria,the rates observed in,0,0.46212688088417053
SAPHRIS,rhabdomyolysis,drug cannot be directly ed to rates in the clinical trials,1,0.48995164036750793
SAPHRIS,rhabdomyolysis,the rates observed in,0,0.4543392062187195
SAPHRIS,rhabdomyolysis,observed,0,0.4767395853996277
SAPHRIS,rhabdomyolysis,in the clinical trials of a drug cannot be,0,0.5148337483406067
SAPHRIS,rhabdomyolysis,ed to rates in the clinical trials of another,1,0.5052604675292969
SAPHRIS,rhabdomyolysis,in the clinical trials of a drug cannot be directly,0,0.5123612880706787
SAPHRIS,rhabdomyolysis,cannot be directly ed to rates in the clinical trials,1,0.4815022945404053
SAPHRIS,rhabdomyolysis,be directly,0,0.48283037543296814
SAPHRIS,rhabdomyolysis,in practice,0,0.47457700967788696
SAPHRIS,rhabdomyolysis,drug cannot be directly,0,0.5036935806274414
SAPHRIS,rhabdomyolysis,drug and may,0,0.5053451061248779
SAPHRIS,acute renal failure,rates in the inical trials of an,1,0.49492502212524414
SAPHRIS,acute renal failure,drug and may,0,0.47717049717903137
SAPHRIS,acute renal failure,of an other drug and may,1,0.48540017008781433
SAPHRIS,acute renal failure,compared to,0,0.4873356819152832
SAPHRIS,acute renal failure,inical trials of an other drug,1,0.508396565914154
SAPHRIS,acute renal failure,Patients with Schizophr,0,0.5108552575111389
SAPHRIS,acute renal failure,trials of an other drug and may not,1,0.4814826548099518
SAPHRIS,"involuntary, dyskinetic movements",in Week Schizophrenia,0,0.5937395095825195
SAPHRIS,"involuntary, dyskinetic movements",Adult Patients in Any PHRIS Dose,1,0.5102607011795044
SAPHRIS,"involuntary, dyskinetic movements",Dose Group and Which Occurr ed at Greater,1,0.5349997282028198
SAPHRIS,"involuntary, dyskinetic movements",Any PHRIS Dose Group and Which Occurr ed at,1,0.535456657409668
SAPHRIS,"involuntary, dyskinetic movements",Which Occurr ed at Greater Incidence Than,1,0.5586284399032593
SAPHRIS,"involuntary, dyskinetic movements",and Which Occurr ed at,1,0.5254747271537781
SAPHRIS,"involuntary, dyskinetic movements",Group and Which Occurr ed,1,0.5029736757278442
SAPHRIS,"involuntary, dyskinetic movements",Placebo Group in Week Schizophrenia Trials Akathisia,0,0.6139156222343445
SAPHRIS,Tardive Dyskinesia," hypersomnia.    
",1,0.5341677665710449
SAPHRIS,Tardive Dyskinesia,"sedation  hypersomnia.    
",1,0.5566346645355225
SAPHRIS,Tardive Dyskinesia,events somnolence,0,0.5329456329345703
SAPHRIS,TD,ia Somnolence,0,0.47368156909942627
SAPHRIS,TD,and S  Also includes the Flexibledose trial,1,0.5135934352874756
SAPHRIS,TD,somnolence sedation and S  Also includes,1,0.48162975907325745
SAPHRIS,TD,the following events,0,0.5759484767913818
SAPHRIS,TD,S  Also includes the,1,0.5607138872146606
SAPHRIS,TD,S  Also,1,0.5540438294410706
SAPHRIS,TD,S  Also includes the Flexibledose,1,0.534443199634552
SAPHRIS,TD,somnolence sedation,0,0.47124338150024414
SAPHRIS,TD,Also includes the Flexibledose trial N,0,0.5307561159133911
SAPHRIS,TD,trial    System Organ Class Preferred Term,1,0.5263009667396545
SAPHRIS,TD,Flexibledose trial,0,0.5221037864685059
SAPHRIS,TD,   System,1,0.5263917446136475
SAPHRIS,TD,S Also includes the Flexibledose,0,0.534443199634552
SAPHRIS,metabolic changes,appetit,0,0.5001134872436523
SAPHRIS,metabolic changes,Nervous system,0,0.6017397046089172
SAPHRIS,metabolic changes,e                ,1,0.4771500825881958
SAPHRIS,metabolic changes,e                 Nervous system disorders,1,0.5567114949226379
SAPHRIS,metabolic changes,e                 Nervous,1,0.532799243927002
SAPHRIS,metabolic changes,Increased appetite,0,0.6758711338043213
SAPHRIS,metabolic changes,"        
   Nervo us",1,0.48923546075820923
SAPHRIS,metabolic changes,"        
   Nervo us system",1,0.4982840418815613
SAPHRIS,metabolic changes,"Increased         
   Nervo",1,0.6644511222839355
SAPHRIS,metabolic changes,"        
   Nervo us system disorders",1,0.5628361701965332
SAPHRIS,metabolic changes,"        
   Nervo",1,0.4888494312763214
SAPHRIS,hyperglycemia,In the short term enia trials t he incidence of akathisia,1,0.508778989315033
SAPHRIS,hyperglycemia,"        
   Nervo",1,0.48360180854797363
SAPHRIS,hyperglycemia,short term enia,1,0.4965830445289612
SAPHRIS,hyperglycemia,the short term enia trials t he incidence of,1,0.5392571091651917
SAPHRIS,hyperglycemia,trials t he incidence of,1,0.5292898416519165
SAPHRIS,hyperglycemia,enia,1,0.500607430934906
SAPHRIS,hyperglycemia,trials t he incidence of akathisia appeared,1,0.5032832622528076
SAPHRIS,hyperglycemia,enia trials t he incidence of akathisia,1,0.5132429599761963
SAPHRIS,hyperglycemia,the short term enia trials t he,1,0.5149799585342407
SAPHRIS,hyperglycemia,of akathisia,0,0.5110654830932617
SAPHRIS,Undesirable alterations in lipids,trapyramidal symptoms excluding Somnolence,1,0.575691819190979
SAPHRIS,Undesirable alterations in lipids,excluding,0,0.5408937931060791
SAPHRIS,Undesirable alterations in lipids,Somnolence ?,1,0.505524754524231
SAPHRIS,Undesirable alterations in lipids,symptoms,0,0.590178370475769
SAPHRIS,Undesirable alterations in lipids,trapyramidal symptoms excluding Somnolence ?,1,0.5573223829269409
SAPHRIS,Undesirable alterations in lipids,"     
      Somnolence  ?         Psychiatric",1,0.5275830030441284
SAPHRIS,Undesirable alterations in lipids,"symptoms excluding      
      Somnolence  ?         Psychiatric",1,0.5503318309783936
SAPHRIS,total cholesterol elevations,in a Week Bipolar Mania,0,0.5192651748657227
SAPHRIS,total cholesterol elevations,at Greater ce Than in the Placebo Group,1,0.569247841835022
SAPHRIS,elevations in triglycerides,terms tachycardia and heart rate increased Includes the preferred ter,0,0.6512224674224854
SAPHRIS,elevations in triglycerides,"ms oral hypoesthesia, oral",1,0.5032273530960083
SAPHRIS,elevations in triglycerides,paresthesia and oral dysesthesia Includes the preferred terms,0,0.4824061393737793
SAPHRIS,elevations in triglycerides,oral dysesthesia Includes the preferred terms abdominal pain abdominal pai,0,0.5055619478225708
SAPHRIS,elevations in triglycerides,paresthesia and oral dysesthesia Includes the preferred terms abdominal pain abdominal pai,0,0.5180045962333679
SAPHRIS,elevations in triglycerides,"oral hypoesthesia, oral paresthesia",1,0.5015408992767334
SAPHRIS,total cholesterol elevations,gue and lethargy.,1,0.5100104808807373
SAPHRIS,total cholesterol elevations,"preferred terms gue and lethargy.    
  5Inc ludes the preferred",1,0.5146459341049194
SAPHRIS,total cholesterol elevations,preferred terms gue and,1,0.5066335201263428
SAPHRIS,total cholesterol elevations,"Includes the preferred terms gue and lethargy.    
  5Inc",1,0.5234485864639282
SAPHRIS,total cholesterol elevations,gue and lethargy. 5Inc,1,0.5247199535369873
SAPHRIS,total cholesterol elevations,terms hyperinsulinemia and blood,0,0.5825777053833008
SAPHRIS,total cholesterol elevations,lower and abdominal,0,0.5311896204948425
SAPHRIS,total cholesterol elevations,blood insulin increased Includes,0,0.6611515283584595
SAPHRIS,elevations in triglycerides,Term Placebo N,0,0.47759512066841125
SAPHRIS,elevations in triglycerides,SAPHRIS mg twice,0,0.5058400630950928
SAPHRIS,elevations in triglycerides,"sedation and somnia.    
  
   System Or",1,0.4495386481285095
SAPHRIS,weight gain, 0         ,1,0.548255443572998
SAPHRIS,weight gain, 0          Metabolism and,1,0.6716060042381287
SAPHRIS,weight gain,Metabolism,0,0.6990218758583069
SAPHRIS,weight gain,increased,0,0.7452340126037598
SAPHRIS,weight gain,nd Mediasti nal Disorders Oro,1,0.5262006521224976
SAPHRIS,weight gain,Respiratory Thoracic nd Mediasti,1,0.4513862729072571
SAPHRIS,Increase in Body Weight,discontinued atment due to an advers e reaction compared with about,1,0.487399160861969
SAPHRIS,Increase in Body Weight,Respiratory Thoracic nd Mediasti,1,0.49885618686676025
SAPHRIS,Increase in Body Weight,an advers e,1,0.5133463144302368
SAPHRIS,Increase in Body Weight,SAPHRIStreated patients discontinued atment,1,0.46631455421447754
SAPHRIS,Increase in Body Weight,common,0,0.47925788164138794
SAPHRIS,Increase in Body Weight,to an advers e reaction compared,1,0.537678599357605
SAPHRIS,Increase in Body Weight,e reaction,0,0.5428725481033325
SAPHRIS,increase in body weight,an,0,0.5292772054672241
SAPHRIS,increase in body weight,to an adverse reaction red with about 11% (18/,1,0.5425909757614136
SAPHRIS,increase in body weight,most common adverse,0,0.4985535740852356
SAPHRIS,increase in body weight,SAPHRIStreated patients discontinued treatment due to,0,0.4876909852027893
SAPHRIS,Hypersensitivity reactions,re depression suicidal ideation bipolar I disorder insomnia and,0,0.49758464097976685
SAPHRIS,hypersensitivity reactions,symptoms,0,0.57839035987854
SAPHRIS,hypersensitivity reactions,More Among SAPHRISTreated Adjunctive Bipolar Patients Adverse,0,0.5331999659538269
SAPHRIS,hypersensitivity reactions,insomnia,0,0.4499984383583069
SAPHRIS,hypersensitivity reactions,Adverse,1,0.5464462041854858
SAPHRIS,hypersensitivity reactions,"
     Adverse Reactions Oc curring at",1,0.7104551792144775
SAPHRIS,hypersensitivity reactions,"depressive 
     Adverse Reactions Oc curring at",1,0.6541958451271057
SAPHRIS,hypersensitivity reactions,depressive Adverse Reactions Oc,1,0.656578540802002
SAPHRIS,angioedema,Reactions Occurring at an of 2% or M ore Among SAPHRISTreated,1,0.5703355073928833
SAPHRIS,angioedema,depressive Adverse Reactions Oc,1,0.6334290504455566
SAPHRIS,angioedema,Reactions Occurring at an,0,0.5523903369903564
SAPHRIS,angioedema,of 2% or M,1,0.49048107862472534
SAPHRIS,angioedema,or M,1,0.497590571641922
SAPHRIS,angioedema,of 2%,1,0.47554105520248413
SAPHRIS,angioedema,Adjunctive Bipolar Patients Adverse reactions,0,0.5679675340652466
SAPHRIS,angioedema,an of 2% or M ore Among SAPHRISTreated Adjunctive,1,0.559808611869812
SAPHRIS,hypotension,Among SAP HRISTreated Adjunctive Bipolar Patients Adverse,1,0.497585266828537
SAPHRIS,hypotension,with the use,0,0.5137782692909241
SAPHRIS,hypotension,an Incidence of,0,0.5697469711303711
SAPHRIS,tachycardia,Among IS-Treated  Adjunctive Bipolar Patients Adverse,1,0.5279618501663208
SAPHRIS,tachycardia,an Incidence of,0,0.5861690044403076
SAPHRIS,tachycardia,IS-Treated  Adjunctive Bipolar Patients Adverse reactions,1,0.5443980693817139
SAPHRIS,tachycardia,or More Among IS-Treated  Adjunctive,1,0.5136221647262573
SAPHRIS,tachycardia,Incidence of,0,0.5568164587020874
SAPHRIS,tachycardia,IS-Treated ,1,0.5279685854911804
SAPHRIS,tachycardia,associated with,0,0.5190919637680054
SAPHRIS,swollen tongue,djunctive) Bip olar Patients Adverse reactions,1,0.590613842010498
SAPHRIS,swollen tongue,or More Among SAPHRISTreated,0,0.5300273895263672
SAPHRIS,swollen tongue,djunctive),1,0.528872013092041
SAPHRIS,wheezing,More Among SAPHRISTreated Adjunctive,0,0.5019732117652893
SAPHRIS,rash,rounded,0,0.5272958278656006
SAPHRIS,rash,reac,1,0.5120022296905518
SAPHRIS,rash,reac tions associated with the use,1,0.5530471801757812
SAPHRIS,rash,reac tions associated with,1,0.5520797371864319
SAPHRIS,rash,to the nearest percent,0,0.5028144717216492
SAPHRIS,rash,Bipolar Patients reac tions associated with,1,0.5260438323020935
SAPHRIS,orthostatic hypotension,that occurred,0,0.4853664040565491
SAPHRIS,orthostatic hypotension,adjunctive therapy at weeks a time when,0,0.5107914805412292
SAPHRIS,orthostatic hypotension,incidence great er than,1,0.4952535033226013
SAPHRIS,orthostatic hypotension,SAPHRIS incidence great er,1,0.4795059561729431
SAPHRIS,orthostatic hypotension,during acute adjunctive therapy at,0,0.5545469522476196
SAPHRIS,syncope,incidence greater an,1,0.55670166015625
SAPHRIS,syncope,an plac ebo that occurred during acute,1,0.6600174307823181
SAPHRIS,syncope,n Tabl e Table Adverse,1,0.5497223138809204
SAPHRIS,syncope,More of Adult,0,0.4852340519428253
SAPHRIS,syncope,the trial are shown n  Tabl e Table Adverse,1,0.5315406322479248
SAPHRIS,syncope,n Tabl e Table Adverse Reactions Reported,1,0.5626801252365112
SAPHRIS,syncope,n Tabl,1,0.516350269317627
SAPHRIS,syncope,the trial are shown n  Tabl e Table Adverse Reactions Reported,1,0.5488021969795227
SAPHRIS,syncope,"ials 
  SAPHRIS",1,0.45875149965286255
SAPHRIS,syncope,mg to mg twice daily with flexible dosing Extrapyramidal symptoms,0,0.5177034735679626
SAPHRIS,syncope,"ials 
  SAPHRIS mg",1,0.47085171937942505
SAPHRIS,syncope,Group at Weeks,0,0.4606814384460449
SAPHRIS,syncope,"ials 
  SAPHRIS mg to mg twice",1,0.5174449682235718
SAPHRIS,syncope,at,0,0.5256825089454651
SAPHRIS,syncope,"ials 
 ",1,0.45108360052108765
SAPHRIS,syncope,Weeks in Adjunctive Bipolar,0,0.5651383399963379
SAPHRIS,syncope,d Term,1,0.45961886644363403
SAPHRIS,syncope,SAPHRIS mg or mg twice,0,0.5207340717315674
SAPHRIS,syncope,N testina l disorders,1,0.5235903263092041
SAPHRIS,syncope,l disorders,0,0.534639835357666
SAPHRIS,neutropenia,"dystonia, p",1,0.4914189279079437
SAPHRIS,neutropenia,Dystonia,0,0.5017026662826538
SAPHRIS,neutropenia,occur in susceptible,0,0.5597108006477356
SAPHRIS,neutropenia,"dystonia, p rolonged abnormal contractions of",1,0.4635785222053528
SAPHRIS,neutropenia,"dystonia, p rolonged abnormal contractions of muscle",1,0.4514215886592865
SAPHRIS,Agranulocytosis,during the f irst few days of treatment,1,0.5090705156326294
SAPHRIS,Agranulocytosis,during the f irst few,1,0.46048182249069214
SAPHRIS,Agranulocytosis,of,0,0.4949222505092621
SAPHRIS,Agranulocytosis,susceptible ls during the,1,0.5194191932678223
SAPHRIS,Agranulocytosis,contractions of muscle groups may occur in,0,0.4702482521533966
SAPHRIS,Agranulocytosis,include spasm of the neck muscles sometimes,0,0.4787251353263855
SAPHRIS,Agranulocytosis,ls during the f,1,0.48918017745018005
SAPHRIS,fatal,few s of,1,0.4756566882133484
SAPHRIS,fatal,spasm of the neck muscles sometimes progressing to,0,0.5367489457130432
SAPHRIS,fatal,of the neck muscles,0,0.4527190327644348
SAPHRIS,fatal,s of treatment Dystonic symptoms include spasm,1,0.5041365623474121
SAPHRIS,fatal,s of treatment Dystonic symptoms include,1,0.47713208198547363
SAPHRIS,fatal,s of,1,0.5307731628417969
SAPHRIS,fatal,of muscle groups may occur in susceptible,0,0.530982494354248
SAPHRIS,increases in QTc interval,adult trials the incidence of EPSre,0,0.5977655053138733
SAPHRIS,increases in QTc interval,for d patients was 6% versus  for placebo In shortterm placebocontrolled,1,0.556516170501709
SAPHRIS,increases in QTc interval,placebocontrolled bipolar mania adult trials,0,0.5370218753814697
SAPHRIS,increases in QTc interval,d patients was,1,0.5052672028541565
SAPHRIS,increases in QTc interval,versus for placebo and the incidence of akathisiarelated,0,0.5730563998222351
SAPHRIS,increases in QTc interval,akathisiarelated events for d patients,1,0.575351357460022
SAPHRIS,QTc increases,events related to akathisia for SAPHRIStreated patients was versus for,0,0.47701388597488403
SAPHRIS,QTc increases,was versus,0,0.48705044388771057
SAPHRIS,QTc increases,f EPS-related events excluding,1,0.5063693523406982
SAPHRIS,QTc increases,f EPS-related events excluding events,1,0.4924209713935852
SAPHRIS,QTc increases,mania,0,0.4886552393436432
SAPHRIS,QTc of >=500 msec,ents was 7% versu s for placebo and the,1,0.5143331289291382
SAPHRIS,QTc of >=500 msec,mania,0,0.49716901779174805
SAPHRIS,QTc of >=500 msec,and the,0,0.5061277747154236
SAPHRIS,QTc of >=500 msec,for SAPHRIStreated,0,0.48175525665283203
SAPHRIS,QTc of >=500 msec,for SAPHRIStreated ents was 7%,1,0.5149877667427063
SAPHRIS,QTc of >=500 msec,for SAPHRIStreated ents was 7% versu s for placebo and,1,0.5077255368232727
SAPHRIS,QT prolongations,disorder,0,0.4881228804588318
SAPHRIS,QT prolongations,pediatric al with bipolar  I disorder the,1,0.4721289277076721
SAPHRIS,QT prolongations,al with bipolar I disorder,1,0.4746007025241852
SAPHRIS,QT prolongations,of EPSrelated events,0,0.5050262212753296
SAPHRIS,delayed ventricular repolarization,daily respectively compared,1,0.47740137577056885
SAPHRIS,delayed ventricular repolarization,as,0,0.4805590510368347
SAPHRIS,delayed ventricular repolarization,twice daily respectively compared to,1,0.48877131938934326
SAPHRIS,delayed ventricular repolarization,oromandibular dystonia m,0,0.49488550424575806
SAPHRIS,delayed ventricular repolarization,twice daily respectively compared to 3% for placebo-treated patients EPSrelated events,1,0.5050719976425171
SAPHRIS,delayed ventricular repolarization,twice daily respectively compared,1,0.49026551842689514
SAPHRIS,delayed ventricular repolarization,daily respectively compared to,1,0.4762391448020935
SAPHRIS,delayed ventricular repolarization,3% for placebo-treated patients EPSrelated,1,0.4763299822807312
SAPHRIS,delayed ventricular repolarization,3% for placebo-treated patients EPSrelated events include bradykinesia,1,0.5217914581298828
SAPHRIS,Hyperprolactinemia,was unitsL compared to a decrease,0,0.5030549764633179
SAPHRIS,Hyperprolactinemia,S-treated patients was unitsL compared,1,0.5106285810470581
SAPHRIS,Hyperprolactinemia,transaminase levels for S-treated patients,1,0.5409882664680481
SAPHRIS,Hyperprolactinemia,to a decrease of unitsL for placebotreated patients The,0,0.4777674674987793
SAPHRIS,Hyperprolactinemia,S-treated patients was unitsL compared to a,1,0.5125659704208374
SAPHRIS,Hyperprolactinemia,S-treated patients was unitsL,1,0.5221360921859741
SAPHRIS,Hyperprolactinemia,schizophrenia adult trials the mean,0,0.5289506912231445
SAPHRIS,suppress hypothalamic GnRH,patients The proportion of patients with transaminase e,0,0.43920326232910156
SAPHRIS,suppress hypothalamic GnRH,for SAPHRIStreated patients 1.6 units/L compared to a,1,0.5030120015144348
SAPHRIS,suppress hypothalamic GnRH,patients,0,0.44999080896377563
SAPHRIS,suppress hypothalamic GnRH,levels for SAPHRIStreated patients 1.6 units/L compared to a  decrease of unitsL for placebotreated,1,0.5249373912811279
SAPHRIS,suppress hypothalamic GnRH,of patients,0,0.43071478605270386
SAPHRIS,suppress hypothalamic GnRH,for placebotreated patients The proportion,0,0.4256654977798462
SAPHRIS,suppress hypothalamic GnRH,trials the,0,0.4189874529838562
SAPHRIS,suppress hypothalamic GnRH,1.6 units/L compared to a,1,0.47907450795173645
SAPHRIS,suppress hypothalamic GnRH,SAPHRIStreated patients 1.6 units/L compared to a,1,0.5004955530166626
SAPHRIS,impairing gonadal steroidogenesis,for placebotreated,0,0.4383700489997864
SAPHRIS,impairing gonadal steroidogenesis,with transaminase  >=3 times ULN (at Endpoint) was  for SAPHRIStreated patients,1,0.5083842277526855
SAPHRIS,impairing gonadal steroidogenesis, >=3 times ULN (at Endpoint) was  for SAPHRIStreated patients,1,0.48783057928085327
SAPHRIS,impairing gonadal steroidogenesis,(at Endpoint) was for SAPHRIStreated patients,1,0.5137247443199158
SAPHRIS,impairing gonadal steroidogenesis,Endpoint) was for SAPHRIStreated,1,0.493790864944458
SAPHRIS,impairing gonadal steroidogenesis,of patients with transaminase  >=3 times ULN (at Endpoint) was  for SAPHRIStreated patients versus for,1,0.5070051550865173
SAPHRIS,impairing gonadal steroidogenesis,SAPHRIStreated patients versus for placebotreated patients,0,0.5019419193267822
SAPHRIS,impairing gonadal steroidogenesis,Endpoint) was for SAPHRIStreated patients versus,1,0.504150390625
SAPHRIS,impairing gonadal steroidogenesis,for placebotreated patients The proportion of patients with,0,0.44898128509521484
SAPHRIS,Galactorrhea,ersus 1.3% f or placebotreated patients,1,0.5594571828842163
SAPHRIS,Galactorrhea,for placebotreated patients The proportion of patients with,0,0.5117309093475342
SAPHRIS,Galactorrhea,SAPHRIStreated patients ersus 1.3% f or placebotreated,1,0.5500810742378235
SAPHRIS,Galactorrhea,ULN at Endpoint was,0,0.5223663449287415
SAPHRIS,Galactorrhea,for SAPHRIStreated,0,0.5349133014678955
SAPHRIS,gynecomastia,ated patient,1,0.5036868453025818
SAPHRIS,gynecomastia,ated patient s In shortterm placebocontrolled,1,0.5095999240875244
SAPHRIS,gynecomastia,for ated patient s In shortterm placebocontrolled bipolar,1,0.4620217978954315
SAPHRIS,gynecomastia,patients versus for ated patient,1,0.48878222703933716
SAPHRIS,gynecomastia,SAPHRIStreated patients versus for ated,1,0.5350024104118347
SAPHRIS,gynecomastia,versus for ated,1,0.4692257344722748
SAPHRIS,hyperprolactinemia,of unitsL in,0,0.5142859220504761
SAPHRIS,hyperprolactinemia,mean increase in transaminase els for,1,0.5690434575080872
SAPHRIS,hyperprolactinemia,mean increase in transaminase els for SAPHRIS-tr eated patients was,1,0.5626863837242126
SAPHRIS,hyperprolactinemia,in transaminase els for,1,0.550092339515686
SAPHRIS,hyperprolactinemia,els for SAPHRIS-tr eated patients was unitsL,1,0.5496508479118347
SAPHRIS,hyperprolactinemia,for SAPHRIS-tr eated patients,1,0.5514312386512756
SAPHRIS,hypogonadism,adult mania trials the mean,0,0.5439356565475464
SAPHRIS,decreased bone density,crease,1,0.5233579874038696
SAPHRIS,decreased bone density,in placebotreated patients The proportion of patients with transaminase elevations times upper,0,0.476291686296463
SAPHRIS,decreased bone density,compared to a crease of 4.9,1,0.5108381509780884
SAPHRIS,decreased bone density,to a crease of 4.9,1,0.4936586320400238
SAPHRIS,decreased bone density,of 4.9 units/L in placebotreated patients The proportion,1,0.5263994336128235
SAPHRIS,decreased bone density,transaminase levels for SAPHRIStreated patients was unitsL compared to a,0,0.5196500420570374
SAPHRIS,decreased bone density,The proportion,0,0.5240529775619507
SAPHRIS,decreased bone density,was unitsL compared,0,0.4624192416667938
SAPHRIS,decreased bone density,crease of 4.9 units/L in placebotreated patients,1,0.5462660193443298
SAPHRIS,decreased bone density,crease of 4.9 units/L in,1,0.48554959893226624
SAPHRIS,abnormal prolactin levels,placebotreated patients In,0,0.49754661321640015
SAPHRIS,abnormal prolactin levels,of mal,1,0.5390191078186035
SAPHRIS,abnormal prolactin levels,a week,0,0.4485761821269989
SAPHRIS,abnormal prolactin levels,upper limit of mal (ULN) (at Endpoint) w as for SAPHRIStreated patients versus,1,0.5794127583503723
SAPHRIS,abnormal prolactin levels,of mal (ULN),1,0.530404806137085
SAPHRIS,abnormal prolactin levels,times upper limit of mal (ULN) (at,1,0.5624572038650513
SAPHRIS,abnormal prolactin levels,elevations times upper limit of,0,0.5242432951927185
SAPHRIS,abnormal prolactin levels,upper limit of mal (ULN) (at Endpoint) w as for,1,0.5570942163467407
SAPHRIS,tumorigenesis,of patients,0,0.5000227689743042
SAPHRIS,tumorigenesis,trials the mean decreases in prolactin levels were ngmL for,0,0.5441581010818481
SAPHRIS,tumorigenesis,proportion of patients with prolactin,0,0.49840492010116577
SAPHRIS,tumorigenesis,patients,1,0.5132939219474792
SAPHRIS,tumorigenesis,patients comp ared to ngmL for placebotreated,1,0.5210375785827637
SAPHRIS,tumorigenesis,patients comp ared to,1,0.5013682246208191
SAPHRIS,Seizures,for SAPHRIStreated patients versus,0,0.5683245658874512
SAPHRIS,Seizures,prolactin =4 times,1,0.5668062567710876
SAPHRIS,Seizures,d to ngmL for placebotreated patients The proportion of patients with prolactin,0,0.5101202130317688
SAPHRIS,Seizures,patients versus,0,0.5315285325050354
SAPHRIS,Seizures,with prolactin =4 times,1,0.5609201788902283
SAPHRIS,Seizures,=4 times ULN at Endpoint were,1,0.5148107409477234
SAPHRIS,Seizures,d to ngmL for placebotreated patients The proportion of patients with prolactin elevations,0,0.5255913734436035
SAPHRIS,Seizures,for SAPHRIStreated patients versus for placebotreated,0,0.5587161779403687
SAPHRIS,Seizures,ngmL for placebotreated patients The proportion of patients with prolactin,0,0.5026180744171143
SAPHRIS,seizures,oint) we re for SAPHRIStreated,1,0.5639642477035522
SAPHRIS,seizures,re for SAPHRIStreated patients versus for placebotreated patients In a longterm,0,0.5429709553718567
SAPHRIS,seizures,times ULN at oint) we re for SAPHRIStreated patients versus,1,0.5522072315216064
SAPHRIS,seizures,oint) we re for,1,0.5726293325424194
SAPHRIS,seizures,for SAPHRIStreated patients versus for,0,0.564185619354248
SAPHRIS,seizures,at oint) we re for SAPHRIStreated patients versus,1,0.5576891899108887
SAPHRIS,seizures,at oint),1,0.5364400744438171
SAPHRIS,seizures,oint) we,1,0.5792272090911865
SAPHRIS,seizures,g-term (,1,0.48481252789497375
SAPHRIS,seizures,In a g-term (,1,0.4925124943256378
SAPHRIS,seizures,placebotreated patients In a g-term (,1,0.5450806617736816
SAPHRIS,seizures,g-term ( week doubleblind comparatorcontrolled,1,0.5484737157821655
SAPHRIS,seizures,g-term ( week doubleblind comparatorcontrolled adult trial,1,0.553913950920105
SAPHRIS,seizures,patients,0,0.5720363259315491
SAPHRIS,seizures,patients In a g-term ( week,1,0.5553368330001831
SAPHRIS,seizures,placebotreated patients In a g-term ( week,1,0.5543092489242554
SAPHRIS,seizures,primarily,0,0.5159831047058105
SAPHRIS,Somnolence,with SAPH RIS mg,1,0.5743597745895386
SAPHRIS,Somnolence,twice,0,0.48192471265792847
SAPHRIS,Somnolence, with SAPH RIS,1,0.5416861772537231
SAPHRIS,Somnolence, with SAPH RIS mg twice,1,0.5591206550598145
SAPHRIS,somnolence,for placebotreated patients There were no reports of,0,0.46287262439727783
SAPHRIS,somnolence,Endpoint) ,1,0.42660897970199585
SAPHRIS,somnolence,were reported in of pa,0,0.457934707403183
SAPHRIS,somnolence,Endpoint)  for patients treated,1,0.42935824394226074
SAPHRIS,somnolence,of prolactin elevations times,0,0.5372639894485474
SAPHRIS,somnolence,prolactin elevations times ULN Endpoint)  for patients treated with SAPHRIS,1,0.5175315141677856
SAPHRIS,somnolence,Endpoint)  for patients treated with,1,0.43997249007225037
SAPHRIS,somnolence,cebo-treat ed patients There,1,0.4811169505119324
SAPHRIS,somnolence,cebo-treat ed,1,0.4991427958011627
SAPHRIS,somnolence,ed patients There were no reports of gynecomastia in this,0,0.4685326814651489
SAPHRIS,somnolence,cebo-treat ed patients There were,1,0.49597087502479553
SAPHRIS,somnolence,with SAP HRIS mg twice daily,1,0.5146298408508301
SAPHRIS,somnolence,for patients d with,1,0.5290818214416504
SAPHRIS,somnolence,patients d with SAP HRIS mg,1,0.49539411067962646
SAPHRIS,somnolence,times ULN at any time were and for patients treate,0,0.5031048059463501
SAPHRIS,somnolence,with SAP HRIS mg twice,1,0.4635576903820038
SAPHRIS,somnolence,as compared,0,0.4538942873477936
SAPHRIS,somnolence,were and for patients d with SAP HRIS,1,0.4614640772342682
SAPHRIS,somnolence,ULN at any time were and,0,0.5095807909965515
SAPHRIS,Somnolence,in schizophrenia and,0,0.530962347984314
SAPHRIS,sedation,ed patients in shortterm fixeddose trials in schizophrenia and bipolar mania The,0,0.5820452570915222
SAPHRIS,sedation,to for bo-treat,1,0.5271229147911072
SAPHRIS,somnolence,>=3 times ULN during,1,0.5038395524024963
SAPHRIS,sedation,The proportion of patients with,0,0.5335553884506226
SAPHRIS,sedation,ULN during a,0,0.5437768697738647
SAPHRIS,sedation, 3-week  trial in pediatric bipolar I,1,0.5229352116584778
SAPHRIS,sedation, 3-week  trial,1,0.587878942489624
SAPHRIS,sedation,ULN during  3-week  trial in pediatric bipolar I,1,0.5183614492416382
SAPHRIS,hypersomnia,in pediatr ic bipolar I disorder,1,0.5312707424163818
SAPHRIS,Somnolence,respectively versus for -treated p,1,0.46908947825431824
SAPHRIS,Somnolence,-treated p,1,0.45146358013153076
SAPHRIS,Somnolence,for -treated p atients Other Adverse,1,0.5273785591125488
SAPHRIS,Somnolence,Observed During the Premarketing Evaluation of SAPHRIS Fo,0,0.531858503818512
SAPHRIS,Disruption of the body's ability to reduce core body temperature,adults or p ediatric patients,1,0.527557373046875
SAPHRIS,Disruption of the body's ability to reduce core body temperature,drugrelated on pharmacologic o,0,0.5302673578262329
SAPHRIS,Disruption of the body's ability to reduce core body temperature,r other grounds. Reactions already listed for either adults or p ediatric patients,1,0.5569287538528442
SAPHRIS,Disruption of the body's ability to reduce core body temperature,patients in other parts of Adverse Reactions or those,0,0.5725533962249756
SAPHRIS,Disruption of the body's ability to reduce core body temperature,already listed for either adults or p ediatric patients,1,0.4980250298976898
SAPHRIS,Disruption of the body's ability to reduce core body temperature,other parts of Adverse Reactions,0,0.6102026700973511
SAPHRIS,Disruption of the body's ability to reduce core body temperature,either adults or p ediatric patients in,1,0.5321231484413147
SAPHRIS,Disruption of the body's ability to reduce core body temperature,r other grounds. Reactions already listed for either adults or p ediatric patients in,1,0.5560940504074097
SAPHRIS,body temperature increases,or,0,0.49277377128601074
SAPHRIS,body temperature increases,included Reactions e further categorized by M edDRA,1,0.5655823945999146
SAPHRIS,body temperature increases,e further categorized by M,1,0.4986371099948883
SAPHRIS,body temperature increases,e further categorized by,1,0.5015314817428589
SAPHRIS,body temperature increases,included Reactions e further categorized by M edDRA system organ class,1,0.569451630115509
SAPHRIS,body temperature increases,are not included Reactions e further categorized by M edDRA system,1,0.5216860771179199
SAPHRIS,body temperature increases,according,0,0.48886144161224365
SAPHRIS,body temperature increases,e further categorized by M edDRA system organ,1,0.5627228021621704
SAPHRIS,body temperature increases,are not included Reactions e further categorized by M edDRA system organ class and,1,0.5382653474807739
SAPHRIS,body temperature increases,liste,0,0.45886850357055664
SAPHRIS,body temperature increases,in the tabulated results from,1,0.5192700028419495
SAPHRIS,body temperature increases,d in the tabulated results from placebocontrolled trials appear in,1,0.5416690111160278
SAPHRIS,body temperature increases,already liste,0,0.5074483752250671
SAPHRIS,body temperature increases,least patients frequent only,0,0.4310203194618225
SAPHRIS,body temperature increases,in,0,0.512453556060791
SAPHRIS,body temperature increases,those occurring in at least patients frequent only those not already liste,0,0.5613948106765747
SAPHRIS,body temperature increases,d in,1,0.5071911811828613
SAPHRIS,body temperature increases,not already d in the tabulated results,1,0.5099384784698486
SAPHRIS,pyrexia,tabulated results rom pla,1,0.5284929871559143
SAPHRIS,pyrexia,rom pla,1,0.49410155415534973
SAPHRIS,pyrexia,rom pla cebocontrolled trials appear in this,1,0.5716121196746826
SAPHRIS,pyrexia,in the tabulated results rom pla cebocontrolled trials appear in,1,0.5612402558326721
SAPHRIS,pyrexia,listing those occurring,0,0.5424176454544067
SAPHRIS,pyrexia,least,0,0.47567853331565857
SAPHRIS,feeling hot,controlled  trials appear in this listing,1,0.4775952100753784
SAPHRIS,feeling hot,controlled  trials appear in,1,0.4747641384601593
SAPHRIS,aspiration,and Precautions or Overdosage that reflect,0,0.520858645439148
SAPHRIS,aspiration,se conside red,1,0.4997609257698059
SAPHRIS,aspiration,Reactions or se conside red in Contraindications Warnings,1,0.5105147361755371
SAPHRIS,aspiration,se conside,1,0.5543575882911682
SAPHRIS,aspiration,or se,1,0.5632855892181396
SAPHRIS,aspiration,Reactions or se,1,0.58890700340271
SAPHRIS,aspiration,either for adults or pediatric patients in other parts of Adverse Reactions or tho,0,0.5135836601257324
SAPHRIS,aspiration,adults,0,0.5477116107940674
SAPHRIS,aspiration,Warnings and Precautions or,0,0.4734480381011963
SAPHRIS,Dysphagia,Contraindications Warnings,0,0.5226384401321411
SAPHRIS,Dysphagia,Precaut,0,0.5449001789093018
SAPHRIS,Dysphagia,in Contraindications Warnings and ions,1,0.5340515375137329
SAPHRIS,Dysphagia,Contraindications Warnings and ions (5)  or Overdosage that reflect,1,0.5220552682876587
SAPHRIS,Dysphagia,ions (5) or Overdosage,1,0.5521281957626343
SAPHRIS,Dysphagia,in Contraindications Warnings and ions (5)  or Overdosage,1,0.5386043787002563
SAPHRIS,dysphagia,Complications,0,0.5748074054718018
CARBAGLU,Infections,adverse reactions in of,0,0.594354510307312
CARBAGLU,Infections,pain pyrexia,0,0.6024171113967896
CARBAGLU,Infections,Infections vomiting abdominal pain pyrexia,1,0.7131122946739197
CARBAGLU,Infections,Infections vomiting abdominal pain,1,0.7068155407905579
CARBAGLU,Infections,Infections vomiting,1,0.7385653853416443
CARBAGLU,Infections,are,0,0.540595531463623
CARBAGLU,Infections,in of,0,0.529700756072998
CARBAGLU,vomiting,ear infection diarrhea nasopharyngitis,0,0.5724995732307434
CARBAGLU,vomiting,of patients are vomiting abdominal pain,1,0.8089187145233154
CARBAGLU,vomiting,vomiting,1,0.9999999403953552
CARBAGLU,vomiting,tonsilitis anemia,0,0.5284512042999268
CARBAGLU,vomiting,vomiting abdominal pain pyrexia,1,0.8010575771331787
CARBAGLU,vomiting,common adverse reactions,0,0.6231201887130737
CARBAGLU,vomiting,adverse,0,0.5872194766998291
CARBAGLU,abdominal pain,patients are Infections abdominal pain,1,0.8278753161430359
CARBAGLU,abdominal pain,reactions in,0,0.49832236766815186
CARBAGLU,abdominal pain,abdominal pain,1,0.9999998807907104
CARBAGLU,abdominal pain,pyrexia tonsilitis anemia ear,0,0.5076605081558228
CARBAGLU,abdominal pain,Infections abdominal pain pyrexia tonsilitis anemia,1,0.7363995313644409
CARBAGLU,abdominal pain,nasopharyngitis,0,0.5264430046081543
CARBAGLU,abdominal pain,Infections abdominal,1,0.7856361865997314
CARBAGLU,pyrexia,Infections vomiting abdominal pyrexia tonsilitis anemia ear,1,0.7167249917984009
CARBAGLU,pyrexia,Infections abdominal,1,0.6046001315116882
CARBAGLU,pyrexia,are Infections vomiting abdominal pyrexia,1,0.8101470470428467
CARBAGLU,pyrexia,tonsilitis anemia ear infection,0,0.521425187587738
CARBAGLU,pyrexia,most common adverse reactions in of patients are Infections vomiting abdominal pain,0,0.5925006866455078
CARBAGLU,pyrexia,The most common adverse reactions in of patients are Infections,0,0.5603138208389282
CARBAGLU,pyrexia,pyrexia tonsilitis,1,0.8216372132301331
CARBAGLU,tonsilitis,tonsilitis anemia ear,1,0.7723528742790222
CARBAGLU,tonsilitis,anemia ear infection diarrhea nasopharyngitis and headache To report,0,0.6296307444572449
CARBAGLU,tonsilitis,and headache To,0,0.5875972509384155
CARBAGLU,tonsilitis,abdominal pain tonsilitis anemia ear infection,1,0.7154867649078369
CARBAGLU,tonsilitis,vomiting abdominal pain tonsilitis anemia ear,1,0.7094782590866089
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea nasopharyngitis,1,0.7850130200386047
CARBAGLU,tonsilitis,Infections vomiting abdominal pain tonsilitis anemia ear,1,0.7090615034103394
CARBAGLU,anemia,pain pyrexia,0,0.5614413619041443
CARBAGLU,anemia,nasopharyngitis and headache To report SUSPECTED ADVERS,0,0.5370295643806458
CARBAGLU,anemia,pain pyrexia anemia,1,0.7641199827194214
CARBAGLU,anemia,vomiting abdominal pain pyrexia anemia,1,0.738584578037262
CARBAGLU,anemia,headache To,0,0.5434740781784058
CARBAGLU,anemia,anemia ear infection,1,0.8110417723655701
CARBAGLU,anemia,nasopharyngitis and headache To report SUSPECTED,0,0.537753701210022
CARBAGLU,diarrhea,infection,0,0.6666980385780334
CARBAGLU,diarrhea,SUSPECTED ADVERSE REACTIONS contact Accr,0,0.5477940440177917
CARBAGLU,diarrhea,tonsilitis anemia ear diarrhea nasopharyngitis and,1,0.6863662600517273
CARBAGLU,nasopharyngitis,nasopharyngitis and,1,0.938402533531189
CARBAGLU,headache,diarrhea nasopharyngitis,0,0.547797679901123
CARBAGLU,headache,headache To report SUSPECTED ADVERSE REACTIONS,1,0.7809228301048279
CARBAGLU,headache,headache To,1,0.9336680769920349
CARBAGLU,headache,headache To report,1,0.8183112740516663
CARBAGLU,headache,headache To report SUSPECTED,1,0.8286823034286499
CARBAGLU,Infections,common adverse reactions occurring in of patients regardless of,0,0.5846028923988342
CARBAGLU,Infections,of patients regardless of causality,0,0.5536808967590332
CARBAGLU,Infections,causality,0,0.5372357964515686
CARBAGLU,Infections,regardless of causality Infections vomiting abdominal,1,0.668258547782898
CARBAGLU,Infections,of,0,0.544413685798645
CARBAGLU,Infections,causality Infections vomiting abdominal pain,1,0.6902515292167664
CARBAGLU,Infections,of causality are,0,0.5112698674201965
CARBAGLU,Infections,ear infection,0,0.7514426708221436
CARBAGLU,Infections,Infections vomiting abdominal pain pyrexia tonsilitis,1,0.7313843369483948
CARBAGLU,vomiting,vomiting abdominal,1,0.9126684665679932
CARBAGLU,vomiting,of patients regardless,0,0.4906041622161865
CARBAGLU,vomiting,nasopharyngitis and,0,0.5918787717819214
CARBAGLU,vomiting,are vomiting abdominal pain pyrexia,1,0.7721685767173767
CARBAGLU,abdominal pain,abdominal pain pyrexia,1,0.8097774982452393
CARBAGLU,pyrexia,pyrexia tonsilitis anemia,1,0.8114824295043945
CARBAGLU,pyrexia,abdominal pain pyrexia,1,0.8758010268211365
CARBAGLU,pyrexia,Table,0,0.5292259454727173
CARBAGLU,pyrexia,ear infection diarrhea nasopharyngitis and headache,0,0.5686535835266113
CARBAGLU,tonsilitis,tonsilitis anemia,1,0.8175772428512573
CARBAGLU,tonsilitis,headache Table summarizes,0,0.5225855112075806
CARBAGLU,tonsilitis,n of patients regardless of causality are Infections vomiting abdominal,0,0.5360058546066284
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea,1,0.7655125856399536
CARBAGLU,tonsilitis,vomiting abdominal pain tonsilitis anemia,1,0.7242300510406494
CARBAGLU,tonsilitis,tonsilitis anemia ear infection,1,0.7800942063331604
CARBAGLU,tonsilitis,abdominal pain tonsilitis anemia ear infection diarrhea nasopharyngitis,1,0.7227722406387329
CARBAGLU,anemia,summarizes adverse reactions,0,0.540816068649292
CARBAGLU,anemia,headache Table summarizes adverse,0,0.5298091173171997
CARBAGLU,anemia,pyrexia anemia ear,1,0.7068641781806946
CARBAGLU,anemia,and headache,0,0.5804310441017151
CARBAGLU,anemia,anemia,1,1.0
CARBAGLU,ear infection,tonsilitis ear infection diarrhea nasopharyngitis and,1,0.7407391667366028
CARBAGLU,ear infection,anemia,1,0.5512596368789673
CARBAGLU,ear infection,ear infection diarrhea nasopharyngitis,1,0.7807950377464294
CARBAGLU,ear infection,tonsilitis ear infection diarrhea nasopharyngitis and headache,1,0.7272223234176636
CARBAGLU,diarrhea,diarrhea nasopharyngitis and headache,1,0.7488468885421753
CARBAGLU,diarrhea,vomiting abdominal pain pyrexia tonsilitis anemia ear,0,0.6402515172958374
CARBAGLU,nasopharyngitis,nasopharyngitis,1,1.0000001192092896
CARBAGLU,nasopharyngitis,tonsilitis anemia ear infection nasopharyngitis and headache Table,1,0.7602185010910034
CARBAGLU,headache,headache Table,1,0.8031393885612488
CARBAGLU,headache,nasopharyngitis and,1,0.581222414970398
CARBAGLU,headache,diarrhea nasopharyngitis headache Table,1,0.7147666215896606
CARBAGLU,headache,headache Table summarizes adverse reactions occurring,1,0.754124641418457
CARBAGLU,headache,pain pyrexia tonsilitis anemia,0,0.6366682052612305
CARBAGLU,headache,headache,1,1.0
CARBAGLU,headache,headache Table summarizes adverse reactions,1,0.7575163841247559
CARBAGLU,headache,nasopharyngitis,0,0.5994970202445984
PROMACTA,Hepatic Decompensation,Warnings and,0,0.5389460325241089
PROMACTA,Hepatic Decompensation,other Hepatic Decompensation in Patients with Chronic Hepatitis,1,0.8753767609596252
PROMACTA,Hepatic Decompensation,Hepatic Decompensation in Patients with Chronic,1,0.9093509316444397
PROMACTA,Hepatic Decompensation,Hepatic Decompensation in,1,0.9899548292160034
PROMACTA,Hepatic Decompensation,sections,0,0.5111574530601501
PROMACTA,Hepatic Decompensation,in Patients with Chronic Hepatitis C see Warnings and Precautions Hepatotoxicity,0,0.6573800444602966
PROMACTA,Hepatotoxicity,Hepatotoxicity see Warnings and,1,0.907192051410675
PROMACTA,Hepatotoxicity,see Warnings and Hepatotoxicity see Warnings and,1,0.8626524209976196
PROMACTA,Hepatotoxicity,and,0,0.5135397911071777
PROMACTA,Thromboembolic Complications,see,0,0.4844723343849182
PROMACTA,Thromboembolic Complications,Precautions Thromboembolic,1,0.8448501825332642
PROMACTA,Thromboembolic Complications,Thromboembolic Complications see Warnings and Precautions,1,0.9171875715255737
PROMACTA,Thromboembolic Complications,Thromboembolic Complications see Warnings and Precautions Cataracts,1,0.8462873697280884
PROMACTA,Thromboembolic Complications,Hepatotoxicity see Warnings,0,0.5611423254013062
PROMACTA,Cataracts,Cataracts see Warnings and,1,0.8592275977134705
PROMACTA,Cataracts,Complications see Warnings and Cataracts,1,0.7937676906585693
PROMACTA,nausea,nausea diarrhea,1,0.8622832298278809
PROMACTA,nausea,to and,0,0.5088027715682983
PROMACTA,nausea,nausea diarrhea upper,1,0.802467942237854
PROMACTA,nausea,nausea diarrhea upper respiratory tract,1,0.7876423597335815
PROMACTA,nausea,and greater than placebo nausea diarrhea upper respiratory tract,1,0.7618106603622437
PROMACTA,nausea,ALT myalgia and urinary tract i,0,0.5475839376449585
PROMACTA,nausea,urinary,0,0.5462042093276978
PROMACTA,diarrhea,diarrhea upper respiratory,1,0.7501354217529297
PROMACTA,upper respiratory tract infection,nausea upper respiratory tract infection vomiting increased ALT myalgia and,1,0.7466702461242676
PROMACTA,upper respiratory tract infection,diarrhea upper respiratory,1,0.7997239828109741
PROMACTA,upper respiratory tract infection,In,0,0.5123268961906433
PROMACTA,upper respiratory tract infection,upper respiratory tract infection vomiting increased ALT,1,0.7893487215042114
PROMACTA,upper respiratory tract infection,myalgia and urinary tract infection In pediatric patie,0,0.5704244375228882
PROMACTA,upper respiratory tract infection,In pediatric,0,0.5208920240402222
PROMACTA,upper respiratory tract infection,than placebo were nausea upper respiratory tract infection,1,0.782305121421814
PROMACTA,upper respiratory tract infection,urinary,0,0.5927243232727051
PROMACTA,upper respiratory tract infection,tract infection vomiting increased ALT,1,0.6736665964126587
PROMACTA,vomiting,vomiting increased ALT myalgia and urinary,1,0.7778698801994324
PROMACTA,vomiting,vomiting increased,1,0.9160423874855042
PROMACTA,vomiting,vomiting increased ALT myalgia,1,0.7936698794364929
PROMACTA,vomiting,and greater than placebo,0,0.5419701337814331
PROMACTA,increased ALT,vomiting,0,0.51334547996521
PROMACTA,increased ALT,placebo,0,0.5376707911491394
PROMACTA,increased ALT,myalgia and urinary tract infection In pediatric patients,0,0.5205138325691223
PROMACTA,increased ALT,upper respiratory tract infection increased,1,0.663336992263794
PROMACTA,increased ALT,tract infection increased ALT,1,0.8218032121658325
PROMACTA,increased ALT,increased ALT,1,1.0
PROMACTA,increased ALT,tract infection In pediatric patients,0,0.4983416795730591
PROMACTA,increased ALT,tract infection increased,1,0.6667826771736145
PROMACTA,increased ALT,upper respiratory tract infection increased ALT,1,0.8080227375030518
PROMACTA,urinary tract infection,the most common adverse,0,0.5272990465164185
PROMACTA,urinary tract infection,age years and older with ITP the most common adverse rea,0,0.548830509185791
PROMACTA,urinary tract infection,patients age years and older,0,0.5533576607704163
PROMACTA,urinary tract infection,urinary tract infection In,1,0.9345441460609436
PROMACTA,urinary tract infection,ALT myalgia urinary tract,1,0.707513689994812
PROMACTA,urinary tract infection,pediatric patients age years and older with ITP the most common,0,0.5344240665435791
PROMACTA,upper respiratory tract infection,rhinitis In patients with chronic,0,0.6443213820457458
PROMACTA,upper respiratory tract infection,tract infection nasopharyngitis and rhinitis,1,0.7818331122398376
PROMACTA,upper respiratory tract infection,upper respiratory tract infection nasopharyngitis,1,0.9009209871292114
PROMACTA,upper respiratory tract infection,than placebo upper respiratory tract infection nasopharyngitis and rhinitis In,1,0.8208560943603516
PROMACTA,upper respiratory tract infection,upper respiratory tract infection nasopharyngitis and rhinitis,1,0.8639240264892578
PROMACTA,nasopharyngitis,upper respiratory tract nasopharyngitis and rhinitis In patients with,1,0.8224160671234131
PROMACTA,nasopharyngitis,In,0,0.5386790037155151
PROMACTA,nasopharyngitis,nasopharyngitis and rhinitis In patients,1,0.8585494756698608
PROMACTA,nasopharyngitis,nasopharyngitis,1,1.0000001192092896
PROMACTA,nasopharyngitis,hepatitis Cassociated thrombocytopenia,0,0.5355977416038513
PROMACTA,nasopharyngitis,ons greater than or equal to,0,0.4978135824203491
PROMACTA,nasopharyngitis,respiratory tract nasopharyngitis and rhinitis In,1,0.8379088640213013
PROMACTA,nasopharyngitis,equal to and greater than placebo were upper,0,0.4874570369720459
PROMACTA,rhinitis,rhinitis In,1,0.9461080431938171
PROMACTA,rhinitis,infection nasopharyngitis rhinitis In,1,0.8252646923065186
PROMACTA,rhinitis,infection nasopharyngitis rhinitis In patients with chronic hepatitis,1,0.7462954521179199
PROMACTA,rhinitis,rhinitis In patients,1,0.8822096586227417
PROMACTA,rhinitis,infection nasopharyngitis rhinitis In patients,1,0.8042980432510376
PROMACTA,rhinitis,and greater,0,0.45986753702163696
PROMACTA,rhinitis,rhinitis In patients with,1,0.8715737462043762
PROMACTA,rhinitis,Cassociated thrombocytopenia,0,0.4638287127017975
PROMACTA,anemia,reactions greater than or equal to and greater than,0,0.5179495811462402
PROMACTA,anemia,diarrhea decreased,0,0.522817075252533
PROMACTA,anemia,were,0,0.57362961769104
PROMACTA,pyrexia,greater than placebo were pyrexia,1,0.8624497652053833
PROMACTA,pyrexia,were,0,0.5141094923019409
PROMACTA,pyrexia,pyrexia fatigue headache nausea diarrhea,1,0.8685507774353027
PROMACTA,pyrexia,pyrexia fatigue headache nausea,1,0.8739807605743408
PROMACTA,fatigue,fatigue headache nausea diarrhea decreased appetite,1,0.7583831548690796
PROMACTA,fatigue,pyrexia fatigue headache nausea,1,0.7447223663330078
PROMACTA,fatigue,than placebo were anemia fatigue headache nausea,1,0.7382286787033081
PROMACTA,fatigue,fatigue headache,1,0.8497189283370972
PROMACTA,fatigue,fatigue,1,1.0
PROMACTA,fatigue,anemia fatigue headache nausea,1,0.7740787267684937
PROMACTA,fatigue,or equal to and greater,0,0.48304903507232666
PROMACTA,fatigue,decreased appetite,0,0.6335309743881226
PROMACTA,nausea,influenzalike illness asthenia insomnia cough pruritus,0,0.6558961868286133
PROMACTA,nausea,nausea diarrhea decreased appetite influenzalike,1,0.7396966218948364
PROMACTA,nausea,nausea diarrhea decreased,1,0.7556769847869873
PROMACTA,nausea,appetite influenzalike illness asthenia insomnia cough pruritus,0,0.6876506805419922
PROMACTA,diarrhea,headache diarrhea decreased appetite influenzalike illness asthenia,1,0.69167160987854
PROMACTA,diarrhea,appetite influenzalike illness asthenia insomnia cough pruritus,0,0.5975919365882874
PROMACTA,decreased appetite,equal to,0,0.4293772876262665
PROMACTA,decreased appetite,to and greater than,0,0.43836647272109985
PROMACTA,decreased appetite,placebo were anemia pyrexia fatigue,0,0.6413354873657227
PROMACTA,decreased appetite,fatigue headache nausea decreased appetite,1,0.8272331953048706
PROMACTA,decreased appetite,pyrexia fatigue headache nausea decreased appetite influenzalike illness asthenia,1,0.750519871711731
PROMACTA,decreased appetite,nausea decreased appetite,1,0.878321647644043
PROMACTA,decreased appetite,illness,0,0.6353051662445068
PROMACTA,decreased appetite,nausea,0,0.6254303455352783
PROMACTA,influenza-like illness,headache nausea diarrhea decreased influenza-like illness,1,0.80600905418396
PROMACTA,influenza-like illness,nausea diarrhea decreased influenza-like illness asthenia,1,0.7702262997627258
PROMACTA,asthenia,peripheral,0,0.5436301231384277
PROMACTA,asthenia,asthenia insomnia cough pruritus chills,1,0.7133793234825134
PROMACTA,asthenia,cough,0,0.544638991355896
PROMACTA,asthenia,asthenia insomnia cough pruritus,1,0.7209969758987427
PROMACTA,asthenia,asthenia,1,1.0000001192092896
PROMACTA,asthenia,appetite,0,0.601927638053894
PROMACTA,asthenia,diarrhea decreased appetite influenzalike asthenia insomnia cough pruritus chills,1,0.6281572580337524
PROMACTA,asthenia,asthenia insomnia,1,0.791143536567688
PROMACTA,insomnia,appetite influenzalike illness,0,0.5075342655181885
PROMACTA,insomnia,insomnia cough pruritus chills,1,0.7461546659469604
PROMACTA,insomnia,insomnia cough pruritus,1,0.7412328720092773
PROMACTA,insomnia,edema,0,0.5353832840919495
PROMACTA,cough,cough pruritus,1,0.8019675016403198
PROMACTA,cough,peripheral edema In patients,0,0.4777478873729706
PROMACTA,cough,cough pruritus chills myalgia alopecia,1,0.7297303080558777
PROMACTA,cough,chills myalgia alopecia,0,0.5629949569702148
PROMACTA,cough,atigue headache nausea diarrhea decreased,0,0.585321843624115
PROMACTA,cough,cough pruritus chills myalgia,1,0.730655312538147
PROMACTA,cough,cough pruritus chills,1,0.7683278322219849
PROMACTA,pruritus,insomnia pruritus chills myalgia alopecia,1,0.8020329475402832
PROMACTA,pruritus,cough pruritus chills,1,0.8128990530967712
PROMACTA,pruritus,asthenia insomnia pruritus,1,0.8550691604614258
PROMACTA,pruritus,pruritus,1,0.9999999403953552
PROMACTA,pruritus,pruritus chills myalgia alopecia and peripheral,1,0.8366354703903198
PROMACTA,pruritus,insomnia pruritus chills,1,0.823128342628479
PROMACTA,pruritus,influenzalike illness asthenia insomnia pruritus chills myalgia alopecia and peripheral,1,0.7443461418151855
PROMACTA,pruritus,pruritus chills,1,0.8822193145751953
PROMACTA,myalgia,decreased appetite influenzalike illness asthenia insomnia cough pruritus,0,0.582146167755127
PROMACTA,myalgia,myalgia alopecia and peripheral edema In,1,0.7706884145736694
PROMACTA,myalgia,influenzalike illness asthenia insomnia cough pruritus chills,0,0.584133505821228
PROMACTA,myalgia,aplastic,0,0.5583210587501526
PROMACTA,myalgia,myalgia alopecia and peripheral,1,0.778750479221344
PROMACTA,myalgia,decreased appetite influenzalike illness asthenia insomnia cough,0,0.561172604560852
PROMACTA,alopecia,with severe aplastic anemia the most common ad,0,0.5611255168914795
PROMACTA,alopecia,alopecia and peripheral edema,1,0.8189648389816284
PROMACTA,alopecia,pruritus chills,0,0.5738720297813416
PROMACTA,alopecia,and peripheral edema In patients with severe aplastic anemia,0,0.5303710699081421
PROMACTA,alopecia,alopecia and peripheral,1,0.8485541343688965
PROMACTA,alopecia,peripheral edema In,0,0.5454051494598389
PROMACTA,alopecia,insomnia cough pruritus chills alopecia and peripheral edema In,1,0.7409108281135559
PROMACTA,alopecia,alopecia and peripheral edema In,1,0.8259807825088501
PROMACTA,peripheral edema,illness asthenia insomnia cough pruritus,0,0.558747410774231
PROMACTA,peripheral edema,alopecia peripheral,1,0.7111122012138367
PROMACTA,peripheral edema,and,0,0.4866998493671417
PROMACTA,peripheral edema,chills myalgia alopecia peripheral edema,1,0.7420830726623535
PROMACTA,peripheral edema,myalgia alopecia peripheral edema,1,0.8258208632469177
PROMACTA,peripheral edema,insomnia cough pruritus chills myalgia alopecia and,0,0.5440075397491455
PROMACTA,peripheral edema,patients with severe aplastic anemia the most common adverse reactions great,0,0.547560453414917
PROMACTA,peripheral edema,influenzalike illness asthenia insomnia cough pruritus chills myalgia alopecia,0,0.5521235466003418
PROMACTA,peripheral edema,alopecia and,0,0.5365209579467773
PROMACTA,peripheral edema,peripheral edema,1,1.0000001192092896
PROMACTA,nausea,nausea fatigue cough,1,0.847832202911377
PROMACTA,fatigue,nausea,0,0.684320867061615
PROMACTA,fatigue,fatigue cough diarrhea and,1,0.7720077633857727
PROMACTA,fatigue,fatigue cough diarrhea and headache EXCERPT,1,0.7707133293151855
PROMACTA,fatigue,fatigue cough,1,0.830451488494873
PROMACTA,fatigue,To,0,0.5626474022865295
PROMACTA,fatigue,common adverse,0,0.540793776512146
PROMACTA,fatigue,EXCERPT To report,0,0.5145566463470459
PROMACTA,cough,report SUSPECTED ADVERSE REACTIONS conta,0,0.5618667602539062
PROMACTA,cough,cough diarrhea,1,0.826874852180481
PROMACTA,cough,to were nausea cough,1,0.8696836233139038
PROMACTA,cough,cough diarrhea and headache,1,0.7512702941894531
PROMACTA,cough,cough,1,1.0
PROMACTA,cough,diarrhea and headache EXCERPT To report,0,0.5618055462837219
PROMACTA,cough,cough diarrhea and headache EXCERPT,1,0.7514173984527588
PROMACTA,diarrhea,diarrhea and headache EXCERPT To report,1,0.792163610458374
PROMACTA,diarrhea,and headache EXCERPT To report SUSPECTED ADVERSE REACTIONS,0,0.5781353116035461
PROMACTA,headache,headache EXCERPT To report SUSPECTED,1,0.8052186965942383
PROMACTA,headache,headache,1,0.9999998807907104
PROMACTA,headache,ADVERSE REACTIONS contact GlaxoSmithKline at,0,0.5194500684738159
PROMACTA,headache,SUSPECTED ADVERSE REACTIONS contact GlaxoSmithKline at,0,0.5170570015907288
PROMACTA,hemorrhage,hemorrhage was the most common,1,0.8296496868133545
PROMACTA,hemorrhage,hemorrhage,1,1.0
PROMACTA,hemorrhage,ed in practice Chronic Immune Idiopathic Thrombocytopenia Adults In,0,0.5628038644790649
PROMACTA,hemorrhagic reactions,hemorrhage was the most common serious,0,0.7240301966667175
PROMACTA,hemorrhagic reactions,clinical trials hemorrhage was the most common serious,0,0.6894818544387817
PROMACTA,hemorrhagic reactions,most common serious adverse,0,0.5748964548110962
PROMACTA,hemorrhagic reactions,hemorrhagic reactions followed discontinuation of PROMACTA Other,1,0.7621016502380371
PROMACTA,thromboembolic complications,Warnings and Precautions The data described below reflect,0,0.5667751431465149
PROMACTA,thromboembolic complications,adverse,0,0.6020041704177856
PROMACTA,thromboembolic complications,adverse reactions included,0,0.6569849252700806
PROMACTA,thromboembolic complications,reactions included thromboembolic complications see Warnings and,1,0.85770583152771
PROMACTA,thromboembolic complications,thromboembolic complications see Warnings,1,0.9184353351593018
PROMACTA,thromboembolic complications,thromboembolic complications see,1,0.9824766516685486
PROMACTA,thromboembolic complications,adverse reactions included thromboembolic complications,1,0.8983128070831299
PROMACTA,thromboembolic complications,Precautions The data described below reflect exposure of PROMACTA to,0,0.5435559749603271
PROMACTA,thromboembolic complications,included thromboembolic complications see Warnings and Precautions,1,0.9032610058784485
PROMACTA,alopecia,alopecia musculoskeletal,1,0.8196404576301575
PROMACTA,alopecia,Precautions The data described below reflect exposure of PROMACTA to,0,0.4819944500923157
PROMACTA,alopecia,mouth were the,0,0.49243927001953125
PROMACTA,alopecia,alopecia,1,1.0
PROMACTA,alopecia,trials,0,0.5064631700515747
PROMACTA,musculoskeletal pain,the adverse,0,0.4945651590824127
PROMACTA,musculoskeletal pain,trials musculoskeletal pain,1,0.8869742155075073
PROMACTA,musculoskeletal pain,controlled clinical chronic ITP trials,0,0.47730350494384766
PROMACTA,musculoskeletal pain,musculoskeletal pain,1,1.0000001192092896
PROMACTA,musculoskeletal pain,dry mouth were the adverse reactions reported in of p,0,0.48377764225006104
PROMACTA,musculoskeletal pain,dry mouth were the adverse,0,0.450003445148468
PROMACTA,blood alkaline phosphatase increased,musculoskeletal blood alkaline phosphatase increased and dry mouth,1,0.8275056481361389
PROMACTA,blood alkaline phosphatase increased,dry mouth were the adverse,0,0.45531901717185974
PROMACTA,blood alkaline phosphatase increased,alopecia musculoskeletal blood alkaline phosphatase increased and dry,1,0.8397407531738281
PROMACTA,blood alkaline phosphatase increased,phosphatase increased,1,0.848726749420166
PROMACTA,blood alkaline phosphatase increased,trials alopecia musculoskeletal blood alkaline phosphatase,1,0.8118103742599487
PROMACTA,blood alkaline phosphatase increased,ITP trials alopecia musculoskeletal blood alkaline phosphatase,1,0.7794982194900513
PROMACTA,dry mouth,dry mouth were,1,0.971868097782135
PROMACTA,dry mouth,phosphatase increased dry,1,0.6671456098556519
PROMACTA,dry mouth,alkaline phosphatase increased dry,1,0.6288713812828064
PROMACTA,dry mouth,musculoskeletal pain blood alkaline phosphatase,0,0.47192543745040894
PROMACTA,dry mouth,dry mouth were the adverse reactions,1,0.8620385527610779
PROMACTA,serum liver test abnormalities,controlled chronic ITP serum liver test abnormalities,1,0.8466571569442749
PROMACTA,serum liver test abnormalities,dry mouth were the adverse reactions,1,0.4809623956680298
PROMACTA,serum liver test abnormalities,the three,0,0.42209839820861816
PROMACTA,serum liver test abnormalities,controlled chronic ITP serum,1,0.6447285413742065
PROMACTA,serum liver test abnormalities,ITP serum liver test abnormalities predominantly Grade or,1,0.8413669466972351
PROMACTA,serum liver test abnormalities,three controlled chronic ITP serum,1,0.643561840057373
PROMACTA,serum liver test abnormalities,controlled,0,0.46870157122612
PROMACTA,serum liver test abnormalities,in severity were reported in and of patients for PROMACTA an,0,0.551581859588623
PROMACTA,serum liver test abnormalities,three controlled,0,0.44780686497688293
PROMACTA,serum liver test abnormalities,Grade or less in severity were reported in and of patients for,0,0.5364188551902771
PROMACTA,serum liver test abnormalities,chronic ITP trials,0,0.5594293475151062
PROMACTA,serum liver test abnormalities,three controlled chronic ITP serum liver,1,0.7541190981864929
PROMACTA,serum liver test abnormalities,three controlled chronic ITP serum liver test abnormalities predominantly Grade,1,0.8242425918579102
PROMACTA,serum liver test abnormalities,liver test abnormalities predominantly Grade or less,1,0.8296040296554565
PROMACTA,serum liver test abnormalities,serum liver test abnormalities,1,1.0
PROMACTA,serum liver test abnormalities,chronic ITP serum liver test abnormalities,1,0.8682317137718201
PROMACTA,hepatobiliary laboratory abnormalities,Seven of the,0,0.4312731623649597
PROMACTA,hepatobiliary laboratory abnormalities,with PROMACTA and three patients in the,0,0.5336754322052002
PROMACTA,hepatobiliary laboratory abnormalities,PROMACTA,0,0.4616660177707672
PROMACTA,hepatobiliary laboratory abnormalities,group discontinued treatment due hepatobiliary laboratory abnormalities Seven of,1,0.8273710012435913
PROMACTA,hepatobiliary laboratory abnormalities,patients treated with PROMACTA in the,0,0.5270239114761353
PROMACTA,hepatobiliary laboratory abnormalities,patients,0,0.5299390554428101
PROMACTA,hepatobiliary laboratory abnormalities,with,0,0.4986759126186371
PROMACTA,hepatobiliary laboratory abnormalities,hepatobiliary laboratory abnormalities Seven,1,0.9484428763389587
PROMACTA,hepatobiliary laboratory abnormalities,due hepatobiliary,1,0.8454091548919678
PROMACTA,hepatobiliary laboratory abnormalities,laboratory abnormalities were reexposed to,1,0.740185022354126
PROMACTA,hepatobiliary laboratory abnormalities,of the patients treated with PROMACTA in the controlled trials,0,0.515893280506134
PROMACTA,hepatobiliary laboratory abnormalities,trials hepatobiliary laboratory abnormalities were reexposed to,1,0.8973530530929565
PROMACTA,hepatobiliary laboratory abnormalities,the patients treated with PROMACTA in the controlled,0,0.537338376045227
PROMACTA,hepatobiliary laboratory abnormalities,hepatobiliary laboratory abnormalities were reexposed,1,0.9279638528823853
PROMACTA,hepatobiliary laboratory abnormalities,laboratory abnormalities were reexposed to PROMACTA in,1,0.7285574078559875
PROMACTA,hepatobiliary laboratory abnormalities,in the extension trial Six of these patients again experienced liver t,0,0.6424314975738525
PROMACTA,liver test abnormalities,trial Six of these patients again,0,0.5231060981750488
PROMACTA,liver test abnormalities,patient,0,0.5452486872673035
PROMACTA,liver test abnormalities,these patients again liver test,1,0.8260952234268188
PROMACTA,liver test abnormalities,test abnormalities predominantly Grade resulting,1,0.7122993469238281
PROMACTA,liver test abnormalities,patients again liver test abnormalities,1,0.91280198097229
PROMACTA,liver test abnormalities,in discontinuation of PROMACTA,0,0.4727104902267456
PROMACTA,liver test abnormalities,liver test abnormalities predominantly,1,0.9261577129364014
PROMACTA,liver test abnormalities,had PROMACTA discontinued due liver test,1,0.7455321550369263
PROMACTA,liver test abnormalities,liver test abnormalities less than,1,0.8957909345626831
PROMACTA,liver test abnormalities,had PROMACTA discontinued due liver test abnormalities,1,0.7794448733329773
PROMACTA,liver test abnormalities,one additional patient had PROMACTA discontinued,0,0.49725860357284546
PROMACTA,liver test abnormalities,due liver test abnormalities,1,0.9551770091056824
PROMACTA,liver test abnormalities,placebocontrolled,0,0.48528435826301575
PROMACTA,liver test abnormalities,due liver test abnormalities less than,1,0.8849868774414062
PROMACTA,liver test abnormalities,PROMACTA discontinued due liver test abnormalities less than or equal,1,0.795193076133728
PROMACTA,liver test abnormalities,trial of PROMACTA in patients with,0,0.5520882606506348
PROMACTA,portal vein thromboses,the placebo group portal vein thromboses see Warnings and,1,0.8416687846183777
PROMACTA,portal vein thromboses,trial of PROMACTA in patients with,0,0.529598593711853
PROMACTA,portal vein thromboses,portal vein thromboses,1,1.0
PROMACTA,portal vein thromboses,portal,1,0.6114698648452759
PROMACTA,portal vein thromboses,vein thromboses see Warnings and,1,0.7573550939559937
PROMACTA,portal vein thromboses,described below,0,0.5035134553909302
PROMACTA,portal vein thromboses,Patients The data described,0,0.5255140066146851
PROMACTA,portal vein thromboses,data described below reflec,0,0.47229713201522827
PROMACTA,portal vein thromboses,placebo group portal,1,0.5361698865890503
PROMACTA,portal vein thromboses,portal vein thromboses see,1,0.9749377965927124
PROMACTA,hyperbilirubinemia,was reported in of patients receiving PROMACTA compared with for placebo,0,0.48310771584510803
PROMACTA,hyperbilirubinemia,chronic hepatitis hyperbilirubinemia was,1,0.8463022708892822
PROMACTA,hyperbilirubinemia,for placebo Total bilirubin gre,0,0.725111722946167
PROMACTA,hyperbilirubinemia,hyperbilirubinemia was reported in of,1,0.9193109273910522
PROMACTA,hyperbilirubinemia,controlled clinical trials in patients with chronic hepatitis,0,0.6178805828094482
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,than or equal to 1.5 x ULN was reported in,1,0.7629271745681763
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,in and of patients receiving,0,0.5095899701118469
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,greater than or equal to 1.5 x ULN was reported in and of,1,0.7789130806922913
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,placebo respectively ALT or AST gr,0,0.5675696730613708
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,and of patients receiving PROMACTA and placebo respectively ALT or AST gr,0,0.5055567622184753
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,with for Total bilirubin greater than or equal to 1.5 x ULN was,1,0.9858605265617371
PROMACTA,AST greater than or equal to 3 x ULN,3 x ULN was reported in and,1,0.7733311057090759
PROMACTA,AST greater than or equal to 3 x ULN,was reported in and of,0,0.4843783974647522
PROMACTA,AST greater than or equal to 3 x ULN,or equal to 3 x ULN was reported in and of,1,0.8322330713272095
PROMACTA,AST greater than or equal to 3 x ULN,reported in,0,0.47925639152526855
PROMACTA,AST greater than or equal to 3 x ULN,ALT AST greater than or equal to 3 x ULN was reported,1,0.9167385697364807
PROMACTA,AST greater than or equal to 3 x ULN,patients receiving PROMACTA and,0,0.47675877809524536
PROMACTA,nausea,greater than or equal to were,0,0.4998341202735901
PROMACTA,nausea,headache Table Adverse,0,0.6142780780792236
PROMACTA,nausea,or equal to nausea fatigue cough diarrhea and,1,0.7896010279655457
PROMACTA,nausea,Adverse,0,0.5926717519760132
PROMACTA,nausea,nausea fatigue cough diarrhea and,1,0.7897545099258423
PROMACTA,nausea,were,0,0.524542510509491
PROMACTA,fatigue,fatigue cough diarrhea,1,0.7682068347930908
PROMACTA,fatigue,were,0,0.5404788255691528
PROMACTA,fatigue,to were fatigue cough diarrhea,1,0.7718503475189209
PROMACTA,cough,reactions greater than or equal to,0,0.5126359462738037
PROMACTA,cough,adverse,0,0.5775624513626099
PROMACTA,cough,cough diarrhea and headache Table,1,0.7214192152023315
PROMACTA,cough,Trial in Adults,0,0.5686683058738708
PROMACTA,cough,cough diarrhea and,1,0.8157095909118652
PROMACTA,cough,The most common adverse,0,0.5524526834487915
PROMACTA,diarrhea,diarrhea,1,0.9999999403953552
PROMACTA,diarrhea,Openlabel Trial in Adults,0,0.5389329791069031
PROMACTA,diarrhea,adverse reactions,0,0.6146209239959717
PROMACTA,headache,Openlabel Trial in Adults with Severe,0,0.5298881530761719
PROMACTA,headache,than,0,0.549185037612915
PROMACTA,headache,headache Table Adverse Reactions from One,1,0.746868908405304
PROMACTA,headache,from One Openlabel Trial in Adults with,0,0.5313690304756165
PROMACTA,headache,Table Adverse Reactions from One,0,0.5508015155792236
PROMACTA,Febrile neutropenia,Febrile neutropenia Abdominal,1,0.8849230408668518
PROMACTA,Febrile neutropenia,yngeal,0,0.42760002613067627
PROMACTA,cytogenetic abnormality,cytogenetic abnormality reported on therapy including patients,1,0.8609074354171753
PROMACTA,cytogenetic abnormality,including patients who had complex changes in chromosome,0,0.7703663110733032
PROMACTA,changes in chromosome 7,changes in chromosome 7 Postmarketing,1,0.8749035000801086
PROMACTA,changes in chromosome 7,including patients who had complex changes in chromosome,0,0.8079161643981934
PROMACTA,changes in chromosome 7,The following adverse reactions have,0,0.5195996165275574
PROMACTA,changes in chromosome 7,including patients who had changes in chromosome 7,1,0.9128677845001221
PROMACTA,changes in chromosome 7,patients who had changes in chromosome,1,0.8492450714111328
PROMACTA,changes in chromosome 7,patients who had changes in chromosome 7 Postmarketing Experience,1,0.8385123014450073
PROMACTA,changes in chromosome 7,in chromosome 7 Postmarketing Experience The,1,0.7689781188964844
PROMACTA,changes in chromosome 7,who had changes in chromosome 7 Postmarketing Experience,1,0.8339030146598816
PROMACTA,changes in chromosome 7,in chromosome 7 Postmarketing Experience The following,1,0.7817580699920654
PROMACTA,Thrombotic microangiopathy,Thrombotic microangiopathy,1,0.9999999403953552
PROMACTA,Thrombotic microangiopathy,Disorders,0,0.5709035396575928
PROMACTA,Thrombotic microangiopathy,acute,0,0.5267624855041504
PROMACTA,Thrombotic microangiopathy,exposure Vascular Thrombotic microangiopathy,1,0.9298617243766785
PROMACTA,Thrombotic microangiopathy,to drug exposure Vascular Thrombotic microangiopathy,1,0.8872532844543457
PROMACTA,Thrombotic microangiopathy,Vascular Thrombotic microangiopathy with,1,0.9540705680847168
PROMACTA,Thrombotic microangiopathy,acute renal,0,0.5506085157394409
PROMACTA,Thrombotic microangiopathy,to drug exposure Vascular Thrombotic,1,0.7364144325256348
PROMACTA,HEPATIC DECOMPENSATION,The g serious adverse reac tions,1,0.5600041151046753
PROMACTA,HEPATIC DECOMPENSATION,to drug exposure Vascular Thrombotic,1,0.5632418990135193
PROMACTA,HEPATIC DECOMPENSATION,described in other sections,0,0.5162578821182251
PROMACTA,HEPATIC DECOMPENSATION,in other sections Hepatic Decompensation in P,0,0.9065256118774414
PROMACTA,HEPATIC DECOMPENSATION,REACTIONS The g serious adverse reac tions,1,0.5655984878540039
PROMACTA,HEPATIC DECOMPENSATION,serious adverse reac tions associated with PROMACTA are,1,0.5392482876777649
PROMACTA,HEPATIC DECOMPENSATION,REACTIONS The g,1,0.5075064897537231
PROMACTA,HEPATIC DECOMPENSATION,g serious adverse reac tions associated,1,0.5705045461654663
PROMACTA,HEPATIC DECOMPENSATION,followin,0,0.47777965664863586
PROMACTA,HEPATIC DECOMPENSATION,ons. * Hepatic Decompensation in Patients with Chronic,1,0.8870253562927246
PROMACTA,hepatic decompensation,see Warnings and Precautions /Thromboembolic Compli cations see Warnings and Precautions,1,0.5530210137367249
PROMACTA,hepatic decompensation,ons. * Hepatic Decompensation in Patients with Chronic,1,0.8870253562927246
PROMACTA,hepatic decompensation,see Warnings and Precautions /Thromboembolic Compli,1,0.5481702089309692
PROMACTA,HEPATIC DECOMPENSATION,Warnings and Precautions Cataracts see,0,0.5428005456924438
PROMACTA,HEPATIC DECOMPENSATION,Cataracts see Warnings,0,0.5286325216293335
PROMACTA,HEPATIC DECOMPENSATION,"see Warnings  Precautions (5.4)]  
 In adult patients",1,0.544645369052887
PROMACTA,HEPATIC DECOMPENSATION,Precautions (5.4)] In,1,0.5075594186782837
PROMACTA,hepatic decompensation,upper respiratory tract infection vomiting increased,0,0.5596792697906494
PROMACTA,hepatic decompensation,and tract infection. (  6. In pediatric patients,1,0.5570940375328064
PROMACTA,hepatic decompensation,diarrhea upper respiratory tract infection,0,0.540803074836731
PROMACTA,hepatic decompensation,ALT myalgia and tract infection. (  6. In pediatric patients age,1,0.5130259394645691
PROMACTA,Hepatotoxicity,REACTIONS The following serious se reactions a ssociated with PROMACTA,1,0.5594357848167419
PROMACTA,Hepatotoxicity,diarrhea upper respiratory tract infection,0,0.5233024954795837
PROMACTA,Hepatotoxicity,ADVERSE REACTIONS The following,0,0.6630660891532898
PROMACTA,Hepatotoxicity,following serious se reactions a ssociated with PROMACTA are,1,0.5616139769554138
PROMACTA,Hepatotoxicity,se,1,0.4632411003112793
PROMACTA,Hepatotoxicity,following serious,0,0.4877682328224182
PROMACTA,Hepatotoxicity,The following serious se reactions,1,0.5496938228607178
PROMACTA,Hepatotoxicity,se reactions a ssociated,1,0.5126283764839172
PROMACTA,Hepatotoxicity,serious se,1,0.47355687618255615
PROMACTA,Hepatotoxicity,following serious se reactions a,1,0.5481505393981934
PROMACTA,Hepatotoxicity,REACTIONS The following serious,0,0.5331872701644897
PROMACTA,Thromboembolic Complications,Patients with Ch ronic,1,0.5574370622634888
PROMACTA,Thromboembolic Complications,in,0,0.4971483647823334
PROMACTA,Thromboembolic Complications,and Precautions Hepatotoxicity see Warnings,0,0.5863240361213684
PROMACTA,Portal vein thrombosis,Hepatitis C [see W arnings and Precautions Hepatotoxicity,1,0.5535656213760376
PROMACTA,Portal vein thrombosis,Patients with nic Hepatitis C [see W arnings and,1,0.5552783608436584
PROMACTA,Portal vein thrombosis,in other sections,0,0.48732560873031616
PROMACTA,Portal vein thrombosis,nic,1,0.48678064346313477
PROMACTA,Portal vein thrombosis,C [see W arnings,1,0.39653491973876953
PROMACTA,Portal vein thrombosis,in Patients with nic Hepatitis C [see W,1,0.565437912940979
PROMACTA,hepatic decompensation,ns In adult patients with,0,0.5600389242172241
PROMACTA,hepatic decompensation,qual to 5% and greater than placebo were nausea,1,0.5322054624557495
PROMACTA,ascites,nausea diarrhea,0,0.5346810817718506
PROMACTA,ascites,"increased LT, mya lgia and urinary tract infection",1,0.5546934008598328
PROMACTA,ascites,"vomiting increased LT,",1,0.5787431001663208
PROMACTA,ascites,infection In pediatric patients age,0,0.4998323321342468
PROMACTA,ascites,"LT, mya lgia and",1,0.5233670473098755
PROMACTA,encephalopathy,and urinary t ract infection In,1,0.5466363430023193
PROMACTA,encephalopathy,infection vomiting increased ALT and urinary,1,0.581027090549469
PROMACTA,hepatic decompensation,associated thrombocyto,1,0.5152121782302856
PROMACTA,hepatic decompensation,associated thrombocyto penia the most common,1,0.49356281757354736
PROMACTA,hepatic decompensation,chronic hepatitis associated thrombocyto,1,0.6266621351242065
PROMACTA,hepatic decompensation,chronic hepatitis,0,0.6721906661987305
PROMACTA,hepatic decompensation,chronic hepatitis associated thrombocyto penia the,1,0.631305992603302
PROMACTA,liver enzyme elevations,appet,0,0.5117795467376709
PROMACTA,liver enzyme elevations,influenza-like ill ness asthenia insomnia cough,1,0.4929661154747009
PROMACTA,indirect hyperbilirubinemia,headache EXCERPT To,0,0.5104044675827026
PROMACTA,indirect hyperbilirubinemia,diarrhea and headache EXCERPT To report SUSPECTED,0,0.561913251876831
PROMACTA,indirect hyperbilirubinemia,"NS, contact GlaxoSmithKline",1,0.5492150187492371
PROMACTA,indirect hyperbilirubinemia,at or,0,0.5329457521438599
PROMACTA,indirect hyperbilirubinemia,diarrhea and headache EXCERPT To,0,0.5632389783859253
PROMACTA,indirect hyperbilirubinemia,cough diarrhea and headache EXCERPT To report,0,0.579771876335144
PROMACTA,indirect hyperbilirubinemia,"NS, contact GlaxoSmithKline at or FDA",1,0.5404253602027893
PROMACTA,indirect hyperbilirubinemia,report SUSPECTED ADVERSE REACTIO,0,0.5992656350135803
PROMACTA,Hepatotoxicity, administered  to patients for,1,0.5352241396903992
PROMACTA,Hepatotoxicity,for at least year Table presents,0,0.4850997030735016
PROMACTA,thrombotic event,Table Adverse tions (>=3%) fro m,1,0.5396142601966858
PROMACTA,thrombotic event,for at least year Table presents,0,0.493177592754364
PROMACTA,thrombotic complications,"    
  Pharyngitis       Back pai",1,0.5163335800170898
PROMACTA,portal venous thrombosis,clinical chronic ITP trials alopecia musculoskeletal pain,1,0.5300049185752869
PROMACTA,portal venous thrombosis,In the three rolled,1,0.45511671900749207
PROMACTA,portal venous thrombosis,increased and dry mouth,0,0.502649188041687
PROMACTA,portal venous thrombosis,rolled clinical chronic ITP trials,1,0.5903193354606628
PROMACTA,portal venous thrombosis,alopecia,0,0.5086803436279297
PROMACTA,portal venous thrombosis,pain,0,0.48500925302505493
PROMACTA,cataracts,ceived PR OMACTA in the,1,0.5448369383811951
PROMACTA,cataracts,singlearm extension trial the adverse reactions occurred in a,0,0.5436795949935913
PROMACTA,cataracts,reactions experienced by greater than or,0,0.5269553065299988
PROMACTA,cataracts,occurred in a,0,0.5265045166015625
PROMACTA,cataracts,placebocontrolled .,1,0.5622239112854004
PROMACTA,cataracts,to,0,0.5605801343917847
PROMACTA,cataracts,. Table 5 presents,1,0.4797433018684387
PROMACTA,cataracts,Reactions from Extension Trial in,1,0.4925069808959961
PROMACTA,cataracts,the extension,0,0.49919524788856506
PROMACTA,cataracts,Reactions from Extension Trial in Adults,1,0.543573260307312
PROMACTA,cataracts,Reactions from Extension,1,0.49116238951683044
PROMACTA,cataracts,extension trial Table Treatmentrelated Reactions from,1,0.5320056080818176
PROMACTA,Cataracts,action    PROMACTA mg,1,0.496652752161026
PROMACTA,Cataracts,Thrombocytopenia Adverse action    PROMACTA,1,0.5020909905433655
PROMACTA,Cataracts,Thrombocytopenia Adverse action    PROMACTA mg n,1,0.5106813907623291
PROMACTA,Cataracts,mg,0,0.5365537405014038
PROMACTA,Cataracts,action    PROMACTA mg n,1,0.49400103092193604
PROMACTA,Cataracts,Adverse Re,0,0.5186806917190552
BESIVANCE,ocular adverse reaction,adverse reaction was conjunctival,1,0.9011149406433105
BESIVANCE,conjunctival redness,of bacterial conjunctivitis The most frequently reported ocular adverse reaction,0,0.7442498207092285
BESIVANCE,conjunctival redness,ocular adverse reaction conjunctival redness reported in approximately of,1,0.8879741430282593
BESIVANCE,conjunctival redness,adverse reactions,0,0.5765538215637207
BESIVANCE,conjunctival redness,adverse reaction conjunctival redness,1,0.9106086492538452
BESIVANCE,conjunctival redness,reported ocular adverse,0,0.707983672618866
BESIVANCE,conjunctival redness,of bacterial conjunctivitis The,0,0.7689812183380127
BESIVANCE,conjunctival redness,reported ocular adverse reaction conjunctival redness reported in approximately,1,0.8748953342437744
BESIVANCE,conjunctival redness,adverse reaction conjunctival redness reported in,1,0.8929199576377869
BESIVANCE,conjunctival redness,reaction,0,0.5092436075210571
BESIVANCE,conjunctival redness,in,0,0.5076170563697815
BESIVANCE,blurred vision,in approximately of patients blurred vision,1,0.8975650072097778
BESIVANCE,blurred vision,blurred vision,1,0.9999999403953552
BESIVANCE,blurred vision,included,0,0.5118340849876404
BESIVANCE,blurred vision,blurred vision eye pain eye,1,0.8796101808547974
BESIVANCE,blurred vision,patients receiving Besivance occurring,0,0.555983304977417
BESIVANCE,blurred vision,patients blurred vision eye pain eye irritation,1,0.804413378238678
BESIVANCE,blurred vision,blurred vision eye pain eye irritation eye,1,0.8271320462226868
BESIVANCE,blurred vision,in approximately of patients blurred vision eye pain,1,0.8266743421554565
BESIVANCE,eye pain,patients included blurred eye pain eye,1,0.8113008141517639
BESIVANCE,eye pain,patients receiving Besivance occurring,0,0.5293688774108887
BESIVANCE,eye pain,most common,0,0.4707118272781372
BESIVANCE,eye irritation,eye irritation eye,1,0.978088915348053
BESIVANCE,eye irritation,eye,1,0.7855905294418335
BESIVANCE,eye irritation,eye irritation,1,1.0
BESIVANCE,eye irritation,reaction reported,0,0.5850106477737427
BESIVANCE,eye irritation,vision,0,0.6215612292289734
BESIVANCE,eye pruritus,common adverse reaction reported in of patients treated,0,0.5629966855049133
BESIVANCE,eye pruritus,reaction reported in of patients treated,0,0.5484319925308228
BESIVANCE,eye pruritus,eye eye pruritus,1,0.9881744980812073
BESIVANCE,eye pruritus,pain eye eye pruritus,1,0.9518696069717407
BESIVANCE,eye pruritus,eye pruritus,1,1.0000001192092896
BESIVANCE,eye pruritus,headache EXCERPT The most common adverse reaction reported in of,0,0.6181691288948059
BESIVANCE,headache,headache EXCERPT The most common,1,0.8050456047058105
BESIVANCE,headache,headache EXCERPT The,1,0.8916217088699341
BESIVANCE,headache,eye pruritus and,0,0.583533763885498
BESIVANCE,headache,approximately of patients included blurred vision eye pain eye irritation,0,0.6617956161499023
BESIVANCE,headache,headache EXCERPT The most,1,0.8363126516342163
BESIVANCE,headache,most common adverse reaction,0,0.5842196941375732
BESIVANCE,conjunctival redness,most common,0,0.4771287143230438
BESIVANCE,conjunctival redness,conjunctival redness,1,0.9999999403953552
BESIVANCE,conjunctival redness,Bausch Lomb,0,0.4233535826206207
BESIVANCE,conjunctival redness,conjunctival redness To report SUSPECTED,1,0.9080856442451477
BESIVANCE,conjunctival redness,adverse reaction reported in,0,0.5873163938522339
BESIVANCE,conjunctival redness,conjunctival redness To report SUSPECTED ADVERSE REACTIONS,1,0.8764675259590149
BESIVANCE,conjunctival redness,The most common adverse reaction reported in of patients treated with,0,0.5532795190811157
BESIVANCE,overgrowth of non-susceptible organisms,"vision eye pain eye itation, eye pruritus and headache.



 EXCERPT The most",1,0.48937150835990906
BESIVANCE,overgrowth of non-susceptible organisms,The most common adverse reaction reported in of patients treated with,0,0.5508347749710083
BESIVANCE,overgrowth of non-susceptible organisms,"eye itation, eye pruritus and headache.",1,0.5238072276115417
BESIVANCE,overgrowth of non-susceptible organisms,blurred vision eye pain,0,0.443783164024353
BESIVANCE,overgrowth of non-susceptible organisms,"eye itation, eye pruritus",1,0.5445826053619385
BESIVANCE,overgrowth of non-susceptible organisms,pruritus and headache. EXCERPT The most,1,0.5242713093757629
BESIVANCE,overgrowth of non-susceptible organisms,"vision eye pain eye itation,",1,0.4588927626609802
BESIVANCE,overgrowth of non-susceptible organisms,"vision eye pain eye itation, eye pruritus and headache.",1,0.4923204779624939
BESIVANCE,overgrowth of non-susceptible organisms,"eye pain eye itation, eye pruritus and headache.



 EXCERPT The most",1,0.4925069212913513
BESIVANCE,overgrowth of non-susceptible organisms,vision eye pain,0,0.4425758123397827
INLYTA,hypertension,hypertension arterial thromboembolic,1,0.798687756061554
INLYTA,hypertension,cardiac failure,0,0.6584485769271851
INLYTA,hypertension,events venous thromboembolic events hemorrhage,0,0.5451440811157227
INLYTA,hypertension,ussed in greater detail in other sections of the label seeWarnings and Precautions,0,0.5388236045837402
INLYTA,arterial thromboembolic events,arterial thromboembolic,1,0.9418293237686157
INLYTA,arterial thromboembolic events,and Precautions arterial thromboembolic events venous thromboembolic,1,0.9030961990356445
INLYTA,arterial thromboembolic events,thromboembolic events venous thromboembolic events,1,0.8360726833343506
INLYTA,venous thromboembolic events,hemorrhage cardiac failure,0,0.5646144151687622
INLYTA,venous thromboembolic events,failure gastrointestinal perforation and,0,0.5950340032577515
INLYTA,venous thromboembolic events,hypertension arterial thromboembolic venous,1,0.752565860748291
INLYTA,venous thromboembolic events,venous thromboembolic events hemorrhage cardiac failure gastrointestinal,1,0.8547606468200684
INLYTA,venous thromboembolic events,hypertension arterial thromboembolic venous thromboembolic events hemorrhage,1,0.8109214305877686
INLYTA,venous thromboembolic events,venous thromboembolic events hemorrhage cardiac failure,1,0.8632904291152954
INLYTA,venous thromboembolic events,Precautions hypertension arterial thromboembolic,0,0.7000582218170166
INLYTA,hemorrhage,thromboembolic events,0,0.6323633193969727
INLYTA,hemorrhage,hemorrhage cardiac,1,0.8555377721786499
INLYTA,hemorrhage,hypertension arterial thromboembolic events venous,0,0.63173508644104
INLYTA,hemorrhage,thromboembolic,0,0.6339554786682129
INLYTA,hemorrhage,hemorrhage cardiac failure gastrointestinal perforation and,1,0.7528433799743652
INLYTA,hemorrhage,events,0,0.5337190628051758
INLYTA,hemorrhage,hemorrhage cardiac failure gastrointestinal perforation,1,0.7352348566055298
INLYTA,cardiac failure,cardiac failure,1,0.9999998211860657
INLYTA,cardiac failure,cardiac failure gastrointestinal perforation and fistula formation,1,0.6783562302589417
INLYTA,cardiac failure,events,0,0.49328547716140747
INLYTA,cardiac failure,gastrointestinal perforation and fistula formation thyroid,0,0.48335960507392883
INLYTA,gastrointestinal perforation,hemorrhage cardiac gastrointestinal perforation,1,0.8639438152313232
INLYTA,gastrointestinal perforation,venous,0,0.543637752532959
INLYTA,fistula formation,fistula formation,1,1.000000238418579
INLYTA,fistula formation,healing complications RPLS proteinuria elevation of liver enzymes,0,0.619083821773529
INLYTA,fistula formation,fistula formation thyroid dysfunction wound,1,0.7900313138961792
INLYTA,fistula formation,perforation fistula formation,1,0.9121490716934204
INLYTA,fistula formation,failure gastrointestinal perforation and,0,0.6149910092353821
INLYTA,fistula formation,perforation fistula,1,0.7833484411239624
INLYTA,fistula formation,cardiac failure gastrointestinal perforation fistula formation thyroid dysfunction wound healing complications,1,0.6845502257347107
INLYTA,fistula formation,fistula formation thyroid dysfunction,1,0.7984246015548706
INLYTA,fistula formation,fistula formation thyroid dysfunction wound healing complications,1,0.783805251121521
INLYTA,thyroid dysfunction,mboembolic events,0,0.4243184030056
INLYTA,thyroid dysfunction,thyroid dysfunction wound,1,0.8568652868270874
INLYTA,thyroid dysfunction,wound healing complications RPLS proteinuria,0,0.5383175611495972
INLYTA,thyroid dysfunction,thyroid dysfunction wound healing complications RPLS proteinuria,1,0.7528432607650757
INLYTA,thyroid dysfunction,perforation and fistula thyroid,1,0.7414454221725464
INLYTA,thyroid dysfunction,and fistula thyroid,1,0.7559726238250732
INLYTA,thyroid dysfunction,thyroid dysfunction wound healing complications,1,0.8132209181785583
INLYTA,thyroid dysfunction,hepatic,0,0.5389082431793213
INLYTA,thyroid dysfunction,formation,0,0.522925853729248
INLYTA,RPLS,RPLS proteinuria elevation of liver enzymes,1,0.6865570545196533
INLYTA,proteinuria,wound healing complications,0,0.4660162925720215
INLYTA,proteinuria,proteinuria elevation of,1,0.8730202913284302
INLYTA,proteinuria,proteinuria elevation of liver,1,0.8101061582565308
INLYTA,proteinuria,healing complications,0,0.4769935607910156
INLYTA,proteinuria,proteinuria elevation,1,0.8713123202323914
INLYTA,proteinuria,proteinuria,1,1.000000238418579
INLYTA,hepatic impairment,of liver hepatic,1,0.8175375461578369
INLYTA,hepatic impairment,dysfunction wound,0,0.6395443081855774
INLYTA,hepatic impairment,hepatic impairment,1,1.0
INLYTA,hepatic impairment,are,0,0.5212567448616028
INLYTA,hepatic impairment,proteinuria elevation of liver hepatic,1,0.7218093276023865
INLYTA,hepatic impairment,liver hepatic impairment and fetal,1,0.8467308282852173
INLYTA,hepatic impairment,hepatic impairment and,1,0.9878974556922913
INLYTA,diarrhea,diarrhea,1,0.9999999403953552
INLYTA,hypertension,nausea dysphonia palmarplantar erythrodysesthesia handfoot synd,0,0.5869630575180054
INLYTA,hypertension,hypertension fatigue decreased appetite nausea dysphonia,1,0.7498199343681335
INLYTA,hypertension,dysphonia palmarplantar,0,0.533634603023529
INLYTA,hypertension,reactions are hypertension fatigue decreased appetite nausea,1,0.7076659798622131
INLYTA,fatigue,fatigue decreased appetite nausea,1,0.7772850394248962
INLYTA,fatigue,fatigue decreased appetite nausea dysphonia,1,0.7802196741104126
INLYTA,fatigue,fatigue decreased appetite nausea dysphonia palmarplantar,1,0.7739976048469543
INLYTA,fatigue,dysphonia palmarplantar,0,0.5126408338546753
INLYTA,fatigue,reactions are diarrhea fatigue decreased appetite,1,0.6953572630882263
INLYTA,fatigue,diarrhea fatigue,1,0.7763918042182922
INLYTA,decreased appetite,decreased appetite nausea,1,0.9090673923492432
INLYTA,decreased appetite,reactions are diarrhea hypertension,0,0.5220068097114563
INLYTA,decreased appetite,diarrhea hypertension decreased appetite nausea dysphonia palmarplantar,1,0.7429450750350952
INLYTA,decreased appetite,are diarrhea hypertension decreased appetite,1,0.7804850339889526
INLYTA,decreased appetite,weight decreased vomit,0,0.6642253398895264
INLYTA,decreased appetite,EXCERPT The most,0,0.44680255651474
INLYTA,nausea,nausea dysphonia palmarplantar,1,0.7260826826095581
INLYTA,dysphonia,dysphonia palmarplantar erythrodysesthesia handfoot,1,0.7807202935218811
INLYTA,dysphonia,palmarplantar erythrodysesthesia handfoot syndrome weight decreased vomiting asthenia and,0,0.5208482146263123
INLYTA,dysphonia,dysphonia palmarplantar erythrodysesthesia handfoot syndrome,1,0.7363637685775757
INLYTA,weight decreased,ADVERSE REACTIONS contact,0,0.45702117681503296
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot syndrome,0,0.4864234924316406
INLYTA,weight decreased,weight decreased vomiting asthenia and,1,0.7940042018890381
INLYTA,weight decreased,SUSPECTED ADVERSE,0,0.5165647864341736
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot weight decreased vomiting asthenia and constipation To,1,0.6602731943130493
INLYTA,weight decreased,weight decreased,1,1.0000001192092896
INLYTA,vomiting,vomiting asthenia,1,0.9028581380844116
INLYTA,vomiting,weight decreased,1,0.5173391103744507
INLYTA,vomiting,handfoot syndrome weight decreased,0,0.459729939699173
INLYTA,vomiting,vomiting,1,0.9999999403953552
INLYTA,asthenia,and constipation To report SUSPECTED ADVERSE REACTIONS,0,0.5439003109931946
INLYTA,asthenia,ADVERSE REACTIONS contact Pfizer Inc,0,0.47771579027175903
INLYTA,asthenia,handfoot syndrome weight decreased asthenia,1,0.6540095210075378
INLYTA,constipation,constipation,1,1.0000001192092896
INLYTA,constipation,ADVERSE REACTIONS contact Pfizer Inc,0,0.5004695057868958
INLYTA,constipation,handfoot syndrome weight decreased vomiting asthenia,0,0.5889492034912109
INLYTA,constipation,erythrodysesthesia handfoot syndrome,0,0.508050799369812
INLYTA,constipation,palmarplantar erythrodysesthesia handfoot syndrome,0,0.51851886510849
INLYTA,constipation,and,0,0.5457766056060791
INLYTA,constipation,constipation To report SUSPECTED ADVERSE REACTIONS,1,0.8063691854476929
INLYTA,constipation,To report SUSPECTED ADVERSE REACTIONS,0,0.5302721261978149
INLYTA,diarrhea,diarrhea hypertension fatigue,1,0.78121018409729
INLYTA,diarrhea,reactions observed,0,0.5750560164451599
INLYTA,diarrhea,diarrhea hypertension fatigue decreased appetite nausea,1,0.7435775995254517
INLYTA,diarrhea,INLYTA diarrhea,1,0.8083364963531494
INLYTA,diarrhea,following treatment with INLYTA diarrhea hypertension fatigue,1,0.725514829158783
INLYTA,hypertension,adverse reactions observed following treatment with INLYTA were diarrhea,0,0.5343433022499084
INLYTA,hypertension,INLYTA were hypertension fatigue,1,0.7907960414886475
INLYTA,hypertension,palmarplantar erythrodysesthesia handfoot,0,0.5816910266876221
INLYTA,hypertension,hypertension fatigue,1,0.802823543548584
INLYTA,fatigue,were diarrhea fatigue decreased appetite nausea,1,0.7182168364524841
INLYTA,fatigue,hypertension fatigue,1,0.7822574377059937
INLYTA,fatigue,fatigue decreased appetite,1,0.7925516366958618
INLYTA,fatigue,with INLYTA were diarrhea fatigue decreased,1,0.6757897138595581
INLYTA,fatigue,fatigue decreased,1,0.8332653641700745
INLYTA,fatigue,with INLYTA were diarrhea fatigue decreased appetite nausea dysphonia,1,0.6835774183273315
INLYTA,fatigue,mon adverse reactions observed following treatment,0,0.5009347796440125
INLYTA,decreased appetite,diarrhea hypertension decreased appetite,1,0.7991445064544678
INLYTA,decreased appetite,were diarrhea hypertension decreased,1,0.5963282585144043
INLYTA,decreased appetite,adverse reactions observed following treatment with INLYTA were diarrhea,0,0.5543428063392639
INLYTA,decreased appetite,decreased appetite nausea dysphonia palmarplantar erythrodysesthesia,1,0.7962982654571533
INLYTA,decreased appetite,decreased appetite,1,0.9999999403953552
INLYTA,decreased appetite,reactions observed following treatment with INLYTA were diarrhea,0,0.5757913589477539
INLYTA,decreased appetite,erythrodysesthesia handfoot syndrome weight decreased,0,0.6397147178649902
INLYTA,decreased appetite,hypertension decreased appetite nausea dysphonia palmarplantar erythrodysesthesia handfoot,1,0.7511039972305298
INLYTA,decreased appetite,hypertension decreased,1,0.6123620271682739
INLYTA,nausea,fatigue decreased,0,0.5936473608016968
INLYTA,nausea,observed,0,0.5235732197761536
INLYTA,dysphonia,d following treatment with,0,0.5629899501800537
INLYTA,dysphonia,decreased appetite nausea,0,0.49296435713768005
INLYTA,dysphonia,dysphonia palmarplantar,1,0.7892647385597229
INLYTA,dysphonia,treatment with INLYTA were diarrhea hypertension,0,0.5056892037391663
INLYTA,dysphonia,decreased appetite dysphonia,1,0.8248283863067627
INLYTA,dysphonia,dysphonia palmarplantar erythrodysesthesia handfoot syndrome weight,1,0.7423564195632935
INLYTA,dysphonia,following,0,0.4393559992313385
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot weight decreased vomiting asthenia and constipation Table,1,0.653334379196167
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot syndrome weight,1,0.5979703664779663
INLYTA,weight decreased,palmarplantar erythrodysesthesia handfoot weight,1,0.6104438304901123
INLYTA,weight decreased,palmarplantar erythrodysesthesia handfoot weight decreased vomiting asthenia,1,0.6584389209747314
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot weight decreased vomiting asthenia and constipation,1,0.6492569446563721
INLYTA,vomiting,decreased,0,0.5053275227546692
INLYTA,asthenia,asthenia and constipation Table,1,0.7348273396492004
INLYTA,asthenia,decreased,0,0.5212016105651855
INLYTA,asthenia,asthenia and constipation Table presents,1,0.7129776477813721
INLYTA,asthenia,asthenia,1,1.0000001192092896
INLYTA,asthenia,syndrome weight decreased asthenia and constipation Table presents,1,0.6750149726867676
INLYTA,asthenia,handfoot syndrome weight decreased asthenia and constipation Table presents adverse,1,0.634814441204071
INLYTA,asthenia,asthenia and constipation,1,0.7795106172561646
INLYTA,asthenia,dysphonia,0,0.5570087432861328
INLYTA,constipation,decreased,0,0.5425675511360168
INLYTA,constipation,vomiting asthenia constipation Table,1,0.771289050579071
INLYTA,constipation,decreased vomiting asthenia constipation Table presents adverse reactions reported,1,0.7315453886985779
INLYTA,constipation,Table presents adverse reactions,0,0.5582504272460938
INLYTA,constipation,adverse reactions reported in patients who received INLYTA or,0,0.532813310623169
INLYTA,constipation,constipation Table presents adverse reactions,1,0.7814455628395081
INLYTA,constipation,Table presents,0,0.5053818821907043
INLYTA,constipation,handfoot syndrome weight,0,0.5120531320571899
INLYTA,dizziness,adverse reactions all grades,0,0.5627784729003906
INLYTA,myalgia,myalgia,1,0.9999996423721313
INLYTA,dehydration,treated with INLYTA included,0,0.5969367623329163
INLYTA,dehydration,tinnitus,0,0.5431339740753174
INLYTA,dehydration,abdominal pain dehydration epistaxis anemia hemorrhoids hematuria tinnitus,1,0.7153781652450562
INLYTA,dehydration,dehydration epistaxis anemia hemorrhoids hematuria,1,0.7748812437057495
INLYTA,dehydration,dehydration epistaxis,1,0.785723090171814
INLYTA,dehydration,hemorrhoids hematuria tinnitus,0,0.5332922339439392
INLYTA,dehydration,upper abdominal pain dehydration epistaxis,1,0.7218322157859802
INLYTA,dehydration,dehydration epistaxis anemia hemorrhoids hematuria tinnitus,1,0.7742459774017334
INLYTA,epistaxis,epistaxis anemia hemorrhoids hematuria tinnitus,1,0.7351411581039429
INLYTA,anemia,dehydration anemia hemorrhoids hematuria tinnitus,1,0.7182896137237549
INLYTA,anemia,epistaxis anemia hemorrhoids hematuria tinnitus,1,0.7134253978729248
INLYTA,anemia,lipase increased,0,0.5176024436950684
INLYTA,hemorrhoids,hemorrhoids,1,1.0
INLYTA,hemorrhoids,hemorrhoids hematuria tinnitus lipase increased,1,0.7552478909492493
INLYTA,hemorrhoids,hematuria tinnitus lipase increased glossodynia,0,0.5993965864181519
INLYTA,hemorrhoids,myalgia dehydration epistaxis hemorrhoids hematuria tinnitus lipase increased,1,0.6675257682800293
INLYTA,hemorrhoids,dehydration epistaxis hemorrhoids hematuria tinnitus lipase increased glossodynia,1,0.6647162437438965
INLYTA,hematuria,glossodynia pulmonary,0,0.447740375995636
INLYTA,hematuria,tinnitus,0,0.5220955610275269
INLYTA,hematuria,pain myalgia dehydration epistaxis anemia,0,0.5978992581367493
INLYTA,hematuria,increased glossodynia pulmonary embolism,0,0.5068099498748779
INLYTA,hematuria,epistaxis,0,0.5347769260406494
INLYTA,lipase increased,hemorrhoids,0,0.48781153559684753
INLYTA,glossodynia,glossodynia,1,1.0
INLYTA,glossodynia,glossodynia pulmonary embolism,1,0.7907655239105225
INLYTA,glossodynia,increased,0,0.5054334402084351
INLYTA,glossodynia,pulmonary embolism rectal,0,0.4423167407512665
INLYTA,glossodynia,glossodynia pulmonary embolism rectal hemorrhage,1,0.747235894203186
INLYTA,glossodynia,hemoptysis deep,0,0.5209771394729614
INLYTA,glossodynia,glossodynia pulmonary embolism rectal hemorrhage hemoptysis,1,0.7598074674606323
INLYTA,pulmonary embolism,pulmonary,1,0.7724299430847168
INLYTA,pulmonary embolism,increased pulmonary,1,0.7265352010726929
INLYTA,pulmonary embolism,increased,0,0.5299026370048523
INLYTA,pulmonary embolism,pulmonary embolism rectal hemorrhage,1,0.7789173722267151
INLYTA,pulmonary embolism,pulmonary embolism rectal hemorrhage hemoptysis deep,1,0.777586817741394
INLYTA,pulmonary embolism,tinnitus lipase increased glossodynia,0,0.4796834886074066
INLYTA,pulmonary embolism,pulmonary embolism,1,1.0
INLYTA,pulmonary embolism,hematuria tinnitus lipase increased pulmonary embolism rectal,1,0.7142800092697144
INLYTA,rectal hemorrhage,hemoptysis deep vein thrombosis retinalvein occlusionthrombosis polycythe,0,0.6154122352600098
INLYTA,rectal hemorrhage,rectal hemorrhage,1,1.0000001192092896
INLYTA,rectal hemorrhage,retinalvein occlusionthrombosis,0,0.5748484134674072
INLYTA,rectal hemorrhage,pulmonary rectal hemorrhage,1,0.8716665506362915
INLYTA,rectal hemorrhage,rectal hemorrhage hemoptysis deep vein,1,0.8388113379478455
INLYTA,rectal hemorrhage,hemoptysis deep vein thrombosis retinalvein occlusionthrombosis,0,0.6223646402359009
INLYTA,rectal hemorrhage,hemoptysis deep vein thrombosis retinalvein,0,0.6304378509521484
INLYTA,hemoptysis,deep vein,0,0.5353620052337646
INLYTA,hemoptysis,deep vein thrombosis retinalvein occlusionthrombosis polycythemia,0,0.5676596164703369
INLYTA,hemoptysis,rectal hemoptysis deep vein,1,0.7774131298065186
INLYTA,hemoptysis,hemoptysis deep vein thrombosis retinalvein occlusionthrombosis,1,0.7645149827003479
INLYTA,hemoptysis,hemoptysis deep vein thrombosis retinalvein,1,0.7519652843475342
INLYTA,hemoptysis,polycythemia,0,0.5804088115692139
INLYTA,hemoptysis,deep vein thrombosis retinalvein occlusionthrombosis,0,0.5437673330307007
INLYTA,hemoptysis,hemorrhage,0,0.7088366150856018
INLYTA,hemoptysis,glossodynia pulmonary embolism,0,0.6442353129386902
INLYTA,deep vein thrombosis,deep,1,0.561368465423584
INLYTA,deep vein thrombosis,glossodynia pulmonary,0,0.4989066421985626
INLYTA,deep vein thrombosis,embolism rectal hemorrhage deep vein thrombosis,1,0.7990097999572754
INLYTA,deep vein thrombosis,deep vein thrombosis retinalvein,1,0.8068910241127014
INLYTA,deep vein thrombosis,glossodynia,0,0.4637966752052307
INLYTA,deep vein thrombosis,hemorrhage deep vein thrombosis retinalvein occlusionthrombosis polycythemia and,1,0.771477460861206
INLYTA,deep vein thrombosis,pulmonary embolism rectal,0,0.6624453067779541
INLYTA,deep vein thrombosis,hemoptysis,0,0.5469586253166199
INLYTA,retinal-vein occlusion,vein,0,0.7110100388526917
INLYTA,retinal-vein occlusion,hemorrhage hemoptysis deep vein retinal-vein occlusion thrombosis polycythemia and transient ischemic,1,0.7863680124282837
INLYTA,retinal-vein occlusion,retinal-vein occlusion thrombosis polycythemia and,1,0.8657969832420349
INLYTA,polycythemia,polycythemia and transient ischemic,1,0.8830647468566895
INLYTA,polycythemia,polycythemia and transient ischemic attack Table,1,0.8195388317108154
INLYTA,polycythemia,attack Table presents,0,0.43284279108047485
INLYTA,hemoglobin increased,with INLYTA hemoglobin,1,0.8051895499229431
INLYTA,hemoglobin increased,and hypercalcemia for,0,0.60081547498703
INLYTA,hemoglobin increased,hemoglobin increased above the upper limit of,1,0.9204616546630859
INLYTA,hemoglobin increased,hemoglobin increased above,1,0.9716330170631409
INLYTA,hypercalcemia,INLYTA versus for sorafenib,0,0.5432097911834717
INLYTA,hypercalcemia,hypercalcemia for INLYTA versus,1,0.855943500995636
INLYTA,hypercalcemia,hypercalcemia for,1,0.9529640078544617
INLYTA,hypercalcemia,versus,0,0.4725133776664734
INLYTA,hypercalcemia,hypercalcemia for INLYTA versus for,1,0.8451629877090454
INLYTA,hypercalcemia,for,0,0.5620524883270264
INLYTA,hypercalcemia,INLYTA versus for sorafenib hypercalcemia for INLYTA,1,0.7758713960647583
INLYTA,hypercalcemia,hypercalcemia,1,1.0000001192092896
INLYTA,Hypertension,are conduct,1,0.5249221920967102
INLYTA,Hypertension,ADVERSE REACTIONS,0,0.5810130834579468
INLYTA,Hypertension,of,0,0.5356321334838867
INLYTA,hypertensive crisis,varying condit,1,0.5138468146324158
INLYTA,hypertensive crisis,varying condit ions,1,0.5223847031593323
INLYTA,hypertensive crisis,drug cannot be,0,0.49541348218917847
INLYTA,hypertensive crisis,are conducted under,0,0.4860278367996216
INLYTA,venous thrombotic events,rates observed in clinical practice The safety of INLYTA has been evaluated,0,0.5698745846748352
INLYTA,fatal,studies which included atien ts with,1,0.5109928846359253
INLYTA,fatal,rates observed in clinical practice The safety of INLYTA has been evaluated,0,0.5534697771072388
INLYTA,fatal,which included atien ts with advanced RCC The,1,0.5151524543762207
INLYTA,fatal,atien ts,1,0.5491155982017517
INLYTA,fatal,monotherapy studies which included atien ts,1,0.495676189661026
INLYTA,fatal,monotherapy studies which included atien ts with advanced RCC The,1,0.513725757598877
INLYTA,fatal,p,0,0.535810112953186
INLYTA,fatal,included p,0,0.5068973898887634
INLYTA,fatal,atien ts with,1,0.5398871898651123
INLYTA,fatal,which included atien ts with,1,0.528243899345398
INLYTA,Hemorrhagic events,INLYTA in 359 pa tients,1,0.5423710942268372
INLYTA,Hemorrhagic events,INLYTA in 359 pa tients with,1,0.5272868275642395
INLYTA,Hemorrhagic events,study versus,0,0.5086982250213623
INLYTA,Hemorrhagic events,359 pa tients with advanced RCC who,1,0.5777168869972229
INLYTA,Hemorrhagic events,with,0,0.5327644348144531
INLYTA,Hemorrhagic events,patients with advanced RCC The data described seeAdverse Reactions reflect exposure,0,0.6060246229171753
INLYTA,Hemorrhagic events,advanced RCC The data described,0,0.5718586444854736
INLYTA,fatal,reflect exposure to INLYTA in,0,0.5125683546066284
INLYTA,fatal,INLYTA in,0,0.5080141425132751
INLYTA,fatal,a,0,0.531038224697113
INLYTA,fatal,advan ced RCC who participated,1,0.4855329692363739
INLYTA,fatal,patients advan ced RCC who,1,0.48108917474746704
INLYTA,fatal,advan ced RCC,1,0.5270950794219971
INLYTA,fatal,advan,1,0.5093008279800415
INLYTA,fatal,patients advan ced RCC who participated,1,0.4607742428779602
INLYTA,fatal,The data described seeAdverse,0,0.4680611789226532
INLYTA,Cardiac failure,sections of the,1,0.48708492517471313
INLYTA,Cardiac failure,detail in er sections of,1,0.591118574142456
INLYTA,Cardiac failure,detail in er,1,0.6157422065734863
INLYTA,Cardiac failure,sections of the label seeWarnings,1,0.49620938301086426
INLYTA,Cardiac failure,er sections of,1,0.5976707339286804
INLYTA,Cardiac failure,action to be,0,0.47470107674598694
INLYTA,Cardiac failure,and Precautions,0,0.4818916916847229
INLYTA,Cardiac failure,following risks including appropriate action to be taken are discussed in greater,0,0.5089417695999146
INLYTA,fatal,label seeWarnings and ecaut ions,1,0.5435531139373779
INLYTA,fatal,following risks including appropriate action to be taken are discussed in greater,0,0.5139591693878174
INLYTA,fatal,the label seeWarnings and ecaut ions hypertension arterial thromboembolic events,1,0.5903452634811401
INLYTA,fatal,ions,0,0.5414287447929382
INLYTA,fatal,ions hypertension arterial thromboembolic events venous,0,0.5489897727966309
INLYTA,fatal,ecaut ions hypertension arterial thromboembolic,1,0.5573879480361938
INLYTA,fatal,ecaut ions hypertension arterial thromboembolic events,1,0.5577346086502075
INLYTA,Gastrointestinal perforation,"hemorrhage, cardiac",1,0.5506400465965271
INLYTA,Gastrointestinal perforation,"hemorrhage, cardiac failure, gastrointestinal perforation",1,0.8044251203536987
INLYTA,death,ation,1,0.5969716906547546
INLYTA,death,gastrointestinal ation and fistula formation,1,0.4601937532424927
INLYTA,death,wound healing complications RPLS proteinuria,0,0.48954734206199646
INLYTA,death,ation and,1,0.6014080047607422
INLYTA,death,wound healing,0,0.5128828287124634
INLYTA,death,formation thyroid dysfunction wound healing complications RPLS,0,0.48896414041519165
INLYTA,death,gastrointestinal,0,0.5174993276596069
INLYTA,death,ation and fistula,1,0.5032016038894653
INLYTA,Hypothyroidism,most,0,0.47737836837768555
INLYTA,Hypothyroidism,"RPLS proteinuria elevation of r enzymes,",1,0.5143692493438721
INLYTA,Hypothyroidism,"of r enzymes, hep atic impairment and fetal",1,0.5673057436943054
INLYTA,Hypothyroidism,"of r enzymes,",1,0.48124146461486816
INLYTA,Hypothyroidism,"r enzymes, hep atic impairment and fetal development",1,0.561362624168396
INLYTA,Hypothyroidism,of r,1,0.49043941497802734
INLYTA,Reversible Posterior Leukoencephalopathy Syndrome,"erythrodysesthesia handfoot syndrome decreased, vomiting, asthenia, and",1,0.602220892906189
INLYTA,RPLS,"and .1)
",1,0.46951818466186523
INLYTA,RPLS,"erythrodysesthesia handfoot syndrome decreased, vomiting, asthenia, and",1,0.4919734597206116
INLYTA,RPLS,".1)
 To report SUSPECTED ADVERSE",1,0.47197699546813965
INLYTA,RPLS,".1)
 To",1,0.5142733454704285
INLYTA,RPLS,"vomiting asthenia and .1)
 To report SUSPECTED",1,0.46500295400619507
INLYTA,RPLS,".1)
 To report",1,0.5022531747817993
INLYTA,RPLS,"decreased vomiting asthenia and .1)
 To",1,0.45538562536239624
INLYTA,RPLS,"decreased vomiting asthenia and .1)
 To report SUSPECTED ADVERSE REACTIONS",1,0.462843656539917
INLYTA,RPLS,REACTIONS contact Pfizer Inc at,0,0.4620059132575989
INLYTA,Liver enzyme elevation,and months range 20.1) for patients who received,1,0.532227635383606
INLYTA,Liver enzyme elevation,REACTIONS contact Pfizer Inc at,0,0.5495538115501404
INLYTA,Liver enzyme elevation,adverse reaction,0,0.5935025215148926
INLYTA,fetal harm,sorafenib The most 0%) advers,1,0.5055090188980103
INLYTA,fetal harm,diarrhea,0,0.5230073928833008
INLYTA,fetal harm,patients receiving,0,0.5354795455932617
INLYTA,fetal harm,receiving sorafenib The most 0%) advers e,1,0.4947793483734131
INLYTA,fetal harm,The most 0%),1,0.4300181567668915
INLYTA,hypertension,Adverse ctions Occur,1,0.5601620078086853
INLYTA,hypertension,Adverse ctions Occur ring in,1,0.5562289357185364
INLYTA,hypertension,reactions reported in patients who received INLYTA or sorafenib Table,0,0.559708833694458
INLYTA,hypertension,ctions Occur,1,0.5458428859710693
INLYTA,hypertension,Adverse ctions Occur ring in of,1,0.5645468235015869
INLYTA,hypertension,sorafenib Table Adverse ctions Occur,1,0.5710447430610657
INLYTA,hypertension,sorafenib Table Adverse ctions,1,0.5669729113578796
INLYTA,hypertension,ctions Occur ring in of Patients,1,0.5537781119346619
INLYTA,hypertension,N N,0,0.5457532405853271
INLYTA,hypertension,        Sora fenib,1,0.598417341709137
INLYTA,hypertension,        Sora fenib N,1,0.5985264778137207
INLYTA,hypertension,        Sora fenib N N All,1,0.5959766507148743
INLYTA,hypertension,Sorafenib Adverse Reaction         Sora fenib N N,1,0.562783420085907
INLYTA,hypertension,        Sora fenib N N All Grades,1,0.5871928930282593
INLYTA,Hypertensive crisis,                 Gr ade All,1,0.5271995067596436
INLYTA,Hypertensive crisis,All,0,0.4706763029098511
INLYTA,hemorrhagic events,pper abdominal pai n myalgia dehydration epistaxis,1,0.6162129044532776
INLYTA,hemorrhagic events,n myalgia dehydration epistaxis anemia,0,0.6051894426345825
INLYTA,hemorrhagic events,INLYTA included dizziness pper abdominal pai,1,0.5895371437072754
INLYTA,hemorrhagic events,dizziness pper abdominal pai,1,0.5816085338592529
INLYTA,hemorrhagic events,included,0,0.5496736764907837
INLYTA,hemorrhagic events,epistaxis anemia hemorrhoids,0,0.6550175547599792
INLYTA,hemorrhagic events,of,0,0.5158916711807251
INLYTA,hemorrhagic events,"%), lipase increas ed glossodynia pulmonary embolism rectal",1,0.5743451118469238
INLYTA,hemorrhagic events,lipase increas ed glossodynia pulmonary embolism,1,0.5693708658218384
INLYTA,hemorrhagic events,"hematuria %), lipase increas",1,0.5948259234428406
INLYTA,hemorrhagic events,"epistaxis anemia hemorrhoids hematuria %),",1,0.6384767293930054
INLYTA,cerebral hemorrhage,"age (2%), hemoptysi s",1,0.5881560444831848
INLYTA,cerebral hemorrhage,pulmonary embolism rectal age,1,0.518439769744873
INLYTA,cerebral hemorrhage,"(2%), hemoptysi s deep vein",1,0.593229353427887
INLYTA,cerebral hemorrhage,"pulmonary embolism rectal age (2%), hemoptysi s deep",1,0.5793754458427429
INLYTA,cerebral hemorrhage,rectal age,1,0.4497518241405487
INLYTA,cerebral hemorrhage,"glossodynia pulmonary embolism rectal age (2%), hemoptysi",1,0.5785579681396484
INLYTA,hematuria,"embolism rectal hemorrhage (2%), dee p",1,0.6294671893119812
INLYTA,hematuria,"glossodynia pulmonary embolism rectal age (2%), hemoptysi",1,0.6008314490318298
INLYTA,hematuria,"pulmonary embolism rectal hemorrhage (2%),",1,0.6167837977409363
INLYTA,hematuria,"embolism rectal hemorrhage (2%), dee",1,0.6303631663322449
INLYTA,hematuria,rectal hemorrhage,0,0.6574254035949707
INLYTA,hemoptysis,rectal hemorrhage hemoptysis vein throm bosis retinalvein occlusionthrombosis,1,0.722725510597229
INLYTA,hemoptysis,rectal hemorrhage,0,0.6448293328285217
INLYTA,lower gastrointestinal hemorrhage,"deep vein sis (1%), retinal-vein",1,0.5407540798187256
INLYTA,lower gastrointestinal hemorrhage,"hemoptysis deep vein sis (1%), retinal-vein occlusion/ thrombosis polycythemia and transient ischemic",1,0.600490927696228
INLYTA,lower gastrointestinal hemorrhage,Table presents the,0,0.4962925910949707
INLYTA,lower gastrointestinal hemorrhage,deep vein thrombo,0,0.6022972464561462
INLYTA,lower gastrointestinal hemorrhage,"vein sis (1%), retinal-vein occlusion/",1,0.5081732869148254
INLYTA,lower gastrointestinal hemorrhage,and transient ischemic attack Table,0,0.5345462560653687
INLYTA,lower gastrointestinal hemorrhage,"sis (1%), retinal-vein occlusion/ thrombosis polycythemia and",1,0.5374636650085449
INLYTA,lower gastrointestinal hemorrhage,"(1%), retinal-vein occlusion/ thrombosis polycythemia and",1,0.5262805223464966
INLYTA,lower gastrointestinal hemorrhage,thrombosis polycythemia and transient ischemic,0,0.5469388961791992
INLYTA,lower gastrointestinal hemorrhage,deep,0,0.5167517066001892
INLYTA,Fatal,ttack Table presents,1,0.46519288420677185
INLYTA,Fatal,transient ischemic ttack Table presents the,1,0.5649689435958862
INLYTA,Fatal,in patients who,0,0.4798961281776428
INLYTA,Fatal,presents the most common laboratory abnormalities reported in,0,0.5319539308547974
INLYTA,Fatal,ischemic,0,0.6173098087310791
INLYTA,hemorrhage,reported in,0,0.54777991771698
INLYTA,gastric hemorrhage,the most common laboratory s reported in >=10 patients who,1,0.5351771712303162
INLYTA,gastric hemorrhage,reported in,0,0.5050954818725586
INLYTA,gastric hemorrhage,s reported in >=10 patients who,1,0.5454349517822266
INLYTA,gastric hemorrhage,most common laboratory abnormalitie,0,0.527755081653595
INLYTA,gastric hemorrhage,patients who received INLYTA or sorafenib Table Laboratory Abnormalities Occurring,0,0.5774288773536682
INLYTA,gastric hemorrhage,reported in >=10 patients,1,0.543648362159729
INLYTA,gastric hemorrhage,s reported in >=10 patients who received,1,0.5333324670791626
INLYTA,gastric hemorrhage,s reported in >=10 patients who received INLYTA or,1,0.5296154022216797
INLYTA,gastric hemorrhage,the most common laboratory s reported in >=10 patients who received INLYTA or,1,0.5265249609947205
INLYTA,gastric hemorrhage,reported in >=10 patients who received,1,0.5229458808898926
INLYTA,gastric hemorrhage,common,0,0.5008602142333984
INLYTA,cardiac failure,aminotransferase AST aspartate,0,0.49298590421676636
INLYTA,cardiac failure,aminotransferase AST,0,0.4875033497810364
INLYTA,cardiac failure,sphatase;,1,0.478176474571228
INLYTA,cardiac failure,AST aspartate aminotransferase Hematology,0,0.5063185691833496
INLYTA,cardiac failure,ALP,0,0.44822970032691956
INLYTA,cardiac failure,sphatase; ALT:,1,0.48144781589508057
INLYTA,cardiac failure,ALP alkaline sphatase;,1,0.4479820132255554
INLYTA,cardiac failure,ALP alkaline sphatase; ALT: ,1,0.4543263018131256
INLYTA,cardiac failure,sphatase; ALT: alanine aminotransferase,1,0.47106972336769104
INLYTA,cardiac failure,                Hemoglobin decreased,1,0.5849336385726929
INLYTA,cardiac failure,AST aspartate aminotransferase                 Hemoglobin,1,0.5173414349555969
INLYTA,cardiac failure,aspartate aminotransferase Hematology,0,0.49968913197517395
INLYTA,Fatal,   32 Lymphocytes absolute decreas,1,0.5086030960083008
INLYTA,Fatal,aspartate aminotransferase Hematology,0,0.5019112825393677
INLYTA,Fatal,Hemoglobin    32 Lymphocytes absolute,1,0.4973870813846588
INLYTA,Fatal,   32 Lymphocytes absolute,1,0.48115208745002747
INLYTA,Fatal,Lymphocytes,0,0.4964023530483246
INLYTA,Fatal,decreased,0,0.5370470285415649
INLYTA,Fatal,   32,1,0.47966092824935913
INLYTA,Fatal,   32 Lymphocytes,1,0.4878138303756714
INLYTA,cardiac failure,decreased,0,0.5469621419906616
INLYTA,cardiac failure,          35    Lymphocytes absolute decreased,1,0.5381085276603699
INLYTA,cardiac failure,          35    Lymphocytes absolute,1,0.4903586506843567
INLYTA,cardiac failure,          35    Lymphocytes,1,0.5082579851150513
INLYTA,gastrointestinal perforation,istry                       ,1,0.44525665044784546
INLYTA,gastrointestinal perforation,          35    Lymphocytes,1,0.5087486505508423
INLYTA,gastrointestinal perforation,istry                        Creatinine,1,0.4883027970790863
INLYTA,gastrointestinal perforation,Creatinine 55,1,0.4853479266166687
INLYTA,gastrointestinal perforation,increased,0,0.5191202759742737
INLYTA,gastrointestinal perforation,Creatinine         55          0       ,1,0.4813452959060669
INLYTA,gastrointestinal perforation,        55          0        Bicarbonate,1,0.4872749447822571
INLYTA,gastrointestinal perforation,Creatinine increased,0,0.49254393577575684
INLYTA,gastrointestinal perforation,55,1,0.48327189683914185
INLYTA,elevations of TSH,Amylase 319 33,1,0.506061315536499
INLYTA,elevations of TSH,319 33,1,0.4916711747646332
INLYTA,elevations of TSH,Amylase   319          33,1,0.506061315536499
INLYTA,elevations of TSH,Amylase 319,1,0.49204254150390625
INLYTA,elevations of TSH,increased,0,0.5804886221885681
INLYTA,elevations of TSH,319 33 ALT,1,0.5186812877655029
INLYTA,RPLS,that were reported in f pa,1,0.5362190008163452
INLYTA,RPLS,f pa,1,0.5678777694702148
INLYTA,RPLS,upper limit of normal for,0,0.5021362900733948
INLYTA,RPLS,f pa tients treated with,1,0.5246181488037109
INLYTA,headache, INLYTA  versus for sorafenib,1,0.48727327585220337
INLYTA,headache, INLYTA ,1,0.4700717329978943
INLYTA,headache, INLYTA  versus for sorafenib and hypercalcemia,1,0.4781109392642975
INLYTA,headache,of normal  INLYTA  versus for,1,0.5116497278213501
INLYTA,headache,normal,0,0.5668174028396606
INLYTA,headache, INLYTA  versus,1,0.48297202587127686
INLYTA,headache,sorafenib and hypercalcemia,0,0.47369885444641113
INLYTA,headache,of,0,0.552992045879364
INLYTA,seizure,reated with INLYTA included hemoglobin increased above the upper limit of,0,0.5171465873718262
INLYTA,seizure,rsus 1% for sorafenib,1,0.46257513761520386
INLYTA,seizure,the upper limit of,0,0.5020978450775146
INLYTA,seizure,INLYTA versus for,0,0.5143580436706543
INLYTA,seizure,for INLYTA rsus 1%,1,0.4844273328781128
INLYTA,seizure,for INLYTA rsus,1,0.4937141537666321
INLYTA,seizure,INLYTA rsus 1%,1,0.4863895773887634
INLYTA,lethargy,th INLYTA included hemoglobin increased above the upper limit of,0,0.5680984258651733
INLYTA,lethargy,for,0,0.5541501045227051
INLYTA,lethargy,normal for INLYTA versus or soraf enib and hypercalcemia,1,0.5719902515411377
INLYTA,lethargy,of normal,0,0.5721230506896973
INLYTA,lethargy,normal,0,0.618780255317688
INLYTA,confusion,versus for ib) and h,1,0.5588104724884033
INLYTA,confusion,ypercalcemia for INLYTA versus for sorafenib,0,0.48385950922966003
INLYTA,blindness,for INLYTA versus for,0,0.5071884989738464
INLYTA,blindness,sorafenib and ercalcemi a for INLYTA versus,1,0.4989757239818573
INLYTA,blindness,ercalcemi a for INLYTA versus,1,0.5136780738830566
INLYTA,blindness,ercalcemi a for INLYTA,1,0.498676598072052
NORTHERA,Supine Hypertension,of the Supine Hypertension see Warnings and Precautions Hyperpyrexia,1,0.8459323048591614
NORTHERA,Supine Hypertension,ercalcemi a for INLYTA,1,0.5135385990142822
NORTHERA,Supine Hypertension,the Supine Hypertension see Warnings and Precautions Hyperpyrexia,1,0.8493412137031555
NORTHERA,Supine Hypertension,in more detail in the Warnings,0,0.505658745765686
NORTHERA,Supine Hypertension,section of the Supine Hypertension see Warnings and Precautions Hyperpyrexia,1,0.8336331844329834
NORTHERA,Hyperpyrexia,Hyperpyrexia and Confusion see,1,0.8967993259429932
NORTHERA,Hyperpyrexia,Hyperpyrexia and Confusion see Warnings and,1,0.857844352722168
NORTHERA,Hyperpyrexia,Precautions,0,0.5576226711273193
NORTHERA,Hyperpyrexia,ons section of the label Supine Hypertension see Warnings,0,0.5785199403762817
NORTHERA,Confusion,Confusion see Warnings and Precautions,1,0.7482781410217285
NORTHERA,Confusion,Confusion see Warnings and Precautions May,1,0.7448979616165161
NORTHERA,Confusion,Warnings and Precautions Hyperpyrexia,0,0.48123979568481445
NORTHERA,Headache,Headache dizziness,1,0.8505905866622925
NORTHERA,Headache,Headache dizziness nausea hypertension and fatigue,1,0.7723485827445984
NORTHERA,Headache,Warnings and Precautions Headache,1,0.7724349498748779
NORTHERA,Headache,and congestive heart failure see Warnings and Precautions EXCERPT,0,0.5400142073631287
NORTHERA,Headache,EXCERPT,0,0.47266167402267456
NORTHERA,dizziness,Precautions EXCERPT dizziness nausea hypertension and fatigue,1,0.7490478157997131
NORTHERA,dizziness,EXCERPT,0,0.47256577014923096
NORTHERA,dizziness,dizziness nausea hypertension and fatigue,1,0.8155895471572876
NORTHERA,dizziness,Warnings and,0,0.5653195977210999
NORTHERA,dizziness,dizziness nausea hypertension,1,0.8566279411315918
NORTHERA,dizziness,dizziness,1,0.9999998807907104
NORTHERA,dizziness,dizziness nausea hypertension and fatigue greater,1,0.8059181571006775
NORTHERA,dizziness,EXCERPT dizziness nausea hypertension and,1,0.815711498260498
NORTHERA,dizziness,see Warnings and Precautions EXCERPT,0,0.5246199369430542
NORTHERA,dizziness,Precautions,0,0.5162104964256287
NORTHERA,nausea,nausea,1,1.0
NORTHERA,nausea,Headache dizziness,0,0.7011502385139465
NORTHERA,nausea,nausea hypertension and fatigue greater than,1,0.7825964689254761
NORTHERA,nausea,Precautions EXCERPT Headache nausea hypertension and fatigue greater,1,0.7383266687393188
NORTHERA,nausea,Precautions EXCERPT Headache dizziness,0,0.686521053314209
NORTHERA,nausea,dizziness,0,0.7430095672607422
NORTHERA,nausea,tive heart failure see Warnings and,0,0.5665594339370728
NORTHERA,hypertension,Headache dizziness nausea,0,0.6167306900024414
NORTHERA,hypertension,Headache,0,0.6403323411941528
NORTHERA,hypertension,hypertension and,1,0.9201412200927734
NORTHERA,fatigue,fatigue greater than,1,0.8633148670196533
NORTHERA,fatigue,hypertension and,1,0.5399594306945801
NORTHERA,fatigue,fatigue greater,1,0.8759864568710327
NORTHERA,fatigue,REACTIONS contact Lundbeck at,0,0.47369876503944397
NORTHERA,fatigue,and,0,0.5631532073020935
NORTHERA,fatigue,fatigue greater than To,1,0.8241564035415649
NORTHERA,fatigue,nausea hypertension fatigue greater than To report SUSPECTED,1,0.7647783160209656
NORTHERA,fatigue,than To report SUSPECTED ADVERSE REACTIONS contact Lundbeck,0,0.5066061615943909
NORTHERA,fatigue,SUSPECTED ADVERSE,0,0.5487155318260193
NORTHERA,headache,were,0,0.5297192335128784
NORTHERA,headache,headache dizziness,1,0.8505905866622925
NORTHERA,headache,headache dizziness nausea hypertension The most,1,0.77592933177948
NORTHERA,headache,placebocontrolled,0,0.5669138431549072
NORTHERA,headache,The most,0,0.5171458125114441
NORTHERA,headache,the three placebocontrolled trials headache dizziness nausea hypertension,1,0.6704431176185608
NORTHERA,headache,three,0,0.5374122858047485
NORTHERA,dizziness,dizziness nausea,1,0.9154625535011292
NORTHERA,nausea,adverse,0,0.5926717519760132
NORTHERA,nausea,adverse reactions leading to,0,0.610144853591919
NORTHERA,nausea,nausea hypertension,1,0.8295430541038513
NORTHERA,nausea,nausea hypertension The,1,0.827213704586029
NORTHERA,nausea,nausea hypertension The most common,1,0.7631528377532959
NORTHERA,nausea,headache nausea,1,0.8840498924255371
NORTHERA,hypertension,from NORTHERA,0,0.4976552724838257
NORTHERA,hypertension,the three placebocontrolled trials were,0,0.5090278387069702
NORTHERA,hypertension,trials were headache dizziness hypertension The most common,1,0.7332831621170044
NORTHERA,hypertension,hypertension The,1,0.9278820753097534
NORTHERA,hypertension,hypertension The most,1,0.8635551333427429
NORTHERA,hypertension,NORTHERA were,0,0.4852335453033447
NORTHERA,hypertension,dizziness hypertension The most common adverse reactions,1,0.7326606512069702
NORTHERA,hypertension,trials were headache dizziness hypertension The,1,0.7442963123321533
NORTHERA,hypertension,placebocontrolled,0,0.5401808023452759
NORTHERA,increased blood pressure,increased blood pressure,1,0.9999998211860657
NORTHERA,increased blood pressure,increased blood pressure and,1,0.9791795015335083
NORTHERA,increased blood pressure,n The most common adverse reactions leading to discontinuation from NORTHERA,0,0.5034373998641968
NORTHERA,increased blood pressure,increased,1,0.7640390992164612
NORTHERA,increased blood pressure,from NORTHERA were,0,0.44537630677223206
NORTHERA,increased blood pressure,discontinuation from NORTHERA were,0,0.40029793977737427
NORTHERA,increased blood pressure,discontinuation from NORTHERA,0,0.4044710695743561
NORTHERA,increased blood pressure,More,0,0.5831667184829712
NORTHERA,increased blood pressure,blood pressure,1,0.8502584099769592
NORTHERA,nausea,nausea Table Most,1,0.8265219926834106
NORTHERA,falls,a mean total exposure of approximately one,0,0.4990285634994507
NORTHERA,falls,falls urinary,1,0.7788567543029785
NORTHERA,falls,urinary tract infections headache syncope and dizziness,0,0.5510281324386597
NORTHERA,falls,adverse events falls urinary tract,1,0.6211641430854797
NORTHERA,falls,falls urinary tract infections,1,0.7464749217033386
NORTHERA,falls,year,0,0.5043652653694153
NORTHERA,falls,falls urinary tract,1,0.7568457126617432
NORTHERA,urinary tract infections,syncope and dizziness,0,0.48071134090423584
NORTHERA,urinary tract infections,headache syncope and,0,0.4817456007003784
NORTHERA,urinary tract infections,urinary tract infections headache,1,0.8134744167327881
NORTHERA,urinary tract infections,reported adverse events were urinary tract infections headache syncope and dizziness,1,0.7328733205795288
NORTHERA,urinary tract infections,events were urinary tract infections headache syncope and,1,0.7693614363670349
NORTHERA,headache,infections,0,0.5779916644096375
NORTHERA,headache,headache syncope and,1,0.7989716529846191
NORTHERA,headache,urinary tract,0,0.5379812717437744
NORTHERA,headache,were falls urinary tract headache,1,0.7551054954528809
NORTHERA,headache,tract infections,0,0.5216005444526672
NORTHERA,headache,headache syncope,1,0.8000079393386841
NORTHERA,headache,tract headache,1,0.7934373617172241
NORTHERA,syncope,syncope,1,0.9999998807907104
NORTHERA,syncope,syncope and,1,0.9458160400390625
NORTHERA,SUPINE HYPERTENSION,following adverse reactions,1,0.5153911113739014
NORTHERA,SUPINE HYPERTENSION,the Warnings,0,0.5150730013847351
NORTHERA,SUPINE HYPERTENSION,the Warnings and Precautions section,0,0.528876781463623
NORTHERA,SUPINE HYPERTENSION,reactions,0,0.5066072940826416
NORTHERA,SUPINE HYPERTENSION,nausea hypertension,0,0.7502862215042114
NORTHERA,SUPINE HYPERTENSION,fatigue er than 5%),1,0.5332921743392944
NORTHERA,SUPINE HYPERTENSION,nausea hypertension and fatigue er than 5%) ( 6.1,1,0.673444390296936
NORTHERA,SUPINE HYPERTENSION,and fatigue er than 5%) (  6.1  To report SUSPECTED ADVERSE,1,0.5330031514167786
NORTHERA,SUPINE HYPERTENSION,( 6.1 To report SUSPECTED,1,0.49172443151474
NORTHERA,SUPINE HYPERTENSION,er than 5%) (  6.1  To report SUSPECTED ADVERSE REACTIONS,1,0.5211113691329956
NORTHERA,SUPINE HYPERTENSION,er than 5%) (  6.1  To report SUSPECTED ADVERSE,1,0.5232775211334229
NORTHERA,cardiovascular risk,in more detail in Warnings and Precau tions section of the,1,0.5639394521713257
NORTHERA,cardiovascular risk,( 6.1 To report SUSPECTED,1,0.46485352516174316
NORTHERA,cardiovascular risk,Warnings and Precau,1,0.5921932458877563
NORTHERA,cardiovascular risk,Warnings and Precau tions section of the label,1,0.5575414896011353
NORTHERA,supine hypertension,s section of the la bel Supine Hypertension,1,0.8201570510864258
NORTHERA,supine hypertension,Warnings and Precau tions section of the label,1,0.5027301907539368
NORTHERA,supine hypertension,s section of the la bel Supine Hypertension see,1,0.821945071220398
NORTHERA,supine hypertension,and,0,0.4637230336666107
NORTHERA,supine hypertension,the la bel Supine,1,0.6777175664901733
NORTHERA,supine hypertension,section of the la bel Supine,1,0.6790590882301331
NORTHERA,confusion,Precautions section of the,0,0.4841064214706421
NORTHERA,Allergic reactions,and congestive,1,0.5356698036193848
NORTHERA,Allergic reactions,disease arrhythmi,0,0.5055498480796814
NORTHERA,Allergic reactions,see Warnings and Precautions EXCERPT Headache dizziness naus,0,0.60752272605896
NORTHERA,Allergic reactions,"existing ischemic heart disease as, and congestive",1,0.4920758605003357
NORTHERA,Allergic reactions,"as, and congestive heart",1,0.536126434803009
NORTHERA,Allergic reactions,"as, and",1,0.5168442726135254
NORTHERA,Allergic reactions,and Precautions May exacerbate existing ischemic heart disease,0,0.5382993221282959
NORTHERA,supine hypertension,"s, nausea, hyperten sion and",1,0.6523206233978271
NORTHERA,supine hypertension,see Warnings and Precautions,0,0.5308983325958252
NORTHERA,neuroleptic malignant syndrome,clinical practice. The,1,0.5174199342727661
NORTHERA,neuroleptic malignant syndrome,in clinical practice. The safety evaluation of NORTHERA,1,0.5333297252655029
NORTHERA,neuroleptic malignant syndrome,based on,0,0.47903406620025635
NORTHERA,NMS,of NORTHERA is based on two placebocontrolled studies to weeks in duration Studie,0,0.5706179141998291
NORTHERA,NMS,fet y evaluation of,1,0.4829151928424835
NORTHERA,NMS,fet y evaluation of NORTHERA,1,0.5733894109725952
NORTHERA,NMS,fet,1,0.49971508979797363
NORTHERA,NMS,fet y,1,0.518197774887085
NORTHERA,NMS,sa,0,0.5621042847633362
NORTHERA,NMS,in clinical practice,0,0.4833938479423523
NORTHERA,NMS,drug and may not reflect the rates observed in,0,0.4910188913345337
NORTHERA,fever,deficiency,0,0.5106388330459595
NORTHERA,fever,rophy pure autonomic failure dopamine,1,0.548595666885376
NORTHERA,hyperthermia,multiple system atrophy re,1,0.521571159362793
NORTHERA,hyperthermia,re autonomic failure dopamine betahydroxylase deficiency,1,0.5902646780014038
NORTHERA,hyperthermia,dopamine betahydroxylase,0,0.5833725333213806
NORTHERA,hyperthermia,deficiency or nondiabetic autonomic,0,0.561387300491333
NORTHERA,muscle rigidity,neuropathy were randomized,0,0.5589059591293335
NORTHERA,muscle rigidity,"autonomic ailure, dopamin e betahydroxylase deficiency or nondiabetic",1,0.5113976001739502
NORTHERA,muscle rigidity,"system atrophy pure autonomic ailure, dopamin e betahydroxylase deficiency or",1,0.543536901473999
NORTHERA,muscle rigidity,"atrophy pure autonomic ailure,",1,0.6019504070281982
NORTHERA,muscle rigidity,"ailure, dopamin e betahydroxylase deficiency",1,0.5012222528457642
NORTHERA,involuntary movements,beta-hydroxylase defi ciency,1,0.5007441639900208
NORTHERA,involuntary movements,pure,0,0.5135174989700317
NORTHERA,involuntary movements,failure beta-hydroxylase defi,1,0.4988681972026825
NORTHERA,altered consciousness,randomized and,0,0.5061648488044739
NORTHERA,altered consciousness,"autonomic failure dopamine betahydroxylase ency,",1,0.5062086582183838
NORTHERA,mental status changes,neuropathy were randomized and treated,1,0.5151001214981079
NORTHERA,allergic-type reactions,blood pressure,0,0.5200960040092468
NORTHERA,allergic-type reactions,common adverse ns leading to discontin uation,1,0.54608154296875
NORTHERA,allergic-type reactions,common adverse ns leading to discontin uation from NORTHERA were hypertension,1,0.5237534642219543
NORTHERA,allergic-type reactions,leading to discontin uation from NORTHERA were hypertension,1,0.5119109153747559
NORTHERA,bronchial asthma,Table Most Common Adverse Reactions,0,0.5009082555770874
NORTHERA,bronchial asthma,NORTHERA were hy pertension or increased blood,1,0.5009756684303284
NORTHERA,bronchial asthma,leading to discontinuation NORTHERA were,1,0.4389912784099579
NORTHERA,bronchial asthma,to discontinuation,0,0.44212809205055237
NORTHERA,bronchial asthma,The,0,0.46777626872062683
NORTHERA,bronchial asthma,were hy pertension or increased blood pressure,1,0.4992518126964569
NORTHERA,bronchial asthma,reactions,0,0.5160707831382751
